<SUBMISSION>
<ACCESSION-NUMBER>0000950134-08-016723
<TYPE>S-1/A
<PUBLIC-DOCUMENT-COUNT>40
<FILING-DATE>20080917
<DATE-OF-FILING-DATE-CHANGE>20080917
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>FLUIDIGM CORP
<CIK>0001162194
<ASSIGNED-SIC>3826
<IRS-NUMBER>770513190
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>S-1/A
<ACT>33
<FILE-NUMBER>333-150227
<FILM-NUMBER>081075230
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>7000 SHORELINE COURT
<STREET2>SUITE 100
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6502666000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>7000 SHORELINE COURT
<STREET2>SUITE 100
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>f39432a9sv1za.htm
<DESCRIPTION>AMENDMENT TO FORM S-1
<TEXT>
<HTML>
<HEAD>
<TITLE>sv1za</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> As filed with the Securities and Exchange Commission on
    September&#160;17, 2008</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B> Registration
    <FONT style="white-space: nowrap">No.&#160;333-150227</FONT></B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">AMENDMENT NO. 9 TO</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT></FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">REGISTRATION
    STATEMENT</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">UNDER</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">THE SECURITIES ACT OF
    1933</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 24pt">FLUIDIGM CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of Registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Delaware</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>3826</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>77-0513190</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number)</FONT></I><FONT style="font-size: 8pt">
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite 100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(650) 266-6000</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number,<BR>
    including area code, of Registrant&#146;s principal executive
    offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Gajus V. Worthington</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>President and Chief Executive Officer</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>7000 Shoreline Court, Suite&#160;100</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>South San&#160;Francisco, CA 94080</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(650)&#160;266-6000</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number,<BR>
    including area code, of agent for service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
    <B>David J. Segre<BR>
    Robert F. Kornegay<BR>
    Asaf H. Kharal<BR>
    Wilson Sonsini Goodrich &#038; Rosati P.C.<BR>
    650 Page&#160;Mill Road<BR>
    Palo Alto, CA 94304<BR>
    Telephone:
    <FONT style="white-space: nowrap">(650)&#160;493-9300</FONT><BR>
    Telecopy:
    <FONT style="white-space: nowrap">(650)&#160;493-6811</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>William M. Smith<BR>
    Vice President, Legal Affairs<BR>
    and General Counsel<BR>
    7000 Shoreline Court, Suite 100<BR>
    South San&#160;Francisco, CA 94080<BR>
    Telephone: (650) 266-6000<BR>
    Telecopy: (650) 871-7152</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Charles K. Ruck<BR>
    B. Shayne Kennedy<BR>
    Latham &#038; Watkins LLP<BR>
    650 Town Center Drive,
    20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>&#160;Floor<BR>
    Costa Mesa, CA 92626<BR>
    Telephone: (714) 540-1235<BR>
    Telecopy: (714) 755-8290</B>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public:</B>&#160;&#160;As soon as practicable after the
    effective date of this Registration Statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this Form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act, as amended, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    please check the following box and list the Securities Act
    registration statement number of the earlier effective
    registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<FONT style="word-spacing: 60pt; white-space: nowrap; font-size: 1pt"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=540 length=60 -->
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Indicate by check mark whether the registrant is a large
    accelerated filer, an accelerated filer, a non-accelerated
    filer, or a smaller reporting company. See the definitions of
    &#147;large accelerated filer,&#148; &#147;accelerated
    filer&#148; and &#147;smaller reporting company&#148; in Ruler
    <FONT style="white-space: nowrap">12b-2</FONT> of the
    Exchange Act. (Check one):
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="24%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Large accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Non-accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Smaller reporting
    company&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="5" align="center" valign="top">
    (Do not check if a smaller reporting company)
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt">CALCULATION OF REGISTRATION
    FEE</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="70%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterright -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
    <B>Proposed Maximum<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
    <B>Amount of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Title of Each Class of<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Registration<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Securities to be Registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Offering Price(1)</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fee(2)(3)</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom" style="border-top: 1px solid #000000">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common Stock $0.001 par value per share
</DIV>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    97,520,000
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    $3,832.54
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Estimated solely for the purpose of
    computing the amount of the registration fee pursuant to Rule
    457(o) under the Securities Act. Includes $12,720,000 of shares
    that the underwriters have the option to purchase to cover
    over-allotments, if any.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Calculated pursuant to Rule 457(o)
    under the Securities Act based on an estimate of the proposed
    maximum offering price.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">$3,593.00 previously paid.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment that
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended, or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD style=text-align:justify>
<FONT style="font-size: 9pt; font-family: Arial, Helvetica; color: #F93F26">The
information in this preliminary prospectus is not complete and
may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange
Commission is declared effective. This preliminary prospectus is
not an offer to sell these securities and is not soliciting an
offer to buy these securities in any state where the offer or
sale is not permitted.<BR>
</FONT>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt; color: #F93F26">PROSPECTUS
    (Subject to Completion)</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 11pt; color: #F93F26"> Issued
    September&#160;17, 2008</FONT></I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">5,300,000&#160;Shares</FONT></I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a9f3943216.gif" alt="(FLUIDIGM LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 12pt">COMMON STOCK</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Fluidigm Corporation is offering 5,300,000&#160;shares of
    its common stock. This is our initial public offering, and no
    public market currently exists for our shares. We anticipate
    that the initial public offering price will be between $14.00
    and $16.00&#160;per share.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have applied to list our common stock on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Investing in our common stock involves risks. See
    &#147;Risk Factors&#148; beginning on page&#160;8.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>PRICE
    <FONT style="font-size: 12pt">$&#160;&#160;&#160;&#160;&#160;</FONT>
    A SHARE</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Underwriting<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Price to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Discounts and<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Fluidigm<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Public</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Commissions</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Corporation</I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <I>Per Share</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$&#160;&#160;&#160;&#160;&#160;</I></B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><I>$</I></B>&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <I>Total</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B><I>$</I></B>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>We have granted the underwriters the right to purchase up to
    an additional 795,000&#160;shares of common stock to cover
    over-allotments.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The Securities and Exchange Commission and state securities
    regulators have not approved or disapproved these securities or
    determined if this prospectus is truthful or complete. Any
    representation to the contrary is a criminal offense.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Morgan Stanley&#160;&#038; Co. Incorporated expects to
    deliver the shares to purchasers
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008.</I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 16pt; font-variant: SMALL-CAPS">MORGAN
    STANLEY</FONT></I>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 16pt; font-variant: SMALL-CAPS">UBS
    INVESTMENT BANK</FONT></I>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="50%"></TD>
    <TD width="50%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <I><FONT style="font-size: 16pt; font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">LEERINK
    SWANN</FONT></I></TD>
    <TD nowrap align="right">    <I><FONT style="font-size: 16pt; font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">
    PACIFIC GROWTH EQUITIES, LLC</FONT></I></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008
    </FONT>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9f3943218.gif" alt="(GRAPHIC)">
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Page</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Prospectus Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Special Note Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Dividend Policy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>Selected Consolidated Financial Data</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>Management</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>Certain Relationships and Related Party
    Transactions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'>Principal Stockholders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    110
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'>Description of Capital Stock</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'>Shares Eligible For Future Sale</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    117
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'>Material U.S. Federal Income and Estate Tax
    Consequences to Non-U.S. Holders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'>Underwriters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'>Where You Can Find Additional Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'>Index to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv1w1.htm">EXHIBIT 1.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv3w1.htm">EXHIBIT 3.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv3w4.htm">EXHIBIT 3.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv4w4.htm">EXHIBIT 4.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv4w5.htm">EXHIBIT 4.5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv4w6.htm">EXHIBIT 4.6</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv5w1.htm">EXHIBIT 5.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv10w9.htm">EXHIBIT 10.9</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv10w19.htm">EXHIBIT 10.19</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv10w20.htm">EXHIBIT 10.20</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="f39432a9exv23w1.htm">EXHIBIT 23.1</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus and in any free writing prospectus prepared by or on
    behalf of us. We have not, and the underwriters have not,
    authorized anyone to provide you with information different
    from, or in addition to, that contained in this prospectus or
    any related free writing prospectus. This prospectus is an offer
    to sell only the shares offered hereby but only under
    circumstances and in jurisdictions where it is lawful to do so.
    The information contained in this prospectus is current only as
    of its date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Through and
    including,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2008 (the 25th&#160;day after the date of this prospectus), all
    dealers effecting transactions in these securities, whether or
    not participating in this offering, may be required to deliver a
    prospectus. This is in addition to a dealer&#146;s obligation to
    deliver a prospectus when acting as an underwriter and with
    respect to an unsold allotment or subscription</B>.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For investors outside the United States: Neither we nor any of
    the underwriters have done anything that would permit this
    offering or possession or distribution of this prospectus in any
    jurisdiction where action for that purpose is required, other
    than the United States. You are required to inform yourselves
    about and to observe any restrictions relating to this offering
    and the distribution of this prospectus.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<A name='101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>This summary highlights information contained in greater
    detail elsewhere in this prospectus. This summary may not
    contain all the information that you should consider before
    investing in our common stock. You should read the entire
    prospectus carefully, including &#147;Risk Factors&#148;
    beginning on page&#160;8 and our consolidated financial
    statements and related notes included elsewhere in this
    prospectus, before making an investment decision. Unless
    otherwise indicated, the terms &#147;Fluidigm,&#148;
    &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
    Fluidigm Corporation.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, address critical industry needs by providing very
    large-scale integration of essential laboratory functions on a
    single microfabricated device. IFCs can measure, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of fluids
    with precise control and reproducibility. Based on their
    similarities to the integrated circuit that revolutionized the
    microelectronics industry, we often refer to our IFCs as
    &#147;integrated circuits for biology.&#148; These devices
    enable our customers to perform thousands of sophisticated
    biochemical reactions and measurements in parallel on samples
    smaller than the content of a single cell, while reducing the
    consumption of expensive laboratory chemicals. Particularly for
    large-scale experimentation, our IFC systems increase
    throughput, decrease costs and enhance sensitivity compared to
    conventional laboratory systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems, consisting of
    instrumentation, software and single-use IFCs, for a wide range
    of life science applications. Researchers and clinicians have
    successfully employed our products in achieving breakthroughs
    across diverse scientific disciplines such as genetic variation,
    cellular function and structural biology. These advances include
    using our systems to help detect life-threatening mutations in
    patients&#146; cancer cells, discover indicators of
    susceptibility to cancer, manage some of the world&#146;s most
    valuable fisheries, analyze the genetic composition of
    individual stem cells, identify fetal chromosomal abnormalities
    from maternal blood samples, analyze the aggressiveness of the
    avian flu virus and assess the quality of agricultural seed
    products. We believe that the flexible architecture of our IFC
    technology will lead to the development of IFC systems for a
    wide variety of additional markets and applications, including
    high-throughput DNA sequencing and molecular diagnostics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our success and continued growth prospects are
    attributable to the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Disruptive Technology.</I>&#160;&#160;We believe we have
    achieved a level of miniaturization in microfluidics that allows
    us to integrate the components required to automate a broad
    range of life science applications in an area less than half the
    size of a credit card. Our IFCs deliver orders of magnitude
    improvements in cost and labor efficiencies, while being easily
    incorporated into existing laboratory workflows and allowing the
    use of broadly accepted chemistries.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Proven Customer Adoption.</I>&#160;&#160;We have sold our
    IFCs to over 100 customers. These customers include many leading
    biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories worldwide.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Broad Application in the Life Science
    Market.</I>&#160;&#160;We have developed and commercialized IFCs
    for several significant life science research applications and
    believe that the inherent flexibility of our technology will
    enable the development of IFCs for a wide variety of additional
    markets and applications.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Strong Research and Development Capabilities and Intellectual
    Property Position.</I>&#160;&#160;We have and will continue to
    invest substantially in research and development to increase the
    density, throughput and functionality of our IFCs. We have
    developed an extensive portfolio of intellectual property,
    including more than 81 issued U.S.&#160;patents and 240 patent
    applications pending worldwide either owned by or licensed to us.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Efficient Manufacturing and Process
    Development.</I>&#160;&#160;Our sophisticated manufacturing
    process, which combines standard semiconductor methods with
    proprietary techniques, enables us to produce large
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    quantities of IFCs to stringent quality standards. We have
    established our manufacturing facility in Singapore because of
    the availability of a skilled workforce, an extensive supplier
    and partner network, lower operating costs and significant
    government support.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Developing
    and applying this knowledge increasingly requires performing
    experimentation on a scale and with a precision that can be
    achieved only through automation. However, the most common forms
    of life science automation rely on cumbersome robotic systems
    that are slow, expensive and labor intensive and, we believe,
    fundamentally constrain life science research. In much the same
    way that integrated circuits overcame the limitations of early
    computers by placing an increasing number of transistors on a
    single silicon chip, our IFCs are designed to overcome many of
    the limitations of conventional laboratory systems by
    integrating an increasing number of fluidic components on a
    single microfabricated IFC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, researchers and clinicians use our IFCs to perform
    large-scale experimentation in the fields of genomics and
    proteomics. Genomics is the in-depth study of the genetic
    makeup, or genome, of microorganisms, plants, animals and
    people, including analyzing variations in genes and gene
    activity. Proteomics is the large-scale study of the structure
    and function of proteins. Our IFC systems support the following
    types of genomic and proteomic studies:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping: </I>determining the specific genetic traits of an
    individual or individuals.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene expression analysis: </I>measuring the activity of genes.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Protein crystallization:</I> determining the
    three-dimensional structure of proteins.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR:</I> quantifying scarce genetic sequences in a
    biological sample.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to Strategic Directions International, in 2005 the
    principal segments of the genomic analysis market, gene
    expression and genotyping, accounted for $4.9&#160;billion
    worldwide in expenditures and are expected to grow annually by
    8% through 2010. We believe that our products may further be
    developed for use in high-throughput DNA sequencing and
    molecular diagnostics. High-throughput DNA sequencing is the
    large scale analysis of DNA sequences, including, for example,
    determining an organism&#146;s genome. Molecular diagnostics is
    a rapidly growing market that seeks to apply information learned
    from genomic and proteomic analysis to clinical practice in
    diagnosing, monitoring and treating disease.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional laboratory systems by enabling researchers and
    clinicians to rapidly perform a large number of experiments at
    one time and in nanoliter volumes, significantly increasing
    throughput, reducing reagent costs, conserving patient samples
    and reducing workflow complexity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz IFC system in the first
    quarter of 2003 and our BioMark IFC system in the fourth quarter
    of 2006. Our first IFC, the 1.96 Dynamic Array for our Topaz
    system, was introduced in the first quarter of 2003 and allowed
    researchers to test a single sample against 96 different
    reagents. In May 2008, we introduced the 96.96 Dynamic Array IFC
    for our BioMark system. This IFC is based on a matrix
    architecture that allows a researcher to test each of 96
    different samples against each of 96 different reagents in
    parallel, and thus perform 9,216 individual experiments
    simultaneously.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over conventional laboratory
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer liquid handling steps than
    conventional systems for the same experiment.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;Our most advanced IFCs
    can conduct up to 24 times more experiments than a conventional
    system can perform in a single run.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    researchers to dispense samples and reagents in nanoliter, or
    billionths of a liter, volumes, which supports high sensitivity
    techniques.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Reagent and Sample Requirements.</I>&#160;&#160;Our
    systems operate on volumes of reagents and samples that are
    typically less than 1% of the volumes required by conventional
    systems.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;For high volume users,
    the cost of purchasing one BioMark system is much lower than the
    cost of purchasing the number of conventional systems required
    to provide the same throughput.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Ease of Adoption.</I>&#160;&#160;Our IFC systems support
    widely-used chemistries and are compatible with standard
    laboratory equipment, allowing researchers to easily incorporate
    our products into their laboratory workflow and processes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our IFC systems also offer significant
    advantages over other high-throughput methods for large scale
    experimentation. These alternative approaches have one or more
    limitations such as lack of flexibility, poor data quality,
    complex and slow workflows or high running costs. However, some
    of these methods are able to detect thousands of genetic markers
    in a single sample and may be more suitable for certain
    applications than our products. In addition, some of these
    alternative approaches are more widely adopted and better
    validated than our systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems address the needs of researchers and clinicians
    who perform large-scale studies in the areas of genomics,
    proteomics and molecular diagnostics. Nevertheless, researchers
    and clinicians may be slow to adopt our IFC systems as they are
    based on technology that is not yet well-established in the
    industry. Moreover, many of the existing laboratories have
    already made substantial capital investments in their existing
    systems and may be hesitant to abandon that investment. In
    addition, our IFC systems are less well suited for smaller scale
    research initiatives where complexity and workflow issues may be
    less pressing and conventional systems may be more economical.
    As life science research continues to evolve and is
    commercialized, we believe that there will be increasing demand
    for life science automation solutions that enable
    experimentation on the scale supported by our IFC systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Affecting Us</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to numerous risks, as more fully
    described in the section entitled &#147;Risk Factors&#148;
    immediately following this prospectus summary, including the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have incurred significant losses since our inception, had an
    accumulated deficit of $149.1&#160;million as of June&#160;28,
    2008 and expect to incur losses for the foreseeable future.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    If our products fail to achieve and sustain market acceptance,
    our revenue will be adversely affected.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our sales cycle for the BioMark and Topaz systems is lengthy and
    unpredictable, which makes it difficult for us to forecast
    revenue and could cause significant quarterly fluctuations in
    revenue and other operating results.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We receive a substantial portion of our revenues from a limited
    number of customers and other entities, and the loss of, or a
    significant reduction in, orders or grants from one or more of
    our major customers or grantors would adversely affect our
    operations and financial condition.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The life science industry is highly competitive and subject to
    rapid technological change, and we may not be able to
    successfully compete.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We have limited experience in producing our products, and we may
    experience development or manufacturing problems or delays that
    could limit the growth of our revenue or increase our losses.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We are dependent on single source suppliers for some of the
    components and materials used in our systems, and the loss of
    any of these suppliers could harm our business.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our ability to protect our intellectual property and proprietary
    technology through patents and other means is uncertain, and we
    are dependent on certain licensed-in technology. In addition,
    our suit seeking declaratory judgments of non-infringement and
    invalidity against Applied BioSystems, Inc. and Applera
    Corporation, as well as future third-party claims of
    intellectual property infringement could adversely affect our
    operations and financial condition.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    History and Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were incorporated in California in May 1999 as Mycometrix
    Corporation, changed our name to Fluidigm Corporation in April
    2001 and reincorporated in Delaware in July 2007. Our principal
    executive offices are located at 7000 Shoreline Court,
    Suite&#160;100, South San&#160;Francisco, California 94080. Our
    telephone number is
    <FONT style="white-space: nowrap">(650)&#160;266-6000.</FONT>
    Our website address is www.fluidigm.com. Information contained
    on our website is not incorporated by reference into this
    prospectus, and should not be considered to be part of this
    prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Fluidigm,&#148; the Fluidigm logo, &#147;Topaz,&#148;
    &#147;BioMark,&#148; &#147;AutoInspeX,&#148; &#147;MSL&#148; and
    &#147;NanoFlex&#148; are trademarks or registered trademarks of
    Fluidigm. Other service marks, trademarks and trade names
    referred to in this prospectus are the property of their
    respective owners.
</DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    OFFERING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Common stock offered by us</TD>
    <TD></TD>
    <TD valign="bottom">
    5,300,000&#160;shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Common stock to be outstanding after this offering</TD>
    <TD></TD>
    <TD valign="bottom">
    24,790,535&#160;shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Use of proceeds</TD>
    <TD></TD>
    <TD valign="bottom">
    We intend to use the net proceeds from this offering to expand
    our sales force, support the commercialization of our products,
    continue research and development, expand our facilities and
    manufacturing operations and for working capital and other
    general corporate purposes. We may also use a portion of the net
    proceeds to acquire other businesses, products or technologies.
    However, we do not have agreements or commitments for any
    specific acquisitions at this time. See &#147;Use of
    Proceeds.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    Proposed NASDAQ Global Market symbol</TD>
    <TD></TD>
    <TD valign="bottom">
    FLDM</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The number of shares of our common stock to be outstanding
    following this offering is based on 19,490,535&#160;shares of
    our common stock outstanding as of June&#160;28, 2008, which
    includes 6,785 shares of common stock subject to repurchase but
    excludes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2,373,978&#160;shares of common stock issuable upon exercise of
    options outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $5.44 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    216,409&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $11.41 per share, after conversion of
    our convertible preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2,601,584&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans, including
    2,000,000&#160;shares of common stock reserved for issuance
    under our 2008 Equity Incentive Plan, which will become
    effective on the date of this prospectus, and any future
    automatic increase in shares reserved for issuance under such
    plan; and
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, this prospectus reflects and assumes
    the following:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a one (1)-for-three and a half (3.5) reverse split of our
    outstanding common stock and convertible preferred stock, which
    was effected on September&#160;16, 2008;
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the conversion of all outstanding shares of our convertible
    preferred stock into an aggregate of 16,625,970&#160;shares of
    common stock upon the closing of this offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the filing of our amended and restated certificate of
    incorporation immediately prior to the effectiveness of this
    offering; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    no exercise by the underwriters of their over-allotment option.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have derived the summary consolidated statement of operations
    data for the years ended December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007 from our
    audited consolidated financial statements included elsewhere in
    this prospectus. We have derived the summary consolidated
    statement of operations data for the six months ended
    June&#160;30, 2007 and June&#160;28, 2008 and the consolidated
    balance sheet data as of June&#160;28, 2008 from our unaudited
    consolidated financial statements included elsewhere in this
    prospectus. Our historical results are not necessarily
    indicative of the results that may be expected in the future.
    The following summary consolidated financial data should be read
    in conjunction with &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and our consolidated financial statements and related notes
    included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="64%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cost and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,462
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (214
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,917
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,219
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (9.21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Pro forma net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
    (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Shares used in computing pro forma net loss per share of common
    stock, basic and diluted (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,149
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    consolidated financial statements included elsewhere in this
    prospectus for an explanation of the method used to calculate
    basic and diluted net loss per share of common stock and pro
    forma net loss per share of common stock.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro
    Forma<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(in thousands)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash and cash equivalents and available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    103,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,644
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    120,513
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma balance sheet data in
    the table above reflects (i)&#160;the conversion of all
    outstanding shares of convertible preferred stock into common
    stock and (ii)&#160;the reclassification of the convertible
    preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in</FONT>
    capital, each effective upon the closing of this offering.
    </FONT></TD>
</TR>
    <FONT style="font-size: 8pt">
    </FONT>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The pro forma as adjusted balance
    sheet data in the table above also reflects the pro forma
    conversions and reclassifications described immediately above
    plus the sale of 5,300,000&#160;shares of our common stock in
    this offering and the application of the net proceeds at an
    initial public offering price of $15.00&#160;per share, the
    midpoint of the range set forth on the cover page of this
    prospectus, after deducting estimated underwriting discounts and
    commissions and estimated offering expenses payable by us.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of $15.00&#160;per share,
    the midpoint of the range set forth on the cover page of this
    prospectus, would increase (decrease) cash, cash equivalents and
    available-for-sale securities and each of working capital, total
    assets and total stockholders&#146; equity by $4.9&#160;million,
    assuming that the number of shares offered by us, as set forth
    on the cover page of this prospectus, remains the same, and
    after deducting estimated underwriting discounts and commissions
    and estimated offering expenses payable by us. Each increase of
    1.0&#160;million shares in the number of shares offered by us
    would increase cash, cash equivalents, available-for-sale
    securities and each of working capital, total assets and total
    stockholders&#146; equity by approximately $14.0&#160;million.
    Similarly, each decrease of 1.0&#160;million shares in the
    number of shares offered by us would decrease cash, cash
    equivalents and available-for-sale securities and each of
    working capital, total assets and total stockholders&#146;
    equity by approximately $14.0&#160;million. The pro forma as
    adjusted information discussed above is illustrative only and
    will be adjusted based on the actual public offering price and
    other terms of this offering determined at pricing.
    </FONT></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    You should consider carefully the risks and uncertainties
    described below, together with all of the other information in
    this prospectus, including our consolidated financial statements
    and related notes, before deciding whether to purchase shares of
    our common stock. If any of the following risks is realized, our
    business, financial condition, results of operations and
    prospects could be materially and adversely affected. In that
    event, the price of our common stock could decline and you could
    lose part or all of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to our Business and Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have incurred losses since inception, and we expect to
    continue to incur substantial losses for the foreseeable
    future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a limited operating history and have incurred
    significant losses in each fiscal year since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million,
    $25.5&#160;million and $15.3&#160;million during 2005, 2006,
    2007 and the six months ended June&#160;28, 2008. As of
    June&#160;28, 2008, we had an accumulated deficit of
    $149.1&#160;million. These losses have resulted principally from
    costs incurred in our research and development programs and from
    our selling, general and administrative expenses. We expect to
    continue to incur operating and net losses and negative cash
    flow from operations, which may increase, for the foreseeable
    future due in part to anticipated increases in expenses for
    research and product development and expansion of our sales and
    marketing capabilities. Additionally, following this offering,
    we expect that our selling, general and administrative expenses
    will increase due to the additional operational and reporting
    costs associated with being a public company. We anticipate that
    our business will generate operating losses until we
    successfully implement our commercial development strategy and
    generate significant additional revenues to support our level of
    operating expenses. Because of the numerous risks and
    uncertainties associated with our commercialization efforts and
    future product development, we are unable to predict when we
    will become profitable, and we may never become profitable. Even
    if we do achieve profitability, we may not be able to sustain or
    increase our profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our products fail to achieve and sustain sufficient
    market acceptance, our revenue will be adversely
    affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends, in part, on our ability to develop and
    market products that are recognized and accepted as reliable,
    enabling and cost effective. Most of our potential customers
    already use expensive research systems in their laboratories and
    may be reluctant to replace those systems. Market acceptance of
    our instrument systems will depend on many factors, including
    our ability to convince potential customers that our systems are
    an attractive alternative to existing technologies. Compared to
    other technologies, our Integrated Fluidic Circuit, or IFC,
    technology is new and unproven, and most potential customers
    have limited knowledge of, or experience with, our products.
    Prior to adopting our technology, potential customers generally
    need to devote significant effort to testing and validating our
    systems and benchmarking them against their current systems and
    performance requirements. Any failure of our systems to meet
    these customer benchmarks could result in customers choosing to
    retain their existing systems or to purchase systems other than
    ours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, many customers intend to publish the results of
    their experiments in scientific and medical journals. Therefore,
    it is important that our systems be perceived as accurate and
    reliable by the scientific and medical research community as a
    whole. Many factors influence the perception of a system
    including its use by leading research groups and the publication
    of their results in well regarded journals. A significant part
    of our sales and marketing efforts have been directed at
    convincing industry leaders of the advantages of our systems and
    encouraging such leaders to publish or present the results of
    their evaluation of our system. If we are unable to induce
    leading researchers to use our system or if such researchers are
    unable to achieve and publish or present significant
    experimental results using our system, acceptance and adoption
    of our systems will be slowed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales cycle is lengthy and unpredictable, which makes
    it difficult for us to forecast revenue and could cause
    significant quarterly fluctuations in revenue and other
    operating results.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The sales cycles for our instrument systems is lengthy, which
    makes it difficult for us to accurately forecast revenues in a
    given period, and may cause revenue and operating results to
    vary significantly from period to period.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due in part to the high up-front cost associated with our
    systems, potential customers for our instrument systems
    typically need to commit significant time and resources to
    evaluate our technology and their decision to purchase our
    instruments may be further limited by budgetary constraints and
    several layers of internal review and approval, which are beyond
    our control. Even after initial approval by appropriate decision
    makers, the negotiation and documentation processes for a
    purchase can be lengthy. As a result of these factors, our sales
    cycle has varied widely and, in certain instances has been
    longer than 12&#160;months. The complexity and variability of
    our sales cycle has made it difficult for us to accurately
    project quarterly revenues, and we have frequently failed to
    meet our internal quarterly projections. Moreover, we do not
    recognize revenue on sales of our systems until the system has
    been delivered to the customer and, in many instances, installed
    and our other revenue recognition criteria have been met. This
    further complicates our ability to project quarterly revenue as
    we may have entered into a sale agreement with a customer for a
    system but cannot predict when that customer will take delivery
    of the system and when we will be able to recognize the revenue.
    We expect that our sales will continue to fluctuate on a
    quarterly basis and that our financial results for some periods
    may be below those projected by securities analysts. Such
    fluctuations could have a material adverse effect on our
    business and on the price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our sales efforts require significant time and effort and
    could hinder our ability to increase sales.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before purchasing one of our systems, customers typically
    require input from one or more scientific evaluators, as well as
    a review by personnel with finance or operational expertise. As
    a result, during our sales effort, we must identify all persons
    involved in the purchasing decision and devote a sufficient
    amount of time to presenting our systems to those individuals.
    The newness and complexity of our products often requires us to
    spend substantial time and effort assisting potential customers
    in evaluating our instruments, including providing
    demonstrations and benchmarking our products against other
    available technologies. This process can be costly and time
    consuming. We expect that our sales process will become less
    burdensome as our products become more widely known and used.
    However, if this change does not occur, we will not be able to
    expand our sales effort as quickly as anticipated and our sales
    will be adversely affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future success is dependent upon our ability to expand
    our customer base and introduce new applications.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our customer base is primarily composed of pharmaceutical and
    biotechnology companies, academic institutions and life science
    laboratories that perform large-scale experimentation for life
    science research purposes. Our success will depend in part upon
    our ability to increase our market share amongst these
    customers, attract life science research customers who do not
    currently perform large-scale experimentation, attract customers
    outside the life science research market and market new
    applications to existing and new customers as we develop such
    applications. Attracting new customers and introducing new
    applications requires substantial time and expense. For example,
    it may be difficult to identify, engage and market to customers
    who do not currently perform large-scale experimentation or are
    unfamiliar with our current applications. In addition, certain
    new applications that we are considering developing are not
    practical to perform with conventional techniques. Any failure
    to expand our existing customer base or launch new applications
    would adversely affect our ability to increase our revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our inability to develop new systems and enhance the
    capabilities of our IFC systems to keep pace with rapidly
    changing technology and customer requirements could adversely
    affect our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends on our ability to develop new applications
    for our IFC technology in existing and new markets, while
    improving the performance and cost effectiveness of our systems.
    New technologies, techniques or products could emerge that might
    offer better combinations of price and performance than our
    current or future product lines and systems. Existing markets
    for our products, including gene expression analysis,
    genotyping, digital polymerase chain reaction, or PCR, and
    proteomics, as well as potential markets for our products such
    as high-throughput DNA sequencing and molecular diagnostics, are
    characterized by rapid technological change and innovation. It
    is critical to our success for us to anticipate changes in
    technology and customer requirements and to successfully
    introduce new, enhanced and competitive technology to meet our
    customers&#146; and prospective customers&#146; needs on a
    timely basis. While we have planned substantial improvements to
    the BioMark system, including enhancing the capabilities of our
    IFCs, we may not be able to successfully implement these
    improvements. Even if we successfully implement some or all of
    these planned improvements, we could incur substantial
    development costs in doing so. We may not have adequate
    resources available to develop new technologies or be
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    able to successfully introduce new applications of, or
    enhancements to, our systems. We cannot guarantee that we will
    be able to maintain technological advantages over emerging
    technologies in the future. If we fail to keep pace with
    emerging technologies, demand for our systems will not grow and
    may decline, and our business, revenue, financial condition and
    operating results could suffer materially.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited resources for marketing, selling and
    distributing our products and we may not be able to develop a
    direct sales and marketing force or distribution capabilities
    that can meet our customers&#146; needs.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited marketing, sales and distribution resources and
    capabilities. We sell our products primarily through our own
    sales force and through distributors in certain territories. Our
    first product line, the Topaz system for protein
    crystallization, was introduced for commercial sale in 2002. Our
    BioMark system was introduced for commercial sale in 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future sales will depend in large part on our ability to
    develop and expand our direct sales force and to increase the
    scope of our marketing efforts. Our products are technically
    complex and used for highly specialized applications. As a
    result, we believe it is necessary to develop a direct sales
    force that includes people with specific scientific backgrounds
    and expertise and a marketing group with technical
    sophistication. Competition for such employees is intense. We
    may not be able to attract and retain personnel or be able to
    build an efficient and effective sales and marketing force,
    which could negatively impact sales of our products, and reduce
    our revenues and profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we may seek to enlist one or more additional
    parties to assist with sales, distribution and customer support
    globally or in certain regions of the world. If we do seek to
    enter into such arrangements, we may not be successful in
    attracting desirable sales and distribution partners, or we may
    not be able to enter into such arrangements on favorable terms.
    If our sales and marketing efforts, or those of any third-party
    sales and distribution partners, are not successful, our
    technologies and products may not gain market acceptance, which
    would materially impact our business operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>The life science industry is highly competitive and
    subject to rapid technological change, and we may not be able to
    successfully compete.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The markets for our products are characterized by rapidly
    changing technology, evolving industry standards, changes in
    customer needs, emerging competition, new product introductions
    and strong price competition. We compete with both established
    and development stage life science companies that design,
    manufacture and market instruments for gene expression analysis,
    genotyping, other nucleic acid detection and additional
    applications using well established laboratory techniques, as
    well as newer technologies such as bead encoded arrays,
    microfluidics, nanotechnology, high-throughput DNA sequencing
    and inkjet and photolithographic arrays. Most of our current
    competitors have significantly greater name recognition, greater
    financial and human resources, broader product lines and product
    packages, larger sales forces, large existing installed bases,
    substantial intellectual property portfolios and greater
    experience in research and development, manufacturing and
    marketing than we do. For example, companies such as Affymetrix,
    Applied Biosystems, BioTrove, Illumina, Roche Diagnostics and
    Sequenom have products that compete in certain segments of the
    market in which we sell our BioMark system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Competitors may be able to respond more quickly and effectively
    than we can to new or changing opportunities, technologies,
    standards or customer requirements. In light of these
    advantages, even if our technology is more effective than the
    product or service offerings of our competitors, current or
    potential customers might accept competitive products and
    services in lieu of purchasing our technology. We anticipate
    that we will face increased competition in the future as
    existing companies and competitors develop new or improved
    products and as new companies enter the market with new
    technologies. We may not be able to compete effectively against
    these organizations. Increased competition is likely to result
    in pricing pressures, which could harm our sales, profitability
    or market share. Our failure to compete effectively could
    materially and adversely affect our business, financial
    condition and results of operations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We receive a substantial portion of our revenue from a
    limited number of customers and other entities, and the loss of,
    or a significant reduction in, orders or grants from one or more
    of our major customers or grantors would adversely affect our
    operations and financial condition.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive a substantial portion of our revenue from a limited
    number of customers and grantors. We received an aggregate of
    approximately 37%, 44%, 38% and 27% of our total revenue from
    our top three customers in 2005, 2006, 2007 and the six months
    ended June&#160;28, 2008. Grant revenue from the Singapore
    Economic Development Board, or EDB, represented 0%, 14%, 24% and
    15% of our total revenue in 2005, 2006 and 2007 and the six
    months ended June&#160;28, 2008. We anticipate that we will
    continue to be dependent on a limited number of customers and
    grantors for a significant portion of our revenue in the near
    future and in some cases the portion of our revenue attributable
    to certain customers or grantors may increase in the future.
    However, we may not be able to maintain or increase sales to our
    top customers or grants from our top grantors for a variety of
    reasons, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our agreements with our customers and grantors do not require
    them to purchase a minimum quantity of our products or make a
    minimum amount of grants in any year;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our customers can stop using our products with limited notice to
    us and suffer little or no payment penalty;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our grants are subject to the achievement of milestones that we
    may not meet;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    many of our customers have pre-existing or concurrent
    relationships with our current or potential competitors that may
    affect the customers&#146; decisions to purchase our products.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have relied in significant part on our strategic
    relationships with customers that are technology leaders in our
    target markets. We intend to pursue the expansion of such
    relationships and the formation of new strategic relationships,
    but we cannot assure you that we will be able to do so. These
    relationships often require us to develop new products that may
    involve significant technological challenges. Our customers
    frequently place considerable pressure on us to meet their tight
    development schedules. Our grantors frequently condition their
    present and future grants on our compliance with certain
    development, hiring and local investment milestones.
    Accordingly, we may have to devote a substantial amount of our
    resources to our strategic relationships, which could detract
    from or delay our completion of other important development
    projects. Delays in development could impair our relationships
    with our strategic customers and grantors and negatively impact
    sales of the products under development or future grant
    activity. The loss of a key customer or grantor, a reduction in
    sales to any key customer, a reduction in grants from a key
    grantor, or our inability to attract new significant customers
    could seriously impact our revenue and materially and adversely
    affect our results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our business depends on research and development spending
    levels of pharmaceutical and biotechnology companies and
    academic, clinical and governmental research institutions and
    any reduction in such spending could limit our ability to sell
    our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our revenue in the foreseeable future will be
    derived primarily from sales of instruments and IFCs to academic
    institutions, biotechnology and pharmaceutical companies and
    life science laboratories worldwide. Our success will depend
    upon their demand for and use of our products. Accordingly, the
    spending policies of these customers could have a significant
    effect on the demand for our technology. These policies may be
    based on a wide variety of factors, including the resources
    available to make purchases, the spending priorities among
    various types of equipment, policies regarding spending during
    recessionary periods and changes in the political climate. In
    addition, academic, governmental and other research institutions
    that fund research and development activities may be subject to
    stringent budgetary constraints that could result in spending
    reductions, reduced allocations or budget cutbacks, which could
    jeopardize the ability of these customers to purchase our
    system. Our operating results may fluctuate substantially due to
    reductions and delays in research and development expenditures
    by these customers. For example, reductions in capital
    expenditures by these customers may result in lower than
    expected system sales and, similarly, reductions in operating
    expenditures by these customers could result in lower than
    expected sales of IFCs. These reductions and delays may result
    from factors that are not within our control, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in economic conditions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in government programs that provide funding to research
    institutions and companies;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the regulatory environment affecting life science
    companies and life science research;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market-driven pressures on companies to consolidate operations
    and reduce costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    mergers and acquisitions in the life science industry;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other factors affecting research and development spending.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any decrease in our customers&#146; budgets or expenditures or
    in the size, scope or frequency of capital or operating
    expenditures as a result of the foregoing or other factors could
    materially adversely affect our operations or financial
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we cannot provide quality technical support, we could
    lose customers and our operating results could suffer.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The placement of our products at new customer sites, the
    introduction of our technology into our customers&#146; existing
    systems and ongoing customer support can be complex.
    Accordingly, we need highly trained technical support personnel.
    Hiring technical support personnel is very competitive in our
    industry due to the limited number of people available with the
    necessary biochemistry background and ability to understand our
    systems at a technical level. We are currently expanding our
    technical support staff and will need to increase it further to
    support expected new customers as well as the expanding needs of
    existing customers. If we are unable to attract, train or retain
    the number of highly qualified technical services personnel that
    our business needs, our business and prospects will suffer.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>To use our products and our BioMark system in particular,
    customers typically need to purchase specialized reagents. Any
    interruption in the availability of these reagents for use in
    our products could limit our ability to market our
    products.</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products and our BioMark system in particular, must be used
    in conjunction with one or more reagents designed to produce or
    facilitate the particular biological or chemical reaction
    desired by the user. Many of these reagents are highly
    specialized and available to the user only from a single
    supplier or a limited number of suppliers. Our customers
    typically purchase these reagents directly from the suppliers
    and we have no control over the supply of those materials. In
    addition, our products are designed to work with these reagents
    as they are currently formulated. We have no control of the
    formulation of these reagents and the performance of our
    products might be adversely affected if the formulation of these
    reagents was changed. If one or more of these reagents were to
    become unavailable or were reformulated, our ability to market
    and sell our products could be materially and adversely affected.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the use of a reagent for a particular process may
    be covered by one or more patents relating to the reagent
    itself, the use of the reagent for the particular process, the
    performance of that process or the equipment required to perform
    the process. Typically, reagent suppliers, who are either the
    patent holders or their authorized licensees, sell the reagents
    along with a license or covenant not to sue with respect to such
    patents. The license accompanying the sale of a reagent often
    purports to restrict the purposes for which the reagent may be
    used. If a patent holder or authorized licensee were to assert
    against us or our customers that the license or covenant
    relating to a reagent precluded its use with our systems, our
    ability to sell and market our products could be materially and
    adversely affected. For example, the current applications of our
    BioMark system, which represented 43% of our product revenue in
    2007, involve real-time polymerase chain reaction, or PCR. The
    primary producers of reagents for PCR reactions are Applied
    Biosystems and Roche Diagnostics, who are our direct
    competitors, and their licensees. These PCR reagents are
    typically sold pursuant to limited licenses or covenants not to
    sue with respect to patents held by these companies. We do not
    have any contractual relationship with Roche Diagnostics or
    Applied Biosystems regarding these PCR reagents, and we cannot
    assure you that these reagents will continue to be available to
    our customers for use with our systems, or that these patent
    holders will not seek to enforce their patents against us, our
    customers, or suppliers.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We are dependent on single source suppliers for some of
    the components and materials used in our systems, and the loss
    of any of these suppliers could harm our business.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on single source suppliers for certain components and
    materials used in our systems. Of these single source suppliers,
    the loss of any of the following would require significant time
    and effort to locate and qualify an alternative source of supply:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    An essential component of our BioMark system is a specialized
    thermal cycler that is available from a limited number of
    suppliers. We purchase this thermal cycler from one supplier,
    Eppendorf AG, which customizes it to our specifications pursuant
    to a supply agreement.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our IFCs are fabricated using a specialized polymer that is
    available from a limited number of sources. In the past we have
    encountered quality issues that have reduced our manufacturing
    yield or required the use of additional manufacturing processes.
    We do not have a long term contract with our current sole
    supplier.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The plastic carriers that hold the core components of our IFCs
    need to be produced to specifications and tolerances that few
    manufacturers are able to meet. We have experienced quality
    issues in the past and, as a result, have recently switched
    suppliers. We do not have a long term contract with either of
    our current sole suppliers for particular carriers.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The reader for our BioMark system requires specialized high
    resolution camera lenses that are available from a limited
    number of sources. We do not have a long term contract with our
    current sole supplier.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our reliance on these suppliers also subjects us to other risks
    that could harm our business, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may be subject to increased component costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are not a major customer of many of our suppliers, and these
    suppliers may therefore give other customers&#146; needs higher
    priority than ours;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may not be able to obtain adequate supply in a timely manner
    or on commercially reasonable terms;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may make errors in manufacturing components that
    could negatively affect the efficacy of our systems or cause
    delays in shipment of our systems;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our suppliers may encounter financial hardships unrelated to our
    demand for components, which could inhibit their ability to
    fulfill our orders and meet our requirements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have in the past experienced supply problems with some of our
    suppliers, such as manufacturing errors, and may again
    experience problems in the future. We may not be able to quickly
    establish additional or replacement suppliers, particularly for
    our single source components. Any interruption or delay in the
    supply of components or materials, or our inability to obtain
    components or materials from alternate sources at acceptable
    prices in a timely manner, could impair our ability to meet the
    demand of our customers and cause them to cancel orders or
    switch to competitive products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have limited experience in producing our products, and
    we may experience development or manufacturing problems or
    delays that could limit the growth of our revenue or increase
    our losses.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have limited experience manufacturing and assembling our
    products in commercial quantities and we may encounter
    unforeseen situations that would result in delays or shortfalls.
    In addition, our production processes and assembly methods may
    have to change to accommodate any significant future expansion
    of our manufacturing capacity. If we are unable to keep up with
    demand for our products, our revenue could be impaired, market
    acceptance for our products could be adversely affected and our
    customers might instead purchase our competitors&#146; products.
    Our inability to successfully manufacture our products would
    have a material adverse effect on our operating results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We first produced the IFCs used in our current Topaz system in
    June 2002 at our facility in South San&#160;Francisco. We have
    since moved our commercial production of IFCs to our facility in
    Singapore, which first produced commercial IFCs for our Topaz
    systems in October 2006 and first produced commercial IFCs for
    our BioMark
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    system in December 2007. Production of the elastomeric block
    that is at the core of our IFCs is a complex process requiring
    advanced clean rooms, sophisticated equipment and strict
    adherence to procedures. Any contamination of the clean room,
    equipment malfunction or failure to strictly follow procedures
    can significantly reduce our yield in one or more batches. Such
    a drop in yield can greatly increase our cost to manufacture our
    IFCs or, in more severe cases, require us to halt the
    manufacture of IFCs until the problem is resolved. Identifying
    and resolving the cause of a drop in yield can require
    substantial time and resources. We have had significant yield
    problems in the past and cannot assure you that these types of
    yield issues will not occur again. Sustained yield problems
    would have a material adverse affect on our business, financial
    condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, developing an IFC for a new application typically
    requires developing a specific production process for that type
    of IFC. While all of our IFCs are produced using the same basic
    processes, significant variations are required to ensure
    adequate yield of any particular type of IFC. Developing such a
    process can be very time consuming, and any unexpected
    difficulty in doing so can delay the introduction of a product.
    For example, in the second quarter of 2006, our ability to
    conduct demonstrations for potential customers for our BioMark
    system was impaired because we were unable to produce sufficient
    quantities of that IFC. Though these production problems were
    resolved, the delay in conducting customer demonstrations
    resulted in the loss and delay of orders from potential
    customers. We cannot assure you that we will not face similar
    difficulties in developing new processes in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we are unable to recruit and retain key executives and
    scientists, we may be unable to achieve our goals.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our performance is substantially dependent on the performance of
    our senior management and key scientific and technical
    personnel, particularly Gajus V. Worthington, our President and
    Chief Executive Officer. We do not maintain fixed term
    employment contracts with any of our employees. The loss of the
    services of any member of our senior management or our
    scientific or technical staff might significantly delay or
    prevent the development of our products or achievement of other
    business objectives by diverting management&#146;s attention to
    transition matters and identification of suitable replacements,
    if any, and could have a material adverse effect on our
    business. We do not maintain significant key man life insurance
    on any of our employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, our research and product development efforts could
    be delayed or curtailed if we are unable to attract, train and
    retain highly skilled employees, particularly, senior scientists
    and engineers. To expand our research and product development
    efforts, we need additional people skilled in areas such as
    molecular and cellular biology, assay development and
    manufacturing. Competition for these people is intense. Because
    of the complex and technical nature of our system and the
    dynamic market in which we compete, any failure to attract and
    retain a sufficient number of qualified employees could
    materially harm our ability to develop and commercialize our
    technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be unable to manage our anticipated growth
    effectively.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The rapid growth of our business has placed a significant strain
    on our managerial, operational and financial resources and
    systems. We have increased the number of our employees from 78
    at December&#160;31, 2005 to 143 at June&#160;28, 2008. In
    addition, since October 2006 we have commenced manufacturing
    operations in Singapore and opened sales offices in Europe and
    Japan. To execute our anticipated growth successfully, we must
    continue to attract and retain qualified personnel and manage
    and train them effectively. We must also upgrade our internal
    business processes and capabilities to create the scalability
    that a growing business demands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our primary commercial manufacturing facility located
    in Singapore is sufficient to meet our short-term manufacturing
    needs. The current lease for our manufacturing facility in
    Singapore expires in October&#160;2011. In order to meet the
    long-term demand for our IFC systems, we believe that we will
    need to add to our existing manufacturing space in Singapore or
    move all of our manufacturing facilities to a new location in
    Singapore. Such a move will involve significant expense in
    connection with the establishment of new clean rooms, the
    movement and installation of key manufacturing equipment and
    modifications to our manufacturing process and we cannot assure
    you that such a move would not delay or otherwise adversely
    affect our manufacturing activities.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Further, our anticipated growth will place additional strain on
    our suppliers and manufacturing facilities, resulting in an
    increased need for us to carefully monitor quality assurance.
    Any failure by us to manage our growth effectively could have an
    adverse effect on our ability to achieve our development and
    commercialization goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our research and product development efforts may not
    result in commercially viable products within the timeline
    anticipated, if at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is dependent on the improvement of our existing
    products, our development of new products to serve existing
    markets and our development of new products to create new
    markets and applications that were previously not practical with
    existing systems. We intend to devote significant personnel and
    financial resources to research and development activities
    designed to advance the capabilities of our IFC technology. Our
    IFC technology is new and complex and the behavior of fluids and
    surrounding compounds in a nanoscale environment is difficult to
    predict in advance. Though we have developed design rules for
    the implementation of our IFC technology, these are frequently
    revised to reflect new insights we have gained about the
    technology. In addition, we have discovered that biological or
    chemical reactions sometimes behave differently when implemented
    on IFCs rather than in a standard laboratory environment. As a
    result, significant research and development efforts may be
    required to transfer even well-understood reactions to our
    technology. In the past, product development projects have been
    significantly delayed when we encountered unanticipated
    difficulties in implementing a process on our IFCs. We may have
    similar delays in the future, and we may not obtain any benefits
    from our research and development activities. Any delay or
    failure by us to develop new products or enhance existing
    products would have a substantial adverse effect on our business
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products, although not currently regulated, could in
    the future be subject to regulation by the U.S. Food and Drug
    Administration or other regulatory agencies.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are currently labeled and sold for research
    purposes only and are not subject to U.S.&#160;Food and Drug
    Administration, or FDA, clearance or approval. However, in the
    future, certain of our products or related applications could be
    subject to the FDA&#146;s regulation, the FDA&#146;s regulatory
    jurisdiction could be expanded to include our products, or both.
    For example, if we wished to label and market our products for
    use in performing clinical diagnostics, FDA clearance or
    approval would be required. Even where a product is exempted
    from FDA clearance or approval, the FDA may impose restrictions
    on how and to whom we can market and sell our products.
    Obtaining FDA approval can be expensive and uncertain, generally
    takes several years to obtain and requires detailed and
    comprehensive scientific and clinical data. Notwithstanding the
    expense, these efforts may never result in FDA approval or
    clearance. Even if we were to obtain regulatory approval or
    clearance, it may not be for the uses we believe are important
    or commercially attractive. As a result, these regulations and
    restrictions could materially and adversely affect our business,
    financial condition and results of operations. Similar laws and
    regulations are also in effect in many foreign countries that
    could affect our ability to market certain products. The number
    and scope of these requirements are increasing. We may not be
    able to obtain regulatory approvals in such countries or may
    incur significant costs in obtaining or maintaining our foreign
    regulatory approvals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our future capital needs are uncertain and we may need to
    raise additional funds in the future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the net proceeds from this offering, together
    with our existing cash and cash equivalents, available for sale
    securities balances and cash receipts generated from sales of
    our products, will be sufficient to meet our anticipated cash
    requirements for at least the next 18&#160;months. However, we
    may need to raise substantial additional capital to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expand the commercialization of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fund our operations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue our research and development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    defend, in litigation or otherwise, any claims that we infringe
    third-party patents or violate other intellectual property
    rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commercialize new products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    acquire companies and in-license products or intellectual
    property.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future funding requirements will depend on many factors,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market acceptance of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of our research and development activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of filing and prosecuting patent applications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of defending, in litigation or otherwise, any claims
    that we infringe third-party patents or violate other
    intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of regulatory clearances or approvals, if
    any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional sales, marketing
    and distribution capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost and timing of establishing additional technical support
    capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the effect of competing technological and market
    developments;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the extent to which we acquire or invest in businesses, products
    and technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we require additional funds in the future, such funds
    may not be available on acceptable terms, or at all.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we do not have, or are not able to obtain, sufficient funds,
    we may have to delay development or commercialization of our
    products or license to third parties the rights to commercialize
    products or technologies that we would otherwise seek to
    commercialize. We also may have to reduce marketing, customer
    support or other resources devoted to our products or cease
    operations. Any of these factors could harm our operating
    results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our products could have unknown defects or errors, which
    may give rise to claims against us and adversely affect market
    adoption of our systems.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems utilize novel and complex technology applied on
    a nanoliter scale and such systems may develop or contain
    undetected defects or errors. We cannot assure you that material
    performance problems, defects or errors will not arise, and as
    we increase the density and integration of our IFCs, these risks
    may increase. While we do not provide express warranties that
    our IFCs will meet performance expectations or be free from
    defects, we have done so in the past, and expect to in the
    future in response to customer concerns in order to preserve
    customer relationships and help foster continued adoption and
    use of our systems. We typically do provide warranties relating
    to other parts of our IFC systems. The costs incurred in
    correcting any defects or errors may be substantial and could
    adversely affect our operating margins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In manufacturing our products, we depend upon third parties for
    the supply of various components. Many of these components
    require a significant degree of technical expertise to produce.
    If our suppliers fail to produce components to specification, or
    if the suppliers, or we, use defective materials or workmanship
    in the manufacturing process, the reliability and performance of
    our products will be compromised.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our products contain defects, we may experience:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a failure to achieve market acceptance or expansion of our
    product sales;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    loss of customer orders and delay in order fulfillment;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    damage to our brand reputation;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased cost of our warranty program due to product repair or
    replacement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    product recalls or replacements;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inability to attract new customers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diversion of resources from our manufacturing and research and
    development departments into our service department;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    legal claims against us, including product liability claims,
    which could be costly and time consuming to defend and result in
    substantial damages.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The occurrence of any one or more of the foregoing could
    negatively affect our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We generate a substantial portion of our revenues
    internationally and are subject to various risks relating to
    such international activities which could adversely affect our
    international sales and operating performance.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, 2006, 2007 and the six months ended June&#160;28,
    2008, approximately 28%, 40%, 52% and 54% of our total revenue
    was generated outside of North America. We believe that a
    significant percentage of our future revenue will come from
    international sources as we expand our overseas operations and
    develop opportunities in additional international areas. Our
    international business may be adversely affected by changing
    economic, political and regulatory conditions in foreign
    countries. Because the majority of our product sales are
    currently denominated in U.S.&#160;dollars, if the value of the
    U.S.&#160;dollar increases relative to foreign currencies, our
    products could become more costly to the international consumer
    and therefore less competitive in international markets, which
    could affect our financial performance. In addition, if the
    value of the U.S.&#160;dollar decreases relative to the
    Singapore dollar, it would become more costly in
    U.S.&#160;dollars for us to manufacture our products in
    Singapore. Furthermore, fluctuations in exchange rates could
    reduce our revenue, particularly with respect to grant revenue
    under agreements in Singapore, and affect demand for our
    products. Engaging in international business inherently involves
    a number of other difficulties and risks, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    required compliance with existing and changing foreign
    regulatory requirements and laws;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    export or import restrictions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    laws and business practices favoring local companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    longer payment cycles and difficulties in enforcing agreements
    and collecting receivables through certain foreign legal systems;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    political and economic instability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potentially adverse tax consequences, tariffs, customs charges,
    bureaucratic requirements and other trade barriers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties and costs of staffing and managing foreign
    operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    difficulties protecting or procuring intellectual property
    rights.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If one or more of these risks occurs, it could require us to
    dedicate significant resources to remedy, and if we are
    unsuccessful in finding a solution, our financial results will
    suffer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We use hazardous chemicals and biological materials in our
    business. Any claims relating to improper handling, storage or
    disposal of these materials could be time consuming and
    costly.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our operations produce
    hazardous biological and chemical waste products. We cannot
    eliminate the risk of accidental contamination or discharge and
    any resultant injury from these materials. In addition, our IFC
    systems involve the use of pressurized systems and may involve
    the use of hazardous materials, which could result in injury. We
    may be sued for any injury or contamination that results from
    our use or the use by third parties of these materials. We do
    not currently maintain separate environmental liability coverage
    and any such contamination or discharge could result in
    significant cost to us in penalties, damages and suspension of
    our operations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If our facilities become inoperable, we will be unable to
    continue manufacturing our products and as a result, our
    business will be harmed until we are able to secure a new
    facility.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We manufacture and assemble our IFCs for commercial sale at our
    facility in Singapore and assemble our instrument platforms at
    our facilities in Singapore and South San&#160;Francisco,
    California. No other manufacturing or assembly facilities are
    currently available to us. Our facilities and the equipment we
    use to manufacture our products would be costly to replace and
    could require substantial lead time to repair or replace. The
    facilities may be harmed or rendered inoperable by natural or
    man-made disasters, including earthquakes, flooding and power
    outages, which may render it difficult or impossible for us to
    perform our research, development and manufacturing for some
    period of time. The inability to perform our research,
    development and manufacturing activities, combined with our
    limited inventory of reserve raw materials and manufactured
    supplies, may result in the loss of customers or harm our
    reputation, and we may be unable to reestablish relationships
    with those customers in the future. Although we possess
    insurance for damage to our property and the disruption of our
    business, this insurance may not be sufficient to cover all of
    our potential losses and may not continue to be available to us
    on acceptable terms, or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>If we fail to maintain effective internal control over
    financial reporting in the future, the accuracy and timing of
    our financial reporting may be adversely affected.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the audit of our consolidated financial
    statements for the years ended December&#160;31, 2005 and 2006
    we, together with our independent registered public accounting
    firm identified material weaknesses in our internal control over
    financial reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The material weaknesses related to our financial statement close
    process, revenue recognition and accrual processes and inventory
    costing, cost of sales, purchases cut-off and stock-based
    compensation. These material weaknesses resulted in the
    recording of numerous audit adjustments over the two year period
    ending December&#160;31, 2006. Since the date of our independent
    registered public accounting firm&#146;s reports on our
    consolidated financial statements for the years ended
    December&#160;31, 2005 and 2006 and through the date of this
    prospectus, we have taken steps intended to remediate these
    material weaknesses, primarily through the hiring of additional
    accounting and finance personnel with technical accounting and
    financial reporting experience. In addition, we have implemented
    procedures and controls in the financial statement close process
    designed to improve the accuracy and timeliness in financial
    accounting and reporting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April and May 2008, we reviewed our internal control over
    financial reporting and concluded that we had certain
    significant deficiencies. A significant deficiency is defined as
    a deficiency, or combination of deficiencies, in internal
    control over financial reporting that is less severe than a
    material weakness, yet important enough to merit attention by
    those responsible for oversight of a company&#146;s financial
    reporting. The significant deficiencies identified by us related
    to: our controls for the consolidation and elimination entries
    relating to intercompany transfer pricing and elimination of
    intercompany profits embedded in deferred costs of our Japanese
    subsidiary; our controls for applying SFAS&#160;123R to option
    grants with non-standard vesting terms and validation of stock
    compensation expenses calculated by our option tracking
    software; and our controls and procedures for the valuation of
    inventory.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame that we will require to
    remediate the significant deficiencies identified. In addition,
    we expect to incur some incremental costs associated with this
    remediation. If we fail to enhance our internal control over
    financial reporting to meet the demands that will be placed upon
    us as a public company, including the requirements of the
    Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, we may be
    unable to report our financial results accurately and prevent
    fraud. While we expect to remediate the significant
    deficiencies, we cannot assure you that we will be able to do so
    in a timely manner, which could impair our ability to accurately
    and timely report our financial position, results of operations
    or cash flows.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     No material weaknesses in internal control over financial
    reporting were identified in our April and May 2008 review.
    However, our management and independent registered public
    accounting firm did not perform an evaluation of our internal
    control over financial reporting as of any date in accordance
    with the provisions of Section&#160;404 of the Sarbanes-Oxley
    Act. Had we and our independent registered public accounting
    firm performed an evaluation of our internal control over
    financial reporting in accordance with the provisions of
    Section&#160;404 of the Sarbanes-Oxley Act, additional control
    deficiencies may have been identified by management or our
    independent registered public accounting firm.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We will incur significant increased costs as a result of
    operating as a public company, and our management will be
    required to devote substantial time to new compliance
    initiatives.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never operated as a public company. As a public company,
    we will incur significant legal, accounting and other expenses
    that we did not incur as a private company. In addition, the
    Sarbanes-Oxley Act, as well as new rules subsequently
    implemented by the Securities and Exchange Commission and the
    NASDAQ Global Market, have imposed various new requirements on
    public companies, including requiring changes in corporate
    governance practices. Our management and other personnel will
    need to devote a substantial amount of time to these new
    compliance initiatives. Moreover, these rules and regulations
    will increase our legal and financial compliance costs and will
    make some activities more time-consuming and costly. For
    example, we expect these new rules and regulations to make it
    more difficult and more expensive for us to obtain director and
    officer liability insurance and we may be required to incur
    substantial costs to maintain the same or similar coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the Sarbanes-Oxley Act requires, among other
    things, that we maintain effective internal control over
    financial reporting and disclosure controls and procedures. In
    particular, commencing in 2009, we must perform system and
    process evaluation and testing of our internal control over
    financial reporting to allow management to report on the
    effectiveness of our internal control over financial reporting,
    as required by Section&#160;404 of the Sarbanes-Oxley Act. Our
    testing, or the subsequent testing by our independent registered
    public accounting firm, may reveal deficiencies in our internal
    control over financial reporting that are deemed to be material
    weaknesses. Our compliance with Section&#160;404 will require
    that we incur substantial accounting expense and expend
    significant management time on compliance-related issues. We
    currently do not have an internal audit group and we will
    evaluate the need to hire additional accounting and financial
    staff with appropriate public company experience and technical
    accounting knowledge. Moreover, if we are not able to comply
    with the requirements of Section&#160;404 in a timely manner, or
    if we or our independent registered public accounting firm
    identifies deficiencies in our internal control over financial
    reporting that are deemed to be material weaknesses, the market
    price of our stock could decline and we could be subject to
    sanctions or investigations by the NASDAQ Global Market, the
    Securities and Exchange Commission or other regulatory
    authorities, which would require additional financial and
    management resources.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Some of our programs are partially supported by government
    grants, which may be reduced, withdrawn, delayed or
    reclaimed.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received and may continue to receive funds under
    research and economic development programs funded by the
    governments of Singapore and the United States. Funding by these
    governments may be significantly reduced or eliminated in the
    future for a number of reasons. For example, some
    U.S.&#160;programs are subject to a yearly appropriations
    process in Congress. Similarly, our grants from the Singapore
    government are part of an official policy to develop a life
    science industry in Singapore; that policy could change or the
    role of grants in it could be reduced or eliminated at any time.
    In addition, we may not receive funds under existing or future
    grants because of budgeting constraints of the agency
    administering the program. A restriction on the government
    funding available to us would reduce the resources that we would
    be able to devote to existing and future research and
    development efforts. Such a reduction could delay the
    introduction of new products and hurt our competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with the Singapore Economic Development Board, or
    EDB, provide that our continued eligibility for incentive grant
    payments from EDB is subject to our satisfaction of agreed upon
    targets for increasing levels of research, development and
    manufacturing activity in Singapore, including the use of local
    service providers, the hiring of personnel in Singapore, the
    incurrence of eligible expenses in Singapore, our receipt of new
    equity investment and our achievement of certain milestones
    relating to new product development or completion of specific
    manufacturing process objectives. These agreements further
    provide EDB with the right to demand repayment of a portion of
    past grants in the event that we did not meet our obligations
    under the applicable agreements. Based on correspondence with
    EDB, we believe that we have satisfied the conditions applicable
    to our EDB grant revenue through June&#160;28, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to use net operating losses to offset future
    taxable income may be subject to certain limitations.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Section&#160;382 of the Internal Revenue Code,
    a corporation that undergoes an &#147;ownership change&#148; is
    subject to limitations on its ability to utilize its pre-change
    net operating losses or NOLs to offset future
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    taxable income. Our existing NOLs may be subject to limitations
    arising from previous ownership changes, and if we undergo an
    ownership change in connection with or after this offering, our
    ability to utilize NOLs could be further limited by
    Section&#160;382 of the Internal Revenue Code. Future changes in
    our stock ownership, some of which are outside of our control,
    could result in an ownership change under Section&#160;382 of
    the Internal Revenue Code. We may not be able to utilize a
    material portion of the NOLs reflected on our balance sheet and
    for this reason, we have fully reserved against the value of our
    NOLs on our balance sheet.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Intellectual Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our ability to protect our intellectual property and
    proprietary technology through patents and other means is
    uncertain.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our ability to
    protect our intellectual property and proprietary technologies.
    We rely on patent protection, where appropriate and available,
    as well as a combination of copyright, trade secret and
    trademark laws, and nondisclosure, confidentiality and other
    contractual restrictions to protect our proprietary technology.
    However, these legal means afford only limited protection and
    may not adequately protect our rights or permit us to gain or
    keep any competitive advantage. Our pending U.S.&#160;and
    foreign patent applications may not issue as patents or may not
    issue in a form that will be advantageous to us. Any patents we
    have obtained or do obtain may be subject to re-examination,
    reissue, opposition or other administrative proceeding, or may
    be challenged in litigation, and such challenges could result in
    a determination that the patent is invalid or unenforceable. In
    addition, competitors may be able to design alternative methods
    or devices that avoid infringement of our patents. To the extent
    our intellectual property, including licensed intellectual
    property, offers inadequate protection, or is found to be
    invalid or unenforceable, we are exposed to a greater risk of
    direct competition. If our intellectual property does not
    provide adequate protection against our competitors&#146;
    products, our competitive position could be adversely affected,
    as could our business. Both the patent application process and
    the process of managing patent disputes can be time consuming
    and expensive. Furthermore, the laws of some foreign countries
    may not protect our intellectual property rights to the same
    extent as do the laws of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of life science companies can be highly
    uncertain and involve complex legal and factual questions for
    which important legal principles remain unresolved. No
    consistent policy regarding the breadth of claims allowed in
    such companies&#146; patents has emerged to date in the United
    States. The laws of some
    <FONT style="white-space: nowrap">non-U.S.&#160;countries</FONT>
    do not protect intellectual property rights to the same extent
    as the laws of the United States, and many companies have
    encountered significant problems in protecting and defending
    such rights in foreign jurisdictions. The legal systems of
    certain countries, particularly certain developing countries, do
    not favor the enforcement of patents and other intellectual
    property protection, particularly those relating to
    biotechnology, which could make it difficult for us to stop the
    infringement of our patents. Proceedings to enforce our patent
    rights in foreign jurisdictions could result in substantial cost
    and divert our efforts and attention from other aspects of our
    business. Changes in either the patent laws or in
    interpretations of patent laws in the United States or other
    countries may diminish the value of our intellectual property.
    We cannot predict the breadth of claims that may be allowed or
    enforced in our patents or in third-party patents. For example:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to make the inventions covered
    by each of our pending patent applications.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We might not have been the first to file patent applications for
    these inventions.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Others may independently develop similar or alternative products
    and technologies or duplicate any of our products and
    technologies.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    It is possible that none of our pending patent applications will
    result in issued patents, and even if they issue as patents,
    they may not provide a basis for commercially viable products,
    or may not provide us with any competitive advantages, or may be
    challenged and invalidated by third parties.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We may not develop additional proprietary products and
    technologies that are patentable.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The patents of others may have an adverse effect on our business.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We apply for patents covering our products and technologies and
    uses thereof, as we deem appropriate. However, we may fail to
    apply for patents on important products and technologies in a
    timely fashion or at all.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we take steps
    to protect our intellectual property and proprietary technology
    by entering into confidentiality agreements and intellectual
    property assignment agreements with our employees, consultants,
    corporate partners and, when needed, our advisors. Such
    agreements may not be enforceable or may not provide meaningful
    protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
    If we were to enforce a claim that a third party had illegally
    obtained and was using our trade secrets, it would be expensive
    and time consuming, and the outcome would be unpredictable. In
    addition, courts outside the United States may be less willing
    to protect trade secrets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We depend on certain technologies that are licensed to us.
    We do not control these technologies and any loss of our rights
    to them could prevent us from selling our products.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on licenses in order to be able to use various
    proprietary technologies that are material to our business,
    including our core integrated fluidic circuit and multi-layer
    soft lithography technologies. We do not own the patents that
    underlie these licenses. Our rights to use these technologies
    and employ the inventions claimed in the licensed patents are
    subject to the negotiation of, continuation of and compliance
    with the terms of those licenses. In some cases, we do not
    control the prosecution, maintenance, or filing of the patents
    to which we hold licenses, or the enforcement of these patents
    against third parties. Some of our patents and patent
    applications were either acquired from another company who
    acquired those patents and patent applications from yet another
    company, or are licensed from a third party. Thus, these patents
    and patent applications are not written by us or our attorneys,
    and we did not have control over the drafting and prosecution.
    The former patent owners and our licensors might not have given
    the same attention to the drafting and prosecution of these
    patents and applications as we would have if we had been the
    owners of the patents and applications and had control over the
    drafting and prosecution. We cannot be certain that drafting
    <FONT style="white-space: nowrap">and/or</FONT>
    prosecution of the licensed patents and patent applications by
    the licensors have been or will be conducted in compliance with
    applicable laws and regulations or will result in valid and
    enforceable patents and other intellectual property rights.
    Enforcement of our licensed patents or defense or any claims
    asserting the invalidity of these patents is often subject to
    the control or cooperation of our licensors. Certain of our
    licenses contain provisions that allow the licensor to terminate
    the license upon specific conditions. Our rights under the
    licenses are subject to our continued compliance with the terms
    of the license, including the payment of royalties due under the
    license. Termination of these licenses could prevent us from
    marketing some or all of our products. Because of the complexity
    of our products and the patents we have licensed, determining
    the scope of the license and related royalty obligation can be
    difficult and can lead to disputes between us and the licensor.
    An unfavorable resolution of such a dispute could lead to an
    increase in the royalties payable pursuant to the license. If a
    licensor believed we were not paying the royalties due under the
    license or were otherwise not in compliance with the terms of
    the license, the licensor might attempt to revoke the license.
    If such an attempt were successful, we might be barred from
    producing and selling some or all of our products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to certain U.S.&#160;government regulations
    because we have licensed technologies that were developed with
    U.S.&#160;government grants. In accordance with these
    regulations, these licenses provide that products embodying the
    technologies will be manufactured substantially in the United
    States. If this domestic manufacturing requirement is not met,
    the government agency that funded the relevant grant is entitled
    to exercise specified rights, referred to as march-in rights,
    which if exercised would allow the government agency to require
    the licensors or us to grant a non-exclusive, partially
    exclusive or exclusive license in any field of use to a third
    party designated by such agency. As of June&#160;28, 2008, most
    of the instrumentation components of our IFC systems were
    manufactured in the United States and all commercial IFC
    components were manufactured in Singapore, though this division
    of manufacturing activities could change in the future. All of
    our IFC system revenue is dependent upon the availability of
    IFCs, which incorporate technology developed with U.S.
    government grants. As there is limited judicial or
    administrative guidance with respect to the interpretation or
    application of the U.S. manufacturing requirement, we are
    uncertain as to whether the current division of manufacturing
    for our IFC systems is in compliance with the requirement. The
    federal regulations allow the funding government agency to
    grant, at the request of the licensors of such technology, a
    waiver of the domestic manufacturing requirement. Waivers may be
    requested prior to any government notification. We are assisting
    the licensors of these technologies with the analysis of the
    domestic manufacturing requirement, and we believe that at least
    one of our licensors will be requesting a
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    waiver with our assistance. If it were to be determined that we
    are in violation of the domestic manufacturing requirement and a
    waiver of such requirement was either not requested or not
    granted, then the U.S.&#160;government could exercise its
    march-in rights. In addition, these licenses contain provisions
    relating to compliance with this domestic manufacturing
    requirement. If it were to be determined that we are not in
    compliance with these provisions and such non-compliance
    constituted a material breach of the licenses, the licenses
    could be terminated. Either the exercise of march-in rights or
    the termination of one or more of our licenses could materially
    adversely affect our business, operations and financial
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be involved in lawsuits to protect or enforce our
    patents and proprietary rights and to determine the scope,
    coverage and validity of others&#146; proprietary rights.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Litigation may be necessary to enforce our patent and
    proprietary rights
    <FONT style="white-space: nowrap">and/or</FONT> to
    determine the scope, coverage and validity of others&#146;
    proprietary rights. Litigation on these matters has been
    prevalent in our industry and we expect that this will continue.
    To determine the priority of inventions, we may have to initiate
    and participate in interference and re-examination proceedings
    declared by the U.S.&#160;Patent and Trademark Office that could
    result in substantial legal fees and could substantially affect
    the scope of our patent protection. Also, our intellectual
    property may be subject to significant administrative and
    litigation proceedings such as invalidity, unenforceability and
    opposition proceedings against our patents. The outcome of any
    litigation or interference proceeding might not be favorable to
    us, and we might not be able to obtain licenses to technology
    that we require. Even if such licenses are obtainable, they may
    not be available at a reasonable cost. In addition, if we resort
    to legal proceedings to enforce our intellectual property rights
    or to determine the validity, scope and coverage of the
    intellectual property or other proprietary rights of others, the
    proceedings could be burdensome and expensive, even if we were
    to prevail. Any litigation that may be necessary in the future
    could result in substantial costs and diversion of resources and
    could have a material adverse effect on our business, operating
    results or financial condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For example, on June&#160;4, 2008 we received a letter from
    Applied Biosystems, Inc., one of our competitors, asserting that
    our BioMark System for gene expression analysis infringes upon
    U.S.&#160;Patent No.&#160;6,814,934, or the &#146;934 patent,
    and its foreign counterparts in Europe and Canada, owned by
    Applied Biosystems&#146; parent company, Applera Corporation. In
    response to this letter, we filed suit against Applied
    Biosystems and Applera in federal district court in the Southern
    District of New York seeking declaratory judgments of
    non-infringement and invalidity of the &#146;934 patent.  In
    response to our action, Applied Biosystems and Applera may file
    suit against us in this and other jurisdictions asserting that
    our products infringe the &#146;934 patent or other proprietary
    rights held by them, or they may seek to dismiss or move our
    suit. Applied Biosystems has recently announced that it expects
    to be acquired by Invitrogen Corporation. This may make it more
    difficult for us to predict the direction of discussions and
    litigation among the parties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into an agreement with Applied Biosystems that
    provides for a stay of our proceedings against Applied
    Biosystems and Applera and provides further that neither party
    may initiate or expressly threaten to initiate any further
    patent litigation proceedings against the other during the term
    of the agreement. Either party may terminate the agreement and
    request that the stay be lifted anytime after September&#160;20,
    2008 by providing seven business days prior written notice to
    the other. The deadline for Applied Biosystems and Applera to
    respond to our complaint is extended to 14 calendar days after
    the lifting of the stay. If the agreement is not terminated
    sooner by one or both of the parties, the agreement will
    terminate on December&#160;15, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Litigation, other proceedings or third party claims of
    intellectual property infringement could require us to spend
    significant time and money and could prevent us from selling our
    products or services or impact our stock price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Applied Biosystems, one of our competitors, has
    asserted that our BioMark System for gene expression analysis
    infringes upon Applera&#146;s &#146;934 patent, and we have
    filed suit against Applied Biosystems and Applera seeking
    declaratory judgments of non-infringement and invalidity of the
    Applera patent. Other third parties have asserted and may assert
    in the future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. For example, numerous significant intellectual property
    issues have been litigated between existing and new participants
    in the PCR market, including litigation initiated by Applied
    Biosystems, Inc. In addition, our competitors and others may
    have patents or may in the future obtain patents and claim that
    use of our products
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    infringes these patents. As we move into new markets and
    applications for our products, incumbent participants in such
    markets may assert their patents and other proprietary rights
    against us as a means of slowing our entry into such markets or
    as a means to extract substantial license and royalty payments
    from us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Patent infringement suits can be expensive, lengthy and
    disruptive to business operations. We could incur substantial
    costs and divert the attention of our management and technical
    personnel in prosecuting or defending against any claims. There
    can be no assurance that we will prevail in our suit against
    Applied Biosystems and Applera in our defense of any claims
    brought against us by Applied Biosystems or Applera or in any
    other suit initiated against us by third parties. If we do not
    prevail in our suit against Applied Biosystems and Applera and
    we are unable to secure any required licenses from such parties,
    we could be precluded from selling our BioMark products, which
    comprised 43% of our total product revenue in 2007 and 61% of
    our total product revenue for the six months ended June&#160;28,
    2008. Parties making claims against us may be able to obtain
    injunctive or other relief, which could block our ability to
    develop, commercialize and sell products, and could result in
    the award of substantial damages against us,&#160;including
    treble damages and attorneys&#146; fees and costs in the event
    that we are found to be a willful infringer of third party
    patents. In addition, our agreements with some of our suppliers,
    distributors, customers and other entities with whom we do
    business may require us to defend or indemnify these parties to
    the extent they become involved in infringement claims against
    us, including the claims described above. We could also
    voluntarily agree to defend or indemnify third parties in
    instances where we are not obligated to do so if we determine it
    would be important to our business relationships. If we are
    required or agree to defend or indemnify any of these third
    parties in connection with any infringement claims, we could
    incur significant costs and expenses that could adversely affect
    our business, operating results, or financial condition. In the
    event of a successful claim of infringement against us, we may
    be required to obtain one or more licenses from third parties,
    which we may not be able to obtain at a reasonable cost, if at
    all. In addition, we could encounter delays in product
    introductions while we attempt to develop alternative methods or
    products to avoid infringing third-party patents or proprietary
    rights. Defense of any lawsuit or failure to obtain any required
    licenses on favorable terms could prevent us from
    commercializing our products, and the risk of a prohibition on
    the sale of any of our products could adversely affect our
    ability to grow and gain market acceptance for our products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, because of the substantial amount of discovery
    required in connection with intellectual property litigation,
    there is a risk that some of our confidential information could
    be compromised by disclosure during this type of litigation. In
    addition, during the course of this kind of litigation, there
    could be public announcements of the results of hearings,
    motions or other interim proceedings or developments. If
    securities analysts or investors perceive these results to be
    negative, it could have a substantial adverse effect on the
    price of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We may be subject to damages resulting from claims that we
    or our employees have wrongfully used or disclosed alleged trade
    secrets of our employees&#146; former employers.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Many of our employees were previously employed at universities
    or other life science companies, including our competitors or
    potential competitors. Although no claims against us are
    currently pending, we may be subject to claims that these
    employees or we have inadvertently or otherwise used or
    disclosed trade secrets or other proprietary information of
    their former employers. Litigation may be necessary to defend
    against these claims. If we fail in defending such claims, in
    addition to paying monetary damages, we may lose valuable
    intellectual property rights or personnel. A loss of key
    research personnel or their work product could hamper or prevent
    our ability to commercialize certain potential products, which
    could severely harm our business. Even if we are successful in
    defending against these claims, litigation could result in
    substantial costs and be a distraction to management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Common Stock and this Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We expect that our stock price will fluctuate
    significantly, and you may not be able to resell your shares at
    or above the initial public offering price.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for
    shares of our common stock. We cannot predict the extent to
    which investor interest in our company will lead to the
    development of an active trading market on the NASDAQ Global
    Market or otherwise or how liquid that market might become. If
    an active trading market does not develop, you may have
    difficulty selling any of our shares of common stock that you
    buy. We and the underwriters will determine the initial public
    offering price of our common stock through negotiation. This
    price will not necessarily
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reflect the price at which investors in the market will be
    willing to buy and sell our shares following this offering. In
    addition, the trading price of our common stock following this
    offering may be highly volatile and could be subject to wide
    fluctuations in response to various factors, some of which are
    beyond our control. These factors include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actual or anticipated quarterly variation in our results of
    operations or the results of our competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements by us or our competitors of new commercial
    products, significant contracts, commercial relationships or
    capital commitments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issuance of new or changed securities analysts&#146; reports or
    recommendations for our stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developments or disputes concerning our intellectual property or
    other proprietary rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    commencement of, or our involvement in, litigation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market conditions in the life science sector;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any major change in our Board or management;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general economic conditions and slow or negative growth of our
    markets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The trading market for our common stock will rely in part on the
    research and reports that equity research analysts publish about
    us and our business. We do not control these analysts or the
    content and opinions included in their reports. Securities
    analysts may elect not to provide research coverage of our
    common stock after the completion of this offering, and such
    lack of research coverage may adversely affect the market price
    of our common stock. The price of our stock could decline if one
    or more equity research analysts downgrade our stock or if those
    analysts issue other unfavorable commentary or cease publishing
    reports about us or our business. If one or more equity research
    analysts ceases coverage of our company, we could lose
    visibility in the market, which in turn could cause our stock
    price to decline.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Purchasers in this offering will experience immediate and
    substantial dilution in the book value of their
    investment.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price of our common stock is
    substantially higher than the net tangible book value per share
    of our common stock immediately after this offering. Therefore,
    if you purchase our common stock in this offering, you will
    incur an immediate dilution of $11.18 in net tangible book value
    per share as of June&#160;28, 2008 from the price you paid,
    based on an assumed initial public offering price of $15.00 per
    share, the mid-point of the range set forth on the cover page of
    this prospectus. In addition, new investors who purchase shares
    in this offering will contribute approximately 32% of the total
    amount of equity capital raised by us through the date of this
    offering, but will only own approximately 21% of the outstanding
    share capital and approximately 21% of the voting rights. The
    exercise of outstanding options and warrants will result in
    further dilution. For a further description of the dilution that
    you will experience immediately after this offering, see
    &#147;Dilution.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Future sales of shares by existing stockholders could
    cause our stock price to decline.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our existing stockholders sell, or indicate an intention to
    sell, substantial amounts of our common stock in the public
    market after the
    <FONT style="white-space: nowrap">lock-up</FONT> and
    other legal restrictions on resale discussed in this prospectus
    lapse, the trading price of our common stock could decline.
    Based on shares outstanding as of June&#160;28, 2008, upon
    completion of this offering, we will have outstanding a total of
    24,790,535&#160;shares of common stock, assuming no exercise of
    the underwriters&#146; over-allotment option. Of these shares,
    only the 5,300,000&#160;shares of common stock sold in this
    offering by us will be freely tradable, without restriction, in
    the public market immediately after the offering. Each of our
    directors and officers, and certain of our stockholders, have
    entered into
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements with the underwriters that restrict their ability to
    sell or transfer their shares. The
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements pertaining to this offering will expire 180&#160;days
    from the date of this prospectus, although they may be extended
    for up to an additional 34&#160;days under certain
    circumstances. Our underwriters, however, may, in their sole
    discretion, permit our officers, directors and other current
    stockholders who are subject to the contractual
    <FONT style="white-space: nowrap">lock-up</FONT> to
    sell shares prior to the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements. After the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements expire, based on shares outstanding as of
    June&#160;28, 2008, up to an additional 19,490,535&#160;shares
    of common stock will be eligible for sale in the public market,
    5,849,026 of which are held by directors and executive officers
    and will be subject to volume limitations under Rule&#160;144
    under the Securities Act and various vesting agreements. In
    addition, 2,373,978&#160;shares of common stock
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    that are subject to outstanding options as of June&#160;28, 2008
    will become eligible for sale in the public market to the extent
    permitted by the provisions of various vesting agreements, the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements and Rules&#160;144 and 701 under the Securities Act.
    If these additional shares are sold, or if it is perceived that
    they will be sold, in the public market, the trading price of
    our common stock could decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our directors and executive officers will continue to have
    substantial control over us after this offering and could limit
    your ability to influence the outcome of key transactions,
    including changes of control.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers, directors and their affiliates will
    beneficially own or control approximately&#160;22.79% of the
    outstanding shares of our common stock, following the completion
    of this offering. Accordingly, these executive officers,
    directors and their affiliates, acting as a group, will have
    substantial influence over the outcome of corporate actions
    requiring stockholder approval, including the election of
    directors, any merger, consolidation or sale of all or
    substantially all of our assets or any other significant
    corporate transactions. These stockholders may also delay or
    prevent a change of control of us, even if such a change of
    control would benefit our other stockholders. The significant
    concentration of stock ownership may adversely affect the
    trading price of our common stock due to investors&#146;
    perception that conflicts of interest may exist or arise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Anti-takeover provisions in our charter documents and
    under Delaware law could make an acquisition of us, which may be
    beneficial to our stockholders, more difficult and may prevent
    attempts by our stockholders to replace or remove our current
    management and limit the market price of our common
    stock.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Provisions in our certificate of incorporation and bylaws, as
    amended and restated upon the closing of this offering, may have
    the effect of delaying or preventing a change of control or
    changes in our management. Our amended and restated certificate
    of incorporation and amended and restated bylaws to become
    effective upon completion of this offering include provisions
    that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that our directors may be removed only for cause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super-majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These provisions may frustrate or prevent any attempts by our
    stockholders to replace or remove our current management by
    making it more difficult for stockholders to replace members of
    our Board of Directors, which is responsible for appointing the
    members of our management. In addition, because we are
    incorporated in Delaware, we are governed by the provisions of
    Section&#160;203 of the Delaware General Corporation Law, which
    limits the ability of stockholders owning in excess of 15% of
    our outstanding voting stock to merge or combine with us.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have broad discretion in the use of the net proceeds
    from this offering and may not use them effectively.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will have broad discretion in the application of the net
    proceeds from this offering and could spend the proceeds in ways
    that do not improve our results of operations or enhance the
    value of our common stock. Our failure to apply these funds
    effectively could have a material adverse effect on our
    business, delay the development of our product candidates and
    cause the price of our common stock to decline.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have never paid dividends on our capital stock, and we
    do not anticipate paying any cash dividends in the foreseeable
    future.</I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have paid no cash dividends on any of our classes of capital
    stock to date, have contractual restrictions against paying cash
    dividends and currently intend to retain our future earnings to
    fund the development and growth of our business. As a result,
    capital appreciation, if any, of our common stock will be your
    sole source of gain for the foreseeable future.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus includes forward-looking statements that relate
    to future events or our future financial performance and involve
    known and unknown risks, uncertainties and other factors that
    may cause our actual results, levels of activity, performance or
    achievements to differ materially from any future results,
    levels of activity, performance or achievements expressed or
    implied by these forward-looking statements. Words such as, but
    not limited to, &#147;believe,&#148; &#147;expect,&#148;
    &#147;anticipate,&#148; &#147;estimate,&#148;
    &#147;intend,&#148; &#147;plan,&#148; &#147;targets,&#148;
    &#147;likely,&#148; &#147;will,&#148; &#147;would,&#148;
    &#147;could,&#148; and similar expressions or phrases, or the
    negative of those expressions or phrases identify
    forward-looking statements. Although we believe that we have a
    reasonable basis for each forward-looking statement contained in
    this prospectus, we caution you that these statements are based
    on our projections of the future that are subject to known and
    unknown risks and uncertainties and other factors that may cause
    our actual results, level of activity, performance or
    achievements expressed or implied by these forward-looking
    statements, to differ. The sections in this prospectus entitled
    &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and &#147;Business,&#148; as well as other sections in this
    prospectus, discuss some of the factors that could contribute to
    these differences.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other unknown or unpredictable factors also could harm our
    results. Consequently, actual results or developments
    anticipated by us may not be realized or, even if substantially
    realized, may not have the expected consequences to, or effects
    on, us. Given these uncertainties, prospective investors are
    cautioned not to place undue reliance on such forward-looking
    statements. Except as required by law, we undertake no
    obligation to update or revise publicly any of the
    forward-looking statements after the date of this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains market data that we obtained from
    industry sources. These sources do not guarantee the accuracy or
    completeness of the information. Although we believe that the
    industry sources are reliable, we have not independently
    verified the information. The market data include projections
    that are based on a number of other projections. While we
    believe these assumptions to be reasonable and sound as of the
    date of this prospectus, actual results may differ from the
    projections.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that the net proceeds from the sale of
    5,300,000&#160;shares of our common stock that we are selling in
    this offering will be $70.8&#160;million, based on an assumed
    initial public offering price of $15.00 per share, the midpoint
    of the range set forth on the cover page of this prospectus,
    after deducting estimated underwriting discounts and commissions
    and estimated offering expenses payable by us. A $1.00 increase
    (decrease) in the assumed initial public offering price would
    increase (decrease) the net proceeds to us by $4.9&#160;million,
    after deducting estimated underwriting discounts and commissions
    and estimated offering expenses, assuming that the number of
    shares offered by us, as set forth on the cover page of this
    prospectus, remains the same. We may also increase or decrease
    the number of shares we are offering. An increase of
    1.0&#160;million shares in the number of shares offered by us
    would increase the net proceeds to us by $14.0&#160;million.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us would decrease the net proceeds to us by
    $14.0&#160;million. If the underwriters&#146; over-allotment
    option is exercised in full, we estimate that we will receive
    net proceeds of $81.9&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the net proceeds that we will receive from this offering, we
    expect to use approximately:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $26.0&#160;million for sales and marketing initiatives,
    including significantly expanding our sales force, to support
    the ongoing commercialization of our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $16.0&#160;million for research and product development
    activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    $2.0&#160;million to expand our facilities and manufacturing
    operations;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the balance for working capital and other general corporate
    purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may also use a portion of our net proceeds to acquire and
    invest in complementary products, technologies or businesses;
    however, we currently have no agreements or commitments to
    complete any such transaction and are not involved in
    negotiations to do so. Pending these uses, we intend to invest
    our net proceeds from this offering primarily in
    investment-grade, interest-bearing instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the date of this prospectus, we cannot specify with
    certainty all of the particular uses for the net proceeds to be
    received upon the completion of this offering. The amount and
    timing of our expenditures will depend on several factors,
    including cash flows from our operations and the anticipated
    growth of our business. Accordingly, our management will have
    broad discretion in the application of the net proceeds and
    investors will be relying on the judgment of our management
    regarding the application of the proceeds from this offering. We
    reserve the right to change the use of these proceeds as a
    result of certain contingencies such as the results of our
    commercialization efforts, competitive developments,
    opportunities to acquire products, technologies or businesses
    and other factors.
</DIV>
<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have never declared or paid any cash dividends on our capital
    stock. We currently intend to retain all future earnings for the
    operation and expansion of our business and, therefore, we do
    not anticipate declaring or paying cash dividends in the
    foreseeable future. In addition, we are subject to several
    covenants under our debt arrangements that place restrictions on
    our ability to pay dividends. The payment of dividends will be
    at the discretion of our Board of Directors and will depend on
    our results of operations, capital requirements, financial
    condition, prospects, contractual arrangements, any limitations
    on payment of dividends present in our current and future debt
    agreements, and other factors that our Board of Directors may
    deem relevant.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    June&#160;28, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma basis to give effect to (1) the conversion of all
    outstanding shares of convertible preferred stock into common
    stock pursuant to an action by written consent to such
    conversion we have obtained from the holders of our preferred
    stock and (2)&#160;the reclassification of the convertible
    preferred stock warrant liabilities to additional
    <FONT style="white-space: nowrap">paid-in</FONT>
    capital, each effective upon the closing of this
    offering;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma as adjusted basis to also give effect to the pro
    forma conversions and reclassifications described above and the
    sale of 5,300,000&#160;shares of our common stock in this
    offering and the application of the net proceeds at the assumed
    initial public offering price of $15.00 per share, the midpoint
    of the range set forth on the cover page of this prospectus,
    after deducting estimated underwriting discounts and commissions
    and estimated offering expenses payable by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should read this table together with &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; and our consolidated financial statements and
    related notes included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>as
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock issuable in series: $0.0035&#160;par
    value, 17,176&#160;shares authorized, 16,626&#160;shares issued
    and outstanding (actual); no shares authorized, issued or
    outstanding (pro forma and pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common stock: $0.0035&#160;par value, 24,967&#160;shares
    authorized, 2,858&#160;shares issued and outstanding (actual);
    $0.0035 par value, 24,967&#160;shares authorized,
    19,484&#160;shares issued and outstanding (pro forma); $0.001
    par value, 300,000&#160;shares authorized, 24,784&#160;shares
    issued and outstanding (pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Preferred stock: $0.0035 par value, no shares authorized, issued
    or outstanding (actual and pro forma); $0.001 par value,
    20,000&#160;shares authorized, no shares issued or outstanding
    (pro forma as adjusted)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    244,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total stockholders&#146; equity
    (deficit)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
    capitalization<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

    <DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=128 iwidth=455 length=48 -->
</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">A $1.00 increase (decrease) in the
    assumed initial public offering price of $15.00 per share, the
    midpoint of the range set forth on the cover page of this
    prospectus, would increase (decrease) each of additional paid-in
    capital, total stockholders&#146; equity and total
    capitalization by $4.9&#160;million, assuming that the number of
    shares offered by us, as set forth on the cover page of this
    prospectus, remains the same, and after deducting estimated
    underwriting discounts and commissions and estimated offering
    expenses payable by us. Each increase of 1.0&#160;million shares
    in the number of shares offered by us, together with a $1.00
    increase in the assumed offering price of $15.00 per share,
    would increase additional paid-in capital, total
    stockholders&#146; equity and total capitalization by
    approximately $19.8&#160;million. Similarly, each decrease of
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">1.0&#160;million shares in the
    number of shares offered by us, together with a $1.00 decrease
    in the assumed offering price of $15.00 per share, would
    decrease additional paid-in capital, total stockholders&#146;
    equity and total capitalization by approximately
    $17.9&#160;million. The pro forma as adjusted information
    discussed above is illustrative only and will be adjusted based
    on the actual public offering price and terms of this offering
    determined at pricing.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2,373,978&#160;shares of common stock issuable upon exercise of
    options outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $5.44&#160;per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    216,409&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $11.41&#160;per share, after
    conversion of our convertible preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2,601,584&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans, including
    2,000,000&#160;shares of common stock reserved for issuance
    under our 2008 Equity Incentive Plan, and any future increase in
    shares reserved for issuance under such plan, each of which will
    become effective on the date of this prospectus; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    6,785&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of June&#160;28, 2008 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you invest in our common stock, your interest will be diluted
    to the extent of the difference between the amount per share
    paid by purchasers of shares of common stock in this initial
    public offering and the pro forma as adjusted net tangible book
    value per share of common stock immediately after completion of
    this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our pro forma net tangible book value as of June&#160;28, 2008
    in the amount of $23.9&#160;million, or $1.23 per share, was
    based on the total number of shares of our common stock
    outstanding as of June&#160;28, 2008, after giving effect to
    (1)&#160;the conversion of all outstanding shares of our
    convertible preferred stock into common stock and (2)&#160;the
    reclassification of the convertible preferred stock warrant
    liabilities to additional
    <FONT style="white-space: nowrap">paid-in</FONT>
    capital, each effective upon the closing of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After giving effect to our sale of 5,300,000&#160;shares of
    common stock in this offering at an assumed initial public
    offering price of $15.00&#160;per share, the midpoint of the
    range set forth on the cover page of this prospectus, and after
    deducting the estimated underwriting discounts and commissions
    and estimated offering expenses, our pro forma as adjusted net
    tangible book value as of June&#160;28, 2008 would have been
    $94.7&#160;million, or $3.82&#160;per share. This represents an
    immediate increase in net tangible book value of $2.59&#160;per
    share to existing stockholders and an immediate dilution in net
    tangible book value of $11.18&#160;per share to purchasers of
    common stock in this offering, as illustrated in the following
    table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Assumed initial public offering price per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Pro forma net tangible book value per share as of June&#160;28,
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in pro forma as adjusted net tangible book value per
    share attributable to new investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.59
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma as adjusted net tangible book value per share after
    this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma dilution per share to new investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11.18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each $1.00 increase (decrease) in the assumed public offering
    price of $15.00&#160;per share, the midpoint of the range set
    forth on the cover of this prospectus, would increase (decrease)
    our pro forma as adjusted net tangible book value by
    approximately $4.9&#160;million, or approximately $0.20&#160;per
    share, and the pro forma dilution per share to investors in this
    offering by approximately $0.80&#160;per share, assuming that
    the number of shares offered by us, as set forth on the cover
    page of this prospectus, remains the same and after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses payable by us. We may also increase or
    decrease the number of shares we are offering. An increase of
    1.0&#160;million shares in the number of shares offered by us,
    together with a $1.00 increase in the assumed offering price of
    $15.00&#160;per share, would result in a pro forma as adjusted
    net tangible book value of approximately $114.5&#160;million, or
    $4.44&#160;per share, and the pro forma dilution per share to
    investors in this offering would be $11.56&#160;per share.
    Similarly, a decrease of 1.0&#160;million shares in the number
    of shares offered by us, together with a $1.00 decrease in the
    assumed public offering price of $15.00&#160;per share, would
    result in an pro forma as adjusted net tangible book value of
    approximately $76.8&#160;million, or $3.23&#160;per share, and
    the pro forma dilution per share to investors in this offering
    would be $10.77&#160;per share. The pro forma as adjusted
    information discussed above is illustrative only and will be
    adjusted based on the actual public offering price and other
    terms of this offering determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters&#146; over-allotment option is exercised in
    full, the pro forma as adjusted net tangible book value per
    share after this offering would be $4.14&#160;per share, the
    increase in pro forma as adjusted net tangible book value per
    share to existing stockholders would be $2.91&#160;per share and
    the dilution to new investors purchasing shares in this offering
    would be $10.86&#160;per share.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents on a pro forma as adjusted basis as
    of June&#160;28, 2008, after giving effect to the automatic
    conversion of all outstanding shares of convertible preferred
    stock into common stock, the differences between the existing
    stockholders and the purchasers of shares in this offering with
    respect to the number of shares purchased from us, the total
    consideration paid, which includes net proceeds received from
    the issuance of common and convertible preferred stock, cash
    received from the exercise of stock options, the value of any
    stock issued for services and the proceeds from the issuance of
    convertible promissory notes which were subsequently converted
    to shares of convertible preferred stock, and the average price
    paid per share (in thousands, except per share amounts and
    percentages):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Consideration</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Existing stockholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,484
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    78.6
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    170,570
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68.2
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    New investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Totals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,784
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    250,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Each $1.00 increase (decrease) in
    the assumed initial public offering price of $15.00 per share,
    the midpoint of the range set forth on the cover page of this
    prospectus, would increase (decrease) the total consideration
    paid to us by new investors and total consideration paid to us
    by all stockholders by $5.3&#160;million, assuming that the
    number of shares offered by us, as set forth on the cover page
    of this prospectus, remains the same, and after deducting
    estimated underwriting discounts and commissions and estimated
    offering expenses payable by us. An increase of 1.0&#160;million
    shares in the number of shares offered by us would increase the
    total consideration paid to us by new investors and total
    consideration paid to us by all stockholders by
    $15.0&#160;million. Similarly, a decrease of 1.0&#160;million
    shares in the number of shares offered by us would decrease the
    total consideration paid to us by new investors and total
    consideration paid to us by all stockholders by
    $15.0&#160;million.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the underwriters exercise their over-allotment option in
    full, our existing stockholders would own 76.2% and our new
    investors would own 23.8% of the total number of shares of our
    common stock outstanding after this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table above excludes the following shares:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2,373,978&#160;shares of common stock issuable upon exercise of
    options outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $5.44 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    216,409&#160;shares of common stock issuable upon the exercise
    of warrants outstanding as of June&#160;28, 2008 at a weighted
    average exercise price of $11.41 per share, after conversion of
    our convertible preferred stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    2,601,584&#160;shares of common stock reserved for future
    issuance under our stock-based compensation plans, including
    2,000,000&#160;shares of common stock reserved for issuance
    under our 2008 Equity Incentive Plan, and any future increase in
    shares reserved for issuance under such plan, each of which will
    become effective on the date of this prospectus; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    6,785&#160;shares of common stock that were legally issued and
    outstanding but were not included in stockholders&#146; deficit
    as of June&#160;28, 2008 pursuant to accounting principles
    generally accepted in the United States, as these shares were
    subject to a right of repurchase by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the extent that any of these options or warrants are
    exercised, new options are issued under our stock-based
    compensation plans or we issue additional shares of common stock
    in the future, there will be further dilution to investors
    participating in this offering.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='108'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have derived the selected consolidated statement of
    operations data for the years ended December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007 and the
    selected consolidated balance sheet data as of December&#160;31,
    2006 and December&#160;29, 2007 from our audited consolidated
    financial statements included elsewhere in this prospectus. We
    have derived the summary consolidated statement of operations
    data for the six months ended June&#160;30, 2007 and
    June&#160;28, 2008 and the consolidated balance sheet data as of
    June&#160;28, 2008 from our unaudited consolidated financial
    statements included elsewhere in this prospectus. We have
    derived the selected consolidated statement of operations data
    for the years ended December&#160;31, 2003 and 2004 and the
    selected consolidated balance sheet data as of December&#160;31,
    2003, 2004 and 2005 from our audited consolidated financial
    statements not included in this prospectus. Our historical
    results are not necessarily indicative of the results to be
    expected for any future period. The following selected
    consolidated financial data should be read in conjunction with
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#148; and our consolidated
    financial statements and related notes included elsewhere in
    this prospectus.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom">
    <B>(in thousands, except per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,603
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    366
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,039
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,690
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,266
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,621
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,462
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (305
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (214
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before provision for income taxes and cumulative of change
    in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,917
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,219
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,838
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss per share of common stock, basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (7.77
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.93
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (9.21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Shares used in computing net loss per share of common stock,
    basic and
    diluted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,227
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Please see Note&#160;2 to our
    consolidated financial statements for an explanation of the
    method used to calculate basic and diluted net loss per share of
    common stock.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2003</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2004</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,518
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,363
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,710
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,644
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    814
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total stockholder&#146;s deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,812
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT&#146;S
    DISCUSSION AND ANALYSIS OF<BR>
    FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following discussion and analysis of the financial
    condition and results of our operations should be read in
    conjunction with the consolidated financial statements and
    related notes included elsewhere in this prospectus. This
    discussion contains forward-looking statements that involve
    risks and uncertainties. Our actual results could differ
    materially from those discussed below. Factors that could cause
    or contribute to such differences include, but are not limited
    to, those identified below, and those discussed in the section
    titled &#147;Risk Factors&#148; included elsewhere in this
    prospectus.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, enable the simultaneous performance of thousands of
    biochemical measurements in extremely minute volumes. We created
    this &#147;integrated circuit for biology&#148; by
    miniaturizing, integrating and automating sophisticated liquid
    handling processes on a single microfabricated device.
    Particularly in large-scale experimentation, our IFC systems,
    consisting of instrumentation, software and single-use IFCs,
    increase throughput, decrease costs and enhance sensitivity
    compared to conventional laboratory systems. We have sold our
    IFCs to over 100 customers, including many leading biotechnology
    and pharmaceutical companies, academic institutions, and life
    science laboratories worldwide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products to help achieve
    breakthroughs in the fields of genetic variation, cellular
    function and structural biology. We believe that the broad
    applicability of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including high-throughput DNA sequencing and
    molecular diagnostics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We were founded in 1999. In the first quarter of 2003, we
    introduced our first product line, the Topaz system for protein
    crystallization based on our first generation Topaz IFC. In
    subsequent years, we enhanced the capability of the Topaz system
    by introducing IFCs with increased throughput. Prior to 2007,
    Topaz system products accounted for substantially all of our
    product revenue. In the fourth quarter of 2006, we announced the
    commercial availability of our BioMark system. We currently sell
    two types of single-use IFCs for use with the BioMark system,
    the Dynamic Array for gene expression and genotyping and the
    Digital Array for digital PCR.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have incurred significant losses since our inception,
    including net losses of $16.4&#160;million, $23.6&#160;million,
    $25.5&#160;million and $15.3&#160;million in 2005, 2006, 2007
    and the six months ended June&#160;28, 2008. As of June&#160;28,
    2008, we had an accumulated deficit of $149.1&#160;million. We
    sell our IFC systems around the world. For 2007 and the six
    months ended June&#160;28, 2008, customers in North America
    accounted for approximately 48% and 46% of our total revenue,
    European customers accounted for 10% and 17% and Asia-Pacific
    customers accounted for 42% and 37%. We distribute our systems
    through our direct field sales and support organizations located
    in North America, Europe and Asia-Pacific and through
    distributors or sales agents in several European and
    Asia-Pacific countries. Our manufacturing operations are located
    in Singapore and South San&#160;Francisco. Our facility in
    Singapore fabricates all of our IFCs for commercial sale and
    some IFCs for our own research and development purposes and
    assembles certain elements of our BioMark and Topaz
    instrumentation. Our South San&#160;Francisco facility also
    assembles certain elements of our BioMark and Topaz
    instrumentation and fabricates IFCs for our own research and
    development purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since 2002, we have received significant revenue from government
    grants. Our most significant grant relationship has been with
    the Singapore Economic Development Board, or EDB. The EDB, an
    agency of the Government of Singapore, promotes research,
    development and manufacturing activities in Singapore and
    associated employment of Singapore nationals by providing
    incentive grants to companies willing to conduct operations in
    Singapore and satisfy the requirements of EDB&#146;s government
    programs. Under our agreements with EDB, we are eligible to
    receive incentive grant payments from EDB, provided we satisfy
    agreed upon targets for increasing levels of research,
    development and manufacturing activity in Singapore, including
    the use of local service providers, the hiring of personnel in
    Singapore, local spending in Singapore, our receipt of new
    equity investment, and our achievement of agreed upon targets
    relating to new product development or completion of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    specific manufacturing process objectives. If we satisfy the
    grant conditions, we receive incentive grant payments equal to a
    portion of the qualifying expenses we incur in Singapore,
    relating to salaries, overhead, outsourcing and subcontracting
    expenses, operating expenses and royalties paid. Expenses not
    qualifying for the incentive grant program include raw materials
    purchases. We submit requests to EDB for incentive grant
    payments on a quarterly basis, and these requests are subject to
    EDB&#146;s review and our satisfaction of the grant conditions.
    Together these agreements provide for incentive funding
    eligibility through 2011, subject to our compliance with the
    requirements of these agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we have entered into collaboration and license
    agreements with other parties that generally provide us with
    up-front and periodic milestone fees or fees based on agreed
    upon rates for time incurred by our research staff.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year Presentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the year ended December&#160;29, 2007, we adopted a 52 or
    53&#160;week year convention for our fiscal years and,
    therefore, our 2007 fiscal year ended on December&#160;29, 2007
    and the first six month periods of 2007 and 2008 ended on
    June&#160;30, 2007 and June&#160;28, 2008. Future fiscal years
    will end on the last Saturday in December of each year. Prior to
    the adoption of this method, we reported our fiscal years on a
    calendar basis. The fiscal years discussed in this
    management&#146;s discussion and analysis of financial condition
    and results of operations ended on December&#160;31, 2005,
    December&#160;31, 2006 and December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies, Significant Judgments and
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our consolidated financial statements and the related notes
    included elsewhere in this prospectus are prepared in accordance
    with accounting principles generally accepted in the United
    States. The preparation of these consolidated financial
    statements requires us to make estimates and assumptions that
    affect the reported amounts of assets, liabilities, revenues,
    costs and expenses and related disclosures. We base our
    estimates on historical experience and on various other
    assumptions that we believe to be reasonable under the
    circumstances. Changes in the accounting estimates are
    reasonably likely to occur from period to period. Accordingly,
    actual results could differ significantly from the estimates
    made by our management. We evaluate our estimates and
    assumptions on an ongoing basis. To the extent that there are
    material differences between these estimates and actual results,
    our future financial statement presentation, financial
    condition, results of operations and cash flows will be affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following critical accounting policies
    involve a greater degree of judgment and complexity than our
    other accounting policies. Accordingly, these are the policies
    we believe are the most critical to understanding and evaluating
    our consolidated financial condition and results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products and services,
    collaboration agreements and government grants. Our products
    consist of single-use IFCs, various instruments and software
    related to our BioMark and Topaz systems. Our services include
    system installation, training and customer support services. We
    also have entered into a number of research and development
    contracts and have received government grants to conduct
    research and development activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record revenue in accordance with the guidelines established
    by the Securities and Exchange Commission, or SEC, Staff
    Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition</I>, or SAB&#160;104. In addition, we have concluded
    that software included with certain of our instruments is
    essential to their functionality. In these instances, we apply
    AICPA Statement of Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition</I>, or
    <FONT style="white-space: nowrap">SOP&#160;97-2.</FONT>
    If the arrangement includes IFCs, we use the separation criteria
    in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables, </I>to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables.
    Revenue is recognized when all of the following criteria are
    met: persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the price to the buyer is fixed
    or determinable and collectibility is reasonably assured. The
    evaluation of these revenue recognition criteria requires
    significant management judgment. For instance, we use judgment
    to assess collectibility based on factors such as the
    customer&#146;s creditworthiness and past collection history, if
    applicable. If we determine that collection of a payment is not
    reasonably assured, revenue
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    recognition is deferred until the time collection becomes
    reasonably assured, which is generally upon receipt of payment.
    We also use judgment to assess whether a price is fixed or
    determinable by reviewing contractual terms and conditions
    related to payment terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, and thereafter, no right of return existed for our
    products. In prior years, if an agreement included a right of
    return, the related revenue was deferred until the right had
    lapsed. Historically, we have not experienced any significant
    returns of our products. Also, accruals are provided for
    estimated warranty expenses at the time that the associated
    revenue is recognized. We use judgment to estimate these
    accruals and, if we were to experience an increase in warranty
    claims or if costs of servicing our products under warranty were
    greater than our estimates, our gross margins could be adversely
    affected in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some of our sales contracts which include items such as our
    BioMark instrument systems or our Topaz readers involve the
    delivery or performance of multiple products and services within
    contractually binding arrangements. Significant contract
    interpretation is sometimes required to determine the
    appropriate accounting, including whether the deliverables
    specified in a multiple element arrangement should be treated as
    separate units of accounting for revenue recognition purposes,
    and, if so, how the price should be allocated among the
    elements, when to recognize revenue for each element, and the
    period over which revenue should be recognized. We use judgment
    to evaluate whether a delivered item has value on a stand-alone
    basis prior to delivery of the remaining items by determining
    whether we have made separate sales of such items or whether the
    undelivered items are essential to the functionality of the
    delivered items. Further, we use judgment to evaluate whether
    there is vendor-specific objective evidence, or VSOE, of fair
    value of the undelivered items, determined by reference to
    stand-alone sales of such items. We recognize revenue for
    delivered elements only when we determine that the fair values
    of undelivered elements are known. For a multiple element
    arrangement that includes both IFCs and instruments we separate
    these elements into separate units of accounting as we consider
    these elements to have standalone value to the customer. We
    recognize revenue for the IFCs under SAB&#160;104 and the
    instruments under SAB&#160;104 or
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    as applicable. If the fair value of any undelivered item related
    to instruments and software included in a multiple element
    arrangement cannot be objectively determined, revenue will be
    deferred until all items are delivered, or until fair value can
    objectively be determined for any remaining undelivered items.
    However, if the only such undelivered element is post-contract
    customer support services, such as maintenance agreements for
    which VSOE has not been established, the entire revenue is
    recognized ratably over the service period. Recognition of
    revenue from these arrangements generally begins upon
    installation of the instruments as installation is deemed
    essential to the functionality of the instruments. The
    corresponding costs of products sold related to multiple element
    arrangements are also deferred and amortized over the same
    period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our deferred revenue balance increased by $1.6&#160;million
    during 2007 and decreased by $0.3&#160;million during the six
    months ended June&#160;28, 2008. The increase during 2007 was
    primarily due to the increase in sales of our BioMark instrument
    systems, all of which included maintenance agreements. We expect
    to establish VSOE for post-contract customer support during the
    second half of 2008 as we enter into renewal agreements for
    maintenance with our customers upon the expiration of the
    initial agreements. If we are able to establish VSOE for
    post-contract customer support, our deferred revenue balance
    will decrease in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes in judgments and estimates regarding application of
    these revenue recognition guidelines as well as changes in facts
    and circumstances including the establishment of VSOE of fair
    value could result in a change in the timing or amount of
    revenue recognized in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue from the sales of our products that are not part of a
    multiple element arrangement is recognized when no significant
    obligations remain undelivered and collection of the receivables
    is reasonably assured, which is generally upon shipment of the
    product and transfer of title to the customer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into collaboration research and development
    arrangements that generally provide us with up-front and
    periodic milestone fees or fees based on agreed upon rates for
    time incurred by our research staff. Revenue is recognized
    either ratably over the term of the agreement or as time is
    incurred on the project. Revenue from government grants is for
    the achievement of agreed upon milestones and expenditures and
    is recognized in the period in which the related costs are
    incurred, provided that the conditions under which the
    government grants are awarded have been substantially met and
    only perfunctory obligations remain outstanding.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, we accounted for our stock
    options granted to employees using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees</I>, or APB 25, and
    related interpretations as permitted by Statement of Financial
    Accounting Standards, or SFAS&#160;No.&#160;123, <I>Accounting
    for Stock-Based Compensation</I>, or SFAS&#160;123, and
    SFAS&#160;No.&#160;148, <I>Accounting for Stock-Based
    Compensation&#160;&#151; Transaction and Disclosure</I>, or
    SFAS&#160;148. Accordingly, any compensation cost relating to
    stock options was recorded on the date of the grant in
    stockholders&#146; equity as deferred compensation and was
    thereafter amortized to expense over the vesting period of the
    grant, which was generally four years. We amortized deferred
    stock-based compensation using the multiple option method as
    prescribed by FASB Interpretation No.&#160;28, <I>Accounting for
    Stock Appreciation Rights and Other Variable Stock Option or
    Award Plans</I>, or FIN&#160;28, over the option vesting period
    using an accelerated amortization schedule.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, we adopted the fair value
    recognition provisions of SFAS&#160;No.&#160;123 (revised 2004),
    <I>Share-Based Payment</I>, or SFAS&#160;123(R), which requires
    companies to measure the cost of employee services received in
    exchange for an award of equity instruments, including stock
    options, based on the grant date fair value of the award. The
    fair value is estimated using the Black-Scholes option-pricing
    model. The resulting cost is recognized over the period during
    which an employee is required to provide service in exchange for
    the award, usually the vesting period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted SFAS&#160;123(R) using the prospective-transition
    method as all prior grants were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;123. The prospective-transition method requires us to
    continue to apply APB 25 in future periods to equity awards
    outstanding at the date of our adoption of SFAS&#160;123(R) on
    January&#160;1, 2006. Under the prospective-transition method,
    any compensation costs that will be recognized from
    January&#160;1, 2006 will include only: (a)&#160;compensation
    cost for all stock-based awards granted prior to, but not yet
    vested as of, December&#160;31, 2005, based on the intrinsic
    value method in accordance with the provisions of ABP 25; and
    (b)&#160;compensation cost for all stock-based awards granted or
    modified subsequent to December&#160;31, 2005, net of estimated
    forfeitures, based on the grant date fair value estimated in
    accordance with the provisions of SFAS&#160;123(R). We amortize
    the fair value of stock-based compensation under
    SFAS&#160;123(R) on a straight-line basis. In accordance with
    the prospective-transition method as prescribed under
    SFAS&#160;123(R), results for prior periods are not restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for stock options issued to nonemployees in
    accordance with the provisions of SFAS 123(R) and EITF Issue No.
    96-18, <I>Accounting for Equity Instruments That Are Issued to
    Other Than Employees for Acquiring, or in Conjunction with
    Selling, Goods or Services,</I> or EITF
    <FONT style="white-space: nowrap">96-18.</FONT> In
    accordance with SFAS 123(R) and EITF
    <FONT style="white-space: nowrap">96-18,</FONT> stock
    options issued to nonemployees are accounted for at their
    estimated fair value determined using the Black-Scholes
    option-pricing model. The fair value of the options granted to
    nonemployees is remeasured as they vest, and the resulting
    increase in value, if any, is recognized as expense during the
    period the related services are rendered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We use the Black-Scholes option-pricing model to calculate the
    fair value of our options on the grant date. This model requires
    inputs such as expected term, expected volatility and risk-free
    interest rate. Further, the forfeiture rate also affects the
    amount of aggregate compensation. These inputs are subjective
    and generally require significant judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our expected volatility is derived from the historical
    volatilities of several unrelated public companies within the
    life science industry because we have little information on the
    volatility of the price of our common stock since we have no
    trading history. When making the selections of our industry peer
    companies to be used in the volatility calculation, we also
    considered the stage of development, size and financial leverage
    of potential comparable companies. Our historical volatility is
    weighted based on certain qualitative factors and combined to
    produce a single volatility factor. The risk-free interest rate
    is based on the U.S.&#160;Treasury yield in effect at the time
    of grant for zero coupon U.S.&#160;Treasury notes with
    maturities approximately equal to each grant&#146;s expected
    life. Given our limited history to accurately estimate the
    expected lives for the various employee groups, we used the
    &#145;simplified&#146; method as provided by Staff Accounting
    Bulletin&#160;No.&#160;107, <I>Share Based Payment</I>. The
    &#145;simplified&#146; method is calculated as the average of
    the
    <FONT style="white-space: nowrap">time-to-vesting</FONT>
    and the contractual life of the options.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning on January&#160;1, 2006 upon the adoption of
    SFAS&#160;123(R), the fair value of each new employee option
    awarded was estimated on the grant date for the periods below
    using the Black-Scholes option-pricing model with the following
    weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="15%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Six Months Ended<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28,&#160;2008</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    53.8%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If in the future we determine that another method is more
    reasonable, or if another method for calculating these input
    assumptions is prescribed by authoritative guidance, and,
    therefore, should be used to estimate expected volatility or
    expected life, the fair value calculated for our stock options
    could change significantly. Higher volatility and longer
    expected lives result in an increase to stock-based compensation
    expense determined at the date of grant. Stock-based
    compensation expense affects our cost of revenue, research and
    development expense, and selling, general and administrative
    expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate our forfeiture rate based on an analysis of our
    actual forfeitures and will continue to evaluate the
    appropriateness of the forfeiture rate based on actual
    forfeiture experience, analysis of employee turnover behavior
    and other factors. Quarterly changes in the estimated forfeiture
    rate can have a significant effect on reported stock-based
    compensation expense, as the cumulative effect of adjusting the
    rate for all expense amortization is recognized in the period
    the forfeiture estimate is changed. If a revised forfeiture rate
    is higher than the previously estimated forfeiture rate, an
    adjustment is made that will result in a decrease to the
    stock-based compensation expense recognized in the consolidated
    financial statements. If a revised forfeiture rate is lower than
    the previously estimated forfeiture rate, an adjustment is made
    that will result in an increase to the stock-based compensation
    expense recognized in the consolidated financial statements. The
    effect of forfeiture adjustments during 2006, 2007 and the six
    months ended June&#160;28, 2008 was insignificant. We will
    continue to use judgment in evaluating the expected term,
    volatility and forfeiture rate related to our own stock-based
    compensation on a prospective basis and incorporating these
    factors into the Black-Scholes option-pricing model.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Also required for the fair value calculation of the options is
    the fair value of the underlying common stock. We have
    historically granted stock options with exercise prices no less
    than the fair market value of our common stock as determined at
    the date of grant by our Board of Directors with input from
    management. The following table summarizes, by grant date, the
    number of stock options granted since January&#160;1, 2007 and
    the associated per share exercise price, which equaled the fair
    value of our common stock for each of these grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93,705
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;7, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,709
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    April&#160;24, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    546,711
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11.16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    June&#160;26, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,426
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11.97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Given the absence of an active market for our common stock prior
    to this offering, our Board of Directors determined the fair
    value of our common stock for our grants of stock options. Our
    Board of Directors determined the estimated fair value of our
    common stock based in part on an analysis of relevant metrics,
    including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the prices of our convertible preferred stock sold to outside
    investors in arms-length transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights, preferences and privileges of our convertible
    preferred stock relative to those of our common stock;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights of freestanding warrants and other similar
    instruments related to shares that are redeemable;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our operating and financial performance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of key personnel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the introduction of new products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our stage of development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the fact that the option grants involve illiquid securities in a
    private company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks inherent in the development and expansion of our
    products and services;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the likelihood of achieving a liquidity event, such as an
    initial public offering or sale of our company given prevailing
    market conditions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From January&#160;2007 through June&#160;2008, our Board of
    Directors performed contemporaneous valuations of our common
    stock for each grant of stock options during this period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The valuations were prepared using the market approach and the
    income approach to estimate our aggregate enterprise value at
    each valuation date. The market approach measures the value of a
    company through the analysis of recent sales of comparable
    companies. Consideration is given to the financial condition and
    operating performance of the company being valued relative to
    those of publicly traded companies operating in the same or
    similar lines of business. When choosing the comparable
    companies to be used for the market approach, we focused on
    companies in the life science industry. Some of the specific
    criteria used to select comparable companies within this
    industry include the business description, business size,
    projected growth, financial condition and historical earnings.
    The income approach measures the value of a company as the
    present value of its future economic benefits by applying an
    appropriate risk-adjusted discount rate to expected cash flows,
    based on forecasted revenue and costs. We prepared a financial
    forecast for each valuation report to be used in the computation
    of the enterprise value for both the market approach and the
    income approach. The financial forecasts took into account our
    past experience and future expectations. The risks associated
    with achieving these forecasts were assessed in selecting the
    appropriate discount rate. There is inherent uncertainty in
    these estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In assessing the fair value of our common stock, our Board of
    Directors applied an equal weighting to the value indications
    presented by the income approach and market approach. In order
    to arrive at the estimated fair value of our common stock, the
    indicated enterprise value of our company calculated at each
    valuation date was allocated to the shares of convertible
    preferred stock and the warrants to purchase these shares, and
    shares of common stock and the options to purchase these shares
    using an option-pricing methodology. The option-pricing method
    treats common stock and preferred stock as call options on the
    total equity value of a company, with exercise prices based on
    the value thresholds at which the allocation among the various
    holders of a company&#146;s securities changes. Under this
    method, the common stock has value only if the funds available
    for distribution to stockholders exceed the value of the
    liquidation preference at the time of a liquidity event, such as
    a strategic sale, merger or initial public offering, assuming
    the enterprise has funds available to make a liquidation
    preference meaningful and collectable by the holders of
    preferred stock. The common stock is modeled as a call option on
    the underlying equity value at a predetermined exercise price.
    In the model, the exercise price is based on a comparison with
    the total equity value rather than, as in the case of a regular
    call option, a comparison with a per share stock price. Thus,
    common stock is considered to be a call option with a claim on
    the enterprise at an exercise price equal to the remaining value
    immediately after the preferred stock is liquidated. The
    option-pricing method uses the Black-Scholes option-pricing
    model to price the call options. This model defines the
    securities&#146; fair values as functions of the current fair
    value of a company and uses assumptions such as the anticipated
    timing of a potential liquidity event and the estimated
    volatility of the equity securities. The anticipated timing of a
    liquidity event utilized in these valuations was based on
    then-current plans and estimates of our Board of Directors and
    management regarding a liquidity event. Estimates of the
    volatility of our stock were based on available information on
    the volatility of capital stock of comparable publicly traded
    companies. This approach is consistent with the methods outlined
    in the AICPA Practice Guide, <I>Valuation of
    Privately-Held-Company Equity Securities Issued as
    Compensation</I>. Also, we considered the fact that our
    stockholders cannot freely trade our common stock in the public
    markets. Therefore, the estimated fair value of our common stock
    at each grant date reflected a non-marketability discount.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is inherent uncertainty in these estimates and if we had
    made different assumptions than those described above, the
    amount of our stock-based compensation expense, net loss and net
    loss per share amounts could have been significantly different.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors performed a contemporaneous valuation in
    order to determine the fair value of our common stock for the
    grant of options on May&#160;8, 2007 which indicated a fair
    value of $4.76 per share for our common stock. Our Board of
    Directors performed a second contemporaneous valuation in order
    to update the determination of the fair value of our common
    stock for the grant of options on September&#160;20, 2007 which
    indicated a fair value of $4.83 per share for our common stock.
    The increase in the fair value between the contemporaneous
    valuation performed for the grant of options on May&#160;8, 2007
    and the date of this contemporaneous valuation was minimal,
    however, it relates mostly to a slight decrease in the
    non-marketability discount rate and the time to a liquidity
    event. Our Board of Directors performed another contemporaneous
    valuation in order to update the determination of the fair value
    of our common stock for the grant of options on
    December&#160;28, 2007 which indicated a fair value of $8.40 per
    share for our common stock. The increase in the fair value
    between the contemporaneous valuation performed for the grant of
    options on September&#160;20, 2007 and December&#160;28, 2007
    valuation relates mostly to the decrease in the
    non-marketability discount rate, the risk-adjusted discount and
    the time to a liquidity event. Our Board of Directors performed
    contemporaneous valuations in order to update the determination
    of the fair value of our common stock for the grant of options
    on April&#160;24, 2008, which indicated a fair value of $11.16
    per share for our common stock, and for the grant of options on
    June&#160;26, 2008, which indicated a fair value of $11.97 per
    share for our common stock. The increase in fair value between
    the contemporaneous valuation performed for the grant of options
    on December&#160;28, 2007 and April&#160;24, 2008 relates
    primarily to the increase in our enterprise value as we moved
    closer to achieving our projected financial goals, achieved
    significant milestones in new product developments and expanded
    into new market applications. In addition, in April&#160;2008,
    our Board of Directors approved the filing of a registration
    statement for the initial public offering of our common stock.
    The increase in fair value between the contemporaneous valuation
    performed for the grant of options on April&#160;24, 2008 and
    June&#160;26, 2008 relates to the increase in our enterprise
    value reflecting continued progression toward achieving our
    projected financial goals, significant new product launches and
    geographical expansion of our sales capabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We recorded stock-based compensation of $5,000,
    $0.1&#160;million, $0.7&#160;million and $1.0&#160;million
    during 2005, 2006, 2007 and the six months ended June&#160;28,
    2008. Included in these amounts was employee stock-based
    compensation of $0, $0.1 million, $0.5&#160;million and
    $0.9&#160;million, and nonemployee stock-based compensation of
    $5,000, $59,000, $0.2&#160;million and $0.1 million during 2005,
    2006, 2007 and the six months ended June&#160;28, 2008. In
    future periods, stock-based compensation expense is expected to
    increase as a result of our existing unrecognized stock-based
    compensation and as we issue additional stock-based awards to
    continue to attract and retain employees and nonemployee
    directors. Certain of our stock options are granted to officers
    with vesting acceleration features based upon the achievement of
    certain performance milestones. The timing of the attainment of
    these milestones may affect the timing of expense recognition
    under SFAS No.&#160;123(R). Additionally, SFAS&#160;123(R)
    requires that we recognize compensation expense only for the
    portion of stock options that are expected to vest. If the
    actual rate of forfeitures differs from that estimated by
    management, we may be required to record adjustments to
    stock-based compensation expense in future periods. As of
    December&#160;29, 2007 and June&#160;28, 2008, we had
    $1.7&#160;million and $5.1&#160;million of unrecognized
    stock-based compensation costs related to stock options granted
    under our 1999 Stock Option Plan, which is expected to be
    recognized over an average period of 2.9 years for both periods.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for Income Taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant management judgment is required in determining our
    provision for income taxes, our deferred tax assets and
    liabilities and any valuation allowance recorded against our net
    deferred tax assets. We have recorded a full valuation allowance
    on our net deferred tax assets as of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008 due to
    uncertainties related to our ability to utilize our deferred tax
    assets in the foreseeable future. These deferred tax assets
    primarily consist of certain net operating loss carryforwards
    and research and development tax credits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted FASB Interpretation No.&#160;48, <I>Accounting for
    Uncertainties in Income Taxes&#160;&#151; an interpretation of
    FASB Statement No.&#160;109</I>, or FIN&#160;48, effective
    January&#160;1, 2007. FIN&#160;48 requires us to recognize the
    financial statement effects of a tax position when it is more
    likely than not, based on the technical merits, that the
    position will
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    be sustained upon examination. Upon adoption, the Company
    recorded a charge of $75,000 as a cumulative effect of a change
    in accounting principle in the accumulated deficit during 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Inventory
    Valuation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We record adjustments to inventory for potentially excess,
    obsolete or impaired goods in order to state inventory at net
    realizable value. The business environment in which we operate
    is subject to rapid changes in technology and customer demand.
    We regularly review inventory for excess and obsolete products
    and components, taking into account product life cycle and
    development plans, product expiration and quality issues,
    historical experience and our current inventory levels. If
    actual market conditions are less favorable than anticipated,
    additional inventory adjustments could be required.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Warrants
    to Purchase Convertible Preferred Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for freestanding warrants related to shares that are
    redeemable in accordance with FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares&#160;That Are Redeemable</I>, or
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase shares of our convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets at fair value because the warrants
    may conditionally obligate us to transfer assets at some point
    in the future. The warrants are subject to remeasurement at each
    balance sheet date, and any change in fair value will be
    recognized as a component of other income (expense), net in the
    consolidated statements of operations. We estimated the fair
    value of these warrants at the respective balance sheet dates
    using the Black-Scholes option-pricing model. A number of our
    assumptions used in the
    <FONT style="white-space: nowrap">Black-Scholes</FONT>
    <FONT style="white-space: nowrap">option-pricing</FONT>
    model, especially the market value and the expected volatility,
    are highly judgmental and could differ materially in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will continue to record adjustments to the fair value of the
    warrants until they are exercised, expire or, upon the closing
    of this offering, become warrants to purchase shares of our
    common stock, wherein the warrants will no longer be subject to
    <FONT style="white-space: nowrap">FSP&#160;150-5.</FONT>
    At that time, the then-current aggregate fair value of these
    warrants will be reclassified from current liabilities to
    additional paid-in capital, a component of stockholders&#146;
    equity, and we will cease to record any related periodic fair
    value adjustments. Upon the closing of this offering, the
    preferred stock warrants will be converted into common stock
    warrants with the same exercise prices and expiration dates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Results
    of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our revenue by source for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Grant revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generate revenue from sales of our products, collaboration
    agreements and government grants. Our products consist of
    single-use IFCs, various instruments, software and service
    related to our BioMark and Topaz systems. We also have entered
    into a number of research and development contracts and have
    received government grants to conduct research and development
    activities.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Total
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total revenue increased $2.5&#160;million, or 84%, for the
    six months ended June&#160;28, 2008 compared to the six months
    ended June&#160;30, 2007. Total revenue increased
    $0.9&#160;million, or 14%, for 2007 as compared to 2006, and
    decreased by $1.3&#160;million, or 17%, for 2006 as compared to
    2005. Total revenue from our five largest customers comprised
    48%, 56%, 47% and 37% of revenue in 2005, 2006, 2007 and the six
    months ended June&#160;28, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand our business through Europe and Asia, we expect our
    sales from outside of North America to increase as a percentage
    of our revenue. The following table presents our revenue by
    geography based on the billing address of our customers for each
    period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="27%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,027
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive product revenue from sales to biotechnology and
    pharmaceutical companies, academic institutions and life science
    laboratories worldwide. These sales are generally made through
    direct sales personnel to customers in North America, Asia
    Pacific and most of Europe and through distributors in parts of
    Europe and the Asia-Pacific region.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue increased by $2.9 million, or 194%, for the six
    months ended June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. Revenue from our BioMark instrument systems
    and related IFCs increased by $2.4&#160;million, and revenue
    from our Topaz instrument systems and related IFCs increased by
    $0.5 million. We sold 10 BioMark instrument systems and
    5&#160;Topaz instrument systems in the six months ended
    June&#160;28, 2008 compared to 6 BioMark instrument systems and
    6 Topaz instrument systems in the six months ended June&#160;30,
    2007. Our deferred product revenue balance decreased from
    $2.7&#160;million as of December&#160;29, 2007 to
    $2.6&#160;million as of June&#160;28, 2008 and increased from
    $0.6&#160;million as of December 31, 2006 to $2.0&#160;million
    as of June 30, 2007. We recognized $1.8 million of the deferred
    product revenue balance as of December&#160;29, 2007 during the
    six months ended June&#160;28, 2008 and $0.3 million of the
    deferred product revenue balance as of December&#160;31, 2006
    during the six months ended June&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Product revenue for 2007 increased by $0.5&#160;million, or 12%,
    compared to 2006. Revenues from our BioMark instrument systems
    and related IFCs which were introduced in late 2006 increased by
    $1.3&#160;million, as we sold 14 BioMark instrument systems
    during 2007 compared to three BioMark instrument systems during
    2006. This increase, however, was mostly offset by a decrease of
    $1.2&#160;million related to a decrease in the sales of our
    Topaz IFCs. The unit sales of our Topaz instrument systems
    remained constant as we sold 10 Topaz instrument systems during
    both 2006 and 2007. In addition, our deferred product revenue
    balance increased from $0.6&#160;million at December&#160;31,
    2006 to $2.7&#160;million at December&#160;29, 2007 as we sold
    more BioMark instrument systems as part of multiple element
    arrangements for which we did not have VSOE on post-contract
    support. We recognized $0.4&#160;million of the deferred product
    revenue balance at December&#160;31, 2006 during 2007. We expect
    the current portion of our deferred product revenue balance as
    of December&#160;29, 2007 in the amount of $2.3&#160;million
    will be recognized as product revenue during 2008. Product
    revenue for 2006 decreased by $2.1&#160;million, or 35%, when
    compared to 2005. The decrease was primarily due to a decrease
    in the sales of our Topaz instrument systems as we sold 10 Topaz
    instrument systems during 2006 compared to 16 Topaz instrument
    systems during 2005; however, sales of our Topaz IFCs remained
    relatively consistent with 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The increase in sales of our BioMark instrument systems in 2007
    and the concurrent decrease in sales of our Topaz systems
    reflect the refocusing of our product development and sales and
    marketing efforts, beginning in
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2005, to focus on the larger markets served by our BioMark
    instrument systems. Since then, we have reduced new Topaz
    product introductions. We will continue to manufacture and sell
    our Topaz instrument systems and IFCs and we expect unit sales
    of Topaz instrument systems and IFCs in 2008 and future periods
    to be consistent with or slightly lower than the 2006 and 2007
    levels. We expect unit sales of our BioMark instrument systems
    and IFCs to increase in 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments from third parties under research and
    development contracts. Fixed-fee research and development
    contracts generally provide us with up-front and periodic
    milestone-based fees. Variable-fee research and development
    contracts generally provide us with fees based on an
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    rate for time incurred by our research staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Collaboration revenue decreased $0.2&#160;million, or 77%, for
    the six months ended June&#160;28, 2008 compared to the six
    months ended June&#160;30, 2007. The decrease relates to the
    completion of one of our development agreements in the first
    quarter of 2007. Collaboration revenue for 2007 decreased by
    $0.9&#160;million, or 67%, compared to 2006. This decrease was
    primarily due to the completion of one of our collaboration
    agreements during 2006 that accounted for $1.0&#160;million of
    our 2006 collaboration revenue. Collaboration revenue for 2006
    decreased by $0.2&#160;million, or 12%, compared to 2005. The
    decrease was primarily due to the termination of one of our
    collaboration agreements in December 2005. We expect
    collaboration revenue to continue to decrease due to the
    completion of our current collaboration agreements during 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive payments in the form of grants from certain
    government entities. Government grants are agreements that
    generally provide incentive grant payments for specified
    research and development activities over a contractually defined
    period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Grant revenue decreased $0.1&#160;million, or 11%, for the six
    months ended June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. The decrease relates to the reduction in
    activity for the National Institutes of Health, or NIH, grant
    agreement that terminated in June&#160;2008. Grant revenue for
    2007 increased by $1.3&#160;million, or 122%, when compared to
    2006, and our grant revenue for 2006 increased by
    $1.0&#160;million when compared to 2005. These increases were
    primarily due to the addition of a grant from the NIH, which was
    entered into in June 2006, and grants from EDB, which were
    entered into in October 2005 and February 2007. We recognized
    revenue from the 2005 EDB grant in the amount of
    $0.9&#160;million during 2006,  $1.1&#160;million during 2007
    and $0.6&#160;million for the six months ended June&#160;28,
    2008. In addition, we recognized revenue in the amount of
    $0.6&#160;million during 2007 and $0.2&#160;million during the
    six months ended June&#160;28, 2008 from the 2007 EDB grant.
    Under our incentive grant agreements with EDB, eligible expenses
    incurred by us in Singapore were $4.0&#160;million in 2006,
    $4.5&#160;million in 2007 and $1.9&#160;million in the six
    months ended June&#160;28, 2008. Also, we recognized revenue
    from the NIH grant in the amount of $0.2&#160;million during
    2006 and $0.6&#160;million during 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our agreements with EDB provide that grants extended to us in
    the past and future grants are subject to our operation of
    increasing levels of research, development and manufacturing in
    Singapore, including the use of local service providers, the
    hiring of personnel in Singapore, the incurrence of research and
    development expenses in Singapore, our receipt of new investment
    in our company and our achievement of certain agreed upon
    milestones relating to the development of our products.
    Development and manufacturing milestones achieved during the
    three years ended December&#160;29, 2007 included completion of
    feasibility studies and prototype development, establishment of
    manufacturing lines, implementation of quality control
    improvements, manufacturing process simplification and cost
    improvements and manufacturing yield improvements for our Topaz
    and BioMark IFCs and related systems. These agreements further
    provide EDB with the right to demand repayment of a portion of
    past grants in the event that we did not meet our obligations
    under the applicable agreements. Based on correspondence with
    EDB, we believe we have satisfied the conditions applicable to
    our EDB grant revenue through June&#160;28, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Although the NIH grant is scheduled to terminate in
    June&#160;2008, we expect grant revenue from the EDB research
    grants to increase in 2008 and remain at such levels through
    2011. As a result, we expect our total grant revenue in 2008
    through 2011 to be consistent with 2007 levels.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cost of
    Product Revenue and Gross Margin</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our cost of revenue and gross
    margin for each period presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gross margin
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue includes manufacturing costs incurred in
    the production process, including component materials, assembly
    labor and overhead, testing, installation, warranty, packaging
    and delivery costs. In addition, cost of product revenue
    includes royalty expenses for licensed technologies included in
    our products, provisions for warranties and stock-based
    compensation expense. Costs related to collaboration and
    government grant revenue are included in research and
    development expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of product revenue increased $1.5&#160;million, or 100%,
    for the six months ended June&#160;28, 2008 compared to the six
    months ended June&#160;30, 2007. The increase related to the
    increase in product revenue from both higher instrument and IFC
    sales. Cost of product revenue in the first six months of 2007
    was adversely affected by
    <FONT style="white-space: nowrap">start-up</FONT>
    costs for our new Singapore manufacturing facility and
    underutilized capacity as we transitioned manufacturing from the
    United States to Singapore. Cost of product revenue for 2007
    increased $0.7&#160;million, or 27%, compared to 2006, primarily
    driven by higher instrument sales, start-up costs for our new
    Singapore manufacturing facility and underutilized capacity as
    we transitioned manufacturing from the United States to
    Singapore. Cost of product revenue for 2006 decreased by
    $2.0&#160;million, or 42%, when compared to 2005, primarily
    driven by a decrease in sales of our Topaz instruments during
    2006. We expect our unit costs to decline in future periods as a
    result of our ongoing efforts to automate our manufacturing
    processes and expected increases in production volumes and
    yields. However, improvement in unit costs may be offset by
    increasing price competition, which could cause our gross
    margins to fluctuate from
    <FONT style="white-space: nowrap">year-to-year</FONT>
    and
    <FONT style="white-space: nowrap">quarter-to-quarter.</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents our operating expenses for each
    period presented (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling, general and administrative
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    27,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,236
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense consists primarily of personnel
    costs, independent contractor costs, prototype expenses and
    other allocated facilities and information technology expenses.
    We have made substantial investments in research and development
    since our inception. Our research and development efforts have
    focused primarily on the tasks required to optimize our
    technologies and to support commercialization of the products
    and services derived from these technologies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Research and development expense decreased $0.1&#160;million, or
    1%, for the six months ended June&#160;28, 2008 compared to the
    six months ended June&#160;30, 2007. The decrease relates to a
    decrease of $0.2&#160;million in supply costs and
    $0.3&#160;million in license costs partially offset by a
    $0.7&#160;million increase in compensation costs due to
    increased research and development headcount. Research and
    development expense decreased in 2007 by $1.2&#160;million, or
    8%, compared to 2006, primarily due to decreased contractor
    costs of $0.6&#160;million and decreased research and
    development license costs of $0.3&#160;million. Research and
    development expense for 2006 increased by $4.1&#160;million,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    or 36%, compared to 2005, primarily due to increased
    compensation costs of $2.1&#160;million due mostly to a
    significant increase in research and development headcount and
    $0.1&#160;million related to the adoption of SFAS&#160;123(R)
    during 2006, $0.6&#160;million attributable to increased
    contractor expenses and $0.6&#160;million in increased license
    costs and royalties. We believe that our continued investment in
    research and development is essential to a long-term competitive
    position and expect these expenses, including stock-based
    compensation, to increase in future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selling,
    General and Administrative</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense consists primarily
    of personnel costs for our sales and marketing, business
    development, finance, legal, human resources and general
    management, as well as professional services, such as legal and
    accounting services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling, general and administrative expense increased
    $3.7&#160;million, or 59%, for the six months ended
    June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. The increase relates to a $0.6&#160;million
    increase for accounting and consulting services, a
    $1.7&#160;million increase in compensation costs due to
    increased head count, a $0.6&#160;million increase in patent
    filings, a $0.3&#160;million increase in advertising and
    promotions, and a $0.2&#160;million increase in supplies.
    Selling, general and administrative expense for 2007 increased
    by $3.2&#160;million, or 33%, compared to 2006, primarily due to
    increased compensation costs of $1.4&#160;million due mostly to
    an increase in headcount and a $0.3&#160;million increase in
    stock-based compensation over 2006, an increase of
    $1.8&#160;million in spending primarily for accounting and legal
    services, $0.3&#160;million resulting from increased advertising
    and promotions, and $0.2&#160;million attributable to increased
    supplies for customer demonstrations. However, this increase was
    partially offset by a decrease of $0.6&#160;million due to fewer
    patent filings. Selling, general administrative expense for 2006
    increased by $1.7&#160;million, or 22%, compared to 2005,
    primarily due to increased compensation costs of
    $0.7&#160;million due to an increase in headcount, an increase
    of $0.6&#160;million in spending primarily for accounting and
    legal services, and $0.4&#160;million due to the filing of
    additional patents. We expect selling, general and
    administrative expense, including stock-based compensation, to
    significantly increase in 2008 and future periods as we continue
    to grow our sales, technical support, marketing and
    administrative headcount, support increased product sales,
    broaden our customer base and incur additional costs to support
    the growth in our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Interest
    Income and Expense</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive interest income from our cash and cash equivalents
    and our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    security balances held with certain financial institutions.
    Conversely, we incur interest expense from our long-term debt
    and convertible promissory notes and the amortization of our
    debt discounts related to these items. The following table
    presents our interest income and expense for each period
    presented (in thousands).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest income decreased by $8,000, or 1%, for the six months
    ended June&#160;28, 2008 compared to the six months ended
    June&#160;30, 2007. Interest income for 2007 increased by
    $0.6&#160;million compared to 2006. The increase in interest
    income was due to higher cash and available-for-sale securities
    balances during 2007 as compared to 2006. Interest income for
    2006 increased by $0.2&#160;million compared to 2005. The
    increase in interest income was also primarily due to higher
    cash and available-for-sale securities balances during 2006 as
    compared to 2005. We expect interest income to increase as we
    invest a portion of the net proceeds from this offering in
    available-for-sale securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Interest expense decreased $0.7&#160;million, or 39%, for the
    six months ended June&#160;28, 2008 compared to the six months
    ended June&#160;30, 2007 due to lower average debt balance due
    to conversion of the $10.0&#160;million promissory notes in
    March&#160;2007. Interest expense for 2007 increased by
    $0.5&#160;million compared to 2006. The increase was primarily
    due to higher debt balances during 2007 as compared to 2006
    primarily due to the $5.0&#160;million convertible promissory
    note issued in April 2007. Interest expense for 2006 increased
    by $1.4&#160;million compared to 2005. The increase was
    primarily due to higher debt balances from the
    $13.0&#160;million loan and security agreement that was
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fully drawn by December 2005. In February 2008, this loan and
    security agreement was amended to provide us with an additional
    credit line in the amount of $10.0&#160;million. We borrowed the
    full $10.0&#160;million under this additional credit line in
    June 2008 and, as a result, we expect our interest expense to
    increase in future periods.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cumulative
    Effect of Change in Accounting Principle</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, we reclassified the fair value of warrants
    to purchase shares of our convertible preferred stock from
    stockholders&#146; equity to liabilities and recorded a
    cumulative effect of a change in accounting principle in the
    amount of $0.6&#160;million during 2005 in the statement of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Sources
    of Liquidity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, we had $29.0&#160;million of cash and
    cash equivalents and $3.5&#160;million of available-for-sale
    securities. As of June&#160;28, 2008, our working capital was
    $28.6&#160;million, and we had an accumulated deficit of
    $149.1&#160;million. Since our inception, we have principally
    funded our operations through issuances of convertible preferred
    stock, which has provided us with aggregate net proceeds of
    $167.5&#160;million, of which $20.0&#160;million was provided by
    entities affiliated with EDB in the form of convertible
    promissory notes that converted into convertible preferred
    stock. We have also received significant funding in the form of
    loans that have provided us with aggregate net proceeds of
    $26.6&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have received funding in the form of grants from government
    entities, the most significant of which have been associated
    with two grant agreements with EDB that have helped support the
    establishment and operation of our Singapore manufacturing,
    research and development facilities in October 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The maximum amount of grant revenue available to us under our
    first grant agreement with EDB from June&#160;28, 2008 through
    July&#160;31, 2010 is SG$5.2&#160;million (approximately US$3.8
    using a June&#160;28, 2008 exchange rate), and the maximum
    amount of grant revenue available to us under our second grant
    agreement with EDB from June&#160;28, 2008 through May&#160;31,
    2011 is SG$2.5&#160;million (approximately US$1.8&#160;million).
    To maintain eligibility for incentive grant payments under these
    agreements, we are required to achieve development and
    manufacturing milestones as agreed to by the parties. In
    addition, to maintain eligibility for incentive grant payments
    under our first grant agreement, we are required to incur annual
    spending in Singapore of at least SG$6.5&#160;million
    (approximately US$4.8&#160;million) in 2008 and 2009 and at
    least SG$8.0&#160;million (approximately US$5.9&#160;million) in
    2010. To maintain eligibility for grant payments under our
    second grant agreement, we are required to incur annual spending
    in Singapore of at least SG$6.5&#160;million (approximately
    US$4.8&#160;million) for the 12&#160;months ending May&#160;31,
    2009 and 2010 and at least SG$9.0&#160;million (approximately
    US$6.6&#160;million) for the 12&#160;months ending May&#160;31,
    2011. For this purpose, spending in Singapore includes overhead,
    salaries, outsourcing and subcontracting expenses, operating
    expenses and royalties paid, with limited exceptions such as raw
    materials purchases. Expenditures that are used to satisfy the
    requirements of one grant agreement are not eligible for
    satisfaction of the other grant agreement. To qualify for
    payment under the second grant agreement, expenditures must
    relate to the development of instrumentation for our IFC systems
    and not our IFCs themselves. Our first grant agreement also
    requires that we employ at least 24 research scientists and
    engineers in Singapore by December&#160;31, 2009, and our second
    grant agreement requires that we employ at least 10 new research
    scientists and engineers in Singapore by May&#160;31, 2009, that
    we employ at least 12 new research scientists and engineers in
    Singapore by May&#160;31, 2011 and that we maintain at least 12
    research scientists and engineers in total until May&#160;31,
    2013. The requirements of the second grant agreement may only be
    satisfied by personnel employed in the research and development
    of IFC instrumentation. As of June&#160;28, 2008, we employed
    16&#160;research scientists and engineers involved in the
    research and development of our IFCs and 10&#160;research
    scientists and engineers involved in the research and
    development of related instrumentation in Singapore. We cannot
    assure you that we will take all actions required to remain
    eligible for grants under our agreements with EDB and, in the
    event that we do not comply with such requirements, whether
    intentionally or unintentionally, we may not receive further
    grants under such agreements. In the event that we do not
    receive grant funding from EDB in the future, we do not believe
    that our liquidity would be materially affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into multiple convertible note purchase
    agreements with Biomedical Sciences Investment Fund&#160;Pte.
    Ltd., or BMSIF, pursuant to which we issued convertible notes
    and received proceeds in the amount of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    $20.0&#160;million through June&#160;28, 2008. BMSIF is
    wholly-owned by EDB Investments Pte. Ltd., whose parent entity
    is EDB. Ultimately, each of these entities is controlled by the
    government of Singapore. As of June&#160;28, 2008, there were no
    outstanding principal and accrued interest balances for our
    convertible note purchase agreements with BMSIF as the final
    remaining note was converted into shares of our Series&#160;E
    preferred stock in April&#160;2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, we entered into a master security agreement
    with a lender under which we borrowed $3.6&#160;million to be
    used for purchases of capital equipment, software and tenant
    improvements. The outstanding principal and accrued interest
    balance for this loan was paid in February 2008. Upon full
    payment of the debt in February 2008, restricted cash in the
    amount of $0.5&#160;million was released by the lender.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, we entered into a loan and security agreement
    with a lender under which we borrowed $13.0&#160;million to be
    used for general corporate purposes. We are currently making
    equal monthly payments of $0.3&#160;million towards the loan
    which is to be paid off in February 2010. The loan is subject to
    prepayment penalties if paid off prior to 2010.  In February
    2008, this loan and security agreement was amended to provide us
    with an additional credit line in the amount of
    $10.0&#160;million that we could draw upon until July&#160;1,
    2008 for general corporate purposes. In June 2008, the Company
    drew down the $10,000,000. The loan will bear interest at 11.5%
    per annum. Interest only payments will be made monthly through
    the remainder of 2008 with monthly payments of principal and
    interest in the amount of $369,000, beginning in January 2009,
    to be made through June 2011. The agreement also requires a
    final payment in the amount of $650,000 in June 2011. As of
    June&#160;28, 2008, the outstanding principal and accrued
    interest balance for this loan and security agreement was
    $16.6&#160;million, net of unamoritized debt discounts of
    $0.4&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The loan and security agreement contains customary covenants
    that, among other things, require us to deliver both annual
    audited and periodic unaudited financial statements by specified
    dates and maintain collateral on company premises and restrict
    our ability, without the consent of the lender, to incur
    additional debt, pay dividends or make certain other
    distributions, or payments in respect of our capital stock,
    engage in transactions with affiliates or engage in the sale,
    lease or license of our assets outside of the ordinary course of
    business. As of June&#160;28, 2008, we were in compliance with
    the above covenants with the exception of the timely delivery of
    our audited financial statements for 2007. In this instance, we
    obtained a waiver from the lender and subsequently complied with
    the covenant. We are currently unaware of any circumstances that
    would prevent us from complying with these covenants in the
    future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Operating Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We derive cash flows from operations primarily from cash
    collected from the sale of our products and related services,
    collaboration agreements and grants from certain government
    entities. Our cash flows from operating activities are also
    significantly influenced by our use of cash for operating
    expenses to support the growth of our business. We have
    historically experienced negative cash flows from operating
    activities as we have expanded our business and built our
    infrastructure domestically and internationally and we expect
    this trend to continue for the foreseeable future as our
    business grows and we continue to expand into new markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $16.0&#160;million for
    the six months ended June&#160;28, 2008. Net cash used by
    operating activities primarily consisted of a net loss of
    $15.3&#160;million, changes in our operating assets and
    liabilities in the amount of $3.2&#160;million and foreign
    exchange gain in the amount of $0.1&#160;million, which were
    partially offset by non-cash expense items such as depreciation
    and amortization of our property and equipment in the amount of
    $0.8&#160;million, adjustments to the fair value of convertible
    preferred stock warrants in the amount of $0.4&#160;million,
    amortization of debt discounts and issuance cost of
    $0.4&#160;million, and stock-based compensation in the amount of
    $1.0&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     Net cash used by operating activities was $21.8&#160;million
    during 2007. Net cash used by operating activities primarily
    consisted of a net loss of $25.5&#160;million, which was
    partially offset by non-cash expense items such as depreciation
    and amortization of our property and equipment in the amount of
    $1.6&#160;million, amortization of debt discounts in the amount
    of $0.5&#160;million, stock-based compensation in the amount of
    $0.7&#160;million, and changes in our operating assets and
    liabilities in the amount of $0.4&#160;million.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $22.3&#160;million
    during 2006. Net cash used by operating activities primarily
    consisted of a net loss of $23.6&#160;million and changes in our
    operating assets and liabilities in the amount of
    $1.2&#160;million. The cash used by operating activities for
    these items was partially offset by non-cash expense items such
    as depreciation and amortization of our property and equipment
    in the amount of $1.4&#160;million, amortization of our debt
    discounts in the amount of $0.1&#160;million, stock-based
    compensation in the amount of $0.1&#160;million, and the
    issuance of convertible preferred stock under a license
    agreement in the amount of $0.6&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used by operating activities was $14.3&#160;million
    during 2005. Net cash used by operating activities primarily
    consisted of a net loss of $16.4&#160;million. The cash used by
    operating activities was partially offset by non-cash expense
    items such as depreciation and amortization of our property and
    equipment in the amount of $1.3&#160;million and increases in
    our operating assets and liabilities in the amount of
    $1.4&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Used in Investing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, our primary investing activities have consisted of
    capital expenditures for laboratory, manufacturing and computer
    equipment and software to support our expanding infrastructure
    and work force; restricted cash related to leased space and
    lending agreements; and purchases, sales and maturities of our
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities. We expect to continue to expand our manufacturing
    capability, primarily in Singapore, and expect to incur
    additional costs for capital expenditures related to these
    efforts in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We generated $3.2&#160;million of cash in investing activities
    for the six months ended June&#160;28,&#160;2008 primarily from
    maturities of available-for-sale securities in the amount of
    $4.3&#160;million, sales of available-for-sale securities in the
    amount of $3.0&#160;million and a reduction of restricted cash
    of $0.6&#160;million, partially offset by purchases of
    available-for-sale securities in the amount of $4.5&#160;million
    and purchases of capital equipment of $0.2&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $6.7&#160;million of cash in investing activities during
    2007, primarily for purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $6.3&#160;million and
    $1.0&#160;million for capital expenditures related to purchases
    of equipment, including $0.6&#160;million for our Singapore
    manufacturing facility, partially offset by maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We used $2.9&#160;million of cash in investing activities during
    2006, primarily for capital expenditures in the amount of
    $2.9&#160;million related to purchases of equipment, including
    $1.9&#160;million for our Singapore manufacturing facility.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, investing activities provided cash of
    $6.8&#160;million. This cash was generated primarily from sales
    and maturities of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $8.9&#160;million, partially offset
    by purchases of
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities in the amount of $0.5&#160;million and capital
    expenditures in the amount of $1.7&#160;million. Our capital
    expenditures during 2005 included $0.8&#160;million related to
    purchases of manufacturing equipment for our Singapore facility,
    which began operations during the year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Cash Provided by Financing Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, we have principally funded our operations through
    issuances of convertible preferred stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the six months ended June&#160;28, 2008, we generated
    $7.6&#160;million of cash from financing activities primarily
    due to proceeds from our amended loan and security agreement in
    the amount of $10.0 million, partially offset by repayment of
    long-term debt. During 2007, we generated $37.6&#160;million of
    cash from financing activities primarily due to
    $35.9&#160;million of net proceeds from sales of our
    Series&#160;E preferred stock and $5.0&#160;million of proceeds
    from the issuance of convertible promissory notes, partially
    offset by repayments of our long-term debt in the amount of
    $3.5&#160;million. During 2006, we generated approximately
    $31.1&#160;million of cash from financing activities primarily
    due to $22.0&#160;million of net proceeds from sales of our
    Series&#160;E preferred stock and $13.0&#160;million of proceeds
    from the issuance of convertible promissory notes, partially
    offset by repayments of our long-term debt in the amount of
    $4.0&#160;million. During 2005, we generated approximately
    $23.0&#160;million of cash from financing activities, primarily
    due to $10.0&#160;million of net proceeds from sales of our
    Series&#160;D preferred stock and $14.7&#160;million of net
    proceeds from the issuance of long-term debt, partially offset
    by repayments of our long-term debt in the amount of
    $1.7&#160;million.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Capital
    Resources</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our existing cash and cash equivalents,
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities, amounts available under current credit lines and the
    net proceeds from this offering, will be sufficient to meet our
    working capital and capital expenditure needs for at least the
    next 18&#160;months. However, we may need to raise substantial
    additional capital to expand the commercialization of our
    products, fund our operations, continue our research and
    development, defend, in litigation or otherwise, any claims that
    we infringe third-party patents or violate other intellectual
    property rights, commercialize new products and acquire
    companies and in-license products or intellectual property. Our
    future funding requirements will depend on many factors,
    including market acceptance of our products, the cost of our
    research and development activities, the cost of filing and
    prosecuting patent applications, the cost of defending, in
    litigation or otherwise, any claims that we infringe third-party
    patents or violate other intellectual property rights, the cost
    and timing of regulatory clearances or approvals, if any, the
    cost and timing of establishing additional sales, marketing and
    distribution capabilities, the cost and timing of establishing
    additional technical support capabilities, the effect of
    competing technological and market developments, and the extent
    to which we acquire or invest in businesses, products and
    technologies, although we currently have no commitments or
    agreements relating to any of these types of transactions. We
    currently expect to use the proceeds from this offering to
    expand our sales force, to support the ongoing commercialization
    of our products, for research and product development
    activities, to expand our facilities and manufacturing
    operations, and for working capital and other general corporate
    purposes. As of the date of this prospectus, we cannot predict
    with certainty all of the particular uses for the proceeds from
    this offering or the amounts that we will actually spend on the
    uses set forth above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may require additional funds in the future and we may not be
    able to obtain such funds on acceptable terms, or at all. If we
    raise additional funds by issuing equity securities, our
    stockholders may experience dilution. Debt financing, if
    available, may involve covenants restricting our operations or
    our ability to incur additional debt. Any debt or additional
    equity financing that we raise may contain terms that are not
    favorable to us or our stockholders. If we raise additional
    funds through collaboration and licensing arrangements with
    third parties, it may be necessary to relinquish some rights to
    our technologies or our products, or grant licenses on terms
    that are not favorable to us. If we are unable to raise adequate
    funds, we may have to liquidate some or all of our assets, or
    delay, reduce the scope of or eliminate some or all of our
    development programs. If we do not have, or are not able to
    obtain, sufficient funds, we may have to delay development or
    commercialization of our products or license to third parties
    the rights to commercialize products or technologies that we
    would otherwise seek to commercialize. We also may have to
    reduce marketing, customer support or other resources devoted to
    our products or cease operations. Any of these factors could
    harm our operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since our inception, we have not had any off-balance sheet
    arrangements as defined in Item&#160;303(a)(4) of the Securities
    and Exchange Commission&#146;s
    <FONT style="white-space: nowrap">Regulation&#160;S-K.</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations and Commitments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summarizes our contractual obligations as of
    December&#160;29, 2007 (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Payments Due by Period</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1&#160;Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1-3&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>3-5&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Thereafter</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,908
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operating lease obligations relate to leases for our current
    headquarters and leases for office space for our foreign
    subsidiaries. Principal and interest on our convertible
    promissory notes are convertible into shares of our
    Series&#160;E preferred stock at the lender&#146;s election, at
    any time, or upon our election upon the achievement of certain
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    milestones or automatically upon the completion of this
    offering. Purchase obligations consist of contractual and
    legally binding commitments to purchase goods. We have entered
    into several patent license agreements in which we are obligated
    to pay annual license maintenance fees, non-refundable license
    issuance fees and royalties as a percentage of sales for the
    sale or sublicense of products using the licensed technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into several license and patent agreements.
    Under these agreements, we pay annual license maintenance fees,
    nonrefundable license issuance fees, and royalties as a
    percentage of net sales for the sale or sublicense of products
    using the licensed technology. If we elect to maintain these
    license agreements, we will pay aggregate annual fees of
    $315,000 in 2008 and $270,000 per year until 2027. Future
    payments related to these license agreements have not been
    included in the contractual obligations table above as the
    period of time over which the future license payments will be
    required to be made, and the amount of such payments are
    indeterminable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003 we entered into a Master Closing Agreement
    with Oculus Pharmaceuticals, Inc. and the UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to $1.5&#160;million upon the
    achievement of a certain milestone and based upon the fair
    market value of our common stock at the time the milestone is
    achieved. We currently do not anticipate achieving this
    milestone in the foreseeable future and do not anticipate
    issuing these shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations in Singapore, which commenced in
    October 2005, have generated incentive grant payments from EDB
    for our research, development and manufacturing activity in
    Singapore. To remain eligible for future incentive grant
    payments, we are required to maintain a significant and
    increasing manufacturing and research and development presence
    in Singapore. Under our current grant agreements with EDB, we
    expect our spending related to these grant agreements to
    increase in order to maintain our manufacturing facility in
    Singapore. Future expenditures related to these grant agreements
    have not been included in the contractual obligations table
    above as the amounts of future expenditures, if any, and the
    timing of when they will be incurred are still indeterminable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subsequent to our year ended December&#160;29, 2007, the
    remaining outstanding principal and accrued interest balance for
    a master security agreement in the amount of $1.1&#160;million
    was paid in February 2008. The loan was originally scheduled to
    be repaid in monthly installments though July 2009 and,
    accordingly, was reflected in the table above as such. Also, the
    convertible promissory notes noted in the table above were
    converted into shares of our Series&#160;E preferred stock
    during April 2008 in accordance with the convertible note
    purchase agreements with BMSIF. In June 2008, we drew an
    additional $10.0 million from our amended loan and security
    agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;No.&#160;157,
    <I>Fair Value Measurement</I>, or SFAS&#160;157, which defines
    and establishes a framework for measuring the fair value of
    assets and liabilities when required or permitted by other
    standards within generally accepted accounting principles in the
    United States but does not require any new fair value
    measurements. SFAS&#160;157 also expands disclosures about fair
    value measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2,</FONT>
    or
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    which delays the effective date of SFAS&#160;157 in accordance
    with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of January&#160;1, 2008. The adoption of SFAS&#160;157 did
    not have a significant impact on our consolidated financial
    statements and the resulting fair values calculated in
    accordance with SFAS&#160;157 were not significantly different
    than the fair values that would have been calculated in
    accordance with the previous guidance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial
    Liabilities</I>, or SFAS&#160;159, including an amendment of
    SFAS&#160;No.&#160;115, <I>Accounting for Certain Investments in
    Debt and Equity Securities</I>, which allows an entity to choose
    to measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    adoption of SFAS&#160;159 did not have a significant impact on
    our consolidated financial statements.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-1,</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and that are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. We are currently assessing the
    impact the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    will have on our consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities</I>, or
    <FONT style="white-space: nowrap">EITF&#160;07-3.</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. We adopted
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    as of December&#160;30, 2007. The adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    did not have a significant impact on our consolidated financial
    statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosures about Market Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Market risk represents the risk of loss that may impact our
    financial position due to adverse changes in financial market
    prices and rates. Our market risk exposure is primarily a result
    of fluctuations in foreign currency exchange rates and interest
    rates. We do not hold or issue financial instruments for trading
    purposes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Exchange Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As we expand internationally our results of operations and cash
    flows will become increasingly subject to fluctuations due to
    changes in foreign currency exchange rates. Our revenue is
    generally denominated in the local currency of the contracting
    party. Historically, the substantial majority of our revenue has
    been denominated in U.S.&#160;dollars. Our expenses are
    generally denominated in the currencies in which our operations
    are located, which is primarily in the United States, with a
    portion of expenses incurred in Singapore where our other
    manufacturing facility is located. Our results of operations and
    cash flows are, therefore, subject to fluctuations due to
    changes in foreign currency exchange rates. Fluctuations in
    currency exchange rates could harm our business in the future.
    The effect of a 10% adverse change in exchange rates on foreign
    denominated cash, receivables and payables as of June&#160;28,
    2008 would have been approximately $0.4&#160;million foreign
    exchange loss recognized as a component of other expense within
    our consolidated statement of operations. To date, we have not
    entered into any foreign currency hedging contracts although we
    may do so in the future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Sensitivity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We had cash and cash equivalents of $25.0&#160;million,
    $34.1&#160;million and $29.0&#160;million and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities of $0.5&#160;million, $6.3&#160;million and
    $3.5&#160;million as of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008. These amounts
    were held primarily in cash on deposit with banks, money market
    funds, commercial paper, corporate notes or notes from
    government-sponsored agencies, which are short-term. Cash and
    cash equivalents and
    <FONT style="white-space: nowrap">available-for-sale</FONT>
    securities are held for working capital purposes and restricted
    cash amounts are held as letters of credit for collateral for a
    security agreement with a lender and for our facility lease
    agreements. Due to the short-term nature of these investments,
    we believe that we do not have any material exposure to changes
    in the fair value of our investment portfolio as a result of
    changes in interest rates. Declines in interest rates, however,
    will reduce future investment income. If overall interest rates
    had decreased by 10% during 2007 or the six months ended
    June&#160;28, 2008, our interest income would not have been
    materially affected.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, the principal amount of our long-term debt
    outstanding was $12.8&#160;million, $9.4&#160;million and
    $16.6&#160;million and the principal and accrued interest amount
    of our convertible promissory notes outstanding was
    $13.1&#160;million, $5.0&#160;million and $0. The interest rates
    on a small portion of our long-term debt and convertible
    promissory notes are fixed, however, a portion of our long-term
    debt outstanding has interest rates that are variable and adjust
    periodically until December&#160;31, 2008 based on the prime
    rate however, thereafter the interest rates are fixed. If
    overall interest rates had increased by 10% during 2007 or the
    six months ended June&#160;28, 2008, our interest expense would
    not have been materially affected.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have material exposure to market risk with respect to
    investments as our investments consist primarily of highly
    liquid securities that approximate their fair values due to
    their short period of time to maturity. We do not use derivative
    financial instruments for speculative or trading purposes,
    however, we may adopt specific hedging strategies in the future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Controls
    and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, in connection with the audit of our
    consolidated financial statements for 2005 and 2006, we
    determined that we had material weaknesses relating to our
    financial statement close and accrual process, revenue
    recognition, inventory costing, cost of sales, purchases cut-off
    and stock-based compensation. A material weakness is defined as
    a deficiency, or combination of deficiencies, in internal
    control over financial reporting, such that there is a
    reasonable possibility that a material misstatement of the
    company&#146;s annual or interim financial statements will not
    be prevented or detected on a timely basis by the company&#146;s
    internal controls. These material weaknesses were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have a sufficient number of personnel in the
    accounting and finance department with sufficient proficiency
    and technical accounting expertise;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place or designed to
    evaluate the accounting implications of our business
    transactions during 2005 and 2006 and to determine if such
    matters had been properly accounted for in a timely
    manner;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we had not designed or maintained effective operating controls
    over the financial statement close and reporting process in
    order to ensure the accurate and timely preparation of our
    financial statements in accordance with generally accepted
    accounting principles.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These material weaknesses resulted in the recording of numerous
    audit adjustments for 2005 and 2006. We have taken steps
    intended to remediate these material weaknesses through:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of additional accounting and finance personnel with
    technical accounting and financial reporting experience,
    including Vikram Jog, our new Chief Financial Officer, who
    joined us in February 2008;
</TD>
</TR>
    <FONT style="font-size: 10pt">
    </FONT>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of a consulting firm to provide further
    accounting expertise to complement the skills of our existing
    team;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the engagement of an accounting firm to advise us on local and
    international tax planning and compliance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the hiring of an experienced finance manager for Fluidigm
    Singapore Pte. Ltd., who joined us in May 2008;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increased scheduled communication and coordination among our
    finance teams in the United States and our foreign subsidiaries;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhanced coordination among, and training of, accounting, sales,
    technical support and legal personnel on transactional issues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancements to our financial statement close process and
    financial close calendar to help enable processes and procedures
    to be completed on a timely basis;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    installation of common accounting software and systems in our
    U.S. and Singapore offices.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April and May 2008, following the audit of our consolidated
    financial statements for 2007 and the review of our financial
    statements for the three months ended March&#160;29, 2008, we
    reviewed our internal control over financial reporting and
    concluded that we had certain significant deficiencies, none of
    which were determined to be material weaknesses. A significant
    deficiency is defined as a deficiency, or combination of
    deficiencies, in internal control over financial reporting that
    is less severe than a material weakness, yet important enough to
    merit attention by those responsible for oversight of a
    company&#146;s financial reporting. These significant
    deficiencies were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review
    consolidation and elimination entries relating to intercompany
    transfer pricing to detect and eliminate intercompany profits
    embedded in deferred costs of our Japanese subsidiary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have effective controls in place designed to apply
    SFAS&#160;123R to option grants with a variety of vesting terms
    and to validate stock compensation expenses calculated by our
    option tracking software;&#160;and
</TD>
</TR>
    <FONT style="font-size: 10pt">
    </FONT>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we did not have sufficient controls in place to review the
    valuation of our inventory.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know the specific time frame needed to remediate the
    significant deficiencies identified. In addition, we expect to
    incur some incremental costs associated with this remediation.
    If we fail to enhance our internal control over financial
    reporting to meet the demands that will be placed upon us as a
    public company, including the requirements of the Sarbanes-Oxley
    Act, we may be unable to report our financial results
    accurately. The actions we plan to take are subject to continued
    management review supported by confirmation and testing, as well
    as audit committee oversight. While we expect to remediate these
    significant deficiencies, we cannot assure you that we will be
    able to do so in a timely manner, which could impair our ability
    to report our financial position, results of operations or cash
    flows accurately and timely.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We develop, manufacture and market proprietary Integrated
    Fluidic Circuit systems that significantly improve productivity
    in the life science industry. Our Integrated Fluidic Circuits,
    or IFCs, integrate a diverse set of critical liquid handling
    functions on a nanoliter scale. Our IFCs can meter, combine,
    diffuse, fold, mix, separate or pump nanoliter volumes of
    fluids, with precise control and reproducibility, many thousands
    of times&#160;&#151; all in parallel on a single chip. This
    technology enables our customers to perform thousands of
    sophisticated biochemical measurements on samples smaller than
    the content of a single cell, with minute volumes of reagents,
    in half the area of a credit card. We achieved this
    &#147;integrated circuit for biology&#148; by miniaturizing and
    integrating liquid handling components on a single
    microfabricated device. Through innovations in material science
    and manufacturing, our IFC architectures are highly flexible,
    and can be designed to support a wide range of applications and
    assay types. For large-scale experimentation, our IFC systems,
    consisting of instrumentation, software and single-use IFCs,
    increase throughput, decrease costs and enhance sensitivity
    compared to conventional laboratory systems. We have sold our
    IFCs to over 100 customers, including many leading biotechnology
    and pharmaceutical companies, academic institutions and life
    science laboratories worldwide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have commercialized IFC systems for a wide range of life
    science applications, including our BioMark system for gene
    expression analysis, genotyping and digital PCR, and our Topaz
    system for protein crystallization. Researchers and clinicians
    have successfully employed our products in achieving
    breakthroughs across diverse scientific disciplines such as
    genetic variation, cellular function and structural biology.
    These advances include using our systems to help detect
    life-threatening mutations in patients&#146; cancer cells,
    discover indicators of susceptibility to cancer, manage some of
    the world&#146;s most valuable fisheries, analyze the genetic
    composition of individual stem cells, identify fetal chromosomal
    abnormalities from maternal blood samples, analyze the
    aggressiveness of the avian flu virus and assess the quality of
    agricultural seed products. We believe that the flexible
    architecture of our IFC technology will lead to the development
    of IFC systems for a wide variety of additional markets and
    applications, including high-throughput DNA sequencing and
    molecular diagnostics.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a9f3943217.gif" alt="(IFC FIGURE)">
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schematic of our 96.96 Dynamic Array IFC including an
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    enlarged section showing four of the IFC&#146;s 9,216 test
    chambers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The life science industry is currently facing challenges similar
    to those faced by the information technology industry when
    computational power was constrained by the inherent limitations
    of the vacuum tube. Life science research efforts, ranging from
    large-scale initiatives, such as the Human Genome Project, to
    more traditional academic and commercial research projects, are
    continuing to reveal the complex biological and chemical
    processes that are fundamental to living organisms. Automated,
    high-precision and large-scale experimentation is increasingly
    necessary to develop and apply this knowledge. However, the most
    common forms of life science automation rely on cumbersome
    robotic systems that are slow, expensive and labor-intensive
    and, we believe,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fundamentally constrain the pace and productivity of life
    science research. In much the same way that integrated circuits
    overcame the limitations of early computers by placing an
    increasing number of transistors on a single silicon chip, our
    IFCs overcome many of the limitations of conventional laboratory
    systems by integrating an increasing number of fluidic
    components on a single microfabricated IFC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that much of analytical biology and chemistry can be
    performed more efficiently and more economically in nanoliter,
    or one billionth of a liter, volumes than in conventional
    microliter volume platforms. Moreover, we believe that these
    advantages can be further enhanced through high levels of
    integration. Our IFC systems overcome many of the limitations of
    conventional methods by integrating on a single device the
    ability to perform thousands of experiments at one time and in
    nanoliter volumes. Our IFCs consist of an elastomeric, or
    rubber-like, core bonded to a specialized hard plastic input
    frame. The input frame is compatible with standard laboratory
    workflow equipment and facilitates loading the IFC with samples
    and reagents. Each IFC contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter chambers across the IFC where individual
    tests can be performed. This high level of nanofluidic
    integration significantly reduces the time and complexity of
    large-scale experimentation and the volume of costly reagents
    and scarce patient samples required. In addition, our IFC
    systems enable users to address problems that would be difficult
    or impractical to solve using conventional life science tools.
    We believe that our ongoing research efforts to increase the
    density and degree of miniaturization of our IFCs will result in
    further such benefits to our customers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Target Markets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biotechnology and pharmaceutical companies, academic
    institutions and life science laboratories collectively spent
    approximately $35&#160;billion in 2007 for analytical and life
    science instruments, according to Strategic Directions
    International, or SDI. Growth in the life science equipment and
    supplies industry has been driven in part by increased demand
    for tools that allow researchers to discover how fundamental
    functional elements of biology, such as nucleic acids, proteins,
    carbohydrates and cells, interact within living organisms. This
    research often entails analyzing or identifying numerous such
    elements across large sample populations. Conducting and
    commercializing this research requires equipment that reliably
    performs experimentation with precision, on a large scale and at
    an affordable cost. The need for equipment with these
    capabilities is particularly evident in the areas of genomics,
    proteomics and molecular diagnostics, which comprise our initial
    target markets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Genomics</FONT></I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genomics is the analysis of nucleic acids, including DNA and
    RNA, the fundamental building blocks of life. The entire DNA
    content of an organism is known as its genome. The genome is
    composed of a long series of nucleotide bases that are organized
    into functional units known as genes, as well as regulatory
    regions. Analysis of variations in genomic sequences, genes and
    gene activity in and between organisms can provide important
    insights into routine genetic functionality, as well as an
    organism&#146;s morbidity and mortality. The worldwide demand
    for genomic analysis instruments and supplies was approximately
    $4.9&#160;billion in 2005, according to SDI. Of this total, SDI
    estimated that 56%, or about $2.7&#160;billion, was spent on
    gene expression analysis, and 20%, or about $1.0&#160;billion,
    was spent on genotyping. In a 2006 report, SDI projected that
    the markets for gene expression analysis and genotyping would
    grow approximately 8% per year from 2005 to 2010. In a separate
    2006 report, Frost and Sullivan indicated that the
    high-throughput DNA sequencing market was in a very early stage
    with revenues of approximately $11&#160;million in 2005, but
    estimated it would grow at an annual rate of 63.8% between 2005
    and 2012, reaching approximately $339&#160;million in 2012. In
    the same report, Frost and Sullivan projected that the total DNA
    sequencing market is expected to grow at an annual rate of 10.1%
    from approximately $400&#160;million in 2005 to approximately
    $800&#160;million in 2012.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gene expression and genotyping today are studied through a
    combination of various technology platforms that characterize
    gene function and genetic variation. Gene expression and
    genotyping are commonly performed using a technique known as
    polymerase chain reaction, or PCR, and often with a chemistry
    branded as TaqMan, which is proprietary to Roche Molecular
    Systems, Inc. and is widely used in the life-sciences industry.
    The PCR method is used to replicate a strand of DNA or RNA into
    millions of copies to facilitate detection in a sample.
    Real-time quantitative PCR, or real-time qPCR, is a more
    advanced form of PCR that makes it possible to identify the
    number
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of copies of DNA present in a sample at a certain time.
    According to Frost and Sullivan, the U.S.&#160;market for
    real-time qPCR was approximately $741&#160;million in 2007,
    growing at approximately 11% per year from 2005 to 2012. Based
    on our estimates, we believe the global market for real-time
    qPCR was approximately $1.7&#160;billion in 2007. Gene
    expression, genotyping, digital PCR and high-throughput DNA
    sequencing are four powerful forms of genomic analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Gene Expression Analysis.</I>&#160;&#160;One of the ways
    genes control cellular activity is through a process known as
    gene expression, when a cell transcribes a section of a
    gene&#146;s DNA to create another nucleic acid sequence, known
    as messenger RNA. This messenger RNA may then be translated by
    the cell into a protein. Messenger RNA can be detected and
    quantified by performing real-time qPCR tests, or assays. Gene
    expression analysis typically entails determining which genes
    are active by measuring messenger RNA levels in a blood or
    tissue sample. These results can be correlated with disease
    activity and clinical outcomes. As multiple genes are involved
    in most biological processes, gene expression analysis usually
    requires assaying the expression levels of many genes
    simultaneously across many samples. We estimate that
    approximately 80% of the market for real-time qPCR involves gene
    expression analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Genotyping.</I>&#160;&#160;Genotyping involves the analysis
    of variations across individual genomes. These variations often
    take the form of single nucleotide changes, known as single
    nucleotide polymorphisms, or SNPs, that can determine the
    characteristics or health of the individual. In SNP genotyping
    studies, the DNA sequences of a group of individuals are
    analyzed to determine patterns of SNPs. Statistical analysis is
    then performed to determine whether a SNP or group of SNPs can
    be associated with a particular characteristic, such as
    propensity for a disease. We estimate that approximately 20% of
    the market for real-time qPCR involves genotyping analysis. We
    believe this percentage share of the real-time qPCR market is
    growing based on technological innovations allowing increasing
    amounts of genetic content to be analyzed more quickly and cost
    effectively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Digital PCR.</I>&#160;&#160;Digital PCR is a technique that
    allows researchers to detect nucleic acid sequences that are
    present in a patient sample in concentrations that are too low
    to be detected by conventional methods. Digital PCR typically
    relies on standard PCR techniques, but increases their
    sensitivity by dividing a sample into hundreds or thousands of
    smaller samples and performing a PCR assay on each such sample.
    The ability to actually count the presence or absence of
    amplification in this assay format provides quantitative
    measurement capabilities known as absolute quantification.
    Digital PCR has the potential to enable early detection of
    diseases and other conditions, thereby improving prospects for
    effective treatment. In addition, this technique enhances the
    precision of single molecule assays and copy number variation.
    While the digital PCR market is currently nascent, we believe it
    has the potential to grow significantly as researchers learn how
    to apply this technique to a broader range of research
    applications and associated diseases.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>High-Throughput DNA Sequencing.</I>&#160;&#160;DNA sequencing
    involves determining the sequence of nucleotide bases in a
    segment of DNA and is widely used in life science research as a
    tool to understand the genetic basis of susceptibility to
    disease, disease progression and response to drug therapy.
    Sequencing technology has rapidly advanced over the last two
    decades and current high-throughput DNA sequencing machines are
    many orders of magnitude faster and less expensive than the DNA
    sequencing technology available at the initiation of the Human
    Genome Project in 1990. However, to most effectively use these
    high-throughput DNA sequencers, researchers must carefully
    prepare the sample to be analyzed both to minimize contamination
    and to precisely quantify the amount of sequenceable template
    DNA in the sample. This process can be difficult, time-consuming
    and expensive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 6%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Proteomics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proteomics is the large-scale study of the function and
    structure of proteins. Proteins are produced by all living
    organisms and directly affect cellular function, the overall
    health of an organism and, in the case of pathogens, how the
    organism interacts with its host. Developing drugs to treat a
    disease often involves identifying molecules that are able to
    interfere with the activity of a particular protein in the
    pathway for that disease. One approach to finding such molecules
    is to first determine the structure of the protein and then look
    for molecules that bind to the structure and interfere with the
    activity of the protein. A technique known as protein
    crystallization is typically used to determine
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    protein structures. Crystallizing a protein can be a
    time-consuming and labor-intensive process because different
    proteins will crystallize in the presence of different reagents
    and under different conditions. As samples of particular
    proteins are often scarce and expensive, researchers usually
    conduct only a limited number of experiments, none of which
    might provide a crystallized protein.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Molecular
    Diagnostics</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Molecular diagnostic tests are used in clinical practice to
    diagnose, classify or monitor a disease; determine a
    patient&#146;s susceptibility to a disease; or monitor a
    patient&#146;s response to therapy by detecting one or more
    biomarkers, such as nucleic acids or proteins, in a blood,
    tissue or other type of patient sample. The advancement of
    molecular diagnostics is being driven by researchers performing
    large-scale experiments analyzing the prevalence of SNPs,
    variations in gene expression levels and patterns of protein
    production. SNPs, gene expression levels and proteins often
    directly cause or control diseases. Molecular diagnostic tests
    based on measuring these biomarkers have the potential to be
    much more accurate, discriminating and robust than conventional
    diagnostics. According to Frost and Sullivan, the
    U.S.&#160;market for molecular diagnostics was estimated at
    $2.0&#160;billion in 2007, growing at a compound annual growth
    rate of 17% from 2005 to 2012.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Limitations of Existing Laboratory Systems</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Scientists increasingly seek to identify and measure a large
    number of characteristics across large populations. The most
    common existing methods of large-scale experimentation require a
    workflow that is complex, labor-intensive and expensive. In this
    workflow, biological samples and chemical compounds, usually in
    solution, are generally dispensed or pipetted into standard
    microwell plates, which usually consist of 96 or 384&#160;wells
    each in a standardized format. The plates may then be moved to
    another station where reagents can be applied to the sample or
    compound to create a single assay in each microwell. The
    microwell plates may be moved again to attain ideal reaction
    temperatures or other conditions. The plates are then generally
    moved into a reader to detect the results of the experiment in
    each well. This process of dispensing materials and conveying
    the plates may include robotically performed steps but generally
    also requires a significant manual labor component. To
    accomplish these steps on a large scale typically requires the
    use of large laboratories equipped with many types of equipment,
    robotics, conveyor systems and personnel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conventional microwell plate workflows have a number of
    characteristics that inherently limit their effectiveness as
    tools for large scale experimentation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Complex Workflow.</I>&#160;&#160;Pipetting stations may have
    to perform hundreds of thousands of pipetting steps using
    hundreds of microwell plates in order to conduct a single set of
    experiments. These microwell plates must typically be moved
    among several work stations to complete and measure the results
    of each assay. Maintaining and overseeing complex workflows
    involving large numbers of microwell plates requires ongoing
    attention from trained technicians.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Throughput.</I>&#160;&#160;Due to the large number of
    pipetting steps, microwell plates and process steps involved in
    a conventional microwell workflow, these systems are often
    unable to perform large-scale experiments in a timely and
    cost-effective manner.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Limited Low Volume Capabilities.</I>&#160;&#160;Conventional
    systems are typically unable to dispense samples and reagents in
    quantities small enough to conduct certain high sensitivity, low
    volume techniques, such as digital PCR.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Large Sample Requirements and Significant Running
    Costs.</I>&#160;&#160;Biological samples are often available in
    only very small quantities. As a result, the sample amount that
    needs to be placed in each well often limits the number of
    experiments that can be performed. In addition, reagents can be
    expensive to purchase or produce, and consuming them in
    microliter or larger quantities results in significant and
    sometimes prohibitive costs.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>High Capital Cost.</I>&#160;&#160;Because of the limited
    throughput of conventional systems, multiple pipetting stations,
    plate handlers and readers may be required to meet the demands
    of large-scale experimentation, resulting in high capital
    equipment costs.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other methods of large-scale experimentation, including
    microarrays, pre-formatted arrays, bead arrays and mass
    spectrometer analysis, have been developed to address some of
    the limitations of conventional microwell plate systems.
    However, each of these high-throughput methods has one or more
    limitations that reduce its utility for large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Microarrays, pre-formatted arrays and bead arrays all lack
    flexibility because researchers must specify the assays they
    wish to perform at the time the products are ordered. This in
    turn limits researchers&#146; ability to refine their assay
    panel during the course of a study. In addition, if researchers
    wish to use assay panels other than a manufacturer&#146;s
    standard panels, it may take weeks for a customized product to
    be produced, and the cost may be significant. Furthermore, it is
    often difficult or impossible to convert existing validated
    assays for use with these technologies or with mass spectrometry
    analysis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The quality of the data produced by microarrays, pre-formatted
    arrays and mass spectrometer analysis is insufficient for
    certain research activities. For genotyping studies, data
    quality is typically measured by a call rate, which is the
    percentage of time that a method provides a reading with respect
    to a particular SNP. Both pre-formatted arrays and mass
    spectrometer analysis generally have call rates lower than
    conventional microwell plate systems. For gene expression
    studies, it is often important to measure expression levels over
    a broad dynamic range to capture all or most of the variation
    typically found among subjects. None of microarrays,
    pre-formatted arrays, bead arrays or mass spectrometer analysis
    routinely measure gene expression levels over as broad a dynamic
    range as conventional microwell plates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The workflow for bead arrays and mass spectrometer analysis is
    complex, time consuming and expensive. For example, standard
    protocols often require multiple complex operations to be
    performed over several days by skilled technicians.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These methods can also be very expensive for certain types of
    large-scale experimentation. For example, a single microarray or
    bead array is capable of analyzing thousands of genes from a
    single sample and these devices have been successfully used for
    surveying the genome to discover basic patterns of gene
    expression and genotyping. These surveys or &#147;association
    studies&#148; are commonly performed on tens or hundreds of
    samples and are intended to identify a subset of genes for
    further study. However, for validation studies, which typically
    require the analysis of thousands or tens of thousands of
    samples, the high per sample cost of microarrays and bead arrays
    often make them uneconomical. Similarly, the high initial setup
    costs for mass spectrometry analysis generally make it
    economical only for very large-scale studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A number of companies have attempted to develop more universal
    <FONT style="white-space: nowrap">&#147;lab-on-a-chip&#148;</FONT>
    solutions which could perform large numbers of complex
    biochemical operations on a single device. These chips typically
    incorporate a variety of micron-level features, such as channels
    and wells, but lack robust methods of fluid control such as
    valves. As a result, the products have been unable to support
    the complex fluidic manipulation required by large-scale
    experimentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitations of existing technologies become even more acute
    when clinicians attempt to translate scientific research into
    molecular diagnostics. Given the commercial nature of their
    operations, clinical laboratories need systems that can test
    large numbers of patient samples at low cost and with minimal
    labor requirements. Moreover, many of the most promising
    research studies rely on measuring each sample across tens or
    even hundreds of SNPs, gene expression levels or protein
    concentrations to diagnose or classify a disease. We believe
    that using standard microwell plate technology to make multiple
    measurements on a large number of samples is often too complex
    and expensive for most clinical laboratories. As a result, the
    molecular diagnostic tests adopted by clinical laboratories have
    generally been relatively simple or have required specialized
    machines to perform. Diagnostic approaches that require
    measuring large numbers of SNPs, gene expression levels or
    protein concentrations are generally not available or are
    available only from a diagnostic laboratory that specializes in
    the particular test.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To achieve and exploit breakthroughs in genomics, proteomics and
    molecular diagnostics, research and clinical laboratories need
    robust systems that deliver increased throughput and simpler
    workflows with decreased costs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Fluidigm Solution</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems are designed to overcome many of the limitations
    of conventional methods by empowering researchers and clinicians
    to rapidly perform a large number of experiments at one time and
    in nanoliter volumes,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    significantly increasing throughput, reducing costs associated
    with reagents and patient samples and reducing the time and
    number of steps involved. Our IFCs deliver these advantages
    through integration of sophisticated nanoliter fluid handling in
    an easy-to-use format. We believe the advantages of our IFC
    systems can be applied to a wide variety of applications across
    many fields using standard chemistries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For each application, we provide a complete IFC system
    consisting of specially designed single-use IFCs,
    instrumentation, software and support services. Our IFC systems
    are designed to be easily incorporated into our customers&#146;
    laboratory environments and analysis workflow. For example, our
    IFCs are the same size and shape as standard 384 microwell
    plates, which facilitate the loading and handling of our IFCs by
    standard laboratory equipment. Each IFC includes an elastomeric,
    or rubber-like, core that contains an extensive network of
    microfluidic components, such as valves, channels, pumps, mixers
    and other components that deliver samples and reagents to
    thousands of nanoliter volume chambers where individual assays
    can be performed. In much the same way that semiconductor
    technology has enabled tremendous computational power to be
    placed onto a single silicon chip, the integration of large
    numbers of miniaturized components on our IFCs enables
    sophisticated fluid handling at high throughput and low cost.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC allows users to individually
    assay 48 samples against 48 primer-probe sets, generating 2,304
    separate real-time qPCR reactions on a single device. In May
    2008, we launched our 96.96 Dynamic Array IFC, which is
    configured to run 96 samples against 96 primer-probe sets,
    generating 9,216 separate reactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table compares the performance of one conventional
    384 microwell plate to that of one of our 48.48 Dynamic Array
    IFCs and one of our 96.96 Dynamic Array IFCs for a genotyping
    study involving 1,000 samples and 96 SNPs:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 48.48<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Fluidigm 96.96<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>384 Microwell<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Dynamic Array<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Plate (5 &#181;l/well)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>IFC</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Runs for Study
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    250
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    42
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    11
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total reaction volume
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    480 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    20 ml
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10 ml
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pipetting Steps
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    192,000
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4,032
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2,112
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The advantages of our IFC systems over existing microwell-based
    systems include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Complexity.</I>&#160;&#160;Loading our IFC requires
    orders of magnitude fewer pipetting steps than
    384&#160;microwell plates for the same experiment, which reduces
    the time, cost and potential for error.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Improved Throughput.</I>&#160;&#160;A single IFC based on our
    96.96 format can conduct 9,216 real-time qPCR or other assays,
    or 24 times more assays than a single 384 microwell plate. The
    improved throughput reduces the time and cost associated with
    complex experiments and expands the number and range of
    experiments that may be conducted.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Nanoliter Precision.</I>&#160;&#160;Our IFC systems allow
    users to dispense samples and reagents in microliter volumes
    which are automatically combined and mixed in nanoliter and
    sub-nanoliter volumes. In addition to cost and workflow
    benefits, this capability makes it practical for users to
    conduct certain high sensitivity, low volume techniques, such as
    digital PCR and single cell analysis.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Reduced Sample and Reagent
    Requirements.</I>&#160;&#160;Obtaining patient samples for
    assays can also be costly, and in many cases the amount of those
    samples is finite. Our systems typically require between 0.5%
    and 1.0% of the amount of sample and reagent per reaction as
    conventional systems, allowing scarce samples and costly
    reagents to be conserved or tested more extensively.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Decreased Capital Cost.</I>&#160;&#160;A single BioMark
    system has the same throughput as the combined throughput of
    multiple conventional systems. As a result, for high volume
    users, the cost of purchasing one BioMark system can be much
    lower than the cost of purchasing the number of competing
    systems and associated robotic equipment required to provide the
    same throughput, even though our BioMark system may cost more on
    a per unit basis.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Compatibility with Existing
    Infrastructure.</I>&#160;&#160;Our IFCs incorporate plastic
    input frames that are the same size as standard microwell plates
    and are designed to work with the most commonly used laboratory
    systems, including existing robotic pipetting systems, bar code
    readers, plate handling systems and other equipment. Our IFCs
    are also designed to work with standard real-time qPCR
    techniques and TaqMan chemistries. As a result, we believe users
    are able to quickly introduce our systems into their
    laboratories and achieve results equal to or better than they
    were obtaining with conventional systems.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems also have significant advantages over other
    high-throughput approaches. For example, our BioMark system can
    detect gene expression levels over a much broader dynamic range
    than microarrays, pre-formatted arrays, bead arrays or mass
    spectrometry analysis. For genotyping, our BioMark system has a
    call rate equal to or better than conventional microwell-based
    systems. Also, our IFC systems provide researchers with needed
    flexibility in assay selection and study design. Unlike
    microarrays, bead arrays and pre-formatted arrays, our IFCs are
    not limited to detecting certain predetermined genetic markers.
    Instead, users can perform experiments with our IFCs using
    assays from their existing libraries, purchased from a wide
    variety of commercial sources or developed in their own
    laboratories. Finally, the efficient workflow of our IFC systems
    enables users to complete an IFC run in less than three hours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Other high-throughput approaches have advantages over
    conventional microwell plate systems that are similar to the
    advantages of our IFC systems. For example, microarrays,
    pre-formatted arrays, bead arrays and mass spectrometry analysis
    all reduce complexity and increase throughput as compared to
    conventional approaches when used for large scale
    experimentation, and, in many instances, are more cost-effective
    than conventional approaches. In addition, pre-formatted arrays
    significantly reduce sample and reagent consumption as compared
    to microwell plates. Also, microarrays and bead arrays have call
    rates for genotyping that are comparable to those obtained with
    our systems or with microwell plate systems. Because these
    systems are designed to detect thousands of genetic markers,
    they are often chosen by researchers to perform very large-scale
    association or survey studies over conventional microwell plate
    systems or our systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC systems address the needs of researchers and clinicians
    who perform large-scale experimentation in the areas of
    genomics, proteomics and molecular diagnostics. In particular,
    for validation studies or projects of a similar scale, our IFC
    systems substantially reduce cost, simplify workflow and
    increase throughput as compared to conventional microwell plate
    systems. Nevertheless, researchers and clinicians may be slow to
    adopt our IFC systems as they are based on technology that,
    compared to conventional technology, is new and not yet
    well-established in the industry. Moreover, many of the existing
    laboratories have already made substantial capital investments
    in their existing systems and may be hesitant to abandon that
    investment. While we believe our systems provide significant
    cost-savings, the initial price of our systems and the price of
    our IFCs is higher than conventional systems and standard
    384&#160;microwell plates. Our IFC systems are less well suited
    for smaller scale research initiatives where complexity and
    workflow issues may be less pressing and conventional systems
    may be more economical. As life science research continues to
    evolve and is commercialized, we believe that there will be
    increasing demand for life science automation solutions that
    enable experimentation on the scale supported by our IFC systems.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Applications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFC technology has the potential to be applied to a vast
    range of research and commercial applications. We have
    commercialized IFC systems for life science research
    applications such as gene expression analysis, genotyping,
    digital PCR and protein crystallization. We believe that these
    applications are relevant to markets beyond life science
    research, such as the development of molecular diagnostics, and
    that IFC systems can be developed for numerous other life
    science applications. We and our academic and corporate
    collaborators have developed non-commercial IFCs for a wide
    variety of applications in the areas of genomics, proteomics,
    cellular biology and synthetic chemistry. As illustrated by the
    examples below, researchers have been able to utilize the
    advantages of our IFC systems in their laboratories to achieve
    significant research successes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Current
    Commercial Applications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gene Expression Analysis.</I>&#160;&#160;Researchers may
    conduct gene expression studies to measure the activity of tens
    or hundreds of genes across hundreds or thousands of
    individuals. For these validation studies, it is often important
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    to know the expression level of a gene, not merely whether the
    gene is &#147;on&#148; or &#147;off,&#148; as often either high
    or low activity level is associated with a particular
    characteristic or disease state. Our IFC systems have been used
    to deliver high-throughput and precise measurements in gene
    expression analysis applications. For example, researchers at
    Myriad Genetics have identified panels of genes that could be
    used to predict cancer progression or select treatment options.
    However, the cost and complexity of high-throughput real-time
    qPCR using conventional microwell plates significantly limited
    researchers&#146; ability to perform the appropriate assays. In
    response, Myriad Genetics adopted our BioMark system which,
    together with our Dynamic Array IFCs, has allowed them to
    significantly reduce their pipetting workload, and therefore
    pursue research projects that may have been prohibitively
    cumbersome without our system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Genotyping.</I>&#160;&#160;Researchers performing genotyping
    studies may begin by surveying the genomes of relatively few
    individuals looking for tens of thousands or even hundreds of
    thousands of SNPs. Analysis of these studies will often reveal
    that a relatively small number of SNPs appear to be correlated
    with the characteristic of interest. To validate this analysis,
    researchers may conduct additional studies involving hundreds or
    even thousands of individuals focused on tens or hundreds of
    SNPs. For example, the National Cancer Institute&#146;s Core
    Genotyping Facility, or the CGF, collaborates with researchers
    at other government research centers and academic institutions
    with the goal of developing screens to identify individuals
    susceptible to particular forms of cancer and guiding the
    development of targeted therapeutics. One of the CGF&#146;s
    primary responsibilities in these collaborations is conducting
    the large-scale experiments necessary to accurately interrogate
    hundreds of SNPs on many patient samples. In a typical
    association study, the CGF runs 30 to 300 assays on 1,000 to
    10,000&#160;patient samples. Such large-scale studies are
    difficult and expensive to perform with conventional microwell
    plate technology. Using our BioMark system, the CGF continues to
    perform the same assays previously developed in its existing
    library of over 5,000 assays.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Genotyping analysis is also used in situations where research
    has already identified particular genetic profiles of interest
    and there is a need to test a group of subjects to determine
    which profile they fit. For example, the Alaska Department of
    Fish and Game uses our BioMark system to perform genotyping
    analysis to determine the region of origin of salmon caught in
    commercial or sport fisheries. By analyzing a large number of
    salmon, the department can gain an understanding of the effects
    that fisheries have on populations of salmon and thereby manage
    the resource more effectively. The department has developed
    panels for three species which range from 40 to 60 SNPs, and its
    throughput approaches 100,000 samples per year. The departments
    of fish and game in the states of Oregon and Washington are also
    using our BioMark system for similar applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Digital PCR.</I>&#160;&#160;The widespread use of genetic
    testing in high-risk pregnancies has created strong interest in
    rapid and accurate molecular diagnostics for certain common
    chromosomal abnormalities. However, conventional methods have
    limitations related to speed, precision and the risks associated
    with sampling a significant amount of material from the fetus
    during an invasive procedure, such as amniocentesis or chorionic
    villi sampling. Digital PCR has been identified as a technique
    for highly sensitive and precise nucleic acid measurement, but
    performing it with conventional laboratory equipment is so
    cumbersome that it has not been widely adopted. In an article
    published by Analytical Chemistry in August 2007, researchers at
    the laboratory of Professor Stephen Quake, our
    <FONT style="white-space: nowrap">co-founder,</FONT>
    at Stanford University demonstrated that digital PCR can be used
    for accurate measurement of trisomy&#160;21, or Down syndrome.
    Using our Digital Array IFC and DNA from human cell lines,
    Dr.&#160;Quake&#146;s laboratory was able to precisely measure
    the number of copies of a DNA sequence from this chromosome and
    at the same time measure the number of copies of a DNA sequence
    from another chromosome whose copy number does not vary. For
    trisomy 21, the ratio of these markers is significantly higher
    than normal. Similar work in pre-natal genetic testing is being
    pursued using our IFCs by other customers at leading academic
    institutions. We believe that with further clinical validation
    and development, such research could be developed into a
    diagnostic test that would require significantly less material
    from the fetus and provide results much more rapidly than
    current methods. We also believe that digital PCR will enable
    such diagnostics to ultimately be used in a non-invasive
    fashion, thus further reducing risk to the fetus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer researchers have identified a particular mutation in
    chronic myeloid leukemia cells that render those cells resistant
    to the drug Gleevec. Gleevec is typically used as the initial
    treatment for this type of leukemia and is often able to put the
    disease into remission for months or years. However, a
    significant proportion of these leukemia patients eventually
    develop mutated leukemia cells that are resistant to Gleevec.
    These mutated cells are initially
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    very scarce and undetectable using conventional systems, but
    they eventually multiply and cause the patient to become
    symptomatic again. Researchers at the Fred Hutchinson Cancer
    Research Center have used our Digital Array IFC in their
    laboratory to test patient samples and have been able to detect
    these mutated cells earlier than with conventional techniques.
    With additional validation and demonstration of clinical
    relevance, we believe a test based on digital PCR could be a
    useful tool for monitoring patients who are diagnosed with
    chronic myeloid leukemia.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Protein Crystallization.</I>&#160;&#160;In order to determine
    how a particular protein interacts with other components of a
    disease pathway, researchers often attempt to determine its
    structure using protein crystallization. Because most proteins
    will crystallize only under very precise conditions that are
    specific to the particular protein, protein crystallization
    involves performing numerous assays to determine the conditions
    under which the protein crystallizes. As described in the April
    2006 issue of the journal <I>Science </I>and supporting online
    material, researchers at the Wilson lab of Scripps Research
    Institute in La Jolla, California used our Topaz system to
    understand how the H5N1 avian flu virus can infect humans.
    Researchers at the Wilson lab had prepared a small sample of the
    protein that the virus uses to attach itself to cells in the
    respiratory tract. With the Topaz system, they were able to
    quickly screen a few microliters of the sample across a wide
    variety of different conditions and determine the optimum
    conditions for protein crystallization. Using this information,
    they were able to grow larger crystals using standard
    crystallization techniques. Subsequent analysis of the structure
    of the crystallized protein revealed why the current form of the
    avian H5N1 virus has not yet acquired the ability to readily
    infect humans compared to other flu viruses.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Future Applications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>High-Throughput DNA Sequencing.</I>&#160;&#160;For many
    years, researchers have wanted to conduct large scale studies of
    genomic variations to better understand gene regulation and gene
    function. However, it was only with the recent introduction of
    ultra high-throughput DNA sequencers, sometimes referred as next
    generation sequencing, that conducting such studies became
    feasible. Accurately performing DNA sequencing with these
    high-throughput machines requires careful preparation of the
    sample to be analyzed, including precisely determining the
    amount of template DNA present in the sample. Quantifying or
    titrating the DNA in the sample using typical methods is often a
    painstaking and lengthy process that can consume a large
    quantity of the sample itself. Stanford University researchers
    working in the laboratory of Dr.&#160;Stephen Quake, who is a
    co-founder of Fluidigm and chair of our Scientific Advisory
    Board, have demonstrated that our Digital Array IFC can be used
    to quantify the amount of DNA in a sample in four hours or less
    with the precision typically needed by high-throughput DNA
    sequencers. This technique is significantly quicker and less
    expensive than conventional methods and allows for more
    efficient use of the high-throughput DNA sequencers by
    eliminating one of the two runs that are generally required to
    sequence a sample. In addition, because the technique consumes
    one one-thousandth of the amount of sample that typical methods
    consume, it can be used in situations where only scarce sample
    is available. Though researchers have just begun to adopt
    high-throughput DNA sequencers, we believe there are over 1,000
    genomic research sites worldwide that are potential users of the
    machines within the next few years. Two of our customers have
    begun using our Digital Array IFC to perform this technique on a
    trial basis, and we expect to make the application more widely
    available beginning in the fourth quarter of this year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Molecular Diagnostics.</I>&#160;&#160;Life science research
    is revealing an increasing number of diseases and conditions
    that can be diagnosed, evaluated and monitored by measuring
    panels of gene expression levels, SNPs, proteins or other
    biomarkers. Validating these research findings and translating
    them into clinically available tests often requires life science
    automation systems that are able to efficiently measure multiple
    biomarkers in a large number of patient samples. Our existing
    IFC systems are able to measure certain nucleic acid biomarkers
    that are commonly used in these tests, and we expect that we
    will be able to develop IFC systems to measure other relevant
    biomarkers. As described above, researchers have used our IFC
    systems to detect clinically relevant biomarkers, such as drug
    resistant leukemia cells and fetal chromosomal abnormalities. We
    believe that the high throughput, flexibility and simplified
    workflow of our IFC systems could make them an attractive
    solution for validating and commercializing a wide range of
    molecular diagnostic tests being developed by researchers. In
    addition, we believe that our IFC systems&#146; ability to
    measure gene expression levels across a broad range and to
    detect nucleic acid sequences present in very low concentrations
    will support the development and commercialization of molecular
    diagnostic tests that would not be practical with conventional
    systems. Our IFC systems have not been cleared or approved by
    the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    U.S.&#160;Food and Drug Administration, or FDA, for use in any
    molecular diagnostic tests and we cannot currently market them
    for the purpose of performing molecular diagnostic tests. We do
    not have any current plans to develop products that are
    regulated by the FDA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Applications.</I>&#160;&#160;We believe that the
    inherent design flexibility of our core technology allows us to
    build IFC systems that can provide significant benefits in a
    wide range of fields and industries. For example, the
    architecture of our Dynamic Array is flexible and supports the
    development of IFCs that create matrixed combinations of a
    variable number of samples versus a variable number of reagents.
    In addition, our IFC technology utilizes a variety of
    microfluidic components, such as pumps, mixers and separation
    columns, that allow the implementation of sophisticated
    biochemical processes on our IFCs. While we have not commenced
    commercial development of IFC systems for these fields, we have
    developed IFCs for internal research purposes in such diverse
    fields as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    immunoassays, which can measure levels of protein expression and
    other molecules in a highly-parallel, multiplexed format;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    high-throughput drug screening, including the analysis of
    molecules that inhibit protein-protein and protein-nucleic acid
    interactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    chemical synthesis, including production of radio-labeled sugars
    which in combination with advanced medical imaging can help
    diagnose and monitor cancer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pharmacogenomics, an emerging field that analyzes how variations
    in human genomes affect the performance and toxicity of
    therapeutic agents;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    systems biology, an effort to understand the collective behavior
    of genes as they collaborate in networks;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    synthetic biology, an emerging field aimed at engineering
    biological systems to build novel biological functions, systems
    and perhaps organisms; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cellular assays, including stem cells and regenerative medicine,
    where our IFCs have been used to isolate, cultivate and analyze
    single cells.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to become a global leader in providing automated
    bio-analytical research and molecular diagnostic systems. Our
    business strategy consists of the following elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Establish our IFC Technology as the Leading Solution for a
    Broad Range of Life Science Applications.</I>&#160;&#160;Our
    initial sales and marketing efforts have been focused on
    establishing our IFC systems as leading solutions for
    high-throughput life science research applications. We intend to
    leverage the market awareness and acceptance created by our
    initial product offerings to market new products and
    applications to life science researchers and to sell new and
    existing applications to customers in other markets, such as
    molecular diagnostics and applied genomics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Increase the Throughput and Efficiency of Our
    IFCs.</I>&#160;&#160;A primary focus of our research and
    development efforts is the development of IFCs with increased
    component density and, therefore, the ability to conduct an
    increased number of experiments on a single IFC. Increasing
    density provides value to our customers by increasing
    throughput, enhancing efficiency, reducing labor costs and
    reducing reagent and sample volumes. We expect that these
    increased capacity IFCs will allow us to deliver additional
    capabilities and cost savings, and further improve our
    competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Expand Recurring IFC Revenue Stream Through Product
    Innovation and System Sales.</I>&#160;&#160;We intend to drive
    revenue growth by increasing the number of installed IFC
    systems, improving the cost per test of our IFCs and developing
    IFCs and systems for additional applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Provide Superior Customer Service.</I>&#160;&#160;We have a
    global sales force and support organization that offers
    technical solutions and customer support through direct
    relationships with our current and potential customers. Through
    the direct connection with our customers, we are able to better
    understand their needs and apprise
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    them of new product offerings and technological advances in our
    current IFC systems, related instrumentation and software, while
    maintaining a consistent marketing message and high level of
    customer service.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Enhance IFC Manufacturing Efficiency.</I>&#160;&#160;We
    intend to enhance our manufacturing efficiency through
    improvements in our existing processes, development of new IFC
    designs and implementation of new manufacturing methods in order
    to improve our manufacturing yields and reduce our manufacturing
    costs. We believe that these improvements will enable us to
    deliver additional value to our customers and to maintain or
    enhance our advantages over competing systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Continue to Develop our Technology and Intellectual Property
    Position.</I>&#160;&#160;Our products are based on a set of
    related proprietary technologies that we have either developed
    internally or licensed from third parties. We intend to continue
    making significant investments in research and development to
    further expand and deepen our technological base. At the same
    time, we intend to maintain and strengthen our intellectual
    property position through the continued filing and prosecution
    of patents in the United States and internationally and through
    the in-licensing of third party intellectual property as
    appropriate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Products</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently market two IFC systems, the BioMark system for
    real-time qPCR and the Topaz system for protein crystallization.
    Each system consists of single-use IFCs, loaders that control
    the IFCs, readers that detect reactions on the IFCs and software
    for analyzing, annotating and archiving the data produced by the
    readers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    BioMark System for Real-Time qPCR</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark system allows users to perform gene expression
    analysis, genotyping and digital PCR using standard TaqMan
    chemistry.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Dynamic Array IFCs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our BioMark 48.48 Dynamic Array IFC is based on matrix
    architecture that allows users to individually assay 48 samples
    against 48 primer-probe sets, generating 2,304 real-time qPCR
    reactions on a single device. One version of this IFC is
    optimized to perform gene expression analysis and another is
    optimized for genotyping, each assay in volumes of
    10&#160;nanoliters or less.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Dynamic Arrays in the fourth
    quarter of 2006 and, as of June&#160;28, 2008, 16&#160;customers
    have purchased Dynamic Array IFCs for use in applications, such
    as SNP association follow-up studies and single stem-cell gene
    expression profiling. In May 2008, we launched our&#160;96.96
    Dynamic Array IFC, which is configured to run 96 samples against
    96 primer-probe sets, generating 9,216 reactions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Digital Array IFCs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The BioMark 12.765 Digital Array IFC is based on partitioning
    architecture that allows users to divide 12&#160;separate
    samples into 765 smaller samples and perform a real-time qPCR
    assay against each sample in less than 10&#160;nanoliter
    volumes. This IFC can be used for digital PCR and to precisely
    quantify the amount of a particular nucleic acid sequence
    present in a sample. We have been selling Digital Array IFCs
    since March 2007 and, as of June&#160;28, 2008,
    16&#160;customers have purchased Digital Array IFCs for use in
    applications, such as characterizing unculturable bacteria,
    cancer detection and high-throughput DNA sequencing.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">BioMark
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our NanoFlex IFC Controller for the BioMark system fully
    automates the setup of IFCs for real-time qPCR-based experiments
    and includes software for implementing and tracking experiments.
    The instrumentation for our BioMark system controls the
    real-time qPCR process and detects the fluorescent signals
    generated using a white light source, emission and excitation
    filters, precision lenses, a licensed thermal cycler and a
    digital camera. We also offer various software packages that
    provide data analysis following data collection. Our analysis
    software shows data as color-coded maps of every position on the
    IFC, as amplification curves and as numeric tabular data.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Topaz System for Protein Crystallization</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz system allows users to screen protein samples against
    a set of reagents in order to determine the optimum conditions
    for crystallizing a protein. The Topaz system includes IFCs
    similar to our Dynamic Array architecture that have been
    optimized for highly efficient protein crystallization screening.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Screening IFCs and Reagents</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1.96, 4.96 and 8.96 Screening IFCs for our Topaz system
    allow users to test 96 different reagents or reagent
    concentrations against one, four or eight different protein
    samples. We estimate that our screening IFCs require only
    1%&#160;the amount of sample used in standard microwell plate
    technologies, which is important because protein samples are
    often extremely scarce or difficult to prepare. The 4.96 and
    8.96 IFCs provide greater fluid handling efficiency by enabling
    the parallel processing of different samples containing a
    particular protein or different constructs of the same protein
    on a single IFC. This parallel processing saves pipetting steps
    and allows the user to determine the best sample or construct to
    use when scaling up production of a protein to generate
    diffraction-quality crystals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also re-sell third party reagents that we have tested with
    our Topaz system. Though our customers may purchase or make
    their own reagents for use with our system, we recommend that
    they use reagents that we have validated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We commercially introduced our Topaz systems in the first
    quarter of 2003 and, as of June&#160;28, 2008, 75&#160;customers
    have purchased Topaz IFCs for use in applications such as
    functional studies and structure-based drug design.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Topaz
    Instrumentation and Software</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The NanoFlex IFC controller for the Topaz system fully automates
    the setup of diffusion-based protein crystallization experiments
    and includes software for tracking experiments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Topaz AutoInspeX II workstation automates the scanning of
    Topaz IFCs and the identification of reaction chambers where
    crystallization has occurred. The AutoInspeX II incorporates
    high-end optical performance and a full suite of software for
    analyzing and archiving crystallization results. The
    sophisticated instrumentation and software included in our Topaz
    system enables users to automatically image and accurately score
    crystals as small as 10 microns by 20 microns.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales and
    Marketing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We distribute our systems through our direct field sales and
    support organizations located in North America, Europe and Asia
    and through distributors or sales agents in parts of Europe and
    Asia-Pacific. Our global sales force is able to apprise our
    current and potential customers of new product offerings and
    technological advances in our current IFC systems, related
    instrumentation and software to help drive revenue growth. As
    our primary point of contact in the marketplace, our sales force
    ensures a consistent marketing message and high level of
    customer service, while enhancing our understanding of customer
    needs. As of December&#160;29, 2007, we had 24 people employed
    in sales, sales support and marketing, including 9 sales
    representatives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our sales and marketing efforts are targeted at laboratory
    directors and principal investigators at leading companies and
    institutions who need reliable, high-throughput life science
    automation solutions to conduct large-scale experimentation. We
    seek to increase awareness of our products among our target
    customers through participation in tradeshows and academic
    conferences including sponsoring scientific lectures by
    prominent users of our systems. Because our systems are
    relatively new and require a capital investment, the sales
    process typically involves numerous interactions and
    demonstrations with multiple people within an organization. In
    addition, potential customers will often wish to conduct
    in-depth evaluations of the system including running identical
    sets of samples and reagents on both our system and competing
    systems. As a result of these factors and the budget cycles of
    our customers, our sales cycle, the time from initial contact
    with a customer to our receipt of a purchase order, can often be
    12&#160;months or longer.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Customers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have sold our BioMark and Topaz systems to a wide variety of
    biotechnology and pharmaceutical companies and to academic,
    governmental and clinical research institutions. As of
    June&#160;28, 2008, 79 of our Topaz systems have been installed
    at customer sites and 24 of our BioMark systems have been
    installed at customer sites. The following is a list of our
    representative customers in each of the listed markets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="19%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="40%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Customer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Market</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Application</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MedImmune
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug development&#160;&#151; real-time qPCR for
    gene expression profiling in research and clinical trials
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Myriad Genetics
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Cancer and diagnostics research&#160;&#151; real-time qPCR for
    differential gene expression in cancer studies
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Merck &#038; Co.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Gene Expression
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Gene expression profiling for pharmaceutical drug development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alaska Department of Fish and Game
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Government wild-life resource management&#160;&#151; SNP
    genotyping for identification of salmon species
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    National Cancer Institute
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Genotyping
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; genotyping for cancer research
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Chinese University of Hong Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Digital PCR
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Academic basic research; clinical diagnostics
    research&#160;&#151; digital PCR for early cancer detection
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vertex Pharmaceuticals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Protein crystallization
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Pharmaceutical drug discovery
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Revenue Concentration.</I>&#160;&#160;We receive a
    substantial portion of our revenue from a limited number of
    customers and grantors. For the year ended December&#160;29,
    2007, the Singapore Economic Development Board, or EDB,
    accounted for 24% of our total revenue. For the year ended
    December&#160;31, 2006, CTI Molecular Imaging accounted for 16%
    of our total revenue, Kikotech Co., Ltd. accounted for 14% of
    our total revenue and EDB accounted for 14% of our total
    revenue. For the year ended December&#160;31, 2005, Kikotech
    accounted for 16% of our total revenue and a collaboration
    agreement accounted for 14% of our total revenue. We anticipate
    that we will continue to be dependent on a limited number of
    customers and grantors for a significant portion of our revenue
    in the near future. The loss of any of these customers could
    have a material adverse effect on our results of operations and
    cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We compete with both established and development stage life
    science companies that design, manufacture and market
    instruments for gene expression analysis, genotyping, other
    nucleic acid detection and additional applications using
    established laboratory techniques. For example, companies such
    as Affymetrix, Applied Biosystems, BioTrove, Illumina, Roche
    Diagnostics and Sequenom have products for gene expression
    <FONT style="white-space: nowrap">and/or</FONT>
    genotyping that compete in certain segments of the market in
    which we sell our BioMark system. In addition, a number of other
    companies and academic groups are in the process of developing
    novel technologies for genetic analysis, many of which have also
    received grants from the National Human Genome Research
    Institute, a branch of the National Institutes of Health.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The high-throughput life science platforms industry is highly
    competitive and expected to grow more competitive with the
    increasing knowledge gained from molecular biology
    experimentation. Many of our competitors are either
    publicly-traded or are divisions of publicly-traded companies
    and enjoy several competitive advantages over us, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    significantly greater name recognition;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater financial and human resources;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    broader product lines and product packages;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger sales forces;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    larger and more geographically dispersed customer support
    organization;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    substantial intellectual property portfolios;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    established customer bases and relationships;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    greater experience in research and development, manufacturing
    and marketing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the principal competitive factors in our markets
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cost of capital equipment and supplies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ease of use;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    accuracy and reproducibility of results;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compatibility with existing laboratory processes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To successfully compete with existing products and future
    technologies, we will need to demonstrate to potential customers
    that the cost savings and performance of our technologies and
    products, as well as our customer support capabilities, are
    superior to those of our competitors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Technology</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our products are based on a tiered set of related proprietary
    technologies that we have either developed internally or
    licensed from third parties.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Multi-Layer
    Soft Lithography</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs are manufactured using a technology known as
    multi-layer soft lithography, or MSL. With MSL, we are able to
    use standard semiconductor manufacturing techniques, along with
    certain proprietary processes, to create complex integrated
    microfluidic devices.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Using MSL technology, we are able to create valves, chambers,
    channels and other fluidic components on our IFCs at high
    density. We combine these components in complex arrangements
    that allow nanoliter quantities of fluids to be precisely
    directed to specific positions within the IFC. Unlike most prior
    microfluidic technologies, our IFCs do not rely on electricity,
    magnetism or similar approaches to control fluid movement.
    Rather, our IFCs control fluid flow with valves. The most
    important components on our IFCs are our NanoFlex valves, which
    are created by the intersection of two channels. When the valve
    is open, fluid is able to flow through the lower channel. When
    the upper or &#147;control&#148; channel is pressurized, the
    material separating the two channels is deflected into the lower
    channel, closing the valve and stopping fluid flow. If pressure
    is removed from the control channel, the channels return to
    their original form, and the valve is again open. The
    elastomeric properties of IFC cores allow our NanoFlex valves to
    form a reliable seal and cycle through millions of openings and
    closings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The elastomer we currently use for our commercial products is a
    form of silicone rubber known as polydimethylsiloxane, or PDMS,
    but we have researched other materials with different properties
    for specific purposes. PDMS is transparent, which allows fluid
    movement to be easily monitored with a variety of existing
    optical technologies, such as bright field or phase contrast
    microscopy. In addition, the gas permeability of PDMS allows the
    reliable metering of fluids with near picoliter precision by
    eliminating the bubble problems encountered by most other
    microfluidic technologies. In essence, we are able to pump
    fluids into closed reaction chambers at sufficient pressure to
    drive any air out of the chamber directly through the chamber
    walls. PDMS also supports an environment that is favorable to
    maintaining cell cultures.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed commercial manufacturing processes to
    fabricate valves, channels and chambers with dimensions in the
    10 to 100 micron range, at high density and with high
    reliability. For research purposes, we have created devices with
    both substantially smaller and larger features. Though our
    manufacturing is based on standard
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    semiconductor manufacturing technologies and techniques, we have
    also developed novel processes for mold fabrication that enable
    mass production of high density IFCs with nanoliter volume
    features.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Integrated
    Fluidic Circuits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our IFCs incorporate several different types of technology that
    together enable us to use MSL to rapidly design and deploy new
    microfluidic applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Microfluidic Components.</I>&#160;&#160;The first level of
    our IFC technology is a library of components that perform basic
    microfluidic functions. We have proven designs for numerous
    elements, such as pumps, mixers, separation columns, control
    logic and reaction chambers. These are readily integrated to
    create circuits capable of performing a wide range of
    biochemical reactions. Even when it is necessary to integrate
    multiple elements to perform a particularly complex reaction,
    the area taken up on a circuit for a single reaction is small
    compared to a typical overall circuit size of three centimeters
    by three centimeters. As a result, we are routinely able to
    develop IFCs that perform thousands of reactions per square
    centimeter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Architectures.</I>&#160;&#160;The second level of our IFC
    technology comprises the architectures we have designed to
    exploit our ability to conduct thousands of reactions on a
    single IFC. The first of these is the Dynamic Array, a matrix
    architecture that allows multiple different samples and multiple
    different reagents to be loaded onto a single IFC and then
    combined so that there is an isolated reaction between each
    sample and each reagent. The primary advantage of this
    architecture is that each sample and reagent has to be pipetted
    only once per IFC rather than once per reaction, as is the case
    with plate-based technologies. For example, a single 48.48
    Dynamic Array IFC can perform a total of 2,304 unique reactions
    between 48 samples and 48 reagents with only 96 pipetting steps.
    With conventional microwell plate-based technologies, the same
    experiment would require about 4,608 pipetting steps and at
    least six conventional microwell plates. Our Digital Array
    architecture provides similar benefits with respect to pipetting
    steps and fluid handling. The Digital Array architecture allows
    a sample to be split into hundreds or thousands of smaller
    samples. Separate reactions can then be conducted on each of the
    smaller samples.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interface and Handling Frames.</I>&#160;&#160;The third level
    of our IFC technology involves the interaction of our IFCs with
    the actual laboratory environment. The elastomeric blocks at the
    center of our IFCs sit in specially designed frames that are
    able to deliver samples and reagents to the block. These frames
    are the same size as standard 384&#160;microwell plates and have
    sample and reagent input ports laid out in a standard
    384&#160;microwell plate format. As a result, our IFCs can be
    loaded with standard laboratory pipetting robots and can be used
    with standard plate handling equipment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Technological Advances.</I>&#160;&#160;In the second quarter
    of 2002, we sold the first prototype of our 1.48 IFC for our
    Topaz system, which featured 22 valves capable of 2.5 assays per
    square centimeter. In the second quarter of 2006, we introduced
    our 12.765&#160;Digital Array IFC, with over 1,000 valves
    capable of more than 1,000 assays per square centimeter, a
    46-fold increase in valve density and a 400-fold increase in
    assay capability. The chart below illustrates the timing of a
    number of our technological advances. We introduced our
    96.96&#160;Dynamic Array IFC in May 2008, which again increased
    the number of valves and assays per square centimeter relative
    to the 48.48&#160;Dynamic Array. In the semiconductor industry,
    Moore&#146;s Law describes the principle that the shrinking of
    features has allowed for a doubling of transistors on a chip
    approximately every 18&#160;months. Based on manufacturing
    processes borrowed from those in the semiconductor industry,
    Fluidigm has similarly achieved significant gains in the density
    and productivity of our IFCs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a9f3943222.gif" alt="(BAR GRAPH)">
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Software
    and Instrumentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed instrumentation technology to load samples and
    reagents on to the IFC and to control and monitor reactions
    within our IFCs. Our NanoFlex controller consists of commercial
    pneumatic components and both custom and commercial electronics.
    It uses precise control of multiple pressures to independently
    move fluid through up to four IFCs simultaneously and can be
    configured for use with either our BioMark or Topaz systems. Our
    Topaz Auto-InspeX II workstation consists of a commercial
    microscope, illumination source, stage and camera system in a
    single package. Our BioMark system consists of a customized
    commercial thermal cycler packaged with a sophisticated
    fluorescence detection system. All of these instruments are
    designed to be easily introduced into standard automated lab
    environments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have developed specialized software packages to manage and
    analyze the unusually large amounts of data produced by our
    systems. Our BioMark gene expression analysis software
    automatically identifies individual real-time qPCR reactions
    from fluorescent images and generates amplification threshold
    crossing values allowing researchers to readily perform complete
    normalized comparative gene expression analysis across large
    numbers of samples and assays. Similarly, the BioMark genotyping
    analysis software automatically clusters fluorescent intensities
    from individual genotype reactions and makes genotype calls
    across individual and multiple IFC runs. Our Topaz system
    software incorporates sophisticated image processing and
    analysis functionality that enables the automatic detection and
    classification of protein crystals. Most of our software
    development uses Microsoft.NET tools to facilitate interaction
    with typical laboratory information management systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Manufacturing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations are located in Singapore and South
    San&#160;Francisco. Our Singapore facility fabricates all of our
    IFCs for commercial sale. IFCs for research and development
    purposes are fabricated at both locations. We manufacture
    instrument systems at both locations, with certain instruments
    assembled in Singapore and others in South San&#160;Francisco.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Singapore facility commenced operations in October 2005 and
    established full process capability for its first product, the
    Topaz Screening IFC, in June 2006 and for its first Dynamic
    Array, the 48.48 Dynamic Array in October 2006. Our Singapore
    facility has been producing components for our Topaz system
    since October 2006 and components for our BioMark system since
    December 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We established our manufacturing facility in Singapore to take
    advantage of the skilled workforce, supplier and partner
    network, lower operating costs and government support available
    there. Our IFC manufacturing process includes photolithography
    and fabrication technologies that are very similar to those used
    in the fabrication of semiconductor chips. As a result, we are
    able to hire from a pool of skilled manpower created by the
    existing semiconductor industry in Singapore. Similarly, the
    Singapore semiconductor industry has created a broad network
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of potential suppliers and partners for our manufacturing
    operations. We are able to locally source a large proportion of
    the raw materials required in our processes and have been able
    to collaborate with local engineering companies to develop
    enabling technologies for IFC fabrication. We have made
    significant improvements in yields through process improvements
    at our Singapore facility and IFC production increased
    three-fold in 2007 compared to 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our manufacturing operations in Singapore have been supported by
    grants from the Singapore Economic Development Board, or EDB,
    which provide incentive grant payments for research, development
    and manufacturing activity in Singapore. Our arrangements with
    EDB require us to maintain a significant and increasing
    manufacturing and research and development presence in Singapore.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our South San&#160;Francisco facility began producing Topaz
    systems in 2002. In 2005, our South San Francisco facility began
    assembling instrumentation for our BioMark system.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect that our existing manufacturing capacity for
    instrumentation and IFCs is sufficient to meet our needs for at
    least the next two years. However, we are considering developing
    additional capacity to ensure that all or most of our products
    are produced by at least two different facilities. We believe
    that having dual sources for our products would help mitigate
    the potential impact of a production disruption at any one of
    our facilities and that such redundancy may be required by our
    customers in the future. We have not determined the timing or
    location of any additional manufacturing capacity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on a limited number of suppliers for certain components
    and materials used in our systems. While we are in the process
    of qualifying additional sources of supply, we cannot predict
    how long that qualification process will last. If we were to
    lose one or more of our limited source suppliers, it would take
    significant time and effort to qualify alternative suppliers.
    Key components in our products that are supplied by sole or
    limited source suppliers include a thermal cycler customized to
    our specifications, a specialized polymer from which our IFC
    cores are fabricated, the plastic carrier that holds the IFC
    core in certain of our products and the specialized high
    resolution camera lenses used in the reader for our BioMark
    system. We are neither a major customer of our suppliers, nor do
    we have long term supply contracts with most of these suppliers.
    These suppliers may therefore give other customers&#146; needs
    higher priority than ours, and we may not be able to obtain
    adequate supply in a timely manner or on commercially reasonable
    terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into a supply agreement with Eppendorf AG to
    provide to us a thermal cycler customized to our specifications.
    Pursuant to this agreement, we have agreed to purchase from
    Eppendorf at least a specified minimum number of units each year
    in exchange for volume discounts. We have also agreed, during
    the term of the agreement, not to manufacture or sell a product,
    in stand-alone form, or compete in any way directly or
    indirectly with the customized thermal cycler provided by
    Eppedorf in stand-alone form. Eppendorf has agreed to refrain
    from providing a similarly customized unit to any person or
    entity until two years after the agreement has terminated.
    Either party may terminate the agreement with good reason, which
    includes a failure to timely deliver conforming units, subject
    to a cure period. Eppendorf may terminate the agreement if we
    purchase fewer than 75% of the specified minimum units for each
    of two consecutive years. After April&#160;1, 2010, either party
    may terminate the supply agreement upon six months prior written
    notice.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have assembled experienced research and development teams at
    our South San&#160;Francisco and Singapore locations with the
    scientific, engineering, software and process talent that we
    believe is required to grow our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">New
    Product and Application Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The largest component of our current research and development
    effort is in the areas of new product and new application
    development. In particular, we are focused on extending and
    supporting the BioMark and Topaz product lines by developing new
    DNA-based applications, improving the introduction of these
    products into existing workflows of our customers and increasing
    the functionality of the products. For example, the addition of
    multi-color analysis allows Digital Array users to analyze as
    many as 36,720 real-time qPCR assays in parallel on a single
    Digital Array.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are also developing new product lines that leverage our
    investment in our Dynamic Array and Digital Array architectures.
    As an example, we have demonstrated Dynamic Array formats that
    can implement over 1,000 immunoassays in parallel. We also
    invest in extending the reach of existing chip designs through
    new chemistries. From time to time, we collaborate with other
    life science companies, universities and government labs on the
    development of prototype IFCs for particular purposes. For
    example, there have been a variety of publications by
    independent researchers demonstrating the use of MSL for
    applications such as immunoassays based on surface-plasma
    resonance, cell culturing and complementary DNA library
    synthesis from single cells.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Process
    Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The second component of our research and development effort is
    process development. We frequently develop new manufacturing
    processes and test methods to support new IFC designs, drive
    down manufacturing cost and increase manufacturing throughput.
    We also invest in manufacturing automation, process changes and
    design modifications to improve yield and lower costs on
    existing IFCs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">New
    Technology Development</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have active research and development efforts to increase the
    density of components on our IFCs and to lower the materials
    cost of our current production methods. We are evaluating new
    materials that can increase the functionality of existing
    products and that would allow our IFCs to be used for a wider
    variety of biological and chemical reactions. Over the longer
    term, we are seeking ways to transfer functionality from
    instrumentation to IFCs to support development of field-based
    and point-of-care applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development expenses were $11.4&#160;million,
    $15.6&#160;million, $14.4&#160;million and $7.2&#160;million in
    2005, 2006, 2007 and the six months ended June&#160;28, 2008. As
    of December&#160;29, 2007, 68 of our employees were engaged in
    research and development activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Scientific
    Advisory Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We maintain a scientific advisory board, consisting of members
    with experience and expertise in the field of microfluidic
    systems and their application, who provide us with consulting
    services. The scientific advisory board generally does not meet
    as a group but instead, at our request, the individual members
    advise us on matters related to their areas of expertise. We
    have entered into agreements with each of our advisors, other
    than Stephen Quake, that require them spend between 6 and
    12&#160;days each year advising us and provide for stock option
    grants to the advisor. Dr.&#160;Quake serves as chair of the
    Scientific Advisory Board pursuant to a broader consulting
    agreement with us. As Chairman, Dr.&#160;Quake advises us on the
    composition of the advisory board and is involved in discussions
    with us more frequently than other advisory board members. When
    the advisory board meets, Dr.&#160;Quake is responsible for
    setting the agenda for the meetings and chairing such meetings.
    Our scientific advisory board consists of the following members:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stephen Quake, Ph.D.</I> is a co-founder of Fluidigm and the
    chair of our scientific advisory board. He is a co-chair of the
    bioengineering department at Stanford University and an
    investigator of the Howard Hughes Medical Institute.
    Dr.&#160;Quake received a B.S. in Physics and a M.S. in
    Mathematics from Stanford University and a Ph.D. in Physics from
    Oxford University. Dr. Quake has been a member of our scientific
    advisory board since June 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Frances H. Arnold, Ph.D.</I> is the Dick and Barbara
    Dickinson Professor of chemical engineering and biochemistry at
    the California Institute of Technology. She is a member of the
    National Academy of Engineering and a fellow at the American
    Institute for Medical and Biological Engineering.
    Dr.&#160;Arnold received a B.S. in Mechanical and Aerospace
    Engineering from Princeton University and a Ph.D. in Chemical
    Engineering from the University of California, Berkeley. Dr.
    Arnold has been a member of our scientific advisory board since
    August 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>James M. Berger, Ph.D.</I> is a Professor of Biochemistry and
    Molecular Biology at the University of California, Berkeley and
    a member of the Physical Biosciences Division, Lawrence Berkeley
    National Laboratory. Dr.&#160;Berger received a B.S. in
    Biochemistry from the University of Utah and a Ph.D. in
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biochemistry from Harvard University. Dr. Berger has been a
    member of our scientific advisory board since June 2002.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Carl Hansen, Ph.D.</I> is an Assistant Professor in the
    Department of Physics and Astronomy at the University of British
    Columbia. Dr.&#160;Hansen received a Ph.D. and M.S. in Applied
    Physics from the California Institute of Technology and a B.S.
    in Engineering Physics/Electrical Engineering/Honors Math from
    the University of British Columbia. Dr.&#160;Hansen has been a
    member of our Scientific Advisory Board since May 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Frank McCormick, Ph.D.</I> is the David A. Wood Distinguished
    Professor of Tumor Biology and the E. Dixon Heise Distinguished
    Professor in Oncology at the University of California,
    San&#160;Francisco, or UCSF. He is also the director of
    UCSF&#146;s Comprehensive Cancer Center. He is a member of the
    Institute of Medicine and a fellow of The Royal Society.
    Dr.&#160;McCormick received a B.Sc. in Biochemistry from the
    University of Birmingham and a Ph.D. in Biochemistry from the
    University of Cambridge. Dr. McCormick has been a member of our
    scientific advisory board since November 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Howard M. Shapiro,&#160;M.D.</I> is a lecturer on Pathology
    at Harvard Medical School, a visiting scientist at the
    Rosenstiel Basic Medical Sciences Research Center at Brandeis
    University and a research associate in Medicine and Pathology at
    Beth Israel Hospital. Dr.&#160;Shapiro received a B.A. from
    Harvard College and an M.D. from New York University School of
    Medicine. Dr.&#160;Shapiro has been a member of our scientific
    advisory board since December 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard N. Zare,&#160;Ph.D.</I> is the Marguerite Blake
    Wilbur Professor of Natural Science and chair of the chemistry
    department at Stanford University. He is a member of the
    National Academy of Sciences, the American Academy of Arts and
    Sciences and the recipient of the National Medal of Science.
    Dr.&#160;Zare received a B.S. in Chemistry and Physics and a
    Ph.D. in Chemical Physics from Harvard University. Dr.&#160;Zare
    has been a member of our scientific advisory board since
    December 2000.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property Strategy and Position</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm&#146;s core technology originated at the California
    Institute of Technology, or Caltech, in the laboratory of
    Professor Stephen Quake, who is a co-founder of Fluidigm.
    Dr.&#160;Quake, his students and their collaborators pioneered
    the application of multilayer soft lithography in the field of
    microfluidics. In particular, Dr.&#160;Quake&#146;s laboratory
    developed technologies that enabled the production of
    specialized valves and pumps capable of controlling fluid flow
    at nanoliter volumes. In a series of transactions, we
    exclusively licensed from Caltech the relevant patent filings
    relating to these developments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreement with Caltech provides us with an
    exclusive, worldwide license to certain patents and related
    intellectual property, as well as the right to prosecute
    licensed patent filings worldwide at our expense and to initiate
    any infringement proceedings. Caltech retains the right to use
    the licensed materials for noncommercial educational and
    research purposes, as well as any rights necessary to comply
    with the statutory rights of the U.S.&#160;government. We have
    issued shares of our common stock to Caltech and, in addition to
    an annual license fee, we agreed to pay to Caltech royalties
    based on sales revenues of licensed products on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis. The license agreement will terminate as to each country
    and licensed product upon expiration of the last-to-expire
    patent covering licensed products in each country. As of
    June&#160;28, 2008, we licensed 38 issued U.S. patents and 42
    pending U.S. patent applications, as well as corresponding
    international patent filings, from Caltech. The early
    termination of our license agreement with Caltech could preclude
    us from manufacturing or selling any of our IFCs and IFC
    systems, which would have a material adverse effect on our
    business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also have co-exclusive licenses to patents and patent
    applications owned by Harvard University, a non-exclusive,
    field-limited license to patents and patent applications
    controlled by Gyros AB and additional patent licenses from other
    academic institutions and companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreements with Harvard University allow sublicenses
    (i)&#160;provided we can demonstrate that we have added
    significant value to the patent rights to be sublicensed and
    that such sublicense also contains a substantial and essentially
    simultaneous license to intellectual property owned by us, or
    (ii)&#160;when we grant a sublicense under other Harvard
    University patent rights licensed to us which are dominated by
    the patent rights to be
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    sublicensed and such sublicense is necessary to practice the
    other Harvard University patent rights. We have issued shares of
    our common stock to Harvard and, in addition to an annual
    license fee, we agreed to pay to Harvard royalties based on
    sales revenues of licensed products on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis. Harvard is responsible for filing and maintaining all
    licensed patents, but we must reimburse Harvard for our share of
    its related patent prosecution expenses. We have the right to
    prosecute any infringement of our licensed patent rights. The
    license agreement will terminate with the last-to-expire of the
    licensed patents. As of June&#160;28, 2008, we licensed five
    issued U.S. patents and four pending U.S. patent applications,
    as well as corresponding international patent filings, from
    Harvard. The early termination of our license agreements with
    Harvard could preclude us from manufacturing or selling any of
    our IFCs and IFC systems, which would have a material adverse
    effect on our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreement with Gyros AB grants us a non-exclusive,
    field-limited license to specified patents and patent
    applications filings in exchange for an upfront fee plus annual
    royalty payments based on net revenues of licensed products
    above an annual license fee. Gyros has the right to terminate if
    we assign our interest to a third party competitor of Gyros or
    if we come under common control of such a third party.
    Otherwise, the license will terminate at the expiration of the
    last-to-expire of the licensed patents. As of June&#160;28,
    2008, we licensed one issued U.S. patent as well as
    corresponding international patent filings from Gyros. The early
    termination of our license agreement with Gyros AB could
    preclude us from manufacturing or selling any of our IFCs and
    IFC systems, which would have a material adverse effect on our
    business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our license agreement with The UAB Research Foundation grants us
    an exclusive worldwide license, including the right to
    sublicense, under certain intellectual property rights. Such
    license grant is subject to prior existing license grants, plus
    the reservation of rights to UAB for internal research, academic
    and educational purposes
    <FONT style="white-space: nowrap">and/or</FONT> for
    performance of services for other institutions and to fulfill
    obligations to the U.S.&#160;government. We prosecute and
    maintain the patent rights licensed under this agreement. The
    license agreement will terminate at the expiration of the
    last-to-expire of the licensed patents. As of June&#160;28,
    2008, we licensed four issued U.S. patents and six pending U.S.
    patent applications, as well as corresponding international
    patent filings, from UAB. The early termination of our license
    agreement with UAB could preclude us from manufacturing or
    selling any of our Topaz IFCs and Topaz IFC systems, which would
    have a material adverse effect on our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our patent strategy is to seek broad patent protection on new
    developments in microfluidic technology and then later file
    patent applications covering new implementations of the
    technology and new microfluidic circuit architectures utilizing
    the technology. As these technologies are implemented and
    tested, we file new patent applications covering scientific
    methodology enabled by our technology. Additionally, where
    appropriate, we file new patent applications covering
    instrumentation and software that are used in conjunction with
    our IFCs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, we own or have licensed 81 issued U.S.
    patents and 62 issued international patents.  There are
    240&#160;pending patent applications, including 116 in the
    United States, 118 international applications and 6 applications
    filed under the Patent Cooperation Treaty. The U.S. issued
    patents we have licensed from Caltech expire between 2017 and
    2024, the U.S. issued patents we have licensed from UAB expire
    between 2020 and 2024, the U.S. issued patents we have licensed
    from Harvard expire between 2019 and 2023, the U.S. issued
    patent we have licensed from Gyros expires in 2012 and the U.S.
    issued patents owned by us expire between 2018 and 2025.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of companies like ours are generally
    uncertain and involve complex legal and factual questions. Our
    patents may not enable us to obtain or keep any competitive
    advantage. Our pending U.S.&#160;and foreign patent applications
    may not issue as patents or may not issue in a form that will be
    advantageous to us. Any patents we have obtained or do obtain
    may be challenged by re-examination, opposition or other
    administrative proceeding, or may be challenged in litigation,
    and such challenges could result in a determination that the
    patent is invalid. In addition, competitors may be able to
    design alternative methods or devices that avoid infringement of
    our patents. To the extent our intellectual property protection
    offers inadequate protection, or is found to be invalid, we are
    exposed to a greater risk of direct competition. If our
    intellectual property does not provide adequate protection
    against our competitors&#146; products, our competitive position
    could be adversely affected, as could our business. Both the
    patent application process and the process of managing patent
    disputes can be time consuming and expensive. Furthermore, the
    laws of some foreign countries may not protect our intellectual
    property rights to the same extent as do the laws of the United
    States.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to pursuing patents on our technology, we have taken
    steps to protect our intellectual property and proprietary
    technology by entering into confidentiality agreements and
    intellectual property assignment agreements with our employees,
    consultants, corporate partners and, when needed, our advisors.
    Such agreements may not be enforceable or may not provide
    meaningful protection for our trade secrets or other proprietary
    information in the event of unauthorized use or disclosure or
    other breaches of the agreements, and we may not be able to
    prevent such unauthorized disclosure. Monitoring unauthorized
    disclosure is difficult, and we do not know whether the steps we
    have taken to prevent such disclosure are, or will be, adequate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success may depend in part on our
    non-infringement of the patents or proprietary rights of third
    parties. Third parties have asserted and may assert in the
    future that we are employing their proprietary technology
    without authorization. Competitors may assert that our products
    infringe their intellectual property rights as part of a
    business strategy to impede our successful entry into those
    markets. In addition, our competitors and others may have
    patents or may in the future obtain patents and claim that use
    of our products infringes these patents. We could incur
    substantial costs and divert the attention of our management and
    technical personnel in defending against any of these claims.
    Parties making claims against us may be able to obtain
    injunctive or other relief, which could block our ability to
    develop, commercialize and sell products, and could result in
    the award of substantial damages against us. In the event of a
    successful claim of infringement against us, we may be required
    to pay damages and obtain one or more licenses from third
    parties, or be prohibited from selling certain products. We may
    not be able to obtain these licenses at a reasonable cost, if at
    all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Government
    Regulation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Federal Food, Drug and Cosmetic Act, or FFDCA, defines
    medical devices to mean, among other things, &#147;an
    instrument, apparatus . . . in&#160;vitro reagent, or other
    similar or related article . . . intended for use in the
    diagnosis of disease or other conditions . . ..&#148; This broad
    definition includes in&#160;vitro diagnostic products, or IVDs.
    Our products are currently labeled and sold for research
    purposes only, and we sell them to pharmaceutical and
    biotechnology companies, academic institutions and life sciences
    laboratories. Because our products are not intended for use in
    clinical practice, they do not fit the definition of a medical
    device under the FFDCA and thus are not subject to regulation by
    the U.S.&#160;Food and Drug Administration, or FDA. However, in
    the future, certain of our products or related applications
    could be subject to the FDA&#146;s regulation, the FDA&#146;s
    regulatory jurisdiction could be expanded to include our
    products, or both. For example, if we wished to label and market
    our products for use in performing clinical diagnostics, they
    would be considered medical devices and FDA clearance or
    approval would be required.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless an exemption applies, each medical device we wish to
    commercially distribute in the United States would require
    either prior 510(k) clearance or prior pre-market approval from
    the FDA. The FDA classifies medical devices into one of three
    classes. Devices deemed to pose lower risk to the patient are
    placed in either class&#160;I or II, which, unless an exemption
    applies, requires the manufacturer to submit a pre-market
    notification requesting FDA clearance for commercial
    distribution pursuant to Section&#160;510k of the FFDCA. This
    process, known as 510(k) clearance, requires that the
    manufacturer demonstrate that the device is substantially
    equivalent to a previously cleared 510(k) device or a
    <FONT style="white-space: nowrap">&#147;pre-amendment&#148;</FONT>
    class&#160;III device for which pre-market approval
    applications, or PMAs, have not been required by the FDA. This
    process typically takes from four to twelve months, although it
    can take longer. Most class&#160;I devices are exempted from
    this requirement. Devices deemed by FDA to pose the greatest
    risk, such as life-sustaining, life-supporting or implantable
    devices, or those deemed not substantially equivalent to a
    legally marketed predicate device, are placed in class&#160;III.
    Class&#160;III devices typically require PMA approval. To obtain
    PMA approval, an applicant must demonstrate the safety and
    effectiveness of the device based, in part, on data obtained in
    clinical studies. PMA reviews generally last between one and two
    years, although they can take longer. Both the 510(k) and the
    PMA processes can be expensive and lengthy and may not result in
    clearance or approval. If we are required to submit our products
    for pre-market review by FDA, we may be required to cease
    marketing while we obtain premarket clearance or approval from
    FDA. There would be no assurance that we could ever obtain such
    clearance or approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes to a device which have received PMA approval typically
    require a new PMA or PMA supplement. Changes to a device that
    receives 510(k) clearance, that could significantly affect its
    safety or effectiveness, or that would constitute a major change
    in its intended use, require a new 510(k) clearance or possibly
    PMA approval. The
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    FDA requires each manufacturer to make this determination
    initially, but the FDA can review any of these decisions. If the
    FDA disagreed with our determination not to seek a new 510(k)
    clearance, the FDA could require us to seek a new 510(k)
    clearance or pre-market approval. The FDA also could require us
    to cease manufacturing
    <FONT style="white-space: nowrap">and/or</FONT>
    recall the modified device until 510(k) clearance or pre-market
    approval was obtained. Also, in these circumstances, we could be
    subject to warning letters, significant regulatory fines or
    penalties, seizure or injunctive action, or criminal prosecution.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, if our products become subject to regulation as a
    medical device, we would become subject to additional FDA
    requirements, and we could be subject to unannounced inspections
    by FDA and other governmental authorities, which could increase
    our costs of doing business. Specifically, manufacturers of
    medical devices must comply with various requirements of the
    FFDCA and its implementing regulations, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Quality System Regulations, labeling regulations,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    medical device reporting, or MDR, regulations,
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    correction and removal regulations,&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    post-market surveillance regulations, which include restrictions
    on marketing and promotion.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We would need to continue to invest significant time and other
    resources to ensure ongoing compliance with FDA quality system
    regulations and other post-market regulatory requirements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our failure to comply with applicable FDA regulatory
    requirements, or our failure to timely and adequately respond to
    inspectional observations, could result in enforcement action by
    the FDA, which may include the following sanctions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fines, injunctions and civil penalties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recall or seizure or our products;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    operating restrictions, partial suspension or total shutdown of
    production;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in clearance or approval, or failure to obtain approval
    or clearance of future product candidates or product
    modifications;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    restrictions on labeling and promotion;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    warning letters, fines, or injunctions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    withdrawal of previously granted clearances or
    approvals;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    criminal prosecution.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    International sales of medical devices are subject to foreign
    government regulations, which vary substantially from country to
    country. The primary regulatory environment in Europe is that of
    the European Union (EU), which includes most of the major
    countries in Europe. Currently, 27 countries make up the EU.
    Other countries, such as Switzerland, have voluntarily adopted
    laws and regulations that mirror those of the EU with respect to
    medical devices. The EU has adopted numerous directives and
    standards regulating the design, manufacture, clinical trials,
    labeling and adverse event reporting for medical devices.
    Devices that comply with the requirements of a relevant
    directive will be entitled to bear the CE conformity marking,
    indicating that the device conforms to the essential
    requirements of the applicable directives and, accordingly, can
    be commercially distributed throughout Europe.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Outside of the EU, regulatory approval needs to be sought on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis in order to market medical devices. Although there is a
    trend towards harmonization of quality system standards,
    regulations in each country may vary substantially which can
    affect timelines of introduction.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, we had 131&#160;employees, of
    which 68 work in research and development, 18 work in general
    and administrative, 21 work in manufacturing and 24 work in
    sales and marketing. None of our employees are represented by a
    labor union or are the subject of a collective bargaining
    agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Environmental Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We lease approximately 35,000&#160;square feet of office and
    laboratory space at our headquarters in South
    San&#160;Francisco, California under leases and subleases that
    expire in March 2011, and 15,400&#160;square feet of
    manufacturing and office space at our facility in Singapore
    under a lease that expires in October 2011. In addition, we
    lease office space in Tokyo and Osaka, Japan. We are in
    negotiations to extend and expand our lease relating to our
    Singapore facility and we believe that our existing office,
    laboratory and manufacturing space, together with additional
    space and facilities available on commercially reasonable terms,
    will be sufficient to meet our needs for at least the next two
    years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our research and development and manufacturing processes involve
    the controlled use of hazardous materials, including flammables,
    toxics, corrosives and biologics. Our research and manufacturing
    operations produce hazardous biological and chemical waste
    products. We seek to comply with applicable laws regarding the
    handling and disposal of such materials. Given the small volume
    of such materials used or generated at our facilities, we do not
    expect our compliance efforts to have a material effect on our
    capital expenditures, earnings and competitive position.
    However, we cannot eliminate the risk of accidental
    contamination or discharge and any resultant injury from these
    materials. We do not currently maintain separate environmental
    liability coverage and any such contamination or discharge could
    result in significant cost to us in penalties, damages and
    suspension of our operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Legal
    Proceedings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On June&#160;4, 2008 we received a letter from Applied
    Biosystems, Inc., one of our competitors, asserting that our
    BioMark System for gene expression analysis infringes upon
    U.S.&#160;Patent No.&#160;6,814,934, or the &#146;934 patent,
    and its European and Canadian counterparts owned by Applied
    Biosystems&#146; parent company, Applera Corporation. In
    response to this letter, on June&#160;9, 2008, we filed suit
    against Applied Biosystems and Applera in the United States
    District Court for the Southern District of New York seeking
    declaratory judgments of non-infringement and invalidity of the
    &#146;934 patent. A response from Applied Biosystems and Applera
    is due September&#160;30, 2008. The Court has yet to set a
    schedule for this litigation. Applied Biosystems has recently
    announced that it expects to be acquired by Invitrogen
    Corporation. This may make it more difficult for us to predict
    the direction of discussions and litigation among the parties.
    The &#146;934 patent is scheduled to expire in May 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into an agreement with Applied Biosystems that
    provides for a stay of our proceedings against Applied
    Biosystems and Applera and provides further that neither party
    may initiate or expressly threaten to initiate any further
    patent litigation proceedings against the other during the term
    of the agreement. Either party may terminate the agreement and
    request that the stay be lifted anytime after September&#160;20,
    2008 by providing seven business days prior written notice to
    the other. The deadline for Applied Biosystems and Applera to
    respond to our complaint is extended to 14 calendar days after
    the lifting of the stay. If the agreement is not terminated
    sooner by one or both of the parties, the agreement will
    terminate on December&#160;15, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Patent infringement suits can be expensive, lengthy and
    disruptive to business operations. We could incur substantial
    costs and divert the attention of our management and technical
    personnel in prosecuting our claims. There can be no assurance
    that we will prevail in our suit against Applied Biosystems and
    Applera or in our defense of any claims against us by Applied
    Biosystems or Applera. Applied Biosystems and Applera may be
    able to obtain injunctive or other relief, which could block our
    ability to develop, commercialize and sell products, and could
    result in the award of substantial damages against us, including
    treble damages and attorneys&#146; fees and costs in the event
    that we are found to be a willful infringer of the asserted
    patent or patents. In addition, we may incur significant costs
    and expenses as a result of our requirement to defend and
    indemnify some of our suppliers, distributors, customers and
    other partners as a result of such claims. In the event that
    Applied Biosystems is
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    successful in its claim of infringement against us, we may be
    required to obtain one or more licenses to the asserted patent,
    which we may not be able to obtain at a reasonable cost, if at
    all. In addition, we could encounter delays in product
    introductions while we attempt to develop alternative methods or
    products to avoid infringing the asserted patent or patents.
    This lawsuit or the failure to obtain any required licenses on
    favorable terms could prevent us from commercializing our
    BioMark products for gene expression, and the risk of a
    prohibition on the sale of any of our products could adversely
    affect our ability to grow and gain market acceptance for our
    products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not engaged in any other material legal proceedings.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='111'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers and Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers and directors, and their ages and
    positions as of June&#160;28, 2008, are as set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    38
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    President, Chief Executive Officer and Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    52
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chief Financial Officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Executive Vice President, Research and Development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    57
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Legal Affairs and General Counsel, Secretary
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    49
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(2),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    68
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael W. Hunkapiller,
    Ph.D<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    59
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones,
    Ph.D.<SUP style="font-size: 85%; vertical-align: text-top">(1),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    53
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(1),(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    55
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A.
    Young<SUP style="font-size: 85%; vertical-align: text-top">(1),(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    76
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Audit Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Compensation Committee
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Member of the Nominating and
    Governance Committee
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm and has
    served as our President and Chief Executive Officer and a
    Director since our inception in June 1999. From May 1994 to
    April 1999, Mr.&#160;Worthington held various staff and
    management positions at Actel Corporation, a public
    semiconductor corporation. Mr.&#160;Worthington received a B.S.
    in Physics and an M.S. in Electrical Engineering from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog </I>has served as our Chief Financial Officer
    since February 2008. From April 2005 to February 2008,
    Mr.&#160;Jog served as Chief Financial Officer for XDx, Inc., a
    molecular diagnostics company. From March 2003 to April 2005,
    Mr.&#160;Jog was a Vice President of Applera Corporation, a life
    science company, and Vice President of Finance for its related
    businesses, Celera Genomics and Celera Diagnostics. From April
    2001 to March 2003, Mr.&#160;Jog was Vice President of Finance
    for Celera Diagnostics and Corporate Controller of Applera
    Corporation. Mr.&#160;Jog received a Bachelor of Commerce degree
    from Delhi University and an M.B.A. from Temple University.
    Mr.&#160;Jog is a member of the American Institute of Certified
    Public Accountants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Robert C. Jones </I>has served as our Executive Vice
    President, Research and Development since August 2005. From
    August 1984 to July 2005, Mr.&#160;Jones held various managerial
    and research and development positions at Applied Biosystems, a
    laboratory equipment and supplies manufacturer that is a
    division of Applera Corporation, including: Senior Vice
    President Research and Development from April 2001 to August
    2005, Vice President and General Manager Informatics Division
    from 1998 to 2001,&#160;and Vice President PCR Business Unit
    from 1994 to 1998. Mr.&#160;Jones received a BSEE and an MSEE in
    Computer Engineering from the University of Washington.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>William M. Smith </I>has served as our Vice President, Legal
    Affairs and General Counsel as well as our Secretary since May
    2000 and served as a Director from May 2000 to April 2008.
    Mr.&#160;Smith served as a partner at the law firm of Townsend
    and Townsend and Crew, LLP from 1985 through April 2008.
    Mr.&#160;Smith received a J.D. and an M.P.A. from the University
    of Southern California and a B.A. in Biology from the University
    of California, San&#160;Diego.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mai Chan (Grace) Yow </I>has served as our Vice President,
    Worldwide Manufacturing, and Managing Director, Fluidigm
    Singapore Pte. Ltd., our Singapore subsidiary, since March 2006.
    From June 2005 to March 2006,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ms.&#160;Yow served as General Manager of Fluidigm Singapore
    Pte. Ltd. From August 2004 to May 2005, Ms.&#160;Yow served as
    Vice President Engineering (Asia) for Kulicke and Soffa, a
    public semiconductor equipment manufacturer. From March 1991 to
    July 2004, Ms.&#160;Yow served as Director, Assembly Operations,
    Plant Facilities and EHS, for National Semiconductor Singapore,
    a semiconductor fabrication subsidiary of National Semiconductor
    Corporation. Ms.&#160;Yow received a BE in Electronic
    Engineering from Curtin University, a Certificate in Management
    Studies from the Singapore Institute of Management and a Diploma
    in Electrical Engineering from Singapore Polytechnic.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Samuel Colella </I>has served as a member of our Board of
    Directors since July 2000. Mr.&#160;Colella is a managing
    director of Versant Ventures, a healthcare venture capital firm
    he co-founded in 1999, and has been a general partner of
    Institutional Venture Partners since 1984. Mr.&#160;Colella is a
    member of the Board of Directors of Alexza Pharmaceuticals,
    Inc., Genomic Health, Inc. and Jazz Pharmaceuticals, Inc.
    Mr.&#160;Colella received a B.S. in business and engineering
    from the University of Pittsburgh and an M.B.A. from Stanford
    University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Hunkapiller, Ph.D. </I>has served as a member of our
    Board of Directors since August 2005. He has been a Partner at
    Alloy Ventures, a venture capital firm, since February 2004.
    From July 1983 to August 2004, he served in various managerial
    and research and development positions at Applied Biosystems,
    most recently as President, from March 1997 to August 2004. He
    received a B.S. in Chemistry from Oklahoma Baptist University
    and a Ph.D. in Chemical Biology from Caltech.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Elaine V. Jones,&#160;Ph.D.</I> has been a member of our
    Board of Directors since October 2001. Since August 2003, she
    has been a general partner of EuclidSR Associates, L.P., which
    is the general partner of EuclidSR Partners, L.P., a venture
    capital fund that focuses on life sciences and information
    technology companies, and also a general partner of EuclidSR
    Biotechnology Associates, L.P., which is the general partner of
    Euclid Biotechnology Partners, L.P., a venture capital fund that
    focuses on the life sciences. Dr.&#160;Jones was an investment
    manager from June 1999 to September 2001, and was a Vice
    President from September 2001 to August 2003, for S.R. One,
    Limited, a venture capital subsidiary of SmithKline Beecham.
    Dr.&#160;Jones received a B.S. in Biology from Juniata College
    and received a Ph.D. in Microbiology from the University of
    Pittsburgh.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Kenneth J. Nussbacher </I>has been a member of our Board of
    Directors since July 2003. Since 2000, Mr. Nussbacher has served
    as an Affymetrix Fellow, a non-executive employee position, at
    Affymetrix, Inc., a biotechnology company. From 1995 to 2000,
    Mr.&#160;Nussbacher was Executive Vice President of Affymetrix,
    Inc. and from 1995 to 1997, he was also Chief Financial Officer
    of Affymetrix. Prior to joining Affymetrix, Mr.&#160;Nussbacher
    was Executive Vice President for business and legal affairs of
    Affymax Technologies N.V. He received a B.S. from Cooper Union
    and a J.D. from Duke University. Mr.&#160;Nussbacher is also a
    member of the Board of Directors of Xenoport, a
    biopharmaceutical company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gajus V. Worthington </I>is a Co-Founder of Fluidigm
    Corporation and has served as our President and Chief Executive
    Officer and a Director since our inception in June 1999.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>John A. Young </I>has been a member of our Board of Directors
    since March 2001. Mr.&#160;Young retired as President and Chief
    Executive Officer of Hewlett-Packard Company, a diversified
    electronics manufacturer, in October 1992, where he had served
    as President and Chief Executive Officer since 1978.
    Mr.&#160;Young received a B.S. in Electrical Engineering from
    Oregon State University and an M.B.A. from Stanford University.
    Mr.&#160;Young serves as a director of Affymetrix, Inc.,
    Vermillion, Inc., a molecular diagnostics company, Perlegen
    Sciences, Inc., a drug development company, and Nanosys, Inc., a
    nanotechnology company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Composition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors is currently composed of six members,
    five of whom are independent within the meaning of the
    independent director guidelines of the NASDAQ Stock Market LLC.
    Immediately prior to this offering, our Board of Directors will
    be divided into three staggered classes of directors. At each
    annual meeting of stockholders, a class of directors will be
    elected for a three-year term to succeed the same class whose
    terms are then expiring. The terms of the directors will expire
    upon the election and qualification of successor directors at
    the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Annual Meeting of Stockholders to be held during the years 2009
    for the Class&#160;I directors, 2010 for the Class&#160;II
    directors and 2011 for the Class&#160;III directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;I directors will be Elaine Jones and Michael
    Hunkapiller.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;II directors will be Samuel Colella and Kenneth
    Nussbacher.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our Class&#160;III directors will be John Young and Gajus
    Worthington.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    provide that the number of our directors, which is currently six
    members, shall be fixed from time to time by a resolution of the
    majority of our Board of Directors. Each officer serves at the
    discretion of the Board of Directors and holds office until his
    successor is duly elected and qualified or until his or her
    earlier resignation or removal. There are no family
    relationships among any of our directors or executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The division of our Board of Directors into three classes with
    staggered three-year terms may delay or prevent a change of our
    management or a change of control. See &#147;Description of
    Capital Stock&#160;&#151; Anti-Takeover Effects of Delaware Law
    and Our Certificate of Incorporation and Bylaws&#148; for a
    discussion of other anti-takeover provisions found in our
    certificate of incorporation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board
    Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board has an audit committee, a compensation committee and a
    nominating and governance committee, each of which has the
    composition and the responsibilities described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Audit Committee.</I>&#160;&#160;Our audit committee oversees
    our corporate accounting and financial reporting process and
    assists the Board in monitoring our financial systems and our
    legal and regulatory compliance. Our audit committee will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    oversee the work of our independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve the hiring, discharging and compensation of our
    independent auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approve engagements of the independent auditors to render any
    audit or permissible non-audit services;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the qualifications and independence of the independent
    auditors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    monitor the rotation of partners of the independent auditors on
    our engagement team as required by law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review our financial statements and review our critical
    accounting policies and estimates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review the adequacy and effectiveness of our internal
    controls;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and discuss with management and the independent auditors
    the results of our annual audit, our quarterly financial
    statements, and our publicly filed reports.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our audit committee are Elaine Jones, Kenneth
    Nussbacher and John Young. Mr. Nussbacher is our acting audit
    committee chairman. Mr.&#160;Young was appointed to our audit
    committee on August&#160;21, 2008. Our Board of Directors has
    concluded that the composition of our audit committee meets the
    requirements for independence under the current requirements of
    the NASDAQ Stock Market LLC and SEC rules and regulations. We
    believe that the functioning of our audit committee complies
    with the applicable requirements of the NASDAQ Stock Market LLC
    and SEC rules and regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Compensation Committee.</I>&#160;&#160;Our compensation
    committee oversees our corporate compensation programs. The
    compensation committee will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and recommend policy relating to compensation and
    benefits of our officers and employees;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and approve corporate goals and objectives relevant to
    compensation of our Chief Executive Officer and other senior
    officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate the performance of our officers in light of established
    goals and objectives;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend compensation of our officers based on its
    evaluations;&#160;and
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    administer the issuance of stock options and other awards under
    our stock plans.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our compensation committee are Samuel Colella,
    Michael Hunkapiller and Kenneth Nussbacher. Mr.&#160;Colella is
    the chairman of our compensation committee. Our Board of
    Directors has determined that each member of our compensation
    committee is independent within the meaning of the independent
    director guidelines of the NASDAQ Stock Market LLC. We believe
    that the composition of our compensation committee meets the
    requirements for independence under, and the functioning of our
    compensation committee complies with, any applicable
    requirements of the NASDAQ Stock Market LLC and SEC rules and
    regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Nominating and Governance Committee.</I>&#160;&#160;Our
    nominating and governance committee oversees and assists our
    Board of Directors in reviewing and recommending nominees for
    election as directors. The nominating and governance committee
    will also:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluate and make recommendations regarding the organization and
    governance of the Board and its committees;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    assess the performance of members of the Board and make
    recommendations regarding committee and chair assignments;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommend desired qualifications for Board membership and
    conduct searches for potential Board members;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    review and make recommendations with regard to our corporate
    governance guidelines.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The members of our nominating and governance committee are
    Elaine Jones, John Young and Samuel Colella. Ms.&#160;Jones is
    the chairman of our nominating and governance committee. Our
    Board of Directors has determined that each member of our
    nominating and governance committee is independent within the
    meaning of the independent director guidelines of the NASDAQ
    Stock Market LLC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors may from time to time establish other
    committees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information concerning
    compensation paid or accrued for services rendered to us by
    members of our Board of Directors for the fiscal year ended
    December&#160;29, 2007. The table excludes Mr.&#160;Worthington
    and Mr.&#160;Smith, who are Named Executive Officers and did not
    receive any compensation from us in their roles as directors in
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cash&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge
    Hsu<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward
    Torres<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J.
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    72,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    compensation expense recognized by us for financial statement
    reporting purposes in fiscal 2007 related to grants of stock
    options, calculated in accordance with Financial Accounting
    Standards Board Statement of Financial Accounting Standards
    No.&#160;123 (Revised 2004) (&#147;SFAS&#160;123(R)&#148;)
    without regard to estimated forfeitures. See Note&#160;10 of
    Notes to Consolidated Financial Statements for a discussion of
    valuation assumptions made in determining the grant date fair
    value and compensation expense of our stock options.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Nussbacher was granted an
    option to purchase 28,571 shares of common stock on
    December&#160;28, 2007 at an exercise price of $8.40, with a
    grant date fair value of $143,151, computed in accordance with
    SFAS&#160;123(R) and was paid fees of $40,000 for services
    rendered pursuant to a consulting agreement with us. This
    consulting agreement was terminated on April&#160;14, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Resigned from the Board of
    Directors on or prior to April 2008.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate number of shares subject to stock options
    outstanding at December&#160;29, 2007 for each director is as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="14%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Aggregate Number of Stock Options<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding as of December&#160;29, 2007&#160;</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Samuel D. Colella
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hingge Hsu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Hunkapiller
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine V. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kenneth J. Nussbacher
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    S. Edward Torres
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    John A. Young
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors do not currently receive any cash compensation for
    their services as members of our Board of Directors or any
    committee of our Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon consummation of our initial public offering, non-employee
    directors will receive an annual retainer of $20,000. The
    chairman of the audit committee will be paid an additional
    annual retainer of $15,000. The chairman of the compensation
    committee will be paid an additional annual retainer of $10,000.
    The chairman of the nominating and governance committee will be
    paid an additional annual retainer of $5,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our outside director equity compensation policy was adopted by
    our Board of Directors on January&#160;29, 2008 and will become
    effective immediately upon the completion of this offering. The
    policy is intended to formalize the granting of equity
    compensation to our non-employee directors under the 2008 Equity
    Incentive Plan. Non-employee directors may receive all types of
    awards under the 2008 Equity Incentive Plan, except for
    incentive stock options, including discretionary awards not
    covered by the policy. The policy provides for automatic and
    nondiscretionary grants of nonstatutory stock options subject to
    the terms and conditions of the policy and the 2008 Equity
    Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the policy, each non-employee director, who first becomes
    a non-employee director following the effective date of the
    first registration statement filed by us and declared effective
    with respect to any class of our securities, will be
    automatically granted a stock option to purchase
    11,428&#160;shares of our common stock on the date such person
    first becomes a non-employee director. A director who is an
    employee and who ceases to be an employee, but who remains a
    director will not receive such an initial award.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, each non-employee director will be automatically
    granted an annual stock option to purchase 2,857&#160;shares of
    our common stock on the date of each annual meeting beginning on
    the date of the first annual meeting that is held at least
    six&#160;months after such non-employee director received his or
    her initial award. In connection with the pricing of this
    initial public offering, each non-employee director serving on
    our Board at the time of this offering will be automatically
    granted an option to purchase 2,857&#160;shares of our common
    stock at the price per share at which such common stock is sold
    in this offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of all stock options granted pursuant to the
    policy will be equal to the fair market value of our common
    stock on the date of grant. The term of all stock options will
    be 10&#160;years. Subject to the adjustment provisions of the
    2008 Equity Incentive Plan, initial awards will vest as to 25%
    of the shares subject to such awards each anniversary of the
    date of grant, provided such non-employee director continues to
    serve as a director through each such date. Subject to the
    adjustment provisions of the 2008 Equity Incentive Plan, the
    annual awards, including such awards granted in connection with
    this offering, will vest monthly over a twelve month period
    following the date of grant, provided such non-employee director
    continues to serve as a director through such date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator of the 2008 Equity Incentive Plan in its
    discretion may change or otherwise revise the terms of awards
    granted under the outside director equity compensation policy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a &#147;change in control,&#148; as defined in
    our 2008 Equity Incentive Plan, with respect to awards granted
    under the 2008 Equity Incentive Plan to non-employee directors,
    the participant non-employee director will fully vest in and
    have the right to exercise awards as to all shares underlying
    such awards and all restrictions on
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    awards will lapse, and all performance goals or other vesting
    criteria will be deemed achieved at 100% of target level and all
    other terms and conditions met.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the completion of this offering, we expect to adopt a
    code of business conduct and ethics that is applicable to all of
    our employees, officers and directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the members of our compensation committee is an officer
    or employee of our company. None of our executive officers
    currently serves, or in the past year has served, as a member of
    the Board of Directors or compensation committee of any entity
    that has one or more executive officers serving on our Board of
    Directors or compensation committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Executive
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We seek to have a compensation program that supports a team
    ethic among our management, fairly rewards executives for
    corporate performance and provides incentives for executives to
    meet or exceed our short and long term goals. The primary
    components of our compensation program are base salary, an
    annual incentive bonus plan, option awards and change of control
    arrangements. In addition, we provide our executive officers a
    variety of benefits that are available generally to all salaried
    employees. The compensation committee of our Board of Directors
    is responsible for evaluating the compensation of our executive
    officers and making recommendations to the Board of Directors.
    The independent members of the Board of Directors have final
    approval authority with respect to executive compensation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Objectives
    and Principles of Our Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary goal of our executive compensation program is to
    ensure that we hire and retain talented and experienced
    executives that are motivated toward achieving or exceeding our
    short-term and long-term corporate goals. As a starting point,
    we believe that it is critical that our executive officers work
    together as a team and look beyond departmental lines to achieve
    overall corporate goals rather than focusing on individual
    departmental objectives. Our compensation philosophy is team
    oriented and our success dependent on what our management team
    can accomplish together. Therefore, we seek to provide the
    executive officers listed in the Summary Compensation table
    below, or our &#147;named executive officers,&#148; with
    comparable levels of base salary, bonuses and equity awards that
    are based largely on overall company performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our fiscal year 2007, our named executive officers were
    Gajus Worthington, President and Chief Executive Officer,
    Richard DeLateur, our former Chief Financial Officer, Michael
    Lucero, our former Executive Vice President, Sales and
    Marketing, William Smith, Vice President, Legal Affairs and
    General Counsel, Robert Jones, our Executive Vice President,
    Research and Development, Grace Yow, Vice President, Worldwide
    Manufacturing and Managing Director, Fluidigm Singapore.
    Mr.&#160;DeLateur resigned as our Chief Financial Officer
    effective February&#160;29, 2008 and Mr.&#160;Lucero resigned as
    our Executive Vice President, Sales and Marketing on
    March&#160;14, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While the compensation level of Mr.&#160;Worthington, our Chief
    Executive Officer, is marginally higher than our other executive
    officers, his compensation has historically been based on our
    team-based compensation philosophy rather than on CEO
    compensation levels reported in market surveys of other
    companies in the life science industry.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We strongly believe that executive compensation should be
    directly linked to our performance. Our compensation program is
    designed so that a significant portion of the potential
    compensation of all of our executive officers is contingent on
    the achievement of our business objectives. In rewarding
    performance, we seek to reward
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    both short and long term performance. We expect our executive
    leadership to manage our company so that we achieve our annual
    goals while at the same time positioning us to achieve our
    longer term strategic objectives. Short term elements of
    compensation include annual salary reviews, stock option awards
    and incentive bonuses that are tied closely to achieving our
    corporate and, to a lesser extent, on achieving individual
    performance objectives. Long term elements have historically
    been limited to stock options with multi-year vesting designed
    to retain executives and align their long term interests with
    those of our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that hiring and retaining well performing executives
    is important to our ongoing success. While we review generally
    available surveys on executive compensation to confirm that our
    compensation decisions do not result in compensation levels that
    are dramatically different from other companies in our industry,
    the compensation committee has not in the past attempted to
    benchmark our executive compensation against any particular
    indices or salary surveys. While occasional review of market
    surveys is considered helpful, the compensation committee has
    historically placed substantially greater weight on internal
    considerations than on position-specific pay differences found
    in the market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as described below, neither the Board of Directors nor
    the compensation committee has adopted any formal or informal
    policies or guidelines for allocating compensation between cash
    and non-cash compensation, among different forms of non-cash
    compensation or with respect to long and short term performance.
    The determination of the Board of Directors or compensation
    committee as to the appropriate use and weight of each component
    of executive compensation is subjective, based on their view of
    the relative importance of each component in meeting our overall
    objectives and factors relevant to the individual executive.
    Historically, our Board of Directors has focused significantly
    on the affordability of our compensation arrangements. As a
    result, when weighting forms of compensation, the Board of
    Directors and the compensation committee have historically
    placed greater emphasis on non-cash equity incentive
    compensation together with base salary. In 2006, the Board of
    Directors determined that our business was of sufficient
    maturity to permit us to establish a cash bonus plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a publicly held company, we expect to periodically engage the
    services of a compensation consultant to assist us in further
    aligning our compensation philosophy with our corporate
    objectives. In particular, in order to attract and retain key
    executives, we may be required to modify individual executive
    compensation levels to remain competitive in the market for such
    positions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Process and Compensation Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007 and January 2008, the compensation committee consisted
    of Messrs.&#160;Colella and Nussbacher and Ms.&#160;Jones. Since
    January&#160;29, 2008, the compensation committee has consisted
    of Messrs.&#160;Colella, Nussbacher and Hunkapiller, each of
    whom is an independent director under the rules of the NASDAQ
    Stock Market LLC and a &#147;non-employee director&#148; for
    purposes of
    <FONT style="white-space: nowrap">Rule&#160;16b-3</FONT>
    under the Securities Exchange Act of 1934, as amended.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee makes recommendations to the Board
    regarding compensation structure, goals and individual
    compensation levels, which recommendations are considered for
    approval by the independent members of the Board. The
    compensation committee makes its compensation recommendations
    based on input from Mr.&#160;Worthington, our Chief Executive
    Officer, the judgment of its members based on their tenure and
    experience in our industry, and, starting with compensation
    levels for 2007, the advice of Compensia, Inc., an independent
    compensation consultant hired by the compensation committee in
    April 2007. The compensation committee has the responsibility of
    formulating, evaluating and recommending to the Board of
    Directors the compensation of our executive officers.
    Historically, our annual compensation review process has been
    initiated by Mr.&#160;Worthington who performs a review of the
    performance of each executive officer in the prior year and
    formulates proposals regarding the elements of compensation,
    corporate and individual goals and compensation levels for our
    executive officers, other than himself.
    Mr.&#160;Worthington&#146;s proposals for compensation
    structure, goals and individual compensation levels are
    typically based on discussions with and directions from members
    of the compensation committee. Mr.&#160;Worthington does not
    prepare proposals or advise the compensation committee on his
    own compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Compensation levels and mix for Mr.&#160;Worthington, our Chief
    Executive Officer, are recommended by the compensation committee
    based on the committee&#146;s assessment of our overall
    corporate performance and Mr.&#160;Worthington&#146;s
    contribution to that performance. Mr.&#160;Worthington does not
    participate in compensation
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    committee or Board deliberations regarding his own compensation.
    As with other members of our executive team, the compensation
    committee determines Mr.&#160;Worthington&#146;s compensation
    based on our achievement of corporate objectives and
    compensation levels of other members of our executive team,
    rather than attempting to tie Mr.&#160;Worthington&#146;s
    compensation to a specific percentile of CEO compensation
    reported in market compensation surveys.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to any limitations or guidelines that may be adopted by
    the Board of Directors in the future, the compensation committee
    does have the authority to approve the grant of stock options or
    stock purchase rights to individuals eligible for such grants,
    including officers and directors. The compensation committee met
    three times during 2007 and we expect that it will meet at least
    quarterly during 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee has the authority under its charter
    to engage the services of outside advisors, experts and others
    for assistance. In April 2007, the compensation committee
    engaged Compensia, Inc., an outside consulting firm, to advise
    it on developing a principles based executive compensation
    strategy to help transition us from a privately held to a
    publicly held company and on matters relating to our equity
    compensation plans as a whole. Compensia reviewed our proposed
    2007 compensation philosophy and compensation levels and
    provided advice regarding the suitability of our executive
    compensation structure for a company at our stage of development
    and the impact the structure was likely to have on executive
    performance and our ability to attract executive talent.
    Compensia did not prepare a formal report or recommend specific
    compensation levels. In 2008, we expect the compensation
    committee will engage an outside consulting firm to review more
    broadly our compensation practices and provide specific
    recommendations on executive compensation levels.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After setting compensation levels for our executive officers for
    2007, but before making its recommendations to the Board, the
    compensation committee reviewed the 2006 Radford Biotechnology
    Survey by Aon Consulting and the 2006 Executive Compensation
    Survey for pre-IPO life science companies by Top Five Data
    Services, Inc. to confirm that the proposed mix and levels of
    compensation for our executive officers was not outside of the
    ranges reported for senior executive officers in general. The
    compensation committee did not benchmark or tie compensation
    levels for our executive officers to any particular compensation
    level provided by the companies included in these surveys.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Corporate
    and Individual Performance Goals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Corporate Goals.</I>&#160;&#160;Our corporate and
    individual performance goals for each year are formulated by the
    Board of Directors with input from the compensation committee
    and our Chief Executive Officer. For 2007, two corporate goals
    were established. The first related to our selling a certain
    number of IFC systems and reaching certain revenue targets,
    whether through system sales or collaboration agreements. The
    second goal related to our equity fund raising activity. The
    compensation committee believed attaining these goals would take
    a high level of executive performance and that such goals would
    be very challenging given the initial lack of market awareness
    of our products in 2007. The committee did not assign weights to
    these goals, except to treat them as equally important.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2007 Individual Goals.</I>&#160;&#160;Individual goals for
    2007 were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>2007 Individual Goals</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving target levels of sales of our IFC systems and
    achieving target revenues, whether through system sales or
    collaboration agreements.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Raising target levels of equity financing.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur, former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Preparing our finance organization for an initial public
    offering and public company status.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Lucero, former Executive Vice President,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Launching our BioMark product and developing a
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    strategy for new market penetration.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining and advancing our intellectual property
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     position with respect to existing and new products.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Deliver commercial genotyping applications, digital
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    array applications and finish feasibility phase of additional
    products.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified IFC manufacturing yields and
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    output levels.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Corporate Goals.</I>&#160;&#160;For 2008, the Board,
    with the participation of the compensation committee and members
    of management, reassessed our corporate goals in light of the
    maturation of our business and commercialization of our
    products. Following this reassessment, the Board approved
    corporate goals that include achieving specified levels of
    product sales and product gross margins, completing an initial
    public offering and keeping expenses and cash outlays within the
    budget approved by the Board of Directors. The Board believes
    that the goals are attainable with a very high level of
    executive performance. The target sales level represents
    significant growth from 2007 levels and will be achieved only if
    we are able to increase market awareness of our products and
    expand our customer base. The targeted gross margin will require
    significant contributions from both our manufacturing and
    research and development groups. Given the uncertainty in global
    financial markets, our ability to complete an initial public
    offering was also uncertain at the time these corporate goals
    were established. Achieving our overall corporate goals while
    staying within our proposed budget will require strong fiscal
    discipline.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>2008 Individual Goals.</I>&#160;&#160;The goals for our
    individual executives in 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008 Individual Goals</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus Worthington, Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving specified levels of product sales and product gross
    margins, completing an initial public offering and keeping
    expenses and cash outlays within the budget approved by the
    Board of Directors.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog, Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Ensuring accurate revenue recognition during each quarter,
    closing our books in an accurate and timely manner, completing
    our 2005, 2006 and 2007 audits and ensuring compliance with
    applicable financial and disclosure regulations of the
    Securities and Exchange Commission.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William Smith, Vice President, Legal Affairs and
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Maintaining our intellectual property position and
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    supporting our initial public offering.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert Jones, Executive Vice President, Research
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Completing market-ready 96.96 BioMark IFC, loaders
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    and readers for 96.96 and certain future applications.
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow, Vice President, Worldwide
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Achieving overall IFC yields sufficient to achieve our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Manufacturing and Managing Director of
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
     gross margin goals, achieving specified yields on our
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    new 96.96 Dynamic Array IFC, maintaining or improving 2007
    quality levels for our IFC systems and ensuring on-time
    manufacture and delivery of IFCs and IFC systems.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Elements
    of Executive Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation program consists of four main
    elements: base salary, an annual incentive bonus plan, option
    awards and change of control arrangements. The following is a
    discussion of each element.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Base Salary.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to 2007, the Board and the compensation committee
    established base salaries based on a number of factors including
    the scope of responsibility of each individual and a desire to
    encourage a team ethic. In 2007, the compensation committee and
    the Board concluded that our company and its stockholders would
    be better served by placing greater emphasis on creating a team
    ethic among our executive officers and that a team ethic would
    be better supported if all executive officers received
    approximately the same salary. Therefore, in May 2007, the
    compensation committee recommended and the Board approved a
    raise in the base annual salaries of Richard DeLateur, Michael
    Lucero, William Smith and Robert Jones to $265,000 effective
    February&#160;1, 2007, which represented a 20% increase for
    Mr.&#160;DeLateur, a 2.2% increase for Mr.&#160;Lucero, a 16%
    increase for Mr.&#160;Smith and a 6% increase for
    Mr.&#160;Jones, based on their salaries for 2006. This salary
    increase was based upon the compensation committee&#146;s
    assessment of the life science industry in the
    San&#160;Francisco Bay Area gathered from the active involvement
    of committee members as investors in such industry and the
    committee&#146;s conclusion that competition for executives in
    our industry was increasing. Ms.&#160;Yow&#146;s salary was set
    at SG$307,224, or US$200,000 using the exchange rate at the time
    such salary was set, to reflect the lower cost of living in
    Singapore where she is based. At the same time, the compensation
    committee also recommended that Mr.&#160;Worthington&#146;s
    salary be increased by 5% to $283,920 based on the factors
    described above. However, Mr.&#160;Worthington requested that
    this salary increase be deferred until his performance during
    2007 could be assessed. In December 2007, the compensation
    committee reviewed Mr.&#160;Worthington&#146;s overall
    performance during the year. In particular, it noted that
    Mr.&#160;Worthington had fully met his individual goal for
    equity financing as we had raised more money than had been
    targeted and had partially met his individual goal for revenue,
    as we had strong sales performance although the target revenue
    level was not achieved. The compensation committee therefore
    recommended and the Board approved the 5% raise that had been
    originally proposed for Mr.&#160;Worthington. The raise was made
    retroactive to February&#160;15, 2007 so that it would be
    effective as of the same date as the raises for all the other
    executive officers.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee reviewed 2008 base
    salaries in light of general market conditions in the
    San&#160;Francisco Bay Area life science industry. The
    compensation committee concluded that competition for executive
    talent remained strong as a result of the solid economic
    performance of the industry and the region overall, the
    continued high level of investment by venture capital firms in
    new and existing life science companies and the specialized
    skills and experiences required to manage life science
    companies. The compensation committee&#146;s assessment of
    general market conditions in the life science industry, and the
    life science industry in the San&#160;Francisco Bay Area in
    particular, was based on the experience of the committee members
    who were and are actively involved in venture capital investing
    in such industry and area. The compensation committee did not
    rely on any formal compensation survey data in making its
    assessment. The compensation committee therefore recommended and
    the Board approved an approximate raise of 4.0% for all
    executive officers other than Messrs.&#160;DeLateur and Lucero,
    who were expected to be leaving Fluidigm in early 2008. This
    approximate 4.0% raise was applied to Ms.&#160;Yow&#146;s salary
    in Singapore dollars, resulting in an increase of SG$12,289. As
    a result, the 2008 base salary for Mr.&#160;Smith and
    Mr.&#160;Jones was increased to $275,600, the 2008 base salary
    for Ms.&#160;Yow was increased to SG$319,513, or US$232,002 on
    the date of the increase, and the 2008 salary for
    Mr.&#160;Worthington was increased to $294,840. These salary
    increases became effective on February&#160;1, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, we entered into an offer letter with Vikram
    Jog, our Chief Financial Officer that provides for him to
    receive a base salary of $278,000 per year and a signing bonus
    of $20,000. The Board approved this departure from our standard
    base salary and bonus practice for executive officers based on
    several factors, including his unique qualifications, the need
    to induce him to leave his existing employment, his base salary
    at his previous employer and our need to fill the position as
    soon as possible.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Incentive Bonus Plan.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2007, the compensation committee and the Board established a
    bonus structure for all named executive officers that provided
    for performance bonuses of up to 35% of base salary. 80% of the
    performance bonus was payable based upon our reaching our
    corporate goals described above, with each corporate goal
    receiving equal weighting and the remaining 20% payable to each
    executive based on the executive&#146;s attainment of his or her
    individual performance goals described above. Payment of
    performance bonuses was allocated among corporate and individual
    goals in this manner in recognition of our compensation
    philosophy in which the compensation committee sought to
    incentivize executive officers to look beyond their individual
    departmental goals and work with other executive officers to
    achieve our overall corporate goals. The compensation committee
    and Board concluded that the corporate goals portion of the
    bonus would not be payable if the goals were less than 80%
    attained, based on the average percentage completion of all such
    goals, and would be paid in full if the goals were 100%
    attained. The compensation committee retained discretion to
    determine the portion of the bonus that would be paid if the
    corporate goals were achieved at a level between 80% and 100%.
    The compensation committee also retained the discretion to
    change the bonus structure and the bonus payment amounts as it
    considered appropriate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee concluded that the
    first 2007 corporate goal described above had been partially met
    and the second 2007 corporate goal had been fully met, but that
    taken together the 80% threshold had not been attained. As a
    result, no 2007 bonuses were paid to our executive officers with
    respect to achievement of corporate goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The compensation committee also considered the achievement of
    2007 individual performance goals in January 2008 and concluded
    that Mr.&#160;Smith had achieved his goals by maintaining and
    advancing our intellectual property position with respect to
    existing and new products. The Board awarded Mr.&#160;Smith 100%
    of his individual performance bonus of $18,550. The compensation
    committee concluded that Mr.&#160;Jones achieved his 2007
    individual goals of delivering a commercial genotyping
    application and digital array applications and awarded him his
    maximum individual performance bonus of $18,550. The
    compensation committee concluded that Ms.&#160;Yow had achieved
    her 2007 individual goals by achieving specified IFC
    manufacturing yields and output levels in 2007 and the Board
    awarded Ms.&#160;Yow 100% of her individual performance bonus of
    $14,000. The compensation committee concluded that
    Mr.&#160;Worthington had partially achieved his 2007 individual
    performance goals of achieving target levels of IFC system sales
    and revenue and raising target levels of equity financing, and
    the Board awarded Mr.&#160;Worthington a partial bonus of
    $14,175. No other individual performance bonuses were awarded to
    our named executive officers for 2007.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee and Board have approved the
    same bonus structure and potential bonus percentages as for 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In making recommendations regarding and approving compensation
    with respect to 2007, the compensation committee and the Board
    have not exercised their discretion to either award compensation
    absent attainment of relevant performance goals or to reduce the
    size of an award or payout following the attainment of relevant
    performance goals. We intend for the bonus plan to provide a
    significant portion of an executive&#146;s potential
    compensation. It is designed to help ensure that executives are
    focused on our near-term performance and on working together to
    achieve key corporate objectives. We expect that corporate and
    individual goals will be reviewed each year and adjusted to
    reflect changes in our stage of development, competitive
    position and corporate objectives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Option Awards.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We grant options to new executives upon the commencement of
    their employment and on an annual basis make additional grants
    to existing executives based on our overall corporate
    performance, individual performance and the executives&#146;
    existing option grants and equity holdings. We believe that
    option awards are an effective means of aligning the interests
    of executives and stockholders, rewarding executives for our
    achieving success over the long term and providing executives an
    incentive to remain with us. Most option grants to our named
    executive officers provide the holder with the right to exercise
    the option and purchase shares prior to vesting, subject to our
    right to repurchase unvested shares pursuant to the terms of our
    restricted stock purchase agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, the compensation committee redesigned our option
    granting policy in light of the shift in our compensation
    philosophy toward team-based compensation. The compensation
    committee concluded that the number of shares that vest each
    year for each executive should be relatively consistent and
    should be comparable to the number of shares that vest for other
    executives. The committee determined that each executive should
    vest in approximately 20,000&#160;shares per year over a four
    year period. For each executive, the exact number of shares that
    vest in any year would be subject to adjustment either upward or
    downward by up to 10,000&#160;shares based on the
    executive&#146;s performance relative to the corporate goals and
    his or her individual performance goals. The compensation
    committee&#146;s selection of 20,000&#160;shares as the target
    number of shares to vest annually for each executive officer was
    based on the committee&#146;s determination that such number of
    shares would provide meaningful compensation to our executive
    officers. The committee did not rely on compensation surveys or
    other third party sources in arriving at the 20,000 annual
    vesting target. In addition to this annual vesting target and
    the possible adjustment of actual vesting amounts by up to
    10,000, the compensation committee retained the authority to
    approve additional option grants to executive officers who
    demonstrated exceptional performance in a given year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of our adoption of this new approach to equity
    compensation, our grants in 2007 were primarily intended to
    regularize each executive&#146;s vesting schedules to
    approximately 20,000 per year. As a result, certain executives
    received option grants where shares were immediately vested
    while others received grants where the vesting occurs largely
    three or four years from the grant of the date. The number of
    shares vesting for each such officer in 2007 were
    19,523&#160;shares for Mr.&#160;Worthington, 53,570&#160;shares
    for Mr.&#160;DeLateur, 31,738&#160;shares for Mr.&#160;Lucero,
    21,428 for Mr.&#160;Smith, 28,571 for Mr.&#160;Jones and 27,856
    for Ms.&#160;Yow. Variations in the number of shares vested in
    2007 for these officers was the result of vesting under options
    granted prior to 2007 rather than intentional variation in 2007
    grants on the part of the compensation committee. In the future,
    once the vesting of existing options are normalized at
    approximately 20,000&#160;shares per year, we intend for
    executives to receive additional grants that vest only in the
    fourth year following the date of their grant. We also expect to
    reconsider the target share amount each year and may in the
    future consider granting restricted stock as a form of equity
    compensation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For 2008, the compensation committee did not alter the target
    amount of annual vesting for any executive. To give effect to
    this target annual vesting rate, the committee recommended and
    the Board approved grants of options to purchase
    20,000&#160;shares each to Mr.&#160;Jones, Mr.&#160;Smith,
    Mr.&#160;Worthington and Ms.&#160;Yow. These options vest fully
    on December&#160;31, 2011, subject to continued service through
    the vesting date. In addition, the compensation committee
    recommended that additional discretionary option grants be made
    to Mr.&#160;Jones, Mr.&#160;Smith, Mr.&#160;Worthington and
    Ms.&#160;Yow for their exceptional performance in 2007.
    Mr.&#160;Smith and Mr.&#160;Worthington received a fully-vested
    option to purchase 20,000&#160;shares and Mr.&#160;Jones and
    Ms.&#160;Yow received a fully-vested option to purchase
    11,428&#160;shares. These grants were issued separately from the
    annual grants and were not considered an adjustment to the
    annual grants. Accordingly, the 10,000&#160;share adjustment
    limit for annual grants did not apply.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed above, the compensation committee retains the
    discretion to grant additional options to executive officers as
    a reward for exceptional performance. In addition, the committee
    may decide to grant options that vest upon the achievement of
    certain performance goals. Finally, the committee is exploring
    the desirability of other forms of equity based compensation
    including restricted stock grants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the Board approved amendments to our 1999 Stock
    Option Plan to permit the use of performance based vesting in
    connection with equity grants under the plan. The amendment
    provided the Board and compensation committee with the ability
    to grant options or other equity awards under the plan that vest
    upon the achievement of specified milestones or goals. These
    amendments were made to enhance the ability of the Board and
    compensation committee to closely align equity compensation with
    the achievement of corporate or individual goals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board adopted our 2008 Equity Incentive Plan in January 2008
    and we expect our stockholders will approve it prior to the
    completion of this offering. Subject to stockholder approval,
    the 2008 Equity Incentive Plan is effective upon its adoption by
    our Board, but is not expected to be utilized until after the
    completion of this offering. Our 2008 Equity Incentive Plan
    provides for the grant of incentive stock options, within the
    meaning of Section&#160;422 of the Internal Revenue Code, to our
    employees and any parent and subsidiary corporations&#146;
    employees, and for the grant of nonstatutory stock options,
    restricted stock, restricted stock units, stock appreciation
    rights, performance units and performance shares to our
    employees, directors and consultants and our parent and
    subsidiary corporations&#146; employees and consultants. Our
    Board and compensation committee are evaluating the costs and
    benefits of the various forms of equity compensation issuable
    under the 2008 plan and may elect to use restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares in the future to further align the
    interests of our management and stockholders and to manage the
    financial statement impact of such forms of equity compensation.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2008, the compensation committee participated in the
    negotiation of a compensation package for Vikram Jog, our Chief
    Financial Officer, in which the compensation committee agreed to
    grant Mr.&#160;Jog compensation that exceeded our standard
    compensation package for the named executive officers. As
    indicated above, the compensation committee approved this
    package based on Mr.&#160;Jog&#146;s unique qualifications, our
    need to fill this position and the need to induce Mr.&#160;Jog
    to leave his then current employer. In February 2008, the
    compensation committee approved the grant of the following
    options to Mr.&#160;Jog in February 2008 under our 1999 Stock
    Option Plan:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="11%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="27%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <B>Accelerated Vesting if<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Shares</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Standard Vesting</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Milestones Met</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Performance Milestones</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    142,857
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting commencement date, and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    14,285&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% on December&#160;31, 2011
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Revenue recognition - no material changes upon quarterly
    reviews and annual audit;<BR>
    (2) Accurate and timely closing of books and reporting
    (timeliness as required by investors and SEC);<BR>
    (3) SEC and Sarbanes-Oxley compliance, as needed; and<BR>
    (4) Produce audited financial statements for 2005, 2006 and 2007
    (and the first quarter of 2008, if necessary) to enable the
    filing of a Form S-1 registration statement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    14,285&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    25% on first anniversary<BR>
    of the vesting  commencement date and 1/48 per month thereafter
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    100% upon achievement<BR>
    of Milestones prior to December 31, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    (1) Achievement of target revenues;<BR>
    (2) Achievement of target margins for 2008;<BR>
    (3) Completion of an initial public offering in 2008; and<BR>
    (4) Compliance with 2008 budget for expenses and cash outflows.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In light of the performance based option grants made to
    Mr.&#160;Jog and our team-based approach to executive
    compensation, the compensation committee recommended to the
    Board, and the Board approved similar grants for all other named
    executive officers other than Mr.&#160;Worthington. Thus,
    Mr.&#160;Jones, Mr.&#160;Smith and Ms.&#160;Yow each received
    two additional options to purchase 14,285&#160;shares on
    April&#160;24, 2008. The first option becomes fully vested on
    the earlier of December&#160;11, 2011 or, with respect to each
    officer, December&#160;31, 2008 if that officer meets his or her
    individual goals for 2008. The second option vest with respects
    25% of the shares subject to the option on February&#160;1, 2009
    and 1/48th&#160;of the shares each month thereafter; provided
    that the option becomes fully vested on December&#160;31, 2008
    if the corporate goals for 2008 are achieved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Employment and Severance Agreements.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into Employment and Severance
    Agreements with each of our named executive officers that
    provide for specified payments and benefits if the
    officer&#146;s employment is terminated without cause, or if the
    officer&#146;s employment is terminated without cause or for
    good reason within 12&#160;months following a change of control.
    The terms of these agreements are described under
    &#147;Potential Payments Upon Termination or Change of
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Control.&#148; We adopted these arrangements because we
    recognize that we will from time to time consider the
    possibility of an acquisition by another company or other change
    of control transaction and that such consideration can be a
    distraction to our executive officers and can cause such
    officers to consider alternative employment opportunities.
    Accordingly, the Board concluded that it is in the best
    interests of our company and its stockholders to provide
    executives with certain severance benefits upon termination of
    employment without cause or for good reason following a change
    of control. Our Board determined to provide such executives with
    certain severance benefits upon their termination of employment
    without cause outside of the change of control context in order
    to provide executives with enhanced financial security and
    incentive to remain with our company. In addition, we believe
    that providing for acceleration of options if an officer is
    terminated following a change of control transaction aligns the
    executive officer&#146;s interest more closely with those of
    other stockholders when evaluating the transaction rather than
    putting the officer at risk of losing the benefits of those
    equity incentives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In determining the amount of cash payments, benefits coverage
    and acceleration of vesting to be provided to officers upon
    termination prior to a change of control or within
    12&#160;months following a change of control, our Board
    considered the following factors:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the expected time required for an officer to find comparable
    employment following a termination event;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    feedback received from potential candidates for officer
    positions at our company as to the level of severance payments
    and benefits they would require to leave other employment and
    join our company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the context of a change of control, the amount of vesting
    acceleration that would align the officer&#146;s interests more
    closely with the interests of stockholders when considering a
    potential change of control transaction;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the period of time following a change of control during which
    management positions are evaluated and subject to a heightened
    risk of elimination.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, all outstanding options granted to our employees
    will become fully vested upon a change of control if the options
    are not assumed by the acquiring company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the resignation of Mr.&#160;Lucero, our
    former Vice President of Sales and Marketing, on March&#160;22,
    2008, we entered into a Settlement Agreement and General Release
    of Claims with Mr.&#160;Lucero that provided for mutual releases
    of us and Mr.&#160;Lucero, our continued payment of
    Mr.&#160;Lucero&#146;s salary and health insurance premiums
    through July 2008 and payment of an additional $144,000 ($90,000
    net applicable payroll withholding taxes) to Mr.&#160;Lucero.
    The amount and timing of payments to Mr.&#160;Lucero under this
    agreement were the result of negotiations between us and
    Mr.&#160;Lucero, with the involvement of the compensation
    committee. The compensation committee concluded that this
    agreement was in the best interests of our company in reaching
    an amicable separation with Mr.&#160;Lucero.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with Mr.&#160;DeLateur&#146;s resignation, we
    entered into a consulting agreement dated February&#160;29,
    2008. Under the consulting agreement, we agreed to pay
    Mr.&#160;DeLateur $200 per hour for performing various
    consulting services, provided that Mr.&#160;DeLateur work no
    more than five hours per week without our written authorization.
    We entered into this arrangement to ensure that
    Mr.&#160;DeLateur would be available as needed to ensure an
    orderly transition to our new Chief Financial Officer,
    Mr.&#160;Jog.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Benefits.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Executive officers are eligible to participate in all of our
    employee benefit plans, such as medical, dental, vision, group
    life, disability, and accidental death and dismemberment
    insurance and our 401(k) plan, in each case on the same basis as
    other employees, subject to applicable law. We also provide
    vacation and other paid holidays to all employees, including our
    executive officers, which we believe are comparable to those
    provided at peer companies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">CEO
    Loan and Stock Repurchase</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    of 3.52% per annum. The loan was secured by the pledge of
    238,095&#160;shares of our common stock held by
    Mr.&#160;Worthington. On April&#160;10, 2008,
    Mr.&#160;Worthington repaid the loan in full in accordance with
    Section&#160;2.2(d) of the note by exchanging shares of our
    common stock held by Mr.&#160;Worthington to us at the fair
    market value of such stock, which was determined by the Board of
    Directors to be $11.16 per share. The note and
    Mr.&#160;Worthington&#146;s loan were repaid in full and
    cancelled in exchange for 25,975&#160;shares of our common stock
    which Mr.&#160;Worthington transferred to us pursuant to the
    terms of a repurchase agreement dated April&#160;10, 2008. This
    loan repayment and share cancellation transaction were approved
    by the Board based on its determination that we received full
    and fair consideration for the cancellation of the loan and that
    the cancellation of the loan was in the best interests of our
    company and its stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    and Tax Considerations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section 162(m) of the Internal Revenue Code of 1986, as amended,
    or the Code, places a limit of $1,000,000 on the amount of
    compensation that we may deduct as a business expense in any
    year with respect to our Chief Executive Officer and certain of
    our highly paid executive officers. We can, however, preserve
    the deductibility of certain performance-based compensation in
    excess of $1,000,000 if the conditions of Code
    Section&#160;162(m) are met. Under applicable tax guidance for
    newly-public companies, the deduction limitation generally will
    not apply to compensation paid pursuant to any plan or agreement
    that existed before the company became publicly held. In
    addition, compensation provided by newly-public companies
    through the first stockholder meeting to elect directors after
    the close of the third calendar year following the year in which
    the initial public offering occurs, or earlier upon the
    occurrence of certain events (e.g., a material modification of
    the plan or agreement under which the compensation is granted),
    will not be included in for purposes of the Code
    Section&#160;162(m) limit provided the arrangement is adequately
    described in this prospectus. Accordingly, we believe that
    deductibility of all income recognized by executives pursuant to
    equity compensation granted by us prior to this offering, as
    well as any equity compensation granted by us under the 2008
    Equity Incentive Plan following this offering through the
    expiration of the reliance period, will not be limited by Code
    Section&#160;162(m). While the compensation committee cannot
    predict how the deductibility limit may impact our compensation
    program in future years, the compensation committee intends to
    maintain an approach to executive compensation that strongly
    links pay to performance. While the compensation committee has
    not adopted a formal policy regarding tax deductibility of
    compensation paid to our executive officers, the compensation
    committee intends to consider tax deductibility under
    Section&#160;162(m) as a factor in compensation decisions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Code Section 409A imposes additional taxes on certain
    non-qualified deferred compensation arrangements that do not
    comply with its requirements. These requirements regulate an
    individual&#146;s election to defer compensation and the
    individual&#146;s selection of the timing and form of
    distribution of the deferred compensation. Code
    Section&#160;409A generally also provides that distributions of
    deferred compensation only can be made on or following the
    occurrence of certain events (i.e., the individual&#146;s
    separation from service, a predetermined date, a change in
    control, or the individual&#146;s death or disability). For
    certain executives, Code Section&#160;409A requires that such
    individual&#146;s distribution commence no earlier than six
    (6)&#160;months after such officer&#146;s separation from
    service. We have and will continue to endeavor to structure our
    compensation arrangements to comply with Code Section&#160;409A
    so as to avoid the adverse tax consequences associated therewith.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents information concerning the total
    compensation of our Chief Executive Officer, Chief Financial
    Officer and our four other most highly compensated officers
    during the last fiscal year (the &#147;Named Executive
    Officers&#148;) for services rendered to us in all capacities
    for the fiscal year ended December&#160;29, 2007:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    270,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    30,672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,175
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    315,247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and Chief<BR>
    Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard A.
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    241,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    71,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    312,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Former Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    247,502
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    281,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Executive Vice President<BR>
    Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    264,517
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    278,886
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Former Executive Vice President,<BR>
    Sales and Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    261,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    35,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    315,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Legal<BR>
    Affairs and General<BR>
    Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace)
    Yow<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    208,044
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    84,327
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    306,371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Worldwide<BR>
    Manufacturing and Managing Director of Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    expense recognized for financial statement reporting purposes
    for fiscal 2007 calculated in accordance with
    SFAS&#160;No.&#160;123(R) without regard for estimated
    forfeitures. See Note&#160;2 of Notes to Consolidated Financial
    Statements for a discussion of assumptions made in determining
    the grant date fair value and compensation expense of our stock
    options.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;DeLateur resigned
    effective February&#160;29, 2008. From August&#160;16, 2007 to
    December&#160;31, 2007, Mr.&#160;DeLateur worked for us on a
    <FONT style="white-space: nowrap">part-time</FONT>
    basis.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Jones took unpaid leave
    during a portion of 2007.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Lucero resigned effective
    March&#160;22, 2008. See &#147;Employment and Severance
    Agreements.&#147;
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Ms.&#160;Yow&#146;s salary was
    converted to US$ using the exchange rate as of December&#160;29,
    2007.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts in this column
    represent total
    <FONT style="white-space: nowrap">performance-based</FONT>
    bonuses earned for service rendered during fiscal 2007 under our
    incentive bonus plan. Under our incentive bonus plan, each
    executive was eligible to receive a cash bonus of up to 35% of
    his or her base salary based on achievement of certain corporate
    goals and certain individual performance goals. Please see
    &#147;Incentive Bonus Plan&#148; under &#147;Compensation
    Discussion and Analysis&#148; above for additional information
    regarding our fiscal 2007 cash bonuses.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grants
    of Plan-Based Awards</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents information concerning grants of
    plan-based awards to each of the Named Executive Officers during
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants of
    Plan-Based Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payouts Under<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant Date<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fair Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Base Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/Sh)<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,285<SUP style="font-size: 85%; vertical-align: text-top">(1</SUP>
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    131,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    99,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,999<SUP style="font-size: 85%; vertical-align: text-top">(2</SUP>
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    115,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,856<SUP style="font-size: 85%; vertical-align: text-top">(6</SUP>
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    69,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,142<SUP style="font-size: 85%; vertical-align: text-top">(3</SUP>
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,714<SUP style="font-size: 85%; vertical-align: text-top">(4</SUP>
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    101,119
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    92,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5/8/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,857<SUP style="font-size: 85%; vertical-align: text-top">(5</SUP>
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    165,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4/24/2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">2,857 of the shares subject to this
    grant were vested as of the grant date, 2,857&#160;shares vested
    on February&#160;1, 2008, 18,571&#160;shares vest on
    February&#160;1, 2009, and 20,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">19,999 of the shares subject to
    this grant were vested as of the grant date and
    20,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">All of the shares subject to this
    grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">2,857 of the shares subject to this
    grant vested on February&#160;1, 2008, 10,857&#160;shares vest
    on February&#160;1, 2009, and 20,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">14,285 of the shares subject to
    this grant were vested as of the grant date, 14,285&#160;shares
    vested on February&#160;1, 2008, 11,428&#160;shares vest on
    February&#160;1, 2009, and 16,859&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">2,856 of the shares subject to this
    grant vest on February&#160;1, 2009 and 20,000&#160;shares vest
    on February&#160;1, 2010.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts represent the aggregate
    grant date fair value of stock options granted in fiscal 2007,
    calculated in accordance with SFAS&#160;No.&#160;123(R) without
    regard to estimated forfeitures. See Note&#160;2 of Notes to
    Consolidated Financial Statements for a discussion of
    assumptions made in determining the grant date fair value of our
    stock options.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our shares of common stock were not
    publicly traded during the 2007 fiscal year; our Board of
    Directors in good faith determined the fair market value on the
    date of grant.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table presents certain information concerning
    equity awards held by the Named Executive Officers at the end of
    the fiscal year ended December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,142
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
     0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,285
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard DeLateur
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,142
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,141
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/20/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,999
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,285
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(22)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,856
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(23)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Y. Lucero
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,714
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,428
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,571
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,857
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,142
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,142
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12/04/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    07/15/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,857
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    04/18/2014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,571
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    01/17/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,571
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/14/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,714
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(18)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,857
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(19)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    08/03/2015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,571
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(20)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    09/26/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,285
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(21)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,572
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    05/08/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Unless otherwise noted, all option
    grants may be exercised pursuant to a restricted stock purchase
    agreement prior to vesting; any shares purchased prior to
    vesting are subject to a right of repurchase in our favor in the
    event the individual ceases to provide services for any reason
    which right lapses in accordance with the vesting schedule of
    the option.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">2,857 of the shares subject to this
    grant were vested as of May&#160;8, 2007, the grant date,
    2,857&#160;shares vested on February&#160;1, 2008,
    18,571&#160;shares vest on February&#160;1, 2009, and 20,000
    vest on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;21, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">19,999 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    and 20,000&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option may not be exercised
    prior to vesting.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. All of the shares subject to this grant vest
    on February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    December&#160;4, 2001 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    July&#160;16, 2003 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    April&#160;19, 2004 and vest over 4&#160;years at the rate of
    2.083% of the shares per month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    January&#160;18, 2005 and vest over 4&#160;years. 20% of the
    shares subject to the stock option vest one year after grant.
    1.667% of the shares vest at the end of each monthly period
    during the subsequent year and 2.5% of the shares vest at the
    end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;15, 2006 vest over 4&#160;years. 1.67% of the shares
    vest each month for the first two years and 2.5% of the shares
    vest each month in the final two years.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(18)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 2,857 of the shares subject to this grant
    vested on February&#160;1, 2008, 10,857&#160;shares vest on
    February&#160;1, 2009, and 20,000&#160;shares vest on
    February&#160;1, 2010.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(19)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    August&#160;3, 2005 and vest over 4&#160;years. 25% of the
    shares vest one year after grant and 2.083% of the shares vest
    at the end of each monthly period thereafter.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(20)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    September&#160;27, 2006. These stock options vest over
    4&#160;years in monthly increments. During the first two years,
    1.67% of the shares vest each month and during the final two
    years, 2.5% of the shares vest each month.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(21)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">14,285 of the shares subject to
    this grant were vested as of May&#160;8, 2007, the grant date,
    14,285&#160;shares vested on February&#160;1, 2008,
    11,428&#160;shares vest on February&#160;1, 2009, and
    16,859&#160;shares vest on February&#160;1, 2010.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(22)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This option was granted on
    August&#160;3, 2005 and vests over 4&#160;years. Twenty-five
    percent of the shares vest one year after grant and 2.083% of
    the shares vest each month thereafter.
    </FONT></TD>
</TR>



<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(23)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">These stock options were granted on
    May&#160;8, 2007. 2,856 of the shares subject to this grant vest
    on February&#160;1, 2009, and 20,000&#160;shares subject to this
    grant vest on February&#160;1, 2010.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements and Offer Letters</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Richard A DeLateur.</I>&#160;&#160;We entered into a
    consulting agreement dated February&#160;29, 2008 with Richard
    A. DeLateur, our former Chief Financial Officer. Under the
    consulting agreement, we agreed to pay Mr.&#160;DeLateur $200
    per hour for performing various consulting services, provided
    that Mr.&#160;DeLateur shall work no more than five hours per
    week without our written authorization. The consulting agreement
    terminated on May&#160;17, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Y. Lucero.</I>&#160;&#160;We entered into to a
    Settlement Agreement and General Release of Claims effective
    March&#160;30, 2008 with Michael Y. Lucero, our former Executive
    Vice President of Sales and Marketing. Under the settlement
    agreement, we agreed, in exchange for a general release of all
    claims and other customary terms and conditions, (i)&#160;to pay
    Mr.&#160;Lucero on each pay day through July&#160;15, 2008 an
    amount equal to what he would have received on that pay day
    based on an annual base salary of $265,000 and (ii)&#160;to
    reimburse Mr.&#160;Lucero for costs of coverage under the
    Consolidated Omnibus Budget Reconciliation Act of 1985, or
    COBRA, that are incurred during April, May, June and July of
    2008, in an amount no greater than the amount we contributed on
    Mr.&#160;Lucero&#146;s behalf for February 2008. We also agreed
    to make a one time payment to Mr.&#160;Lucero of $144,000
    ($90,000 net of applicable payroll withholding taxes).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vikram Jog.</I>&#160;&#160;We are a party to an offer letter
    dated January&#160;29, 2008, with Vikram Jog, our Chief
    Financial Officer. Under the offer letter, we employ
    Mr.&#160;Jog on an at-will basis for no specified term and
    agreed to pay Mr.&#160;Jog an annual base salary of $278,000,
    which continues to be his base salary. We also agreed to pay
    Mr.&#160;Jog a signing bonus of $20,000 pursuant to his offer
    letter. Pursuant to the offer letter, we granted Mr.&#160;Jog an
    initial options to purchase a total of 171,428&#160;shares of
    our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    Payments Upon Termination or Change of Control</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, we entered into employment and severance
    agreements with Gajus V. Worthington, William M. Smith, Mai Chan
    (Grace) Yow, Robert C. Jones and Vikram Jog, which require us to
    make payments if the named executive officer&#146;s employment
    with us is terminated in certain circumstances.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, a &#147;change of control&#148; is
    defined as the occurrence of the following events:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any &#147;person,&#148; as such term is used in
    Sections&#160;13(d) and 14(d) of the Securities Exchange Act of
    1934, as amended, is or becomes the &#147;beneficial
    owner,&#148; as such term is defined in
    <FONT style="white-space: nowrap">Rule&#160;13d-3</FONT>
    under said Act, directly or indirectly, of our securities
    representing 50% or more of the total voting power represented
    by our then outstanding voting securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a change in the composition of our Board occurring within a
    two-year period, as a result of which fewer than a majority of
    our directors are &#147;incumbent directors,&#148; which term is
    defined as either (i)&#160;our directors as of the execution
    date of the relevant agreement or (ii)&#160;directors who are
    elected, or nominated for election, to our Board with the
    affirmative votes of at least a majority of the incumbent
    directors at the time of such election or nomination (but will
    not include an individual whose election or nomination is in
    connection with an actual or threatened proxy contest relating
    to the election of our directors);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of our merger or consolidation with
    any other corporation that has been approved by the our
    stockholders, other than a merger or consolidation that would
    result in our voting securities outstanding immediately prior
    thereto continuing to represent (either by remaining outstanding
    or by being converted into voting securities of the surviving
    entity) more than 50% of the total voting power represented by
    our voting securities or such surviving entity outstanding
    immediately after such merger or consolidation, or our
    stockholders approve a plan of our complete liquidation;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the date of the consummation of the sale or disposition by us of
    all or substantially all of our assets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with our
    named executive officers, &#147;cause&#148; is defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an act of dishonesty in connection with a named executive
    officer&#146;s responsibilities as an employee;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a conviction of, or plea of <I>nolo contendere </I>to, a felony
    or any crime involving fraud, embezzlement or any other act of
    moral turpitude;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    gross misconduct;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an unauthorized use or disclosure of any of our proprietary
    information or of any other party to whom he or she owes an
    obligation of nondisclosure as a result of his or her
    relationship with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a willful breach of any obligations under any written agreement
    or covenant with us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a named executive officer&#146;s continued failure to perform
    his or her employment duties after he or she has received a
    written demand of performance from us and has failed to cure
    such non-performance to our satisfaction within 10 business days
    after receiving such notice.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreements with Gajus
    V. Worthington, William M. Smith, Robert C. Jones and Vikram
    Jog, &#147;good reason&#148; means the occurrence of one or more
    of the following events effected without the named executive
    officer&#146;s prior consent, provided that he or she terminates
    his or her employment within one year thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to the named executive officer of any duties or a
    reduction of the named executive officer&#146;s duties, either
    of which significantly reduces his or her responsibilities;
    provided that the continuance of his or her responsibilities at
    the subsidiary or divisional level following a change of
    control, rather than at the parent, combined or surviving
    company level following such change of control shall not be
    deemed &#147;good reason&#148; within the meaning of this clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of the named executive officer&#146;s base
    salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of the named executive officer to a facility or a
    location greater than 50&#160;miles from his or her present
    location;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our employment and severance agreement with Mai Chan
    (Grace) Yow, &#147;good reason&#148; means the occurrence of one
    or more of the following events effected without her consent,
    provided that she terminates her employment within one year
    thereafter:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the assignment to Ms.&#160;Yow of any duties or a reduction of
    her duties, either of which significantly reduces her
    responsibilities; provided that the continuance of her
    responsibilities at the subsidiary or divisional level following
    a change of control, rather than at the parent, combined or
    surviving company level following such change of control shall
    not be deemed &#147;good reason&#148; within the meaning of this
    clause;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material reduction of Ms.&#160;Yow&#146;s base salary;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relocation of Ms.&#160;Yow to a facility or a location
    outside the country of Singapore;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material breach by us of any material provision of the
    employment and severance agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, no act or omission by us shall constitute &#147;good
    reason&#148; if we fully cure that act or omission within
    30&#160;days of receiving notice of receiving notice from the
    named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements provide that in the
    event the named executive officer&#146;s employment is
    terminated by us or our successor without &#147;cause&#148;
    prior to a &#147;change of control&#148; or after 12&#160;months
    following a &#147;change of control&#148; and the named
    executive officer executes a standard release of claims with us,
    the named executive officer is entitled to receive, in addition
    to such officer&#146;s salary payable through the date of
    termination of employment and any other benefits earned and owed
    through the date of termination, the following cash payments:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in accordance with our customary payroll
    practices, equal to six&#160;months of the named executive
    officer&#146;s base salary in effect immediately prior to the
    time of termination;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six&#160;months, provided that such coverage
    is timely elected under COBRA or similar applicable state
    statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The employment and severance agreements further provide that in
    the event the named executive officer&#146;s employment is
    terminated by (i)&#160;us or our successor without
    &#147;cause&#148; and within 12&#160;months following a
    &#147;change of control&#148; or (ii)&#160;by the executive
    officer for &#147;good reason&#148; and within 12&#160;months
    following a &#147;change of control&#148;, and in each case the
    named executive officer executes a standard release of claims
    with us, the executive officer is entitled to receive, in
    addition to such officer&#146;s salary payable through the date
    of termination of employment and any other benefits earned and
    owed through the date of termination, the following cash
    payments and benefits:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an amount, payable in a lump sum, equal to the greater of
    (i)&#160;six&#160;months of the named executive officer&#146;s
    base salary in effect immediately prior to the change in control
    or (ii)&#160;six&#160;months of the named executive&#146;s
    officer&#146;s base salary in effect immediately prior to the
    time of termination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all outstanding unvested stock options, equity appreciation
    rights or similar equity awards then held by the named executive
    officer as of the date of termination will immediately vest and
    become exercisable as to all shares underlying such options;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any shares of restricted stock, restricted stock units and
    similar equity awards then held by the named executive officer
    will immediately vest and any of our rights of repurchase or
    reacquisition with respect to such shares will lapse as to all
    shares;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of costs and expenses incurred by the executive
    officer and his or her eligible dependents for coverage under
    group health plans, policies or arrangements sponsored by us for
    a period of up to six months, provided that such coverage is
    timely elected under COBRA or similar applicable state statute.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table describes the payments and benefits that
    each of our named executive officers would be entitled to
    receive pursuant to the employment and severance agreements,
    assuming that each of the following
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    100
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    triggers occurred in December&#160;29, 2007: their employment
    was terminated without &#147;cause&#148; prior to or after
    12&#160;months following a &#147;change of control&#148; and
    (ii) their employment was terminated without &#147;cause&#148;
    or for &#147;good reason&#148; within 12&#160;months following a
    &#147;change of control&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Employment Terminated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>without Cause Prior<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>to or After 12 Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Following Change of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Employment Terminated within 12 Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Control</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Following Change of
    Control<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Severance<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Health Care<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acceleration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payments<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Benefits<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Principal Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gajus V. Worthington
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    President and Chief Executive Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    William M. Smith
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Legal Affairs and General Counsel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mai Chan (Grace) Yow
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106,130
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    106,130
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Vice President, Worldwide Manufacturing and Managing Director of
    Fluidigm Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Robert C. Jones
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    132,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Executive Vice President, Research and Development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vikram Jog
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    139,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: 0pt; margin-left: 10pt">
    Chief Financial Officer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 0pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Includes involuntary termination
    other than for cause, death or disability, and voluntary
    termination for good reason.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to 6&#160;months of the named executive officer&#146;s
    base salary as of December&#160;29, 2007.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to the spread value between (i)&#160;the unvested
    portion of all outstanding stock options, equity appreciation
    rights or similar equity awards held by the named executive
    officer on December&#160;29, 2007 and (ii)&#160;the initial
    public offering price of our common stock, which we have assumed
    to be the midpoint of the price range set forth on the cover
    page of this prospectus.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amounts shown in this column
    are equal to the cost of covering the named executive officer
    and his or her eligible dependents coverage under our benefit
    plans for a period of six months, assuming that such coverage is
    timely elected under COBRA.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amount shown has been converted
    from Singapore dollars to U.S. dollars based on the interbank
    exchange rate for December&#160;29, 2007 of 1&#160;Singapore
    dollar = 0.6909 U.S. dollars.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the benefits described above, our 2008 Equity
    Incentive Plan and 1999 Stock Option Plan provide for full
    acceleration of all outstanding options in the event of a change
    of control of our company where the successor company does not
    assume our outstanding options and other awards in connection
    with such acquisition transaction. We estimate the value of this
    benefit for each named executive officer to be equal to the
    amount listed above in the column labeled &#147;Equity
    Acceleration.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">2008
    Equity Incentive Plan.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors adopted our 2008 Equity Incentive Plan on
    January&#160;29, 2008, and we expect our stockholders will
    approve it prior to the completion of this offer. Subject to
    stockholder approval, the 2008 Equity Incentive Plan is
    effective upon its adoption by our Board of Directors, but is
    not expected to be utilized until after the completion of this
    offering. Our 2008 Equity Incentive Plan provides for the grant
    of incentive stock options, within the meaning of
    Section&#160;422 of the Internal Revenue Code, to our employees
    and any parent and subsidiary corporations&#146; employees, and
    for the grant of nonstatutory stock options, restricted stock,
    restricted stock units, stock appreciation rights, performance
    units and performance shares to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A total of 2,000,000&#160;shares of our common stock are
    reserved for issuance pursuant to the 2008 Equity Incentive
    Plan, of which no options are issued and outstanding. In
    addition, the shares reserved for issuance under our 2008 Equity
    Incentive Plan will also include (a)&#160;those shares reserved
    but unissued under the 1999 Stock Option
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    101
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Plan as of the effective date of the first registration
    statement filed by us and declared effective with respect to any
    class of our securities and (b)&#160;shares returned to the 1999
    Stock Option Plan as the result of expiration or termination of
    options (provided that the maximum number of shares that may be
    added to the 2008 Equity Incentive Plan pursuant to (a)&#160;and
    (b)&#160;is 3,000,000&#160;shares). The number of shares
    available for issuance under the 2008 Equity Incentive Plan will
    also include an annual increase on the first day of each fiscal
    year beginning in 2009, equal to the lesser of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1,200,000&#160;shares;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    4% of the outstanding shares of common stock as of the last day
    of our immediately preceding fiscal year;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    such other amount as our Board of Directors may determine.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors or a committee appointed by our Board
    administers our 2008 Equity Incentive Plan. Our compensation
    committee will administer our 2008 Equity Incentive Plan after
    the completion of the offering. In the case of options intended
    to qualify as &#147;performance-based compensation&#148; within
    the meaning of Section&#160;162(m) of the Internal Revenue Code,
    the committee will consist of two or more &#147;outside
    directors&#148; within the meaning of Section&#160;162(m).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of our 2008 Equity Incentive Plan, the
    administrator has the power to determine the terms of the
    awards, including the exercise price, the number of shares
    subject to each such award, the exercisability of the awards and
    the form of consideration, if any, payable upon exercise. The
    administrator also has the authority to amend existing awards to
    reduce their exercise price, to allow participants the
    opportunity to transfer outstanding awards to a financial
    institution or other person or entity selected by the
    administrator and to institute an exchange program by which
    outstanding awards may be surrendered in exchange for awards
    with a higher or lower exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 2008 Equity
    Incentive Plan must at least be equal to the fair market value
    of our common stock on the date of grant. The term of an
    incentive stock option may not exceed 10&#160;years, except that
    with respect to any participant who owns 10% of the voting power
    of all classes of our outstanding stock, the term must not
    exceed 5&#160;years and the exercise price must equal at least
    110% of the fair market value on the grant date. Subject to the
    provisions of our 2008 Equity Incentive Plan, the administrator
    determines the term of all other options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. However, in no event may
    an option be exercised later than the expiration of its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock appreciation rights may be granted under our 2008 Equity
    Incentive Plan. Stock appreciation rights allow the recipient to
    receive the appreciation in the fair market value of our common
    stock between the exercise date and the date of grant. Subject
    to the provisions of our 2008 Equity Incentive Plan, the
    administrator determines the terms of stock appreciation rights,
    including when such rights become exercisable and whether to pay
    any increased appreciation in cash or with shares of our common
    stock, or a combination thereof, except that the per share
    exercise price for the shares to be issued pursuant to the
    exercise of a stock appreciation right will be no less than 100%
    of the fair market value per share on the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Restricted stock may be granted under our 2008 Equity Incentive
    Plan. Restricted stock awards are grants of shares of our common
    stock that vest in accordance with terms and conditions
    established by the administrator. The administrator will
    determine the number of shares of restricted stock granted to
    any employee, director or consultant. The administrator may
    impose whatever conditions to vesting it determines to be
    appropriate (for example, the administrator may set restrictions
    based on the achievement of specific performance goals or
    continued service to us); provided, however, that the
    administrator, in its sole discretion, may accelerate the time
    at which any restrictions will lapse or be removed. Shares of
    restricted stock that do not vest are subject to our right of
    repurchase or forfeiture.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Restricted stock units may be granted under our 2008 Equity
    Incentive Plan. Restricted stock units are bookkeeping entries
    representing an amount equal to the fair market value of one
    share of our common stock. The administrator determines the
    terms and conditions of restricted stock units including the
    vesting criteria (which may include accomplishing specified
    performance criteria or continued service to us) and the form
    and timing of payment. Notwithstanding the foregoing, the
    administrator, in its sole discretion may accelerate the time at
    which any restrictions will lapse or be removed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Performance units and performance shares may be granted under
    our 2008 Equity Incentive Plan. Performance units and
    performance shares are awards that will result in a payment to a
    participant only if performance goals established by the
    administrator are achieved or the awards otherwise vest. The
    administrator will establish organizational or individual
    performance goals in its discretion, which, depending on the
    extent to which they are met, will determine the number
    <FONT style="white-space: nowrap">and/or</FONT> the
    value of performance units and performance shares to be paid out
    to participants. After the grant of a performance unit or
    performance share, the administrator, in its sole discretion,
    may reduce or waive any performance objectives or other vesting
    provisions for such performance units or performance shares.
    Performance units shall have an initial dollar value established
    by the administrator prior to the grant date. Performance shares
    shall have an initial value equal to the fair market value of
    our common stock on the grant date. The administrator, in its
    sole discretion, may pay earned performance units or performance
    shares in the form of cash, in shares or in some combination
    thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2008 Equity Incentive Plan provides that all non-employee
    directors will be eligible to receive all types of awards
    (except for incentive stock options) under the 2008 Equity
    Incentive Plan. Please see the description of our Outside
    Director Equity Compensation Policy below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 2008 Equity
    Incentive Plan generally does not allow for the transfer of
    awards and only the recipient of an award may exercise an award
    during his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2008 Equity Incentive Plan provides that in the event of a
    merger or &#147;change in control,&#148; as defined in the 2008
    Equity Incentive Plan, each outstanding award will be treated as
    the administrator determines, including that the successor
    corporation or its parent or subsidiary will assume or
    substitute an equivalent award for each outstanding award. The
    administrator is not required to treat all awards similarly. If
    there is no assumption or substitution of outstanding awards,
    the awards will fully vest, all restrictions will lapse, all
    performance goals or other vesting criteria will be deemed
    achieved at 100% of target levels and the awards will become
    fully exercisable. The administrator will provide notice to the
    recipient that he or she has the right to exercise the option
    and stock appreciation right as to all of the shares subject to
    the award, all restrictions on restricted stock will lapse, and
    all performance goals or other vesting requirements
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan, as amended</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan was adopted by our Board of Directors
    and approved by our stockholders on May&#160;12, 1999. Our 1999
    Stock Option Plan was most recently amended on April&#160;24,
    2008. Our 1999 Stock Option Plan provides for the grant of
    incentive stock options, within the meaning of Section&#160;422
    of the Internal Revenue Code, to our employees and any parent
    and subsidiary corporations&#146; employees, and for the grant
    of nonstatutory stock options to our employees, directors and
    consultants and our parent and subsidiary corporations&#146;
    employees and consultants. Our Board of Directors has decided
    not to grant any additional options under our 1999 Stock Option
    Plan following the completion of this offering. However, our
    1999 Stock Option Plan will continue to govern the terms and
    conditions of the outstanding stock options previously granted
    thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of our 1999 Stock Option Plan, the
    maximum aggregate number of shares which may be subject to
    option and sold under our 1999 Stock Option Plan is
    4,228,571&#160;shares. As of June&#160;28, 2008, options to
    purchase 2,373,978&#160;shares of our common stock were
    outstanding and 601,584&#160;shares were available for future
    grant under the 1999 Stock Option Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our compensation committee appointed by our Board of Directors
    currently administers our 1999 Stock Option Plan. Under our 1999
    Stock Option Plan, the administrator has the power to determine
    the terms of the stock options, including the employees,
    directors and consultants who will receive stock options, the
    number of shares subject to each stock option, the vesting
    schedule, any vesting acceleration, and the exercisability of
    stock options.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator also has the authority to initiate an option
    exchange program whereby stock options are exchanged for stock
    options with a lower exercise price. The administrator may also
    reduce the exercise price of any option to the then current fair
    market value if the fair market value of our common stock has
    declined since the date the option was granted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under our 1999 Stock
    Option Plan must at least be equal to the fair market value of
    our common stock on the date of grant. The term of an incentive
    stock option may not exceed 10&#160;years, except that with
    respect to any optionee who owns 10% of the voting power of all
    classes of our outstanding stock as of the grant date, the term
    must not exceed 5&#160;years and the exercise price must equal
    at least 110% of the fair market value on the grant date.
    Subject to the provisions of our 1999 Stock Option Plan, the
    administrator determines the terms of all other options in its
    discretion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the termination of service of an employee, director or
    consultant, he or she may exercise his or her option for the
    period of time stated in his or her option agreement. Generally,
    if termination is due to death or disability, the option will
    remain exercisable for 12&#160;months. In all other cases, the
    option will generally remain exercisable for three months
    following the termination of service. In some cases, options
    issued to consultants pursuant to our 1999 Stock Option Plan
    provide that they may be exercised at anytime prior to the
    expiration of the ten year term of the option. However, in no
    event may an option be exercised later than the expiration of
    its term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the administrator provides otherwise, our 1999 Stock
    Option Plan generally does not allow for the transfer of awards
    and only the recipient of an award may exercise an award during
    his or her lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 1999 Stock Option Plan provides that in the event of a
    merger of our company or a sale of substantially all of our
    assets, each outstanding stock option will be assumed or an
    equivalent option or right substituted by the successor
    corporation. If there is no assumption or substitution of
    outstanding options (or portions thereof), the options (or
    portions thereof) will fully vest and become fully exercisable.
    In such case, the administrator will provide notice to the
    optionee that he or she has the right to exercise the option as
    to all of the shares subject to the option for a period of at
    least 15&#160;days. The option will terminate upon the
    expiration of the period of time the administrator provides in
    the notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has the authority to amend, suspend or
    terminate the 1999 Stock Option Plan provided such action does
    not impair the rights of any optionee without his or her written
    consent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Retirement
    Plans</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>401(k) Plan.</I>&#160;&#160;We maintain a tax-qualified
    retirement plan that provides eligible employees with an
    opportunity to save for retirement on a tax advantaged basis.
    Eligible employees are able to participate in the 401(k) plan as
    of the first&#160;day of the month on or following the date they
    begin employment and participants are able to defer up to 60% of
    their eligible compensation subject to applicable annual
    Internal Revenue Code limits. All participants&#146; interests
    in their deferrals are 100% vested when contributed. The 401(k)
    plan permits us to make matching contributions and profit
    sharing contributions to eligible participants, although we have
    not made any such contributions to date. Pre-tax contributions
    are allocated to each participant&#146;s individual account and
    are then invested in selected investment alternatives according
    to the participants&#146; directions. The 401(k) plan is
    intended to qualify under Sections&#160;401(a) and 501(a) of the
    Internal Revenue Code. As a tax-qualified retirement plan,
    contributions to the 401(k) plan and earnings on those
    contributions are not taxable to the employees until distributed
    from the 401(k) plan and all contributions are deductible by us
    when made.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitation
    on Liability and Indemnification Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    that will become effective upon the completion of this offering
    contain provisions that limit the personal liability of our
    directors for monetary damages to the fullest extent permitted
    by Delaware law. Consequently, our directors will not be
    personally liable to us or our stockholders for monetary damages
    for any breach of fiduciary duties as directors, except
    liability for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any breach of the director&#146;s duty of loyalty to us or our
    stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any act or omission not in good faith or that involves
    intentional misconduct or a knowing violation of law;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    unlawful payments of dividends or unlawful stock repurchases or
    redemptions as provided in Section&#160;174 of the Delaware
    General Corporation Law;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any transaction from which the director derived an improper
    personal benefit.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation that will
    become effective upon the completion of this offering, provides
    that we indemnify our directors to the fullest extent permitted
    by Delaware law. In addition, our amended and restated bylaws,
    that will become effective upon the completion of this offering,
    provides that we indemnify our directors and officers to the
    fullest extent permitted by Delaware law. Our amended and
    restated bylaws, that will become effective upon the completion
    of this offering, also provide that we shall advance expenses
    incurred by a director or officer in advance of the final
    disposition of any action or proceeding, and permit us to secure
    insurance on behalf of any officer, director, employee or other
    agent for any liability arising out of his or her actions in
    that capacity, regardless of whether we would otherwise be
    permitted to indemnify him or her under the provisions of
    Delaware law. We have entered and expect to continue to enter
    into agreements to indemnify our directors, executive officers
    and other employees as determined by the Board of Directors.
    With certain exceptions, these agreements provide for
    indemnification for related expenses including, among others,
    attorneys&#146; fees, judgments, fines and settlement amounts
    incurred by any of these individuals in any action or
    proceeding. We believe that these bylaw provisions and
    indemnification agreements are necessary to attract and retain
    qualified persons as directors and officers. We also maintain
    directors&#146; and officers&#146; liability insurance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The limitation of liability and indemnification provisions in
    our amended and restated certificate of incorporation and
    bylaws, that will become effective upon the completion of this
    offering, may discourage stockholders from bringing a lawsuit
    against our directors for breach of their fiduciary duty of
    care. They may also reduce the likelihood of derivative
    litigation against our directors and officers, even though an
    action, if successful, might benefit us and other stockholders.
    Further, a stockholder&#146;s investment may be adversely
    affected to the extent that we pay the costs of settlement and
    damage awards against directors and officers. At present, there
    is no pending litigation or proceeding involving any of our
    directors, officers or employees for which indemnification is
    sought, and we are not aware of any threatened litigation that
    may result in claims for indemnification.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    105
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the director and executive compensation
    arrangements discussed above in &#147;Management,&#148; we have
    been a party to the following transactions since January&#160;1,
    2005, in which the amount involved exceeded or will exceed
    $120,000, and in which any director, executive officer or holder
    of more than 5% of any class of our voting stock, or any member
    of the immediate family of or entities affiliated with any of
    them, had or will have a material interest.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Sales of
    Series&#160;E Preferred Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below summarizes purchases of shares of our
    Series&#160;E preferred stock since January&#160;1, 2005, by our
    directors, executive officers, holders of more than 5% of any
    class of our voting securities, or any member of the immediate
    family of or any entities affiliated with any of the foregoing
    persons. In connection with these sales, we granted the
    purchasers certain registration rights with respect to their
    securities. See &#147;Description of Capital Stock&#160;&#151;
    Registration Rights.&#148; Each outstanding share of our
    preferred stock will be converted automatically into one share
    of our common stock upon the completion of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series E<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Preferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchasers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    644,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Bruce
    Burrows<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,578,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    847,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biomedical Sciences Investment Fund&#160;Pte
    Ltd<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,273,793
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,833,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with InterWest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    199,976
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Lehman Brothers Holdings,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    638,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lilly
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    358,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Entities affiliated with Versant
    Ventures<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    999,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,650,143
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    23,102,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 605&#160;shares
    purchased by Alloy Partners 2002, L.P., 22,430&#160;shares
    purchased by Alloy Ventures 2002, L.P. and 23,035&#160;shares
    purchased by Alloy Ventures 2005, L.P. Michael Hunkapiller, an
    affiliate of Alloy Ventures, is a member of our Board of
    Directors.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Bruce Burrows served as member of
    our Board of Directors from January&#160;3, 2000 to
    January&#160;15, 2008.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 30,250&#160;shares
    purchased EuclidSR Biotechnology Partners, L.P. and
    30,250&#160;shares purchased by EuclidSR Partners, L.P. Elaine
    Jones, an affiliate of Euclid SR Partners, is a member of our
    Board of Directors.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of shares issued to
    Biomedical Sciences Investment Fund&#160;Pte Ltd in connection
    with the conversion of convertible promissory notes.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 652&#160;shares
    purchased by InterWest Investors VII, L.P. and
    13,632&#160;shares purchased by InterWest Partners VII, L.P.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 11,410&#160;shares
    purchased by Lehman Brothers Healthcare Venture Capital L.P.,
    2,552&#160;shares purchased by Lehman Brothers Offshore
    Partnership Account 2000/2001, L.P., 21,840&#160;shares
    purchased by Lehman Brothers P.A., LLC, and 9,840 purchased by
    Lehman Brothers Partnership Account 2001/2001, L.P. Hingge Hsu,
    an affiliate of Lehman Brothers Holdings, Inc., served as a
    member of our Board of Directors at the time of the financing.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Ed Torres, an affiliate of Lilly
    Ventures, served as a member of our Board of Directors at the
    time of the financing.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 1,428&#160;shares
    purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-A,</FONT>
    L.P., 3,000&#160;shares purchased by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;1-B,</FONT>
    L.P., 1,285&#160;shares purchased by Versant Side Fund&#160;I,
    L.P. and 65,714&#160;shares purchased by Versant Venture
    Capital&#160;I, L.P. Sam Colella, an affiliate of Versant
    Ventures, is a member of our Board of Directors.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transactions
    with the Singapore Government</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Convertible
    Note Financings</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2003, we entered into a convertible note
    purchase agreement (as amended December&#160;17, 2004)&#160;with
    Biomedical Sciences Investment Fund&#160;Pte Ltd, or BMSIF, an
    investment arm of the Singapore Economic Development Board, or
    EDB. Upon execution of the agreement, BMSIF purchased a
    convertible promissory note in the principal amount of
    $2,000,000 at an interest rate equal to 8% per annum. The
    principal and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    106
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    interest on this note was convertible into our Series&#160;D
    preferred stock at a price of $9.80 per share, which was equal
    to the per share purchase price of our Series&#160;D preferred
    stock sold to other investors in December 2003. This note was
    converted into 237,895&#160;shares of our Series&#160;D
    preferred stock on December&#160;15, 2005. Additionally, the
    agreement provided for the issuance of up to two additional
    convertible promissory notes, each in the principal amount of
    $1,500,000, or a single additional convertible promissory note
    in the principal amount of $3,000,000, and all at an interest
    rate of 8% per annum. Pursuant to the terms of the agreement, on
    June&#160;20, 2006 we issued a single note in the principal
    amount of $3,000,000 to BMSIF. The principal and interest on
    this note was also convertible into our Series&#160;D preferred
    stock at a price of $9.80 per share. This note was converted
    into 330,612&#160;shares of our Series&#160;D preferred stock on
    July&#160;2, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;7, 2006, we entered into a second convertible
    note purchase agreement with BMSIF pursuant to which BMSIF
    purchased three convertible promissory notes each in the
    principal amount of $5&#160;million, for an aggregate principal
    amount of $15,000,000, and each at an interest rate equal to 8%
    per annum. The principal and interest on these notes was
    convertible into our Series&#160;E preferred stock at a price of
    $12.60 per share, which represented a 10% discount on the $14.00
    per share price at which our Series&#160;E preferred stock was
    sold to other investors in our Series&#160;E preferred stock
    financing which occurred between June 2006 and December 2007.
    The first note was issued on August&#160;7, 2006 and was
    converted into 417,351&#160;shares of our Series&#160;E
    preferred stock on March&#160;31, 2007. The second note was
    issued on November&#160;20, 2006 and was converted into
    426,744&#160;shares of our Series&#160;E preferred stock on
    March&#160;31, 2007. The last note was issued on April&#160;19,
    2007 and was converted into 429,698&#160;shares of our
    Series&#160;E preferred stock on April&#160;30, 2008. Each such
    conversion was completed following the agreement of the parties
    that the required milestones had been met to the parties
    satisfaction or waived.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Government
    Incentive Grants</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2005, Fluidigm Singapore entered into a letter
    agreement providing for up to SG$10&#160;million (approximately
    US$7.3&#160;million using June&#160;28, 2008 exchange rates) in
    incentive grants from the Singapore Economic Development Board,
    or EDB. The incentive grants are payable for the period
    August&#160;1, 2005 through July&#160;31, 2010 in connection
    with the establishment and operation of a research, development
    and manufacturing center for IFCs in Singapore. Incentive grant
    payments are calculated as a portion of qualifying expenses we
    incur in Singapore relating to salaries, overhead, outsourcing
    and subcontracting expenses, operating expenses and royalties
    paid. Fluidigm Singapore is required to submit requests for
    incentive grant payments on a quarterly basis along with reports
    regarding its compliance with the development, hiring,
    expenditure and other conditions through the end of the
    applicable quarter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;11, 2006, Fluidigm Singapore and EDB entered
    into a supplement to the October 2005 letter agreement. This
    supplement was entered into to create a process whereby Fluidigm
    Singapore and EDB would agree on new quarterly development
    targets at the start of each year, Fluidigm Singapore would
    submit to EDB a progress report and evidence of the achievement
    of targets on a quarterly basis and the parties would resolve
    any disagreements regarding the satisfaction of targets using an
    established procedure and the parties would be entitled to
    obtain a third party audit of our incentive grant payment
    requests on a semi-annual rather than an annual basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Singapore&#146;s continued eligibility for such
    incentive grant payments is subject to its compliance with
    increasing levels of research, development and manufacturing
    activity in Singapore, including employment of specified numbers
    of research scientists and engineers, its incurrence of
    specified levels of research and development expenses in
    Singapore over the course of each calendar year, its use of
    local service providers, its manufacture in Singapore of the
    products developed in Singapore and its achievement of certain
    targets relating to new product development or completion of
    specific manufacturing process objectives. Specifically, this
    agreement requires that we must employ at least 24 research
    scientists and engineers in Singapore by December&#160;31, 2009
    to remain eligible for incentive grant payments. As of
    June&#160;28, 2008, we employed 16&#160;research scientists and
    engineers involved in the research and development of our IFCs.
    These required levels of research, development and manufacturing
    activity in Singapore and the associated increases from one year
    to the next are the result of negotiations between the parties
    and are generally consistent with our business strategy for our
    Singapore operations. All ownership rights in the intellectual
    property developed by Fluidigm Singapore remain with Fluidigm
    Singapore and no such rights are conveyed to EDB under the
    agreement.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On February&#160;12, 2007, Fluidigm Singapore entered into a
    second letter agreement with EDB which provided for up to an
    additional SG$3.7&#160;million (approximately
    US$2.7&#160;million using a June&#160;28, 2008 exchange rate) in
    incentive grant payments. The terms and conditions of this
    letter agreement are substantially the same as the October 2005
    letter agreement, with the exception of the size of the
    potential grant, the term of the agreement and the specific
    levels of research, development and manufacturing activity
    required to maintain eligibility for such grants. This letter
    agreement requires that we employ at least 10 new research
    scientists and engineers in Singapore by May&#160;31, 2009, that
    we employ at least 12 new research scientists and engineers in
    Singapore by May&#160;31, 2011 and that we maintain at least 12
    research scientists and engineers in total until May&#160;31,
    2013 to remain eligible for incentive grant payments. The
    requirements of the February 2007 agreement may only be
    satisfied by personnel employed in the research and development
    of IFC instrumentation. As of June&#160;28, 2008, we employed
    10&#160;research scientists and engineers involved in the
    research and development of our IFC instrumentation. The primary
    focus of this grant agreement was the ongoing development and
    manufacture in Singapore of instrumentation to be used with our
    IFCs. This letter agreement applies to research, development and
    manufacturing activity by Fluidigm Singapore in Singapore from
    June&#160;1, 2006 through May&#160;31, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;27, 2008, Fluidigm Singapore entered into amended
    and restated versions of our October 2005 and February 2007
    letter agreements with EDB. The purpose of these amendments was
    to consolidate and streamline the original agreements to
    eliminate sub-categories of eligible expenditures and rely on
    more general descriptions of the eligible expenditures that the
    parties had been applying in practice, to consolidate certain
    administrative terms and conditions of the incentive grant
    payments, and to remove various forms attached to the original
    letter agreements that had changed over time or were not part of
    the ongoing agreement between the parties. The January 2006
    supplement to the October 2005 letter agreement remains in
    effect.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Loan to
    Gajus Worthington</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;20, 2004, we entered into an Employee Loan
    Agreement, Secured Promissory Note and Stock Pledge Agreement
    with Mr.&#160;Worthington pursuant to which we loaned
    Mr.&#160;Worthington $250,000 at an interest rate of 3.52% per
    annum and the principal and interest were not due and payable
    until 7&#160;years after the date of the loan or upon the
    earlier occurrence of certain events. The loan was secured by
    the pledge of 238,095&#160;shares of our common stock held by
    Mr.&#160;Worthington and was otherwise non-recourse. The loan
    was extended to Mr.&#160;Worthington to assist him in purchasing
    a home for his personal residence in Northern California. On
    April&#160;10, 2008, Mr.&#160;Worthington repaid the loan in
    full in accordance with Section&#160;2.2(d) of the note by
    selling shares of our common stock held by Mr.&#160;Worthington
    to us at the fair market value of such stock on the date of such
    sale, which was determined by the Board of Directors to be
    $11.16 per share. The note and Mr.&#160;Worthington&#146;s loan
    were repaid in full and cancelled in exchange for
    25,975&#160;shares of our common stock which
    Mr.&#160;Worthington transferred to us pursuant to the terms of
    a repurchase agreement dated April&#160;10, 2008. This loan
    repayment and share cancellation transaction was approved by the
    Board based on its determination that we received full and fair
    consideration for the cancellation of the loan and that the
    cancellation of the loan was in the best interests of our
    company and its stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consulting
    Agreement with Stephen Quake</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2006, we entered into an agreement with Stephen Quake
    pursuant to which we have agreed to pay Dr.&#160;Quake $8,333
    per month for providing various consulting services to us
    including serving on our Scientific Advisory Board. The
    agreement has a term of 10&#160;years and is terminable by us
    only for cause. At approximately the same time, we repurchased
    from Dr.&#160;Quake approximately 35,421&#160;shares of our
    common stock for aggregate consideration of $69,425. In 2005 and
    2006, we paid Dr. Quake $45,000 and $97,000 pursuant to a
    consulting agreement that was entered into in 2000 and
    terminated in 2006. Dr.&#160;Quake served as a director of
    Fluidigm from its inception until December 2005 and, at the time
    of these transactions, was the holder of more than 5% of our
    outstanding common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Engagement
    of Townsend and Townsend and Crew LLP</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since before 2005, the law firm of Townsend and Townsend and
    Crew LLP, or Townsend, has served as our primary outside patent
    counsel. William Smith, our Vice President, Legal Affairs and
    General Counsel as well as our Secretary since May 2000 and a
    director from May 2000 until April&#160;7, 2008, was a partner
    at Townsend from
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1985 to April&#160;1, 2008. Amounts paid to Townsend for
    services and direct patent fees were $880,000, $960,000,
    $576,000 and $312,000 for 2005, 2006, 2007, and the six months
    ended June&#160;28,&#160;2008. Accrued amounts payable to
    Townsend were $174,000, $257,000, and $411,000 as of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of our preferred stock and our co-founders are entitled
    to certain registration rights with respect to the common stock
    issued or issuable upon conversion of the preferred stock. See
    &#147;Registration Rights&#148; under &#147;Description of
    Capital Stock&#148; below for additional information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain stock option grants to our directors and executive
    officers and related option grant policies are described above
    in this prospectus under the caption &#147;Management.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Arrangements and Indemnification Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment arrangements with certain of our
    executive officers. See &#147;Management&#160;&#151; Employment
    Agreements and Offer Letters&#148; above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have also entered into indemnification agreements with each
    of our directors and executive officers. The indemnification
    agreements and our certificate of incorporation and bylaws
    require us to indemnify our directors and executive officers to
    the fullest extent permitted by Delaware law. See
    &#147;Management&#160;&#151; Limitations on Liability and
    Indemnification Matters&#148; above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Related
    Party Transaction Policy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a formal policy that our executive officers,
    directors, holders of more than 5% of any class of our voting
    securities, and any member of the immediate family of and any
    entity affiliated with any of the foregoing persons, are not
    permitted to enter into a related party transaction with us
    without the prior consent of our audit committee, or other
    independent members of our Board in the case it is inappropriate
    for our audit committee to review such transaction due to a
    conflict of interest. Any request for us to enter into a
    transaction with an executive officer, director, principal
    stockholder, or any of their immediate family members or
    affiliates, in which the amount involved exceeds $120,000 must
    first be presented to our audit committee for review,
    consideration and approval. In approving or rejecting any such
    proposal, our audit committee is to consider the relevant facts
    and circumstances available and deemed relevant to the audit
    committee, including, but not limited to, whether the
    transaction is on terms no less favorable than terms generally
    available to an unaffiliated third party under the same or
    similar circumstances and the extent of the related party&#146;s
    interest in the transaction. All of the transactions described
    above were entered into prior to the adoption of this policy.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    109
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    STOCKHOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth certain information with respect
    to the beneficial ownership of our common stock at June&#160;28,
    2008, as adjusted to reflect the sale of common stock offered by
    us in this offering, for:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person who we know beneficially owns more than five percent
    of our common stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our named executive officers;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers as a group.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have determined beneficial ownership in accordance with SEC
    rules. Except as indicated by the footnotes below, we believe,
    based on the information furnished to us, that the persons and
    entities named in the table below have sole voting and
    investment power with respect to all shares of common stock that
    they beneficially own, subject to applicable community property
    laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Applicable percentage ownership is based on
    19,490,535&#160;shares of common stock outstanding at
    June&#160;28, 2008. For purposes of the table below, we have
    assumed that 24,790,535&#160;shares of common stock will be
    outstanding upon completion of this offering, based upon an
    assumed initial public offering price of $15.00 per share. In
    computing the number of shares of common stock beneficially
    owned by a person and the percentage ownership of that person,
    we deemed to be outstanding all shares of common stock subject
    to options, warrants or other convertible securities held by
    that person or entity that are currently exercisable or
    exercisable within 60&#160;days of June&#160;28, 2008. We did
    not deem these shares outstanding, however, for the purpose of
    computing the percentage ownership of any other person.
    Beneficial ownership representing less than one percent is
    denoted with an &#147;*.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, the address of each beneficial owner
    listed in the table below is
    <FONT style="white-space: nowrap">c/o&#160;Fluidigm</FONT>
    Corporation, 7000 Shoreline Court, Suite&#160;100, South
    San&#160;Francisco, California 94080.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Beneficial Ownership<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Prior to the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>After the Offering</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Stockholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Alloy
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,066,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.47
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,066,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with EuclidSR
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,399,710
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.18
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,399,710
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.65
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with the Singapore
    government<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,573,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.21
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,573,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.38
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Fidelity
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,785,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,785,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
     7.20
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with InterWest
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(5)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,079,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.54
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,079,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.35
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Lehman
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(6)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,055,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.41
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,055,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.26
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    SMALLCAP World Fund,
    Inc.<SUP style="font-size: 85%; vertical-align: text-top">(7)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,251,055
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.42
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,251,055
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.05
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entities affiliated with Versant
    Funds<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,679,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,679,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.78
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Bruce Burrows
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,042,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.35
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,042,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.20
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Named Executive Officers:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gajus V.
    Worthington<SUP style="font-size: 85%; vertical-align: text-top">(9)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    810,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.13
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    810,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Richard
    DeLateur<SUP style="font-size: 85%; vertical-align: text-top">(10)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Robert C.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(11)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    197,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.00
</TD>
<TD nowrap align="left" valign="bottom">
    %*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    197,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael Y.
    Lucero<SUP style="font-size: 85%; vertical-align: text-top">(12)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    William M.
    Smith<SUP style="font-size: 85%; vertical-align: text-top">(13)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    319,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    319,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.28
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mai Chan (Grace)
    Yow<SUP style="font-size: 85%; vertical-align: text-top">(14)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Vikram
    Jog<SUP style="font-size: 85%; vertical-align: text-top">(15)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Samuel
    Colella<SUP style="font-size: 85%; vertical-align: text-top">(8)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,679,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.62
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,679,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.78
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Michael
    Hunkapiller<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,066,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.47
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,066,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Elaine V.
    Jones<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,399,710
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.18
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,399,710
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.65
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Kenneth
    Nussbacher<SUP style="font-size: 85%; vertical-align: text-top">(16)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    John
    Young<SUP style="font-size: 85%; vertical-align: text-top">(17)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All directors and executive officers as a group (12&#160;persons)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,849,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28.72
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,849,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22.79
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(*)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Less than one percent.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 533,239&#160;shares
    held of record by Alloy Ventures 2005, L.P., 519,220&#160;shares
    held of record by Alloy Ventures 2002, L.P., and
    14,018&#160;shares held of record by Alloy Partners 2002, L.P.
    Michael Hunkapiller, a member of our Board of Directors, is a
    Managing Member
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">of Alloy Ventures 2005, LLC, the
    General Partner of Alloy Ventures 2005, L.P. Alloy Ventures
    2002, LLC is the General Partner of Alloy Ventures 2002, L.P.
    and Alloy Partners 2002, L.P. The Managing Members of Alloy
    Ventures 2002, LLC are Craig C. Taylor, <BR>
    John&#160;F. Shoch, Douglas E. Kelly, Daniel I. Rubin and Tony
    Di Bona. Each of the Managing Members of Alloy Ventures 2002,
    LLC is also a Managing Member of Alloy Ventures 2005, LLC. The
    individuals listed herein may be deemed to have shared voting
    and dispositive power over the shares which are or may be deemed
    to be beneficially owned by Alloy Ventures 2005, L.P., Alloy
    Ventures 2002, L.P. and Alloy Partners 2002, L.P. Each Managing
    Member disclaims beneficial ownership of the shares except to
    extent of their pecuniary interest therein. The address of the
    entities affiliated with Alloy Ventures is 400 Hamilton Avenue,
    Fourth Floor, Palo Alto, CA 94301.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 699,855&#160;shares
    held of record by EuclidSR Partners, L.P. and
    699,855&#160;shares held of record by EuclidSR Biotechnology
    Partners, L.P. Elaine V. Jones, a member of our Board of
    Directors shares voting and investment power with Graham D.S.
    Anderson, Raymond J. Whitaker, Milton J. Pappas and Stephen K.
    Reidy, each of whom are General Partners of EuclidSR Associates,
    L.P., the General Partner of EuclidSR Partners and EuclidSR
    Biotechnology Associates, L.P., the General Partner of EuclidSR
    Biotechnology Partners. Each General Partner of EuclidSR
    Associates, L.P. and EuclidSR Biotechnology Associates, L.P.
    disclaims beneficial ownership of the shares except to the
    extent of their pecuniary interest therein. The address of the
    entities affiliated with EuclidSR Associates, L.P. and EuclidSR
    Biotechnology Associates, L.P. is 45 Rockefeller Plaza, Suite
    3240, New York, NY 10111.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 2,352,504&#160;shares
    held of record by Biomedical Sciences Investment Fund Pte Ltd
    which includes 429,698&#160;shares issued upon conversion of a
    convertible promissory note, and 221,484&#160;shares held of
    record by Singapore Bio-Innovations Pte Ltd, EDB Investments Pte
    Ltd. EDB Investments Pte Ltd, or EDB Investments, is the parent
    entity of Biomedical Sciences Investment Fund Pte Ltd and
    Singapore Bio-Innovations Pte Ltd. The Economic Development
    Board of Singapore, or EDB, is the parent entity of EDB
    Investments. EDB is a Singapore government entity. EDB
    Investments, EDB and the Singapore government may be deemed to
    have shared voting and dispositive power over the shares owned
    beneficially and of record by Biomedical Sciences Investment
    Fund&#160;Pte Ltd and Singapore Bio-Innovations Pte Ltd. The
    address associated with entities affiliated with EDB is 20
    Biopolis Way, #09-01 Centros, Singapore 138668.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 137,477&#160;shares
    held of record by Fidelity Contrafund: Fidelity Advisor New
    Insights Fund, 1,254,247&#160;shares held of record by Fidelity
    Contrafund: Fidelity Contrafund and 393,990&#160;shares held of
    record by Variable Insurance Products Fund&#160;II: Contrafund
    Portfolio. Each of these entities is a registered investment
    fund (each, a &#147;Fund&#148;) advised by Fidelity
    Management&#160;&#038; Research Company (&#147;FMR Co.&#148;), a
    registered investment adviser under the Investment Advisers Act
    of 1940, as amended. The address of FMR Co., a wholly-owned
    subsidiary of FMR Corp. and an investment adviser registered
    under Section&#160;203 of the Investment Advisers Act of 1940 is
    82&#160;Devonshire Street, Boston Massachusetts 02109. Edward C.
    Johnson 3d, FMR Corp., through its control of FMR Co., and each
    Fund has power to dispose of the securities owned by such Fund.
    Neither FMR Corp. nor Edward C. Johnson 3d, Chairman of FMR
    Corp., has sole power to vote or direct the voting of the shares
    owned directly by each Fund, which power resides with each
    Fund&#146;s Board of Trustees. Each Fund is an affiliate of a
    broker-dealer. Each Fund purchased the securities in the
    ordinary course of business and, at the time of the purchase of
    the securities, no Fund had any agreements or understandings,
    directly or indirectly, with any person to distribute the
    securities. No Fund intends to sell, transfer, assign, pledge or
    hypothecate or otherwise enter into any hedging, short sale,
    derivative, put or call transaction that would result in the
    effective economic disposition of the securities through an
    affiliated broker-dealer.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 49,313&#160;shares held
    of record by InterWest Investors VII, L.P. and
    1,029,794&#160;shares held of record by InterWest Partners VII,
    L.P. InterWest Management Partners VII, L.L.C. has sole voting
    and investment control over the shares owned by InterWest
    Partners VII, L.P. and InterWest Investors VII, L.P. Harvey B.
    Cash, Philip T. Gianos, W. Scott Hedrick, W. Stephen Holmes,
    Gilbert H. Kliman, Thomas L. Rosch and Arnold L. Oronsky, each
    Managing Directors of InterWest Management Partners VII, LLC,
    have shared voting and investment control over the shares owned
    by InterWest Partners VII, L.P. and InterWest Investors VII,
    L.P. Stephen C. Bowsher, Alan W. Crites, Rodney A. Ferguson and
    Karen A. Wilson are Members of InterWest Management Partners
    VII, L.L.C. All Managing Directors and Members disclaim
    beneficial ownership of the shares owned by InterWest Partners
    VII, LP and InterWest Investor VII, LP except to the extent of
    their pro rata partnership interests in such shares. The address
    of the entities affiliated with InterWest is 2710 Sand Hill
    Road, Second Floor, Menlo Park, CA 94025.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 263,849&#160;shares
    held of record by Lehman Brothers Healthcare Venture Capital,
    L.P., 59,009&#160;shares held of record by Lehman Brothers
    Offshore Partnership Account 2000/2001, L.P.,
    505,010&#160;shares held of record by Lehman Brothers P.A., LLC
    and 227,530&#160;shares held of record by Lehman Brothers
    Partnership Account 2000/2001, L.P. Hingge Hsu, a former member
    of our Board of Directors, was formerly employed by Lehman
    Brothers Inc., and now serves as a consultant of Lehman Brothers
    Inc. In each of the limited partnerships referenced above,
    Lehman Brothers Inc. controls the general partner of the limited
    partnership. In the limited liability company, Lehman Brothers
    Inc. controls the manager of the limited liability company. In
    all four entities listed above, Lehman Brothers Holdings Inc., a
    public reporting company under the Securities Exchange Act of
    1934, as amended, ultimately controls the manager and the
    general partners of the entities and ultimately has voting and
    investment control over the shares held by such entities. The
    address of the entities affiliated with Lehman Brothers Inc. is
    399 Park Avenue,
    11<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
    Floor, New York, NY 10022.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 1,251,055&#160;shares
    held of record by SMALLCAP World Fund, Inc, or SMALLCAP.
    SMALLCAP is an investment company registered under the
    Investment Company Act of 1940. Capital Research and Management
    Company, or CRMC, an investment adviser registered under the
    Investment Advisers Act of 1940, is the investment adviser to
    SMALLCAP and has sole dispositive power over these shares.
    Gordon Crawford, J.&#160;Blair Frank, Jonathan Knowles,
    Brady&#160;L. Enright, Mark&#160;E. Denning and Claudia&#160;P.
    Huntington are the primary portfolio counselors of CRMC. In such
    capacity, CRMC Messrs. Crawford, Frank, Knowles, Enright,
    Denning and Ms.&#160;Huntington may be deemed to beneficially
    own the shares held by SMALLCAP. CRMC, however, each disclaims
    such beneficial ownership. The address of the SMALLCAP is The
    Capital Group Companies, 333, South Hope Street, Los Angeles,
    California 90071.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 1,536,575&#160;shares
    held of record by Versant Venture Capital&#160;I, L.P.,
    28,188&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., 83,183&#160;shares held of record by Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P. and 32,042&#160;shares held of record by Versant Side
    Fund&#160;I, L.P. Voting and investment power over the shares
    directly held by Versant Venture Capital&#160;I, L.P., Versant
    Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-A,</FONT>
    L.P., Versant Affiliates
    <FONT style="white-space: nowrap">Fund&#160;I-B,</FONT>
    L.P., and Versant Side Fund&#160;I, L.P. is held by Versant
    Ventures&#160;I, LLC, their sole General Partner. Samuel D.
    Colella, a member of our Board of Directors
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    111
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">is a Managing Member of Versant
    Ventures&#160;I, LLC but he disclaims beneficial ownership of
    these shares, except to the extent of his pecuniary interest in
    such shares. The individual Managing Members of Versant
    Ventures&#160;I, LLC are Brian G. Atwood, Samuel D. Colella,
    Ross A. Jaffe, William J. Link, Barbara N. Lubash, Donald B.
    Milder, and Rebecca B. Robertson, all of whom share voting and
    dispositive control. Each respective individual General Partner
    disclaims beneficial ownership of these shares, except to the
    extent of their pecuniary interest in such shares. The address
    of the entities affiliated with Versant Ventures is 3000 Sand
    Hill Road, Building Four, Suite&#160;210, Menlo Park, CA 94025.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 668,881&#160;shares
    held of record by Gajus Worthington and Jami A. Worthington as
    TTEES of the Worthington Family Trust dtd 3-6-07 and options to
    purchase 141,426&#160;shares of Common Stock that are
    exercisable within 60&#160;days of June&#160;28, 2008, of which
    75,711&#160;shares are vested as of August&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;DeLateur held options to
    purchase an additional 16,407&#160;shares which expired on
    August&#160;17, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    197,139&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008 of which 97,141&#160;shares
    are vested as of August&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">No options are currently
    outstanding or exercisable.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of 85,714&#160;shares held
    of record by William M. Smith and options to purchase
    233,424&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008, of which 223,283 are vested
    as of August&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    88,332&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008, of which 79,403 are vested
    as of August&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    171,427&#160;shares of common stock that are exercisable within
    60 days of June&#160;28, 2008, none of which are vested as of
    August&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Consists of options to purchase
    40,178&#160;shares of common stock that are exercisable within
    60&#160;days of June&#160;28, 2008, all of which are vested as
    of August&#160;27, 2008.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(17)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Young disclaims beneficial
    ownership of 77,142&#160;shares as all of the shares were
    subsequently transferred to his children, Diana Young, Gregory
    Young and John Peter Young. As of August&#160;27, 2008
    4,762&#160;shares of common stock are subject to a right of
    repurchase at cost. The right of repurchase lapses at a rate of
    approximately 595&#160;shares of common stock per month.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='114'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF CAPITAL STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the rights of our common stock and
    preferred stock and of certain provisions of our restated
    certificate of incorporation and bylaws, as they will be in
    effect upon the completion of this offering. For more detailed
    information, please see our restated certificate of
    incorporation and bylaws, which are filed as exhibits to the
    registration statement of which this prospectus is part.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately following the completion of this offering, our
    authorized capital stock will consist of
    320,000,000&#160;shares, all with a par value of $0.001 per
    share, of which:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    300,000,000&#160;shares are designated as common stock;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    20,000,000&#160;shares are designated as preferred stock.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, we had outstanding
    19,490,535&#160;shares of common stock held of record by
    252&#160;stockholders, assuming the automatic conversion of all
    outstanding shares of our preferred stock on a one-for-one basis
    into 16,625,970&#160;shares of common stock. This automatic
    conversion of our preferred stock has been approved by the
    holders of our outstanding preferred stock and will be effective
    upon the closing of this offering. In addition, as of
    June&#160;28, 2008, 2,373,978&#160;shares of our common stock
    were subject to outstanding options and 216,409&#160;shares of
    our capital stock were subject to outstanding warrants. No
    options will expire prior to the completion of this offering.
    For more information on our capitalization, see
    &#147;Capitalization&#148; above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Common
    Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of our common stock are entitled to one vote per
    share on all matters to be voted on by our stockholders. Subject
    to preferences that may be applicable to any outstanding shares
    of preferred stock, holders of common stock are entitled to
    receive ratably such dividends as may be declared by our Board
    of Directors out of funds legally available for that purpose. In
    the event of our liquidation, dissolution or winding up, the
    holders of common stock are entitled to share ratably in all
    assets remaining after the payment of liabilities, subject to
    the prior distribution rights of preferred stock then
    outstanding. Holders of common stock have no preemptive,
    conversion or subscription rights. There are no redemption or
    sinking fund provisions applicable to the common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Preferred
    Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately after the completion of this offering, no shares of
    preferred stock will be outstanding (assuming the automatic
    conversion of all outstanding shares of our preferred stock on a
    one-for-one basis into 16,625,970&#160;shares of common stock
    immediately prior to the completion of this offering). Though we
    currently have no plans to issue any shares of preferred stock,
    upon the closing of this offering and the filing of our restated
    certificate of incorporation, our Board of Directors will have
    the authority, without further action by our stockholders, to
    designate and issue up to 20,000,000&#160;shares of preferred
    stock in one or more series. Our Board of Directors may also
    designate the rights, preferences and privileges of the holders
    of each such series of preferred stock, any or all of which may
    be greater than or senior to those granted to the holders of
    common stock. Though the actual effect of any such issuance on
    the rights of the holders of common stock will not be known
    until our Board of Directors determines the specific rights of
    the holders of preferred stock, the potential effects of such an
    issuance include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    diluting the voting power of the holders of common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive dividend payments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reducing the likelihood that holders of common stock will
    receive payments in the event of our liquidation, dissolution,
    or winding up;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delaying, deterring or preventing a
    <FONT style="white-space: nowrap">change-in-control</FONT>
    or other corporate takeover.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Warrants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, we had outstanding warrants to
    purchase an aggregate of 216,409&#160;shares of our preferred
    stock, all of which will be converted into warrants to purchase
    an equal number of shares of our common stock at exercise prices
    ranging from $9.03 per share to $14.00 per share. These warrants
    will expire at various times between March&#160;2012 and
    February 2015. In the event of a distribution of dividends, a
    stock split, a reorganization, a reclassification, a
    consolidation, or a similar event, each warrant provides for
    adjustment of the exercise price and the number of shares
    issuable upon exercise. In June 2008, the number of shares
    subject to a certain warrant to purchase Series&#160;E Preferred
    Stock issued to Lighthouse Capital Partners&#160;V, L.P.
    increased by 57,142&#160;shares pursuant to its terms as a
    result of our borrowing an additional $10&#160;million under our
    loan agreement with Lighthouse.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Issuance of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;7, 2003, we entered into a Master Closing
    Agreement with Oculus Pharmaceuticals, Inc. and The UAB Research
    Foundation, or UAB, related to certain intellectual property and
    technology rights licensed by us from UAB. Pursuant to the
    agreement, we are obligated to issue UAB shares of our common
    stock with a value equal to approximately $1,500,000 upon the
    achievement of a certain milestone and based upon the fair
    market value of our common stock at the time the milestone is
    achieved. We currently do not anticipate achieving this
    milestone in the foreseeable future and do not anticipate
    issuing these shares. The potential issuance discussed above is
    not reflected in the number of shares of common stock
    outstanding in this prospectus.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, the holders of an aggregate of
    18,199,960&#160;shares of our common stock, which includes
    16,621,278&#160;shares of common stock issued on conversion of
    outstanding preferred stock and 216,409&#160;shares of common
    stock issuable upon the exercise of warrants and conversion of
    preferred stock underlying such warrants, are entitled to the
    following rights with respect to the registration of such shares
    for public resale under the Securities Act, pursuant to an
    investor rights agreement by and among us and certain of our
    stockholders. In addition, the aggregate number above includes
    an additional 1,362,273&#160;shares of common stock entitled to
    the rights described below, in the section titled
    &#147;Piggyback Registration Rights.&#148; We refer to these
    shares collectively as &#147;registrable securities.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration of shares of common stock as a result of the
    following rights being exercised would enable the holders to
    trade these shares without restriction under the Securities Act
    when the applicable registration statement is declared
    effective. Ordinarily, we will be required to pay all expenses,
    other than underwriting discounts and commissions, related to
    any registration effected pursuant to the exercise of these
    registration rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registration rights terminate upon the earlier of five years
    after completion of this offering, or, with respect to the
    registration rights of an individual holder, when the holder of
    one percent or less of our outstanding common stock can sell all
    of such holder&#146;s registrable securities in any three-month
    period without registration, in compliance with Rule&#160;144 of
    the Securities Act or another similar exemption.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Demand
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering the holders of at least a
    majority of the registrable securities request in writing that
    we effect a registration that has a reasonably anticipated
    aggregate price to the public in excess of $20,000,000, we may
    be required to register their shares. At most, we are obligated
    to effect two registrations for the holders of registrable
    securities in response to these demand registration rights.
    Depending on certain conditions, however, we may defer such
    registration for up to 90&#160;days. If the holders requesting
    registration intend to distribute their shares by means of an
    underwriting, the managing underwriter of such offering will
    have the right to limit the number of shares to be underwritten
    for reasons related to the marketing of the shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Piggyback
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after this offering we propose to register any
    shares of our common stock under the Securities Act, subject to
    certain exceptions, the holders of registrable securities will
    be entitled to notice of the registration
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and to include their shares of registrable securities in the
    registration. If our proposed registration involves an
    underwriting, the managing underwriter of such offering will
    have the right to limit the number of shares to be underwritten
    for reasons related to the marketing of the shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    Registration Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If at any time after we become entitled under the Securities Act
    to register our shares on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    a holder of registrable securities requests in writing that we
    register their shares for public resale on
    <FONT style="white-space: nowrap">Form&#160;S-3</FONT>
    and the reasonably anticipated price to the public of the
    offering exceeds $2,000,000, we will be required to use our best
    efforts to effect such registration; provided, however, that if
    such registration would be seriously detrimental to us or our
    stockholders, we may defer the registration for up to
    90&#160;days.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the provisions of our amended and restated certificate of
    incorporation to become effective upon completion of this
    offering, holders of our common stock are entitled to one vote
    for each share of common stock held by such holder on any matter
    submitted to a vote at a meeting of stockholders. In addition,
    our amended and restated certificate of incorporation provides
    that certain corporate actions require the approval of our
    stockholders. These actions, and the vote required, are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the removal of a director requires the vote of a majority of the
    voting power of our issued and outstanding capital stock
    entitled to vote in the election of directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amendment of provisions of our amended and restated
    certificate of incorporation relating to blank check preferred
    stock, the classification of our directors, the removal of
    directors, the filling of vacancies on our Board of Directors,
    cumulative voting, annual and special meetings of our
    stockholders and the amendment of certain provisions of our
    restated certificate of incorporation require the vote of 66
    2/3% of our then outstanding voting securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Anti
    Takeover Effects of Delaware Law and Our Certificate of
    Incorporation and Bylaws</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain provisions of Delaware law and our restated certificate
    of incorporation and bylaws that will become effective upon
    completion of this offering contain provisions that could have
    the effect of delaying, deferring or discouraging another party
    from acquiring control of us. These provisions, which are
    summarized below, are expected to discourage certain types of
    coercive takeover practices and inadequate takeover bids. These
    provisions are also designed in part to encourage anyone seeking
    to acquire control of us to first negotiate with our Board of
    Directors. We believe that the advantages gained by protecting
    our ability to negotiate with any unsolicited and potentially
    unfriendly acquirer outweigh the disadvantages of discouraging
    such proposals, including those priced above the then-current
    market value of our common stock, because, among other reasons,
    the negotiation of such proposals could improve their terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Certificate
    of Incorporation and Bylaws</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our amended and restated certificate of incorporation and bylaws
    to become effective upon completion of this offering include
    provisions that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    authorize our Board of Directors to issue, without further
    action by the stockholders, up to 20,000,000&#160;shares of
    undesignated preferred stock;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require that any action to be taken by our stockholders be
    effected at a duly called annual or special meeting and not by
    written consent;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that special meetings of our stockholders can be called
    only by our Board of Directors, the Chairman of the Board, the
    Chief Executive Officer or the President;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish an advance notice procedure for stockholder approvals
    to be brought before an annual meeting of our stockholders,
    including proposed nominations of persons for election to our
    Board of Directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that directors may be removed only for cause;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    115
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide that vacancies on our Board of Directors may be filled
    only by a majority of directors then in office, even though less
    than a quorum;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish that our Board of Directors is divided into three
    classes, Class&#160;I, Class&#160;II, and Class&#160;III, with
    each class serving staggered terms;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    specify that no stockholder is permitted to cumulate votes at
    any election of the Board of Directors;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require a super majority of votes to amend certain of the
    above-mentioned provisions.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Delaware
    Anti-Takeover Statute</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to the provisions of Section&#160;203 of the
    Delaware General Corporation Law regulating corporate takeovers.
    In general, Section&#160;203 prohibits a publicly-held Delaware
    corporation from engaging, under certain circumstances, in a
    business combination with an interested stockholder for a period
    of three years following the date the person became an
    interested stockholder unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the date of the transaction, the Board of Directors of
    the corporation approved either the business combination or the
    transaction which resulted in the stockholder becoming an
    interested stockholder;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    upon completion of the transaction that resulted in the
    stockholder becoming an interested stockholder, the interested
    stockholder owned at least 85% of the voting stock of the
    corporation outstanding at the time the transaction commenced,
    excluding for purposes of determining the voting stock
    outstanding, but not for determining the outstanding voting
    stock owned by the interested stockholder, (1)&#160;shares owned
    by persons who are directors and also officers, and
    (2)&#160;shares owned by employee stock plans in which employee
    participants do not have the right to determine confidentially
    whether shares held subject to the plan will be tendered in a
    tender or exchange offer;&#160;or
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at or subsequent to the date of the transaction, the business
    combination is approved by the Board of Directors of the
    corporation and authorized at an annual or special meeting of
    stockholders, and not by written consent, by the affirmative
    vote of at least
    66<FONT style="vertical-align: text-top; font-size: 70%;">2</FONT>/<FONT style="font-size: 70%;">3</FONT>%
    of the outstanding voting stock which is not owned by the
    interested stockholder.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, a business combination includes a merger, asset or
    stock sale, or other transaction resulting in a financial
    benefit to the interested stockholder. An interested stockholder
    is a person who, together with affiliates and associates, owns
    or, within three years prior to the determination of interested
    stockholder status, did own 15% or more of a corporation&#146;s
    outstanding voting stock. We expect the existence of this
    provision to have an anti-takeover effect with respect to
    transactions our Board of Directors does not approve in advance.
    We also anticipate that Section&#160;203&#160;may discourage
    business combinations or other attempts that might result in a
    premium over the market price for the shares of common stock
    held by our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The provisions of Delaware law and our restated certificate of
    incorporation and bylaws to become effective upon completion of
    this offering could have the effect of discouraging others from
    attempting hostile takeovers and, as a consequence, they may
    also inhibit temporary fluctuations in the market price of our
    common stock that often result from actual or rumored hostile
    takeover attempts. These provisions may also have the effect of
    preventing changes in our management. It is possible that these
    provisions could make it more difficult to accomplish
    transactions that stockholders may otherwise deem to be in their
    best interests.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Transfer
    Agent and Registrar</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The transfer agent and registrar for our common stock is
    Computershare Trust Company, N.A. The transfer agent&#146;s
    address is 250&#160;Royall Street, Canton, MA 02021, and its
    telephone number is (781) 575-2900.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">NASDAQ
    Global Market Listing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have our common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    116
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='115'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Before this offering, there has not been a public market for
    shares of our common stock. Future sales of substantial amounts
    of shares of our common stock, including shares issued upon the
    exercise of outstanding options, in the public market after this
    offering, or the possibility of these sales occurring, could
    cause the prevailing market price for our common stock to fall
    or impair our ability to raise equity capital in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, a total of
    24,790,535&#160;shares of common stock will be outstanding,
    assuming that there are no exercises of options or warrants
    after June&#160;28, 2008. Of these shares, all
    5,300,000&#160;shares of common stock sold in this offering by
    us, plus any shares sold upon exercise of the underwriters&#146;
    over-allotment option, will be freely tradable in the public
    market without restriction or further registration under the
    Securities Act, unless these shares are held by
    &#147;affiliates,&#148; as that term is defined in Rule&#160;144
    under the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The remaining 19,490,535&#160;shares of common stock will be
    &#147;restricted securities,&#148; as that term is defined in
    Rule&#160;144 under the Securities Act. These restricted
    securities are eligible for public sale only if they are
    registered under the Securities Act or if they qualify for an
    exemption from registration under Rules&#160;144 or 701 under
    the Securities Act, which are summarized below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the lock up agreements described below and the
    provisions of Rules&#160;144 and 701 under the Securities Act,
    these restricted securities will be available for sale in the
    public market as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
     On the date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Between 90 and 180&#160;days after the date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    At various times beginning more than 180&#160;days after the
    date of this prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,490,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, of the 2,373,978&#160;shares of our common stock
    that were subject to stock options outstanding as of
    June&#160;28, 2008, options to purchase 1,098,706&#160;shares of
    common stock were vested as of June&#160;28, 2008 and will be
    eligible for sale 180&#160;days following the effective date of
    this offering.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;144</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144 as currently in effect, once we
    have been subject to public company reporting requirements for
    at least 90&#160;days, a person who is not deemed to have been
    one of our affiliates for purposes of the Securities Act at any
    time during the 90&#160;days preceding a sale and who has
    beneficially owned the shares proposed to be sold for at least
    six months, including the holding period of any prior owner
    other than our affiliates, is entitled to sell those shares
    without complying with the manner of sale, volume limitation or
    notice provisions of Rule&#160;144, subject to compliance with
    the public information requirements of Rule&#160;144. If such a
    person has beneficially owned the shares proposed to be sold for
    at least one year, including the holding period of any prior
    owner other than our affiliates, then that person is entitled to
    sell those shares without complying with any of the requirements
    of Rule&#160;144.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144, as currently in effect, our
    affiliates or persons selling shares on behalf of our affiliates
    are entitled to sell upon expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements described above, within any three-month period
    beginning 90&#160;days after the date of this prospectus, a
    number of shares that does not exceed the greater of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1% of the number of shares of common stock then outstanding,
    which will equal approximately 247,905&#160;shares immediately
    after this offering;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the average weekly trading volume of the common stock during the
    four calendar weeks preceding the filing of a notice on
    Form&#160;144 with respect to that sale.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales under Rule&#160;144 by our affiliates or persons selling
    shares on behalf of our affiliates are also subject to certain
    manner of sale provisions and notice requirements and to the
    availability of current public information about us.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    117
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;701 as currently in effect, any of
    our employees, consultants or advisors who purchase shares from
    us in connection with a compensatory stock or option plan or
    other written agreement in a transaction before the effective
    date of this offering that was completed in reliance on
    Rule&#160;701 and complied with the requirements of
    Rule&#160;701 will, subject to the lock up restrictions
    described below, be eligible to resell such shares 90&#160;days
    after the effective date of this offering in reliance on
    Rule&#160;144, but without compliance with certain restrictions,
    including the holding period, contained in Rule&#160;144.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Lock Up
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all of our directors and officers, as well as the other
    holders of substantially all shares of common stock outstanding
    immediately prior to this offering, have agreed that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, we and they will
    not, during the period ending 180&#160;days after the date of
    this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    shares of our common stock or any securities convertible into or
    exercisable or exchangeable for shares of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of our common stock,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any transaction described above is to be settled by
    delivery of shares of our common stock or such other securities,
    in cash or otherwise. This agreement is subject to certain
    exceptions, and is also subject to extension for up to an
    additional days, as set forth in &#147;Underwriters.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, the holders of
    18,199,960&#160;shares of common stock or series of common stock
    issuable upon exercise of warrants or their transferees will be
    entitled to various rights with respect to the registration of
    these shares under the Securities Act. Registration of these
    shares under the Securities Act would result in these shares
    becoming fully tradable without restriction under the Securities
    Act immediately upon the effectiveness of the registration,
    except for shares purchased by affiliates. See &#147;Description
    of Capital Stock&#160;&#151; Registration Rights&#148; for
    additional information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Statements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act covering all of the shares of common
    stock subject to options outstanding or reserved for issuance
    under our stock plans. We expect to file this registration
    statement as soon as practicable after this offering. In
    addition, we intend to file a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    under the Securities Act for the resale of shares of common
    stock issued upon the exercise of options that were not granted
    under Rule&#160;701. We expect to file this registration
    statement as soon as practicable after this offering. However,
    none of the shares registered on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    will be eligible for resale until the expiration of the lock up
    agreements to which they are subject.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    118
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='120'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MATERIAL
    U. S. FEDERAL INCOME AND ESTATE TAX<BR>
    CONSEQUENCES TO NON-U. S. HOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a general discussion of certain material United
    States federal income and estate tax considerations with respect
    to the acquisition, ownership and disposition of shares of our
    common stock applicable to
    <FONT style="white-space: nowrap">non-U.S.&#160;holders.</FONT>
    In general, a
    <FONT style="white-space: nowrap">&#147;non-U.S.&#160;holder&#148;</FONT>
    is any holder other than:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual who is a citizen or resident of the United States
    for United States federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity treated as a corporation for
    United States federal income tax purposes) created or organized
    in or under the laws of the United States, any state thereof or
    the District of Columbia;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate, the income of which is includible in gross income for
    United States federal income tax purposes regardless of its
    source;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if (a)&#160;a court within the United States is able to
    exercise primary supervision over the administration of the
    trust and one or more United States persons have the authority
    to control all substantial decisions of the trust or (b)&#160;it
    has a valid election in effect under applicable Treasury
    regulations to be treated as a United&#160;States person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion is based on current provisions of the Internal
    Revenue Code, final, temporary or proposed Treasury regulations
    promulgated thereunder, judicial opinions, published positions
    of the Internal Revenue Service and all other applicable
    authorities, all of which are subject to change (possibly with
    retroactive effect). We assume in this discussion that a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    holds shares of our common stock as a capital asset (generally
    property held for investment).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not address all aspects of United States
    federal income and estate taxation that may be important to a
    particular
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    in light of that
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    individual circumstances, nor does it address any aspects of
    United States state or local taxes or
    <FONT style="white-space: nowrap">non-U.S.&#160;taxes.</FONT>
    This discussion also does not consider any specific facts or
    circumstances that may apply to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    subject to special treatment under the United&#160;States
    federal income tax laws, including, without limitation:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    banks, insurance companies or other financial institutions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    partnerships or other pass-through entities or persons that hold
    shares of our common stock through such entities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-exempt organizations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    tax-qualified retirement plans;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    dealers in securities or currencies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    traders in securities that elect to use a mark-to-market method
    of accounting for their securities holdings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    United States expatriates;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    persons that will hold common stock as a position in a hedging
    transaction, &#147;straddle&#148; or &#147;conversion
    transaction&#148; for tax purposes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accordingly, we urge prospective investors to consult with their
    own tax advisors regarding the United States federal, state and
    local income and
    <FONT style="white-space: nowrap">non-U.S.&#160;income</FONT>
    and other tax considerations of acquiring, holding and disposing
    of shares of our common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership or other pass-through entity holds shares of
    our common stock, the tax treatment of a partner in such
    partnership or an owner of such other pass-through entity will
    generally depend upon the status of such partner or other owner
    and the activities of such partnership or other entity. Any
    partnership or other pass-through entity that holds shares of
    our common stock or any partner in such partnership or owner of
    such other entity should consult its own tax advisors.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    119
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we make cash or other property distributions on our common
    stock, such distributions will constitute dividends for United
    States federal income tax purposes to the extent paid from our
    current or accumulated earnings and profits, as determined under
    United States federal income tax principles. To the extent those
    distributions exceed both our current and our accumulated
    earnings and profits, such excess will constitute a return of
    capital and will first reduce the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    adjusted tax basis in our common stock, but not below zero. Any
    remaining excess will be treated as gain from the sale or other
    disposition of shares of our common stock (as described under
    &#147;&#151;&#160;Gain on Sale or Other Disposition of Common
    Stock&#148; below).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, dividends we pay, if any, to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States withholding tax at a rate of
    30% of the gross amount. The withholding tax might not apply or
    might apply at a reduced rate under the terms of an applicable
    income tax treaty between the United States and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    country of residence. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    must demonstrate its entitlement to treaty benefits by
    certifying, among other things, its nonresident status. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    generally can meet this certification requirement by providing
    an Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8BEN</FONT>
    or appropriate substitute form to us or our paying agent. Also,
    special rules apply if the dividends are effectively connected
    with a trade or business carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States and, if a treaty applies, are
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United States. Dividends effectively connected with
    this United States trade or business, and, if a treaty applies,
    attributable to such a permanent establishment of a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder,</FONT>
    generally will not be subject to United States withholding tax
    if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    files certain forms, including Internal Revenue Service
    <FONT style="white-space: nowrap">Form&#160;W-8ECI</FONT>
    (or any successor form), with the payor of the dividend, and
    generally will be subject to United States federal income tax on
    a net income basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that is a corporation may be subject to an additional
    &#147;branch profits tax&#148; at a rate of 30% (or a reduced
    rate as may be specified by an applicable income tax treaty) on
    the repatriation from the United States of its &#147;effectively
    connected earnings and profits,&#148; subject to certain
    adjustments. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock eligible for a reduced rate of
    United States withholding tax pursuant to an income tax treaty
    may obtain a refund of any excess amounts withheld by timely
    filing an appropriate claim for refund with the Internal Revenue
    Service.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Gain on
    Sale or Other Disposition of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will not be subject to United States federal income tax on any
    gain realized upon the sale or other disposition of the
    holder&#146;s shares of our common stock unless:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the gain is effectively connected with a trade or business
    carried on by the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    within the United&#160;States and, if required by an applicable
    income tax treaty as a condition to subjecting a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    to United States income tax on a net basis, the gain is
    attributable to a permanent establishment of the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    maintained in the United States, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to United States federal income tax on any gain
    realized upon the sale or other disposition on a net income
    basis, in the same manner as if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    were a resident of the United States. Furthermore, the branch
    profits tax discussed above may also apply if the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is a corporation;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    is an individual and is present in the United States for
    183&#160;days or more in the taxable year of disposition and
    certain other tests are met, in which case a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    will be subject to a flat 30% tax on any gain realized upon the
    sale or other disposition, which tax may be offset by United
    States source capital losses (even though the individual is not
    considered a resident of the United States);&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we are or have been a United States real property holding
    corporation (a USRPHC) for United States federal income tax
    purposes at any time within the shorter of the five-year period
    preceding the disposition and the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    holding period. We do not believe that we are or have been a
    USRPHC, and we do not anticipate becoming a USRPHC. If we have
    been in the past or were to become a USRPHC at any time during
    this period, generally gains realized upon a disposition of
    shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    that did not directly or indirectly own more than 5% of our
    common stock during this period would not be subject to United
    States federal income tax, provided that our common stock is
    &#147;regularly traded on an established securities market&#148;
    (within the meaning of Section&#160;897(c)(3) of the Internal
    Revenue Code). Our common stock will be treated as regularly
    traded on an established securities market during any period in
    which it is listed on a registered national securities exchange
    or any over-the-counter market.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    120
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    States Federal Estate Tax</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares of our common stock that are owned or treated as owned by
    an individual who is not a citizen or resident (as defined for
    United States federal estate tax purposes) of the United States
    at the time of death will be includible in the individual&#146;s
    gross estate for United States federal estate tax purposes,
    unless an applicable estate tax treaty provides otherwise, and
    therefore may be subject to United States federal estate tax.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Backup
    Withholding, Information Reporting and Other Reporting
    Requirements</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, we must report annually to the Internal Revenue
    Service and to each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    the amount of dividends paid to, and the tax withheld with
    respect to, each
    <FONT style="white-space: nowrap">non-U.S.&#160;holder.</FONT>
    These reporting requirements apply regardless of whether
    withholding was reduced or eliminated by an applicable tax
    treaty. Copies of this information also may be made available
    under the provisions of a specific treaty or agreement with the
    tax authorities in the country in which the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    resides or is established.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    United States backup withholding tax is imposed (at a current
    rate of 28%) on certain payments to persons that fail to furnish
    the information required under the United States information
    reporting requirements. A
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    of shares of our common stock will be subject to this backup
    withholding tax on dividends we pay unless the holder certifies,
    under penalties of perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Treasury regulations, the payment of proceeds from the
    disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a United States office of a broker generally
    will be subject to information reporting and backup withholding
    unless the beneficial owner certifies, under penalties of
    perjury, among other things, its status as a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    (and we or our paying agent do not have actual knowledge or
    reason to know the holder is a United States person) or
    otherwise establishes an exemption. The payment of proceeds from
    the disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker generally will not be subject to backup withholding
    and information reporting, except as noted below. In the case of
    proceeds from a disposition of shares of our common stock by a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    made to or through a
    <FONT style="white-space: nowrap">non-U.S.&#160;office</FONT>
    of a broker that is:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a United States person;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a &#147;controlled foreign corporation&#148; for United States
    federal income tax purposes;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign person 50% or more of whose gross income from certain
    periods is effectively connected with a United States trade or
    business;&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a foreign partnership if at any time during its tax year
    (a)&#160;one or more of its partners are United States persons
    who, in the aggregate, hold more than 50% of the income or
    capital interests of the partnership or (b)&#160;the foreign
    partnership is engaged in a United States trade or business;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    information reporting (but not backup withholding) will apply
    unless the broker has documentary evidence in its files that the
    owner is a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    and certain other conditions are satisfied, or the beneficial
    owner otherwise establishes an exemption (and the broker has no
    actual knowledge or reason to know to the contrary).
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Backup withholding is not an additional tax. Any amounts
    withheld under the backup withholding rules from a payment to a
    <FONT style="white-space: nowrap">non-U.S.&#160;holder</FONT>
    may generally be refunded or credited against the
    <FONT style="white-space: nowrap">non-U.S.&#160;holder&#146;s</FONT>
    United States federal income tax liability, if any, provided
    that the required information is furnished to the Internal
    Revenue Service in a timely manner.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    EACH PROSPECTIVE HOLDER OF SHARES OF OUR COMMON STOCK SHOULD
    CONSULT HIS, HER OR ITS OWN TAX ADVISOR WITH RESPECT TO THE
    UNITED STATES FEDERAL, STATE AND LOCAL TAX CONSEQUENCES AND
    <FONT style="white-space: nowrap">NON-U.S.&#160;TAX</FONT>
    CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF
    OUR COMMON STOCK.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    121
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='121'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNDERWRITERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms and subject to the conditions contained in an
    underwriting agreement dated the date of this prospectus, the
    underwriters named below, for whom Morgan Stanley&#160;&#038;
    Co. Incorporated is acting as the representative, have severally
    agreed to purchase, and we have agreed to sell to them,
    severally, the number of shares indicated in the table below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="90%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Morgan Stanley&#160;&#038; Co. Incorporated
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    UBS Securities LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leerink Swann LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pacific Growth Equities, LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters are offering the shares of common stock subject
    to their acceptance of the shares from us and subject to prior
    sale. The underwriting agreement provides that the obligations
    of the several underwriters to pay for and accept delivery of
    the shares of common stock offered by this prospectus are
    subject to the approval of certain legal matters by their
    counsel and to certain other conditions. The underwriters are
    obligated to take and pay for all of the shares of common stock
    offered by this prospectus if any such shares are taken.
    However, the underwriters are not required to take or pay for
    the shares covered by the underwriters&#146; over-allotment
    option described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters initially propose to offer part of the shares
    of common stock directly to the public at the offering price
    listed on the cover page of this prospectus and part to certain
    dealers at a price that represents a concession not in excess of
    $&#160;&#160;  per share under the public offering price. After
    the initial offering of the shares of common stock, the offering
    price and other selling terms may from time to time be varied by
    the representative.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted to the underwriters an option, exercisable for
    30&#160;days from the date of this prospectus, to purchase up to
    an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional
    shares of common stock at the public offering price set forth on
    the cover page of this prospectus, less underwriting discounts
    and commissions. The underwriters may exercise this option
    solely for the purpose of covering over-allotments, if any, made
    in connection with the offering of the shares of common stock
    offered by this prospectus. To the extent the option is
    exercised, each underwriter will become obligated, subject to
    certain conditions, to purchase approximately the same
    percentage of the additional shares of common stock as the
    number listed next to the underwriter&#146;s name in the
    preceding table bears to the total number of shares of common
    stock listed next to the names of all underwriters in the
    preceding table.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table shows the per share and total public
    offering price, underwriting discounts and commissions and
    proceeds before expenses to us. These amounts are shown assuming
    both no exercise and full exercise of the underwriters&#146;
    option to purchase up to an additional 795,000&#160;shares of
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>No exercise</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Full Exercise</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Public offering price
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Underwriting discounts and commissions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds, before expenses, to us
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The estimated offering expenses payable by us, exclusive of the
    underwriting discounts and commissions are approximately
    $3.1&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters have informed us that they do not intend sales
    to discretionary accounts to exceed five percent of the total
    number of shares of common stock offered by them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to have the common stock listed on the NASDAQ
    Global Market under the symbol &#147;FLDM.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    122
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and all directors, officers and substantially all of our
    other security holders have agreed that, without the prior
    written consent of Morgan Stanley&#160;&#038; Co. Incorporated
    on behalf of the underwriters, we and they will not, during the
    period ending 180&#160;days after the date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend, or
    otherwise transfer or dispose of directly or indirectly, any
    shares of common stock or any securities convertible into or
    exercisable or exchangeable for common stock;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the common stock; or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in our case only, file or cause to be filed a registration
    statement, including any amendments with respect to the
    registration statement of any shares of common stock or
    securities convertible, exercisable or exchangeable into our
    common stock or any other securities of the company (other than
    any registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8),</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of common stock or such other securities, in cash or
    otherwise. In addition, each such person agrees that, without
    the prior written consent of Morgan Stanley&#160;&#038; Co.
    Incorporated on behalf of the underwriters, they will not,
    during the period ending 180&#160;days after the date of this
    prospectus, make any demand for, or exercise any right with
    respect to, the registration of any shares of common stock or
    any security convertible into or exercisable or exchangeable for
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to certain restrictions, the restrictions described in
    the immediately preceding paragraph do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale of shares to the underwriters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to shares of common stock or other
    securities acquired in this offering or in open market
    transactions after the completion of this offering, provided
    that no filing under Section&#160;16(a) of the Securities
    Exchange Act of 1934, as amended, shall be required or shall be
    voluntarily made in connection with subsequent sales of common
    stock or other securities acquired in such transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of any options to acquire common stock or
    conversion of any convertible security into common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock as a bona fide gift;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    distributions of shares of common stock or any security
    convertible into common stock to limited partners, members or
    stockholders of the transferor;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of shares of common stock or any security convertible
    into common stock by will or intestacy to the transferor&#146;s
    immediate family or to a trust, the beneficiaries of which are
    members of the transferor&#146;s immediate family;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of a trading plan pursuant to
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Exchange Act for the transfer of shares of common
    stock, provided that such plan does not provide for the transfer
    of common stock during the restricted period;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the issuance of shares of, or options to purchase shares of,
    common stock to our employees, officers, directors, advisors or
    consultants pursuant to our employee benefit plans;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the filing of a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8</FONT>
    for the registration of shares of common stock issued pursuant
    our employee benefit plans;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the issuance of shares of common stock, or any securities
    convertible into or exercisable or exchangeable for common
    stock, in an amount having an aggregate value equal to 15% of
    the gross proceeds from this offering in connection with a
    merger or acquisition transaction.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    123
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The <FONT style="white-space: nowrap">180-day</FONT>
    restricted period described in the preceding paragraph will be
    extended if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    during the last 17&#160;days of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we issue a release regarding earnings or
    regarding material news or events relating to us;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prior to the expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    restricted period, we announce that we will release earnings
    results during the
    <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the
    <FONT style="white-space: nowrap">180-day</FONT>
    period,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    in which case, the restrictions described in the preceding
    paragraph will continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event, unless such
    extension is waived, in writing, by Morgan Stanley&#160;&#038;
    Co. Incorporated on behalf of the underwriters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to facilitate the offering of the common stock, the
    underwriters may engage in transactions that stabilize, maintain
    or otherwise affect the price of the common stock. Specifically,
    the underwriters may sell more shares than they are obligated to
    purchase under the underwriting agreement, creating a short
    position. A short sale is covered if the short position is no
    greater than the number of shares available for purchase by the
    underwriters under the over-allotment option. The underwriters
    can close out a covered short sale by exercising the
    over-allotment option or purchasing shares in the open market.
    In determining the source of shares to close out a covered short
    sale, the underwriters will consider, among other things, the
    open market price of shares compared to the price available
    under the over-allotment option. The underwriters may also sell
    shares in excess of the over-allotment option, creating a naked
    short position. The underwriters must close out any naked short
    position by purchasing shares in the open market. A naked short
    position is more likely to be created if the underwriters are
    concerned that there may be downward pressure on the price of
    the common stock in the open market after pricing that could
    adversely affect investors who purchase in the offering. As an
    additional means of facilitating the offering, the underwriters
    may bid for, and purchase, shares of common stock in the open
    market. Finally, the underwriting syndicate may reclaim selling
    concessions allowed to an underwriter or a dealer for
    distributing the common stock in the offering, if the syndicate
    repurchases previously distributed common stock to cover
    syndicate short positions or to stabilize the price of the
    common stock. These activities may raise or maintain the market
    price of the common stock above independent market levels or
    prevent or retard a decline in the market price of the common
    stock. The underwriters are not required to engage in these
    activities, and may end any of these activities at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the underwriters have agreed to indemnify each other
    against certain liabilities, including liabilities under the
    Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A prospectus in electronic format may be made available on
    websites maintained by one or more underwriters participating in
    this offering. Other than the prospectus in electronic format,
    the information on the underwriters&#146; websites is not part
    of this prospectus. The underwriters may agree to allocate a
    number of shares of common stock to underwriters for sale to
    their online brokerage account holders. Internet distributions
    will be allocated by Morgan Stanley&#160;&#038; Co. Incorporated
    to underwriters that may make Internet distributions on the same
    basis as other allocations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">European
    Economic Area</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In relation to each Member State of the European Economic Area
    which has implemented the Prospectus Directive, each underwriter
    has represented and agreed that with effect from and including
    the date on which the Prospectus Directive is implemented in
    that Member State it has not made and will not make an offer of
    the common stock to the public in that Member State, except that
    it may, with effect from and including such date, make an offer
    of the common stock to the public in that Member State:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to legal entities which are authorized or regulated
    to operate in the financial markets or, if not so authorized or
    regulated, whose corporate purpose is solely to invest in
    securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time to any legal entity which has two or more of
    (1)&#160;an average of at least 250&#160;employees during the
    last financial year; (2)&#160;a total balance sheet of more than
    &#128;43,000,000 and (3)&#160;an annual net turnover of more
    than &#128;50,000,000, as shown in its last annual or
    consolidated accounts;&#160;or
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    124
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at any time in any other circumstances which do not require the
    publication by us of a prospectus pursuant to Article&#160;3 of
    the Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the purposes of the above, the expression an &#147;offer of
    the common stock to the public&#148; in relation to any shares
    of common stock in any Member State means the communication in
    any form and by any means of sufficient information on the terms
    of the offer and the common stock to be offered so as to enable
    an investor to decide to purchase or subscribe shares of common
    stock, as the same may be varied in that Member State by any
    measure implementing the Prospectus Directive in that Member
    State, and the expression Prospectus Directive means Directive
    2003/71/EC and includes any relevant implementing measure in
    that Member State.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    Kingdom</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each underwriter has represented and agreed that it has only
    communicated or caused to be communicated and will only
    communicate or cause to be communicated an invitation or
    inducement to engage in investment activity (within the meaning
    of Section&#160;21 of the Financial Services and Markets Act
    2000)&#160;in connection with the issue or sale of shares of
    common stock in circumstances in which Section&#160;21(1) of
    such Act does not apply to us and it has complied and will
    comply with all applicable provisions of such Act with respect
    to anything done by it in relation to any shares of common stock
    in, from or otherwise involving the United Kingdom.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Relationships</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2007, we sold shares of our Series&#160;E preferred
    stock in a private placement transaction. Leerink Swann LLC
    acted as the placement agent in the October 2007 offering and
    received a fee of $1,000,000 for services rendered. Entities
    affiliated with Leerink Swann LLC also participated in the
    October 2007 offering and purchased an aggregate of
    40,357&#160;shares of our Series&#160;E preferred stock for an
    aggregate purchase price of $565,000. One or more of the
    underwriters may in the future provide investment banking
    services to us for which they would receive customary
    compensation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of the Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for our
    common stock. The initial public offering price will be
    determined by negotiations between us and the underwriters.
    Among the factors to be considered in determining the initial
    public offering price are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future prospects and those of our industry in general;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our sales, earnings and certain other financial and operating
    information in recent periods;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the price-earnings ratios, price-sales ratios and market prices
    of securities and certain financial and operating information of
    companies engaged in activities similar to ours.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An active trading market for the shares may not develop. It is
    also possible that after the offering the shares will not trade
    in the public market at or above the initial public offering
    price.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    125
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='116'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock offered hereby will
    be passed upon for us by Wilson Sonsini Goodrich&#160;&#038;
    Rosati, Professional Corporation, Palo Alto, California.
    Latham&#160;&#038; Watkins LLP, Costa Mesa, California is acting
    as counsel to the underwriters. Members of Wilson Sonsini
    Goodrich &#038; Rosati, Professional Corporation and investment
    funds associated with that firm hold 45,987 shares of our common
    stock.
</DIV>
<A name='117'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ernst &#038; Young LLP, independent registered public accounting
    firm, has audited our consolidated financial statements at
    December&#160;31, 2006 and December&#160;29, 2007, and for each
    of the three years in the period ended December&#160;29, 2007,
    as set forth in their report. We have included our consolidated
    financial statements in the prospectus and elsewhere in the
    registration statement in reliance on Ernst &#038; Young
    LLP&#146;s report, given on their authority as experts in
    accounting and auditing.
</DIV>
<A name='118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND ADDITIONAL INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have filed with the SEC a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-1</FONT>
    under the Securities Act with respect to the shares of common
    stock offered hereby. This prospectus, which constitutes a part
    of the registration statement, does not contain all of the
    information set forth in the registration statement or the
    exhibits and schedules filed therewith. For further information
    about us and the common stock offered hereby, we refer you to
    the registration statement and the exhibits and schedules filed
    thereto. Statements contained in this prospectus regarding the
    contents of any contract or any other document that is filed as
    an exhibit to the registration statement are not necessarily
    complete, and each such statement is qualified in all respects
    by reference to the full text of such contract or other document
    filed as an exhibit to the registration statement. Upon
    completion of this offering, we will be required to file
    periodic reports, proxy statements, and other information with
    the SEC pursuant to the Securities Exchange Act of 1934. You may
    read and copy this information at the Public Reference Room of
    the SEC, 100 F. Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You may obtain information on the
    operation of the public reference rooms by calling the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330.</FONT>
    The SEC also maintains an Internet website that contains
    reports, proxy statements and other information about issuers,
    like us, that file electronically with the SEC. The address of
    that site is www.sec.gov.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to provide our stockholders with annual reports
    containing financial statements that have been audited by an
    independent registered public accounting firm, and to file with
    the SEC quarterly reports containing unaudited financial data
    for the first three quarters of each year.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    126
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='119'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#300'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'>Consolidated Balance Sheets</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'>Consolidated Statements of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Convertible Preferred
    Stock and Stockholders&#146; Equity (Deficit)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Cash Flows</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Notes to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-8
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='300'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Report of
    Independent Registered Public Accounting Firm</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors and Stockholders<BR>
    Fluidigm Corporation
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Fluidigm Corporation as of December&#160;31, 2006 and
    December&#160;29, 2007, and the related consolidated statements
    of operations, convertible preferred stock and
    stockholders&#146; equity (deficit), and cash flows for each of
    the three fiscal years in the period ended December&#160;29,
    2007. These financial statements are the responsibility of the
    Company&#146;s management. Our responsibility is to express an
    opinion on these financial statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Company&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Company&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the financial statements referred to above
    present fairly, in all material respects, the consolidated
    financial position of Fluidigm Corporation at December&#160;31,
    2006 and December&#160;29, 2007, and the consolidated results of
    its operations and its cash flows for each of the three fiscal
    years in the period ended December&#160;29, 2007, in conformity
    with U.S.&#160;generally accepted accounting principles.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in Note&#160;2 to the consolidated financial
    statements, Fluidigm Corporation changed its method of
    accounting for preferred stock warrants as of July&#160;1, 2005,
    its method of accounting for stock-based compensation as of
    January&#160;1, 2006, and its method of accounting for uncertain
    tax positions as of January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young LLP</DIV>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Palo Alto, California
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     April 12, 2008,<BR>
    except for Note&#160;16 as to which the date is<BR>
    September&#160;16, 2008
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='301'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Balance Sheets</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity as of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="17" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Assets</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Current assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Accounts receivable (net of allowances of $3, $0 and $0;
    includes accounts receivable from related parties of $272, $690
    and $609, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Prepaid expenses and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,329
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    256
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other assets (includes receivables from related parties of $277,
    $287 and $71, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    688
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="17">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="17" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Liabilities, Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Current liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Accounts payable (includes accounts payable to related parties
    of $174, $290 and $428, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Accrued compensation and related benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Other accrued liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Deferred revenue, current portion (includes deferred revenue
    from related parties of $227, $276 and $253, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Long-term debt, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,834
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,081
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Convertible preferred stock warrant liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deferred revenue, net of current portion (includes deferred
    revenue from related parties of $493, $359 and $253,
    respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term debt, net of current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible promissory notes from related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,048
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Commitments and contingencies (Note&#160;6)&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Convertible preferred stock issuable in series: $0.0035&#160;par
    value, 14,501, 17,176 and 17,176&#160;shares authorized, 12,367,
    16,192 and 16,626&#160;shares issued and outstanding as of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008 (unaudited), respectively; aggregate liquidation preference
    of $171,228 as of June&#160;28, 2008 (unaudited); no shares
    authorized, issued or outstanding pro forma (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Stockholders&#146; equity (deficit):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Common stock: $0.0035&#160;par value, 22,244, 24,967 and
    24,967&#160;shares authorized, 2,714, 2,829 and
    2,858&#160;shares issued and outstanding as of December&#160;31,
    2006, December&#160;29, 2007 and June&#160;28, 2008 (unaudited),
    respectively; $0.0035 par value, 24,967&#160;shares authorized,
    19,484&#160;shares issued and outstanding pro forma (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    23,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total liabilities, convertible preferred stock and
    stockholders&#146; equity (deficit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    54,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    49,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->



<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='302'>


<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Operations</FONT></B>
</DIV>
</A>


<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Product revenue (includes product revenue from related parties
    of $205, $241, $15, $0&#160;and $96, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Collaboration revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Grant revenue (includes grant revenue from related parties of
    $0, $879, $1,758, $843 and $810, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Cost of product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Research and development (includes research and development
    expenses from related parties of $84, $128, $100, $50 and $50,
    respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,449
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Selling, general and administrative (includes selling, general
    and administrative expense from related parties of $946, $809,
    $660, $288 and $616, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,843
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,526
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,462
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest expense (includes interest to related parties of $160,
    $445, $1,286, $980 and $417)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,261
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,790
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other income (expense), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (170
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (214
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss before provision for income taxes and cumulative effect of
    change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,917
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,219
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.60
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (9.21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (9.21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Pro forma net loss per share of common stock, basic and diluted
    (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Shares used in computing pro forma net loss per share of common
    stock, basic and diluted (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,149
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- landscape -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='303'><B>Consolidated Statements of Convertible
    Preferred Stock and Stockholders&#146; Equity (Deficit)</B>
</DIV>
</A>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-left: 3%; margin-right: 0%">
<TABLE border="0" width="97%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity (Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,551
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,870
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (68,334
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (65,471
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock for cash
    at $9.80 per share, net of issuance costs of $11
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of convertible preferred stock warrants in connection
    with financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $9.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Reclassification of convertible preferred stock warrants to
    liabilities upon adoption of FSP
    <FONT style="white-space: nowrap">150-5</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,473
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Unrealized gain on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,349
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,647
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (84,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (83,154
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock at $9.80
    per share upon exercise of warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $14.00 per share, net of issuance costs of $133
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Issuance of Series&#160;D convertible preferred stock at $9.80
    per share under license agreement, net of issuance costs of $3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (36
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 28pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,590
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (108,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,172
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock for cash
    at $14.00 per share, net of issuance costs of $1,189
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;D convertible preferred stock upon
    conversion of promissory note at $9.80 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    331
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock upon
    conversion of promissory notes at $12.60 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    844
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Beneficial conversion feature for convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Unrealized loss on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Total comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,569
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Balance as of December&#160;29, 2007 (carried forward)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->
<!-- landscape -->
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Consolidated Statements of Convertible Preferred Stock and
    Stockholders&#146; Equity (Deficit)&#160;&#151; (Continued)</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands, except per share amounts)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="margin-left: 5%; margin-right: 0%">
<TABLE border="0" width="95%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stockholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity (Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of December&#160;29, 2007 (brought forward)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (133,798
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (130,331
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of common stock upon exercise of stock options for cash
    and for vesting of stock options that were exercised early
    (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Stock-based compensation expense (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Repurchase of common stock (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (290
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (290
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;E convertible preferred stock upon
    conversion of promissory notes at $12.60 per share (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Issuance of Series&#160;C convertible preferred stock at $7.63
    per share upon net-share exercise of warrants (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Comprehensive loss:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Foreign currency translation adjustment (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (116
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (116
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Unrealized gain on available-for-sale securities (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 21pt">
    Net loss (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Total comprehensive loss (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,368
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Balance as of June&#160;28, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (149,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (144,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 100%; margin-left: 0%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='304'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Statements of Cash Flows</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(in
    thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Adjustments to reconcile net loss to net cash used in operating
    activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,643
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    837
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Stock-based compensation expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    373
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign exchange gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (141
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Adjustment to fair value of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Loss on retirement of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of debt discount and issuance cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    402
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Issuance of common stock for services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    136
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (637
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Changes in assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (287
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (470
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (955
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,514
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Prepaid expenses and other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,552
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (847
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,255
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    773
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (308
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (320
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,428
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,292
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,306
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,440
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,972
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Investing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Purchases of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,990
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,511
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Maturities of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Sales of available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Purchase of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,656
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,932
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (973
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (374
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (217
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash provided by (used in) investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,943
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,740
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Financing activities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,651
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Repayment of long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,745
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,503
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,868
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,442
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from exercise of stock options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from issuance of convertible preferred stock, net of
    issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,042
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Proceeds from issuance of convertible promissory notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Repurchase of common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (69
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash provided by financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Effect of exchange rate changes on cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (33
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,294
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,111
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents as of beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash and cash equivalents as of end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    34,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    18,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Supplemental disclosures of cash flow information</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash paid for interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Conversion of convertible promissory notes into convertible
    preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cashless net exercise of convertible preferred stock warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Issuance of warrants in connection with long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    484
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Issuance of convertible preferred stock under license agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>
<A name='305'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial Statements</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Description
    of Business</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Corporation (the Company) was incorporated in the state
    of California on May&#160;19, 1999, to commercialize
    microfluidic technology initially developed at the California
    Institute of Technology. In July 2007, the Company was
    reincorporated in Delaware. The Company&#146;s headquarters are
    located in South San&#160;Francisco, California.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company develops, manufactures and markets proprietary
    Integrated Fluidic Circuit systems that significantly improve
    the productivity of life science research. The Company&#146;s
    Integrated Fluidic Circuits (IFCs), enable the simultaneous
    performance of thousands of biochemical measurements in
    extremely minute volumes. The Company created this
    &#147;integrated circuit for biology&#148; by miniaturizing,
    integrating and automating sophisticated liquid handling
    processes on a single microfabricated device. The Company&#146;s
    customers include many leading biotechnology and pharmaceutical
    companies, academic institutions, and life science laboratories
    worldwide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has incurred significant net losses since inception.
    As of June&#160;28, 2008, the Company had an accumulated deficit
    of approximately $149.1&#160;million and cash, cash equivalents
    and available-for-sale securities of approximately
    $32.5&#160;million. The Company expects to incur significant
    expenses to fund operations to develop new products and to
    support existing product sales. Failure to generate sufficient
    revenues, achieve planned gross margins, control operating
    costs, or to raise sufficient additional funds may require the
    Company to modify, delay, or abandon some of its future
    expansion or expenditures, which could have a material adverse
    effect on the Company&#146;s business, operating results,
    financial condition, and ability to achieve its intended
    business objectives.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    of Significant Accounting Policies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Basis of
    Presentation and Consolidation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of the Company have been
    prepared in conformity with U.S.&#160;generally accepted
    accounting principles and include the accounts of the Company
    and its wholly owned subsidiaries. The Company has wholly owned
    subsidiaries in Singapore, the Netherlands, Japan, France and
    the United Kingdom. All subsidiaries, except for Singapore, use
    their local currency as their functional currency. The Singapore
    subsidiary uses the U.S.&#160;dollar as its functional currency.
    All intercompany transactions and balances have been eliminated
    in consolidation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fiscal
    Year</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, the Company adopted a 52 or 53&#160;week year
    convention for its fiscal years and, therefore, the 2007 fiscal
    year ended on December&#160;29, 2007 and the quarterly periods
    for 2007 ended on March&#160;31, June&#160;30 and
    September&#160;29. For 2008, the quarterly periods end on
    March&#160;29, June&#160;28 and September&#160;27. Future fiscal
    years will end on the last Saturday in December of each
    respective year. Prior to 2007, the Company used a calendar
    year. The fiscal years presented in these consolidated financial
    statements ended on December&#160;31, 2005, December&#160;31,
    2006 and December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Interim Financial Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying interim consolidated balance sheet as of
    June&#160;28, 2008, the interim consolidated statements of
    operations and cash flows for the six months ended June&#160;30,
    2007 and June&#160;28, 2008 and the interim consolidated
    statements of convertible preferred stock and stockholders&#146;
    equity (deficit) for the six months ended June&#160;28, 2008 are
    unaudited. The unaudited interim consolidated financial
    statements have been prepared on the same basis as the annual
    consolidated financial statements and, in the opinion of
    management, reflect all adjustments, which include only normal
    recurring adjustments, necessary to present fairly the
    Company&#146;s financial position as of June&#160;28, 2008 and
    its results of operations and its cash flows for the six months
    ended June&#160;30, 2007 and June&#160;28, 2008. The financial
    data and the other financial information disclosed in these
    notes to the consolidated financial statements
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    related to the six month periods are unaudited. The results of
    operations for the six months ended June&#160;28, 2008 are not
    necessarily indicative of the results to be expected for 2008 or
    any other interim period or for any other future year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Pro Forma Stockholders&#146; Equity</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of the convertible preferred stock outstanding will
    automatically convert into shares of common stock upon
    completion of a qualifying initial public offering (see
    Note&#160;16). In addition, the convertible preferred stock
    warrant liabilities will be reclassified to additional paid-in
    capital upon completion of an initial public offering. Unaudited
    pro forma stockholders&#146; equity, as adjusted for the assumed
    conversion of the convertible preferred stock to common stock
    and warrants to purchase shares of convertible preferred stock
    to warrants to purchase shares of common stock, is set forth in
    the accompanying consolidated balance sheets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Use of
    Estimates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements requires
    management to make estimates and assumptions that affect the
    amounts reported in the consolidated financial statements and
    accompanying notes. The Company regularly assesses these
    estimates which affect the fair value of undelivered elements
    for revenue recognition purposes, the valuation of accounts
    receivable, the valuation of inventories, accrued liabilities,
    the fair value of the Company&#146;s convertible preferred stock
    and common stock, warrants, stock-based compensation, beneficial
    conversion features, and valuation allowances associated with
    deferred tax assets. The Company bases its estimates on
    historical experience and on various other assumptions believed
    to be reasonable, the results of which form the basis for making
    judgments about the carrying values of assets and liabilities.
    Actual results could differ materially from these estimates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets and liabilities of
    <FONT style="white-space: nowrap">non-U.S.&#160;subsidiaries</FONT>
    that use the local currency as their functional currency are
    translated into U.S.&#160;dollars at exchange rates in effect at
    the balance sheet date, with the resulting translation
    adjustments recorded to a separate component of accumulated
    other comprehensive income (loss) within stockholders&#146;
    equity. Income and expense accounts are translated at average
    exchange rates during the year. Foreign currency transaction
    gains and losses for
    <FONT style="white-space: nowrap">non-U.S.&#160;subsidiaries</FONT>
    that use the U.S.&#160;dollar as their functional currency are
    recognized in other income (expense), net. The Company had net
    foreign currency transaction losses of $27,000, $70,000 and
    $64,000 during 2005, 2006 and the six months ended June&#160;30,
    2007, respectively, and net foreign currency transaction gains
    of $72,000 and $141,000 during 2007 and the six months ended
    June&#160;28, 2008, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash and
    Cash Equivalents</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company considers all highly liquid financial instruments
    with maturities at the time of purchase of three months or less
    to be cash equivalents. Cash and cash equivalents consist of
    cash on deposit with banks, money market funds, commercial
    paper, corporate notes, and notes from government-sponsored
    agencies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Available-for-Sale
    Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Available-for-sale securities are comprised of corporate notes
    and notes from government-sponsored agencies. Investments
    classified as &#147;available-for-sale&#148; and are recorded at
    estimated fair value, as determined by quoted market rates, on
    the consolidated balance sheets with any unrealized gains and
    losses reported in stockholders&#146; equity as a component of
    accumulated other comprehensive income (loss). Realized gains
    and losses and declines in the fair value of available-for-sale
    securities below their cost that are deemed to be &#147;other
    than temporary&#148; are reflected in interest income. No
    &#147;other than temporary&#148; unrealized losses have been
    incurred to date and realized gains and losses were immaterial
    during the years presented. The cost of securities sold is based
    on the specific-identification method.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Restricted
    Cash</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company had restricted cash balances of $900,000, $881,000
    and $256,000 as of December&#160;31, 2006, December&#160;29,
    2007 and June&#160;28, 2008, respectively. Included in
    restricted cash is cash amounts that collateralize the
    Company&#146;s standby letters of credit issued under operating
    lease agreements for office facilities that it currently
    occupies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, the respective carrying values of the
    Company&#146;s financial instruments, including accounts
    receivable, restricted cash, and accounts payable, approximated
    their fair values due to their short period of time to maturity
    or repayment. Based on borrowing rates currently available to
    the Company for loans with similar terms, the carrying value of
    long-term debt and convertible promissory notes approximated
    their fair values.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;No.&#160;157, <I>Fair Value Measurement</I>
    (SFAS&#160;157), clarifies that fair value is an exit price,
    representing the amount that would be received to sell an asset
    or paid to transfer a liability in an orderly transaction
    between market participants. As such, fair value is a
    market-based measurement that should be determined based on
    assumptions that market participants would use in pricing an
    asset or liability. As a basis for considering such assumptions,
    SFAS&#160;157 establishes a three-tier value hierarchy, which
    prioritizes the inputs used in measuring fair value as follows:
    (Level I) observable inputs such as quoted prices in active
    markets; (Level II) inputs other than the quoted prices in
    active markets that are observable either directly or
    indirectly; and (Level III) unobservable inputs in which there
    is little or no market data, which requires the Company to
    develop its own assumptions. This hierarchy requires the Company
    to use observable market data, when available, and to minimize
    the use of unobservable inputs when determining fair value. The
    Company&#146;s financial assets that are measured at fair value
    on a recurring basis consist of cash equivalents and
    available-for-sale securities. The Company&#146;s liabilities
    that are measured at fair value on a recurring basis consist of
    convertible preferred stock warrant liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of the Company&#146;s cash equivalents and
    available-for-sale securities are classified within Level I or
    Level II of the fair value hierarchy because they are valued
    using quoted market prices, market prices for similar
    securities, or alternative pricing sources with reasonable
    levels of price transparency. Instruments valued based on quoted
    market prices in active markets, i.e. level I, include the
    Company&#146;s money market funds. Instruments valued based on
    other observable inputs, i.e. level II, include notes from
    government-sponsored agencies, corporate notes and commercial
    paper. The Company&#146;s convertible preferred stock warrant
    liabilities are classified within Level III of the fair value
    hierarchy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The changes in the value of the convertible preferred stock
    warrant liabilities were as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fair value as of December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Issuances or settlements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    442
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Change in fair value
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fair value as of June&#160;28, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The valuation of the convertible preferred stock warrants are
    discussed in Note 8.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Accounts
    Receivable</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Trade accounts receivable are recorded at net invoice value. The
    Company considers receivables past due based on the contractual
    payment terms. The Company reviews its exposure to accounts
    receivable and reserves specific amounts if collectibility is no
    longer reasonably assured based on historical experience and
    specific customer collection issues. The Company reevaluates
    such reserves on a regular basis and adjusts its reserves as
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    needed. Write-offs of accounts receivable were insignificant
    during 2005, 2006, 2007 and the six months ended June&#160;30,
    2007 and June&#160;28, 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Concentrations
    of Credit Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Financial instruments that potentially subject the Company to
    credit risk consist of cash, cash equivalents,
    available-for-sale securities, and accounts receivable. The
    Company maintains cash, cash equivalents, and available-for-sale
    securities with major financial institutions. The Company&#146;s
    cash, cash equivalents, and available-for-sale securities
    consist of deposits held with banks, commercial paper, money
    market funds, and other highly liquid investments that, at
    times, exceed federally insured limits. The Company performs
    periodic evaluations of its investments and the relative credit
    standing of these financial institutions and limits the amount
    of credit exposure with any one institution.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company does not require collateral to support credit sales.
    To reduce credit risk, the Company performs periodic credit
    evaluations of its customers. The Company has had no credit
    losses to date. Customers with revenues of 10% or greater of
    total revenues for 2005, 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="16" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage of Total Revenue</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Customers:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    24%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16%
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents less than 10% of total revenues.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s products include components that are
    currently available from a single source or a limited number of
    sources. The Company believes that other vendors would be able
    to provide similar components; however, the qualification of
    such vendors may require
    <FONT style="white-space: nowrap">start-up</FONT>
    time. In order to mitigate any adverse impacts from a disruption
    of supply, the Company attempts to maintain an adequate supply
    of critical limited-sourced components.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories are stated at the lower of cost (which approximates
    actual cost on a
    <FONT style="white-space: nowrap">first-in,</FONT>
    first-out method) or market. Inventories include raw materials,
    <FONT style="white-space: nowrap">work-in-process,</FONT>
    and finished goods that may be used in the research and
    development process, and such items are expensed when they are
    designated for use in research and development. Provisions for
    slow moving, excess, and obsolete inventories are recorded based
    on product life cycle, development plans, product expiration,
    and quality issues.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment, including leasehold improvements, are
    stated at cost less accumulated depreciation, which is
    calculated using the straight-line method over the estimated
    useful lives of the assets, which range from three to five
    years. Leasehold improvements are amortized using the
    straight-line method over the estimated useful lives of the
    assets or the remaining term of the lease, whichever is shorter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;No.&#160;144, <I>Accounting for the
    Impairment or Disposal of Long-Lived Assets</I>, if indicators
    of impairment exist, the Company assesses the recoverability of
    the affected long-lived assets by determining whether the
    carrying value of such assets can be recovered through
    undiscounted future operating cash
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    flows. If impairment is indicated, the Company measures the
    future discounted cash flows associated with the use of the
    asset and adjusts the value of the asset accordingly. While the
    Company&#146;s current and historical operating and cash flow
    losses are indicators of impairment, the Company believes the
    future cash flows to be received from the long-lived assets
    recorded as of June&#160;28, 2008 will exceed the assets&#146;
    carrying value, and, accordingly, the Company has not recognized
    any impairment losses through June&#160;28, 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reserve
    for Product Warranties</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company generally provides a one-year warranty on
    instruments. The Company reviews its exposure to estimated
    warranty expenses associated with instrument sales and
    establishes an accrual based on historical product failure rates
    and actual warranty costs incurred. This expense is recorded as
    a component of cost of product revenue in the consolidated
    statements of operations. Warranty accruals and expenses were
    immaterial for all periods presented.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company generates revenue from sales of its products and
    services. The Company&#146;s products consist of single-use
    IFCs, various instruments, software, and reagents. The
    Company&#146;s services include instrument installation,
    training, and customer support services. The Company has also
    entered into a number of research and development agreements and
    received government grants to conduct research and development
    activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company records revenue in accordance with the guidelines
    established by the Securities and Exchange Commission (SEC)
    Staff Accounting Bulletin&#160;No.&#160;104, <I>Revenue
    Recognition </I>(SAB&#160;104). In addition, the Company has
    concluded that pursuant to AICPA Statement of Position
    <FONT style="white-space: nowrap">97-2,</FONT>
    <I>Software Revenue Recognition
    </I><FONT style="white-space: nowrap">(SOP&#160;97-2),</FONT>
    software included with certain of its instruments is more than
    incidental to their functionality. Accordingly, the Company
    applies
    <FONT style="white-space: nowrap">SOP&#160;97-2</FONT>
    to sales of such instruments and related deliverables. Revenue
    is recognized when all of the following criteria are met:
    persuasive evidence of an arrangement exists, delivery has
    occurred or services rendered, the seller&#146;s price to the
    buyer is fixed or determinable, and collectibility is reasonably
    assured.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Product
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sells instruments in arrangements that may include
    related installation and training, customer support services and
    software and may also include single-use IFCs. If the
    arrangement includes IFCs, the Company uses the separation
    criteria in EITF Issue
    <FONT style="white-space: nowrap">No.&#160;00-21,</FONT>
    <I>Revenue Arrangements with Multiple Deliverables</I>, to
    separate revenues related to IFCs, which are non-software
    related deliverables, from software related deliverables. IFC
    revenue is recognized upon delivery. Revenue from software
    related deliverables is recognized in accordance with
    <FONT style="white-space: nowrap">SOP&#160;97-2</FONT>
    and related pronouncements. Under
    <FONT style="white-space: nowrap">SOP&#160;97-2,</FONT>
    the Company recognizes revenue for delivered elements only when
    it determines that undelivered elements are not essential to the
    functionality of the delivered elements and the vendor-specific
    objective evidence (VSOE) of fair values of undelivered elements
    are known. Installation is deemed essential to the functionality
    of certain instruments; for those instruments recognition of
    revenue begins after installation has been completed. Fair value
    of undelivered elements is established by reference to VSOE
    which is based on stand-alone sales of such elements. If any
    undelivered element does not have VSOE of fair value, revenue is
    deferred until all of such elements are delivered, or until VSOE
    of fair value can objectively be determined for any remaining
    undelivered elements. However, if the only undelivered element
    is post-contract customer support services, such as those
    included in the Company&#146;s maintenance agreements, revenue
    on the software related deliverables is recognized ratably over
    the service period. When revenues are deferred, the
    corresponding costs of products sold are also deferred in other
    assets in the consolidated financial statements and recognized
    over the same period. If VSOE of fair value exists for all
    undelivered elements, but does not exist for the delivered
    elements in the arrangement, revenue is allocated to the
    undelivered elements based on their VSOE of fair values, with
    the residual amount allocated to the delivered elements and
    recognized upon their delivery.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2005, 2006, 2007 and the six months ended June&#160;28,
    2008, the Company did not have VSOE of fair value for software
    support services. Therefore, revenue and the corresponding costs
    of software-related deliverables is deferred and recognized over
    the customer support period ranging from one to three years. All
    revenue from these arrangements has been classified as product
    revenue in the statements of operations, as the amount
    attributed to services was immaterial.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007 and thereafter, no right of return has existed for the
    Company&#146;s products. In prior years, if there was a right of
    return, the entire revenue from the arrangement was deferred
    until the right had lapsed. The Company has not experienced any
    significant returns of its products. Accruals are provided for
    anticipated warranty expenses at the time the associated revenue
    is recognized. Amounts received in advance of when revenue
    recognition criteria are met are recorded as deferred revenue on
    the consolidated balance sheets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sells its products to third-party resellers located
    in certain international markets. From time to time, these
    arrangements may be subject to contingencies such as completion
    of the instrument delivery to or installation at the end
    customer. The Company recognizes revenue on sales of products to
    the resellers if all revenue recognition criteria have been met
    and any contingency provisions related to the sale have been
    satisfied.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into agreements with third parties,
    including government entities, to provide research and
    development services. Fixed-fee research and development
    agreements generally provide the Company with up-front and
    periodic milestone fees. Variable-fee research and development
    agreements generally provide the Company with fees based upon
    agreed upon rates for time incurred by research staff. Under
    <FONT style="white-space: nowrap">EITF&#160;00-21,</FONT>
    the Company evaluates whether these arrangements contain
    multiple units of accounting by evaluating whether delivered
    elements have value on a stand-alone basis and whether there is
    objective and reliable evidence of fair value of the undelivered
    items. During 2005, 2006, 2007 and the six months ended
    June&#160;28, 2008, the Company concluded that these
    arrangements consisted of a single unit of accounting, namely,
    research and development services. Accordingly, the Company
    recognizes the fees under these arrangements over the period the
    Company performs these services. Costs associated with the
    research and development agreements are included in research and
    development expense.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Grant
    Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Government grants provide the Company with incentive payments
    for certain types of research and development activities
    performed over a contractually defined period. Revenue from
    government grants is recognized during the period during which
    the related costs are incurred, provided that the conditions
    under which the government grants were provided have been met
    and the Company has only perfunctory obligations outstanding.
    Amounts received in advance of when revenue recognition criteria
    are met are recorded as deferred revenue on the consolidated
    balance sheets. Costs associated with the grants are included in
    research and development expense.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Shipping
    and Handling Costs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shipping and handling costs incurred for product shipments are
    included within cost of product revenue in the consolidated
    statements of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Research
    and Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses research and development expenditures in
    the period incurred. Research and development expense consists
    of personnel costs, independent contractor costs, prototype
    expenses, and allocated facilities and information technology
    expenses. These costs include direct and research-related
    overhead expenses.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Advertising
    Costs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company expenses advertising costs as incurred. The Company
    incurred advertising costs of $237,000, $324,000, $701,000,
    $349,000 and $629,000 during 2005, 2006, 2007 and the six months
    ended June&#160;30, 2007 and June&#160;28, 2008, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company uses the liability method to account for income
    taxes, whereby deferred income taxes reflect the impact of
    temporary differences for items recognized for financial
    reporting purposes over different periods than for income tax
    purposes. Valuation allowances are provided when the expected
    realization of deferred tax assets does not meet a &#147;more
    likely than not&#148; criterion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company adopted Financial Accounting Standards Board (FASB)
    Interpretation No.&#160;48, <I>Accounting for Uncertainties in
    Income Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109 </I>(FIN&#160;48), effective January&#160;1, 2007.
    FIN&#160;48 requires that the Company recognize the financial
    statement effects of a tax position when it is more likely than
    not, based on the technical merits, that the position will be
    sustained upon examination. Upon adoption, the Company recorded
    a charge of $75,000 as a cumulative effect of a change in
    accounting principle in the accumulated deficit during 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock-Based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2006, the Company accounted for its
    employee stock option plans using the intrinsic value method
    prescribed by Accounting Principles Board Opinion No.&#160;25,
    <I>Accounting for Stock Issued to Employees </I>(APB 25), which
    required the Company to recognize the difference between the
    exercise price of an employee option and the fair value of the
    underlying common stock as of the grant date. The resulting
    stock-based compensation expense, if any, was recorded on the
    date of the grant in stockholders&#146; equity as deferred
    compensation and amortized to expense over the vesting period of
    the grant, which was generally four years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2004, the FASB issued SFAS&#160;No.&#160;123
    (revised 2004), <I>Share-Based Payment </I>(SFAS&#160;123(R)),
    that addresses the accounting for stock-based payment
    transactions in which a company receives services in exchange
    for equity instruments, including stock options. The Company
    adopted SFAS&#160;123(R) beginning January&#160;1, 2006 using
    the prospective-transition method, as options granted prior to
    January&#160;1, 2006 were measured using the minimum value
    method for the pro forma disclosures previously required by
    SFAS&#160;No.&#160;123, <I>Accounting for Stock-Based
    Compensation </I>(SFAS&#160;123). Under the
    prospective-transition method, the Company continues to apply
    APB 25 to employee equity awards outstanding at the date of the
    Company&#146;s adoption of SFAS&#160;123(R). Any compensation
    costs recognized from January&#160;1, 2006 onward consists of:
    (a)&#160;compensation cost for all stock-based awards granted
    prior to, but not vested as of, December&#160;31, 2005 based on
    the intrinsic value determined in accordance with the provisions
    of APB 25; and (b)&#160;compensation cost for all stock-based
    awards granted or modified subsequent to December&#160;31, 2005,
    net of estimated forfeitures, based on the grant date fair value
    estimated in accordance with the provisions of SFAS&#160;123(R).
    The Company recognizes stock-based compensation expense on a
    straight-line basis over the vesting period of the respective
    grants. In accordance with the prospective-transition method,
    results for prior periods have not been restated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company applies SFAS&#160;123(R) and EITF Issue
    <FONT style="white-space: nowrap">No.&#160;96-18,</FONT>
    <I>Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling,
    Goods or Services
    </I><FONT style="white-space: nowrap">(EITF&#160;96-18),</FONT>
    to options and other stock-based awards issued to nonemployees.
    In accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    the Company uses the Black-Scholes option-pricing model to
    measure the fair value of the options at the measurement dates.
    The nonemployee options are subject to periodic reevaluation
    over their vesting terms.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Loss</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive loss is comprised of net loss and other
    comprehensive income (loss). Other comprehensive income (loss)
    includes unrealized holding gains and losses on the
    Company&#146;s available-for-sale securities and foreign
    currency translation adjustments. Total comprehensive loss for
    all periods presented has been disclosed in the consolidated
    statements of convertible preferred stock and stockholders&#146;
    equity (deficit).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accumulated other comprehensive income (loss) consists of the
    following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrealized gain (loss) on available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign currency translation adjustment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (123
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (239
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (241
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock Warrants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Freestanding warrants related to shares that may be redeemable
    are accounted for in accordance with FASB Staff Position (FSP)
    <FONT style="white-space: nowrap">No.&#160;150-5,</FONT>
    <I>Issuer&#146;s Accounting Under FASB Statement No.&#160;150
    for Freestanding Warrants and Other Similar Instruments on
    Shares That Are Redeemable
    </I><FONT style="white-space: nowrap">(FSP&#160;150-5),</FONT>
    an interpretation of SFAS&#160;No.&#160;150, <I>Accounting for
    Certain Financial Instruments with Characteristics of Both
    Liabilities and Equity</I>. Under
    <FONT style="white-space: nowrap">FSP&#160;150-5,</FONT>
    freestanding warrants to purchase the Company&#146;s convertible
    preferred stock are classified as liabilities on the
    consolidated balance sheets and carried at fair value because
    the warrants may conditionally obligate the Company to transfer
    assets at some point in the future. The warrants are subject to
    remeasurement at each balance sheet date, and any change in fair
    value is recognized as a component of other income (expense),
    net in the consolidated statements of operations. The Company
    will continue to adjust the liability for changes in fair value
    until the earlier of the exercise or expiration of the warrants,
    the completion of a deemed liquidation event, conversion of
    preferred stock into common stock, or until the convertible
    preferred stockholders can no longer trigger a deemed
    liquidation event. At that time, the convertible preferred stock
    warrant liabilities will be reclassified to convertible
    preferred stock or additional paid-in capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    is effective for all periods beginning after June&#160;30, 2005,
    and accordingly, it was adopted by the Company on July&#160;1,
    2005. Upon adoption, the Company reclassified the fair value of
    its warrants to purchase shares of its convertible preferred
    stock as of the adoption date from additional paid-in capital to
    liabilities and recorded a gain of $637,000 as the cumulative
    effect of a change in an accounting principle in the
    consolidated statement of operations during 2005.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Net Loss
    and Pro forma Net Loss per Share of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s basic net loss per share of common stock is
    calculated by dividing the net loss by the weighted-average
    number of shares of common stock outstanding for the period. The
    weighted-average number of shares of common stock used to
    calculate the Company&#146;s basic net loss per share of common
    stock excludes those shares subject to repurchase related to
    stock options that were exercised prior to vesting as they are
    not deemed to be issued for accounting purposes until they vest.
    The diluted net loss per share of common stock is computed by
    dividing the net loss by the weighted-average number of common
    stock equivalents outstanding for the period determined using
    the treasury-stock method. For purposes of this calculation,
    convertible preferred stock, options to purchase common stock,
    common stock subject to repurchase, warrants to purchase
    convertible preferred stock, and shares of convertible preferred
    stock subject to conversion of the Company&#146;s convertible
    promissory notes are considered to be common stock equivalents
    but have been excluded from the calculation of diluted net loss
    per share of common stock as their effect is anti-dilutive.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pro forma basic and diluted net loss per share of common stock
    has been computed to give effect to the conversion of the
    convertible preferred stock into common stock. Also, the
    numerator in the pro forma basic and diluted net loss per share
    calculation has been adjusted to remove gains and losses
    resulting from remeasurements of the convertible preferred stock
    warrant liabilities as these warrants will become warrants to
    purchase shares of the Company&#146;s common stock upon a
    qualifying initial public offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth the computation of net loss per
    share of common stock (in thousands, except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Historical</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loss before cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17,022
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (12,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing net loss per share of common stock,
    basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock before cumulative effect of
    change in accounting principle, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.60
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (9.21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle, basic and
    diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6.35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (8.82
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (9.21
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (4.74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pro Forma
    (Unaudited)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="78%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net Loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in fair value of convertible preferred stock warrant
    liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    359
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss used in computing pro forma net loss per share of
    common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,206
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (14,903
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing net loss per share of common stock
    above, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma adjustments to reflect assumed conversion of
    convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,812
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shares used in computing pro forma net loss per share of common
    stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,149
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (1.52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.78
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following outstanding shares of common stock equivalents
    were excluded from the computation of diluted net loss per share
    of common stock for the periods presented because including them
    would have been anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited))</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,647
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,679
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options to purchase common stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,728
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common stock subject to repurchase
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Warrants to purchase convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    346
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Convertible promissory notes convertible into shares of
    convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In September 2006, the FASB issued SFAS&#160;157, which
    establishes a framework for measuring the fair value of assets
    and liabilities when required or permitted by other standards
    within generally accepted accounting principles in the United
    States but does not require any new fair value measurements.
    SFAS&#160;157 also expands disclosures about fair value
    measurements. SFAS&#160;157 is effective for all financial
    statements issued for fiscal years beginning after
    November&#160;15, 2007. However, in February 2008 the FASB
    issued FSP
    <FONT style="white-space: nowrap">No.&#160;157-2</FONT>
    <FONT style="white-space: nowrap">(FSP&#160;157-2)</FONT>
    which allows companies to delay the effective date of
    SFAS&#160;157 for all nonfinancial assets and liabilities,
    except those that are recognized or disclosed at fair value in
    the financial statements on a recurring basis, until fiscal
    years beginning after November&#160;15, 2008. Generally, the
    provisions of this statement should be applied prospectively as
    of the beginning of the fiscal year in which this statement is
    initially applied. The Company adopted SFAS&#160;157 in
    accordance with the provisions in
    <FONT style="white-space: nowrap">FSP&#160;157-2</FONT>
    as of December&#160;30, 2007. The adoption of SFAS&#160;157 did
    not have a significant impact on the Company&#146;s consolidated
    financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, the FASB issued SFAS&#160;No.&#160;159, <I>The
    Fair Value Option for Financial Assets and Financial Liabilities
    </I>(SFAS&#160;159), including an amendment of
    SFAS&#160;No.&#160;115, A<I>ccounting for Certain Investments in
    Debt and </I>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Equity Securities</I>, which allows an entity to choose to
    measure certain financial instruments and liabilities at fair
    value. Subsequent measurements for the financial instruments and
    liabilities an entity elects to measure at fair value will be
    recognized in earnings. SFAS&#160;159 also establishes
    additional disclosure requirements. SFAS&#160;159 is effective
    for fiscal years beginning after November&#160;15, 2007. The
    Company adopted SFAS&#160;159 as of December&#160;30, 2007 but
    chose not to measure the financial instruments and liabilities
    permitted by the standard to be measured at fair value.
    Therefore, the adoption of SFAS&#160;159 did not have a
    significant impact on the Company&#146;s consolidated financial
    statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-1,</FONT>
    <I>Accounting for Collaborative Agreements
    </I><FONT style="white-space: nowrap">(EITF&#160;07-1),</FONT>
    which addresses the accounting for participants in collaborative
    agreements, defined as contractual arrangements that involve a
    joint operating activity, that are conducted without the
    creation of a separate legal entity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    requires participants in a collaborative agreement to make
    separate disclosures for each period a statement of operations
    is presented regarding the nature and purpose of the agreement,
    the rights and obligations under the agreement, the accounting
    policy for the agreement, and the classification of and amounts
    arising from the agreement between participants. These
    arrangements involve two or more parties who are both active
    participants in the activity and are exposed to significant
    risks and rewards dependent on the commercial success of the
    activity.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    provides that a company should report the effects of adoption as
    a change in accounting principle through retrospective
    application to all periods and requires specific additional
    disclosures.
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2008. The Company is currently assessing
    the impact of the adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-1</FONT>
    on the Company&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2007, the FASB ratified EITF Issue
    <FONT style="white-space: nowrap">No.&#160;07-3,</FONT>
    <I>Accounting for Nonrefundable Advance Payments for Goods or
    Services to Be Used in Future Research and Development
    Activities
    </I><FONT style="white-space: nowrap">(EITF&#160;07-3).</FONT>
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    provides clarification surrounding the accounting for
    nonrefundable research and development advance payments, whereby
    such payments should be recorded as an asset when the advance
    payment is made and recognized as an expense when the research
    and development activities are performed.
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    is effective for interim and annual reporting periods beginning
    after December&#160;15, 2007. The Company adopted EITF 07-3 as
    of December&#160;30, 2007. The adoption of
    <FONT style="white-space: nowrap">EITF&#160;07-3</FONT>
    did not impact the Company&#146;s consolidated financial
    statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">License,
    Development, Collaboration and Grant Agreements</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">License
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2003, the Company entered into a license agreement to
    obtain an exclusive worldwide license for certain technology
    regarding nanovolume crystallization arrays. The Company may, in
    its sole discretion, cancel the license agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last patent to expire. Under the terms of the agreement,
    the Company is obligated to issue up to $2,100,000 of shares of
    the Company&#146;s common or convertible preferred stock if the
    Company achieves certain milestones. As a result of achieving
    one of these milestones during 2006, the Company issued
    61,223&#160;shares of Series&#160;D convertible preferred stock
    at $9.80 per share for an aggregate value of $597,000, net of
    issuance costs. During 2003, the Company also entered into a
    separate research sponsorship agreement under which the Company
    agreed to pay a total of $900,000 over 5&#160;years in 20
    quarterly installments of $45,000 to sponsor certain research.
    As of June&#160;28, 2008, the entire $900,000 had been paid.
    Following the final $45,000 payment, which was paid during the
    six months ended June&#160;28, 2008, the agreement terminated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a license agreement
    to obtain a nonexclusive worldwide license for certain
    technology regarding submicroliter protein crystallization. The
    Company may, in its sole discretion, cancel the agreement with a
    <FONT style="white-space: nowrap">30-day</FONT>
    notice; otherwise, the license terminates at the end of the life
    of the last licensed patent to expire. Pursuant to the
    agreement, the Company made four payments for annual
    nonrefundable license fees, each in the amount of $250,000,
    beginning in January 2004 with subsequent payments made in
    January 2005, 2006 and 2007. Also pursuant to the agreement, the
    Company began making quarterly payments in the amount of $25,000
    starting in the first quarter of 2007. These quarterly payments,
    which are scheduled to continue until the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    agreement is terminated, could increase in future periods if the
    Company meets certain sales volumes. The annual nonrefundable
    license fee payments were recorded as expense during the year in
    which they were paid.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Development
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2004, the Company entered into a development agreement
    to evaluate two application areas of interest. Under the
    agreement, the Company performed research and development
    services, manufactured prototypes, and licensed certain
    nonexclusive rights. In addition, the Company issued a fully
    vested warrant to purchase 144,973&#160;shares of Series&#160;D
    convertible preferred stock at $9.80 per share (see
    Note&#160;8). As consideration, the Company received payments
    totaling $1,500,000 during 2004 and 2005. The Company determined
    that the license, research and development services, and
    prototypes should be accounted for as a combined unit of
    accounting and recognized the revenues ratably over the
    <FONT style="white-space: nowrap">12-month</FONT>
    project period. The fair value of the warrant issued was
    estimated to be $750,000, as determined using the Black-Scholes
    option-pricing model, and was recognized as a reduction to the
    collaboration revenue. The Company recognized collaboration
    revenue of $366,000 and $384,000 related to this agreement
    during 2004 and 2005, respectively. The agreement terminated
    during 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2005, the Company entered into another development
    agreement to develop another application area of interest. Under
    the agreement, the Company performed research and development
    services and manufactured prototype instruments. The agreement
    provided for payments to the Company in the amount of $942,000,
    to be paid in installments over the
    <FONT style="white-space: nowrap">30-month</FONT>
    life of the agreement. The Company determined that the research
    and development services and the manufacturing of prototype
    instruments should be accounted for as a combined unit of
    accounting and revenue was therefore recognized ratably over the
    estimated project period. The Company recognized revenue of
    $94,000, $377,000, $377,000, $188,000 and $89,000 related to
    this agreement during 2005, 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008, respectively. The
    agreement terminated during the six months ended June&#160;28,
    2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Collaboration
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2005, the Company entered into a collaborative
    agreement to develop and commercialize radiopharmaceutical
    manufacturing products for use in the positron emission
    tomography field. As consideration, the Company received an
    up-front fee of $1,000,000, which the Company deferred and
    recognized over the obligation period of approximately two
    years, with $458,000 and $542,000 recognized as revenue during
    2005 and 2006, respectively. Also, the Company recognized
    additional revenue of $635,000 and $500,000 during 2005 and
    2006, respectively, related to payments for research and
    development activities under the agreement based on agreed upon
    rates for time incurred by the research staff. The agreement
    terminated on December&#160;31, 2006.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">National
    Institutes of Health</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2006, the Company was awarded a government grant from
    the National Institutes of Health (NIH) in the amount of
    $1,048,000 to be earned over a two-year period. Under the grant,
    the Company performs research and development activities to
    design a diffraction capable Topaz screening chip. The agreement
    provides for quarterly reimbursement of the eligible research
    and development expenses, including salaries, equipment,
    scientific consumables, and certain third-party costs. The grant
    revenue is recognized as the related services are performed and
    costs associated with this grant are reported as research and
    development expense in the period incurred. The Company
    recognized revenue of $184,000, $606,000, $355,000 and $258,000
    during 2006 and 2007 and the six months ended June&#160;30, 2007
    and June&#160;28, 2008,  respectively, under this grant. This
    agreement terminated in June&#160;2008.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Singapore
    Economic Development Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2005, Fluidigm Singapore, a wholly owned subsidiary
    of the Company, entered into a letter agreement providing for up
    to SG$10.0&#160;million (approximately US$7.3&#160;million using
    June&#160;28, 2008 exchange rates) in grants from the Singapore
    Economic Development Board (EDB). The grants are payable for the
    period August&#160;1, 2005 through July&#160;31, 2010 in
    connection with the establishment and operation by Fluidigm
    Singapore of a research, development and manufacturing center
    for IFCs in Singapore. Grant payments are calculated as a
    portion of qualifying expenses incurred in Singapore relating to
    salaries, overhead, outsourcing and subcontracting expenses,
    operating expenses and royalties paid. Fluidigm Singapore is
    required to submit incentive payment requests for qualifying
    expenditures on a quarterly basis along with reports regarding
    its compliance with the incentive payment conditions, as
    described below, through the end of the applicable quarter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2006. Fluidigm Singapore and EDB entered into a
    supplement to the October&#160;2005 letter agreement. This
    supplement was entered into to create a process whereby Fluidigm
    Singapore and EDB would agree on new quarterly development
    targets at the start of each year, Fluidigm Singapore would
    submit to EDB a progress report and evidence of the achievement
    of targets on a quarterly basis and the parties would resolve
    any disagreements regarding the satisfaction of targets using an
    established procedure and the parties would be entitled to
    obtain a third party review of the incentive payment requests on
    a semi-annual rather than an annual basis. These agreements
    further provide EDB with the right to demand repayment of a
    portion of past grants in the event the Company does not meet
    its obligations under the agreements. Based on correspondance
    with EDB, the Company believes that it has fulfilled its
    obligations under the grants and it will, therefore, not have to
    repay any of the grant proceeds received through June&#160;28,
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fluidigm Singapore&#146;s continued eligibility for such grants
    is subject to its compliance with the following conditions:
    increasing levels of research; its development and manufacturing
    activity in Singapore, including employment of specified numbers
    of research scientists and engineers; its incurrence of
    specified levels of research and development expenses in
    Singapore over the course of each calendar year; its use of
    local service providers; its manufacture in Singapore of the
    products developed in Singapore and its achievement of certain
    targets relating to new product development or completion of
    specific manufacturing process objectives. These required levels
    of research, development and manufacturing activity in Singapore
    and the associated increases from one year to the next are the
    result of negotiations between the parties and are generally
    consistent with Company&#146;s business strategy for its
    Singapore operations. All ownership rights in the intellectual
    property developed by Fluidigm Singapore remain with Fluidigm
    Singapore and no such rights are conveyed to EDB under the
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2007, Fluidigm Singapore entered into a second
    letter agreement with EDB which provided for up to an additional
    SG$3.7&#160;million (approximately US$2.7&#160;million using
    June&#160;28, 2008 exchange rates) in grants. The terms and
    conditions of this letter agreement are substantially the same
    as the October&#160;2005 letter agreement, with the exception of
    the size of the potential grant, the term of the agreement and
    the specific levels of research, development and manufacturing
    activities required to maintain eligibility for such grants. The
    primary focus of this letter agreement is the ongoing
    development and manufacture in Singapore of certain
    instrumentation. This letter agreement applies to research,
    development and manufacturing activity by Fluidigm Singapore in
    Singapore from June&#160;1, 2006 through May&#160;31, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized revenue of $879,000,  $1,758,000,
    $843,000 and $810,000 related to EDB grants during 2006, 2007
    and the six months ended June&#160;30, 2007 and June&#160;28,
    2008, respectively. As of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008, the Company had
    deferred revenue of $720,000, $635,000 and $506,000,
    respectively, related to incentive payments for equipment
    expenditures, which is being recognized ratably over the
    estimated useful life of the equipment of four years. As of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008, the Company had accounts receivable from EDB in the
    amounts of $272,000, $679,000 and $349,000, respectively.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Balance
    Sheet Data</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cash
    Equivalents and Available-for-Sale Securities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following are summaries of cash equivalents and
    available-for-sale securities (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Amortized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unrealized<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Estimated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Cost</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Gain</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Loss</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;31, 2006:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of December&#160;29, 2007:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Commercial paper
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Corporate notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,999
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,283
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,985
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    36,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    As of June&#160;28, 2008 (unaudited):
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Money market funds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,170
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Notes from government-sponsored agencies
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Reported as:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,920
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Available-for-sale securities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,503
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, the contractual maturities of the
    Company&#146;s available-for-sale securities were less than one
    year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Inventories consist of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Raw materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    803
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,551
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,942
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Work-in-process</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    291
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Finished goods and demonstration units
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,644
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,498
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Property
    and Equipment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property and equipment consists of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Computer equipment and software
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,356
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lab and manufacturing equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Office furniture and fixtures
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,722
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less accumulated depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,885
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">Construction-in-progress</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation and amortization expense was $1,309,000,
    $1,379,000, $1,643,000, $832,000 and $837,000 for 2005, 2006,
    2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008, respectively. During 2005, 2006, 2007 and
    the six months ended June&#160;30, 2007 and June&#160;28, 2008,
    the Company recognized a loss on retirement of property and
    equipment of $0, $111,000, $20,000, $14,000 and $1,000,
    respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Long-Term
    Debt</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2002, the Company entered into a master security
    agreement with a lender. Per the terms of the agreement, the
    Company could draw up to $4,000,000 for purchases of capital
    equipment, software, and tenant improvements. A second master
    security agreement entered into in March 2004 increased the
    amount of the allowable draw for the Company to $11,000,000. The
    draw down period expired on December&#160;31, 2005, at which
    time the Company had drawn down $3,584,000 under the agreement.
    The loan, which was secured by the underlying equipment and a
    letter of credit, carried an interest rate between 8.0% and
    10.5% per annum, and each draw under the agreement was to be
    repaid in 42 varying monthly installments, which was originally
    scheduled to end on July&#160;1, 2009. In connection with the
    execution of the second agreement in 2004, the Company issued a
    warrant to purchase 10,714&#160;shares of Series&#160;D
    convertible preferred stock at $9.80 per share (see
    Note&#160;8)&#160;which was recorded on the consolidated balance
    sheet at fair value of $90,000 as a debt discount that was
    amortized to interest expense over two years. As of
    December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal balance of this loan was $2,267,000 and
    $1,130,000, respectively. In February 2008, prior to the due
    date, the Company paid off the outstanding principal and accrued
    interest balance and paid a prepayment fee in the amount of
    $41,000 to the lender. Accordingly, the entire outstanding
    principal balance for this loan as of December&#160;29, 2007 was
    classified as a current liability on the consolidated balance
    sheet. Upon full payment of this debt, restricted cash in the
    amount of $500,000 was released by the lender and thus has been
    classified as a current asset as of December&#160;29, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2005, the Company entered into a loan and security
    agreement with another lender. Under this agreement the Company
    borrowed $13,000,000 during 2005 for general corporate purposes.
    This loan is secured by the Company&#146;s assets except for
    intellectual property; however, the security interest does
    include proceeds from sales of the intellectual property. The
    loan was originally scheduled to be repaid by 2009; however, the
    agreement was amended in August 2006 to extend the final
    repayment date to February&#160;1, 2010. The agreement carried a
    variable interest rate of prime plus 2.5% through March 2006.
    Thereafter, the agreement carried a fixed interest rate of 10.0%
    through July 2006 and a fixed interest rate of 9.75% following
    the amendment to the agreement in August 2006. In August 2006,
    the Company began making monthly payments in the amount of
    $310,000 for principal and interest under the agreement. The
    agreement also requires payment of fees in March 2009 in the
    amount of $1,612,500. The fees are accreted as interest expense
    over the term of the loan. The agreement restricts the
    Company&#146;s ability to pay dividends. The Company is subject
    to a prepayment fee in the amount of 1% of the outstanding
    principal amount being prepaid if paid during 2008 or 2009. In
    connection with the execution of this
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    loan and security agreement, the Company issued a warrant to
    purchase 53,061&#160;shares of Series&#160;D convertible
    preferred stock at $9.80 per share (see Note&#160;8)&#160;which
    was recorded on the consolidated balance sheet at fair value of
    $54,000 as a debt discount. In connection with the final draw
    down of this loan, the Company issued another warrant to
    purchase 53,061&#160;shares of Series&#160;D convertible
    preferred stock at $9.80 per share (see Note&#160;8)&#160;which
    was recorded on the consolidated balance sheet at fair value of
    $50,000 as a debt discount. The debt discounts are amortized to
    interest expense over the life of the agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, the Company amended this loan and security
    agreement to provide the Company with an additional credit line
    in the amount of $10,000,000 that the Company could draw upon
    until July&#160;1, 2008 for general corporate purposes. In
    connection with the amendment of this loan and security
    agreement, the Company issued a warrant to purchase
    28,572&#160;shares of Series E convertible preferred stock at
    $14.00&#160;per share (see Note&#160;8). The warrant was
    recorded on the consolidated balance sheet as a deferred charge
    at a fair value of $111,000 and was amortized to interest
    expense over the period of the availability of the funds. In
    June&#160;2008, the Company drew down the $10,000,000 available.
    The loan will bear interest at 11.5%&#160;per annum. Interest
    only payments will be made monthly through the remainder of 2008
    with monthly payments of principal and interest in the amount of
    $369,000, beginning in January 2009, to be made through June
    2011. The agreement also requires a final payment in the amount
    of $650,000 in June 2011. In addition, the Company issued to the
    lender an additional warrant to purchase up to
    57,142&#160;shares of Series E convertible preferred stock at
    $14.00&#160;per share in accordance with the terms of the
    agreement which was recorded on the consolidated balance sheet
    at fair value of $373,000 as a debt discount. As of
    December&#160;31, 2006, December&#160;29, 2007 and June&#160;28,
    2008, the outstanding principal balance of these loans was
    $10,570,000, $8,232,000 and $16,558,000, respectively, net of
    the unamortized debt discounts of $58,000, $31,000 and $391,000,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The amortization of the debt discounts for the Company&#146;s
    long-term debt agreements was recorded as interest expense in
    the consolidated statements of operations in the amounts of
    $9,000, $37,000, $27,000, $14,000 and $11,000 during 2005, 2006,
    2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008, respectively. As of June&#160;28, 2008, the
    Company was either in compliance with all loan covenants or had
    obtained waivers from the respective lenders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table does not include principal payments for the
    master security agreement with a principal balance of $1,130,000
    as of December&#160;29, 2007 that was paid off in February 2008.
    The scheduled principal payments of the Company&#146;s other
    long-term debt as of December&#160;29, 2007 are as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    610
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total principal payments due in future periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: debt discounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,232
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The scheduled principal payments of the Company&#146;s long-term
    debt as of June&#160;28, 2008 are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="91%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Remainder of 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,453
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total principal payments due in future periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,949
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: debt discounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (391
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- TABLE 05 -->

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Commitments
    and Contingencies</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operating
    Leases</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company leases its headquarters in South San&#160;Francisco,
    California, under multiple noncancelable lease agreements that
    expire in February 2011. These agreements include renewal
    options which provide the Company with the ability to extend the
    lease terms for an additional three years. The Company also
    leases office and manufacturing space under noncancelable leases
    in Singapore that expire in October&#160;2011. The
    Company&#146;s other operating leases are for office space in
    the Netherlands, Japan, and France and are on a month-to-month
    basis. As of December&#160;29, 2007, future minimum lease
    payments under noncancelable operating leases were as follows
    (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,436
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,374
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total minimum payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Singapore office and manufacturing space leases were renewed
    in August&#160;2008 as they were originally scheduled to expire
    in September 2008. Future minimum lease payments on the new
    Singapore leases in the amount of SG$14,000 (approximately
    US$10,000 using June&#160;28, 2008 exchange rates) per month are
    not included in the table above. The Company&#146;s lease
    payments are recognized as an expense on a straight-line basis
    over the life of the lease. Rental expense under operating
    leases for 2005, 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008 totaled $1,468,000,
    $1,494,000, $1,574,000, $719,000 and $730,000, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Commitments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has entered into a supply agreement with a vendor to
    provide inventory components customized to the Company&#146;s
    specifications. Pursuant to this agreement, the Company has
    agreed to purchase from the vendor a specified minimum number of
    units each year in exchange for volume discounts. After
    April&#160;1, 2010, either party
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    may terminate the supply agreement upon six months prior written
    notice. As of December&#160;29, 2007, future minimum payments
    under the supply agreement were as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Years:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total minimum payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contingencies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2008, the Company received a letter from a competitor
    asserting that the Company had infringed upon a patent currently
    held by the competitor. In response, the Company filed a suit
    against the competitor seeking declaratory judgments of
    non-infringement and invalidity of the patent. Subsequent to the
    filing of the suit, the Company and this competitor entered into
    an agreement that provides for a stay of the proceedings and
    provides further that neither party may initiate any further
    patent litigation proceedings against the other during the term
    of the agreement. The Company is party to other various claims
    arising in the ordinary course of business. These claims relate
    to intellectual property rights and employment matters. While
    there is no assurance that an adverse determination of any of
    such matters will not occur, management does not believe, based
    upon information known to it, that a potential resolution of any
    of these matters will have a material adverse effect upon the
    Company&#146;s financial position, results of operations, or
    cash flows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Indemnifications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From time to time, the Company has entered into indemnification
    provisions under certain of its agreements with other companies
    in the ordinary course of business, typically with business
    partners, customers, and suppliers. Pursuant to these
    agreements, the Company may indemnify, hold harmless, and agree
    to reimburse the indemnified parties on a case by case basis for
    losses suffered or incurred by the indemnified parties in
    connection with any patent or other intellectual property
    infringement claim by any third-party with respect to its
    products. The term of these indemnification provisions is
    generally perpetual from the time of the execution of the
    agreement. The maximum potential amount of future payments the
    Company could be required to make under these indemnification
    provisions is typically not limited to a specific amount. In
    addition, the Company has entered into indemnification
    agreements with its officers and directors. The Company has not
    incurred material costs to defend lawsuits or settle claims
    related to these indemnification provisions. As of June&#160;28,
    2008, the Company had not accrued a liability for these
    indemnification provisions because the likelihood of incurring a
    payment obligation was remote.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF"><!-- TABLE 05 -->

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Promissory Notes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2003, the Company entered into a convertible note
    purchase agreement with the Biomedical Sciences Investment
    Fund&#160;Pte Ltd (BMSIF). BMSIF is wholly-owned by EDB
    Investments Pte. Ltd., whose parent entity is EDB. Ultimately,
    each of these entities is controlled by the government of
    Singapore. Under this agreement BMSIF agreed to provide a
    $2,000,000 credit facility to be used for general corporate
    purposes. In December 2003, the Company issued a $2,000,000
    convertible promissory note to BMSIF. The note, which was
    unsecured, carried an interest rate of 8% per year. Per the
    agreement, principal and interest were convertible into the
    Company&#146;s Series&#160;D convertible preferred stock at
    $9.80 per share at the lender&#146;s election, at any time, or
    upon the election of the Company upon the achievement of certain
    milestones by the Company. In June 2005, the agreement was
    amended to allow the Company to issue additional convertible
    promissory notes in the amount of $3,000,000 if the Company
    achieved certain milestones. In December 2005, upon the
    successful completion of specified milestones, the $2,000,000
    convertible promissory note and interest of $331,000 converted
    into 237,895&#160;shares of Series&#160;D convertible preferred
    stock at $9.80 per share as settlement of the outstanding
    balance on the date of the conversion.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2006, the Company issued a $3,000,000 convertible
    promissory note, which was also unsecured, that carried an
    interest rate of 8% per year. Principal and interest were also
    convertible into the Company&#146;s Series&#160;D convertible
    preferred stock at $9.80 per share at the lender&#146;s
    election, at any time, or upon the election of the Company upon
    the achievement of certain milestones by the Company or upon the
    completion of an initial public offering in which the
    convertible preferred stock has converted into common stock. As
    of December&#160;31, 2006, the outstanding principal and accrued
    interest balance for the convertible promissory note was
    $3,128,000. In June 2007, upon the successful completion of
    specified milestones, the principal balance in the amount of
    $3,000,000 for the convertible promissory note and accrued
    interest of $240,000 converted into 330,612&#160;shares of
    Series&#160;D convertible preferred stock at $9.80 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2006, the Company entered into another convertible
    note purchase agreement with BMSIF. Under this agreement, BMSIF
    agreed to provide a $15,000,000 credit facility, to be issued in
    three separate $5,000,000 tranches, and to be used for general
    corporate purposes. The Company issued two $5,000,000
    convertible promissory notes against equal amounts of borrowings
    under this facility, each unsecured and carrying an interest
    rate of 8% per year, in August and November 2006. In March 2007,
    BMSIF exercised the conversion provision of the convertible note
    purchase agreement and the Company issued 844,095&#160;shares of
    Series&#160;E convertible preferred stock at $12.60 per share as
    settlement of the outstanding principal and accrued interest
    balance on the date of the conversion in the amount of
    $10,636,000. Upon conversion of these convertible promissory
    notes, the Company issued the third and final $5,000,000
    convertible promissory note against an equal amount of borrowing
    under this facility with an interest rate of 8% per year in
    April 2007. BMSIF exercised the conversion provision for the
    third and final convertible promissory note in May&#160;2008,
    and the Company issued 429,698&#160;shares of Series E
    convertible preferred stock at $12.60 per share as settlement of
    the outstanding principal and accrued interest balance on the
    date of the conversion in the amount of $5,414,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For these convertible note purchase agreements in which the
    repayment was in the form of Series&#160;E convertible preferred
    stock, the conversion price of $12.60 per share was a discount
    to the estimated fair values of $12.98 and $14.00 per share for
    the Series&#160;E convertible preferred stock at the times of
    the borrowings. The intrinsic value of the embedded beneficial
    conversion option associated with each borrowing of convertible
    promissory notes under the arrangement was measured as the
    difference between the conversion price and the fair value of
    Series&#160;E convertible preferred stock on the commitment date
    and the resulting debt discount is being amortized to interest
    expense over the two year contractual term of the debt. Upon
    conversion of the notes to convertible preferred stock, any
    remaining unamortized debt discount was immediately recognized
    as interest expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2006 and 2007, the Company recognized debt discounts of
    $306,000 and $485,000, respectively, related to the beneficial
    conversion feature of the notes. Amortization of the debt
    discounts for the convertible note purchase agreements was
    recorded as interest expense in the consolidated statements of
    operations in the amount of $43,000, $468,000, $360,000 and
    $280,000 during 2006, 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006 and December&#160;29, 2007, the
    outstanding principal and accrued interest balance for the
    convertible note purchase agreements with BMSIF was $9,944,000
    and $4,997,000 net of the unamortized debt discounts of $263,000
    and $280,000, respectively. As of June 28, 2008, there were no
    remaining amounts outstanding related to the convertible note
    purchase agreements with BMSIF.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock Warrant Liabilities</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company issued warrants to purchase 346,055&#160;shares of
    the Company&#146;s convertible preferred stock at various times
    between 2001 and 2005 and warrants to purchase
    85,714&#160;shares during the six months ended June&#160;28,
    2008. The Company did not issue any warrants to purchase
    convertible preferred stock during 2006 or 2007. The convertible
    preferred stock warrants are generally exercisable immediately
    and can only be exercised for cash or net share settled. Changes
    in the fair value of the underlying stock do not affect the
    settlement amounts of the warrants, therefore, the maximum
    amount of shares to be issued upon the settlement of these
    warrants is noted in the table below. As of December&#160;29,
    2007, the following warrants were issued and outstanding:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Issue Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May 2001
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    11,795
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    7.63
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) May 14, 2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.03
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 27, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    November 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8,859
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.03
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December 16, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September 2003
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Collaboration agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    57,142
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.03
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    December 31, 2007
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 18, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53,061
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53,061
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March 29, 2012
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    199,632
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2007, warrants to purchase 1,450&#160;shares of
    Series&#160;C convertible preferred stock expired. Upon
    expiration, the related warrant liability was eliminated and
    reflected as other income (expense), net. During 2006, warrants,
    issued in connection with a collaboration agreement (see
    Note&#160;3), to purchase 144,973&#160;shares of the
    Series&#160;D convertible preferred stock were exercised
    utilizing a cashless exercise option that allowed the holder to
    receive 76,530&#160;shares of convertible preferred stock. The
    fair value of the warrants and the shares of convertible
    preferred stock issued upon the cashless exercise was $729,000
    on the exercise date, calculated as the fair value of the shares
    of convertible preferred stock issued.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of June&#160;28, 2008, the following warrants were issued and
    outstanding (unaudited):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="14%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="29%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Warrant to Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Reason for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Convertible<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Issue Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Preferred Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Expiration</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5,000
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.03
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;27, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    November 2002
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series C
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    8,859
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.03
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) December&#160;16, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10,714
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;18, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    March 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53,061
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;29, 2012
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series D
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53,061
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    9.80
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) March&#160;29, 2012
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series E
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    28,572
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    14.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) February&#160;15, 2015
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    June 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Debt Financing
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Series E
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    57,142
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    14.00
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Earlier of (i) the closing of an acquisition of the Company or
    (ii) February 15, 2015
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    216,409
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the six months ended June&#160;28, 2008, the Company
    issued warrants to purchase 85,714&#160;shares of Series&#160;E
    convertible preferred stock in connection with the amendment of
    a loan and security agreement and the subsequent draw down on
    the agreement (see Note&#160;5). Warrants to purchase
    57,142&#160;shares of the Company&#146;s Series C convertible
    preferred stock expired unexercised on December&#160;31, 2007
    and warrants to purchase 11,795&#160;shares of the
    Company&#146;s Series&#160;C convertible preferred stock were
    exercised in May&#160;2008 utilizing a cashless exercise option
    that allowed the holder to receive 4,692&#160;shares of
    convertible preferred stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the warrants to purchase
    convertible preferred stock outstanding and their fair values as
    of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares as of</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Fair Value as of</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Warrants to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchase</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,246
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,859
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    61,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    85,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    194,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    632,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series E
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    552,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    201,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,409
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    223,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,269,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair values of the outstanding convertible preferred stock
    warrants were measured using the Black-Scholes option-pricing
    model with the following weighted-average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="11%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.6%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    49.7%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    49.2%
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life (equals the remaining contractual term)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.7 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    2.8 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5.0 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.3%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A decrease in fair value of the convertible preferred stock
    warrant liabilities in the amount of $72,000 and $26,000 during
    2005 and the six months ended June&#160;30, 2007, and increases
    in fair value in the amounts of $138,000, $245,000 and $359,000
    during 2006, 2007 and the six months ended June&#160;28, 2008,
    respectively, were recognized as other income (expense), net in
    the consolidated statements of operations. Upon adoption of
    <FONT style="white-space: nowrap">FSP&#160;150-5</FONT>
    on July&#160;1, 2005, the Company recorded a gain of $637,000 as
    a cumulative effect of a change in accounting principle in the
    consolidated statement of operations during 2005.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Convertible
    Preferred Stock</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2006, December&#160;29, 2007, and
    June&#160;28, 2008 (unaudited) convertible preferred stock was
    comprised of the following (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;29, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;E
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,581
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    112,295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    162,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;28, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Liquidation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Designated</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Net Proceeds</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series B
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,846
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series C
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,072
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,263
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series D
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,034
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series E
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    167,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    171,228
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s convertible preferred stock had been
    classified as temporary equity on the consolidated balance sheet
    instead of in stockholders&#146; equity (deficit) in accordance
    with EITF Abstracts Topic
    <FONT style="white-space: nowrap">No.&#160;D-98,</FONT>
    <I>Classification and Measurement of Redeemable Securities</I>.
    Upon certain change in control events that are outside of the
    control of the Company, including liquidation, sale or transfer
    of control of the Company, holders of the convertible preferred
    stock can cause its redemption. Accordingly, these shares are
    considered contingently redeemable. The Company has not adjusted
    the carrying values of the convertible preferred stock to their
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    redemption values since it is uncertain whether or when a
    redemption event will occur. Subsequent adjustments to increase
    the carrying values to the redemption values would be made if it
    becomes probable that such redemption will occur. The
    significant rights, privileges, and preferences of the
    convertible preferred stock are as follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each share of convertible preferred stock is convertible, at any
    time at the option of the holder, into common stock based upon a
    conversion rate of one share of common stock for each share of
    convertible preferred stock regardless of the series.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conversion is automatic upon: (i) the closing of an underwritten
    initial public offering of the Company&#146;s common stock at an
    offering price of not less that $19.91&#160;per share
    (appropriately adjusted for any stock splits, stock dividends,
    recapitalization, or similar events) and with aggregate gross
    proceeds of not less than $25,000,000, (ii) the closing of an
    underwritten initial public offering of the Company&#146;s
    common stock at an offering price of less than $19.91&#160;per
    share (appropriately adjusted for any stock splits, stock
    dividends, recapitalization, or similar events) or with
    aggregate gross proceeds of less than $25,000,000 and written
    consent of the holders of two-thirds of all shares of
    convertible preferred stock voting together for such automatic
    conversion, or (iii) the written consent of the holders of
    two-thirds of all shares of convertible preferred stock voting
    together, except that the written consent of the holders of
    greater than two-thirds of all shares of Series E convertible
    preferred stock voting separately is required for Series E
    convertible preferred stock to convert if such conversion is not
    in connection with the closing of an underwritten initial public
    offering of the Company&#146;s common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of Series&#160;A, B, C, D, and E convertible preferred
    stock are entitled to noncumulative dividends of $0.38, $0.63,
    $0.91, $1.05, and $1.50 per share, respectively, if and when
    declared by the Board of Directors (adjusted for any stock
    splits, stock dividends, recapitalization, or similar events)
    and subject to the preferences described below. Holders of
    Series&#160;D and E convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A, B, or C convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Payments of any dividends to the
    holders of Series&#160;D and E convertible preferred stock shall
    be on a pro rata, pari passu basis in proportion to the entitled
    dividend rates for these respective series, as applicable.
    Holders of Series&#160;C convertible preferred stock shall be
    entitled to receive dividends, when and if declared, in
    preference and priority to any declaration or payment of
    dividends to holders of Series&#160;A and B convertible
    preferred stock or common stock, other than for dividends
    payable in only common stock. Holders of Series&#160;A and B
    convertible preferred stock shall be entitled to receive
    dividends, when and if declared, in preference and priority to
    any declaration or payment of dividends to holders of common
    stock, other than for dividends payable in only common stock.
    Payments of any dividends to the holders of Series&#160;A and B
    convertible preferred stock shall be on a pro rata, pari passu
    basis in proportion to the entitled dividend rates for these
    respective series, as applicable. No dividends have been
    declared or paid through June&#160;28, 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidation
    Preferences</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a liquidation, dissolution, or winding up of the
    Company, holders of Series&#160;E convertible preferred stock
    shall be entitled to receive a liquidation preference of $14.00
    per share, together with any declared but unpaid dividends,
    prior to any payment or distribution to holders of Series A, B,
    C, or D convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;E convertible
    preferred stock, holders of Series&#160;D convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $9.80 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A, B, or C convertible preferred stock or common stock.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;D convertible
    preferred stock, holders of Series&#160;C convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $9.03 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series A or B convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;C convertible
    preferred stock, holders of Series&#160;B convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $6.23 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    Series&#160;A convertible preferred stock or common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After payment to the holders of Series&#160;B convertible
    preferred stock, holders of Series&#160;A convertible preferred
    stock shall be entitled to receive a liquidation preference of
    $3.85 per share, together with any declared but unpaid
    dividends, prior to any payment or distribution to holders of
    common stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After the payment to the holders of convertible preferred stock
    or their respective liquidation preferences, the entire
    remaining assets of the Company shall be distributed on a pro
    rata basis to the holders of common stock. A change of control
    or a sale, transfer, or lease of all or substantially all of the
    assets of the Company is considered to be a liquidation event.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of convertible preferred stock are entitled to the
    number of votes they would have upon conversion of their
    convertible preferred stock into common stock on the applicable
    record date. So long as 571,428&#160;shares of Series&#160;D
    convertible preferred stock remain outstanding, the holders of
    Series&#160;D convertible preferred stock are entitled to elect
    two members to the Company&#146;s Board of Directors, and so
    long as 571,428&#160;shares of Series&#160;C convertible
    preferred stock remain outstanding, the holders of Series&#160;C
    convertible preferred stock are entitled to elect three members
    to the Board of Directors. The holders of Series&#160;A, B, and
    E convertible preferred stock and the holders of common stock,
    voting together as a single class, are entitled to elect any
    additional members to the Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Option Activity</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">1999
    Stock Option Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On May&#160;12, 1999, the Board of Directors adopted the 1999
    Stock Option Plan (the Stock Plan) under which incentive stock
    options and nonstatutory stock options may be granted to
    employees, officers, and directors of, or consultants to, the
    Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options granted under the Stock Plan expire no later than ten
    years from the date of grant. The exercise price of each
    incentive stock option granted to an employee shall be at least
    110% of the fair market value of the underlying common stock on
    the date of grant if, on the grant date, the employee owns stock
    representing more than 10% of the voting power of all classes of
    the Company&#146;s capital stock; otherwise, the exercise price
    shall be at least 100% of the fair market value of the
    underlying common stock on the date of grant. The exercise price
    for each nonstatutory stock option granted to a service provider
    shall be at least 110% of the fair market value of the
    underlying common stock on the date of grant if, on the grant
    date, the service provider owns stock representing more than 10%
    of the voting power of all classes of the Company&#146;s capital
    stock; otherwise, the exercise price shall be at least 85% of
    the fair market value of the underlying common stock on the date
    of grant. The fair market value of the underlying common stock
    shall be determined by the Board of Directors until such time as
    the Company&#146;s common stock is listed on any established
    stock exchange or national market system. Options may be granted
    with different vesting terms from time to time, but the vesting
    terms may not exceed five years from the date of grant.
    Generally, outstanding options are immediately exercisable and
    vest at a rate of 25% on the first anniversary of the option
    grant date and
    <FONT style="vertical-align: text-top; font-size: 70%;">1</FONT>/<FONT style="font-size: 70%;">48</FONT>
    of the total grant each month thereafter.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Stock Plan is the
    Company&#146;s only stock-based compensation plan and a total of
    3,657,142&#160;shares of common stock have been authorized for
    issuance under the Stock Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Activity under the Stock Plan is as follows (in thousands,
    except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Outstanding Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Available for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price per<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Share</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of January&#160;1, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.09
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;31, 2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (347
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (127
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;31, 2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    251
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    571
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (584
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (73
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.72
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (104
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as of December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,134
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional shares authorized (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    571
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options granted (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (778
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    778
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.47
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options exercised (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (64
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.72
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Options canceled (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Balance as of June&#160;28, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.46
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercised during 2005, 2006, 2007 and the six months
    ended June&#160;28, 2008  exclude options that are exercised
    prior to vesting. These shares generally vest over a four-year
    period. Unvested shares, which amount to 18,571, 9,524 and 6,785
    as of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, respectively, are subject to a repurchase
    option held by the Company at the original exercise price and
    are not deemed to be issued for accounting purposes until those
    shares vest.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2006, the Company adopted the
    provisions of SFAS&#160;123(R). The fair value of each new
    employee option awarded was estimated on the grant date using
    the Black-Scholes option-pricing model using the following
    weighted-average assumptions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="8%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Six Months<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Ended June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Ended June&#160;28,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    72.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    63.0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    53.8%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.1&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0 years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    6.0 years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.8%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.4%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    4.6%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3.2%
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    0%
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted-average fair value of options granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $1.92
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $3.22
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $2.96
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    $5.65
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Expected volatility is derived from historical volatilities of
    several unrelated public companies within the biomedical
    instrument and system industry. Each company&#146;s historical
    volatility is weighted based on certain qualitative factors and
    combined to produce a single volatility factor used by the
    Company. The risk-free interest rate is based on the
    U.S.&#160;Treasury yield curve in effect at the time of grant
    for zero coupon U.S.&#160;Treasury notes with maturities
    approximately equal to the option&#146;s expected life. Given
    the limited history to accurately estimate expected lives of
    options granted to the various employee groups, the Company used
    the &#147;simplified&#148; method as provided by the SEC Staff
    Accounting Bulletin&#160;No.&#160;107, <I>Share Based Payment
    </I>(SAB&#160;107). The &#147;simplified&#148; method is
    calculated as the average of the time-to-vesting and the
    contractual life of the options. The Company estimates its
    forfeiture rate based on an analysis of its actual forfeitures
    and will continue to evaluate the adequacy of the forfeiture
    rate based on actual forfeiture experience, analysis of employee
    turnover behavior, and other factors. The impact from a
    forfeiture rate adjustment will be recognized in full in the
    period of adjustment, and if the actual number of future
    forfeitures differs from that estimated by the Company, the
    Company may be required to record adjustments to stock-based
    compensation expense in future periods. Adjustments to the
    forfeiture rates have not had a significant impact on any of the
    periods presented. Each of these inputs is subjective and
    generally requires significant judgment to determine.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The absence of an active market for the Company&#146;s common
    stock required the Company&#146;s Board of Directors, with input
    from management, to estimate the fair value of the common stock
    for purposes of granting options and for determining stock-based
    compensation expense for the periods presented. In response to
    these requirements, the Company&#146;s Board of Directors
    estimated the fair value of the common stock at each meeting at
    which options were granted based on factors such as the price of
    the most recent convertible preferred stock sales to investors,
    the preferences held by the convertible preferred stock classes
    in favor of common stock, the valuations of comparable
    companies, the hiring of key personnel, the status of the
    Company&#146;s development and sales efforts, revenue growth and
    additional objective, and subjective factors relating to the
    Company&#146;s business. The Company has historically granted
    stock options at not less than the fair value of the underlying
    common stock as determined at the time of grant by the
    Company&#146;s Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Information regarding the Company&#146;s stock option grants
    during 2007 and the six months ended June&#160;28, 2008,
    including the grant date; the number of stock options issued
    with each grant; and the exercise price, which equals the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    grant date fair value of the underlying common stock for each
    grant of stock options, is summarized as follows (in thousands,
    except per share amounts):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>per Share of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Common Stock</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    May&#160;8, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    September&#160;20, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;28, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;7, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    April&#160;24, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    547
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11.16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    June&#160;26, 2008 (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11.97
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of December&#160;29, 2007
    is summarized in the following table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.52
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $1.05
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    491
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $1.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $1.96
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $2.90
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $4.76
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    453
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    354
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $4.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $8.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,134
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of December&#160;29, 2007 had a
    weighted-average remaining contractual life of 7.4&#160;years, a
    weighted-average exercise price per share of $2.59, and an
    aggregate intrinsic value of $3,662,000.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additional information regarding the Company&#146;s stock
    options outstanding and exercisable as of June&#160;28, 2008 is
    summarized in the following table (unaudited):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Subject<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exercise Price</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>to Options</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $0.52
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $1.05
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    232
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    232
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $1.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $1.96
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    541
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    540
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $2.90
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $4.76
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    409
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $4.83
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $8.40
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $11.16
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    $11.97
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Certain options under the Stock
    Plan may be exercised prior to vesting but are subject to
    repurchase at the original exercise price in the event the
    optionees&#146; employment is terminated.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options exercisable as of June&#160;28, 2008 had a
    weighted-average remaining contractual life of 8.0 years, a
    weighted-average exercise price per share of $5.18, and an
    aggregate intrinsic value of $14,561,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of December&#160;29, 2007 are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,097
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    871
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate intrinsic value was
    calculated as the difference between the exercise price of the
    underlying options and the fair value of the Company&#146;s
    common stock in the amount of $8.40&#160;per share as of
    December&#160;29, 2007.
    </FONT></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Options outstanding that have vested and are expected to vest as
    of June&#160;28, 2008 are summarized as follows (unaudited):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Aggregate<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Intrinsic<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>per Share</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Vested
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,099
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total vested and expected to vest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,299
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,171
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate intrinsic value was
    calculated as the difference between the exercise price of the
    options and the fair value of the Company&#146;s common stock in
    the amount of $11.97&#160;per share as of June&#160;28, 2008.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The total intrinsic value of options exercised during 2006, 2007
    and the six months ended June&#160;30, 2007 and June&#160;28,
    2008 was $167,000, $259,000, $40,000 and $420,000, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There were no stock-based compensation tax benefits during 2005,
    2006, 2007 or the six months ended June&#160;28, 2008.
    Capitalized stock-based compensation costs were insignificant
    during 2005, 2006, 2007 and the six months ended June&#160;28,
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company recognized stock-based compensation expense of
    $5,000, $145,000, $708,000, $374,000 and $1,001,000 during 2005,
    2006, 2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008. Included in these amounts was employee
    stock-based compensation expense of $0, $86,000, $526,000,
    $232,000 and $936,000  and nonemployee stock-based compensation
    expense of $5,000, $59,000, $182,000, $142,000 and $65,000
    during 2005, 2006, 2007 and the six months ended June&#160;30,
    2007 and June&#160;28, 2008, respectively. As of
    December&#160;29, 2007 and June&#160;28, 2008, there was
    $1,698,000 and $5,051,000 of total unrecognized compensation
    costs related to stock-based compensation arrangements granted
    under the Stock Plan, which is expected to be recognized over an
    average period of 2.9&#160;years for both periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain of our stock options are granted to officers with
    vesting acceleration features based upon the achievement of
    certain performance milestones.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Stock
    Options Granted to Nonemployees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company accounts for options granted to nonemployees under
    the fair value method in accordance with SFAS&#160;123(R) and
    <FONT style="white-space: nowrap">EITF&#160;96-18.</FONT>
    The fair value of these options was estimated using the
    Black-Scholes option-pricing model with the following
    assumptions for 2005, 2006 and 2007 and the six months ended
    June&#160;30, 2007 and June&#160;28, 2008: risk-free interest
    rates of 3.5% to 5.0%, dividend yield of 0%, expected volatility
    of 53.5% to 82.9%, and an expected life of the options equal to
    the remaining contractual terms of one to ten years. In
    accordance with
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    options granted to nonemployees are remeasured at each
    accounting period-end until the award is vested.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company granted options to nonemployees to purchase 4,871,
    25,214, 67,429, 22,286 and 5,714 shares of common stock during
    2005, 2006 and 2007 and the six months ended June&#160;30, 2007
    and June&#160;28, 2008, respectively. As of December&#160;29,
    2007 and June&#160;28, 2008, there were 36,310 and
    41,429&#160;shares, respectively, subject to unvested options
    held by nonemployees with a weighted-average exercise price of
    $5.70 and $8.12, respectively, and an average remaining vesting
    period of 2.7&#160;and 3.0&#160;years, respectively.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Shares
    Reserved for Issuance</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007 and June&#160;28, 2008, the Company
    has reserved shares of common stock for future issuance as
    follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options outstanding
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,134
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Options available for grant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of outstanding convertible preferred stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible preferred stock upon exercise of
    warrants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,825
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The above table does not include shares of common stock reserved
    for potential conversions of the convertible promissory notes
    (see Note&#160;7)&#160;into shares of convertible preferred
    stock. The only outstanding convertible promissory note as of
    December&#160;29, 2007 was converted in April&#160;2008, at
    which time the Company issued 429,698&#160;shares of
    Series&#160;E convertible preferred stock. There were no
    outstanding convertible promissory notes as of June&#160;28,
    2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s net loss before the provision for income
    taxes is as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="68%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Domestic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (15,181
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (21,816
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,372
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    International
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,737
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,079
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss before provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,385
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (23,553
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (25,451
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s provision for
    income taxes are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Federal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total current provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Federal
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred provision
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total provision for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of the benefits for income taxes at the statutory
    rate to the provision for income taxes is as follows:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax benefit at federal statutory rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    State income taxes (net of federal benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effective tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )%
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant components of the Company&#146;s deferred tax assets
    and liabilities are as follows (in thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Reserves and accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Tax credit carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net operating loss carryforwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,177
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52,747
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Recognition of deferred tax assets is appropriate when
    realization of these assets is more likely than not. The Company
    has incurred losses since its inception; accordingly, the net
    deferred tax assets have been fully offset by a valuation
    allowance. The valuation allowance increased by $5,954,000,
    $8,534,000 and $9,570,000 during 2005, 2006 and 2007,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;29, 2007, the Company had net operating loss
    carryforwards for federal income tax purposes of $121,531,000
    which expire in the years 2019 through 2026 and federal research
    and development tax credits of $2,749,000 which expire in the
    years 2008 through 2016. As of December&#160;29, 2007, the
    Company had net operating loss carryforwards for state income
    tax purposes of $119,340,000 which expire in the years 2012
    through 2016 and state research and development tax credits of
    $2,722,000 which do not expire. As of December&#160;29, 2007,
    the Company had foreign net operating loss carryforwards of
    $4,768,000. A significant portion of the foreign net operating
    losses relate to activity in Singapore that has an indefinite
    carryforward period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Utilization of the net operating loss carryforwards and credits
    may be subject to a substantial annual limitation due to the
    ownership change limitations provided by the Internal Revenue
    Code of 1986, as amended, and similar state provisions. The
    annual limitation may result in the expiration of net operating
    losses and credits before utilization. If an ownership change
    has occurred at different dates or in addition to the dates
    preliminarily identified, the utilization of net operation loss
    and credit carryforwards could be significantly reduced.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has not provided for U.S. federal and state income
    taxes on all of the non U.S. subsidiaries&#146; undistributed
    earnings as of December&#160;29, 2007, because such earnings are
    intended to be indefinitely reinvested under APB&#160;23. Upon
    distribution of those earnings in the form of dividends or
    otherwise, the Company would be subject to applicable U.S.
    federal and state income taxes.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Uncertain
    Tax Positions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Effective January&#160;1, 2007, the Company adopted the
    provisions of FIN&#160;48. As a result, the Company recorded a
    liability for net unrecognized tax benefits of $75,000, and
    recognized a cumulative effect of a change in accounting
    principle that resulted in a charge to the accumulated deficit.
    The liability for unrecognized tax benefits is classified as
    non-current.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate changes in the balance of the Company&#146;s gross
    unrecognized tax benefits during 2007 were as follows (in
    thousands):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Increases in balances related to tax provisions taken during
    current periods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    December&#160;29, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accrued interest and penalties related to unrecognized tax
    benefits are classified as income tax expense and were
    immaterial. As of December&#160;29, 2007, unrecognized tax
    benefits of $162,000, if recognized, would affect the
    Company&#146;s effective tax rate. The remaining unrecognized
    tax benefits were netted against deferred tax assets with a full
    valuation allowance, and if recognized, would not affect the
    Company&#146;s effective tax rate. The Company does not
    anticipate that the amount of existing unrecognized tax benefits
    will significantly increase or decrease within the next
    12&#160;months. The Company files income tax returns in the
    United States, various states and certain foreign jurisdictions.
    The tax years 1999 through 2007 remain open in most
    jurisdictions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Benefit Plans</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company sponsors a 401(k) plan that stipulates that eligible
    employees can elect to contribute to the plan, subject to
    certain limitations, up to the lesser of 60% of eligible
    compensation or the maximum amount allowed by the IRS on a
    pretax basis annually. The Company has not made contributions to
    this plan since its inception.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Related-Party
    Transactions</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed further in Note&#160;7, the Company has entered
    into multiple Convertible Note Purchase Agreements with BMSIF
    pursuant to which the Company issued convertible notes and
    received proceeds in the amount of $20.0&#160;million. Principal
    and interest on the notes was convertible into shares of
    Series&#160;E convertible preferred stock at the lender&#146;s
    election, at any time, and automatically converted upon the
    achievement of certain targets or upon the completion of an
    initial public offering in which the convertible preferred stock
    was converted into common stock. Through June&#160;28, 2008, all
    $20.0&#160;million of these notes had been converted to shares
    of Series&#160;E convertible preferred stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BMSIF and its related companies held 2,573,988&#160;shares of
    the Company&#146;s convertible preferred stock as of
    June&#160;28, 2008, which constitutes 11.3% of the outstanding
    shares on a fully diluted basis. In addition, the Company&#146;s
    manufacturing operations in Singapore, which commenced
    operations in October 2005, have been supported by grants from
    EDB which provide incentive payments for research, development
    and manufacturing activity in Singapore by the Company. These
    agreements are discussed further in Note&#160;3.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2004, the Company loaned an officer of the Company
    $250,000 in connection with the purchase of a new home, which
    was secured by 238,095&#160;shares of the Company&#146;s common
    stock held by the officer. The loan carried an interest rate of
    3.52% per annum. The outstanding balance of this loan, including
    accrued interest, was $277,000 and $287,000 as of
    December&#160;31, 2006 and December&#160;29, 2007, respectively.
    On April&#160;10, 2008, the principal amount of this note and
    all accrued interest was settled with 25,975&#160;shares held by
    the officer at fair value of the common stock, which was
    determined by the Board of Directors to be $11.16 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Stephen Quake, who is a professor of bioengineering at
    Stanford University, is one of the Company&#146;s founding
    stockholders and as such held 664,821&#160;shares of common
    stock as of December&#160;31, 2006, December&#160;29,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2007 and June&#160;28, 2008. In June 2006, the Company
    repurchased 35,421&#160;shares of the Company&#146;s common
    stock held by Dr.&#160;Quake for $1.96 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dr.&#160;Quake also serves as a consultant to the Company and is
    a member of the Company&#146;s Scientific Advisory Board. The
    Company paid consulting fees of $45,000, $97,000, $67,000,
    $50,000 and $58,000 to Dr.&#160;Quake during 2005, 2006, 2007
    and the six months ended June&#160;30, 2007 and June&#160;28,
    2008, respectively, and accrued amounts payable to
    Dr.&#160;Quake related to these payments were $0, $33,000 and
    $17,000 as of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, respectively. The Company recognized
    $205,000, $241,000, $15,000, $0 and $96,000 in revenue related
    to products and services sold to Stanford University during
    2005, 2006, 2007 and the six months ended June&#160;30, 2007 and
    June&#160;28, 2008, respectively, and had accounts receivable
    balances related to these sales of $0, $11,000 and $260,000 as
    of December&#160;31, 2006, December&#160;29, 2007 and
    June&#160;28, 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s general counsel was  also a member of a law
    firm whose services are utilized by the Company. On
    April&#160;1, 2008, the Company&#146;s general counsel resigned
    his position from such law firm. Amounts paid to the law firm
    for services and direct patent fees were $880,000, $960,000,
    $576,000, $352,000 and $312,000 for 2005, 2006, 2007 and the six
    months ended June&#160;30, 2007 and June&#160;28, 2008,
    respectively, and accrued amounts payable to the law firm were
    $174,000, $257,000 and $411,000 as of December&#160;31, 2006,
    December&#160;29, 2007 and June&#160;28, 2008, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Information
    about Geographic Areas</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;No.&#160;131, <I>Disclosures about Segments of an
    Enterprise and Related Information</I>, establishes standards
    for reporting information about operating segments. Operating
    segments are defined as components of an enterprise about which
    separate financial information is available that is evaluated
    regularly by a company&#146;s chief operating decision maker, or
    decision making group, in deciding how to allocate resources and
    in assessing performance. The chief operating decision maker for
    the Company is the Chief Executive Officer. The Chief Executive
    Officer reviews financial information presented on a
    consolidated basis, accompanied by information about revenue by
    geographic region, for purposes of allocating resources and
    evaluating financial performance. The Company has one business
    activity and there are no segment managers who are held
    accountable for operations, operating results or plans for
    levels or components below the consolidated unit level.
    Accordingly, the Company has determined that it has a single
    reporting segment and operating unit structure which is the
    development, manufacturing and commercialization of IFCs and
    complementary laboratory instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue by geography is based on the billing address of the
    customer. The following tables set forth revenue and long-lived
    assets by geographic area (in thousands):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2005</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,027
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Europe
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,398
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FLUIDIGM
    CORPORATION</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Notes to
    Consolidated Financial
    Statements&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Long-lived
    Assets</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;28,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    United States
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,818
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Singapore
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Japan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Subsequent
    Events</FONT></B>
</TD>
</TR>

</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August&#160;2008, the Board of Directors approved a 1-for-3.5
    reverse stock split of the Company&#146;s convertible preferred
    stock and common stock. The reverse split became effective on
    September&#160;16, 2008. All share and per share amounts have
    been retroactively restated in the accompanying financial
    statements and notes for all periods presented.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors authorized 2,000,000 shares of common
    stock reserved for issuance under the 2008 Equity Incentive
    Plan, which is subject to shareholder approval.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors increased the authorized capital stock of
    the Company to consist of 300,000,000 shares of common stock and
    20,000,000 shares of preferred stock effective upon the
    completion of the Company&#146;s initial public offering.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company obtained approval from the convertible preferred
    stockholders to update the automatic conversion feature to
    require the outstanding shares of the convertible preferred
    stock to convert to shares of the Company&#146;s common stock
    upon the closing of the Company&#146;s initial public offering.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a9f3943219.gif" alt="(DYNAMIC ARRAY SCHEMATIC GRAPHIC)">
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9f3943220.gif" alt="(CIRCUITS &#38; SYSTEMS GRAPHIC)">
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="f39432a9f3943216.gif" alt="(FLUIDIGM LOGO)">
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;13.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Expenses of Issuance and Distribution.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth all expenses to be paid by the
    registrant, other than estimated underwriting discounts and
    commissions, in connection with this offering. All amounts shown
    are estimates except for the SEC registration fee, the NASD
    filing fee and the NASDAQ Global Market listing fee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,833
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASD filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NASDAQ Global Market listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    105,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing and engraving
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    390,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,700,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    850,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Blue sky fees and expenses (including legal fees)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Transfer agent and registrar fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,967
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;14.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    of Directors and Officers.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;145 of the Delaware General Corporation Law
    authorizes a corporation&#146;s board of directors to grant, and
    authorizes a court to award, indemnity to officers, directors
    and other corporate agents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As permitted by Section&#160;102(b)(7) of the Delaware General
    Corporation Law, the registrant&#146;s certificate of
    incorporation includes provisions that eliminate the personal
    liability of its directors and officers for monetary damages for
    breach of their fiduciary duty as directors and officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, as permitted by Section&#160;145 of the Delaware
    General Corporation Law, the bylaws of the registrant provide
    that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant shall indemnify its directors and officers for
    serving the registrant in those capacities or for serving other
    business enterprises at the registrant&#146;s request, to the
    fullest extent permitted by Delaware law. Delaware law provides
    that a corporation may indemnify such person if such person
    acted in good faith and in a manner such person reasonably
    believed to be in or not opposed to the best interests of the
    registrant and, with respect to any criminal proceeding, had no
    reasonable cause to believe such person&#146;s conduct was
    unlawful.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may, in its discretion, indemnify employees and
    agents in those circumstances where indemnification is not
    required by law.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant is required to advance expenses, as incurred, to
    its directors and officers in connection with defending a
    proceeding, except that such director or officer shall undertake
    to repay such advances if it is ultimately determined that such
    person is not entitled to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant will not be obligated pursuant to the bylaws to
    indemnify a person with respect to proceedings initiated by that
    person, except with respect to proceedings authorized by the
    registrant&#146;s Board of Directors or brought to enforce a
    right to indemnification.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The rights conferred in the bylaws are not exclusive, and the
    registrant is authorized to enter into indemnification
    agreements with its directors, officers, employees and agents
    and to obtain insurance to indemnify such persons.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    The registrant may not retroactively amend the bylaw provisions
    to reduce its indemnification obligations to directors,
    officers, employees and agents.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The registrant&#146;s policy is to enter into separate
    indemnification agreements with each of its directors and
    officers that provide the maximum indemnity allowed to directors
    and executive officers by Section&#160;145 of the Delaware
    General Corporation Law and also provides for certain additional
    procedural protections. The registrant also maintains directors
    and officers insurance to insure such persons against certain
    liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These indemnification provisions and the indemnification
    agreements entered into between the registrant and its officers
    and directors may be sufficiently broad to permit
    indemnification of the registrant&#146;s officers and directors
    for liabilities (including reimbursement of expenses incurred)
    arising under the Securities Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriting agreement filed as Exhibit&#160;1.1 to this
    registration statement provides for indemnification by the
    underwriters of the registrant and its officers and directors
    for certain liabilities arising under the Securities Act and
    otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;15.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Sales of Unregistered Securities.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the three years prior to the filing of this registration
    statement, the registrant has issued the following unregistered
    securities:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, issued and sold an
    aggregate of 134,561&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $1.05 to $2.90, for
    aggregate consideration of $188,442. From July&#160;18, 2007
    through May&#160;22,&#160;2008, the registrant issued and sold
    an aggregate of 71,634&#160;shares of its common stock upon the
    exercise of options issued to certain employees, directors and
    consultants under the registrant&#146;s 1999 Stock Option Plan,
    as amended, at exercise prices ranging from $1.05 to $4.76 per
    share, for aggregate consideration of $123,346.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;From March 2005 through July&#160;17, 2007, Fluidigm
    Corporation, a California corporation, granted to certain of its
    employees, directors and consultants under the registrant&#146;s
    1999 Stock Option Plan, as amended, options to purchase an
    aggregate of 1,138,869&#160;shares of its common stock at
    exercise prices ranging from $1.05 to $4.76 per share. From
    July&#160;18, 2007 through May&#160;22, 2008, the registrant
    granted to certain of its employees, directors and consultants
    under the registrant&#146;s 1999 Stock Option Plan, as amended,
    options to purchase an aggregate of 129,200&#160;shares of the
    registrant&#146;s common stock at exercise prices ranging from
    $4.83 to $8.40 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (c)&#160;In March and December 2005, Fluidigm Corporation, a
    California corporation, pursuant to a loan and security
    agreement, issued and sold warrants to purchase
    106,122&#160;shares of its Series&#160;D Preferred Stock to one
    accredited investor at an exercise price of $9.80 per share. In
    connection with the registrant&#146;s reincorporation into the
    State of Delaware on July&#160;18, 2007, the warrant was
    converted into a warrant to purchase an equal number of shares
    of the registrant&#146;s Series&#160;D Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;In November 2005, Fluidigm Corporation, a California
    corporation, issued and sold 20,000&#160;shares of its common
    stock to one accredited investor at an issuance price of $1.96
    per share for aggregate monetary consideration of $39,200, which
    amount was deemed paid by the transfer of certain rights granted
    to registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;In December 2005, Fluidigm Corporation, a California
    corporation, issued 237,895&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the conversion of a convertible promissory note at a conversion
    price per share of $9.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued to one accredited investor a convertible
    promissory notes in an aggregate principal amount of $3,000,000
    convertible into shares of its Series&#160;D Preferred Stock. In
    July 2007, the notes were converted into 330,612&#160;shares of
    Series&#160;D Preferred Stock at a conversion price per share of
    $9.80.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (g)&#160;In April 2006, Fluidigm Corporation, a California
    corporation, issued an aggregate of 61,223&#160;shares of its
    Series&#160;D Preferred Stock to UAB Research Foundation
    pursuant to the terms of a Master Closing Agreement by and among
    UAB Research Foundation, Oculus Pharmaceuticals, Inc. and
    Fluidigm Corporation, at an issuance price of $9.80 per share,
    for aggregate monetary consideration of $599,998, which
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
     amount was deemed paid by the transfer of certain rights
    granted to registrant pursuant to the terms of such agreement
    and the achievement of certain milestones thereunder; at the
    request of UAB, 26,530 of such shares were issued to Oculus
    Pharmaceuticals, Inc., 10,204 of such shares were issued to
    Athersys, Inc. and 24,489 of such shares were issued to UAB
    Research Foundation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (h)&#160;In June 2006, Fluidigm Corporation, a California
    corporation, issued 76,530&#160;shares of its Series&#160;D
    Preferred Stock to one accredited investor in connection with
    the exercise of a warrant to purchase shares of its
    Series&#160;D Preferred Stock at an exercise price per share of
    $9.80.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;From August 2006 through April 2007, Fluidigm
    Corporation, a California corporation, issued three convertible
    promissory notes to one accredited investor in an aggregate
    principal amount of $15,000,000, all of which were convertible
    into shares of its Series&#160;E Preferred Stock. In March 2007,
    two of the notes were converted into an aggregate of
    844,095&#160;shares of the Series&#160;E Preferred Stock of
    Fluidigm Corporation, a California corporation. In connection
    with the registrant&#146;s reincorporation into the State of
    Delaware on July&#160;18, 2007, the remaining outstanding
    convertible promissory note was made convertible into shares of
    the registrant&#146;s Series&#160;E Preferred Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (j)&#160;In March 2007, Fluidigm Corporation, a California
    corporation, issued 28,571&#160;shares of its common stock to
    one accredited investor at an issuance price of $2.90 per share,
    for aggregate monetary consideration of $83,000, which amount
    was deemed paid by the transfer of certain rights granted to
    registrant pursuant to the terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (k)&#160;In May 2007, Fluidigm Corporation, a California
    corporation, granted to seven of its employees and directors
    under the registrant&#146;s 1999 Stock Option Plan, as amended,
    options to purchase an aggregate of 219,142&#160;shares of its
    common stock at an exercise price of $4.76 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (l)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    2,770,285&#160;shares of common stock to a total of 128
    stockholders in exchange for the outstanding shares of common
    stock Fluidigm Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (m)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of 779,220&#160;shares
    of the registrant&#146;s Series&#160;A Preferred Stock to a
    total of 41 investors in exchange for the outstanding shares of
    Series&#160;A Preferred Stock of Fluidigm Corporation, a
    California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (n)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    1,845,907&#160;shares of the registrant&#146;s Series&#160;B
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;B Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (o)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    4,675,666&#160;shares of the registrant&#146;s Series&#160;C
    Preferred Stock to a total of 62 investors in exchange for the
    outstanding shares of Series&#160;C Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (p)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    3,484,626&#160;shares of the registrant&#146;s Series&#160;D
    Preferred Stock to a total of 52 investors in exchange for the
    outstanding shares of Series&#160;D Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (q)&#160;In connection with the registrant&#146;s
    reincorporation into the State of Delaware on July&#160;18,
    2007, the registrant issued an aggregate of
    2,562,810&#160;shares of the registrant&#146;s Series&#160;E
    Preferred Stock to a total of 35 investors in exchange for the
    outstanding shares of Series&#160;E Preferred Stock of Fluidigm
    Corporation, a California corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (r)&#160;From October 2007 through December 2007, the registrant
    issued and sold an aggregate of 2,512,841&#160;shares of
    Series&#160;E Preferred Stock to a total of seven investors at
    $14.00 per share, for aggregate proceeds of $35,179,780.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (s)&#160;In December 2007, the registrant issued
    1,714&#160;shares of its common stock to one accredited investor
    at an issuance price of $4.76 per share for aggregate monetary
    consideration of $8,160, which amount was deemed paid by the
    transfer of certain rights granted to registrant pursuant to the
    terms of a licensing agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (t)&#160;In December 2007, the registrant granted to one of its
    directors under the registrant&#146;s 1999 Stock Option Plan, as
    amended, options to purchase an aggregate of 28,571&#160;shares
    of the registrant&#146;s common stock at an exercise price of
    $8.40 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (u)&#160;In February and June 2008, the registrant issued a
    warrant to purchase 28,572 and 57,142&#160;shares of the
    registrant&#146;s Series&#160;E Preferred Stock to one
    accredited investor at an exercise price of $14.00 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (v)&#160;In February 2008, the registrant granted to one of its
    executive officers under the registrant&#146;s 1999 Stock Option
    Plan, as amended, options to purchase an aggregate of
    171,427&#160;shares of the registrant&#146;s common stock at an
    exercise price of $8.40 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (w)&#160;In April 2008, the registrant granted to 110 of its
    employees, consultants and directors under the registrant&#146;s
    1999 Stock Option Plan, as amended, options to purchase an
    aggregate of 546,711&#160;shares of its common stock at an
    exercise price of $11.16 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (x)&#160;On May&#160;12, 2008, the registrant issued
    4,692&#160;shares of its Series&#160;C Preferred Stock to
    Imperial Bank pursuant to Imperial Bank&#146;s net exercise of
    its warrant to purchase up to 11,795&#160;shares of
    Series&#160;C Preferred Stock. The remainder of the warrant was
    cancelled pursuant to the terms of the net exercise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (y)&#160;In June 2008, the registrant granted to seven of its
    employees and consultants under the registrant&#146;s 1999 Stock
    Option Plan, as amended, options to purchase an aggregate of
    24,426&#160;shares of its common stock at an exercise price of
    $11.97 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (z)&#160;In August 2008, the registrant granted to eight of its
    employees under the registrant&#146;s 1999 Stock Option Plan, as
    amended, options to purchase an aggregate of 18,426&#160;shares
    of its common stock at an exercise price of $12.71 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of the foregoing transactions involved any underwriters,
    underwriting discounts or commissions, or any public offering,
    and the registrant believes that each transaction was exempt
    from the registration requirements of the Securities Act in
    reliance on the following exemptions:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (a)&#160;and (b), Rule&#160;701 promulgated under the Securities
    Act as transactions pursuant to a compensatory benefit plan
    approved by the registrant&#146;s Board of Directors;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs (1)
    through (q), Rule&#160;145(a)(2) promulgated under the
    Securities Act as transactions pursuant to a plan or agreement
    for statutory merger or similar plan or acquisition in which
    securities of the registrant were exchanged for the securities
    of Fluidigm Corporation, a California corporation, the sole
    purpose of which was to change the registrant&#146;s domicile
    solely within the United States, and a Permit granted pursuant
    to Section 25121 of the California Corporations Code;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    with respect to the transactions described in paragraphs
    (c)&#160;through (k) and paragraphs (r) through (z),
    Section&#160;4(2) of the Securities Act, or Rule&#160;506 of
    Regulation&#160;D promulgated thereunder, as transactions by an
    issuer not involving a public offering. Each recipient of the
    securities in this transaction represented his or her intention
    to acquire the securities for investment only and not with a
    view to, or for resale in connection with, any distribution
    thereof, and appropriate legends were affixed to the share
    certificates issued in each such transaction. In each case, the
    recipient received adequate information about the registrant or
    had adequate access, through his or her relationship with the
    registrant, to information about the registrant.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;16.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Exhibits
    and Financial Statement Schedules.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;<I>Exhibits.</I>&#160;&#160;The following exhibits are
    included herein or incorporated herein by reference:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through December&#160;31, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte Ltd and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte Ltd dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .6
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Action By Written Consent of the holders of Preferred Stock of
    the Registrant effective as of August&#160;25, 2008 consenting
    to the Conversion of all Preferred Stock.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended April&#160;24,
    2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment, effective as of December&#160;1, 2007, to the
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Letter Agreement between President and Fellows of Harvard
    College and the Registrant dated December&#160;22, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .19
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Sublease, dated March&#160;25, 2004, between Genome Therapeutics
    Corporation as Sublessor and Fluidigm Corporation as Sublessee
    and amendment thereto, and related master lease agreements and
    amendments thereto.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .20
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Tenancy for Flatted Factory Space in Singapore between JTC
    Corporation and the Registrant dated July 27, 2005 and August
    12, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">To be filed by amendment.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Confidential treatment has been
    requested with respect to certain portions of this exhibit.
    Omitted portions have been filed separately with the Securities
    and Exchange Commission.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Previously filed.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;<I>Financial Statement Schedules.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All schedules have been omitted because the information required
    to be presented in them is not applicable or is shown in the
    consolidated financial statements or related notes.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;17.&#160;&#160;<I>Undertakings.</I></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriters at the closing specified in the underwriting
    agreement certificates in such denominations and registered in
    such names as required by the underwriters to permit prompt
    delivery to each purchaser.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act of 1933&#160;may be permitted to directors,
    officers and controlling persons of the registrant pursuant to
    the foregoing provisions, or otherwise, the registrant has been
    advised that in the opinion of the Securities and Exchange
    Commission such indemnification is against public policy as
    expressed in the Act and is, therefore, unenforceable. In the
    event that a claim for indemnification against such liabilities
    (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the
    registrant in the successful defense of any action, suit or
    proceeding) is asserted by such director, officer or controlling
    person in connection with the securities being registered, the
    registrant will, unless in the opinion of its counsel the matter
    has been settled by controlling precedent, submit to a court of
    appropriate jurisdiction the question whether such
    indemnification by it is against public policy as expressed in
    the Act and will be governed by the final adjudication of such
    issue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;For purposes of determining any liability under the
    Securities Act of 1933, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant pursuant to
    Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities
    Act shall be deemed to be part of this registration statement as
    of the time it was declared effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;For the purpose of determining any liability under the
    Securities Act of 1933, each post effective amendment that
    contains a form of prospectus shall be deemed to be a new
    registration statement relating to the securities offered
    therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;For the purpose of determining liability under the
    Securities Act of 1933 to any purchaser, if the registrant is
    subject to Rule&#160;430C, each prospectus filed pursuant to
    Rule&#160;424(b) as part of a registration statement relating to
    an offering, other than registration statements relying on
    Rule&#160;430B or other than prospectuses filed in reliance on
    Rule 430A, shall be deemed to be part of and included in the
    registration statement as of the date it is first used after
    effectiveness; provided, however, that no statement made in a
    registration statement or prospectus that is part of the
    registration statement or made in a document incorporated or
    deemed incorporated by reference into the registration statement
    or prospectus that is part of the registration statement will,
    as to a purchaser with a time of contract of sale prior to such
    first use, supersede or modify any statement that was made in
    the registration statement or prospectus that was part of the
    registration statement or made in any such document immediately
    prior to such date of first use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;For the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser to
    the initial distribution of the securities, the undersigned
    registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell
    the securities to the purchaser, if the securities are offered
    or sold to such purchaser by means of any of the following
    communications, the undersigned registrant will be a seller to
    the purchasers and will be considered to offer or sell such
    securities to such purchaser:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be
    filed pursuant to Rule&#160;424;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used
    or referred to by the undersigned registrant;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;The portion of any other free writing prospectus
    relating to the offering containing material information about
    the undersigned registrant or its securities provided by or on
    behalf of the undersigned registrant;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, the
    Registrant has duly caused this Amendment No.&#160;9 to the
    registration statement to be signed on its behalf by the
    undersigned, thereunto duly authorized, in the City of South San
    Francisco, State of California, on the 17th day of September
    2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>FLUIDIGM CORPORATION</B>
</DIV>

<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="center">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Gajus V. Worthington
</DIV>

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>President and Chief Executive Officer</I>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    Amendment No. 9 to the registration statement has been signed by
    the following persons in the capacities indicated on the 17th
    day of September&#160;2008.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="38%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="17%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Date</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Gajus
    V. Worthington
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    President, Chief Executive Officer and Director (Principal
    Executive Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Vikram
    Jog</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Vikram
    Jog
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Chief Financial Officer (Principal Accounting and Financial
    Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Samuel
    Colella
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Michael
    W. Hunkapiller
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Elaine
    V. Jones
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->Kenneth
    Nussbacher
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%"><FONT style="font-variant: SMALL-CAPS">*</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=198 length=0 -->John
    A. Young
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    September&#160;17, 2008
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    *By:
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Gajus
    V. Worthington</FONT></DIV><BR>
    <CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=208 iwidth=174 length=0 -->Gajus
    V. Worthington<BR>
    Attorney-in-Fact
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;INDEX</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certificate of Incorporation of the Registrant, as currently in
    effect.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Restated Certificate of Incorporation of the Registrant,
    to be in effect upon the completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Bylaws of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Amended and Restated Bylaws of the Registrant, to be in
    effect upon completion of this offering.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Common Stock Certificate of the Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;E Preferred Stock Purchase Agreement dated
    June&#160;13, 2006 through December&#160;31, 2007 between the
    Registrant and the Purchasers set forth therein, as amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Eighth Amended and Restated Investor Rights Agreement between
    the Registrant and certain holders of the Registrant&#146;s
    common stock named therein, including amendments No.&#160;1 and
    No.&#160;2.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Loan and Security Agreement No.&#160;4561 between the Registrant
    and Lighthouse Capital Partners&#160;V, L.P. dated
    March&#160;29, 2005, including amendments Nos. 1 through 4.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Preferred Stock Purchase Warrant issued to Lighthouse Capital
    Partners&#160;V, L.P. effective March&#160;29, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .4B<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Negative Pledge Agreement by and between the Registrant and
    Lighthouse Capital Partners&#160;V, L.P. dated March&#160;29,
    2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Note Purchase Agreement by and between Biomedical
    Sciences Investment Fund&#160;Pte Ltd and the Registrant dated
    August&#160;7, 2006.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Convertible Promissory Note issued to Biomedical Sciences
    Investment Fund&#160;Pte Ltd dated April&#160;19, 2007, as
    amended.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    4
</TD>
<TD nowrap align="left" valign="top">
    .6
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Action By Written Consent of the holders of Preferred Stock of
    the Registrant effective as of August&#160;25, 2008 consenting
    to the Conversion of all Preferred Stock.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement between the Registrant and its
    directors and officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    1999 Stock Plan of the Registrant, as amended April&#160;24,
    2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 1999 Stock Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Forms of agreements under the 2008 Equity Incentive Plan.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated License Agreement by and between
    California Institute of Technology and the Registrant effective
    as of May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Addendum, effective as of March&#160;29, 2007, to Second
    Amended and Restated License Agreement by and between California
    Institute of Technology and the Registrant effective as of
    May&#160;1, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to Co-Exclusive License Agreement between
    President and Fellows of Harvard College and the Registrant
    effective as of October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Co-Exclusive License Agreement between President and Fellows of
    Harvard College and the Registrant effective as of
    October&#160;15, 2000.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Patent License Agreement by and between Gyros AB and the
    Registrant dated January&#160;9, 2003.
</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left"><FONT size="1">

</FONT></DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="85%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Description</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 dated January&#160;9, 2005 to Patent
    License Agreement by and between Gyros AB and the Registrant
    dated January&#160;9, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Master Closing Agreement by and between UAB Research Foundation,
    Oculus Pharmaceuticals, Inc. and the Registrant dated
    March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement by and between UAB Research Foundation and the
    Registrant dated March&#160;7, 2003.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    October&#160;7, 2005), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10A<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Supplement Dated January&#160;11, 2006 to Letter Agreement
    Relating to Application for Incentives under the Research
    Incentive Scheme for Companies (RISC), dated October&#160;7,
    2005 between Singapore Economic Development Board and Fluidigm
    Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Letter Agreement Regarding Application for
    Incentives Under the Research Incentive Scheme for Companies
    (RISC) dated March&#160;27, 2008 (originally dated
    February&#160;12, 2007), by and between Singapore Economic
    Development Board and Fluidigm Singapore Pte. Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment, effective as of December&#160;1, 2007, to the
    Distribution Agreement by and between Eppendorf AG and the
    Registrant effective as of April&#160;1, 2005.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Employment and Severance Agreement between the
    Registrant and each of its executive officers.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consulting Agreement by and between the Registrant and Richard
    DeLateur dated February&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employee Loan Agreement with Gajus Worthington dated
    January&#160;20, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15A<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Repurchase Agreement between the Registrant and Gajus V.
    Worthington dated April&#160;10, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Offer Letter to Vikram Jog dated January&#160;29, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Settlement Agreement and General Release of all Claims by and
    between Michael Ybarra Lucero and the Registrant dated
    March&#160;20, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18<SUP style="font-size: 85%; vertical-align: text-top">(2)(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Letter Agreement between President and Fellows of Harvard
    College and the Registrant dated December&#160;22, 2004.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .19
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Sublease, dated March&#160;25, 2004, between Genome Therapeutics
    Corporation as Sublessor and Fluidigm Corporation as Sublessee
    and amendment thereto, and related master lease agreements and
    amendments thereto.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .20
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Tenancy for Flatted Factory Space in Singapore between JTC
    Corporation and the Registrant dated July 27, 2005 and August
    12, 2008.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    List of subsidiaries of Registrant.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Wilson Sonsini Goodrich&#160;&#038; Rosati,
    Professional Corporation (included in Exhibit&#160;5.1).
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    24
</TD>
<TD nowrap align="left" valign="top">
    .1<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Power of Attorney.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 12pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">To be filed by amendment.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Confidential treatment has been
    requested with respect to certain portions of this exhibit.
    Omitted portions have been filed separately with the Securities
    and Exchange Commission.
    </FONT></TD>
</TR>



<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Previously filed.
    </FONT></TD>
</TR>

</TABLE>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>f39432a9exv1w1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv1w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>5,300,000 SHARES</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>COMMON STOCK, PAR VALUE $0.001 PER SHARE</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>UNDERWRITING AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">September &#091;__&#093;, 2008
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">September &#091;__&#093;, 2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. Incorporated<BR>
UBS Securities LLC<BR>
Leerink Swan LLC<BR>
Pacific Growth Equities LLC

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">c/o</TD>
    <TD>&nbsp;</TD>
    <TD>Morgan Stanley &#038; Co. Incorporated<BR>
1585 Broadway<BR>
New York, New York 10036</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes to issue and sell to
the several Underwriters named in Schedule&nbsp;I hereto (the &#147;<B>Underwriters</B>&#148;) 5,300,000 shares of its
common stock, par value $0.001 per share (the &#147;<B>Firm Shares</B>&#148;). The Company also proposes to issue
and sell to the several Underwriters not more than an additional 795,000 shares of its common
stock, par value $0.001 per share (the &#147;<B>Additional Shares</B>&#148;) if and to the extent that you, as
Manager of the offering, shall have determined to exercise, on behalf of the Underwriters, the
right to purchase such shares of common stock granted to the Underwriters in Section&nbsp;2 hereof. The
Firm Shares and the Additional Shares are hereinafter collectively referred to as the &#147;<B>Shares</B>.&#148; The
shares of common stock, par value $0.001 per share, of the Company to be outstanding after giving
effect to the sales contemplated hereby are hereinafter referred to as the &#147;<B>Common Stock</B>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a
registration statement, including a prospectus, relating to the Shares. The registration statement
as amended at the time it becomes effective, including the information (if any) deemed to be part
of the registration statement at the time of effectiveness pursuant to Rule&nbsp;430A under the
Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), is hereinafter referred to as the
&#147;<B>Registration Statement</B>&#148;; the prospectus in the form first used to confirm sales of Shares (or in
the form first made available to the Underwriters by the Company to meet requests of purchasers
pursuant to Rule&nbsp;173 under the Securities Act) is hereinafter referred to as the &#147;<B>Prospectus</B>.&#148; If
the Company has filed an abbreviated registration statement to register additional shares of Common
Stock pursuant to Rule 462(b) under the Securities Act (the &#147;<B>Rule&nbsp;462 Registration Statement</B>&#148;),
then any reference herein to the term &#147;<B>Registration Statement</B>&#148; shall be deemed to include such Rule
462 Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;<B>free writing prospectus</B>&#148; has the meaning set forth in Rule
405 under the Securities Act, &#147;<B>Time of Sale Prospectus</B>&#148; means the preliminary prospectus together with the free writing prospectuses, if any, each identified in
Schedule&nbsp;II hereto, and &#147;<B>broadly available road show</B>&#148; means a &#147;bona fide electronic road show&#148; as
defined in Rule&nbsp;433(h)(5) under the Securities Act that has been made available without restriction
to any person. As used herein, the terms &#147;Registration Statement,&#148; &#147;preliminary prospectus,&#148; &#147;Time
of Sale
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Prospectus&#148; and &#147;Prospectus&#148; shall include the documents, if any, incorporated by reference
therein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<I>Representations and Warranties</I>. The Company represents and warrants to and agrees with
each of the Underwriters that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Registration Statement has become effective; no stop order suspending the
effectiveness of the Registration Statement is in effect, and no proceedings for such purpose are
pending before or, to the Company&#146;s knowledge, threatened by the Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;(i)&nbsp;The Registration Statement, when it became effective, did not contain and, as amended
or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not
misleading, (ii)&nbsp;the Registration Statement and the Prospectus comply and, as amended or
supplemented, if applicable, will comply in all material respects with the Securities Act and the
applicable rules and regulations of the Commission thereunder, (iii)&nbsp;the Time of Sale Prospectus
does not, and at the time of each sale of the Shares in connection with the offering when the
Prospectus is not yet available to prospective purchasers and at the Closing Date (as defined in
Section&nbsp;4), the Time of Sale Prospectus, as then amended or supplemented by the Company, if
applicable, will not, contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, (iv)&nbsp;each broadly available road show, if any, when considered together
with the Time of Sale Prospectus, does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading and (v)&nbsp;the Prospectus does not contain
and, as amended or supplemented, if applicable, will not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, except that the representations and
warranties set forth in this paragraph do not apply to statements or omissions in the Registration
Statement, the Time of Sale Prospectus or the Prospectus based upon information relating to any
Underwriter furnished to the Company in writing by such Underwriter through you expressly for use
therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Any statistical and market-related data included in the Registration Statement, the Time
of Sale Prospectus and the Prospectus are based on or derived from sources that the Company
believes to be reliable and accurate, and is consistent with the sources from which they are
derived.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not an &#147;ineligible issuer&#148; in connection with the offering pursuant to
Rules&nbsp;164, 405 and 433 under the Securities Act. Any free writing prospectus that the Company is
required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with
the Commission in accordance with the requirements of the Securities Act and the applicable rules
and regulations of the Commission thereunder. Each free writing prospectus that the Company has
filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was
prepared by or on behalf of or used or referred to by the Company complies or will comply in all
material respects with the requirements of the Securities Act and the applicable rules and
regulations of the Commission thereunder. Except for the free writing
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">prospectuses, if any, identified in Schedule&nbsp;II hereto, and electronic road shows, if any, furnished to you before first
use, the Company has not prepared, used or referred to, and will not, without your prior consent,
prepare, use or refer to, any free writing prospectus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company has been duly incorporated, is validly existing as a corporation in good
standing under the laws of the jurisdiction of its incorporation, has the corporate power and
authority to own its property and to conduct its business as described in the Time of Sale
Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction
in which the conduct of its business or its ownership or leasing of property requires such
qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a material adverse effect on the Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Each subsidiary of the Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of the jurisdiction of its incorporation, has the
corporate power and authority to own its property and to conduct its business as described in the
Time of Sale Prospectus and is duly qualified to transact business and is in good standing in each
jurisdiction, to the extent that the concept of &#147;good standing&#148; is applicable under the laws of
such jurisdiction, in which the conduct of its business or its ownership or leasing of property
requires such qualification, except to the extent that the failure to be so qualified or be in good
standing would not have a material adverse effect on the Company and its subsidiaries, taken as a
whole; all of the issued shares of capital stock of each subsidiary of the Company have been duly
and validly authorized and issued, are fully paid and non-assessable and are owned directly by the
Company, free and clear of all liens, encumbrances, equities or claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;This Agreement has been duly authorized, executed and delivered by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;The authorized capital stock of the Company conforms as to legal matters to the
description thereof contained in the Section entitled &#147;Description of Capital Stock&#148; in each of the
Time of Sale Prospectus and the Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The shares of Common Stock outstanding prior to the issuance of the Shares have been duly
authorized and are validly issued, fully paid and non-assessable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;The Shares have been duly authorized and, when issued, delivered and paid for in
accordance with the terms of this Agreement, will be validly issued, fully paid and non-assessable,
and the issuance of such Shares will not be subject to any preemptive or similar rights which have
not otherwise been waived.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;The execution and delivery by the Company of, and the performance by the Company of its
obligations under, this Agreement will not contravene any provision of (i)&nbsp;applicable law; (ii)&nbsp;the
certificate of incorporation or bylaws of the Company; (iii)&nbsp;any agreement or other instrument
binding upon the Company or any of its subsidiaries that is material to the Company and its
subsidiaries, taken as a whole; or (iv)&nbsp;any judgment, order or decree of any governmental body,
agency or court having jurisdiction over the Company or any subsidiary, except that in the case of
clause (iii)&nbsp;as would not have a material adverse effect on the Company and its subsidiaries, taken
as a whole, or on the power or ability of the Company to perform its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">obligations under this Agreement, and no consent, approval, authorization or order of, or qualification with, any
governmental body or agency is required for the performance by the Company of its obligations under
this Agreement, except such as may be required by the securities or Blue Sky laws of the various
states or the rules and regulations of the Financial Industry Regulatory Authority (&#147;<B>FINRA</B>&#148;) in
connection with the offer and sale of the Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;There has not occurred any material adverse change, or any development involving a
prospective material adverse change, in the condition, financial or otherwise, or in the earnings,
business or operations of the Company and its subsidiaries, taken as a whole, from that set forth
in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;There are no legal or governmental proceedings pending or to the Company&#146;s knowledge
threatened to which the Company or any of its subsidiaries is a party or to which any of the
properties of the Company or any of its subsidiaries is subject (i)&nbsp;other than proceedings
accurately described in all material respects in the Time of Sale Prospectus and proceedings that
would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, or
on the power or ability of the Company to perform its obligations under this Agreement or to
consummate the transactions contemplated by the Time of Sale Prospectus or (ii)&nbsp;that are required
to be described in the Registration Statement or the Prospectus and are not so described; and there
are no statutes, regulations, contracts or other documents that are required to be described in the
Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement
that are not described or filed as required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;Each preliminary prospectus filed as part of the registration statement as originally
filed or as part of any amendment thereto, or filed pursuant to Rule&nbsp;424 under the Securities Act,
complied as to form when so filed in all material respects with the Securities Act and the
applicable rules and regulations of the Commission thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;The Company is not, and after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in the Prospectus will not
be, required to register as an &#147;investment company&#148; as such term is defined in the Investment
Company Act of 1940, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;The Company and its subsidiaries (i)&nbsp;are in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health
and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(&#147;<B>Environmental Laws</B>&#148;), (ii)&nbsp;have received all permits, licenses or other approvals required of
them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in
compliance with all terms and conditions of any such permit, license or approval, except where such
noncompliance with Environmental Laws, failure to receive required permits, licenses or other
approvals or failure to comply with the terms and conditions of such permits, licenses or approvals
would not, singly or in the aggregate, be reasonably likely to have a material adverse effect on
the Company and its subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;There are no costs or liabilities associated with Environmental Laws (including, without
limitation, any capital or operating expenditures required for clean-up, closure of properties or
compliance with Environmental Laws or any permit, license or approval, any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">related constraints on
operating activities and any potential liabilities to third parties) which would, singly or in the
aggregate, be reasonably likely to have a material adverse effect on the Company and its
subsidiaries, taken as a whole.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;The accountants who certified the financial statements and supporting schedules included
in the Registration Statement are independent public accountants with respect to the Company as
required by the Securities Act and the applicable rules and regulations of the Commission
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)&nbsp;The financial statements of the Company filed with the Commission as a part of the
Registration Statement and included in each of the Time of Sale Prospectus and the Prospectus
present fairly in all material respects the consolidated financial position of the Company and its
subsidiaries as of the dates indicated and the results of their statement of operations,
stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been
prepared in conformity with generally accepted accounting principles as applied in the United
States (&#147;<B>GAAP</B>&#148;) applied on a consistent basis throughout the periods involved. The financial data
set forth in the Prospectus under the captions &#147;Prospectus Summary &#151; Summary Consolidated
Financial Data,&#148; &#147;Selected Consolidated Financial Data&#148; and &#147;Capitalization&#148; present fairly in all
material respects the information set forth therein on a basis consistent with that of the audited
financial statements contained in the Registration Statement, the Time of Sale Prospectus and the
Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t)&nbsp;Except as described in the Time of Sale Prospectus, there are no contracts, agreements or
understandings between the Company and any person granting such person the right to require the
Company to file a registration statement under the Securities Act with respect to any securities of
the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement,
except as otherwise have been waived in connection with the issuance and sale of the Shares
contemplated hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u)&nbsp;Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any
director, officer, agent, representative, employee or affiliate of the Company or of any of its
subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a
violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules
and regulations thereunder (the &#147;<B>FCPA</B>&#148;), including, without limitation, taking any action in
furtherance of an offer, payment, promise to pay, or authorization or approval of the payment or
giving of money, property, gift or anything else of value, directly or indirectly, to any &#147;foreign
official&#148; (as such term is defined in the FCPA) or to any foreign political party or official
thereof or any candidate for foreign political office in contravention of the FCPA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;The operations of the Company and those of its subsidiaries are, and have been conducted,
in compliance with (i)&nbsp;all applicable financial recordkeeping and reporting requirements, including
those of the Bank Secrecy Act of 1970 and Title III of the Uniting and Strengthening America by
Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT
Act) except where noncompliance would not, singly or in the aggregate, be reasonably likely to have
a material adverse effect on the Company and its subsidiaries, taken as a whole, and (ii)&nbsp;to the
best of the Company&#146;s knowledge, all other applicable anti-money laundering statutes of all
jurisdictions, the rules and regulations
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any governmental agency (the &#147;<B>Anti-Money
Laundering Laws</B>&#148;). No action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its subsidiaries with respect
to (i)&nbsp;the Bank Secrecy Act of 1970 and Title III of the USA PATRIOT Act or (ii)&nbsp;the Anti-Money
Laundering Laws is pending or, to the best of the Company&#146;s knowledge, threatened.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w)&nbsp;None of the Company, any of its subsidiaries or, to the knowledge of the Company, any
director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is an
individual or entity (&#147;<B>Person</B>&#148;) that is currently the subject of any U.S. sanctions administered by
the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC-administered
sanctions</B>&#148;); and the Company will not directly or indirectly use the proceeds of the offering of
Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other Person, to fund activities of or business with any Person, or in any
country or territory, that is the subject of OFAC-administered sanctions, or in a manner that would
otherwise cause any Person (including any Person involved in or facilitating the offering of the
Shares, whether as underwriter, advisor, or otherwise) to violate any OFAC-administered sanctions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;Subsequent to the respective dates as of which information is given in each of the
Registration Statement, the Time of Sale Prospectus and the Prospectus, (i)&nbsp;the Company and its
subsidiaries have not incurred any material liability or obligation, direct or contingent, nor
entered into any material transaction; (ii)&nbsp;the Company has not purchased any of its outstanding
capital stock other than capital stock from its employees or other service providers in connection
with the termination of their service pursuant to employee benefit plans disclosed in the
Registration Statement or agreements to provide employment or consulting services to the Company,
nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock
other than ordinary and customary dividends; and (iii)&nbsp;there has not been any material change in
the capital stock, short-term debt or long-term debt of the Company and its subsidiaries, except in
each case as described in each of the Registration Statement, the Time of Sale Prospectus and the
Prospectus, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y)&nbsp;Neither the Company nor its subsidiaries own any real property. The Company and its
subsidiaries have good and marketable title to all personal property owned by them which is
material to the business of the Company and its subsidiaries taken as a whole, in each case free
and clear of all liens, encumbrances and defects of title except such as are described in the Time
of Sale Prospectus or do not materially affect the value of such property and do not interfere with
the use made and proposed to be made of such property by the Company and its subsidiaries; and any
real property and buildings held under lease by the Company and its subsidiaries are held by them
under valid, subsisting and enforceable leases with such exceptions as are not material and do not
materially interfere with the use made and proposed to be made of such property and buildings by
the Company and its subsidiaries, in each case except as described in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z)&nbsp;Except as described in the Registration Statement, Time of Sale Prospectus, and the
Prospectus: (i)&nbsp;the Company owns, or possesses, or has rights to, or can acquire on reasonable
terms all Intellectual Property reasonably necessary to conduct the business of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company as described in the Registration Statement, Time of Sale Prospectus, and the Prospectus (&#147;<B>Company
Intellectual Property</B>&#148;), except where the failure to own or possess or the inability to acquire on
reasonable terms any of the foregoing would not, individually or in the aggregate, have a material
adverse effect on the Company and its susidiaries taken as a whole; (ii)&nbsp;to the Company&#146;s
knowledge, there is no infringement, misappropriation, or violation by third parties of any Company
Intellectual Property, which individually or in the aggregate would have a material adverse effect
of the Company and its subsidiaries taken as a whole; (iii)&nbsp;neither the Company nor any of its
subsidiaries has received any written threat or notice of action, suit, proceeding, or claim by
others challenging the Company&#146;s rights in or to the Company Intellectual Property, nor is there
any such action or proceeding currently pending; (iv)&nbsp;neither the Company nor any of its
subsidiaries have received any written threat or notice of action, suit, proceeding, or claim by
others claiming the invalidity or unenforceability of the Company Intellectual Property, nor is
there any such action or proceeding currently pending and (v)&nbsp;neither the Company nor any of its
subsidiaries has received any written threat or notice of infringement of or conflict with asserted rights of
others with respect to any Intellectual Property which, with respect to (iii)&nbsp;through (v),
individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding,
would have a material adverse effect on the Company and its subsidiaries taken as a whole. The
term &#147;<B>Intellectual Property&#148; </B>as used in this section means all material, valid, and enforceable
patents, patent applications, trade and service marks, trade and service mark registrations, trade
names, copyrights, licenses, inventions, trade secrets, technology, and know-how.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa)&nbsp;No material labor dispute with the employees of the Company or any of its subsidiaries
exists, except as described in the Time of Sale Prospectus, or, to the knowledge of the Company, is
imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by
the employees of any of its principal suppliers, manufacturers or contractors that would be
reasonably likely to have a material adverse effect on the Company and its subsidiaries, taken as a
whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb)&nbsp;The Company and each of its subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as are prudent and customary in
the businesses in which they are engaged; neither the Company nor any of its subsidiaries has been
refused any insurance coverage sought or applied for; and neither the Company nor any of its
subsidiaries has any reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers as
may be necessary to continue its business at a cost that would not be reasonably likely to have a
material adverse effect on the Company and its subsidiaries, taken as a whole, except as described
in the Time of Sale Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc)&nbsp;The Company and its subsidiaries possess all certificates, authorizations and permits
issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct
their respective businesses, except where the failure to obtain such certificates, authorizations,
or permits would not, individually or in the aggregate, have a material adverse effect on the
Company and its subsidiaries, taken as a whole, and neither the Company nor any of its subsidiaries
has received any notice of proceedings relating to the revocation or modification of any such
certificate, authorization or permit which, singly or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, would have a material adverse effect on
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Company and its subsidiaries, taken as a whole, except as described in the Time of Sale Prospectus.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd)&nbsp;All United States federal income tax returns of the Company and its subsidiaries required
by law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which
are due and payable, have been paid, except assessments against which appeals have been or will be
promptly taken and as to which adequate reserves have been provided. The Company and its
subsidiaries have filed all other tax returns that are required to have been filed by them pursuant
to applicable foreign, state, local or other law except insofar as the failure to file such returns
would not, singly or in the aggregate, result in a material adverse effect on the Company and its
subsidiaries taken as a whole, and has paid all taxes due pursuant to such returns or pursuant to
any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are
being contested in good faith and as to which adequate reserves have been provided.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee)&nbsp;The Company and each of its subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are recorded as
necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted
only in accordance with management&#146;s general or specific authorization; and (iv)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. Except as described in the Time of
Sale Prospectus, since the end of the Company&#146;s most recent audited fiscal year, there has been (i)
no material weakness in the Company&#146;s internal control over financial reporting (whether or not
remediated) and (ii)&nbsp;no change in the Company&#146;s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control
over financial reporting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff)&nbsp;The Company has taken all necessary actions to ensure that, upon the effectiveness of the
Registration Statement, it will be in compliance in all material respects with all provisions of
the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing
the provisions thereof (the &#147;<B>Sarbanes-Oxley Act</B>&#148;) that are then in effect and which the Company is
required to comply with as of the effectiveness of the Registration Statement, and is actively
taking steps to ensure that it will be in compliance with other provisions of the Sarbanes-Oxley
Act which the Company is not required to comply with, upon the applicability of such provisions to
the Company, at all times after the effectiveness of the Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg)&nbsp;Except with respect to any such failure to comply that has been corrected by the date of
this Agreement, or would not, individually or in the aggregate, have a material adverse effect on
the Company, (i)&nbsp;all stock option awards granted by the Company have been duly authorized by all
necessary corporate action, including, as applicable, approval by the board of directors of the
Company or a duly authorized committee thereof, including approval of the exercise or purchase
price or the methodology for determining the exercise or purchase price and the substantive terms
of the stock options awards, and any required stockholder approval by the necessary number of votes
or written consents; and (ii)&nbsp;no stock option awards granted by the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company have been retroactively
granted, or the exercise or purchase price of any stock option award determined retroactively;
there is no action, suit, proceeding, formal inquiry or formal investigation before or brought by
any court or governmental agency or body, domestic or foreign, or the Nasdaq Global Market or any
self regulatory organization, now pending, or, to the knowledge of the Company, threatened, against or affecting the Company
in connection with any stock option awards granted by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh)&nbsp;Except as described in the Time of Sale Prospectus, the Company has not sold, issued or
distributed any shares of Common Stock during the six-month period preceding the date hereof,
including any sales pursuant to Rule&nbsp;144A under, or Regulation&nbsp;D or S of, the Securities Act, other
than shares issued pursuant to employee benefit plans, qualified stock option plans or other
employee compensation plans or pursuant to outstanding options, rights or warrants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<I>Agreements to Sell and Purchase. </I>The Company hereby agrees to sell to the several
Underwriters, and each Underwriter, upon the basis of the representations and warranties herein
contained, but subject to the conditions hereinafter stated, agrees, severally and not jointly, to
purchase from the Company the respective numbers of Firm Shares set forth in Schedule&nbsp;I hereto
opposite its name at $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a share (the &#147;<B>Purchase Price</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the representations and warranties contained in this Agreement, and subject to
its terms and conditions, the Company agrees to sell to the Underwriters the Additional Shares, and
the Underwriters shall have the right to purchase, severally and not jointly, up to 795,000
Additional Shares at the Purchase Price. You may exercise this right on behalf of the Underwriters
in whole or from time to time in part by giving written notice not later than 30&nbsp;days after the
date of this Agreement. Any exercise notice shall specify the number of Additional Shares to be
purchased by the Underwriters and the date on which such shares are to be purchased. Each purchase
date must be at least one business day after the written notice is given and may not be earlier
than the closing date for the Firm Shares nor later than ten business days after the date of such
notice. Additional Shares may be purchased as provided in Section&nbsp;4 hereof solely for the purpose
of covering over-allotments made in connection with the offering of the Firm Shares. On each day,
if any, that Additional Shares are to be purchased (an &#147;<B>Option Closing Date</B>&#148;), each Underwriter
agrees, severally and not jointly, to purchase the number of Additional Shares (subject to such
adjustments to eliminate fractional shares as you may determine) that bears the same proportion to
the total number of Additional Shares to be purchased on such Option Closing Date as the number of
Firm Shares set forth in Schedule&nbsp;I hereto opposite the name of such Underwriter bears to the total
number of Firm Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<I>Terms of Public Offering</I>. The Company is advised by you that the Underwriters propose to
make a public offering of their respective portions of the Shares as soon after the Registration
Statement and this Agreement have become effective as in your judgment is advisable. The Company
is further advised by you that the Shares are to be offered to the public initially at $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
share (the &#147;<B>Public Offering Price</B>&#148;) and to certain dealers selected by you at a price that
represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a share under the Public Offering Price, and that
any Underwriter may allow, and such dealers may reallow, a concession, not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a share, to any Underwriter or to
certain other dealers.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<I>Payment and Delivery. </I>Payment for the Firm Shares shall be made to the Company in Federal
or other funds immediately available in New York City against delivery of such Firm Shares for the
respective accounts of the several Underwriters at 10:00&nbsp;a.m., New York City time, on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2008, or at such other time on the same or such other date, not later than <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2008, as
shall be designated in writing by you. The time and date of such payment are hereinafter referred
to as the &#147;<B>Closing Date</B>.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment for any Additional Shares shall be made to the Company in Federal or other funds
immediately available in New York City against delivery of such Additional Shares for the
respective accounts of the several Underwriters at 10:00&nbsp;a.m., New York City time, on the date
specified in the corresponding notice described in Section&nbsp;2 or at such other time on the same or
on such other date, in any event not later than <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2008, as shall be designated in writing by
you.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Firm Shares and Additional Shares shall be registered in such names and in such
denominations as you shall request in writing not later than one full business day prior to the
Closing Date or the applicable Option Closing Date, as the case may be. The Firm Shares and
Additional Shares shall be delivered to you on the Closing Date or an Option Closing Date, as the
case may be, for the respective accounts of the several Underwriters, with any transfer taxes
payable in connection with the transfer of the Shares to the Underwriters duly paid, against
payment of the Purchase Price therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<I>Conditions to the Underwriters&#146; Obligations</I>. The obligations of the Company to sell the
Shares to the Underwriters and the several obligations of the Underwriters to purchase and pay for
the Shares on the Closing Date are subject to the condition that the Registration Statement shall
have become effective not later than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(New York City time) on the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The several obligations of the Underwriters are subject to the following further conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subsequent to the execution and delivery of this Agreement and prior to the Closing Date:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) there shall not have occurred any downgrading, nor shall any notice have been
given of any intended or potential downgrading or of any review for a possible change that
does not indicate the direction of the possible change, in the rating accorded any of the
securities of the Company or any of its subsidiaries by any &#147;nationally recognized
statistical rating organization,&#148; as such term is defined for purposes of Rule&nbsp;436(g)(2)
under the Securities Act; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) there shall not have occurred any change, or any development involving a
prospective change, in the condition, financial or otherwise, or in the earnings, business
or operations of the Company and its subsidiaries, taken as a whole, from that set forth in
the Time of Sale Prospectus as of the date of this Agreement that, in your judgment, is
material and adverse and that makes it, in your judgment, impracticable to market the
Shares on the terms and in the manner contemplated in the Time of Sale Prospectus.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Underwriters shall have received on the Closing Date a certificate, dated the Closing
Date and signed by an executive officer of the Company, to the effect set forth in Section&nbsp;5(a)(i)
above and to the effect that the representations and warranties of the Company contained in this
Agreement are true and correct as of the Closing Date and that the Company has complied with all of
the agreements and satisfied all of the conditions on its part to be performed or satisfied
hereunder on or before the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The officer signing and delivering such certificate may rely upon the best of his or her
knowledge as to proceedings threatened.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Underwriters shall have received on the Closing Date an opinion of Wilson Sonsini
Goodrich &#038; Rosati, Professional Corporation, outside counsel for the Company, dated the Closing
Date, substantially in the form attached hereto as <U>Exhibit&nbsp;A</U>, which shall be rendered to
the Underwriters at the request of the Company and shall so state therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Underwriters shall have received on the Closing Date an opinion of Townsend and
Townsend and Crew LLP, outside intellectual property counsel for the Company, dated the Closing
Date, substantially in the form attached hereto as <U>Exhibit&nbsp;B</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Underwriters shall have received on the Closing Date an opinion of Latham &#038; Watkins
LLP, counsel for the Underwriters, dated the Closing Date, with respect to such matters as the
Underwriters may reasonably request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Underwriters shall have received, on each of the date hereof and the Closing Date, a
letter dated the date hereof or the Closing Date, as the case may be, in form and substance
satisfactory to the Underwriters, from Ernst &#038; Young LLP, independent public accountants,
containing statements and information of the type ordinarily included in accountants&#146; &#147;comfort
letters&#148; to underwriters with respect to the financial statements and certain financial information
contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus; <I>provided</I>
that the letter delivered on the Closing Date shall use a &#147;cut-off date&#148; not earlier than the date
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The &#147;lock-up&#148; agreements, each substantially in the form of <U>Exhibit&nbsp;C</U> hereto,
between you and all stockholders, optionholders, officers and directors of the Company other than
those persons listed on Schedule&nbsp;III attached hereto relating to sales and certain other
dispositions of shares of Common Stock or certain other securities,
delivered to you on or before the date hereof, shall be in full force and effect on the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The several obligations of the Underwriters to purchase Additional Shares hereunder are
subject to the delivery to you on the applicable Option Closing Date of such documents as you may
reasonably request with respect to the good standing of the Company, the due authorization and
issuance of the Additional Shares to be sold on such Option Closing Date and other matters related
to the issuance of such Additional Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<I>Covenants of the Company</I>. The Company covenants with each Underwriter as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;To furnish to you, without charge, five signed copies of the Registration Statement
(including exhibits thereto) and for delivery to each other Underwriter a conformed copy of the
Registration Statement (without exhibits thereto) and to furnish to you in New York City, without
charge, prior to 10:00&nbsp;a.m. New York City time on the business day next succeeding the date of this
Agreement and during the period mentioned in Section 6(e) or 6(f) below, as many copies of the Time
of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the
Registration Statement as you may reasonably request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Before amending or supplementing the Registration Statement, the Time of Sale Prospectus
or the Prospectus, to furnish to you a copy of each such proposed amendment or supplement and not
to file any such proposed amendment or supplement to which you reasonably object, and to file with
the Commission within the applicable period specified in Rule 424(b) under the Securities Act any
prospectus required to be filed pursuant to such Rule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To furnish to you a copy of each proposed free writing prospectus to be prepared by or on
behalf of, used by, or referred to by the Company and not to use or refer to any proposed free
writing prospectus to which you reasonably object.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Not to take any action that would result in an Underwriter or the Company being required
to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing
prospectus prepared by or on behalf of the Underwriter that the Underwriter otherwise would not
have been required to file thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;If the Time of Sale Prospectus is being used to solicit offers to buy the Shares at a time
when the Prospectus is not yet available to prospective purchasers and any event shall occur or
condition exist as a result of which it is necessary to amend or supplement the Time of Sale
Prospectus in order to make the statements therein, in the light of the circumstances, not
misleading, or if any event shall occur or condition exist as a result of which the Time of Sale
Prospectus conflicts with the information contained in the Registration Statement then on file, or
if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time
of Sale Prospectus to comply with applicable law, forthwith to prepare, file with the Commission
and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or
supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as
so amended or supplemented will not, in the light of the circumstances under which they were made
when the Time of Sale Prospectus is delivered to a prospective purchaser, be misleading or so that
the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the
Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will
comply with applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;If, during such period after the first date of the public offering of the Shares as in the
opinion of counsel for the Underwriters the Prospectus (or in lieu thereof the notice referred to
in Rule 173(a) under the Securities Act) is required by law to be delivered in connection with
sales by an Underwriter or dealer, any event shall occur or condition exist as a result of which it
is necessary to amend or supplement the Prospectus in order to make the statements therein, in the
light of the circumstances when the Prospectus (or in lieu thereof the notice referred to in Rule
173(a) under the Securities Act) is delivered to a purchaser, not misleading, or if, in the opinion
of counsel for the Underwriters, it is necessary to amend or supplement the Prospectus to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">comply with applicable law, forthwith to prepare, file with the Commission and furnish, at its own
expense, to the Underwriters and to the dealers (whose names and addresses you will furnish to the
Company) to which Shares may have been sold by you on behalf of the Underwriters and to any other
dealers upon request, either amendments or supplements to the Prospectus so that the statements in
the Prospectus as so amended or supplemented will not, in the light of the circumstances when the
Prospectus (or in lieu thereof the notice referred to in Rule 173(a) under the Securities Act) is
delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will
comply with applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;To endeavor to qualify the Shares for offer and sale under the securities or Blue Sky laws
of such jurisdictions as you shall reasonably request, other than in jurisdictions which would
require the Company as a condition thereto to qualify to do business or to file a general consent
to service of process in any such jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;To make generally available to the Company&#146;s security holders and to you as soon as
practicable an earning statement covering a period of at least twelve months beginning with the
first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy
the provisions of Section 11(a) of the Securities Act and the rules and regulations of the
Commission thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Whether or not the transactions contemplated in this Agreement are consummated or this
Agreement is terminated, to pay or cause to be paid all expenses incident to the performance of its
obligations under this Agreement, including: (i)&nbsp;the fees, disbursements and expenses of the
Company&#146;s counsel and the Company&#146;s accountants in connection with the registration and delivery of
the Shares under the Securities Act and all other fees or expenses in connection with the
preparation and filing of the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, the
Prospectus, any free writing prospectus prepared by or on behalf of, used by, or referred to by the
Company and amendments and supplements to any of the foregoing, including all printing costs
associated therewith, and the mailing and delivering of copies thereof to the Underwriters and
dealers, in the quantities hereinabove specified, (ii)&nbsp;all costs and expenses related to the
transfer and delivery of the Shares to the Underwriters, including any transfer or other taxes
payable thereon, (iii)&nbsp;the cost of printing or producing any Blue Sky or Legal Investment
memorandum in connection with the offer and sale of the Shares under state securities laws and all
expenses in connection with the qualification of the Shares for offer and sale under state
securities laws as provided in Section 6(g) hereof, including filing fees and the reasonable fees
and disbursements of counsel for the Underwriters in connection with such qualification and in
connection with the Blue Sky or Legal Investment memorandum, (iv)&nbsp;all filing fees and the
reasonable fees and disbursements of counsel to the Underwriters incurred in connection with the
review and qualification of the offering of the Shares by the FINRA, (v)&nbsp;all fees and expenses in
connection with the preparation and filing of the registration statement on Form 8-A relating to
the Common Stock and all costs and expenses incident to listing the Shares on the NASDAQ Global
Market, (vi)&nbsp;the cost of printing certificates representing the Shares, (vii)&nbsp;the costs and charges
of any transfer agent, registrar or depositary, (viii)&nbsp;the costs and expenses of the Company
relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing
of the offering of the Shares, including, without limitation, expenses associated with the
preparation or dissemination of any electronic road show, expenses associated with the production
of road show slides and graphics, fees and expenses of any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">consultants engaged in connection with
the road show presentations with the prior approval of the Company, travel and lodging expenses of
the representatives and officers of the Company and any such consultants, and one-half of the cost
of any aircraft chartered in connection with the road show, (ix)&nbsp;the document production charges
and expenses associated with printing this Agreement and (x)&nbsp;all other costs and expenses incident
to the performance of the obligations of the Company hereunder for which provision is not otherwise
made in this Section. It is understood, however, that except as provided in this Section, Section
8 entitled &#147;Indemnity and Contribution&#148; and the last paragraph of Section&nbsp;10 below, the
Underwriters will pay all of their costs and expenses, including fees and disbursements of their
counsel, stock transfer taxes payable on resale of any of the Shares by them and one-half of the
cost of chartering any aircraft in connection with any road show presentation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also covenants with each Underwriter that, without the prior written consent of
Morgan Stanley &#038; Co. Incorporated on behalf of the Underwriters, it will not, during the period
ending 180&nbsp;days after the date of the Prospectus, (1)&nbsp;offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of the Common Stock, whether any such
transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock
or such other securities, in cash or otherwise or (3)&nbsp;file any registration statement with the
Commission relating to the offering of any shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The restrictions contained in the preceding paragraph shall not apply to (a)&nbsp;the Shares to be
sold hereunder, (b)&nbsp;the issuance of shares of, or options to purchase shares of, Common Stock to
employees, officers, directors, advisors or consultants of the Company pursuant to employee benefit
plans disclosed in the Prospectus or an employee benefit plan assumed by the Company in a merger or
acquisition transaction, (c)&nbsp;the filing of a registration statement on Form S-8 for the
registration of shares of Common Stock issued pursuant to employee benefit plans disclosed in the
Prospectus or an employee benefit plan assumed by the Company in a merger or acquisition
transaction, or (d)&nbsp;the issuance of shares of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock in an amount having an aggregate value (determined as
of the date of issuance) equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in connection with a merger or acquisition transaction;
provided prior to any issuance pursuant to clauses (b)&nbsp;or (d), the Company shall cause each
recipient of such shares or options to execute and deliver to you a &#147;lock-up&#148; agreement
substantially in the form of <U>Exhibit&nbsp;C</U> hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, if (1)&nbsp;during the last 17&nbsp;days of the 180-day restricted period
the Company issues an earnings release or material news or a material event relating to the Company
occurs; or (2)&nbsp;prior to the expiration of the 180-day restricted period, the Company announces that
it will release earnings results during the 16-day period beginning on the last day of the 180-day
period, the restrictions imposed by this agreement shall continue to apply until the expiration of
the 18-day period beginning on the issuance of the earnings release or the occurrence of the
material news or material event. The Company shall promptly notify Morgan Stanley &#038; Co.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Incorporated of any earnings release, news or event that may give rise to an extension of the
initial 180-day restricted period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<I>Covenants of the Underwriters</I>. Each Underwriter severally covenants with the Company not
to take any action that would result in the Company being required to file with the Commission
under Rule 433(d) a free writing prospectus prepared by or on behalf of such Underwriter that
otherwise would not be required to be filed by the Company thereunder, but for the action of the
Underwriter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<I>Indemnity and Contribution. </I>(a)&nbsp;The Company agrees to indemnify and hold harmless each
Underwriter, each person, if any, who controls any Underwriter within the meaning of either Section
15 of the Securities Act or Section&nbsp;20 of the Exchange Act and each affiliate of any Underwriter
within the meaning of Rule&nbsp;405 under the Securities Act from and against any and all losses,
claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) caused
by any untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement or any amendment thereof, any preliminary prospectus, the Time
of Sale Prospectus, any issuer free writing prospectus as defined in Rule 433(h) under the
Securities Act, any Company information that the Company has filed, or is required to file,
pursuant to Rule 433(d) under the Securities Act, or the Prospectus or any amendment or supplement
thereto, or caused by any omission or alleged omission to state therein a material fact required to
be stated therein or necessary to make the statements therein not misleading, except insofar as
such losses, claims, damages or liabilities are caused by any such untrue statement or omission or
alleged untrue statement or omission based upon information relating to any Underwriter furnished
to the Company in writing by such Underwriter through you expressly for use therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the
Company, its directors, its officers who sign the Registration Statement and each person, if any,
who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or Section
20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to such
Underwriter, but only with reference to information relating to such Underwriter furnished to the
Company in writing by such Underwriter through you expressly for use in the Registration Statement,
any preliminary prospectus, the Time of Sale Prospectus, any issuer free writing prospectus or the
Prospectus or any amendment or supplement thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In case any proceeding (including any governmental investigation) shall be instituted involving any
person in respect of which indemnity may be sought pursuant to Section 8(a) or 8(b), such person
(the &#147;<B>indemnified party</B>&#148;) shall promptly notify the person against whom such indemnity may be
sought (the &#147;<B>indemnifying party</B>&#148;) in writing and the indemnifying party, upon request of the
indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to
represent the indemnified party and any others the indemnifying party may designate in such
proceeding and shall pay the reasonably incurred fees and disbursements of such counsel related to
such proceeding. In any such proceeding, any indemnified party shall have the right to retain its
own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified
party unless (i)&nbsp;the indemnifying party and the indemnified party shall have mutually agreed in
writing to the retention of such counsel or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;the named parties to any such proceeding
    (including any impleaded parties) include both the indemnifying
    party and the indemnified party and representation of both
    parties by the same counsel would be inappropriate due to actual
    or potential differing interests between them. It is understood
    that the indemnifying party shall not, in respect of the legal
    expenses of any indemnified party in connection with any
    proceeding or related proceedings in the same jurisdiction, be
    liable for the fees and expenses of more than one separate firm
    (in addition to any local counsel) for all such indemnified
    parties and that all such fees and expenses shall be reimbursed
    as they are incurred. Such firm shall be designated in writing
    by Morgan Stanley&#160;&#038; Co. Incorporated, in the case of
    parties indemnified pursuant to Section&#160;8(a), and by the
    Company, in the case of parties indemnified pursuant to
    Section&#160;8(b). The indemnifying party shall not be liable
    for any settlement of any proceeding effected without its
    written consent, but if settled with such consent or if there be
    a final judgment for the plaintiff, the indemnifying party
    agrees to indemnify the indemnified party from and against any
    loss or liability by reason of such settlement or judgment.
    Notwithstanding the foregoing sentence, if at any time an
    indemnified party shall have requested an indemnifying party to
    reimburse the indemnified party for fees and expenses of counsel
    as contemplated by the second and third sentences of this
    paragraph, the indemnifying party agrees that it shall be liable
    for any settlement of any proceeding effected without its
    written consent if (i)&#160;such settlement is entered into more
    than 45&#160;days after receipt by such indemnifying party of
    the aforesaid request, (ii)&#160;such indemnifying party shall
    have received notice of the terms of such settlement at least
    30&#160;days prior to such settlement being entered into, and
    (iii)&#160;such indemnifying party shall not have reimbursed the
    indemnified party in accordance with such request prior to the
    date of such settlement. No indemnifying party shall, without
    the prior written consent of the indemnified party, effect any
    settlement of any pending or threatened proceeding in respect of
    which any indemnified party is or could have been a party and
    indemnity could have been sought hereunder by such indemnified
    party, unless such settlement includes an unconditional release
    of such indemnified party from all liability on claims that are
    the subject matter of such proceeding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (d)&#160;To the extent the indemnification provided for in
    Section&#160;8(a) or 8(b) is unavailable to an indemnified party
    or insufficient in respect of any losses, claims, damages or
    liabilities referred to therein, then each indemnifying party
    under such paragraph, in lieu of indemnifying such indemnified
    party thereunder, shall contribute to the amount paid or payable
    by such indemnified party as a result of such losses, claims,
    damages or liabilities (i)&#160;in such proportion as is
    appropriate to reflect the relative benefits received by the
    Company on the one hand and the Underwriters on the other hand
    from the offering of the Shares or (ii)&#160;if the allocation
    provided by clause&#160;8(d)(i) above is not permitted by
    applicable law, in such proportion as is appropriate to reflect
    not only the relative benefits referred to in
    clause&#160;8(d)(i) above but also the relative fault of the
    Company on the one hand and of the Underwriters on the other
    hand in connection with the statements or omissions that
    resulted in such losses, claims, damages or liabilities, as well
    as any other relevant equitable considerations. The relative
    benefits received by the Company on the one hand and the
    Underwriters on the other hand in connection with the offering
    of the Shares shall be deemed to be in the same respective
    proportions as the net proceeds from the offering of the Shares
    (before deducting expenses) received by the Company and the
    total underwriting discounts and commissions received by the
    Underwriters, in each case as set forth in the table on the
    cover of the Prospectus, bear to the aggregate Public Offering
    Price of the Shares. The relative fault of the Company on the
    one hand and the Underwriters on the other hand shall be
    determined by reference to, among other things, whether the
    untrue or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    alleged untrue statement of a material fact or the omission or
    alleged omission to state a material fact relates to information
    supplied by the Company or by the Underwriters and the
    parties&#146; relative intent, knowledge, access to information
    and opportunity to correct or prevent such statement or
    omission. The Underwriters&#146; respective obligations to
    contribute pursuant to this Section&#160;8 are several in
    proportion to the respective number of Shares they have
    purchased hereunder, and not joint.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (e)&#160;The Company and the Underwriters agree that it would
    not be just or equitable if contribution pursuant to this
    Section&#160;8 were determined by <I>pro rata </I>allocation
    (even if the Underwriters were treated as one entity for such
    purpose) or by any other method of allocation that does not take
    account of the equitable considerations referred to in
    Section&#160;8(d). The amount paid or payable by an indemnified
    party as a result of the losses, claims, damages and liabilities
    referred to in Section&#160;8(d) shall be deemed to include,
    subject to the limitations set forth above, any legal or other
    expenses reasonably incurred by such indemnified party in
    connection with investigating or defending any such action or
    claim. Notwithstanding the provisions of this Section&#160;8, no
    Underwriter shall be required to contribute any amount in excess
    of the amount by which the total price at which the Shares
    underwritten by it and distributed to the public were offered to
    the public exceeds the amount of any damages that such
    Underwriter has otherwise been required to pay by reason of such
    untrue or alleged untrue statement or omission or alleged
    omission. No person guilty of fraudulent misrepresentation
    (within the meaning of Section&#160;11(f) of the Securities Act)
    shall be entitled to contribution from any person who was not
    guilty of such fraudulent misrepresentation. The remedies
    provided for in this Section&#160;8 are not exclusive and shall
    not limit any rights or remedies which may otherwise be
    available to any indemnified party at law or in equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (f)&#160;The indemnity and contribution provisions contained in
    this Section&#160;8 and the representations, warranties and
    other statements of the Company contained in this Agreement
    shall remain operative and in full force and effect regardless
    of (i)&#160;any termination of this Agreement, (ii)&#160;any
    investigation made by or on behalf of any Underwriter, any
    person controlling any Underwriter or any affiliate of any
    Underwriter or by or on behalf of the Company, its officers or
    directors or any person controlling the Company and
    (iii)&#160;acceptance of and payment for any of the Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    9.&#160;<I>Termination.</I> The Underwriters may terminate this
    Agreement by notice given by you to the Company, if after the
    execution and delivery of this Agreement and prior to the
    Closing Date (i)&#160;trading generally shall have been
    suspended or materially limited on, or by, as the case may be,
    any of the New York Stock Exchange, the American Stock Exchange,
    the NASDAQ Global Market, the Chicago Board of Options Exchange,
    the Chicago Mercantile Exchange or the Chicago Board of Trade
    (ii)&#160;trading of any securities of the Company shall have
    been suspended on any exchange or in any over-the-counter
    market, (iii)&#160;a material disruption in securities
    settlement, payment or clearance services in the United States
    shall have occurred, (iv)&#160;any moratorium on commercial
    banking activities shall have been declared by Federal or New
    York State authorities or (v)&#160;there shall have occurred any
    outbreak or escalation of hostilities, or any change in
    financial markets or any calamity or crisis that, in your
    judgment, is material and adverse and which, singly or together
    with any other event specified in this clause (v), makes it, in
    your judgment, impracticable or inadvisable to proceed with the
    offer, sale or delivery of the
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares on the terms and in the manner contemplated in the Time
    of Sale Prospectus or the Prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    10.&#160;<I>Effectiveness; Defaulting Underwriters</I>. This
    Agreement shall become effective upon the execution and delivery
    hereof by the parties hereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If, on the Closing Date or an Option Closing Date, as the case
    may be, any one or more of the Underwriters shall fail or refuse
    to purchase Shares that it has or they have agreed to purchase
    hereunder on such date, and the aggregate number of Shares which
    such defaulting Underwriter or Underwriters agreed but failed or
    refused to purchase is not more than one-tenth of the aggregate
    number of the Shares to be purchased on such date, the other
    Underwriters shall be obligated severally in the proportions
    that the number of Firm Shares set forth opposite their
    respective names in Schedule&#160;I bears to the aggregate
    number of Firm Shares set forth opposite the names of all such
    non-defaulting Underwriters, or in such other proportions as you
    may specify, to purchase the Shares which such defaulting
    Underwriter or Underwriters agreed but failed or refused to
    purchase on such date; <I>provided </I>that in no event shall
    the number of Shares that any Underwriter has agreed to purchase
    pursuant to this Agreement be increased pursuant to this
    Section&#160;10 by an amount in excess of one-ninth of such
    number of Shares without the written consent of such
    Underwriter. If, on the Closing Date, any Underwriter or
    Underwriters shall fail or refuse to purchase Firm Shares and
    the aggregate number of Firm Shares with respect to which such
    default occurs is more than one-tenth of the aggregate number of
    Firm Shares to be purchased on such date, and arrangements
    satisfactory to you and the Company for the purchase of such
    Firm Shares are not made within 36&#160;hours after such
    default, this Agreement shall terminate without liability on the
    part of any non-defaulting Underwriter or the Company. In any
    such case either you or the Company shall have the right to
    postpone the Closing Date, but in no event for longer than seven
    days, in order that the required changes, if any, in the
    Registration Statement, in the Time of Sale Prospectus, in the
    Prospectus or in any other documents or arrangements may be
    effected. If, on an Option Closing Date, any Underwriter or
    Underwriters shall fail or refuse to purchase Additional Shares
    and the aggregate number of Additional Shares with respect to
    which such default occurs is more than one-tenth of the
    aggregate number of Additional Shares to be purchased on such
    Option Closing Date, the non-defaulting Underwriters shall have
    the option to (i)&#160;terminate their obligation hereunder to
    purchase the Additional Shares to be sold on such Option Closing
    Date or (ii)&#160;purchase not less than the number of
    Additional Shares that such non-defaulting Underwriters would
    have been obligated to purchase in the absence of such default.
    Any action taken under this paragraph shall not relieve any
    defaulting Underwriter from liability in respect of any default
    of such Underwriter under this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Agreement shall be terminated by the Underwriters, or
    any of them, because of any failure or refusal on the part of
    the Company to comply with the terms or to fulfill any of the
    conditions of this Agreement, or if for any reason the Company
    shall be unable to perform its obligations under this Agreement,
    the Company will reimburse the Underwriters or such Underwriters
    as have so terminated this Agreement with respect to themselves,
    severally, for all out-of-pocket expenses (including the fees
    and disbursements of their counsel) reasonably incurred by such
    Underwriters in connection with this Agreement or the offering
    contemplated hereunder.
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    11.&#160;<I>Entire Agreement</I>. (a)&#160;This Agreement,
    together with any contemporaneous written agreements and any
    prior written agreements (to the extent not superseded by this
    Agreement) that relate to the offering of the Shares, represents
    the entire agreement between the Company and the Underwriters
    with respect to the preparation of any preliminary prospectus,
    the Time of Sale Prospectus, the Prospectus, the conduct of the
    offering, and the purchase and sale of the Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;The Company acknowledges that in connection with the
    offering of the Shares: (i)&#160;the Underwriters have acted at
    arms length, are not agents of, and owe no fiduciary duties to,
    the Company or any other person, (ii)&#160;the Underwriters owe
    the Company only those duties and obligations set forth in this
    Agreement and prior written agreements (to the extent not
    superseded by this Agreement), if any, and (iii)&#160;the
    Underwriters may have interests that differ from those of the
    Company. The Company waives to the full extent permitted by
    applicable law any claims it may have against the Underwriters
    arising from an alleged breach of fiduciary duty in connection
    with the offering of the Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    12.&#160;<I>Counterparts</I>. This Agreement may be signed in
    two or more counterparts, each of which shall be an original,
    with the same effect as if the signatures thereto and hereto
    were upon the same instrument.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    13.&#160;<I>Applicable Law</I>. This Agreement shall be governed
    by and construed in accordance with the internal laws of the
    State of New York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    14.&#160;<I>Headings</I>. The headings of the sections of this
    Agreement have been inserted for convenience of reference only
    and shall not be deemed a part of this Agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    15.&#160;<I>Notices</I>. All communications hereunder shall be
    in writing and effective only upon receipt and if to the
    Underwriters shall be delivered, mailed or sent to you in care
    of Morgan Stanley&#160;&#038; Co. Incorporated, 1585 Broadway,
    New York, New York 10036, Attention: Equity Syndicate Desk, with
    a copy to the Legal Department and Latham&#160;&#038; Watkins
    LLP, 650 Town Center Drive 20th&#160;Floor, Costa Mesa,
    California 92626, Attention: Charles K. Ruck; and if to the
    Company shall be delivered, mailed or sent to 7000 Shoreline
    Court, Suite&#160;100, South San&#160;Francisco, California
    94080, Attention: Chief Executive Officer with a copy to Wilson
    Sonsini Goodrich&#160;&#038; Rosati,&#160;P.C., 950
    Page&#160;Mill Road, Palo Alto, California 94304, Attention:
    David J. Segre and Robert F. Kornegay.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Very truly yours,
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    FLUIDIGM CORPORATION
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:center; width:90%">&#160;&#160;&#160;<FONT style="font-variant: SMALL-CAPS">&#160;</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:
</DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Title:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Accepted as of the date hereof<BR>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Morgan Stanley&#160;&#038; Co. Incorporated
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    UBS Securities LLC
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Leerink Swan LLC
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pacific Growth Equities, LLC
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: -4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acting severally on behalf of themselves<BR>
    and the several Underwriters named<BR>
    in Schedule&#160;I hereto.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By: Morgan Stanley&#160;&#038; Co. Incorporated
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    By:&#160;</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:center; width:90%">&#160;&#160;&#160;<FONT style="font-variant: SMALL-CAPS">&#160;</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 3%; width: 31%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=144 -->

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:
</DIV>

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Title:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>SCHEDULE&#160;I</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD>         <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="22%" align="right">&nbsp;</TD>   <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Firm Shares To<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Underwriter</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Be Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Morgan Stanley&#160;&#038; Co. Incorporated
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    UBS Securities LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leerink Swan LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pacific Growth Equities, LLC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total:&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->I-1<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SCHEDULE&#160;II</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Time of
    Sale Prospectus</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;Preliminary Prospectus issued September&#160;5, 2008.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->II-1<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SCHEDULE&#160;III</FONT></B>
</DIV>
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;&#160;Allen May, Trustee, Intervivos Trust Dated 5/14/91
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;&#160;Bobey, Lynn
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;&#160;Chu, Stephen
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;&#160;Collier, Matthew
</DIV>


<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;&#160;Ferguson/Egan Family Trust Dated 6/28/99
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;&#160;Fernandes, Dave
</DIV>


<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;&#160;Garcia, Greg
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;Godley, Shelley
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    9.&#160;Hao, Casey
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    10.&#160;Jacobson, Joseph M.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    11.&#160;Javadi, Shervin
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    12.&#160;Lei, Hao
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    13.&#160;Liau, Yish hann
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    14.&#160;Lucas, Jeffrey
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    15.&#160;Lynch, Timothy P.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    16.&#160;Manger, Ian
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    17.&#160;McBride, Lincoln
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    18.&#160;Moore, Charles C.&#160;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    19.&#160;Pat and Betsy Collins Revocable Trust
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    20.&#160;Relova, Anna
</DIV>


<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    21.&#160;Taylor, Colin
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


</DIV><!-- End box 1 -->


<P align="center" style="font-size: 10pt"><!-- Folio -->III-1<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXHIBIT&#160;A</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FORM&#160;OF
    OPINION OF WILSON SONSINI GOODRICH &#38; ROSATI, P.C.</FONT></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXHIBIT&#160;A</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FORM&#160;OF
    OPINION OF WILSON SONSINI GOODRICH&#160;&#038;
    ROSATI,&#160;P.C.</FONT></B>
</DIV>
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;The Company is a corporation duly incorporated and
    validly existing under, and by virtue of, the laws of the State
    of Delaware, and is in good standing under such laws. The
    Company has the corporate power and authority to own or lease
    its properties and assets and to carry on its business as
    described in the Time of Sale Prospectus. The Company is
    qualified to do business and is in good standing as a foreign
    corporation in the State of California.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;The authorized capital stock of the Company conforms in
    all material respects as to legal matters to the description
    thereof contained in each of the Time of Sale Prospectus and the
    Prospectus.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;The shares of Common Stock outstanding prior to the
    issuance of the Shares have been duly authorized and are validly
    issued, fully paid and nonassessable.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;The Shares have been duly authorized and, when issued
    and delivered and paid for in accordance with the terms of the
    Underwriting Agreement, will be validly issued, fully paid and
    nonassessable, and the issuance of such Shares will not be
    subject to any preemptive or similar rights arising from or
    pursuant to the Certificate of Incorporation or Bylaws of the
    Company, or to our knowledge, any other written agreement or
    instrument to which the Company or any subsidiary of the Company
    is a party, other than such rights as have been duly and
    properly waived.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    5.&#160;The Underwriting Agreement has been duly authorized,
    executed and delivered by the Company.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    6.&#160;The execution and delivery by the Company of, and the
    performance by the Company of its obligations under, the
    Underwriting Agreement do not violate any provision of
    (i)&#160;applicable U.S.&#160;federal or California state law,
    rule or regulation known to us to be customarily applicable to
    transactions of the nature contemplated by the Underwriting
    Agreement; (ii)&#160;the Delaware General Corporation Law;
    (iii)&#160;the Certificate of Incorporation or Bylaws;
    (iv)&#160;any Reviewed Agreements; or (v)&#160;to our knowledge,
    any judgment, order or decree of any governmental body, agency
    or court having jurisdiction over the Company. No consent,
    approval, authorization or order of, or qualification with, any
    governmental body or agency is required for the valid execution
    and delivery of the Underwriting Agreement or the performance by
    the Company of its obligations thereunder, or the offer, sale,
    or issuance of the Shares, except such as have been obtained or
    made under the Securities Act or the Securities Exchange Act of
    1934, as amended.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    7.&#160;The statements included in the Time of Sale Prospectus
    and the Prospectus under the captions &#147;Description Capital
    Stock,&#148; &#147;Material U.S.&#160;Federal Income and Estate
    Tax Consequences to
    <FONT style="white-space: nowrap">Non-U.S.&#160;Holders&#148;</FONT>
    and &#147;Underwriters&#148; (to the extent of the description
    of the Underwriting Agreement), in each case insofar as such
    statements constitute summaries of legal matters, documents or
    proceedings referred to therein, fairly summarize in all
    material respects such legal matters, documents or proceedings.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    8.&#160;We do not know of any (i)&#160;legal or governmental
    proceeding; (ii)&#160;U.S.&#160;federal or California state
    statute or regulation; or (iii)&#160;provision of the Delaware
    General Corporation Law required to be described in the
    Registration Statement or the Prospectus which is not described
    in all material respects therein as required nor of any
    contracts or documents of a character required to be filed with
    the Registration Statement that are not filed as required.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    9.&#160;The Company is not, and after giving effect to the
    offering and sale of the Shares and the application of the
    proceeds thereof as described in the Prospectus will not be, an
    &#147;investment company&#148; as such term is defined in the
    Investment Company Act.
</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    10.&#160;The Registration Statement was declared effective under
    the Securities Act on September&#160;[&#160;&#160;], 2008, and
    the Prospectus was filed with the Commission pursuant to
    Rule&#160;424(b) under the Securities Act on
    September&#160;[&#160;&#160;], 2008. To our knowledge, no stop
    order suspending the effectiveness of the Registration Statement
    or any part thereof has been issued, and, to our knowledge, no
    proceedings for that purpose have been instituted or are pending
    or threatened by the Commission.
</DIV>
</DIV><!-- End box 1 -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXHIBIT&#160;B</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FORM&#160;OF
    OPINION OF</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TOWNSEND
    AND TOWNSEND AND CREW LLP</FONT></B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->B-1<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT B</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF OPINION OF TOWNSEND AND TOWNSEND AND CREW LLP</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Based upon
and subject to the foregoing, we are of the opinion that:
</div>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;To
our knowledge, (a)&nbsp;the Company is the exclusive owner of all
right, title and interest in the Fluidigm Patent Rights and CIT is
the exclusive owner of all right, title and interest in the
Fluidigm/CIT Patent Rights, with the following exceptions: five
U.S.&nbsp;patents and seven U.S.&nbsp;patent applications, and
foreign equivalents thereof, are coassigned to the Company and the
Regents of the University of California (&#147;UC&#148;), and one
U.S.&nbsp;patent application and foreign equivalents are coassigned
to the Company, CIT, UC and Siemens Medical Solutions USA, Inc.;
(c)&nbsp;the patent applications within the Company Patent Rights are
valid and have been recorded in the U.S.&nbsp;Patent and Trademark
Office (assignments in three pending patent applications have not yet
been obtained or recorded); (e)&nbsp;the patent applications within
the Company Patent Rights are pending and being prosecuted so as to
avoid abandonment thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Except
as noted in the Prospectus, to our knowledge, no actions, suits,
claims or proceedings have been asserted or threatened in writing
against the Company alleging that the operation of the Company&#146;s
business conflicts with or infringes the patent rights of any third
party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;To
our knowledge, no court has issued any order, judgment, decree or
injunction restricting the operation of the Company&#146;s business on
the basis of a conflict with or infringement of the patent rights of
any third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;To
our knowledge, and without having conducted a freedom to operate
analysis, we are not aware of any third party patents that would be
infringed by the Company&#146;s manufacture, use or sale of products
described in the Prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;To
our knowledge, and without having done any investigation beyond
review of our files in the normal course of prosecution, we are
unaware of any facts that lead us to believe that any
U.S.&nbsp;patents in the Company Patent Rights were not prosecuted,
or any U.S.&nbsp;patent applications in the Company Patent Rights are
not being prosecuted, in compliance with the duty of disclosure under
37&nbsp;C.F.R.&#167;1.56.
</div>
<P align="center" style="font-size: 10pt"><!-- Folio --><B>B-</B>1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>EXHIBIT&#160;C</B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">FORM&#160;OF
    <FONT style="white-space: nowrap">LOCK-UP</FONT>
    LETTER</FONT></B>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->C-1<!-- /Folio -->
<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Lock-Up Agreement</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">_________, 2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Morgan Stanley &#038; Co. Incorporated<BR>
UBS Securities LLC<BR>
Leerink Swan LLC<BR>
Pacific Growth Equities, LLC

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">c/o</TD>
    <TD>&nbsp;</TD>
    <TD>Morgan Stanley &#038; Co. Incorporated<BR>
1585 Broadway<BR>
New York, NY 10036</TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned understands that Morgan Stanley &#038; Co. Incorporated (&#147;<B>Morgan Stanley</B>&#148;) proposes
to enter into an Underwriting Agreement (the &#147;<B>Underwriting Agreement</B>&#148;) with Fluidigm Corporation, a
Delaware corporation (the &#147;<B>Company</B>&#148;), providing for the public offering (the &#147;<B>Public Offering</B>&#148;) by
the several Underwriters named in Schedule&nbsp;I to the Underwriting Agreement, including Morgan
Stanley (the &#147;<B>Underwriters</B>&#148;), of shares (the &#147;<B>Shares</B>&#148;) of the Common Stock, par value $0.001 per
share, of the Company (the &#147;<B>Common Stock</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To induce the Underwriters that may participate in the Public Offering to continue their
efforts in connection with the Public Offering, the undersigned hereby agrees that, without the
prior written consent of Morgan Stanley on behalf of the Underwriters, it will not, during the
period commencing on the date hereof and ending 180&nbsp;days after the date of the final prospectus
relating to the Public Offering (the &#147;<B>Prospectus</B>&#148;), (1)&nbsp;offer, pledge, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock or (2)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of the Common Stock, whether any such
transaction described in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or
such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a)
transactions relating to shares of Common Stock or other securities acquired in open market
transactions after the completion of the Public Offering, <I>provided </I>that no filing under Section
16(a) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), shall be required or
shall be voluntarily made in connection with subsequent sales of Common Stock or other securities
acquired in such open market transactions, (b)&nbsp;transfers of shares of Common Stock or any security
convertible into Common Stock as a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->C-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">bona fide gift, (c)&nbsp;distributions of shares of Common Stock or any security convertible into
Common Stock to limited partners, members or stockholders of the undersigned, (d)&nbsp;transfers of
shares of Common Stock or any security convertible into Common Stock by will or intestacy to the
undersigned&#146;s immediate family or to a trust, the beneficiaries of which are the undersigned and a
member or members of the undersigned&#146;s immediate family (for purposes of this agreement, &#147;immediate
family&#148; shall mean any relationship by blood, marriage or adoption, not more remote than first
cousin) or (e)&nbsp;the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act
for the transfer of shares of Common Stock, <I>provided </I>that such plan does not provide for the
transfer of Common Stock during the restricted period; <I>provided further</I>, that in the case of any
transfer or distribution pursuant to clause (b) &#151; (d), (i)&nbsp;each donee or distributee shall sign and
deliver a lock-up letter substantially in the form of this letter and (ii)&nbsp;no filing under Section
16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock,
shall be required or shall be voluntarily made during the restricted period referred to in the
foregoing sentence
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the undersigned agrees that, without the prior written consent of Morgan Stanley
on behalf of the Underwriters, it will not, during the period commencing on the date hereof and
ending 180&nbsp;days after the date of the Prospectus, make any demand for or exercise any right with
respect to, the registration of any shares of Common Stock or any security convertible into or
exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the
entry of stop transfer instructions with the Company&#146;s transfer agent and registrar against the
transfer of the undersigned&#146;s shares of Common Stock except in compliance with the foregoing
restrictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>during the last 17&nbsp;days of the restricted period the Company issues an earnings release or
material news or a material event relating to the Company occurs; or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>prior to the expiration of the restricted period, the Company announces that it will
release earnings results during the 16-day period beginning on the last day of the restricted
period;</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the restrictions imposed by this agreement shall continue to apply until the expiration of the
18-day period beginning on the issuance of the earnings release or the occurrence of the material
news or material event.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned shall not engage in any transaction that may be restricted by this agreement
during the 34-day period beginning on the last day of the initial restricted period unless the
undersigned requests and receives prior written
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->C-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">confirmation from the Company or Morgan Stanley that the restrictions imposed by this
agreement have expired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby represents and warrants that the undersigned has full power and
authority to enter into this agreement. The undersigned understands that the Company and the
Underwriters are relying upon this agreement in proceeding toward consummation of the Public
Offering. The undersigned further understands that this agreement is irrevocable and shall be
binding upon the undersigned&#146;s heirs, legal representatives, successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether or not the Public Offering actually occurs depends on a number of factors, including
market conditions. Any Public Offering will only be made pursuant to an Underwriting Agreement,
the terms of which are subject to negotiation between the Company and the Underwriters.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This agreement will terminate and the undersigned will be released from all of its obligations
hereunder if (a)&nbsp;the closing of the Public Offering shall not have occurred on or before the one
year anniversary of the date of this agreement first set forth above, or (b) (i)&nbsp;if the Company
withdraws the registration statement registering the Shares or (ii)&nbsp;the Underwriting Agreement is
executed but is terminated prior to payment for and delivery of any Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This agreement shall be governed by and construed in accordance with the laws of the State of
New York, without regard to the conflict of laws principles thereof.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
<BR>
<BR>
<HR noshade size="1" width="90%" align="left">
(List names of all individuals and entities<BR>
that hold shares of Fluidigm stock)<BR>
<BR>
<BR>
<BR>

<HR noshade size="1" width="90%" align="left">
(Signature)<BR>
<BR>
<BR>
<BR>
<BR>

<HR noshade size="1" width="90%" align="left">
(Name of Authorized Signatory)<BR>
<BR>
<BR>
<BR>

<HR noshade size="1" width="90%" align="left">
(Address)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->C-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature Page to Fluidigm Lock-Up Agreement&#093;</I>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;
</div>

<P align="center" style="font-size: 10pt"><!-- Folio -->C-5<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>f39432a9exv3w1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv3w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><B>Exhibit 3.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDED AND RESTATED</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATE OF INCORPORATION OF</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a corporation organized and existing under the laws of the State of
Delaware (the &#147;<B>Corporation</B>&#148;), certifies that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;The name of the corporation is Fluidigm Corporation. The original Certificate of
Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on
March&nbsp;29, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;This Second Amended and Restated Certificate of Incorporation was duly adopted in
accordance with Sections&nbsp;242 and 245 of the General Corporation Law of the State of Delaware and
restates, integrates and further amends the provisions of the Corporation&#146;s Certificate of
Incorporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The text of the Amended and Restated Certificate of Incorporation is amended and restated
to read as set forth in EXHIBIT A attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Fluidigm Corporation has caused this Second Amended and Restated
Certificate of Incorporation to be signed by Gajus V. Worthington, a duly authorized officer of the
Corporation, on September&nbsp;16, 2008.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                   /s/ Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name of the corporation is Fluidigm Corporation (the &#147;<U>Corporation</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Corporation is to engage in any lawful act or activity for which a
corporation may be organized under the General Corporation Law of Delaware.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The address of the Corporation&#146;s registered office in the State of Delaware is Corporation
Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801. The name of its
registered agent at such address is The Corporation Trust Company.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Reverse Stock Split</U>. Immediately upon the filing of this Second Amended and
Restated Certificate of Incorporation, each three and one-half (3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT>) outstanding shares of Common
Stock and each three and one-half (3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT>) outstanding shares of Preferred Stock will be exchanged and
combined, automatically and without further action, into one (1)&nbsp;share of Common Stock and one (1)
share of Preferred Stock, respectively (the &#147;<U>Reverse Split</U>&#148;). The Reverse Split shall be
effected on a certificate-by-certificate basis and no fractional shares shall be issued upon the
exchange and combination. In lieu of any fractional shares to which the holder would otherwise be
entitled, the Corporation shall pay an amount of cash equal to the product of (i)&nbsp;the fractional
share to which the holder would otherwise be entitled and (ii)&nbsp;the then fair value of a share as
determined in good faith by the Board of Directors. All share and per share amounts set forth in
this Second Amended and Restated Certificate of Incorporation, including such amounts set forth
elsewhere in this Article&nbsp;IV, have been revised to reflect the Reverse Split, and, accordingly, no
further adjustment in accordance with the terms of this Second Amended and Restated Certificate of
Incorporation is necessary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Reverse Split shall occur automatically without any further action by the holders of the
shares affected thereby, and whether or not the certificates representing such shares are
surrendered to the Corporation or its transfer agent. The Corporation shall not be obligated to
issue certificates evidencing the shares of Common Stock or Preferred Stock, as the case may be,
resulting from the Reverse Split unless the certificates evidencing such shares of Common Stock or
Preferred Stock are either delivered to the Corporation or its transfer agent as provided above, or
the holder notifies the Corporation or its transfer agent that such certificates have been lost,
stolen, or destroyed and executes an agreement satisfactory to the Corporation to indemnify the
Corporation from any loss incurred by it in connection with such certificates. The Corporation
shall, as soon as practicable after such delivery, or such agreement and indemnification in the
case of a lost, stolen or destroyed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">certificate, issue and deliver at such office to such holder of Common Stock or Preferred
Stock, as the case may be, a certificate or certificates for the number of shares of Common Stock
or Preferred Stock and a check payable to the holder in the amount of any cash amounts payable as
the result of a conversion of fractional shares into cash to which he or she shall be entitled as
aforesaid.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Classes of Stock</U>. The total number of shares of stock that the Corporation shall
have authority to issue is 42,143,033, consisting of 24,967,382 shares of Common Stock, $0.0035 par
value per share (&#147;<U>Common Stock</U>&#148;) and 17,175,651 shares of Preferred Stock, $0.0035 par
value per share (&#147;<U>Preferred Stock</U>&#148;). The Preferred shall be divided into series. The first
series shall consist of 779,220 shares and shall be designated Series&nbsp;A Preferred Stock
(&#147;<U>Series&nbsp;A Preferred Stock</U>&#148;). The second series shall consist of 1,845,907 shares and shall
be designated Series&nbsp;B Preferred Stock (&#147;<U>Series&nbsp;B Preferred Stock</U>&#148;). The third series shall
consist of 4,815,606 shares and shall be designated Series&nbsp;C Preferred Stock (&#147;<U>Series&nbsp;C
Preferred Stock</U>&#148;). The fourth series shall consist of 3,989,217 shares and shall be designated
Series&nbsp;D Preferred Stock (&#147;<U>Series&nbsp;D Preferred Stock</U>&#148;). The fifth series shall consist of
5,745,699 shares and shall be designated Series&nbsp;E Preferred Stock (&#147;<U>Series&nbsp;E Preferred
Stock</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and provisions of the Common Stock and Preferred Stock are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Definitions</U>. For purposes of this Article&nbsp;IV, the following definitions shall
apply:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &#147;<U>Conversion Price</U>&#148; shall mean $3.85 per share for the Series&nbsp;A Preferred Stock,
$6.23 per share for the Series&nbsp;B Preferred Stock, $9.03 per share for the Series&nbsp;C Preferred Stock,
$9.80 per share for the Series&nbsp;D Preferred Stock, and $14.00 for the Series&nbsp;E Preferred Stock (each
subject to adjustment from time to time as set forth elsewhere herein).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Convertible Securities</U>&#148; shall mean any evidences of indebtedness, shares or other
securities (other than shares of Common Stock) convertible into or exchangeable for Common Stock.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Corporation</U>&#148; shall mean Fluidigm Corporation.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Dividend Rate</U>&#148; shall mean an annual rate of $0.385 per share for the Series&nbsp;A
Preferred Stock, an annual rate of $0.63 for the Series&nbsp;B Preferred Stock, an annual rate of $0.91
per share for the Series&nbsp;C Preferred Stock, an annual rate of $1.05 per share for the Series&nbsp;D
Preferred Stock, and an annual rate of $1.505 per share for the Series&nbsp;E Preferred Stock (each
subject to adjustment from time to time as set forth elsewhere herein).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Liquidation Preference</U>&#148; shall mean $3.85 per share for the Series&nbsp;A Preferred
Stock, $6.23 per share for the Series&nbsp;B Preferred Stock, $9.03 per share for the Series&nbsp;C Preferred
Stock, $9.80 per share for the Series&nbsp;D Preferred Stock, and $14.00 per share for the Series&nbsp;E
Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Options</U>&#148; shall mean rights, options or warrants to subscribe for, purchase or
otherwise acquire Common Stock or Convertible Securities.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Original Issue Price</U>&#148; shall mean $3.85 per share for the Series&nbsp;A Preferred
Stock, $6.23 for the Series&nbsp;B Preferred Stock, $9.03 per share for the Series&nbsp;C Preferred Stock,
$9.80</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">per share for the Series&nbsp;D Preferred Stock, and $14.00 per share for the Series&nbsp;E Preferred
Stock (each subject to adjustment from time to time as set forth elsewhere herein).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Preferred Stock</U>&#148; shall mean the Series&nbsp;A Preferred Stock, the Series&nbsp;B Preferred
Stock, the Series&nbsp;C Preferred Stock, the Series&nbsp;D Preferred Stock, and the Series&nbsp;E Preferred
Stock.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Dividends</U>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;D and Series&nbsp;E Preferred Stock</U>. The holders of outstanding shares of
Series&nbsp;D Preferred Stock and the holders of outstanding shares of Series&nbsp;E Preferred Stock shall be
entitled to receive dividends, when and as declared by the Board of Directors, out of any assets at
the time legally available therefor, at the Dividend Rates specified for such shares of Preferred
Stock, payable in preference and priority to any declaration or payment of any distribution on
Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock or Common Stock
(collectively, the &#147;<U>Junior Stock</U>&#148;) of the Corporation other than a dividend payable solely
in Common Stock. No distributions shall be made with respect to the Junior Stock during any fiscal
year of the Corporation, other than dividends on the Common Stock payable solely in Common Stock,
until all dividends at the applicable Dividend Rate on the Series&nbsp;E Preferred Stock and Series&nbsp;D
Preferred Stock have been declared and paid or set apart for payment to the holders of Series&nbsp;E
Preferred Stock and the holders of Series&nbsp;D Preferred Stock. Payment of any dividends to the
holders of the Series&nbsp;E Preferred Stock and the Series&nbsp;D Preferred Stock shall be on a <U>pro</U>
<U>rata</U>, <U>pari</U> <U>passu</U> basis in proportion to the Dividend Rates for the Series&nbsp;E
Preferred Stock and Series&nbsp;D Preferred Stock, as applicable. The right to receive dividends on
shares of Series&nbsp;E Preferred Stock and Series&nbsp;D Preferred Stock shall not be cumulative, and no
right to such dividends shall accrue to holders of Series&nbsp;E Preferred Stock and Series&nbsp;D Preferred
Stock by reason of the fact that dividends on said shares are not declared or paid in any year.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;C Preferred Stock</U>. The holders of outstanding shares of Series&nbsp;C Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
with respect to the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock during any
fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common
Stock, until all dividends at the applicable Dividend Rate on the Series&nbsp;C Preferred Stock have
been declared and paid or set apart for payment to the holders of Series&nbsp;C Preferred Stock. The
right to receive dividends on shares of Series&nbsp;C Preferred Stock shall not be cumulative, and no
right to such dividends shall accrue to holders of Series&nbsp;C Preferred Stock by reason of the fact
that dividends on said shares are not declared or paid in any year.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock</U>. The holders of outstanding
shares of Series&nbsp;A Preferred Stock and the holders of outstanding shares of Series&nbsp;B Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any distribution on Common Stock of the Corporation other than a dividend payable solely in
Common Stock. No distributions shall be made with respect to the Common Stock, other than dividends
payable solely in Common Stock, until all dividends at the applicable Dividend Rate on the
Preferred Stock have been declared and paid or set apart for payment to the Preferred Stock
holders. Payment of any dividends to the holders of the Series&nbsp;A Preferred Stock and Series&nbsp;B
Preferred Stock shall be on a <U>pro</U> <U>rata</U>, pari passu basis in proportion to the
Dividend Rates for the Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock, as applicable. The
right to receive dividends on shares of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock shall
not be cumulative, and no right to such dividends shall accrue to holders of Series&nbsp;A Preferred
Stock or Series&nbsp;B Preferred Stock by reason of the fact that dividends on said shares are not
declared or paid in any year.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Distribution</U>. For purposes of this Section&nbsp;4, unless the context otherwise
requires, a &#147;<U>distribution</U>&#148; shall mean the transfer of cash or other property without
consideration whether by way of dividend or otherwise, payable other than in Common Stock, or the
purchase or redemption of shares of the Corporation other than (i)&nbsp;repurchase of shares of Common
Stock issued to or held by employees, consultants, officers and directors of the Corporation or its
subsidiaries upon termination of their employment or services pursuant to agreements providing for
the right of said repurchase and at the original purchase price paid by such employees,
consultants, officers and directors; and (ii)&nbsp;repurchase of Common Stock issued to or held by
employees, officers, directors or consultants of the Corporation or its subsidiaries pursuant to
rights of first refusal contained in agreements providing for such rights, provided that such
repurchase is unanimously approved by the Board of Directors; and (iii)&nbsp;any other repurchase or
redemption of capital stock of the corporation unanimously approved by the Board of Directors and
approved by the holders of the majority of the Common Stock and the holders of more than two-thirds
(2/3) of the outstanding shares of the Preferred Stock, voting as separate classes.</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Common Stock</U>. Dividends may be paid on the Common Stock as and when declared by
the Board of Directors, subject to the prior dividend rights of the Preferred Stock and Section&nbsp;8
below.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Non-Cash Distributions</U>. Whenever a distribution provided for in this Section&nbsp;4
shall be payable in property other than cash, the value of such distribution shall be deemed to be
the fair market value of such property as determined in good faith by the Board of Directors.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Consent to Certain Repurchases</U>. If Sections&nbsp;502 and 503 of the California
Corporations Code are determined to apply to the Corporation, as authorized by Section&nbsp;402.5(c) of
the California Corporations Code, Sections&nbsp;502 and 503 of the California Corporations Code shall
not apply with respect to payments made by the Corporation in connection with (i)&nbsp;repurchase of
shares of Common Stock issued to or held by employees, consultants, officers and directors of the
Corporation or its subsidiaries upon termination of their employment or services pursuant to
agreements providing for the right of said repurchase and at the original purchase price paid by
such employees, consultants, officers and directors, and (ii)&nbsp;repurchase of Common Stock issued to
or held by employees, officers, directors and consultants of the Corporation or its subsidiaries
pursuant to rights of first refusal contained in agreements providing for such rights, provided
that such repurchase is unanimously approved by the Board of Directors, and (iii)&nbsp;any other
repurchase or redemption of Common Stock unanimously approved by the Board of Directors and
approved by the</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">holders of more than two-thirds (2/3) of the outstanding shares of Preferred Stock voting together as
a single class.</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Liquidation Rights</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution or winding up of the Corporation,
either voluntary or involuntary, distribution of the assets of the Corporation legally available
for distribution to the Corporation&#146;s stockholders shall be made in the following manner:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;E Liquidation Preference</U>. The holders of the Series&nbsp;E Preferred Stock
shall be entitled to receive, prior and in preference to any distribution of any of the assets of
the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock, the Series&nbsp;B
Preferred Stock, the Series&nbsp;C Preferred Stock, or the Series&nbsp;D Preferred Stock, by reason of their
ownership of such stock, an amount per share for each share of Series&nbsp;E Preferred Stock held by
them equal to the sum of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and
unpaid dividends on such share of Series&nbsp;E Preferred Stock. If the assets of the Corporation
legally available for distribution to the holders of the Series&nbsp;E Preferred Stock are insufficient
to permit the payment to such holders of the full amounts specified in this Section&nbsp;5(a), then the
entire assets of the Corporation legally available for distribution shall be distributed with equal
priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;E Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this Section
5(a).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;D Liquidation Preference</U>. After payment to the holders of Series&nbsp;E
Preferred Stock of the full amounts specified in Section 5(a) above, the holders of the Series&nbsp;D
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the assets of the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock, the
Series&nbsp;B Preferred Stock or the Series&nbsp;C Preferred Stock by reason of their ownership of such
stock, an amount per share for each share of Series&nbsp;D Preferred Stock held by them equal to the sum
of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on
such share of Series&nbsp;D Preferred Stock. If the remaining assets of the Corporation legally
available for distribution to the holders of Series&nbsp;D Preferred Stock are insufficient to permit
the payment to such holders of the full amounts specified in this Section&nbsp;5(b), then the entire
remaining assets of the Corporation legally available for distribution shall be distributed with
equal priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;D Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this Section
5(b).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;C Liquidation Preference</U>. After payment to the holders of Series&nbsp;E
Preferred Stock and to the holders of Series&nbsp;D Preferred Stock of the full amounts specified in
Sections 5(a) and 5(b) above, the holders of the Series&nbsp;C Preferred Stock shall be entitled to
receive, prior and in preference to any distribution of any of the assets of the Corporation to the
holders of the Common Stock, the Series&nbsp;A Preferred Stock or the Series&nbsp;B Preferred Stock by reason
of their ownership of such stock, an amount per share for each share of Series&nbsp;C Preferred Stock
held by them equal to the sum of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all
declared and unpaid dividends on such share of Series&nbsp;C Preferred Stock. If the remaining assets of
the Corporation legally available for distribution to the holders of the Series&nbsp;C Preferred Stock
are insufficient to permit the payment to such holders of the full amounts specified in this
Section&nbsp;5(c), then the entire remaining assets of the Corporation legally available for
distribution shall be</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">distributed with equal priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;C
Preferred Stock in proportion to the full amounts they would otherwise be entitled to receive
pursuant to this Section&nbsp;5(c).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Series&nbsp;B Liquidation Preference</U>. After the payment to the holders of Series&nbsp;E
Preferred Stock, the holders of Series&nbsp;D Preferred Stock, and the holders of Series&nbsp;C Preferred
Stock of the full amounts specified in Sections&nbsp;5(a), 5(b), and 5(c) above, the holders of the
Series&nbsp;B Preferred Stock shall be entitled to receive, prior and in preference to any distribution
of any of the remaining assets of the Corporation to the holders of the Common Stock or Series&nbsp;A
Preferred Stock by reason of their ownership of such stock, an amount per share for each share of
Series&nbsp;B Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation Preference for such
shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;B Preferred Stock. If the
remaining assets of the Corporation legally available for distribution to the holders of the Series
B Preferred Stock are insufficient to permit the payment to such holders of the full amounts
specified in this Section&nbsp;5(d), then the entire remaining assets of the Corporation legally
available for distribution shall be distributed with equal priority and <U>pro</U> <U>rata</U>
among the holders of the Series&nbsp;B Preferred Stock in proportion to the full amounts they would
otherwise be entitled to receive pursuant to this Section&nbsp;5(d).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Series&nbsp;A Liquidation Preference</U>. After the payment to the holders of Series&nbsp;E
Preferred Stock, the holders of Series&nbsp;D Preferred Stock, the holders of Series&nbsp;C Preferred Stock,
and the holders of Series&nbsp;B Preferred Stock of the full amounts specified in Sections&nbsp;5(a), 5(b),
5(c) and 5(d) above, the holders of the Series&nbsp;A Preferred Stock shall be entitled to receive,
prior and in preference to any distribution of any of the remaining assets of the Corporation to
the holders of the Common Stock by reason of their ownership of such stock, an amount per share for
each share of Series&nbsp;A Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation
Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;A
Preferred Stock. If the remaining assets of the Corporation legally available for distribution to
the holders of the Series&nbsp;A Preferred Stock are insufficient to permit the payment to such holders
of the full amounts specified in this Section&nbsp;5(e), then the entire remaining assets of the
Corporation legally available for distribution shall be distributed with equal priority and
<U>pro</U> <U>rata</U> among the holders of the Series&nbsp;A Preferred Stock in proportion to the
full amounts they would otherwise be entitled to receive pursuant to this Section&nbsp;5(e).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Remaining Assets</U>. After the payment to the holders of Preferred Stock of the full
amounts specified in Sections&nbsp;5(a), 5(b), 5(c), 5(d) and 5(e) above, the entire remaining assets of
the Corporation legally available for distribution shall be distributed <U>pro</U> <U>rata</U> to
holders of the Common Stock of the Corporation in proportion to the number of shares of Common
Stock held by them.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Shares Not Treated as Both Preferred Stock and Common Stock in Any Distribution</U>.
Shares of Preferred Stock shall not be entitled to be converted into shares of Common Stock in
order to participate in any distribution, or series of distributions, as shares of Common Stock,
without first foregoing participation in the distribution, or series of distributions, as shares of
Preferred Stock.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Reorganization</U>. For purposes of this Section&nbsp;5, a liquidation, dissolution or
winding up of the Corporation shall be deemed to be occasioned by, or to include, (i)&nbsp;the
acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, any stock acquisition, reorganization, merger or
consolidation but excluding any merger effected exclusively for the purpose of changing the
domicile of the Corporation) other than a transaction or series of transactions in which the
holders of the voting securities of the Corporation outstanding immediately prior to such
transaction or series of transactions continue to retain (either by such voting securities
remaining outstanding or by such voting securities being converted into voting securities of the
surviving entity), as a result of shares in the Corporation held by such holders prior to such
transaction, at least fifty percent (50%) of the total voting power represented by the voting
securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or other conveyance of all
or substantially all of the assets of the Corporation.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Valuation of Non-Cash Consideration</U>. If any assets of the Corporation distributed
to stockholders in connection with any liquidation, dissolution, or winding up of the Corporation
are other than cash, then the value of such assets shall be their fair market value as determined
in good faith by the Board of Directors, <U>except that</U> any securities to be distributed to
stockholders in a liquidation, dissolution, or winding up of the Corporation shall be valued as
follows:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the securities are then traded on a national securities exchange or the Nasdaq Stock
Market System (or a similar national quotation system), then the value of the securities shall be
deemed to be to the average of the closing prices of the securities on such exchange or system over
the ten (10)&nbsp;trading day period ending five (5)&nbsp;trading days prior to the distribution;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;if the securities are actively traded over-the-counter, then the value of the securities
shall be deemed to be the average of the closing bid prices of the securities over the ten (10)
trading day period ending five (5)&nbsp;trading days prior to the distribution; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;if there is no active public market for the securities, then the value of the securities
shall be deemed to be the fair market value thereof as determined in good faith by the Board of
Directors which determination shall include consideration of the illiquidity of the securities.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a merger or other acquisition of the Corporation by another entity, the
distribution date shall be deemed to the date such transaction closes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Section&nbsp;5(i), &#147;<U>trading day</U>&#148; shall mean any day on which the
exchange or system on which the securities to be distributed are traded is open, and &#147;<U>closing
prices</U>&#148; or &#147;<U>closing bid prices</U>&#148; shall be deemed to be: (i)&nbsp;for securities traded
primarily on the New York Stock Exchange, the American Stock Exchange or Nasdaq, the last reported
trade price or sale price, as the case may be, at 4:00 p.m., New York time, on that day and (ii)
for securities listed or traded on other exchanges, markets and systems, the market price as of the
end of the &#147;regular hours&#148; trading period that is generally accepted as such for such exchange,
market or system. If, after the date hereof, the benchmark times generally accepted in the
securities industry for determining the market
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">price of a stock as of a given trading day shall change from those set forth above, the fair
market value shall be determined as of such other generally accepted benchmark times.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Conversion</U>. The holders of the Preferred Stock shall have conversion rights as
follows (the &#147;<U>Conversion Rights</U>&#148;):
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right to Convert</U>. Subject to Section&nbsp;6(c), each share of Preferred Stock shall be
convertible, at the option of the holder thereof, at any time after the date of issuance of such
share at the office of the Corporation or any transfer agent for the Preferred Stock, into that
number of fully-paid, nonassessable shares of Common Stock determined by dividing the Original
Issue Price for the relevant series by the Conversion Price for such series. (The number of shares
of Common Stock into which each share of Preferred Stock of a series may be converted is
hereinafter referred to as the &#147;<U>Conversion Rate</U>&#148; for each such series.) Upon any decrease
or increase in the Conversion Price for any series of Preferred Stock, as described in this Section
6, the Conversion Rate for such series shall be appropriately increased or decreased.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Automatic Conversion</U>. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then effective Conversion
Rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial
public offering on Form S-1 (or successor form) filed under the Securities Act of 1933, as amended
(the &#147;<U>Securities Act</U>&#148;), covering the offer and sale of the Corporation&#146;s Common Stock,
provided that the offering price per share is not less than $19.915 (as adjusted for subdivisions
and combinations of the Common Stock and changes in the Common Stock as set forth in Sections 6(e)
and 6(g)) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or
(ii)&nbsp;upon the receipt by the Corporation of a written consent or request for such conversion from
the holders of two-thirds of the shares of Preferred Stock then outstanding, or, if later, the
effective date for conversion specified in such requests (each of the events referred to in (i)&nbsp;and
(ii)&nbsp;being hereinafter referred to as an &#147;<U>Automatic Conversion Event</U>&#148;). Notwithstanding the
foregoing, the Series&nbsp;E Preferred Stock shall not be subject to an Automatic Conversion Event
unless either (x)&nbsp;such Automatic Conversion Event is approved by the written consent of holders of
more than two-thirds of the shares of Series&nbsp;E Preferred Stock then outstanding, or (y)&nbsp;such
Automatic Conversion Event is the closing of a firm commitment underwritten initial public offering
on Form S-1 (or successor form) filed under the Securities Act and the requirements of Section
6(b)(i) or 6(b)(ii) are met.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Mechanics of Conversion</U>. No fractional shares of Common Stock shall be issued
upon conversion of Preferred Stock. In lieu of any fractional shares to which the holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then
fair market value of a share of Common Stock as determined by the Board of Directors. For such
purpose, all shares of Preferred Stock held by each holder of Preferred Stock shall be aggregated,
and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of
Preferred Stock shall be entitled to convert the same into full shares of Common Stock, and to
receive certificates therefor, he shall either surrender the certificate or certificates therefor,
duly endorsed, at the office of the Corporation or of any transfer agent for the Preferred Stock,
or notify the Corporation or its transfer agent that such certificate or certificates have been
lost, stolen or destroyed and execute an agreement satisfactory to the Corporation to indemnify the
Corporation from any loss incurred by it in connection with such certificate or certificates, and
shall give written notice to the Corporation at such office that he elects to convert the same;
<U>provided</U>, <U>however</U>, that on</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the date of an Automatic Conversion Event, the outstanding shares of Preferred Stock shall be
converted automatically without any further action by the holders of such shares and whether or not
the certificates representing such shares are surrendered to the Corporation or its transfer agent;
<U>provided further</U>, however, that the Corporation shall not be obligated to issue
certificates evidencing the shares of Common Stock issuable upon such Automatic Conversion Event
unless either the certificates evidencing such shares of Preferred Stock are delivered to the
Corporation or its transfer agent as provided above, or the holder notifies the Corporation or its
transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement
satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in
connection with such certificates. On the date of the occurrence of an Automatic Conversion Event,
each holder of record of shares of Preferred Stock shall be deemed to be the holder of record of
the Common Stock issuable upon such conversion, notwithstanding that the certificates representing
such shares of Preferred Stock shall not have been surrendered at the office of the Corporation,
that notice from the Corporation shall not have been received by any holder of record of shares of
Preferred Stock, or that the certificates evidencing such shares of Common Stock shall not then be
actually delivered to such holder.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall, as soon as practicable after such delivery, or after such agreement and
indemnification, issue and deliver at such office to such holder of Preferred Stock, a certificate
or certificates for the number of shares of Common Stock to which he shall be entitled as aforesaid
and a check payable to the holder in the amount of any cash amounts payable as the result of a
conversion into fractional shares of Common Stock, plus any declared and unpaid dividends on the
converted Preferred Stock. Such conversion shall be deemed to have been made immediately prior to
the close of business on the date of such surrender of the shares of Preferred Stock to be
converted, and the person or persons entitled to receive the shares of Common Stock issuable upon
such conversion shall be treated for all purposes as the record holder or holders of such shares of
Common Stock on such date; <U>provided</U>, <U>however</U>, that if the conversion is in
connection with an underwritten offer of securities registered pursuant to the Securities Act the
conversion may, at the option of any holder tendering Preferred Stock for conversion, be
conditioned upon the closing of the sale of securities pursuant to such offering, in which event
the person(s) entitled to receive the Common Stock issuable upon such conversion of the Preferred
Stock shall not be deemed to have converted such Preferred Stock until immediately prior to the
closing of the sale of such securities.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Adjustments to Conversion Price for Diluting Issues</U>.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Special Definition</U>. For purposes of this Section&nbsp;6(d), &#147;<U>Additional Shares of
Common</U>&#148; shall mean all shares of Common Stock issued (or, pursuant to Section&nbsp;6(d)(iii), deemed
to be issued) by the Corporation after the filing of this Certificate of Incorporation, other than:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) &#091;omitted&#093;;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;shares of Common Stock issued or issuable to officers, directors and employees of, or
consultants and other service providers to, the Corporation pursuant to stock grants, option plans,
purchase plans or other employee stock incentive programs or arrangements approved by the Board of
Directors or upon exercise of options or warrants granted to such parties pursuant to any such
plan, program or arrangement;</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;shares of Common Stock issued upon the exercise or conversion of Options or Convertible
Securities outstanding as of the date of the filing of this Certificate of Incorporation;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;shares of Common Stock issued or issuable as a dividend or distribution on Preferred Stock
or pursuant to any event for which adjustment is made pursuant to Section&nbsp;6(e), 6(f) or 6(g)
hereof;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;shares of Common Stock issued in a registered public offering under the Securities Act
pursuant to which all outstanding shares of Preferred Stock are automatically converted into Common
Stock pursuant to an Automatic Conversion Event;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;shares of Common Stock issued or issuable pursuant to the acquisition of another
corporation by the Corporation by merger, purchase of substantially all of the assets or other
reorganization or to a joint venture agreement, provided, that such issuances are unanimously
approved by the Board of Directors;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;shares of Common Stock issued or issuable to banks, equipment lessors or other financial
institutions pursuant to a commercial leasing or debt financing transaction approved by the Board
of Directors;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)&nbsp;shares of Common Stock issued or issuable in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements, or
strategic partnerships or relationships, if the issuance is approved by the Board of Directors; and</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)&nbsp;shares of Common Stock issued or issuable upon conversion of convertible promissory notes
issued or issuable to Biomedical Sciences Investment Fund Pte Ltd. or its affiliates
(&#147;<U>BMSIF</U>&#148;) pursuant to that certain Convertible Note Purchase Agreement, dated as of August
7, 2006, between the Company and BMSIF, as amended by the Letter Agreement dated November&nbsp;15, 2006
(as amended, the &#147;<U>Note Purchase Agreement</U>&#148;) (as such Note Purchase Agreement may be further
amended from time to time after the date hereof) or upon any failure of the milestones to be
satisfied under such convertible promissory notes; and shares of Common Stock issued or issuable
upon conversion of up to $3&nbsp;million in aggregate principal amount (plus interest) of convertible
promissory notes originally issued or issuable to BMSIF pursuant to that certain Convertible Note
Purchase Agreement, dated as of December&nbsp;18, 2003, between the Company and BMSIF.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <U>No Adjustment of Conversion Price</U>. No adjustment in the Conversion Price of a
particular series of Preferred Stock shall be made in respect of the issuance of Additional Shares
of Common unless the consideration per share (as determined pursuant to Section&nbsp;6(d)(vii)) for an
Additional Share of Common issued or deemed to be issued by the Corporation is less than the
Conversion Price in effect on the date of, and immediately prior to such issue, for such series of
Preferred Stock.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <U>Deemed Issue of Additional Shares of Common</U>. In the event the Corporation at
any time or from time to time after the date of the filing of this Certificate of Incorporation
shall issue any Options or Convertible Securities or shall fix a record date for the</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">determination of holders of any class of securities entitled to receive any such Options or
Convertible Securities, then the maximum number of shares (as set forth in the instrument relating
thereto without regard to any provisions contained therein for a subsequent adjustment of such
number) of Common Stock issuable upon the exercise of such Options or, in the case of Convertible
Securities, the conversion or exchange of such Convertible Securities or, in the case of Options
for Convertible Securities, the exercise of such Options and the conversion or exchange of the
underlying securities, shall be deemed to have been issued as of the time of such issue or, in case
such a record date shall have been fixed, as of the close of business on such record date, provided
that in any such case in which shares are deemed to be issued:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;no further adjustment in the Conversion Price of the Preferred Stock shall be made upon
the subsequent issue of Convertible Securities or shares of Common Stock in connection with the
exercise of such Options or conversion or exchange of such Convertible Securities pursuant to the
terms of such Options or Convertible Securities;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;if no adjustment in the Conversion Price of the Preferred Stock was made upon the original
issue of (or upon the occurrence of a record date with respect to) such Options or Convertible
Securities and such Options or Convertible Securities are revised to provide, or by their terms
provide, with the passage of time or otherwise, for any increase or decrease in the consideration
payable to the Corporation, or any increase or decrease in the number of shares of Common Stock
issuable, upon the exercise, conversion or exchange thereof, then such Options or Convertible
Securities as so revised (and the Additional Shares of Common subject thereto) shall be deemed to
have been issued effective upon such increase or decrease becoming effective;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;if such Options or Convertible Securities are revised to provide, or by their terms
provide, with the passage of time or otherwise, for any increase or decrease in the consideration
payable to the Corporation, or any increase or decrease in the number of shares of Common Stock
issuable, upon the exercise, conversion or exchange thereof, the Conversion Price of the Preferred
Stock computed upon the original issue thereof (or upon the occurrence of a record date with
respect thereto), and any subsequent adjustments based thereon, shall, upon any such increase or
decrease becoming effective, be recomputed to reflect such increase or decrease insofar as it
affects such Options or the rights of conversion or exchange under such Convertible Securities;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;no readjustment pursuant to clause (3)&nbsp;above shall have the effect of increasing the
Conversion Price of the Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion
Price of the Preferred Stock on the original adjustment date, or (ii)&nbsp;the Conversion Price of the
Preferred Stock that would have resulted from any issuance of Additional Shares of Common between
the original adjustment date and such readjustment date;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;upon the expiration of any such Options or any rights of conversion or exchange under such
Convertible Securities which shall not have been exercised, the Conversion Price computed upon the
original issue thereof (or upon the occurrence of a record date with respect thereto) and any
subsequent adjustments based thereon shall, upon such expiration, be recomputed as if:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;in the case of Convertible Securities or Options for Common Stock, the only Additional
Shares of Common issued were the shares of Common Stock, if</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any, actually issued upon the exercise of such Options or the conversion or exchange of such
Convertible Securities and the consideration received therefor was the consideration actually
received by the Corporation for the issue of such exercised Options plus the consideration actually
received by the Corporation upon such exercise or for the issue of all such Convertible Securities
which were actually converted or exchanged, plus the additional consideration, if any, actually
received by the Corporation upon such conversion or exchange, and</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;in the case of Options for Convertible Securities, only the Convertible Securities, if
any, actually issued upon the exercise thereof were issued at the time of issue of such Options,
and the consideration received by the Corporation for the Additional Shares of Common deemed to
have been then issued was the consideration actually received by the Corporation for the issue of
such exercised Options, plus the consideration deemed to have been received by the Corporation
(determined pursuant to Section&nbsp;6(d)(vii)) upon the issue of the Convertible Securities with
respect to which such Options were actually exercised; and</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;if such record date shall have been fixed and such Options or Convertible Securities are
not issued on the date fixed therefor, the adjustment previously made in the Conversion Price which
became effective on such record date shall be canceled as of the close of business on such record
date, and thereafter the Conversion Price shall be adjusted pursuant to this Section&nbsp;6(d)(iii) as
of the actual date of their issuance.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <U>Adjustment of Conversion Price of Series&nbsp;E Preferred Stock Upon Issuance of
Additional Shares of Common</U>.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;For so long as the Conversion Price of the Series&nbsp;E Preferred Stock is greater than $9.03
(as adjusted for subdivisions and combinations of the Common Stock and changes in the Common Stock
as set forth in Sections 6(e) and 6(g)) (the &#147;<U>Series&nbsp;D/E Ratchet Amount</U>&#148;), in the event
this Corporation shall issue Additional Shares of Common (including Additional Shares of Common
deemed to be issued pursuant to Section&nbsp;6(d)(iii)) for a consideration per share less than the
applicable Conversion Price of the Series&nbsp;E Preferred Stock in effect on the date of and
immediately prior to such issue, but for a consideration per share equal to or greater than the
Series&nbsp;D/E Ratchet Amount, then the Conversion Price of the Series&nbsp;E Preferred Stock shall be
reduced concurrently with such issue to a price (calculated to the nearest cent) equal to the per
share price of the Additional Shares of Common.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;In the event this Corporation shall issue Additional Shares of Common (including
Additional Shares of Common deemed to be issued pursuant to Section&nbsp;6(d)(iii)) without
consideration or for a consideration per share less than the Series&nbsp;D/E Ratchet Amount, then the
Conversion Price of the Series&nbsp;E Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series&nbsp;D/E Ratchet Amount (the &#147;<U>Series&nbsp;E Adjusted Conversion Price</U>&#148;), and
such Series&nbsp;E Adjusted Conversion Price shall be further reduced, concurrently with such issue, to
a price (calculated to the nearest cent) determined by multiplying such Series&nbsp;E Adjusted
Conversion Price by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately prior to such issue plus the number of shares of Common Stock which
the aggregate consideration received by the Corporation for the total number of Additional Shares
of Common so issued would purchase at such Adjusted Conversion Price, and the denominator of which
shall be the number of shares of Common Stock outstanding immediately</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">prior to such issue plus the number of such Additional Shares of Common so issued. For the
purposes of this Section&nbsp;6(d)(iv)(2), all shares of Common Stock issuable upon exercise of
outstanding Options or the conversion of outstanding Convertible Securities and shares of Preferred
Stock, and all Additional Shares of Common deemed issued pursuant to Section&nbsp;6(d)(iii) hereof,
shall be deemed to be outstanding. Section&nbsp;6(d)(iv)(3) shall govern adjustments to the Conversion
Price of the Series&nbsp;E Preferred Stock after the first adjustment to the Conversion Price of the
Series&nbsp;E Preferred Stock pursuant to this Section&nbsp;6(d)(iv)(2).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;After any adjustment to the Conversion Price of the Series&nbsp;E Preferred Stock pursuant to
Section&nbsp;6(d)(iv)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to Section&nbsp;6(d)(iii)) without
consideration or for a consideration per share less than Conversion Price of the Series&nbsp;E Preferred
Stock in effect on the date of and immediately prior to such issue, then, the Conversion Price of
the Series&nbsp;E Preferred Stock shall be reduced concurrently with such issue, to a price (calculated
to the nearest cent) determined by multiplying such Conversion Price by a fraction, the numerator
of which shall be the number of shares of Common Stock outstanding immediately prior to such issue
plus the number of shares of Common Stock which the aggregate consideration received by the
Corporation for the total number of Additional Shares of Common so issued would purchase at such
Conversion Price, and the denominator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of such Additional Shares of Common so
issued. For the purposes of this Section&nbsp;6(d)(iv)(3), all shares of Common Stock issuable upon
exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares
of Preferred Stock, and all Additional Shares of Common deemed issued pursuant to Section&nbsp;6(d)(iii)
hereof, shall be deemed to be outstanding.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <U>Adjustment of Conversion Price of Series&nbsp;D Preferred Stock Upon Issuance of Additional
Shares of Common</U>.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;For so long as the Conversion Price of the Series&nbsp;D Preferred Stock is greater than the
Series&nbsp;D/E Ratchet Amount, in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to Section&nbsp;6(d)(iii)) for a
consideration per share less than the applicable Conversion Price of the Series&nbsp;D Preferred Stock
in effect on the date of and immediately prior to such issue, but for a consideration per share
equal to or greater than the Series&nbsp;D/E Ratchet Amount, then the Conversion Price of the Series&nbsp;D
Preferred Stock shall be reduced concurrently with such issue to a price (calculated to the nearest
cent) equal to the per share price of the Additional Shares of Common.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;In the event this Corporation shall issue Additional Shares of Common (including
Additional Shares of Common deemed to be issued pursuant to Section&nbsp;6(d)(iii)) without
consideration or for a consideration per share less than the Series&nbsp;D/E Ratchet Amount, then the
Conversion Price of the Series&nbsp;D Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series&nbsp;D/E Ratchet Amount (the &#147;<U>Series&nbsp;D Adjusted Conversion Price</U>&#148;), and
such Series&nbsp;D Adjusted Conversion Price shall be further reduced, concurrently with such issue, to
a price (calculated to the nearest cent) determined by multiplying such Series&nbsp;D Adjusted
Conversion Price by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately prior to such issue plus the number of shares of Common Stock which
the aggregate consideration received by the Corporation for the total number of</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Additional Shares of Common so issued would purchase at such Series&nbsp;D Adjusted Conversion
Price, and the denominator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of such Additional Shares of Common so issued. For
the purposes of this Section&nbsp;6(d)(v)(2), all shares of Common Stock issuable upon exercise of
outstanding Options or the conversion of outstanding Convertible Securities and shares of Preferred
Stock, and all Additional Shares of Common deemed issued pursuant to Section&nbsp;6(d)(iii) hereof,
shall be deemed to be outstanding. Section&nbsp;6(d)(v)(3) shall govern adjustments to the Conversion
Price of the Series&nbsp;D Preferred Stock after the first adjustment to the Conversion Price of the
Series&nbsp;D Preferred Stock pursuant to this Section&nbsp;6(d)(v)(2).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;After any adjustment to the Conversion Price of the Series&nbsp;D Preferred Stock pursuant to
Section&nbsp;6(d)(v)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to Section&nbsp;6(d)(iii)) without
consideration or for a consideration per share less than Conversion Price of the Series&nbsp;D Preferred
Stock in effect on the date of and immediately prior to such issue, then, the Conversion Price of
the Series&nbsp;D Preferred Stock shall be reduced concurrently with such issue, to a price (calculated
to the nearest cent) determined by multiplying such Conversion Price by a fraction, the numerator
of which shall be the number of shares of Common Stock outstanding immediately prior to such issue
plus the number of shares of Common Stock which the aggregate consideration received by the
Corporation for the total number of Additional Shares of Common so issued would purchase at such
Conversion Price, and the denominator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of such Additional Shares of Common so
issued. For the purposes of this Section&nbsp;6(d)(v)(3), all shares of Common Stock issuable upon
exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares
of Preferred Stock, and all Additional Shares of Common deemed issued pursuant to Section&nbsp;6(d)(iii)
hereof, shall be deemed to be outstanding.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <U>Adjustment of Conversion Price of Series&nbsp;A, B and C Preferred Stock</U>. In the
event this Corporation shall issue Additional Shares of Common (including Additional Shares of
Common deemed to be issued pursuant to Section&nbsp;6(d)(iii)) without consideration or for a
consideration per share less than the applicable Conversion Price of the Series&nbsp;A Preferred Stock,
Series&nbsp;B Preferred Stock or Series&nbsp;C Preferred Stock in effect on the date of and immediately prior
to such issue, then, the Conversion Price of the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock
or Series&nbsp;C Preferred Stock (if affected) shall be reduced, concurrently with such issue, to a
price (calculated to the nearest cent) determined by multiplying such Conversion Price by a
fraction, the numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of shares of Common Stock which the aggregate
consideration received by the Corporation for the total number of Additional Shares of Common so
issued would purchase at such Conversion Price, and the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such
Additional Shares of Common so issued. For the purposes of this Section&nbsp;6(d)(vi), all shares of
Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding
Convertible Securities and shares of Preferred Stock, and all Additional Shares of Common deemed
issued pursuant to Section&nbsp;6(d)(iii) hereof, shall be deemed to be outstanding.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <U>Determination of Consideration</U>. For purposes of this Section&nbsp;6(d), the
consideration received by the Corporation for the issue (or deemed issue) of any Additional Shares
of Common shall be computed as follows:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) <U>Cash and Property</U>. Such consideration shall:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;insofar as it consists of cash, be computed at the aggregate amount of cash received by
the Corporation before deducting reasonable discounts, commissions or other expenses allowed, paid
or incurred by the Corporation for any underwriting or otherwise in connection with such issue (or
deemed issue);</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;insofar as it consists of property other than cash, be computed at the fair market value
thereof at the time of such issue, as determined in good faith by the Board of Directors; and</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;in the event Additional Shares of Common are issued together with other shares or
securities or other assets of the Corporation for consideration which covers both, be the
proportion of such consideration so received, computed as provided in clauses (A)&nbsp;and (B)&nbsp;above, as
reasonably determined in good faith by the Board of Directors.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) <U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common deemed to have been issued pursuant to Section
6(d)(iii) shall be determined by dividing</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)&nbsp;the total amount, if any, received or receivable by the Corporation as consideration for
the issue of such Options or Convertible Securities, plus the minimum aggregate amount of
additional consideration (as set forth in the instruments relating thereto, without regard to any
provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible
Securities, or in the case of Options for Convertible Securities, the exercise of such Options for
Convertible Securities and the conversion or exchange of such Convertible Securities by</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)&nbsp;the maximum number of shares of Common Stock (as set forth in the instruments relating
thereto, without regard to any provision contained therein for a subsequent adjustment of such
number) issuable upon the exercise of such Options or the conversion or exchange of such
Convertible Securities.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Adjustments for Subdivisions or Combinations of Common Stock</U>. In the event the
outstanding shares of Common Stock shall be subdivided (by stock split, by payment of a stock
dividend or otherwise), into a greater number of shares of Common Stock, the Conversion Price of
each series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently
with the effectiveness of such subdivision, be proportionately decreased. In the event the
outstanding shares of Common Stock shall be combined (by reclassification or otherwise) into a
lesser number of shares of Common Stock, the Conversion Prices in effect immediately prior to such
combination shall, concurrently with the effectiveness of such combination, be proportionately
increased.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Adjustments for Subdivisions or Combinations of Preferred Stock</U>. In the event the
outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock
split, by payment of a stock dividend or otherwise), into a greater number of shares of Preferred
Stock, the Dividend Rate, Original Issue Price and Liquidation Preference of the affected series of
Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the
effectiveness of such subdivision, be proportionately decreased. In the event the outstanding
shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or
otherwise) into a lesser number of shares of Preferred Stock, the Dividend Rate, Original Issue
Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately
prior to such combination shall, concurrently with the effectiveness of such combination, be
proportionately increased.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Adjustments for Reclassification, Exchange and Substitution</U>. Subject to Section&nbsp;5
above (&#147;<U>Liquidation Rights</U>&#148;), if the Common Stock issuable upon conversion of the Preferred
Stock shall be changed into the same or a different number of shares of any other class or classes
of stock, whether by capital reorganization, reclassification or otherwise (other than a
subdivision or combination of shares provided for above), then, in any such event, in lieu of the
number of shares of Common Stock which the holders would otherwise have been entitled to receive,
each holder of such Preferred Stock shall have the right thereafter to convert such shares of
Preferred Stock into a number of shares of such other class or classes of stock which a holder of
the number of shares of Common Stock deliverable upon conversion of such series of Preferred Stock
immediately before that change would have been entitled to receive in such reorganization or
reclassification, all subject to further adjustment as provided herein with respect to such other
shares.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>No Impairment</U>. The Corporation will not through any reorganization, transfer of
assets, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms to be observed or performed
hereunder by the Corporation but will at all times in good faith assist in the carrying out of all
the provisions of this Section&nbsp;6 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of Preferred Stock against
impairment. Notwithstanding the foregoing, nothing in this Section 6(h) shall prohibit the
Corporation from amending its Certificate of Incorporation with the requisite consent of its
stockholders and the board of directors.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or
readjustment of the Conversion Price pursuant to this Section&nbsp;6, the Corporation at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based.
The Corporation shall, upon the written request at any time of any holder of Preferred Stock,
furnish or cause to be furnished to such holder a like certificate setting forth (i)&nbsp;such
adjustments and readjustments, (ii)&nbsp;the Conversion Price at the time in effect and (iii)&nbsp;the number
of shares of Common Stock and the amount, if any, of other property which at the time would be
received upon the conversion of Preferred Stock.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <U>Notices of Record Date</U>. In the event that this Corporation shall propose at any
time:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to declare any dividend or distribution upon its Common Stock, whether in cash, property,
stock or other securities, whether or not a regular cash dividend and whether or not out of
earnings or earned surplus;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;to effect any reclassification or recapitalization of its Common Stock outstanding
involving a change in the Common Stock; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a
liquidation, dissolution or winding up of the corporation pursuant to Section&nbsp;5(h);</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then, in connection with each such event, this Corporation shall send to the holders of the
Preferred Stock at least 14&nbsp;days&#146; prior written notice of the date on which a record shall be taken
for such dividend or distribution (and specifying the date on which the holders of Common Stock
shall be entitled thereto) or for determining rights to vote in respect of the matters referred to
in (ii)&nbsp;and (iii)&nbsp;above.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each such written notice shall be given by first class mail, postage prepaid, addressed to the
holders of Preferred Stock at the address for each such holder as shown on the books of this
Corporation.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right of the holders of the Preferred Stock to notice hereunder may be waived by the
holders of more than two-thirds (2/3) of the outstanding shares of the Preferred Stock voting
together as a single class. Notwithstanding the foregoing, no waiver of notice under this Section
6(j) shall constitute a waiver of notice with respect to the Series&nbsp;E Preferred Stock unless such
waiver shall have been approved by the written consent of holders of more than two-thirds (2/3) of
the shares of Series&nbsp;E Preferred Stock then outstanding.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <U>Reservation of Stock Issuable Upon Conversion</U>. The Corporation shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the
purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares
of Common Stock as shall from time to time be sufficient to effect the conversion of all then
outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued
shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding
shares of the Preferred Stock, the Corporation will take such corporate action as may, in the
opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purpose.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <U>Waiver of Adjustment of Conversion Price</U>. Notwithstanding anything herein to the
contrary, any downward adjustment of the Conversion Price of any series of Preferred Stock may be
waived by the consent or vote of the holders of more than two-thirds (2/3) of the outstanding shares
of such series. Any such waiver shall bind all future holders of shares of such series of Preferred
Stock.</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Voting</U>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Restricted Class&nbsp;Voting</U>. Except as otherwise expressly provided herein or as
required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together
and not as separate classes.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>No Series&nbsp;Voting</U>. Other than as provided herein or required by law, there shall
be no series voting.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Preferred Stock</U>. Each holder of Preferred Stock shall be entitled to the number
of votes equal to the number of shares of Common Stock into which the shares of Preferred Stock
held by such holder could be converted as of the record date. The holders of shares of the
Preferred Stock shall be entitled to vote on all matters on which the Common Stock shall be
entitled to vote. Holders of Preferred Stock shall be entitled to notice of any stockholders&#146;
meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be
permitted and any fractional voting rights resulting from the above formula (after aggregating all
shares into which shares of Preferred Stock held by each holder could be converted), shall be
disregarded.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Common Stock</U>. Each holder of shares of Common Stock shall be entitled to one vote
for each share thereof held.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Adjustment in Authorized Common Stock</U>. The number of authorized shares of Common
Stock may be increased or decreased (but not below the number of shares of Common Stock then
outstanding) by an affirmative vote of the holders of a majority of the outstanding Common Stock
and Preferred Stock, voting together as a single class.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Election of Directors</U>. So long as at least 571,428 shares of Series&nbsp;D Preferred
Stock (as adjusted for stock splits, subdivisions, combinations or stock dividends with respect to
such shares) remain outstanding, the holders of the Series&nbsp;D Preferred Stock, voting as a separate
class, shall be entitled to elect two (2)&nbsp;members of the Corporation&#146;s Board of Directors at each
meeting or pursuant to each consent of the Corporation&#146;s stockholders for the election of
directors. So long as at least 571,428 shares of Series&nbsp;C Preferred Stock (as adjusted for stock
splits, subdivisions, combinations or stock dividends with respect to such shares) remain
outstanding, the holders of Series&nbsp;C Preferred Stock, voting as a separate class, shall be entitled
to elect three (3)&nbsp;members of the Corporation&#146;s Board of Directors at each meeting or pursuant to
each consent of the Corporation&#146;s stockholders for the election of directors. Any additional
members of the Corporation&#146;s Board of Directors shall be elected by the holders of Common Stock,
Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, and Series&nbsp;E Preferred Stock, voting together
as a single class.</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Amendments and Changes Requiring Approval of Preferred Stock</U>. As long as any of
the Preferred Stock shall be issued and outstanding, the Corporation shall not, without first
obtaining the approval (by vote or written consent as provided by law) of the holders of at least
two-thirds (2/3) of the outstanding shares of the Preferred Stock voting together as a single class:
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation or By-laws of the
Corporation (including pursuant to a merger) if such action would adversely alter the</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rights, preferences, privileges or powers of, or restrictions provided for the benefit of the
Preferred Stock or any series thereof;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;enter into any transaction or series of related transactions deemed to be a liquidation,
dissolution or winding up of the Corporation pursuant to Section 5(h) above;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;voluntarily liquidate or dissolve;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section 4(d) except for distributions upon
a liquidation or dissolution) with respect to the Common Stock of the Corporation;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;permit any subsidiary of the Corporation to sell securities to a third party (other than
directors&#146; qualifying shares in the case of subsidiaries outside the United States);</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;authorize or create (by reclassification, merger or otherwise) any new class or series of
capital stock having rights, preferences or privileges with respect to dividends, liquidation,
redemption, conversion or other rights senior to or on a parity with any series of Preferred Stock
or with respect to voting senior to any series of Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;increase or decrease the authorized number of directors of the Corporation; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend this Section&nbsp;8.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;E Preferred Stock</U>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As long as any of the Series&nbsp;E Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least 60% of the outstanding shares of the Series&nbsp;E Preferred Stock:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation (including pursuant to a merger) if such action would adversely alter the rights,
preferences, privileges or powers of, or restrictions provided for the benefit of the Series&nbsp;E
Preferred Stock in a manner different from any other series of Preferred Stock; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;9(a).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As long as any of the Series&nbsp;E Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least a majority of the outstanding shares of the Series&nbsp;E Preferred
Stock:</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;declare or pay any distribution (as defined in Section 4(d) except for distributions upon
a liquidation or dissolution) with respect to the Common Stock or Preferred Stock of the
Corporation; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;9(b).</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;As long as any of the Series&nbsp;E Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least 66 2/3% of the outstanding shares of the Series&nbsp;D Preferred Stock
and Series&nbsp;E Preferred Stock voting together as a single class on an as converted to Common Stock
basis:</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;E Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;authorize or create (by reclassification, merger or otherwise) any new class or series of
capital stock having rights, preferences or privileges with respect to dividends, payments upon
liquidation or other rights senior to or on a parity with the Series&nbsp;E Preferred Stock or with
respect to voting senior to the Series&nbsp;E Preferred Stock; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;amend this Section&nbsp;9(c).</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;D Preferred Stock</U>.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As long as any of the Series&nbsp;D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least 60% of the outstanding shares of the Series&nbsp;D Preferred Stock:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;D Preferred Stock in a manner different from
any other series of Preferred Stock; or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;10(a).</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As long as any of the Series&nbsp;D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of at least a majority of the outstanding shares of the Series&nbsp;D Preferred
Stock:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;D Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;D Preferred Stock or with respect to
voting senior to the Series&nbsp;D Preferred Stock;</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;declare or pay any distribution (as defined in Section 4(d) except for distributions
upon a liquidation or dissolution) with respect to the Common Stock or Preferred Stock of the
Corporation;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;increase the authorized number of directors of the Corporation above eleven (11); or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;amend this Section&nbsp;10(b).</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;C Preferred Stock</U>. As
long as any of the Series&nbsp;C Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of at least two-thirds (2/3) of the outstanding shares of the Series&nbsp;C Preferred Stock:
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;C Preferred Stock in a manner different from
any other series of Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;C Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;C Preferred Stock or with respect to
voting senior to the Series&nbsp;C Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section 4(d) except for distributions upon
a liquidation or dissolution) with respect to the Common Stock or Preferred Stock of the
Corporation;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;increase the authorized number of directors of the Corporation above eleven (11); or</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;amend this Section&nbsp;11.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;B Preferred Stock</U>. As
long as any of the Series&nbsp;B Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of at least two-thirds of the outstanding shares of the Series&nbsp;B Preferred Stock:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Certificate of Incorporation of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Series&nbsp;B Preferred Stock in a manner different from
any other series of Preferred Stock;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;B Preferred Stock; or</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;amend this Section&nbsp;12.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Status of Converted Stock.</U> In the event any shares of Preferred Stock shall be
converted pursuant to Article&nbsp;4 hereof, then the shares so converted shall be cancelled and shall
not be issuable by the Corporation. The Certificate of Incorporation shall be appropriately amended
to effect the corresponding reduction in the Corporation&#146;s authorized capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Notices</U>. Any notice required by the provisions of this Article&nbsp;IV to be given to
the holders of Preferred Stock shall be deemed given if deposited in the United States mail,
postage prepaid, and addressed to each holder of record at such holder&#146;s address appearing on the
books of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation reserves the right to amend, alter, change, or repeal any provision contained
in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all
rights conferred upon the stockholders herein are granted subject to this right.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation is to have perpetual existence.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Elections of directors need not be by written ballot unless a stockholder demands election by
written ballot at the meeting and before voting begins or unless the Bylaws of the Corporation
shall so provide.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise set forth herein, the number of directors which constitute the Board of
Directors of the Corporation shall be designated in the Bylaws of the Corporation .
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IX
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In furtherance and not in limitation of the powers conferred by statute, the Board of
Directors is expressly authorized to make, alter, amend or repeal the Bylaws of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE X
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Limitation of Directors&#146; Liability</U>. To the fullest extent permitted by the General
Corporation Law of the State of Delaware as the same exists or as may hereafter be amended, a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">director of the Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Indemnification</U>. The Corporation may indemnify to the fullest extent permitted by
law any person made or threatened to be made a party to an action or proceeding, whether criminal,
civil, administrative or investigative, by reason of the fact that such person or his or her
testator or intestate is or was a director, officer or employee of the Corporation, or any
predecessor of the Corporation, or serves or served at any other enterprise as a director, officer
or employee at the request of the Corporation or any predecessor to the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Amendments</U>. Neither any amendment nor repeal of this Article&nbsp;VII, nor the adoption
of any provision of the Corporation&#146;s Certificate of Incorporation inconsistent with this Article
VII, shall eliminate or reduce the effect of this Article&nbsp;VII, in respect of any matter occurring,
or any action or proceeding accruing or arising or that, but for this Article&nbsp;VII, would accrue or
arise, prior to such amendment, repeal, or adoption of an inconsistent provision.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XI
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings of the stockholders may be held within or without the State of Delaware, as the
Bylaws may provide. The books of the Corporation may be kept (subject to any provision contained in
the statutes) outside of the State of Delaware at such place or places as may be designated from
time to time by the Board of Directors or in the Bylaws of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * *
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>4
<FILENAME>f39432a9exv3w4.htm
<DESCRIPTION>EXHIBIT 3.4
<TEXT>
<HTML>
<HEAD>
<TITLE>exv3w4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;3.4</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED BYLAWS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(amended and restated on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>)

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B><U>Page</U></B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="82%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE I &#151; CORPORATE OFFICES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REGISTERED OFFICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OTHER OFFICES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE II &#151; MEETINGS OF STOCKHOLDERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PLACE OF MEETINGS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ANNUAL MEETING</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SPECIAL MEETING</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NOTICE OF STOCKHOLDERS&#146; MEETINGS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">QUORUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADJOURNED MEETING; NOTICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADMINISTRATION OF THE MEETING</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VOTING</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NO STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING CONSENTS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROXIES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LIST OF STOCKHOLDERS ENTITLED TO VOTE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADVANCE NOTICE OF STOCKHOLDER BUSINESS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADVANCE NOTICE OF DIRECTOR NOMINATIONS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE III &#151; DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POWERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NUMBER OF DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RESIGNATION AND VACANCIES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PLACE OF MEETINGS; MEETINGS BY TELEPHONE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REGULAR MEETINGS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SPECIAL MEETINGS; NOTICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">QUORUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">WAIVER OF NOTICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ADJOURNED MEETING; NOTICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FEES AND COMPENSATION OF DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REMOVAL OF DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE IV &#151; COMMITTEES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COMMITTEES OF DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">COMMITTEE MINUTES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MEETINGS AND ACTION OF COMMITTEES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="CENTER" style="font-size: 10pt; margin-top: 12pt"><B>TABLE OF CONTENTS</B></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="82%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="font-size: 8pt; border-bottom: 1px solid #000000" align="center" colspan="4">Page</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE V &#151; OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">APPOINTMENT OF OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SUBORDINATE OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REMOVAL AND RESIGNATION OF OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VACANCIES IN OFFICES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REPRESENTATION OF SHARES OF OTHER CORPORATIONS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AUTHORITY AND DUTIES OF OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VI &#151; RECORDS AND REPORTS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MAINTENANCE AND INSPECTION OF RECORDS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INSPECTION BY DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VII &#151; GENERAL MATTERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHECKS; DRAFTS; EVIDENCES OF INDEBTEDNESS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">STOCK CERTIFICATES; PARTLY PAID SHARES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SPECIAL DESIGNATION ON CERTIFICATES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LOST CERTIFICATES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIVIDENDS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FISCAL YEAR</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SEAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRANSFER OF STOCK</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">STOCK TRANSFER AGREEMENTS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REGISTERED STOCKHOLDERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">WAIVER OF NOTICE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VIII &#151; NOTICE BY ELECTRONIC TRANSMISSION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NOTICE BY ELECTRONIC TRANSMISSION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DEFINITION OF ELECTRONIC TRANSMISSION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INAPPLICABILITY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE IX &#151; INDEMNIFICATION OF DIRECTORS AND OFFICERS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POWER TO INDEMNIFY IN ACTIONS, SUITS OR PROCEEDINGS OTHER THAN THOSE BY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OR IN THE RIGHT OF THE CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POWER TO INDEMNIFY IN ACTIONS, SUITS OR PROCEEDINGS BY OR IN THE RIGHT</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OF THE CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AUTHORIZATION OF INDEMNIFICATION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GOOD FAITH DEFINED</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INDEMNIFICATION BY A COURT</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EXPENSES PAYABLE IN ADVANCE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NONEXCLUSIVITY OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="CENTER" style="font-size: 10pt; margin-top: 12pt"><B>TABLE OF CONTENTS</B><BR><B>(continued)</B></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="82%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="font-size: 8pt; border-bottom: 1px solid #000000" align="center" colspan="4">Page</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INSURANCE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CERTAIN DEFINITIONS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SURVIVAL OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LIMITATION ON INDEMNIFICATION</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INDEMNIFICATION OF EMPLOYEES AND AGENTS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EFFECT OF AMENDMENT OR REPEAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE X &#151; MISCELLANEOUS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROVISIONS OF CERTIFICATE GOVERN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CONSTRUCTION; DEFINITIONS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SEVERABILITY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AMENDMENT</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED BYLAWS<BR>
OF<BR>
FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLE I &#151; CORPORATE OFFICES</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 REGISTERED OFFICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registered office of Fluidigm Corporation shall be fixed in the corporation&#146;s certificate
of incorporation, as the same may be amended and/or restated from time to time (as so amended
and/or restated, the &#147;<U>Certificate</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 OTHER OFFICES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation&#146;s Board of Directors (the &#147;<U>Board</U>&#148;) may at any time establish other
offices at any place or places where the corporation is qualified to do business.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II &#151; MEETINGS OF STOCKHOLDERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 PLACE OF MEETINGS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings of stockholders shall be held at any place within or outside the State of Delaware as
designated by the Board. The Board may, in its sole discretion, determine that a meeting of
stockholders shall not be held at any place, but may instead be held solely by means of remote
communication as authorized by Section&nbsp;211(a)(2) of the Delaware General Corporation Law (the
&#147;<U>DGCL</U>&#148;). In the absence of any such designation or determination, stockholders&#146; meetings
shall be held at the corporation&#146;s principal executive office.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 ANNUAL MEETING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The annual meeting of stockholders shall be held each year on a date and at a time designated
by the Board. At the annual meeting, directors shall be elected and any other proper business may
be transacted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 SPECIAL MEETING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise required by law or the Certificate, special meetings of the stockholders may
be called at any time, for any purpose or purposes, only by (a)&nbsp;the Board, (b)&nbsp;the Chairperson of
the Board, (c)&nbsp;the chief executive officer or (d)&nbsp;the president of the corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No business may be transacted at such special meeting other than the business specified in the
notice to stockholders of such meeting.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 NOTICE OF STOCKHOLDERS&#146; MEETINGS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All notices of meetings of stockholders shall be sent or otherwise given in accordance with
either Section&nbsp;2.5 or Section&nbsp;8.1 of these bylaws not less than ten (10)&nbsp;nor more than 60&nbsp;days
before the date of the meeting to each stockholder entitled to vote at such meeting, except as
otherwise required by applicable law. The notice shall specify the place, if any, date and hour of
the meeting, the means of remote communication, if any, by which stockholders and proxy holders may
be deemed to be present in person and vote at such meeting, and, in the case of a special meeting,
the purpose or purposes for which the meeting is called. Any previously scheduled meeting of
stockholders may be postponed, and, unless the Certificate provides otherwise, any special meeting
of the stockholders may be cancelled by resolution duly adopted by a majority of the Board members
then in office upon public notice given prior to the date previously scheduled for such meeting of
stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever notice is required to be given, under the DGCL, the Certificate or these bylaws, to
any person with whom communication is unlawful, the giving of such notice to such person shall not
be required and there shall be no duty to apply to any governmental authority or agency for a
license or permit to give such notice to such person. Any action or meeting which shall be taken
or held without notice to any such person with whom communication is unlawful shall have the same
force and effect as if such notice had been duly given. In the event that the action taken by the
corporation is such as to require the filing of a certificate with the Secretary of State of
Delaware, the certificate shall state, if such is the fact and if notice is required, that notice
was given to all persons entitled to receive notice except such persons with whom communication is
unlawful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever notice is required to be given, under any provision of the DGCL, the Certificate or
these bylaws, to any stockholder to whom (A)&nbsp;notice of two (2)&nbsp;consecutive annual meetings, or (B)
all, and at least two (2), payments (if sent by first-class mail) of dividends or interest on
securities during a 12&nbsp;month period, have been mailed addressed to such person at such person&#146;s
address as shown on the records of the corporation and have been returned undeliverable, the giving
of such notice to such person shall not be required. Any action or meeting which shall be taken or
held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such
person shall deliver to the corporation a written notice setting forth such person&#146;s then current
address, the requirement that notice be given to such person shall be reinstated. In the event
that the action taken by the corporation is such as to require the filing of a certificate with the
Secretary of State of Delaware, the certificate need not state that notice was not given to persons
to whom notice was not required to be given pursuant to Section 230(b) of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The exception in subsection (A)&nbsp;of the above paragraph to the requirement that notice be given
shall not be applicable to any notice returned as undeliverable if the notice was given by
electronic transmission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 MANNER OF GIVING NOTICE; AFFIDAVIT OF NOTICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice of any meeting of stockholders shall be given:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;if mailed, when deposited in the United States mail, postage prepaid, directed to the
stockholder at his or her address as it appears on the corporation&#146;s records;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;if electronically transmitted, as provided in Section&nbsp;8.1 of these bylaws; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;otherwise, when delivered.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An affidavit of the secretary or an assistant secretary of the corporation or of the transfer
agent or any other agent of the corporation that the notice has been given shall, in the absence of
fraud, be <I>prima facie </I>evidence of the facts stated therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice may be waived in accordance with Section&nbsp;7.12 of these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 QUORUM.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the Certificate or required by law, stockholders representing a
majority of the voting power of the issued and outstanding capital stock of the corporation,
present in person or represented by proxy, shall constitute a quorum for the transaction of
business at all meetings of the stockholders. If such quorum is not present or represented at any
meeting of the stockholders, then the chairperson of the meeting, or the stockholders representing
a majority of the voting power of the capital stock at the meeting, present in person or
represented by proxy, shall have power to adjourn the meeting from time to time until a quorum is
present or represented. At such adjourned meeting at which a quorum is present or represented, any
business may be transacted that might have been transacted at the meeting as originally noticed.
The stockholders present at a duly called meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding
the withdrawal of enough stockholders to leave less than a quorum unless the number of stockholders
who withdrew does not permit action to be taken by the stockholders in accordance with the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 ADJOURNED MEETING; NOTICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When a meeting is adjourned to another time or place, unless these bylaws otherwise require,
notice need not be given of the adjourned meeting if the time, place if any thereof, and the means
of remote communications if any by which stockholders and proxy holders may be deemed to be present
in person and vote at such adjourned meeting are announced at the meeting at which the adjournment
is taken. At the continuation of the adjourned meeting, the corporation may transact any business
that might have been transacted at the original meeting. If the adjournment is for more than 30
days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of
the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting
in accordance with the provisions of Section&nbsp;2.4 and Section&nbsp;2.5 of these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 ADMINISTRATION OF THE MEETING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings of stockholders shall be presided over by the chief executive officer of the
corporation. If the chief executive officer will not be present at a meeting of stockholders, such
meeting shall be presided over by such chairperson as the Board shall appoint, or, in the event
that the Board shall fail to make such appointment, any officer of the corporation elected by the
Board. The secretary of the meeting shall be the secretary of the corporation, or, in the absence
of the secretary of the corporation, such person as the chairperson of the meeting appoints.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board shall, in advance of any meeting of stockholders, appoint one (1)&nbsp;or more
inspector(s), who may include individual(s) who serve the corporation in other capacities,
including without limitation as officers, employees or agents, to act at the meeting of
stockholders and make a written report thereof. The Board may designate one (1)&nbsp;or more persons as
alternate inspector(s) to replace any inspector, who fails to act. If no inspector or alternate has
been appointed or is able to act at a meeting of stockholders, the chairperson of the meeting shall
appoint one (1)&nbsp;or more inspector(s) to act at the meeting. Each inspector, before discharging his
or her duties, shall take and sign an oath to faithfully execute the duties of inspector with
strict impartiality and according to the best of his or her ability. The inspector(s) or
alternate(s) shall have the duties prescribed pursuant to Section&nbsp;231 of the DGCL or other
applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board shall be entitled to make such rules or regulations for the conduct of meetings of
stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and
regulations, if any, the chairperson of the meeting shall have the right and authority to
prescribe such rules, regulations and procedures and to do all acts as, in the judgment of such
chairperson, are necessary, appropriate or convenient for the proper conduct of the meeting,
including without limitation establishing an agenda of business of the meeting, rules or
regulations to maintain order, restrictions on entry to the meeting after the time fixed for
commencement thereof and the fixing of the date and time of the opening and closing of the polls
for each matter upon which the stockholders will vote at a meeting (and shall announce such at the
meeting).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 VOTING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The stockholders entitled to vote at any meeting of stockholders shall be determined in
accordance with the provisions of Section&nbsp;2.11 of these bylaws, subject to Section&nbsp;217 (relating to
voting rights of fiduciaries, pledgors and joint owners of stock) and Section&nbsp;218 (relating to
voting trusts and other voting agreements) of the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the provisions of Section&nbsp;213 of the DGCL (relating to the
fixing of a date for determination of stockholders of record), each stockholder shall be entitled
to that number of votes for each share of capital stock held by such stockholder as set forth in
the Certificate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In all matters, other than the election of directors and except as otherwise required by law,
the Certificate or these bylaws, the affirmative vote of a majority of the voting power of the
shares present or represented by proxy at the meeting and entitled to vote on the subject matter
shall be the act of the stockholders. Directors shall be elected by a plurality of the voting
power of the shares present in person or represented by proxy at the meeting and entitled to vote
on the election of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The stockholders of the corporation shall not have the right to cumulate their votes for the
election of directors of the corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 NO STOCKHOLDER ACTION BY WRITTEN CONSENT WITHOUT A MEETING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any action required or permitted to be taken by the stockholders of the corporation (if the
corporation has more than one stockholder at such time) must be effected at a duly called annual or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">special meeting of stockholders of the corporation and may not be effected by any consent in
writing by such stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 RECORD DATE FOR STOCKHOLDER NOTICE; VOTING; GIVING CONSENTS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order that the corporation may determine the stockholders entitled to notice of or to vote
at any meeting of stockholders or any adjournment thereof, or entitled to receive payment of any
dividend or other distribution or allotment of any rights, or entitled to exercise any rights in
respect of any change, conversion or exchange of stock or for the purpose of any other lawful
action, the Board may fix, in advance, a record date, which record date shall not precede the date
on which the resolution fixing the record date is adopted and which shall not be more than 60 nor
less than ten (10)&nbsp;days before the date of such meeting, nor more than 60&nbsp;days prior to any other
such action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Board does not fix a record date in accordance with these bylaws and applicable law:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The record date for determining stockholders entitled to notice of or to vote at a meeting
of stockholders shall be at the close of business on the day next preceding the day on which notice
is given, or, if notice is waived, at the close of business on the day next preceding the day on
which the meeting is held.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The record date for determining stockholders entitled to consent to corporate action in
writing without a meeting, when no prior action by the Board is necessary, shall be the first day
on which a signed written consent setting forth the action taken or proposed to be taken is
delivered to the corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The record date for determining stockholders for any other purpose shall be at the close
of business on the day on which the Board adopts the resolution relating thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A determination of stockholders of record entitled to notice of or to vote at a meeting of
stockholders shall apply to any adjournment of the meeting; provided, however, that the Board may
fix a new record date for the adjourned meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 PROXIES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each stockholder entitled to vote at a meeting of stockholders may authorize another person or
persons to act for such stockholder by proxy authorized by an instrument in writing or by a
transmission permitted by law and filed with the secretary of the corporation, but no such proxy
shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a
longer period. A stockholder may also authorize another person or persons to act for him, her or
it as proxy in the manner(s) provided under Section 212(c) of the DGCL or as otherwise provided
under Delaware law. The revocability of a proxy that states on its face that it is irrevocable shall be governed
by the provisions of Section&nbsp;212 of the DGCL.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13 LIST OF STOCKHOLDERS ENTITLED TO VOTE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The officer who has charge of the stock ledger of the corporation shall prepare and make, at
least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders
entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each
stockholder and the number of shares registered in the name of each stockholder. The corporation
shall not be required to include electronic mail addresses or other electronic contact information
on such list. Such list shall be open to the examination of any stockholder, for any purpose
germane to the meeting for a period of at least ten (10)&nbsp;days prior to the meeting: (a)&nbsp;on a
reasonably accessible electronic network, provided that the information required to gain access to
such list is provided with the notice of the meeting, or (b)&nbsp;during ordinary business hours, at the
corporation&#146;s principal place of business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the corporation determines to make the list available on an electronic
network, the corporation may take reasonable steps to ensure that such information is available
only to stockholders of the corporation. If the meeting is to be held at a place, then the list
shall be produced and kept at the time and place of the meeting during the whole time thereof, and
may be inspected by any stockholder who is present. If the meeting is to be held solely by means
of remote communication, then the list shall also be open to the examination of any stockholder
during the whole time of the meeting on a reasonably accessible electronic network, and the
information required to access such list shall be provided with the notice of the meeting. Such
list shall presumptively determine the identity of the stockholders entitled to vote at the meeting
and the number of shares held by each of them.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14 ADVANCE NOTICE OF STOCKHOLDER BUSINESS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only such business shall be conducted as shall have been properly brought before a meeting of
the stockholders of the corporation. To be properly brought before an annual meeting, business
must be (a)&nbsp;specified in the notice of meeting (or any supplement thereto) given by or at the
direction of the Board, (b)&nbsp;otherwise properly brought before the meeting by or at the direction of
the Board, or (c)&nbsp;a proper matter for stockholder action under the DGCL that has been properly
brought before the meeting by a stockholder (i)&nbsp;who is a stockholder of record on the date of the
giving of the notice provided for in this Section&nbsp;2.14 and on the record date for the determination
of stockholders entitled to vote at such annual meeting and (ii)&nbsp;who complies with the notice
procedures set forth in this Section&nbsp;2.14. For such business to be considered properly brought
before the meeting by a stockholder such stockholder must, in addition to any other applicable
requirements, have given timely notice in proper form of such stockholder&#146;s intent to bring such
business before such meeting. To be timely, such stockholder&#146;s notice must be delivered to or
mailed and received by the secretary of the corporation at the principal executive offices of the
corporation not later than the close of business on the ninetieth (90<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day, nor
earlier than the close of business on the one hundred twentieth (120<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day, prior to the
anniversary date on which the corporation first mailed its proxy statement to stockholders in
connection with the immediately preceding annual meeting; provided, however, that in the event that
no annual meeting was held in the previous year or the annual meeting is called for a date that is
not within thirty (30)&nbsp;days before or after such anniversary date, notice by the stockholder to be
timely must be so received not later than the close of business the tenth (10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) day
following the day on which such notice of the date of the meeting was mailed or public disclosure
of the date of the meeting was made, whichever occurs first.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be in proper form, a stockholder&#146;s notice to the secretary shall be in writing and shall
set forth:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the name and record address of the stockholder who intends to propose the business and the
class or series and number of shares of capital stock of the corporation which are owned
beneficially or of record by such stockholder;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;a representation that the stockholder is a holder of record of stock of the corporation
entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to
introduce the business specified in the notice;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;a brief description of the business desired to be brought before the annual meeting and
the reasons for conducting such business at the annual meeting;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;any material interest of the stockholder in such business; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;any other information that is required to be provided by the stockholder pursuant to
Regulation&nbsp;14A under the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, in order to include information with respect to a stockholder
proposal in the proxy statement and form of proxy for a stockholder&#146;s meeting, stockholders must
provide notice as required by, and otherwise comply with the requirements of, the Exchange Act and
the regulations promulgated thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No business shall be conducted at the annual meeting of stockholders except business brought
before the annual meeting in accordance with the procedures set forth in this Section&nbsp;2.14. The
chairperson of the meeting may refuse to acknowledge the proposal of any business not made in
compliance with the foregoing procedure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15 ADVANCE NOTICE OF DIRECTOR NOMINATIONS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only persons who are nominated in accordance with the following procedures shall be eligible
for election as directors of the corporation, except as may be otherwise provided in the
Certificate with respect to the right of holders of Preferred Stock of the corporation to nominate
and elect a specified number of directors, if any. To be properly brought before an annual meeting of stockholders,
or any special meeting of stockholders called for the purpose of electing directors, nominations
for the election of director must be (a)&nbsp;specified in the notice of meeting (or any supplement
thereto), (b)&nbsp;made by or at the direction of the Board (or any duly authorized committee thereof)
or (c)&nbsp;made by any stockholder of the corporation (i)&nbsp;who is a stockholder of record on the date of
the giving of the notice provided for in this Section&nbsp;2.15 and on the record date for the
determination of stockholders entitled to vote at such meeting and (ii)&nbsp;who complies with the
notice procedures set forth in this Section&nbsp;2.15.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to any other applicable requirements, for a nomination to be made by a
stockholder, such stockholder must have given timely notice thereof in proper written form to the
secretary of the corporation. To be timely, a stockholder&#146;s notice to the secretary must be
delivered to or mailed and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">received at the principal executive offices of the corporation, in the
case of an annual meeting, in accordance with the provisions set forth in Section&nbsp;2.14 of these
bylaws, and, in the case of a special meeting of stockholders called for the purpose of electing
directors, not later than the close of business on the tenth (10th) day following the day on which
notice of the date of the special meeting was mailed or public disclosure of the date of the
special meeting was made, whichever first occurs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be in proper written form, a stockholder&#146;s notice to the secretary must set forth:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;as to each person whom the stockholder proposes to nominate for election as a director (i)
the name, age, business address and residence address of the person, (ii)&nbsp;the principal occupation
or employment of the person, (iii)&nbsp;the class or series and number of shares of capital stock of the
corporation which are owned beneficially or of record by the person, (iv)&nbsp;a description of all
arrangements or understandings between the stockholder and each nominee and any other person or
persons (naming such person or persons) pursuant to which the nominations are to be made by the
stockholder, and (v)&nbsp;any other information relating to such person that is required to be disclosed
in solicitations of proxies for elections of directors, or is otherwise required, in each case
pursuant to Regulation&nbsp;14A under the Exchange Act (including without limitation such person&#146;s
written consent to being named in the proxy statement, if any, as a nominee and to serving as a
director if elected); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;as to such stockholder giving notice, the information required to be provided pursuant to
Section&nbsp;2.14 of these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of any holders of Preferred Stock of the corporation, if any, no person
shall be eligible for election as a director of the corporation unless nominated in accordance with
the procedures set forth in this Section&nbsp;2.15. If the chairperson of the meeting properly
determines that a nomination was not made in accordance with the foregoing procedures, the
chairperson shall declare to the meeting that the nomination was defective and such defective
nomination shall be disregarded.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III &#151; DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 POWERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of the DGCL and any limitations in the Certificate, the business and
affairs of the corporation shall be managed and all corporate powers shall be exercised by or under
the direction of the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 NUMBER OF DIRECTORS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized number of directors shall be determined from time to time by resolution of the
Board, provided the Board shall consist of at least one member. No reduction of the authorized
number of directors shall have the effect of removing any director before that director&#146;s term of
office expires.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 ELECTION, QUALIFICATION AND TERM OF OFFICE OF DIRECTORS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in Section&nbsp;3.4 and Section&nbsp;3.13 of these bylaws, directors shall be elected
at each annual meeting of stockholders to hold office until the next annual meeting. Directors
need not be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">stockholders unless so required by the Certificate or these bylaws. The Certificate or
these bylaws may prescribe other qualifications for directors. Each director, including a director
elected to fill a vacancy, shall hold office until such director&#146;s successor is elected and
qualified or until such director&#146;s earlier death, resignation or removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in the Certificate or Section&nbsp;3.4 of these bylaws, directors shall be
classified, with respect to the time for which they severally hold office, into three (3)&nbsp;classes,
as nearly equal in number as possible, one (1)&nbsp;class to be originally elected for a term expiring
at the annual meeting of stockholders to be held in 2008, another class to be originally elected
for a term expiring at the annual meeting of stockholders to be held in 2009, and another class to
be originally elected for a term expiring at the annual meeting of stockholders to be held in 2010,
with each class to hold office until its successor is duly elected and qualified. At each
succeeding annual meeting of stockholders, commencing with the first annual meeting (a)&nbsp;directors
elected to succeed those directors whose terms then expire shall be elected for a term of office to
expire at the third succeeding annual meeting of stockholders after their election, with each
director to hold office until his or her successor shall have been duly elected and qualified, and
(b)&nbsp;if authorized by a resolution of the Board, directors may be elected to fill any vacancy on the
Board, regardless of how such vacancy shall have been created (as set forth in Section&nbsp;3.4 below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 RESIGNATION AND VACANCIES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any director may resign at any time upon written notice or by electronic transmission to the
corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of the holders of any series of Preferred Stock of the corporation then
outstanding, if any, and unless the Board otherwise determines, newly created directorships
resulting from any increase in the authorized number of directors, or any vacancies on the Board
resulting from the death, resignation, retirement, disqualification, removal from office or other
cause shall, unless otherwise required by law, be filled by the affirmative vote of a majority of
the remaining directors then in office, even though less than a quorum of the Board, or by a sole
remaining director. A person so elected by the directors then in office to fill a vacancy or newly
created directorship shall hold office until the next election of the class for which such director
shall have been chosen and until his or her successor shall have been duly elected and qualified.
When one or more directors resigns and the resignation is effective at a future date, a majority of
the directors then in office, including those who have so resigned, shall have power to fill such
vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall
become effective, and each director so chosen shall hold office as provided in this Section&nbsp;3.4 in
the filling of other vacancies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 PLACE OF MEETINGS; MEETINGS BY TELEPHONE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may hold meetings, both regular and special, either within or outside the State of
Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by the Certificate or these bylaws, members of the Board, or any
committee designated by the Board, may participate in a meeting of the Board, or any committee, by
means of conference telephone or other communications equipment by means of which all persons
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">participating in the meeting can hear each other, and such participation in a meeting shall
constitute presence in person at the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 REGULAR MEETINGS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regular meetings of the Board may be held without notice at such time and at such place as
shall from time to time be determined by the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 SPECIAL MEETINGS; NOTICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of the Board for any purpose or purposes may be called at any time by the
chairperson of the Board, the chief executive officer, the president, the secretary or a majority
of the authorized number of directors. The person(s) authorized to call special meetings of the
Board may fix the place and time of the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice of the time and place of special meetings shall be:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delivered personally by hand, by courier or by telephone;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sent by United States first-class mail, postage prepaid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sent by facsimile; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sent by electronic mail,</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">directed to each director at that director&#146;s address, telephone number, facsimile number or
electronic mail address, as the case may be, as shown on the corporation&#146;s records.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the notice is (i)&nbsp;delivered personally by hand, by courier or by telephone, (ii)&nbsp;sent by
facsimile or (iii)&nbsp;sent by electronic mail, it shall be delivered or sent at least 24 hours before
the time of the holding of the meeting. If the notice is sent by United States mail, it shall be
deposited in the United States mail at least four days before the time of the holding of the
meeting. Any oral notice may be communicated either to the director or to a person at the office
of the director who the person giving notice has reason to believe will promptly communicate such
notice to the director. The notice need not specify the place of the meeting if the meeting is to
be held at the corporation&#146;s principal executive office nor the purpose of the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 QUORUM.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise required by law or the Certificate, at all meetings of the Board, a
majority of the authorized number of directors (as determined pursuant to Section&nbsp;3.2 of these
bylaws) shall constitute a quorum for the transaction of business, except to adjourn as provided in
Section&nbsp;3.11 of these bylaws. The vote of a majority of the directors present at any meeting at
which a quorum is present shall be the act of the Board, except as may be otherwise specifically
provided by statute, the Certificate or these bylaws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A meeting at which a quorum is initially present may continue to transact business
notwithstanding the withdrawal of directors, if any action taken is approved by at least a majority
of the directors present at that meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 WAIVER OF NOTICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever notice is required to be given under any provisions of the DGCL, the Certificate or
these bylaws, a written waiver thereof, signed by the person entitled to notice, or a waiver by
electronic transmission by the person entitled to notice, whether before or after the time stated
therein, shall be deemed equivalent to notice
.. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting,
except when the person attends a meeting solely for the express purpose of objecting, at the
beginning of the meeting, to the transaction of any business because the meeting is not lawfully
called or convened. Neither the business to be transacted at, nor the purpose of, any regular or
special meeting of the directors, or members of a committee of directors, need be specified in any
written waiver of notice or any waiver by electronic transmission unless so required by the
Certificate or these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by the Certificate or these bylaws, any action required or
permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken
without a meeting if all members of the Board or committee, as the case may be, consent thereto in
writing or by electronic transmission and the writing or writings or electronic transmission or
transmissions are filed with the minutes of proceedings of the Board or committee. Such filing
shall be in paper form if the minutes are maintained in paper form and shall be in electronic form
if the minutes are maintained in electronic form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 ADJOURNED MEETING; NOTICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a quorum is not present at any meeting of the Board, then a majority of the directors
present thereat may adjourn the meeting from time to time, without notice other than announcement
at the meeting, until a quorum is present.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 FEES AND COMPENSATION OF DIRECTORS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by the Certificate or these bylaws, the Board shall have the
authority to fix the compensation of directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.13 REMOVAL OF DIRECTORS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise restricted by statute, the Certificate or these bylaws, any director, or all
of the directors, may be removed from the Board, but only for cause, and only by the affirmative
vote of the holders of at least a majority of the voting power of all the then outstanding shares
of capital stock of the corporation then entitled to vote at the election of directors, voting
together as a single class.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV &#151; COMMITTEES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 COMMITTEES OF DIRECTORS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may designate one or more committees, each committee to consist of one or more of
the directors of the corporation. The Board may designate one or more directors as alternate
members of any committee, who may replace any absent or disqualified member at any meeting of the
committee. In the absence or disqualification of a member of a committee, the member or members
thereof present at any meeting and not disqualified from voting, whether or not such member or
members constitute a quorum, may unanimously appoint another member of the Board to act at the
meeting in the place of any such absent or disqualified member. Any such committee, to the extent
provided in the resolution of the Board or in these bylaws, shall have and may exercise such
lawfully delegable powers and duties as the Board may confer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 COMMITTEE MINUTES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each committee shall keep regular minutes of its meetings and report to the Board when
required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 MEETINGS AND ACTION OF COMMITTEES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings and actions of committees shall be governed by, and held and taken in accordance
with, the provisions of:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.5 (relating to place of meetings and meetings by telephone);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.6 (relating to regular meetings);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.7 (relating to special meetings and notice);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.8 (relating to quorum);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.9 (relating to waiver of notice);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.10 (relating to action without a meeting); and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Section&nbsp;3.11 (relating to adjournment and notice of adjournment)</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of these bylaws, with such changes in the context of those bylaws as are necessary to substitute
the committee and its members for the Board and its members.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;the time of regular meetings of committees may be determined either by resolution of the
Board or by resolution of the committee;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;special meetings of committees may also be called by resolution of the Board; and
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;notice of special meetings of committees shall also be given to all alternate members,
who shall have the right to attend all meetings of the committee. The Board may adopt rules for
the government of any committee not inconsistent with the provisions of these bylaws.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V &#151; OFFICERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 OFFICERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The officers of the corporation shall be a president and a secretary. The corporation may
also have, at the discretion of the Board, a chairperson of the Board, a vice chairperson of the
Board, a chief executive officer, a chief financial officer or treasurer, one or more vice
presidents, one or more assistant vice presidents, one or more assistant treasurers, one or more
assistant secretaries, and any such other officers as may be appointed in accordance with the
provisions of these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any number of offices may be held by the same person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 APPOINTMENT OF OFFICERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board shall appoint the officers of the corporation, except such officers as may be
appointed in accordance with the provisions of Section&nbsp;5.3 of these bylaws, subject to the rights,
if any, of an officer under any contract of employment. Each officer shall hold office until his
or her successor is elected and qualified or until his or her earlier resignation or removal. A
failure to elect officers shall not dissolve or otherwise affect the corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 SUBORDINATE OFFICERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may appoint, or empower the chief executive officer or, in the absence of a chief
executive officer, the president of the corporation to appoint, such other officers and agents as
the business of the corporation may require. Each of such officers and agents shall hold office
for such period, have such authority, and perform such duties as are provided in these bylaws or as
the Board may from time to time determine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 REMOVAL AND RESIGNATION OF OFFICERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any officer may be removed, either with or without cause, by an affirmative vote of the
majority of the Board at any regular or special meeting of the Board or, except in the case of an
officer appointed by the Board, by any officer upon whom such power of removal may be conferred by
the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any officer may resign at any time by giving written notice to the corporation. Any
resignation shall take effect at the date of the receipt of that notice or at any later time
specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance
of the resignation shall not be necessary to make it effective. Any resignation is without
prejudice to the rights, if any, of the corporation under any contract to which the officer is a
party.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 VACANCIES IN OFFICES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any vacancy occurring in any office of the corporation may only be filled by the Board or as
provided in Section&nbsp;5.3 of these bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6 REPRESENTATION OF SHARES OF OTHER CORPORATIONS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The chairperson of the Board, the chief executive officer, the president, any vice president,
the treasurer, the secretary or assistant secretary of this corporation, or any other person
authorized by the Board, the chief executive officer, the president or a vice president, is
authorized to vote, represent, and exercise on behalf of this corporation all rights incident to
any and all shares or other equity interests of any other corporation or entity standing in the
name of this corporation. The authority granted herein may be exercised either by such person
directly or by any other person authorized to do so by proxy or power of attorney duly executed by
such person having the authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7 AUTHORITY AND DUTIES OF OFFICERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the foregoing authority and duties, all officers of the corporation shall
respectively have such authority and perform such duties in the management of the business of the
corporation as may be designated from time to time by the Board.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI &#151; RECORDS AND REPORTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 MAINTENANCE AND INSPECTION OF RECORDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation shall, either at its principal executive office or at such place or places as
designated by the Board, keep a record of its stockholders listing their names and addresses and
the number and class of shares held by each stockholder, a copy of these bylaws, as may be amended
to date, minute books, accounting books and other records.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any such records maintained by the corporation may be kept on, or by means of, or be in the
form of, any information storage device or method, provided that the records so kept can be
converted into clearly legible paper form within a reasonable time. The corporation shall so
convert any records so kept upon the request of any person entitled to inspect such records
pursuant to the provisions of the DGCL. When records are kept in such manner, a clearly legible
paper form produced from or by means of the information storage device or method shall be
admissible in evidence, and accepted for all other purposes, to the same extent as an original
paper form accurately portrays the record.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder of record, in person or by attorney or other agent, shall, upon written demand
under oath stating the purpose thereof, have the right during the usual hours for business to
inspect for any proper purpose the corporation&#146;s stock ledger, a list of its stockholders, and its
other books and records and to make copies or extracts therefrom. A proper purpose shall mean a
purpose reasonably related to such person&#146;s interest as a stockholder. In every instance where an
attorney or other agent is the person who seeks the right to inspection, the demand under oath
shall be accompanied by a power of attorney or such other writing that authorizes the attorney or
other agent to so act on behalf of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">stockholder. The demand under oath shall be directed to the corporation at its registered
office in Delaware or at its principal executive office.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 INSPECTION BY DIRECTORS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any director shall have the right to examine the corporation&#146;s stock ledger, a list of its
stockholders, and its other books and records for a purpose reasonably related to his or her
position as a director.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII &#151; GENERAL MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 CHECKS; DRAFTS; EVIDENCES OF INDEBTEDNESS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, the Board shall determine by resolution which person or persons may sign or
endorse all checks, drafts, other orders for payment of money, notes or other evidences of
indebtedness that are issued in the name of or payable to the corporation, and only the persons so
authorized shall sign or endorse those instruments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 EXECUTION OF CORPORATE CONTRACTS AND INSTRUMENTS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in these bylaws, the Board, or any officers of the corporation
authorized thereby, may authorize any officer or officers, or agent or agents, to enter into any
contract or execute any instrument in the name of and on behalf of the corporation; such authority
may be general or confined to specific instances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 STOCK CERTIFICATES; PARTLY PAID SHARES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of the corporation shall be represented by certificates, provided that the Board
may provide by resolution or resolutions that some or all of any or all classes or series of its
stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by
a certificate until such certificate is surrendered to the corporation. Every holder of stock
represented by certificates and upon request every holder of uncertificated shares shall be
entitled to have a certificate signed by, or in the name of the corporation by the chairperson or
vice-chairperson of the Board, or the president or vice-president, and by the treasurer or an
assistant treasurer, or the secretary or an assistant secretary of the corporation representing the
number of shares registered in certificate form. Any or all of the signatures on the certificate
may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose
facsimile signature has been placed upon a certificate has ceased to be such officer, transfer
agent or registrar before such certificate is issued, it may be issued by the corporation with the
same effect as if he or she were such officer, transfer agent or registrar at the date of issue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation may issue the whole or any part of its shares as partly paid and subject to
call for the remainder of the consideration to be paid therefor. Upon the face or back of each
stock certificate issued to represent any such partly paid shares, and upon the books and records
of the corporation in the case of uncertificated partly paid shares, the total amount of the
consideration to be paid therefor and the amount paid thereon shall be stated. Upon the
declaration of any dividend on fully paid shares, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">corporation shall declare a dividend upon partly paid shares of the same class, but only upon the basis of the percentage of the
consideration actually paid thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 SPECIAL DESIGNATION ON CERTIFICATES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the corporation is authorized to issue more than one class of stock or more than one series
of any class, then the powers, designations, preferences, and relative, participating, optional or
other special rights of each class of stock or series thereof and the qualifications, limitations
or restrictions of such preferences and/or rights shall be set forth in full or summarized on the
face or back of the certificate that the corporation shall issue to represent such class or series
of stock; <U>provided</U>, <U>however</U>, that, except as otherwise provided in Section&nbsp;202 of
the DGCL, in lieu of the foregoing requirements there may be set forth on the face or back of the
certificate that the corporation shall issue to represent such class or series of stock a statement
that the corporation will furnish without charge to each stockholder who so requests the powers,
designations, preferences, and relative, participating, optional or other special rights of each
class of stock or series thereof and the qualifications, limitations or restrictions of such
preferences and/or rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 LOST CERTIFICATES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in this Section&nbsp;7.5, no new certificates for shares shall be issued to
replace a previously issued certificate unless the latter is surrendered to the corporation and
cancelled at the same time. The corporation may issue a new certificate of stock or uncertificated
shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen
or destroyed, and the corporation may require the owner of the lost, stolen or destroyed
certificate, or such owner&#146;s legal representative, to give the corporation a bond sufficient to
indemnify it against any claim that may be made against it on account of the alleged loss, theft or
destruction of any such certificate or the issuance of such new certificate or uncertificated
shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 DIVIDENDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board, subject to any restrictions contained in either (a)&nbsp;the DGCL or (b)&nbsp;the
Certificate, may declare and pay dividends upon the shares of its capital stock. Dividends may be
paid in cash, in property, or in shares of the corporation&#146;s capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may set apart out of any of the funds of the corporation available for dividends a
reserve or reserves for any proper purpose and may abolish any such reserve.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 FISCAL YEAR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fiscal year of the corporation shall be fixed by resolution of the Board and may be
changed by the Board.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 SEAL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation may adopt a corporate seal, which shall be adopted and which may be altered by
the Board. The corporation may use the corporate seal by causing it or a facsimile thereof to be
impressed or affixed or in any other manner reproduced.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 TRANSFER OF STOCK.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfers of stock shall be made only upon the transfer books of the corporation kept at an
office of the corporation or by transfer agents designated to transfer shares of the stock of the
corporation. Except where a certificate is issued in accordance with Section&nbsp;7.5 of these bylaws,
an outstanding certificate for the number of shares involved shall be surrendered for cancellation
before a new certificate is issued therefore. Upon surrender to the corporation or the transfer
agent of the corporation of a certificate for shares duly endorsed or accompanied by proper
evidence of succession, assignation or authority to transfer, it shall be the duty of the
corporation to issue a new certificate to the person entitled thereto, cancel the old certificate,
and record the transaction in its books.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 STOCK TRANSFER AGREEMENTS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation shall have power to enter into and perform any agreement with any number of
stockholders of any one or more classes or series of stock of the corporation to restrict the
transfer of shares of stock of the corporation of any one or more classes or series owned by such
stockholders in any manner not prohibited by the DGCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11 REGISTERED STOCKHOLDERS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;shall be entitled to recognize the exclusive right of a person registered on its books as
the owner of shares to receive dividends and to vote as such owner;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;shall be entitled to hold liable for calls and assessments on partly paid shares the
person registered on its books as the owner of shares; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;shall not be bound to recognize any equitable or other claim to or interest in such share
or shares on the part of another person, whether or not it shall have express or other notice
thereof, except as otherwise provided by the laws of Delaware.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.12 WAIVER OF NOTICE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever notice is required to be given under any provision of the DGCL, the Certificate or
these bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic
transmission by the person entitled to notice, whether before or after the time of the event for
which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a
meeting shall constitute a waiver of notice of such meeting, except when the person attends a
meeting solely for the express purpose of objecting at the beginning of the meeting, to the
transaction of any business because the meeting is not lawfully called or convened. Neither the
business to be transacted at, nor the purpose
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic
transmission unless so required by the Certificate or these bylaws.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII &#151; NOTICE BY ELECTRONIC TRANSMISSION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 NOTICE BY ELECTRONIC TRANSMISSION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the manner by which notice otherwise may be given effectively to stockholders
pursuant to the DGCL, the Certificate or these bylaws, any notice to stockholders given by the
corporation under any provision of the DGCL, the Certificate or these bylaws shall be effective if
given by a form of electronic transmission consented to by the stockholder to whom the notice is
given. Any such consent shall be revocable by the stockholder by written notice to the
corporation. Any such consent shall be deemed revoked if:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the corporation is unable to deliver by electronic transmission two consecutive notices
given by the corporation in accordance with such consent; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;such inability becomes known to the secretary or an assistant secretary of the corporation
or to the transfer agent, or other person responsible for the giving of notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">However, the inadvertent failure to treat such inability as a revocation shall not invalidate any
meeting or other action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice given pursuant to the preceding paragraph shall be deemed given:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;if by facsimile telecommunication, when directed to a number at which the stockholder has
consented to receive notice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;if by electronic mail, when directed to an electronic mail address at which the
stockholder has consented to receive notice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;if by a posting on an electronic network together with separate notice to the
stockholder of such specific posting, upon the later of (A)&nbsp;such posting and (B)&nbsp;the giving of such
separate notice; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;if by any other form of electronic transmission, when directed to the stockholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An affidavit of the secretary or an assistant secretary or of the transfer agent or other
agent of the corporation that the notice has been given by a form of electronic transmission shall,
in the absence of fraud, be prima facie evidence of the facts stated therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 DEFINITION OF ELECTRONIC TRANSMISSION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An &#147;electronic transmission&#148; means any form of communication, not directly involving the
physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed
by a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 INAPPLICABILITY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice by a form of electronic transmission shall not apply to Section&nbsp;164 (relating to
failure to pay for stock; remedies), Section&nbsp;296 (relating to adjudication of claims; appeal),
Section&nbsp;311 (relating to revocation of voluntary dissolution), Section&nbsp;312 (relating to renewal,
revival, extension and restoration of certificate of incorporation) or Section&nbsp;324 (relating to
attachment of shares of stock or any option, right or interest therein) of the DGCL.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX &#151; INDEMNIFICATION OF DIRECTORS AND OFFICERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 POWER TO INDEMNIFY IN ACTIONS, SUITS OR PROCEEDINGS OTHER THAN THOSE BY OR IN THE RIGHT OF
THE CORPORATION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;9.3 of these bylaws, the corporation shall indemnify, to the fullest extent
permitted by the DGCL, as now or hereafter in effect, any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other than an action by or in the right
of the corporation) by reason of the fact that such person (or the legal representative of such
person) is or was a director or officer of the corporation or any predecessor of the corporation,
or is or was a director or officer of the corporation serving at the request of the corporation as
a director or officer, employee or agent of another corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise, against expenses (including attorneys&#146; fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection
with such action, suit or proceeding if such person acted in good faith and in a manner such person
reasonably believed to be in or not opposed to the best interests of the corporation, and, with
respect to any criminal action or proceeding, had no reasonable cause to believe such person&#146;s
conduct was unlawful. The termination of any action, suit or proceeding by judgment, order,
settlement, conviction, or upon a plea of <I>nolo contendere </I>or its equivalent, shall not, of itself,
create a presumption that the person did not act in good faith and in a manner which such person
reasonably believed to be in or not opposed to the best interests of the corporation, and, with
respect to any criminal action or proceeding, had reasonable cause to believe that such person&#146;s
conduct was unlawful.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 POWER TO INDEMNIFY IN ACTIONS, SUITS OR PROCEEDINGS BY OR IN THE RIGHT OF THE CORPORATION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;9.3 of these bylaws, the corporation shall indemnify, to the fullest extent
permitted by the DGCL, as now or hereafter in effect, any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action or suit by or in the
right of the corporation to procure a judgment in its favor by reason of the fact that such person
(or the legal representative of such person) is or was a director or officer of the corporation or
any predecessor of the corporation, or is or was a director or officer of the corporation serving
at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">employee benefit plan or other enterprise against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the
defense or settlement of such action or suit if such person acted in good faith and in a manner
such person reasonably believed to be in or not opposed to the best interests of the corporation;
except that no indemnification shall be made in respect of any
claim, issue or matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the Court of Chancery or the court in which such
action or suit was brought shall determine upon application that, despite the adjudication of
liability but in view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem
proper.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 AUTHORIZATION OF INDEMNIFICATION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any indemnification under this Article&nbsp;IX (unless ordered by a court) shall be made by the
corporation only as authorized in the specific case upon a determination that indemnification of
the director or officer is proper in the circumstances because such person has met the applicable
standard of conduct set forth in Section&nbsp;9.1 or Section&nbsp;9.2 of these bylaws, as the case may be.
Such determination shall be made, with respect to a person who is either a director or officer at
the time of such determination or a former director or officer, (i)&nbsp;by a majority vote of the
directors who are not parties to such action, suit or proceeding, even though less than a quorum,
or (ii)&nbsp;by a committee of such directors designated by a majority vote of such directors, even
though less than a quorum, or (iii)&nbsp;if there are no such directors, or if such directors so direct,
by independent legal counsel in a written opinion or (iv)&nbsp;by the stockholders (but only if a
majority of the directors who are not parties to such action, suit or proceeding, if they
constitute a quorum of the board of directors, presents the issue of entitlement to indemnification
to the stockholders for their determination). To the extent, however, that a present or former
director or officer of the corporation has been successful on the merits or otherwise in defense of
any action, suit or proceeding described above, or in defense of any claim, issue or matter
therein, such person shall be indemnified against expenses (including attorneys&#146; fees) actually and
reasonably incurred by such person in connection therewith, without the necessity of authorization
in the specific case.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 GOOD FAITH DEFINED.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of any determination under Section&nbsp;9.3 of these bylaws, to the fullest extent
permitted by applicable law, a person shall be deemed to have acted in good faith and in a manner
such person reasonably believed to be in or not opposed to the best interests of the corporation,
or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe
such person&#146;s conduct was unlawful, if such person&#146;s action is based on the records or books of
account of the corporation or another enterprise, or on information supplied to such person by the
officers of the corporation or another enterprise in the course of their duties, or on the advice
of legal counsel for the corporation or another enterprise or on information or records given or
reports made to the corporation or another enterprise by an independent certified public accountant
or by an appraiser or other expert selected with reasonable care by the corporation or another
enterprise. The term &#147;another enterprise&#148; as used in this Section&nbsp;9.4 shall mean any other
corporation or any partnership, joint venture, trust, employee benefit plan or other enterprise of
which such person is or was serving at the request of the corporation as a director, officer,
employee or agent. The provisions of this Section&nbsp;9.4 shall not be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable
standard of conduct set forth in Section&nbsp;9.1 or 9.2 of these bylaws, as the case may be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5 INDEMNIFICATION BY A COURT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any contrary determination in the specific case under Section&nbsp;9.3 of this
Article&nbsp;IX, and notwithstanding the absence of any determination thereunder, any director or
officer may apply to the Court of Chancery in the State of Delaware for indemnification to the
extent otherwise permissible under Section&nbsp;9.1 and Section&nbsp;9.2 of these bylaws. The basis of such
indemnification by a court shall be a determination by such court that indemnification of the
director or officer is proper in the circumstances because such person has met the applicable
standards of conduct set forth in Section&nbsp;9.1 or Section&nbsp;9.2 of these bylaws, as the case may be.
Neither a contrary determination in the specific case under Section&nbsp;9.3 of these bylaws nor the
absence of any determination thereunder shall be a defense to such application or create a
presumption that the director or officer seeking indemnification has not met any applicable
standard of conduct. Notice of any application for indemnification pursuant to this Section&nbsp;9.5
shall be given to the corporation promptly upon the filing of such application. If successful, in
whole or in part, the director or officer seeking indemnification shall also be entitled to be paid
the expense of prosecuting such application.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6 EXPENSES PAYABLE IN ADVANCE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent not prohibited by the DGCL, or by any other applicable law, expenses
incurred by a person who is or was a director or officer in defending any civil, criminal,
administrative or investigative action, suit or proceeding shall be paid by the corporation in
advance of the final disposition of such action, suit or proceeding; provided, however, that if the
DGCL requires, an advance of expenses incurred by any person in his or her capacity as a director
or officer (and not in any other capacity) shall be made only upon receipt of an undertaking by or
on behalf of such person to repay such amount if it shall ultimately be determined that such person
is not entitled to be indemnified by the corporation as authorized in this Article&nbsp;IX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7 NONEXCLUSIVITY OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indemnification and advancement of expenses provided by or granted pursuant to this
Article&nbsp;IX shall not be deemed exclusive of any other rights to which those seeking indemnification
or advancement of expenses may be entitled under the Certificate, any bylaw, agreement, vote of
stockholders or disinterested directors or otherwise, both as to action in such person&#146;s official
capacity and as to action in another capacity while holding such office, it being the policy of the
corporation that indemnification of the persons specified in Section&nbsp;9.1 and Section&nbsp;9.2 of these
bylaws shall be made to the fullest extent permitted by law. The provisions of this Article&nbsp;IX
shall not be deemed to preclude the indemnification of any person who is not specified in Section
9.1 or Section&nbsp;9.2 of these bylaws but whom the corporation has the power or obligation to
indemnify under the provisions of the DGCL, or otherwise. The corporation is specifically
authorized to enter into individual contracts with any or all of its directors, officers, employees
or agents respecting indemnification and advances, to the fullest extent not prohibited by the
DGCL, or by any other applicable law.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.8 INSURANCE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the fullest extent permitted by the DGCL or any other applicable law, the corporation may
purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
or
agent of the corporation, or is or was a director, officer, employee or agent of the
corporation serving at the request of the corporation as a director, officer, employee or agent of
another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise
against any liability asserted against such person and incurred by such person in any such
capacity, or arising out of such person&#146;s status as such, whether or not the corporation would have
the power or the obligation to indemnify such person against such liability under the provisions of
this Article&nbsp;IX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.9 CERTAIN DEFINITIONS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Article&nbsp;IX, references to &#147;the corporation&#148; shall include, in addition to
the resulting corporation, any constituent corporation (including any constituent of a constituent)
absorbed in a consolidation or merger which, if its separate existence had continued, would have
had power and authority to indemnify its directors or officers, so that any person who is or was a
director or officer of such constituent corporation, or is or was a director or officer of such
constituent corporation serving at the request of such constituent corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust, employee
benefit plan or other enterprise, shall stand in the same position under the provisions of this
Article&nbsp;IX with respect to the resulting or surviving corporation as such person would have with
respect to such constituent corporation if its separate existence had continued. For purposes of
this Article&nbsp;IX, references to &#147;fines&#148; shall include any excise taxes assessed on a person with
respect to an employee benefit plan; and references to &#147;serving at the request of the corporation&#148;
shall include any service as a director, officer, employee or agent of the corporation which
imposes duties on, or involves services by, such director or officer with respect to an employee
benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a
manner such person reasonably believed to be in the interest of the participants and beneficiaries
of an employee benefit plan shall be deemed to have acted in a manner &#147;not opposed to the best
interests of the corporation&#148; as referred to in this Article&nbsp;IX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.10 SURVIVAL OF INDEMNIFICATION AND ADVANCEMENT OF EXPENSES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The rights to indemnification and advancement of expenses conferred by this Article&nbsp;IX shall
continue as to a person who has ceased to be a director or officer and shall inure to the benefit
of the heirs, executors, administrators and other personal and legal representatives of such a
person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.11 LIMITATION ON INDEMNIFICATION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything contained in this Article&nbsp;IX to the contrary, except for proceedings
to enforce rights to indemnification (which shall be governed by Section&nbsp;9.5 of these bylaws), the
corporation shall not be obligated to indemnify any director or officer in connection with a
proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof) was
authorized or consented to by the board of directors of the corporation.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.12 INDEMNIFICATION OF EMPLOYEES AND AGENTS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The corporation may, to the extent authorized from time to time by the board of directors,
provide rights to indemnification and to the advancement of expenses to employees and agents of the
corporation similar to those conferred in this Article&nbsp;IX to directors and officers of the
corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.13 EFFECT OF AMENDMENT OR REPEAL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither any amendment or repeal of any Section of this Article&nbsp;IX, nor the adoption of any
provision of the Certificate or the bylaws inconsistent with this Article&nbsp;IX, shall adversely
affect any right or protection of any director, officer, employee or other agent established
pursuant to this Article&nbsp;IX existing at the time of such amendment, repeal or adoption of an
inconsistent provision, including without limitation by eliminating or reducing the effect of this
Article&nbsp;IX, for or in respect of any act, omission or other matter occurring, or any action or
proceeding accruing or arising (or that, but for this Article&nbsp;IX, would accrue or arise), prior to
such amendment, repeal or adoption of an inconsistent provision.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X &#151; MISCELLANEOUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 PROVISIONS OF CERTIFICATE GOVERN.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any inconsistency between the terms of these bylaws and the Certificate, the
terms of the Certificate will govern.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 CONSTRUCTION; DEFINITIONS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the context requires otherwise, the general provisions, rules of construction, and
definitions in the DGCL shall govern the construction of these bylaws. Without limiting the
generality of this provision, the singular number includes the plural, the plural number includes
the singular, and the term &#147;person&#148; includes both a corporation and a natural person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 SEVERABILITY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that any bylaw or the application thereof becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remaining bylaws will continue in
full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 AMENDMENT.
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The bylaws of the corporation may be adopted, amended or repealed by a majority of the voting
power of the stockholders entitled to vote; provided, however, that the corporation may, in its
Certificate, also confer the power to adopt, amend or repeal bylaws upon the Board. The fact that
such power has been so conferred upon the Board shall not divest the stockholders of the power, nor
limit their power to adopt, amend or repeal bylaws. Notwithstanding the foregoing and any
provision of law that might otherwise permit a lesser vote or no vote, the affirmative vote of the holders at least
sixty-six and two-thirds percent (66 2/3%) of the voting power of the issued and outstanding shares
of capital stock of the corporation
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then entitled to vote shall be required to amend or repeal Section&nbsp;2.3, the last paragraph of Section&nbsp;2.9 (relating to no cumulative voting), Section&nbsp;2.10,
Section&nbsp;2.14, Section&nbsp;2.15, Section&nbsp;3.2, Section&nbsp;3.3, Section&nbsp;3.4, Section&nbsp;3.13 and Section&nbsp;9.13 of
these bylaws, or this sentence of this Section&nbsp;10.4.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-24-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION<BR>
a Delaware corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATE OF ADOPTION OF AMENDED AND RESTATED BYLAWS</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby certifies that he or she is the duly elected, qualified, and acting
Secretary of Fluidigm Corporation, a Delaware corporation, and that the foregoing amended and
restated bylaws, comprising 26 pages, were adopted as the corporation&#146;s bylaws (i)&nbsp;on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> by the corporation&#146;s board of directors and (ii)&nbsp;on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> by
the stockholders of the corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has hereunto set his or her hand this <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2008.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">Print Name:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000" >&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000" >&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION<BR>
a Delaware corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTIFICATE OF AMENDMENT OF BYLAWS</B>

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby certifies that he or she is the duly elected, qualified, and acting
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>of Fluidigm Corporation, a Delaware corporation, and that the foregoing
bylaws, comprising <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> pages, were amended and restated as the corporation&#146;s bylaws (i)&nbsp;on
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>, 2008 by the corporation&#146;s board of directors and (ii)&nbsp;on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>, 2008 by the
stockholders of the corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has hereunto set his or her hand this <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2008.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap valign="top">Print Name:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000"> &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>f39432a9exv4w4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.4</B></DIV>



<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Loan
and Security Agreements</B></FONT></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>This
Loan and Security Agreement</B> </FONT><B>No.&nbsp;4561</B> (this <I>&#147;Agreement&#148;) </I>is entered into as of March
29, 2005, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital
Partners</B></FONT> <B>V, L.P.</B> <I>(&#147;Lender&#148;) </I>and
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT>, a California corporation <I>(&#147;Borrower&#148; </I>or sometimes referred to herein as <I>&#147;Debtor&#148;)</I>
and sets forth the terms and conditions upon which Lender will lend and Borrower will repay money.
In consideration of the mutual covenants herein contained, the parties agree as follows:</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>1.</B> <FONT style="font-variant: SMALL-CAPS"><B>Definitions and Construction</B></FONT></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>1.1 Definitions.</B> Initially capitalized terms used and not otherwise defined herein are
defined in the California Uniform Commercial Code <I>(&#147;UCC&#148;).</I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;ACH&#148; </I>means the Automated Clearing House electronic funds transfer system.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Advance&#148; </I>means a Loan advanced by Lender to Borrower hereunder.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>means a variable <I>per annum </I>rate of interest equal to the Index plus the Interest
Margin which shall be subject to adjustment as provided in the Loan Agreement and/or the Note. On
and after the Loan Commencement Date the Basic Rate shall be fixed and not subject to any further
adjustments.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Borrower&#146;s Books&#148; </I>means all of Borrower&#146;s books and records, including records concerning
Collateral, Borrower&#146;s assets, liabilities, business operations or financial condition, on any
media, and the equipment containing such information.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Change
of Management or Board Composition&#148; </I>means that <B>(i)</B>&nbsp;Borrower&#146;s senior management shall not
include Gajus Worthington; <B>(ii)</B>&nbsp;Versant Ventures shall cease to have a representative (currently
Samuel Colella) serving on Borrower&#146;s Board of Directors; or<B>(iii)</B> Lehman Brothers shall cease to
have a representative (currently Hingge Hsu) serving on Borrower&#146;s Board of Directors;.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Collateral&#148; </I>means: <B>(i)</B>&nbsp;all property listed on <I><B>Exhibit&nbsp;A</B> </I>attached hereto; and <B>(ii)</B>&nbsp;all products
and proceeds of the foregoing, including proceeds of insurance and proceeds of proceeds, <I>provided
that, </I>notwithstanding anything to the contrary contained in this Agreement, the term Collateral
shall not include (a)&nbsp;any property that is subject to a Lien that is otherwise permitted pursuant
to subsection (v)&nbsp;of the definition of &#145;Permitted Liens&#148; and Lender agrees to execute any
instruments or documents necessary to evidence the intent of the foregoing; (b)&nbsp;more than 65% of
the issued and outstanding voting securities of any Subsidiary of Borrower that is not
incorporated or organized in the United States; or (c)&nbsp;any of the Company&#146;s Intellectual Property
(as defined below).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment&#148; </I>means
$13,000,000.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Fee&#148; </I>means $10,000.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Termination Date&#148; </I>means the earliest to occur of <B>(i)</B>&nbsp;the earlier to occur of (a)&nbsp;June
1, 2005, if Borrower has not borrowed at least $2,000,000 by such date; (b)&nbsp;September&nbsp;1, 2005, if
Borrower has not borrowed an additional $3,000,000 by such date or (c)&nbsp;December&nbsp;1, 2005; <B>(ii)</B>&nbsp;any
Default or Event of Default that has not been cured by Borrower or waived in writing by Lender, or
<B>(iii)</B>&nbsp;Change of Management or Board Composition (unless Lender has waived this condition in
writing).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Control Agreement&#148; </I>means an agreement substantially in the form <I>of <B>Exhibit&nbsp;I</B> </I>or otherwise
reasonably acceptable to Lender.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Default&#148; </I>means any event that with the passing of time or the
giving of notice or both would become an Event of Default.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Default Rate&#148; </I>means the lesser of
5% per annum above the otherwise applicable rate or the highest rate permitted by applicable
law.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Disclosure Schedule&#148; </I>means the Disclosure Schedule, dated as of the date hereof, and delivered to
Lender in connection with the execution and delivery of this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Event of Default&#148; </I>is defined in <B>Section&nbsp;8.</B></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Funding Date&#148; </I>means any date on which an Advance is made to or on account of Borrower hereunder.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Indebtedness&#148; </I>means <B>(i)</B>&nbsp;all indebtedness for borrowed money or the deferred purchase of property
or services, <B>(ii)</B>&nbsp;all obligations evidenced by notes, bonds, debentures or similar instruments,
<B>(iii)</B>&nbsp;all capital lease obligations, and <B>(iv)</B> all contingent obligations, consisting of guaranties
of Indebtedness of other persons and obligations of reimbursement with respect to letters of
credit.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio --></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Incumbency Certificate&#148; </I>means the document in the form <I>of <B>Exhibit&nbsp;E.</B></I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Index&#148; </I>means the prevailing variable Prime Rate of annual interest as quoted from time to time in
the western edition of the Wall Street Journal.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Intellectual Property&#148; </I>means, collectively, all rights, priorities and privileges of the Borrower
relating to intellectual property, in any medium, of any kind or nature whatsoever, now or
hereafter owned or acquired or received by Borrower, or in which Borrower now holds or hereafter
acquires or receives any right or interest, whether arising under United States, multinational or
foreign laws or otherwise, including, without limitation, any and all property of the Borrower
that is subject to, listed in or otherwise described in the Negative Pledge Agreement dated March
29, 2005 between Borrower and Lender, and shall include, in any event, all copyrights, copyright
licenses, patents, patent licenses, trademarks, trademark licenses, trade secrets, internet domain
names (including any right related to the registration thereof), proprietary or confidential
information, mask works, sources object or other programming codes, inventions (whether or not
patented or patentable), technical information, procedures, designs, knowledge, know-how,
software, data base, data, skill, expertise, recipe, experience, process, models, drawings,
materials or records. Notwithstanding the foregoing, Intellectual Property as defined above does
not include proceeds or other revenue consisting of accounts, accounts receivable, royalties,
licensing fees, or payment intangibles, obtained or owed from or on account of the licensing or
other exploitation or disposition of Intellectual Property, and all of which are included as
Collateral in the security interest granted by Borrower to Lender.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Interest Margin&#148; </I>means 2.5% per annum.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Lender&#146;s Expenses&#148; </I>means all reasonable costs or expenses (including reasonable attorneys&#146; fees
and expenses) incurred in connection with the preparation, negotiation, modification,
administration, or enforcement of the Loan or Loan Documents, or the exercise or preservation of
any rights or remedies by Lender, whether or not suit is brought. Lender will apply deposits
(including the Commitment Fee) received by Lender, if any, towards Lender&#146;s Expenses.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Lien&#148; </I>means any lien, security interest, pledge, bailment, lease, mortgage, hypothecation,
conditional sales and title retention agreement, charge, claim, or other encumbrance.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Liquidation Event&#148; </I>means any of: <B>(i)</B>&nbsp;a merger of Borrower with another entity, other than a
merger whereby the shareholders of Borrower immediately prior to such merger own at least 50% of
the outstanding voting securities of Borrower immediately after such merger; <B>(ii)</B>&nbsp;the sale (in one
or a series of related transactions) of all or substantially all of Borrower&#146;s assets; or <B>(iii)</B>
any transaction (or series of related transactions) whereby the shareholders of Borrower
immediately prior to such transaction(s) own less than 50% of the outstanding voting securities of
Borrower immediately after such transaction(s).</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan&#148; </I>means all of the Advances, however evidenced, and all other amounts due or to
become due hereunder.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan
Commencement Date&#148; </I>means March&nbsp;1, 2006.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan Documents&#148; </I>means, collectively, this Agreement, the Warrant, the Notes, the Financing
Statement and Security Agreement in the form attached as <I><B>Exhibit&nbsp;A</B> </I>and all other documents,
instruments and agreements entered into between Borrower and Lender in connection with the Loan,
all as amended or extended from time to time.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Negative Pledge Agreement&#148; </I>means an agreement, dated as of the date hereof, in the form <I>of <B>Exhibit
H.</B></I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Note&#148; </I>means each Secured Promissory Note in the form <I>of <B>Exhibit&nbsp;B,</B> </I>delivered in connection with
each Advance.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Notice
of Borrowing&#148; </I>means the form attached as <I><B>Exhibit D.</B></I></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Obligations&#148; </I>means all Loans, debt, principal, interest, fees, charges, Lender&#146;s Expenses and
other amounts, obligations, covenants, and duties owing by Borrower to Lender of any kind or
description (whether pursuant to the Loan Documents or otherwise (with the exception of the
Warrant), and whether or not for the payment of money), whether direct or indirect, absolute or
contingent, due or to become due, now existing or hereafter arising, and including any of the same
obtained by Lender by assignment or otherwise, and all amounts Borrower is required to pay or
reimburse by the Loan Documents, by law, or otherwise.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><I>&#147;Permitted Indebtedness&#148; </I>means: <B>(i)</B>&nbsp;the Loan; <B>(ii)</B>&nbsp;unsecured trade debt incurred in the ordinary
course of Borrower&#146;s business; <B>(iii)</B>&nbsp;Indebtedness secured by clause <B>(ii)</B>&nbsp;and <B>(v)</B>&nbsp;of Permitted
Liens; <B>(iv)</B>&nbsp;Subordinated Indebtedness; <B>(v)</B>&nbsp;Indebtedness existing as of the date hereof and listed
on the Disclosure Schedule; <B>(vi)</B>&nbsp;Indebtedness arising from the endorsement of negotiable
instruments for deposits or
collections or similar transactions in the ordinary course of business; <B>(vii)</B>&nbsp;other Indebtedness
consisting of letters of credit and</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio --></DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reimbursement obligations in an amount not to exceed $250,000; <B>(viii)</B>&nbsp;Indebtedness of (A)&nbsp;Borrower
to any Subsidiary that is unsecured, (B)&nbsp;one Subsidiary to another Subsidiary, or (C)&nbsp;any
Subsidiary to Borrower in an amount not to exceed $4,500,000 in the aggregate; <B>(ix)</B>&nbsp;other
Indebtedness in an outstanding principal amount not to exceed $150,000 in the aggregate; and <B>(x)</B>
Indebtedness incurred in connection with the extension, renewal or refinancing of any Indebtedness
of the type described in clauses (i)&nbsp;through (ix)&nbsp;above, provided that the principal amount of such
Indebtedness does not increase other than any reasonable premium in connection therewith.
Notwithstanding the foregoing, the restrictions on Indebtedness for Subordinated Indebtedness and
referenced in clause (v)&nbsp;of the definition of Permitted Liens shall cease at the effective date of
a public offering of Borrower&#146;s capital stock which results in proceeds of at least $25,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Permitted Liens&#148; </I>means: <B>(i)</B>&nbsp;Liens in favor of Lender; <B>(ii)</B>&nbsp;Liens disclosed in the Disclosure
Schedule; <B>(iii)</B>&nbsp;Liens for taxes, fees, assessments or other governmental charges or levies not
delinquent or being contested in good faith by appropriate proceedings, that do not jeopardize
Lender&#146;s interest in any Collateral; <B>(iv)</B>&nbsp;Liens to secure payment of worker&#146;s compensation,
employment insurance, old age pensions or other social security obligations of Borrower on which
Borrower is current and are in the ordinary course of its business; provided none of the same
diminish or impair Lender&#146;s rights and remedies respecting the Collateral; and <B>(v)</B>&nbsp;Liens upon or
in any equipment (including any accessions, attachments, replacements, improvements or proceeds
thereto) acquired or held by Borrower to secure the purchase price of such equipment or
Indebtedness incurred solely for the purposes of financing such equipment, provided that the
aggregate outstanding principal amount of all such financing shall not exceed $5,000,000, <B>(vi)</B>
license or sublicenses of Intellectual Property granted in the ordinary course of business; <B>(vii)</B>
banker&#146;s Liens, rights of setoff and similar Liens incurred on deposit and securities accounts in
the ordinary course of business; <B>(viii)</B>&nbsp;Liens arising from judgments in circumstances not
constituting and Event of Default; <B>(ix)</B>&nbsp;Liens in favor of customs and revenue authorities arising
as a matter of law to secure payments of customs duties in connections with the importation of
goods; <B>(x)</B>&nbsp;Liens on insurance proceeds in favor of insurance companies granted solely as security
for financed premiums; <B>(xi)</B>&nbsp;carriers&#146;, warehousemen&#146;s, mechanics&#146;, landlords&#146;, materialmen&#146;s,
repairmen&#146;s or other similar Liens arising in the ordinary course of business which are not
delinquent or remain payable without penalty or which are being contested in good faith and by
appropriate proceedings; <B>(xii)</B>&nbsp;Liens with respect to cash collateral to secure Indebtedness
otherwise permitted pursuant to clause (vii)&nbsp;of the definition of Permitted Indebtedness; and
<B>(xiii)</B>&nbsp;Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness
secured by Liens of the type described in clauses (i)&nbsp;through (xi)&nbsp;above, provided that any
extension, renewal, or replacement Lien shall be limited to the collateral securing the existing
Lien and the principal amount of such Indebtedness does not increase other than any reasonable
premium in connection therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Regulated Substance&#148; </I>means any substance, material or waste the use, generation, handling,
storage, treatment or disposal of which is regulated by any local or state government authority,
including any of the same designated by any authority as hazardous, genetic, cloning, fetal, or
embryonic.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Responsible Officer&#148; </I>means each person as authorized by the board of directors of Borrower as set
forth on the Incumbency Certificate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Subordinated Indebtedness&#148; </I>means Indebtedness of Borrower to Singapore EDB and Invus Group that
is subordinated in both security and right of payment to the Obligations on terms and conditions
reasonably satisfactory to Lender in an amount not to exceed $6,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Subsidiary&#148; </I>shall mean any entity of which a majority of the outstanding equity interests
entitled to vote for the election of directors is owned by Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Term&#148; </I>means the period from and after the date hereof until the full, final and indefeasible
payment and performance of all Obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Warrant&#148; </I>means the Warrant, dated as of the date hereof, in favor of Lender and its affiliates to
purchase securities of Borrower substantially in the form <I>of <B>Exhibit&nbsp;C.</B></I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.2 Interpretation.</B> References to &#147;Articles,&#148; &#147;Sections,&#148; &#147;Exhibits,&#148; and &#147;Schedules&#148; are to
articles, sections, exhibits and schedules herein and hereto unless otherwise indicated. &#147;Hereof,&#148;
&#147;herein&#148; and &#147;hereunder&#148; refer to this Agreement as a whole. &#147;Including&#148; is not limiting. All
accounting and financial computations shall be computed in accordance with generally accepted
accounting principles consistently applied <I>(&#147;GAAP&#148;). </I>&#147;Or&#148; is not necessarily exclusive. All
interest computation interest shall be based on a 360-day year and actual days elapsed.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>2. The Loans</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.1
Commitment. </B>Subject to the terms hereof, Lender will make Advances to Borrower up to the principal amount of the Commitment,
before the Commitment Termination Date. Notwithstanding anything in the Loan Documents to the contrary, Lender&#146;s obligation to make any Advances or to lend the undisbursed portion of the Commitment shall terminate on the Commitment Termination Date. Repaid principal of the Advances may not be re-borrowed.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">

<DIV style="font-size: 10pt; margin-top: 6pt"><B>2.2 The Advances. </B>A Note setting forth the specific terms of repayment will evidence each
Advance. No Advance will be made for
less than $1,000,000, unless less than $1,000,000 remains available under the Commitment for
borrowing. Absence of a Note evidencing
any portion of the Loan shall not impair Borrower&#146;s obligation to repay it to Lender.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>2.3
Terms of Payment, Repayment.</B>
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Repayment. </B>Borrower shall repay the principal and pay interest on each Advance on the
terms set forth in the applicable Note. Amounts not paid when due hereunder or under the Note shall bear interest
at the Default Rate. If a court of competent jurisdiction determines that Lender has received payments that, if interest, would
exceed the maximum lawfully permitted, Lender will instead apply such money to fees and expenses and then to early prepayment of
principal (provided that notwithstanding anything contained in any Loan Document, any such prepayment shall not trigger any
Prepayment Fees).
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;ACH.</B> All payments due to Lender must be, at Lender&#146;s option, paid to Lender in cash or
through ACH. Borrower
shall execute and deliver the ACH Authorization Form substantially in the form of <B><I>Exhibit&nbsp;G.</I></B>
Lender shall provide Borrower an
invoice for any Obligations that are to be transferred by ACH at least 10&nbsp;days in advance of
the date of any ACH funds transfer with
respect to Obligations which have become due and payable and are to be transferred by ACH.
If the ACH payment arrangement is
terminated for any reason, Borrower shall make all payments due to Lender at Lender&#146;s
address specified in <B>Section&nbsp;11.</B>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Default Rate. </B>While an Event of Default has occurred and is continuing, interest on the
Loan shall be increased to
the Default Rate. Lender&#146;s failure to charge or accrue interest at the Default Rate during
the existence of a Default shall not be deemed
a waiver by Lender of its right or claim thereto.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Date. </B>Whenever any payment due under the Loan Documents is due on a day other than a
business day, such
payment shall be made on the next succeeding business day, and such extension of time shall
be included in the computation of interest or fees, as the case may be.
</DIV>
<DIV style="font-size: 10pt; margin-top: 6pt"><B>2.4 Fees.</B> Borrower shall pay to Lender the following:
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Commitment Fee. </B>The Commitment Fee, which has been previously paid by Borrower,
and shall be applied by Lender to Lender&#146;s Expenses and other Obligations;
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Late Fee. </B>On demand, a late charge on any sums due hereunder that are not paid when due,
in an amount equal to 2%
of the past due amount, payable on demand.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Lender&#146;s Expenses. </B>The payment of all Lender&#146;s Expenses, which may become due to Lender
by Borrower
hereunder shall be payable by Borrower as set forth in <B>Section 2.3(b).</B> Lender&#146;s Expenses not
paid when due shall bear interest as
principal at the Default Rate.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>3.</B> <FONT style="font-variant: SMALL-CAPS"><B>Conditions of Advances; Procedure for Requesting Advances</B></FONT>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>3.1 Conditions Precedent to any and all Advances. </B>The obligation of Lender to make any Advances is
subject to each and
every of the following conditions precedent in form and substance satisfactory to Lender in its
sole discretion: <B>(i)</B>&nbsp;this Agreement, a
Note evidencing the Advance, the Warrant, and all other UCC financing statements, and other
documents required or as specified herein
have been duly authorized, executed and delivered; <B>(ii)</B>&nbsp;no Default or Event of Default has
occurred and is continuing; <B>(iii)</B>&nbsp;delivery of a
Notice of Borrowing with respect to the proposed Advance; <B>(iv)</B>&nbsp;Lender&#146;s security interests in the
Collateral are valid and first priority,
except for Permitted Liens; and <B>(v)</B>&nbsp;all such other items as Lender may reasonably deem necessary
or appropriate have been delivered or
satisfied. The extension of an Advance prior to the receipt by Lender of any of the foregoing
shall not constitute a waiver by Lender of
Borrower&#146;s obligation to deliver such item.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>3.2 Procedure for Making Advances. </B>For any Advance, Borrower shall provide Lender an irrevocable
Notice of Borrowing at
least 7 business days prior to the desired Funding Date and Lender shall only be required to make
Advances hereunder based upon
written requests which comply with the terms and exhibits of this Loan Agreement (as the same may
be amended from time to time),
and which are submitted and signed by a Responsible Officer. Borrower shall execute and deliver to
Lender a Note and such other
documents and instruments as Lender may reasonably require for each Advance made.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>4.</B> <FONT style="font-variant: SMALL-CAPS"><B>Creation of Security Interest</B></FONT>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt"><B>4.1
Grant of Security Interest. </B>Borrower grants to Lender a valid, first priority,
continuing security interest in all present and future Collateral in order to secure prompt,
full, faithful and timely payment and performance of all Obligations.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.2 Inspections. </B>Lender shall have the right upon reasonable prior notice to inspect Borrower&#146;s
Books, including computer files,
and to make copies, and to test, inspect and appraise the Collateral, in order to verify any matter
relating to Borrower or the Collateral.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.3 Authorization to File Financing Statements. </B>Borrower irrevocably authorizes Lender at any time
and from time to time to
file in any jurisdiction any financing statements and amendments that: <B>(i)</B>&nbsp;name Collateral as
collateral thereunder, regardless of
whether any particular Collateral falls within the scope of the UCC; <B>(ii)</B>&nbsp;contain any other
information required by the UCC for
sufficiency or filing office acceptance, including organization identification numbers; and <B>(iii)</B>
contain such language as Lender
determines helpful in protecting or preserving rights against third parties. Borrower ratifies any
such filings made prior to the date
hereof.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>5.</B> <FONT style="font-variant: SMALL-CAPS"><B>Representations and Warranties</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as set forth on the Disclosure Schedule, Borrower represents and warrants as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.1 Due Organization and Qualification. </B>Borrower is a corporation duly formed, existing and in good
standing under the laws
of its state of incorporation and qualified and licensed to do business in, and is in good standing
in, any state in which the conduct of its
business or its ownership of property requires that it be so qualified or in which the Collateral
is located, except to the extent that such
non-compliance would not reasonably be expected to result in an adverse effect on Borrower&#146;s
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.2 Authority. </B>Borrower has all corporate power and authority, and has taken all actions, and has
obtained all third party
consents necessary to execute, deliver, and perform the Loan Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.3 Disclosure Schedule. </B>All information on the Disclosure Schedule is true, correct and complete.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.4 Authorization; Enforceability. </B>The execution and delivery hereof, the granting of the security
interest in the Collateral, the
incurring of the Obligations, the execution and delivery of all Loan Documents and the consummation
of the transactions herein and
therein contemplated have been duly authorized by all necessary action by Borrower. The Loan
Documents constitute legal, valid and
binding obligations of Borrower, enforceable in accordance with their terms, except as
enforceability may be limited by bankruptcy or
similar laws relating to enforcement of creditors&#146; rights generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.5 Name and Location. </B>Borrower has not done business under any name other than that specified on
the signature page hereof.
The chief executive office, principal place of business, and the place where Borrower maintains its
records concerning the Collateral
is set forth in <B>Section&nbsp;11. </B>The Collateral is presently located at the address(es) set forth in
<B>Section&nbsp;11 </B>and on the Disclosure Schedule
or any other location that Borrower has provided Lender with written notice thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.6 Litigation. </B>All actions or proceedings pending by or against Borrower that could reasonably
be expected to result in a
material adverse effect on Borrower&#146;s business before any court or administrative agency are set
forth on the Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.7 Financial Statements. </B>All financial statements delivered by Borrower to Lender present fairly
in all material respects
Borrower&#146;s financial condition for the periods indicated. All statements respecting Collateral that
have been or may hereafter be
delivered by Borrower to Lender are true, complete and correct in all material respects for the periods indicated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.8 Solvency. </B>Borrower is solvent and able to pay its debts (including trade debts) as they come due.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.9 Taxes. </B>Borrower has filed and will file all required tax returns, and has paid and will pay all
taxes it owes other than where
the failure to comply would not reasonably be expected to have a material adverse effect on
Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.10 Rights; Title to Assets. </B>To Borrower&#146;s knowledge, Borrower possesses, owns, or has the right
to use all necessary assets,
rights, trademarks, trade names, copyrights, patents, patent rights, franchises and licenses which
are required to conduct of its business
as now operated, except where the failure to possess or own could not reasonably be expected to
have a material adverse effect on
Borrower&#146;s business. Borrower has good title to its assets, free and clear of any Liens, except for
Permitted Liens.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.11 Full Disclosure. </B>No written representation, warranty or other statement made by Borrower in
any Loan Document, certificate
or statement furnished to Lender contains any untrue statement of a material fact or omits to state
a material fact necessary in order to
make the statements contained in such certificates or statements not misleading (it being
recognized by Lender that projections and
estimates as to future events are not to be viewed as facts and the actual results during the
period or periods covered by any such
projections and estimates may differ from projected or estimated results).
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.12 Regulated Substances. </B>Borrower complies and will comply with all laws respecting Regulated
Substances, except where the
failure to comply could not reasonably be expected to have an adverse effect on Borrower&#146;s
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.13
Reaffirmation. </B>Each Notice of Borrowing will constitute <B>(i)</B>&nbsp;a warranty and representation in
favor of Lender that there does
not exist any Default and <B>(ii)</B>&nbsp;subject to any amended Disclosure Schedule delivered to Lender or
any other written disclosure required
to be sent to Lender pursuant to the terms hereof, a reaffirmation as of the date thereof of all of
the representations and warranties
contained in this Agreement and the Loan Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>6.</B> <FONT style="font-variant: SMALL-CAPS"><B>Affirmative Covenants</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">So long as any Obligations (other than inchoate indemnity obligations) remain outstanding,
Borrower covenants and agrees that it shall do all of the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.1 Good Standing and Compliance. </B>Borrower shall maintain all governmental licenses, rights and
agreements necessary for its
operations or business and comply in all respects with all statutes, laws, ordinances and
government rules and regulations to which it is
subject except where the failure to comply would not reasonably be expected to result in a material
adverse effect on Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.2 Financial Statements, Reports, Certificates. </B>Borrower shall deliver to Lender: <B>(i)</B>&nbsp;as soon as
prepared, and no later than 30
days after the end of each calendar month, a balance sheet, income statement and cash flow
statement covering Borrower&#146;s operations
during such period; <B>(ii)</B>&nbsp;as soon as prepared, but no later than 90&nbsp;days after the end of the fiscal
year, or such other timeframe formally
approved by Borrower&#146;s audit committee, audited financial statements prepared in accordance with
GAAP, together with an opinion
that such financial statements fairly present Borrower&#146;s financial condition by an independent
public accounting firm reasonably
acceptable to Lender; <B>(iii) </B>immediately upon notice thereof, a report of any legal or
administrative action pending or threatened in
writing against Borrower which is likely to result in liability to Borrower in excess of $100,000
(provided that Borrower shall not be
required to report notices of possibly relevant third party patents, or proposals or demands to
license intellectual property); and
<B>(iv)</B>&nbsp;such other financial information as Lender may reasonably request from time to time. Financial
statements delivered pursuant to
subsections <B>(i)</B>&nbsp;and <B>(ii)</B>&nbsp;above shall be accompanied by a certificate signed by a Responsible
Officer (each an <I>&#147;Officer&#146;s Certificate&#148;) </I>in
the form <B><I>of Exhibit&nbsp;F.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.3 Notice of Defaults. </B>Upon any Default or Event of Default, an Officer&#146;s Certificate setting
forth the facts relating to or giving
rise thereto, and the Borrower&#146;s proposed action with respect thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.4
Use; Maintenance. </B>Borrower, at its expense, shall <B>(i)</B>&nbsp;maintain the tangible Collateral in good condition, reasonable wear
and tear excepted, and will comply in all material respects with all laws, rules and regulations
regarding use and operation of the
tangible Collateral and <B>(ii)</B>&nbsp;repair or replace any lost or damaged Collateral except to the extent
that Borrower in its good faith
judgment deems it to be in its best interest not to repair or replace such lost or damaged
Collateral, so long as applied to a purchase or
acquisition useful to Borrower&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.5 Insurance. </B>Borrower, at its own expense, shall maintain insurance in amounts and coverages reasonably satisfactory to
Lender. Each insurance shall: <B>(i)</B>&nbsp;name Lender loss payee or additional insured, as appropriate,
<B>(ii)</B>&nbsp;provide for insurer&#146;s waiver of its
right of subrogation against Lender and Borrower, <B>(iii)</B>&nbsp;provide that such insurance shall not be
invalidated by any action of, or breach
of warranty by, Borrower and waive set-off, counterclaim or offset against Lender, <B>(iv)</B>&nbsp;be primary
without a right of contribution of
Lender&#146;s insurance, if any, or any obligation on the part of Lender to pay premiums of Borrower,
and <B>(v)</B>&nbsp;require the insurer to give
Lender at least 30&nbsp;days prior written notice of cancellation. Borrower shall furnish all
certificates of insurance required by Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.6 Loss Proceeds. </B>So long as no Event of Default has occurred and is continuing, any proceeds of
insurance on or
condemnation of Collateral shall, at Borrower&#146;s election and so long as Lender&#146;s security interest
in such proceeds remains first
priority, be used either to repair or replace such Collateral or otherwise applied to the purchase
or acquisition of property useful to
Borrower&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.7 Further Assurances. </B>At any time and from time to time, Borrower shall execute and deliver such further instruments and
take such further action as Lender may reasonably request to effect the intent and purposes hereof,
to perfect and continue perfected
and of first priority Lender&#146;s security interests in the Collateral, and to effect and maintain ACH
payment arrangements.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>7.</B> <FONT style="font-variant: SMALL-CAPS"><B>Negative Covenants</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">So long as any Obligations (other than inchoate indemnity obligations) remain outstanding, Borrower
will not do any of the following:
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.1 Location of Collateral. </B>Change its chief executive office or principal place of business or
remove, except in the ordinary course of Borrower&#146;s business, the Collateral or Borrower&#146;s Books
from the premises listed in <B>Section&nbsp;11 </B>and the Disclosure Schedule (or otherwise provided to Lender
in writing pursuant to this <B>Section 7.1</B>) without giving 30&nbsp;days prior written notice to Lender.
Borrower&#146;s practice of delivering and maintaining inventory at a customer&#146;s location pending
testing, validation and/or acceptance of such inventory by such customer shall be deemed to be in
the &#147;ordinary course of business&#148; for purposes of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.2 Extraordinary Transactions. </B>Enter into any transaction not in the ordinary course of
Borrower&#146;s business, including the sale, lease, license or other disposition of its assets, other
than <B>(i)</B>&nbsp;sales of inventory in the ordinary course of
Borrower&#146;s business; and <b>(ii)</b>&nbsp;licenses of
intellectual property assets entered into in the ordinary course of business (provided that
licensing arrangements involving universities, governmental agencies, research institutions and
corporate partners shall be deemed in the &#147;ordinary course of business&#148;). The parties hereto
agree (a)&nbsp;strategic partnerships, strategic collaborations, sponsored research collaborations and
development transactions, (b)&nbsp;transactions otherwise permitted in this <B>Article 7,</B> and (c)
transactions for fair value involving the sale or exclusive licensing of Intellectual Property,
that is outside the scope of Borrower&#146;s business in the biotechnology field, that is not being
commercialized or monetized by the Borrower; in each case, shall be deemed to be in the &#147;ordinary
course of business&#148; for purposes of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.3 Restructure. </B>Make any material change in Borrower&#146;s corporate structure or business other than
the business of the type conducted by Borrower as of the date of this Agreement or any business
reasonably related or incidental thereto; or suspend operation of Borrower&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.4 Liens. </B>Create, incur, assume or suffer to exist any Lien of any kind with respect to any of its
property, whether now owned or hereafter acquired, except for Permitted Liens.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.5 Indebtedness. </B>Create, incur, assume or suffer to exist any Indebtedness, other than Permitted
Indebtedness or cause or suffer any Subsidiary to create, incur, assume or suffer to exist any
Indebtedness, other than Permitted Indebtedness.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.6 Distributions. </B>Pay any dividends or distributions, or redeem or purchase, any capital stock,
except for <b>(i)</b>&nbsp;repurchases of capital stock from employees, consultants or directors, under
incentive stock option plans, restricted stock purchase agreements, repurchase agreements or other
similar agreements approved by the Borrower&#146;s Board of Directors
and <b>(ii)</b>&nbsp;dividends payable solely
in capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.7 Transactions with Affiliates. </B>Directly or indirectly enter into any transaction with any
affiliate which is on terms less favorable to Borrower than would be obtained in an arm&#146;s length
transaction with a non-affiliated entity; <I>provided, </I>any such transaction shall not be a breach of
this Section&nbsp;7.7 if <b>(i)</b>&nbsp;approved by a disinterested majority of the Borrower&#146;s Board of Directors,
or <b>(ii)</b>&nbsp;such transaction involves sales, licensing or other transfers of property between Borrower
and its Subsidiaries, or between Subsidiaries if the consideration for such sale or transfer is not
less than cost (or the fair market value of such property, if lower),
or <b>(iii)</b>&nbsp;such transaction
involves intercompany loans that are otherwise permitted by <B>Section&nbsp;7.5.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.8
Compliance. </B><b>(i)</b>&nbsp;Become regulated as an &#147;investment company&#148; under the Investment Company Act of
1940 or extend credit to purchase or carry margin stock; <b>(ii)</b>&nbsp;fail to meet the minimum funding
requirements of ERISA; <B>(iii) </B>permit a Reportable Event or Prohibited Transaction, as defined in
ERISA, to occur; <b>(iv)</b>&nbsp;fail to comply with the Federal
Fair Labor Standards Act; or <b>(v)</b>&nbsp;violate any
other material law or material regulation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.9 UCC Effectiveness. </B>Change its name, jurisdiction of organization, or take any other action
that could render Lender&#146;s financing statements misleading under the Code, without giving Lender 30
days advance written notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.10 Deposit and Securities Accounts. </B>Maintain any deposit accounts or accounts holding securities
owned by Borrower except accounts in which Lender has obtained a perfected first priority security
interest with the exception of <b>(i)</b>&nbsp;account number &#091;***&#093; with Silicon Valley Bank or a
successor account with Wells Fargo Bank securing a letter of credit in favor of Borrower&#146;s landlord
in an amount not to exceed $250,000 in principal amount; <b>(ii)</b>&nbsp;account number &#091;***&#093; with
Comerica Bank or a successor account with Wells Fargo Bank securing a letter of credit in favor of
a lender providing equipment financing to Borrower in an amount not to exceed $500,000 in principal
amount; or <b>(iii)</b>&nbsp;account number &#091;***&#093; with Wells Fargo Bank securing a letter of credit in favor
of Borrower&#146;s landlord in an amount not to exceed $137,527 in
principal amount; or <b>(iv)</b>&nbsp;any other
accounts at Silicon Valley Bank or Comerica Bank (other than those specified in clause (i)&nbsp;or (ii)
of this <B>Section&nbsp;7.10, </B>provided that such accounts are closed and such funds are move to deposit or
securities accounts in which Lender has a perfect first priority security interest, on or before
June&nbsp;30, 2005.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>8. </B><FONT style="font-variant: SMALL-CAPS"><B>Events of Default</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any one or more of the following shall constitute an Event of Default by Borrower hereunder:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.1
Payment. </B>Borrower fails to pay when due and payable in accordance with the Loan Documents any
portion of the Obligations, or cancels an ACH payment or transfer Lender has initiated in
conformity with the terms hereof <I>provided, however,</I> that an Event of Default shall not occur on
account of a failure to pay due solely to an administrative or operational error if Borrower had
the funds to make the payment when due and makes the payment the business day following Borrower&#146;s
knowledge of such failure to pay.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.2 Certain Covenant Defaults. </B>Borrower fails to perform any obligation under <B>Section&nbsp;6.5 </B>or <B>6.6,</B>
or violates any of the covenants contained in <B>Section&nbsp;7.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.3 Other Covenant Defaults. </B>Borrower fails or neglects to perform, keep, or observe any other
term, provision, condition, covenant, or agreement contained in this Agreement, in any of the other
Loan Documents, or in any other present or future agreement between Borrower and Lender and has
failed to cure such failure within 30&nbsp;days after its occurrence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.4 Attachment. </B>Any material portion of Borrower&#146;s assets is attached, seized, subjected to a
government levy, lien, writ or distress warrant, or comes into the possession of any trustee or
receiver and the same is not returned, removed, waived, stayed, discharged or rescinded within 15
days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.5 Other Agreements. </B>There is a default in any agreement to which Borrower is a party resulting in
a right by a third party, whether or not exercised, to accelerate the maturity of any Indebtedness,
in an amount greater than $ 100,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.6 Judgments. </B>One or more judgments for an aggregate of at least $100,000 is rendered against
Borrower and remains unsatisfied and unstayed for more than 30&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.7 Injunction. </B>Borrower is enjoined, restrained, or in any way prevented by court order from
continuing to conduct any material part of its business affairs, or if a judgment or other claim
becomes a Lien upon any material portion of Borrower&#146;s assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.8 Misrepresentation. </B>Any representation, statement, or report made to Lender by Borrower was
false or misleading when made in any material respect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.9 Enforceability. </B>Lender&#146;s ability to enforce its rights against Borrower or any Collateral is
impaired in any material respect, or Borrower asserts that any Loan Document is not a legal, valid
and binding obligation of Borrower enforceable in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.10 Involuntary Bankruptcy. </B>An involuntary bankruptcy case remains undismissed or unstayed for 60
days or, if earlier, an order granting the relief sought is entered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.11 Voluntary Bankruptcy or Insolvency. </B>Borrower commences a voluntary case under applicable
bankruptcy or insolvency law, consents to the entry of an order for relief in an involuntary case
under any such law, or consents or is subject to the appointment of or taking possession by a
receiver, liquidator, assignee, trustee, custodian or other similar official of Borrower or any
substantial part of its property, or makes an assignment for the benefit of creditors, or fails
generally or admits in writing to its inability to pay its debts as they become due, or takes any
corporate action in furtherance of any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.12 Merger without Assumption. </B>Borrower or all or substantially all of Borrower&#146;s assets are
acquired by or merged into any other business entity where more than 50% of Borrower&#146;s voting power
is transferred by existing shareholders of Borrower, and such acquirer or resulting entity either:
<b>(i)</b>&nbsp;does not pay off the Obligations at the closing of
the acquisition, merger or sale; or <b>(ii)</b>
does not provide an unconditional, unlimited guaranty of the Obligations in form and substance
satisfactory to Lender and is of a credit quality unacceptable to Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.13
Liquidation Event. </B>Borrower consummates a Liquidation Event where the acquirer or resulting
entity either: <b>(i)</b>&nbsp;does not pay off the Obligations at the closing of the acquisition, merger or
sale; or <b>(ii)</b>&nbsp;does not provide an unconditional, unlimited guaranty of the Obligations in form and
substance satisfactory to Lender and is of a credit quality unacceptable to Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>8.14 General Electric Capital Corporation Indebtedness. </B>The outstanding principal balance of
Borrower owed to General Electric Capital Corporation in connection with any equipment financing
shall be greater than $2,500,000 at any time after December&nbsp;31, 2006.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>9. </B><FONT style="font-variant: SMALL-CAPS"><B>Lender&#146;s Rights and Remedies</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.1 Rights and Remedies. </B>Upon the occurrence and continuance of any Event of Default, Lender
may, at its election, without notice of election and without demand, do any one or more of the
following, all of which are authorized by Borrower: <b>(i)</b>&nbsp;accelerate and declare the Loan and all
Obligations immediately due and payable; <b>(ii)</B>&nbsp;make such payments and do such acts as Lender
considers necessary or reasonable to protect its security interest in the Collateral, with such
amounts becoming Obligations bearing interest at the Default Rate;
<b>(iii)</b>&nbsp;exercise any and all other
rights and remedies available under the UCC or otherwise; <b>(iv)</b>&nbsp;require Borrower to assemble the
Collateral at such places as Lender may designate; <b>(v)</b>&nbsp;enter premises where any Collateral is
located, take, maintain possession of, or render unusable the
Collateral or any part of it; <b>(vi)</b>
without notice to Borrower, set off and recoup against any portion of
the Obligations; <b>(vii)</b>&nbsp;ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell
the Collateral, in connection with which Borrower hereby grants Lender a license to use without
charge Borrower&#146;s premises, labels, name, trademarks, and other property necessary to complete,
advertise, and sell any Collateral; and <b>(viii)</b>&nbsp;sell the Collateral at one or more public or private
sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.2 Power of Attorney in Respect of the Collateral. </B>Borrower hereby irrevocably appoints Lender
(which appointment is coupled with an interest) its true and lawful attorney in fact with full
power of substitution, for it and in its name to, during the
existence of an Event of Default: <b>(i)</b>
ask, demand, collect, receive, sue for, compound and give acquittance for any and all Collateral
with full power to settle, adjust or compromise any claim, <b>(ii)</b>&nbsp;receive payment of and endorse the
name of Borrower on any items of Collateral, <b>(iii)</b>&nbsp;make all demands, consents and waivers, or take
any other action with respect to, the Collateral, <b>(iv)</b>&nbsp;file any claim or take any other action, in
Lender&#146;s or Borrower&#146;s name, which Lender may reasonably deem appropriate to protect its rights in
the Collateral, or <b>(v)</b>&nbsp;otherwise act with respect to the Collateral as though Lender were its
outright owner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.3 Charges. </B>If Borrower fails to pay any amounts required hereunder to be paid by Borrower to any
third party, Lender may at its option pay any part thereof and any amounts so paid including
Lender&#146;s Expenses incurred shall become Obligations, immediately due and payable, bearing interest
at the Default Rate, and secured by the Collateral. Any such payments by Lender shall not
constitute an agreement to make similar payments or a waiver of any Event of Default.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.4 Remedies Cumulative. </B>Lender&#146;s rights and remedies under the Loan Documents and all other
agreements with Borrower shall be cumulative. Lender shall have all other rights and remedies as
provided under the UCC, by law, or in equity. No exercise by Lender of one right or remedy shall be
deemed an election, and no waiver by Lender of any Event of Default shall be deemed a continuing
waiver. No delay by Lender shall constitute a waiver, election, or acquiescence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>9.5 Application of Collateral Proceeds. </B>Lender will apply proceeds of sale, to the extent
actually received in cash, in the manner and order it determines in its sole discretion, and as
prescribed by applicable law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>10. </B><FONT style="font-variant: SMALL-CAPS"><B>Waivers; Indemnification</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10.1 Waivers. </B>Without limiting the generality of the other waivers made by Borrower herein, to the
maximum extent permitted under applicable law, Borrower hereby irrevocably waives all of the
following: <b>(i)</b>&nbsp;any right to assert <I>against Lender </I>as a defense, counterclaim, set-off or
crossclaim, any defense (legal or equitable), set-off, counterclaim, crossclaim and/or other claim
(a)&nbsp;which Borrower may now or at any time hereafter have against any party liable to Lender in any
way or manner, or (b)&nbsp;arising directly or indirectly from the present or future lack of perfection,
sufficiency, validity and/or enforceability of any Loan Document, or
any security interest; <b>(ii)</b>
notice of presentment, dishonor, notice of intent to accelerate, protest, default, nonpayment,
maturity; <b>(iii)</b>&nbsp;the benefit of all marshalling,
valuation, appraisal and exemption laws; <b>(iv)</b>&nbsp;the
right, if any, to require Lender to (a)&nbsp;proceed against any person liable for any of the
Obligations as a condition to or before proceeding hereunder; or (b)&nbsp;foreclose upon, sell or
otherwise realize upon or collect or apply any other property, real or personal, securing any of
the Obligations, as a condition to, or before proceeding hereunder;
<b>(v)</b>&nbsp;any demand for possession
before the commencement of any suit or action to recover possession
of Collateral; and <b>(vi)</b>&nbsp;any
requirement that Lender retain possession and not dispose of Collateral until after trial or final
judgment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10.2 Lender&#146;s Liability for Collateral. </B>Lender shall not in any way or manner be liable or
responsible for: <b>(i)</b>&nbsp;the safekeeping of any Collateral (except to the extent mandated by the UCC);
<b>(ii)</b>&nbsp;any loss or damage thereto occurring or arising in
any manner or fashion from any cause; <b>(iii)</b>
any diminution in the value thereof; or <b>(iv)</b>&nbsp;any act or default of any carrier, warehouseman,
bailee, forwarding agency, or other person or entity whomsoever. All risk of loss, damage or
destruction of the Collateral shall be borne by Borrower. Lender will have no responsibility for
taking any steps to preserve rights against any parties respecting any Collateral. Lender&#146;s powers
hereunder are conferred solely to protect its interest in the Collateral and do not impose any duty
to exercise any such powers. None of Lender or any of its officers, directors, employees, agents or
counsel will be liable for any action lawfully taken or omitted to be taken hereunder or in
connection herewith (excepting gross negligence or willful misconduct), nor under any circumstances
have any liability to Borrower for lost profits or other special, indirect, punitive, or
consequential damages. Lender retains any documents delivered by Borrower only for its purposes and
for such period as Lender, at its sole discretion, may determine necessary, after which time Lender
may destroy such records without notice to or consent from Borrower.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<div style="border: 1px solid black; padding: 11px">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>10.3 Indemnification. </B>Borrower shall, on an after tax basis, defend, indemnify, and
hold Lender and each of its officers, directors, employees, counsel, partners, agents and
attorneys-in-fact (each, an <I>&#147;Indemnified Person&#148;) </I>harmless from and against any and all
liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, charges,
expenses or disbursements (including Lender&#146;s Expenses and reasonable attorney&#146;s fees and the
allocated cost of in-house counsel) of any kind or nature whatsoever with respect to the execution,
delivery, enforcement, performance and administration of this Agreement and any other Loan
Documents, or the transactions contemplated hereby and thereby, with respect to noncompliance with
laws or regulations respecting Regulated Substances, government secrecy or technology export, or
any Lien not created by Lender or right of another against any Collateral, even if the Collateral
is foreclosed upon or sold pursuant hereto, and with respect to any investigation, litigation or
proceeding before any agency, court or other governmental authority relating to this Agreement or
the Advances or the use of the proceeds thereof, whether or not any Indemnified Person is a party
thereto (all the foregoing, collectively, the <I>&#147;Indemnified Liabilities&#148;); provided, </I>that Borrower
shall have no obligation hereunder to any Indemnified Person with respect to Indemnified
Liabilities arising from the gross negligence or willful misconduct of such Indemnified Person. The
obligations in this Section shall survive the Term. At the election of any Indemnified Person,
Borrower shall defend such Indemnified Person using legal counsel satisfactory to such Indemnified
Person, at the sole cost and expense of Borrower. All amounts owing under this Section shall be
paid within 30&nbsp;days after written demand.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>11. </B><FONT style="font-variant: SMALL-CAPS"><B>Notices</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All notices shall be in writing and personally delivered or sent by certified mail, postage
prepaid, return receipt requested, or by confirmed facsimile, at the respective addresses set
forth below:
</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">If to Borrower:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Lender:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fluidigm Corporation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lighthouse Capital Partners V, LP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">7100 Shoreline Court
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">500 Drake&#146;s Landing Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">South San Francisco, California 94080
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Greenbrae, California 94904</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Attention:
General Counsel,</div>
<DIV style="margin-left:60px; text-indent:-0px">Director of
Finance</div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Contract Administrator</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">FAX: (650)871-7152
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FAX: (415)925-3387</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>12. </B><FONT style="font-variant: SMALL-CAPS"><B>General Provisions</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.1 Successors and Assigns. </B>This Agreement shall bind and inure to the benefit of the parties&#146;
respective successors and permitted assigns. Borrower may not assign any rights hereunder without
Lender&#146;s prior written consent, which consent may be granted or withheld in Lender&#146;s sole
discretion. Lender shall have the right without the consent of or notice to Borrower to sell,
transfer, negotiate, or grant participations in all or any part of any Loan Document, <I>provided </I>that
Lender shall not sell, transfer, negotiate, or grant participations in all or any part of any Loan
Document to any competitor of Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.2 Time of Essence. </B>Time is of the essence for the performance of all Obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.3 Severability of Provisions. </B>Each provision hereof shall be severable from every other
provision in determining its legal enforceability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.4 Entire Agreement. </B>This Agreement and each of the other Loan Documents dated as of the date
hereof, taken together, constitute and contain the entire agreement between Borrower and Lender
with respect to their subject matter and supersede any and all prior agreements, negotiations,
correspondence, understandings and communications between the parties, whether written or oral.
This Agreement is the result of negotiations between and has been reviewed by the Borrower and
Lender as of the date hereof and their respective counsel; <I>accordingly, </I>this Agreement shall be
deemed to be the product of the parties hereto, and no ambiguity shall be construed in favor of or
against Borrower or Lender. This Agreement may only be modified with the written consent of Lender.
Any waiver or consent with respect to any provision of the Loan Documents shall be effective only
in the specific instance and for the specific purpose for which it was given. No notice to or
demand on Borrower in any one case shall entitle Borrower to any other or further notice or demand
in similar or other circumstances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.5 Reliance by Lender. </B>All covenants, agreements, representations and warranties made herein
by Borrower shall, notwithstanding any investigation by Lender, be deemed to be material to and to
have been relied upon by Lender.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.6 No Set-Offs by Borrower. </B>All sums payable by Borrower pursuant to this Agreement or any of the
other Loan Documents shall be payable without notice or demand and shall be payable in United
States Dollars without set-off or reduction of any manner whatsoever.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<div style="border: 1px solid black; padding: 11px">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.7 Counterparts</B>. This Agreement may be executed in any number of counterparts, each
of which shall be deemed to be an original, and all of which, when taken together, shall constitute
one and the same original instrument.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.8 Survival. </B>All covenants, representations and warranties made in this Agreement shall continue
in full force and effect so long as any Obligations (other than inchoate indemnity obligations)
remain outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>12.9 No
Original Issue Discount.</b> Borrower and Lender acknowledge and agree that the Warrant is part
of an investment unit within the meaning of Section&nbsp;1273(c)(2) of the Internal Revenue Code, which
includes the Loan. Borrower and Lender further agree as between them, that the fair market value of
the Warrant is $100 and that, pursuant to Treas. Reg. &#167; 1.1273-2(h), $100 of the issue price of the
investment unit will be allocable to the Warrant and the balance shall be allocable to the Loans.
Borrower and Lender agree to prepare their federal income tax returns in a manner consistent with
the foregoing and, pursuant to Treas. Reg. &#167; 1.1273, the original issue discount on the Loan shall
be considered to be zero.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.10 Relationship of Parties. </B>The relationship between Borrower and Lender is, and at all times
shall remain, solely that of a borrower and lender. Lender is not a partner or joint venturer of
Borrower; nor shall Lender under any circumstances be deemed to be in a relationship of confidence
or trust or have a fiduciary relationship with Borrower or any of its affiliates, or to owe any
fiduciary duty to Borrower or any of its affiliates. Lender does not undertake or assume any
responsibility or duty to Borrower or any of its affiliates to select, review, inspect, supervise,
pass judgment upon or otherwise inform any of them of any matter in connection with its or their
property, the Loans, any Collateral or the operations of Borrower or any of its affiliates.
Borrower and each of its affiliates shall rely entirely on their own judgment with respect to such
matters, and any review, inspection, supervision, exercise of judgment or supply of information
undertaken or assumed by Lender in connection with such matters is solely for the protection of
Lender and neither Borrower nor any affiliate is entitled to rely thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.11
Choice of Law and Venue; Jury
Trial Waiver.<FONT style="font-variant: SMALL-CAPS"> This Agreement shall be governed by and construed in
accordance with, the internal laws of the State of California,
without regard to principles of conflicts of law. Each of Borrower
and Lender hereby submits to the exclusive jurisdiction of the State
and Federal courts located in the City and County of San Francisco,
State of California. Borrower and lender hereby waive their
respective rights to a jury trial of any claim or cause of action
based upon or arising out of any of the Loan Documents or any of the
transactions contemplated therein, including contract claims, tort
claims, breach of duty claims, and all other common law or statutory
claims. Each party further waives any right to consolidate any action
in which a jury trial has been waived with any other action in which
a jury trial cannot be or has not been waived.</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>12.12 Termination. </B>Upon the full, faithful and indefeasible payment and performance of all
Obligations(other than inchoate indemnity obligations) and the termination of any commitment to
extend credit under this Agreement, the security interest granted herein and under the other Loan
Documents shall terminate and this Agreement and the other Loan Documents (other than the Warrant)
shall terminate, except for any inchoate indemnity obligations under
<b>Section&nbsp;10.3</b> of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>In
Witness Whereof, </B></font>the parties hereto have executed this Agreement as of the date first above written.
</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse
Management Partners </B></FONT><B>V, L.L.C.,</B> <BR>
its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top">PRESIDENT &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Exhibit A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collateral Description<BR>
Exhibit&nbsp;B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Note<BR>
Exhibit&nbsp;C&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Preferred Stock Warrant<BR>
Exhibit&nbsp;D&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Notice of Borrowing<BR>
Exhibit&nbsp;E&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Incumbency Certificate<BR>
Exhibit&nbsp;F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Officers Certificate<BR>
Exhibit&nbsp;G&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ACH Authorization<BR>
Exhibit&nbsp;H&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Negative Pledge Agreement<BR>
Exhibit&nbsp;I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Control Agreement

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>



</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit </B></FONT><b>A</b></div>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Collateral</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This FINANCING STATEMENT and SECURITY AGREEMENT covers all of Debtor&#146;s interests in all of the
following types or items of property described on this <B>Exhibit&nbsp;A </B>(collectively, the <I>&#147;Collateral&#148;),</I>
wherever located and whether now owned or hereafter acquired, and Debtor hereby grants Secured
Party a security interest therein as collateral for the payment and performance of all present and
future indebtedness, liabilities, guarantees and obligations of Debtor to Secured Party, howsoever
arising. Debtor agrees that said security interest may be enforced by Secured Party in accordance
with the terms of all security and other agreements between Secured Party and Debtor, the
California Uniform Commercial Code, or both, and that this document shall be fully effective as a
security agreement, even if there is no other security or other agreement between Secured Party or
Debtor:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All assets of the Debtor; all personal property of Debtor;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All &#147;accounts&#148;, &#147;general intangibles&#148;, &#147;chattel paper&#148;, &#147;contract rights&#148;, &#147;documents&#148;,
&#147;instruments&#148;, &#147;deposit accounts&#148;, &#147;inventory&#148;, &#147;farm products&#148;, &#147;fixtures&#148; and &#147;equipment&#148;, as
such terms are defined in Division 9 of the California Uniform Commercial Code in effect on the
date hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All general intangibles of every kind, including without limitation, federal, state and local tax
refunds and claims of all kinds; all rights as a licensee or any kind; all customer lists,
telephone numbers, and purchase orders, and all rights to purchase, lease sell, or otherwise
acquire or deal with real or personal property and all rights relating thereto;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All returned and repossessed goods and all rights as a seller of goods; all collateral securing
any of the foregoing; all deposit accounts, special and general, whether on deposit with Secured
Party or others;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All life and other insurance policies, claims in contract, tort or otherwise, and all judgments now
or hereafter arising therefrom;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All right, title and interest of Debtor, and all of Debtor&#146;s rights, remedies, security and liens,
in, to and in respect of all accounts and other collateral, including, without limitation, rights
of stoppage in transit, replevin, repossession and reclamation and other rights and remedies of an
unpaid vendor, lienor or secured party, and all guarantees and other contracts of suretyship with
respect to any accounts and other collateral, and all deposits and other security for any accounts
and other collateral, and all credit and other insurance;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All notes, drafts, letters of credit, contract rights, and things in action; all drawings,
specifications, blueprints and catalogs; and all raw materials, work in process, materials used or
consumed in Debtor&#146;s business, goods, finished goods, returned goods and all other goods and
inventory of whatsoever land or nature, any and all wrapping, packaging, advertising and shipping
materials, and all documents relating thereto, and all labels and other devices, names and marks
affixed or to be affixed thereto for purposes of selling or identifying the same or the seller or
manufacturer thereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All inventory wherever located; all present and future claims against any supplier of any of the
foregoing, including claims for defective goods or overpayments to or undershipments by suppliers;
all proceeds arising from the lease or rental of any of the foregoing;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All equipment and fixtures, including without limitation all machinery, machine tools, motors,
controls, parts, vehicles, workstations, tools, dies, jigs, furniture, furnishings and fixtures;
and all attachments, accessories, accessions and property now or hereafter affixed to or used in
connection with any of the foregoing, and all substitutions and replacements for any of the
foregoing; all warranty and other claims against any vendor or lessor of any of the foregoing;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All investment property;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All books, records, ledger cards, computer data and programs and other property and general
intangibles at any time evidencing or relating to any or all of the foregoing; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All cash and non-cash products and proceeds of any of the foregoing, in whatever form, including
proceeds in the form of inventory, equipment or any other form of personal property, including
proceeds of proceeds and proceeds of insurance, and all claims by Debtor against third parties for
loss or damage to, or destruction of, or otherwise relating to, any or all of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOTICE &#151; PURSUANT TO AN AGREEMENT BETWEEN DEBTOR AND SECURED PARTY, DEBTOR HAS AGREED NOT TO
FURTHER ENCUMBER THE COLLATERAL DESCRIBED HEREIN (EXCEPT AS EXPRESSLY PERMITTED PURSUANT TO SUCH
AGREEMENT), THE FURTHER ENCUMBERING OF WHICH MAY CONSTITUTE THE TORTIOUS INTERFERENCE
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt">1</div>
</div>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="width: 99%; border: 1px solid black; padding: 11px">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WITH SECURED PARTY&#146;S RIGHTS BY SUCH ENCUMBRANCER. IN THE EVENT THAT ANY ENTITY IS GRANTED A
SECURITY INTEREST IN DEBTOR&#146;S ACCOUNTS, CHATTEL PAPER, GENERAL INTANGIBLES OR OTHER ASSETS CONTRARY
TO THE ABOVE, THE SECURED PARTY ASSERTS A CLAIM TO ANY PROCEEDS THEREOF RECEIVED BY SUCH ENTITY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding any of the foregoing, this Financing Statement and Security Agreement does not
cover any of Debtor&#146;s interests in, and the Collateral shall not under any circumstance include,
and no security interest is granted in, (i)&nbsp;any property that is subject to a Lien that is
otherwise permitted pursuant to subsection (v)&nbsp;of the definition of &#147;Permitted Liens&#148; as defined
in that certain Loan and Security Agreement, dated as of March&nbsp;29, 2005, by and between Secured
Party and Debtor, and Secured Party agrees to execute any instruments or documents necessary to
evidence the intent of the foregoing, (ii)&nbsp;more than 65% of the issued and outstanding voting
securities of any subsidiary of Debtor that is not incorporated or organized in the United States,
or (iii)&nbsp;Debtor&#146;s Intellectual Property, including, without limitation, any and all property of
the Debtor that is subject to, listed in or otherwise described in the Negative Pledge Agreement
dated March&nbsp;29, 2005 between the Secured Party and the Debtor. <I>&#147;Intellectual Property&#148; </I>means,
collectively, all rights, priorities and privileges of the Debtor relating to intellectual
property, in any medium, of any kind or nature whatsoever, now or hereafter owned or acquired or
received by Debtor, or in which Debtor now holds or hereafter acquires or receives any right or
interest, whether arising under United States, multinational or foreign laws or otherwise, and
shall include, in any event, all copyrights, copyright licenses, patents, patent licenses,
trademarks, trademark licenses, trade secrets, internet domain names (including any right related
to the registration thereof), proprietary or confidential information, mask works, sources object
or other programming codes, inventions (whether or not patented or patentable), technical
information, procedures, designs, knowledge, know-how, software, data base, data, skill,
expertise, recipe, experience, process, models, drawings, materials or records. Notwithstanding
the foregoing, Intellectual Property as defined above does not include proceeds or other revenue
consisting of accounts, accounts receivable, royalties, licensing fees, or payment intangibles
obtained or owed from or on account of the licensing or other exploitation or disposition of
Intellectual Property, none of which are excluded, and all of which are included as collateral in
the security interest granted by Debtor to Secured Party.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD colspan="3" valign="top" align="left"><B>&#147;<FONT style="font-variant: SMALL-CAPS">Debtor</font>&#148;</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" valign="bottom" align="left"><FONT style="font-variant: SMALL-CAPS"><B>&#147;Secured
Party&#148;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation, </B></FONT>a California corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="bottom"><FONT style="font-variant: SMALL-CAPS"><b>Lighthouse Capital Partners V, L.P.</b></font></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>By:</B></font>
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse
Management Partners V, L.L.C.,</B></font><br>
its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">By:</TD>
    <TD>&nbsp;</TD>

<TD align="right" valign="bottom"><DIV style="font-size: 1px; border-bottom: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Name:</TD>
    <TD>&nbsp;</TD>
<TD align="right" valign="bottom"><DIV style="font-size: 1px; border-bottom: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="right" valign="top"><DIV style="font-size: 1px; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit </B></FONT><b>B</b>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&#093;

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Secured Promissory Note</B></FONT>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This
<FONT style="font-variant: SMALL-CAPS">Secured Promissory Note
</FONT>(this <I>&#147;Note&#148;) </I>is made
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
200<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>,
by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation
(</B>&#147;</FONT><I>Borrower&#148;) </I>in favor
of <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse
</B><B>Capital Partners</b></FONT> <B>V, L.P. </B>(collectively with its assigns, <I>&#147;Lender&#148;).</I>
Initially capitalized terms used and not otherwise defined herein are defined in that certain Loan
and Security Agreement No.&nbsp;4561 between Borrower and Lender
dated March&nbsp;29, 2005 (the <I>&#147;Loan
Agreement&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">For Value Received, </FONT>Borrower promises to pay in lawful money of the United States, to the
order of Lender, at 500 Drake&#146;s Landing Road, Greenbrae, California 94904, or such other place as
Lender may from time to time designate <I>(&#147;Lender&#146;s Office&#148;), </I>the principal
 sum of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (the &#147;Advance&#148;), including interest on the unpaid balance and all other amounts due or to
become due hereunder according to the terms hereof and of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>means a variable <I>per annum </I>rate of interest equal to the Index plus the Interest
Margin which shall be subject to adjustment as provided herein. On and after the Loan Commencement
Date the Basic Rate shall be fixed and not subject to any further adjustments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Final Payment&#148; </I>means 9% of the Advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Index&#148; </I>means the prevailing variable Prime Rate of annual interest as quoted from time to time in
the western edition of the Wall Street Journal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Interest
Margin&#148; </I>means 2.5% per annum.</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan
Commencement Date&#148; </I>means March&nbsp;1, 2006.</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Maturity Date&#148; </I>means the last day of the Repayment Period, or if earlier, the date of prepayment
under the Note.</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Payment Date&#148; </I>means the first day of each calendar month.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Prepayment
Fee&#148; </I>means (i)&nbsp;if prepaid in the calendar year 2006, 3% of the outstanding principal
amount being prepaid; (ii)&nbsp;if prepaid in the calendar year 2007, 2% of the outstanding principal
amount being prepaid; and (iii)&nbsp;if prepaid in the calendar year 2008 or 2009, 1% of the
outstanding principal amount being prepaid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Repayment Period&#148; </I>means the period beginning on the Loan Commencement Date and continuing for 36
calendar months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Repayment. </B>Borrower shall pay principal and interest due hereunder from the Funding Date, until
this Note is paid in full, on
each Payment Date pursuant to the terms of the Loan Agreement and this Note. Prior to the Loan
Commencement Date, Borrower
shall pay to Lender, monthly in advance on each Payment Date, interest calculated using the Basic
Rate prevailing on the first business
day of such calendar month. Beginning on the Loan Commencement Date and on each Payment Date
thereafter during the Repayment
Period, Borrower shall make equal installments of principal and interest in advance, calculated at
the Basic Rate. On the Maturity
Date, Borrower shall pay, in addition to all unpaid principal and interest outstanding hereunder,
the Final Payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. Interest. </B>Interest not paid when due will, to the maximum extent permitted under applicable law,
become part of principal, at
Lender&#146;s option, and thereafter bear like interest as principal. Interest shall be computed on the
basis of a 360&nbsp;day year. All
Obligations not paid when due shall bear interest at the Default Rate unless waived in writing by
Lender. All amounts paid hereunder
will be applied to the Obligations in Lender&#146;s discretion and as provided in the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.
Voluntary Prepayment. </B>Borrower may prepay the Note if and only if
Borrower pays to Lender <b>(i)</b>
the outstanding principal
amount of this Note and any unpaid accrued interest
<b>(ii)</b>&nbsp;the Final Payment, <b>(iv)</b>&nbsp;the Prepayment
Fee, and <b>(v)</b>&nbsp;all other sums, if any, that
shall have become due and payable hereunder with respect to this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Collateral. </B>This Note is secured by the Collateral.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Waivers. </B>Borrower, and all guarantors and endorsers of this Note, regardless of the time, order or
place of signing, hereby
waive notice, demand, presentment, protest, and notices of every kind, presentment for the purpose
of accelerating maturity, diligence
in collection to the fullest extent permitted by law.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><B>6.
Choice of Law; Venue. <FONT style="font-variant: SMALL-CAPS">This
Note shall be governed by, and construed in accordance with the
internal</font></B>
<FONT style="font-variant: SMALL-CAPS"><B>laws of the State of
California, without regard to principles of conflicts of law. Each of
Borrower and Lender hereby submits to the exclusive jurisdiction of
the State and Federal courts
located in the City and County of San Francisco, State of California.
Borrower and Lender each
hereby waive their respective rights to a jury trial of any claim or cause of action based upon or
arising out of this Note. Each party further waives any right to consolidate any action in which a
jury trial has been waived with any other action in which a jury trial cannot be or has not been
waived.</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.
Miscellaneous. </B> The Note <FONT style="font-variant: SMALL-CAPS">
may be modified only by </FONT>
<FONT style="font-variant: SMALL-CAPS">a writing signed by Borrower and
Lender. </FONT>Each provision hereof is severable from every other provision hereof and of the Loan Agreement when determining its
legal enforceability. Sections and
subsections are titled for convenience, and not for construction. &#147;Hereof,&#148; &#147;herein,&#148; &#147;hereunder,&#148;
and similar words refer to this Note
in its entirety. &#147;Or&#148; is not necessarily&#146; exclusive. &#147;Including&#148; is not limiting. The terms and
conditions hereof inure to the benefit of
and are binding upon the parties&#146; respective permitted successors and assigns. This Note is subject
to all the terms and conditions of
the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">In Witness Whereof</FONT>, Borrower has caused this Note to be executed by a duly authorized
officer as of the day and year first above written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></td>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV style="width: 99%; border: 1px solid black; padding: 11px">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit
</B></FONT><b>C</b></div>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Warrants</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt; margin-top: 18pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

</div>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
<I>&#147;1933 ACT&#148;), </I>OR ANY APPLICABLE STATE
SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN
ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR THE COMPANY HAS
RECEIVED AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, TO THE EFFECT THAT SUCH SALE
OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">PREFERRED STOCK PURCHASE WARRANT
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Warrant No.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Number of Shares: initially, 185,714</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Series&nbsp;D Preferred Stock</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">subject to increase as set forth below</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><b>Fluidigm
Corporation</b></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Effective
as of March&nbsp;29, 2005

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Void after March&nbsp;29, 2012

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Issuance</B>.
This Preferred Stock Purchase Warrant (the <I>&#147;Warrant&#148;)
</I>is issued to <FONT style="font-variant: SMALL-CAPS"><b>Lighthouse
Capital Partners </b></FONT><b>V, L.P.</b> by <FONT style="font-variant: SMALL-CAPS">
<b>Fluidigm Corporation,</b> </FONT>a California corporation
(hereinafter with its successors
called the <I>&#147;Company&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Purchase Price; Number of Shares.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The registered holder of this Warrant (the <I>&#147;Holder&#148;), </I>commencing on the date hereof, is
entitled upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the
principal office of the Company, to purchase from the Company, at a price per share of $2.80 (the <I>&#147;Purchase
Price&#148;), </I>185,714 fully
paid and nonassessable shares of the Company&#146;s Series&nbsp;D Preferred Stock, (the <I>&#147;Exercise
Quantity&#148;), </I>$0.001 par
value (the <I>&#147;Preferred Stock&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>On the Commitment Termination Date, the Exercise Quantity shall automatically be increased
by
such additional number of shares (rounded to the nearest whole share) of Series&nbsp;D Preferred
Stock, if any, as is equal
to the amount determined by dividing (A)&nbsp;4% of the Aggregate Advances under the Loan
Agreement, if any, by (B)
the Purchase Price
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition to other terms which may be defined herein, the following terms, as used in this
Warrant, shall have the following meanings:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(i)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Aggregate Advances&#148; means the aggregate original dollar amount of all
Advances made under the Loan Agreement, whether such Advances are outstanding or
prepaid, at the time of any scheduled adjustment to the Exercise Quantity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(ii)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Loan Agreement&#148; means that certain Loan and Security Agreement No.&nbsp;4561 dated
March&nbsp;29, 2005 between the Company and Lighthouse Capital Partners V, L.P..</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any capitalized term not defined herein shall have the meaning as set forth in the Loan Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Until such time as this Warrant is exercised in full or expires, the Purchase Price and the
securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter
provided. The person or persons in whose name or names any certificate representing shares of
Preferred Stock is issued hereunder shall be deemed to have become the holder of record of the
shares represented thereby as at the close of business on the date this Warrant is exercised with
respect to such shares, whether or not the transfer books of the Company shall be closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;</B><b>Payment
of Purchase Price.</b> The Purchase Price may be paid (i)&nbsp;in cash or by check, (ii)&nbsp;by
the
surrender by the Holder to the Company of any promissory notes or other obligations issued by
the Company, with
all such notes and obligations so surrendered being credited against the Purchase Price in an
amount equal to the
principal amount thereof plus accrued interest to the date of surrender, or (iii)&nbsp;by any
combination of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4</B>.&nbsp;<b>Net
Issue Election.</b> The Holder may elect to receive, without the payment by the Holder of
any
additional consideration, shares of Preferred Stock equal to the value of this Warrant or any
portion hereof by the
surrender of this Warrant or such portion to the Company, with the net issue election notice
annexed hereto duly
executed, at the principal office of the Company. Thereupon, the Company shall issue to the
Holder such number of
fully paid and nonassessable shares of Preferred Stock as is computed using the following
formula:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>X</I><SUB style="font-size: 85%; vertical-align: text-bottom"><I>=</I></SUB>
</TD>

    <TD colspan="2" align="center" valign="top"><I>Y(A-B)</I>
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
A<I></I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">where:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">X =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock to be issued to the
Holder pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Y =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock covered by this
Warrant in respect of which the net issue election is made
pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Fair Market Value (defined below) of one share of
Preferred Stock, as determined at the time the net issue
election is made pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">B =
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Purchase Price in effect under this Warrant at the time
the net issue election is made pursuant to this <b>Section&nbsp;4.</b></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;Fair <I>Market Value&#148; </I>of a share of Preferred Stock (or fully paid and nonassessable shares of
the Company&#146;s common stock, $0.001 par value (the <I>&#147;Common Stock&#148;) </I>if the Preferred Stock has been
automatically converted into Common Stock) as of the date that the net issue election is made (the
<I>&#147;Determination Date&#148;) </I>shall mean:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i) </B>If the net issue election is made in connection with and contingent upon the closing of the
sale of the Company&#146;s Common Stock to the public in a public offering pursuant to a Registration
Statement under the Securities Act of 1933, as amended (a <I>&#147;Public Offering&#148;), </I>and if the Company&#146;s
Registration Statement relating to such Public Offering <I>(&#147;Registration Statement&#148;) </I>has been
declared effective by the Securities and Exchange Commission, then the initial &#147;Price to Public&#148;
specified in the final prospectus with respect to such offering multiplied by the number of shares
of Common Stock into which each share of Preferred Stock is then convertible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii) </B>
If the net issue election is not made in connection with and
contingent upon a Public Offering, then as follows:</div>


<!-- link3 " (ii)&nbsp;If the net issue election is not made in connection with and contingent upon a Public Offering, then as follows:" -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>If traded on a securities exchange or the Nasdaq National Market, the fair
market value of the Common Stock shall be deemed to be the average of the closing or last reported
sale prices of the Common Stock on such exchange or market over the five day period ending five
trading days prior to the Determination Date, and the fair market value of the Preferred Stock
shall be deemed to be such fair market value of the Common Stock multiplied by the number of
shares of Common Stock into which each share of Preferred Stock is then convertible;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If otherwise traded in an over-the-counter market, the fair market value
of the
Common Stock shall be deemed to be the average of the closing ask prices of the Common Stock over
the five day period ending five trading days prior to the Determination Date, and the fair market
value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock
multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then
convertible; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>If
there is no public market for the Common Stock, then fair market value shall
be determined in good faith by the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Partial Exercise. </B>This Warrant may be exercised in part, and the Holder shall be entitled
to
receive a new warrant, which shall be dated as of the date of this Warrant, covering the
number of shares in respect
of which this Warrant shall not have been exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;Fractional Shares. </B>In no event shall any fractional share of Preferred Stock be issued upon
any
exercise of this Warrant. If, upon exercise of this Warrant in its entirety, the Holder would,
except as provided in
this <B>Section&nbsp;6, </B>be entitled to receive a fractional share of Preferred Stock, then the Company
shall issue the next
higher number of full shares of Preferred Stock, issuing a full share with respect to such
fractional share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Expiration Date; Automatic Exercise. </B>This Warrant shall expire at the close of
business on
March&nbsp;29, 2012, and shall be void thereafter (the <I>&#147;Expiration Date&#148;). </I>Notwithstanding the
term of this Warrant
fixed pursuant to this <B>Section 7,</B> and provided Holder has received advance written notice of
at least twenty (20)
days and has not earlier exercised this Warrant, and provided this Warrant has not been
assumed by the successor
entity (or parent thereof), upon the consummation of a Merger (as defined below), this Warrant
shall automatically
be exercised pursuant to <B>Section&nbsp;4 </B>hereof, without any action by Holder. <I>&#147;Merger&#148; </I>means: (i)
a sale of all or
substantially all of the Company&#146;s assets to an Unaffiliated Entity (as defined below), or
(ii)&nbsp;the merger,
consolidation or acquisition of the Company with, into or by an Unaffiliated Entity (other
than a merger or
consolidation for the principle purpose of changing the domicile of the Company or a bona fide
round of preferred
stock equity financing), that results in the Company&#146;s shareholders immediately prior to such
merger, consolidation,
or acquisition holding, immediately thereafter, less than a majority of the outstanding
voting securities of the
successor corporation or its parent. <I>&#147;Unaffiliated Entity&#148; </I>means any entity that is owned or
controlled by parties
who own less than twenty percent (20%) of the combined voting power of the voting securities
of the Company
immediately prior to such merger or sale of assets, consolidation or acquisition.
Notwithstanding the foregoing, in
the event that any outstanding warrants to purchase equity securities of the Company (it being
acknowledged and
agreed that options to acquire common stock issued to officers, directors, employees and
consultants shall not be
deemed &#147;warrants&#148;) are assumed by the successor entity of a Merger (or parent thereof), this
Warrant shall also be
similarly assumed and the automatic exercise provision in this <B>Section 7</B> shall have no effect.
The Company agrees
to give the Holder written notice promptly after it has entered into a definitive agreement
relating to any proposed
Merger and written notice of termination of any definitive agreement relating to any proposed
Merger.
Notwithstanding anything to the contrary in this Warrant, (i)&nbsp;the Holder may expressly make
any voluntary exercise
of this Warrant contingent on, and effective immediately prior to, the consummation of such
Merger and (ii)&nbsp;any
automatic exercise of this Warrant in connection with a Merger shall be conditioned on
consummation of such
Merger and shall be effective immediately prior thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Reserved Shares; Valid Issuance. </B>The Company covenants that it will at all times from and
after
the date hereof reserve and keep available such number of its authorized shares of Preferred
Stock and Common
Stock free from all preemptive or similar rights therein, as will be sufficient to permit,
respectively, the exercise of
this Warrant in full and the conversion into shares of Common Stock of all shares of Preferred
Stock receivable
upon such exercise. The Company further covenants that such shares as may be issued pursuant
to such exercise
and/or conversion will, upon issuance, be duly and validly issued, fully paid and
nonassessable and free from all
taxes, liens and charges with respect to the issuance thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Stock Splits and Dividends. </B>If after the date hereof the Company shall subdivide the
Preferred
Stock, by split-up or otherwise, or combine the Preferred Stock, or issue additional shares of
Preferred Stock in
payment of a stock dividend on the Preferred Stock, the number of shares of Preferred Stock
issuable on the exercise
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock
dividend, or proportionately decreased in the case of a combination, and the Purchase Price shall
forthwith be proportionately decreased in the case of a subdivision or stock dividend, or
proportionately increased in the case of a combination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;Adjustments for Diluting Issuances. </B>The antidilution rights applicable to the Series&nbsp;D
Preferred
Stock of the Company are set forth in the Amended and Restated Articles of Incorporation, as
amended from time to
time (the <I>&#147;Articles&#148;), </I>a true and complete copy in its current form which has been made
available to Holder. Such
rights shall not be restated, amended or modified in any manner which affects the Holder
differently than the holders
of outstanding Series&nbsp;D Preferred Stock without such Holder&#146;s prior written consent. The
Company shall provide
the Holder hereof with any restatement, amendment or modification to the Articles promptly
after the same has been
made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;Mergers and Reclassifications. (a) </B>Except as set forth in <B>Section 7,</B> If after the
date hereof the Company shall enter into any Reorganization (as hereinafter defined), then, as a
condition of such Reorganization, lawful provisions shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that
the Holder shall thereafter have the right to purchase, at a total price not to exceed that
payable upon the exercise of this Warrant in full, the kind and amount of shares of stock and
other securities and property receivable upon such Reorganization by a holder of the number of
shares of Preferred Stock which might have been purchased by the Holder immediately prior to such
Reorganization, and in any such case appropriate provisions shall be made with respect to the
rights and interest of the Holder to the end that the provisions hereof (including without
limitation, provisions for the adjustment of the Purchase Price and the number of shares issuable
hereunder and the provisions relating to the net issue election) shall thereafter be applicable in
relation to any shares of stock or other securities and property thereafter deliverable upon
exercise hereof. For the purposes of this <B>Section&nbsp;11, </B>the term <I>&#147;Reorganization&#148; </I>shall include
without limitation any reclassification, capital reorganization or change of the Preferred Stock
(other than as a result of a subdivision, combination or stock dividend provided for in <B>Section&nbsp;9</B>
hereof), or any consolidation of the Company with, or merger of the Company into, another
corporation or other business organization (other than a merger in which the Company is the
surviving corporation and which does not result in any reclassification or change of the
outstanding Preferred Stock), or any sale or conveyance to another corporation or other business
organization of all or substantially all of the assets of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Notwithstanding any other provision of this Warrant, in the event of an automatic
conversion of the Company&#146;s outstanding Series&nbsp;D Preferred Stock into Common Stock in accordance
with the Company&#146;s Articles, as in effect from time to time, this Warrant shall thereafter
represent the right to acquire for the aggregate Purchase Price (as then in effect) the number of
shares of Common Stock into which the number of shares of Preferred Stock issuable upon exercise
of this Warrant would have then been convertible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Certificate of Adjustment. </B>Whenever the Purchase Price is adjusted, as herein provided,
the
Company shall promptly deliver to the Holder a certificate of the Company&#146;s chief financial
officer (or other
appropriate officer) setting forth the Purchase Price after such adjustment and setting forth
a brief statement of the
facts requiring such adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;Notices of Record Date, Etc. </B>In the event of:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend or other
distribution, or any right
to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any
class or any other
securities or property, or to receive any other right;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>any reclassification of the capital stock of the Company, capital reorganization of the
Company, consolidation or merger involving the Company, or sale or conveyance of all or
substantially all of its
assets; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>any voluntary or involuntary dissolution, liquidation or winding-up of the
Company;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then in each such event the Company will provide or cause to be provided to the Holder a written
notice thereof. Such notice shall be provided at least twenty (20)&nbsp;business days prior to the date
specified in such notice on which any such action is to be taken.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;Representations, Warranties and Covenants. </B>This Warrant is issued and delivered by the
Company and accepted by each Holder on the basis of the following representations, warranties
and covenants made
by the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>The Company has all necessary corporate power and authority to issue, execute and
deliver this Warrant and to perform its obligations hereunder. This Warrant has been duly
authorized issued,
executed and delivered by the Company and is the valid and binding obligation of the Company,
enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy or similar
laws relating to the
enforcement of creditors&#146; rights generally.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>The shares of Preferred Stock issuable upon the exercise of this Warrant have been duly
authorized and reserved for issuance by the Company and, when issued in accordance with the
terms hereof, will be
validly issued, fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)
</B>The issuance, execution and delivery of this Warrant do not, and the issuance of the shares of Preferred Stock upon the exercise of this Warrant in accordance with the terms
hereof will not, (i)&nbsp;violate
or contravene the Company&#146;s Articles or by-laws, or any law, statute, regulation, rule,
judgment or order applicable
to the Company, (ii)&nbsp;violate, contravene or result in a breach or default under any contract,
agreement or instrument
to which the Company is a party or by which the Company or any of its assets are bound or
(iii)&nbsp;require the consent
or approval of or the filing of any notice or registration with any person or entity (other
than such notices or filings
as may be required under applicable securities laws).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d) </B>As long as this Warrant is, or any shares of Preferred Stock issued upon exercise of this
Warrant or any shares of Common Stock issued upon conversion of such shares of Preferred Stock
are, issued and
outstanding, the Company will provide to the Holder the financial and other information
described in that certain
Loan and Security Agreement No.&nbsp;4561 between the Company and Lighthouse Capital Partners
V, L.P. dated as of
March&nbsp;29, 2005.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e) </B>As of the date hereof, the authorized capital stock of the Company consists of (i)
65,500,000 shares of Common Stock, of which 8,909,357 shares are issued and outstanding and
185,714 shares are
reserved for issuance upon the exercise of this Warrant with respect to Common Stock and the
conversion of the
Preferred Stock into Common Stock if this Warrant is exercised with respect to Preferred
Stock, (ii)&nbsp;2,727,273
shares of Series&nbsp;A Preferred Stock, of which 2,727,273 are issued and outstanding shares,
(iii)&nbsp;6,460,675 shares of
Series&nbsp;B Preferred Stock, of which 6,460,675 are issued and outstanding shares, (iv)
20,551,163 shares of Series&nbsp;C
Preferred Stock, of which 16,364,832 are issued and outstanding shares, and (v)&nbsp;13,887,716
shares of Series&nbsp;D
Preferred Stock, of which 7,292,127 are issued and outstanding shares. Company has delivered
a capitalization
table to Holder summarizing the capitalization of the Company. At the request of Holder, not
more than once per
calendar quarter, the Company will provide Holder with a current capitalization table
indicating changes, if any, to
the number of outstanding shares of common stock and preferred stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;Registration Rights. </B>The Company grants to the Holder all the rights of a &#147;Holder&#148; &#091;and
an
&#147;Investor&#148;&#093; under the Company&#146;s Amended and Restated Investors&#146; Rights Agreement dated as of
December&nbsp;18,
2003 (the <I>&#147;Rights Agreement&#148;), </I>including, without limitation, the registration rights
contained therein, and agrees to
amend the Rights Agreement so that (i)&nbsp;the shares of Common Stock issuable upon conversion of
the shares of
Preferred Stock issuable upon exercise of this Warrant shall be <I>&#147;Registrable Securities,&#148; </I>and
(ii)&nbsp;the Holder shall be
a &#147;Holder&#148; &#091;and an &#147;Investor"&#093; for all purposes of such Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;Amendment. </B>The terms of this Warrant may be amended, modified or waived only with the
written consent of the Holder and the Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5.<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>17.&nbsp;Representations and Covenants of the Holder. </B>This Warrant has been entered into by the
Company in reliance upon the following representations and covenants of the Holder, which by its
execution hereof the Holder hereby confirms:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Investment Purpose. </B>The right to acquire Preferred Stock or the Preferred Stock
issuable upon exercise of the Holder&#146;s rights contained herein will be acquired for investment and
not with a view to the sale or distribution of any part thereof, and the Holder has no present
intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Accredited Investor. </B>Holder is an &#147;accredited investor&#148; within the meaning of Rule&nbsp;501 of
Regulation&nbsp;D, promulgated under the 1933 Act as presently in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Private Issue. </B>The Holder understands (i)&nbsp;that neither the issuance of this Warrant nor
the issuance of any shares of the Company&#146;s capital stock issuable upon exercise of the Holder&#146;s
rights contained herein has been registered under the 1933 Act or qualified under applicable state
securities laws on the ground that the issuances contemplated by this Warrant will be exempt from
the registration and qualifications requirements thereof, and (ii)&nbsp;that the Company&#146;s reliance on
such exemption is predicated on the representations of the Holderset forth in this <B>Section&nbsp;17.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Financial Risk. </B>The Holder has such knowledge and experience in financial and business
matters as to be capable of evaluating the merits and risks of its investment and has the ability
to bear the economic risks of its investment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>18.&nbsp;Notices, Transfers, Etc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a) </B>Any notice or written communication required or permitted to be given to the Holder may be
given by certified mail or delivered to the Holder at the address most recently provided by the
Holder to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) </B>Subject to compliance with applicable federal and state securities laws, this Warrant may
be transferred by the Holder with respect to any or all of the shares purchasable hereunder. Upon
surrender of this Warrant to the Company, together with the assignment notice annexed hereto duly
executed, for transfer of this Warrant as an entirety by the Holder, the Company shall issue a new
warrant of the same denomination to the assignee. Upon surrender of this Warrant to the Company,
together with the assignment hereof properly endorsed, by the Holder for transfer with respect to a
portion of the shares of Preferred Stock purchasable hereunder, the Company shall issue a new
warrant to the assignee, in such denomination as shall be requested by the Holder hereof, and shall
issue to such Holder a new warrant covering the number of shares in respect of which this Warrant
shall not have been transferred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c) </B>In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall
issue a new warrant of like tenor and denomination and deliver the same (i)&nbsp;in exchange and
substitution for and upon surrender and cancellation of any mutilated Warrant, or (ii)&nbsp;in lieu of
any Warrant lost, stolen or destroyed, upon receipt of an affidavit of the Holder or other evidence
reasonably satisfactory to the Company of the loss, theft or destruction of such Warrant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>19.&nbsp;No Impairment. </B>The Company will not, by amendment of its Articles or through any
reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets,
dissolution, liquidation, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance of performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such action as
may be necessary or appropriate in order to protect the rights of the Holder. In no event shall any
reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets,
dissolution, liquidation, issue or sale of securities or any other transaction be deemed an
&#147;impairment&#148; for purposes of this Section&nbsp;18 if the shares of the Company&#146;s capital stock issuable
upon exercise of this Warrant are affected thereby in the same manner as outstanding shares of such
capital stock.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>20.&nbsp;Governing Law. </B>The provisions and terms of this Warrant shall be governed by and construed
in accordance with the internal laws of the State of California without giving effect to its
principles regarding conflicts of laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>21.&nbsp;Successors and Assigns. </B>This Warrant shall be binding upon the Company&#146;s successors and
assigns and shall inure to the benefit of the Holder&#146;s successors, legal representatives and
permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>22.&nbsp;Business Days. </B>If the last or appointed day for the taking of any action required or the
expiration of any rights granted herein shall be a Saturday or Sunday or a legal holiday in
California, then such action may be taken or right may be exercised on the next succeeding day
which is not a Saturday or Sunday or such a legal holiday.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>23.&nbsp;Value. </B>The Company and the Holder agree that the value of this Warrant on the date of
grant is $100.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Subscription</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby subscribes for <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> shares of Preferred Stock covered by this Warrant. The
certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise
indicated below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mailing Address
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Net Issue Election Notice</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby elects under <B>Section&nbsp;4 </B>to surrender the right to purchase shares of
Preferred Stock pursuant to this Warrant. The certificate(s) for such shares issuable upon such
net issue election shall be issued in the name of the undersigned or as otherwise indicated below:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mailing Address
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Assignment</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For value received <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sells, assigns and transfers unto
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: rule%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: rule%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="font-size: 10pt">&#091;Please print or typewrite name and address of Assignee&#093;</DIV>


<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: rule%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="left" style="font-size: 10pt">the within Warrant, and does hereby irrevocably constitute and appoint
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
its attorney to transfer the within Warrant on the books of the within named Company with full
power of substitution on the premises.</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Signature</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Name for Registration</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">In the Presence of:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><FONT style="font-variant: SMALL-CAPS">Exhibit</FONT> A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Amended and Restated Certificate of Incorporation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>See attached pages.</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit </B></FONT><B>A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Amended and Restated Articles of Incorporation</B>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLES OF INCORPORATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gajus V. Worthington and William Smith certify that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;They are the President and Secretary, respectively, of Fluidigm Corporation, a California
corporation (the &#147;Corporation&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The Articles of Incorporation of the Corporation are amended and restated in full to read
as set forth in <U>EXHIBIT&nbsp;A</U> attached hereto and incorporated by reference as if fully set
forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Said Amended and Restated Articles of Incorporation have been duly approved by the
Corporation&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Said Amended and Restated Articles of Incorporation have been duly approved by the required
vote of shareholders in accordance with Sections&nbsp;902 and 903 of the Corporations Code. The total
number of outstanding shares of the corporation is 7,753,917 shares of Common Stock, 2,727,273
shares of Series&nbsp;A Preferred Stock, 6,460,675 shares of Series&nbsp;B Preferred Stock and 14,315,608
shares of Series&nbsp;C Preferred Stock. The number of shares voting in favor of the amendment equaled
or exceeded the vote required. The percentage vote required was more than 50% of the outstanding
Common Stock, voting as a single class, more than 66 2/3% of the outstanding Series&nbsp;C Preferred
Stock, voting as a single class, more than 66 2/3% of the outstanding Preferred Stock voting as a
single class and more than 50% of the outstanding Common Stock and Preferred Stock, voting together
as a single class.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I further declare under penalty of perjury that the matters set forth in the foregoing
certificate are true and correct of my own knowledge.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executed
at Palo Alto, California, this &#95;&#95;&#95; day of October, 2002.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%"><FONT style="border-bottom: 1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><BR>
Gajus V. Worthington<BR>
President

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%"><FONT style="border-bottom: 1px solid #000000">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><BR>
William Smith<BR>
Secretary

</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Exhibit&nbsp;A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDED AND RESTATED</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLES OF INCORPORATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name of the corporation is Fluidigm Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of this corporation is to engage in any lawful act or activity for which a
corporation may be organized under the General Corporation Law of California other than the banking
business, the trust company business or the practice of a profession permitted to be incorporated
under the California Corporations Code.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total number of shares of stock that the corporation shall have authority to issue is
Seventy-Four Million Three Hundred Ninety Thousand Two Hundred Seventy-Four (74,390,274),
consisting of Forty-Four Million Six Hundred Fifty-One Thousand One Hundred Sixty-Three
(44,651,163) shares of Common Stock, $0.001 par value per share, and Twenty-Nine Million Seven
Hundred Thirty-Nine Thousand One Hundred Eleven (29,739,111) shares of Preferred Stock, $0.001 par
value per share. The first series of Preferred Stock shall be designated &#147;Series&nbsp;A Preferred
Stock&#148; and shall consist of Two Million Seven Hundred Twenty&#150;Seven Thousand Two Hundred
Seventy&#150;Three (2,727,273) shares. The second series of Preferred Stock shall be designated
&#147;Series&nbsp;B Preferred Stock&#148; and shall consist of Six Million Four Hundred Sixty Thousand Six Hundred
Seventy-Five (6,460,675) shares. The third series&nbsp;of Preferred Stock shall be designated &#147;Series&nbsp;C
Preferred Stock&#148; and shall consist of Twenty Million Five Hundred Fifty-One Thousand One Hundred
Sixty-Three (20,551,163) shares.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and provisions of the Common Stock and Preferred Stock are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. For purposes of this Article&nbsp;IV, the following definitions shall
apply:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &#147;<U>Conversion Price</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred Stock,
$1.78 per share for the Series&nbsp;B Preferred Stock and $2.58 per share for the Series&nbsp;C Preferred
Stock (each subject to adjustment from time to time as set forth elsewhere herein).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Convertible Securities</U>&#148; shall mean any evidences of indebtedness, shares or other
securities (other than shares of Preferred Stock) convertible into or exchangeable for Common
Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Corporation</U>&#148; shall mean Fluidigm Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Dividend Rate</U>&#148; shall mean an annual rate of $0.11 per share for the Series&nbsp;A
Preferred Stock, an annual rate of $0.18 for the Series&nbsp;B Preferred Stock and an annual rate of
$0.26 per share for the Series&nbsp;C Preferred Stock (each subject to adjustment from time to time as
set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Liquidation Preference</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred
Stock, $1.78 per share for the Series&nbsp;B Preferred Stock and $2.58 per share for the Series&nbsp;C
Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Options</U>&#148; shall mean rights, options or warrants to subscribe for, purchase or
otherwise acquire Common Stock or Convertible Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Original Issue Price</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred
Stock, $1.78 for the Series&nbsp;B Preferred Stock and $2.58 per share for the Series&nbsp;C Preferred Stock
(each subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Preferred Stock</U>&#148; shall mean the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred
Stock and the Series&nbsp;C Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Dividends</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;C Preferred Stock</U>. The holders of outstanding shares of Series&nbsp;C Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock (collectively,
the &#147;<B>Junior Stock</B>&#148;) of the Corporation other than a dividend payable solely in Common Stock. No
distributions shall be made with respect to the Junior Stock during any fiscal year of the
Corporation, other than dividends on the Common Stock payable solely in Common Stock, until all
declared dividends on the Series&nbsp;C Preferred Stock have been paid or set apart for payment to the
Series&nbsp;C Preferred Stock holders. The right to receive dividends on shares of Series&nbsp;C Preferred
Stock shall not be cumulative, and no right to such dividends shall accrue to holders of Series&nbsp;C
Preferred Stock by reason of the fact that dividends on said shares are not declared or paid in any
year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock</U>. The holders of outstanding
shares of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock shall be entitled to receive
dividends, when and as declared by the Board of Directors, out of any assets at the time legally
available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable in
preference and priority to any declaration or payment of any distribution on Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with respect to the Common Stock, other than dividends payable solely in Common Stock, until
all declared dividends on the Preferred Stock have been paid or set apart for payment to the
Preferred Stock holders. Payment of any dividends to the holders of the Series&nbsp;A Preferred Stock
and Series&nbsp;B Preferred Stock shall be on a pro-rata, pari passu basis in proportion to the Dividend
Rates for the Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock, as applicable. The right to
receive dividends on shares of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock shall not be
cumulative, and no right to such dividends shall accrue to holders of Series&nbsp;A Preferred Stock or
Series&nbsp;B Preferred Stock by reason of the fact that dividends on said shares are not declared or
paid in any year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Distribution</U>. For purposes of this Section&nbsp;2, unless the context otherwise
requires, a &#147;<B>distribution</B>&#148; shall mean the transfer of cash or other property without consideration
whether by way of dividend or otherwise, payable other than in Common Stock, or the purchase or
redemption of shares of the Corporation other than (i)&nbsp;repurchase of shares of Common Stock issued
to or held by employees, consultants, officers and directors of the Corporation or its subsidiaries
upon termination of their employment or services pursuant to agreements providing for the right of
said repurchase and at the original purchase price paid by such employees, consultants, officers
and directors; and (ii)&nbsp;repurchase of Common Stock issued to or held by employees, officers,
directors or consultants of the Corporation or its subsidiaries pursuant to rights of first refusal
contained in agreements providing for such rights, provided that such repurchase is unanimously
approved by the Board of Directors; and (iii)&nbsp;any other repurchase or redemption of capital stock
of the corporation unanimously approved by the Board of Directors and approved by the holders of
the majority of the Common Stock and the holders of more than two-thirds (2/3) of the outstanding
shares of the Preferred Stock, voting as separate classes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Common Stock</U>. Dividends may be paid on the Common Stock as and when declared by
the Board of Directors, subject to the prior dividend rights of the Preferred Stock and Section&nbsp;6
below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Non-Cash Distributions</U>. Whenever a distribution provided for in this Section&nbsp;2
shall be payable in property other than cash, the value of such distribution shall be deemed to be
the fair market value of such property as determined in good faith by the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Consent to Certain Repurchases</U>. As authorized by Section&nbsp;402.5(c) of the
California Corporations Code, Sections&nbsp;502, 503 and 506 of the California Corporations Code shall
not apply with respect to payments made by the Corporation in connection with (i)&nbsp;repurchase of
shares of Common Stock issued to or held by employees, consultants, officers and directors of the
Corporation or its subsidiaries upon termination of their employment or services pursuant to
agreements providing for the right of said repurchase and at the original purchase price paid by
such employees, consultants, officers and directors, and (ii)&nbsp;repurchase of Common Stock issued to
or held by employees, officers, directors or consultants of the Corporation or its subsidiaries
pursuant to rights of first refusal contained in agreements providing for such rights, provided
that such repurchase is unanimously approved by the Board of Directors, and (iii)&nbsp;any other
repurchase or redemption of capital stock of the Corporation unanimously approved by the Board of
Directors and approved by the holders of more than two-thirds (2/3) of the outstanding shares of
the Preferred Stock voting together as a single class.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Liquidation Rights</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;C Liquidation Preference</U>. In the event of any liquidation, dissolution or
winding up of the Corporation, either voluntary or involuntary, the holders of the Series&nbsp;C
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the assets of the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock and
the Series&nbsp;B Preferred Stock by reason of their ownership of such stock, an amount per share for
each share of Series&nbsp;C Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation
Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;C
Preferred Stock. If upon the liquidation, dissolution or winding up of the Corporation, the assets
of the Corporation legally available for distribution to the holders of the Series&nbsp;C Preferred
Stock are insufficient to permit the payment to such holders of the full amounts specified in this
Section&nbsp;3(a), then the entire assets of the Corporation legally available for distribution shall be
distributed with equal priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;C
Preferred Stock in proportion to the full amounts they would otherwise be entitled to receive
pursuant to this Section&nbsp;3(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;B Liquidation Preference</U>. After the payment to the holders of Series&nbsp;C
Preferred Stock of the full amounts specified in Section&nbsp;3(a) above, the holders of the Series&nbsp;B
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the remaining assets of the Corporation to the holders of the Common Stock and the Series&nbsp;A
Preferred Stock by reason of their ownership of such stock, an amount per share for each share of
Series&nbsp;B Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation Preference for such
shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;B Preferred Stock. If
the remaining assets of the Corporation legally available for distribution to the holders of the
Series&nbsp;B Preferred Stock are insufficient to permit the payment to such holders of the full amounts
specified in this Section&nbsp;3(b), then the entire remaining assets of the Corporation legally
available for distribution shall be distributed with equal priority and <U>pro</U> <U>rata</U>
among the holders of the Series&nbsp;B Preferred Stock in proportion to the full amounts they would
otherwise be entitled to receive pursuant to this Section&nbsp;3(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;A Liquidation Preference</U>. After the payment to the holders of Series&nbsp;C
Preferred Stock and the holders of Series&nbsp;B Preferred Stock of the full amounts specified in
Sections&nbsp;3(a) and 3(b) above, the holders of the Series&nbsp;A Preferred Stock shall be entitled to
receive, prior and in preference to any distribution of any of the remaining assets of the
Corporation to the holders of the Common Stock by reason of their ownership of such stock, an
amount per share for each share of Series&nbsp;A Preferred Stock held by them equal to the sum of
(i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such
share of Series&nbsp;A Preferred Stock. If remaining assets of the Corporation legally available for
distribution to the holders of the Series&nbsp;A Preferred Stock are insufficient to permit the payment
to such holders of the full amounts specified in this Section&nbsp;3(c), then the entire remaining
assets of the Corporation legally available for distribution shall be distributed with equal
priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;A Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this
Section&nbsp;3(c).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Remaining Assets</U>. After the payment to the holders of Preferred Stock of the full
amounts specified in Sections&nbsp;3(a), 3(b) and 3(c) above, the entire remaining assets of the
</DIV>
 <P align="right" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Corporation legally available for distribution shall be distributed <U>pro-rata</U> to
holders of the Common Stock of the Corporation in proportion to the number of shares of Common
Stock held by them.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Shares Not Treated as Both Preferred Stock and Common Stock in Any Distribution</U>.
Shares of Preferred Stock shall not be entitled to be converted into shares of Common Stock in
order to participate in any distribution, or series of distributions, as shares of Common Stock,
without first foregoing participation in the distribution, or series of distributions, as shares of
Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Reorganization</U>. For purposes of this Section&nbsp;3, a liquidation, dissolution or
winding up of the Corporation shall be deemed to be occasioned by, or to include, (i)&nbsp;the
acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, any stock acquisition, reorganization, merger or
consolidation but excluding any merger effected exclusively for the purpose of changing the
domicile of the Corporation) other than a transaction or series of transactions in which the
holders of the voting securities of the Corporation outstanding immediately prior to such
transaction or series of transactions continue to retain (either by such voting securities
remaining outstanding or by such voting securities being converted into voting securities of the
surviving entity), as a result of shares in the Corporation held by such holders prior to such
transaction, at least fifty percent (50%) of the total voting power represented by the voting
securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or other conveyance of all
or substantially all of the assets of the Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Valuation of Non-Cash Consideration</U>. If any assets of the Corporation distributed
to shareholders in connection with any liquidation, dissolution, or winding up of the Corporation
are other than cash, then the value of such assets shall be their fair market value as determined
in good faith by the Board of Directors, <U>except that</U> any securities to be distributed to
shareholders in a liquidation, dissolution, or winding up of the Corporation shall be valued as
follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the securities are then traded on a national securities exchange or the Nasdaq Stock
Market System (or a similar national quotation system), then the value of the securities shall be
deemed to be to the average of the closing prices of the securities on such exchange or system over
the ten&nbsp;(10) trading day period ending five&nbsp;(5) trading days prior to the distribution;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;if the securities are actively traded over-the-counter, then the value of the securities
shall be deemed to be the average of the closing bid prices of the securities over the ten&nbsp;(10)
trading day period ending five&nbsp;(5) trading days prior to the distribution; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;if there is no active public market for the securities, then the value of the securities
shall be deemed to be the fair market value thereof as determined in good faith by the Board of
Directors which determination shall include consideration of the illiquidity of the securities.
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a merger or other acquisition of the Corporation by another entity, the
distribution date shall be deemed to the date such transaction closes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this subsection&nbsp;3(g), &#147;<B>trading day</B>&#148; shall mean any day on which the
exchange or system on which the securities to be distributed are traded is open, and &#147;closing
prices&#148; or &#147;closing bid prices&#148; shall be deemed to be: (i)&nbsp;for securities traded primarily on the
New York Stock Exchange, the American Stock Exchange or Nasdaq, the last reported trade price or
sale price, as the case may be, at 4:00&nbsp;p.m., New York time, on that day and (ii)&nbsp;for securities
listed or traded on other exchanges, markets and systems, the market price as of the end of the
&#147;regular hours&#148; trading period that is generally accepted as such for such exchange, market or
system. If, after the date hereof, the benchmark times generally accepted in the securities
industry for determining the market price of a stock as of a given trading day shall change from
those set forth above, the fair market value shall be determined as of such other generally
accepted benchmark times.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Conversion</U>. The holders of the Preferred Stock shall have conversion rights as
follows (the &#147;<B>Conversion Rights</B>&#148;):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right&nbsp;to&nbsp;Convert</U>. Subject to Section&nbsp;4(c), each share of Preferred Stock shall be
convertible, at the option of the holder thereof, at any time after the date of issuance of such
share at the office of the Corporation or any transfer agent for the Preferred Stock, into that
number of fully-paid, nonassessable shares of Common Stock determined by dividing the Original
Issue Price for the relevant series by the Conversion Price for such series. (The number of shares
of Common Stock into which each share of Preferred Stock of a series may be converted is
hereinafter referred to as the &#147;<B>Conversion Rate</B>&#148; for each such series.) Upon any decrease or
increase in the Conversion Price for any series of Preferred Stock, as described in this Section&nbsp;4,
the Conversion Rate for such series shall be appropriately increased or decreased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Automatic Conversion</U>. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then effective Conversion
Rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial
public offering on Form&nbsp;S-1 (or successor form) filed under the Securities Act of 1933, as amended
(the &#147;<B>Securities Act</B>&#148;), covering the offer and sale of the Corporation&#146;s Common Stock, provided
that the offering price per share is not less than $7.10 (as adjusted for stock splits or stock
dividends) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or
(ii)&nbsp;upon the receipt by the Corporation of a written request for such conversion from the holders
of two-thirds of the shares of Preferred Stock then outstanding, or, if later, the effective date
for conversion specified in such requests (each of the events referred to in (i)&nbsp;and (ii)&nbsp;being
hereinafter referred to as an &#147;<B>Automatic Conversion Event</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Mechanics of Conversion</U>. No fractional shares of Common Stock shall be issued
upon conversion of Preferred Stock. In lieu of any fractional shares to which the holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then
fair market value of a share of Common Stock as determined by the Board of Directors. For such
purpose, all shares of Preferred Stock held by each holder of Preferred Stock shall be aggregated,
and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of
Preferred Stock shall be entitled to convert the same into full shares of Common Stock, and
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to receive certificates therefor, he shall surrender the certificate or certificates therefor,
duly endorsed, at the office of the Corporation or of any transfer agent for the Preferred Stock,
and shall give written notice to the Corporation at such office that he elects to convert the same;
<U>provided</U>,<U> however</U>, that on the date of an Automatic Conversion Event, the
outstanding shares of Preferred Stock shall be converted automatically without any further action
by the holders of such shares and whether or not the certificates representing such shares are
surrendered to the Corporation or its transfer agent; <U>provided further</U>, however, that the
Corporation shall not be obligated to issue certificates evidencing the shares of Common Stock
issuable upon such Automatic Conversion Event unless either the certificates evidencing such shares
of Preferred Stock are delivered to the Corporation or its transfer agent as provided above, or the
holder notifies the Corporation or its transfer agent that such certificates have been lost, stolen
or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation
from any loss incurred by it in connection with such certificates. On the date of the occurrence
of an Automatic Conversion Event, each holder of record of shares of Preferred Stock shall be
deemed to be the holder of record of the Common Stock issuable upon such conversion,
notwithstanding that the certificates representing such shares of Preferred Stock shall not have
been surrendered at the office of the Corporation, that notice from the Corporation shall not have
been received by any holder of record of shares of Preferred Stock, or that the certificates
evidencing such shares of Common Stock shall not then be actually delivered to such holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall, as soon as practicable after such delivery, or after such agreement and
indemnification, issue and deliver at such office to such holder of Preferred Stock, a certificate
or certificates for the number of shares of Common Stock to which he shall be entitled as aforesaid
and a check payable to the holder in the amount of any cash amounts payable as the result of a
conversion into fractional shares of Common Stock, plus any declared and unpaid dividends on the
converted Preferred Stock. Such conversion shall be deemed to have been made immediately prior to
the close of business on the date of such surrender of the shares of Preferred Stock to be
converted, and the person or persons entitled to receive the shares of Common Stock issuable upon
such conversion shall be treated for all purposes as the record holder or holders of such shares of
Common Stock on such date; <U>provided, however</U>, that if the conversion is in connection with
an underwritten offer of securities registered pursuant to the Securities Act the conversion may,
at the option of any holder tendering Preferred Stock for conversion, be conditioned upon the
closing of the sale of securities pursuant to such offering, in which event the person(s) entitled
to receive the Common Stock issuable upon such conversion of the Preferred Stock shall not be
deemed to have converted such Preferred Stock until immediately prior to the closing of the sale of
such securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Adjustments to Conversion Price for Diluting Issues</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Special Definition</U>. For purposes of this paragraph&nbsp;4(d), &#147;<B>Additional Shares of
Common</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to paragraph 4(d)(iii), deemed
to be issued) by the Corporation after the filing of these Articles of Incorporation, other than:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;shares of Common Stock issued or issuable upon conversion of shares of Preferred Stock;
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;shares of Common Stock issued or issuable to officers, directors and employees of, or
consultants and other service providers to, the Corporation pursuant to stock grants, option plans,
purchase plans or other employee stock incentive programs or arrangements approved by the Board of
Directors or upon exercise of options or warrants granted to such parties pursuant to any such
plan, program or arrangement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;shares of Common Stock issued upon the exercise or conversion of Options or Convertible
Securities outstanding as of the date of the filing of these Articles of Incorporation;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;shares of Common Stock issued or issuable as a dividend or distribution on Preferred Stock
or pursuant to any event for which adjustment is made pursuant to paragraph&nbsp;4(e), 4(f) or 4(g)
hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;shares of Common Stock issued in a registered public offering under the Securities Act
pursuant to which all outstanding shares of Preferred Stock are automatically converted into Common
Stock pursuant to an Automatic Conversion Event;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;shares of Common Stock issued or issuable pursuant to the acquisition of another
corporation by the Corporation by merger, purchase of substantially all of the assets or other
reorganization or to a joint venture agreement, provided, that such issuances are unanimously
approved by the Board of Directors; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;shares of Common Stock issued or issuable to banks, equipment lessors or other financial
institutions pursuant to a commercial leasing or debt financing transaction approved by the Board
of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>No&nbsp;Adjustment&nbsp;of&nbsp;Conversion&nbsp;Price</U>. No adjustment in the Conversion Price of a
particular series of Preferred Stock shall be made in respect of the issuance of Additional Shares
of Common unless the consideration per share (as determined pursuant to paragraph&nbsp;4(d)(v)) for an
Additional Share of Common issued or deemed to be issued by the Corporation is less than the
Conversion Price in effect on the date of, and immediately prior to such issue, for such series of
Preferred Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Deemed Issue of Additional Shares of Common</U>. In the event the Corporation at
any time or from time to time after the date of the filing of these Articles of Incorporation shall
issue any Options or Convertible Securities or shall fix a record date for the determination of
holders of any class of securities entitled to receive any such Options or Convertible Securities,
then the maximum number of shares (as set forth in the instrument relating thereto without regard
to any provisions contained therein for a subsequent adjustment of such number) of Common Stock
issuable upon the exercise of such Options or, in the case of Convertible Securities, the
conversion or exchange of such Convertible Securities or, in the case of Options for Convertible
Securities, the exercise of such Options and the conversion or exchange of the underlying
securities, shall be deemed to have been issued as of the time of such issue or, in case such a
record date shall have been fixed, as of the close of business on such record date, provided that
in any such case in which shares are deemed to be issued:
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;no further adjustment in the Conversion Price of the Preferred Stock shall be made upon
the subsequent issue of Convertible Securities or shares of Common Stock in connection with the
exercise of such Options or conversion or exchange of such Convertible Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;if such Options or Convertible Securities by their terms provide, with the passage of time
or otherwise, for any increase in the consideration payable to the Corporation, or decrease in the
number of shares of Common Stock issuable, upon the exercise, conversion or exchange thereof, the
Conversion Price of the Preferred Stock computed upon the original issue thereof (or upon the
occurrence of a record date with respect thereto), and any subsequent adjustments based thereon,
shall, upon any such increase or decrease becoming effective, be recomputed to reflect such
increase or decrease insofar as it affects such Options or the rights of conversion or exchange
under such Convertible Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;no readjustment pursuant to clause&nbsp;(2) above shall have the effect of increasing the
Conversion Price of the Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion
Price of the Preferred Stock on the original adjustment date, or (ii)&nbsp;the Conversion Price of the
Preferred Stock that would have resulted from any issuance of Additional Shares of Common between
the original adjustment date and such readjustment date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;upon the expiration of any such Options or any rights of conversion or exchange under such
Convertible Securities which shall not have been exercised, the Conversion Price computed upon the
original issue thereof (or upon the occurrence of a record date with respect thereto) and any
subsequent adjustments based thereon shall, upon such expiration, be recomputed as if:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;in the case of Convertible Securities or Options for Common Stock, the only Additional
Shares of Common issued were the shares of Common Stock, if any, actually issued upon the exercise
of such Options or the conversion or exchange of such Convertible Securities and the consideration
received therefor was the consideration actually received by the Corporation for the issue of such
exercised Options plus the consideration actually received by the Corporation upon such exercise or
for the issue of all such Convertible Securities which were actually converted or exchanged, plus
the additional consideration, if any, actually received by the Corporation upon such conversion or
exchange, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;in the case of Options for Convertible Securities, only the Convertible Securities, if
any, actually issued upon the exercise thereof were issued at the time of issue of such Options,
and the consideration received by the Corporation for the Additional Shares of Common deemed to
have been then issued was the consideration actually received by the Corporation for the issue of
such exercised Options, plus the consideration deemed to have been received by the Corporation
(determined pursuant to Section&nbsp;4(d)(v)) upon the issue of the Convertible Securities with respect
to which such Options were actually exercised; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) if such record date shall have been fixed and such Options or Convertible Securities are
not issued on the date fixed therefor, the adjustment previously made in the Conversion Price which
became effective on such record date shall be canceled as of the close of
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">business on such record date, and thereafter the Conversion Price shall be adjusted pursuant
to this paragraph&nbsp;4(d)(iii) as of the actual date of their issuance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Adjustment of Conversion Price Upon Issuance of Additional Shares of Common</U>. In
the event this Corporation shall issue Additional Shares of Common (including Additional Shares of
Common deemed to be issued pursuant to paragraph&nbsp;4(d)(iii)) without consideration or for a
consideration per share less than the applicable Conversion Price of a series of Preferred Stock in
effect on the date of and immediately prior to such issue, then, the Conversion Price of the
affected series of Preferred Stock shall be reduced, concurrently with such issue, to a price
(calculated to the nearest cent) determined by multiplying such Conversion Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately prior to
such issue plus the number of shares of Common Stock which the aggregate consideration received by
the Corporation for the total number of Additional Shares of Common so issued would purchase at
such Conversion Price, and the denominator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of such Additional Shares of Common so
issued. For the purposes of this Subsection&nbsp;4(d)(iv), all shares of Common Stock issuable upon
exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares
of Preferred Stock, and all Additional Shares of Common deemed issued pursuant to
Subsection&nbsp;4(d)(iii) hereof, shall be deemed to be outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;<U>Determination&nbsp;of&nbsp;Consideration</U>. For purposes of this subsection&nbsp;4(d), the
consideration received by the Corporation for the issue (or deemed issue) of any Additional Shares
of Common shall be computed as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;<U>Cash&nbsp;and&nbsp;Property</U>. Such consideration shall:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;insofar as it consists of cash, be computed at the aggregate amount of cash received by
the Corporation excluding amounts paid or payable for accrued interest or accrued dividends;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;insofar as it consists of property other than cash, be computed at the fair market value
thereof at the time of such issue, as determined in good faith by the Board of Directors; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;in the event Additional Shares of Common are issued together with other shares or
securities or other assets of the Corporation for consideration which covers both, be the
proportion of such consideration so received, computed as provided in clauses (a)&nbsp;and (b)&nbsp;above, as
reasonably determined in good faith by the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;<U>Options&nbsp;and&nbsp;Convertible&nbsp;Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common deemed to have been issued pursuant to
paragraph&nbsp;4(d)(iii) shall be determined by dividing
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X) the total amount, if any, received or receivable by the Corporation as consideration for
the issue of such Options or Convertible Securities, plus the minimum aggregate amount of
additional consideration (as set forth in the instruments relating
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">thereto, without regard to any provision contained therein for a subsequent adjustment of such
consideration) payable to the Corporation upon the exercise of such Options or the conversion or
exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such
Convertible Securities by
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)&nbsp;the maximum number of shares of Common Stock (as set forth in the instruments relating
thereto, without regard to any provision contained therein for a subsequent adjustment of such
number) issuable upon the exercise of such Options or the conversion or exchange of such
Convertible Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Adjustments for Subdivisions or Combinations of Common Stock</U>. In the event the
outstanding shares of Common Stock shall be subdivided (by stock split, by payment of a stock
dividend or otherwise), into a greater number of shares of Common Stock, the Conversion Price of
each series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently
with the effectiveness of such subdivision, be proportionately decreased. In the event the
outstanding shares of Common Stock shall be combined (by reclassification or otherwise) into a
lesser number of shares of Common Stock, the Conversion Prices in effect immediately prior to such
combination shall, concurrently with the effectiveness of such combination, be proportionately
increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Adjustments for Subdivisions or Combinations of Preferred Stock</U>. In the event the
outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock
split, by payment of a stock dividend or otherwise), into a greater number of shares of Preferred
Stock, the Dividend Rate, Original Issue Price and Liquidation Preference of the affected series of
Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the
effectiveness of such subdivision, be proportionately decreased. In the event the outstanding
shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or
otherwise) into a lesser number of shares of Preferred Stock, the Dividend Rate, Original Issue
Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately
prior to such combination shall, concurrently with the effectiveness of such combination, be
proportionately increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Adjustments for Reclassification, Exchange and Substitution</U>. Subject to Section&nbsp;3
above (&#147;<B>Liquidation Rights</B>&#148;), if the Common Stock issuable upon conversion of the Preferred Stock
shall be changed into the same or a different number of shares of any other class or classes of
stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision
or combination of shares provided for above), then, in any such event, in lieu of the number of
shares of Common Stock which the holders would otherwise have been entitled to receive each holder
of such Preferred Stock shall have the right thereafter to convert such shares of Preferred Stock
into a number of shares of such other class or classes of stock which a holder of the number of
shares of Common Stock deliverable upon conversion of such series of Preferred Stock immediately
before that change would have been entitled to receive in such reorganization or reclassification,
all subject to further adjustment as provided herein with respect to such other shares.
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>No Impairment</U>. The Corporation will not through any reorganization, transfer of
assets, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms to be observed or performed
hereunder by the Corporation but will at all times in good faith assist in the carrying out of all
the provisions of this Section&nbsp;4 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of Preferred Stock against
impairment. Notwithstanding the foregoing, nothing in this Section&nbsp;4(h) shall prohibit the
Corporation from amending its Articles of Incorporation with the requisite consent of its
shareholders and the board of directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or
readjustment of the Conversion Price pursuant to this Section&nbsp;4, the Corporation at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based.
The Corporation shall, upon the written request at any time of any holder of Preferred Stock,
furnish or cause to be furnished to such holder a like certificate setting forth (i)&nbsp;such
adjustments and readjustments, (ii)&nbsp;the Conversion Price at the time in effect and (iii)&nbsp;the number
of shares of Common Stock and the amount, if any, of other property which at the time would be
received upon the conversion of Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <U>Notices&nbsp;of&nbsp;Record&nbsp;Date</U>. In the event that this Corporation shall propose at any
time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to declare any dividend or distribution upon its Common Stock, whether in cash, property,
stock or other securities, whether or not a regular cash dividend and whether or not out of
earnings or earned surplus;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;to effect any reclassification or recapitalization of its Common Stock outstanding
involving a change in the Common Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a
liquidation, dissolution or winding up of the corporation pursuant to Section&nbsp;3(f);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then, in connection with each such event, this Corporation shall send to the holders of the
Preferred Stock at least 14&nbsp;days&#146; prior written notice of the date on which a record shall be taken
for such dividend, distribution or subscription rights (and specifying the date on which the
holders of Common Stock shall be entitled thereto) or for determining rights to vote in respect of
the matters referred to in (ii)&nbsp;and (iii)&nbsp;above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each such written notice shall be given by first class mail, postage prepaid, addressed to the
holders of Preferred Stock at the address for each such holder as shown on the books of this
Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right of the holders of the Preferred Stock to notice hereunder may be waived, either
prospectively or retroactively and either generally or in a particular instance, by the holders of
more
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">than two-thirds&nbsp;(2/3) of the outstanding shares of the Preferred Stock voting together as a
single class.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <U>Reservation&nbsp;of&nbsp;Stock&nbsp;Issuable&nbsp;Upon&nbsp;Conversion</U>. The Corporation shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the
purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares
of Common Stock as shall from time to time be sufficient to effect the conversion of all then
outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued
shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding
shares of the Preferred Stock, the Corporation will take such corporate action as may, in the
opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purpose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <U>Waiver of Adjustment of Conversion Price</U>. Notwithstanding anything herein to the
contrary, any downward adjustment of the Conversion Price of any series of Preferred Stock may be
waived, either prospectively or retroactively and either generally or in a particular instance, by
the consent or vote of the holders of more than two-thirds&nbsp;(2/3) of the outstanding shares of such
series. Any such waiver shall bind all future holders of shares of such series of Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Voting</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Restricted Class&nbsp;Voting</U>. Except as otherwise expressly provided herein or as
required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together
and not as separate classes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>No Series&nbsp;Voting</U>. Other than as provided herein or required by law, there shall
be no series voting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Preferred Stock</U>. Each holder of Preferred Stock shall be entitled to the number
of votes equal to the number of shares of Common Stock into which the shares of Preferred Stock
held by such holder could be converted as of the record date. The holders of shares of the
Preferred Stock shall be entitled to vote on all matters on which the Common Stock shall be
entitled to vote. Holders of Preferred Stock shall be entitled to notice of any shareholders&#146;
meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be
permitted and any fractional voting rights resulting from the above formula (after aggregating all
shares into which shares of Preferred Stock held by each holder could be converted), shall be
disregarded.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Common Stock</U>. Each holder of shares of Common Stock shall be entitled to one vote
for each share thereof held.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Election of Directors</U>. So long as at least 2,000,000 shares (as adjusted for
Recapitalizations) of Preferred Stock remain outstanding, the holders of Series&nbsp;C Preferred Stock,
voting as a separate class, shall be entitled to elect three (3)&nbsp;members of the Corporation&#146;s Board
of Directors at each meeting or pursuant to each consent of the Corporation&#146;s shareholders for the
election of directors. Any additional members of the Corporation&#146;s Board of Directors shall be
elected by the holders of Common Stock, Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock,
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">voting together as a single class. If a vacancy on the Board of Directors is to be filled by
the Board of Directors, only directors elected by the same class or classes of shareholders as
those who would be entitled to vote to fill such vacancy shall vote to fill such vacancy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Amendments and Changes Requiring Approval of Preferred Stock</U>. As long as any of
the Preferred Stock shall be issued and outstanding, the Corporation shall not, without first
obtaining the approval (by vote or written consent as provided by law) of the holders of more than
two-thirds&nbsp;(2/3) of the outstanding shares of the Preferred Stock voting together as a single
class:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation or By-laws of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Preferred Stock or any series thereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;enter into any transaction or series of related transactions deemed to be a liquidation,
dissolution or winding up of the Corporation pursuant to Section&nbsp;3(f) above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;voluntarily liquidate or dissolve;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section&nbsp;2(c)) with respect to the Common
Stock of the Corporation;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;permit any subsidiary of the Corporation to sell securities to a third party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, liquidation, redemption,
conversion or other rights senior to or on a parity with any series of Preferred Stock or with
respect to voting senior to any series of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;increase or decrease the authorized number of directors of the Corporation; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend this Section&nbsp;6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;C Preferred Stock</U>. As
long as any of the Series&nbsp;C Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of two-thirds of the outstanding shares of the Series&nbsp;C Preferred Stock:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
restrictions provided for the benefit of the Series&nbsp;C Preferred Stock in a manner different from
any other series of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;C Preferred Stock;
</DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;C Preferred Stock or with respect to
voting senior to the Series&nbsp;C Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section&nbsp;2(c)) with respect to the Common
Stock or Preferred Stock of the Corporation;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;increase the authorized number of directors of the Corporation above nine (9); or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;amend this Section&nbsp;7.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;B Preferred Stock</U>. As
long as any of the Series&nbsp;B Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of two-thirds of the outstanding shares of the Series&nbsp;B Preferred Stock:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
restrictions provided for the benefit of the Series&nbsp;B Preferred Stock in a manner different from
any other series of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;B Preferred Stock; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;amend this Section&nbsp;8.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Status of Converted Stock.</U> In the event any shares of Preferred Stock shall be
converted pursuant to Article&nbsp;4 hereof, then the shares so converted shall be cancelled and shall
not be issuable by the Corporation. The Articles of Incorporation shall be appropriately amended
to effect the corresponding reduction in the Corporation&#146;s authorized capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Notices</U>. Any notice required by the provisions of this Article&nbsp;IV to be given to
the holders of Preferred Stock shall be deemed given if deposited in the United States mail,
postage prepaid, and addressed to each holder of record at such holder&#146;s address appearing on the
books of the Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Limitation of Directors&#146; Liability</U>. The liability of the directors of this
Corporation for monetary damages shall be eliminated to the fullest extent permissible under
California law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <U>Indemnification of Corporate Agents</U>. This Corporation is authorized to provide
indemnification of agents (as defined in Section&nbsp;317 of the California Corporations Code) through
bylaw provisions, agreements with agents, votes of shareholders or disinterested directors or
</DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">otherwise, in excess of the indemnification otherwise permitted by Section&nbsp;317 of the
California Corporations Code, subject only to the applicable limits set forth in Section&nbsp;204 of the
California Corporations Code with respect to actions for breach of duty to this Corporation and its
shareholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Repeal or Modification</U>. Any repeal or modification of the foregoing provisions of
this Article&nbsp;V shall not adversely affect any right of indemnification or limitation of liability
of an agent of this Corporation relating to acts or omissions occurring prior to such repeal or
modification.
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">(THE GREAT SEAL OF THE STATE OF CALIFORNIA - OFFICE OF THE SECRETARY OF STATE)
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;d</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Notice of Borrowing</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, ________
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lighthouse
Capital Partners V, L.P.<BR>
500 Drake&#146;s Landing Road<BR>
Greenbrae, CA 94904-3011

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reference
is made to the Loan and Security Agreement No.&nbsp;4561 dated as of March&nbsp;29, 2005 (as
it has been and may be amended from time to time, the <I>&#147;Loan Agreement,&#148; </I>initially capitalized
terms used herein as defined therein), between <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital </B><B>Partners </B></FONT><B>V, L.P. </B>and
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT>(the <I>&#147;Company&#148;)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned is the President and CEO of the Company, and hereby irrevocably requests an
Advance under the Loan Agreement, and in that connection certifies as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The amount of the proposed Advance is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>. The business day of the proposed Advance is <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The
Loan Commencement Date for this Advance shall be March&nbsp;1, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;As of this date, no Event of Default, or event which with notice or the passage of time
would constitute an Event of Default, has occurred and is continuing, or will result from the
making of the proposed Advance, and the representations and warranties of the Company contained in
<B>Section&nbsp;5</B> of the Loan Agreement are true and correct in all material respects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;No event that could reasonably be expected to have a material adverse effect on the
ability of Borrower to fulfill its obligations under the Loan Agreement has occurred since the
date of the most recent financial statements, submitted to you by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to notify you promptly before the funding of the Advance if any of the
matters to which I have certified above shall not be true and correct
on the Funding Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Very truly yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;e</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Incumbency Certificate</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned, William Smith, hereby certifies that:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.</B> He/She is the duly elected and acting General Counsel and Vice
President of Legal Affairs of
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></font>, a California
corporation (the <I>&#147;Company&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.</B> That on the date hereof, each person listed below holds the office in the Company indicated
opposite his or her name and that the signature appearing thereon is the genuine signature of each
such person:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">NAME</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">OFFICE</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">SIGNATURE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gajus Worthington
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</div>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">William Smith
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">General Counsel and Vice <BR>
President of Legal Affairs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="middle"><DIV style="font-size: 1pt; border-bottom: 1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.</B>
Attached hereto as <B><I>Exhibit A</I></B> is a true and correct copy of the Articles of Incorporation of the
Company, as amended, as in effect as of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.</B> Attached hereto as <B><I>Exhibit&nbsp;B </I></B>is a true and correct copy of the Bylaws of the Company, as
amended, as in effect as of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5.</B> Attached hereto as <B><I>Exhibit&nbsp;C </I></B>is a copy of the resolutions of the Board of Directors of the
Company authorizing and approving the Company&#146;s execution, delivery and performance of a loan
facility with Lighthouse Capital Partners V, L.P.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed this Incumbency Certificate on March
29, 2005.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
William Smith
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
    <TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">General Counsel and Vice President of Legal Affairs</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I, the President and CEO of the Company, do hereby certify that William Smith is the duly
qualified, elected and acting General Counsel and Vice President of Legal Affairs of the Company
and that the above signature is his or her genuine signature.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed and delivered this Officer&#146;s Certificate on
March&nbsp;29, 2005.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>

</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top"><!-- Blank Space -->
 <TD>&nbsp;</TD></TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">1</div>

</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;f</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Officer&#146;s Certificate</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned, to induce <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B></FONT><B> V, L.P. </B><I>(&#147;Lender&#148;), </I>to extend or
continue financial accommodations to <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>, a California corporation (the
<I>&#147;Borrower&#148;) </I>pursuant to the terms of that certain
Loan and Security Agreement dated March&nbsp;29, 2005
(the <I>&#147;Loan Agreement&#148;), </I>hereby certifies that on the date hereof:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I am the duly elected and acting <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> of Borrower.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I am a Responsible Officer as that term is defined in the Loan Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The information submitted herewith complies with <B>Sections
</B><B>5.7</B> and <B>6.2 </B>of the Loan
Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The financial statements delivered herewith fairly present the financial condition of
Borrower</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Borrower is currently able to meet its obligations as they come due.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I understand that Lender is relying upon the truthfulness, accuracy and
completeness hereof in connection with the Loan Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I will advise you if it comes to my attention that, as of the date hereof, the
information submitted herewith was not in fact true, correct and complete.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed this Officer&#146;s Certificate on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>


</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">1</div>
</div>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<div style="width: 100%; border: 1px solid black; padding: 11px">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;g</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Authorization for Automatic Payment</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The
undersigned <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation </B></font><I>(&#147;Borrower&#148;) </I>authorizes
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners
</B></font><B>V, L.P.</B>
and any and all affiliated funds (collectively, <I>&#147;Lender&#148;) </I>and the bank / financial institution
(<I>&#147;Bank&#148;) </I>named below to initiate variable debit and/or credit entries to Borrower&#146;s deposit,
checking or savings accounts as designated below and to cause funds transfers to an account of
Lender as payment of any and all amounts due under the Loan and Security Agreement between
Borrower and Lender dated March <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2005 (the <I>&#147;Loan Agreement&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1.</B> Lender is hereby authorized to initiate
variable debit and/or credit transactions and
resulting funds transfers in Borrower&#146;s designated accounts with respect to amounts calculated
by Lender to be due and owing to Lender by Borrower periodically under the Loan Agreement.
Borrower consents to all such debit and/or credit transactions and resulting funds transfers and
hereby authorizes Lender to take all such actions as may be required by Bank with respect to
such transactions. Borrower acknowledges and agrees that such credit and/or debit entries may be
made in amounts due under the Loan Agreement in order to cause timely payments as required by
the terms of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.</B> Borrower hereby authorizes Lender to
release to Bank all information concerning Borrower that
may be necessary or desirable for Bank to investigate or recover any erroneous funds transfers
that may occur.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.</B> Borrower acknowledges and agrees that
all such debit and/or credit transactions and funds
transfers are intended to be made through an Automated Clearing House system and in compliance
with the NACHA Rules and in compliance with Bank&#146;s security procedures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4.</B> Borrower represents and warrants that the account information set forth below is accurate and
complete and that each of the account(s) set forth below is a business account maintained in
Borrower&#146;s name and for Borrower&#146;s account.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Consent shall be effective as of March&nbsp;29, 2005 and shall remain in effect until the Loan
Agreement has been terminated. Any cancellation by Borrower of this consent shall (i)&nbsp;be made in
writing and (ii)&nbsp;delivered to Bank and Lender in such time as to afford Bank and Lender a
reasonable opportunity to act on said cancellation.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wells Fargo Bank
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Name of Borrower&#146;s Bank)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;420 Montgomery St.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">San Francisco
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CA
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">94104&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Address of Bank)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(City)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(State)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="71%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bank Routing Number
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(between these symbols &#147; </I>/:&#148; &#147;:/&#148; <I>on bottom left of check)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Account Number:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#091;***&#093;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(checking /deposit /savings)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><I>(circle one)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Copy of a voided check is attached to this form</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Borrower Name:</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></font></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Borrower Address:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><U>7100 Shoreline
Court</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><U>South San Francisco.
CA 94080</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Authorized by:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date authorized:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Internal ACH Authorizations from Lender:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Approved by:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
</DIV>








<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->

</div>
</div>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;h</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Negative Pledge Agreement</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>This Negative Pledge Agreement </B></FONT>is made as of March&nbsp;29, 2005, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT><I>(&#147;Borrower&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B>
<I>(&#147;Lender&#148;)</I><I>.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In consideration of the Loan and Security Agreement between the parties of proximate date herewith
(the <I>&#147;Loan Agreement&#148;), </I>Borrower agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as otherwise permitted in the Loan Agreement, Borrower shall not sell, transfer, assign,
mortgage, pledge, lease, grant a security interest in, or encumber any of Borrower&#146;s owned
intellectual property, including, without limitation, the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(a)</B>&nbsp;Any and all copyright rights, copyright applications, copyright registration and like
protection in each work or authorship and derivative work thereof, whether published or
unpublished and whether or not the same also constitutes a trade secret, now or hereafter
existing, created, acquired or held (collectively, the <I>&#147;Copyrights&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(b)</B>&nbsp;Any and all trade secrets, and any and all intellectual property rights in computer software
and computer software products now or hereafter existing, created, acquired or held;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(c)</B>&nbsp;Any and all design rights which may be available to Borrower now or hereafter existing,
created, acquired or held;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(d)</B>&nbsp;All patents, patent applications and like protections, including, without limitation,
improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part
of the same, including, without limitation, the patents and patent applications (collectively, the
<I>&#147;Patents&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(e)</B>&nbsp;Any trademark and servicemark rights, whether registered or not, applications to register and
registrations of the same and like protections, and the entire goodwill of the business of
Borrower connected with and symbolized by such trademarks (collectively, the <I>&#147;Trademarks&#148;);</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(f)</B>&nbsp;Any and all claims for damages by way of past, present and future infringements of any of the
rights included above, with the right, but not the obligation, to sue for an collect such damages
for said use or infringement of the intellectual property rights identified above;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(g)</B>&nbsp;Any and all licenses or other rights to use any of the Copyrights, Patents or Trademarks and
all license fees and royalties arising from such use to the extent permitted by such license or
rights
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(h)</B>&nbsp;Any and all amendments, extensions, renewals and extensions of any of the Copyrights,
Patents or Trademarks; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>(i)</B>&nbsp;Any and all proceeds and products of the foregoing, including, without limitation, all payments
under insurance or any indemnity or warranty payable in respect of
any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It shall be an Event of Default under the Loan Agreement if there is a breach of any term of this
Negative Pledge Agreement. Borrower agrees to properly execute all documents reasonably required
by Lender in order to fulfill the intent and purposes hereof.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="middle" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="left">By: <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management Partners </B></FONT><B>V, L.L.C</B>., its</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" colspan="3" valign="top"> general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;I</B></FONT>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Control Agreement</B></FONT>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;In form and substance acceptable to Lender in its reasonable discretion&#093;

</DIV>
<DIV align="Center" style="font-size: 10pt; margin-top: 34pt">&nbsp;</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943201.gif" alt="(WELLS FARGO LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RESTRICTED ACCOUNT AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>(ACCOUNT RESTRICTED AFTER INSTRUCTIONS &#151; Standing Wire Transfers)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This <B>Restricted Account Agreement</B> (the &#147;Agreement&#148;), dated as of the date specified at the end of
this Agreement, is entered into among <B>Fluidigm Corporation </B>(&#147;Company&#148;), <B>Lighthouse Capital Partners
V, L.P. </B>(&#147;Secured Party&#148;) and the Wells Fargo Bank identified in the signature block at the end of
this Agreement (&#147;Bank&#148;), and sets forth the rights of Secured Party and the obligations of Bank
with respect to the deposit account(s) of Company at Bank identified at the end of this Agreement
as the &#147;Restricted Account(s)&#148;. As used in this Agreement, the term &#147;Restricted Account&#148; refers,
individually and collectively, to each such deposit account.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Secured Party&#146;s Interest in Restricted Account. </B>Secured Party represents that it is either
(i)&nbsp;a lender who has extended credit to Company and has been granted a security interest in
the Restricted Account or (ii)&nbsp;such a lender and the agent for a group of such lenders (the
&#147;Lenders&#148;). Company hereby confirms, and Bank hereby acknowledges, the security interest
granted by Company to Secured Party in all of Company&#146;s right, title and interest in and to
the Restricted Account and all sums now or hereafter on deposit in or payable or withdrawable
from the Restricted Account (the &#147;Account Funds&#148;). Except as specifically provided otherwise
in this Agreement, Company has given Secured Party complete control over the Account Funds. Secured
Party hereby appoints Bank as agent for Secured Party only for the purpose of perfecting
the security interest of Secured Party in the Account Funds while they are in the
Restricted Account. Company and Secured Party would like to use the Restricted Account
Service of Bank described in this Agreement (the &#147;Service&#148;) to further the arrangements
between Secured Party and Company regarding the Restricted Account and the Account Funds.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Access to Restricted Account. </B>Secured Party agrees that Company will be allowed access to the
Account Funds until Bank receives written instructions from Secured Party directing that
Company no longer have access to any Account Funds (the &#147;Instructions&#148;). Company agrees that
the Account Funds should be paid to Secured Party after Bank receives the Instructions, and
hereby irrevocably authorizes Bank to comply with the Instructions even if Company objects in
any way to the Instructions. Company further agrees that after Bank receives the Instructions,
Company will not have access to any Account Funds.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Balance Reports. </B>Bank agrees, at the telephone request of Secured Party on any Business Day
(a day on which Bank is open to conduct its regular banking business, other than a Saturday,
Sunday or public holiday), to make available to Secured Party a report (&#147;Balance Report&#148;)
showing the opening available balance in the Restricted Account as of the beginning of such
Business Day, either on-line or by facsimile transmission, at Bank&#146;s option. Company expressly
consents to this transmission of information. Secured Party and Company understand and agree
that the opening available balance in the Restricted Account at the beginning of any Business
Day will be determined after deducting from the Restricted Account the face amount of all
Returned Items (as defined in Section&nbsp;8 of this Agreement).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Transfers to Secured Party. </B>Bank agrees that on each Business Day after it receives the
Instructions it will transfer to the Secured Party&#146;s account specified at the end of this
Agreement</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 1</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>with the bank specified at the end of this Agreement (the &#147;Secured Party Account&#148;) the full
amount of the opening available balance in the Restricted Account at the beginning of such
Business Day. Bank will use the Fedwire system to make each funds transfer unless for any
reason the Fedwire system is unavailable, in which case Bank will determine the funds
transfer system to be used in making each funds transfer and the means by which each
transfer will be made. Bank, Secured Party and Company each agree that Bank will comply with
instructions given to Bank by Secured Party directing disposition of funds in the Restricted
Account without further consent by Company, subject otherwise to the terms of this Agreement
and Bank&#146;s standard policies, procedures and documentation in effect from time to time
governing the type of disposition requested. Company authorizes all such transfers. Except
as otherwise required by law, Bank will not agree with any third party to comply with
instructions for disposition of funds in the Restricted Account originated by such third
party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Delays in Making Funds Transfers. </B>Secured Party and Company understand that a funds transfer
may be delayed or not made if (a)&nbsp;the transfer would cause Bank to exceed any limitation on
its intra-day net funds position established in accordance with Federal Reserve or other
regulatory guidelines or to violate any other Federal Reserve or other regulatory risk control
program, or (b)&nbsp;the funds transfer would otherwise cause Bank to violate any applicable law or
regulation. If a funds transfer cannot be made or will be delayed, Bank will notify Secured
Party by telephone.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reliance on Identifying Numbers. </B>If Secured Party indicates a name and an identifying number
for the bank of the person or entity to receive funds transfers out of the Restricted Account,
Secured Party and Company understand and agree that Bank may rely on the number Secured Party
indicates even if that number identifies a bank different from the bank Secured Party named.
If Secured Party indicates a name and an account number for the person or
entity to receive funds transfers out of the Restricted Account, Secured Party and Company
understand and agree that Bank may rely on the account number Secured Party indicates
even if that account number is not the account number for the person or entity who is to
receive the transfers.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Reporting Errors in Transfers. </B>If Secured Party or Company learns of any error in a funds
transfer or any unauthorized funds transfer, then the party learning of such error or
unauthorized transfer (the &#147;Informed Party&#148;) must notify Bank as soon as possible by telephone
at (800)&nbsp;AT- WELLS (which is a recorded line), and provide written confirmation to Bank of
such telephonic notice within two Business Days at the address given for Bank on the signature
page of this Agreement. In no case may such notice to Bank by an Informed Party be made more
than fourteen (14)&nbsp;calendar days after such Informed Party learns of the erroneous or
unauthorized transfer. If a funds transfer is made in error and Bank suffers a loss because an
Informed Party breached its agreement to notify Bank of such error within the time limits
specified in this Section&nbsp;7, then such Informed Party shall reimburse Bank for the loss
promptly upon demand by Bank; provided, however, that in the event both Secured Party and
Company breach this notification requirement, Secured Party shall not be obligated to
reimburse Bank for the loss unless Company fails to satisfy Bank&#146;s demand for reimbursement
within fifteen (15)&nbsp;calendar days after demand is made on Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Returned Item&nbsp;Amounts. </B>Secured Party and Company understand and agree that the face amount
(&#147;Returned Item&nbsp;Amount&#148;) of each Returned Item will be paid by Bank debiting the Restricted
Account, without prior notice to Secured Party or Company. As used in this Agreement, the term
&#147;Returned Item&#148; means (i)&nbsp;any item deposited to the Restricted Account and returned unpaid,
whether for insufficient funds or for any other reason, and without regard to the timeliness
of such return or the occurrence or timeliness of any drawee&#146;s
notice of non-payment; (ii)&nbsp;any
item subject to a claim against Bank of breach of transfer or presentment warranty under the
Uniform Commercial Code, as adopted in the applicable state; (iii)&nbsp;any automated clearing
house (&#147;ACH&#148;) entry credited to the Restricted Account and returned unpaid</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 2</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>or subject to an adjustment entry under applicable clearing house rules, whether for
insufficient funds or for any other reason, and without regard to the timeliness of such
return or adjustment; (iv)&nbsp;any credit to the Restricted Account from a merchant card
transaction, against which a contractual demand for chargeback has been made; and (v)&nbsp;any
credit to the Restricted Account made in error. Company agrees to pay all Returned Item
Amounts immediately on demand, without setoff or counterclaim, to the extent there are not
sufficient funds in the Restricted Account to cover the Returned Item&nbsp;Amounts on the day
they are to be debited from the Restricted Account. Secured Party agrees to pay all Returned
Item&nbsp;Amounts within thirty (30)&nbsp;calendar days after demand, without setoff or counterclaim,
to the extent the Returned Item&nbsp;Amounts are not paid in full by Company within fifteen (15)
calendar days after demand on Company by Bank, and to the extent Secured Party received
proceeds from the corresponding Returned Items.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bank Fees. </B>Company agrees to pay all Bank&#146;s fees and charges for the maintenance and
administration of the Restricted Account and for the treasury management and other account
services provided with respect to the Restricted Account (collectively &#147;Bank Fees&#148;),
including, but not limited to, the fees for (a)&nbsp;the Balance Reports provided on the Restricted
Account, (b)&nbsp;the wire transfer services received with respect to the Restricted Account, (c)
Returned Items, (d)&nbsp;funds advanced to cover overdrafts in the Restricted Account (but without
Bank being in any way obligated to make any such advances), and (e)&nbsp;duplicate bank statements
on the Restricted Account. Before Bank receives the Instructions, the Bank Fees will be paid
by Bank debiting the Restricted Account, and after Bank receives the Instructions the Bank
fees will be paid by Bank debiting one or more of the demand deposit operating accounts of
Company at Bank specified at the end of this Agreement (the &#147;Operating Accounts&#148;). All such
debits will be made on the Business Day that the Bank Fees are due without notice to Secured
Party or Company. If there are not sufficient funds in the Restricted Account, or after Bank
receives the Instructions, the Operating Accounts, to cover fully the Bank Fees on the Business Day they
are debited from the Restricted Account or the Operating Accounts, or if no Operating
Accounts are indicated at the end of this Agreement, such shortfall or the amount of
such Bank Fees will be paid by Company sending Bank a check in the amount of such
shortfall or such Bank Fees, without setoff or counterclaim, within fifteen (15)
calendar days after demand of Bank. After Bank receives the Instructions, Secured Party
agrees to pay the Bank Fees within thirty (30)&nbsp;calendar days after demand, without
setoff or counterclaim, to the extent such Bank Fees are not paid in full by Company by
check within fifteen (15)&nbsp;calendar days after demand on Company by Bank. Bank may, in
its discretion, change the Bank Fees upon thirty (30)&nbsp;calendar days prior written notice
to Company and Secured Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Account Documentation. </B>Secured Party and Company agree that, except as specifically provided
in this Agreement, the Restricted Account will be subject to, and Bank&#146;s operation of the
Restricted Account will be in accordance with, the terms and provisions of Bank&#146;s deposit
account agreement governing the Restricted Account (&#147;Account
Agreement&#148;), a copy of which
Company and Secured Party acknowledge having received.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bank Statements. </B>After Bank receives the Instructions, Bank will, if so indicated on the
signature page of this Agreement, send to Secured Party by United States mail, at the address
indicated for Secured Party after its signature to this Agreement, duplicate copies of all
bank statements on the Restricted Account which are sent to Company. Company and/or Secured
Party will have thirty (30)&nbsp;calendar days after receipt of a bank statement to notify Bank of
an error in such statement. Bank&#146;s liability for such errors is limited as provided in the
&#147;Limitation of Liability&#148; section of this Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Partial Subordination of Bank&#146;s Rights. </B>Bank hereby subordinates to the security interest of
Secured Party in the Restricted Account (i)&nbsp;any security interest which Bank may have or
acquire in the Restricted Account, and (ii)&nbsp;any right which Bank may have or acquire to set
off or otherwise apply any Account Funds against the payment of any indebtedness from time to
time</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 3</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>owing to Bank from Company, except for debits to the Restricted Account permitted under this
Agreement for the payment of Returned Item&nbsp;Amounts or Bank Fees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Bankruptcy Notice; Effect of Filing. </B>If Bank at any time receives notice of the commencement
of a bankruptcy case or other insolvency or liquidation proceeding by or against Company (a
&#147;Bankruptcy Notice&#148;), Bank will continue to comply with its obligations under this Agreement,
except to the extent that any action required of Bank under this Agreement is prohibited under
applicable bankruptcy laws or regulations or is stayed pursuant to the automatic stay imposed
under the United States Bankruptcy Code or by order of any court or agency. With respect to
any obligation of Secured Party hereunder which requires prior demand upon Company, the
commencement of a bankruptcy case or other insolvency or liquidation proceeding by or against
Company shall automatically eliminate the necessity of such demand
upon Company by Bank, and
shall immediately entitle Bank to make demand on Secured Party with the same effect as if
demand had been made upon Company and the time for Company&#146;s performance had expired.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Legal Process, Legal Notices and Court Orders. </B>Bank will comply with any legal process, legal
notice or court order it receives if Bank determines in its sole discretion that the legal
process, legal notice or court order is legally binding on it.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Indemnification for Following Instructions. </B>Secured Party and Company each agree that,
notwithstanding any other provision of this Agreement, except to the extent caused by Bank&#146;s
gross negligence or willful misconduct Bank will not be liable to Secured Party or Company for
any losses, liabilities, damages, claims (including, but not limited to, third party claims),
demands, obligations, actions, suits, judgments, penalties, costs or expenses, including, but
not limited to, attorneys&#146; fees, (collectively, &#147;Losses and Liabilities&#148;) suffered or incurred
by Secured Party or Company as a result of or in connection with, (a)&nbsp;Bank complying with any
binding legal process, legal notice or court order referred to in Section&nbsp;14 of this
Agreement, (b)&nbsp;Bank following any instruction or request of Secured Party, or (c)&nbsp;Bank
complying with its obligations under this Agreement. Further, Company, and to the extent
not paid by Company within fifteen (15)&nbsp;calendar days after demand, Secured Party, will
indemnify Bank against any Losses and Liabilities Bank may suffer or incur as a result of
or in connection with any of the circumstances referred to in clauses (a)&nbsp;through (c)&nbsp;of
the preceding sentence.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>16.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>No Representations or Warranties of Bank. </B>Bank agrees to perform its obligations under this
Agreement in a manner consistent with the quality provided when Bank performs similar services
for its own account. However, Bank will not be responsible for the errors, acts or omissions
of others, such as communications carriers, correspondents or clearinghouses through which
Bank may perform its obligations under this Agreement or receive or transmit information in
performing its obligations under this Agreement. Secured Party and Company also understand
that Bank will not be responsible for any loss, liability or delay caused by wars, failures in
communications networks, labor disputes, legal constraints, fires, power surges or failures,
earthquakes, civil disturbances or other events beyond Bank&#146;s control. <B>BANK MAKES NO EXPRESS
OR IMPLIED REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE SERVICE OTHER THAN THOSE
EXPRESSLY SET FORTH IN THIS AGREEMENT.</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>17.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Limitation of Liability. </B>In the event that Secured Party, Company or Bank suffers or incurs
any Losses and Liabilities as a result of, or in connection with, its or any other party&#146;s
performance or failure to perform its obligations under this Agreement, the affected parties
shall negotiate in good faith in an effort to reach a mutually satisfactory allocation of such
Losses and Liabilities, it being understood that Bank will not be responsible for any Losses
and Liabilities due to any cause other than its own negligence or breach of this Agreement, in
which case its liability to Secured Party and Company shall, unless otherwise provided by any
law which cannot be</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 4</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>varied by contract, be limited to direct money damages in an amount not to exceed ten (10)
times all the Bank Fees charged or incurred during the calendar month immediately preceding
the calendar month in which such Losses and Liabilities occurred (or, if no Bank Fees were
charged or incurred in the preceding month, the Bank Fees charged or incurred in the month
in which the Losses and Liabilities occurred). Company will indemnify Bank against all
Losses and Liabilities suffered or incurred by Bank as a result of third party claims;
provided, however, that to the extent such Losses and Liabilities are directly caused by
Bank&#146;s negligence or breach of this Agreement such indemnity will only apply to those Losses
and Liabilities which exceed the liability limitation specified in the preceding sentence.
The limitation of Bank&#146;s liability and the indemnification by Company set out above will not
be applicable to the extent any Losses and Liabilities of any party to this Agreement are
directly caused by Bank&#146;s gross negligence or willful misconduct. <B>IN NO EVENT WILL BANK BE
LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT OR PUNITIVE DAMAGES, WHETHER ANY
CLAIM IS BASED ON CONTRACT OR TORT, WHETHER THE LIKELIHOOD OF SUCH DAMAGES WAS KNOWN TO BANK
AND REGARDLESS OF THE FORM OF THE CLAIM OR ACTION, INCLUDING, BUT NOT LIMITED TO, ANY CLAIM
OR ACTION ALLEGING GROSS NEGLIGENCE, WILLFUL MISCONDUCT, FAILURE TO EXERCISE REASONABLE CARE
OR FAILURE TO ACT IN GOOD FAITH. </B>Any action against Bank by Company or Secured Party under
or related to this Agreement must be brought within twelve months after the cause of action
accrues.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>18.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Termination. </B>This Agreement and the Service may be terminated by Secured Party or Bank at any
time by either of them giving thirty (30)&nbsp;calendar days prior written notice of such
termination to the other two parties to this Agreement at their contact addresses specified
after their signatures to this Agreement; provided, however, that this Agreement and the
Service may
be terminated immediately upon written notice from Bank to Company and Secured Party
should Secured Party fail to make any payment when due to Bank from Secured Party under
the terms of this Agreement. Secured Party and Company agree that the Restricted Account
may be closed by Bank as provided in the Account Agreement. Company&#146;s and Secured
Party&#146;s obligation to report errors in funds transfers and bank statements and to pay
the Bank Fees, as well as the indemnifications made, and the limitations on the
liability of Bank accepted, by Company and Secured Party under this Agreement will
continue after the termination of this Agreement and/or the closure of the Restricted
Account with respect to all the circumstances to which they are applicable existing or
occurring before such termination or closure, and any liability of any party to this
Agreement, as determined under the provisions of this Agreement, with respect to acts or
omissions of such party prior to such termination or closure will also survive such
termination or closure. Upon any termination of this Agreement and the Service or
closure of the Restricted Account all collected and available balances in the Restricted
Account on the date of such termination or closure will be transferred to Secured Party
as requested by Secured Party in writing to Bank.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>19.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Modifications, Amendments, and Waivers. </B>This Agreement may not be modified or amended, or any
provision thereof waived, except in a writing signed by all the parties to this Agreement;
provided, however, that the Bank Fees may be changed after thirty (30)&nbsp;calendar days prior
written notice to Company and Secured Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>20.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Notices. </B>All notices from one party to another shall be in writing, or be made by a telecommunications
device capable of creating a written record, shall be delivered to Company,
Secured Party and/or Bank at their contact addresses specified after their signatures to this
Agreement, or any other address of any party notified to the other parties in writing, and
shall be effective upon receipt. Any notice sent by one party to this Agreement to another
party shall also be sent to the third party to this Agreement. Bank is authorized by Company
and Secured Party to act on any instructions or notices received by Bank if (a)&nbsp;such
instructions or notices</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 5</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>purport to be made in the name of Secured Party, (b)&nbsp;Bank reasonably believes that they are
so made, and (c)&nbsp;they do not conflict with the terms of this Agreement as such terms may be
amended from time to time, unless such conflicting instructions or notices are supported by
a court order.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>21.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Successors and Assigns. </B>Neither Company nor Secured Party may assign or transfer its rights
or obligations under this Agreement to any person or entity without the prior written consent
of Bank, which consent will not be unreasonably withheld. Bank may not assign its rights or
obligations under this Agreement to any person or entity without the prior written consent of
Secured Party, which consent will not be unreasonably withheld; provided, however, that no
such consent will be required if the assignee is a bank affiliate of Bank.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>22.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Governing Law. </B>Company and Secured Party understand that Bank&#146;s provision of the Service
under this Agreement is subject to federal laws and regulations. To the extent that such
federal laws and regulations are not applicable this Agreement shall be governed by and be
construed in accordance with the laws of the state in which the office of Bank that maintains
the Restricted Account is located, without regard to conflict of laws principles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>23.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Severability. </B>To the extent that this Agreement or the Service to be provided under this
Agreement are inconsistent with, or prohibited or unenforceable under, any applicable law or
regulation, they will be deemed ineffective only to the extent of such prohibition or
unenforceability and be deemed modified and applied in a manner consistent with such law or
regulation. Any provision of this Agreement which is deemed unenforceable or invalid in any
jurisdiction shall not affect the enforceability or validity of the remaining provisions of
this Agreement or the same provision in any other jurisdiction.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>24.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Usury. </B>It is never the intention of Bank to violate any applicable usury or interest rate
laws. Bank does not agree to, or intend to contract for, charge, collect, take, reserve or
receive (collectively, &#147;charge or collect&#148;) any amount in the nature of interest or in the
nature of a fee, penalty or other charge which would in any way or event cause Bank to charge
or collect more than the maximum Bank would be permitted to charge or collect by any
applicable federal or state law. Any such excess interest or unauthorized fee shall,
notwithstanding anything stated to the contrary in this Agreement, be applied first to reduce
the amount owed, if any, and then any excess amounts will be refunded.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>25.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Counterparts. </B>This Agreement may be executed in any number of counterparts each of which
shall be an original with the same effect as if the signatures thereto and hereto were upon
the same instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>26.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Entire Agreement. </B>This Agreement, together with the Account Agreement, contains the entire
and only agreement among all the parties to this Agreement and between Bank and Company, and
Bank and Secured Party, with respect to (a)&nbsp;the Service, (b)&nbsp;the interest of Secured Party and
the Lenders in the Account Funds and the Restricted Account, and (c)&nbsp;Bank&#146;s obligations to
Secured Party and the Lenders in connection with the Account Funds and the Restricted Account.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Agreement has been signed by the duly authorized officers or representatives of Company,
Secured Party and Bank on the date specified below.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 6</i></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Date:
March&nbsp;29, 2005</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Restricted Account Number(s):</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD nowrap align="left" valign="top"><B>&#091;***&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Operating Account Number(s):</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD nowrap align="right" valign="top"><B>&#091;***&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Secured Party Account Number:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;***&#093;</B></TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Bank of Secured Party Account:</B>
</DIV></TD>
    <TD>&nbsp;</TD>

<TD nowrap colspan="3" align="left" valign="top"><DIV style="margin-left:125px; text-indent:90px"><B>Comerica
Bank</B></div>
</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Secured Party is to be sent duplicate Bank Statements.</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="54%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="34%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>&#091;Company&#093; FLUIDIGM CORPORATION</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;Secured Party&#093; LIGHTHOUSE CAPITAL</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PARTNERS V, L.P.</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>BY: LIGHTHOUSE MANAGEMENT</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PARTNERS V, L.L.C. ITS GENERAL</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>PARTNER</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Name: <B>Gajus Worthington</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Name: <B>Thomas Conneely</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Title: <B>CEO</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Title: <B>Vice President</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Address For All Notices:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Address For All Notices:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Fluidigm Corporation</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Lighthouse Capital Partners V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>Attn: James Neesen</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>500 Drakes Landing Road</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>7100 Shoreline Court</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Greenbrae, CA 94904</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Attn: Contracts Administration</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>WELLS FARGO BANK
</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, N.A.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Name: <B>Scott M. Van Gorder</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" valign="top" align="left">Title: <B>Vice President, Senior Relationship Manager</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>Address For All Notices:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>420 Montgomery
Street,
9</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th</b></SUP>
<b>Floor</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>MAC A0101-096</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>San Francisco, CA 94108</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><I>Restricted Account Agreement<BR>
(Revised 09/21/01)</I>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><i>Page 7</i></TD>
</TR>
</table>
<P align="right" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>


</div>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">March&nbsp;29,
2005
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Morgan Stanley &#038; Co. Incorporated </B>(the &#147;Broker&#148;)<BR>
555 California Street 14<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor<BR>
San Francisco, CA 94104

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Re: <U><B>Notice of Pledge and Security</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please be advised that the undersigned, Fluidigm Corporation (&#147;Pledgor&#148;), has pledged a security
interest in Account No.&nbsp;&#091;***&#093; (the &#147;Account&#148;) held by Broker, as securities intermediary,
and in all of the securities, proceeds, cash or other assets now or hereafter held in the Account
(collectively, the &#147;Collateral&#148;), to Lighthouse Capital Partners V, L.P. (&#147;Pledgee&#148;) pursuant to
the terms and provisions of a certain Loan and Security Agreement (the &#147;Agreement&#148;), dated March
29, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Broker,
Pledgor and Pledgee, by signing this letter, hereby agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">a) The
Account shall be retitled &#147;Fluidigm Corporation &#151; Pledgor/
Lighthouse Capital &#150; Pledgee&#148;;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">b) Pledgee has a security interest in the Collateral and is authorized to instruct the Broker
with regard to the Account without further consent needed by Pledgor;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">c) Broker is hereby notified of Pledgee&#146;s security interest, and agrees to comply with all
instructions and entitlement orders of Pledgee with regard to the Account. Broker shall
not comply with instructions and entitlement orders with respect to the Collateral or the
Account that are originated by the Pledgor except as described in Paragraph&nbsp;D below.
Broker is also hereby authorized and agrees to send duplicate copies of any and all
statements and confirmations, as well as any other appropriate correspondence, relating to
the Account directly to the Pledgee at the address indicated below, or to such other
address as Pledgee may designate in writing. This pledge will remain in full force and
effect until Pledgee notifies Broker in writing to the contrary;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">d) Pledgee hereby instructs Broker that until further instruction in writing from an
Authorized Officer of Pledgee (as defined below) that Pledgee is assuming exclusive
control over the Account (&#147;Notice of Exclusive Control&#148;), the Broker shall comply with
directions of Pledgor with respect to any transactions, including withdrawals, in the
Account. Notwithstanding anything contained herein, upon receipt of a Notice of
Exclusive Control (it being understood that Broker shall have no duty or obligation
whatsoever to investigate or determine whether the Notice of Exclusive Control was
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rightfully or legally issued), Broker shall only follow the directions and instructions of
Pledgee with regard to the Account. In that case, if Pledgee so requests, Broker will proceed to
liquidate the assets of the Account in accordance with Pledgee&#146;s instructions and to deliver the
proceeds to Pledgee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Agreement, &#147;Authorized Officer of Pledgee&#148; shall refer to any one of
the following individuals: Richard Stubblefield and Thomas Conneely. If Pledgee finds it
necessary to designate a replacement for any of the designated Authorized Officers of Pledgee,
written notice of replacement shall be given to Broker, which notice shall be signed by the
President, an Executive Vice President, a Senior Vice President, or such other officer of Pledgee
as Broker may approve. However, Broker shall be entitled to rely on any notice it receives from
someone whom it reasonably believes is an Authorized Officer of Pledgee;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">e) Broker shall have no obligation to monitor the Account for any purpose in connection
with the pledge granted hereunder. The Pledgee accepts and acknowledges full
responsibility for reviewing daily confirmations and monthly statements to ensure that it
is adequately secured;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">f) Pledgor and Pledgee hereby agree to indemnify and hold harmless Broker, its affiliates,
officers, and employees from and against any and all claims, causes of actions, liabilities,
lawsuits, demands, and/or damages, including, without limitation, any and all court costs and
reasonable attorney&#146;s fees, that might result by reason of the actions of Broker under this
Agreement. Broker shall not be responsible for any losses, claims, damages, liabilities and
expenses incurred by Pledgor or Pledgee, except to the extent that such losses, claims,
damages, liabilities or expenses arise out of the bad faith, gross negligence, or criminal
acts or omissions on the part of Broker;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">g) Broker may terminate this Agreement at any time by canceling the Account and
transferring all funds and securities in the Account to Pledgee;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">h) As of the date hereof, the Collateral has not been paid to or withdrawn by the Pledgor; Broker
is not in receipt of any notice of withdrawal or redemption with regard to the Collateral or
notice not to renew the Account, and Broker has not given any notice that the Account will not be
renewed or extended, as the case may be;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">i) Broker&#146;s records indicate that the value of the Collateral, as of the date hereof, is
approximately &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">j) Broker subordinates any right of offset Broker may now or hereafter have against the
Collateral for any indebtedness now or hereafter owing to Broker by the Pledgors to the security
interest of Pledgee; <U>provided that</U> Broker shall continue to have a first perfected
security interest in the Collateral with respect to any charges incurred in connection with the
operation of the Account, including, but not limited to, fees, commissions and any costs related
to unsettled securities transactions.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">k) This Agreement shall be governed by the law of the State of New York, excluding its conflict of
law rules. The parties hereby agree that (i)&nbsp;the &#147;securities intermediary&#146;s jurisdiction&#148; with
respect to the Account and the Collateral is New York and (ii)&nbsp;the parties shall not agree with any
other person that such securities intermediary&#146;s jurisdiction is any jurisdiction other than New
York.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Very truly yours,
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By: &nbsp;&nbsp;&nbsp;James Neeson</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Controller</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Read and Agreed to:<BR>
<B>MORGAN STANLEY &#038; CO. INCORPORATED</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>LIGHTHOUSE CAPITAL PARTNERS V, L.P.</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="95%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>By:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Lighthouse Management Partners V, L.L.C.</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>its general partner</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Thomas Conneely
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Address: 500 Drakes Landing Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><div style="margin-left: 26%">Greenbrae, CA 94904</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUBORDINATION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This SUBORDINATION AGREEMENT (this &#147;Agreement&#148;), dated as of March&nbsp;29, 2005, is between, on
the one hand, each undersigned holder (each a &#147;Holder&#148; and collectively the &#147;Holders&#148;) of
Convertible Promissory Notes issued pursuant to those certain Convertible Note Purchase Agreement
dated December&nbsp;18, 2003, as amended from time to time (each a &#147;Note&#148; and collectively the &#147;Notes&#148;)
issued by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation,</B> </FONT>a California corporation (&#147;Company&#148;), and, on the other
hand, <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital
Partners</B> </FONT><B>V, L.P.,</B> a Delaware limited partnership (&#147;LCP&#148;), lender
under that certain Loan and Security Agreement No.&nbsp;4561, dated March&nbsp;29, 2005 (the &#147;Loan
Agreement&#148;) with Company (all obligations of payment and performance due or to become due pursuant
to the Obligations or the Loan Documents as those terms are defined therein, as the same may be
amended from time to time, are the &#147;LCP Obligations&#148;), with reference to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, in order to induce LCP to enter into the Loan Agreement, the Holders agree to enter
into this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties
hereby agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Subordination</U>. Each Holder agrees that it shall not receive any payment of any
amounts on account of the Notes until the LCP Obligations have been paid and performed in
full.
Regardless of (i)&nbsp;any agreement of any Holder or LCP with Company, (ii)&nbsp;the time, place,
manner or order of attachment, perfection, or the filing of UCC-1 filings or other documents,
or
(iii)&nbsp;the giving or failure to give notice, each Holder does hereby subordinate payment by
Company on its Notes to the full and final payment to LCP of the LCP Obligations. Each Holder
agrees that all payments and the proceeds received by Holders on account of the Notes shall be
held by them in trust for LCP for the payment of the LCP Obligations, and turned over to LCP
in
kind upon receipt of notice from LCP that Company has failed to pay LCP any of the LCP Obligations. Holders hereby agree they have no security interest in any property of the Company.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notwithstanding anything in this Agreement, (i)&nbsp;in the event the Convertible Note, dated as of
December&nbsp;18, 2003 (the &#147;Initial EDB Note&#148;), issued by Company to Biomedical Sciences Investment Fund
Pte Ltd (&#147;BMSIF&#148;) has not been converted according to the terms set forth in Section&nbsp;2 of such
Initial EDB Note by the Payment Date (as defined in such Initial EDB Note), BMSIF may receive
payment by the Company in an amount not to exceed 50% of the principal amount outstanding under
such Initial EDB Note, and (ii)&nbsp;each Holder may convert any Note into capital stock of the Company
and accept cash in lieu of fractional shares in connection with any such conversion. Upon
conversion of any Note into capital stock of the Company and acceptance of cash in lieu of
fractional shares in connection with any such conversion, this Agreement shall terminate with
respect to such Note and any proceeds received by a Holder in connection with the conversion of
such Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Bankruptcy</U>. (Subject to paragraph (1)&nbsp;above), Each Holder agrees that upon any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">distribution of assets or readjustment of indebtedness of Company, whether by liquidation,
bankruptcy, assignment for the benefit of creditors, or otherwise, LCP shall receive payment in
full on the LCP Obligations before Holder receives payment of any amounts due under the Notes and
Holders shall pay over to LCP any amounts so received by them related to the Notes until the LCP
Obligations are paid in full. In furtherance thereof, each Holder authorizes LCP to make and vote
(without LCP being obligated to make or vote) any and all proofs of claim respecting the Notes in
any such proceeding and to receive and collect all dividends or other payments thereupon; provided
that LCP will pay over to Holders a pro rata distribution of amounts received by it in excess of
that necessary for the full and final satisfaction of the LCP Obligations. Holders agree to execute
such instruments of assignment and other documents as may be necessary to enforce such claims and
collect such dividends or to otherwise carry out the intent and purpose hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations</U>. Each party hereto warrants and represents to the others
that it has full power and authority to enter hereinto and to perform all obligations hereunder,
that this Agreement is valid, binding and enforceable in accordance with its terms and that
execution and performance hereof does not violate any agreement with any other person or entity.
Each Holder represents and warrants that it (i)&nbsp;is the owner of the Notes, free and clear of the
claims of any others, (ii)&nbsp;has not heretofore subordinated or assigned the Notes or its interest
therein to any entity, (iii)&nbsp;will not transfer any Notes to any entity other than one which agrees
to be bound hereby, and (iv)&nbsp;waives any rights to claim that the enforceability of this Agreement
may be affected by any subsequent modification, release, extension,
or change in LCP obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>No Third Party Beneficiaries.</U> Company has no rights hereunder. This
Agreement is made only for the benefit of Holders and LCP and their successors and assigns, and may
not be relied upon by any other third party, including Company or any successor thereto or any
judgment lien creditor thereof. Nothing herein shall constitute a commitment or agreement by either
of LCP or Holder to provide funds to Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Miscellaneous</U>. This Agreement: (i)&nbsp;may only be amended by a writing signed by
LCP and the affected Holder; (ii)&nbsp;contains the entire agreement between Holders and LCP with
respect to its subject matter, and all prior negotiations, documents and discussions are
superseded
hereby; (iii)&nbsp;shall be governed by the laws of the state of California; (iv)&nbsp;may be executed
in
counterparts delivered by telefacsimile, all of which, when taken together, shall constitute
one
and the same original document; and (v)&nbsp;may be attached to a Form UCC-1 and filed in the
public records of any jurisdiction; and (vi)&nbsp;shall terminate upon the full, final and
indefeasible
payment and performance by Company to LCP of all LCP Obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Waiver of Jury Trial.</U> TO THE FULLEST EXTENT PERMITTED BY LAW,
EACH OF THE PARTIES HERETO WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY
JURY IN RESPECT OF LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF,
UNDER OR IN CONNECTION WITH THIS AGREEMENT. EACH PARTY FURTHER
WAIVES ANY RIGHT TO CONSOLIDATE ANY ACTION IN WHICH A JURY TRIAL HAS
BEEN WAIVED WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE
OR HAS NOT BEEN WAIVED.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above
written.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">Lighthouse
Capital Partners </FONT>V, L.P.</B><BR>
a Delaware limited partnership

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">by:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lighthouse Management Partners V, L.L.C.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">by:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">500 Drakes Landing Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Greenbrae, CA 94904</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Contracts Administration</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (415)&nbsp;464-5900</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (415)&nbsp;925-3387</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HOLDERS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical
Sciences Investment Fund </b><b>Ptd </b></FONT>
<FONT style="font-variant: SMALL-CAPS"><B>Ltd</B></FONT>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Lily Chan
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Lily Chan, PhD</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6395-7700</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6395-7796</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">Invus,
L.P.</font></B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors, LLC
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;Its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="bottom"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD >&nbsp;</TD>
    <TD align="left" valign="bottom" style="border-bottom: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">135 East 57<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Phillipe J. Amouyal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (212)&nbsp;371-1717</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (212)&nbsp;371-1829</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company hereby acknowledges and consents to the Agreement, promises to take all such action as may
be necessary to fulfill its essential intent and purpose, agrees that failure to do so shall be an
Event of Default under the LCP Obligations, and acknowledges that in the transactions referenced
herein it has been advised to seek, and has selected, counsel of its own choosing, namely Wilson,
Sonsini, Goodrich &#038; Rosati of Palo Alto, California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Signature page to Fluidigm Corporation<BR>
Subordination Agreement
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Fluidigm Confidential</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HOLDERS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical
Sciences Investment Fund Ptd Ltd</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: General Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6395-7700</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6395-7796</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Invus,
L.P.</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors, LLC
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;Its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By: <BR>
Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Aflalo Guimaraes
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Managing Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">135 East
57<SUP style="font-size: 85%; vertical-align: text-top">th</sup> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Phillipe J. Amouyal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (212)&nbsp;371- 1717</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (212) 371-1829</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company hereby acknowledges and consents to the Agreement, promises to take all such action as may
be necessary to fulfill its essential intent and purpose, agrees that failure to do so shall be an
Event of Default under the LCP Obligations, and acknowledges that in the transactions referenced
herein it has been advised to seek, and has selected, counsel of its own choosing, namely Wilson,
Sonsini, Goodrich &#038; Rosati of Palo Alto, California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By</DIV></TD>
    <TD >&nbsp;</TD>

<TD align="left" valign="top" style="border-bottom:1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HOLDERS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">Biomedical
Sciences Investment Fund Ptd</FONT>
<FONT style="font-variant: SMALL-CAPS">Ltd</FONT></B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: General Manager</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6395-7700</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6395-7796</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Invus,
L.P.</B></font>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Invus Advisors, LLC
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  style="border-bottom: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">135 East 57<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Street</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10022</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attn: Phillipe J. Amouyal</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (212)&nbsp;371-1717</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (212)&nbsp;371-1829</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company hereby acknowledges and consents to the Agreement, promises to take all such action as may
be necessary to fulfill its essential intent and purpose, agrees that failure to do so shall be an
Event of Default under the LCP Obligations, and acknowledges that in the transactions referenced
herein it has been advised to seek, and has selected, counsel of its own choosing, namely Wilson,
Sonsini, Goodrich &#038; Rosati of Palo Alto, California.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><FONT style="font-variant: SMALL-CAPS">
Fluidigm Corporation</FONT></B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 01 (&#147;<I>Amendment</I>&#148;)<BR>
TO LOAN AND SECURITY AGREEMENT NO. 4561</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Entered into as of August&nbsp;4, 2006 by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P. </B><I>(&#147;Lender&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT><I>(&#147;Borrower&#148;).</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower and Lender have previously entered into that certain Loan and Security
Agreement No.&nbsp;4561 dated as of March&nbsp;29, 2005 (the <I>&#147;Loan and Security Agreement&#148;; </I>all initially
capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Loan and Security Agreement), together with the other agreements and instruments entered
into in connection therewith (collectively, the <I>&#147;Loan Documents&#148;); </I>and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower and Lender each have agreed to amend the Loan Documents subject to
Borrower&#146;s performance of the terms and conditions hereof; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as of August&nbsp;31, 2006, Borrower and Lender mutually agree that the outstanding
principal balance of the Loans is $11,093,832.04;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein
contained, the parties hereby agree to modify the Loan Documents by entering into this Amendment
and Borrower agrees to perform such other covenants and conditions as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>A) Loan and Security Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Definitions</U> &#151; The definition <I>of &#147;Subordinated Indebtedness&#148;, </I>shall be amended and
restated to read as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%"><I>&#147;Subordinated Indebtedness&#148; </I>means Indebtedness of Borrower to Singapore EDB (including
its investment fund BioMedical Sciences Investment Fund Ptd Ltd) and Invus Group that is
subordinated in both security and right of payment to the Obligations on terms and
conditions reasonably satisfactory to Lender in an amount not to exceed $8,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>B) Secured Term Promissory Note</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(i) <U>Definitions</U> &#151; The following definitions shall be added to the Notes, and to the
extent these terms are already defined in the Loan Documents, they shall be deleted in their
entirety and replaced with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Final Payment&#148; </I>means 11.25% of the Advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Basic Rate&#148; </I>means a variable <I>per annum </I>rate of interest equal to the Index plus the
Interest Margin which shall be subject to adjustment as provided herein. On and after March&nbsp;1,
2006 through and including August&nbsp;31, 2006, the Basic Rate shall be fixed at 10.00%. On and
after September&nbsp;1, 2006, the Basic Rate shall be fixed at 9.75%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Repayment
Period&#148; </I>means the period beginning on the Loan Commencement Date and continuing
for 48 calendar months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>C) Additional Terms and Conditions</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Repayment.</U> Notwithstanding anything contained in any Note issued in connection
with the Loan and Security Agreement, Section&nbsp;1 of each such Note shall be superseded by the following payment
terms: for and on account of all of the Notes, from March&nbsp;1, 2006 through and including August&nbsp;31,
2006, Borrower will pay Lender $416,006.71 per month. On and after September&nbsp;1, 2006 through February&nbsp;28,
2010, Borrower shall pay Lender $310,305.95 per month. In addition to all other amounts due or to
become due hereunder, the Final Payment is due on the earliest to occur of the Maturity Date or March
1, 2009.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Restructure Fee.</U> In addition to all other amounts due or to become due
hereunder, on the earliest to occur of (i)&nbsp;the Maturity Date; (ii)&nbsp;the date of prepayment of all of the Notes, or (ii)&nbsp;March&nbsp;1,
2009, Borrower shall pay to Lender a restructure fee in the amount of $150,000, in cash.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Expenses.</U> Borrower shall pay reasonable fees and expenses incurred by
Lender&#146;s legal counsel in connection with the preparation and negotiation of documentation related to this Amendment.
Such restructure expenses are due and payable when billed.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acknowledgments; Representations and Warranties.</B> Borrower warrants and represents to
Lender, as a material inducement to Lender&#146;s entering hereinto, as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Further Funding Obligations.</U> Lender has no obligations to make further Advances to
Borrower.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Waivers.</U> Lender has made no separate oral or written waiver of any existing
or future Default or Event of Default by Borrower under any Loan
Document.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Set-Off.</U> Borrower has no claims or rights of set-off against Lender of any
kind under any Loan Document or otherwise. Borrower has no defenses to payments of any amounts owed to Lender as
the same become due and payable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Representations and Warranties of Borrower.</U> The representations and warranties contained in the Loan Agreement are true and complete in all material respects as of the date hereof, except with
respect to any such representation or warranty which speak only as of a specific date prior to the date
hereof. Borrower warrants and represents that no Events of Default have occurred. Borrower warrants and
represents that it has not reached any settlement with any other creditor of Borrower that has not been
disclosed in writing to Lender.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Release.</B> Borrower for itself and for its agents, partners, stockholders, employees and
affiliates and its or their successors and assigns hereby (a)&nbsp;agrees to waive, release and further
discharge Lender and its officers, directors, stockholders, partners, successors, assigns, agents
and employees of and from any and all manner of claims arising in connection with the Loan
Documents for damages at law or in equity with respect to any matter occurring prior to the date
hereof which Borrower or such other releasing party may have had, and (b)&nbsp;waives California Civil
Code Section&nbsp;1542, which reads: &#147;A general release does not extend to claims which the creditor
does not know or suspect to exist in his favor at the time of executing the release, which if
known by him must have materially affected his settlement with the debtor.&#148; Each provision of this
release shall be severable from every other provision when determining its legal enforceability.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as amended hereby, the Loan Documents remain unmodified and unchanged and ratified by
Borrower as though fully set forth herein. In the event of any contradiction between any term
of this Amendment with any other Loan Document, the terms under this Amendment shall control
Lender and Borrower have executed this Amendment as of the date first written above.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Borrower:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lender:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners</B> </FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><B><FONT style="font-variant: SMALL-CAPS">Partners
</FONT>V, L.L.C.,</B> its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 02 <I>(&#147;Amendment&#148;)</I><BR>
TO LOAN AND SECURITY AGREEMENT NO. 4561</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Entered
into as of November&nbsp;16, 2006 by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P. </B><I>(&#147;Lender&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT><I>(&#147;Borrower&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Without limiting or amending any other provisions of the Agreement, as amended, Lender and Borrower
agree to the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;1.1</B> of the Agreement, the definition of <I>&#147;Subordinated Indebtedness&#148;, </I>shall be amended and
restated to read as follows:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%"><I>&#147;Subordinated Indebtedness&#148; </I>means Indebtedness of Borrower to Singapore EDB (including its
investment fund BioMedical Sciences Investment Fund Ptd Ltd) and Invus Group that is
subordinated in both security and right of payment to the Obligations on terms and
conditions reasonably satisfactory to Lender in an amount not to exceed $13,000,000.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Agreement.</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Borrower:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lender:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Partners</B>
</FONT><B>V, L.L.C.,</B> its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Rich Delateur
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Darren Haggerty
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rich Delateur
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Darren Haggerty</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director of Portfolio Analysis</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDMENT NO. 03</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Dated August&nbsp;8, 2007
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">TO
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">that certain Loan and Security Agreement No.&nbsp;4561<BR>
dated as of March&nbsp;29, 2005, as amended <I>(&#147;Agreement&#148;), </I>by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P. </B><I>(&#147;Lender&#148;) </I>and<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>, a Delaware corporation (formerly a California corporation) <I>(&#147;Borrower&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(All capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Agreement.)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Without limiting or amending any other provisions of the Loan Documents, Lender and Borrower
agree to the following:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Effective
March&nbsp;29, 2007, Borrower&#146;s state of incorporation has reincorporated from the State
of California to the State of Delaware.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as amended hereby, the Loan Documents remains unmodified and unchanged.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>BORROWER:</b></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>LENDER:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B><FONT style="font-variant: SMALL-CAPS">Lighthouse Capital Partners </FONT>V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 0px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><B><FONT style="font-variant: SMALL-CAPS">Partners </FONT>V, L.L.C.,</B> its general partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Tom Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tom Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"> Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ORIGINAL</B>
</DIV>

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 04</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Dated February&nbsp;15, 2008

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">TO

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">that certain Loan and Security Agreement No.&nbsp;4561<BR>
dated as of March&nbsp;29, 2005, as amended <I>(&#147;Agreement&#148;), </I>by and between<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners
V, L.P.</B></FONT> <I>(&#147;Lender&#148;) </I>and<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT><I> (&#147;Borrower&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant: SMALL-CAPS"><B>this Amendment No.</B></FONT><B> 04 </B><I>(&#147;Amendment 04&#148;) </I>to that certain Loan and Security Agreement
No.&nbsp;4561 dated March&nbsp;29, 2005 (as amended to date, the <I>&#147;Agreement) </I>is entered into as of February
15, 2008, by and between
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners V, L.P.</B></FONT> <I>(&#147;Lender&#148;) </I>and <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT>, a Delaware corporation
<I>(&#147;Borrower&#148;)</i>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower and Lender have previously entered into and amended the Agreement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Borrower has requested Lender provide an additional term loan financing, which
Lender has agreed to provide subject to the terms of this Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the mutual covenants herein contained,
the parties hereby agree to modify the Agreement and to perform such other covenants and conditions
as follows:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(All capitalized terms not otherwise defined herein shall have the meanings given to such terms in
the Agreement.)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>I. Section&nbsp;1.1</B>, the following definitions shall be added to the Agreement:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Change
of Management or Board Composition &#148; </I>means that <B>(i) </B>Borrower&#146;s senior management shall not
include Gajus Worthington; <B>(ii) </B>Versant Ventures or any of its affiliated funds shall cease to
have a representative (currently Samuel Colella) serving on Borrower&#146;s Board of Directors; or
<B>(iii) </B>Alloy Ventures or any of its affiliated funds shall cease to have a representative
(currently Mike Hunkapiller) serving on Borrower&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment One&#148; </I>means the Commitment as that term is used in the Agreement prior to the
effect of this Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Two&#148; </I>means $10,000,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Two Warrant&#148; </I>mean the Warrant in favor of Lender to purchase securities of Borrower,
substantially in the form <I>of <B>Exhibit&nbsp;C-2</B></I> attached to this Amendment 04 and issued in conjunction
with Commitment Two.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>II. Section&nbsp;1.1</B>, the following definitions of the Agreement shall be deleted in its entirety and
replaced with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>(i)&nbsp;under Commitment One, as defined in the Notes, as amended pursuant to Amendment
No.&nbsp;01, and (ii)&nbsp;under Commitment Two, as defined in the Notes for Advances under Commitment Two.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment&#148; </I>means Commitment One and Commitment Two.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Fee&#148; </I>means $10,000 under Commitment One and $10,000 under Commitment Two.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Commitment Termination Date&#148; </I>has occurred for Commitment One, and for Commitment Two it means the
earliest to occur of <B>(i) </B>July&nbsp;1, 2008; <B>(ii) </B>any Default or Event of Default, or <B>(iii) </B>Change of
Management or Board Composition (unless Lender has waived this condition in writing).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Disclosure Schedule&#148; </I>means the Disclosure Schedule delivered to Lender in connection with the
execution and delivery of Amendment No.&nbsp;04 to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan Commencement Date&#148; </I>means <B>(i) </B>for Advances under Commitment One, as defined in the Notes, as
amended pursuant to Amendment No.&nbsp;01, and <B>(ii) </B>for Advances under Commitment Two, as defined in
the Notes for Advances under Commitment Two.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Note&#148; </I>means (i)&nbsp;in connection with Advances under Commitment One, Secured Promissory Notes in the
form <I>of </I><B><I>Exhibit&nbsp;B</I></B><I>, </I>and (ii)&nbsp;in connection with Advances under Commitment Two, Secured Promissory
Notes in the form <I>of </I><B><I>Exhibits B-2 </I></B>to Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Notice of Borrowing&#148; </I>means (i)&nbsp;in connection with Advances under Commitment One, the form
attached as <B><I>Exhibit&nbsp;D, </I></B>and (ii)&nbsp;in connection with Advances under Commitment Two in the form of
<B><I>Exhibit&nbsp;D-2 </I></B>attached to Amendment 04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Warrant&#148; </I>means (i)&nbsp;all Warrants issued by Borrower to Lender prior to the date of Amendment 04,
and (ii)&nbsp;the Commitment Two Warrant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>III. </B><B>Section&nbsp;6.2 </B>&#151; Section&nbsp;6.2 of the Agreement shall be amended deleted in its entirety and
replaced with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>6.2
Financial Statements, Reports, Certificates. </B>Borrower shall deliver to Lender: <B>(i)</B>&nbsp;as soon as
prepared, and no later than 30&nbsp;days after the end of each calendar quarter, a balance sheet,
income statement and cash flow statement covering Borrower&#146;s operations for each of the three
months during such period, provided for each calendar month ending after the calendar quarter
ending on September&nbsp;30, 2008, Borrower shall deliver to Lender as soon as prepared, and no later
than 30&nbsp;days after the end of each calendar month, a balance sheet, income statement and cash flow
statement covering Borrower&#146;s operations during such period; <B>(ii) </B>as soon as prepared, but no
later than 90&nbsp;days after the end of the fiscal year, or such other timeframe formally approved by
Borrower&#146;s audit committee, audited financial statements prepared in accordance with GAAP,
together with an opinion that such financial statements fairly present Borrower&#146;s financial
condition by an independent public accounting firm reasonably acceptable to Lender; <B>(iii)</B>
immediately upon notice thereof, a report of any legal or administrative action pending or
threatened in writing against Borrower which is likely to result in liability to Borrower in
excess of $100,000 (provided that Borrower shall not be required to report notices of possibly
relevant third party patents, or proposals or demands to license intellectual property); and <B>(iv)</B>
such other financial information as Lender may reasonably request from time to time. Financial
statements delivered pursuant to subsections <B>(i) </B>and <B>(ii) </B>above shall be accompanied by a
certificate signed by a Responsible Officer (each an <I>&#147;Officer&#146;s Certificate&#148;) </I>in the form <I>of<B>
Exhibit&nbsp;F.</B></I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IV. Section&nbsp;3 &#151; Conditions of Advances; Procedure for requesting Advances; </B>the following new
<B>Sections&nbsp;3.2 and 3.3 </B>shall be added:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.2 Procedure for Making Advances. </B>For any Advance, Borrower shall provide Lender an irrevocable
Notice of Borrowing at least 15 business days prior to the desired Funding Date and Lender shall
only be required to make Advances hereunder based upon written requests which comply with the
terms and exhibits of this Loan Agreement (as the same may be amended from time to time), and
which are submitted and signed by a Responsible Officer. Borrower shall execute and deliver to
Lender a Note and such other documents and instruments as Lender may reasonably require for each
Advance made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.3. Conditions Precedent to Initial Advance under Commitment Two. </B>The obligation of Lender to
make the Initial Advance under Commitment Two is subject the satisfaction of each of the following
conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>This Amendment 04 duly executed by Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The Commitment Two Warrant to be issued to Lender duly executed by
Borrower.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>Delivery to Ledner of an officer&#146;s certificate of Borrower with copies of
the following documents
attached: <B>(i) </B>the certificate of incorporation and by-laws or other organizational documents of
Borrower certified by Borrower as being in full force and effect as of the date of Amendment 04,
<B>(ii) </B>incumbency and representative signatures, and <B>(iii) </B>resolutions authorizing the execution and
delivery of Amendment 04 and each of the other Loan Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>Delivery to Lender of a good standing certificate from Borrower&#146;s state of
incorporation or formation
and the state in which Borrower&#146;s principal place of business is located, together with
certificates of the applicable governmental authorities stating that Borrower is in compliance with
the franchise tax laws of each such state, each dated as of a recent date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>Borrower has obtained all necessary consents of shareholders, members, and
other third parties with
respect to the execution, delivery and performance of the Agreement, Amendment 04, the Commitment
Two Warrant, and the other Loan Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;</B>Borrower shall have satisfied all the conditions set forth in <B>Section&nbsp;3.1
and 3.2 </B>of the Agreement.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.4 Reaffirmation </B>Subject to the Disclosure Schedule attached hereto as Schedule&nbsp;1, Borrower
reaffirms the representations and warranties made to Lender in the Agreement as of the date hereof
as though fully set forth herein.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>


</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3.5 Existing Notes </B>Notes for Advances under Commitment Two are not affected by
Amendment No.&nbsp;01 and Notes for Advances under Commitment One remain subject to Amendment No.
01
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>V. Further Terms and Conditions of this Amendment 04.</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Representations and Warranties of Borrower</U>. Borrower warrants and
represents, as a significant material inducement to
Lender to enter hereinto, that: (i)&nbsp;no Events of Default have occurred and are
continuing that have not been disclosed to
Lender by Borrower in writing; (ii)&nbsp;it is not and has no reason to believe it may be
named as a party to any judicial or administrative proceeding, litigation or
arbitration, and has not received any written communication from any person or entity
(whether
private or governmental) threatening or indicating the same, except
to the extent that
any such written communication could not
reasonably be expected to result in a material adverse effect on Borrower&#146;s business;
and (iii)&nbsp;it is in full compliance with Section
7.10 of the Loan and Security Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Control.</U> Borrower warrants and represents, as a significant material
inducement to Lender to enter hereinto, that none of
Lender nor any affiliate, officer, director, employee, agent, or attorney of Lender,
have at any time, from Borrower&#146;s date of
formation through to the date hereof, (i)&nbsp;exercised management or other control over the
Borrower, (ii)&nbsp;exercised undue influence
over Borrower or any of its officers, employees or directors, (iii)&nbsp;made any
representation or warranty, express or implied, to any
party on behalf of Borrower, (iv)&nbsp;entered into any joint venture, agency relationship,
employment relationship, or partnership with
Borrower, (v)&nbsp;directed or instructed Borrower on the manner, method, amount, or identity
of payee of any payment made to any
creditor of Borrower, and further, Borrower warrants and represents that by entering
hereinto with Lender has not, are not and will
not have engaged in any of the foregoing.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Integration Clause.</U> This Agreement represents and documents the entirety
of the agreement and understanding of the parties
hereto with respect to its subject matter. All prior understandings, whether oral or
written, other than the Loan Documents,
are hereby merged hereinto. <B>NEITHER THE LOAN AND SECURITY AGREEMENT NOR THIS AGREEMENT
MAY BE MODIFIED EXCEPT BY A WRITING SIGNED BY LENDER AND BORROWER. </B>Each provision hereof
shall be severable from every other provision when determining its legal enforceability
such that Lender&#146;s rights and
remedies under this Agreement and the Loan Documents may be enforced to the maximum
extent permitted under applicable
law. This Agreement shall be binding upon, and inure to the benefit of, each party&#146;s
respective permitted successors and
assigns. This Agreement may be executed in counterpart originals, all of which, when
taken together, shall constitute one
and the same original document. No provision of any other document between Lender and
Borrower shall limit the
effectiveness hereof or the rights and remedies of Lender against Borrower. In the
event of any contradiction or
inconsistency among the terms and conditions of this Agreement or any Loan Document, the
interpretation most favorable to
the interests of Lender shall prevail.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Except as amended hereby, the Agreement remains unmodified and unchanged.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>BORROWER:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LENDER:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>FLUIDIGM CORPORATION</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>LIGHTHOUSE CAPITAL PARTNERS V, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" colspan="3" nowrap><B>LIGHTHOUSE MANAGEMENT PARTNERS V, L.L.C.,</B></TD>


</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Name:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">its general partner&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Thomas Conneely
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thomas Conneely</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Vice President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;B-2 </B></FONT><BR>
<FONT style="font-variant: SMALL-CAPS"><B>(Commitment Two)</B></FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>&#091;</B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><B>&#093;</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Secured Promissory Note</B></FONT>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This
<FONT style="font-variant: SMALL-CAPS">Secured Promissory
Note</FONT> (this <I>&#147;Note&#148;) </I>is
made <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> , 2008, by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B>
</FONT><I>(&#147;Borrower&#148;) </I>in favor of <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital Partners </B></FONT><B>V, L.P.</B> (collectively with its assigns, <I>&#147;Lender&#148;). </I>Initially
capitalized terms used and not otherwise defined herein are defined in that certain Loan and
Security Agreement No.&nbsp;4561 between Borrower and Lender dated
March&nbsp;29, 2005, as amended (the <I>&#147;Loan
Agreement&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">For
Value Received, </FONT>Borrower promises to pay in lawful money of the United States, to the
order of Lender, at 500 Drake&#146;s Landing Road, Greenbrae, California 94904, or such other place as
Lender may from time to time designate (&#147;<I>Lender&#146;s Office&#148;), </I>the principal
sum of
$<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>
(the <I>&#147;Advance&#148;), </I>including interest on the unpaid balance and all other amounts due or to
become due hereunder according to the terms hereof and of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Basic Rate&#148; </I>means a fixed per <I>annum </I>rate of interest equal 8.5%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Final Payment&#148; </I>means 6.5% of the Advance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Loan Commencement Date&#148; </I>means January&nbsp;1,2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Maturity Date&#148; </I>means the last day of the Repayment Period, or if earlier, the date of prepayment
under the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Payment Date&#148; </I>means the first day of each calendar month.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Prepayment Fee&#148; </I>means (i)&nbsp;if prepaid in the calendar years 2008 or 2009, 3% of the outstanding
principal amount being prepaid; (ii)&nbsp;if prepaid in the calendar year 2010, 2% of the outstanding
principal amount being prepaid; and (iii)&nbsp;if prepaid in the calendar year 2011 or thereafter, 1%
of the outstanding principal amount being prepaid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>&#147;Repayment Period&#148; </I>means the period beginning on the Loan Commencement Date and continuing for 30
calendar months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Repayment. </B>Borrower shall pay principal and interest due hereunder from the Funding Date, until
this Note is paid in full,
on each Payment Date pursuant to the terms of the Loan Agreement and this Note. Borrower shall
pay to Lender, monthly in
advance on each Payment Date, interest calculated using the Basic Rate. Beginning on the Loan
Commencement Date and on each
Payment Date thereafter during the Repayment Period, Borrower shall make equal installments of
principal and interest in advance,
calculated at the Basic Rate. On the Maturity Date, Borrower shall pay, in addition to all unpaid
principal and interest outstanding
hereunder, the Final Payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2.
Interest. </B>Interest not paid when due will, to the maximum extent permitted under applicable law,
become part of principal,
at Lender&#146;s option, and thereafter bear like interest as principal. Interest shall be computed on
the basis of a 360&nbsp;day year. All
Obligations not paid when due shall bear interest at the Default Rate unless waived in writing by
Lender. All amounts paid hereunder
will be applied to the Obligations in Lender&#146;s discretion and as provided in the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>3. Voluntary Prepayment. </B>Borrower may prepay the Note if and only if Borrower pays to Lender <B>(i</B>)
the outstanding principal
amount of this Note and any unpaid accrued interest <B>(ii)</B>&nbsp;the Final Payment, <B>(iv)</B>&nbsp;the Prepayment
Fee, and <B>(v)</B>&nbsp;all other sums, if any, that
shall have become due and payable hereunder with respect to this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Collateral. </B>This Note is secured by the Collateral.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Waivers. </B>Borrower, and all guarantors and endorsers of this Note, regardless of the time, order
or place of signing, hereby
waive notice, demand, presentment, protest, and notices of every kind, presentment for the purpose
of accelerating maturity, diligence
in collection to the fullest extent permitted by law.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><B>6. Choice of Law; Venue. </B><FONT style="font-variant: SMALL-CAPS"><B>This Note shall be governed by, and construed in accordance with the
internal
laws of the State of California, without regard to principles of conflicts of law. Each of
Borrower and
Lender hereby submits to the exclusive jurisdiction of the State and Federal courts located in
the City and</B></FONT>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>County of San Francisco, State of California. Borrower and Lender each hereby waive their
respective rights to a jury trial of any claim or cause of action based upon or arising out of this
Note. Each party further waives any right to consolidate any action in which a jury trial has been
waived with any other action in which a jury trial cannot be or has not been waived.</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7. Miscellaneous. </B><FONT style="font-variant: SMALL-CAPS">This Note may be modified only by a</font> <FONT style="font-variant: SMALL-CAPS">writing signed by Borrower and
Lender. </FONT>Each provision
hereof is severable from every other provision hereof and of the Loan Agreement when determining
its legal enforceability. Sections and subsections are titled for convenience, and not for
construction. &#147;Hereof,&#148; &#147;herein,&#148; &#147;hereunder,&#148; and similar words refer to this Note in its
entirety. &#147;Or&#148; is not necessarily exclusive. &#147;Including&#148; is not limiting. The terms and conditions
hereof inure to the benefit of and are binding upon the parties&#146; respective permitted successors
and assigns. This Note is subject to all the terms and conditions of the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS">In Witness Whereof, </FONT>Borrower has caused this Note to be executed by a duly authorized
officer as of the day and year first above written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>


</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT
C-2</B>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NEITHER THIS WARRANT NOR THE SHARES OF CAPITAL STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE <I>&#147;1933 ACT&#148;), </I>OR ANY APPLICABLE STATE
SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN
ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR THE COMPANY HAS
RECEIVED AN OPINION OF COUNSEL, REASONABLY ACCEPTABLE TO THE COMPANY, TO THE EFFECT THAT SUCH SALE
OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">PREFERRED STOCK PURCHASE WARRANT
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Warrant No.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Number of Shares: initially, 100,000</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Series&nbsp;E Preferred Stock</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">subject to increase as set forth below</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Effective as of February&nbsp;15, 2008
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Void after February&nbsp;15, 2015

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>1.&nbsp;Issuance. </B>This Preferred Stock Purchase Warrant (the <I>&#147;Warrant&#148;) </I>is issued to
<FONT style="font-variant: SMALL-CAPS"><B>Lighthouse</B></FONT>
<FONT style="font-variant: SMALL-CAPS"><B>Capital Partners</B>
</FONT><B>V,
L.P.</B> by <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation,</B> </FONT>a Delaware corporation
(hereinafter with its successors
called the <I>&#147;Company&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>2.&nbsp;Purchase Price; Number of Shares.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The registered holder of this Warrant (the <I>&#147;Holder&#148;), </I>commencing on the date hereof, is
entitled
upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the
principal office of
the Company, to purchase from the Company, at a price per share of $4.00 (the <I>&#147;Purchase
Price&#148;), </I>100,000 fully
paid and nonassessable shares of the Company&#146;s Series&nbsp;E Preferred Stock, (the <I>&#147;Exercise
Quantity&#148;), </I>$0.001 par
value (the <I>&#147;Preferred Stock&#148;).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>On the Commitment Termination Date, the Exercise Quantity shall automatically be increased
by
such additional number of shares (rounded to the nearest whole share) of Series&nbsp;E Preferred
Stock, if any, as is equal
to the amount determined by dividing (A)&nbsp;8% of the Aggregate Advances under the Loan
Agreement, if any, by (B)
the Purchase Price
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition to other terms which may be defined herein, the following terms, as used in this
Warrant, shall have the following meanings:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(i)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Aggregate Advances&#148; means the aggregate original dollar amount of all
Advances made under Commitment Two of the Loan Agreement, whether such Advances are
outstanding or prepaid, at the time of any scheduled adjustment to the Exercise
Quantity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(ii)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Loan Agreement&#148; means that certain Loan and Security Agreement No.&nbsp;4561 dated
March&nbsp;29, 2005 between the Company and Lighthouse Capital Partners V, L.P., as
amended.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any capitalized term not defined herein shall have the meaning as set forth in the Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Until such time as this Warrant is exercised in full or expires, the Purchase Price and the
securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter
provided. The person or persons in whose name or
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">names any certificate representing shares of Preferred Stock is issued hereunder shall be deemed
to have become the holder of record of the shares represented thereby as at the close of business
on the date this Warrant is exercised with respect to such shares, whether or not the transfer
books of the Company shall be closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>3.&nbsp;Payment of Purchase Price. </B>The Purchase Price may be paid (i)&nbsp;in cash or by check, (ii)&nbsp;by
the
surrender by the Holder to the Company of any promissory notes or other obligations issued by
the Company, with
all such notes and obligations so surrendered being credited against the Purchase Price in an
amount equal to the
principal amount thereof plus accrued interest to the date of surrender, or (iii)&nbsp;by any
combination of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>4.&nbsp;Net Issue Election. </B>The Holder may elect to receive, without the payment by the Holder of
any
additional consideration, shares of Preferred Stock equal to the value of this Warrant or any
portion hereof by the
surrender of this Warrant or such portion to the Company, with the net issue election notice
annexed hereto duly
executed, at the principal office of the Company. Thereupon, the Company shall issue to the
Holder such number of
fully paid and nonassessable shares of Preferred Stock as is computed using the following
formula:
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>X=</I><U><I>Y(A-B)</I></U><BR>A

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">where:&nbsp;&nbsp;X=
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock to be issued to the Holder
pursuant to this <B>Section&nbsp;4</B>.</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Y=
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the number of shares of Preferred Stock covered by
this Warrant in respect of which the net issue election is made pursuant to
this <B>Section&nbsp;4</B>.</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">A=
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Fair Market Value (defined below) of one share of
Preferred Stock, as determined at the time the net issue election is made
pursuant to this <B>Section&nbsp;4</B>.</TD>
</TR>
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">B=
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Purchase Price in effect under this Warrant at the
time the net issue election is made pursuant to this <B>Section&nbsp;4</B>.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>&#147;Fair Market Value&#148; </I>of a share of Preferred Stock (or fully paid and nonassessable shares of
the Company&#146;s common stock, $0.001 par value (the <I>&#147;Common Stock&#148;</I>) if the Preferred Stock has been
automatically converted into Common Stock) as of the date that the net issue election is made (the
<I>&#147;Determination Date&#148;</I>) shall mean:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(i)&nbsp;</B>If the net issue election is made in connection with and contingent upon the
closing of the
sale of the Company&#146;s Common Stock to the public in a public offering pursuant to a Registration
Statement under the Securities Act of 1933, as amended (a <I>&#147;Public Offering&#148;</I>), and if the Company&#146;s
Registration Statement relating to such Public Offering (<I>&#147;Registration Statement&#148;</I>) has been
declared effective by the Securities and Exchange Commission, then the initial &#147;Price to Public&#148;
specified in the final prospectus with respect to such offering multiplied by the number of shares
of Common Stock into which each share of Preferred Stock is then convertible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(ii)&nbsp;</B>If the net issue election is not made in connection with and contingent upon a Public
Offering, then as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>If traded on a securities exchange or the Nasdaq National Market, the fair
market value of the Common Stock shall be deemed to be the average of the closing or last reported
sale prices of the Common Stock on such exchange or market over the five day period ending five
trading days prior to the Determination Date, and the fair market value of the Preferred Stock
shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares
of Common Stock into which each share of Preferred Stock is then convertible;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>If otherwise traded in an over-the-counter market, the fair market value
of the
Common Stock shall be deemed to be the average of the closing ask prices of the Common Stock over
the five day period ending five trading days prior to the Determination Date, and the fair market
value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock
multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then
convertible; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>If there is no public market for the Common Stock, then fair market value shall
be determined in good faith by the Company&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>5.&nbsp;Partial Exercise. </B>This Warrant may be exercised in part, and the Holder shall be entitled
to
receive a new warrant, which shall be dated as of the date of this Warrant, covering the
number of shares in respect
of which this Warrant shall not have been exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>6.&nbsp;Fractional Shares. </B>In no event shall any fractional share of Preferred Stock be issued
upon any
exercise of this Warrant. If, upon exercise of this Warrant in its entirety, the Holder
would, except as provided in
this <B>Section&nbsp;6, </B>be entitled to receive a fractional share of Preferred Stock, then the Company
shall issue the next
higher number of full shares of Preferred Stock, issuing a full share with respect to such
fractional share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>7.&nbsp;Expiration Date; Automatic Exercise. </B>This Warrant shall expire at the close of
business on
February&nbsp;15, 2015, and shall be void thereafter (the <I>&#147;Expiration Date&#148;). </I>Notwithstanding the
term of this Warrant
fixed pursuant to this <B>Section&nbsp;7,</B> and provided Holder has received advance written notice of
at least twenty (20)
days and has not earlier exercised this Warrant, and provided this Warrant has not been
assumed by the successor
entity (or parent thereof), upon the consummation of a Merger (as defined below), this Warrant
shall automatically
be exercised pursuant to <B>Section&nbsp;4 </B>hereof, without any action by Holder. <I>&#147;Merger&#148; </I>means: (i)
a sale of all or
substantially all of the Company&#146;s assets to an Unaffiliated Entity (as defined below), or
(ii)&nbsp;the merger,
consolidation or acquisition of the Company with, into or by an Unaffiliated Entity (other
than a merger or
consolidation for the principle purpose of changing the domicile of the Company or a bona fide
round of preferred
stock equity financing), that results in the Company&#146;s shareholders immediately prior to such
merger, consolidation,
or acquisition holding, immediately thereafter, less than a majority of the outstanding
voting securities of the
successor corporation or its parent. <I>&#147;Unaffiliated Entity&#148; </I>means any entity that is owned
or controlled by parties
who own less than twenty percent (20%) of the combined voting power of the voting securities
of the Company
immediately prior to such merger or sale of assets, consolidation or acquisition.
Notwithstanding the foregoing, in
the event that any outstanding warrants to purchase equity securities of the Company (it being
acknowledged and
agreed that options to acquire common stock issued to officers, directors, employees and
consultants shall not be
deemed &#147;warrants&#148;) are assumed by the successor entity of a Merger (or parent thereof), this
Warrant shall also be
similarly assumed and the automatic exercise provision in this <B>Section&nbsp;7 </B>shall have no effect.
The Company agrees
to give the Holder written notice promptly after it has entered into a definitive agreement
relating to any proposed
Merger and written notice of termination of any definitive agreement relating to any
proposed Merger.
Notwithstanding anything to the contrary in this Warrant, (i)&nbsp;the Holder may expressly make
any voluntary exercise
of this Warrant contingent on, and effective immediately prior to, the consummation of such
Merger and (ii)&nbsp;any
automatic exercise of this Warrant in connection with a Merger shall be conditioned on
consummation of such
Merger and shall be effective immediately prior thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>8.&nbsp;Reserved Shares; Valid Issuance. </B>The Company covenants that it will at all times from and
after
the date hereof reserve and keep available such number of its authorized shares of Preferred
Stock and Common
Stock free from all preemptive or similar rights therein, as will be sufficient to permit,
respectively, the exercise of
this Warrant in full and the conversion into shares of Common Stock of all shares of Preferred
Stock receivable
upon such exercise. The Company further covenants that such shares as may be issued pursuant
to such exercise
and/or conversion will, upon issuance, be duly and validly issued, fully paid and
nonassessable and free from all
taxes, liens and charges with respect to the issuance thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>9.&nbsp;Stock Splits and Dividends. </B>If after the date hereof the Company shall subdivide the
Preferred
Stock, by split-up or otherwise, or combine the Preferred Stock, or issue additional shares of
Preferred Stock in
payment of a stock dividend on the Preferred Stock, the number of shares of Preferred Stock
issuable on the exercise
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock
dividend, or proportionately decreased in the case of a combination, and the Purchase Price shall
forthwith be proportionately decreased in the case of a subdivision or stock dividend, or
proportionately increased in the case of a combination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>10.&nbsp;Adjustments for Diluting Issuances. </B>The antidilution rights applicable to the Series&nbsp;E
Preferred Stock of the Company are set forth in the Amended and Restated Certificate of
Incorporation, as amended from time to time (the <I>&#147;Articles&#148;</I>), a true and complete copy in its
current form which has been made available to Holder. Such rights shall not be restated, amended
or modified in any manner which affects the Holder differently than the holders of outstanding
Series&nbsp;E Preferred Stock without such Holder&#146;s prior written consent. The Company shall provide
the Holder hereof with any restatement, amendment or modification to the Articles promptly after
the same has been made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>11.&nbsp;Mergers and Reclassifications. (a) </B>Except as set forth in <B>Section&nbsp;7</B>, If after the date
hereof the Company shall enter into any Reorganization (as hereinafter defined), then, as a
condition of such Reorganization, lawful provisions shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that the
Holder shall thereafter have the right to purchase, at a total price not to exceed that payable
upon the exercise of this Warrant in full, the kind and amount of shares of stock and other
securities and property receivable upon such Reorganization by a holder of the number of shares of
Preferred Stock which might have been purchased by the Holder immediately prior to such
Reorganization, and in any such case appropriate provisions shall be made with respect to the
rights and interest of the Holder to the end that the provisions hereof (including without
limitation, provisions for the adjustment of the Purchase Price and the number of shares issuable
hereunder and the provisions relating to the net issue election) shall thereafter be applicable in
relation to any shares of stock or other securities and property thereafter deliverable upon
exercise hereof. For the purposes of this <B>Section&nbsp;11, </B>the term <I>&#147;Reorganization&#148; </I>shall include
without limitation any reclassification, capital reorganization or change of the Preferred Stock
(other than as a result of a subdivision, combination or stock dividend provided for in <B>Section&nbsp;9</B>
hereof), or any consolidation of the Company with, or merger of the Company into, another
corporation or other business organization (other than a merger in which the Company is the
surviving corporation and which does not result in any reclassification or change of the
outstanding Preferred Stock), or any sale or conveyance to another corporation or other business
organization of all or substantially all of the assets of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>Notwithstanding any other provision of this Warrant, in the event of an automatic
conversion of the Company&#146;s outstanding Series&nbsp;E Preferred Stock into Common Stock in accordance
with the Company&#146;s Articles, as in effect from time to time, this Warrant shall thereafter
represent the right to acquire for the aggregate Purchase Price (as then in effect) the number of
shares of Common Stock into which the number of shares of Preferred Stock issuable upon exercise
of this Warrant would have then been convertible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>12.&nbsp;Certificate of Adjustment. </B>Whenever the Purchase Price is adjusted, as herein provided,
the
Company shall promptly deliver to the Holder a certificate of the Company&#146;s chief financial
officer (or other
appropriate officer) setting forth the Purchase Price after such adjustment and setting forth
a brief statement of the
facts requiring such adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>13.&nbsp;Notices of Record Date, Etc. </B>In the event of:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend or other
distribution, or any right
to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any
class or any other
securities or property, or to receive any other right;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>any reclassification of the capital stock of the Company, capital reorganization of the
Company, consolidation or merger involving the Company, or sale or conveyance of all or
substantially all of its
assets; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>any voluntary or involuntary dissolution, liquidation or winding-up of the
Company;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then in each such event the Company will provide or cause to be provided to the Holder a written
notice thereof. Such notice shall be provided at least twenty (20)&nbsp;business days prior to the date
specified in such notice on which any such action is to be taken.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>14.&nbsp;Representations, Warranties and Covenants. </B>This Warrant is issued and delivered by the
Company and accepted by each Holder on the basis of the following representations, warranties and
covenants made by the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;</B>The Company has all necessary corporate power and authority to issue, execute and
deliver this Warrant and to perform its obligations hereunder. This Warrant has been duly
authorized issued,
executed and delivered by the Company and is the valid and binding obligation of the Company,
enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy or similar
laws relating to the
enforcement of creditors&#146; rights generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;</B>The shares of Preferred Stock issuable upon the exercise of this Warrant have been duly
authorized and reserved for issuance by the Company and, when issued in accordance with the
terms hereof, will be
validly issued, fully paid and nonassessable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;</B>The
issuance, execution and delivery of this Warrant do not, and the issuance of the shares of Preferred Stock upon the exercise of this Warrant in accordance with the terms
hereof will not, (i)&nbsp;violate
or contravene the Company&#146;s Articles or by-laws, or any law, statute, regulation, rule,
judgment or order applicable
to the Company, (ii)&nbsp;violate, contravene or result in a breach or default under any contract,
agreement or instrument
to which the Company is a party or by which the Company or any of its assets are bound or
(iii)&nbsp;require the consent
or approval of or the filing of any notice or registration with any person or entity (other
than such notices or filings
as may be required under applicable securities laws).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;</B>As long as this Warrant is, or any shares of Preferred Stock issued upon exercise of this
Warrant or any shares of Common Stock issued upon conversion of such shares of Preferred Stock
are, issued and
outstanding, the Company will provide to the Holder the financial and other information
described in that certain
Loan and Security Agreement No.&nbsp;4561 between the Company and Lighthouse Capital Partners V,
L.P. dated as of
March&nbsp;29, 2005, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;</B>As of the date hereof, the authorized capital stock of the Company consists of (i)
87,385,839 shares of Common Stock, of which 9,946,605 shares are issued and outstanding and
300,000 shares are
reserved for issuance upon the exercise of this Warrant with respect to Common Stock and the
conversion of the
Preferred Stock into Common Stock if this Warrant is exercised with respect to Preferred
Stock, (ii)&nbsp;2,727,273
shares of Series&nbsp;A Preferred Stock, of which 2,727,273 are issued and outstanding shares,
(iii)&nbsp;6,460,675 shares of
Series&nbsp;B Preferred Stock, of which 6,460,675 are issued and outstanding shares, (iv)
16,854,624 shares of Series&nbsp;C
Preferred Stock, of which 16,364,832 are issued and outstanding shares, (v)&nbsp;13,962,261 shares
of Series&nbsp;D Preferred
Stock, of which 13,353,333 are issued and outstanding shares and (vi)&nbsp;20,109,947 shares of
Series&nbsp;E Preferred
Stock, of which 17,764,781 are issued and outstanding shares. Company has delivered a
capitalization table to
Holder summarizing the capitalization of the Company. At the request of Holder, not more than
once per calendar
quarter, the Company will provide Holder with a current capitalization table indicating
changes, if any, to the
number of outstanding shares of common stock and preferred stock.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>15.&nbsp;Registration Rights. </B>The Company grants, upon effectiveness of the Rights Agreement
referenced herein, to the Holder all the rights of a &#147;Holder&#148; and an &#147;Investor&#148; under the
Company&#146;s Eighth Amended
and Restated Investors&#146; Rights Agreement dated as of June&nbsp;13, 2006, as amended from time to
time (the <I>&#147;Rights
Agreement&#148;</I>), including, without limitation, the registration rights contained therein, and
agrees to solicit approval to
amend the Rights Agreement so that (i)&nbsp;the shares of Common Stock issuable upon conversion of
the shares of
Preferred Stock issuable upon exercise of this Warrant shall be <I>&#147;Registrable Securities,&#148; </I>and
(ii)&nbsp;the Holder shall be
a &#147;Holder&#148; and an &#147;Investor&#148; for all purposes of such Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>16.&nbsp;Amendment. </B>The terms of this Warrant may be amended, modified or waived only with the
written consent of the Holder and the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>17.&nbsp;Representations and Covenants of the Holder. </B>This Warrant has been entered into by the
Company in reliance upon the following representations and covenants of the Holder, which by
its execution hereof
the Holder hereby confirms:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Investment Purpose. </B>The right to acquire Preferred Stock or the Preferred Stock
issuable upon exercise of the Holder&#146;s rights contained herein will be acquired for investment
and not with a view to
the sale or distribution of any part thereof, and the Holder has no present intention of
selling or engaging in any
public distribution of the same except pursuant to a registration or exemption.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b)&nbsp;Accredited Investor. </B>Holder is an &#147;accredited investor&#148; within the meaning of Rule&nbsp;501
of Regulation&nbsp;D, promulgated under the 1933 Act as presently in effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Private Issue. </B>The Holder understands (i)&nbsp;that neither the issuance of this Warrant nor
the issuance of any shares of the Company&#146;s capital stock issuable upon exercise of the
Holder&#146;s rights contained
herein has been registered under the 1933 Act or qualified under applicable state securities
laws on the ground that
the issuances contemplated by this Warrant will be exempt from the registration and
qualifications requirements
thereof, and (ii)&nbsp;that the Company&#146;s reliance on such exemption is predicated on the
representations of the Holderset
forth in this <B>Section&nbsp;17.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Financial Risk. </B>The Holder has such knowledge and experience in financial and
business matters as to be capable of evaluating the merits and risks of its investment and has
the ability to bear the
economic risks of its investment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>18.&nbsp;Notices, Transfers, Etc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>(a)</b>&nbsp;Any notice or written communication required or permitted to be given to the Holder may
be given by certified mail or delivered to the Holder at the address most recently provided by
the Holder to the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>(b)</b>&nbsp;Subject to compliance with applicable federal and state securities laws, this Warrant may
be transferred by the Holder with respect to any or all of the shares purchasable hereunder.
Upon surrender of this
Warrant to the Company, together with the assignment notice annexed hereto duly executed, for
transfer of this
Warrant as an entirety by the Holder, the Company shall issue a new warrant of the same
denomination to the
assignee. Upon surrender of this Warrant to the Company, together with the assignment hereof
properly endorsed,
by the Holder for transfer with respect to a portion of the shares of Preferred Stock
purchasable hereunder, the
Company shall issue a new warrant to the assignee, in such denomination as shall be requested
by the Holder hereof,
and shall issue to such Holder a new warrant covering the number of shares in respect of which
this Warrant shall
not have been transferred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>(c)</b>&nbsp;In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall
issue
a new warrant of like tenor and denomination and deliver the same (i)&nbsp;in exchange and
substitution for and upon
surrender and cancellation of any mutilated Warrant, or (ii)&nbsp;in lieu of any Warrant lost,
stolen or destroyed, upon
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">receipt of an affidavit of the Holder or other evidence reasonably satisfactory to the Company of
the loss, theft or destruction of such Warrant
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>19.&nbsp;No Impairment. </B>The Company will not, by amendment of its Articles or through any
reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets,
dissolution, liquidation,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance of performance of any
of the terms of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and in the
taking of all such action as may be necessary or appropriate in order to protect the rights of
the Holder. In no event
shall any reclassification, capital reorganization, consolidation, merger, sale or conveyance
of assets, dissolution,
liquidation, issue or sale of securities or any other transaction be deemed an &#147;impairment&#148;
for purposes of this
Section&nbsp;18 if the shares of the Company&#146;s capital stock issuable upon exercise of this Warrant
are affected thereby in
the same manner as outstanding shares of such capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>20.&nbsp;Governing Law. </B>The provisions and terms of this Warrant shall be governed by and construed
in
accordance with the internal laws of the State of California without giving effect to its
principles regarding conflicts
of laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>21.&nbsp;Successors and Assigns. </B>This Warrant shall be binding upon the Company&#146;s successors and
assigns and shall inure to the benefit of the Holder&#146;s successors, legal representatives and
permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>22.&nbsp;Business Days. </B>If the last or appointed day for the taking of any action required or the
expiration
of any rights granted herein shall be a Saturday or Sunday or a legal holiday in California,
then such action may be
taken or right may be exercised on the next succeeding day which is not a Saturday or Sunday
or such a legal
holiday.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>23.&nbsp;Value. </B>The Company and the Holder agree that the value of this Warrant on the date of
grant is
$100.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7.<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Subscription</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="right" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby subscribes for&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;shares of Preferred Stock covered by this
Warrant. The
certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise
indicated below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 18pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 18pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mailing Address
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Net Issue Election Notice</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned hereby elects under <B>Section&nbsp;4 </B>to surrender the right to purchase shares of
Preferred Stock pursuant to this Warrant. The certificate(s) for such shares issuable upon such net
issue election shall be issued in the name of the undersigned or as otherwise indicated below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 18pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 18pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Mailing Address
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Assignment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">For value received _____________________________ hereby sells, assigns and transfers unto
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 18pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt">&#091;Please print or typewrite name and address of Assignee&#093;</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt">the within
Warrant, and does hereby irrevocably constitute and appoint
_____________________________ its attorney to transfer the within Warrant on the books of the within named Company with full
power of substitution on the premises.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="52%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="line-height: 18pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name for Registration
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">In the Presence of:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px;">



<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Exhibit&nbsp;D-2</B></FONT>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Notice of Borrowing</B></FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, ________
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lighthouse
Capital Partners V, L.P.<BR>
500 Drake&#146;s Landing Road<BR>
Greenbrae, CA 94904-3011

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reference
is made to the Loan and Security Agreement No.&nbsp;4561 dated as of March&nbsp;29, 2005 (as
it has been and may be amended from time to time, the <I>&#147;Loan Agreement,&#148; </I>initially capitalized
terms used herein as defined therein), between <FONT style="font-variant: SMALL-CAPS"><B>Lighthouse Capital </B><B>Partners </B></FONT><B>V, L.P. </B>and
<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation </B></FONT>(the <I>&#147;Company&#148;)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned is the President and CEO of the Company, and hereby irrevocably requests an
Advance under the Loan Agreement, and in that connection certifies as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The amount of the proposed Advance is $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>. The business day of the proposed Advance is <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The
Loan Commencement Date for this Advance shall be March&nbsp;1, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;As of this date, no Event of Default, or event which with notice or the passage of time
would constitute an Event of Default, has occurred and is continuing, or will result from the
making of the proposed Advance, and the representations and warranties of the Company contained in
<B>Section&nbsp;5</B> of the Loan Agreement are true and correct in all material respects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;No event that could reasonably be expected to have a material adverse effect on the
ability of Borrower to fulfill its obligations under the Loan Agreement has occurred since the
date of the most recent financial statements, submitted to you by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to notify you promptly before the funding of the Advance if any of the
matters to which I have certified above shall not be true and correct
on the Funding Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Very truly yours,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Schedule&nbsp;1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Disclosure Schedule</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Deposit and Securities Accounts</B></FONT>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="41%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="41%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Account Information:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Contact Information for</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Account:</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Account</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Wells Fargo Bank</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Gerry Klein</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Number</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 420 Montgomery Street, 9<SUP style="font-size: 85%; vertical-align: text-top">th</SUP></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 415.396.2961</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Floor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 415.975.7573</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip:    San Francisco, CA 94104</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E-mail: gerry.h.klein@wellsfargo.com</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Type of Account:   Checking, Payroll</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Account number: [***], [***]</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Account</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Morgan Stanley</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Thomas Piliero/WAXMAN</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Number</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 555 California Street, Suite 1400</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 415-576-2016</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip: San Francisco, CA 94104</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 415-576-2060</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 415.576.2016</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E-mail: Thomas.Piliero@morganstanley.com</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 415-576-2060</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Type of Account: Investment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Account number: [***]</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Account</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Silicon Valley Bank</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Michael White</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Number</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 3003 Tasman Drive, HF 195</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 415.512.4215</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip: Santa Clara, CA 95054</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 415.856.0810</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 510.284.1129</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E-mail: mwhite@svbank.com</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 510.284.1127</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Type of Account: Checking, CDs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Account number: [***], [***],</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">[***]</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Account</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Comerica Bank</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Heather Lynam</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Number</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 226 Airport Parkway</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 650.213.1726</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip: San Jose, CA 95110</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 650.213.1710</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 650.213.1716</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E-mail: hlynam@comerica.com</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 650.213.1710</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Type of Account: Checking, Sweep, LC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Account number: [***], [***],</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">[***]</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Subsidiaries</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Fluidigm Singapore Pte. Ltd.<BR>
Fluidigm KK<BR>
Fluidigm Europe BV<BR>
Fluidigm France SARL
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Prior Names</B></FONT>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Mycometrix
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Litigation and Administrative Proceedings</B></FONT>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">None

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: SMALL-CAPS"><B>Business Premises</B></FONT>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="41%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="41%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Each Location Address where Lighthouse</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Landlord/Property Management</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Capital Partners has financed assets:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Information:</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name:     Jim Neesen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Bob Farrell, Controller Facility</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Headquarters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 7000 Shoreline Court, Suite</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Operations</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">(Location 1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">100</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Oscient Pharmaceuticals</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip:   South San Francisco, CA</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 1000 Winter Street City, State,</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">94080</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Zip:          Waltham, MA 02451</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: (650) 226-6000</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: (781) 398-2604</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650) 871-7152</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (781) 398-2350</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name:   Stephen Richardson</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Alexandria Real Estate</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Equities, Inc.</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 2929 Campus Drive, Suite 400-A</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip: San Mateo, CA 94403</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: (650) 286-1200</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650) 286-1256</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Location</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Mr. Takeshi Iwabuchi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Mr. Jyun Kusakabe</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name:   Fluidigm KK (Sales office)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: Sankou estate K.K</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address:      Level 5 Ginza TK Bldg, 1-1-7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: Shibuyanomurasyouken building</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Shintomi</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-14-16 Shibuya, Shibuya-Ku,</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip: Chuo-Ku, Tokyo, 104-0041</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tokyo, 150-0002</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Japan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JAPAN</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: &#043;813-3555-2351</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: &#043;813-3409-1411</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: &#043;813-3555-2353</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: &#043;813-3409-1413</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Location</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name: Ms. Akemi Minamino</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name:    Fluidigm KK (Sales Office)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: K.K. HIT</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: Level 3-123 Soukendoshomachi bldg</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: Level 25 Osakaekimae daisan bldg</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-1-10 Doshomachi, Chuo-Ku,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-1-3 Umeda, Kita-Ku, Osaka-Shi</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Osaka-Shi, Osaka 541-0045</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Osaka 530-0001</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JAPAN</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JAPAN</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip:    Osaka</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: &#043;816-6345-1210</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: &#043;816-6220-0500</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: &#043;816-6347-0660</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: &#043;816-6220-0660</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Location</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name:   Grace Yow</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact Name:   Phoa Cheng Han</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name:   Fluidigm Singapore</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company Name: JTC Corporation</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 39 Robinson Road</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Address: 8 Jurong Town Hall Road</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#07-01 Robinson Point</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip: Singapore 609434</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">City, State, Zip:   Singapore 068911</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: 65 9748 2922</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65 62825531</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Please see attached Disclosure Schedule which by this reference shall be deemed to be a part
hereof.
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>6
<FILENAME>f39432a9exv4w5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.5</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONVERTIBLE NOTE PURCHASE AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(US$15 Million Credit Facility)

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>August&nbsp;7, 2006</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="2"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>1.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">The First Note</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization; Purchaser&#146;s Obligation to Purchase</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">First Note Procedure</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Closing of First Note Purchase</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Change in Series E Preferred Stock</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>2.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Representations and Warranties of the Company</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization, Good Standing and Qualification</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Power</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiaries</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Capitalization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Valid Issuance of Note and Conversion Shares</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employees</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patents and Other Intangible Assets</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance with Other Instruments</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Permits</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Environmental and Safety Laws</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Property and Assets</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreements; Action</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Financial Statements</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.17</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Changes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.18</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers or Finders</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.19</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employee Benefit Plans</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.20</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Matters</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.21</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Insurance</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.22</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Corporate Documents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.23</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Disclosure</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.24</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Offering</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.25</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Returns and Complaints</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>3.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Representations and Warranties of the Purchasers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Experience</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rule&nbsp;144</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Public Market</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Data</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Accredited Investor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS<br>(Continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2"  style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Public Solicitation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Advisors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Purchaser Counsel</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Brokers or Finders</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-United States Persons</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>4.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Covenants of the Company</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiary Business Plan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Subsidiary Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Affirmative Covenants</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preservation of Existence</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Payment of Taxes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance with Laws</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Maintenance of Properties</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Government Authority</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Company Counsel</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>5.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Covenants of the Purchaser</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transfers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Convertible Promissory Notes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>6.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Termination</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD>7.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Miscellaneous</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">California Corporate Securities Law</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Survival</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Successors and Assigns</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement; Amendment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices, etc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts; Facsimile</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Expenses</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Titles and Subtitles</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jury Trial</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jurisdiction; Venue</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Currency</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">EXHIBITS</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Promissory Note (First Note)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">B
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Promissory Note (Second Note)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Convertible Promissory Note (Third Note)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compliance Certificate</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">E
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment Representation Statement</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">F
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Legal Opinion</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-iii-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONVERTIBLE NOTE PURCHASE AGREEMENT</B><BR>
(US$15 Million Credit Facility)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This <B>Convertible Note Purchase Agreement </B>(the &#147;<B>Agreement</B>&#148;) is made as of August&nbsp;7,&nbsp;2006, by
and between Fluidigm Corporation, a California corporation (the &#147;<B>Company</B>&#148;), and Biomedical Sciences
Investment Fund Pte Ltd (&#147;<B>Purchaser</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Purchaser has agreed to purchase, pursuant to the terms of this Agreement and
upon the election of the Company, up to US$15,000,000 in aggregate principal of Convertible
Promissory Notes of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Purchaser has agreed that the Company may elect to sell to the Purchaser within
the time periods set forth herein, and the Purchaser has agreed to purchase should the Company so
elect, a Convertible Promissory Note in the principal amount of US$5,000,000 in substantially the
form attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<B>First Note</B>&#148;), the principal and interest on which
are convertible into shares of Series&nbsp;E Preferred Stock of the Company upon the happening of
certain events described in the First Note;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, provided that the First Note has converted (as set forth in the First Note), the
Purchaser has agreed that the Company may elect to sell to the Purchaser within the time periods
set forth herein, and Purchaser has agreed to purchase should the Company so elect, a second
Convertible Promissory Note of the Company in the principal amount of US$5,000,000, in
substantially the form attached hereto as <U>Exhibit&nbsp;B</U> (the &#147;<B>Second Note</B>&#148;), the principal and
interest on which are convertible into shares of Series&nbsp;E Preferred Stock of the Company upon the
happening of certain events as described in the Second Note; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, provided that the Second Note has converted (as set forth in the Second Note), the
Purchaser has agreed that the Company may elect to sell to the Purchaser within the time periods
set forth herein, and Purchaser has agreed to purchase should the Company so elect, a third
Convertible Promissory Note of the Company in the principal amount of US$5,000,000, in
substantially the form attached hereto as <U>Exhibit&nbsp;C</U> (the &#147;<B>Third Note</B>,&#148; and together with
the First Note and the Second Note, an &#147;<B>Additional Note</B>&#148; or the &#147;<B>Additional Notes</B>&#148;), the principal
and interest on which are convertible into shares of Series&nbsp;E Preferred Stock of the Company upon
the happening of certain events as described in the Third Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties hereby agree as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>The First Note</U>.&nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Authorization; Purchaser&#146;s Obligation to Purchase</U>.&nbsp; The Purchaser shall, at the
Company&#146;s election and in accordance with the procedures set forth in this Section&nbsp;1, purchase the
First Note. Such election shall indicate that the Company has authorized the sale and issuance of
the First Note in the principal amount of US$5,000,000, convertible (i)&nbsp;at the election of the
Purchaser, (ii)&nbsp;upon the achievement of certain Milestones (as set forth in the First Note), or
(iii)&nbsp;as otherwise as set forth in the First Note into shares of Series&nbsp;E Preferred Stock of the
Company at a conversion price of US$3.60 per share. Shares of Series&nbsp;E Preferred Stock together
with any other securities which may be issued upon conversion of any of the Additional Notes are
referred to herein as the &#147;<B>Note Shares</B>.&#148; The Additional Notes, the Note Shares and securities of
the Company issued or issuable upon conversion thereof are referred to herein as the &#147;<B>Securities</B>.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>First Note Procedure</U>.&nbsp; Subject to Section&nbsp;1.1, the Company may exercise its option to
require the Purchaser to purchase the First Note at any time on or before September&nbsp;30, 2006 by
giving Purchaser written notice thereof (the &#147;<B>First Note Election Notice</B>&#148;). The First Note
Election Notice shall state that the Company has elected to require the Purchaser to purchase the
First Note and shall indicate the date, time, and location of the closing of the purchase and sale
of the First Note (the &#147;<B>First Note Closing</B>&#148;), which shall occur no sooner than 14&nbsp;days or later
than 25&nbsp;days after the date of the First Note Election Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <U>Closing of First Note Purchase</U>.&nbsp; At the First Note Closing, the Company shall deliver
to the Purchaser the First Note and a duly executed Compliance Certificate in the form attached
hereto as <U>Exhibit&nbsp;D</U> (the &#147;<B>Compliance Certificate</B>&#148;). At the First Note Closing, the
Purchaser shall deliver to the Company (i)&nbsp;the aggregate principal amount of the First Note
totalling US$5,000,000 by check or wire transfer and (ii)&nbsp;the Investment Representation Statement,
duly executed by Purchaser, in the form attached hereto as <U>Exhibit&nbsp;E</U> (the &#147;<B>Investment
Representation Statement</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <U>Effect of Change in Series&nbsp;E Preferred Stock</U>.&nbsp; The form of the First Note will be
modified upon the happening of certain events as set forth in Section&nbsp;5.2(d).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Representations and Warranties of the Company</U>.&nbsp; Except as set forth in the Schedule of
Exceptions dated of even date hereof and separately delivered to Purchaser contemporaneously with
the execution and delivery of this Agreement (the
&#147;<B>Schedule of Exceptions</B>&#148;), the Company represents and warrants to Purchaser as of the date
hereof as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Organization, Good Standing and Qualification</U>.&nbsp; The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of California and has
all requisite corporate power and authority to carry on its business as currently conducted. The
Company is duly qualified to transact business and is in good standing in each jurisdiction in
which the failure to so qualify, individually or in the aggregate, would have a material adverse
effect on its business (as now conducted), properties, or financial condition.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Corporate Power</U>.&nbsp; The Company has all requisite legal and corporate power and
authority to execute and deliver this Agreement and to carry out and perform its obligations under
the terms of this Agreement. Subject to the corporate authorization of and election to sell and
issue any of the Additional Notes hereunder, the Company will have all requisite legal and
corporate power and authority to (i)&nbsp;sell and issue the Additional Notes hereunder and (ii)&nbsp;issue
the Series&nbsp;E Preferred Stock initially issuable upon conversion of any of the Additional Notes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Subsidiaries</U>.&nbsp; The Company does not presently own or control, directly or indirectly,
any interest in any other corporation, association, or other business entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Capitalization</U>.&nbsp; The authorized capital stock of the Company consists of 77,857,144
shares of Common Stock (&#147;<B>Common Stock</B>&#148;), of which 9,422,895 shares are issued and outstanding and
51,687,948 shares of Preferred Stock (&#147;<B>Preferred Stock</B>&#148;), 2,727,273 of which are designated
Series&nbsp;A Preferred Stock of which 2,727,273 are outstanding, 6,460,675 of which are designated
Series&nbsp;B Preferred Stock of which 6,460,675 are outstanding, 17,000,000 of which are designated
Series&nbsp;C Preferred Stock, 16,364,832 of which are issued and outstanding, 15,500,000 of which are
designated Series&nbsp;D Preferred Stock, 12,196,191 of which are issued and outstanding, and 10,000,000
of which are designated Series&nbsp;E Preferred Stock, 1,250,000 of which are issued and outstanding.
All such issued and outstanding shares have been duly authorized and validly issued in compliance
with applicable laws, and are fully paid and nonassessable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the sale and issuance of any Additional Notes, the Company will have
reserved 4,166,667 shares of Series&nbsp;E Preferred Stock for issuance upon conversion of such
Additional Note (the &#147;<B>Conversion Shares</B>&#148;) and 4,166,667 shares of Common Stock for issuance upon
conversion of such Conversion Shares. As of the date of this Agreement, the Company has reserved:
(i)&nbsp;10,000,000 shares of Common Stock for issuance upon conversion of the outstanding shares of
Series&nbsp;E Preferred Stock; (ii)&nbsp;12,196,191 shares of Common Stock for issuance upon
conversion of the outstanding shares of Series&nbsp;D Preferred Stock; (iii)&nbsp;408,928 shares of
Series&nbsp;D Preferred Stock for issuance upon exercise of outstanding warrants and 408,928 shares of
Common Stock for issuance upon conversion of such Series&nbsp;D Preferred Stock; (iv)&nbsp;16,364,832 shares
of Common Stock for issuance upon conversion of the outstanding shares of Series&nbsp;C Preferred Stock;
(v)&nbsp;294,868 shares of Series&nbsp;C Preferred Stock for issuance upon exercise of outstanding warrants
and 294,868 shares of Common Stock for issuance upon conversion of such Series&nbsp;C Preferred Stock;
(vi)&nbsp;6,460,675 shares of Common Stock for issuance upon conversion of the outstanding Series&nbsp;B
Preferred Stock; (vii)&nbsp;2,727,273 shares of Common Stock for issuance upon conversion of the
outstanding Series&nbsp;A Preferred Stock; and (viii)&nbsp;an aggregate of 10,800,000 shares of Common Stock
for issuance to employees and consultants of the Company pursuant to the Company&#146;s 1999 Stock Plan,
pursuant to which options to purchase 5,276,828 shares are granted and outstanding and 1,727,039
shares are available for future grant. Other than with respect to the shares reserved for issuance
in the preceding sentence, or as set forth in this Agreement, the Investor Rights Agreement (as
defined below) or the Voting Agreement (as defined below), there are no outstanding rights,
options, warrants, conversion rights, preemptive rights, rights of first refusal or similar rights
for the purchase or acquisition from the Company of any securities of the Company. There are no
outstanding obligations of the Company to repurchase or redeem any of its securities.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as contemplated in the Eighth Amended and Restated Investor Rights Agreement dated
June&nbsp;13, 2006 (the &#147;<B>Investor Rights Agreement</B>&#148;), the Company has not granted or agreed to grant any
registration rights, including piggyback rights, to any person or entity. Except as contemplated
in the Second Amended and Restated Voting Agreement dated August&nbsp;16, 2005 (the &#147;<B>Voting Agreement</B>&#148;),
the Company is not a party or subject to any agreement or understanding, and to the Company&#146;s
knowledge, there is no agreement or understanding between any person or entities, which relates to
the voting or the giving of written consents with respect to any security of the Company or by a
director of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Authorization</U>.&nbsp; All corporate action on the part of the Company, its officers,
directors and shareholders necessary for the authorization, execution and delivery of this
Agreement, the performance of all obligations of the Company under this Agreement has been taken,
subject to corporate authorization of any election to require the Purchasers to purchase Additional
Notes pursuant to this Agreement. This Agreement constitutes a valid and legally binding
obligation of the Company, enforceable in accordance with its terms, subject to: (i)&nbsp;judicial
principles limiting the availability of specific performance, injunctive relief, and other
equitable remedies; and (ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium or other similar
laws now or hereafter in effect generally relating to or affecting creditors&#146; rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Valid Issuance of Note and Conversion Shares</U>.&nbsp; Any Additional Note that is purchased
by the Purchaser hereunder, when issued, sold and delivered in accordance with the terms of this
Agreement, will be free of restrictions on transfer other than restrictions on transfer under this
Agreement, such Additional Note, and the Investor
Rights Agreement and under applicable state and federal securities laws as in effect on the
date of issuance of such Additional Note. Any Conversion Shares (and the shares of Common Stock
issuable upon conversion thereof) will have been duly and validly reserved for issuance, and, upon
issuance in accordance with the terms of the applicable Additional Note and the Amended and
Restated Articles of Incorporation of the Company as amended through the date of issuance of such
Additional Note (the &#147;<B>Restated Articles</B>&#148;), will be duly and validly issued, fully paid, and
nonassessable and will be free of restrictions on transfer other than restrictions on transfer
under this Agreement, the terms of the applicable Additional Note, and the Investor Rights
Agreement and under applicable state and federal securities laws as in effect on the date of
issuance of such Additional Note. The Conversion Shares (and the shares of Common Stock issuable
upon conversion thereof) may be issued without any registration or qualification under state and
federal securities laws as such laws are in effect as of the date of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <U>Governmental Consents</U>.&nbsp; As of the date of this Agreement, no consent, approval, order
or authorization of, or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority on the part of the Company would be required in
connection with the offer, sale or issuance of any of the Additional Notes or the Conversion Shares
(and the shares of Common Stock issuable upon conversion thereof) or the consummation of any other
transaction contemplated hereby, except in connection with the sale and issuance of Additional
Notes for filings that may be required pursuant to applicable federal and state securities laws and
blue sky laws, which filings, the Company covenants to complete within the required statutory
period.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <U>Litigation</U>.&nbsp; There is no action, suit, proceeding or investigation pending or, to the
Company&#146;s knowledge, currently threatened against the Company before any court, administrative
agency or other governmental body which questions the validity of this Agreement or the Investor
Rights Agreement or the right of the Company to enter into any of them, or to consummate the
transactions contemplated hereby or thereby, or which could result, either individually or in the
aggregate, in any material adverse change in the condition (financial or otherwise), business,
property, assets or liabilities of the Company, nor is the Company aware that there is any basis
for the foregoing. The Company is not a party or subject to, and none of its assets is bound by,
the provisions of any order, writ, injunction, judgment or decree of any court or government agency
or instrumentality. There is no action, suit, proceeding or investigation by or involving the
Company currently pending or that the Company intends to initiate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <U>Employees</U>.&nbsp; Each employee of the Company has executed a proprietary information and
invention assignment agreement substantially in the form or forms made available to the Purchaser.
To the Company&#146;s knowledge, no officer or key employee is in violation of any prior employee
contract or proprietary information agreement. No employees of the Company are represented by any
labor union or covered by any collective bargaining agreement. There is no pending or, to the
Company&#146;s
knowledge, threatened labor dispute involving the Company and any group of its employees. The
Company is not aware that any officer or key employee intends to terminate his or her employment
with the Company within the six months after the date of this Agreement. The Company does not have
a present intention to terminate the employment of any officer or key employee. Each officer and
key employee is devoting 100% of his or her business time to the conduct of the business of the
Company. The Company is not aware that any officer or key employee intends to work less than full
time during the six months after the date of this Agreement. Subject to general principles related
to wrongful termination of employees, the employment of each officer and employee of the Company is
terminable at will.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 <U>Patents and Other Intangible Assets</U>.&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company owns, or is licensed or otherwise has the legally enforceable right to use,
all copyrights, domain names, maskworks, applications for the issuance or registration of any of
the foregoing, trade secrets, confidential or proprietary know-how, data and information, ideas,
inventions, designs, developments, algorithms, processes, schematics, techniques, computer
programs, applications and other software, works of authorship, creative effort and, to the
Company&#146;s knowledge after such investigation as the Company deemed reasonable, patents, patent
applications, trademarks (including service marks and design marks) and applications therefor,
tradenames (all of the foregoing generically, &#147;<B>Intellectual Property Rights</B>&#148;) utilized in, or
necessary for, its business as now conducted (collectively, the &#147;<B>Company Intellectual Property</B>&#148;)
without infringing upon the right of any person, corporation or other entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Section&nbsp;2.10 of the Schedule of Exceptions lists (i)&nbsp;all patents and patent applications
and all registered and unregistered trademarks, trade names, copyrights and maskworks and
registered domain names included in the Company Intellectual Property, including the jurisdictions
in which each such intellectual property right has been issued or registered or in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which any
application for such issuance or registration has been filed, (ii)&nbsp;all licenses, sublicenses,
collaborations and other agreements (or options for any of the foregoing) to which the Company is a
party and pursuant to which any person, corporation or other entity is authorized to use any of the
Company Intellectual Property, and (iii)&nbsp;all licenses, sublicenses, collaborations and other
agreements (or options for any of the foregoing) to which the Company is a party and pursuant to
which the Company is authorized to use any Intellectual Property Right of any third party (other
than standard licenses for commercially available software). Each of the agreements in (ii)&nbsp;and
(iii)&nbsp;above remain in full force and effect and, to the Company&#146;s knowledge, no party to any such
agreement is in material breach or default under such agreement, and the Company is not aware of
any act or failure to act by a party which would constitute a material breach or default under any
such agreement, give rise to a right of the licensor to terminate any such agreement or otherwise
result in termination of, or suspension or loss of exclusive rights under, any such agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To the Company&#146;s knowledge, the Company has not infringed or misappropriated any
Intellectual Property Right of any other person, corporation or other entity. The Company has not
received any communication or otherwise received any information alleging any
such conduct by the Company or asserting a claim by any third party to the ownership of, or
right to use, any of the Company Intellectual Property, and the Company does not know of any basis
for any such claim. The Company is not aware of any action, suit, proceeding or investigation
pending or currently threatened against the Company (or any third party owner or licensor of rights
to the Company of any of the Company Intellectual Property) which would have a material impact on
the Company&#146;s ownership of or exclusive or co-exclusive rights to use, the Company Intellectual
Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not aware that any of its employees is obligated under any agreement, or
subject to any judgment, decree or order of any court or administrative agency, that would
materially interfere with his or her ability to fully and freely perform their duties to the
Company or that would conflict with the Company&#146;s business. To the Company&#146;s knowledge, neither
the execution and delivery of this Agreement nor the issuance of any of the Additional Notes nor
the carrying on of the Company&#146;s business by the employees of the Company, will conflict with or
result in a material breach of the terms, conditions, or provisions of, or constitute a default
under, any agreement under which any such employee is now obligated. The Company does not utilize,
and will not be required to utilize, any invention, development or work of authorship of any of its
employees (or persons it currently intends to hire) made prior to their employment by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except as described in Schedule&nbsp;2.10, (i)&nbsp;the Company is not obligated, or under any
liability whatsoever to make any payments by way of royalties, fees or otherwise, to any owner or
licensor of, or other claimant to, any Company Intellectual Property, and (ii)&nbsp;the Company is not a
party to any agreement concerning the Company Intellectual Property or any other Intellectual
Property Right used or to be used by the Company in its business as conducted. No founder,
director, officer or employee of the Company, or, to the Company&#146;s knowledge, no shareholder of the
Company has any interest in the Company Intellectual Property.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except with respect to any rights granted under the agreements described in Schedule&nbsp;2.10,
the Company owns exclusively all rights arising from or associated with the research and
development efforts of the Company, its founders, employees and independent contractors relating to
the Company&#146;s business as now conducted, and all such rights form part of the Company Intellectual
Property. The Company has secured valid written assignments from all employees and independent
contractors who contributed to the creation or development of any of the Company Intellectual
Property of the rights to such contributions that the Company does not already own by operation of
law. The Company has not received notice of any claim being asserted by any current or former
employee, independent contractor or other third party to the ownership, of or right to use, any of
the Company Intellectual Property, or challenging or questioning the validity of any of the Company
Intellectual Property, and the Company is not aware of any basis for any such claim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The Company has taken reasonable steps to protect and preserve the confidentiality of all
material trade secrets included in Company Intellectual Property not otherwise protected by patents
or copyright (&#147;<B>Confidential Information</B>&#148;). All disclosure of Confidential Information to a third
party has been pursuant to the terms of a written confidentiality or non-disclosure agreement
between the Company and such third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;The Company hereby represents and warrants that the data, written and oral reports and
other representations and information that the Company provided to its investors (or their counsel)
pertaining to the Company Intellectual Property, when taken as a whole, were truthful and, to the
Company&#146;s knowledge, accurate in all material respects, and there was no omission therefrom which
made such information misleading, or incomplete in any material way.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 <U>Compliance with Other Instruments</U>.&nbsp; The Company is not in violation or default of any
provision of its Articles of Incorporation or Bylaws, each as amended and in effect on and as of
the date hereof. The Company is not in violation or default of any material provision of any
instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order or
obligation to which it is a party or by which it or any of its properties or assets are bound or,
to the best of its knowledge, of any provision of any federal, state or local statute, rule or
governmental regulation. The execution, delivery and performance of and compliance with this
Agreement, the Investor Rights Agreement and the Voting Agreement and the issuance and sale of the
Additional Notes, will not result in any such violation, be in conflict with or constitute, with or
without the passage of time or giving of notice, a default under any such provision, license,
indenture, instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order
or obligation; or require any consent or waiver under any such provision, license, indenture,
instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order or
obligation (other than any consents or waivers that have been obtained); or result in the creation
of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the
Company pursuant to any such provision, license, indenture, instrument, mortgage, deed of trust,
loan, contract, commitment, judgment, decree, order or obligation.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 <U>Permits</U>.&nbsp; The Company has all franchises, permits, licenses, and any similar authority
necessary for the conduct of its business as now being conducted by it. The Company is not in
default in any material respect under any of such franchises, permits, licenses, or other similar
authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13 <U>Environmental and Safety Laws</U>.&nbsp; To its knowledge, the Company is not in violation of
any applicable statute, law, or regulation relating to the environment or occupational health and
safety, and to its knowledge, no material expenditures by the Company are or will be required in
order to comply with any such existing statute, law, or regulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14 <U>Title to Property and Assets</U>.&nbsp; The Company has good and marketable title to all of its
properties and assets free and clear of all pledges, mortgages, liens, security interests, charges
and encumbrances, except liens for current taxes and assessments not yet due and possible minor
liens and encumbrances which do not,
in any case, individually or in the aggregate, materially detract from the value of the
property subject thereto or materially impair the ownership or use of said property or assets, or
the operations of the Company. With respect to the property and assets it leases, the Company is
in compliance with such leases and, to the best of its knowledge, holds a valid leasehold interest
free of all liens, claims or encumbrances. The Company&#146;s properties and assets are in good
condition and repair in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15 <U>Agreements; Action</U>.&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except for agreements contemplated by this Agreement, there are no agreements,
understandings or proposed transactions between the Company and any of its officers, directors,
affiliates, or any affiliate thereof other than standard option grants and stock purchase
agreements entered into prior to the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There are no agreements, understandings, instruments, contracts, proposed transactions,
judgments, orders, writs or decrees to which the Company is a party or by which it is bound that
may involve (i)&nbsp;obligations (contingent or otherwise) of, or payments by the Company in excess of,
US$100,000, other than in the ordinary course of business, (ii)&nbsp;the license of any patent,
copyright, trade secret or other proprietary right to or from the Company other than standard
commercial software licenses, (iii)&nbsp;provisions restricting or adversely affecting the development,
manufacture or distribution of the Company&#146;s products or services, or (iv)&nbsp;indemnification by the
Company with respect to infringements of proprietary rights other than indemnifications entered
into in the ordinary course of business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For the purposes of subsection&nbsp;(b) above, all indebtedness, liabilities, agreements,
understandings, instruments, contracts and proposed transactions involving the same person or
entity (including persons or entities the Company has reason to believe are affiliated therewith)
shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such
subsection.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company is not a party to and is not bound by any contract, agreement or instrument,
or subject to any restriction under its Restated Articles or its Bylaws that adversely affects its
business as now conducted, its properties or its financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company is not a guarantor or indemnitor of any indebtedness of any other person or
entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Company has not engaged in the past three months in any discussion (i)&nbsp;with any
representative of any entity or entities regarding the merger of the Company with or into any such
entity or entities or any affiliate thereof, (ii)&nbsp;with any representative of any entity or any
individual regarding the sale, conveyance or disposition of all or substantially all of the assets
of the Company or a transaction or series of related transactions in which more than fifty
percent (50%) of the voting power of the Company would be disposed of, or (iii)&nbsp;regarding any
other form of liquidation, dissolution or winding up of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16 <U>Financial Statements</U>.&nbsp; The Company has fully provided the Purchaser with all the
information that the Purchaser has requested for deciding whether to enter into this Agreement and
to acquire the Additional Notes. The Company has made available to Purchaser its audited balance
sheets dated as of December&nbsp;31, 2005 and the audited statement of operations for the fiscal year
then ended, its unaudited balance sheets as of March&nbsp;31, 2006, and its unaudited statement of
operations and cash flow statement covering the three month period then ended (collectively, the
&#147;<B>Financial Statements</B>&#148;). The Financial Statements are complete and correct in all material
respects and have been prepared in accordance with generally accepted accounting principles applied
on a consistent basis throughout the periods indicated. The Financial Statements accurately set
out and describe the financial condition and operating results of the Company as of the date, and
during the periods, indicated therein. Except as set forth in the Financial Statements, the
Company has no material liabilities, contingent or otherwise, other than (i)&nbsp;liabilities incurred
in the ordinary course of business subsequent to March&nbsp;31, 2006 and (ii)&nbsp;obligations under
contracts and commitments incurred in the ordinary course of business and not required under
generally accepted accounting principles to be reflected in the Financial Statements, which, in
both cases, individually or in the aggregate are not material to the financial condition or
operating results of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17 <U>Changes</U>.&nbsp; Since March&nbsp;31, 2006:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the Company has not (i)&nbsp;declared or paid any dividends or authorized or made any
distribution upon or with respect to any class or series of its capital stock, (ii)&nbsp;incurred any
indebtedness for money borrowed or any other liabilities outside the ordinary course of its
business individually in excess of US$100,000 or, in the case of indebtedness and/or liabilities
individually less than US$100,000, in excess of US$200,000 in the aggregate, (iii)&nbsp;made any loans
or advances to any person, other than ordinary advances for reimbursable businesses expenses,
(iv)&nbsp;sold, exchanged, assigned, transferred, licensed or otherwise disposed of any of its assets or
rights (including Company Intellectual Property), other than the sale of its inventory in the
ordinary course of business, (v)&nbsp;waived or compromised a valuable right or a material debt owed to
it, (vi)&nbsp;materially changed any compensation arrangement or agreement with any employee, officer,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">director or shareholder, or (vii)&nbsp;arranged or committed to do any of the things described in this
subsection&nbsp;(a); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;there has not been (i)&nbsp;a loss of, or a material order cancellation by, any major customer
of the Company, (ii)&nbsp;any damage, destruction or loss, whether or not covered by insurance,
materially and adversely affecting the business, properties, or financial condition of the Company,
(iii)&nbsp;any change in the assets, liabilities, financial condition or operating results of the
Company from that reflected in the Financial Statements, except changes in the ordinary course of
business that have not been, in the aggregate, materially adverse, (iv)&nbsp;any resignation or
termination
of any officer or key employee of the Company, and the Company is not aware of the impending
resignation or termination of employment of any such officer, or (v)&nbsp;to the best of the Company&#146;s
knowledge, any other event or condition of any character that would materially and adversely affect
the business, properties, or financial condition of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18 <U>Brokers or Finders</U>.&nbsp; The Company has not agreed to incur, directly or indirectly, any
liability for brokerage or finders&#146; fees, agents&#146; commissions or other similar charges in
connection with this Agreement or any of the transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19 <U>Employee Benefit Plans</U>.&nbsp; The Company does not have any Employee Benefit Plan as
defined in the Employee Retirement Income Security Act of 1974 other than the Company&#146;s 401(k)
Plan. The Company is in material compliance with the terms of the Company&#146;s 401(k) Plan and has
not received notice of any material increase in the costs of such plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20 <U>Tax Matters</U>.&nbsp; The Company has filed all tax returns and reports as required by law.
These returns and reports are true and correct in all material respects. The Company has paid all
taxes and other assessments due. The Company has not elected pursuant to the Code, to be treated
as a Subchapter S corporation or a collapsible corporation pursuant to Section&nbsp;1362(a) or
Section&nbsp;341(f) of the Code, nor has it made any other elections pursuant to the Code (other than
elections that relate solely to methods of accounting, depreciation or amortization) that would
have a material effect on the business, properties or condition (financial or otherwise) of the
Company. None of the Company&#146;s tax returns have ever been audited by any governmental authorities.
The Company has withheld or collected from each payment made to its employees the amount of all
taxes (including without limitation, federal income taxes, Federal Insurance Contribution Act taxes
and Federal Unemployment Tax Act taxes) required to be withheld or collected therefrom, and has
paid the same to the proper tax receiving officers or authorized depositories.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21 <U>Insurance</U>.&nbsp; The Company has in full force and effect fire and casualty insurance
policies, with extended coverage, sufficient in amount (subject to reasonable deductibles) to allow
it to replace any of its properties that might be damaged or destroyed. The Company has obtained
term life insurance payable to the Company on the lives of Stephen Quake and Gajus Worthington in
the amount of US$500,000. The Company has in full force and effect directors and officers
liability insurance, covering its directors, with aggregate coverage in the amount of US$2,000,000.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.22 <U>Corporate Documents</U>.&nbsp; The Restated Articles and By-Laws of the Company are in the form made available to the
Purchaser. The copy of the minute books of the Company made available to Purchaser&#146;s counsel
contains true and correct minutes of all meetings of directors (including any committees thereof)
and shareholders and all actions by written consent taken without a meeting by the directors and
shareholders since December&nbsp;18, 2003.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.23 <U>Disclosure</U>.&nbsp; The Company has fully provided Purchaser with all the information which
Purchaser has requested in connection with the purchase of the Additional Notes hereunder, as well
as all information which the Company in its judgment believes is reasonably necessary to enable
Purchaser to make a decision as to whether to enter into this Agreement and to invest in the
Company. Neither this Agreement with the Exhibits hereto, nor any other statements, certificates
or documents made or delivered in connection herewith or therewith, contains any untrue statement
of a material fact or omits to state a material fact necessary to make the statements herein or
therein not misleading in light of the circumstances under which they were made. The financial
projections made available to the Purchaser (the &#147;<B>Projections</B>&#148;) were prepared in good faith and
based upon assumptions that the Company believes are reasonable, and represent the Company&#146;s good
faith estimate of its future plans and results; provided however, that the Company does not
represent or warrant that it will achieve any of the Projections.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.24 <U>Offering</U>.&nbsp; Subject in part to the truth and accuracy of Purchaser&#146;s representations
set forth in this Agreement, the offer, sale and issuance of the Additional Notes as contemplated
by this Agreement would be, if issued as of this date of this Agreement, exempt from the
registration requirements of the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), and
neither the Company nor any authorized agent acting on its behalf will take any action hereafter
that would cause the loss of such exemption.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.25 <U>Returns and Complaints</U>.&nbsp; The Company has not received customer complaints concerning
alleged defects in the design of its products that, if true, would have, individually or in the
aggregate, a material adverse effect on its business, properties, or financial condition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Representations and Warranties of the Purchasers</U>.&nbsp; Purchaser hereby represents,
warrants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Experience</U>.&nbsp; Purchaser is experienced in evaluating start-up companies such as the
Company, is able to evaluate and represent its own interests in transactions such as the one
contemplated by this Agreement, has such knowledge and experience in financial and business matters
such that
Purchaser is capable of evaluating the merits and risks of Purchaser&#146;s investment in the
Company, and has the ability to bear the economic risks of its investment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Investment</U>.&nbsp; Purchaser is acquiring and will acquire, the Securities, for investment
for Purchaser&#146;s own account and not with the view to, or for resale in connection with, any
distribution thereof. Purchaser understands that the Securities have not been registered under the
Securities Act by reason of a specific exemption from the registration provisions of the Securities
Act, which depends upon, among other things, the bona fide nature of Purchaser&#146;s investment intent
as expressed herein. Purchaser further represents that it does not have any contract, undertaking,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">agreement or arrangement with any person to sell, transfer or grant participation to any third
person with respect to any of the Securities other than a transfer not involving a change of
beneficial ownership. Purchaser understands and acknowledges that the offering of the Securities
pursuant to this Agreement will not be registered under the Securities Act on the ground that the
sale provided for in this Agreement is exempt from the registration requirements of the Securities
Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Rule&nbsp;144</U>.&nbsp; Purchaser acknowledges that the Securities must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is
available. Purchaser is aware of the provisions of Rule&nbsp;144 promulgated under the Securities Act,
which permit limited resale of shares purchased in a private placement subject to the satisfaction
of certain conditions. Purchaser covenants that, in the absence of an effective registration
statement covering the securities in question, Purchaser will sell, transfer, or otherwise dispose
of the Securities only in accordance with applicable securities laws and in a manner consistent
with Purchaser&#146;s representations and covenants set forth in this Agreement and the applicable
Additional Note. In connection therewith, Purchaser acknowledges that the Company will make a
notation on its stock books regarding the restrictions on transfer set forth in this Agreement and
the applicable Additional Note and will transfer securities on the books of the Company only to the
extent not inconsistent therewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>No Public Market</U>.&nbsp; Purchaser understands that no public market now exists for any of
the securities issued by the Company, and that the Company has made no assurances that a public
market will ever exist for the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>Access to Data</U>.&nbsp; Purchaser has received and reviewed information about the Company and
has had an opportunity to discuss the Company&#146;s business, management and financial affairs with its
management and to review the Company&#146;s facilities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.6 <U>Authorization</U>.&nbsp; This Agreement when executed and delivered by the Purchaser will constitute a valid and
legally binding obligation of the Purchaser, enforceable against the Purchaser in accordance with
its terms, subject to: (i)&nbsp;judicial principles respecting election of remedies or limiting the
availability of specific performance, injunctive relief, and other equitable remedies; and
(ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in
effect generally relating to or affecting creditors&#146; rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.7 <U>Accredited Investor</U>.&nbsp; Purchaser acknowledges that it is an &#147;accredited investor&#148; as
defined in Rule&nbsp;501 of Regulation&nbsp;D as promulgated by the United States Securities and Exchange
Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act and shall submit to the Company such further
assurances of such status as may be reasonably requested by the Company. The principal address of
such Purchaser is as set forth on the signature page hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8 <U>Public Solicitation</U>.&nbsp; Purchaser knows of no public solicitation or advertisement of an
offer in connection with the proposed issuance and sale of the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 <U>Tax Advisors</U>.&nbsp; Purchaser has reviewed with its own tax advisors the tax consequences
of the purchase of the Securities and the transactions contemplated by this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Purchaser
is relying solely on such advisors and not on any statements or representations of the Company or
any of its agents and understands that Purchaser (and not the Company) shall be responsible for the
Purchaser&#146;s own tax liability that may arise as a result of the Purchase of the Securities or the
transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 <U>Purchaser Counsel</U>.&nbsp; Purchaser acknowledges that it has had the opportunity to review
this Agreement and the exhibits hereto and the transactions contemplated by this Agreement with its
own legal counsel. Purchaser is relying solely on such counsel and not on any statements or
representations of the Company or any of its agents for legal advice with respect to this
investment or the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.11 <U>Brokers or Finders</U>.&nbsp; The Company has not incurred and will not incur, directly or
indirectly, as a result of any action taken by such Purchaser, any liability for brokerage or
finders&#146; fees or agents&#146; commissions or any similar changes in connection with this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.12 <U>Non-United States Persons</U>.&nbsp; Purchaser hereby represents that Purchaser is satisfied as to the full observance of the
laws of Purchaser&#146;s jurisdiction in connection with any invitation to subscribe for the Securities
and the Additional Notes (and securities issuable upon conversion thereof) or any use of this
Agreement, including (i)&nbsp;the legal requirements within Purchaser&#146;s jurisdiction for the purchase of
the Securities and the Additional Notes (and securities issuable upon conversion thereof), (ii)&nbsp;any
foreign exchange restrictions applicable to such purchase, (iii)&nbsp;any governmental or other consents
that may need to be obtained and (iv)&nbsp;the income tax and other tax consequences, if any, that may
be relevant to the purchase, holding, redemption, sale or transfer of such securities. Purchaser&#146;s
subscription and payment for, and Purchaser&#146;s continued beneficial ownership of, the Securities and
the Additional Notes (and securities issuable on conversion thereof) will not violate any
applicable securities or other laws of Purchaser&#146;s jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Covenants of the Company</U>.&nbsp; The Company hereby covenants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Subsidiary Business Plan</U>.&nbsp; The Company has incorporated a wholly owned (either
directly or indirectly through another subsidiary of the Company) subsidiary of the Company in
Singapore (the &#147;<B>Subsidiary</B>&#148;). Unless prohibited by applicable law, or unless the Company and the
Purchaser otherwise agree in writing, from and after incorporation of the Subsidiary, the Company
shall cause the Subsidiary to use commercially reasonable efforts to conduct, its activities
materially in accordance with the provisions of the business plan as established by the Board of
Directors of the Subsidiary and described to the Purchaser, including the Subsidiary&#146;s plans with
respect to the BioMark II project, as may be modified as set forth in this Section&nbsp;4.1 (the
&#147;<B>Subsidiary Business Plan</B>&#148;); <U>provided</U>, <U>however</U>, that the Company and the Subsidiary
shall have no such obligation in the event the Subsidiary does not receive a grant under the
Singapore Research Incentive Scheme for Companies (&#147;<B>RISC</B>&#148;) and tax incentives from the Economic
Development Board of Singapore (the &#147;<B>EDB</B>&#148;) consistent with the application submitted by the Company
to the EDB. Notwithstanding any provision in this Agreement to the contrary, the Company and
Purchaser agree that the Subsidiary Business Plan may only be modified by the Board of Directors of
the Subsidiary.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Subsidiary Board of Directors</U>.&nbsp; Unless the Purchaser or its affiliates (as such term
is defined under Rule&nbsp;12b-2 promulgated by the Commission under the Securities Exchange Act of
1934, as amended) shall fail to hold 500,000 shares of the Company&#146;s Common Stock (on an as
converted basis), the Company agrees that it will vote the voting securities of the Subsidiary now
or hereafter held by the Company in such a manner as may be necessary to elect a nominee of
Purchaser to the Board of Directors of the Subsidiary (the &#147;<B>Nominee</B>&#148;). The Purchaser may notify
the Company in writing of an intention to remove from the Subsidiary&#146;s Board of Directors any
incumbent Nominee or notify the Company in writing of an intention to select a new Nominee. In
such event the Company shall take reasonable actions necessary to facilitate such removal and
election of the new Nominee to the Board of Directors of the Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Affirmative Covenants</U>.&nbsp; So long as any of the Additional Notes (if issued) shall
remain unpaid or unconverted or the Purchaser shall have any obligation to purchase any of the
Additional Notes hereunder, the Company agrees that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Preservation of Existence</U>.&nbsp; It will maintain and preserve, through itself or any
successor to its business, its corporate existence and its rights to transact business and will
maintain and preserve, through itself or any successor to its business, such other rights,
franchises and privileges as it may in good faith determine necessary or desirable in the normal
course of its business and operations and the ownership of its material properties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Payment of Taxes</U>.&nbsp; It will pay and discharge all taxes, fees, assessments and
governmental charges or levies imposed upon it or upon its properties or assets prior to the date
on which material penalties attach thereto, and all lawful claims for labor, materials and supplies
which, if unpaid, might become a material lien upon any properties or assets of the Company, except
to the extent such taxes, fees, assessments or governmental charges or levies, or such claims, are
being contested in good faith by appropriate proceedings and are adequately reserved against in
accordance with generally accepted accounting principles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Compliance with Laws</U>.&nbsp; It will comply in all material respects with the requirements
of all applicable laws, rules, regulations and orders of any governmental authority and the terms
of any material indenture, contract or other instrument to which it may be a party or under which
it or its properties may be bound, except to the extent failure to so comply would not have a
material adverse effect on the Company&#146;s business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Maintenance of Properties</U>.&nbsp; It will use commercially reasonable efforts to maintain
and preserve all of its material properties, as it may in good faith determine to be necessary or
useful in the proper conduct of its business, in good working order and condition in accordance
with the general practice of other corporations of similar character and size, ordinary wear and
tear accepted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <U>Government Authority</U>.&nbsp; It will use commercially reasonable efforts to obtain and
maintain all authorizations, consents, filings, exemptions, registrations and other governmental
approvals necessary in connection with the execution, delivery and performance of this Agreement,
the consummation of the transactions contemplated hereby or the operation and conduct of its
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">business and ownership of
its properties, except to the extent such failure to obtain or maintain would not have a
material adverse effect on the Company&#146;s business or financial condition or its ability to deliver
or perform under this Agreement or consummate the transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 <U>Opinion of Company Counsel</U>.&nbsp; Contemporaneously with the execution and delivery of this
Agreement, the Purchaser will receive from Wilson Sonsini Goodrich &#038; Rosati, P.C., counsel for the
Company, an opinion, dated as of the date of this Agreement, in the form attached hereto as
<U>Exhibit&nbsp;F</U> (the &#147;<B>Legal Opinion</B>&#148;), relating to the sale and issuance of the First Note
pursuant to this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Covenants of the Purchaser</U>.&nbsp; The Purchaser hereby covenants and agrees as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Transfers</U>.&nbsp; Purchaser shall be bound by the restrictions on transfer of the Securities
as set forth in the applicable Additional Note. Any permitted purchaser, assignee, transferee or
pledgee of securities issued on conversion of the applicable Additional Note shall agree in writing
to take and hold such securities subject to and upon the conditions set forth in the this
Agreement, the applicable Additional Note, the Investor Rights Agreement, and the Voting Agreement,
as each may be amended from time to time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Additional Convertible Promissory Notes</U>.&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Purchaser&#146;s Obligation to Purchase</U>. In the event that the First Note is converted
as set forth in the First Note, the Purchaser shall, at the Company&#146;s election, purchase the Second
Note in the principal amount of US$5,000,000 (the &#147;<B>Additional Note Principal</B>&#148;) in accordance with
Section&nbsp;5.2(b), and in the event the Second Note is converted as set forth in the Second Note, the
Purchaser shall, at the Company&#146;s election, purchase the Third Note in the principal amount equal
to the Additional Note Principal in accordance with Section&nbsp;5.2(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Additional Notes Procedure</U>. Subject to Section&nbsp;5.2(a), the Company may exercise
its option to require the Purchaser to purchase the (i)&nbsp;Second Note at any time within 45&nbsp;days
following the conversion of the First Note and (ii)&nbsp;the Third Note at any time within 45&nbsp;days
following the conversion of the Second Note by giving Purchaser written notice thereof (the
&#147;<B>Election Notice</B>&#148;). The Election Notice shall state that the Company has elected to require the
Purchaser to purchase the Second Note or the Third Note, as the case may require, and shall
indicate the date, time and location of the closing of the purchase and sale of the Second Note or
the Third Note, as the case may require (each, an &#147;<B>Additional Note Closing</B>&#148;), which shall occur no
sooner than 28&nbsp;days or later than 50&nbsp;days after the date of the Election Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Closing of Subsequent Purchase</U>. At an Additional Note Closing, the Company shall
deliver to the Purchaser the Second Note, or the Third Note, as the case may require, and a duly
executed Compliance Certificate in substantially the form attached hereto as <U>Exhibit&nbsp;D</U>. At
an Additional Note Closing, the Purchaser shall deliver to the Company (i)&nbsp;the Additional Note
Principal by check or wire transfer and (ii)&nbsp;the Investment Representation Statement, duly executed
by Purchaser.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Effect of Change in Series&nbsp;E Preferred Stock on Additional Notes</U>. The forms of
any then-unissued Additional Notes attached hereto as <U>Exhibits&nbsp;A, B, and C</U> shall be
modified upon the happening of certain events as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;In the event the Company should at any time prior to the First Note Closing or an
Additional Note Closing split or subdivide the outstanding shares of its Series&nbsp;E Preferred Stock
(or other securities that would be issuable upon conversion of any then-unissued Additional Note)
or issue additional shares of Series&nbsp;E Preferred Stock (or other securities that would be issuable
upon conversion of any then-unissued Additional Note) to the holders thereof as a dividend or make
any other distribution payable in additional shares of Series&nbsp;E Preferred Stock (or other
securities that would be issuable upon conversion of any then-unissued Additional Note) to the
holders thereof without payment of any consideration by such holder for the additional shares of
Series&nbsp;E Preferred Stock (or such other securities), then, as of the date of such dividend,
distribution, split or subdivision, the Conversion Price as set forth in the form of Additional
Note shall be appropriately decreased so that the number of shares of Series&nbsp;E Preferred Stock or
other securities issuable upon conversion of the Additional Note shall be increased in proportion
to such increase of outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable
upon conversion of the Additional Note, as applicable. If the number of shares of Series&nbsp;E
Preferred Stock (or other securities that would be issuable upon conversion of any then-unissued
Additional Note) outstanding at any time prior to the First Note Closing or an Additional Note
Closing is decreased by a combination of the outstanding shares of Series&nbsp;E Preferred Stock (or
such other securities), then, following the record date of such combination, the Conversion Price
set forth in the form of Additional Note shall be appropriately increased so that the number of
shares of Series&nbsp;E Preferred Stock or other securities issuable upon conversion of the Additional
Note shall be decreased in proportion to such decrease in outstanding shares of Series&nbsp;E Preferred
Stock or other securities issuable upon conversion of the Additional Note, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;In case of any reclassification, capital reorganization, or change in the Series&nbsp;E
Preferred Stock (or other securities that would be issuable upon conversion of any then-unissued
Additional Note) of the Company prior to the First Note Closing or an Additional Note Closing,
including conversion of such shares pursuant to the Company&#146;s Articles of Incorporation then in
effect (other than as a result of a split, subdivision, combination, or stock dividend provided for
in Section&nbsp;5.2(d)(i)), then appropriate adjustment shall be made to the Conversion Price and kind
of securities or other property issuable upon conversion of the form of Additional Note so that the
Additional Note if purchased shall be convertible upon the terms set forth therein as of the date
of such First Note Closing or Additional Note Closing, as applicable, into the kind and amount of
shares of stock and other securities and property receivable in connection
with such reclassification, reorganization, or change by a holder of the same number of shares
of Series&nbsp;E Preferred Stock or other securities as would be issuable on conversion of the
Additional Note as of the First Note Closing or such Additional Note Closing, as the case may
require.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;If at any time prior to the First Note Closing or an Additional Note Closing, as the
case may require, there shall be an acquisition of the Company by merger, consolidation or
otherwise where the Company is not the surviving corporation or as a result of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which all of the
outstanding capital stock of the Company is exchanged for capital stock of another corporation,
then, as a part of such acquisition, the Conversion Price and kind of securities issuable upon
conversion of the form of Additional Note shall be appropriately adjusted so that if such
Additional Note is purchased such Additional Note shall initially be convertible into, the number
of shares of stock or other securities or property of the surviving or successor corporation
resulting from such acquisition (or the corporation the capital stock of which is issued in
exchange for the capital stock of the Company), to which a holder of the securities that would be
issuable upon conversion of such Additional Note would have been entitled in such acquisition if
such Additional Note had been converted immediately before such acquisition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Transfer</U>. In the event that the Company issues any of the Additional Notes to the
Purchaser, each issued Additional Note and any securities issued on conversion thereof (including
securities issued on conversion of such securities) shall be subject to Section&nbsp;4.1 of this
Agreement, the Investment Representation Statement and the restrictions on transfer set forth in
such Additional Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Termination</U>.&nbsp; This Agreement shall terminate and shall be of no further force or
effect at such time as (i)&nbsp;the Company has paid to Purchaser in cash, by check or by wire transfer
the principal amount and accrued interest owing under all outstanding Additional Notes or all
outstanding Additional Notes have been converted into Note Shares in accordance with their Terms
and (ii)&nbsp;the Company has no further right to require the Purchaser to purchase any Additional Notes
pursuant to this Agreement; <U><I>provided</I></U>, <U><I>however</I></U>, that in the event of the conversion
of any of the Additional Notes, Section&nbsp;12 of each such Additional Note, and Section&nbsp;3, Section&nbsp;5.1
and Section&nbsp;8 hereof shall survive such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Miscellaneous</U>.&nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Governing Law</U>.&nbsp; This Agreement and the Additional Notes (if issued) shall in all
respects be governed by and construed and enforced in accordance with the laws of the State of
California, without reference to the conflicts of law provisions thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>California Corporate Securities Law</U>.&nbsp; THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED
WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH
SECURITIES OR THE PAYMENT AND RECEIPT OF ANY PART OF THE CONSIDERATION THEREFROM PRIOR TO SUCH
REGISTRATION IS UNLAWFUL UNLESS AN EXEMPTION FROM SUCH QUALIFICATION IS AVAILABLE. THE RIGHTS OF
ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON REGISTRATION BEING OBTAINED, UNLESS
THE SALE IS SO EXEMPT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Survival</U>.&nbsp; The representations, warranties, covenants and agreements made in this
Agreement shall survive any investigation made by any party hereto and the closing of the
transactions contemplated hereby.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Successors and Assigns</U>.&nbsp; Except as otherwise provided herein, the provisions hereof
shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties hereto; <I>provided</I>, <I>however</I>, that the covenants and agreements of the
Company set forth in Section&nbsp;4 and the obligation of the Purchaser to purchase the Additional Notes
as set forth in Section&nbsp;1.1 and Section&nbsp;5.2 shall not be assigned or transferred by Purchaser by
operation of law or otherwise without the prior written consent of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <U>Entire Agreement; Amendment</U>.&nbsp; This Agreement (including its exhibits), the Schedule of
Exceptions, the Business Plan, and the Additional Notes constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof, and
no party shall be liable or bound to any other party in any manner by any warranties,
representations, or covenants except as specifically set forth herein or therein. Except as
expressly provided herein, neither this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument signed by the party against whom
enforcement of any such amendment, waiver, discharge or termination is sought.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <U>Notices, etc</U>.&nbsp; Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally or by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Purchaser:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chu Swee Yeok</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:&nbsp;&nbsp;65-6336-2288</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:&nbsp;&nbsp;65-6334-8478</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Company:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California  94080</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:  Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:&nbsp;&nbsp;(650) 266-6000</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:&nbsp;&nbsp;(650) 871-7195</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich &#038; Rosati, P.C.</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, California  94304-1050</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention:  Ken Clark and Robert Kornegay</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel:&nbsp;&nbsp;(650) 493-9300</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax:&nbsp;&nbsp;(650) 493-6811</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <U>Counterparts; Facsimile</U>.&nbsp; This Agreement may be executed in counterparts, each of
which shall be enforceable against the party or parties actually executing such counterparts, and
all of which together shall constitute one instrument. This Agreement may be executed by facsimile
signature.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <U>Severability</U>.&nbsp; In the event that any provision of this Agreement becomes or is
declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement
shall continue in full force and effect without said provision.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 <U>Expenses</U>.&nbsp; Except as set forth in the Purchase Agreement, each party shall pay all
costs and expenses that it incurs with respect to the negotiation, execution and delivery and
performance of this Agreement. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, or any of the Additional Notes, the prevailing party shall
be entitled to reasonable
attorney&#146;s fees, costs and necessary distributions in addition to any other relief to which
such party may be entitled.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10 <U>Titles and Subtitles</U>.&nbsp; The titles and subtitles used in this Agreement are used for
convenience only and are not considered in construing or interpreting this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11 <U>Jury Trial</U>.&nbsp; EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST
EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER
SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.12 <U>Jurisdiction; Venue</U>.&nbsp; The parties hereto agree to submit to the jurisdiction of and
venue in the federal and state courts of San Mateo County, California with respect to the breach or
interpretation of this Agreement or the enforcement of any and all rights, duties, liabilities,
obligations, powers, and other relations between the parties arising under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.13 <U>Currency</U>.&nbsp; Any reference to &#147;dollars&#148; or &#147;$&#148; in this Agreement shall refer to the
lawful currency of the United States of America.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Remainder of Page Intentionally Left Blank; Signature Page to Follow&#093;</I></B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have caused this Convertible Note Purchase Agreement to be
duly executed and delivered by their proper and duly authorized officers as of the date and year
first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>COMPANY:</B><BR>
<BR style="font-size:10pt">

<FONT style="font-variant: SMALL-CAPS"><B>Fluidigm
Corporation</B></FONT><br><BR style="font-size: 10pt">
</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Gajus&nbsp;V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>PURCHASER</B>:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Print Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chu Swee Yeok
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><b>[SIGNATURE PAGE TO CONVERTIBLE NOTE PURCHASE AGREEMENT]</b>


</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><b>
EXHIBIT&nbsp;A</b></DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

 <DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;). SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT. THIS NOTE MAY ONLY BE TRANSFERRED UPON
THE TERMS AND CONDITIONS CONTAINED IN THE NOTE AND IN AN AGREEMENT BETWEEN HOLDER
AND THE COMPANY</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>

<DIV align="center" style="font-size: 10pt">a California corporation</DIV>



<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CONVERTIBLE PROMISSORY NOTE

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">NOTE NUMBER&nbsp;E-1
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">US$5,000,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">August &#95;&#95;&#95;, 2006</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">South San Francisco, California</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Principal and Interest</U>. <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT> (the &#147;<U>Company</U>&#148;), a
California corporation, for value received, hereby promises to pay to the order of Biomedical
Sciences Investment Fund Pte Ltd (the &#147;<U>Holder</U>&#148;) in lawful money of the United States of
America, the principal amount of Five Million Dollars (US$5,000,000), or such lesser amount as
shall equal the outstanding principal amount hereof, together with interest from the date of this
Note on the unpaid principal balance at a rate equal to 8.00% per annum, computed on the basis of
the actual number of days elapsed and a year of 365&nbsp;days, compounded annually.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Convertible Promissory Note (&#147;<U>Note</U>&#148;) is the first Note issued pursuant to that
certain Convertible Note Purchase Agreement dated August &#95;&#95;&#95;, 2006 (as amended, modified or
supplemented, the &#147;<U>Note Purchase Agreement</U>&#148;) between the Company and the Holder. Unless
defined herein, capitalized terms shall have the same meanings ascribed to them in the Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless converted in accordance with Section&nbsp;3, this Note shall become due and payable as to
both accrued interest and principal on the Payment Date (as defined in Section&nbsp;3). This Note may
be prepaid by Company at any time after January&nbsp;31, 2007, in accordance with the terms of Section&nbsp;2
of this Note. Upon payment in full of all principal and interest payable hereunder (including upon
any conversion), this Note shall be surrendered to the Company for cancellation. All payments
hereon shall be applied first to accrued interest and second to the reduction of principal.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
 <DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Prepayment of Note</U>. At any time after January&nbsp;31, 2007, upon five days prior
written notice to Holder (the &#147;<U>Prepayment Notice</U>&#148;), the Company may prepay this Note in
whole or in part; provided that any such prepayment will be applied first to the payment of
expenses due under this Note, second to interest accrued on this Note and third, if the amount of
prepayment exceeds the amount of all such expenses and accrued interest, to the payment of
principal of this Note. In the event that the Holder desires to avoid prepayment of the Note by
the Company, the Holder must within five days of its receipt of the Prepayment Notice deliver to
the Company the Conversion Notice pursuant to Section&nbsp;3(c)(iii) electing to convert this Note, in
which case this Note will not be prepaid as provided in the Prepayment Notice and will instead be
converted into shares of Series&nbsp;E Preferred Stock of the Company in accordance with Section&nbsp;3 of
this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Conversion</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Conversion Events</U>. Upon the earlier to occur of (i)&nbsp;an Initial Public Offering
(as defined below) or (ii)&nbsp;satisfaction of each of the Milestones (as defined below) (either, a
&#147;<U>Conversion Event</U>&#148;), all of the then outstanding principal and accrued interest owing under
this Note shall convert into that number of shares of Series&nbsp;E Preferred Stock of the Company
determined by dividing (i)&nbsp;the aggregate principal and accrued interest owing under this Note as of
the date of such Conversion Event by (ii)&nbsp;the Conversion Price (as defined below). Notwithstanding
the foregoing, by complying with Section&nbsp;3(c)(iii) hereof, the Holder may at any time earlier elect
to convert this Note into that number of shares of Series&nbsp;E Preferred Stock determined by dividing
(i)&nbsp;the aggregate principal and accrued interest owing under this Note as of the date of the
Conversion Notice (as defined in Section&nbsp;3(c)(iii)) by (ii)&nbsp;the Conversion Price (as defined
below).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Definitions</U>. For purposes of this Note, the following terms shall have the
following meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The term &#147;<U>Change of Control Transaction</U>&#148; shall mean (i)&nbsp;the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding
any merger effected exclusively for the purpose of changing the domicile of the Corporation) other
than a transaction or series of transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of transactions continue to
retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company
held by such holders prior to such transaction, at least fifty percent (50%) of the total voting
power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or
other conveyance of all or substantially all of the assets of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The term &#147;<U>Conversion Price</U>&#148; shall mean US$3.60, subject to adjustment as set
forth in Section&nbsp;5 below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The term &#147;<U>Initial Public Offering</U>&#148; shall mean the first sale of securities of
the Company pursuant to an effective registration statement under the Securities Act of 1933 (the
&#147;<U>Securities Act</U>&#148;) after or in connection with which the outstanding shares of Preferred
Stock of the
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company have been converted into Common Stock pursuant to the Company&#146;s then existing Articles
of Incorporation or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Unless otherwise agreed in writing between the Company and the Holder, the term
&#147;<U>Milestones</U>&#148; shall mean satisfaction of the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;The Company will have an approved System Architecture for a BioMark II Chip Loader, as
demonstrated by a System Architecture approval form duly signed-off. The approval is typically
characterized by the completion of the Product Marketing Specifications and the Product Development
Plan (including Budget and Staffing Plans), as well as the development of working breadboards for
critical subsystems;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;This approved System Architecture will have been reviewed with at least three prospective
early adopter customers; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;The Subsidiary will have hired four (4)&nbsp;Research and Development Engineers in conjunction
with the BioMark II project. These new employees shall have received training by the Company at
its headquarters (or such other facility as may be necessary or appropriate) in accordance with the
position and job function of each such employee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;The term &#147;<U>Payment Date</U>&#148; shall mean &#091;INSERT DATE TWO YEARS FROM DATE OF NOTE&#093; or
such later date as may be mutually agreed in writing by Holder and the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Conversion Procedure</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Conversion in Connection with Initial Public Offering</U>. Upon the occurrence of an
Initial Public Offering as set forth in Section&nbsp;3(a), this Note shall convert automatically without
further action on the part of the Holder hereof. Written notice shall be delivered to Holder at
the address last shown on the records of Company for Holder or given by Holder to Company for the
purpose of notice notifying Holder of the conversion effected or to be effected, specifying the
Conversion Price, the date on which such conversion occurred or is expected to occur and calling
upon such Holder to surrender to Company, in the manner and at the place designated, the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>Conversion in Connection with Satisfaction of Milestones</U>. If the Company
reasonably believes that it has satisfied all of the Milestones, it may send written notice thereof
(the &#147;<U>Milestone Completion Notice</U>&#148;) to the Holder (at the address last shown on the records
of the Company for the Holder or given by Holder to Company for the purpose of notice) specifying
the Conversion Price, the date on which the Company reasonably believes all of the Milestones were
satisfied (the &#147;<U>Notified Milestone Completion Date</U>&#148;), together with a duly executed
compliance certificate dated as of the Notified Milestone Completion Date substantially in the form
attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<U>Compliance Certificate</U>&#148;), and calling upon
Holder to surrender to the Company the Note. In the event that the Holder reasonably believes that
any of (i)&nbsp;the Milestones have not been satisfied or (ii)&nbsp;the representations and warranties made
in the Compliance Certificate are inaccurate in any material respect, the Holder may provide
written notice (the &#147;<U>Milestone </U>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Response Notice</U>&#148;) to the Company of such disagreement and/or inaccuracy within 30&nbsp;days
of its receipt of the Milestone Completion Notice. The Milestone Response Notice shall specify in
reasonable detail the reasons for such disagreement and/or basis for belief that any of the
representations and warranties made in the Compliance Certificate are inaccurate and shall be
accompanied by reasonably available support documentation evidencing the basis for such
disagreement or belief. If the Holder shall fail to provide the Milestone Response Notice within
such time period, the Milestones shall be deemed satisfied as of the Notified Milestone Completion
Date and this Note shall be automatically converted as set forth in Section&nbsp;3(a). If the Holder
shall have timely provided the Milestone Response Notice, the Company and the Holder shall in good
faith attempt to resolve their disagreement as to the satisfaction of the Milestones and/or the
accuracy of the representations and warranties in the Compliance Certificate. If the Company and
Holder are unable to resolve their disagreement within 30&nbsp;days of the Company&#146;s receipt of the
Milestone Response Notice, the Company may pay to the Holder the principal and interest owing under
this Note as of the Notified Milestone Completion Date (in which case the Note shall be cancelled
and surrendered) or may pursue any other remedy that may be available to it under applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Elective Conversion</U>. If the Holder wishes to voluntarily convert this Note as
set forth in Section&nbsp;3(a) hereof prior to a Conversion Event, the Holder shall surrender this Note
to the Company and provide the Company with a written notice (the &#147;<U>Conversion Notice</U>&#148;) to
that effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Certificate; Time of Conversion</U>. Upon conversion of this Note, the Holder shall
promptly surrender this Note, duly endorsed, at the principal office of Company. At its expense,
the Company shall, as soon as practicable thereafter, issue and deliver to such Holder at such
principal office a certificate or certificates for the number of shares to which Holder shall be
entitled upon such conversion (bearing such legends as are required by this Note and the Note
Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which Holder is entitled upon such
conversion under the terms of this Note, including a check payable to Holder for any cash amounts
payable as described in Section&nbsp;3(d). Any such conversion of this Note shall be deemed to have
been made immediately prior to the Conversion Event as described in Section&nbsp;3(a) (or in the case of
delivery of the Conversion Notice as set forth in Section&nbsp;3(c)(iii), upon the Company&#146;s receipt of
such Conversion Notice); <U>provided</U>, <U>however</U>, the Holder shall not be deemed a record
holder of such shares or a purchaser of such shares until the Holder has delivered the Note for
conversion. On and after such date, the Holder shall be treated as a purchaser of such shares
under the Note Purchase Agreement and shall be bound by the applicable terms of this Note and Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Fractional Shares</U>. No fractional shares will be issued upon any conversion of
this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the
Company will pay to the Holder in cash that amount of the unconverted principal and interest
balance of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Reservation of Shares</U>. The Company will at all times reserve and keep available
out of its authorized but unissued shares or shares held in treasury, sufficient shares of Series&nbsp;E
Preferred Stock or other securities to permit the full conversion of the outstanding principal
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and interest of this Note pursuant to the terms of this Note. In the event the Company shall
have insufficient shares of Series&nbsp;E Preferred Stock or other securities to permit the full
conversion of the outstanding principal and accrued interest of this Note pursuant to the terms
hereof, the Company hereby covenants and agrees that the Company shall use its commercially
reasonable efforts to seek board and shareholder approval of an amendment to the Company&#146;s Articles
of Incorporation in order to authorize an increase in the number of authorized shares of Series&nbsp;E
Preferred Stock or other securities of the Company in a sufficient amount so that the aggregate
number of shares of Series&nbsp;E Preferred Stock or other securities issuable upon conversion of this
Note will then be authorized and available for issuance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Change of Control Transaction</U>. The Company shall provide the Holder with 15&nbsp;days
written notice of the closing of a Change of Control Transaction, specifying in reasonable detail
the terms of such Change of Control Transaction. If the Holder shall not have voluntarily elected
to convert this Note as set forth in Section&nbsp;3(c)(iii) within such 15&nbsp;day period, the Company may
prepay the entire principal amount and interest owing under this Note as of the date of such
prepayment. The Holder shall thereafter promptly return the Note to the Company for cancellation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Change in Series&nbsp;E Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Split, Subdivision or Combination of Series&nbsp;E Preferred Stock</U>. In the event the
Company should at any time or from time to time after the date of issuance hereof split or
subdivide the outstanding shares of its Series&nbsp;E Preferred Stock (or other securities issuable upon
conversion of this Note) or issue additional shares of Series&nbsp;E Preferred Stock (or other
securities issuable upon conversion of this Note) to the holders thereof as a dividend or make any
other distribution payable in additional shares of Series&nbsp;E Preferred Stock (or other securities
issuable upon conversion of this Note) to the holders thereof without payment of any consideration
by such holder for the additional shares of Series&nbsp;E Preferred Stock (or such other securities),
then, as of the date of such dividend, distribution, split or subdivision, the Conversion Price of
this Note shall be appropriately decreased so that the number of shares of Series&nbsp;E Preferred Stock
or other securities issuable upon conversion of this Note shall be increased in proportion to such
increase of outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable. If the number of shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note) outstanding at any time after the date
hereof is decreased by a combination of the outstanding shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note), then, following the record date of such
combination, the Conversion Price for this Note shall be appropriately increased so that the number
of shares of Series&nbsp;E Preferred Stock or other securities issuable on conversion hereof shall be
decreased in proportion to such decrease in outstanding shares of Series&nbsp;E Preferred Stock or other
securities issuable upon conversion of this Note, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Reclassification etc</U>. In case of any reclassification, capital reorganization, or
change in the Series&nbsp;E Preferred Stock (or other securities issuable upon conversion of this Note)
of the Company, including conversion of such shares pursuant to the Company&#146;s Articles of
Incorporation then in effect (other than as a result of a split, subdivision, combination, or stock
dividend provided for in Section&nbsp;5(a) above), then appropriate adjustment shall be made to the
Conversion Price and kind of securities or other property issuable upon conversion of this Note so
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">that this Note shall be convertible upon the terms set forth herein into the kind and amount
of shares of stock and other securities and property receivable in connection with such
reclassification, reorganization, or change by a holder of the same number of shares of Series&nbsp;E
Preferred Stock or other securities as are issuable on conversion of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Merger or Consolidation</U>. Other than a Change of Control Transaction in connection
with which this Note has been converted or prepaid, if at any time there shall be an acquisition of
the Company by merger, consolidation or otherwise where the Company is not the surviving
corporation or as a result of which all of the outstanding capital stock of the Company is
exchanged for capital stock of another corporation, then, as a part of such acquisition, the
Conversion Price and kind of securities issuable upon conversion hereof shall be appropriately
adjusted so that the Holder shall receive upon conversion of this Note, the number of shares of
stock or other securities or property of the surviving or successor corporation resulting from such
acquisition (or the corporation the capital stock of which is issued in exchange for the capital
stock of the Company), to which a holder of the securities issuable upon conversion of this Note
would have been entitled in such acquisition if this Note had been converted immediately before
such acquisition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Payment Due Date</U>. If not previously converted into shares of Series&nbsp;E Preferred
Stock pursuant to Section&nbsp;3 hereof and if not sooner prepaid by the Company pursuant to Section&nbsp;2
hereof or accelerated and declared due and owing by the Holder pursuant to Section&nbsp;7 hereof, the
principal amount and any accrued interest due thereon then outstanding under this Note will become
due and payable on the Payment Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Default</U>. The Company shall be deemed to be in default under this Note in the event
(i)&nbsp;the Company shall fail to materially perform any covenant or agreement of the Company contained
in Section&nbsp;4 of the Note Purchase Agreement for a period of 30&nbsp;days after written notice of such
failure from Holder; (ii)&nbsp;the Company shall have failed to make payment of principal or interest
due on the Note when such principal and interest becomes due; or (iii)&nbsp;the Company shall commence,
whether voluntarily or involuntarily a case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or consent to any such relief or to the appointment of or
taking possession of its property by any official in an involuntary case or other proceeding
commenced against it. In the case of an event of default, the Holder may, by written notice to the
Company, declare the unpaid principal amount of this Note, all interest accrued and unpaid hereon,
and all other amounts payable hereunder to be immediately due and payable, without presentment,
demand, protest, or further notice of any kind, as well as enforce all other rights and remedies
available to the Holder under applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Notices</U>. Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Holder:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chu Swee Yeok</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6336-2288&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6334-8478&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Company:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650)&nbsp;266-6000&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;871-7195&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich&nbsp;&#038; Rosati, P.C.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, California 94304-1050&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Ken Clark and Robert Kornegay</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650)&nbsp;493-9300&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;493-6811&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments</U>. This Note may be amended and any provision hereof waived with the
consent of the Company and the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>No Rights as Shareholder</U>. Nothing in this Note shall be construed as conferring
upon the Holder or any other person the right to vote or to consent or to receive notice as a
shareholder in respect of meetings of shareholders for the election of directors of the Company or
any other matters or any rights whatsoever as a shareholder of the Company until, and only to the
extent that, this Note shall have been converted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Successors and Assigns</U>. Subject to the restrictions on transfer described in
Section&nbsp;12 and in the Note Purchase Agreement, the rights and obligations of the Company and
Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and
transferees of the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Transfer of Note and Securities Issuable on Conversion Hereof</U>. Prior to the
conversion of this Note, this Note (or the underlying securities issuable upon conversion hereof)
may not be sold, assigned, transferred, pledged or otherwise disposed of by the Holder, in whole or
in part, without the prior written consent of the Company. With respect to any sale, assignment,
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">transfer, pledge or other disposition of the securities into which this Note may be converted
after conversion of this Note, the Holder may only transfer such securities pursuant to, and on the
conditions set forth in that certain Eighth Amended and Restated Investor Rights Agreement dated
June&nbsp;13, 2006 between the Company and certain investors in the Company (including Holder), as may
be amended from time to time (the &#147;<U>Rights Agreement</U>&#148;). The Holder shall cause any proposed
purchaser, assignee, transferee or pledgee of such securities to agree in writing to take and hold
such securities subject to and upon the conditions specified in this Note, the Note Purchase
Agreement, and the Rights Agreement, including, without limitation, Sections&nbsp;1.2, 1.3, 1.4, and
1.14 of the Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Highest Lawful Rate</U>. Anything herein to the contrary notwithstanding, if during
any period for which interest is computed hereunder, the amount of interest computed on the basis
provided for in this Note, together will all fees, charges, and other payments or rights which are
treated as interest under applicable law, as provided for herein or in any other document executed
in connection herewith, would exceed the amount of such interest computed on the basis of the
Highest Lawful Rate, the Company shall not be obligated to pay, and the Holder shall not be
entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful
Rate, and during any such period the interest payable hereunder shall be computed on the basis of
the Highest Lawful Rate. As used herein, &#147;<U>Highest Lawful Rate</U>&#148; means the maximum
non-usurious rate of interest, as in effect from time to time, which may be charged, contracted
for, reserved, received, or collected by the Holder in connection with this Note under applicable
law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate
shall be applied towards the prepayment of principal then outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Miscellaneous</U>. The Company agrees to pay on demand all of the losses, costs, and
expenses (including, without limitation, attorneys&#146; fees and disbursements) which the Holder incurs
in connection with enforcement of this Note, or the protection or preservation of the Holder&#146;s
rights under this Note, whether by judicial proceeding or otherwise. Such costs and expenses
include, without limitation, those incurred in connection with any workout or refinancing, or any
bankruptcy, insolvency, liquidation, or similar proceedings. The Company hereby waives
presentment, demand for performance, notice of non-performance, protest, notice of protest, and
notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall
operate as a waiver of such right or any other right. This Note is being delivered in and shall be
construed in accordance with the laws of the State of California without regard to the conflicts of
law provisions thereof. Any reference to &#147;dollars&#148; or &#147;$&#148; in this Note shall refer to the lawful
money of the United States of America.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Remainder of Page Left Blank Intentionally&#093;</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Company has caused this Convertible Promissory Note to be executed by
its officer thereunto duly authorized as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Dated: August ______, 2006</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT><br>
a California corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acknowledged and Agreed:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Holder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><b>[Convertible Promissory Note Signature Page]</b></div>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
 <DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FORM OF COMPLIANCE CERTIFICATE</B>

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<b>EXHIBIT&nbsp;B</b></DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

 <DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;). SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT. THIS NOTE MAY ONLY BE TRANSFERRED UPON
THE TERMS AND CONDITIONS CONTAINED IN THE NOTE AND IN AN AGREEMENT BETWEEN HOLDER
AND THE COMPANY</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>

<DIV align="center" style="font-size: 10pt">a California corporation</DIV>



<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CONVERTIBLE PROMISSORY NOTE

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">NOTE
NUMBER&nbsp;E-2
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">US$5,000,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&#95;&#95;&#95;&#95;&#95;&#95; &#95;&#95;&#95;, 20&#95;&#95;&#95;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">South San Francisco, California</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Principal and Interest</U>. <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT> (the &#147;<U>Company</U>&#148;), a
California corporation, for value received, hereby promises to pay to the order of Biomedical
Sciences Investment Fund Pte Ltd (the &#147;<U>Holder</U>&#148;) in lawful money of the United States of
America, the principal amount of Five Million Dollars (US$5,000,000), or such lesser amount as
shall equal the outstanding principal amount hereof, together with interest from the date of this
Note on the unpaid principal balance at a rate equal to 8.00% per annum, computed on the basis of
the actual number of days elapsed and a year of 365&nbsp;days, compounded annually.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Convertible Promissory Note (&#147;<U>Note</U>&#148;) is the second Note issued pursuant to that
certain Convertible Note Purchase Agreement dated August &#95;&#95;&#95;, 2006 (as amended, modified or
supplemented, the &#147;<U>Note Purchase Agreement</U>&#148;) between the Company and the Holder. Unless
defined herein, capitalized terms shall have the same meanings ascribed to them in the Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless converted in accordance with Section&nbsp;3, this Note shall become due and payable as to
both accrued interest and principal on the Payment Date (as defined in Section&nbsp;3). This Note may
be prepaid by Company at any time,  in accordance with the terms of Section&nbsp;2
of this Note. Upon payment in full of all principal and interest payable hereunder (including upon
any conversion), this Note shall be surrendered to the Company for cancellation. All payments
hereon shall be applied first to accrued interest and second to the reduction of principal.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
 <DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Prepayment of Note</U>. Upon five days prior
written notice to Holder (the &#147;<U>Prepayment Notice</U>&#148;), the Company may prepay this Note in
whole or in part; provided that any such prepayment will be applied first to the payment of
expenses due under this Note, second to interest accrued on this Note and third, if the amount of
prepayment exceeds the amount of all such expenses and accrued interest, to the payment of
principal of this Note. In the event that the Holder desires to avoid prepayment of the Note by
the Company, the Holder must within five days of its receipt of the Prepayment Notice deliver to
the Company the Conversion Notice pursuant to Section&nbsp;3(c)(iii) electing to convert this Note, in
which case this Note will not be prepaid as provided in the Prepayment Notice and will instead be
converted into shares of Series&nbsp;E Preferred Stock of the Company in accordance with Section&nbsp;3 of
this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Conversion</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Conversion Events</U>. Upon the earlier to occur of (i)&nbsp;an Initial Public Offering
(as defined below) or (ii)&nbsp;satisfaction of each of the Milestones (as defined below) (either, a
&#147;<U>Conversion Event</U>&#148;), all of the then outstanding principal and accrued interest owing under
this Note shall convert into that number of shares of Series&nbsp;E Preferred Stock of the Company
determined by dividing (i)&nbsp;the aggregate principal and accrued interest owing under this Note as of
the date of such Conversion Event by (ii)&nbsp;the Conversion Price (as defined below). Notwithstanding
the foregoing, by complying with Section&nbsp;3(c)(iii) hereof, the Holder may at any time earlier elect
to convert this Note into that number of shares of Series&nbsp;E Preferred Stock determined by dividing
(i)&nbsp;the aggregate principal and accrued interest owing under this Note as of the date of the
Conversion Notice (as defined in Section&nbsp;3(c)(iii)) by (ii)&nbsp;the Conversion Price (as defined
below).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Definitions</U>. For purposes of this Note, the following terms shall have the
following meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The term &#147;<U>Change of Control Transaction</U>&#148; shall mean (i)&nbsp;the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding
any merger effected exclusively for the purpose of changing the domicile of the Corporation) other
than a transaction or series of transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of transactions continue to
retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company
held by such holders prior to such transaction, at least fifty percent (50%) of the total voting
power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or
other conveyance of all or substantially all of the assets of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The term &#147;<U>Conversion Price</U>&#148; shall mean US$3.60, subject to adjustment as set
forth in Section&nbsp;5 below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The term &#147;<U>Initial Public Offering</U>&#148; shall mean the first sale of securities of
the Company pursuant to an effective registration statement under the Securities Act of 1933 (the
&#147;<U>Securities Act</U>&#148;) after or in connection with which the outstanding shares of Preferred
Stock of the
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company have been converted into Common Stock pursuant to the Company&#146;s then existing Articles
of Incorporation or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Unless otherwise agreed in writing between the Company and the Holder, the term
&#147;<U>Milestones</U>&#148; shall mean satisfaction of the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;The
Company will have an approved System Architecture for a BioMark II
Endpoint Reader, as
demonstrated by a System Architecture approval form duly signed-off. The approval is typically
characterized by the completion of the Product Marketing Specifications and the Product Development
Plan (including Budget and Staffing Plans), as well as the development of working breadboards for
critical subsystems;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;This
approved System Architecture will have been represented to at least
three (3) target customers; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;The
Subsidiary will have hired three (3) more&nbsp;Research and
Development Engineers, with at least one (1) being a Software Engineer, in conjunction
with the BioMark II project (i.e., 7 total hires based on the
satisfaction of the Milestones in the First Note and the Milestones
in this Second Note). These new employees shall have received training by the Company at
its headquarters (or such other facility as may be necessary or appropriate) in accordance with the
position and job function of each such employee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;The term &#147;<U>Payment Date</U>&#148; shall mean &#091;INSERT DATE TWO YEARS FROM DATE OF NOTE&#093; or
such later date as may be mutually agreed in writing by Holder and the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Conversion Procedure</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Conversion in Connection with Initial Public Offering</U>. Upon the occurrence of an
Initial Public Offering as set forth in Section&nbsp;3(a), this Note shall convert automatically without
further action on the part of the Holder hereof. Written notice shall be delivered to Holder at
the address last shown on the records of Company for Holder or given by Holder to Company for the
purpose of notice notifying Holder of the conversion effected or to be effected, specifying the
Conversion Price, the date on which such conversion occurred or is expected to occur and calling
upon such Holder to surrender to Company, in the manner and at the place designated, the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>Conversion in Connection with Satisfaction of Milestones</U>. If the Company
reasonably believes that it has satisfied all of the Milestones, it may send written notice thereof
(the &#147;<U>Milestone Completion Notice</U>&#148;) to the Holder (at the address last shown on the records
of the Company for the Holder or given by Holder to Company for the purpose of notice) specifying
the Conversion Price, the date on which the Company reasonably believes all of the Milestones were
satisfied (the &#147;<U>Notified Milestone Completion Date</U>&#148;), together with a duly executed
compliance certificate dated as of the Notified Milestone Completion Date substantially in the form
attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<U>Compliance Certificate</U>&#148;), and calling upon
Holder to surrender to the Company the Note. In the event that the Holder reasonably believes that
any of (i)&nbsp;the Milestones have not been satisfied or (ii)&nbsp;the representations and warranties made
in the Compliance Certificate are inaccurate in any material respect, the Holder may provide
written notice (the &#147;<U>Milestone </U>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Response Notice</U>&#148;) to the Company of such disagreement and/or inaccuracy within 30&nbsp;days
of its receipt of the Milestone Completion Notice. The Milestone Response Notice shall specify in
reasonable detail the reasons for such disagreement and/or basis for belief that any of the
representations and warranties made in the Compliance Certificate are inaccurate and shall be
accompanied by reasonably available support documentation evidencing the basis for such
disagreement or belief. If the Holder shall fail to provide the Milestone Response Notice within
such time period, the Milestones shall be deemed satisfied as of the Notified Milestone Completion
Date and this Note shall be automatically converted as set forth in Section&nbsp;3(a). If the Holder
shall have timely provided the Milestone Response Notice, the Company and the Holder shall in good
faith attempt to resolve their disagreement as to the satisfaction of the Milestones and/or the
accuracy of the representations and warranties in the Compliance Certificate. If the Company and
Holder are unable to resolve their disagreement within 30&nbsp;days of the Company&#146;s receipt of the
Milestone Response Notice, the Company may pay to the Holder the principal and interest owing under
this Note as of the Notified Milestone Completion Date (in which case the Note shall be cancelled
and surrendered) or may pursue any other remedy that may be available to it under applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Elective Conversion</U>. If the Holder wishes to voluntarily convert this Note as
set forth in Section&nbsp;3(a) hereof prior to a Conversion Event, the Holder shall surrender this Note
to the Company and provide the Company with a written notice (the &#147;<U>Conversion Notice</U>&#148;) to
that effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Certificate; Time of Conversion</U>. Upon conversion of this Note, the Holder shall
promptly surrender this Note, duly endorsed, at the principal office of Company. At its expense,
the Company shall, as soon as practicable thereafter, issue and deliver to such Holder at such
principal office a certificate or certificates for the number of shares to which Holder shall be
entitled upon such conversion (bearing such legends as are required by this Note and the Note
Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which Holder is entitled upon such
conversion under the terms of this Note, including a check payable to Holder for any cash amounts
payable as described in Section&nbsp;3(d). Any such conversion of this Note shall be deemed to have
been made immediately prior to the Conversion Event as described in Section&nbsp;3(a) (or in the case of
delivery of the Conversion Notice as set forth in Section&nbsp;3(c)(iii), upon the Company&#146;s receipt of
such Conversion Notice); <U>provided</U>, <U>however</U>, the Holder shall not be deemed a record
holder of such shares or a purchaser of such shares until the Holder has delivered the Note for
conversion. On and after such date, the Holder shall be treated as a purchaser of such shares
under the Note Purchase Agreement and shall be bound by the applicable terms of this Note and Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Fractional Shares</U>. No fractional shares will be issued upon any conversion of
this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the
Company will pay to the Holder in cash that amount of the unconverted principal and interest
balance of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Reservation of Shares</U>. The Company will at all times reserve and keep available
out of its authorized but unissued shares or shares held in treasury, sufficient shares of Series&nbsp;E
Preferred Stock or other securities to permit the full conversion of the outstanding principal
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and interest of this Note pursuant to the terms of this Note. In the event the Company shall
have insufficient shares of Series&nbsp;E Preferred Stock or other securities to permit the full
conversion of the outstanding principal and accrued interest of this Note pursuant to the terms
hereof, the Company hereby covenants and agrees that the Company shall use its commercially
reasonable efforts to seek board and shareholder approval of an amendment to the Company&#146;s Articles
of Incorporation in order to authorize an increase in the number of authorized shares of Series&nbsp;E
Preferred Stock or other securities of the Company in a sufficient amount so that the aggregate
number of shares of Series&nbsp;E Preferred Stock or other securities issuable upon conversion of this
Note will then be authorized and available for issuance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Change of Control Transaction</U>. The Company shall provide the Holder with 15&nbsp;days
written notice of the closing of a Change of Control Transaction, specifying in reasonable detail
the terms of such Change of Control Transaction. If the Holder shall not have voluntarily elected
to convert this Note as set forth in Section&nbsp;3(c)(iii) within such 15&nbsp;day period, the Company may
prepay the entire principal amount and interest owing under this Note as of the date of such
prepayment. The Holder shall thereafter promptly return the Note to the Company for cancellation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Change in Series&nbsp;E Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Split, Subdivision or Combination of Series&nbsp;E Preferred Stock</U>. In the event the
Company should at any time or from time to time after the date of issuance hereof split or
subdivide the outstanding shares of its Series&nbsp;E Preferred Stock (or other securities issuable upon
conversion of this Note) or issue additional shares of Series&nbsp;E Preferred Stock (or other
securities issuable upon conversion of this Note) to the holders thereof as a dividend or make any
other distribution payable in additional shares of Series&nbsp;E Preferred Stock (or other securities
issuable upon conversion of this Note) to the holders thereof without payment of any consideration
by such holder for the additional shares of Series&nbsp;E Preferred Stock (or such other securities),
then, as of the date of such dividend, distribution, split or subdivision, the Conversion Price of
this Note shall be appropriately decreased so that the number of shares of Series&nbsp;E Preferred Stock
or other securities issuable upon conversion of this Note shall be increased in proportion to such
increase of outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable. If the number of shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note) outstanding at any time after the date
hereof is decreased by a combination of the outstanding shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note), then, following the record date of such
combination, the Conversion Price for this Note shall be appropriately increased so that the number
of shares of Series&nbsp;E Preferred Stock or other securities issuable on conversion hereof shall be
decreased in proportion to such decrease in outstanding shares of Series&nbsp;E Preferred Stock or other
securities issuable upon conversion of this Note, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Reclassification etc</U>. In case of any reclassification, capital reorganization, or
change in the Series&nbsp;E Preferred Stock (or other securities issuable upon conversion of this Note)
of the Company, including conversion of such shares pursuant to the Company&#146;s Articles of
Incorporation then in effect (other than as a result of a split, subdivision, combination, or stock
dividend provided for in Section&nbsp;5(a) above), then appropriate adjustment shall be made to the
Conversion Price and kind of securities or other property issuable upon conversion of this Note so
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">that this Note shall be convertible upon the terms set forth herein into the kind and amount
of shares of stock and other securities and property receivable in connection with such
reclassification, reorganization, or change by a holder of the same number of shares of Series&nbsp;E
Preferred Stock or other securities as are issuable on conversion of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Merger or Consolidation</U>. Other than a Change of Control Transaction in connection
with which this Note has been converted or prepaid, if at any time there shall be an acquisition of
the Company by merger, consolidation or otherwise where the Company is not the surviving
corporation or as a result of which all of the outstanding capital stock of the Company is
exchanged for capital stock of another corporation, then, as a part of such acquisition, the
Conversion Price and kind of securities issuable upon conversion hereof shall be appropriately
adjusted so that the Holder shall receive upon conversion of this Note, the number of shares of
stock or other securities or property of the surviving or successor corporation resulting from such
acquisition (or the corporation the capital stock of which is issued in exchange for the capital
stock of the Company), to which a holder of the securities issuable upon conversion of this Note
would have been entitled in such acquisition if this Note had been converted immediately before
such acquisition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Payment Due Date</U>. If not previously converted into shares of Series&nbsp;E Preferred
Stock pursuant to Section&nbsp;3 hereof and if not sooner prepaid by the Company pursuant to Section&nbsp;2
hereof or accelerated and declared due and owing by the Holder pursuant to Section&nbsp;7 hereof, the
principal amount and any accrued interest due thereon then outstanding under this Note will become
due and payable on the Payment Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Default</U>. The Company shall be deemed to be in default under this Note in the event
(i)&nbsp;the Company shall fail to materially perform any covenant or agreement of the Company contained
in Section&nbsp;4 of the Note Purchase Agreement for a period of 30&nbsp;days after written notice of such
failure from Holder; (ii)&nbsp;the Company shall have failed to make payment of principal or interest
due on the Note when such principal and interest becomes due; or (iii)&nbsp;the Company shall commence,
whether voluntarily or involuntarily a case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or consent to any such relief or to the appointment of or
taking possession of its property by any official in an involuntary case or other proceeding
commenced against it. In the case of an event of default, the Holder may, by written notice to the
Company, declare the unpaid principal amount of this Note, all interest accrued and unpaid hereon,
and all other amounts payable hereunder to be immediately due and payable, without presentment,
demand, protest, or further notice of any kind, as well as enforce all other rights and remedies
available to the Holder under applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Notices</U>. Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Holder:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chu Swee Yeok</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6336-2288&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6334-8478&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Company:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650)&nbsp;266-6000&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;871-7195&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich&nbsp;&#038; Rosati, P.C.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, California 94304-1050&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Ken Clark and Robert Kornegay</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650)&nbsp;493-9300&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;493-6811&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments</U>. This Note may be amended and any provision hereof waived with the
consent of the Company and the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>No Rights as Shareholder</U>. Nothing in this Note shall be construed as conferring
upon the Holder or any other person the right to vote or to consent or to receive notice as a
shareholder in respect of meetings of shareholders for the election of directors of the Company or
any other matters or any rights whatsoever as a shareholder of the Company until, and only to the
extent that, this Note shall have been converted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Successors and Assigns</U>. Subject to the restrictions on transfer described in
Section&nbsp;12 and in the Note Purchase Agreement, the rights and obligations of the Company and
Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and
transferees of the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Transfer of Note and Securities Issuable on Conversion Hereof</U>. Prior to the
conversion of this Note, this Note (or the underlying securities issuable upon conversion hereof)
may not be sold, assigned, transferred, pledged or otherwise disposed of by the Holder, in whole or
in part, without the prior written consent of the Company. With respect to any sale, assignment,
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">transfer, pledge or other disposition of the securities into which this Note may be converted
after conversion of this Note, the Holder may only transfer such securities pursuant to, and on the
conditions set forth in that certain Eighth Amended and Restated Investor Rights Agreement dated
June&nbsp;13, 2006 between the Company and certain investors in the Company (including Holder), as may
be amended from time to time (the &#147;<U>Rights Agreement</U>&#148;). The Holder shall cause any proposed
purchaser, assignee, transferee or pledgee of such securities to agree in writing to take and hold
such securities subject to and upon the conditions specified in this Note, the Note Purchase
Agreement, and the Rights Agreement, including, without limitation, Sections&nbsp;1.2, 1.3, 1.4, and
1.14 of the Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Highest Lawful Rate</U>. Anything herein to the contrary notwithstanding, if during
any period for which interest is computed hereunder, the amount of interest computed on the basis
provided for in this Note, together will all fees, charges, and other payments or rights which are
treated as interest under applicable law, as provided for herein or in any other document executed
in connection herewith, would exceed the amount of such interest computed on the basis of the
Highest Lawful Rate, the Company shall not be obligated to pay, and the Holder shall not be
entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful
Rate, and during any such period the interest payable hereunder shall be computed on the basis of
the Highest Lawful Rate. As used herein, &#147;<U>Highest Lawful Rate</U>&#148; means the maximum
non-usurious rate of interest, as in effect from time to time, which may be charged, contracted
for, reserved, received, or collected by the Holder in connection with this Note under applicable
law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate
shall be applied towards the prepayment of principal then outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Miscellaneous</U>. The Company agrees to pay on demand all of the losses, costs, and
expenses (including, without limitation, attorneys&#146; fees and disbursements) which the Holder incurs
in connection with enforcement of this Note, or the protection or preservation of the Holder&#146;s
rights under this Note, whether by judicial proceeding or otherwise. Such costs and expenses
include, without limitation, those incurred in connection with any workout or refinancing, or any
bankruptcy, insolvency, liquidation, or similar proceedings. The Company hereby waives
presentment, demand for performance, notice of non-performance, protest, notice of protest, and
notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall
operate as a waiver of such right or any other right. This Note is being delivered in and shall be
construed in accordance with the laws of the State of California without regard to the conflicts of
law provisions thereof. Any reference to &#147;dollars&#148; or &#147;$&#148; in this Note shall refer to the lawful
money of the United States of America.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Remainder of Page Left Blank Intentionally&#093;</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Company has caused this Convertible Promissory Note to be executed by
its officer thereunto duly authorized as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Dated: &#95;&#95;&#95;&#95;&#95;&#95;  &#95;&#95;&#95;, 20&#95;&#95;&#95;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT><br>
a California corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acknowledged and Agreed:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Holder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><b>[Convertible Promissory Note Signature Page]</b></div>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
 <DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FORM OF COMPLIANCE CERTIFICATE</B>

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><b>EXHIBIT&nbsp;C</b>
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

 <DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>THIS NOTE AND THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT
AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&#147;SECURITIES ACT&#148;). SUCH SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE
ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL
(WHICH MAY BE COUNSEL FOR THE COMPANY), OR OTHER EVIDENCE, REASONABLY ACCEPTABLE TO
IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS
DELIVERY REQUIREMENTS OF THE SECURITIES ACT. THIS NOTE MAY ONLY BE TRANSFERRED UPON
THE TERMS AND CONDITIONS CONTAINED IN THE NOTE AND IN AN AGREEMENT BETWEEN HOLDER
AND THE COMPANY</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT>
</DIV>

<DIV align="center" style="font-size: 10pt">a California corporation</DIV>



<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CONVERTIBLE PROMISSORY NOTE

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">NOTE
NUMBER&nbsp;E-3
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">US$5,000,000
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95;&#95; &#95;&#95;&#95;, 20&#95;&#95;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">South San Francisco, California</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Principal and Interest</U>. <FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT> (the &#147;<U>Company</U>&#148;), a
California corporation, for value received, hereby promises to pay to the order of Biomedical
Sciences Investment Fund Pte Ltd (the &#147;<U>Holder</U>&#148;) in lawful money of the United States of
America, the principal amount of Five Million Dollars (US$5,000,000), or such lesser amount as
shall equal the outstanding principal amount hereof, together with interest from the date of this
Note on the unpaid principal balance at a rate equal to 8.00% per annum, computed on the basis of
the actual number of days elapsed and a year of 365&nbsp;days, compounded annually.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Convertible Promissory Note (&#147;<U>Note</U>&#148;) is the third Note issued pursuant to that
certain Convertible Note Purchase Agreement dated August &#95;&#95;&#95;, 2006 (as amended, modified or
supplemented, the &#147;<U>Note Purchase Agreement</U>&#148;) between the Company and the Holder. Unless
defined herein, capitalized terms shall have the same meanings ascribed to them in the Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless converted in accordance with Section&nbsp;3, this Note shall become due and payable as to
both accrued interest and principal on the Payment Date (as defined in Section&nbsp;3). This Note may
be prepaid by Company at any time, in accordance with the terms of Section&nbsp;2
of this Note. Upon payment in full of all principal and interest payable hereunder (including upon
any conversion), this Note shall be surrendered to the Company for cancellation. All payments
hereon shall be applied first to accrued interest and second to the reduction of principal.
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><b>&#091;Convertible
Promissory Note Signature Page&#093;</b></div>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
 <DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Prepayment of Note</U>. Upon five days prior
written notice to Holder (the &#147;<U>Prepayment Notice</U>&#148;), the Company may prepay this Note in
whole or in part; provided that any such prepayment will be applied first to the payment of
expenses due under this Note, second to interest accrued on this Note and third, if the amount of
prepayment exceeds the amount of all such expenses and accrued interest, to the payment of
principal of this Note. In the event that the Holder desires to avoid prepayment of the Note by
the Company, the Holder must within five days of its receipt of the Prepayment Notice deliver to
the Company the Conversion Notice pursuant to Section&nbsp;3(c)(iii) electing to convert this Note, in
which case this Note will not be prepaid as provided in the Prepayment Notice and will instead be
converted into shares of Series&nbsp;E Preferred Stock of the Company in accordance with Section&nbsp;3 of
this Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Conversion</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Conversion Events</U>. Upon the earlier to occur of (i)&nbsp;an Initial Public Offering
(as defined below) or (ii)&nbsp;satisfaction of each of the Milestones pursuant to Section 3(b)(iv) below (either, a
&#147;<U>Conversion Event</U>&#148;), all of the then outstanding principal and accrued interest owing under
this Note shall convert into that number of shares of Series&nbsp;E Preferred Stock of the Company
determined by dividing (i)&nbsp;the aggregate principal and accrued interest owing under this Note as of
the date of such Conversion Event by (ii)&nbsp;the Conversion Price (as defined below). Notwithstanding
the foregoing, by complying with Section&nbsp;3(c)(iii) hereof, the Holder may at any time earlier elect
to convert this Note into that number of shares of Series&nbsp;E Preferred Stock determined by dividing
(i)&nbsp;the aggregate principal and accrued interest owing under this Note as of the date of the
Conversion Notice (as defined in Section&nbsp;3(c)(iii)) by (ii)&nbsp;the Conversion Price (as defined
below).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Definitions</U>. For purposes of this Note, the following terms shall have the
following meanings:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The term &#147;<U>Change of Control Transaction</U>&#148; shall mean (i)&nbsp;the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding
any merger effected exclusively for the purpose of changing the domicile of the Corporation) other
than a transaction or series of transactions in which the holders of the voting securities of the
Company outstanding immediately prior to such transaction or series of transactions continue to
retain (either by such voting securities remaining outstanding or by such voting securities being
converted into voting securities of the surviving entity), as a result of shares in the Company
held by such holders prior to such transaction, at least fifty percent (50%) of the total voting
power represented by the voting securities of the Company or such surviving entity outstanding
immediately after such transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or
other conveyance of all or substantially all of the assets of the Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The term &#147;<U>Conversion Price</U>&#148; shall mean US$3.60, subject to adjustment as set
forth in Section&nbsp;5 below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;The term &#147;<U>Initial Public Offering</U>&#148; shall mean the first sale of securities of
the Company pursuant to an effective registration statement under the Securities Act of 1933 (the
&#147;<U>Securities Act</U>&#148;) after or in connection with which the outstanding shares of Preferred
Stock of the
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company have been converted into Common Stock pursuant to the Company&#146;s then existing Articles
of Incorporation or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;Unless otherwise agreed in writing between the Company and the Holder, the term
&#147;<U>Milestones</U>&#148; shall mean satisfaction of the
following on or before April 30, 2008:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;The
Company will have released the  BioMark II Chip Loader to
manufacturing, as
demonstrated by a Manufacturing Release approval form duly signed-off. The approval is typically
characterized by having completed standard prototype development,
including building and testing of suitable prototypes;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)  The approved BioMark II Chip Loader (or a subsequent version thereof)
will be made generally available to customers,
as demonstrated by a Company product announcement;
</div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;The Subsidiary will also have produced prototype BioMark II End Point Readers and made them available to at least three (3) customers;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;The Subsidiary will have at least maintained the number of
Research and Development Engineers hired to achieve Milestones in the First
Note and the Milestones in the Second Note; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;The Company will be manufacturing the BioMark II Chip Loader through the
Subsidiary in Singapore, and the Company&#146;s then-current financial and business
plan will provide for the manufacturing of the BioMark II End Point Readers
through the Subsidiary in Singapore; <I>provided that</I> if the Holder provides the Company with a
Milestone Response Notice pursuant to Section 3(c)(ii) below, then the Company shall
have 30 days following the Company&#146;s receipt of the Milestone
Response Notice (the &#147;Milestones Cure Period&#148;) to cure any failure to
satisfy the Milestones identified by the Holder in the Milestone
Response Notice.</div>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;The term &#147;<U>Payment Date</U>&#148; shall mean &#091;INSERT DATE TWO YEARS FROM DATE OF NOTE&#093; or
such later date as may be mutually agreed in writing by Holder and the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Conversion Procedure</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Conversion in Connection with Initial Public Offering</U>. Upon the occurrence of an
Initial Public Offering as set forth in Section&nbsp;3(a), this Note shall convert automatically without
further action on the part of the Holder hereof. Written notice shall be delivered to Holder at
the address last shown on the records of Company for Holder or given by Holder to Company for the
purpose of notice notifying Holder of the conversion effected or to be effected, specifying the
Conversion Price, the date on which such conversion occurred or is expected to occur and calling
upon such Holder to surrender to Company, in the manner and at the place designated, the Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>Conversion in Connection with Satisfaction of Milestones</U>. If the Company
reasonably believes that it has satisfied all of the Milestones, it may send written notice thereof
(the &#147;<U>Milestone Completion Notice</U>&#148;) to the Holder (at the address last shown on the records
of the Company for the Holder or given by Holder to Company for the purpose of notice) specifying
the Conversion Price, the date on which the Company reasonably believes all of the Milestones were
satisfied (the &#147;<U>Notified Milestone Completion Date</U>&#148;), together with a duly executed
compliance certificate dated as of the Notified Milestone Completion Date substantially in the form
attached hereto as <U>Exhibit&nbsp;A</U> (the &#147;<U>Compliance Certificate</U>&#148;), and calling upon
Holder to surrender to the Company the Note. In the event that the Holder reasonably believes that
any of (i)&nbsp;the Milestones have not been satisfied or (ii)&nbsp;the representations and warranties made
in the Compliance Certificate are inaccurate in any material respect, the Holder may provide
written notice (the &#147;<U>Milestone </U>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Response Notice</U>&#148;) to the Company of such disagreement and/or inaccuracy within 30&nbsp;days
of its receipt of the Milestone Completion Notice. The Milestone Response Notice shall specify in
reasonable detail the reasons for such disagreement and/or basis for belief that any of the
representations and warranties made in the Compliance Certificate are inaccurate and shall be
accompanied by reasonably available support documentation evidencing the basis for such
disagreement or belief. If the Holder shall fail to provide the Milestone Response Notice within
such time period, the Milestones shall be deemed satisfied as of the Notified Milestone Completion
Date and this Note shall be automatically converted as set forth in Section&nbsp;3(a). If the Holder
shall have timely provided the Milestone Response Notice, the Company and the Holder shall in good
faith attempt to resolve their disagreement as to the satisfaction of the Milestones and/or the
accuracy of the representations and warranties in the Compliance Certificate. If the Company and
Holder are unable to resolve their disagreement within the Milestones Cure Period,  the Company may pay to the Holder the principal and interest owing under
this Note as of the Notified Milestone Completion Date (in which case the Note shall be cancelled
and surrendered) or may pursue any other remedy that may be available to it under applicable law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Elective Conversion</U>. If the Holder wishes to voluntarily convert this Note as
set forth in Section&nbsp;3(a) hereof prior to a Conversion Event, the Holder shall surrender this Note
to the Company and provide the Company with a written notice (the &#147;<U>Conversion Notice</U>&#148;) to
that effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Certificate; Time of Conversion</U>. Upon conversion of this Note, the Holder shall
promptly surrender this Note, duly endorsed, at the principal office of Company. At its expense,
the Company shall, as soon as practicable thereafter, issue and deliver to such Holder at such
principal office a certificate or certificates for the number of shares to which Holder shall be
entitled upon such conversion (bearing such legends as are required by this Note and the Note
Purchase Agreement and applicable state and federal securities laws in the opinion of counsel to
Company), together with any other securities and property to which Holder is entitled upon such
conversion under the terms of this Note, including a check payable to Holder for any cash amounts
payable as described in Section&nbsp;3(d). Any such conversion of this Note shall be deemed to have
been made immediately prior to the Conversion Event as described in Section&nbsp;3(a) (or in the case of
delivery of the Conversion Notice as set forth in Section&nbsp;3(c)(iii), upon the Company&#146;s receipt of
such Conversion Notice); <U>provided</U>, <U>however</U>, the Holder shall not be deemed a record
holder of such shares or a purchaser of such shares until the Holder has delivered the Note for
conversion. On and after such date, the Holder shall be treated as a purchaser of such shares
under the Note Purchase Agreement and shall be bound by the applicable terms of this Note and Note
Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Fractional Shares</U>. No fractional shares will be issued upon any conversion of
this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the
Company will pay to the Holder in cash that amount of the unconverted principal and interest
balance of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Reservation of Shares</U>. The Company will at all times reserve and keep available
out of its authorized but unissued shares or shares held in treasury, sufficient shares of Series&nbsp;E
Preferred Stock or other securities to permit the full conversion of the outstanding principal
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and interest of this Note pursuant to the terms of this Note. In the event the Company shall
have insufficient shares of Series&nbsp;E Preferred Stock or other securities to permit the full
conversion of the outstanding principal and accrued interest of this Note pursuant to the terms
hereof, the Company hereby covenants and agrees that the Company shall use its commercially
reasonable efforts to seek board and shareholder approval of an amendment to the Company&#146;s Articles
of Incorporation in order to authorize an increase in the number of authorized shares of Series&nbsp;E
Preferred Stock or other securities of the Company in a sufficient amount so that the aggregate
number of shares of Series&nbsp;E Preferred Stock or other securities issuable upon conversion of this
Note will then be authorized and available for issuance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Change of Control Transaction</U>. The Company shall provide the Holder with 15&nbsp;days
written notice of the closing of a Change of Control Transaction, specifying in reasonable detail
the terms of such Change of Control Transaction. If the Holder shall not have voluntarily elected
to convert this Note as set forth in Section&nbsp;3(c)(iii) within such 15&nbsp;day period, the Company may
prepay the entire principal amount and interest owing under this Note as of the date of such
prepayment. The Holder shall thereafter promptly return the Note to the Company for cancellation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Change in Series&nbsp;E Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Split, Subdivision or Combination of Series&nbsp;E Preferred Stock</U>. In the event the
Company should at any time or from time to time after the date of issuance hereof split or
subdivide the outstanding shares of its Series&nbsp;E Preferred Stock (or other securities issuable upon
conversion of this Note) or issue additional shares of Series&nbsp;E Preferred Stock (or other
securities issuable upon conversion of this Note) to the holders thereof as a dividend or make any
other distribution payable in additional shares of Series&nbsp;E Preferred Stock (or other securities
issuable upon conversion of this Note) to the holders thereof without payment of any consideration
by such holder for the additional shares of Series&nbsp;E Preferred Stock (or such other securities),
then, as of the date of such dividend, distribution, split or subdivision, the Conversion Price of
this Note shall be appropriately decreased so that the number of shares of Series&nbsp;E Preferred Stock
or other securities issuable upon conversion of this Note shall be increased in proportion to such
increase of outstanding shares of Series&nbsp;E Preferred Stock or other securities issuable upon
conversion of this Note, as applicable. If the number of shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note) outstanding at any time after the date
hereof is decreased by a combination of the outstanding shares of Series&nbsp;E Preferred Stock (or
other securities issuable upon conversion of this Note), then, following the record date of such
combination, the Conversion Price for this Note shall be appropriately increased so that the number
of shares of Series&nbsp;E Preferred Stock or other securities issuable on conversion hereof shall be
decreased in proportion to such decrease in outstanding shares of Series&nbsp;E Preferred Stock or other
securities issuable upon conversion of this Note, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Reclassification etc</U>. In case of any reclassification, capital reorganization, or
change in the Series&nbsp;E Preferred Stock (or other securities issuable upon conversion of this Note)
of the Company, including conversion of such shares pursuant to the Company&#146;s Articles of
Incorporation then in effect (other than as a result of a split, subdivision, combination, or stock
dividend provided for in Section&nbsp;5(a) above), then appropriate adjustment shall be made to the
Conversion Price and kind of securities or other property issuable upon conversion of this Note so
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">that this Note shall be convertible upon the terms set forth herein into the kind and amount
of shares of stock and other securities and property receivable in connection with such
reclassification, reorganization, or change by a holder of the same number of shares of Series&nbsp;E
Preferred Stock or other securities as are issuable on conversion of this Note.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Merger or Consolidation</U>. Other than a Change of Control Transaction in connection
with which this Note has been converted or prepaid, if at any time there shall be an acquisition of
the Company by merger, consolidation or otherwise where the Company is not the surviving
corporation or as a result of which all of the outstanding capital stock of the Company is
exchanged for capital stock of another corporation, then, as a part of such acquisition, the
Conversion Price and kind of securities issuable upon conversion hereof shall be appropriately
adjusted so that the Holder shall receive upon conversion of this Note, the number of shares of
stock or other securities or property of the surviving or successor corporation resulting from such
acquisition (or the corporation the capital stock of which is issued in exchange for the capital
stock of the Company), to which a holder of the securities issuable upon conversion of this Note
would have been entitled in such acquisition if this Note had been converted immediately before
such acquisition.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Payment Due Date</U>. If not previously converted into shares of Series&nbsp;E Preferred
Stock pursuant to Section&nbsp;3 hereof and if not sooner prepaid by the Company pursuant to Section&nbsp;2
hereof or accelerated and declared due and owing by the Holder pursuant to Section&nbsp;7 hereof, the
principal amount and any accrued interest due thereon then outstanding under this Note will become
due and payable on the Payment Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Default</U>. The Company shall be deemed to be in default under this Note in the event
(i)&nbsp;the Company shall fail to materially perform any covenant or agreement of the Company contained
in Section&nbsp;4 of the Note Purchase Agreement for a period of 30&nbsp;days after written notice of such
failure from Holder; (ii)&nbsp;the Company shall have failed to make payment of principal or interest
due on the Note when such principal and interest becomes due; or (iii)&nbsp;the Company shall commence,
whether voluntarily or involuntarily a case or other proceeding seeking liquidation, reorganization
or other relief with respect to itself or its debts under any bankruptcy, insolvency or other
similar law now or hereafter in effect or consent to any such relief or to the appointment of or
taking possession of its property by any official in an involuntary case or other proceeding
commenced against it. In the case of an event of default, the Holder may, by written notice to the
Company, declare the unpaid principal amount of this Note, all interest accrued and unpaid hereon,
and all other amounts payable hereunder to be immediately due and payable, without presentment,
demand, protest, or further notice of any kind, as well as enforce all other rights and remedies
available to the Holder under applicable law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Notices</U>. Any notice, request, other communication, or payment required or
permitted hereunder shall be in writing and shall be deemed to have been duly given upon delivery,
if delivered personally by facsimile, or by recognized overnight courier service, or five days
after deposit, if deposited in the United States mail for mailing by registered or certified mail,
postage prepaid, and addressed as follows:
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Holder:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Biopolis Way</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">#09-01 Centros</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Singapore 138668&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chu Swee Yeok</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 65-6336-2288&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 65-6334-8478&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to the Company:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Chief Executive Officer</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650)&nbsp;266-6000&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;871-7195&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich&nbsp;&#038; Rosati, P.C.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, California 94304-1050&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Ken Clark and Robert Kornegay</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: (650)&nbsp;493-9300&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: (650)&nbsp;493-6811&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the above addressees may change its address or facsimile number for purposes of this
paragraph by giving to the other addressee notice of such new address in conformity with this
paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments</U>. This Note may be amended and any provision hereof waived with the
consent of the Company and the Holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>No Rights as Shareholder</U>. Nothing in this Note shall be construed as conferring
upon the Holder or any other person the right to vote or to consent or to receive notice as a
shareholder in respect of meetings of shareholders for the election of directors of the Company or
any other matters or any rights whatsoever as a shareholder of the Company until, and only to the
extent that, this Note shall have been converted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Successors and Assigns</U>. Subject to the restrictions on transfer described in
Section&nbsp;12 and in the Note Purchase Agreement, the rights and obligations of the Company and
Investor shall be binding upon and benefit the successors, assigns, heirs, administrators and
transferees of the parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Transfer of Note and Securities Issuable on Conversion Hereof</U>. Prior to the
conversion of this Note, this Note (or the underlying securities issuable upon conversion hereof)
may not be sold, assigned, transferred, pledged or otherwise disposed of by the Holder, in whole or
in part, without the prior written consent of the Company. With respect to any sale, assignment,
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">transfer, pledge or other disposition of the securities into which this Note may be converted
after conversion of this Note, the Holder may only transfer such securities pursuant to, and on the
conditions set forth in that certain Eighth Amended and Restated Investor Rights Agreement dated
June&nbsp;13, 2006 between the Company and certain investors in the Company (including Holder), as may
be amended from time to time (the &#147;<U>Rights Agreement</U>&#148;). The Holder shall cause any proposed
purchaser, assignee, transferee or pledgee of such securities to agree in writing to take and hold
such securities subject to and upon the conditions specified in this Note, the Note Purchase
Agreement, and the Rights Agreement, including, without limitation, Sections&nbsp;1.2, 1.3, 1.4, and
1.14 of the Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Highest Lawful Rate</U>. Anything herein to the contrary notwithstanding, if during
any period for which interest is computed hereunder, the amount of interest computed on the basis
provided for in this Note, together will all fees, charges, and other payments or rights which are
treated as interest under applicable law, as provided for herein or in any other document executed
in connection herewith, would exceed the amount of such interest computed on the basis of the
Highest Lawful Rate, the Company shall not be obligated to pay, and the Holder shall not be
entitled to charge, collect, receive, reserve, or take, interest in excess of the Highest Lawful
Rate, and during any such period the interest payable hereunder shall be computed on the basis of
the Highest Lawful Rate. As used herein, &#147;<U>Highest Lawful Rate</U>&#148; means the maximum
non-usurious rate of interest, as in effect from time to time, which may be charged, contracted
for, reserved, received, or collected by the Holder in connection with this Note under applicable
law. In accordance with this section, any amounts received in excess of the Highest Lawful Rate
shall be applied towards the prepayment of principal then outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Miscellaneous</U>. The Company agrees to pay on demand all of the losses, costs, and
expenses (including, without limitation, attorneys&#146; fees and disbursements) which the Holder incurs
in connection with enforcement of this Note, or the protection or preservation of the Holder&#146;s
rights under this Note, whether by judicial proceeding or otherwise. Such costs and expenses
include, without limitation, those incurred in connection with any workout or refinancing, or any
bankruptcy, insolvency, liquidation, or similar proceedings. The Company hereby waives
presentment, demand for performance, notice of non-performance, protest, notice of protest, and
notice of dishonor. No delay on the part of the Holder in exercising any right hereunder shall
operate as a waiver of such right or any other right. This Note is being delivered in and shall be
construed in accordance with the laws of the State of California without regard to the conflicts of
law provisions thereof. Any reference to &#147;dollars&#148; or &#147;$&#148; in this Note shall refer to the lawful
money of the United States of America.
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Company has caused this Convertible Promissory Note to be executed by
its officer thereunto duly authorized as of the date first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Dated: &#95;&#95;&#95;&#95;&#95;&#95; ___, 20&#95;&#95;&#95;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Fluidigm Corporation</B></FONT><br>
a California corporation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acknowledged and Agreed:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Holder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" valign="top" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><DIV style="font-size: 1pt; border-bottom:1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><b>[Convertible Promissory Note Signature Page]</b></div>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
 <DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FORM OF COMPLIANCE CERTIFICATE</B>

</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT D</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>COMPLIANCE CERTIFICATE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>(Issuance of First Note)</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm Corporation, a California corporation (the &#147;<U>Company</U>&#148;), hereby represents and
warrants to Biomedical Sciences Investment Fund Pte Ltd (the &#147;<U>Purchaser</U>&#148;) as follows,
effective as August&nbsp;7, 2006. This Compliance Certificate is delivered in connection with the sale
and issuance to the Purchaser of the Company&#146;s Convertible Promissory Note dated as of August&nbsp;7,
2006 in the principal amount of $5,000,000.00 (the &#147;<U>Convertible Note</U>&#148;) and issued pursuant
to the Convertible Note Purchase Agreement dated as of August&nbsp;7, 2006, (the &#147;<U>Purchase
Agreement</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The Company is a corporation duly organized, validly existing, and in good standing under
the laws of the State of California and has all requisite corporate power and authority to carry on
its business as currently conducted. The Company is duly qualified to transact business and is in
good standing in each jurisdiction in which the failure to so qualify would have a material adverse
effect on its business (as now conducted), properties, or financial condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The Company has all requisite legal and corporate power and authority to (i)&nbsp;execute and
deliver this Compliance Certificate; (ii)&nbsp;sell and issue the Convertible Note; (iii)&nbsp;issue the
shares of Series&nbsp;E Preferred Stock issuable upon conversion of the Convertible Note (the
&#147;<U>Series&nbsp;E Shares</U>&#148;) and the Common Stock issuable upon conversion of such Series&nbsp;E Shares
(the &#147;<U>Common Conversion Shares</U>&#148;); and (iv)&nbsp;carry out and perform its obligations under the
terms of this Compliance Certificate, the Convertible Note, and the Purchase Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;All corporate action on the part of the Company, its officers, directors, and shareholders
necessary for the authorization, execution, and delivery of this Compliance Certificate, the
performance of all obligations of the Company under this Compliance Certificate, the Convertible
Note, and the Purchase Agreement, the sale and delivery of the Convertible Note, and the
authorization and issuance of the Series&nbsp;E Shares and the Common Conversion Shares has been taken.
Each of the Eighth Amended and Restated Investor Rights Agreement dated as of June&nbsp;13, 2006 among
the Company and certain of its shareholders (as amended to date, the &#147;<U>Rights Agreement</U>&#148;)
and the Second Amended and Restated Voting Agreement dated as of August&nbsp;16, 2005 (as amended to
date, the &#147;<U>Voting Agreement</U>&#148;) remain effective, subject only to such amendments as to which
the Purchaser has been previously notified in writing and unless earlier terminated in accordance
with their terms (for which the Company has also provided the Purchaser notice in writing). Each
of this Compliance Certificate, the Purchase Agreement, the Convertible Note and to the extent not
terminated in accordance with its terms, each of the Rights Agreement and the Voting Agreement,
constitute valid and legally binding obligations of the Company, enforceable against the Company in
accordance with their terms, subject to (i)&nbsp;judicial principles limiting the availability of
specific performance, injunctive relief, and other equitable remedies; (ii)&nbsp;bankruptcy, insolvency,
reorganization, moratorium and other similar laws now or hereafter in effect generally relating to
or affecting creditors&#146; rights; and (iii)&nbsp;limitations on the enforceability of the indemnification
provisions of the Rights Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The Convertible Note, when issued, sold and delivered in accordance with the terms of the
Purchase Agreement will be free of restrictions on transfer other than restrictions on transfer
under the Purchase Agreement, the Convertible Note, the Rights Agreement and the Voting Agreement
and under applicable state and federal securities laws. The Series&nbsp;E Shares, when issued upon
conversion of the Convertible Note, in accordance with the Convertible Note and the Purchase
Agreement, will be duly and
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">validly issued, fully paid, and nonassessable, and will be free of restrictions on transfer
other than restrictions on transfer under the Purchase Agreement, the Rights Agreement, and the
Voting Agreement and under applicable state and federal securities laws. The Common Conversion
Shares, when issued upon conversion of the Series&nbsp;E Shares in accordance with the terms of the
Company&#146;s Articles of Incorporation as currently in effect, will be duly and validly issued, fully
paid, and nonassessable, and will be free of restrictions on transfer other than restrictions on
transfer under the Purchase Agreement, the Rights Agreement, and the Voting Agreement, and under
applicable state and federal securities laws. The Series&nbsp;E Shares and the Common Conversion Shares
may, subject to the continued accuracy of the representations and warranties provided by Purchaser
pursuant to the Purchase Agreement, be issued without any registration or qualification under state
and federal securities laws as such laws are currently in effect.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;No consent, approval, order or authorization of, or registration, qualification,
designation, declaration or filing with, any federal, state or local governmental authority is
required in connection with the offer and sale of the Convertible Note or the issuance of the
Series&nbsp;E Shares or the Common Conversion Shares or the consummation of any other transaction
contemplated by the Convertible Note or the Purchase Agreement, except for filings required
pursuant to applicable federal and state securities laws and blue sky laws, which filings the
Company covenants to complete within the required statutory period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The Company is not in violation or default of any provision of its Articles of
Incorporation or Bylaws, each as amended and in effect as of the date hereof. The Company is not
in violation or default of any provision of any instrument, mortgage, deed of trust, loan,
contract, commitment, judgment, decree, order, or obligation to which it is a party or by which it
or any of its properties or assets is bound or, to the best of its knowledge, of any provision of
any federal, state, or local statute, rule, or governmental regulation, except to the extent such
violations or defaults would not reasonably be expected, individually or in the aggregate, to have
a material adverse effect on the Company&#146;s business (as now conducted), properties, or financial
condition or an adverse effect on the Company&#146;s ability to consummate the transactions contemplated
by this Compliance Certificate, the Convertible Note, and the Purchase Agreement. None of the
execution, delivery, and performance of and compliance with this Compliance Certificate, the
continued performance by the Company under the Purchase Agreement, the Rights Agreement (unless
terminated prior to the date hereof) and the Voting Agreement (unless terminated prior to the date
hereof), the sale and issuance of the Convertible Note, or the issuance of the Series&nbsp;E Shares or
the Common Conversion Shares will (i)&nbsp;result in any violation, be in conflict with, or constitute,
with or without the passage of time, or giving of notice, a default under any such provision,
license, indenture, instrument, mortgage, deed of trust, loan, contract, commitment, judgment,
decree, order, or obligation, except where such violation or conflict would not reasonably be
expected to have a material adverse effect on the Company&#146;s business (as now conducted),
properties, or financial condition or an adverse effect on the Company&#146;s ability to consummate the
transactions contemplated by this Compliance Certificate, the Convertible Note, and the Purchase
Agreement; (ii)&nbsp;require any consent or waiver under any such provision, license, indenture,
instrument, mortgage, deed of trust, loan, contract, commitment, judgment, decree, order, or
obligation (other than such consents or waivers that have been obtained or such consents or waivers
that if not obtained would not reasonably be expected to have a material adverse effect on the
Company&#146;s business (as now conducted), properties, or financial condition or an adverse effect on
the Company&#146;s ability to consummate the transactions contemplated by this Compliance Certificate,
the Convertible Note, and the Purchase Agreement; or (iii)&nbsp;result in the creation of any mortgage,
pledge, lien, encumbrance, or charge upon any of the properties or assets of the Company pursuant
to any such provision, license, indenture, instrument, mortgage, deed of trust, loan, contract,
commitment, judgment, decree, order, or obligation (other than such mortgages, pledges, liens,
encumbrances, or charges as would not reasonably be expected to have a material adverse effect on
the Company&#146;s business (as now conducted), properties, or financial condition or an adverse effect
on the Company&#146;s ability to consummate the transactions contemplated by this Compliance
Certificate, the Convertible Note, and the Purchase Agreement).
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;The representations and warranties of the Company contained in Section&nbsp;2 of the Purchase
Agreement were true in all material respects on and as of the Closing (as defined in the Purchase
Agreement) of the sale of the First Note (as defined in the Purchase
Agreement) on August&nbsp;7, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;This Compliance Certificate shall be governed by the laws of the State of California,
without reference to the conflicts of law provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executed
as of August&nbsp;7, 2006.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>FLUIDIGM CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD nowrap colspan="2" valign="top">Print Name:&nbsp;&nbsp;</TD>

    <TD align="left" style="border-bottom: 1px solid #000000">Gajus Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;&nbsp;&nbsp;CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;Signature Page to Compliance Certificate&#093;</I>
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT E</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INVESTMENT REPRESENTATION STATEMENT</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">PURCHASER:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Biomedical Sciences Investment Fund Pte Ltd (the &#147;Purchaser&#148;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">COMPANY:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation (the &#147;Company&#148;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SECURITY:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Convertible Promissory Note (US$5,000,000 in principal amount) (the &#147;Additional Note&#148;) the principal and
accrued interest on which are convertible into shares of Series&nbsp;E Preferred Stock of the Company</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE::
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">August&nbsp;7, 2006</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Investment Representation Statement is entered into in connection with the sale by the
Company of an Additional Note to Purchaser as set forth in that certain Convertible Promissory Note
Purchase Agreement between the Company and Purchaser dated August&nbsp;7, 2006 (the &#147;<U>Note Purchase
Agreement</U>&#148;). Capitalized terms used but not otherwise defined herein have the meanings given
to such terms in the Note Purchase Agreement. In connection with the purchase of the Second Note
and the securities issued or issuable upon conversion thereof (the &#147;<U>Conversion
Securities</U>&#148;), the undersigned Purchaser represents to the Company the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Experience</U>. Purchaser is experienced in evaluating start-up companies such as the
Company, is able to evaluate and represent its own interests in transactions such as the purchase
of the Additional Note and the Conversion Securities, has such knowledge and experience in
financial and business matters such that Purchaser is capable of evaluating the merits and risks of
Purchaser&#146;s investment in the Company, and has the ability to bear the economic risks of its
investment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Investment</U>. Purchaser is acquiring and will acquire, the Additional Note and the
Conversion Securities, for investment for Purchaser&#146;s own account and not with the view to, or for
resale in connection with, any distribution thereof. Purchaser understands that the Additional
Note and the Conversion Securities have not been registered under the Securities Act of 1933, as
amended (the &#147;<U>Securities Act</U>&#148;) by reason of a specific exemption from the registration
provisions of the Securities Act, which depends upon, among other things, the bona fide nature of
Purchaser&#146;s investment intent as expressed herein. Purchaser further represents that it does not
have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant
participation to any third person with respect to any of the Additional Note or Conversion
Securities other than a transfer not involving a change of beneficial ownership. Purchaser
understands and acknowledges that the offering of the Additional Note and Conversion Securities
will not be registered under the Securities Act on the ground that the sale provided for is exempt
from the registration requirements of the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Rule&nbsp;144</U>. Purchaser acknowledges that the Additional Note and Conversion
Securities must be held indefinitely unless subsequently registered under the Securities Act or an
exemption from such registration is available. Purchaser is aware of the provisions of Rule&nbsp;144
promulgated under the Securities Act, which permit limited resale of shares purchased in a private
placement subject to the satisfaction of certain conditions. Purchaser covenants that, in the
absence of an effective registration statement covering the securities in question, Purchaser will
sell, transfer,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or otherwise dispose of the Additional Note and the Conversion Securities only in accordance
with applicable securities laws and in a manner consistent with Purchaser&#146;s representations and
covenants set forth herein and in the Note Purchase Agreement between Holder and the Company and
the Additional Note. In connection therewith, Purchaser acknowledges that the Company will make a
notation on its stock books regarding the restrictions on transfer set forth herein, in the Note
Purchase Agreement and the Additional Note and will transfer securities on the books of the Company
only to the extent not inconsistent therewith.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>No Public Market</U>. Purchaser understands that no public market now exists for any
of the securities issued by the Company, and that the Company has made no assurances that a public
market will ever exist for the Second Note or the Conversion Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Access to Data</U>. Purchaser has received and reviewed information about the Company
and has had an opportunity to discuss the Company&#146;s business, management and financial affairs with
its management and to review the Company&#146;s facilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Authorization</U>. This Investment Representation Statement when executed and
delivered by the Purchaser will constitute a valid and legally binding obligation of the Purchaser,
enforceable against the Purchaser in accordance with its terms, subject to: (i)&nbsp;judicial principles
respecting election of remedies or limiting the availability of specific performance, injunctive
relief, and other equitable remedies; and (ii)&nbsp;bankruptcy, insolvency, reorganization, moratorium
or other similar laws now or hereafter in effect generally relating to or affecting creditors&#146;
rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Accredited Investor</U>. Purchaser acknowledges that it is an &#147;accredited investor&#148; as
defined in Rule&nbsp;501 of Regulation&nbsp;D as promulgated by the United States Securities and Exchange
Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act and shall submit to the Company such
further assurances of such status as may be reasonably requested by the Company. The principal
address of such Purchaser is as set forth on the signature page hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Tax Advisors</U>. Purchaser has reviewed with its own tax advisors the tax
consequences of the purchase of the Additional Note and the Conversion Securities. Purchaser is
relying solely on such advisors and not on any statements or representations of the Company or any
of its agents and understands that Purchaser (and not the Company) shall be responsible for the
Purchaser&#146;s own tax liability that may arise as a result of the Purchase of the Additional Note and
the Conversion Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Brokers or Finders</U>. The Company has not incurred and will not incur, directly or
indirectly, as a result of any action taken by such Purchaser, any liability for brokerage or
finders&#146; fees or agents&#146; commissions or any similar changes in connection with the Note Purchase
Agreement or the Additional Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Non-United States Persons</U>. Purchaser hereby represents that Purchaser is
satisfied as to the full observance of the laws of Purchaser&#146;s jurisdiction in connection with any
invitation to subscribe for the Additional Note and the Conversion Securities or any use of the
Note Purchase Agreement, including (i)&nbsp;the legal requirements within Purchaser&#146;s jurisdiction for
the purchase of the Additional Note and the Conversion Securities, (ii)&nbsp;any foreign exchange
restrictions applicable
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="right" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to such purchase, (iii)&nbsp;any governmental or other consents that may need to be obtained and
(iv)&nbsp;the income tax and other tax consequences, if any, that may be relevant to the purchase,
holding, redemption, sale or transfer of such securities. Purchaser&#146;s subscription and payment
for, and Purchaser&#146;s continued beneficial ownership of, the Additional Note and the Conversion
Securities will not violate any applicable securities or other laws of Purchaser&#146;s jurisdiction.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Other Agreements</U>. Purchaser acknowledges and agrees that Purchaser and the
Additional Note and the Conversion Securities are subject to the Additional Note, and Investor
Rights Agreement and the restrictions on transfer set forth therein and in the Note Purchase
Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><I>&#091;Remainder of Page Left Blank Intentionally&#093;</I></B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="right" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Purchaser has caused this Investment Representation Statement to be
executed by its officer thereunto duly authorized as of the date first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>PURCHASER:</B><BR>
<BR>
<BR>
<FONT style="font-variant: SMALL-CAPS"><B>Biomedical Sciences Investment Fund Pte Ltd</B></FONT><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Chu Swee Yeok
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left" COLSpaN="2" style="border-bottom: 1px solid #000000">Chu Swee Yeok&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left" COLSpaN="2" style="border-bottom: 1px solid #000000">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT
F<br>
LEGAL OPINION</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">August __, 2006
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte. Ltd.<BR>
20 Biopolis Way<BR>
#09-01 Centros<BR>
Singapore 138668

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Re: <U><B>Convertible Note Purchase Agreement</B></U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reference is made to the Convertible Note Purchase Agreement dated as of August &#95;&#95;&#95;, 2006 (the
&#147;<B>Agreement</B>&#148;) by and among Fluidigm Corporation, a California corporation (the &#147;<B>Company</B>&#148;), and
Biomedical Sciences Investment Fund Pte. Ltd. (the &#147;<B>Purchaser</B>&#148;), which provides for the sale and
issuance by the Company to the Purchaser of the First Note, the Second Note and the Third Note
(each as defined in the Agreement). This opinion is rendered to the Purchaser pursuant to Section
4.9 of the Agreement, and all terms used herein have the meanings defined for them in the Agreement
and/or the First Note, unless otherwise defined herein. Reference in this opinion to the Agreement
excludes any schedule or substantive agreement attached as an exhibit to the Agreement, unless
otherwise indicated herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have acted as counsel for the Company in connection with the negotiation of the Agreement
and the issuance of the First Note. As such counsel, we have made such legal and factual
examinations and inquiries as we have deemed advisable or necessary for the purpose of rendering
this opinion. In addition, we have examined originals or copies of such corporate records of the
Company, certificates of public officials and such other documents which we consider necessary or
advisable for the purpose of rendering this opinion. In such examination we have assumed the
genuineness of all signatures on original documents, the authenticity and completeness of all
documents submitted to us as originals, the conformity to original documents of all copies
submitted to us and the due execution and delivery of all documents (except as to due execution and
delivery by the Company) where due execution and delivery are a prerequisite to the effectiveness
thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In our examination of the documents identified above and for purposes of this opinion, we have
relied solely upon and assumed, and express no opinion as to, the current accuracy and completeness
of (i)&nbsp;the information obtained from public officials; (ii)&nbsp;the representations and warranties of
the Company and the Purchaser as to factual and other matters set forth in the
Agreement and in any certificate delivered pursuant thereto or any ancillary agreement
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte. Ltd.<BR>
August &#95;&#95;&#95;, 2006<BR>
Page 2

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">referenced therein; and (iii)&nbsp;the representations and warranties as to factual and other matters
made by representatives of the Company to us, including without limitation, those set forth in a
management certificate executed by an executive of the Company.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in this opinion, the expression &#147;to our knowledge,&#148; &#147;known to us&#148; or similar language
with reference to matters of fact means that, after an examination of documents made available to
us by the Company, and after inquiries of officers of the Company, but without any further
independent factual investigation, we find no reason to believe that the opinions expressed herein
are factually incorrect. Further, the expression &#147;to our knowledge,&#148; &#147;known to us&#148; or similar
language with reference to matters of fact refers to the current actual knowledge of the attorneys
of this firm who provided material legal representation to the Company in connection with the
Agreement and the transactions contemplated thereby. Except to the extent expressly set forth
herein or as we otherwise believe to be necessary to our opinion, we have not undertaken any
independent investigation to determine the existence or absence of any fact, and no inference as to
our knowledge of the existence or absence of any fact should be drawn from our representation of
the Company or the rendering of the opinions set forth below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this opinion, we are assuming that the Purchaser has all requisite power and
authority, and has taken any and all necessary corporate or partnership action, to execute and
deliver the Agreement and the First Note and to effect any and all transactions related to or
contemplated thereby. In addition, we are assuming that the representations and warranties made by
the Purchaser in the Agreement and pursuant thereto are true and correct. We are also assuming
that the Purchaser has purchased the First Note (and the Note Shares issuable upon conversion
thereof) for value, in good faith and without notice of any adverse claims within the meaning of
the California Uniform Commercial Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are members of the Bar of the State of California, and we express no opinion as to any
matter relating to the laws of any jurisdiction other than the federal laws of the United States of
America and the laws of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The opinions hereinafter expressed are subject to the following additional qualifications:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;We express no opinion as to the effect of applicable bankruptcy, insolvency,
reorganization, moratorium or other similar federal or state laws affecting the rights of
creditors.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;We express no opinion as to the effect or availability of rules of law governing specific
performance, injunctive relief or other equitable remedies (regardless of whether any such remedy
is considered in a proceeding at law or in equity).</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte. Ltd.<BR>
August &#95;&#95;&#95;, 2006<BR>
Page 3

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;This opinion is qualified by the limitations imposed by statutes and principles of law and
equity that provide that certain covenants and provisions of agreements are unenforceable where
such covenants or provisions are unconscionable or contrary to public policy or where enforcement
of such covenants or provisions under the circumstances would violate the enforcing party&#146;s implied
covenant of good faith and fair dealing.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;We express no opinion regarding any of (i)&nbsp;the rights or remedies available to any party
for violations or breaches of any provisions which are immaterial or the enforcement of which would
be unreasonable under the then-existing circumstances; (ii)&nbsp;the rights or remedies available to any
party for material violations or breaches which are the proximate result of actions taken by any
party to the Agreement or the First Note other than the party against whom enforcement is sought,
which actions such other party is not entitled to take pursuant to the Agreement or the First Note
or which otherwise violate applicable laws; (iii)&nbsp;the rights or remedies available to any party
which takes discretionary action which is arbitrary, unreasonable or capricious, or is not taken in
good faith or in a commercially reasonable manner, whether or not the Agreement or the First Note
permits such action; (iv)&nbsp;the effect of the exercise of judicial discretion, whether in a
proceeding in equity or at law; (v)&nbsp;the enforceability of any provision deemed to be
&#147;unconscionable&#148; within the meaning of Section&nbsp;1670.5 of the California Civil Code; (vi)&nbsp;the
enforceability of any provision authorizing the exercise of any remedy without reasonable notice
and opportunity to cure; or (vii)&nbsp;the effect of any provision of the Agreement or the First Note
purporting to give the Purchaser the right to make any conclusive determination in its sole
discretion.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;We express no opinion as to the legality, validity, binding nature or enforceability of
(i)&nbsp;any provisions in the Agreement or the First Note providing for the payment or reimbursement of
costs or expenses or indemnifying a party, to the extent such provisions may be held unenforceable
as contrary to public policy; (ii)&nbsp;any provision of the Agreement or the First Note insofar as it
provides for the payment or reimbursement of costs and expenses or indemnification for claims,
losses or liabilities in excess of a reasonable amount determined by any court or other tribunal;
(iii)&nbsp;any provisions regarding the Purchaser&#146;s (or its agent&#146;s) ability to collect attorneys&#146; fees
and costs in an action involving the Agreement or the First Note, if the
Purchaser (or such agent) is not the prevailing party in such action (we call your attention
to the effect of Section&nbsp;1717 of the California Civil Code, which provides that, where a contract
permits one party thereto to recover attorneys&#146; fees, the prevailing party in any action to enforce
any provision of the contract shall be entitled to recover its reasonable attorneys&#146; fees); (iv)
any provisions of the Agreement or the First Note imposing penalties or forfeitures, late payment
charges or any increase in interest rate, upon delinquency in payment or the occurrence of a
default to the extent they constitute a penalty or forfeiture or are otherwise contrary to public
policy; (v)&nbsp;any rights of set-off; (vi)&nbsp;any provision of the Agreement or the First Note to the</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte. Ltd.<BR>
August &#95;&#95;&#95;, 2006<BR>
Page 4

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">effect that a statement, certificate, determination or record shall be deemed conclusive absent
manifest error (or similar effect), including, without limitation, that any such statement,
certificate, determination or record shall be <I>prima facie </I>evidence of a fact; or (vii)&nbsp;any
provision of the Agreement or the First Note which provides that notice not actually received may
be binding on any party.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;We express no opinion with respect to the legality, validity, binding nature or
enforceability of (i)&nbsp;any vague or broadly stated waiver, including without limitation, the waivers
of diligence, presentment, demand, protest or notice; (ii)&nbsp;any waivers or consents (whether or not
characterized as a waiver or consent in the Agreement or the First Note) relating to the rights of
the Purchaser or duties owing to them existing as a matter of law, including, without limitation,
waivers of the benefits of statutory or constitutional provisions, to the extent such waivers or
consents are found by courts to be against public policy or which are ineffective pursuant to
California statutes and judicial decisions; (iii)&nbsp;any waivers of any statute of limitations; or
(iv)&nbsp;covenants to the extent they are to be enforced as independent requirements as distinguished
from conditions that may trigger an event of default.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;We express no opinion with respect to the legality, validity, binding nature or
enforceability of any provision of the Agreement or the First Note to the effect that rights or
remedies are not exclusive, that every right or remedy is cumulative and may be exercised in
addition to any other right or remedy, that the election of some particular remedy or remedies does
not preclude recourse to one or more other remedies or that failure to exercise or delay in
exercising rights or remedies will not operate as a waiver of any such right or remedy.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;We note the obligations of the Company under the Agreement and the First Note relating to
the Business Plan and the Milestones and the effects of deemed satisfaction of the Milestones on
the conversion of the First Note. We express no opinion as to the enforceability of these
provisions to the extent that they may be deemed vague or overly broad.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;We express no opinion as to any provision of the Agreement or the First Note requiring
written amendments or waivers of such documents insofar as it suggests that oral or other
modifications, amendments or waivers could not be effectively agreed upon by the parties or that
the doctrine of promissory estoppel might not apply.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;We express no opinion as to compliance with the anti-fraud provisions of applicable
securities laws.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;We express no opinion as to the enforceability of any indemnification or contribution
provision to the extent the provisions thereof may be subject to limitations of public policy and
the effect of applicable statutes and judicial decisions.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte. Ltd.<BR>
August &#95;&#95;&#95;, 2006<BR>
Page 5

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;We express no opinion as to the enforceability of choice of law provisions, waivers of
jury trial or provisions relating to venue or jurisdiction.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;We have made no inquiry into, and express no opinion with respect to, any federal or state
statute, rule, or regulation relating to any tax, antitrust, land use, safety, environmental,
hazardous material, patent, copyright, trademark or trade name matter, as to the statutes,
regulations, treaties or common laws of any other nation (other than the United States), state or
jurisdiction (other than the State of California), or the effect on the transactions contemplated
in the Agreement or the First Note of noncompliance under any such statues, regulations, treaties,
or common laws. Without limiting the foregoing, we express no opinion as to the effect of, or
compliance with, the Investment Advisors Act of 1940, as amended, the Employee Retirement Income
Security Act of 1974, as amended, or the California Finance Lenders Law. We further disclaim any
opinion as to any statute, rule, regulation, ordinance, order, or other promulgation of any
regional or local governmental body or as to any related judicial or administrative opinion.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;Our opinions relate solely to the express written provisions of the Agreement and the
First Note, and we express no opinion as to any other oral or written agreements or understandings
between the Company and the Purchaser.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;Our opinion set forth in paragraph 1 below is based solely on the certificates of certain
state authorities and filing officers referenced above as to the legal existence and corporate good
standing of the Company in the State of California.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon and subject to the foregoing, and except as set forth in the Schedule of Exceptions
to the Agreement, we are of the opinion that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The Company is a corporation duly incorporated and validly existing under, and by virtue
of, the laws of the State of California and is in good standing under such laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The Company has all requisite legal and corporate power to execute and deliver the
Agreement and the First Note, to sell and issue the First Note under the Agreement, to issue the
Note Shares issuable upon conversion of the First Note and the Common Stock issuable upon
conversion of the Note Shares, and to carry out and perform its obligations under the terms of
the Agreement and the First Note.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;All corporate action on the part of the Company, its directors and shareholders necessary
for the authorization, execution and delivery of the Agreement and the First Note by the Company,
the authorization, sale, issuance and delivery of the First Note (and the Note Shares issuable upon
conversion of the First Note and the Common Stock issuable upon
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Biomedical Sciences Investment Fund Pte. Ltd.<BR>
August &#95;&#95;&#95;, 2006<BR>
Page 6

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conversion thereof) and the
performance by the Company of its obligations under the Agreement and the First Note has been
taken. Each of the Agreement and the First Note has been duly and validly executed and delivered
by the Company and constitutes a valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms. </DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This opinion is furnished to the Purchaser solely for its benefit in connection with the
purchase of the First Note, and may not be relied upon by any other person or for any other purpose
without our prior written consent. We assume no obligation to inform you of any facts,
circumstances, events or changes in the law that may arise or be brought to our attention after the
date of this opinion that may alter, affect or modify the opinions expressed herein.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
<BR>
<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>7
<FILENAME>f39432a9exv4w6.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<HTML>
<HEAD>
<TITLE>exv4w6</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.6</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ACTION BY WRITTEN CONSENT</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>OF THE STOCKHOLDERS OF</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Effective as of August&nbsp;25, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with Section&nbsp;228 of the Delaware General Corporation Law and the Bylaws of
Fluidigm Corporation, a Delaware corporation (the &#147;<U>Company</U>&#148;), the undersigned, constituting
the holders of outstanding shares of stock of the Company having not less than the minimum number
of votes that would be necessary to authorize or take action at a meeting at which all shares of
the Company entitled to vote thereon were present and voted, hereby adopt the following resolutions
which shall be effective as of the date that the minimum number of votes necessary to effect the
following resolutions are received by the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Consent to Automatic Conversion of Preferred Stock</I></B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><B>WHEREAS</B></U><B>: </B>Section&nbsp;4(b) of the Company&#146;s Amended and Restated Certificate of
Incorporation (the &#147;<U>Current Certificate</U>&#148;) provides as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;<U>Automatic Conversion</U>. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then
effective Conversion Rate for such share:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;immediately prior to the closing of a firm commitment underwritten initial
public offering on Form&nbsp;S 1 (or successor form) filed under the Securities Act of
1933, as amended (the &#147;Securities Act&#148;), covering the offer and sale of the
Corporation&#146;s Common Stock, provided that the offering price per share is not less
than $5.69 (as adjusted for subdivisions and combinations of the Common Stock and
changes in the Common Stock as set forth in Sections 4(e) and 4(g)) and the aggregate
gross proceeds to the Corporation are not less than $25,000,000, or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y)&nbsp;upon the receipt by the Corporation of a written consent or request for such
conversion from the holders of two-thirds of the shares of Preferred Stock then
outstanding, or, if later, the effective date for conversion specified in such
requests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><B>WHEREAS</B></U><B>: </B>The Company is currently in the process of completing an initial public
offering of its Common Stock, as described in the Company&#146;s Registration Statement on Form
S-1 (Registration No.&nbsp;333-150227) (the &#147;<U>Offering</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><B>WHEREAS</B></U><B>: </B>The undersigned holders collectively hold at least two-thirds of the shares
of Preferred Stock now outstanding.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><B>WHEREAS</B></U><B>: </B>The undersigned holders of Preferred Stock of the Company believe it to be
in the best interests of the Company and its stockholders for all outstanding shares of
Preferred Stock to be converted to Common Stock at the then applicable Conversion Rate (as
defined in the Current Certificate) prior to the closing of the Offering, subject only to
the conditions set forth herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><B>NOW, THEREFORE, BE IT RESOLVED</B></U><B>: </B>That, effective at 9:00 am Eastern on the third
business day prior to the closing of the first sale of Common Stock in the Offering, and
subject only to the approval of the price per share at which Common Stock is to be sold in
the Offering by at least 75% of the members of the Board of Directors of the Company, all
outstanding shares of Preferred Stock of the Company shall automatically and without further
action on the part of the holders of such Preferred Stock be converted into shares of Common
Stock of the Company in accordance with Section&nbsp;4(b)(y) of the Current Certificate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><U><B>RESOLVED FURTHER</B></U><B>: </B>That any and all actions taken by the directors and officers of
the Company to carry out the purposes and intent of the foregoing resolutions prior to, on
or after their adoption are authorized, approved, ratified and confirmed.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * *
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This action by written consent shall be effective as of the date the Company receives the
requisite consent of the Company&#146;s stockholders. By executing this action by written consent, each
undersigned stockholder is giving written consent with respect to all shares of the Company&#146;s
preferred stock held by such stockholder in favor of the above resolutions. This action by written
consent may be executed in any number of counterparts, each of which shall constitute an original
and all of which together shall constitute one action. Any copy, facsimile or other reliable
reproduction of this action by written consent may be substituted or used in lieu of the original
writing for any and all purposes for which the original writing could be used, provided that such
copy, facsimile or other reliable reproduction is a complete reproduction of the entire original
writing. This action by written consent shall be filed with the minutes of the proceedings of the
stockholders of the Company.
</DIV>
<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">AllianceBernstein Venture Fund&nbsp;I, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/14/08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>AllianceBernstein ESG Venture Management, L.P., its general
partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>AllianceBernstein Global Derivatives Corporation, its general
partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Mona Bhalla</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Mona Bhalla</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Vice President</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Alloy
Ventures 2005, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/12/08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Alloy Ventures 2005, LLC<BR>its General
Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Craig C. Taylor</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Craig C. Taylor</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD>Managing Member of Alloy
Ventures 2005 LLC<BR>Managing Member of Alloy Ventures 2005, L.P.</TD>
</tr>










<TR valign="bottom" style="padding-top: 24pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Alloy
Ventures 2002, L.P.<BR>Alloy Partners 2002, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/12/08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Alloy Ventures 2002, LLC<BR>its General
Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Craig C. Taylor</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Craig C. Taylor</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD>Managing Member of Alloy
Ventures 2002 LLC<BR>Managing Member of Alloy Partners 2002, L.P. and
Alloy Ventures 2002, L.P.</TD>
</tr>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-14-08</TD>
</TR>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="border-bottom: 1px solid #000000">/s/ Bruce
Burrows</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD colspan="3"><B style="font-variant: small-caps">Bruce Burrows</B></TD>
</tr>



<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">EuclidSR
Partners, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">August 12, 2008</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>EuclidSR Associates, L.P.<BR>its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Elaine V. Jones</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Elaine V. Jones</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">General Partner</TD>
</tr>



<TR valign="bottom" style="padding-top: 24pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">EuclidSR
Biotechnology Partners, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">August 12, 2008</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>EuclidSR Biotechnology Associates, L.P.<BR>its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Elaine V. Jones</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Elaine V. Jones</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">General Partner</TD>
</tr>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Fidelity
Contrafund:<BR>Fidelity Advisor New Insights fund</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/25/08</TD>
</TR>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Paul M. Murphy</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Paul M. Murphy</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Assistant Treasurer</TD>
</tr>







<TR valign="bottom" style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Fidelity
Contrafund:<BR>Fidelity Contrafund</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/25/08</TD>
</TR>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Paul M. Murphy</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Paul M. Murphy</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Assistant Treasurer</TD>
</tr>






<TR valign="bottom" style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Variable
Insurance Products Fund II:<BR>Contrafund Portfolio</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/25/08</TD>
</TR>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Paul M. Murphy</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Paul M. Murphy</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Assistant Treasurer</TD>
</tr>



<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Interwest
Partners VII, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-12-08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>InterWest Management Partners VII, LLC<BR>its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Michael Sweeney</TD>
</tr>


<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Michael Sweeney</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">As agent for the general
partner</TD>
</tr>



<TR valign="bottom" style="padding-top: 24pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Interwest
Partners VII, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-12-08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>InterWest Management Partners VII, LLC<BR>its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Michael Sweeney</TD>
</tr>


<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Michael Sweeney</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">As agent for the general
partner</TD>
</tr>

<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Lehman
Brothers Healthcare Venture Capital, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Aug 14, 2008</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Lehman Brothers HealthCare Venture Capital Associates
L.P.,<BR>its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>LB I Group Inc., its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD>Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Its:</TD>
<TD>&nbsp;</TD>
<TD>Senior Vice President</TD>
</tr>




<TR valign="bottom" style="padding-top: 24pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Lehman
Brothers P.A., LLC</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Aug 14, 2008</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD>Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Its:</TD>
<TD>&nbsp;</TD>
<TD>Senior Vice President</TD>
</tr>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Lehman
Brothers Partnership Account 2000/2001, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Aug 14, 2008</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>LB I Group Inc., its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD>Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Its:</TD>
<TD>&nbsp;</TD>
<TD>Senior Vice President</TD>
</tr>




<TR valign="bottom" style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Lehman
Brothers Offshore Partnership Account 2000/2001, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Aug 14, 2008</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>LB I Offshore Partners Group Ltd., its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD>Deborah Nordell</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Its:</TD>
<TD>&nbsp;</TD>
<TD>Senior Vice President</TD>
</tr>

<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Lilly
BioVentures, Eli Lilly&nbsp;&amp; Company</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">19 Aug 08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Darren J. Carroll</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Darren J. Carroll</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Executive Director</TD>
</tr>

<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Eli Lilly and Company</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">SightLine
Healthcare Fund&nbsp;III, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-13-08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>SightLine Healthcare Management&nbsp;III, LP, its GP</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Maureen Harder</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Maureen Harder</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Managing Director of
SightLine Partners LLC, its GP</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">SMALLCAP
World Fund, Inc.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/22/08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Capital Research and Management Company<BR>Its investment adviser</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Michael J. Downer</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Michael J. Downer</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Vice President and
Secretary</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Versant
Affiliates Fund&nbsp;1-A, L.P.<BR>
Versant Affiliates Fund&nbsp;1-B, L.P.<BR>
Versant Side Fund&nbsp;I, L.P.<BR>
Versant Venture Capital&nbsp;I, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8/13/08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Versant Ventures&nbsp;I, LLC<BR>its General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Samuel D. Colella</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Samuel D. Colella</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Managing Director</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Cross
Creek Capital, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-14-08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Cross Creek Capital GP, L.P.<BR>its Sole General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Cross Creek Capital, LLC<BR>Its Sole General Partner</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Wasatch Advisors, Inc.<BR>Its Sole Member</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Daniel Thurber</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Daniel Thurber</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Vice President</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3" style="font-weight: bold; font-variant: small-caps">Cross
Creek Capital Employee&#146;s Fund, L.P.</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-14-08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Cross Creek Capital GP, L.P.<BR>Its Sole General Partner</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Cross Creek Capital, LLC<BR>Its Sole General Partner</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Wasatch Advisors, Inc.<BR>Its Sole Member</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Daniel Thurber</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Daniel Thurber</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Vice President</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STOCKHOLDERS:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

    <TD width="6%">&nbsp;</TD>

    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD colspan="4">&nbsp;</TD>
<TD colspan="3"><font style="font-weight: bold; font-variant: small-caps">Wasatch
Funds,
Inc.</font><BR>Wasatch
Small Cap Growth Fund</TD>
</TR>
<TR>
<TD>Date:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">8-14-08</TD>
</TR>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD>Wasatch Advisors, Inc.</TD>
</tr>
<TR>
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Its:</TD>
<TD>&nbsp;</TD>
<TD>Investment Advisor</TD>
</tr>
<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">By:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">/s/ Daniel Thurber</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Name:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Daniel Thurber</TD>
</tr>

<TR style="padding-top: 12pt">
<TD colspan="4">&nbsp;</TD>
<TD valign="top">Title:</TD>
<TD>&nbsp;</TD>
<TD style="border-bottom: 1px solid #000000">Vice President</TD>
</tr>


<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">[<I>Action by Written
Consent of Stockholders of Fluidigm Corporation&#151;Consent to
Automatic Conversion</I>]
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>8
<FILENAME>f39432a9exv5w1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv5w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;5.1</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">September&nbsp;16, 2008</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm Corporation<BR>
7000 Shoreline Court, Suite&nbsp;100<BR>
South San Francisco, CA 94080</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Re: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U><B>Registration Statement on Form&nbsp;S-1</B></U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are acting as counsel to Fluidigm Corporation, a Delaware corporation (the &#147;Company&#148;), in
connection with the registration of 6,095,000 shares of the Company&#146;s Common Stock, par value
$0.001 per share, including 795,000 shares subject to an over-allotment option (collectively, the
&#147;Shares&#148;), pursuant to a Registration Statement on Form S-1 (Registration No.&nbsp;333-150227), as
amended (the &#147;Registration Statement&#148;), filed with the Securities and Exchange Commission under the
Securities Act of 1933, as amended.</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As counsel for the Company, we have examined originals or copies, certified or otherwise
identified to our satisfaction, of such documents, corporate records, certificates of public
officials and other instruments as we have deemed necessary for the purposes of rendering this
opinion. In our examination, we have assumed the genuineness of all signatures, the authenticity
of all documents submitted to us as originals and the conformity with the originals of all
documents submitted to us as copies.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon the foregoing, we are of the opinion that the Shares to be registered for sale by
the Company have been duly authorized by the Company and, when issued, delivered and paid for in
accordance with the terms of the underwriting agreement referred to in the Registration Statement, will be,
validly issued, fully paid and nonassessable.</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the use of this opinion as an exhibit to the Registration Statement, and we
consent to the reference of our name under the caption &#147;Legal Matters&#148; in the Prospectus forming a
part of the Registration Statement.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Very truly yours,</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">WILSON SONSINI GOODRICH&nbsp;&#038; ROSATI<BR>
Professional Corporation</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Wilson Sonsini Goodrich &#038; Rosati, P.C.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>9
<FILENAME>f39432a9exv10w9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w9</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Exhibit&nbsp;10.9</b>
</DIV>

<div style="border-bottom: 3px double #000000">&nbsp;</div>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MASTER CLOSING AGREEMENT
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">By and Among
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FLUIDIGM CORPORATION,<BR>
a California corporation,
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">OCULUS PHARMACEUTICALS, INC.,<BR>
a Delaware corporation,
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">and
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">THE UAB RESEARCH FOUNDATION
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">dated
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">March&nbsp;7, 2003
</DIV>

<div style="border-bottom: 3px double #000000">&nbsp;</div>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE I DEFINITIONS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Affiliate&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Ancillary Documents&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Assigned Rights&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Cash Consideration&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing Cash Consideration&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing Date&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Encumbrances&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Fluidigm Series C Preferred Stock&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;License Agreement&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;New License Agreement&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Sponsored Research Agreement&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Technology&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Transfer Taxes&#148;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE II TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Transfer of Rights and License of Technology</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Excluded Assets and Liabilities</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Payment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Taxes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assigned Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Unassignable Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE III THE CLOSING</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Closing</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination of License Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreements Between Fluidigm and UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other Documents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF OCULUS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Conflicts; Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Assigned Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Assignment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation and Claims</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Distribution Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">6</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE V REPRESENTATIONS AND WARRANTIES OF FLUIDIGM</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Organization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Conflicts; Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation and Claims</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS<br> (continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Securities Laws Exemptions</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VI REPRESENTATIONS AND WARRANTIES OF UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorization</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No conflicts; Consents</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title to Technology</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Litigation and Claims</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Distribution Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investment Representations</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restrictions</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Restrictive Legend</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Proposed Transfers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Standoff Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">11</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VII COVENANTS OF OCULUS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conduct of Business</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Information</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Approvals</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Satisfaction of Conditions Precedent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE VIII COVENANTS OF UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conduct of Business</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Access to Information</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Approvals</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Satisfaction of Conditions Precedent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE IX COVENANTS OF FLUIDIGM</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Regulatory Approvals</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Satisfaction of Conditions Precedent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE X MUTUAL COVENANTS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Confidentiality</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Publicity</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governmental Filings</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XI CONDITIONS TO CLOSING</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Each Party&#146;s Obligations</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Obligations of  Oculus and UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Conditions to Obligations of Fluidigm</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XII POST-CLOSING MATTERS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Payments by Fluidigm</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">12.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Settlement of Lawsuit</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">TABLE OF CONTENTS<BR>
(continued)
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Page</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XIII TERMINATION OF AGREEMENT</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination by Fluidigm</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination by UABRF</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mutual Consent</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">13.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Effect of Termination</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XIV SURVIVAL OF REPRESENTATIONS AND WARRANTIES</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">14.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Survival of Representations and Warranties</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="left">ARTICLE XV GENERAL</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Governing Law</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Assignment; Binding upon Successors and Assigns</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.3</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Severability</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.4</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Entire Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Counterparts</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.6</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Expenses</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other Remedies</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.8</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.9</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waiver</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.10</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Informal  Resolution</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.11</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mediation</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.12</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notices</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.13</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Construction and Interpretation of Agreement</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">22</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.14</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No Joint Venture</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">22</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.15</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Absence of Third Party Beneficiary Rights</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">22</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15.16</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Further Assurances</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBITS AND SCHEDULES</U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">

<TD nowrap align="center" style="border-bottom: 0px solid #000000"><u>Exhibit</u></TD>
    <TD>&nbsp;</TD>

<TD nowrap align="left" style="border-bottom: 0px solid #000000"><u>Description</u></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amended and Restated Articles of Incorporation of Fluidigm</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">B
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of New License Agreement</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Sponsored Research Agreement</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Description of Technology</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 8pt">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><u>Schedule</u>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><u>Description</u></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">4.6
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pending Litigation</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iv<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MASTER CLOSING AGREEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS
MASTER CLOSING AGREEMENT is entered into as of March&nbsp;7, 2003 by and among FLUIDIGM
CORPORATION, a California corporation (<u>&#147;Fluidigm&#148;</u>), OCULUS PHARMACEUTICALS, INC., a Delaware
corporation (<u>&#147;Oculus&#148;</u>), and THE UAB RESEARCH FOUNDATION (<U>&#147;UABRF&#148;</U>).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>RECITALS</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.&nbsp;Oculus and UABRF have entered into a license agreement dated September&nbsp;21,
2001 (together with all amendments and modifications thereto, the &#147;<U>License Agreement</U>&#148;)
under which Oculus was granted an exclusive license to practice the intellectual property and
technology relating to nanovolume crystallization arrays described in Schedule&nbsp;A to the
License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.&nbsp;The parties hereto have entered into a binding letter agreement dated
December&nbsp;19, 2002 (the &#147;<U>Letter Agreement</U>&#148;) under which Oculus and UABRF have agreed to
terminate the License Agreement, UABRF has agreed to grant to Fluidigm an exclusive license
to practice the intellectual property and technology relating to nanovolume crystallization
arrays covered by the License Agreement, and Fluidigm and UABRF have agreed to enter into a
sponsored research agreement. In exchange for the rights to be acquired by Fluidigm as
contemplated by the Letter Agreement, Fluidigm has paid cash in the amount of &#091;***&#093;
pursuant to the Letter Agreement and has agreed to the payment of additional cash and
securities as specified in the Letter Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.&nbsp;The parties desire to enter into this Agreement to set out additional terms and
conditions related to the closing of the transactions, and the payments to be made by
Fluidigm, contemplated by the Letter Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the representations, warranties and agreements herein
contained, the parties agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>DEFINITIONS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in this Agreement, the following terms shall have the meanings set forth or
referenced below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 &#147;<U>Affiliate</U>&#148; of any specified person shall mean any other person directly or
indirectly controlling or controlled by or under direct or indirect common control with such
specified person. For purposes of this definition, &#147;control&#148; when used with respect to any
specified person means the power to direct or cause the direction of the management and policies of
such person, directly or indirectly, whether through the ownership of voting securities, by
contract or otherwise; and the terms &#147;controlling&#148; and &#147;controlled&#148; have meanings correlative to
the foregoing.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-1-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 &#147;<U>Ancillary Documents</U>&#148; shall mean all documents or agreements required by this
Agreement to be executed or delivered by any party hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 &#147;<U>Assigned Rights</U>&#148; shall mean any intellectual property rights owned by Oculus that
pertain in any way to the Technology, including without limitation any Inventions (as such term is
defined in Section&nbsp;11 of the License Agreement) and any other patent rights and other intellectual
property rights therein owned by Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 &#147;<U>Cash Consideration</U>&#148; shall mean the sum of cash in the amount of &#091;***&#093; paid in
accordance with the Letter Agreement and the Closing Cash Consolidation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <U>&#147;Closing</U>&#148; shall mean the closing of the transactions contemplated by this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 <U>&#147;Closing Cash Consideration</U>&#148; shall mean cash in the amount of &#091;***&#093;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7
&#147;<U>Closing Date</U>&#148; shall mean March&nbsp;7, 2003, or such other date to which the parties
shall mutually agree in writing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 <U>&#147;Encumbrances</U>&#148; shall mean restrictions on or conditions to transfer or assignment,
claims, liabilities, licenses, immunities from lawsuits to third parties, liens, pledges, mortgages
or security interests of any kind, whether accrued, absolute, contingent, or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 <U>&#147;Fluidigm Series&nbsp;C Preferred Stock</U>&#148; shall mean the Series&nbsp;C Preferred Stock of
Fluidigm having the rights, preferences and privileges set forth in Fluidigm&#146;s Articles of
Incorporation attached hereto as <U>Exhibit&nbsp;A</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 &#147;<U>License Agreement</U>&#148; shall mean the license agreement between Oculus and
UABRF as described in Recital A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 &#147;<U>New License Agreement</U>&#148; shall mean the license agreement between Fluidigm and
UABRF in the form of <U>Exhibit&nbsp;B</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 &#147;<U>Sponsored Research Agreement</U>&#148; shall mean the sponsored research agreement
between Fluidigm and UABRF in the form of <U>Exhibit&nbsp;C</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 &#147;<U>Technology</U>&#148; shall mean all intellectual property and other rights relating
to nanovolume crystallization arrays described in <U>Exhibit&nbsp;D</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14
&#147;<U>Transfer Taxes</U>&#148; shall mean all sales taxes, use taxes, conveyance taxes,
transfer taxes, filing fees, recording fees, reporting fees and other similar duties, taxes and
fees, if any, imposed upon, or resulting from, the transfer of the Assigned Rights hereunder,
except federal, state or local income or similar taxes based upon or measured by revenue, income,
profit or gain from the transfer of the Assigned Rights or the operation of Oculus&#146; business prior
to the Closing or by any increase in the value of any of the Assigned Rights through the Closing
Date.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>TRANSFER OF ASSIGNED RIGHTS AND LICENSE OF TECHNOLOGY</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1
<U>Transfer of Rights and License of Technology.</U> Oculus and UABRF have mutually
terminated the License Agreement as of January&nbsp;30, 2003 and Oculus has surrendered all rights under
the License Agreement to UABRF. Subject to and upon the terms and conditions of this Agreement,
effective as of the Closing, Fluidigm and UABRF will enter into the New License Agreement. It is
the intent of the parties that all intellectual property rights subject to the License Agreement as
of November&nbsp;27, 2002 shall be transferred and/or assigned to Fluidigm, and that all such rights
owned by UABRF shall be licensed to Fluidigm under the New License Agreement, subject to the
reservation by UABRF of certain rights as set forth in the License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Excluded Assets and Liabilities</U>. Notwithstanding the provisions of Section&nbsp;2.1,

(a)&nbsp;Fluidigm and Oculus expressly acknowledge and agree that Oculus shall not sell, transfer,
assign, convey or deliver to Fluidigm, and Fluidigm shall not purchase, acquire or accept from
Oculus, any right, title or interest of Oculus in or to any other property or assets of Oculus, and

(b)&nbsp;Fluidigm does not assume, and Oculus does not transfer or assign, any liabilities or
obligations, whether presently fixed and determined, contingent or otherwise, of Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Payment</U>. In
consideration of the execution of the New License Agreement and the
transfer of the rights thereunder, Fluidigm will deliver to UABRF the Closing Cash Consideration
and [&nbsp;*&nbsp;*&nbsp;*&nbsp;] shares of Fluidigm Series&nbsp;C
Preferred Stock valued at 2.58 per share, the price at
which Fluidigm sold and issued shares of its Series&nbsp;C Preferred Stock to other investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Taxes</U>. Fluidigm and Oculus shall each pay (or reimburse the other for) one-half of
all Transfer Taxes, whether imposed by law on Fluidigm and Oculus or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Assigned Rights</U>. Oculus hereby sells, assigns and transfers to Fluidigm
all Assigned Rights, free and clear of all Encumbrances (except to the extent that the
settlement agreement pertaining to the Lawsuit (as such term is defined in Section&nbsp;6.3) may
include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <U>Unassignable Rights</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Notwithstanding any provision of this Agreement or any of the Ancillary Documents, but
subject to Section&nbsp;11.3(c), to the extent that any of the Assigned Rights are not assignable or
otherwise transferable to Fluidigm, or if such assignment or transfer would constitute a breach
thereof or a violation of any applicable law, then neither this Agreement nor such Ancillary
Documents shall constitute an assignment or transfer (or an attempted assignment or transfer)
thereof until such consent, approval or waiver of such party or parties has been duly obtained.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If any consent required to transfer the Assigned Rights to Fluidigm has not been obtained
as of the Closing Date and Fluidigm nevertheless determines to proceed with the
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Closing, Oculus and UABRF shall, at their own expense, continue to cooperate with Fluidigm and use
commercially reasonable efforts to obtain such consent after the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If any Assigned Right is not transferred to Fluidigm at the Closing pursuant to this
Agreement, Oculus and Fluidigm shall cooperate with each other in any reasonable arrangement
designed to provide for Fluidigm all of the benefits of such Assigned Rights. At Fluidigm&#146;s
request, Oculus shall take all reasonable actions requested by Fluidigm to enforce for the benefit
of Fluidigm any and all rights of Oculus with respect to any such Assigned Right that is not
otherwise transferred pursuant to the provisions of this Agreement. Oculus agrees to hold in trust
for, and remit promptly to, Fluidigm all future collections or payments received by Oculus in
respect of all such Assigned Rights (net of all costs and expenses incurred by Oculus in respect
thereto); <U>provided,</u> <u>however,</U> that nothing herein shall create or provide any rights or
benefits in or to third parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If any intellectual property rights that are described in the New License Agreement cannot
be licensed to Fluidigm by UABRF under the New License Agreement without the consent of any third
party or without resulting in a breach or default of any agreement affecting such rights, UABRF
covenants and agrees that it shall not sue or otherwise take any legal action to restrict or
prevent Fluidigm and Fluidigm&#146;s permitted assignees and sublicensees from practicing such
intellectual property rights as purported to be granted under the terms of the New License
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;If, subsequent to the Closing, a claim brought by any party challenging any of the
transactions contemplated hereby results in any ruling or order which has the result of frustrating
in a material way the transfer of any of the Assigned Rights hereunder to Fluidigm or the grant of
rights to Fluidigm under the New License Agreement or Fluidigm&#146;s use thereof as provided herein,
Oculus and UABRF shall cooperate with Fluidigm in any reasonable arrangement designed to give
Fluidigm, as nearly as practicable, the same economic benefits as if such transfer or license, as
the case may be, had been consummated in accordance with the provisions hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Nothing in this Section&nbsp;2.6 shall be deemed to modify in any respect any of the
representations or warranties of Oculus and UABRF set forth herein or the conditions to Fluidigm&#146;s
obligations contained in this Agreement, be deemed a waiver by Fluidigm of its right to have
received on or before the Closing Date an effective assignment of all of the Assigned Rights or be
deemed to constitute an agreement to exclude any assets from the Assigned Rights.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>THE CLOSING</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>The Closing</U>. The Closing shall take place at the offices of Gray Cary Ware &#038;
Freidenrich <FONT style="font-variant: SMALL-CAPS">llp, </FONT>400 Hamilton Avenue, Palo Alto, California, at 11:00&nbsp;a.m., Pacific Time,
on the Closing Date, or at such other time and place as Oculus, Fluidigm and UABRF may agree.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Termination of License Agreement</U>. On or before the Closing, Oculus and UABRF
shall deliver to Fluidigm an agreement and acknowledgment that the License
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement has been terminated and such other agreements and instruments as may be necessary or
appropriate to evidence the return by Oculus to UABRF of all rights under the License Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3
<U>Agreements Between Fluidigm and UABRF</U>. At the Closing, Fluidigm and UABRF shall execute and deliver the New License Agreement and the
Sponsored Research Agreement.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Other Documents</U>. Each party shall deliver to the other at the Closing such other
documents, certificates, schedules, agreements and instruments required by this Agreement to
be delivered at such time.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>REPRESENTATIONS AND WARRANTIES OF OCULUS </U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Oculus hereby represents and warrants to Fluidigm as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Organization</U>. Oculus is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware and has all requisite corporate power to
own, lease and operate its properties and to conduct its business as it is currently being
conducted. Oculus is duly qualified or licensed to do business as a foreign corporation in
each jurisdiction in which the failure to be so qualified or licensed would have a material adverse
effect on Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u> Authorization</u>. This Agreement and all of the Ancillary Documents to which
Oculus is or will be a party have been, or upon their execution and delivery hereunder will have
been, duly and validly executed and delivered by Oculus and constitute, or will constitute, valid
and binding agreements of Oculus, enforceable against Oculus in accordance with their respective
terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors&#146; rights generally or by principles of public policy
or general equitable principles or the exercise of judicial discretion in accordance with such
principles. Oculus has the requisite corporate power and authority to execute and deliver this
Agreement and the Ancillary Documents to which Oculus is or will be a party and, at the time of the
Closing, will have the requisite corporate power and authority to carry out the transactions
contemplated by this Agreement and the Ancillary Documents. The execution, delivery and performance
by Oculus of this Agreement and the Ancillary Documents have been duly and validly approved and
authorized by the Board of Directors and shareholders of Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>No Conflicts; Consents</U>. The execution and delivery by Oculus of this Agreement
and the Ancillary Documents to which Oculus is or will be a party do not, and the consummation
of the transactions contemplated hereby and thereby and compliance by Oculus with the
provisions hereof and thereof will not, contravene, conflict with, result in a breach of,
constitute a default (with or without notice or lapse of time, or both) under or violation of, or result
in the creation of any Encumbrance pursuant to, (i)&nbsp;any provision of the Certificate of Incorporation
or Bylaws of Oculus, (ii)&nbsp;any judgment, order, decree, rule, law or regulation of any court or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">governmental authority, foreign or domestic, applicable to Oculus or to any of the Assigned Rights,
except where any such contravention, conflict, breach or default could not reasonably be expected
to have a material adverse effect on Fluidigm&#146;s ownership of the Assigned Rights, or (iii)&nbsp;any
provision of any material agreement, instrument or understanding to which Oculus is a party or by
which Oculus is bound or any of the Assigned Rights are affected, except where any such
contravention, conflict, breach or default could not reasonably be expected to have a material
adverse effect on Fluidigm&#146;s ownership of the Assigned Rights, nor will such actions give to any
other person or entity any interests or rights of any kind, including rights of termination,
acceleration or cancellation, in or with respect to any of the Assigned Rights, or result in the
creation of any Encumbrance on any of the Assigned Rights. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of Oculus to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Title to Assigned Rights</U>. Oculus has good and marketable title to all of the
Assigned Rights. All of the Assigned Rights are free and clear of any Encumbrances (except to the
extent that the settlement agreement pertaining to the Lawsuit (as such term is defined in Section
6.3) may include an immunity from lawsuits for conduct arising prior to the date of the settlement
agreement). At the Closing, Oculus will sell, convey, assign, transfer and deliver to Fluidigm
good, valid and marketable title and all right and interest in and to all of the Assigned Rights,
free and clear of any Encumbrances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>No Assignment</U>. Oculus has not sublicensed or otherwise transferred any material
rights under the License Agreement to any third party. As of
December&nbsp;19, 2002, the License
Agreement was in full force and effect in accordance with its terms. Prior to the termination of
the License Agreement, no provisions of the License Agreement had been waived in any
material respect. <U>Exhibit&nbsp;D</U> lists all of the patent filings subject to the License
Agreement. To the knowledge of Oculus, UABRF is the owner of the patent rights within the
technology and inventions subject to the License Agreement and has not granted a license to such
technology and inventions to any person or entity other than Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Litigation and Claims</U>. Except as set forth on Schedule&nbsp;4.6 attached hereto, there
are no claims, actions, suits, proceedings arbitrations or investigations in progress or pending
(or, to the knowledge of Oculus, threatened) before any court, tribunal or governmental agency
against Oculus that relate to any of the Assigned Rights. Oculus is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial or
arbitration proceeding with any governmental authority) with respect to any of the Assigned Rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Distribution Agreement</U>. Oculus has entered into a mutually acceptable
agreement with UABRF regarding the distribution of any and all consideration to be paid by
Fluidigm in connection with the transactions contemplated by this Agreement.
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>REPRESENTATIONS AND WARRANTIES OF FLUIDIGM </U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fluidigm hereby represents and warrants to Oculus and UABRF as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Organization</U>. Fluidigm is a corporation duly organized, validly existing and
in good standing under the laws of the State of California and has all requisite corporate power to
own, lease and operate its properties, to conduct its business as it is currently being conducted.
Fluidigm is duly qualified or licensed to do business as a foreign corporation in each jurisdiction
in which the failure to be so qualified or licensed would have a material adverse effect on
Fluidigm.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2
<U>Authorization</U>. This Agreement and all of the Ancillary Documents to which Fluidigm
is or will be a party have been, or upon their execution and delivery hereunder will have been,
duly and validly executed by Fluidigm and constitute, or will constitute, valid and binding
agreements of Fluidigm, enforceable against Fluidigm in accordance with their respective terms,
except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors&#146; rights generally or by principles of public policy or general
equitable principles or the exercise of judicial discretion in accordance with such principles.
Fluidigm has the requisite corporate power and authority to execute and deliver this Agreement and
the Ancillary Documents to which Fluidigm is or will be a party and, at the time of the Closing,
will have the requisite corporate power and authority to sell, issue and deliver the Securities
pursuant to this Agreement and to carry out the other transactions contemplated by this Agreement
and the Ancillary Documents. The execution, delivery and performance by Fluidigm of this Agreement
and the Ancillary Documents have been duly and validly approved and authorized by Fluidigm&#146;s Board
of Directors and by all requisite action of Fluidigm&#146;s stockholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3
<U>No Conflicts; Consents</U>. The execution and delivery by Fluidigm of this Agreement
and the Ancillary Documents to which Fluidigm is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by Fluidigm with the provisions
hereof and thereof will not, contravene, conflict with, result in a breach of, constitute a default
(with or without notice or lapse of time, or both) under or violation of, or result in the creation
of any Encumbrance pursuant to, (i)&nbsp;any provision of the Articles of Incorporation or Bylaws of
Fluidigm, (ii)&nbsp;any judgment, order, decree, rule, law or regulation of any court or governmental
authority, foreign or domestic, applicable to Fluidigm except where such any such contravention,
conflict, breach or default could not reasonably be expected to have a material adverse effect on
the consummation of the transactions contemplated hereby, or
(iii)&nbsp;any provision of any agreement, instrument or understanding to which Fluidigm is a party or
by which Fluidigm is bound, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on the consummation of the
transactions contemplated hereby. No consent, approval, order or authorization of, or registration,
declaration or filing with, any third party or any governmental authority is required to be
obtained on the part of Fluidigm to permit the consummation of the transactions contemplated by
this Agreement or the Ancillary Documents.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Litigation and Claims</U>. There are no claims, actions, suits, proceedings,
arbitrations or investigations in progress or pending (or, to Fluidigm&#146;s knowledge, threatened,
other than potential claims relating to the Interfering Patent (as such term is defined in Section
12.1(a) below), including, but not limited to, a possible interference) before any court, tribunal
or governmental agency, against or relating to Fluidigm, which, if determined adversely to
Fluidigm, would be likely to have a material adverse effect upon Fluidigm&#146;s financial condition or
materially impair its ability to carry out and perform its obligations hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5 <U>Securities Laws Exemptions</U>. Based in part on the representations of UABRF
contained in Section&nbsp;6.5, the issuance of the Securities pursuant to the terms of this Agreement
will be exempt from the registration requirements of the Securities Act and the regulations
thereunder, and the registration, permit or qualification requirements of any applicable state
securities laws.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VI
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>REPRESENTATIONS AND WARRANTIES OF UABRF</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the best knowledge of the UABRF Director and Dr.&nbsp;Larry DeLucas, UABRF hereby represents to
Fluidigm as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Authorization</U>. This Agreement and the Ancillary Documents to which UABRF is
or will be a party have been, or upon their execution and delivery hereunder will have been, duly
and validly executed and delivered by UABRF and constitute, or will constitute, valid and binding
agreements of UABRF, enforceable against UABRF in accordance with their respective terms, except as
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting creditors&#146; rights generally or by principles of public policy or general equitable
principles or the exercise of judicial discretion in accordance with such principles. UABRF has
full power and authority to execute and deliver this Agreement and the Ancillary Documents to which
UABRF is or will be a party and, at the time of the Closing, will have all requisite power and
authority to carry out the transactions contemplated by this Agreement and the Ancillary Documents.
All university, foundation and other internal approvals necessary for UABRF to consummate the
transactions contemplated by this Agreement and the Ancillary Documents to which UABRF is or will
be a party have been obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>No Conflicts; Consents</U>. The execution and delivery by UABRF of this Agreement
and the Ancillary Documents to which UABRF is or will be a party do not, and the consummation of
the transactions contemplated hereby and thereby and compliance by UABRF with the provisions hereof
and thereof will not, contravene, conflict with, result in a breach of, constitute a default (with
or without notice or lapse of time, or both) under or violation of, or result in the creation of
any Encumbrance pursuant to, (i)&nbsp;any provision of the charter documents of UABRF, (ii)&nbsp;any
judgment, order, decree, rule, law or regulation of any court or governmental authority, foreign or
domestic, applicable to UABRF or to the Technology, except where any such contravention, conflict,
breach or default could not reasonably be expected to have a material adverse effect on Fluidigm&#146;s
rights under the New License Agreement or the consummation of the transactions contemplated hereby,
or (iii)&nbsp;any provision of any agreement, instrument or understanding to which UABRF is a party or
by which UABRF is bound or any of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Technology is affected, except where such any such contravention, conflict, breach or default
could not reasonably be expected to have a material adverse effect on Fluidigm&#146;s rights under the
New License Agreement or the consummation of the transactions contemplated hereby, nor will such
actions give to any other person or entity any interests or rights of any kind, including rights
of termination, acceleration or cancellation, in or with respect to any of the Technology, or
result in the creation of any Encumbrance on any of the Technology. No consent, approval, order or
authorization of, or registration, declaration or filing with, any third party or any governmental
authority is required to be obtained on the part of the UABRF to permit the consummation of the
transactions contemplated by this Agreement or the Ancillary Documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Title to Technology</U>. UABRF is the sole owner of the technology, inventions and
patent rights in the Technology and subject to the License Agreement and has not granted a
license to such technology, inventions and patent rights to any person or entity other than
Oculus. The License Agreement has been mutually terminated by UABRF and Oculus and
neither Oculus nor any other party has any rights thereunder. UABRF has the right to grant an
exclusive license to the technology, inventions, patent rights and other rights under the New
License Agreement to Fluidigm, free and clear of any Encumbrances of any nature whatsoever,
subject to those liens, encumbrances or restrictions which may arise as a result of the
settlement of the litigation between Oculus and Syrrx, Inc. (&#147;<U>Syrrx</U>&#148;) described in Schedule&nbsp;4.6
(the &#147;<U>Lawsuit</U>&#148;), provided that Syrrx shall have no rights that may be exercised after the
Closing to practice the technology, inventions, patent rights and
other rights subject to the New License Agreement, and the potential infringement by Diversified Scientific, Inc. of the Licensed IP
Rights (as such term is defined in the New License Agreement) described in Section&nbsp;2.2.3 of
the New License Agreement. <U>Exhibit&nbsp;D</U> lists all of the patent filings subject to the
License Agreement. UABRF is not aware of any third-party challenges to the ownership, validity or
entitlement to priority date of any of the patent filings subject to the License Agreement or
the New License Agreement, except for the Lawsuit between Oculus and Syrrx and the settlement
agreement related to said Lawsuit provided to Fluidigm pursuant to Section&nbsp;7.2 of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Litigation and Claims</U>. Except as set forth on Schedule&nbsp;4.6 attached hereto, there
are no claims, actions, suits, proceedings, arbitrations or investigations in progress or
pending (or, to the knowledge of UABRF, threatened) before any court, tribunal or governmental agency<BR>
against UABRF that relate to any of the Technology. UABRF is not a party to any judgment,
decree, order or arbitration award (or agreement entered into in any administrative, judicial
or arbitration proceeding with any governmental authority) with respect to any of the Technology,
except to the extent that UABRF may be deemed to be a party thereto as a result of UABRF&#146;s
status as a shareholder of Oculus and having a member on the Board of Directors of Oculus as
well as the status of Dr.&nbsp;Larry DeLucas as a member of the Board of Directors of Oculus and a
shareholder of Oculus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Distribution Agreement.</u> UABRF has entered into a mutually acceptable
agreement with Oculus regarding the distribution of any and all consideration to be paid
by Fluidigm in connection with the transactions contemplated by this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Investment Representations</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;UABRF is acquiring the shares of Fluidigm capital stock to be issued
hereunder (the &#147;<U>Securities</U>&#148;) for investment and not with the view to the public resale
or distribution thereof, and UABRF has no present intention of selling, granting any
participation in, or otherwise distributing the Securities, other than in accordance with the terms of a
Termination Agreement dated as of &#95;&#95;&#95;&#95;, 2003 between UABRF and Oculus.
UABRF understands that the Securities have not been registered under the Securities Act by reason
of a specific exemption thereunder, which depends upon, among other things, the bona fide nature of
UABRF&#146;s investment intent as expressed herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;UABRF acknowledges that the Securities must be held indefinitely unless they are
subsequently registered under the Securities Act or Fluidigm receives an opinion of counsel
satisfactory to Fluidigm that such registration is not required. UABRF is aware of the provisions
of Rule&nbsp;144 promulgated under the Securities Act which permit limited resale of stock purchased in
a private placement subject to the satisfaction of certain conditions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;UABRF understands that no public market now exists for the Securities and that there can
be no assurance that a public market will ever exist for the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;UABRF is an &#147;accredited investor&#148; as defined in the Securities Act, and has such knowledge
and experience in financial and business matters that it is capable of evaluating the merits and
risks of the investment in the Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;UABRF has been given the opportunity to obtain any information or documents related to,
and ask questions and receive answers about Fluidigm and its business, prospects and risks which
UABRF deems necessary, to evaluate the merits and risks related to UABRF&#146;s investment in the
Securities and to verify the information UABRF received.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;UABRF&#146;s financial condition is such that it can afford to bear the economic risk of
holding the Securities for an indefinite period of time, and it has adequate means of providing for
its current needs and contingencies and to suffer a complete loss of its investment in such
Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Restrictions</U>. No Securities shall be sold, assigned, transferred or pledged except
upon the conditions specified in this Agreement. UABRF will cause any proposed purchaser, assignee,
transferee or pledgee of the Securities to agree in writing to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <U>Restrictive Legend</U>. Each certificate representing the Securities shall (unless
otherwise permitted by the provisions of Section&nbsp;6.9 below) be stamped or otherwise imprinted with
a legend in the following form (in addition to any legend required under applicable state
securities laws):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;). SUCH
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">SECURITIES MAY NOT BE SOLD, TRANSFERRED OR PLEDGED IN THE ABSENCE
OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF
COUNSEL (WHICH MAY BE COUNSEL FOR THE COMPANY) OR OTHER EVIDENCE
REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS
EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS
OF THE SECURITIES ACT.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A MARKET
STAND-OFF AGREEMENT IN THE EVENT OF A PUBLIC OFFERING, A COPY OF WHICH
IS ON FILE WITH THE SECRETARY OF THE COMPANY.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UABRF consents to Fluidigm making a notation on its records and giving instructions to any
transfer agent of the Securities in order to implement the restrictions on transfer established in
Sections&nbsp;6.7 through 6.10 of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <U>Notice of Proposed Transfers</U>. UABRF and any transferee of any certificate
representing the Securities, by acceptance thereof, agrees to comply in all respects with the
restrictions on transfer contained in Sections&nbsp;6.7 through 6.10 of this Agreement. Prior to any
proposed sale, assignment, transfer or pledge of any Securities (other than any transfer not
involving a change in beneficial ownership), unless there is in effect a registration statement
under the Securities Act covering the proposed transfer, the holder thereof shall give written
notice to Fluidigm of such holder&#146;s intention to effect such transfer, sale, assignment or pledge.
Each such notice shall describe the manner and circumstances of the
proposed transfer, sale, assignment or pledge in sufficient detail, and shall be accompanied at such holder&#146;s expense by
either (i)&nbsp;a written opinion of legal counsel who shall, and whose legal opinion shall be,
reasonably satisfactory to Fluidigm, addressed to Fluidigm, to the effect that the proposed
transfer of the Securities may be effected without registration under the Securities Act, or (ii)&nbsp;a
&#147;no action&#148; letter from the Securities and Exchange Commission (the &#147;Commission&#148;) to the effect
that the transfer of such Securities without registration will not result in a recommendation by
the staff of the Commission that action be taken with respect thereto, or (iii)&nbsp;any other evidence
reasonably satisfactory to counsel to Fluidigm, whereupon the holder of such Securities shall be
entitled to transfer such Securities in accordance with the terms of the notice delivered by the
holder to Fluidigm; provided, however, that no such legal opinion, &#147;no action&#148; letter or other
evidence shall be required with respect to a transfer to an affiliate of the holder. Each
certificate evidencing the Securities transferred as above provided shall bear, except if such
transfer is made pursuant to Rule&nbsp;144, the appropriate restrictive legend set forth in Section&nbsp;6.8
above, except that such certificate shall not bear such restrictive legend if, in the opinion of
counsel for such holder and Fluidigm, such legend is not required in order to establish compliance
with any provisions of the Securities Act or this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <U>Standoff Agreement</U>. UABRF agrees in connection with Fluidigm&#146;s initial sale of
securities pursuant to an effective registration statement, upon notice by Fluidigm or the
underwriters managing such offering, not to sell, make any short sale of, loan, pledge (or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">otherwise encumber or hypothecate), grant any option for the purchase of, or otherwise directly or
indirectly dispose of any Securities (other than those included in the registration) without the
prior written consent of Fluidigm and such managing underwriters for such period of time as
Fluidigm&#146;s Board of Directors establishes pursuant to its good faith negotiations with such
managing underwriters; provided, however that:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;such agreement shall not exceed one hundred eighty (180)&nbsp;days;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;such agreement shall not apply to transfers to an affiliate, provided that such
affiliate agrees to be bound by the terms of such agreement, to the same extent as if such
transferee were the original party thereunder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;UABRF shall not be subject to such agreement unless (A)&nbsp;all executive officers and
directors of Fluidigm, (B)&nbsp;all shareholders of Fluidigm holding more than 1% of Fluidigm&#146;s
outstanding capital stock and (C)&nbsp;all holders of registration rights, are subject to or obligated
to enter into similar agreements; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;if and when any person identified in clause (iii)&nbsp;is released, in whole or in part,
from such agreement (whether or not such release is contemplated at the time of the offering) or if
any such agreement is terminated, UABRF shall be concurrently released on a pro rata basis based on
the number of Securities held by such person and UABRF.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;UABRF agrees that prior to the initial public offering it will not transfer
securities of Fluidigm unless each transferee agrees in writing to be bound by all of the
provisions of this Section&nbsp;6.10, provided that this Section&nbsp;6.10 shall not apply to transfers
pursuant to a registration statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UABRF hereby consents to the placement of stop transfer orders with Fluidigm&#146;s transfer agent
in order to enforce the foregoing provision and agrees to execute a market standoff agreement with
said underwriters in customary form consistent with the provisions of this Section&nbsp;6.10.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>COVENANTS OF OCULUS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Conduct of Business</U>. During the period from the date of this Agreement to the
Closing, Oculus will conduct its business in the ordinary course consistent with past
practices. During the period from the date of this Agreement to the Closing, Oculus will not
without the prior written consent of Fluidigm:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;encumber or permit to be encumbered any of the Technology or Assigned Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;dispose of any of the Technology or Assigned Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;waive or release any right or claim relating to any Technology or Assigned Rights; or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;agree to do any of the things described in the preceding clauses of this Section&nbsp;7.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm agrees that the foregoing restrictions will not prevent Oculus from entering into a
settlement agreement with Syrrx to settle the Lawsuit, provided that such settlement does not
involve the sale, transfer or assignment of the Technology or the Assigned Rights, or any rights in
any of the foregoing, or result in the creation of any Encumbrance on the Technology, the Assigned
Rights, or any rights in any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Access to Information</U>. Until the earlier of the termination of this Agreement or
the Closing, Oculus will allow Fluidigm and its agents reasonable access upon reasonable notice and
during normal working hours to its files, books, records, and offices relating to the Technology
and Assigned Rights, except where prohibited by contract or protected by privilege. In furtherance
of the above, Fluidigm and its counsel and advisors shall have reasonable access during normal
business hours to pertinent contracts of Oculus, including an unsigned final version of the
settlement agreement between Oculus and Syrrx related to the Lawsuit, and drafts of such settlement
agreement (to the extent it is permissible under applicable confidentiality terms and with the
understanding that Oculus may be required to obtain the return or destruction by Fluidigm of the
final version and drafts of such settlement agreement prior to its execution), as well as all
scientific notebooks, invention records and other documents related to the conception and reduction
to practice and prosecution of the patent filings listed on
<U>Exhibit&nbsp;D</U>, including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations and
research related to the Technology, the License Agreement and the New License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Regulatory Approvals</U>. Prior to the Closing, Oculus will execute and file, or join
in the execution and filing of, any application or other document that may be reasonably necessary
in order to obtain the authorization, approval or consent of any governmental entity that may be
required in connection with the consummation of the transactions contemplated by this Agreement.
Oculus will use commercially reasonable efforts to obtain all such authorizations, approvals and
consents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4
<U>Satisfaction of Conditions Precedent</U>. Oculus will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transactions contemplated hereby.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE VIII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>COVENANTS OF UABRF</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Conduct of Business</U>. During the period from the date of this Agreement to
the Closing, UABRF will not without the prior written consent of Fluidigm:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;encumber or permit to be encumbered any of the Technology;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;dispose
of any of the Technology;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;waive or release any right or claim relating to any Technology; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;agree to do any of the things described in the preceding clauses of this
Section&nbsp;8.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Fluidigm agrees that the foregoing restrictions will not prevent UABRF from consenting to a
settlement agreement between Oculus and Syrrx to settle the Lawsuit, provided that such
settlement does not involve the sale, transfer or assignment of the Technology or the
Assigned Rights, or any rights in any of the foregoing, or result in the creation of any
Encumbrance on the Technology, the Assigned Rights, or any rights in any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Access to Information</U>. Until the earlier of the termination of this
Agreement or the Closing, UABRF will allow Fluidigm and its agents reasonable access upon
reasonable notice and during normal working hours to its files, books, records, and offices
relating to the Technology and Assigned Rights, except where prohibited by contract or
protected by privilege. In furtherance of the above, Fluidigm and its counsel and advisors
shall have reasonable access during normal business hours to pertinent scientific notebooks,
invention records and other documents related to the conception and reduction to practice
and prosecution of the patent filings listed on <U>Exhibit&nbsp;D,</U> including, without
limitation, all patent searches, patent file wrappers, legal and scientific investigations
and research related to the Technology, the License Agreement and the New License Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3 <U>Regulatory Approvals</U>. Prior to the Closing, UABRF will execute and file, or
join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any governmental entity
that may be required in connection with the consummation of the transactions contemplated by
this Agreement. UABRF will use commercially reasonable efforts to obtain all such
authorizations, approvals and consents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 <U>Satisfaction of Conditions Precedent</U>. UABRF will use commercially
reasonable efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing
hereunder, and to cause the transactions contemplated hereby to be consummated, and, without
limiting the generality of the foregoing, to obtain all consents and authorizations of third parties
and to make all filings with, and give all notices to, third parties which may be necessary or
reasonably required on its part in order to effect the transactions contemplated hereby.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt">ARTICLE IX
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><U>COVENANTS OF FLUIDIGM</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>Regulatory Approvals</U>. Prior to the Closing, Fluidigm will execute and
file, or join in the execution and filing of, any application or other document that may be
reasonably necessary in order to obtain the authorization, approval or consent of any
governmental entity that may be required in connection with the consummation of the
transactions contemplated by this Agreement. Fluidigm will use its commercially reasonable
efforts to obtain all such authorizations, approvals and consents.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U>Satisfaction of Conditions Precedent.</U> Fluidigm will use commercially reasonable
efforts to satisfy or cause to be satisfied all the conditions precedent to the Closing hereunder,
and to cause the transactions contemplated hereby to be consummated, and, without limiting the
generality of the foregoing, to obtain all consents and authorizations of third parties and to make
all filings with, and give all notices to, third parties which may be necessary or reasonably
required on its part in order to effect the transaction contemplated hereby.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE X
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>MUTUAL COVENANTS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <U>Confidentiality.</U> The parties acknowledge that the Confidential Disclosure
Agreement dated as of October&nbsp;8, 2002 between Fluidigm and Oculus and the Confidential Disclosure
Agreement dated December&nbsp;19, 2002 between Fluidigm, Oculus and UABRF are binding upon the parties
hereto and in full force and effect, except to the extent that the provisions hereof supersede
provisions to similar effect contained in the Confidential Disclosure Agreements. The terms of the
Confidential Disclosure Agreements (exclusive of such superseded provisions) are incorporated in
this Agreement by this reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <U>Publicity.</U> Except as may otherwise be required by law, none of the parties hereto
shall make or cause to be made any public announcements in respect of this Agreement or the
transactions contemplated herein or otherwise communicate with any news media without the prior
written consent of the other party, provided, however, that following the Closing Fluidigm may
issue a press release to announce the closing of the transactions contemplated hereby and the
execution and delivery of the New License Agreement and Sponsored Research Agreement with UABRF
provided that such press release shall not be issued prior to the execution by Syrrx
of a settlement agreement with Oculus to settle the litigation described in Schedule&nbsp;4.6 but in any
event the press release may be issued no later than 30&nbsp;days from the execution date of the New
License Agreement. Except for the press release issued by Fluidigm, none of the parties hereto will
make any public disclosure prior to the Closing or with respect to the Closing unless all parties
agree on the text and timing of such public disclosure, except as required by law. Nothing
contained in this Section shall prevent any party at any time from furnishing any information
pursuant to the requirements of any governmental entity; <U>provided,</U> <U>however,</U> that
if such party is required to furnish such information, it will provide a copy to the other parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 <U>Governmental Filings.</U> As promptly as practicable after the execution of this
Agreement, each party shall make any and all governmental filings required with respect to the
transactions contemplated in this Agreement and the Ancillary Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XI
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>CONDITIONS TO CLOSING</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 <U>Conditions to Each Party&#146;s Obligations.</U> The respective obligations of each party
to effect the transactions to be performed by such party at the Closing are subject to the
satisfaction at or prior to the Closing of the following conditions any of which may be waived in
writing by each party:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;No order shall have been entered, and not vacated, by a court or administrative agency
of competent jurisdiction, in any action or proceeding which enjoins, restrains or prohibits the
sale of the Assigned Rights, the grant of rights under the New License Agreement or the
consummation of any other transaction contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All permits, authorizations, approvals and orders required to be obtained under all
applicable statutes, codes, ordinances, rules and regulations in connection with the transactions
contemplated hereby shall have been obtained and shall be in full force and effect at the Closing
Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There shall be no litigation pending or threatened by any regulatory body or private
party in which (i)&nbsp;an injunction is or may be sought against the transactions contemplated hereby,
or (ii)&nbsp;relief is or may be sought against any party hereto as a result of this Agreement and in
which, in the good faith judgment of the Board of Directors of either Fluidigm, Oculus or UABRF
(relying on the advice of their respective legal counsel), such regulatory body or private party
has the probability of prevailing and such relief would have a material adverse affect upon such
party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2 <U>Conditions to Obligations of Oculus and UABRF.</U> The obligations of Oculus and UABRF
to effect the transactions to be performed by Oculus and UABRF at the Closing are subject to the
satisfaction at or prior to the Closing of the following additional conditions any of which may be
waived in writing by Oculus and UABRF:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All of the representations and warranties of Fluidigm set forth in Article&nbsp;V hereof
shall be true in all material respects on and as of the Closing Date with the same force and effect
as if they had been made at the Closing, except for changes contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Fluidigm at or prior to the Closing shall have been duly complied with and performed
in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3 <U>Conditions to Obligations of Fluidigm.</U> The obligations of Fluidigm to effect the
transactions to be performed by it at the Closing are subject to the satisfaction at or prior to
the Closing of the following additional conditions any of which may be waived in writing by
Fluidigm:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All of the representations and warranties of Oculus and UABRF set forth in Articles IV
and VI hereof shall be true in all material respects on and as of the Closing Date with the same
force and effect as if they had been made at the Closing, except for changes contemplated by this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the terms, covenants and conditions of this Agreement to be complied with and
performed by Oculus and UABRF at or prior to the Closing shall have been duly complied with and
performed in all material respects.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;All required consents from third parties required to allow the consummation of the sale
of the Assigned Rights, the grant of rights under the New License
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">Agreement and the other transactions contemplated hereby shall have been obtained and delivered to
Fluidigm.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Fluidigm shall have received an opinion from the attorney(s) prosecuting the patent
filings listed on <U>Exhibit&nbsp;D</U>, in form and substance reasonably acceptable to Fluidigm, as to
the following matters: (i)&nbsp;assignments of the inventions covered by the patent filings to UABRF
have been properly filed with the United States Patent and Trademark Office (&#147;USPTO&#148;), (ii)&nbsp;UABRF
is named as the sole owner of the inventions covered by the patent filings listed on <U>Exhibit
D</U>, (iii)&nbsp;a declaration of interference was timely requested with at least one of the pending
U.S. patent applications listed on <U>Exhibit&nbsp;D</U> and U.S. Patent No.&nbsp;6,296,673 with the USPTO
in accordance with U.S.C. Section&nbsp;135, (iv)&nbsp;none of the patents listed on <U>Exhibit&nbsp;D</U> have
been held to be permanently revoked, unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and none of the patents listed on <U>Exhibit&nbsp;D</U> have been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, and (v)&nbsp;the patent applications listed on
<U>Exhibit&nbsp;D</U> were filed in good faith and have not been abandoned or finally disallowed
without the possibility of appeal or refiling of such application.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XII</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>POST-CLOSING MATTERS</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 <U>Additional Payments by Fluidigm.</U> In addition to the consideration delivered by
Fluidigm at the Closing, Fluidigm will pay the following amounts to UABRF upon the achievement of
the following milestones:</DIV>




<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
<U>Milestone 1</U>. Milestone 1 shall be satisfied
upon a declaration by the USPTO of an interference between a pending patent
application in the Technology and U.S. Patent No. 6,296,673 (the &#147;Interfering Patent). Within
thirty (30)&nbsp;days after
Fluidigm receives written notice of the USPTO declaration of interference, Fluidigm will issue shares of its stock having a
value of $600,000 (based on the fair value of the stock at the time Milestone 1 is achieved),
subject to compliance with applicable securities laws.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
<U>Milestone 2.</U> Milestone 2 shall be satisfied upon the achievement of freedom to
operate (as specified below) with respect to relevant claims in the Interfering Patent for
Fluidigm&#146;s Topaz3 crystallization microprocessor, as determined by Fluidigm in
its sole discretion that either (i)&nbsp;a U.S. patent has issued from an application listed on
<U>Exhibit&nbsp;D</U> or subsequent applications claiming priority thereto with claims that the USPTO
has determined are entitled to priority in view of claims in the Interfering Patent and which
claims cover the Topaz crystallization microprocessor, or (ii)&nbsp;a cross-license for the Technology
has been signed by Fluidigm and a third party controlling the Interfering Patent and related
applications such that the interference is terminated and Fluidigm has freedom to operate with
respect to the Interfering Patent and related filings. Within thirty (30)&nbsp;days after
such determination by Fluidigm, Fluidigm will issue shares of its
stock having a value of $1,500,000
(based on the fair value at the time Milestone 2 is achieved), subject to compliance with
applicable securities laws. In addition,
(i)&nbsp;Fluidigm will enter into a non-transferable site license with
Athersys, Inc.</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(&#147;Athersys&#148;) under which Athersys will have the right to use the Technology
 for internal drug efforts, but not to provide service or equipment
 to third parties.</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Stock to
be Issued.</U> If Fluidigm is a private company at the time a milestone is
achieved, upon achievement of a milestone Fluidigm will issue shares of the series of Fluidigm
Preferred Stock that was issued in Fluidigm&#146;s most recent financing and the shares will be valued
at the price at which the shares were sold in such financing. If Fluidigm is a public company at
the time a milestone is achieved, upon achievement of a milestone Fluidigm will issue shares of
Fluidigm Common Stock and the shares will be valued at the average closing price of Fluidigm&#146;s
Common Stock over the five trading days preceding the achievement of the milestone.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2
<U>Settlement of Lawsuit</U>. If the Lawsuit has not been settled or dismissed as of the
Closing Date:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Oculus agrees that Fluidigm and its counsel and advisors shall have reasonable access
during normal business hours to the final version of the settlement agreement between Oculus and
Syrrx related to the Lawsuit, and drafts of such settlement agreement (to the extent permissible
under applicable confidentiality terms), in the manner contemplated by Section&nbsp;7.2 of this
Agreement, until the Lawsuit is settled or dismissed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Oculus and UABRF agree that if a settlement agreement related to the Lawsuit is entered
into after the Closing Date, the settlement will not involve the sale, transfer or assignment of
the Technology or the Assigned Rights, or any rights in any of the foregoing, or result in the
creation of any Encumbrance on the Technology, the Assigned Rights, or any rights in any of the
foregoing.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XIII
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>TERMINATION OF AGREEMENT</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.1 <U>Termination by Fluidigm.</U> This Agreement may be terminated at any time before the
Closing by action of the Board of Directors of Fluidigm upon written notice to Oculus and UABRF,
specifying the basis for such termination, if (i)&nbsp;Oculus or UABRF shall have breached in any
material respect any of their covenants or agreements contained in this Agreement, or (ii)&nbsp;any
representation or warranty of Oculus or UABRF contained in this Agreement shall have been
materially inaccurate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.2 <U>Termination by UABRF.</U> This Agreement may be terminated at any time before the
Closing by action of the Board of Directors or other governing body of UABRF upon written notice to
Fluidigm, specifying the basis for such termination, if (i)&nbsp;Fluidigm shall have breached in any
material respect any of its covenants or agreements contained in this Agreement, or (ii)&nbsp;any
representation or warranty of Fluidigm contained in this Agreement shall have been materially
inaccurate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.3 <U>Mutual Consent.</U> This Agreement may be terminated at any time before the Closing,
by the mutual written consent of Fluidigm, Oculus and UABRF.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.4
<U>Effect of Termination</U>. Upon any termination of this Agreement, all parties hereto
shall be relieved of all further obligations under this Agreement, except for the provisions of
Section&nbsp;2.5 regarding the assignment by Oculus to Fluidigm of Assigned Rights, together with all
patent rights and all other intellectual property rights therein, Section&nbsp;15.6 regarding the
payment of certain expenses and Section&nbsp;10.1 regarding the continuing obligations of the parties
under the Confidential Disclosure Agreements.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XIV</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>SURVIVAL OF REPRESENTATIONS AND WARRANTIES</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 <U>Survival of Representations and Warranties</U>. The representations and warranties set forth
in this Agreement shall survive the Closing for a period equal to the greater of 12&nbsp;months after
the Closing Date or the date on which both Milestones specified in Section&nbsp;12.1 have been achieved.
After the expiration of such period, such representations and warranties shall expire and be of no
further force and effect.</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE XV</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>GENERAL</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1
<U>Governing Law</U>. It is the intention of the parties hereto that the internal laws of
the State of California (irrespective of its choice of law principles) shall govern the validity of
this Agreement, the construction of its terms, and the interpretation and enforcement of the rights
and duties of the parties hereto; provided, however, that any disputes involving UABRF shall be
governed by the internal laws of the State of Alabama (irrespective of its choice of law principles
and any disputes involving UABRF shall be resolved Birmingham, Alabama in accordance with the
provisions of Section&nbsp;15.11 and UABRF shall have the right to raise all of the defenses available
to the University of Alabama at Birmingham.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.2
<U>Assignment; Binding upon Successors and Assigns</U>. None of the parties hereto may
assign any of its rights or obligations hereunder (whether by operation of law or otherwise)
without the prior written consent of the other party; provided, however, that any party may assign
its rights and obligations under covenants and agreements to be performed after the Closing in
connection with the sale of all or substantially all of such party&#146;s business. This Agreement will
be binding upon and inure to the benefit of the parties hereto and their respective permitted
successors and assigns.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.3
<U>Severability</U>. If any provision of this Agreement, or the application thereof,
becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable,
the remainder of this Agreement will continue in full force and effect and the application of such
provision to other persons or circumstances shall be interpreted so as best to reasonably effect
the intent of the parties hereto. The parties further agree to replace such illegal, void or
unenforceable provision of this Agreement with a valid and enforceable provision which will
achieve, to the extent possible, the economic, business and other purposes of the illegal, void or
unenforceable provision.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.4 <U>Entire Agreement.</U> This Agreement (including the Exhibits and Schedules hereto) the
Ancillary Agreements, the documents and instruments and other agreements among the parties hereto
referenced herein and therein, and the exhibits thereto, constitute the entire understanding and
agreement of the parties hereto with respect to the subject matter hereof and thereof and supersede
all prior and contemporaneous agreements or understandings, inducements or conditions, express or
implied, written or oral, between the parties with respect hereto and thereto including, without
limitation, the Letter Agreement. To the extent that any provision of this Agreement conflicts with
any provision of the New License Agreement or the Sponsored Research Agreement between Fluidigm and
UABRF, the applicable provision of the New License Agreement or the Sponsored Research Agreement,
as the case may be, shall control and supersede the applicable provision of this Agreement.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.5 <U>Counterparts.</U> This Agreement may be executed in any number of counterparts, each of
which shall constitute an original and all of which together shall constitute one and the same
instrument.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.6 <U>Expenses.</U></DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The parties shall each pay their own legal, accounting and financial advisory fees and
other out-of-pocket expenses incurred incident to the negotiation, preparation and carrying out of
this Agreement and the transactions herein contemplated, whether or not the transactions
contemplated hereby are consummated.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each party shall indemnify the other against, and agrees to hold the other harmless from,
all liabilities and expenses (including reasonable attorneys&#146; fees) in connection with
any claim by any person for compensation as a broker, finder or in any similar capacity, by
reason of services allegedly rendered to the indemnifying party in connection with the
transactions contemplated hereby.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.7 <U>Other Remedies.</U> Except as otherwise provided herein, any and all remedies herein
expressly conferred upon a party shall be deemed cumulative with and not exclusive of any other
remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not
preclude the exercise of any other.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.8 <U>Amendment.</U> Any term or provision of this Agreement may be amended by a written
instrument signed by Fluidigm, Oculus and UABRF; provided that any term or provision that pertains
only to UABRF and Fluidigm may be amended by a written instrument signed by UABRF and Fluidigm.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.9 <U>Waiver.</U> Any party hereto may, by written notice to the other party: (i)&nbsp;waive any
of the conditions to its obligations hereunder or extend the time for the performance of any of the
obligations or actions of another party; (ii)&nbsp;waive any inaccuracies in the representations of
another party contained in this Agreement or in any documents delivered pursuant to this Agreement;
(iii)&nbsp;waive compliance with any of the covenants of the other contained in this Agreement; or (iv)
waive or modify performance of any of the obligations of another party. Except as specifically
contemplated by this Agreement, no action taken pursuant to this Agreement, including without
limitation any investigation by or on behalf of any party, shall be</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">deemed to constitute a waiver by the party taking such action of compliance with any
representation, warranty, condition or agreement contained herein. Waiver of the breach of any one
or more provisions of this Agreement shall not be deemed or construed to be a waiver of other
breaches or subsequent breaches of the same provisions.</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.10
<U>Informal Resolution</U>. In the event of any controversy or claim arising under this
Agreement, officers or comparable officials of UABRF, Oculus and Fluidigm shall promptly meet and
attempt in good faith to reach a resolution of such controversy or claim.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.11
<U>Mediation</U>. Any controversy or claim between any of the parties hereto arising out
of or relating to this Agreement that is not resolved by the parties within thirty (30)&nbsp;days after
delivery of notice of such controversy or claim, upon written notice of either Fluidigm, Oculus or
UABRF, shall be submitted for resolution by mediation in accordance with commercial mediation
guidelines. Any mediation proceeding shall be conducted in the County of Cook, City of Chicago, in
the State of Illinois. The mediation shall be concluded within a ninety (90)&nbsp;day period after
notice.</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.12
<U>Notices</U>. All notices and other communications hereunder will be in writing and will
be deemed given (i)&nbsp;upon receipt if delivered personally (or if mailed by registered or certified
mail), (ii)&nbsp;the next business day after dispatch if sent by overnight delivery
service, (iii)&nbsp;upon dispatch if transmitted by facsimile (and confirmed by a copy delivered in
accordance with clause (i)&nbsp;or (ii)), properly addressed to the parties at the following addresses:</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Fluidigm:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">South San Francisco, CA 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention:&nbsp;&nbsp;President</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (650)&nbsp;871-7192</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">with a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">South San Francisco, CA 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: General Counsel</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (650)&nbsp;871-7195</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Oculus:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Oculus Pharmaceuticals, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">1601 12th Avenue South</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Birmingham, AL 35205</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: B.J. Lehman</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No: (216)&nbsp;361-9495</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Oculus Pharmaceuticals, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">3201 Carnegie Avenue</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Cleveland, OH 44115</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: B.J. Lehman</TD>
</TR>


<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (216) 361-9495</TD>
</TR>


<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">UABRF:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">The UAB Research Foundation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">1120G Administration Building</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">701 20th Street South</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Birmingham, AL 35294-0111</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Attention: Director</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Facsimile No.: (205)&nbsp;975-5560</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any party may change its address for such communications by giving notice thereof to the other
party in conformity with this Section.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.13 <U>Construction and Interpretation of Agreement.</U>
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Agreement has been negotiated by the parties hereto and their respective attorneys,
and the language hereof shall not be construed for or against any party.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The titles and headings herein are for reference purposes only and shall not in any
manner limit the construction of this Agreement, which shall be considered as a
whole.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Any reference to a &#147;material adverse effect&#148; with respect to any entity or group of
entities means a material adverse effect on the business, assets (including intangible assets),
financial condition, properties, liabilities, results of operations or prospects of such entity.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Any reference to a party&#146;s &#147;knowledge means such party&#146;s actual
knowledge after reasonable inquiry of its directors, officers and other management level employees
that have responsibility for the referenced matters.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;When reference is made to a Section or Article, such reference shall be to a Section or
Article of the Agreement, unless otherwise indicated.
</DIV>


<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.14 <U>No Joint Venture.</U> Nothing contained in this Agreement shall be deemed or construed
as creating a joint venture or partnership between any of the parties hereto. No party is by virtue
of this Agreement authorized as an agent, employee or legal representative of any other party. No
party shall have the power to control the activities and operations of any other and their status
is, and at all times, will continue to be, that of independent contractors with respect to each
other. No party shall have any power or authority to bind or commit any other. No party shall hold
itself out as having any authority or relationship in contravention of this Section.
</DIV>

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.15 <U>Absence of Third Party Beneficiary Rights.</U> No provisions of this Agreement are
intended, nor shall be interpreted, to provide or create any third party beneficiary rights or any
other rights of any kind in any client, customer, affiliate, shareholder, partner of any party
hereto or any other person or entity unless specifically provided otherwise herein, and, except as
so provided, all provisions hereof shall be personal solely between the parties to this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-22-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.16 <U>Further Assurances.</U> In connection with this Agreement and the transactions
contemplated hereby, each party shall execute and deliver any additional documents and instruments
and perform any additional acts that may be reasonably necessary or appropriate to effectuate and
perform the provisions of this Agreement and such transactions and the intention of the parties.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-23-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth
above.</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">/s/ Gajus Worthington</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>



<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top">Title:</TD>
    <TD>President &#038; CEO</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" colspan="3">OCULUS PHARMACEUTICALS, INC.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>

    <TD>&nbsp;</TD>
    <TD valign="top">/s/ (ILLEGIBLE)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top">Title:</TD>
    <TD>President &#038; CEO</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top">THE UAB RESEARCH FOUNDATION</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">/s/ (ILLEGIBLE)</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" valign="top">Title:</TD>
    <TD>Director</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">Acknowledged and agreed to</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">this March&nbsp;7, 2003.</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">/s/ Dr.&nbsp;Larry DeLucas
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Dr. Larry DeLucas</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-24-<!-- /Folio --></DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SCHEDULE 4.6</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lawsuit filed by Syrrx, Inc. against Oculus on April&nbsp;30, 2002 in the United States District Court
for the District of Delaware &#151; Syrrx and Oculus may enter into a settlement agreement to settle the
Lawsuit prior to the Closing under the Agreement; as part of the settlement a judgment or other
order will be entered against Oculus by the court in which the Lawsuit was filed.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT A</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Amended and Restated<BR>
Articles of Incorporation of Fluidigm

</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Superseded by Exhibit 3.1 filed with Registration Statement on April 14, 2008.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLES OF INCORPORATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gajus V. Worthington and William Smith certify that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;They are the President and Secretary, respectively, of Fluidigm Corporation, a California
corporation (the &#147;Corporation&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The Articles of Incorporation of the Corporation are amended and restated in full to read
as set forth in <U>EXHIBIT&nbsp;A</U> attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;Said Amended and Restated Articles of Incorporation have been duly approved by the
Corporation&#146;s Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Said Amended and Restated Articles of Incorporation have been duly approved by the required
vote of shareholders in accordance with Sections&nbsp;902 and 903 of the Corporations Code. The total
number of outstanding shares of the corporation is 8,363,318 shares of Common Stock, 2,727,273
shares of Series&nbsp;A Preferred Stock, 6,460,675 shares of Series&nbsp;B Preferred Stock and 16,364,832
shares of Series&nbsp;C Preferred Stock. The number of shares voting in favor of the amendment equaled
or exceeded the vote required. The percentage vote required was more than 50% of the outstanding
Common Stock, voting as a single class, more than 66 2/3% of the outstanding Series&nbsp;C Preferred
Stock, voting as a single class, more than 66 2/3% of the outstanding Preferred Stock voting as a
single class and more than 50% of the outstanding Common Stock and Preferred Stock, voting together
as a single class.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I further declare under penalty of perjury that the matters set forth in the foregoing
certificate are true and correct of my own knowledge.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executed at Palo Alto, California, this 17<SUP style="font-size: 85%; vertical-align: text-top">th</sup> day of December, 2003.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                  /s/  Gajus V. Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Gajus V. Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                                    /s/ William Smith
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">William Smith&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Exhibit&nbsp;A</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMENDED AND RESTATED</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ARTICLES OF INCORPORATION OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FLUIDIGM CORPORATION</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE I
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The name of the corporation is Fluidigm Corporation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE II
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of this corporation is to engage in any lawful act or activity for which a
corporation may be organized under the General Corporation Law of California other than the banking
business, the trust company business or the practice of a profession permitted to be incorporated
under the California Corporations Code.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE III
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The total number of shares of stock that the corporation shall have authority to issue is One
Hundred Nine Million One Hundred Twenty-Six Thousand Eight Hundred Twenty-Seven (109,126,827),
consisting of Sixty-Five Million Five Hundred Thousand (65,500,000) shares of Common Stock, $0.001
par value per share, and Forty-Three Million Six Hundred Twenty-Six Thousand Eight Hundred
Twenty-Seven (43,626,827) shares of Preferred Stock, $0.001 par value per share. The first series
of Preferred Stock shall be designated &#147;Series&nbsp;A Preferred Stock&#148; and shall consist of Two Million
Seven Hundred Twenty&#150;Seven Thousand Two Hundred Seventy&#150;Three (2,727,273) shares. The second
series of Preferred Stock shall be designated &#147;Series&nbsp;B Preferred Stock&#148; and shall consist of Six
Million Four Hundred Sixty Thousand Six Hundred Seventy-Five (6,460,675) shares. The third
series&nbsp;of Preferred Stock shall be designated &#147;Series&nbsp;C Preferred Stock&#148; and shall consist of
Twenty Million Five Hundred Fifty-One Thousand One Hundred Sixty Three (20,551,163) shares. The
fourth series of Preferred Stock shall be designated &#147;Series&nbsp;D Preferred Stock&#148; and shall consist
of Thirteen Million Eight Hundred Eighty-Seven Thousand Seven Hundred Sixteen (13,887,716) shares.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE IV
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and provisions of the Common Stock and Preferred Stock are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Definitions</U>. For purposes of this Article&nbsp;IV, the following definitions shall
apply:
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) &#147;<U>Conversion Price</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred Stock,
$1.78 per share for the Series&nbsp;B Preferred Stock, $2.58 per share for the Series&nbsp;C Preferred Stock
and $2.80 per share for the Series&nbsp;D Preferred Stock (each subject to adjustment from time to time
as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Convertible Securities</U>&#148; shall mean any evidences of indebtedness, shares or other
securities (other than shares of Common Stock) convertible into or exchangeable for Common Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Corporation</U>&#148; shall mean Fluidigm Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Dividend Rate</U>&#148; shall mean an annual rate of $0.11 per share for the Series&nbsp;A
Preferred Stock, an annual rate of $0.18 for the Series&nbsp;B Preferred Stock, an annual rate of $0.26
per share for the Series&nbsp;C Preferred Stock and an annual rate of $0.30 per share for the Series&nbsp;D
Preferred Stock (each subject to adjustment from time to time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Liquidation Preference</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred
Stock, $1.78 per share for the Series&nbsp;B Preferred Stock, $2.58 per share for the Series&nbsp;C Preferred
Stock and $2.80 per share for the Series&nbsp;D Preferred Stock (each subject to adjustment from time to
time as set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Options</U>&#148; shall mean rights, options or warrants to subscribe for, purchase or
otherwise acquire Common Stock or Convertible Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Original Issue Price</U>&#148; shall mean $1.10 per share for the Series&nbsp;A Preferred
Stock, $1.78 for the Series&nbsp;B Preferred Stock, $2.58 per share for the Series&nbsp;C Preferred Stock and
$2.80 per share for the Series&nbsp;D Preferred Stock (each subject to adjustment from time to time as
set forth elsewhere herein).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Preferred Stock</U>&#148; shall mean the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred
Stock, the Series&nbsp;C Preferred Stock and the Series&nbsp;D Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Dividends</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;D Preferred Stock</U>. The holders of outstanding shares of Series&nbsp;D Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock or
Common Stock (collectively, the &#147;<B>Junior Stock</B>&#148;) of the Corporation other than a dividend payable
solely in Common Stock. No distributions shall be made with respect to the Junior Stock during any
fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common
Stock, until all declared dividends on the Series&nbsp;D Preferred Stock have been paid or set apart for
payment to the holders of Series&nbsp;D Preferred Stock. The right to receive dividends on shares of
Series&nbsp;D Preferred Stock shall not be cumulative, and no right to such dividends shall accrue to
holders of Series&nbsp;D Preferred Stock by reason of the fact that dividends on said shares are not
declared or paid in any year.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;C Preferred Stock</U>. The holders of outstanding shares of Series&nbsp;C Preferred
Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out
of any assets at the time legally available therefor, at the Dividend Rate specified for such
shares of Preferred Stock payable in preference and priority to any declaration or payment of any
distribution on Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
with respect to the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Common Stock during any
fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common
Stock, until all declared dividends on the Series&nbsp;C Preferred Stock have been paid or set apart for
payment to the holders of Series&nbsp;C Preferred Stock. The right to receive dividends on shares of
Series&nbsp;C Preferred Stock shall not be cumulative, and no right to such dividends shall accrue to
holders of Series&nbsp;C Preferred Stock by reason of the fact that dividends on said shares are not
declared or paid in any year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock</U>. The holders of outstanding
shares of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock shall be entitled to receive
dividends, when and as declared by the Board of Directors, out of any assets at the time legally
available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable in
preference and priority to any declaration or payment of any distribution on Common Stock of the
Corporation other than a dividend payable solely in Common Stock. No distributions shall be made
with respect to the Common Stock, other than dividends payable solely in Common Stock, until all
declared dividends on the Preferred Stock have been paid or set apart for payment to the Preferred
Stock holders. Payment of any dividends to the holders of the Series&nbsp;A Preferred Stock and
Series&nbsp;B Preferred Stock shall be on a pro-rata, pari passu basis in proportion to the Dividend
Rates for the Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock, as applicable. The right to
receive dividends on shares of Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock shall not be
cumulative, and no right to such dividends shall accrue to holders of Series&nbsp;A Preferred Stock or
Series&nbsp;B Preferred Stock by reason of the fact that dividends on said shares are not declared or
paid in any year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Distribution</U>. For purposes of this Section&nbsp;2, unless the context otherwise
requires, a &#147;<B>distribution</B>&#148; shall mean the transfer of cash or other property without consideration
whether by way of dividend or otherwise, payable other than in Common Stock, or the purchase or
redemption of shares of the Corporation other than (i)&nbsp;repurchase of shares of Common Stock issued
to or held by employees, consultants, officers and directors of the Corporation or its subsidiaries
upon termination of their employment or services pursuant to agreements providing for the right of
said repurchase and at the original purchase price paid by such employees, consultants, officers
and directors; and (ii)&nbsp;repurchase of Common Stock issued to or held by employees, officers,
directors or consultants of the Corporation or its subsidiaries pursuant to rights of first refusal
contained in agreements providing for such rights, provided that such repurchase is unanimously
approved by the Board of Directors; and (iii)&nbsp;any other repurchase or redemption of capital stock
of the corporation unanimously approved by the Board of Directors and approved by the holders of
the majority of the Common Stock and the holders of more than two-thirds (2/3) of the outstanding
shares of the Preferred Stock, voting as separate classes.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Common Stock</U>. Dividends may be paid on the Common Stock as and when declared by
the Board of Directors, subject to the prior dividend rights of the Preferred Stock and Section&nbsp;6
below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Non-Cash Distributions</U>. Whenever a distribution provided for in this Section&nbsp;2
shall be payable in property other than cash, the value of such distribution shall be deemed to be
the fair market value of such property as determined in good faith by the Board of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Consent to Certain Repurchases</U>. As authorized by Section&nbsp;402.5(c) of the
California Corporations Code, Sections&nbsp;502 and 503 of the California Corporations Code shall not
apply with respect to payments made by the Corporation in connection with (i)&nbsp;repurchase of shares
of Common Stock issued to or held by employees, consultants, officers and directors of the
Corporation or its subsidiaries upon termination of their employment or services pursuant to
agreements providing for the right of said repurchase and at the original purchase price paid by
such employees, consultants, officers and directors, and (ii)&nbsp;repurchase of Common Stock issued to
or held by employees, officers, directors or consultants of the Corporation or its subsidiaries
pursuant to rights of first refusal contained in agreements providing for such rights, provided
that such repurchase is unanimously approved by the Board of Directors, and (iii)&nbsp;any other
repurchase or redemption of capital stock of the Corporation unanimously approved by the Board of
Directors and approved by the holders of more than two-thirds (2/3) of the outstanding shares of
the Preferred Stock voting together as a single class.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Liquidation Rights</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution or winding up of the Corporation, either
voluntary or involuntary, distribution of the assets of the Corporation legally available for
distribution to the Corporation&#146;s shareholders shall be made in the following manner:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Series&nbsp;D Liquidation Preference</U>. The holders of the Series&nbsp;D Preferred Stock
shall be entitled to receive, prior and in preference to any distribution of any of the assets of
the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock, the Series&nbsp;B
Preferred Stock and the Series&nbsp;C Preferred Stock by reason of their ownership of such stock, an
amount per share for each share of Series&nbsp;D Preferred Stock held by them equal to the sum of
(i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such
share of Series&nbsp;D Preferred Stock. If the assets of the Corporation legally available for
distribution to the holders of the Series&nbsp;D Preferred Stock are insufficient to permit the payment
to such holders of the full amounts specified in this Section&nbsp;3(a), then the entire assets of the
Corporation legally available for distribution shall be distributed with equal priority and
<U>pro</U> <U>rata</U> among the holders of the Series&nbsp;D Preferred Stock in proportion to the
full amounts they would otherwise be entitled to receive pursuant to this Section&nbsp;3(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Series&nbsp;C Liquidation Preference</U>. After payment to the holders of Series&nbsp;D
Preferred Stock of the full amounts specified in Section 3(a) above, the holders of the Series&nbsp;C
Preferred Stock shall be entitled to receive, prior and in preference to any distribution of any of
the assets of the Corporation to the holders of the Common Stock, the Series&nbsp;A Preferred Stock and
the Series&nbsp;B Preferred Stock by reason of their ownership of such stock, an amount per share for
each
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">share of Series&nbsp;C Preferred Stock held by them equal to the sum of (i)&nbsp;the Liquidation
Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such share of Series&nbsp;C
Preferred Stock. If the remaining assets of the Corporation legally available for distribution to
the holders of the Series&nbsp;C Preferred Stock are insufficient to permit the payment to such holders
of the full amounts specified in this Section&nbsp;3(b), then the entire remaining assets of the
Corporation legally available for distribution shall be distributed with equal priority and
<U>pro</U> <U>rata</U> among the holders of the Series&nbsp;C Preferred Stock in proportion to the
full amounts they would otherwise be entitled to receive pursuant to this Section&nbsp;3(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Series&nbsp;B Liquidation Preference</U>. After the payment to the holders of Series&nbsp;D
Preferred Stock and Series&nbsp;C Preferred Stock of the full amounts specified in Sections&nbsp;3(a) and
3(b) above, the holders of the Series&nbsp;B Preferred Stock shall be entitled to receive, prior and in
preference to any distribution of any of the remaining assets of the Corporation to the holders of
the Common Stock and the Series&nbsp;A Preferred Stock by reason of their ownership of such stock, an
amount per share for each share of Series&nbsp;B Preferred Stock held by them equal to the sum of
(i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared and unpaid dividends on such
share of Series&nbsp;B Preferred Stock. If the remaining assets of the Corporation legally available
for distribution to the holders of the Series&nbsp;B Preferred Stock are insufficient to permit the
payment to such holders of the full amounts specified in this Section&nbsp;3(c), then the entire
remaining assets of the Corporation legally available for distribution shall be distributed with
equal priority and <U>pro</U> <U>rata</U> among the holders of the Series&nbsp;B Preferred Stock in
proportion to the full amounts they would otherwise be entitled to receive pursuant to this
Section&nbsp;3(c).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Series&nbsp;A Liquidation Preference</U>. After the payment to the holders of Series&nbsp;D
Preferred Stock, the holders of Series&nbsp;C Preferred Stock and the holders of Series&nbsp;B Preferred
Stock of the full amounts specified in Sections&nbsp;3(a), 3(b) and 3(c) above, the holders of the
Series&nbsp;A Preferred Stock shall be entitled to receive, prior and in preference to any distribution
of any of the remaining assets of the Corporation to the holders of the Common Stock by reason of
their ownership of such stock, an amount per share for each share of Series&nbsp;A Preferred Stock held
by them equal to the sum of (i)&nbsp;the Liquidation Preference for such shares and (ii)&nbsp;all declared
and unpaid dividends on such share of Series&nbsp;A Preferred Stock. If the remaining assets of the
Corporation legally available for distribution to the holders of the Series&nbsp;A Preferred Stock are
insufficient to permit the payment to such holders of the full amounts specified in this
Section&nbsp;3(d), then the entire remaining assets of the Corporation legally available for
distribution shall be distributed with equal priority and <U>pro</U> <U>rata</U> among the
holders of the Series&nbsp;A Preferred Stock in proportion to the full amounts they would otherwise be
entitled to receive pursuant to this Section&nbsp;3(d).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Remaining Assets</U>. After the payment to the holders of Preferred Stock of the full
amounts specified in Sections&nbsp;3(a), 3(b), 3(c) and 3(d) above, the entire remaining assets of the
Corporation legally available for distribution shall be distributed <U>pro-rata</U> to holders of
the Common Stock of the Corporation in proportion to the number of shares of Common Stock held by
them.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Shares Not Treated as Both Preferred Stock and Common Stock in Any Distribution</U>.
Shares of Preferred Stock shall not be entitled to be converted into shares of Common Stock in
order to participate in any distribution, or series of distributions, as shares of Common
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Stock, without first foregoing participation in the distribution, or series of distributions,
as shares of Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Reorganization</U>. For purposes of this Section&nbsp;3, a liquidation, dissolution or
winding up of the Corporation shall be deemed to be occasioned by, or to include, (i)&nbsp;the
acquisition of the Corporation by another entity by means of any transaction or series of related
transactions (including, without limitation, any stock acquisition, reorganization, merger or
consolidation but excluding any merger effected exclusively for the purpose of changing the
domicile of the Corporation) other than a transaction or series of transactions in which the
holders of the voting securities of the Corporation outstanding immediately prior to such
transaction or series of transactions continue to retain (either by such voting securities
remaining outstanding or by such voting securities being converted into voting securities of the
surviving entity), as a result of shares in the Corporation held by such holders prior to such
transaction, at least fifty percent (50%) of the total voting power represented by the voting
securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (ii)&nbsp;a sale, transfer, lease or other conveyance of all
or substantially all of the assets of the Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Valuation of Non-Cash Consideration</U>. If any assets of the Corporation distributed
to shareholders in connection with any liquidation, dissolution, or winding up of the Corporation
are other than cash, then the value of such assets shall be their fair market value as determined
in good faith by the Board of Directors, <U>except that</U> any securities to be distributed to
shareholders in a liquidation, dissolution, or winding up of the Corporation shall be valued as
follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If the securities are then traded on a national securities exchange or the Nasdaq Stock
Market System (or a similar national quotation system), then the value of the securities shall be
deemed to be to the average of the closing prices of the securities on such exchange or system over
the ten&nbsp;(10) trading day period ending five&nbsp;(5) trading days prior to the distribution;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;if the securities are actively traded over-the-counter, then the value of the securities
shall be deemed to be the average of the closing bid prices of the securities over the ten&nbsp;(10)
trading day period ending five&nbsp;(5) trading days prior to the distribution; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;if there is no active public market for the securities, then the value of the securities
shall be deemed to be the fair market value thereof as determined in good faith by the Board of
Directors which determination shall include consideration of the illiquidity of the securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a merger or other acquisition of the Corporation by another entity, the
distribution date shall be deemed to the date such transaction closes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of this Section&nbsp;3(h), &#147;<B>trading day</B>&#148; shall mean any day on which the exchange
or system on which the securities to be distributed are traded is open, and &#147;closing prices&#148; or
&#147;closing bid prices&#148; shall be deemed to be: (i)&nbsp;for securities traded primarily on the New York
Stock Exchange, the American Stock Exchange or Nasdaq, the last reported trade price or sale price,
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">as the case may be, at 4:00&nbsp;p.m., New York time, on that day and (ii)&nbsp;for securities listed or
traded on other exchanges, markets and systems, the market price as of the end of the &#147;regular
hours&#148; trading period that is generally accepted as such for such exchange, market or system. If,
after the date hereof, the benchmark times generally accepted in the securities industry for
determining the market price of a stock as of a given trading day shall change from those set forth
above, the fair market value shall be determined as of such other generally accepted benchmark
times.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Conversion</U>. The holders of the Preferred Stock shall have conversion rights as
follows (the &#147;<B>Conversion Rights</B>&#148;):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Right&nbsp;to&nbsp;Convert</U>. Subject to Section&nbsp;4(c), each share of Preferred Stock shall be
convertible, at the option of the holder thereof, at any time after the date of issuance of such
share at the office of the Corporation or any transfer agent for the Preferred Stock, into that
number of fully-paid, nonassessable shares of Common Stock determined by dividing the Original
Issue Price for the relevant series by the Conversion Price for such series. (The number of shares
of Common Stock into which each share of Preferred Stock of a series may be converted is
hereinafter referred to as the &#147;<B>Conversion Rate</B>&#148; for each such series.) Upon any decrease or
increase in the Conversion Price for any series of Preferred Stock, as described in this Section&nbsp;4,
the Conversion Rate for such series shall be appropriately increased or decreased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Automatic Conversion</U>. Each share of Preferred Stock shall automatically be
converted into fully-paid, non-assessable shares of Common Stock at the then effective Conversion
Rate for such share (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial
public offering on Form&nbsp;S-1 (or successor form) filed under the Securities Act of 1933, as amended
(the &#147;<B>Securities Act</B>&#148;), covering the offer and sale of the Corporation&#146;s Common Stock, provided
that the offering price per share is not less than $5.69 (as adjusted for stock splits or stock
dividends) and the aggregate gross proceeds to the Corporation are not less than $25,000,000, or
(ii)&nbsp;upon the receipt by the Corporation of a written consent or request for such conversion from
the holders of two-thirds of the shares of Preferred Stock then outstanding, or, if later, the
effective date for conversion specified in such requests (each of the events referred to in (i)&nbsp;and
(ii)&nbsp;being hereinafter referred to as an &#147;<B>Automatic Conversion Event</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Mechanics of Conversion</U>. No fractional shares of Common Stock shall be issued
upon conversion of Preferred Stock. In lieu of any fractional shares to which the holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the then
fair market value of a share of Common Stock as determined by the Board of Directors. For such
purpose, all shares of Preferred Stock held by each holder of Preferred Stock shall be aggregated,
and any resulting fractional share of Common Stock shall be paid in cash. Before any holder of
Preferred Stock shall be entitled to convert the same into full shares of Common Stock, and to
receive certificates therefor, he shall surrender the certificate or certificates therefor, duly
endorsed, at the office of the Corporation or of any transfer agent for the Preferred Stock, and
shall give written notice to the Corporation at such office that he elects to convert the same;
<U>provided</U>,<U> however</U>, that on the date of an Automatic Conversion Event, the
outstanding shares of Preferred Stock shall be converted automatically without any further action
by the holders of such shares and whether or not the certificates representing such shares are
surrendered to the Corporation or its transfer agent; <U>provided further</U>, however, that the
Corporation shall not be obligated to issue
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">certificates evidencing the shares of Common Stock issuable upon such Automatic Conversion
Event unless either the certificates evidencing such shares of Preferred Stock are delivered to the
Corporation or its transfer agent as provided above, or the holder notifies the Corporation or its
transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement
satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in
connection with such certificates. On the date of the occurrence of an Automatic Conversion Event,
each holder of record of shares of Preferred Stock shall be deemed to be the holder of record of
the Common Stock issuable upon such conversion, notwithstanding that the certificates representing
such shares of Preferred Stock shall not have been surrendered at the office of the Corporation,
that notice from the Corporation shall not have been received by any holder of record of shares of
Preferred Stock, or that the certificates evidencing such shares of Common Stock shall not then be
actually delivered to such holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Corporation shall, as soon as practicable after such delivery, or after such agreement and
indemnification, issue and deliver at such office to such holder of Preferred Stock, a certificate
or certificates for the number of shares of Common Stock to which he shall be entitled as aforesaid
and a check payable to the holder in the amount of any cash amounts payable as the result of a
conversion into fractional shares of Common Stock, plus any declared and unpaid dividends on the
converted Preferred Stock. Such conversion shall be deemed to have been made immediately prior to
the close of business on the date of such surrender of the shares of Preferred Stock to be
converted, and the person or persons entitled to receive the shares of Common Stock issuable upon
such conversion shall be treated for all purposes as the record holder or holders of such shares of
Common Stock on such date; <U>provided, however</U>, that if the conversion is in connection with
an underwritten offer of securities registered pursuant to the Securities Act the conversion may,
at the option of any holder tendering Preferred Stock for conversion, be conditioned upon the
closing of the sale of securities pursuant to such offering, in which event the person(s) entitled
to receive the Common Stock issuable upon such conversion of the Preferred Stock shall not be
deemed to have converted such Preferred Stock until immediately prior to the closing of the sale of
such securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Adjustments to Conversion Price for Diluting Issues</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Special Definition</U>. For purposes of this Section&nbsp;4(d), &#147;<B>Additional Shares of
Common</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to Section&nbsp;4(d)(iii), deemed to
be issued) by the Corporation after the filing of these Articles of Incorporation, other than:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;shares of Common Stock issued or issuable upon conversion of shares of Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;shares of Common Stock issued or issuable to officers, directors and employees of, or
consultants and other service providers to, the Corporation pursuant to stock grants, option plans,
purchase plans or other employee stock incentive programs or arrangements approved by the Board of
Directors or upon exercise of options or warrants granted to such parties pursuant to any such
plan, program or arrangement;
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;shares of Common Stock issued upon the exercise or conversion of Options or Convertible
Securities outstanding as of the date of the filing of these Articles of Incorporation;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;shares of Common Stock issued or issuable as a dividend or distribution on Preferred Stock
or pursuant to any event for which adjustment is made pursuant to Section&nbsp;4(e), 4(f) or 4(g)
hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;shares of Common Stock issued in a registered public offering under the Securities Act
pursuant to which all outstanding shares of Preferred Stock are automatically converted into Common
Stock pursuant to an Automatic Conversion Event;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;shares of Common Stock issued or issuable pursuant to the acquisition of another
corporation by the Corporation by merger, purchase of substantially all of the assets or other
reorganization or to a joint venture agreement, provided, that such issuances are unanimously
approved by the Board of Directors;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;shares of Common Stock issued or issuable to banks, equipment lessors or other financial
institutions pursuant to a commercial leasing or debt financing transaction approved by the Board
of Directors;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)&nbsp;shares of Common Stock issued or issuable in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements, or
strategic partnerships or relationships, if the issuance is approved by the Board of Directors; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)&nbsp;shares of Common Stock issued or issuable upon conversion of up to $5&nbsp;million in aggregate
principal amount (plus interest) of convertible promissory notes originally issued or issuable to
Biomedical Sciences Investment Fund Pte Ltd. or its affiliates and upon conversion of up to $3
million in aggregate principal amount (plus interest) of convertible promissory notes originally
issued or issuable to Invus, L.P. or its affiliates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;<U>No&nbsp;Adjustment&nbsp;of&nbsp;Conversion&nbsp;Price</U>. No adjustment in the Conversion Price of a
particular series of Preferred Stock shall be made in respect of the issuance of Additional Shares
of Common unless the consideration per share (as determined pursuant to Section&nbsp;4(d)(vi)) for an
Additional Share of Common issued or deemed to be issued by the Corporation is less than the
Conversion Price in effect on the date of, and immediately prior to such issue, for such series of
Preferred Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;<U>Deemed Issue of Additional Shares of Common</U>. In the event the Corporation at
any time or from time to time after the date of the filing of these Articles of Incorporation shall
issue any Options or Convertible Securities or shall fix a record date for the determination of
holders of any class of securities entitled to receive any such Options or Convertible Securities,
then the maximum number of shares (as set forth in the instrument relating thereto without regard
to any provisions contained therein for a subsequent adjustment of such number) of Common Stock
issuable upon the exercise of such Options or, in the case of Convertible
</DIV>
 <P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Securities, the conversion or exchange of such Convertible Securities or, in the case of
Options for Convertible Securities, the exercise of such Options and the conversion or exchange of
the underlying securities, shall be deemed to have been issued as of the time of such issue or, in
case such a record date shall have been fixed, as of the close of business on such record date,
provided that in any such case in which shares are deemed to be issued:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;no further adjustment in the Conversion Price of the Preferred Stock shall be made upon
the subsequent issue of Convertible Securities or shares of Common Stock in connection with the
exercise of such Options or conversion or exchange of such Convertible Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;if such Options or Convertible Securities by their terms provide, with the passage of time
or otherwise, for any increase in the consideration payable to the Corporation, or decrease in the
number of shares of Common Stock issuable, upon the exercise, conversion or exchange thereof, the
Conversion Price of the Preferred Stock computed upon the original issue thereof (or upon the
occurrence of a record date with respect thereto), and any subsequent adjustments based thereon,
shall, upon any such increase or decrease becoming effective, be recomputed to reflect such
increase or decrease insofar as it affects such Options or the rights of conversion or exchange
under such Convertible Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;no readjustment pursuant to clause&nbsp;(2) above shall have the effect of increasing the
Conversion Price of the Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion
Price of the Preferred Stock on the original adjustment date, or (ii)&nbsp;the Conversion Price of the
Preferred Stock that would have resulted from any issuance of Additional Shares of Common between
the original adjustment date and such readjustment date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;upon the expiration of any such Options or any rights of conversion or exchange under such
Convertible Securities which shall not have been exercised, the Conversion Price computed upon the
original issue thereof (or upon the occurrence of a record date with respect thereto) and any
subsequent adjustments based thereon shall, upon such expiration, be recomputed as if:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;in the case of Convertible Securities or Options for Common Stock, the only Additional
Shares of Common issued were the shares of Common Stock, if any, actually issued upon the exercise
of such Options or the conversion or exchange of such Convertible Securities and the consideration
received therefor was the consideration actually received by the Corporation for the issue of such
exercised Options plus the consideration actually received by the Corporation upon such exercise or
for the issue of all such Convertible Securities which were actually converted or exchanged, plus
the additional consideration, if any, actually received by the Corporation upon such conversion or
exchange, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;in the case of Options for Convertible Securities, only the Convertible Securities, if
any, actually issued upon the exercise thereof were issued at the time of issue of such Options,
and the consideration received by the Corporation for the Additional Shares of Common deemed to
have been then issued was the consideration actually received by the Corporation for the issue of
such exercised Options, plus the consideration deemed to have been
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">received by the Corporation (determined pursuant to Section&nbsp;4(d)(v)) upon the issue of the
Convertible Securities with respect to which such Options were actually exercised; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;if such record date shall have been fixed and such Options or Convertible Securities are
not issued on the date fixed therefor, the adjustment previously made in the Conversion Price which
became effective on such record date shall be canceled as of the close of business on such record
date, and thereafter the Conversion Price shall be adjusted pursuant to this Section&nbsp;4(d)(iii) as
of the actual date of their issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;<U>Adjustment of Conversion Price of Series&nbsp;D Preferred Stock Upon Issuance of
Additional Shares of Common</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;For so long as the Conversion Price of the Series&nbsp;D Preferred Stock is greater than $2.58
(as adjusted for subdivisions and combinations of the Common Stock and changes in the Common Stock
as set forth in Sections 4(e) and 4(g)) (the &#147;<B>Series&nbsp;D Ratchet Amount</B>&#148;), in the event this
Corporation shall issue Additional Shares of Common (including Additional Shares of Common deemed
to be issued pursuant to Section&nbsp;4(d)(iii)) for a consideration per share less than the applicable
Conversion Price of the Series&nbsp;D Preferred Stock in effect on the date of and immediately prior to
such issue, but for a consideration per share equal to or greater than the Series&nbsp;D Ratchet Amount,
then, the Conversion Price of the Series&nbsp;D Preferred Stock shall be reduced concurrently with such
issue to a price (calculated to the nearest cent) equal to the per share price of the Additional
Shares of Common.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;In the event this Corporation shall issue Additional Shares of Common (including
Additional Shares of Common deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without
consideration or for a consideration per share less than the Series&nbsp;D Ratchet Amount, then, the
Conversion Price of the Series&nbsp;D Preferred Stock immediately prior to such issue shall be deemed to
be equal to the Series&nbsp;D Ratchet Amount (the &#147;<B>Adjusted Conversion Price</B>&#148;) and such Adjusted
Conversion Price shall be further reduced, concurrently with such issue, to a price (calculated to
the nearest cent) determined by multiplying such Adjusted Conversion Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately prior to
such issue plus the number of shares of Common Stock which the aggregate consideration received by
the Corporation for the total number of Additional Shares of Common so issued would purchase at
such Adjusted Conversion Price, and the denominator of which shall be the number of shares of
Common Stock outstanding immediately prior to such issue plus the number of such Additional Shares
of Common so issued. For the purposes of this Section&nbsp;4(d)(iv)(2), all shares of Common Stock
issuable upon exercise of outstanding Options or the conversion of outstanding Convertible
Securities and shares of Preferred Stock, and all Additional Shares of Common deemed issued
pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be outstanding. Section&nbsp;4(d)(iv)(3) shall
govern adjustments to the Conversion Price of the Series&nbsp;D Preferred Stock after the first
adjustment to the Conversion Price of the Series&nbsp;D Preferred Stock pursuant to this Section
4(d)(iv)(2).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;After any adjustment to the Conversion Price of the Series&nbsp;D Preferred Stock pursuant to
Section&nbsp;4(d)(iv)(2), in the event this Corporation shall issue Additional Shares of Common
(including Additional Shares of Common deemed to be issued pursuant to
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Section&nbsp;4(d)(iii)) without consideration or for a consideration per share less than Conversion
Price of the Series&nbsp;D Preferred Stock in effect on the date of and immediately prior to such issue,
then, the Conversion Price of the Series&nbsp;D Preferred Stock shall be reduced concurrently with such
issue, to a price (calculated to the nearest cent) determined by multiplying such Conversion Price
by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such issue plus the number of shares of Common Stock which the aggregate
consideration received by the Corporation for the total number of Additional Shares of Common so
issued would purchase at such Conversion Price, and the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such
Additional Shares of Common so issued. For the purposes of this Section&nbsp;4(d)(iv)(3), all shares of
Common Stock issuable upon exercise of outstanding Options or the conversion of outstanding
Convertible Securities and shares of Preferred Stock, and all Additional Shares of Common deemed
issued pursuant to Section&nbsp;4(d)(iii) hereof, shall be deemed to be outstanding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;<U>Adjustment of Conversion Price of Series&nbsp;A, B and C Preferred Stock</U>. In the event
this Corporation shall issue Additional Shares of Common (including Additional Shares of Common
deemed to be issued pursuant to Section&nbsp;4(d)(iii)) without consideration or for a consideration per
share less than the applicable Conversion Price of the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred
Stock or Series&nbsp;C Preferred Stock in effect on the date of and immediately prior to such issue,
then, the Conversion Price of the Series&nbsp;A Preferred Stock, Series&nbsp;B Preferred Stock or Series&nbsp;C
Preferred Stock (if affected) shall be reduced, concurrently with such issue, to a price
(calculated to the nearest cent) determined by multiplying such Conversion Price by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately prior to
such issue plus the number of shares of Common Stock which the aggregate consideration received by
the Corporation for the total number of Additional Shares of Common so issued would purchase at
such Conversion Price, and the denominator of which shall be the number of shares of Common Stock
outstanding immediately prior to such issue plus the number of such Additional Shares of Common so
issued. For the purposes of this Section&nbsp;4(d)(v), all shares of Common Stock issuable upon
exercise of outstanding Options or the conversion of outstanding Convertible Securities and shares
of Preferred Stock, and all Additional Shares of Common deemed issued pursuant to Section&nbsp;4(d)(iii)
hereof, shall be deemed to be outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;<U>Determination&nbsp;of&nbsp;Consideration</U>. For purposes of this Section&nbsp;4(d), the
consideration received by the Corporation for the issue (or deemed issue) of any Additional Shares
of Common shall be computed as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;<U>Cash&nbsp;and&nbsp;Property</U>. Such consideration shall:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;insofar as it consists of cash, be computed at the aggregate amount of cash received by
the Corporation before deducting reasonable discounts, commissions or other expenses allowed, paid
or incurred by the Corporation for any underwriting or otherwise in connection with such issue (or
deemed issue);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;insofar as it consists of property other than cash, be computed at the fair market value
thereof at the time of such issue, as determined in good faith by the Board of Directors; and
</DIV>
 <P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;in the event Additional Shares of Common are issued together with other shares or
securities or other assets of the Corporation for consideration which covers both, be the
proportion of such consideration so received, computed as provided in clauses (A)&nbsp;and (B)&nbsp;above, as
reasonably determined in good faith by the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;<U>Options&nbsp;and&nbsp;Convertible&nbsp;Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common deemed to have been issued pursuant to
Section&nbsp;4(d)(iii) shall be determined by dividing
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(X)&nbsp;the total amount, if any, received or receivable by the Corporation as consideration for
the issue of such Options or Convertible Securities, plus the minimum aggregate amount of
additional consideration (as set forth in the instruments relating thereto, without regard to any
provision contained therein for a subsequent adjustment of such consideration) payable to the
Corporation upon the exercise of such Options or the conversion or exchange of such Convertible
Securities, or in the case of Options for Convertible Securities, the exercise of such Options for
Convertible Securities and the conversion or exchange of such Convertible Securities by
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Y)&nbsp;the maximum number of shares of Common Stock (as set forth in the instruments relating
thereto, without regard to any provision contained therein for a subsequent adjustment of such
number) issuable upon the exercise of such Options or the conversion or exchange of such
Convertible Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Adjustments for Subdivisions or Combinations of Common Stock</U>. In the event the
outstanding shares of Common Stock shall be subdivided (by stock split, by payment of a stock
dividend or otherwise), into a greater number of shares of Common Stock, the Conversion Price of
each series of Preferred Stock in effect immediately prior to such subdivision shall, concurrently
with the effectiveness of such subdivision, be proportionately decreased. In the event the
outstanding shares of Common Stock shall be combined (by reclassification or otherwise) into a
lesser number of shares of Common Stock, the Conversion Prices in effect immediately prior to such
combination shall, concurrently with the effectiveness of such combination, be proportionately
increased.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Adjustments for Subdivisions or Combinations of Preferred Stock</U>. In the event the
outstanding shares of Preferred Stock or a series of Preferred Stock shall be subdivided (by stock
split, by payment of a stock dividend or otherwise), into a greater number of shares of Preferred
Stock, the Dividend Rate, Original Issue Price and Liquidation Preference of the affected series of
Preferred Stock in effect immediately prior to such subdivision shall, concurrently with the
effectiveness of such subdivision, be proportionately decreased. In the event the outstanding
shares of Preferred Stock or a series of Preferred Stock shall be combined (by reclassification or
otherwise) into a lesser number of shares of Preferred Stock, the Dividend Rate, Original Issue
Price and Liquidation Preference of the affected series of Preferred Stock in effect immediately
prior to such combination shall, concurrently with the effectiveness of such combination, be
proportionately increased.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Adjustments for Reclassification, Exchange and Substitution</U>. Subject to Section&nbsp;3
above (&#147;<B>Liquidation Rights</B>&#148;), if the Common Stock issuable upon conversion of the Preferred Stock
shall be changed into the same or a different number of shares of any other class or classes of
stock, whether by capital reorganization, reclassification or otherwise (other than a subdivision
or combination of shares provided for above), then, in any such event, in lieu of the number of
shares of Common Stock which the holders would otherwise have been entitled to receive, each holder
of such Preferred Stock shall have the right thereafter to convert such shares of Preferred Stock
into a number of shares of such other class or classes of stock which a holder of the number of
shares of Common Stock deliverable upon conversion of such series of Preferred Stock immediately
before that change would have been entitled to receive in such reorganization or reclassification,
all subject to further adjustment as provided herein with respect to such other shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>No Impairment</U>. The Corporation will not through any reorganization, transfer of
assets, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance or performance of any of the terms to be observed or performed
hereunder by the Corporation but will at all times in good faith assist in the carrying out of all
the provisions of this Section&nbsp;4 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of Preferred Stock against
impairment. Notwithstanding the foregoing, nothing in this Section&nbsp;4(h) shall prohibit the
Corporation from amending its Articles of Incorporation with the requisite consent of its
shareholders and the board of directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or
readjustment of the Conversion Price pursuant to this Section&nbsp;4, the Corporation at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and
furnish to each holder of Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based.
The Corporation shall, upon the written request at any time of any holder of Preferred Stock,
furnish or cause to be furnished to such holder a like certificate setting forth (i)&nbsp;such
adjustments and readjustments, (ii)&nbsp;the Conversion Price at the time in effect and (iii)&nbsp;the number
of shares of Common Stock and the amount, if any, of other property which at the time would be
received upon the conversion of Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <U>Notices&nbsp;of&nbsp;Record&nbsp;Date</U>. In the event that this Corporation shall propose at any
time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;to declare any dividend or distribution upon its Common Stock, whether in cash, property,
stock or other securities, whether or not a regular cash dividend and whether or not out of
earnings or earned surplus;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;to effect any reclassification or recapitalization of its Common Stock outstanding
involving a change in the Common Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;to voluntarily liquidate or dissolve or to enter into any transaction deemed to be a
liquidation, dissolution or winding up of the corporation pursuant to Section&nbsp;3(f);
</DIV>
 <P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">then, in connection with each such event, this Corporation shall send to the holders of the
Preferred Stock at least 14&nbsp;days&#146; prior written notice of the date on which a record shall be taken
for such dividend or distribution (and specifying the date on which the holders of Common Stock
shall be entitled thereto) or for determining rights to vote in respect of the matters referred to
in (ii)&nbsp;and (iii)&nbsp;above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each such written notice shall be given by first class mail, postage prepaid, addressed to the
holders of Preferred Stock at the address for each such holder as shown on the books of this
Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The right of the holders of the Preferred Stock to notice hereunder may be waived, either
prospectively or retroactively and either generally or in a particular instance, by the holders of
more than two-thirds&nbsp;(2/3) of the outstanding shares of the Preferred Stock voting together as a
single class.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) <U>Reservation&nbsp;of&nbsp;Stock&nbsp;Issuable&nbsp;Upon&nbsp;Conversion</U>. The Corporation shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the
purpose of effecting the conversion of the shares of the Preferred Stock, such number of its shares
of Common Stock as shall from time to time be sufficient to effect the conversion of all then
outstanding shares of the Preferred Stock; and if at any time the number of authorized but unissued
shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding
shares of the Preferred Stock, the Corporation will take such corporate action as may, in the
opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock
to such number of shares as shall be sufficient for such purpose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) <U>Waiver of Adjustment of Conversion Price</U>. Notwithstanding anything herein to the
contrary, any downward adjustment of the Conversion Price of any series of Preferred Stock may be
waived, either prospectively or retroactively and either generally or in a particular instance, by
the consent or vote of the holders of more than two-thirds&nbsp;(2/3) of the outstanding shares of such
series. Any such waiver shall bind all future holders of shares of such series of Preferred Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Voting</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Restricted Class&nbsp;Voting</U>. Except as otherwise expressly provided herein or as
required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together
and not as separate classes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>No Series&nbsp;Voting</U>. Other than as provided herein or required by law, there shall
be no series voting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Preferred Stock</U>. Each holder of Preferred Stock shall be entitled to the number
of votes equal to the number of shares of Common Stock into which the shares of Preferred Stock
held by such holder could be converted as of the record date. The holders of shares of the
Preferred Stock shall be entitled to vote on all matters on which the Common Stock shall be
entitled to vote. Holders of Preferred Stock shall be entitled to notice of any shareholders&#146;
meeting in accordance with the Bylaws of the Corporation. Fractional votes shall not, however, be
permitted
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and any fractional voting rights resulting from the above formula (after aggregating all
shares into which shares of Preferred Stock held by each holder could be converted), shall be
disregarded.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Common Stock</U>. Each holder of shares of Common Stock shall be entitled to one vote
for each share thereof held.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Election of Directors</U>. So long as at least 2,000,000 shares of Series&nbsp;D Preferred
Stock (as adjusted for stock splits, subdivisions, combinations or stock dividends with respect to
such shares) remain outstanding, the holders of the Series&nbsp;D Preferred Stock, voting as a separate
class, shall be entitled to elect one (1)&nbsp;member of the Corporation&#146;s Board of Directors at each
meeting or pursuant to each consent of the Corporation&#146;s shareholders for the election of
directors. So long as at least 2,000,000 shares of Series&nbsp;C Preferred Stock (as adjusted for stock
splits, subdivisions, combinations or stock dividends with respect to such shares) remain
outstanding, the holders of Series&nbsp;C Preferred Stock, voting as a separate class, shall be entitled
to elect three (3)&nbsp;members of the Corporation&#146;s Board of Directors at each meeting or pursuant to
each consent of the Corporation&#146;s shareholders for the election of directors. Any additional
members of the Corporation&#146;s Board of Directors shall be elected by the holders of Common Stock,
Series&nbsp;A Preferred Stock and Series&nbsp;B Preferred Stock, voting together as a single class.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Amendments and Changes Requiring Approval of Preferred Stock</U>. As long as any of
the Preferred Stock shall be issued and outstanding, the Corporation shall not, without first
obtaining the approval (by vote or written consent as provided by law) of the holders of more than
two-thirds&nbsp;(2/3) of the outstanding shares of the Preferred Stock voting together as a single
class:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation or By-laws of the
Corporation if such action would adversely alter the rights, preferences, privileges or powers of,
or restrictions provided for the benefit of the Preferred Stock or any series thereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;enter into any transaction or series of related transactions deemed to be a liquidation,
dissolution or winding up of the Corporation pursuant to Section&nbsp;3(f) above;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;voluntarily liquidate or dissolve;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section&nbsp;2(d)) with respect to the Common
Stock of the Corporation;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;permit any subsidiary of the Corporation to sell securities to a third party (other than
directors&#146; qualifying shares in the case of subsidiaries outside the United States);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, liquidation, redemption,
conversion or other rights senior to or on a parity with any series of Preferred Stock or with
respect to voting senior to any series of Preferred Stock;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;increase or decrease the authorized number of directors of the Corporation; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend this Section&nbsp;6.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;D Preferred Stock</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As long as any of the Series&nbsp;D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of 60% of the outstanding shares of the Series&nbsp;D Preferred Stock:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
restrictions provided for the benefit of the Series&nbsp;D Preferred Stock in a manner different from
any other series of Preferred Stock; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;amend this Section&nbsp;7(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As long as any of the Series&nbsp;D Preferred Stock shall be issued and outstanding, the
Corporation shall not, without first obtaining the approval (by vote or written consent as provided
by law) of the holders of a majority of the outstanding shares of the Series&nbsp;D Preferred Stock:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;D Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;D Preferred Stock or with respect to
voting senior to the Series&nbsp;D Preferred Stock;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;declare or pay any distribution (as defined in Section&nbsp;2(d)) with respect to the Common
Stock or Preferred Stock of the Corporation;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;increase the authorized number of directors of the Corporation above eleven (11); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;amend this Section&nbsp;7(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;C Preferred Stock</U>. As
long as any of the Series&nbsp;C Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of two-thirds of the outstanding shares of the Series&nbsp;C Preferred Stock:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">restrictions provided for the benefit of the Series&nbsp;C Preferred Stock in a manner different
from any other series of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;C Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;authorize or create (by reclassification or otherwise) any new class or series of capital
stock having rights, preferences or privileges with respect to dividends, payments upon liquidation
or other rights senior to or on a parity with the Series&nbsp;C Preferred Stock or with respect to
voting senior to the Series&nbsp;C Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;declare or pay any distribution (as defined in Section&nbsp;2(c)) with respect to the Common
Stock or Preferred Stock of the Corporation;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;increase the authorized number of directors of the Corporation above eleven (11); or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;amend this Section&nbsp;8.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Amendments and Changes Requiring the Approval of the Series&nbsp;B Preferred Stock</U>. As
long as any of the Series&nbsp;B Preferred Stock shall be issued and outstanding, the Corporation shall
not, without first obtaining the approval (by vote or written consent as provided by law) of the
holders of two-thirds of the outstanding shares of the Series&nbsp;B Preferred Stock:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend, alter or repeal any provision of the Articles of Incorporation of the Corporation
if such action would adversely alter the rights, preferences, privileges or powers of, or
restrictions provided for the benefit of the Series&nbsp;B Preferred Stock in a manner different from
any other series of Preferred Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;increase or decrease (other than for decreases resulting from conversion of the Preferred
Stock) the authorized number of shares of Series&nbsp;B Preferred Stock; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;amend this Section&nbsp;9.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Status of Converted Stock.</U> In the event any shares of Preferred Stock shall be
converted pursuant to Article&nbsp;4 hereof, then the shares so converted shall be cancelled and shall
not be issuable by the Corporation. The Articles of Incorporation shall be appropriately amended
to effect the corresponding reduction in the Corporation&#146;s authorized capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Notices</U>. Any notice required by the provisions of this Article&nbsp;IV to be given to
the holders of Preferred Stock shall be deemed given if deposited in the United States mail,
postage prepaid, and addressed to each holder of record at such holder&#146;s address appearing on the
books of the Corporation.
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">ARTICLE V
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Limitation of Directors&#146; Liability</U>. The liability of the directors of this
Corporation for monetary damages shall be eliminated to the fullest extent permissible under
California law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Indemnification of Corporate Agents</U>. This Corporation is authorized to provide
indemnification of agents (as defined in Section&nbsp;317 of the California Corporations Code) through
bylaw provisions, agreements with agents, votes of shareholders or disinterested directors or
otherwise, in excess of the indemnification otherwise permitted by Section&nbsp;317 of the California
Corporations Code, subject only to the applicable limits set forth in Section&nbsp;204 of the California
Corporations Code with respect to actions for breach of duty to this Corporation and its
shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Repeal or Modification</U>. Any repeal or modification of the foregoing provisions of
this Article&nbsp;V shall not adversely affect any right of indemnification or limitation of liability
permitted under California law relating to acts or omissions occurring prior to such repeal or
modification.
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt">(THE GREAT SEAL OF THE STATE OF CALIFORNIA - OFFICE OF THE SECRETARY OF STATE)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT B</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Form of New License Agreement

</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093; Indicates
text has been omitted from this Exhibit pursuant to a confidential treatment
request and has been filed separately with the Securities and Exchange Commission.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>8805. LICI.001</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>UAB Research Foundation</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>LICENSE AGREEMENT</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS LICENSE AGREEMENT (this &#147;Agreement&#148;) dated as of March&nbsp;7, 2003 (the &#147;Effective Date&#148;), is
entered into between The UAB Research Foundation, an Alabama not for profit organization (&#147;UABRF&#148;),
having a place of business at 1120G Administration Building, 704 20th Street, Birmingham, Alabama
35294, and Fluidigm Corporation, a California corporation (&#147;Fluidigm&#148;), having a place of business
at 7100 Shoreline Court, South San Francisco, California 94080.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, UABRF owns or has rights in certain technology regarding nanovolume crystallization
arrays.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, UABRF and Oculus Pharmaceuticals, Inc. (&#147;Oculus&#148;) have entered into that certain
License Agreement dated as of September&nbsp;21, 2001 (&#147;Oculus Agreement&#148;) pursuant to which UABRF has
granted to Oculus an exclusive license to the Oculus Agreement Technology (as defined below), on
the terms and conditions of the Oculus Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
UABRF and Oculus have terminated the Oculus Agreement effective as of January&nbsp;30,
2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, UABRF has licensed to Diversified Scientific, Inc. (&#147;DSI&#148;) rights in certain other
technology, which certain technology is identified in the attached <U>Exhibit&nbsp;A</U> (&#147;UABRF/DSI
Technology&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, DSI is performing certain research pursuant to one or more grants, existing as of
December&nbsp;19, 2002, between UAB (as defined below) and DSI under Defense Small Business Innovation
Research Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Fluidigm desires to obtain an exclusive worldwide license under the Licensed IP
Rights (as defined below), on the terms and conditions of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
herein contained, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;DEFINITIONS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 &#147;<U>Affiliate</U>&#148; shall mean, with respect to any Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control with, such Person. A
Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, at least forty percent (40%) of the voting stock or other ownership interest of the other
Person, or if it directly or indirectly possesses the power to direct or cause the direction of the
management and policies of the other Person by any means whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 &#147;<U>Confidential Information</U>&#148; shall mean, with respect to a party, all information of
any kind whatsoever, and all tangible and intangible embodiments thereof of any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">kind whatsoever, which is disclosed by such party to the other party and is marked, identified as
or otherwise acknowledged to be confidential at the time of disclosure to the other party.
Notwithstanding the foregoing, Confidential Information of a party shall not include information
which the other party can establish by written documentation (a)&nbsp;to have been publicly known prior
to disclosure of such information by the disclosing party to the other party, (b)&nbsp;to have become
publicly known, without fault on the part of the other party, subsequent to disclosure of such
information by the disclosing party to the other party, (c)&nbsp;to have been received by the other
party at any time from a source, other than the disclosing party, rightfully having possession of
and the right to disclose such information, (d)&nbsp;to have been otherwise known by the other party
prior to disclosure of such information by the disclosing party to the other party, or (e)&nbsp;to have
been independently developed by employees or agents of the other party without access to or use of
such information disclosed by the disclosing party to the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 &#147;<U>Fluidigm Series&nbsp;C Preferred Stock</U>&#148; shall have the meaning set forth in Section
1.9 of the Master Closing Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 &#147;<U>Licensed IP Rights</U>&#148; shall mean, collectively, the Licensed Patent Rights and the
Licensed Know-How Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 &#147;<U>Licensed Know-How Rights</U>&#148; shall mean all trade secret and other know-how rights
in all information and data disclosed on or before the Effective Date that (i)&nbsp;is not generally
known (including, but not limited to, information and data regarding formulae, procedures,
protocols, techniques and results of experimentation and testing), (ii)&nbsp;is developed by Dr.&nbsp;Larry
DeLucas in his capacity as a UAB faculty member or by UAB personnel under the scientific direction
and scientific supervision of Dr.&nbsp;Larry DeLucas, and (iii)&nbsp;is necessary or useful for Fluidigm to
research, develop, make, use, sell or seek regulatory approval to market a composition, or to
practice any method or process, at any time (a)&nbsp;comprising the Oculus Agreement Technology or (b)
claimed or covered by in any issued patent or pending patent application within the Licensed Patent
Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &#147;<U>Licensed Patent Rights</U>&#148; shall mean (a)&nbsp;those certain patent applications and
patents listed on <U>Exhibit&nbsp;B</U> hereto; (b)&nbsp;all patent applications heretofore or hereafter
filed or having legal force in any country which claim any Oculus Agreement Technology; (c)&nbsp;all
patents that have issued or in the future issue from the patent applications described in clauses
(a)&nbsp;and (b)&nbsp;of this Section&nbsp;1.6, including utility, model and design patents and certificates of
invention; and (d)&nbsp;all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patent applications and patents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 &#147;<U>Master Closing Agreement</U>&#148; shall mean a Master Closing Agreement between
Fluidigm, UABRF and Oculus of even date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 &#147;<U>NanoScreen Patent Rights</U>&#148; shall mean (a)&nbsp;those certain patent applications and
patents listed on <U>Exhibit&nbsp;B</U> hereto; (b)&nbsp;all patents that have issued or in the future issue
from any such patent applications, including utility, model and design patents and certificates of
invention; and (c)&nbsp;all divisionals, continuations, continuations-in-part, reissues, renewals,
extensions or additions to any such patent applications and patents.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 2 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 &#147;<U>Oculus Agreement Technology</U>&#148; shall mean collectively, the technology, processes,
inventions, trade secrets, know-how and other proprietary property described in <U>Exhibit&nbsp;C</U>
hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10 &#147;<U>Person</U>&#148; shall mean an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, pool, syndicate,
sole proprietorship, unincorporated organization, governmental authority or any other form of
entity not specifically listed herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11 <U>&#147;Third Party</U>&#148; shall mean any Person other than UABRF, Fluidigm and their
respective Affiliates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.12 &#147;<U>UAB</U>&#148; shall mean the University of Alabama at Birmingham.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.13 &#147;<U>UABRF/DSI
License Agreements</U>&#148; shall mean, collectively,
&#091;***&#093;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.14 &#147;<U>UAB Related Entities</U>&#148; shall mean and include UAB, UABRF, University Hospital,
The University of Alabama Health Services Foundation (&#147;UAHSF&#148;), Southern Research Institute and all
other entities within the UAB Medical Center, which are under the control of the Board of Trustees
of The University of Alabama or are associated with said Board of Trustees through an affiliation
agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;REPRESENTATIONS AND WARRANTIES
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Mutual Representations and Warranties</U> Each party hereby represents and warrants to
the other party as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.1 <U>Corporate Existence</U>. Such party is a corporation duly organized, validly
existing and in good standing under the laws of the state in which it is incorporated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.2 <U>Authorization and Enforcement of Obligations</U>. Such party (a)&nbsp;has the corporate
power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder, and (b)&nbsp;has taken all necessary corporate action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has
been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding
obligation, enforceable against such party in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.3 <U>No Consents</U>. All necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained by such party in connection with
this Agreement have been obtained.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1.4 <U>No Conflict</U>. The execution and delivery of this Agreement and the performance of
such party&#146;s obligations hereunder (a)&nbsp;do not conflict with or violate any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 3 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">requirement of applicable laws or regulations, and (b)&nbsp;do not conflict with, or constitute a
default under, any contractual obligation of it.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>UABRF Representations and Warranties</U>. UABRF represents and warrants to
Fluidigm as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.1
<U>Ownership</U>. UABRF is the sole owner of the Licensed IP Rights (other than those
listed under Item&nbsp;No.&nbsp;3 of <U>Exhibit&nbsp;B</U>), and as of the Effective Date has no knowledge of any
Third Party having any license or other interest in such Licensed IP Rights. UABRF shall use its
commercially reasonable efforts to provide Fluidigm with (a)&nbsp;evidence of UABRF&#146;s sole ownership of
those Licensed IP Rights listed under Item&nbsp;No.&nbsp;3 of <U>Exhibit&nbsp;B</U>, and (b)&nbsp;a letter from DSI to
Fluidigm stating that DSI has no license or other interest in NanoScreen Patent Rights except to
the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants (as
defined below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.2 <U>No Injunction</U>. No action, suit or proceeding before any court or government body
is instituted (or is pending) by any government authority or any other Person to restrain or
prohibit this Agreement or the consummation of the transactions contemplated hereby. No preliminary
or permanent injunction or other order issued by any federal or state court of competent
jurisdiction preventing this Agreement or the consummation of the transactions contemplated hereby
is in effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2.3 <U>No Infringement</U>. As of the Effective Date, UABRF and Dr.&nbsp;Larry DeLucas (a)&nbsp;are
not aware of any Third Party patent, patent application or other intellectual property rights that
would be infringed by practicing any process or method or by making, using or selling any
composition which is claimed or disclosed in the Licensed Patent Rights or which constitutes
Licensed Know-How Rights; (b)&nbsp;are not aware of any infringement or misappropriation by a Third
Party of the Licensed IP Rights; and (c)&nbsp;are not aware of any license or other right granted to DSI
or any other Third Party under the NanoScreen Patent Rights. Provided however, UABRF has disclosed
to Fluidigm the potential infringement by DSI of the Licensed IP Rights to the extent necessary for
DSI to perform its research obligations pursuant to one or more grants (the &#147;SBIR Grants&#148;),
existing as of December&nbsp;19, 2002, between UAB and DSI under the Defense Small Business Innovation
Research (SBIR)&nbsp;Program, with the understanding that neither DSI nor any other third party would
have the right to commercialize any results of such SBIR grants that would infringe the Licensed IP
Rights without first obtaining a license from Fluidigm under the Licensed IP Rights. Not later than
ten (10)&nbsp;days following the Effective Date, UABRF shall provide Fluidigm with copies of all
documents and instruments relating to such SBIR Grants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;LICENSE GRANT
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Licensed IP Rights</U>. UABRF hereby grants to Fluidigm an exclusive, perpetual,
irrevocable, royalty-free, worldwide license (including the right to grant sublicenses) under the
Licensed IP Rights. The license grant under the Licensed IP Rights (other than the NanoScreen
Patent Rights) is subject to the licenses previously and expressly granted by UABRF to DSI pursuant
to the UABRF/DSI License Agreements regarding the UABRF/DSI Technology only to the extent necessary
for DSI to exercise its license rights under the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 4 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">UABRF/DSI Technology granted thereunder. The license grant under the NanoScreen Patent Rights is
not subject to any previously granted licenses other than those certain rights which may have been
granted to DSI to the extent necessary for DSI to perform its research obligations pursuant to the
SBIR Grants. To the extent any of the rights, title and interest in and to the Licensed IP Rights
can be neither assigned nor licensed by UABRF to Fluidigm without (a)&nbsp;the consent of, or (b)
breach by UABRF of any agreement with, any Third Party, UABRF hereby irrevocably waives and agrees
never to assert such non-assignable and non-licensable rights, title and interest against Fluidigm
or any of Fluidigm&#146;s successors in interest to such non-assignable and non-licensable rights
during the term of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Sublicenses</U>. Fluidigm shall not sublicense the Licensed IP Rights prior to the
first (1st) anniversary of the Effective Date except in connection with settlement of any action or
claim relating to the technology that is the subject of the Licensed IP Rights. Fluidigm shall give
UABRF prompt written notice of each sublicense under this Agreement. Each sublicense shall be
subject to the terms and conditions of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Availability of the Licensed IP Rights</U>. UABRF shall provide Fluidigm with all
information available to UABRF regarding the Licensed IP Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Reservation of Rights</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.1 <U>Research Use</U>. UABRF hereby retains the right to, and this Agreement shall not
limit UABRF&#146;s ability to, utilize the Licensed IP Rights for internal research, academic and
educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB,
for patient care at UAB and UAB Related Entities, and/or for the performance of services for
for-profit or not-for-profit institutions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4.2 <U>Obligations to U.S. Government</U>. UABRF agrees that during the term of this
Agreement UABRF shall not use the Licensed IP Rights in any manner except for internal research,
academic and educational purposes at UAB, UAB Related Entities and academic institution
collaborators of UAB, for patient care at UAB and UAB Related Entities, and/or for the performance
of services for for-profit or not-for-profit institutions as provided in Section&nbsp;3.4.1 above and as
may be necessary or appropriate to fulfill the obligations of UABRF or UAB under the National
Institutes of Health (&#147;NIH&#148;) grant used to fund the research resulting in the development of
certain portion of the Licensed IP Rights. In determining the actions required under such grant,
UABRF shall consult with Fluidigm and keep Fluidigm informed, but UABRF shall have the ultimate
right to determine the necessary and appropriate actions relative thereto. UABRF&#146;s rights to the
Licensed IP Rights for use in fulfilling UAB&#146;s obligations under
the NIH grant shall only relate to
those portions of the Licensed IP Rights funded by such NIH grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>Non-Assertion Covenant</U>. To the extent the research activities of DSI
conducted in accordance with the SBIR Grants infringe the rights granted to Fluidigm under this
Section&nbsp;3, Fluidigm agrees not to assert such rights against DSI. Fluidigm agrees not to assert
against DSI such rights only to the extent expressly stated herein. No license or other right by
Fluidigm in favor of DSI shall be created hereunder by implication, estoppel or otherwise.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 5 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;LICENSE ISSUE FEE
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within thirty (30)&nbsp;days after the Effective Date Fluidigm shall (a)&nbsp;pay UABRF the sum in cash
of [***] and (b)&nbsp;issue to UABRF such number of Fluidigm Series&nbsp;C
Preferred Stock as provided in Section&nbsp;2.3 of the Master Closing Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;RESEARCH AND DEVELOPMENT OBLIGATIONS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Research and Development Efforts</U>. Fluidigm shall use commercially reasonable
efforts to research, develop and commercialize the Licensed IP Rights as Fluidigm determines
commercially feasible. Appendix&nbsp;1 of the Sponsored Research Agreement sets forth the components of
Fluidigm&#146;s Topaz System which Fluidigm plans to release commercially.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Records</U>. Fluidigm shall maintain records, in sufficient detail and in good
scientific manner, which shall reflect all work done and results achieved in the performance of its
research and development regarding the Licensed IP Rights (including all data in the form required
under all applicable laws and regulations).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Reports</U>. Within ninety (90)&nbsp;days following the end of each calendar year during
the term of this Agreement, Fluidigm shall prepare and deliver to UABRF a written summary report
which shall describe the research and development of the Licensed IP Rights during such year.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;CONFIDENTIALITY
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Confidential Information</U>. During the term of this Agreement, and for a period of
five (5)&nbsp;years following the expiration or earlier termination hereof, each party shall maintain in
confidence all Confidential Information disclosed by the other party, and shall not use, disclose
or grant the use of the Confidential Information except on a need-to-know basis to those directors,
officers, employees, consultants, clinical investigators, contractors, (sub)licensees, distributors
or permitted assignees, to the extent such disclosure is reasonably necessary in connection with
such party&#146;s activities as expressly authorized by this Agreement. To the extent that disclosure is
authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any
such person or entity to hold in confidence and not make use of the Confidential Information for
any purpose other than those permitted by this Agreement. Each party shall notify the other
promptly upon discovery of any unauthorized use or disclosure of the other party&#146;s Confidential
Information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Terms of this Agreement</U>. Except as otherwise provided in Section&nbsp;6.1 or 6.3,
neither party shall disclose any terms or conditions of this Agreement to any third party without
the prior consent of the other party. Notwithstanding the foregoing, prior to execution of this
Agreement, the parties have agreed upon the substance of information that can be used to describe
the terms of this transaction, and each party may disclose such information, as modified by mutual
agreement from time to time, without the other party&#146;s consent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Permitted Disclosures</U>. The confidentiality obligations contained in this Section&nbsp;6
shall not apply to the extent that the receiving party (the &#147;Recipient&#148;) is required (a)&nbsp;to
disclose information by law, order or regulation of a governmental agency or a court of
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 6 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">competent jurisdiction, or (b)&nbsp;to disclose information to any governmental agency for purposes of
obtaining approval to test or market a product, provided in either case that the Recipient shall
provide written notice thereof to the other party and sufficient opportunity to object to any such
disclosure or to request confidential treatment thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;PATENTS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Prosecution and Maintenance</U>. Fluidigm shall be responsible for and shall
control, at its sole cost, the preparation, filing, prosecution, defense (including without
limitation prosecution, defense and settlement of any interference or opposition) and maintenance
of the Licensed Patent Rights. Fluidigm shall give UABRF an opportunity to review and comment on
the text of each patent application within the Licensed Patent Rights before filing, and shall
provide UABRF with a copy of such patent application as filed, together with notice of its filing
date and serial number. UABRF shall cooperate with Fluidigm, execute all lawful papers and
instruments and make all rightful oaths and declarations as may be necessary in the preparation,
prosecution and maintenance of the Licensed Patent Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Enforcement</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.1 Each party shall notify the other party of any infringement known to such party of any
Licensed Patent Rights and shall provide the other party with the available evidence, if any, of
such infringement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2.2 Fluidigm, at its sole expense, shall have the right to determine the appropriate course
of action to enforce the Licensed Patent Rights or otherwise abate the infringement thereof, to
take (or refrain from taking) appropriate action to enforce the Licensed Patent Rights, to control
any litigation or other enforcement action and to enter into, or permit, the settlement of any such
litigation or other enforcement action with respect to the Licensed Patent Rights, and shall
consider, in good faith, the interests of UABRF in so doing. UABRF shall cooperate with Fluidigm in
the execution of any action to enforce the Licensed Patent Rights. Fluidigm shall retain all monies
recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent
Rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;TERMINATION
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Expiration</U>. Subject to the provisions of Section&nbsp;8.2 below, this Agreement
shall expire on the expiration of the last to expire of the Licensed Patent Rights. Upon
expiration of this Agreement under this Section&nbsp;8.1, Fluidigm shall have a paid-up,
exclusive, worldwide license under the Licensed Know-How Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Termination by Fluidigm</U>. Fluidigm may terminate this Agreement, in its sole
discretion, upon thirty (30)&nbsp;days prior written notice to UABRF. Upon termination of this Agreement
by Fluidigm under this Section&nbsp;8.2, Fluidigm shall have a paid-up, non-exclusive, worldwide license
under the Licensed Know-How Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Expiration or Termination</U>. Expiration or termination of this Agreement
shall not relieve the parties of any obligation accruing prior to such expiration or termination,
and the provisions of Sections&nbsp;6, 7 and 9 shall survive the expiration or termination
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 7 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of this Agreement. Except as the parties otherwise agree in writing, termination of this
Agreement shall not affect the Master Closing Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;INDEMNIFICATION
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>Indemnification</U>. Fluidigm shall defend, indemnify and hold the UABRF harmless from
all losses, liabilities, damages and expenses (including reasonable attorneys&#146; fees and costs)
resulting from any claims, demands, actions and other proceedings by any Third Party to the extent
resulting from Fluidigm&#146;s use of the Licensed IP Rights under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U>Procedure</U>. UABRF promptly shall notify Fluidigm of any claim, demand, action or
other proceeding for which UABRF intends to claim indemnification. Fluidigm shall have the right to
participate in, and to the extent Fluidigm so desires jointly with any other indemnitor similarly
noticed, to assume the defense thereof with counsel selected by Fluidigm; provided, however, that
UABRF shall have the right to retain its own counsel, with the fees and expenses to be paid by
UABRF, if representation of UABRF by the counsel retained by Fluidigm would be inappropriate due to
actual or potential differing interests between UABRF and any other party represented by such
counsel in such proceedings. The indemnity obligations under this Section&nbsp;9 shall not apply to
amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is
effected without the prior express written consent of Fluidigm, which consent shall not be
unreasonably withheld or delayed. The failure to deliver notice to Fluidigm within a reasonable
time after notice of any such claim or demand, or the commencement of any such action or other
proceeding, if prejudicial to its ability to defend such claim, demand, action or other proceeding,
shall relieve such Indemnitor of any liability to UABRF under this Section&nbsp;9 with respect thereto,
but the omission so to deliver notice to Fluidigm shall not relieve it of any liability that it may
have to UABRF other than under this Section&nbsp;9. Fluidigm may not settle or otherwise consent to an
adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights
or interests of UABRF without the prior express written consent of UABRF, which consent shall not
be unreasonably withheld or delayed. UABRF, its employees and agents, shall reasonably cooperate
with Fluidigm and its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by this Section&nbsp;9.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <U>Insurance</U>. Fluidigm shall maintain insurance with respect to the research,
development and commercialization of products by Fluidigm pursuant to this Agreement in such
amount as Fluidigm customarily maintains with respect to the research, development and
commercialization of its similar products. Fluidigm shall maintain such insurance for so long as
it continues to research, develop or commercialize any products pursuant to this Agreement, and
thereafter for so long as Fluidigm customarily maintains insurance covering the research,
development or commercialization of its similar products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;MISCELLANEOUS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <U>Notices</U>. Any consent, notice or report required or permitted to be given or
made under this Agreement by one of the parties to the other shall be in writing and addressed to
such other party at its address indicated below, or to such other address as the addressee shall
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 8 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">have last furnished in writing to the addressor, and shall be effective upon receipt by the
addressee.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to UABRF:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">UAB Research Foundation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1120G Administration Building</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">704 20th Street</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Birmingham, Alabama 35294</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">If to Fluidigm:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: President</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">with a copy to:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">South San Francisco, California 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Attention: General Counsel</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <U>Assignment</U>. Except as otherwise expressly provided under this Agreement neither
this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred
(whether voluntarily, by operation of law or otherwise), without the prior express written consent
of the other party; provided, however, that either party may, without such consent, assign this
Agreement and its rights and obligations hereunder in connection with the transfer or sale of all
or substantially all of its business, or in the event of its merger, consolidation, change in
control or similar transaction. Any permitted assignee shall assume all obligations of its assignor
under this Agreement. Any purported assignment or transfer in violation of this Section&nbsp;10.2 shall
be void.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 <U>Applicable Law</U>. This Agreement shall be governed by and construed in accordance
with the laws of the State of Alabama, without regard to the conflicts of law principles thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4 <U>Entire Agreement</U>. This Agreement and the Master Closing Agreement (together with
the Ancillary Agreements, as defined in the Master Closing Agreement) contain the entire
understanding of the parties with respect to the subject matter hereof. All express or implied
representations, agreements and understandings, either oral or written, heretofore made are
expressly superseded by this Agreement and the Master Closing Agreement. To the extent that any
provision of this Agreement conflicts with any provision of the Sponsored Research Agreement
between the parties of even date hereof (&#147;Sponsored Research Agreement&#148;), the applicable provision
of this Agreement shall control and supersede the applicable provision of the Sponsored Research
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5 <U>Independent Contractors</U>. Each party hereby acknowledges that the parties shall be
independent contractors and that the relationship between the parties shall not constitute a
partnership, joint venture or agency. Neither party shall have the authority to make any
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 9 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other party, without the prior consent of the other party to do so.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6 <U>Waiver</U>. The waiver by a party of any right hereunder, or of any failure to
perform or breach by the other party hereunder, shall not be deemed a waiver of any other right
hereunder or of any other breach or failure by the other party hereunder whether of a similar
nature or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7 <U>Force Majeure</U>. Neither party shall be held liable or responsible to the other
party nor be deemed to have defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure
or delay is caused by or results from causes beyond the reasonable control of the affected party
including but not limited to fire, floods, embargoes, war, acts of war (whether war be declared or
not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts
of God or acts, omissions or delays in acting by any governmental authority or the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="14%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">UAB RESEARCH FOUNDATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ (ILLEGIBLE)
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<tr>
    <TD>&nbsp;</TD>
</tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President &#38; CEO</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Acknowledged and agreed to</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">this March&nbsp;7, 2003.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Dr.&nbsp;Larry DeLucas
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Dr.&nbsp;Larry DeLucas
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 10 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>UABRF/DSI TECHNOLOGY</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 11 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT B
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>PATENT RIGHTS</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 12 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 13 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT C
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>OCULUS AGREEMENT TECHNOLOGY</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Copies of all documentation describing the foregoing, in particular, drawings, operations
manuals.</TD>
</TR>
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 14 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT C</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Form of Sponsored Research Agreement

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>8805.SRA.001&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<BR>
UAB Research Foundation</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FORM OF </DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 0pt">SPONSORED RESEARCH AGREEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS SPONSORED RESEARCH AGREEMENT (this &#147;Agreement&#148;) dated as of March&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2003 (the &#147;Effective
Date&#148;), is entered into between The UAB Research Foundation, an Alabama not for profit organization
(the &#147;UABRF&#148;), having a place of business at 1120G Administration Building, 704 20th Street,
Birmingham, Alabama 35294, and Fluidigm Corporation, a California corporation (&#147;Fluidigm&#148;), having
a place of business at 7100 Shoreline Court, South San Francisco, California 94080. The parties
agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;DEFINITIONS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 &#147;<U>Confidential Information</U>&#148; shall mean, with respect to a party, all information of
any kind whatsoever, and all tangible and intangible embodiments thereof of any kind whatsoever,
which is disclosed by such party to the other party and is marked, identified as or otherwise
acknowledged to be confidential at the time of disclosure to the other party. Notwithstanding the
foregoing, Confidential Information of a party shall not include information which the other party
can establish by written documentation (a)&nbsp;to have been publicly known prior to disclosure of such
information by the disclosing party to the other party, (b)&nbsp;to have become publicly known, without
fault on the part of the other party, subsequent to disclosure of such information by the
disclosing party to the other party, (c)&nbsp;to have been received by the other party at any time from
a source, other than the disclosing party, rightfully having possession of and the right to
disclose such information, (d)&nbsp;to have been otherwise known by the other party prior to disclosure
of such information by the disclosing party to the other party, or (e)&nbsp;to have been independently
developed by employees or agents of the other party without access to or use of such information
disclosed by the disclosing party to the other party (each, a &#147;Confidentiality Exception&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 &#147;<U>Derived</U>&#148; or &#147;<U>derived</U>&#148; shall mean obtained, developed, created, designed,
derived or resulting from, based upon or otherwise generated (whether directly or indirectly, or in
whole or in part).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 &#147;<U>Master Closing Agreement</U>&#148; shall mean a Master Closing Agreement between Fluidigm,
UABRF and Oculus Pharmaceuticals, Inc. of even date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 &#147;<U>Materials</U>&#148; shall mean the proprietary materials provided by one party to the
other under this Agreement, together with all derivatives and parts thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5
&#147;<U>Principal Investigator</U>&#148; shall mean [***].
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &#147;<U>Program</U>&#148; shall mean the research program described in Section
2.1.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 &#147;<U>Program Period</U>&#148; shall mean the period commencing on the Effective Date, and
continuing through the fifth (5th) anniversary of the Effective Date, unless terminated earlier as
provided below.
</DIV>
 <P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.8 &#147;<U>Program Technology</U>&#148; shall mean, collectively, all inventions,
discoveries, data and information (whether patentable or not patentable) generated in connection
with the Program, excluding the Materials. Unless subject to a Confidentiality Exception, all
Program Technology shall be Confidential Information of UABRF.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 &#147;<U>Research Plan</U>&#148; shall mean the annual written research workplan for the Program.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;SPONSORED RESEARCH
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Statement of Work</U>. During the Program Period, UABRF shall conduct the Program in
accordance with the Research Plan. The Research Plan for the first (1st) year of the Program is
attached hereto as <U>Exhibit&nbsp;A</U>. No later than ninety (90)&nbsp;days prior to each anniversary of
the Effective Date (other than the fifth (5th) anniversary thereof) during the term
of this Agreement the parties shall mutually agree upon the Research Plan for the upcoming year of
the Program and shall amend <U>Exhibit&nbsp;A</U> by attaching such mutually agreed upon Research Plan
thereto. Except as provided in this Section&nbsp;2.1 or except by the mutual written agreement of the
parties, the Research Plan shall not be altered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Principal Investigator</U>. UABRF shall conduct the Program under the
direction of the Principal Investigator. The Principal Investigator shall be responsible for the
supervision and administration of the Program, including all budgeting and revisions to the budget
in accordance with all applicable policies of UABRF. Fluidigm shall consider in good faith
utilizing on mutually acceptable terms and conditions the engineering capability available at the
Principal Investigator&#146;s laboratory for the continuing development of Fluidigm&#146;s Topaz
microprocessor product line as reasonably required by, but at the sole discretion of, Fluidigm at
additional compensation over and above the amounts set forth in Section&nbsp;4.1 of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Records and Reports</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3.1 UABRF shall keep complete and accurate records of the work performed under this
Agreement in accordance with established good laboratory practices and appropriate for patent
purposes. Fluidigm shall have the right, upon reasonable notice and during reasonable business
hours, to inspect and make copies of such accounts, notes, data and records.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3.2
Within [***] after the end of each calendar quarter
during the Program Period, UABRF shall prepare and provide Fluidigm with quarterly written reports
describing the work performed during such calendar quarter under this Agreement and all resulting
Program Technology. Within [***] after the expiration or earlier termination of the
Program Period, UABRF shall prepare and provide Fluidigm with a comprehensive written report
describing all work performed under this Agreement and all resulting Program Technology. At
Fluidigm&#146;s request, upon reasonable notice, UABRF also shall provide interim summary reports and
copies of all data generated under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Informal Consultations</U>. At reasonable times during the Program Period, Fluidigm&#146;s
representatives may consult informally with the Principal Investigator regarding the Program
personally, by telephone, email or other means of communication.
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;MATERIAL TRANSFER
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Materials</U>. Each party shall provide to the other party (the &#147;Recipient&#148;) those
Materials required to be provided under the Research Plan. The Recipient of any Materials hereby
acknowledges that, as between the parties, the other party is the sole owner or licensee of such
Materials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Permitted Use</U>. The Recipient shall use the Materials solely as permitted under
the Research Plan and not for any other purpose. THE RECIPIENT UNDERSTANDS THAT THE MATERIALS ARE
PROVIDED SOLELY FOR CERTAIN RESEARCH USE ONLY AND HAVE NOT BEEN APPROVED FOR HUMAN USE. THE
RECIPIENT SHALL NOT ADMINISTER THE MATERIALS TO HUMANS IN ANY MANNER OR FORM. Provided however,
upon the Fluidigm Materials becoming commercially available (&#147;Commercial Fluidigm Materials&#148;), the
restrictions of this Section&nbsp;3.2 shall terminate as to the Commercial Fluidigm
Materials, and the UABRF /UAB shall have the right to use the Commercial Fluidigm
Materials on the same terms and conditions as Fluidigm generally makes the Commercial Fluidigm
Materials commercially available to third parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>No Transfer</U>. The Recipient shall not transfer the Materials to any third party
without the prior express written consent of the other party. The Recipient shall limit transfer
and disclosure of the Materials on a need to know basis, as reasonably necessary for the conduct
of the Program, to its directors, officers and employees who are bound by written agreements with
the Recipient to not use or transfer the Materials for any purpose other than those permitted by
this Agreement. The Recipient shall notify the other party promptly upon discovery of any
unauthorized use or transfer thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <U>Return of Materials</U>. Upon expiration or termination of the Program Period,
the Recipient shall promptly return or destroy (as requested by the other party) all
remaining Materials to the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 <U>No Warranty</U>. THE RECIPIENT ACKNOWLEDGES THAT THE MATERIALS ARE EXPERIMENTAL IN
NATURE AND ARE PROVIDED &#147;AS IS.&#148; THE PARTY PROVIDING THE MATERIALS MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRES OR IMPLIED, WITH RESPECT TO THE MATERIALS OR THE USE THEREOF, AND DISCLAIMS ALL
IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE OR NONINFRINGEMENT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;FUNDING
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Budget and Payment</U>. Subject to the terms and conditions of this Agreement,
Fluidigm shall support the Program by an aggregate grant to UABRF of [***], payable in [***]&nbsp;equal quarterly installments of [***] on or before the thirtieth (30th) day of each calendar quarter after the Effective Date.
Fluidigm shall have no obligation to provide funds to UABRF in excess of such amount. All payments
by Fluidigm to UABRF under this Agreement shall be originated from a United States bank located in
the United States and made by bank wire transfer
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the following account: Account Name: UAB Research Foundation; Bank Name: First
Commercia1 Bank; ABA Number: [***], Account Number: [***].
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>Accounting</U>. Upon request by Fluidigm, UABRF shall provide to Fluidigm
a report of expenditures shown by major cost categories.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;PROGRAM TECHNOLOGY
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Ownership</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.1 All right, title and interest in all Program Technology (a)&nbsp;made or
conceived solely by employees or others acting on behalf of UABRF (the &#147;UABRF Inventions&#148;)
shall be owned solely by UABRF; (b)&nbsp;made or conceived solely by employees or others acting
on behalf of Fluidigm (the &#147;Fluidigm Inventions&#148;) shall be owned solely by Fluidigm; and
(c)&nbsp;made or conceived jointly by employees or others acting on behalf of Fluidigm and by
employees or others acting on behalf of UABRF (the &#147;Joint Inventions&#148;) shall be owned jointly
by Fluidigm and UABRF. Each party shall have the right, subject to the provisions of this
Agreement, to freely exploit, transfer, license or encumber its rights in any Joint
Inventions, and the patent rights and other intellectual property rights therein, without the
consent of, or payment or accounting to, the other party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1.2 The transfer of physical possession of any materials or technology
owned by, and the physical possession and use of any materials or technology by, Fluidigm or
UABRF, as the case may be, shall not be (nor construed as) a sale, lease, offer to sell or
lease, or
other transfer of title of such materials or technology to UABRF or Fluidigm, as the case
may be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Disclosure</U>. UABRF promptly shall disclose to Fluidigm any Program
Technology made or conceived by or on behalf of UABRF, and provide Fluidigm with copies of
all information available to UABRF regarding such Program Technology.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <u>Options and Licenses</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.1 UABRF hereby grants to Fluidigm a nonexclusive, worldwide,
royalty-free license (together with the right to grant sublicenses), under UABRF&#146;s rights in the
Program Technology, to use all unpatented Program Technology for all purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.2 With respect to each discovery or invention comprising Program
Technology, UABRF hereby grants to Fluidigm an exclusive option to obtain an exclusive,
worldwide, royalty-bearing license (with the exclusive right to sublicense) under any issued
patents relating to such discovery or invention for all purposes. The option with respect to
each
such discovery or invention shall be exercisable for the [***] following disclosure
to
Fluidigm of all information available to UABRF regarding such discovery or invention. The
license shall be on mutually acceptable terms and conditions. Upon exercise by Fluidigm of
the
option with respect to each such discovery or invention, the parties shall negotiate in good
faith,
and shall use good faith efforts to execute a written agreement evidencing such license prior
to
the expiration of [***]&nbsp;days following the expiration of the one-year
option
term described above. The actual royalty rate shall be negotiated in good faith based on
reasonable factors including without limitation [***]
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">[***]. Fluidigm shall have the right to control the filing,
prosecution, maintenance and enforcement of all patent applications and patents that are so
licensed to Fluidigm.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3.3 If Fluidigm fails to obtain a license under Section&nbsp;5.3.2 with respect to any patent
rights, during the [***]&nbsp;day negotiation period under Section&nbsp;5.3.2 (&#147;Option
Negotiation Period&#148;), UABRF for a [***]&nbsp;month period following the expiration of the Option
Negotiation Period shall [***].
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Patent Rights</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4.1 UABRF shall control the preparation, filing, prosecution and
maintenance of all patents and patent applications to the extent they claim UABRF Inventions or
Joint Inventions. Fluidigm shall advise UABRF no later than ninety (90)&nbsp;days after disclosure by
UABRF of a UABRF Invention or a Joint Invention whether it intends to reimburse UABRF for the
reasonable out of pocket costs of preparing, filing and prosecuting patent applications covering
such UABRF Invention or Joint Invention. If Fluidigm declines to reimburse UABRF for all reasonable
costs of preparing, filing and prosecuting a patent application for a patentable UABRF Invention or
Joint Invention in any jurisdiction, UABRF may do so at its sole cost, but such patent application
and patent shall be excluded from Fluidigm&#146;s option to license under Section&nbsp;5.3 above; provided,
however, UABRF shall not file or prosecute a patent application when Fluidigm has demonstrated to
UABRF that the filing or prosecution of such patent application would be prejudicial to the
optimization of such UABRF Invention or Joint Invention. UABRF shall give Fluidigm an opportunity
to review the text of, and shall reasonably consider Fluidigm&#146;s comments with respect to, each
patent application for a UABRF Invention or a Joint Invention before filing, and shall supply
Fluidigm with a copy of such application as filed, together with notice of its filing date and
serial number. UABRF shall prepare, file and prosecute patent applications covering UABRF
Inventions or Joint Inventions in all jurisdictions requested by Fluidigm, provided that Fluidigm
has not declined to reimburse UABRF for all reasonable costs of preparing, filing and prosecuting
such patent applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4.2 Fluidigm shall control, at its sole expense, the preparation, filing,
prosecution and maintenance of all patents and patent applications to the extent they claim
Fluidigm Inventions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4.3 Each party shall cooperate with the other party, execute all lawful
papers and instruments and make all rightful oaths and declarations as may be necessary in the
preparation, filing, prosecution maintenance and enforcement of all patents and patent
applications described in this Section&nbsp;5.4.
</DIV>
 <P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;CONFIDENTIALITY AND PUBLICATION
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Confidential Information</U>. During the term of this Agreement, and for a
period of five (5)&nbsp;years following the expiration or earlier termination hereof, each party
shall
maintain in confidence all Confidential Information disclosed by the other party, and shall
not
use, disclose or grant the use of the Confidential Information except on a need-to-know
basis to
those directors, officers, employees, consultants, clinical investigators, contractors,
(sub)licensees, distributors or permitted assignees, to the extent such disclosure is
reasonably
necessary in connection with such party&#146;s activities as expressly authorized by this
Agreement.
To the extent that disclosure is authorized by this Agreement, prior to disclosure, each
party
hereto shall obtain agreement of any such person or entity to hold in confidence and not
make
use of the Confidential Information for any purpose other than those permitted by this
Agreement. Each party shall notify the other promptly upon discovery of any unauthorized use
or disclosure of the other party&#146;s Confidential Information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Terms of this Agreement</U>. Except as otherwise provided in Section&nbsp;6.1 or
6.3, neither party shall disclose any terms or conditions of this Agreement to any third
party
without the prior consent of the other party. Notwithstanding the foregoing, prior to
execution of
this Agreement, the parties shall agree upon the substance of information that can be used
to
describe the terms of this transaction, and each party may disclose such information, as
modified
by mutual agreement from time to time, without the other party&#146;s consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>Permitted Disclosures</u>. The confidentiality obligations contained in this
Section&nbsp;6 shall not apply to the extent that the receiving party is required (a)&nbsp;to disclose
information by law, order or regulation of a governmental agency or a court of competent
jurisdiction, or (b)&nbsp;to disclose information to any governmental agency for purposes of
obtaining
approval to test or market a Product, provided in either case that the receiving party shall
provide
written notice thereof to the other party and sufficient opportunity to object to any such
disclosure or to request confidential treatment thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <u>Publication</u>. Fluidigm acknowledges UABRF&#146;s interest in publishing
certain results of the Program to obtain recognition within the scientific community and to
advance the state of scientific knowledge. Each party also recognized their mutual interest
in
obtaining valid patent protection and protecting business interests. Consequently, if UABRF
desires to make a publication (including any oral disclosure made without obligation of
confidentiality) of any results of the Program, UABRF shall provide Fluidigm with a copy of
the
proposed written publication at least [***]&nbsp;days prior to submission for
publication, or
an outline of such oral disclosure at least [***]&nbsp;days prior to presentation.
Fluidigm shall
have the right (a)&nbsp;to propose modifications to the publication for patent reasons, and (b)
to
request a reasonable delay in publication in order to protect patentable information. If
Fluidigm
requests such a delay, UABRF shall delay submission or presentation of the publication for a
period of [***]&nbsp;days to enable patent applications to be prepared and filed. Upon the
expiration of such [***]&nbsp;day period (in the case of proposed written disclosures)
or
[***]&nbsp;day period (in the case of proposed oral disclosures) from receipt by Fluidigm,
UABRF shall be free to proceed with the written publication or the presentation,
respectively,
unless Fluidigm has requested the delay described above.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

 <DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;TERM
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Expiration</U>. Unless terminated earlier pursuant to Section&nbsp;7.2, this
Agreement shall expire on the expiration of the Program Period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Termination for Cause</U>. A party may terminate this Agreement upon or
after a material breach of this Agreement by the other party, if the breaching party has not
cured
such breach within thirty (30)&nbsp;days after notice thereof from the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Effect of Expiration and Termination</U>. Expiration or termination of this
Agreement shall not relieve the parties of any obligation accruing prior to such expiration or
termination. The provisions of Sections&nbsp;5, 6 and 8 shall survive the expiration or termination
of this Agreement. Except as the parties otherwise agree in writing, termination of this
Agreement shall not affect the Master Closing Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Outstanding Commitments</U>. Upon the giving of notice of termination by
either party, UABRF shall use best efforts to limit or terminate any outstanding
commitments in
connection with the Program. Fluidigm shall reimburse UABRF for all direct costs incurred by
it for all work performed through the effective termination date, and for all
outstanding
obligations which cannot be cancelled; provided, however, that Fluidigm&#146;s aggregate
funding
obligation under this Agreement shall not exceed the amount set forth in Section&nbsp;4.1 above.
Within thirty (30)&nbsp;days after the effective date of termination, UABRF shall furnish Fluidigm
with a final statement for settlement of all costs to be reimbursed. This statement may
include
costs incurred before the notice of termination was given but which were not yet billed. If
funds
received by UABRF exceed expenses incurred, UABRF shall reimburse Fluidigm for any such
excess funds at the time such final statement is furnished to Fluidigm.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;INDEMNIFICATION
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 <U>Indemnification</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1.1 Fluidigm shall defend, indemnify and hold UABRF harmless from
all losses, liabilities, damages and expenses (including reasonable attorneys&#146; fees and costs)
resulting from any claims, demands, actions and other proceedings by any unaffiliated third
party
to the extent resulting from Fluidigm&#146;s gross negligence or willful misconduct under this
Agreement or use of the UABRF Materials or UABRF Confidential Information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1.2 UABRF shall (to the fullest extent to which University of Alabama
at Birmingham has the right under applicable law to do so) defend, indemnify and
hold Fluidigm
harmless from all losses, liabilities, damages and expenses (including reasonable
attorneys, fees
and costs) resulting from any claims, demands, actions and other proceedings by any
unaffiliated
third party to the extent resulting from UABRF&#146;s gross negligence or willful misconduct under
the Agreement, or use of the Fluidigm Materials or Fluidigm Confidential
Information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1.3 A party (the &#147;Indemnitee&#148;) that intends to claim indemnification
under this Section&nbsp;8.1 shall promptly notify the other party (the &#147;Indemnitor&#148;) of any
liability or
action in respect of which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so
desires,
</DIV>
 <P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel
selected by the Indemnitor; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such
Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or
potential differing interests between such Indemnitee and any other party represented by such
counsel in such proceedings. The indemnity agreement in this Section&nbsp;8.1 shall not apply to amounts
paid in settlement of any loss, claim, damage, liability or action if such settlement is effected
without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.
The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of
any such action, if prejudicial to its ability to defend such action, shall relieve the Indemnitor
of any liability to the Indemnitee under this Section&nbsp;8.1, but the omission so to deliver notice to
the Indemnitor will not relieve it of any liability that it may have to the Indemnitee otherwise
than under this Section&nbsp;8.1. The Indemnitor may not settle the action or
otherwise consent to an adverse judgment in such action that diminishes the rights or interests of
the Indemnitee without the express written consent of the Indemnitee. The Indemnitee, its employees
and agents, shall cooperate fully with the Indemnitor and its legal representatives in the
investigation and defense of any action, claim or liability covered by this indemnification.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 <U>Representation</U>. UABRF hereby represents that to the knowledge of UABRF and
the Principal Investigator the rights and obligations of UABRF under this Agreement do not conflict
with rights and obligations provided under other agreements which it has with third parties,
including the federal and local governments. During the Program Period (or while Fluidigm is
providing any subsequent funding), neither UABRF nor the Principal Investigator shall enter into
any other agreements which conflict with rights and obligations provided hereunder, including any
rights and obligations which survive termination hereto. UABRF shall enter into written agreements
with its employees. consultants and such others as is necessary to obtain ownership of inventions,
discoveries and other useful research results, products and processes made by them pursuant to
activity carried out in connection with the Program.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;MISCELLANEOUS
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 <U>Notices</U>. Any consent, notice or report required or permitted to be given or
made under this Agreement by one of the parties to the other shall be in writing and addressed to
such other party at its address indicated below, or to such other address as the addressee shall
have last furnished in writing to the addressor, and shall be effective upon receipt by the
addressee.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="10%" nowrap align="left">If to UABRF:&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>UAB Research Foundation<BR>
1120G Administration Building<BR>
 704 20th Street<BR> Birmingham, Alabama 35294<BR>
Attention: Director</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="10%" nowrap align="left">If to Fluidigm:&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fluidigm Corporation<BR> 7100 Shoreline Court<BR>
South San Francisco, California 94080<BR> Attention: President</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="10%" nowrap align="left">with a copy to:&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fluidigm Corporation<BR> 7100 Shoreline Court<BR>
South San Francisco, California 94080<BR> Attention: General Counsel</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 <U>Assignment</U>. Except as otherwise expressly provided under this
Agreement neither this Agreement nor any right or obligation hereunder may be assigned or
otherwise transferred (whether voluntarily, by operation of law or otherwise), without the
prior
express written consent of the other party; provided, however, that either party may,
without such consent, assign this Agreement and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its business, or in the
event of its merger, consolidation, change in control or similar transaction. Any permitted
assignee shall assume all obligations of its assignor under this Agreement. Any purported
assignment or transfer in violation of this Section&nbsp;9.2 shall be void.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3 <U>Applicable Law</U>. This Agreement shall be governed by and construed in
accordance with the laws of the State of Alabama, without regard to the conflicts of law
principles thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4 <U>Entire Agreement</U>. This Agreement and the Master Closing Agreement
(together with the Ancillary Agreements, as defined in the Master Closing Agreement) contain
the entire understanding of the parties with respect to the subject matter hereof. All express
or
implied representations, agreements and understandings, either oral or written, heretofore
made
are expressly superseded by this Agreement and the Master Closing Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5 <U>Independent Contractors</U>. Each party hereby acknowledges that the parties
shall be independent contractors and that the relationship between the parties shall not
constitute
a partnership, joint venture or agency. Neither party shall have the authority to make any
statements, representations or commitments of any kind, or to take any action, which shall be
binding on the other party, without the prior consent of the other party to do so.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6 <U>Waiver</U>. The waiver by a party of any right hereunder, or of any failure to
perform or breach by the other party hereunder, shall not be deemed a waiver of any other
right
hereunder or of any other breach or failure by the other party hereunder whether of a similar
nature or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7 <U>Counterparts</U>. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have duly executed and delivered this Agreement as of the date
first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">UAB RESEARCH FOUNDATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="0" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">FLUIDIGM CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="0" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">Acknowledged and agreed to<br> this
March&nbsp;&nbsp;&nbsp;&nbsp;, 2003.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Dr. [***],&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD colspan="3" align="left">Principal Investigator&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

</TABLE>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>RESEARCH PLAN</U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="center" style="font-size: 10pt; margin-top: 18pt">APPENDIX 1 <BR>(To Exhibit&nbsp;A
(&#147;Research Plan&#148;)
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#091;***&#093;

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Part Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Item</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Quantity</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="left" valign="top">&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD>&#091;***&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;***&#093;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Other Materials included:</b> &#091;***&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT D </U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PATENTS AND PATENT APPLICATIONS</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">[***]

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>10
<FILENAME>f39432a9exv10w19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w19</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.19</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Oscient</b>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SUBLEASE</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This SUBLEASE is made as of March&nbsp;25, 2004, by and between Genome Therapeutics Corporation, a
Massachusetts corporation having a place of business at 100 Beaver Street, Waltham, Massachusetts
02453 (&#147;Sublessor&#148;) and Fluidigm Corporation, a California corporation having an address at 7100
Shoreline Court, San Francisco, California 94080 (&#147;Sublessee&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>WITNESSETH:</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, pursuant to that certain Agreement of Lease dated as of November&nbsp;9, 1999, by and
between Mountain Cove Tech Center, L.L.C., as &#147;landlord&#148;, (&#147;Master Lessor&#148;) and MJ Research
Company, Inc., as &#147;tenant&#148;, (&#147;Prime Lessor&#148;) (the &#147;Master Lease&#148;), Master Lessor leases to Prime
Lessor the land and building known as and numbered 7000 Shoreline Court, San Francisco, California
(the &#147;Building&#148;) (all as more particularly described in the Master Lease a true and complete copy
of which is attached hereto as <U><B>Exhibit&nbsp;A-1</B></U>, the &#147;Master Premises&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, pursuant to that certain Agreement of Lease dated as of October&nbsp;6, 2000 by and
between Prime Lessor, as &#147;landlord&#148; and Sublessor, as &#147;tenant&#148; (as successor in interest to
Genesoft, Inc.), as amended by a First Amendment to Lease dated December&nbsp;5, 2002 and a Second
Amendment to Lease dated March&nbsp;25, 2004 (such lease, as so amended, and all renewals, modifications
and extensions thereof being hereinafter collectively referred to as the &#147;Prime Lease&#148;), a true
and complete copy of which is attached hereto as <U><B>Exhibit&nbsp;A-2</B></U>, Prime Lessor leases to
Sublessor approximately 68,460 rentable square feet of space located on the first, second and third
floors of the Building (all as more particularly described in the Prime Lease, the &#147;Premises&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Sublessee subleases other space in the Building directly from Prime Lessor pursuant
to that certain Sublease dated December&nbsp;1, 2001 (as amended to date, the &#147;MJ Research Sublease&#148;);
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Sublessee desires to sublease a portion of the Premises from Sublessor and Sublessor
is willing to sublease the same, all on the terms and conditions hereinafter set forth;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties covenant and agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Sublease of Subleased Premises</U>. For the rent and upon the terms and
conditions herein, Sublessor hereby subleases to Sublessee, and Sublessee hereby subleases from
Sublessor approximately 14,503 rentable square feet of office and lab space located on the 1st
floor of the Building as shown on <U><B>Exhibit&nbsp;B</B></U> attached hereto (the &#147;Subleased Premises&#148;).
Sublessee acknowledges that any reference to the square
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">footage of the Subleased Premises is an approximation. Nevertheless, the parties agree that such
approximation shall be final and binding for all purposes hereunder, and that no adjustment shall
be made to the Rent if the actual square footage of the Subleased Premises differs from any
reference to square footage contained herein. During the term hereof, Sublessee shall have access
to the Subleased Premises and the parking lot(s) adjacent to the Building twenty-four (24)&nbsp;hours a
day, 7&nbsp;days a week, subject to the terms of the Prime Lease and this Sublease. Sublessor also
grants Sublessee the right to use, without additional charge during the term of this Sublease,
those items of personal property identified on <U><B>Exhibit&nbsp;C</B></U> attached hereto and made a part
hereof (the &#147;Furniture&#148;), together with the existing network wiring/equipment (including handsets)
and fixtures in the Subleased Premises as of the Commencement Date. Sublessee accepts possession of
the Furniture and said network wiring/equipment and fixtures &#147;as is, where is&#148; and in their current
condition, Sublessor having made no representation or warranty of any kind, express or implied
(including, but not limited to, any warranty of fitness for any particular use or purpose) with
respect to any of the same. Prior to the Commencement Date, Sublessee shall, upon prior notice to
the Sublessor, have the right to enter the Subleased Premises for the purposes of inspecting the
same, taking measurements, installing its furniture, fixtures and equipment, and preparing for the
move into the Subleased Premises. Sublessor shall have the right to have a representative present
any time such early entry right is exercised. If Sublessee enters the Subleased Premises prior to
the Commencement Date, Sublessee shall be responsible for complying with all of the terms of this
Sublease (other than the payment of Rent) and, to the extent incorporated herein by reference, the
Prime Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Term</U>. The Term of this Sublease (the &#147;Initial Term&#148;) shall commence on March
1, 2004 (the &#147;Commencement Date&#148;), and shall expire on December&nbsp;31, 2007 (the &#147;Expiration Date&#148;) or
such earlier date upon which said Initial Term may expire, be canceled or be terminated pursuant to
any of the terms or provisions of the Prime Lease, this Sublease or applicable law. Sublessee shall
have one option to extend the term of this Sublease from January&nbsp;1, 2008 until December&nbsp;31, 2010
(the &#147;Extension Term&#148;) following the Initial Term on the same terms and conditions as herein
specified (other than the payment of Rent), which option shall be exercisable upon Sublessee&#146;s
providing Sublessor with written notice no later than six (6)&nbsp;months prior to the Expiration Date,
time being of the essence. Failure on the part of Sublessee to give timely such notice exercising
the extension option for the Extension Term shall render said extension option void and of no
further force or effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the conditions (any one or more of which conditions Sublessor may waive, at its election,
by written notice to Sublessee at any time) that at the time of option exercise Sublessee is not in
default of its covenants and obligations under this Sublease beyond all applicable cure periods,
Sublessee may elect to exercise its right to the Extension Term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Rent for the Extension Term shall be 95% of the then current fair market rental value
(&#147;FMRV&#148;) for comparable space in South San Francisco, California under a three (3)&nbsp;year sublease,
taking into account all relevant factors.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FMRV shall be proposed by Sublessor within thirty (30)&nbsp;days of the receipt of Sublessee&#146;s
notice that it intends to extend the term of the Sublease (the &#147;<U>Sublessor&#146;s Proposed Market
Rent</U>&#148;). The Sublessor&#146;s Proposed Market Rent shall be deemed to be the FMRV unless
Sublessee notifies Sublessor, within thirty (30)&nbsp;days of Sublessee&#146;s receipt of the Sublessor&#146;s
Proposed Market Rent notice, that the Sublessor&#146;s Proposed Market Rent is not satisfactory to
Sublessee (the &#147;<U>Sublessee&#146;s Rejection Notice</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the FMRV is not otherwise agreed upon by Sublessor and Sublessee within fifteen
(15)&nbsp;days after Sublessor&#146;s receipt of the Sublessee&#146;s Rejection Notice, then:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the MJ Research Sublease has been extended for a period coterminous
with the Extension Term hereunder and the &#147;fair market rent&#148; for such
extension has been determined in good faith under and pursuant to the
process set forth in Section&nbsp;4 of the MJ Research Sublease, the FMRV
shall be determined by multiplying such fair market rent per rentable
square foot by the rentable square footage of the Subleased Premises.
However, if for any reason such fair market rent has not been so
determined as of the commencement of the Extension Term hereof, the
FMRV shall be determined as set forth in subparagraphs (2)&nbsp;through (8)
below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sublessor and Sublessee shall notify one another within ten (10)&nbsp;days
after the commencement of the Extension Term of the name and address
of the appraiser designated by each. Such two (2)&nbsp;appraisers shall, within
twenty (20)&nbsp;days after the designation of the second appraiser, make their
determination of the FMRV in writing and give notice thereof to each
other and to Sublessor and Sublessee. Such two (2)&nbsp;appraisers shall have
twenty (20)&nbsp;days after the receipt of notice of each other&#146;s determinations
to confer with each other and to attempt to reach agreement as to the
determination of the FMRV. If such appraisers shall concur in such
determination within said twenty (20)&nbsp;day period, then they shall give
notice thereof to Sublessor and Sublessee and such concurrence shall be
final and binding upon Sublessor and Sublessee. If such appraisers shall
fail to concur as to such determination within said twenty (20)&nbsp;day
period, then they shall give notice thereof to Sublessor and Sublessee and
shall immediately designate a third appraiser. If the two (2)&nbsp;appraisers
shall fail to agree upon the designation of such third appraiser within five
(5)&nbsp;days after said twenty (20)&nbsp;day period, then they or either of them
shall give notice of such failure to agree to Sublessor and Sublessee and,
if Sublessor and Sublessee fail to agree upon the selection of such third
appraiser within five (5)&nbsp;days after the appraiser(s) appointed by the
parties give notice as aforesaid, then either party on behalf of both may
apply to the American Arbitration Association or any successor thereof
to designate a third appraiser, or on such association&#146;s failure, refusal or
inability to act, to a court of competent jurisdiction, for the designation of
such third appraiser.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All appraisers shall be commercial real estate brokers who shall have had
at least five (5)&nbsp;years&#146; continuous experience as a commercial real estate
broker, including some experience leasing biotech space, in the South
San Francisco, California area.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The third appraiser shall conduct such investigations as he or she may
deem appropriate and shall, within ten (10)&nbsp;days after the date of his or
her designation, make an independent determination of the FMRV.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If none of the determinations of the appraisers varies from the mean of
the determinations of the other appraisers by more than ten percent
(10%), the mean of the determinations of the three (3)&nbsp;appraisers shall be
the FMRV for the Subleased Premises. If, on the other hand, the
determination of any single appraiser varies from the mean of the
determinations of the other two (2)&nbsp;appraisers by more than ten percent
(10%), the mean of the determination of the two (2)&nbsp;appraisers whose
determinations are closest shall be the FMRV.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(6)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The determination of the appraisers, as provided above, shall be
conclusive upon the parties and shall have the same force and effect as a
judgment made in a court of competent jurisdiction.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(7)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Each party shall pay fees, costs and expenses of the appraiser selected by
it and its own counsel fees and one-half (1/2) of all other expenses
and fees of the third appraiser.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(8)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should the arbitration process extend beyond the Initial Term the
monthly Rent will increase by 3.5% of the then monthly Rent until the
new monthly Rent is established by the appraisers as provided herein and
any Rent paid by Sublessee during such period shall be adjusted
accordingly based on the outcome of the arbitration process.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References herein to the &#147;Term&#148; of this Sublease shall be deemed to mean and include the
Initial Term and the Extension Term (and the Expiration Date shall be deemed extended accordingly)
if and when Sublessee has given timely such notice exercising the same.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Appurtenant Rights</U>. Sublessee shall have, as appurtenant to the Subleased
Premises, rights to use in common with Sublessor and others entitled thereto Sublessor&#146;s rights in
driveways, walkways, hallways, stairways and passenger elevators convenient for access to the
Subleased Premises and the lavatories nearest thereto. In addition, Sublessor grants Sublessee the
right to use not less than 44 parking spaces in the lot(s) adjacent to the Building on a
non-exclusive basis. Sublessor shall not oversubscribe its parking rights under the Prime Lease.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Rent</U>. Sublessee shall pay to Sublessor the following amounts
as rent (the &#147;Rent&#148;) during the Initial Term, which is intended to be full service
gross rent, during the term of this Sublease:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Lease Period</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Annual Rent</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Monthly Rent</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">P.R.S.F.</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">3/1/04 - 9/30/04</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">69,904.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">57.84</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">10/01/04-12/31/04</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">43,509.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">36.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/05 -12/31/05</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">522,108.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">43,509.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">36.00</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/06 -12/31/06</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">540,381.78</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">45,031.82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">37.26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">1/1/07-12/31/07</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">559,235.68</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">46,602.97</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">38.56</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Rent includes the following: (i)&nbsp;all utility charges (including electricity consumed by
Sublessee in the Subleased Premises); (ii)&nbsp;janitorial and all cleaning charges Monday
through Friday (except federal holidays); (iii)&nbsp;non-hazardous waste disposal; (iv)&nbsp;RO/DI
water; (v)&nbsp;vacuum/compressed air; (vi)&nbsp;emergency/back-up generator power, which generator
shall provide at least the same amount of power that is currently available to Sublessee;
(vii)&nbsp;use of common shipping/receiving area; (viii) waste water PH neutralization system;
(ix)&nbsp;common on-site fitness room, lunch room and adjacent patio; (x)&nbsp;access cards; (xi)
Taxes and property insurance; (xii)&nbsp;use of existing telephone and data wiring
infrastructure; (xiii)&nbsp;common loading dock area; and (xiv)&nbsp;all maintenance and repair of
the Subleased Premises excluding, subject to paragraph 7 of this Sublease, damage caused
by the negligence or willful misconduct of Sublessee its employees, agents, contractors
and invitees. Sublessor shall promptly and diligently perform the services required of it
as set forth above. Rent does not include any Sublessee-specific operational items,
including, but not limited to: (a)&nbsp;telecom/high speed data service through local service
providers; (b)&nbsp;liquid nitrogen or any other specialty gas provisions; (c)&nbsp;hazardous waste
disposal; and (d)&nbsp;any Sublessee-specific operating license(s) requirement(s).
Environmental, health and safety and other consulting services are available through
Sublessor at additional cost on a per case or as needed basis. Sublessee shall begin
paying Rent to Sublessor on the Commencement Date. In addition to Rent, Sublessee shall
also pay to Sublessor the sum of $35,000.00 per month as tenant improvement recovery, up
to a total payment of (including the payment owing as of March&nbsp;1, 2004 and all payments
owing through the final scheduled $35,000.00 payment in December&nbsp;1, 2004) $350,000.00. All
monthly payments of Rent are due and payable in advance on the first day of each calendar
month, without demand, deduction, counterclaim or setoff. Rent for any partial month shall
be prorated and paid on the first of such month. Sublessee shall pay as additional rent
(&#147;Additional Rent&#148;) all sums of money or other charges required to be paid by Sublessee
under this Sublease whether or not such sums and other charges are specifically designated
as &#147;Additional Rent.&#148; Sublessor shall have the same remedies for a default in the payment
of Additional Rent as for a default in the payment of Rent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Permitted Uses</U>. Sublessee shall use the Subleased Premises for
research and development, light manufacturing and general office uses and uses accessory
thereto to the extent permitted by applicable law and under the Prime Lease, including
without limitation, Article&nbsp;5 of the Prime Lease as and to the extent hereinafter
incorporated by reference and for no other purpose or purposes.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-5-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Condition of Subleased Premises</U>. On the Commencement Date, the Subleased
Premises shall be delivered to Sublessee in the condition existing on the date hereof, with all
electrical, plumbing, gas, safety, security, sewer, fire suppression, restrooms, and water systems
in good operating condition. Sublessee acknowledges that it has had an opportunity thoroughly to
inspect the condition of the Subleased Premises, and Sublessee agrees that, subject only to the
foregoing, Sublessee is leasing the Subleased Premises on an &#147;AS IS&#148; basis, with all defects,
without any representation or warranty by Sublessor or its agents as to the condition of the
Subleased Premises or their fitness for Sublessee&#146;s use, and subject to all applicable zoning,
municipal, county and state laws, ordinances and regulations governing and regulating the use of
the Subleased Premises, and any easements, covenants or restrictions of record. Sublessee
acknowledges that Sublessor and its agents have not made any representations or warranties that the
Subleased Premises or the Building comply with legal requirements, including, but not limited to,
the ADA, Title 24, any Transportation Management Plans, or any laws relating to hazardous
substances or materials, and as a material inducement to Sublessor, Sublessee assumes
responsibility for causing the Subleased Premises to comply with all legal requirements throughout
the Term to the extent and only to the extent the same become applicable as a result of the
introduction of hazardous substances to the Subleased Premises by Sublessee or any of its agents,
contractors or employees, special circumstances of Sublessee&#146;s employees (and not generally
applicable to the Building under the ADA), Sublessee&#146;s particular use of (or change of use from
that currently obtaining in) the Subleased Premises, or Sublessee&#146;s construction of alterations in
the Subleased Premises. Sublessee acknowledges that it has satisfied itself that the Subleased
Premises are suitable for its intended use. Sublessor shall have no obligation to do any work in
and to the Subleased Premises in order to prepare the Subleased Premises for occupancy or use by
Sublessee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublessee shall make no alterations, installations, removals, additions or improvements in or
to the Subleased Premises or any other portion of the Building except with the consent of (a)
Sublessor, which shall not be unreasonably withheld or delayed, (b)&nbsp;Prime Lessor in accordance with
and to the extent required by Article&nbsp;10 of the Prime Lease and (c)&nbsp;Master Lessor in accordance
with and to the extent required by Article&nbsp;10 of the Master Lease; provided, however, that, subject
to the last sentence of this paragraph, Sublessor shall be entitled to condition its consent upon
Sublessee&#146;s removal of the proposed alterations upon the expiration or earlier termination of this
Sublease. Any alterations, installations, removals, additions or improvements consented to by
Sublessor, Prime Lessor and Master Lessor shall be performed at Sublessee&#146;s sole cost. At the time
Sublessee submits plans to Sublessor for Sublessor&#146;s approval, Sublessor shall, upon request of
Sublessee, inform Sublessee whether it will require any alteration or improvement to be removed
from the Subleased Premises upon the expiration of the Sublease term, provided, however, that
Sublessor shall not unreasonably require that any alteration or improvement be so removed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All trade fixtures and personal property, including furniture, furnishings, and audio
visual or other similar technical or specialty installations, installed in the Subleased
Premises at Sublessee&#146;s expense (&#147;Tenant&#146;s Property&#148;) shall at all times remain Sublessee&#146;s
property and Sublessee shall be entitled to all depreciation,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-6-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">amortization and other tax benefits with respect thereto. Except for Tenant&#146;s Property, which
cannot be removed without material injury to the Subleased Premises, at any time Sublessee may
remove Tenant&#146;s Property from the Subleased Premises, provided Sublessee repairs all damage caused
by such removal and restores the Subleased Premises to a condition consistent with the then
condition of the balance of the Subleased Premises. Upon request, Sublessor shall execute a lien
waiver in reasonable form acknowledging its lack of any interest or title in Tenant&#146;s Property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublessee shall not misuse the Furniture, fixtures and equipment (other than Tenant&#146;s
Property) and shall keep the same in clean condition, reasonable wear and tear and damage by fire
or other casualty, Master Lessor, Prime Lessor, Sublessor or their respective agents, employees and
contractors, and hazardous substances not introduced to the Subleased Premises by Sublessee or its
agents, employees or contractors excepted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Sublease, Sublessee shall have no obligation
to perform, construct, repair, maintain, make or reimburse Sublessor for any improvement, (i)
necessitated by the acts or negligence of Sublessor, Master Lessor, Prime Lessor, any other
occupant of the building or the project, or their respective agents, employees, invitees or
contractors, (ii)&nbsp;occasioned by the exercise of the power of eminent domain or any peril that would
be covered by the customary form of so-called &#147;special form, extended coverage&#148; casualty insurance,
(iii)&nbsp;to the structure or common areas of the building or the project or the heating, ventilating,
air conditioning, electrical, water, sewer, and plumbing systems serving the Subleased Premises,
the building, or the project, unless caused by the acts or negligence of Sublessee or its agents,
employees or contractors, (iv)&nbsp;to any portion of the building or the project outside of the
demising walls of the Subleased Premises, unless caused by the acts or negligence of Sublessee or
its agents, employees or contractors, (v)&nbsp;occasioned by the presence of any hazardous substance on
or about the Subleased Premises, other than hazardous substances introduced into the Subleased
Premises by Sublessee or its agents, employees or contractors, or persons under its control, (vi)
which is expressly the obligation of the Prime Lessor under the Prime Lease or the Master Lessor
under the Master Lease, (vii)&nbsp;except to the extent Sublessee&#146;s obligation under the first paragraph
of this Section&nbsp;6, required as a consequence of any law, rule, regulation, ordinance, covenant,
condition or restriction or occasioned by any construction defect or legal violation of the
Subleased Premises, the building or the project, (viii)&nbsp;which would customarily be reimbursable
under any &#147;special form, extended coverage&#148; casualty insurance policy, or (ix)&nbsp;except to the extent
Sublessee&#146;s obligation under the first paragraph of this Section&nbsp;6, which could be treated as a
&#147;capital expenditure&#148; under generally accepted accounting principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Insurance</U>. Sublessee shall maintain throughout the term of this Sublease such
insurance in respect of the Subleased Premises and the conduct and operation of business therein,
with Sublessor, Prime Lessor and Master Lessor (and Master Lessor&#146;s members, property managers and
other parties in interest as Master Lessor may from time to time reasonably designate to Sublessee
in writing), listed as additional insureds on the liability coverage component thereof, as is
required of &#147;Tenant&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-7-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">pursuant to the terms of the Prime Lease (including, without limitation, Article&nbsp;13 as and to the
extent hereinafter incorporated by reference) and the terms of the Master Lease with no penalty to
Sublessor, Prime Lessor or Master Lessor resulting from deductibles or self-insured retentions
effected in Sublessee&#146;s insurance coverage, and with such other endorsements and provisions as
Prime Lessor or Master Lessor may reasonably request under and pursuant to the Prime Lease and
Master Lease, respectively. If Sublessee fails to procure or maintain such insurance and to pay all
premiums and charges therefor within five (5)&nbsp;days after notice from Sublessor, Sublessor may (but
shall not be obligated to) do so, whereupon Sublessee shall reimburse Sublessor upon demand. All
such insurance policies shall, to the extent obtainable, contain endorsements providing that (i)
such policies may not be canceled except upon thirty (30)&nbsp;days&#146; prior notice to Sublessor, and if
they are required hereunder to be named as additional insureds thereunder, Prime Lessor and Master
Lessor, (ii)&nbsp;no act or omission of Sublessee shall affect or limit the obligations of the insurer
with respect to any other named or additional insured and (iii)&nbsp;Sublessee shall be solely
responsible for the payment of all premiums under such policies and Sublessor, notwithstanding that
it is or may be a named insured, shall have no obligation for the payment thereof. Such insurance
shall otherwise be in both form and substance as is customarily carried by landlords of comparable
buildings in the South San Francisco, California area. On or before the Commencement Date,
Sublessee shall deliver to Sublessor, Prime Lessor and Master Lessor either a fully paid-for policy
or certificate, at Sublessee&#146;s option, evidencing the foregoing coverages. Any endorsements to such
policies or certificates shall also be delivered to Sublessor, and if they are required hereunder
to be named as additional insureds thereunder, Prime Lessor and Master Lessor upon issuance
thereof. Sublessee shall procure and pay for renewals of such insurance from time to time before
the expiration thereof, and Sublessee shall deliver to Sublessor, Prime Lessor and Master Lessor
such renewal policies or certificates at least thirty (30)&nbsp;days before the expiration of any
existing policy. In the event Sublessee fails so to deliver any such renewal policy or certificate
at least thirty (30)&nbsp;days before the expiration of any existing policy, Sublessor shall have the
right, but not the obligation, to obtain the same where upon Sublessee shall reimburse Sublessor
upon demand.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublessee shall include in all such insurance policies any clauses or endorsements in favor of
Prime Lessor and Master Lessor including, but not limited to, waivers of rights of subrogation,
which Sublessor is currently required to provide pursuant to the provisions of the Prime Lease.
Notwithstanding anything to the contrary in this Sublease, Sublessee and Sublessor, for themselves
and their agents, employees, and contractors hereby waive any and all damages, losses, liabilities,
costs, and expenses, (i)&nbsp;to the extent the same would be covered by the standard form in California
of so-called full replacement cost, &#147;special form&#148; extended coverage casualty insurance and (ii)&nbsp;to
the extent the same are actually covered by insurance carried by said party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublessor shall maintain the insurance required of it under Section&nbsp;13.1(b) of the Prime
Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Indemnification</U>. Except to the extent arising out of the negligence,
willful misconduct or violation of law by Sublessor, Master Lessor, Prime Lessor or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-8-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">their respective agents, employees or contractors, or the breach of this Sublease, the Prime Lease
or the Master Lease by Sublessor, Master Lessor, or Prime Lessor, Sublessee agrees to protect,
defend (with counsel reasonably approved by Sublessor), indemnify and hold Sublessor, Prime Lessor
and Master Lessor and their respective officers, agents and employees harmless from and against any
and all claims, costs, expenses, losses and liabilities to the extent arising: (i)&nbsp;from the conduct
or management of or from any work or thing whatsoever done in the Subleased Premises during the
term hereof; (ii)&nbsp;from any condition arising, and any injury to or death of persons, damage to
property or other event occurring or resulting from an occurrence in the Subleased Premises during
the Term hereof; and (iii)&nbsp;from any breach or default on the part of Sublessee in the performance
of any covenant or agreement on the part of Sublessee to be performed pursuant to the terms of this
Sublease or from any willful misconduct or negligence on the part of Sublessee or any of its
agents, employees, licensees, invitees or assignees or any person claiming through or under
Sublessee. Sublessee further agrees to indemnify Sublessor, Prime Lessor and Master Lessor and
their respective officers, agents and employees from and against any and all damages, liabilities,
costs and expenses, including reasonable attorneys&#146; fees, incurred in connection with any such
indemnified claim or any action or proceeding brought in connection therewith. Except to the extent
arising out of the negligence, willful misconduct or violation of law by Sublessee, Master Lessor,
Prime Lessor or their respective agents, employees or contractors, or the breach of this Sublease,
the Prime Lease or the Master Lease by Sublessee, Master Lessor, or Prime Lessor, Sublessor agrees
to protect, defend (with counsel reasonably approved by Sublessee), indemnify and hold Sublessee
and its respective officers, agents and employees harmless from and against any and all claims,
costs, expenses, losses and liabilities to the extent arising from any willful misconduct or
negligence on the part of Sublessor or any of its agents, employees or contractors. Sublessor
further agrees to indemnify Sublessee and its officers, agents and employees from and against any
and all damages, liabilities, costs and expenses, including reasonable attorneys&#146; fees, incurred in
connection with any such indemnified claim or any action or proceeding brought in connection
therewith. The provisions of this Paragraph are intended to supplement any other indemnification
provisions contained in this Sublease and in the Prime Lease to the extent incorporated by
reference herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>No Assignment or Subletting</U>. Sublessee shall not assign, sell, mortgage,
pledge or in any manner transfer this Sublease or any interest herein, or the term or estate
granted hereby or the rentals hereunder, or sublet the Subleased Premises or any part thereof, or
grant any concession or license or otherwise permit occupancy of all or any part of the Subleased
Premises by any person, entity or any Competitor (as defined in Section&nbsp;14.2 of the Prime Lease) of
Prime Lessor, without the prior written consent of Sublessor, which shall not be unreasonably
withheld or delayed and, if and to the extent required under the terms of the Master Lease or the
Prime Lease, the consent of Prime Lessor and Master Lessor. Notwithstanding anything to the
contrary in this Sublease, the consent of Sublessor shall not be required for any sublease of the
Subleased Premises or any assignment of this Sublease to any entity controlled by, under common
control with, or which controls Sublessee for so long as such entity is controlled by, under common
control with, or controls Sublessee, or in connection with any merger of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-9-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sublessee with any other entity (provided the surviving entity has at least the net worth of
Sublessee immediately prior to the merger) or the sale of substantially all of the assets of
Sublessee located in the Subleased Premise. Neither the consent of Sublessor, Prime Lessor or
Master Lessor to an assignment, subletting, concession, or license, nor the references in this
Sublease to assignees, subtenants, concessionaires or licensees, shall in any way be construed to
relieve Sublessee of the requirement of obtaining the consent of Sublessor, Prime Lessor and Master
Lessor to any further assignment or subletting or to the making of any assignment, subletting,
concession or license for all or any part of the Subleased Premises. Notwithstanding any assignment
or subletting, including, without limitation, any assignment or subletting permitted or consented
to, the original Sublessee named herein and any other person(s) who at any time was or were
Sublessee shall remain fully liable under this Sublease. If this Sublease is assigned, or if the
Subleased Premises or any part thereof is underlet or occupied by any person or entity other than
Sublessee, Sublessor may, after default by Sublessee following the lapse of any cure period,
collect rent from the assignee, undertenant or occupant, and apply the net amount collected to the
rents payable by Sublessee hereunder, but no assignment, underletting, occupancy or collection
shall be deemed a waiver of the provisions hereof, the acceptance of the assignee, undertenant or
occupant as tenant, or a release of Sublessee from the further performance by Sublessee of the
covenants hereunder to be performed on the part of Sublessee (except to the extent such amounts are
so applied). Any attempted assignment or subletting without the prior written consent of Sublessor,
Prime Lessor and Master Lessor, to the extent required, shall be void.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Primacy and Incorporation of Prime Lease</U>.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;This Sublease is and shall be subject and subordinate to the Prime Lease and to all
matters to which the Prime Lease is or shall be subject and subordinate, and to all amendments,
modifications, renewals, extensions and replacements of or to the Prime Lease that do not adversely
affect Sublessee, this Sublease or the rights of Sublessee, under this Sublease in the Subleased
Premises or the use thereof by Sublessee, and Sublessor purports hereby to convey, and Sublessee
takes hereby, no greater rights then those accorded to or taken by Sublessor as &#147;Tenant&#148; under the
terms of the Prime Lease. To the extent expressly incorporated herein below, Sublessee covenants
and agrees that it will perform and observe all of the provisions contained in the Prime Lease to
be performed and observed by &#147;Tenant&#148; thereunder as applicable to the Subleased Premises, except
that &#147;Rent&#148; shall be defined for purposes of this Sublease as set forth in Paragraph&nbsp;4 hereof.
Notwithstanding the foregoing, Sublessee shall have no obligation to (i)&nbsp;cure any default of
Sublessor under the Prime Lease, (ii)&nbsp;perform any obligation of Sublessor under the Prime Lease
which arose prior to the Commencement Date and Sublessor failed to perform, (iii)&nbsp;repair any damage
to the Subleased Premises caused by Sublessor, (iv)&nbsp;remove any alterations or additions installed
within the Subleased Premises by Sublessor, (v)&nbsp;indemnify Sublessor or Prime Lessor with respect to
any negligence or willful misconduct of Sublessor, its agents employees or contractors, or (vi)
discharge any liens on the Subleased Premises or the Building which arise out of any work
performed, or claimed to be performed, by or at the direction of Sublessor. Except to the extent
inconsistent with the context hereof,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-10-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in
the Prime Lease. Further, except as set forth below, the terms, covenants and conditions of the
following specified provisions of the Prime Lease are incorporated herein by reference as if such
terms, covenants and conditions were stated herein to be the terms, covenants and conditions of
this Sublease, so that except to the extent that they are inconsistent with or modified by the
provisions of this Sublease, for the purpose of incorporation by reference each and every
referenced term, covenant and condition of the Prime Lease binding upon or inuring to the benefit
of the &#147;Landlord&#148; thereunder shall, in respect of this Sublease and the Subleased Premises, be
binding upon or inure to the benefit of Sublessor, and each and every referenced term, covenant and
condition of the Prime Lease binding upon or inuring to the benefit of the &#147;Tenant&#148; thereunder
shall, in respect of this Sublease, be binding upon or inure to the benefit of Sublessee, with the
same force and effect as if such terms, covenants and conditions were completely set forth in this
Sublease: Articles/Sections: 2.3, 5.2, 5.3(a), 5.3(b), 5.3(c) (excluding the fourth, fifth, sixth
and seventh sentences), 5.3(d), 5.3(e), 5.3(f), 5.3(g), 5.3(h) through the word &#147;contractors,&#148; 5.4,
6.5, 6.6, the last two sentences of 7.8, 8, the fourth sentence of 10, 11, 12, 13.1 (excluding
13.1(b) and, subject to the additional qualification that Sublessor shall exercise its rights
thereunder only as and to the extent Prime Lessor exercises the same against Sublessor, 13.1(g),
13.2, 13.3, 13.4, 15 (excluding 15.5 and 15.6), 16 (as amended), 17, 19, 20, 22, 23.3, the first
paragraph of 24, 27.1, 27.2, 27.3, 27.4, 27.12 and 27.13, and Exhibits B, C and D. Notwithstanding
the foregoing, for purposes of this Sublease, as to such incorporated terms, covenants and
conditions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references in the Prime Lease to the &#147;Demised Premises&#148; shall be deemed
to refer to the &#147;Subleased Premises&#148; hereunder;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references in the Prime Lease to &#147;Landlord&#148; and to &#147;Tenant&#148; shall be
deemed to refer to &#147;Sublessor&#148; and &#147;Sublessee&#148; hereunder, respectively, except that
where the term &#147;Landlord&#148; is used in the context of ownership or management of the
entire Building, such term shall be deemed to mean &#147;Prime Lessor&#148;;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references in the Prime Lease to &#147;this Lease&#148; shall be deemed to refer
to &#147;this Sublease&#148; (except when such reference in the Prime Lease is, by its terms
(unless modified by this Sublease), a reference to any other section of the Prime
Lease, in which event such reference shall be deemed to refer to the particular
section of the Prime Lease);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references in the Prime Lease to the &#147;Term Commencement Date&#148; shall be
deemed to refer to the &#147;Commencement Date&#148; hereunder;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references in the Prime Lease to the &#147;Yearly Fixed Rent&#148;, &#147;Fixed
Rent&#148;, &#147;Additional Rent&#148; and &#147;rent&#148; shall be deemed to refer to the &#147;Rent&#148; as defined
hereunder;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-11-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vi)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sublessee shall not be required to name Sublessor, Prime Lessor, Master
Lessor or any other party as an additional insured on its worker&#146;s compensation,
business interruption or personal property insurance; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(vii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reference to &#147;Article&nbsp;14&#148; in Section&nbsp;19.1 shall mean Paragraph&nbsp;9 of
this Sublease.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, the following provisions of the Prime Lease, Exhibits and
Schedules annexed thereto are not incorporated herein by reference and shall not, except as to
definitions set forth therein, have any applicability to this Sublease: Articles/Sections&nbsp;1, 2.1,
2.2, 2.4, 3, 4, 5.1, the fourth, fifth, sixth and seventh sentences of 5.3(c), everything after the
word &#147;contractors&#148; in 5.3(h), 6 (excluding 6.5 and 6.6), 7 (except the last two sentences of 7.8),
9, 10 (except the fourth sentence), 13.1(b), 13.5, 14, 15.5, 15.6, 18, 21, 23.1, 23.2, the second
paragraph of 24, 25, 26, 27.5, 27.6, 27.7, 27.8, 27.9, 27.10, 27.11, 27.14, 28 and 29 and Exhibits
A, A-l, A-2, E, F, G and H.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where reference is made in the following Sections to &#147;Landlord&#148;, the same shall be deemed to
refer to &#147;Master Lessor&#148; and &#147;Prime Lessor&#148;: Sections&nbsp;7 (other than the last sentence of 7.8) 8,
13.5, 15.1 and 16.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where reference is made in the following Section to &#147;Landlord&#148;, the same shall be deemed to
refer to &#147;Prime Lessor&#148;: the fourth sentence of Section&nbsp;15.6.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where reference is made in the following Sections to &#147;Landlord&#148;, the same shall be deemed to
refer to &#147;Master Lessor&#148;, &#147;Prime Lessor&#148; and &#147;Sublessor&#148;: Sections&nbsp;5.3(b), 5.3(d), 5.3(f), 5.3(g),
5.4, the last two sentences of 7.8, 10, 11,13.1, 13.2, 13.3, 13.4, 15.2, 15.3, 15.6 (excluding the
fourth sentence), 15.7 and 17.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where reference is made in the following Sections to &#147;Landlord&#148;, the same shall be deemed to
refer to &#147;Prime Lessor&#148; and &#147;Sublessor&#148;: Sections&nbsp;5.3(c) and 5.3(e).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;(Intentionally omitted)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding anything to the contrary contained in the Prime Lease,
the time limits (the &#147;Notice Periods&#148;) contained in the Prime Lease for the giving of
notices, making of demands or performing of any act, condition or covenant on the part
of the &#147;Tenant&#148;, thereunder, or for the exercise by the &#147;Tenant&#148;, thereunder of any right,
remedy or option, are changed for the purposes of incorporation herein by reference by
shortening the same in each instance by five (5)&nbsp;days, so that in each instance Sublessee
shall have five (5)&nbsp;fewer days to observe or perform hereunder than Sublessor has as the
&#147;Tenant&#148; under the Prime Lease; <U>provided</U>, <U>however</U>, that if the Prime Lease
allows a Notice Period of six (6)&nbsp;days or less, then Sublessee shall nevertheless be allowed the
number of days equal to one-half of the number of days in each Notice Period to give
any such notices, make any such demands, perform any such acts, conditions or
covenants or exercise any such rights, remedies or options; provided, further, that if one-half of the number of days in the Notice Period is not a whole number, Sublessee shall
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-12-<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be allowed the number of days equal to one-half of the number of days in the Notice Period rounded
up to the next whole number.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding anything to the contrary contained in this Sublease (including,
without limitation, the provisions of the Prime Lease incorporated herein by reference), Sublessor
makes no representations or warranties whatsoever with respect to the Subleased Premises, this
Sublease, Prime Lease or any other matter, either express or implied, except as set forth in this
Sublease, and except that Sublessor represents and warrants (i)&nbsp;that it is the sole holder of the
interest of the &#147;Tenant&#148; under the Prime Lease, (ii)&nbsp;that the Prime Lease is in full force and
effect and that there are no modifications of the Prime Lease which will affect Sublessee&#146;s rights
or obligations hereunder, (iii)&nbsp;that no notices of default have been served on Sublessor under the
Prime Lease which have not been cured and to the best of Sublessor&#146;s knowledge Sublessor is not
otherwise in default of its obligations under the Master Lease, and (iv)&nbsp;to the best of Sublessor&#146;s
knowledge, Prime Lessor is not in default under the Prime Lease or the Master Lease and Master
Lessor is not in default under the Master Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Certain Services and Rights</U>. Except as otherwise expressly set forth herein, the
only services or rights to which the Sublessee is entitled hereunder, are those expressly set forth
herein and those services and rights to which Sublessor is entitled under the Prime Lease,
including without limitation those set forth in Sections&nbsp;7.3, 7.4, 7.6 and 7.7(a) of the Prime
Lease. Notwithstanding anything to the contrary contained herein, in no event shall Sublessor be
deemed to be in default under this Sublease or liable to Sublessee for any failure of the Prime
Lessor to perform its obligations under the Prime Lease. With respect to all work, services,
utilities, repairs, restoration, maintenance, compliance with law, insurance, indemnification or
other obligations or services to be performed or provided by Prime Lessor under the Prime Lease,
Sublessor&#146;s sole obligation shall be, without expense to itself, to exercise commercially
reasonable efforts to require Prime Lessor to comply with the obligations of Prime Lessor under the
Prime Lease, provided that in no event shall Sublessor be required to file suit against Prime
Lessor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Compliance with Prime Lease</U>. Sublessee shall neither do nor permit its agents,
employees or contractors to do anything which violates the Prime Lease and which would cause the
Prime Lease to be terminated or forfeited by reason of any right of termination or forfeiture
reserved or vested in Prime Lessor under the Prime Lease, and Sublessee shall defend, indemnify and
hold Sublessor harmless from and against any and all claims, liabilities, losses, damages and
expenses (including reasonable attorneys&#146; fees) of any kind whatsoever if the Prime Lease is
terminated or forfeited in whole or in part as a result of a breach or default on the part of
Sublessee. Sublessee covenants and agrees that Sublessee will not do anything which would
constitute a default under the provisions of the Prime Lease or omit to do anything which Sublessee
is obligated to do under the terms of this Sublease, which would constitute a default under the
Prime Lease. Except if the same results in whole or in part from a breach on the part of Sublessee
or any of its agents, employees or contractors of the obligations of Sublessee hereunder, Sublessor
shall not cause or permit the Prime Lease to be terminated or forfeited by reason of any default on
the part of Sublessor thereunder and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-13-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sublessor shall indemnify, defend and hold harmless Sublessee from any such termination
or forfeiture.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Default</U>. In the event that Sublessee shall default in any of its obligations
hereunder beyond applicable cure periods, including any default of the nature described in the
herein incorporated provisions of the Prime Lease beyond applicable cure periods as modified by
Paragraph 10(c) hereof, Sublessor shall have available to it all of the rights and remedies
available to Prime Lessor under the Prime Lease, including without limitation Article&nbsp;19 thereof as
incorporated herein by reference, as though Sublessor were the &#147;Landlord&#148; thereunder and Sublessee
the &#147;Tenant&#148; thereunder. Sublessee further agrees to reimburse Sublessor for all costs and expenses
incurred by Sublessor in asserting its rights hereunder against Sublessee or any other party. The
non-prevailing party shall also pay the attorneys&#146; fees and costs incurred by the prevailing party
in any post-judgment proceedings to collect and enforce the judgment. The covenant in the preceding
sentence is separate and several and shall survive the merger of this provision into any judgment
on this Sublease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Brokerage</U>. Sublessee and Sublessor represent that they have not dealt with any
broker in connection with this Sublease other than CRESA Partners (the &#147;Broker&#148;). Each party agrees
to indemnify and hold harmless the other from and against any and all liabilities, claims, suits,
demands, judgments, costs, interests and expenses (including, without being limited to, reasonable
attorneys&#146; fees and expenses) which the indemnified party may be subject to or suffer by reason of
any claim made by any person, firm or corporation other than the Broker for any commission, expense
or other compensation as a result of the execution and delivery of this Sublease, which is based on
alleged conversations or negotiations by said person, firm or corporation with the indemnifying
party. Sublessee shall pay the Broker the brokerage fees/commissions due under a separate agreement
between and among Sublessee and Broker. Each party shall indemnify and hold the other harmless from
and against any and all liabilities, claims, suits, demands, judgments, costs, interest and
expenses (including, without being limited, reasonable attorneys&#146; fees and expenses) which said
other party may be subject to or suffer by reason of any claim made by any other Broker for any
brokerage fees/commissions, expense of other compensation as a result of the execution and delivery
of this Sublease in breach of the indemnified parties representation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <U>Security Deposit</U>. On January&nbsp;1, 2005, the cash security deposit then currently
held by Sublessor for the Subleased Premises shall be released to Sublessee and exchanged for a
letter of credit in accordance with the following: Sublessee at its sole cost and expense shall
deliver to Sublessor, in a form and from a financial institution acceptable to Sublessor, an
irrevocable, unconditional standby letter of credit in the amount of $130,527.00 (the &#147;Letter of
Credit&#148;), as security for the full and faithful performance and observance by Sublessee of
Sublessee&#146;s covenants and obligations under this Sublease (the &#147;Security Deposit&#148;). Sublessee shall
be solely responsible for all costs and expenses of obtaining, amending, renewing or replacing such
Letter of Credit. The Letter of Credit shall have an expiration date not earlier than thirty (30)
days following the expiration of the Term of this Sublease. If Sublessee defaults in the full and
prompt payment and performance of any of Sublessee&#146;s covenants and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-14-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">obligations under this Sublease, including, but not limited to, the payment of Rent specified in
Paragraph&nbsp;4 hereof, Sublessor may, after the giving of any required notices and the lapse of any
cure period, but without giving any other notice to Sublessee, draw upon the Letter of Credit to
the extent required for the payment of any Rent or any other sums as to which Sublessee is in
default or for any sum which Sublessor may expend or may be required to expend by reason of
Sublessee&#146;s default in respect of any of the terms, covenants and conditions of this Sublease,
including, but not limited to, any damages or deficiency in the reletting of all or any portion of
the Subleased Premises, whether such damages or deficiency accrue before or after summary
proceedings or other re-entry by Sublessor. If Sublessor draws upon the Letter of Credit to cure
any default, Sublessee shall cause the Letter of Credit to be restored to its original amount (or
shall make a cash security deposit with Sublessor in said amount) within fifteen (15)&nbsp;days of such
drawing and failure to do so shall be deemed a default hereunder. Sublessee understands that its
potential liability under this Sublease is not limited to the amount of the Security Deposit. Use
of said Security Deposit by Sublessor shall not constitute a waiver, but is in addition to other
remedies to Sublessor under this Sublease and under law (except to the extent of the amount so
applied). In the event of any sale of Sublessor&#146;s interest in the Premises, Sublessor shall either
return the Security Deposit to Sublessee or assign its interest in the Security Deposit to the
transferee or assignee and Sublessor shall thereupon be released by Sublessee from all liability
for the return or payment thereof; and Sublessee shall look solely to the new sublessor for the
return or payment of the same delivered to the new sublessor; and the provisions hereof shall apply
to every transfer or assignment made of the same to a new sublessor. Sublessee shall not assign or
encumber or attempt to assign of encumber the Security Deposit and neither Sublessor nor its
successors or assigns shall be bound by any such assignment, encumbrance, attempted assignment or
attempted encumbrance. Sublessee waives the provisions of California Civil Code Section&nbsp;1950.7, and
all other provisions of law now in force or that become in force after the date of execution of
this Sublease that provide that Sublessor may claim from a security deposit only those sums
reasonably necessary to remedy defaults in the payment of Rent, to repair damage caused by
Sublessee, or to clean the Subleased Premises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<U>Notices</U>. All notices, consents, approvals, demands, bills, statements and requests
which are required or desired to be given by either party to the other hereunder shall be in
writing and shall be governed by Article&nbsp;25 of the Prime Lease as incorporated herein by reference,
except that the mailing addresses for Sublessor and Sublessee shall initially be those first set
forth above, except that after the Commencement Date the address for Sublessee shall be the
Subleased Premises or such other address as Sublessee shall designate by written notice to
Sublessor. Communications and payments to the Prime Lessor shall be given in accordance with, and
subject to, Article&nbsp;25 of the Prime Lease. Communications to the Master Lessor shall be given in
accordance with, and subject to, Article&nbsp;25 of the Master Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<U>Interpretation</U>. This Sublease shall be construed without regard to any presumption
or other rule requiring construction against the party causing this Sublease to be drafted. Each
covenant, agreement, obligation or other provision of this Sublease shall be deemed and construed
as a separate and independent covenant of the party
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-15-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">bound by, undertaking or making the same, which covenant, agreement, obligation or other provision
shall be construed and interpreted in the context of the Sublease as a whole. All terms and words
used in this Sublease, regardless of the number or gender in which they are used, shall be deemed
to include any other number and any other gender as the context may require. The word &#147;person&#148; as
used in this Sublease shall mean a natural person or persons, a partnership, a corporation or any
other form of business or legal association or entity. Terms used herein and not defined shall have
the meaning set forth in the Prime Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;<U>Fire or Casualty; Eminent Domain</U>. In addition to the provisions of Article&nbsp;16 of
the Prime Lease as and to the extent incorporated herein by reference, Sublessor also agrees if the
MJ Research Sublease is terminated by Prime Lessor, Master Lessor or Sublessee because of a fire or
other casualty, then Sublessee may terminate this Sublease. Sublessee may exercise the termination
right described in the previous sentence by giving written notice to Sublessor within thirty (30)
days of Sublessee&#146;s receipt or giving of the termination notice under the MJ Research Sublease and
the effective date of the termination of this Sublease will be the same date as the termination
date of the MJ Research Sublease. Upon execution of this Sublease by Sublessee and Sublessor and
the delivery of the Consent described in Paragraph&nbsp;28 hereof, Sublessor shall deliver to Sublessee
in electronic format and hard copy the plans in Sublessor&#146;s possession as of the date hereof for
the tenant improvements and will assign any rights Sublessor has in such plans for purposes of
using such plans to rebuild any tenant improvements existing in the Subleased Premises as of the
date hereof. In the event of a fire or casualty to the Subleased Premises where Prime Lessor has
decided to restore the Building including the Subleased Premises, Sublessor shall turn over to
Prime Lessor the proceeds of insurance required to be carried by Sublessor under Section&nbsp;13.1(b) of
the Prime Lease for the rebuilding of the tenant improvements by Prime Lessor, unless this Master
Lessor terminates the Master Lease, Prime Lessor terminates the Prime Lease, or Sublessor or
Sublessee terminates this Sublease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. <U>Right to Cure Sublessee&#146;s Defaults</U>. If Sublessee shall at any time fail to make
any payment or perform any other obligation of Sublessee hereunder within fifteen (15)&nbsp;days (except
in the case of an emergency) of receiving Sublessor&#146;s notice of such failure to make payment or to
perform, then Sublessor shall have the right, but not the obligation, after notice to Sublessee in
accordance with Paragraph&nbsp;16 of this Sublease, or without notice to Sublessee in the case of any
emergency, and without waiving or releasing Sublessee from any obligations of Sublessee hereunder,
to make such payment or perform such other obligation of Sublessee in such manner and to such
extent as Sublessor shall deem necessary, and in exercising any such right, to pay any incidental
costs and expenses, employ attorneys, and incur and pay reasonable attorneys&#146; fees. Sublessee shall
pay to Sublessor upon demand all sums so paid by Sublessor and all incidental costs and expenses of
Sublessor in connection therewith, together with interest thereon at an annual rate equal to the
rate four percent (4%) above the base rate or prime rate then announced as such by Citibank, N.A.
or its successor, or the maximum rate permitted by law. Such interest shall be payable with respect
to the period commencing on the date such expenditures are made by Sublessor and ending on the date
such amounts are repaid by Sublessee. If Sublessor shall at any time fail to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-16-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">perform any obligations on its part to be performed under Paragraph&nbsp;4 of this Sublease which
interfere (or are reasonably likely to imminently interfere with the use of the Subleased Premises
by Sublessee) and Sublessor shall fail to commence to cure such default within fifteen (15)&nbsp;days
(or such longer period of time as is reasonably necessary in the exercise of reasonable diligence
to cure such failure to perform) following written demand for such performance by Sublessee and
thereafter to diligently complete such cure, then, in addition to its other rights and remedies,
Sublessee shall have the right, but not the obligation, without waiving or releasing Sublessor from
any obligations of Sublessor hereunder, to perform such obligation of Sublessor. Notwithstanding
anything to the contrary in this Sublease, the cost reasonably incurred by Sublessee in completing
such cure shall be paid by Sublessor to Sublessee within five (5)&nbsp;days of receiving Sublessee&#146;s
bill for the same. The foregoing, however, shall not apply to any of the services to be provided by
Prime Lessor directly to Sublessor as set forth in Paragraph&nbsp;11 and, in such case, the obligations
of Sublessor subject to this Section shall be limited to the obligations of Sublessor under
Paragraph&nbsp;11. The provisions of this Paragraph shall survive the Expiration Date or the sooner
termination of this Sublease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;<U>Termination of Prime Lease</U>. Subject to the rights, if any, of Sublessee to
recognition of Sublessee&#146;s rights hereunder by Master Lessor or Prime Lessor, if for any reason the
term of the Prime Lease shall terminate prior to the Expiration Date, this Sublease shall thereupon
automatically terminate as to the premises demised under the Prime Lease and Sublessor shall not be
liable to Sublessee by reason thereof except in the event of a breach by Sublessor of its
obligations under Paragraph&nbsp;12 hereof; <U>provided</U>, <U>however</U>, that Sublessor agrees
that so long as Sublessee is not in default hereunder beyond any applicable cure periods, Sublessor
shall not voluntarily surrender the Prime Lease except in accordance with the Prime Lease in the
event of a taking or casualty. Notwithstanding the foregoing, if the Prime Lease gives Sublessor
any right to terminate the Prime Lease in the event of the partial or total damage, destruction, or
condemnation of the Subleased Premises or the Building, the exercise of such right by Sublessor
shall not constitute a default or breach hereunder.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Upon the expiration or termination of this Sublease, whether by forfeiture, lapse of time or
otherwise, or upon the termination of Sublessee&#146;s right of possession, Sublessee shall at once
surrender and deliver the Subleased Premises and the Furniture in the condition and repair required
by, and in accordance with the provisions of, this Sublease and the Prime Lease, including without
limitation Article&nbsp;20 of the Prime Lease as incorporated herein by reference, including the
Furniture, which shall be in the same condition as at the date possession of the Subleased Premises
was delivered to Sublessee, reasonable wear and tear, alterations made by Sublessee in compliance
herewith that Sublessee is permitted to surrender, acts of God, casualties, condemnations,
hazardous materials not introduced to the Premises by Sublessee, its agents, employees or invitees
and the acts of Sublessor, Prime Lessor, Master Lessor or other occupants if the building (other
than Sublessee, its agents, employees or invitees) and their respective agents, employees and
contractors excepted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;<U>Consents and Approvals</U>. All references in this Sublease to the consent or approval
of Prime Lessor, Master Lessor and/or Sublessor shall be deemed to mean
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-17-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the written consent or approval of Prime Lessor, Master Lessor and/or Sublessor, as the case may
be, and no consent or approval of Prime Lessor, Master Lessor and/or Sublessor, as the case may be,
shall be effective for any purpose unless such consent or approval is set forth in a written
instrument executed by Prime Lessor, Master Lessor and/or Sublessor, as the case may be. In all
provisions requiring the approval or consent of Sublessor (whether pursuant to the express terms of
this Sublease or the terms of the Prime Lease incorporated herein), Sublessee shall be required to
obtain the approval or consent of Sublessor and then to obtain like approval or consent of Prime
Lessor to the extent Prime Lessor&#146;s consent is required under the Prime Lease and Master Lessor to
the extent Master Lessor&#146;s consent is required under the Master Lease. Sublessor agrees its consent
shall not be unreasonably withheld or delayed, except as otherwise provided herein. If Sublessor is
required or has determined to give its consent or approval to a matter as to which consent or
approval has been requested by Sublessee, Sublessor shall cooperate reasonably with Sublessee in
endeavoring to obtain any required Prime Lessor&#146;s or Master Lessor&#146;s consent or approval upon and
subject to the following terms and conditions: (i)&nbsp;Sublessee shall reimburse Sublessor for any
reasonable out-of-pocket costs incurred by Sublessor in connection with seeking such consent or
approval, (ii)&nbsp;Sublessor shall not be required to make any payments to Prime Lessor or Master
Lessor or to enter into any agreements or to modify the Prime Lease, or this Sublease in any manner
which will prejudice Sublessor in order to obtain any such consent or approval, (iii)&nbsp;if Sublessee
agrees or is otherwise obligated to make any payments to Sublessor, Master Lessor or Prime Lessor
in connection with such request for such consent or approval, Sublessee shall have made
arrangements satisfactory to Sublessor for such payments and (iv)&nbsp;Sublessee shall indemnify and
hold Sublessor harmless from and against all liabilities, losses, damages or expenses, including,
without being limited to, reasonable attorneys&#146; fees and expenses Sublessor shall suffer or incur
in connection with seeking such consent or approval. Nothing contained in this Article shall be &#147;
deemed to require Sublessor to give any consent or approval merely because Prime Lessor or Master
Lessor has given such consent or approval. Sublessor shall promptly forward to Prime Lessor and
Master Lessor, as the case may be, such requests as Sublessee may submit for approval or consent
from Prime Lessor and Master Lessor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;<U>No Privity of Estate</U>. Nothing contained in this Sublease shall be construed to
create privity of estate or of contract between Sublessee and Prime Lessor and Master Lessor, and
Prime Lessor and Master Lessor are not obligated to recognize or to provide for the non-disturbance
of the rights of Sublessee hereunder except as expressly set forth in separate agreements, if any,
between said party or parties and Sublessee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;<U>No Waiver</U>. The failure of Sublessor or Sublessee to insist in any one or more
cases upon the strict performance or observance of any obligation of the other hereunder or to
exercise any right or option contained herein shall not be construed as a waiver or relinquishment
for the future of any such obligation, right or option. Sublessor&#146;s receipt and acceptance of Rent
or Sublessor&#146;s or Sublessee&#146;s acceptance of performance of any other obligation by the other party,
with knowledge of a breach of any provision of this Sublease, shall not be deemed a waiver of such
breach. No waiver by Sublessor or Sublessee of any term, covenant or condition of this Sublease
shall be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-18-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">deemed to have been made unless expressed in writing and signed by the party to be charged. .
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.&nbsp;<U>Complete Agreement</U>. This Sublease constitutes the entire agreement between the
parties and there are no representations, agreements, arrangements or understandings, oral or
written, between the parties relating to the subject matter of this Sublease which are not fully
expressed in this Sublease. This Sublease cannot be changed or terminated orally or in any manner
other than by a written agreement executed by both parties. This Sublease shall not be binding upon
either party unless and until it is signed and delivered by and to both parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.&nbsp;<U>Successors and Assigns</U>. The provisions of this Sublease, except as herein
otherwise specifically provided, shall extend to bind and inure to the benefit of the parties
hereto and their respective personal representatives, heirs, successors and permitted assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26.&nbsp;<U>Waiver of Jury Trial and Right to Counterclaim</U>. To the extent permitted by law,
the parties hereto hereby waive any rights which they may have to trial by jury in any summary
action or other action, proceeding or counterclaim arising out of or in any way connected with this
Sublease, the relationship of Sublessor and Sublessee, the Subleased Premises and the use and
occupancy thereof, and any claim for injury or damages. Sublessee also hereby waives all right to
assert or interpose a counterclaim (other than mandatory counterclaims) in any summary proceeding
or other action or proceeding to recover or obtain possession of the Subleased Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.&nbsp;<U>Estoppel Certificates</U>. Sublessee and Sublessor shall each, within fifteen (15)
days after each and every request by the other party, execute, acknowledge and deliver to the other
party or any party reasonably designated by the other party, without cost or expense to the other
party, a statement in writing (a)&nbsp;certifying that this Sublease is unmodified and, to its
knowledge, is in full force and effect (or if there have been modifications, that the same is in
full force and effect as modified, and stating such modifications); (b)&nbsp;specifying the dates to
which Rent has been paid; (c)&nbsp;stating whether or not, to its knowledge, the other party is in
default in the performance or observance of such other party&#146;s obligations under this Sublease and,
if so, specifying each such default; (d)&nbsp;stating whether or not, to its knowledge, any event has
occurred which, with the giving of notice or passage of time, or both, would constitute a default
by the other party under this Sublease, and, if so, specifying each such default; (e)&nbsp;stating
whether or not, to its knowledge, any event has occurred which, with the giving of notice or
passage of time, or both, would constitute a default by the other party under this Sublease, and,
if so, specifying each such event; (f)&nbsp;stating whether or not, to its knowledge, any event has
occurred which, with the giving of notice or passage of time, or both, would constitute a default
by Prime Lessor under the Prime Lease with respect to the Subleased Premises, and, if so,
specifying such event; (g)&nbsp;describing all notices of default submitted by it to the other party and
Prime Lessor with respect to this Sublease, or the Prime Lease from and after the date hereof; and
(h)&nbsp;containing such other information with respect to the Subleased Premises or this Sublease as
the other party shall reasonably request. Each party hereby acknowledges and agrees that any such
statement delivered pursuant to this Paragraph may be relied upon by any prospective
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-19-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">assignee, transferee or mortgagee of the leasehold or subleasehold estate of the other party
or any prospective lender or investor to the requesting party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.&nbsp;<U>Consent of Prime Lessor</U>. This Sublease is subject to the concurrent approval and
consent of Prime Lessor, which Sublessor agrees to use all reasonable efforts to obtain. This
Sublease shall not become effective unless and until a written approval and consent (the &#147;Consent&#148;)
is executed and delivered by the Prime Lessor, which Consent shall consent to this Sublease. After
the Sublessor receives the Consent
from the Prime Lessor, Sublessor agrees to promptly deliver a fully-executed original of the
Consent to Sublessee. The effect and commencement of this Sublease is subject to and
conditional upon the receipt by Sublessor and Sublessee of the Consent. To the extent that
Sublessor has not already done so, upon execution of this Sublease by Sublessee, Sublessor
will promptly apply to the Prime Lessor for the Consent and Sublessor will promptly inform
Sublessee as to receipt of the Consent (if and when it is received) and deliver to Sublessee a
copy of the same. If the Consent is not received by May&nbsp;1, 2004 (the &#147;Sunset Date&#148;), then from
the Sunset Date this Sublease will cease to have any further effect and the parties hereto
will have no further obligations to each other with respect to this Sublease and any funds
paid hereunder by Sublessee shall be promptly refunded by Sublessor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29.&nbsp;<U>Holding Over</U>. If Sublessee shall fail to surrender and deliver the Subleased
Premises as and when required hereunder, the Sublessee shall become a tenant at sufferance only,
subject to all of the terms, covenants and conditions herein specified. Sublessee agrees to
protect, defend (with counsel reasonably approved by Sublessor), indemnify and hold Sublessor and
its officers, agents and employees harmless from and against any and all claims, costs, losses,
damages, liabilities and expenses (including, without being limited to, reasonable attorneys&#146; fees)
that Sublessor may suffer by reason of any holdover by Sublessee hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30.&nbsp;<U>Limitation of Liability</U>. No director, officer, shareholder, employee, adviser or
agent of Sublessor shall be personally liable in any manner for the obligations of the Sublessor
under this Sublease. Except as set forth in Paragraph&nbsp;29 hereof, in no event shall Sublessor or
Sublessee or any of their directors, officers, shareholders, employees, advisers or agents be
responsible for any indirect, special or consequential damages or interruption or loss of business,
income or profits, nor shall Sublessor be liable for loss of or damage to artwork, securities or
other property not in the nature of ordinary fixtures, furnishings and equipment used in general
administrative and executive office activities. No director, officer, shareholder, employee,
adviser or agent of Sublessee shall be personally liable in any manner for the obligations of the
Sublessee under this Sublease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31.&nbsp;<U>Conflict</U>. In the event of any conflict between the obligations of Sublessee set
forth in this Sublease and the obligations of Sublessee under the Prime Lease as and to the extent
incorporated herein by reference, the more restrictive provision shall control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32.&nbsp;<U>Security</U>. Sublessee expressly assumes all responsibility for security, in the
Subleased Premises, and, except to the extent arising out of the negligence, willful
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-20-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">misconduct, violation or law or breach of this Sublease or the Master Lease or Prime Lease by
Sublessor or its agents, employees or contractors, Sublessor shall not be liable for any damage to
goods, wares, merchandise or other property located in the Subleased Premises, or injury or death
to Sublessee&#146;s employees, invitees, customers or any other person in or about the Subleased
Premises. The foregoing waiver includes criminal acts of third parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33.&nbsp;<U>Recording</U>. Sublessor and Sublessee agree that neither party may record this
Sublease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34.&nbsp;<U>Attorney&#146;s Fees</U>. If either Sublessor or Sublessee shall bring any action or legal
proceeding for an alleged breach of any provision of this Sublease, to recover rent, to terminate
this Sublease or otherwise to enforce, protect or establish any term or covenant of this Sublease,
the prevailing party shall be entitled to recover as a part of such action or proceeding, or in a
separate action brought for that purpose, reasonable attorneys&#146; fees, court costs, and expert fees
as may be fixed by the court. &#147;Prevailing party&#148; as used in this Paragraph includes a party who
dismisses an action for recovery hereunder in exchange for sums allegedly due, performance of
covenants allegedly breached or considerations substantially equal to the relief sought in the
action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35.&nbsp;<U>Existing Sublease</U>. The existing Sub-Sublease Agreement dated as of May&nbsp;31, 2001 by
and between Sublessor and Sublessee (the &#147;Existing Sub-Sublease Agreement&#148;) is hereby terminated.
Sublessee agrees to deliver to Sublessor on or before the Commencement Date, the second and third
floor space that was the subject of said Existing Sub-Sublease Agreement (i)&nbsp;in broom clean
condition, (ii)&nbsp;with all of Sublessee&#146;s machinery, furniture, fixtures, and equipment, and
hazardous materials removed from such space, and (iii)&nbsp;such space cleaned by Pass Janitorial
Service. When so surrendered, the surrender obligations of Sublessee for such space as set forth in
the existing sublease shall be deemed to have been performed in all required respects.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-21-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Sublessor and Sublessee have executed this Sublease as a sealed instrument
as of the date first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Genome Therapeutics Corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Stephen Rauscher
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Stephen Rauscher&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Sr VP&#043;CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Fluidigm Corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Gajus Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A-1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;See below for Agreement of Lease dated as of November&nbsp;9, 1999, by and between Mountain Cove Tech<BR>
Center, L.L.C. and Fluidigm Corporation&#093;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A-2
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;See below for Agreement of Lease dated as of October&nbsp;6, 2000 by and between Prime Lessor, as<BR>
&#147;landlord&#148; and Sublessor, as &#147;tenant&#148; as amended by a First Amendment to Lease dated December&nbsp;5,<BR>
2002 and a Second Amendment to Lease dated March&nbsp;25, 2004&#093;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT B
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Diagram depicting 14,503 rentable square feet of office and lab space located on the first floor<BR>
of the Building&#093;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT C
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">None.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FIRST AMENDMENT TO SUBLEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This First Amendment to Sublease is made as of the December&nbsp;7, 2007 by and between Oscient
Pharmaceuticals Corporation (formerly known as Genome Therapeutics Corporation), a Massachusetts
corporation with a place of business at 1000 Winter Street, Suite&nbsp;2200, Waltham, Massachusetts
02451 (&#147;Sublessor&#148;), and Fluidigm Corporation, a Delaware corporation, with a place of business at
7000 Shoreline Court, South San Francisco, California 94080 (&#147;Sublessee&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">WITNESSETH THAT:
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, pursuant to that certain Agreement of Lease dated as of October&nbsp;6, 2000 by and
between ARE-San Francisco No.&nbsp;17, LLC (&#147;Prime Lessor&#148;) (as successor in interest to Mountain Cove
Tech Center, L.L.C. by acquisition of the fee interest in the property, and MJ Research Company,
Inc., by an Assignment and assumption of Subleases dated as of October&nbsp;6, 2000 to Mountain Cove
Tech Center, L.L.C.), as &#147;landlord&#148; and Sublessor, as &#147;tenant&#148; (as successor in interest to
Genesoft, Inc.), as amended by a First Amendment to Lease dated December&nbsp;5, 2002 and a Second
Amendment to Lease dated March&nbsp;25, 2004 (such lease, as so amended, and all renewals, modifications
and extensions thereof being hereinafter collectively referred to as the &#147;Prime Lease&#148;), a true and
complete copy of which is attached hereto as <U><B>Exhibit&nbsp;A</B></U><B>, </B>Prime Lessor leases to Sublessor
approximately 68,460 rentable square feet of space located on the first, second and third floors of
the Building (all as more particularly described in the Prime Lease, the &#147;Premises&#148;); and
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, pursuant to that certain Sublease Agreement dated as of March&nbsp;25, 2004, by and
between Sublessor, as &#147;sublessor&#148; and Sublessee, as &#147;sublessee&#148; (the &#147;Sublease&#148;), a true and
complete copy of which is attached hereto as <U><B>Exhibit&nbsp;B</B></U><B>, </B>Sublessor subleases to Sublessee
approximately 14,503 rentable square feet of office and lab space located on the first floor of the
Building (all as more particularly described in the Sublease, the &#147;Subleased Premises&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the term of the Sublease ends on December&nbsp;31, 2007; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Sublessor and Sublessee desire to amend the Sublease to, among other things,
extend said term all subject to the provisions hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties covenant and agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>Term</U>. Notwithstanding anything to the contrary in the Sublease, the term of
the Sublease is hereby extended for a period commencing on January&nbsp;1, 2008 (the &#147;Extension
Effective Date&#148;) and expiring on February&nbsp;28, 2011 (the &#147;Expiration Date&#148;) or such earlier date
upon which said term may expire, be cancelled or be terminated pursuant to any of the terms of
provisions of the Prime Lease, the Sublease, this First Amendment to Sublease or applicable law
(the &#147;Additional Term&#148;). Said extension shall be subject to all terms, covenants and conditions
contained in the Sublease except as otherwise set forth herein. References herein and in the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Sublease to the Term shall be deemed to mean and include the Initial Term and Additional Term
(and the Expiration Date shall be deemed extended accordingly). Sublessee acknowledges and agrees
that it has no further right to extend the term of the Sublease and that any such right set forth
in Section&nbsp;2 of the Sublease is null and void.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Termination For Convenience.</U> Sublessee is granted a one-time right to terminate
(&#147;Termination Right&#148;) the Sublease on July&nbsp;1, 2009, Sublessee shall provide Sublessor written
notification of its intent to terminate no later than October&nbsp;1, 2008. If Sublessee exercises
this Termination Right, Sublessee shall pay Sublessor an amount equal to $332,500.00 on or before
July&nbsp;1, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Rent</U>. Notwithstanding anything to the contrary contained in Section&nbsp;4 of the
Sublease, commencing on January&nbsp;1, 2008, the Rent due under the Sublease shall be equal to the
following amounts during the periods set forth below:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Term Period</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Monthly Rent</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">P.R.S.F. Per Year</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1/1/08 &#151; 12/31/08
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">57,172.24</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">47.305</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1/1/09 &#151; 12/31/09
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">58,477.51</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">48.385</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1/1/10 &#151; 12/31/10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">59,637.75</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">49.345</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1/1/11 &#151; 2/28/11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">60,943.02</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">50.425</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Rent specified above is inclusive of all services previously provided by Sublessor
pursuant to Section&nbsp;4 of the Sublease as well as all other provisions contained in Sections&nbsp;4 and
11 of the Sublease. Section&nbsp;4 (ii)&nbsp;is hereby deleted. The parties agree that the Sublessee shall
be responsible for the janitorial and cleaning services. The fifth sentence from the bottom of
Section&nbsp;4 is hereby deleted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Assignment and Subletting</U>. The references in the first two sentences of Section&nbsp;9
of the Sublease to &#147;Competitors&#148; and to net worth shall be deleted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Financial Statements</U>. Section&nbsp;27.13 of the Prime Lease, as incorporated into the
Sublease, shall be revised such that (a)&nbsp;Section&nbsp;27.13 shall not apply if Sublessee is a publicly
traded company, (b)&nbsp;if Sublessee is not a publicly traded company, Sublessee shall only be required
to provide Sublessor with audited financial statements once they have been completed, provided
Sublessee uses commercially reasonable efforts to complete such statements with a reasonable time
frame and (c)&nbsp;Sublessor shall hold all of Sublessee&#146;s financial statements confidential.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Proper Authority</U>. Each party represents to the other that (i)&nbsp;it has not assigned,
encumbered or hypothecated any of its right, title or interest in the Sublease or any portion
thereof or interest therein, (ii)&nbsp;it is duly authorized to enter into and perform its obligations
under
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">this First Amendment to Sublease and to modify its rights under the Sublease as set forth in this
First Amendment to Sublease, and (iii)&nbsp;the parties executing this First Amendment to Sublease on
behalf of each party are duly authorized to bind the party they purport to represent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Brokerage</U>. Sublessee and Sublessor represent that they have not dealt with any
broker in connection with this First Amendment to Sublease other than CRESA Partners on behalf of
Sublessee. The Sublessor shall not be responsible for a commission or other fee, if any, is due to
CRESA Partners. Each party agrees to indemnify and hold harmless the other from and against any and
all liability, claims, suits, demands, judgments, costs, interest and expense (including, without
being limited to, reasonable attorneys&#146; fees and expenses) which the indemnified party may be
subject to or suffer by reason of any claim made by any person, firm or corporation for any
commission, expense or other compensation as a result of the execution and delivery of this First
Amendment to Sublease, which is based on alleged conversations or negotiations by said person, firm
or corporation with the indemnifying party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Condition</U>. This First Amendment to Sublease is subject to (a)&nbsp;approval and consent
of Prime Lessor in accordance with this Section&nbsp;6 and (b)&nbsp;the full execution of the Third Amendment
to Lease currently being negotiated between Sublessee and Prime Lessor to extend the term of the MJ
Research Sublease (the &#147;MJ Research Amendment&#148;). This First Amendment to Sublease shall not become
effective unless and until a written approval and consent to this First Amendment to Sublease is
executed and delivered by Prime Lessor to Sublessor and the MJ Research Amendment is fully
executed. If the above conditions are not satisfied within ten (10)&nbsp;business days of Sublessee&#146;s
execution of this First Amendment to Sublease, either party may terminate this First Amendment to
Sublease by delivering written notice to the other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Security Deposit</U>. Sublessee shall maintain in effect throughout the Additional Term
a Letter of Credit as required under Section&nbsp;15 of the Sublease. Within ten (10)&nbsp;days of the
Extension Effective Date, Sublessee at its sole cost and expense shall deliver to Sublessor, an
extension of the existing Letter of Credit or a replacement of the existing Letter of Credit in a
form and from a financial institution reasonably acceptable to Sublessor. Sublessee may at any time
substitute a cash security deposit for the Letter of Credit, and upon such substitution, Sublessor
shall return the Letter of Credit to Sublessee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Miscellaneous</U>. Unless the context requires otherwise, the terms used herein shall
be construed in conformity with the definitions set forth in the Sublease. References in the
Sublease to the MJ Research Sublease shall mean the MJ Research Sublease as amended, including by
the MJ Research Amendment. As hereby modified, the Sublease is ratified and confirmed and remains
in full force and effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Sublessor and Sublessee have caused this instrument to be executed under
seal as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OSCIENT PHARMACEUTICALS CORPORATION<br>a Massachusetts corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Ph. M. MAITRE
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Ph. M. MAITRE&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">SVP &#038; CFO.&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">FLUIDIGM CORPORATION,<br>a Delaware corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Sublessor and Sublessee have caused this instrument to be executed under
seal as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OSCIENT PHARMACEUTICALS CORPORATION<br>a Massachusetts corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">FLUIDIGM CORPORATION,<br>a Delaware corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gajus Worthington
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Gajus Worthington&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">CEO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;See below for Agreement of Lease dated as of October&nbsp;6, 2000 by and between Prime Lessor, as<BR>
&#147;landlord&#148; and Sublessor, as &#147;tenant&#148; as amended by a First Amendment to Lease dated December&nbsp;5,<BR>
2002 and a Second Amendment to Lease dated March&nbsp;25, 2004&#093;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT B
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;See above for Sublease Agreement dated as of March&nbsp;25, 2004.&#093;
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AGREEMENT OF LEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGREEMENT
OF LEASE made as of the 1st day of December, 2001, by and
between MJ Research Company, Inc. (hereinafter referred to as &#147;Landlord&#148;) and Fluidigm Corporation
(hereinafter referred to as &#147;Tenant&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">WITNESSETH:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord hereby leases to Tenant and Tenant hereby hires from Landlord a portion of the
building (the &#147;Building&#148;) in South San Francisco, as described in Section&nbsp;1.1(4) below and shown on
the plan attached hereto as Exhibit&nbsp;A and made a part hereof (hereinafter referred to as the
&#147;Premises&#148; or the &#147;Demised Premises&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">1. REFERENCE DATA
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Definitions</U>. Each reference in this Lease to any of the terms and
titles contained in this Article shall be deemed and construed to incorporate the data stated
following that term or title in this Article.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Rent:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sums or other charges payable by Tenant to
Landlord under this Lease, other than
Monthly Fixed Rent, all of which shall be
payable as additional rent under this Lease.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Broker:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">None.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Business Day:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">All days except Saturdays, Sundays, days
defined as &#147;legal holidays&#148; for the entire
state under the laws of the State of California, and such other days as Tenant
presently or in the future recognizes as
holidays for Tenant&#146;s general staff.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Demised Premises:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Space on the first floor of the Building at
7000 Shoreline Court, South San Francisco,
California 94080 (the &#147;Building&#148;), which
space is shown on the plans attached as
Exhibit&nbsp;A.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Environmental Laws:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;5.3 (a) (1).</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">6)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Event of Default:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The occurrence of an event listed in Section
19.1.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">7)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hazardous Materials:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;5.3 (a) (2).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">8)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Interest Rate:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">18% per annum, or the maximum
interest rate Landlord is
permitted to charge Tenant under
applicable law, whichever is
less.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">9)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Land:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The parcel of land on which the
Building is situated.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord&#146;s Address:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7000 Shoreline Court, So. San
Francisco, CA 94080, Attn: Edward
Breakell</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">11)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord&#146;s Architect:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Any licensed architect from time
to time designated by Landlord.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">12)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lease Year:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A twelve (12)&nbsp;month period
beginning on the Term
Commencement Date and each
succeeding twelve (12)&nbsp;month
period during the Term of this
Lease, except that if the Term
Commencement Date shall be other
than the first day of a
calendar month, the first Lease
Year shall include the partial
calendar month in which the Term
Commencement Date occurs as well
as the succeeding twelve (12)
full calendar months.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">13)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mortgage:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A mortgage, deed of trust, trust
indenture, or other security
instrument of record creating an
interest in or affecting title to
the Land or Building or any part
thereof, and any and all
renewals, modifications,
consolidations or extensions of
any such instrument.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">14)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mortgagee:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The holder of any Mortgage.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">15)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Permitted Use:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Office and light engineering,
subject to the provisions
contained herein involving the
use of hazardous materials.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">16)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Prime Landlord:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mountain Cove Tech Center LLC, a
California limited liability
company.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">17)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Prime Lease:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The lease dated November&nbsp;9, 1999
between Prime Landlord and
Landlord.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">18)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Property:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Land and Building.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
2
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">19)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rent:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Monthly Fixed Rent and Additional Rent.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">20)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rentable Area of
the Demised Premises:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;<BR>Agreed to be 12,501 rentable square feet
plus the loading space shown on Exhibit&nbsp;A.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">21)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Security Deposit:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">$90,000.00</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">22)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant&#146;s Address:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7100 Shoreline Court, South San Francisco,<BR>
California 94080</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term<BR>Commencement<BR>
Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><BR><BR>December&nbsp;8, 2001</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term of this Lease:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Approximately 37&nbsp;months</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">25)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">January <I>7, </I>2005</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">26)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Monthly Fixed Rent:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">$48,700.00 per month ($584,400.00 per year)
for the first lease year, which amount
shall be increased annually by four
(4.0%) compounded annually.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>Exhibits</U>. The following exhibits are attached hereto and made a part
hereof:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">A &#151; Plan of Demised Premises<BR>
B &#151; Cleaning Specifications<BR>
C &#151; Rules and Regulations<BR>
D &#151; List of Environmental Reports Given to Tenant<BR>
E &#151; Form of Prime Landlord Consent
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">2. DESCRIPTION OF DEMISED PREMISES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Demised Premises</U>. The Demised Premises are that portion of the
Building as described above (as the same may from time to time be constituted after
changes therein, additions thereto and eliminations therefrom pursuant to rights of
Landlord hereinafter reserved).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Appurtenant Rights</U>. Tenant shall have, as appurtenant to the
Demised Premises, rights to use in common, subject to reasonable rules from time
to time made by Landlord of which Tenant is given notice, those common roadways,
walkways, elevators, hallways and stairways necessary for access to that portion of
the Building occupied by the Demised Premises. There is also appurtenant to the
Demised Premises at no additional charge the nonexclusive use, in common with
Landlord and other entitled thereto, of the parking lot appurtenant to the Building,
which lot is designed to have three (3)&nbsp;parking spaces per 1,000 rentable-square feet
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
3
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in the Building. Landlord agrees that such parking lot shall be on a non-exclusive basis for
Tenant and others&#146; entitled thereto. Tenant may not store cars in the parking lot, i.e., leave
cars parked for more than seven (7)&nbsp;days.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Reservations</U>. All the perimeter walls of the Demised Premises except
the inner surfaces thereof, any balconies, terraces or roofs adjacent to the Demised
Premises, and any space in or adjacent to the Demised Premises used for serving
other portions of the Building exclusively or in common with the Demised Premises,
including without limitation (where applicable) shafts, stacks, pipes, conduits, wires
and appurtenant fixtures, fan rooms, ducts, electric or other utilities, sinks or other
Building facilities, and the use thereof, as well as the right of access through the
Demised Premises for the purpose of operation, maintenance, decoration and repair,
are expressly reserved to Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Certain Amenities</U>. The named Tenant, Fludigm Corporation shall
have access to on a nonexclusive basis, the following facilities:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The exercise room. Landlord may charge a reasonable fee for towel service (if provided) and janitorial service.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The lunchroom and adjacent patio.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event the named Tenant Fluidigm Corporation occupies less than all of the
Premises, Landlord may eliminate said amenities or assign them exclusively to Landlord or
other occupants of the Building. Such amenities shall not be available to assignees or
subtenants of Tenant unless permitted in writing by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <U>Conference Room</U>. Tenant may have the use of the executive
conference room for up to an additional four (4)&nbsp;days per month at the rate of
$700.00 for a full day or $400.00 for a half day. Use of the executive conference
room must be booked through the Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">3. TERM OF LEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Term</U>. The Term of this Lease is approximately 37&nbsp;months and (or until
such Term shall sooner cease or expire) commencing on the Term Commencement Date and ending
on January&nbsp;7, 2005 (the &#147;Termination Date&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">4. PREPARATION OF PREMISES; TENANTS ACCESS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>As Is</U>.&#148; The Premises are leased &#147;as is.&#148;
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
4
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">5. USE OF PREMISES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Permitted Use</U>. Tenant shall occupy and use the Demised Premises for
the Permitted Use set forth in Article&nbsp;1 and for no other purpose. Service and
utility areas (whether or not a part of the Demised Premises) shall be used only for
the particular purpose for which they are designated. Tenant shall have access to
the Demised Premises 24 hours per day, 7&nbsp;days per week.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Prohibited Uses</U>. Tenant shall not use, or suffer or permit the use of,
or suffer or permit anything to be done in or anything to be brought into or kept in,
the Demised Premises or any part thereof (i)&nbsp;which would violate any of the
covenants, agreements, terms, provisions and conditions of this Lease, (ii)&nbsp;for any
unlawful purposes or in any unlawful manner, or (iii)&nbsp;which, in the reasonable
judgment of Landlord shall in any way (a)&nbsp;impair or tend to impair the appearance
or reputation of the Building, (b)&nbsp;impair or interfere with or tend to impair or
interfere with any of the Building services or the proper and economic heating,
cleaning, air conditioning or other servicing of the Building or with the use of any of
the other areas of the Building, or (c)&nbsp;occasion discomfort, inconvenience or
annoyance to any of the other tenants, or occupants of the Building, whether
through the transmission of noise or odors or vibrations or dust or otherwise.
Without limiting the generality of the foregoing, no food shall be prepared or served
for consumption by the general public on or about the Demised Premises; no
intoxicating liquors or alcoholic beverages shall be sold or otherwise served for
consumption by the general public on or about the Demised Premises; no lottery
tickets (even where the sale of such tickets is not illegal) shall be sold and no
gambling, betting or wagering shall otherwise be permitted on or about the
Demised Premises; no loitering shall be permitted on or about the Demised
Premises; and no loading or unloading of supplies or other material to or from the
Demised Premises shall be permitted on the Land except at times (excluding
Business Days from 7:00 to 9:30 a.m. and from 4:00 to 6:00 p.m.) and in locations to
be reasonably designated by Landlord, except for the freight elevator described in
Section&nbsp;7.4, which Tenant may use at any time. The Demised Premises shall be
maintained in a sanitary condition. Tenant shall suitably store all trash and
rubbish in the Demised Premises or other locations designated by Landlord from
time to time. All Hazardous Materials must be disposed of in compliance with
Section&nbsp;5.3. Tenant specifically agrees that its indemnification obligations pursuant
to Section&nbsp;13.2 shall extend to any claim arising from the consumption of
intoxicating liquors or alcoholic beverages on or about the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 Hazardous Materials,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Definitions.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
5
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Environmental Law means any governmental statute,
code ordinance, regulation, rule or order and any amendment thereto
governing or regulating materials that are toxic, explosive, corrosive,
flammable, radioactive, carcinogenic, dangerous or otherwise
hazardous. Environmental Laws include, without limitation, the Comprehensive
Environmental Response Compensation and Liability Act, 42 U.S.C. &#167;9601 <I>et seq., </I>the
Resource Conservation and Recovery Act, 42 U.S.C. &#167;6901 <I>et seq., </I>the California Hazardous
Substances Act at California Health and Safety Code Section&nbsp;108100 <I>et seq., </I>the
provisions regarding hazardous waste control at California Health and Safety Code
Sections&nbsp;25100 through 25250.25 and the California Medical Waste Management Act at
California Health and Safety Code &#167;117600 <I>et seq</I>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Hazardous Materials shall mean any substance: (A)&nbsp;that
now or in the future is regulated or governed by, requires investigation
or remediation under, or is defined as a hazardous waste, medical
waste, hazardous substance, pollutant or contaminant under any
Environmental Law or (B)&nbsp;that is toxic, explosive, corrosive, flammable, radioactive, carcinogenic, dangerous or otherwise
hazardous, including gasoline, diesel fuel, petroleum hydrocarbons,
polychlorinated biphenyls (PCBs), asbestos, radon and urea
formaldehyde foam insulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Tenant&#146;s Covenants</U>. No Hazardous Materials shall be stored, placed, handled,
used or released by Tenant or its employees, contractors, sublessees, guests or visitors at or
about the Demised Premises or Property without Landlord&#146;s prior written consent. Notwithstanding
the foregoing, storage and use of routine office and janitorial supplies in usual and customary
quantities and the Permitted Materials as defined in subsection (c)&nbsp;below are permitted without
Landlord&#146;s prior written consent, provided that Tenant&#146;s activities at or about the Demised
Premises and Property shall comply at all times with all Environmental Laws. Tenant shall keep
Landlord fully and promptly informed of all storage, placement, handling, use or release by Tenant
or its employees, contractors , sublessees, guests or visitors of all Hazardous Materials. At the
expiration or termination of the Lease, Tenant shall remove from the Demised Premises all Hazardous
Materials brought or released in or on the Building as a result of the activities of Tenant or its
employees, agents, servants, invitees, visitors, customers, contractors, sublessees, and those
other persons for whom Tenant is legally responsible (collectively &#147;Tenant Parties&#148;). Landlord
shall have the right to perform an environmental assessment of the Demised Premises after such
removal, which assessment shall be conducted at Landlord&#146;s expense, unless it reveals that Tenant
has not complied with the requirements set
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
6
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">forth in this Section&nbsp;5.3, in which case Tenant shall reimburse Landlord for the reasonable cost
thereof within ten days after Landlord&#146;s request therefor. Nothing in this Section&nbsp;5.3 shall
require Tenant to indemnify Landlord for any matters arising out of or caused by the actions or
omissions of Landlord, its employees, agents, contractors, licensees, or invitees.. Tenant shall
be responsible and liable for the compliance with all of the provisions of this Section by all of
Tenant Parties and all of Tenant&#146;s obligations under this Section (including its indemnification
obligations under subsection (e)&nbsp;below) shall survive the expiration or termination of this Lease.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Tenant may request permission to use the loading dock to accept
deliveries of Hazardous Materials for use in Tenant&#146;s subleased space in the
Building. Landlord shall grant such permission in its sole and absolute
discretion. Tenant will operate under all applicable Federal, State and Local
laws governing the use, storage and management of hazardous materials for
building Occupancy Groups A3, B and H Divisions 2, 3 and 7, as allowable,
including Title 22 of the CFR as defined under the Uniform Building Code
and Uniform Fire Code developed by the International Fire Code Institute
(the &#147;Allowable Class&nbsp;Facilities&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Compliance</U>. Tenant shall at Tenant&#146;s expense promptly take all
actions required by any governmental agency or entity in connection with or
as a result of the storage, placement, handling, use or release by Tenant
Parties of Hazardous Materials at or about the Demised Premises or
Property, including inspection and testing, performing all cleanup, removal and remediation work required with respect to those Hazardous Materials,
complying with all closure Laws and postclosure monitoring, and filing all
required reports or plans. Tenant shall never use any of the Landlord&#146;s trash
receptacles for disposing of any hazardous waste. All of the foregoing work
shall be performed in a good, safe and workmanlike manner by consultants
qualified and licensed to undertake such work and in a manner that will not
interfere with any other tenant&#146;s quiet enjoyment of the Property or
Landlord&#146;s use, operation, leasing and sale of the Property. Tenant shall
deliver to Landlord prior to delivery to any governmental agency, or promptly
after receipt from any such agency, copies of all permits, manifests, closure or
remedial action plans, notices, and all other documents relating to the
storage, placement, handling, use or release by Tenant Parties of Hazardous
Materials at or about the Demised Premises or Property. Upon prior written
notice from Landlord, Tenant shall make available to Landlord for Landlord&#146;s
inspection and copying all of Tenant&#146;s documents, materials, data,
inventories and other documentation (including, without limitation, Material
Safety Data Sheets relating to Hazardous Materials as may be present or
suspected to be present in, on or about the Demised Premises. If any lien
attaches to the Demised Premises or the Property in connection with or as a
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
7
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">result of the storage, placement, handling, use or release by Tenant Parties of Hazardous
Materials, and Tenant does not cause the same to be released, by payment, bonding or otherwise,
within ten (10)&nbsp;days after the attachment thereof, Landlord shall have the right but not the
obligation to cause the same to be released and any sums expended by Landlord in connection
therewith shall be payable by Tenant on demand. Notwithstanding anything in the foregoing to the
contrary, Tenant shall not be responsible for Hazardous Materials not introduced to the Premises,
the Building or the Land by Tenant Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Tenant shall give Landlord immediate telephone notice and
prompt written notice (which means as soon as practicable and, in no event,
more than one (1)&nbsp;day following Tenant&#146;s knowledge of the applicable event)
of any (i)&nbsp;spill, discharge, dumping, or other release of any Hazardous
Materials (including, without limitation, the Permitted Materials) on, in,
under or from the Demised Premises, the Building, or any portion of the
Project, or the groundwater thereof, (ii)&nbsp;any oral or written notice from any
governmental agency received by Tenant of any such spill, discharge,
dumping, or other release of any Hazardous Materials, and (iii)&nbsp;any oral or
written notice of any violation, warning, deficiency, non-compliance, or other
alleged or actual failure by Tenant to comply strictly with any Environmental
Law and/or any requirement, provision, or stipulation of any governmental
permit, license, registrations, or approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Landlord&#146;s Eights</U> .Subject to the provisions of Section&nbsp;15.2,
Landlord shall have the right, but not the obligation, to enter the Demised
Premises at any reasonable time upon 24 hours notice except in case of
emergency (i)&nbsp;to confirm Tenant&#146;s compliance with the provisions of this
Section, and (ii)&nbsp;to perform Tenant&#146;s obligations under this Section if Tenant
has failed to do so after reasonable notice to Tenant. Landlord shall also
have the right to engage qualified Hazardous Materials consultants to
inspect the Demised Premises and review the storage, placement, handling,
use or release by Tenant or its employees, contractors, sublessees, guests or
visitors of Hazardous Materials, including review of all permits, reports,
plans, and other documents regarding same. Tenant shall pay to Landlord
on demand the reasonable costs of Landlord&#146;s consultant&#146;s fees if Tenant is
found to have violated the terms of this Section&nbsp;5.3 any and all reasonable
costs incurred by Landlord in performing Tenant&#146;s obligations under this
section. Landlord shall use reasonable efforts to minimize any interference with Tenant&#146;s
business caused by Landlord&#146;s entry into the Demised Premises, but Landlord shall not be
responsible for any interference caused thereby, unless such interference arises out of or is
caused by the gross negligence or willful misconduct of Landlord, its employees, agents,
contractors, licensees, or invitees.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
8
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Tenant&#146;s Indemnification</U>. Tenant agrees to indemnify, defend and hold
harmless Landlord and its members, managers, directors, officers, agents and employees and
their partners, members, managers, directors, officers, shareholders, employees and agents
from all shall mean all costs and expenses of any kind, damages, including foreseeable and
unforeseeable consequential damages, fines and penalties incurred in connection with any
violation of and compliance with the Environmental Laws by Tenant Parties and all losses of
any kind attributable to the diminution of value, loss of use or adverse effects on
marketability or use of any portion of the Demised Premises or Property by Tenant Parties
and all other claims, actions, losses, damages, liabilities, costs and expenses of every
kind, including reasonable attorneys&#146;, experts&#146; and consultants&#146; fees and costs, incurred
at any time and arising from or connection with the storage, placement, handling, use or
release by Tenant or its employees, contractors, sublessees, guests or visitors of
Hazardous Materials at or about the Property or Tenant&#146;s failure to comply in full with all
Environmental Laws with respect to the Demised Premises and the Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Licenses and Permits</U>. If any governmental license or permit shall be required
for the property and lawful conduct of Tenant&#146;s business, and if the failure to secure such license
or permit would in any way affect Landlord, Tenant, at Tenant&#146;s expense, shall duly procure and
thereafter maintain such license or permit and submit the same to inspection by Landlord. Tenant,
at Tenant&#146;s expense, shall at all times comply with the terms and conditions of each such license
or permit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">6. RENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Monthly Fixed Rent</U>. Tenant shall pay to Landlord, without any set-off
or deduction, at Landlord&#146;s office, or to such other person or at such other place as
Landlord may designate by notice to Tenant, the Monthly Fixed Rent set forth in
Article&nbsp;1, subject to annual adjustment as set forth in said Article&nbsp;1. The Monthly
Fixed Rent shall be paid in equal monthly installments in advance on or before the
first Business Day of each calendar month during the Term of this Lease and shall
be apportioned for any fraction of a month in which the Term Commencement Date
or the last day of the Term of this Lease may fall.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Taxes</U>. Tenant shall timely file business property statements with
respect to Tenant&#146;s personal property and trade fixtures and pay when due all taxes
imposed on such personal property and trade fixtures. Tenant shall also pay all
real estate taxes attributable to Alterations made by Tenant to the Demised
Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Obligations Survive Termination</U>. All obligations and liabilities of
Tenant relating to any period prior to the termination of the Term of this Lease,
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
9
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">including without limitation the obligation to pay any Additional Rent due pursuant to the
provisions of this Article, shall survive such termination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Payment to Mortgagee</U>. Landlord reserves the right to provide in any
Mortgage given by it or by Prime Landlord of the Property that some or all rents,
issues, and profits and all other amounts of every kind payable to the Landlord
under this Lease shall be paid directly to the Mortgagee for Landlord&#146;s account and
Tenant covenants and agrees that it will, after receipt by it of notice from Landlord
or Mortgagee designating such Mortgagee to whom payments are to be made by
Tenant, pay such amounts thereafter becoming due directly to such Mortgagee until
excused therefrom by notice from such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Additional Rent</U>. Tenant shall also pay as additional rent without
notice, except as required under this Lease, and without any abatement, deduction
or setoff except as provided herein, all sums, impositions, costs, expenses and other
payments which Tenant in any of the provisions of this Lease assumes or agrees to
pay, and, in case of any nonpayment thereof, Landlord shall have in addition to any
other rights and remedies, all of the rights and remedies provided by law or&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;provided for in the Lease for the nonpayment of Monthly Fixed Rent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Place of Payment of Rent</U>. All payments of Rent shall be made by
Tenant to Landlord without notice or demand at such place as Landlord may from
time to time designate in writing. The initial place for payment of rent shall be
7000 Shoreline Court, So. San Francisco, CA 94080. Any extension of time for the
payment of any installment of rent, or the acceptance of rent after the time at which
it is due and payable shall not be a waiver of the rights of Landlord to insist on
having all other payments made in the manner and at the times herein specified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Cleaning</U>. Tenant shall arrange for cleaning of the Tenant space in
accordance with the cleaning schedule attached hereto as Exhibit&nbsp;B with a cleaning
contractor subject to Landlord&#146;s approval, which approval shall not be unreasonably
withheld. Tenant shall pay all such costs of cleaning. In addition, Landlord may
provide such cleaning services to the Premises at a cost plus a ten percent (10%)
administrative fee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">7. UTILITIES AND LANDLORD&#146;S SERVICES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Electricity</U>. Landlord shall furnish, at Landlord&#146;s cost, all electrical energy
that Tenant requires for operation of the lighting fixtures, appliances and equipment servicing the
Demised Premises. Landlord shall not be liable in any way to Tenant for any failure or defect in
the supply or character of electrical energy furnished to the Demised Premises by reason of any
requirement, act or omission of the public utility serving the Building. Tenant&#146;s use of electrical
energy in the Demised Premises shall not at any time exceed the capacity of any of the electrical
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
10
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conductors and equipment in or otherwise serving the Demised Premises. In order to insure that
such capacity is not exceeded and to avert possible adverse effect upon the Building electrical
services Tenant shall give notice to Landlord and obtain Landlord&#146;s prior written consent
whenever Tenant shall connect to the Building electrical distribution system any fixtures,
appliances or equipment other than lamps, typewriters, personal computers and similar small
machines. Landlord shall install and replace all light fixtures, bulbs, tubes, lamps, lenses,
globes, ballasts and switches used in the Demised Premises.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Water</U>. Landlord shall furnish cold water for ordinary cleaning, toilet and drinking purposes and hot and cold water for lavatory purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Heat and Air Conditioning</U>. Landlord shall furnish to and distribute in
the Premises and common areas of the Building heat and air conditioning as normal
seasonal changes may require on Business Days from 8:00 a.m. to 6:00 p.m. and on
Saturdays from 9:00 a.m. to 1:00 p.m., provided Landlord may run common area
HVAC on an economy mode on Saturdays. Without limiting the generality of the
foregoing, all windows in the Demised Premises must remain closed at all times
notwithstanding the fact that such windows may be operable. The air conditioning
system servicing the Building is designed to provide cooling based upon an
occupancy of not more than one person per one hundred (100)&nbsp;square feet of floor
area, and upon a combined lighting and standard electrical load not to exceed 3.0
watts per square foot. In the event Tenant exceeds such condition or introduces
into the Demised Premises equipment which overloads such system, or in any other
way causes such system not to adequately perform its proper functions,
supplementary systems may at Landlord&#146;s option be provided by Landlord at
Tenant&#146;s, expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Elevator Service</U>. Landlord shall provide non exclusive passenger
elevator service consisting of two (2)&nbsp;elevators to the Demised Premises on Business Days from 8:00 a.m. to 6.00 p.m. and on a reduced basis at all other times.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <U>Cleaning</U>. Landlord shall furnish cleaning services to the common
areas of the Building substantially in accordance with the specifications attached
hereto as Exhibit&nbsp;B and made a part hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <U>Repairs and Other Services</U>. Except as otherwise provided in Articles 8
and 16, and subject to Tenant&#146;s obligations in Article&nbsp;12 and elsewhere in this
Lease, Landlord shall at Landlord&#146;s expense (a)&nbsp;keep and maintain the roof, exterior
walls, structural floor slabs and columns of the Building in as good condition and
repair as they are in on the Term Commencement Date, reasonable use and wear
excepted, (b)&nbsp;keep and maintain in workable condition the Building&#146;s sanitary,
electrical, heating, air conditioning and other systems, (c)&nbsp;keep all walkways on the
Property clean and remove all snow and ice therefrom, (d)&nbsp;provide grounds
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
11
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">maintenance to all landscaped areas and (e)&nbsp;keep and maintain the parking lot adjacent to
the Building in good condition and repair.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <U>Landlord&#146;s Further Responsibilities</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Landlord shall allow Tenant to have full access to and use of the
largest conference room on the third floor of the Building up to two (2)&nbsp;times
per month, as reasonably agreed to in advance by Landlord and Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Landlord shall be responsible at its sole cost and expense for the
removal of all trash and garbage (excluding Hazardous Materials, laboratory,
biological and animal waste) from the designated containers outside of the
Building. Landlord will control the keys to the dumpster locks.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Landlord shall comply with all obligations imposed on it in the CCR&#146;s (defined in Section&nbsp;27.10) and shall pay its share of any future costs of
providing BART shuttle service.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <U>Interruption or Curtailment of Services</U>. Landlord reserves the right to
interrupt, curtail, stop or suspend the furnishing of services and the operation of
any Building system, when necessary by reason of accident or emergency, or of
repairs, alterations, replacements or improvements in the reasonable judgment of
Landlord desirable or necessary to be made, or of difficulty or inability in securing
supplies or labor, or of strikes, or of any other cause beyond the reasonable control
of Landlord, whether such other cause be similar or dissimilar to those hereinabove
specifically mentioned, until said cause has been removed. Landlord shall use
reasonable efforts to minimize interruption to Tenant by any such interruption or
curtailment of services. Landlord shall have no responsibility or liability for any
such interruption, curtailment, stoppage, or suspension of services or systems,
except that Landlord shall exercise reasonable diligence to eliminate the cause of
same. Notwithstanding the foregoing, if utilities or Building services are
interrupted due to the fault of Landlord (Tenant acknowledging that Landlord shall
have no responsibility for failure of municipal or public utility suppliers to supply
utilities to the Building), and such disruption continues for more than fifteen (15)
days, rent shall abate if the Demised Premises are unusable and Tenant in fact
vacates the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">8. CHANGES OR ALTERATIONS BY LANDLORD
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord reserves the right, exercisable by itself or its nominee, including without
limitation Prime Landlord, at any time and from time to time without the same constituting an
actual or constructive eviction and without incurring any liability to Tenant therefor or otherwise
affecting Tenant&#146;s obligations under this Lease, to make such changes, alterations, additions,
improvements, repairs or
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
12
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">replacements in or to the Building and the fixtures and equipment thereof, as well as in or to the
street entrances, halls, passages, elevators, and stairways thereof, as it may deem necessary or
desirable, and to change the arrangement and/or location of entrances or passageways, doors and
doorways, and corridors, elevators, stairs, toilets, or other public parts of the Building,
provided, however, that there be no unreasonable obstruction of the right of access to, or
unreasonable interference with the use and enjoyment of, the Demised Premises by Tenant, except
that Landlord shall not be obligated to employ labor at so-called &#147;over-time&#148; or other premium pay
rates. Nothing contained in this Article shall be deemed to relieve Tenant of any duty, obligation
or liability of Tenant with respect to making or causing to be made any repair, replacement or
improvement or complying with any law, order or requirement of any governmental or other authority.
Neither this Lease nor any use by Tenant shall give Tenant any right or easement or the use of any
door or any passage or any concourse connecting with any other building or to any public
convenience, and the use of such doors, passages and concourses and of such conveniences may be
regulated or discontinued at any time and from time to time by Landlord without notice to Tenant
and without affecting the obligations of Tenant hereunder or incurring any liability to Tenant
therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">9. FIXTURES, EQUIPMENT AND IMPROVEMENTS &#151; REMOVAL BY TENANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All fixtures, equipment, leasehold improvements and appurtenances attached to or built into
the Demised Premises prior to or during the Term, whether by Landlord at its expense or at the
expense of Tenant (either or both) or by Tenant, except for personal property, equipment or trade
fixtures paid for by Tenant regardless of whether or not they are affixed to the Premises, shall be
and remain part of the Demised Premises and shall not be removed by Tenant at the end of the Term
unless otherwise expressly provided by notice from Landlord to Tenant. Upon the request of
Landlord, Tenant will remove such fixtures, equipment, leasehold improvements and appurtenances
added by Tenant after the Term Commencement Date as are directed by Landlord and shall restore any
damage caused by such removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">10. ALTERATIONS AND IMPROVEMENTS BY TENANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall make no alterations, decorations, installations, removals, additions or
improvements in or to the Demised Premises without Landlord&#146;s prior written consent and then only
by contractors or mechanics approved by Landlord. No such installations or other work shall be
undertaken or begun by Tenant until Landlord has approved written plans and specifications
therefor; and no amendments or additions to such plans and specifications shall be made without
prior written consent of Landlord. Any such approved alterations, decorations, installations,
removals, additions and improvements shall be done at the sole
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
13
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">expense of Tenant and at such times and in such manner as Landlord may from time to time reasonably
designate. Subject to the terms of Section&nbsp;9 herein, if Tenant shall make any alterations,
decorations, installations, removals, additions or improvements, then Landlord may elect to require
Tenant at the expiration of this Lease to restore the Demised Premises to substantially the same
condition as existed at the Term Commencement Date, such election to be made and advised to Tenant
at the same time as Landlord grants consent to the making of such Alterations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">11. TENANTS CONTRACTORS - MECHANICS&#146; - AND OTHER LIENS - STANDARD OF TENANT&#146;S PERFORMANCE -
COMPLIANCE WITH LAWS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever Tenant shall make any alterations, decorations, installations, removals, additions or
improvements or do any other work in or to the Demised Premises, Tenant will strictly observe the
following covenants and agreements:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In no event shall any material or equipment be incorporated in
or added to the Demised Premises in connection with any such alteration,
decoration, installation, addition or improvement which is subject to any lien,
charge, mortgage or other encumbrance of any kind whatsoever or is subject
to any security interest or any form of title retention agreement. Any
mechanic&#146;s lien filed against the Demised Premises or the Building for work
claimed to have been done for, or materials claimed to have been furnished to
Tenant shall be discharged by Tenant within twenty (20)&nbsp;days thereafter, at
the expense of Tenant, by filing the bond required by law or otherwise. If
Tenant fails so to discharge any lien, Landlord may do so at Tenant&#146;s expense
and Tenant shall reimburse Landlord for any expense or cost incurred by
Landlord in so doing within fifteen (15)&nbsp;days after rendition of a bill therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All installations or work done by Tenant under this or any other
Article of this Lease shall be at its own expense (unless expressly otherwise
provided) and shall at all times comply with (i)&nbsp;laws, rules, orders and
regulations of governmental authorities having jurisdiction thereof and (ii)
plans and specifications prepared by and at the expense of Tenant theretofore
submitted to Landlord for its prior written approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Tenant shall procure all necessary permits before undertaking
any work in the Demised Premises; do all such work in a good and
workmanlike manner, employing materials of good quality and complying
with all governmental requirements, and defend, save harmless, exonerate
and indemnify Landlord from all injury, loss or damage to any person or
property occasioned by or growing out of such work.
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Tenant shall notify Landlord no later than ten (10)&nbsp;days prior to
starting work on any alterations so that Landlord shall have the opportunity
to post a &#147;Notice of nonresponsibility&#148; at the Demised Premises and record
said notice in the county in which the Property is located pursuant to
California Civil Code Section&nbsp;3094.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) all contractors and subcontractors shall be approved by
Landlord, which approval shall not be unreasonably withheld, and all work
by Tenant shall be performed by such contractors and subcontractors and in
such manner as to maintain harmonious labor relations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">12. REPAIRS BY TENANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant, at its expense, shall keep or cause to be kept, all and singular, the
Demised Premises in good repair, order and condition, reasonable use and wear thereof and damage by
fire or by unavoidable casualty excepted. Without limiting the generality of the foregoing, Tenant
shall keep all interior windows and other glass whole, and shall replace the same whenever broken
with glass of the same quality and shall repair or replace all exterior windows if damaged by
neglect or wrongdoing of Tenant. Tenant hereby waives the benefits of California Civil Code Section
1932(1). Notwithstanding any contrary implication, Tenant shall have no obligation to make any
repairs, replacements or improvements of a capital nature (as determined pursuant to generally
accepted accounting practices) to the Premises unless required as a result of tenant&#146;s or its
agent&#146;s negligence or willful misconduct.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">13. INSURANCE, INDEMNIFICATION, EXONERATION AND EXCULPATION
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.1 Tenant&#146;s Insurance
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Liability Insurance</U>. Tenant shall maintain in full force throughout
the Term commercial general liability and property damage insurance providing coverage on an
occurrence form basis with limits of not less than Five Million Dollars ($5,000,000.00) each
occurrence for bodily injury and property damage combined, Five Million Dollars
($5,000,000.00) annual general aggregate, and Five Million Dollars ($5,000,000.00) products
and completed operations (if applicable) annual aggregate. Tenant&#146;s liability insurance
policy or policies shall: (i)&nbsp;include premises and operations liability coverage,
automobile, products and completed operations liability coverage (if applicable), broad form
property damage coverage including completed operations (if applicable), blanket contractual
liability coverage with, to the maximum extent possible, coverage for the indemnification
obligations of Tenant under this Lease, and personal and advertising injury coverage; (ii)
provide that the insurance company has the duty to defend all insureds
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
15
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">under the policy; (iii)&nbsp;provide that defense costs are paid in addition to and do not deplete any
of the policy limits; (iv)&nbsp;cover liabilities arising out of or incurred in connection with
Tenant&#146;s use or occupancy of the Premises or the Property; and (v)&nbsp;extend coverage to cover
liability for the actions of Tenant&#146;s employees, contractors, sublessees, guests and visitors.
Tenant&#146;s required insurance may be maintained by a combination of underlying and &#147;umbrella&#148;
coverage.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Personal Property Insurance.</U> Tenant shall at all times
maintain in effect with respect to Tenant&#146;s fixtures, equipment and personal
property located at or within the Demised Premises, commercial property
insurance providing coverage, at a minimum, for &#147;broad form&#148; perils, to the
extent of 100% of the full replacement cost of covered property. Tenant may
carry such insurance under a blanket policy, provided that such policy
provides equivalent coverage to a separate policy. During the Term, the
proceeds from any such policies of insurance shall be used for the repair or
replacement of such fixtures, equipment and personal property so insured.
Landlord shall be provided coverage under such insurance to the extent of its
insurable interest and, if requested by Landlord, both Landlord and Tenant
shall sign all documents reasonably necessary or proper in connection with
the settlement of any claim or loss under such insurance. Landlord shall have
no obligation to carry insurance on any such Tenant&#146;s leasehold
improvements or on Tenant&#146;s fixtures, equipment or personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Workmen&#146;s Compensation Insurance.</U> Tenant shall maintain
worker&#146;s compensation insurance as required by law and employer&#146;s liability
insurance in an amount not less than Five Hundred Thousand Dollars
($500,000).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Business Interruption/Extra Expense Insurance.</U> Tenant shall
maintain loss of income, business interruption and extra expense insurance
in such amounts as will reimburse Tenant for direct or indirect loss of
earnings and incurred costs attributable to the perils commonly covered by
Tenant&#146;s property insurance described above but in no event less than Five
Hundred Thousand Dollars ($500,000.00). Such insurance shall be carried
with the same insurer that issues the insurance for the personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Other Coverage.</U> Tenant, at its cost, shall maintain such other
insurance as Landlord may reasonably require from time to time, but in no
event may Landlord require any other insurance which is (i)&nbsp;not then being
required of comparable tenants leasing comparable amounts of space in
comparable buildings in the vicinity of the Building or (ii)&nbsp;not then available
at commercially reasonable rates.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
16
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Insurance Criteria.</U> Each policy of insurance required under this
Section shall: (i)&nbsp;be in a form, and written by an insurer, reasonably
acceptable to Landlord, (ii)&nbsp;be maintained at Tenant&#146;s sole cost and expense,
and (iii)&nbsp;require at least thirty (30)&nbsp;days&#146; written notice (or twenty (20)&nbsp;days
in case of nonpayment of premium) to Landlord prior to any cancellation,
nonrenewal or modification of insurance coverage. Insurance companies
issuing such policies shall have rating classifications of &#147;A&#148; or better and
financial size category ratings of &#147;XIII&#148; or better according to the latest
edition of the A.M. Best Key Rating Guide. All insurance companies issuing
such policies shall be licensed to do business in the State of California. Any
deductible amount under such insurance shall not exceed maximum
deductible amounts currently required under similar leases for buildings in
the vicinity of the Building, with Tenant having the burden of proof. Tenant
shall provide to Landlord, upon request, evidence that the insurance required
to be carried by Tenant pursuant to this Section, including any endorsement
affecting the additional insured status, is in full force and effect and that
premiums therefore have been paid.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Increase in Amount of Insurance.</U> Tenant shall increase the
amounts of insurance as required by any Mortgagee, and, not more
frequently than once every three (3)&nbsp;years, as recommended by Landlord&#146;s
insurance broker, if, in the reasonable opinion of either of them, the amount
of insurance then required under this Lease is not adequate. Any limits set
forth in this Lease on the amount or type of coverage required by Tenant&#146;s
insurance shall not limit the liability of Tenant under this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Insurance Provisions</U>. Each policy of liability insurance required by this
Section shall: (i)&nbsp;contain a cross liability endorsement or separation of insureds clause; (ii)
provide that it is primary to and not contributing with, any policy of insurance carried by
Landlord or Prime Landlord covering the same loss; (iii)&nbsp;provide that any failure to comply with
the reporting provisions shall not affect coverage provided to Landlord, Prime Landlord, their
officers, directors, shareholders, members, property managers and mortgagees; and (iv)&nbsp;name Prime
Landlord, Mortgagees, Landlord, their officers, directors, employees, shareholders, members,
property managers and such other parties in interest as Landlord may from time to time reasonably
designate to Tenant in writing, as additional insureds. Such additional insureds shall be provided
the same extent of coverage as provided to Tenant under such policies. All endorsements affecting
such additional insured status shall be acceptable to Landlord and shall be at least as broad as
additional insured endorsement form number CG 20 11 11 85 promulgated by the Insurance Services
Office.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
17
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Evidence of Coverage.</U> Prior to occupancy of the Premises by Tenant,
and not less than thirty (30)&nbsp;days prior to the expiration of any policy thereafter, Tenant
shall furnish to Landlord a certificate of insurance reflecting that the insurance required
by this Section is in force accompanied by an endorsement showing the required additional
insureds satisfactory to Landlord in substance and form. Notwithstanding the requirements
of this paragraph, Tenant shall, at Landlord&#146;s request, provide to Landlord within a
commercially reasonable time a certified copy of each insurance policy required to be in
force at any time pursuant to the requirements of this Lease or its Exhibits. Tenant&#146;s
failure to furnish Landlord with such certificates of insurance within a reasonable time
(not to exceed ten (10)&nbsp;days) after Landlord&#146;s request shall be deemed a material default
under this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.2 <U>General</U>. Tenant will save Landlord harmless, and will exonerate and indemnify
Landlord and Prime Landlord, from and against any and all claims, liabilities, penalties, damages
or expenses (including without limitation reasonable attorneys&#146; fees) asserted against or incurred
by Landlord or Prime Landlord:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) on account of or based upon any injury to person, or loss of or
damage to property sustained or occurring on the Demised Premises on
account of or based upon the act, omission, fault, negligence or misconduct of
any person whomsoever (other than Landlord, Prime Landlord or their
agents, contractors or employees);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) on account of or based upon any injury to person or loss of or
damage to property, sustained or occurring elsewhere (other than on the
Demised Premises) in or about the Building (and, in particular, without
limiting the generality of the foregoing on or about the elevators, stairways,
public corridors, sidewalks, roof, or other appurtenances and facilities used in
connection with the Building or Demised Premises) arising out of the use or
occupancy of the Building or Demised Premises by Tenant, or any person
claiming by, through or under Tenant (other than those caused by or
attributable to the negligence or willful misconduct of Landlord, Prime
Landlord or their agents, contractors or employees);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) on account of or based upon (including moneys due on account
of) any work or thing whatsoever done (other than by Landlord, Prime
Landlord or their contractors, or agents or employees of any such party) in
the Demised Premises during the Term of this Lease and during the period of
time, if any, prior to the Term Commencement Date that Tenant may have
been given access to the Demised Premises; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) on account of or resulting from the failure of Tenant to perform
and discharge any of its covenants and obligations under this Lease;
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
18
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">and, in case any action or proceeding be brought against Landlord or Prime Landlord by reason of
any of the foregoing, Tenant upon notice from Landlord shall at Tenant&#146;s expense resist or defend
such action or proceeding and employ counsel therefor reasonably satisfactory to Landlord, it
being agreed that such counsel as may act for insurance underwriters of Tenant engaged in such
defense shall be deemed satisfactory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.3 <U>Property of Tenant</U>. In addition to and not in limitation of the
foregoing, and subject only to provisions of applicable law, Tenant covenants and
agrees that all merchandise, furniture, fixtures and property of every kind, nature
and description which may be in or upon the Demised Premises or elsewhere on the
Property during the Term of this Lease, shall be at the sole risk and hazard of
Tenant, and that if the whole or any part thereof shall be damaged, destroyed,
stolen or removed from any cause or reason whatsoever other than the negligence or
misconduct of Landlord or Prime Landlord or their contractors, or agents or
employees of any such party, no part of said damage or loss shall be charged to, or
borne by Landlord or Prime Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.4 <U>Bursting of Pipes, etc.</U> Landlord shall not be liable for any injury or
damage to persons or property resulting from fire, explosion, seismic events,
earthquakes, falling plaster or tiles, steam, gas, electricity, electrical disturbance,
water, rain or snow or leaks from any part of the Building or from the pipes,
appliances or plumbing works or from the roof, street or sub-surface or from any
other place or caused by any other cause of whatever nature, unless caused by or
due to the negligence of Landlord, its agents, servants or employees; nor shall
Landlord or its agents be liable for any such damage caused by other tenants or
persons in the Building or caused by operations in construction of any private,
public or quasi-public work; nor shall Landlord be liable for any latent defect in the
Demised Premises or elsewhere in the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.5 <U>Landlord&#146;s Insurance</U>. Landlord shall, at its sole expense, carry so-called &#147;all risk&#148; full replacement cost casualty insurance on the Building (exclusive
of Tenant&#146;s leasehold improvements, fixtures and equipment).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">14. ASSIGNMENT, MORTGAGING, SUBLETTING, ETC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 <U>Generally</U>. Tenant shall not voluntarily, involuntarily or by operation of law
assign, transfer, mortgage or otherwise encumber this Lease or any interest of Tenant therein, in
the whole or in part of the Premises or permit the Premises or any part thereof to be used or
occupied by others, without the prior written consent of Landlord and Landlord&#146;s mortgagee. Except
in connection with a public stock offering, a transfer of any of Tenant&#146;s stock or a transfer or
change of control of Tenant (if Tenant is a corporation), or a change in the composition of persons
or entities owning any interest in Tenant (if Tenant is not a corporation), or any
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
19
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">transfer
of Tenant&#146;s interest in the Lease by operation of law or by merger or consolidation of
Tenant with or into any other entity, firm or corporation, shall be deemed an assignment for
purposes of this Article&nbsp;14. Notwithstanding anything to the contrary in this Lease, except with
respect to Corporate Transfers (hereinafter defined) to a Competitor (as defined in Section&nbsp;14.2),
Tenant shall not be required to obtain Landlord&#146;s consent, and the terms of Sections&nbsp;14.2 and 14.3
of this Lease shall not apply, to any transfer of Tenant&#146;s stock or a transfer or change of
control of Tenant or other transfer to an entity which controls, is controlled by or is under
common control with Tenant or any successor to Tenant or which succeeds to substantially all of
Tenant&#146;s assets and business by merger, consolidation, reorganization or purchase or in connection
with an initial public offering (collectively referred to as &#147;Corporate Transfers&#148;). Tenant shall
give Landlord written notice at least thirty (30)&nbsp;days prior to the effective date of such
Corporate Transfer. As used herein, the terms &#147;controlled&#148; or &#147;controls&#148; or &#147;control&#148; shall mean
ownership of at least fifty-one percent (51%) of voting control of the relevant entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2 <U>Landlord&#146;s Options</U>. In connection with any request by Tenant for Landlord&#146;s
consent to assignment or subletting, Tenant shall submit to Landlord in writing (&#147;Tenant&#146;s Sublease
Notice&#148;) (i)&nbsp;the name of the proposed assignee or subtenant, (ii)&nbsp;such information as to its
financial responsibility and standing as Landlord may reasonably require, and (iii)&nbsp;all of the
terms and provisions upon which the proposed assignment or subletting is to be made. Within ten
(10)&nbsp;business days after receipt from Tenant of Tenant&#146;s Sublease Notice and receipt of the
information required hereunder, Landlord shall have the following options: (a)&nbsp;reasonably
withholding its consent; (b)&nbsp;withholding consent in its absolute discretion if the proposed
assignee or sublessee is a &#147;Competitor&#148; (as that term is hereinafter defined); (c)&nbsp;if the request
is to sublet a portion of the Premises, to take back such portion of the Premises for the proposed
term of such sublease and to abate the Monthly Fixed Rent and Additional Rent accordingly; or
(d)&nbsp;if the request is to assign this Lease or sublet all of the Premises, to take back the Premises
for the proposed term of such assignment or sublease and to abate the Monthly Fixed Rent and
Additional Rent accordingly; in each case under clauses (c)&nbsp;and (d)&nbsp;above, effective as of the
date set forth in Tenant&#146;s Sublease Notice for commencement of the sublease term or for the
assignment. The term &#147;Competitor,&#148; as used herein shall mean any person or entity engaged in the
manufacture or sale of instruments for DNA sequencing or amplification, including, without
limitation, the following businesses and any affiliates, subsidiaries, parents or successors
thereto: PE Corp., Applera Corporation, PE Biosystems, Inc., Applied Biosystems, Inc., Celera
Genomics, Inc., Celera Genomics Group, F. Hoffmann-LaRoche Ltd., Hoffmann-LaRoche, Inc., Roche
Diagnostics Corporation, Roche Molecular Systems, Inc., Amersham Pharmacia Biotech, Ltd.,
Molecular Dynamics, Inc., Perkin Elmer Corporation, Strategene, Hybade Ltd., Ericomp, Techne
Corporation, MWG Biotech
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
20
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">AG,
Whatman Biometra, Labreco, Inc., Bio-Rad Laboratories, Inc., and Cepheid. In the event Landlord
shall exercise either option (c)&nbsp;or (d)&nbsp;above, Tenant shall sublease the Demised Premises, or
relevant portion thereof or assign this Lease to Tenant upon the terms and conditions set forth in
said Tenant&#146;s Sublease Notice. In the event Landlord shall exercise such option under clauses (c)
and (d), Tenant shall surrender possession of the entire Premises, or the portion which is the
subject of the option, as the case may be, on the date set forth in such notice in accordance with
the provisions of this Lease relating to surrender of the Premises at the expiration of the Term.
If the foregoing abatement of Monthly Fixed Rent relates only to a portion of the Premises or to a
portion of the Term, the abatement shall relate to the particular space and period of time in
question taking into account the rent paid per square foot for such space.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3 <U>Conditions</U>. Any subletting or assignment pursuant to this Article shall
be subject to and conditioned upon the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) at the time of any proposed subletting or assignment, Tenant
shall not be in default under any of the terms, covenants, or conditions of this
Lease beyond applicable grace periods;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the sublessee or assignee shall conduct its business in
accordance with the Permitted Use;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) prior to occupancy, Tenant and its assignee or sublessee shall
execute, acknowledge and deliver to Landlord a fully executed counterpart of
a written assignment of lease or a written sublease, as the case may be, by
the terms of which:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) in case of an assignment of this Lease in its entirety,
Tenant shall assign to such assignee Tenant&#146;s entire interest in this
Lease, together with all prepaid rents hereunder, and the assignee
shall accept said assignment and assume and agree to perform directly
for the benefit of Landlord, all of the terms, covenants and conditions
of this Lease on Tenant&#146;s part to be performed; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) in case of a subletting, the sublessee thereunder shall
agree to be bound by and to perform all of the terms, covenants and
conditions of this Lease on the Tenant&#146;s part to be performed during
the term of the sublease to the extent of the premises sublet, except the
payments of rents, charges and other sums reserved hereunder, which
Tenant shall continue to be obligated to pay and shall pay to Landlord;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Tenant shall pay to Landlord monthly fifty percent (50%) of the excess of the
rents and other charges received by Tenant pursuant to the
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
21
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">assignment or sublease over the rents and other charges reserved to Landlord under this
Lease attributable to the space assigned or sublet, less the reasonable costs and expenses
of subleasing and less the unamortized cost of Tenant&#146;s leasehold improvements (but not
trade fixtures or equipment) paid for by Tenant, which cost shall be amortized over a ten
year basis commencing on the Term Commencement Date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Tenant and any guarantor of Tenant&#146;s obligations hereunder (hereinafter
&#147;Guarantor&#148;) shall acknowledge that, notwithstanding such assignment or sublease and
consent of Landlord thereto, Tenant and Guarantor shall not be released or discharged from
any liability whatsoever under this Lease and will continue to be liable with the same
force and effect as though no assignment or sublease had been made; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Tenant shall pay Landlord&#146;s reasonable costs including but not limited to
attorney&#146;s fees and Landlord&#146;s administrative and overhead costs, incurred in connection
with each such assignment or subletting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.4 <U>No Waiver</U>. The consent by Landlord to an assignment or subletting shall not in
any way be construed to relieve Tenant from obtaining the express consent of Landlord to any
further assignment or subletting for the use of all or any part of the Premises, nor shall the
collection of rent by Landlord from any assignee, sublessee or other occupant after default by
Tenant be deemed a waiver of this covenant or the acceptance of such assignee, sublessee or
occupant as tenant or a release of Tenant from the further performance by Tenant of the
obligations in this Lease on Tenant&#146;s part to be performed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">15. MISCELLANEOUS COVENANTS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1 <U>Rules and Regulations</U>. Tenant and Tenant&#146;s servants, employees, agents,
visitors and licensees will faithfully observe such Rules and Regulations as are attached hereto as
Exhibit&nbsp;C and made a part hereof or as Landlord hereafter at any time or from time to time may make
and may communicate in writing to Tenant and which in the reasonable judgment of Landlord shall be
necessary for the reputation, safety, care or appearance of the Property, or the preservation of
good order therein, or the operation or maintenance of the Property, or the equipment thereof, or
the comfort of tenants or others in the Building, provided, however, that in the case of any
conflict between the provisions of this Lease and any such Rules and Regulations, the provisions of
this Lease shall control, and provided further that nothing contained in this Lease shall be
construed to impose upon Landlord any duty or obligation to enforce such Rules and Regulations or
the terms, covenants or conditions in any other lease as against any other tenant and Landlord
shall not be liable to Tenant for violation of the same by any other tenant, its servants,
employees, agents, visitors, invitees or licensees.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
22
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.2 <U>Access to Premises</U>. Tenant shall: (i)&nbsp;permit Landlord to erect, use and
maintain pipes, ducts and conduits in and through the Demised Premises, provided the same do not
materially reduce the floor area or materially adversely affect the use or appearance thereof; (ii)
permit the Landlord and any Mortgagee to have free and unrestricted access to and to enter upon the
Demised Premises at all reasonable hours (upon 24 hours prior notice except in case of emergency)
for the purposes of inspection or of making repairs, replacements or improvements in or to the
Demised Premises or the Building or equipment (including, without limitation, sanitary, electrical,
heating, air conditioning or other systems) or of complying with all laws, orders and requirements
of governmental or other authority or of exercising any right reserved to Landlord by this Lease
(including the right during the progress of any such repairs, replacements or improvements or while
performing work and furnishing materials in connection with compliance with any such laws, orders
or requirements to take upon or through, or to keep and store within, the Demised Premises all
necessary materials, tools and equipment); and (iii)&nbsp;permit Landlord, at reasonable times and upon
24 hours prior notice, to show the Demised Premises during ordinary business hours to any
Mortgagee, prospective purchaser of any interest of Landlord in the Property, prospective
Mortgagee, or prospective assignee of any Mortgage, and during the period of twelve months next
preceding the Termination Date to any person contemplating the leasing of the Demised Premises or
any part thereof. If Tenant shall not be personally present to open and permit any entry into the
Demised Premises at any time when for any reason an entry therein shall be necessary or permissible
pursuant to the terms of this Lease or by law, Landlord or Landlord&#146;s agents must nevertheless be
able to gain such entry by contacting a responsible representative of Tenant, whose name, address
and telephone number shall be furnished by Tenant. Provided that Landlord shall not be obligated to
employ labor at so-called &#147;over-time&#148; or other premium pay rates, Landlord shall exercise its
rights of access to the Demised Premises permitted under any of the terms and provisions of this
Lease in such manner as to minimize to the extent practicable interference with Tenant&#146;s use and
occupation of the Demised Premises. Notwithstanding the foregoing, any entry (other than in case of
emergency) by Landlord, any Mortgagee or any of their agents or representatives shall be subject to
Tenant&#146;s reasonable health, safety and security requirements, including but not limited to the
requirement that a representative of Tenant accompany such parties when in certain parts of the
Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.3 <U>Accidents to Sanitary and other Systems</U>. Tenant shall give to Landlord prompt
notice of any fire or accident in the Demised Premises or in the Building and of any damage to, or
defective condition in, any part or appurtenance of the Building&#146;s sanitary, electrical, heating
and air conditioning or other systems located in, or passing through, the Demised Premises.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
23
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.4 <U>Signs, Blinds and Drapes</U>. Tenant shall not place any signs on the
exterior of the Building or on or in any window, public corridor or door visible from
the exterior of the Demised Premises. No drapes or blinds may be put on or in any
exterior window.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.5 <U>Estoppel Certificate</U>. Tenant shall at any time and from time to time
upon not less than ten business (10)&nbsp;days&#146; prior notice by Landlord, Prime Landlord
or by a Mortgagee to Tenant, execute, acknowledge and deliver to the party making
such request a statement in writing certifying that this Lease is unmodified and in
full force and effect (or if there have been modifications, that the same is in full
force and effect as modified and stating the modifications), and the dates to which
Rent has been paid in advance, if any, and stating whether or not to the actual
knowledge and belief of the signer of such certificate Landlord is in default in
performance of any covenant, agreement, term, provisions or condition contained in
this Lease and, if so, specifying each such default of which the signer may have
knowledge, it being intended that any such statement delivered pursuant hereto
may be relied upon by any prospective purchaser of any interest in the Property,
any Mortgagee or prospective Mortgagee, any lessee or prospective lessee thereof,
any prospective assignee of any Mortgage, or any other party designated by
Landlord. The form of any such estoppel certificate requested by a Mortgagee shall
be reasonably satisfactory to such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.6 <U>Requirements of Law &#151; Fines and Penalties</U>. Tenant at its sole expense
shall comply with all laws, rules, orders and regulations of Federal, State, County
and Municipal Authorities and with any direction of any public officer or officers,
pursuant to law, which shall impose any duty upon Landlord or Tenant with respect
to and arising out of Tenant&#146;s use or occupancy of the Demised Premises. If Tenant
receives notice of any violation of law, ordinance, order or regulation applicable to
the Demised Premises, it shall give prompt notice thereof to Landlord. Without
limiting the generality of the foregoing, Tenant shall be responsible for compliance
with requirements imposed by the Americans with Disabilities Act relative to the
Demised Premises, including without limitation all such requirements applicable to
removing barriers, furnishing auxiliary aids and ensuring that, whenever
alterations are made, the affected portions of the Demised Premises are readily
accessible to and usable by individuals with disabilities. Notwithstanding anything
in the foregoing to the contrary, if the requirement of additional work in the
Demised Premises is caused by governmental action solely as result of work being
done by Landlord in parts of the Building other than the Demised Premises or as a
result of the general use or occupancy of the building itself, then Landlord shall be
responsible for the cost of such ADA work. Conversely, if additional ADA work in
the Building is caused by governmental action solely as a result of work in the
Demised Premises by Tenant or as a result of Tenant&#146;s particular use of the
Premises, then Tenant shall be responsible for the cost of such ADA work.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.7 <U>Tenant&#146;s Acts &#151; Effect on Insurance</U>. Tenant shall not do or permit to be done
any act or thing upon the Demised Premises or elsewhere in the Building which will invalidate or be
in conflict with any insurance policies covering the Building and the fixtures and property therein
and shall not do, or permit to be done, any act or thing upon the Demised Premises which shall
subject Landlord to any liability or responsibility for injury to any person or persons or to
property by reason of any business or operation being conducted on the Demised Premises or for any
other reason. Subject to the terms of this Lease and except as otherwise specifically set forth to
the contrary herein, Tenant at its own expense shall comply with all applicable provisions of the
California Health and Safety Code and all regulations promulgated thereunder and with all rules,
orders, regulations or requirements of the underwriter(s) of the fire and other hazard insurance for
the Property and the Demised Premises and shall not do, or permit anything to be done, in or upon
the Demised Premises, or bring or keep anything therein, that is not permitted by the City of South
San Francisco Fire Department, or other authority having jurisdiction, and then only in such
quantity and manner of storage as will not increase the rate for any insurance applicable to the
Building. If by reason of failure of Tenant to comply with the provisions hereof the insurance rate
applicable to any policy of insurance shall at any time thereafter be higher than it otherwise
would be, then Tenant shall reimburse Landlord for that part of any insurance premiums thereafter
paid by Landlord, which shall have been charged because of such failure by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.8 <U>Miscellaneous</U>. Tenant shall not suffer or permit the Demised Premises or any
fixtures, equipment or utilities therein or serving the same, to be overloaded, damaged or defaced.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">16. DAMAGE BY FIRE, ETC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of loss of, or damage to, the Demised Premises or the Building by fire or other
casualty, the rights and obligations of the parties hereto shall be as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If the Demised Premises, or any part thereof, shall be damaged by fire or
other casualty, Tenant shall give prompt notice thereof to Landlord, and Landlord, upon
receiving such notice and the insurance proceeds for such casualty, shall proceed in a
commercially reasonable manner, subject to unavoidable delays, to repair, or cause to be
repaired, such damage to the extent hereinafter provided. If the Demised Premises or any
part thereof shall be rendered untenantable by reason of such damage, whether to the Demised
Premises or to the Building, Yearly Fixed Rent shall proportionately abate for the period
from the date of such damage to the date when such damage shall have been repaired by
Landlord.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
25
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If, as a result of fire or other casualty, the whole or a substantial portion
of the Building is rendered untenantable and the nature and extent of the damage is such
that in Landlord&#146;s opinion, taking into account a reasonable time for adjusting loss and
obtaining plans and permits for restoration, the Demised Premises cannot be made tenantable
within 180&nbsp;days after such event, Landlord, within ninety (90)&nbsp;days from the date of such
fire or casualty, may terminate this Lease by notice to Tenant, specifying a date not less
than thirty (30)&nbsp;nor more than sixty (60)&nbsp;days after the giving of such notice on which the
Term of this Lease shall terminate. If Landlord does not so elect to terminate this Lease,
then Landlord shall (to the extent that proceeds of insurance required to be carried by
Landlord, net of any portion thereof retained by a Mortgagee, are made available for such
purpose) proceed with diligence to repair the damage to the Demised Premises and all
facilities serving the same, if any, which shall have occurred, and the Yearly Fixed Rent
shall meanwhile proportionately abate, all as provided in Paragraph (a)&nbsp;of this Section.
However, if such damage is not repaired and the Demised Premises restored to substantially
the same condition as they were prior to such damage within one (1)&nbsp;year from the date of
such damage, Tenant within thirty (30)&nbsp;days from the expiration of such one (1)&nbsp;year period
or from the expiration of any extension thereof by reason of unavoidable delays as
hereinafter provided, may terminate this Lease by notice to Landlord, specifying a date not
more than sixty (60)&nbsp;days after the giving of such notice on which the Term of this Lease
shall terminate. The period within which the required repairs may be accomplished shall be
extended by the number of days, lost as a result of unavoidable delays, which
term shall be defined to include all delays referred to in Article&nbsp;24.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If the Demised Premises shall be rendered untenantable by fire
or other casualty during the last year of the Term of this Lease, Landlord may terminate this Lease effective as of the date of such fire or other casualty
upon notice to Tenant given within ninety (90)&nbsp;days after such fire or other
casualty. Notwithstanding the foregoing to the contrary, in the event
Landlord exercises the foregoing termination right, if Tenant has available to
it the option to extend and validly exercises said option, Tenant may defeat
said termination notice by the valid exercise of said option term so as to add
an additional five years on to the Term of this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Landlord shall not be required to repair or replace any of
Tenant&#146;s leasehold improvements, fixtures, business machinery, equipment,
cabinet work, furniture, personal property or other installations (all of which
shall, however, be restored by Tenant within a reasonable time after
Landlord shall have completed any repair or restoration required under the
terms of this Article), and no damages, compensation or claim shall be
payable by Landlord for inconvenience, loss of business or annoyance arising
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
26
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">from any repair or restoration of any portion of the Demised Premises or of
the Building.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The provisions of this Article shall be considered an express
agreement governing any instance of damage or destruction of the Building
or the Demised Premises by fire or other casualty, and any law now or
hereafter in force providing for such a contingency in the absence of express
agreement shall have no application.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) In the event of any termination of this Lease pursuant to this
Article, the Term of this Lease shall expire as of the effective termination
date as fully and completely as if such date were the date originally fixed
herein for the end of the Term of this Lease. Tenant shall have access to the
Demised Premises for a period of fifteen (15)&nbsp;days after the date of
termination in order to remove Tenant&#146;s personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Landlord&#146;s Architect&#146;s certificate, given in good faith, shall be
deemed conclusive of the statements therein contained and binding upon
Tenant with respect to the performance and completion of any repair or
restoration work undertaken by Landlord pursuant to this Article or Article
18.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">17. WAIVER OF SUBROGATION
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any case in which Tenant shall be obligated under any provision of this Lease to pay to
Landlord or Prime Landlord any loss, cost, damage, liability, or expense suffered or incurred by
Landlord or Prime Landlord, Landlord shall allow to Tenant as an offset against the amount thereof
(i)&nbsp;the net proceeds of any insurance collected by Landlord for or on account of such loss, cost,
damage, liability, or expense, provided that the allowance of such offset does not invalidate the
policy or policies under which such proceeds were payable and (ii)&nbsp;if such loss, cost, damage,
liability or expense shall have been caused by a peril against which Landlord has agreed to procure
insurance coverage under the terms of this Lease, the amount of such insurance coverage, if not
actually procured by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any case in which Landlord or Prime Landlord shall be obligated under any provision of this
Lease to pay to Tenant any loss, cost, damage, liability or expense suffered or incurred by Tenant,
Tenant shall allow to Landlord as an offset against the amount thereof (i)&nbsp;the net proceeds of any
insurance collected by Tenant for or on account of such loss, cost, damage, liability, or expense,
provided that the allowance of such offset does not invalidate the policy or policies under which
such proceeds were payable and (ii)&nbsp;if such loss, cost, damage, liability or expense shall have
been caused by a peril against which Tenant has agreed to procure insurance
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
27
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">coverage under the terms of this Lease, the amount of such insurance coverage, if not actually
procured by Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto shall each endeavor to procure an appropriate clause in, or endorsement on,
any fire or extended coverage insurance policy covering the Demised Premises and the Building and
personal property, fixtures and equipment located thereon or therein, pursuant to which the
insurance companies waive subrogation or consent to a waiver of right of recovery, and having
obtained such clauses and/or endorsements of waiver of subrogation or consent to a waiver of right
of recovery each party hereby agrees that it will not make any claim against or seek to recover
from the other for any loss or damage to its property or the property of others resulting from fire
or other perils covered by such fire and extended coverage insurance; provided, however, that the
release, discharge, exoneration and covenant not to sue herein contained shall be limited by the
terms and provisions of the waiver of subrogation clauses and/or endorsements or clauses and/or
endorsements consenting to a waiver of right of recovery and shall be co-extensive therewith. If
either party may obtain such clause or endorsement only upon payment of an additional premium, such
party shall promptly so advise the other party and shall be under no obligation to obtain such
clause or endorsement unless such other party pays the premium.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">18. CONDEMNATION - EMINENT DOMAIN
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the whole or more than 40% of the Building shall be taken or appropriated by
eminent domain or shall be condemned for any public or quasi-public use, or (by virtue of any such
taking, appropriation or condemnation) shall suffer any damage (direct, indirect or consequential)
for which Landlord or Tenant shall be entitled to compensation then (and in any such event) this
Lease and the Term hereof may be terminated at the election of Landlord by a notice in writing of
its election so to terminate which shall be given by Landlord to Tenant within sixty (60)&nbsp;days
following the date on which Landlord shall have received notice of such taking, appropriation or
condemnation. In the event that more than fifty percent (50%) of the floor area of the Demised
Premises or a substantial part of the means of access thereto within the perimeter of the Property
so as to substantially interfere with the use of the Demised Premises shall be so taken,
appropriated or condemned, then (and in any such event) this Lease and the Term hereof may be
terminated at the election of Tenant by a notice in writing of its election so to terminate which
shall be given by Tenant to Landlord within sixty (60)&nbsp;days following the date on which Tenant
shall have received notice of such taking, appropriation or condemnation. Tenant hereby waives the
benefits of California Code of Civil Procedure Section&nbsp;12165.130.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the giving of any such notice of termination (either by Landlord or Tenant) this Lease
and the Term hereof shall terminate on or retroactively as of the
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
28
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">date on which Tenant shall be required to vacate any part of the Demised Premises or shall be
deprived of a substantial part of the means of access thereto, provided, however, that Landlord may
in Landlord&#146;s notice elect to terminate this Lease and the Term hereof retroactively as of the date
on which such taking, appropriation or condemnation became legally effective. In the event of any
such termination, this Lease and the Term hereof shall expire as of the effective termination date
as fully and completely as if such date were the date originally fixed herein for the end of the
Term of this Lease. If neither party (having the right so to do) elects to terminate Landlord will,
with reasonable diligence and at Landlord&#146;s expense, restore the remainder of the Demised Premises,
or the remainder of the means of access thereto, as nearly as practicably may be to the same
condition as obtained prior to such taking, appropriation or condemnation in which event (i)&nbsp;a just
proportion of the Yearly Fixed Rent, according to the nature and extent of the taking,
appropriation or condemnation and the resulting permanent injury to the Demised Premises and the
means of access thereto, shall be permanently abated, and (ii)&nbsp;a just proportion of the remainder
of the Yearly Fixed Rent, according to the nature and extent of the taking, appropriation or
condemnation and the resultant injury sustained by the Demised Premises and the means of access
thereto, shall be abated until what remains of the Demised Premises and the means of access thereto
shall have been restored as fully as may be possible for permanent use and occupation by Tenant
hereunder. Except for any award specifically reimbursing Tenant for moving or relocation expenses
and Tenant&#146;s moveable personal property (but not leasehold improvements), there are expressly
reserved to Landlord all rights to compensation and damages created, accrued or accruing by reason
of any such taking, appropriation or condemnation, in implementation and in confirmation of which
Tenant does hereby acknowledge that Landlord shall be entitled to receive and retain all such
compensation and damages, grants to Landlord all and whatever rights (if any) Tenant may have to
such compensation and damages, and agrees to execute and deliver all and whatever further
instruments of assignment as Landlord may from time to time request. In the event of any taking of
the Demised Premises or any part thereof for temporary use, (i)&nbsp;this Lease shall be and remain
unaffected thereby, and (ii)&nbsp;Tenant shall be entitled to receive for itself any award made for such
use, provided, that if any taking is for a period extending beyond the Term of this Lease, such
award shall be apportioned between Landlord and Tenant as of the Termination Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">19. DEFAULT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.1 <U>Events of Default</U>. Occurrence of any of the following events shall constitute
an Event of Default under this Lease: (a)&nbsp;Tenant shall neglect or fail to perform or observe any of
the Tenant&#146;s covenants herein, including (without limitation) the covenants with regard to the
payment when due of Rent, which default continues, in the case of payment of Rent, for five (5)
days after notice of default or, in the case of defaults other then payment of Rent, for thirty
(30)&nbsp;days
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
29
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">after such notice of default (provided that if more time, but not more than 30 additional days) is
required lo complete such performance, Tenant shall not be in default if Tenant commences such
performance within the thirty (30)&nbsp;day period and thereafter diligently pursues its completion); or
(b)&nbsp;Tenant shall default in payment of Rent under Subparagraph (a)&nbsp;above more than two (2)&nbsp;times in
any consecutive twelve (12)&nbsp;month period, in which case no prior notice shall be required; or (c)
Tenant shall be involved in financial difficulties as evidenced by an admission in writing by
Tenant of Tenant&#146;s inability to pay its debts generally as they become due, or by the making or
offering to make a composition of its debts with its creditors; or (d)&nbsp;Tenant shall make an
assignment or trust mortgage, or other conveyance or transfer of like nature, of all or a
substantial part of its property for the benefit of its creditors; or (e)&nbsp;the leasehold hereby
created shall be taken on execution or by other process of law and shall not be revested in Tenant
within sixty (60)&nbsp;days thereafter; or (f)&nbsp;a receiver, sequester, trustee or similar officer shall
be appointed by a court of competent jurisdiction to take charge of all or a substantial part of
Tenant&#146;s property and such appointment shall not be vacated within sixty (60)&nbsp;days; or (g)&nbsp;any
proceeding shall be instituted by or against Tenant pursuant to any of the provisions of any Act of
Congress or State law relating to bankruptcy, reorganization, arrangements, compositions or other
relief from creditors, and, in the case of any such proceeding instituted against it, if Tenant
shall fail to have such proceeding dismissed within thirty (30)&nbsp;days or if Tenant is adjudged
bankrupt or insolvent as a result of any such proceeding; or (h)&nbsp;any event shall occur or any
contingency shall arise whereby this Lease, or the term and estate thereby created, would (by
operation of law or otherwise) devolve upon or pass to any person, firm or corporation other than
Tenant, except as expressly permitted under Article&nbsp;14 hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.2 <U>Remedies Available upon Default</U>. Upon the occurrence of an Event of Default,
Landlord shall have the following remedies to the extent available under applicable law, which
shall not be exclusive but shall be cumulative and shall be in addition to any other remedies now
or hereafter allowed by law:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Landlord may terminate Tenant&#146;s right to possession of the Premises at any
time by written notice to Tenant. Tenant expressly acknowledges that in the absence of such
written notice from Landlord, no other act of Landlord, including re-entry into the
Premises, efforts to relet the Premises, reletting of the Premises for Tenant&#146;s account,
storage of Tenant&#146;s personal property and trade fixtures, acceptance of keys to the Premises
from Tenant or exercise of any other rights and remedies under this Section, shall
constitute an acceptance of Tenant&#146;s surrender of the Premises or constitute a termination
of this Lease or of Tenants right to possession of the Premises. Upon such termination in
writing of Tenant&#146;s right to possession of the Premises, as herein provided, this Lease
shall terminate and Landlord shall be entitled to recover damages from Tenant as provided in
California Civil
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
30
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Code Section&nbsp;1951.2 and any other applicable existing or future Law providing for
recovery of damages for such breach, including the worth at the time of award of the amount
by which the rent which would be payable by Tenant here under for the remainder of the Term
after the date of the award of damages, including Additional Rent as reasonably estimated
by Landlord, exceeds the amount of such rental loss as Tenant proves could have been
reasonably avoided, discounted at the discount rate published by the Federal Reserve Bank
of San Francisco for member banks at the time of the award plus one percent (1%).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Landlord shall have the remedy described in California Civil
Code Section&nbsp;1951.4 (Landlord may continue this Lease in effect after
Tenant&#146;s breach and abandonment and recover rent as it becomes due, if
Tenant has the right to sublet or assign, subject only to reasonable
limitations).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Landlord may immediately, or at any time thereafter, without
notice, cure said Event of Default for the account of Tenant. If Landlord at
any time is compelled to pay of elects to pay any sum of money, or do any act
which will require the payment of any sum of money, by reason of the failure
of Tenant to comply with any provision hereof, or if Landlord is compelled to
or does incur any expense, including without limitation reasonable attorneys&#146;
fees, in instituting, prosecuting and/or defending any action or proceeding
arising by reason of any default of Tenant hereunder, Tenant shall on
demand pay to Landlord by way of reimbursement the sum or sums so paid
by Landlord with all interest, costs and damages together with interest at the
Interest Rate for the period such sums remain outstanding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Landlord may remove all of Tenant&#146;s property from the
Premises, and such property may be stored by Landlord in a public
warehouse or elsewhere at the sole cost and for the account of Tenant. If
Landlord does not elect to store any or all of Tenant&#146;s property left in the
Premises, Landlord may consider such property to be abandoned by Tenant,
and Landlord may thereupon dispose of such property in the manner and as
prescribed by California Civil Code Section&nbsp;1980 et seq. Any proceeds realized
by Landlord on the disposal of any such property may be applied to offset all
expenses of storage and sale and as permitted under California Civil Code
Section&nbsp;1980 et seq.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The damages recoverable by Landlord pursuant to this Section
shall in all events include reimbursement of any concessions made by
Landlord in connection with the leasing of the Demised Premises to Tenant,
including without limitation (a)&nbsp;abated Rent, (b)&nbsp;allowances or improvements
in excess of any Building standard work, (c)&nbsp;sums paid to any former landlord
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
31
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">of Tenant under a so-called &#147;take-over&#148;, lease assumption or similar agreement and (d)
signing bonuses and other incentive payments. Any allowances, abated rent, signing bonuses,
incentive payments or takeover payments shall be deemed commercially reasonable if
recommended to Landlord by a reputable commercial real estate broker as being appropriate
and necessary for the leasing of said Premises to a creditworthy tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.3 <U>Grace Period</U>. Notwithstanding anything to the contrary in this Article
contained, Landlord agrees not to take any action to terminate this Lease (a)&nbsp;for default by Tenant
in the payment when due of Rent, if Tenant shall cure such default within five (5)&nbsp;days after
written notice thereof given by Landlord to Tenant, unless there has been two (2)&nbsp;or more defaults
in any 12-month period as set forth in Section&nbsp;19.1(b), or (b)&nbsp;for default by Tenant in the
performance of any other covenant, if Tenant shall cure such default within a period of thirty (30)
days after written notice thereof given by Landlord to Tenant (except where the nature of the
default is such that remedial action should appropriately take place sooner, as indicated in such
written notice), or with respect to covenants other than to pay a sum of money within such
additional period as may reasonably be required to cure such default if (because of governmental
restrictions or any other cause beyond the reasonable control of Tenant) the default is of such a
nature that it cannot be cured within such thirty (30)-day period, provided, however, (1)&nbsp;that
there shall be no extension of time beyond such thirty (30)-day period for the curing of any such
default unless, not more than ten (10)&nbsp;days after the receipt of the notice of default, Tenant in
writing (i)&nbsp;shall specify the cause on account of which the default cannot be cured during such
period and shall advise Landlord of its intention duly to institute all steps necessary to cure the
default and (ii)&nbsp;shall as soon as may be reasonable duly institute and thereafter diligently
prosecute to completion all steps necessary to cure such default and, (2)&nbsp;that no notice of the
opportunity to cure a default need be given, and no grace period whatsoever shall be allowed to
Tenant, if the default is incurable or if the subject of the breach which gave rise to the default
had, by reason of regular repetitive breaches on prior occasions (i.e., showing a pattern of
intentional conduct or indifferent regard to performance of the Lease), been the subject of prior
notices hereunder to cure such defaults.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">20. END
OF TERM &#151; ABANDONED PROPERTY
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the expiration or other termination of the Term of this Lease, Tenant shall peaceably
quit and surrender to Landlord the Demised Premises and all alterations and additions thereto which
Tenant is not entitled or required to remove under the provisions of this Lease, broom clean in
good order, repair and condition excepting only reasonable use and wear and damage by fire or other
casualty for which, under other provisions of this Lease, Tenant has no responsibility of repair or
restoration. Tenant&#146;s obligation to observe or perform this covenant shall survive the expiration
or other termination of the Term of this Lease. If the last day of the
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Term of this Lease or any renewal thereof falls on a day other than a Business Day, this Lease
shall expire on the Business Day immediately following. Tenant shall pay two (2)&nbsp;times the amount
of Rent applicable to each month (or fraction thereof) during which Tenant remains in possession
of any part of the Demised Premises in violation of the foregoing covenants, without prejudice to
eviction and any other remedy available to Landlord on account thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any personal property in which Tenant has an interest which shall remain in the Building or on
the Demised Premises after the expiration or termination of the Term of this Lease shall to the
extent in accordance with California Civil Code Section&nbsp;1980 et seq., be conclusively deemed to
have been abandoned, and may be disposed of in such manner as Landlord may see fit; provided,
however, notwithstanding the foregoing, that Tenant will, upon request of Landlord made not later
than ten (10)&nbsp;days after the expiration or termination of the Term hereof, promptly remove from the
Building any such personal property or, if any part thereof shall be sold, that Landlord may
receive and retain the proceeds of such sale and apply the same, at its option, against the
expenses of the sale, the cost of moving and storage, any arrears of Rent payable hereunder by
Tenant to Landlord and any damages to which Landlord may be entitled under Article&nbsp;19 hereof or
pursuant to law, with the balance if any, to be paid to Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">21. RIGHTS OF MORTGAGEES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.1 <U>Entry and Possession</U>. Upon entry and taking possession of the
Property by a Mortgagee, for the purpose of foreclosure or otherwise, such
Mortgagee shall have all the rights of Landlord, and shall be liable to perform all
the obligations of Landlord arising and accruing during the period of such
possession by such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.2 <u>Right to Cure</u>. No act or failure to act on the part of Landlord which
would entitle Tenant under the terms of this Lease, or by law, to be relieved of
Tenant&#146;s obligations hereunder or to terminate this Lease, shall result in a release
or termination of such obligations or a termination of this Lease unless (i)&nbsp;Tenant
shall have first given written notice of Landlord&#146;s act or failure to act to first
Mortgagees of record, if any, and to any other Mortgagees of whom Tenant has been
given written notice, specifying the act or failure to act on the part of Landlord
which could or would give basis to Tenant&#146;s rights; and (ii)&nbsp;such Mortgagees, after
receipt of such notice, have failed or refused to correct or cure the condition
complained of within a reasonable time thereafter, but nothing contained in this
paragraph shall be deemed to impose any obligation on any such Mortgagees to
correct or cure any such condition.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reasonable time&#148; as used above means and includes a reasonable time to obtain possession of
the land and Building if any such mortgagee elects to do so and
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
33
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">a reasonable time to correct or cure the condition if such condition is determined to exist.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.3 <U>Prepaid Rent</U>. No Rent shall be paid more than thirty (30)&nbsp;days prior
to the due dates thereof and, as to a first Mortgagee of record and any other
Mortgagees of whom Tenant has been given written notice, payments made in
violation of this provision shall (except to the extent that such Rent is actually
received by such Mortgagee) be a nullity as against such Mortgagee and Tenant
shall be liable for the amount of such payments to such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.4 <u>Continuing Offer</u>. The covenants and agreements contained in this
Lease with respect to the rights, powers and benefits of a Mortgagee (particularly,
without limitation thereby, the covenants and agreements contained in this Article)
constitute a continuing offer to any person, corporation or other entity, which by
accepting or requiring an assignment of this Lease or by entry or foreclosure
assumes the obligations herein set forth with respect to such Mortgagee; every such
Mortgagee is hereby constituted a party to this Lease as an obligee hereunder to the
same extent as though its name was written hereon as such; and such Mortgagee
shall be entitled to enforce such provisions in its own name.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.5 <u>Subordination</u>. This lease shall be subordinate to all mortgages
encumbering the Land and/or Building, but Tenant shall nevertheless have the
benefit of the non-disturbance provisions hereinafter set forth, and Tenant agrees,
at the request of Landlord or any Mortgagee, to execute and deliver promptly any
certificate or other instrument which Landlord or such Mortgagee may reasonably
request subordinating this Lease and all rights of Tenant hereunder to any
Mortgage, and to all advances made under such Mortgage and/or agreeing to attorn
to such Mortgagee in the event that it succeeds to Landlord&#146;s interest in the
Property. Landlord shall use reasonable efforts to request that (i)&nbsp;the holder of each
such Mortgage shall execute and deliver to Tenant said Lender&#146;s customary
non-disturbance agreement to the effect that, in the event of any foreclosure of such
Mortgage, such holder will not name Tenant as a party defendant to such
foreclosure nor disturb its possession under the Lease. In addition if the Prime
Lease shall be terminated due to foreclosure of the mortgage made by Prime
Landlord in favor of its mortgagee or due to such mortgagee&#146;s acceptance of a deed
in lieu of foreclosure, Tenant shall attorn to mortgagee as landlord hereunder and
this lease shall continue in full force and effect for its remaining term as a direct
lease between Tenant and such mortgagee without the necessity of any additional
act or agreement; provided, however, if requested by such Mortgagee, Tenant shall
execute and deliver a new lease with such mortgagee on the same terms and
conditions as set forth herein except that the term of such new lease shall be equal
to the then remaining term hereunder. Landlord represents and warrants that as
of the date of this Lease, Bank of America is the sole mortgagee of the Land and
Building. Landlord shall use reasonable efforts to obtain from Bank of America for
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
34
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the benefit of Tenant a Subordination, Non-Disturbance and Attornment Agreement in a commercially
reasonable standard form, which Tenant will also execute for the benefit of Bank of America,
providing for the subordination of the Lease, the attornment of Tenant to Bank of America, and the
non-disturbance of Tenant under this Lease and the other subleases of space within the Building as
long Tenant is not in default hereunder or thereunder. Tenant will reimburse Landlord for all
costs and expenses in connection with obtaining said agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.6 <U>Limitations on Liability</U>. Nothing contained in the foregoing Section
21.6 or in any such non-disturbance agreement or non-disturbance provision shall however, affect
the prior rights of the holder of any Mortgage with respect to the proceeds of any award in
condemnation or of any fire insurance policies affecting the Building, or impose upon any such
holder any liability (i)&nbsp;for the erection or completion of the Building, or (ii)&nbsp;in the event of
damage or destruction to the Building or the Demised Premises by fire or other casualty, for any
repairs, replacements, rebuilding or restoration except such repairs, replacements, rebuilding or
restoration as can reasonably be accomplished from the net proceeds of insurance actually received
by, or made available to, such holder, or (iii)&nbsp;for any default by Landlord under the Lease
occurring prior to any date upon which such holder shall become Tenant&#146;s landlord, or (iv)&nbsp;for any
credits, offsets or claims against the Rent as a result of any acts or omissions of Landlord
committed or omitted prior to such date, or (v)&nbsp;for return of any security deposit or other funds
unless the same shall have been received by such holder, and any such agreement or provision may so
state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>22. </I>QUIET ENJOYMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord covenants that if, and so long as, Tenant keeps and performs each and every covenant,
agreement, term, provision and condition herein contained on the part and on behalf of Tenant to be
kept and performed, Tenant shall quietly enjoy the Demised Premises from and against the claims of
all persons claiming by, through or under Landlord subject, nevertheless, to the covenants,
agreements, terms, provisions and conditions of this Lease and to all Mortgages to which this Lease
is subject and subordinate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without incurring any liability to Tenant, Landlord may permit access to the Demised Premises
and open the same, whether or not Tenant shall be present, upon any demand of any receiver,
trustee, assignee for the benefit of creditors, sheriff, marshall or court officer entitled to, or
reasonably purporting to be entitled to, such access for the purpose of taking possession of, or
removing Tenant&#146;s property or for any other lawful purpose (but this provision and any action by
Landlord hereunder shall not be deemed a recognition by Landlord that the person or official making
such demand has any right or interest in or to this Lease, or in or to the Demised
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
35
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Premises), or upon demand of any representative of the fire, police, building, sanitation or other
department of the city, county, state or federal governments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">23. ENTIRE AGREEMENT &#151; WAIVER &#151; SURRENDER
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.1 <U>Entire Agreement</U>. This Lease and the Exhibits made a part hereof
contain the entire and only agreement between the parties relating to the lease of
the Premises and any and all statements and representations, written and oral,
including previous correspondence and agreements between the parties hereto, are
merged herein. Tenant acknowledges that all representations and statements upon
which it relied in executing this Lease are contained herein and that Tenant in no
way relied upon any other statements or representations, written or oral. Any
executory agreement hereafter made shall be ineffective to change, modify,
discharge or effect an abandonment of this Lease in whole or in part unless such
executory agreement is in writing and signed by the party against whom
enforcement of the change, modification, discharge or abandonment is sought.
Nothing herein shall prevent the parties from agreeing to amend this Lease and the
Exhibits made a part hereof as long as such amendment shall be in writing and
shall be duly signed by both parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.2 <u>Waiver by Landlord</u>. The failure of Landlord to seek redress for
violation, or to insist upon the strict performance, of any covenant or condition of
this Lease, or any of the Rules and Regulations promulgated hereunder, shall not
prevent a subsequent act, which would have originally constituted a violation, from
having all the force and effect of an original violation. The receipt by Landlord of
Rent with knowledge of the breach of any covenant of this Lease shall not be
deemed a waiver of such breach. The failure of Landlord to enforce any of such
Rules and Regulations against Tenant and/or any other tenant or subtenant in the
Building shall not be deemed a waiver of any such Rules and Regulations. No
provisions of this Lease shall be deemed to have been waived by Landlord unless
such waiver be in writing signed by Landlord. No payment by Tenant or receipt by
Landlord of a lesser amount than the monthly rent herein stipulated shall be
deemed to be other than on account of the stipulated rent, nor shall any
endorsement or statement on any check or any letter accompanying any check or
payment as rent be deemed an accord and satisfaction, and Landlord may accept
such check or payment without prejudice to Landlord&#146;s right to recover the balance
of such rent or pursue any other remedy in this Lease provided.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.3 <u>Surrender</u>. No act or thing done by Landlord during the term hereby
demised shall be deemed an acceptance of a surrender of the Demised Premises,
and no agreement to accept such surrender shall be valid, unless in writing signed
by Landlord. No employee of Landlord or of Landlord&#146;s agents shall have any power
to accept the keys of the Demised Premises prior to the termination of this Lease.
The delivery of keys to any employee of Landlord or of Landlord&#146;s agents shall not
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
36
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">operate as a termination of the Lease or a surrender of the Demised Premises. In the event that
Tenant at any time desires to have Landlord underlet the Demised Premises for Tenant&#146;s account,
Landlord or Landlord&#146;s agents are authorized to receive the keys for such purposes without
releasing Tenant from any of the obligations under this Lease, and Tenant hereby relieves Landlord
of any liability for loss of or damage to any of Tenant&#146;s effects in connection with such
underletting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">24. INABILITY TO PERFORM &#151; EXCULPATORY CLAUSE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly provided in this Lease, this Lease and the obligations of Tenant
to pay Rent hereunder and perform all other covenants, agreements, terms, provisions and conditions
hereunder on the part of Tenant to be performed shall in no way be affected, impaired or excused
because Landlord is unable to fulfill any of its obligations under this Lease or is unable to
supply or is delayed in supplying any service expressly or impliedly to be supplied or is unable to
make or is delayed in making any repairs, replacements, additions, alterations, improvements or
decorations or is unable to supply or is delayed in supplying any equipment or fixtures if Landlord
is prevented or delayed from doing so by reason of any cause whatsoever beyond Landlord&#146;s
reasonable control, including but not limited to governmental preemption in connection with a
national emergency or by reason of any rule, order or regulation of any department or subdivision
thereof of any governmental agency or by reason of strikes, labor troubles, shortages of labor or
materials or conditions of supply and demand which have been or are affected by war, hostilities or
other similar or dissimilar emergency. In each such instance of inability of Landlord to perform,
Landlord shall exercise reasonable diligence to eliminate the cause of such inability to perform.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall neither assert nor seek to enforce any claim for breach of this Lease against any
of Landlord&#146;s assets other than Landlord&#146;s or Prime Landlord&#146;s interest in the Building of which
the Demised Premises are a part and in the rents, issues and profits thereof, and Tenant agrees to
look solely to such interest for the satisfaction of any liability of Landlord under this Lease, it
being specifically agreed that in no event shall Landlord (which term shall include, without
limitation any of the officers, trustees, directors, partners, beneficiaries, joint venturers,
managers, members, stockholders or other principals or representatives, disclosed or undisclosed,
of Landlord or any managing agent) ever be personally liable for any such liability. This paragraph
shall not limit any right that Tenant might otherwise have to obtain injunctive relief against
Landlord or to take any other action which shall not involve the personal liability of Landlord to
respond in monetary damages from Landlord&#146;s assets other than the Landlord&#146;s interest in said real
estate, as aforesaid. In no event shall Landlord ever be liable for consequential damages arising
from a breach of this Lease.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
37
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">25. BILLS AND NOTICES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notices required under this Lease shall be in writing and delivered by hand or mailed by
registered or certified mail or by nationally recognized overnight delivery service (such as
Federal Express) for next business day delivery to Landlord or Tenant at the addresses set forth in
Article&nbsp;1. Either party may at any time change the Address for such notices, consents, requests,
bills, demands or statements by delivering or mailing, as aforesaid, to the other party a notice
stating the change and setting forth the changed Address, provided such changed Address is within
the United States. Notices shall be deemed delivered upon the earlier of receipt or refusal of
receipt.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All bills and statements for reimbursement or other payments or charges due from Tenant to
Landlord hereunder shall be due and payable in full fifteen (15)&nbsp;days, unless herein otherwise
provided, after submission thereof by Landlord to Tenant. Tenant&#146;s failure to make timely payment
of any amounts indicated by such bills and statements within applicable notice and grace periods,
whether for work done by Landlord at Tenant&#146;s request, reimbursement provided for by this Lease or
for any other sums properly owing by Tenant to Landlord, shall be treated as a default in the
payment of Rent, in which event Landlord shall have all rights and remedies provided in this Lease
for the nonpayment of Rent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">26. SUCCESSORS AND ASSIGNS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The covenants, agreements, terms, provisions and conditions of this Lease shall bind and
benefit the successors and assigns of the parties hereto with the same effect as if mentioned in
each instance where a party hereto is named or referred to, except that no violation of the
provisions of Article&nbsp;14 hereof shall operate to vest any rights in any successor or assignee of
Tenant and that the provisions of this Article shall not be construed as modifying the conditions
of limitation contained in Article&nbsp;19 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If in connection with or as a consequence of the sale, transfer or other disposition of the
real estate (Land and/or Building, either or both, as the case may be) of which the Demised
Premises are a part Landlord ceases to be the owner of the reversionary interest in the Demised
Premises, Landlord shall be entirely freed and relieved from the performance and observance
thereafter of all covenants and obligations hereunder accruing thereafter on the part of Landlord
to be performed and observed, it being understood and agreed in such event (and it shall be deemed
and construed as a covenant running with the land) that the person succeeding to Landlord&#146;s
ownership of said reversionary interest shall thereupon and thereafter assume, and perform and
observe, any and ail of such covenants and obligations of Landlord.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
38
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">27. MISCELLANEOUS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.1 <U>Separability</U>. If any provision of this Lease or portion of such provision
or the application thereof to any person or circumstance is for any reason held
invalid or unenforceable, the remainder of the Lease (or the remainder of such
provision) and the application thereof to other persons or circumstances shall not be
affected thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.2 <u>Captions</u>. The captions are inserted only as a matter of convenience
and for reference, and in no way define, limit or describe the scope of this Lease nor
the intent of any provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.3 <u>Broker</u>. Each party represents and warrants that it has not directly or
indirectly dealt, with respect to the leasing of space in the Building, with any broker
or had its attention called to the Demised Premises or other space to let in the
Building, by any broker. Each party agrees to exonerate and save harmless and
indemnify the other against any claims for a commission by any other broker,
person or firm, with whom such party has dealt in connection with the execution
and delivery of this Lease or out of negotiations between Landlord and Tenant with
respect to the leasing of other space in the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.4 <u>Governing Law</u>. This Lease is made pursuant to, and shall be
governed by, and construed in accordance with, the laws of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.5 <U>Assignment of Lease and/or Rents</U>. With reference to any assignment
by Landlord or Prime Landlord of its interest in this Lease and/or the Rent payable
hereunder, conditional in nature or otherwise, which assignment is made to or held
by a bank, trust company, insurance company or other institutional lender holding
a Mortgage on the Building, Landlord and Tenant agree:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that the execution thereof by Landlord and acceptance thereof
by such Mortgagee shall never be deemed an assumption by such Mortgagee
of any of the obligations of the Landlord hereunder, unless such Mortgagee
shall, by written notice sent to the Tenant, specifically otherwise elect; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that, except as aforesaid, such Mortgagee shall be treated as
having assumed the Landlord&#146;s obligations hereunder only upon foreclosure
of such Mortgagee&#146;s Mortgage and the taking of possession of the Demised
Premises after having given notice of its intention to succeed to the interest of
the Landlord under this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.6
<u>Memorandum of Lease</u>. Neither party shall record this Lease;
provided, however, that either party shall at the request of the other, execute and
deliver a recordable memorandum of this Lease setting forth the parties to this
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
39
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lease, a description of the Demised Premises and the term of this Lease for recordation in
the Official records of the County of San Mateo.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.7 <U>Sublease</U>. Notwithstanding anything to the contrary herein, Landlord
and Tenant acknowledge that this is a sublease and that Landlord derives its estate
to the Demised Premises through the Prime Lease. Landlord represents and
warrants that, as of the date hereof, Prime Landlord and Landlord are under
common control. At such time as Landlord and Prime Landlord are no longer under
common control, the responsibility for furnishing services, repairs, restoration and
other similar functions of Landlord shall be performed by Prime Landlord, and
Landlord shall be required to use reasonable efforts to enforce the provisions of the
Prime Lease relating thereto, but without obligation to provide such services,
repairs, restoration, and the like, and Prime Landlord, by its consent hereto, agrees
that Tenant may enforce the provisions of the this Lease to provide such services
directly against Prime Landlord. Landlord shall have the right, but not the
obligation, to assign this Lease to Prime Landlord, and after such assignment this
Lease shall no longer be a sublease, but rather a direct lease between Tenant and
Prime Landlord. The effectiveness of this Lease is conditioned upon obtaining the
consent of Prime Landlord to this Lease in the form attached hereto and made a
part hereof as Exhibit&nbsp;E on or before December
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2001.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.8 <U>Holdover</U>. If for any reason Tenant retains possession of the Premises
or any part thereof after the termination of the Term or any extension thereof, such
holding over shall constitute a tenancy from month to month, terminable by either
party upon thirty (30)&nbsp;days prior written notice to the other party, and Tenant shall
pay Landlord monthly rental during the month to month tenancy computed at 200%
of the rent (including Yearly Fixed Rent and all additional rent) payable hereunder
for the final month of the last year of the Term prior to such holding over. The
month to month tenancy shall otherwise be on the same terms and conditions aa set
forth in this Lease, as far as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.9 <u>Lease Amendments</u>. Tenant acknowledges that amendments to this
Lease may be required in connection with the financing of the Land or Building and
Tenant hereby agrees that it will enter into any reasonable modifications requested
by a mortgagee in connection with such financing, provided the same do not
(a)&nbsp;increase the Monthly Fixed Rent or additional rents payable by Tenant or increase Tenant&#146;s
financial obligations hereunder; (b)&nbsp;reduce or extend the Term hereof; (c)&nbsp;change the Permitted
Use; or (d)&nbsp;otherwise materially impair Tenant&#146;s rights hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.10 <U>Sierra Point CCRs</U>. This Lease shall be subject to the Amended and
Restated Declaration of Covenants, Conditions and Restrictions for Sierra Point
recorded in the Official Records of San Mateo on October&nbsp;23, 1998, as Document No.
98-172218, as amended by that certain First Amendment to Amended and Restated
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
40
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Declaration of Covenants, Conditions and Restrictions for Sierra Point recorded in the Official
Records of San Mateo on August&nbsp;6, 1999, as Document No.&nbsp;1999-134787 (as amended, the &#147;CCRs&#148;).
Tenant shall comply with the CCRs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.11 <U>Financial Statements</U>. Tenant shall furnish Landlord with complete audited
financial statements within one hundred twenty (120)&nbsp;days after the close of each fiscal year of
Tenant prepared by a certified public accountant (but not necessarily certified statements) and
shall, upon written request from Landlord, provide copies of Tenant&#146;s quarterly unaudited
financial statements within fifteen (15)&nbsp;days after Landlord&#146;s request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">28. SECURITY DEPOSIT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.1 <U>Security Deposit</U>. Tenant has deposited with Landlord the Security Deposit
described in Article&nbsp;1 hereof as security for the faithful performance and observance by Tenant of
the terms, provisions, covenants and conditions of this Lease, and it is agreed that if an Event of
Default by Tenant exists in respect of any of the terms, provisions, covenants and conditions of
this Lease, including, but not limited to, the payment of Rent, Landlord may use, apply or retain
the whole or any part of the security so deposited to the extent required for the payment of any
Rent or any other sum as to which there exists an Event of Default by Tenant or for any sum which
Landlord may expend or may he required to expend by reason of Tenant&#146;s Event of Default in respect
of any of the terms, provisions, covenants and conditions of this Lease, including, but not limited
to, any damages or deficiency accrued before or after summary proceedings or other re-entry by
Landlord. Upon the expiration or earlier termination of this Lease, and providing there exists no
default or Event of Default hereunder, any remaining balance of the Security Deposit (including,
without limitation, any and all interest accrued thereon) shall be returned by Landlord to Tenant
after the date fixed as the end of the Term and not later than thirty (30)&nbsp;days after delivery of
entire possession of the Premises to Landlord as provided hereunder. In the event of a sale of the
Land and Building or leasing of the Building, of which the Premises form a part, Landlord shall
have the right to transfer the security to the vendee or lessee and Landlord shall thereupon be
released by Tenant from all liability for the return of such security, and Tenant agrees to look
solely to the new Landlord for the return of said security, and it is agreed that the provisions
hereof shall apply to every transfer or assignment made of the security to a new Landlord. Tenant
further covenants that it will not assign or encumber or attempt to assign or encumber the monies
deposited herein as security and that neither Landlord nor its successors or assigns shall be bound
by any such assignment, encumbrance, attempted assignment or attempted encumbrance. In the event
Landlord applies pr retains any portion or all of the security deposited pursuant to the terms of
this Section&nbsp;28.1, Tenant shall forthwith restore the amount so
applied or retained so
that at all times the amount deposited shall be the full amount of the security deposit required at
the relevant time.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
41
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Landlord shall not be responsible for the payment of any interest on the Security
Deposit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">29. FURNITURE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Premises includes nineteen (19)&nbsp;new modular offices and twenty nine (29)&nbsp;new workstations,
which are the property of Landlord and must be returned to Landlord upon the termination of this
Lease for any reason in good and first class condition, reasonable wear and tear and acts of God
excepted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Landlord and Tenant have caused this instrument to be executed under seal,
all as of the day and year first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">MJ RESEARCH COMPANY, INC.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">FLUIDIGM CORPORATION</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Illegible
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Illegible</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Its
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VP MFG</TD>
</TR>


<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>


<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">title (duly-authorized)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">title (duly-authorized)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943247.gif" alt="(MAP OF FACILITY)">
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943248.gif" alt="(1ST FLOOR LEASING PLAN)">
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT B</u>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><u>CLEANING SCHEDULE</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">I. <U>Premises</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Daily on Business Days</U>:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empty all waste receptacles and ash trays and remove waste materials
from the Premises.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and dust mop all uncarpefced areas using a dust-treated mop.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Vacuum all rugs and carpeted areas.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Hand dust and wipe clean with treated cloths all horizontal cleared
surfaces including desk tops, office equipment, window sills, door<BR>
ledges, chair rails and counter tops, within normal reach.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash clean all water fountains.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon completion of cleaning, all lights will be turned off and doors
locked, leaving the Premises in an orderly condition.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quarterly</U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Render high dusting not reached in daily cleaning to include:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting all pictures, frames, charts, graphs and similar wall hangings.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting all vertical surfaces, such as walls, partitions, doors and ducts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting of all pipes, ducts and high moldings.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">II. <U>Lavatories</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Daily on Business Days</U>:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and damp mop floors.<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clean all mirrors, powder shelves, dispensers and receptacles, bright
work, flushometers, pipes and toilet seats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash both sides of all toilet seats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash all basins, bowls and urinals.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dust and clean all powder room fixtures.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empty and clean paper towel and sanitary disposal receptacles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">g.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Remove waste paper and refuse.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">h.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Refill tissue holders, soap dispensers, towel dispensers, vending
sanitary dispensers; materials to be furnished by Landlord,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A sanitizing solution will be used in all lavatory cleaning.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Monthly</U>:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Machine scrub lavatory floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash all partitions and tile walls in lavatories.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">III. <U>Main Lobby, Elevators, Building Exterior and Corridors</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Daily on Business Days</U>:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and wash or spray buff all marble floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep all entrance mats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clean elevators, wash or vacuum floors, wipe down walls and doors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Spot clean any metal work surrounding building entrance doors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Monthly</u>:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All resilient tile floors in public areas to be treated equivalent to spray
buffing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">IV. <u>Window Cleaning</u>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The outside of exterior wall windows will be washed once every three months, weather
permitting, and the inside of exterior wall windows will be washed every six months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">V. Tenants requiring services in excess of those described above shall request
same through Landlord, at Tenant&#146;s expense.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
2
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT C<BR>RULES AND
REGULATIONS</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The sidewalks, entrances, passages, courts, elevators, vestibules,
stairways, corridors or halls of the Building shall not be obstructed or encumbered
or used for any purpose other than ingress and egress to and from the premises
demised to any tenant or occupant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;No awnings or other projections shall be attached to the outside walls
or windows of the Building without the prior consent of Landlord. No curtains,
blinds, shades, or screens shall be attached or hung in, or used in connection with,
any window or door of the premises demised to any tenant or occupant, without the
prior consent of Landlord. Such awnings, projections, curtains, blinds, shades,
screens, or other fixtures must be of a quality type, design and color, and attached
in a manner, approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;No sign, advertisement, object, notice or other lettering shall be
exhibited, inscribed, painted or affixed on any part of the outside or inside of the
premises demised to any tenant or occupant or of the Building without the prior
consent of Landlord. Interior signs on doors and directory tables, if any, shall be of
a size, color and style approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The sashes, sash doors, skylights, windows, and doors that reflect or
admit light and air into the halls, passageways or other public places in the
Building shall not be covered or obstructed, nor shall any bottles, parcels, or other
articles be placed on any window sills.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;No show cases or other articles shall be put in front of or affixed to any
part of the exterior of the Building, nor placed in the halls, corridors, vestibules or
other parts of the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The water and wash closets and other plumbing fixtures shall not be
used for any purposes other than those for which they were constructed, and no
sweepings, rubbish, rags, or other substances shall be thrown therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;No tenant or occupant shall mark, paint, drill into, or in any way
deface any part of the Building or the premises demised to such tenant or occupant,
except to the extent required for the mounting of pictures and other normal office
fixtures. No boring, cutting or stringing of wires shall be permitted, except with the
prior consent of the Landlord, and as Landlord may direct. No tenant or occupant
shall install any resilient tile or similar floor covering in the premises demised to
such tenant or occupant except in a manner reasonably approved by Landlord.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;No bicycles, vehicles or animals of any kind (other than, animals
allowed under the Permitted Uses) shall be brought into or kept in or about the
premises demised to any tenant. Bicycles may be stored in racks, if any, furnished
for such purpose by Landlord in a common area of the Property. No cooking shall
be done or permitted in the Building (other than microwave use and coffee
machines) by any tenant without the approval of Landlord. No tenant shall cause
or permit any unusual or objectionable odors to emanate from the Premises demised
to such tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;Without the prior consent of Landlord, no space in the Building shall
be used for manufacturing, or for the sale of merchandise, goods or property of any
kind at auction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;No tenant shall make, or permit to be made, any unseemly or
disturbing noises or disturb or interfere with other tenants or occupants of the
Building or neighboring buildings or premises whether by the use of any musical
instrument, radio, television set or other audio device, unmusical noise, whistling,
signing, or in any other way. Nothing shall be thrown out of any doors or windows.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Each tenant must, upon the termination of its tenancy, restore to Landlord all keys of stores, storage areas, offices and toilet rooms, either furnished
to, or otherwise procured by, such tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;All removals from the Building, or the carrying in or out of the
Building or the premises demised to any tenant, of any sales, freight, furniture, or
bulky matter of any description must take place at such time and in such manner as
Landlord or its agents may determine, from time to time. Landlord reserves the
right to inspect all freight to be brought into the Building and to exclude from the
Building all freight which violates any of the Building Rules or the provisions of
such tenant&#146;s lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;No tenant shall use or occupy, or permit any portion of the premises
demised to such tenant to be used or occupied, as an office for a public stenographer,
messenger service or typist, or as a barber or manicure shop, or as an employment
bureau. No tenant or occupant shall engage or pay any employees in the Building,
except those actually working for such tenant or occupant in the Building, nor
advertise for laborers giving an address at the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;No tenant or occupant shall purchase spring water, ice, food, beverage,
lighting maintenance, cleaning towels or other like service, from any company or
person not approved by Landlord, such approval not unreasonably to be withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;Landlord shall have the right to prohibit any advertising by any tenant or occupant which, in Landlord&#146;s opinion, tends to impair the reputation of the
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
2
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Building or its desirability as a building for offices, and upon notice from Landlord, such
tenant or occupant shall refrain from or discontinue such advertising.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;Landlord reserves the right to exclude from the Building, between the
hours of 6:00 p.m. and 8:00 a.m. on Business Days and otherwise at all hours, all
persons who do not present adequate identification or a pass to the building signed
by the Landlord. Landlord will furnish passes to persons for whom any tenant
requests such passes. Each tenant shall be responsible for all persons for whom it
requests such passes and shall be liable to Landlord for all wrongful acts of such
persons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;Each tenant, before closing and leaving the premises demised to such tenant at any time, shall see that all entrance doors are locked and windows closed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;Each tenant shall, at its expense, provide artificial light in the
premises demised to such tenant for Landlord&#146;s agency, contractors, and employees
while performing janitorial or other cleaning services and making repairs or
alterations in said premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;No
premises shall be used, or permitted to be used, for lodging or sleeping, or for any immoral or illegal purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;There shall not be used in the Building, either by any tenant or
occupant or by their agents or contractors, in the delivery or receipt of merchandise,
freight or other matter, any hand trucks or other means of conveyance except those
equipped with rubber tires, rubber side guards and such other safeguards as
Landlord may require.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;Canvassing, soliciting and peddling in the Building are prohibited and each tenant and occupant shall co-operate in seeking their prevention.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;If the premises demised to any tenant become infested with vermin,
such tenant, at its sole cost and expense, shall cause its premises to be
exterminated from time to time, to the satisfaction of Landlord, and shall employ
such exterminators therefor as shall be approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;No premises shall be used, or permitted to be used, at any time,
without the prior approval of Landlord, as a store for the sale or display of goods,
wares or merchandise of any kind, or as a restaurant, shop, booth, bootblack or
other stand, or for the conduct of any business or occupation which predominantly
involves direct patronage of the general public in the premises demised to such
tenant, or for manufacturing or for other similar purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.&nbsp;No tenant shall move, or permit to be moved, into or out of the
Building or the premises demised to such tenant, any heavy or bulky matter,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
3
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">without the specific approval of Landlord. If any such matter requires special handling, only a
person holding a Master Rigger&#146;s license shall be employed to perform such special handling. No
tenant shall place, or permit to be placed, on any part of the floor or floors of the premises
demised to such tenant, a load exceeding the floor load per square foot which such floor was
designed to carry and which is allowed by law. Landlord reserves the right to prescribe the weight
and position of safes and other heavy matter, which must be placed so as to distribute the weight.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.&nbsp;The requirements of tenants will be attended to only upon application at the office
of the Building. Building employees shall not be required to perform, and shall not be requested by
any tenant or occupant to perform, any work outside of their regular duties, unless under specific
instructions from the office of the managing agent of the Building.
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT D</U>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>LIST OF ENVIRONMENTAL REPORTS GIVEN TO TENANT</U>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ENVIRONMENTAL DUE DILLIGENCE REVIEW OF THE SIERRA POINT ASSOCIATES TWO PROPERTIES
BRISBANE AND SOUTH SAN FRANCISCO, CALIFORNIA</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared for</I><BR>
Jon K. Wactor of Luce Forward, Hamilton and Scripps as attorney for potential purchaser
Opus West Corporation, Plessanton, California
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared By</I><BR>
ENVIRON Corporation, Emeryville, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
February&nbsp;4, 1998<BR>
Project No.&nbsp;03-6248A

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>UPDATE OF ENVIRONMENTAL DUE DILLIGENCE REVIEW, PARCEL 10, SHORELINE COURT, SIERRA
POINT, SOUTH SAN FRANCISCO, CALIFORNIA</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared For</I><BR>
MJ Sierra Point, LLC, South San Francisco, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared By</I><BR>
Harding Lawson Associates, Novato, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
December&nbsp;14,1998<BR>
HLA Project No.&nbsp;43142 001

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIRST AMENDED AND RESTATED DECLARATION OF COVENANTS, CONDITIONS AND ENVIRONMENTAL
RESTRICTIONS RELATING TO
ENVIRONMENTAL COMPLIANCE FOR SIERRA POINT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Recorded By</I><BR>
Luce, Forward, Hamilton and Scripps, San Diego, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
August&nbsp;5, 1999

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUPPLEMENTAL ENVIRONMENTAL DUE DILLIGENCE, PARCEL 10,
SHORELINE COURT, SIERRA POINT, SOUTH SAN FRANCISCO, CALIFORNIA</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared by</I><BR>
Harding Lawson Associates, Novato, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
August&nbsp;24, 1999
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT E</U>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>FORM OF PRIME LANDLORD CONSENT</U>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>FORM OF<BR>CONSENT OF<BR>MASTER LANDLORD</B></U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mountain Cove Tech Center LLC (&#147;Master Landlord&#148;),
the lessor, under that certain Lease, dated as of November&nbsp;&nbsp;&nbsp;&nbsp;, 1999 (herein the &#147;Master Lease&#148;) with MJ Research, Incorporated.,
(&#147;Landlord&#148;) as lessee, affecting that certain 141,677 square foot premises commonly known as the
Mountain Cove Tech Center, South San Francisco, California (&#147;Master Lease Premises&#148;), hereby
consents to the above First Amendment to Lease, relating to that certain Lease, dated as of
December&nbsp;1, 2001, by and between Landlord, as lessor, and Fluidigm Corporation, a California
corporation (&#147;Tenant&#148;), as lessee (as so amended, the &#147;Lease&#148;) subject to and in consideration of
the covenants, representations and agreements set forth below in this Consent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;In consideration of such consent the Master Landlord, Landlord, and Tenant hereby agree and acknowledge that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">A. All capitalized terms not defined in this Consent shall have the meanings given to such terms in the First Amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">B. A true correct and complete copy of the Master Lease is attached as Exhibit&nbsp;F to the First Amendment;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">C. As of the date hereof, the Master Lease is in full force and
effect and, to the actual knowledge of Master Landlord there is no
default (nor any circumstance which with the giving of notice or the
passage of time would result in a default) by Landlord or Master
Landlord under the Master Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;This Consent shall not be deemed to release the lessee under the
Master Lease or be a consent to any other or future amendment of the Lease, nor a
waiver of the restriction on assignment and subletting contained in the Master
Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;So long as the Lease has not been terminated and notwithstanding anything to the contrary in the Master Lease or the Lease:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">A. Master Landlord agrees to perform the obligations of
Landlord under Sections 16(a) and 16(b) of the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">B. (Intentionally Omitted)
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">C. The consent of Master Landlord for subleasing and
assignment shall not be withheld if the consent of Landlord may not
be withheld under Section&nbsp;14 of the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">D. The insurance required of Tenant under the Lease will
satisfy any insurance requirement that may become applicable to
Tenant as a consequence of the Master Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">E. Tenant shall not be liable for, have any duty to reimburse
Master Landlord, Landlord, or any other party for, nor to perform
any order, requirement, liability, claim, action, judgment, loss, cost
or expense arising out of any hazardous substances located on or
about the Premises (other than those hazardous substances placed
on or about the Premises by Tenant or its agents, employees,
contractors, invitees, successors or assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The Lease is and remains subject and subordinate to the Master Lease and, except as
herein provided, a termination of the Master Lease may, at the election of Landlord, result in a
termination of the Lease. Notwithstanding the foregoing, if the Master Lease should terminate for
any reason, other than because of a breach of Tenant&#146;s obligation under the Lease, a taking by
eminent domain or subject to Section&nbsp;16 of the Lease above, the election of Master Landlord not to
restore the Building following a casualty, then this Lease shall become a direct lease between
Landlord and Tenant on the terms and conditions of the Lease and this Consent (except that the
Tenant shall look solely to the Landlord for return of the Security Deposit held by Landlord).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;SIGNATURES APPEAR ON NEXT PAGES&#093;</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Landlord has caused this instrument to be executed effective as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">MOUNTAIN COVE TECH CENTER LLC<BR>a California limited liability company<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;SIGNATURES CONTINUE ON FOLLOWING PAGES&#093;</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Landlord has caused this instrument to be executed effective as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">MJ RESEARCH, INCORPORATED,<BR>a Massachusetts corporation<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;SIGNATURES CONTINUE ON FOLLOWING PAGES&#093;</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">AGREED AND ACCEPTED:
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">FLUIDIGM CORPORATION;<BR>a California corporation<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left" style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B><I>First Amendment to Sublease</I></B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This First Amendment made as of this 25<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March, 2004 between MJ Research,
Incorporated (&#147;Landlord&#148;) and Fluidigm Corporation (&#147;Tenant&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">RECITALS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
and Tenant are parties to a certain Sublease dated December 1st, 2001 (the
&#147;Lease&#148;) with respect to space on the first floor at 7000 Shoreline Court, South San Francisco,
California (the &#147;Building&#148;). The parties agree that the Lease was dated as of December&nbsp;1, 2001.
The parties wish to amend the Lease by (i)&nbsp;amending the rent and term, (ii)&nbsp;adding on April&nbsp;1,
2004 an additional 6,323 rentable square feet to the first floor space, bringing the total of
first floor space to 18,824 rentable square feet, and (iii)&nbsp;adding 10,720 rentable square feet on
the second floor (the &#147;Second Floor Space&#148;). All of the existing space currently leased by Tenant
and the new space to be added on the first and second floors are located on the east wing of the
Building. This First Amendment to Sublease is sometimes hereinafter called the &#147;Amendment&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In consideration of the mutual promises and covenants herein made, the parties hereby agree
to amend the Lease as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;<U>First Floor Space</U>. Effective April&nbsp;1, 2004, the additional space on the
first floor comprising 6,323 rentable square feet shown as on the attached Exhibit&nbsp;A
is added to the Premises, and the total first floor space leased by Tenant will be
18,824 rentable square feet. The new first floor space is leased in an as-is condition,
provided that on or before April&nbsp;1, 2004, Landlord will, at its expense, install up to
two fume hood exhaust connections and ducting into the dry lab area in locations
designated by Tenant. Additionally, Landlord and Tenant agree to share the cost of
an air compressor and air dryer installation on or before June&nbsp;1, 2004 pursuant to
specifications mutually approved by Landlord and Tenant, which approval shall not
be unreasonably withheld or delayed, to be located on the first floor (up to a total
maximum cost of $20,000.00) (i.e., $10,000 each), the use of which compressor and
dryer system shall be equally shared between Landlord and Tenant. The location of
the exhaust connection, air compressor and air dryer system are set forth on Exhibit
A attached hereto. Said air compressor and dryer system shall remain the property
of the Landlord at the expiration of this Lease. Landlord hereby consents to Tenant
making the installations set forth on Exhibit&nbsp;B-l at Tenant&#146;s sole cost and expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;<U>Term</U>. The term of the Lease is extended so as to end on December&nbsp;31, 2007.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 1 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;<U>Second Floor Space</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 Effective on the Second Floor Term Commencement Date (as that term
is hereinafter defined) the Premises shall also include the 10,720 rentable square
feet on the second floor shown on Exhibit&nbsp;B-l attached hereto being the Second
Floor Space. The Second Floor Space shall be built out (&#147;Landlord&#146;s Work&#148;) on or
before the Second Floor Term Commencement Date by Landlord in accordance with
the outline specifications attached as Exhibit&nbsp;B-2 (the &#147;Outline Specifications&#148;) and
the architectural floor plan attached as Exhibit&nbsp;B-l and the &#147;Final Second Floor
Plans&#148; as described below. Attached to this Amendment as Exhibit&nbsp;B-l is the
preliminary architectural layout of the Second Floor (the &#147;Second Floor Plans&#148;)
approved by Landlord and Tenant. Landlord shall develop a final architectural
floor plan (the &#147;Final Second Floor Plans&#148;) for Tenant&#146;s review and approval, which
approval shall not be unreasonably withheld or delayed and which shall be
exercised in accordance with this Section&nbsp;3.1. Said plan shall be consistent with
and a logical extension of Exhibit&nbsp;B-l, the Outline Specifications and build-out of
the East wing. Tenant may require modifications to Exhibit&nbsp;B-l with respect to
open work areas and perimeter offices (but not lab locations) provided such
modifications (a)&nbsp;as to perimeter offices, have walls aligned with window mullions,
and (b)&nbsp;otherwise are consistent with the Outline Specifications. Finishes and
colors shall be as selected by Landlord and shall be generally consistent with those
in the East wing of the Building. Tenant shall within ten (10)&nbsp;days after
presentation by Landlord of the proposed final architectural Second Floor Plan,
respond with any comments or requested changes. Tenant shall also cooperate with
Landlord in an informal review process and shall meet with Landlord or its
architect from time to time as reasonably requested by Landlord. When the Second
Floor Plans have been so approved by the Tenant as provided herein, they shall be
deemed the Final Second Floor Plans and any clarifications or changes to the Final
Second Floor Plans shall require the written approval of Landlord and Tenant,
which approvals shall not be unreasonably withheld provided the same does not
materially delay completion of Landlord&#146;s Work (or the requesting party bears the
rental expense for such delay) or increase the cost thereof (or the party requesting
the change pays the additional cost thereof) or interfere with the intended use of the
Second Floor Space by Tenant. The completed working or construction drawings
and plans shall be logical evolutions of the Final Second Floor Plans; however,
Tenant agrees that its sole approval rights hereunder shall be with respect to the
architectural floor plan, not complete working or construction drawings and plans.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 Landlord agrees to use diligent efforts to substantially complete
Landlord&#146;s Work on or before January&nbsp;1, 2005, the Anticipated Second Floor Term
Commencement Date, but except as hereinafter set forth, shall have no liability to
Tenant if the actual Second Floor Term Commencement Date occurs later than
January&nbsp;1, 2005. If for reasons other than those beyond the control of Landlord, the
Second Floor Space is not ready for occupancy by June&nbsp;1, 2005, Tenant shall receive
a credit against the Rent payable for the remainder of the Premises equal to one (1)
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">day of free rent for the Second Floor Space for each day of such delay in addition until the Second
Floor space is deemed ready for occupancy as provided herein, provided, however, that the June&nbsp;1,
2005 date shall be extended one day for each day that completion of the Second Floor Space is
actually delayed because of (a)&nbsp;delays caused by change orders requested by Tenant after the Final
Second Floor Plans have been approved by Tenant as hereinbefore provided, (b)&nbsp;the failure of Tenant
to respond in a timely manner to the proposed Final Second Floor Plans as required above, or (c)
other acts of omissions of Tenant which are not corrected by Tenant within 48 hours after notice to
Tenant that the same is delaying the work. Landlord shall have access, as needed, to Tenant&#146;s space
on the first floor for purposes of performing Landlord&#146;s work, provided such access shall not
unreasonably interfere with the conduct of Tenant&#146;s business. Landlord shall use reasonable efforts
to minimize disruption to Tenant in connection with said construction, but shall not be deemed in
violation of the covenant of quiet enjoyment or other provision of the Lease by virtue of said
construction activities, provided such construction does not unreasonably interfere with the
conduct of Tenant&#146;s business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 The Second Floor Term Commencement Date shall occur on the date
on which (a)&nbsp;Landlord&#146;s Work shall have been substantially completed in accordance
with the Final Second Floor Plans as the same may be modified in accordance with
Section&nbsp;3.1 (with the exception of minor items (and adjustment of equipment and
fixtures) which do not create and can be completed without material interference to
Tenant&#146;s use of the Premises), all as certified by Landlord, (b)&nbsp;a temporary or final
certificate of occupancy shall have been issued by the City of South San Francisco
for the Second Floor Space permitting Tenant to occupy such space for the conduct
of its business; and (c)&nbsp;all utilities are hooked up and all services to be provided by
Landlord are available to the Second Floor Space. Notwithstanding the foregoing,
the Second Floor Term Commencement Date shall be deemed to occur if all of the
conditions to the Second Floor Commencement Date have been fulfilled, except that
(i)&nbsp;Landlord has not been able to complete items of Landlord&#146;s Work as describe in
subpart (a)&nbsp;of the preceding sentence, solely because of work or improvements
performed by Tenant or to be performed by Tenant are not completed, and/or (ii)&nbsp;a
Certificate of Occupancy cannot be obtained due solely because work or alterations
performed by Tenant, or which should have been performed by Tenant, have not
been completed or properly completed. If such substantial completion has occurred
and the Second Floor Term Commencement Date is a date prior to January&nbsp;1, 2005,
Tenant may by written notice to Landlord, defer occupancy of the Second Floor
Space and the Second Floor Term Commencement Date to January&nbsp;1, 2005 or may
elect to occupy the Second Floor Space, in which case rent shall commence upon
such occupancy of the Second Floor Space for the conduct of its business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 If the Landlord is unable to give possession of the Second Floor Space
on the originally stated Anticipated Second Floor Term Commencement Date to the
extent of delays caused by, or chargeable to, Tenant or anyone employed by Tenant,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">including without limitation, change orders requested by Tenant or any other actions or inactions
by Tenant or anyone employed by Tenant in violation of this Lease, Tenant&#146;s failure to complete
work or improvements to be performed by Tenant in the Premises which prevents or delays Landlord in
performing or completing any construction or work to be performed by Landlord or its contractors,
including without limitation Landlord&#146;s Work, Tenant shall pay to Landlord for each day of such
delay actually delays the Second Floor Commencement Date beyond January&nbsp;1, 2004, an amount equal to
one day&#146;s Annual Fixed Rent, provided, however that such additional rent for change orders shall
not exceed the maximum amount of delay set forth in any change order approved by Tenant. Any
payments due Landlord under this clause shall be paid within five (5)&nbsp;days of the invoice from
Landlord stating the charge.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 Landlord shall complete all incomplete punch-list items and other defective or incomplete
Landlord&#146;s Work with due diligence and will use good faith efforts to complete all such incomplete
items as soon as reasonably practicable, but within sixty (60)&nbsp;days after the Second Floor Term
Commencement Date. Tenant shall permit Landlord access to the Premises for purposes of performing
such work, which work may, at Landlord&#146;s option, be completed during business hours on business
days, provided such work does not unreasonably interfere with the conduct of Tenant&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;<U>Option to Extend</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 Provided Tenant gives at least 270&nbsp;days prior written notice of its
election to extend, time being of the essence, Tenant is not in default under the
Lease after any applicable notice and grace period, and Tenant has caused the final
expiration date of the letter of credit referred to in Section&nbsp;6 to be extended to
March&nbsp;31, 2011, Tenant is hereby granted the option to extend the Term for an
additional three (3)&nbsp;years commencing January&nbsp;1, 2008 at a fixed rent which is the
greater of (a)&nbsp;103.5% of the fixed rent rate in effect (without abatement) during
December, 2007, and (b)&nbsp;ninety five percent (95%) of fair market rent for the
Premises as of the commencement of the extension period. The fixed rent for said
option term shall increase by three and one-half percent (3.5%) (compounded)&nbsp;on
January&nbsp;1, 2009 and on January&nbsp;1, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 If the parties are unable to agree upon a fair market rent prior to four
(4)&nbsp;months before the commencement of the option term, the matter shall be
referred to appraisal as set forth in the following sections.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 Whenever the issue of fair market rent shall be referred to appraisal,
such appraisal shall be by three disinterested appraisers, one to be appointed by the
Landlord, one to be appointed by the Tenant and the third to be appointed by the
two appraisers so named. Within thirty (30)&nbsp;days after the selection of the third
appraiser, the three appraisals shall be added together and their total divided by
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">three; the resulting quotient shall be the fair market rent for the Premises. If, however, the low
appraisal and/or the high appraisal are more than ten (10%) percent lower and/or higher than the
middle appraisal, the low appraisal and/or high appraisal shall be disregarded, as applicable. If
only one appraisal is disregarded, the remaining two appraisals shall be added together and their
total divided by two; the resulting quotient shall be the fair market rent for the Premises. If
both the low appraisal and the high appraisal are disregarded as stated in this paragraph, the
middle appraisal shall be the fair market rent of the Premises. Each party shall pay the costs of
the appraiser selected by such party, and the parties shall share equally the cost of the third
appraiser. Each individual appraiser shall have at least ten years of experience in appraising fair
market rents of comparable properties and shall hold one or more of the following designations: MAI
of the American Institute of Real Estate Appraisers, SREA from the Society of Real Estate
Appraisers or ASA from the American Society of Appraisers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 If the fair market rental value per year is not determined prior to the commencement of
the option term, the Tenant shall pay Fixed Rent as though the Fixed Rent was that Fixed Rent in
effect (without abatement) during the last year of said preceding lease year period until such
determination has been made. Following such determination, the Tenant shall promptly pay the
Landlord the difference, if any, between the aggregate rent which would have been paid during said
period and the aggregate rent actually paid. Thereafter, all rent shall be computed and paid in
accordance with Section&nbsp;4.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;<U>Rent</U>. The annual fixed rent for the Premises, shall, commencing April
1, 2004, be $3.00 per rentable square foot per month. Rent shall increase by three
and one half percent (3.5%) compounded on the first day of each April commencing
April&nbsp;1, 2005. Rent for the Second Floor Space shall commence, on a prorated basis,
as of Second Floor Term Commencement Date. Rent for the option term shall be as
set forth in Section&nbsp;4. The above rent is inclusive of (and Landlord shall provide to
Tenant) utilities, maintenance, janitorial services, window washing, access cards,
real estate (but not personal property) taxes, telephone and data wiring
infrastructure currently in the Building or as set forth on Exhibit&nbsp;B or constructed
by Landlord pursuant to Section&nbsp;3, and other services to be provided by Landlord
as set forth in the Lease as amended hereby. The cleaning specifications attached
to the Lease as Exhibit&nbsp;B are amended to provide that cleaning of the Premises
shall be done every other business day and window washing every six (6)&nbsp;months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;<U>Security Deposit</U>. The security deposit is hereby increased to
$250,000.00 and shall take the form of a Letter of Credit. Section&nbsp;28 of the Lease is
hereby amended and replaced with the following new Section&nbsp;28:
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.&nbsp;<U>Security Deposit</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(a)&nbsp;Amount.</B> Simultaneously with the execution of this
Lease, Tenant shall deposit with Landlord the sum of Two Hundred Fifty
Thousand and No/100 Dollars ($250,000.00) as a security deposit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(b) Security. </B>Such security deposit shall be considered as
security for the payment and performance by Tenant of all of Tenant&#146;s
obligations, covenants, conditions and agreements under this Lease except as
hereinafter provided.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(c)&nbsp;Form. </B>The security deposit shall, as of the date hereof,
be a cash deposit given to Landlord. Tenant shall use best efforts to deliver
to Landlord by April&nbsp;30, 2004, an irrevocable letter of credit (the &#147;Letter of
Credit&#148;), in the amount of Two Hundred Fifty Thousand and No/100 Dollars
($250,000.00). Thereafter, Tenant shall maintain the Letter of Credit in full
force and effect throughout the entire term of this Lease and until ninety (90)
days after the end of the calendar year in which the Expiration Date occurs,
and shall cause the Letter of Credit to be renewed or replaced not less than
thirty (30)&nbsp;days prior to its expiry date, subject to the terms and conditions of
Section 28(g) of this Lease. Upon delivery of said letter of credit, the initial
cash deposit shall be refunded by Landlord. The Letter of Credit shall (i)&nbsp;be
unconditional, irrevocable, transferable, payable to Landlord on sight at a
financial institution located in San Francisco, California, in partial or full
draws, (ii)&nbsp;be substantially in the form attached hereto and incorporated
herein as <U>Exhibit&nbsp;C</U>, and otherwise be in form and content acceptable to
Landlord and Tenant, (iii)&nbsp;shall be issued by Silicon Valley Bank or another
financial institution reasonably acceptable to Landlord which meets the asset
and credit rating tests set forth in Section&nbsp;28(d)(2)(i)), and (iv)&nbsp;contain an
&#147;evergreen&#148; provision which provides that it is automatically renewed on an
annual basis unless the issuer delivers sixty (60)&nbsp;days&#146; prior written notice of
cancellation to Landlord and Tenant. Any and all fees or costs charged by the
issuer in connection with the Letter of Credit shall be paid by Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(d)&nbsp;Right to Draw.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(1)&nbsp;</B>In the event of any default (after the expiration of any applicable cure period expressly
set forth in this Lease, except in the event a bankruptcy has been filed by or with respect to
Tenant; in which case, no such notice and cure period shall be required) by Tenant hereunder,
Landlord shall have the right, but shall not be obligated, to draw upon the Letter of Credit in
whole or in part and apply the proceeds thereof as may be necessary to compensate Landlord for any
default under this Lease on the part of Tenant, and Tenant, within fifteen (15)&nbsp;days after
Landlord delivers written demand therefore to Tenant, shall forthwith either restore the Letter
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of Credit to (or, if Tenant is unable to obtain a letter of credit, delivery to Landlord a cash
security deposit in) the amount required to be maintained under this Lease; provided, however,
neither the application of the security deposit as set forth above nor the restoration by Tenant of
such security deposit shall operate to cure such default or to estop Landlord from pursuing any
remedy to which Landlord would otherwise be entitled. Should Landlord elect to draw the full amount
of the Letter of Credit as permitted by this Lease upon a default by Tenant, Tenant expressly
waives any right it might otherwise have to prevent Landlord from drawing on the Letter of Credit
and agrees that an action for damages and not injunctive or other equitable relief shall be
Tenant&#146;s sole remedy in the event Tenant disputes Landlord&#146;s claim to any such amounts. At the
expiration of the Term, Landlord shall use reasonable efforts to assess any damage to the Premises
and notify Tenant of the same within sixty (60)&nbsp;days after said expiration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(2)</B>&nbsp;In addition to Landlord&#146;s rights set forth in Section&nbsp;28(d)(l) above, Landlord shall have
the right to draw upon the Letter of Credit in any of the following circumstances: (i)&nbsp;if the
total assets of the issuer of the Letter of Credit are at anytime less than Three Billion Dollars
($3,000,000,000.00), or such issuer has a Standard &#038; Poor&#146;s commercial paper rating of less than
A-l (provided if at anytime the current Standard &#038; Poor&#146;s commercial paper rating system is no
longer in existence, a comparable rating of a comparable commercial paper rating system from a
comparable company shall be selected by Landlord, in its reasonable discretion, for purposes of
this Section&nbsp;28) and Tenant fails to deliver to Landlord a replacement Letter of Credit complying
with the terms of this Lease within thirty (30)&nbsp;days of request therefore from Landlord, (ii)&nbsp;the
issuer of the Letter of Credit shall enter into any supervisory agreement with any governmental
authority, or the issuer of the Letter of Credit shall fail to meet any capital requirements
imposed by applicable law, and Tenant fails to deliver to Landlord a replacement Letter of Credit
complying with the terms of this Lease within thirty (30)&nbsp;days of request therefore from Landlord,
or (iii)&nbsp;if Tenant fails to provide Landlord with any renewal or replacement Letter of Credit
complying with the terms of this Lease at least thirty (30)&nbsp;days prior to expiration of the
then-current Letter of Credit. In the event the Letter of Credit is drawn upon due solely to the
circumstances described in the foregoing clauses (i), (ii)&nbsp;or (iii)&nbsp;or in an amount exceeding the
damages owing by Tenant to Landlord on account of a default, the amount drawn shall be held by
Landlord (with interest payable thereon at the prevailing money market rate of the financial
institution in which such funds are deposited) as a security deposit to be otherwise retained,
expended or disbursed by Landlord for any amounts or sums due under this Lease to which the
proceeds of the Letter of Credit could have been applied pursuant to this Lease, and Tenant shall
be liable to Landlord for restoration, in cash or
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Letter of Credit complying with the terms of this Lease, of any amount so expended to the same
extent as set forth in this Section&nbsp;28.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(e)&nbsp;Right to Assign. </B>Landlord shall have the right,
with Tenant&#146;s written consent, to assign its interest in the security deposit
and proceeds thereof to any assignee of Landlord&#146;s interest in the Lease
Premises and/or the Prime Lease, provided that such consent by Tenant shall
not be unreasonably withheld, conditioned or delayed and Tenant shall
respond in writing to Landlord&#146;s request for such consent within ten (10)&nbsp;days
after Landlord delivers to Tenant a written request for such consent, and
provided further that no such consent shall be required for assignment to a
corporation or other entity controlling, controlled by or under common control
with Landlord. In the event of any such assignment, Landlord shall have
the right to transfer the security deposit to such assignee, in which event
Tenant shall look solely to the new Landlord for the return of the security
deposit and Landlord shall thereupon be released from all liability to Tenant
for the return of such security deposit, provided that the Landlord has
transferred such security deposit to such assignee and such assignee has
actually received such security deposit. If the security deposit is in the form
of a Letter of Credit and if requested by any such assignee, Tenant shall
cooperate with Landlord at no material cost to Tenant to obtain an
amendment to the Letter of Credit which names such assignee as the
beneficiary thereof in lieu of Landlord. This security deposit shall not be
transferable by Tenant to any subtenant, but shall be held and returned
directly to Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(f)&nbsp;Reservation of Rights. </B>No right or remedy
available to Landlord as provided in this Section&nbsp;28 shall preclude or
extinguish any other right to which Landlord may be entitled. In furtherance
of the foregoing, it is understood that in the event Tenant fails to perform its
obligations hereunder, any amounts recovered from the security deposit shall
not be deemed liquidated damages. Landlord may apply such sums to reduce
Landlord&#146;s damages and such application of funds shall not in any way limit
or impair Landlord&#146;s right to seek or enforce any and all other remedies
available to Landlord to the extent allowed hereunder, at law or in equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(g)&nbsp;Return of Security Deposit. </B>Unless already
returned to Tenant pursuant to Section (f)&nbsp;above, then upon the expiration of
the term hereof, Landlord shall (provided that Tenant is not in default under
the terms hereof) return and pay back any security deposit to Tenant not
previously returned to Tenant, less such portion thereof as Landlord shall
have retained to make good any default by Tenant with respect to any of
Tenant&#146;s aforesaid obligations, covenants, conditions or agreements.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;<U>Definitions</U>. Consistent with the foregoing, certain defined terms as
set forth in the reference data comprising Article&nbsp;1.1 are hereby amended.
Specifically, the Premises shall be, until April&nbsp;1, 2004, the space shown on
Exhibit&nbsp;A to the Lease. From and after April&nbsp;1, 2004, the Premises shall be the
space on the first floor set forth on Exhibit&nbsp;A attached hereto, and from and after
the Second Floor Term Commencement Date, the Premises shall also include the
Second Floor Space. The rentable area of the Premises shall be 12,501 square feet
up until April&nbsp;1, 2004; 18,824 square feet from April&nbsp;1, 2004 until the Second Floor
Term Commencement Date, and 29,544 rentable square feet from and after the
Second Floor Term Commencement Date. The Termination Date shall be December
31, 2007, and the term of this Lease shall be adjusted accordingly; provided,
however, that the Termination Date and Term may be extended in accordance with
this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;<U>Conference Room</U>. The fee for use of the conference room, as set forth
in Section&nbsp;2.5 of the Lease, is reduced to $500.00 for a full day and $300.00 for a
half day.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;<U>Maintenance, Repairs and Liability</U>. Notwithstanding anything to the
contrary in the Lease, Tenant shall have no obligation to indemnify, defend, or
reimburse Landlord or Master Landlord, with respect to, nor any obligation to
perform, construct, repair, maintain or make any improvement, (i)&nbsp;to the extent
necessitated by the acts or omissions of Landlord, Master Landlord, any other
occupant of the building or the project, or their respective agents, employees or
contractors, (ii)&nbsp;occasioned by the exercise of the power of eminent domain or any
peril that would be covered by the customary form of so-called &#147;special form,
extended coverage&#148; casualty insurance, (iii)&nbsp;required as a consequence of any Law
(other than those only applicable to the Premises because of Tenant&#146;s peculiar use of
the Premises or alterations to the Premises by Tenant), (iv)&nbsp;occasioned by any legal
violation of the Premises or the Project as of the date Tenant took (or takes)
possession of the affected portion of the Premises, (iv)&nbsp;for which Landlord or Master
Landlord has a right of reimbursement from any insurer or other third party, (vi)&nbsp;to
the structure or common areas of the building or the project or the heating,
ventilating, air conditioning, electrical, water, sewer, and plumbing systems serving
the Premises, the building, or the project not due to the fault or neglect of Tenant,
(vii)&nbsp;to any portion of the Building or the Project outside of the demising walls of the
then existing Premises not due to the fault or neglect of Tenant, (viii)&nbsp;occasioned by
the presence of any Hazardous Material on or about the Premises, other than
Hazardous Materials introduced to the Premises by Tenant or its invitees,
employees, agents or contractors or those for whom Tenant is legally responsible,
(ix)&nbsp;which is a repair or modification to the Premises or the Project not caused by
the fault or neglect of Tenant and which must be capitalized under generally
accepted accounting rules, or (x)&nbsp;which is expressly the obligation of the Master
Landlord under the Prime Lease or of the Landlord under this Lease.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;<U>Signage</U>. At no additional cost, Tenant shall have permission for one
(1)&nbsp;lobby sign of the size and style set forth on Exhibit&nbsp;E, plus signage on any
building directory comparable to signs for other tenants. Tenant may, upon
payment of a monthly fee in amount mutually approved by Tenant and Landlord
not exceeding $2,500 per month, maintain an exterior sign in accordance with plans
approved by Landlord. At the expiration of the term, said signs shall, at Tenant&#146;s
expense, be removed by Landlord, who shall restore the surfaces of the building
(interior or exterior) to their condition prior to the installation of said signage, and
Tenant shall promptly reimburse Landlord for the reasonable cost therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;<U>Permitted Uses</U>. The Permitted Uses are amended to include research
and development, light manufacturing, office, and related ancillary uses as
permitted by applicable law and the Master Lease, provided the same are permitted
by the Allowable Class&nbsp;Facilities set forth in Section&nbsp;5.3(c) of the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;<U>Access &#038; Egress</U>. Notwithstanding anything to the contrary in this
Lease, with respect to access and egress to, through and from the Premises the
parties agree as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(A)&nbsp;A common data room is located within the Premises on the first floor of
the Building. Only limited representatives of Landlord reasonably approved
by Tenant shall have 24 hour access to the data room through the Premises.
Other representatives of Landlord shall have access to the data room during
normal business hours, provide reasonable email or telephonic notice is
provided to Tenant and a representative of Tenant is allowed to be present
during such entry. All representatives of Landlord accessing the data room
through the Premises shall comply with Tenant&#146;s reasonable security
requirements and shall minimize, to the extent reasonably possible, any
interference with Tenant&#146;s use of the Premises as a consequence of such
access.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(B)&nbsp;Tenant will have card key access to the data room on the first floor.
Said access shall be in common others entitled thereto as described above.
Any servers or other equipment installed by Tenant must be approved by
Landlord, which approval shall not be unreasonably withheld.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(C)&nbsp;Landlord shall arrange for reasonable access to the second floor freight
elevator upon reasonable telephonic or email notice. Such access shall
require escort by building management.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(D)&nbsp;Tenant may also use the other elevator serving the second for delivery
of its operating materials and other freight deliveries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;<U>Energy Conservation</U>. Tenant understands and recognizes that the
Building is designed and operated as an energy efficient building. Energy efficiency
includes, without limitation, the use of electric conservation methods such as
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">motion detectors and timers to avoid unnecessary use of electric lights and other equipment after
business hours. Tenant agrees that it will not alter, remove or render inoperative any such energy
saving devices without the prior written consent of Landlord.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;<U>Subleasing Profit</U>. Section&nbsp;14.3(d) of the Lease is amended to delete
fifty (50%) percent and substitute therefor sixty two and one half (62.5%) percent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;<U>Landlord Access</U>. Section&nbsp;15.2 of the Lease is modified to permit
Landlord twenty-four (24)&nbsp;hour card access to the Premises for purposes of
maintenance, cleaning, repairs and the provision of other services required to be
provided by Landlord; provided, however that access to the data room is allowed
solely pursuant to Section&nbsp;12.A. Any such entry by Landlord shall comply with
Tenant&#146;s security regulations and shall minimize to the extent reasonably possible
any interference with Tenant&#146;s use of the Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;<U>Furniture</U>. Landlord will provide the modular offices and work
stations for the Second Floor Space as set forth in Exhibit&nbsp;B-2. The provision of
said offices and work stations shall be subject to the provisions of Section&nbsp;29 of the
Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;<U>Damage and Destruction</U>. Notwithstanding anything to the contrary
in the Lease, in the event the Premises or any space in the building being subleased
by Tenant from Genome Therapeutics Corporation (&#147;Genome&#148;) or its successor (or
access thereto or systems serving the same) are the subject of a fire or other
casualty that interferes with the use and enjoyment by Sublessee of a material
portion of such space, and such interference is not reasonably likely to be (or has not
been) remedied and tenantable occupancy restored (in the case of said space
subleased from Genome, to either a cold shell or cold shell plus TI, all as set forth in
Sections 16(a) and 16(b) of the lease between Landlord and Genome) after one (1)
year (or such longer period as has been agreed to in writing between Landlord
and/or Master Landlord and Tenant or is attributable to unavoidable delays) from
the date such interference was first experienced, Tenant may, by notice to Landlord
terminate this Lease by notice given within 30&nbsp;days after the expiration of said one
year (or mutually agreed longer) period. Sections 16(a) and 16(b) of the Lease are
modified to provide that the parties understand that Master Landlord, not
Landlord, is the party responsible for restoration after a casualty, that Master
Landlord shall be the party to make the determination as to the estimated time to
restore after a casualty. Sections&nbsp;16(a) &#151; (c)&nbsp;of the Lease are deleted and replaces
with the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;If the Demised Premises, or any part thereof, shall be damaged by fire or other casualty,
Tenant shall give prompt notice thereof to Landlord, and Landlord, upon receiving such notice and
the insurance proceeds for such casualty, shall proceed in a commercially reasonable manner,
subject to unavoidable delays,
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to repair, or cause to be repaired, such damage to the extent hereinafter provided. If the Demised
Premises or any part thereof shall be rendered untenantable by reason of such damage, whether to
the Demised Premises or to the Building, Yearly Fixed Rent shall proportionately abate for the
period from the date of such damage to the date when the Demised Premises shall have been restored
by Landlord.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If, as a result of fire or other casualty, the whole or a substantial portion of the
Building is rendered untenantable, within ninety (90)&nbsp;days from the date of such fire or casualty,
Landlord shall notify Tenant of its opinion of the time required to restore the Demised Premises,
taking into account a reasonable time for adjusting loss and obtaining plans and permits for
restoration. If in Landlord&#146;s opinion the Demised Premises cannot be made tenantable within one (1)
year after such event, Landlord, within ninety (90)&nbsp;days from the date of such fire or casualty,
may terminate this Lease by notice to Tenant, specifying a date not less than thirty (30)&nbsp;nor more
than sixty (60)&nbsp;days after the giving of such notice on which the Term of this Lease shall
terminate. In addition, if in Landlord&#146;s opinion said estimated time for restoration exceeds one
(1)&nbsp;year and Landlord does not elect to terminate this lease, Tenant shall, by notice given to
Landlord within fifteen (15)&nbsp;days of Landlord&#146;s notice as aforesaid, elect (a)&nbsp;to terminate this
Lease, or (b)&nbsp;accept Landlord&#146;s estimated restoration period ( the &#147;Longer Restoration Period&#148;). If
Tenant accepts a Longer Restoration Period, Tenant&#146;s right to terminate as hereinafter provided
shall be effective only if actual restoration takes more than 60&nbsp;days beyond such estimated Longer
Restoration Period, such termination to be elected within 30&nbsp;days after the expiration of said
Longer Restoration Period plus 60&nbsp;days. If neither Landlord or Tenant elects to terminate this
Lease as provided above, then Landlord shall (to the extent that proceeds of insurance required to
be carried by Landlord, net of any portion thereof retained by a Mortgagee, plus any sums
contributed by Tenant or any subtenant of Tenant, are made available for such purpose) proceed with
diligence to repair the damage to the Demised Premises and all facilities serving the same, if any,
which shall have occurred, and the Yearly Fixed Rent shall meanwhile proportionately abate, all as
provided in Paragraph (a)&nbsp;of this Section. However, if such damage is not repaired and the Demised
Premises restored to substantially the same condition as they were prior to such damage within one
(1)&nbsp;year ( or, if elected, the Longer Restoration Period plus 60&nbsp;days) from the date of such
damage, Tenant, within thirty (30)&nbsp;days from the expiration of such one (1)&nbsp;year period (or, if
elected, the Longer Restoration Period plus 60&nbsp;days) or from the expiration of any extension
thereof by reason of the delays set forth in the following sentence, may terminate this Lease by
notice to Landlord, specifying a date not more than sixty (60)&nbsp;days after the giving of such notice
on which the Term of this Lease shall terminate. The period within which the required repairs may
be accomplished shall be extended by the number of days, lost as a result of unavoidable delays,
which term shall be defined to mean all delays referred to in Article&nbsp;24.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If the Demised Premises shall be rendered untenantable by fire or other casualty and less
than two (2)&nbsp;years would remain left in the Term after Landlord&#146;s estimated date of completion of
restoration, Landlord may terminate this Lease effective as of the date of such fire and other
casualty upon notice to Tenant given within ninety (90)&nbsp;days after such fire and other casualty.
Notwithstanding the foregoing to the contrary, in the event Landlord exercises the foregoing
termination right, if Tenant has available to it the option to extend and validly exercises said
option, Tenant may defeat said termination notice by the valid exercise of said option term so as
to add an additional five years on to the Term of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;<U>Alterations and Additions</U>. Section&nbsp;10 of the Lease is amended to add, after the second sentence thereof, the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;Notwithstanding the foregoing, Landlord&#146;s consent shall not be required for any alteration,
addition or improvement that either (a)&nbsp;costs less than Ten Thousand Dollars ($10,000.00) or (b)
satisfies all of the following criteria: (i)&nbsp;is of a cosmetic nature such as painting,
wallpapering, hanging pictures and installing carpeting, (ii)&nbsp;is not visible from the exterior of
the Premises or Building, and (iii)&nbsp;will not affect the systems or structure of the Building,
provided, however, in any such instance Tenant provides plans and specifications for such work not
less than ten (10)&nbsp;days before commencing such work.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, Landlord agrees to advise Tenant, upon request, which alterations and additions
to be made by Tenant Landlord will require to be so removed at the end of the Term.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;<U>Ratification</U>. Except as modified herein, the Lease is hereby ratified
and confirmed in full force and effect. To the best of their knowledge, neither
Landlord nor Tenant are aware of any default by the other party in the terms and
conditions of this Lease. Any defined term used herein and not specifically defined
herein shall have the meaning ascribed to it in the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;<U>Exhibits</U>. Attached hereto and made a part hereof are:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="79%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">First Floor Plan</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;B-l
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Second Floor Plan</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;B-2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Outline Specifications for Second Floor</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Letter of Credit</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Permitted Signage</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;E
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Master Lease</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
- 13 -
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executed under seal as of this 25<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of March&nbsp;2004.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">MJ RESEARCH, INCORPORATED,<BR>a Massachusetts corporation</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Illegible</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Illegible</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: VP Finance</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Fluidigm Corporation</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Gajus Worthington</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
- 14 -
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A<BR>
FIRST FLOOR PLAN
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[Diagram depicting the first floor layout.]
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
- 15 -
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT B-l<BR><BR>
SECOND FLOOR PLAN
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[Diagram depicting the second floor layout.]
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
- 16 -
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT B-2<BR><BR>
OUTLINE SPECIFICATIONS
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
- 17 -
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><U>EXHIBIT B-2</U></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>2</B><SUP style="font-size: 85%; vertical-align: text-top"><B>nd</B></SUP> <B>Floor Improvement Outline Specification &#151; Landlords Work</B></U><BR>
Based on Exhibit&nbsp;B -1 (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> Floor Plan)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1. Building Type and Use: </B>3 Story, Group B, Type III, 1 Hour Rated, fully
sprinklered office building. All design and construction in conformance with the
1998 (CBC)&nbsp;Building Standards Administrative Code of the California Building
Standards Commission (CBSC)&nbsp;and the City of South San Francisco amendments, all applicable codes
and regulations. All building improvements
shall be furnished fully ADA compliant, where required and meet the energy and
access requirements set forth in the California Title 24 Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>2. Tenants Program (General Description of Areas): </B>Based on the attached
Exhibit&nbsp;B &#151; 1 (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> Floor Plan), the tenant&#146;s space will consist of the following
programmatic components.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>a. Offices: </B>General open office areas to house up to (20)&nbsp;modular workstations,
(12)&nbsp;offices with modular glass panels parallel to the building perimeter and (2)
conference rooms with modular glass panels parallel to the building perimeter. All
office finished will be consistent with tenants 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> Floor, East Wing office space
with the exception of the open lofted ceiling. Due to the excess laboratory
mechanicals an acoustical suspended ceiling with recessed lighting is necessary
to conceal all HVAC equipment and wiring. To maintain the buildings tall and airy
affect all ceilings throughout will be mounted at a height of 11&#146;-0&#148; above the
finished floor. Landlord reserves the right to add architectural treatments and
lighting to enhance the interior environment of the space including wall facets,
columns and metal ceiling accents. All door frames and trim will be brushed
chrome or anodized aluminum and all door leafs and other laminates will be light
maple to match the existing. Flooring will consist of stained concrete, VCT and
carpet where appropriate. Tenant may elect to substitute other office type
improvements as approved by landlord that do not adversely affect the buildings
design integrity or construction cost. These changes will be addressed on the
final floor plans, prior to submission to the building department.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>b. Laboratories: </B>(1)&nbsp;Open Plan Biology Laboratory and (1)&nbsp;Open Plan
Chemistry Laboratory will be provided, each not to exceed 1,500 square feet of
floor area. Each laboratory will be equipped with (1)&nbsp;fume hood exhaust
connection and ducting. Copper vacuum and compressed air piping will be
connected to each hood. Each laboratory will also be provided with (1)&nbsp;working
laboratory type sink complete with hot, cold and de-ionized pure water sources.
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any ultra-pure Dl water connections and equipment are the tenant&#146;s sole responsibility. Locations
of hoods and sinks where reasonably feasible and as designated by tenant. Up to (4)&nbsp;Stainless steel
ceiling mounted lab utility distribution panels will be provided in each laboratory room. Each
panel can accommodate electric, data, vacuum and compressed air as specified by tenant and similar
to those used by tenant in West Wing of building. Laboratory finishes to consist of vinyl coated
acoustical ceiling panels, recessed lighting, tile or sheet vinyl resilient flooring and painted
gypsum board walls. Landlord reserves the right to add architectural treatments as appropriate that
will not interfere with tenants use.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>c. Ancillary Rooms: </B>Ancillary rooms, such as storage, equipment, utility, kitchen, conference or
others can be substituted for the improvements described herein and depicted on Exhibit&nbsp;B -1 (2nd
Floor Plan) provided that they are approved by the landlord and do not adversely affect the
buildings design integrity, use group classification or construction cost.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3. Utilities:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>a. Gas: </B>Gas utilities to be provided for general heating of air and to heat water to
common building heating devices and domestic water supplies only. No specific
gas connections to tenant&#146;s laboratories or capital equipment will be provided.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>b. Electric: </B>Electric utilities including distribution panels, cabling and receptacles
will be provided to tenants space at a ratio common to office use and not less
than the minimum set forth in the National Electric Code. Additional high voltage
power for laboratories containing tenant specific equipment will be provided in a
flexible manner via ceiling mounted panels or wall mounted metal wireways at
locations as specified by tenant. Up to (4)&nbsp;ceiling panels or wireways will be
provided in each laboratory to house the lab specific utilities. Each panel or
wireway will contain up to (4)&nbsp;standard 115V receptacles in metal gang boxes,
suspended but cords, (1)&nbsp;UPS or Emergency Back-up receptacle and (1)&nbsp;high
voltage receptacle with plug configuration as specified by tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>c. Telephone and Data Connections: </B>Each office and workstation will receive
(2)&nbsp;Category 5e communications jacks for use with either telephone or computer
networking equipment. Each cable will be pulled to common Tele/Data
distribution room as shown on 2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> Floor Plan. Cable terminations, phone and
networking equipment and distribution panels will not be provided and are the
sole responsibility of the tenant. Tenant may make use of landlord pre-existing
racks for purposes of mounting their equipment. Conference and laboratory
rooms shall receive up to (4)&nbsp;phone or data connections each.
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>d. Specialty Laboratory and House Utilities: </B>Vacuum and compressed air copper feeds and connections
will be provided to each laboratory hood or ceiling panel locations as designated by tenant.
Connections not to exceed (4)&nbsp;per laboratory. Vacuum connections will be made to pre-existing house
vacuum system. Compressed air connections will be made to new air compressor and dryer subject to
joint specification and installation by tenant and landlord. De-ionized water to be provided to
each sink location and connected to pre-existing house system. Each laboratory sink location will
be provided with chemical and Dl resistant waste lines. Tenant is responsible to monitor at point
of use and downstream, the lab waste lines to ensure that no chemicals are being released into the
laboratory waste system or public sewer utility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>4. Design: </B>For the improvements described herein and on Exhibit&nbsp;B-1 (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> Floor
Plan), all design, architecture, engineering, color schemes and finish selections
will be provided by landlord at landlord&#146;s expense and discretion. All final
construction and permit documents will be provided by landlords licensed
consultants as required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>5. Construction: </B>All construction procedures, materials and methods will be
provided in a workmanlike and professional manner under the supervision of the
landlord and will be built in accordance with all applicable codes and industry
standards. All consultants, vendors, contractors and subcontractors performing
the work as described herein and in Exhibit&nbsp;B &#151; 1 (2nd Floor Plan) will be under
the direct contract and supervision of the landlord only. Access for construction
equipment, building materials and furniture will be provided through an exterior
window unit that will serve as a temporary freight passage. This passage will be
available to tenant only until landlords work prohibits the handling of materials in
that area wherein the window will be re-installed and sealed. Once sealed, the
window will not be subject to further removal by landlord. It is understood that the
2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> floor improvements will be ongoing with tenants occupancy of the below
1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>
floor space. Access, particularly in the ceiling plenum, to the 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> floor space may
be required for the duration of the project for purposes of facilitating the
construction above. Inherently, some noise, vibration and disruption may
occasionally be experienced in the space below and in the adjacent areas.
Reasonable accommodations will be made by landlord to minimize such
disruptions during regular working hours.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT C<BR>
FORM OF LETTER OF CREDIT
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943241.gif" alt="(LETTERHEAD)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF002780</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">DATE: APRIL 01, 2004
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BENEFICIARY:<BR>
MJ RESEARCH, INC.<BR>
7000 SHORELINE COURT<BR>
SOUTH SAN FRANCISCO, CA 94080

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">APPLICANT:<BR>
FLUIDIGM CORPORATION<BR>
7100 SHORELINE COURT<BR>
SOUTH SAN FRANCISCO, CA 94080

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">AMOUNT:
US$250,000.00 (U.S. DOLLARS TWO HUNDRED FIFTY THOUSAND EXACTLY)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">EXPIRATION DATE: MARCH 31, 2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LOCATION: SANTA CLARA, CALIFORNIA
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">DEAR SIR/MADAM:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF002780 IN YOUR FAVOR
AVAILABLE BY YOUR DRAFTS DRAWN ON US AT SIGHT IN THE FORM OF &#147;EXHIBIT B&#148; ATTACHED AND ACCOMPANIED
BY THE FOLLOWING DOCUMENTS:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. SIGHT DRAFTS DRAWN ON US.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. A DATED
STATEMENT FROM THE BENEFICIARY SIGNED BY AN OFFICER OR AN AUTHORIZED REPRESENTATIVE OF THE BENEFICIARY, FOLLOWED BY HIS/HER
DESIGNATED TITLE, STATING THE FOLLOWING:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
&#147;THE UNDERSIGNED STATES BENEFICIARY IS ENTITLED TO DRAW UPON THIS
LETTER OF CREDIT PURSUANT TO THE TERMS OF THAT LEASE DATED AS OF
DECEMBER 1, 2001 BETWEEN BENEFICIARY AND FLUIDIGM CORPORATION, AS SAID
LEASE IS AMENDED FROM TIME TO TIME, FOR THE AMOUNT DRAWN HEREUNDER.
THE UNDERSIGNED BENEFICIARY HEREBY MAKES DEMAND FOR THE PAYMENT OF
US $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> (DRAW AMOUNT) UNDER THIS LETTER OF CREDIT.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THE LEASE MENTIONED ABOVE IS FOR IDENTIFICATION PURPOSES ONLY AND IT IS NOT INTENDED THAT SAID
LEASE BE INCORPORATED HEREIN OR FORM PART OF THIS LETTER OF CREDIT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PARTIAL DRAWS ARE ALLOWED. THIS ORIGINAL LETTER OF CREDIT MUST ACCOMPANY ANY DRAWINGS HEREUNDER FOR
ENDORSEMENT OF THE DRAWING AMOUNT AND WILL BE RETURNED TO THE BENEFICIARY UNLESS IT IS FULLY
UTILIZED.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS LETTER OF CREDIT MAY ONLY BE TRANSFERRED IN ITS ENTIRETY BY THE ISSUING BANK, ASSUMING SUCH
TRANSFER TO SUCH TRANSFEREE WOULD BE IN COMPLIANCE WITH THEN APPLICABLE LAW AND REGULATIONS,
INCLUDING BUT NOT LIMITED TO THE REGULATIONS OF THE U.S. DEPARTMENT OF TREASURY AND U.S. DEPARTMENT
OF COMMERCE, UPON OUR RECEIPT OF THE ATTACHED &#147;EXHIBIT A&#148; DULY COMPLETED AND EXECUTED BY THE
BENEFICIARY AND ACCOMPANIED BY THE ORIGINAL LETTER OF CREDIT AND ALL AMENDMENT(S), IF ANY, TOGETHER
WITH THE PAYMENT OF OUR TRANSFER FEE 1/4 OF 1% OF THE TRANSFER AMOUNT (MINIMUM USD250.00) .
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-variant: small-caps">3003 Tasman Drive &#124; Santa Clara, CA  95054 &#124; 408.654.7400 &#124; svb.com<BR>
Swift Address: SVBKUS6S &#124; Telex No. 6732567 &#124; Answerback: SVB TF</font></div>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="RIGHT" style="font-size: 10pt">
<!-- Folio -->
PAGE -1-<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943241.gif" alt="(LETTERHEAD)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IRREVOCABLE
STANDBY LETTER OF CREDIT NO. SVBSF002780</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">DOCUMENTS MUST BE FORWARDED TO US BY OVERNIGHT DELIVERY SERVICE TO: SILICON VALLEY BANK, 3003
TASMAN DRIVE, SANTA CLARA, CA 95054, ATTN: INTERNATIONAL DIVISION.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WE HEREBY AGREE WITH THE DRAWERS, ENDORSERS AND BONAFIDE HOLDERS THAT THE DRAFTS DRAWN UNDER AND IN
ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON
PRESENTATION TO THE DRAWEE, IF NEGOTIATED ON OR BEFORE THE EXPIRATION DATE OF THIS CREDIT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS
(1993 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 500.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">SILICON VALLEY BANK,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ John M. Dossantos
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Edward D. Machado</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">AUTHORIZED SIGNATURE
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AUTHORIZED SIGNATURE</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">John M. Dossantos
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Edward D. Machado</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943242.gif" alt="(LETTERHEAD)">
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
PAGE -2-
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT &#147;B&#148;</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943252.gif" alt="(SIGHT DRAFT)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GUIDELINES TO PREPARE THE DRAFT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. DATE: ISSUANCE DATE OF DRAFT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. REF. NO.: BENEFICIARY&#146;S REFERENCE NUMBER, IF ANY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. PAY TO
THE ORDER OF: NAME OF BENEFICIARY AS INDICATED IN THE L/C (MAKE
SURE BENEFICIARY ENDORSES IT ON THE REVERSE SIDE).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4. US$: AMOUNT OF DRAWING IN FIGURES.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5. USDOLLARS: AMOUNT OF DRAWING IN WORDS.<BR>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6. LETTER OF CREDIT NUMBER: SILICON VALLEY BANK&#146;S STANDBY L/C NUMBER THAT
PERTAINS TO THE DRAWING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">7. DATED: ISSUANCE DATE OF THE STANDBY L/C.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">8. BENEFICIARY&#146;S NAME: NAME OF BENEFICIARY AS INDICATED IN THE L/C.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">9. AUTHORIZED SIGNATURE: SIGNED BY AN AUTHORIZED SIGNER OF BENEFICIARY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IF YOU NEED FURTHER ASSISTANCE IN COMPLETING THIS DRAFT, PLEASE CALL OUR L/C PAYMENT SECTION AND
ASK FOR:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ALICE DA LUZ: 408-654-7120<BR>
EFRAIN TUVILLA: 408-654-6349

</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT &#147;A&#148;</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<TR valign="bottom">
    <TD valign="top">DATE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">TO:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SILICON VALLEY BANK</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">3003 TASMAN DRIVE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RE:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">STANDBY LETTER OF CREDIT</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SANTA CLARA, CA 95054</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NO. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ISSUED BY</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ATTN:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INTERNATIONAL DIVISION.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SILICON VALLEY BANK, SANTA CLARA</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">STANDBY LETTERS OF CREDIT
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">L/C AMOUNT:</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">GENTLEMEN:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY HEREBY IRREVOCABLY TRANSFERS TO:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(NAME OF TRANSFEREE)<BR>
(ADDRESS)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS
AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY THIS TRANSFER, ALL RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE
TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE RIGHTS AS BENEFICIARY THEREOF,
INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER
AMENDMENTS, AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO
THE TRANSFEREE WITHOUT NECESSITY OF ANY CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THE ORIGINAL OF SUCH LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER
ON THE REVERSE THEREOF, AND FORWARD IT DIRECTLY TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF
TRANSFER.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">SINCERELY,
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">(BENEFICIARY&#146;S NAME)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">SIGNATURE OF BENEFICIARY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">SIGNATURE AUTHENTICATED</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">(NAME OF BANK)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="1" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AUTHORIZED SIGNATURE **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By affixing his/her signature, he or she is certifying that the Bank
on whose behalf he or she is signing is regulated either by the FED, the OCC, or the FDIC, and that
the Bank has implemented AML (Anti-Money Laundering) procedures in accordance with the Bank Secrecy
Act, and that the Transferor named above has been approved under his/her Bank&#146;s own CIP (Customer
Information Program). VERIFICATION OF TRANSFEROR&#146;S SIGNATURE(S) BY A NOTARY PUBLIC IS
UNACCEPTABLE.</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">


</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT D<BR>
PERMITTED LOBBY SIGNAGE
</DIV>



<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
-19-
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>Exhibit&nbsp;D</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943253.gif" alt="()">
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<P align="center" style="font-size: 10pt">
<!-- Folio -->
&nbsp;
<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>Exhibit&nbsp;E</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[SEE ABOVE FOR
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SUBLEASE
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">BETWEEN
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">MJ RESEARCH COMPANY, INC.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AND
FLUIDIGM CORPORATION]
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AGREEMENT OF LEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGREEMENT OF LEASE made as of the 6<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of October, 2000, by
and between MJ Research Company, Inc. (hereinafter referred to as &#147;Landlord&#148;)
and Genesoft, Inc. (hereinafter referred to as &#147;Tenant&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">WITNESSETH:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord hereby leases to Tenant and Tenant hereby hires from Landlord a portion
of the building (the &#147;Building&#148;) in South San Francisco, as described in Section
1.1(4) below and shown on the plan attached hereto as Exhibit&nbsp;A and made a part
hereof (hereinafter referred to as the &#147;Premises&#148; or the &#147;Demised Premises&#148;).
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>REFERENCE DATA</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Definitions</U>. Each reference in this Lease to any of the terms
and titles contained in this Article shall be deemed and construed to incorporate the
data stated following that term or title in this Article.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1) Additional Rent:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sums or other charges payable by Tenant to Landlord
under this Lease, other than Yearly Fixed Rent, all of
which shall be payable as additional rent under this
Lease.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2) Broker:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">None.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3) Business Day:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">All days except Saturdays, Sundays, days defined as
&#147;legal holidays&#148; for the entire state under the laws of
the State of California, and such other days as Tenant
presently or in the future recognizes as holidays for
Tenant&#146;s general staff.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4) Demised Premises:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Space on the first, second and third floors of the
Building at 7000 Shoreline Court, South San Francisco,
California 94080 (the &#147;Building&#148;), which space is shown
on the plans attached as Exhibit&nbsp;A.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5) Environmental Laws:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;5.3 (a) (1).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">6) Event of Default:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The occurrence of an event listed in Section&nbsp;19.1.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">7) Hazardous Materials:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;5.3 (a) (2).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">pigs and relocate such
animals off-site or,
within a reasonable period
of time (not to exceed two
(2)&nbsp;business days) make
such arrangements as are
necessary to eliminate
such picketing, signage or
other disruption.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">16) Prime Landlord:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mountain Cove Tech Center
LLC, a California limited
liability company.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">17) Prime Lease:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The lease dated November
9, 1999 between Prime
Landlord and Landlord.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">18) Property:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Land and Building.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">19) Rent:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Yearly Fixed Rent and
Additional Rent.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:19px; text-indent:-19px">20) Rentable Area of the Demised Premises:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom"><br>Approximately 68,460
rentable square feet. The
rentable square footage of
the Demised Premises upon
completion of Landlord&#146;s
Work shall be measured by
Landlord according to the
most recent BOMA
standards, but in any
event shall include for
computation purposes 50%
of all common areas of the
Building, including,
without limitation,
elevators, lobbies,
hallways, exercise room,
security desk, and lunch
room. If Tenant disagrees
with Landlord&#146;s
computation of the
rentable square footage of
the Premises, Tenant may,
at its expense, by notice
given no later than ten
(10)&nbsp;days after written
notice by Landlord of the
rentable square feet of
the Demised Premises,
submit the matter of the
square footage as to
arbitration as set forth
in Section&nbsp;27.7 herein.
The inclusion of
elevators, hallways, the
exercise room,
security
desk and lunchroom in the
computations of rentable
square footage shall not
be deemed to make Tenant
liable for such facilities
as if it were the
exclusive lessee thereof.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">21) Security Deposit:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">One Year&#146;s Yearly Fixed
Rent, subject to decrease
as provided in Section
28.3.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">22) Tenant&#146;s Address:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Until the Term Commencement
Date, Two Corporate Drive
South, San Francisco,
California 94080, and
thereafter, the Demised
Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:19px; text-indent:-19px">23) Term Commencement Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">As defined in Section&nbsp;3.2.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24) Term of this Lease:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;3.1.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">25) Termination Date:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;3.1.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">26) Yearly Fixed Rent:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">$4.50 per rentable square
foot per month for the
first lease year, which
amount shall be increased
annually commencing with
the third lease year by
three and one half percent
(3.5%) compounded annually.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <U>Exhibits</U>. The following exhibits are attached hereto and made a part
hereof:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A &#151; Plan of Demised Premises
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A-l &#151; Plans and Specifications for Landlord&#146;s Work<BR>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A-2 &#151; Landlord&#146;s Work Necessary for Tenant Improvement Work
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B &#151; Cleaning Specifications
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C &#151; Rules and Regulations
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D &#151; Sign Criteria
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E &#151; Form of Letter of Credit<BR>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F &#151; List of Environmental Reports Given to Tenant
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G &#151; List of Permitted Hazardous Materials<BR>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H &#151; List of Fixtures and Equipment to be Removed
</DIV>


<DIV style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>DESCRIPTION OF DEMISED PREMISES</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Demised Premises</U>. The Demised Premises are that portion of the
Building as described above (as the same may from time to time be constituted after
changes therein, additions thereto and eliminations therefrom pursuant to rights of
Landlord hereinafter reserved).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Appurtenant Rights</U>. Tenant shall have, as appurtenant to the
Demised Premises, rights to use in common, subject to reasonable rules from time
to time made by Landlord of which Tenant is given notice, those common roadways,
walkways, elevators, hallways and stairways necessary for access to that portion of
the Building occupied by the Demised Premises. There is also appurtenant to the
Demised Premises at no additional charge the nonexclusive use, in common with
Landlord and other entitled thereto, of the parking lot appurtenant to the Building,
which lot is designed to have three (3)&nbsp;parking spaces per 1,000 rentable square feet
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in the Building. Landlord agrees that such parking lot shall be on a non-exclusive basis for Tenant
and others entitled thereto and shall not exclusively assign portions of the parking area without
providing equivalent and comparable exclusive assignments to Tenant, provided that, subject to
casualty and eminent domain, in no event shall Tenant have the use (non-exclusive or otherwise) of
not less than nor more than, three (3)&nbsp;spaces per 1,000 rentable square feet of the Demised
Premises during the Term, provided that there shall be deducted from the parking available to
Tenant any parking spaces lost due to Tenant&#146;s outside storage facility referred to in Section
5.3(c). Tenant may not store cars in the parking lot, i.e., leave cars parked for more than seven
(7)&nbsp;days.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Reservations</U>. All the perimeter walls of the Demised Premises except the inner
surfaces thereof, any balconies, terraces or roofs adjacent to the Demised Premises, and any space
in or adjacent to the Demised Premises used for serving other portions of the Building exclusively
or in common with the Demised Premises, including without limitation (where applicable) shafts,
stacks, pipes, conduits, wires and appurtenant fixtures, fan rooms, ducts, electric or other
utilities, sinks or other Building facilities, and the use thereof, as well as the right of access
through the Demised Premises for the purpose of operation, maintenance, decoration and repair, are
expressly reserved to Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <U>Certain Amenities</U>. The named Tenant, Genesoft, Inc. shall have access to on
a nonexclusive basis, the following facilities:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The exercise room. Landlord may charge a reasonable fee for towel service and
janitorial service.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) A security desk in the main lobby of the Building to be staffed from 9:00 a.m.
through 5:00 p.m. on all Business Days.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The lunchroom and adjacent patio.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event the named Tenant Genesoft occupies less than 50% of the Building,
Landlord may eliminate said amenities (other than the security desk) or assign them
exclusively to Landlord or other occupants of the Building. Such amenities shall not be
available to assignees or subtenants of Tenant unless permitted in writing by Landlord.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>TERM OF LEASE</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Term</U>. The Term of this Lease is ten (10)&nbsp;years (or until such Term shall
sooner cease or expire) commencing on the Term Commencement Date and ending on the day
immediately prior to the tenth (10<SUP style="font-size: 85%; vertical-align: text-top">th)</SUP> anniversary thereof, except that if the Term
Commencement Date shall be other than the first day of a calendar month, the Term of this Lease
shall end on the last day of the calendar month in which said 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> anniversary of the
Term Commencement Date shall fall (which date
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">on which the Term of this Lease is scheduled to expire is hereinafter referred to as the
&#147;Termination Date&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Term Commencement Date</U>. The Term Commencement Date shall be the earlier of (a)&nbsp;the
date on which, pursuant to permission therefor duly given by Landlord, Tenant undertakes Use of
the Demised Premises for the purposes set forth in Article&nbsp;1, (b)&nbsp;the date on which the Demised
Premises are ready for Tenant&#146;s occupancy in accordance with the provisions of Section&nbsp;4.2, or (c)
March&nbsp;1, 2001, but in no event prior to the date on which Landlord&#146;s Work (as defined herein) is
substantially completed, unless and only to the extent that the lack of such substantial completion
is due to the fault, delay, or inaction by Tenant or to the roof work necessitated by Tenant&#146;s
mechanical and other equipment to be placed on the roof. Notwithstanding the foregoing to the
contrary, if the work set forth on Schedule&nbsp;A-2 is not substantially complete by January&nbsp;1, 2000
and the lack of such substantial completion is not due to fault, delay or inaction of Tenant or to
roof work necessitated by Tenant&#146;s mechanical and other equipment to be placed on the roof, then
for each day beyond January&nbsp;1, 2001 for which the work on Schedule&nbsp;A-2 is not substantially
complete, the March&nbsp;1, 2001 date shall be extended for one day. Further notwithstanding anything in
the foregoing to the contrary, for purposes of determining when the Premises are ready for
occupancy for purposes of determining the Term Commencement Date, the Premises shall not be deemed
ready for occupancy until Tenant has completed its Tenant improvement work and obtained a
certificate of occupancy therefor. Tenant further acknowledges that if Landlord has completed its
work on Schedule&nbsp;A-2 on or before January&nbsp;1, 2000 and made the Premises available to Tenant, Tenant
assumes the risk of delay for Tenant improvement work and acknowledges that (subject to Landlord&#146;s
obligations as to substantial completion of Landlord&#146;s Work) the Term will commence on March&nbsp;1,
2001 whether or not Tenant has completed its work and obtained such a certificate of occupancy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <U>Option to Extend</U>. Provided Tenant is not in default of the terms and covenants of
this Lease beyond applicable notice and grace periods, and provided Tenant has not assigned this
lease or subleased all or any portion of the Premises, it shall have the option to extend the Term
for five (5)&nbsp;years, exercisable by written notice given to Landlord no later than twelve (12)
months before the expiration of the original Term. All of the terms, conditions and covenants of
this Lease shall apply to the option term, except that there shall be no further extension beyond
that permitted above and that yearly Fixed Rent for the option term shall be computed as set forth
in Section&nbsp;6 herein.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PREPARATION OF PREMISES; TENANT&#146;S ACCESS</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Plans and Specifications</U>. Landlord shall construct the Demised Premises in
accordance with the plans and specifications (the &#147;Plans&#148;) referenced in Exhibit&nbsp;A-l attached
hereto and made a part hereof (&#147;Landlord&#146;s Work&#148;). Tenant
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">acknowledges that Landlord&#146;s Work will produce a so-called &#147;cold shell&#148; that will not be ready for
Tenant&#146;s occupancy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>When Landlord&#146;s Work is Done</U>. Landlord&#146;s Work shall be conclusively deemed
finished after Landlord gives notice to Tenant that Landlord&#146;s Work has been substantially
completed by Landlord. Notwithstanding anything to the contrary in this Lease, the Landlord&#146;s Work
shall not be deemed &#147;substantially completed&#148; prior to the date on which: (a)&nbsp;construction and
installation of the improvements listed on <U>Exhibit&nbsp;A-1</U>, attached hereto, have been
substantially completed; (b)&nbsp;Tenant has direct access from the street to the elevator lobby on the
first floor; and (c)&nbsp;utility services are ready to be furnished to the Premises consistent with the
work set forth on Exhibit&nbsp;A-l. Such work shall not be deemed incomplete if only minor or
insubstantial details of construction or mechanical adjustments remain to be done, or if a delay is
caused in whole or in part by Tenant. Landlord&#146;s Architect&#146;s certificate of substantial completion,
as hereinabove stated, given in good faith, or of any other facts pertinent to such work, shall be
deemed conclusive of the statements therein contained and binding upon Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Conclusiveness of Landlord&#146;s Performance</U>. Tenant shall be conclusively deemed to
have agreed that Landlord has performed all of its obligations under this Article&nbsp;4 unless not
later than the end of the second calendar month next beginning after the Landlord&#146;s notice of
substantial completion under Section&nbsp;4.2 unless Tenant shall give Landlord written notice
specifying the respects in which Landlord has not performed such obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Entry by Tenant; Interference With Construction; Applicability of Lease Terms</U>.
The Demised Premises shall be made available by Landlord to Tenant on or before January&nbsp;1, 2001
(the &#147;Estimated Tenant Improvement Commencement Date&#148;) to undertake such work as is to be
performed by Tenant pursuant and subject to this Lease in order to prepare the Demised Premises
for Tenant&#146;s occupancy. Such entry shall be deemed to be pursuant to a license from Landlord to
Tenant and shall be at the risk of Tenant. In no event shall Tenant interfere with any
construction being performed by or on behalf of Landlord in or around the Building or with the use
of the Building by Landlord or any other occupants; without limiting the generality of the
foregoing, Tenant shall comply with all instructions issued by Landlord&#146;s contractors relative to
the moving of Tenant&#146;s equipment and other property into the Demised Premises and shall pay any
fees or costs imposed in connection therewith. Once Tenant makes such entry, Tenant will be bound
by all terms and conditions of this Lease as if the Term had commenced, excepting payment of Rent.
Landlord agrees to use its good faith and reasonable efforts to coordinate with Tenant the
build-out of the Building shell and the tenant improvements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5 <U>Tenant Plans</U>. Tenant shall perform no construction work in the Building
unless and until Landlord has approved all plans, specifications and the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">identity of contractors and major subcontractors therefor and such plans have been consented to by
Landlord&#146;s mortgagee. Landlord agrees that unless it has disapproved any Tenant plans within ten
(10)&nbsp;business days after receipt thereof, the plans shall be deemed approved. Tenant shall, upon
Landlord&#146;s request, provide payment performance and lien bonds in commercially reasonable amounts
and terms. All of the provisions of Articles 9, 10 and 11 shall apply to Tenant&#146;s work hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 <U>Tenant Improvement Allowance</U>. Provided Tenant is not in default hereunder,
Landlord will provide Tenant with a Tenant Improvement Allowance of $25.00 per rentable square
foot. There shall be deducted from said Tenant Improvement Allowance the following: (i)&nbsp;50% of the
cost of purchase and installation of the emergency generator for the Building, (ii)&nbsp;50% of all
costs of upgrading the power capacity of the Building from 3500 amps to 4000 amps, including,
without limitation, any delay costs (not to exceed $5,000.00) imposed upon Landlord under its
construction contract with Opus attributable to said power capacity upgrades, (iii)&nbsp;all costs to
Landlord associated with using the roofer under contract with Opus, Tenant acknowledging and
understanding that use of said roofer in connection with the installation of Tenant&#146;s rooftop
equipment and screens is required in order to maintain the roof warranty on the Building, and (iv)
the cost of supporting, extending and connecting all screens on the roof, including, without
limitation, all new screens, vertical steel beams, secondary structural support and all related
costs. Landlord shall fund the Tenant Improvement Allowance on a pro rata basis as Tenant pays its
contractor for Tenant&#146;s work. Landlord&#146;s contribution shall be funded based on the fraction of each
construction draw, the numerator of which is $25.00 per rentable square foot and the denominator of
which is the total cost of all work by Tenant to prepare the Demised Premises for Tenant&#146;s
occupancy. Landlord shall have the right to reasonably approve Tenant&#146;s schedule of estimated
construction disbursements. Landlord shall require Tenant to provide appropriate lien waivers and
other evidence of payment contractors, subcontractors and material suppliers prior to funding any
of the Tenant Improvement Allowance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7 <U>Inspections and Scheduling</U>. Tenant may inspect the Building and the Premises
during the construction of the Landlord&#146;s Work as it progresses. Landlord agrees to be available to
Tenant from time to time, on reasonable prior notice, as necessary or desirable to review the
Landlord&#146;s Work.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8 <U>Permits and Approvals</U>. Landlord, at its sole cost and expense, shall obtain all
approvals, permits and other consents required to commence, perform and complete the Landlord&#146;s
Work. Landlord agrees that the Landlord&#146;s Work will comply with all applicable laws and other
governmental regulations as of the date of substantial completion including, but not limited to,
the Americans With Disabilities Act of 1990 (42 U.S.C. &#167;12101 et seq.) and the City of South San
Francisco and State of California Building and fire codes, as the same may be amended from time to
time.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9 <U>Construction Guaranty</U>. Landlord guaranties the Landlord&#146;s Work against defective
workmanship and/or materials for a period of 11&nbsp;months from the date of substantial completion of
the Landlord&#146;s Work, and Landlord agrees, at its sole cost and expense, to repair or replace any
defective item occasioned by poor workmanship and/or materials during said 11&nbsp;month period. Nothing
in this Section&nbsp;4.9 shall limit Landlord&#146;s other repair obligations under this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10 <U>Walkthrough and Punch List</U>. Tenant shall be entitled to a walkthrough and punch
list with Landlord&#146;s architect with respect to Landlord&#146;s Work. The determination of the punch list
shall be at the sole and exclusive approval of Landlord&#146;s architect. Landlord shall remedy all
punch list items within a commercially reasonable time.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>USE OF PREMISES</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Permitted Use</U>. Tenant shall occupy and use the Demised Premises for the Permitted
Use set forth in Article&nbsp;1 and for no other purpose. Service and utility areas (whether or not a
part of the Demised Premises) shall be used only for the particular purpose for which they are
designated. Tenant shall have access to the Demised Premises 24 hours per day, 7&nbsp;days per week.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Prohibited Uses</U>. Tenant shall not use, or suffer or permit the use of, or suffer
or permit anything to be done in or anything to be brought into or kept in, the Demised Premises or
any part thereof (i)&nbsp;which would violate any of the covenants, agreements, terms, provisions and
conditions of this Lease, (ii)&nbsp;for any unlawful purposes or in any unlawful manner, or (iii)&nbsp;which,
in the reasonable judgment of Landlord shall in any way (a)&nbsp;impair or tend to impair the appearance
or reputation of the Building, (b)&nbsp;impair or interfere with or tend to impair or interfere with any
of the Building services or the proper and economic heating, cleaning, air conditioning or other
servicing of the Building or with the use of any of the other areas of the Building, or (c)
occasion discomfort, inconvenience or annoyance to any of the other tenants or occupants of the
Building, whether through the transmission of noise or odors or vibrations or dust or otherwise.
Without limiting the generality of the foregoing, no food shall be prepared or served for
consumption by the general public on or about the Demised Premises; no intoxicating liquors or
alcoholic beverages shall be sold or otherwise served for consumption by the general public on or
about the Demised Premises; no lottery tickets (even where the sale of such tickets is not illegal)
shall be sold and no gambling, betting or wagering shall otherwise be permitted on or about the
Demised Premises; no loitering shall be permitted on or about the Demised Premises; and no loading
or unloading of supplies or other material to or from the Demised Premises shall be permitted on
the Land except at times (excluding Business Days from 7:00 to 9:30 a.m. and from 4:00 to 6:00
p.m.) and in locations to be reasonably designated by Landlord, except for the freight elevator
described in Section&nbsp;7.4, which Tenant may use at any time. The Demised Premises shall be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">maintained in a sanitary condition. Tenant shall suitably store all trash and rubbish in the
Demised Premises or other locations designated by Landlord from time to time. All laboratory waste,
Hazardous Materials and medical waste must be disposed of in compliance with Section&nbsp;5.3. Tenant
specifically agrees that its indemnification obligations pursuant to Section&nbsp;13.2 shall extend to
any claim arising from the consumption of intoxicating liquors or alcoholic beverages on or about
the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 Hazardous Materials.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Definitions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Environmental Law means any governmental statute, code ordinance,
regulation, rule or order and any amendment thereto governing or regulating
materials that are toxic, explosive, corrosive, flammable, radioactive,
carcinogenic, dangerous or otherwise hazardous. Environmental Laws include, without
limitation, the Comprehensive Environmental Response Compensation and Liability Act,
42 U.S.C. &#167;9601 <I>et seq., </I>the Resource Conservation and Recovery Act, 42 U.S.C. &#167;6901
<I>et seq., </I>the California Hazardous Substances Act at California Health and Safety
Code Section l08100 <I>et seq., </I>the provisions regarding hazardous waste control at
California Health and Safety Code Sections&nbsp;25100 through 25250.25 and the California
Medical Waste Management Act at California Health and Safety Code &#167;117600 <I>et seq.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Hazardous Materials shall mean any substance: (A)&nbsp;that now or in the future
is regulated or governed by, requires investigation or remediation under, or is
defined as a hazardous waste, medical waste, hazardous substance, pollutant or
contaminant under any Environmental Law or (B)&nbsp;that is toxic, explosive, corrosive,
flammable, radioactive, carcinogenic, dangerous or otherwise hazardous, including
gasoline, diesel fuel, petroleum hydrocarbons, polychlorinated biphenyls (PCBs),
asbestos, radon and urea formaldehyde foam insulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Tenant&#146;s Covenants</U>. No Hazardous Materials shall be stored, placed,
handled, used or released by Tenant or its employees, contractors, sublessees, guests or
visitors at or about the Demised Premises or Property without Landlord&#146;s prior written
consent, which consent shall not be withheld provided the Hazardous Materials comply with
the criteria set forth in 5.3(c) for Permitted Materials. Landlord shall, within five (5)
business days after receipt of the proposed HMIS, either approve the same or provide Tenant
written notice of the reasons for its disapproval. Tenant shall submit to Landlord for
prior approval as above any HMIS (defined in Section&nbsp;5.3(c))
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">prior to submission to applicable governmental authority. Notwithstanding the foregoing, storage
and use of routine office and janitorial supplies in usual and customary quantities and the
Permitted Materials as defined in subsection (c)&nbsp;below are permitted without Landlord&#146;s prior
written consent, provided that Tenant&#146;s activities at or about the Demised Premises and Property
shall comply at all times with the laws all Environmental Laws. Tenant shall keep Landlord fully
and promptly informed of all storage, placement, handling, use or release by Tenant or its
employees, contractors , sublessees, guests or visitors of all Hazardous Materials. At the
expiration or termination of the Lease, Tenant shall remove from the Demised Premises all Hazardous
Materials brought or released in or on the Building as a result of the activities of Tenant or its
employees, agents, servants, invitees, visitors, customers, contractors, sublessees, and those
other persons for whom Tenant is legally responsible (collectively &#147;Tenant Parties&#148;). Landlord
shall have the right to perform an environmental assessment of the Demised Premises after such
removal, which assessment shall be conducted at Landlord&#146;s expense, unless it reveals that Tenant
has not complied with the requirements set forth in this Section&nbsp;5.3, in which case Tenant shall
reimburse Landlord for the reasonable cost thereof within ten days after Landlord&#146;s request
therefor. Nothing in this Section&nbsp;5.3 shall require Tenant to indemnify Landlord for any matters
arising out of or caused by the actions or omissions of Landlord, its employees, agents,
contractors, licensees, or invitees.. Tenant shall be responsible and liable for the compliance
with all of the provisions of this Section by all of Tenant Parties and all of Tenant&#146;s obligations
under this Section (including its indemnification obligations under subsection (e)&nbsp;below) shall
survive the expiration or termination of this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Landlord hereby authorizes Tenant to use and store, in connection with its Permitted
Use, those materials and medical supplies listed on the Hazardous Material Inventory Statement
(&#147;HMIS&#148;) to be provided to the City of South San Francisco by Tenant with regard to the Demised
Premises (the &#147;Permitted Materials&#148;), provided the classes and quantities of Permitted Materials
comply with all applicable laws and do not alter the legal classification of the laboratories and
storage room, and storage tanks, under the Allowable Class&nbsp;Facilities (defined below). Tenant will
operate under all applicable Federal, State and Local laws governing the use, storage and
management of hazardous materials for building Occupancy Groups A3, B and H Divisions 2, 3 and 7,
as allowable, including Title 22 of the CFR as defined under the Uniform Building Code and Uniform
Fire Code developed by the International Fire Code Institute (the &#147;Allowable Class&nbsp;Facilities&#148;).
Landlord shall have the right to approve in writing Tenant&#146;s construction and operation of said
storage facilities, including, without limitation, fire suppression, seismic restraint, enclosure
and landscaping features. In addition, Tenant may construct an outside storage facility for
storage of up to a total of 2,000 gallons of waste materials, provided no single
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">tank shall exceed 1,000 gallons, such outside storage is in compliance with all applicable laws and
regulations and does not cover a footprint of greater than 250 square feet. Landlord shall have the
right to approve all fire, safety, and seismic restraints, as well as all other plans and
specifications for said outside storage. Additional rent for said outside storage area shall be
$5,000.00 per year. Any consent or approval by Landlord of Tenant&#146;s proposed use, handling and
storage of the Permitted Materials and/or the installation and operation or maintenance of said
tank shall not constitute an assumption of risk by Landlord respecting the same nor warranty or
certification by Landlord that Tenant&#146;s proposed use, handling and storage of the Permitted
Materials and/or the installation, operation or maintenance of the tanks is safe, reasonable or in
compliance with Environmental Laws. All references to Hazardous Materials in this Lease shall
include the Permitted Materials.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Compliance</U>. Tenant shall at Tenant&#146;s expense promptly take all actions
required by any governmental agency or entity in connection with or as a result of the storage,
placement, handling, use or release by Tenant Parties of Hazardous Materials at or about the
Demised Premises or Property, including inspection and testing, performing all cleanup, removal and
remediation work required with respect to those Hazardous Materials, complying with all closure
Laws and postclosure monitoring, and filing all required reports or plans. All medical waste
regulated by any Environmental Laws that is brought to the Demised Premises shall be stored in
leak-proof, closeable containers, which containers shall be stored in a specified &#147;dirty storage
area&#148; of the Demised Premises that shall be protected from leaks or any other type of contamination
of the Demised Premises. Tenant shall never use any of the Landlord&#146;s trash receptacles for
disposing of any medical waste. All of the foregoing work shall be performed in a good, safe and
workmanlike manner by consultants qualified and licensed to undertake such work and in a manner
that will not interfere with any other tenant&#146;s quiet enjoyment of the Property or Landlord&#146;s use,
operation, leasing and sale of the Property. Tenant shall deliver to Landlord prior to delivery to
any governmental agency, or promptly after receipt from any such agency, copies of all permits,
manifests, closure or remedial action plans, notices, and all other documents relating to the
storage, placement, handling, use or release by Tenant Parties of Hazardous Materials at or about
the Demised Premises or Property. Upon prior written notice from Landlord, Tenant shall make
available to Landlord for Landlord&#146;s inspection and copying all of Tenant&#146;s documents, materials,
data, inventories and other documentation (including, without limitation, Material Safety Data
Sheets relating to Hazardous Materials as may be present or suspected to be present in, on or about
the Demised Premises. If any lien attaches to the Demised Premises or the Property in connection
with or as a result of the storage, placement, handling, use or release by Tenant Parties of
Hazardous Materials; and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Tenant does not cause the same to be released, by payment, bonding or otherwise, within ten (10)
days after the attachment thereof, Landlord shall have the right but not the obligation to cause
the same to be released and any sums expended by Landlord in connection therewith shall be payable
by Tenant on demand. Notwithstanding anything in the foregoing to the contrary, Tenant shall not be
responsible for Hazardous Materials not introduced to the Premises, the Building or the Land by
Tenant Parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Tenant shall give Landlord immediate telephone notice and prompt written notice
(which means as soon as practicable and, in no event, more than one (1)&nbsp;day following the
applicable event) of any (i)&nbsp;spill, discharge, dumping, or other release of any Hazardous Materials
(including, without limitation, the Permitted Materials) on, in, under or from the Demised
Premises, the Building, or any portion of the Project, or the groundwater thereof, (ii)&nbsp;any oral or
written notice from any governmental agency received by Tenant of any such spill, discharge,
dumping, or other release of any Hazardous Materials, and (iii)&nbsp;any oral or written notice of any
violation, warning, deficiency, non-compliance, or other alleged or actual failure by Tenant to
comply strictly with any Environmental Law and/or any requirement, provision, or stipulation of any
governmental permit, license, registrations, or approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Landlord&#146;s Rights</U>. Subject to the provisions of Section&nbsp;15.2, Landlord
shall have the right, but not the obligation, to enter the Demised Premises at any reasonable time
upon 24 hours notice except in case of emergency (i)&nbsp;to confirm Tenant&#146;s compliance with the
provisions of this Section, and (ii)&nbsp;to perform Tenant&#146;s obligations under this Section if Tenant
has failed to do so after reasonable notice to Tenant. Landlord shall also have the right to
engage qualified Hazardous Materials consultants to inspect the Demised Premises and review the
storage, placement, handling, use or release by Tenant or its employees, contractors, sublessees,
guests or visitors of Hazardous Materials, including review of all permits, reports, plans, and
other documents regarding same. Tenant shall pay to Landlord on demand the reasonable costs of
Landlord&#146;s consultant&#146;s fees if Tenant is found to have violated the terms of this Section&nbsp;5.3 any
and all reasonable costs incurred by Landlord in performing Tenant&#146;s obligations under this
section. Landlord shall use reasonable efforts to minimize any interference with Tenant&#146;s business
caused by Landlord&#146;s entry into the Demised Premises, but Landlord shall not be responsible for
any interference caused thereby, unless such interference arises out of or is caused by the gross
negligence or willful misconduct of Landlord, its employees, agents, contractors, licensees, or
invitees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Tenant&#146;s Indemnification</U>. Tenant agrees to indemnify, defend and hold
harmless Landlord and its members, managers, directors, officers,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">agents and employees and their partners, members, managers, directors, officers,
shareholders, employees and agents from all shall mean all costs and expenses of any kind,
damages, including foreseeable and unforeseeable consequential damages, fines and penalties
incurred in connection with any violation of and compliance with the Environmental Laws by
Tenant Parties and all losses of any kind attributable to the diminution of value, loss of
use or adverse effects on marketability or use of any portion of the Demised Premises or
Property by Tenant Parties and all other claims, actions, losses, damages, liabilities,
costs and expenses of every kind, including reasonable attorneys&#146;, experts&#146; and consultants&#146;
fees and costs, incurred at any time and arising from or connection with the storage,
placement, handling, use or release by Tenant or its employees, contractors, sublessees,
guests or visitors of Hazardous Materials at or about the Property or Tenant&#146;s failure to
comply in full with all Environmental Laws with respect to the Demised Premises and the
Property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Landlord shall be responsible (at Landlord&#146;s cost and expense) for any
remediation (to the extent required by law) of any Hazardous Materials placed on the
Premises by Landlord or Landlord&#146;s agents or contractors and existing contamination
disclosed in the environmental assessments set forth on Exhibit&nbsp;F attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 <U>Licenses and Permits</U>. If any governmental license or permit shall be required
for the property and lawful conduct of Tenant&#146;s business, and if the failure to secure such license
or permit would in any way affect Landlord, Tenant, at Tenant&#146;s expense, shall duly procure and
thereafter maintain such license or permit and submit the same to inspection by Landlord. Tenant,
at Tenant&#146;s expense, shall at all times comply with the terms and conditions of each such license
or permit.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>RENT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1
<U>Yearly Fixed Rent</U>. Tenant shall pay to Landlord, without any set-off or deduction,
at Landlord&#146;s office, or to such other person or at such other place as Landlord may designate by
notice to Tenant, the Yearly Fixed Rent set forth in Article&nbsp;1. The Yearly Fixed Rent shall be paid
in equal monthly installments in advance on or before the first Business Day of each calendar month
during the Term of this Lease and shall be apportioned for any fraction of a month in which the
Term Commencement Date or the last day of the Term of this Lease may fall.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Rent During Option Term</U>. Yearly Fixed Rent for the five (5)&nbsp;year option term shall
be an amount equal to the greater of (i)&nbsp;95% of the fair-market rent for the first year of the
option term, or (ii)&nbsp;103.5% of the Yearly Fixed Rent payable (without abatement) for the last year
of the original term. If the parties are unable to agree upon a fair market rent prior to ten (10)
months before the commencement of the applicable option term, the matter shall be referred to
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">appraisal as set forth in the following sections. Yearly Fixed Rent during the option term shall
increase annually commencing with the second year of the option term by three and one-half percent
(3.5%) compounded annually. The term fair market rent, for purposes of this Section&nbsp;6.2, shall be
deemed to be the fair market rent for the Demised Premises finished to a level of completion for
ready to occupy first class office space.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Appraisal</U>. Whenever the issue of fair market rent shall be referred to
appraisal, such appraisal shall be by three disinterested appraisers, one to be appointed by the
Landlord, one to be appointed by the Tenant and the third to be appointed by the two appraisers so
named. Within thirty (30)&nbsp;days after the selection of the third appraiser, the three appraisals
shall be added together and their total divided by three; the resulting quotient shall be the fair
market rent for the Premises. If, however, the low appraisal and/or the high appraisal are more
than ten (10%) percent lower and/or higher than the middle appraisal, the low appraisal and/or high
appraisal shall be disregarded, as applicable. If only one appraisal is disregarded, the remaining
two appraisals shall be added together and their total divided by two; the resulting quotient shall
be the fair market rent for the Premises. If both the low appraisal and the high appraisal are
disregarded as stated in this paragraph, the middle appraisal shall be the fair market rent of the
Premises. Each party shall pay the costs of the appraiser selected by such party, and the parties
shall share equally the cost of the third appraiser. Each individual appraiser shall have at least
ten years of experience in appraising fair market rents of comparable properties and shall hold one
or more of the following designations: MAI of the American Institute of Real Estate Appraisers,
SREA from the Society of Real Estate Appraisers or ASA from the American Society of Appraisers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <U>Interim Rent</U>. If the fair market rental value per year is not determined
prior to the commencement of the five year option term, the Tenant shall pay Fixed Rent as though
the Fixed Rent was that Fixed Rent in effect (without abatement) during the last year of said
preceding lease year period until such determination has been made. Following such determination,
the Tenant shall promptly pay the Landlord the difference, if any, between the aggregate rent
which would have been paid during said period and the aggregate rent actually paid. Thereafter,
all rent shall be computed and paid in accordance with Section&nbsp;6.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Taxes</U>. Tenant shall timely file business property statements with respect to
Tenant&#146;s personal property and trade fixtures and pay when due all taxes imposed on such personal
property and trade fixtures. Tenant shall also pay all real estate taxes attributable to the
Demised Premises being improved to a standard in excess of first class office space.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <U>Obligations Survive Termination</U>. All obligations and liabilities of Tenant
relating to any period prior to the termination of the Term of this Lease,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">including without limitation the obligation to pay any Additional Rent due pursuant to the
provisions of this Article, shall survive such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7 <U>Payment to Mortgagee</U>. Landlord reserves the right to provide in any Mortgage given
by it or by Prime Landlord of the Property that some or all rents, issues, and profits and all
other amounts of every kind payable to the Landlord under this Lease shall be paid directly to the
Mortgagee for Landlord&#146;s account and Tenant covenants and agrees that it will, after receipt by it
of notice from Landlord or Mortgagee designating such Mortgagee to whom payments are to be made by
Tenant, pay such amounts thereafter becoming due directly to such Mortgagee until excused therefrom
by notice from such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8 <U>Additional Rent</U>. Tenant shall also pay as additional rent without notice, except
as required under this Lease, and without any abatement, deduction or setoff except as provided
herein, all sums, impositions, costs, expenses and other payments which Tenant in any of the
provisions of this Lease assumes or agrees to pay, and, in case of any nonpayment thereof, Landlord
shall have in addition to any other rights and remedies, all of the rights and remedies provided by
law or provided for in the Lease for the nonpayment of Yearly Fixed Rent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9 <U>Place of Payment of Rent</U>. All payments of Rent shall be made by Tenant to Landlord
without notice or demand at such place as Landlord may from time to time designate in writing. The
initial place for payment of rent shall be 384 Oyster Point Blvd, So. San Francisco, CA 94080. Any
extension of time for the payment of any installment of rent, or the acceptance of rent after the
time at which it is due and payable shall not be a waiver of the rights of Landlord to insist on
having all other payments made in the manner and at the times herein specified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10 <U>Cleaning and Utilities</U>. Tenant shall pay for all utilities used or consumed in
the Demised Premises, including without limitation water, gas, electricity, sewer, telephone, and
all electricity used in heating, ventilating and air conditioning the Demised Premises. In the
event such utilities are not separately billed by the applicable utility supplier, Tenant shall pay
its share of the amount of such bill for the entire Building as measured by submeters or check
meters measuring consumption of such utilities in the Demised Premises. In addition, Tenant shall
arrange for cleaning of the Tenant space in accordance with the cleaning schedule attached hereto
as Exhibit&nbsp;B with a cleaning contractor subject to Landlord&#146;s approval, which approval shall not be
unreasonably withheld. Tenant shall pay all such costs of cleaning.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.&nbsp;UTILITIES AND LANDLORD&#146;S SERVICES</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Electricity</U>. Tenant shall purchase directly from the public utility serving the
Building all electrical energy that Tenant requires for operation of the lighting fixtures,
appliances and equipment servicing the Demised Premises. The
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">costs of initially installing any required meter, submeter or check meter and related installation
equipment shall be paid by Landlord. Landlord shall not be liable in any way to Tenant for any
failure or defect in the supply or character of electrical energy furnished to the Demised Premises
by reason of any requirement, act or omission of the public utility serving the Building.
Notwithstanding the foregoing, the design electrical capacity for the Building is 4000 amperes of
electricity, and Tenant shall be entitled to the use of half of the electricity available for
Tenant spaces, i.e., a minimum and a maximum of 2000 amperes. Tenant&#146;s use of electrical energy in
the Demised Premises shall not at any time exceed the capacity of any of the electrical conductors
and equipment in or otherwise serving the Demised Premises. In order to insure that such capacity
is not exceeded and to avert possible adverse effect upon the Building electrical services Tenant
shall give notice to Landlord and obtain Landlord&#146;s prior written consent whenever Tenant shall
connect to the Building electrical distribution system any fixtures, appliances or equipment other
than lamps, typewriters, personal computers and similar small machines. Landlord&#146;s consent to the
plans for Tenant&#146;s initial improvements shall, to the extent that Tenant&#146;s electrical system and
loads are shown on said plans, suffice as consent for the purposes of this Section&nbsp;7.1. Any feeders
or risers to supply Tenant&#146;s electrical requirements, shall be installed by Landlord upon Tenant&#146;s
request, at the sole cost and expense of Tenant, provided that such feeders and risers are
permissible under applicable laws and insurance regulations and the installation of such feeders or
risers will not cause permanent damage or injury to the Building or cause or create a dangerous
condition or unreasonably interfere with other tenants of the Building. Tenant agrees that it will
not make any alteration or addition to the electrical equipment in the Demised Premises without the
prior written consent of Landlord in each instance first obtained, which consent will not be
unreasonably withheld. Landlord, at Tenant&#146;s expense, shall purchase, install and replace all light
fixtures, bulbs, tubes, lamps, lenses, globes, ballasts and switches used in the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Water Charges</U>. Landlord shall furnish cold water for ordinary cleaning, toilet,
drinking purposes in accordance with Exhibit&nbsp;A-l and hot and cold water for lavatory purposes.
Tenant shall pay for its share of water and related sewer charges in accordance with Section&nbsp;6.10.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <U>Heat and Air Conditioning</U>. Landlord shall furnish to and distribute in the common
areas of the Building heat and air conditioning as normal seasonal changes may require on Business
Days from 8:00 a.m. to 6:00 p.m. and on Saturdays from 9:00 a.m. to 1:00 p.m., provided Landlord
may run common area HVAC on an economy mode on Saturdays. Tenant agrees to lower and close the
blinds or drapes when necessary because of the sun&#146;s position whenever the air conditioning system
is in operation, and to cooperate fully with Landlord with regard to, and to abide by all the
regulations and requirements which Landlord may prescribe for the proper functioning and
protection of, the heating and air conditioning system. Without limiting the generality of the
foregoing, all windows
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in the Demised Premises must remain closed at all times notwithstanding the fact that such windows
may be operable. The air conditioning system servicing the Building is designed to provide cooling
based upon an occupancy of not more than one person per one hundred (100)&nbsp;square feet of floor
area, and upon a combined lighting and standard electrical load not to exceed 3.0 watts per square
foot or 2,000 amperes for the entire Demised Premises. In the event Tenant exceeds such condition
or introduces into the Demised Premises equipment which overloads such system, or in any other way
causes such system not to adequately perform its proper functions, supplementary systems may at
Landlord&#146;s option be provided by Landlord at Tenant&#146;s expense. Tenant shall be responsible for
furnishing heat and air conditioning to the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Elevator Service</U>. Landlord shall provide non exclusive passenger elevator service
consisting of two (2)&nbsp;elevators to the Demised Premises on Business Days from 8:00 a.m. to 6:00
p.m. and on a reduced basis at all other times. Freight elevator service shall be available in
common with other tenants on Business Days from 9:30 a.m. to 4:00 p.m. and at other times at
reasonable charge. Tenant shall be responsible for constructing a freight elevator exclusively to
serve the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <U>Cleaning</U>. Landlord shall furnish cleaning services to the common areas of the Building
substantially in accordance with the specifications attached hereto as Exhibit&nbsp;B and made a part
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <U>Repairs and Other Services</U>. Except as otherwise provided in Articles 8 and 16, and
subject to Tenant&#146;s obligations in Article&nbsp;12 and elsewhere in this Lease, Landlord shall at
Landlord&#146;s expense (a)&nbsp;keep and maintain the roof, exterior walls, structural floor slabs and
columns of the Building in as good condition and repair as they are in on the Term Commencement
Date, reasonable use and wear excepted, (b)&nbsp;keep and maintain in workable condition the Building&#146;s
sanitary, electrical, heating, air conditioning and other systems, (c)&nbsp;keep all walkways on the
Property clean and remove all snow and ice therefrom, (d)&nbsp;provide grounds maintenance to all
landscaped areas, (e)&nbsp;arrange for the extermination of rodents and vermin in the Building (other
than rodents arising out of Tenant&#146;s small animal facility), and (f)&nbsp;keep and maintain the parking
lot adjacent to the Building in good condition and repair.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 Landlord&#146;s Further Responsibilities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Landlord shall be responsible at its sole cost and expense for the removal of
all trash and garbage (excluding Hazardous Materials, laboratory, biological and animal
waste) from the designated containers outside of the Building.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Landlord shall allow Tenant to have full access to and use of the largest
conference room on the third floor of the Building up to eight (8)&nbsp;days per year, as
reasonably agreed to in advance by Landlord and Tenant and upon payment of a reasonable fee
for each such use.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Landlord shall comply with all obligations imposed on it in the CCR&#146;s (defined in
Section&nbsp;27.12) and shall pay its share of any future costs of providing BART shuttle
service.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <U>Interruption or Curtailment of Services</U>. Landlord reserves the right to
interrupt, curtail, stop or suspend the furnishing of services and the operation of any Building
system, when necessary by reason of accident or emergency, or of repairs, alterations, replacements
or improvements in the reasonable judgment of Landlord desirable or necessary to be made, or of
difficulty or inability in securing supplies or labor, or of strikes, or of any other cause beyond
the reasonable control of Landlord, whether such other cause be similar or dissimilar to those
hereinabove specifically mentioned, until said cause has been removed. Landlord shall use
reasonable efforts to minimize interruption to Tenant by any such interruption or curtailment of
services. Landlord shall have no responsibility or liability for any such interruption,
curtailment, stoppage, or suspension of services or systems, except that Landlord shall exercise
reasonable diligence to eliminate the cause of same. Notwithstanding the foregoing, if utilities or
Building services are interrupted due to the fault of Landlord (Tenant acknowledging that Landlord
shall have no responsibility for failure of municipal or public utility suppliers to supply
utilities to the Building), and such disruption continues for more than seven (7)&nbsp;days, rent shall
abate if the Demised Premises are unusable and Tenant in fact vacates the Demised Premises.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CHANGES OR ALTERATIONS BY LANDLORD</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord reserves the right, exercisable by itself or its nominee, including without
limitation Prime Landlord, at any time and from time to time without the same constituting an
actual or constructive eviction and without incurring any liability to Tenant therefor or
otherwise affecting Tenant&#146;s obligations under this Lease, to make such changes, alterations,
additions, improvements, repairs or replacements in or to the Building and the fixtures and
equipment thereof, as well as in or to the street entrances, halls, passages, elevators, and
stairways thereof, as it may deem necessary or desirable, and to change the arrangement and/or
location of entrances or passageways, doors and doorways, and corridors, elevators, stairs,
toilets, or other public parts of the Building, provided, however, that there be no unreasonable
obstruction of the right of access to, or unreasonable interference with the use and enjoyment of,
the Demised Premises by Tenant, except that Landlord shall not be obligated to employ labor at
so-called &#147;over-time&#148; or other premium pay rates. Nothing contained in this Article shall be
deemed to relieve Tenant of any duty, obligation or liability of Tenant with respect to making or
causing to be made
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any repair, replacement or improvement or complying with any law, order or requirement of any
governmental or other authority. Landlord reserves the right to prior to the Commencement Date
create two (2)&nbsp;addresses for the Building. Neither this Lease nor any use by Tenant shall give
Tenant any right or easement or the use of any door or any passage or any concourse connecting with
any other building or to any public convenience, and the use of such doors, passages and concourses
and of such conveniences may be regulated or discontinued at any time and from time to time by
Landlord without notice to Tenant and without affecting the obligations of Tenant hereunder or
incurring any liability to Tenant therefor.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIXTURES, EQUIPMENT AND IMPROVEMENTS &#151; REMOVAL BY TENANT</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All fixtures, equipment, leasehold improvements and appurtenances attached to or built into the
Demised Premises prior to or during the Term, whether by Landlord at its expense or at the expense
of Tenant (either or both) or by Tenant shall be and remain part of the Demised Premises and shall
not be removed by Tenant at the end of the Term unless otherwise expressly provided by notice from
Landlord to Tenant. Upon the request of Landlord, Tenant will remove such fixtures, equipment,
leasehold improvements and appurtenances as are directed by Landlord and shall restore any damage
caused by such removal. Notwithstanding the foregoing to the contrary, Tenant may, in
connection with the initial Tenant improvements or any other fixtures, alterations or additions to
the Demised Premises, upon presentation of detailed plans and specifications therefor, request in
writing that Landlord advise Tenant which of said improvements, alterations or additions Landlord
will require Tenant to remove at the end of the Term. Landlord shall advise Tenant in writing
within thirty (30)&nbsp;days after receipt of such written request and the accompanying plans and
specifications. If Landlord shall, in said written notice, require Tenant to remove an item at the
end of the Term, Landlord shall have the right to rescind that decision and require Tenant to leave
said item in place at the end of the Term by subsequent written
notice to Tenant. Tenant shall
remove the fixtures and equipment on Exhibit&nbsp;H and shall remediate all environmental contamination
and Hazardous Materials associated with said items. All such removal shall be done in a good and
workmanlike manner, and Tenant shall repair and restore any damage to the Building caused by such
removal. In addition, any duct work, controls and rooftop exhaust equipment associated with the
exhaust hoods must also be removed. Tenant shall structurally in-fill patch, flash and cap the roof
to a weather-tight condition consistent with the four-ply built-up construction so as not to void
the roof warranty. The in-wall and above ceiling copper and plastic piping associated with the
vacuum compressed air or DI system and any specialty gas piping must be removed and remediated if
any of the same is shown to be contaminated as provided in the environmental inspection of the
Demised Premises made pursuant to Section&nbsp;5.3(b). Any contaminated rooftop HVAC units and
associated duct work shall also require removal at the Landlord&#146;s discretion. Also, office
workstations must be removed and remediated.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ALTERATIONS AND IMPROVEMENTS BY TENANT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall make no alterations, decorations, installations, removals, additions or
improvements in or to the Demised Premises without Landlord&#146;s prior written consent and then only
by contractors or mechanics approved by Landlord. No such installations or other work shall be
undertaken or begun by Tenant until Landlord has approved written plans and specifications
therefor; and no amendments or additions to such plans and specifications shall be made without
prior written consent of Landlord. Such approval shall not be unreasonably withheld provided such
installations or work are non-structural, do not affect the exterior of the Building, and do not
interfere with or impair utilities and systems in the Building. Notwithstanding the foregoing,
Landlord&#146;s consent shall not be required for any alteration, addition or improvement that either
(a)&nbsp;costs leas than Twenty-Five Thousand Dollars ($25,000.00) or (b)&nbsp;satisfies all of the following
criteria: (i)&nbsp;is of a cosmetic nature such as painting, wallpapering, hanging pictures and
installing carpeting, (ii)&nbsp;is not visible from the exterior of the Premises or Building, and (iii)
will not affect the systems or structure of the Building, provided, however, in any such instance
Tenant provides plans and specifications for such work not less than ten (10)&nbsp;days before
commencing such work. Any such alterations, decorations, installations, removals, additions and
improvements shall be done at the sole expense of Tenant and at such times and in such manner as
Landlord may from time to time reasonably designate. Subject to the terms of Section&nbsp;9 herein, if
Tenant shall make any alterations, decorations, installations, removals, additions or improvements,
then Landlord may elect to require Tenant at the expiration of this Lease to restore the Demised
Premises to substantially the same condition as existed at the Term Commencement Date.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>TENANT&#146;S CONTRACTORS &#151; MECHANICS&#146; AND OTHER
LIENS &#151; STANDARD OF TENANT&#146;S
PERFORMANCE &#151; COMPLIANCE WITH LAWS</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever Tenant shall make any alterations, decorations, installations, removals, additions
or improvements or do any other work in or to the Demised Premises, Tenant will strictly observe
the following covenants and agreements:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In no event shall any material or equipment be incorporated in or added to
the Demised Premises in connection with any such alteration, decoration, installation,
addition or improvement which is subject to any lien, charge, mortgage or other
encumbrance of any kind whatsoever or is subject to any security interest or any form of
title retention agreement. Any mechanic&#146;s lien filed against the Demised Premises or the
Building for work claimed to have been done for, or materials claimed to have been
furnished to Tenant shall be discharged by Tenant within twenty (20)&nbsp;days thereafter, at
the expense of Tenant, by filing the bond required by law or otherwise. If
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Tenant fails so to discharge any lien, Landlord may do so at Tenant&#146;s expense and Tenant
shall reimburse Landlord for any expense or cost incurred by Landlord in so doing within
fifteen (15)&nbsp;days after rendition of a bill therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All installations or work done by Tenant under this or any other Article of this
Lease shall be at its own expense (unless expressly otherwise provided) and shall at all
times comply with (i)&nbsp;laws, rules, orders and regulations of governmental authorities having
jurisdiction thereof and (ii)&nbsp;plans and specifications prepared by and at the expense of
Tenant theretofore submitted to Landlord for its prior written approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Tenant shall procure all necessary permits before undertaking any work in the
Demised Premises; do all such work in a good and workmanlike manner, employing materials of
good quality and complying with all governmental requirements, and defend, save harmless,
exonerate and indemnify Landlord from all injury, loss or damage to any person or property
occasioned by or growing out of such work.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Tenant shall notify Landlord no later than ten (10)&nbsp;days prior to starting work on
any alterations so that Landlord shall have the opportunity to post a &#147;Notice of
nonresponsibility&#148; at the Demised Premises and record said notice in the county in which,
the Property is located pursuant to California Civil Code Section&nbsp;3094.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) all contractors and subcontractors shall be approved by Landlord, which approval
shall not be unreasonably withheld, and all work by Tenant shall be performed by such
contractors and subcontractors and in such manner as to maintain harmonious labor relations.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">12.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>REPAIRS BY TENANT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant, at its expense, shall keep or cause to be kept, all and singular, the Demised Premises
in good repair, order and condition, reasonable use and wear thereof and damage by fire or by
unavoidable casualty excepted. Without limiting the generality of the foregoing, Tenant shall keep
all interior windows and other glass whole, and shall replace the same whenever broken with glass
of the same quality and shall repair or replace all exterior windows if damaged by neglect or
wrongdoing of Tenant. Tenant hereby waives the benefits of California Civil Code Section&nbsp;1932(1).
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INSURANCE, INDEMNIFICATION, EXONERATION AND EXCULPATION</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.1 Tenant&#146;s Insurance
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Liability Insurance</U>. Tenant shall maintain in full force
throughout the Term commercial general liability and property damage
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">insurance providing coverage on an occurrence form basis with limits of not less than Five Million
Dollars ($5,000,000.00) each occurrence for bodily injury and property damage combined, Five
Million Dollars ($5,000,000.00) annual general aggregate, and Five Million Dollars ($5,000,000.00)
products and completed operations (if applicable) annual aggregate. Tenant&#146;s liability insurance
policy or policies shall: (i)&nbsp;include premises and operations liability coverage, automobile,
products and completed operations liability coverage (if applicable), broad form property damage
coverage including completed operations (if applicable), blanket contractual liability coverage
with, to the maximum extent possible, coverage for the indemnification obligations of Tenant under
this Lease, and personal and advertising injury coverage; (ii)&nbsp;provide that the insurance company
has the duty to defend all insureds under the policy; (iii)&nbsp;provide that defense costs are paid in
addition to and do not deplete any of the policy limits; (iv)&nbsp;cover liabilities arising out of or
incurred in connection with Tenant&#146;s use or occupancy of the Premises or the Property; and (v)
extend coverage to cover liability for the actions of Tenant&#146;s employees, contractors, sublessees,
guests and visitors. Tenant&#146;s required insurance may be maintained by a combination of underlying
and &#147;umbrella&#148; coverage.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Leasehold Improvements Personal Property Insurance.</U> Tenant shall at all
times maintain in effect with respect to Tenant&#146;s leasehold improvements and fixtures, equipment
and personal property located at or within the Demised Premises, builder&#146;s risk and commercial
property insurance providing coverage, at a minimum, for &#147;broad form&#148; perils, to the extent of
100% of the full replacement cost of covered property. Tenant may carry such insurance under a
blanket policy, provided that such policy provides equivalent coverage to a separate policy.
During the Term, the proceeds from any such policies of insurance shall be used for the repair or
replacement of such leasehold improvements, fixtures, equipment and personal property so insured.
Landlord shall be provided coverage under such insurance to the extent of its insurable interest
and, if requested by Landlord, both Landlord and Tenant shall sign all documents reasonably
necessary or proper in connection with the settlement of any claim or loss under such insurance.
Landlord shall have no obligation to carry insurance on any such Tenant&#146;s leasehold improvements
or on Tenant&#146;s fixtures, equipment or personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Workmen&#146;s Compensation Insurance.</U> Tenant shall maintain worker&#146;s compensation
insurance as required by law and employer&#146;s liability insurance in an amount not less than Five
Hundred Thousand Dollars ($500,000).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>Business Interruption/Extra Expense Insurance.</U> Tenant shall maintain loss of
income, business interruption and extra expense insurance
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">in such amounts as will reimburse Tenant for direct or indirect loss of earnings and incurred costs
attributable to the perils commonly covered by Tenant&#146;s property insurance described above but in
no event less than One Million Five Hundred Thousand Dollars ($1,500,000.00). Such insurance shall
be carried with the same insurer that issues the insurance for the personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Other Coverage.</U> Tenant, at its cost, shall maintain such other insurance as
Landlord may reasonably require from time to time, but in no event may Landlord require any other
insurance which is (i)&nbsp;not then being required of comparable tenants leasing comparable amounts of
space in comparable buildings in the vicinity of the Building or (ii)&nbsp;not then available at
commercially reasonable rates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>Insurance Criteria.</U> Each policy of insurance required under this Section shall:
(i)&nbsp;be in a form, and written by an insurer, reasonably acceptable to Landlord, (ii)&nbsp;be maintained
at Tenant&#146;s sole cost and expense, and (iii)&nbsp;require at least thirty (30)&nbsp;days&#146; written notice to
Landlord prior to any cancellation, nonrenewal or modification of insurance coverage. Insurance
companies issuing such policies shall have rating classifications of &#147;A&#148; or better and financial
size category ratings of &#147;XIII&#148; or better according to the latest edition of the A.M. Best Key
Rating Guide. All insurance companies issuing such policies shall be licensed to do business in the
State of California. Any deductible amount under such insurance shall not exceed maximum deductible
amounts currently required under similar leases for buildings in the vicinity of the Building, with
Tenant having the burden of proof. Tenant shall provide to Landlord, upon request, evidence that
the insurance required to be carried by Tenant pursuant to this Section, including any endorsement
affecting the additional insured status, is in full force and effect and that premiums therefore
have been paid.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Increase in Amount of Insurance.</U> Tenant shall increase the amounts of insurance as
required by any Mortgagee, and, not more frequently than once every three (3)&nbsp;years, as recommended
by Landlord&#146;s insurance broker, if, in the reasonable opinion of either of them, the amount of
insurance then required under this Lease is not adequate. Any limits set forth in this Lease on the
amount or type of coverage required by Tenant&#146;s insurance shall not limit the liability of Tenant
under this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Insurance Provisions</U>. Each policy of liability insurance required by this
Section shall: (i)&nbsp;contain a cross liability endorsement or separation of insureds clause; (ii)
provide that it is primary to and not contributing with, any policy of insurance carried by
Landlord or Prime Landlord covering the same loss; (iii)&nbsp;provide that any failure to comply with
the reporting provisions shall not affect coverage provided to Landlord, Prime Landlord,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">their officers, directors, shareholders, members, property managers and mortgagees; and (iv)
name Prime Landlord, Mortgagees, Landlord, their officers, directors, employees,
shareholders, members, property managers and such other parties in interest as Landlord may
from time to time reasonably designate to Tenant in writing, as additional insureds. Such
additional insureds shall be provided the same extent of coverage as provided to Tenant under
such policies. All endorsements affecting such additional insured status shall be acceptable
to Landlord and shall be at least as broad as additional insured endorsement form number CG
20 11 11 85 promulgated by the Insurance Services Office.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Evidence of Coverage.</U> Prior to occupancy of the Premises by Tenant,
and not less than thirty (30)&nbsp;days prior to the expiration of any policy thereafter, Tenant
shall furnish to Landlord a certificate of insurance reflecting that the insurance required
by this Section is in force accompanied by an endorsement showing the required additional
insureds satisfactory to Landlord in substance and form. Notwithstanding the requirements of
this paragraph, Tenant shall, at Landlord&#146;s request, provide to Landlord within a
commercially reasonable time a certified copy of each insurance policy required to be in
force at any time pursuant to the requirements of this Lease or its Exhibits. Tenant&#146;s
failure to furnish Landlord with such certificates of insurance within a reasonable time (not
to exceed ten (10)&nbsp;days) after Landlord&#146;s request shall be deemed a material default under
this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.2 <U>General</U>. Tenant will save Landlord harmless, and will exonerate and indemnify
Landlord and Prime Landlord, from and against any and all claims, liabilities, penalties, damages
or expenses (including without limitation reasonable attorneys&#146; fees) asserted against or incurred
by Landlord or Prime Landlord:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) on account of or based upon any injury to person, or loss of or damage to property
sustained or occurring on the Demised Premises on account of or based upon the act,
omission, fault, negligence or misconduct of any person whomsoever (other than Landlord,
Prime Landlord or their agents, contractors or employees);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) on account of or based upon any injury to person or loss of or damage to property,
sustained or occurring elsewhere (other than on the Demised Premises) in or about the
Building (and, in particular, without limiting the generality of the foregoing on or about
the elevators, stairways, public corridors, sidewalks, roof, or other appurtenances and
facilities used in connection with the Building or Demised Premises) arising out of the use
or occupancy of the Building or Demised Premises by Tenant, or any person claiming by,
through or under Tenant;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) on account of or based upon (including moneys due on account of) any work or thing
whatsoever done (other than by Landlord, Prime Landlord or their contractors, or agents or
employees of any such party) in the Demised Premises during the Term of this Lease and
during the period of time, if any, prior to the Term Commencement Date that Tenant may have
been given access to the Demised Premises; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) on account of or resulting from the failure of Tenant to perform and discharge any
of its covenants and obligations under this Lease;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and, in case any action or proceeding be brought against Landlord or Prime Landlord by reason of
any of the foregoing, Tenant upon notice from Landlord shall at Tenant&#146;s expense resist or defend
such action or proceeding and employ counsel therefor reasonably satisfactory to Landlord, it being
agreed that such counsel as may act for insurance underwriters of Tenant engaged in such defense
shall be deemed satisfactory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.3 <U>Property of Tenant</U>. In addition to and not in limitation of the foregoing, and
subject only to provisions of applicable law, Tenant covenants and agrees that all merchandise,
furniture, fixtures and property of every kind, nature and description which may be in or upon the
Demised Premises or elsewhere on the Property during the Term of this Lease, shall be at the sole
risk and hazard of Tenant, and that if the whole or any part thereof shall be damaged, destroyed,
stolen or removed from any cause or reason whatsoever other than the negligence or misconduct of
Landlord or Prime Landlord or their contractors, or agents or employees of any such party, no part
of said damage or loss shall be charged to, or borne by Landlord or Prime Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.4 <U>Bursting of Pipes, etc.</U> Landlord shall not be liable for any injury or damage to
persons or property resulting from fire, explosion, seismic events, earthquakes, falling plaster or
tiles, steam, gas, electricity, electrical disturbance, water, rain or snow or leaks from any part
of the Building or from the pipes, appliances or plumbing works or from the roof, street or
sub-surface or from any other place or caused by any other cause of whatever nature, unless caused
by or due to the negligence of Landlord, its agents, servants or employees; nor shall Landlord or
its agents be liable for any such damage caused by other tenants or persons in the Building or
caused by operations in construction of any private, public or quasi-public work; nor shall
Landlord be liable for any latent defect in the Demised Premises or elsewhere in the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.5
<U>Landlord&#146;s Insurance</U>. Landlord shall, at its sole expense, carry so-called &#147;all
risk&#148; full replacement cost casualty insurance on the Building (exclusive of Tenant&#146;s leasehold
improvements, fixtures and equipment).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ASSIGNMENT, MORTGAGING, SUBLETTING, ETC.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1 <U>Generally</U>. Tenant shall not voluntarily, involuntarily or by operation of law
assign, transfer, mortgage or otherwise encumber this Lease or any interest of Tenant therein, in
the whole or in part of the Premises or permit the Premises or any part thereof to be used or
occupied by others, without the prior written consent of Landlord and Landlord&#146;s mortgagee. Except
in connection with a public stock offering, a transfer of any of Tenant&#146;s stock or a transfer or
change of control of Tenant (if Tenant is a corporation), or a change in the composition of persons
or entities owning any interest in Tenant (if Tenant is not a corporation), or any transfer of
Tenant&#146;s interest in the Lease by operation of law or by merger or consolidation of Tenant with or
into any other entity, firm or corporation, shall be deemed an assignment for purposes of this
Article&nbsp;14. Notwithstanding anything to the contrary in this Lease, except with respect to
Corporate Transfers (hereinafter defined) to a Competitor (as defined in Section&nbsp;14.2), Tenant
shall not be required to obtain Landlord&#146;s consent, and the terms of Sections&nbsp;14.2 and 14.3 of this
Lease shall not apply, to any transfer of Tenant&#146;s stock or a transfer or change of control of
Tenant or other transfer to an entity which controls, is controlled by or is under common control
with Tenant or any successor to Tenant or which succeeds to substantially all of Tenant&#146;s assets
and business by merger, consolidation, reorganization or purchase or in connection with an initial
public offering (collectively referred to as &#147;Corporate Transfers&#148;). Tenant shall give Landlord
written notice at least thirty (30)&nbsp;days prior to the effective date of such Corporate Transfer. As
used herein, the terms &#147;controlled&#148; or &#147;controls&#148; or &#147;control&#148; shall mean ownership of at least
fifty-one percent (51%) of voting control of the relevant entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2 <U>Landlord&#146;s Options</U>. In connection with any request by Tenant for Landlord&#146;s
consent to assignment or subletting, Tenant shall submit to Landlord in writing (&#147;Tenant&#146;s
Sublease Notice&#148;) (i)&nbsp;the name of the proposed assignee or subtenant, (ii)&nbsp;such information as to
its financial responsibility and standing as Landlord may reasonably require, and (iii)&nbsp;all of
the terms and provisions upon which the proposed assignment or subletting is to be made. Within
ten (10)&nbsp;business days after receipt from Tenant of Tenant&#146;s Sublease Notice and receipt of the
information required hereunder, Landlord shall have the following options: (a)&nbsp;reasonably
withholding its consent if the proposed sublease is at least 10,000 rentable square feet, or if
the proposed sublease is less than 10,000 rentable square feet, withholding consent in its sole
and absolute discretion; (b)&nbsp;withholding consent if the proposed assignee or sublessee is a
&#147;Competitor&#148; (as that term is hereinafter defined); (c)&nbsp;if the request is made after the third
(3rd) anniversary of the commencement of the Term and is to sublet a portion of the Premises, to
elect to match said offer and sublease the Demised Premises or relevant portion thereof on the
same terms and conditions as set forth in Tenant&#146;s Sublease Notice; (d)&nbsp;if the request is made
after the third (3rd) anniversary of the commencement of the Term and is to assign this Lease or
sublet all of the Premises, elect to match said offer
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and accept an assignment of this Lease on the same terms and conditions set forth in Tenant&#146;s
Sublease Notice, or (e)&nbsp;consenting to the proposed assignment or such leasing. The term
&#147;Competitor,&#148; as used herein shall mean any person or entity engaged in the manufacture or sale of
instruments for DNA sequencing or amplification, including, without limitation, the following
businesses and any affiliates, subsidiaries, parents or successors thereto: PE Corp., Applera
Corporation, PE Biosystems, Inc., Applied Biosystems, Inc., Celera Genomics, Inc., Celera Genomics
Group, F. Hoffmann-LaRoche Ltd., Hoffmann-LaRoche, Inc., Roche Diagnostics Corporation, Roche
Molecular Systems, Inc., Amersham Pharmacia Biotech, Ltd., Molecular Dynamics, Inc., Perkin Elmer
Corporation, Strategene, Hybade Ltd., Ericomp, Techne Corporation, MWG Biotech AG, Whatman
Biometra, Labreco, Inc., Bio-Rad Laboratories, Inc., and Cepheid. In the event Landlord shall
exercise either option (c)&nbsp;or (d)&nbsp;above, Tenant shall sublease the Demised Premises or relevant
portion thereof or assign this Lease to Tenant upon the terms and conditions set forth in said
Tenant&#146;s Sublease Notice. In the event Landlord elects to match this offer in Tenant&#146;s Sublease
Notice as set forth in clause (d)&nbsp;above, Tenant shall remain responsible for removal of leasehold
improvements and equipment as required in Sections&nbsp;9 and 10 at the end of the Term or earlier
termination of this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3 <U>Conditions</U>. Any subletting or assignment pursuant to this Article shall be
subject to and conditioned upon the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) at the time of any proposed subletting or assignment, Tenant shall not be in
default under any of the terms, covenants, or conditions of this Lease beyond applicable
grace periods;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the sublessee or assignee shall conduct its business in accordance
with the Permitted Use;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) prior to occupancy, Tenant and its assignee or sublessee shall execute,
acknowledge and deliver to Landlord a fully executed counterpart of a written assignment of
lease or a written sublease, as the case may be, by the terms of which:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) in case of an assignment of this Lease in its entirety, Tenant shall assign
to such assignee Tenant&#146;s entire interest in this Lease, together with all prepaid
rents hereunder, and the assignee shall accept said assignment and assume and agree
to perform directly for the benefit of Landlord, all of the terms, covenants and
conditions of this Lease on Tenant&#146;s part to be performed; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) in case of a subletting, the sublessee thereunder shall agree to be bound
by and to perform all of the terms, covenants and conditions of this Lease on the
Tenant&#146;s part to be performed, except
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">the payments of rents, charges and other sums reserved hereunder, which Tenant
shall continue to be obligated to pay and shall pay to Landlord;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Tenant shall pay to Landlord monthly one-half of the excess of the rents and other
charges received by Tenant pursuant to the assignment or sublease over the rents and other
charges reserved to Landlord under this Lease attributable to the space assigned or sublet,
less the reasonable costs and expenses of subleasing and less the unamortized cost of
Tenant&#146;s leasehold improvements (but not trade fixtures or equipment) paid for by Tenant,
which cost shall be amortized over a ten year basis commencing on the Term Commencement Date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Tenant and any guarantor of Tenant&#146;s obligations hereunder (hereinafter &#147;Guarantor&#148;)
shall acknowledge that, notwithstanding such assignment or sublease and consent of Landlord
thereto, Tenant and Guarantor shall not be released or discharged from any liability
whatsoever under this Lease and will continue to be liable with the same force and effect as
though no assignment or sublease had been made; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Tenant shall pay Landlord&#146;s reasonable costs including but not limited to
attorney&#146;s fees and Landlord&#146;s administrative and overhead costs, incurred in connection
with each such assignment or subletting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.4 <U>Landlord&#146;s Consent</U>. Landlord shall not unreasonably withhold its consent to a
sublease of at least 10,000 rentable square feet or assignment pursuant to the preceding Section
14.1, subject to Landlord&#146;s options in subclauses (c)&nbsp;and (d)&nbsp;of Section&nbsp;14.2. If Landlord elects
to pursue its option under Section&nbsp;14.2 to match the terms of Tenant&#146;s Sublease Notice, this
Section&nbsp;14.4 is not relevant. Landlord&#146;s failure to consent shall be deemed unreasonable if the
conditions set forth in Subsections 14.3(a)-(f) are met, Landlord&#146;s Mortgagee has consented thereto
and if:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The proposed assignment or subletting is made to a party other than a Competitor;
or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The proposed assignee or subtenant has a good credit rating, which shall be at
least equal to that of Tenant as of the Term Commencement Date, and demonstrable ability to
comply with the terms and conditions of this Lease, a good reputation in the community, and
the proposed use by such subtenant or assignee (even though Permitted Use) could not in
Landlord&#146;s reasonable opinion be expected to detract from the character of the Building at
the time of the proposed assignment or sublease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.5 <U>No Waiver</U>. The consent by Landlord to an assignment or subletting shall not in
any way be construed to relieve Tenant from obtaining the express consent of Landlord to any
further assignment or subletting for the use of all or any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">part of the Premises, nor shall the collection of rent by Landlord from any assignee, sublessee or
other occupant after default by Tenant be deemed a waiver of this covenant or the acceptance of
such assignee, sublessee or occupant as tenant or a release of Tenant from the further performance
by Tenant of the obligations in this Lease on Tenant&#146;s part to be performed.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>MISCELLANEOUS COVENANTS</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1 <U>Rules and Regulations</U>. Tenant and Tenant&#146;s servants, employees,
agents, visitors and licensees will faithfully observe such Rules and Regulations as
are attached hereto as Exhibit&nbsp;C and made a part hereof or as Landlord hereafter at
any time or from time to time may make and may communicate in writing to
Tenant and which in the reasonable judgment of Landlord shall be necessary for the
reputation, safety, care or appearance of the Property, or the preservation of good
order therein, or the operation or maintenance of the Property, or the equipment
thereof, or the comfort of tenants or others in the Building, provided, however, that
in the case of any conflict between the provisions of this Lease and any such Rules
and Regulations, the provisions of this Lease shall control, and provided further
that nothing contained in this Lease shall be construed to impose upon Landlord
any duty or obligation to enforce such Rules and Regulations or the terms,
covenants or conditions in any other lease as against any other tenant and Landlord
shall not be liable to Tenant for violation of the same by any other tenant, its servants, employees, agents, visitors, invitees or licensees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.2 <u>Access to Premises</u>. Tenant shall: (i)&nbsp;permit Landlord to erect, use and maintain pipes, ducts and conduits in and through the Demised Premises,
provided the same do not materially reduce the floor area or materially adversely
affect the appearance thereof; (ii)&nbsp;permit the Landlord and any Mortgagee to have
free and unrestricted access to and to enter upon the Demised Premises at all
reasonable hours (upon 24 hours prior notice except in case of emergency) for the
purposes of inspection or of making repairs, replacements or improvements in or to
the Demised Premises or the Building or equipment (including, without limitation,
sanitary, electrical, heating, air conditioning or other systems) or of complying with
all laws, orders and requirements of governmental or other authority or of
exercising any right reserved to Landlord by this Lease (including the right during
the progress of any such repairs, replacements or improvements or while
performing work and furnishing materials in connection with compliance with any
such laws, orders or requirements to take upon or through, or to keep and store
within, the Demised Premises all necessary materials, tools and equipment); and
(iii)&nbsp;permit Landlord, at reasonable times and upon 24 hours prior notice, to show
the Demised Premises during ordinary business hours to any Mortgagee,
prospective purchaser of any interest of Landlord in the Property, prospective
Mortgagee, or prospective assignee of any Mortgage, and during the period of twelve
months next preceding the Termination Date to any person contemplating the
leasing of the Demised Premises or any part thereof. If Tenant shall not be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">personally present to open and permit any entry into the Demised Premises at any time when for any
reason an entry therein shall be necessary or permissible pursuant to the terms of this Lease or by
law, Landlord or Landlord&#146;s agents must nevertheless be able to gain such entry by contacting a
responsible representative of Tenant, whose name, address and telephone number shall be furnished
by Tenant. Provided that Landlord shall not be obligated to employ labor at so-called &#147;over-time&#148;
or other premium pay rates, Landlord shall exercise its rights of access to the Demised Premises
permitted under any of the terms and provisions of this Lease in such manner as to minimize to the
extent practicable interference with Tenant&#146;s use and occupation of the Demised Premises.
Notwithstanding the foregoing, any entry (other than in case of emergency) by Landlord, any
Mortgagee or any of their agents or representatives shall be subject to Tenant&#146;s reasonable
security requirements, including but not limited to the requirement that a representative of Tenant
accompany such parties when in certain parts of the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.3 <U>Accidents to Sanitary and other Systems</U>. Tenant shall give to
Landlord prompt notice of any fire or accident in the Demised Premises or in the
Building and of any damage to, or defective condition in, any part or appurtenance
of the Building&#146;s sanitary, electrical, heating and air conditioning or other systems located in, or passing through, the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.4 <u>Signs, Blinds and Drapes</u>. Tenant shall not place any signs on the exterior of the Building (except as provided in Section&nbsp;27.11) or on or in any
window, public corridor or door visible from the exterior of the Demised Premises.
No drapes or blinds may be put on or in any exterior window nor may any Building drapes or blinds be removed by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.5 <u>Estoppel Certificate</u>. Tenant shall at any time and from time to time upon not less than ten business (10)&nbsp;days&#146; prior notice by Landlord, Prime Landlord
or by a Mortgagee to Tenant, execute, acknowledge and deliver to the party making
such request a statement in writing certifying that this Lease is unmodified and in
full force and effect (or if there have been modifications, that the same is in full
force and effect as modified and stating the modifications), and the dates to which
Rent has been paid in advance, if any, and stating whether or not to the actual
knowledge and belief of the signer of such certificate Landlord is in default in
performance of any covenant, agreement, term, provisions or condition contained in
this Lease and, if so, specifying each such default of which the signer may have
knowledge, it being intended that any such statement delivered pursuant hereto
may be relied upon by any prospective purchaser of any interest in the Property,
any Mortgagee or prospective Mortgagee, any lessee or prospective lessee thereof,
any prospective assignee of any Mortgage, or any other party designated by
Landlord. The form of any such estoppel certificate requested by a Mortgagee shall
be reasonably satisfactory to such Mortgagee.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.6 <u>Requirements of Law &#151; Fines and Penalties</u>. Tenant at its sole expense
shall comply with all laws, rules, orders and regulations of Federal, State, County
and Municipal Authorities and with any direction of any public officer or officers,
pursuant to law, which shall impose any duty upon Landlord or Tenant with respect
to and arising out of Tenant&#146;s use or occupancy of the Demised Premises. If Tenant
receives notice of any violation of law, ordinance, order or regulation applicable to
the Demised Premises, it shall give prompt notice thereof to Landlord. Without
limiting the generality of the foregoing, Tenant shall be responsible for compliance
with requirements imposed by the Americans with Disabilities Act relative to the
Demised Premises, including without limitation all such requirements applicable to
removing barriers, furnishing auxiliary aids and ensuring that, whenever
alterations are made, the affected portions of the Demised Premises are readily
accessible to and usable by individuals with disabilities. Notwithstanding anything
in the foregoing to the contrary, if the requirement of additional work in the
Demised Premises is caused by governmental action solely as result of work being
done by Landlord in parts of the Building other than the Demised Premises, then
Landlord shall be responsible for the cost of such ADA work. Conversely, if
additional ADA work in the Building is caused by governmental action solely as a
result of work in the Demised Premises by Tenant, then Tenant shall be responsible for the cost of such ADA work.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.7 <u>Tenant&#146;s Acts &#151; Effect on Insurance</u>. Tenant shall not do or permit to be done any act or thing upon the Demised Premises or elsewhere in the Building
which will invalidate or be in conflict with any insurance policies covering the
Building and the fixtures and property therein and shall not do, or permit to be
done, any act or thing upon the Demised Premises which shall subject Landlord to
any liability or responsibility for injury to any person or persons or to property by
reason of any business or operation being conducted on the Demised Premises or for
any other reason. Subject to the terms of this Lease and except as otherwise
specifically set forth to the contrary herein, Tenant at its own expense shall comply
with all applicable provisions of the California Health and Safety Code and all
regulations promulgated thereunder and with all rules, orders, regulations or
requirements of the underwriter(s) of the fire and other hazard insurance for the
Property and the Demised Premises and shall not do, or permit anything to be done,
in or upon the Demised Premises, or bring or keep anything therein, that is not
permitted by the City of South San Francisco Fire Department, or other authority
having jurisdiction, and then only in such quantity and manner of storage as will not increase the rate for any insurance applicable to the Building. If by reason of failure of
Tenant to comply with the provisions hereof the insurance rate applicable to any policy of
insurance shall at any time thereafter be higher than it otherwise would be, then Tenant shall
reimburse Landlord for that part of any insurance premiums thereafter paid by Landlord, which shall
have been charged because of such failure by Tenant.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.8 <U>Miscellaneous</U>. Tenant shall not suffer or permit the Demised Premises or any
fixtures, equipment or utilities therein or serving the same, to be overloaded, damaged or defaced.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">16.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>DAMAGE BY FIRE, ETC.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of loss of, or damage to, the Demised Premises or the Building by fire or other
casualty, the rights and obligations of the parties hereto shall be as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If the Demised Premises, or any part thereof, shall be damaged by fire or other
casualty, Tenant shall give prompt notice thereof to Landlord, and Landlord, upon receiving
such notice and the insurance proceeds for such casualty, shall proceed in a commercially
reasonable manner, subject to unavoidable delays, to repair, or cause to be repaired, such
damage to the extent hereinafter provided. Landlord shall be responsible to restore only to
the &#147;cold shell&#148; condition as set forth on Exhibit&nbsp;A-l, and Tenant shall be responsible for
restoration of all leasehold improvements beyond such cold shell. If the Demised Premises
or any part thereof shall be rendered untenantable by reason of such damage, whether to the
Demised Premises or to the Building, Yearly Fixed Rent shall proportionately abate for the
period from the date of such damage to the date when such damage shall have been repaired
by Landlord to the condition set forth on Exhibit&nbsp;A-l.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If, as a result of fire or other casualty, the whole or a substantial
portion of the Building is rendered untenantable and the nature and extent of the damage
is such that in Landlord&#146;s opinion, taking into account a reasonable time for adjusting
loss and obtaining plans and permits for restoration, the Demised Premises cannot be made
tenantable within 180&nbsp;days after such event, Landlord, within ninety (90)&nbsp;days from the
date of such fire or casualty, may terminate this Lease by notice to Tenant, specifying a
date not less than thirty (30)&nbsp;nor more than sixty (60)&nbsp;days after the giving of such
notice on which the Term of this Lease shall terminate. If Landlord does not so elect to
terminate this Lease, then Landlord shall (to the extent that proceeds of insurance
required to be carried by Landlord, net of any portion thereof retained by a Mortgagee,
are made available for such purpose) proceed with diligence to repair the damage to the
Demised Premises and all facilities serving the same, if any, which shall have occurred,
and the Yearly Fixed Rent shall meanwhile proportionately abate, all as provided in
Paragraph (a)&nbsp;of this Section. However, if such damage is not repaired and the Demised
Premises restored to substantially the same condition as they were prior to such damage
within one (1)&nbsp;year from the date of such damage, Tenant within thirty (30)&nbsp;days from the
expiration of such one (1)&nbsp;year period or from the expiration of any extension thereof by
reason of unavoidable delays as hereinafter provided, may terminate this Lease by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">notice to Landlord, specifying a date not more than sixty (60)&nbsp;days after the giving of such notice
on which the Term of this Lease shall terminate. The period within which the required repairs may
be accomplished shall be extended by the number of days, lost as a result of unavoidable delays,
which term shall be defined to include all delays referred to in Article&nbsp;24.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If the Demised Premises shall be rendered untenantable by fire
or other casualty during the last two (2)&nbsp;years of the Term of this Lease,
Landlord may terminate this Lease effective as of the date of such fire or
other casualty upon notice to Tenant given within ninety (90)&nbsp;days after such
fire or other casualty. Notwithstanding the foregoing to the contrary, in the
event Landlord exercises the foregoing termination right, if Tenant has
available to it the option to extend and validly exercises said option, Tenant
may defeat said termination notice by the valid exercise of said option term
so as to add an additional five years on to the Term of this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Landlord shall not be required to repair or replace any of
Tenant&#146;s leasehold improvements, fixtures, business machinery, equipment,
cabinet work, furniture, personal property or other installations (all of which
shall, however, be restored by Tenant within a reasonable time after
Landlord shall have completed any repair or restoration required under the
terms of this Article), and no damages, compensation or claim shall be
payable by Landlord for inconvenience, loss of business or annoyance arising
from any repair or restoration of any portion of the Demised Premises or of
the Building.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The provisions of this Article shall be considered an express
agreement governing any instance of damage or destruction of the Building
or the Demised Premises by fire or other casualty, and any law now or
hereafter in force providing for such a contingency in the absence of express
agreement shall have no application.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) In the event of any termination of this Lease pursuant to this
Article, the Term of this Lease shall expire as of the effective termination
date as fully and completely as if such date were the date originally fixed
herein for the end of the Term of this Lease. Tenant shall have access to the
Demised Premises for a period of fifteen (15)&nbsp;days after the date of
termination in order to remove Tenant&#146;s personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Landlord&#146;s Architect&#146;s certificate, given in good faith, shall be
deemed conclusive of the statements therein contained and binding upon
Tenant with respect to the performance and completion of any repair or
restoration work undertaken by Landlord pursuant to this Article or Article
18.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">17.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>WAIVER OF SUBROGATION</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any case in which Tenant shall be obligated under any provision of this Lease to pay to
Landlord or Prime Landlord any loss, cost, damage, liability, or expense suffered or incurred by
Landlord or Prime Landlord, Landlord shall allow to Tenant as an offset against the amount thereof
(i)&nbsp;the net proceeds of any insurance collected by Landlord for or on account of such loss, cost,
damage, liability, or expense, provided that the allowance of such offset does not invalidate the
policy or policies under which such proceeds were payable and (ii)&nbsp;if such loss, cost, damage,
liability or expense shall have been caused by a peril against which Landlord has agreed to procure
insurance coverage under the terms of this Lease, the amount of such insurance coverage, if not
actually procured by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any case in which Landlord or Prime Landlord shall be obligated under any provision of this
Lease to pay to Tenant any loss, cost, damage, liability or expense suffered or incurred by Tenant,
Tenant shall allow to Landlord as an offset against the amount thereof (i)&nbsp;the net proceeds of any
insurance collected by Tenant for or on account of such loss, cost, damage, liability, or expense,
provided that the allowance of such offset does not invalidate the policy or policies under which
such proceeds were payable and (ii)&nbsp;if such loss, cost, damage, liability or expense shall have
been caused by a peril against which Tenant has agreed to procure insurance coverage under the
terms of this Lease, the amount of such insurance coverage, if not actually procured by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto shall each endeavor to procure an appropriate clause in, or endorsement
on, any fire or extended coverage insurance policy covering the Demised Premises and the Building
and personal property, fixtures and equipment located thereon or therein, pursuant to which the
insurance companies waive subrogation or consent to a waiver of right of recovery, and having
obtained such clauses and/or endorsements of waiver of subrogation or consent to a waiver of right
of recovery each party hereby agrees that it will not make any claim against or seek to recover
from the other for any loss or damage to its property or the property of others resulting from
fire or other perils covered by such fire and extended coverage insurance; provided, however, that
the release, discharge, exoneration and covenant not to sue herein contained shall be limited by
the terms and provisions of the waiver of subrogation clauses and/or endorsements or clauses
and/or endorsements consenting to a waiver of right of recovery and shall be co-extensive
therewith. If either party may obtain such clause or endorsement only upon payment of an
additional premium, such party shall promptly so advise the other party and shall be under no
obligation to obtain such clause or endorsement unless such other party pays the premium.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">18.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CONDEMNATION &#151; EMINENT DOMAIN</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the whole or more than 40% of the Building shall be taken or appropriated by
eminent domain or shall be condemned for any public or quasi-public use, or (by virtue of any such
taking, appropriation or condemnation) shall suffer any damage (direct, indirect or consequential)
for which Landlord or Tenant shall be entitled to compensation then (and in any such event) this
Lease and the Term hereof may be terminated at the election of Landlord by a notice in writing of
its election so to terminate which shall be given by Landlord to Tenant within sixty (60)&nbsp;days
following the date on which Landlord shall have received notice of such taking, appropriation or
condemnation. In the event that more than fifty percent (50%) of the floor area of the Demised
Premises or a substantial part of the means of access thereto within the perimeter of the Property
so as to substantially interfere with the use of the Demised Premises shall be so taken,
appropriated or condemned, then (and in any such event) this Lease and the Term hereof may be
terminated at the election of Tenant by a notice in writing of its election so to terminate which
shall be given by Tenant to Landlord within sixty (60)&nbsp;days following the date on which Tenant
shall have received notice of such taking, appropriation or condemnation. Tenant hereby waives the
benefits of California Code of Civil Procedure Section&nbsp;12165.130.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the giving of any such notice of termination (either by Landlord or Tenant) this Lease
and the Term hereof shall terminate on or retroactively as of the date on which Tenant shall be
required to vacate any part of the Demised Premises or shall be deprived of a substantial part of
the means of access thereto, provided, however, that Landlord may in Landlord&#146;s notice elect to
terminate this Lease and the Term hereof retroactively as of the date on which such taking,
appropriation or condemnation became legally effective. In the event of any such termination, this
Lease and the Term hereof shall expire as of the effective termination date as fully and completely
as if such date were the date originally fixed herein for the end of the Term of this Lease. If
neither party (having the right so to do) elects to terminate Landlord will, with reasonable
diligence and at Landlord&#146;s expense, restore the remainder of the Demised Premises, or the
remainder of the means of access thereto, as nearly as practicably may be to the same condition as
obtained prior to such taking, appropriation or condemnation in which event (i)&nbsp;a just proportion
of the Yearly Fixed Rent, according to the nature and extent of the taking, appropriation or
condemnation and the resulting permanent injury to the Demised Premises and the means of access
thereto, shall be permanently abated, and (ii)&nbsp;a just proportion of the remainder of the Yearly
Fixed Rent, according to the nature and extent of the taking, appropriation or condemnation and the
resultant injury sustained by the Demised Premises and the means of access thereto, shall be abated
until what remains of the Demised Premises and the means of access thereto shall have been restored
as fully as may be possible for permanent use and occupation by Tenant hereunder. Except for any
award specifically reimbursing Tenant for moving or relocation expenses and Tenant&#146;s moveable
personal property
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(but not leasehold improvements), there are expressly reserved to Landlord all rights to
compensation and damages created, accrued or accruing by reason of any such taking, appropriation
or condemnation, in implementation and in confirmation of which Tenant does hereby acknowledge that
Landlord shall be entitled to receive and retain all such compensation and damages, grants to
Landlord all and whatever rights (if any) Tenant may have to such compensation and damages, and
agrees to execute and deliver all and whatever further instruments of assignment as Landlord may
from time to time request. In the event of any taking of the Demised Premises or any part thereof
for temporary use, (i)&nbsp;this Lease shall be and remain unaffected thereby, and (ii)&nbsp;Tenant shall be
entitled to receive for itself any award made for such use, provided, that if any taking is for a
period extending beyond the Term of this Lease, such award shall be apportioned between Landlord
and Tenant as of the Termination Date.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">19.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>DEFAULT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.1 <U>Events of Default</U>. Occurrence of any of the following events shall constitute
an Event of Default under this Lease: (a)&nbsp;Tenant shall neglect or fail to perform or observe any of
the Tenant&#146;s covenants herein, including (without limitation) the covenants with regard to the
payment when due of Rent, which default continues, in the case of payment of Rent, for thirty (30)
days after notice of default or, in the case of defaults other then payment of Rent, for twenty
(20)&nbsp;days after such notice of default (provided that if more time, but not more than 30 additional
days) is required to complete such performance, Tenant shall not be in default if Tenant commences
such performance within the thirty (30)&nbsp;day period and thereafter diligently pursues its
completion); or (b)&nbsp;Tenant shall default in payment of Rent more than two (2)&nbsp;times in any
consecutive twelve (12)&nbsp;month period; or (c)&nbsp;Tenant shall be involved in financial difficulties as
evidenced by an admission in writing by Tenant of Tenant&#146;s inability to pay its debts generally as
they become due, or by the making or offering to make a composition of its debts with its
creditors; or (d)&nbsp;Tenant shall make an assignment or trust mortgage, or other conveyance or
transfer of like nature, of all or a substantial part of its property for the benefit of its
creditors; or (e)&nbsp;the leasehold hereby created shall be taken on execution or by other process of
law and shall not be revested in Tenant within sixty (60)&nbsp;days thereafter; or (f)&nbsp;a receiver,
sequester, trustee or similar officer shall be appointed by a court of competent jurisdiction to
take charge of all or a substantial part of Tenant&#146;s property and such appointment shall not be
vacated within sixty (60)&nbsp;days; or (g)&nbsp;any proceeding shall be instituted by or against Tenant
pursuant to any of the provisions of any Act of Congress or State law relating to bankruptcy,
reorganization, arrangements, compositions or other relief from creditors, and, in the case of any
such proceeding instituted against it, if Tenant shall fail to have such proceeding dismissed
within thirty (30)&nbsp;days or if Tenant is adjudged bankrupt or insolvent as a result of any such
proceeding; or (h)&nbsp;any event shall occur or any contingency shall arise whereby this Lease, or the
term and estate thereby created, would (by operation of law or otherwise) devolve upon or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">pass to any person, firm or corporation other than Tenant, except as expressly permitted
under Article&nbsp;14 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.2 <U>Remedies Available upon Default</U>. Upon the occurrence of an Event of Default,
Landlord shall have the following remedies, which shall not be exclusive but shall be cumulative
and shall be in addition to any other remedies now or hereafter allowed by law:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Landlord may terminate Tenant&#146;s right to possession of the
Premises at any time by written notice to Tenant. Tenant expressly
acknowledges that in the absence of such written notice from Landlord, no
other act of Landlord, including re-entry into the Premises, efforts to relet the
Premises, reletting of the Premises for Tenant&#146;s account, storage of Tenant&#146;s
personal property and trade fixtures, acceptance of keys to the Premises from
Tenant or exercise of any other rights and remedies under this Section, shall
constitute an acceptance of Tenant&#146;s surrender of the Premises or constitute a
termination of this Lease or of Tenant&#146;s right to possession of the Premises.
Upon such termination in writing of Tenant&#146;s right to possession of the
Premises, as herein provided, this Lease shall terminate and Landlord shall
be entitled to recover damages from Tenant as provided in California Civil
Code Section&nbsp;1951.2 and any other applicable existing or future Law
providing for recovery of damages for such breach, including the worth at the
time of award of the amount by which the rent which would be payable by
Tenant hereunder for the remainder of the Term after the date of the award
of damages, including Additional Rent as reasonably estimated by Landlord,
exceeds the amount of such rental loss as Tenant proves could have been
reasonably avoided, discounted at the discount rate published by the Federal
Reserve Bank of San Francisco for member banks at the time of the award
plus one percent (1%).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Landlord shall have the remedy described in California Civil
Code Section&nbsp;1951.4 (Landlord may continue this Lease in effect after
Tenant&#146;s breach and abandonment and recover rent as it becomes due, if
Tenant has the right to sublet or assign, subject only to reasonable
limitations).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Landlord may immediately, or at any time thereafter, without
notice, cure said Event of Default for the account of Tenant. If Landlord at
any time is compelled to pay or elects to pay any sum of money, or do any act
which will require the payment of any sum of money, by reason of the failure
of Tenant to comply with any provision hereof, or if Landlord is compelled to
or does incur any expense, including without limitation reasonable attorneys&#146;
fees, in instituting, prosecuting and/or defending any action or proceeding
arising by reason of any default of Tenant hereunder, Tenant shall on
demand pay to Landlord by way of reimbursement the sum or sums so paid
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">by Landlord with all interest, costs and damages together with interest at the Interest Rate
for the period such sums remain outstanding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Landlord may remove all of Tenant&#146;s property from the Premises, and such
property may be stored by Landlord in a public warehouse or elsewhere at the sole cost and
for the account of Tenant. If Landlord does not elect to store any or all of Tenant&#146;s
property left in the Premises, Landlord may consider such property to be abandoned by Tenant,
and Landlord may thereupon dispose of such property in the manner and as prescribed by
California Civil Code Section&nbsp;1980 et seq. Any proceeds realized by Landlord on the disposal
of any such property shall be applied first to offset all expenses of storage and sale, then
credited against Tenant&#146;s outstanding obligations to Landlord under this Lease, and any
balance remaining after satisfaction of all obligations of Tenant under this Lease shall be
delivered to Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The damages recoverable by Landlord pursuant to this Section shall in all
events include reimbursement of any concessions made by Landlord in connection with the
leasing of the Demised Premises to Tenant, including without limitation (a)&nbsp;abated Rent, (b)
allowances or improvements in excess of any Building standard work, (c)&nbsp;sums paid to any
former landlord of Tenant under a so-called &#147;take-over&#148;, lease assumption or similar
agreement and (d)&nbsp;signing bonuses and other incentive payments. Any allowances, abated rent,
signing bonuses, incentive payments or takeover payments shall be deemed commercially
reasonable if recommended to Landlord by a reputable commercial real estate broker as being
appropriate and necessary for the leasing of said Premises to a creditworthy tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.3 <U>Grace Period</U>. Notwithstanding anything to the contrary in this Article
contained, Landlord agrees not to take any action to terminate this Lease (a)&nbsp;for default by Tenant
in the payment when due of Rent, if Tenant shall cure such default within five (5)&nbsp;days after
written notice thereof given by Landlord to Tenant, unless there has been two (2)&nbsp;or more defaults
in any 12-month period as set forth in Section&nbsp;19.1(b), or (b)&nbsp;for default by Tenant in the
performance of any other covenant, if Tenant shall cure such default within a period of thirty (30)
days after written notice thereof given by Landlord to Tenant (except where the nature of the
default is such that remedial action should appropriately take place sooner, as indicated in such
written notice), or with respect to covenants other than to pay a sum of money within such
additional period as may reasonably be required to cure such default if (because of governmental
restrictions or any other cause beyond the reasonable control of Tenant) the default is of such a
nature that it cannot be cured within such thirty (30)-day period, provided, however, (1)&nbsp;that
there shall be no extension of time beyond such thirty (30)-day period for the curing of any such
default unless, not more than ten (10)&nbsp;days after the receipt of the notice of default, Tenant in
writing (i)&nbsp;shall specify the cause on account of which the default cannot
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be cured during such period and shall advise Landlord of its intention duly to institute all steps
necessary to cure the default and (ii)&nbsp;shall as soon as may be reasonable duly institute and
thereafter diligently prosecute to completion all steps necessary to cure such default and, (2)
that no notice of the opportunity to cure a default need be given, and no grace period whatsoever
shall be allowed to Tenant, if the default is incurable or if the covenant or condition the breach
of which gave rise to the default had, by reason of a breach on a prior occasion, been the subject
of a notice hereunder to cure such default.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">20.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>END OF TERM &#151; ABANDONED PROPERTY</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the expiration or other termination of the Term of this Lease, Tenant shall peaceably
quit and surrender to Landlord the Demised Premises and all alterations and additions thereto which
Tenant is not entitled or required to remove under the provisions of this Lease, broom clean in
good order, repair and condition excepting only reasonable use and wear and damage by fire or other
casualty for which, under other provisions of this Lease, Tenant has no responsibility of repair or
restoration. Tenant&#146;s obligation to observe or perform this covenant shall survive the expiration
or other termination of the Term of this Lease. If the last day of the Term of this Lease or any
renewal thereof falls on a day other than a Business Day, this Lease shall expire on the Business
Day immediately following. Tenant shall pay twice the amount of Rent applicable to each month (or
fraction thereof) during which Tenant remains in possession of any part of the Demised Premises in
violation of the foregoing covenants, without prejudice to eviction and any other remedy available
to Landlord on account thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any personal property in which Tenant has an interest which shall remain in the Building or on
the Demised Premises after the expiration or termination of the Term of this Lease shall be
conclusively deemed to have been abandoned, and may be disposed of in such manner as Landlord may
see fit; provided, however, notwithstanding the foregoing, that Tenant will, upon request of
Landlord made not later than ten (10)&nbsp;days after the expiration or termination of the Term hereof,
promptly remove from the Building any such personal property or, if any part thereof shall be sold,
that Landlord may receive and retain the proceeds of such sale and apply the same, at its option,
against the expenses of the sale, the cost of moving and storage, any arrears of Rent payable
hereunder by Tenant to Landlord and any damages to which Landlord may be entitled under Article&nbsp;19
hereof or pursuant to law, with the balance if any, to be paid to Tenant.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">21.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>RIGHTS OF MORTGAGEES</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.1 <U>Entry and Possession</U>. Upon entry and taking possession of the Property by a
Mortgagee, for the purpose of foreclosure or otherwise, such Mortgagee shall have all the rights of
Landlord, and shall be liable to perform all
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the obligations of Landlord arising and accruing during the period of such possession by
such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.2 <U>Right to Cure</U>. No act or failure to act on the part of Landlord which would
entitle Tenant under the terms of this Lease, or by law, to be relieved of Tenant&#146;s obligations
hereunder or to terminate this Lease, shall result in a release or termination of such obligations
or a termination of this Lease unless (i)&nbsp;Tenant shall have first given written notice of
Landlord&#146;s act or failure to act to first Mortgagees of record, if any, and to any other Mortgagees
of whom Tenant has been given written notice, specifying the act or failure to act on the part of
Landlord which could or would give basis to Tenant&#146;s rights; and (ii)&nbsp;such Mortgagees, after
receipt of such notice, have failed or refused to correct or cure the condition complained of
within 30&nbsp;days thereafter for a monetary default and 60&nbsp;days for a non-monetary default, but
nothing contained in this paragraph shall be deemed to impose any obligation on any such Mortgagees
to correct or cure any such condition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.3 <U>Prepaid Rent</U>. No Rent shall be paid more than thirty (30)&nbsp;days prior
to the due dates thereof and, as to a first Mortgagee of record and any other
Mortgagees of whom Tenant has been given written notice, payments made in
violation of this provision shall (except to the extent that such Rent is actually
received by such Mortgagee) be a nullity as against such Mortgagee and Tenant shall be liable for the amount of such payments to such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.4 <u>Continuing Offer</u>. The covenants and agreements contained in this Lease with respect to the rights, powers and benefits of a Mortgagee (particularly,
without limitation thereby, the covenants and agreements contained in this Article)
constitute a continuing offer to any person, corporation or other entity, which by
accepting or requiring an assignment of this Lease or by entry or foreclosure
assumes the obligations herein set forth with respect to such Mortgagee; every such
Mortgagee is hereby constituted a party to this Lease as an obligee hereunder to the
same extent as though its name was written hereon as such; and such Mortgagee shall be entitled to enforce such provisions in its own name.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.5 <u>Subordination</u>. This lease shall be subordinate to all mortgages encumbering the Land and/or Building, but Tenant shall nevertheless have the
benefit of the non-disturbance provisions hereinafter set forth, and Tenant agrees,
at the request of Landlord or any Mortgagee, to execute and deliver promptly any
certificate or other instrument which Landlord or such Mortgagee may reasonably
request subordinating this Lease and all rights of Tenant hereunder to any
Mortgage, and to all advances made under such Mortgage and/or agreeing to attorn
to such Mortgagee in the event that it succeeds to Landlord&#146;s interest in the
Property. Landlord shall provide that (i)&nbsp;the holder of each such Mortgage shall
execute and deliver to Tenant a non-disturbance agreement to the effect that, in the
event of any foreclosure of such Mortgage, such holder will not name Tenant as a
party defendant to such foreclosure nor disturb its possession under the Lease, or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(ii)&nbsp;each such Mortgage shall contain provisions substantially to the same effect as those
contained in such a non-disturbance agreement. The form of the non-disturbance agreement shall be a
commercially reasonable form reflecting then current commercial lending practices for loans of the
size and type as that related to the Building. Tenant agrees that a subordination, non-disturbance
and attornment agreement substantially in form as that attached hereto shall be deemed commercially
reasonable. In addition if the Prime Lease shall be terminated due to foreclosure of the mortgage
made by Prime Landlord in favor of its mortgagee or due to such mortgagee&#146;s acceptance of a deed in
lieu of foreclosure, Tenant shall attorn to mortgagee as landlord hereunder and this lease shall
continue in full force and effect for its remaining term as a direct lease between Tenant and such
mortgagee without the necessity of any additional act or agreement; provided, however, if requested
by such Mortgagee, Tenant shall execute and deliver a new lease with such mortgagee on the same
terms and conditions as set forth herein except that the term of such new lease shall be equal to
the then remaining term hereunder. Landlord represents and warrants that as of the date of this
Lease, Bank of America is the sole mortgagee of the Land and Building.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.6 <U>Limitations on Liability</U>. Nothing contained in the foregoing Section&nbsp;21.6 or
in any such non-disturbance agreement or non-disturbance provision shall however, affect the prior
rights of the holder of any Mortgage with respect to the proceeds of any award in condemnation or
of any fire insurance policies affecting the Building, or impose upon any such holder any liability
(i)&nbsp;for the erection or completion of the Building, or (ii)&nbsp;in the event of damage or destruction
to the Building or the Demised Premises by fire or other casualty, for any repairs, replacements,
rebuilding or restoration except such repairs, replacements, rebuilding or restoration as can
reasonably be accomplished from the net proceeds of insurance actually received by, or made
available to, such holder, or (iii)&nbsp;for any default by Landlord under the Lease occurring prior to
any date upon which such holder shall become Tenant&#146;s landlord (unless and to the extent said
default continues after such date upon which the holder becomes Tenant&#146;s landlord, in which event
such mortgagee shall be responsible for correcting such default continuing after such date), or
(iv)&nbsp;for any credits, offsets or claims against the Rent as a result of any acts or omissions of
Landlord committed or omitted prior to such date, or (v)&nbsp;for return of any security deposit or
other funds unless the same shall have been received by such holder, and any such agreement or
provision may so state.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">22.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>QUIET ENJOYMENT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord covenants that if, and so long as, Tenant keeps and performs each and every covenant,
agreement, term, provision and condition herein contained on the part and on behalf of Tenant to be
kept and performed, Tenant shall quietly enjoy the Demised Premises from and against the claims of
all persons claiming by, through or under Landlord subject, nevertheless, to the covenants,
agreements,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">terms, provisions and conditions of this Lease and to all Mortgages to which this Lease is subject
and subordinate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without incurring any liability to Tenant, Landlord may permit access to the Demised Premises
and open the same, whether or not Tenant shall be present, upon any demand of any receiver,
trustee, assignee for the benefit of creditors, sheriff, marshall or court officer entitled to, or
reasonably purporting to be entitled to, such access for the purpose of taking possession of, or
removing Tenant&#146;s property or for any other lawful purpose (but this provision and any action by
Landlord hereunder shall not be deemed a recognition by Landlord that the person or official making
such demand has any right or interest in or to this Lease, or in or to the Demised Premises), or
upon demand of any representative of the fire, police, building, sanitation or other department of
the city, county, state or federal governments.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">23.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ENTIRE AGREEMENT&#151;WAIVER&#151;SURRENDER</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.1 <U>Entire Agreement</U>. This Lease and the Exhibits made a part hereof contain the
entire and only agreement between the parties and any and all statements and representations,
written and oral, including previous correspondence and agreements between the parties hereto, are
merged herein. Tenant acknowledges that all representations and statements upon which it relied in
executing this Lease are contained herein and that Tenant in no way relied upon any other
statements or representations, written or oral. Any executory agreement hereafter made shall be
ineffective to change, modify, discharge or effect an abandonment of this Lease in whole or in part
unless such executory agreement is in writing and signed by the party against whom enforcement of
the change, modification, discharge or abandonment is sought. Nothing herein shall prevent the
parties from agreeing to amend this Lease and the Exhibits made a part hereof as long as such
amendment shall be in writing and shall be duly signed by both parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.2 <U>Waiver by Landlord</U>. The failure of Landlord to seek redress for violation, or
to insist upon the strict performance, of any covenant or condition of this Lease, or any of the
Rules and Regulations promulgated hereunder, shall not prevent a subsequent act, which would have
originally constituted a violation, from having all the force and effect of an original violation.
The receipt by Landlord of Rent with knowledge of the breach of any covenant of this Lease shall
not be deemed a waiver of such breach. The failure of Landlord to enforce any of such Rules and
Regulations against Tenant and/or any other tenant or subtenant in the Building shall not be
deemed a waiver of any such Rules and Regulations. No provisions of this Lease shall be deemed to
have been waived by Landlord unless such waiver be in writing signed by Landlord. No payment by
Tenant or receipt by Landlord of a lesser amount than the monthly rent herein stipulated shall be
deemed to be other than on account of the stipulated rent, nor shall any endorsement or statement
on any check or any letter accompanying any check or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">payment as rent be deemed an accord and satisfaction, and Landlord may accept such check or payment
without prejudice to Landlord&#146;s right to recover the balance of such rent or pursue any other
remedy in this Lease provided.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.3 <U>Surrender</U>. No act or thing done by Landlord during the term hereby demised
shall be deemed an acceptance of a surrender of the Demised Premises, and no agreement to accept
such surrender shall be valid, unless in writing signed by Landlord. No employee of Landlord or of
Landlord&#146;s agents shall have any power to accept the keys of the Demised Premises prior to the
termination of this Lease. The delivery of keys to any employee of Landlord or of Landlord&#146;s agents
shall not operate as a termination of the Lease or a surrender of the Demised Premises. In the
event that Tenant at any time desires to have Landlord underlet the Demised Premises for Tenant&#146;s
account, Landlord or Landlord&#146;s agents are authorized to receive the keys for such purposes without
releasing Tenant from any of the obligations under this Lease, and Tenant hereby relieves Landlord
of any liability for loss of or damage to any of Tenant&#146;s effects in connection with such
underletting.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">24.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>INABILITY TO PERFORM &#151; EXCULPATORY CLAUSE</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly provided in this Lease, this Lease and the obligations of Tenant
to pay Rent hereunder and perform all other covenants, agreements, terms, provisions and conditions
hereunder on the part of Tenant to be performed shall in no way be affected, impaired or excused
because Landlord is unable to fulfill any of its obligations under this Lease or is unable to
supply or is delayed in supplying any service expressly or impliedly to be supplied or is unable to
make or is delayed in making any repairs, replacements, additions, alterations, improvements or
decorations or is unable to supply or is delayed in supplying any equipment or fixtures if Landlord
is prevented or delayed from doing so by reason of any cause whatsoever beyond Landlord&#146;s
reasonable control, including but not limited to governmental preemption in connection with a
national emergency or by reason of any rule, order or regulation of any department or subdivision
thereof of any governmental agency or by reason of strikes, labor troubles, shortages of labor or
materials or conditions of supply and demand which have been or are affected by war, hostilities or
other similar or dissimilar emergency. In each such instance of inability of Landlord to perform,
Landlord shall exercise reasonable diligence to eliminate the cause of such inability to perform.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall neither assert nor seek to enforce any claim for breach of this Lease against any
of Landlord&#146;s assets other than Landlord&#146;s or Prime Landlord&#146;s interest in the Building of which
the Demised Premises are a part and in the rents, issues and profits thereof, and Tenant agrees to
look solely to such interest for the satisfaction of any liability of Landlord under this Lease, it
being specifically agreed that in no event shall Landlord (which term shall include, without
limitation any of the officers, trustees, directors, partners, beneficiaries, joint venturers,
managers, members, stockholders or other principals or representatives, disclosed or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">undisclosed, of Landlord or any managing agent) ever be personally liable for any such liability.
This paragraph shall not limit any right that Tenant might otherwise have to obtain injunctive
relief against Landlord or to take any other action which shall not involve the personal liability
of Landlord to respond in monetary damages from Landlord&#146;s assets other than the Landlord&#146;s
interest in said real estate, as aforesaid. In no event shall Landlord ever be liable for
consequential damages.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">25.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>BILLS AND NOTICES</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notices required under this Lease shall be in writing and delivered by hand or mailed by
registered or certified mail or by nationally recognized overnight delivery service (such as
Federal Express) for next business day delivery to Landlord or Tenant at the addresses set forth in
Article&nbsp;1. Either party may at any time change the Address for such notices, consents, requests,
bills, demands or statements by delivering or mailing, as aforesaid, to the other party a notice
stating the change and setting forth the changed Address, provided such changed Address is within
the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All bills and statements for reimbursement or other payments or charges due from Tenant to
Landlord hereunder shall be due and payable in full fifteen (15)&nbsp;days, unless herein otherwise
provided, after submission thereof by Landlord to Tenant. Tenant&#146;s failure to make timely payment
of any amounts indicated by such bills and statements within applicable notice and grace periods,
whether for work done by Landlord at Tenant&#146;s request, reimbursement provided for by this Lease or
for any other sums properly owing by Tenant to Landlord, shall be treated as a default in the
payment of Rent, in which event Landlord shall have all rights and remedies provided in this Lease
for the nonpayment of Rent.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">26.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUCCESSORS AND ASSIGNS</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The covenants, agreements, terms, provisions and conditions of this Lease shall bind and
benefit the successors and assigns of the parties hereto with the same effect as if mentioned in
each instance where a party hereto is named or referred to, except that no violation of the
provisions of Article&nbsp;14 hereof shall operate to vest any rights in any successor or assignee of
Tenant and that the provisions of this Article shall not be construed as modifying the conditions
of limitation contained in Article&nbsp;19 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If in connection with or as a consequence of the sale, transfer or other disposition of the
real estate (Land and/or Building, either or both, as the case may be) of which the Demised
Premises are a part Landlord ceases to be the owner of the reversionary interest in the Demised
Premises, Landlord shall be entirely freed and relieved from the performance and observance
thereafter of all covenants and obligations hereunder accruing thereafter on the part of Landlord
to be performed
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and observed, it being understood and agreed in such event (and it shall be deemed and construed as
a covenant running with the land) that the person succeeding to Landlord&#146;s ownership of said
reversionary interest shall thereupon and thereafter assume, and perform and observe, any and all
of such covenants and obligations of Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">27. MISCELLANEOUS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.1 <U>Separability</U>. If any provision of this Lease or portion of such provision
or the application thereof to any person or circumstance is for any reason held
invalid or unenforceable, the remainder of the Lease (or the remainder of such
provision) and the application thereof to other persons or circumstances shall not be
affected thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.2 <u> Captions</u>. The captions are inserted only as a matter of convenience
and for reference, and in no way define, limit or describe the scope of this Lease nor
the intent of any provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.3 <u>Broker</u>. Each party represents and warrants that it has not directly or
indirectly dealt, with respect to the leasing of space in the Building, with any broker
or had its attention called to the Demised Premises or other space to let in the
Building, by any broker other than the Broker (if any) listed in Article&nbsp;1 whose
commission shall be the responsibility of Landlord. Each party agrees to exonerate
and save harmless and indemnify the other against any claims for a commission by
any other broker, person or firm, with whom such party has dealt in connection
with the execution and delivery of this Lease or out of negotiations between
Landlord and Tenant with respect to the leasing of other space in the
Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.4 <u>Governing Law</u>. This Lease is made pursuant to, and shall be
governed by, and construed in accordance with, the laws of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.5 <U>Assignment of Lease and/or Rents</U>. With reference to any assignment
by Landlord or Prime Landlord of its interest in this Lease and/or the Rent payable
hereunder, conditional in nature or otherwise, which assignment is made to or held
by a bank, trust company, insurance company or other institutional lender holding
a Mortgage on the Building, Landlord and Tenant agree:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) that the execution thereof by Landlord and acceptance thereof
by such Mortgagee shall never be deemed an assumption by such Mortgagee
of any of the obligations of the Landlord hereunder, unless such Mortgagee
shall, by written notice sent to the Tenant, specifically otherwise elect; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that, except as aforesaid, such Mortgagee shall be treated as
having assumed the Landlord&#146;s obligations hereunder only upon foreclosure
of such Mortgagee&#146;s Mortgage and the taking of possession of the Demised
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Premises after having given notice of its intention to succeed to the interest of the
Landlord under this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.6 <U>Memorandum of Lease</U>. Neither party shall record this Lease;
provided, however, that either party shall at the request of the other, execute and
deliver a recordable memorandum of this Lease setting forth the parties to this
Lease, a description of the Demised Premises and the term of this Lease for
recordation in the Official records of the County of San Mateo.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.7 <u> Arbitration of Certain Matters</u>. At the election of either party, if any
dispute as to the rentable square footage of the Demised Premises, the allocation of
real estate taxes or operating expenses under Sections&nbsp;6.5 and 6.6, the abatement of
Yearly Fixed Rent pursuant to Article&nbsp;16 or the abatement of Yearly Fixed Rent
pursuant to Article&nbsp;18 remains unresolved 30&nbsp;days after written complaint by
Tenant has been delivered to Landlord as to an allocation, reduction, apportionment
or abatement made or proposed by Landlord, the matter may be submitted to
binding arbitration pursuant to California Code of Civil Procedure Section&nbsp;1280 et
seq.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.8 <u>Sublease</u>. Notwithstanding anything to the contrary herein, Landlord
and Tenant acknowledge that this is a sublease and that Landlord derives its estate
to the Demised Premises through the Prime Lease. Landlord represents and
warrants that, as of the date hereof, Prime Landlord and Landlord are under
common control. At such time as Landlord and Prime Landlord are no longer under
common control, the responsibility for furnishing services, repairs, restoration and
other similar functions of Landlord shall be performed by Prime Landlord, and
Landlord shall be required to use reasonable efforts to enforce the provisions of the
Prime Lease relating thereto, but without obligation to provide such services,
repairs, restoration, and the like. Landlord shall have the right, but not the
obligation, to assign this Lease to Prime Landlord, and after such assignment this
Lease shall no longer be a sublease, but rather a direct lease between Tenant and
Prime Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.9 <U>Holdover</U>. If for any reason Tenant retains possession of the Premises
or any part thereof after the termination of the Term or any extension thereof, such
holding over shall constitute a tenancy from month to month, terminable by either
party upon thirty (30)&nbsp;days prior written notice to the other party, and Tenant shall
pay Landlord monthly rental during the month to month tenancy computed as the
rent (including Yearly Fixed Rent and all additional rent) payable hereunder for the
final month of the last year of the Term prior to such holding over plus fifty (50%)
percent of said rent. The month to month tenancy shall otherwise be on the same
terms and conditions as set forth in this Lease, as far as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.10 <u>Lease Amendments</u>. Tenant acknowledges that amendments to this
Lease may be required in connection with the financing of the Land or Building and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tenant hereby agrees that it will enter into any reasonable modifications requested
by a mortgagee in connection with such financing, provided the same do not
(a)&nbsp;increase the Yearly Fixed Rent or additional rents payable by Tenant or increase
Tenant&#146;s financial obligations hereunder; (b)&nbsp;reduce or extend the Term hereof;
(c)&nbsp;change the Permitted Use; or (d)&nbsp;otherwise materially impair Tenant&#146;s rights
hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.11 <u>Signage</u>. Tenant shall be entitled to maintain exterior Building
signage in accordance with the sign criteria attached hereto as Exhibit&nbsp;D. Landlord
shall use commercially reasonable efforts to ensure that, subject to any contrary
requirements of law or the OCR&#146;s, Tenant has proportional directional and
monument signage within the project.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant may maintain a sign on the northern elevation of the Building of equal size to the sign
on the western elevation to be maintained by Landlord, which signs shall be the exclusive company
signs on the facades of the Building. If additional signage rights are obtained for the roof or
facade, the signage shall be shared on a pro rata basis based on square footage leased. Nothing
herein shall be deemed to grant Tenant permission to install signs other than in accordance with
the attached sign criteria and all applicable laws, regulations and private restrictions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant may maintain a sign on the right hand wall of the Building lobby of comparable size and
design to Landlord&#146;s lobby wall sign.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.12 <U>Sierra Point CCRs</U>. This Lease shall be subject to the Amended and
Restated Declaration of Covenants, Conditions and Restrictions for Sierra Point
recorded in the Official Records of San Mateo on October&nbsp;23, 1998, as Document No.
98-172218, as amended by that certain First Amendment to Amended and Restated
Declaration of Covenants, Conditions and Restrictions for Sierra Point recorded in
the Official Records of San Mateo on August&nbsp;6, 1999, as Document No.&nbsp;1999-134787
(as amended, the &#147;CCRs&#148;). Tenant shall comply with the CCRs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.13 <u>Financial Statements</u>. Tenant shall furnish Landlord with complete
audited financial statements within ninety (90)&nbsp;days after the close of each fiscal
year of Tenant prepared by a certified public accountant (but not necessarily
certified statements) and shall, upon written request from Landlord, provide copies
of Tenant&#146;s quarterly unaudited financial statements within fifteen (15)&nbsp;days after
Landlord&#146;s request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.14 <u>Communications Dish</u>. Tenant shall have the right to install,
maintain and operate, at Tenant&#146;s sole cost and expense (without rental charge
from Landlord), communications dishes or antennae, which receive and/or send
signals (hereinafter called the <I>&#147;Communications Dishes&#148; on </I>the roof of the Building
and fully contained (both vertically and horizontally) within the screens over the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">portion of the third floor leased to the Tenant, and to run lines and conduits and cables necessary
for the operations of the Communications Dishes from the roof of the Building into the Premises,
provided that (and in the event Tenant makes such installation, Tenant hereby covenants and agrees
that): (a)&nbsp;such installation is performed in accordance with all laws and requirements of public
authorities and does not cause structural damage to the Building, (b)&nbsp;Tenant indemnifies and holds
Landlord harmless from (i)&nbsp;any liability, cost or expense incurred by Landlord in connection with
the erection, installation, maintenance and operations of the Communications Dishes and any related
equipment installed by Tenant pursuant to the provisions of this Section&nbsp;27.14 and (ii)&nbsp;any and all
claims, costs, damages and expenses (including reasonable attorneys&#146; fees) arising out of
accidents, damage, injury or loss to any and all persons and property resulting from or arising in
connection with the erection, installation, maintenance and operations of the Communications Dishes
(including without limitation claims or damages due to interference with other signals or its own
signal clarity and other claims or damages), (c)&nbsp;Tenant promptly reimburses Landlord for repairs
made necessary by any damage caused to the roof or other portions of the Building by reason of such
installation, including, without limitation, any repairs, restorations, maintenance, renewals or
replacement of the roof necessitated by or in any way caused by or relating to such installations,
(d)&nbsp;Tenant removes such installations and lines and repairs any resulting damage to the Building
and restores the affected portion of the roof and the Building to a condition that is in all
material respects the same as the condition which existed prior to any such installation, ordinary
wear and tear and damage by casualty excepted, all at or prior to the expiration of the Term of
this Lease, (e)&nbsp;Tenant shall not install the Communications Dishes without Landlord&#146;s prior
approval of the manner of such installation and detailed plans and specifications for such
installation, which approval shall not be unreasonably withheld, delayed or conditioned, (f)&nbsp;said
Communication Dishes may not be used by anyone other than the Tenant and any Corporate Transferees
lawfully occupying the Demised Premises and specifically may not be used by anyone in the business
of broadcasting or providing wireless communications, (g)&nbsp;the electric current necessary to operate
the Communications Dishes shall be obtained by Tenant from the public utility furnishing electric
to the Premises and Landlord shall have no obligation to furnish any electric current in connection
therewith, and (h)&nbsp;the installation of the Communications Dishes or their operation not interfere
with Building operations or the use by other tenants or occupants of antennae or communication
dishes installed by such tenants or occupants prior. Tenant shall have access to the roof as
reasonably required in connection with the operation, installation and maintenance of the
Communications Dishes; provided, however, Tenant shall always be accompanied on the roof by a
representative of Landlord. Tenant agrees that Landlord shall have the right, at Landlord&#146;s sole
cost and expense, to relocate the Communications Dishes, provided that such relocation does not
affect the functioning of the Communications Dishes. Landlord makes no representation whether or
not the roof of the Building is suitable for or conductive
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the operation of a Communications Dish and Tenant hereby agrees that Landlord shall have no
liability to Tenant in the event that the Communications Dishes shall not operate in a manner
satisfactory to Tenant.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">28.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SECURITY DEPOSIT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.1 <U>Security Deposit</U>. Subject to Section&nbsp;28.2 below, Tenant has deposited
with Landlord the Security Deposit described in Article&nbsp;1 hereof as security for the
faithful performance and observance by Tenant of the terms, provisions, covenants
and conditions of this Lease, and it is agreed that if an Event of Default by Tenant
exists in respect of any of the terms, provisions, covenants and conditions of this
Lease, including, but not limited to, the payment of Rent, Landlord may use, apply
or retain the whole or any part of the security so deposited to the extent required for
the payment of any Rent or any other sum as to which there exists an Event of
Default by Tenant or for any sum which Landlord may expend or may be required
to expend by reason of Tenant&#146;s Event of Default in respect of any of the terms,
provisions, covenants and conditions of this Lease, including, but not limited to, any
damages or deficiency accrued before or after summary proceedings or other re-
entry by Landlord. Upon the expiration or earlier termination of this Lease, and
providing there exists no default or Event of Default hereunder, any remaining
balance of the Security Deposit (including, without limitation, any and all interest
accrued thereon) and the Letter of Credit (as defined below) shall be returned by
Landlord to Tenant after the date fixed as the end of the Term and not later than
thirty (30)&nbsp;days after delivery of entire possession of the Premises to Landlord as
provided hereunder. In the event of a sale of the Land and Building or leasing of the
Building, of which the Premises form a part, Landlord shall have the right to
transfer the security to the vendee or lessee and Landlord shall thereupon be
released by Tenant from all liability for the return of such security, and Tenant
agrees to look solely to the new Landlord for the return of said security, and it is
agreed that the provisions hereof shall apply to every transfer or assignment made
of the security to a new Landlord. Tenant further covenants that it will not assign
or encumber or attempt to assign or encumber the monies deposited herein as
security and that neither Landlord nor its successors or assigns shall be bound by
any such assignment, encumbrance, attempted assignment or attempted
encumbrance. In the event Landlord applies or retains any portion or all of the
security deposited pursuant to the terms of this Section&nbsp;28.1, Tenant shall forthwith
restore the amount so applied or retained so that at all times the amount deposited
shall be the full amount of the security deposit required at the relevant time.
Landlord shall not be responsible for the payment of any interest on the Security
Deposit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.2 <u>Letter of Credit</u>. In satisfaction of the Security Deposit obligation
contained in Section&nbsp;28.1 above, Tenant shall deliver to Landlord, and shall
maintain in effect at all times during the Initial Term following delivery thereof, a
clean, unconditional and irrevocable letter of credit, in substantially the form
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>





<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">annexed hereto as Exhibit&nbsp;E (the &#147;Letter of Credit&#148;) in the amount of the Security Deposit
described in Article&nbsp;1 hereof issued by Imperial Bank or another banking corporation (&#147;Bank&#148;)
reasonably satisfactory to Landlord. Such letter of credit shall have an expiration date no earlier
than the first anniversary of the date of issuance thereof and it shall be automatically renewed
from year-to-year unless terminated by the Bank by notice to Landlord given not less than
forty-five (45)&nbsp;days prior to the then expiration date therefor. It is agreed that in the event
there exists an Event of Default in respect of any of the terms, covenants or provisions of this
Lease, including, but not limited to, the payment of Rent, or if any letter of credit is terminated
by the Bank and is not replaced within thirty (30)&nbsp;days prior to its termination or expiration that
(A)&nbsp;Landlord shall have the right to require the Bank to make payment to Landlord of so much of the
entire proceeds of the letter of credit as shall be reasonably necessary to cure the Event of
Default (or the entire proceeds if notice of termination is given as aforesaid and the letter of
credit is not replaced as aforesaid), and (B)&nbsp;Landlord may apply said sum so paid to it by the Bank
to the extent required for the payment of Rent or any other sum as to which an Event of Default by
Tenant exists or for any sum which Landlord may expend or may be required to expend by reason of an
Event of Default by Tenant in respect of any of the terms, covenants and conditions of this Lease,
including, but not limited to, any damages or deficiency in the reletting of the Premises, whether
such damages or deficiency accrue before or after summary proceedings or other re-entry by
Landlord, without thereby waiving any other rights or remedies of Landlord with respect to such
Event of Default. If Landlord applies any part of the proceeds of a letter of credit, Tenant, upon
demand, shall deposit with Landlord promptly the amount so applied or retained (or increase the
amount of the letter of credit) so that the Landlord shall have the full deposit on hand at all
times during the Term. If, subsequent to a letter of credit being drawn upon, a new letter of
credit meeting all the requirements set forth in this Section&nbsp;28.2 is delivered to Landlord, any
proceeds of the former letter of credit then held by Landlord shall be promptly returned to Tenant.
If Tenant shall fully and faithfully comply with all of the terms, covenants and provisions of this
Lease, any letter of credit, or any remaining portion of any sum collected by Landlord hereunder
from the Bank, together with any other portion or sum held by Landlord as security, shall be
returned to Tenant within thirty (30)&nbsp;days after the last day of the Initial Term of this Lease. In
the event of an assignment by Landlord of its interest under this Lease, Landlord shall have the
right to transfer the security to the assignee, and Tenant agrees to look to the new Landlord
solely for the return of said security and it is agreed that the provisions hereof shall apply to
every transfer or assignment made of the security to a new Landlord.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.3 <U>Reduction of Security Deposit</U>. Provided Tenant is not then in default and there
has never been an Event of Default under this Lease, the Security Deposit will be reduced to an
amount equal to six (6)&nbsp;months Yearly Fixed Rent upon the later of (a)&nbsp;the commencement of the
twenty-fifth month of the Lease Term or (b)&nbsp;the date on which Tenant has sustained for a period
of six months a tangible
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">net worth in a total amount including cash and cash balances equal to or exceeding
$30,000,000, as set forth in audited financial statements provided by Tenant, which
financial statements shall be computed in accordance with generally accepted
accounting principles. The date upon which Tenant is entitled to such a reduction in
the Letter of Credit is hereinafter deemed the Reduction Date. Provided Tenant has met
the conditions of this Section&nbsp;28.3, upon the written request of Tenant made on or
after the Reduction Date, Landlord shall exchange the Letter of Credit for a
replacement letter of credit provided by Tenant in the amount equal to six (6)&nbsp;months
Yearly Fixed Rent upon the same terms and conditions as the Letter of Credit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">29. SALE OF BUILDING
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29.1 Except as otherwise provided, provided Tenant is not in default hereunder
beyond any applicable notice and cure period, and the named Tenant Genesoft, Inc. is
occupying not less than 50% of the Demised Premises, Landlord shall, prior to
marketing the Building for sale to an unaffiliated third party, provide a pre-sale
notice to Tenant advising Tenant of Landlord&#146;s intention to market the Building.
Landlord will refrain from marketing the Building for a period of thirty (30)&nbsp;days,
during which time Tenant may submit an offer to purchase to Landlord for Landlord&#146;s
consideration without any obligation. Nothing herein shall require Landlord to accept
any such offer submitted by Tenant. Notwithstanding the foregoing, said pre-sale
notice shall not apply to (a)&nbsp;an unsolicited offer to purchase submitted to Landlord
without marketing efforts by Landlord, (b)&nbsp;a deed of trust or mortgage and to the
foreclosure of the same or the granting of a deed in lieu of foreclosure, or (c)&nbsp;a
sale of the Building to an affiliate of Landlord or to anyone owning an equity
interest in Landlord, or to the sale or transfer of equity interests in Landlord. The
provisions of this Section&nbsp;29 are (a)&nbsp;personal to Genesoft, Inc. and its Corporate
Transferrees (but not to any assignee thereof) and shall apply only to the first sale
of the Building to which this Section&nbsp;29 applies, but not to any subsequent sale.
Tenant agrees that a foreclosure or deed in lieu of foreclosure of a mortgage or deed
of trust shall extinguish this Section&nbsp;29.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Landlord and Tenant have caused this instrument to be
executed under seal, all as of the day and year first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">MJ RESEARCH COMPANY, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">GENESOFT, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Illegible
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ David B. Singer</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its PRESIDENT<BR>
title (duly-authorized)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Its President &#038; CEO<BR>
title (duly-authorized)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943236.gif" alt="(CHART)">
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943237.gif" alt="(CHART)">
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943238.gif" alt="(CHART)">
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><u>EXHIBIT A-1</u>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><u>LANDLORD&#146;S WORK</u>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Building Type:</b> 3 Story, Group B, Type III, 1 Hour
Rated, fully sprinklered office
building. All design and construction in conformance with the 1998 (CBC)&nbsp;Building
Standards Administrative Code of the California Building Standards
Commission (CBSC)&nbsp;and
the City of South San Francisco amendments, applicable codes and regulations. The building
exit&#146;s, lavatories and common space will be furnished fully-ADA compliant throughout.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Site Development:</b> Bituminous paved parking lots with concrete curbing. Parking
allocation as per lease Section&nbsp;2.2. Walks are concrete and masonry pavers. All parking
areas and walkways are illuminated to required minimum code
specifications. BCDC path is
paved in bituminous with benches, drinking fountain and open pavilion area. Loading door
into tenant space with shared trash enclosure and fencing around utility yard. Entire site
fully landscaped including palm tree lined roadway, burms, waterfront lawn area, extensive
shrubbery and automatic irrigation system.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Tenant&#146;s proposed future chemical containment facility subject to all approvals, rules and
regulations of Sierra Point Owners Association, Sierra Point Environmental Management Association
and all pertaining governmental agencies. Although owner will use reasonable efforts to accommodate
the proposed facility, it is at tenant&#146;s sole risk and responsibility to obtain approvals and
permits. The unit will be required to contain an approved automatic fire suppression system. The
facility and finish will be screened, constructed and landscaped with materials and methods
consistent with the integrity of the project and site. Any parking allocation eliminated by the
siting of the facility will be deducted from tenant&#146;s non-exclusive allocation. Public access to
BCDC path will be in no way hindered by facility. Upon termination of the lease, it will be
required that the unit be removed and remediated and the site is returned to its originally
landscaped condition.</I>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Telephone, Gas and Electric Utilities:</b> Gas and electric will be provided to
separately metered services within the building. A 4000 amp electric service will be
divided equally between the 2 tenants and plumbed to individual sub panel distribution
rooms. Tenant is responsible for 50% of any upgrade costs incurred by landlord to increase
from 3500 amp service to 4000 amp&#146;s as proposed by tenant.
Emergency generator will be provided for back up power for tenant&#146;s use, emergency
lighting, life safety systems and laboratory support equipment. Tenant is responsible for
50% of all cost&#146;s associated with the purchase and installation of generator to be
specified by owner. Generator size will not exceed twice
tenant&#146;s load requirement. Two telephone service entrance conduits (4&#148;) are provided into
buildings common electrical
room and are to be shared by all building tenants. Tenant&#146;s telephone service requirements
are tenant&#146;s sole responsibility and will need to be further
accessed by Pac Bell or other
service provider.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Water Service:</b> Domestic hot and cold water to core bathrooms and showers will be
provided. House meter in landlord&#146;s space will be affixed to tenant&#146;s water feed to
calculate consumption of water to areas other than common space. Base building fire
sprinkler system will be provided with only upturned heads throughout.
Modifications to base system to accommodate tenant improvements are the sole
responsibility of tenant.<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Sanitary and Laboratory Sewer:</b> Additional provisions
have been made below the
1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> floor
slab for both normal and laboratory waste systems. Both systems are oversized with
6&#148; piping. The lab system is of chemical and DI resistant plastic
piping. Stub ups for waste connections on the 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> floor
have been provided intermittently,
along the central column lines. Tenant is responsible to monitor, downstream, the DI resistant
waste line to insure that no chemicals are released into the laboratory waste system.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Foundation / Superstructure:</b> The structure is founded on cathodically protected steel
pilings, concrete footings, structural slab and skirt wall supporting a rigid structural
steel frame. Joists are I-beam shaped and protected with sprayed on monokote fireproofing.
The main floor is a concrete topping slab structural concrete main slab. The floor to
floor dimension is 16&#146;-6&#148; on the first floor and 17&#146; on the
2<SUP style="font-size: 85%; vertical-align: text-top">nd </SUP>and
3<SUP style="font-size: 85%; vertical-align: text-top">rd </SUP>floors.
The floor live loading is 140 lbs. per square foot. The upper 2 floors are
poured concrete on metal decking. The roof load is designed with 24 lb. per square foot
loading. A continual central band of 50 lb. per square foot loading is provided for
rooftop mechanical equipment. Rooftop screen areas are oversized to house intensive
rooftop equipment. Any alterations required to support, distribute, screen or house the
tenant&#146;s rooftop mechanical equipment is at the sole responsibility and cost of the
tenant. Any alterations to the roof that require the penetration, removal, flashing, or
capping shall be constructed in a fashion as not to void the landlord&#146;s warranty of the
roof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Envelope: </b>Exterior wall system is Glass Fiber Reinforced Concrete (GFRC)&nbsp;with a glass curtain
wall system and aluminum frames. Window heights are (floor to head) 10&#146; on 1<SUP style="font-size: 85%; vertical-align: text-top">st </SUP>floor
and 11&#146; on 2<SUP style="font-size: 85%; vertical-align: text-top">nd </SUP>and 3<SUP style="font-size: 85%; vertical-align: text-top">rd </SUP>floors
with spandrel glass above. Windows are 1/4&#148; monolithic vision glass, tinted &#145;Blue Sapphire&#146; and manufactured by Interpane.
GFRC system is white with brown base and darker stone aggregate. Rooftop mechanical
screens are &#043;- 9&#146;-6&#148; tall at EIFS and &#043;- 12&#146; tall at the spandrel glass curtain wall, built on
galvanized steel frames. Roofing system is a 4-ply built up membrane over rigid insulation. Any
alterations to the roof that require penetration, removal, flashing or capping shall be the
sole responsibility of the tenant and be constructed by a manufacturers certified installer as
not to void the landlords warranty on the roof. Landlord does not warranty to tenant any
roofing areas that are affected by tenant&#146;s alterations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Tenant Area Improvements:</b> Bathroom cores, all floors, complete and functional with
fixtures, accessories, lighting and finishes consistent with core improvements.
The general finish concept is to create a high-tech industrial but
warm feeling. Stained and colorized concrete floors, granite tile walls, brushed stainless steel accents,
partitions, hardboard paneling and laminates and accent lighting will be used. Galvanized
spiral ductwork and exposed ceilings may be used in bathrooms and core for accents. Open
areas will be furnished with perimeter wall and column furring throughout. Horizontal
window blinds will be provided at all windows. Rated stair shafts and doors along with
electrical distribution rooms will be constructed on all floors. Automatic fire sprinkler
system with up-turned heads and basic fire alarm panel will be provided. Exit signs at all
major exits. Stairwells will be provided with colorized concrete stair pans or rubber
studded tile treads. Painted steel railings with horizontal balustrade will be provided at
tenant stairwell. Future elevator pit and shaft provisions have been provided for tenant&#146;s
use. Elevator improvements other than the 2 core elevators are not included. If tenant
elects to provide additional elevator it is at their sole cost.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Common Area Improvements:</b> Lobby complete with architectural security desk, oversized
wood doors, lighted soffits, semi-exposed ceilings, spiral ductwork, colorized concrete
floors, accent lighting, hardboard paneling and etc. Elevator finishes to be brushed
stainless steel with light wood hardboard paneling. Feature stair to be provided with
architectural stainless steel railing &#038; balustrade, flooring consistent with core
improvements. Finishes and other common areas such as fitness and lunch room to match the
integrity and concept of the described core improvements. Lunchroom to be fully equipped
with sinks, casework, counters, interior and exterior seating.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT A-2</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>LANDLORDS WORK NECESSARY FOR TENANT IMPROVEMENTS</u>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Building Type:</b> 3 Story, Group B, Type III, I Hour Rated, Sprinklered Office Building.
All design and construction progress in conformance with the 1998 (CBC) Building Standards
Administrative Code of the California Building Standards Commission
(CBSC)&nbsp;and the City of
South San Francisco amendments, applicable codes and regulations. ADA compliance may not
be completed prior to tenant&#146;s construction commencement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Site Development:</b> Walks, paving and parking lots will be substantially complete.
Striping may not be complete. Loading areas and paths of travel will be provided to allow
for the interior and exterior construction of improvements.
Substantial sitework and
landscaping will be in place and must be adequately protected by tenant&#146;s construction
team. Any damage to these areas will need to be adequately repaired or replaced by tenant.
A tenant construction trailer, storage container and debris container will be allowed on
site subject to approval and siting by landlord&#146;s representative. Any damage to these
designated areas will need to be adequately restored to original condition by tenant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Telephone Gas and Electric Utilities:</b> 2000 amps of permanent electric will be
provided to the tenant&#146;s pull section in common electrical room and can be used for
construction power subject to delays in tenant&#146;s request for upgrade. Upgrade from 3500
amp to 4000 amp main service and switchgear, subject to additional tenant cost. Gas meter
and service will be provided subject to tenant&#146;s mechanical loads and installation
schedule. Telephone entrance conduits only are provided to common electrical room.
Temporary jobsite telephone is tenant&#146;s sole responsibility.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Water Service:</b> Water service to building and main meter in vault outside
building. Tie in subject to tenants requirements and schedule.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Sanitary and Laboratory Sewer:</b> Below slab plumbing to be provided. Tie in and
activation subject to tenant&#146;s loads and installation schedule.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Foundation / Superstructure:</b> To be provided as per Section&nbsp;6 in Lease Exhibit&nbsp;A-1,
Landlord&#146;s Work.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Envelope:</b> Building to be substantially &#145;dried in&#146; complete with GFRC exterior wall
system, glass curtain wall system, exterior doors and roofing. A section of window and
frame will be left void, on each upper floor, to allow for the delivery and handling of
construction materials. It is the tenant&#146;s sole responsibility to protect the opening from
weather as well as protect the GFRC and surrounding area from damage.
When reasonably requested by tenant, landlord will then install window unit in coordination
with tenants contractor. Roofing system will be substantially complete in areas not
affected by tenants extensive rooftop alterations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Tenant Area Improvements:</b> Work in central core areas will be progressing
simultaneously with tenant&#146;s work. Efforts will be made to leave areas free of obstruction
and debris. If deemed necessary, temporary dust barriers will be constructed to segregate
the simultaneous build outs. Vertical circulation will be provided via the tenant
stairwell. Stairwell shafts will be enclosed and operational but will remain unfinished
until appropriate time in coordination with tenant&#146;s build out.
Perimeter and column furring will be provided throughout. Automatic fire sprinkler with
upturned heads only will be provided throughout. Provisions have been
made to zone off
the sprinkler mains per each floor. Any shut downs to accommodate tenant&#146;s sprinkler
installation will need to be coordinated with landlord&#146;s
contractor. Freight elevator pit will be constructed be and left void with temporary railing surround.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Common Area Improvements:</b> Work in central core and common areas will be accessible
but work will be progressing simultaneously with tenant&#146;s work. Common Electrical room
will be constructed. Completion of electrical room is subject to schedule and coordination
of power upgrade, generator installation, and telephone equipment installation. Central
stair will be under finish construction and restricted for access by tenant&#146;s contractors
except for cases of material handling hardships. The intention is to preserve and maintain
the architectural finishes of the central stair, until actual building occupancy.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT B</u>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>CLEANING SCHEDULE</u>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">I.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Premises</u></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Daily on Business Days</u>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empty all waste receptacles and ash trays and remove waste materials from the
Premises.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and dust mop all uncarpeted areas using a dust-treated mop.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Vacuum all rugs and carpeted areas.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Hand dust and wipe clean with treated cloths all horizontal cleared surfaces
including desk tops, office equipment, window sills, door ledges, chair rails and counter
tops, within normal reach.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash clean all water fountains.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon completion of cleaning, all lights will be turned off and doors locked, leaving
the Premises in an orderly condition.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Quarterly</u></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Render high dusting not reached in daily cleaning to include:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting all pictures, frames, charts, graphs and similar wall hangings.<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting all vertical surfaces, such as walls, partitions, doors and ducts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting of all pipes, ducts and high moldings.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>II.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Lavatories</u></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Daily on Business Days</u>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and damp mop floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clean all mirrors, powder shelves, dispensers and receptacles, bright
work, flushometers, pipes and toilet seats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash both sides of all toilet seats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash all basins, bowls and urinals.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dust and clean all powder room fixtures.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empty and clean paper towel and sanitary disposal receptacles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">g.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Remove waste paper and refuse.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">h.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Refill tissue holders, soap dispensers, towel dispensers, vending
sanitary dispensers; materials to be furnished by Landlord.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A sanitizing solution will be used in all lavatory cleaning.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Monthly</u>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Machine scrub lavatory floors.<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash all partitions and tile walls in lavatories.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">III.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Main Lobby, Elevators, Building Exterior and Corridors</u></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Daily on Business Days</u>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and wash or spray buff all marble floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep all entrance mats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clean elevators, wash or vacuum floors, wipe down walls and doors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Spot clean any metal work surrounding building entrance doors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Monthly</u>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All resilient tile floors in public areas to be treated equivalent to spray buffing.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">IV.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Window Cleaning</u></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The outside of exterior wall windows will be washed once every three months, weather
permitting, and the inside of exterior wall windows will be &#183;washed every six months.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">V.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenants requiring services in excess of those described above shall request same
through Landlord, at Tenant&#146;s expense.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT C</u>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><u>RULES AND REGULATIONS</u>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The sidewalks, entrances, passages, courts, elevators, vestibules, stairways, corridors or
halls of the Building shall not be obstructed or encumbered or used for any purpose other than
ingress and egress to and from the premises demised to any tenant or occupant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;No awnings or other projections shall be attached to the outside walls or windows of the
Building without the prior consent of Landlord. No curtains, blinds, shades, or screens shall be
attached or hung in, or used in connection with, any window or door of the premises demised to any
tenant or occupant, without the prior consent of Landlord. Such awnings, projections, curtains,
blinds, shades, screens, or other fixtures must be of a quality type, design and color, and
attached in a manner, approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;No sign, advertisement, object, notice or other lettering shall be exhibited, inscribed,
painted or affixed on any part of the outside or inside of the premises demised to any tenant or
occupant or of the Building without the prior consent of Landlord. Interior signs on doors and
directory tables, if any, shall be of a size, color and style approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air
into the halls, passageways or other public places in the Building shall not be covered or
obstructed, nor shall any bottles, parcels, or other articles be placed on any window sills.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;No show cases or other articles shall be put in front of or affixed to any part of the
exterior of the Building, nor placed in the halls, corridors, vestibules or other parts of the
Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The water and wash closets and other plumbing fixtures shall not be used for any purposes
other than those for which they were constructed, and no sweepings, rubbish, rags, or other
substances shall be thrown therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;No tenant or occupant shall mark, paint, drill into, or in any way deface any part of the
Building or the premises demised to such tenant or occupant, except to the extent required for the
mounting of pictures and other normal office fixtures. No boring, cutting or stringing of wires
shall be permitted, except with the prior consent of the, Landlord, and as Landlord may direct. No
tenant or occupant shall install any resilient tile or similar floor covering in the premises
demised to such tenant or occupant except in a manner reasonably approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;No bicycles, vehicles or animals of any kind (other than animals allowed under the
Permitted Uses) shall be brought into or kept in or about the
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">premises demised to any tenant. Bicycles may be stored in racks, if any, furnished for such
purpose by Landlord in a common area of the Property. No cooking
shall be done or permitted in the
Building (other than microwave use and coffee machines) by any tenant without the approval of
Landlord. No tenant shall cause or permit any unusual or objectionable odors to emanate from the
Premises demised to such tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;Without the prior consent of Landlord, no space in the Building shall be used for
manufacturing, or for the sale of merchandise, goods or property of any kind at auction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;No tenant shall make, or permit to be made, any unseemly or disturbing noises or disturb
or interfere with other tenants or occupants of the Building or neighboring buildings or premises
whether by the use of any musical instrument, radio, television set or other audio device, unmusical noise, whistling,
signing, or in any other way. Nothing shall be thrown out of any doors or windows.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Each tenant must, upon the termination of its tenancy, restore to
Landlord all keys of stores, storage areas, offices and toilet rooms, either
furnished to, or otherwise procured by, such tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;All removals from the Building, or the carrying in or out of the
Building or the premises demised to any tenant, of any sales, freight, furniture, or bulky
matter of any description must take place at such time and in such manner as Landlord or
its agents may determine, from time to time. Landlord reserves the right to inspect all
freight to be brought into the Building and to exclude from the Building all freight which
violates any of the Building Rules or the provisions of such tenant&#146;s lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;No tenant shall use or occupy, or permit any portion of the premises
demised to such tenant to be used or occupied, as an office for a public stenographer,
messenger service or typist, or as a barber or manicure shop, or as an employment bureau.
No tenant or occupant shall engage or pay any employees in the Building, except those
actually working for such tenant or occupant in the Building, nor advertise for laborers
giving an address at the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;No
tenant or occupant shall purchase spring water, ice, food,
beverage, lighting maintenance, cleaning towels or other like service, from any company or person not
approved by Landlord, such approval not unreasonably to be withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;Landlord shall have the right to prohibit any advertising by any
tenant or occupant which, in Landlord&#146;s opinion, tends to impair the reputation of the Building or
its desirability as a building for offices, and upon notice from Landlord, such tenant or
occupant shall refrain from or discontinue such advertising.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;Landlord reserves the right to exclude from the Building, between the hours of 6:00 p.m.
and 8:00 a.m. on Business Days and otherwise at all hours, all persons who do not present adequate
identification or a pass to the building signed by the Landlord. Landlord will furnish passes to
persons for whom any tenant requests such passes. Each tenant shall be responsible for all persons
for whom it requests such passes and shall be liable to Landlord for all wrongful acts of such
persons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;Each
tenant, before closing and leaving the premises demised to such tenant at any time,
shall see that all entrance doors are locked and windows closed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;Each
tenant shall, at its expense, provide artificial light in the premises demised to
such tenant for Landlord&#146;s agency, contractors, and employees while performing janitorial or other
cleaning services and making repairs or alterations in said premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;No premises shall be used, or permitted to be used, for lodging or sleeping, or for any
immoral or illegal purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;There shall not be used in the Building, either by any tenant or occupant or by their
agents or contractors, in the delivery or receipt of merchandise, freight or other matter, any hand
trucks or other means of conveyance except those equipped with rubber tires, rubber side guards and
such other safeguards as Landlord may require.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;Canvassing, soliciting and peddling in the Building are prohibited and each tenant and
occupant shall co-operate in seeking their prevention.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;Subject to Section&nbsp;7.6, if the premises demised to any tenant become infested with vermin,
such tenant, at its sole cost and expense, shall cause its premises to be exterminated from time to
time, to the satisfaction of Landlord, and shall employ such exterminators therefor as shall be
approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;No premises shall be used, or permitted to be used, at any time, without the prior
approval of Landlord, as a store for the sale or display of goods, wares or merchandise of any
kind, or as a restaurant, shop, booth, bootblack or other stand, or for the conduct of any
business or occupation which predominantly involves direct patronage of the general public in the
premises demised to such tenant, or for manufacturing or for other similar purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.&nbsp;No tenant shall move, or permit to be moved, into or out of the Building or the premises
demised to such tenant, any heavy or bulky matter, without the specific approval of Landlord. If
any such matter requires special handling, only a person holding a Master Rigger&#146;s license shall be
employed to perform such special handling. No tenant shall place, or permit to be placed, on any
part of the floor or floors of the premises demised to such tenant, a load exceeding
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the floor load per square foot which such floor was designed to carry and which is allowed by law.
Landlord reserves the right to prescribe the weight and position of safes and other heavy matter,
which must be placed so as to distribute the weight.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.&nbsp;
The requirements of tenants will be attended to only upon application at the office of
the Building. Building employees shall not be required to perform, and shall not be requested by
any tenant or occupant to perform, any work outside of their regular duties, unless under specific
instructions from the office of the managing agent of the Building.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT D</u>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SIGN CRITERIA</u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notes:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Total tenant signage area not to exceed 100 square feet and shall be consistent
with Landlord and Sierra Point format as approved by The City of South San Francisco
Building Department and Planning Commission.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Tenant shall use Landlords sign contractor. Signage shall not be permitted in
areas beyond those shown on elevations below.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943239.gif" alt="(BUILDING PLANS)">
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Letter of Credit is subject to the Uniform Customs and Practice for Documentary Credit (1993 Revision) International Chamber of Commerce Publication No.
500 and any subsequent revisions thereof approved by a Congress of the International Chamber of Commerce and adhered to by Bank.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">IMPERIAL BANK INTERNATIONAL 3,696,840 <U>00</u> <U>CTS</u>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><IMG src="f39432a9e3943240.gif" alt="(IMPERIAL BANK LOGO)"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="center">International Division<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>IMPERIAL BANK</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;x&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2015 Manhattan Beach Blvd.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091; &#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">456 Montgomery St.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SWIFT IMPBUS66</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>California&#146;s Business Bank</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Redondo Beach, CA 90278
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4th Floor, Suite&nbsp;420
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telex: 3730628</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Member FDIC</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">San Francisco, CA 94104
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Answer Back: Imperial INW</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE: 11/07/00</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">FROM:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">IMPERIAL BANK<BR>INTERNATIONAL DIVISION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">2015 MANHATTAN BEACH BLVD</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">REDONDO BEACH, CA 90278</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">U.S.A.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">TELEX: 3730628 (IMPERIAL INW)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SWIFT: IMPBUS66</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">APPLICANT:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">GENESOFT, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">TWO CORPORATE DRIVE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SOUTH SAN FRANCISCO, CA 94080</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">IN FAVOR OF:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">MJ RESEARCH COMPANY, INC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">384 OLYMPIC POINT BLVD.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SOUTH SAN FRANCISCO, CA 94080</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">WE HEREBY ESTABLISH OUR IRREVOCABLE TRANSFERABLE STANDBY LETTER OF CREDIT
NO. OSF00001477 EXPIRING 11/07/01 AT OUR S.F. INTL. DIV. COUNTERS FOR AMOUNT:
USD3,696,840.00 (THREE MILLION SIX HUNDRED NINETY SIX THOUSAND EIGHT HUNDRED
FORTY EXACTLY).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CREDIT IS AVAILABLE WITH IMPERIAL BANK
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">INTERNATIONAL DIVISION<BR>
275 BATTERY STREET SUITE 1100<BR>
SAN FRANCISCO, CA 94111 U.S.A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY PAYMENT OF DRAFTS AT SIGHT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">DRAFTS DRAWN ON:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">IMPERIAL BANK<BR>
INTERNATIONAL DIVISION<BR>
275 BATTERY STREET SUITE 1100<BR>
SAN FRANCISCO, CA 94111 U.S.A.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">REQUIRED DOCUMENTS:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. THE ORIGINAL OF THIS LETTER OF CREDIT AND AMENDMENT(S) IF ANY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. BENEFICIARY&#146;S STATEMENT DATED AND PURPORTEDLY SIGNED BY AN AUTHORIZED
OFFICER CERTIFYING THAT THE &#147;TENANT&#148; (AS DEFINED IN THE LEASE) IS IN DEFAULT OR THAT AN EVENT OF
DEFAULT HAS OCCURRED UNDER ONE OR MORE OF THE TERMS OF THAT CERTAIN LEASE AGREEMENT DATED OCT. 6,
2000 THAT EXISTS BETWEEN GENESOFT, INC. AND MJ RESEARCH COMPANY, INC. (THE &#147;LEASE&#148;) AND THAT ANY
APPLICABLE CURE PERIOD HAS LAPSED WITHOUT REMEDY.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">ADDITIONAL CONDITIONS:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ALL INFORMATION REQUIRED UNDER DOCUMENT REQUIREMENT NO. 2 WHETHER INDICATED BY BLANKS, BRACKETS OR
OTHERWISE, MUST BE COMPLETED AT THE TIME OF DRAWING.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ALL SIGNATURES MUST BE MANUALLY EXECUTED IN ORIGINALS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PAGE 1 OF 3 TO IRREVOCABLE STANDBY LETTER OF CREDIT NO. OSF00001477
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Letter of Credit is subject to the Uniform Customs and Practice for Documentary Credit (1993 Revision) International Chamber of Commerce Publication No.
500 and any subsequent revisions thereof approved by a Congress of the International Chamber of Commerce and adhered to by Bank.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><IMG src="f39432a9e3943240.gif" alt="(IMPERIAL BANK LOGO)"></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" valign="top" align="center">International Division<BR></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>IMPERIAL BANK</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#091;X&#093;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2015 Manhattan Beach Blvd.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091; &#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">456 Montgomery St.
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SWIFT IMPBUS66</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>California&#146;s Business Bank</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Redondo Beach, CA 90278
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4th Floor, Suite&nbsp;420
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telex: 3730628</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Member FDIC</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">San Francisco, CA 94104
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Answer Back: Imperial INW</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PAGE 2 OF 3 TO IRREVOCABLE STANDBY LETTER OF CREDIT NO. OSF00001477
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">PARTIAL DRAWINGS MAY BE MADE UNDER THIS LETTER OF CREDIT, PROVIDED, HOWEVER, THAT EACH SUCH
DEMAND THAT IS PAID BY US SHALL REDUCE THE AMOUNT AVAILABLE UNDER THIS LETTER OF CREDIT.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IT IS A CONDITION OF THIS LETTER OF CREDIT THAT IT SHALL BE DEEMED
AUTOMATICALLY EXTENDED WITHOUT AMENDMENT FOR ONE YEAR PERIODS FROM THE PRESENT
EXPIRATION DATE HEREOF, UNLESS FORTY FIVE (45)&nbsp;DAYS PRIOR TO ANY SUCH DATE, WE
SHALL NOTIFY YOU IN WRITING BY CERTIFIED MAIL OR COURIER SERVICE AT THE ABOVE
LISTED ADDRESS THAT WE ELECT NOT TO CONSIDER THIS IRREVOCABLE LETTER OF CREDIT
RENEWED FOR ANY SUCH ADDITIONAL PERIOD. UPON RECEIPT BY YOU OF SUCH NOTICE, YOU
MAY DRAW HEREUNDER BY MEANS OF YOUR DRAFT(S) ON US AT SIGHT ACCOMPANIED BY YOUR
ORIGINAL SIGNED STATEMENT WORDED AS FOLLOWS: MJ RESEARCH COMPANY, INC. OR THE &#147;LANDLORD&#148; UNDER THE &#147;LEASE &#148; HAS RECEIVED A NOTICE FROM IMPERIAL BANK THAT
THE EXPIRATION DATE OF LETTER OF CREDIT NO.&nbsp;OSF00001477 WILL NOT BE EXTENDED FOR
AN ADDITIONAL PERIOD. AS OF THE DATE OF THIS DRAWING, MJ RESEARCH COMPANY, INC.
OR SUCH &#147;LANDLORD&#148; HAS NOT RECEIVED A SUBSTITUTE LETTER OF CREDIT OR OTHER INSTRUMENT
ACCEPTABLE TO MJ RESEARCH COMPANY, INC., OR SUCH &#147;LANDLORD&#148; IN ITS SOLE DISCRETION, AS SUBSTITUTE FOR IMPERIAL BANK LETTER
OF CREDIT NO. OSF00001477.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOTWITHSTANDING THE ABOVE, THE FINAL EXPIRATION DATE SHALL BE APRIL 1, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS LETTER OF CREDIT IS TRANSFERABLE IN WHOLE ONLY. YOU MAY TRANSFER THIS LETTER OF CREDIT TO YOUR TRANSFEREE OR SUCCESSOR
UPON SATISFACTORY DELIVERY AND PRESENTATION TO THE ISSUING BANK OF (1)&nbsp;THE ORIGINAL L/C AND AMENDMENTS,
IF ANY, FOR PROPER ENDORSEMENT (2)&nbsp;A REQUEST FOR TRANSFER ON THE ISSUER&#146;S USUAL TRANSFER FORM (3)&nbsp;VERIFICATION OF SIGNATURE
AND AUTHORITY ON SUCH TRANSFER FORM SIGNING FOR THE BENEFICIARY (4)&nbsp;PAYMENT OF A TRANSFER FEE OF USD 1,000 AND (5) ANY OTHER REQUIREMENTS RELATIVE TO
THE UCP 500 AND U.S. GOVERNMENT REGULATIONS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IMPERIAL BANK, UPON RECEIPT OF BENEFICIARY&#146;S REQUEST IN A MANNER AS STATED HEREIN, TO TRANSFER THIS LETTER OF CREDIT,
WILL REQUIRE THAT THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENTS THERETO, IF ANY, BE RETURNED TO US FOR CANCELLATION.
UPON OUR RECEIPT OF SAME, A NEW LETTER OF CREDIT SHALL BE ISSUED TO THE TRANSFEREE, AS BENEFICIARY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ALL DRAFTS AND DOCUMENTS REQUIRED UNDER THIS LETTER OF CREDIT MUST
BE MARKED: &#147;DRAWN UNDER IMPERIAL BANK LETTER OF CREDIT NO. OSF00001477.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ALL DOCUMENTS ARE TO BE DISPATCHED IN ONE LOT BY COURIER SERVICE TO
IMPERIAL BANK INTERNATIONAL DIVISION, 275 BATTERY STREET, SUITE 1100, SAN
FRANCISCO, CA 94111.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS LETTER OF CREDIT SETS FORTH IN FULL THE TERMS OF OUR
UNDERTAKING AND SUCH UNDERTAKING SHALL NOT BE IN ANY WAY MODIFIED, AMENDED OR
AMPLIFIED BY REFERENCE TO ANY DOCUMENT, INSTRUMENT OR AGREEMENT REFERRED TO
HEREIN OR IN WHICH THIS LETTER OF CREDIT IS REFERRED TO OR TO WHICH THIS LETTER
OF CREDIT RELATES, AND ANY SUCH REFERENCE SHALL NOT BE DEEMED TO INCORPORATE
HEREIN BY REFERENCE ANY DOCUMENT, INSTRUMENT OR AGREEMENT.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943240.gif" alt="(IMPERIAL BANK LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IMPERIAL BANK</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">FROM:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">IMPERIAL BANK</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INTERNATIONAL BANKING DIVISION</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2015 MANHATTAN BEACH BLVD., 2ND FLOOR</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REDONDO BEACH, CA 90278</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TEL: 310 725-4488 FAX: 310 649-3407</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DATE:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11/07/00</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">TO:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MJ RESEARCH COMPANY, INC</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">384 OLYMPIC POINT BLVD.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SOUTH SAN FRANCISCO, CA 94080</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ATTN:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">REAL ESTATE OR LETTER OF CREDIT DEPARTMENT</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">AT THE REQUEST OF THE ACCOUNT PARTY, WE ENCLOSE HEREWITH ORIGINAL OF OUR STANDBY LETTER
OF CREDIT NO.&nbsp;OSF00001477.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">SINCERELY,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(ILLEGIBLE SIGNATURE)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">AUTHORIZED SIGNATURE
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT
F</U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>LIST OF ENVIRONMENTAL REPORTS GIVEN TO TENANT</u>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ENVIRONMENTAL DUE DILLIGENCE REVIEW OF THE SIERRA POINT ASSOCIATES TWO PROPERTIES
BRISBANE AND SOUTH SAN FRANCISCO, CALIFORNIA</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared for</I><BR>
Jon K. Wactor of Luce Forward, Hamilton and Scripps as attorney for potential purchaser
Opus West Corporation, Plessanton, California
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared By</I><BR>
ENVIRON Corporation, Emeryville, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
February&nbsp;4, 1998<BR>
Project No.&nbsp;03-6248A

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>UPDATE OF ENVIRONMENTAL DUE DILLIGENCE REVIEW, PARCEL 10, SHORELINE COURT, SIERRA
POINT, SOUTH SAN FRANCISCO, CALIFORNIA</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared For</I><BR>
MJ Sierra Point, LLC, South San Francisco, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared By</I><BR>
Harding Lawson Associates, Novato, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
December&nbsp;14,1998<BR>
HLA Project No.&nbsp;43142 001

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>FIRST AMENDED AND RESTATED DECLARATION OF COVENANTS, CONDITIONS AND ENVIRONMENTAL
RESTRICTIONS RELATING TO
ENVIRONMENTAL COMPLIANCE FOR SIERRA POINT</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Recorded By</I><BR>
Luce, Forward, Hamilton and Scripps, San Diego, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
August&nbsp;5, 1999

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>SUPPLEMENTAL ENVIRONMENTAL DUE DILLIGENCE, PARCEL 10,
SHORELINE COURT, SIERRA POINT, SOUTH SAN FRANCISCO, CALIFORNIA</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Prepared by</I><BR>
Harding Lawson Associates, Novato, California

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Dated</I><BR>
August&nbsp;24, 1999
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="Center" style="font-size: 14pt; margin-top: 6pt">EXHIBIT G<BR>
<U>PERMITTED HAZARDOUS MATERIALS</U><BR>
<B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-METHYLPIPERAZINE<BR>
1-Methylpiperazine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" >0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-NAPHTHALENESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">Corr</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-NAPHTHOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">99</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-NAPHTHOYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Carr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-NAPHTHYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Carc
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-OCTANOL<BR>
Octanol
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
lrr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.13 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-OCTYNE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-PHENYL-2-PROPANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-PIPERAZlNECARBOXALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
lrr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(&#043;/-)-10-CAMPHORSULFONIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,1<SUP style="font-size: 85%; vertical-align: text-top">1</SUP>-CARBONYLDIIMIDAZOLE<BR>
1,1<SUP style="font-size: 85%; vertical-align: text-top">1</SUP>-Carbonyldiimidazole
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">WR-1<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,1-DICHLOROPROPENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1B<BR>
lrr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">OHH</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,10-PHENANTHROLINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,2-DIBROMOETHANE<BR>
1,2-Dibromoethane
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,2-Dichloroethane<BR>
1,2-Dichloroethane
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Carc
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">2.1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,2-DIMETHOXYETHANE<BR>
Ethylene glycol dimethyl ether
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1B
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,3-CYCLOHEXANEBIS(METHYLAMINE)
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,3-DIBROMOPROPANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,3-DIMETHYL-3,4,5,6-TETRAHYD<BR>
RO-2(1H)PYRIMIDINONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.06 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.06 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,4-DIAMINOBUTANE<BR>
putrescine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">99</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15-CROWN-5
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.06 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,5-DIAMINOPENTANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">18-CROWN-6<BR>
18-Crown-6 ether
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,8-DIAZABICYCLO&#091;5.4.0&#093;UNDEC-
7-ENE
1,8-Diazabicyclo(5.4.0)Undec
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr-Base
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.13 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(1S,2R-)-(-)-CIS-1-AMINO-2-INDANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(1S,2R)-(&#043;)-NOREPHEDRINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(2-AMINOETHYL)-1-METHYLPY<BR>
RROLIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(4-METHOXYPHENYL)ETHYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(4-PYRIDYL)ETHANESULFONIC<BR>
ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(BROMOMETHYL)NAPHTHALENE<BR>
2-(Bromomethyl) naphthalene
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(METHYLAMINO)PYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(TRIBUTYLSTANNYL)FURAN
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(TRIMETHYLSILYL)ETHOXYMETHYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-II<BR>
Corr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-ACETAMIDO-4-METHYL-5-THIA<BR>
ZOLESULFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2
MedChem.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINO-5-CHLOROBENZOXAZOLE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINO-5-DIETHYLAMINOPENTANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINO-5-NITROPHENOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINO-6-METHYLPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINOBIPHENYL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
OHH<BR>
FS
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINOFLUORENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-AMINOPYRIDINE<BR>
2 - Aminopyridine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055&nbsp;Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-benzylalniline
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.11 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BIPHENYLYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.00026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BROMOBENZYL BROMIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Irr<BR>
Corr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BROMOETHANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">95</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(2-BROMOETHYL)BENZENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BROMOETHYL METHYL ETHER
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1C<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BROMOMETHYL-1,3-DIOXOLANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
WR-1<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BROMOPHENYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-BROMOTEREPHTHALIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLORO-1-METHYLPYRIDINIUM<BR>
IODIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.00022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLORO-3-NITROPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Fs<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLORO-4-METHYL-3-NITROPY<BR>
RIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROBENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROBENZOYL CHLORIDE<BR>
Chlorobenzoyl chloride
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROBENZYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROETHANESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Tox<BR>
Corr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROETHYL PHENYL<BR>
SULFIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Tox<BR>
Irr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROETHYL PHENYL<BR>
SULFONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Sens<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CHLOROPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-CYCLOHEXEN-1-ONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tax<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-DECALONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-DIMETHYLAMINOETHYL<BR>
CHLORIDE HYDROCHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-ETHOXYBENZYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-FLUOROBENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-FLUOROBENZYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.00026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-FLUOROPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">98</TD>
    <TD nowrap valign="bottom">%</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">fl2<BR>
irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-FUROYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Corr<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-IODOBENZOIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Sens<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-IODOPROPANE<BR>
Iso-Propyl Iodide
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">1.43 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-MESITYLENESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Corr<BR>
Tax<BR>
WR-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-METHOXYBENZYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-METHOXYETHYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1B<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-METHOXYPROPENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1A
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-NAPHTHOYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-NITROIMIDAZOLE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tax<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0088 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-NITROPHENYLACETIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">OHH<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-PHENYL-1-PROPANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-PYRIDINECARBOXALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="top">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="top">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-THIENYLLITHIUM
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1b<BR>
Corr<BR>
Irr<BR>
WR-2
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.052 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-THIOPHENECARBOXALDEHYDE<BR>
100
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
N/R
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-THIOPHENESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,2<SUP style="font-size: 85%; vertical-align: text-top">1</sup>-AZOBIS(ISOBUTYRONITRILE)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>UR-3<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,2-DIMETHYL-1,3-DIOXOLANE-4-<BR>
METHANAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">O.Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,2-DIPHENYLETHYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,2,6,6-TETRAMETHYLPIPERIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1C<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,3-DIBROMOPROPENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-II<BR>
OHH<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,3-DICHLORO-5,6-DICYANO-1,4-<BR>
BENZOQUINONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Tox<BR>
WR-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,3-DIHYOROFURAN
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4-DI-TERT-BUTYLPHENOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4-DIBROMOPHENOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIA<BR>
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4-DICHLOROBENZYL<BR>
ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">CL-IIIB<BR>
OHH<BR>
Irr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4-DIMETHOXYBENZOYL
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4-DIMETHOXYPHENYL<BR>
ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Carr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4-DINITROFLUOROBENZENE<BR>
2,4-dinitro-1-f1uorobenzene
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">99</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4,5-TRIBROMOIMIDAZOLE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4,6-COLIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,4,6-TRIISOPROPYLBENZENESU<BR>
LFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,5-DIMETHYL-3-PYRROllNE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0039&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
</TR>



















<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,6-DIAMINOPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,6-DICHLOROPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.55 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,6-HEPTADIENOIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,6-LUTIDINE<br>
2.6-Lutidine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(2R,8AS)-(&#043;)-(CAMPHORYLSULFO<BR>
NYL)OXAZlRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0022&nbsp;Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-(TRIFLUOROMETHYL)BENZALD<BR>
EHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-(TRIFLUOROMETHYL)BENZEN<BR>
ESULFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-(TRIFLUOROMETHYL)BENZOYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-ACETYL-1-PROPANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-AMINO-1-PHENYLBUTANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-AMINO-1-PROPANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-AMINO-1,2-PROPANEDIOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-AMINOPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.&#183;
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-BROMOPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-BUTEN-1-0L
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-BUTENYLMAGNESIUM<BR>
BROMIDE<BR>
BUTENYLMAGNESIUM<BR>
Tetrahydrofuran
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">.5M</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
WR-2<BR>
UR-3<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-BUTYN-1-OL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CHlOROBENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CHlOROBENZOYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1<BR>
Corr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CHlOROPEROXYBENZOIC<BR>
ACID<BR>
M-Chloroperoxybenzoic Acid
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CHlOROPROPANESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CYANOPHENYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CYANOPHENYLBORONIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0022&nbsp;Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-CYCLOPENTYLPROPIONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-FLUORO-P-ANISALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-FLUOROANllINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-FLUOROBENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-METHOXYBENZVLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
IIT
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-METHYLACETOPHENONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-METHYLBENZYLISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr<BR>
Sens<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-METHYLNORCAMPHANE-2-METHANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-NITROBENZOYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-4<BR>
WR-1<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-NITROPHENYLACETONITRILE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PENTENOIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0065&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PHENOXYPROPYL BROMIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PHENYL-1-PROPYNE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PHENYLPROPYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0026&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PYRIDINECARBOXALOEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">99</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PYRIDYLCARBINOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.0013&nbsp;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-PYRROLINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Tox<BR>
Corr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.00104 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.00026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,3-DIMETHYLBUTYRALDEHYOE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,4-DICHLOROANILINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Sens<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,4-DIHYORO-2H-PYRAN<BR>
3,4 Dihydro-2H-pyran
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,4-DIMETHOXYBENZENESULFO<BR>
NYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,4,5-TRIMETHOXYPHENYL<BR>
ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.00026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-BIS(TRIFLUOROMETHYL)BEN<BR>
ZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-BIS(TRIFLUOROMETHYL)BRO<BR>
MOBENZENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-DICHLORO-2-HYDROXYBENZ<BR>
ENESULFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Care<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-DICHLOROANILINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-DICHLOROBENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-DIFLUOROBENZVLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,5-0IMETHYLPIPERIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-(AMINOMETHYL)PIPERIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Cl-lIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-(DIMETHYLAMINO)PYRIDINE<BR>
Dimethylaminopyridine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed&nbsp;Occupancy&nbsp;Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-(TRIFLUOROMETHOXY)BENZE<BR>
NESULFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-(TRIFLUOROMETHYL)-2-PYRIMI<BR>
DINETHIOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-(TRIFLUOROMETHYL)BENZALD<BR>
EHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-(TRIFLUOROMETHYL)BENZYLA<BR>
MINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4"-CHLOROACETOPHENONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-AMINO-1-BUTANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-AMINOBENZOTRIFLUORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-AMINOBIPHENYL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-AMINOPYRIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.<BR>Irr<BR>OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-BENZYLPIPERIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-BIPHENYLSULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-BROMO-2-METHYL-2-BUTENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Corr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 &#183;Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-BROMOBENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-BROMOBUTYRONITRILE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-CHLOROBENZALDEHYDE<BR>
4-Chlorobenzaldehyde
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.55 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed&nbsp;Occupancy&nbsp;Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-CHLOROBENZENESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Corr<BR>
WR-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-CHLOROBENZOYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Corr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.00022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-CHLOROPHENYL<BR>
ISOTHIOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-CYANOBENZOYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
WR-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-CYANOPHENYL&nbsp;ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
Sens<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0044 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-DIMETHYLAMINO-2,2,6,6-TETR<BR>
AMETHYLPIPERIDINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-DIMETHYLAMINOAZOBENZENE<BR>
-4<SUP style="font-size: 85%; vertical-align: text-top">1</sup>-SULFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-ETHYLPHENYL&nbsp;ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-FLUOROBENZALDEHYDE<BR>
4-Fluorobenzaldehyde
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-FLUOROBENZENESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-FLUOROBENZYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-FLUORONITROBENZENE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-METHOXY-1-NAPHTHALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-METHOXYBENZYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed&nbsp;Occupancy&nbsp;Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5-CHLOROVALERYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Corr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5,6-DIMETHYLBENZIMIDAZOLE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6-AMINOCAPROIC ACID<BR>
6-Aminohexanoic Acid
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6-PHENYL-1-HEXANOL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>Irr</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7-OXOOCTANOIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">8-QUINOLINESULFONYL<BR>
CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A,A,A-TRIFLUORO-P-TOLYL
ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACETALDEHYDE<BR>
Acetaldehyde
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACETIC ANHYDRIDE<BR>
Acetic Anhydride
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
WR-2<BR>
Corr-Acid
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.26418 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.26418 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetone
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>Irr</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">2.1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetone
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">3 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACETONE CYANOHYDRIN
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.<BR>CL-IIIA<BR>Irr<BR>OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>




<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACETYL&nbsp;CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>FL-1B
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>


<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACETYLACETONE<BR>Acetylacetone
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">%</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>Irr<BR>OHH<BR>Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>













<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ALLYL ALCOHOL<BR>
Allyl Alcohol
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Corr<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed&nbsp;Occupancy&nbsp;Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ALLYL BROMIDE<BR>
Allyl Bromide
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ALUMINUM CHLORIDE<BR>
ALUMINUM CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1.76 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AMMONIA<BR>
Ammonia, Anhydrous
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
FG<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Cu.Ft.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Cu.Ft.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">6.3 Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AMMONIUM SULFAMATE<BR>
ammonium sulfamate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">%</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1<BR>
UR-1<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">2.2 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ANILINE<BR>
Aniline
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
Tox<BR>
CL-IIIA
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ANISOLE<BR>
Anisole
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
CL-II
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChern
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ANTHRANILIC ACID<BR>
anthranilic acid
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">99</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1.1 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">B-BROMOCATECHOLBORANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.11 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BARIUM HYDROXIDE<BR>
OCTAHYDRATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.<BR>Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BDCS SILYLATION REAGENT<BR>
Tert-Butyl Dimethylsilyl
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
CORR
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr<BR>
OHH<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZENESUlFONYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1<BR>
Corr<BR>
CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZIMIDAZOLE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZO&#091;B&#093;FURAN-2-CARBOXALD<BR>
EHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZOPHENONE IMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed&nbsp;Occupancy&nbsp;Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZOYL CHLORIDE<BR>
Benzoyl Chloride
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-1<BR>
WR-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZOYL PEROXIDE<BR>
Benzoyl peroxide 77-95%
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">77-95</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Perox-II<BR>
Oxy-3
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYL<BR>
1-PIPERAZINECARBOXYLATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYL ALCOHOL<BR>
Benzyl Alcohol
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Tox<BR>
Irr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYL BROMIDE<BR>
BENZYL BROMIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYL CHLOROFORMATE<BR>
Benzyl Chloroformate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>Corr<BR>WR-1
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr<BR>
Sens<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYLAMINE<BR>
Benzylamine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYLTRIETHYLAMMONIUM<BR>
CHLORIDE<BR>
benzyltriethylammonium
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CF (Comb.<BR>Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZYLTRIMETHYLAMMONIUM<BR>
HYDROXIDE<BR>
benzyltrimethylammonium
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">40</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
Tox<BR>&#151;<br>
&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BETA-METHYLPHENETHYLAMIN
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BIS(1,5-CYCLOOCTADIENE)NICKEL(O)
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Tox<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0044 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BIS(CYCLOPENTADIENYL)TITANIUM
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.11 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BIS(TRI-N-BUTYLTIN) OXIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BOC-4-PIPERIDONE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
UR-2<BR>
WR &#183;2<BR>
Carc
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BORANE TETRAHYDROFURAN<BR>
COMPLEX<BR>
Borane-tetrahydrofuran
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1A<BR>
WR-2<BR>
UR-2
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BORANE &#183;METHYL SULFIDE<BR>
COMPLEX
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BORON TRIBROMIDE<BR>
Boron Tribromide
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
WR-2<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BORON TRIFLUORIDE<BR>
Boron trifluoride etherate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
WR-2<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMINE<BR>
Bromine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Corr<BR>
Oxy-3
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOACETALDEHYDE<BR>
DIMETHYL ACETAL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOACETIC ACID<BR>
Bromo Acetic Acid
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOACETONITRILE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOACETYL BROMIDE<BR>
Bromoacetyl bromide
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
WR-2
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOACETYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr<BR>
WR &#183;2
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOETHANE<BR>
bromoethane
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BUTYL CHLOROFORMATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BUTYLLITHIUM
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1A<BR>
Tox<BR>
Corr<BR>
WR-3
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL<BR>
ACETYLENEDICARBOXYLATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Corr<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL AZODICARBOXYLATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
CL-II<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL CHLOROPHOSPHATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
WR-1<BR>
Corr<BR>
H.T.<BR>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL GLUTACONATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL KETOMALONATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL OXALATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIETHYL PHOSPHITE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIISOBUTYLALUMINUM HYDRIDE<BR>
Diisobutylaluminum Hydride
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Pyro<BR>
UR-2<BR>
WR-3<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIISOPROPYLAMINE<BR>
Diisopropylamine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
FL-1B<BR>
Corr-Base
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYL<BR>
CYANODITHIOIMINOCARBONATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Tox<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.11 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dimethyl formamide (DMF)
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Carc<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">2.1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYL ITACONATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1.1 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYL SULFATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
WR-1<BR>
Carc<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity </TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYL SULFIDE<BR>
Methyl Sulfide
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
FL-1B
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dimethyl Sulfoxide (DMSO)<BR>
Dimethylsulfoxide (DMSO)
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
CL-IIIB<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">2.1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYLAMINE<BR>
Dimethylamine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYLCARBAMYL CHLORIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr<BR>
Carc<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dioxane<BR>
1,4-Dioxane
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr<BR>
Carc<BR>
FL-1B
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIPHENYLACETALDEHYDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIPHENYLPHOSPHORYL AZIDE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DL-ADRENALINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.055 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EATON&#146;S REAGENT<br>
Phosphorous Pentoxide<br>
Methanesulfonic Acid
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<br>
H.T.<br>
WR-2
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EPICHLOROHYDRIN
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
UR-1<BR>
Carc<BR>
Tox
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ethanol<BR>
Ethyl Alcohol
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">2.1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHANOLAMINE<BR>
Ethanolamine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.&#183;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHER ANHYDROUS
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1A
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">2.1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL 1-METHYLNIPECOTATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL 3-AMINOBENZOATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
&#060;/R&#062;

<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL 3-BROMOPROPIONATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS<BR>
Irr<BR>
Sens<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL 5-OXOHEXANOATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ethyl acetate<BR>
ethyl acetate-1-13C
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">%</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">6.3 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ethyl acetate<BR>
ethyl acetate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">%</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">3 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL ACETOACETATE<BR>
Ethyl Acetoacetate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL CHLOROFORMATE<BR>
Ethyl Chloroformate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1<BR>
FL-1B
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ethyl ether
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1A<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">4.2 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL HYDROGEN MALONATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL LEVULINATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL NIPECOTATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL<BR>
(R)-(-)-2-HYDROXY-4-PHENYLBUT
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL TRIFLUOROACETATE<BR>
Ethyl trifluoroacetate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYL VINYL ETHER
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1A<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYLENE GLYCOL<BR>
1,2 Ethanediol
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYLENEDIAMINE<BR>
Ethylenediamine
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.00026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
&#060;/R&#062;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="Center" style="font-size: 14pt; margin-top: 6pt"><B>Inventory for Building Occupancy Classification</B>

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ETHYLENEIMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
UR-3D<BR>
Carc<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.104 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">EXO-2-AMINONORBORNANE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FENOPROFEN
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.022 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FORMALDEHYDE<br>
Formaldehyde Sol&#146;n
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">37</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Carc<BR>
Tox<BR>
Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FURFURYLAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C<BR>
Tox<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GLYOXYLIC ACID
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">50</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.22 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HEXAMETHYLPHOSPHORAMIDE<BR>
Hexamethylphosphoramide
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hexane<BR>
Hexane
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">3 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">1 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">hexanes, ACS HPLC grade;<br>
hexanes, anhydrous<br>
hexanes, mixed isomers
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B<BR>
Irr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">6.3 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HEXYL ISOCYANATE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II<BR>
Irr
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0013 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HISTAMINE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Irr<BR>
Sens
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.011 Lbs.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDRAZINE HYDRATE<BR>
Hydrazine, monohydrate
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox<BR>
Corr<BR>
CL-IIIA<BR>
Carc
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hydrochloric Acid &#062;30%<BR>
Hydrogen Chloride
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">2<BR>
MedChem
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDROCINNAMOYL CHLORIOE
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom">100</TD>
    <TD nowrap valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB<BR>
Corr<BR>
OHH
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">.0065 Gal.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="17" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity </TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ISOPROPYLSULFONYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ISOVALERYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">KARL FISCHER REAGENT</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-METHOXYETHANOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">L-PROLINE METHYL ESTER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDROCHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LITHIUM ALUMINUM HYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lithium Aluminum Hydride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LITHIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BIS(TRIMETHYLSILYL)AMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LITHIUM BOROHYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.11 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lithium Borohydride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LITHIUM CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lithium Chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LITHIUM DIISOPROPYLAMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.208 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lithium Diisopropylamide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LITHIUM TETRAFLUOROBORATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">M-TOLUOYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MAGNESIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">magnesium</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MAGNESIUM PERCHLORATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HEXAHYDRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHANESULFONIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHANESULFONYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methanesulfonyl Chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>



<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity </TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methanol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methyl Alcohol, Anhydrous</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methanol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methyl Alcohol, Anhydrous</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHOXYAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDROCHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methoxylamine Hydrochloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">1-CYCLOPENTENE-1-CARBOXYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.00026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2-(BROMOMETHYL)ACRYLATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL 2-BROMOBENZOATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.02 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL 3-BROMOPROPIONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">METHYL 4-BROMOCROTONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.052 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-METHOXYACETOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL BROMOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methyl Bromoacetate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL CHLOROFORMATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methyl Chloroformate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL CROTONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1b</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">METHYL CYCLOHEXYLACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL ISOCYANATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.007 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Methyl Isocyanate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL OXALYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL PROPIOLATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL PYRUVATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL TRANS-3-PENTENOATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0078 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYLUTHIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Pyro</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MOLYBDENUM HEXACARBONYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MORPHOLINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Morpholine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-(2-AMINOETHYL)CARBAMIC</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACID TERT-BUTYL ESTER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-(3&#146;-AMINOPROPYL)-2-PYRROLI</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DINONE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-(BENZYLOXYCARBONYLOXY)S</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">UCCINIMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N,N&#146;,N&#146;-TETRAMETHYLETHYLE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NEDIAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetramethylethylenediamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N,N&#148;-TRIMETHYL-1,3-PROPANE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N&#146;-DICYCLOHEXYLCARBODIIMI</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.25 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N-Dicyclohexylcarbodiimide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N&#146;-DIETHYL-1,3-PROPANEDIAM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">INE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N&#146;-DIISOPROPYLCARBODIIMID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1,3-Diisopropylcarbodiimide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-diisopropylethylamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-diisopropylethylamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-DIMETHYLANILINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N,N-DIMETHYLETHYLENEDIAMIN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-DIMETHYLFORMAMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DI-TERT-BUTYL ACETAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-DIMETHYLFORMAMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.&#183;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DIMETHYL ACETAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-Dimethylformamide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-DIMETHYLNEOPENTANEDIA</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-(TERT-BUTOXYCARBONYL)-D-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.00026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROLINAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-ACETYLSULFANILYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 lbs</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-BROMOSUCCINIMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Bromosuccinimide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-BUTYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-CARBOBENZYLOXY-L-SERINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">METHYL ESTER</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-CHLOROSUCCINIMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHLOROSUCCINIMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-ETHYLMETHYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-HEXYLMETHYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl Pyrrolidone (NMP)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">26 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">6 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl Pyrrolidone (NMP)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-METHYL-N&#146;-NITRO-N-NITROSO</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GUANIDINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-METHYL-N-PROPARGYLBENZY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">LAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-METHYLANILINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-methylaniline</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-METHYLSENZYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">N-METHYLHOMOVERATRYLAMIN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-methylmorpholine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">4.2 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-methylmorpholine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-METHYLPHENETHYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-PROPYL ISOCYANATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-TRIMETHYLSILYLIMIDAZOLE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NICKEL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nickel (Raney Activated)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NICOTINOYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDROCHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nitric Acid 41-86%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nitric Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">41-86</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NITROMETHANE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nitromethane</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NITROSONIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRAFLUOROBORATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nitrosonium Tetrafluoroborate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">O-ANISALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">O-ANISIDINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">o-Anisidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH,sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">O-PHENYLENEDIAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22  Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phenylenediamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">O-PHTHALALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">O-XYLENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.26418 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OSMIUM TETROXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Osmium(VlII) Oxide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OXALIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.065 GaL</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Oxalic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OXALYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Oxalyl chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-ANISALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-ANISIDINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-ANISOYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-Anisoyl chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(&#043;)-P-MENTH-1-EN-9-OL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-TOLUALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-TOLUENESULFONIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CF (Comb.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22  Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MONOHYDRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">p-toluenesulfonic acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-TOLUENESULFONYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.26418 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toluenesulfonyl Chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-TOLUOYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">p-Toluoyl chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P-TOLYL ISOTHIOCYANATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PALLADIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palladium on activated</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PARAFORMALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PARAFORMALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PERFLUORO-1-BUTANESULFON</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">YL FLUORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PERIODIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.66 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Periodic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Petroleum Ether</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1A</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">2.1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Petroleum Ether</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENETHYL ISOCYANATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENETHYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.208 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENOTHIAZINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">phenothiazine</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">&#043;98</TD>
    <TD nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENYL CHLOROFORMATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phenyl chloroformate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENYL ISOTHIOCYANATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENYLACETALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENYLACETYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENYLACETYLENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHENYLLITHIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Pyro</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">cyclohexane ethher</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1.8M</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSGENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.052 Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">2.6 Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phosgene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHOMOLYBDIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phosphomolybdic Acid,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHORIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem &#183;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phosphorous Trichloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phosphorous Trichloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHORUS OXYCHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.006 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POCL3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHORUS PENTACHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phosphorus Pentachloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHORUS PENTOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phosphorous Pentoxide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHORUS (V) TRIBROMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.052 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OXIDE, 98%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHTHALOYL DICHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PIPERIDINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PIPERONAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POLYPHOSPHORIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.26 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.11 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">potassium</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BIS(TRIMETHYLSILYL)AMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Potassium bis (trimethyl silyl)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toluene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM BOROHYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011  Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM CARBONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.065  Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM CYANIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Potassium Cyanide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM FLUORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13   Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Potassium Fluoride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM HYDROGEN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SULFATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Potassium Bisulfate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM NITRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">potassium nitrate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NITROSODISULFONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM TERT-BUTOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Potassium tert-Butoxide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">POTASSIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.165 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLSILANOLATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROCAINAMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDROCHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROPARGYLALCOHOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">&#183;.026Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Propargyl Alcohol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROPARGYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BENZENESULFONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROPIOLIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CI-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PROPIONALDEHYDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="13%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pyridine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Fl-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pyridine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PYRIDINE-3-SULFONIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.055 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-Pyridine Sulfonic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PYRIDINE-4-METHANOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Cl-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PYRIDINIUM CHLOROCHROMATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pyridinium Chlorochromate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PYRIDINIUM DICHROMATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pyridinium Dichromate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PYRROLIDINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Pyrrolidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(R)-(&#043;)-1-PHENYL-1-BUTANOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">R(-)-1-PHENYL-2-PROPANOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.00026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(R)-(&#043;)-2-METHYL-1-PHENYL-1-PR</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">OPANOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(R)-(&#043;)-2-PHENYL-1-PROPANOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.00026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.00026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(R)-(-)-EPICHLOROHYDRIN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(S)-(&#043;)-EPICHLOROHYDRIN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SAMARIUM(II) IODIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Iodine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">.1m</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrahydrofuran</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SELENIUM DIOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right" nowrap>1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Selenium(lV) Oxide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SILVER (II) OXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SILVER NITRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Silver Nitrate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="15%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">sodium</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM AZIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sodium Azide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.208 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BIS(TRIMETHYLSILYL)AMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM BOROHYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sodium Borohydride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM CYANOBOROHYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.11 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sodium Cyanoborohydride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM DITHIONITE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM ETHOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM HYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM HYPOCHLORITE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.26418 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM HYPOCHLORITE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">12-15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM METAPERIODATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sodium Metaperiodate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM METHOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CF/D (loose)</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM NITRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sodium Nitrate</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM NITRITE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sodium Nitrite</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM TERT-BUTOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SODIUM THIOMETHOXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SOLKETAL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TBTU</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-PIPERAZINECARBOXYLATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL ALCOHOL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.26418 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tert Butyl Alcohol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL BROMOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL HYDROPEROXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Perox-I</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-(3-AMINOPROPYL)CARBAMAT</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYL NITRITE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-l</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TERT-BUTYLACETYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.26418 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRA-N-BUTYLAMMONIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIBROMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-l</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRABUTYLAMMONIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">FLUORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrabutylammonium fluoride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRAETHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrahydrofuran</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1&nbsp;Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrahydrofuran</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrahydrofuran</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrahydrofuran</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>





<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRAHYDROFURFURYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRAMETHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ORTHOCARBONATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRAPROPYLAMMONIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PERRUTHENATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">THIONYL BROMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">THIONYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.26418 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thionyl chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">THIOPHENE &#183;2-CARBONYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">THIOPHOSGENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thiophosgene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">THIOUREA</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Thiourea</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TIN(IV) CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tin (IV) chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TITANIUM(IV) CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2 &#183;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.44 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Titanium Tetrachloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CORR</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toluene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">2.1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toluene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toluene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toluene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRANS-1,4-DIAMINOCYCLOHEXA</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">NE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRANS-DICHLOROBIS(TRIPHENY</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0242 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">L-PHOSPHINE)PALLADIUM (II)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRI-N-BUTYLTIN CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRI-N-BUTYLTIN HYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tributyltin Hydride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIBUTYL BORATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0234 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRICHLOROMETHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CHLOROFORMATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIETHYL ORTHOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Triethylamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Triethylamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIETHYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HYDROCHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIETHYLSILANE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Triethylsilane</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIFLUOROACETIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIFLUOROACETIC ANHYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoroacetic anhydride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIFLUOROMETHANESULFONIC</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoromethanesulfonic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIFLUOROMETHANESULFONIC</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">. 0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ANHYDRIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoromethanesulfonic</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIISOPROPYL BORATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0208 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4-BROMOORTHOBUTYRATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYL ORTHOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYL ORTHOFORMATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYL ORTHOVALERATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">PHOSPHONOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FG</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">5.5 Cu.Ft.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trimethylamine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLOXONIUM</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.044 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TETRAFLUOROBORATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLSILYL</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">BROMOACETATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLSILYL CYANIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trimethylsilylcyanide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLSILYLDIAZOMETHAN</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">E</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIMETHYLTIN CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">H.T.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIPHOSGENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.22 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Triphosgene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRYPTAMINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.11 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">UREA HYDROGEN PEROXIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Oxy-3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VALERYL CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">VINYLMAGNESIUM BROMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tetrahydrofuran</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1M</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Xylene</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">2.1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mixed Xylenes</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ZINC</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CF/D (loose)</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">2.2 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ZINC         METAL DUST</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ZINC         CHLORIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.55 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Zinc Chloride</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ZINC         CYANIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ZINC         IODIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.11 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">zinc iodide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right"></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt">Inventory for Building Occupancy Classification
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetic Acid,       Glacial</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.5 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.5 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Biology</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dichloromethane</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3  Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Peptide</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ethanol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">2  Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Biology</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ethyl Alcohol</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl Pyrrolidone (NMP)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3  Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Peptide</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl Pyrrolidone (NMP)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.75Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.25 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Peptide</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIFLUOROACETIC ACID (TFA)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.75Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.25 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Peptide</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TRIFLUOROACETIC ACID</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Waste</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">4 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Peptide</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Total Quantity. Includes aggregate quantity in use and storage
per UBC.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Open Use &#151; Use of a solid or liquid hazardous material in a vessel or system that is continuously
open to the atmosphere during normal operations and where
vapors are liberated, or the product is exposed to the atmosphere during normal operations.
Examples of open systems for liquids include dispensing from or into
open beakers or containers; dip tank operations: plating operations: etc.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Closed Use &#151;  Use of a solid or liquid hazardous
material in a closed vessel or system that remains
closed during normal operations where vapors emitted by the
product are not liberated outside of the vessel or system and the product is not exposed to the
atmosphere during normal use: and all uses of compressed gases.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Examples of closed systems for solids and liquids include product conveyed through a piping system
into a closed vessel, system, or piece of equipment; reaction
process operations;</TD>
</TR>

</TABLE>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> 1998 Integrated Engineering Services. All rights reserved.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>Inventory for Building Occupancy Classification</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">H3
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">H3</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetonitrile</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">330 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">330 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cyanomethane/Methyl</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dichloromethane</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">160 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dimethyl formamide (DMF)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">32 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dimethyl formamide (DMF)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Flammable Solvent Waste</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1000 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cyanomethane/Methyl</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#060;20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl Pyrrolidone (NMP)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">160 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl Pyrrolidone (NMP)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-18</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">32 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">H3</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoroacetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">32 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Store</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoroacetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">1</SUP>&nbsp;Total Quantity. Includes aggregate quantity in use and
storage per UBC.</DIV>

<DIV align="left" style="font-size: 8pt"><SUP style="font-size: 85%; vertical-align: text-top">2</SUP>&nbsp;Open Use &#151; Use of a solid or liquid hazardous material in a vessel or system that is continuously
open to the atmosphere during normal operations and where
vapors are liberated, or the product is exposed to the atmosphere during normal operations.
Examples of open systems for liquids include dispensing from or into
open beakers or containers; dip tank operations; plating operations;
etc.</DIV>

<DIV align="left" style="font-size: 8pt"><SUP style="font-size: 85%; vertical-align: text-top">3</SUP>&nbsp;Closed Use &#151; Use of a solid or liquid hazardous material in a closed vessel or system that
remains dosed during normal operations where vapors emitted by the
product are not liberated outside of the vessel or system and the product is not exposed to the
atmosphere during normal use; and all uses of compressed gases.
Examples of closed systems for solids and liquids include product conveyed through a piping system
into a closed vessel, system, or piece of equipment; reaction process
operations;</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> 1998 Integrated Engineering Services. All rights reserved.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>Inventory for Building Occupancy Classification</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-(2-AMINOETHYL)PIPERIDINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-(3-AMINOPROPYL)IMIDAZOLE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-(3-DIMETHYLAMINOPROPYL)-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3-ETHYLCARBODIIMIDE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-ADAMANTYL ISOCYANATE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.011 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-AMINO-4-METHYLPIPERAZINE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-CHLORO-2,4-DINITROBENZENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1.1 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Sens</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-CHLORO-3-IODOPROPANE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.026 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-CHLORO-4-ETHYNYLBENZENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FS</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.0022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="right">.0022 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Lbs.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-CHLORO-4-PHENYLBUTANE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIB</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-ETHYNYLCYCLOHEXENE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1C</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0013 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-HEPTYNE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.0065 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-IODOBUTANE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.13 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">2</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1-METHYLIMIDAZOLE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-IIIA</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">0 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MedChem</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N-Methyl imidazole</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">1</SUP>&nbsp;Total
Quantity. Includes aggregate quantity in use and storage per UBC.</DIV>

<DIV align="left" style="font-size: 8pt"><SUP style="font-size: 85%; vertical-align: text-top">2</SUP>&nbsp;Open Use &#151; Use of a solid or liquid hazardous material in a vessel or system that is continuously
open to the atmosphere during normal operations and where
vapors are liberated, or the product is exposed to the atmosphere during normal operations.
Examples of open systems for liquids include dispensing from or into
open beakers or containers; dip tank operations; plating
operations; etc.</DIV>


<DIV align="left" style="font-size: 8pt"><SUP style="font-size: 85%; vertical-align: text-top">3</SUP>&nbsp;Closed Use &#151; Use of a solid or
liquid hazardous material in a closed vessel or system that remains
closed during normal operations where vapors emitted by the
product are not liberated outside of the vessel or system and the product is not exposed to the
atmosphere during normal use; and all uses of compressed gases. Examples of closed systems for solids and liquids include product conveyed through a piping system
into a closed vessel, system, or piece of equipment; reaction
process operations;</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> 1998 Integrated Engineering Services. All rights reserved.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>Inventory for Building Occupancy Classification</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Plan Check No.:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">Proposed Occupancy Classification:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">B
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Control Area No.:</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Is this area protected by a fire sprinkler system?</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Yes</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="16%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature of Preparer:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9/18/2000
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">3.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">5.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">6.</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">1.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">2.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">UBC Class(es)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">4.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Stored in</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Room</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Chemical Name &#038;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Physical &#038; Health</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">in Use</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Approved</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Concentration</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Hazards</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Stored<SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Open<SUP style="font-size: 85%; vertical-align: text-top">2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Closed<SUP style="font-size: 85%; vertical-align: text-top">3</SUP></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Cabinet?</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetic Acid, Glacial</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">CL-II</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">6 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">2 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr-Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetonitrile</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">60 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cyanomethane/Methyl</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Buffer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">55 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Acetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chloroform</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Carc</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chloroform</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">OHH</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">HPLC Waste</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">4 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cyanomethane/Methyl</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-Dimethylformamide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Irr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:30px; text-indent:-15px"></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">N,N-Dimethylformamide</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">UR-1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">FL-1B</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.75 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">.25 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Yes</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Piperidine</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">1</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoroacetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">WR-1</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">3  Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">1 Gal.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="right">Gal.</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">HPLC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Trifluoroacetic Acid</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Tox</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">Corr</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="23" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left" style="font-size: 8pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">1</SUP>&nbsp;Total
Quantity. Includes aggregate quantity in use and storage per UBC.</DIV>


<DIV align="left" style="font-size: 8pt"><SUP style="font-size: 85%; vertical-align: text-top">2</SUP>&nbsp;Open Use &#151; Use of a solid or liquid hazardous material in a vessel or system that is continuously
open to the atmosphere during normal operations and where
vapors are liberated, or the product is exposed to the atmosphere during normal operations.
Examples of open systems for liquids include dispensing from or into
open beakers or containers; dip tank operations; plating operations;
etc.</DIV>

<DIV align="left" style="font-size: 8pt"><SUP style="font-size: 85%; vertical-align: text-top">3</SUP>&nbsp;Closed Use &#151;  Use of a solid or liquid hazardous material in a closed vessel or system that
remains closed during normal operations where vapors emitted by the
product are not liberated outside of the vessel or system and the product is not exposed to the
atmosphere during normal use; and all uses of compressed gases.
Examples of closed systems for solids and liquids include product conveyed through a piping system
into a closed vessel, system, or piece of equipment; reaction
process operations;</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> 1998 Integrated Engineering Services. All rights reserved.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT H</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Casework and Hoods (including benches)<BR>
Cagewasher<BR>
Glasswasher<BR>
Autoclave<BR>
Vac Unit<BR>
CDA Unit<BR>
DI Water System<BR>
Hazardous Materials Storage Structures and Tank<BR>
Any Plumbing Carrying Hazardous Materials and/or Animal Shower and
Cleaning Facilities.

</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>












<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">FIRST AMENDMENT TO LEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement made as of this 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of December, 2002, between MJ
Research, Incorporated (&#147;Landlord&#148;) and Genesoft, Inc. (&#147;Tenant&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, Landlord and Tenant are parties to a certain lease dated as of October&nbsp;6, 2000 with
respect to premises at 7000 Shoreline Court, South San Francisco, California (the &#147;Lease&#148;) and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, Tenant has requested that Landlord partially defer certain payments of Fixed
Rent as more particularly set forth herein, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whereas, Landlord is willing to do so upon the terms and conditions set forth herein,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Now, therefore, the parties agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Yearly Fixed Rent, as defined in the Lease, shall continue to accrue and be owed at the
rates set forth in the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;Provided Tenant is not otherwise in default under the Lease, Landlord agrees to defer
temporarily (with respect to the Rent Deferred Space as hereinafter defined) receipt of Fixed Rent
in excess of $3.00 per rentable square foot per month for the months of December, 2002 and January
through June, 2003 (the &#147;Deferral Period&#148;), but only with respect to 38,229 s.f. of the Premises
(the &#147;Rent Deferred Space&#148;). Said deferred rent shall be hereinafter referred to as the &#147;Deferred
Rent.&#148; All Deferred Rent shall continue to accrue and be fully earned by Landlord, who, as a
convenience to Tenant, has agreed to defer receipt of payment of the same, subject to the
conditions of this Agreement. Tenant shall continue to pay when due during the Deferral Period
Fixed Rent at the rate of $3.00/s.f./month and any additional rent or charges due under the Lease
with respect to the Rent Deferred Space. Tenant shall also pay in full all Fixed Rent and other
charges, without deferral of any kind, on the portion of the Premises other than the Rent Deferred
Space.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;The parties agree that the total amount of Fixed Rent deferred under this Agreement is
$425,488.77. Tenant may defer payment of the entire December payment of Fixed Rent with respect to
the Rent Deferred Space ($172,030.50), and the balance of the Deferred Rent shall be deferred on a
monthly basis of $38,190.77 per month for January and February, 2003, and $44,211.84 per month for
March through June, 2003. All Deferred Rent shall be due and payable in full on July&nbsp;1, 2003.
Notwithstanding the foregoing, if after the date hereof there shall occur an Event of Default, all
Deferred Rent theretofore accrued but unpaid shall be immediately due and payable, and Fixed Rent
shall no longer be deferred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Article&nbsp;28 is hereby modified to provide as follows:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In case of an Event of Default, Landlord may draw upon the letter of credit to the
extent of any Deferred Rent in addition to any other damages or costs for which Landlord has
the right to so draw; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Section&nbsp;28.3 is hereby deleted from the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;Section&nbsp;2.4 of the Lease is modified to delete subsection (b)&nbsp;thereof and also to delete
the words &#147;(other than the security desk)&#148; from the last paragraph of Section&nbsp;2.4.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Capitalized terms not otherwise defined herein shall have the meaning set forth in the
Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Tenant hereby confirms that the Lease is in full force and effect, that it has no claims
against Landlord or right to offset against rent or other charges, and the Landlord is not in
default of its obligations under the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;This Agreement shall be null and void unless the Tenant pays all December rent (not
deferred by this Agreement) on or before December&nbsp;6, 2002.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executed under seal as of the date first set forth above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">MJ Research, Incorporated<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Illegible
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Duly Authorized&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD colspan="3" align="left">Genesoft, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top" align="left">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David B. Singer
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Duly Authorized&nbsp;<br><br></TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">David B. Singer<BR>
Chairman and CEO<BR>
Genesoft, Inc.&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>SECOND AMENDMENT TO LEASE</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement made as of this 25th day of March, 2004 between MJ Research, Incorporated
(&#147;Landlord&#148;) and Genome Therapeutics Corporation (&#147;Tenant&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Landlord and Genesoft, Inc. executed a certain Agreement of Lease dated as of October
6, 2000, as amended by a First Amendment to Lease dated December&nbsp;5, 2002 (the &#147;Lease&#148;), and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Genome Therapeutics Corporation is the successor by merger to Genesoft, Inc., and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties desire to further amend the Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, for consideration paid, the receipt and sufficiency of which is hereby
acknowledged, the parties agree to amend the Lease as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;Section&nbsp;16(a) and 16(b) of the Lease are deleted and replaced with the following Section
16(a) and 16(b):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(a)&nbsp;If the Demised Premises, or any part thereof, shall be damaged by fire or other
casualty, Tenant shall give prompt notice thereof to Landlord, and Landlord, upon receiving
such notice and the insurance proceeds for such casualty, shall proceed in a commercially
reasonable manner, subject to unavoidable delays, to repair, or cause to be repaired, such
damage to the extent hereinafter provided. Landlord shall be responsible to restore only to
the &#147;cold shell&#148; condition as set forth on Exhibit&nbsp;A-1, and Tenant shall be responsible for
restoration of all leasehold improvements beyond such cold shell (the &#147;TI&#148;).
Notwithstanding the preceding sentence to the contrary, solely with respect to the portion
of the Demised Premises subleased pursuant to that certain Sublease ( the &#147; Fluidigm
Sublease&#148;) dated as of April&nbsp;1, 2004 between Tenant and Fluidigm Corporation ( the
&#147;Fluidigm Space&#148;), provided that if within thirty (30)&nbsp;days of the date of the casualty,
Landlord is furnished with (a)&nbsp;a full set of the approved working construction plans, in
electronic form, used by Tenant in Tenant&#146;s construction of the TI (the &#147;TI Plans&#148;),
together with a full release or assignment of rights to use said plans, and (b)&nbsp;the
proceeds of insurance required to be carried by Tenant under Section&nbsp;13.1(b) with respect
to the TI, which proceeds, together with any other sums contributed by Tenant or any
subtenant thereof, shall be sufficient to pay for the full cost of reconstructing the TI in
the Fluidigm Space, Landlord shall also reconstruct the TI in the Fluidigm Space. Tenant
agrees to maintain separate insurance required under Section&nbsp;13.1(b) of the Lease for the
TI in the Fluidigm Space, and, if Landlord has agreed to reconstruct said TI, to make the
proceeds thereof available to Landlord. Tenant shall cooperate, at no expense to Tenant, in
making available such TI
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Plans as may be in the possession or control of Tenant. Landlord shall be under no obligation to
furnish the TI Plans. If the foresaid conditions are met with respect to reconstructing the TI in
the Fluidigm Space, for purposes of Sections 16(a) and 16(b), the term Demised Premises shall be
deemed to be the &#147;cold shell&#148; as to the space leased by Tenant exclusive of the Fluidigm Space and
both cold shell and TI with respect to the Fluidigm Space; if said conditions are not met, all
restoration shall be to a cold shell. If the Demised Premises or any part thereof shall be rendered
untenantable by reason of such damage, whether to the Demised Premises or to the Building, Yearly
Fixed Rent shall proportionately abate for the period from the date of such damage to the date when
the Demised Premises shall have been restored by Landlord.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If, as a result of fire or other casualty, the whole or a substantial portion of the
Building is rendered untenantable, within ninety (90)&nbsp;days from the date of such fire or
casualty, Landlord shall notify Tenant and the lessee under the Fluidigm Sublease of its
opinion of the time required to restore the Demised Premises, taking into account a reasonable
time for adjusting loss and obtaining plans and permits for restoration. If in Landlord&#146;s
opinion the Demised Premises cannot be made tenantable within one (1)&nbsp;year after such event,
Landlord, within ninety (90)&nbsp;days from the date of such fire or casualty, may terminate this
Lease by notice to Tenant, specifying a date not less than thirty (30)&nbsp;nor more than sixty
(60)&nbsp;days after the giving of such notice on which the Term of this Lease shall terminate. In
addition, if in Landlord&#146;s opinion said estimated time for restoration exceeds one (1)&nbsp;year
and Landlord does not elect to terminate this Lease, Tenant shall, by notice given to Landlord
within fifteen (15)&nbsp;days of Landlord&#146;s notice as aforesaid, elect (a)&nbsp;to terminate this Lease
or (b)&nbsp;accept Landlord&#146;s estimated restoration period (the &#147;Longer Restoration Period&#148;). If
Tenant accepts a Longer Restoration Period, Tenant&#146;s right to terminate as hereinafter
provided shall be effective only if actual restoration takes more than 60&nbsp;days beyond such
estimated Longer Restoration Period, such termination to be elected within 30&nbsp;days after the
expiration of said estimated Longer Restoration Period plus 60&nbsp;days. If neither Landlord or
Tenant elects to terminate this Lease as provided above, then Landlord shall (to the extent
that proceeds of insurance required to be carried by Landlord, net of any portion thereof
retained by a Mortgagee, plus any sums contributed by Tenant or any subtenant of Tenant, are
made available for such purpose) proceed with diligence to repair the damage to the Demised
Premises and all facilities serving the same, if any, which shall have occurred, and the
Yearly Fixed Rent shall meanwhile proportionately abate, all as provided in Paragraph (a)&nbsp;of
this Section. However, if such damage is not repaired and the Demised Premises restored to
substantially the same condition as they were prior to such damage within one (1)&nbsp;year (or, if
elected, the Longer Restoration Period plus 60&nbsp;days) from the date of such damage,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Tenant, within thirty (30)&nbsp;days from the expiration of the later of such one (1)&nbsp;year period (or,
if elected, the Longer Restoration Period plus 60&nbsp;days), or from the expiration of any extension
thereof by reason of the delays set forth in the following sentence, may terminate this Lease by
notice to Landlord, specifying a date not more than sixty (60)&nbsp;days after the giving of such notice
on which the Term of this Lease shall terminate. The period within which the required repairs may
be accomplished shall be extended by the number of days, lost as a result of unavoidable delays,
which term shall be defined to mean all delays referred to in Article&nbsp;24. &#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as modified hereby, the Lease is ratified and confirmed in full force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executed under the date first set forth above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">MJ RESEARCH INCORPORATED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ [ILLEGIBLE]
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">VP, Finance, Duly authorized&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GENOME THERAPEUTICS
CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ [ILLEGIBLE]</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="right">, Duly authorized&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>




<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">AGREEMENT OF LEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGREEMENT OF LEASE made as of the ____ day of November, 1999, by and
between Mountain Cove Tech Center, L.L.C., a Delaware limited liability company (hereinafter
referred to as &#147;Landlord&#148;) and MJ Research Company, Inc. (hereinafter referred to as &#147;Tenant&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">W I T N E S S E T H:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord hereby leases to Tenant and Tenant hereby hires from Landlord the entire land and
building (the &#147;Building&#148;) in South San Francisco a portion, as shown on the plan attached hereto as
Exhibit&nbsp;A and made a part hereof (hereinafter referred to as the &#147;Premises&#148; or the &#147;Demised
Premises&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">1. REFERENCE DATA
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <U>Definitions</U>. Each reference in this Lease to any of the terms and titles
contained in this Article shall be deemed and construed to incorporate the data stated following
that term or title in this Article.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Additional Rent:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Sums or other charges payable by Tenant to Landlord under
this Lease, other than Yearly Fixed Rent, all of which
shall be payable as additional rent under this Lease.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">2)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Broker:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">3)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Business Day:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">All days except Saturdays, Sundays, days defined as
&#147;legal holidays&#148; for the entire state under the laws of
the State of California, and such other days as Tenant
presently or in the future recognizes as holidays for
Tenant&#146;s general staff.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">4)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Environmental Laws
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;5.3 (a) (1).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">5)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Event of Default:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The occurrence of an event listed in Section&nbsp;19.1.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">6)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hazardous Materials
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;5.3 (a) (1).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">7)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Interest Rate
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2 <SUP style="font-size: 85%; vertical-align: text-top">1</SUP>/<SUB style="font-size: 85%; vertical-align: text-bottom">2</SUB>% per month or the maximum
interest rate Landlord is permitted to charge Tenant
under applicable law, whichever is less.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">8)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Land:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The parcel of land on which the Building is situated.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">9)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord&#146;s Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Landlord&#146;s Architect:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Any licensed architect from time to time designated by
Landlord.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">11)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lease Year:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A twelve (12)&nbsp;month period beginning
on the Term Commencement Date and
each succeeding twelve (12)&nbsp;month
period during the Term of this Lease,
except that if the Term Commencement
Date shall be other than the first
day of a calendar month, the first
Lease Year shall include the partial
calendar month in which the Term
Commencement Date occurs as well as
the succeeding twelve (12)&nbsp;full
calendar months.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">12)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mortgage:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">A mortgage, deed of trust, trust
indenture, or other security
instrument of record creating an
interest in or affecting title to the
Land or Building or any part thereof,
and any and all renewals,
modifications, consolidations or
extensions of any such instrument.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">13)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mortgagee:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The holder of any Mortgage.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">14)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Operating Expense Base:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">15)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Property:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Land and Building.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">16)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rent:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Yearly Fixed Rent and Additional Rent.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">17)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rentable Area of the
Demised Premises:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">141,677 square feet.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">18)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tax Base:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">19)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant&#146;s Address:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Until the Term Commencement Date, _______,
and thereafter, the Demised Premises.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">20)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant&#146;s Operating
Expense Share:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">100%&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">21)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tenant&#146;s Tax Share:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">100%&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">22)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term Commencement Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;3.2.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">23)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Term of this Lease:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;3.1.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">24)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Termination Date:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">As defined in Section&nbsp;3.1.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">25)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Use of Demised Premises:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">26)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Yearly Fixed Rent:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 5%">1.2 Exhibits. The following exhibits are attached hereto and made a part hereof:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 2 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">A - Plan of Demised Premises<BR>
A-l - Plans and Specifications for Landlord&#146;s Work<BR>
B - Cleaning Specifications<BR>
C - Rules and Regulations
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">2. DESCRIPTION OF DEMISED PREMISES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <U>Demised Premises</U>. The Demised Premises are that portion of the Building as
described above (as the same may from time to time be constituted after changes therein,
additions thereto and eliminations therefrom pursuant to rights of Landlord hereinafter
reserved).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <U>Appurtenant Rights</U>. Tenant shall have, as appurtenant to the Demised Premises,
rights to use in common, subject to reasonable rules from time to time made by Landlord of
which Tenant is given notice, those common roadways, walkways, elevators, hallways and
stairways necessary for access to that portion of the Building occupied by the Demised
Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <U>Reservations</U>. All the perimeter walls of the Demised Premises except the inner
surfaces thereof, any balconies, terraces or roofs adjacent to the Demised Premises, and any
space in or adjacent to the Demised Premises used for serving other portions of the Building
exclusively or in common with the Demised Premises, including without limitation (where
applicable) shafts, stacks, pipes, conduits, wires and appurtenant fixtures, fan rooms, ducts,
electric or other utilities, sinks or other Building facilities, and the use thereof, as well
as the
right of access through the Demised Premises for the purpose of operation, maintenance,
decoration and repair, are expressly reserved to Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">3. TERM OF LEASE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <U>Term</U>. The Term of this Lease is ten (10)&nbsp;years (or until such Term shall sooner
cease or expire) commencing on the Term Commencement Date and ending on the day
immediately prior to the 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> anniversary thereof, except that if the Term
Commencement Date
shall be other than the first day of a calendar month, the Term of this Lease shall end on the
last
day of the calendar month in which said 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> anniversary of the Term Commencement
Date shall
fall (which date on which the Term of this Lease is scheduled to expire is hereinafter
referred to
as the &#147;Termination Date&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <U>Term Commencement Date</U>. The Term Commencement Date shall be the earlier
of (a)&nbsp;the date on which, pursuant to permission therefor duly given by Landlord, Tenant
undertakes Use of the Demised Premises for the purposes set forth in Article&nbsp;1, or (b)&nbsp;the
date on
which the Demised Premises are ready for Tenant&#146;s occupancy in accordance with the provisions
of Section&nbsp;4.2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">4. PREPARATION OF PREMISES; TENANT&#146;S ACCESS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <U>Plans and Specifications</U>. Landlord shall lay out the Demised Premises for
Tenant&#146;s occupancy in accordance with the plans and specifications (the &#147;Plans&#148;) referenced in
Exhibit&nbsp;A-l attached hereto and made a part hereof.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->- 3 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <U>When Premises Deemed Ready</U>. The Demised Premises shall be conclusively
deemed ready for Tenant&#146;s occupancy after Landlord gives notice to Tenant that the
installations
to be done by Landlord in the Demised Premises (as set forth in Section&nbsp;4.1) have been
substantially completed by Landlord. Such work shall not be deemed incomplete if only minor
or insubstantial details of construction or mechanical adjustments remain to be done, or if a
delay
is caused in whole or in part by Tenant. Landlord&#146;s Architect&#146;s certificate of substantial
completion, as hereinabove stated, given in good faith, or of any other facts pertinent to
such
work, shall be deemed conclusive of the statements therein contained and binding upon Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <U>Conclusiveness of Landlord&#146;s Performance</U>. Tenant shall be conclusively deemed
to have agreed that Landlord has performed all of its obligations under this Article&nbsp;4 unless
not
later than the end of the second calendar month next beginning after the Landlord&#146;s notice of
substantial completion under Section&nbsp;4.2 Tenant shall give Landlord written notice specifying
the respects in which Landlord has not performed such obligations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 <U>Entry by Tenant; Interference With Construction</U>. Tenant may enter the Demised
Premises prior to the Term Commencement Date to undertake such work as is to be performed
by Tenant pursuant and subject to this Lease in order to prepare the Demised Premises for
Tenant&#146;s occupancy. Such entry shall be deemed to be pursuant to a license from Landlord to
Tenant and shall be at the risk of Tenant. In no event shall Tenant interfere with any
construction being performed by or on behalf of Landlord in or around the Building; without
limiting the generality of the foregoing, Tenant shall comply with all instructions issued by
Landlord&#146;s contractors relative to the moving of Tenant&#146;s equipment and other property into
the Demised Premises and shall pay any fees or costs imposed in connection therewith.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">5. USE OF PREMISES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <U>Permitted Use</U>. Tenant shall continuously during the Term of this Lease occupy
and use the Demised Premises for the permitted Use set forth in Article&nbsp;1 and for no other
purpose. Service and utility areas (whether or not a part of the Demised Premises) shall be
used
only for the particular purpose for which they are designated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <U>Prohibited Uses</U>. Tenant shall not use, or suffer or permit the use of, or suffer
or
permit anything to be done in or anything to be brought into or kept in, the Demised Premises
or
any part thereof (i)&nbsp;which would violate any of the covenants, agreements, terms, provisions
and
conditions of this Lease, (ii)&nbsp;for any unlawful purposes or in any unlawful manner, or (iii)
which,
in the reasonable judgment of Landlord shall in any way (a)&nbsp;impair or tend to impair the
appearance or reputation of the Building, (b)&nbsp;impair or interfere with or tend to impair or
interfere with any of the Building services or the proper and economic heating, cleaning, air
conditioning or other servicing of the Building or with the use of any of the other areas of
the
Building, or (c)&nbsp;occasion discomfort, inconvenience or annoyance to any of the other tenants
or
occupants of the Building, whether through the transmission of noise or odors or vibrations or
dust or otherwise. Without limiting the generality of the foregoing, no food shall be prepared
or
served for consumption by the general public on or about the Demised Premises; no intoxicating
liquors or alcoholic beverages shall be sold or otherwise served for consumption by the
general
public on or about the Demised Premises; no lottery tickets (even where the sale of such
tickets
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 4 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">is not illegal) shall be sold and no gambling, betting or wagering shall otherwise be permitted on
or about the Demised Premises; no loitering shall be permitted on or about the Demised Premises;
and no loading or unloading of supplies or other material to or from the Demised Premises shall be
permitted on the Land except at times (excluding Business Days from 7:00 to 9:30 a.m. and from 4:00
to 6:00 p.m.) and in locations to be designated by Landlord. The Demised Premises shall be
maintained in a sanitary condition. Tenant shall suitably store all trash and rubbish in the
Demised Premises or other locations designated by Landlord from time to time. Tenant specifically
agrees that its indemnification obligations pursuant to Section&nbsp;13.3 shall extend to any claim
arising from the consumption of intoxicating liquors or alcoholic beverages on or about the Demised
Premises.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3 <U>Hazardous Materials</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Definitions</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Environmental Law means any governmental statute, code, ordinance,
regulation, rule or order and any amendment thereto governing or regulating materials that are
toxic,
explosive, corrosive, flammable, radioactive, carcinogenic, dangerous or otherwise hazardous.
Environmental Laws include, without limitation, the Comprehensive Environmental Response
Compensation and Liability Act, 42 U.S.C. 9601 <I>et seq., </I>the Resource Conservation and
Recovery Act, 42 U.S.C. 6901 <I>et seq., </I>the California Hazardous Substances Act at California
Health and Safety Code Section&nbsp;108100 <I>et seq., </I>the provisions regarding hazardous waste
control at
California Health and Safety Code Sections&nbsp;25100 through 25250.25 and the California Medical
Waste Management Act at California Health and Safety Code 117600 <I>et seq.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;Hazardous Materials shall mean any substance: (A)&nbsp;that now or in the future
is regulated or governed by, requires investigation or remediation under, or is defined as a
hazardous waste, hazardous substance, pollutant or contaminant under any Environmental Law or
(B)&nbsp;that is toxic, explosive, corrosive, flammable, radioactive, carcinogenic, dangerous or
otherwise
hazardous, including gasoline, diesel fuel, petroleum hydrocarbons, polychlorinated biphenyls
(PCBs), asbestos, radon and urea formaldehyde foam insulation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Tenant&#146;s Covenants</U>. No Hazardous Materials shall be stored, placed, handled, used
or released by Tenant or its employees, contractors, sublessees, guests or visitors at or
about the
Demised Premises or Property without Landlord&#146;s prior written consent, which consent may be
granted, denied, or conditioned upon compliance with Landlord&#146;s requirements, all in
Landlord&#146;s
absolute discretion. Notwithstanding the foregoing, normal quantities and use of those
Hazardous
Materials customarily used in the conduct of general office activities, such as copier fluids
and
cleaning supplies may be used and stored at the Demised Premises without Landlord&#146;s prior
written
consent, provided that Tenant&#146;s activities at or about the Demised Premises and Property shall
comply at all times with the laws all Environmental Laws. Tenant shall keep Landlord fully and
promptly informed of all storage, placement, handling, use or release by Tenant or its
employees,
contractors, sublessees, guests or visitors of Hazardous Materials, other than Hazardous
Materials
permitted by the preceding sentence. At the expiration or termination of the Lease, Tenant
shall promptly remove all Hazardous Materials from the Demised Premises. Tenant shall be responsible
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 5 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and liable for the compliance with all of the provisions of this Section by all of Tenant&#146;s
employees, contractors, sublessees, guests and visitors and all of Tenant&#146;s obligations under this
Section (including its indemnification obligations under subsection (e)&nbsp;below) shall survive the
expiration or termination of this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Compliance</U>. Tenant shall at Tenant&#146;s expense promptly take all actions required by
any governmental agency or entity in connection with or as a result of the storage, placement,
handling, use or release by Tenant or its employees, contractors, sublessees, guests or
visitors of
Hazardous Materials at or about the Demised Premises or Property, including inspection and
testing, performing all cleanup, removal and remediation work required with respect to those
Hazardous Materials, complying with all closure Laws and postclosure monitoring, and filing
all
required reports or plans. &#091;Insert if applicable: &#145;All medical waste regulated by any
Environmental
Laws that is brought to the Demised Premises shall be stored in leak-proof, closeable
containers,
which containers shall be stored in a specified &#147;dirty storage area&#148; of the Demised Premises
that
shall be protected from leaks or any other type of contamination of the Demised Premises.
Tenant
shall never use any of the Landlord&#146;s trash receptacles for disposing of any medical waste.&#146;&#093;
All of
the foregoing work shall be performed in a good, safe and workmanlike manner by consultants
qualified and licensed to undertake such work and in a manner that will not interfere with any
other
tenant&#146;s quiet enjoyment of the Property or Landlord&#146;s use, operation, leasing and sale of the
Property. Tenant shall deliver to Landlord prior to delivery to any governmental agency, or
promptly after receipt from any such agency, copies of all permits, manifests, closure or
remedial
action plans, notices, and all other documents relating to the storage, placement, handling,
use or
release by Tenant or its employees, contractors, sublessees, guests or visitors of Hazardous
Materials at or about the Demised Premises or Property. If any lien attaches to the Demised
Premises or the Property in connection with or as a result of the storage, placement,
handling, use or
release by Tenant or its employees, contractors, sublessees, guests or visitors of Hazardous
Materials, and Tenant does not cause the same to be released, by payment, bonding or
otherwise,
within ten (10)&nbsp;days after the attachment thereof, Landlord shall have the right but not the
obligation
to cause the same to be released and any sums expended by Landlord in connection therewith
shall
be payable by Tenant on demand.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Landlord&#146;s Rights</U>. Landlord shall have the right, but not the obligation, to enter
the
Demised Premises at any reasonable time (i)&nbsp;to confirm Tenant&#146;s compliance with the provisions
of
this Section, and (ii)&nbsp;to perform Tenant&#146;s obligations under this Section if Tenant has failed
to do so
after reasonable notice to Tenant. Landlord shall also have the right to engage qualified
Hazardous
Materials consultants to inspect the Demised Premises and review the storage, placement,
handling,
use or release by Tenant or its employees, contractors, sublessees, guests or visitors of
Hazardous
Materials, including review of all permits, reports, plans, and other documents regarding
same.
Tenant shall pay to Landlord on demand the costs of Landlord&#146;s consultants&#146; fees and all costs
incurred by Landlord in performing Tenant&#146;s obligations under this section. Landlord shall
use
reasonable efforts to minimize any interference with Tenant&#146;s business caused by Landlord&#146;s
entry
into the Demised Premises, but Landlord shall not be responsible for any interference caused
thereby.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 6 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Tenant&#146;s Indemnification</U>. Tenant agrees to indemnify, defend and hold harmless
Landlord and its members, managers, directors, officers, agents and employees and their partners,
members, managers, directors, officers, shareholders, employees and agents from all shall mean all
costs and expenses of any kind, damages, including foreseeable and unforeseeable consequential
damages, fines and penalties incurred in connection with any violation of and compliance with the
Environmental Laws and all losses of any kind attributable to the diminution of value, loss of use
or adverse effects on marketability or use of any portion of the Demised Premises or Property and
all other claims, actions, losses, damages, liabilities, costs and expenses of every kind,
including reasonable attorneys&#146;, experts&#146; and consultants&#146; fees and costs, incurred at any time and
arising from or connection with the storage, placement, handling, use or release by Tenant or its
employees, contractors, sublessees, guests or visitors of Hazardous Materials at or about the
Property or Tenant&#146;s failure to comply in full with all Environmental Laws with respect to the
Demised Premises and the Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4 Licenses and Permits. If any governmental license or permit shall be required for the
proper and lawful conduct of Tenant&#146;s business, and if the failure to secure such license or permit
would in any way affect Landlord, Tenant, at Tenant&#146;s expense, shall duly procure and thereafter
maintain such license or permit and submit the same to inspection by Landlord. Tenant, at Tenant&#146;s
expense, shall at all times comply with the terms and conditions of each such license or permit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">6. RENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <U>Yearly Fixed Rent</U>. Tenant shall pay to Landlord, without any set-off or
deduction, at Landlord&#146;s office, or to such other person or at such other place as Landlord
may
designate by notice to Tenant, the Yearly Fixed Rent set forth in Article&nbsp;1. The Yearly Fixed
Rent shall be paid in equal monthly installments in advance on or before the first Business
Day
of each calendar month during the Term of this Lease and shall be apportioned for any fraction
of a month in which the Term Commencement Date or the last day of the Term of this Lease
may fall.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <U>Taxes</U>. Tenant shall pay to Landlord as Additional Rent Tenant&#146;s Tax Share of all
real estate taxes imposed against the Property during any calendar year (including without
limitation all so-called linkage and impact fees, betterment assessments, fire and police
service
availability fees and similar charges for customary governmental services and charges in lieu
of
such taxes, assessment district assessments, governmental charges, fees or assessments for
traffic
or transit mitigation, personal property taxes assessed on personal property of Landlord used
in
the operation of the Property, increases in the foregoing due to changes in values, tax rate,
alterations made by Tenant or other factors and the reasonable cost of contesting by
appropriate
proceedings the amount or validity of any of the foregoing) in excess of the Tax Base,
prorated
with respect to any portion of a calendar year in which the Term of this Lease begins or ends.
As
soon as Tenant&#146;s share of real estate taxes with respect to any calendar year can be
determined,
the same will be certified by Landlord to Tenant (which certification shall be accompanied by
copies of the relevant tax bills) and will become payable to Landlord within ten (10)&nbsp;days
thereafter. If Landlord shall receive any refund of real estate taxes of which Tenant has paid
a
portion pursuant to this Section, then, out of any balance remaining after deducting
Landlord&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 7 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">expenses incurred in obtaining such refund, Landlord shall pay to Tenant the same proportionate
share of said balance, prorated as set forth above. Tenant shall, if as and when demanded by
Landlord and with each monthly installment of Fixed Rent, make tax fund payments to Landlord. &#147;Tax
fund payments&#148; refer to such payments as Landlord shall determine to be sufficient to provide in
the aggregate a fund adequate to pay, when they become due and payable, all payments required from
Tenant under this Section. In the event that tax fund payments are so demanded, and if the
aggregate of said tax fund payments is not adequate to pay Tenant&#146;s share of such taxes, Tenant
shall pay to Landlord the amount by which such aggregate is less than the amount of said share,
such payment to be due and payable at the time set forth above. Any surplus tax fund payments shall
be accounted for to Tenant after payment by Landlord of the taxes on account of which they were
made, and may be credited by Landlord against future tax fund payments or refunded to Tenant at
Landlord&#146;s option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, Tenant shall timely file business property statements with respect to Tenant&#146;s
personal property and trade fixtures and pay when due all taxes imposed on such personal property
and trade fixtures.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <U>Operating Expenses</U>. Tenant shall pay to Landlord as Additional Rent Tenant&#146;s
Operating Expense Share of all costs and expenses incurred by Landlord during any calendar year in
the operation and maintenance of the Building and the Land in accordance with generally accepted
operational and maintenance procedures in excess of the Operating Expense Base, including, without
limiting the generality of the foregoing, all such costs and expenses in connection with (1)
insurance, license fees, janitorial service, landscaping and snow removal, (2)&nbsp;wages, salaries,
management fees, employee benefits, payroll taxes, on-site office expenses, administrative and
auditing expenses, and equipment and materials for the operation, management and maintenance of the
Property, (3)&nbsp;any capital expenditure (amortized, with interest, on such reasonable basis as
Landlord shall determine) made by Landlord for the purpose of reducing other operating expenses or
complying with any governmental requirement, (4)&nbsp;the furnishing of heat, air conditioning,
electricity and other utilities, and any other service to the extent to which Landlord is not
reimbursed by tenants, and (5)&nbsp;the furnishing of the repairs and services referred to in Article&nbsp;7
(the foregoing being hereinafter referred to as &#147;operating expenses&#148;). If, during any portion of a
calendar year for which operating expenses are being computed pursuant to this Section, less than
the entire rentable area of the Building is occupied or Landlord is not supplying all occupants
with the same services being supplied hereunder, such costs and expenses shall be reasonably
extrapolated in order to take into account the costs and expenses which would have been incurred
had the entire rentable area of the Building been occupied and had such services been supplied to
all occupants. As soon as Tenant&#146;s share of operating expenses with respect to any calendar year
can be determined, the same will be certified by Landlord to Tenant and will become payable to
Landlord within ten (10)&nbsp;days following such certification, subject to proration with respect to
any portion of a calendar year in which the Term of this Lease begins or ends. Tenant shall, if as
and when demanded by Landlord and with each monthly installment of Yearly Fixed Rent, make
operating fund payments to Landlord. &#147;Operating fund payments&#148; refer to such payments as Landlord
shall determine to be sufficient to provide in the aggregate a fund adequate to pay, when they
become due and payable, all payments required from Tenant under this Section. In the event that
operating fund payments are so demanded, and if the aggregate of said operating fund payments
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 8 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">is not adequate to pay Tenant&#146;s share of operating expenses, Tenant shall pay to Landlord the
amount by which such aggregate is less than the amount of said share, such payment to be due and
payable at the time set forth above. Any surplus operating fund payments shall be accounted for to
Tenant after such surplus has been determined, and may be credited by Landlord against future
operating fund payments or refunded to Tenant at Landlord&#146;s option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4
<U>Obligations Survive Termination</U>. All obligations and liabilities of Tenant
relating to any period prior to the termination of the Term of this Lease, including
without
limitation the obligation to pay any Additional Rent due pursuant to the provisions of
this
Article, shall survive such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <U>Payment to Mortgagee</U>. Landlord reserves the right to provide in any Mortgage
given by it of the Property that some or all rents, issues, and profits and all other amounts
of
every kind payable to the Landlord under this Lease shall be paid directly to the Mortgagee
for
Landlord&#146;s account and Tenant covenants and agrees that it will, after receipt by it of notice
from
Landlord or Mortgage designating such Mortgagee to whom payments are to be made by Tenant,
pay such amounts thereafter becoming due directly to such Mortgagee until excused therefrom
by notice from such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">7. UTILITIES AND LANDLORD&#146;S SERVICES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <U>Electricity</U>. Tenant shall purchase directly from the public utility serving
the Building all electrical energy that Tenant requires for operation of the lighting fixtures,
appliances and equipment servicing the Demised Premises. The costs of initially installing any
required meter and related installation equipment shall be paid by Landlord. Landlord shall not be
liable in any way to Tenant for any failure or defect in the supply or character of electrical
energy furnished to the Demised Premises by reason of any requirement, act or omission of the
public utility serving the Building. Tenant&#146;s use of electrical energy in the Demised Premises
shall not at any time exceed the capacity of any of the electrical conductors and equipment in or
otherwise serving the Demised Premises. In order to insure that such capacity is not exceeded and
to avert possible adverse effect upon the Building electrical services Tenant shall give notice to
Landlord and obtain Landlord&#146;s prior written consent whenever Tenant shall connect to the Building
electrical distribution system any fixtures, appliances or equipment other than lamps, typewriters,
personal computers and similar small machines. Any additional feeders or risers to supply Tenant&#146;s
electrical requirements in addition to those originally installed and all other equipment proper
and necessary in connection with such feeders or risers, shall be installed by Landlord upon
Tenant&#146;s request, at the sole cost and expense of Tenant, provided that such additional feeders and
risers are permissible under applicable laws and insurance regulations and the installation of such
feeders or risers will not cause permanent damage or injury to the Building or cause or create a
dangerous condition or unreasonably interfere with other tenants of the Building. Tenant agrees
that it will not make any alteration or addition to the electrical equipment in the Demised
Premises without the prior written consent of Landlord in each instance first obtained, which
consent will not be unreasonably withheld. Landlord, at Tenant&#146;s expense, shall purchase, install
and replace all light fixtures, bulbs, tubes, lamps, lenses, globes, ballasts and switches used in
the Demised Premises.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 9 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <U>Water Charges</U>. Landlord shall furnish hot and cold water for ordinary cleaning,
toilet, lavatory and drinking purposes. If Tenant requires, uses or consumes water for any
purpose other than for such purposes, Landlord may (i)&nbsp;assess a reasonable charge for the
additional water so used or consumed by Tenant or (ii)&nbsp;install a water meter and thereby
measure
Tenant&#146;s water consumption for all purposes. In the latter event, Landlord shall pay the cost
of
the meter and the cost of installing any equipment required in connection therewith, and
Tenant
shall keep said meter and installation equipment in good working order and repair, and shall
pay
for water consumed, as shown on said meter, together with the sewer charge based on said meter
charges, as and when bills are rendered. On default in making such payment Landlord may pay
such charges and collect the same from Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <u>Heat and Air Conditioning</u>. Landlord shall furnish to and distribute in the
Demised Premises heat and air conditioning as normal seasonal changes may require on
Business Days from 8:00 a.m. to 6:00 p.m. when reasonably required for the comfortable
occupancy of the Demised Premises by Tenant. Tenant agrees to lower and close the blinds or
drapes when necessary because of the sun&#146;s position whenever the air conditioning system is in
operation, and to cooperate fully with Landlord with regard to, and to abide by all the
regulations
and requirements which Landlord may prescribe for the proper functioning and protection of,
the
heating and air conditioning system. Without limiting the generality of the foregoing, all
windows in the Demised Premises must remain closed at all times notwithstanding the fact that
such windows may be operable. The air conditioning system servicing the Building is designed
to provide cooling based upon an occupancy of not more than one person per one hundred (100)
square feet of floor area, and upon a combined lighting and standard electrical load not to
exceed
3.0 watts per square foot. In the event Tenant exceeds such condition or introduces into the
Demised Premises equipment which overloads such system, or in any other way causes such
system not to adequately perform its proper functions, supplementary systems may at Landlord&#146;s
option be provided by Landlord at Tenant&#146;s expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <U>Additional Heat and Air Conditioning Services</U>.
Landlord shall, upon reasonable
advance written notice from Tenant of its requirements in that regard, received before 3:00
p.m.
on the preceding Business Day, furnish additional heat or air conditioning services to the
Demised Premises on days and at times other than as provided in this Article. Tenant will pay
to
Landlord a reasonable charge for any such additional heat or air conditioning service required
by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <u>Elevator Service</u>. Landlord shall provide passenger elevator service to the
Demised Premises on Business Days from 8:00 a.m. to 6:00 p.m. and on a reduced basis at all
other times. Freight elevator service shall be available in common with other tenants on
Business Days from 9:30 a.m. to 4:00 p.m. and at other times at reasonable charge.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <U>Cleaning</U>. Landlord shall furnish cleaning services to the Building substantially
in
accordance with the specifications attached hereto as Exhibit&nbsp;B and made a part hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <U>Repairs and Other Services</U>.
Except as otherwise provided in Articles 16 and 18,
and subject to Tenant&#146;s obligations in Article&nbsp;12 and elsewhere in this Lease, Landlord shall
(a)
keep and maintain the roof, exterior walls, structural floor slabs and columns of the Building in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 10 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">as good condition and repair as they are in on the Term Commencement Date, reasonable use and wear
excepted, (b)&nbsp;keep and maintain in workable condition the Building&#146;s sanitary, electrical, heating,
air conditioning and other systems, (c)&nbsp;keep all walkways on the Property clean and remove all snow
and ice therefrom, (d)&nbsp;provide grounds maintenance to all landscaped areas and (e)&nbsp;arrange for the
extermination of rodents and vermin in the Building.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <U>Interruption or Curtailment of Services</U>.
Landlord reserves the right to
interrupt, curtail, stop or suspend the furnishing of services and the operation of any Building
system, when necessary by reason of accident or emergency, or of repairs, alterations, replacements
or improvements in the reasonable judgment of Landlord desirable or necessary to be made, or of
difficulty or inability in securing supplies or labor, or of strikes, or of any other cause beyond
the reasonable control of Landlord, whether such other cause be similar or dissimilar to those
hereinabove specifically mentioned, until said cause has been removed. Landlord shall have no
responsibility or liability for any such interruption, curtailment, stoppage, or suspension of
services or systems, except that Landlord shall exercise reasonable diligence to eliminate the
cause of same.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">8. CHANGES OR ALTERATIONS BY LANDLORD
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord reserves the right, exercisable by itself or its nominee, at any time and from time
to time without the same constituting an actual or constructive eviction and without incurring any
liability to Tenant therefor or otherwise affecting Tenant&#146;s obligations under this Lease, to make
such changes, alterations, additions, improvements, repairs or replacements in or to the Building
and the fixtures and equipment thereof, as well as in or to the street entrances, halls, passages,
elevators, and stairways thereof, as it may deem necessary or desirable, and to change the
arrangement and/or location of entrances or passageways, doors and doorways, and corridors,
elevators, stairs, toilets, or other public parts of the Building, provided, however, that there be
no unreasonable obstruction of the right of access to, or unreasonable interference with the use
and enjoyment of, the Demised Premises by Tenant, except that Landlord shall not be obligated to
employ labor at so-called &#147;over-time&#148; or other premium pay rates. Nothing contained in this Article
shall be deemed to relieve Tenant of any duty, obligation or liability of Tenant with respect to
making or causing to be made any repair, replacement or improvement or complying with any law,
order or requirement of any governmental or other authority. Landlord reserves the right to from
time to time change the address of the Building. Neither this Lease nor any use by Tenant shall
give Tenant any right or easement or the use of any door or any passage or any concourse connecting
with any other building or to any public convenience, and the use of such doors, passages and
concourses and of such conveniences may be regulated or discontinued at any time and from time to
time by Landlord without notice to Tenant and without affecting the obligations of Tenant hereunder
or incurring any liability to Tenant therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">9. FIXTURES, EQUIPMENT AND IMPROVEMENTS &#151; REMOVAL BY TENANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All fixtures, equipment, improvements and appurtenances attached to or built into the Demised
Premises prior to or during the Term, whether by Landlord at its expense or at the expense of
Tenant (either or both) or by Tenant shall be and remain part of the Demised Premises and shall not
be removed by Tenant at the end of the Term unless otherwise expressly
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 11 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provided in this Lease. Where not built into the Demised Premises, and if furnished and installed
by and at the sole expense of Tenant, all removable electric fixtures, air conditioning, carpets,
drinking or tap water facilities, furniture, or trade fixtures or business equipment shall not be
deemed to be included in such fixtures, equipment, improvements and appurtenances and may be, and
upon the request of Landlord will be, removed by Tenant upon the condition that such removal shall
not materially damage the Demised Premises or the Building and that the cost of repairing any
damage to the Demised Premises or the Building arising from such removal shall be paid by Tenant,
provided, however, that any of such items toward which Landlord shall have granted any allowance or
credit to Tenant shall be deemed not to have been furnished and installed in the Demised Premises
by or at the sole expense of Tenant.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">10. ALTERATIONS AND IMPROVEMENTS BY TENANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall make no alterations, decorations, installations, removals, additions or
improvements in or to the Demised Premises without Landlord&#146;s prior written consent and then only
by contractors or mechanics approved by Landlord. No such installations or other work shall be
undertaken or begun by Tenant until Landlord has approved written plans and specifications
therefor; and no amendments or additions to such plans and specifications shall be made without
prior written consent of Landlord. Any such alterations, decorations, installations, removals,
additions and improvements shall be done at the sole expense of Tenant and at such times and in
such manner as Landlord may from time to time designate. If Tenant shall make any alterations,
decorations, installations, removals, additions or improvements, then Landlord may elect to require
Tenant at the expiration of this Lease to restore the Demised Premises to substantially the same
condition as existed at the Term Commencement Date.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">11.</TD>
    <TD>&nbsp;</TD>
    <TD>TENANT&#146;S CONTRACTORS &#151; MECHANICS&#146; AND OTHER LIENS &#151; STANDARD
OF TENANT&#146;S PERFORMANCE &#151; COMPLIANCE WITH LAWS</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever Tenant shall make any alterations, decorations, installations, removals,
additions or improvements or do any other work in or to the Demised Premises, Tenant will
strictly observe the following covenants and agreements:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In no event shall any material or equipment be incorporated in or added to the
Demised Premises in connection with any such alteration, decoration, installation, addition or
improvement which is subject to any lien, charge, mortgage or other encumbrance of any kind
whatsoever or is subject to any security interest or any form of title retention agreement.
Any
mechanic&#146;s lien filed against the Demised Premises or the Building for work claimed to have
been done for, or materials claimed to have been furnished to Tenant shall be discharged by
Tenant within ten (10)&nbsp;days thereafter, at the expense of Tenant, by filing the bond required
by
law or otherwise. If Tenant fails so to discharge any lien, Landlord may do so at Tenant&#146;s
expense and Tenant shall reimburse Landlord for any expense or cost incurred by Landlord in so
doing within fifteen (15)&nbsp;days after rendition of a bill therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All installations or work done by Tenant under this or any other Article of this
Lease shall be at its own expense (unless expressly otherwise provided) and shall at all times
comply with (i)&nbsp;laws, rules, orders and regulations of governmental authorities having</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 12 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">jurisdiction thereof and (ii)&nbsp;plans and specifications prepared by and at the expense of Tenant
theretofore submitted to Landlord for its prior written approval.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Tenant shall procure all necessary permits before undertaking any work in the
Demised Premises; do all such work in a good and workmanlike manner, employing materials of
good quality and complying with all governmental requirements, and defend, save harmless,
exonerate and indemnify Landlord from all injury, loss or damage to any person or property
occasioned by or growing out of such work.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;No work shall be commenced prior to the time Landlord has posted a &#147;Notice
of nonresponsibility&#148; at the Demised Premises and recorded said notice in the county in which
the Property is located pursuant to California Civil Code Section&nbsp;3094.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">12. REPAIRS BY TENANT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant, at its expense, shall keep or cause to be kept all and singular the Demised Premises
in such repair, order and condition as the same are in on the Term Commencement Date or may be put
in during the Term hereof, reasonable use and wear thereof and damage by fire or by unavoidable
casualty excepted. Without limiting the generality of the foregoing, Tenant shall keep all windows
and other glass whole, and shall replace the same whenever broken with glass of the same quality.
Tenant hereby waives the benefits of California Civil Code Section&nbsp;1932(1).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">13. INSURANCE, INDEMNIFICATION, EXONERATION AND EXCULPATION
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.1 <U>Tenant&#146;s Insurance</U></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Liability Insurance</U>.
Tenant shall maintain in full force throughout the Term
commercial general liability and property damage insurance providing coverage on an occurrence
form basis with limits of not less than Two Million Dollars ($2,000,000.00) each occurrence
for
bodily injury and property damage combined, Two Million Dollars ($2,000,000.00) annual general
aggregate, and Two Million Dollars ($2,000,000.00) products and completed operations annual
aggregate. Tenant&#146;s liability insurance policy or policies shall: (i)&nbsp;include premises and
operations
liability coverage, automobile, products and completed operations liability coverage, broad
form
property damage coverage including completed operations, blanket contractual liability
coverage
with, to the maximum extent possible, coverage for the indemnification obligations of Tenant
under
this Lease, and personal and advertising injury coverage; (ii)&nbsp;provide that the insurance
company
has the duty to defend all insureds under the policy; (iii)&nbsp;provide that defense costs are
paid in
addition to and do not deplete any of the policy limits; (iv)&nbsp;cover liabilities arising out of
or incurred
in connection with Tenant&#146;s use or occupancy of the Premises or the Property; and (v)&nbsp;extend
coverage to cover liability for the actions of Tenant&#146;s employees, contractors, sublessees,
guests and
visitors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Personal Property Insurance</U>.
Tenant shall at all times maintain in effect with
respect
to tenant improvements and Tenant&#146;s trade fixtures and personal property located at or within
the
Demised Premises, commercial property insurance providing coverage, at a minimum, for &#147;broad</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 13 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">form&#148; perils, to the extent of 100% of the full replacement cost of covered property. Tenant may
carry such insurance under a blanket policy, provided that such policy provides equivalent
coverage to a separate policy. During the Term, the proceeds from any such policies of insurance
shall be used for the repair or replacement of such tenant improvements, trade fixtures and
personal property so insured. Landlord shall be provided coverage under such insurance to the
extent of its insurable interest and, if requested by Landlord, both Landlord and Tenant shall
sign all documents reasonably necessary or proper in connection with the settlement of any claim
or loss under such insurance. Landlord shall have no obligation to carry insurance on any such
tenant improvements or on Tenant&#146;s trade fixtures or personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Workmen&#146;s Compensation Insurance</U>.
Tenant shall maintain worker&#146;s compensation
insurance as required by law and employer&#146;s liability insurance in an amount not less than
Five
Hundred Thousand Dollars ($500,000).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Business Interruption/Extra Expense Insurance</U>.
Tenant shall maintain loss of
income, business interruption and extra expense insurance in such amounts as will reimburse
Tenant
for direct or indirect loss of earnings and incurred costs attributable to the perils commonly
covered
by Tenant&#146;s property insurance described above but in no event less than One Million Dollars
($1,000,000). Such insurance shall be carried with the same insurer that issues the insurance
for the
personal property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Other Coverage</U>.
Tenant, at its cost, shall maintain such other insurance as
Landlord
may reasonably require from time to time, but in no event may Landlord require any other
insurance
which is (i)&nbsp;not then being required of comparable tenants leasing comparable amounts of space
in
comparable buildings in the vicinity of the Building or (ii)&nbsp;not then available at
commercially
reasonable rates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<U>Insurance Criteria</U>.
Each policy of insurance required under this Section shall:
(i)&nbsp;be
in a form, and written by an insurer, reasonably acceptable to Landlord, (ii)&nbsp;be maintained at
Tenant&#146;s sole cost and expense, and (iii)&nbsp;require at least thirty (30)&nbsp;days&#146; written notice to
Landlord
prior to any cancellation, nonrenewal or modification of insurance coverage. Insurance
companies
issuing such policies shall have rating classifications of &#147;A&#148; or better and financial size
category
ratings of &#147;XIII&#148; or better according to the latest edition of the A.M. Best Key Rating Guide.
All
insurance companies issuing such policies shall be licensed to do business in the State of
California.
Any deductible amount under such insurance shall not exceed $5,000. Tenant shall provide to
Landlord, upon request, evidence that the insurance required to be carried by Tenant pursuant
to this
Section, including any endorsement affecting the additional insured status, is in full force
and effect
and that premiums therefore have been paid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Increase in Amount of Insurance</U>.
Tenant shall increase the amounts of insurance as
required by any Mortgagee, and, not more frequently than once every three (3)&nbsp;years, as
recommended by Landlord&#146;s insurance broker, if, in the opinion of either of them, the amount
of
insurance then required under this Lease is not adequate. Any limits set forth in this Lease
on the
amount or type of coverage required by Tenant&#146;s insurance shall not limit the liability of
Tenant
under this Lease.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 14 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<U>Insurance Provisions</U>.
Each policy of liability insurance required by this Section
shall: (i)&nbsp;contain a cross liability endorsement or separation of insureds clause; (ii)&nbsp;provide
that it is primary to and not contributing with, any policy of insurance carried by Landlord
covering the same loss; (iii)&nbsp;provide that any failure to comply with the reporting provisions
shall not affect coverage provided to Landlord, its members, property managers and mortgagees; and
(iv)&nbsp;name Landlord, its members, property managers and such other parties in interest as Landlord
may from time to time reasonably designate to Tenant in writing, as additional insureds. Such
additional insureds shall be provided the same extent of coverage as provided to Tenant under such
policies. All endorsements affecting such additional insured status shall be acceptable to Landlord
and shall be at least as broad as additional insured endorsement form number CG 20 11 11 85
promulgated by the Insurance Services Office.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<U>Evidence of Coverage</U>.
Prior to occupancy of the Premises by Tenant, and not less
than thirty (30)&nbsp;days prior to the expiration of any policy thereafter, Tenant shall furnish to
Landlord a certificate of insurance reflecting that the insurance required by this Section is in
force accompanied by an endorsement showing the required additional insureds satisfactory to
Landlord in substance and form. Notwithstanding the requirements of this paragraph, Tenant shall,
at Landlord&#146;s request, provide to Landlord a certified copy of each insurance policy required to
be in force at any time pursuant to the requirements of this Lease or its Exhibits. Tenant&#146;s
failure to furnish Landlord with such certificates of insurance shall be deemed a material default
under this Lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.2 <U>General</U>.
Tenant will save Landlord harmless, and will exonerate and indemnify
Landlord, from and against any and all claims, liabilities, penalties, damages or expenses
(including without limitation reasonable attorneys&#146; fees) asserted against or incurred by Landlord:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;on account of or based upon any injury to person, or loss of or damage to
property sustained or occurring on the Demised Premises on account of or based upon the act,
omission, fault, negligence or misconduct of any person whomsoever (other than Landlord or its
agents, contractors or employees);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;on account of or based upon any injury to person or loss of or damage to
property, sustained or occurring elsewhere (other than on the Demised Premises) in or about
the
Building (and, in particular, without limiting the generality of the foregoing on or about the
elevators, stairways, public corridors, sidewalks, roof, or other appurtenances and facilities
used
in connection with the Building or Demised Premises) arising out of the use or occupancy of
the
Building or Demised Premises by Tenant, or any person claiming by, through or under Tenant;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;on account of or based upon (including moneys due on account of) any
work or thing whatsoever done (other than by Landlord or its contractors, or agents or
employees
of either) in the Demised Premises during the Term of this Lease and during the period of
time,
if any, prior to the Term Commencement Date that Tenant may have been given access to the
Demised Premises; and</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 15 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;on account of or resulting from the failure of Tenant to perform and discharge any of its covenants and obligations under this Lease;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and, in case any action or proceeding be brought against Landlord by reason of any of the
foregoing, Tenant upon notice from Landlord shall at Tenant&#146;s expense resist or defend such action
or proceeding and employ counsel therefor reasonably satisfactory to Landlord, it being agreed that
such counsel as may act for insurance underwriters of Tenant engaged in such defense shall be
deemed satisfactory.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.3 <U>Property of Tenant</U>.
In addition to and not in limitation of the foregoing, and
subject only to provisions of applicable law, Tenant covenants and agrees that all
merchandise,
furniture, fixtures and property of every kind, nature and description which may be in or upon
the Demised Premises or elsewhere on the Property during the Term of this Lease, shall be at
the
sole risk and hazard of Tenant, and that if the whole or any part thereof shall be damaged,
destroyed, stolen or removed from any cause or reason whatsoever other than the negligence or
misconduct of Landlord, no part of said damage or loss shall be charged to, or borne by
Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.4 <U>Bursting of Pipes, etc</U>.
Landlord shall not be liable for any injury or damage to
persons or property resulting from fire, explosion, falling plaster or tiles, steam, gas,
electricity,
electrical disturbance, water, rain or snow or leaks from any part of the Building or from the
pipes, appliances or plumbing works or from the roof, street or sub-surface or from any other
place or caused by any other cause of whatever nature, unless caused by or due to the
negligence
of Landlord, its agents, servants or employees; nor shall Landlord or its agents be liable for
any
such damage caused by other tenants or persons in the Building or caused by operations in
construction of any private, public or quasi-public work; nor shall Landlord be liable for any
latent defect in the Demised Premises or elsewhere in the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">14. ASSIGNMENT, MORTGAGING, SUBLETTING, ETC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant covenants and agrees that neither this Lease nor the term and estate hereby granted nor
any interest herein or therein, will be assigned, mortgaged, pledged, encumbered or otherwise
transferred (whether voluntarily or by operation of law), and that neither the Demised Premises,
nor any part thereof, will be encumbered in any manner by reason of any act or omission on the part
of Tenant, without the prior written consent of Landlord in every case.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with any request by Tenant for such consent, Tenant shall submit to Landlord, in
writing, a statement containing the name of the proposed assignee, such information as to its
financial responsibility and standing as Landlord may require, and all of the terms and provisions
upon which the proposed transaction is to take place. Tenant shall reimburse Landlord promptly, as
Additional Rent, for reasonable legal and other expense incurred by Landlord in connection with any
request by Tenant for any consent required under the provisions of this Article.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The listing of any name other than that of Tenant, whether on the doors of the Demised
Premises or on the Building directory, or otherwise, shall not operate to vest any right or
interest</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 16 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in this Lease or in the Demised Premises or be deemed to be the written consent of Landlord
mentioned in this Article, it being expressly understood that any such listing is a privilege
extended by Landlord revocable at will by written notice to Tenant.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Lease be assigned, Landlord may at any time and from time to time, collect rent and
other charges from the assignee, and apply the net amount collected to the Rent and other charges
herein reserved, but no such collection shall be deemed a waiver of this covenant, or the
acceptance of the assignee as a tenant, or a release of Tenant from the further performance by
Tenant of covenants on the part of Tenant herein contained. The consent by Landlord to an
assignment shall not in any way be construed to relieve Tenant from obtaining the express consent
in writing of Landlord to any further assignment. Tenant shall remain fully and primarily liable
for all its obligations hereunder notwithstanding any assignment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, Tenant may assign this lease to an Affiliate,
meaning, for purposes hereof, a corporation or other entity controlling, controlled by or under
common control with Tenant. In addition, Tenant may, without Landlord&#146;s consent, sublease any or
all of the Demised Premises, and any so-called &#147;subleasing profits&#148; or subrents in excess of the
rent reserved herein shall belong to Tenant. Landlord shall, upon request of Tenant, not
unreasonably withhold its consent to a nondisturbance agreement for the benefit of any such
subtenants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">15. MISCELLANEOUS COVENANTS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1 <U>Rules and Regulations</U>.
Tenant and Tenant&#146;s servants, employees, agents, visitors
and licensees will faithfully observe such Rules and Regulations as are attached hereto as
Exhibit
C and made a part hereof or as Landlord hereafter at any time or from time to time may make
and may communicate in writing to Tenant and which in the reasonable judgment of Landlord
shall be necessary for the reputation, safety, care or appearance of the Property, or the
preservation of good order therein, or the operation or maintenance of the Property, or the
equipment thereof, or the comfort of tenants or others in the Building, provided, however,
that in
the case of any conflict between the provisions of this Lease and any such Rules and
Regulations, the provisions of this Lease shall control, and provided further that nothing
contained in this Lease shall be construed to impose upon Landlord any duty or obligation to
enforce such Rules and Regulations or the terms, covenants or conditions in any other lease as
against any other tenant and Landlord shall not be liable to Tenant for violation of the same
by
any other tenant, its servants, employees, agents, visitors, invitees or licensees.
Notwithstanding
Paragraph&nbsp;22 of Exhibit&nbsp;C, Landlord shall be required to arrange for extermination of vermin
within the Building pursuant to Section&nbsp;7.7.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.2 <U>Access to Premises</U>.
Tenant shall: (i)&nbsp;permit Landlord to erect, use and maintain
pipes, ducts and conduits in and through the Demised Premises, provided the same do not
materially reduce the floor area or materially adversely affect the appearance thereof; (ii)
permit
the Landlord and any Mortgagee to have free and unrestricted access to and to enter upon the
Demised Premises at all reasonable hours for the purposes of inspection or of making repairs,
replacements or improvements in or to the Demised Premises or the Building or equipment
(including, without limitation, sanitary, electrical, heating, air conditioning or other
systems) or</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 17 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of complying with all laws, orders and requirements of governmental or other authority or of
exercising any right reserved to Landlord by this Lease (including the right during the progress of
any such repairs, replacements or improvements or while performing work and furnishing materials in
connection with compliance with any such laws, orders or requirements to take upon or through, or
to keep and store within, the Demised Premises all necessary materials, tools and equipment); and
(iii)&nbsp;permit Landlord, at reasonable times, to show the Demised Premises during ordinary business
hours to any Mortgagee, prospective purchaser of any interest of Landlord in the Property,
prospective Mortgagee, or prospective assignee of any Mortgage, and during the period of twelve
months next preceding the Termination Date to any person contemplating the leasing of the Demised
Premises or any part thereof. If during the last three (3)&nbsp;months of the Term, Tenant shall have
removed all of Tenant&#146;s property therefrom, Landlord may immediately enter and alter, renovate and
redecorate the Demised Premises, without elimination or abatement of rent, or incurring liability
to Tenant for any compensation, and such acts shall have no effect upon this Lease. If Tenant shall
not be personally present to open and permit any entry into the Demised Premises at any time when
for any reason an entry therein shall be necessary or permissible, Landlord or Landlord&#146;s agents
must nevertheless be able to gain such entry by contacting a responsible representative of Tenant,
whose name, address and telephone number shall be furnished by Tenant. Provided that Landlord shall
not be obligated to employ labor at so-called &#147;over-time&#148; or other premium pay rates, Landlord
shall exercise its rights of access to the Demised Premises permitted under any of the terms and
provisions of this Lease in such manner as to minimize to the extent practicable interference with
Tenant&#146;s use and occupation of the Demised Premises. If an excavation shall be made upon land
adjacent to the Demised Premises or shall be authorized to be made, Tenant shall afford, to the
person causing or authorized to cause such excavation (subject to the same provisions applicable
hereunder in the case of work to be performed by Landlord), license to enter upon the Demised
Premises for the purpose of doing such work as said person shall deem necessary to preserve the
Building from injury or damage and to support the same by proper foundations without any claim for
damage or indemnity against Landlord, or diminution or abatement of Rent.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.3 <U>Accidents to Sanitary and other Systems</U>.
Tenant shall give to Landlord prompt
notice of any fire or accident in the Demised Premises or in the Building and of any damage
to,
or defective condition in, any part or appurtenance of the Building&#146;s sanitary, electrical,
heating
and air conditioning or other systems located in, or passing through, the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.4 <U>Signs, Blinds and Drapes</U>.
Tenant shall not place any signs on the exterior of the
Building or on or in any window, public corridor or door visible from the exterior of the
Demised Premises. No drapes or blinds may be put on or in any window nor may any Building
drapes or blinds be removed by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.5 <U>Estoppel
Certificate</U>. Tenant shall at any time and from time to time upon not
less
than ten (10)&nbsp;days&#146; prior notice by Landlord or by a Mortgagee to Tenant, execute, acknowledge
and deliver to the party making such request a statement in writing certifying that this Lease
is
unmodified and in full force and effect (or if there have been modifications, that the same is
in
full force and effect as modified and stating the modifications), and the dates to which Rent
has
been paid in advance, if any, and stating whether or not to the best knowledge of the signer
of
such certificate Landlord is in default in performance of any covenant, agreement, term,</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 18 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">provisions or condition contained in this Lease and, if so, specifying each such default of which
the signer may have knowledge, it being intended that any such statement delivered pursuant hereto
may be relied upon by any prospective purchaser of any interest in the Property, any Mortgagee or
prospective Mortgagee, any lessee or prospective lessee thereof, any prospective assignee of any
Mortgage, or any other party designated by Landlord. The form of any such estoppel certificate
requested by a Mortgagee shall be satisfactory to such Mortgagee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.6 <U>Requirements of Law &#151; Fines and Penalties</U>.
Tenant at its sole expense shall
comply with all laws, rules, orders and regulations of Federal, State, County and Municipal
Authorities and with any direction of any public officer or officers, pursuant to law, which
shall
impose any duty upon Landlord or Tenant with respect to and arising out of Tenant&#146;s use or
occupancy of the Demised Premises. If Tenant receives notice of any violation of law,
ordinance, order or regulation applicable to the Demised Premises, it shall give prompt notice
thereof to Landlord. Without limiting the generality of the foregoing, Tenant shall be
responsible for compliance with requirements imposed by the Americans with Disabilities Act
relative to the Demised Premises, including without limitation all such requirements
applicable
to removing barriers, furnishing auxiliary aids and ensuring that, whenever alterations are
made,
the affected portions of the Demised Premises are readily accessible to and usable by
individuals
with disabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.7 <U>Tenant&#146;s Acts &#151; Effect on Insurance</U>.
Tenant shall not do or permit to be done any
act or thing upon the Demised Premises or elsewhere in the Building which will invalidate or
be
in conflict with any insurance policies covering the Building and the fixtures and property
therein and shall not do, or permit to be done, any act or thing upon the Demised Premises
which
shall subject Landlord to any liability or responsibility for injury to any person or persons
or to
property by reason of any business or operation being conducted on the Demised Premises or for
any other reason. Tenant at its own expense shall comply with all applicable provisions of the
California Health and Safety Code and all regulations promulgated thereunder and with all
rules,
orders, regulations or requirements of the underwriter(s) of the fire and other hazard
insurance
for the Property and the Demised Premises and shall not (i)&nbsp;do, or permit anything to be done,
in
or upon the Demised Premises, or bring or keep anything therein, except as now or hereafter
permitted by the City of South San Francisco Fire Department, or other authority having
jurisdiction, and then only in such quantity and manner of storage as will not increase the
rate for
any insurance applicable to the Building, or (ii)&nbsp;use the Demised Premises in a manner which
shall increase such insurance rates on the Building or on property located therein, over that
applicable when Tenant first took occupancy of the Demised Premises hereunder. If by reason
of failure of Tenant to comply with the provisions hereof the insurance rate applicable to any
policy of insurance shall at any time thereafter be higher than it otherwise would be, then
Tenant
shall reimburse Landlord for that part of any insurance premiums thereafter paid by Landlord,
which shall have been charged because of such failure by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.8 <U>Miscellaneous</U>.
Tenant shall not suffer or permit the Demised Premises or any
fixtures, equipment or utilities therein or serving the same, to be overloaded, damaged or
defaced.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 19 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">16. DAMAGE BY FIRE, ETC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of loss of, or damage to, the Demised Premises or the Building by fire or other
casualty, the rights and obligations of the parties hereto shall be as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;If the Demised Premises, or any part thereof, shall be damaged by fire or
other casualty, Tenant shall give prompt notice thereof to Landlord, and Landlord, upon
receiving such notice, shall proceed promptly and with due diligence, subject to unavoidable
delays, to repair, or cause to be repaired, such damage. If the Demised Premises or any part
thereof shall be rendered untenantable by reason of such damage, whether to the Demised
Premises or to the Building, Yearly Fixed Rent shall proportionately abate for the period from
the date of such damage to the date when such damage shall have been repaired.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If, as a result of fire or other casualty, the whole or a substantial portion of
the Building is rendered untenantable, Landlord, within ninety (90)&nbsp;days from the date of such
fire or casualty, may terminate this Lease by notice to Tenant, specifying a date not less
than
thirty (30)&nbsp;nor more than sixty (60)&nbsp;days after the giving of such notice on which the Term of
this
Lease shall terminate. If Landlord does not so elect to terminate this Lease, then Landlord
shall
(to the extent that insurance proceeds, net of any portion thereof retained by a Mortgagee,
are
made available for such purpose) proceed with diligence to repair the damage to the Demised
Premises and all facilities serving the same, if any, which shall have occurred, and the
Yearly
Fixed Rent shall meanwhile proportionately abate, all as provided in Paragraph (a)&nbsp;of this
Section. However, if such damage is not repaired and the Demised Premises restored to
substantially the same condition as they were prior to such damage within nine (9)&nbsp;months from
the date of such damage, Tenant within thirty (30)&nbsp;days from the expiration of such nine (9)
month period or from the expiration of any extension thereof by reason of unavoidable delays
as
hereinafter provided, may terminate this Lease by notice to Landlord, specifying a date not
more
than sixty (60)&nbsp;days after the giving of such notice on which the Term of this Lease shall
terminate. The period within which the required repairs may be accomplished shall be extended
by the number of days, not to exceed one hundred eighty (180)&nbsp;days, lost as a result of
unavoidable delays, which term shall be defined to include all delays referred to in Article&nbsp;24.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If the Demised Premises shall be rendered untenantable by fire or other
casualty during the last two (2)&nbsp;years of the Term of this Lease, Landlord may terminate this
Lease effective as of the date of such fire or other casualty upon notice to Tenant given
within
ninety (90)&nbsp;days after such fire or other casualty.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Landlord shall not be required to repair or replace any of Tenant&#146;s
business machinery, equipment, cabinet work, furniture, personal property or other
installations
(all of which shall, however, be restored by Tenant within thirty (30)&nbsp;days after Landlord
shall
have completed any repair or restoration required under the terms of this Article), and no
damages, compensation or claim shall be payable by Landlord for inconvenience, loss of
business or annoyance arising from any repair or restoration of any portion of the Demised
Premises or of the Building.</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 20 -<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The provisions of this Article shall be considered an express agreement
governing any instance of damage or destruction of the Building or the Demised Premises by
fire
or other casualty, and any law now or hereafter in force providing for such a contingency in
the
absence of express agreement shall have no application.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;In the event of any termination of this Lease pursuant to this Article, the
Term of this Lease shall expire as of the effective termination date as fully and completely
as if
such date were the date originally fixed herein for the end of the Term of this Lease. Tenant
shall have access to the Demised Premises for a period of fifteen (15)&nbsp;days after the date of
termination in order to remove Tenant&#146;s personal property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Landlord&#146;s Architect&#146;s certificate, given in good faith, shall be deemed
conclusive of the statements therein contained and binding upon Tenant with respect to the
performance and completion of any repair or restoration work undertaken by Landlord pursuant
to this Article or Article&nbsp;18.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">17. WAIVER OF SUBROGATION
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any case in which Tenant shall be obligated under any provision of this Lease to pay to
Landlord any loss, cost, damage, liability, or expense suffered or incurred by Landlord, Landlord
shall allow to Tenant as an offset against the amount thereof the net proceeds of any insurance
collected by Landlord for or on account of such loss, cost, damage, liability or expense, provided
that the allowance of such offset does not invalidate or prejudice the policy or policies under
which such proceeds were payable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In any case in which Landlord shall be obligated under any provision of this Lease to pay to
Tenant any loss, cost, damage, liability or expense suffered or incurred by Tenant, Tenant shall
allow to Landlord as an offset against the amount thereof (i)&nbsp;the net proceeds of any insurance
collected by Tenant for or on account of such loss, cost, damage, liability, or expense, provided
that the allowance of such offset does not invalidate the policy or policies under which such
proceeds were payable and (ii)&nbsp;if such loss, cost, damage, liability or expense shall have been
caused by a peril against which Tenant has agreed to procure insurance coverage under the terms of
this Lease, the amount of such insurance coverage, if not actually procured by Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto shall each endeavor to procure an appropriate clause in, or endorsement on,
any fire or extended coverage insurance policy covering the Demised Premises and the Building and
personal property, fixtures and equipment located thereon or therein, pursuant to which the
insurance companies waive subrogation or consent to a waiver of right of recovery, and having
obtained such clauses and/or endorsements of waiver of subrogation or consent to a waiver of right
of recovery each party hereby agrees that it will not make any claim against or seek to recover
from the other for any loss or damage to its property or the property of others resulting from fire
or other perils covered by such fire and extended coverage insurance; provided, however, that the
release, discharge, exoneration and covenant not to sue herein contained shall be limited by the
terms and provisions of the waiver of subrogation clauses and/or endorsements or clauses and/or
endorsements consenting to a waiver of right of recovery and shall be co-extensive therewith. If
either party may obtain such clause or endorsement only
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->- 21 -<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">upon payment of an additional premium, such party shall promptly so advise the other party and
shall be under no obligation to obtain such clause or endorsement unless such other party pays the
premium.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">18. CONDEMNATION &#151; EMINENT DOMAIN
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that the whole or any part of the Building shall be taken or appropriated by
eminent domain or shall be condemned for any public or quasi-public use, or (by virtue of any such
taking, appropriation or condemnation) shall suffer any damage (direct, indirect or consequential)
for which Landlord or Tenant shall be entitled to compensation then (and in any such event) this
Lease and the Term hereof may be terminated at the election of Landlord by a notice in writing of
its election so to terminate which shall be given by Landlord to Tenant within sixty (60)&nbsp;days
following the date on which Landlord shall have received notice of such taking, appropriation or
condemnation. In the event that more than fifty percent (50%) of the floor area of the Demised
Premises or a substantial part of the means of access thereto within the perimeter of the Property
so as to substantially interfere with the use of the Demised Premises shall be so taken,
appropriated or condemned, then (and in any such event) this Lease and the Term hereof may be
terminated at the election of Tenant by a notice in writing of its election so to terminate which
shall be given by Tenant to Landlord within sixty (60)&nbsp;days following the date on which Tenant
shall have received notice of such taking, appropriation or condemnation. Tenant hereby waives the
benefits of California Code of Civil Procedure Section&nbsp;12165.130.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the giving of any such notice of termination (either by Landlord or Tenant) this Lease
and the Term hereof shall terminate on or retroactively as of the date on which Tenant shall be
required to vacate any part of the Demised Premises or shall be deprived of a substantial part of
the means of access thereto, provided, however, that Landlord may in Landlord&#146;s notice elect to
terminate this Lease and the Term hereof retroactively as of the date on which such taking,
appropriation or condemnation became legally effective. In the event of any such termination, this
Lease and the Term hereof shall expire as of the effective termination date as fully and completely
as if such date were the date originally fixed herein for the end of the Term of this Lease. If
neither party (having the right so to do) elects to terminate Landlord will, with reasonable
diligence and at Landlord&#146;s expense, restore the remainder of the Demised Premises, or the
remainder of the means of access thereto, as nearly as practicably may be to the same condition as
obtained prior to such taking, appropriation or condemnation in which event (i)&nbsp;a just proportion
of the Yearly Fixed Rent, according to the nature and extent of the taking, appropriation or
condemnation and the resulting permanent injury to the Demised Premises and the means of access
thereto, shall be permanently abated, and (ii)&nbsp;a just proportion of the remainder of the Yearly
Fixed Rent, according to the nature and extent of the taking, appropriation or condemnation and the
resultant injury sustained by the Demised Premises and the means of access thereto, shall be abated
until what remains of the Demised Premises and the means of access thereto shall have been restored
as fully as may be for permanent use and occupation by Tenant hereunder. Except for any award
specifically reimbursing Tenant for moving or relocation expenses, there are expressly reserved to
Landlord all rights to compensation and damages created, accrued or accruing by reason of any such
taking, appropriation or condemnation, in implementation and in confirmation of which Tenant does
hereby acknowledge that Landlord shall be entitled to receive and retain all such compensation
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> - 22 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and damages, grants to Landlord all and whatever rights (if any) Tenant may have to such
compensation and damages, and agrees to execute and deliver all and whatever further instruments of
assignment as Landlord may from time to time request. In the event of any taking of the Demised
Premises or any part thereof for temporary use, (i)&nbsp;this Lease shall be and remain unaffected
thereby, and (ii)&nbsp;Tenant shall be entitled to receive for itself any award made for such use,
provided, that if any taking is for a period extending beyond the Term of this Lease, such award
shall be apportioned between Landlord and Tenant as of the Termination Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">19. DEFAULT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.1 <U>Events of Default</U>. Occurrence of any of the following events shall constitute an
Event of Default under this Lease: (a)&nbsp;Tenant shall neglect or fail to perform or observe any of
the Tenant&#146;s covenants herein, including (without limitation) the covenants with regard to the
payment when due of Rent; or (b)&nbsp;Tenant shall be involved in financial difficulties as evidenced by
an admission in writing by Tenant of Tenant&#146;s inability to pay its debts generally as they become
due, or by the making or offering to make a composition of its debts with its creditors; or (c)
Tenant shall make an assignment or trust mortgage, or other conveyance or transfer of like nature,
of all or a substantial part of its property for the benefit of its creditors; or (d)&nbsp;the leasehold
hereby created shall be taken on execution or by other process of law and shall not be revested in
Tenant within sixty (60)&nbsp;days thereafter; or (e)&nbsp;a receiver, sequester, trustee or similar officer
shall be appointed by a court of competent jurisdiction to take charge of all or a substantial part
of Tenant&#146;s property and such appointment shall not be vacated within sixty (60)
days; or (f)&nbsp;any proceeding shall be instituted by or against Tenant pursuant to any of the
provisions of any Act of Congress or State law relating to bankruptcy, reorganization,
arrangements, compositions or other relief from creditors, and, in the case of any such proceeding
instituted against it, if Tenant shall fail to have such proceeding dismissed within thirty (30)
days or if Tenant is adjudged bankrupt or insolvent as a result of any such proceeding; or (g)&nbsp;any
event shall occur or any contingency shall arise whereby this Lease, or the term and estate thereby
created, would (by operation of law or otherwise) devolve upon or pass to any person, firm or
corporation other than Tenant, except as expressly permitted under Article&nbsp;14 hereof; or (h)&nbsp;Tenant
shall vacate all or substantially all of the Demised Premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.2 <U>Remedies Available upon Default</U>. Upon the occurrence of an Event of Default,
Landlord shall have the following remedies, which shall not be exclusive but shall be cumulative
and shall be in addition to any other remedies now or hereafter allowed by law:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Landlord may terminate Tenant&#146;s right to possession of the Premises at any time by written
notice to Tenant. Tenant expressly acknowledges that in the absence of such written notice from
Landlord, no other act of Landlord, including re-entry into the Premises, efforts to relet the
Premises, reletting of the Premises for Tenant&#146;s account, storage of Tenant&#146;s personal property and
trade fixtures, acceptance of keys to the Premises from Tenant or exercise of any other rights and
remedies under this Section, shall constitute an acceptance of Tenant&#146;s surrender of the Premises
or constitute a termination of this Lease or of Tenant&#146;s right to possession of the Premises. Upon
such termination in writing of Tenant&#146;s right to possession of the Premises, as herein provided,
this Lease shall terminate and Landlord shall be entitled to recover damages from Tenant as
provided in California Civil Code Section&nbsp;1951.2 and any other applicable existing or future Law
providing for
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> - 23 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">recovery of damages for such breach, including the worth at the time of award of the amount by
which the rent which would be payable by Tenant hereunder for the remainder of the Term after the
date of the award of damages, including Additional Rent as reasonably estimated by Landlord,
exceeds the amount of such rental loss as Tenant proves could have been reasonably avoided,
discounted at the discount rate published by the Federal Reserve Bank of San Francisco for member
banks at the time of the award plus one percent (1%).
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Landlord shall have the remedy described in California Civil Code Section&nbsp;1951.4 (Landlord
may continue this Lease in effect after Tenant&#146;s breach and abandonment and recover rent as it
becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Landlord may immediately, or at any time thereafter, without notice, cure said Event of
Default for the account of Tenant. If Landlord at any time is compelled to pay or elects to pay any
sum of money, or do any act which will require the payment of any sum of money, by reason of the
failure of Tenant to comply with any provision hereof, or if Landlord is compelled to or does incur
any expense, including without limitation reasonable attorneys&#146; fees, in instituting, prosecuting
and/or defending any action or proceeding arising by reason of any default of Tenant hereunder,
Tenant shall on demand pay to Landlord by way of reimbursement the sum or sums so paid by Landlord
with all interest, costs and damages together with interest at the Interest Rate for the period
such sums remain outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Landlord may remove all of Tenant&#146;s property from the Premises, and such property may be
stored by Landlord in a public warehouse or elsewhere at the sole cost and for the account of
Tenant. If Landlord does not elect to store any or all of Tenant&#146;s property left in the Premises,
Landlord may consider such property to be abandoned by Tenant, and Landlord may thereupon dispose
of such property in the manner and as prescribed by California Civil Code Section&nbsp;1980 <I>et seq.</I>
Any proceeds realized by Landlord on the disposal of any such property shall be applied first to
offset all expenses of storage and sale, then credited against Tenant&#146;s outstanding obligations to
Landlord under this Lease, and any balance remaining after satisfaction of all obligations of
Tenant under this Lease shall be delivered to Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The damages recoverable by Landlord pursuant to this Section shall in all events include
reimbursement of any concessions made by Landlord in connection with the leasing of the Demised
Premises to Tenant, including without limitation (a)&nbsp;abated Rent, (b)&nbsp;allowances or improvements in
excess of any Building standard work, (c)&nbsp;sums paid to any former landlord of Tenant under a
so-called &#147;take-over&#148;, lease assumption or similar agreement and (d)&nbsp;signing bonuses and other
incentive payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.3 <U>Grace Period</U>. Notwithstanding anything to the contrary in this Article
contained, Landlord agrees not to take any action to terminate this Lease (a)&nbsp;for default by Tenant
in the payment when due of Rent, if Tenant shall cure such default within five (5)&nbsp;days after
written notice thereof given by Landlord to Tenant, or (b)&nbsp;for default by Tenant in the performance
of any other covenant, if Tenant shall cure such default within a period of thirty (30)&nbsp;days after
written notice thereof given by Landlord to Tenant (except where the nature of the default is such
that remedial action should appropriately take place sooner, as indicated in such written notice),
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> - 24 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or with respect to covenants other than to pay a sum of money within such additional period as may
reasonably be required to cure such default if (because of governmental restrictions or any other
cause beyond the reasonable control of Tenant) the default is of such a nature that it cannot be
cured within such thirty (30)-day period, provided, however, (1)&nbsp;that there shall be no extension
of time beyond such thirty (30)-day period for the curing of any such default unless, not more than
ten (10)&nbsp;days after the receipt of the notice of default, Tenant in writing (i)&nbsp;shall specify the
cause on account of which the default cannot be cured during such period and shall advise Landlord
of its intention duly to institute all steps necessary to cure the default and (ii)&nbsp;shall as soon
as may be reasonable duly institute and thereafter diligently prosecute to completion all steps
necessary to cure such default and, (2)&nbsp;that no notice of the opportunity to cure a default need be
given, and no grace period whatsoever shall be allowed to Tenant, if the default is incurable or if
the covenant or condition the breach of which gave rise to the default had, by reason of a breach
on a prior occasion, been the subject of a notice hereunder to cure such default.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">20. END OF TERM &#151; ABANDONED PROPERTY
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the expiration or other termination of the Term of this Lease, Tenant shall peaceably
quit and surrender to Landlord the Demised Premises and all alterations and additions thereto which
Tenant is not entitled or required to remove under the provisions of this Lease, broom clean in
good order, repair and condition excepting only reasonable use and wear and damage by fire or other
casualty for which, under other provisions of this Lease, Tenant has no responsibility of repair or
restoration. Tenant&#146;s obligation to observe or perform this covenant shall survive the expiration
or other termination of the Term of this Lease. If the last day of the Term of this Lease or any
renewal thereof falls on a day other than a Business Day, this Lease shall expire on the Business
Day immediately preceding. Tenant shall pay twice the amount of Rent applicable to each month (or
fraction thereof) during which Tenant remains in possession of any part of the Demised Premises in
violation of the foregoing covenants, without prejudice to eviction and any other remedy available
to Landlord on account thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any personal property in which Tenant has an interest which shall remain in the Building or on
the Demised Premises after the expiration or termination of the Term of this Lease shall be
conclusively deemed to have been abandoned, and may be disposed of in such manner as Landlord may
see fit; provided, however, notwithstanding the foregoing, that Tenant will, upon request of
Landlord made not later than ten (10)&nbsp;days after the expiration or termination of the Term hereof,
promptly remove from the Building any such personal property or, if any part thereof shall be sold,
that Landlord may receive and retain the proceeds of such sale and apply the same, at its option,
against the expenses of the sale, the cost of moving and storage, any arrears of Rent payable
hereunder by Tenant to Landlord and any damages to which Landlord may be entitled under Article&nbsp;19
hereof or pursuant to law, with the balance if any, to be paid to Tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">21. RIGHTS OF MORTGAGEES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.1 (Intentionally omitted)
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 25 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.2 <U>Entry and Possession</U>. Upon entry and taking possession of the Property by a
Mortgagee, for the purpose of foreclosure or otherwise, such Mortgagee shall have all the rights of
Landlord, and shall be liable to perform all the obligations of Landlord arising and accruing
during the period of such possession by such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.3 <U>Right to Cure</U>. No act or failure to act on the part of Landlord which would
entitle Tenant under the terms of this Lease, or by law, to be relieved of Tenant&#146;s obligations
hereunder or to terminate this Lease, shall result in a release or termination of such obligations
or a termination of this Lease unless (i)&nbsp;Tenant shall have first given written notice of
Landlord&#146;s act or failure to act to first Mortgagees of record, if any, and to any other Mortgagees
of whom Tenant has been given written notice, specifying the act or failure to act on the part of
Landlord which could or would give basis to Tenant&#146;s rights; and (ii)&nbsp;such Mortgagees, after
receipt of such notice, have failed or refused to correct or cure the condition complained of
within a reasonable time thereafter, but nothing contained in this paragraph shall be deemed to
impose any obligation on any such Mortgagees to correct or cure any such condition. &#147;Reasonable
time&#148; as used above means and includes a reasonable time to obtain possession of the Land and
Building if any such Mortgagee elects to do so and a reasonable time to correct or cure the
condition if such condition is determined to exist.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.4 <U>Prepaid Rent</U>. No Rent shall be paid more than thirty (30)&nbsp;days prior to the due
dates thereof and, as to a first Mortgagee of record and any other Mortgagees of whom Tenant has
been given written notice, payments made in violation of this provision shall (except to the extent
that such Rent is actually received by such Mortgagee) be a nullity as against such Mortgagee and
Tenant shall be liable for the amount of such payments to such Mortgagee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.5 <U>Continuing Offer</U>. The covenants and agreements contained in this Lease with
respect to the rights, powers and benefits of a Mortgagee (particularly, without limitation
thereby, the covenants and agreements contained in this Article) constitute a continuing offer to
any person, corporation or other entity, which by accepting or requiring an assignment of this
Lease or by entry or foreclosure assumes the obligations herein set forth with respect to such
Mortgagee; every such Mortgagee is hereby constituted a party to this
Lease as an obligee hereunder
to the same extent as though its name was written hereon as such; and such Mortgagee shall be
entitled to enforce such provisions in its own name.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.6 <U>Subordination</U>. Notwithstanding the foregoing provisions of this Article, Tenant
agrees, at the request of Landlord or any Mortgagee, to execute and deliver promptly any
certificate or other instrument which Landlord or such Mortgagee may request subordinating this
Lease and all rights of Tenant hereunder to any Mortgage, and to all advances made under such
Mortgage and/or agreeing to attorn to such Mortgagee in the event that it succeeds to Landlord&#146;s
interest in the Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.7 <u>Limitations on Liability</u>. Nothing contained in the foregoing Section&nbsp;21.6 or in any such
non-disturbance agreement or non-disturbance provision shall however, affect the prior rights of
the holder of any Mortgage with respect to the proceeds of any award in condemnation or of any fire
insurance policies affecting the Building, or impose upon any such holder any liability (i)&nbsp;for the
erection or completion of the Building, or (ii)&nbsp;in the event of damage or
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 26 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">destruction to the Building or the Demised Premises by fire or other casualty, for any repairs,
replacements, rebuilding or restoration except such repairs, replacements, rebuilding or
restoration as can reasonably be accomplished from the net proceeds of insurance actually received
by, or made available to, such holder, or (iii)&nbsp;for any default by Landlord under the Lease
occurring prior to any date upon which such holder shall become Tenant&#146;s landlord, or (iv)&nbsp;for any
credits, offsets or claims against the Rent as a result of any acts or omissions of Landlord
committed or omitted prior to such date, or (v)&nbsp;for return of any security deposit or other funds
unless the same shall have been received by such holder, and any such agreement or provision may so
state.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">22. QUIET ENJOYMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord covenants that if, and so long as, Tenant keeps and performs each and every covenant,
agreement, term, provision and condition herein contained on the part and on behalf of Tenant to be
kept and performed, Tenant shall quietly enjoy the Demised Premises from and against the claims of
all persons claiming by, through or under Landlord subject, nevertheless, to the covenants,
agreements, terms, provisions and conditions of this Lease and to all Mortgages to which this Lease
is subject and subordinate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without incurring any liability to Tenant, Landlord may permit access to the Demised Premises
and open the same, whether or not Tenant shall be present, upon any demand of any receiver,
trustee, assignee for the benefit of creditors, sheriff, marshall or court officer entitled to, or
reasonably purporting to be entitled to, such access for the purpose of taking possession of, or
removing Tenant&#146;s property or for any other lawful purpose (but this provision and any action by
Landlord hereunder shall not be deemed a recognition by Landlord that the person or official making
such demand has any right or interest in or to this Lease, or in or to the Demised Premises), or
upon demand of any representative of the fire, police, building, sanitation or other department of
the city, county, state or federal governments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">23. ENTIRE AGREEMENT &#151; WAIVER &#151; SURRENDER
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.1 <U>Entire Agreement</U>. This Lease and the Exhibits made a part hereof contain the
entire and only agreement between the parties and any and all statements and representations,
written and oral, including previous correspondence and agreements between the parties hereto, are
merged herein. Tenant acknowledges that all representations and statements upon which it relied in
executing this Lease are contained herein and that Tenant in no way relied upon any other
statements or representations, written or oral. Any executory agreement hereafter made shall be
ineffective to change, modify, discharge or effect an abandonment of this Lease in whole or in part
unless such executory agreement is in writing and signed by the party against whom enforcement of
the change, modification, discharge or abandonment is sought. Nothing herein shall prevent the
parties from agreeing to amend this Lease and the Exhibits made a part hereof as long as such
amendment shall be in writing and shall be duly signed by both parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.2 <U>Waiver by Landlord</U>. The failure of Landlord to seek redress for violation, or to
insist upon the strict performance, of any covenant or condition of this Lease, or any of the Rules
and Regulations promulgated hereunder, shall not prevent a subsequent act, which would have
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> - 27 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">originally constituted a violation, from having all the force and effect of an original violation.
The receipt by Landlord of Rent with knowledge of the breach of any covenant of this Lease shall
not be deemed a waiver of such breach. The failure of Landlord to enforce any of such Rules and
Regulations against Tenant and/or any other tenant or subtenant in the Building shall not be deemed
a waiver of any such Rules and Regulations. No provisions of this Lease shall be deemed to have
been waived by Landlord unless such waiver be in writing signed by Landlord. No payment by Tenant
or receipt by Landlord of a lesser amount than the monthly rent herein stipulated shall be deemed
to be other than on account of the stipulated rent, nor shall any endorsement or statement on any
check or any letter accompanying any check or payment as rent be deemed an accord and satisfaction,
and Landlord may accept such check or payment without prejudice to Landlord&#146;s right to recover the
balance of such rent or pursue any other remedy in this Lease provided.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.3 <U>Surrender</U>. No act or thing done by Landlord during the term hereby demised
shall be deemed an acceptance of a surrender of the Demised Premises, and no agreement to accept
such surrender shall be valid, unless in writing signed by Landlord. No employee of Landlord or of
Landlord&#146;s agents shall have any power to accept the keys of the Demised Premises prior to the
termination of this Lease. The delivery of keys to any employee of Landlord or of Landlord&#146;s agents
shall not operate as a termination of the Lease or a surrender of the Demised Premises. In the
event that Tenant at any time desires to have Landlord underlet the Demised Premises for Tenant&#146;s
account, Landlord or Landlord&#146;s agents are authorized to receive the keys for such purposes without
releasing Tenant from any of the obligations under this Lease, and Tenant hereby relieves Landlord
of any liability for loss of or damage to any of Tenant&#146;s effects in connection with such
underletting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">24. INABILITY TO PERFORM &#151; EXCULPATORY CLAUSE
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise expressly provided in this Lease, this Lease and the obligations of Tenant
to pay Rent hereunder and perform all other covenants, agreements, terms, provisions and conditions
hereunder on the part of Tenant to be performed shall in no way be affected, impaired or excused
because Landlord is unable to fulfill any of its obligations under this Lease or is unable to
supply or is delayed in supplying any service expressly or impliedly to be supplied or is unable to
make or is delayed in making any repairs, replacements, additions, alterations, improvements or
decorations or is unable to supply or is delayed in supplying any equipment or fixtures if Landlord
is prevented or delayed from doing so by reason of any cause whatsoever beyond Landlord&#146;s
reasonable control, including but not limited to governmental preemption in connection with a
national emergency or by reason of any rule, order or regulation of any department or subdivision
thereof of any governmental agency or by reason of strikes, labor troubles, shortages of labor or
materials or conditions of supply and demand which have been or are affected by war, hostilities or
other similar or dissimilar emergency. In each such instance of inability of Landlord to perform,
Landlord shall exercise reasonable diligence to eliminate the cause of such inability to perform.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant shall neither assert nor seek to enforce any claim for breach of this Lease against any
of Landlord&#146;s assets other than Landlord&#146;s interest in the Building of which the Demised Premises
are a part and in the rents, issues and profits thereof, and Tenant agrees to look solely to
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 28 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such interest for the satisfaction of any liability of Landlord under this Lease, it being
specifically agreed that in no event shall Landlord (which term shall include, without limitation
any of the officers, trustees, directors, partners, beneficiaries, joint venturers, members,
stockholders or other principals or representatives, disclosed or undisclosed, of Landlord or any
managing agent) ever be personally liable for any such liability. This paragraph shall not limit
any right that Tenant might otherwise have to obtain injunctive relief against Landlord or to take
any other action which shall not involve the personal liability of Landlord to respond in monetary
damages from Landlord&#146;s assets other than the Landlord&#146;s interest in said real estate, as
aforesaid. In no event shall Landlord ever be liable for consequential damages.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">25. BILLS AND NOTICES
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice, consent, request, bill, demand or statement hereunder by either party to the other
party shall be in writing and, if received at Landlord&#146;s or Tenant&#146;s Address, shall be deemed to
have been duly given when either delivered or served personally or mailed in a postpaid envelope,
deposited in the United States mails addressed to the respective party at its Address as stated in
Article&nbsp;1 or if any Address for notices shall have been duly changed as hereinafter provided, if
mailed as aforesaid to the party at such changed Address. Either party may at any time change the
Address for such notices, consents, requests, bills, demands or statements by delivering or
mailing, as aforesaid, to the other party a notice stating the change and setting forth the changed
Address, provided such changed Address is within the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All bills and statements for reimbursement or other payments or charges due from Tenant to
Landlord hereunder shall be due and payable in full thirty (30)&nbsp;days, unless herein otherwise
provided, after submission thereof by Landlord to Tenant. Tenant&#146;s failure to make timely payment
of any amounts indicated by such bills and statements, whether for work done by Landlord at
Tenant&#146;s request, reimbursement provided for by this Lease or for any other sums properly owing by
Tenant to Landlord, shall be treated as a default in the payment of Rent, in which event Landlord
shall have all rights and remedies provided in this Lease for the nonpayment of Rent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">26. SUCCESSORS AND ASSIGNS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The covenants, agreements, terms, provisions and conditions of this Lease shall bind and
benefit the successors and assigns of the parties hereto with the same effect as if mentioned in
each instance where a party hereto is named or referred to, except that no violation of the
provisions of Article&nbsp;14 hereof shall operate to vest any rights in any successor or assignee of
Tenant and that the provisions of this Article shall not be construed as modifying the conditions
of limitation contained in Article&nbsp;19 hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If in connection with or as a consequence of the sale, transfer or other disposition of the
real estate (Land and/or Building, either or both, as the case may be) of which the Demised
Premises are a part Landlord ceases to be the owner of the reversionary interest in the Demised
Premises, Landlord shall be entirely freed and relieved from the performance and observance
thereafter of all covenants and obligations hereunder accruing thereafter on the part of Landlord
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 29 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to be performed and observed, it being understood and agreed in such event (and it shall be deemed
and construed as a covenant running with the land) that the person succeeding to Landlord&#146;s
ownership of said reversionary interest shall thereupon and thereafter assume, and perform and
observe, any and all of such covenants and obligations of Landlord.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">27. MISCELLANEOUS
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.1 <U>Separability</U>. If any provision of this Lease or portion of such provision or the
application thereof to any person or circumstance is for any reason held invalid or unenforceable,
the remainder of the Lease (or the remainder of such provision) and the application thereof to
other persons or circumstances shall not be affected thereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.2 <U>Captions</U>. The captions are inserted only as a matter of convenience and for
reference, and in no way define, limit or describe the scope of this Lease nor the intent of any
provisions thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.3 <U>Broker</U>. Each party represents and warrants that it has not directly or indirectly
dealt, with respect to the leasing of space in the Building, with any broker or had its attention
called to the Demised Premises or other space to let in the Building, by any broker other than the
Broker (if any) listed in Article&nbsp;1 whose commission shall be the responsibility of Landlord. Each
party agrees to exonerate and save harmless and indemnify the other against any claims for a
commission by any other broker, person or firm, with whom such party has dealt in connection with
the execution and delivery of this Lease or out of negotiations between Landlord and Tenant with
respect to the leasing of other space in the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.4 <U>Governing Law</U>. This Lease is made pursuant to, and shall be governed by, and
construed in accordance with, the laws of the State of California.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.5 <U>Assignment of Lease and/or Rents</U>. With reference to any assignment by Landlord of
its interest in this Lease and/or the Rent payable hereunder, conditional in nature or otherwise,
which assignment is made to or held by a bank, trust company, insurance company or other
institutional lender holding a Mortgage on the Building, Landlord and Tenant agree:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;that the execution thereof by Landlord and acceptance thereof by such Mortgagee shall
never be deemed an assumption by such Mortgagee of any of the obligations of the Landlord
hereunder, unless such Mortgagee shall, by written notice sent to the Tenant, specifically
otherwise elect; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;that, except as aforesaid, such Mortgagee shall be treated as having assumed the
Landlord&#146;s obligations hereunder only upon foreclosure of such Mortgagee&#146;s Mortgage and the taking
of possession of the Demised Premises after having given notice of its intention to succeed to the
interest of the Landlord under this Lease.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.6 <U>Memorandum of Lease</U>. Neither party shall record this Lease; provided, however,
that either party shall at the request of the other, execute and deliver a recordable memorandum of
this Lease setting forth the parties to this Lease, a description of the Demised Premises and the
term of this Lease for recordation in the Official records of the County of San Mateo.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 30 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.7 (omitted)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.8 (omitted)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.9 <U>Arbitration of Certain Matters</U>. At the election of either party, if any dispute
as to the allocation of real estate taxes or operating expenses under Section&nbsp;6.2, the abatement of
Yearly Fixed Rent pursuant to Article&nbsp;16 or the abatement of Yearly Fixed Rent pursuant to Article
18 remains unresolved 30&nbsp;days after written complaint by Tenant has been delivered to Landlord as
to an allocation, reduction, apportionment or abatement made or proposed by Landlord, the matter
may be submitted to binding arbitration pursuant to California Code of Civil Procedure Section&nbsp;1280
<I>et seq.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, Landlord and Tenant have caused this instrument to be executed under
seal, all as of the day and year first above written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">MOUNTAIN COVE TECH CENTER, L.L.C.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">MJ RESEARCH COMPANY, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; John Finney
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John Finney
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Its President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Mike Finney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mike Finney</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Its Managers</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --> - 31 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">PLAN OF DEMISED PREMISES
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Diagram depicting the entire land and building in South San Francisco.&#093;
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT A-1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">PLANS AND SPECIFICATIONS FOR LANDLORD&#146;S WORK
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">None.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT
B<br></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>CLEANING
SCHEDULE</U>

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">I.</TD>
    <TD>&nbsp;</TD>
    <TD><U>Premises</U></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Daily on Business Days</U>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empty all waste receptacles and ash trays and remove waste materials from the
Premises.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and dust mop all uncarpeted areas using a dust-treated mop.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Vacuum all rugs and carpeted areas.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Hand dust and wipe clean with treated cloths all horizontal cleared surfaces
including desk tops, office equipment, window sills, door ledges, chair rails and
counter tops, within normal reach.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash clean all water fountains.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon completion of cleaning, all lights will be turned off and
doors locked, leaving the Premises in an orderly condition.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Quarterly</U></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Render high dusting not reached in daily cleaning to include:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting all pictures, frames, charts, graphs and similar wall hangings.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting all vertical surfaces, such as walls, partitions, doors and ducts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dusting of all pipes, ducts and high moldings.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">II.</TD>
    <TD>&nbsp;</TD>
    <TD><U>Lavatories</U></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Daily on Business Days</U>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and damp mop floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clean all mirrors, powder shelves, dispensers and receptacles, bright
work, flushometers, pipes and toilet seats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash both sides of all toilet seats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash all basins, bowls and urinals.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dust and clean all powder room fixtures.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empty and clean paper towel and sanitary disposal receptacles.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">g.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Remove waste paper and refuse.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">h.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Refill tissue holders, soap dispensers, towel dispensers, vending sanitary
dispensers; materials to be furnished by Landlord.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">i.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A sanitizing solution will be used in all lavatory
cleaning.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Monthly</U>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Machine scrub lavatory floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wash all partitions and tile walls in lavatories.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">III.</TD>
    <TD>&nbsp;</TD>
    <TD><U>Main Lobby, Elevators, Building Exterior and Corridors</U></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Daily on Business Days</U>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep and wash or spray buff all marble floors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Sweep all entrance mats.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clean elevators, wash or vacuum floors, wipe down walls and doors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Spot clean any metal work surrounding building entrance doors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><u>Monthly:</u></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All resilient tile floors in public areas to be treated equivalent to spray buffing.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">IV.</TD>
    <TD>&nbsp;</TD>
    <TD><u>Window Cleaning</u></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The outside of exterior wall windows will be washed once every three months, weather
permitting, and the inside of exterior wall windows will be washed every six months.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">V.</TD>
    <TD>&nbsp;</TD>
    <TD>Tenants requiring services in excess of those described above shall request same through
Landlord, at Tenant&#146;s expense.</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>EXHIBIT C</U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>RULES AND REGULATIONS</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The sidewalks, entrances, passages, courts, elevators, vestibules, stairways,
corridors or halls of the Building shall not be obstructed or encumbered or used for any
purpose
other than ingress and egress to and from the premises demised to any tenant or occupant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;No awnings or other projections shall be attached to the outside walls or windows
of the Building without the prior consent of Landlord. No curtains, blinds, shades, or screens
shall be attached or hung in, or used in connection with, any window or door of the premises
demised to any tenant or occupant, without the prior consent of Landlord. Such awnings,
projections, curtains, blinds, shades, screens, or other fixtures must be of a quality type,
design
and color, and attached in a manner, approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;No sign, advertisement, object, notice or other lettering shall be exhibited,
inscribed, painted or affixed on any part of the outside or inside of the premises demised to
any
tenant or occupant or of the Building without the prior consent of Landlord. Interior signs on
doors and directory tables, if any, shall be of a size, color and style approved by Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;The sashes, sash doors, skylights, windows, and doors that reflect or admit light
and air into the halls, passageways or other public places in the Building shall not be
covered or
obstructed, nor shall any bottles, parcels, or other articles be placed on any window sills.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;No show cases or other articles shall be put in front of or affixed to any part of the
exterior of the Building, nor placed in the halls, corridors, vestibules or other parts of the
Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The water and wash closets and other plumbing fixtures shall not be used for any
purposes other than those for which they were constructed, and no sweepings, rubbish, rags, or
other substances shall be thrown therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;No tenant or occupant shall mark, paint, drill into, or in any way deface any part
of the Building or the premises demised to such tenant or occupant. No boring, cutting or
stringing of wires shall be permitted, except with the prior consent of the Landlord, and as
Landlord may direct. No tenant or occupant shall install any resilient tile or similar floor
covering in the premises demised to such tenant or occupant except in a manner approved by
Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;No bicycles, vehicles or animals of any kind shall be brought into or kept in or
about the premises demised to any tenant. Bicycles may be stored in racks, if any, furnished
for
such purpose by Landlord in a common area of the Property. No cooking shall be done or
permitted in the Building by any tenant without the approval of Landlord. No tenant shall
cause
or permit any unusual or objectionable odors to emanate from the Premises demised to such
tenant.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;Without the prior consent of Landlord, no space in the Building shall be used for
manufacturing, or for the sale of merchandise, goods or property of any kind at auction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;No tenant shall make, or permit to be made, any unseemly or disturbing noises or
disturb or interfere with other tenants or occupants of the Building or neighboring buildings
or
premises whether by the use of any musical instrument, radio, television set or other audio
device, unmusical noise, whistling, signing, or in any other way. Nothing shall be thrown out
of
any doors or windows.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Each tenant must, upon the termination of its tenancy, restore to Landlord all keys
of stores, storage areas, offices and toilet rooms, either furnished to, or otherwise procured
by,
such tenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;All removals from the Building, or the carrying in or out of the Building or the
premises demised to any tenant, of any sales, freight, furniture, or bulky matter of any
description must take place at such time and in such manner as Landlord or its agents may
determine, from time to time. Landlord reserves the right to inspect all freight to be brought
into
the Building and to exclude from the Building all freight which violates any of the Building
Rules or the provisions of such tenant&#146;s lease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;No tenant shall use or occupy, or permit any portion of the premises demised to
such tenant to be used or occupied, as an office for a public stenographer, messenger service
or
typist, or as a barber or manicure shop, or as an employment bureau. No tenant or occupant
shall
engage or pay any employees in the Building, except those actually working for such tenant or
occupant in the Building, nor advertise for laborers giving an address at the Building.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;No tenant or occupant shall purchase spring water, ice, food, beverage, lighting
maintenance, cleaning towels or other like service, from any company or person not approved by
Landlord, such approval not unreasonably to be withheld.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;Landlord shall have the right to prohibit any advertising by any tenant or occupant
which, in Landlord&#146;s opinion, tends to impair the reputation of the Building or its
desirability as
a building for offices, and upon notice from Landlord, such tenant or occupant shall refrain
from
or discontinue such advertising.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;Landlord reserves the right to exclude from the Building, between the hours of
6:00 p.m. and 8:00 a.m. on Business Days and otherwise at all hours, all persons who do not
present a pass to the building signed by the Landlord. Landlord will furnish passes to persons
for
whom any tenant requests such passes. Each tenant shall be responsible for all persons for
whom it requests such passes and shall be liable to Landlord for all wrongful acts of such
persons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;Each tenant, before closing and leaving the premises demised to such tenant at
any time, shall see that all entrance doors are locked and windows closed.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left"><FONT size="1">

</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;Each tenant shall, at its expense, provide artificial light in the premises demised to
such tenant for Landlord&#146;s agency, contractors, and employees while performing janitorial or
other cleaning services and making repairs or alterations in said premises.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;No premises shall be used, or permitted to be used, for lodging or sleeping, or for
any immoral or illegal purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;There shall not be used in the Building, either by any tenant or occupant or by
their agents or contractors, in the delivery or receipt of merchandise, freight or other
matter, any
hand trucks or other means of conveyance except those equipped with rubber tires, rubber side
guards and such other safeguards as Landlord may require.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;Canvassing, soliciting and peddling in the Building are prohibited and each tenant
and occupant shall co-operate in seeking their prevention.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;If the premises demised to any tenant become infested with vermin, such tenant,
at its sole cost and expense, shall cause its premises to be exterminated from time to time,
to the
satisfaction of Landlord, and shall employ such exterminators therefor as shall be approved by
Landlord.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;No premises shall be used, or permitted to be used, at any time, without the prior
approval of Landlord, as a store for the sale or display of goods, wares or merchandise of any
kind, or as a restaurant, shop, booth, bootblack or other stand, or for the conduct of any
business
or occupation which predominantly involves direct patronage of the general public in the
premises demised to such tenant, or for manufacturing or for other similar purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.&nbsp;No tenant shall move, or permit to be moved, into or out of the Building or the
premises demised to such tenant, any heavy or bulky matter, without the specific approval of
Landlord. If any such matter requires special handling, only a person holding a Master
Rigger&#146;s
license shall be employed to perform such special handling. No tenant shall place, or permit
to be placed, on any part of the floor or floors of the premises demised to such tenant, a load
exceeding the floor load per square foot which such floor was designed to carry and which is
allowed by law. Landlord reserves the right to prescribe the weight and position of safes and
other heavy matter, which must be placed so as to distribute the weight.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.&nbsp;The requirements of tenants will be attended to only upon application at the office
of the Building. Building employees shall not be required to perform, and shall not be
requested
by any tenant or occupant to perform, any work outside of their regular duties, unless under
specific instructions from the office of the managing agent of the Building.
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>11
<FILENAME>f39432a9exv10w20.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w20</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><B>Exhibit&nbsp;10.20</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&nbsp;1&nbsp;
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><B>Please quote our reference when replying<BR>Our Ref: JTC(L) 8339/859 Vol 1</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="right"><IMG src="f39432a9f3943223.gif" alt="(JTC LOGO)"><BR></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>25 July&nbsp;2005</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt"><B>JTC Corporation</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">The JTC Summit</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>FLUIDIGM SINGAPORE PTE. LTD.</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left" nowrap style="font-size: 8pt">8 Jurong Town Hall Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>39 ROBINSON ROAD</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">Singapore 609434</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>#07-01 ROBINSON POINT</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>SINGAPORE(068911)</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">customer<BR>service hotline
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"  nowrap style="font-size: 8pt">1 800 568 7000&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>By Local Urgent Mail</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">main line
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">(65) 6560 0056&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>(Attention: MR PAUL WYATT)</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">facsimile
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">(65) 6565 5301&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">website
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap style="font-size: 8pt">www.jtc.gov.sg</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Dear Sirs,</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>OFFER OF TENANCY FOR FLATTED FACTORY SPACE</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are pleased to offer a tenancy of the Premises subject to the covenants, terms and
conditions in the annexed Memorandum of Tenancy No. <B>27.09 </B>(&#147;<U>the MT</U>&#148;) and in this letter
(collectively called &#147;<U>the Offer</U>&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent"><B>2</B></TD>
    <TD width="3%" nowrap align="left"><B>2.1</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Premises :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Private Lot <B>A2045700</B> also known as Unit
<B>#07-3532/3534/3536/3538 </B>(&#147;<U>the Premises</U>&#148;) in
<B>BLK 1026 TAI SENG AVENUE </B>(&#147;<U>the Building</U>&#148;) in the <B>TAI SENG
INDUSTRIAL ESTATE SINGAPORE 534413 </B>as delineated and edged in red on the plan
attached to the Offer.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Term of Tenancy :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>3 </B>years (&#147;<U>the Term</U>&#148;) with effect from <B>1 October&nbsp;2005 </B>(&#147;<U>the Commencement Date</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Tenancy:</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Your due acceptance of the Offer in accordance with Clause 3 of this
letter shall, together with the Offer, constitute a binding tenancy agreement
(&#147;<U>the Tenancy</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any inconsistency or conflict between any
covenant, term or condition of this letter and the MT, the relevant covenant, term or
condition in this letter shall prevail.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF)
30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943224.gif" alt="(LOGOS)">
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Area :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Approximately <B>1385 square metres</B> (&#147;<U>the Area</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Rent :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Discounted rate of <B>$9.22 </B>per square metre per month on the Area, for so
long as you shall occupy by way of tenancy an aggregate floor area of 1,000
to 4,999 square metres in the Building or in the various flatted factories
belonging to us; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Normal rate of <B>$9.50 </B>per square metre per month on the Area, in the event
that the said aggregate floor area occupied is at any time reduced to below
<I>1,000 </I>square metres (when the discount shall be totally withdrawn) with effect
from the date of reduction in the said aggregate floor area,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(&#147;<U>Rent</U>&#148;) to be paid without demand and in advance without
deduction on the 1st day of each month of the year (i.e. 1st of
January, February, March, etc.). After your first payment is made in
accordance with Clause 3 of this letter and the attached Payment
Table, the next payment shall be made on
<B>01 March&nbsp;2005</B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Service Charge :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>$2.25 per square metre per month </B>(&#147;<U>Service Charge</U>&#148;) on the Area as charges
for services rendered by us, payable by way of additional and further rent
without demand on the same date and in the same manner as the Rent, subject to
our revision from time to time and in any case such revision to be to a rate no
higher than that charged to other tenants in the Building.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Security Deposit/Banker&#146;s Guarantee :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Ordinarily we would require a tenant to lodge with us a security deposit
equivalent to <B>three (3)&nbsp;months&#146; </B>rent and service charge. However, as an
off-budget measure and as payment by GIRO has been made a condition
with which you must comply under clause 3 of this letter, you shall, at
the time of your acceptance of the Offer, place with us a deposit
equivalent
to <B>one (1)&nbsp;month&#146;s</B> Rent (at the discounted rate) and Service Charge (&#147;<U>Security Deposit</U>&#148;) as security against any breach of the covenants, terms and
conditions in the Tenancy, as follows :</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF) 30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Security Deposit may be in the form of cash or acceptable Banker&#146;s
Guarantee in the form attached (effective from
<B>1 August&nbsp;2005</B> to <B>31 December&nbsp;2008</B>), or such other form of security
as we may in our reasonable discretion permit or accept.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Security Deposit shall be maintained at the same sum throughout the
Term and shall be repayable to you without interest, or returned to you for
cancellation within 30&nbsp;days, after the termination of the Term (by expiry or
otherwise) or expiry of the Banker&#146;s Guarantee, as the case may be, subject to
appropriate deductions or payment to us for damages or other sums due under the
Tenancy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to Clause 2.6, if the Service Charge is increased, or any
deductions are made from the Security Deposit, you shall immediately pay the
amount of such increase or make good the deductions so that the Security
Deposit shall at all times be equal to <B>one (1)&nbsp;month&#146;s </B>Rent (at the normal or
discounted rate, as the case may be) and Service Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If at any time during the Term, your GIRO payment is discontinued, then you
shall place with us, within two (2)&nbsp;weeks of the date of discontinuance of your
GIRO payment, the additional sum equivalent to <B>two (2)&nbsp;months&#146; </B>Rent and Service
Charge, so that the Security Deposit shall at all times be equal to three (3)
months&#146; Rent (at the normal or discounted rate, as the case may be) and Service
Charge for the remaining period of the Term.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If at any time during the Term the off-budget measure is withdrawn you
shall, if required in writing by us, also pay to us the additional sum
equivalent to <B>two (2)&nbsp;months&#146; </B>Rent and Service Charge, so that the Security
Deposit shall at all times be equal to <B>three (3)&nbsp;months&#146; </B>Rent (at the normal
or discounted rate, as the case may be) and Service Charge for the remaining
period of the Term.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Mode of Payment :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Your first payment to be made with your letter of acceptance in accordance
with Clause 3 of this letter and the attached Payment Table shall be by
non-cash mode (eg, Cashier&#146;s Order, cheque).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF) 30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Thereafter during the Term, you shall pay Rent, Service Charge and GST
by Interbank GIRO or any other mode to be determined by us.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We enclose the GIRO authorization form for your completion.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Authorised Use :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall use the Premises for the purpose of <B>manufacture of
elastomeric microfluidic chips with carriers, including associated research
and development activities </B>only and such other purposes as may be agreed in
writing by the Landlord and Tenant (&#147;<U>the Authorised Use</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.10</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Approvals :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenancy is subject to approvals being obtained from the relevant
governmental and statutory authorities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.11</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Possession of Premises :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to your acceptance of the Offer, keys to the Premises shall be
made available to you within the period of two (2)&nbsp;months prior to the
Commencement Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From the date you accept the keys to the Premises
(&#147;<U>Possession Date</U>&#148;) until the Commencement Date, you shall be
deemed a licensee upon the same covenants, terms and conditions as in
the Tenancy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If you proceed with the Tenancy after the Commencement Date, the licence
fee payable from the Possession Date to the Commencement Date shall be waived
(&#147;<U>Rent-Free Period</U>&#148;).
Should you fail to so proceed, you shall:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>remove everything installed by you;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reinstate the Premises to its original state and condition; and</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pay us a sum equal to the prevailing market rent payable for the
period from the Possession Date up to the date the installations are
removed and reinstatement completed to our reasonable satisfaction,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>without prejudice to any other rights and remedies we may have
against you under the Tenancy or at law.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF) 30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.12</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Loading Capacity :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Normal (Ground &#038; Non-ground) Floor Premises :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall comply and ensure compliance with the following restrictions :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maximum loading capacity of the goods lifts in the
Building; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maximum floor loading capacity of <B>10 </B>kiloNewtons per square metre
of the Premises on the <B>07 </B>storey of the Building PROVIDED THAT any such
permitted load shall be evenly distributed.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.13</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Take-over of Premises :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Vacant Possession :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Offer is subject to <B>EEMS Singapore Pte Ltd </B>returning vacant possession of the
Premises by <B>31 July&nbsp;2005.</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B><U>Take-over of Fixtures and Fittings</U> :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, however, you are taking over the Premises in its existing
state and condition, including all the fixtures and fittings
installed by or belonging to <B>EEMS Singapore Pte Ltd
</B>(&#147;<U>the Said Installations</U>&#148;) then :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall accept the Premises including the Said Installations
in its condition existing at the Commencement Date or the acceptance
of the keys to the Premises by you, whichever is the earlier (&#147;<U>the Control Date</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall, within such period of time as the parties agreed upon, at
your own cost and expense, ensure that :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="16%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2.1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Said Installations have been approved in writing by us
and that plans on the Said Installations have been submitted to
and approved in writing by us;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF) 30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="16%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2.2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Said Installations comply fully with all our
guidelines and requirements (through the Building Control Unit),
and those of the relevant governmental and statutory
authorities, prevailing at the Control Date;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="16%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2.3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>such or all of the Said Installations not approved by us
under (b2.1) or which have failed to comply with (b2.2) are
demolished and removed, subject to clauses 2.11, 2.12 and 2.13
of the MT; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.14</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Option for Renewal of Tenancy :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You may within 3&nbsp;months before the expiry of the Term make a written
request to us for a further term of tenancy of 3&nbsp;years (&#147;the further term&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We may grant you a further term of tenancy of the Premises subject to
the following:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>there shall be no breach of your obligations at the time you
make your request for a further term, and at the expiry of the Term;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the duration of the further term shall be mutually agreed upon;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rent payable shall be at a revised rate to be determined by
us, having regard to the market rent of the Premises at the time of
granting the further term. Our determination of the rent shall be final
and conclusive: and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the tenancy for the further term shall be upon the same
covenants, terms and conditions except for the duration, rent,
security deposit (which shall be equivalent to three (3)&nbsp;month&#146;s rent
and service charge instead of two (2)&nbsp;months), and excluding a
covenant for renewal of tenancy.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF) 30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Mode of Due Acceptance :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Offer shall lapse if we do not receive the following by <B>31 July&nbsp;2005 </B>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Duly signed letter of acceptance <B>(in duplicate) </B>of the Offer, in the form set out
in the <U><B>Letter of Acceptance</B></U> attached. <B>(Please date as required in your letter of
acceptance)</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Payment of the sum set out in the <U><B>Payment Table</B></U> attached.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Duly completed GIRO authorization form.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Please note that payments made prior to your giving us the other items listed above may
be cleared by and credited by us upon receipt. However, if those other items are not
forthcoming from you within the time stipulated herein, the Offer shall lapse and there
shall be no contract between you and us arising hereunder. Any payments
received shall then be refunded to you without interest and you shall have no claim of
whatsoever nature against us.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Rent-Free Period :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As the Commencement Date will not be deferred, we advise you to accept the Offer as
soon as possible and to collect the keys to the Premises on
the scheduled date in order to maximize the Rent-Free Period referred to in Clause
2.11(c)&nbsp;of this letter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Variation to the Tenancy :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any variation, modification, amendment, deletion, addition or otherwise of the Offer
shall not be enforceable unless agreed by both parties and reduced in writing by us.
No terms or representation or otherwise, whether expressed or implied, shall form part
of the Offer other than what is contained herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Season Parking&nbsp;:</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Season parking tickets for car parking lots within the Estate can be purchased
at our <B>Contact Centre, The JTC Summit, Level 1, 8 Jurong Town Hall Road Singapore
609434 (Contact Centre Hotline: 1800-5687000) </B>or applied online via Krypton, JTC&#146;s
Customer Portal, <U>http://krypton.jtc.gov.sg</U> . Please note that the number of season
parking ticket(s) that can be purchased by you will depend on eligibility rules set
out by us.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF)
30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Electricity Connection:</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon your acceptance of the Offer, you are advised to proceed expeditiously to
engage a registered electrical consultant to submit two sets each of electrical
single-line diagrams and electrical layout plans to and in accordance with the
requirements of our <B>Facilities Management Section, Operations Support Department of
our Customer Services Group, </B>for endorsement before an application is made to SP
Services Ltd to open an account for electricity connection.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Please contact the Facilities Management Section at <B>Blk 25 Kallang Avenue
#05-02 Kallang Basin Industrial Estate Singapore 339416 </B>for their requirements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To guide and assist you, we enclose a <B>Schedule of Statutory Controls </B>for Flatted
Factory Occupants.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Yours faithfully
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">/s/ Chern Shiong NG<div style="width: 26%; border-top: 1px solid #000000">
<B>Chern Shiong NG</B><BR>
INDUSTRIAL DEVELOPMENT (HIGH-RISE) DEPARTMENT<BR>INDUSTRIAL PARKS
DEVELOPMENT GROUP JTC CORPORATION<BR>
DID&nbsp;: <B>68833414</B><BR>
FAX&nbsp;: <B>68855900</B><BR>
Email&nbsp;: <B>ngcs@jtc.gov.sg</B>
</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ENCS:

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT face="Wingdings">&#254;</FONT> Payment Table
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT face="Wingdings">&#254;</FONT> GIRO Form(s)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT face="Wingdings">&#254;</FONT> Specimen BG Plan</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT face="Wingdings">&#254;</FONT> Specimen Acceptance Form
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT face="Wingdings">&#254;</FONT> MT No.&nbsp;27.09</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT face="Wingdings">&#254;</FONT> Schedule of Statutory Controls (SC2)&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF)
30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B><U>PAYMENT TABLE</U></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PREMISES&nbsp;:
PRIVATE LOT AT UNIT #07-3532/3534/3536/3538 BLK 1026 TAI SENG AVENUE
TAI SENG
INDUSTRIAL ESTATE SINGAPORE 534413</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Amount</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>&#043;5% GST</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">**Rent at <B>$9.22 </B>per square
metre per month on <B>1385</B>
square metres for the period <B>1</B>
<B>February&nbsp;2006</b> to <B>28
February&nbsp;2006</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">12769.70</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">638.49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">**4&nbsp;months rental free granted from 1
October&nbsp;2005 to 31 January&nbsp;2006</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>$2.25 </B>per square metre per
month on <B>1385 </B>square metres
for the period <B>1 October&nbsp;2005</B>
to <B>31 October&nbsp;2005</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3116.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">155.81</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Rent Payable (inclusive
of Service Charge)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15885.95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">794.30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Security Deposit </B>equivalent
to three (3)&nbsp;months&#146; Rent and
Service Charge (in cash or
Banker&#146;s Guarantee provided
in accordance with Clause 2.7
of this letter)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">47657.85</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><U>Less</U>:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equivalent of two (2)&nbsp;month&#146;s
Rent and Service Charge (re Off-budget Measure and GIRO)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">31771.90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15885.95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF)
30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943225.gif" alt="(JTC LOGO)">
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="64%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Stamp fee </B>payable on Letter
of Acceptance (which we will
stamp on your behalf)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Note: If the Letter is not
returned to us within 14&nbsp;days
of the date of the Letter, you
will have to pay penalty on the
stamp duty which is imposed
by Stamp Duty Office of IRAS.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1392.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sub-Total Payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">33163.90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">794.30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px"><B><U>Add:</U> </B>GST@5%</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">794.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Payable inclusive of GST</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">33958.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">LO(FF)
30.003&#043;MT 27.09/09 July&nbsp;2002/IDG (New Allocation)<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>MEMORANDUM</B>
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>OF</B>
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>TENANCY</B>
</DIV>


<DIV align="center" style="font-size: 14pt; margin-top: 18pt"><B>NO. 27.09</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl
</DIV>


</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<DIV style="width: 100%; border: 1px solid black; padding: 11px; width: 40%">
<DIV align="left" style="font-size: 10pt; margin-top: 12pt">
<B>Index of clauses in Memorandum of Tenancy</B>
</DIV>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Clauses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Pages</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B><U>Easements, Rights
and Privileges</U></B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B><U>Exceptions and
Reservations</u></B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B><U>Covenants and
Conditions</U></B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">1.1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">1.2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interpretation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2</TD>
    <TD>&nbsp;</TD>

<TD><DIV style="margin-left:15px; text-indent:-15px"><B><U>Tenant&#146;s
Covenants</U></B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Rent &#038; Service Charge</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.5</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of Performance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.6</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of Enforcement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.7</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">GST</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.8</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.9</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Uniform External Appearance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.10</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Signages</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.11</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Modifications</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.11(a)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tenant&#146;s Installations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.11(b)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">All Installations Fixtures &#038; Fittings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.12</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Power Surge &#038; Vibration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.13(a)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Safety of Building</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July 2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- ii -<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Clauses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Pages</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.13(b)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Certificate of Statutory Completion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.14</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Thermal Insulation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.15</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Maintenance and Repair</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.16</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Responsibility for Damage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.17</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Landlord&#146;s Right of Inspection and Repair</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>&#149;</B>&nbsp;&nbsp;&nbsp;Removal of Installations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>&#149;</B>&nbsp;&nbsp;&nbsp;Emergency</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.18</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cease Activities for Repairs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.19(a)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">No assignment, Subletting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.19(b)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sole-Proprietor/Partners</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.20</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Obstructions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.21</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Disposal of Waste</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.22(a)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Yield Up at Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.22(b)</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Permit Viewing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.23</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Compliance with Landlord&#146;s Rules &#038; Regulations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.24</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Compliance with Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.25</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Head Lease</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.26</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Hazardous Placement of Objects</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.27</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Nuisance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.28</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Application of Restrictive Covenants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2.29</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->- iii -&nbsp;<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Clauses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Pages</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3</TD>
    <TD>&nbsp;</TD>

<TD><DIV style="margin-left:15px; text-indent:-15px"><B><U>Landlord&#146;s
Covenants</U></B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Quiet Enjoyment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">General Services</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property Tax</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Insurance of Building</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4</TD>
    <TD>&nbsp;</TD>

<TD><DIV style="margin-left:15px; text-indent:-15px"><B><U>Landlord
and Tenant by Agreement</U></B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forfeiture of Tenancy</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Service of Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Service of Process</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Business Address</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Refurbishment Works</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Landlord&#146;s Self-Help</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.8</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-Waiver</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.9</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Landlord&#146;s Works</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.10</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exemption of Liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.11</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Distress Act</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.12</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.13</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Third Party Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.14</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Governing Jurisdiction and Law</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><U>EASEMENTS, RIGHTS AND PRIVILEGES</U></B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">A</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The full right and liberty for the Tenant and the persons authorised by him (in common
with all other persons entitled to the like right), at all times, by day or night to go,
pass and repass over and along the main entrance of the Building and the common
passageways, landings and stairways and to use the lifts PROVIDED THAT the Tenant shall not
cause or permit any obstruction to the common passageways, landings, stairways and other
common parts of and accesses to the Building.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">B</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The free and uninterrupted passage and running of water, electricity and gaseous products
from and to the Premises through the sewers, drains, water-courses, channels, pipes,
shafts, flues, cables and wires which now are or may at any time during the Term be in,
under or passing through the Building.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">C</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The right of support and protection for the benefit of the Premises as is now enjoyed
from the other premises and all other parts of the Building.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><U>EXCEPTIONS AND RESERVATIONS</U></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BUT RESERVING unto the Landlord and all others to whom the Landlord has granted or may
grant :</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">D</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The easements, rights and privileges over, along and through the Premises equivalent to
those above.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">E</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All other easements, ancillary rights and obligations as are or may be implied by the
Land Titles Act.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">F</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The free and uninterrupted passage and running of telecommunication facilities from,
through and to the Premises.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">G</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The right of support and protection for the benefit of the other premises and all other
parts of the Building as is now enjoyed from the Premises.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">H</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The right to develop, redevelop, erect, alter or in any way deal with or use or let the
Building or any other part of the Estate in such manner as shall be approved by the
Landlord, the superior lessor or the Authorities notwithstanding that the access of light
or air or any easement granted or appertaining to or enjoyed with the Premises may be
obstructed or interfered with or that the Tenant might otherwise be entitled to object
PROVIDED THAT if the same is undertaken by the Landlord, the Landlord shall endeavour to
ensure minimum disruption to the Tenant&#146;s operations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B><U>COVENANTS AND CONDITIONS</U></B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Definitions</B>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following expressions shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(a)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Authorities&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; all relevant governmental and statutory authorities.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(b)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Building&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; the building in which the Premises is situated and of which it
forms a part, including but not limited to the common parts and other premises
in the building.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(c)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Carpark&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; all parking lots, driveways, roads, ramps and loading bays,
whether within or outside any building, in the Estate.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(d)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Commencement Date&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; as defined in the Tenancy.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(e)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Estate&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; the estate in which the Building is situated and of which it
forms a part, including but not limited to the Carpark, compounds, grounds,
gardens, bin centres, structures, other buildings and drains, cables and pipes
above or below ground in the estate.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(f)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Law&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; all laws, statutes, legislation, by-laws, rules, orders or
regulations now or hereafter in force.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(g)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Landlord&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; the Jurong Town Corporation (also known as &#147;JTC Corporation&#148;)
incorporated under the Jurong Town Corporation Act, its successors-in-title,
and assigns.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(h)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Premises&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; as defined in the Tenancy.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(i)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Rent&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; as defined in the Tenancy.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(j)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Service Charge&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; as defined in the Tenancy.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(k)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Tenant&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; the Tenant as defined in the Tenancy and includes his personal
representatives, successors-in-title, and permitted assigns (if any).</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF)
27.09 &#043; LO(FF)30.003/09 July 2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="80%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(l)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Tenancy&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; the tenancy offer made by the Landlord to the Tenant in respect of the Premises and duly accepted by the Tenant.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(m)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Tenant&#146;s Obligations&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; covenants, conditions, terms, stipulations and obligations to be observed or performed by the Tenant.</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 12pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(n)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Term&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:11px; text-indent:-11px">:&nbsp;&nbsp; as defined in the Tenancy.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Interpretation</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>words importing the singular include the plural and vice versa;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>words importing the masculine gender include the feminine gender and vice versa;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the expression &#147;person&#148; includes a body corporate;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reference to a specific Act of Singapore shall include any amendment, revision or replacement
made to it from time to time;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>where the Tenant consists of two or more persons all Tenant&#146;s Obligations shall be deemed to be
binding on such persons jointly and severally;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all marginal notes are for ease of reference only and shall not be taken into account in the
construction or interpretation of the clause or paragraph to which they refer.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Tenant&#146;s Covenants</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Tenant covenants with the Landlord as follows:</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Rent &#038; Service Charge</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay without demand and without deduction the Rent, Service Charge and all
other sums charged or imposed upon the Premises or the Tenant by the Landlord in
accordance with the Tenancy PROVIDED THAT&nbsp;:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Landlord shall be at liberty from time to time to revise the amount of Service Charge upon
giving a written notice to the Tenant PROVIDED THAT such revision shall not be to a rate higher
than that charged to other tenants in the Building; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the revised Service Charge shall be payable from the date specified in the said notice.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043; LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Interest</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay interest (&#147;Interest&#148;) at the rate of 8.5% per annum on any outstanding amount
due and payable under the Tenancy from the due dates until payment in full is accepted
by the Landlord PROVIDED
THAT&nbsp;:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Landlord may revise the Interest to a higher rate from time to time at
its absolute discretion; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Landlord shall refuse to accept the tender of the outstanding amount
because of any breach of the Tenant&#146;s Obligations, the Interest shall
nevertheless remain due and payable.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Taxes</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay the Landlord any increase in property tax, which may be imposed whether by
way of an increase in the annual value or an increase in the rate per centum, in the
proportion attributable to the Premises as determined by the Landlord in its absolute
discretion.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Cost of Documents</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay all costs, disbursements, fees and charges, legal or otherwise, including
stamp and registration fees in connection with the preparation, stamping and issue of
the Tenancy and any prior, accompanying or future documents or deeds, supplementary,
collateral or in any way relating to the Tenancy.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Cost of Performance</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To perform and observe all the Tenant&#146;s Obligations at his own cost and expense.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Cost of Enforcement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay all costs and fees, legal or otherwise, including costs as between solicitor
and client in connection with the enforcement of the Tenant&#146;s Obligations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>GST</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay, in addition to and together with all taxable sums, the Goods And Services
Tax (&#147;GST&#148;) at the prevailing rate to the Landlord as collecting agent for the
Authorities.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Insurance</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">2.8</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to do or suffer to be done anything whereby any insurance for the time being
effected on the Premises or the Building may be rendered void or voidable or be in any
way affected.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay to the Landlord on demand all sums paid by the Landlord by way of
increased premium and all costs and expenses incurred by the Landlord in
connection with insurance rendered necessary by a breach or non-observance of
sub-clause (a)&nbsp;above without prejudice to any other rights and remedies available
to the Landlord.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Uniform External Appearance</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to alter in any way the external appearance of the Premises including but not
limited to the colour and type of all external parts such as doors, windows, grilles and
walls without the prior written consent of the Landlord, such consent not to be
unreasonably withheld.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Signages</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to affix, paint or otherwise exhibit any name plate, banner, advertisement,
flag-staff or any other thing except only the name of the Tenant in such places and
manner as approved in writing by the Landlord such approval not to be unreasonably
withheld or delayed.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043; LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Modifications</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to do, permit or suffer to be done any of the following without the
Landlord&#146;s prior written consent such consent not to be unreasonably withheld
or delayed:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Tenant&#146;s Installations</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>installation of air-conditioning system, ventilation system,
electrical system, telecommunication equipment, plant, machinery,
fixtures, fitting or other installations (&#147;Tenant&#146;s Installations&#148;) in
the Premises; and</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>All installations
Fixtures &#038; Fittings</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>alter, remove, add or in any way interfere or tamper with fixtures,
fittings and installations including the Tenant&#146;s Installations in the
Premises, including but not limited to any existing fire alarm and
extinguishing system, ventilation system, air-conditioning system, walls
or floor finishes (including any tilings), pipes, wirings, equipment,
power and light points and outlets.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Power Surge &#038;
Vibration</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">2.12</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to install or use any electrical, mechanical or telecommunication
equipment, plant, machinery, fixtures, fittings, appliance or installations
(&#147;the Equipment&#148;) that causes heavy power surge, high frequency voltage and
current, noise, vibration or any electrical or mechanical interference or
disturbance whatsoever (&#147;the Interference&#148;) which:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>may prevent or prevents in any way the service or use of
any communication system of the Landlord, other lessees, tenants
or occupiers; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>affects the operation of equipment, plant, machinery,
fixtures, fittings, appliances or installations of the Landlord,
other lessees,&#183; tenants or occupiers.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To allow the Landlord or any authorised person to inspect at all
reasonable times, the Equipment in the Premises to determine the source
of the Interference.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To take suitable measures to eliminate or reduce the Interference to
the Landlord&#146;s reasonable satisfaction, if it is found by the Landlord or
such authorised person that the Equipment is causing or contributing to
the Interference.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Safety of Building</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">2.13</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to do, permit or suffer to be done anything which affects the
structure or safety of the Building.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Certificate of
Statutory
Completion</B>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to do, permit or suffer to be done nor omit to do anything which
may delay or prevent the issuance of the Certificate of Statutory
Completion in respect of the Building.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Thermal Insulation</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to clauses 2.11, 2.12 and 2.13 and the Landlord&#146;s prior written
consent such consent not to be unreasonably withheld or delayed, to provide
thermal insulation to the floor, ceiling and the walls of the Premises if the
Tenant&#146;s activities results or may result in :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>moisture condensation on the floors, ceilings or walls of adjoining
premises or common parts of the Building; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the generation of excessive heat or heat which causes or may cause
undue discomfort to the Landlord, its lessees or tenants or the occupiers
of any adjoining or neighbouring premises.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Maintenance and
Repair</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.15</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to clauses 2.11, 2.12 and 2.13, to maintain and in good and
tenantable repair and condition, fair wear and tear and damage caused by an event
which in the Landlord&#146;s reasonable opinion is beyond the Tenant&#146;s control,
excepted :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the ceilings, doors, windows, glass and all the interior of the
Premises including but not limited to walls, soffit, false ceiling, floor
and all fixtures and fittings;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the pipes, sumps, grease interceptors and sanitary installations
whether in the floor, ceiling, walls or any part of the Premises; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all party walls, floors and ceilings separating the Premises from
other premises in the Building jointly with the adjoining lessees,
tenants or occupiers.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Responsibility
for Damage</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.16</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the cause of any damage to the Estate can be traced directly or
indirectly back to the Tenant&#146;s activities&nbsp;:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to reinstate the Estate to the reasonable satisfaction of the Landlord
as required by the Landlord in its reasonable discretion and within such
time as the Landlord may reasonable stipulate; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any event, to pay for all proceedings, costs, expenses, claims,
losses, damages, penalties and liabilities arising out of the above
including but not limited to such costs and expenses as reasonably
determined by the Landlord.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Landlord&#146;s
Right of Inspection
and Repair</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.17</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon prior reasonable notice to the Tenant, to permit the Landlord, its
employees, agents and all persons authorised by it or them, with or without any
necessary materials and appliances, at reasonable times during the day or night,
to enter upon the Premises to :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>view or examine the state and condition of the Premises or the
Building including but not limited to all windows,</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>doors, pipes, ducts, drains, cables and
wires;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>execute any repairs or works to or in connection with the Building or
the Premises which it or they may think fit, including but not limited
to installation or replacement of windows, doors, pipes, ducts, drains,
cables and wires;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>verify, by photographs or other means, that the Tenant&#146;s Obligations
are observed and performed;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>carry out Refurbishment Works referred to in clause 4.5; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take inventories of equipment, plant, machinery, fixtures, fittings,
appliances, installations, goods, materials and articles to verify that
the Tenant&#146;s Obligations are observed and performed,</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Removal of
Installations</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AND if so reasonable required by the Landlord, to remove any equipment,
plant, machinery, installation, fixtures, fittings, appliances,
partitions, goods, materials and articles to facilitate the above. The
Landlord shall endeavour to ensure minimum disruption to the Tenant&#146;s
operations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Emergency</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>PROVIDED THAT </B>in respect of (c)&nbsp;and (e)&nbsp;above, the Landlord, before
performing the works, shall enter into a non-disclosure agreement with
the Tenant in the format attached as Annex A <B>PROVIDED FURTHER THAT </B>in a
situation which in the Landlord&#146;s opinion is an emergency or exigency,
the Landlord shall have the full right and liberty to enter the Premises
immediately, with or without the Tenant&#146;s consent, to take such action
as the Landlord in its reasonable discretion deems fit.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Cease Activities
for Repairs</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.18</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To cease activities to such extent and during such hours as the Landlord
may specify by reasonable prior written notice to the Tenant for any maintenance
or repair work to be executed by the Landlord <B>PROVIDED THAT </B>in a situation which
in the Landlord&#146;s opinion is an emergency or exigency, the Landlord shall be
entitled to request the Tenant to cease activities immediately and the Tenant
shall comply fully with such request.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>No
Assignment,
Subletting</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">2.19</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to demise, assign, charge, create a trust or agency, mortgage, let,
sublet, grant a licence or part with or share the possession or occupation of
the Premises in whole or in part <B>PROVIDED THAT </B>with the Landlord&#146;s prior written
consent, such consent not to be unreasonably withheld, the Tenant may let,
sublet, grant a licence or part with or share the possession or occupation of
the Premises in part or assign or novate the Premises in whole.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Sole-proprietor/Partners</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to sub-clause (a)&nbsp;above, if the Tenant is a sole-proprietor
or comprises of partners carrying on business under a business name
registered under the Business Registration Act, not to effect any change
in the</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>constitution or membership of the sole-proprietorship or partnership without the Landlord&#146;s prior
written consent.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Obstructions</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.20</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to place, permit or suffer to be placed any object, article or thing in
or obstruct the accesses, stairways, passageways, pipes, drains, and other
common parts of the Estate.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Disposal of Waste</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.21</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make good and sufficient provision for and to ensure the safe and
efficient disposal of all waste, including but not limited to pollutants and
refuse, to the reasonable requirements and reasonable satisfaction of the
Landlord.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Yield Up at
Termination</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">2.22</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At the termination of the Term, by expiry or otherwise :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to yield up the Premises to the Landlord in good and
tenantable repair and condition, fair wear and tear and damage
caused by an event which in the Landlord&#146;s reasonable opinion is
beyond the Tenant&#146;s control, excepted;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="4%" style="background: transparent">(a2)</TD>
    <TD width="3%" nowrap align="left">(a2.1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to remove all tenant&#146;s fixtures and fittings;</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2.2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to reinstate the Premises; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2.3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if so required by the Landlord, to redecorate by
painting the interior of the Premises,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to the reasonable satisfaction of the Landlord,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and in accordance with the Tenant&#146;s Obligations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Permit Viewing</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To permit intending tenants and others, authorised by the Landlord or
its agents, at reasonable times and by prior appointment with the Tenant,
to enter and view the Premises during the three calendar months
immediately preceding the determination of the Term.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Compliance
with Landlord&#146;s
Rules &#038; Regulations</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.23</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To observe and comply with and ensure observance and compliance with all
rules, notices, regulations and stipulations which may, from time to time, be
made by the Landlord in respect of the Estate and which have been furnished to
the Tenant.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Compliance
with Laws</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">2.24</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To comply with the Law and all directions and requirements of the
Authorities&nbsp;:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>relating to the Estate (where applicable);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>relating to the use, occupation or otherwise of the
Premises; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in respect of the observance or performance of the Tenant&#146;s
Obligations,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>whether to be complied with by the Landlord or the Tenant and
notwithstanding any consent which the Landlord may grant under any
clause in the Tenancy or otherwise.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To inform the Landlord without undue delay in writing of any notice
received in relation to sub-clause (a)&nbsp;above.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Head Lease</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.25</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To perform and observe the express and implied covenants on the Landlord&#146;s
part in the head lease made between the President of the Republic of Singapore
and the Landlord so far as they are not varied herein.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Hazardous
Placement of
Objects</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.26</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to place, permit or suffer to be placed any object, article or thing by
any window or balcony or any part of the Premises in a manner which in the
Landlord&#146;s reasonable opinion may cause or is likely to cause any damage or
injury to any property or person.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Nuisance</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.27</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Not to do, permit or suffer to be done upon the Premises anything which in
the opinion of the Landlord may be or become :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a nuisance, annoyance or cause damage or inconvenience to; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an interference with the business or quiet or comfort of</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Landlord, its tenants or lessees or the occupiers of any adjoining
or neighbouring premises.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Application of
Restrictive
Covenants</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.28</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To comply with all restrictive covenants as set out in the Tenancy or at
Law relating to the Premises as if they are also restrictive covenants relating
to the Building or the Estate, where the context so admits.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Indemnity</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.29</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for all loss, injury or damage whatsoever to any person or to the
Building or the Estate, and any moveable or immovable property, arising
directly or indirectly out of or in connection with :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="15%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the occupation or use of the Premises; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="15%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any act or omission (whether with or without the Landlord&#146;s
consent), neglect or default of the Tenant, the Tenant&#146;s
employees, agents, authorised persons or visitors; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in respect of any act, matter or thing done, omitted to be done,
permitted or suffered to be done, in contravention of the Tenant&#146;s
Obligations,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AND to fully indemnify and keep indemnified the Landlord against all
proceedings, costs, expenses, claims, losses, damage, penalties and
liabilities arising out of the above PROVIDED THAT the Tenant&#146;s <B>liability
to the Landlord, if </B>any, is limited to direct damages suffered by the
Landlord and shall not include indirect, economic or consequential loss
or damages.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Landlord&#146;s Covenants</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Landlord covenants with the Tenant as follows :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Quiet Enjoyment</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the Tenant performing and observing all the Tenant&#146;s Obligations,
the Tenant may peaceably and quietly hold and enjoy the Premises without any
unlawful interruption or disturbance from or by the Landlord.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>General Services</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">(a)&nbsp;</TD>
    <TD>To keep the exterior and roof of the Building and the lifts, entrances,
passageways, staircases, common toilets and other conveniences intended for the
use of the Tenant in repair and in sanitary and clean condition.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;&nbsp;</TD>
    <TD width="1%">&nbsp;&nbsp;</TD>
    <TD width="1%">&nbsp;(b)&nbsp;</TD>
    <TD>To keep the stairs and passageways leading to the Premises and the
lifts and toilets sufficiently lit.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Property
Tax</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To pay property tax payable in respect of the Premises PROVIDED THAT if the
rate of such property tax shall be increased whether by way of an increase in the
annual value or an increase in the rate percent, then the Tenant shall pay such
increase as provided under Clause 2.3.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Insurance of
Building</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To keep the Building insured against loss or damage by fire and in the event
of such loss or damage (unless resulting from some act or default of the Tenant,
the Tenant&#146;s employees, agents, authorised persons or visitors) to rebuild and
reinstate the damaged part of the Building PROVIDED THAT such insurance shall not
include the contents in the Building nor loss due to the Premises being rendered
out of commission.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Landlord and Tenant agree to the following :</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forfeiture of
Tenancy</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Landlord is entitled to forfeit the Tenancy by entering the Premises or any
part thereof, if :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Rent, Service Charge, or any other sums due under or by virtue of
the Tenancy, or any part thereof is unpaid for fourteen (14)&nbsp;days after
becoming payable (whether the same is formally demanded or not);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Tenant is in breach of any of the Tenant&#146;s Obligations and the
Landlord has given to the Tenant prior written notice specifying the
breach and the Tenant has failed to rectify the breach within such period
as set out in such notice;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any writ of seizure and sale or its equivalent made in respect of the
Premises is enforced by sale or by entry into possession;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Tenant enters into liquidation, whether compulsory or
voluntary (save for the purpose of reconstruction or amalgamation);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a bankruptcy petition is filed or a bankruptcy order is made against the Tenant;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Tenant makes an assignment for the benefit of the Tenant&#146;s creditors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Tenant enters into any arrangement with its creditors by composition or otherwise; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Tenant suffers any distress, attachment or execution on or against the Tenant&#146;s goods,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PROVIDED THAT the above is without prejudice to the Landlord&#146;s other rights and remedies in
respect of any breach of the Tenant&#146;s Obligations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Service of Notices</B>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any written notice shall be sufficiently served if effected :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the Landlord by registered post to its business address;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the Tenant by registered or ordinary post to or by leaving or
affixing it at the business address or the Premises NOTWITHSTANDING THAT
it is returned by the post office undelivered;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>by facsimile to the party to be served and the service shall be deemed
to be made on the day of transmission if transmitted before 4 p.m. on a
working day or 12 noon on a Saturday, but otherwise on the following
working day; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the Solicitor for the party in the manner provided in this clause.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Service of Process</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any process, by writ, summons or otherwise, shall be sufficiently served if
effected on :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Landlord by registered post to its business address;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Tenant by registered post to or by leaving or affixing it at the
business address or the Premises NOTWITHSTANDING THAT it is returned by
the post office undelivered; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Solicitor for the party in the manner provided in this clause.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Business Address</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The business address for the purposes of clauses 4.2 and 4.3
shall be :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the business address of the Solicitor (if any) who is acting for the
party in the matter or proceedings in connection with which the service of
the notice or process in question is to be effected;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Tenant is a sole-proprietor or comprises of partners carrying or
formerly carrying on business under a business name registered under the
Business Registration Act, the principal or last known place of business;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the case of a body corporate, the registered or principal office of
the body.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Refurbishment Works</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">4.5</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenant accepts the Premises with full knowledge that refurbishment and
upgrading works are being or may be carried out in the Estate (&#147;Refurbishment
Works&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenant shall remove, relocate or modify, temporarily or
permanently, every installation, fixture, fitting, device, equipment and
article outside the Premises which are installed by the Tenant as the
Landlord may specify for the purpose of :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permitting the Landlord, its employees, agents or authorised
persons to properly carry out the Refurbishment Works; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>improving the appearance or aesthetics of the Building.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>PROVIDED THAT </B>the Landlord shall endeavour to ensure minimum
disruption to the Tenant&#146;s operations.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Consents</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Wherever it is provided in the Tenancy that the Tenant shall not do an act or
thing without the Landlord&#146;s prior written consent, the Landlord may in its
reasonable discretion :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>refuse to grant consent without giving any reason, and without
refunding any administrative fee paid; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if it grants consent, in addition to the terms and conditions expressly
provided (if any) in the relevant clause, impose reasonable terms and
conditions including but not limited to any payment of monies, fees or
deposit to the Landlord in accordance with prevailing rates or computation
applicable to other tenants in the Building, and the restrictions in Section
17 of the Conveyancing and Law of Property Act shall not apply.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Landlord&#146;s
Self-Help</B>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">4.7</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any breach of any of the Tenant&#146;s Obligations, the Landlord,
in addition to its rights of forfeiture and any other rights and remedies, shall
have reasonable discretion to :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>repair, rectify or make good anything done or omitted to be
done by the Tenant or perform any act which the Tenant is to perform
under the Tenancy;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>demolish, remove, relocate or modify and confiscate any
equipment, plant, machinery, fixtures, fittings, appliances,
installations, obstructions, partitions, goods materials, articles or
structures including but not limited to grilles, doors, gates, or
tilings erected, constructed or substituted by the Tenant in the
Premises or at the stairways, passageways or other common parts of
the Building;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reinstate the Landlord&#146;s fixtures or fittings with such
materials as the Landlord may reasonably elect; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>carry out such other remedial measures as the Landlord
reasonably thinks necessary.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Nothing in this clause shall be deemed to place on the Landlord an
obligation to exercise the above rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For the purpose of enabling the Landlord to exercise the above rights,
the Tenant shall grant to the Landlord, its employees, agents and
all persons authorised by it or them the right of entry with or without
materials and appliances at reasonable times.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenant shall pay to the Landlord :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the reasonable costs of all such works and materials used by
the Landlord together with such costs and expenses as reasonably
determined by the Landlord; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Tenant yields up the Premises at the termination of the
Term, by expiry or otherwise without reinstating it to the standard
required under the Tenancy, the sum equivalent to the Rent, Service
Charge, tax or other sums which the Landlord would have been
entitled to receive from the Tenant had the period within which such
reinstatement works are effected by the Landlord been added to the
Term,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and the same shall be recoverable from the Tenant as a debt.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Non-Waiver</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following shall not prejudice nor waive the Landlord&#146;s rights or remedies
in respect of any breach of the Tenant&#146;s Obligations :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any failure or omission of the Landlord to exercise any of its rights
as Landlord under the Tenancy or Law;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any receipt or acceptance of any Rent, Service Charge or other sums by
the Landlord; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver, expressed or implied by the Landlord of any other breach of
the same or any other Tenant&#146;s Obligations,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" style="background: transparent">&nbsp;</TD>
    <TD colspan="3">PROVIDED THAT the Landlord shall be under no obligation to enforce or
impose any covenants, conditions or terms against any lessees or tenants of
any premises comprised in the Estate.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Landlord&#146;s
Works</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If required by Law or in the event of Refurbishment Works or any breach of any
Tenant&#146;s Obligations, the Landlord undertakes any work affecting the Premises, the
Landlord may reinstate the Premises :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to the original state the Premises was in at the Commencement Date
so far as possible fair wear and tear excepted; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If it deems fit, with such materials and finishing of similar quality.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenant shall bear all the reasonable costs and expenses for the
reinstatement work. If the Landlord deems in its reasonable discretion that
such costs and expenses are to be borne by more than one person, the
Landlord&#146;s apportionment shall be binding and conclusive and the Tenant
agrees to pay his share as determined by the Landlord.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exemption of
Liability</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Landlord shall not be liable to the Tenant or his employees, agents,
authorised persons or visitors, or his or their property in respect
of any :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>interruption in the services provided by the Landlord by
reason of any :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>repair, maintenance, damage or Refurbishment Works; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>mechanical or other defect or breakdown including but not
limited to breakdown in electricity, gas and water supply, pumps and
lifts;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>act, omission, default, misconduct or negligence of the Landlord, its
employees, agents and all persons authorised by it or them in connection with :</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF)
27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the performance or purported performance of any service which the Landlord provides;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the carrying out or purported carrying out of the Refurbishment Works;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the exercise or purported exercise of the Landlord&#146;s rights under clause 2.17 or 4.9 or
self-help under clause 4.7; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any accident, injury, loss or damage to the Tenant or his employees, agents, authorised
persons or visitors, or his or their property;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>loss, damage, injury, liability, claim, penalty, proceedings, cost, expense, or inconvenience
that may be suffered by the Tenant or his employees, agents, authorised persons or visitors, or his
or their property resulting from or in connection with :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any breakage of or defect in any pipes, wires or other apparatus of the Landlord
used in or about the Building;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any subsidence or cracking of the ground floor slabs, production floor slabs or apron
slabs of the Premises or the Building; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any defect, inherent or otherwise in the Premises or the Building.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>unless, only in respect of 4.10 (a)&nbsp;and 4.10 (c)&nbsp;above, any loss or damage suffered by the
Tenant is caused by the gross negligence or willful misconduct of the Landlord PROVIDED THAT the
Landlord&#146;s liability, if any, is limited to direct damages suffered by the Tenant and shall not
include indirect, economic or consequential loss or damages.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Distress Act</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For the purpose of the Distress Act, the Service Charge shall be deemed to be
rent recoverable in the manner provided in the said Act.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Severability</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If at any time any provision or any part of a provision of the Tenancy is or
becomes illegal, invalid or unenforceable in any respect, the remaining provisions or
parts of the provision (to the extent that they are severable from such illegal,
invalid or unenforceable provisions or part of the provision) shall in no way be
affected or impaired thereby.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Third Party Rights</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A person who is not a party to the Tenancy shall have no right under the
Contracts (Rights of Third Parties) Act to enforce any of the covenants, terms or
conditions of the Tenancy.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Governing
Jurisdiction and Law</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenancy shall be interpreted in accordance with the laws
of Singapore and any legal proceedings, actions or claims arising from or in connection with the
Tenancy shall be commenced in and heard before the courts of Singapore and the Tenant
agrees to submit itself to the jurisdiction of the courts of Singapore.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MT(FF) 27.09 &#043; LO(FF)30.003/09 July&nbsp;2002<BR>
GO&#043;AN&#043;LPN&#043;WCL&#043;TGP/LBL(CTG)/zmy&#043;sr&#043;vfm&#043;at&#043;sl

</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943227.gif" alt="(FLUIDIGM LOGO)">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">27 July&nbsp;2005
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">INDUSTRIAL DEVELOPMENT (HIGH-RISE) DEPARTMENT<BR>
JTC Corporation<BR>
The JTC Summit<BR>
8 Jurong Town Hall Road<BR>
Singapore 609434

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><U>Attn
: Chern Shiong NG</U></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ACCEPTANCE
OF OFFER OF TENANCY FOR THE PREMISES AT UNIT # 07-3532/3534/3536/3538
BLK 1026 TAI SENG AVENUE TAI SENG INDUSTRIAL ESTATE SINGAPORE 534413</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We refer to your letter of offer and eStatement letter, both dated <B>25 July&nbsp;2005 </B>for the
Tenancy and hereby confirm our acceptance of all the covenants, terms and conditions of
the Offer and the eStatement letter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are currently opting to pay by GIRO, thus we enclose herewith a cheque for the
amount of <B>$ 33958.20 </B>as confirmation of our acceptance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We have enclose herewith a duly completed GIRO authorization form.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are fully aware that the Tenancy is subject to necessary approvals and clearances from
the relevant governmental and statutory authorities (including but not limited to Pollution
Control Department of the National Environment Agency and the Public Utilities Board). We
shall be responsible to obtain and comply with such approvals and clearances.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We understand and agree that we will only be able to view our Statement of Accounts (SA)
in Krypton and confirm that the following email addresses are the authorized recipients to
receive the email notification to view our SA or eStatement in Krypton.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Email address 1 :&nbsp;&nbsp; Grace.Yow@Fluidigm.com<BR>
Email address 2 :&nbsp;&nbsp; Jim.Neesen@Fluidigm.com</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Singapore Pte Ltd</B><BR>
39 Robinson Road #07-01, Robinson Point, Singapore 068911 www.fluidigm.com
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="f39432a9f3943227.gif" alt="(FLUIDIGM LOGO)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We have enclosed a completed application for EASY access code.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Yow Mai Chan
<DIV style="width: 25%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Name of authorized signatory :<BR>
Designation: General Manager
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>For and on behalf of :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">
/s/ Yow Mai Chan
<DIV style="width: 25%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
<B>FLUIDIGM SINGAPORE PTE. LTD. :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>In the presence of :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">
/s/ Phoa Cheng Han
<DIV style="width: 25%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
Name of witness : PHOA CHENG HAN<BR>
NRIC No : 52577445 J
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Fluidigm Singapore Pte Ltd</B><BR>
39 Robinson Road #07-01, Robinson Point, Singapore 068911 www.fluidigm.com
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="MIDDLE"><DIV style="margin-left:0px; text-indent:-0px"><B>Please quote our reference when replying<BR>Our Ref : JTC(L) 8339/859</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><IMG src="f39432a9e3943223.gif" alt="(JTC LOGO)"></TD>
</TR>
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>1 August&nbsp;2008</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>FLUlDlGM SINGAPORE PTE. LTD.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>1026 TAI SENG AVENUE</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left"><B>JTC Corporation</B><br></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>#07-3532</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">The JTC Summit<br></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><B>SlNGAPORE(534413)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">8 Jurong Town Hall Road<br></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By Local Urgent Mail</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Singapore 609434</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>(Attention : GRACE YOW)</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">JTC hotline
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1800 568 7000</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">main line
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(65) 6560 0056</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">facsimile
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(65) 6565 5301</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">website
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">WWW.jtc.gov.sg</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dear Sirs,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>OFFER OF TENANCY FOR FLATTED FACTORY SPACE</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are pleased to offer a tenancy of the Premises subject to the
covenants, terms and conditions in the annexed Memorandum of Tenancy
No. <B>27.09 </B>(&#147;<U>the MT</U>&#148;) and in this letter (collectively called
&#147;<U>the Offer</U>&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent"><B>2</B></TD>
    <TD width="3%" nowrap align="left"><B>2.1</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Premises </B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Private Lot <B>A2045701 </B>also known as Unit <B>#02-3536 </B>(&#147;<U>the
 Premises</U>&#148;) in <B>BLK 1026 TAI SENG AVENUE</B> (&#147;<U>the
Building</U>&#148;) in the <B>TAI SENG INDUSTRIAL ESTATE SINGAPORE 534413</B>
as delineated and edged in red on the plan attached to the Offer.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Term of Tenancy </B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>3</B> years (&#147;<U>the Term</U>&#148;) with effect from <B>1 November&nbsp;2008 </B>(<U>&#147;the Commencement Date</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Tenancy</B>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Your due acceptance of the Offer in accordance
with Clause 3 of this letter shall, together with the Offer,<BR>
constitute a binding tenancy agreement (&#147;<U>the
Tenanc</U>v&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any inconsistency or conflict between any covenant, term or condition of this letter and the MT, the
relevant covenant, term or condition in this letter shall
prevail.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="f39432a9e3943235.gif" alt="(40 YEARS LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><IMG src="f39432a9e3943226.gif" alt="(SERVICE CLASS LOGO)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Area </B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Approximately <B>193 square metres </B>(&#147;<u>the Area</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Rent</B>:<br>
<B><I>Discounted Rent</I></B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Discounted rate of <B>$8.00 </B>per square metre per month on
the Area, for so long as you shall occupy by way of
tenancy an aggregate floor area of 1,000 to 4,999 square
metres in the Building or in the various flatted factories
belonging to us; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Normal rate of <B>$8.25 </B>per square metre per month on the
Area, in the event that the said aggregate floor area
occupied is at any time reduced to below <I>1,000 </I>square
metres (when the discount shall be totally withdrawn) with
effect from the date of reduction in the said aggregate
floor area.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(&#147;<u>Rent</U>&#148;) to be paid without demand and in advance without deduction
on the 1st day of each month of the year (i.e. 1st of January,
February, March, etc.). After your first payment is made in
accordance with Clause 3 of this letter and the attached Payment
Table, the next payment shall be made on <B>01 December&nbsp;2008 </B>.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Service Charge :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&nbsp;</B></TD>
    <TD width="1%"><B>&nbsp;</B></TD>
    <TD><B>$2.25 per square metre per month </B>(&#147;<U>Service Charge</U>&#148;) on the Area as
charges for services rendered by us, payable by way of additional and
further rent without demand on the same date and in the same manner as the
Rent, subject to our revision from time to time.</TD>
</TR>

</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Security Deposit/Banker&#146;s Guarantee </B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Ordinarily we would require a tenant to lodge with us a security deposit
equivalent to <B>three (3)&nbsp;months&#146; </B>rent and service charge. However, as payment
by GlRO has been made a condition with which you must comply under clause 3
of this letter, you shall, at the time of your acceptance of the Offer,
place with us a deposit equivalent to <B>one (1)&nbsp;month&#146;s </B>Rent (at the
discounted rate) and Service Charge (&#147;<U>Security Deposit</U>&#148;) as security
against any breach of the covenants, terms and conditions in the Tenancy, as
follows :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Security Deposit may be in the form of cash or
acceptable Banker&#146;s Guarantee in the form attached<BR>
(effective from <B>1 September&nbsp;2008 </B>to <B>31 January&nbsp;2012 </B>), or
such other form of security as we may in our absolute discretion permit
or accept.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Security Deposit shall be maintained at the same sum
throughout the Term and shall be repayable to you without
interest, or returned to you for cancellation, after the
termination of the Term (by expiry or otherwise) or expiry of
the Banker&#146;s Guarantee, as the case may be, subject to
appropriate deductions or payment to us for damages or
other sums due under the Tenancy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Rent at the discounted rate is increased to the normal
rate, or Service Charge is increased, or any deductions are
made from the Security Deposit, you shall immediately pay
the amount of such increase or make good the deductions
so that the Security Deposit shall at all times be equal to
<B>one (1)&nbsp;month&#146;s </B>Rent (at the normal or discounted rate, as
the case may be) and Service Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If at any time during the Term, your GlRO payment is
discontinued, then you shall place with us, within two (2)
weeks of the date of discontinuance of your GIRO payment,
the additional sum equivalent to <B>two (2)&nbsp;months&#146; </B>Rent and
Service Charge, so that the Security Deposit shall at all
times be equal to three (3)&nbsp;months&#146; Rent (at the normal or
discounted rate, as the case may be) and Service Charge
for the remaining period of the Term.</TD>
</TR>

</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Mode of Payment</B>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Your first payment to be made with your
letter of acceptance in accordance with Clause 3 of this letter and
the attached Payment Table shall be by non-cash mode (eg,
Cashier&#146;s Order, cheque).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Thereafter during the Term, you shall pay Rent, Service
Charge and GST by Interbank GlRO or any other mode to<BR>
be determined by us.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You have an existing GlRO account with us, the limit of
which has to be increased to cover all the aforesaid
payments. Please write to your Banker to authorize the
same (&#147;<U>the letter of authorization</U>&#148;) and let us have a copy
thereof in accordance with the Mode of Due Acceptance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>However, pending finalisation for the GlRO arrangement,
you shall pay Rent, Service Charge and GST as they fall
due by cheque or Cashier&#146;s Order.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Authorised Use </B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall use the Premises for the purpose of <B>manufacture and testing of
elastomeric microfluidic and life science instruments, including associated
research and development activities </B>only and for no other purpose
whatsoever (&#147;<U>the Authorised Use</U>&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.10</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Approvals </B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Tenancy is subject to approvals being obtained from the relevant
governmental and statutory authorities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.11</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Possession of Premises </B>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to your acceptance of the Offer, keys to the
Premises shall be made available to you within the period of<BR>
two (2)&nbsp;months before the Commencement Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From the date you accept the keys to the Premises
(&#147;<U>Possession Date</U>&#148;) until the Commencement Date, you
shall be deemed a licensee upon the same covenants,
terms and conditions as in the Tenancy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If you proceed with the Tenancy after the Commencement
Date, the licence fee payable from the Possession Date to
the Commencement Date shall be waived (&#147;<U>Rent-Free</U>
<U>Period</U>&#148;). Should you fail to so proceed, you shall :</TD>
</TR>

</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(cl)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>remove everything installed by you;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reinstate the Premises to its original
state and condition; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pay us a sum equal to the prevailing market
rent payable for the period from the Possession Date up to the
date the installations are removed and reinstatement completed to
our satisfaction,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>without prejudice to any other rights and remedies we may have against
you under the Tenancy or at law.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.12</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Loading Capacity:</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>(a)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Normal (Ground &#038; Non-ground) Floor Premises</B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall comply and ensure compliance with the following restrictions :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(al)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maximum loading capacity of the goods lifts
in the Building; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>maximum floor loading capacity of <B>12.5</B>
kiloNewtons per square metre of the Premises on the 02 storey of
the Building PROVIDED THAT any such permitted load shall be
evenly distributed.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You shall therefore, subject to our prior written consent,
provide at your own cost suitable and proper foundation for
all machinery, equipment and installation at the Premises.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>2.13</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Option for Renewal of Tenancy</B>:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>You may within 3 months before the expiry of the Term
make a written request to us for a further term 3&nbsp;years.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We may grant you a further term of 3&nbsp;years of tenancy of
the Premises subject to the following :</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(bl)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>there shall be no breach of your
obligations at the time you make your request for a further term,
and at the expiry of the Term;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rent payable shall be at a revised rate to be
determined by us, having regard to the market rent of the
Premises at the time of granting the further term. Our
determination of the rent shall be final and conclusive; and</TD>
</TR>

</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="12%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the tenancy for the further term shall be upon the same
covenants, terms and conditions except for the rent, security
deposit (which shall be equivalent to three (3)&nbsp;month&#146;s rent and
service charge instead of two (2)&nbsp;months), and excluding a
covenant for renewal of tenancy.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Mode of Due Acceptance</B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Offer shall lapse if we do not receive the following by <B>15 August&nbsp;2008:</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Duly signed letter of acceptance <B>(in duplicate) </B>of the Offer, in the
form set out in the <U><B>Letter of Acceptance</B></U> attached. <B>(Please date</B><BR><B>
as required in your letter of acceptance)</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Payment of the sum set out in the <U><B>Payment Table</B></U>
attached.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A copy of the letter of authorization from you to your Banker.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Please note that payments made prior to your giving us the other items listed above may be
cleared by and credited by us upon receipt. However, if those other items are not
forthcoming from you within the time stipulated herein, the Offer shall lapse and there
shall be no contract between you and us arising hereunder. Any payments received shall then
be refunded to you without interest and you shall have no claim of whatsoever nature
against us.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Rent-Free Period</B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As the Commencement Date will not be deferred, we advise you to accept the Offer as soon
as possible and to collect the keys to the Premises on the scheduled date in order to
maximize the Rent-Free Period referred to in Clause 2.11(c) of this letter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Variation to the Tenancy</B>:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any variation, modification, amendment, deletion, addition or otherwise of the Offer shall
not be enforceable unless agreed by both parties and reduced in writing by us. No terms or
representation or otherwise, whether expressed or implied, shall form part of the Offer
other than what is contained herein.</TD>
</TR>

</TABLE>
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Car-Parking Scheme :</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The carpark for <B>BLK 1026 TAI SENG AVENUE </B>is currently managed by <B>P-PARKING
INTERNATIONAL PTE LTD </B>and you will have to observe and be bound by all the rules
and regulations governing the use and operation of the carpark. You are requested
to contact :</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>736B GEYLANG ROAD<BR>
SINGAPORE 389647</B><BR>
<b>Tel: 67494119</b><BR>
<b>Fax: 67493689</b>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on your use of the carpark.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Electricity Connection:</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon your acceptance of the Offer, you are advised to proceed expeditiously to
engage a registered electrical consultant to submit two sets each of electrical
single-line diagrams and electrical layout plans to and in accordance with the
requirements of our <B>Facilities Management Section, Operations Support Department
of our Customer Services Group, </B>for endorsement before an application is made to
SP Services Ltd to open an account for electricity connection.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Please contact the Facilities Management Section at <B>The JTC Summit, 8 Jurong Town
Hall Road Singapore 609434 </B>for their requirements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To guide and assist you, we enclose a <B>Schedule of Statutory Controls for
Flatted, Ramp-up and Stack-up Factory Customers.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Yours faithfully

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">/s/ Daniell WONG<div style="width=25%; border-top: 1px solid #000000">
<B>Daniell WONG</B><BR>
INDUSTRIAL CLUSTERS DEVELOPMENT DEPARTMENT<BR>
INDUSTRIAL PARKS DEVELOPMENT GROUP<BR>
JTC CORPORATION<BR>
DID : <B>68833405</B><BR>
FAX : <B>68855901</B><BR>
Email : <B>daniellw@jtc.gov.sg</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ENCS:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;x&#093; Payment Table
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;x&#093; GIRO Form(s)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;x&#093; Specimen BG Plan</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;x&#093; Specimen Acceptance Form
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;x&#093; MT No.&nbsp;27.09
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">&#091;x&#093;
<B>Schedule of Statutory Controls for Flatted, Ramp-up and Stack-up
Factory Customers</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif"></div>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>PAYMENT TABLE</B></u>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>PREMISES
:
PRIVATE LOT A2045701 UNIT #02-3536&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BLK 1026 TAI SENG
AVENUE TAI SENG INDUSTRIAL ESTATE SINGAPORE 534413</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Amount</b></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>&#043;7% GST</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rent at <B>$8.00 </B>per square metre
per month on <B>193 </B>square metres
for the period <B>1&nbsp;November&nbsp;2008</B>
to <B>30 November&nbsp;2008</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">1544.00</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">108.08</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>$2.25 </B>per square metre per
month on <B>193 </B>square metres for
the period <B>1 November&nbsp;2008 </B>to
<B>30 November&nbsp;2008</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">434.25</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">30.40</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Total Rent Payable (inclusive
of Service Charge)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">1978.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>


    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">138.48</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Security Deposit </B>equivalent to
three (3)&nbsp;months&#146; Rent and
Service Charge (in cash or
Banker&#146;s Guarantee provided in
accordance with Clause 2.7 of
this letter)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">5934.75</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Less:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Equivalent of two (2)&nbsp;month&#146;s
Rent and Service
Charge (<u>re</u> GIRO)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">3956.50</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">1978.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943225.gif" alt="(JTC Logo)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Stamp fee </B>payable on Letter of
Acceptance (which we will stamp on your
behalf)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Note: If the Letter is not returned to us
within 14&nbsp;days of the date of the Letter,
you will have to pay penalty on the stamp
duty which is imposed by Stamp Duty Office
of IRAS.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">192.00</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sub-Total Payable
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">4148.50</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">138.48</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B><u>Add:</u> </B>GST&nbsp;@&nbsp;7%
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">138.48</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Total Payable inclusive of GST
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">$</TD>
    <TD align="right" valign="top">4286.98</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="f39432a9e3943230.gif" alt="(ALLOCATION PLAN)">
</DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943227.gif" alt="(fluidigm Logo)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">12 August&nbsp;2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">INDUSTRIAL
DEVELOPMENT (HIGH-RISE) DEPARTMENT<BR>
JTC Corporation<BR>
The JTC Summit<BR>
8 Jurong Town Hall Road<BR>
Singapore 609434

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>Attn
: Daniell Wong</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ACCEPTANCE OF OFFER OF TENANCY FOR THE PREMISES AT UNIT # 02-3536 BLK 1026 TAI SENG AVENUE TAI SENG
INDUSTRIAL ESTATE SINGAPORE 534413</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We refer to your letter of offer and eStatement letter, both
dated <B>1 August&nbsp;2008</B> for the Tenancy and hereby confirm
our acceptance of all the covenants, terms and conditions of the Offer and the eStatement letter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are currently on GIRO, thus we enclose herewith a cheque for the
amount of <b>$ 4,286.98</b> as confirmation of our acceptance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are fully aware that the Tenancy is subject to necessary approvals and
clearances from the relevant governmental and statutory authorities
(including but not limited to Pollution Control Department of the National
Environment Agency and the Public Utilities Board). We shall be
responsible to obtain and comply with such approvals and clearances.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">/s/ Yow Mai Chan, Grace<div style="width=25%; border-top: 1px solid #000000">
Yow Mai Chan, Grace<BR>
Managing Director
</DIV>
</DIV>

<DIV align="center" style="font-size: 7pt; margin-top: 18pt"><B>Fluidigm Singapore Pte Ltd<br>
Block 1026, #07-3532, Tai Seng Avenue, Singapore 534413 WebSite:
www.fluidigm.com Reg No: 200311994M Tel : 68587316 Fax: 68587311
</B></DIV>

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="f39432a9e3943227.gif" alt="(FLUIDIGM LOGO)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt"><B>For
and on behalf of :</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Fluidigm
Singapore Pte Ltd<BR>
(Reg. No.&nbsp;200311994M)<BR>
Block 1026 Tai Seng Avenue<BR>
#07-3532 Singapore 534413<BR>
Tel: 6858 7318 Fax: 6282 5531<BR>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>


<br><B>FLUIDIGM
SINGAPORE PTE. LTD. :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt"><B>In the
presence of :</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">/s/ Tan Suan Hui<div style="width=26%; border-top: 1px solid #000000">
Name of witness : TAN SUAN HUI<BR>
NRIC No : 50110335J
</div>
</DIV>

<DIV align="center" style="font-size: 7pt; margin-top: 18pt"><B>Fluidigm Singapore Pte Ltd<BR>
Block 1026, #07-3532, Tai Seng Avenue, Singapore 534413 WebSite:
www.fluidigm.com Reg No: 20011994M Tel : 68587316 Fax: 68587311</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>f39432a9exv23w1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Consent of Independent Registered Public Accounting Firm</B>
</DIV>

<DIV align="left"><FONT size="1">

</FONT></DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report
dated April&nbsp;12, 2008 (except Note&nbsp;16, as to which the date is
September&nbsp;16, 2008) in Amendment No.&nbsp;9 to the Registration
Statement (Form&nbsp;S-1 No.&nbsp;333-150227) and related Prospectus of Fluidigm
Corporation for the registration of 6,095,000&nbsp;shares of its common stock.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">     /s/&nbsp;&nbsp;Ernst &#038; Young LLP
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Palo Alto, California<BR>
September&nbsp;16, 2008
</DIV>
<DIV align="left"><FONT size="1">

</FONT></DIV>


<div>&nbsp;</div>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>f39432a9f3943216.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943216.gif
M1TE&.#EAG`%>`-4F`(>/ODI7GL/(W]7=[1TMA?'R]WZ8R&ESKM/6YZ6LSSM)
ME>+D[RP[C5IEII:=QDI7G<+'WJFZVGB!MK2ZU]3<['Z8Q]_F\5Y_NF)OK+_,
MXZ"OTG.0P[&[V?7W^X^CS:F[VFF'OI2JT8FAS%-VM?___PX???___P``````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"8`+`````"<`5X```;_
M0)-P2"P:C\BD<LEL.I_0J'1*K5JOV*QVBQQYOV"O@4LNF\_HM'K-;J_#\-'8
M3:_;[_B\?K^,A^=\@8*#A(6&='Y@@(>,C8Z/D(.)7XN1EI>8F9I.DV*;GZ"A
MHH:=<J.GJ*FJ9*65JZ^PL;&MLK6VMZ"TN+N\O82ZOL'"PVK`Q,?(R5+&RLW.
MFP@.`-/4U=;7V-41V]S=VQK9UL_CY'H%``PEZNOL[>[O[B3R\_3R$/#MY?K[
M:PX$^``#QJM'\)Y`?@@39BEP0*!#AP0+.E1(L2*4``\S`HQ8SV!`BR!#&I&@
ML>0[CO0\`A3)$J0`DS#9H9RG$E_+FPHQQHPYT]Y$_YQ`R[W<R;-G37A!DSXC
M211F3Q)'WRF=FDQ!4Z=&?^X)-VT!L@1<O5(-=!7KS*CNR`(4@$PG/+9C^90U
M^11M/KEKV^:-NT>@`@&``PL>3+@PX`J($RM&[,'P8+7XX!)S^TXR7SP"`Y1A
MUBB@Y3P"N"9(0]G=9Q.APYV^;"7SYDZNL*3F2IN:9<^!``#4C*9TN].Z\0%@
MO<4U*]A;$C28JV[X$-Q\@L/C?<8W.^``G1/'8IP+YRD"TC%O3@3ZUMVD]Q*1
M_D[[]M8!J6_Y'B7!>';NS>MA[TY^&>OK8"?<>]S%]]HDL4%AWWWKY*?>?NCU
M]J`0_+7C'H%3=#<?<E44\/\/@^0]-R$>%;+C'QD`JB,@/!=B&(6&6M#GA`,@
M-EC>B'>4N,Z)7*18PHKMN5@%C%G(V,1R-9;@8&2Y15C=B#J&**041&)A)!,^
M_NC8EH&))81^H(F6'I-%S(;-:E,R4>455RZ1)1=@!N,CFFG":>!Q"%KQ9G$X
M]C)GG55DF:1`=6EEQ)Y:Q.G+GX!.(>B@&V5U$!*(9J&HGWTVZB:D.Q4ZZ1&5
M%D@F+`A,<(T`!1#!:!H(""!--0X(X.4="PC6H6"S/LFI62C9Q4X2H5X!IIG7
MC-;$`K090:PUQCI1@'(?PL/``0B8L.H0RU9#9Q$(2"`H`0W$NJ6VZX5UQ`02
M6.7_#K@.I+H$`@``J(`$U2K1JKL7[<HK1[ZN`^Q'?(Y*H9-+#&53$5&6P.,1
M!4@0K4,!J/N6$0FW6$0!#H@'XI(3#W&.Q@`18+$0"4@<7ZY"^$.`50?@V\2C
M^K;C*<"@TFSIA`DOK*S-`^.C\WH/SP6D.R,+,4'0#')<V1#^E*2`RR9,`+)#
M!-0[Q`$$P+5``P1`K03,,:\S\TJ4\BPLS@0K83!2"*=M!`(FCS>TA4DTQ*G2
MIIFP0-P945<`DB81X.5+".@40`$!'/`$V&&7,/;!-9.=*-H^.[&V5&U7GH0`
M2#,W-WY(V'WWC9$ET'E&HR$P=4F*"W&`X@$`4,"/$Y2P_WCC&3W.=N20WRRP
M"3E;;G;P2"R8Y.<VCA0SWNTP#H\"QA/E;NS6)BZX"258O2GN$$E:8P#@AR_^
M^.1K_R7ETPDO^1#$OWWZNN&O#F5V.PM$[1#=OD^_B-R;9"SUX&L``TPP.Y25
MK7\!T1T"KV,$,+6O8,-S&P'UIPX"T.MB"7@4\J0TA"PIP'Q"V%M`#D"86<&$
M`0X0B^EB<C_4\(UN)DB7M627O00,T`G.BYD"%ZBB!J+O'3\CPN72DKGT&0%P
M^&B`UXA`HSA5C%L!Z5H2"O!"=AB0?P\A@`,H9I*6E2D@#0BA%B4PF@.8KF@C
M(9\:!4(`-;KQC>2C@!SG2$<Y<O\`CN'#W6D<*,$C#/$NZW%;[4;8A(3]B(L#
M8F)`FH6$/[)#`DK0B!*/L`"-_`4)\MO1$$Q'0@%PL@QKLD*;L->X/?ZP/^KK
M7<^,2(1,KJ-U3$"`$_<W!"2ZXX9+J*(Z?I:1+28A(UX\("OU=H``,C)@FO,.
MAY:@1Q_^[H%JBV`RA>#(=3!@B4B892([V,<B,$5:D60C"(OPJ&,B<IAL"&45
M1MG,(O!QFM%<WRJ!6`31P<.<X?P=\&@I!!\%<9ZWS"<^GH:E*(ZSB/2D@SJI
MP,Y2.K-C[.OF%^6Y3WCJCP!1N!9`8<A-?.!2";I4F$#?$<SM2>N@"$6E0N^D
MS#P%RC/_7'*,U]Z)SLU)<YBR!`@L<3B_;;KN4D.HI$Y'FK>7\5,)T%S#0J<P
MRG]1%#[/E*@0;YI0DBTRHSUE41&B]PZ"(H&*5_UEILAYU"0D50U+7<8R'64V
MJ$)THR9*Y>XB.DU#;HMW2TLI1X4PNX`HP("(BR(SQZJJLB+AK&E(:Q2:*LRY
MBNJM%:UI(ZFJ4K@R,%_Z?&(]V7C!$`*`@B7PI5CUV5BB.0&Q:%`L%!B+5\Q-
M+JKPM"E%'VA7K&:VK!X"T3^!2E:?(E6JH&3IAEQ*A6"Y-:]TE:P?*=N\0`)D
M`K:%;&2#5+_Q>)6HO^&I;\T*7#*H]@FL/51;AW3*YC:!JT1T_^XP#8G&UF97
MKZ`[`GJ)<K@F\+:PVSUL=^VTW]6N50K&)2]LE;O53R6WJJCQ:W21>V#3(N%H
M96DOZ:1;VKW^-K95L,``-LSA#G/X`2`.L8A!C`$/F_C$*.YP>'NKRK,-&,&A
M,Y1E=TF$O@+DBD@(Z0:5I(2_$>4`.#["?3NJU4+VEPD&*,4(GA(!)3OYR0G2
M;HN/6]0&FQ<)(I3Q="LKA)"6((Q.L">#9\QC)2S`E4E,`#:Q>]F"YO<(J)5"
MDDO!Y"?;^;\+=JWO()NPCQ8!P@\Y)XR;"!!\&D',8]ZRA6N,Z`JJ$0"QHO)[
MW5QD)L0Y"G/N1)WOS&DX?$!/XZ4"3?_A@3*&E$307)Y@%+?E8X'L>&2?A8<$
MUNQB"KLWOI8^\A(R/8E-=_K7(Q@`J)\J8#X3TF.Q/C5\-;EL"WGM'*#M8;/+
M3`2XP2-KB24LD:F;:PQ3@=>)\#6P[PR"*P18U!.:;_.F@;68H/K*'D/S.@A@
M1L`XH-T9>36WWH?2U]I:O&]^=URU`&X_B'O<3\Z`N4.=H0D)M2D4%#BS)PHI
M?7M,?Q/H]V,376%<+^'24"AX'`Z.\%)L``OG;K@^<]B\0;88L>J6F\0Y2.C[
M,"!V&A]R/PT+9UTK0>1P('G)$W$!"Z"<X50:434=,IREVV[:.HOY0XJ956XK
MFD$,@&XVM;W_\X!#?0M`#X/0AQX'A1^=V.@F[3<M62^GSURD20!T%ZU5=0=;
M=5<[G3#';YV\;A-8SDH>.]F_<`%A9R'E22>M"6HN$`8PTNU?[W&C0^9+C5Z]
M[T*P99(@^="]`[S2'_=Y$L(.!L$/7@0=V`+B7Y2I!>`[S=5U[.5IS`37@Y8!
MLMMVE:WL<0I%^RH@U#G=O:Y>&%N!]%\P/<(O$`*C#\-5`&A`^*9QUSL4`%T!
M>%@;`:#Q,SS+RU?A/#(TG.(/C_C\)2Z_^LOO?$V=8NVZK<AWW>^++#<OIH)!
M1\CD+USZ.P,!G7--4A!2_"=Z_E<+``@/W7<$FC=Q"3%_!U@+"W`ZGGGG!`]'
M4@7H;1$H)_BP@!<34H96#A"X@:]P@;O7!*H#$'Z&$"-(@JJP=!]D@9/'#B$H
M@OWG@K[@="700@\V@^P`9AGX=SAH"SG%1K%3#0<`?NMP7131@D-X"BSG-+2F
M#T[XA**0@)O'$E5HA:&`A?=Q25IX@URX"PL0A<]3@V.8AHT@``VH$0S066H8
4AYFP`,HA;^S``.'B@7(H!4$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>f39432a9f3943218.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943218.gif
M1TE&.#EA[@*_`_<``,?&R"%">I>IR9&.CM:MGTE4;IBGN3-'>&]L;.CHW+JY
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M0]#.S.4E+#`Y4G^HNQ=$AEHY7&1JFZ>;KB$I4\:]P"E"<)9I6(JSE;;(J!V?
MVT(P+&5#.S9CG/7W^$AEACQ3>8=425U99\3.Z1P5%2(I0B-*E+:MN7IG@+A9
M3:["Y9(W3#U,976T>B$I<Q@I8];.V0@A0Y)'/C=P;LS?\][GW5=\N6=8C):,
MH^%$.J>XJ!=HLB<A(!<8'VN4I`M4HX]A;2TW>EMI7'9JFC5*E+<R.XN]T??W
MZ:S!>L[6S6J4MJ^MQD!<ID1WF];>]RE:9BE2<^?>ZA`A2CMY2!<Q2??OXI2"
MLQ@I4GM:H>?GYQ@Q8RPI63,H0!YOFQ@84#^'PA@I6B%*A"%*C!`I4B%"A#DK
M:A`A0A@Y:RE:G-[>WBE2E,DT.2$Q8RDY8BDY:STK<1`A4M;6UB$Y8Q@Q:][>
MYR$Y:R%2E"E:E.?G\._OX];6WA@A2M[>[];6YRE*@A@I2M;>YRE2G1DA6B$Q
M<1`I6M_>U._O[][6UA@A4M;>WBM"C"E*C"M"A!DA02%"C"HQ8Q@I/N?O[];>
M[Q`I2A@Y8BDQ;][6Y];>UM[6WA`I0IVQV>_GYV*$F-;6[^?OYC]!0$6`=!`Y
M:R!<E*&4PA`Y6N_W[____R'Y!```````+`````#N`K\#``C_`/\)'$BPH,&#
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MLMK=R]=/GB_WM.6-]Y]Z8@78GED")M?==.SU1QYZ6F$5WWGH3<??7`%:2-]^
M"TZX77$.GB8?AA7ZIZ%[(>K777S[S?6?AO")=R&+_7U(''L)<C>B6*_5".!>
M4C%7X&PF`I@ABM]M6"*(%OH7)'@MEA5@A-D%*563."))&7R5S29>@QB^EQIZ
MX45YWF^3>7FA@0^]6"18<#+X('56EC=;8RN>B"!<:0:67VWV:29B:(&MEV:@
M1\KX)6',22CC>;<MB.29]$D:YX9;/@FC@X[2"*6@Y!&JJ'<1\JCGE>:)IIA?
M:O79Z*ADXO\W6H]"PNHDK'*]>>JBJF+Z*:QT3LDE75AZ1NRAC\57*J_X`?@8
M@LN&&MYI@.5I;&BO^I;>ILP6B>5N]#V$8IR7RGFF9@)""":(E(X+[67#7B@M
MI_R9>*M]=LY(9G.0/BK?90"[I9N_J(6Z)*((WOHBB516.Z[!\28HI[JZHOJO
MNE+::]ZD\]KYZ(,;?PFGP7A)[&*I\`XJ,H89RYN>LPJO6K"3"U\'<)-:QCJR
MA@5#2""DY\;J5\KU_ANR542?#+3/#7\WL)3[+BQKT,I1?&3`$G+,,J4L7]7F
M@\J.+.G$8%DW;)RIFNH<CZEB=25=:OJ[Y=`GCHW9V#H>=J>Y-[[_O6?=$_LM
M+)6(S3HTR(51V/9N[=9:Y]'K5IEDEQ&[7&NY%NM';*XDWJ@=X%/F[:5Q"5L=
MVJ8>VD4@N"H>!KB6UMJL)Y`V9PXZO-)R6.FN8)>^I[N-AVH[TK;M[IG==A_.
MX-W<"ENLZ.6):SJ#M0L=<[$8*PKC:CVJ:V/UVZ?5/=J!+ECWQM?[F?;$+)^<
MHV*U[XS[][G79W&%HNT,>8$^1Q[A6Y)[7?9@1S)$L:U?26O6AO07.O^1+F?B
MRUK@)(>RV"QM?Q+4''1:Q$#$V>Y6R\)?O0Q&.8HYBVR+P9H*H2:OSP6+A"TR
M$(<XU3/U48]^(`1/9[RGN*U\+7'I<E8(_^L7N,G]27S_P]?L/K4T++$E6HK;
M&PR_I41\X2DRYIMB$?>F)PL1+W/*VASWWE4YOED)AH72FV^N^)8H98B!1422
MC4AHOAHV#RQHU-[*W`)`(Q4G2UTTX!&I."=!P4V/#GK;$(&V0=7E+UX]]*`4
M;T:O=7T)B(5D'2`CQ2\;;7)`X7LA"MFVO2Y6$"O2DQL*1=@H[=00=\EA&F>T
MQIHU18LTE>S2"/O&&6H(+6>*HR,M&;4QX5&0?:5ZF"6I-L=1,6E"+K/?B<"6
M*F9BD(2W89KWZ-<KM?1-@-D#X6"2U3$\OHZ!3O(E',>"3`02DYW#*=!MC$F\
M<9)N=A[\&'(PAO_.*1;*F^7,6#.]19S]80V@R/R+G"J#2"2&+IN.U(W7'/(D
ME.$F=12"42"'%;$#+:]JJ_N@!O/&T9)]U'`O6YZ,^#@G?=Z/8;^DD;5BQ,G]
M(`Y[$X08D5(*L3:R\:3$6NFNIF<QDX(LI.;Z7R5')S!T4;!Z+H3AJS:'2$@)
MKYTX^U7R;GJSI.:)6YE\F3E?]$6G9=)\;HR1`=/E,9D&<DQ2RF;)M/@_O+`H
MI4C](/7FI1Y>38YGWI%A5*2#**O^+8<YXJ@"E1G'6'&JL;@C7S-MB+ZPJ@9%
M]>%GLX+7+W;^KGCY3-]X(&BRDL;S8!H3EMB&Z:835C*K\H.H.1U&H=K_7A-B
M]HOD4%4S*CM2I48YQ!I#^;?)]61SM,*=7QY?AMM0*C6.-<3L9"_6NK7*M6-^
MNB35ND/`XD&36FX#J_M,AK1&]L>74YP?6*1'4M>Y!J:__2C-@./%G34'GBMR
M6!\]]D]3HHU4$T2H1'G'-U^YUY-"FNL^)<77#0+V-]'4)#W[1LU*%2V$\$2,
M1+NG+XOZR+,')A19GR@[U=&7/L<;8&9BF;LV-K9^K\1EOZI5WP7*&,;WA=9?
M%&F\5_[Q1[&$:X9V4]TT[M>4^'WQ?R;:$"0G4H^IH1E0%2I>6N(*2!D>JF'R
MV,&_LD9YV,05(/G5F+2-L[O-]1Y$;9-/^AX7_X\P:]OQ0,9E+;T9,]J\:M5>
M?-E:.CE+DHD+0HWU0.$26-!+'B@PD3A+LR(LCT`6T7TCN.8P'W>Z\Z4SF[&K
M/6S:D[31Y-Z7O8C/TKG9OLOJ,OL&2U%0C@R-\E,S'2N4%?2JB618K/3JJ%'6
MSV"9DVC)9*6O&L8O)WA*VKJNDQM-(/0FJGZU'-N5P*MI\7KV5%[AM3>GXTMD
MLE@O!N.UD%XZ:Q=O1=Q*Q:RTUXTJ=-.GVXMR',_.7692>PJT)-6V>UM<:5(G
M,2K.ON5F>G5I+PJZ+P9N,[(7`^)E?_G#M@;L<4=XR]Y%&\4S?>_#^\7KJJ#*
MS92QN+@!2MB;IK>E#O]UE]%68>M^CR69!D_H8`(.44J#^-*5[39H7LXEG$\\
MPV`)>(9#9L[/PB4N#Z<U5+3-<X0"?)_&3KID!@V;&0M/TXF4^L'YPO1Y8KO6
M4!?9FJ]--/0BW<\0NOH6K3+LH=/+GXP1^MB][O&8XW.V"JWY-.T-VU'SYNU_
M#DO+A\Y.>W[6S@</*+?5OM*9`[3MV[XV$O6=]TLFTX."IKN&VI2N&;_K222U
MU`#?2_C[A!@TY&'Z+RA/U<RA$>ZE:=3.HTX-O-5%C5OVJVSA:4B"DRJND)G/
MH+,,[$BUI=Q)WSL4K\[=O%+Y\LI:XZ$E/V`PIMV9#C=X?#/%3M7K.L#@_HW_
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M1F\?QSQ'R(`%-5R/IW5P4VO<AX:_Q5T]9P[`YH!X_W9=&K1ZH$9\?Z@]>,2(
MASB(BFAWMX&)3[12>J:!TV:(BMB!DKASDG>*?X=Y0H1U@@@MA%AX6_B(_$=J
M2-9QTW<M+>9%GDAX40B+^E-Q5YB$?K0*GLB"CR=4A"2)I:@6J80C:2=-%JA<
M8?B%.=@]N%@H%)AWB_9T1"A70JB#W<ARU6B%Q#B!#9.-?:2$E,45^I9&*^B+
MZO*.@>>+MQ1T%4B'U:AY-=1Q2KA]X8B.-I*-+O>-<S9T[PA[_M9'!<-R.M9F
MO`%-I\A;(B@;=4%YR4>,=7A\,^>"YNB-``5GZ$&0>T*!PR9;2H61R9&#&_<9
M+WA&6[A!>)20R&&`:!-)>O^G(PN#@]O'B`12A7/2=2:'A0NU?4J%B1I5@D(D
MA<LCE.51=R%6;"JUAWJ7CTY6<*E8?I)X;<$7CDU7?-Q%>BMF@[8(B%=!DC7V
M@HO'=^Q8>VFY;=4&B09WEI+D=$48;Q[)A,5HB^)8?Y_84DYY<V/A?>$U=HM'
M?MQ(9]$G<!'X>**G9URB<\I(CK\#E9>TE8#E=JJ'*WI(;#+BCSZW8X7D3UJ!
MD8&T"NRU:M?WDA\"D"%X5'O9<R#BD`"W/S<U@'#V6Z6)DG#Y(72W??@XF+,G
M7:,EDWY'>4X8/K-E3R))EW*$@4_93$4(FE/(4<5)@%^)G$1)=K\)@\*I;![X
M9*3_:8AS1(1BEV[7:8AO!XC1R9+"XX\80WZ?1D&AHIWIQR5X-U9)9Y_0J9MH
M5I_Y*&349'_?R)^AF2#%5#D.:6=VV)ZC1W^M68FR.4>Z:2'PV6CBLGNQYF^<
MI).X=7P+.95X""\-JI%N.**"6995Z8,JJ**]N7MDR(3G1Y3;&99UEXI@&(/[
MMF)+Z:)#QV!I>$ICN)V!`YEQ.8-<J7'&EX9F@8M"*"\?ET6NZ(C35*%"ZG&O
M9X[,=Z`UUX,,%I8I2GA/BGD?27[%EZ7SUWPWUXP]6*2;R)[QF(^NMX-P2F\;
MB7EJ>G`7R*$G=1L&^#?E*68#LH\WE$/S!&=+):?BF(Q^_T9M$J@J<SAJ^1&G
M1W-Y$<B24OAW>]5(`5FI5':#9_:5`NE_XAF0"N6$AG>#^VB"21AE(KB@@MF!
M6,B@GU:1#-IV^W>./_JC&T>J2'AF#&5"*[I?O"FIEAJ%"!B.3OB2E7JH:">2
MG9IWS=EHH/JJPQ>CFE>MB^IU]F2`W-IKO`=Z2;1T2AE`7LDH.$BC2?9R6Q)?
ME&A^>JIL3:>2I"J6QO<S[-ITK`,=+`2"=OA<C3B'LNAS9%JE5FA55$&0H<B*
MK:*86]F*EL>3R!=FA5.+9%F5=E>'!MNHL+B=&=FI?16I,7B7\-BO<(ES28J#
MM':FM7DJ=&:>^(>E'_N-+QI,R_^JHWV*6<_Y($+IBC]9?RM;A``+CG[J$&)J
M1J$:0<'H=#(XB]Z9='@G70VXK!O)IZBJAW.IJ!M(AEFWJ,!Z3P4W6Y@:@ND9
M7G'4I;,7B#;8I0(&M3-;IK,:+US81K4:M^DIM0S)A:/JJ:(8KEXIMH\*&+**
MCBGG<F7+MEMVM3#7J0%[6Y%!B%V+>'3[FIDG?JSILA7(MU[HMD9:>,CHK<Z*
M91PZAPJ&MCRG/Z7(?/!$<XBI=W,)ICE(D*G+L)#A+#0WA5?BCVRJ=3.+>KI9
MH9XENZ-+I_QGK7$XE\YD*3V(L1K+KO[Y1+O)B;7X@Y`FJEKJI@N)L:]9I&3J
M=X%!DQS_6JO9:Z1HAZT6.UQFJ;8,>ZAB2IE?J:^DQ[YL.Z;SQX$DBR`D.:M6
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MPUBU0JRWOGS#<@>/TEN.K>S#:XR$4IR$<<S`76IVSBRTGFRGMBK+N/2DK`MY
MT3J"X'S$SDRCE!F%8RS#!"R/\PN#3%S/&OG+Q-S,;MR#<A>3[QN/U^S&8TJ#
M\5R&1HO'S;'"H)FVS@JI&8S%!WW0S$K$X9I-]/K&&*W'B@S!=RK,=*>PW)RC
MV$R_D[RMC`S29^?-_^N=3EK%F?K)SO_YKA+<P3JZJC-MJT_KJY%LT3O\R@/L
MTBVKPG<JJQ6]T?(\Q1IMED#<T6J,MK+,TXA[N_H,T?"\P:&,QZR1RRG]QV[<
M<?T<IXX(LS8\Q*MZUCD<RPF]UA\\;+8\3?O(RTW\U3A]U$1LS#=\=H;\S3U\
MR<C+TG?=UW\=U"&HCE(]R7J[H%6\UR[=Q*R1SFAWR9'MQ+7)UP3+M1A,V1R(
MLU>-PMZ\V6F-S8)=R;@[3\0LTS]=Q!F<UI7LUZ>ME$3-Q-1@D_4*G8W=JL.H
M,A7(NF^]R]FJVGO]<`39S@:GDK\-DJN`#?_<UI7MT5Z'#7.L%LB]UNH)<*K,
MAR)=U>[8W(C_W=CYFHW4P-S_6]U1?=E10=YMIXZ\[$N$G,:2",ZKFWG;K-V`
M;=;.K8H/"U'9J-Y(9]YY/9'+/=W\G<(/+83%_:X`OJ>PNMR=+)R#.-%..MXJ
M#.!K7=SL>YCO/<!@EQ72;9773=P2#E$?GLNSZI0^W:BW?<S,_7)F5]!A#-HL
M1]Y%O=R%K-9N_.$XO<V<;<3N2./W[;Y2W<+4#>2@B<P]SM)Q`>29R^.,3>0S
M[K$O3MU##M<M'N0PKGETO>0=6-_+6VG4P`[ZUM^O&N.DK>.47>-(3=5A_HXO
MGL]1#>8M7N/8<..YS>7`[=)T_=5M[N(0'L1A_!<4/A9UCMHW?L;#_X;FX@WG
MH5UIS+WG0B[9<GK`-#++)1W8&JRQ$1T9#VWF6D'C#^NW+*?*GMZRZ/WDEQW/
M>@R@AWG#@]G!MAPA1I[8=$GJZIK>`-KA(YW;/JS?'[WKUHW87>=]*ASHJNWF
M2OG<QIZM9.Z."'[GJ6ZAK.[J:1S7Q_[<@VWI.)VM0'[EBGW@,5[!S@WF$PWB
M1:W4R@[MGU[@69ONPRUX!5[FJR?661TA9-[1]'[G\"[M8V'B5`ZSFPO2YVS0
MTGSER+[MJ/WNO4V>:E[JR\YR[/#G1JS6CYWF%A_K%!_N22[>"-_<,7[P$U_,
MX0[R&)_P"L_9-:YS&M_Q"__G)2_<'W_D$O^_\O#\G2G?[C`?QO`)\B/_[C8?
MZ2?O\Q:OZE7N\8==<_[X\D:/].P^].$>V[T=\3VN]$;]T&,N]43_]`K=$`'K
MGRBOB_`-A9H>J?/:Z1_/X?.'X1IO\A7MXDR_]F'_WC:?ZG#O\VXOQW4_Y@\O
MY'5_&VB.N"X^['VO]ZY[]WR\]M;N<SK.\CJ_R'),]3;\Z^?(Y&8?^?'.N(*?
M]VA_W'Z-^"NLE&KO^2$.UR'?\P@_?B0-]QCNTHN?Y$.^Z(\=TY5O^?F<H2]-
M]P^4[0WMV@O/]``GYK3^S6)^^A<_])`^F%>.X\C.#B2^JOZM_(9H]>1+X8Y]
M\<Q_Y-4XWB4O\;S_AOW9G_S0#W#/3_3N..B>ONBPG\%A_O3&K^J)/^##+?[J
MZ?O$:/[&/N;^K>;C-_X0#!#45OU:M4I@08(&!Q9$R)`:MH4,)2:D]HNBQ(("
M$S;,"'$C1H(:,ZZ"R-`C0X(;2WY$.3*D0HD:-U+$)A)C0YL'#V;\F-+@PX@@
M78XL67!E0YH8=RX$&I)=2X4S_TVE6M6J1`P^6R[U23#KPH]+P:[ZJC5HRJ)1
M.;Z\R!(J3H%BQ\(<&G/@3*-T(_H46W'BVX4UA2*E6]1MT,!Q.<[%B7"I3;`Z
M_XY]C'CFKX,$V2E>G'*SP\83\9($F=!LP<\C=UI$:;$FUY9LZ][LF7?R_VFC
MD`='3'N6J5W@G0<*OAU1]V'6+06O)DPW<^6S!"%RS3SR=^W%B7?S7?CY<'1J
MJ86__#U0+MY?)3F;+C_;[UK>@]E7)C_9ZOVJM+<B)MS5^,F%,!CKM+`:.FDF
MD43B;C3C/O.(0<P>;(M!U4CCCR.9`K-,+X$$,PLS#5E+",`+=SI0.`5=DLTY
MB!ZT+C01FYJL0M).2_`NWI++[B>2_**0I)30@A$TDRC#JSKR=`PI*1E9FM`X
M)6^BID,?H:+(/Q(1XPPRV$[$[#B#+FJ1,0P9JVC%F#HDLTP1:YQ-(2K)O+'-
M\*)4BC1L/E3NKA%QU$TR%_5*<L&_*FL2)9%.-/_*3OP:_0X]_1(JRSB8_"/+
MTKN\&XJ[_2[T[2CB=G0,L+>D8ZHW'2'#S;(IF4IMU21O\BW#Y405"L0990-J
M-2=CTP^EM$*%E50P,]ML/5G=0I:^'NE:LM0+\0*5.2>Q4W$_BX":42VH'@+A
M#%K.^#;<;\6=SC"F<+4..8R.$F]84J.KU$+`P/R5J01?W2LG6Z4U$#99"]U.
MK5V;(]4M?TVBEDAKH6T4/Z78J>U1`=G3"EE+<:NNOVCOY0\Z7W.%-CB]U@P8
MWM"VO;=A@YYZT>!^B76Y9':3'?G&W0(&[#N:.Q8N7IU7M3G>G<3B.4R@B:07
M9E&Q*020#Z*6>NH/"FG_8VB5LV-)KIQ_WM"AF8WV=&2=QZZ9PJTI_:M7K[>>
M&>N=-S:[Y+&]1NSA^_CB&M.U+QU+/?B\PI)D_Q"^M5NX134\X743YT_/I8%F
MN^^&Q%,9MUZQLS?DRWVCFW#]T)66ZTB[)G`53=\B?4?(=?-YLH4K+SKFKMM8
M`>]_[MCCZIH['VUOCQ7W_#S',Q>X[*Q+E[U(T$W_>O.L+R*SOG@Q5]XXW/,#
M>]["0<M8[3HYGJLZ+TVF5&B<LDR:)\K.-TA],U/6V,#L7$?TJ56KDY%AI4TR
MZ[WPN,I3/$N1NMRDEHW8SRY"2Q"``":4%+%O7D<YG*PB>*>.?,QDTL%46UJF
M_Z4-1J4->\!=!W9WLCMY\#`-'"#)D,87BN#O@X:S&9*@`B!%26Y34L+9Z6BH
M*`#*,(!;0U\!;8)#_E`0)$,LT2JR1Y4D;DPK"1R0WQH4.\&]K'%5I*)O?M2X
M+DJO/`0$3A=_(S="<6:'E)N(#6WEQFVIRG,58LZ+7J(_QE!OA]02F\BTF++*
MB>Q(P?E?_*YS2"G5:WQ#XE#SG"4HAM@N>P7@W>.&T[@+KM!@%UR?"POID[1`
MBF2*T<I1:)C'F^C+@*_3DV1B]\@'$NIE*>+C$I$BMR=.Q4*FZAM[2N?+C,1E
MBAQ!HO%\61&0T2\D)]G8*P'IE_`=L'VB<MV<WF?)P?^0\F5]6B;;.C0?U+6G
M,7U*E]),<Q`92N0DS&2F!84WSKQ(1XXP><\";08J6\FJ-TKQ(!-I>;RBS*Z;
MN8'40?(4GWJ.L(0GK%^9@N40#WKH<^Y$I*NX21N`229MIEKFU^S8/]C(:'_`
MJ:?W/A=-!R)&AO515C_;63>0UL4CN?P'TB9ZN*=P34#F08T:"^G*?`)S7O22
M3,F8$R>>&D9-+YL.0D)IT#^Y"IHTDEMWEGK'?R7RD3/2%O5X210:03`W_1.C
M0@(*SP0J\8@4%:1Z4HH3\0C$03U+*_TV=E8,RN:.*Q&;$N&T&NIDL$`$`<'M
M\-:!`HA.G8O1GUQ(]\_P:"3_I_>;'6BJ:AV)`BXAFRF02>MH&ZQ:E4B5U5RS
M(C(S7IK*H$-MS$-P5J:,3-:.JTG-2@"GG9?1M"CIW*7YPHE*N.J0B4&IDB]?
M\K9?H>HM^T3>6H.605E93BC(S5E3,4+=&_9O,;=E7G/G&!-TV<:6_"M;`#$(
M'PQA]R;<?6X9D\;<WQ;G@\C[H%R0.QKX;E>+,U/H81E:,NO&MFR/TF*`73B9
MM-P7NG=2KX8")C&'&%B+FY6(RU9W4ITM);][6B_6]&BM@IWW9]B@:60_BT+N
M*/=CJC3MY\HJ5#::TX\J[BV!\>(RS4@6,J;4:L-RO$4XRGAD)4&M>'N%KD0M
MKRXV_RPR\+:R6@?#EJ>,#`V.$S>YVA"GF4S+64_BVL+Q?C<DZ-3O*B3IWTH^
M.58U[C(*B1H4*RNK?:7]1>J<N46MH6ZJIST8+$<,6O%:\I]3#J9)9S@W'W]9
M)4`3"$W-.JMPHF\W.WTP23DF-N.>EG@MXYF%`TK=M]7SH!FFJI3>QA<(;T^K
MTM2S/;E5WK.R),'2ZZR(]QGJ!J4M8MH--#%ANF"Q2#B&OW8.<J4;GZ,I;9_[
M7#1]Y_LY=O3W88AM`W:+PEQFQS.YW>V-&K=[-)>E12S']F"%V;K/<;N/K=K"
ML/\$[.Q/KQIQ\J91>%,9'T=;;B/DKF(XI4@P.*6OQ="J(_^((V?=4-$/K'B,
M+`^+M*+:7K.A?5'8E,D96P7)5:[7-1'_B'.N+4OXV@(%MD2Q:CG.9#M4+<KX
MNQERK(=/L$CLWK>W"V/-9DU'4V8$;\7_DIIC$2>!UNZXESM^J.F<>=I[$+IM
M<KIS0-FEXXW3\FNJ]'3'OCS)%-%XBU^BGII7'%<=#:;)>UHR\>#UJ^?BL&S/
M/M:AI*;A)U*,Y=)>5'GVM.&@>9?>G9C+:U,N=0&#<A/K&Y.=$[?"F:8B!0,O
M&T_C%LF]-6^HY!(LFW=(B1'J+E1]OK0X7?RE%M)?N-OE)G59GI?LUA;%):J6
M=JKK,>QM6:ND9WGFD:^HH$$BW*?_KK_IF#<O%-0)B63O7,".U2EPIXN%9:AE
MI11VH;"PCDC5\[8QJ<U-.YG90R-7^Y14_O>=)\[;YNH]=H<M+X47OEGY-4,-
M%SKOD9O241+5I>U%*"[8OZ;T9,3;9]L[']D_Z""Q7/*UP2BR[MFFH<F\TGD_
M;,(&"5P_AU@J93,J\/JX^"L4H`LV#*D)(D,GDC,M\=`WHRB_*0&15FFFJ*,G
MCH`%%`0K4YNZ1S,.6/@,`20MHOHRQULY$>RUCRN,%WJ?6@D\JJ-!\J(&&/2Y
MN6N7XNNP"-/`\3,.`N0[#:,%P\(;2F)"F+"P#_2^NB,FG?@RX`O"\5,)&K2N
M$9%`Q=@M_YWPB0Y\N2V2P&"Y/02L/<LB)@U<+`[QOH#CC8830+G+JD!KO]P(
M*/5PM.@"H9O2.L;2.3YT.Y-9BG0"IEU!PE!:FMZXK4",/.A*B@7C0SPT+]9#
M+LLCD0#;E8A[.U$\N&*+B^L;0U$S$4.Q,&U!Q.XBO].C)\$(%;D++W'#M:+Y
MC%^,L#MYPE9L%@$TPC!R103TQ3$LLY]0/Z("`1+R+^ISN80+(%J<QG?K*I>C
MO_AR+4U4-;#Q/([#./$JQ5T+QXWKB+@@14]4)R0\.&1D/<>#B6Z+*W+$Q7`,
MP#MA)UC<'D7D,S<R1,XIQS^JP0&+KT84P;3KO!*DFY)PP_2C0?]2)(VC4D<]
M8SV_T\A6D["9"TECQ,-6Z\2-.3^2%*_RZ\(J1`TX"37<@SL<I)=-?#N5;#VY
MJTF1U#DRT\D?=#J8)+R(9#>W6JV&J\G%VCNC:`,JN(%"*(`"*`2JE,JJC$JL
MQ,JII$JMU,H"8`*J"<L/8(*MG,JRS,JK<<F%@ZZ]VTF3M"Q^C$5NDT,+Q*P*
MJS\B@;E1/$G&`KT.3$.U#"\UZ3@WQ,FC`SV-#+4X[,C<PSH+*D&C;+0#3"3U
M:K]>>4E>X\8-2R$&?+.N6ZK!+,GO8S>3;*JFBBPC'$J%"<;],TF5_+YS[#Y]
MC$GW`TIWVL:FPL'N>XC41+!R[#J$ZQ'_V7P3<H3'P^-&DD@P)$0J"MR[W"S.
M%I/)RC!">23-Q^.]@X"%,R@$)L`"(8@$-@A/\13/$QA/\SS/&!C/2!B#/9!*
M]WQ/J1R#]#S/\8R!0A!!X>O%LT-.$$2\_;).A@3)0&2^]2)-6%A!Q\23;GRP
M$'N-5A/0Q.3(B,''-AQ)$%Q0V)G`#`+-#K0\RRR24U2(R=(MD%!*/FM$?VLQ
MTF$[%/TM/6+*PUNPUXA(D,*&)6PURSE0>&P5`E4*&$1*O0BH`XU,[>+-"D2Y
M$$S%NTP?Z`-)5F3.BXR)&]W+SAO2Y02O*84(M]/1@M#1JBM2&W4EV;H["Q2^
M9KK1G*K+$-31_\J:#1N%B#:X`2QP@SN@*3N=BFB(A&28DA7D4X.(@6C`G3M8
M@?>@0^#POLVX+<C$TF%\$2[=%7_L+8.8TJ"4N/>Q0''#"!@$'.0TSD3ED>A\
MC!_ENYO+""^508?<C"GERURD/AHMQ#`EU9V`!47D&I&$4<*ST5Q$'-*DKPUL
MO4P%T2[,#4F\MN7`*^;AKB9E29_L'T@4-V1-"S:=R=JS.2VS-B\%&3Y]S2#,
MO0EDROB+K+LK5I.85F?5R$W</9O,UE$:4V#C0R--N(=JS7-\MI&#"!!``@;H
M@#OMUV:(@<[;%4`55$@XRK?,5.I3HVOEMEYLTT?K5-,R4Y-@.9*!Q/_94YJB
M.=;@",X%1<CDU+S@\-,`TU#$)$)+#5(1Y5$JK0\EI!(O!)L2>]!4RKK-;,,+
MF]BF2C:%M)!N0UDGS$7K^M&;%,)V=`[2HSYY+40HE-G$?(@#Y;]=[+D7F2LE
M[$]'7%(IK<>CY-*\0#D?K50'784#C54*3$9+Y<$3%$<__+RA;5FN);U=+5-Z
M5`CM9(-FX-=^O5,*B(2E5<*!Q9MO(-2J4\+36]O.6\HNK=I=K-1@HL8:)-QM
M)%>I9=J&$]HEW<#)55FK#5/E)-JLS<5B?%N(3;BS+9JYNU!X_;LG&@GI(K.H
M)<JTO=E)_4=2,XIL7,C1/=2-C4(,1-;Y:M3_%F/#1LI/Q'O'4KU4H[*<8/7<
M>Z7(=E5-$[E=76V_>,Q%A$Q#TFW%7\78D4O8=-0N(E,V$X%$WGM>S%4/$(B!
MN\U;?P58Q#6*OWV8087.Z>6_C/5/X"4JP:`NB54UX%TY_83+@*G(`2X^>D55
ME85;.9S=CNA)%V2>+V.^;Q5&QXW1`C75ZR4-111))PW(YLH^^FI89]O+PJ-,
M_-7>-`VXNC31[^O9I<K-=*1$BK/0>NW93U,C8T.JNG.]>H4.Q^3&`1U*Q7P1
M,#PK&&5A[HHK!P&JUE7B1N)(`@[B>J7=3#V6:&.":,!;]K73O9W!C(C?1@G<
MIXTZ'MX>S.79C9-B_U:U#8P,N'CKL,=X65<41"U2TZEMP=;#3*"-+NZK0F+T
M-K?K.E&DVA2V8X,HR&=;VO<UQ],<88H=8:.$Y'&$S;*U.\?"M?PRTEZK2T[6
MI\_K58!\QP-^D644X'.\6/],7`FM2W,<S7DD3>.UWD3^6:6E7M6<99L4S0#M
M8-H5S39XFBW.VW\=7I<!8_RX@X)=9;^,XZR#XG&;3KNXM8F5Y5OK"^3"4'"5
MKM8U1%K,J9HPO1F&UJ+-TCAF,+NX9K9M5&M&Y+>T2R^F*)<Y-BEID<V<W+?E
MXYW=XU#<9:;,7C]<52"4672;U5D]/1GVV58LBE6EO:621&;5958VL&63B/]'
MO=V5++3>U&>Q!4,/3M&H93>`5ENS]4-T``(M#F::D@6^35>%,.;[&%2%AN9H
M'FG1A&6E7;EUB]1=?>1C"Y5'M>&.[K6XNEWK/&*%]61@P^3"I6F&X%J+%N2\
M8.=19N-$(E\,!&6#MMKR,KWP11X0!KWKH]N3Q9/BI2>HY=D_%-:E?./?]6:R
MGNESU&GJY&41M>BWOF7U@"ING>,*CC?4G.-TE&,B-DX/],L=3-W$5=>OONN=
MY<;-*(`/0.GV]=Z(@85("%2\F=_L,S]O^^JG-F.T7JQ,)5Y1K$B(';Y=9&OJ
M').;],#E)=J:H&RX9EVM+;3D3&O&YF7,=6R@`&K_AV!G5"UK<VM95D1LG<DI
MI/5JA[#H>OYJ+;W?+LWHQ6;*590XXF;:Y]9==V9@[F[B^./H!4/3,E;K7#8(
M7HCI/9973"5BXLA2CO/:PM3?I@Y![1Y)VS8HI];>R$GNW%M0"80$69!LO5UI
MI84%E[8*F"9<7KO)A^K0^=YIQ+R[=50/+E5>[)9;HI)>Z7WGX";@\);NDO7'
M6:7PA!XX#Z]ND.[-$BZQ:Y9GUUWNUZQJ[U)&V!57?/15>_V]S8@V$.AQ$*`%
M'__Q-GC3&C;.^6K6.B:)A=Y9YQO(`E[R_#1";&B#'@?R*O=QMJ/4QTU-TRQ2
M)<_42"7@6G$Y*F'N(/V]_T8F<XA850O<<<RR\8K=Z$6V5%+$5R0X:0'/GF:(
M!--;Z`.O"F3V\).EYZ7TM,H*30C_YO*5R&LZX.GD6A:UU"A>Q^+55?(.7O>S
M<'JD5)2K;M;V<B)?=#J?K#%/9!#,1D?C&E8N6X7YU/(:N*@=8^4^7/HR4?::
MCA48`UT7@C'@]5X?`TJ:DJ)LKIE93#T+X`HE9;:]VM5<Y#XN"!`H`%Z?]EW7
M]4+(QM<XJUM-9U9,U/76UJ:NU&#39`3FW@4N,&&GRP>6R>Y2WF\64^Z3%>K[
M!2H8@R?J`'S/=WW?=W[O]W]H!A3HB+'=%0.7A7[7]\"E;W3/9EN=6X%.$]2]
MZ/_=51KE%?9PQ=AE!T*\7+^)9!%F9VDPQWA5=DT-"V!6+VY(KUB\9/%+;GB_
MCNT0QN7!-O4Z/^=>([P6[BXVP.R7QH(S,%5C+.Q-#HX;3?E];.7=YM+`@]&T
M.`,LP!LFN!I+%UMZ9'<(?QFE+]ZS/EE*7&[VZ^EDS%]+QSUT0WJ2R?I+#\"2
MN`$AP)UF4``#8(,/$,^YE_OPK/N[SWN[MWL#B`%@-TOX-,LQ8(.XIWOQ+/P"
M<-BP0?L(C7.<+]>F+M\S'EI'+>'%#L82!_I`LVI[;<>4R\923&#Y3N7/I?JT
M1V6F:G6C2'78Q%6,BZO%=B>L#CQ!CVVM+NU:;W/HI@;_`^!Y!,<"$`C%':=!
M5Z_N):[(A^K6R&?CD3OVZ*XXWZ4&IX?ZX-=0DA5-S&/)M>9&,U]>!:^MCDO4
MDJ!4$)96*5?]UK/KAM:PPEMMS13M<[?40H@$W/D`2#@#*C"&,]!__@>(,\8$
M$AQ(Y0S!@@BI,)DV+1Y$AP[C.81TX^#`C&?0$6RS:A6VCR!%A@1)K20V6")'
MEAPI\N1'=M0^MG0)<]7-ERYWFJ1)<F5(:C=AU0R);6;/GQ^1'OTI$UM)HDI;
M-OTH=14[DDAE9A6:=95*H"YEBGSJ\RS6F4=1%DVZDUI8LCR#)H7U[R[>O'I'
M4I/[L^]*EG#/PJP9^*]AG2^S_U(]&?;PSL200\+*Z9(RFVAZ\79``@(NY96%
M+1]5:50ISL=$3R+UR:YRX*9&PU8%VW(U3JU/:Q)%-V9S7B9GD!*M7+.OX]8L
M!5LEJ3HEX)]KJ:I$?O3K[9*@O985&OHO2--+M=(FZA>G4>5K?=YV+K)X].90
MU0>562@2\+P?"IQ^*73F8R95!^!X;>R1'V=[5*929:VQQLM(8>5T%6B5?97:
M<B2M1Q=/5Z74'WLGM25>52T-9M5Z8MDFFFQ]/=;8>TTY2-F)-`EEHU9+P2:@
M9:.9V)-Q[[WT7(VN@9B28"BM=)5MU""XV5)D&29E8-MA<]YURD&6H8J1O07B
M80%*%O_;BLWIN$IF^77V66ES.:9==DH!!A5*@[%35!L%&,#&"6RPL6>?;##A
MT8OHW30?F*6U5A((6"#8`1"TU&D"$'[R>6F?8Q2P5'N<GI6B4-45Y=A[3*DF
MYV/(F1432!Z=:1532,$DHD^%58GDJZ!Y"I:AVMFZ)*EFID:-"?@]^4$ALU(%
M%H7:>2@K""L\>5<!KD*5JH0[MG?4H:,!R^2+<<6:EH1MC@H=I\0M&B5(4/DD
MJFC%E872CH6:%-6&0.DJ+*XE&N4N>A&N]-2++;GZ:5H`TTI:L&"9*N2GAX(T
M;5ZBG>=I?&O)%&"46D*&G);1F=B?DH&U<4,!2`@A1"21H-#_\LLNPSQSS#*C
M($2R[AJ@&7!W8$'+A6#BQMQ\;H6G6ZT.G@&)++)0X+0J3CL]1AM^H7MO=[G1
M1%1ZKZURAJ,(,@'"T:O<%PT%3S\=C2S12+""6G&["S"*G"Y['-=J@?246K7M
M6W2MU-DZ]W4\.6PH=GJ_MQK?7/VJH=U:Q?>FW#2%=-^TR`(XTX5Y$VU632!`
M,FT'"J(XJY2L&5YB3B4%O=IIZ:58EK89=PB=XPD'5=2+(L\%NTD@U[DDG"V1
MM2@LL,T=/)@U`OXXL[+E=AV89;*&'4]68LTMEU?3BA/%>)$I&<DQ6B;=EB]5
MSY3%?:.UBC%[8!$#*0PT$PW^W^#?_S;;^_O_C3K4@;]H?.,=I@-)FH#3`2Q\
M)FMP2DY(-A:5G,CD)JI#'TY`P(0G"4%2L0F73E+$+1%2`VQ/&MO1J%$(-B`(
M`$Q`TL9*%9M9!2E==9H-O6!5DU7M:SF^P@8O5%?#(K7+.>J)#'*:11S#@*HM
M%LP2++"C'<P=JQ#LL<E1@D@O4SF(#-)Z4@=6X!%2?:AN9N14N<2$'!O"97,3
M/`[`KI:6MQ1&)1MC2FVP-JR.O64U%L)0:D8E+H[UAS6*&E97=K2U"5Z(2CBQ
M4K;P%9@:#JU7,3'DCMJ8L`_J4"3ANTN5#&>CV:V%.V*)3_I6):?Q6=`J)D`"
M*7CV28I]8_\%M#'`-]2$!3),CF_.*I&V:".QZOVK+QKD(`C8$K?<.;!;%((%
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MF)@008$`05@JLT($,2";?!.0H9+WRYB<"X0HA4X2RU@V7BVFAW/UFD-A%Q8M
M[DH^M8OBPI`DHGU1-F`=PU7`YNHP%1H+06S8%(L"!#NRB/:J3_WBH_:`UR&5
MID6[,TXDV46\A,(K2-<"+5GGZ!_0A@>EHI4*N)9%'FP]14H>6M!@&:LCN3JT
M71=-GO/*)9;@;D]Y7NUH<BM[5O>0L#[P8:F9@DK4"O)N.M%QG%"K-QGO7/)]
M6-/G!Z8ZU6\48$%HDJ5>.C-&W@B6+WE<11OH99STI(K`1SGF6@F%TCN:-25<
MX]7R5M&H)P$AF=HI``OSXT*W3-0JR$WL_Y"&E.!-BN>,JQE*6U:"4)B(YR8E
MYA%D"V<TP9HSC\`]\5]1DY(5%['%*RI6Y@H1#J`@-()Z\PN1KZKA`X%Q!9+J
M\7B:=+H6*9)WOL70;2+9E]E$QS+)DTJ6.F2J!0-6O$^5C6F40\GY)'91R&N0
MPS)<)J[%KH:W0S-(:U1@"S6LCPE.(E_*^I%#B[22*IFE*ODXJHX>IGJ^3%]:
M5/G1*L''!&.X@WZIJB#*["P_6X68B$Q3,"%M-E[:P6F[,'L&M>:'K4RTEV>O
M6B0)U76:9.-+(:Z9'R<PX2Q!W`W>)`G(:^4Y1SUA-E!P#3!Y$==$=S1,)I5[
MK05A2SH7W!IQ4O]L&U4O27T@V6=^D,58QRRHS.W9CHQIK2;9KD5,HUSLUK[2
M8!2INC6T84DE@S4ARR$71J[Y]AX]ZQ)J=QE?:B$DKA>>O#O9.RT/QYNLX$1P
MRHS,VWG<5[,(+D%S6Y1)Z+T32=1[X';VAW%:XM:%.A;S+9E3+C-?)#960(I0
MS[*6VUA*5@/\,^K@Y#5R#%@<7^X\]>$+%K-&IB"=3:[B7IBEV(CF"7\-F+V*
M&!*_0/JXR)-QYS2E.!]?Y^'(X^Q0X;"27"(B[E`CE533+42PTM=5N!*Y"M7&
M<1)"-W!.BQY"?\C'2SUP0<$HV_/FJ'??W)'7+ED=L[?&:\;C6"5Y-_C_HZNJ
M3A!ZE^NT5ENJJX=`4R?[NFQD&@N3!HF3U+'Q-&GAGEZQ3D'3I,*+R/<C.D\]
M?U3X+"&:&#)?,E^!Z2SZDLJ>-OG9U5B8QJ.FP0``3)\!U:<^]JV??>P[H;\A
MX470\W('SUS&J;H*_0@MQZJ2>39(H!'=TU01_Z?)HAEC8),]&3EX--*W5+T&
MSMA\GU#<1]/0'_U5@P*L@+Z<5/+E2&DD4N&=4_%=TCU%3%Y]2(^L2MT!!DSP
M4!0-7C6E"UFL"H1LF@="H)%UWD<`WF:H6R"!6Z(4G?K1!"W`EIH4`)L8F6!(
MT5+0TR5U1;]\V2@]D<8=R2+!"O"4"NHXB",Q_P9Z7<OW$%9.V)C>*)?`"6%.
M)4[B%)U`T0L08F#,_8K5#)59C%R%M!X5OMI%=4KP/1NGP=`2GH\CZ4L085I@
MY8TB31(LC$$NY<<W1`(0,($@,@$0<$(@!D(@<L(@+N(@4D%5A!]G8$'5)-%%
M\<VW(=H$Q@?DR8U`40,(%,(8A*(HBJ(0*(A,'%OJ691,(=J5E-[_;083`,U[
M,`0ICN(8`$&R=(=,>=M7;6(0^=9<Q8??"8G?]`Z%H4L,<@@UH.)76(UU:52B
M91KG3,].5)#'%5V#T!X7+N,JW$!II5NRN!][K9'Z9!*AL4,;V*`"'=1<[51.
M+8NF.:!%R0Y2:8USJ?](ZE3'G=@*3OW>2_$*^Y02>W'+YV%(19UBZVT9H:&9
MF;F%42W&4AQ;@\20385(H>B8=`U&FVS6@YA;EV5:?=5*&SKAK;%&JC!'N=5=
M6AP;INV&':$2DPD!@.F%*A3`1?T'KES8?^SD?S`(-91:SY#?8LE1FV@%W2B6
MHC$+&GF*2A1D4P:3<FC@<\7+%+ZB7@Q*=GU>96AEJ%1>J)3CZ^G(2X)+[L%+
MOBV@B7&4PZ@2@V`1QTA73@+74C%EJ6#;5P4A4H``"-#"&>BE7^KE&=!"`<3`
MM)#"'O"E7R*F7_;E7S:F7K8!1^PE%:R`,#1#90K#95IF,X@#)##F7])"8N+_
MU8EH48"P9''ATP\VY`=B!7$!$D^!%B;.T>_UT*[`Q4OB"BKRQIC15ER9V$HE
MB9!H8&M*UQ\U#(TUEMZ](/'H2-/]!)/DIGM\4U2P0QL&UE:4$G8]GG3M"L<<
M9_IL1QO='.T(01\"!P78).U4A=M-AFE`XETL$-G`&U*.Q(VM973D(7$637U.
ME"*MXKI-R7VJY[G$!]:)35OEE?MQUUJJ$:[4IYF,7/2X1Q[&&8[$2UEEA=L1
MFE%RH]'PU'/QAK#$D,8-#&Q`*&[`POQ<2@RL*!O$`)_0#_0]23.00I^<`(O:
MZ(VV:(NRJ([NJ(O::"1H2@'LP0H40`%`PI`:*20(_\&*LNB/^F@,])?KZ<M"
MG<YV66AM<$SDQ1UM7H=J=>1V"HOGI%US=!EL"-,,906%E<F[:(U)[.*K1"<&
MGJ;JN<GOX6>XQ!F3:*2<I=WY?%QU7M(JPIB\Q,;LL%BE16%O?LA;FHP0J`."
MU&3G<$YV#F>8_.1,XH7/-%E,X-EJ@EY=#L5]=B&XK:5S:F)1+E:)0B6^\>='
M6&5P)%,G;8<JT5C4P8J^2=*;N&:$:**+)&5Y+"6;8IB]/9.SE:BN_-Z*!,A)
MF.:>*EMV.@8@?,,=5&L'W,&U9BNV2M6T8&NU>JNV7JNU@BNYAFLS1,)3;8-M
M6E@;)%@,-$.X?FNVUA)TK/^F7-Y=1V$HWFFBJ8)%+^;*B684QX6J_JW(WT@%
M\I%;\3F/M;T@J2#?@J8867(AKA87@(`HDUQ;Q:Y(9PT:O\H1<GU$Q\*D>I4;
M47S>87%:!1HE5ERIENB=!&%DF)`G@IPGI6;'-"I?6A@`/:@)$DB*K=YGM'UE
MG4:43V*HG0R-U?A1.$5>:!6M1$UAXQ2HKUWL!3I+M`&2QLY1X<";3)D4>0D%
MA*A.8_CG(0F60+7LFU+0,N9L6TK0Y%5%D2`)</7?>`72S<Y)&TA`>?*<WX9/
M,\0`19U(<<1`INK%'4""10%A"FT,8S")WZSB3DG9F31:X53=[[CFFJY1),6M
MK-S_7KV5U=UPHZ[\XF/XA<;:5%587FZX''8E$E`$Q:D8C^R2G<6&)%:L!ISR
MQ6,PXV',TOG`1WT@(8`V'Z\H:Z_J9FHVVV30;'ZHPAYP+:TB:Z,NB7O^PU9Q
M8]DMG+6=E]&R+%^46'^8)MS>Q"\"AA;YX(*U`144PI"N`!-`0I$6`A7@%3;`
M*EZ,35AE4=-&V]60)G&<0?L:*9&N0)$60"'T)=)FE-F);+[N"F6QF834(3H*
ML/L6@@GT)6YM!15N#?O>@`D4`@;?P&SQ&URUV/#"65>61!N0`JC]+0Q/"P6@
M:]JZ%RP8;K=:U2J<K[[-Q-C2"/\Z&1QY#VG:2!T2Y(.D_Z'_(FMX!(V3L9:M
M0F3KQAT(]C`/+I@FU6IXY)U&3I>:#@:MW*F)""].:%$=ME/;XFT-@<B;]`ZZ
MH%U@S)([YNY\[*D3HI)\G08J\4T)AI,7<^@D.2]P-$-_$:Y(38C'!`8;0*H"
M2>)"N:^11K(DHT."^5D2MH$)2+(F%P`53,@9;+(D.Z*B8,].P`((G$$AK``6
M1`(;D`+V20`;!"D3</(-2!,`?L9C?"(H&VDAH(-"@A[[%L(>,,$8L#(I2``R
M`P(IL($08,$LT^]%1#,5W(`(5S,"FP"-4<$N&ZDC+I7393(A%G/+",$8,$&1
M4G)7,%86W:_[,D$@L,PXE_,*T/]O)7NG*9]!!B-4RY[NQ+:!`KQP#`?T9JA"
M#(CL5B@2#C_)'=C2$(XM$**LMI0;105)"7Z'##;+J72%7TB6V+4L3>4NK*$=
M!O84W4YCW%P@271.=P"/J-1(.A,)%SHA[;3:2G9P<M9G1&NEKCDAG)+C[WX2
MY2I*H;)(';X$#W\0$?GK8*1*([51H^YAW^I%-/!'C9WN=PWK\5WO^/T:@[#!
M0S1#/%@#1+S#-"3"V`#4I_K7#8S!5X.U6(-U7[UM#8JU-0C#.S0#6(,U`QVO
MKUK%)X\!WY(.`XS!DF:=4]W'-+R#,,3#.X1U/#0#("B@A])$&_RU!$0#MS[*
M'30#,Z__##FO3,OPPP>0@AMH@!M@@6D8`Q(TPS38M5U_M3"@4*N`@`DP`1LT
M`T#G10=\PVF3\%60)B97RC3D-F=$@P)@02'@%>PZ70$P@2(F]U#QZKBYL$!7
M=U[,,$392%8$44(CR!TP`6^M1%%G=R?Y*W/BJTG&G&I],2!U5A`6'\B667$R
M%MH%%[C`,>3&1;]ZB*O42!3O<TFIZ:M04K#JD%5W6S,B*YSDE;_1)F3,TJ&=
MKV_*;)`04JJ>-R&MZQDAU5ONX0@@2#,H"$(5V`S]<")_Q/7"9[)*`'%SQEVY
M2W;N'RR8@!`@2#0X\D1!6*UYQ$3!4+WL02SIUS=$M5Y$BK[!_P*(\54V,0AE
MA`4([,$'M+AU-X,0M-$9_`:"(`$ZFXT0),(LF;6L'N]:?T-F3TL\C,%68A<5
MQ``6%``JLP$0..)!;Q&&MH$42+EU_VW@IG6]8$-WFQHD7(D-Q5GGY%;DQ9"\
MD/BR`DBX2!*H^"1R?:E4&-WBG/?50"&:[:D?49J)=?J;(B&#&-UM(`>$W*E3
MX1!+K9Y2D@1E7<UK?"#(Y2IH&,4DLEKU?D3PF9TPU2M,[N);CEYW0%N,M%M2
M<8W)P<*CVKA-,FHB7[6E@M_A8J]G<-S>XGD'#$JK,$A"L2!>T`,6](N.`P=;
MF4]P87(,C$"95[=LLT:P89-381>2G_\`9N?Y9L2#$%B%,6!Y(Y_!U47"<.N7
M_:&#A8$BO.K7"(S!&:P&".S'"H0B`Y4S%1#C@JP3"+`XO5=WX')PDV?1]6JJ
M+7$QM_D;U3'+YG@ZWW7;AUBQAC.XFO)XMK,IP31<A&H3@D;%H7TJDG"7Y941
M6B>2A(RX?VN[>B;1Y)6J8IT9FYYA241PIGLZ=ST5LZBTI>+Z)X%%DPUL0^]K
M&.XB*H4G=3"J\HWRDO`AB.]!,DBN>.:NY$%&BF/!<)2Z/UL[$#19%&&N8W#[
M7=PXW:X".LC;9@C!&90C0A$4E*O"Q=\%"J$+UP%'7[613%T+D,M"NE^\,-P[
M2%"!O@,'$F3_\FU//L5T@`3,O0;=-IY/RS3@(#:TP7W,&B<40IL70"#8)*63
MO*FV<.D?_BS)0D&/&[_AQ)_W3*#/[9M%T*1G)_7:1L[3"5*^!J=J&8G#(70Q
M>9PM2_*LV.Q?6+]8;-O6?5(0S.`SR^0I3S/..HRWHKN4U)MUNENQ)J56"),+
M=;21^(E>;L*L7I,;G2EMF\-Y4M4#!#M8;6#!PF9P5<)5![%1PZ8P(2R'O*A!
M="@1%L15&*FQ6_CPH,&,&A6R:W,2I4$00K[]<_GR9;0"#3.RHY;QX2J/"0]V
M7"@1(B\VT6#"O(,%A$-LV-I(N%/TY1TF(!"NNGB0)ZQ"D:"^E(6E_RHU$$RZ
MOA1"=6=(;&-)M2S[%F[1J3=[%C#PU@T3CR)7M3'1-FXT!@`D,/C6(6Y984)R
M&AL#-Q*6#^H2O_WVP002"40K=^T@Y(982$!H`1G#)%(A*D"8]&2X%*/5C0J>
M=K9]^RV%2`AIP@X9@[/E%0;I\E0K$3:UJQTK_AR9/.'%A1$+OF9XE;C"ZS\=
M;J3[7*3(Y:Y'6BUHO"KR\K"1-_3=$ZC.FT`9)J38,VUU@^3A=\_Z<+Z*/%H*
M*_..NPC!_10*\*>&(L(O.O5HNBDAVVP*KZH%*>(EIX1LZDFGDF[R3SOLFA.I
MH9U(`F$%)EIT$9(6/ZBMJV_&*`#'''7<D?_'-CI,:*BR.D`JI(V<$I*),RB,
M2+J>"A'BK6BP:&.O5<X@ZRTA:$GQNS:8`(3&LM291@)2I`"D,%DZ`^(,H`HJ
MA(VW&(!D+X3.&`,Q(:,!1`C6F`!""$":R;.L;V29!E%$)<#B(5CNA(L!!L+T
M:C`&FHEKFC&FF?2?#KZ91@,&HB&T*PD*6&6LJ9#H\P-T0$""B?,FW`@AC]H@
MA5/<=.U,E1@*<A.H^8"+ZXX5?,R.N/`:I?#"G#*J3B=HY5/P688*JNA7\VJE
MAD.)ZNQP*6X[0C$D;+W-=CKQ!%J2IYMLZA9#;<>MJE%O:6TN70"[I0E8D,[S
M<+Z'!(K/.WO)E97_K_HVVNB@;[7;;A6*,'JM)MO2(Z@XB,*%1<4/8].X6Q4C
MONBYI18N4*-"OKGCCI5;9IG4KJI)!-%$:+89YYQMGL9F`*BBR+X@N[H#"1"*
MA.7(H8%("N7]J@OG!B@+G;*B@]#!LBPAE/P5I$*2+G2:#\:`),<5L#AAFL/@
MZH`TA`:RZRT`6MN/ES8*N%3(9CXHX%B"[(YDFIAA:H84(<8X?`PLACN("BQP
MZT`P-K!@`HD8\'Z+4\@9$/O/#X2!2Y45F"H`"W0"P0).*L[@)-:,OG/./!"^
MWI7VRIKQ]6!KVQCVK0Z*C8AAMTF^D#Z$L;)6NG;#&U`D7C[BF#OBF:LN_V/S
M1N2R.N=!M)96-[&#Z%GDM#W^WR)#JC99<+&KU_Q_$X861;Z85"LK@YPOCOY?
M+U2*7?5&8MXJ6"F(Q1XTD'`IY'[[P5=$V)$BB\!'([^ZBD+$0Y)5%")7M:O,
M-XR6(:%!94CHJ-I`9@>3#C"A#=Y144]2N`H32*TK4CJ?H[#6E;,8A"`):8I;
MA,2&`J"#2E8YB7+@%)RRM`U:<(I;ZW@2-;@T(Q))N1;Q0``$541I#,;(2`+%
M@HU'W488*"C$?&!!"\?AYAM"*`0M7(>.2/`0A"C$!BTD<`,@<((*+F("$PJ!
M$9Q`2RT@`(3+?,<R0\),<%`YY"(9V<A#%O(.M_\#`4I.,A""#.0$S7"D(;]!
MIP?ED#K\BA9O?I5";+7P0A0\B(^H$SY__?%7P;J6>316D!;>2X+=TY:T!@(>
M[>!P)`%K'[!RR2"!@&^5SDH6*5T72_`$<SVEG);3^N4<A1DP*[^L'JUFA0V+
MO6:4\EL00YPW3G%F93[38D]YT(,RJV!0@[NZ@]%^$K$/%N4H(-@)"3-XAZ5%
M")IMF,]6WO(56S[D:G`Y"ZJJ@PXD)#(F3#`&*Y4E$5Z`8`QJ>LM4LD.-0GS@
M+1J(%5;"40``8"X29P!1*+'A4(C^(R\K94I!'&.;-!;BDBA"A]HJ(XL3G*&2
M'+O)"D@!EZ)A@QV0$$+_DOQPM=2(Q";U"YY$0%#525;U)%AM`T'ALC>K?A6L
M7T6)5JMZ!JM>21;14*M:T\I6520IK%;-:H%F>AZ$-8=DUISJ1O)#P9P:I%F_
M=%V1&EB=AE$G*R#@9J,<U$J]6@LV62FG6+CF-G;6!T7=@TX](T(0^C6L.45R
MCKGR^I-RKO([2!U1B*:85_W02C89BF5.1#82B\VRLQ-24;($%"&Z_$AB[ED8
M&;&RDQ$I2"'PC"<:M9A-`QC1A%@@`VQA01LD;2F!4_W5DZ(TI7>AJH90$<*Q
M<&A2N$R#2"$2+86P052X3*5`L"A`G,HB-_0P`;HP$6FU&%:OK3+@+5#L5O<,
M_T*%QU1&;E0@;P`'(JG$W$$"0*#"84/"CD+$`"YM$TL!@(`%#_-1H/4<,"#K
MYQ[`7L4$7.EJ`21$H!&F$#;LV%=(<HJ.%;RT4WM(RH=8&=EP$:\Z0310\!HT
M'>FEDEL"K&Q\SC/B;"G36>(Z9BG/%QTEOW(ZYC$EAW(BW"4'4\GS`A#S@,*+
MFA1'/^7RR)*8"9)P/BBVWW&FE0%D6=>1V5]=YI95!')`D<'VMO:CH`2!9I\$
ME80[V"@G3P9VGF954)L%\F@&EVN9-D&O(/<T2NGJB;1^PG?/R0&F1U4<PS'<
M4BSA+4H4^74#3E`:BC=@IWZ8%XX+OU>QY8);?6/%D__2O-2'%'P=PZA`WQH9
M`):],<&!X?(-4JR`GMS[B03@&,,80*)-]S(/U&#8%?@>A!8WP-$>;@!*ACG$
M)[A]GJ*?QR3N=K6/`+5/@TIVHNZ<CPR02`S?[*-FS@[S5\[;BV[3.6BZNLZ:
M,V2W@9846?6*]N#>.A_*_'7OD6@O6R,LL<)KTNF1%&2%N3Q(.0T[P_C`YYFU
MC"^[U>*02RZ\05@9-H.AR?(]C\]>M;PM34J29HW`YT=R7J`?_]B=B2&09/Y1
M;J4[\PUT(*L-!JCV2X9D-&N!"4FYKG-Z"I+B[LK*2JJ&B=;,-5^X/#L<"!DP
MNITGD1?BNH!*+`L#F-"=BY[_L2PQ&&,!*721,Y1:D1\0*"]A<0-F*^8$QHK>
M8<W\@:D/+@8%4&QFVXZ-96>8%@/#1MK#\?(0W<3,>U9*Q'C.Y%=R]2U[8W-C
M$4*A9XDK6[%D45PZ8*S@+F2?1G=T97UB(`[-C_1_=!:[L<G-[.PE8-93)\.F
M!?O6IUE`<F82>!@[,LLZRT<K?;1/5H\3I#*)>/5R6H?(17K==^3@YFH(O"!D
M%0XMZ4/1<I#:>;ZNW!-GT?NTS<0)UDO[X0OE:JNT2@Q=N.-?>JY<3*`9THH!
MHR&M*,TEON$;HF$"OT$=*K`"*5`#*[`9K$X_-"TJCLJ/2HCJIJ)^*JHOWJTK
MON(X_VA![,R"*C:B#5;@<PI%2P9NM89L(0P,UW)OU[K"OH#B#/"N*R+O`*6-
M&J@`PPKE`SHH8"2B<>!"-V;"C_#*;1SO+4:`#7#J_NB%"KH-*HJFHE[/T=`)
M%D[K8ZCC1'K"Z^#"A]:+8SXF8RI**9:"%E:`]HS%X;BC@$1M0L0I//[#7>1M
MES0O#LGHER`N?)IC70B0UF;N/J9HJLBO]\0#^N)0TOP(XY;%ROH%(YI%Z`J(
MZY*'LP+D:%Y/M.@MM/Q(E3R$R6X.Z!;-0VSC0:IG*7R$61(QY[[%9#2+:U2N
M0/*#+N[$<(2@&(T1`"@-PMC@!)B1#0S@&9W1&9N1&MD@!O\4ZR98R0#H04BF
MA#N:(H,Z(!#HJ>#0A1W:,(88A9O&0J%\A"!```M>2FZ@9SY$1F%X<*.R+2+,
MCM=@JXI>2@+V(.T\I&!JP@1.JBRBP5=8208]XHO*(C4JHN``AC@^(+\B4`*H
M`BAPL"J<Z"TX01_11?KX#IHZSA59*X78P2-3KQ"VH3XHPMR:3X?B`Y0NZ@6I
M;@^>[G\02Y=ZLL_8Q5J>Z<^@Q\R"B$'H#5R.3@8[Q&'Z(N74$'IV:11%Q'U`
MJ?@*IO?*Y2GWZ6)V`I3V)RJI:WH.4%MT0K2R17IVTH^X<H$&)D*TIVDJ2&1H
ML94$S4,\JPQ'ILJ$38*"988BZ"+_9%$KN88N;H(EHH3%]L-OVF"2S,PZ`M'X
MA.(B_R&?7-'3RL*?0*#RTNP\J&$EH>(;P((ZV#%+-%(K``\JWC`EZ]'0/FX(
M<4W2"N$NRL()F(#Y8($)K@@S46!KUB,DKN2E&$`T,<0@C($(PU"+,"XL"X(B
ML+`K*(`->J,\UN4\+N\M@$`G]\H,%PUYZH0@TXF,J`$=RV)OM-/^5&DS]:,S
M9Y#V]@`O$Y'>7*D\U'-!(/-?,.X_T"<JCZO_N(DGX2PH@_*78$L4GS):IN<X
M)%&[`"HN:^E!4.X(8^F7SM,D$.WYN&8O?Z(1\_/C3%)\2,Y`PZ/W5H$6UXQZ
MU/)$J?)C__*#?LS,L$AD$2].%!>(@L:`,LJB&?8@&7;"10TH+"VH?&"!#6X4
MA+RKLTC0)4Y(BIKIKGAA/(M"2BB*&JX$,E1J(PH`I++$!,!38JS/7%[S.MG(
MT>0."$>*5@H`$"!E#-"A_0KB2A"R+$BA`)QO6?"Q+$HGOBC$,<W#.:'"I[HG
M%]/,3KN"-#XK/88-^=Q'[9@%6FX"]<AS[U[+/YFO',GG(69O;10OOLZES?@0
M4/\G0)Z%^;IT8,R%E/IM>:;)008LL-#ER5RG[9*%(N5'4><%SY(/EY(RL_C"
M17E2?Y(GN-3.`!]"8ASF5:\%0D*51TU1_A!+,`]US7KTYF"!@/^F*9=:J2?*
MZ5ONLQ#%A^C8J;`4YEV^PR-VZS`3L@!DT7_0I9Q`U*Y@P2(Q$RG`Q[J&AJ-.
M45$_$TK!@C<2*DO8B")6($W?`@O:A'[Z;(I^!4S+XEX+PM9FLROVRSEN(!XM
M@P'&H!!,4RP*`0MPY2V$84W#IS.QH::ZL3>[3((&ID^+0A9BP%IG"3[TM2B*
M!I?*TBR="5M<E%A)1M%<ZS3C8F_(,$A35D0EM,_8<VUTS!6SE60DQJ)@A\S0
MY7RBBCXE="\/4,[.3$*=XZX,"V8S)"AK@NBVU?GT4ZIHCCGEI5;ZH]&HR?M.
M[GS8:VNU<EP2]`RY`PV-EHPZ5&$B9E;_K>^T`D9B+&9:(<MO%2Y$:C'G?/$`
MX\=OW2^=YO.X;BXBA&`R_R%'DV'>[M8IBRLH&H:WME%(:-9O+],SD@3VV-8[
M5!`JHK1`_#5KJ*(C($$"X*)@T^XL$Q8YC!,V8XD?RW1<N,5N`*QWHB$2F&`/
M<@0U$D$9?4A9,.LANP()=%)/37$^5A8FHH$-^C![NL<ZRX(3-/*P>+4NUR\4
M18Y),^))H>(#"B$<1NDEBV-#Q"P'"P)3>P?:]@R0B`D3X2R4H"58P4-N2>;U
MOL5YG);PLI7(LO4/%;5T]Y:Q/N87062VA"<JKP6`$5%DY\4`YU!8B6[XY#>=
M*%@ZE2EQ9VM9_WCU*!^W-4%B1&*57ZBU,\YISCJ1T`;-:"&4<Z?O:?,39<)5
M6#=B#![/)61B.J4#9[5U21`1!%VB,BD(22D3"'H,Y*S/=5B79?FU.D@S=AEB
M!6KW+<:`"A*U]:S/;Z,7*DQPIJCA=Z%BOP8Q";&`IS#'&AA``C:%]A@`VG0"
ME-*I9#T#"(S!]5JO3FP">[WB!.83%]U'/,&P*-AD/CL4:$RB"@>NBBM"8D+-
M1[@-:!/3MZIBRKJCL/AV(>ZP/65WS<P8=FS6'',H@ZO,)T8NE*QOZP2K'),/
M0&C%1.E1EC.FY;A.6LZV3<O55=\US\K'2V.U0].-_,CKXPXV7;3VF?]B-=1.
ME'D"9$!8F(6)AY8!RK-NJ_<VLT#:[CT?MSNK$D1(3MI(#A$?%X/G4PB(%"HR
M=[>@+`UMR942XKFZ4;%*%^M.5[&Z]&2>=GUC@E&2A8MM*-=@06`AHQ!"24^U
M;2.B<*,Z""$^:HG8#(<.68.B805H(7H.-R,65GHS+WBF]>/88`3*0A;8P+)2
MR#'UU_","AV`YRQWEI7<LB"?-BYWHJ!AHGVI0<C4DRL]HE>!9Y82VC,@P:*I
M@RUMFNLB!IMR-YVH60TW]YE'PK,6(HAZ]3X5]>.D.MV`)8B:+&NOFIL79I8R
MN2BQ#.<&;=!\PJKAIXH'H@OU%ZR!QX-/:8/_@V^;Y@V!9CF51B:G;(.`P6=K
MS?*O(@B?PRFQYX<LR6/6['.($7.+X!IA4U8&_<]OFY@R23<BHOB$!N]=2WL/
MBHJEA]--;_(?4LIUL+2K]B"2!X+(:(6DH6)I,-ANLK0KZ&Z+B`L$(N%R-&@$
MW,`$8)H@$/@G!K4HAN0,7+$>8\,D./H?*,!E]<?D1N8+>V=Z8:<<8Z^&34L3
MZW(C'K4K]B:G6&MB_H6,VK9[D+9W=(P.79$@&LUFI]:92A)"6VE>A*^5VE9:
M(!0K[L.5P7N$0*Z4&G<,[U(]K+)#U7-KB>Y>E)EG=7F7]C9"D>>WP5NH]A?!
MX^4$.5<693&MZ;J7_P)M$*VXPNRCEQ0&XU[.T6+8G2L+J^5'X/9V(RRWH%@L
M*-@,01\\F#V[ZC97M#F*FM2,+8CX'Z1$0`H"=A7Z5W[:):9A#;A.T6+0.=CA
MCPD5B.JDC8O"OIR6QO*(%'`L+KYA48Z[PHC+KIB[*/`46^O;.:B[I9.!>@CL
M7V;Z(YV0KH'L)_!2F;QD#`SG<(IQT`]]<O9(T?]$T3GAT`F]T!\=<23]T0F]
M&'E;2"0OAG?6S@(F<F<)GQ7X?+;:^)#U79,,K-D5P^NGT7I#E\-SLVF57VY)
M?VJ]PY.-CWU.JE<)>NRV7DJU1\-IQ?&<;]G<LKBEEVCE/=NN,.=39!:MG?\K
M>(`ZHR[+(SR'-K'M%A9%-'`?&\BL/;-AX5R[(G1Z>)3NI6W%[#X]^XE_PF,]
M8QQ/O5E60P'DN77Y-2*HM#1[8@A?ZALB@0HZ4P8O"5#-NRCB73Q^T(WK3LU:
MG`I6(`;,O+GO@`$D!Q+*C<#L^U^VO+F1X-*\>9#;@,X3F?_B1WT/#[<_GK#R
MVVZ#E`UH9AJL(5$011@0A122!!W.P!C.0'5R?N=7@`V:`5%D7N:GH>:%7NB)
M'E&$/E%J?NFG0:-ZA]_L%V%@*0ZE>0RS6ULP1N-U-\0K*T"IHY*4NY?RRN2<
MZ2_?^\.]A>!!K[]97L*)A^"/]>K5KZ+L]F;'?H3_"2W)2AW"MQ;#%W'1M#7+
MSUZ&*X.6@SA>V&=76[XY$'A)F)TO/BY4IS5@VF#<_91OR@SV^`J@9LO"5V&?
M/:-@,=E(PK%@\]M^,X-Y`V,,F@P6\DBAV@395V`:X$("YH9;!`+&16(UP)AA
M+=H@R!0JYE'UW70/A&!2.F`:FF$!G7\:[%@!#.!X"T#!*IA?]O*VWUR+7EKU
MJ5M[06YJ(7B[]SR6"HUK6GTAFCUB;@4"_R'W2W*9"@"UF:XS.L`$PL>9T9YK
M`(+7*E[48,&BQLY@FU78L!6$A6T5K(1M#%K$9C$CQ%4##3ID5Q$6PX<&J?'"
M&!(C1(T6.4KT^'*CRH(1_WG!:A/2(TN8`Q]&M(B0Y$^).75>;,GN946&+6<>
M3%HP)4N5&SEFC!DQH<.J)V'JY"C0I56G0"7^.XLVK5IJ5DE*=+ESE4F2+6/6
M#9HQXJJD&0NZI"I29%*5((1\4YM6U0J@29G^%$G08QL03Q^N8A,-\=D[6"CK
MA:7@CN9_'2*!8+CT)JU"8T2/3AL-2TF,9YB\_A?I3.4";&Z/*&&BI-&0U,YP
M`G#['Q,0#ZF%*V3@-0`F-YD:!%F(":G#:#NHTC`&1:08,2*-P<*D@(F<*E/?
M1,@8EK$QKSM@T6U0HDIL(25^X(X8!6P(5Q)![*@4S@U"W(8$"`<NA0U!5*%V
MD/]`"0D%PG;)2<#$6WW9U$8!I"1'8HEJ=2"+9RLI)-),%,E$5U3Y,6492^X]
MU=)$),&7GT#44$7730=1:-U0$TXHETT&1981A.^]^!9@='$$9$)-YL>?CD+.
M926!<UEW$&`*L>.62E%F].!!(@7)T8]Y7?366XT)N:)(JYCXST!%YD<FDV/J
MB5&9;V*3E(\ZF90D33,&IJB=5MW4AF&O-;-"."TQV9%>3$UV!F4O<60`/:/9
M1UE@L)#BFF824$$5;4Q(@&<T8^0%@FVO"8%.&Q11`40'MT7S`0@I@3F9$,*0
M"`0ZUQE42&^C,<!$41:M(`&`:`D3R7H6A=.3D!5%A%'_J6(>!8L)]+V&A+)N
M,53J2AIJ)LL)=EG9K4$F+/A:LF\*2:9%729IU*G^;,C$0VV<%-5)!0""9\.W
M?2,!-?VAM%/`</H+$9D#A?3MILL>]2V=7:[(D%T5'>BMDA^7A-/*'O7YDEL)
MJ5@Q8"@;]5:C,N4T<DPO$KJOGBQY/!6:0CXVT9+=JM0GTT`AQ19!,4D5&)XS
MUOL41Q3UM^:+:/)8ED!J*JVQ1EK+17*+"DDZFBH%8&3F8*8&)A$(9U!Q1L@2
M838:9Z?E!\M_K]V!!!43)0A$M0W'=I.PL-!BZVA".%AJ&X6,>%L''%+A'@@F
M(,&`B4S@QU`X!43W+'5.-7N'_Z]J?5``+)Z:5-)>_%'&(V!=561216V86U^Z
M*.&N<D:"PQL#46J^U!A_A>`[6B".$ZUVQTT1Y3@@UFKF!G57E57`!PZ/CU@B
MU$W?*I:,M:S^R2\1)%`K[-OULD)B%Z445(!O2AF3NOI+#<I8J5V!X5UDR-2G
MR0"N#;I;17]`DA,P/8INC<.11I`&'_RAI%XE4\B-2!:ADU$,8QV+FU*N)J27
M/$9L5%J6]29B-81X:$7P`QN?Z%>[>CE$(#_QR9>8!#</T:6'(&&;9IJQAV0<
M18B1V<M>9-<I$&Q%('S33`?&($45"J$9MYE&#,XC!`G$8WLD8AS[:G.;R6D$
M!'L80?]ROL&`#P@!"$Q@`A9B((%II"HY0*!%@:C!&^EX+S#A4X5FA,&$7%EI
MA?UBGT=<1+N=G`$+MTE6N"ZHI(*PP8V:B<:`S+82I10B$I4TAL5LQB>8@.A@
M&=JCJ@8Y,I6$CWRT_,<W/F`,QUV$)/VR2/&*UQ3+@$277ME(D(RF$9/0:VNM
M0*:.8A*D<3'$)HB"5%Z41*@A9@28U_')7A3H3*0MR9E7H=<J-=(EO!#(8D#I
MRIJ*-Q1>]*D@?,D:N9!B$*ME+2(^Z1%;I%0\#8*I0F")D<:DU)@#B2F$1D1,
M-`I@(&3VJ4)L*8BPBD(-`V1&,W[;R$V`@)SZ1.,'B6B&Z]3_\IV0P@L+;9"?
M0:@0.<T(03?ZD8@QA"`+$GWC'0"0@`82$0U7)F<YZ82.(&/VO(TZ5`@KV$,!
MG@K5J#IU!4]U:@$*005CI`9NR\+&?.IS'Q;1J84&.1YB5&$`"&'$4&KZ'?0T
MPXDSC$R&@(F9"BU2D582C)YVD8CI,%?+AFDN6G2JB(7,Q$X$$H=><Q,KA)AW
MSS#U=38X%"M;"G3*O<CHB?FABTOY==F/3<BC$RO)R!S[(^M(*&DK0:#(*+M.
MW]6N:!=AJT>'Q+30FC9)$^310`5CF8+H<T9BVTK6_`2G(,EP:5B22"]U%)9D
MUA"OI&VH6IH1NPD"SE1.M)!8,7(9_Z6>**S5#)]0\90(%(SA!*^1%2Q6B<9;
M*7*"S>)B+3LPC6E4DA:]7$4@1Z.!#CWD5?69!BD^P`8$*SC!">;'!Q[\X!.P
M00AC``(D"D"%+)9E%50XUVBP8+@0LJ=>'Q`O;#XY-Y-0A1WW8A!S?$8_S2Y)
M*`H!@13.FQ8.M2DO3%E88!W&`!`#S9$S#**_`';D)-]D=R%AA]C&9JH(31"\
M5GKR<.`$3,[R,\O+*QY1/ENO&O'$;)C"JY78Q\*K1)*W??G7FV0K3ZRDDD\Q
M<B>3JEDG/>&YGF\*BCO-8J(+=O`J6;$.[T[+&-T62"YS;9%^&*,U.F7$NK#)
M+KB&9J:A(/^D*-C0:-\Z0R!:8$&_X[L#`\90B.>]1AVRB4E\)=<NNQ8@!B8E
M7P>$(01G14^`$@$DZC0S'<%@@Q.)^'%R9*$`+!1"@`\YR5=?`^(*L42&O&B#
M6=4BH)@\RF`'H<);$:,OWSXF9DP"$8XFH[WD=.^]S"O(2?P+6&-GKAFHWNXV
M!VW:9L?,2NHT=R0/MMLLJR0R$6H.OREV0E_:T(+R?,C-.J(VCU3;;.)LK`K)
MC5C#4N.S2!&3:AT>'YVXIRA).2W8+MX4C#WEN>]%%+Y10T"MZ98=>#IM07$F
M-;%>[-Y8PY)M>R1CA2/W)@FA-%K<-B3X#0WHA;(+<ZJ(&/LP4&3_]\+Q:^!8
M`.:8@)2C<>^2L8&.F")F<FP2B;E,;*)O*)N2KUG.=O^K&6C1C0D*D'=R[J`8
M/T(<%AUF$'XJYJ%KIR5>G-62RA5TF[BRVV;J%">BW_4:#K49XOX5G]T?AH7@
MT,7F0R_\1IC$Y_>B$^"=+5[H':TDSZ.3S/WDH=DBV=B6&%8X`ND\2!*=R<KZ
M,FWTFXN:?;9Y<E*09#;G[M@D*&?-UCY("I2AG=Y=$3Q5O-"8'*@!\0T3N>7(
MB:`DJYB\9I`QD!$M#^V)$ZFB<6,:*(/O!4&)/\T<FX!`0C`-78E4\8$5@,`S
M+>ZZ;#R%#;621NA@'3+4+R`P2N/7=1^P_QY]UW:4L1#L8#J6!VS>DQ2U0FJ7
MUS>C(Q@5005L-QKZ(CMT]2'4('AH(0LQ$%$'HSP%I&KH8DJIM!1ZHC+*0SLA
M@RH;L@(#QVBT`TCQIH%HT0P?<`.EPBZ.9C:GQR-<`F/\`D%#,E?:-W%H\WF,
MUCFV,QEGXDO3E!.U9T!ELT"`PVS\QB<VUR468AU/=#)/^$^$-E`(X2(Y=QIG
MED$+<6G7@VGSAQ"N)6RF=61F:("0\B+P0R4]81-X8F67XGSM-$YH!A8`E2CW
M%AAUE1![MV0XU`9`0`H2P(F=R(EN0`H%P"U.-A=<5GO=93)"``B>R(K1,BYM
M<`8%@`0?P`#?</]2I/$-T_`!6+`')L`<)?$YK/B)$@`(0!!!;.0$;I",3N")
M;@!JT*1T-V$,*S`&$E!KG20!3,4Y`?@JG>@&WB@!^O<QK.$$&O"-K,@&BR$<
MZ%``D4`!MQB$9R$!L6,J9Y`XPB@!W\B!WQ-C0K")S<B)@#`&5J9[5!`(^)B/
MX1AS[11)0\<2;#`-%*`*LB"1%3F1%``(RP$"Z+!_'6DW(%!($BD+T=`,%*D*
M%DF1LE"2*RD+*NF2%MD,`'`"6(!A!'050S=1-ZDTVE8QBLAZ9-9<.=*30==.
MO?<O$%=Q/\F/H!24,]:3D#$EB=AR>&AO.\$745EVJL23E'=\C:472C?_&:0'
M7,O'%WA2,AX'/](T+L\D)CYR,P$W4#QD:$:A,I83507@5%95`.C`A"4W+G`8
M)293"'=YEX;CA_W1!E2`ETP`!%AP'EC`"4RP!X7@BX;U$K1@`GA9505P84\5
M'"-C#)NIF5!U`_U1@T>!#IEI1^-A``AF`)&`'I,I+`3Q.YK9F:/).7.#@)PI
M54^%549C.4P@!`P`CQI(#T!@A(^3F9RIEYWIBW4B&,DTF)MYFU?E,RIW,IZC
MEZ*)8=+U/N2V/BQ1`"O`!.191^59GI#`F%@@!$(0"9'0GNT)GT*`!8&`GN>Y
M`NJ)GN9YGNK)G^EIGOFY`ECE.+L3<:ZW32KV_R%.*6VSMR69Y$X=1W&852?L
M%R%*$Z%A@FC:1A8303%OJ7JVPY0I9FY;`WL#H3MPN$T/)Y0086YH8HG[-*+:
M-A@T"C7H9#).LD^`0G,F<HHL82$DT62`5WN`41,]AX0?(C32TH,9$0X%00W)
MD`NPD`M+47(>,C5=J">%XG"^PSO.<1!0^CTM:A`;>0;&T"D&82D+RB)KVHA<
M`SCA,*6Y4*6PX*9D>EL0@1/&,)U1E2L[<4P&4:?0V5;;HJ9B:C94@`0`<(O1
MP`#$&)"0*JF=R`"J4)QI,0;:0B@OR@N6(BT],F,XQ&V&NB\Y`J=V:A%56J<L
M%WNLM7N@^C1>FA.6$_\)K6.K=V"K'7`'L..E-B(COM-,+-(R6=)2:K*6ID)M
M2_=ZU]233Z9]0#FFNV0C]C9#.AFMES*4_L1-]!,A'M>3O<1/<2%=0#JM2%.M
M"C>N7T.(=74I<\5->?H6!C(0>!(4)>>=9Y:$&B&O8E*O]XI#F`B5Q2<1VPH9
M3L19.>%G7!*&!1)/3^FJ'52CWK5Z]O:B(1>=0I*<"4H1Y597;;"FEB)E>&58
M%[J%8VIZ9+IW(4$+*Z`!UG('I$"3`KH'`BJS*T">=]2RKQ$)A4!H2\9+GYJ&
M0%-C0Z*OO6-!(Z,RZ60R?KA-5`%Z0J(R/!)1U*4CHY0<L`.D)]<E+2.5)C'_
MA62:25URAV/5EJ/E0LFT3)MF31''M)"Q$THRM0R!KX<VH?8&?BWZK$;80.CJ
MHG22>EMX,RTCMUUHM*:B)`[*<#PB6PLGM`2E?'RVA'PH:6VK,O)J((@H-+_%
MJA/SKX1X;P@*0-$(%`=#&)>"0S^*H^OGN18Q?ULJ-!-QMZ\[$?FS=Y2W?`TW
MM53931,7>C1J4=J69>S`9X4WL-0:&/WC3WB5ENUVFI>R%)$1$L:`!!T`CPRP
M!\+A(3/HJ9<E(J\1`_28([T4C5EQB?;C,576@NS&"S78D$LH$`>30&+9N4%Q
M,"=JMOZ$O"S8?Z_Q`86PIGS!@MO'M3V2HO(4NB<C_[66\60.@JTWF4'C&W1^
MTA'("ZL^6XF6:;XEZT\A`;<)XSX/&Q&>4D_0^!)_<QU<%A,2FW,57,)"*Y4#
MP6?/E9,$29OC-)49/$U8NKHW#)6LJZZ[];S41J^6JWJ52V02NX6YNV@9&K`9
MT;H5@RBG18@;>HK1R#$UE);2YIVR4Q0U!"7;)S5D268@L:1.!EG;=8,5TC\+
ME\*3E6*G-7NI49>)N#'1"7OU]**C5)QWH']&6[LM2@TF`()C9P)9!J'@.3<=
M07IQ+!A<YKSLAL;K:\/_(SM(K#0GK$)B\V=PG#2X\X+\6P`!_%Y3""*<"K6P
M5Y5U[*R7K!%MT#OURWE`A_^N-1BU+N4UOY7"-_ADJ&%E)^LI\D3)3U9-I_&T
MD+PBA[;&L=QR$V<JZ30R+F5NH'LC-!PF&ORBX2*QMW>[F9MF%'IN4F2$/7&&
M$W>[F)MF.6IXW;=T2#I/0V-ETC)TW5RR_TI!LBL[0"<V[D:D]]QD-`B\EVR(
M>#9M4MD70ED4$&C,XJIS7U>527/$@6HJG^H6+&(3SV-?:=$!,9";%2R6&N%C
M'W8&J!RM'5UN,B*R.2*D=>&PV^6@".N0#3TEIOJF2W8#7`?*TD*R">=!J@1X
MB.;-.BUI!,VW5LF@<5P1K2#01:LRWNJV14%D[R4MOO>I479"`^23+)&3RCJ5
M3CW_+-\*T:)7(11SN`S9?5@<K_7RTA%4L.L,&4.,*"Q4NMODSK]%-VB)HD,#
M?AJWK:)KNIQ'@PTI::7(D^+:Q:5HOP"]S77)P:VLO)R\-?>&?L\[R6!=N7Z[
MT+`'3G6\T!=46$!@?VIQ!QHIV5<BE*QQT6HA#)"@AULKRE3[JE1;L15\SR+-
MV8P-U#!\TC$ZU6`=,I+VR:/!!A`%SR2T(E:`42-SJC8")M',#L2D/F5J0(S]
MMLZ4$N^<L:YMPRLQ<OFZTV#MVB0M+?A3/->-W4YKV4']SI(]J\ED(_C:3L!4
M>Q1USI6M<^)=BA-2SCZ:N6N]WI-8UF06H\,'H])]I',-_YU#D;6$&%`WZ2'.
M2C^W9[JHRZ#5%*]2?<\CXS5K1=NO#:O@]&8G4TPK#<GAXM38/;L[80)L<%X=
ML`*YLMOAS1J?C1A86Q,6-=7I$]8B3E'0W8C:#:TB#I;.?26+I'LL8;6W`3L!
MA#,ZSLI<[*H._>,KW2T>/JT0^M7N?#LEOMFL^I2/,1F>PB(S,Z+3+8D5Q-MC
M;4Y,KJ!A2=K[(LDZGHB("Y4_"HW$9,BOBZ5M;2*"+<_4]=9H*=)?TI;V+->!
MG<5*"M]:F,3G&M1O;</%Z\2LA<6.OB2'S$+Q+6F[/6-G1K(@3EUJJ.E*?<]C
M[=U"B=`]J=<4'4#4,BICD'4<4_\QD\&.)W#::O$-^]B@-KG9/4Q`WV+(93JY
M-0,_`PRU6=O<_>U+:GUFI*XDSV'3HX&U0%K"O-VW3'GJNTY!MMPX"%&7;BOD
MS:K(XP3FS`RJE2/ES-XR3@:4'@[KTHZOM]PDTV3F3[D0:D/!Q*.OTZ[C2:)+
MU>;I43ZY\ZV@I"VJGNO/\&/.>3[3`&W@^8[IV[=&//RY(FV(#:_62SJT\[Q.
M6&,WB5S%%I[+!L\2]RYZ..$GQ''/=F(_NC[`I2)_@='M+.+E/;E_(@%.O.#R
ME=4&3*!241<)63?J91H9(,"GXG>I:/$!&]W1."%`*?_R]+/(K0VD>45Z^2OU
M%]$?NG?_N/US.YT,U@[D+YEM\[^M&:%(N@H$]4K2/T6.L>)>\GJ(W:;IP?8S
MM"=1H!?N;@@[5L#<YGE5\DLR/>]ZRH+?]FKOT/4;Z\E[,)^J0/(W>Q3\W0W-
MV)/1%<@[/:BNONI\3\_+S5$Q?RDONYP_YX+MUA+>JFMM<@\_8WQ=L%:MKUO,
M>0NGX$IM6+$-N)X./]5V-WA3@@K^Q[(<[J)WZHO/V+/Y\M$<[J5B$KT^K;+#
M]<4.=!`H+(KL]VW.Q2T-"]U;'Z9V`H%P529P`R90""N`!1^0@5>G`5*D,BX/
M[,T?$H[C9"TOT/.3\EHNLD;M977)'.[=_``!"U8;$+!X"2QX_U#@*E[A"D7Z
M%U'BQ'\?"@C$*)!@&X/80'!<-9`70XQM.%([6#"CQI6P/O(Z:!(F2(,87Z)4
MB3`CQX$#$^I4N)`73Y7L?`[DR;+DQYHF:QI$N=2@470]12;M21!65)5#M\(<
MR@L$B%78Q&)MR5,KNZ$<@XXLR9&M2XYH5VXTBQ2F0%Y1,X8,:A=62(8D;3[]
MBC&F0<(C':.D&'FB8\(9L2E>V1?N2H9^_V[.R`M;2+5N.V=&&3+S:<Z:,V-4
MW;%E;-I]75(Y8ZR-0LIP*_=D1PVV[9:S73;-N35I;)3"Q_YLN;@F4Y$LB4/U
M*1CS2YUW!1J+<4?RQ#NJIC$``$`#`/\&B9I%$S\^HBR+NX6[I%X\II7I=N72
MWNHYONR2;JCDE#)JH<'P*PZSXV)B*JF3WEK%!(CDJZB0<+IBT+N@%O3IP-<D
MU$H@X7B*;;.QW&I0IY"HDQ`[H1#BKD46Z4KKNLTV\HZO%Z52S"D0%WR1J0\Q
MT^I%M51SZ[[!(!0Q*0@3S$^C@E*,+2?#$`NJLP^7ZPFTVBIK#$.*-(MM2`6-
M2U.H-A5\\TBK7$,--(Q2D[.P'A-TT[B_GC3PC)S::`Y-W]ZZ4[H6Y4SK-;YH
M5.K/%B-UT"`#5;++21MW6@&0#LP$5;X.&!"B`!01TL[$2:VJ]$D>6WUSU2$5
M&HO2.Q=E5:#_RS*RT$R+>MPI(TTA='3-2=$*"B6",(U.TQ$G->I5NV)=]<,B
ME?J046`?7;/67$WD,[IO/Z12+3^/+59-50%CCL))@^+3,SLU"S6BQUJ]=S9&
M?VLMW.*PTE-?9XDL#C";D"U4UB=1NNRCG'HCD\[$_F5,VS`7U$HTV.[BR,AA
M"8QJVI8*6E;=E7YB2$J!J&!"@OCJK5>8#S@II(TW"S)RUP%+JHG)<WDN,;@6
M03A(LQ)7=:HH_>;$F+\N><5"@O4T<$,#J:\6HF:>B];(:<6<_2CH@0^#1>CC
M.$NK#2N4;I`GT7Q^^BZ<W=)YY)JHY-;DC8H:&]O[H#.6I1+M/)FO_Y!;&KAC
M@@ZB]F+5.#36X-#(W/A=G:GU]S.8^4VST"T3_=Q'Q#:.+>-)0_=13CQ7`U'$
MPD9"754WMTS.\T,]"\D*%MU.>-'&'Y4)%MU)?E)<V#(WBZ8'LTMTI;R:?PT;
MEB60Y5.8Y?NF&5(+>/AL`Y>3T]HC&>5N1<,MGK%!DIQ**;E8K?VY+70*8(()
M3H!@(I#Z]]^#BAN_ZANWW"(6ZJ"$-VA)3:2R=10K22I=;TI1=[XW'.,MQ%EU
M4]9/S#>Q8A'.9+HSB,-"HQ\4U4T@?*(5<G@7&%@\+W!YVYG$%-,9/N6E+C-4
M4[*\XB0$\@)FH!&?GB3WM>L,)U:L$='X^/]%NH+)<$;$4XF7HO*F&_EF2#>L
M6,02>#:K4(-H3PJ8=4ZT0.7QK&R%.^+2*F?&KH5&4V5<C`XU0H5(-,-ZUZ/(
M-S0PAD(4Q$DG.J%2B.87,%408PKY7VMR!:#=?$9"_(D6JQARI#2M`CJ-/%DK
MXK*2@;WO3R#8%>#0=A7&7&PW<B3;8FXX1&/UA3\ED1-6UN9`C5PG@B\,DT=6
MHTKL8#)O&FM*(*U21D>B9HV4.M#Z$&++2JW/:`M#FYZ\HA!CS&F+@>L+=$0$
MBQ^ND7%$HHR^4+>Z4>;D):LXHF-:@SHOX:J`X7Q=L";7F[,-TE"-*51;@F7%
MQE2'+P;J65#RDAS_MY&R>*%1%#JSQ3X$N>\M-Y+)$F/2L3T(00+?N-XW&!")
M%9C`/@XBZ$["0L@1\N2:EF+HQ3@YDN2D,)[_I$L*@WE,)$U(F8_;Y)<6Q$M$
MVM0R9VG*[N:)E9ETQ3-!1>2C7HE+97YEDLJ#Z%<`%K[N\*MH1D+*Z$P$$Z*Y
M39]0B=M/!L<J#S;5B?I,R0"GNL^J#DE>PU$B&)6"C6I6C)S`>TI2F"40F.$+
M3U*T4Y,8Y<3,"`FL^CDJ$_55.#9NC)^,W2K!NB:3QZ"I>/OIS^WV@KI(0M-P
M!X(<P.)7F=W@#56'=2-;76)9D9SHE>@PP0T*`0D@C.$$'_@`*4B!6]Q&_V(,
M3"A`(4Q@`NYD$RIJRTA"PA<GZTA,-4M%;A$-I]KS76Y.0LJ<!T/V3=%\$9DR
M$@A_V#FY(9'&CV?+G,G4%$;1#$Y(TO7@UD@+%[4U,F,^FRY9YTF-5^(WIN\#
M)$;"%4:#&!:]!1[ANYJS6IQJ))%K)%E@8/(YGPU8/[^I%9@8$IPBMDDKBEMJ
M7T<'F"F6DI5$;-:1"BJ@1P%XL(D]WVE756+-!`99[&*L9A)8M#>F.&&_PV6+
MGD=40VKU70J#(?IXDHN!4($*A2A`E*5<""J;@`I5H<8*D0QC(W^(RPW:2V:.
M-*S&]9"JA@1RNB+[0/0ILLA>;K.:80C#+W_+A?\);E&=5ZH?].D9;6-68ZM6
MQ5G$&1,SB*(I!4.48D"55'@=`Q(WZS4Z'G,W*G#95Y<]DY^Z&);$BV6T<8BE
MWQ3CF%9JP72)R583U_SFE&-]5*O!FU^M8N5`1TT5GMGH+4&OL:!M&]"!+@-(
MCH0C',.<,UZ[(V<D0[9&03:9Q224Q&9+^V`_2_2JO/ML(ZO78LD!')<'FVR]
M%CG1MTSNJGL]9R5?>Y3,[K5>$58P,VJ+<H&&7@/_K.KM@)@C:U-)-]UHZ6^2
M.'Q?!@RDEYV?2X?Z3VFTRO`&,V0*RAJ1Q+.X8JCC&HDME6F.I;&Y6>)Q2J=I
MF\FF6%X-9JZ:D!Q;C:+_<U`VOC61-ONHD&N0RZD[.A`B9D+?PM7/D7WF=>,K
MA!*LN<)^S<%EU_M;6!',S5'NE73+$\X]Z5ZSK9YOZX@<YE=7=[%2A?.\Y4<L
M1S9X89E>+6$5_,X^`2&G"R)BOHSFL&FOC,18Y$E6@:":7&NIN`7/*$R:W2_N
MZQEJB7=WF#?RQ$>)X\!W*G5$5K[I23[M@V,8&O=B1[P%QIFJ5.8AGRRPQ719
MJLSSNL`#+3"MR^-BY(/4%8ARC8%\6;R*D8/@Z1SV5;RO%-534L'FK,TD@TQN
M>G$?(\M#:3O"?_YIIUG+O.:^@E1'U5N<5+2DP="7KZE53,;G[F#6?H0X1]3K
M_Z.*UX6*DB4)JDL4DX[BM#<2^I%F/_4-)K'O`=Q;LQ0Q@IL\[CJL<2,\6J$.
M@S&\%S/`Y&(1$6FX[DD[F4(95O.GE^`=[^F)E0,>`1PBE?&JT5.JQ!"K;@NS
M7^JVIQB4T6$1V5LZ2O,>_XBU%^022:$]%=0U[NN(`M&5%*(ZG-"(ACNE=)F)
M1[FDF;+`%^2:[P.]WDNJ%G0T5BLH0J$5+V.'G+@,^(DUA#H)H*"^UUB,MT(T
M;M$@BMO"*4Q"S^`*MUBQZ2O"K\@ZO,(I'FRI#CJJQ9A#E:(^#TQ"Q/`+B3.J
M(M3!Q!LB8ED6<PI`&E/$@@,KSQ`L3<$J'$&Q*B$LU/\BHK]90<22K@)D&)8(
MQ$O[OJ4"C`@AFDI3*?M;1-1PFX9)*FU#.B+DHER1+G/JMNUSCA2$N9?0J1;Z
M&MB#M[/QKS$C*--KHX'P&IG3$4!2%(I1B;&(+\RXQ7%K$+(SGBE<QEV#PK_X
M-:%RQ=)C.\B[BUA*I?"Z%0&*#O-SP+S21L3(Q$GY(FK,H5PA,F?3*A"XM'MD
M1#VTC?KRF&\*$BLRQ>02(:V8NTE+1;SC1-L#0WV#+#*L0ZK2EJ(Z#GC<J:5)
M.^%A(*Y)L_99$0+,M(P[DE>*,^`1JW<*NHQPN5.SB3K$-X7)"8E;.UT[LJ-Y
M%<`3L\9R%(+J.0\K.G$QG=__:T6M.QESRHDO\S,R=,#^N@N11++7@Q"3TCVA
M9,B242]!$PR9FJP>C,6>+*F2A,K+P\4$@Y&C@3&.P\>P9$B.HSF#R3NY.8J`
MJQ=31$B+PT=(5)`)ZKF/S"HXH;<XJR]+A#>$A+05.LIE-+@[/!59RY+PN\7;
M\RYU4XF\7$GS\Q;!<)NC@2%O4100T+E5*Q&FI!'WRX_';#K7Z9IG>T>BJ#7\
M&QW-[#LF7,G#F$?\2`A(')0C`3=DF4PY,2?>E`H1[!!!.KGO\L+81$)>J\>J
M:Q77++>N4\Y9PL@A$9!]E+'5:DAJHY'=>24823F`PHPL2;*Z5#%:_+,1JK2S
M-$Z<_SF('SI(QB.XABNRL1H*R43`0]/$XBC),(&QWD$\CMLVQP*^G4%)\X1/
M&#I,VV,Q5NFY;WE)NUE,Y<3,W6LZ_E`)KN"U"RV6O0HF/T+`02'/EEC0(,$S
MY+0U\$L*EQ.Z!#V:UI,Q_BBW+KR4#XW%H%C0KJ@=CE1.%KV]CI&IPT.'05FJ
M%52]I]M`T,/0L,-*[X@B'&5('8VPX51!7JO1#%7.M@N1($VWL[NXL%N>+2TP
M&$T8W]0Y1CQ/LY2ASP0)$.@KNI3+A"3$DGBE!]02=8RQK7P\&0H_<I3`D]$[
MR4N1$ODBPBC%Y30E,SV<;&DXPN"1%25*F"B74[/)W$0]&?_3S(&JNF5L'TAQ
MS`S,TSQ-+E=J1KTR)\<;OB9L3>28FU7+TP8#QQEE$%Y;T;UCD(.H*ZHJD5@U
M5>ZST:[0F<=DBB/-2)2`SEF]5!RAR49E-:R"G((0R5LM'[4(1/?BD#KDD0M]
M1R+*&"\2S<<A&:)<200U0E]2S_#"E(3XB.U$&8`:-4SM#DI,U-:).\UCO`EL
MN`_I*LC9'/>L2+8<P#`52#K]DU)5O(<9/$W-E>Y1,0+<4^Y+TA,K"P0T!K$J
M4QP,IC*U42X"5F.,E%]K1H><#BRE5)WXO+/+B@Y529>`KCCEHL0"H?ILH/FT
MKW;DT%J:N00%UOHBV0@[')+!I&7_P4K.],1@Z9YV#$[H'-8(A32ID],/75&L
M&Z8L[#O<T\R,-3"%T\&_-$Z4#2%S@JZ5Y:J@9=*8DD3=<1J%B\E=I3VFY2)S
M<8VN@KI.9<-1Y1D*358Q<YO*/)\(#+TUHSDSG5<P.ZPU7<0P/4NUQ+`J0;#4
M<Q*"?;W3(T<D";T*%+6F(P[D.CU+^A"/R[3;$)3(K,A\M+6VC$1F!=1TZTCA
MP<[GV+:.U;=S_4G`L8WA25NS7=M4+4TZF4X&P=IAQ9F7Q,Z.\1KJD%MC+)E,
MC3RO\%3673:",+YO_3C:W(M:(=LFM5G8/8Q:Q9$:Y8E94M83_4.JO,)FC$S+
M[=W_7`DJ_WF.^IS>O9Q(W^62OX&%O]/4#XW7WK,)W$4'.9W(\"JW/(W07@*X
MZ5#>40V]3'VW2-Q*C'Q7=;,_,!//`93-NQP,F!E<KE',Q"/31^O=7E-(EN2U
M#H8-<)._(:U(61S2WIFI.24YKC$&*DC01N2X,9RU5>'=<T4V/]Q:X1T:`7[<
M1\L6)K7<D?'6PQ`E!$0+S;56F`._#5+>^8Q,$FT5"SV0$%TXG?P?X2`@Q$4+
M:S7;D`H9$9(GT`M29N7?U$7.V,N.]O&X]76L9=E>6TGBM36>YU#-Z,S:6NG8
M(@Y-8#%@_"`YT-2X,T;C_\-;<B1&-$:Y%Q(A5!*U']/71T.Q;O^:0(+A5QTS
M7+D1R31**J<YO#EMDW$-3DN,+JDKX7]KL<X4%Z+YC<Z]WP*4K!M4535ZXW_5
M-LX49)>4%0&Y9?Z%9!ZNY5!NMC.6$]W06JD$VE[39?=;"9*34HSP.#Q.CLXL
M8&"NXKTM#A>]/$H48H?1XWH:2C4+X%T&T>?,T5_UFDEAYEP>BP`^"$#.9BB%
M%'&^X0*C8A>A7,?U2849/H@\RXN,/<B8-'K-N$J&X:[+,$*]R\7SV"W,VE53
M2$E"0M0R93VK9PGNT-8BTX832=+%2.!<GL5YBF'E%OZ@4&ZV%)HM5N,]6*QC
ML:N"):T%U]>@6S]&X(5;.BAM1HE3B.W_C,V8OL;V=<WHU*"?:&=8UE,:&5;L
M(\\P^U^R@6;O*]:F@SJ@IL:?:-F6.SFZ55WT.U&B)E?[W4Q;GE80A4*1-D*=
MV&`Z76J*)51=%B"2[1";C&A`EK_'@U.QQ+U\OA4^E)CNZ:8+?D]#]4?H`*&6
M_4-K2B%./C61[&17M6/)F6G<Q4C)P3B<(`JFMN.!L]!9+=R$&6K[53P-O!*>
M`3<$S!T\'FG.FZXZ/&<-JB85-L96=*6N<2EB_=%EX@H-/.?#J$()<FOP?.;6
M@6LM!<<54<J<';&MG,^:0`=-$HC;/I491:[G*DXKN)80RM_5.CQ?%.ZQ5FD!
M:>WHW.<`BZ[H_Y+$^-U;$K:D-9GET+A08FX2M*91DO)N8M5E#MO?*CPJKS%O
MSLR@:5ZVF?@\;VYG%6Q;H.#/Z'7&@O*O[>#AVA1`62M&'PIH?27HC*X\8@S$
MXV!L$CZ\GFMLZ%3`@!59AIYHF]0=N!X+@RGLBPVYB935"-]?IXVQ48R]O2I5
M"N3E]!XY.*2YS([<H!W:XB2+AUDQ#A>D/<1(</-"X@[:=M5`1'Y<EC)"NL7F
MXP`3Y>72WE.X.C[G]5T,R8QFI];89?UH_M6,L9[(Y;8^DGW`*6<:2.O:T'-$
MV.@YIGQ)2&,6H`VM!";JL29=N!YDT7;.J-I;G@XMP^ZY+W+!G18*A?^VX(CS
MNPJTR1RW8]6U#P*<Y%Z6M%")\$)YX(#LYE1R1,4N<0N4WM)$O`#?-`#M:-2*
MNRP=DN'A#R_"X,T>8<)MV^;D0V?^V#HE"]1MZ$"_#RH&6MSEUIZ&9,%"\E2*
MW2H]9OD^'*;,5D<W6.0$<"3'2O!TRF(F1R@$9>@\P>1"5Z0,'!%.O(\>XA(_
M;&TR<5\.Y:+$K.`^K!1'B')O.=QV9EF"\"_$V!+$2!*6J6^:UN94MU(-7J]I
M$P(:]C]Y)7O76@S;1`>AV[;L$*RRY$)W6=4U=<K)>+J%F7`XB&3`8)%GM:@@
M^252GY"&:*?;:<OM9-J=I>->-<GYR[[&,X#_(SF23ZR$>"6_4+T\-=2FJ.'$
M('FUQ*+A._JN-,YVQMHA3:J&Z.TE1UYV3#!3/@P#6MNBW\4JO1CRR5J!_=["
M4<C%&-\C=&<F/RRQ,MIC=VBT3C<A+&=SU#D-2K0`%G;37;,MA@63)\=;?.(;
M`?,!Y6WA_FI-3:&;/NN*!+<Q/M6S/G)86/H\=YH/YG2O+XBE-SJ:8DIN16W)
M_]P))6+:[$?0UTC$H%#!'?F$1`F3=PW-%Q?8A^2B.;9'&UF=N.D7CA&!(/F4
MOFO3/WC\^#<H]$?9'2&1=T1>._IZ?5RS-D789V-!X]IY)&.>&U#?U%A'N?EO
M)WRL?/@@QD%W-N\=_[YW./=U'(3G[,=:D(*]F<Y)@3UFP8"<!46?\7UX<_P?
MA<YL9WYB@``!:R`L7@1A"1QH$):5-@<)+B28D.%$A03;6+&($);#A1T?;J1(
M,.-!C!`ODCSH<2`(D@(K+FQ(,MS!BB<=LI0(,F+#@B-Q7@0)*YE/FSYU#B3*
M$H11@[RH\0H7\6%+IB^M)HSJ%*K4@ER7_@LK=BQ9GZL4=M4ZU*?2LS&##G0+
MZVS)E#R!6A1(,J8Q$":SYE29DR14G0*=#DPYEZ'#J@.E<D6\5&_2HXDI3B3Z
M-*I.@TR1JI4[%2]2D4N%YK1)>2#0E"U+,ZS)T.[+O*4G?BXXT7/(@B9-4O\=
MB;OI1J.K>[N6_?`MR(P5C<H\'7AD[]*\<`N7B%WA\;=&@[,^S%&C\X?ED0*W
M,ARN=_/`KU._G7)O<?#B)R8_S?MH;9\N2TZGGG;Q@6?808KYA-ASEE7WUVL@
M=;48?,*U@15"G\$4860),D66AV.MY11-!8UHD68%QC:54TK%)MY*/7$6&`@L
M@H#.A1H=R"!C)UV6&4H.[=4&.L`E2`U:-^9VTGX5AK394>=A)%YO+!K9WH")
M-=809;Q%=%6..%V79$*-50>"@A=N-YR9L<FHG']H3O6<>/\EM*9@5Z;&'W;.
MG9<33U89EI%GVVTD(&BI,=7E26+FR9&*NG&49'W_B3'ZDI;\*6K%D#HIQJA(
MNU57W(/L59A?;0L6A>:398I'9IT,TB63C0;B^5]/=GZ$J)M+[15AJIVUJ=Z$
M"/&4(%K[G?:9>A8N9-")3]4$PH?3XC@48B<*QF63-(FH)$X"E<@+D9(E:6A?
MHRKZT50-25:HCJ;E>5B)#`H(&+;1#LO=KL0A%B>;0BWT7;[+;A0PF^0J.IU@
MN<UIII1#/=<&<_G>J)&EU>Z:G%.`+@C3908QZ2=KT1X<TL-ERH:L=/CU5BQL
MWV&&LDW7Y:<ML44EM%=_**(Z8<`V9=03@Q79&/#$%7>\L$7&V&;PSRWW-U5P
MCZI66TSO\6@LI,#"QQ29_VXZ%"[/5C&-IH_5&FS%M!\FZ*M%SFH=*H_/"A6=
MU*#R)FF-`A%)'7V!@?D3NWHR++C$),+]LZ$1,2>2H+[AERO*L'2E6809F>1R
MDP2R6>[A(X-GD%V,->YICZOF*#6!A5,',[*JNX:=P?\BAR-]]\G.V.*T%[PZ
M=X7/WJERFN=UV&=I0[2;<0"N;"?FC_>^>7,CS2HW@E)")Q2CR`,K]W-/Y]M=
MR3!_S%#U"XY>.>(Y7J8=H%K/I]&]V&-5)V#76E;>VAXR;BR+;]?M6#CB3+MV
MPCZJ>,IK`(P-7KCG'NA1I#%`&U?6["?`Z>SL9X!JEL(PMBZ.(&A0L&%>=,H%
MPO_E!"AGTWO-\5""&H20!$%UZ9&4GC>07)`L,,+#H:AD0YS>``=H+XF2:D(E
M.D*A2CB*$9K(*E:[T[%P@O_ACT1(TK<Z.0<O5L#A=SQU/=;()%'4P<G?<F,H
M\TQ*4G++C@X?**H:M@:!I1'>"=4#/8SDJH!H&]F@WO>N@J5%:W+""AX5HY1V
M`6=_95&+`!,WKQ=VJU\+U%W63J@@ID2'4JN1FF(B`I1V522&22J6B^`G025M
M[5^YT)E5_H8:^A`P?U$ZD`I[LY[)I(@@N5!C2)AX0NFH"B0[8Z#)5J<FU"CK
M0+^Q@@R=Z,>KG1%+/<&<,/W21Q@I$V:9Q&!"=CE*&JK_9IHO%%-NUJ5&OD6'
MC'AJ)4CP&$JD\-"6.?.C+IW(DN<1*79K6A8V?U+$O[`)*.3T"X^\>9*4`+2:
MDR$-)2V3.#0*#DV==(_J!%D4?B:J0E(RR+PJHD@0&4MJDD26QU!)D/_M"D5F
M.Z?XP&B[EN6(;[\;E0]/6DEV4HY$"-4-F<+DG*X$TBXFB9`>Z;DFKU$,F!R+
MZ:AN:<U?X@=#P=&;;F07Q&,"QCE4=6;[8'BEJE6OEZPSV8,P^4N6:)0[+K'J
M6MW7H&7AIJV`<TGLX,48$##-:>_;SADQB;78].4B]I/8.^%E5B&:;JR$NI$,
M_2B@,,V15X/QJG"V>CR6W=6M_P\;IF`"B1R&V9"#J%2+BK!SE9=0(;!'"5@\
M#?)1L9"H,B**2(FP)QFUC`A;DBRF95Y5,$!!T!A`JMM?-Y*+PRE*C&D$)4P3
MAB$]"C-4:Q(M!BN)+;S:[U4.DR,,[Q.J<TF'8..[Y:06@@[@,JRLQ</E8(!2
M(=4N2X32/:H8;\4?\%XH:&9<KU*E=RX+(JTDZ=U37HPQ)*UJISPQ&7";)`)>
M?E;LL4HU[4.,`=_T]FEE?8T>",Z07O8N*E$XO5C`P.LU!"MXPCJI4$30<6$S
M:33#2)/P,)?UK9*2:S(4_B,`=PN+7;H2%L8PP0U,0`6;MK=9KPW+;@-)MXE(
M3FN25/\?![?8W--J<)L#"6PI)VNQ'548>(U2SIH.*4^8YJXXT3Q)(+%G4U!>
M1:Y"YE&2RD:K^ESVJ>64K!-I%D2$1.EP>=XL[M;K/"\UCSQF+"*%\WREITDG
M;P:RB@@A:Q&"A6FZO#TQ.8$9'OI>NC]2/2]![-S""9^IT6*L\T%93<55ZP6O
M507UDV!-9K1NQ!@N,0;XUAG*66+N*H=#1TK*MN")V'G,]_RPF4<T*`1SZJDC
M/8BS1V@Q$Q3"!(%-[FIAL>1_0,2S%41=MX[4/Q36=HU[A4V77O.Y$69*3W!]
MR"YS^33D^FYF]_&760'YKN]5*YXCSNYDCO@U@_EQKQ_6TBW_Z5@NA<>9S_VV
M$PC3JN/FG?:K7]8;@QG[/O$"YJYJ.BV*G2E5,A\S9G#-M"8[&.N#X/>P'9\X
M4T<>S&0J,&9%Q/3-E=7Q``<,P0N).<%[[I)U65RBB8Y9RT/.62"QSL<6XC#7
MVK9;:$;/O%2PYI]!-9!O,])_1XGGOQAI]O4Y.6Y;PAFBJU@UA+16(CR\VP'?
MAW2,@8#L2B$)#W<WO&09;V[&6E`L.RWJD0.8=]C-[LX&W.D[+2NOD6K)5=WW
M861B5[,\)"?(,>M@QY]YI2WG73!U;D7$`_.*F5_*+)LW;Z[61+42?7S]0`S!
MA&-(SK6W)P*W;:&R,IZ\FY4]Q]:Z_]8-.K:W`X7J/*=NPM8)L8UO?J-.]F[M
M<'.T@%$C&<B2J1'7+CFDCRE@#`'V-K$URU=P&^%I0P[#S!7S9.[J[?LKZY?;
MP_3'E`?@=OH6SS+.V_U@3.=T"ITHS("EDY;%WGXU%"P4@_W8$)"QC[@L'A2Y
M57XYQ"KAT:$PA6HM5L<%S0:ZE&><EPK9T06V4@9ZWX]9WFJ(%]*\CS>-RN!<
MB'"51[WET%+EE_E58*$0R<0I"]0U4PWZ5I]PS&'=4QSA3&`)331AF,DXH4*\
M5^%LT_*Q$!/)2<S=D%/M5R&-$TV]$-F-!Q?1T0T94-8\2DW`4GRDX-5]VV.L
M#]V!3AQ2CO^*`-4`K06]70@7)9A-S-(P99`9EE3I:9?2--,PP<>29%*:7=Q,
MC%\='H5`R55\=14+S9?OZ)BLY1MES=H!+@6QV5W'.(9V2,Q[(%Z2")SNO)W"
M&)]1N=#)P5[[M%+"^=`H2EP5X=+#51%`"0JEC4<J=2`A5M:%_.`'SMK4V5)Y
M5(1!G156Y=TFLM`1^9:,R!HM<DKK]1<WU<_LP)V:Y="_A!)G+40JXJ(Q@@[-
M/-IJN4T/Z0@FT=-)O&&[S!:']8_9$96Q!-*TJ2+NV-<EO>`-I9A.U%M$R&!`
M;A^6#"1_X"!G'!V6A,3F+=#O]1B.)*1?(8F_8*%"R4?[,5HO5DW_?JQ,":(*
M[G"068F+/FT95C@7I6BD-HI>345:58$DTI3@[7"B<@$3%N;&?WT960U-Y+#=
M2R(<SL1)$C$C5@A/122;9)VDVZT4E#7DGDW>16F2<_#DU?0.3MH3[@2?;"C&
M4L9B])173\*'EE!,$KT&!8K5^H@?;^S.SQ#1XT@&V(44MU27CYG4N>D1W61:
MO5P4_$&.W?E&BBV8T%R3)JJAU_FEO_0-,C74Z`Q("]EACBT%I`W>Y,A(_&S9
MYTF7)9GB'"5>-=[.SK!8^_P@SGQ:5:2:QC28+')E]/AE5=W&KY@<)[*C)?45
M-\J>B26F;;#DY&"20;@89P%BJEC:F?4E_]9<3!.-B9T@V^=PV1TMSN)\X*`<
M#F_"I,@8#U^!GILU%14!VA']RE!^7Y/@%=,(H&%194KNBE+D(SNV&VB)WQL2
MA&=M6+:$R)WT2XE83D6EH-<=))(,C?1XF9JHB_ZM6:-TR3;]QX)UEP$]S2BY
M#;E$D5<5U4W>2-`E&#OZU9_<S*2\3*R=2OX!8C3I)(*)J,SX4!GNX'(2YQF]
M'K"`',$<9&P*J'+(X/MAT8>":(_VAC<IXYTA:$5@8R7Z7/PM2J24(RUIUHR=
M6G$ZG2[EWH=)2;U%3O3Q"IF(4A0^QZ4T#C@&!V3RA@S:V6XY)YW`E7IQD$AY
M552]7T90P=8M!_]=%I`6F924J>.C3)M:=%QR-58FC2,V+FB_S1L$@5!+2(87
M6HRA+!:B[(?VL=-M,8A/L83L^9B-JA&-`9]KR,0XSE^&^D?#<=P2'<<W?5:=
M+`,MT12$Z0=XUJ93JF$^N5_S\9DJ4D5?S>J&[B`8T90M5HR#JAA+AE-3N1)]
M0:#@9(5,X*I%2=RH)!2O?N-OOBI%K)DMGJ">]%&MDI@TK8>_S&9O5M#N590M
M:9950*38:1^CVA(5%-FV^40\YB?MA%#<K"E^_A%B"`MFH(N!2(9,,!1GZ2M2
M^*LL^9WC1)=`K%+[_(F8X4A52$J]'ALPU:-/8&/"TA^U0ETXVDT2LI'_ACZH
MJJ1-5C7>Z(AJ.`$FO/A=$^+<KYGH_MW3K4)KS'#;U7QG3ZI*I.I?=0"9Y]&F
M7S'<BM;4N3Z)H#E&OTG3`TGBQ5(KTQF$E::$E7:L0ZJ<Q>7-$ET1G2E1K8H$
MF!22$B:,C!Z$!JXA0O0%,V$-<_WF?VHAA!H+PU&>:V";D3T(^+T6"I'K).GC
M:$VD]L5J@GXLT$;B-FD0E!9K@B[G@MY*OL1G_J7*U%&7QQ9?)?EI]Z@7TS$:
M5>#@64'A+2*K5\;5MT+8L$[$<5TK$.4'R*EAYH[9?5+6NH&KKGCB/?6E;=;8
M<IKH;XK7[;0>R+S@:;[LS05NKV*H?*S,5-UJ_U8(KVG07.-:[1G](%W=8M,N
MK9"^$]I*5[56(#K&S73(X!%6X-SJ2+N="[[!`CH0V0K"Z]?F:WFBH4-)KOC1
MF+X4[+8&'?P=D83-GN3=;\C`I((XASG!B5A2"A/>J585;+L1Q`.BYM5MH<P,
MAYS18+W,1]0`&,11+NV"ZLD!J5)!CSM"7W88"C.^8)2&8^9>(7LA)OZ&4?)(
MX&`TW^8U:E4$R=LB1=%]7.#8Z+)E!_`YF)0.+9=Z[A82E)!-1#&,7=LIZ[>D
M[:!)ZVU^R@[#,*JRT;)U3"J>$0"[W&<)(WYZQJYA!9>-HF'F94J:*D(<V6_2
MYQ33X`N][YVPL>F@!/\8+B>3+H\E5JKW_._Q(D@.4VOF>=T=&ZU]`*RPTN@4
MUVMJU!4U3B--+4,;X%>4/)8O/O#P3H:%+>E2G"L[N:G[$-^K,NJ1LJ)?R)X$
M9V/HSN1+$-\(SQ,N76NO=F!<-54%@S(G1EZR6>OG6DBJ-C$1&H;PH3#[O;(@
M,E,GMNYK&$KI5L4H-YZI_3)L1)YID5?6G)$1UR(LYJO?1F;]F)@RGR&E.+)C
MJ`Y^9$0:JZ?='O(`HE`XSV3KA`H?][%YY-W#!;+<X2]F^)(.(Q#93%0F;B^M
MEM*)O@QJ+&AC+JNTVD39;)CJL@H;J:X'[C`\[\L4`Y=`M?#+E&&GE$TL*Y[_
M&H(FS+U<$F*I79$7C783P#Y>@`C4CJ+5JD85IY;&45ZR&K/,%*&PI!41+GYK
M\0HIRAJEG)2)`K(QF$;+,G"6\.#E&Y&-PZ;@&@FKCB(31)(S?LP=C[&QZHQK
MS5:2@+A2Z?Y(8YG5(A:L5C>':AIO"Y:Q)LUS=?DJ>D77;XZK-[*$P#463FNB
MI-B12R<&37-GXO5HIXCA2,HG%>,T[.%U7<M)>H!C^0'GY8$89@KM)R>$+=_D
M?<1/S:I'1D,E.*\B],(@7Z_U%)?&59&$+5?A!%=B.3+VSLH=1[,V626$`B_;
M$`;<!R*E,(E24&M5_>1>FP[ASM0+&"XB?;*N^;W+_^/N$;"N$=(%V2SUJPB6
MZ]"6C+(%2OZ8+#*JG<.^$B*;HKBZ*OB:U,#ZTEC]2R'C;!J%VG`]8TMGB2M6
M;GBM,I98BD9ASPF&4^P>*CKY8J/("0YALU9GW)NP4#'"TP/+L`+5KU9%+%-7
M!1$%LD,,5PZQ+L&$D5VG1ZY085?YJU)K;&`\6USW"4:E*:<JZE<=,QD5>(S:
M*E531]_=F'5?HVR[\"OOWC36&D.0G<,>(DO0Y^<2=U!S,3;P`COP`I!W7TGT
MRRJP@T\D.4>T`I@L.9-#!)"#T&B>$H,XN""]Y4H+QI6/!\@P34<,>9BGBD:!
MN8+T7<7A!#8X+K,"6H+P@O^D.CA!84.;</DO5@R9DW"2?(MZP'2EMD&25TB@
M%P20Q_G#./BWE&*Q"<2<`XKDR#<5M4$;-+F=2Z%?,+K7$&G;=9?W,L6<*^FE
MRQ0L`'KI*>-G=,2B,9XEBWK[[;!5E*9H5ZH?M0*F$ZG(W2TQXA).C+H"+7FD
MCX>DNY=V9"MIN.W!SN@=Q[K>P)5<8W=[)PDZ$#67RK;49*X=:?@K\9+V9.*Z
M573?"E-2)7"'A!^/![55XR%"M,)`-#DVK`(U5$B3I[NHQP2[S[FD,SDAT?NL
M6P49V#N[LT:D@T#<>AB_#\2<6X&^DX&EMWO:X%&Z>SJ@-02\6X6'M0(UJ'F'
M607_-CC\*JP"H^O[&4@Z-<B%+?71&<#"K)\!&<`"-K!#O;?"PLO3G\,\NOL[
M4]P`","[R9_%&1A#DW=ZO2.)%0P\SNN\1)P!D6G;&:1[DE</HU8(MMW\NJ,)
MO`=Z&YB\SRO]A7CZ80"\,11"(0@7-K3!Q7?Z*@S*S=,[4Z`\SJ^\I%M%*W@8
MSL,]1URZ"1"9,7A82L<Z+YC`"OA`'IP!-H@]WN.\UPB^V@.[AYU!X)^%7\SZ
MUYO`K/\Y-?QVX?2]#Q2`,?S"*FB4!V94D159X'NZ!!4BH`U9Z">\Q5?(&;"#
MNQ-4A_VYFJOY&4`^"*B\V*M]SG=8UJ^"VC.%TFM4S>^[_V\XA.*+^EDX!-XC
MO8<)/C9<V,L"BM-RG*K#X!19J<+]K8!(-AN',(8X!ECZ.$@40T-P&5%W\86<
M6SR+H:<)4U]\6TD/X;F%/SL8`QJTP/W?_R=\`3:D`T`4^-2BQ98;OWZ9PS/0
M![8S!"%&;(&F$(85:"027&+BURIL(/(L:9&#9(X62PIA2V=,I,1/]4Q@6\4+
MEI4V(`I!W,$1V\UZ&2-V.7/&!]`67\C\`H$QXJ<E*T!TA,6KC158L$!<_9G1
MJ;E?7SXYQ;!JU=6L(2<6ZOC+1!*")LRU6L$U:8$M$M%<PM.&##5V5N:Z/(/M
M%SM87="0C&`291ML6*V`L,H+&__:DCG0X$F*9F#$>C?(Y,R(QL?@J[#8&0.;
M8W&.3Y<.%A))L2,V$RU3G@G<M%6!ED8/8BMT:63)@C=:P:H*@CF(FR!$?O*A
M",/PC%\(7P1Z26V;5I9+HL%.MKE9YK"PL:LW\!+A52",,8^<E3GQRY>,^6UC
M[.K\JU1-Z.*3RUKXI``R?!CHDT):>>R,K>HY`P-Y=DCL,M+.N*$SH)8HP)P"
MF)(()0Q::0F-//QX#!;16A"J(W96$.FR3Y)(B1KG(CL-*_YJBN\T^;(ZS1C^
M)`.RR/ERT='''H.LJ;P?C82%Q_]T[,_(*;&"K$HJM]S2)JN:D\S*,77,L4DO
MNSQM/F/__FG3S3?A)#--+KND::K3>%F%I>)(^N0+/WX1J"0?0,#@EP1S\.&)
M,RYK%+-";,##PD;1N,%0$!(<J4#.3'+Q#`LA(FFB`A`J"Y8`PRM`D5]ZJL?1
MR^HA`\%7$P7!AJ5>=:H`=J0Z$QM7'3T)@R>^(`@-#%:ULPT0'S7TEQLN(>D@
M,N8B\)-T/IS4.*=N@(75:K<EPRL0?A(U+))*^X4:*9L4L+AS6[CD#!LX-0XI
M;`HPKCB"NKA!IE6LZW,@UWRPH9#$*D6(FN%(*L0<:ODTZ9,GF*4UAS/2J1B-
MC0=LH1`R>KIJ&3%_'>B+)VQXUCY16_#A%PP$=10E<\SY8M*P_T9:X@Q6L6H#
MO9O:R/,7,GZ2#H/'GEN2W)&2\&$#DR+\I8V;G&2.LCSL^V1C"_\\`PB2=%8W
M)]?4\J/<B9:P\+.'6G,4C15LB+E1E!("%0USTJ'&&&!S`&+G0Q/;E%/2$,(J
M2##+:\XJ*W,T,TR:0%C&O";G$_-)L_R[*A?ZP-1RSO)\3!+S\^8L7<S-:ZI2
M3+/4I*]TTXL$`<[9W^Q/]-?I+)TR=FXXV#78R,#`8#[1*.`)BT8J^(E"F"\V
M@A8*8!XT&RYR;87>I4_'!D4JWJ"0H6X`\8MYR>#ZAMX[[@+05?PZN.TOTC$4
MF_"97P+LZ`O8V0\?2*HG>N8_=KSR/?_O"[VK7KPJ,I.J7,4QP*((``MQ`QO8
MX`LF08,-#%467K`#1!&HE*$488)HY>`&3QC:#<I5/`E2S$(%")_-^G<&<V"C
M%2C\A`?S)\`5#.@30(C@#2ZR@J3TY#PXZ1AWSE>`2T3(!AF*UD1`8\)"+*9#
MO:L@9DAE#A!<@H<^.-\-?'")+QAL"1ZT%+9$N)@2#JT0Y:JB#?P0O@(48#%^
M`N`O'D22`IXA#.&KE!_2,;FLG&%`&["4"=.A&_OEX`L?FZ"@Q!-!Z0'*=R?Y
M7O@VL`1Q8>,CA2A`'@H1'YF\C&%H$!<U:!*?\]R@A>FX`4E@8P[#S*=SK2A6
M@6[`QS,4X@O_0$C'\M#PO`(D$E@^(,,3-(29%0R%##?XPOB6Q[P*+>9_TRO$
M@$@#P>GY(9BBDF&@)A6KH07N,V3HXPJ`L`)#&8X^\F'G<A97M?B(#CZ*LZ>1
M2%>>'$')G:,[DI;LU+KF)&EU9DG2/O&$.\X55$<+K$DQX%F,-`4T39'9)^TP
MBI7;S8FB5;)31\DRK,3T<((3S(.F8ABI`16LI`8+'!E**KP=8D9[$[3$!#%@
MMI&@X0PWG>#R;J"],]BO!1*<H$@B($ZRP*):&,F!O%*6D%\\X0D[&(DO;8`R
M&\PJ!RO0WDU]:H-6!+.H$TQ')>N1CHXXM('/NX1-;>!3#-SR@AF<_PHX,;-&
M#$"+-0?!(/5&$JN2YB%P*'L"M7CH57/(%&$U?589^W9,L[I0K1\QBS&Z`+9"
M:'51CL1@!4]2TE\4HG\PM4$8^E0`&YR5AUC-:APAY;M*/8$:YN!K!/PJ/$0)
M]J=430=)*!)6V9!D!5K-*FCR1L3^G"$/)O&J)1*"`0P0C36;Q:F@EH"/EI;4
M/BCA[!D.-+0"?"$):4M"(SGY,JXZC%5AN@I+%B/$5T8V(64A79+.D`3@&G>K
M)80C_W+@/4B>X0D?8DVEPDH&C)44F"1)AR6&A4'LWL"GED`9!M*A+:_NKR01
M0,IAZWBRDB:2P($TR\B8<U#2:11*JIP<0O_U&::L;"Z?\:P<Y=PY8YMLE'6*
MJXE#-V<5U.'.HZB3C,^J)&1!VH3(6P+2:3!*.X8VN:,>O=/+Z$4P!D-202>K
M%MQ:FLP6\)=Z"`.-K&0U0=])9[L_%1XWI653^P`A>+^0!V:%B3"X40<APP)"
M"SQLW.D"N("R.D-2,%@^DQAU@NO!C(1,=9I?,<8/:$8TL8PU0:GPXA>$S:L-
MO,)7$AYO>S/EK4M)8MQT[&`QXTM9I(*YA)I^2%.,%AX&$X)DY;"2N%J]]:NS
M"MJWFI6T.=B!:<D`7-76+&>,_BO*9&-&FHUVA#O+J@T2E%0_7&!8TH4C:U`2
MYD5Z[]"_Q.D,XPG_"RJXZA,2E"ZV\+@#:5TX;C=$2:5EI;TG:$I1.,WJ5&'&
ME*VU"!LS).6`_L0JGT7&,7+)V3/30H9T@$PY!07!TTR2/XGS=U'DQ'AQ5YLO
MUQ3:W&WV70YJ^NIK8M'2?C`L6;'93.(,B)'B2K9)O$<&0,9413O*BD5]["0U
M#<F>AHMG/U5YXQ1#+MTC*P;E3C/D+`4T,C1>\>IR416FZZC*:3)R/.V4BWVJ
M$@1=GTQ%Y7.[*,_N3!/57>[^LPJ$C'2,N"[`2)YIYIFRU-LK;T%-I7LHFC>E
M'L>K7J4FZ`?%JU6K)6I8.EPYDD_`3:K,&O-ZXA5XA-"L7*Y%"%'T!1$"_T^7
MK+9F5O$0\IBRPR(=P)K(UL(]UYU.<*EDD:V[J=W77X#:'-7:`$RE6[T<&'>T
ML)3@RR[B0>WE=`5]\G5T#27+\IA`4Y#"(`:\(ET3_L)5\9J@.?PPQ0"7\`Q7
M_`P&[5,//^"TS\*[?8%M"]D2(@MY`8;IRW;_B]]BQ@$XQ4`>C6,)&HG4?B%+
MLN13D@KXULH/`%`M,"AC.D9KM@9N]L]`SBW[4L9^7N/0VJBXCH8:5"8'-&F&
M?L0*",,<D,J"PB".YL@T#(<7J`$;BL4XT&`##N3Z,$SD2F)B<.H&(D97@B=E
MD(5B%FG]KN]#!B\B1.P7$&8#!J2-PJ*"/`RFGO]@(")@,2;"B[0'(:9FQ7P.
M<H(DQ^JIGNYD=8Z,.21'221CZUZ0G]H.<TIP3,2$%TZ'Q3Q'ZG"'HH`N34#@
MZ2(#2W0DZ%3GGZ!L[=ZDZZB,R.9.R["OTQ".`V90/)('IQ1!$2II^59%$7P@
M,=KF>9(@JV:*IVS@!A9I,>JA%;:J%!4CX[8P!B'D`DC1C%+&(PKN)SS,''`-
MC[Z@;2[#KS[%)"!%^]:L`+!/]=`#&Y)@,92QCE0+TR8"UU#)6PA+%J5+U$IH
MVG8+IE:E8M8O\%XI`I;`4E(F%(]I0II/!)<O]52"DU#).6#!!R.@W7(Q!M5*
M[OQ`WD*KP'J#-2YC,:#_ZJA&8@=0QBL\0JVJ(YAX"OO"K]HPR"M6(U:<A2RH
M@0RH*!C-857.8(3XD8J2XF@@PS&,822\"M>FYAV!I1#2<::6L=6V2MDT36H(
M@U4")QSYRU`<H_SB<9.0C"J4`UQ,XJVBC:?,(1HC@QU6`4$`C35:HZAVSU`R
M;`>M3W@")6)$907\(*<(X^1<SED"Y8;XD1_K8??,`6&^H/D4I!Z*#2F.RZG:
M)EXLI3!NPL8N)T?H,'&(SN+H(Q?`,!`'BG7Z0Z*LY'(^*L4$R0ZGH@_CL"Y/
MX^G@XTZ:K.J\\+*8`YXHJHC.@^J*),D,L78"JNMHPC/A[DY@\"G])!?OCI$L
M_P$`::Y@D$7N_"X=Y0Y1*L72@._P)"@C"<(480H;0(7FNLJQ;&L41LZ5-/`+
M4L\Q?L&JC$U[R.(]KJC0T`S@$+"H`B];'L6$/J+L/.)I)B)#SF?!OL*"-&TF
MO.7VG`5:U,@K$"(;00VOA@__,L;XI/+PRE$A^F0+?X$R&DK2J&_14B:0#.,J
M8G#2O&^Q_$#D0L4UY@77B".IF!,]CG&TS"QES.$V^HHZ"FP&!<O$T(,B'^4!
M8[*9OF`)K)"XDJ(L<J053("XXJ>]4"./(@`EHV^'/.AZO@BF?BL>E\TC&.AE
M'*U`G*(THLH[0*\%Q,4<#)`J5NX2G`;G8`@-6B&G`O\Q(1AP!>J!+3'C*OM,
M4%I@`]@/(0ZK`'9`1A:#-M*A#=RS11&B*_FOY1Y0SVYN_!R`-=1R6$+C"[A(
M,5[B"3R"%_;IOE;'3!BS+MVK=1!JG_YTQCP'%M(0%H(L,LD$/I).-.4$!$0G
M%](0#:6$ZQ+J,W6$QB(CH.1C2?!03.+#H@(3H:QD,]W$[:ZB&ZRL,[>D,U<!
MSDKS>+@'[R;(`7R3D<838#JF1<D"<###M/R-C.)1>>Z4-03+#\JH91Q`"L-1
M>`QE$Y\G+TATOTB0&N2A\UK4*,N/-8RGS?`H<(P*`]C!"8L5U"KN&/7+^QCL
M>#!-!'&-?8S2?1`O(6Y#C8[_QU#F(@%Q3?A0YO/JH=7N3Q%"<?U,B$MOP"MD
M0O5*<G$<PD*\RB9_!@0X"1OP<0DT;1\CX!+FB*RL4M/^3`2/3T4^`IQD$2%(
MD20(;'N^8D`$JP"G9FJ`*QC91^+LM)E\(X:DXL?:`!X+X"I-3":,0=YRP&$*
M3!YF"C9^:JJR2E/@YVCT$P220C>XZ%V,:88<9!>-E%VSA!V6X1R1PFLDAB#J
MH2$-$"O4:K6:J8T`K05VQED4C<W^,[VRJA7.J4]\0'XXR$)^B6LY:$#^T=^>
MX"F#BRG@)RWO3UXK+0PJ9@F\8EVJ1C)NQPPGLW*^1'%$1W/]B4H(,\CH2:#<
M20]C_V=(;L=T%\?B*F=2915V_M0_"-.BQ*Z=+!,R"-,QF8-5VX12:8+'$)%3
M*2J@;'6,`D]0ON"FR."*T*5>1RM8<8U79),,+&Q8FI*Z)L*TEJ>T4O%Y-FNH
M]&A>%"$=LD8"!T9NTX$=?R6P?HE]5B%<NXH*A?!EIG.ST@$$!*4T,8R=/*+[
MO#2FL,\<NF#V]`\6DB,$)P_4,L9"$&T]"REXAL73<L`K&!!1%N1XO((^HRH6
M^R:HD!1_"P%C6R%(V($,,NMC4;*]"B$/_"5%NN^MI.M`2^L):+1XEF_E>J@5
M<LT$/"G^".9X)/1YQ'<]1^+WY,<YV*$5RG2ST%4X<JBDEO^7-8Y-_R)M?D3R
MF$(F3U#H\;`/`I\J#&+J^KIKF&8()_(`8RIME_;`/F#C%_P`%O2&W;24B,`$
MP'[/$JC+)5-F;<$+)2OL-.5V^_1OI#:!]JAAEX:II6ZN!3S0C84/4'B&&O)@
M0,(QJZS7A,82BRZ@`(#@"_"!8DB"SL1+LLQJD98@(7JNGQP5%HIA<:P@="(G
M2!Y547'74LVBE37'25P9=6A,+QTU3$3G=WWN<?#D4EFLZB3S#^LIW>X$5CNJ
M=H]$/H0L46,'2*Q@<U`,[*#9"GCW'Z;"F&D"5F%UE;_94\/9,7W9+)@G<.0%
MT4[S"VZ-E5K#>#L"6$UB_>J96-__!GLBJ$4KIIQT@UEAB@R>58(L86R.XBIQ
MY24VH0!6($:(RP^X=GW[)GXXB1U`P/S^AWG.0!Z:*'!6@'DVD2`,"=><Q!@X
MJ?N2X`*N#R$@[VMPB7D^J2)TJCMW"6DU*65"PXWR1\(L1)*NU"34\H0<;4&^
M"6),8@<DR6;PX`PH-RL\(IF>*G\*`0^6`"V?A6&Z,RG.JG^V+1TPCFY6JUS\
MQ!C"IPL$<+JVHE(RQ(WBYV'@%ASSIS:NXN8H`H-BT*K1\M!"8P.$*7AZ[BI^
M$2)5I!6,`:(3Y6/,01X$Y1),*_JFRO**9Y=6X!)TA@PHZW`W@7`M)6/Y"@VV
MT+)`8(3O_PZ')J[8L`B##=`*VN@ISJS\<N:M09`W&9%5C"%!\."UBRW<U.5O
M'0P[T0.2O$B20`/#$*89-VYY#'917N)[9(65"F2,%&XRSJ-S?PXRGHZ=CLX*
M_-"78X>>S@15&><P;;ER;?ERR:[JSMDQG82>KEG&)/54@WFCQOEV+"KISL1R
MC>Z5&Z<Y3C4KA!E(NOD_?%F<BSF7Q_E5[R2='?/D+L,X;6"2&4FKTN$<$X7V
M>`6'KW)5J&$5K-5M_,H/9JI/ZN78MBIPK,\&-F"G5H!["@F,;8"E10X-`*4G
MS,%;:<LQ,II6D(+T>%%4G-:DFZ.!<.[Z.!P6!)@J+<C];F9?K/^+#/`@6#RZ
M8AHE7HQ0AJL\"''S57P@2GLB1Q`"+)1\`^9%6_0H*8J-M\B@.,@<@Z"%3]ZE
M[DZN0)P<9;B*0.J1B&XV9;"!&H1O(LX7M'FO2=XC6O)5.0I!.!OE9"RBD"3$
M6=BQ9GHU/``)(]"@'L2\!8``GWM"4(``B,M"<F[2;K*6(,CF"3@)<J1$(S=&
M4XH*@S,680K&',@#P%RC7B9/>U+$'$+"P6R`1[%AQ.<&4N"L>+:K^&JNB79P
M8T2ES15N#E,,3(0LGT:F+I,$5@OUES.S=E?W#>V0+JL&W*W.!)I$3`P\P:M[
M322U#4;&&-#!1V#5EY,D23RU<^-#E=;_V^KHPT=0E>P`?-Z?K)MYX5*%.>J:
M^5,-?IS'.2OV)"P<?B0/QD]V#]<X(X$S"&!FHQL]`F$KWN$'HI*U[PQVP#>C
MNV'AB(ODT:RR%B6<,(']C13#X@P4CY,0PT\LVD$2Q.,?'A4)6N?10*F?#QL@
M!QU&>^0O7=.B$3TR1>>=HJ2\QC<_P7MP"K&8?O>&0^<%T*B.A[&!%&=,B3K&
M448D!IK0U7"0TV#4M4^X0WM(5.<_[)K\!/A<*BS2*O&T0U3$0WL?!.J#?&AV
MJ.O#0JUH'1O6_#4@9896P@?$WH)8*F5\YCPXJ=@JM@"O7N==)FXX@XG2UTX*
MSK8<3>V;4<SQ_SZ1"P=^1R\_68>3B.9\)R\,;"8L5H`P>F:T"T!=6^/238MG
MVF"HM`9N!/<&@&!@FOUE<RHJE"CPI>LQ\`4CF)X[0(TXPHU"W3@GI(,*1UHI
M3V)H<>K+$9-0C8&@)(,_Y@,P^W!Q"!4^Z/T\&K4/Z]#`D^3[K<2ZV5^7-[4/
M`7YQ;B?]RYLY5`D@C(&`!4)@05BY8,'BE8O7PH0('1($41"$%8@082T;N'&@
M,2L$!1H$44RA%8L4%?Y;R;*E2X4(%6*$U4TFS(PU8<9$N*P-NU]^_#P9.A2#
M#1N_GI@[BD$1!@Q/TCTQJN@7ME7RTIE[8J,J.VJKM$J5&O6)GU^_FO\:39>.
MS!DR9+@R_<5V*E,,=8<J&CKWESES9,W1Q4;-#UNC>-O`PI:7J-2E3^N2Y6OC
M:56=%*F1,?RK,KM5,!FS%?KX2>?*3[*ZA2OWJ5\RDRE#W1K[+@:@I<E"?0JU
M+=S-107#.FFE#3:H0'\+/5IVJU"[:W6;!CS4W&VC25?#MO1T:E(_JZ7>-0<^
M]E1SV*[^@NW]URIJV`RW?1N7J^N)*>E^RK&D$%JK08U%%%)1B8<!-HHMM!A@
M0?U&%E-/_%9?9>MA4P`:+:!QE%4W4>0'@V2$L9T-0[&55CJAQ3<:?>)1B`T(
M;;3U'%ZP&/>+:MH=A11ZZ8E6U"_P+<8>48;_*85:B]3\ETZ1G6&WI'*ZN8?-
M1"<A1-QP`R4DT'!58IDEE@:!A&4N%EDYT$XY06110BDE1"9%'6DD4Y<3*913
M3F,B1)$Q?(XT$D@9N;D3F<541-&9-,%2*"P"G300G!5]Y.BD9^;BTJ4M/633
MIA@QY)"@-<U4)BSL6*>CCD]5UA=:1LT%VBIIJ8K!*J_&VBI3)/J%EE.HV27K
M=5PYY=14ON)ZH!_8"(88D.FA-1<UK2AFZJEW-8DJB<NZIY!$!%T%'9#<8A.K
M7-3>EI9116TH&*NWGMJNL4A9=96JU^*U+E*J<G<;@C#!"`LUBLC:&E+OHGJ:
M#7^A92JZNB*&K8X)_Z=J;67FQC>QNE->U:II4HJKJFDZ<@Q:F#:N\$D+7YSQ
M7ZKN0K;LK`2)"8MAJ+6*F*\7RVM"/2U\LH*+B%(D+G*RTKMAD`JU81W#!FN;
M&:N53:E8.@X7ZQ=8BPU=F3G4L*.0'ZF^>YVL0*XR)2S3FHON;<PUF4Z"E.Y$
M7$*.J@D"W<6(61&5"AU:)J"<WA0SWC`Y*E"A,A-4#-VC!FK2WWOVZ?='CGNJ
M$W&/8@X1YHYZR>?>%)T4)N.8EC[HI@QI&E-#@D>D**+_\B9[5:S27JME:+WZ
M$^Y>\\(+K.RF]5^0XJ8UU6Z_T.Z78%Q?E6S"M9O;AM#0`ZE0LJS^(I%QZ?^<
M:]E?@,'*VW2"L44-MS'!F-ZZJW@-DXU^8;"N9:L@V_VY%#-;O&FS5R7[?^S+
M&/"492YV9$QAQM,5>M!1.!BU(DEH.=YM_J(VM2'0/<@B3!NR)R_L0:TI/`J+
MLNR"%JW4*%GR6]IM4-0&^$$0-"!0C_>.)R_\@`1&ZZG')]"P@OLIC#>Z^D\$
ML>&^N]5H(,R3V/((R+]]M=`':/C$%](1KSIU+EE4(QC'SD47:O2+5"O;S02E
M)K3EH05:`S'.=9JT+R(2Y%])6N'[8I06`BH,,`!,!VAJY!,AXE%X[1&,%Q'E
MJ#+EXDI>>IRB]&81*]2-45]"G!%;-Y/'N8DB:A+_24IV4J<WQ21U&-FDH]"A
M2='-Q'$)D22@.'>H0E+*4*%[DZ$>!X+28<I.-A'4Z02'D[Y]:2#%JXKR/D.K
M]_0.%NUSS_ET\AEYO`=]S?(+8]""C6B=B5;_"4MZS/:9'L&B%37Z5WHRV#T8
M4J2%(##'5]RGF!ZY+VE9$V(-%P.\]R!(,;!C'99::)QE;BN<U(`/>N"3GJZ!
M@!8P(H,0/P-/YXFK*L7\#`#3DZ#ID8J@R9('LMZ'S&0UBZ*A:V!Q%@/!P62-
MH(+ID=F,<[;IQ;!XJU!,.ZFA1VI:-&G%(XRV+(J@*2%+'MJ*63L)8\X$,48P
M9KN*#?T60PP48@7U\`$9__[2HQ+VJ*=*39"7_*48V/RGI>O+*1_/\(5ZK.`&
M6SN;WTXRO6AVD#'$ZYLQAGH_]*CSB"CA)U'[%:WT:`4M\FCAXT""(#WB5:;Q
MF6;N*$J8*>WQBMX\80D+PZ'I"61S*+G;FKQTD4D-#C^9K<A%?!E2Q^5RL`L)
MZ:'X5))*(NXD^JSD<!:W51!L9%%;,BWC8BE2T1K*D:O];7!M:T0K%,J6E]JE
MZUC'W$0E"B.+PE+B%J,@G9Q-)SI!'W;1![N!>-$ATT/D5Y)V4V[!J"!:910_
M^P82T0D6N_Z"79W.Y!#P/@J[L#A#(;&KIN(<ZI^L.U-%\=DO@Y`*F9=#E&##
MI?]=?`I$(@).R4V[-+T$@>`,QO@LE<[)"Z^UX89<%7"_SM`O$U08,X54ZAM=
M>E]X*F1+"CD#5QNX)ZV6Z;_I/=/>&#62@R'L%X)5*UX?9>'V'H07%"&Q5AWR
M*(J,]Z;QN955X$8%'0N$G[P@XW_[Q9%S=HL7+72(@7E\7LQX9"!%''*=W@@F
MF!ADP7W##Y?W>].4,+D-3,9P)T$+X\Z%J4N+RL7GAO,Y3#XD=),\):>N]";<
MCF103(8Q)RNYR4@5),.,JO+J;$(IB5P2EGRBDJ!_R\"3;&0DH46N2]SDZ=/I
MLI(.>20B%53?ZOY3N[7&KZW9J\A;UQ:^CVS@X;!KC$+_[7BMHZ*E<;%;2-C%
MK;J&RK";]'GCCQ@R)B=A<B(Q724[XQ>VJ<5TKFM]$BHT*B0@0')!F*SC5C;2
M(FTPQIL2@F1CF/M,,"Z(D;F,2;^!U@H0MC>FMSQH4>YI4O)N=@--L"71R173
M'Z$E2B;5;5A1R`\R%M.Y]<VWB1@;)27QMYO/8.YP"UA9NJ*&X107.LS1ER+W
MGDC$=RQN=^<M)8@&G!5(#N.&[PV1J,XPSCW;-W,O0ZX:O_%`U(USOEF[M81F
M+=-OV',U;>0D'X]92!]>[41O6D\@SG"&C4N1UL[$(:$"Y:8;\A'$;9A/!2@$
MPRD]\;5'770>`:XF_UMH8US=_PJ%KJ6J67+:A*3=\)]$?"ZT="9POSIPJ4-(
MJ%R-^,,S>I./)T[>-D62S@6XE6(ZI.1"7A)*C=9,A](E25#R*5\R.B22$]0E
MV_LG31D2TR'A<;Y#K_:8Z>E+NR03JIN<-\L"3B,]%V68?N^WHT/*AC$IU,#/
MO<C2@CJS0B>N38[=Y\Y;V2`&?O0RT)$X/M&^<8]2#X*86LB0GYMNYP9\I3*K
M-_`C6B`]2H?SY)HECF/)V+&&:AN!;G@7>J)S0P/(.)YG6ZC6;(ZR>6P2?YKV
M>U6B)<,G?._6)@JQ#,F7)<V62K`46C=W==AV$*\C;8I3-P%X*#?W);(G$V57
M;F+B@/_/A1`OJ&B>=&W]0@5Q9P*:YB;&A4B9!TDH@1][!UR6]B@BT2B#QQ*+
M%Q$WZ&IK9VA!>%HU,7G-U1`OJ'8O&'W%94A<*'&GQSAY$WK_QUN99A`#6#C&
M=A&891$E,7F9M3BMMWIE\G&?0ULQ41-*%X,E>$.``P+H8`)R9P)@]X2O-C=4
MXBF(1RFG=A$5P7@#078N5W8EN'J8(WV3"#KG]G&+TA'%A77T=R@#N"=@HEEV
M"(?:MUMEAW.B%1*E1TI&UH(*QSCKA4^7-HG#)EJ-QG>\Y4AMB&B71G41!C>M
MV'R7B(FK=5EX%W5LPGZM9#?*:#A;,DL_IXK"N%D/N%;2-W/_/C>`9.=N5[<Y
MHIB-S,AQILARRFB)K*ASV8AU=I=*`GB)E/B"AV=WMC5;@/.$(&`"/FB)-!B%
M]+AZGQ,FP15XN5@13;@25KB'4*AXJ0./LU4I\6AWFQ8JKZ9VW8!(;O=X@B**
M^^B`@N)NSWAI!O:$F1B2F+A<KK0Z[:=:'/A?L@<YM)@^(`&!+^:#_C@0F_=<
M#(%9E]230-@F(<B"ZVA^!'%U10B"N0@F!M&&QF9L,<D1C5*$6Q5_A=:"J5@H
M<8)L/4F-_9>'3#66G9ASDX02QD!BIWB,D&*'C5*`FW65W!9X'W=.V*>+PCB4
M@.=S>Q>,1KEQB(:3QH:4HQ8FA7*8_\+(ESR)?J)S=.C62H@9C$@I6N&5/I$C
M)L7PE'8(DL35=75W2*D($5'I;J,E>X9#$GMF>FT0A:Q9B:\F:)JVC4)8@R\X
M-\3U)ZW8@`6)#@>QD/^`B*L3AO%H<.E6D5J8.E?HD*!2D;*V6:P6A2!W?)IW
M;;PPFI1R;ZB9C#JXC3;X.!UI$J=)6JWHDZCY)B#).+SF)F=`2J&FB%$HD9V7
M*/N%A"O)@&O9$RNG)R7Q<!'7;*K5GP59;?L9A!"Q$2;0A_.I?996>F/&6R9Y
MAY-#=4<G.B)QB@VQE+"GF*L7=4HH$L5Q@*['./:6@<%U=[#72HP"CH86=<4&
MF@U(@&1F8/^9V7AQ61!5MHFDN(D/EHM\N9^((Z(-]TH2>HH&)G_M%6@96GIC
M274,6DHPNG4RMZ)NMVSUN#IWV3=0EQ)5^)'*^76O@W5=&%+R]Z/&N6F%M(03
M%RF-LH2E)'A-F$MAB)'(^7N+]WH"R9IA*'M<."J`5WC&*8R;]G''AX??MY+D
MB!*ZY(DR49+E^3B?XUF`]TAL`BACEUEF,JF:(G^1>&U8^(>_%Q.-DG6=8R6-
M@H'%89";IXB`=Z#^ADAPZ5NFN(:7QZJ6J!'SIV\4BGU8QT@Q006TJJ7HIZ+G
M9I!?""B9Z:%:BGM[<J59)V^,XR;+<*,H&G&.BGU;1701)WHW&B?_W\F+CSIJ
M((>E@-*/F@EBC'19G:F.D>I+;B(Y_]6<^B9\E8JNHV)(JQIOJU>=C=,1%U&D
M<*(X%/B$M7=(.D&M&DB).<<F4->3C2JI%2E=UR8H/SJ,<,J:V(:FC!*E5:F)
MFB1VOFF<>1H3&Z&`78JG4=BI6KAIEX40\A:/(8MD4:E+(+D3#TIV(=$1M+5;
MWSF1*TJ&SKFL($`%4*=N-KLY(6=DJ6>;^^B4UF9$%JN(!_$GQ?:'HTI]>K(E
MZJ:SD5,068J*`,>5Q$8%F/F%D(*FHKF)Q'@YW3=:B,.F?&*T7<:RN!>!7^BS
M#VH"^_AT2KB?$&%^SPA_A72@GV,WHO=B_S!VH:$F:HR"ATM(;Y;8GZ3$>7AK
M$AD&LQ:!IF*[.6.W>3M6$WO9MZ,5M3Q*.2]VD_A&K0^GL$;4M*/KN*H$>YS6
MC[1TH85B>*TH,XAH:"J:=S)!.5G[?ZEU-RYW$7D:D;?[=;GHCRAHL1\)M*A9
MD!ZZET$[2P?ZL<]9D;Q`B6M;ILP;LC?(D1'+O7*#HD/IAS5QK,LZ@X\*?"FX
MG3EGI:U(M+EZ?$SU:=G+IW9()GG2O#>:6][+L@1;#";6KX<+@Y@(FDXK2<5J
MN%3'JE`GBOOYBZN%>E=[8PS'CJ_D)2AYO)W3C'NY?+5%J8`C2:UU)7O9P+7:
MBSBZ2BQHK&'Y;O\7;*\$:29'!X*[ZB4,\7/NBEG&1JHE>'.E1R:TAVD<^&AV
MRUFH9WT6O(G8&8@HZGFY\'$U7%I^IXMJ>(FUJ[@(.Z#2YBB>NUH$BQ'P>3A]
M.BA!ZH&&5@QQ0AQ+&X5MJ)(<:`(%4``,5[)V)XK\NHQ[PZ:&,J/&X)LG"X5)
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MCK(,F.QQ?#K5,_W2IOI\LEFGRIR4C>-9Z7N8CC0];;C*\=F2%&QJ:^*'JY>`
M4LV"-A%=K^J*ABJ2;*W!8AU:`-W/!:UTW)S2_X\,P<,<GP@,D';80-0,JZCY
MU2%\A@8(K'YGV.J8J@\XKH::@OIIKDELU69:CI3\:BV'S\<H$N>LRM=JNG8H
MQX5`Q^1GG!L]@WJLQP'*HVXZ>"9;R7N#LPV9LJI\@Z!DO)"CT!79J5&MS*Q8
M;"!&7)!<$!T1QEN%D^V\R;F8UK,M-U;]SB7QG6=:>BHM*'UGW%$8DR;*G,`<
MB2XI;7M"MZP8E^$(W@4,CZ*CI"M+@Q"[6:7JJ8(&COMM!<B<6A_WC#6</O8L
M<RZ**(HZD5/*<1G1GSI\6??KRQ",EVZ8SJ.U<4@I75F,U191;T[+UZ^HWB]I
M$L!\@!^9K:S%H?Z<S/^0^G[I3+!O"Z-4LK+=7&\[385:RLT.N+37=TJN>V.<
MZR>16*6)C&T5'E)M0`4\.,?[?8/O>TE+R+%]4I5N:[TA>[Y%;)"5"X0Q[9/,
M*VO4&MSB&XQ#O;X0*I.D2M0_['CI7*LGN"<%?I6;UL=58J=GJCE?1Z&A%N;>
MAW6E*IPI?=^;7*DMR)68IV_9&M@8GCZ;I\!JG(_0"B<R(\KHO%N+M\W+6KX-
MJ\S>W8?-UZBK)3/ZYLP/G,:7^X`%+IN@"JG9*7JZN(TS"H1/Z84;:IZV_CJ8
M2,:.#J61WK*>],59,K*L"^P0_,/9V:>T'LE&2::.E&$)J.N&5EHO;<#F6J#_
M?CB4#*>W;4RYNP66JPJKP9V;B)V3!7``LGC'RFTF"-F/N#VZ!0'(PV&FC&-N
MYB9V*''@.!B19MKO=/.16C*NF$8W_G['!']V=OC`?>>LE'O`)G%O6:RU@,)D
MO.QV[CZUV-:V.]T1,TX2B.<Y"0=U7GZ0Q@TX&NZ8[+PZF`7@^FVZQ$BW_Z>^
M$CG1,4[6N?6V1%N@,?OF+?M(4WO"]=:R$GRYR'Y[+@^+6#*YP=:G4PM_M8K+
M]BTFYJ9QR8RB&]B&C`<2`,K>?O=BR0:*5K>2;C>R,ICT)7FV@F;+C#)JP>Q9
MU'>@5$?;Y&NKXLQ9@A:!0M_UMHH1UG;@#+YT$QN^_S;[.EDJ?54/"U-O]_.N
MU$9V;^XZO21\2(WX[Y0;>R:1$.A0<N;9O%@_[ZMG^+GH^`/!JI]391^K<^,;
MT@$:DE;2^EXNW:P_)[,KJ:S_^J@?G-\FR<7@8%8[W6K+YA"&J+&;OIZS9?PF
M7ZTT5UBR2R'HDC!(==.#@RTI?>G#0+J&&6EMJE_ZCCSA@NA@6>W&>J`EGK)T
MJ_R&E'[&;^:ZI'0ZR+%,G.$?.F.V9K\W:*!E1%FW8>#ZA68&$"",&8-5$,1!
M=`6M""0(Z^#!8@]!%'0X,5>NA2"*&5M&4:(56`N-3:Q84:)"$"`-@L@UD*1)
MDAL/@AQY$"8LC,8NK@2!SO_F39XK*V;\F9(BT9$H(2I]F8LB2J4X;\X4B-%F
MKF4L03I5F9,EPY$#=88UMG6F5*<A"UH5>]8I1H<$K>2Z:B5CQ*ZP(CZD"59@
MRK]B!R[\5]CP8<1<WZJE.Y)*8"HNMZJ52IGK6H6+YTK=C'-A,9P:0>8EC9EQ
MR,5/>6'C5;"-R58\#[Z&U;I-UI^PL!T<N9!BZU9MA!=L#9.DQI`V7[.K';1U
M:Z+'519?>`9$FY^:Z=IM,W(X9J?771>EB%TU+.;%86*T:E7ESX4J(WHT9MVA
M4O.S#987[]KC4^QJ>F^BB6S[SR#:8$GPK.1FHRVZ\@XL2<'?<C-N/,#*$ZD-
M;!3_3,J*^9)[JI797G+(/*@2G)!"VU[B[2&/^`HO0EZP>RE!VEJ\SL3K?$O.
M*OHF"HXV!JVHKS^%7E-QO^9R:T,E"E'RCB2[;'IH28J8\P^JE:R3#B700-2*
ML[2B<TFPC$;"ZR#V4.-,HQ<U:A.U^$*:[S.W0L(3-+;(>O%,EPY";-##+)N,
MKJP`#;1,G.!ZZ]"MNH+24<\RLJJ80T^C=--,><EC!3SP`%54//+PHXT;\@AU
M!6.P$<X840NQHL.,3"`U#U<ELA7445?(XP;B8#%F!1_P.&-%6_$H5M0\3)`'
MED^9_84:API1]EB'6C,A#Q^^^*(+'U8HQ)@VU%-I(;JX_PVU$-84,L;:6%M=
M!5H\"C!AE39,*&!59L>M#;N(.KJH2I#@7<&$#AT:3:!/OZ@'W`(*>>K=;KTM
MMA`.C5&U6%Z+Y3!?44VH2:^9"N&85%!O``&;,T@]V=Z5)P3!Y'43-*:`97LE
M%80SK.4UU`):H0:$:`^F#59Q=YQ(8SR\!1>/<1/\C%Z=.?8!UYF+M:\@6WV0
MF#F<246YD/Y$6@AHA`$C256=R=XMU'!1S@,$>4#P(6Z=CWU2K8R6L?:+';XH
MUMZ$&5;V81\B!J&53XOE&&%LC#GYYW%=53567JB].51L/>366\'S,*:554`0
MNV,\8NY.U6^_7:&`ABJU:6I.2?_&%"QC(H-(H+VF-I2NO0#KW;.U1+L43J.X
MPM,N.W$?:1E%>TN)4.H5.RJ\0,5Z;#3-,"OMJ<VL5T@AO-P[5[OKTQ^?HDL^
M:<%]^#])(ITV"ED"_A6PH::5&]SOXHQ5S.L@7T##^]"PLLA-Q`=HB-\G/H&&
M+MR`&NS`1AX*B(8SD&%OM5D!`]]GP!5@X!?U<.`#0;"*7TBN!2U@EZM@<8!Z
M%#`'.6A!#M!0CP(D;#'A$<@E5OB)+Y"!6A[R@?M:D(1"_`*%[4-#"!710?@9
M\!)>:]='K+*T)/S0!ZWHD$UX80(?+*&&,[1A/<BPBMVL((MD?-\EZ%:(`J[P
M@^\[PR__6E&`%7[A#(4+RQ?D^$'W?>&$A8AB"6^(,=;,Q`3UT"(`L<&./(Q"
MCE'\8"%N4$0'_G`)(/C%#=KW/A\($1LF*&`]SB"/UYB,@3.LX2>6D+\NBNB3
ME/SA)<AP`T:RD$-O6Z$/.(F-^QG1B"WHPLK:T!@";:$%:,##+W8#HR0(\WU)
MN$$GASG,)52S?W\$)+NPPYZ'X.%^-&SE$G+X2#"*D8T0/,,9"GA-//@!&X68
MY`];<(DDIF.6ES@#-4:Y@Q7N$1O86$8'QSA#-`CR%^X$9#>=:;=QKI"&YC3'
MO-82'[HDCS)J68I@'+,[DF6D,V9!WL(B@A<RS:0Q:II(I$YJ_Y2[,`0P'CV3
MF*A'J-/,930R`0'T7H06397F46FIW:/.8B2B/JHRX7-39M"R&AGFH)`;,(<Y
MX$C&3W#R%R:HH2D5\8O:&.,2,XQ`#@J1#C2>H0U?^,0,,^G6>IC#F05H:PL$
M2AM(CM.MK[0!!AA)QA6D`P,@^,(,;S#0-KB3E:[T(!#E21%''82>9.3G0`LB
MN;+2\`N"_84//^$#&_RB`&A8K$1MZ"QJO0BEO!AM#LJ*07/$B(1N18,'<^"'
MN;95J@QT7P[J2,C2PJ^.9%C!#/7XBP`=Q`2%)2<@5T"&3F(UDV5=0B$F6!&Z
MNC8'^%3B*@KQR8/:LQ!G6$%O(]!&,O]@X`Q+T.XG#NN'_D4@"75,!PA\2,,'
MUG:%2T#K7US3/B-F]H.7\,,9ZE'6L_K!(<P-HCG2(<;S`M*QO^`+=L[0UD^L
MP`;XRE`2HBI5,T:WK`W-YD+'^#[XH2&)"JY)2O+`2C0L(9@M\,$O%#S;W<H0
M@V=H'QL_48!T^*$0/OY@/0J!`0RH4ZI?\(,Y;M"%&9[!#Z5;P1CSVU8TW$"]
M)Y9P/H=,PQ@O(8Y?^`58+VH%GT2D=HWZ2TO.!+V1>(5VJ$&4:#@CTCB?ABIP
M/A3R,-6\GCZD+&=ZC(#*`H*;#FJH="DT2X3UO+(H=2=,#1^GM#/IBT2Z,9<I
MJF(63;RTL(/_O2W8P!/28>H@V\`&-V!O9H.XY1R8$@.KF.!H,YN#+D`WM6RU
M(1EL0(8-(/07#J9K!#Y!!G/$DAKID,>%:5B()ZC:!HP4\'!]4-8;5)7'KRU`
MM&V0CA5<X@O)?M(.6P%&[4:@B1C@$#N&I5T;AM`&8ERW#?!`VBR;>@5+*&M6
ME0B+1!D#-`6YKW9OD`X7PH+7]_1#7\/`UB>(EKTYR.83+$$&/)[A"<!UKQ_2
MD0XRI*.O&'?MJU=QAMX\V;4K"(/'PY".7X3V!M2]@:D+T6\?F,.?`BEL9C.,
M`9BS@PQ#)T,K`QMD;Q-WAJ:,-@98#6]3.KFMIK0!-HJK69';8.,;_UB".1XK
M$%B<G.C,!<(-R.#Q50<[!S?`;8&9&THDJ].,0:;[$]C=&X<H]K.A745&VA!R
M(-00#:I^@I-G6%U3>QSF3[A!"]1=``X$.>1(IC`(3``"7B@V!X&5]AF^H&$,
ME)>&EPB#JLGPA27XFO'UF.%9GU#XF^=@`]`&N1\B;HE?J'/$=31P6=.;CNSF
M8`<:O_@7+G&#7[?2]1\_M0TT[X.&:_T&GY=K:S13ELXXRGI(-5)8EH)FNZBY
M376&Z?7+0F?/-`8WO;E(H$,44X@XY?(RG?]\(I/HQ&QF(50PDF@"71-)8X]/
MTSX!3#]),Q*=ZJE&&9C*>`H'=,"W@`M>,/^'.*J'"Y`V:<,`^^FW\P*RHHLU
MZ*HH=B"A94(#8],R)4J'(J*XK"NL>RH\<\BN8QLV&PD[#""#3SA!54.R7!HC
M6R(#'S`LFW.\3R@$2\#`)_"#]%*PY%&)JW*E_8HX#@&!JQNCU+,!S]*P)[`U
M-"@]57NZS8.NUC`&D;&)_K&AB3NN1X(%TJ(X;[,$#'@"9'L"/Z*AAK,[W`LY
M&R`D8^,`&[A`#%2Z'&BPPH&%Y2JK;L-`PKL!UR(]5;.$&FJ!%5"$^IJGL8JU
MKH(N;/@%)/LV#"L`PNNK7RL`X_*UO@+#')1$D,O!#?`U$&C#YT)"D/.Z+IH(
M=ABV)"3%"`@B:7O_`AZ+LE](0B!TK5"*-G7Z@B/\PQU$N+BXCE8P030`K5]@
M#H'8(PRHP\%3-2>C+E-4Q#-PO"Q31%6;%Y%!A^[0K5!"PIC#@#8THU`$N:PS
M,"&$P2^K!R_$P+B+Q!DB,,^;(3*0PY[CKQU\O3,0K&^TH1L`1`P$`=WZ`C_L
M17,`.LB:BQT:/XM$"H'HOY`XO[W0C."A2`/,R`6<C(C(G66XHEQXJ92X(MS(
MBHUTGOX3B8'`OT(9&+_`C93`J/`!R0*\R)WHR4H3$Y`H'_0+EN9X#O0X2LBJ
M#'98A8E+J+OYO#/0.ON1JJO#IP\,L61[11L2'!H*K%G[!0*RRALPJ./3_[I?
MX,-/$"Q4`HQT4`1G<Z^^LKL->)\E&"M)+$O7.@.O6X&RLB5Q%,53@9.T@`4\
MZ*H.0LAD8QD\*"L@&+5ZP,)ETC`;:"TTZ$857#I.*IV_P`W1JP<'P#(4C!S2
MVCL;,`>[$Z$;9#V*([Q@Q`#;<[JZJ@?0^0)HPX!6\,M!1+:$`0F5HSAO`0)O
M@:Y.^DO5^S(T`$5S>(T%LJ$P:*OJ&K9-+#,_^,0=K*I?`#[CBKZT9*\,.[Q"
MP,%8.P/U<JM"Z$4,F,O0LA&0P`9:Z\OMW$&G4[M+Z((=J(<-:,-T-`=U2BC!
M^3PM4["*((A75#?02C:3P*W`LR&M$R%&7++76?^!%:@CYXM$VF0";RD$W#('
MB0`!5GLM<5L!LTO/T(I$T-(ZN4I/)//%`S.K.'2P(5.W#:B8+V`[51,C5_+.
M`KB!'?!'];K$%?"VB,/%Y#LO<;L;KQ$Y,IBX3PC1@TO/[,0.GJ3(H(S`N1"-
M8E!)G2J&CA!*FX232/G),*6S+V6(G7H>Y+`*W"B?^,`=B2`+8Z!)P\"(_1.9
M%A,X*VV4G113/M53*[522PDI3Z,(6_D40_451#54$]"2\9G`J/HC<Y(Y?NM"
M,6H!V\Q$Z<RN#0B#,%BZ&_BJ7UC!9;J?_9K*89-!7P,K&*&P5$2^81NA]RF[
M&EJ";HDR.0S"010Y/U#_E0)X'>1K`Q*Q,UXP!BA;.V"3JAJ3)_*:H5XMS?6:
M3%6SS%0%NB_+)J`3GK^HU.=B+B`;-N!JHKYR,&K@Q!\%L>L<*#]`,N!JKA6J
MAW051$*TF2\0L#^J.<-3MR_`&;P,HB=(*]8#(DOPK"]X`G_"AB8S!Z-3-1O#
M!H33Q5<;MJ?+LKIL@1T`+EMB/(2:2C^0T%X5%TXD`Y6ZCH&"5U\3H4X:JPB3
M(S+R@5/C3\=CU^240HG`#A/,L*H;"F#U@RX0O`;%V`CCK1]+KS-@HS]2PR=Y
M"/(*+U>R3<$B`[<"11'"!NPLLX5BS=NT,5)DI3]:`=Q*,E!R@!JZA!5@S88#
M_T/DHSRIE2MS.$AVM51?DP<\\C%Q,SL:U,D(-$"\70B<K!(Q18[/J)*7`LJ+
MX%/ET8@UR4F96DF]W1V[V).>4A-,@3.7D-/"N%(J$)G+XXB#.,FM&+\I[=.!
M^5,]]0P[PPN*I!2%`UI#6MW/<D_KRQ(FO<N[-#)U92_^NBHTJ$OA2Z]D\R%+
M-37!*X`R4X0%.J\P@Y^!+3,93-=IO(V#P(8SE$L',X<LE,QEND3R',9!M+TO
M8Z4NL('4"IC:*(!1(P-+\*,66`+II$+#P@<?Z"I\PX-HQ;>IK*IY<JTE(,_>
MY(V#5+$M7#J^!#XL4TXTTHVW_$6*[:N'FHB/X\-1O?\$&>-:<\"XLGJUH5&)
M?I0J&8/@U(/86R,CV=,XN4K++4!(&P`"Z)0G/WC>=,`P#7.FX'"(J].C)(1>
M]KK,&\"W#6BK5MPX_)U*MD6HPAM0F=J?&4XOJC4!E(TQ#D;'DE6G')4QV@4K
M`6D%=S+0TUP*!6D%(,"O<+U?XPTS%;.]Q@,SV17;LWN0D6@%,M@!4CTHQ",#
M;M,Z:M@?#BFS5;@!M:LY#.!077P@V:VNQ</1;@NV>YHX7_O0M8LY9U*0@6(9
MQQM5V5V!5@@M/P`"_8+C0D#0NZ"SSQU4X`FTE6P3*\@*-=T=EA@J4`-)*G6_
ME7PIL3C3S943D<J*@%$;W%G_!LK]A[`HP\T]DY'T4[P57&$.7=+],P1LE*)4
MN!)J9A2+'Y9M9+7@A5^(HPU(A\CS.+M;M4F--MTEHQWP-?JIJR`B@S;<++LK
M7C1P`#)XN#9T/8Y+50%ZWOAR+Q%*!VKP(7#5O)?5N(U=NG_L'](RMLA$+H?`
M#6:6JJ$;RQ8(P66-`&@#0X2B3`M2-R2NKZNLHQ5ND)MI1'9&SFZ3.JLLO,)I
M@U\@`[R\!-Q#KH>0VNQJ`7PX-26TO0D^8A&J"'>;U\U[.3_@@-CTX?.:KA:H
MN=!"*U[+,B#$MQ6C`K7"AE8"1?IQC8<&@CI*-A.85#*X`!R;H1Y&3N0SY]ZR
MH22D_\:V()#BVL4E;,I"2`)F/;MT>#AB+-G[`@(RB+RA@SGDPCM8N&*;99DS
MP!2ZT%F>!3HRB-'D#(,SP(>"++RAE2H'.#6Z"[+7(`JI9;RQ726N/CNW"E+]
M$0H4N@&V-JLRF^`7DSW::SF[*[QW<H`*927?6[5+[%9S:(WG-3''QN:/2\W7
M+,O\U"T0I#"#6`:>%-Q%*V7>8,#!G9KN8[\Q%<!/(PKAUE.&*,F9T@A;;I#@
MB6X$;`L3P(Y=)L/<N;R%L--(Z]P]'<!/SMM,LPBP"UWK60V#C6SFF^_<1K+B
M<(I'&K4O4$8,5(2JY*\+0&D0K@<0^+;8`V'*0D'10X.DZ__B'``"D0.NAD8R
MBW*(4<*PLTVVNLRP"^2US")/'Y8JY)M+TK)4&U"$R8Z(<YLX>,NL`I`K[3W/
M$'<M<*U,^E7@IXN`YXJX1R.02TPW,DK>="CQ2["[A&F%5OF%'J4ADGZ-S`.!
M=."XK-O!OLK-"D;B6.K'"$A$?$R'!\W?,$!9?NHK:C!GLB*C$8LKD+T.\<RP
MB&..C)AA4^W.7OLVM7,M4[($9\L!X=6Z)_BKKL.`9\*[@S@#7.7%TADE[$W&
M)[@ZZ+O1&MIO1=S*@VX#=N#*:+2!4[&PA%#RP;:Q&`5,PK,[V\8@)%Q,WAD/
M1>2`-AQSW7)7=O,(`,KC%H4VN;K_7Q#$Q\++O?<!Q6FKH<SRM=,KJVN>EBK:
M1&,`QS-02(5--F\C/!DZ/@Q0&)PH;\(=9K-(%%*VR?5COY]D"RJUTJS("IUR
MBI(<B)S@")6L=C'1"(+X28]J"42C7"I8!A-XC(W('9<076,F;FSG4P2\%"HM
MYMH@U\#$QQ-O9+B`A6IN5SA,A^E%L@]%@ZQK+<?T-6Q@S=J2,1GZK&A;0?ZR
MA"WDM\V+-C@RMH+T@^!`(/AJU1,7H>K]-M9TK1LXPO7Z2Z*V@=+<@2HGDC:X
M-^.5,;VB>!O(S=:+-C_0:76C:&BLN3NZKQE$T-B9K%&-L3;<@*F\1@S;K&1K
M&33`K=8:_T\RP(96@*-LB^?7@^R/E7.0PPX.\;RRVG&(A[D^#G5A-\$'/P-%
MB,&ZLGI2E2J(MY&#_+'0,@@2*8`KY\1.V@*+CE:2CP!W3'H:#U)5VP$L"ZUG
M$D#>..N'U8WOFD?8/.+35"<(CS@8#+*6\HUG-+:!+3"44ZM;=,'!&](OG\HO
MEJMO5+>:*SR(]X,51H>D$);DG/)IRT$SNH`5!"+H\@-8J0<3D"?0;KTFR\[8
MVX#=S\XFRT?"UW06SX%_%*TQFE"$:P,?J(=/'?QJ.GT8'WYILX0LBH`-:`41
M4BD\\5OT'ER,V(C^&US4``@0QHP)7`;"2JY<"!6"`%&,8$)8"/^M-"RV+&$N
M6+F*@3`XT`K%@0:7331FA>,RC@L1/APH\*"Q?S)GTJPI<.!`$U1,F$R(4*/"
MC$&%+M18=*A1H@ZMP#+XTZ=0A;"FRON%01&&K%JW8OCU:]54C5/9+<F1X].E
M>AO2KL!:J.R2=#9L^/G2PFR]5C;.?(J`I@"9P&0VM&AQR8\-'VARM-B@%LW=
M3V0PV"CTR>R22YHUMRKTI2QF'X5L8"#\R<=<&P661#![YLDO/X7NMEA2;\6*
MRRWJD<8&<FJ;2X4O"2;C8'&+,[_2%6A=2.X3OCG\XIE;`/FEM9#/%GIBXU=#
MIKQ`X#$+Y(;@&Y?15+=Q0_C9)/7J+8'_G.X)&1\M(GRR7>_28LI9%H%A:ZU5
M#QGFM+*"6?U=DMDE>)QQQA>MH;&$@9<\]TLA9A%GPQ.SG>4#&;_4<U<]9PBV
MFEDW+->&BI=]4@!IK;1A3`$`-GB)#^F8<T-9:)`Q%QEVM;;!D-$AA\9M*VR'
MQA-=-01"1ARU`8(/9GU1XB^PM,%B#C>8`UM^9I'XW1*195=/$I>LX`<[5V9D
M!8S(?=+F@_7@8<X*]2S&V&TEWH#9D!B8@PVBZ9BP7VW_'7A&.C>&A\VB:%SR
MA0\K?+'>"D2FV0):\]6'QH2?718!AH7XD4Z'9]F6'8\WP);F7W,]X>1T.2"V
M%Q`[S@<@&B;8_T`&;1@F<:"+9[1@Z1>X;9H#&BL\\00[L'!$Y4T=41D44$Q%
M]!-(QEATT+<M40&20U0:I1)!!F%TDK8@^=2000=QA)-+5%*$4KQ*>23NOB#4
M-#!-(1FS$Q54$/04MU!U&Q7#$4?%43%,J>0PQAE-M4I5OU3UL<<A4U/M5#_!
M@LUV9JEL&&E`^B575B[GL$."K2*8F@VXHG%#8FBTQAACGVS0*666J7QT"V1<
M=S2TJ&%PXB>;D(:!'_JU.*8YZ?BPA&Z??%+8$C3^@LV54QFS&!JHI5:D62ND
MPYQ9SSUASB]VG=6I#7GXO/*R0T?YBSD-B67")7%[9ZMPC?T"VPU^FO]5F*M1
M1O?%GX6!/:31N:Y\ACED,/CST4"4RK3*)/XR:`Y+A#'7+X1!^^9BG^!-Y!=:
M^D$-V6U$)K:7QG3!]+*3O0=MH:=?<N1DBQ=03]>0@?K%W[`LU9$5O"PXW9;+
M>5E(X6'2W7F6.9"(P1-IDIY#7EV&-Q4(>S/]"?3P:;Z!<H.B>H8-\F`35ALW
M[$?Z)PJ!J"F!`!9G,!^HO+:L%0SI.X5@7H,BLX%6G.%/1W.;.3H$.I5IJ"MI
MFA%I?D&&$YEE,C9(1^.^QIC(W$Q9FEM9=\X`'Z]];8')*QGU;N*2BCWL81#C
M5S$D0I%_Z<M>$DG7,@B2+H:,1%T,&1</-W+_,'RARR#\`E?`K*BM)!*LB^C*
MR4>\=90Q1@0I9BS*2APBD6N1<4Y0T5A8XBA'7H1E(1K#QA?4XICY.&8%E*%0
M/7ID`ZR0X8&7*,"J'KB!&\`,-F?PP:5X5@`@I,4Q?905B'Y!H0U84BWS0>$7
M.KF!+XPF9_4@)?E^H8@;=&$M"3('+%D5R@=AZ`L%4,[8*)(+7K#R4O@S!VED
MDQ9$&F^1L,P:(+_`,_>$<C[S:=8RGQ"I-D@$%NPP03-W!1M3!C(=5M'D"C:P
MA'&>LA#`))_G_C/.M!3B%\,"@J,\J9;)R.,]GMSC(1-Y(%$^!P-D8$NA]N))
M/`SFE/BS%:O40J)#_R'*F3?(2K7.D"-1?@$Q^1EEH?R9(SV186Y7N4$XQYD9
M(*S@H8>:RKT*.)5"K*6?93L#'ESI%6R`@'L:DIP/'(7/#12`;JN@B$I'F!W'
MK(F4.=M!)>?#0!&F9:'[BZ,,_Z-'3RKG4/627@%F2<MZ/(<TDCM#GT1:3FGF
MT4#S,6<Z9"A*M:P`?T_(HS)9E\%6UL,/43+416D926"FXYXZK<=#92G.!UT"
M"*J:2^`T0B^3X,LI922C1#*B1*=`\2#NRF*ZJ-`1E/"+7$&A5WA^(I"=$*1=
M4]+B4(88'H;<I(L$.XC!3%!`C+CQ6QB)[%/:F!2%+"Q<NC6C5*12S>$RQ?\H
M8I$*1;!!&9PQ=[FIZ8I5F'NXYV:-;LP%T753XQ6Z.3>[WLT*SF")#7-T-VMD
M`^9WTA$8G`%.>BI=A7.IYA6O?'=NV/"#.W$&WN]*Z2!B@45TY](5<ZPB'<[]
MVW(5$9AT6`)$T`4<9=2[*OUZ=VJD\>YTN_O<*.D7<`'.[C>I,:;EPI(:J["*
M=U*)#5Y@X\/ZC2_=`(=>$,$RNHJ09F"F"[BRA:2X[,AO"&G:!J\<;L#CC2_Y
M-/S<KTC/&%,9+\X:3.'LDN^YZ:`&'<,"Y>S&F'T@:$,K*+.<'%,7O\[U`QD8
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M.(3?\8,?8)&U#[=[W93A\+3GYN\VV^"<'KXKSJ)4XVF+MT19`;E7O>(EB7]O
M;.3^,?G<3<=5T`WEAMJX_X?)UF(9FT,>8(9YFY<K)?<J!!W^A<4J6MP5/U#S
MRR*^^2J0C8V**V*['`]A5]S+%'6CF#+GO##&KQUC=QIJMEM7^M>3K#T<%M#,
MJ9&<5^($@A9CI>%D/^;%Q;[M`QO[F]S],S96H8BIX2[PR_EWN\U1;`'/[:[+
M<3'`(T7'33?D8!XA=#&@XFKDONLF)GC(JA6B$J?DRR2D5IB\++;%6-<KB5/4
M(>BAHJV.^&2-QN")J6MB!720)!=4LB*O<:WKX6N^\^=*",&#HFM>;][5S2\^
M0R`"[1.O`KZ"KW[UYSNVL$1]NXA"%,>>6D!RIR/IX[TOO7=>8"]]^63^]KZ/
ML/^A",%[A1H1'_)\Y?YE$.!W;`0DM_8M!^X(#KQLC/>!0+J]UWQ17[8AX/3%
M'35X1?797XNE@P$5T$F8Q%3P0M2=&#N(W\FL2M*UG_N-#<2-($'P`NZ,W2I$
M'*)T3(&=WTR=S*'4WWU%X'V!@/=AW]@@"KF=F`46T-S-ES?A3M))RI.1`3;@
MCO0@70\V70%]X'A=V8DQE,"5'TTU1.`QW1*ZE^&-C7E57Q".Q!%QA/148-FX
M%P"235CP`KE]7^!%V_E%X')$7'BD5(O16XQ%VXE]1;11@S?Y(1PVX$$(#OKU
M(;VUEYRPULD$HE?<#ANZ5PBJTJ'X0?5A@Q+:H`3N3Z+_\.#;?!_-?5_9!%X?
MDLV7J6"T?84@>DE5K"`%XI<Y>`D[G!A6+*`IUIKK#<2G45JV+)\OBMX4R=;P
M[=[":-:X6($QY&*A,5%%,,5$@`#OD<M+6`1.)$4&HH0U3LE`Y%[!*%H:H9KS
MO='S_>)G>805.!;SB6,ZIJ.N;1:Z%-#^@$6UL)@<P4*6Q1')2$\;[&,<`=4^
MDJ![@8"-;"#;\2.+5<L^4E,;J"`]7DD:AD7EI9N7$5`4FMC^7`D(G(OT+`,^
MLH_"3(DU:9F7A<1#9MG^#.0^`E5H@5X</54=-40:JN3)4!/[421P;,S^V"1P
M@!E-2N).ZN.774E#G@Q"7@E!_T`D2$(D38;'_ZF43P)':3FEC?2D&D[DE"2D
M,PJ./0Z<5M(+.+X$"+BA0C81/[)?<7F)43H9<.P?4L*62EPE/SY;V9#,/P*D
M$-+D.2Y,$Z+E/@YD&68E`<'"R``E!E[+R:P<6AX$/\J=/>XD2()%7?+/^CP9
M028E-06>EY7-4K)/3Q90TE5?/L++%^'$3A2$PA!$YI%C&NFB0%3,4'0$.B"C
MMK`+:::+O?!+:FW6Q61@:2TCO%B1O#!C2E@!-\[$;+HF0J"C:JKC+SI$Q;Q$
M."ZG\JDC.VZ$8W5$/6:G''%+/UX)4*V$>[D$G0@.`8E10!Y=6VJE5:(G,N;+
M^ISCE/^<I7NYGFAN9WO>A!P5%P%J5E)J#$6P3[WX'DDPA5[:YYR4I^_YEU9:
M0;J!A&$"%42Z)]N%%GEVY?HL*(8JD7_!RV1BX)3XWD<<T42H!/O@Q/HDZ(7^
MQFH]!&Q]Z'=ZF8:*WFPZ*+;`5DAXJ(>:X1%I*(Z^YQV2BVQFI7XZY8WZ*%/Z
M7L7LRQ%=J#0N!3`:G84")X3^YXYNG846EVS&YY+ZJ+?\UU3(*&`BI>L%YDAJ
M778^&F\F#$_T9C)*)[J,BVEYEFAF9&7ARP[-'G`J'V@!*8C>:9**6K?,IKX4
MITST1(\%A7)2)_$QWV6UYCK^HINJ(W1FX'1&EJ6"BZ**Q6__+L5*F*@[)FA*
M\&D5A=:\F".X%,1JW:@N]D2I$IP8+5JZI*;FZ1!$="DNIMI(R"JJ_J944`Q"
MB`MR,J='P%;T/:.A#E$0B:;!A$NR(B,;(9]32`3`*`1\XB)LB>=F'5&];*BV
M,%%J!@QK@00R4@%O2>.XP);M&:LS*JNR\N*@B2NH4>MU.H6XIL0:J5%[!E&(
MRJ:JW2L/!>B;7FN+#H2V0FN\"%&T-J,0K:1#,(0P)I]J&8/R5:NU8&<5)6GR
M]2+!241*]);F[=8S-BIRZE`2Z8M1T"N)8NJ\I*8.81Y./*J,`F=*)-%S6E')
M7DO'X@MGO1ZQ`B-*:)ZY7&MG<>1$_YRCT:5$4!#J/TALN&C6:D;JHRZ,%#T?
MS$YGU=8:K8$HU4+MHFZ1ODA1,F8D2406O["J@XJ+N^BIN!AJ0C0125#/[JUI
ML.[>I@'M%)'A\YFH"82CC,X:JAIJ1IXFP%ACK2;1<NY+;V7D,Q[?OF1@K='>
M#EF!,%(KVB8IP(0+K=&>WV*MP<"$U#IK$D5?LSIMX_:+HK5$!C(NOUQ$!AI%
MH>W>V4)KQ8AG,<@6M3Y$[+W$$S&MDR:N2?#>P@P$<I86ZW8K2)#N6^(KL-X$
M;X[HZOTL;_6>JSZ$P;;$<TYN!B8?Q:Q1$MUKN`QL>P:O[9;KYT)?.QJJU#[$
MYPE:.U*O0_]<1*XQ$=;R!*6UBTL\*NXNA4:@IHE2HTEHD0GD(C(:S.UY%C-B
MI]HZ1)NF6FG-*MIBH$(H+<$90VQ"8^H50VQRK3@RKJUI\-6*H[5,ZT!\,,P.
MWVD5XEO*K>Q9D=E6[$C8K:-F9=A206R&L$O4JD_@+M,>*/V.L"]NUNL-(].&
M:FD]HVP%\#AF;?*QX]JBP^M:!.B9Z#7^ZMYFX.=];I8>C']1C*(E(]-.JZ=E
MKDXD8VHVA0*_KJ?!YDW4;&J*!&_I1`<+Z+U\;F\Z:V^A;Z=1&A70[)P,L$AD
M'C"N+?/*INA-[NWMD$^$[=HJW[DH$;8B[;@6XB''\6P*;V2M+6/_X:[C]BE3
M+(-.%$.G%:OP2F.N-C&S.NRUFL#G.:FS.C'?-B?2SEHQ_&PAT$NNF6C\JFWT
M*8SKI>;GQ:]JV:N>&H0)Q.8HFYY+K.E2G*;@CFRNUM[.GFV:?JUP?JVU*.U)
M[/&(LJUC>?``?Y$W6VVDMB:!BJJBGG,NLP0+T]I]]LOM>F,:S9ZN+4.NXA:I
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MMDCLO'RD5,]+3`^%12AM]+:Q<E+,!UN,R&[M.7LV.\*M+`=G.(NSPTRS0%O6
M9E'S$`&?\\+SG+#H<":R%HMG])FC3V0@/;LF`_MF;B^%2$`R\O%06&?O</;$
M915?O#BN:F:DW*[M'"L:D%JOP3PG&0,II<F6UY):Q_)0-MM+0;!6#`N$W/;T
M'-_+\"X,=:?4=/^3E@+C+JD=H^T!C!/3:U0ZX^U1`12AYDVTWF-+\N4"494<
M,MHZ,6/1,[T4[4CO]&]6-2C3+Q!O$6,1:Q+%)C4NA6P/+T^T'@6/A$L#LER3
MM$"'+7*Z7DJ,"^M.9\B>,>TV]ETOZDJ`GDK`2TIE[SRCQ"L/T0U;UCW;]#J;
M*&KV<M:JGC<J7V`##`:/:L_^)C8CZ8S.<NI1SP<?X[[P]BNC\XL[L.7.+98S
M9Y?GI4MTLZB9-&@Y'XK/+>4EZ_NNJJSRYFQ3:^7A:R[0K.5%IT'O-`([Z$7,
M.%+G]&KQFJ_V&*3:Z4<$-DE8K^^%A'Z';Q'1-<G>*>J1VHC2IP[=;A+_:1%.
MF/BX'KH6LT2^=JZX)B-PTFJAB^?-GL2RMF=LBMZP\J87`PQ]DMH3N1ZNPKDY
MSC*ASZXQ,F^BK_?K@M:ACZE44S>=.NB@N8M(3'J\^"].S*ZDB<3"2O5HC>TL
MSZB`FM8^=[,X_G.SRRA_'ZXZ.G0+@\11]PM061%N:=X7V6S+-ONF31&)_\OK
MQBRI,M&8ZKD:6SF_-#F\^+#18C?;`O.C36UTFG:65Z>S@G,ZFZ_!XV]K3A%R
M6G7#*OARQ_9JIUZ_MPN4UZ_'GBTYOXM1I^:YTB^K=;!(0"QO<2R(E^RP)RD(
M5_FO.NG$@IX""UI@6U;8VG%B8W#.LWI\I^["_U!ZIU.C,2/1;"-NIJ_TIX7O
M/Z/$`^<LNLIVQYZ$$PM:MJST<*(J%)M65N:L>O<O\]Y\O\^L1^3IZN;\6'>$
M-OOZ%OT+<N8O[39[=7.$,-Y+J'KXQ,_YHGU]IP][W+?+T4;N1A*VO'3L^\[H
M#XO$R2N[E%9G;A[WDJ=:Q82JT>:IB@^%WN]L,S?VYB<V,_MSA@]S8W,J+UO$
MS+>+TK*N1:-O,E*K@0^C.`:XH:8[C!<?\6VM)L]YUB)\PQ=\.+KC,IRFE1>U
M\<8L]1HY54_LP]_QR>]P]'W\1$1C3[QO[4+GQ/:>(E?U`">HJX6M"12"Z1'M
MY7]O]#I?2I=$I35_D/_C1`"_,49/-T&P[[3WL@!3\"$3[4<>*K,>\AH!A`EC
M((P5!%&L8+%E!1E:@;706"XK`ZU(1%C01,6)5`8N+';1F!6"&(M9$6D"A)6/
MRR3F6D;0!+J*,$$L7*8P(41C`DO"XID+H4:5RS@N@Z52(,%ERR8F;&J,8\6&
MN8R5E#AQF4"-#"$6&QF2X<Z2$TT4@Z70JA5T"U%:W#ERI4&<.RD6TRHRY$R%
M"UM.1/@Q),%B+:\>9)N2:EJ"0`<2UN@X5U_&55]*ELH2K[&U!QV:M!Q98TV%
M`AD&+<@QZ<VOI"-6]-K1K$:%FRLNQ<LQ)2R+IJW\\_T;>/!E,J^:#ASX9E7_
MR9:IR`[Y^7%%R]&74W=K5;-TZML_=^=>$T3DL"^E2P1_L^]KA"V/(GS)LB_&
MD`A3NE_OV<I"@BD?>VPNTBBB:B(N-)9NPNLOB63*+RT%32A@@4(&:@TZB:IR
MB"C/J*HJI.'\(E`LE:C@R<.I)@K/H9UXPLJK`W5;T2Z4<B**I;.4<\B$'`<R
M[2:KLJ+BJ)UPX]`@B3R,#`0=P4J.LZ.R,@FFYJI2*J_76E*QK/<$&RN7NWZL
M:4JG3&KN*BHD#)-%Q*!Z3DF"FD+OQ-"4]`N\L9H:C*BDPBS(O,JDTK'%@^:;
MZ2X5E7KMQF+(-&G-`RTT2:2Q^)0./"LXHBA."_E;_TR[P;CK3*6.*'PL.[($
MJ_"Q]!@B[<!53P,0(=*H2.E"8Y*3;#]'"262P!:#RB6X8('+[SF3LD),1-68
MJC`H*(M%%3*AH.T+04:1M4X[:#^5["5)2PJ4J?XVPZPX+=-[;U2(0"BJI8M^
MI;0@OAX3#$VJJ'AIU/MJ"E4T1H'R*KT'(2D@2^ZHO9"Q4*-*DC^_G'V*,[PR
M8DS2;H6$*3;ZQFRQ()5<NZM9A5)"QX1+1_3,S0T%W=&S8T.UJED5!S(!LSA#
M?8I+2ZGXMM@+U\UQ782;W;(AJX(V%K&_1!HQK-@Z=LDPCG(.L44+PQT1-Y1,
MJMJPD0[4Z*=?159+R(N,&O]SZY#0*6A!!3O.5&GS8*/NW85J.\@N9STE[U&W
M9F)(VU`YC*ZVTNZ*EMDUY9I05J9$/8U#QVWEM##*D`6*+8H64VI?B83]?$/T
MK/9TRLZW,];'C[9-5</5H4/+0CM!HU;;ZJZRK/-^M_[K<@#!H]8^3_O4'03#
M+A;J-0\UFF5`>8NS=?*2XAT0O];\=*^RO/B6LX!"[CT(58W(RPP\IR0Z2[3&
MFM(0)"B7LM"@*)\>2M"T";R-/WV[PJAD%&^^4$31:0BCQ@(7F)#&4PP2#6.6
M5;A)P8Y8JJ'+I(8"&">MI25@NM'7-+@1!(:&0_R!"GZ>XCY/&1`JI)&-LGAV
M.77_0<DK*K$/1J0&*=YISU;Q28B1QI*@M"V0<`#,%6#2XAXCY>]K?R&/KE"%
MD_OTA2"7TD^#5E>3A7S/8I#SR%>*LA20<(1`??)B>HI7&F/%2R%]^9RPNA5#
MUW0+CIR9#N8V%:[:N<YUPY$4?T"#+3S6;H$?Z9W(MF>1X3`Q/Y5ZC,@HH[HD
MH;%3C22AV:CXN)2(1DM;N1NDBG?(YZ0Q.C&ZU_QF1[>OE8PI=N$C\FSR+;YU
MRV&^VTBM6(4L1A:P@9@<7TT8LS"F>:1`M,E4G+SRK1C:Y4)V*0J7]E*IL>5"
M-%8<7@EG&:_"9-)71UQ)?7@)$HE<:G*06DI5]OC&E"21_S.*RHOBMH>5XMVM
MAW'<6KB@0D\I(@MZ::P?YEZR+Y7P,C]\(Z0<^Y._";:3?C)<EB*+@LG>36<H
M+%,5TT[RK&W=$HX084WR)K@C,`GD4LBS''Y6(L^EX28Z:PQ6:\!4/8-\;8Z*
M!.(=:;H=P:2-A*6\74T_A1:DX>>:2F-EO^*CNVMR!7Z40=@/$>D>`);K--KD
M4%I2641&:JZ!M[,40Q8%+2M>!&\6O:9@1"BHM`"0/O%BDJV$2C],83*&T'24
MK<9)3BT!4RKV&=U]Q@:@Y"P%3+F"TWEP2<2MQ--K![$BF(HXU7FVJ#.Z8BM=
M5T;8K1S*:D1-Y#PUB#=\Q>V?-_\)5YV*Y</R`19=AW+.37UGMY^&MD\]08O=
M+.-3%<UJ.T*-F&J>$C^8&BQ4@`6A3F)5B(FMCJT'*A]KWH.02Z4&40<]8295
M150O9BYG(%!I<(I%%#L%12%`91U:Q?I'\ZIJ++2MZ1UM.CY,?6:@T=%/N%:(
M+\DHBB=*,=*$@&JV:^%E/^?"2%X):!NJ;/(J'G$*00,V,^%]JG`9(4M>7O>2
M>[EFA"0%(%T4]APW[<PY7G1@6M8WIKJ(B4AG;6E2Y<O2J-BK2I,K+;Z2]K:^
MX)8L/+N7D=9"D>L`$"("O,E1:JA.@X:W)3+R4SUO9Z595F1$-;9)?3GEKNC\
M9R,L<2[_9I0:FSM]DBC/N1)]$>;:V-&VQ5/ZR78\$J0:WPN96:$C'M.:RN@U
MI1`%*,`!RAL?G`@%<@A$5,D:LI3,+7-'D]6J39BX)K-ET!C;!4['.L8CP(CW
M8"<<U7DY?1VI4+C3G89E8C#-RL&I:HRA64NS]@L]FJ%ZJ8+[57%&247GCA1!
M;HIQ*!T<*N@DZ5YE"9^%:BBD;<7N;0[S\S<7]VI(2<F6'2&.B-NEG-,PY9'"
MH^M3$[(HYT44?JUZ,:/X>Q7'OHQ:$VN?E:]3%AN&L'`)W-`9<0MLH>AGJ7#.
M2U.H)2^&T.K"UTF92%8=XP<KRH'-@0L($V21LFRPJ\HF8&T6_P5@.&4P1^HD
M973TZ[!8I15H,AP5=(*+3!]NM1A#6%>IZ?C>"'.D.8"E2Y0M5<VR*,4*J`1H
MY7SH%KI8+;B2_@U9Z"N@O62+<%AV$^O6:UZAXE:GH:X=.2?N.E_9L3;C:G&_
M@O(S"LH-M)-A=>$@TF^F+=6)4[H9\-9$J].)#*14M(RM&`7BO)%<4RA&UG^\
MBQ2ZQWIG=#<DAZ9)E7!ER.\)S?M3@_*?A&$N+Q?>,EY6>&H"LC5(/233#JV,
M]@F1"WO3EN/;UF:LJ("VF35+2,\^2?><Z[@D`V=1L?S2K=C]C=P\LROH)_1=
MZ,$'KT@&=`]O]++MX<0$A4COR,7%9?]'TVQ5R_PVR6/%80'F4.+M&J?LU`*1
M[ZD9(\DIR7.EE!S(-2CMH:SKHM2)$*'[)O>C&U^%,>/3IM\_G+&4.J=#YOK`
MS0:1+"L^\"4[7*+ML"Z@PNDJW@1\G*/'M`J9XD4V]L(I/H):D`*<2BV:H$_N
MMB(FZBY<>BZWQ@D]]D)IOH)8..(L4FV&%F2&'JLN($(U2N:QQ*>NED^HE(@S
MIL?**,_G5"N11&RV&J.N\@.EL&*UQ*23^.JO=$]Z[D*S<,(C("]D%*P^(*F&
MUBZB@'!ROB9R="^55D1W^$4)(2D(GVA>'&4*SZA?SN-2B*^G<BA/ZJFA".U`
ME*>)4B@JU"__F9X*0"QO>+QHLFCH4*(O(32(--R-YV+-/?9%:>2C&-[O'UR#
ML.J$6<8'+8[B_OAOP[)J_^X(=NR/<*C/(QI(H5CFWAIE*-"ED.)"5P3GMXA%
M`;>F9'*DXM"BGAB%S12G`P5IJ]AJ.U[JD&")12YJ+K9&OX#IWX"QKZ!&%2-J
MEX00760L!`7J(K)0*;R0&95%QI;/.10G/'"B<[;O9?QKC""K-L+,];"'F^S&
M5QKQZ&1)Y!R-W/`*C7PE&WWJZ`:O*!XK&I6K1VQ"D23.^UQO]5RID-1OM(1F
M*7J,8TK"M=PC#E]#("I2BM[BNAXJS3[(,@`+:F`&7RXNN(3(U;AB_[E@SG+D
MXPVUK!17Z99B0R?6I#?>[]T2(KP^A7A^:Q/G2#;2QICZ[!-[ZFO&A_\<4CO2
M!Z8,$-&(3ZCZ))_0BZU@K8>B).-$*LQ\C6[B)<-P)PSSZ?I,KS5\JABI[QBW
MYF5HT05]YD@F+`?/3752;<TPI:WHPA[M`QF)Q>=JT/!Z2.<.)"X*B&=LR-U@
MY9_.BB?6T2TA4G7NY/;0K</J$A@G`G7.*"0>8J[HR^181HEZ*#!-8FWJSQAF
MP48,DR&FS2ME".]8J\WF\3"YA!C]D%H*$:1&Y##'(^QX#20D$E=<2S2D4'6@
MZA6A`C5@0QU9A0([BDE"\N"`<"LN<ADDL?^[**.=+I"\6&X4S8L/A<K,3@?O
MKI-V6,E;L+/?K(B^KD-70,+ZW$+$K)(198S7@"E#8F7<S$TF+:HY;441>:WN
M',L\W.TU2&K):`^^OO#9#`HS:4LBGTR5T@:OB(7X&@8)'R54)F:':H_VY"5"
M.8O<((5F!.=N@,EO?LB&Q,8VLLPD!O,O`$@>FP52JG-"*^(N+.60`*V!8DUW
MT$IK+L*0=/,LY:IF+JV"QL0_CRNM(&78E,W,Y/,MC/1F@HLGE6CFSDZ#$&X?
M)XFM>`:O,BUM[A%`6:LY945P9FZRH@@UFJ(F6A-`^:L_4J@U(NW][(:M9$^K
MSC*`<LI.I44H[O3_`F6D0]=G3O_43@$53X5"=T!,3P,5J/9G`2/H#N=C@O*4
M/O"00=L3>B!E:T9I#W4"\1*,3;_&2B%Q3N\CQ7#4(O'4B)!B4!?U]TIB,&'B
M3\YIPUZ*,F+T!96P4#8OQO*I*E"I1;U21<7D`T_5(![N)FCPQXZ#^'`UE?X#
M,*"'0P;S9>C.M9#B"O_#]2S%74*B?[;"5Q,H%]6I@JQFA+*$!MTG.0)J;_:P
MAA!O2K426NWBY/#T`@T5\4!B1?+4'?U0O%JIHT9$J#)"D6Y'P7QO+4[F*ZOO
MM_()`9'OPJ2$T&@&YQ*Q.6)N30YGGBJ5/<5$$K/LSP2U+4DH5>]4O`;U_]G0
MB$@L55!3-F0'-3*Q;`%5-D^AZEW44R93$&,KYUSQ0U-%RO),3T?(!B*AQR4%
MHBM>ED&IH!\A,)7.*?`DI60NS$[E4L($U2]2B/B2@R-F(5\QHV2^!6A4U&SV
M,(":AEG7:0\[RO<^SC.4:H2`$8!H+N?TI'J(:Y[,#UW.$IEH$26@-KA(AL+@
M%(TDS"#[5$@B\\N@E6W!0I"PSV#CMBK8CZZR4(FZ:%(NY$<8)>/`EEAC%F5I
MU.$HRPZI2$3V3:M>5B+/+MAXQHDF*469E$',AX0:94D/BZX.QE9DXE#(;X90
M0XJ>HA9WC$'7`E*]\B\BD29GY3U<%[UP:F2IUO]HY]14F08WKO([5Q9Z5_;>
M7-#`E/=0[]0WK930^$7\SO/L2"Q,20RL=`78FH:3O)(^\?,ZNXYHS1>\&G7*
M%.6KH'<6R(O$H!=+#*2&1F19MW15;4(KGT='C"0J+O?USF@N5D93.35'[,S=
M.$RHB*1MQ\-320:5#/!"_+5)I=!D=;4U)$8@6`R9S,HG-8.M1NFOS"U'_#-$
M.&Q:(X?2-$/!+)6#+5?RRO5M9N/?]F<-;;9-L6]1(45X)^PS9;!A%C!G0-:)
M0^*7#`)=]>]Y0%3#L"]F.U6WR%'6#JD89B%,"6U*-"IT.81IYM?.&G2_VNHB
MH%.T?M-U5]$S7Y%S1?;_`J'7+6RQ-)+-:+NW=+MW*#2T>0'YCJWH6I726>,)
MC",*:;/46!B-/>TD+"AJ>;B"F>B0=&WH0.XI=N<IW(1W/H1ODK3QB;5*9IQ5
ME<U&?$:DEV(L9V.%:#%9K9+MXZ0':@U8\YB+KA0,L,1X=!UG#W.S194$).H*
M3,CL]`;HF-,&4%I)4W4G5F!U'052;X7Q=OGUNV`$9`RXF-^0A(>1DE?DD2&R
MQVJTG%.LU"IH)/KQ+_O74J'X*^]%!CUSG>#DG^C*3B`5`9_':BM(ER_6."U5
M2)B&`M-8K2[B:7-"K9+XBE44`Z%39')&:7V$]NY87DGV>>F-C\/,N_[8>@LY
M_V0O.(RO,Z1!>H5]SU42"!=%JT,>&:+/UU*=ROPF]%X3K"O$R60\M5R>`HL=
MQE.U,F^:=%!O-!;]^32T(D:>$,N(F2ZNUJZX`FG!@B?P"P3$>"4D+T0PQUUP
M(O!H</+"+)Z*C">`>571,Q?%FBQ<<-UJ%BO81A9W%<1D4FUUC((32)?!Y%ZF
MFE7+XB/*>BAP@WGNM6I[)"Q^[JESSE!QN9,[U$AR>K^ZPHN+6BRR`D4#NG._
M<U$EDIR6"J]ZY(Q`6[.Y-TS-B"B6:?D@4</.;A#%-"01.NT^2&=M8D'$:2<V
M=EJ/F%%"$,NXDV0Y5X]%)-A&24=BE"<%.:1%"^CB.?^D\Q3"&,U`')70<F8N
M[E69?CJX'(^`#?;6V%@*(5<^:\8YR&UP.#E<<^]GWV50+WB3GXV"/]#1HF@^
M!-@(Q^-Y(M!K_54A$*V"5:AI?O6*WH8V/]BOQ3K`93'PR$N+)A3.U/9;5<BC
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M!/B,%I\G]P[U`DT/LN-9V"8,DD'ZB&F:DL%)PD18(.O=@),Y`FDP(T[[[&QC
MKXO[W@)/O".H*J#SS,UF,/TXLSLWHS$Z/J:Z.6)X/ND\CTF;9/E7D.<<WF=:
M9AR4_U')94*]M,(/?23M*$;D>BRTMHL@=7/#R]%`;2+$6'AI^IMP*CX*`!)6
M(`\"3Y!Q%(E]IGA``!;`XRA@P1C.X))<7"?V`Q:0/C<J*EX4[EI5\5*(?D):
MJD<56^F=_IV>/C.*GFV*?C\2--E261DQLVOW^^;^NR3V%V;,Y!CP'"^4F>X,
MVCU<V"<YE(QKY5=I\,`U%?NB,LK+8I1*CA9IZ<+&HVP;")D,=19\SUC0H1W$
M9]4V%RDTKVYA-AAS.NFRNEQ-58[[BRMB5T>8`IR@QP7]^G;W[1K)6'IHR,5=
M#6EI1B*=BKIS>":%SBJ`V0K`O,L@:*--FLS7F5N).X4<!?^81UN>V]PYL%KP
M\)BT+WZT$59RO[<F4TU$#E.,.17%D@-0LKR\O7^R.DR]ZS=H9Y3N6/125V`!
M"N!Q879_#V]G-"H/5@`/>%Y"VJ!X`"+/I7IG0(`P9J68%2O+J%"Q8B(/GCRP
M8!TT@6=%H8+&3"A,B&Y9+F/%EA4S1L4@GDM?VA14>'+AR64@,MI<`0)6Q(QY
M"N`I!**-,6,^??@H8,(8B(4D%S:T,I1*4H?+K,R"6G49PI-#07Q<9L)C0I-,
M36H-VU%LPJ;&S`XU^37I6(1K3:),VO'A7(5M2U)IFW!AV(]-&;I%V_$CUEQ:
MBYVD0E8A6"J2"Q>N>SF73*V;8;K_]4RWL=.F("(7T[P0M174JDL.;:J:X>N[
MIU-O%KTZM=;7"W4/-0$9*EJMD=L2!YS[)'"I=I4G-6'7[E_@N[FVA=W[;>%_
MW+M[_VY;L_*_QH<JUAQ;M?K>"3_&3FYVF?R[*,G:9O\>?>[]N?7GUGI5257=
MMY]^Z_&'('_BR:>55("AMIM]"QWTEF(-)64?(G/-1E9>?>TWFWM7S3844]HM
M<]5">D5VG&,=*J0?6$B1=Y]FL[`V%F%)E58(&FAL@<82HW1Q0QL@%(#&)2!0
M8Y`5L*Q6FDJ7H%'/#:O`4D@7/ZY@S!G&H+/4DU[11--:.=73PA9^&)F3%0?)
MU)&//RZQ_T0K?N"QQ(]!HN$#"/*8\,4H<E)99$4&P?B:?%+A]5%)KE7%56^N
ME9CC6G^9%!:-5@D8$U3(K65>67!"YMREV2$4G'+L<<6B9W_YA=A"LS@:*G&2
M)NI4<1:^=EYVD%HWWX"5>DI85;-$2-9ZRFY8&'JS2'6IA*MQ*M=5FNV&W(V@
M7D<2?:'.=)Q]N;CFH''C`??6;M!6^!JZBEEUG;C?S>M=;+/<A9=)?Q'87V\'
M)O>A@:.U15E"@\D5GA4:+IN>O_QV5I?#UCJ,7XW]^L<?7,*]JIACURFDH6P5
M_L<<22EN&-;`\;[;XLE8_2;9?#,5HV%3G<K6&&#WKI;B2.MZ-/]Q@:L"5LR.
M(.210PY4+M%"#@6T0D8A7ZR0SB_87(173B!\\4D$GWSQRR\^H)'T"F2X9$PA
M&%IA9$=*0154/4J;\XN7",%"&@@F;/!)"RV@L8,YZ>R00PM+;'#))6:;P_4G
M2=:39R'IM*VV4CHU!5:^C1XWVE=DD6J8QZ"O2REFGH,6^HA9=925@[C-]*$5
MH,?D8LR2(7P7<2G.UQ=C]O4UT[4HR@;CRVWA.**.>-&E6F&BS2P<2LTJB*"`
MH>Y^EUYM:8N57[$#^R[L,+E-'Z3$@5L\J`WU13"Z'IF7EX.P`Y>I;<=^O!^]
M^B^DH7-H%?VHBR6L7_MYE%[X4S3(A$K_>M"Q2FYZ9I5_$5`S(2/@3$0EM%P$
M38`APY'%4',_A3R+0QG#G\)$1BGQ4.=!<,I4`%F%$`U:I2&B`6&[LN*8EPT(
M<S&<RUG&)S$504<JLN*9$?4SD_?1I!`1:$$AGG"&3^3`!WZH6P$*D`X,I,,$
M/JA'/7Q0B%9@8Q5<*]PGGD`&N26M`&18Q0V^T(4DU&,%)FB%3O#P$XS<((TY
M6((-?E&(HQBC(F\!`3;\4`_'%>`)&'A"%Y0F.3*D(QU/:$/2+G&#)SSA!D2R
M8A?JT04PMNUCX.KAHW05NUFHI6CA*IJG&M(Q!0XH9\**G0))\I"^M*@WT"D=
M9'"#%945XY>`_[DE?'B#&;JH2(2<\=V`1B(SH<TL+0V4(0@+!A6]3#-[QG!9
M@I#(.V9>YR\!XDSWW(:56:4K1?V+UV80DQC9\4X^BE'G?%X)%@_%)"^(,<MT
MT/60<II0)OJC5\CNY9$#=,M]"+F*MAZ:L(<RAB3YU(NU$IBRWR@S@OQ[((YL
MQ#,;4=!?$NT=1(HAT1M9:V(RU!`$5TH@')G35L>)(?9P<RWMN&PX&\U+YD0"
M)X*=4":]K$K('B46^21SAK4[&2R3HA`JJ/2$FJ&-6D)6P=B`0*$3,D$!FOC$
M*.8@D^DH@-+(\(0>-;%I:,!#V'S0-RG>8`5H\)O3PK:"''RB;Y`$9/]<I9@'
M/Q#.CX7HVQ?.<"6(/(0:O^`:&@IA@S\"`9*3](,YGO#53Q3"$AB(K")L<`:Y
MM2"NE_`#+_"&,%9)%4[G$XQ>*MA`X4B&B$[QB$=$*+M(,:2!VAI)-PVF3:Z.
MACBHN=0Q/B(5]XSE&%5%V&!D\LN'".\U5[D03$]Z+6T.)62-4<M0APF=!(H0
M-;!%J<%2Q!R(T,\$N<%JO[AGO)"T12Q%VQV-H-J8"_'*-C7=S&^@6C3H1(AY
MJ\&6,2#D$-)5!3J92BYQ*BH7H)EGM0`KZ+QD=<-_4D=6(!3I"7OFT&$6+0\+
MX`$-:,"#%)NX"P]8PXE?K.(8RWC&-*XQC4__G&(<VWC'/*ZQCDVLXQ>C6,9"
M)G*154R#-3S@QT*FP9*-#.,8'QG))^X"BH-<9!S_&,A9]G&3A[SC!;SO.F=`
M6N'LN@$R_-&L:$A':`V7CC3^[0PV@"N56C`E.I%M!8R,\Q/*BH:OV>`&?4/#
M%WP0AG1\X:Q]6]PO\%8:=,#"#UQ;0@$BFX[)GGFT5%LT&NBL10Q@`)!->R(4
M;V".JX&`B,580).E'&4@PSK',*XRK&,]Y2W+&L@/X#*3<7WD6'.9UT,&MK%[
MG>,'X.'65$;RK76]XE?;&,LF7K*060QM'K_XR6M@]J[S<`#V[B93PJH9KB::
MJ`W#TYP./1&'2^61_^,L1RY]00N&AO(L#!VP?Y"Q\'>TY2UJ!H=["W,@2#4H
M0X.%8-D+"/<!'OYP$H,[#^!N.,5-$&Z,AR7C'->XP\.B\8V#O.,1@?@!P!WR
MC(<\Y2-ON<H[_G&3E_SA;PAWS4\.<8^?'-PQCWC.#U!SBD^<YSBG>,XQ'O$W
M\'SC/D>Y"6YN\:6;?.<.ST/(;RYTG[L\Z#M?.LO#;76R`,<@A;BD#[Y0UWI(
MLNQH2.L2/N&#R!;`<9!%^Q)6L`&_?0'M3M/D&0I0CPW4]1-=&'2@J?:$7SQA
MT2W80`XPR<A?E,@@QL"&8R\]:L9O8.\KR*2G04V-*OI5:?7X`ALQX`>O&/^L
M'6_`^LEU3G2,HQSG$2>ZT:<N^XD[O.E(?[CL(6[TW_M\]SRWNNMG_WJ3*WWV
MM\?YTWE/?)DSG^8<=[[6F^[[WTN\]Q_W./>U+W2CB[_[,6]Y[K-^]:+7?@$,
MOQ#]C#I#=V[HP9,YRZ5H=L((C7<NS#D?M,+R8-F3+^,F/T9T'/[F'1AV;^NU
M403W0`\H0V#!?@L`;F_0#K+1<D-Q#""7%+,P"^V@$"!H!2)(@E9Q@1^(4A=8
M#"<X/"(H'\>P.MWT@0FA@BQX%228@C2X$.TP*RQH@O-G!<?P2SO($/>#*R/H
M&L<P%#PX@IGS%DB8.2#'('BQ@>3$@LN#(BAH#!O_B&\NR(&\U0[8@B$-<8),
M>!;VMH(Y.((=H4KH8@PXB(0^Q1!_07:%@T5D8%:?<`/IP'9N]PDK$%D]\@F7
MM@*?8&DW8(<.0#:+U`H^0"=[5U=`,&B*%%F)1SAXIC0W\$=7HQ3R<09MT`64
MF'E*PT9A($F8I5=/%#8N$6<%,"5[=7=/H&H^](%GT1$P&(:O`8/WPX7S@2[V
M%X/&<HN9<H&S<0P@:&"\<QT;R%Y&6(L:"("^N(7+D(LFH(3S(837$8VL,BM:
MH808DHMN4Q7.L(5/.(-:V!9A.(38F"[M\A?'&"%(.(+S&"$(E2GAIF$;=BQ$
MB(+GZ'X`>(,IZ#JW>'(+_\!^&:=`XO0AZL0A?($8T"(LUJ-4DH(MY_,;Y<([
MB^)@VK@H#;4I\8*`W0$:[;)?&M)!)\,]*5DT>$`#"Q`?RD-N40A50@-1(,0O
MK/%2O<$@=<%.[&%P[`%?J@%?J;%!](0S*`E"K80:CZ(4$^.-YH$:U%0>YL,K
M)U,,2FA2/G09@G&1^T$<5,$0*`52"5$N:C&6)W$5;B@LVA*`Z4)V3;1(?`A6
M?*@TFY1W7Z!)A8@&FDA72_!$+$$&-["(-E`(3/,%Z7`#;R>)A(8&E]9G:#*(
M=>4#9/`+;0`+NX$.5A!:CK,"?O`$C*,T=)9X?W0#34,D9-`*&'$&@5D(*P`$
M9/^S!.E@#D:R0X5QE?01,R-3'9RR#%@9+&/Q.Q=I+.'B0W-Q+^PR/*_3(!AR
M%;XI0J;"&8_B&B)4.EP!@+E9*['C0=TS42BB0=S2CI#2E,2#'RER07/X'`^Y
M//!5006TG-:XE4PY@!AW8N&V,A4I4(FR.@ZQ/";SD2/C4,CB*?\UD+TI</34
M$!II'M6E'580DMQ15,=B;\=51`[E0!8*4Q*Z``_@DD$U(@Y1.2C1D1]AH44T
MEC)T%2[5&QCZ0*)Q+P."E!/#HASUDPZ5<!=ZG`QJ+$/E0*RU/2M*G.9Y*<IT
M$I637ACV&SV*,Z7C%++T4&69(@$"&3/Y6T:T%@Q6I5'_*B!!J&\8"D`SA#`'
M478Y4`\%L`)+$)II59?I8&<W4`B7@&=/8`.%N`2:J$F&UW>%^36855=?`%J!
MAGGI@$A]-*><645/LB\UP32?4`^2TUB9R%F_8`YTLZB*LP+U\%AOM(=A`*>E
M]0OL<!#FI82[8XV8XJ-56AFD*E`!\J/YUDT#!SL#,CXP&EZ"P4P6%6"O9!6]
MU!0AUJN[,5P+`8-?H5"ZI8PEJJ11*AOE5$M;2!T#QY/=PU$H.7#\)(5;>*1(
M:423DBBOTFYVT8'L$Q8T@`<'\!0^I3/<:BO#I(W6.)T#:DX:I*X*V)'FL3X-
MQE[<\AS1)3)/,0L/^@\0@3GK_U)$!J>L06.>QI`'/.`#*%%=\.F!;G,`4E$(
M!U`(OV6A*%JP):JL8XF2Y"E/-GJA%=I1&SNR/<JQRSJ'PS.R+#I@(TN<#M0@
MC7$OE`%RY-2CW85;_;I:YAFA94%-.WN&QP`1+#HBU,%;2CI,\$)$0"-$%(5O
M"_$D9I4T5;N7-J"F;6<#9'`)5?MXFEBH=8JUD268?4<&BY8T@=8"?LJ8EV8U
M?.1'EM"U?OEHR'$&7ELX?S99>YEXOP`"E,FU35.U=5H(@ILT?OE'%7%!QQE5
M#01`.KJ0)5)=%D54U+D5`&@PLCIF#@6M3IL0.;JKMV,":4EA]V:YYJ4[@9&Z
M1/-<8/\Q2[.!H>1%LD\!*@[T?TZ;L+\%&0?;H\&Q6PYRG=0QHQCJ;L?)+J\:
M;[G$@7G0DIB2%E&KKL@A8.-6&/#YA$6D'3L;8/1S/UJA4.DUNL];")/2AM>1
M(@`;OKR!K!][LA[H0")68D2K495Q.VF#CQ3&NRF;<!JKK",+O=Z5L;Q[LLF*
MLB3K&O$'HP5\LA%"M%&*GSK).@[2G)7#&19*0ZVJ/@$EL^314"_J-F+AL].A
MP3`[I?JXK;]E'$KD4!-;/Q,#"]AP`ZM)!C,<63:@130<6;\0-1M!28T$-:?(
M6+_@!V=P!NF`M7X0-44\P^E@"5`4!JTP:M2`#42L9C:`Q*C_Z;=G0!-D1\6K
M:<-D0,1A<S5G@`YM$#:LN1%RJL-G4`B%D&B,Y`=@4A4_FCFN03\'%*N[T6[`
M<3]RL;CB:)T=^)$R`\()9!;/!;T2_%\Z\TKY6J47`J[=],?4`5[0DKM*2*+M
M^T"NY($`,FZ82[)OP5XGJ[$_&F"WZXP*S)`-@9(IW('ZAHV9`APF=@#JM2B5
MH8'_.RD`\A;VF"WJLY5B^*J*\AS<4KZ#`8/V!\I6`;#:`8,MJ\H%'*#7@6+"
MN"^[2A*P@A8"G++YJ\D8"B#12L`I2K(K^LT#S"DX`\WK?(.)@EM&6,$?*84,
M\8VEFJ7TC$P,:D+5=8UT(:[F2%13_^J?ROK)C-QNE9&Y42O+5>HDL,`.@J-X
MH\9(BC!J82-JHO8+DW19DQHV@F,.&(`-;=`&V#!)D2<XE*1)C*1%?B";YL`.
ML,`+AW19LMG1:^);04'2B?=GHB:H660.JZ84(.`'HW;2DBJGC31)BB?$L-`&
M]/2BL#);*V1>QUF`3UW'+V@860%5OAPJ(K.!J/O/F-*-O\6%N^J&4TV2XF3'
MW60<+XJ>6BW5[88K`=+-P5H2"QBAROJN1EM$KI&6ZC(8]S*JT\HL4]U"!].M
M[E<R/%"N#&B@Y5@AW5N1J(N5;H-;UB&#/%-3`;@H6!@5#<:."^V^Q0"PZT-=
MTLS.%5I3Y/]J+*S2KW/<D>>,VGRMR7Z=U=#\L=U,VWR=SJG+HBH*S:S"LF/=
MUK*2.>3QS`$&H'-QC19ZFWUAGD^)(A6LEA9*/K'EI23Q?G01H-,]//J)3Q@K
MM;"P"I+Z"XTDQ.8@#V'#WNV-`>:0>F3PPMAP2"'=)2],#4&<:I-J#M1PTOV=
M#O2=$_.])GX@>JG7!MDT2(>T"D0MJ-APTFQ22!!^WD]@X'Z`#1U--ZC7)))K
M8-H!GO9QADF%7QOY6Q59'FVAA(,MH=N,+0B5S<TXH-S2EJW:$>%V&+#"UL4!
MV33NSO'WB\<YW"W[(1X"/P!MP9K<L@%X+)M-OCTZKR=;A;\1+)/_D2EO46)Y
MH*!GZ&X#ULLZ"7+E.#Q1[H'`PL]I`9'R!MH+Y=CF4]IA@96S?<XZVIO+@&*V
MV4JZ\^/>S-?#*\T[N;BX/<XD2]M+?N*[*^BI_8'N[,")PJK`6RT&DR_._=C#
MH\_0[5\@+A]P#M!%,U^].K+L=96,,K(/L:6S4-D,TE0]6A'T3=\.;1`5$=,O
M71'L0`V3`P(%81"[?A"]'A0541$N,=(A30N&%-*\WM"Y;A!&PB;8$NL0O@JJ
M%NR]/C`YX>JT4!`B+=]^T`K,/M?1LV!;'835D9:<SB'Q\N7C@8$-G,N_M;WG
M#N_OB[EU/!;DJ#-HWJT@_N5<NCT%^-PB_TX^E>Z^T%Q3VVP\)L'-@@ZYE]VO
M?K&CQFO05J$Z&@6U:`Y5;>%J5D<=5IX4UPC,D;W!<(XSP&+I*$061ZN1#[9>
M`_C9/A6`Z'NS?:[H...Z5I!B@@POT,&J&&O;=:WP/S^-\%+R?B[S/P_.)X[!
M=>WG2\JR6BD@^1KF%MQ/REJ.(#Q#MP3.0P105,B&F_*>XLVJ1TLP#]^,X2S8
M3[4Z/:H9P+[K3\(9P.XD<;_K_[44>L,6)M`F<Q_KJQ8F;J(4E$%YO3X4"8Y.
MGMXF?E\0?I\22-H5O$XA@Y1-2U'XZM3<EOV?.:.O.I\6DOXKMG@LS&&YK!,A
M):Q.YMKB9:XHI/]B7?X5@/E4UG5\+UPU*ZIT?VX38KSJOKNQ@?,4S<HQ7P/G
MP5$K\S-JD>]\^=-)W#^JY,<BO]KXO+S,DO:I0/96JIF++)DLS&6>+[^,+0WL
M0!:?2[NA4!M/&<][`).BW`#;D</?LA9,*O5C8@8?L:-+SS@OH;O=Y\-_D:HT
M]`!A999`@K,&'CQ84&%"AL:,#5QVS)B5A109+F2XS*'#C!M-4!%HS,3'9282
M%CM@8J/"951*+DM8TEA)A<5&FEAFQ>:L8BU+%H-HS*9*$PN7+>MI[!C.F0>%
M6M&84*3-0L=TFA0XD"!%*RXIMA282ZL5A\4H4AFY4:1&AT71JH2*5JC_0ZXV
MK:3]FE:H"8DSIQI#"Y*L2K,X"7HT8;8K41`;0:KTFW:61I6S`!N$JE3FP*$.
M-:(MYGC639@M<89^*/#GR)P\JWJ&_)GIS8%RD29VZA#TP)M[`<\DVK8RY:*G
M+:H$&_0V<I%9G4\^]C:I58'.A+ZL>#$C89P70U,).O.83ZW:8X(7.?*`R.MH
M%]!(F3C]2.FCCZHUFUOI1"HS%TML336'),I((M9V2L^8`]B"B;Z1;.KIHYO^
MH;!""R\\H(#4,.,PNX):0@TFI6C`(R>-@`K)MLQ0Y*DIBYXK2+OG!I+(+.P0
M@M&\['#LL,6'+!MOQAR%U$ZC\38,::G*RJ(L_S28*!I*(JL0\HDC@KYKJ;S.
ME"QH*L-VLLDE\!0J:C+=(DK-R9X"G,R$`A;`*3F,"'*),ZR<(FFP_M:ZRK!E
M"OFH/Y[PZBJUJPXH9$R5]BPS/8%N8LVRD:!T45*\VA(3*;(*`:HD^L8+K3))
M$1(I#RJ`8J^O)Q^TK"K)ALK/RD$1/0:H10<T:ZG4;J+"JZ5`XNU)R^)[2*F/
M^!PM,:A,2`FM-BLCZ\>0:!,H5)V:LDG8D&;RU*RD,(M()Y?R&[)'U1*K<R&E
MIL5)61G--=)!E[(<"0\:\HB0U[1@9<NZA@"$:2"1]EQ/JOV0[,FEF8H1U$'Y
M@'OKV-N$&^E"BRWDB__<'AGB\43V.#/F`1Z`&JW2_0Y"[B"-`N8X1QZ[1`HZ
M:5_FD&::YURSTZ9NKGG.CC>*&:*1#/1O4%7!)0U)F3E2&;`3S0R5OHSV1$HH
M23=B2-FH@/[QJ:BN/&:%`@XX]:B><503JEH-FHJRICQC^[>6`&Q'J7DY6AFH
M8@"%K$ZVO`7L2%491BXBG2>:)6+V3$QW;K_Z0\I(OUK[J4^F"`Q1((GF/:9&
MV9(*>&&="B%[<3,UE9RM>=V^SR`G!:("T+86)L],IVV+L#\G#7HZ,Z98?'+E
M:X5=V2?A+4LM(A-E/5G'@VS"VJC(W$2\91Y1AO2^H^CC@8?2]>U;+P!)U@G_
MS4HM92Y@\P.N=F47H8_X;@/?FMS3P):Y.'^EK7?9_:-U(I&(-H*B$"&O1IPY
MBL:<Y[*DV*A2+O-9N:[7/M2)SGK.XY_K-).FOJ2G5EEIB6?R8RD1/B]U5.(:
MMGK#OA9)Z2@BZL_XG**S%L*M3G;AT#(0E9831?!T`N/6XG8#E1,9[V/Y\11/
M5N:C>$GH3FNRS`O7PJ)]10LB[M.7U9#W0]/9Z%6BVV"")$/$R)E$<I-AEX!R
MXJ0FW@2)35G=4GIB)^.LRTS6F8]<<G.Z"%G04\N#R;>JM9%C%*DI>7.?B\K2
MHI@]+6?N$Y;S]C,>'H4*+6\JA#,R>)&(T,<S`Z*/_[V(`BF2*"DP%BS?@+1U
M%/K9CBVR2J5F2,4KA1'GE)^$U'[R=['6;#)&:E0*Z%#4/9S4ZH7!`]#JS)9*
M%D*09L++F\U^*4US]8A;DTG7V::YP!XEDBW0X2&'!@0W=HFP2YMC$YJ&ELH]
M/1!-`#))3P#DQX<DT$RJ6ECB+J*XDFBS0]$4"27Y4C0$`J=3T/)1/GVBMI&@
M;UQJ/"!Y!`0@MC7R0/,QF?D>]10E[J<T.QO:<@ZD1@@!25.V&]?I&#J77#9-
M)N7#C6J.5@P"/0LI_#Q(!UM#&)!!SH%K]..1@@:SPR&'0"`T&T`;>2;M3?!?
MY,1,.]YR@!5``D[DHZ;JC/\ZD\",9`$\,)7#-D?*E(%0+1Q"#=$ZA9;.Q<RL
M?7%.U'BHU:&)!S!.9,LN+38S9SZ'0=VYUI1X0(,QAF9*;"O8M<84MQ%.TV7(
M6R,E?>A+:F;E6]C4U@5]1EG)-=1,>PH29CIW,H)XBJ(F-!"+EK6O):XEFRT:
MY4^9(BU0?2U45<K)^:J5E@?U58,B:NAM.>8DR`TJD$IA9/GN5IFAX"2;54H-
MW"I'42MXCB0DI*X!782Y?%JI=>DQ2X)Z]\H*?O1'7\J2IQXR%)<`-F%+;"!D
MHXBBTR1Q,)"1;,DHFBU4%?(HA<S,JMB7K:,B)&U+6<]KMZ6<D,1,0?7+YC:G
M]1/_U%YR`9!8`4*=:5C-&&X^BWI/'D@)&H>I*&Y2*LATWC8>^UDM*X2<681*
M,J]3Z<NPQ*%//_&G5PLQC;*JF9=DGF45&BS@;]CDBU1P8QH7MZFQE9WOHUCX
MXXTYMD/RM)%7SH;!R1KE)E9!I`L_A!8*<R8E?9G:2S`3I6X][W(QFDHA2F,5
MAFT/=FN\DZ28W"*-T>D`T'ORD#HC8W=I9SR0VZA$P):\?1$%S]!;\VSC]A'@
M&492XQIH3G3ZXO$HJX]-[N=*);44G<`SJAW46[M8:`)G[#8Q=5N+I+(5:30)
M*&.Y:8U<BF$3BAY,6'U#D:[*!%,!(2Z?&Q5)AQH\5CEG_R?4M4:>TSSY$$MO
M<C6A,U!T"E&`V%1992H!U;GR:()VO"<^;UD&.O+@0=;`;9Q3WJ"P;KF@*[V3
M3;`&D0B=F)C$>"J7?BD&CRV$O$![>W8BTE5_:<"#=@`I98M,4LJ6J$8J'["D
M78:R4]LW)<V4BT@2IN:SVI)?M;0:7%,)[:!(LEB(9&I0\J36M[%F0KXP1V>=
MGN]H&M*N,IGD>MTJF&8-,NH6X6NS74'3JL"#PD".,254_"9$).*,,ADI1J%6
M$HT^XA0I;2C9@$TVF?06T%GE)U0[&:1UCK+1AJCP2V1#8KND%<*(T"C";=(Z
M5G3%]9E7%^?7BJGK8JH\&DF+IO_M>EE((S7!DAJ6-\C)'NPVE,&7Q!#Q,#V<
MS28Y^;MDKR7V6H!XNYH]%LLENYD9S]I*VYM9RSCEJ+_,N>*WL$5!"AV='(C`
M*\3(2&XRH(-$J`E(1#+V9*6L5T-9-J^[91/^:.+^O&`&9^2ZIY602-?C&<=P
M1'=3LM`Z:%:97(IVWR.Q*$)2\DHGNXW`T<;8W_^=:/&JQC(@Z[%."&DY1H?N
M,\^@WVG[[Q%8HR@T.3DP@QRBH:Z(`+][6B0"5"Z8`!APFSD@@2J?2*DRHZF)
M2+JNFXKVJ:5!.AH"Y!U*^@EC`1JS"XXW.C3>H0L6!(IYZKJ:F@47^A$]NZ%^
MRHT/Z:[_#_HL"GLQ$^";_YHR'0R=&4.WB(D3ILD*FFDNOCB5YNN4KZD9MJB1
M@C"0E;,)&KB7NB*K'$.3M\@O!FPRF1F)5LO`@\$J\^&H4H.4U,.Q4EHO@=`]
M"E$.K%K")0P/9%JQ!\`#DS,2A).E%@+$0_(HI^JHCPH:0QPZ[,.^.U2BI*(D
M0[R^1ES$.\Q`V$*.$5(QEL&FJ3LN#G0&K**8CMH\%@&2J=-$!0$WG[N6_?`;
MCF)!)?&+ZUD3#SHI_`,\X!H.W;JR[R/$Z^BPI<!$5XK%1=K$GY*G8B&,H8@<
M*SE&4J0D-MJBSZBGBY(L#ML9*B1$!XL<9TF<AHHFLNBZ0$H=_YT1(.`JH_IZ
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MMM88QVW1"*@<QQD+F)29!:GJI$-"M?_3P9N#"RA$)!DI.9"E(4?Q:$:`F:(?
M`LS)7$RE."VAZB6NQ!8_RK3_XJJ^,$>C9*9D(:6QFB)HV\?G0<*98<&E8A\%
MQ$F9X4Q/L9<\L$R'R;2QDI"=2:N=22769!#]>RNF7,Z`TLR"Q$@YG,,XK!OZ
M6TF@5$*-*)C!VCK.V+L663JV$97;JIWIDR_4V,=)]$FV'+JD@$J)VC+W+,I*
M9$&?6Z(36C-UHK_`20^LU(RZY"W`PJ;]`$L9NS^A48G$XIWVZHX\B[2:ZXY]
M!!/>,L5#;`>B`)VX&<+]NT>^P+-Z"I?.:!/SRL@&9:Z78)I8(X\$R3G[<(J(
M"1U5XHE>,P;_J`S0:.*IN."5H&#-3K2=J:POK3DV)4D)<G2NT.D.PI-.&8T0
ML_.W"I7`IMN9GP,IM\H6\5,S]H2.WHM/CR$E8M$A;MF>#]4@"HVU*50H$@R.
M`8N7'TD8M!@L$;.?H6$.?H.4&:2=_RE&'H3-NV*9/PS#I#2I#VNOR1@A@S!)
MS[I1+<*_@6P'&42-8B"F\&2H@\H8$'S0,S5$SY"R1;5/1H1/*EFZEZK/^_S)
MGCD\#U69>ES"A-D/KH24-,2O4*7(CA115E2B8JJ>0*U0<7,6@:15G%B/1;63
MO)LUT2H:.3(^]<&-@72=P+0L&42HUB,,S>$4/N4="<1*RI'!FEK6_UDHA.L0
ME;8J-"!!25:$MK;2NFKTR^J<M5#MULR[T6T]3U\5IYV!*K644:@X@%J9U=$P
MD%ZZ3[:X,VAUHV#ETZ;33BHQB;NZB920MKJ2T9]Q-"])Q(E*DL`1481`O\/J
M$RH8K)18-^IDL7WK)P_JN(S<CS(9.HR:M3],5P5$+G9I0^!8Q(-HU./+KDAU
MQ):=0>'C`81CG^AX.)+3E>TQQ1E1BH93LU*5VMJ$3ZLSJ96\OJF55J2)KC!4
MFP&90BD!L!$$-X-UG$B)FNBHP5ST.9GK'+[KC?T[O`?QVFXEBD**U*UIBY?(
M#V;94P!4RU!K3V8=R1,5/.<#CQ":RB.)E/](^5JJ`\Q8@9;N"+ND"RG[TK,F
MM:-1^:&:6@O3ZHE,`D&XF5<U,Q,]`TSU:Y#!`ZV-LLA8FS6FR19_>Y8T+3.5
MO$,%%!C)`D.CJ\0!?$(AB5)_<Y5=/2CYRB'V:-N7,$L\R3M1X;3"!9<K#$Z*
M88T@0XMFZ3<*W53,V#P0G1O'#92V,#"9B,0'S:56G3Z3A$#DO":5K$UN$9"%
MVZGSW;M'J5""!8ZAVL<&)%:L'=Q55<G[>$&IE,0`+E4!I<>'%<-(^MZF.1KV
MHPUY<AM%<]E:6L22&*W<-`81DT&;6KSG@)ZX74ERH^"R1966PC\U,2[\Q+^7
M%<K%+%C1Y)::"JG_)M2BI#RM=SNTTEBRD90K?ZV2(!TUOP"8OP0O]6LKF3J8
M"O7/@Y&9&R6)YCH@!HP.LTD*HWH)I"0SN;+@V_)7GR1`T/D^/,4JAEQ0(E$>
MT_@R5CGB*3,2.?K6SLE0`Z+(17TWX-F\KSHS2%&8*UPAYU)A>AQ0U-H@2DJ/
M-]`B(%,>4[2;@*7+*>/9.>S6^]-@!H[4.U(?^BUBFD3D3*-`$=Q9ZLM1>!SE
MVI16]<3#BS1:YCME%\[DG06A[NA0HU0Q2)4GZ=4@3XQ/EAU`8W@#*J#4=[K2
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MR^KRX<\DD`CL:J;I3:,>B76[CXSYH\114F$>)__!Z<PV`12^C).E,*::&JUZ
M#**")9F6FDQFW)[\[)P8U*]L5(_KV+M?824E38MZ-*P--D^*3>?E,*8;,L$K
M9@X7BL4#V6)4G@6UVYXJY8N?Y1VC!%K+%>1ZJJUH)5O6WED@SF1_X\L7^NQ$
M).:`R0/XR%EURB5?=!@&L=E$M.,-<>[+-.N=I6&$.U^I-DFN^J].,Y:J/F41
M!,\D`Z>,/(:@ZZ3MJ<%(I>!'=>_^]N^=O3'#_>\!=V_*8,&&[N\'=AVJ6],1
M%&L"T3^7=;0,5NRUH3Y50RYQGHH4;9<%C4\SXJV/7!@MTHQB:KJJ;N2K[>KX
MV=61E$ZHA(Z".>RXZ%+_TY)L8\!']H;G#6W2)`7,7];>M;AQTXC$N252_:QP
M385IR!M)R6;FDE@0FS+/SA2)]:BKNQ*/PNT4']>A)3-?EAF:@A64JJ9AM!8\
M#<YK_)0@S^C*KE$AM1ZH_,Y@L%S$/J(-(%%LE;#(%IJZH?LJ$?-"GG,C`*EO
MJC0),,3F9/Q@]8L3RK7,.G\)&?3N4S;)-X!G9E%-`C>(29V)[E%`3;7PL_M2
MTWWETV)K34=U>GQ0.4]U`L<]%?_O[\/!F"6:#"YQ6L[Q11_)N;[DMNU5$VS?
M70\8"/G;G<4-)1G7&6S&F.6WDSG?4P[<N:;O;NZ/<RZ&=9.G0F!)Y@4.Z+VV
M_Y^84B)=KZJ83YD044$=NE7L-,-B%DT5=[ZN$3=R\,JS*Q_O8!_&#?%P-%E,
MT4@'E;^-E`?3F3=-#Y91\(&J%4'FQ.5F#;.4B<T`X/)8"*_4,3K?KR85MH7_
M;PW^B.\[<OG>],^VZ.J.CS^<TO;"L?A(V9>&=&]U68EXNC;1E0\F-(WO;Y,L
M&1]VZE27"!)9W(_%9ELLLU>6.&EO]0$/9]0]>E378$%D>K'E1-%<]/DHHR+V
M=3O_R%TG[]\&Q\@P76[!TU%NTIIK'AG=T`S&"4R*D/Z.=CJ7>=>)CYJ+DDZ;
M6"_"#>38+?6JC0+%<60/9O58.E7D;\!4C]U:D+K"1_\%G-AJI%PG7HL\0`?>
MH=BL$V;(4P_*C7E@7M<N;[HE+R9DI]"4./(6_G%QE6Q5>W7R[AQF`0$5O\1D
M>YFMD'C`,ZA5#D0'V7!47VOGD\X['T&WMHPZ+=@9(Z6$>6G(,^E!C?2L-Q"3
MZHFPRF_*`)%4QWD^U15L3O6(6+B&.SPYK>MV._7EMIH47WK_GM2>&,M"+G^D
M?\M)W_AQ'+JZ<?+XQ$=CL?!.L@Z+_^WHGWF`6#9KX*QE)HZ9,#'PF+-E"(\=
M,S;01#%C"0T*)+C,6#&'&P]&'&A,8C&%!&>AR[,"THH#LTQD/'G28[&",`F6
MA"C1Q$B=`BW>3)C08C&$/*W_S!JYS(J5D@<2)HT(<6-!HS834N'I\&)5B0.I
M'"AT<&-$F,<$&H39SFC"B&F-H;U9D$J>BQN-25WV\V))H5E?#EW(4618K0[Q
MGB79-JF)IQ>!4NQ*$&C(@GA_PNTH5_!6F,7:79Y5S!G<I*5G(4W-=#7KFF1#
M(QW8\>PLHPAKRIS5#G?NVG@/\DXKM#+9J;Q'+N!Q`"U$H6V741'>N.=9YS!O
MOCX;7.>QFJ"/9<VZV6'$Z+W/G_RG?CW[]@/?.CL;$SW]931X9"2_UVW4D6_F
MRT066L8XPQM]!]8G%7_&_&<@@@^>AY%H'D&8VVQYX42>9UVQ=8Q&Y.'5CD:4
M>36A_TZG6684%=^)]M!(+^GV$'@Q%;7,;.1%)-$R#54T7S$'K,#$`H64Y&!N
M&^D555PP_::C3E5!I&!F!L%U5U,C%6,%9,90H=UA(N*(&$^,C8779X==Y=A8
M2MHH9I1>)M00@35Q&5<>70[5SF',1?F;?`^]UM5NQH1U0%;R[1F53EA5^5Q(
M'>'UGHPVOB<I2:%9%I];VGTWH(>F+84:4YHM4(`)3.726D\HOG>8<Y\&B*E,
M;L:D%UB&P50<J^3AH1Q2G;65HT'B@:2A<U3`I>!4,TF%HG`N@HD8;16FUYZU
MZ\5U5F74YF;%?=,6E^ME,,57HH5(2L8MMT5=-R:5ZN+T'/^"Y+FV+;Q0\C?0
M=PCI%9%F\LIFT%0T/K3A>P>]@2)H0N'E53LFO#'5318I&---)55UT$VT;<2;
M%>X44.H!EP%X9$0B-OQ;0\"UFIA\?$W&4Y;0;3D29`EE656_+X\G[Z,@L@6P
MOQBM==!N!V-7Y4LZ$<N5S@*^)=I$!\#IJ45-FW3C2XWV["Y_:*9XF8,4KE6E
MRU[15+9K+UJV#`@V&K3`"B@(L8(Q5J2:*E.'Y7N2=09KU-QF!P.:(4^+_<O3
MM)::L``>+K7X:KC.O6;=6?_99F]QBR=.T6$5)6POM]>27EVRL-Y+$`\\C.G:
M8AGK->9Y6I=4<NH1L@7BX-3&'N3_`KO':M)=MT_6YTF:V:8;B2;%W#"SA\\G
M\+*R.7.`8].R2S%'KE*<$9SO681199&=9)%CLJ*')KL*]76,B($S2%OMJ&E6
M3'3%@&!"`4PPL4)"(&@)*W+1C/.4)!L_9<1=:;'1,=1DL:T(I"C@6I2E)@*5
M65C/!%W*#V)*`YV8A&],"P-3G&8!%L?4ZCH1_*"D`+8A"4$)?0>+H&U@*))I
MY<HF6:J(!GE2"!\(80-.^,`."G`W6.1M5*N*7@/Y,KBB).N"$](8YS3DLMT,
MAT9A2LX;3"04*))&38<#3$+.]Q&VE`A2)HB/%J,TLB4ISESJ(MVU&M,0B!`/
M)ZLC3^`B_R.P=Z%G>H#+XWF&<Y$WR$Y=)5D`$+"`@@WXSW89NZ$DX>60A#%/
M)(UQET+T,SB*X1$G"`G?3`YBD9D4XBFI9!X$+P*:E?T&?`+!WFV&(A#@]25J
M"'I8[+B22&9U3S2<W.%(3/"%$_P@&D[`0B'N!@*;E22-BC-)P];R*4!.Q2A[
MF6:))":0A=D$;=B!2%],@,5#G5)247+=,JSI'=F)3RAD4B%NJ)0P2FYE(;+3
MBC`S4K0GR61^"*D+\,`F,]10Q`KY2T@!@$`"%*!`"B?8@`\*`,!<P`)O>VL8
M*Q$BG@@:3"L7X9=-"E>\A[10<)G$T5GRH)S:1.D_9OG;RX)FEO_J.+"/-@PG
M0I;6KSR0]'9TM!9/"DA(*_``#S697FV*M=/<\/.IA(1J8\)2$F0Y(Y,5,@80
MQU"``JS@JS?0*N%$\I^I]E%6RQ`C*\-GGIB-$2<4.\CS#/(9HIA/@S.Q2/5T
MU$D*^L8FY0,)7=D6H,;\R'T06LP"Z7,X'&IP-<\LQ`J`@`(/,$`"0O"!!HT!
MP/Q59#`Q%%Y;WF<3&Q6MD_*$:93T112Y-'8RYC'(R)HZSNO4LV(6?*LPJ?D4
M!EX0(W0]6"S)A#H8+@LCN`&E''M;E@(8J8):Z@Y2(%.`':"`!$%D@@2P`(0=
M`"$/L,AH1E?#0X/,16,23&"RC/&PLK#_JV"+6]KK-/D4CWX*,0D3T0(6,+)C
M(#(CO]FD+2E"X+%,TSE9Y5,Z`P:2;C+L3J:]UU#;HZU*PJL8JQ-1IY#V$4KU
M1FTZBRY:<V("L=B4?!!:1AY4$B0@?+4`>2C$#<ZJ$7Z*#:V!RPL6/[):!Z,/
M:+Q)+3EU6KBL#F6E:#0(F$9I%J]LYI]0H5!N;D;6WJ2E.PLD\0WKU!29::D0
M8&7"!H00`PE(00A`H+%G,QI:+*F3A0(K)7.@4L[E&F^&&PKJ#*^2F,9P4(7@
MBQC'^$F0GI+1O=HD7+YT-Y"L'E=VWZD7I?8ENI?<5V.25%_'K*`_'V!7"$+8
M`:F_H($-`.$+_SYH"0C&B\14T2DZALQ/H=>8Y>I(ISLGJ=AVA,+@/@G$"LD!
M:M_:02RJ+2-TUHFGY>"BN"A%CYYPU>`?A5IA;.50QTG-;6DLTL%SZ85"1M7Q
M\_R"D)P^J"-OR,-7F3"&,0@!"3(N0"'J_081$5!2&.8R@BXDI:O4=S=OJI7T
M4!3?1%Z(L<V1T?$Z1+ZM#/PE!C*6AX!7TN'0IR-8E193L9RRI51$S.T&@@^0
ML`$V:.`#J*:W"4``@E0]TV8[#I'64K0S#1$HE#O3CB:79<T5PNETBZ*U*6F-
M&.9PD#9C67C#!!RLENED-U0FRTP<(G7BA,FTOT$Q%$OV*[@T92/[(_]!#"`:
M1%*3W`!86/6J5U`(II17;SS,XH=<5IT'DT8HOQU1<Y($/L%U.R$10U%RJ#8X
MZ/CEIC0UUO5P1'>H:RYH4,+P@:Z]GDOG4<,\,"U+<81ED'",(93/HW0TMLI!
MHJ<=;SA`BX,444"<(`8593>-"_$?/O:KN>F&D)Y4"B7"^AU?5828?/HXRE(Z
MBGT%3^%P=/W[P!2_CQ?)]O%F6G3<*22U[91AK+@$%V/\$`D^``+Y@[2!&'P@
M!N#]:C-=GM&[N`4MA/:@?-@(\:OX%6WQ&QA,UZ0?LOQ+.RW:FDP$M`T(H2%=
MOX2;7<B3?BS$I$Q1E$A=KG3<Y*7+1D1,#FG_R%-(1-D`2&H@B4$P@9E]@`$(
M`0F@'7CY``FP'=OY3ZN-UVK,DQ3%#'<$BQM1CFM!H#H-S%0@&0$6Q+#QG#KY
MFE18CD?0E+:4D=.8"+01Q,(`&+4IRNB=A^6I!^K@1![1`!X$B(L8S9&,3&E%
MTX21FT80"T04QG#U1G`D6XN!U1<(P0=(@`0`@@$`05BU6+V)A9U161G.2A89
MA\`<'H"=$FY`H1IF3%#]"UM\B*8AGU%PGL9,V7P!7+$<"8^TA<5UQAV]3@6B
MAJB$UHG]T`:<0/D%R1<``1)L5T71VPUXED8]TUNXSM%%Q9I$B4BMR?RD",9M
M35`%2^^5199!&;A(_R)%]%XP"2+<7,?=C9-7'-P7"I?3;5`AH18,A4ON"0R#
MT-"TI(:H6,3^R*$!/-(.K-T7H.(:@-H*^``3D)PZ^H\5()%&S=V/R<9[#5@V
M;M+U_-7"12)$W%/&',1]O8]#X`$-4`WGO4EUE!.!*>$2QLDMHINB-%@B^@M)
M28B#\-M`6.$_0$A&]L8>=>%T?-[2&1@53A6AK-&)+9ILI)XSM-B,K8`CB9H!
M?(`<"L$7L-^,U1OD<)\?^ME*7IRY?-C@R(CS)>(PI<53\(9F9)5HV1:A1-NY
MU00NV5%@](;G`-H@S=F/#)<(D9),J(:G,0&I"8$4V&&,@94Z]D]:BIPK7O_4
MEVF,.!47R2P+DCU@7#A,T'B%-TF*,'D%5*:+TR3E;0A?`BV$>7!E7-399*C)
M-2WC0@3?5>J:<L6())[%<O09.'7C:I@`$'R`!Z"`#V#!#HSE#GS!6*K:F*VC
M#[#F^/F/JS&%MV$%>OD-0UQ$5DA'XV4.(@)&W\P"(CV6[$!$X3%+WR'-@7F2
M`RT8@16"`QH$H;%DT=B0%*[5O@641EIAOUWG\7#G0&SA&H)8N1E%?!2",UA(
M%G8G2_;A=;;%*0D%<#)#1NY('N!!(:C$%Y29J)49^F77#O@`'N0!*NAD>4X/
M1JXA>LBGK2VA@<C7\W0<9632,V*'KVT&\D`$O@'_RW#52QGIXF%)HM3(Q,3$
MB1JF!6XDTGNY3DVHAJB8`!#M0&4AP1B<`"L6P#J&%5JBI?^<@?M=598@&C[N
M6).QCSZ5544\14'45M$LF'=8H\&0AXB0%%=*!"E=$J;D!+[Q1TTTI06:SU22
M5G-H)TS%A7F*1EXA5FR<UL&H1D5@@0200MVLP!@\$A:@(!9L`!/@P5?E*1Z$
MU0KXZ?AQUGC%')>HD8081($`'ULXT&TT9C\^J%$<`)T@4I04Y`'$!L0I%D$X
MQ\@LF*)20:?JG:;-58X@I*"!*$`!(81L9'09:(74Q(89B>V442K%%)]Q"Q;Q
M2W015E!$9(0X0RKDH3IB_X&H"0'=%"L*G(`0+`$*KIJ,S=@-U$5XLB1Z@NBT
M(NAAP5''":)1Q@Y`*<\H+4YJ'>D?(<2"[5HF'IK&W!?R!4O)%`-PUI??V$A6
M-661<:6O'8VE*&98F@"9J9F?(H$J&@`D?=6-]BG[U1N]K<`9>-8SQ2)0T%K?
M"8@%202DQ4Z=+5Q$4$U-(,\::49&(-EG\`N]2"?E-,8U[9^BT09H4,U5S`*D
M"1^_K*3C;>>1A`8?_6:H8J1G6,2HF$"</A([#NL)?`#=D,`&J-J?IF4!Y"G3
MJN4=-BPT;11,W,K=102]SNI_Z81C*&7Q'$KPO8DEHB2`.4ZDXHLYQ430R&RH
M%O\+V][4N0',44IKC,#)G]2L3&SDNMRM3-P'M1KHIDHBGM#(W>)&/>TJ@#Q+
MN8+K/YZGGKQ!*LR;:.Y`?HH:1"&K%&17=F$!@,H8*N@A,%"KM;HJEN'>+?J$
M1L2'!F4JOA`(3D!:@=+6<-"?$[I&ZI[,QQX#BL%*[#2FZ`J'0!X/:2C@F[@7
M8#P%9F8A39A&EFB)2I`?_R!!#)2``<2``9Q`6(G<O!7L#20L6!D1P]Z-CW$)
MY%DB2Q&O?OP+)_I:[1(6'O4>Z!F@Z-7&;TE'ZZ;(PED-=[A%N?@9[Y96073>
M[*AG5@&P_A*8N:P-EGA:C9(C.^Z`$%BO`8CC!JC@GZ[_VI[B(5BQ)BKZCV>]
M8FI41.[<8%D06%9H2D*<'M!9XDEIQ<_!K3%P$90D#,&I%&G@26.&[1)FT[+M
M&%--W),,V,D@2-X*\+6FI]2`I.@RZ+(=6($<R%+J%!6ED/7<%Y(U1$&D7K(=
MP+Q55GYN0)G1S0E`E`%(0'8MP1)0\`HT;1YPKSFU:K6F3ND6FA-"72Y:!@(:
M#AW_X";5BFZ]!Z39&DTTGEP9GA092$KZVGSPTG>`!J%Y2-#,;=O023%15O^L
M``)L@`%H``.D'-'>:(Q],KW16,&ZW0U0@<L]4V?YBVYLA4"R2R]IRQN(;$/2
MLG'0+1^7E%[0;T^1!D[96M42_V!GM.R.(-A%+!@Q6ZTN9^(U)=M#[,9:A*>!
M6!-`JM3($L37X05E?1<3C-_YO8`'&,`+Q,`54'`+^JF?YJD:]^GXF6/_\$2K
ML89-Z&ZP($8&C2BD;I+$2G'=0<055V*<E.USRHJ_:8MMAJH-'MBS'>$!MA8<
MZ]2MV;%#SP(1O_$;P[&!?.<3OP0B74_O[BUX\HLM3N@6FPI)#BYZ[LBZL=L*
M?,'0&NT8/!0)%"T*Q(`8QS0)D$`7K$`>,`*[<>^]@2B)L:H``Z/`84\`I]0:
M%>=7%L3K-DHO[=V-&:=L%$Q#.(1M1:F?[9V!U`YM9?5$F"=Z\0T%_@D9HH:5
M;(28N?\=6%F6!$N`!H`S"AC`P;J8TR+LTOI`(5`!^'I6CSCI%H\%DG5&07]3
M%DGQP"50'M!O(CO*I_S@0G9KE`[4;XVG<%RL:"#9+>),P8!8[#8D@!2N3V55
M&-Z11]G(FAK$"IQ@.V+!![R``*B`"D@`:)Y@&K==J>PIG_(I.[;F=YD*>6E4
M;YEL<QQO)L8N0P[8"A<P(3)?L#2.<C!(:+@&><QP9391$1*W[,H4U_Z?B[@/
MOVV%I@@'F=8L$0>UW^XM5\\"2(:VM2[D&MDGXIRGOIRW!=%61HP&U:82"F7E
M=X>NZKFA2IR?.,8A1.$T";2V.$(4*<3`T28!1/VGC/6T?4+_3GM+M$1#L6S0
M%3%'T(UE((A*V:=L*$+D:U-%X<7D,^!D6=;H!B!7ATT\A;D^FG7@VZYU!TI>
MY$14K/"$-,[N#@B/1+WYJ0,4`A!4KPG*M`<4;=TH+([&6--Z;\%:U!E0@609
MF)-DXI':1CEU>!/-TI$6($C`N"3VRV]E=N%NDC"UK)^9TU,:-DF:[8QCYKGI
M2[GF$%.FN2)>97L"E7<4S-UX8QY8E@1,E"-IP"!LP2,4`0^<``-\@'9E5X2#
M%6ZOLSFKFF\OPWCIS:@`Q@()Q>E=!R*!>GBG,(@"<FG@ADK1"0_00%WD*D&\
MKAL?3'%S^";117BC9(H#"\RB=X@B_]MTK*L23W1V^E.&;^?[>(?HWH>Q(WN,
M9%H><"7JU%/HZ@;AK'C:*O861VICE#IZ=@3KT1M8[8`8GT#L3=1#?4#*C7NQ
M5L`.6*\99Q<)``&`TJ?GIA(9U@JUUCB6\=(D=2?$#9!M79"0RKB6+F$N6\2D
MYBO$(2]F[VKD0*52"Q.DQCF:.P.1?>%L-$2#L')**O9.>(RH6,%:/6]8,8$!
M2)39"4&Y(X%J;X`>%JQ*Z*F?.ODY&\..`M"7(=Z&.T=^0PRFY4H1IJ1)^>/Z
M-M$;&04S"(?Q4BTDMU"60;6"(IN7>_;-9$4]+<<7(GRF!7R^VD88@M#W><YU
M?7&CP_4'5/\`#L!`$=#`&M!`$;B`!DA`T7[Q&N`A.JNC;M.\!9/:"F0Z/*;*
M)_+02V1%!G$@HQXO@?IR6*".Z9:JC&2?$+8Y58->N1E*^/Q@IA&S0RHHW%9H
MZ.;'3)W%D#@&B/,&$?N(:7G'ZM<C'.-;.]P'F.A+;BEAZ>70T>1KB>][20'*
MS_66C%&1"1!4L5=[5A5`W3BOF;$!]98[LIX`V6E`YA:K"1YK!2@K"2S!J.4I
M?=+>`>Q^[ALBB,^^;KA.6/N<U+P^IK:3OKAXX?[3MAB$J\<)Q@[7U6F:(2KJ
MQ>]P0Y,+0)@H=,S$LEFS#,XJ6,R9"8+'(!YL%W%9P8.SC)DX`&G_19YEQY85
MLS)KI)5EQ@HP0?'A@X$8!EYLV'!"@A0@$B08$!(#!9,"A0H5*(!GJ-`5*_"L
M^!E4J%`KQD`4@V6E&!43&@TV/.#PZK&&#C]>U0BR8AYGRSX>*];NI-4\%C,>
M^.KPJU>Q&JD@W.ILXD*$!`L=.#9KXE:Q(,6&O;K5H,:":0VBY6JB7;%9<RN"
M;#AXEF7"$`D>,/9W]$@J(8\5`K(#"!,L*!AH<&$`QX,B/+H@0<+CP0D/'D[L
M0+&AB](\*WPD]Y$43]+CR;\``;("A!4K4ZV/1%C0\8$#:9T9V^I]LF/S"]L9
M@_@&Y,&U#[VR?8B'QH(#GM\39%_Y8%B"_P[M6BPQB`0TK*&*#!-L+<OX:T<B
MSPZ:Z[#`N.+//0?_R5###3E$Z"(+UWK0/<(N"M'#SB:B@8:$.GNPO,;,4VM$
M"UE,B,%B,OMO,(:N<J:8T/`:[RW./F0H#Y44&`,((81`X00#3N`)A94D0"&&
M%V+XH((-A#AA@RV=G)($%+;8`(CF\F!DJ3<2LO#$-]V\\:_!('/33;1`:\^R
M9>8ZIL&T0'-0K/%,<.8BQ2!*",^N#(U,0CZ-.>LJ]HR9"*3_3&"S1(C8*E1'
M/W\$U002.S,A)286*,B894HJQIB@5E!)`@T\D,(`6W?20`(L--``5R`V\`FH
M`HY*"JEBA1I6J?\5S@#!V>J>NBLM]>CJ--,?)[7*&8*LBHS3[<C+,Z-$+]L*
ML;L([,H@@I:I;)D#W@+P&/4@.DNAJ]`B3ZP^YTP(T_;P;+10/LGJ+U%,]S2F
MM(Q,6&$U)GQ@@@0#&(C-`Q5@*.4!&M;HHI12&A!`@@^8%,),HGSX`F+DDEH.
M*1]VV*$+(-;(HSI8<LFN188/*.0P3`WCJN<\@LZSHC=,6+4_/KE""\6K>*!A
M2$>;;C,ML`C&]#!/![V*BG3OLHC4%AWL[R*@A3Z,,`8[X]#M#25J<6P60_2L
MQA+[>H"'QT04;S)+N;*71#G7OK#%L!#%\R%#!PTLC\#R:G"M-PY800C_"1CX
M($N7K#S!R1,NSRD&SQF(@80FA8A)3!26F!*'#;Y`DZA"\@!5Q,(''[QLPM+J
MUS,'?[<[,[`^!&W@P]D#"SY3S35H3TP%QS'=&O\3K/=[>ZQ(4L'`8C`\21=E
MU]+&0CK[.(Y&/8VJ96Y@BE@49M6`%`-F?4G7&#1H28J>3$9@V..&4BQD_818
M36D6")81E5>9P"KXZA2=")0N3F%*(5Z1S*5,$"]U6>HLPS,>FRJ"%7K!Z"P$
MT:!#^H41I(%-+0@JR&;D4[!,J<ML^6F7>O@B/0*M:E[N6E5%"K`:$BCG-1ZH
MV`\8X($7/.(!3?Q8$4J!`P&\0"=<(L$7D(,<_Y<Q)SDK^`(6=K"&Z'RA$,:P
M3BYR9AU7!8TKU3O/50H1@J`8!FP`<MJ<Z&*BK]"`!]Q3G!T5I9^(_&4Q05/,
M>2)XGLR4#T5D"]YG-$*AZK$+;[-XVR7AA)_=V6AL)EK0@51TK<,Y(VB;02%;
M\!,WNQWJ(MOASF-TA)8#*28/!>B*B=CBC#>DX@8%&(,$`("3D<6@`E.B7Y4^
M@`(#0`E^*!C3E*0@!!)LX)D5:%TQES,45/PD%7R1V^XRB3<<.22&!@&>*F^W
M&7)1[2%EDX]#O!.9#!Y&4?XI5"-S9)$]:<4A&>D/@"ASS[K@RV!^2I0]SQ(>
MA?CHG,:HY5N,<1I7]?_R)PXH``)0H`$D.N$#&LC<!R1@1`GLA`$&0`&3S-1+
M`2*%6,QIRE&"4D9G*4QA@SI-9[1'$$,=8RMQ0Q"=B#<\>#I&3V!IB+5VA!#*
M661;2D,7H>ZIP\R`RS)K0="J^A*2;>GI(84R47^09AG0&.,-D1*;0D8SSD(P
MH4D;V,$7=D!-W_3*&MFHF`H:8)LB0!&*,#B!%(+3I"OZX%A<A(X8F0"$+RQV
M!TRP&7;26!$J2)([XRD:>;QS@`)0`1@`"A?U`/2&P2DF:@>8Q7]6V!X4P:=2
M#`(2HPIEGD)LE:R6;6-[=O?5-ZVE@4,2T(YR>\FWH3.<C5REV1!R(&/H;3/_
M_BI`+0U3#.LYDE2$8]':VM$CK$A$/`GY2DB01H54^4EN9TF%"6Z`WA6@(!&D
M2`0`DMFE)DFA2D(P@$<_,+$F.1,+!B!!,4G@.13@``5H0,$.FI/@7LHE=[AS
M<(WNR;1V?5-N=',06;G2RKX\A&P(\MFBF%$`P1`$0B?AGJ'6M@RDB6=LQ[`E
MTL06PO_XJ"&;">M!3FF1L!R(('^Y;C&JPL"K&*-]2X'5!EY0,27\0`).H%5-
MA$`K)_U`5Q^020R44D#F'(ME1#%*(590B&99I3H9*<0B_TD@G'KU,DG;#&$(
MRM-1?<26`"I;5W1,D#LGC9(JWM%8,`*O##OH:E[9_XXWO_+F?'EK5)"LL:(,
M9H+W.*8BSBL)%59EJ@T8H`+2E`D6-J!,#\R*`3_X@34T<(6\ZM4V/(!!275B
MI2L4]F5:5`YTOB!&Q3XVLI@6\KDB26G'$$T@A')A8"*#8T'2R"%OH`(>>)`'
MRQ!U5&7S#WM,I&(&U@YIX4E0TZKG,WP=:),S*O&%>`HD$T[8<,)U6W%9!*)S
MOBDL"CE`%WBPKH+PM`":P/-W3DE=W578;`!MFGO8M:W`G9:.$M$ETFZ0WAND
M`@]`4(!'-6#2$PACF2<X`4A7$NLI>=R9(Q_.!K`PIF(N80FP:PXC\!"4/#3H
M1'8JL?:D1QD(V=QLP&N'PO\IN=K)H-L[J.V,='W68_[84[1VZVJRR[68T1CL
M.WO1GHP/4)EM-<90[Q$-C$OEO(.4)".O2E8A'``K)(C,`[<Z(N:H3+]>Y6\#
M#!@I%NR[E`!N&0^$)6R6PZR4&X#@#%"):#&XHUH94T:%B.GZHT\+SXRP*;:I
M]9!.!_9S21,46SX:'HP;\C7,=]W/8*D,0(%[E8.,BY#>%<VURF;5'@/F+9XI
MR5/`W-_9N,0`^45I:X1@Q"5;@P\:$``,FMA$ON+`!3DA`19>@`*E,`<(7?C"
MK96SV.NWQF;7`8&O1W.2@F!6-.&.I+][9AYS1=C9?5X]>]@E`AJL7R/W6?K3
M!Q?_^J=7KY1SL2R!Q&ZWYLW"<(J-U*+\,L4]W(U#W.E&&M#G/,1"""U3CL8$
M^(AWZB^#Y`(PR*/K",VG#`>7I`LT0"A0",GT0`-/5J@=8.P&,N(&4"$/8(9+
M0`JPG(0!0,=)9@5*/*XEGBG43@=*A,":IF3`EJ`"*J`>EB/!@,(CZ`V=/K#&
M8LA0'$0"3\2<&@DAM*U>K$U"((EG!&-M2&G]L@W&5*\RV&*%(@Q<%N,*M088
MR"I\'N,C%FK"#ND[)F+J2((D<._L'*!]P`Q8A`!8YDH#E""DFDP*\F=6HLD:
M[,ZD-@#+",BPL&]9:HDISN`I%$:-^`PD9._@$,1>'.1`_]K,(R1#,-PE<-C)
MJSY",*A0J0SM7<#";_AB"PL%#6?(T+[B#?3H##GL(]C$7;C'$WVN%;G"9_9P
M?4P%"%9BU#[@!3Q`5TX`"Z1#.K"`)D[-&J;!&@:!'Y!/^8K`-G``)PQ@">QK
M`UQ&U\0(.FYM-19+L0K!"D"`IHQ!)!#";])O4&Q+'S,07Y9'I]I$X9#&(!:@
MC]ZHVH#N>-;"E#3E&)#F#7R&CF*K.ZCE#&NN;CZP<"0''QT"1^B/,!80;MK$
MN!Z0)#W$ST;(&53$7B*)V.`I7G`+GU0)`A?2X$0K\N[IG4`ET1;D(=&+R$P@
M!ONN"W8`U"YG?B)A)?X*2J3@`_\$C"8$[*0@<4J6P$N$P!R/<.7>ZN5F)Q4<
M$+DR,E#J1$[04$1H+D3"!V"2BRO:#T_2[UOZPES4$E$43^$R9>I"2$#,)H2:
M1])^#GIZ;.M01-O$PE6<9B1P9+(J"NV8XBB88&688`,ZR@FH;.X\BGZ2Z`,8
M@+XD(`:`0"?"3"BP;SF48W:2A5@4A@K.@%5,(H((#>A`"(90Y-'FPBX;S1EL
M3&F8IMM(*`*Q!L:\(C0JA1G\8UX(8ZNJY2L6Y"]YL1V885S^,E(@*5-4B]!<
MK"L2121.(B64B11P8M3B1P+<ZC$3:P?&@&*63`FF@0%<H`*82&/>\P%4P!E'
M+EA\H/K_KN_6B)(U8@:Q5*:,:*HZ2"(L\A%(>D8B,2M&TH8"S8DAX&/""C)>
M#N`T`!+_7K.-DHW_L-/_?N8-&L4L3;)-R#)/$F4RD,:20C)#9C(+RQ(CW7`]
M.K(=HN:>%L.6Q&,KI@:Y1M)&(##1#J.$5LA'+J->PH(]:O$-WB"]T"L5:*<Y
M9@:NZF%B`,$E/.>8PN1)3"J9G*283(H$GLD`K*A)#&P+G*D>8J<YPBP/FA,L
MKW"KYD1():<!-5(F,7!Q2(1I%B.AJ"!HV.1Y8H1%;%,4MP,^',0A?\MY!"5<
M(LR#*.D6#Z5ZT$)IHB6F"B#MC.(H,/52F7%6G"PV2(T4>F56_ZHD&DG&2I`@
MR[I(.6R-L)K"*`I@\.91))YB7H+*@V3I>)KK*YCA1V.TT.S%5TLH/B*/8%YH
M:XZG`F,1&'7*4@"&7-"PG;:*"H^A@6QGG.JO'D_B)'+/`$9-`YP@/.<G!JA1
M.A)K-81`,ZWAU!B`#US@"IBH"-X57BM@U%3'2ZXO/[,/KMPJ9A9+UWS`9YPE
M.USEMQH'JA;#9RB$+N["7#ZP2#V1,`HR!'ZT+R;E6SZ12/_I/!3N1O>%`B]R
MX-#2+-G&JMX)_N9),%(T0VCN"E>T;GBGQE"K752$,9RA@226=D3LIEBVYG;6
M1]G$+DO0(DH6E@H%(I54YA*,-+N@"_^H:25:@@V<A"6J]`-(04NDTJ2ZY$N*
M4"?(M)J.T,!V8#G.U`$\`ABRS:>VZITF3'+8U$5W%D;UI#)"0S04[D?4D`H9
M@D\;5"#7L,UF3*D$Y'BT3F.]:X9Z9*%6B4`+`M.T]2@J%58<4SJRC%@P%0CP
MYP5"5>X\*J22:"7F+@::9`<P=55)<[%\0"B,A5AD:AZM8SL6*2O:J%`/1K1"
M**&\HU*N#A8!J8)T2JFH0%+X(C0DXW`IT#+4"5<?M,TD!21HCFD\CY(V[!;Q
MI"+S`O%,124ZJE><;'-UPAJID0E4QAKAQQK251O9$_GV:J]LXQ$JX%NE<AJQ
M2#FZP`?V$]3_6"/7[K<URN@ZJ**FJ,`JG.U`$Q:>;$LN8\NR$%4@F7=M(A3S
MVD-?;.?G5B@8^Z,AD.;U0,.V+/1C:3(CV;9'Z;;^A.(`4O8?2`720!8"*X/%
MZ&)X\.V[=.DJ1,PP=+1M(="50I'J4$P6[X_!?NX`F%0@P,RMSC0/G)0HZP$%
MN+0FHI)^[,ND1FY^3F`)3`I*GH]U3F":1@X-3@`)E\#Z\&"Q8LXL;KAP_63'
M-#)D4[B&(S#TD*8*3TN#&&,Z&P(MBX'8@N[G]E0\!@,-_0_'!D4_V.:G]N(D
M9V@K+,5-$((*"H!AKL)A5B#M+`HY0"U8,O52$PL+-#-^=,6(?L`#_V)@&@R`
M#9:IHS[`!\[Q!J;OUKP(U/Z.6%CU=$$`%A1&5BLB+IBJV?R2@MYEA[A'H`)N
MA@(#5%;L.Z;-.R9-@AYRVAQU%T6L7;1M(-O,%;]R+<2#+[Y"Z-B%71`O4A5F
M6SDU?DIMI*0#":AQ7"/&>X6``1R1`9:L/1_A$<*Q"%A@?5\`B:#8O_R.!K0O
MKL:$!!0+KL((KLB(?R.J[$JE@&.K=BADF/&E.PP)<)<518PA:MXBTKH&"P>J
M0:.W:6!,7[@&A<^R@]FX>=EEQ*XB!`J@A%=6I$URTJYJS_3&(*Q.SE*%"ICA
M;'>6)H]&1W(R\B0E<)XU4Y"F$-*K$'R`2_^$(!+"MCE,X0M,86D;X)D^SBGS
M.>.*Z>,TH"I-3IE8IP(\SJ268)JHN`+0P*Q/P$Q]X*E_0DT'KERR0L]ZCBS9
M9J?I>D@/KMM"XRV8P4.T(B,^M!@HRPU?CQ?%\"$,A"!$+,/,B:<&`A4KN"ON
M(RW`:<TR(B648I*/@AFQ@`E&MRG`+%8@A@E"Z@,\P-1.P*-BP^Z02',<L3.M
M!`A@I>_N=37<ZI)#,\QF66$$5+H8B*?D"9ZTT%!(*21^N+6ZK<V:+KN*;KH<
MLKLBHS$T118;I<=VK"9=T:NRRR$Y!4?@V&VAE:#@>BLRC21<)2@VK59>0`J<
MH&+L;A"!8%RKD37_6B.3BW(#-"`;?H`/IH'*2`$&TC?`'Z`"0LID?"-L<8T&
MA,-SPG8U^%4Z6",/-)&F1H)AWJ)GJ(!RH$J#''(?)S*\@LX@D*8@OT,,WZCI
M!JHLB_243.G"`0IOK0U$752G1?0XO8-V>N2Y2OB$;5@FL\M##3>'.HN/).0L
M]G288WRG&XG01LPA@Y6A"),L0.,X3>"\Q`(Y$FL,8H`GL,`4\,`4Z+<+ZF$'
MDCBK04I+PT3CI"#ZL)2*GBE,-JT(O=3CSMH`T(`$K"]VOB!9&"JRH;EW&S2-
M>9R#R5(+U;`K&.XN[O2G(NPY%57%S="P":VHK8>4TN5$@WL\U*)LOH(Q_R("
M0JP#!(9%*!S`8>A;)E;F[QSWI49[!?HK?OA`"GX#[C(J)U!`$7T%!?K+)V#Y
M"VC@/E&*51UW<@NA.F(5]QZ#H&*8((!A+9U&T8BSV]ZI,KSC-);!+-;R(2:L
M>_HBAYY\QTSL.VKW!+N;I-&2PW85A`)-6IY"LY@12V^EO3L7"^B]&KVWWL,7
M")"@*-<9B0"`#S[Y"@`\?>,97D>M[3PG..27*$\'?J8Q9F)F9F:&"?"@\#9Q
M5MU(+'`<JF+X*ER<0/BI=ZTS:4J+TP,9-Q764#&RJVQ'V[8BZ6"L+#GXI9.\
MQJU-/)ZK4":4A%.VI7M\+7;5:'3I=X\SE'AQ6__*"ABZZD-W=B1K\M+I&*P2
M$"<?SF>*3+3C^R62B03>ZJFC6LRGFBJ=UG/V"^$[SJJU-*LYK2J1T+^:%@V6
MR8NQ0,_Q0$W(.+D2!>FQ,`+ONN9%-HTMF#PT;U)HZ#+R\EL4ERX>!,9.]/)`
MFCT6I=FRXBLD*0H1R4$0<V"9PJ+V(-2F9#Q'-U./HI8H%V*26A%)35<D8,DT
M\\ERPNZ&@R>6!3D8RZN%(&RS:')_HA40J*:FE6>B6Y#"@YRH?@NOVS8!:HZ+
MU$@=,B24OD<VXRP@__G+0\Y$BSD!!+MH'EO.^&M"(B^O`@2N-]3"FA0\H+WK
M2[ZM,;[/F1H;JUSO&W[_UK74L'K@X56>BP`&YK/M7@,@4-3[XN-+EQT;EJ`P
M@(+$AAT0#0(YN*.`"1!6K!0S9L($E8XFCAT8:>)`H0,=CX7LB!*EB3?'1)9$
MZ6Q6NV++G+TTL8#'@5G+EKT!V='9,IDOCRV["53ET&,WV\W267*GLY@UI1:3
M"G26S6(V9VT5JY7K,J]GOX:=)3+/@3PK_\F=2[?NVK1IRY)MNC*DU*$FG&WE
M0>.E396!I5X-W+5QWKU'#U`-:13P,:--+PNM"MA$H0(%@(C>$,G`!PD&A.SH
MPKIUEWHD%)(@L?##"12X49\P4.&#AQ.[%_)>B+L"BN!+8N]&4\&`@26L\7S!
M_X.GP`%@1V&V.ZH9K5JFX+TW!@^6?-AC)Y-VG'K,,M[)C&U2(4F9Z>*49X\2
M19D7<<BE.NGD$E1D^=?165:T`X()-WSF0"%[K`"$`5)\@`(6/JR@X88<@E9`
M'AIFZ`,30D@A@1,__""!!QJTJ*($/VB`0HL?,"3$!DR$^,476*!@FP8Q()'A
MAI^!9@P(('!DS"P<#7@63CNE)%5[._EW65'.&#.243-A*55?1;&W$V!#!053
M3E5E.1)*EVVEWU"831757C:UHQ)4^BE)%(@["''<":>U*,$'0F`!!!*B)0K$
M#DA@X:BCHGTA&A8;G+`!"A(PH`$#FKY0P2-%A"KJ`_\PO""%`214<()J7?C0
MQ0:4'G>I$$GL4,]$J^V`Q0YY&&-%DL90$2R8+M'WQF1KIA333.G5!!15,2V`
MQT^+M:<43%E6%=A8V:7$#%?P'7"G47J-5]Y>8XWEF%?A=;7,?!^R6=>\=+6+
M%[M[+7;?&\LP`Q*_L]!`PU#%W,=84!V9)=YC!?OGS'V:P6G3?0<`=D.#A:SP
MA818^`G<:0H8\)!KK^V0A$+)X2:%%,#M!AQ#4KQ@`!J[22$`;B@LP=L2NS57
MP1)"T(R&`+PET<6.IJR0,;__V9G8PM^5=^ZZ44>=DTLSN>O4?^>I5]-9SI@T
MU!O<.O/4`<;H*R!-73U<)9K_;KMTEE;+'/!11U8L8TR#!13B0`$2;O!!C:L.
MR>'A@.<!FH8Y2HCIIC\X(84'I*1HJJ8?<"HH$+<!(:(//=88C10;`,'$D'T7
M>88Q9P@+94<<*=4.,\MT%,(!RQ3\$IIH`Z/2646]@5+:VH8$U;<LY:'49F^P
M15/MQP!CS)E57<E9?`;7]#"!Z9;U.Y/X>98Q$[3AYMP/UJAX@J&*)OKHHTA`
MQ/ZB8_AXX^,M:FH`#`^(^LC_15"!S$YU'!1`9`<DH)00#+"#AI"@'JQ9PXX@
M4KI>&>."&#R+EEC2$N,%AB0F@595TE.4-[5G&3TY0#M2$I)G[0<E85D,3$S0
ME8:%_^0I*W'6O;Y#IQWF16IA45=46&*18]#KB'<13[DBL\++Z,0I;C/!,GC`
M`YV,+8K.HHH.E=@5J=1.,EXL"6:H$A6AY"$5A6!01R3$!"!@X0047.`))*"!
M#R209*^!C:IF8P!25,@YQS%1;XX#2`D`1P7.J5'.C(,JA_",:#.K@-%VU`4\
MW&!:4/%=?.YE'GLI$8CDD8J6(I.>(&JR(\V+BDK$M<EBN&4GZG+&?)#R-?K\
M)"R1&5=@OKB2W&D%=@?BF]]N4``D".<$+T!!XP[7H1549P6+"]&(=A"#R*%O
M&@SP0#.LD3\/<,HT&I`"I5*S(1\LD(X,``X*-K`QT'RF$/\^L`A&+FB")=7N
MB;GSG74.Y)(W:$E<5/**@*0X4.!5"2S%.(!U)..?NN'G`-^:2DFNY!+=U5.%
M6QFH\9Z'+JG<I&YZ(THA%L"C#9#@90R8!OHD((3V`8$3HHE?HQBE*T;M"@OE
M4PVL+L4I)W!*`BA@`:A"-=0'X*"/'MB`$"IP(X1`!`6DV$%R-M"`>@RD"Q-Y
M%0F`@`=A95`C(4G/21##2_H$IBIFM>(-U]..%-X))NH22<5`HA2VL-"C4X%3
M"YWVM4\&46%4ZR2=YE0,8,RG)4>DER?'(Y;%?-$8'BV)+Q-J@@?@H28I^<I(
M@F*3W0&685P)DU?*1!4XM<-L[RS_A&HW,"(W"H$-3(CM"K#`!`,`@E"W6<UK
M#M*`DSG'`PSI(^$`Y8'FF,8#$FC.0HA&`E15@&8G^`W-&"(`-*#!`$2#("6_
M0$S<#65V/ZR:8`,+RO*()"@#54E6#A.E(`I(O>`RR4J`H363H&0[_TD)[AJ#
M&+TR@RJXBX\5A-61(A7B!@YHT`HN%1QF`@YQ&GIPA%<@A!_0U@=`B($&6)2^
M$[1H4PSX`#9-HRD&2`$%0A!"`3`L'`-X(,5-;56$%U>`,_RJ$%18AA7$TA>C
ML/(EO7(:[E8(0]JM#;)I8N_89L%"]$C&;,J[6B$$4Q.D^&XD!-+7?BT*F*N(
MRQGE\@KX_Z1HC,^8KHV5,H`&4F0-"90NMJ:+L_O<2&>;Z@H%F//3`9_*`'3J
MKP']\U\1_H?<$RC$.:4;T@XP;*MZV*H!!\$I!;EJ@M45(V]2O!O6!CJ2-$H&
M)/*EB7KMZQ>P]`0NIOT*8DQ".\1L#2KE$2&89Q%1K@A67>&]]1+Q5;:9)'9>
M2337++"C5R@6MA@OB>(!:%#%O$K17R`1S']+J$1FQ!(HV-I*,3HCF#=X&R2?
M60'H6KHHI:(`"2F.'XP#^0&C03"/)DWQ<'HC@5,9X#8N/H$`"$<S4_'FWJ9!
M0W,+J!SL&ER21S-%/?#@3+B`N;S?BN@.]9(N^G82VE"!%@X%H_\8*K'5A:BL
M:S'DFD-VU:U8B<G)UIQUVOX>2#]WJN<LP*K:U"4XW'VZD>F:.6%H]MR9&JK4
MN<NY`V]R*D8:R)0U3*R$&@W.`/6F5`Q0`(0-6'T#&DXQCKX`01\\D\8W.-(%
M=0P4#^).DR[1J)6&,CRV>Z1,W_)XQ51.DAD>2%OI-1M1=NEL^`X[Y&WG&EC$
MXI6/%`)$I],00A:"3@G$``M(B&T;VX@H.K/O\@B)A#<'MR(A^(#1BX*Z!IR@
M`25(`0<P8(%0*2'4(ACU!1Y@V1)LLV@?Z"JKJZE'5>N1!"&08,^4QLB[C'$,
MXD=[3YSY'0B5]Q29D&36;>5!"(HR)X__[X3NK%1*1/5N6MH!A1GB+49$O_\=
MB7L%&.6)J/?_ZIAW'>#7=;G)^.<F%OH^L3W\NLIE)M;?H#R`!["V+Y5Q&8KQ
M$DOB4>(G%>C'%<1&@!+U$J=E,7OS&5]`36RP4R3@)QW34I3B$(!2(P^T`[LW
M&QFH$#]S'!_P`H33'*CA'+^U&_\6@XQT7<^A$-=%--<E<%=52=`4`N01<6H1
M7O9G$]8F%1%56,.6?B5D16!66@YX$YWQ!M['.\;C12J!:HD!;1R$/9LA)6"Q
M+\KC-/KA5;7S3@_R((#31CM@.H;#3(?#<!SB`^:&`C$`!$JS8B2"3AJ`31P6
M(].`7!N&9XY'_TA",`9RIDPZLEN?`TV@<0._<D&7AA,B81U+L4ICLBQ?AE8T
M$39?EAT9M4H641G%<RS"0QG,`D,SH13J!3:6F&5.87Q9HA)<,7-04@!KH"MC
M,$V7XF(>8"&%(AIM-"F61V?$N"A"<!J#0PJ]:$"?]WE?P`0;`'4K,@UU=`);
MP`(J,&C^LP7*B"HH\&([4(&.-HZZ9U5)0((/L6=XL`S`$E+$1WPS!$+*PG;V
M]1%R1T+',&PH1`,.=Q9&-B9&82WTZ(`Y,38'PVNSXT5$6$.S0WX*N17K%Q7G
MPA3TA7Y?,3LO`7]T\2U(J!7`(''6DA);@1B"T7=2(3"2,3%/\1?4A_]MV]*0
MX4$[(/DT9N-MWA9V-^`9>>`J0$`""A`#&>@G=0@IE&)2/E(A))`$5I64*:80
M)W`))_`S/.-'A.-B+LB+SK$;,K,047EOQJ4J-FAP1%,!E\`:`Z$A>?`&\E<6
MY\*11(A78X$=>P$>U@8GHMA7:G4LP]84E@%F<?<O!&(G]!$3ZA4VS;)>I>47
M_$<4"`,4'V$2-5<`9Q@BB9(C$B9A;BANI_-Y0"`$,3!UN)$AB\-B=+1FV4`*
M'Y8B'[!FCL=-]98:J;%,$U80>70T7\!:/E<`&`$LE_9%<+$LRP(GO*,47;)6
MJ&043_0M8;-/,]0>5)!M:=**>T<9F_$PIX7_=\\2$\@#9K5#!4P!/K:WBS&`
M$$*@E:D!*7)V*.TS><_(!,\8.O56,Q\`E*+1C!GR!21P&J6Y82J``RP``[@0
M*KCP`(]0`1[P&RZS!%B`5;7R&E6EE$D0H;.Q`8X6$7!A#'J303P&&'#!)F>3
M'JP$&!UD%6:#!S00`OD(##>A5FWR@"Q1"-K7<BD1)VM9:^<W'N!W+V,!DV@!
M?D-(7VZID,ZV#!HY%W1)?^!U7F02D*BT%,[V,"@I12II`O_E,"ZDEPD9<0A(
M7RK'&'J'1CF9DZ@@'5CU>:@1"7[2$'"V*#B5@15`1RB0!!MPCGZR!*I2`<UE
M',:!7"HX'`877<X!_TD>\`);\%S.@08\<P)HD$S*(0".6EUQ"D%G>7C.H**T
MUB]9V@X)2800R:4W6I$Q%#8Y49T+J4E.\22S\VJHZG)^*9C*DR;7N6DUD5%1
MLE[Z,5'$IV-EM@*R=8:@X1"&8ID;@ID^%X<CTEH]XGA^PA!,P'`/AF$>%B/<
MY`3(E3ZGT6<?\`.`:`!`,)^&4P#N61#B.(YT5JR%L)MCAVPG,1\=@1WW5)!]
M,4/+``PS03R!`0Q/Y&5PP1EEEW_0@TK&$S>!83;[1VV)"7U=$1-!@6RYPR09
M,P8X%0/+B((G9H<C,GG`*'DCPDQXT$:8,B@+00H60AO)$8[BEB'DHV;4FO]T
MSX$#`@!```0#*L`B$M!<#.%H#LI[$:JSO.<05.5HBW*AO+EC0+$F;,)"+;%I
M2=M!UD=%&)6J8_.$:P.PFN$4,8&`'.E1UD9?$/E]>)460PA>;[FC68M+YZ<?
M-5&D<I&$%A=QVE.K:C6PNT,[]/H275!%';%]1(%%M$85F"J341&D$N5/;Y$*
M83>!U'$T7H<'72`%I)`:L+(#LS4&DHL0LP%5#(`J2B4$=GH;2Y`<UW4;C'1<
M'\""+;@;P!5="X$&Q_$;,X.Z`A<;:.`!1..H9"FI7Y`Q>5"I4Y&$"8F$81M1
M7.J6<\,,T@-&5#&\OYN8"NEEJ`2\,B&<WX(.;I'_'K23B=D'JM"R7QZU06A3
M.\N0!TP`$24PF_5P(XT#..I;K,1:3K%%3=ZZ$#%P(XD&384@*3MP`IKS`]3H
M`=:0/IKB`3$"=2:&8E+04O&$88NR6Q":!)?0DT*R.#>`$5;`$?5D>"C!+\K9
M8X)I`NT`I/RJ1;%J/&Z1P42H7TTH1G*R-BE,0W7+<2*$J?@B>/5D#'PR(EAG
M*;XA!15`6S4G>6=V.K$E(D`7(D+`*5.7*5*`0(MT8JHQ'4/R!4(@`<*@9@$\
M#]@(H*(R:!4@!1K`1R=0*P8!&TFYLQ$:H3C@$*^Q*]/A51DQ<TSF&9MVBFD"
M:AUZ5B%!$DZ;D`?;+_VR_VJXPPR6D;V]V[:96EB_*W'"Z[5:&J1:RK9[:7\2
MTPYJ^P]9Z@P1Y\?HQR;V)T8W`0PTT9`E\7]7,["T-E&GQ0P.ISV;-:OVE\G>
M-SN*HUHXF0?4L2/4P;BL\0$BNTZZLKE`4`!,S)6IX1"TX;D92#XHT!PTLQ`L
M8F\N"(,':C._!5PHPQO/E5PXN%Q#0[N2)*E=`$^I<#SRAWX_BH0U8<Y[B<D?
MB<G5B2:!L;6]F\[;FQ6M1A1#^%ZFC'X%L``[T3OS*A("C:G8H5\-"Q;+D$8<
M40AM]$:;8BF;BR-WZ"$4#1J*XR',U*V.US$V8F[`Q4X,ES&@$P-*P"D!?*TJ
MDO^M'H`"4J!2FU(IXYDA56=5)J.4CJ:4"($CJK4"$_PK!\(D(_$1>@FO(C$5
M5($\NT09LR`\_4(25`@2,GE>XA+0@4R2(F$,Q,88PA,]#RBJ9#%X'!$4QK!B
M&9(Q*'`%#6`$Y)`':YAX*W#1DR=YFUE.(>)A#(`;3F!(R\IX@I(S&/)Y#`<Z
MR`6(#/`"&Z!Z+!`JJO<_,RL!NF$I1F,REU#&.GO&EV)`6+4H>.`K&:$1*G$W
M>%P2%N&A']1I:!,\+5$`/#`MK6:0ZNQEKG8`A96*67@6K[W.N)W.QY;/X`6X
MC:P]D&S.%B63SE#)P*T]L'R=6<B$DW$LA:43S*9W1;'_P<<BW7)[G!_YMWZL
MG&]PT>YT>'@`V.$=WF9)`O7&!B<PO\9LS.4Y=3?B>\6Q!%>P`8QX`_5`2--%
M(?66N@;P`AJ`3"XH`/DI,\YAH*E+-#*3'$O@J`;P"42S!4JY6P6`![O;+[?]
MVK"LW=_2R;O$A+A=D<>F=^J%SJL$=Z>5F-%#6290PI*1R62BP8IAD$XJ%@N=
M,>)VC"W2BZLBN:ES>!9=T1]2K)J98<I*'%:W$"MSH"(CFBN&;A^@!"#V4^C3
M9PQ`"G0T*$EWY'6H(17(&A0*:1!:H4A@OP5PN,#"$3G68X<Q-L<"K\GV,`$2
MD`/2&53R%/,:%-G'I,?IDMJ7_VS5J3TXU+!>H1$6/*RSM0/_5PI&D`*=P`.B
MH;X8/<1"W#A#8DZ.;0`QX,7S61O(14<`T-<.T8PA@@69,GKZ4P&M5P2X,%2/
ML`4M\AS'`1'C>,:TG@2C$!N^=Q"20A`@D`N$'CM!H7PD\:J82&IBU!G[RFS7
ML37Q#%Y#H241LQ+V5:GH'-S`6\C8_I%\;.W"?>'53J^7T<F5/#OIS+;53B7N
M+$,#JU[HYPP/4!C7_3!B@B6`.=6^7>YF\Q:@@05C@,`$L;C480I=(/`F\X&#
MLRJ76SZXX1`IIJ?K-"1(@`0WL`([8%SWIF]6WHN!VH(&YP$Z$Z@W<ZB'"EP5
M8*C8Y?^HM+L$-GV6T]*JOMW;O;W=VSW;V,*$B"R3?PM>>>F7`?TO_6+4UX,M
MPK-/!&AD=)Z07?K3E^89'K('&U`":[8IJ>$Y]AN9&+V^T%3IG5DC,9#>N"&4
M'V`B*Q(S2^YSE+>:FZ($T_`"F5)BF:,B!J`I?T2'SK@HYFA5E5VA=JA:!V9C
M"^(1.V9\$H.O</M>/^]E=XYE7B8NV/%JV=U?_`(,I7C<TTVP<IX3?%$F7K$1
M"F7C"\"K:]``-%`*I)\"I:`-(D`#EGG1BJ.9FBGJ3/!&%5(CI@&#HJ<Y'_;I
M/&QU_Q[8,[(B+>($A#I4HC*@CR``&O`"+=,0.%O99WP)MW[_"29E*^$XOGG`
MCAF*H6XB$R?13X"<?!Q4=Z?6W$:AG%NCEIU<+/=EO.@,\R]_[_-,:[/SHQ]>
MR-7NX8*!$I6LX>X/$,N8M3OVQH3`9<Y,'#CFK)U!$P[;T:!QX$TQ8!"=`4NX
M\""S-P=,%(SH;!8PC"F!.7M3*$^A`E@^2%%P`DL7'WAT=NGRA2?/#2@,?"`E
MX0,*I$ACH""Q80.)"BBBDMBQ8@63#3$^,"FT8D,%`08,H#EAP(,$#P;"BEUK
M5L58LR_0&"@;MD):-`).+,DK`(T'#VB6)*G7I9Z/%7D.J#S)V.3CQL`B+S/H
MK.,;9Q@%MF.VN?/`@21-O#G&.:%H_\P#@1TST7JAY6,'#A0PB%G@+):C1RZ;
M-:O=LI%4#BX[`[/`GA5`##CY88V!A@\;F*PHX++0]0(%K&K7;M4J$R!"M'Y8
M:B!I#"D2)&B0(,6#^P\&=N"AKIV)$`D,]$][G__'CP_T\R#`_!B00HBC@/CB
MBQVZ2.+!PNK9`4(@=D"BNNMN``$$8TR@@K=VC&%MM,T4,J@A9U@[AJ.!*E/(
M-9(LXBA%W1I:2;?1BGGQF(&<,7&S8PIRJ#4?9P&.-6.6668V)ICP83KP&FB@
M%"JK+"4%;198P8<"\LCNR^^V=)*)'5`@2@(#V!CJ!*'68^`__0#00`,Y-9#B
M!"&P6-`'Q/]V."$]]J:1X`08'BD"ER**>,10'`0`S(,*#*B`A,(<?#")49*X
M!-,'FR)L!P:[R,,$8THUQHK>0I3M@$(8PI%5V6I<M=76WL"#AP5TPPPWW&H;
M+;,>%Q*)M-TD,\G8R'B%#"5F3^K1L60A.Q:C7M\H,383_M%V6VZ[999::4_B
ME37,,'IQH]9$<H89&G@0J9W<U.TLMY54=.:`9>`5]]B$#GC)OA@D`,"H&(#P
MX2=3OC#E)P=)0.%/]NB*@<U)G7*83::`R&X,]#Z(;X]"?"!!+;%.0".]]^QR
MM()(ZU(K+0%>>%D`H>:2BX0E/O#`40'\&JP>H.G#XPW.EDT6V6__F8WMF(0J
M,PVT<)<EETBHL27QLY!6;7JD6*_.]\7*>"O&2.%:N\&X/;#Z0#T-?N"#C00Q
MA,DE+[VS6\SPU#-`B*'V'L"`]=BSLSTII!#@@Q.^0$P[()B(08/G?GC.`PV:
MJ2:_P1E8FP$/D-(`B2Y`K>?2!R=,8@/"L&)"[ANHV+##L6=1T6L3B7RHI&58
M\Y'(>X==TIAU*1N-M&4XJG4DCIPV<5F%&IJ%2-Z`$[$U)G`68@,L?!"B@0>H
M+(+*%*XL11MM2GFRRR_SL.K)J\);6X.RVCMA8LI_F.;^'\IX;LXYY92B@H+A
MY`LKV,$&EL,``TS#0`;`P0,2A8M%*0H&_P*8D\D01X(D?&%T25C"$G"`J4UE
MJBD[:,`.3+B#/)C*"J@J!G`\XIK>K0I&'BE`K`Z@$![08`&CBLAGA%>;8I@F
M-QYQR(F.Q2ND@6M?T4*B$ILU+:3A1G<.21&^LM4M+&YKB<M2B6J6%RR-O`@8
M[:I=25I3/-P<KXH(^0QGX/6&EW3E/F+Y@`+DAX*?^(1A/*D'"4@@!!0494#F
M$4(A4;`$J2`%"RLH!!.&(@6/E8`\U?F"4,)2E@K,1&9S,8OAPG(6F7T@+W`9
M2\\<Y8&]5&`NGQ``*U\@@)\1ADMXV`@3C04:SP`)7S>*2&14XD35F&MX)F@C
MC6HS+1.$H!#&D/_-BG14P]J@48JN,D8[>F.%97P))@[PBA0TD!8#5&X:*-@`
M&X0@M[EEQVY0>A(6I#"-^<W$/&8*'/_44SA(%JYSBK-*XY#PN,@U`RW6:(9^
MG%`Y:]1/@72)3H-\0#J(^K$>JLM.AD"P0F-\J#=+.I>/3%296=0F-KMK)C-,
MT"K++&E%`H%(99BA$(;<$".5V0V_@F4"SIQQH\+IRL/B<X*R7*%[#BS%]ZH4
M/O(M8)'HJ\_ZP/.!:0!@?NN9)^`8<+]IV$]R<>H?Y"HX@!VLP2<F'-D/7J`?
M/GP3!HEBJZ(>,,%!;4$L!L"@@[:PA5$L082CX&L2<."4'=0#"!(JP$7_485-
M#Z4K(B(YZ:A$0I+8A."D-R32`F@PJCQDAD6^(F:).&L0EHXFB:-E3-*6^,2C
MX0:7G0$M:%X#KRS&UK105.)CJ":0A3@3&*-Z``\Z<L.BR4:SQ5"7[=KXTGO%
ML0#A04$,Q'.",WU`"%39XQ[[Z$<#`(@I6-C!$LK"%!3LX#J.DT()AC()2'Z@
M!"C8PPVP(-=-1FH]@Q1`I-1R`L"\[`7N6<M=8&F6)>QL"5O`[RE]1AC"=*$`
MM$1MU'`#KH4DY%XF``9JF]5@)(*MAPB!2&M>^JI17<18L^&:D7R3NY&,Q`K%
M,,$.]N8#(.QA`Q^(V%7;4SDI8&$`*,!"EZSC_^,P;<D'8P@0GMJS-WKR3TX#
MLV/A/&8XP*#`8'C0C@_^R0#G9(,!:('<-`JG0`2E1PD:<+%T?7"82VUP4YM*
M`DZD`Q-&FL"P'1);.T3BKUWN"%_,8,TN1],0QD(@-@EQ8?!TXZ^(/.0`S&Q(
M,6*SJ]4*Y$>R(Y613$#`/P+N/QI`P16X5XKN>>^H6-)&)Y9:M[K)A`)2!9P$
M8D#'_&15UO;3SW.>(R<&`$!R&C#/!AH4NAV0X`3L\>8/)(""0CWP$2Q8%`S"
M:=:28;"/'<14IJH]"JC0-;`*PH,)5HA-*HQ(1Y59U6Q,U&?9%$`3$0X)#;JP
M`,:NU%<K>HR&?<1G?/\9L[;*.IH3H75$VB8-./*"Z4><$=LL(BO@_&96;H+G
M\!>98`T\6->Y(XZ9<_V*WY9Y0RJPPP0L_+&Y#YL8(`9U/2Q4:H\-FA#J^(:4
MZ387DXML9%;Z9EZ/32*2&VCO$B+U2KB\0&<O`"?ES"(6P.3%DV%AN@%>*>!+
M+$$`\_#`)^8AERT09G1?P$,>WG!A?RO<1<W;R+^;*)D&YP:DQ\(68S%^#&B.
M1%^1U4W9C32B#A4""$D1#PJD<%`T714Z'Z"`H)82@PU@R$M,W=(*9"*%PY.G
MN08`%/_L23AYXO,]2]B!#[X`!-#/N-9P\H#E=NTFH>L'D`9`O`8-`R&M/VC_
M4Y_?`!*\4YU362&C^7)TJ_I\&E]MQ$=+BDA'BK\,9OJ()`B)%;E\Q,S:S(B-
MN0P6TT+4F@+X(.0*PD(X&>"$HS3@$:`NJE'#5Z6D5H6ICA/84-B#N!@(8#W_
MP:I6M[ID.D%./_\QR@`V,%8&^8IF<`']TX`78#:V>H0'6,`&H*#_B93P0K!K
MXZM+R*LMZ"`42`(38H)1R0580+X..88@DB+,8BS*NC/':HVVHPC%*`A?,2)F
MP`B2J`QC$9Z-(`DN0KM?&JTM\B4='*T9C`@5I"F$PZ*B83BS0PF6P`S."$(?
MZ:W2\)%YNS@<+!YP>8.6\!+MFZX-B(2E2`HS\8"E_R@DZJHNH$F"IE@"0T(*
MEB&GU7&\OY$D`Y"D)W,R\DB\`A@9IR,9LT`+3P(,1WF9M-B94YJ+OO`+7IL+
MDS$+1Z$ZP8B]G,BLI`D[C%#!W;&-XZ*^HO&A-IH17?&1HHD1AC`FMUL18'`-
M-3(QY,,^QPND]"H+_3.*:=``4O"F-S&`,2BGQ+B.Q5.G\#B\^4$!\1`+!>@J
M_).`)DNOF=`9P/@`SE.0Q@&",<@N!N"#^ZD?_>"U:;`&2!(0-*$+7S.A,V2S
M#2J=';@>NY$S*^"08T@2(CJ&/*`W>^N5DH`XEK#'A0`)CSA%AGBC3YP,3N2-
MNRL5$]`.!MF!QM$^%*`<C_\!*D\COU`[JBM)@6&@@>G0#@0A!8_12(^)CQ>`
M'/NY'W&POZVB$UL;O:U"D^O1(U#9`">HIQ_@-`54-D-Y!!AX`;2(CTDA`3;C
M*[[2*PO$-N^2-CPX@`\TE20QL2I*P0Z;%5<QB%7Q`1H0@>,I18>8E^-9J<ZX
M$=MPOI?BC`OKMTE4.%O:P=PH"'5)'I$HPFY)0K=T.*S\E8FHB(=;B#>@QZ<<
MOAYA"8_3#BS8`$`J)$!2"F&$+B'`&"%(L,!BF`9XBC]R&!0@"V$$@A5`#B08
MBO@PKTF80\S\`)V#/"2X`1]8`J1;B[-`BY3YI$_:&9C)+].$)2?("P%;`JJK
M.@__F`>\0K##*,I:@J+5XD>/<A%?<K`<W+C:P<3?"K%HPI83.:;989I90"PX
MH[UP8H^'D0+[<;4WV;(/>`$O<R[$HPZ7R`[U`8*@6,-",J#*L[S\(S8[I#Q]
MTALAZ#S$&+(-T+_F8(]:TYPW.0L[L9^]&8H3,AW2V:`E`#V'`3TG*0!CN*A5
M1$7%HB*U&Z:-$)Z(@(B&X)V"0\58J3C7((VKG+[C^@W6R`,R04C04QSSQ*\U
MH0ON(:JBLI+Q&1\1H(%V2@_X0Y.R`)20_`%QJ+^MJK7\V[\WD9R8A+SY_#6?
M6$CV<(&%JH!D*X('B*`'P`'*X34V'(P'L<"[PJM1N*N'_V&*4?@".>.04A&;
MNTN78>&:5KFSJH25',HL-94L:ZFW87*F'IF%#\.,C!@)+&0:'BQ.*-HX'VRB
M)62F>B02MN26"NLB-CK"1F46>"$18."SL*&!!^"=#RL)',RWDY#"OERN,1BY
M2!#&P0PD8303H7"N0B*KQ0PL/Q+&BZ&+ZUF=Y4*/H:##^/`8SE3&^-`"O?LY
M/I0_P)`9I^,<<`I$`8`R0DRZUD0#G`&,3W@4O[@$H!F%GLB#L7P:@1BIWT*C
MQX`:9Q$(L*M4</V,J4F-IC%!@NLS87&>2]P-8SB;]4&,%1`"RC$*,]&`[_0/
M#7`N73.0[AN#Q*B.?AH#(0`]I/^HO3!;CSJYM3FY)SNL0V^BG+38`)RXBMH#
MJ.:8AC%C@&:81;:IH+9!L@,1Q]%A,]V4LA5`@I>3CL)*$MU;"&,P*41+R\MX
MUTFMC6$Y)A>!QY*`([>3M$,C)N'3+!-KAV(8&^`@H(2%,1-:'RP0"BF@"Z:8
MDJ&*4?&Y$FU(`<MRIV/3BOGAF[\KTI`4R:P*TOV!G(#=*C@Q$,0KC`9A$!2`
M''^5`!58JT2AT@?8`A=P`@,@3?.XE$O8`C3HT@M4)14@S24@`1^0LU(!@65`
ME33M,&(1B1"0H=I!M!!@0=*`%9=8$=R8T*_#",[82AVY&F%Y#8QXJ9<ZN]:5
M-"1$&M?_S25>.C<:7-1MD31FN*5-)-?6A9?7/9?B,9$#:!<(@)Z5P,):&2GA
M]9$\^)=[)3DV>353_:.CR#0I(`6E,(\N:(H&,`P_BKF'81/.*X`S`(*.42]>
MG01),B_XG0E(TCD#J`X@D$VUL!D[V9F9J4V+!<2D&XN_8$V8,:5'F=;#S91Z
M&`Q:6I=;XMTU(BF!V,K/J+B-"\C/8):M9,Z/.)&%4`P*(]<258SB@1>":(V\
MZX[M("`4P,EP>C4-L(8?:`88_E?1^P$%V(!IU!@O"8\-H,S[``($"(K"*<9Z
MJI,ZD=B.?#+_M%@!`!4^,9CN\RH&H`#`P++V")""`I0WT0!\_TU,"2E'-N/)
M>E`<$D"@\,H#6."092@;(4R7+VH'""B$$*BA=2&B8H`WY3N`#XLINXRXX^G=
M"3.!S)K4&^I=(QF(C3(!']B`$S`8!<F^IL+75\,3H5I`4;,2I,J2-6"/8P,]
M(<#)MOF/LQU)_-FT.,DU_=N_1'A;.R$G">D)'W`Q>Y(<#\`!0]E;FY32NP`G
MND*=3+FK!-Z"L+@K1_&UQWT=P_*-$?D5L$&TEUB^<HO'!>`!R2HWQJHXGN61
M'JE@J'&10SN`E7B:2MV(WLW@UBUGT/#==3G"X-E4F)(I8-!=;:G4HC%7<Q7D
MD]!@<I5"=>7'WNJ7'K*,QZH,<X&C?_^YCU>+A+Y+3S`\3^L=BC\JBQ-`'8O^
M(T1*)$32F!M@@HZ\N3G<5;'0S$>R0\BKCAVX"Z`;BXC-+T$4Q*K[@%-Z)4=I
M`;#PBZI;@DLP@$'P@$%P`E@JW%'HF2[X.M4Z%MO*MPFCHG)VEDVLN-[%B$JM
M,-6HW=XUOJPIB=U2K*\D*1519$=K#;UKJJOX`K\4BU'5BOQ0`NF*`0J0'/&`
M'"1[VD*B#AC+#B0PD\)1#X?MG_U!1GSB58H-',#0`#1H$`5I9"*;X2HV-C>A
M`'MZ',"9D^LYD,&R%`G9`6L=A7KXRQE#DQZ#A75L#1!X'G7)#%>)"(Z8#3=E
MWF9R#4]5B%'_\9$.S8@U#9Z0>*'%6H8@BL%K,H8"F+'$(6LP*8"R**2E(`%,
M#C7SXUHL,0(F^+Z$9;\B;66L^M&T#5*3+$"S55O]0-+`*N-9KH"V(84?&#-4
M@@$'DE(88`$IM=(?<`+OJNAZV`(2^%)B_@3#5<2+28+'-88V^+;G.1Y\]@A_
M$8X39!4>.@`\T*&%:--"&*+@2XC8'=Z5Z)779JQX?*E\GKY(%5Z$R.=PE=U(
M!2,<7`EZ_@=S499N9A87;]UVAF=!-H$NH+@(W1$:/(EC2(5_F=KY^:Y@9)-@
M;`JEP!C$09RDP"#LP8*,/B0>RPZ%ED/WC8_-5"\#V$R<PSGY3:\!_P`9$I!-
MFGX4:J4@)Q!S0&2Z:249,?\F-%`EJFN!M*B`)=B`%VB!)SYDI"Z:L?L51'9Q
MV1U4!]:1;M:7=ZXP4401/T5%1);"&AE!(SD;\*".JV`D^T`"1PX*<A(":XB!
M5Y."JR*G#V@&.4GKK*#,RK2*K-AR#S#BKK(\PO%5^>7KENX<"5$0)`@/;U*"
M(MVR:0A9_;RJPID3UFLN(7BH+W"*E#T=4#'/LYA,$&@#*C`5%E,7(YDP<DNQ
M#VZ(EA#GV)`1DGJ-8VA3>"F&%_10BSBTI0&1L;&"2^,;(:".?WF)7KQ7JST!
M$GA1K971318!_(@.*ZO;(ITU(&4`_<G&.O_!SQ]H9<D1A?W[IAB@"@E9$#_Y
MV/US`A6H22E=[RI=CQ.(B@P$(?S."_.]WB6H!SP0[5S`J&,0#MU:C0_V"*B$
ME57!(1TJ`&'YW&X_=P>^:IZW9T$>J4.S>1F!<4'.YY6@X'9^YQ&/Z@MW8-S%
MEP-(\0K;Y]YUYZO&YZW$#27\4R6D"'5!#6P!Q8V8UQLH@+2>F`\H5:1@$^F"
M.2'P^%1]&-8[3$#`$S]ZBD-J"DG/:SJL\ESE3/B].<^$3WRJV@LI`*%XE)>9
M$P`6\YX1\VD]<P.@.K^(39H>"[DX"P.X!,JO@*)F$;0#&]HN/A8)]`HKGJ)?
M"6.QY^"9ZJUD$<K_0+1/K"(B,M?C/(;?+@"L*/;ZP`YU8@*DR,5"VC*".8%L
MB`\V\/0?N)X!P)-WGX[D(%M\DO6'I1/U4(#WB`\ZBG4N.XO\XKPN4-"@"!`%
M6H?XEH""NJ?S[L[U6(\O_&%?&YU,,:'/<]E7ZS6;;]`'G9ZR`PAG)@Z8R&/"
MF;,W!PR::$C0Q)N&$`<23'C@P)MC#8$!<Z8QXAMGRQ(.;!CQ6,9CLZP<RU.`
MB9`30@H4JIFG9J$"+@L`B8E"R$\8#QZ4(EJD5*D42+6ET*9M@1`#*+#X0!)#
MPX\?TZ9I[?J#`5@&`#20U0``[->L7\.F92`EQI(=#>KMV+'!0%D&UGZ\_\`A
MM,BC(H(?-+CB08('`TM(;-A2`<T6`XE/&#!0`87E+:/PP+)B!<0R*AI'M@,V
M"R5%@B`+7GP(D0>-!1<E1J1H\`VP9<R6`6/FK)UOX,YV"X1(\&*>$*J9`2L&
M#+AI9[UU0W>N^WGO=L-+[Y[.G#I)E`3_D2]O_KSSYKF#^^[>7;WOY\P11I3>
M[@$-@AT50JS/>_X9-Q2P0B0&G!!##">@L."",1@`E((;"`'43U(=N.`)'R@H
MQ!(H++$%"22L<8,#44UBP`<?H/C!B248X**+'[AX8HHI2G&C%)-(80`2-S"Q
MA``>"!FD$QH@YD&004H0I)`>.&'`"T)^DI@`G_\($"0:4AH@`!KS:#!(8DT*
ML`0-TCDGW4#'(-30<+UU])Q]OLWBS"SJS9G==MD1QXQP'964&I_[E132F\4U
M9,Q*)JP`5`Q?T(033@6\M`&E&Z!P@A0,?"#$!M.0]0$*'DQ3`H.8`0$$$TP@
ML4$,'T@AP:L*E&76K+!*46,)-MYXF!P2^"J%!U*<0$(]7>S@@X0H2&`-`]-8
M8^0/&C!@I+0W(B;!-`\N:-<&=B51#Q!?^``$%DLH:"`*/A1B#`@@'+K,,AJU
M&=$!LM%7TD4A*8211@O-YE$A&'E4D:"J#5?<&QD=9$Q&QAPSX`HK`('"!H_6
M)"E--.4A,8647='`4$C_E7*4R*5HDU0G/)`0@Q!?,+$!&UAQ-;-::TE+E@1D
MH9566SM'^]8&]0AM%PX>3"NS!B^H\-<#13Q@;`,52/"DN15L:4!D'KSPP@=<
MH\CE%GG`TAD(QIAPC#&_G<F?1!.UEL=#SA"$1VRS@=32`0$?<`QSO?W&7D>E
M%3S;0`50=$Q'<DKGGID<?3<=Y.JM-WFA)XUW'N;E<90>>[\M_A]OGL<'G4"$
MTI#?021E=`!"D$?$Q!@[H,"&@3%<ZB#+"3(X8;FW;UJJ@IAY>`+QBWUQPPHH
MY,KBBS*^6!F,!M!8XR0VNGJCJS$`<<,.%3`9I=:'B>F!!D,&.8AD3+KPB61-
M_V:)9)9H?.E!"QX,,H@&+7!)*)T*(200Z];#&^?(R3L<:=-V/C><T.&)."<Y
MQD4*D3H'.B0D=1J)1D:SC$(`@0TJ6D$A;@"IB]6$"5@0PAB$,#%834@!8-E4
M#'Z@!`:48`,?L!VJ4+6!`1C@5;XBRUC*`@!?*2!8*:H,BH#U*B,=1HD",!!=
M=O"%";%*6DK(RK,T8(UF,.`%.I.`BK)UJ1-0BC%UV0$0JD*I2V'F!'$Q@3'B
M&$<3P,LCJ9.;3FAS#`BF+E[_\I=&)L(?Q,E-37ZRF^<RDAO_F&UC`QJ0$)B@
MDYSD9`4ZN<E.IG@@4)$`9$4Y"F$>(3*G:&,8-+#4!O]<9D,&:(5F:Q'+K()8
MAIJQLI:LS`I7-/"6)/`R"23HD!/`H@1G,<`%%7C$4(K0@%71H`$"V!&F?@@J
M-L0@"UQ@0P\(``@V<',`A:!%N^1HC&7,XDXF29B?Z&60VT`$@C3HP@(*P4=Z
M(<<A(F&<<.JD.``6Q""M^9=IWG2G[MS).LQ)SW5`M[F.U&E.VJF/"3(GT8).
M[C]T8JATYL2GW<0G=!$!!@UX4+K^0%`[?&I3'I!E`):M-'@K-1`)4'##!0'%
M4C^)BDV#=RDP7L9`"B)!%\@`!`?52'K/BUZ,JL<B%4G!13AZZ@<<4(AZ,&E*
M3&)`DYHT#RF13TPM6)(!T%#_)0^(=0E+$.N5I@0FK"A!`O.81QZ<X1R%C`2`
MDT/@2?<4N.[H9H&0:X])2T,2D<AM-@?0S@$A6)N_M6,9$3&;HH00+`,P(80X
M,<$(.4BI"0E!`FK!`EY`U2I6?F!5;^$4$I@`!$NY*F<Y`V*ML*>B&.'(5^2S
M[8UZ"$6Z?`$(2-A!#&S9#`D8@)5@_("T&"`!%$1K6@]:[8)0R2A8W06,'#*!
MN[!KA66<[:$'*4@(\H"WD&AG;Q;Q(T&*(1T`L@Z`OU%LZ&AC@MQ$9S=[@Y<Q
M<F("B/D`8RZY24XFJ9,!`<%`E3G!QXA"E`8,@A\X$%E3M!$"'EB**D`8@V==
M&98@_^9L+&-A92*R8LNUT%(#!AC`MW@Y/`_,$"O92!H.D.FTNO#@`2IX`;`\
ML!<)8-,+.A`#D($L""$+@A!J.`,5YEC.66AG("#9J-S\*=XT400V(A@(/PMP
MG+T)S&^!;=-UM(/'$.@D(UI.TWH':E*&)FX]H@.=XNJ[N(X4QQD2S5Q&%W=/
M^L:YH.N%<G<:\@"1.L,@J&G=2)AS##Q`-P8D8)0!)""$!-EN0QMX]&4FA*$V
MHB`&E^ZT2RE3@<7XX`P(>-X1CVK4V5JO1MBS%E1SLH/VB2EG3A#2/()4OJ[.
MHWY;$M(@F.2!+>QP$EF8!+(G(0<%2*$%?-#`)]`@`4(I1/]-<CN(27FCF]"Y
M9R3Z/)A\I--7DRYP.!#Y'[^<?!"^\E%@P"G&,LRV`E4)X0,2B,&C,(L3$4HP
M)TP@08$K\P%6C@$+$LC&5[`@A6C-%"BH52,*EDBK(`X15K!2$?1L=)B</15'
ME7EB$J0(!.!&I5D,J$:TOJ(!"BA7`T^Z(5ZD$/%H58/E8)3`M`0P<)G0!0MM
M.(,QSF""<G+W&+PIR$&.40C9$&Q-7,;@1MZ[K_E:A)`580Y_(A*?Z'#W#<4P
MQJ/FW5]+1@Q2`!ZPI!A-1ID:X`HA*\H#8,`/&"`E!1'N!%0HIEHD>%8M8`DB
MK0@@!AT0@"U^'W&(0ZR!#Z1P`[[_K(`41BWMO?"A&<QRP0M"YK2H&8TL]!"\
M&,P@^M&3OO2B]X21SU",=JC7)&>C,S/4^1!ZL88&:X@KOO+P!N7TZP#D%%UN
M_.J;OLXI-1>!H$'R_+C.0>Y,^83<WSP7[FP#XW)W-L^9.J=1^M(IS_+A-F_H
M_(8NB)1-!-N^8TV`AS6,?`><>G0,2!$B`SE<IS?]](*D<BET5<!!!D8#\51`
M/5A2@3&/\ZC()'#!B2A5C2R5]<":K0R`I"2!L+V`E725^0R"!(")D-P:DGC`
ME.2('$P!"3;!%#0!"IZ@"9K@%(3")*3+(1U#>1%*=X!;`N55XH3.FBF4>H3?
M,E0$0K27_]/5!YC1G@GP"='MU[PA@1!H`!98#`GU6Z0PP50("V;\0*N@R%<,
ME19-"Q+0#L7X%KFPBA0`WJPP46XY3Q(%"ZP8B:TPE6Y]P!*$W!FM2J21&+6@
MG+V5!7$!"[+%02@8@B`:0@8,8B$.8BK=`+N`P&>8`.NE7V'M#010Q$1X#C\%
M$&K$WKF5#D)`$+K-UTC07DBPQRQP%T30Q'Y]P0Y8TB2-D,:DG:2LP`8H2`R\
M@!`(Q=NIP#PTP%(D15.(0/*@@,B-`5J`!<Z\E@:(@20,7BW5C#(4XRTM7@SP
M$`K\4@5\P+!]B`!H$5<,$Q^XP!7`0`/`0`6X`%DD`@'\F"1(@O_H28(G"$(5
M5$$F9((7S&,\"L(BL*/H$0/JJ0$5\$=[J4=M',Y#^$LAG`[OU5,>_..Y,9#B
M!(I?7=1P!-(!G%D%)81(^$U"Z=7D.-\"+=^XW>!#7=]YL%E?'9!&_<9?@5L-
M<E0[',/I$,2AK9=Z"$0AX($/Y"2W/)I,C1'+<,CN4(BFW<Z"7(:CQ42D4894
M`&!<#`@2+(]1N4@HD&`6I(A25<^MY,CUO`I7P@H2%,`>B)68Z!H39964;",'
M2L$(DN`)MB4)3B5;EB`+3L$$:,%M!&'J"`=!-4[T"9!W=!_SM8>@_`]$\(:8
MG1/B]%5M$`0YE:*^20P2H``36%)-Z%O_9N7-"KB?I1@`*7@*`ZR4!#1##[G*
M-#``%K#*5.P`%IR*A,0`,I:%',2!;-X*$B41L,@*Q]G*K:3($XU)T-1%MVQ`
M)""7I^R8!PR7K_B*6\AF'`PB(68`=$:G=$HG(Z#"#7B&%9C-ZO7+1)3$'JG;
M>EUB)PY*(B4,?9B77?E&PCB92NY&*382",W;!DA2*V)2(>P$?NJ$#_A$&WE2
MTUS!TO!B4I"2-AC!OPD!%O26:QHCSL#6CXD!`90!`;A!XKU26.@2@MB.AR`1
M&HS:AUB-!F3#7HB8"V">`+@`*Z6C,IJ!.RZ"%WB!%@3!'NQ!$*S``#"!C&K!
M'M3!BPJ")Q"#_QGPHY%)$$(@UD?(I.LIQT*8``_P@.Y%D&&91)I)'WQP&V(Y
M1WD=A^ZAQNRQF5P=4'>H5T@TCIOE4^/L27B2I'F`J4IV'_?M"6)I6]]DWW/@
M!T;4!W"$WV^\@03A@9_Z0#TTP&:Q$8+0E%!6(QO1U(%<QKF,08>@B($`X*6,
M6A>`Y5TH%8J\0%O*@0,^H*[4UJ_P"$V0P)5DU8E^"6)DR?EDE1S(P%K.Y13(
M013,:@],@AN40`]$00_(0%PV@0[4I>&PR<$@5GRDQ[`BD.2<B9O=B276!S"L
M9YO1V>PE$$DTA-&U`PA$"KFD"F56YF6YXJ*LBKT9#1;6&Q<Q`((TB_^&_@0)
M(,%J0I>]>9C+R<$@[F:,])"U;-RO[&:-H(&')$'0Q)2$`,4'_(`3_,"S.<$T
M>,!7W$AL&B)T.J<@!J)S%F)TYD-UI@+K89LQ_,N^4-N?6.)QC"E_M(YOG%N3
MW5%%A*(@=5\IS@)DL>)J'0O&C-!.H!W&],1/R%0%@(R"X8`*7($H09A3B(#L
M"`$:684$C`4ROA8!/*T;R`"$SA(#S)+-2$`)K*ME1(EEC!H.?,@6B!4?6,->
M7)%>2$LB2.B*MF@=!,&J[`&)%((#[('V%(`#V.T-H$`DQ.@B+`*0$@,A&%GK
MX"415M]`W"=%X`$/A`!K^$MM*!(!M8E'UJ3_WR3.2QY'.P'0OA!2G8#9?%0K
M7DE'1QCK`;7)EZEI>="DERG?FS1'Z!;*`>E&3&(938);2]@$3AJ++_&DA,34
M@3@<394*IUC-H@H/&V4(NJ"!@9!:(=`MKIS(6BI`"1R;CK!(Q\&:+NW(5P[(
M!E1)D'S56'75EDS)KHF@"I*@JP)"B4K%I6$*Q6P`$AA`%BC`JYJ@!>Q!`8AN
M7ZJN\W$#]W4NL>JO0-T+81)*\+W)1PBKWZS&,<";OO&$$$B,Q>B;9;HBLIR0
M5.#<2KD*`R@!@A@-5PC!`("*:B+!J0"%Q.7,)#2G(9Q('&0<L/Q0KP1+L-"F
M5"P!I=1#B$1<B%#*_P"0S[34$K;\P,-*YR`R)PI,`@CN"'-6;'2R`BI$Q$A(
M!$8XQ$'0F7'PS[6QR;.>6_!M8D?(9!#R#[V8)Y/-PM?IVP*LP+CLP&2RXLWN
MQ`K\UX!E)A5)!0YXDC(!J%`LQ<DX!1Z<$`F@$:O("JVX%A"!A1M`J`PD@AM$
M*%C`BNWP4`PH+UF\0(=NP1:`K29O`<->D0R!!1^4@1OH`#M*`C'H01#8[0H@
M`1*LP-R"I8T"08WB;XD(P2;,J!94@2#\+2$@0]H$DK.NUS\5``3!!MQ<A.%4
M!/]PA$/JV0%%L[@=C'F:1!4#$DTRT'FRIY>V;GR\QTD.!^J21YO]6>O6;O\T
M%\I\M"Y(E9_^KG-'_&`JW&<!^$`7!$WONA^%4`R[MA%0]-^F,8COTI34F!BC
M6@VQX<$9Q"\#E@".Z(@)8F567J^MQ,`>Y`00A*V0E$6P&8!::4!OLBH*FF`H
MM,H'/--AH`MF>,"",(9DI`ABR.446,`5B]LYW_2:T61\J&[M#C-&J#/LEC'5
M*>9$L$M^Y<1^2M)%6Q:DM.)]TC.E8`';D:L$\)V)S8X!?`4*,*$4=`L6F'!/
MQ(#$E8\<(-L'-.<+V^:UN)9N5@:G;,!IU@-F7(;0G(K[W8P&*(&1B`*]&O%L
MTB;&U69EO,"ER.9S7FPJ<!=&7*[`*#`$\=$T&Y;_H."&W!CP>M&N8JW7X\[7
M=IH-%6`,`=(L&Q?"'/M7?@Z8#T@UI\2$"OAL*30`"_!#T"Y%A)'#*?W$%ZQ*
MQ%%+@WY8&20"<(-#&0!9X1$7"O#0J&UCM/CK8SR&8W0R9$@`'ZP%'XB%X+6C
M'N@H_+XR`C#!)ES8!@`!`B`!`LCB`&S`>(MW3XP!$@1"%>BC)ZA!!07D(?G+
M0!@#;,A&,F=QZP#UX$KS.:_SX!;6ZBQ``2Q`7'VSGE&$PE!=.=,9[`IP1XSS
M/Z"S3E_X3=>N@(>4A4?X,JQ3Q@2J#H<(9?PS?P:/$,34I4P("5#&N93X!E@-
MQJ%`9!A(0I_!!N1*5KK:_P?(018X[!34L,7]"@JLP!D4P`Z<%9,@;+"=)5ER
MH`:,8`J&0@FP@5)6!@W79F`+]HW,PP=,90KN@2-6;N7N]-;Q=(97[B86$NRV
M^1`&I',$4D-D)TW((BOFFROF>0%@`1IA1@PHK`<@P0DXRP](P`8`0%O!7"20
M$5PCRZ1)@1LB!O8P9XK$@1*_EFT5T8XP!J4D>0P$"PH`K"^MD83<3%;T=<0:
M@FRB00Q<!@I<1@4HB*RS$8<HY20(HG3F`RJP"26B20"-,45<]G%(1^\9$C1;
MQ"=>]N.F'[R80#%\MH$7`-*.W=A-TDV@W<;@03V#%F-<"@X015'(W3RX75*8
M3/]3#,.BD%$7^-9N&PG3)E=6E($R_("$$H`"&,"+ZH`!7`)>>(H*+$$%/,8)
M`&"'HD'!/P;YS)!8F++H+4(@I-8FC`'\^E9XK\H`F+`0F/``>-H><(IO#4#&
MC[<%P,$^$H($_;J@4"(?Y3?2B8?OL2E'!'CB0/-.W[1)//9"'+AX1?C*$@0$
M^(\T]PV&*SB%R[R&I[,Y9WC?<+B$(^LBY4$>X$$>W``>[,"HISBY#&7P"H^"
M7,8:G0N&5,;^'9&Y*.\)@$A-V)"K6._:_[@49,$(,IO%W4B1WZT/)('57(D7
M<6"5@+0';)6T_/TD$$$*$D!5HLB5#W9EV`Z4"#82/9'_BIQ`#X#Y3!="A$.X
MTI<S/!>*P`0A(07]@Z,&$7Z'0"09=F$6Q%P,%.*$?=*S2T@,%C"!4FKPO>&<
M%"`!N;J%$.P(Q?S6JD0%I./6CKA(9=RZI2<G'TH%IW#+2M\P"5S"\W,Z&GWZ
MM.#Z(::U@3F^]EL(BB0&&ACVQ48QOT!KZ2!.&/\380X[,'R$`/>T$&+9?A3D
M'FEG(Y+V@*#1V&D[ML,BV0$$GA4^A'P@@2)&A2L/'I1ZT$"%BD>E2FDKE4*;
M-B-XA*#8L`,($A02)&@P:9)!RA\_&+!T4R*&`2]BO!AP\4/#BPI;EFQ!HP+-
MB9]H*@Q%<W1>RD0Z))DAI@<?_Y(-"`KL<5!@TQ@46K!6W50"B=<"#F+$0%!H
M3X%""(2,V5.'F%-":IP!J^OLS0$3!XX=R^OL``T:"Q;X-?'FF#-GS(#9M<MX
ML>.ZDB5#9E:7\9N]>?+H-6$"TH$#;R8[^SSYF.C#!RXWOOO8,>6Z_VC7MGT;
M\VM@K5_GIMR:MUT:/$H'[^VL4!X\>%(5^K(CR082'P^B0'$"14<A)T[$L'[]
M>X43!H14,(`]^W@/'DX4'8]FR0ZT&R9)L?_AOGTI"N3(4,!?!CG`*J"`%8`@
MP0`!UEMP/30$4-`%#UI8CP\-Y)"CB29"Z2$**0RP3@@#I!#```,^^!"+#43\
M4`@5/?\H\<0/6MQ@@"RF:&**"?9H9[?)>MPM-MWN\NVRPQ33[(T@99-MK\/>
M:(>9998QC0ICK#2AD$(*S))`+;/\,@\NDRL@CP)\``((+%#X0`.5A(C!)`,D
MD),!"80HZ(09T^Q(1`GT^^!$`THP8)(X)BEIDDGD\-.Z#>I)<3L3*T!A"1R6
M((&$2S*=KJ,8"C4D@PP,,622$DT]%=54K3/@A1>O0R...$`-E9$\$@/&,+LT
M4PR8`_(X;*]C@'DCKV#M>JVU(/]23+1E=-VKD,^.6<:*:D$P@<`"F`#)AQ56
M()/`,@O`(]QOR<7CB^Z$(&$\&!IZX)$75."GH10JRDB;!7C_R&X#-)&(P0,)
M`#!IX#)6:DD#"6(TH(<>V-!@*1TB6:(G\=`PP"B@B@)*!0$T`(`I,P2!Z@PD
M!F#B*@<<6&&,`;Y-:X\5/MA@CTW2(BL&)K"R"H@!-M#"@4P$D8N*NS3;BS1=
M11-L@29'D\Q'7GO[T3'C&CL6+]$6*(187SDSTC32[O*,V-,>\ZVXWFY;VS;=
ME*RZLJEYC6TXRF"+;+(W.%M.RR_J22(Z3._\SCOKT!-B">ZR6Q6[QLDK\04/
MN0O*@`J66*&0%=:4`C_\]+-/`2DDX"]'G?=@8@.@UCO)@P<_>=#!"5O_1`,9
M9,`QQPT`-F"''38X8;T37Q3"AR\,_QB^>/Q>^,`#YC_:00@IY-`!QPD*X!4R
MUX;,WC<F#SAR5]<84W*QT@#[3.Q99I&2"A.,N3;+&[[5,ELRD\LRS/SI-[-?
M%$S\("4=D4!*&%"0-GV@+"5"`1:P`(0-O$E.4O"`?01E*L]Y0`Z3,(2'4'")
M#:1H`_XKD>5X0BF>D"`)FKH$"@:PA%&)RA!Q6()T'B@=/J5*52)4H`@U.*L,
M,&)8B$&2,_Q"+,V(!B]Y2!*S]L(7N=T-&,O0"VFD:`+%I$8THCF&^JIEA6L1
M:`7;`L*WO@6N,JU@`2L0R`+&52`LL&A-5VA`0QX1$17@H"$620%&M"&"':!@
M.CN02I]00O_`E&B`<P:(":N<P``-D((FB!/"`#`&%*%P["@^<9`+%!"RD2&`
M9U,I``*8L`($($$("#`E$IB`@!A,)22JC,$`@'#*6DIE#*5$@A>&1@Q"4,$P
M4Y3:,4)0"*8=T8I"&A_WLG<W'UE-,5ABHVH.4(`#A,"*X8OF]\I6K+GU9GQW
M:0W;R-D8RR#+?+$QIX_B-ASLI3-(IMD;'@J!!R#4PX:!7-=UX/@=\)Q@.HG[
MT'E*-!Y3D0)CXQG/%DB@%@2(Z'.?\Q-)I-`#"VQ"?APZGH)*XD@/O$X`1W&0
MZP3P"2G<"$=(.-/N@,`$(`!,"LMKW@9\P(3C&6`#83P>\YKG@7[_'<@^`PC%
MC;Q0"!Y]LYGB_$UI]J*8L,EM,L&A3&J:I)AVK&\957+?&;)T%;442"U@TE*9
MZ">N%6"A12`:X.9(,8T"&J!-*2%!#*1P@@U\T'?6D2`%`U4"S@6L)+%"@Z/N
MBD\4+*\"FMH""G9B.8I=(@DDH-@&0A6J&&Z@E-[2[+9BP)W.=L>S"OW.>$;+
M'0/(JK*H4`U>P-;$HXGF5U+3BUZBBAF[;=.IHV&M:`IQ`&,L8Q;5RH473>`#
M,P%A!]UJ([G,5:`5Y,%;XU)CB`")'1+,\2$PN((*6$`1C/!1&WE`ZPQ#0DF2
M#,R0?EI8!3R`L!<LP0N1(,$DQ5"4GVSL_R@A[=@\--#)IDA"#ZA#@H$04$L6
M;@`)4DEP61`LA`63!PEC0+#N7IE@"P]`"+PT@QG4\!G/F&\S@ND,7I2Y),B4
MYEA7TPUPQE8`PA0@+ZFQYE^.I3=A9<V*NH7:DF)#3K:Y#6]0+)]L6'PU=U;&
M-<?BC3-2H1P\A`D/]4#ANGK7$7]*AY^E797_K&,>\*!``%+00.6$4J(M)*$`
M-]A`1.U#43])80`%X.H74-"$#`I`>'Q@P"`\\(+7.4BD(\5@A@A0`I```04>
MB`$0OH#H"98(>3Y@%4Z]M5,3A?EY&V@>$"PP@0Q9P`3BNZV*KR8;&@-&;$HR
MSF6"W(YB[25*ZO]KAS&V6J5"R*]+8!6KN,P(KA6<`*W^\T`SIO&#F3FR+(!*
MR5UC\`(42(6!(8R!YTXT*!/I1P/-6P(2=F#9[4@`D)I:0@6*XIX3`BX)+JRL
M(9:`!<Q]Z4L$XM0,U[6N^=80R_RZJR0W<`D?HL*;0]3;]R"`+5O1UBY51.*0
MS)<LTWP/5ZIY@S$Z(RTN5@L6(("NF;@%1C,)I(W+E>Z9N-P1A32`(@ZY`C]@
MD')M?/</"U!3?`0Y@`^4!`"']%`,0E<B#5#`&AX@H:7FZP5)),2^0-'O44Q"
MBDB(P0R2T((I';R'"+<4PPFFT8('D.`2(#@&)1#")LJRX!@D>))H0L'_&!"0
MB:80H\-Z@1J23,`#'G0FU6_C'I*!]*-TRLT$;%R`$K&(Q&.Y=INC.<9G[L9,
MW_AX;4EV.)%C(]7;VEU(MB5U8U+C9%04P@=_DS+BK#-?PWVY121`0^$V8!X+
M%E2!)B)*B4**@GH4@`QTU8^;Y:#H0I"A$`?:0H(\9(!0-$$4/U#"#SR@@9"*
MU'4.PI"=92"%U-\433N0TWI$YP&/;(!Y,AJ(!!D$[L&M!R1(\'03+%`([9F8
M2+DY#;.2]C84W[]J#\\+<($["UI;Z0:PY`9T36>XA*S`)5S(Y+D0[8-.0`I0
M@"5DQ`,H8!KXX`-0H$VD@`T4Z3SNZB-NR$-B_\1S1`>GLD_*EN"F#.$2Q&WX
M@H(HT("A("LZ9B6&8DH(WLU+PJH`U@10>HK:FF<\>.H#S"/\]DJ#*BL5#`^+
M@&6V2&.VDHE9?.5[`(.V(L-[DD0*F^HSMO#BK"`78&'C5H`$QDBZ#(1`SJ5`
M\.!,OJ#1H(<\N`R[*.(!6(!>*L)>7DX;AD'FK*,>T$[,'(ESZ.H#AD\#FB$:
MA*XG*(8$1J%BA`(->H`F0DH2F^\%3@`2-VP"`L$!;F`32V;15*805L;F4&8L
M1DD"7"9E;L!/@$!E./&E7`8?;@`?UJ('FL(3]N!6&J-KFFH!'F`!#L!9)$]N
MQF?'W`8V\D_)3",$*O_N"8=DX9IH"O6BX"!NQ4IM,B`/-ZQ&R)(,68(D6=Q)
M,<()G23#U>8I.4(OLI9@75`'R]##<`9*<5KO/-JC/4S%M"2H<DP%!G=`+6)@
MHDB"45;@#&[`!S9@"4:**/PG"V1`%)1`%(A`%%IGZ:!O$C)D"K*@>;Y/3@P@
M^V"J528(!7HG_'+*!UHEIF+*^_9M@M)/J'`$`4+M&+GQ_L9&;):%?,()2*S0
MMH8$?:RH'8#+"JRD?>!M2PJAE,(D!S>N3):R0$*H1<B#%!+FYN"$`6(`"P`H
M)<BCKEH$A&X(4$SDVGPJ^WQ'110H"3)@!2D&!2[&!7>"8I*@'FC0$&)@]7+_
M*DL,A`RUY"#0X#JX@SLF!3NLK*#\"3L^1`50*P/R`15D:^&R*+=FRVB<9HH0
MKK;NHHD\S%:>Y6B`LHLTSENVY0N^!;JZA;G&A0E\`#7/!#7_B#RPXPIP8"(:
MPB&*X`JNH.7L4!LZ@0?4A`3P"97\)($^0"@D0`FR@0$JAR<LA1$9,>DLT0MT
MX"=ZP*\JT0/<@"F(81'83BVLX@;^)2RF;@\0``5*``AB1I6`X!1;B94<8#\&
M#`E4Z5\6[714*1!ZP`LV[)>N9O$@TQGT!>*P1IV.(R:/@YFX,<GV,P^:1K?J
M`HN6B*IXI4&;BM6D1B>!`1MM8TF&3*G@J1NUY\B<_VK(N-'A]$8Y.*,`ZD'*
M,(4$U"0\`(FQW)&Q/N152&N$U!$%U^,%CB)!SF,)NN`,F("N$$D.#$!G!O`+
M5.]!,$:$PDP&<HX(IH`(I.#/`DT`)N%&ID`!EJ<$=X"E7`I@EB=0B`<(1$0`
M<LJF8NH#7L!$^L5W).C0-D`!;D0'-F%J@(/4>.,P$F.(GBA#^[3&/DQ]BL$*
M/N,&C"'>NB2ZP(HI>4T@U`AU6N1-VHN`UJQ.\(,J<<I_/NBN(,5_3B0$/^2G
MD.L@:A2%5O`2*,80+D9C'"M3+L&R#,$>[5)+HHM+4-"@<$A&3V55<'56\B$5
MSL=ID,E!BV4*AZ5)+E,:4?],,GP%&H'Q64Q@\99!4+O(&,`*)#)+C;HEC=*H
M>-#D.;Z`";[@C=SQ-1NB"!@"!N2%Y?(H(T2`(P#)`P<@)KS#YZR!`5K'+15Q
M"1C1)U0@0="`#0)6!3Z`)C8P8'0`ZJ2.E3;!EC9AZWIFP@;@V41B`'R&#9ZM
M+'RF+-K".S`,P\;`9!PLPI!@:#Q!#1*#JI"F,?QSJ81$&+%'?%Q6F5YC/ZMJ
M;#[L?)(&6(VH6*DFQ9SA0FM#R0Q40XG6F=2I;IY(:9VA'9IL.<(D]%341N_$
MREHT3_@)CA1(*+K,?TS2`/QU1^%C!;I31&9F#^ZR'H:/1$;H>%XD!CA*%*9`
M!B+_)X.`0D?EX$:R(%!"4NW4%"3^*%#4U*Z*QP')XPLD+5!,I8&@)W(0S'<^
M(`IN9`(*06E3#&N6I>#JCT]Y8\FVD8DTXQBN:AF,@0JHX`RP)12+$JS*B-<0
M4+,,I(9.H`=3`@GHQ)$V("H50)&\8T8^XH$Z58$0S*4<*$04Z%(\")].5582
M*I..U]\L*PY.A7AT4`=78)%P=3!%R'%.)5"DX(5^2#2P*6M&PXANC*H6;K=F
MBWR-Q-2@$5H7E+66H2]^RPNK!5O"B%N\!375R%O4T(%(H%O_5D5&Z[ID\P'X
M81XB@N5PLX]\H/3B]55>`&$0D6)X8CDK1ND04@"6YSG9_X`4.DD,)($8X*``
MWG,%_B65%"P^!V`,QN"5;`Z!QL``*G8JY766;*X$6.C`**G"6A@.XN*7PH9\
M)X-E^Y1/IV;'5LUH=TMJFFH7_],TL@E)JC!JN#%H::-RR2=#H>I#C3A#YPD5
M"J`+I&,)&$M3Y\O+#`<[Q&.@#')KWU%P(4T"/.!B2$0`$BM+1`();JT`@&#<
M#&`>/*0HCL<%I*",(:WY[E4"IF!(CZ("K%1#(N$\K*-W?L=#\*IJ9=1W@><"
M!:DZ_`<[/'!-/&!&H&<#CF].C<&+I699SH="C;AR!31EWT!*W&=TMS`',:=^
M$%`YTM"Y]#>$'@BGX,0)HN?F;O_WF%-B!Q!H13?U@81@]82@'M`$34((/PQ`
MLC(%<%@PT&#E5)=@FZ%W;0LJI[XJ6U:@++&7G'=`3?H'<BX-+`W`AYI#BP`C
MMAXN,IF5,84HFW0L,HD%[YC(,J=E?J<U%ZZ%7-AYC`8"-9E@.0;B2%$@37R'
M!'8@7289FPL87>V(!5#NNS(B!/[H4NKA4@Z2%%9"Z'A"I1.Q@C7)CAUD'M;#
M`-C@`YS`#0@`ZD0F"`I@#,8(`1",IY]M!7PFP5`@"A(LZY!``9[M37[&/AJ,
MEESX[`3LE&:X`!;!*>(.:5[#/P549E<9EGD,G\<F#W@E+XHUB2#@2*:(?<'I
M+J[X'[[_&JK`>C+`D:XIXPU283F>;`5V0%.L(SYF[FK7Y8\_1#Q(I"_+F`1<
M#Z!"I/G&S$$2Y([KX08&D@QNX$CKN([;-ML$P#I,H@*D@,]>I';D0*1:<@H0
MX`L\T`,/8GD\HEL&@H;N:CH2[0(_0G\/I+5'-26!H*9.^$9"(=1BV2Z:BOZ(
M&[E_5C)25B^FQ0J6P01N`'[2;'X*A-?.*+8+I*6Z!74X\CK8A`)8PCL2IB".
MQY&0``N\PW?7.U2SKR#6@Z%*>E-.=0L&>3S\C=VF(Q\J*WIQR"[9L$`01)U/
M16?0F4#2&49,Q0,0,Q]H.8OX8D&-&U>4"'Y9>0J'J+C)=S2,_]N;F(5IH=L8
MNLB+H,M`L"`T5^!P?QNB670:`.JN?$#[9)2Q%D(VM6LA+L(B\%`;0B"$`"F%
M3H`X-0"@$G&E>V(4MJ"^-?M!FL\)2L0)$D8""&##/*$.8O'LTFP3\6$#2F`,
MQL(!UH*N6+$4D4`48F`%6M$!/B8L.+$[$0@!9)$3:W<`;J`./,$,/&$TG$@R
MC(`'#J`8PSJYE_9/G5$TQ$;"J3#""[W#,Q2N!3W0R:>+'[TN?&6OY6<'LIFQ
MON,@7&]-L*.,UQ)Q[HI57N1X!'G29+J.Z1@-Y.,,O@`'-/L$6F6.%<0#^$P#
MG(#4D]0#5B)A4&`%UB]'JMDC/GE%*/_9MU=[1@13<K(C-6>[4Q+-V0!IC'P`
M"WI@"J8`#HYJB7L%"I5(:E99TK6GB2BW&&BMW`'02ZI;9Y;RN4H<"`K$=[@2
M_'PG)E#`K;Q#`IHA)<KB@&1<"%)$@)$+N4)(81RK4HXWA2QED#&&)\#9HBLK
M5.+`GZX,<Y0+G1=G<;1#XUNDC-Z]C[4#L+^CC'T(#)8A+\KZN,]'K9F(,H<$
M<W6+?%LY+Y;(\$"W'4S#&,[=BS0+N4JII@[W"Y:CIG[G![X/"VC@.3I].PJX
M%(H@Y5(.O/!P`4)D4MJKR8F<8E@ZZY%<@Q][/4HBD:<!$)I"#X(@%.7S=#:A
M$.1U`S8AP4[_B:Z0``A:)L&JTF1B8`Q60`$D`&2](\*BX.Q"=L%R:@#$@!C@
M+C-[@V4=_:[G&JJJT"X:LXD8D^6CL6RH438:O?$;'_,V_S6DR,G"9`5.L/0:
MR"`G!;!=CZ"N`U-B[SP4I*[,`[#4U(XKQT:'8J/0X+%#:M8O1DTOIOF40/BE
M(*?R80*N=`)^-QZK2TU#*-ZQEE+6!7CR1)2_NT3FJXP!Q0.USW]*X$IO16D7
M]-0\W_,'[FB<.RBOY*O*R$RRY8SZNE_>J-[5SB.T8X``Y0%Q(CLD50,``L48
M`R@V&-RP(V&]#2AB&*B`8LN2)1*7D!A%XM*2"F@,H$%306)!'P4R_Y@T%,>`
MRI4KA9`$`F3%"B$L:]H$4F#%DIP;#'SPZ?.#@`]$T1@RR>B`B3<F#CAS]D8I
M,&=-GSY5>L"ILZG`IE9U=NQ`G@-,M4ZEJA7M4Z9O9BTS`=>8,2O&\*SP`82)
MC[L^?'SA"V2'D!="A)!(Z'?#"0,D"%[!`:-4J2*2)6LKE:*4MA3:.O$0XD&"
MAQ-+,)*PN`1':8I;)&Y!(P"V`!<:--#6(,$)`P8:2.DP(PD.$B";D`Q'$D,(
MD@T#Q@R,$:,A]!A2I'R(40*Z%`E2H&>/H4!*">DH4)0P,(#Y&.1>))DA9)7K
M4R,\G,J_OS6_?/W\\?O/3]93P$05(%19"?\8%EE3$6A5@F]$U=]6_TQ(8846
M1OC?61D*F!\-/'"XX7]/Y9$''GB@4@@>22P1$0I+*(;""2>4)\1B!*%`0@4&
MG(`&"@(8\*,!'GCP4'DOA.;!CTG&YI$`.@(I@)*#:$!DE#TN\1!L'O"A!`,&
M;`#$%U],,$43/:"PXP<>_+2!8=09@,5A#JGD@10$D=#3!RXB%,-/0M:)(XLO
M?'"0$'9^((4<919R#(;.D-4H6R`Z&B*E^3$%5U9*%3.+%<6`8(P)A110R`H%
MD"K3J7;EL0(33``AP330H0`3$(6UB8(4N^$FA`0:_'0=;R@@0=,.;2*T0STD
ME%?!1*ZE9M$E%Y'_L`5')U00TA)"[,#$"AL<98@ADPPUZ*!KZLE$(6#>U2>1
M+TA1[@>#ROL33BN@P),4=0XYI+Y#&G")21F@\L9::4D%U5(+-O65A@D7+%8!
M(2S%GX$%E[7P,6_!%1<(I?:%!1!]^=77%VN$N<,)&V"Q`Q!=^+7#LM&5AP(.
M#TR&<V:<<:9-SPO00-,6ER1!0A*C0#L1:ZR]%N61M3GQM`:\.>$"(&*8(4@F
M(>^Q`1(K##0``D*DAT0)UPV`W=C<L3&`!"48"D`)8R@@`0H#*'"=>>B-D=T8
M0L0P`!,#3""(&<0TBM\"]57*N*7X/6H"AYI&#GG!5V%U##!*%3Q55DV5_S4I
M,!:.7F'CINOGH>..OY&*B206\L5IY5W+XNPZQ@B1`4)TM&-Y`DCQHU!^=L3O
MDD,R^6/RL0GP"=1.+$_:)01IJ8$3`!M+0CT3-#%%#T+^N2:+2YSPPI<X&@#O
M!Z)],&.,=I;7V+S]MH^"O$*@<#^1Z+M1I@4F.'R6KT2%<ZH[G7^.\:`W'",/
MA5#*,CIEA66`R@2D.M4*1I4J5IE*)DSX03/0)`21^8`A0MA`#"H0`PDP0`(;
M\$!M>K.!VNB)9B4\"`GN=YK34,1%$\%(TCC"D8\4)"]`0,(2P!4'?OD+7D-"
MP1<*T+*[H.!=:RK>OO;U`7OA:R9'LJ(28U`/@?\1+(!:&2!4V+(PK,1G*PC$
MB@D6D`<"[N=S!J(<ICC&L648@U5X"=E=](*7OJP`"%)`2)B^4#(@-,9V)&C`
M`RA3&<M@9C,^H\$&DH#))`PM(ZH9A6L\V9HH#<D)4'OAU(;T@AZX1P]["$(!
M'#"L%6P""`@HQ`#0LP+C(``)!E#`&(IHG#'\H`3!),YN!@#,30S`.EY#`!,V
M,8;NY&0/>B"&&=20.?[0QSX%[.:&#&251SFE+%4Y2U80&)5R/J4J;#$C?T@'
MSVYZ<RNI,V"$WE`B$Y5J11S9D6!.8R,6/:D"BYE1!4BP&/T9H(L[6BB_A!0E
MAR8)-AV)4FWXH($?]<C_1VAX#9#0,)$5D:9,4?">G?0%+X(XY'TS6BB=ZJ22
MA.XH.M\3DKYB^KT9R<A/+\B"'+@7.8>!\V%KM.?IR/(&8"2(8\Z`X*?.,"H,
M6C!5IV)5`0BI`1H)\@OWN]4.#`"`NN%-A5+HE0H9(`4LY(T$;"T()MDZD9!(
M)",7H0@0(7("$A#Q?DLX24K\!)25H"!=4?1!_7PR**`(Q2=!TB)/Z#6O>+T@
M!D!@A4GRD0JNN/-1EH/05@:H%`Y]5BQD\5Q^*K:YSEWLC50X!AY-``(*[F5E
MB"09(DT%!`V$#`@T0.07>KL#-,4(1S:[&21U1LF=:4,$:ZA')HMVM.BZIC5;
M_Q"`"VOC`E]53VHN2)(!QI`)PZD!'V?`QPUB@(0].*`0#KC!``BUAU<6H&P`
M2.\F5L`U87P``2O00GS+\(,QX#>^T21F`=2;2RF@P`$.*$`UKTF%BBGN`$:=
MYWX@9,X\6(5!5A&+@#B\%@V/MK1!S0\\25=AQJ7.PA5S1CY-5(`O\%,E%6#(
M2I:U@1RI!`4Z^A>0?MSC'[%(`+Z20&R*MSR*+J\%M?F!!@;Q4HTNX1);.-HE
M4,"=)C0A%"M9S._>53Z5`*LF\DJIF.E4DZ&L:26(RFF8?<(%+1=@4E_A;%%9
MW+C0#N@`KE4*7-I1#"L(^BVCLF`A2K4JF<B$J[K#PO\7`(F7OV'!`#%X`0.F
M\0,&]$0"A%()65=VHP\<QKG.=5;2+K(BUH`$I"5<07`+@H)0@`L-.I61K4\0
M@PWXH!!AXHE.A_N0&,BH(3,BB;=.A848H$'8MB8(09;`!$9<-A4`LMR"`@2!
MAH7%G6=Y0P'@R&<Z_N=`%F-8`X]!!5*)"@3>W@O+]K*"VFXP!K454V_%U(57
MET?8*C!N)"5)R9Z%8`>97)'15B/=CT#-`[=Q@@=X8V0!.$$(*Z!"'0P7!%FN
M(`BY7H'8TFL>(2``;<LI@0328[;F#',#)C<``C0`@+'1;0#O?=LR2["!,20'
M`09@`^'>0P7\;!//+%;+5++_/1;+-8PJ25^G6=!2H*9L+BOR.?'HB%XI'GPH
MQ:/%IXE@W(5E$;1W+D+3CX4$$1;!INPGL&)B*V!=ZQK/`Q_YB`H^LKS9:*`1
M/U#"#S#J@D\@A%HOTM&/B,"]$BR&?5TNB&+*MQ@T^<E&*##6"7XR(YK8I(1Q
M(A+\ZH=Y`Y2@3`@H,6<A,"+$8;V;!8H*XLH2EF58`8(>.U5.*B@3/!3`!]UR
MM0>P`&^^^*4QO"3(!ZS!@(9((!N\H8G4*$VS["6A'L[%Y!9XB&H=MH;6M.H6
M=.ZGKZ-DP!!CM@E!T@43*0+E4#\I7_M58B\2\`2Q0K&.D(A"JP+D`RD0L_9I
M0ULY_^;$89JS%`>P`(RR9R6V'Q9S%222%6-A`J%2".A@`F=@#'OQ!2VS%WY1
M6X:U`8CT,F)B;_E&,Q#12#>#,Y@Q2<K%&7E`<$9C<-$U"IZ$!B[D<$^C+U3R
M`M9E`'E@#&>@!H2`-;N4<S!A'-@!'0,P-BDD!7CC'1(```P``-5A-@P@#```
M`$1A<E+X*TBH/@J0'0-@-Q]0`I%0!6;@"6J0.(NS>HTC3N%$;J7U='$H=9*C
M%5AQAW7(%59G(5P7(O5$=`/D=7CP!::0!U"T!"#A$8:!)P5U+3X"/'3R$RB@
M)4\B490X)**Q)$[246AP=W7G`9^P)7WW=QY`*T-S"1M0&O]:,@FAT`03L!SW
MYWY?`A.Y8@`M$UP^%CY,\`5M]P$NX0,+91WEXP';`@0;H"]@<HS_(B^`X(H3
M,&>J93"ATX88XDZ?(Q^P9P*R%V@15&B%P`2D4BJ*9GM`$`.*)A,CDX$J(UP;
M(`$_`!0QT'PHX`'34!M_0Q#45W!T51I%@TE'4RU#!`1QTB8[%@<"@R5G-F:3
M^!+P)GE#`9'O-XOVLA/>\CV(\F7"0RN,L'\9D`]-=T]1L0P0@$9@X3ED\3E-
MT4:6$R#WT6TBEB!Q5`!^YF<1"!=]$1C=XA=K4%L[L`9=8#)?T`7`U05%B5#.
M)@05@`,-D(*5D1F7$7`\L`-#8S3_,PB06S!*#%<]N8$;R7,"0%`(9P`";5`+
M0LA*"$!+>X!>181+0O`VO#0>`V!R8W@VT_`![Z4`Z*4,/P`XHJ=SW#$`R!&8
M0I"7WH($@:`'XB5'SK!-?MA-33<5(`EB+J8@!L)-XM19Y&:9:\2'%5*-__$`
M'U)`_E$6`U0B/M`%NH<']<!C-%8>#>41K_D"!K48.WAFR?,OK^D!#D=W5O(1
M0<0143(/'C`(/\!\!O`BF'1)SO(1UU<F$X``7U5%:D*+0$"/!H`$7V".=6(N
M915O,4`D&]`J/N$![Z(FRMA":043R.A^[Y(%3:`##J!:%U,@CMD5E))`!N-_
M9&0"QV`,_[07*KAG>U1502BP0;HW,GZ!!8:Q;[&"&WKB*Y3V$\V'*]6724/C
M0P4G+:>!!,:"$$@P7($B,!OP$_I3/N7S(RBP:^EW+RX59C2#:XAE`/%W*GFR
M)D,A/)Z'$YMP601#C6FD5`.41IJ23@63;0]21XYB1DPQDP=0`&-!!:(2I<8`
M`GF`DSN0CH>4;SL@@J@IE$6Y`R1(/SP&`_ZF@E#),SW#7$8S-*5!@_SB!+YR
M70[W(S6V`A$(`B``"VK@"690!S?`7H"*<YNP!_'E`-0Q`/V%7T@@!3&W"4R`
M`&(C"PI`2S&Q!\T@#"@0J;(T`%,H8%K@<4*@`25P8.H5!&9P3?\A($<3]IF6
MXD:H=Y)703&=HT:8V6$,`ZNS6CGOU)D3@B&,XY+]`8A<0:Q;L2$DF1664R)"
MN0)XX`,D0&LK`1$\9B.&MR/7\CT048,F"E$OQ2]1$ANO\1IU!QNB^*`%<0G.
M)2V)2%!+0'W]XP.\-)V#HHS762OTN"94)`3:28^_>!?DJ2;O(@0LLP%'LEO(
MF*^($@7<LP</4D84\ZNMNF>9N9C=QC'^"4'>:$&G\C&F8GL[D!.YEZ!]T2;W
MTU!20RBZ(@$20!#O.$/E<4D%AQ%427T)H9U%A`4'04(EM`,"DP\]<69LMF,-
M*1.2%UAF)R-G9B]"D!,T,2CD$A1#D7__'8E9EL*`#Z(PE@F!E1FD#S*QCD)'
MV7:`(3"3KS47QY`3VOD7=_&3@1$F]U:4+E.41:F*,[(L*``#3`E)3LD9F,$9
MS[`&U%*5%`$^F<B5HO$C>E4(5)JGL(`-:F!-#,9>ZR4W,L%?ARH%@8.6N_0!
M`#`&NV0<`]`,4H`$8Q"8"/`#RC`LI0L$RW273&`<@I,=>U!$K>0>:@`7!#1T
M]NFJ9:$I"?.['39.4G>934&2Z906X(0?O3HAP6I`&3*L^F$Z49$'V10`5MH%
MII`37;`1TLJ:R_)C,?(]%?40I-&M2H*X0%(;H0@ES;EJ2F8`UW=J4\D1U3)E
MJ<D$I.=JZ/.T_S\QL%]E)]QBG76B9@JV`Y,&+^(9C/IBGJ:()Z!12.LY)&I2
M)U*@90VK(`.$>O?)P902(B("@-S6'P."1[(G:""P#(5F*N.8*NFX%R:R@0GZ
M!?A3(R&D*WI""E(@0_4S#;SQBZ)6<)I4</7P,NB88RMS/PF1%RN`"@+3&.;7
M$N&8?CZ@>4,14]5!))=7/EAJ6#)!HBYE?K1R%^*'"I7"@,C:86.1!Q-3,5]1
MG_T!`>?D#'&\Q@U4`/W9,59@`LZ*%Z9"B"W36T#I%ULZMV":!&C2$VS52$WY
ME&DJ&0T0(Y?@27!W/*$A&G):I_)7@>@@EK`@:&J`JH4*N\0Q+$64'?\(8!X"
M(06`X!W=$0,PIR=9&`,`(`X:T#8``!T_4`;7088-408G]S>!*1Y"$`BWZ[`7
M,V%^Z(9()1:-LID`(F)[EKSX]&&:.50NR;S_X!_%ZKS&.L+&&IK<W,T9DB#Y
M$0"$F)IVD035`B1VBR9#H4/DBR7^HB1@MJU$,CY30B76-0^=:'?D6@\ZT2R7
M(%<=40&2W`4B``$.,`53$!.3UB_]XGCWUS+;>46CD;,VY1),4+BA@3\,,22&
MU$(3W"]E@@3V84;/^\T=S-)V!A71O"'IY%K=*&C>9FBCTA<6%"8)>F]]`90W
M9!"Z8P!24QN$Y`2YYA,16D)?8J&CD$GU\$3_%<0$8"(8C/&!,3$7EI4!-A93
MP_9K2R`RA@0$XV-V*]$O.V+%)31<-H9YMS9LE?<%8>21J+#2]^%.!X*'8_%T
MP(!ZH)54W?R&8#&3:\PPQJ!'C'L`PJ=H&2B"(EC(^=8%1*PL-S([_289>ZN"
M*9`9.'`D>@(;\@(DQ5,;#[$C0/"#IZVG5@`+>]JGD:H>RU&Z;S(KV!%6```(
MB"(%;L``R@``=!,>/R`,*Q16=",*4KC*XJ'#;H.$AG*7/Z<&^ID'-$`#UR"]
MCL/-$=O!!!*V#8-TV,;=)M!TV686X@TB5<>\WCS.Z*W>UPT,@+C>V[S>F+D@
M>%"4)K("!!VMTNIE_W;B4#&2B'6:B$)")4C6T>3JSQU%D6TZ)$L@`!,Q-$G7
M#@6@OP!\D8Q1B^63G4S0KXGUB_Q:/@K<)S(J:BU#HB^P6UC0GBM1)EI@%=7[
MH^)<UROMS:W'9QER'WT6*B8L:(66$X5P`^GHPC)<6X5,0CVQ&*30PPZA`?8H
M`33!'86Q!"'C7$X]"D1\08?F:CO@`PY10UAJ#&W@R4V,$F8'HPVU&,(&H\/U
MQ%?L8T3Q)"AE(SNR!'-B?C$0+AG`")IP*0(2K.FT%:3U(%NK(,7J>NE];1"#
MA^?6#F]!I<MP`#@);PJZI310R&$*IOE&?9^'(XZTMT\I&3BPF[OB!,V0)?\D
M73TO$*U?4(%4:@Q4():"1A>0:P;QA9:F4@+(!*(#H):XC`1HPQP*("O(`3A"
M<`>>FX1`(`OJ$`.FJQRS;,M,L!X@R@`?0+L(4*A7LP<FT-?5JW4A$-\<#-\P
M_DU5H==S>(?!2ZN70V[I7MU[>-[L/9K?[B'LK2$?#""5^>A%^05Y\`7C4U%H
M<!!8(@`&)5%T`GERAP;`8[@UJ,_/XXGN&]`^0&KX'24540\+\`;(>@`,[="Y
MU'9G%P/<,L,_P:4#S!(JXQ>@1W%,4`$*I1+H^2XB_68[,@"NB`#7_.TR'N[W
MY-TM">_9K9+;".L@D`H<NP*`RA?-VA=\[#(E\Z7_,0,G!,$04B,$P+)"A?&.
M*ZLR,,&F1>SC@)'(*],RAZ:GL-`/EF4(X[-C9F<=:T8D]((^+Q_G;0=3U[G?
M:Y*TO2.)Y9E2^G*0^8`'S)RL\!['3D%:R;I4![#!IU7>?.[-:.%.3)$PQS`+
MH<*X)M`77)J."?'8EA[9F-X%#3#9.%(0)]B4I?``.$!*"H4;-5$]67R+A9"G
MIRV6H!)HK2[K!4!>YN4`F;L"#'8#AXK+IE*H2*``JKL'LB0X_E!?D(I?LO`-
M,<!?UC[+,;<'TS\`#$"JA5H`07"[)QD6E+X`&VQ4`-3N=NUZR9H?D+E`YIY4
M8#$6DL,Y\)W-$LL?H;EZ_XQ/1]?[I0#Q!<^&+09.&!"`HD*%@R\,5$"!QH.'
M$Q70(/3P0H"`B1XX#II8P8`'"1KX"$"3<LN6>O5VM*RWI*`'-!'KT<!SP-G.
M-P=63&FR`<@&$BB$Q#B!`H50+"@<"A&Z08@0%$F7"-V!(B.*'3LV?*6J=(-7
M(2.7[AB*I:A1$D"U]'RS$YBSN77ETL5K5R_=O7;?O#$!P=F!`W'GYD5<M^XQ
M$XV-+;,2V5BA`I4+468"9,4*/#Y6^/#1Q<>7T%U,=R$;UH"&9B4-Q/"@X:B!
M#Q.1QB"QH4(])BLJ?V8B56G7+P4*43EC#`2L=J@R&(J#PH`!I09>3*S=4;M#
M%/]`NF)!XG7,!BS>D0`I*\7#!S0QIE?WH%Y];?4>XAC*P(CP?L*&$SL#C#`3
M0LA#)V!Z.L"$PN[J"R_$$(1K)PF=8>R898RA0KEE\A@-""8\^P*U+K[8X;27
M2JRG"YB22(H$%TFXHH$'2BFEB`8J4.$$]6*HSHD/JGM!`H\>(F$%$T!`,CD3
MT+$"!&.>-,&8.H@Q(XA"]EAACP)BV`"!X,;8(P8I8D!B`!3&$*($#6(8HX08
M8AC@!RF.RH+-,GZ`\X,2CI)"`10&>&T`(3Z(`8$_D4!`$C/4V`]!&AY88,'_
M&IRT4L2<@4#`!`7;+[#!%IRKT[CZDS#!N"H%YA]55V7_M=5+&X0551IX0-7!
M6.N"(,"XWL!#Q2[P^&(#-"S2R(":1)IN.HD,FHXD8ZWSP`GMAIQH$`T\$J""
M2^K!8HDD6DIB"Y2,)>'7`B4E;(\IIAA@+"#"*VJ)W')#X8,?L?)N`Z.(^JK>
M#T[X*K.AEA`B-Z*DHT@(M(#PX:O<=@`*`4GMJK76P_H*D"=0+=X+L,:H@"PR
M$_(P;H7+"O!AA\U``VU$&D@+,6:OC*HWMFD8^/<#!D9Z,[:1)"!4@PT\6YDL
M%$C8X0N333@#!*:5LX*5YY8XB#KI[.U("BE>F"\^ZC8#.^RP"]A@I/6JMIJV
M:>N3(HX,\LF)OP0E3>R8`\Y5_]`$PQ!4\`#!;*VX/P7?Z#C*92Y4SIC/NNIM
MA1!+-`UR%1MHB7+*22"87B%P:$#&!E3(:+H*A%@"8>H.VGHZ$H`HP!A>VG`R
M]L>L**8Q!0FA<H]-RD2"B7;+E**$#6)P<P`)`%#@`RXD*.&#'Z9)'H#@?XA&
M%#4!^$"*:<11(`9`@B_A!P!X=',#!:2(Q`)%U>@[;QX:6*'`OV^U^-7_G!F\
M;YT0),S!_GOJVUT((YA8.:-5!V15_>C7H%E!8($*Q%3_G"&"7J4H-"38PD6X
M$R^.>,``2[C.D#B2+(F`Q&S6DL`G.L('%2XA:3+90!(N,8J"H($$2>A"'B!4
M&`05`/\H4-D!:(92,.&0X`0?2`C2&#:4HQ511PDARA>`,,2EA*5F*+B*=ZB8
MFXCIY'X%I%]BX/*&7&T,@L!83&/>`++(+*,0)//-95;`,):%:$1?P&-H2!,Y
M`TC%/0;XP0^`)H62>,`]$F#`>KCF@69L@`D?\@%ZFDB:`E`!%B!`1QLPA!QC
M.`<ZTDG;=;;&MOA,Y"E@*X#84+F"'9A-"FA+RDCJ,RW[X`<5FNK/&"D&H`3E
M08=V\R(O_V*J!QX&0B$XP#'TL@S&+*,8B#-!(2))G,^0Z#0I0DT]DO"2RFDS
M"6(Y`>9PM!#:6,U%U9E.0QXB+R,MITF)`X$5GO28:"9(#9[_,$,F$.`5)"#A
M3U@8`*$&$`-"Q>!\4OB``C0`B`^X07J`$%]#&:```]R)H6Z0P/<PZJ;SO6E,
M2`B4!:C$J`0A\P`\Z`(/(K6Q8I[15F.\VS$T%LS!Y$%";T#F77K"H$HAT*<M
M!>H#:.72,/XO#S30YH@VL`2+",!86,2(`<1I-@$LP0,NN%8')R*`#ZAPJQ-A
M`$BJN@42C&()9D7#%BYQB2ZL5(<:TZ$)U,6N)?1.BB2@2FZ2<D0#4&5A2%A+
MP93B%.K@E0E8($I%CC98`\P)*D/15T1B((2($=5^13W5&VQJ6;UXC#&1L8(;
M4[D9.3*LFG8\S6GP^(5Z[*LJ'W#"_P\TX*,-2$`*1HG/"_I5DJ5\@0FM7$H7
M>E.(IEWR#$VZP9,.(#5#4.T]5WM!;;AVG1=05PK4F2(6T()8J)1GBCXH2RG1
MALZ)R*>44L!//E!1T[@H:"?]\PL/D1D7"+AW+CO]E`,=5#\`PA<O[0"0"0YG
MC(\YSBL?^@QJ2H0B%=7#<N!*0A*82I72G8`D!V&+ONBEE!,D!8L5P$(AE@,+
M*S3-&$T#+8%-0(4#%.(`]ZR2`_:`@!4XX+9>&@,2MC0^!&P@QP.0@C#()(0!
M`/0.`!C/`,:``%FHHP1(&$..8U"&\3&AGTB(P0\4,&,$%$`/9EA43T0PLJ/2
M`!(Z+!!/@?_JTAV>2H*A(M6G_!=,^OD4@9RMWZSP3"DX`R@/7?@6:.J109$X
MQ*G2X4AT$STL`ZC0J3.Q5D<N$ALE@"21EY#P)="`$AG68P$!H`NI!+.``/VD
M">W2UP<:.Y$^]LN#0\F*0[)#'5=S2;OU4MM$EJ(OZXSE*Z2`EM8,T(0F[&'-
MELV4%R-TL3/:I1V,,4$SVTBRT58FDGA(L&H?9\<4[8!@5#&`!*9A#4%F3PE.
M4,\+IH@""3A!`HZ,[%@\<R1X@F`9\:2"[1CQ'$.XYT=525;`!6Z0(E7&X`<W
M>"%`.LID_<NY`T\6?C*0"F8G^[U>!$8N0W`,`%Z<<(/QU-U*E>;_^IVK,(>A
M"S.@;;L5//*N1)-B-UU".9A0+L(1+LJ\9'DTKWP%"]HD@4@*5CH2%``61R>Q
MB6<7F5D0V,4FP-\>"&&&1>#C!F$X@XT'4&,'%,(!,:BR[O:`!`DH`P6;6(&7
M!M`!`%RY-_?X!IF`@``$3%D#6Z>[[^0TVB!\V1-4D"EA%K"`-=!`!&]80`#Q
M3-2,Z5""%[_XX^4,.%C9^8#,YC-1&WBIRT+0X[Q**FF,F!(!.*0>F(OJI$F2
MD8ZPIR/&$L(+-'`M#_"!`7R@R24RN`5OU0,/\[TI#PM#F``X0`=-Z,%7+"S+
M]2CEX?K:P!.SHVH.4_\J1^1J*16BD`^\_X!T5%F/*TO0A"D86\V66C."/(YY
MRGM>01@*V3)&2]H"`($TCKOCXT:D(FY&MEYET0`&6!/9DX"^`J\*F"6I>!BE
M(:[E``&E<Q)Y<KI]RX`E"#B#^8H,1"S$(H\,+`H/`Z6TP:*#Z`A0XHX,1,$,
MO(0,>!M4Z!ATT0G!.3E>THGZ@L&=&!`(V2GZ`2:10R,'R1L3*(#&&0VO@+EL
MHKG*B3`'^Y:;<Q&'J0"AX98=X,`D*(H/PAP28((C03HGF:=X*H99F`7&Z"7Z
M4H.I$P0M>!<@V`,4Z*<-<!,@`!0ETQHW*8'N,0`````W88`Q`0!E<(,8T`#L
M*0$`Z,,2^!XWT?\`"7@30"`30"B!`1`$,_B[4BF$!:`!PRN0`O$/,#J_S$N,
M7(&+_C@,3IR+8R"Y/FLIRW,5BMF+^CD_H>J\5_3$PTBVGD`J'!H-F9B.C5`(
MA!B)A\`(FB#!J_*(3WB(27,!#[`6/IB]04C&)5B"FQ`!4#,5O."/P7&&0IB`
M)@@%=#JBW#J=9&&L9"FE=`JX$_BC9E$/@?L`D8B!"E`U=LR")M`!!P"#/:N8
MOX"ZC&.IB@'%PVB,8WB2)GDC5"J$.;J_T&@9;#(-FML!O!JL&$"D1"K`?=$P
M</N`AV&8`F@,=X*%"TD.`BN&=LBW-Z!`0P`E#YN*EA2L@OD^+%I)$A3_$NIX
MC<'",,;B$:.@BI;$*[QB0?5ZQ4QQLSQ(/%*4$(O+%+VA04PQ@4C1&PBA'QO4
MQKH(D$)8L0*`!./XL_)H'!*AG"ZPN16YN;(LF-Q8@HWL0)Q#2VG40N-H@Z-K
M$B^<G5FP@C&T';UA2A/X,F+(A`WXG=\QJ`\8J-<`.PU('D+B`D#8'@WX@#)(
M'F6(AA_@`D-,*'$0AH7J$WM1ACTDGLDZ'QV81$*@@@FYFT=9@6S4+WW,O,["
MI<@+.9IZ//:C359DE=;\1(O9/)3[(LN"D`4`M'H0B"Y@JI3`EF?AB(T8"2=`
MB`X"B:I!HH[X!)/0`&O1``%8B119@%1PD`CY_Y3A,XQ"L`!O+(&#^!>$Z+[7
M,,]D01OK2$^;=`B(FX[X!*5Y3,?I`(10:(()*(#]*B#&ZY\R(J-9)%#%V"_;
M>8QEB*;-Z(V2`8UJNB81>4@4Z9?HDP(-^(%$4@J8%`KTF`YYBZ,SH`*0E$`5
M*TD"6P8*K,"J0(H..P@TZ#"#^*.#6,>&6SW[+$>KB5'Y3!:W>1N*^X\Q&IF5
M^KCXHJ^>`+6^Z0F3`\\BE9`7;)3["L(5BR;;P8.7T(QJ<C!M8L(F+,N;(PH2
MN(2UF)>E>A$749E*@II+>I(,<::[9";;>0.9`J!R4`,PTZ?ST`(#&(!^XA(L
MZY[A>1.#*H/74)X88/^#9AB?[-D391`&0M$3X@$`1ARHR:+($O`=(?""]:$"
MNZBO1UDI)=TI_0(&4G6&&L@+`LK-77I%&?P?_C#-&NR\_[#-5<E-6(0565PS
M6CP_".F50/.!02,]*4@(IC(;CY`(6DH)D0")>9C.ZH16#Y@'--@6P_LXO+C%
M-KNI32`_+O"W@3N:^7P/ZPBX?RF8<C*(URK7$X"*>GD!$'Q/`R@!H+"`&T#5
M7:T8HMR5?_0\^GFVCW&,D4DE'S".@06-$$D1E_"5!@,"U(@^()`.<4LD#$,:
MTD"/<%(:C\20!X0:*X"%8H`2K&P'O5F&-V#!"N11^52U>5S9\UH/KF*6^4#_
MEF21-:ZR%WLQ`!]E!3"`%?[0K`+`N/TB2@`9U;[)`S)#IL`(4&8#G&3+I011
MHV::I\E(F1T@0FX:RR1H@"\M2Z^P0@W+0J,84Z%8@.1*$B2!DB<I!CC%G[PY
M%6`8D#R`,3T(@@)P@`*8$QJC,0=0DT+I)P08`P5H!K_MI[4#@`V`,B18`7JX
M`S*!LKIC``!``00XC[H3!2G`$BWX,C,`/%3%BS?@`1HPRL)P6E*A36QU+_1[
MT@99RG*XFX]3/_UZ,P)%C%I5E3!B/]4%A@9RQ?-CD-7<)<^U2L(X*BX%EDM8
M"(DH5A3HH)J8-+&Z"(3Q@$\0@$4$B>F="#3PEB3(_X,`0"-5%4@"F9NWW8E"
M(+\>,*+P2Q8AL#\4N*ZOR(K404\A((V:85\@",?HH@VN");X4!CO\!K:D`)B
M6X%.7-53!4AL]!3-FI_>+%64LPOAK925,X'(H(R6(UAK(XW2>(FP+)&&Q::8
MR`KWS88,O4@DB"3(2AJ368XV,%LJH`+0"BT",P:;XK@WZ(>3[;>4Y5'[Y%$.
M(\<03-G[8$%&Z$UG$%^<RBGP-288Y)25.H`0*`!2@[R*06+]V0]EBE/(0!S@
M!-$BY-(F!#JNM5A^D9?!\I;<\($;8)K8`8%\HV%C*,E96(:V)0QE*I4#&#R_
MJP,'\&/"S)(]V(-"`+L8>/\D'),"98B!=^FG2/"'MHLR1*&`;WBR\<`R*AL`
M*_/3/DR[3)A$3\"4Q`C=H_2;`=$;3OP/S_T4'5+5]BLJ\'ROS:IBW&1:V_T'
M!+Y7_;I77)Z+7:8+!P+F4J4+6<P+7#'0&OC!![85!P(&X=7E3UF`+UC"T%B"
M99T6JQ(2UKN688G"0=B(V&#&Z=T(:IU&/``UIE7FTM4)5+W7-P"*";``"\N(
MVO@`^O4!]^VC1W+?]:@/(8@DK?B`#?@,V%BDZ^@.[U"/#MV`Z<H>.2"_&]B)
M7>YE!!;FWJ48=J8+]?L4F4KGB?YE6YEH9?[>25'0%E.QR<B#ECNXT1@-0&LP
M%'G_B9=NBG`=-R60`*[H.1`M@!MP)WER$A.X@1B^2SH&IJ,%#&=(R7):V>YC
MZNARZJUAZ%*:KHQ@N&:Q+9HU+_-:)`.0.%30!US^:']<@!58``J!+V;FBS(R
M$.+=Q#RP&Z,L`$[L'U7^05-UADU<*;DX'/PQ!MIYDA5P6((MPK+TIB\5#1))
M@JF0BL*RPM4YCB/A:2^D`JR,DEEH!SKVF-GU1\(H@#LU`R\0`L4M,B00`HK"
MLC<Q'NDAGNX),F%@'MOB@A^X!V5(*.R1`&$0!@#X'H1*9`9P$]26`!U8'SSV
MZ`7@@1#`E'/YBP48W4[TZ+O1B1"`NEQ69@E&56`^593K_Q]8_64)PNB0_N6+
MP6A;!N_#^&Y,P>CL!EX&D45@OFYC)J!@7F;SSFYL/0S"^%4<,HUJWC0!F-:E
MVC1)F[1K\2KK'!+JQ:(D^#WO1>#P!AQMC&@$-H'Q#`4S\>&^8IC8ZR/0<(KX
MC"Y_AEC:$.A[QMGIN*WMZC4/V8':F`XN>.?`>&#L]EQ?KFC!$(SO=J#8[0^)
MQHL9[W&*7N^*!AR>R$O',(942"4&3*6&%30'PR,5P2'A%#30*!M$NFFP.($5
M]L@S*(;B0ENGB1(!L^Q9P!^/W`]]<([GB`.G5J2F9NHV7X_<BO,X[YJJR>:J
M2;>M,:7SDCA&X$Z,SF5-`3XYB__Q7480P?"E/"`0\5404DLS!D9@".#Q"(IK
MHUQ=9_C7OO[I*^46WPB-'?!2PQ8T!9.*,'V1'3`.&$X.+SR#(E\&.F:&O)G-
M[QR<$*`209B`,9##''/?2/Q,%'`#Q+07H($HURZ!,D`H!E"',O@``-"`$I`"
M<9@&[/D>-G">\4$!-T&"'A`#2E2#7][E&C#N:_`X4QYKYB:C]^:481J^=>8+
MN8AO'H]Q8>X/49L\9^[H9V[P5+%=L)[W\'[F&L!NCQ;XN="S"([PB49K82[X
MB4;F@8_P3"G>)62ME=@T8I6.ZQ"K9EE&CA"2ZZ7>89%&&E@`<H_H9YYW&]^)
M8(8S!%C_%QV(`ZJ>+JX``MC(YR_89_KP`*[0%_40@H$6):H&&+7P>?O#@MSZ
M`(<NMCI&>$"/<.K^<>'USCAS>K#&\>H>>(C_W`6QF^.8IY0F&LJ(I-4B$3R*
MZ0TF#6S+BNGX%YX$4:Q,DB>))R>Y$(!=AG9@AO<R*1T"@Y.-@ZVQ%XV@9P&X
M+E5SZNX;I46:OO(RB-JXZF8II=S2FNHBXOR@./E&U7HW%=(%IM_]Y8R)XK:&
M8CW.I0CQ<5WN&RDV7;JH8V;JZPM)::]0FL7AV@A;K1')#*(H&"N\A!W`@RU'
M#B\$\RH=R&6`6_V1J>YNE&/(%=R1!$'0$CYE@AY37(HDD_$8_P,@*P,R^1,B
MHP``$!0X08)I$(82R/XS`3M&+),?>_85J`))(`9".(:"QY0'-F[D_DZ3,\I(
M(5^`<';@@#,(;P8>)`@!V$((SH`YJ_'0H42)$!\ZRSAPHT:"$0LRO/@18LB/
M-1;^2ZER)4N'(1=.+#EQ9,:7(R'4H,$C0$.&-TM6C!FS)\:>,`_FZ7(I29(N
M2BN@02/`@X!!&CQ(D#!UGH=/'CQ8_?I)P(NH).K12/7&),:@)#%"A!D7Z9X)
M3:9P\2#%PP>])S;L,,!W`Q`F*/:^V.LAQHX-)UYX$++B2P7%4B#'(+%A@UXA
M0(#LV"L%T)32)M@&3?VSIE&&!]^L1?^(DZU/U25)RJ4IU-G!T\Y,``=NS-B;
M`BM\K"A0:/(7'\YW?'':Q?EQ/,D+;$!AX`2*[DNP?$E>Z`P(6"!`H!MNS(J)
M8LM,'`"^MN:Q/'DVZF.4(8,A`P*D"/"!%`:\8$!F&V`!&((;+/&!8'TE%N$'
M+SAX`H$>;&=AA!%Z0"$*)!ABR'ZI'+#6137`5B)"KI78T1NS^<3B&_`=D$<(
M>12PP'TF++"1BK"Y))=!/OHX'TG+'&/">L/EX4,]6"!WW`Y)++%%!4O4L\-T
M70#QQ0Z-"7')!B0DX8-RQMQ`Q1G#@3"<"84$1\6,)O06GXD=#60"3!`4X(D9
MG@3AP`<#K+#_AQ8K.!`#`#$@@``0FXRAP`^,(E&I$-\P4.D82*P0S3<&5(H$
M`HH"0*BH0`S`@!1:$/.G&C#5\%8-"_!P34=YZ!A?"`5`<M^+!0V4$6\(<20K
M;1G9YI!#>19)$5RHT>26,RQ1NQ(PM]$$D42P'JOM2`_P\*RW%B%[++G&GAO3
M&R'@P502]73QQ1)13>6!!AI8-8B]5'UEK[Z?^(<&"DTM\.*XT)XT+K?#VIB'
M!:7)`0AD$QJ`P@Y`'&8`83Z@H)=@!GR``F@H?/#!!L>17'*!(5^\06*$?8$%
MQ5F49D$["./,;;K`O/;BNGJ.&]+!JFU[(K37#ND1G<?\9HR2R^!X_]QU*W3I
MPQ=7:QD>=<HMMX-V%0BQA!`[(`?GFN59T::;[RTSBS'QP7?:13X6\$8J^?!G
MB(,&\-WW#M<5$+AQ3%C8M^$@\\U=X15KU_?>?0.1#]X9L`(&0A$QA-!K'PT[
M7Q[SD7N4BC76N.N-(9AP'T?!`C7L1BF:$$*)1A;33I++I&U"`5V0`$24/FP@
MF`<G0.?4%Z`E.&829ZU0"!4FG$$%%>>I%UP>=&)/Y)T"O1ZD0(000\PB0<2P
M`0),B+I"#`K$`,0&FP[P`0,Q(#&`$`,,(`L`]\<P`!+""*,$_-L`J>AG/R2L
MKP2+"!\AJ$"1ES#$"#Q0"%)XM9$%Z,A7W/\KB#,"P*P9!2MA;&G-1W+#L]%Y
M!&D0#-(*A>:0:L$P9Q`\VFQL`RX.!@5G1"NA6QK20V`<XP!38DH]G+0%>GE@
M'@:XU[T$((!/2.!?3A2``9:PA"3@(14NT>%-A&*1(=W'/H70P5VR8+B_.$<(
M!=J`<TA6H+Z=S`="`)ED,/8!*L*Q,(&)S&=VX*`23.$N!>#B#EO8$.XYY`V?
M^V()AX:SD!0RD<$:UC&`T0ZG*>D,4#L.$)0CI2Y]86,^Z,(*\E"(P"T'8P:H
M`,R2D\GI60$65D@;%=QD@F,@Z9:C$U9\#G"C`]QM/QD0F.)BT!TS%2*9RCPE
M"5!@H6="<SO=T8[_@[H3@V=N1YHH6,'D,I"*`'2N(/"!31Z<M:V$0$`VV)(1
M?`IP@!X5HD>74V0Z6^2MA,BF(-=[74V<<4D3X,YI3AK;"J0D`0HTPP/P8H*7
MOJ29>FP@"3LH@#'49(SQJ`T$P2E$+V$#GUU=;FX^P@BP#K`'0IB!&)G8%!*$
M((42(`$%,3"F&P`PH!)(@0U2^($R)!`#";ST![+X`2`4H(`/2$H9;BC9!W#*
M``W,M`>1:)4G7N6M9]$J!!,Y"`9_"1_5;62+-2I(0C;7PK:8RR0)R0-(3(C6
MM\!U(1"!8;6((BUTI54U.@F`T6JP0]60\*YI%:*[BGB)(SJQ!5_1%QKT_R4!
M?$TQ*E6BP1O`Z44N>FN&&[%/?1YVEPHD#@6$4:4!A(`%TC9.M%_2C@<LM@,A
M3%.:@&F,`:0@6BQX#06A*`T"EG'6'1+%6"?4DT`^AZW0.3*2CCRA1P;"-&<P
M8QF_`2AP`N>#3B[GNKY#PI=VP`14)K.@0JB`:)U#T5B>P00@6-,L9UD,I[VM
M$$R33R\)@J(\04*1C)A<'$33KQCX(+P%+>@I2::7`ROF*P/BVUX>)X4'7^9Q
MW<P'B=82@,]I3JN-Q`A2[#F4D:#SG>^470%"$)O1O0&"^$QA1NH94G]&-TE*
MHD(A:)"E+DUI"PSX@0&8TMTQU2,)."#!"J"G)O_@I-<8R\`D1P\`)X%\]3X+
M(&Y$B*0N'Q'"3Y+8%*H&A,#^#4`!&I#"3-D7`YY^0%%I!H#^8B`%G\9`&3]@
M7PG2'(,RE$H(/1"$&<R@!A/IK"!XX$$(2I+.!3!A!?(\AHYDQQK[$"1S]W'&
MY_J)F];]E:P@88TA,=U("-"56I=N30T)29L;9CK3</V)#VF3R!`$F2E.68(`
MI-(O?'U%`EZ92JVOU(4\@--9R<5L6[A:(A'@R"Y-F(`0QK29S5#38KZ3DA`T
M\^P&50PP*V!H8ZR]F3EZ@)6?\8%G)U"(50^;7%]\"3JY]ZODIAM:KLY<L.II
MZ5DL8QG/8Y)QOI#H5`K_00(,`(`!R%;0::_@M1MH3G*,T0;JJ:VB[L4W?.IS
MFH.XCIZ(?,.4@[F?.!Q.,N%M3'A.&;S#(<YPVOE/Q0J'1Y4+D\+N=@:C4?Q#
M90E$6<>=24)J#I\>E;3=7USQIA<2Q!61U+?O$8[3NM#=+M2#!/:J0#V`X/3&
M3*D>I;S!<&Y@Y.G-F*.ZNV7%3U<`#!]@6?P4W48"8`(UM$H,$R@4`A"%`O;Y
MX'P(0`(@`(""O5<J?Q((%:>FX0CZ?08!*'"#!`A5]Q5,0`Q];N"F#7VMK`HE
MB"%8@#M_-NF%E)58*!Y(JU,M[T!?6ESSQDBH69(MU9M^AWL=8:=-O3,2NF8!
M_UU(PB6"[)^/+9:)5*FU9+N`AQ"`,_7`Y:)!7D2DAC'!+E,8@+<_Y$84+`$)
MSF$"$*S=3-C>\03-=LYUFPWM[A"H.X1!0"!UL`D3=)K49R7):]1N,$+:E?DS
M3$A)A24L8+3->[A)U`!!<E#-F8U`,TB`R!A@07G)9XC'V9P'"%B!>CB-%;1#
M[4Q7C>B)1Q!=O=E(C0B3(8"<@[P`"GP!UUS'*:T`-5'("T887_0-8O0-A5`,
MXHC(?C!"/X!!Z)%.B00:N53>4&06]Q!)G@S)6BC2KTB$]J!5$]+)(<%%<``'
M"$"-#R1!1#$%&IS`%4'4EP09'L")FDA/FM12]<!'(?]<SSA%68F)7K-L59$4
MA!J@E"1401`8QQXD"OML@MXAP4ZA@!94"A",@3H`@*8`@18(0S303Z4H'@`T
MW@J("@((@B28`2%$868)":T<0.L45PC\DG/%A:^`$9"L6*39GKQYVKIQD4FT
MGK7(7ZG%'EN``0_0`!&J7KPIU[.DQAO@01>,0A*,@@&,1;_DVB"X0%<8`!I0
M'0V(@)'D7P^Y6[(8(4+$CCO=1R%L0B"%0A1T1S,M0>$(P=@TQF9P1]B$#<ED
M6^]\FS-]2#-IAQ2(S69('P(4`B^^'KJ]51*>V'SHWQ,2&VZTFVQ(Q+.T0[XI
MR47AB`\D&A,$QC10P`\L8`'_LF#57$="1H\Q4.`LP=<M!2`0?15'2!*1.(3J
M7(-^?-PD=,B`G`S7H%(!^,"%^!>"?47%P)9-QB-?Z$5BQ$$.,D(JU$2'K<ND
M'<Q+%"0KCAJ]P0Y"2`3_U=-:),V*'-)+)%\_9<2<!,=Z+`,>3`D)D$"5;`&9
M2%26&%\F44^:).32O8GJ9,\!N-,OK1A875GWN`8=FH$D+`(";$H+E@`*M-0`
M;$#\L(\0S-0`Q``#*(!,94$,C($&`$!?E@`;S-2#H<``L,$`5`%5J0$5]-5;
M8=[!($4HSD:'C:1#\(;LT$C:I6(A/1(-U<9'O*)*P(5;S:+L[<1LKN)J1HO\
M`0L/_US"*%2)5'R"$]2+6%!1!2P%'C!AMO#F0-C(6JB&<]8(;!R$"'"@VR'`
M780"%Y2/]3G(9KQ6##!8@8A6,_&-^9V<\(1,M2T!@6S&`"B;!3@`,%2$7056
M1`1:/272Y_"F:NAF?;((0:1(BI7+_T67VRC)FUB'OX52QP!5Q4P4"QK<&))'
M>JD)[EA![73DG4B:7)+5$59C*J!DB#Q88A!/\Q14X'S!8238@1GC9;`1$_3.
M"@A!7R@8A?3D?N0#*N@#?0*+[,"A;5S6#+V%NZT+D)0+1QAILP@7:^A&G1R#
MDJG7>S@)E6S!%ES1EQC/`FBD1K;)\R3DC#F96W:4<YK.Z_^43@ANF@?1Y8?N
M0:L0@Q?H``J,`?[<SX/960G$0`DP@"B0V4LIBC!H0)UQ@0'P*6+JZ4S%@!N(
M@22$CQIH0L($H:`1FK?TQ%IY1,:)GFFRZ6N(9&[6)FI$(SY*1&RFA+2$JG+=
M4'#])Q'B'CYFS@Z,`AI<Z1%Y`!IX!54LXQ9<`@UTHCGA8EP12X^`4U#XTG-:
M&1!>I1<T01.$P@>(C7D:`!98#`J\T5>L9S-]0!<VF[4RV%=,4SPV6Q2T7R$L
M9Y-^$:K.Q.<HX3,*&T"FZM&X3I6UB)!F!#.TPR7!5]1X"1*,R1+(%*,8H'6<
M"7G$TKX-1S',$KX%41#Y(\V%H'W_6%943IJGY@$8C&`<E,Q_M$\A6$U!!<^$
MB.P+1,AE-!@6&$=+!@]?_(<`3$(.9@`J@(&S^$C!N!NP,@1RF9!1H(@BK1V[
M?=X/(MT*W55#>*K<O)?U0-WR+(%F0-T.X(&2K-=Z#<>:6""-J*$U#H3I>-7U
MW(@IV2Q$K!@TTD@(P-U=BL$`(``!;0`"Z>G]L$%@2L"B#(`;&,`82$$92`'>
M)F:8*4!I1:803(`.6*(G$$(E69K\\<`$L6J`EM!8@9%'+`M;)<T2PFNK(J6K
M&I*I_H-)3&JJP@2X\)7F!F$L%B7IJM@U+$$%$-]4?`(:?`6M;@$-E%-N:HM1
MN-M8J=.A_RE:CA27:FY8(2C;%'!'XS`.-7TK>2+O-"U.8F#(=HCG"\1`*#3K
M%-Q`.UP+@)JNJ,K(Y-[)]FIO_`%%0XCD[L;%18A$.S"#>U2AF?B`UX`,"HSC
MPA44'B@']"B)>;!)1P;@S011W`1)C>0!H]T?;ZC.`E29SUQL-QG"-`G!%WAL
M`2:<.S)O=Q1O\18@=B0'QCB3,<6!,,6L/H"!;SVESP*AY0)HL/+F[5:C?<'%
MNA"$+\D3#A5;BAT2N?B(W"Q#.\S"FP#'"KP+$4'=%ZB7_D:<DF3HTI'I1M0'
M4MC(E*%3!H%B$T<E$/J$]JB!G]RE`PP`(`C!)A2`'B*``>Q/&/_O@20J8-WM
M00$XP`\(`Z&L,1=+@0),@!9750!(*G[J8U;A%9MRT(7=!_FJ)C``,O"2#@3P
M)\+<9VK@7B.O6JF:JNE*,M&RA2U.Q.W]UI#R[.>R10#@`:U1Q:X1'QK40Q[8
MRIZ([R$AQ(UP4%B]0:_DRA+NKKH4P`0$TA24P.%(;]^<0(#T10WR387H\N%P
M02`MVSV"05N="[?4'G/97ZL1Z2*K<%*&%?=8UOFR!5SLL'O`EW4`SQ*-6?E0
M1R$LPWIEDGJDS=(EB3]Q6'TIB^8UC$($Z%B9&%FE`BHPL$IJ3"&X3T%UC&)(
M0*[M14!CA0><S`HL07)LP$![0(@(D\S_>HOH]:-#U+.0M$YNK-ML?`21U&=3
M_B"N0*51;FTG<IJ+3=)%4*&2+$"0-0!:K(!&RI(LK4E"%L,L\/!:DBEP'`"C
MV<C9A9Z4N=,;MEU,D&0-!``=PJD81,$7HP_ZE$#CZ:6F"(,4U(__,`$`_(!?
M'I`0Z`#A3IX:'$/^$>U"+&[:K1`B180/4IIJWM?H(+);D][\H>[.WH:09+2D
M<B[FNF9#B&Y;X,2HAJ\>LRHC&Q*P=($`X-JMHH$*D("O)I\NOC"QD&('22<&
MU6P(WI]JU/(M1T$N]XWQ+H[\9L=G<P?*B=\&"`'-W,4$[`$T^O7X@BK_W2SZ
M8G3I_A:L$`5'_W2J8#O2_^';0=:2&EH-"50`=RR<F9A`VK3)3)O`#2AL$E,A
M@>()Z[@8CCC:.=6(/)4(1`P$/N]'B$Q"'&P`/\<H"F3%>9^W$Z!W5ART9!2`
M$&#%R\(L(XAP6DNT0^PV.AW7)/MU1+!I6-F$``.I%6_T9J6=I%J9_V$/<-22
M(EU-*25W+*6-FPQ'`,Y"D@@M"N$*D.(3KOC2\V%VDOJ(::*(&NB!EHE!%5A`
M81*F`*$`3AE33I&,!*09C,=`4_5`%31J2A'"GYFF^'X$'W?R)!D$*9)F1ES8
M"9..STPGZ7$O)TNJPMQN4@H%YZ;RE9-:.SP`#93>7"^SNETRSV(6!/\L``D,
M@CCPP2`(0`48GSS_-98_I40WY:Y@$%AQ7JZXZK8X0R'``?5.02ADP0<TF]=0
MB,I=S!RQC-?<8/PBP03TP"W/'51F]/S%8ED]98M%^9MKKFOB8M*`TT`4ZURO
M6@92G#'DP7%\P;L87!YPW02"0#&DEW#8M`;J-)V(!-$!@R\%4:Z8M3B%HK)Z
MT#TSL"%L0`&X#W)T3$$7=$`3-$$?-`J8R09,@APX=`;DPT\F7YS;$^A=3I[P
MU5^#>;*<!"N.+4D=Q->BF-$:^"2YCI.#7F\\3?6(T?3(DG(GJ)+Q<#',R9C6
MUSO9AWW@T^E`&D(TS"_-1@"L6+:?^P)D<:O_2((@Z$`/](#]],_=^=0`Z&F8
MZ:U,#4H,=/6.7R(F0H`T3WI9EUI"X#%E?Q[*V[>O\(SL$.@I'L"W8SF04W*Z
M3@3G0KENXL;L93+1:'JFZR*I900-+!&/50#M$L5E_55<ODBG#LD"*%K-SC"P
M!@4$8&=IE-$`%.!A%(C)/K`<U=;)&$9MP6`4#,!NW84]2M>UZ/&\`?:P<#A_
MPH0.3?+V)DW&13.V<,Y#'.A!.LVIX\&#FU*7GLV$FT`M/8WZ:@2-0&<'$5W]
M@=6O9HX\!;+8#H3'Q5PH;=M"NVB_S.1E8`'(%E0]Y*@P_23,=ZIL"`E:7PYN
MV[S\C2U/=#CJ/+/3_[<=T9%4?542-PO'OFWD$2M934M7:IJ`)JC(+[FAC]C'
M\ON(Z:A.BZV8]VP$?-"A)SB\&'A!)CCZ&"#``/@E$OA42_4/`D0!%WB!%^PX
M,1CNGTTZ;^>?D)^$'R.Y1+.[#_+?_`NU"]\<0`"#()"@LQK."`Y46/!@C84&
M!_Z3.)%B180+,2;4"*&A,XP'@3W@X;'C1H$&48+DF/*B284=5:)\0^/$BP9Y
MWIQ,J+)C1@@'#KPYL.``!&?.#N0I*C3$@15`%RS(`^F`1XT!'@)#Z,#+E"9-
M0DU`@.*#%`$?7GQ`P03(!@,OA*SP(>3M![M9O'Z=LL*$U8P!>FI5*;`GT/^?
M>?)`,$K8)V&6,%EJO"BTZL^@D%=>//CP:#MG[8JU,T8EZ8H"!0HM@P6"BK$;
M5*Q8,3;;F`EC59TMTTH9J%5G;][@!`J\:E*@>0)8%4H4\9N.2<'DRS"=>KT5
M*]P:T*[]@W8!V[7ON+XAGW3J&1BE$AH<Z/`0SC6CM&STP'N2D1L/1*DU8?OA
M_HFKK+WWF`J.-P"?:^\-S]H1S81";*,MMMJHL&V96=I99AD`/1)**:E"4,K`
M$`IH:H$`#RB1Q*!P0@I`Q_PK"H(WU""$&#-PE$0,,3()PH$?$2B#BSU\K".(
M'27!$4="U#`AN97X\VV_CWC@H:B#*#.J!@\[/&[_I0"2ZC*/$#PZ*LP9AVOQ
MHY80.FHG-A5J$[*2(*C(3HJ,6DP_H^33:L^6]A0H`(%$&C0E/?U,J$\MRW3H
MHD=U8C1.16?TRQDP/,+T4C<9W4RK__)`2JFD+'OCL*$@00R2)X%)3E"M#!UT
MH`#>V&2"KYJ8(A0N2M`N+11VV("N#TB0BRXIN`@EKR9TV&268W":M4RMCDJN
M(2WUA,A`^EK<%$Z='@U,TI,.@LC%HEQD-4Y,X^R(38268::=69:IS80\C`$!
M%BM@,::0V2*\<)EC#CBFD#?:_*V]4.5[0P3*WB#3P_>ZG7',^A*#B%:E\##O
MO`R6F,2#D4DN>60)I-C@_PN/ST,%#'W`,%`J%H_RU*KD7,QI6W(9[1,E68&&
M5=3C%#2*/?H6,"'B42'`*829BR)WU*#<9.88VPHY(-]Z[:W0!`:9.?<`$_@\
MC*BDVSL&1*F@+6>YH0HHQ[`\1/!/H9QB+#MB2/3PY$8E<?3$$T%V),9OP`,G
MQ%3%?).U76PA=:9*,EOMS:@`$$,73*HA`%.I)Y72#_/0/<J\Z7*.TB]2@2#`
MM*!`LW54=G.-NM/V5D_"2BLPC-)4TUA_%EJ@941RYLF#=/=-4^21AW525Q=S
M%6=V6^W]YOV\];UFXYDWWJ,T#W@RJ8PM*\JX!5)%N-4V#=VS7)QK**0`+2Q8
M=O^*^^7((HH-!HA!BBQB8($)*&M931#+P;J$&X1@Y5+ZP92L-@7!+"'E/8IQ
M'C!,Y2W`,.IXQH-5]W27G/8,Y'.-.HJFJI<[D[0)-*"I5X1`$!O6V,L$)KA0
MA@;F'T[Q!CDK01-00O0]($;L#>PZ3HA"A3.+T0T5+)N.(0P1!RE.P@!4M*(4
M#?$QZK@,9JE[PP*0&+[->&IZ0D18TX!S$G8USWNB@Q6U]F0"J<PL3ZR;6E!"
M%)0T?2A4?-K<</CTFQH.TC:S*`:$:G@,T`!C&0=2WT`6=J*FO`UJ>L18B>XX
M%*)49H$#0IA5_`-&-=3(;W]#G)(,QR0U:"*#C4N4!V'_&:L/+H`'(M@2(#$X
MR?]$S2@BZDT(G%2M76X.8DIQ7@-31ZTR_:Q<'_3@8N[S3-O=*7K4,E3VMM>X
MBP`O)#R0GC;7=T+?N-%[LK/6-\.)PC(NT"#PVU[K7.E!B#7%<LZ@I_$N5IP\
M1"5\TW)5+-^X0-ZL0`L(F,#]<I6K^RV4H7J9@@XFH(4\9"UJM#(,"OFD*?:]
MTJ+H$I$XW9C.:H'+6AYI'T?/]<.,FM1/ZDQ85MSD#`S1ZX6TJ=<R0%`;1"[#
M,[O18;D<^<Q0FFJ7[=$*3B)6`,-LZC!*R0,C&.'$#$"1JE6%HA;SP0@PO&Q]
ME1L?VSH74'-="F)H>@/.V$G._Y+&TUKCN]CU,#@F$QA'0?49BE(FB4$`0?,-
M<YVKAJXVR*S9L$T'(AM*_$-/RB`Q<_Y!3(CH>1S$C"F#'06D!V,TU[&IH0![
MJ-%GF:3*439):4_B9E@!FEI#3<Y`\,%<4-!$NN2(*+:PQ2>Z/`3;W-;Q*`L4
M5#N%]CY'^0FDLG33-.WD+5AZJYF70QXY$?4`&B@WG1F%IG&CQ\ZNCA,E[.S3
M-Q_%.V\)KTREBM$G#P2@W$9KN]R<GM$<^X9"[,&@/?!"*'2@*_WN=P(3L``"
M$+"",QK'B[T1*?=@.9`,KH>HL$5A@K,I.FFI$)Q/HHP(^_D[:KGT@M`K2)OD
M9<AEV/]FD,:PPH@)J;ZC$,QNK'-D(!UK413!]@!N2PH]X;<TC*4"%8Q@A52U
MB%5&H**([<`95H!B@CP")3GMTV"Y2G6N03%0>-D"3"P%"L3&_K-\=HT1B<)8
M5P65E#<F.(:\1ISD)+NIKPIJF'H7-J82M4?)8ZHD$,$\JD$%U<)[!4HY(*`)
M!0UR;":@@JD"<`P?DA>[KPR4529G',7L]C>35'`>C997;NG6<KFT;0K=N\`X
MA5J#SF0J<BN2)]>A%IZMUG`YGXDSD:C:+QMVD[JPVTYS=?6;\-2UKX?+J@#H
M!J2_O>7"3.4AW5$F6@6:45G9:;-L&>3+R4Y1`3:Q"2UH&P[_"-!"0;V]AX,!
MIX>Y/:OQUG/.=QJW!GHMRL;.G2E7=D[7W0U:;]D%O([^\)/9;!^'O?=A:E&K
MA;.@H87,;`RAU!`X;>IRL@7RX@>V)VEOD!M]%,3@H2C9MH<Q41%AUN.H8G4Z
M^?CQD*$1G!-U]=DQTB%(??O,"Y?O>J+3-85%=Z#(GMNR23G08S?I6,5"SY'*
M?-!$":TPN[7SQ966<S[MBAA,6O*N3],LU9>*;@#A;#@-7ER>\F1"7_^6HZ\*
M*VH-900>-%:/>9";)?WH\UWF"6+_(5.3EUJ#?[J3N^O;S,]NSJ?-0!`,J*;(
MIMYH/6QREXT>+M[RD$D]5B7XN2F,_]Z$&>C2\4HONVKDH*C_0Q0+BS[B/A>(
M'"NC&)]C!832`IIP]/B>KMNG0[`_:XLB+AP"A>]RP7F2N4[:1LP!QV*_A[QQ
M?6>]2)7:(W=3BIE@>Q#Q7GGS/QLU9**4H7D]B)!]\8Q?>P,2'N:$[J.JF(LJ
MF<`PO6=C4T,FQH9R5C#40!\!2,4U4I&*K>I?'_K@?\R:0_38J>NBI3[8`X):
MQ6:NK%0L)MXJ3W<N)U&PXH>ZCJZ6`JDHZV$&!(Q&Q4#VB6G*)*C:1+.:0Y!<
M[E$6J^.6QLYL#"I"X&GPB"D0HY*"XX[\HNDLJ#W,*$[*RU$P:N]`**!BY>]X
M@`9$`/:.\/\H=(R!/,<HY`8QJN4P)BV/SBAGF,KR6H_E$`QZY`.9KDE3#&\B
M\J2DKFEV6@UH@H?>:J!08*Z<A"W6R"7@3.LD)HS6.,(.>>UZRH5Z\@14S"LQ
M<`E,9`\0J<:,8`UX'$6$B"*#A@*V+`9=?F(1,^W=?D,2'S$$ZT;7!B\.P>2L
M#F-QR$5=Q&XSM$?OS"7?8&6$&/"92JUWM(0,NZM=8DHKK(;04F06V2/\^A`G
MZD8A*%`$?NV+;JR?;ND]CG`I1`!:O.12DFRR*@-T]DGV<@(,@`%3'&(8$8-Q
M_+#\C@:"SLZ-+*/)HN7LMJ>DR!$8SJL/*4[`(D:QG$8J\B!N+HS_.8CB%9F-
M:LHELZCFBRXF@S"N:#;EB$(%J?)H!::F:4*D`)@C]JJNLI0.D!S"[R:(`,].
MW5I'3\@P#F41'&DI!"`@Z&1D@I8(M^I#,48R3T)'4/).\?SNWM1M$]50W=:G
MU2XE#"5B4[KG(IGJU2`0`N^C>!:P@>AP)A506D9M*%FO3"3/>F;%*"V/J9AG
MGLA'TKXG6JIR*H'"B(#"["S%'$?H((RJ:20-+`WCM2RG?`3"_2"@*9YO$V.-
M,G:0C.HH\UR1N2[G*.OH'PU"1!1%O.[P"F%Q\"J/4:A%*([BZ-;#X:Z.3)AJ
M0*I"5L:O>I!BDY2"=RB0LH2BHX(#X\`D_^AN,/Z:@\H8*&*2`A[%TD,>!CYF
M1`-M:PBW<`=]CYG4T*2L+T9(0AWWR>(R!V)F)C=#[ZY&"!WM)D[\HR^Z##A/
MJ'Q(AR/2R^YF\`6I#HP@BS1+LQ'/J`9BA/!N4S-_XAB#HM<X42$@*`@[IRD]
M:')*QS^(Z=(L:7.JQ9[:$R+A,O-NQCSC9".=3#+7Z#Z8TB;_P0Z]Y0QIYWW\
M1%;8A0W/T2)GDGK<$"+,CO,6M.;,T2FMA2G=;6F`">]Z`W/HR2&8XC'SJ?1T
M$0T3T4,GJ.<L;D,?,BC@<DL<Z4.'TQL%)4M.<PY?47E`BEWXD!7AR11'B$9=
MK;C4B"1Z\BBWI_]<%.883%#-SD@@LO-F\J;Y/K2"3"J?&,91%L9\6-3+B,-4
MV.[LB(8H1$U;=,^I\(BR8`LRU7-1'.>W1(1`'")HRE,PVFJOW+`TS;2N3`3J
M,.:Q,@F("I$"LVXR\Y01[31FU&NQXA',YHHMB6+.0FD&VR,YFDX[[V:7="R#
MXE37CDR%>O)5VN@D[(`'0H!2(XNV6H6VS(V!1,2B2$?OD.I&6RT4Y:TB]\1Q
M:$=':]4@_).ID,G7],,'71%4-64@@%(N9U(_R]$702T*68<H;VU<F)!Q0N@*
M!35&1-3ER*\YAZ/TV`]Y[N/*'&>$OB=$M-&85,]<.X?`.F=I)M`XRJK_PQ+H
MK"[+AZ"21[MK#X=5^1A(!XD)F_`2,&TN=\BH"]=#KX"CZ`R"W,8,OG2(78H.
M`J"E`/9)])"'V4(G,5#4,.#/<FZ)*#!M3#MQ.3[0Y3A'B/PU)]G(KC:3/XDK
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M"`>/,W7T#ME\ESK9KSZ0=@6:@GN,`FE99,%J%EV6K)YRL3D8QU$B)A+/1D0<
M!F(JU#$/UT9/,V*$[[?(4>]@U!.MM?0RZ;'F#)@P9HY<+BI:=5:R])..;4R0
MRD.FYJRR%9B6UT]U"2H`6&GGR'YQ=CA,ZQ1K#NJ0%G5#D0XAR$8U&-\DAU2A
M1UOI*D#B#D#J*0"4K%',\_><;%T6",IZ5Q2%]83\,YQ\]7?`53[^CBX]Z%CK
MDVW;R;F8R8?%*Q'/U_\Q[E)@P[4N(?`WQ4<`?^A)4&^#G&UH)K!M&<AW.R>'
M8Y,^9(]%K;(!#=!`+$SW9BZ)[:CADD(4V>5>7?.]?/6(U11=1K<I]?-P#U'"
M>G<+?\B,H(R'O)`]HK?/V))U+]/G(.!>3N1SZ`ZR*,LA'A%>RX=BSFI+-!`>
MQ?4.A4,A)54Q3(`U$496P`>"<+),6+8W7(<)"6("@VK1CGC28`]IERQBZ@QI
M#R1I^"GLHI1=,NEA.K,?&>=XQ16(E&I\QT<A=RZ/0.2.GH:R[B-J?Y5F@4(A
M]7=:*6P+_RX!$XQZJN0`P!6,JS8QCI:9D:S<\H@)??:2V38GZW)'.4)<I>W_
MN6K8(_#VAW_-7(AX)U&B6`DE<&D2=^AM5H`71[V0$\UNC6D-I#HO5K:W[@`1
M)T!Y81A0]82#$!'-"GNT5KT1D!31$0UYHQ?'D#LDZ,@G6=O5H3^16LMKC64T
M+U=J5HV2*FG+%,'U))A*5BPO,.UX4#IZJ<*.<A\&(DZE/M[,[9YOD9-BNC33
M[71184Y$$IMO5.J1`!U&1KR8+1'7GB)FC@88.T6DAT+0::+O%5-95,3V,A#E
MGX73:!LT(AT'C3YPGZZ.'\',0,16*:!WA#R'*A7CM>B)B_$J*C3UCYKBETF3
MGIH"6I#V41T3'LT5JHGB*5":)H4M51'XBY0J1%33_QO]4BF;SX1^SR'PP(/%
MTVMYXW*&PT--)SW'D*=9RM[2\'=HTQ3%\T'EK27IL%<MU0O-<_KR>2Z-`BB)
MRR>EK[RT]O?LV#[3"IO;YY))&G(CL8+RFH'ZNBK[Z:2KLH+*9S/8%52O#V5)
M>:D66+LMQTP=XHZHU8)&TW)*-R^5*RBGCXX[2(^==*DT[7?1^^^ZV7MH\TMX
M%BPK:#[OPS*%XF'8K_R.8X-:A>.,J5_WR3@&^Y'O[AKI!O68BCH70(@VYD=+
MM33%6"'4[$0X[DR&J$4LTRQY+YU]>-(`]9-OF'>R<UC%=2;;Z(M,Y#TBZVR"
M;F*B(GOI*GISD&C.2&+?6O]!CJTI#@LPTO%#D]G&C^-L[/<]X'&?3G.X`=HH
MQ20$H/>O\8J`>QB;Q6OZ!`5Q.0(]23H7YT9&C">!-Z?)G.'Y0FB,V#;,]=N'
MJ+QYKMKRV)M=YEFR(Y='$T*%IP4"`/=)^%!.<1+7-'$,-;%"!7<FV\?F9!NV
M,1>^[&-T#&-=0X=#@2).)<W$U[5#*Y30;\9]-WU=X4QSSNM]+XM`(:DL4?6<
M0G&T6_J;9-LM_\C4KW96&F*#S\[O6$U=(/8:.*WCUC@$L756<HL25:_%,+0Z
MQQ!&C1HXL<5#%O'2SPN<AY%J)BY%P\>QEAV/()%T??9P';U2^V--`P[L&L6X
M\=3_`I'HSN[W9JONLL"@?QD(.RMXQL:,(!S3'U7NKJ[NKN`:5#3),;DY;P&/
M.8<"RRESDQS2NG[+WLB.T3^REFP;DDZU-5O5W"YG;#&ZM3VLRKVQG*SG6K+K
M#'.G5]=8I3'"^ECQRG@'=Z0+P7S7GZU9#Y627XF;":WO[[(X5!4/`M'D/3ST
M:2N#6RT'Z1.K,O*P+DV[-\JUAZ([ZK'"<[H88?+MN2Z,@CZ9CIL2GMTVK224
M9R]LZYL2QMDD@P$/N/*9[`UCYG!'B$WJ?4W+R\2H2]BRV\>F/J`F=UZ<-Z!F
M^I*J;L9=:8D*K^KU[?L(4&FL9MGV.`.`\%KYO%+9,A2+_[U#R.N]JCIU%B3C
MW?,3FW/2NCY4>&&@<^BGYGC2D6T5.&RU#$1BA`/OK'*_L(?S+3B>!O8;?`&E
MSX_4?:5WVQGL@`:N@3_?[\]"YY84F31=RV<1+WKL7+=C"8B5>%,E4Y:P>,]U
M%23F$`*W7[]EI5#,CJ#G\N7USID=PJ`E3P__;;\-FN3)MQ@=VD,61P;/2ME,
M.S0];NEP%2!J!`#FS-E`"!`"'#CP)H#!A6\@O#F0)T3$`&_>Y(DXT2+$`!"<
M"706LL;$`R`I-BP9$HQ!8"$/`G-8$B3-F2)KDG1Y,B%$"#5*O@Q9$R;1@P8A
MP`P0U!D8HC,5+I3XDV1.F"Z).O_3N-"B4H04%S*$X%+J`1$J,>99<"#$6)(0
MQ&Y,J/%-B#QH#QB5N*!BQ8@SQ=X]$)>AVX^%MX9`>#*L0Y5BG<%T)O>`P<N3
M9\(4C#)F8X8N1R8DZ%`@Z8=B4[==6^!P5XI][YJ0V[=`GLY4*;I-FK&B6!,;
M[:Z=2A)C6[%?S0Y.G8=U"!.'\>9IW74BX-(@BY.<S)+KVMO'.5XL&!KSP?-6
M:UR&@(?'XJPN"08-JSI/.8@+LRO,0S3KP-)6W>143G`1Y)]5!)XGWU?%35;#
M/Q!&*.&$+PWX$DB:)853A3;!!)-Z#_#@T%,XE07494\Y%9-Z,>&DU(@#EH73
M?R^*5*'_BL!$%..%0-G5F7%>*=372G%91-(!;*TTD0AO'+G1<0:QJ&)2_V58
MY$K.E/.D176)I)!'!YB@)4@MV?A4`&X]QN1V(ZZ(8E(7#C4@4`YA2)./1XX5
M4YQVJO>?>C+6Z*>?,X6$G#-N-5DEC.31*1%X>0RDHY9B94=512N@Y"-7%`60
MHEJ4&L2?<)VZ^`9;@[G8UJG!306>137DIU%I<=EW&TA:GG1-4H51"N"?ZU4&
MTDF)MN3FKPT6%IY$%L6VUF=L%<#661WUM8!K$?E%G%+'_261EGGU56=N8@%*
MF6H+:5E1;`N<=-NURRTP&D)S:E;CHB0)MRYAKT:ZHYV%&M20_V1,#54##SR@
M9&9"*CYZD@AYY'M7I$M1=!F&4YY9(IQEQ:C5H'7Z2?"`,'H(TH0H2TC6>AV/
M%%J=W`U$\HPTB'CQ4E[*Z=+.#=+TWTX%(3722*=I#)*,/Z\\VGJW`5;81/Q!
M-.!"UT`V5F#1[1>1R!V[-*>"5UZ&I)YOH$74V%!#Y:BD<VF-$';DO6G:S`S#
M]Z;`L1+7](OV`C@2C*/!S?//+Z<%P6T(B2Q:UVPN65<-.-%G66AV07(-6H@K
MMM`"<:L5GE?#U55C7YN7J35;&(7PT$:1%F8<PVIM2AE:HN.D4;N!:Q=461K=
MQYG"4/TL4."D5;;GJ;!9]&1S!T""[?]W"[16@._,']9BMWK"]!VV)KV&I5EM
MY1N6LZI/NP!;TXX=H(N,HR>:01-71%+U<UWV/ED:(8Y=B0OP($*A,"):``+0
MKJXPK")'R0^=2$,HA^!D<<ER")_8%\&<07!$*<M@BV1&(Y(%;48&.I920I2=
MCLVH@03;TZ<"9J+V>:Q@'"0-`^-$,G-!(%$TT4V='`.6YB"D5H1QDD>\4J)C
MN0B$V3E.H:`4@-O<YBG@4:!FZB2953G$6Q[C4<:B%*>-<9$I&H%8?A"EL+)P
MC60O:N"]_/2B>U'&*R>9(,R^^#6H67$II&K=?E8S)#)1Q%;?\Y%*HK::7.40
M-LVA(K-(IY'_F%`D5U-IXAL^I0E(.<17&SF/1"0($G-Y+2M<Z0MX]#,3-N*D
ME$D1S,">(AS2=:4Y(3C?8*@GR[^`YWQ[4]%"?&,G=_7E(:Y1H"Z/8YD<#N=:
MLU&>*!<`'88TI$TT3%''/`A*361$-V*Y5B;/R,HHHB1@!4.8"`B&PA1))"\0
M25-2,@?#(JH(FC_[V12--4'SW&M#*<I@RE8&-PX.R#3]'-FB2$@W1BEH@&<9
M(,D.4#6%SB@`:%$H_D*0BFO4;2M5N\;`A`>S>1EG(0(QRZ,.,Y.R+4`$:K%>
M$P5SJWF]`83$0T]4D!.8U+R!>@RI2LL>$\E5Y6Z*7MH8/Y?R0,`-_T0W)J#=
MX0CS!D+ECF%_ZUM1+13/P,SE)/JQX$&_-IF.T-0G]#E)0[9'&+5\9U4J(M9J
M(O*[LA*+D7_3C5\B0A6W#"8D:YK1+MLBD4WM1I'Q%`WA'F6MMW2,GQX<#6=T
M]%%L(FDMN$S?+L]'`QKT[P!:6@`-NM"NICYF+0C+R#4^ZAJ+T``/U_K)Y<1X
M&!V!H2/#84XLM453"^TT3E%5FHGX(A81+(`)0WJJYQ*ESGFV)P0NLY\$01G%
MO0U0?ST#6D'G%!_!"92"'LV9?_"I3Y2Q4$-M<IGI`$7/%)%P@YVKD4&NP0,:
MA(A)`VQOB$+0,8C*-V&O%8%\.3>C$#S@O_\\6,"N.ABHH31&?*])#4E$8%EB
MHDLW[F52H5!I(G`NXTQ^JM21[H(1(%:-H5,"UH<;DI8)CVN>7BRP&5%4I+.@
MJR$`#3%00RSC$CICM=>8B6\1]F&&7.@`1D#IC?6+!Y3"#*)&6$"273G@/+D%
M8@TAU6`:,ULKAL`]J<'=JC:'!R,TR2W0\<TDQ4>ZB):4I?RZ"'>PEY+#&*E*
M7%RAG3:\O3$7;,5R;C%$2JE6EIYO!:[L[5IHT(`&/,#0OL7#&AYP*XQH*98!
M#@`/BGR<1%%$!#"P;!^!L0``5XHIC5U.MZQEUS$>V71MK.',."FPVT1G`9`8
MTIND`K[\*$Z<J3[_4\;`<IB(;B4_<X2FC.ZVL\#=BYY5!>\]WP2![DXH=S'^
MFW:!QC=&@:%F51UJX$S"`Q@\X@$PX(%&,?UM'N1A=S?F`0L>\(@&B.@:CX#!
M?_&@L6LL@`6&?L0C:!"`AB)4HQF%KY!..EJ3%MDMYQLM@]T3&]_ZYCA&8`$+
MQ/V0BJ(DHPQ5B`A"H%&%C%;C;>M-E+?,$%+ZK"=:,WG.:');NW%T3L"!I5R8
MM*>5Q6EE4;U)L`VR@$=T83'Z;?>^:6>G`_"@W0+I]+<?(>2R'/K;#[#L78)D
M',CFP9J#$2->TH2DOJ`EEDR'6@CPD%--A8`&WD9I?L;6-(6:]"[MTH]O_Q#X
MDS:9I>U64UAR#Q*H.ITD-G6G[E`ZQBG0A$20F;P=:\XG6>@UP-N$9@%G.TV#
M$$!,!$9`+6AY\(9X6Q:T)W6+N@/<]@`\8!3>[HKEKP'W\W&>\9]G/")7<L&5
MX^Q`VSW/<4B'<$#3W"%I6YWORLAS_YVRH[^""5?$VI;E1DGG0TG:-%V.%6:[
MC^715]I`G"TA$U-PSM+DTQJ=<=XL!LI/UP`WD](.;Q@07*$@$<'C3_5MWTY<
MP*N4B+I1VG,8!/D!3"("`&@$[G5H(G(J#Y`$CR!@5V9H[M9>X58V"(,D/-`%
M`/89X#8*3/<448<P218B_N-?7?`([I%^G'=E"?^S$4\!`>5@$8DR)O229RU%
M$;##-6629REF+#`T4@L`:*MB2$`%0S363C12*&5A!%W``C"`4MWV`'CP`"P0
M=Y,A:?$V"G'A>?>6,)W4>9GVA/>'2Q['4+^%,-H42XPW=ALG`AO7'K@42Z-U
M%IK66H@"A:/P`!IG>:CE6ZA2`[$4>Y:'$@0$+YED))\2$EKB*WPA5@DQ*!>C
M1H*4&CC$8B]Q'976&<618+QV3-+R+(C$%N#V>C#``I4U?T<'`Z:XA$\(@!(G
M;PO@;::8,/=&`Z_B#`)HBBP0*9UF:"'R>%T``Q``;DH(`WE@@`>`=BC50#($
M,`[4)B?T3OD"6>>S.8#_)B[=PQ\"H2^-\2>XUHQVQT:@LA"^!D,H)(1Y1DT;
MA&Q(-%YW0R/<%R'&=G-])WA,<5&C05"'%8],<0"?2&YX$`*KJ(1X@&XB\`@L
M(`)VP(JFH(029X<,HPOWYF4!@`>9AFDT8`3J9G201Y`A@&3]9P3#.'&A*&^A
MV#^&9GKRUEX08Q%H(F^?:!"A^&WMH80/L`"IX#_@1@/70`,L8'3[]B6*0AE#
M0H-`TT%<X1.95!/:5U3?%Q2@9EL7LB[7TBZNM!B"ESL[`FTO=PVZN(08R9*/
M@!),R6G_%6\#!&XD&(54%`#Z9F0LL(#=9F[>AC`2)W$-T"ZNJ(3`%9)T&8J,
M_P:%&P>%IEB7AA$`1G"*.'`;.AF*[A62,``&X!:2BB9O91.%T.,,]D$\"3%<
M_'%.NS0>\>@?5,96KM9V0PD4+B$7&5$FK@922^4;SN,6T%-8G99I=]$`++`&
M/&";"_!X#8`'C\=>WQ8`#3!T%:%?WH9:Z[:1)T$#[:9N"T"%=7@^\18B$.!;
M:">*N[EOO]DAF$DXT[8R!W)0![`"D+`14HE+AO$CFR))R#$0"*,Z38E8N640
M!*0;.C(\?7=[T050-2*?1T9MTA=]7-6.$#)^P@9>6R03T$1"`.-:X&42`^EM
M^.:1Z\9>WJ8?!!1O#5"'`EB0M<@Y=;)_\15NI@=UC_\``4>'D_O'D[888&39
MA%<6A>!FAZ9(`WFQ$>FV;M,Y6FD'`>E7D`T1H7P)41,WG./48J+R&F]3*"8Q
M0'8Q,-[21MP(3@G*B$=3'+?S1Q:Q`D_&$.Y$8`U#(W]#)P+S"*8PF^96BZ'8
M`*,5$P,Y:5#8$*4H<4;P)YW7`$9@$(^79/K6BI:5A"*`!^WF=3SPF`NP!NO6
M7@5I!,VY?[GY`%5C;A/S!NPFEWTQHSOF;0N`!TUD!,!H6<-9J#"@44B2DE=C
M4)6T2Y=4$9)D<C5RFMY#%(A71J9#1L<!:B8!FR6W5"$`F_$"=V=%J3`P>5!H
MDZ,*>=TVJKOY``=@BFQ!;F;_>3[8J2EYP)CK]@:"V@`5(9&0VF]F&8J^9983
M=QU?LVL7)2DJ]*IP81>PM@8/5XR;HA2L0E>/1E/OB31J]$ZB491%V$DP,F=$
M2%0V!K`VJ$6?V3/-1J#T:$+(YY0'150$)5XP%3+7D`<$.'$;EWI']PBTB`<`
MAWF>QUXL\'_^AQ/VQ@+]V'\BP!Z/@'H+``:YR0,UN:B'-I"C$&"/1X6R.'J$
M]@!<F#"6]TS^)7EFB0<0(&_*J9,HX5]+>),8<8H^RTJP95.Y\UJT!1)M!SM3
M];`+&WWLLR1CTQ:,E[4CX4'#XWS+R%4#=`W!&))&9VB%"J3]%I&G*'$5^5_2
M:J.!_Y-V&-&6>?"CO3B3.GD^C^>B41=OQBFX'GJ3.EFHWR8J%1%+(7"*?.E?
M22`B>?"HZ/-?D8=:(UBX3AH"!8!-V<5*5=,<*R$6/L)/ZNI@,`9J851R*%0#
MKZ(GFI.UCH4?FHA+FN`6X.9N.CF37I@'C_<`O3BJN?F5\>8>>""*W=:;68A.
MR?I?IAAT#2"VWQ81K6B!NID':!>*8`DXMT4CNM4W:MMJ?>$\NW17(?5PS_4Y
M*-$>1VHW+C<RP[,2V.>=K#NQ7IN_:T2/`8H>VT6@_P!^.FB@PR->DLB@KZJ.
M97%EF_4($-F$S9FA(E"QAPN`9>.57;`K9Z)N8\F@0\NFSO]P=.*F;K'TB>`F
MG8VY`$D`@(/[J/HH;Y4E+R9A!,/Y@208`/(V3NPU"LAE=!,WHR`!A4F0I_,H
M%>BT$C.21X#H4P-;8ZCF3A@FB68U&-#H%04+IN6(9_F",.RV;B;)65!H!$#F
M'OHEJB.;G5VV;N=V&8_PP@08;BAQ;_AF65#8%XVZ;NRFK%VHDVC1;NZ%LFB'
MIVKH+&@'=:8XC/MF%]WV<T@"`_D6A9IEFRRPD6"!*LU189VT80K39JUU:F"U
M+"="$]="5^0K%8=A)\HQ<LM1+&)K=:65R`TP@M:RPD_W>)=<@<QZ:`_`IQE\
M4NZW.=Z[;T76;?WS7PPA@#A)?UO_J4U0V``#U,!91(0):J!&@1$0PWNW*C!<
MARVJ40[WBFIH5$0'T13]VD;DN"(#N\7?!;#O[,XGH[!"=;!5^T441$+ZJ6T_
M(X#_)7#I9[SB5IT:+(!#9Q.%V@45:1,&X<\*;<9!D7[RIF.1)H"I<&6<"X#7
M\(02F#"Y>18(TQS,.71,R6!Y"@8+9WH>RW.0FA#^7*A&5I@/L)%#&18J*;#Y
MDQ?1@25F!%7]*J#])+`"<T[F4Q&CB\I)F;]!I=1G&Z8\N1&.:[PS;70`*!)\
M>'3I!G5';%'_X<LCR*Q/@6FB*-+NEY/"BP.'V\$#:5G=MG$1)I')3,/F-BV/
M)V`86<DX_TG5//!H/F>\2PAV2OC)3>1$N+-3*X,E(_%(R`$?&5%JJ_1\EKFD
M/LT5Q7)F=N7*M4L8]&$MM>N][J70$*,EA.;9AZ:I[9$P^E615]8%".,>;^`_
M^Z%9_G,<-=->9*<02=85[<4#%FE7GWA&$J&4XLMLXQN6A[?-O'<1['J)")02
M4822UP7`WP=4.;=R8;E5N654WW>^_,24`TJ@!DQ-LS8H=6,ZP,#`5*QL`X01
M5RJK5.0?3AI^F4D386H08.`S-S:"1H"?9!(X#0&:5E2--H$D>X2K=+2()''=
M>[+>]&D0W<:I\6F4387@:H$^K^:90VD:N3-8SQ0G]<40/0:LO?^Z4463%%V3
M$.C5E#)C(K#Q=6?1/^(V0&YH$YWZ$&E,<R*39$EF9/"#N&:(DQ!UP=>`F^WA
M9?:FAZAU%FB1D]I4,_"R2Y.FDD>N645V*N:6$)O7/Z>KD[(X,(LT6TPL;(GC
M,YX3&;P3JTW1W1L^4[I*(VB2&D;9%I0293>:!Y"08+$9M*_4%YL5QIHV+4JC
M$9<=%#[1J\]2=<'$,'75*1S#R%P=54\QIOAI1"%S:B8R+,`:,8SQ6",7,:QT
M:7916:E0WG?&(^EL=^_$0C&U:W:RX5M\1@=*L`9!P.P,V28R/-U]-.<Z$P2U
MB/]YME/HW:"FZ[E5)F3AZV_#."NH(B[_H5^XXYTA4]XJ\A=^Y!%;0B25#FI&
M^*]I9"GH43.C]4)),3P`]!UW/DMZ9(11@N)BVB$8T4>+B.("T1QB!!*`!Z),
MR;HNQ)_QJ6L:TRD@D2;QOC[:MZ2=A.SQ22;OE`>B.'"&DR\;]Q%!P:Y%.3SH
M^9RY$0`T<!P(41;/0CKW>Z/R4L)U#5%E=3BW$TM4DMZX"A8Z31C`4(GX^S?7
MS2=R40XQ01:04@[S4VIM5Q>]^H?VL>>BQ!#MXG#GLV,VN@+;O)D@<='AT2&O
MT>:LLLI`X:/=XNX(L5H1848,W=X!S,_.&"@YCW)8#I^NMAATT7QU@9(JKNY(
M8VSCNQ3WQ-!>_U_.E>[KD`UJ'8^P+63BM/[W;@Y`YIR.37E>[5/=]TWS*+XQ
M5^HI?<_M2$3S.[C>K$O>QJWB+;9$?Y$F,/(4)W[JI53I&W/?9+*"_GI[=-$<
MM?18@S'-H=\P_BXP3#(8G'P[]^$62W6K!J_N?^+K![5`J.Z3'_6ON/KX)S0B
MK8Y&^"H<&SD8T-\D9[(:-'B_L:0;O'%6F42#2`*;[\2NW7]RN]<0EJ<\JR$J
MQK$`N6(TQL;W(_%H9?.(X5OZ[7^VG$&?N6J?">&KMPH0`0Z(")#G@,$#`=X@
M7+`@SX(#!T(<>-/PX8*%$Q^&:'@P(;"($4.\">`,#(2)$RE"*!>"(?_$`,`"
M0!!Y$`($F1!BS@P0H$;)DT!-FM29<V=1H#I]EMQ)=.?/-Q-G0JB84.<!B"2=
M!7`XM=P"&@]@.C4*X611G4.7XERZU>A/MT)];G5*%&E<"'7!T#V[5RA2"/\$
M#R9<6"?<M4>;-O5KU/$#'DQ_`EXL<ZO`:]=V)FT;U');LUM_*KSV1C/3NTSC
MSO2[MS'KRR%+YIDH@H?6UWKY*C5]+?7DGE)+(LWYTVC4!2(>1G3H,D1:O\`M
M@[F6Q_?,-R$E;@\M\")"EPD5:I7.&"E<SSR/OCY(,GL(GI0_Y_1+%G9NOU0G
M:O9(<B#WG20R"+ZMJ,J#-IMD>D.$CD3(+@__G0[4J*0::&K.(-@$Y"B[`WS;
M3B*4*,)JP`,*S*^^_'Z**(^*$*1HJOP4FHZLE#`L*JK^>CI()8/\2^F_%R&H
M;@&.()JHG(.^"\FYA@I0Z<D<=>)0I3>"P@JB`4FBZ4.MVE(MM;?D0FQ,GCX#
M#KVT"K)*(1$\FJG'H$CLR2`>'E!NS1F!8LHQN4)[K3C6H!.M3$('E:]0\_H$
MHS!&"5.+S]]@2XQ/9R#K"4W.S-)))]L>"&L!S>:3%-(`HBO)MK`\[4DMHEP3
MU$O[NGOO0Q'P>""^H-`\\;(%>*AS@9X.*^F:7A_PU(@JZ5*LNQT=$I`&&GA@
M,=%'3^7!"*(^[)!#_ZNNM(C'`S8U:T^>JH7N5=UX"@DE7_$`M2=1A54+O;BV
M(M:(!8P8R2^5G"G'1H6<"W(F`2.Z-.`[1^)!!)>(I$VJJ$A<LZ)H:8")MXBB
M]?7=FBB"+^*42,K3P6!CW,ZB#AM23+:3ZA/H0]6N$6DDA33<3L<E$4R6)A$*
M<`@A`1UJ;KN&'Y+X9XE(JF$KHBF:[,&'RN%PUJ1O2N\GXPB]R]16!ZW7RSQC
M$\^9C+@U6$K:N)WH#1YH:--@$_&2B=Y)46L9J<4F"XI5%,^5RZGN$(.T4<(#
M]9+,2+M3RRQ+Z?M:U#P>@,'8+A;6*0014KE.\VLF\DMF$4)E;8%18'BDB_];
M,R,I,](D*DU'U7NZILV>V`SA]8<6YJA.]ZK33*=K-+]=,H$DE_R1`[(V:P'C
M'W@$#\U,HUW'5$)0B<&&L*>A@4=`E;GVA&3NG*``1'@`#X$X$D$Y!\<G\J"&
M%BC`9@>[4_Q$O_D.G%S9K@FK`6,!2R:U&U?M5A44`FYF`8\PEEA.XZ;JT(PG
M$6N/`27B'"W5`'XN,1^1%G(AB`S$>G(*P#4>P+T&N.T`G\$*``'8A06HB#8&
M:=.#WB8<IOC/"`HY(/@N8J2PG.8-"[F3`76DDA>-1B33>H_$?+2B*`6L2#4I
MVM!6]!TD&N1;6L)9>$BB+B:9(&`NHEEW'->9N$G_2F]Q62-G](*4!]TD8`N(
MC4/DF)T%;.H@(KA)G?!0$S')96ZC0A1>&,,70Y+I<3P1'/'LAR+"-6I>G,&:
MHEZE*:&H*E&8=$H`>,""!Y`$<Z4Q0IUX`*P05,Q2`0B!K<ZG&;\887*A@X^O
M&.:K-Q@A6L9"EFTV-KM4M8]YQH*/"``H%@:ES@@-S`,KVV;*Z\@D!(]X!`^H
M"9]R7>,1,(A,5$+'%6,M;$&0"<MMP'+"1ZPA<C"87"EY,!+S'<!7T>K"#FV3
M1U.$!772"D&=C-4`H4$"1_%+VMZ"@DE%MFQ0><(D@&@`RFOQKH28$T]V(G@:
M5BI'=#KY9#47!CHC-:QS_YC3$?8TBCGX8`5[XB'6`O#`$3R0[QIKH$'N'D(#
M=RGG7Q01`41GV<Q-F1"4T%*5-]^9/>LMS$C)^2970!FZ#M6L-"UU%PV!E;Y3
M,FA`#!OA?Q*SG3R40T<T%(E[$-*FZ55(33MBT<F$=M:*6`0C'X*(14K%-)@Q
MBV@5\4]'1@(!3$UG4P;UV]8VI1A%=D9*!WG:B-QC$Y_@D8GMT8FMDL,MPV&*
M,F>ZSZLXFRY,AI:P7L)DF`P524:I45*:RI4CS>,72PWV:](Q'PQ"ER^&78,%
M-%BF;64YN4>PH$W.RQ<+;J.4GK*`G8]PQ@(!*-P`'.^3OF6!<NU0IT?D89NE
M-/]=KQBTS;;EZP$L\.3DK`F#:QBA`9.#`0N`A4`>C$*Y(N#M-8@B@B38*03X
MNBT+C(`'!C*(!=M4;D/8><+=TH"=2N5F;:-K.@6S0)X,#``[8=``4!Y`NL&E
M`20<XJ"'K,`E,YFD8!.S/]'*RSM?S,.`"7*9\AW/O?)4;G4?T"$>F&YR>8`O
M*!=@!\R--P22@^%XJSNY!Q\X!!:F<(Z5:]L<6Y@&2WX`YMBI7+>MH;K5;4!X
M4K)-[L$0*V_@%`L:\-*-0,`.ZPUNK3#<7N."Y<WN7>:1G?>(\G&SSG"&S'J)
M%=PC$\G(U>W"?S*H)I7LQ3D&Z9%`4#E#JZ"-@^'B*_;_EK,=MH7`9QB9JU8A
M@:#GO$PE4[E*P6ZBH8MPL;2$]-IZ#)6>PN)/4@7!IH$^AJ501RC4`\+F3]KF
MH+E.)$W">F3<8.TJU1+[H"A"I!L#U3?$E@FUA:FDBA&SN-$J+R:KI,]A.3MD
M&"1GF]V;KH479ES;^'>!I6LO#:X12_,:@2!@B/*M`D"#:CX87TB^MW()_./V
M,A!SP6UGY,C+/8A\\KMX_B2P1+/`R8%RMP?PBP@"+(+VGF^\C\!P]^RP6UN%
M&P]F=JF/&7B:R3GO`96JYC44S@,`YH&=T>+>&SC.@U0\U-*:<)>'K:)9Q>XD
M3&DR$QC-VE,[_=;=#\CO`DR7_VYW=Q?I,,^W2=CVY`8L#,`99YCD\F`$CJ?"
M>+;I`D37.TTSGY)YH)1W'A[JJ?&Z_,*]8@$>>HN1-K42T&&9W$(2TE-?K1<&
M47]$M"YLS&HN8+<\,(7(NVL$XW9(P>;KGH99\&>`;O,`ZK4MACW%3K?O.%R`
M#=B.R`R!-H&:9@/Q>WCD2!6&I8TW<L7(DX3V/G@:S6$A`36&M@*&!R4M6`7I
M2);TYUJ$)AO:H&4V=J0"%0]>!2:1O9BC$P)]3]V:1WXZ5/Y:6Z!,<29>B?GL
M4DSL?;]-FS#E6@L"@7._8:\VMJIM8PW8-DOGXNNI1I"W+-\)>7'+.A&0-_50
M//W")O_)&3`R8[K(V"ZG6[GR>@!YXX'.P8/S2HYBF9RU"X";<SGA`K!0RC$[
M@(T<DT`:D"\[T!(PT+!9>J@4&B^EDC?%LQC)&<`=^R3>.AT$W";;`H,3HL#Q
ML@T&.H#NHKH#6"^Q&"\TBQ\/"RNE6#5KNP]C&ZPT$3XDZ1`S,X(\^"0[,1Y3
ML@UNXL!Z4KS*"2#U*,%44(ZDJBZ,,"'TJBUP,X+.&2]].BJ.XSBPN,,&V#=/
M":X\,"88Z`(M<QL%VR'FP$%JFKD?F;JU`RC3@0S(@+C;@"C)(1*$`[R>>,!1
M<+<A8P'3N+EMZA7N,3A?Z2X%N[%`P9%&\XX?6;U%C`BE847_X9N)&OA#GPD/
M`>F9W?,(K>H(HOD9J3B,]U@;$DL?H_$1%301V=(:5RN7T0(<63,+'%$/2'N3
M%]D*1DL('.$BV@@+^,C&F^D^KLDV\:L;8E,,4GD_9GM&@U*_P<@4EQF@Q7%&
M/UFH54*<1`F`WC*6I\.X?9(6_VLEX1HR!OH5T9&E_`H+3^J":@K#'&O(*@/!
MO5BFPJN3]3$6\.J4!]A$72(O`*LF[B$6Y_$D]T(-L$LYKF,*KN`X!",GB,*I
MCL0IR7&7E*M![2H\$7`&]5)`EBN\_.JG!NB")7N$[X*!5+K#]G*8!5@!B^@2
M$X-&%8O*H`N)%83%!X,,+@0WK'PG_SL(PTL<,%^Y%J?@PE[Y,.Z9')D9+U%\
M!#<$EJMK('=C/,G9Q%1AI^28'!HH.U_9IK"(,\DQ@JLP.-1I+VXB&NTRK[*S
MK0,+2^W*NA8SP=URNNY!.H*H+?<*GB"D.I@3N5#,L;T,1,][`[B0F0MZ+"]K
MM)JH1DU9HFF1HPO:"+IZ*[K:-(F!'V<A()G)DN&3F1&BG??@HKE)%O/3FN_;
M&WK4$WGQBVG<BM]<$1R:QB69F!ZQ+*E8(I(8K6X[',[HC.-\(\7PSNXP'/3C
M#'<4#/4HNO10+'(\#$LQ$4*)CYT8IP?8IX2P`[CL.B,8"#LIGU3I`H)`+HQ$
M'9>[EB&+#/_)`2X'Z:"9$$EF,I]]FAU_LI/O*J$Z09U>\I48(Y^?$,E]\A2"
MF(QKL)4[!*)C.I\U&+QS:H@(I8&>\*<=FB9N8IP#$PN.@(P\R#J)J),_Q+<D
M:"^-:*6L6*W7N)_+T#;$$);TT4;A0#V&Y$<*'*:PY(A'P!9C"1UCT1A@D1)K
M`J#G$<)A`I7QPLC(L";RL3A/"0OZ\I5P.E/G"1T`LL!C2J&&B#-\>S%GNC!T
M*KSJ$)`M12>AQ+>M])_GH;*OHYS!6Q\`HD`/1"]6>COGD9919)X&V,*L8YX+
MR[@)`JLOTA`O\HZ(B#T\036Q4@I.]8@D^98G*9)=U(C;6PG@:YK_-`F^D!"!
M<M`/BCBH@SFL<3&LH*L+1,&DB)D@CN`)YTB+8-41.T*;JWJF%W$TDC$4XKD,
MP(&5EHE67`6_[D0@91&D@_'.K2C/?T`/^$1.!%**5N,)V(H,<RT5G6B-(N4)
MUI$2X/DB'N(-WL`H>#$B]5!),,"WV[A.I9`,TZ#7$OH=V3'8!#*-X5N5!%+)
M$B(S`[(2Y_BCVG$.CF#*X@,6A'@=]6"Q`#L)?WW8MV&8Z?$.!JF3"TLIH1D;
M9N15U'C/<3$*V=A&]=@='K"#A``#5/DH!H&/?/$-MOFEX>LG3U$J#"66KEL\
MC"B?ZMM"8XFI7K&E`R`JMPD`78@?WMH!_\B`#_^!6AI8$YIP):6JLJC0"(TD
M$B+!@W*"IU/JVF)B3)?0I7?*)>.2'1ALVWY"6UQJ%Q5M`"04#P0)J['"19I9
MD(*9GLN8(6$K$(](&X7@-+FBFI]QB*]X$-DD1B^S"C`H/>O9U&GQ#J9PC4+:
MC/!L5VP=BLV]C%VMF<M2B%2K&0D2"`9Y+`CI"3QR$&<H!9P:EV"EC*#0ULW%
MFW=-$[T)I,58"O4H,4;J5O=3R9\`5];0D\]02=05389-WF!9)>J]7FG-5VP=
M#=6MUD'!5>%]6?/="EW:(71U3R0%O^[=UFV5E<-2R0&:7^-DSK49FK2H(AJ@
MB1]R7,30UF5"'_^3L$!LX2ON,-R@VLP`@PC]V"GD=<\!`E\$D@F_4(V[6K'2
M*YDJ>4*&+:`TZ=:#J1VKL[\1HXD3[HD5E!R$'1>],9`$_2(I23T"*8@V(1(1
M*Y=OP0BH>%S'`BK91>!PX8H!J5V":8B*"+6*#:MFF@GS@2[4&R\?2ID5D1KE
M6``,JZ[NR4:7J%5CK(T7P0I:<Q/>4%P59,4:&KZ7ND4$-AI($!BN:)BZ6J(?
M&>*2,$P9YADE'9C0;5<_5LGP-(D36]Y&PK20<ET!85=:(PE>&S[:>%R7J[)-
M.1#V6XP+EE;@:U[DY-[@+1G3'2U`SN#T7-?H+1#HW5YS3=W475BEL&#_3-8D
M\,W7Z/V)<I5E00YAU>7>#(XL;2WEH/@B079/^%4/4E[7=0W?W^O>[<7@7SZK
MA/`(*7&I)F21(@&86';8<1TK5J+D,:(X@E$.+5$.(U[.4M;E5';>T*VC/?:V
M2E;F9%[E7'Y/J!@Q3TV3V""?9<YE"@K&P4V:&OJ7*0.8#](B,K,2HV&8BCJ(
M?QDU1IL0@AF)E=62JT"K(<HHE1R(JU`)7#/<'^(!J)T(A_FKB$&0Z;$)+&F3
MPUH0#-K5A\&0I<@(E($G2^,(Y_R.M-%HAP%F5@(K<0&C(1:^ZW1G7/&:NW$C
M\OVJSNT*9(6/:,8FZYL@I5Y!L+`<KHBTHP:__]&PX'6]9%N^WND5ZLT0:DS6
M$V76"7#=ZLN01UWFZF6.%NS-9UTFZQY:#:%VUQ$.9E1.7G@>OO>-Z[XV3O;C
MZDON9/S-Q2\*C\>-'Y!>2@\BYAX*X?I-TI00MH))"*:ISH=9$Y%X:['V:KX>
MJ]=D6;:.Y^Z]X.YHC1!VB2=:6&R%Z_B4$HH*QHRFC2`]5>>8H)4R"&99CC_D
MHO]0PRT!X\(]&00A80HJ6;4&;8DP$M9[J[IB5:.1&EHCZ3"N$>M9DR_^7&P4
M&"X"F4MC5:&I8[FJ8Y<P&I9U3CZ^:)?0CQD"XNP$O]!B/W:&UL&2;`PQ7&Y$
M[/(I(UH3#CJI6I>.O_]7^[W#4I8"OUY23FO.EN5K1N:YCFOH!>NRWF4)CRX6
M)5V_WEQY7&7Z7?#M->T,]_#3Q0Y<[6-SWFL,ENM\ON",L)DO?F;=BQ\D3G"&
M57#UKHDFJLZS>7$.`6+9F/!Q)6T.OIF5#G'5[>#K#>`)_\T`@&`:7_$.%U87
M\>V+N)WM:(D_A"S7;8XE9:7DV)!,!>EFPI$EJBAJ3@Z`@=WMR.5)OAYPY`@E
M^=$?:I/<;$51`BO]OF,-X2)/+=G@;A,DN>X8UX[R;@B!"9J(WMR"X>\WR,X+
MDL7J"^6\?N]L3B#P^Q#KZ5S;M1[)%@\I$C6IL"7'/:RC/G!V]A/XC#]C]NO_
MN$[N5F9E!(?>^?5@$6?MZVU/AAWM!Z=>#E>+97[R"G=M;!VD%`?R^`UE8T=P
M*3)5L'IFJ2AT'X@?&<[U6XYK0F]B5B16@S!H;$*.B1$.O-[>TE;F!";&\X1U
M7I=T4[_>F^'-MR[FKOYUD.F0T5B0"PG&!:$-VHGF7=2C`\$*_C9&F("8'RD-
M\ED.<)\3TWMK7E.]@0CO*OZ.$.*@0X?QF0$89XB@X@:C\/!B]G8]5HP?,EIN
M\_[%*E=HT]BKZ(WLV."UH'F1UDJ^09YU$E;V8"$1;AZCP^[M35]:1VOB\"(9
M^<[5EUUW=#WU$G_GL1Z78%?FY.[>LV;8KV9U>QZ^_[18I:9?WL3`7EKWX#3Z
M=5M/YP_.UU47=L=F^0\&<>SES20&G^@+8I#QL&=E];PF<P[R;9*1"'#FB7_Q
M#P&AUP71Z;Q>\(S>8Q+NY%E[^DJVOV5[V3$SQG:V^0F?W\N@(!8)S!'IBLJG
M:8"!`$/O;=C6/?%8K#^LO8K"D@/XEYH)W-&?DY`!Y"3.<B`Q]#?6F=N;XX/>
M$=NU#E[$[HQP/=<T8T<6F,,">-ATD"K2=^:XDAD*=$C[JY<UE7$9$>:XX5IS
M[(:-YX"%L8"M^2.2F:N*F/"GYSD2^H.8"OM$'W3'5J9/H,U%7N)=?ZO7^A"F
M]08/^_`UZ_(L^K$'"&<!`O]`(&BP(,(`P`8B?,!C($$P`00FK''0(,6!`@U:
MG"A1X,:-!2=&%`@FY$$P!2T6S$B2I,N1"Q.BS-B28X".-W<&>),GQ)L%>42\
M,1@BSX&>0_.4>Q-B`=0#(Q-"4*D1(\2@3D,D+8<4X0$1/Z6^$9&T8%FS(0(<
M6'"VIUFL)&_.O7@`*1BG20G2?)GPI3.K(S=:!&F0[8*"U^Y"^.O2<,RZ?@<Z
M9;J@\L`#-$(</>C3K=NK"U9P76#0:SFAH0\_C7I@;P"U2-<>*!T@=,*C;:\2
M#,K5;-D\4(4BK=T6JO#7PXD#11R`\]$0"<M&WUOP;O2B$`3^''LS.&FN!X**
M&/[_]'7T%6)#NQ7NMCG$P_$[WGW.-0\-X7GB0RC*.[Y)&\DGX$CQ98;4;6&M
M%51M:T$T5%'O.=@3#P^LA19_!@KX$D,0C:13`"<Q)-%A4W68D6%4\99B71G]
M\R*,,<IX$8HT`H;58"0YA.-%*5%DE8B%\5C57T(2>9%CO/VUDU4VVI13AT>6
MB.1%,PU40UBOQ64<0D>)L"57;&$G54LB\D156,_EL5]C8KT5UGX#Z7;:FET*
M-9)/4N%THXG7$<56F)/UA1*4?2'T8:&8L84@3U>IR%-'-8Y43EL'X`$4!%[=
M91:;E#TU)U_(M?4&!+6]$51WA[TQJE!D*E5:G*:V=Q9:_\;E4523/@'%*7)N
MP=G640O<MYQ^F1%U7Z#7(25"<S44]%-TJD87YDC8A5`>>IP1]U-9M4%5'E=A
M]FJ:AU,6"%>PH+G7688=&O@NO/%"!!VJ$`$;WP)_(A;G0'D\L!E$)&K8[G\"
MBF1@DU5%M'!@!3HLT4T;6?DH5C):'".5%<TE6,94F4+#B":R:"B2'+,X<:$#
M6?GC2EB-/*2@=:D8F$!6KNR1BMT&VU@`8QET%[]#[;5JF"#._'-QT"5EK9Z`
M+CW;FV$R;=`UR69<%]%%+3:>DQ<9Z6.(2UY465%W68<CQ4=3G)%30G%V5]G1
ML3G2FLRR6=G;"-;6L[#U\8SJ4_\B\-63;J'MW>!1?TV=D7''Z9?EM:KY6MH*
MYDEH*U?:`5I=A[5!JUU_G'GWL^CC40HK<F_#.1QVBPV%'+-OD'BNB91]Z=YQ
MJO$K,+R\R_NN[W>5`UV_\/7,K(,_X1L"#S0(_COT!I[KKL-*4@]EP`F1"'&4
M9LH<P,7A\Q092Q[AR'%##WG?<*$B/LD^70A9=3#)&O<)\>P\0AD9_#CU;ZY\
M>*(7N2VM.FAY6Z8XEQFND*Q\I#O*J3P7@J88AW0^J^!UHG,-HN4!+(&23,M(
M5\"SJ>UJ)5P(V[A2CLV1ZGN#*DF/;C:5@GA%*&*)RP+'`KKA=0<HF5N,TKP2
M`*]`ZRW_SU$7;#;7-R$ZS6IJ>IM=KN4>:,D-.6,)%PTJEZ^V0.UMLE-66/[$
M,^QP*RNB:PY%)`@?S^F'60?P2K#T\S9MZ>XNU^`91#8DG]J4!RI>$M9EHB=(
MA,FK06K,"K,`!2V(7$-Y/.#!\P;BNT$.<D/G.IB'>%<[`X%H0`8)W\4`F+*C
MN>Q$`=C1E:AT$:N`2"`="5)*S%<5D<#2,0D;7/GD)[:6E8DN)6N4*V.YE<;-
M\0!`A$V6D$(T9(9@@YVDV+T.M$9&+6J:;X*0G%:SJ+,TB7Y.(QS7!D>2CL`P
M1__SY6$J6,$H@7`^AV&)R:;4$^/TD2GI/*/F@O.4,A*N._4Y_^)KROBL];BE
M,6A94]^F":J1(.LMH=/=?6JH&M6E:P&02`Y$$<27K?CL@<HT8Q'CH\_7,*1M
MJ@FHMZ:HFSBZS2S:E`],[>4>'WA).)&D9(AP^JZ5EH>13_'/M2)9M><]4@23
MG*1.?T>[=U4O>R&39.TV61!06HR=/9+).V'J0&#\:W"(BDB?NB?/JUK5@;7K
M)/NL&M5;!A"J(Y)GDPR2*P@*BS+`*LJJ]+6JNA).7VS1UY$4%IAT^C4L<?N2
M?_YZV%M!!#6`:M6K+A/5>R9%+^6*:RJSJC"-X,]$SLI,(#W'SLEZU5V8)"?;
M]K97MXC16-B1EE!XD$1=M29N68K+L_]X*)3$]BMUR.34V736VNA`0FFH8IVO
MNK,<MVQ&CDGL&>>JU<-R$5"D/?1/042WQ;=)KCM52U=YS/+:I+:F-2DE9.^2
MZCN!S3$/U^CM`MX+W<1B$PQ%36IZ\2M(L<5KLS&=*E4Q=C^R@G6T[$1EB"*S
MIQ#&A'L,R^PNN2<B>3(XP1;&7D$6(M>"<`Q[M"P16[>"*L;V2U\V+`=#-;H4
M%"]0<Y.94I;LQ3E-V0MYE<5A?Y:RM"]QYC;8#1N0X8:N3$ZEPY--TH)!F\-R
M43BS@G$P:0U21NJ8+4X(H4YG"I0'2"3(0+J1[7/&T\@&#80H98EO(`_C-N&D
MTS2XE;)MG.;_SRP-)SG6DIQR5G"</AZ*.AWU4[0Z!"V--J:1].I<=,HS0/U$
MQ<?UA`00)X3?3=5909;-KR3UN],>"VLH`V&MI!$+$3LX;WN9UC2J=<I?Z`48
M8V3M"*S=%>L%HW(D^,/96XL,X5W?$D1H[=`M=4W:)3E8P5\-:XG&'&,H&LM-
MVV0(9[[TM*9A\-:(DBZUQ6*4@AXH:-SN"5\K$U#M0'F>S^,262<+)&$#N7:*
M6B?/V(I)_LZ:PWA*9`"N$<BV9:E`</2;O5CKJGF"9H-ATE3B3'67!=!X7FXC
M%Y[>TRDYW8HX,?YWI_LVEEXA*S62`Y6"!)K=I4C:ST63)@[G9<A^_WEKH@T*
MBN2.ISQ4&]JF<+'A[N35K53G^R?Z%BI?/\VO@=R7YZ=.-5*3.KV!M!I&(/9F
MDT&<DEH3&,FDG??U%B8_K5_/R+EVL%F_'B#J?81[F]49F_MYELJ0*RW7)-<3
M12A/7R^0F=*YHMTWM[<%TF:.$\I17JIV1^-HCF.&QSJ&92T?=L$[ISG*JER#
M26&S]XQKIHK/M(RH1MYN:N8R=8V#?K6?,!TEI+TI#T(Y/\?!.:6/?6-((S\N
M/$:?U'.N7Y-Q1">6%1KE)\`IZ;3DFT/.<-Z?-79/I\-%T*&$Z[GZO0;R.B.L
MR`T=7OH.-*KGB.^@7_]=13<Z^-&+WJ3+J__I+W*46$V4L'(/IJL*LW?Z@;SN
MK\LRLT:SWF$&6R;(`Y[>:LUUUQW,6-C8$P7*,BF2`:J3`=6=0F3=N:P3`AH3
M!`:4U'P0&36?V$C$`:X3]PP62("=RG0=_,F5KCQ-<SS>^Y'=BQV;NVP%`QI(
M#VG>M+00X4B1$3G%1=V.C$%+7/@&U*18L)S@\$W<7F6'!]59\XV+6G@.$G(7
MR;E8YSE(!@F-YA61\&U.C]78MUQ1NMA4I5QAJ@'%-53-=D$%#QB/@4`?%4G:
M\PT:\OA4,[T+J=U4^/'<>E&2[R26^?V#4X75A*D;+14$@CU>*YF6XC496UT;
MA!4;DVG88.3/GIS_%B(B'EH(''H8$O'-2Q&AA_"M5#/9$>F\UPBF8+58H/*$
MCD8A!GR`"MY`X-9E5YA<6H_`U+`QXE@=Q0J162:)()!)70H^6#^]X*&@RT+U
MW,N!%/8)'7*PV.:LB8.8QAGM!3WYT8\U"#45C[/U$[8DH4I)7#T5T4^81Q(I
M2.8@(X[UG.@PXQ/Q4PVF3K@@W^T\!1B"'QE6C7#0@`_DRSS:H_8Y'WE!1T_I
M0KX=Q3P&0/,,0QTFI$+N(55TEO6("%LY4`VXG_P5&?PUR3,!&PIJY(89XL(D
M'N3E7R*VVZY-"48:1-NLXFJTGG^D9(VUY*<`%8F1S56,Y($D%BC:GO`U_])[
MP8D(]"3QG6/MO,9><$M#:M8BYI\#-LD_>8XN<>0*EB3BU:`P_D4_L0O21`N>
M7`NH@-84$=9Q),5^X`U10`!7;%#R0:%[X09$R,9[#1KDA".>50KM29!F?*5,
M)2-T)6/(L>&@E9SHA"/>]`JSP)%"@I:VT!$-7,H5#I6<(,]/\EP1Q5>9P9WW
M0=)AHAKOF!H>!DQ\[*%4.AE_.>*!/80#HM\*?D1)@L@?EI7]\:(H>59)$ILL
ME=L>V9.RW!&JI)S9]!9O(LB9!8H-P4;_703T,=,BQ1A!^.1:>(4;,0C9;40%
M[1R3?56!F>19[=IN*)+TS)U'9B?VD&89]69;W?\;4IA&@1@:5H)6I4`$(%D4
M#Y@(@PA%F:E=?+F@<(B.NXP*CCV+ML#E7Z64'[5.KS"%>(U+1_7ECXD%7S)H
M'&JB7D;CI[4<\Z!']25D(XE`/N8+9ZS!MS`2ON6;V^A;0<J+0`[$B3X'LUQ?
MOI@HJ1E!9MIA?I'?[S#D(8I2)YDD05"D2+[58<P?U[U8N0'):7;D6(V@UTU)
MO;D+2<P?4S*0G'A)4F1B#0K--SWF!065,;$EAS$991T?W;!E:G20VNF;BUFE
M8:$C.XVDKND?5,KGWHU7D>"?M;TID^8%OJ5)UL'4>;Q9-0$<8HZ%WD1%FAG+
MA\+=J"2-4DS?A=;9;7+_D?$LG!=N'/)=2T`1BU"4@UDPJ.<5SR+E)?%IF8/&
M1U]>X;C`21;&Z/5YZ'_2P(="7PB<**QR9?<)I*T&P*W>*HI"Q(G2JC[B*K#J
MZO>E:(SB%XWJ%&@J94DFGH-UTT`,HFTJHK)V9+#U8H&,G9UB3T>0IERL7Y""
M9U-AW02FW?'`AA0]"&^*6KDJYR_F"(CHXN9@X80HH.?PWH]Z2JQ\4%.Q)G^-
M(E1FHE8N)=>I']:Q%7`V7M1=);5(!#]>2.\%(<55U^=UA[U"AY<4A1OY7O'I
M)^:YE/%$3KY,3D5EZK(0B^CL)I7"Q0V-H]T`)E=*6L-ND"9NH<7R5F;J&P_@
M_P%4Z-MRP*I_7-\UZ`*)<F52I:A`0I^PE"BP5HC@G&BN!BO4%FMGYA0E,61<
M[:N7=NF'*02/.IE)V%*!A%U(;AWV!%"TMA7#U*F'G>8MV6:.7JE]%!"S;47?
M==0&`J2D"9O`/*`%5L>JI"+3,!NR*2!\;.1UJE_MZ)^#51Y0&I&1CE4BEAWD
MN6#<MLM4JLF?#=%UL89Y#),]NE&!1$Y,,M0?B>4[ABJ$9IFG:!!!_$9^WAD2
M4JIYJ$5K^%%\\&/*J0GR7*'<&(]Z?I!]?,G.NE>^Q:BNML9BZF,?K6B^(>T8
MBBADKL733B_4YBIGO)?31JTN%)6N1@_U/JW4JA?3F?^?V2YK*C45DR$89GDI
ML^I:DT4*DRYI^0Y;D7Z5_%;/K0%@E,)DZ1SC58X%!&;>IOQ89LUB7$V@NIZ'
MPWG.V7SD,`UD.$&$3K"?M18PD[[&5@!E]>'OD<UFUKV;OF:M5?$CH1ECRCI.
MOA`ON"E0-BV<$4%+B[[&&)Z1*/)=[D(7@UZ@V03F1/U&[29'%:4.KFR%M-TN
M@&HB\B16I*7J0/:0MBBM3GWO3BT`#U!QM'THK@[5B@;5RS*+%'^Q]NYJ?`@D
MTXYQ]4;M((%O^`I2LO[B+I:MXU&MJ4%`5^GH974G4Y'(K(D?'G\K_?DK'*\O
M\`#RGIJ1I$73\<B72^;%M0C_W^M>"R<1C'_M460>R'L9&I@8$_`.92S.G.^0
MUMEZ)N;9U)^,%QY?*R3JZ+F0DWU($U-%#Z#]E!$?FCXQU]"TQI<`5E@&G7V^
M5RRR5O71V7,AW_0U!QP1LUWF!W(TDD2ESLS=4*>6JAG%HY?Y7A)EZ/6B(Q2G
M,?0\;>V&%R1G\9?@:BZ+@"[H@J]B[QG;*CL':ZZV\SGCZHG:P0.8LQAG+["N
M\QG#"[&:\1I#1+(R*2Q'#X+U\5'%!R0NG5.)\JE!XO:@[[WR<;Q@5@A%=+PH
MIYJ\%WE\$*C4C=9<D95-]$<6$N!.RU]]#F5&\@O>L!R'K54!6^]`P%"XU)1Z
MGD(G__0=`P^\C&?*;9(@\9ME:JZ7=%E9T$![2M_#^53N/%?M4B[?M"BIFD:G
M[E,(X`$[\FQXY1YRY(>TG9D5)52B,;$TS\NHQ@>S,.^\0(<*%VT^H_&NJK'U
MYHOS?(FM\NSS_ARP\FPSQ5<\]S4\P[,\NW-@.^WV\@",QK,^)S8^P_4^YW,_
M'V9`(_31R<O>\D[S7`-2'>MF,C1GZS3T*+0<>S8AD>U"2_;X>5G?=G4`CRIS
M=M]IXW'2&::QQ`F6I:F\=`88F'(?3S1H:]+M:)L-L2%.+2Z\^-?,;:=I*Q63
M`O4X<N4*R%?A0"RX$6H+&1;L>!EIN`TBI8J!M$?RG.Y+$?]4#H]LTLJE.#(?
M$G8L\_&6@\)LM*VU[HXS3N&S/^_S8K]SOC%+79TSK)*H?_,WCZVH%__U8.,W
M@;.SK3*M@0\V@V>O@SLVA/.S&7<O^$7V[W`FU::7$=``C`[2L8HVB">W1&>V
MT9&X2+^@[D+HS+:EH/ICJL$K\50'$QN(HA`/'PL,AJ-7@3!RI;J47V%:AK]V
MD!>/L=AL&%(1J;J'"/#0"G5A?*R+\C22FG2:2.W3%OF4QI(J\D`+=(?C@KQW
MJ_R&R?K<J6XYGHTRK8XRCRFQE^1NM&D;-XLQKT:X/A^X//^WT";M&"Z`$333
MT0H+?W,H7?OU.2-XH1MZH<OSH>O_@@@\P`,8>H,;N%_7>1B#+X53>EL/$FB2
MWX</N9Q4R'L=](5+M&DGW1T.^8>?^AH_<`W6-+/91]_Y,)"'MOCQ#GK8E8P#
M[Z8MS>7-^JC?MG!`PII%FW"#>(XKU7>]P3%U=J>_BZ8:7S9EW(.:5*I*JA?]
M">HQ\4:3*P(^Z`+U$6RTGMN<D<6.;!<C'SC6+H>F-8/R;BZ[=YJ3=;P;K6+/
M>?<BN&`?>%WWMS@#^I['JM!"7Y\'?+Z\^Z$K^J0?/*'_=8480:(_/,0G?(%/
M?%_G>V-?NH'0.\8;B(5/]G`;2*/S@,QZ>HC[>HPV.ZE[/'YE<Y3FNKE2D6BE
MO,D;R#HU_^S>Q8MX#"0:DGSV#86KVE0*ZWKXD0@(%SO/I<4;#M-ZD%C/,0>^
MV%#TZ:Z"X,OKO)1]L"/?Y&=W0U0Y1H?)VAXD]!&QUZ[.ZL88SO0'#17SW2X7
M3\@,MWOQRGG&W_-;HZBNZCO%"^V@ZWTY0Y\Y`_B[E_-/YO+"+WK$+WI@CV$I
M/(`=C"&^5SSD*WS>3[ZE-WABR_U`]();CV_3B3CXA;RW_[/HCWXP>DK0$>2#
M](U\%VN,-<B8Q4M1H#YTA6]Y^=$4\;)"0H!C5FYF/GM;&!KA;$:(#B0@)1'L
MG">@8(OG:5<57Z$/2IIYG7Y^EA>I5K$?Z5M8?`L/.&-I+`>X</^EL(@%[Y(<
M(\6&%,'LNY<H]59OPC_^T1HZ]A[Z&(YSP-/U-1B!\`:\WP>M"`"$$1$BKET;
M&$+$@FNZ%C+4Y1!B0XD/%Q8\(L)(`SLB'G9LV!$DR`"Z1HI\6!(EPY0D3[8<
M^?(ERY@P99(,<!.GS9O_>/;T^1-G4*%#B>($0_0:CT</%H@H^A1JU)O7I%:U
M>A6K4*I;#P:@*B)/B((+FH8(@%#$@:8'MGK-.G5H6ZHAFH*]MD!LT+D+>-`U
M>S>OW+=1K^49N.8`71XT:.!M6Y2JU<AZ#1\XB]<MSLF#'Y_-@W>-V&M^#2<,
M&B)/7\=>[S:FJW!T6+Q-M\Y>0?;O5+S_";^&I:M6+-V"AD/@:?O:!UF\K_DJ
M%^%W`1ZR>$+0-<R#['/6`1)V+_A]8-GOH[O#'G\>?7KUZ]F#ITWN2`CL!`TN
M,`+>"`_Z"1<<*2B"!_T`O(:<]MK#Z(%''B'(HY`<I.C!DEHRB:4*5TI)PIEL
MJDG##F'Z"42?!AOL#1'LH.&!%%5<D<4677P1QAAEG)'&&FU4L0$6'VD@QQ0;
MV/&!'WN\D<@6@1R2Q09@R+&!+GPL$DH<F=R11R2CI''(1YR\DLA'8`A22"F#
M;#&)()=:4<D'OGPR02;95'-,'9G\$4TSK<P1R#'Q[''')<,$<DD_GZ02R#/A
MW-'0)^DT=,]$_VTT%%(5(TUQJ4HIO?3,'Q5,$%$%.^W"TT)#K=133CL=%=54
M2^5!H(D:A/!!!S^*-<*.+G0)5PPWO&E7#DD*$=@11RPHN.I&*_;8ZI`U5MEF
MF57VV&@12M8@L9Z;%B%GFR6H6&6YO=;8YPPBK[IOR1OM6'"E#2X\<<,SHMSL
M`!3M66JU;3;99[.5-MWLNB4(.^>:>X[;X-9=UEQL"T;WH(0";HXO:/6MMUQR
M%9:87?W0H@YA=+O]^%Y\BTTE.N5XH"[=[OIB%F+'JN.+ACP:ZPZA[)JJ"T`\
M^,/VN@5HN)8@AZ4K>"#]E!N8/Q%HD"[`XFYN+$#[;@XP:OORJ,\Y@_\&2L@(
M>;4^6J"MQ1Z;[++-/IOLL#'*3VPC\`@[/P'#9G7M`+<V(K^Z\L.[:[3]%F$8
M_V"%:'!879T5),1CE7!"77&UT%=>:1H)V!"%O1SSS#47]JC-;T)ML@/2\@HU
M9=_P_*HW1B,*+.?*S0/SPLQZJO3G$DO(L#PL0YVHL`)XH[K=>2=*8K)\UZPZ
MW2<KD3C8I_K,>&6G0FVY$`X`?B#?@E(+KZN#4JZZH(`WS-_(L,[.M]:5\^WE
MH]DO]Z#)R!LH,I*T%G=7#<&H:?^4TFCI?[02($6TUI!V+:0[1WC(`77A'8O8
MAT$8&=NK%.<J`DZD(H23R*PJ6#C#?7"`(6'_7(8:QZ')50Y$PU/A"EG80N)9
M#R>E\XUA3N="K#"'+&HY`'&$!;QLU5`HJ`F/9:CG%Q?&YG,PM&$`$F.6$BV@
M-+.[B>A^J!FP#$1X3YQ9'IR'/2B6SC/*.IYGNB<6"(0Q+&.\R7/()[S"',UZ
M;#19%*'G'#:V2UQ6/(@4_Q,_F72H0K4*).1D%1(.:HTB`Q&(VNY3$'*L;6O#
MN(\N+B+!M*VM(@JLR#7\4Y%=9+`@#+G&)QE"2E!"R((1,60A$Q="QMG*)#&!
MG(<"@$*@+!&7N=2E5'P8&>#A171.V654U"*SZ.$F?".2H4*T\IK$O`\APEOA
M-1(S136Z\#FGDUTT_Q<@E!V"\280*$="A(.3-RP@.?S9WFXP$X`%4!%T/C3+
M#*GI/2I>4XZ3L0X/B&,]Y0QM.<]QGUAF$SWY$4P[]KL?020WRUC61(2K5&4K
M&Z1(45ZDD1*<9`,Q4A"^;10C_;D&WC"BP)`VDI0*%)Q**<)2_RB0DA/YY$PQ
M>$J;4I"BK\KI0V'IH)50Z"&V%-$PB5K47()NC6(QC%&+\AKK5,<'U'/>8&P7
M3>W$4#DT\*(T77B\:.;RG;JYR?C*:<7DB>\W:EP?#8;R3K*<KIN>*<<7A;<<
MLNBEF^V,85KB6CMDR@:.OW$:.:N5E*/EI%I=80E:I@510LK2IZQ4G$X=LO\0
M<O`EE)<5"$..8)^&'"$_H>QL(SD)0<YZ]H'W.<)+2TD@SEJD(N1@B&P+Q%E*
M1@2FG+PM2V5KV<J>LG`<].!.@?I8B+Y$J#UAZG*9RSLAI@4PS=T>6`Y`@_8U
M1J]O"0L2O7(\F:V@,>ZLIQ1;>,[9J267A8D,:H+(5VD&DRY"^0PX?^>S=_+@
MO5?L9C*90]X`U+&M0FSO7<JBG=+)QSG`(7!S]F6\^>1QH519K-@@2\@0@E"B
M%@PE)SVJ2`];$F\+N8C>/&P12!IA&!)\J8HY?`3X<-(_+W;Q$7:Q6MWZI\:<
M+%"+=5$@!?KXIKG=+8<_"4H,9IBRJ1P@2CZ27)[_2!?*47X+0M+H7^DZM8XY
M')88FX*\TFQ1??&U85C/PM`E2N\L>0DB^[97.Z'0;*K\L2]YL78U[[V1ASC!
M'5+W>E8OOV:,-8->_(YV,V4UY6$*`=K6"O*2L7U$EJ]\)4Z1C,K6WM@AE3RI
M".`#28N00R#^X1NG_3,,_?@GI"FF)*@!U^(6^QC(G7QIK%\]:U?'.*8OY7"N
M*[N+3&.ZMD8FW+`[.%$!(M?)4E;VLI]"S:Y$>;WS75]VL1*;;09:.9!82PBP
M>\WA52N)7&7A-V\2%G%_#BS)3&+IEO>9:WT.>FO0'DZXAQ:V!#/=LSNP;S8#
M/V'VF38Q3`WX#EWH`QN<_WXWH]]"2+<UL?3JPI,U]F]?JTE=F#*FG!Q(BD\]
M4L^NMF@BL/&I08ZW%&/4"*M%N<AG#!^7JUSE+W_Y:F<>XY?.6,<VEKFN8WQK
M`NGVE"HE\B8K2U'$"7>`3OX'LYG>='0#\<SGCJ'UFK6^J[XE-E3<B[[)LK3=
M&'.I+:1F"$Y'7Q>B^:N02=[5F5@N-7OEBMHACWVI>QHHT@R&8H06W+,ES=KY
M-^ZSFSMNKF6RNL3K:(67<T)9X_#)3EJB$]]@:S\I.-NRUN;72+%&/;QB29Y8
MY(]<&TE3G'(7+Y+F,%=]S5??\I;#I^6O]GFM9>S:G^,8TQ;W;28]&=PD$S<D
M2O]W^O")?_:U-+4NON->]H2U72-V%S/%)'QCM&UEWG$7S4N\:EF?<CL^/\_L
MHMO-]:ISSIA-*R@).8!TCA<;9VHF+'GL\W;33V6JU`6*W0N/='`#F$)KK3H>
MAD%&`BWHQ\(>)(,&YY!^S?(^2[=V[)-H3?,TBJ14#I)`BV\LL`(_BN4N,.8N
M8L98+O5"#P133_5F[`-1<.=2S]5D[.4XK$!VS*5$[.)H4-A2">F*+OB2K?AZ
MT`<S!W0^8S,^YZWB)XVH#2NJZIT,S*W,0H?(`A*6QKIL""S03>I4B,SH`NJ:
MK72823.68ZJ@+UO8*P#P`!($:IV@,*ZPBBR&4/_Z32'_L@L`<8.'``/!D,DQ
M$@TP"`Q`<(8`Q4;B6JG8BLXB8BK3<@T&<VWG8.^E2"H#-:\"48[F)(D'`F?E
M2B[E+%'D+-$25RMP1%#E`@?V2)`$35`%39`<%A'F:L_%;@W(8M`0-:GRADQP
M..PC<O"#A.\'=Y$7K0*+LH7MLNJ=J&<(!P.8JI")YLN:A&EJWFK,],U[EN@N
M(N,SJNTWLLO[UC``RF']P,<RY$PM)J/0_NTR%`*?7L8-T2*(XK`LOA".Q,7P
MXB<\_J]L!NCH%+#BAF[((C#G:HWG7`X^AD'C2*H21T\@)"G4CL#4%@EP-H(3
M'=(388X3%5+U`N<3(](B*3(C_R>2(EWL(D\0]E+1]4#RYF`/!F4-!GU+MG[L
M(6JQ%G.JR7BP%V>2)O7,6^!M=LAB!;#CP-@.ZVRG.ZS(>>K#*<1O`2"A&*]O
M^\S,AKZ*/*Z0=JJ,,MBH%Y#G[C"C?<;/*[Z(\$@G#\KA[_2B=OHMW<AQ-&;C
M[1S&T&JF912-+2/&X>2%058)Z3"(YVK0UU;RYUSP'UTO)&$.QE9KD2CQY#[*
M$]=&(4=M&`*';TYN(S=Q$T%P,2.3(RLS(CL2Y#"S(TDQ!5UL!3_P+V^N'W6-
MR&)J%O52E&!2%VN2-7<QW\(NC,"BVP"-#`>C',QMAOB(6=*GS)21A9C'*ZU/
MA<`)_?^PK@#)R_NBD8EPYZYNLW5RYV6XY>[X+8G>[<_>KC>-Y30<CB30PE\(
M9AP/(AX1BBSF`Q?Q,1\?`C5YK@5M+/5F+C!'$",%TR`MDE4LDA)1+,7L`,42
MD_06<S$5<B/Q$T`%M$`#%'`$]"+P,T$!9R(#%#,?U`(]\2]7\,54$?9ZC#1C
M#4*$[B5C,KE:4T2+[RS7;G2(,+#J:""V#'ZV3H]&QXC"13@S1VO6#9?0#(N$
M97[8SB"(XZ`,+<V(,GJ\Q]UPHX92AL[NR(V.<S(:B,H(*BZ],_$$BC_ZI@#[
M$()ND=(JJQ9]K0%[+N=F#B!1L")#LA//U#\_*@,!1TU1S.3_%K,Q-=)`#10_
M-7(CZ51`*?,C(30CYY,C,[,3&=$43W`D=RY,7ZNWA*ZU#!%"5G-$'W79!"M\
MBO,:HK#;6N/N6#0QR*P^V&**VNF-I(C<KD\9S4[LO(K,A"4Y-^.>WNZ-Z#`G
MCV:<B`B.^DTVTI%^MG-?ZN\U_,C_WO$@6$4Y`"-I'FPN/4C$@&X?:RTP79%,
M/W`81C%"(Y(R3>ZC`I1OH$&2^%,_,=`.`+1`-W%`Y[1.`[1<R15<%=1<S_5!
M^_1.+;+30O!969%`W!/&9(P?9S#C!,=1(=5?FRN^GL^=,`,P;B,`C[++1H1]
MEM`LKE%4F1`XS`IUR.7N9G1XVDG,_VBT"S=CKHQ'+Y3&7W+2-=JQO]3(VKP0
M)P)*?J81,V0B6`VCT;PB8+!C&N7,6#VN:Q!-D4))@U9JE%ZKR%82Y_SR%%>Q
M3R]33LN50:&!;_A30.V`![1U,?E36[45;Z263L%5:[>6:[LV3]55:1TT3P\T
M:2]30COR(LD!33M33&^NDV`1QW*M7_^5;HFJG]BH89/G+YYF`<"K+X0%F,+N
MC82I1J<(=V[".9&''#$'8U'6A<*1")-RRV0#.<73FZPK*,NM#;^H.\P+(=8Q
MNN!/H'"5*<]R&BND/`WM:P3P+O:/;4*@;^@R43.IQW+N/4FR,X]67/UT0956
M(]O4"+B5/_^'@6KAM'B'`1JJ5GF1=WF3EWF?UWFCMWF1EWJ[=FN3-ET==%T5
MM&S_-%`MT4*)%C!]K+7FMF[/=XFJQWN*Z!KDJ<RZ3LLX`VCTBLJ>)V'A+J[X
MD-[434?E#C7*X4:ORBZN+UM,MF'DQWCN:GIP(WJ<(C9,`Z^RY6/CKTG'L'2A
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MR26;/M<S(#@K#N(`\&N!]0D/A(<W-(,&A$<^W,AQ)8,,3;6%0!4)><<HM7$;
M=T.*LB=@(J,7R@&[D`FKJ.AC1S>"5U0FA`,V>L%^\*\I0(+;'(;3%$UJY@-N
M@*W'.*M"4YAH-1%M/7E[KW==/[F6>;AJ_X,W&.Q`HU%Y&#*:HU?9E7<XED7:
ME2T:I&&YI$E:EG?XAR4:3].5EQ]:0D7Q%&6NF(\9IP=#.-ZM.+/3"6&C@`'8
M&H,#5#_#4R\C+VYS-9AH-;C8?*`K*PHW^XXHC[AOFIA#FF2'_OZ+.:":J0-K
MO0@&.[/%<0$#9C>$K!^N)#087B1L-&@@A+NC#_,F;"YBE%SK+NLU-`6U$Z=5
M,XOX$SF10"NZI6DYAHF7/^U@E37:"%Y9>IDV>5'LI"?;>1L;I1];I%F9I:>W
ML&VYI8TXI@.[>S43,QEQYFXZIU.[*GA#8'%#S_0J?LOLB]^,ZLK(=%$VNC#X
M"QNV">G-)PG#F?_%>9KPHNS0F85*M*QW0YC<Q;JPLIL(C'O62<"L<AH/BM%B
M@F7SPGZ"]1;5LF\\KCG8IJ-DK.+@<V@[<[0G^EVSUK,)^[$=>Y5'V0Y*(1A*
M&96M]I4;.[-+6K+AVZ3?^[U+.L!OV;T].VO1-:*=>(65V+2/`+55&\)9)RW0
MPOGB3XKVQ2^N3H(E(SOL5YB"R;>AR'#_K3Z&<D5'G,/U38[%CIE,5Y?TN7+1
MT%AV"'.A:+W:<`IW&Y^Q*G2G0CQK@E@Y@B7JH[KO)SM&JFBZ1C\N2S]$J?+T
MNFAG#$T1%'L1'(:#&,L!?+^=M[Z#H12@8:-'N;Y/6K]5V;(E^\Q=&<W_I3?-
MF5:4(_O-W=RQ4]J_81F4#1MZ75C/4RRB*;*)%?+E'CS"!]V=O,6/'6/L!.]E
MUG>,IYHP8%.-ZX./!+?#GX=P*UW2I:*-_S>`_R+MTNNYZ&PL6>:P%AAZDO1E
M]()87?6`L;O`&$Z49F-L1*\_(+DO%NGVA':AQ]3/99J(V;MZ\9RR9SF_(]O,
M&?N4C:"^UYS-39K.'=NR,]NB^3O.]=NR\5N([7RS*[J68;J3ZW0^'5PF"9W<
M@Z(7^@E4Z4*8:N;"3YR+T1B<G3G-@H,W26=:%GDJSJ4TZ.?0)'=Z\J*GSRZ9
M!GB8R"//O$)TTF=OP>??U-U?`)F0=>(X96*A_T*@):XT<=BZ*00GI/BB:P2B
M*6#-YE1QO>U43O6TO7_XSI\]>L\<SB%[ECOZE$OAAJ%=>=L<Y[$]VHT=LB6)
MYYF]OZ<=YIFWS>?\LH\^SW&X>MG;3A,T%`6]W(_98JZHT<@%2;6X6)[M/V8;
MWM$-9F7;?'*G??TBK',TU'-5[1B=ZS5'>LC%J.;'@,/#>\`P?LJ,.^09X`(C
MJ9YM)"+L&JI2%[SSX1)I'H6\QP!$R14I(5O,]0*SKR52(9%8O:M6(5=>R^,[
MSK<<YET>&H+AE&\>VT<:LX?]>7=>]$__Y5T^I(>^V7V>]8V>P(,=0+$V\N<4
M;3<1ZG-:)W+Z+!.>6/^NYL8KH\QB5HBN!GO,!W3\O;TN_)VXHOE'8IH#@^R)
M,##(Z>#C(KA_>[@!_IN'*1LWXU?-`KHR/&_'8C<DC#74^:!NE>)Q!M8#/SP&
MGY(FJ(^49C`'0N0+]3)W=Y<!8MB180()#AP&#2'!A`P1,GP(#:)#AQ$I&DEX
M$5K&B14K!C,2+")$AA>'93R)L"1*C1$WMFR9\J7&F#-%<JSIDB5+BAPSCNPH
M\B%'A0D)&CR*M."1?TR;.GT:(&I475*K6KV*]2K5K%R[>K6Z]2M8KF$#E!7[
M]2Q6M6BKLHUZ+<2"N`M"2%T@PFY4N2+NSI4J5V^`!74!B[B65>VUN8@#++;_
M*W=QXP#E_@8N#+<NW0`B1!P8"S<OXA!YI;YMZU7RWK]K37L][9ILW+RL0Y->
M$"!$B&MT'^?.PWE!'KE6'^?IN[4W8[.]'HM8H(NJ+MYS\4:/?DV$D>='LFO7
MCE<$#UU'RA\A=]X\^H'E!;8_R-ZH_(5$@=H,"BT8S9/YC="D*%1_,OGDD'\?
M892?1"$!R)-(^G5TT8,2`;4@4/Q5>%].!2)X'TL?W33234,U)-]!(L2WU%,J
M-A5;;-*9!6-5O<#X(HUN385C65O5J&,`,Y[5XXTVQJ@6CSD>*>2+81E)U8Q#
MQ@CECDCV:"2.4HF0QVR=[198:7N)%L)P7N8&9EUC_X89@I1:296=8-GA%5I?
MF<'I&)V./=>79E:&]=AHM25Y8Y6!%J=:;V,M.6B+4B):U6Y6PA598<D]1]A@
M>EVV&VYO5C=9G9W]115UCRF)5V374=?98==@]]T"V[UZS3`\;-==>NNE)]")
M[I58T'SUB1@43R'YE^"#QC*HD7XG#>M10@N&E*Q-T!ITW8ZG7M,>?0^!%)&$
M.BV[4X(U!1BA3OJ%!"U("$W+K8'-MMO2@SZ%V-%021FU8KY1QNCDFC6NV:*0
M/NXI5;__'KDHDE`:3'#!8M78;\"/!LPHOQ,S#/"^N85WP&QZZJ:7Q[O%I1ND
MSV696\E?"F:C6KK)2>9A=?_2R5MGB+TIYS7'D>;H6FTZ1MID2A)\%L-`QLCS
MG2A/S/2A70'IG0CE8$57TG`=L``/E`HFUW%XC49;TJ'*Q0-AC4W7Y6ZZS.A=
M9*M&1TYXT)WZG*RNGHAMK+;:JM2)V2KEJU$-_21LL<V&ZZ!#'Z*[;GZ*#P-M
M@AM2&Y8SEA>#>>;<9#Y$YIE;;CD$$`0`QE38F;>0X^\^Q.RYJK].(8.10RYM
M[!7>3CN]@Q-EU$'YKIC8H&\-W=J_IQT/I<`9/ZU\RT\FSR3TR0=/I/).$A]\
M7,=!6BF9F'G\)6;>AU97J,_95>20!^2U%<AMDP:8;B23=AC/6/*&L&/#C:8R
M:@?_1WPP,ME%9S*K'EL$Y1KBU6A^HE$8:7;6J#S4!0\]B]ES^*>E_E&*,`4T
M"_W89Y::I>IMT4F5S4[7&2/<+6^U0@^VV..WO\&P=]KZ%5`4IQ.AS*Y8N5/=
MM,2%P\,9)3I2$1WHF%&,(>1B"-M@XA"4Z,1M2'&*V\B%%'.Q1"QV[G/<")TS
M1`>6Z_Q-=]!RW;`:YSK'E3%W&?&6Y,3%$,9%+EB[*\HP?J<BYS4O?^G#7O$F
MYL<$.NUH0SL8HF`S/40^KY#/`\V0^MC(V82,9Y+TDB1)MB63\>9E8**4('U6
MCOTYAH`HHZ1CUG>_JN7%:M.;#=#ZQ\A`3DEZNJ#D)<G2_[2$*1)M)2,9_HI#
M/TD!C0=RP0Q5^&(V^7&&?I!9)6&TMJH?F3!-THD:^UB50A&0(V_D2"&MT`/.
M]!S!;X#[V[WJ^),(/0Y=0#P0AKJ%0]H]2T`&Z<YTHE(#T!5C%EF$8A:G2(LF
M"G0;`:6B00^*4"PJ=`A6*`8SEF&Y&H`Q1],A#^I25Y,?)FZC\/3AZW"G49C<
M<'<(21$>6>0OI^$2-HQLS1\)^<>'K52/BW1>^M)"4^8-#TJS^>4#2Q.TQG0-
MJ,LA$P3#M"7B4.E)->L8T/3T)KWHX@#$;,SYCM,IU_14@*C)'_,RXZC("+)*
MLA2>C3#(IJ`1;'VZ*2K6ZF(VN/]L+`04)%F=;B-6ZBR`!C(SWZ=X@QU=A$=5
MU\'3=GA3*Q7.ZD3A?(]29@@X;0V.7FF$G0X[*L>-8D@A[#E"Y9@QBV+D(HE6
MS&(_ERC%@A)4BD-0+4*G&(YMQ/:UM*5B:16*B'TN`Q@0<$94P"!&\QR$=\G*
M71J-1:$XUBZSE1UI44[JE)PV,I9F#>!8JYM2LV)7339]S?)>RL?II;2EUW6D
M6J."ISDUABXP(PS7[.3>,`D-+6)=S2;ARC6B#J8TB!F:=T8SG/!2=Y!/HDIA
M#-55['X%39W:C)K0!M>I38<VA,%-6BNLFSR8#R\T$-IBRG:8']624_V=3GB,
ML*H4DX/_!XO!&SE6O!WM"+<\,>S5O>A#7/S($S\28B<[NP7D8$6NC`FQ9P`@
ML`S,F7;)6*PB:[?1AB:V(1>N32U":7&+-MP"RUJ6XBUN(=LPUW;,"(5%%14Z
MVF(`PQDU``-P+7H$^W@+N89KG+/@^)..=D@AT$6I2C_Y59V*=]")`G2A7>K=
ME@:2O&T9<*+'>Q6K7=)^DRP3*RD9&;4NE;P_FU/..F.82GV-*[[9:H(-W9J\
M$@=0U+6NBVAJL^35-]+5"=EA./BG:ZR!4B)(SEY--:?PK,HL(VXQ"7$&G6-K
M;3OH8;$1:'6-6_5JG+D:KD(D"ZPY&@[(`')0D'UL$\]&I;>8_VNH$IE\;M0.
MM(IMB.*ZGQQ%+`<4S-N@]Y;%7._4SG;+MPA';/\=YMF2><QF1O,L9K%;8)`N
M.NWQ-NL<#F1P_WC;]^DS4Z0;P%8+6+P9[^ZA,9Y3C7?5U1MG-*0736B>@LQD
M'[/D;1C3:8\=1C3S1:23M`27_]Z)9EN*=?[Z9&I==K?C0^-+8.Y[MNHU>KK9
M.V]:'7662CIJ+L5T.GO="[1/)4U+)ASV=%I\0E;A!<7=V45V8JS"8:10VB+8
M57QL7!3[4`3<%`^RX29.9&I)Q7+N\-P2TPUX+$Z9B5.&LA3][6\H,S&@C!<H
M$ZEH[UM@P!RW,`<&*D_YS%?^%M2@QO^7/4^-</"[WZ)'/.(#?GA\D_FV"L7<
M+)P!#.!Z>\BSQX_M\<S#B%C\'S%%]:E137+@#YKDP;^NR(W_>Y,'#Z;&,\PD
MNX=7ED=E?=\['VF<"EY!T0]2\ENES;Q?0+6P%:U[Q"E;4,5!'V&U:24?/BV3
M%W3N2S5&["W-7_!T0D\31A>KY#IM-MEUTL%_`3@=W11CJN)9SV$$B^4?Y"1<
M@2,?Z#1WMJ=M>'=[-B$0UQ$57W0YGN-/6B1XY[8-9B9;G;<*U+`*M[`*EO<+
M&!!Z5O1X\-9$M+!X4Z1EYO`$.&@..\B#/>B#/;AY.QB$7Z9YFE=YDX>$EF<.
MH3=PMI4+5@#_!CUD=W,D<10W<:JS>R#'?$/'A1_G:`KC5>6U7<F7<AJG?.WW
M<4)R<Y*&::E2:5SBAMJ38367<H[4)D+5&7E0#B*4%Q`T**XT/X[Q?F:8*!,V
M6%F22718?-KE>WSB<VG503C"=9@V6!6$:UK30-Z!86-#@'=B0M?R*=MA=NCQ
M;`M@$IWQ'BA2;?,Q60!">S]VA7!4(0;Q-GOG#`[E@:2E15.6"VU@9K`0#M0`
M"R:X"K_0@BV(`1APC#U(#>T614SD"^[@#D]$C:W%1%1P`VIP`S=`!?AP`V>@
M!F<@CF=`"V=0"[1PCNE8"[7@!^MH#K7PCO'X@^9@"1A@`_>(C_AX_WD`)W`(
M)7"YX`QQ9H6U=X$0%W$LD879Y7N_QW2(1'2])X;9QX5;J$B"5I$/B4!@LUY\
M051[^%29Q)%YH2KNUX5R%52KD28[QS."\2_E$&NL)#'^<R.D04QF0BE999'2
M!88*$Q:BL4!!<S!18R8=,QPVB8?/L0(TX"@W4V%S040FQA<DU$V?LDW800YH
MAQ[\]VS?X1[C]';P(3C7-E*TQV-E.4>]0T1'!CJ;XSF9TXN"EPNP()<F>`O(
MF(S)B(S&:`Z_D`X[F`[IX`=^0`8@``+H@`[N<)B^@`Z^8`(A4`!U40`A8`*:
M8`)48`),L`9`P`E(P`E,T)E`P`2AR00K`/\)*[`">U``J%D`JUD(K>D`)J"-
MWSB.8>`+YHB.3X`!]:B;-F`)O'EY!'5O_"AF`#=:NE"!!GEWR5EW"9*%*$>1
M$ZF%!/:0#N-'Q*>32V>=A"A+QZ<P$:-TFG0EXA-7>T%,?O$RC7$]B21H*,DF
MA4$<#01(WI%U++-IT+D5/T(^-,!!NE&>23=@WDE@C(B?[5E!G)@558-U06.4
M62<"NU8^,"(><"6`=Q5V$X9BQ%11TX%VYX%V9.=88!F!-E0[4[AM=-<?1A`=
M8,"!W+`Y;.EW<=EYG7>7^6@#]FB/2LB#?QF8@DD&;4`&XF@,-V`"K2E!"P`)
M-,`)6,`)I7D%I.#_!(!`"OQP`E<@!#AP!5<0"51*`EM*`EBPI5@`IETJIF+J
MI5@P!F"*I@V`IFN*!%@`!`7`CO-8CS;0;V36C]M0#&!PD+`XD+='9-N6D%&1
MGDUB:!'CG4YBJ("&GX2:J$,RJ(Y4GX0Z,,AW?(_Z(C/2+X@J(X(Z,$.3J9SZ
MJ!A#4S_I<I9V)IHA%ZCT2^^WJ'H4=9T1*INR7TFG51]3&VJBJ9RJJ[GZ+W*A
MG_KY<F_`8@ZSJYQZ2(XJ2+EJ,3#B)/EW85Y'?X'!5W72"ZBT:EO#5YW1'#W'
M*0((=LDF=BUF3]NTE5FC';3B=B!:0ZU(HB:*>W87`KT%`<?01>[`#7UG_Z^;
MTP;VV`<T2J-X:0Z`B0U^``*#>09!.J2%D`>/Z0,TL`9=L`8-(+$22P);H`("
MX`(:(`%C4``HX`0:X`2D(``G4`%76@$G<`(H4`$GN[(MN[(D"[,P>[(H>P(J
M4+,TR[(DBP)7NK-5.@9=BJ:<L`:=R020X`.08*0+\)B160`'8`)/2P512P7H
M<`P!<!'<\J<6F)Q9*XO-63V8BB.:>JP%-DMBRZR36K:=:C'-UZJ:BC&7"JJ3
MFJM@RRB\VC"/]"A@B[>N0;=G*ZD#"D!L>).2%$(O=X?&>B3I.3!Z.Z`O@DEQ
M8DKW27^:$7]D]2CDI2/%A)25@6M2LR_1<[:+B_^VDFNI2(*?LW$`C4L:4Q.Z
M5W=K-W,^U<$8'!2[O(&@@!5"J3(WK'*`W8$>*<0#:K<=79DK2#%<`4*0[EJB
MR;D=!S"O+`H!]EH,TMMWN<"O^-B;3X";`8L-!CND![":"Y"4#;L&Y?L`#1"Q
M$SNQ,-``.."^5Z`"+Y"Q3L"Q%2`!("NR)'L%+]NR*LNS^TNR+1O`+CO`+)NS
M`MRR^[NS)7NE0G`%*.#`5'H%)$"E#BP$)/`*79K!98H%:MK!)-``(*R^#=`%
M#U#"#[`&#T`#/,#"+&P'/&`'=E`*=F`$,?QL!V('(;%[?=NX:DNH/QRW$+.V
M%J.X?HNXZHFX`ZHQ86O_Q!ISK)*K=`]FQ(#[N0V3GCVLMM_I583[5!86?=YC
M2\C**-@CQ`-*/^_30;$*,ORE::)K)?@)QVBKQ"^"%Q5&*64S:FH+0),*Q%+<
MJG$;NDK,-FT\R"&&),54*B.C)?LY&$W)8OTUB:?R08=!-Z]R&(EU8FHW0^8D
M..Q*9%7(IU78'R)P#*)#K^[@#-QPRL7`#>BP#?2HO1Q@L);9F@60!RNP`'C0
ML`X+L>@[PA++OL#<`.P+PDD``SA0`?'K`DX@`9&P`A4POZ1@`/H+P"K;OR5;
M`=9\LMJLLRZ;S=Z\LMJLL@7,O]S,OP.LS0F\LE?ZOU=@I5R*`URZI4D0P@U`
M_\\CO`,IW`40:\(TH,+^3`,)63%28K=-S*@&G<5&<L7+:B-M2S!4#,5,#,1-
M;#1Z_,:O]JA@**F>.DMX^\=NS,63%H?,E"6(8;;(>KFBRUW'Y(9MW"0X8S.!
M2#19S,2N&KK[1;M[Q4$F+=%5',A\V],$C;=EH7/]XDN3\2-O`F(%M!AVW&MM
ME36:44W35"W!1%@3]AUD%P+/=HIN9V/'*Z+BPJ?+&\IBG1=O,*]IK0EOH`GE
M<`!O[;0F(*2%\)BF20,.VP#G^\M[O;Y];<_U/,PD@`,6*[\@&PE[X+$@^P(O
MH+_I;,W[^\V1O<T(W,TO.\[C?+)7,,`R:\TR:\`(W/^_^_O`_[NS.RO![$S!
M\8P#55JE)'#!7%JF73JQ';P#M;T&^;Q[8TS3!L3'#5,6<PQ(%LU3G]*4Q<W(
MG*I7QEW</LE]_46L0AW<#OTO/-S;B-*WTZ/$>5O=5C(;Y3`VX<$E=7R>2Z72
M9/O;O(V2K#0I<@.'\Q?$/ORU20S?O%9A^IG&RQK'TO,\6-S;"]VJA^NX;=PH
M.ETVPQ87V5HIFX)?7O>M)%1+1A`WVC0=W1%CIIC5W_&`ZDI<-U'6H$S6PV`'
M(%XJ!Q`").XUSW37Y9N^?,WBPGS/]SS"QMS7)'#,R2R_3N`&SNRQ3A"R-LO`
MWFS-V@S9!.RRZ5S`1\Z_WHS_SI_]V.2\P*(]VNPLP:EMP:LMV!<<S_)<ST"K
MIEU^VPVP`UF8WV/[MD`]TVEKW2DM`EB@`J3@`A[@`6_NYF[N`:10`31P5C1`
MYW$^YV]>YQY0`6L@57NU!GC>PV,.WU2\,$H7JL(-Q!_-T0FCMST9?N=CGK,F
MQ$)-W9"NJ^VC->C#K,@6-JPQT1%]T%J\(\TQ,^&Q!BWV&7!;T1#=Z?`-WX:4
MN&ZA)T;]'/.]08(^2G#U',.ZGRQ6/M54*DY94==`3(<%-V<G*\LF8^VA*V^W
MKLM%UF*MG,4"$C',`RF>PBT.[BT.X[\<S,$LS,3<OH.MS(:-V//[`B.+S=\L
MY"6[_\#^2^0"C.3]&\";;<#[KMGG_-GJ#.78'.57NMI4&L\3',^M+<]D"L(=
M3-NT?=MA;G&2N]'E7>H^O>G:S;80N@8CT!0=(/(BKR).T`!0$@)KP!0C[Q0=
M\`\NSQ0F[QAK,,$[8.A&'!9Q7,1P:_')FM"*LJG^/<37/=&7AJIS$6NG+L2,
M3L0]O=O$2C_Z&1X!4)Z9_M#5$Y5XB\CE0S8!,*T3W=`7W<=9W.AV"]Q#HG,V
M$AE@:S/KPU?'3CX1"DU359.]5BT7Q&+5TF*N0@YP,TY9<Y7,EHHV%I;(NZ=;
MFQ\?$<-%P`.,_P"/K[[L:^[A3OGB[M<2>\^2/['TS+[NF__,&*NQ.NX!3N`"
MI.#C5XJRZKS`DIWDX.S923ZE,CO`_][OL"_`M$_OHFW:IMW`5TK!!G_![LS:
M5LZE:@K"L@WQ.X"^%-]G/K)40C_%9\OI82_4DNI!:V`-'>`"0J#BW>_]^JFV
MV:'B^>S]*EX!#!`-3M#J:["EG,`#HQ07\<\E\D__MNO<_9U`>QP;<9PP`!%`
ME\!>`00:'#@0X<*%O:Y="P$QA`@1(01"7)#Q&L6'!@L>5%A08<*'$2->.P@R
M@,B5(U6.W+B`1T:*"RHNL+@R9<J/+@=.K.E19X`0&2<N>"@B(TZ4/1GJ3#AT
MH%.G*H5:/?A1)56#$$5<*_C1:T?_BN6\TM1X,"8-FQ4%%J7X]6+,HB%T7;M+
M3H01I=>.^`W!8]A>$<..&#YRV/#BP]"&.8;F.!BTR96A&;&3.3./(@\\/^C2
MX$$#TJ4;)"&-VO1JUJQ5GR[].G9KVJE)PRA-`@8)'%M4O'"A04*D/14\.)'P
MPL")"A6N-*_`'`5TZM6C7S_!G#EV[=VC:\?^/?QU[%>8/W>>_LIS]E>$K$>Q
MWKU['$+JXR`AA#<)_OVQD,"B@0`#W(&3!G;X)T$%%V30H*U2FNK!K*P*":H)
M6<(00H0*HN&%#@Q8PZ801B21Q(HB6F@@KTID\2@LG(B&E&MH,'`-$0(0@83L
M=N11!1ZS_^-GQROP6X,&N4*J<*J1>O%IIP@K="I"EI(<*@`:S/,QNP9PZDHI
MH/!*4:<,=2DHA"MWY*<"$L84RJ6P+'2()DC:0BNBJ"Y,*,,5E:((PL"6`HJC
M`U"<\,E"GSHTPRF'6K0E"P]5D2.7-JJ((Z(JBHDFD(H*T4M=[JJ)HD\_I32N
M48^(:R]R4#6"K\)$2.PP5!<;IM9:(3,B&,WL*(*S!WCX[#/1&@BMMMIPDXVV
M9&M;UMC2<)O--!A@P*&"WUQ`+I(54,#6!5)\K"`^\J`35USJP,NNN>[29=<[
M=,5S]]WMJKM"7/;*E6\^'-8C84C[WKN"A%?Z`Y"$!@P&4$#2=O]H@$&'%R1(
MS#"U,I2KGA9],RHV(U;HF@:$J<9(&M;888T&2$:Y9)778+EEDQDNV6268]XR
M1VNB66HFE!8@I0.??^[@CJ"%)MKG.[X9(9IF&'#"@"NPH`%%)35DTL&JWTQ4
M0RDEU!BD%^\`NX-H)+@BZE(GRBE#"E>Z9H$&#(BFZ!@KEO`EJ)1:JJ:9TFI3
MJBH12BI0M,'"B*V91C3*;C:Y,M1O2"5VTV^Z&PJ`4I0BC,FMP3.-JZNB>,![
M`;7B8FK44D7-BS!7^6+]B%5EK54QQ2)[S`Y@@_5L6&=-4ZWW9VV+UMEF6<.M
M^-N`W[UXU'#H[5KAB#OAN.0,4"&]<*W_LPX\>,-;%]YV=^0N?![A1:\Y]LQW
MKE[UXYO/OH#?SP\__@;F[[\!%<:"X8?WUQIR1Q??BD+\MS5#5>PG5_B&!MIF
M``8T\`<-;*`2(,@`/CSP@0QX8#,TJ$$-7-"!#&A`"-;@@0ZL(2<ZX8$+&&0T
MH+6P`P\3VPM"=#D'<6Q#3;I3E/QWJ`M=J`$,8-`=FG$"MN"D*#1LD@[;1@(&
MO'!!(W""U7JH)*RQI&U*X<%19)*6JMW)BTRJ&E#@HB*FM"U$;.%3720&0+H9
M\']3I-J#=-@2M95N=!II&XKJPB>DG`UT1F$2J&Q2NKM<PU4+((?I"#,3UL%J
M58B!Y.QN]9C1_Q@/-I>T#;)6,[S=M8:3T-K=\'RG2>(QSUK`T8`;M%4!"3C!
M6^"RWO6:,YUS00=\W1M?=K)T@EV":Y??^1&ZM#<OZ*#G.?:*#_O6`[#W+7,_
M!$.8_?"'H/TYS"H8FUC6,!05`FHS40NH0#0$$(`%O&`:#YQ&!W\`@&9HX)P8
M3.<T&BC/HWWC#M'0@##4B<$?<$($/#A!![`@@BZ24P(+ZL`WHK%0642CH0^E
MP#>^X;.'C>`$//`(F=R$DHRNT5&&`@N9D/BX`F(!B`[K@!,&>D0X8O,:/"#%
M-RH:13(]CF)RQ!M<EH*4K#6%;36\U%<T59`K*H4M0%D`#?+(S6S2S?^GD^M:
MUZX&1SPY"*1ET4FJC'*7HJCHB#1!$5H6D)!/!6:IIFL+#_!RC5U<@QR,)(SK
M$`,K6]7U5HXQP@-@@!I2!F\UH)36[S0)+5`"MI.8;``HD\5)UQP/8<U#I1,B
MH87H(4<Y\TH7]L[%KN]4KT>\U&5H1?M9T8+K1]N+CGG*%Z[SM4>9_I)/O_JE
M'_R\XF#_.1C^2%--AQ70?QF+HQ<IISB[Y?`@"[A"-`Q0#IA2H!G"B(8P-"B.
M:(BC&120+@6F@5UA4$`<"3+:-*)[W>[*H@$B@$1`29"VRBU`A0J:QAH>,E_Z
MSO<H#7A!,U;H@37L)%,TJ5IQH;(1&O5+/4+_.!E.I*JX'U;3HDIEJG"GLI$K
MW*&:WW`"E0K8"[S-9"8W:AM-1!`U+KYEIR=&L4QNDI0;_80&+Z:!AV5F(QJ*
M!+@8"EW>Z*NBJ4:5AU%ME$8/93E=<*07!]`91FB(D:2*("$XR<A,1B40YO()
M+Y]"%5)X0(ZVN@YTK8)58AX).]@]QLR1T>NT`MO83?I56;_CW9H/&^<VA_*O
MU7+><+;5K6]M!SW$S![WL),E0@<3M*#U42]'>^A<CDM[Y#*F>E#`S'TQ,[;0
M+-AM!80%WC;(QY^&"C9]&V'BDKK(X1PG)`0@#'%L]P?"F(:K63T-Z_Z@&;&^
M]=".9NL?B`/6S1!'_P/R`-`.A+"F`X'I@I307P&KJ"0+6,,+9*J@:+S`(AH5
MP16F80TE:.`*'#UV5I9X`B<DPAK9J$8U%AH-552C&=:P!@->0(*H!5<@)ET0
MV!84HP:,U-0B](`J]NV$)TK@HSH!BDA"@`4^6"/6\5:!46*2Q;1$983P5L*V
ME8!QCO_`&HE@@`:<\+2]#6201Q6"$S0XC1>(CJD"#@$)2,'M;;M@!S(1`G)?
MC(51-WM1.+RIGO@D`K.@+50C;=L?[8*CB,CDB*/2!5PD54C"V"3+A''DF!D3
MNTE"AC(/P,'QY+PLQO)5>,8J^YS5GEC=0#8XDEU!9:=7O=5J5M#:V26B=_^D
M@D3S_;-9LA:C$[WW7+Y+7<6DCOK2QSYFSK8^[MD/;C.=L$XOR-3-[M_E-8_Y
MJ""7'N/DP0=N/8UF]/J<LFA&--2QT&_(8@0-58<LA&9/(=Y!%A3(QJNM,5`:
MJ.`.ZUU(VPBNH!^L8?,LP=$($<H`XSMH`2>@]@E(#9$KO8`!U;"P@G3M1/".
M(!&DJ("-2-V+!BM(`R]P`O>C,?(C"9@'5X"1@K[A@O4\,<,O"=2->A'M%29B
M2TG1,8W1A37X@<I#J`X8@6K0`%+@!Q(0'2T"G1/0KP1Q@K'B/*+@`15@@!%(
MD&]X@2TIBBM`K@!I@`M\.3?ZHLO['+O8G#$""2;_2Y6H.Q$1NQQ!<A6\:"N]
MH`@C6``PXPO728PP([.Z\KK'R"LU,Y["^JO6,*PX`RS9>,*U.ZS7X*37X(U3
M<H)!4*4]<R52$`#,`K3#$Y^\TSM=(D-$&[R^"ZU"\[OON3OLH27T4;QDRI?8
MJBV"N2W*,\!_,,'B^KD^W+P($X%PXH<`"#U@D[5L$"]_8*%_L#"*(AJAZ0!_
M<$1UN#4-.J\%X(=_P().4(ED4Q!KZ*_Q"R`<:8#L2Y!F6!."6``5H#85\#=R
MPJ]I<*)H8)K+XI$7(`4-L(9I^X=H<`$2@`12*[\$^<`=>(%H4!`ANH(LBK!>
M$*$3H,505($068."P[]*_Q&1$+@":W"8:DN5$?F*D0J`-5`":F,:)U!'=10Y
M)VB@9A@![J.`D4,*I**!$Z@&!:E`SC,C`YBH?_B&'ZC&:Q,!+`B!!M`/^?I#
MS5M(D+@IIH+!P;F(B0"+B<245/D*3`F,N+`+4N&CK\`R<N`+'O#!PO"+6!E"
MNX*,QPB&8`"[Q(*-X6E"F!0[.:-)3Y)"M,O)9^$-WX@L;4&!=50.6,*>$S"/
M[>F1P#LTOEL.OG-*O4O#,C2TO!,?\B`FHT0\Q8,/^7B/?X$\^?&/:-K#?PA$
M`0/$LR0U<!*GMLFO6],N1!2:?S`:1Y1+"Y/$N'S$;P`V#>*]$_B]I2.C]TJ0
M9?\KRZBXAC501@5IABOH/.A+D&B0OI=`KD2H1080@"OHE!,1QY&Y`E)0`E^L
MAA-`"F[J!7Q3D`]0JG*R!E2\@Q.@,7$3@370`%^\`SX0`K42`6I*$"CBICP2
MHZ02S&KX1R':FYP`$VX:P`),$`;`3)=A&`/IERNPOG^4RV\008Q0BA?(1PIT
MLF8K"B9Z(;&AQX40H<!8`T[`*+0,$U([.(U9$4.TB>.L'$LI!XI8NE)!BC(2
M,9`<%3[ABROSBXQHI+]8%7(@!\:0'5LIPLC(*]VPI&BAPILD'N31R;5C+#K+
M26HYI;?K@15@I2ZDGEHR2C#D#JA<2A/E)>JA'J@</%[_ZKNG=%&J%*8WM([U
M.2;UB:V`L8_YZ8\Q.)BQ5,\\"=(@12[EZH70>R=QV*>C`1N)2JB$FKTF;5*`
ME`5Y^H$?."\>X(<.`+ZHX(&#@J]1!,0CG<!4O`*0:,571+H32$Q'-(`LZ@I3
MBSK91,4..($62XEB_(<7H('*X<8F6A`&(`&"NH@%$(+M3)`[$,6<B$UL)`FF
MB$^BD$#P(K?$Y%(1^93U%(@U\,8$<0$QE4&AL@D,3,8GVI+V$H%)I4"7*Z[#
M]`!?C`854*I6[:*&-+4@LQL!LT^!4+%R4(GZ'*O.(0DOH8F'R,^:N#)0H3@1
M2"2W(LD0^,'7&;,R4XPSDPS*_W#)L`NLF:RS3*I)-]O)<%6[).A)YX$[%#@.
M)_#"S)*7=NDLO%M#IZ0>%9A7ZOE"'Q&`J.R[>45#P3LT[FG7<9%#YWBM^8"?
M^NB/@ZF?L2S,7&W8A[4;M10`MJ0`YXHN"D`][H-2=:@G?_!%N>38;U`'YY(%
M\QHVOS2VK'`O96N^ACW,CRV^QHP^C<F1!;$&$HC%$WP+595+$02)<M!3/DT)
M@/I8##.^F-,`!K&&"@!,#KM&!>'-M\"4Q-&%!5!.L3&9X>N`9OBPCF*J8G0"
M,?U-["0J)EH0":"QMCF!3OV'"H1(AQ"!%^!`\)*`>C-+">O#&AN_Z9.4MMD9
MGC+,/_\IAP@[H@^S'#I)UH?XLJ]XJ[@P`K=RG0)-C*U3T#-[#,HXPFE1,TQ2
MPF^]4,/B5G$5W=;`,U3:P@K`%B=X@1<@RG7I#K]+0WU-47P]@2_,U]I5@7O-
M5Q7-7=#275V:5]AMT5LB7LX*0T@KV'^1'_N0/"`5LF/[PXI\7ANSH7`CS>IM
MMD&,!GY@2V6X4F'@)P9@4B%ZM7RZTG.R)WM2!P8`WQ^0IUC;DN?CTFL[B"]=
MD/BZ0"22WV5T@A8KB#1]3%@4B<-DVZ6]-NK=O.=KT_B23],TQCY5D7)PFZ2%
M6FN03FN86T=\@1UH/Z)XVMTTN%#U38Y@T\?T@!<K8;D4S8?_$-)P6X-$4)!/
M'0C[M++V$IV-X(<VK8;X=0AMTT=6S9."U(!XE,MIN`*W:.&?L[%;=<@@'>"R
M6!&4B`DDFF(D"B2,*(JQ\ENZ>%Q%2JNV:!6_((>3E*LR4TF6I`QL?4G@@1;5
MZ%QCZ:O1)9;5*)8YMF,YYHTK$(#(8H,5B('475W32C1UT5<U=-%Z[=W<Y;M\
MY0?JX0?=;62G3+3;S5U^2.0U+"VE;`[/"CQ@.CRL5`^"Q5'Z0%C^P(__<%Z$
MF)KG=5@3O!H>6Q(!)(A,+=(7,$31BS4*L#5Q4(:@>:'J*KW1R[6?^08&T.5L
M@#7IXCU^^,L\:1O!_(=E*Z@)F^6J_YF1;EP0#<#9+@+@7U0!M0`G)^H`/K7F
MK&!E`1Q`#UA&T9RPH*4!LIK/:&O3#NA%[K-@(ZGF(OO@?^!-HU,PC."!U93+
MF[4)+*#@?V"`'6@*'!K`<TP0M)5!+2*H(EN*RFF`@[Z#9AQ5;%[5J3$3?N"#
M[&L&&1K-6>:)<^X*,-*H5Q8WE59IDV8JAZ#(B*Y!)6,2)3O.:::48NTCO6B+
MCM0%O>#!4MA!9OV+6'D=6C'C!<56.T@S)&26";7)T'668@F-.K[JTJACTP@-
MANGJ.<[JK&88UG`[/G""#JT`)Q"Y0(Y13);D0UYD>HUKVWWDNJ[=?!6`?'T!
MW*5KO+;DO?].Y$6.4>%%4=#29/`16#FDP^AT'TQC6)&X7M*T7I%ZZ95V99A^
MB5Y02P,XTOQB->T2AFP0!U^^`W7H+ENC->TB[8"LTNG"Q'\*J$Y4B048O@2)
MKT]Q"#"Z'/L:L08X`1A.5&];@"5^ONC#"R99@Y/ZAVJX@@/VPY4.MVSSQ;"-
M"G<.-16Y1_%UF`1RP)!2B4:%6@E`FZ.PD\`0@EHD!31:`]_K0!',$\LFDQW@
M@Q@VH4JAX4IINHCHD`413:#PX031@+$"HP4@@?SJ0&^+FA;FF"5I8I<`"05W
M\&<,M_<<G-[D"$IIV@?7;2P:I&8EA[9@UBO[<-#9BP48!C&.W,G_57&[NEPT
MKHQ@2"Q+>E`HE.JH-A:KOF/2&(VM-HT='Y9B&8TYX_$DV!<5F`<)$+E(8`+C
M$#D7>(%\?5%)EFM[Q=T59=T7X(>]?O(GS^N\?F0!>&0#>.1*SFL#`',!,/-%
M'G,QAW(79=&V]BQ#WHXY+Y_I:`^N#!B!B3P28-C,IJ)SGN:&0&<Z$K(`4Y'V
M/*[DFM@%^(!S(CU;R[6)NB=7TR[KF@:P:=(?D(4?4$33Z\OY[:)GMED'-)RD
MVB+#81D2,`"!1L!F<((M8:INCM6#B+D,UH`=D.PNBO!9/DR'7FXA..YK<.!_
M0$W<AF?-)H'X`Z]J<(%^4YR-V&<H,B(O_YG!-:AM;8XR0YUO"I0OO!W`:5`0
M"3BOFW`R8RV=EPH,QTR0%6Z;"NC4#F"`&U:*;@Q/8#RORRDHA_B?3`VDCX+G
M8XNP8X=N<UZ1NV"*]BRJBJ!F4PNQ`-2%(Q@D_L2Z'J0(R945K:.5KKM<RW!)
M!ST>-Y8ST-U)'"^-1R"6($=YL)[C(`=RE0_KE;_CK$ZL?=ECM3YK+G3RUK6E
MSHIR,F?*+A]S+!?Z+0=S+C?Z+-]CI,=R`[CRWCUS>V7*%W5S-83=1GLTUF*?
M?0D8_-A1/M]#S-;99Q2(3&5BAD9.L-=>[N6!_&JUB)I+2=<WF0H;1AR:A')$
MI9F&T,[$+;UW-/^M;;E4&FMXM\$7?,&/!NH$KWD<*!8.-UF'13+9WP?&U??&
M7EV@`5)81A4X8.OV"6N.MD<<(L"%\(-<D`02JN[L,"QPHCN(.)MXL350=XNR
M"\BN9G/4Q\5WNMU6L/;B@7M<D`H834TL4PTP$C.I[:TU`*+SMWXG>Y_C&-J'
M[^?//(&PST_9_>97DJT:^WRN565]J7\V^!)WUAW<LKA"\0--R:Z+C!=OR6R=
M2<!J8SA;.Y+7'=!X@!U`^:OV\='P<8#H\J!!%X(-!@X\J!`AP8$"%1K$L47%
M"Q=.G$1:0:*"B@I7<#0(*3(DB08X2."XHE*EQPHG.)Y0H2*F`!4U!>#_%,#O
M!<47`E[LW/GS!=&?0GF^.($T)[^:36W:/"%`JDR9,:]>=:GUI<LK)ZY4\(AB
MI1"R)T_^2ZMV+5M=`=SJZ@57[ENWU][*I:L+;@"Y?/6^K=LW[ES"@0OW6E"!
MGH!K"TA1:-9,UIT._^Y<_M=AL^;+EC%WJ)RYPS<*XB@(:["`AHH[)$+@O<O#
M!=O:MMG>X7."!(T0UWH%]KO@A-IH)^S2>+'VQ(*]>MWZ#6XWKR['Q-6^:![@
M6@,&:U_0*,QW;P`1:YJ]6'/-.5SHY$/L6#O"B>,%(@:'6-#`B5H&#:XY%@(-
MJS6CE@98N'=8``%TIY83:X3`PS4AB"`"7(Z)_Q#AA%AHH%8'S&EXA34.+K#&
M"]\4!]Y=[B4XGF#14?=BBW\91EY[>.UU385W.0;@7NY%-QYT*RK8RXHZ+K#`
M-318^",Y]D7(`X5&B$`.#\.(8(01Y!QQ!)==#G/$,&&..0PT9IH9##1J!C.,
M'0_``(-(<LK90!(-U#G2G2+M.9*??Q:D4$$#K:'0&@\,VD"ABR):Z`..*DJH
MI`(=2@,-/&#*0Y(9'G#-&P&4L]TP/,!)P@Y,^*#HI2&4HPD$W,#JSC'<E#,.
M#S2LD2NNNEZZ`*:76AHLL)FN]NNMF0J+J[*Y,LML`YR(A$4#)&!!`DHIK<32
M5E9AY=)+)WP;5EA7C/\U5EDD?"2$M;?9%I>"+A(&G%N"Q7O8<SCB%9B"=0$V
M[P)71"-`.3Q\,,T/##2C3F@H?G/''=_X0]K"I#G<<`?W_/.-+`9/,TT#(@S7
MP6OC+2`!NR?C]DTUUFB@PAKW\;6`"L6IL.(:M*EUA79SO7N8NX?]NY8'-.2%
MA7?8T9!OS]5%J"21[MKX5@AKR.?$`B%0:.%V_Z*H6060A*!+?O;1<(5:([P0
M=GORZK)&(@YB(:74(%^8I&\A5%"-6M:H9E\`5TS3WPL,C&#9/TZH%K:\2_/+
M,[QLT[LX7_0ZEZ]=.TZ8X7H+0LTY=85%3ICH]27)@PCKK4>.")I.6>4U5%+_
MF:679!XA@IAEHGGFFKNS&<P#.,09DIQWYFDGGB,5[^<C?QJ$4*$%=?'\HP=1
M*A"BUQ_Z*`T/'*OI`D9<?;IO=WWZ*03'0.",.^X,T7XQW$`0P"Y&\-#`#I`4
ML(:T:RPPCB;<N.-][X,?!,:QFC4$RU=)6B`#&^C`!G:"@1&<X`(FV(G\=&*"
M6-M@""X8@G%XD%4<W&"%DF22F7@+7.#22E=:0JYL78$$KT`+RM0"NAI%YRTK
MLA&\I/,N(3UG/$:JBV*B80#'O*`9PI@&!1KVL-%([!NDB9@4-[,9*7Y#'<V8
MAF1VL)H3N"8$U'$,SM)B'&NA,8UI!(M2&!`-#S7#_PD5"(]P9F;&$VQN#?S)
MV0)\-A@@Q66'@@F:6D@1GNTT"&D\C%?4?.0BP,C%/&OYAA/"ECF8Z;$_+[./
MV+!6HC=JQAIKZ&';E.`@U30I/Q62"X"@U``-8$8S)Y`2R/XVHK180PF@O,PL
MB60D%OE0D#>BT6#ZLKEADJ=??-'1Z<2FN?8(25\]5.8?K_$DD&TJ1Z^S3^R.
M<`UOPBY+MOL2F<J9.]VM*1A&"(8ZX92$."5/>,B;YT@>L:=X"JHAV8O>]81U
M+`4NL$(9&A^`KE&.3P7@#:XZ'P08R@WT%8,9[9OH$-[7EV$<<`6%6`,)$-@)
M_\&*&\6HZ$,A<(U.7,I[#O^DX$HKZ%(-AC"$Y<#:3&?*JG+@-*<X[84F`J")
M5D%`$ZX2:E"+*M2CSI0&#9@)4[^E0G&]!"POO,*Y<*"N&JJ%<4)TW-("Z;-^
MY<5>"OH-O40`L!?T@@:D$$?'4!.9`E7F81386#2:,==FA":NTY"%,)3(17%\
M;`'\$!EL^,(#D^VM`2-<K$!]5:@K)'$MS3"`TP(@,YK9;(]IT5GEHF87SNDP
M,+]9``G6\J"Z)#(MX`'MO(1(UND<YC?NFE`#)JD!2XZ-0A4H4%HJ8!^0^68O
M^8&E&3V@N!7E90=\@!N%LI:A'6U'!#0@@1.Z]@\&0`A`%1*16GYP`B>`\@ZD
M4,W_,6.#([;193U>]6QHMVJY]MH+0,UU9G`M5[G7S@6Y._1+=%"W@-KY:D>Z
MJ%#L7.<E7=0.=EJR73EO-R9TLBF=Z803G>0Y/'H>;T[,\U,_AY52394"#YL2
MJ&_*8=!>A"H`#5TQ^M#GT/^MN*'N>-6K8#52BI(4`KV(X*T6D#]%5;!5L'*?
M2.$W4PB^E()*SF`'L1;"Q=8TRCK5Z4^K[%,H+'2A137JEK4,@7*0=B9706&X
MN.)"&,;0;%C]!PZG\UF[$'.8YWU:D-[ERP3)I8@O>`,/#&"P'XB#`3\8],,<
MU@Q`,\!@#`ATQ1ZF@6P(^F`=P\(7[_"QX)!Q+3]0#^JJ_^-I`&V'2!/B006B
M83C-7,%"CK'C/XS#RAV4\1\ZVXYH@9E,0.I(S6D9FEU2^P_P.$>0PL37>G+8
M'DFJY0Y6NV1^,FG&EX&L1RL*P17TIIEO2&@P=WG+&@*7%L0E"5?V"7>XUW`"
M4VOF#C_0&>JLP]M_:$"II+#V/Q*A,[4];3LWDJTT]>*7PN1[F6"]4'.W5M_^
M<L[-,FK1'^N2(R4]:=RJ`U\(J,2E:^SBF^0@QX)A1SO<G3--:UHG.WV'I^#!
MX)X:9MZ>EN<GZST@I=_[[?C*`1P5XSS&75[Q0EV\8@(R5,;_F]7YN.$,D;9O
M&Q2%7P#^X"L:%*`03%!5)USE#O^DDW3&$(A@DKA.00PN,(+Y62S6QO'!F]XT
MRFFG,I5Y6HZ@0B&H1,VRW+E,U&N06LQ8>2H+OU*!L5`US:5=<ZWQ5:/XWE!R
MM';15Q>?EZ>M2`2EYH<N>$`*R4R&BTH\=6FB(8RZ4J"NDYQ&-)BH1`I0X&,T
M.`%A+V19S?Y#E*0T_.(,>J*U1(,&H1H.9KFM'+7X=FW#9%N^[T)(U2;-+;Y>
M;7YIWSGR%!XN(AA\6N8S-NV(X`7T'AHG`S#V'XF`N+)L)HY*N;<7:"M;!GB!
M$ZP1R[1\PS^^\HT.3W#+Z[Z,!R<807$,N9T8!5S"U=F;_9^](`9^I1=>5(@E
M78WKB0?_[2T>YR#7C_S2IVD.-JV.Z53<Z7A3QGE3EZA.*1R!EAB!@SF8F>A.
M[[#3A*'<RAV/RM5)#-93S&W)YMQ<_.2<BGG94''9SC54ELW*0FG=C/D<_&A=
MD4T4+1"9CHV#")0").3!1@%9U4%``!'9^WS9]7'=V%V0W8A=!379DW&03=54
MVJ$=3OT44.T4W?'@SO'@C-'=3)%`4^V=M[#0F9G%FK%9,4V3Z/@0,DE'C+"'
M=$S.OZ77OT3#"R#1GPG##W3,#SQ,:!R:,&A`H"%:HZD#`PA#HG',-&"!=('1
M:^A%IG77*%''&'756RS`_:4%"33'9=T17="``2Q'TD#2C?B;_Q#IGX<8@`BP
MTO+1T:WY$;RT"%V`3&V=C02(30/J`@W<WQTP"3/6QWW\!@DL%_S1P%TDH*_I
MX3_,ARM*"89L#G=]VX@U`%ZIQ3<H5C114VO96I%$4^$%(C/YEWKA(N.Y%P\-
M!G_9XUY`'/C,GT#I`CD@&,9QR9=X"0\H&)C@CNX,0X2Q"<E1V/'DR87)TX;E
MR0,LP,TM2/S$6-S]8$AZF0_2'?J,I-:Y"OP8817*F$K>V!`H7?L0$#ET@J84
M0/[DRM5`P=5AW2%@X=:YE$MUT-5<T!>*X0;AE-F9W1GB%%.RW4]A&4]A6=S1
MG4@&%3>T(0\&@/[MG=[9X4N@@%A,E?]*Z"'4T-F^$&,N&AYKB14Q2E-=2%[`
M!(!:"0-;A=X=^`.*Q%5>WD$T/$S#*$Q>?<,/')HX+)$2J=Y@C4R^'-9:R!YH
MO0MZ\<PUB%]O*0DLMEK-O(59G=J#R)D^`A%<J-797$%A,<C1(!];LA=B4$Y@
ME!`R5I\3S,WID((ZQ*9!94V`9(TJOD`L?8B2\,P:L.*:C0!O!)1<C,U>``Z)
M($F)O,`N58,!Z)Y@'%-8@:8!*I-:7F=U8,[W"9/B_<A[=18T!=N/J-<"D,.$
M4,GW5$@'(AA!?N!!CB`):@G(H1,TI%/)E1PT4%B%O>!%6AB`BH22J!@4J)A'
M(NC;\=R"9F7_2&Y90Q4AA,(/T5E=2[Z*,[P/CN58`?%8U.E*_VC"U=W82,'*
MEX$9&%[-!GTA!CE9DW504]+4!TG9E-$H&KJ=)O1"0UV9W5DE#_KH&Y`#3,0$
M4WFEF4F51TQ560;BK=VC(/*A6ZXFDSYI,?T+8R"19(A#-*!(:'C&9F#&EF*&
MPX0&:3"1YHF#9%":_H71*"Y`K&U:?[%C-`UD9?Z#;UD6JQD'880`">R2-9"`
M>NTCPSEI=33`_25"`_Q(.0!C/K9C,?G;`I+6)#D!7#0;NF6,$ZS1N9!`64P+
M=5D7WYBF\J'F-*!?!:#+IH+%;AG.':B`DHR-U&R*+1G(N&7(:EQ!_X>D136,
ME];<"YXA1EK.WJVQ4G<^$Z8]3I,"XN=4X(]<#9*H3H7`)\9]D\;%9Y=T7'V6
MB4/N3G[J9W]6F']29)_T29Y(2:C$3T\UE((JJ%:ZH0^R6(,>@Y:I9-$YU*S,
M"M;%I$PVE"YPW0(4@K+T3XWYI/N\SS'4RDL-I=@Y68JF*-G-E-G-:(VVRL2F
MX9=!`4_!'8_V8!M:Y37@`+@TE9A9Q5:(BU0!GAXZG#3):6NI)G8FW@\-HWWI
MV5Q^P!8Q417Y0\;DU9=>1F5(D9C*`F$Z(ELU`V"!C&*&#6.2@F..DN$1!J"Z
ME@@PP*G)VBOBJ696A[-E3*N*I_"]I5O\R__["4#2K`@)H.:O)=_S-=[SW4AS
M@0SU>6,E^==UI,4=5`,#X"T?)((UY"T#Z"W>5L/[_6:Q[87;G)("-=:M5,`T
MQ-(TN&)ZA@^DFM7]:0#-V8=CD(`+=,T(:`"[!2N]M.77ALY[,5/8--<QL:UU
MQJP!.EQYYHAP58E`'4$(="#&%>0N5.M!8HD=D&"VYHX*ZN>:]"=%8IB`_LD"
MV-R7-52.'NB!(NB6^92#MJO.>1F%3B@!76^-%<-+3A06!L`X/`D/1)VR=(*0
M6:%,_B2%,"P'%>7"MN@&C</#L@K$/JS$TBB.XN^.9BR6]>CT+E0`X("WA&RW
M:(57_)U4D>6:H2[_H%:@OL&9IP6)>HF:C4R@,MG@Y@"J8JB"`&SE"[`585H,
MPPAF%&&1P^!E,R",(W),:JQ&:[R&;%7'`L#>IGF:#OE;L4FP#IW'6EC:?6!F
M-*C`TRK&J6G`?SB<L,76Z&AM-)"`+U;':7X''>T0`\.9#I$'#NO";QVC;3E-
M.=``:HYI7.55&(]I&??'?US(&IC2MW%:LU8'F*V>-1@.'[AB*UUN*]F?@4!;
M+3'-&G@`NG5`-8"(IQ%R#H_'D5!P>\`P?'&GY@2((RTK!AOK`TOP`RMK/_IC
M[%I(Q@TD@@UD[FY<EX@)?6K)F?PN?NIGMYY<AJ5<G1"/"R:/"."4BKU=__3:
MLJN\754^J"YO6;S*6(Q-*(V]"OK,ZXQA'4Q.%`'M@A/ZV+^N`20@;X@BW8T!
MD(Z5`TR%88HJK$QY4*V<G3<GY=I)+!24`SE;;#FW2HYJF8_V;\^YRD:`K%6(
M[`J%B[B(I9(^\=,JLC['EA7[C'H!1S\N2"4S$@S/5A$U!B0DD61H:<6L10?X
M0R1&=*'U)>J1GNG953.H'NM](@5;'M..CKR4E^OJ2'5)%@\<0!;3+1!/\0[#
MGPLTQYL%TH\H\M;<'O(-T5Y@P34BWP[EU^L^[7/D]-A42'R<C1,`%VD9#FE8
M0U,W0U-#M61`M34\=3/L4@<(@':LAW"JA0NHQ_\RJLTR\@#`[$UIME*3X-T)
MT!L#_%9,/VWV[=(_N$!O'"LKO6[D$&X^/[!Y#EB&Q'!8,_+GU/!=WY#H4"`F
M9W(,[T(G2^OM>@D(BDED#P/]3'8IHR#P[B<[#6]%"BAG^PD-C`,M+Z^.>:3S
M.F]5-FA1N5C/_2"%TAA6$O,O$W.&)MT2?B^/^2LDK`$/E.__%,,A=*](!543
M'F6+$B7[EEW]YI2,1FRM2"S^8BS^3B6/LC,[KQ@\,Y4!R',=?H7?10*2ZF$_
MVF!U/-Z0Y(C#52#A.O";C;>^N?<3+VN5"D#E&<"@)9H&V'>A^0,*3X,&3`/>
M'HQ]#YH&4**`_\`GKE[_!RC6D6REFXZ2-A*R%0_VA&AMW39Q#./I<<!9",#F
M951N.=#T!-;%#O&`$_!?6DR#A``T=YPML.6S/?:S74_X7@@4LL$??6A*:OG'
MPW&2</4XZ:S!^_&!$%QQ:GFF#D%7#.O'B?]#=(X/I%X#.1Z.IF@-!@?2*YU:
M-7!6(;O9&-TU*VE;RLI6GC63M!&V(?]?4(\.)?\J4-/TCF`4079R07ZR?'))
MF-R.F/``-!@![YZ)G_-.*OL./'UK2,`@G]!3;X"*\M9RW-WR#YHV&TKO@X8D
MT*&/U@GSC!GSO7(OP>XKUT4='GA4JUQ=11$9TQD0&+*H!XE=^S[94L*OC,8O
M__WF5/S2*(KQ5"]<;$\9J":0\W2O<SOW5`,(\)@9^U-U=\E60%DRTF"?]^O^
MFR7/5G@:M#WZ]!73M!47$3_@W>45;>GUE3AP!FD(`P64:;DSD3#TU19M3+A+
MAFKP@&(V22`U9F(YUW.16`FM!K$[03,P>:N]@"S[X]7:HY'@S2[=`0-<@934
M-`2/FA#P0=?<@37T!N&N!S`:"7_-M+,_#03KD/IV^'Q<C9JFQ8<P28`(Y'KD
M9N0F1[)9S8\8;EIXM0338W4X1J%(D6940]I,B-U$N;==U\F'.,&MGK4%<GH0
MKEVW%WYQO!]"+3WVO"417[-/N)@;=IK3M.MF/3-=4_\G$V2TYNYCCXF#\6Z?
M][D=H+V@Y^=$%KH,'GJ&A00/V!RZ'FB.UG)I,^B"ZKV6F21+%I4Q%Y5*:D*+
M8:](=?J&@N\"_>N`A(!0V5AP$U`3MFA,=1T7JNCE*^79)?>L*W>-DO/<2V4Y
M*Z_R#A7_IK:K,$@\&\!3;'>1VK-'Z&$#0SA\$S*8S[1H'7&TC[E/\QM`2[N>
M(1%;<1&@&8P)]R47:>*@->(6`=HF%F;'G"F"&X"E69(.M:FD$D7V:W_VDX('
M7`3"_'L')$(%\$`^\YX9!;'MX]T5,$`LW4$BN,!N-("E*!`/K,$.?*P+R+$9
MC1=`A-`U,$`O70<:,/BW\-__"QJZ`NBZ!G$B1(L5!THT>-'@-1$+2##\]TU#
M"(1.&#)8(^*C"(DA6`Z\=FW!`A$S0RP0TH&A-1(=URAAZ&3-P(XP;P[,J;,9
MSP[1*BRX!G-!@"O6&&J0JLM@UXD;/U[1P#":$Q(A9D+L-3'BM8@R"\K,&.#:
M1JX2/29EB?9B7(IM_;YUF_'OW+IW.Q(F3([E3"/7=E4\<HW<+G)'CER^/.P(
MYV&?AQFQ([J4$=)V@J6&EIKU`QBO&\"(W6"V;-NT<<N>W8!'N7*]()2#T$M3
M``@0C&LZKEPY\N7'GT-HSOSXL>7<HC?';AT[=G<0NA<;,IX\-^S#A]4L4&C!
MF@4A_X2[XR9^O#MFWP.,"]$I1/_W_/?[;[_^!AQ0O_[XT^_`<@X<QS<&'_0-
MBEXB'$>37J`(#HH+-=DP0^JDR^ZX<AJHX`053A!``'Y4,.!$%5`TT<039*S`
M1I%PS-$HB3(Z+*->Z'I+,8QV;`M(MBR2*"*[N!KL*XI$N"(:#6@ZP04)/'""
ME"M)T4`#!C1PXDH/L)1`2R<\N-(%4B38LDP75EK#A3O6X,LH'B3(\8X]^>SS
MC@YXRO&?$1AX@80%RL%H`17(4H%(BT!ZX8<[%GHJ$2U7-("?%TAQPIIHR-+@
MA)6$Q"@AD1RJJ*V+9`+2J+I6O:LNFAH0B:2/5`!UH2ND^O](H*EJ2@K8I'*B
M@0]*1](@J36P6H@HN)1J#*\%>%#!FD";X74FEBIH]A^M*AI,,%D7:,")$1:Z
M(Q$<WI/+78HVHHLK>0F"*R^!D`J7,'KKU5?(M0@;K%["$AN2)7)T66"RR!B6
M"#-R(.9,A,XH!DVTB^TH@H<B1F/-8]=>NTTWW7*CC63<&D`T@.*<,\XYY(QS
M.43J0&P.NN>XF>X8[R#86;KS>'9GYV*X(6^\8HA&KA=R:EJ`/1H6Z$0Y^<@3
M[SQ-].-/ZP#YBSKJG+8&,.L0#B2;['+.=E#M!QV4T&WBX.8P0^$ZG/DYF@-H
MX(03-6UQ10%0#'SO&FVLX`I!$8?_-M[#``XX7H/HBE>C'XFTBW'%-@JW@6JB
M@7H-+$AH@`020&\`A]))3UUTT5-'??301Z^)A&:BV<K)!5Q`7/=_`.W@FVBB
M:8:/0DG@P<Z-%CB!(55.V)')$'BXP@4EFAD!6<0[N".::A@P(&4>=YSUU$H%
M>"@QN[JB/,D=9=5%A%H9&L&)<C4(M)J57I**JIS2`C:O]TX0#:?<@09HV0$?
M&`*G]LGD/1/9UAI.,(U`6>,*/)A)\IK5@?D-#'Q,DL@:/%`-2CVE`@5DBU>8
MM!'TW04OVQ(!6FB"EO1YI4A/6M+DU'*Y5Q$,?(H92&..L`!R4$871]#%93+S
ML"16[#.=__E,*49C!SN4X@$/*$(*C!",U;0&-K"IC<EV<[+;\,8WP!$.W(X3
M@`P1!SDV@X[-X&BWFVGB/"'ZCG*XPQT(?"<\]!G/(9(6@',P;0'K60`D$*6<
M^0R!/O/Y3B_*AB`"<2TG`2I0?\:V-?TPR&R;]&2$'@2%,G:(..68D-R6DZ&[
MA0@Z)#`1C%2$(@&<B)8JF-'>:$2C"NP.1^Q[TOIF^*,>!8R%C4N?O"R'&!ZE
M[QHT((4&C3?$1)5#FI0A!WQVL8MQ-&DMU"3'.(9XC0>)<RKF^H83*F*7!9`"
M>.UTYSO?V0QK:(`4*A!"RF8U3*XDKYW6:%[CE(F3-52`%)_R4_^?HE$H7AV/
MA3XR5SN_<0(:``Q]E?,A"REBD1"L(1KJ`%XS7B""%UCC=]$HGT"40JT%I!2E
MNL@)#T3`-!IHP)TJ6.D::`J\%Q3E20"CB0@`]M(KT,ZC#+@"6A9P!0:TTP4K
M;94R$>/`17VJI#MU%T;2UR19"09Z.7FA1-K50QYVT(<%(T@ZA7G1(1V1);NP
MR1$BX[#*)'$S3'3B,*`A1=*(AF,/X$$*/!8,.X"LB[5)PA='AC+<J*P<`8A9
M&B'[LE5.YXW0L4[/[!B=Y_#Q.-OQ+`2(9K2C06<7G:A)'@H!MG+043[%.`0C
MYS,BM(T-;+4U;2=,.Z"H;<U`F!Q'@SK_"2%0FO(WFG`;UJ"P,@Q!P$/,\1`K
M0]2+$O%-!?Q0D74%%S@9Z?(*N^0E0U18S+3V\"W!S*HQU>J\'J90(C28QC^B
MX8$37(&^ANLN?>E[J(!=(WKT10%^ZUM?!GQ#@T[=H0-GDN#^);B%:$VG`Y7)
M)`8_V(,>O"`/:$"#-:P!:D+4UV&P:A@%,SAS*ZPH#<7;(X_8),$M27!-6IHO
ML-J$@2^,R8C3TF"TJN^G'?DI](:5$\:P.,%9)>N.>33BR04SK>'-2$WXVRZ:
MA)C)4%W+>3'*OA1KN8>0^<@NCM#6(E[#B$B$V!(]`YK/F(:*/("B:!Z0,2D&
M0QM2C$W([OQ%_]P<EF1CA('*E'NAX3A'.-))3F196;/H6$>1UZ$C=+EQ#$7F
MT3Q($VT@R6':!1R@$`?PS<^()AZK<>,[P2D;@'AKR=L.*&R2!-!^&O1;6?]6
MN!22$(4PA"%3QDTZ4-B0W7[=:Q+L#7`&^)L*9@FX[.8RE][][C^X[&1N8A2@
MCY*V>;-LY*Q.A08NB,8((`J\WXV[+&OHZ4:C45)PDQMX(_B&/VF0EA6FE]X\
M#*\'H9IO]3JO(HGJ#TZ&J-Y[CU>86.9REL<K[9?$)'\WL0E+7+)P$93C/1#_
MJ<4O:N2R^@@O'^D1C"?"-..Y6*U,UGB3$5YP]E%TQ1^Y>%A3KN5?RO^%O?.F
M]EK=)8+'_#0R1L0,72OF1"9^1HJ#+8)H,A;G.4LQ!82%#9_!.,;=*+8W`?C-
M8PL-',FNDNN)UJP<CU/JG'46.MT!CQ^K=IZE70,"M+@!.I#FG4J_-M3+45"!
M>+MJO>/=0)R4M=D2M+:U,4B4OR$N<46Y(0P]MVYUFUF&\D;+OQD`V=9ET8MP
MV6P3/7LA*K]Y605N98*#7L(55@H-&G`%6F8>17OC1_$4`SW69S[S.$A92W^)
M;=U'>*RA'RM:33]ZL1(3X0/'M\U17&4G;QLI,EG*3?(2\:F0_",/EU:$+5IE
MJ"(%8"Q9:<N]VE-]']SD]M:WPLLA`AXTS?O_+#:_ML6+Y>!O.<M$HDQ;C7"3
MN%Z&S)G13-#5#!K6;+`V!HJDJ!0X)AB@*!@("[%$)NH0BS80Y=,*PCG8R&6$
M8V5NQNLX,(XN:X]`$`3UJ&<>#3R<H=)$*[;"+A>HP1S\P!RH81MRH1C``P6'
MP#P>26T(Y-6TQFMNZVLT29(*Y.Y^*VV$JVT&;]<L!&YV3=`ZI&Y^C8VDHQ=<
M"=E2!'!>`+M.9):TB]EHA/.@+=NT3/GH[=IXK^8\CX668OW84*7:4(9DY2/:
M$&K:</T0!?B$K]XR+OY(+PWW+:IZ[PSY\.!X[_/R<-[8:_KXHN52BL8D@N2>
M[_J.+^;^\..$)?H@_^[Z2D[T\&T0A\3@.D+]%@!J6J+Z*I&L`C':#+$3UPHR
M/,((W$<$AH',P.S_Z@HS0..N\`JOC("*-*;HY&S.&#!D8`#J:`/J$FOJ<*,W
M&JL@BB.Y+#`X-E#1[(:RH(L:W:C1,&OL%DFT;A`"G&$(J`$#,,`&GL`<R/$6
MMB'4_"AII`.<6$T(<<L'@5`>`6\_9JN3R$9!9DVXV*;P)D24QF%N3JD@G4N-
M%`\"8*`"6L3R7J!%7B!%`F?9F@T,!\X0QVKW,)*83B[X+`?'%&SX5*S(<*P,
M0V_WL(W@M*_X6-+\Q@]S8+(0>\_$5`X1*S$OTH(Q;*P4%S&&O$_&:A(FM?\O
MF"YH$2/1$34R%<LO*-FKH421!M;/^[PO^_)-_CQQ#`E1GW1A%[;2Y<@A_Q"&
MS)#H&H;A_SA#Z$!#`+7("#1&8U*@Z!(P-4`FSQ0K"1Y0-I"1-JKNC%H&\B)+
M`].(LJQ1LVSF`RFKU'X&/*QC9^8#[8YF/LC1!FP``Y[`#\@1`]31/!:):$@-
M.="&[_*.DK1F:S+MFCKA[A*$;$[3;"!$UGYC\`KOUBPD((4C"I7CUP2-"D_`
MNJY0!1[R(4_@(2EO]5IO\SA/%6\._M++#%/R#Y43)06Q.:'3X/30)"_2)<?O
M.962_I3S_;`R%;\3#=T'YJIO*WPE(\I3)_%0*)?_DQ)_BD>,)_PHT?=.;N4H
MT>"X[:7>@UJJ3P2XLC[)#_32T.9\"",F(C*^<C)T;B*`SLR&[JX$,$+S*F,X
MAF.FB#4&BQBG[A'T[`&GCAF=$3BTKM!(=(XJZT2ID0,ORV<TX0/!XT7G;CS:
MH#R*81LD\S*?X`QNX3)OX09=RT?KZ+>N:1SX0P2TQDCI<1[%AN^RQN]6LPC[
ML36/4$(2;]?@)B&AD#ET32$9TMA6Y"&/K;JXL/5B9&_`T/-L+L2B\SLW<?[L
MLSKA=#[W<$VG,Q!7,D[Q-$_AE"9]+\4Z,A9=PB!:HDFBLB-@RJM4\4^'DO?N
M[X5ZQ1%/,N5,CSH%$>5<_XX4GS)8Q)`H.?$J-U(K]:6(=/((\F\R@"Z)/,.N
MTA*O@F$8!`N*XBPN@X$M34=#N^@N4:88=Z/J!&UEU,@X@,-7(>O0JI$P4?18
MR4[2(JTY^,@Q82L7+O,RJ>$&MN$6K%4=0VO4&&UI0)-KE#1LC#0>M29K4+.3
M9LTU!<_P$*\7V#7QV/4)H^LVWV!"2$"6K.L%!`!?CXWR8`3S:,G9O@LY:9)`
M!71@SR\Y44[W+@<Z(S4E61%/'U9/)79B*;83;3(-IT]8J,(G&\/Z(NXZ_9`]
MT^NEI/(4V?/>'L53T50F1+%I,`S&L#,FA4\\,=+^>H0K(>,K=7)B;'&)AFY5
M)?]TBP0K8[(H-8JN`45&9`XKSY*1C(#D5Z%Q.%C&.2A+9N+(6$4D:S<PTN2.
M&<AC&XZF1GG46MN@$&BA6JUU&]P!:0#)/(X#DH:TU;HF2?=C-"4IDQ@$2L]5
M;UN3UL9!UW*M2G7-UU+I-GOM-ZI015[@`S;E7E.$-_NUELR4\RZ28.W38?,P
M9#V28C<Q3HV/3CDW=$5W=.MM^3;U$1GN&C0-^OH3XQ*5)5>R.:G")LKA9%]R
M4KE3)K.,D&S"#M>/H9AR9:UR)M7*9K?R>/DKIG1.5)?H%IM(S791+;?("-X2
M-01+`5'#Z334+L/(&)-Q+P<-6`<-.9(+&JW61"<+6:'_B]'&CK,PZP3I@Q;(
M`Y"V(1W3M@T*8`C.=ANJ%07GPVWSXYI,,UR5M&[C,02^:4"HJ1_59F\;&`DA
M24IO34.("Y+DIO%Z;0JA8-AF*0OS-5\?5]G&E#B5YSC%$&$M-R.#EV:U,U%N
MHG:C2LE8*%$:2OP2)21E`B3#)<>&9"H0.&4+E(@*-.`RXH:#&&%\R(@)0XGQ
M`HES^(4>A885XS-Y&,L2#(8P2IPDCIRH+U@>#H?7@L&$*<%@6!=N^$EP>"#\
MC>3X38P)!B<8RB#.6%84;.*H\EX@KFF:)@2X4F4#5&:KDN",=RO#Q:V&0><4
MIF>1Z$'3,FB-5HJTX9&+0"Z)_Y%[\4SJ,'D9BRM8H5'K@(-EIA9]P6XPK=$Z
M$',:05`^NG$\P)9HT#9MAP!_W6$(^+=:W8%J--/N$/A(<<M(<0O5J&D?TW7P
M',36U`:2;,WPV/4U?Z-=3>D)S0A#+L37IN-#F$N->@$'&/(W\]4WO7F6(+=?
MM>M,^>U3^7`IY?1/`[$F,BS#8$X7VCG#C">'UP"F*D)392*>H7(BTJ^=.2S#
MA&44?8A:,HS#DH+>1`"@AV2CYEDBHO*J1I$&8#A<^%-?1M&I/`)J*N(CVAE2
M^:LW,D*F_CGBU"JBY?DF.F(472*C:6"E]^(G-:P!-LR@0Y&FBTG]W$.J.`PC
M1,"@9?]%PS9,IM>/2!(::IB))H!:IK=")GA@PV"**S",P[S8)B2L/&-"_8P`
MGU52)JT29,WY77B$*R>C$]8OJWE`B1PT5=,L`",T-9".-9#N:&VUL"*P`2QY
M5QM+1%E&KP<M6-OHKT]TE#O0Z_"(6<,.',V#E<O#'7+A6F6P&&BA`';F;&GY
M&&;Y?YU!.2!)/[[I2"^I;?P1USA$C79-0S2$0D2)N:ZT0YJ0.$Y)ZS+$0W)-
MT%0ICAH+!T(X"_'5@\.47_VUA)]-8(,R*U&N8;$3_M[G!5Q@MRLH?9R`GEX@
M"Y."XD:`%.+-C$G`(;HB!+R$%/#U"FXBH:/;4S0`7^O$?1K_P!H,5`1P8$U^
M\[QQ3B+,Q04:0%_(@0>^P2%J]QJN0`4F"B-"@`2L@0$.FD=4;PWBZH->H`*&
MB!P:@!3JVXQI0`6<P#>OX"$F0J1.@*2CQPFP\+K5B@1<P`6"DR@BKARNP`/,
M32+R5:)_J&F81@"JH:2B@0^V(@1HX`XTH"B$B08,8`1PP"5$@`3D9Z76`K^M
M8<7=1P.LYZ.<H((89PU&Z@H(`WH$(!':B0)4("G6(H1&0+NOP5J^@0]6@G5X
M_"A@JOHNJ#__$V'G=&:/6Y")CY#9RH(R(ZL5>9&?-\TBE%5?U7J'%K`$JPCN
M[))CXZ[K.K&8443'E]&)`P,1+1NO_W$#`SM$+@N/,(L[6LL;OV,(TE9^BP$$
M"J`<W`%LSY:.7(LS1P2<,FV7^ZZQ.(2-!A.5LY8Z/L0X?BVV,]@:F\N:KW8*
M<5MQ\W6W!4!3BEU,,2]R+7+?+-='-++$K#,F=VP</H`HX/!1C,K(`V8!$DH%
MBJ(<LAO#W8</P%LB:E>%=@$+5.`G"`,DF@&&W>H$G(`&B!C"Q&HB0L`)/B"Z
MB7@\"46BCLA$'J)':.`*GKL!"OP:&)+'-WH-JJ&`(.@$D#BIG.`2638BA>4*
M=LK>T^O`)2(X!]ZEZJFEF<4]I.]0;2*`G``'VAFE$OH?R'R'>H$&7N`.P+L7
M0.(?-LBE:/_@'ZJAOM="!/C@&P2`6G#`&N[`NC-"3JJA`NZBIP7H!1J@H.-M
M(\AAP#K`J!)&";[A#I3`/5+O"G@<K&!J)32-!\*2XU]WV[KZ%%,8K"7C(V;Q
M*Q/Y5,E!K74Q>O$*&M[:K2WTD1_!5A'++G%UZB2:0J3V5\<7TDV46..(9L`.
MTMRH[+9QE<>#U(K!L1D)'0I`$V:9EK>A9_ZW,YF+L\OA2!U$.B1-$PJ;!!E-
M/F[YEG>&CAA-CD"D&F\?NBA]`T_Y.!0>173[7C=%7[\YV6F)G)O2Q#B.%7-O
MA6G.S=OK?@YZ875!`TK(XE(Z&AK@(>,MW+M"!++]BQ5C^QN@C&G_I1HJ`MU,
M2"3?I1SDI`&PX%EDXKY'8/M5P((J@!_$72+Z&R`:7'&R0)>N:P8K\%NS"Z'!
M:T9(.%FCHL("<@A%D&!PY:+!APM>G.CDL`$I`30<?ESY\8H*$@MH..GX\1H-
M`2?6:%@C(H0($>5X^/QY344T)R1XT%C@,`2-?PS6K.REB\:+#E=$Z%I`H@-!
M@^2>5EOC4`2#._Q$7!,AA$^S"E1UK7'QMA="&J0Z"%@@8H%?I@;M5JOV@X\+
M$5>:3;/6C(0('IQ(-+AF-R:--7Y_/E9)M3/EP+KB/OPH&C1+T9]%VS7M4*7#
M7;K(B3`BX@BY!4;(';'-6[?N84>`#Q,^_WP8-./!C-A)$:RYG>7/E1<Q\@"&
M]>L-8&3?WB![DNW:PW?G4:Y7N0!0`D#HI:D7!/3P(4`H)_\]!$WU-:G'7_^^
M?/['_!<@-YH<PPT$!D+@#@0',L@@-\4,(>&$[C@SQ"VW;+/-$,704H`F$6I(
M"S<D%D,B@NV5,TXGXX3022<AC%/.C"V&8&.-G903XXXU]JBBCC*V"&2+1,[(
M8XP_SJAD>4S."(5Y4,@'!7WED:."`2\(\$*66VJI@@#\X*3"F`:,J<())ZCP
MSYILMNDF::$=I!I+",7569QWQFD:2P_E"2><:ZT1#0\8:43"%>2!I<%,.%RQ
M1@@(W?;-&@WPH_\"5R_0\)%9,Y&`PZ,KD</)"R2LE`97U3C$U0AJK=3:0;`>
M1,X+5UPV9JPA\#!I`R=4($(%*F@**P]GQK0.3[HTI$N:9"F;;`@+N.!"!6N0
M\]!M#0#KJ%8&A70"M]<L()!"#;2JTDI7D')"HPPT4-!'G6#AI5KD0,N79AB=
M$$TT##A!2E94B?`4'U+%29E5=V2U%0G_:%#0-3;]T\QDH2W`P`@5A)#L&DY$
M(X!#<ZER16`-,-"!8^*2XL(+/"`$<335O.!$5$YH(',U5Y3STU^RQ<0#;GWQ
M==%G?.H)VIUSVHGGT;$:79JK!CD+$5\8&4%;;+WM1@YQP17G-7+*V>'_7#"E
MV&%$,'84\5PPU5UW71+8B2<>=]HU0,.,\*5G7WWJS9>??_\%_K?@@P?>(.#X
MN8,?-P9".*&$W+A3#(;A;-CAA^X,L>$V[I1(8H-3CM,B.2WFJ&,G"[R8^NJH
MOPCCBRZ^[J*+I<?(8HRBBWYD[KR+_B,4,D[Y9'O$W\=>+\.,"::66W(9Y@LJ
MO!#FF6.FB::;V+>YIYY).]WT::PAO32<W8<FPAHCI*2+"`U(U(#&!VE`BF2<
MT#`,2.FG?`4)F78F`A\O:``6&M`REC0@@.<25ZHRTH!O>*1IKOG(;:QQ@O:]
M@`$/S-4W?L:_1IT@);#9!19<4,$&6*,"!;S&_RXJ4,&/.(L<5YB&8V#CD-NL
M@01GJM9!C`"]5AU$8+QZ`4]@\SU=7.$%%>!$`\XDK(\L0`51J4E?IFBM:^BK
M&:0X4[D0XA2H%`PT-\&*6A:``Z^\*RS_J,8.RL*';YS`6KHH635.$)>YO.4S
M:S!95E)VASM4"V(AZ(`UKG"":JC@&RH82#.RHL)KW&8!2EG*SG[F%X@QS4]/
MFPKX:F*T\1&MDRY[2`BG:)O90.P(NLB:;FPCG.!T;3C0B&78@C$,L:6M.6A3
MFS;8YK:ZR4UNW8'!=WQIMQ#T`CUO>(_>_&:?_?3'/_CA#W\(%\V_1?.:"#H<
M@AX4H<=Q"`(7RI#E0/^`N5QHCG,D&@*)`K0>%9&.12((TF.42,\&U).>6+AG
M=Y1HSWXJD5+Z!*@_N^//-4"B$YH8QY3*,25-0`$*#I42!*9$CA.`B4O0DYZ6
MEE>FY:6)>FK*7O:4IC36U(2DH4E-G?[$IY4^+2XK/0@/[`$3B(UC`8EX7V#X
M0).FW29]X9((/S)5%HZ(P"[G.L@!2^5"KC0#([L(P1JL42Z,C`:"W6H`'TYP
M!9=056..U!4/QL&#@4"OB9T@A4BZ*C.R6&L7S&IDJ'32`#B"Q9&.;,!,5)5%
M;LG*D1:SR+E40L@&[*(<):/80Q#C!*W$I6<^K&@T7%`NOI3#(`+[!U5Y!K'_
M!9R@`Z3@P?D^*P"M0.PI$Z/,6BYV*;\(H!E.:,!#0C:R@]SD#A/Q2P.B<0<:
M:$PV4&E?,ZKQ#0&ZH!H6$4$5!1;)>]&`!C]K528=`E.D?3)/XDLI:O3TR2)*
M<(J.-*5NL.8;K7'M:\<91G*>H][U/L=L[\5EV]P&GOJ&!YAU>P!0VB.?OM%'
M/NYA3P`"<)YRO&%&!U[2`<IQ@!`TN,$VLM$"H$7AOUAX`9I8T($.U+AN3BAR
M0PB'.#GDH3>X8T.TV$;D(/0YX^EN'-=8D8K(>@47D,)?TI*`"YS@`AWSV`E`
M[K'*_"6!(`/YR$A.LI*1[((K0(*A4%91+YX4I6KJ_^<(5V)>])K'I8M>R4QF
MNIY(L0<:Z@;&S)@LVI]4DYKQ,>W-5+$B4N[%@W;!3Q<:0)1F+!DNH(9+`-9P
M01-#P--[^?`C#?B`8A&BP-8\,2I"\4D(B#A8'M`JGG]^P0)H*%;`OL`:F3K(
M+FC`AW)UBR-&<`BPRO43J!YD#01K34.FR+Y_T9"'WUHN7Z"5YTU?]2$N>1];
M8GLNQ#BLI42TB[Z$R*<N1H-672T@^Z(Q@OVIH!DCX(1CG=*!9I`%LV>A+`E(
M$8U%%H0J=JS`9\[7#-R>X%#?2!]8%^!%CG4@*@UP@2K>R)?."FPIY!!M3/@"
MFY)F%Z9\0GBL.#.5Z[+TJO^1RI5O^F*;5%Y#E;MQ9==>"<M9JO>]S$F;+ITS
M7V&Z#6[9$>9VAAG,EH>@//<)P#3926#SV`C"]K+P<R^SAIX+4(`D$,(5A(XF
M-`G@`UM2F02<O*`%.<AQWC11.+=!BUR@@YP9IOJ&.E>,0YBH/N;)W>W,,PR]
M\J$P?)@&`_BP]K:SG0%P;SO<WQ[WM]/][G'/.]PUP`?Y84&A$$WH0]GCGRA-
MM!S),\!&N:RE,(5I>=2SWIG&3&:6*BVI!EM:G#.924YF?GM7)<<:!#"SFKG@
MVW9Q02+BK@$:5'$!UFC9847@A%!C=F9LUP`&+TLR?L@V5N)B@%4;0@X2N&#O
ML87_5`@=THFI>B2J-+"&ZW6!NMA?7#8,^"!LR,%"]>V"^]1*UC4&D@B^M^M=
M1^`80U28+*[T?5$D2#5LGNBK2$FD[QPAE"5IV$B)]*OV-.!7!]$)QB>`#'<0
M5Y`(*-%=3C$8P]4,WG94@<(`T?`-U4!L,,4#U1!K`=,QWV"!,^%;HK$&%U1;
M8/%$&E`-^P)J!=2`F4(#5Y!G/$""V6<$F0%8??$S/,<7W/-K#^<9I8%=GL1Y
M<M)2XB=^CX$1Y&"#%6<MJ)0UMO$;KO0UPV`$/&`V'U<V8H,V:X-+I?`(](5?
M]@4><U,N2_(>`N8@`:`1'\`\'D`*'N`"'O!C/N9C1L9D_S^V8SPFAS_VAE>0
M8?W181+2!I`3(1BB(216`,>0.9O3.5[78BFB.S,F(V6G`7QGB9CX?HOB8X.`
MB9YHB=)2,YNX8YXHBAK0B4!VBC439*_`4.,`.+!((/Y1#E@6/5O&>%WR>)`7
M9B%%>6RR/6:V)W'&79JD4M5U9D,HC']R#3YQ859U$']A@T,3*4,#$N8"C1=V
M/ZVQ9Z+V0[X&*[NP,Z7@%Y-V5<HR&\](#K<Q#"XS#!<!1[>A7"[3%^2P?>M#
M<,G2%^.8&4>P?4OH5RIT!/KH%R0A053S$*CS%P4I:H,5-+A1C:Y"C[^V&G$R
M17<&4[=!23?X$/9"2?#C,H\D`O^4YA<:*8^DT8R.!9)!0TDF"5@Z=Q%]L0:B
M%5X%\4@Q@1D'62><$8QX@GG#6(0^6(1V87!%Y#(VJ(2B!4='<''7!X4;1X7#
M,1WOI1QADP)I8P3,P85V4'*]E')D"$SU]7+G$1_H`0'%L!XWL24>X`$O,`]L
MN99K^0)P.9=QZ99R>9=LJ99ZZ0$"(`2:X`P*$IA0]SA2)V*("`+D5`XG=DY<
M]XA@]V(P(B/E0`YZ)8I\<)ELUW>THBW`$HH"\"4R4T$5("T!M`4OL#(RXP*?
M.29.(`#2X@$J$(>UUXI0)E'/U!^3>272PV6,%SW+(R;\4"9IXHO:PY,*=U5!
MJ(P1I&;_!]@GSHE5CO2,9?9]T3E8+?4JWZ>.W^<JQ!<UX"A7KZ*.CH1*KW&$
M#<%^1+24$$-#J"0KL>%JVOD:CD2=#:&>OO&,]AD;R<*0XQDUK3%\U]*$['>$
M#*F.PX<0SD*@/H@:ZHB,HP$QU6E7^ZF$L3*,5O49Q(=7=.*?500U&6I5&&EH
M^N>2&+$6E20;-D@#M`%'2954Q[D:/YDGUQ5*WD61+%%%-D@O5+.4];D+4'B?
M4T@<QE&%9J,<9>,<6C@V1\J57]D`<&,=W@&E90@43J(>[J$>9VD3`C`/6C(/
M78(#,(`#./`E`E"FGRFF7W(%V;*:`E`!.+`%9O*9P%*F))!A_XS#((+X.)(S
M==M@3B6VF"G6.=PP!()Z'\!#))U`.I28;T`V"/TB,T[0=XGD)8T"9JN92)Y2
M`17053B@)5>``RNCJ1612%\"+'&H5B00/.-@'L?C4-$$4>\A`LK#F[FX)8\W
M/9<ZG,2Y)K#RDVI6-*7Q*B_JH'1RG)[7>1#WJ\M9-`E:$\H20;(F2F#!D.Y)
M1-)*0]>Z"R$D?@U!0]T**XW4K>'*K8UD+>;:C=S)K?KIG]OJ,L\J-2XD5]A*
M1,IBK9['29@'*+_JG*]RKT;X:]:YH?]JH8:VD3BHCGVQHCNS%);4JSVHDU##
M20H74X.5H#X)K:1T&[EQ<>+WA$X8A?\9-X4<-QQ4^1RE``WK-7)<6`3-P976
M@7)2FG)U0S?9H5]C::7Y<2!50:99LE'=(1EOZJ9BB@,-\`!B:C<X4`$-L`5N
M"@.>T@!)ZRG54Z<-LF'I-"&$*'6W4#E45PQ8QXA;!R&."6`J$B/U(IGLLV,N
M8(G00XI.P`]C>B:-`BPXM"7K\@J;VE4NX1*)A`,O8`#`@D3[<P6:*@`JPY:<
M@%"K"F4/11^&EQ_)PSS,PYL;Q5$J$)QAMJN\^CTT>J_]6I2<^Z_?\Y.8][D\
M&;`V&K!&B*WFBJ`2-!H=NJ[[.:'J^JW;RJ((RGY+B4KEQ;&\$2G]V)Z\87'U
M&1O?>JY0-:#_L@N.^VF/L0*OX!H;H42CN3N[+9JL^=JY/OBYT0N4V;M=&YJZ
M-6&B^!*/512/NQ8N:H$Z5*2ZUWM2$;MPQ:JL0;E]]%@O-A@I'/M]NUM>OM%*
M4#D<ZU65\94<5AE?;0.F<6-R7CE,84A05'H>>M,W\K&S9*H\*K`&C5*T73"S
M#;`##]``74`#4$L"#_"TA_(`)(P##U`!9:("6/"7"\(?$.)A$M(Y?.JG'U(,
M5*<Y):).D3-1[?%BOH-X#2";BP(]-2.IA_*I>JNTIXFJ756F%2`2.)`FA#LF
M4]Q5W>$2TB(M_)"JPJ,D$`6KT/0>D3NYM"H]NODE%@52O4B<6"6P_T$9NNCJ
M7<OZH)[7N<O:KZJ+592&K4<XO=3*?I'RND3T5ONI$MW92(VTNTW)E#SJA)&B
MK?+:GH^<NY1<GQSKNX\L?BQJC\X[H-]JR-XJN^%JRO%*QWB\QY2&O?L*L'L<
MOWG,N;)!*`0I*T)10S]3CO%80_T&NK0<OW-LQ_DZRVM!*+)!<?9(R:JT-5KS
ME!QW'-`0-D:J-K@$<KGDLG&3<D^J<F)H3.=Q3.L1<VC(`W-*N%Y"`S@@&0VP
M!C0`IR1``P_@*`1EPNW3'5<\PO0,+&9"M=G4.(-I.8-*#2.&F!\RJ!J"3H/Z
M=2[6.TB2MCRV*'QIB7S@!"HPIM!#M(1[0/]Q*`#C\@(JXP+\T%7``K=<!;5+
M)1"Q*8<K\PH*I0F,.R6W*1^(IWAKO"6^F5&7>ZEBHKG_,,STZUVL+,MZ[*'O
M:]3^>LRN>\?/>H1OI<I)9:_VZKI6A;S!JT+;68\3"AM/J+L'\83$>W$^6H\^
MFDK<VH_ZV8]O-<F23%ZBY*[^.;OU>LC4*JX,V:P*"KK'3,S#O)RU[+E!":VQ
M44D/V2I_85J%K1;ADJ/`?(UVO+U'7<QY[,<W2H^`903.`LG\VY2](85".J2P
M-!QV4`I:Z1Q%@,U<R)7?W)5B.#=`06#O@1]]LR!5,:?940&?&4D/T`4J[!(L
MK,':TC[L3%`J7+3_--`%.%`F91+#)R(?!F+#-VR(&5)U0^`AFJ`YUZUB.-QB
M$]4+O2.992>;D;IVF*D!)2W2+O`*6!!L`K"68:S.:IO24,O1A.M[M#(F8QJ'
M'A#&,C)E#N6XTA0X`9`\SY/3.@T]97HF8C)YFAO9EOVOW"N_DNW7R5KA&%[,
MG"NN[WKAJES7I]RZNUN\2ZF?[(G6NSO6VLJC9-V_P<O)7\T;/OK))*Z[S1S6
M38F\Z#FMM"NM<E7(I3P:@ES'%*Z]W%NZ13W9`9O'\1@"M,&,05,;/?-=0,.,
M^0L6$JGA[BNP6U['T&J#(;"4N+&>TOM]9:U*PP#-0CJRZ86RR:$VI9U+_Z>M
M-B'LVKUD<MT<L^]#&>>Q'NJA'@?2"^C\):!Y5DEK-RI,MP^P!G":2-U1"O!,
MPN],M%#;PO^L"0VB80SB31PRJ!F2(4,``FWP(1*RT(UI(H`Y'^#=.S,BT6N[
M*.6]*!DM$&+*MR6MMP+@$J?98XGD$BK#MRJ01:1Z$D=D8Z0R#JY:M0H2Q$XW
M'\F#X%["TQHU)M-S`D`MV$-=RQ/^QQ7>UY$-X1$[K]'+?AT*XE8]U_1Z2F1=
MCV0=KC%^O%D=O+J1XRX^GO3>XI+<NV(]7E4DUOVHU2Z3XBR>[@3?C=%JR`=!
MRMR^[:*[U!D^X=^^O1`Q27AURTH8-&#A$\I\C_\/$QM]<>3$W.5T#-CWN@OW
MHH[]]JU8D\G^&\VM-+*P1,T?%S9PCMK/H0T)?.<HU]I.FN?=83H!IDQ8NAX\
M`*=F*BW!0E#T3%`B#+7`HK240NE0JZ;M4P$D@$-G0K4#(A\U/"$$S:?;<#G'
M4.HIMF)`?"#ML>J\,R/CS6.#X`1O;XEO/^V%WB5E*M)JJ6.HN26DF71[?YIJ
M"<8P+2-";,8U38N@J<9KC*MO_,)Q[(O@3N$A+]08'MBF._D.+^2:G]?]6N[1
M"D<J[^XJU._F&KQYW:/O[N+SGC7TCA$>J_HCCG'LWH\<[KN^L=7CNJZGO'"G
M+&OC6IY_7-G=[J\//\O_&0Z[!9N3YFNB3VX0T$(O":M<LM)J#B_\V"[RVSL;
M\H@;KK_(/,K6:+Y*`!S:;1X,;OY>5YFR6UCG;_.R#QPW+%<WD&(>\.$>7$_T
M<_HE7*H"3`\0)!I<@4$"!@X<5U2HJ(`#1@6&.$A`E*BPX4(5)#1Q@]#Q&#>0
M0T2.',)MR*UPMVAM*T:K@":1VV2ZXU;LD#MFQSKV*C>NU[AQY'R6$]'`A007
M3IPD3:K4A8>G+D@Y@2J!E%076;5.A7H5*RFO+SR0>B&V[-,7),9I@@*E7"\H
M$#1ID@L!"ET(`<BI$%#6[U\5+P(+$,!/`,:%)U3\8]S8\6-=D:]%IBRYLJ[)
M_Y@K9[;<V;-FSYQ!BP;]6?1IRIEW@=Z5^5IKS+!A3Y9-.[)L7>1RYSZBF]R1
M:T=VZ3X2._COW[MZ%T<.?/GO:\VE/Z<^_;ASZ,ZOZUK.G+OK[\J#OZ:M^K6N
MU;IWP]YMW#UZ]*A-I]Y\F3-X^OD_SZ^/F9R(!0`4@1QR`M0MN@!%,"*$`@>,
MK$$1(FSPP`G[TZ\T#$G+$+[2,OMO@1".",&(!71CS[?>>(NNN]^&:?&(86`<
M9D9H9ARF1FB"&2:88.Q(P0X@?RS"#AZ#>>`@&)*$H8$EE702AB249++)!AH0
MX:VW`H!"RP`Z@N`:'B!";*$M$*K@S!/.A`@BQ50XH?]-Q.!L4[$3-.+('2]!
M*H:D(=S9\Q9`96JI@&.&V(860_4\I!B:Y(+BIY]Z&FH8HY:*"BI,I1K+4K)<
M$$M34L;R`*JS//BKKQ<,>Z&OP_IR@1\LQKG++5KC\K(CNO0Z["]>_2J,L%]5
M,`"CQXIU;,/0;NO0PF4OO._"SIYUED/45K--,_7(>S"VW6Q++SYKM2N./._&
M:TTX=,6K;MWIVF7W77>1&X\ZY<A1M[5S33R.N_:VC38^R6`[<+72V.,OV?RL
MO<Q@#`/^]V#_1."AP`4G"X$'!W/C(<`',?9P8Q&L]?C!`%TCF#.&Y5,8V<Y6
MON9BZ!988-SUNL6NNAA;C-'_1IYOK#&8'*$Q(A@C["@BF"&'+-*.(Y]TL@$<
MHH2RR2B9K!J&!Z[D*2^NN^Q2ES#79&@A,<D>VTVSQ59S[3.W:$A,.W6JJQB3
M^*3[))FV$0F$E_;,V\]#^N1H)RC&Z>DGP\LAIP&H/"T+6%0?'VO5P`)[O%>^
M'A\3HS0A:B`P3U]9BR?#9ZWK](Z&R;Q7P%85C*\3#$/;6-H3EA;A@^7#73Z4
MD5VY998UFZTVX2<K[]O5=CEWN-SR%6Y>Y>J]^;IXUSV"Q>NO_ZV[[+G/OOKF
M5-0N^N?.73&WX+:U-GE]'3;9>&HO2[C9WYO5';_/ZD?M")FO(7$!(Z!'9OV;
M3($6_S"9`8H`6P!$D,Q$4!X2W2YXNIN6LTBDFQ$M@#W(VQ=QFK.<G%W/1C+B
MV<]^5J0>'6U(1.)1*1[A-*=-:4I-HM*2K/06")3#2WC929A44"8@(F0+5ZA`
MF1""`R-NP6T52`(.,G(0'#0@"4RJ4A)XX,0Z;00"'-&)GNQFDD!M(Q>#@HFA
M5J(HNN&)+9`"RN'*<0VC2,!4KOL+6EY@QU[-T2]S[(H>65<63/&C`>6X2U[P
MPD-NR`T"QSB""E3UQ[+(+E6M0@SMC,6R\V3H9,I23;,L<S)0[H=;MJD6?Q06
MRH$9#U_=2D_R5FF^WLS+7*]9CKK`1YWNY;(WV^.E]EA$(/\":0^8V]/E+:U3
M'.R$ZS?H*\XKCS?*]9&'/9D\#\JLR:S3$`QX&NHD_EA3F@*!C$`)_,\%(^;`
MWLC,6A\"X#@U6$``J4=_!-L@LJZ5R0T%*$3DP%C[5@D<YJ&K73N;$8Q(:"-H
MF!!H*.R1'8PPI!\!J6E*,@@,E22U&E)1!$,)P-9ZT26=]")L1Q3BV\XD1"*R
MK8@0&6)"6GK2BZ0)"S11)$WV],5<A!%1("A$&?\&$IJ`9">2.ESB>D$#`3PE
M5%_1"E:8>JFC9.4JC?.*5*,B%E,Y3H]7H`%;<!476W7D3H-3'1U[59A5$88O
MCA0`G"Q9+/@\:V6GG"!]-KG)EO'_SC[8A$\]NQE7]Q30,L]\)7&&,QSAV$NQ
MTI.>,8LYS&"2PT6]<9%D@?F<%\$HF#'2[#"]USW'*N<[B66F^9"7O/($##S:
MPLT]^6I7AP',=KF+'UXM$P*)D>,:T<GM9"16HMS\9V*\C6!KA*O;70#("/#L
MGR:G=5=.Q@^PK2'1`RM$6/&-YX.3[0Y!2T@CA3(T&*7P$9"&I(V)6C2&5'O:
M#0-0C@!P:4L0*$9>>+!$E:J)(6LZTW[-EC8`HTT%7*6;6,5:$SXA&%"W$.,0
M7%(H,V[#BWCBR!J+&JEQ0$`$:^`<VM+4N2N@X`HCQH$0KH`0$I``!U@0B$"P
M4*4&<*(!_VN8,8W7<&,<KX$&.J;!`CK1"Z_BR<#N"*K<`B""U;U@'F<53*H$
M8X##"/BMD+EG*)W+K=ABN91:ABY@N>SE;48W-<-KSS/MU4IPH2\\U'-.8^'U
M2\]F+V>3_2`Q+6M0[0TC.'3N[B^%&<PWZ[9\!.*.O'HCVF\U#YK&&5XW;2N\
M3T;:=U=>WYC!#&DM=\)`_C$0.QWT,@-=`T";1I!U1ST@40,0N/.Q,J;Q5\I4
M=T(7PV#@;B--G-<HMCHM0@Y!#TJC&RTT1^(%$GF/9J09.JFBZJ5BE6RX42Q!
MH!=<VV)>BD)2%:/8(2DN"-1:+!`8A[M*.X`QN<FMXP,,02XZ^?\(@K]X$@8?
M*A=\<T=,9A(2D`P.+C[A"8;+48X\T&#'`B<XP1?0XQXO8&,;DUDI&CY`3?M8
M!)KNQ,0GW@F,DZ,3!)(44$Q7%V[P,$^I&PPD7<>772VD,`N9\K'F2LJ^RE72
M,+^-RLPC9M%4>N;2-4TTIRG;U'(0H`!%#KYHZ=A<$I.S?%8Z"+?'73_G,H23
MS1FOB;E+T+Z+EMPQ^O.`DS[DH6>5J=V-;S;4:M=:&3=GW_FC79N?4I.G00!D
MT*:'$Z`$D<,(#S0NWB?.OU$':+EKKW(%8TXM;7[H@1$Z8'OTE3S>)`>7O=S9
MKV\$WAT-F]@1#=*1'/(DC$H-HTF:H4;_L?311TF;OAW1A0@*3@,>Q%[V#E_X
M`/^7P`#E(4(1"D$(7K;;<KR!R"/?HKM'4HP_Q3L7(B%43,Y8$S\-;HT^H3[B
MVJB)?_\;^W.92SFPG_V>='P<G0!*^<=_?O.;7RC4Y[=/V@+D1]$*+K/BOB;>
MH+K(L8X?399=8!0SK,5H.<9P-3#[JYVSM&\J/"WCD$K+)MAR-<A;+6Y1#PH4
M.[$[CV0:NEP3J#<#+<BZLSHS*!#$,\G*LUXS01>9.E_J)<HZP<O"GG@IM$.;
MP>C@ET0CGC+3#&J*P,W@0;>+KE#2G]IR&+KB%H41$'W9F!!IO9$)#I!9C8MY
MH([AF.@`&8G9_RV\$L*XHB?\^!TLS*V[,P)"TQ9%RY?=>#/OLCR?6:AA&!KQ
MXA&C01H[>"'U<AJ!F!H9>C:?B*\MT80N\1(NF;:.ZH@_!$1J\QI"3,0=NI5#
MNI73H0N<((DV&(*[T:EY*X!Z.Y1[.X1\$S(VZC?KTSB-&S^,VZCU`XKU(S_R
M"XJ,RSA29,553,7T*[_"@0M"(B3XHS^[V,6XZ(4_2+*R6#)?Z0N4Z[]*$L!_
M\+(-,D"_`L($%+-EK+E(<T"`<3MMNI;'(SLSN\"N6Q'$0KH_H[IB$L$0HKP3
M)"%T+"C.$J'GF#I>^YZDPYXW8ZRBRX[S<":@6Z4#H:;Z^$'4$K,#E/^MN2+`
M!^PD7>@$$ED@O@N0C1&86ON?Y2*9P7.@XGK&?YRNO.*YY'J@"]*M"'(/?027
M](DL$.*>RNN9RZN1S'M#AC*:'YFHSTL2@QB]IR$]F[PAC\J++9DO+=D)1:0V
M1ZP+D5M$N2G*15HDNN`A=O,BDE"PE&BP!S,40Y$P1JD)Z2N<1Y$57/P)C9.9
MVG.X!0!+L(PX'_.Q4L0XA*0XAT/(LF3+M,2X\AO%59Q%K7P4NI@577"B_&.=
MRA&,73F!M@I``21(2%/`M(NMP_PR3(/`^5%``F2M:GR-L#.1ZJ@7Z9F7Z?BS
M$NPERTK!=C0HG@%-=51'T11-&Y&L$:H\$J3_.F"JNLKRGA@DND/3M:TSD;%3
M&%4JPGMDS#!#.^G2S7[,LK=+M<'C+0<B!]P"+N/LM'AZ$.4JD8X$R()1&8MT
M3J\L$>*,CMI`K=48M)O!NCE#280"MH5BR9:4*"1YDAE:-HMJ-G*`+QWR0UQ!
MG4)<Q$><3T9T1$7RB,&Y$R]1)(XP/I)(/IG8J9ZRMVT(JI+@!D]\%%R,/TW@
MB8Y;1:)J([JDRU0<!K3<4+3\@[D$BG-`Q7'X@_(+T7.`@A,UG4+JA5[`@;UD
MLLKY%3@1S)93QIN;+64L3&AD#6]Y.^"\-!\M'H$!R?/0%V32%MJ4'AED06$"
MS3Z[.G8\2=*<4BD-_TTK=5+O.LV"TJQX[!XZ`[3,E+R1!*C@,#I\"<EL[!=\
MHD;"ZT%I[#(V54#"HR?N"`$&"J[<RHW?,I$(&2YV8BZ\`Y'[X$*-3,S3.`(`
M*07E$@%:X[OC*5+ED::BPQYQQ%+Q3*B5=$,48B$B$1+/HZ@ZG)J+<A(:"`&>
M&,1`U,DN`3)#^L/Z_$G4B57[#$JE/$JF'())5+!`&:.HC+`THANABM!:E#^X
M\$,'C<\<JHN>Q$6?"%&A,%'S\U"@V#B@(%$23;_XVS=H/8<0A0M;;(O[;%%@
MY)7]FR3_:Y4V0<9D-$R,7$!K;+MI=$:VXTT"_!:S<[PTRT8WTS7)"],71/_#
MS@Q/*BW--%PZ&8G2GCE8+,6S79H1JZ.S=>3,RN37>L&,9K(71<N6VR0[(YPT
MQ_PK.+U&Z33`:$FN`/FZ1B60YS0>31N0<F+.O:.[1/,,OR+4'"U2Y<*8YQ1#
M@,)7]:C,%938T>P9'+D\86O)-T3/4+6HJYDB&*`!<NBWMW"+5=5)KIDVU=.A
M9-U:^93/6$W*_`3;H[R5L>(3D2!0O1D">HNP!#6)?/.21_%66O&J0AK*13RD
M]\-*%OV)$*U6$34_$V51NYR5^).5^6L+0O(JD:,+<?T+83R5DVL5P^`'ED-&
M&Y7&R[U9S<U<5A/(ZJQ.?Y*F"40/LZ-!?$$1>WG_%^ZY,Q%LW77TM:6#W=2<
MW82M7815PRN%QZSC4JR;QWI,K&JJ-+-CGL=+L]AJ4P1$WIDC5-M2WK4CF`89
ME[F3D$W+#;\;D$"-D+U3CTA+F4(]O/CXD(535`#QT_;83DE%K,CS)7BD76`S
M6LTSSQXIDA3XU)B$(=&3$OV%VK>(T%6-T&25+ZN=-KS06EAU1*_]0[O53[)%
M/I&81$I$V^5S"71`T#2BQ&#]5@UV%!ZB"^GC1<+=M[A%41/MVVWE5EG!2KIE
MBZ3,6R!CU;9`I%L)`!=]T5ZA7'-ME6%15]Z$.2LS5#@=PH^5URVCQH%9#]8J
M4IMQEWW%+,KRP))$32O-_])TK%+QO.(K/EB#-<V$[<PG[EW8K"5Z`0[B4+04
MV<%%H\;/75,BYL'&_$V"=)G(0,(IU+/DXH&(K,(`:8UA`)D+&M3-)<+SK4'?
M>`V)B;TUP#LCZ`2,Z5E(/;HQOCKI.$G<Q=2C71I,%J_T6EH8DJ$',-6WX(DM
M85'5$T15+65JTZ$`N,M&S$_4`=L%#KGBXY,$909X*U!<Q<2IO+<%'1R[$-P'
M]:J.**3Y9.5"0MR[,%S$A=9Q0.$0C;]LU46[6*.Y/=Q8':N=<"*3(T;*H:1C
M',R7P]R,U-R!9$:0#3/8:L9V/>(C5IXS1.+$.JSE6-+/8M\[8TTM)E@KQN+:
MY?]G?\YB2AXA>[8S7F)BS+K,LN,Z)(Y4,S5>Y<6RAV;C-^W<><TYVJ"U!5B@
MB+Q.N?M(F:FXB:E&4ZJ9>ZU!XDDNVJ.!YXP]`PG),TW?=LG,H1W/E%Q)^=U4
M'OE43@8]_5V#]V11^"+E:2,D`>:2CM!:5;:5^BS$5I95_`1;G:";FTI;2KSE
M!FL#75Z)E9#JH!(RMIA:7&1A8CZ=N/`J^&-A8"X<0BH<%&X+67GF6ZP56VEE
M:D[<L:XV7Z9ARQ'&Q[T<M.*+_0/,RAU,=JTTG7L[Q!Q"'2U(Q'OCD!W=A7X\
M#_I&="E3U;6S=3R"/S!-+9[I?_YLT`[MT3PHA?7,$M3_W>E`K,-*7;`3W7^T
MUP5L5XG6S6MT8]J6;1\\WLFHN)GA-``:$,8K#NLED07Y8\JH6?BXUU1::,D<
MCO+=F%+`&-A#)]\X%S-N#LN>#G$L02S&D1RQ:9R&0TWFY&5S6AHB/1KX,5$6
MZE&^6M4[Y:U593^DZUGMX*]U1`6U&[3=*5W6FVVX!7=8%*O$%;F=6KN$6_M6
MW+D6X6\UW&9NYJSTN&^=6[AUE%^&O[H(JT9I%([0:TA"E<$(EBA3#!Y^N=>.
M5W)^1LY59^"\R-Y$XC?%0%JJEV4B$-6V'M1F3:J;XLX6;1__<?&L8H+-+(EE
M7^J@9\7BC>@AWL-;I9JA-,2&_V@V?M>><Q:1I0P%R6CCDI@0T%.'0ZY%E1GD
MJO)$$ZPDAKQ(M5@1H#V,.3CH'I!OB6<R76T<;]\J)EKXY9'XO6DC29+[94]0
M72\FX5\6[2@@ZR@`GC9%?^]#5\2>?%7\C-577=P\<>`''H)%@3<&RX5<P.I"
M*=!M6)2@8E"X?="PKML8MG`=*FNP0F81=O#X>^84_E96QD]4-QT9)G5?;MS\
MZ^O'V3^U$NS#X.$>Q='8DB?&Q(U7@C1D+W;&EFUEJ4`SE4Q=&XZC:V)WD<?K
MV6P1,MC1!G)P#_<@Y_$YX]T5?)>*#9_%VLV0?')'2]YW%\X=75.;'4CN[=@B
MS2`R%O\0$5E9Q?MMZ%KV3%)ND>0@AN8GA@M+V2N1H3NLXW`S\BGHA@6A+,7S
M[RY//I]?(Z'#G1[5_57O%][;^5KTG;3:93UJ0J3OH)15^QXYFC!;!]8IM=7E
M7590H<*5$YWP8L5UL.)@7'_APLW;MRZ<!T?F&-[Y6>WY2!\<(9MA%]WF)ML5
MV9E<&IVRB\3'FG-Q2(M&(!5GAN%>@6]RD9ZFX5$>$\$UAI[-H1NZ#S+R=]32
M7\-=<9_[<.=B/-N9MH='[$:7>)8\\I$F?4123N)"PM]"RC"1-#-L*;=9W3YN
M>G=\.DXG[<5>XNY3C$7\UIIVBRV@UD:>??\/L#2"V"-N&W__GB6O1VS7)4M5
MPZ(](?EE(8;2Z3J\7YN4F@9X@)\N=*K=R9[$VD>/BS_$6@/^2;&UVY;'SW:[
M*0BNZC!:/JRN8#.ZA:IDT)N//U.'T`-GX6$&8&EC"V26%?#76Q0%_Q0F)%D1
M5K$52ET4.9JJ-KP0U[[P==<IU_U;*[7:8<MM=NA-[L$'"%VZR.G:5?!:P8,&
M=UU;.#`APX4-$Q(4R##A0XH6,QJLV/$AP88B=QTA1Y+<D5TF2[)LB?+E$9?D
M_@R+.:PFSILY=?+LZ?,GM&'0@@X52O2HT:1(?S)M>O/(SII'_L3\0PXE2ZPP
M&68]<LTD6)6[Q#:\2+#B08@()0H4_SCQHT6$;2>F-:CK+<>'=O%ZS"C0HTH>
M(LZ2X[%`A$$1AD4H#GEDKL.1UR2K/,+XJD*0(HP8$7%XLV$>@K&*3=FP)%>4
MNF*>C*FU9$UR.J$R+1H,VNU@NG7;V>W[]X-',&#@&&Z<^'$8)(PW8#Y\#;ER
MO:9/#]`K`)1R$"#TXNZ].P3LX34%V`Y!TW;TY\V7-[_>O?KUW-QS*S;D/OXA
M]F_=VK9M2!MM%.#.$/[YYTY]W"AH7B_90=&@)@V6`P44FE18X7D88F@A!`XV
M.`X4XYP38HCGC".BB"%J`J*%$*9G'A0=;G?A=O/9",%\[O6"@P`O^/@CD#T*
MH,(+`O#S@O\*1JJPY#]-.ODDE'%)M)==%V665D)KY47771IE:=>65=(5D91_
MI7760!V-M9))*KUT&DJM8>5:3"SA)!MM3T7E5&U*$75344@%^B>A@`K*)Z)0
MY7D32K&UU!5I*:'&TFDGJ5F62%NJM1%!;+755Z=F?CGJE60:-":J=E744`A&
M+"`7.0L8T=!AG;A*3JH498JI2@_)NL`"7HTUDF*N"@;5`CR4<EB<*[F9$DS1
MNE0G2E0INB=/A`8SS&_=>JM;$<B)6]QPRQV'0W/)-?=`"--)U\N$V)77G;Q0
MB'=OC.!IMUU[[KT7GWGQ`:R>.SC:EY]^0_!W2SA#Y#)$`>@,08O_@?H=4@R"
M`3<HH8<1"BPCC11",*&%#Y8((HI0F'C.RB!N'+*_Z,D<H\SFY>@O=S@D">2/
M/19Y9))#(BG`"4-">?23FIIY:F2J<HH177A)'1=&:)$I*M.C9OW02'I=(RF;
MT+8FIVMS7E4353C1=BVB/@TJ%-Q(Y<8M;G1O.S?>1Q6Z5-M,7?LW3'72^=)J
M69465D8A111U9&J)Z7B9I6IY5]-:=^FTY6,.%*L1A'GFZC"RJG8UKI13-I%(
MH"?;N;/DB%"*89SQT(GHC%%U%6K-;F7:X-2^Q.BBBP(*=V[%[];;M[X]D&YR
MXBK7?/,-L`OO=!$&H%V#\H;787GV;M^>_[[IE0<P?"^:_YYYQ]1W<!OW%;-?
M?]NT#\*`!5+\'X(*WKQQA!3V'^-Z:(:A7EC(0MIYT(=0=K*6I0A$%+H0R3"4
MGAA1L$/DLQGZ>K$%G_&L9T5"TM#XD:0EG0!I)J3:E;1DJEQEYB*>^@A<KA0F
MJKWP<G6A#$A*(Y;=Q6E:=+(6GG(BO+XMY6UYNUO=CFBW)>)MB8'R4]^:DC9%
M28M.+%E-M$@RMHET*E.ATHM;'D>ER%W-A4L+(PW1&$,S4HZ&7XO5`O[BJLY\
M1G%EPE5$VF22@91D,Y_;3+!>8@0:$'(QQ;H*(BWUIM9@L7==H9-49N.4/QDO
M>=\J@G#(E1Q-0O_/.3!80[O>E;T'66=>WKD7]_*UG7WU*V`ONN#'W%,P'-4'
M81=36/QRD0L!2:Q`_M&/.RYV,PIQK$$.JAF')C@RFA&00@X$D8E4AB(3H:@7
MXS"@_P"H"?0($#WE2":.PAFSG!&)@QX$VL^&)(`AC="$2`,CZ;QTJD]M1&IL
MF1(*V6BUR8&JG@ZI2$@ZA28MBJTK8\N*5GX7Q#RMC8AQ,Q04[\:MB2*QHKJQ
M6Q(S*M&W_6EX0>'3WX3H*+.]AH>5:8A`88C#-LHP5%?S"TS[PB6^^)-4;*1I
MU:X1NEDQAHZ=J=*90)*9M:#4C[(:S#`V<Q7%T(`'-%@69V05`FI-"BS_+#EH
M%<LF%9KH"2AQDZ@EP[J\3IZK>>9*PG"D%QWJ4.\Z]GJK]KSGO>V-C%_J(0][
MQCDP5[XG?_CY3_O@%XY?TH]`_J'%+1"DGP6MTF00.J8V7WDAF4'(922"YLEV
M<:*5$1."%4KFABC((8#EZ&8=VA$'Y]%!GY632/P@&CO=>31ZIO!QDJOGIN9Y
MS[J(RB]=E"<8_=(1'(:%33N\ZB,?-:>0=K5M>Z.D1G&#F]PDT3?2_4UU+TK=
M)M[F4%'D24A?TSNLP"EWR.UBKQ;WSYJ*"J!/Z]H9P;@JC8R1M_"42POO$BM`
M]G2/ZI7,2"+2JSX>E0:=\TKH0$-(5X'&5:5`_TPBFW5>L"7W4;!AVYX^"MU*
M\B:LX'H$)\M*UG2EBUW2$25VW*J]N):G7G0%CW?&8[Z]QM(]QZ#EP?(#O_X\
MC)<3JUC^\G>>"173030S'P`#>!YCDFA$*)OF9E$TH<[2"#ZBM:"_3)LC].RH
MG#]2+9#*^=H1LI-)LDW:JN`2*IJJE[<NY6*7TMQ2VHJ*<6A<VDC06QDMAFW"
MN%MN$(,H22)JBZ(:U:YNIHM=#E]W-XU&=$4-_=".@E0G>+*)X`2W.PI;52QN
MNA294$6JO'!M(XF+'%K6#!GZPIEK:L;S,&+WNLD\QHNN5F^O-K>9SLQ.="QQ
MJFAHL)E2$+*I(ACI(_][*"VSN608@E9;GX;"80]W:WDL<!XG0XS6Z+%K'&S-
MGKSHY3UZ<8]?'=K7OM#3GG[=%7WN-A\WG)'C]KD/EX?=9?T,A+\AZ`]&'(-L
M`5^I9/50D,@.@J:(5M:R!Z[H@2139L@N*,XM;T>#1.K@!WOT6A"..4DB//.3
M7/@6HDJ)Y%X;JLCOFQF/V!J^Z%UY;WN%F=*@%%)^MF))_HQA;-6&4$'9+K>T
MVVA%4]O#UWTTT.?VQ(\Z9>>-"IS.E]V51H[%:^E=8]<41_)7WQ!S&6&SR>/9
M:K/`.EFO@CF:BKLFA>SBJ$;@0:-\'0)B+U@PR3+V,"IE<[(%SL**8ML0>T+_
MR:`3/1C(HS8F0TS6Q4NO$^YB:SFL\YW)BYL[>`T`7NDJXW_A+);D4U"._Y,P
M_@P6L!&[S_T6B[&;&;R9_)NQE;-I<`5"F9K1C.:$<B^RB&]H1IP7I_EZ40$O
M8]Q'/2+2")%D`#.#_!]P7J%*LR9GU)'IMR)_=:M=W4:Y?.7.9L)CF[ZB0YM+
MG:H+!2^A#15IXR&]Z.X/ZZ.96+>])4I/55%N[T[R1F@)2_R>%@E::)\=P9ED
MG%JFF,[7?01=O-QON9=[V9KIN$Z<P!FN,.":7*#K=`;L+(`@&09*&`:Q/5BQ
MT8"SF=_-09T5/1US-5>V;%CA=4MOI(#AR>!OA,MP_RB><>`@#*!5B87`-8A2
M]E`'Y:72>'3'6WT'-[U!DNE5^9P/>B!(CNF8O<D/OAD6D/$;8[6(A["(_[C2
M9&&9R4R(9340`YW(B5"([CU6N^V>P(T3^CP(C_A,:AD?""$?DHP0\X&<E9#<
M?%7?J?GA;YV<'PH@`OKA(#:@XYA$680-WTU8<DD%<P6>3G24M&$4HKT@M1W>
M;AA!AP4#)[Y?HBV:_#V4WW055,C&,%A%IE61U&D1KX#%R<%<J$5?(1(7GET?
MK+B%4"$@(9K18Q#.L!17FGR:7@A29\R1JQR!VW$@(`W24S75@?50(_8=;+Q&
M"4+;H`G>)`K%W4Q;AZ7`X?_9`0W*H!TDWN+E(.,]0"><&`&Q%7<\R.29TA$2
M$%VUDHRUFQN^&P3<&.CA![WMV#8\3"Z<WC;<3S$(DY!YEL&=0XL,C`1-D!8J
M$,N@C.U!F9&)X91UR&0=607A(\Z0TP?Y")C1H9$(C<?A8?,UR>G,XO/E8BS:
M4>D,%/=)WRUV34O&5P[IT7$1!/GUY(6A8D](XJ3)GT6!XK=HHE$FS]#E#=UX
M5"G.QM_T9"OFS@Z1A2%:W?9E#?6U)%Q0G]6UFO5E'1J%Q*9`AO^A%`96Y4ED
MX.MT1@;R0&?<!.B`Q@(\@&ATCE1(W7+YD*)8RU2@'Z+8QM'!H&[08#`89F'N
M1A'_-,"U:1*YZ.!Q,,\:=,(U?%L0JM@0DINXS8MZ[,OV+"$R.2'Z<(/Z_!5^
MP,^]"8AA^=(0$$B_5=R_M=YHT<AHR8BW><AE+=`TD<C!F8P`B8<`2=;YA!/!
M6=R7!<D+',DZW>%KE9D*I.0_*,16?@1Z9<I%$&!7DIU86HD#8F6:=9]W>EKX
M8=7-Y9QL8,538!K/;6/<_!Q%)>4G(H]\_L9\&EXG(L\GNI^B952AU)_:7)@)
M2AT?68IX(@Y'<%]UJM0-W:)0+<Y7_B$%2B<N/LU8K)TB6J7,I=T<B8"!:05<
MBL`1V`I<)E4I.",'CI=4XIQ6,(K].==#=:.'@:-OT&!O_Y0CB"V>8W;2NC@>
M$`HA]K1C/,[C*E6<>V`>[.6CQ.'8Q!1(O?&'?_38Z=V/Z"4(-Q0,-J$A,?4/
M.('3DI7,AY@,-$4313Y9;NJ>C$10<#*<C&B":3&(SNP,Q@F)"!6)QY49=(JE
M>UVG(48H6*(<%R%$(,J9>[51=?[%XB12S9'$_NDEIKG&%*VG-E;B=@UFT2'E
M82;F#&(J.8ZCAUEJMTP740ZE3P0/\.!)2?6D(JW)6>R07/P7=:8%#K5:RW&G
MA+H:0J`.`C(@1.3%J@:83GX:2_C1V]%.-';"B"K&ZQR;8MQE"695IE&55:#-
MI0W1SC'%I%92?LIH8HIC8LK@8O]"9HZ.V`.(@&4&H;UTAXK!%9%FA[EQWERU
M4LV(9E_54G[0PNC%3T"JIB\AECL<I)#-B":,",DPV6Q:".9UI#$9G!B*:>TU
M4&XZD,<\5H9,+#?!DIN:TTC*J9`LR1V2T'.FI$SR8J]>#DH)XDS>JJNV*J!*
MZ*Z0W7>:V@6B5%AX18J>JK6T**1"UWLFY8S&(/*0XZ5R:]".8XUN:@S:YV]\
M8GXJY;;\'*7]!*GZI7@I&Z6<%R+Q3IJ@A4T*5:&"W_=!3@&^:M<&52P2U?4-
MRZ>Y27']8DEP!F/`';(<&+(H"XCN%&P,`V=08T(]TNVX1G.M8,\I15$2YF$6
M;8?]+`__/,*UW2`Z0H\.JN,/6B8IP=6X;8\1@@^1MNOOD4^-W9AZ].-]B-Y]
M+(S\.,SI^=*48@QQ%MDU&=ELHD_%JH@S79;"T1YO]D(T%=F%-!/,+"'PZ<@6
M<*PY>5#R+0D>YN&9[:E5HJQ86F?:8>4L#H2LYA'+,LU64L9*+"*JVER=T,3Y
M!2:@;(LEMA_A\@9B<BJF#FVF%NZE:FJF"BVU-1I&B6K]F0VR3>555%W^HDGW
M)6A6YE`!/J"#MEG81BC_ZNE!O%F%IH9."A3-M@:#O5TIX,[;+<#-OET'EH*=
M+(`&FZ=X404(WVTV"J7;?)4E)NV,[H8,<NH*]\9B,J[CGJ-Q_TRF+I3K=)RK
MO6C/*'D'N[Z'9VI>/@ZGOZ@/O8HN:OZ2OA;D+Q5#E3*6!8U(_TC(78E69%5(
M-(7APMG>PMFN91W3B%2($=+F0YH6-^F"SL2IC]BA"HR9<Y902MKJL&3E\K:0
MV=I:],TJKP"@FLBD@.U1<1D7U3;BM,P)"TJBAAD%C(*BC`*MC!X>C6XJIOZL
M?=+H^QIF(Q]/\GQB=,%-T]T);?2M0=T<G\'$@)(=]5YH@Z(EUZ8)9;AJFQ4J
M`%/G*RNJVK[12WQ:M/C1LKSM3G$&ZUC&V^&MV_+`-8*.>LY$-0(/M*DG8'H5
M*>*-)Y:OMM8HTOYL<(28XCTF6:EC6_]]FW5,;KV8$BIY#[L=V>_QU3G;#+U*
M(>FV`;X90^C^$I5N&98R9,AHR.92D.O.+F?=GNWF+HE,F3U/685@1\E\I+_`
MX9(("7**V3J)4)*<@/%"9TJM*BQJG?ZRLH6B[2J'11ZK%RH?<)X!U2U_C:5P
M6HKF7-K$1C9&*C<^&OGJ1GP6IN$>[=&V<"4?[@I/LGUR*Z>*XTV7+],.Y=,&
M97KFW"!+96I\!4^N!4B#!"KGF>GX8<G*W`5"'_9:KP(NQ#^9ETGGG$KHW4N0
M`^@8AD[,D;,!4C%SL+*Z[3-`A=O>["D*$0E#ZO"\Z'4%7?)8<J;NM-"68W,4
M1[:1E>(U0`/_=$(-ERLIH6MFAH>]1(@/M^NZ-:$0FT_!S-MI3J'I62'%+-9K
MGIO_,%D$!1"7>I:'+.P"B6F)Y&9O3EDSE0QMPAXWS(QUQ.%JI?'0J!,>$LW'
M-I^#%N!(#U0.3755,^]3YY&``2H@8B!Q'P2T@`6CAHTUM@0+EO"+GC"U\;5-
M!RW2MN\CMR]/!S4U"^TE<RM2+BUN<&)>WP8I0FU731&*XF]E2!@%IJS,:?3S
MJDDJ<R>NE:QPA[1\%017R*QT-TLC)=4PN^55?*BSO5U<RL:(PO6(EF")/L6S
M,10V1A'3%8HW8C)-JW`U6[(18-+B-BYR0.9Q/``Y>%NYEA(\,C9C_^NPYC:A
M1PYGDH(N.SNI._L8ZO(;$__KE9Z6P48<P.+S[I;,F$J3/S<9%SO(E(D'A_CN
M>L1KAYBQ'3(T;JNQ\6YY;X,<%Z476D9URF:MJPJC2%LU6F**2$_U__%?(U$M
M"L9Y2UOW1VU7**)P-:\O>8>W=\OG(O_&GYNW^5XJ)'NWGA>==''R70-F0VE:
M?!O45L!B20C5(JZR?=MBF7^Y?Q%7@*WD8YA7M/"DU.V:8ABK$432L<*EKT'%
MB`9SB=9MK)VZ4>.L))$P)8:OW=BYMP1ZH7]W"GSKN#!NN,)P9(8`.=BPR6`'
M]@2I*4$V7F7>.(T/9;O2$Z[/?=#;Z(5#_/\`2+ZEWNIEH48.;)379L`!T$;F
M2V<AW))SL9,Y&99JQT$'')5;66W#*<^H<<=R.?+*UH6N;+_G9(5>*!XI=\#G
M:DX^;X*Z*IGS2F5L3N[`.?=.=W6S)X?']*ZS+]%NZ]#Z^;8:K?KN>8CK]-&"
MN*<ZVK6V=U.<8@A'-TKKW)[U+R[*<E9?-)X68U!5I<!;]0)/H%7M[WSS7[2X
M+0;'K;/)1K(0,ZN?.DJ\SEW*!F>DYX0#WJBZZ"&[8&XL;7Y*LOKF>2.;H_-L
MDHFKBXJSN`V'6V.'LV.G_93KH[R2#S^:9I/B*[[U4L4P,1-7*8,TI$96+)85
MN6P^")+/;L*=X43_JLS#GDP8Y@LW?622=AGQA230E.0(2?260R>9HPE$''"7
ME*ST]HI(8*]T$K?8KNH.:9^`<<6>\=#>#3)=\\E17"N>JS!2>GPC,_*']W0T
M^[(OIS!0MZ]Y[W3'\WXG?JK2L>=3`BBSL7P/\5&E]VKII]WSB_[RFHI"_)87
M*7Q$F$:<4%WA*"I*+"I9+T#H*,M+B(;XPP;L9'!)T`0&WP2SGK6L3_W$.[-'
M:91>6Q+0]CXD@Z/M`T21!BQ@X(!QL.!!@P81-G38H%,OB1,I0I$8`$J`7A`V
M=N0(`4(`"%!`0M`44I-(D`%.FA39LF1,D#"Y%2LV!&?.F[=NA=M&*U>;_P+N
MAFPSNFT(MT/NN'&#X%0322A138XT2?(D5JN:>D6%`J7<U%Y@H8R#<L[LN'-H
MR[:U^%9M6[-AI[Z]6E5FWG,X5+P0\,(O8+\"!/1545A%8L4G5/QS_!AR9'*Z
MKNVZIFMRYLJ8,5LFM^MS9=&@.U?.#-IRZL^K48]V;9GR+LZM5^LZ0N[S$<Q'
M0-_V3>ZW[]O#A!\9=MSX<>7#H#$_WKQY,&C!J%</9J2ZG6`IM*<(9H<[=>_5
MH4$_(N*\B%0'KJU/]>:&L1LWSM2O3\:^L?KZ^><_HW\_^N3[[P83"C0!P3<0
M-.$`(["SCKQ@AI'.N>:6(VXYXX[0$+C@@`-N%_\//[RM-]0RZRRVURX[,;36
M8#.1,W),8S$UT3IS\</*>/MP1-Q`!#$X$7@P8@$'BQS&00=Y&`:X881$T@@1
MC%@RN2FA3%(Y+)&[D$LNH7NNP@F9DU`Z"*M[4+OOQ%L3/#6IZ^[-(AYAR"$Z
M%7((SP=PHXA/C3B2Z".,!/TH(PC*60DDDE@J"::86GI4IF.>RFF(-G#:B2>C
M@BH`G:)H,6H(FVKBQIV2IIKIU*@@3?2JK[[JZJMQO!K+++1LK34MLG+-=:RP
MNKJ+U;QDZH6OO_H"["]^7C#L,'X06ZRQR*1];+(C3.M,LQI),\W$&JW5=D48
M;3RM1=9@S/8S;$G[K;?_'CTLCAP,M^Q2.0O)G*Y,,Z4S@CGTU%/O@(`71%"^
M@NT[`S^$R5B8C'0X<-AA#I[@@&*'&>9@X3#(T'AAC#7F>&.&0P[#XXWKNR$/
M?*F;#M\)OW2.7GGC_:U#=]T-L=J<=0%7-759>^TT<6MD,4:?43N:MQUWQ!FX
M:ZRU.6D>IRPRWBFC-([(X\A1TL'CM'2PE*[!%@'#4I:,F5X+81:SS#%55EG?
M-=5LL\WMOAM/._!XF!,&@A9"R,Z$\#RH`7(D*H?/Q#_R2*2-&L?K4)<258FD
MJDX-*:]&:Z)4IR$R_6E3HHY"RIU#BF'*J:M4994JO$[*RM"OZ")+U[+.L=WV
M_[C&X56NV\VB_:N8*A<V)F(/$^ROP!!S]C#%G(]V6FG5=>VS$LNM,4;>N/U9
M-W)GH_%GV8AN<;1O<:/Y77>'V]`W>;M4^TN6R1,A!/=,4!#!^.S#+^..R<"8
M`R3;V,,D1K&)%?`)E2C@`BE&,9)Q`!\1#`,^)DC!,%P0@QG,X/\RB`\'%$($
MUS'3=-@&OWFY3VO$X5!P<)8^WZ"F>SMC40Q',QD<I<9HVRL:T5R#(M8LK7OH
M`Y'3@-2C8="`7Q\:$I.0A,04#HEL2%IB<H;$+RE:\8I8C%G\UL;%\MPK7W%+
MT]WL5K>\X<UNW)&3W_#$D,`-#@8/"$'B$J>1B2PN4/^%\HA57O*2F0AK58T"
M25-N@A-+A<ISM]B&(C?5J9^`RB:':$JI$B65UZ'JDENI"ZQD]2JWJ&5WMK/5
MK>1REEV1I2LLN9Q58N*4U('$>,L2C&#ZXJS"W%(%C$D,8Z(W+1EUKS>5L<RW
MN.4T(I*&7)[1UOAP9)L3Z4A&(3*FTGZT"VO^QIDL?-=M_K`A)F;H?6-RF;Y$
M<(-6_,]A$SM@``.(P0B^TP$>=,`\Z8D/``*09/G,9SLU>$%Y>A"@[Q3H!"M8
M4`I&,)X.T((#0@"A!Y6)BV#BDC>)PZ,C=-.%/7+F-8!3&NW=IF@@!2ENL.5,
M<)'H1"--FC5+A+06RH9F+2S_H@M#M"'<#&EFY"B2E(8TQ>,LT6IA6TX5@YJD
ML"T1;?52*@G;%L8SZ>M!WC&CW-HD531N1R""^YL;[]20P!6.CHG+B$?(^I&/
M<$5RA0J)HOZX2D"6Q!V%K!2E<L$3G_Q$**([RA"(P@UT%(,;DM+$ZR15E=;!
M!"9CX8I<>A6KVXDR=VKQ'5QZ)[NZ#(]XQ#->\OKR%V,1AGG/<UXOI:4TIV$+
MI<%,;8^&N9O=M`NEU@KB::89&NVQAD:B66U&M[D^%'IIJ=&!&S3R<,$;(!2>
M>PC"'C:AW"`$H0#/C>YS'1"$>5K7NM>MKG;IV5WO=A>Y`[5@.]FI3W]6T(,(
M0!EX_QYJG0FM3$)JHU=RAM%-)MF4MS)56HBZ=5H@Z<BUF2$1$66;FI7F1C6M
M3?!(K<DCV'84:A%N'TZKQ(,E5>UL?Q"!V<X&I>683:C#L`,/PF8$.VC1BUTD
M4YC>YE3KI&D\=E-3>*KZIJN&YP&/Z%M7>0Q'ASR@$X8+*T4$E1$C#VHC>12)
M2I*\J.&I))"1@H!<BT(IGC"RD9Z"9*7:X`=S^`',8?YR&T!0C$M6#E)9D0JL
M8D597*V%+6RAE2G;@I:H*'9X:&[E4XI7K&,ASR_\.(P`0@LMZ)'6,;^\EFQU
M^Z'^$G.8N2$IH[U5FV_)%K>QC;1(G=92WD+M#_&:V3<U!/_<Z)00OM3)PW&E
M:]WI0C>[V?WN=V_@@%KCH]:YGD\A;%V(&_C:U[\NQ+`+<8!"Y.$`>5!V"/(@
M`F<O0`1%,JH12F&'4CR@`8\@022\4(<].*``[1UA?&'VLOD:ITF?INEJ5GJ;
M:G%4FDW#F6V@V>`2E<_`_-VO;D@4-7>K^V89E>)%G41MY5A8BU;Z*8FSI'`1
ME_C$8++0Q"NTXO*\-T)QHTY[SWA&,DJ5C!^'L4`"9Z>2P[%PAAM'6,=Z9,PY
M#H\B*118,(?6FO\QLR8I[.9P@I2<U%61H,MK&Q9ICDH\P1*6Z,/2F;[T"_3A
MZ7VPA`+]@(["FFHD7-%Z7<;AJ[G_]&XMH/3=V'''.]B]=<\EV:SR9-E9Q#SK
M>2=`-&2HN=L9UA:VP7RWB=AES';Q'<+$'+#YK(=2":OOONC^[7+DRYSHZ(NX
M\_EV`2A?B`)8GO*4S\,*"J#LSBL;]`O(PP*@37HBG9X'IA]2D:1M-;"-&,0D
M-ML#:/``V]^^`0V`@>YU#X,M)(8?;.B!=?=0@`6`?./Y:AF%&G\A^B8'.-T\
MO(BB)L-UF2:(K_6[;UX+1/XB.-/=^I&/_#W]@$.MX*5HDI2BE"2'*^E*!O<:
MM:%A8K`9@>)=9%O%QSE.Y;]87[QC/*PJ.Z@JQK8C;];HY`!'<'RL<'9AR"3"
M(ORDK!@G_U`PA\E6HG5@">=6!:ZF+">0XI`2:9%R(2ANP`^03NFB#NJ@[@)>
M\`5=,`:GC@-JH19H(2M>QR)&PE7&@G9.:>SB[)1XQP<Q0BMR+G5>R7@,XP64
M!5D$C=!P*>X.#=%^*:4<K6D(S[:(QC>P[Y@:+9BN#](N;0M5"X9*A*:V*5[N
M*ZGB9\4@ZJGR((*L:P=\P`=HP`=X(`]I@`?XD`\M#!!O3Q!S+-MX;_<`9R%P
M0!$KX`H8L0(>L0)$BS`\:Y8\P!(E@!0D0!.=P`D8```T``"X``$<H/CR``"M
M@V4<C_'69J)&C7W,ST-@"$A@"/NVD#=PIL&6IIK`3]^^K_QF"O\6@Y%]_J#@
M'*1*2@Q*2J'AJLAK(HXYJBULK`V+*(ZI5%%E,`YNS$3<9NQ-[@9.P*,[/,X;
MV22K=NR-W@B.'D`$5BX");#(D`R//$*M#D6/4,(>!8E16DFND,+G@,XHJ"$%
M:V$%87#IIJX%GPXA89`%*T&!:I`*O$)5Q&+KYLPL*!+.Q*[LSL)5PL)76"FS
M7HG/^"P`_`Q9`LVSFD>T%F/N'B.V2F.8MH??OG"V5(/P"(S=O!#P9O*8(.P,
MQ^]=]&M$*BHYZ&OQRNWQXF;5;@"Z*@`'&!$'KD`1HY(OH/(*6*`1(S$2G8<P
M9@DP/$`3-5$#)$`#&(`L$^$'E`$ME4'_&+S!&Q+`+1-@!M[2+:4A`>CR+>U2
M+M\2`"8`'[2@\^K&.K913,PM9H:#24(-X+2)-/@.)X_I[UZHT[P/B'`+%U=#
M&"]SFY@(J7ZJ:[+H.(*!!R*.:RS$]4[,W.`'.NZE__XO&S6N&V6,`!'0`,6#
MO=2(;Q""(+2*`1VP$W:!'>EH`L<J);JB`E]NK<PJ<E2B)*"L`_](4G@.*6C!
MRGC"')".(*/NZ1BRZ1#R(!6R#QB2(6O0ZDY%43;25=YB+"CR+(2P+=*S++R"
M'O'Q.?G,E9S!E?AL"9<E>3RK,/03)0UM)1.-WM8%"S$--!;-T@C,"P>,0*5)
MM;RG[\R'WOH-_PV#4?J48RC#"4S`"&X>)`_.`!^^+0:D0`(40`&400'*``#<
M(`O<P!MD@`C:$B_ITBY=82[S4B[Q$D=WE$=[E$==@0AZ`!]&L1"N2MQ(Z.),
MR/DPQ!5K1ILBC.]ZD1<G\Q9)Q'JN=$IE"C,E#"C?Q;[:9QB0*EZ$RFHVD]JF
M[<1,+!I/3$*>@ZFJ$8Q<#*I>,TW,".3`L8P&4!P!4P`%@HT6$!T?8AC:D2+^
MI"/>L1YA3N8B)\FRCG)B0CECXAAXKLKZD2>>0`9;L.F6KA*8[CH3,@8Y%3PK
MH1;.`#ZSS@>GXNMJ1^S28K*^(BKH`B]*8E*;PE:?PCYQU58!RRD"(/\2^U.6
MVFY9G$?0G(>7`A2UX$VWDO6ELK"8PC#PALA\M%"V7'(GS0?\=D08\:NBP.E"
M7N;B4LU,5BU$@X`+B"!&VY(M$X`MV]5'?=1&Z_(MXS5'[W)>[S4OVU5?O2%&
MT;5=9:`$0A3<3.P`,PY.PP1#EW34I"\Q1Z29=L0V9#$7)6W?SM#=>,1A&S8-
MI^^BA@,W4F@80NP(J,W"#DX9O:84B@"HK.W$I/$Y5#-^Y,?_X*LU-0YO"'``
MR0A/98QN:.P[Y,0@<K,AV,C'&@(B5NXWA\S(BO-Q',?(,`=J(V<YHPSGGL(F
M0M#*9)`%.753-94[#S)31Q4\R2`'1X(C5Y7_([]BLDBI(B$R+]S!/KF!&::L
M*>S3&9SA*49%;VU5%Q0C6+>R>?QS"A,C0/_!0('Q)<.0HTPJ"^7-<0?4T6++
M[VS+)AFWP+*U2Z&&OM:0*#7T31W*.LI)*0L@"B9!1=V`"&"4"+(@"F2@+=^5
M7=EU7V>7=FO7=M?U1Q.`7MU2!N:I^#@N,%%1%5<Q896C21+O)S.*W:3T^YKW
MA7#1>B3-1V8J<S46&%VHFXC1%3'$.'AJ.::D36%O&<,W&H7*XMS&-5WSH<8H
MY&:SX_*4-D.N;@30"/RT3@:'JP9''<GA'"+0(GI!4`"E."WP.%FB45M":M$.
M`FK5D*H,)_S`$F(P_SO!T^FZ5H)=L(*_E@/`<X-M4"Q0"946:[%\I92"1U)=
MJ29$I1B8P28`JQCBUE:Y(5=3Y^IVX5<[2UF8\'F>19=.H`(*]R8/M#5B:WDE
M%T?JCMUV0\!@LM,RS;;49;^X5`U+S5N5BL5<DSM283Z"8!,&(`O*0`9<5W53
M-UUI5W9C%W;36%W5U2U?-XW=<G>)()Z@*P_"XZIH]@T)<TF9"-TP:DM!XX=R
M@UN^Y3%_!'WT;4OS:YL0LS@4#_I`=OY.-AE#-DGL@#2M[3OLCTW'Z1KAL&8A
MA'VKPXZS@\:0+V?G%\9L+'[;1`$;\&\:L&B/]AKZMQV#\XZ8%H^.TU`N4/\F
M/'"!0<(9]M&0JI,@O[-K1;53P18[N9,[1W6#&1(==)!VZ.+.JODM[`(D2H60
M6+B%N=F;]Q8D>WDY=T$Q^G,_A34E1RM`N_"EV&7P++,R@P,,Y_EPV<46/\1R
MJZG?A#'4C#>I-G0UG\I-C."XHFL"PE@&P)A?T36,4Q=&Q9B-T?B-)QI'%QJ,
MQSB,P=A$4[<,.CI&@R!$5\`492QX(61X"9,H5TB%\"L8,U9BHT:F*C.18;%Z
M-9>;%.]XTZU+W"]+0I-?U/2+U+1EPP:,`CI]!1J48^QF15F5W]>JPE%^1_EG
M;W-H=[-H"8=):-E_`3@XX]&K/2(EU"K)-@(?A87_*?;Q4XAY(;6SZ2J!#BA8
M@I=Y.S55;!FR%L:S%^@B+$8"SW@05FBU*5@8D6X"$6Z"A4?E*>93G`=K5D&"
M''Y564ZR[?YSEW;I$8&X72C3<5N2B(^8W0HT_)*XFFJQ7099>A/3FW2Z<XG7
M.>343(Z@$#QH#Y!`HQO:H64@"W`[C+/@1=V8HB=Z=^&8",H@+-D`$$H`$)*;
M#13@`]A@N14`$+)``5Q4"_!AN8HT;TAZW%R&M;ED#5/(2:\W8W&C6_99%I=W
MIJWWA7CKHCK$D?D8DKUU2.S%IX]CQ!RD.5C6_IHJXS3N0;0AE%^3J;D13^E&
M;F(S/'@V9]VD%/A&:*T:_Y8'YVAU0:LC<'&<%E&+#`,SXB3&F@/)NCE_&230
MVAP&<H+9^COIX*V3&51#59G;6H'$MA:HH"Y\I6SY2'-6^"9N(A>&H+!9F!ED
M&"2EPK"$9[$#@)P38RN-I>VB,)TCL7`-%)N,V'$E[<$Z^[,?[$&9)A8U;3*A
MIIVCC^`4#VTFKJCU)1R-P-<<8!.T8+>S(`O0];;).'5]^[?3F%[CU49=P1M$
M@0$D`!#8(!)BX`,`00B2&Q!,U`U,5`$`(`$L($0O+Y4'&A571N*Z)*6[5848
M=KRIC[4B%]3_[7S2^_S6^_#\.+6W9-384%XZ%QK"AC2K[?6(^DQ9MCHX^:A=
M<__2$SR-X$3!YV:443FJ/<X.Y,2KNBI0)3RK"74BQNI/#&7)+O!QZG')PEHF
M(C52Y+:!PR&"79R"&5+%W]I3,7AKMW93PS/&P9,6C@%64]54<IS'A\`$>]PF
MF($IC%P"T],C5T>S'CMPF;`_*=MYL)(*24NT_PZT*Q3A`6_3!*PV=O&CQ.]I
M@(F\*13,WZ5;T6VUB3=)(P3`1XC72#$('AI&99<MB4`N]1R.5Y[E=7?E59[E
M@WM'Z5(9RD`9AEM%`:`,P&&XA]L-`&!%IUL4!L"#@J`0"EQN1"A"D!1ANX1S
MFR2\3?U)0UL7#4_J,3/,G]1+-P2C.I;,#?.]_QE)JBW_UGF@"/CE.\SF.]@T
MUP6:?2<=-NO49Y]:9P]<9Q-\J=G$.QJ<:'?SE9.]`43@'&:Y%RI<K+AZ(C+\
MR$C":0D%(^QQEUVG:JV64B(8@YGNK<.]#L0]@YEYKH^Y#S;XF;]3@6AA=G0P
MQWMNWG.AWHO!5-+BZWCEL#`+'U/B#[(26'48[IZG`ACCA]<YU.LMX>&-B-D9
M"Q'>GMUYU)4_S+D<%K67>R?JTN'TD\UHS;_-#61``;A@`!0@"K@`SL,X=WLT
MN/5\=_65"$1!%%14`Q2@1"U1``S`]RM@"Z!2$1$BV^:$!5A`!0""C1<'^!P4
M,!(L6`J%"1LZ;#@,&K1@PR)6_[PX[,A%C4?(53QRY$_'D;M&DC.)\J3*DN14
M=G0),Z5,ER59'K%Y$B=*D2)!@OQ3T>/)C!XU>L2(5"/2BM!*\;`8S`X/BE%+
MV;%3"F'"80\=:M7ZT$["A6/%VB&;0NS8A&+1LEUH-BW#LV6CDCVK%FZ1!SA@
M^/7+XB^,P'[[%A;LMT&G7>?.]7H,.7)D*`$H6P[0"T+F`)HA0"D'H3+GT%!"
M0SA=^;3JU:J/0>!6;,B0;>8N]+E@NT^?2G3HU*FS:%$=.I5TV\Y]7/?NY<J5
M5WI.G,/SW95JH8.@J73VT]Q@#\FU+9?X(<6*=5?="\JX<^O50X&B*7WZ[:SI
MU]>\J_^""@$J7@CP_T)_*@Q((($GJ*"??O\LR&"##I*S2T[DZ+)2A4=<$^%-
M'64(88<9<G@$A;M<LR&$)(HHX4T=4OC231BV5%.*-&EX4D@C#7/44$A!<Q&/
M3$7T$%@-J96'`S=L$D06,I11A@S>R$!$E$24(0H1HE`)```*2+"E%%)X\$&8
M!AAP0ID5G(G#%CB00$(2)#20!`P-/-+`G',^<.<C#^S)9Y]][O7`7G_A(!`^
M!>VQ@%QQ1960D,%,5-&C/RZ55(XVSJ@33!&J)&%.,WWJ:4THV93I2#;^42-(
M.`J54:M%X=@JI4KM:-$P1EQ%U:U37865'8X^I(U:73'JEEW_>1G;D*)S*0K7
M6LO6Q9!==:E5RB,L]$488MINFU@G$/;BF&.2C:M99KU49FYGFW7&66KMQJ=:
M`-F]H9HFI[D&P3'>M='&;?[JUAMPB^BAAW#$-6=<;KI-]UQQ"U,G7<0.5\)!
M+=J5!H$[L7TG7B[DP;9:>NZ-\YY\FE3V7CGOL>89=BS'F]^``<XL8(#\%5C@
M@14XR'.#)N'$$H<?PFBAIA4"_;.F'9&H-(0D;=AB3#%U%"O5E$X*)%>0=M76
M7'G<@,\F!0PPYLT&W(S@@!48IJV=C[S]@)Y^SCWWVW;*>1@.+%RQ-]]GZD<@
M?R^\X((+I+A!@`-A.+!"'LX6^]#6_S[ZF-1&.F8$4DRE2@TUYY[+5*JHG_/D
MDZI"J1KK449]M-2L5ULTT:V^-FI'$5E=]6LP7SG4=;3%DJ70L<$3RY;O;S&*
MU[)M+2HM0VGMQ7;>,/05/;=R#L/8N-I#\1CWF)F;;OCJLNL99Y1U]C)KW<76
M1FW^\B8P''!XX445<`SGL+\**R?=;M(U#$`.2(<X`*P.%52C,8YYK#SF40WW
MVE..])",>_!YCW9Z89_7I(\;&D0-.?0CN/T(@!_\01O.3I`@!?6L9QT*40M?
M.#2@'>U%*KJ0BH36PA$-[88F6AH/G08BS='(1IESE>N6,CFM#2LL"LE#(?"Q
M!P=\03!QF_\3G1[A%SUI$4]7Q%L#\)8W'.A-;Q5@`>`&5,+!#8X4+I"`!)S@
M!`!H```,8$`B$C&-/`ICCS-(@!__*(T$>",(B]/"`>)B%J\D9"*+Y(HC8?<Z
MHJSN4D_;7$I:`JI,>BI4FD0)U4[G$QQ-DBBM.F(D(4FYBAC!*@@)5A%N994E
MRO)Q:TE>\I@EK+LH3UK"@PM:A$<76R:D"-;25K8(P[;J)09[NP"7,[47&<QP
M[S&80=?X-G.^U&0&"F\HS6@@`)K5V"M?KXF-'VYC&]\L8G[T:Z<7](`_A,FS
M@!1CV',$&)UZ6N*>9,@8,V0SGO(P@X.>80][H'#0<8@,@]QS8&G_X),^[KR&
M@P0]3<S0.,+_"&@_..OHSE;(,Y(T#8<NBE#0I(9#G.@B:2+MW,]<RA(9C<HD
M(GG5ZE['(QX]:J=<462Q[""")SK``4S809KZ<@4<7.$*%6!J@OJCQL&U$8YT
MM*,RKKI'8?S1C]((I%<3$$BN@G6K@"3K5L-J5C]JP5!:*,1"W/+6)6H-DK5J
MW5$DZ9,9?4Z(>YVIZ(;H$IF0CB>8"Z6E6'=74YZR5I/;:>QBV:M>=44KPJ)E
M\6[IK.$!3UG!-!XOB_>LX=&E>6^M'5\&9;W4+G,<S7PF-+L'&<ZD1YJRO29I
M;FL^TWCS-..\EVK,T[[WU6%^.BBN<750_S_\Y2]_"ZMGP^CPOWMR`+H2(R#%
M:D&>CI''/`3MQ3C:0[)SE"QE\,E,R[3SLO-0=*+L54W,,NJ?$I*PHRI`(8)0
M^%&0-BB'-,PA28MFTAS2!(8"%MI+`ES#`)LTDS91U8ULNI%)48XJC!S671;B
M1+"%00M1`(`REK2D,A#!#0IH4AG`D5:TIG7%8S6K*\P:UAB+=:PO7K$WO&$!
M0^VA$(ADE"(7V9"MU?5J'%$=CFHZT[XJ^6E\S9RI4D6ZTBGEDZ*L\B@O5[FK
M4<Y'%''D3F'YRMKESB&_,U9<G[6\:&&VM)I=U/+BVC6YJ!EXR0L&,:\%F.GI
M&;6J;8`(&*.+<_\$^K71G.:YO#=-VZ8+MZA!GVEZ>R]FN(,:Z*S$<(^+:2_<
MKS<%=`[%IMLP?-Z3-],%=3X!R*^/-?`T#'T/R40&&@JJK&4154UW*,H-=^!Z
MH@1];\T$E%'ZJBU!^G702V6$PY5ZJ$0HZ6^$E'TA&1X[4S%E\@N3G#E450U6
M.(W41+;6$+#`57="Y0`"LN`-82@C`42XL3>(X*0;EY6L7VWQ5P-98S]Z0Y""
MO'&4W/UN@/M;X%(2N+SWG8`!X&-Q>TC!F<_\8\GU:,BQPDB1,=>33BY9KYX,
M;(W(,=C2P8I55"LYK&;%D<5J^4<4=NQ.=5<[,8<;M-%2WIF#26=?FKG_+G)Q
M"UWB*N?1I@7..O_Y6J"7VN@E$S$-T,:WQ$5H^5"3,H\AG_BPV1G*P$N<WVS-
M1-OP!'_1`0Z8+CL\K<L;>G(ZU*".V'2I^VGG7K<8DG9&O3`FLHN58SL9E*C?
M-7CK7`=^\*NY*$=MAD;ZXA=!9RKV?CE$X!K*E,`(!A&"/22A#%TC\P+^H24]
M7CJ1G+SBE$KBRYG8YF"((!5#Y4`0HG`E!<P`2E'*0A;^;?!]YW[W[N9W[UF<
M5H0#/ZU14)P#]G"5H>-<(6-6(L4K-TG1?[QT?]TXDTU5$E/YI"<9'_GH;<3M
ME$^9=:U3>5USZF5P)^M6KY3E9HGGO#@K'^C._RL+_9G5K#7O/'CW1Y9<[GP8
M@Y%G`YA:?L88S10NKJ4]Y0);\F%;HG$^YV->6,<9D(8O$%`,;6`)N-$'04`_
M97=<>M`;(\@;UB5`I59/`A0&GP9=8?!V<0=W`H0.YN$.JP%1GF$OZ%4?]H)K
MNA9X[@"$N>8.0^`.A^"#@W<>$.!K-L,/&V4@:I,V*>1X#')LT`9#&%(B)Y42
M*75L*C)26WA]GR,J161D1W1$6]9R/=45/<<0T%`DQM<#,B`*3O)O41)OPB=O
MOM=O^G9P?)B'PP=\!0=P@F2'[28E[98%A`1%"%%FLO1M799$J41ZH\013M9D
M??57>>5D-#44II,1(?_';1]Q5^1'>N:'$8V5?E0!$4$B+$8`.7A!=+>D++]4
M=$.W2[8X;J5%?]*BB\=#?\1D&-FR9\-8@$9P#N20@%$G&52'&:0!@:*A:.4C
MC;3&6[;F#-P0=K91"<0%@L7U3OA#'-`ECJ0&=RD8'>(8!G3@@J)V@J1&"^BP
M:Q)%4.IU:T?8'4!HCYH@>/?(#49X"+EFA(37:V<40B9$7T_5>%/X#YV'>9+G
MD)3'D#S$;)PW*D#44IN429MH%)18>G75<JA7?V=A!*SG`!S@``-@A[37;D]R
MB'<H?(`(DS&9`$P"`#*@``K@!C)@DS?)!FY0!C=)8DVBB'O``[>T?,SW$#W_
M]6U8(RM6-@P]L2JE@Y&8V'%/IHE0J1*?B#H65TIE6$J3:'[H!TE4X7RGMT2Z
M9%EL2'3U)V?]IW_&TW.PV&:Z&&=Q)EII44S*1(QZ^1=^AHR`EHS;(QGH`HWK
M4EM81X&-%AKCA"_XX@XV('86T(TAR&GG2%WX!&HI>(*8F8[I>)D#=(+6L8]!
M6(_[R(\_")"GB82#IVOVJ%X6=48!PE%.."`Z$X5_HY#_\%)8"&"8M&S75C1#
MM&!3J2%!DS2DTDF6"!3@MVW=)CFJJ#L^QX9VX$2*@P\#H)-1$`4Z27M18'NV
MQP7<^9)DE6_Y!I/FF0#FZ0K>H`$,(`$E$`.1$`-L__`!D<`&"C`&;N`&)?`!
M;A`#(H8`88`/0;``T)`"KAA:E>400L98KX-R0U$CRRE$EH2<&OE@('=R(?&)
M%U$4G<AMKQ)AIMB1C$66+C=+".ICO\1+;Q67\:=SOK1\](=SMN1PSB(\--<L
M<Y$L#8%TJ@5&7P2D<E(G?C8.Y7`-O1!!RB@?Z')HSTA!3NJ,WE0:VP1IOE5.
M3\"!^.`%W4@`Q@6.H.F"GPE=HU9JTQ4&G9F.9;J9O%$+;4"$IMF:^J@)<WH(
MV6&G<\H-4,`-<KJG?:J//FB/_HB$&J0+9R0SARIL")F04\B0E3=@I,))%JE7
M,5))24:IU?<I#=:)'@JB*_^G4UXV2VMAB]6)#S=@`3K9)(=HB(<XGNGI1^I)
MGJ\JJ[.Z5366;X%4!@Q`!(D``(```&XP)5E2!LI0!ED"`&7@!CBV<'M0`&V!
MBX_S*Q(GB2%*BD^YD:FBB9ST5]D76*:"*J%T<56#9217<2DGHDB$-9_J<DH4
MJIGU<T"7%T8G="_*?PG:+/WG8PMJED#V;1(1$1(A$48@L$;``S3@`P9+`RM@
ML`>[`C[0L`^+!PZ+!ROPL`NP`H5@`AB;L0=P`(\!=>/R/8<VF*91F+K5+HUV
MLM5H:\?@#(>0C97@@3V`:5VJ`S0['/F$F;UQ@F,J79O9F>IXIIL)7;5P3[2@
MCX/_IPG_F+3=L;1+NZ=*"[50R[3^V)K_"*@"J82QB:@FI#.V^3?YY7C3QE+;
MFF#8AJDI@IR8JK:9JGTF\97BAZZ1`B2/&"07YCM`50@$@0](D`5,H@`R8'O<
M>7LO::M_5)ZUBK@K5KBQ"E93\F[%RB12H@RKBGL),`'&MP*8A2Q+Q$B/!(F1
M-&4VE7)3`UB>9*$?ASDG)WJI:V0>6JZE>*X_PF59TW+J-RPH6G.XDP<'D`>]
MV[N\Z[O`N[N%<`"%X$3&:P).I+S&R[R%X+S/"[T%4`C26P#56[W0F[?8Z[P.
M,+W3:Q#6NP<4&[[ANP+CNP?F6[[GNP),L`?LRP3KJP7O_XL`3,`$\SN_3!`(
M]8N_3%``2:JD4]>,5:<RM749FE'`GU%KY60.MU$)6K"E.B"S!-"E$ERS.@".
M]X2.H,D!*]BS$=."9XH/8[J9HB::NJ:/==J/]XC"14BG2>O"*.S"3ZO"14C#
M`1EX[=4+ACJ;!@F%9\)X396;,%2I.A$ZPNE71IRV&@<Z5>FA1-24M`(52GF6
M+AH5T)"W8(,`44`$"E`""J`D\/9O+I96Z&FX,@E\@81P,Z![_`9\Q;<X3%"7
M:CD6CO*(GSJMY#=^TC<2&5>54M:MW%<41B%]'[&1S4F*BG6N8AF)J:B&[0I:
M*<`##P`#6%``-V#)EXS)F6S)A?]PR9R<O=S[R7E+O09A$,QJRN<[O@6`RJN,
MRN6K!7N@!>7KRNN+``@`!$@0"$B`RT!@O[P,!('PR[HLS,-,S,2,!<,\!LF,
M!&/`OV_PL?\[38F&0>)#/J-AS>/$F!F3,=1@";NA!5I`,-Q(LS2["&A':FVW
ML_3DL^JHCNT('1)3"[0PFDQKPG5JS_H(!8>@IWSZPOTLM4FK:S8\J+VP!3A3
M0B=4FP220F!;;-=7Q$E,Q,6IQ-:'G!.Z?7L\*Q`VHL]988U2BUTCDGFK.!P&
M;TL2)7_4JF:LTBN-TB*6T@G`!8J(`,DG?R`M2UYVBJ?$D4;1H40T?2H!R"TA
M2B$!897_^+K;ALBQ"\4E6L<?>;LY^DL-0`(Q(`0%(*!@@]6E"C9&0A!</51>
MS;U?/50%<'Q#%46LO`*QC``KL-8($+^;P`3Q:\O&?,M,H,MSK<O)G,P;,`;+
M3,Q]#=AZ#=C%3-BX_-=C@``%H`G/3&BB<2Z/'8V7,:7H8UX;%!MA![._H0?L
M5+,4W*4W&T#BF+,"5$!NYX(AC()D&FJT$)`^^(^"NL)ZZ@Y04(1Z>L_WW*>I
M682"YYI'"`&Z<`7UA4;S=9`__,-7$,0?<L2<(RIK:WW/7:E34R.DE+KCUVUR
MZ\BB.EIN>`.$%`0]($B+R]);]8<QR9(OO6(EG=+2H`!:(*`(_S`5=*E9<QPY
M/$41=TRMI:3'U?T3%LK'G;C36OFAUFVN2DTKZ+=E46S?LC1FHK4$)V```U``
M"W<&!9'5I6HH60TV9V`D6CU4-^#5("[6I*S*K&SB)AZ_\0O+::V^KZP%]EO+
MM5R_\YOB,V[CM1P(]AO7.]Z^/<Z^Y<OC6L#,A?`&RFAH(BMUEK%-T)A-DWT^
M*MM;KA$;YF`#F5T'FST!,UM<Y6Q/I2;"F%G:.[O!85`+I%T)3S!J#5,+-4S#
M3UO/_@C0\(';37O;+PR$K^V:MZ896Z##!XTS@+/0BQJVSCW$1DS1V,9Q9"N&
M_2U*@1R*B(R&95FW]F>4*>"&#K`)B_\S`,#WA^CIZ808QFQ,WOK6;S*PG40@
MZN2-<`:7ZG\D`Q9PIO`MEPK!AC4W+(Z41*#+H>(GR(%,1%&FNB7'$<L9X'AL
MX*>$BFGX<E+<KKU36E-M`"@0!&<@H!5^IM=^IM2.[0)Z[=:N[=1>X6<@[C=P
M!EAM[IJ,[IE<[IFL!I;<[C>@!L[;[D;2[O4.[R`>[P81[X40[_NNO=%+O?&.
M!`B`L0K%V(U-&=44']#X@./C,JN!+]S@#+&1"^;P!&H`3\/UP!+,\1;,:1#3
MSJK-`;O1S9JI@BC(`?L$0-2!750KJ/U(PR],VW!>YRAL\[M=A`)=#,=@'MRE
M&3Z<>".$T/?_%>C(K9`6W=RE"]V+?HF=E'V_[F"B9]V19'J-S#4[6J]1D0HW
MX-X.,`$L!KAR(`/!QV+>(/:NBI[O-O:L2KFT.@-L0``YF07>R9TRP`6H?E9$
M,`%GJ@4T4`1L]G.CI:!!9M^Y3F1(;41/*10GH6U",<APRY'E=^R>JN#>5J*$
M[WZ454MM-M4Q@`)[<`/77@OIP`%^4/JF3P:UD/JI?P9D(.ZO7^Y4@,D9F['.
MJ[P%L`"XOP(+8+$+@`>0P`-X0`/#3P-K8/P/L`;(7_P/0`-TX_Q[`?U%(/W3
M3_W37PJV4PK9?_W:_S8P\`J1X`5K,`:!4``FX+%**DV/;2[H<C*2_^VD[E(O
M$#]1L;$-?N``<$`P&A\%Q46S`*%C$1TZE?KTJ<2!`QT.E1PV;.BPDB6)"A7B
ML]@0H42#$SG0.N0NY$B1)0]I.G3R$!1W4%"^5.F.&\J9(6NZDWF(F[,W)L[D
M&C*D&(1>6U0<12I`A5*D1RNH>%I!ZM1_5:U>Q7IDEU:NY+H>\1H6[%BQ9<F>
M-9L6[5JU1]S^>7MD&+EA<H?5I6O7[EV^PZ#Q#38L&+3!P0P?1IPB6`H[C!4'
M:QQ,Q(U-8?`A\98@<P+.G;UM)M)9M`P";KQ%D2-#M6HY661T=L79&P$V,U03
M6?WY<VS8FF<D()*EA_`HHCGSCCT`7Y@@:__L0%8<_?GCQXBM!PY\]V]?[G?U
MYH4+USOXN^3E'A&/_GS=NW_XKM_;7?Y\^=L)"\:/77#A^]>M&S&,N@`7(Y"Q
M)%`P`(4]'`@CC!L*,:4("2>DL$(+)2S%P@PS+(+##3'$L!01.YSP0Q(WY/!"
M%5=D<<(''H$!1BQ>\6*-`1`HP(1Q>N&Q1Q]_Y#&`7J`(@,@AA20JR0"4)!*"
M)"&`PDDIISR&F:#:H&4/+^#0`PXOO=!!!P+$U*$.@AQ":*$P(H(H(80L2=,B
MAN:,B"**T-P()&Y,HLDDD6!"Z4]N3AHT4)50TDFE/;EY`XE0+*C%F&.X(4JJ
MI/AA"JD3H.)T*JG_KJ@`*U&OXFHK4]E"52U54V6U+;>\@DN]N>3*:SWOYMON
M+OVP^\^PYPZCKK''C"ADCQOPL:`,>KP@`C<9N)#!-1F(2*TWSL!QHXP$LN`B
M"VF](>(SXWP++;AO-QM7MF9Q4T`&!0`0)5XWW!`%'D>\<22!'AAT8`<>I&.L
MP%^K`_`PP0C#SC[Z;KU5+_9DA9@]\=@;1CRZ^HIO88V[^ZOC_#[FU6#_1K:N
M.ND6:\R(`V-`804&+2N@GGH>:."1!V[&^<6<;VZQYQ5YQMGF1X8F>N@884`:
M:19@8*%IIYM6@86HFU)*J7D$F"=KK;<>I&LGG"`%BS&0V*,0(,_^$0H?_XE"
MDD=-BNP%@B*+?#)NN2'0A$H(N"FFF*!\04('/>JH0P\OO)@@3,4'XN@AACB"
MZ,X[,U)H3870O-.@@YZH122=1-ISI)?^%%U11`'5B9N99%)=)&>6*6`3!T"0
M:5)=<&AJ*=USCPHJ3T$=-?A6AU^U+:_<0CYYY9=7/CSUT#./O;PH7MCCA`W;
M#]@!&^/^,>ZA*20(?/!!0(89``''FVA=BT(&<-U/UYL9?HOVMM`T`U>TS(@H
M`X#6%%"`!N`EBC(H`!!E<(2]A)$``'C``Q^8A!0<.`@-#$(")XB!!Y20C6Q0
MP!%1"`(''``$&C@F0`$3EJ]&UA_\^&5C#*O5P__>8YZ+>46&\*'>"W6H'>WL
M"F2$Z0_)KF,$[Q&(0)%1#!(;@"`4:(%!9WA0/9(`@YH=+6E7A`$.D`8C&%UQ
M:5]\6ABG)C6I(:6,N[.:"JZV-39J;1#S<,$@XM@U.M(Q`EWC0P3XP(=!Z'&/
MC>!#(P`YR$`V8A`D&-L>#E".7IP#;6B;6X^B5`XC)2EN2R)2E.QF-RGE34I^
M&P(Z]M`#'7C!3(4[G.+&-)""=(1.%7F(0RQ!$3DIA`Z6DT@?,G<0A-3B<R1)
M":)*$BA#%3-TA-H338#ICF(PZ@W&8`;KN-$+2QTE4YIRBN\^-94K!&]4IRH>
M\<0ISG`V[SQ_B&%Z=NC_0ET=##$%^U6!!&9$8A7``?C80Q82D#[U2<LUNBE#
MN-"E&?ZI)@L!U``#1,$``!A0%.(0Q[W@(0H!G&`2)3#`)^8Q00\(`0L&X$,V
M&B&.!$@`#4O8P`:6@`8!?,(#@_#`!G9P`@TH8:2RR((6.(`/(#P`8-,1F,D*
M9IV/\?"%#IM+>]Q2%X<ME5:TFL]YGK'.^K@P5R`#V6$`E+V1I6"H\4Q,4%$6
MC!V@@&5,>!D^"C!%%N``!RS8PEOA^E:GE-$H6&MCUMXXQSKV=1!\Q&,?!2O8
M.](1L';,XU_WN%C&^C$"@`SD8A\;627HL;*"C*P@E7#(,8RA;`%PY",AR2.V
M_ZE-;J:-6VJ=1+=-3DE*QX"`W]Q1@#$0@`!>6`3AZ@"'5"ZN(*UT7$0:)Q%:
MUI(#87C<1-Z$)UU68@B>\Y-.8#*2TAGJ3SDQ5.ARHKIB+,,9?0,O44"UJ=SQ
MSG<JN`)40`4\;V:%G.]E'O)@%1?GU5<]]G7>7-Q##O?4Q3VRDJ'&<E48(0XH
MB0'[*33RX(![[B$*TF`H`&10!@EH(*$79@,@-`!1B#I"%![8PA:BL%(!M/2E
M!A#"!EY@4P["0P-;&$5*EU#B>;1@$`+8@0^$H,%&_,`1&A#`)9B`@`U@S0,N
M:($'@!`((3B!#TI0@B/<8('C(H`'T)EG9(P(5L1@]?^J4;WAP^PR/:>&V589
MHRJNC.K#70'Q>@4.1L&J8\0#8QG+*4A!%Y;`,B0XX`8-*@!47%`U%RQET$>9
MQQNQ-@@5\-6OCW[T8>L(V,0&5H]]S",?*=VUPO95TY&&=*B[UH`!($$+!=#$
M+D0+)*(<B4=-(FTY+#EK(N6-DYZ$[=[Z5H!`V'9,>@#VE\(4A5^?J1*M9(A&
M&M>0R2U$3KBDR$9DR<M*@,0F-B%=2-R!.N@>*I@D$>:@1%(,9QRC$"8(2C.G
M6<WRJF!348$W-RO0S?9>)9SW'HORQ')??C_/G/%]GGVE]QTT;TQA;+8.6('J
M&"TS)A5!*``^'-"#!*!A"RC_B(,!6*K1%KC``R38`$U9+(P/;^$+FV`""33Z
MTD.N8`4[@'(CLB$.4:"A'DA`P@;FX5()4-`#D/!`0G^@!)(+``UQ"$5&:^P"
M?GS@%4]G`S\DP`=AE$$Y8=`"#Z;S'"2.5<L%+BH[Y5/PB\7*OW:QF/3&GN:J
M'ARK;X9SPJ\#U"/B.:@,S[,0,(B%>P):`%#^`0/XV`@YB,*F@D2\9I\L:5&'
MFH]W+*RD]_A72"<ZKR6N&AG'^#0L'HUH."O"`XKP"!SP8&R0*,`;5HVV5JM-
M2)F$VZSC)NLGW6U)3LJU.ZA06P*484Q<\I+BR$0`0?SVV`592"NEG1"#%+=R
M#$&N_[(GDLN#.(0:T37)ZE(2$V];5]S4Q<FBW"&4-R`@%%H(`SID`H';58"\
M[>Z4-M<[[U#5VRJO>N^^Y8M?]9#C>/FE"_Z*&/X*P+2KH0"4(1LJC_?0H>T@
ML`?TC^A`H6!Y#&AP@$V0N`&0!HOS@14`@DO(FB.#*298`2&0@$:P*6&`!P^P
MN"B(@Q+S@"1SH!/@!#:0``E@`"40!R*PN$D(A4D0@)>JJ*>+A:=[!7[0P1]@
M00.8@@AZJ1<0@EB0PBFD*9J+@N78`SSHGI^*#B."C.M@(?U0&#!K*HRY&(JQ
M%31D.X[QB^P(0W<*&>PI#*Z",R+Z0N\QH3K#0P)Y`!*(@?\8V("T<@`<@*D(
M0@,T<`$T^(26:B.LP3PT8",!@*M)#".F21JC^3R;T1G18Y$4T!`5$;V<L9F:
M>80&\"*W>JLK.*.E$``<P#D<T835>Z32ZH6V.:VYR:0D@0)9XR2\>:UCX#UP
ML"T=J((JZ"U?LRTXJ(-C8\;?X@!>JC[FFYSH2[9DF[[,8:Y*\*64P#YAZA-"
MH2[M$AUQ&Q1LXX8A6(850(`@H!W8X@9=8+=VLY2I0*]MN@)ZL[]_P#?].R?P
M8!ZS$P]T2BI904!T4B>H.H^(B9A9";""XPX'S"J2.1F[0[#G@`;P00`&0P)I
M,+HE&(`H4`&72K(7(`4AX(17^`#_4G`"'10&D]J"4`@%*7"I03/"6#C)5UBQ
M:8`'HXN"4)"#E9."5X"$*93",>"#'UC!0^R!4&!!`8!"3H#*J#P!)_@!92@!
M?EF!(@@6`]NZ.0/#.13#-4S#O3C#AEE#OO"8`?LA7D$8.!0BKY([D]$>`?FI
M>:(!$D"#&(@$/VN00F@`M\HBSR-%H=F9PC2:I<$BFGD14JPB+-(B,&(!59R:
M\JH:&FLC.<+,QM/,.BJT0$`"'#$!6:S%T23-(!F2'BFM)5&M)FF2NW$M30@$
M,4'&,#E&V;0M03"3XVNEA8#&YJJ38\N(,*B$Z),^CJ"V/L`);@0F;?LV/M&V
MF[")[\N^__'C!G0PAD*@@B'8DZ'H!1QPO_)ZM_@#E=^9MWRL"OQ3BUCA-_7$
M/X-$0`0\C^GAK[-30_,(#^JQH8LY)[:SGNQ!F+D+D(7C.H!A#`L$`ME!@@1@
M032`R4F`HT$3@E?@A"(\223T,0U@*9B4@A#T`$X8RJ&,!4C@!PWX`6\P.@/H
M20\X`0/P`!3@A#&`RC%XA1,8!`9P!`DPN@'`J$@0@C^,`3:X`KT#!"FH47C(
M@GMR@!4HA0%%F3S4LE^Q0_\(NS2+CRIEP+/DH?MXN_P0F?\LL*&2NY+AR@/K
MGC&=#E/8@!@X`13HNS!P@+]L*[=:&BVB4\!$&BU*KU6TIJ6X1_]YLY02XQ3T
M"M0'Y:LY2K2N<;0X4M1!<`*O\:M&;=0*BM2NJ2!&I50*JB,-*#0FP`(F*``J
M$$T@,1*U&4U+@C5=Q*14]44GT80W@`3;]#7:5"5DO*TZV`AC.S8X@4:.*"XZ
M<3;@LI,TT1R$&()E,E9B4HED_9QCPCZ2&`)?0`8U0`9D8";5H::G<#=YU"9Y
MN\=[-$]]1!6PX,=7.;N#S*_\D@N!S$^*(3.&5+NERJ&)P:$7NJI=(9F!:=+%
MP+.M6PR,/%`$(`(@BX&>G`0/@*,3P`*BM,E7.$IA`#(#&(`?-(`8,``I@-&H
M["P#<`(;]0`!,*L8^(`-&`,V^`"018'_*SB!H+,P%RLQ$L`!`^@L!$DH%<"!
M%V"`"F*`'Y`!]`N#%="ZB6S2A1L0*05+JQ)+AKE2I*4JCV&GZ^%2+C4,+WU+
M>`)0.C.PL<([?F4,.R`!!(D!OG20-7@!%W@!`7`!-A``4B!)4E!))[A!4KA!
M/JB&N3V%:!B!=;"P1%,!?C@!IWP!!W*!K_&X%_A;`W@!PYV@R?NT"JI4.4I4
M.GJI.'JIR86IRHVCGHNC1K4@1[U<"FI4%S``)OC,/0C-4.T1(3%-N$%-U5*M
MNEFM*=&$`K``6A4^58)5`A`#0BB(/L#59SR("VBN2GB"YDNV-:G&RT&(X&6N
M/J"%Z+*NY2P)_^P"/Y(0QY)X5F2`A$S(!&D-OVOPSG8CK]XA3U#!`7RTO[@0
M0/KB-_U:3X:$*KQ`R/]BF/603[-L5[!@JAQ:6AXB,#J,L^O`.^A`(F%YCD+X
M3"TH'P8X1*0K`1`S`)CE!"R(T3%``0W@@XF:!S3HT0\X@<Z2@@^XP1>H`,%C
M7'B0@$]``Q+PP[$1@HK]`15H``%@``:0(Q=CP08H!15`@24X`1>H,!QH@"O0
M``D(.IU%`$`KH3LK4Q-2(<C0!NMHR[`4NX5Q2/W%THMDLS>40P*3VB\=VK#J
MPL@08R>EP'RU@Y";V(@+@S/@*5F0A9M-!`D`@#F>8P5@@!D0ACR>`?]9Z`!1
MB89U<`*6.H%(0)`2*]N.%0##_5L'(N(;M+`A]@`)4(`;!(`*`X#`>V0^L.`?
M.,JCA+)/!F507CS&8BP+QM1+A2D!6`$D"(0<8233E:37"Q+4DCU4C1*Y\20G
M"8'8C-7:%;XQZ>5E1`C@8KX^`%YCGC[-L27HLZ7+D:6.B(B-J(7G@EY@*J;2
M(9WH4L[D%`DU\((Q(00U4`-*Z87TRE9L<@I/&5]O-<^PF`L")-?C01X`Q(N*
M><\`RPL%G!ZS1"KN.(*IPIBD;4#^C4C_B"<*K$BL#08#1@)US((?4(H3J``I
M*(%`&(,8*(&<#4*JI&$2_3`!(($&`#D@6`'_`_@`#7@!'"@%%[C9H'.Q>:@`
M&BB%$FMA#Y`"/GB!-5"!F]4`#X`'&JZH"IB@K@'9B?51!V*`,I@`0--"/$.P
M)@U@KP13ITT8++7JO@B,OV`S_XW:N"N8KZI:ND.PK'7JBAQK`C80LS(`L+V!
M%;B#?^@`"E`"/C"@#P`$4L@P/JZWN]4`*7@!*5``*2!2)4BHFY6"BJ6@ABH@
M8;B*=;A9-U"`$B@!NWX7"3``%=`XS$:#%46#!_;LSW[@#ZA8"2)MP39M*:!D
M298!AHJ7'P``2&#ELADMU*7MTTU=4JU%6F9=)G%-"#@&2.@!6L5=7[9=WSH(
M8TM>8P9>X`U62RC>_^3C@%IX',F1-FJS!%_`9F-MUI)H'>T>B3T9`F30DBG0
M@7"F5O;SSJ=X/Z3HG?2BO_F[`ASX5K#X+_00,^@Q0/_"YX">U_[NCKWP[S0\
M2RUVLR$RF3&&#L=0\.=(!2#X3`2(`4?(X-)K``]@@@VH6`MK`!JX`CZ@80\0
M!V70@$\@@5*X@K\5@$%`;90F@9LEXD%8J(YUMQAL5"DP*Q3`<1S/J(4",@UF
M40K2@`\P[0JS,`:`!R+H@>5P`#R8P`#NNBT#._V8XJM.,RUVR_P((B&::J_\
MPJO50Z\+XP67P.DP(3M8H@=>D`:Y@3T8@7^0!4[V`"U*&N^,!OOC:R:*@?\>
MH%C/_H`^_P";1NU)!B!)%G0)<`,Y!@`WB($!&%@ND&PNB`(VB'0][X$2N`-_
MN(-,O_0[^`9_^`9UB`8/RF-A4(92+X/^D3#(S@+<S0)PB`99*(-5!H*R>658
M)E7<;AO6A;TFF9O77(%O%FXQ(&Y?SBV#H(.-2-X+6.YC'E9;$LY;2K[ABD;-
M,0AKZ[9L/M:0>-YFW;[Q"V\U@`1"F%9-4)WVPU9LFD=U7J][+-]OE>=9B>=W
M/<BR(\L`"^A[3]HJ7KLUU&JHC;NZ$W.S7HP\0(`#'H![Z-@*".*.'=L'T@"H
M,``)D"`/8``1GP<4T+L4/S&CUCN*1>H/\X`'5EG_"ZNP=Z%CA8*'B4KT$I`"
M;Y$"&1`%98`';TAYFL<7;\@")5\`,A=0IU[B*-]2*M^ACLF.K;Z>+O[W7XDG
ML-I*?>U*M$XALQ[@H"TKBEV0Y0B#`J"`#N!T=1"'%Y``4DA))]``65"&1'<#
M92B#;\"*.\#;$L@&+@"`4:>`9FB&F<L&81"':1"&:2CU'^B?")OC>8%L!8B"
M'HCTPQ]8-JCT*"@!QX\"*0`$;\F"R6_Y+)"";K'\;L%\`/+\SW>#T@"`4W]M
MG"L;U?,1(5%]TJSMTS422<KM2SK52X*2VW.2/("$8QR35`*38=<!0?`$7B*(
MWE1V9>_-/I"3.1G.Y"*N_^I.7EH8`ICH-FNFKM,QUNGU'&J>5FJ5"7<@BO16
M[W..-VZ=MVZ=[_183ZB:SP4<2#6TTK$4>BM>)P*/PW=*(GD2\P0?8Q%P<(``
M@@")-`_ST)!`X6+0H!8>8GPP<,*``2D>!HF"]\.#!RE2)&@(J4&!%`4F%6@`
MD-&;*`F3I,A`*4-E1G@VX7F#ER`!$1D&8D2*)&1,I`]L(K&10*0,$2+>$LC`
MA\]!`3LIK`:SBE5KBF!=O0;+&G8LV;'#@IT=!FT8V[9NW\*-*]<MVKII@T&K
M6W9O62-CC72U$U;PWJZ&LQZ^&E@Q6*LI'G-EO!@RY"XH3IQ8X>!,F#.%FG7X
MU__ASC>5`-RX`:!,6)F39<I\^R=;]AT*&F*4*:$``._>I]TH`"X\./&3QH%S
M*2$E.1<N6:1D,0DHRW3JSZ-;;\YE>18N@$H&!WX<@((K@%0K`\`$"9(]!325
MZR5_/OWZ]N=#"=!+/X1>^?/W%V`O$`1`(`0''JB)"7MDHD<F7N@@1A40BA&A
M#A=B6&$5==#11R4=]A%B'Q>0.**(?5C2!P<<T!$&BRNVR$$EE7@X8X@STNAA
M+;0<<H@[/AZB"9`__C@DD442.62/2`(YA)+N<,.-,[W@4$$%*IR@@I96JF"E
MEU=4`.855^`P)@ZSH9GF;.0<P>8P;)+SYC!_Q!GG,&W_MG4$6W:^I:>>=P(Z
MEUM_LN6GH(<>NA9;=C'*5UF&"7:55XY%ZAA>`R&!``*@:.""%#&4P)$$HWKD
MD0(2H,0`3O`P`,!(4O`VDRBB,%"&(][<ZLA.WG`120PQ"#&`$$B1@I0;336U
MJP*<8,$L)\^^0@*S@+S&U%/>.!`&/E5!ZI6DCTTZJ:1AI>!766?E=1>ZB+*;
MJ%J+HJM76/$Z6J^]B)%+[F*4/D89OUA!)JYCWSK6Q1(GQ,"$`_B$$48A/]PA
MVC]WR/!#&:B5L=IIY+T6&YH=V-8#`%%(,1QP4I20LLHE9/'<=-!-=])IJ)[D
MA@2I\98:<#>'A_/,Y`EW,VH^_P\='`"MF0>`,,(`P`D2@3!1P!O[45UUU?I9
M#85\_06@]8!;?RV@V`:6@Z`FFE"AAAYP3.C%A#I`B*'<<"]"R(TY7F`BB26>
MN.*+?]-!AXTUWIUC)9;0(J0[12[9H^)/.AZDDI#[.(0[0UC.33&'%!.E+E5R
MB>665U[1I95BADGFF&JR+ML1?[S.)NR`&BHG[87>7GN[>>[>>Z*,IGNO6&`A
MIICQ_(H%S0KL(;")-/"(8AITW2E`A#)-/;63]CQQ$4,/W@/%Q@=&L2%*4^9+
MDX`WD:P!B?L++`#)&IR$``D;`,Q4AK+/<C(&%F-<P2A%`8`WLJ>]A>&C$#PP
M'@,C\_^ML1"&+WF9%Z/>Y;O=`:^"C;J7N?X2F,&`,#&(P4IC#L.5$D+J>"9,
M858>((08G``!#KB!MFZ@@8C=832S*@-O,J8,'O80`#-(4P>BH8$2W&$W2UNB
M,-+#!>*@IC>HJ9G/@`;%W>2,/"8!#@`D,).<%<=F1MO-3(HC,V5D@8N]&0,2
M!%(`*L1'/W*\VGRP)A\[UE%K7=MCV,(6(`0!$@+N0,<>V`:AMEVH0G*KD-L6
MT0?!X6U$)<J;WCSTMP^Q*`R0])`E#E<CPU6"1T":').2E"12-DY)F!N"YJ($
M)<^5Z4JR-)WI3F=+,YFI=:SSDYOT5"=`\8E0NKL@,8L9E[7_K$6#\B)+!P=C
M&!423%Q741X2-L"$321`&JT!1`G8`"Q?&2`28XB!`F10!G->"P!GT\3BA+2`
M]L$O5DS9U0<`B!0VX/,#;D@C$=*7ONWM)'W>D($,LA`%+LC@6@74GA:DHL!^
M`2Q2X7K@5_ZRE[MH4%'&?$LRU;7!L$Q0>&0A3$7'(L*)IO!?X%+,O\!"L`92
M)@5=2$@,@%``AH7A!BX8`6WNL$,@*@,</PRB+$(SFPZ,X#8=4"(3EP:`$@S'
M-V'$8LY0)9XJ[H8X0).J%L5C'.B4I`3;24X6=*,,!81"#J*0A3JF(81,,6$/
M)H@/??I#-3[.QZ[^N:,>O;:?_X`M_T![--"!C@$!9[AC#W+S@AB\X-A$S@UN
M@NC0AT*TM\M2<D0VJ,2+9D2'%T$2E(7C9"V&\#@F0<Z40'K<*$]YN<MUCANL
MC"V5N'2E+M4R3%]*'2[/I,LTX>EUN!LN[P(UJ+@0:J/*E4M&*;B79N9KA(LI
M'O(<4P`D#*!YRDB`$!:`C'76#Q+26L,K2,&49.T*$*=R0R*4X8;F`,(-,DB`
M*[9GP.VU1K[E=`JRM%>&,7"""[TIZ`"BT#.,[<0"#',`'B0SL,@@3Z1XJ4OP
MX*718E;XHQJV%V"&5QB7"N:$_HKIP%BZTA)#>(7B:N$&)H*$&3;L!B^(S6CN
M\,-:G;.)/_]$S0]EH28C(I&I31W9<?:I@.LHQR31X<(DDL,RE75'K"N;LI2I
M'(4J1WFL6G:#,DHB!YZY`06!<*,)`E".`*"9:ERCXWV\AK4"^8>/_0'0@`RD
MB4`6PQT(B-N%JC"AQF9H;AORD(CRMC<359*S*YJ1)C-IHTX.CM`BJL4V>I3:
MUF+:M:/$]"%6J3EW;"Y*W`@`Z&R;V]V*J4RJ\^UO9Q.H.OTI3H:J77*7:VMW
ML:6C&PRIHPA#TA1"LU(!*\`&!@"$/<RW#*0`1'RY^2LV`"(&62`"0+4'#J8H
MPQL]`0Y!SXNL[`'B6>?!GT$'P`7YXN^<"RT#"CA1SFKM4[[=*:#_`0>0K1LT
M>,44I=1$?1T6Z%Y4@VFQ(*[QXM$,\UK"?*'H"%V:4F`+.U+^$M@S(P[1%?.`
MIAO8`T[#<()HR&8T\#C::12@C*%NK`Q%3=,(^!"#;Z2FJ4LK`ZA4MIV4.5FL
MUED.(+3<LI<]QSG<F4YUEL,=YSS1.$I^F7-(PN4CJ]<DPF`#$)@0"+G2AS]5
MTVN;^2H?KW%-:V(;4($("TAGH`,2<%N[V]K&9T$O(G!X,S1F+7L!1=,(DS#"
M48@Z*:)([XC3J&7<ID^;2M=BKM/<\%'GBM&?6)I:EKI%W9A63:96HTFX>T+N
MK3M_060V%Z-\`7ACI,FO8#\F#]A%PB:X_^"-&?`P$07L2<NB(P-D+<6``(Z!
M&UZSS^0HH%K5REX6A(`%+\I@GU'H00EB4DYZ[\H-@/@A08E03G,25%?;BT*V
M'+`"?,%T*S&5,,(K"'J"$_S\:,GPP17>X0B"WUO2]197+#5=%=*?@9*1[OX?
M#!D>)`$*&,`8[`%G-$P%5$-/"8,&E%'PH=P7"4/$H,D(,,`'.`)OK$93E4$/
M=,=V*`#2&=T330_3M8P4J-=SB%5SK$S.41D;=%.549G*L`')G%7,F$09``(3
M,`$"K,`-E,.9\9'6O=E]X!%>Q=E_".$?08'900`W'$,0/!:$.!;;1-9BP4'@
M2-IE(9K>X%V(^/_-9\D(C:1(I)U()=R"+VS:X#4.:HW2*F$.+6S#-L!A'%H.
M*UV.J'%#;7E);H')Y/&6Y;$:YAD7YPVBYQGBA;V+HAB<,BT37_A;_D73\?1;
M"JC>`&#!)O2`-Y0!/XS34OA>"41![V'?:U#;3F#!&D3"]7U@%$1!RU2?4V2/
M>W&9MA%4.4U;]='7]OP3+0X4]BQ4+NZ$#-Q;`4`4"Y%8_A%/N?R;!(T%^RUB
M(D)C^K7?62A<O4305V!C1#&<B06,"DD42U'<Q9G8)*8`#]0#"L0`"NP!#34,
M"30#;71``FC`:]Q@$UV,SBB#Q\Q&RTE!>AR-S(E"#WS`=K0,#";'=&C_1PRR
MH,K$0!0TY`P^Y/*!S_<X)$6"3T5.9!9<3!0,`%0=C0+HX-7=P!S)T1RMV7V@
MY-?T41\)%H*471,>@]H84MNX715*5MP)CMT=FJ%)$F?EB(K("(M\UN#\Y(F@
M2"U8&J8YB9/0@AO"X1#`(1RV01QN0QN$PRV$0U92`S7<`N84P^;D&>=$R37@
M0*E)WBVE3IBH6IF4)>:MR7`=P:P9XEP>4ZZIA<!1V(11HZ-TF$N!W^F)'_Z)
M`!`,P`8@P``0`0",`21@`0_-A`QP010D7^_!HGV5`3@L!1%T($%)IAO<E_;X
MD[;Y8K61IO;45VEJ#Q$$@514!;YH(V!B(P@1_X^C3"->>E2\W*993)A(/6)L
MJMB^](N)`4SQ,`:*28;QA"/`P%16%,$."*`ZXM098,$TP*,T*(`HW&,&ED'+
MI$8^LEPVC`00R5P9..25L4$/S*`W4:1%1H%Z-N1[LB)$?D\/S*?W6.1$-F1%
MQN=^-B0H*L=I#(`6B(PPR((;Z&![%((FE&1^[(><I>1=V0<>"4B!O.1+'LA7
M^H(:U($>5`$<>"@<O-V%$`"&.)8>!`Z(:"'?(%H8W@W@V`@9EB&EN2%4#H$<
MVN@V7.56W@)78L`M8$"/8H`YW(*0;F4X4&4;6(Y8SA;GN,/G]"&JW9*8F`E;
MX@`)N*5L'%<ATB6N0?\C-"`3,JD%F'HIO*!%;@8/!^W%<+X4ZDGB$3!!80Y$
M*6I/064!9T9FG7XF:);F/^W$::+FG@+4:?)I0/4IH>X$QVW+Z>U;-]8?N,@F
MZ9V+;N;FI.(EFGJ824E4N*A4,7YC.%+7B.5?2W7+.+Y45C3`9<3`.C9,&##!
M#X3</TB#!LP*</B0%96!*DC@;-Q!-O`!%_CC>.JG1=+G1<Y@"?2G]\3@E?EG
M#$Y9E!U9%@PD"K:,`NC&D6&1S;A*#QVH%A2"F9%D2;+9@Y(DV*GDV+DD@F@.
M.M0!'"Q"N[8KB*Z=37K!(G!(3F(63UH6X13.9PVEX1AE&9H#D/YHD/;H5F[_
M956V02ZL4C$,`3HT[!`P[(S.*,,JGN70EJIYB2Q17F]9WN5=:>YLZ3%]:9AV
M:33J6EHX(Z6&E.@)S\-1AFN^;&`JSQAD%P*(@C]ETY]^FU/\::"6IJ`6:LX"
MHY\::BZFCRL<K33XJ0R%@0,LD**>$/),UZ7>"S52JIG*RUYRF$F1Q5>HJ0.M
M6&2$:O^!R^F%XV2,&-F2F!U8QD3LP<(TS`HP@&A$S#?(@"BDAPR<',KUWFJD
MR1U4`Q^4@#"@QGCB7,I<F10H:UD]F9-A1W1\H'>0!%1%D9&9C,[T1G!8E555
MD<[LQH@2@-3]`!`$`A)HAH+R!TE^#1X]*'TPZ)QI_UU+,N%A%0,ZJ($A.5;N
MQDT/S$WNLFN]ZLU.&F6D>990L@B,;J&'-*4[',/B_$@=0J_$2N_TUJ%LP1;G
M'`(W-"GD]2'E_2$@EJ65?JR6=I[!C2R8VF;Z7JTR:6W"C9YL7F/#!9OI010U
MU=0FZ$_/YN+M$=3M;8^?^BF?_I,K9,^@#K`NGF8!`?#_]D1!R8`<9($<]-,$
M+,P-\("^*2=LJNEL*F,P0"I(1:I>G*ENAI3[]AJY=.K])6>_"(Q?<J,D@J/+
MBMA+/5B_6<:O]*`!%@`#1$QH^(-*N-?1U&H/E8$P_"T%]"K3N(',*8-N`$?4
M49%7U<S,2'%X2$#F:JY72?^1#("9<-@,SJ0&%V,,LIR<,*@"%EB=%KP'FI7D
M'IFDN%J-';UNN=99G;UDNJI-[EY(%,H-[TJA%_QNW%7"O6;6W]%(WOCDWFV2
MI)U(WE@"4B8IYEP.]4KO)+NA)7L:YBP>P[82J4$>Z?AAY94E('JL6^).K2G7
MF-IERJIO*]<F!>6%"3-3UW(ML$$B;.)?,"Q/#+3'?`7M`6_/[?4$S_JL:58;
M]/TO0`U4_]:I,*O/,C]%`O?O-%/;`*SF#?A`<<KP_8D8U=K+!.'F;FHMRSK7
M<_U;2?FF_,X?"\VP</ZFHI)J_*58"9D>VZ*``&H&3A7"#4W,Q)0!=A[-#YU<
MRBG_@X]]3#0(KB,`!Q-G0<E!D<_4C.9*T>62!Q9SF]#$BA?QC!9Q]$R(T9%!
MQQ(G0B+\``-,PS=@P9@AP!NQ,9H1")K-L=5D79N]\6"1W8%8:!,RK.UJ04WJ
M<=S\\13J@1[4`8=(TB2)2(KHZXWP*[_RW;^>B#G,J&Q1<E5/+UAB[^;,%C>0
M995T;RB+<F]5:95>Z3]TGIC:I?F2Z?JR=?H&SP@K7&_F"S<*&PQ'5#"H'B]O
M@@)XPS_Y]3'C'C$'+3`^,^X)LT(E%$`U<$$Y1_4MLRO26V#3FR9*0Q3L@;9D
M<P.!F#1YXUR3U`>3!;V`<%Z.L-8Z2DG)-0V?V)H*C%8T_ZK_>6/%Q;8X.A#R
M&,$:'$P,:,:J%H($T-@_^,,_7PQZ\*UJ&/11(70)%.@2-]59>94:9>Y5E=/&
M*!UX6&N3Q>`DK$QYYN>O]$!%?O<`](!XDPPX]!X#,$`SW($0(``3:(%<M;00
MPAGKMJ[7\94<(>$?W3'#M@$5U('NPHWN>H$?!_B'Z@&]UD'P2I*^/G6-@-:'
M%&6AE>%23C+G+*7$8O(E2_*&7[AL63A8:J\GHPY:XA*9L.6J!6*KD2^&W66+
MM[7*YF4X\\4X2YBY].5<4YS\5==D!"8E`D$/;%P)Y"EA1S;MW=YD:]M]+;,#
M.S`L$A1"\>SL\:]H^F(K=D?_-O^P*\*B-S!``B@``N###:P`--$U-Z_4;%;C
MC).%^YKV+"^C6&"C,=:?'=A!$=1Y$>!YGA>!*13!`_CYGS_"G^NYG=NYU/*?
M-*TP/1=G'GR!$`@@T\88*<0&#LW*;[S&CE5T$1-1R\6`+)#'WN[MQ;`,6#T'
M202=%&CW=P#"!ZS,K[CZKPQ`)`S`K-,Z=DW``"#!!$P`>R"!!2"`!5A`IL"!
MKVO!L*]`)L#!K7N`,A``.`C5'=S!"4#-2E/!U,3W?-\1'&.-7W5-MH<=G!U(
MG1V(,T0L+00!(DDAVP7X%!HX'!RX3F86I'V2(3?UHD5X9N7-$VRXA5.XAL_H
M)$<LP*__TO5"+/86_/;&DO=6'L>&[Q60`%F/[T9U5$>]>(R'<*26MEZN>8US
M[4@EXVN26,C#5!Z\Z0!@(A'4UVD2+4\05#,[=NVQHAS\(I5+-E34:013LQPT
M=O:(P@]HV[2QXI5/,YZ>IA(D0!F`.3Y\GX/)MF:[\V8/#VBK>9H_2G1EH\#H
M^9\_``QP/0YL@9:HP`NXP-@/0DCPP0]DPS3P04BX@)9L`0PTP`/@>:-R:@N/
M:FW37QX4@`]LP&4``8SEU`=00$_1RCT&=+6HAM*HR0@H0:<;&4BK8!1LP`2,
MP:Y3?JZSAT#`U0HPP0I`P@J`_N=[_@*L0/SX`!#40]5E0`8`_P$2K/YZ9,"N
M6\`$9`*P(T$FR/[L`T'M[_H&6`P1S(`L%-4=?$#5(<`>4,&U4RC7<%U]X_==
M,2C9`4C9[?<0M($O[-D?LYV`L_N'>J@CY2M/^B2.'+(7P@@D+7*AQ3LM=$[U
M1N_[8_+E=)H;\GN'.TG$BF4O//R8I"5`7+E2X0J.@@=Q&$Q((N$_AP\A1APV
MD6)%BQ:##<N8$9I&CQL_:H06C"1)C25-!AN94B3*DB==QI19T@A*(RE(IK`3
M#*=.G\'LI.CIDVC0HD)W"C7"9,"`%0-D9(D2I8<,(D2\9;UJ]6K7K#+`9LDB
M(PI8L%S&$DFP5M0/(E&YE`TKPYL,-_]BUR;PEDV8-R)3XV9Y:Q;L5AE2I&K!
M=\.!4:`]@QH-^ABI4)Z1>>:467-F9\\D.>\$6G*R3LHIBN!XH8'/CQ_3K&6S
M)F[VM&RVQ67++4Y<LVR^A?WNG8VO[MBRIS$8Y$2`B@HX8#PHPI-H9<D]3T?.
M4V#%!A0&D!3`%R;,F1C5'':X(TP4```*`)01INQ]%@5NE'6(.()/#%ENI%`@
MBQ)*Z*$$`-RP(!\@F``B`TB80&(#!BV8X(M`,LG0@@TS06(".`2IL(HJ)O#"
M"T&J$$3%%%$<<40OX/!B@@F0@",#))"H\$8/,QA`"0!T(,`N>CJ0`(D]`EGA
MAC<":#(`")K_A#*`7GJ9DLHKL<RR%RBHM/)*"'H!$TH(H'@2@C,A<&:(-=&Q
M0`<OWHS3Q#EAA,-..TV\LXX^+N"SCS__K$10#@0%M(]*Z$@T#`[H0-301_OL
M@Q8(N'&'&VZ*.213=X;@M-,UU_045%!%)76(3$\]9,UB.@T@H8%@%>@Y@10J
MR""&%B(AHETANLA7C"CJJ".0-DHIIH]>4NDSEU9:UC/.4,))-,U*,\HGR2Y#
MZK)M3;,#&A_&0`$!)*P:*PHNY``K7;.R\"8O941Q):JYT+)*!CG$4FNM9G[P
MZ]X>Q`J8,':SB"&&`2;8$`$M&`["88<="")B!RBF&!]\&JO.L:,J_[O6,LBD
MW=;9D6V:"3MIA:JL`A<8>&V::7CCJQEAFIFY9IIMKEGGG2EHAH*?@98%Z)JS
M44*)'_C0P(4'KBOM*&NKS2./[E`XX<@;R,-'"&L<NN,.>$0I0Q0W`%!&&&'*
MN"\^8?2#Z`XE2A#F/0$!*2&*`^7P$(A`JLB`!C@J1"(0.&C,I`HO,MEP1B!D
MM"#&A!U7?()`9IR\<LEYM#R#A"?87$=#&`!@!E?HD<6?;P#`@@DFM%C2R2F;
MK#*`,KO4\DHO;9\2S#!Y']-W2EEMPY<@X"S^S3GOA$./.V%$?A$Z'@6T$D(%
MK;YZ#K!/5-!&HX_T3W,T(?/,\"^UM!AN-/_EYE-6-=5TU/?75)754T$]W]6#
M!(H5(5MMO14'AG@5P%]=1%@3&4E(B(6LC32+9`UL8$UNXA*<:"8S/W&,TSAV
M'8ZI9`5(B,&X!#,6L9CE+F')@ASRX@TE)(`(4D%+P,82E;N<4"PE,!C")H``
M'6IA80MCV`^U$(0]0$QB#KC8$<<3AB2.!XF+<4`1)G/!#((,9)&9X`0S$T'1
MU,0.VGC@:$HRP<EDYC&9F4P1/-`RU_Q`&2\3!\QVTXSAS`QH/Q.:+/"81SQ&
M0Q9\5(<L_JB.>T1CD+(89#-44`2B9"N*'ZN63O)0B!5@X3L;V$,2PT""::3G
M#K(H0]G<4`:S*:/_#&X@FS)4L:NWQ4`<:;,/@=A0`K(A`0@6&!$0#`>X0'BA
M"CFJ`N$LD`DO5&AP'TH<C#(4B$`8HD:=RY$S`V&!#`"!<)[K7(6<.:,,C$$#
M&J`'*+RFGD1@00M,0(`)F.0D*4D)=K9S9^VJQ"4JT4Y,8GH2%,[DC/G1X@8Q
MHE.=E*<'+>AA>7BBDYVX)[U`3<]Z#6T4]1H%O>Y)+WQD"E]%N4&IC%;J4NK#
M5/M0-;]2P8]^0^#&-1@B*QP0)'^U4@@)"I)2``9P5P/L"+!4,A%B';!8/77@
M3T<&+=)$2S1),6K*H#9%I6*F@U$``@)"2$,W$&R&91&+%$H0%\AQKG(S_ZK0
MABR@PX5M0HA%-*(1FYA6)&:-/.3!WEL7E;6+W8`'=D@J4K75,2M2IX(Y$0T6
M@>J9::&,6U;4R0,\H`$&++9E:G29&V$FC-[T<9#?4(=EU:&.:`A2L_?@["`%
MN=G.=I8"?&":QZC3-+QF)I(KV`$*8B"$/6"-/%A@0-<Z<(_XT$>4RJ`/@M9V
MAXC<81T?*(,K%6"W&$1!`0JPP"ZKD"$3!3-&&H+1AX)I`1C5:)@;&J;@`K$!
M&B2.0>15I@60P`0=Y2@#&_`0C6HY`2!@00(:^$8XA=N,,:Q@;ZY[G93*-#O<
MO3-+5IH2/:E4SS"9"7AKVL;PM(`G.^DA"!2N0_\=*FQ0.OWR>=*KQ*$.U=#J
M'8I0C;K>AR'E)TMP`Z.4@H`FH`#CBKJXHQRU5/E,^BGW#4%5[RN&.UR5$(/D
MCR`N%?+_KL`0)=.TI@,<QK`\\F0$H@0F,`GLE9T5092,$3N-I,QILG44RFA0
M)PM``'@0P-PH#(`J@*%*4YH"N1UJ80\3.^MB%G.#N59L#WW>PR;J;-:*#9K0
M%<,']LB0:`Z0X0F-ML03+!%IN8Z'!WBUCEXM?>F]8L<E6P1L,"`(1IJ$C(R$
M19EED@J#^@*@FZP&P&(!\(/&KO%EPB!D-+XQR'M8-M??P/6N-_OKT0)RM'R$
M@2)3YK'J:$PGJ9`D$*K_)H36M14(&L"M-#[9GMZ2$KAEDT5$.K`.";C'#25(
M;H&B\($$D>BY@DC8X&3$!$$,$T/=#2:-HDDC',WH"S1@@@_\O08FK($&`J<!
M)&A``R1,,T(X`L(7ZH&$+WP!"$#8@0(DH(X.J$<]WQB#.1%P`Q.\CN0";B>!
M;Z<E+XEIP6=BL)J&D(MM/%@-#K/PA>EPX0L+U)_%FY,>3&P]$(LXZ(.J'AT(
M-5%`N8-2%V7QI31QJ1=#@>I4%]^+-=I1\]W8'>?K5*8RQ0U7P516M'+I07"U
MD/_IBLF]^M5-"XC`DRAP)E[$,DFV6!)M[$2H>.=):#1SQ;XZC<Q)U>#A._:3
M_P6L(`H;T"$2=O@P0Z/UK(266!`*@'F'9=YA0QPB$FS(!BE\8``(R/S$ZEQH
M0H^'4$_@0*,A_>BW8D^)>#Y#'D93F=0F7K7)=J1?1=;7OYNL[V+$HN"571T<
MC%L#KFYU\YL?.L:V;!J`]/7U97%]8%MVUY[=[*XS"TC0XE$%#TC^TZB(D]9"
M.P;BHFT8F""!:S=?&:'<-KGE\PUPK^,'4D"0N0DD"MC`/B8@10P01<3@`%LD
MNH!@`MPK$-H+O7"D1AX."!`.$M8@`Y%`=0XNX3#PX%;G"U:'09@@$-(KF@9`
M"C(.O]3CXQ"`"1Q@Y)H$#-1)=G@'Y=X)=W2G=\S$3/\P!53:8.9H80AI@1IN
MP0^>X%#PX<(TS.=@Y'D:*L2D<'NX1\1&S$_^I$^TL`V8[DRH#L:@[NG",.JP
M+GRX!)_P"<:F+J/(YQBT+@#2KB`(HL@0XE74[G_^I^W<SB(**(%\RLKN[C.T
MS"8^#=0^S3+(*/?P3O`:*=.L1?<0CV-T0@16H`<&`.0V@<Z&B&($S6(P)F(\
MK\_*R@$V<0].+_,L@`'(YCU&;Q-4;]":2,_(@PP6Y?4JX0FF9_9@K]$6#1H<
M4:F6S8H,JS2$+UI*;:CX*A&OJ)$*#Z\JH+ZBKYN>#_J:[]5"YP>$0;-Z+;.^
M`9`(Z8]\[;)^;;/H(9"^$9#_-*`!DNTQR(S9[.``N.,+4.`[5L`!VFH%2"$]
M_N$;1$$&1`$^?.N3X$.4A($>P*VTLN"39(E`[$:6!D"9.&%U!HX)(&0-(,3?
M."&9?(!O(,$',D&95B<3!`[BF&`#;@0(3'("?"`E\6":A`G?ODN[<(1P-B`*
M-&`:SF8^S$8(2A`!"D$&9Y"=VFG`<+!*4FYWD+*>T$2?8F[FAL`IM^$6I/(6
MS.$"K+(2\*&@3.1X?JX.BBYZ`@7I$JI00BRALA!0^L0<T.$0I.X8R&1+JB[&
MHB[J:JPN-TKJ,@KKT!!-(.`:&N`@MJ"E:(5_\/"E_J<!]/`A"$BG#&C*6@*H
M^B[W_T(#L)8Q)P2OKRZ3C)*"6PH+_7AOJ3!-]XR@``;`_1R@'C%I]EKO%ET/
M'S;O\B(F\V03-H5H$W1H!;0`T.KL_8ZHK18->_S@K7#1]5BS.'>1`\*@$`JA
M``HA#PPK&#_S_)+-\#@SBBCH&('/-`;OTJ+3#E3`"5BMU<8-&L/3^5B-`:;A
MLD!+V+3/LK(/V,!OL][3UP8I&W``BJ`S^1XQ%;C#!V#K!$*NK0K@`X1+N/RA
M/8C@/H[+MTQIM_0/(CH@&OA`"MJ#N0(PEA1@`&AI!)%@))$@X3;4WP)!X"AR
M=91)F?:F0RHD$_Q)PESD164D1PA'</JFEBID`V)`L4II%?]_(!*>"@9-0$IH
M$';`Y.2*4N6PA)YT9TQ\D%5HX2FW@1:VX2FGDBJMLD^P<A-ZCBMA1`^\DBRQ
MT%"R!\6BQ\12C$^>X.LZ2J.P3GSB,L;BTJ+2\,78D"\KJJ+\LE8&<W^.;.WP
MD`38+C&#1<HRXLG\D(&^:%H,D8(X+1'!B#*-:JA,8U*3$638<3HQ]=0L+1(+
M#QI(4UPR;P_"@`R0LU3C"CGC2HE>T1.-2!:7Z`S*@SQ@-=$2[0QL]59O0.1R
MU00*X0;.@%1G+U7;BCQRU5?/X`:8H`NDP_!"$SJ%L6,P4QG]3CL)*_`(ZY&B
MTR<$0!K#L[Y6#?K,4P/*X`<(B=?_MF\^QU'7.BO7RO76!JG\,+4=#4\$"J``
M_#,&3@`([)$6"\``A$L_[J`]QH9L"+*Y!E(8P(T_N(`!RF`AN:`A,Y3A*&<#
M2E":("$3'#!%-228$H=#*@0.$N=#9`2[9(1PNLNKUHMR;D2:<D2:)B`.NHF4
MW$`!SB8&&`0!]@"=2BYVAO)(<Z=VD/))&.Q,6"47GE)*H70JPZ$JK_10ZB#"
M_BE/*,Q,T3),$>4*'T7HPA1+:2%]MN[&((#I\K)-T>2BT&2CV!1MI8[I`J`!
M[+`.^R>FDNQ/W390]7!0*2*GB"59$!6H*%."(K51J36,&)5P)W48XY4[W3$T
M(Y$HC"`/_SP("``M"(9U6)E(B3`7S_0L5X\U##CW5D$W=(VU6&]`.95S.U!W
M!1:`.[:#-]WJ=2MW41K-#PH`"S:@`1[`%/"S67O/]Q;WJ,SH.BE59)"O&;MS
M6[N)`32`^9R/&LM3`WX@^\11/4,KD*27UZI7&\$1D&3!!6#@.3USV41`.5=@
M'@T`!MNJ$&)`_PI4%-QW%7U+&&;V8'>%/TJ`/A:2(64I!O`-<&@4#F@4K%*D
M>4H$<`I8NR:`10UXJVX$8S,@F#8'1UP6`3J'<QY81P:`#\KF!V96&'Z`'\C)
M]&Z`G894:(W49XW22P1LP<*D3'Z'5:(4*J6T2LV!3YJ6`^K`9/]+9$Z>J\[(
M4@O])%*P-GJ&.%(NP!*>E"U-JL;.Y\?*YXDYZBYM#(KM$E/$K@%22D^-+*82
MHFYQ`(L3TR$:TU#SMLJ4):C`2(LN4SN]##O+J%++R,N\["?"-_&8+5,YE?>"
M003&Q14+P0%H<5A+536Q)QUH572-0>1,P`2<+16D1FKP(`\B>04*``]6X)(Q
M>1-P<P^T8`7,"I-.U?5P\=$@#=(X(!UV$1\Z2`B$@`0:H`B@J'$?\5G)[%(Y
MT]2H92@N]:[NBME6@QJ?+US-DV&S<1MY[=>N3QW*L1RO5_P(R9`(B0&VP#-G
M&:_L0`1X=066`%_U]09J(0P<``6^8>/__N%KVL(][N^44$F5^.`#2&DAZ^9N
M%(`+:DF8`!@.H@L)1H1C>2F'7A()A&E#^"9ADFE&6M9""&=O$EIQ-L<+-J=$
M'EJ;QB!I7$T"QNT#L&`/F&`/SB"=9I!GC1*%?Q;!6NYWF/(IH51*HU(JMZ&&
MK]0J^X`#@D##$J9#2R$$:H%,;1B(`Z6GB7B(#:4-ODY3NNX0NHZCS@=3S*>C
MDKJ)K=CKG+H8G/J*XY!/[5#M`'7M[+;M;DK*Y.Z,T=@8-=/OHO5D`C=;LA,S
M@S',VE'9GI-90?..@^$(^@$$:#4=+(&051-8\:$0\``/%@`/*ID[ZI4Y'4#/
M\`%6]RQB@@`W_SNY87IS5+$G]B#-!OH@TBS!LC%[LS=[=I$35L_``9A`"-J/
M!!YA=WEYV?!8M8]J,W&YRW:/=W]1)WY9>9OWML$U>7\@F2VK'-N3V#)+LP))
MUVZM&]5!%01`D:I9/Y/-"!9Y!83@.Y#`'HDU$M"C0-GCD]"90;<;88<+;D1!
M&0XDJVR(N;(@$!!`1C*$H&.TF"A613XR1>)[1)A@GZ/)`NJA!)%@!R`A$(!`
MX`#\"SIG`R`A`S*`X@P<P2<$")1``GPK/@!`&$@AHW'V!H[AHTLNA44:GC0<
M=KC$Y<X$4XPVAE%ZI6_!""WAI6W@T5S33BH$"Q[AM!7)!&JA:K,0IO^S5J<7
MBDR-N`_\H&L_Q:/"+L?<`:32YWR.7%74!Z2>NLG;-HN-S'\*4\G<%HS#V(#\
M<&\!<3,(%SM/AM-09B=2VXR&8J\(+Z[!-S]9FW%EVPZ,@)+K]0:>H/8NYLXF
M#V/P[!,M#V)6[V+<"E@?+=`C[;(Y&[./>-`U.\4YV_5^DQ89XX]]M1`0(+IC
M8`M>N7$]!G&M&5HOC9$R71*-E]D2ZWE#AUNC<9A%X9A[S5U%BWN[\1X,*8_.
MAI24X8Z2N_>6^UJ,(!5N@&K`0SP<?0R4H&O6PWV/:]L^:17+H&T>H@/XH`08
M-@L`X)4$<&;MA*`/QY8.AY=<1!"88,!IR<#_*\[`(6$#'#"]`!Q"_GLB#8X)
M_,T'?`!"_@T2,'`BF<"V)*`]N,`-N$`9-&"_-MJ_2&YWB'+#5RZ>!.QW(&!^
M9H[$3;RE+0%-8:$=VL$*6L$!M&`#8_RT<0&6GX'&>1R(<=S#?AI,(^4)GC2D
M>HQ3P,[(445]6A[LZ$?F5?Y\(`"+A0QNCTS)LKIN73F,_Z&K&=-8LDRLV=A2
MP_Q:PJPZ=H^6-_6.,=VM[UCJXWI24\`(!+L0S@"5+6%Z_'Q1CLA4@?4W=5$U
M&=T6B7,X.2#28J_0"YW05]S0V7[119GV&*-8^[I>5X`)2``%MB`)7KF.5WNY
MG[6*TF^V>YF7$RNW_\%5>4O=\1W_U2C+L_!HU@5R0-YL#-#+A_@\"!!`&!Q!
M&`3`_`B?V:C#"-[`!*CF!#(:'[XY#+"`#W"+/>+#E'J+W-:&V1]""3X@"QY6
M`@;$;IA+`V#D<`P'<33D(Y,)0V@)`8*IO#)AX.!@7(#`!P:NXD30O2H."'#$
M!VAI<#X48[\?#C9`F6QD>1D6`$2!`>A#MBH<*%^G2HJTX#<\GHS2=Q@,AI]T
M2AL>(&X)#'?K29\+K<`H!-8N#XU'#W`5P?5H8A$[/)@$H=.GX\&/%SYZK%3)
M8T>2'$V&K-1FR*%B+X?`+.9RYLN;,X=PHYES9\R<-'=R"]"`!(DK.)`JQ?^1
ME"D.$DR-XBA:])_5JUBS#@NV%1K78%Z#B1U+=JP1LBG$V@F6EJW;MG92Q$T;
M=Z[<%'?OUL7+-R]>NW:#`?Y+6&]?OW[M%I[+>#'?N@4*.;@1AHRE)Y4X:*[T
M1#,'S)<M<19MZ7*ETJA3E^Z3^LF3T*5/6V(]^X(-VC9LUSZHNK7KSAS(D`GC
M8$^!/2L*,%G!!`@6%`8,G-A"(LF#BWWW[D6\?;#AM'D%?_?N/7$*#QK2`]"P
M'@`#]1K>NU]?)CX#8;+R"W.#!(%_+4$$X<"`#N!C(#YTA.&99F$$D8TPS;SP
MP&-Y*3:8'7:D<D,>&Z`0PP8K5!9&&$AH8%4'=\C_(@H``+CA1AG**%.&&P"4
M488P=V3UCQ(?1,%&"0HHP$4);,2@```6!*)D)DHVB8222`#!!"1,,K&&DFM`
MHB0-3&#9'!),(#'!DQ.,:8$%968R`1QJ(F$!'!.<":>;7DP`A`0:*!.-+'M&
M(PP*>S"QQPTF!&#HH8;VTDL`BC::1J.01@HIHXM6NB@4`4`!00`0=`J!,S3E
M,L0VI-(RJD"W;$.-.0<9HTL:1T!CQP./U%K$1+56A,L5'T2221UTE&121R$-
M6Y*P?9!T[+"FPB33(4/H].RT-E7[TT_1TD2M3D1!U=2W34$E+E5&D5"5CNC^
M,\PPT*S[U5=;E25O7&>-_T576W*QQ9B^AS56(87=F??=OP0#3%AY`1/L;WAV
MY#%@`9,I^-IL%,.VVFRW58S:!:EUI!IKLM%F"<<<HR;RQ:A-G+)KEW5623H<
MC'A#`<XA@<4&`P@A!`K0O>"S="=4]\!UBF5WL-&.&5P8T@4C_!=Z[;$G=7Q2
MOV=U?.Z)(PP%S8@2!3X*;J8L:,)2[)$E'#BPM3`"3&CAT4OCE4HA!>S`LQ!:
MX$-&+6$`X<2)*8JB01D*T!ACBS7>^(V.U4@10P]`"EE"%#T<.0827T!"`Q)K
M-`<$YV$"<663@0#!)!"!G+ZDF!.H&2><7KPY0>QP>!%[!O6TZ:8%&2"1">]`
M*/\@03-W=&!\!]&PL0(2@Q:*:`!@'&JIHY)6;SVCF_8"@?:;=KI3M*62>NI`
MM[#:QS*Z8+(/K;D^@@LENKJO@@:)`%#"&'4`2\?^RI)DK/_'`J!'0N*'FM0$
M6M**%DZN!11LQ<2`02D&-R!0%&\M!2E.$==3-DBN=*%K*R`42[SD199ZV>M>
M8@%/7/C%+[R(ASQ)ZQ?3WI:TQA2-AHA1F&,PQ,.+&,%ADB'0#313FMQH;&,?
M,2)M:..:D_4&9;_!C&LX`QS/N.8S5!P-:+9X13+@PP%8V)F'8G`"#T'G`QYX
MP0>`AH(RDJ`+#^#AP-ZV,!O.<#P4$IAYT",%*4@M:NO_D0_6K,8`!BC#$100
MAB@BP8&R]>$V(2'9R`X2R=*DS1'"$(8')@0W'.YE`87(`Q#:*(054"9F3""%
M58HGC141[DC*$$:+"@<`92PN*^H``.5*4`(W\))(1QI`!J04B&%V:0(;8(*:
M-H"`3-3.=56HPNR\`#MJUBF:7JA"[:AI@3JQJ4QGFD#OD)"!<983">3,`""&
MAZ+BW>$.RD/`'AQ@@C<\3WJ4LIX^J[<]167JG]WS%$W"-ZKQI2H<K+(!"(ZP
MCQ2X[Z$2L4BM6'"*:G`M$6X80"``5`<UU`$?^MM?L`#8OV4ERR.U:$FV$"B3
M;'&CI=5Z5@-A2M.6#J4H,!`"_[@VN$&HD*N"Y_(@5M@5PA&2L"QK:8M;EGJ7
M%MH1:?ZZT+]@",."=5*/"8OJ7S!4!!Z8@@8TP(-D;G"#R90U8BHK&6IL,+))
M/K*MEE10;$RSH`6%P4`$&M`7\[K7S;R&-2&9)%Q+\X3A%&<#8N298A4;@\4N
M5@@D&,,.,"3#@0F,CGF\(U;S:`?TQ"`&@/@C>^1#6JHQ(&O-P*0H>A"&25[@
MM9'D#<E.UAD'I#9"C^`.W!`3#!$4HA"CY!D3]#:B/1A@E1WXQ@_D(`Q:'BY(
MA;.ECCH@C"S\J)>\C$$4LI!19$)"$+T+!)PV$`AI)JD*L3M3G9@`)PL@H79V
MRD05(/]Q3@1L8)SB]%WOT"3.;HIS`M+,@.W$.0D)X,B=QE,>\^AI3T2!H5+Y
MA-2C]MDH1N7SG]KC'J<\%2U:;&-4V_#P-E"5*FITY`Q'*`(E<!$1]DGDQ2Q0
MP@BB0>-FQ,.7;"C2`"(Q@#'X>`!NT@.P^C?29`E+6$^@!4UB\L`$OO2E+<5)
M2VG:Y&SII!@4E`I3EI(4#6JP`4^ABE"U`J^CEJ5>2EUA4_<BGGOIMJH+8YH>
M+[O#RB[MAC5,@1&2LX(5(*`YR^GS#?P0,[#=`!]G=0`9)J96T7RFD9CA3!9#
M(QO12)&*E_&,I*4XQ2O6U8HLLP1;4Z89O"YO#!NX'!:`\&?_!*S`.`Z`&*)'
M1`;-+)H#9\@#'I5&U3LFK&E;W0<TH)&'/.P!`1,H@2SA$[736LT]]OG!VLH0
M@T:FIM+7ADT5'8#)9FS2,'&6JA$*80(?*!8!IPQ#`4[0@7^T4QD`D.6+8@D.
M``3)#<*X)592)(4>:%<!DXM"%$H`@`&@3@R"2%TTX;"':#+)=MVT0"8R04UG
MPJ$*3(*#(#+QW=Y1?$SBM9-X-P`$-.TWOT`H9YA4'@D/6,,?QG,G*9C@:GI2
M`5&+LG#.*<SS2F&J4IW:<*=`!>(0?YA4J")5&V9CCE2HN%8L9K%%BL""0=!X
M!.KX1C2:D8AI3.,'B6``1@$A!0DP_\#KUF"``C(ATDJ,%%DG[4,MJBS3E?+D
MI<5PEK.F9>4IP_2FYL+@4:+R97,9O@$='/-50OB5L,PKA9!G:@OS;%D=FB=@
MO:8\GI]Z><H'`Y0#VL,>-N%G)IC>E+<>41@.358#5>8U@7VBR5C3D8PYL6.$
MS<RGZUKKX/A^0:?YC6>&HWK7B^CW"^H,<*H8LS"<H1!LJ7-FPSWG.UN?+T5P
M(;%3\?P])!N0I@U_(9T]#6&HEK6=WO2E37-I!JFM&9ILP&&FFMFTC/L&YBXC
M$"C#MP)$(D<`N"*R5",R`F\N4DO*H"-W0`\*,`#^YDN\%`4Q4'#4-`&I4R=)
M`EZITUX3%_\[[U4FNX-,R(9,@6`EIB<EG<,$-)""7Q(E0/""Q`0$/@!H-!`#
M$C`-WX!@=R`!4J(%!7`##>9@T]-S^G1AC9(]0><]`U50X4-BVQ`.&6,,*7`K
MN3)UN,`"\[`.(["%,T9CJM`,8`B&:3=^:&<--N8&D1!2;S<L?<`!T>)D;S@3
M0`%!?<<3=?B&,C%!1;%!@I=!/?444H$%YM(`BG<5C6=FP6!"**1F*_146J4T
MEE<T<5,>=$9_<D:)D9@"#I-HQX$<I#<HFG%%8<`W=]5Z"K)H!C%;JC@RN0$2
M;75[O,%$6?1HP+<9NV<9P8<9O+=[OJ=ZQ3<B!Q*,L?9"DPALEB7_575D?=TQ
M;'ZV"4@0`W]$6N[A;`Q0!M-H2&LC"C$0!IFA>Y?&:<$G:>YG?M[V",1(?4>#
M!QJR`DO`,TA`&3(C!/[@;B@"#P``#X93@-;((K&D@/Z@`/[6`Q(P))/#!FX0
M`]D4.]AT<8*03=CD!4R")D_B7KN#3IF`!/F`!#ZP!IW3D9P#"1MI)3[P@NA$
M3%'B`Q=)3!8P`!KP`[*`(C`I`5AP;#_H/(<2/=`SA+TP841XA(JR/9RB89X"
M`0-E=$<W8@.A*JE(!B*@8A3Q8K@B`'RPA>JPA5H7#5VX=13@==-@ALU0#5\9
MA@#`!A804OUC$I5@*C"%0-HB+=:B=W>(_X=6)D'%0!05Y!1]6'A4016"6(A6
M\2Z(R!9HAA9)A8Y:A6>6!VZ[Q7F/N'F+R6LU-%9F12"=>$I/D#&<P2"E>&CX
M$(H3PU8AD3$<\TBD*9H=,VJV%QJOH3*$U7Q@$XQ?U)EU=8J^Z(NP&9MZQ5<%
M$ILSDWG7AUEQ\YN/$7W?(1@[`P2;(`0L4DCV,8W..7[N47Z.T#6L55>921*1
M)D6SJ380\@+R5UG;D4,_9`PKP#,Q@`4.H"!A4`ACL#@`"`\:@(_SE@@R@CC*
MH`H*V`$*((%1X$M#(H$R@)!PP"835Z`85Z"_,W%(4`^^@TY/$@A?\`5,L@8C
MV1P[\()?`&0C^?\Y)*DD[A4(9_(D'NA?&]"2LH!@'0``0K`'6M`\]_1@E!)A
M/5EAD_)SW2-TWW.4'F90MT`+!=$1?N!T15`1[G,K5\@'%&"5W\"%T7"56U<-
M71F&%@668`F&TP`(^--V1>81'*"6!D2'#62'#V2'?A>'.O$&B"<N5^`M'#05
M/0544T&(?EE41S68^*)F.M281G,A=1$7%_&GMV('@7HKA%JHAGH1>HJ8U\=9
MCI$'9#49B#89!!(&Z<!HKV5IGT$<D%H95L0;@[4:MT%[LM<:IB%I)%%7Q:$%
M6N`?K(H`+;I7>957`L)7L*E7L7D@M7E7NC9GO\9YG9>,%7*HMW(=*"#_!<DQ
M!F502,E:C87TG-2(C8FD#-L8-G7%?+-Y5_@0!.(PG1Z06]I1C$?3,!LB1NAY
M`WQS`UA``>[V#W<@##*@#(7S(C8R(S1R(PIX!P?I(PH@!1%H)%D`)IS`!)R`
M@I"P!BMH@C1`)26H3"6(.@O;)$`P)JPS`4S07_QU)G)B)A+9)A@[`?5@=L(0
M<RB2""OZ:N2&<S<YH]8#!?[T<X:R/4DH4""VHT;GA`AU$!QP`$YI*Q)1=:=@
ME2-P!R.PI%M88V+XE100#11``=70M&'8#-,``#V@!6VG+"-1"S7%$PQ44U/6
MEG(YESJ191K495X69H<GB`V`!7):B(P7F&.1_U0I5)C@>I@R)*B%.C1X2RN(
MAW@PX!1.L045$+@J4`$G,+@P4!&/")E.HZ=RX5MFA6B0*ZER!4FP!3*E"+FT
M%C,H8S:AFC(M8ZVNB:UX12`"$B!!H*HLN@FJVJ*;,*NQ&JNW>5>R&XRR.R*:
MIADW(`*^68F/:6=U-*0P0`(P`+@J4+P"(`4`@``%@`0,(`J%Y+S-&[W..[W,
M.@V81`&B4`*J%S/(IYFC&P2CAP!(,`"WY0$P,'^,V1>)F`=T0P(H4`%(4`#$
MU3?-P*[L*@ZB\`/WAH`S4C@P@BX=X`8],`#]F05<P`5L$`5!8B=2P@0D5[`9
M<((,NH*08'J=`R6ID_\)&S!QX11-T20((!S"'KR0PZ0FO8-LXY1.\8$C,-D!
MTW`"+.JBSP.C.JFREF)A+,LI&[9AWT.S1XD!2?>C??`$)J!B0QIUN#`(U1`-
M5<F%0+MU3VM1-*:T3,LU3@N6UH!1;!<L:^@1+9$38_H3/D&F9/JU<?@26$8N
M?\@4>PAFXS(5A^>7_Q"8@_D6_&)#?EH$>0L1?)L$P8L#6X`#@4NXA'L"T:$"
MT6$`B*S(B2P`!N#(C_S('^#(+V``E2P`D+Q&+Z`"4Q%'D`BN.:2GP<"^7\1Z
MAF8@K?<9(P-;K\4:1%3*>L,!MRFK#F"Z`=*ZX'O+ICL@I6O+KXN;I+L'`A+_
MC'0`-L5,NV&0(-PK-B0Q&V>3:7?E`"NP`,!Z5=*GC,;HIT[P`U_'S3^@!#_P
M`PP@`3$0)<]8`A*0K*)`O=0KSM`;2Q2`26YPRZLJ)@0\"0HP./DK#MOJ"(@4
MSP`M"TX``^<(RMKQ0QS",QL@OWQS!DPP#>L:.*+@!D%"@+/T(@#0;EF!KS$P
M`.A\P+Q4.1F5D>(U3"&'.G62`=\%PG62D-T$D;.S)F\B)KV3<KUS7QZ;<F-B
MTX'P7R97)EZ0`1.0S^(@LG?0#!^@'/-43S<)/3*J*!-V#C;LLIR"*0'5*4L8
M/DB7E*M2+&1@!"E`$0_E`EAIE4)+M-%0I51:Q5,\_Z7-P+1/*X:)P`9ZT,4C
MT2Q=:W=AO)9?Z[5VJ(=W6;8D\`ING+9[:=AKJWA=X;9RP0-YVP4-\,<DL`57
M0-GOBP);<-F#?`*$?`*>70&,G,B(;,B+',FAG<B2W,B3+,D?\`("X-J3+`"#
M6P$X`!'8@4>+JWGK6PAD=0;XX-NKA\JSILJYP<I#C+N[20:U7``!4LO.'2#,
M#;[._;K4#;NTNU>NZWK6V4B-I"P5HQ*4Q,JMW)JKAQQ,X`,\($?'R*B0*(E5
ME0(-X`'C%\Y?U\WB+`%!4A]2\`$EP-\?\`'(6XT_H`SA7`:B4'ZRL#:%(P$L
M`@#Y&\["H#5<@TC3B4F9=/_APL``+J`"'C`/\R``6Y!]<T2<>F8$!<`A.X,%
M*S"_*\``R*4B-L(B-S(#]D9+99`N$-A+6="O^1PGOE,%YP7DY85QY24(<?([
M=2)>:.),L3-Q(=<?=0($<""1"%`G]5#EXG0[<>+3XO0%?C0-*"H+@%``\D1/
M#L8H.%G#/-ES.,PH5KW#2C@J(B;G2"D0(V8^0TP&ST`)0XJ%6NC$3/JD7SFE
M3(N52MNT<-VT6-P,UF`-45L"O^)V_G/72U;I=9<3>:TM7IOIW'`,B/>'7Q:\
MYL(4:GNVB3UFB'@6=)&(>.`#@B@$2($"0E`!;63(MN[9GBT=NF[KNK[KBLSK
MBSS_VHV,R(X,R:\=R95\R9:\[,G^VL5+VX=+-`8-GC5$;*1\:&=P5]DNW*<D
M&ZR,J;\--M4][K9ZFP>RF]H-?+JGS&)C-N`MWO!NW*,YFJ/6&<.!#X40*.>-
MWAC29KVZ6[\JG#"`'NF1'O,=S@3.S\+P`];X1_@M`7T$"/\-",(C"ELC"XX@
M"_%,X4N+'XE$X1J?\6\=SV\-(1$^#4K@Z%TYT(JJ';Z5!_6P,QLP*+4P''OP
M-^YV!_<`;]8H`S<B#*_D(LJ@T?MF;P"0!?9&D)73@`C031P,D8%0)P7:.A7W
M.P/*Y'``HO`E<227.O7@L%&B3%)"TR6'3.@T)E\0L5+R_P$W")/%\PT24``M
M^H-!Z-0Z]]0V[$\9!K-#B=5#("I&!V*H$@ZJ<@LFX0=-*3]\4-9<>)5PO;2$
MGK1=Z-9N#8;9P.B-_NAE>98G40MXO99::X>8[M=WR!-V*16%9[9[.8AJBWAR
M#)A'11<B4`#*X1PZXUAMU$9`<^M`X^NYSNN^WNNAK0(?<`*97.S+3LF3K$8"
MT-IJQ/RM_=JR70$PT``0@;>$*JB*F8GY8@2^U7J4$>Z^C<JV^QJ4BQJ:*;K&
M9^ZXFLP*PNZ?YMVT1RP@04GA'>^MG/^R]5:]`1!/+%EZ\H3#DW0<_)`)X\!!
M@8>%)!X082?%Q106+VK4N#$CQO^.($5^S(C#@P0-*%%J8`E``X,?PL0U$T:3
MICB9HC0HD-+3IP(&PAQ1D$64PE!90X\V<T23@C`*S8@Z*CI4*86G6+%:<U'D
M8\>0*8*)2%4`"`D4&YC@"\.!S!X/__YUN/--I[(R`,HH`Y<(@`(W`)1]DUM8
M+@#!"A0#*A$E!N`!%N!,R)3)RP0+F29;J%)E0B#-7BP@L8P$"1PO2"RLMK`A
M$!`F:YC,YL2$AFT:-"`!R8>$23TD0(!\"2X<P1<@!B1,H]O\CIL"3/8X,/$F
MP'4P`;)G[]7=>QKOX<6+#]`]`)3R$'I!"`"!O7MWS(;0VC9D6_W[M_3K#_?D
M0I\^+`G_8X<B'F%AD%-&&.$;!4>()IJHJJ%`0@HA?!#"""=LIIIFUFFF&6M`
M!#&11"3P@HY**@%PQ3[\&**8%X>(,488BSD$1AIEU'%&'&4LAIMC&FB`A`9P
M(`&'(8T4DD@2L!!RC1W66.,V&@RS\LI@LM0R2R.RM"C+%$0HY(8;'F("B#&$
M0&'--4]`X00X#8AS3CE/D/-.._,TP``5]C1`@#T!_=.`%_X4X(-"$R7T!$#Y
M$<!.%4Z(E$])X92T3Q5P@$'(!Q[@X=-2C(!&2X](XJC48.R`)H\QR0R#K3/P
MN>'5&_!AZR!+^KA@U_\LJ80#8(']-<5@@TVQDEP#7/$_9GEU__99:)W5E5E=
M![+V6H(*TK:@@Q(BX]MOSR#C#'+!)<.M8`TBXX91+3JU5'<Q(NDK4T>R2`4/
M4I)@7WTU<((EF*816)R99I**)IF$F4884?XJHZ:G;'*JJJ*R@DHHICYLJB9A
M.O:XXZB:><"KD>BUPXA"\C@+!2$0F#6,,`H00"ZZOH%'!F40>UB8G`&003!9
M.K#RCISSRD*!+$HHH8<L)!C`"\\RJ4(T.#KSHNK.JL@$B0TR0"*0KK^>8`+3
M1JMGMBEGPT(X(&1CP@?9`CD3"+F9^/K,S-:P(`HI?KC#N3L86&$/PF^P[KKK
M>@'#O%[*"P^\\2+W[KS&T7L/"O<RA_\QE_OPH^\6#&ZY+YQ;5JS$@0]@8,$%
M)1I<T,$(-_P0JPL?U)!"#B?,AL,0K?'=]VD8D"`3.E@TO18?;TS^Q4-XW%''
M'G&,/H`E26!22$X:R)X3*:>$Q(<%5E@@CSP.N/)\N;94?TNQ@F&57'+++&`%
M+(2H(`8WV7P33_[UU+-//NV)47("%*,^<*A#\>.`+T`4HAQEJ0I<X0I"N(+U
MG+2#!G0O-PO@X`)$$`(0'J`<Y=#$&S0!`4V4PP[O8F')4@`-,9&)7###1ZQ@
M%JM;"<02T-(5@*+U0R`&45K4PM9`!+(M@Q@$6.<"5QC@=P,31#$5!TA%*D0@
M@E%!8U2I`$'_.FQ@"1O8H`]?_&(Z\A",DKW+(V"15ZGJ=1$![$N._)KC2Q@`
MDQ_D,8\$DXG`_-B,HA2E&02;Q@\8\))I,"4J%HM*4S;V,66(XP?*^($H*OD#
MG&!%!46(EQLO$@PCD.\+&T`!"8"`#S+4HB$GD,O?OB$.!2@C,'LI0R+R$AAE
MW.%\P@"`&QC`!04PQC%'ZP'6.H.:RH`F$,L,!">2.1M!!`(2@>A,)@(!ATS,
MI@O%X9IID)"!#4`B`QF@6Q7`-@$XC&8"55`-99`P@1X`PF_-H0L#F*"%Z13B
M&(C#CG8:]T_Q0$YRX7'</QWWGO:XAQL]V@9][+.-_8@N'+GZ3QA6_T`*`3B!
M#]F(Q@CJ\J`/58-WTU!",VH'H0U-2*4<XETSLN%2$`'/+X#00_&,%R!J2,]Y
M,%*>3I_G4Q\!:4A#)4'WP+>`0AP@BL9@JC&H0(4H%B`/Z#O?^D")1C#9(4MY
M(),,GUBF%3"!E)9B4P4LU3\_^0E.$90@"830I`8X"0O=FQ(/.KB`$(9`A`<H
MH2;\>@P4^E43Q^@K834A0A.4XP!Z+4<(&@M"QY:#'/"B[+SB99%0UJI69X!9
M9V]HJ[8(9%I").VN>LBL9"GK6CI\0B64Z)9PC0N*4#1!%45PA",,0XNCPJJ\
M4N7&WWXE&$=81CK`*,8O/L$$T.@D&^F5QO_G.G>%\Z"C$^1H795HH`P,R`L#
M1'%'9<#DD`#3P#2(`I4?>.`%+S@)2A8F$V7$5QFB*(,,D#:)*/1@`&/#C!P0
M\U_$Q&0ICW"NR4)9"!^04@A(N($JPU`((0B-+G<0AA1DZ8:]Q+>7O50&/:Y$
M`>&Y01Q1<$/2N!"%#[BA!UC036P@P8EEKB&9D-!,UJI``T$(PIK'!$UG:)`!
MLG$-,T*&`Q,RH+78U.-J@7AG%;XP-CB\TPL]F,0/OO&W._QM&IP@W!X*80Q^
M9H>?!1THX\:#GO94+J$)S1P$-G<?^SPTHMN@ACG^TP<Z[$$"#+#&-#1`"HY&
MXT.R^P$?&*"$$)W_-*44B`:%I,+2E_8.>(9D@!/8$`2;WM0</%(>\WKT/.CY
M2-0U@H"0L(`D2.1A?!PLP`+P``D:^"`W4^K>`]9`52Q9%4R[=E]7?7V#K\Z/
M"?5[TUI1L(,5)%O9A)O?'@K0:E47(`1Y@"Q>(7OM5H?@KMOF`206\*D%T"#<
MX]YVN<NM;;R60P0-&%D++=O&C(#R"%P%=@T]>^\PG$NT.^35:7OX[UP-)$!%
M-&(1D27P9`V$`U:\(@RA(:K==DE47=*JR:*[1D]F"1I'2`49Y`'&)Y#A`-"`
M[KR>:W(WOJL([<6N!+#;+SO>\8X`\*YW->`2EFC@!X!DBC!^X))#ZL4E_U'@
M+V98LYI-6(`52E?Z)@:@@/_>'`"B6)A45/"`=_LVE'E(,%H8W)8PW&`,NL1R
M,^0`#S<`1B]E2+MB@J*.;\3]0<&3@`)D\9@2L,$Q49!`%+``B<XL4VHWAIHU
M+:.U94ZS;M-DPHNEZ8.Q60`(%L`,WB:P&[)-?@*7`3+GO>"%SF=@`'T+VM_H
M(@P2=!F*8=9.>5P/4(&6V:!0Z(YZKF.Y]R@41_3I''U"IQ^(/@%`E;"H!IKA
M9U*00N<AXE`S?C`-/DS#&KM[$.PV!"$*:<A#'^I=3*TA<P8`(!-U8!&U6N3I
MY.GTTS\5-?2*$8`U-``&3LH@7;O7!2C%54@8;/\`!G%MI?7IDO;Y$JW*@S,`
M-AE*P`.,GT(0-F*+@0H0`F0K!"J`'PND!2J`-5B3#4B0C37H0`]<`^Z1$N[A
MA"@Q012T/Q6D@2G)C=R`A&X+-V\3-W'K(,C"@DUIM\IBHT[*"!AZ'WP+0GTC
M.&MAK2*\EH%+0HJB*'][%@!)AR[1$@+<P8O@I"*X0BR\0CO@)),[E<L:KE1X
M@V5X@U08AAZ4KBX4B>:RER)P.3K2@'R1HY1X"9JC.9DK`^T:KY70N6@0I$K*
MB[Q`#`7H@4W(@$U@A4-D!41<.E:``T:T@`RP@$D`,)HK@Q_("@:``36ZK%7)
M@Q78`#79@%E1I1O``D;_DX4/$9X_(P7U*I1(J0"SJ@`54($(8H$KP`&S4H!O
MZ`$%X`*EB0$2*P$LH":MJ8S.@`2H,:?/,Z?7N`WA\$#8N(VS`8(ATSRZH3PF
M"(35T$;0RX#/&R?/Z#S^D@,E$`;GZ(!FB`35JP[MV`[L:!PR^P[9FQR#4@^$
M:C-GD!'.L0]:D+/]H#/_X`!\V`,AF(9J$!X7$"_9`1$^2(3IRYW:R;[F&[1(
M>ZE(`QYKH+1$8``V()Z;TI4G:(-1&TE0DQ$0V!'U>Y%2&Q(B61*B>DFYTK\+
M^C_#T#5>^R2N6D`$/,"=_"HS`8+ZH2`L\($"&!,0``$_\(-T\(,V$`(LL!ZW
M_YH@J10""J+*J70KJ'Q*F<0>#%+!%H0U'J`!NQ*W&*Q!&P2A,1```5"!!GBC
M`I.7D("A5``VA@C">Q,69,E+7[$6);RI9BDM:.$`,\R(%;+"+!P94^@4Q6R`
M+A"2)!"2QGP`=E/,3M%"KP@+L7BA44G#RL(X3TJY-2J".9RC.EJ)\#ND[:*Y
M[]+#.=2YHKB8GP,P/`R%37!$I4LG.,B`W"S$0F2Z39A$2PK.YVN*J+BZM[P(
M&"J$3T2+,7B96K@!)GB!>9A%6KQ%'+A.3;E.&-`4&.A.[^Q.7#R!+/"'Q_!%
M+M`[!2B!,;",POL\';.`PJ,\K7FG;!RR=OJ:R0""3/_81FX$#=0`#='8S\E`
M)]"[FLA;C;'A@DDZQVHX@2YS@!M@/3%[O7@D#X`R*.^P/<M9L\Q9*!GI'#B#
MJ/T@'8%P``1``0FH!F&P+CYS*9$"'D1;APG)/JQHOC[#R-_)AAS]'>D3+P9(
M!#<8@SK(M'_K@Y",$>7IM!DI2:!ZD6*```PB$B>Y'J@D*BDU-2%I`)HLC``4
M"ZWZ+:T*`07<203L*@LDDT+8`_H!1:H<R@(@%Q`@`UB@A4BH@$BX@CM%`0FB
MH#V=H*JD(!(8@R9IDJ>,20SBGOIC01=TP1F\JQA<`&_C(!!Z!08PM"T@&7>S
M.,^T@U0P`<[RK+H,0EP1N&G_&2W`/-5=L81T6(`MY($B4,S&;,PL=9(-J%42
MV`#KP=6WHJ`U00NH?,P&>(3*M,S+>K=-]$S07,-2>54WE(!!X)<XE$,[LD-J
M#;KLNCEQ@!!'\+F&Z5;$T(`)8(5P#=<,:$1%=$1TU4W1DP&<T)A!RPHG@(%D
MS8AA2`7RP=6T<(`PJ`4RP(<%Z$[*?(!'"%;YP\XK@,597*_DVQ<G8(!@NH/R
M5!K'0!ITVKS.&!M!\`S.2"?.J((!A0/4L%C/\(*,W3QDJ@POL*;5P*:5S:8,
MT`,M0``+@-FDH]G:C`*8.$=9^(`"(!P*[*<)79S$":B!BD<-O0[W6`\V@P!G
MV!R'_\(/B/H].B,(+/@`!DC%ANT="0&10ON!=9#(0?N0X`$_/IL^C)2^/I.^
MYZO4L>T!C_Q(&[B%''&>]@NU]JN1(>"&E:0_J+0>HBI4_0O<'=B!+4T?7<O,
MS.PU,M5)"^1)8..L^+D!Y7S*-:F@+N`J$*#3$Z@`/;73RI5*T*U*J'P%)WD%
MN)*K_*,K177!3P&W<C-+20T!3E""2MVD3,7,CT`CDM"%3OV6?(,9M\`W#C!5
M5"W>9[&!)P@#']B!0MT`+,#5Y\6"P1V.MWF;%?"!ZA6.P65>7`5%ZZ%*M$`!
M6"0!&!!6+@P)]+47N,RZ]?4D.WB`EHM6T@28.K0C#=`)//_,N=;\`5FHF&D0
MA>^ZI/F*`G4-U]R$Q`..1`6>@#@``'?]D(21BFP0`))!.3NHUV?;`;38@`(`
MNS/8`XQ2`?9B@/CRAAF8@01(815>X15VA10N`P6X@RC@"2[X@/Q2C$@(*VH*
M!!X(!$'HP,K(A#6@IHR=#*V1C"H0A!5(8CBXIDR@1G3"`W32`BK6@B"X8H>P
M%=#28BYV`'QP`!2`"2RK&5(8G.F(T-9SQS1SO0HU,\>A',>A/7M46O=@,P^%
MVB$02=*)*&IX@ALX@9WCD/+Z'9,"D3O2`&M@-'4`*1$)GI9CB1\($>^3/K5]
M/CY8V^!)!`404A7QH1XBB/K`VR7_73\=R06[]9'WB[_`91(<T,KKH3]8%I+"
M_0?U$4`OR<P"7-R>W&7&/5/)W0,L*#8^28(#0()7T-,[/5@_I:!D%MVW.EV9
M'-PUZ`)J[H+![0*Q;%T[X('&=-7$5$S8E51(O2,E$`"L<TLU--9/T@6.(P."
MX(!][2R&8"+B-5[C%2.">#!E4S8?Z.=^3K9G8Q6)D(AG*^@5F)^PFAN@=%Z&
M_MXE$%]8Q`'SK9=C/3EU/M85@M^4>%8Z>E:8P\.9.TV:8PE^(>F@B(:F$"3B
MO!A1&``@FX!0"(4H"`4YD`$9((*;)@)14`:?4P:!T:-"8@#S@@H-T$2*1DXC
MD"H@(*4-_]@#F&&(`L"+,B@#(B""^K)I-[CI!'#AK>YJ%DYA&<B"#ICA+.`"
M7^1%-Q@`&@N\3,@Q)I":E&4")M8#2-`#/<#B.O!B+M9BF*&#+@X"!PB"31CL
M/:!KR8`#!##9=JH"R)L$[>H`Y_B&'^A9+[N!?6H]S&X<]IC'-W;C\TBS.FXS
M]\C'(>"<AH+:.>OC#3`^'8UD$#'(1K,&)YAM:^@H!6D&LM67/6M1D0J9/E."
ML8VY1#`T/@N_$LB$2D"1F[H%D;21)2U)?612&ME;4U,2)M%*5Z8_#!K<699"
M]4G<>!,!,]7E,XV?7C[30``$XF8``\`#)H@$/;T"9);O"GI>JO^\;_UAWA/X
M@`]PN9B[(SX(\$VRA4?8`A)X`$IX!#08A>YD`1:0S#7H-M@-@0*H5`:8AP:X
M77@SN6"`!C`X@F!(A5;H%4L`%K`#.PZP9Q5_%H)8%P=HP*(L:!F7"`7T930E
M:(0.*^0``N;=@88F@2M8@@BJ@"V0Z)$IN?0]3O9-@2(PA?EMKSIJB:`[Y$,*
MO]'<PQ_HPZ/`BD'R.980AJH&8/D2!G@H<T>@)$M:F$)Z/D-:<YC()&OP`$QM
M(U5):I5AZCWXU)CQF:,IL;+F@BP(]"PHL1+3:J[VZ@0H@RSXAA*@88E5`*>Y
MXB#(ZR^N@R_V8KVN=(>XXKL.`KL.@DS_T`,XB%D$R(#C*'4F*/71(([*VQK[
M="?*@P-Q\H(H$(PQ[H!O4`7*AE`($#,U9@_$N=`+[6S*Z04Y_NS0SCW=^]"'
MXKW?NX5PH`8R\`"A]AVN93X*^+Z72.0'486Q#9%I`(!_X6T)P3[N&]M_:5@+
M#YY()A%`&``44>Y_<Y&Y!2J1?!Y3+FV4?%+^<TGK:64DT<K`C4E9+MQ:]M(!
MW(BY7-PGZN7'??C')1<'2._?40(7T`WZOM,ZQ=,3(`5)62\"(A12>`$2V`)$
M-JEH8)`1\(<&48=&$`!*P`48J`")?@08F`<'SWF9%TMQBU2\0@8`B#X7P`$J
MQ+@58O(K-(4B_\`#(^`!.\@#$`"C"S"B2N!78!&(%5]QY'H"/W!<!!SH5HEX
M,F@%<XFMKY)<&$]H[1W<Z+6>SH7%(L_!.:>L]#5ZT,P(^+4NCE8).42)*J=6
M[1IIDKY6!JB8CI&`"IK%(7&"F7`$J\@*JI")/!+JYRLD@<&C-D^DJ"CJH\Z(
MK1LEMUH!?'`P!Y``;PCK0(^"$S-KLQ9T05]A:5AA(L@"63B:8"H!7Y2"M"8<
M/:B#/?!T/?A]N]:#`AA^/<@$+0B$X]<"&LLFP9,;;[2`+_!&)GLGR8L\N]D\
MS-#^L;D,[8\"&3!'P)$%,W[QRU;C&E`S8:?'?[*]>ER/RTEVS7':$/_-CQ&E
MA16(/D1[J4(""&O5*%1K9DW@P&;-IC%@8$TAPX,#HU&L6-`@0PD:`6AHZ-':
MM!\,``!20Z=2I3XJ^URHU&9(L2$R8\*4:?.FS5PW8Q8[=&Q-@P98@I(@T<`H
M4J%&AP;=T6#'CG]2IU*M&NRJG:LI@FU-8<?K5A$W;IPA2[;L&;1ISZ95:W9L
M@4!LLAV<YJ1!@4@HKD2ZPO<*BA,,G+C0H,'%"P$OG/#1(&!0M`Y5_W7H<&?$
MB%.#'L&8)T"%"C2/6>!B\>@TCC4\(/$H!6E!B`6:2#'X,:C"5[`I4A0I\N#W
M[].G83QJ`"/)TP9=:.0A8Z./C0O2+:%\8LG_DO3LVK=S[^[]^P4;EOR0(9/6
M/!FV:4&0:=4*6ZMTV-*E(R._//ZR-PKQ+[!BA0],K`$$5$YA410)2UQ1`8,J
M5(`##`_TIEMNNWU5886[Z48A;P\XH9%&@X0H@08?DC@2`QIPA&**'&E`(HR&
M"4.!+!3810,-1]'`PPG3-$,!!<TX0L&,/Q*I`2DO&"#`#R$U*=*3/_P@S(S6
MS'.AAF`%8T0>>?B`!0H;,($/&;60X<`'KA"1119NL"E#%G"Z(0.=<\J00`+2
MX.D*G@F4H4`S"BC@A@(E&)J%`I$@L`<<56022!6.0AHI#6)$FLFC@03R*!.:
M,M$I$T`,.($%/B#A_P420"!A@05?($`J$Q9XD<$$M4Y`:ZVT>C%!'#((<X=E
MP7ZS`A-[.'"#,0$H&P`88"RK;"\!1-O+M-)2VPL$U&:+;;10!.`M%!`$``&Y
MXY(+`3?%Z+3--K2P.\0M&-PR;QLFG$#7-$I,8\T/#R4T4$(8,;2O0@=5=#!%
M0!:4$2D2.&&881XQP(<U#;F1"1TGJ72!2I8\81---`T!`DY#Z*133C/!!`$-
M:SA%U%$'QFR44$(-Y913D^DLU54]8]55EG:(A19;9QG=EGIFK;4'$I$89(T2
M&I"01R05^,57!57S`P`?2O`Q"&,ON,#'.NN0'<T=:5]V&68CJ$.!.GS,,__/
M#X8-HL'7:+"@PA8"?`;#CC2\M@!LY;#A1")\"&`A;[YQAL,6?(.F@@`&J&`Y
M@U?@0,(./N31RA/11<<2>*6;?GITEHCG<7WXD8?>&>VY1Q]]\J0CSWSSO==*
M&VVEQ5\A!2P`(!`$0H6%4PA>H2"#%8!6082]8;CAAECF-KU7#[QH(H@>@/@B
MQ"RN"$"*+\8(XP^RU+@0#`W@H'D#KTQ#P9".-".,.,((&:0+5S2PQAI<P("0
M.,E)M?%1D'[P``UAR2O!P(.7ZB&$#0`!'V$@0Q@<8(`$>(-.1)`!$8C@#6_T
M*0%\XE,)72$-%!)!`>`@%*$,U8,2*"`&2.!$%03_\:@J>`%37H@4)"X5""`P
M07#%HP$3D)"J)$[@4Q-`@A.A&`@+-'&*%N"$K6HUJPG`X58_S$`&HN`&;P0+
M6,!B@A:,58AD,<M98!#7N,8UK6M12UIVK%:VOA5'<9$K7.<ZES-DDHMM#(%=
M[MK&O.9%!28H82%0ZI>_?A2-BX"D(7S8U[[Z%0VW(8P"DRS8-)#T`0D`@",N
M"I_$>G"2E+"DE9:@1DUB*3*9O`0G*-M),8IA@@5TX2D'(@$6<!"SH#"%*0W@
MQ%/6L#.=7<4(P?B*5K*"I6"(16EN40LVL7FTN(SA('310`7R\)>^[(4O)R`%
M9?X1#26L(VJ#:,S=&*,$_VLTIIX:>.<@\OG.>^)-"4JPQRE&D#;)1*,":\`1
M#VA`N`648PQ.^`$?7E"$W3P`!I%+S&<^8[D3-*]YFC-*%_"0"M"ICG31.1U*
M4ZJ=T=G`!D^@CQ]H5YY6R(X,V+@I3K'!#OC<E*8@:,5/EW$&8YB@J'DH@']\
MX`.7"24)OU0>#CKJO.<]8J(9:B#U&*?5K_A&1!HQ'XQ:\+TRJ"A\Y.L(1V`4
M(\/\2!8_*I%#%/*C(0%)''5C@/YDX8C^->`!-*B`$PCXR"@)8TC5J$`1,F2A
M+7EI!R00`A;"$`8.U.(&*#`A9D]8PCY)`Q2@D`8)\_19/'6PE()2`""B$`-$
MQ?_``H'X816Z^$/9"D(0&>BA!8`P`21:(%53))4%X."%#0@Q4G#8E""J$,38
M0@I7<+!`!JKPJ@DH][9>R,*OS&B9?W!B!<9R`!O;R*QG0>N.T,JCM_0XK6RQ
MEX][_&.Z9&)(0B(RD=LH@`>:40V)Z2L;``/2TQ@BL8]L\ALC0-@D@V201$C@
M`Q]X6$<TX`80.:PC(W&"'E;9RI580F4XB<DM!7D3E-VR&!@X0\M@AA0LP&`,
M1ZF94)S"U&5.QF<]`QK0A#86HJVEQ[Y+&M+*4H`DQL,:=%%<'L903B'P92\G
M8$,]&X,W/O!A8DJHAL&^<0=AJ()*758``!3`)C=\@\;_4NF`"@XJN`4H%#:Q
MD``#E.`"&,"@`GZCW$8WFKDE;*[/14G"#KJP@$*T0QZ*:&EX5*KHT25:=>$1
M#Z15YU)%/,%V/75/&\CPTTT#%:A66`8(EB%J8QCC#44M:B$.T*4N+0`/"6W9
MRXJ"@_=MP2]2[>CD5("#!V!5JV!I(/:*\`B-<,^K:B61A350AI&@M7SF`Q^R
ME4$C(-6(?M.FZY"$(6!Q`,D1PB#%YBKP`@;8M4G3$"P!VZH$7O^:0M#P@6,G
M>`;)D@$?0MCL9E&(0GQOUAM_4@:B%,`%+L2`"X6:@&TC9<4J:,H"#&=")B*5
MW.@*8E>SG<`/,^$%!%#QN$C`_W@F@&`(00R1BWM`@!;T$(1-!*$.#L`'S&%.
M!RU$@1ZR**-EA/!=!U`!`LT2KWOA.$?S+BN/><26N<SUQS\6@QF%=%<AV85(
M>17@!`)9B,2J,1!/$J1@4#MWE;W6C$VV[6`*`R4#/F``4JAH,"`BA12^ZA$-
M1,(D=-@8QRY@B5OH)&0E,YDM4Z8R&QC#!T&9&3!A(+.A,.5E.#,S56SLP'9#
MLYI*.YKO,A]DM3B@4]/`EYP7P`DA[`4%?<D:"MBP-H$*5&T#%3@-`>`&V;N!
M2F4H0R*4H0P`W`'R__#`_Q`*"86&`!(N2)QCG'<"%2S_!!SE*(-0,&L$%:4!
MR%$.#__R8()EI(/2V,'.25'*:-$]6M*2;NGY(>U2##SA%[^0A^U@T6D0T'\9
MI":U"4IM`E.?V@0'2/6JY8$(Y,%"X4&K\0`>X`@-=$$O'04);$ZM7<$6W-JM
M/<^#5%6[^1H#;>"O/<*'0-N(?`_$N,A9D559J16T=80PU,B,Z%6W75N0Z(\X
MB,/]B,/G"9B^-(,-GMN3')"43(/]4,`6+%"64(@=[,`&3)`%A4$MG`$6\!L4
M1F$)E4$6R`(-%4H)1`$-E<`80,(:2,JF,!RF5`$G1%RD5`$3B($.94*C/`H;
MZL$>J%P0S*$#!($#N%S,X8,#[&$=SJ$?;H(>:,$F(``<:('_;F7!-R@#SMW!
M%>R!L9!%#3!+#;A1'.V1>46+M+#7>76+'IV+TBT=-\A7U+D++202.F"!!OQ(
M)DV,?W%=-'3=0SS$TQS$V!V8@2',ORR8!K"!`<2=$P"`1D@!*<"=$PQ8F(U!
M$)A$2G`,=,"2A\U2B$7CB,'$B=&`@;S8BQ43,37%_^R`,OG>/VR)5D03CGG%
M$>R8-6&>YFG36A3"'@1"(GA3U.`!$PA!7_B%Z57`"?!#F2V39?P`,)(2E:S@
M-Q2D07Z#+*0-9KSB*?@3E>63"ZA``^`(:[39`E`!;2@!`[P`\U%@\RC(YE0?
M<B!'H*D&'HC``2Q#*QA:Z(Q?HHF.__FA7TO)I.K4I$NYU!,\`:4IPB_<3DZY
M1RM8`5#97_\5@O\50BJLFJJMV@+D`1X8@0&V&N&X&E7R0$*]6LL\0"\UX`/.
MF@1:C4=*U?-L`0Y4U?5L(+!Q8!$T0(AXC[&!R`>N2-O-I0E^U?<@V_S(PHQ0
M&PS>3]T@T(Q,`YS1X/WHCS!D`P\:4"@58ULYP2-8#UHZUA((P0V421C@`Q,D
M0`B)0AE\4!F$EA1RT&81`1>H0PD@2@EP@:$(W!C00,1E"AS`P3OJ`1P&0<K5
M@1W6`6[.(6[6X6X&P1YLPB:DD7!N0G`:YR`.8A!DPB!:@!X`07!Q'!>MR@1D
M@30HHG;=P?\):$$![.$9,(O/@:>RE`L<'9VRI)?1<4M[)=W2`5*Z#-*[2%U]
M,<$+6,,Z+,1!](N1$$37%41!4,!]^N<F(=B!=1W:20`;?$##4!C<-4QM'(1'
M```;C$$@!,'=K80-T,(SBM@T"A[@\40Q@$`!-."+%<50+,4V)H<W_@\XAJ//
M;`570"8UF<#E7=,ZKJ/1%``0N(&1'00?(-$K[$5?5$V0Q@`]2,8(K,-!+"D]
M00W43`R51:D^#8(+S(V5?@8:J``+;"F7XD)QJ-EJM)DF\,/$,(`'4"`*6$WI
M7<$#4A\W:N6.-&4JO,%/_0*ES21TQ&1,A@Z?4IK[N9_MR`,[M`+_._"">PBE
M%5A!J-G?_9G:`9A`'BPEJQ'@0DDE#RP``EIEIFKJ55IEX&"E`C[`&FCEX1W%
MK,W:!*9J1TT@@[#JY$"/A$Q45E4/X]A!$GC5BW@/A3T;L[5(BK2(8:"@76K`
ME*A#,[B@M=7(D#3##TC`E``)!8A#1XB#_4A)D]A52#``*5B-$VB."N!5D"!6
M$5[/$28A95Y0&)S!"B2`,MP>9Y:!*(!F"8T09DF#O=HKGA!!"=S!::*6H1B<
M`HQ!`="F'P:!'M2A'!ILR^E!'10`;N+F'M2!'-)F<+(*`C`!K201K:S!K4R`
MIOP6J]1*R)**%D5!(B[B!Q1+$)"%,SC+_R1:HGNE%R:.)])Y"Q\A'1^U)[DX
M`[F(3+O$Y[S8BT/L2RRV8H)=A%P!C'Y-!$4<6$4LI('6!0-(P`DX&(5)`"F,
M4D>8FT8V!(*.`1*H02VHQ!/PG=]MZ-]Q*,@XPP(`1:PEQ8G"F(JJ:(LVTU;T
M&@-5$X]EDWK@Z%K<0`$@`2!X$]1T`21@P0E<#3GM(P"4S2`LAA-$+F(H!I59
M@STH`0YPZ9;"@)=2`BY0`NB&KNB.+B4\0LL,GT(IE"9$0F`Q@`M$7P6L*6#4
MVJG*6O4%11>`*0(V94K^E#S\`I^V5)^Z7SJ\GZ`.:BO('RPH:J@MJJB]`?0Z
M:BI(:@BPVE1:*O^G9NJ.>.I5?JKW=B^HXHA?M4P7B*IR$$57VEI4M>JJ4N#S
M1,]9IJ56"1N(B(CY#(*NVB_$S"7YR.5=G@\`3$,T5)M>_8C^G)L--HF0%.8,
M0H1('!`/:L`5&,$"7`$-E$(#&$!;S1ED_EH7%`4*W(!DU4(8%(!FAE`(>4,*
MTVN?$$$92,,W@((_@$+:@$*^[FMJ"HIJMHD"#(`>MEPRZN8>&*P6P`$A7HH@
MN*:C[%"F8`HG;(#(ZM;&23$"U(.L!$*H8%QO85P6:=$$A((P8&<924"Q>.<;
M1&(DOM%[5:+-JN=XF@NVY"QYZFS/.EU\'A(B8<%#08F1Z9<G!8Q^"83_?_V7
M)R%8TWX#17B=@`%"U9*"K@:C@_9+MGJ$$P`"&T0"$CA`+<R+AJ)M+-T2B>4$
MB$+`&I#HXL'M-B+3#JBRR]1M5Y"CC!Y!(?!8C?K8C;I%7+#!OM"%-23!"B`N
M"I#>.'&4:>P-52C!/%!.-$S%'3R"YWII:70NZ4YSZ!:!*:C9\*W&`HS#&)`"
M1(&3FDK@\K`I/BI(FR)(<BS']N[N`!Z`,2R#_+$#.QRO/!_JIX'`.S,J]/H?
MI$KJ`%JO`08TIKJ:51(TIWHO0G>O`BXT0S<T0XLJJ3[`X<%`5T+.@U0`JV(T
M^VIT\^0:#"16$=*J`ZWE6VJ$KFK`(^_J_@(K_UB!%;+]`(WLCXV<V]06!H`1
M24C0H+5EPP,W"6(.D`JT1E#X%0X0"058@[ARH%=TP0:0``HX`+J6L)^PR9AE
M`1=$09R@T`B)@C3<@RPDP%<[`KUZP[Y^`**H9@P,``VQP0*<X:.H81A6`:G`
M%B1@L1<*R/#E]1I\RA=04:E\P1,Q`6`3T1<@@9A$5\=ND:W<UJW$@8K@7`<`
M0+$8RQDX@S,$0"3RK"=N]GG)4<ZRYQS3\;G0!![3%RU0@08LI@;$XM;UIT$T
M`UWHU]("R8!61"$/:)`LZ30D@@8PLM6"5<-TA!(\L$=,`S!^`!L(`1/X0BW)
M$L@\=]J&\LHPU<N4*/_C;:-3L#(`?:/O;0F,EF/0Z&TMW_*/(0U9.``01$(\
M\O(6+`#B,ME?.!D)A"X+3,4(#,(\W`%^-\*9L0#HID#H8D+H`KB`%W@*8$*!
M([B`VX&H*B!K+(`(<,*X55D%@.1CX8`08/CF^$57GO/U+:`"%O1"=<D!0&^I
ME1K_26J7B$`!7J^K86I!QWCVSOA!(S1#)]3X.K1?[7BHT@"/E^\"0O16'EX2
M4/2I8K0X:W2M<71&-PAHX$!O/!.'S"\,2(`'?`BN7KD$O"7W7&VP_F]+`X`P
M#'"0O,`:8'!?\4`#Z`_]-`,#2,$/_,A<(>8/SG2V%J/^*$00RH)C8A4T=4'_
M$CAU(8@P"1<".(B0:&86OOG;[94![:7(#VAF%'0`%R"*%&1!":R6&\3`'IAA
M)N"0#KT6<V4<$U!0J"!!/111!@`!))0Z%"G1;FD<$@1"H\0U''""&&2`(>B`
M%X1"*$2!K\M!%A"`',@``+1K&:6-,DSV#>##,?B<9D/`97-VT*UQ:'^BSO(L
MS^;2ND!=NU"!8%CM0S32;?NG;&>#?OF7D=2V;;]BPH!2)358#'S`"VS$KC;$
M2GL$UJJ=P'J8<_L[X`4\RH1,,9`R-\H,S=0,%KC,&OC`"N0!?^0?"-3M.$+F
M-(D`C=:HQI-WC^V'IC``;-.%`/PR.0'&.`E!$8`N_PR,@%3D4R-T0"/DDQ)0
MA@H408(K.,[GO,XK.(,+SD+S0/&1J4:J``K8KH:3`)N&)/4A"$GF^#I3)>$$
M(%-*Y4+MK@%NJHP;M*9J??8&#D(YM(_C.([[N/CR>([S.(ZHLU8*N41+-(EV
M)5E"CCA/8%3-?51%59._+TB+=%8(FXFXI<-<[98+OET6OI=_SP^0.9]?@57Z
M#P9[`%W!=I/,2!`>IF$:=9[+U;1M/@.H0-`P#@TTM1`4@`5AT`U\D)O`"57'
M2130"0GY6[NZ:QG`@^YIYKX&G%67P`RY00EH',8E%W7Q$,;%UO!G`G`%UW`!
M/\;M2@]X`:^3@`[H`!NP`?\7$``@D((;9+\3S)X<R($"2,$DE``;1($!:*%J
MGF86-#H1Z)XR`(%W'<LR\&P-:+NX1#NUOY=HY[][RA=]`<2V(<>8>/A@0`(#
M:]:F5:,0#2(%AQ,E-JLV$6+&B!`G-FNV<!I#`!+8G/CP08($#1)(I73"0`,`
M)P`T,&`PC0%+4A].+$`W!&BQH$"'""5Z%&BNI$!!$`U`8T>#!FNH,H&TH$`!
M$UM-&*.RM5"(`@L6K/AW%FU:M<&"I;#3MFV*N"GHVA%QXPQ>O6?R]N7[]R]>
MOGMO%&(2B,%':]D\\.`DY`H*R)$J4(Y4!!.E1];^17,QZ,Z(1NH&#5+2X05F
M3*O_6;=V[3K-ZC1V'JRA00/2;;(+(C%0PD``#A+#B1<7?IP$<JE3N]R^S0-Z
M=#P\R.)90)W'].O3HW?W#IW&=_#/G9>__<`\#?3GV:MW3Z-Y\P==YJ.O_V#^
M\@9)DI.H\%\%`P084(`7#'R!0!44_&^+*QB\8@L&_ZM@01P>*<*.NNARBZXB
MDG!"@D%2\D`E#T`D,2655-0`Q1136BE%&%?20`-99*&`@FF<4*$")PY,C`)A
M@O2(`D<HN!%)'&T\4LDDE[21#Q4XS)##%+K88;@];@BCEC!N`(`(&60@@LPQ
MRQ23"&_43$!--6=(P)$$$B""BV\4N%,!+DKHH00%2D`@_Q`DX*@B$""JJ`()
M)":H8@PLO/!"!QUZB*('':*8A``"LL@BTTVYT/,$-J)@@XT22OB`BP^R``1/
M">YT0P(9``!`AC)LM;566V<%D10L]MC#@1O0<898"(IU!@)C(7@CV0`@<#;9
M:*6=EEIDD566&Z%RH66;;FD9HH`*=GI!`R48LL8AC31ZZ*%H)()HA'7=O<BC
M<S_"R0E`##"I)0E&BI$FFQA(9*%F&'!"BIW86(&*HH@RRBB'AU!J*:0>'@*"
M-:::*H]"\LAC+*Q$7J&L\JA:0ZV4TWJ+K2E=SC`8$4P@K"_!]O)K,)SQ<F"%
M0-RPIIELK!G$AS7&0.&*I"-Q,/^2$S"CY`$G_BE-"74::82"=4H;6K768L,D
MMK#!!CN-LLG^`QKT;,--MP->*9>/%X0KCF[BYIY[N"2DVF$]\L3KCCOOI@N/
M<!X(+_QPO]-;O#W[G),/OLCORV^YX8Y+^K\3%%2AP!<\\,`%)T37P`G217?"
MA=0-''#S_R!\/<(*(EP0A@<PU'#*1SX/48(35_)@)1$]$#Y&%V%\T<45IUF2
M`H-_\$B89HID$LDGG:R>22.#W#YZ87X08,,J,S1EAPV$6&%+,L(X(U9<T1P3
M?C3E3$`:^N>?WQLN9,%3"E.CZ),+2!C#&'0P`,CH(!(QX`<;=%"!4'%A4B7@
M`B`V)07_*=PI)0IPU0;=@*=7*:"#'J0@(*1`0A*2XG,I]`""6*<"-*A@"P]8
MP:_P88QC64M9UXH6M*!%+1]&2X?8@D#$ML&M(9A@!P;Y@!-^L)#%5$-=490B
MO-HU+\6$!(LXD<`'V!`#`T@!>3&R"1^:N`Z+-",1`-B)`3ZP!A-<3&(2BQA2
ME$(QBA4C8U'9P1I"EINB444_#8C*&O;8!92I3&5PD<M<PE>7N]3,+S?+66!R
MMI="[,%GBQ$:'[K`!"R<0#)+JTP%^,&#9V"B""\8@0#X()H(1,`>(SC%(.:A
MA`<\HVQEV\79TO",/SS#E\,(AC:,8(12'),VM;'-VJX2`BPX_R$1#'!!W>J&
MM[L-9V\-H(]Y#.>=\'C'!^#IIG/&21[&+<YQCE//-M%#GRXTX`':#.1^&F`W
M!U%(0)YS@4I*UT_3G:YWH3O=($Q'NG^FS@4":)WL'-2@"6T.![:C4I6*D$H5
MNH1W(U(1\)+'HN,9KZ,,N$<TGD2](Y'T2$Y**9*DYXAF"*-[+X6I.(1!4YI^
MSV55X@&6-L`$?(2!#!PX`ZMDH(`L<&%3GLJ"&S8U)F_<3TZNP%\6A!'"+)0@
M"C'X7PD&\($7N*IT-:$1C4"D@!("H@3].ZH4CGK426S*@[,"@"C*P("ZVH1&
M$GB!@$Y0@:3A``:!3<(CDE"/1Y@"L?^FP,5B&;L"!SP6!,22+`YQF"QF_1"S
MU[+6L2#`#6=H:PC=$@@D3K`3#]SD7-FHXA0S$B]Y6;%>/V#`#V1KC41H8"<G
MX%<87V23D)S1(S#9(A<YD8<X0@R.$UL*Q98BE&(X0V,:DPH)YKDWC>UQ8]%%
M9"+9DB'OOHPN,J/9S<@+&)M5LA!``,0T@I:-'S3`DZ#$G&5B0(-AH+("?)C'
M*3K0`=&,(#1*8($M?8F)/_QA%P=^!C&/61NIX,!!"GJ!0%5`%1JL(3>&"P$G
M2*$$/FA`.%@@@8BIV9_BP"!O4GEG%PS)N'(JSG").V=ZUI-.^1BR/NY<0XZE
M@F((`VA`GSO_G4$-ZH*5B,Y$GW,!Z)B<PB4S><FH$QU"J5SE%\RC0A5@@>RX
M3*$*P*`(XJL+#"I@``'M3@(HXFB+@-=FC;Z(H\B3D2P@0F<[D_1)1I)%,US:
M/9K6%*:!%L>@"6W3FM[T!>&C4H9XT(4-D(`)6^I2&`Q`*S&Y00:>BL)2D[HI
M(D#U?MYP@R@ZJ*<!#&`,IT9U#&)0*JR^6H)9`*%3GPIJ8<#C!S3);5__"@/`
M!K8!CPAVL/'S"-OQK0B/&,4C-A"%*`S@"U_801(8R]@"/-8!(%C&9+E=6<Q6
M2UG)HFP.N>$.9H266P(Q`0E8(H5R3<-<U;#(:EDK17;)6S$"\\U'_]QP$#:P
M$8PJ>E%-%C-O>MV6%*0PP`O&4("@('<H$:>C<IL+`:A(!0L8;T#&,QX5J417
MD,PYY';3HLA@3+21;A%!(2!Y7I=7<I)Z*0P2V`"`:@#-&B3P`2=`^8H3-(TR
M)^!$)W81#!CP`0TL0$/2E9[T>=220A-V`A^44`T`=X#D:KF#!@RY3-PLH!.<
M8,-L-5`!O5%WQ&BG)MZP25UM[GC'%^[;C.GNGMK8^.[K7"?EDB"<""_<<Z,C
MJT'[J9+0"3G)3W:!YSRW0L<;R`.=.]#C%0^Z)5\>RI97W3P0]!\<.'1"#&I`
MF#>4H2VP4`#_>>&9TYR\C@J<1:XWGCB0Y/]21P1:IH$&M.X!;>AL&!KXO?>>
M`+Z+.SLXF@1(2!\'PH"",HA)3&T"]?395/TV1>%32*W5FEPA#5=(=7["4$89
M5K(3%9S@K[^&@50>(>Q'!)8%+-@""Q1$__IK607T9\$5`-M^VZV!!TJ!!^S`
M%/``#QCA`+.B$`JA`!80VQS@5X1EVYCAN3:+LZ9%LW)(`R7+LSK+6K@A6[)E
M*;H%"U`B)6YBMN:-WNI-7CKB7@2&#P@&C4C"`/[M`_I%1@@.:!RB(JQ!MH;K
M`X0`$A`A8B`NCBB.N>KH8:!K8S1NGK`KN["+*K*NY+JK],`K!<1KO%HNYB)I
M,*C@!FX`"2)!`MK_RQHJ@`:``/U0H*^:Y@H4J$!<8![D\.GJT`X_@P^L#L#N
MH+^H,&4Z@`^FXL+6A@9$`!(BX3?XH`)&;./JJ9XR3NWJ!L7<3C]8;#XN[#UH
MK#S:R3[B[A)Y;+J2`T!.0/)4B,DD8)]"!Q51)\F<H,D<[_$B[T`.1*$VAT<T
M9Q$+I',D;Q873\DP[_(N;\(N[^D4J@)P0,NZ[!B3`$,6#0<:[W-0SP#0H`+0
MP,QVI\U^!\["*/;"2!RD1Z9>*O=R#_=H*AN$[\^^$?ALJM"F(=&N<$H<;0.P
M0-+(H!:$H`S:Y*GVD?KZD4V485;,:M?Z"@5P``>6`S\>H!04,IYD)_]L_]$6
MM6S+XN\A'W(+Y@_%!&D'F,`'F&`/LJ(!'?"Q/G(35D`+3A(!5@`!5G(ED4`+
M$``($&`/@N`,EN&YBN$FG2%;C(6SQLTGN0%;/$LGC\6SLL4H1`L=4""L7F*V
MJNY=6)#>J@BX0((/!*:)A"$G;-`D`N[(:N('LL'@<.0C;DL"`,$D(L$'',8(
MBY`H[$BYE#`7\`@J]&@Y,BZ;0HZ0UJ#K?,`'S,(/_P$N8`;E%`T:"F$+:88+
MNS`,Q7`,`.'FA$8`.I(?4&!I?JXR3"(1(&(=-(`/.K,S/8SJ[&$=K&$$L.XO
MT6($UJ$S2^/#8.!DV(8&R&(,8I`/#,#M1&SCT/^NGB)Q$H<C(_4CGG:,/O3R
M[CQ1[M1#+]=)*OC#(%$@<TB1%!&$\;#1%:=,RDC$%%5H.F>Q%@/D"DC@GH[Q
M"@ID$1O@[PZRGBA$%V=QA>9AA51GR89Q&-\3=.1S\6JQ02)$/X^Q=L(L0V!@
MPK*30`P@0%SH!*QQX3[GHSXJSF)$&8(D>GP/'87A'(//'`]M0BUT&CR@^,2'
M!C8`1!T@##A`?=1+`62@UMC$&XB@#`*R+*7@)$Y@7W3+K[;`(`'+(%G`UV!`
M1]OO$1J-/A2R"(ZI"!X@"3AG0.CO(@U2;W8`"#82"#J2+_NR+U72))E`"YA@
M)57R5WXE"+QT#V32`5S_$@(GX+&T`%@L(`P<(`A$%*A``">+@0(_*R<[T"=]
MTEA`<"B!LACTM"@I\-S:H(BVH0`,0&"<`"?B32)6,".B<B/HY8IDRRH9HBQK
ML`9O$/88@`]V$$=P!-]^4&%.@`G<X2C6LBV7ZRTI[KD`:3D\;H^HHDH5T##Y
M@DO\X#3?POC`*V9FYC`A"6=T)C!N``@"`1`^(AN4P`.H0I269ED_(![.X@ZB
M800`;%KOP%KYT%I-,RWZBUNY]5KY,$JV`(9@8`M2;Q`M["H6@!-FBP\$@+KL
MT@D9L>V(8S=13&^6XYV$DQ/A8SZ$4SGKZ<<T)Y\:;Y]$IW=0$6$K3SL?;V`%
M_R`Z>40]*P!I2.#\5.`*&N#"#+(\O>S!KD!!Y@9`.&<6KXSQ?''QX--D45:?
MAA'+>,0@82=IDL!VW`)`,2\[5PA!]B5ST$!&S>P#T$SV'%0LA>'VQO%";:H9
M)-1",[0=/8#TQ(P`L0!$EZ\6?&``M*H$)F$22B`."%1G9<<@`TML8<!'?;38
MRK9L\4,$OL`'KF,W1$`$%@`/I&T'ZK9N@0!OL70%9JA+@:5-'^MO'Q!P!_<!
M\0$?V/2GVC0,PF`/.(`##/=Q*^$)N.0).,`<VB!.XY0"0_"YA'(#\[0HB_*S
M/(L91+=T<=(HE4(@MF$'2$%@.'.V>#!=&-5=U*5='/_B(^[%&O1-8$;"WWS6
M)6BB)J8A&W@P(IK'MD9BC6)@#1I&CN!HCMP2+I7+&6B`+R%A;U<`)`LA6,Y@
M<6NA%ARW$BK!$BRA#_K@--MBH@:S]%8N#+EP"WUUO$S@,`!A,19C$#92")!F
M676+#1)A!*KA%`9X'2@@6[NU`[`U@;_56JEU6A\8P%R`;($-!SCG-6U#PSA!
M`Q*!#SP`!_1H!^PR">Q27M%N;G:3GN;I[MSI[NYN.9!QX0K68$%DGY)L86-1
MGU;(8?')975+./[#[1QH*FJC0)>#!BI808;#\S0V=CB'<P#D0-QS9:L,&%.'
M/D\6BY5,H3[O99'1(*D+0P#_-/-NU@.D0(?-K*^68$)\MHS1K$54XD%A*FF3
M-D/KV-"F01BF01E^0!D(#4-M:AI<X'86K2Z@XM%$U`^8KP!`=`,N80/RH1[R
M@1&*H`&$(-C0MOU\C;"&S79LAP=,0>^RPSHZ9@$+P006,`P%=P^T@$M7DDTA
M\$O;-'`?RW`-=W%'U''%]PG&EWQ[V7'[8)=[>9>'^0F*V9C](!W:P`HR-W,I
ML$YUDAGVM'-)-W2=H72AN4_[%%"5RUMZA"'T#5WFQ=YJMU$?%=]`8G=YUR;*
MDHMDE`U>0`K"2@?G+2)4`7EERPE(X=^8EPK8\@A1-56GMRA0&2^X)'R?H'S-
MMP]L_Z`/+J"A;<"A(SI]6X:0OXM*M+!7)>F\6BX,]X`)/B`DA(8!D@`2L&`R
ME28R^.$$$F$08"C^Z$\)3H$"('@CJ@B"'_A:N?4?JL%'2H<!UJ$:7.!D;`,2
M>``20@`22.$'E,`)+M95&W&Z'%$W26`24?A>50PAX4DXA;.>$M1'TLP4&6_R
M:%$Z`\_R1`=!SB,YKH`'ZDFZI(L&_"JBNB`Y(@2&%:1`(!)`CO'S/`]B56`[
M339`L7B*4388X=-SL.Q&%_M&F;%F,^_);MB,5\BKS(P:EV`X4``%?C9%6N1!
MA^3VTG&F*!30ID$<I@&U]UB/]U@91($!9N4'_OC0:,IIX?_1NW9*:@MA1(/*
M`3)@`C(@`WH`N%DA'WA`"**`JA^!!?ROHGB@;1?@8TQY,6GUEO'A!@SW`64Y
M"&+Y5QP``6(`$-!J`!+EIX"*`]+AO"NWF'LYH?O`?-N[?-T[H>>[?(N9`Q*9
M1(%J<?\"!*P`3I=YF9E93N4T6Z(YFOO4FHN2P!,\FXVRP`M\P(5B4+?!`YHH
MG6?+&MH%1\BYWC0<>:_HPL4J)UCB(+S(`'#0*SF57=RE7J*)Q'^.$PX@XB*F
M*8Y0>@-Z8N+[O1VZH<\WHGO\QR\`HM'W+W.*?1UI5C,:YN`W,`H@$/Y7:(X5
M![Z`YZZ`,J[@YW3+#2H@V?`C!1K_8!`>.('[\#0[X!N(%O?R^"9PHNL(D2P@
M@1]^X,,JH&X)*>2B8@,P+A+KM>V6,Y#>R<'B22K*;/$F3P!P5CH')-$)I$`6
M;D!<@`$4!'@^#,L,B4(.4F/\HX5$-J\YQV.W&*\1!+"1M!0-Q#WE\,H\0(KC
M$V6A#*%<O3[A4_-.%H88NXL_#QK)^&8]9[*EP$`J>U]0X(M:[T7$84@`K4+I
M^!QK:OS<H`1B8+R1@"57$@AB``!:]`<&;;8!V0D&V?AVJGR"Q1[)P`%8P=S/
MW=Q1X09FYB_61[_#X*=J^7`%EY8/MY87E_ER^;PYP)@KEW'1%`*!I1;ZO9@M
M`:$3FJ%M_V"^[;MRT9L,'EZ_SX`,`(,*:E+;0`#C^QL$8,$*.!X6<L&_<Z&_
M!5QS47<HKWES`56;!QP$!]R9G7EB1&L(%*(9ID'.K4$)I&<CRGF<YZ5Y=)>V
M7I<F9*(LMZC5V`@E:L(FS"A=,J(C;#XG<BL2=L#ADHNY4%4)<3P7VH"A+\`2
M>%S('SK(OQ[(>_PTY2)7+5HNH.$`WC>CX[=FP#`,TRL&W"`;A.8'*F`-F$"W
M+`/+48`?$J)TS`5=1N`;[N`;#O\TH94"-&`>/D$`T&`+DB`)6*P+EH`!IN)D
M<B,V(6$,V+4"IF*/ZC;D&E$W4=@W4]_MKKH2'^P$RGH75T<7`?^/0#Y@/6]?
MZD!GR@P$KXTQ9"F$1YR8T7FQ<SBOK-LSL2<L^5G=/H-QUJV8RF9=\YI?U6N=
ML4F@(,<3LE4(A73=US^GU^'Y&CL[)3Z;M"U4&5Q%"L9[`ZXV!J1@5L1J5D2!
MMES[T/#XM&W*!1[`M@$B13`[0'9L*'`#7Q@R8?`Y?!BF8<*$^,XXC(B10Q@.
M'#M6XE#I2<A*(RU5,FDII<HG+%L^\4,FIDPRK6KV6[;,1*H\A0J=(<.!S)DS
M-X8:/1/FYTPRZ<CX29=N&0@05JA:L0(+*ZRML')M]6HEE]A<Q<@6FU4L+;-B
M:YEQ4_MV;=QB<>?255ML2-DA0[:U&:+_I)DU!C^F6?M1C4*TQ8JC-6Z\V'%D
M"M6:"3X\C<%@!@`T>)8`&M`'`S%.G/@`6@,#S=D23W9<V=IF":0^Q$#!J0#?
MO'KY^AZ2ZS??X'^#&P>^+>6%/C:6.^_CW-+S"]*A0_^'/;OV[0-3V$GA';QX
M\7:,%"IZ`SW1]>K9LZ>B/OV90H$B29"=S9J`-4P,G+B"0B05G!#)"8`D(M@/
M"C+@F0<>2"%!,]M-N-TW/Z"!QBAH;+'%)5O4@T<J/DA!0@-KG$@##9`LL``G
M2O#!@`H-?$'#&CLT<..-#32`Q8Y8E`AD`R20`,.0#12Y8Q([+KDC"2H(8,`+
M`@@@Y0M13EDE_Y54?J#E"UEZ2>4+'DPYI0I2"O"D"FF2R6:87K[I@9@OS!.G
M"W6Z,*>#+^#)YYYW[LFG"X(.:F>A@WI`***``DJHH%ZJL`4.DN)`PJ0H5/"D
MF`YNRFFG#I+BH!0>@"K%"Z5*\<$''DBP*FCB4"!,,\*((\RLS=`JS@]E`,"`
M`E)DH8`$98CRPZRTSCJ-,LH`\(,RTS3;F1LO0`I#$=V!]YUW/'2Q`Q8%.'`#
M1D!Q-"Y0YG+@!T?I<"222"BI!&\?EO1!;W3TJM14*V<8<T-/>12`QPH^?&$C
M%AN0(`0*I1D0I94D%,(4&?(9M51,?CP%53I/:&R55EQ]#+)78K4Q5O]99*&%
M5EMLT:6RRBOC=5=::?66"SHF+`#)-,T\*QM^KTD&-&-`4V:9-<^NQD<BJSGA
MA!M.2`!(;1^P<0(;!JCJF6;6-$,!9(M5)EAF#-#VP0E"8`%);VH#-US;Q[W-
M=BXD2U?==-9%9_<%RU'(]WC9?@=X>,&(<$!Z\;EW>.*&+X[$&(!DDY]^.T#"
M!C\H\%.!@`4"PNR8`F#(X1))[$""%-_P3>$W#(QB2CU)C+[##BN8T$\A,5QA
M(HHITK``$X0I84`#-/A0HXTX'M^DD,H/B8.00):(9`-*+HF#"E=:^26677;Y
M9O?>@_DDEF>.[WV<'LPC9YUBHA_H^G@JZJC_HO"W?VBBC1J***+W.UJH_BZ@
M&:E)54I22[@"#K:`*3)IBE.@`E6G1/6@&`@A!J0Q`(1``YII"`-6M,K&K&PE
M#&4T2QFTFL8TB+4K"2A``1\H00QB,``A#&`,`YCA!L8PA@TTX`%%L$.VP@-$
M.W0!"%A80;@8,JYUN62)+H%7O%0B+WDY<8HI><(9?&"0(56@`EAR@1,&H0$^
M**$1IZ"`.D;@CQ%TP!\=J,8+"O"$7Y`!!/IJA<4N=K&,026.+?E%*T`&R$!Z
MI2M=$<M>@H.6E;4,+W)AY,O.TIN\Y.(`3!""U:I1C9XU(S_5&!IL%`-*3U*@
M:+)9C=@8!(#02$%J_U9;&"DDH)H?;,TUD7',*'>V&0"0P@!L.-L*=N,;WO@F
M.,.,FS&-LPWFW*UNT&'F=.J&N@EUYV_C\1LTSH.>Q"%NFT5A3WJ`,`8VX,<:
M+MB!#TP3H,QEKFJL&H4[1_$ZUWU!!'@@P0RBN9T[,&`#J0C8"@I0@$*8X`RM
ML-T)=G`B%$&"!SAS@C7X\`(2X`$/PUM#%]:`/!TE;TA%JE0#*-71CT(/>A4P
M@/:JA-+OJ72EZ%-IG.@D)YCB2:9[JBF?X/<G_BV*4(#RGZ!\"M2?[D]_1!VJ
MH-`T*0'BX`I$>L0C8`"#I7*1>UX2E:D^Y:`/H``(>T``$AKW`2F("D*OJO_5
M!W$EC&<M*U@*`(042L"&%\YP#$A``!/V\"UP.:`0X"H$0/-`32`&T0Y?*(@1
M+<8!C;%$8XS5(U0PML<GS`N*3CP)O$XB12FBP@-*6,<Z*#`"--ZA`VOLP!WN
MX(_3AG:U(U`'!4[Q@D(\H15TK(ECGV`.)K+$!D_@+3M`A@U84`,6V!AN<84K
MR+$8,A>ST(LBG^NRM<@L+\5`1%JL:]TA'`,++K",=[_K7<I0!I.)Z61Y05G>
MHAT-::O1``"<0(JHI6IJH[&:`5ZI&MEPK9:P\:[1EB8!VYR-"8<(YF^(Z;8$
MPRT7R6GF,Y>SS+LM$Y_:^2$U`_>=8!BA<(LCBC;_%>?-&\#G!DRHSR:--@@2
M0*)`Z+S"?ZH&"`&8PA0G0`,*2(`"%/C@!L98@3`HK)UIQ,`$;WB#"7KBUSVL
M``L`^$#NUI`B'D`B!)``!!]^X`(2L`@/Q+,H1C7ZH^5]5$@=+5)4B61F(CDI
M3&[R7IN_A[XX>^E\Z5N?G=77I_F)*5"&VFF?>2I41C7*I_N[7U$+C;]&":`"
M255JI6#PB![:@0<-P)0*,&52*IG/JE(XP0J&HA!\[.&%%A1KL6Z5K&8UBS-N
M^`!=@8"`/>"5KX9CCU",TLU^`=0.U[(PMK!%@R]\X;!"B4E-;-(.G+0##&\`
M@RYT<80C[`2@A>"`NZ!8_R^]:7O;V[:!,:JG@GFX8!!*.,4961M:=;CV%(UH
M!!_>/8A!".$,)L!#'DS0BG0H0A%/P$"_7<);&P2\MS9@!S;800V$KV+A#%\X
M-59!C7!$?+@A*Z0AK3O=1\YLXY',;G,E.00>:`"3)C2,881A-,,(9N7@K0PF
MQ0NVGJUF-4I[KPIKP\N<U_=J$G`"`Y0P2_Y&)C;_'9L$J":$,:R!NKM!,-L.
M?,QCML$&=:,;=9Y3]0LTYVY`QLZOOUY-[URSUF1'G'SBHS@2!R(&AK&&$AB`
M`CR,@1\$4F>!^`&(&*1"'V](=C]:P0YV**(5/N[Z';X1C1^`!E6F06<%A(`[
M3O\D5$4I8E$D'JH!'."A`'E8P`HH:KP<,6E('&5>D2B%@],/L%)O7JF7XOS2
M.-4Y]GMRDYW\A'O^T0_00N6]4`E=OT3W/JB&,FKP#3VH>3`ZJ:NO0!B=T``1
MI.((=CC2%IXTC^R3206IWZ&]SZ,0!Z!@`TQ@`A$C(=<Q("#6#@!7&,*%E*/$
M/]?93`\V>U(`@?$@&.0!^]\&P@,\4![0<`30$`P'.$T)R&L+"![;0@,K(!W<
M)H$3J&W0D0H2\%I\,`B+!@-,T@"CH`+Q)H*#,&[9-P]74`CRP"U=,#P\D6\$
M)W`"9PF\-8,S2'6_P`X,]PNKL(,[V'`.%W'"%0[A\!7_%C<60V`%D20S2OAQ
MB#`$S4460Y!=25@,[J`!S>`8S;`:O-(9&.09O*(@"F(T8ZAR6W,913=S[04U
MI!!7,=!*5C,:J0)+#*!R7M-?WK5>J:159\,)PB1,PG$<4?<V;9`<*5$O]+),
M>&,=#M8'7?</OA8>&"80&]9AV<1-'N9A\.%AB[,'3!`)6B,.2J`"/L`)C7<Y
M!1(@I*``&^`#/E!^0``$C3-!@*!>[05?I&`E+<94)(`%/>*+O<@))B)Y"05E
M*;(B"S`&#``C%6!O_\(BPU,\2](C)=(DS&.-9]9HDM)Z<)(G=88^L?>-[+-G
MM6=3NZ<_/<53_D-\QQ=\P(=H_^]X:/8S:+TG5(O6:`.$`Q7@`E?0!7@@4.W0
M#F\`#0_P""S@5+A@"D700T:`!T8@`L[0"NE2"6'P0CDF!$``4`#E`$-1%$DQ
M?T.QD?:7'GW%5WSU+1E9""NP`C0@@($C6(&U@`,ADY%83?P7=MC"`\$&@=!!
M@3VY;7UP!@*@@2+H`B9H@BHP"A^8?24X"/.08@5`!GE`(ZWX>0%E`DPA#Y(5
M@S%8@P+W"U_YE1CP"XH@EF+)@S^X<.&0ED3(%<IE'(B`%D[XA'/I<2`GA78Y
M!,:P!I\5&3O#&4TC`6Z`0:#1&:J1AFE8&-,0.8?97H(Y-:7Q0I'IAJDB!4Z@
M`;+4#/^=!!DP1TK6H#0:<'21(`1"T(=KLS9.5QQNTP;40`WF():_`!,RP0'*
M(2^*>(@0MC==YW\W*7;81'9I=XF&,V(W4`">Z`9G:`#\438L=@(54!HG4!N1
M$"`!\D(G4!H?4!M6P@_^T9Q7`'E","0_XHL\T@#!*'G"2(P*Q9(L$@M\D!FC
M>`"%D`>=MP`410,7I5'+@R1JAGK9."F9(GO?."<Q]5*:XB7O@Z`[%7OO*(_%
M1X_NR(Z%=FCQV*`,2H]O@B8J\!\&]%'9.$`"L`5=L`#SF0HE*@)%\%0LP`(P
ML*(/$(`IT@7W=@8:<P8E<#6DX2T!Y1/P1W\CV2][Y5<!I9'_&>D``+4"!8%0
M+NI#?K.;@O623"J)49J375``$>B35VH#K5`!(\BE\:9]U')`1HD#")$*GZ>2
M&:FCW80Q+-&5,LA;&$"69(D!<PJG<_H+9HF6$P<+1.B68D$S>N&$P5%=AZ07
M@FH<95$,!^`!=B@8`#:8@^DTL$28[F68LF%"A_D9M-%*DJDP5X.='A!+UI`8
MCR%>WV6I/\`@1W<".+0#?EA,Q41,QK&:KHD!-F"GO]`4Q;80UD8WAP@=-G`W
MP'H!C@B)43J)''9VEGAV(X:)RKHX#N")@-`S2N`!DU,VC6<:+,8&;.@?W(FM
MER*=F>.=W@F>K_`CYLJ+XVF>PHA0_^E9C)"@(E3V<PRP'SP1G\ZX`,1#`P]P
M(SVBGY5")/WIG_GX)@(JH.9C4PF;H/-S:.,H?!!JH11JH?!(CSP%/AI:`5=@
M0.%9GD\&93C#(@NP!E'5:$G@43P@?;KP!@$``7GP40B4)HQ&`J]3(M]'%"LP
M7RY41/]T'MBT5S=0I$$*4$R@DN5G?@A1I$"Z`CN@)FJRHI#&0PKYI$$TM2[I
M-W:@D$7`0P_`M3Q`/%6J-SQYI128#B0@;B3HE.)6E$ZYM@(@*21;`0=A`@4`
M99QGMSK:$Q/S$T_!IBIA`XI@JW,JIW1ZIV1YIZN``6BY"D,XA-M02,#AIX0*
M<MD%-WOAA/\FP`G9(#1].1B)X%Z/"KJ@X03O-7.)N1FHI`&.:1LO))TQ@'XQ
M@)VH,H?6T!J=9$N)L3.H2H>&L85'AP*CB07NL#9_Z'2Q*G&_('"UZF\L<3$S
M,10;P0%:=W5U`ZR+Z(A-&G9V,';)VJSUU[W=BQY'Q@3A5`V1XP%)4`"D@*UT
M9QHQP+Y58YV60R#I=`61,*[?^0JD-P;DB04XP`E8L*X[<)[N6B.[PR('P"M\
M<+X"=60',)];EB+&LR1!TCP#VVA7H&ERDGLVE5.%XF?^XV<3.Z'MR*`0BWQX
M`B92TK3-F;$::R3#N%`A&P*:,,.:X`XW?`@Y?,/N<`CN$`)K<(__2&($NA``
M->`,L[`5>8`#98(F&7IIC)8$4#91/K`!"D-!%ZF2>)4>>]`315J<KL@$L?,C
M4J4F!>!A>^4`*V"V14F"30FB+1JUD@:EX9&U=?P`IL"U!.E41\*B',)]-,!E
M8#NV/FD)Z;`#`F""36F4BXS(W,>"*U`(!44#YI21/(%DAF,"W40Q,;%',[AO
MM@K*="K*=LJ#B>MPR4`-J#R$L+`-1[A@P`%R48@.QD`%A:`&)D`%5-!C+Q!*
M_!4;NNM>@!FZG5&ZI]I>[P6:HD$UDGD;L`LAJP1+LC2J71,-8#,-H#FZA)$(
M,/(T;/"[8Q"\!@9,4`<<;1`.M0K*;_IO_^N"1PSA86%0"8B(F_-"'<PQK%U7
MK#29892X.,GZF\XZG,.9'N,;"8*1'TYP!05`->SKOI>#`MAZ`O(;`^MT!;=C
MO_8K!*^``^`Y!KQHKJ_`(_[:(\%H(YS0KL0(KY2W`,@@`=R,`SQQ9`U<`%N6
MDR<RP<XC*?@X*0;$:`94/0>JL#OEL+KG>Q)*PA-[PA([?.^CP6=R:08TTBK"
M(B%0#II@PS?,#=QP"-S`P[[0PSS<PV'-P\*KPSV\`!V:>D0B/3QP#1#@#&GA
M%4K<M)>F`FBP17>]1084Q6O@`TN60T0+"4)Z`SR;?_F8*6K;*+'U?D6*5SZ`
M`VG;E)'=QD7)??^/$+58ZQUV3)#6QP)J@LCC-@@:^&ZBK8&C&,@1V!R#/('I
M\`B(O,A&B<AE<FE;X"TV80*=%S"6C&0QW<^:_+Q*H3%_F[RA+,J#:\H_&'&,
MV\HDXZ=O$ZAY@0[17<N!D`F1H`.1L`>0``DHP)>:R5_C-8:,69B'F0A*8')%
M-[I-@W.1:9V1:4&#Z7.T6UZ,,4K7'#5S6!BKX9B1,`9G0P7#*QQ0!PO^YF^@
MW%N2M41!(10B.2_5:XB5=;U3F[W;6W_.6G_,^L^&0]"7D0T:4`$+0#40?0(/
MG:UU1R!78#GUJ^(83:[YF[\E\HLA79XC[:Y09N,QO`#EP`8`P`<>#M/_F6P"
M1_;`]5DC73#!%>R?/)V/^;A%5')30NU[Z$AH\6C")8S4B?(H&5LBG"#5"T#5
M5NT.7%W66BWFOJ#56YW#::[F:3X$;%Y@.=SF;7X(FK``C88DO-/6SI`+5H`(
M!\#'4!55434*.)`$A`X#2M(C.[```A6D>U41?G`&4`D3A5`I6W`%6^39KCT/
M-/`39^``>`500'"VD,W&;4R4V;<%4Y)]\3;:K4[:H0WK\";:H5T!/A`PA6"E
MVI;:8VL=?H`',!!N:6N"&1HI2F)OR]`*_8`'DI($_9@'!V`"_')D/7L#F9P>
MUGYV1R$3,+B5M3JX=WJGB6O*J<RX1-C*S1UU_\5`'Q9@W3K@[CI```0`[VX`
M`"]G2[7D->.5F6$#=&/8,_]NJ4L3J9H:5^T-F3PWF/F5F3!7WTWV2H01\!H`
M7W&5=.$<2:\:A<%!#?^&`3;H\6YJ"2T1$T3A5S<`$BO!$1'1?GM`K/VGST!D
M!'G0VYN8'@+MSY58[>FQ`H$P!L(`.6ZG`G)G-?!K&G3GOHVG.2.>]"K^G1M-
M>A[MT0T`TO];GB>=GC62TKRS`)KP"JK!!P;@C]4.Y$'NP!!<(Z/'/$G%:!EK
MZ0ADV$,M:'QFY2),]T.EPEJ>.\<8`E1]`%5MU7^O"5^]U6!-^&MN^&/=PW).
MUCP\!&/=^%_M#G\?`O\TL'S1TP6$L_?E\`;.<``!:`0+8`0!Z*(Y&8`!.%'U
M60"9[%=>G!YD8`Z0_@N6X$<S/5$4Q;720[(X8`QM0`8C=MMF&]GC!MK#;^KQ
MMK;-<Y\X`-I#*>O-#^NL'F\5L`*>YP#"&K:JS6UDX`.OT]<\4112T0ZM8`7)
MO@S&T$]=<$``U('?-U!T-$<>EK<YW\_N,12<W!);&;ASBKAHJ98`$4[@MFVY
M#.8:8C#A$"I[O$3204`'FXDZN$0$Q&":M6K1HE&H!O*C1Y(EHX6L5JU9,Y4K
M7;ZT-BV1!)H22`'ZP.9$#)XQ3K`Q\.&#%`D:BFKXP1$D!:;-$@$0Z@%I,VO_
MS60"T(`3Q1@A6(X-*38$[-BP8<6VP6;.W!.V-I[8L&$)KERZ<2T](4/F1J%"
M#L[<<+`)`0(DA0N/&?-/\6+&C5.DL/,8LF3*D*'E^7M#\^;,FS53\;P9=&C-
M>P()240UFQ(/>#@!Y6?@YPG:M6M'JA#IRHE7*'I?T:W[E1`2KTB,P8&E@7(L
MS!MP>KY&^O0UD-;0P`YIP?9R@9PPX",`CPD3-TP8.T^^4)X\"_!@[]*@`0D2
M..S;OX*C@OX*_?U74$$`%P9TP0,"#31PP`075)#`!A]D\$`'$7SA!0%4N.(*
M$I:3C@;MMEL@!!$/T*1$3=Q!T9U#5%3Q$!=7=+'%_Q=;9!%&%E,TL9P#1`01
M1$AX@,1#[-9@@@8FK.O//AB2:&"-$-YPYI@WI#Q`A!"ON88<([;D4@01KGDC
M3&.,@>6,`O9888\]"KB!#`R>^`4N#'X!81ECWKC&2A[V?*#/!HX!(=!CCC%&
MA`;FF<>%0>891%%$+ZQ@"QPVQ&*'-7:@P8<%V#N@@D'X^!1440?YE%13036U
M@A46**"0/BZXX%589Z6UUE=M@/4N8\PS(8\"3.AGF4)6P,.'+[H`8H=ZZ@OP
M416V:,`'7_,H1#-CR`@4!//V(JVS&S([XPQ\PLV+C'3@A,L&#-95!(-5WJ5F
M%8$$@@66@A#"=X@V"@ED`/\=(OHWX'\!<2.1C5AB2J6E/**`88='8NJDI5":
M>*5I&*")%"EP\JDG%'@*Z@-2)&"@9`T8J(IB5:QB@!2AG$BJF6Q8QI@4-F(0
MHBLJQN+9K+)R:<./M=9*-RZ[XNK#AJ0MN2L=,L`-XX8]-AAC`"$&&``%K`=H
MK&O&(GL,[,C&GLR.8?+H-FW/1EM[V\T*8$((-V2VQAH/:`C$`'X^J$TGVB+Y
M._!(4+B"\$B$N`)QXHPK#@OC''=..4YV@(ZZZX0,<@$:M@L!$E*48,"#+@HI
M;]<QT^NU/3QXD$Z^#>^S;S_9__-/P!<&O#U!"1WDO7??':SP0A4JR(^^RJ_[
M,$3_$4L\Y$07?3D$F11AI'[&&*]?$44320QAQQ!ZU'R!(&D@<KHCSU\AS0+6
M+\"!]AUP8"\@DMRP@2Y"*,8@9HIQ1I,P`WA#.:XQC&&08Q<'W(4N`@`!9Q2C
M&%8(!P@*P;Y6G<$/[?K%G'ZQ"EA881G+@(`N1,`E.Y2"!W9HH`,;Z(QKT$`_
M."@>?3;0@!W4$`C(`L(7ON`#'S#A"TQ800&``0-2H:I4I1J5$4UU!3RLKQ"6
MJ!6M9!4K6.%J5K)ZP@U\A8<N[&"'/J!!?.ICGU$T:QX"...%<)`$&N!A6GRI
M5KC.L"O.8,M;I,%CN,*0EW2<ZPGK`B2\8!&.;=CK(/C*_T4QU!`(+PCL7UZH
M@A>\P(:"U2T;'?E(2I;2,(B5A),.:U@H.TF51!@%$%(0R@=Z$H-(\.0$0B'*
MR7Y0LJ1<<F+6F$E4-%(WJL@$8X`PP%:Z\I6RB*688_%#,H76EKHL[0)QH6)<
MGL"!IX5ACT_;PP!BD#5M:O-C7@-GV"0#MLH\YC)X%$UH[JB9=98';F-00#6L
MD0UK.*$>D'CE3_1&&[_=I@*\R0UP!)JXQ"V./E@@`4*7LQS)18<ZF%L`#WJT
MO$*0HF0N:`#ISC.F&]CI3B8XP'9X@!WY-&!2^)D=[?ZC@ML5:$*]B]!+"Q0\
MX9V@/QG:$">D\Z$0F,@=W#@$-_]4A(Q#0,]&V'L1]6ZDO>UIX@#>^]YV?F0=
M3D"'$UBX:G.P,(;F(`$(3&""FO8`OQO@`Q]A\`,'.%`)2_1ABDJ[@1!48!_Y
MT"`/^4OD+'(Q"RLX$`)X"D&6#*B+7?0"`@QTQOX2*:6-&@,$L(@7.ZA1K[XR
MPQD0"(`NCD`.`G96!,XPQC(&1:7W&(N'/DA?^GP`!-869@,;L-K'>(("((`!
M!RX0%:J4:"K>FHH$[+O!JX1+1>):D;A3?)4?OK`%%33W0@+8`AN[*)\=-``&
M:'C4&=&@`A:PL8D%\!4<X;@M8X2K%:U`)VD<T)?VM3=^-]CCN=)ACE]L<!74
M",<@87'_D(6@HP"9:*07,E&%3!1X$4'(1"0`D8BJ5"5A*J'8PT0YX8>9Y",K
MNY@$<"(4-MQL)S'X&!N$,C*2)666O*28530LXI/Q<F;6F*5-;I8S++@#'3WK
M&="4R8$G-%-I%X!B6X$,9*8](1W4Y$`Z_/"T`FQ@FZM\,CB]1DZQE:ULYTSO
M9[),FO)HQ@%[B`0;5D)/#20!$FP@Q=YF0QM^!"YPQ,--<!)G',8YK@&O:,`8
M&/J<YUBJ0Q\J0/<.8`(J4`$=AQX"+7QQ`E)XX`4DZ++I/#HF]*S'/>2K[GQ@
M=P7:#<_3`!*`[GPG:@F]P-$6>H$*3I`?G6XN1"5RQXFX,6L7_Q%51C4Z:E)K
ME"(<Q5H3Y>!1D-8`'2P@CC;_M.D)"$=C)(!53?"S9BTJP=:D1=':UK8$%OI#
M`AA@Z@!X/:1"BH$(O^))@.7H10`6>-@&6I:!B'7@7AVXO\NJ6]V]T`66]'V`
M/`R:+^Q;P296P%H@(.&U6>N)`4HPE"Q(00H*@/C#/R"$-&PA5'S`>&XS?L3>
MDH!:;(+B,V<5\BM&\5:Q2@<0[+.%+41J>)'"`<N9*X!'L``-:%3!/)J[QC:Z
M$;RM$J]XV>DM<'U+C^'RLOO6I*8TJ>];YH+3+^)ER#8<!!UJ@`@D]4"(.G2=
M#K6HQ1X^H(1YKH1B%!.)*$?2$0JK_?]A5&$``#:<$]FPLB>O'`I-3K81&&\D
MQ4YQV0LL^H.#-3@1<0?FX;KBCB$P`\<)H04(R%"+R0M-+L[$E:R4=K2[L,7S
MU+Q!`9#`DQY`.092[IHX55_.%$!#!%L.39<W(WO9;Z80D!A`)%8R3PU4H`!X
MI\T^_=;F$P!N-Y&(<X9TD[.$8E6G1Q(?Y]1P@$+;N`T$(21!VA".6VSC%MSG
M/C6V,00L')L$&IVCG>KTP=/Q.Z)A=%U]_+,%3G^ZN9X60$L1]*`#6<BF&[H.
M[BB16?NI7<,>&JD>7$/`[/$U8),J\M&T^CL!O9$-94.!KL`"('HV^`J#M6*:
M:P/!$`S!/1#_@OVP'QXP`7`+MQ44-V<(H'1;H&/@!F>800:2P6*@-V>(DC!1
MCPE:G]3:!"9H+8.S&FV*`84K`2F8A(=3@(>3`070`!G0``#`"BJL0@!@``5`
M@5W`@8O#N$9HA'4X!3`,PT90@D;8N$'8@DT1@4(`@>%ZJ^(:,BC*/"+SP1]4
M+;#Z@DMA%I9C`1Q@@0NQ.19H@$QAE9\#.K[@#'+YBS,@`V5ZQ&3*"TA\@B7;
MHSV2&B!"`"9``"#81"#R"W.I+VJ@AC9H"!V`I"H@!#J0BS.H!1LPAS-P@JHP
MN[-KAHGAI%SL)%T<B5ZD``Q["IO(B0\P`-/#.Z+0.Y29IXVXI%M4_XEID(!4
MDH`?(#NJZ*4,`X09XRIW"`N$:(,V($527#+*2ZL>8QHK&JX@8RNFZ;S.8PNG
MN8$5&`/3ZPG4:PPJ&R<KBPPC>+TLZXQU<AO-Z+)JB4?$&+-U8``!R(-((,8/
M4#/;.)SAX"HL&#8/T8Y6H3XJL#$0H(5$0P=:0`<J0(9""($"6(`58((U:(Z<
MH0T!&`,JH(9;^#Z9E,EP:(,=0`%EVP#RN($Q.8-E^,DSJ)/V:X\A<9W[\(^7
MN[^E9"G<J1`,T9`F<341*0<3.9$3F1[K6<`%/"JFVI'M(!^5G`\2(*@,R1`:
MPP)/5)_X.:NTXK%U3!JWFB*3BR81M,M:N?\!+)B4)EF`-\B?_6)!1&!!?'$@
M;C@&=2,4].C!.TR?("PX@SLXK0&9*%BX)70XB(,XH[#"*62`,M``40"`,J#"
MSA0%!A"%TPQ-"3B!9X`!-'(!1%$4C%,"/CC#,T1#)5*!+N`!:-"%?O@QD8,B
M68%#*GJ5X'R"P-""34C.P1B,@MN`%?#!]`$O$6`!G=N/'?`!.)(C<DFF,R@$
M.2H$?#"'<;DF#N0`/P@#?'A$:^*Q#IPFM`J#]=H#)O`J+#`,KVJV-/E.-7`(
M+]BZKV,KHWD"?#``L[NDLPN)36*[3@J)3O)%A@$)N`,`#:.[&+@9$.N8H)""
MD7$"69H9NF&)D%C_"0!P&9'9NX-YL0PC!9[(&21`BS8X`]`XDS1IDS"@O%HP
MA[;*O)/#%:;I`W8$4G9\1^]<`2$H@2-%THU1`'MDC-4CIW*R@WZ$O=D32-@K
MA#VPSW>P1M;(@ZNJ*K""A`*`!+XX@$(8-.I;3!\,4TB`!+!2R>8@`<3)2=KX
M`,$S-2?`4S[0`(PS@$*H29F,R>_+!4[X)PTIG8X:DV6HDT6U$_(H2O@S*1A:
M*?M;RBOX,Q`1$63H*:RTM>I)*J6Z'A81JA+Y2JF:#OE0#OJ@#^)H#K`*J[%B
MRVA3J[6:MK8:KKO$U5P%P3!0N;K"`[\LI%S8+\`,MZH;3+`HAC<8EO01_\+'
MI)HB7*4DO4PF-`HIM,*X*TT`$(4R,$W3+,ULG<(H_-8R^%:,B8%GJ+E/P*[M
MLCDT",1/F(=/Z*TC$H`DL(-4N('@)$Y8.3D>+4X@<XL@$#@$6(%.)(S[#*(]
M4,0)6H$=PH,%X(OR>!K-R`OX\@,C<P#X/"LRN$0RX(#T/(,DXP`'\-A:V*./
MO5@.N(%:.,^//0/W00`LH!JJ$0*J&0,D0``M&+!,6,5IBTL;J`0'B(0?R"2$
MP<6ST\6D!24(39B5$(:2H5`#`(H+O3L1$YED9(`?2`F7L"6+B<8Z+8JDX+MK
M9``WL!F<$8(Q0$GZ1(*MZHH]L-$]J@5SU-<>_?_12NBQX@S2(F,+O2@$)DA"
M!:`)-Y``-YA0)ET,?-3'*T,;*O4,VDNO+JN]O3`-+"@*!M``#1"`,B6/0CLT
M6F@#=$"&!=@#-F73E*RJK'J%W9C`.W4"V0S#=9#=4UB'1J#=,B1#,W0!/_W3
M6PC4FT2!"D`!2"N=\@+*#_K)0&D_DV2=-9`/I`00`&'*YMJ/GH(`3>C*7/-4
M`\P>$^$1'PG+84.HY&@^+`@$9UL3LCJK#GS+#YQ+787?^`U!/V""#<&4OBR&
M>A'6@B#6<"L(@C"(;;B^@C`!((`M(XR"H"@!RY2`S(3"*;1"+`1-<B7-;OW6
M"Z;@TT1-!7C"SOR!,IC_I=+TS!-(`UR8`Q-F@3E(X17&A13^!!;XA$]H@188
MA`C`N#++@U1PE;J-E3I,QR&#ICYX@CW0`N9LSL(PV+%J'\!```M`C$!`@&=[
MMB`@XB"(&O4\SSV:)H[M0"ZF)FOR6''A,3+`X@Y,J[/:8K8(@[]0$[9]UC%@
M`IT%,`O(!`<X*QZ["WP0`B5@.[3SXX1INUTD";6C@-T[/+/-B:GMF%8Z0E@Z
MBI-!F6;X")<046M@`&#*.P90`L(C/,,KVQ5%6Q1HI:F5VAA``/CBV'*T51\&
M,KQ=1W:,E2`ULJ<I!"!P`PB.8"I$7,5P4M8S)RE]W-@3YH#TC&JI%K@!`A%[
M_P&^N8)E@`7?I4EH;H,"8(,[W=-&L(8R/(4QE-TRK%TPK%W:!.=UF$TE,&<S
M/.?:=0+>C>::S`4LV`T42(+B_<GC/0,/JN=&Y;?WH(&CK+_I94H<*`>@LIY/
ME1$;\36GTH3NB2KK&+;E4%6M:HZO>E7X65\/?%\1S&CYY6CXY8`5J)_-24&#
MJ)?\"E;M0VD!)HC_+8AICH&':^!PE8$J%$T1WM8RR&`-_@%1V&F>/LV=!FJ>
M9@!E`&H0!@`IB()M4H!O_>`/CKL3V`5*F(.IINJJMNI/F(,8UNH6F`=3T&$'
M"#*1$\XY[%$@<RLB&^(@U`).Y$2!4Q,V\0P$Z`&`X?^"'NB!`7@(+\!K?_&"
MC%UC:SK9([,FP<8'/ZB%.PX#*V:+D54K]OS8]G1/]N18P%`3@RVK(!@#";`&
M!8B!F]V#((`?%&``IL!%B4':!FW00.;%HK6*#).Q4H:R"60#AW.!R\W:ND%M
MLROD1'"#AG0!62H9/MBE:<#&G<B9&"@!A;/:$A@#O[91/*XV?GVF'P72XHQ+
M(%WLIW&`#<CE7-[E?U#<Q=U':IE2QQWFR;W2%2B<X*T`$F@'[FMGF6P#2"!#
MV\3=W`7G^A9G)6`4<S[#UT24>5""1AD$):#=02@`0(WO-EB#X!U>GC3>?#:&
M5E!4Y46/?0XCYY4_Z0T0Y^K_\.9:`.=!P%WCM1)QP`60#DX@R]T0WH*RS[!J
MGXMFJXZF\1JW\0L88OM=@_'(WT&BET("\ESX7WL!<H(PI&U8@`^@0G(-S6\E
M:I_FZ:#>::*F<E%0AJ&V\A]0!BL'X42P<IXN@RW_`3>P`+,*@P$(S0\>5PU8
M35S0ZD%H@:R>:JR6<ZNV:FC0X>#2UUOYT2'[USZW"TO@@`+8A/2%GU89E['Z
M%K+*A!X@@$>']$B7B$?2`34@SY,UV;S@L2>(F@[,6/1T@%FE)J;)V/>$[,;F
M,0Y`X[C5C%KP`['SB`;;/5I,[01%VJ.-&`I[T$&.AMV[F`G%B:G]L)X`BJNU
M[=N^_T76WCT2%;%8THB+*9GA_B6>.!P4$+&@`(H3V`/XNE&X/.M_9<<^3\<B
M$](D(P,M8`/1[&Y=WN5>]N4H-6\\JCV"K%*"K!83,.8"*%(''UYG@.];P(!H
MGN;\_D*,T[F6RSF,\W`8:("Y>H"<PP$8:`0<.",8@`$<4`$^&$,*0,,$C^^8
M'%3VAK2>#$I%/0,*#Q1%9;]*`TOGU310R[\*L1`!H'D5:`!-$"J$CC4'A$"R
M1+;"854@>+8[SML;-_JCMW%+*("%$NG'"@?\FA<C!_(C)_*5;ND"4'(IYVEE
MX'IA4`9A`'NPYWH0KG(JUW(MM_*A1OM9,GL05@`$8,\!D/\`G_Y@;@4``]B%
M1XA7&=9X,!S#1I#A"(B`'(AS.[<#:JD$<`=WLO[9NZB$<@F])7Y$P("O;_$,
M"Q`8`D@$28_T1^IKRHL?#A`7,+Y$TE>K:5)C]^1T#A#T,+"$2G!LMA"[=9@&
M54("N)6+)T""CA@!>8H)7C):B0DE6\=UI5V8I`6)E8D)S(W:V/:)8D=&2$X*
M7LI%"'O:KQ4\6;+D6:(E7,*8G$#;&.`PH>AL&[U1Z`9.(O-16^7SZM;1S@L#
M),AEPG4#S/QNQ26;_'<];@D-@"ATP\2-@@4)%A1X0^%"@PD+%5A!`@6*"BA(
M`*-V"\.MCAYI%6JTKE&C08,$S!O_-&_+O'DP8+!0,:C1%AQ;4&I@(4`%#)8P
M;,*H4&&+"Y*G&BF!%*ZC1H_AM@$1(I0$P3/&SK1:=F89"!#&LF[=:LR8B0-Y
M\-!8TZ`!C@HJ5`AXX<$%W1=V!518$&+!@K0-.#7`0@(+%DY,(.TIX`!?F#"U
M.%2R9*F/C3X7+%_(K'DSY\Z>/X,.+7HTZ=*6"NQHL&,-'A-6J"5;E8Q:N-I/
MMVV#A7LW[S:[\WPH(TK9#V7&A0E3EEP8/./*E0V';OS'\.+5B2LK4YR!<>W:
MH2M`$(;Q``G"$XFBS@"`@6>4*,V)_VD.BT_UYW^:ES]"_/[Q\11R1F6567)!
M@7T42*!D_Y(]\00''#Q!A@-A^(%/0614J-@-9R@6QAD.[*$#%P202*(.)Q*`
M8HDG>@''A&$X<$-C#IS!6&,WAO$@A)94PD$83U22HX,Y1C8>C'N,(44SU5@C
MS`_K11*&)6&@0$$TZHS0C#763#.--<TL24$U8I(YYIAAFDEF-%9:N>:8:T8#
M)P5@6L/`>A*0\@$;,;!Q0@Q_QN#G!Q]((8$$&MCY@Y?9A!EG-'0F@N>@'TC@
MA)W3,%`G`S]P::<"I/PYAA`Q$%JH`C%,2(9CD$E&F64+PGK9!39<!BN"!DI6
MR1.;Q*"`&VXH$*RP"@#RC[''(IML"BG8L2RSSD*[K!TB)%2M0?\,7>M0MMD*
M!-$*0E14$0G.P.(11QY10\51ZR@QB%LIK22`"S`T$-0@ZU00TSQ\-*+"%OKB
M@$-+*K1D$A\CC;3"4AXYM0TGX5)EU59=+=.*,14;`P)7RRPSE@EE+8"66B1<
MX99==#F1LA.#N/!"`VNLD)B&,=J8XX-`MEJ:SCOSW+////=12&H[T-!:,;)1
MLTHXR=BV33BZ.0WU;;T5$)QUV"F7G'(S<$U$<F5@9UUQT(U]77%GAZV=`DAP
M@`\^`RB07GIE,"`*`!_LLH\MMNAMARVX_(V+X+BP0#@:_L6'2RIO&/-$@8\S
M"*MD#^9H"3YD/"A0&*K><#D9-]`HH4'_6DQPH@XD`E)BBBF>OJ(77F021&.,
MJ7IC+3<^B#F$1?[X!#X0^LC!#4$@$0FI@&@PS9I@,J\!VP[$T.8(<UK#Z9:,
MHEFFF,V(F:::;$;S9IP4D*_*G,UT>2<@@/1I`*!^GF``&X2Z<*B=F6ZY9#6.
M/MH,`Q(`X@,&^``I[,<`)21""5[ZTC02H0$)?"`&D1""$$J@`0!@4`ICP$<M
M=+<CRM1J00CJPZLN@Z!66>95#`K#&+@P+$`H(`N`R$()N)"L&R*K6=)R5K-Z
M^*Q@B`!;UFJ(MA32+8<(T5M"N`)%+I*1C73D7+=(UTA(,@BX#((/\QB*`%B`
M`[BD)"XI:<0I_US0$A=H$8U\,(D2E,`'/IR"`B2!1!O0Q;`VK$$J%:"*,38$
M@K!\16-=$63'/`8R/*B%+14X@0I>X(*5:4`#?&``'S30@#V<8565B,R"?N;)
M3X(RE#QSP!JP\#*CA6,5JX`-;9J6&]P\Y3:WR05N@.,=K&5-=26:07:P$QWI
M4"=LP`1;=8BIC+51;@,*(,YW?E`&#7S@&ET@P09(0()+;.`2ETB"-D>1!%R8
MPA:4V-L^**$W4UPC`(PC0R<E0R0@-<A!-VL,YL(@(U5]2$9G*`2-/.0`+03B
M=0(]40]T>3H4'50'L,-'A2CD(YLU9IXV<UQC=)6C6OP3`0/X0/*J`?\F\6GI
M2^B3P!Z$(`'RC6`$X=.2E[STT25Q+TT>E6F9Y,0F\L')HUI*Q/\D%<$]!>I/
M>YJ4H2*YJ45]M$TKG88;\L2&`7K`"8A*U#04]25K),(-$`S5&(*3B"?U(`B/
M(<-C<$9"R;6*5BFTU8%,R*-=14$*Z^,"%TI@URC8M0<XW.L.^QHM:5&K(=AB
MB`F..$3!5DL@!2C`'D@&,6<LC&$="0<Z$-:(-<YDC?.`"TJR6+`W\JN-H'VC
M&]_(1I*@MA%,J*-DI[B-/)[@(@2Y"E>RXI5!<D5C8OG8Q_+0%QHT@`1M@8LC
M$<4':RAA2R0(`ZU$Z=SG0A>ZEKC!%U3#F@/_@``6JU1E*IMV&]W$$C>^P4TN
MJB8<K!4''L(PG1AT(`8"S(`(QD3;V'PI3&&FYZL`F$#G'#````33F<Z$YC4,
MD*EI0*<,90"`#(`EA1)@001'N(8NWI"*`UCX`-<XPC.&<0/'=9(Q#>H1/#F`
MN2?0TT<UPF>,[.F``ES.`0&%W2(R48775:%UJD,HZUZG!\;H***4@Q"*A=RV
M&^$#1$FRAO;4-+XN36-)UD@>]^*4TO!E@TM?PIZ98"I3[I$IS'(:LT[1ARE#
M`<*I07V?_`95U/OE+ZEMLI+_2)&G0=7/J)NJWI88R(`'LH$-D<#"&&)`G*PB
M@8/!V]%D%&0)LV;&_U6M:BNM)O/H,/3`KB7`*QMZX.E(#"#4>\6A#I_U+!_V
M$(B&/>Q@$5N((\*Z(!%9(D6N@)&F<$2*U*!%:M]X6248Y13"EN,Z1M(N/K3+
MC"TIV$X$L`48#`+8TE8M.EK;$3SJD8]GZ,JVMZV5?FR;D&,A"V]]ZQ?AFNP%
M4CWNFSQP@P)%-][RGC=ISL"$M<`,N[#HKBIG8QOO.BW@Y,6->='F'&',0`SM
M7;@.P-'+J]'7;/:%N'1$(84!D`H`8!,P=@`@A6NH0`/BN(<W$F#RDY_<``]8
M>1%*P0,1@"$`:=C%,S#QC`(0.9XB=N?-V@8\(VW.`85@J(;LF9@P!,$"+?]:
M1!WT`(<JZ,'I!S4HZUCD!2T(*7A#^IV/DNP`$.U!"PA``!+*`V8WD:\:8\)I
MG*K'@"AK:>U6OG)(L\R\F88IIME+4_C$-+Z<G@^KZI/"4T\`U*#.KU25HJHU
M&.71-9F/`JK0$@`,18H\ZYF2TU"@EK&JU0@*`0G%<PX;@N"'A^Y.,KAZ-&1<
M):L33B:%D3XA!Q`0`T_W(-2AGL`8)C`!"UA@U#?T:ZG_.BTD%B1&AEVUJXDH
M6(A`8@-,1(&MW[`**+:V#<`N-FJ/0L9&R-'[<E3"/#J[;!>8)/VH+;9E*\F$
M:EM[&TQ@XAXW1%LR<`4KN-5M(4U@C#>411Z8&W#_-<`57`$C/9*EK$,TC$`C
M%`"\T5L$2J"\]4$8K(!J=`$/Z%O2J%+2U$8K!5QXR9)X+4!PH)=R@$/"*5Q[
M20)\@0,&P6!Z3,<)TA?9B`TS`8`"`(`,CHV`>1PY5(`33`,%P(,,B`(\>$,2
M)B$12(`*N-$+:(`35,#*K=PCK!P3?%T6@LAB<,"4="&*U0SNI(.+G0$'O%CG
M))\61)W4J8A"F4[5)535O4X=V`P9Z,H>&`"B*$$S,,KUZ,_^\,^:I%U-24\U
M8(J=G!W_7!GUB!2:P-0CXIU'-1GY@$_:H<^36%X`/=7[\(D!#!"E&)"7S-3W
MZ)1.V<E4;<K]7(KU:%F7_U3>GHP!$C`!$HC">B#`8P@9B,'*0T4&9B@("6U&
M[%6&&0Z`[XV!!?R>!2"!,C(C$@A?LI2:#J':J:D:$2F?\RW?JS4?K`E=(4@$
MN#`1";Q!4V#?N80#LJT?2<C1]XW$.AY%&[E1%'K`"\26$!#&&AS&`A3`JYD`
M%:`#.FP#.4J6_$G%1;S!#?Q1M[7";56,5FS,Q?@?``9@R*3%R!Q@(SU2IC#)
M"CS!!'KD1X92'Y#!"I@2S.0!"%!#2JJ2*MV"OWF7".X&+>4!(`28="B'*N@8
MB23"#)2!&VB`&VA<#0KE"<Z@V(@"#PK3#U0>.1A8,SC"$<(#/!#!$7I#+1H*
MIO],E1.X`"FD3!1*00P,P!AL0*B)GN@Y@(-,3N6HBHW8".AL2-N<`2XZ@!YD
M`AP0E(JLR.KDI>GPI1<$`1T\P1D4Q`9P"O/<'27.V9@)XINPG:/XSY\Q0"+.
M79QXE!]*XDR5F6$^8DQY3Y>ACYT8BA3HB?OLB9_L29L5BJ%<BDCAE%)MSYGP
MU*98U:8H`6URR@+ME!,H@*"-`1-H`1``Y0`XP.UH$EH%3R_*"H]TDNP=B&3@
M`P(PHS(N(W12Y]@AP#,B"_']%0\%D5MVRS7RT_,EWS9J8[<P%@D4I!/!@A1A
MWQ1I@+25ECR^@`%8A#T2!A,PP0KHXV(=0"'P%A4`Z#__H@,(T`(M#$$;A$,;
M"&1KA</\B8L)G$&W@8#%>)O%:(S%C!NY]99O\0`-T$`7K`6Z$=>Z,0`3<`!(
MHFB*DL:KD$$!6!<-'(`Q<"!+7A]3W$)MA*#`C5=YD4(Q89!P($<6D,BO`((;
MQ-<."H<,)N62#F4-XI<R<$?EB<`'<`=Q"(,XB,,TB,*"5=X'+-$!]LF?Q-85
M1,()G,`'E`"@Q(!8AIH6*">"[(C6^9R)-48M%)G-.$`0P($7](#I]&E.[B7K
MP*%"7=T>\,`#=($`))7:-2;_5.+WI!V<6)E'_9D0BL]D+D_CO13>?50?\N&G
M1J(C,L\A:I4FR@_BQ8#\#%!J_TZ52U694BW/DBQ/576>EEE/2_49ES@0^Z``
M$@3""@0"&[C!'CB&D,&*/-G,9&B&K<A*<M)>$$"G!52GM%KGV$DK=AY+-/+0
MJ?W0`BR$0`B=8(&G=WYKM_`3-[[:K-&?06I$KK76&NP`8>P`?D*"?BX6/_:C
M/Z)#@6X#+=S"-MSHC7Y@.*3D4TQ1P$96_#$!"5B$MH7;MEG!MGU%_FV,__U?
M69A%R'3H&B02R2P21DK5"I"!BI)LR6J&['&`BQ*-#^1!,7#@+:Q"KIU+*P'<
MU&Q#&RR`%'R'*%P0V,###"A`"<`0('"!&R3'4?Y`DS+ITBIMV3"``H@`"I2`
M#HI",_^(@]4JI08H``11'PK`#T7$0!-50`D,RB38%5BR*1)PDN0\2&0$B>,L
M&ABV+3YD0B:T2"9$7=UZ020`JD$AE.EXP01@`4RPP"!D`Z,V:B`Z"D[QG2!*
MJDHQR9]U%*Q>6?_8G:@R3Q]FF=TUHF8R2OI47IJ-YE.59B<.2@&IYJ8X'B4&
MXO8X9BOF*J?(;I_9'::X`>%%PA@@`!,@0"3T``?9R"8Q".7<B+)&VIO"VUK5
M2B5D5+52Z[1:)[8:BW9N)[-T9[B>*[F&YW?&VJMUHP,4EAIX(Q901`547[N:
M"_:U`2WX!H(2K(TZQ13]V_PFZ/S:D;7A;X/2'PEL2+>1`;?_60'&4$PA&=*&
M+@`/=.@#)-)/E,R(.H&)FFP$I^BK]$$ZH(9JT$`AH,-*QNSUL:?`QA*..HUO
M\*AS4$=T(`<`_`I0[J#6U)=SP#`N,6U1/BG:_$\>"$$/%&T98"ER9&WE28`"
MZ(F:2E`1?P"Q2`$7H&D,;,`$#$"O<L`)P=ZC#>_D_`Z03)3O!($>U`$^T`$=
MU`(=U,$69T*?ZM*.K0Y?1L(KL$`;#X)D+J[B_IV8L1VL4N:990KE+JZ6;*IF
M7D^N9L/F7A5+I8^=5!XIB.9H\DFJIFKBL2H`[%FC**[D@51(;4E+*0KGY6I(
M80H`D`(;A"40:`$3Z.[L/,:"$*_;_X1!)6#&ZMU*I!&(@2`(TE5K+4LK$E`G
M+DOO/VCK#DUC,!A!>89K-RZ$\L$:N'KO,9]K`2R`]#61.)(C>W($P6H$_0J<
M;1PL_FKS-EM;@X++'OE?A/[1A$YHN+6#MUG%N$EDQAYP6H#H6@3,Q\K%`X^L
M!-MS!&)&"E5"(<#K&M!`'BR#*G%$S`YT>]*OS=)"SBHI=B2'-T3E<7@#<M#@
MDM[7"U=TV`Q'W3``W1RE!"R``A"!?`$81P\8!D'0&``!`@`![_)NS)"=T";Q
M@T4!J=C5!$C)%$\:@D3&D.B*/.',)OWT6_5(+>"#%GA!W^X87^I`#^!`&V_!
M(%RJ'+?N^/_0E&(NKB$N7I4YRB)^JMYE[B6#]0)E6>-Q22&#)IX$T.ANHJH.
MBA04T%05)F/&<9QLIIE!V2'>#RMJ:I/4R>W"8B#P;B"X#9`QR-;EZ6)4PF;H
MM++*7F,SK]A1I[1*=BY']BY3[W;:03`+G?)QMC"?JS&7YZMEKV@S%@517_7Q
M0GNR)P@D+#>[]FLSS`=/UL(V+(3^[_^V@K>!`+AIC$,6\!N8A6^A15H\0(@*
M5P.?#!"$P3TS][PQYQ,4`A"H!LL:PW9U<-+H&L**<,#E0BZL`$W.H#*(@S)$
MM#>4@0S(0+!D018H`-C$\'N_<`_B4M("P`6MAUL7BFA*P$A[M!3_R(`<R$$&
MZ2`D7]!/&@`2K$"")_@>)$:,[$&OR)449$$$G>T8!(&NK*UR[F*&YPJ0Z,B0
M?3AD](@:P($9#^D95QT;-+4;V[%4MVYG5J+B4JI41>96\T]EUC4A@W4KWK4J
M(DKEE>H'I/4F=J(C%Q4D%Z96*ZYAI@]0&DJ8SD^A6,H/@`GV7/+_L(\0H/3N
M8IVB<9)A[\$F3$@KOU4^9X:R6MJ4:,%DX_(M1S9E[W(O<RNJ!5%Y%C.X?NOS
M<>]GBS:?DV3)H,`2D$``X%HYMF?ZNNNYR+:AI^^A2]:B=T0R0`+#H@`.W,!5
MA-M"YO:$+D/$]O98+(,)K+-O423'I@9;_[3%(L6%"RAW<[OZ<S$GC]P`O!)-
M'AB#=LWH]27-P2[%_")H3$*"%,QW=L00>P<+"P?E1!.'?#NI#4O`/`I0:`9Q
M:F[*,^'!H<A!L'A<H2S8?N?@!Z#`!F!!/0`!$'R!#^Q!YQ0`W`C+@Y4`QH$E
M`BS()K5M4"<9UWTXB>F*B#M(C^B(OX>!'N@`&Y2(&Z!XBK!!&[/`4[>XBSLJ
M3>U/C%-UG2Q>-BCB^&AFE5^R`BE*TJ;/DZ@B)*^'$TB`6P\*Z9(F6Q-*42%*
M7#?\2C6#,'0R^["!?99[O'HMI3A!<HF4G[F!GD2"Z+'TA+`*ZXW'BVE!$.`#
M*Y\Y)P'CF>-*"/]!]F13*[7B<IN3G66;VM8;GV;S^9UO[V;S>2&(KV>3-DDV
M4?65"Z(;NKNVEJ(S>MM'T=Q#D6Q_,#5,.D5$#!FTPFV/<VX)$FV1!;D%M\9Z
MZ#L'%PXTL`$XT@Z<P:M#_B=AQN,@R`WX``;;>DHFS>;3:#77QK_&TK^*UPI(
M0'B/=W;T;-T<Y4(/97A;-`W_F:$82GW7=R35=T8#P+77(NUO+0S^Y+0;@!`L
M`0K\"47H[M>51Q`'<="FZ9],0+WO#F3<3)`PAK^'N([@3&%3CMN`"`),P%&/
MR,&3"#\0+@OP@:.HPY7$2?KS#_O_79?1<1QWV0\\D`1$V<5OCV%><E7_515`
M_&`PD"!!`!HT,-``P(D;"8!(??C`Q@#%&!4-2"0E0<)"!C^L-6M&(5I)D]$H
MB&PV;1H#-Z0BC<$"9"8G(#NP;!!RXH,+`'RFB;3&TB4I-BB0!$J*`%^M2I:@
M/@F#[T:034'PA>ESX8*E2D\L;>7:AZQ8J);P(;"```$2MFW7PE4+U\(_NW?Q
MYK63@N_>OBGV!DX1S$@APPX*W2B$&+'BQ88A'XZ,>'*A`BNP7$&AF<0;6!AN
M@09]B_3HT*5/8QAM^C1JTJ]AOV8->S;I;2M(H*A`PL09$+[)@`#1:KAO$,O.
M+%MFC+F)-R9,',BS8`$/&FL>K&G0@`2.*Q5._Z@@Y0++&:[GT:=7OYY]>_?O
MX<>7/S_^5K)/;C#9L6:%"1"P8*$FP'"HH8;`<)()1\%M%@QGFVW:>#`72!3X
M01EEQ,%0&0LOY/`'#S>\4,012=QPFA!'_$$4!E9DD445E6&Q#`M_<(,'*0#(
M40$%<@2`@1Q_!$`!*4HP0`HI)-A1BAB00,(`-WK,\4@N)BDAAJL<<`"?K,+@
MP$L.GOCRJS'#_#*,J;;,,H@]]F"KR3$&Z*&'"73H@8`[\<R3#18>84&%04P:
M(1IUHA'TI$--HJ`:11FM!J5'HUFTFFJ:L281)SJ:9M%#*54II&FL`8D!:T8M
M:*"%$O)Q(8XDD$*B#_\PBH$-BCX@!<F.$AI5I$T156F:1%SZ("8@:,II`Q+&
M($&(G0SPP`E=*QTJD59+&#80(/8(XZFH."`C2P?V<(".2L[S*BQ++A!K*W3/
MY2"(MN9:*RYYU4+"`@N:S$M?O/[JEZ]_^RJLL<<2DXPRQ@I1PV#(#C:L@#VP
M0&$S%$@X`!;:4LNX-=96PQBUCEN3[>/88*,&DMQVZPV$X%C^[3CDECGN#&.@
MHSFZ/*9;``\:KMN..QQPJ$`%%5[P8(,;Z$M:Z:69;MII=BTY8X4U\#@`'5C:
MP!K`<&#AFFM8&`0;P@?)EI`)"6@<,4,:1>$0Q0M/C-O"##.,>\1I+,0[1!C_
MW4:1QC(T6*"$)(>4(,<R?A1%\1^3-#Q*(17(@D<`VBX#``G<4)*+&`;@O$DL
MM3SS3`Y$/W-+?++<I$TDX.P\BB)+B%WV'KP80(<Z\\R3'Q9@8($%/D@Z25!"
M"47T44HE992DX!M5="4&)""%`4V#+RDEH4!E2:"6!"KH((,4.H@CB"1BXR)9
M#<CH@UL]`BFDZJV/5"1A6H+>_)FP4!:%$TZ(@?_T,T(*#2A!*$-IB1L`P89(
M)`4(6L`'![9E"2^A#EQ!T)99MB66='6E+&%Y0EKH92^XV(N$)<37OE#H%\#\
M2S""(<QC&H8PR11LA@<K`,$0<YG,2`P'G;F8:D`F_YJ/"3&(&PL9R#0V&].P
M!C<2X\T9SD"&*`H'!%;P32MBEASF+`,Z790.=:R3G1ULISM!"\\+2"$$I#F-
MC6UT8WVZLD'TV$>.=*1CN<)P@`,<XVK8P$8;`*DU00(H%V`S9(3&EHM<G*U$
M(.*(*$Y$-PU)\D0:FJ2&*EE)$:6-;<I8G.4T@$`>#&Y'.SJ<Y1B`.,ME3@H*
M,!Q',E>"5@*N#(B#7"L_8"4#R$YV4>#<&!"@NC5MHBUPBD$,>"F[7)9@F<QD
M)A=RR88)6,`+=<(=GKC`CSX]`@V`*HF@#&4HXUGO>B)I'J0HD)))56H:E_/`
M]!R5*.QICU0MX0.P3/4CA?_\*"$.`<2K+$*1BJQO(QPAR#2R,9)'!<]1V/M1
M`E$0"2Q@00@H2%^M7B`%4GA``DY`R`^:48UL#&4H#'`"D188"`1D*X)A"H.:
M@N``#JBK$D\ARQS9E2Y+A.%=^)(7"7T*5'M-P%XHW)>_5`BP@#'L,0IK*@P)
M]I@;VE"J.A1"!9QHL25F3#1"=,U611:RK\:FB+<P1VQ,1@+-X$!EQFG9&:P(
M,^30S&;0P1EU=K:&+OBLC!40F@%<<`4'O)&PA5U:'Z!BIBZ)#DQEB6-.UQ5'
M._;!!D_8QC&.48P`F>,)Z?!#<(2C2$4.0;2E->T0&.E)%AWD<H:KP`<^DB%+
MRI;_DI:<[27G5B)E`,`-62@!&WHP!B`P8068^4`I)T>Y5(KB0H"[')0L!P#+
M$8ZU,]*1%``!B"Q(X76RS,(')K%,(CFSF<TD+S/%*TOO`F)*V`4$%VCGA6K>
MC@WT90,,'H$+%0`O4(,J2?$019)UJH12C$)G\H3"!P!L1`,@710%5%&I#^63
MPJH*7_@P18I_LN$#%Z$(&YBI48YX9%0AX57\5"(,QDWD!,]RP0=X4M`1(R0A
M?+#&I"AE#1T?,(%":)(6;N"4LW0+'P40)C[(I5,.A.4\9&'RN22(CZ!.&5_3
M1`)1L3R&"8S!J/I2X9=7V,+"X+"&#)MJ`7(H50=,U3*/_\%,15&P!!^.K*M&
M).+(0G-GC6%,B:XA61,K((3>D('09VC%%;,H,^8TIXLWPRO/UJ"=GP4-/`)X
M@6!M8%A-:QJQEGA");Y$NC1]BX(4#!V8H-+I#=JGTXA=]1/"P8S,YN(,!;@!
M&3C[!'-\%@3H$$XQBC$$8`L[%Z0E;3&`(`%E:`!6Z3M!1B0`O8]<B+;45IMM
M.Y1M9=22MYN+`5&UX`"L;&F8"&`"`G(B2QXM1'$68F[:VK8W>*]HVS\HPX:B
MZX90#FF[W_TN("8A!2X<:;L#!Z]ZB;3=(TE!X=@=TL-;64K"<2$2$_!"#^A[
MNTC@UW?>].]_Q\F\=*HSI"$U,/_S)"722D&/51]A"=[P>2H*%R15^SR(&UQ5
M/@-X6'U'&O%`?H!0D<2O)`U=R;0`<4P#.`&D+7$!IIS@4800!"39D%2TCBZ!
M#H\A$$RP8"4Z[5)P86FFZUHRNC1H'[1#!1^;(*H%L'QE+<]]RW6G>Y?U4@13
M/(#O#^C"`[:3A`8D@00D2`(0V*PPA"W^,&Q.\PT7P^8"Z%`S%;A"Q3Y#9ZYN
M7C4>&ZO(O.IGT9<,,UC%02&@N#+5NRPY(-@B<V[0:.G@#`_6Z1D9N_,=%0B`
M%"@HP*:!#Y]UW50]?:C$Z$IW.E-KZ5MH9E.X'-`E,($%*H\=_EG.`NMB9+88
MA1B#</?_@'HR/$'7?O`#.HR!#F"OG_W`WH$&/(FKUE+N0QL2AHADJVVWK=*W
M<AK`VX'@+58``8HK2TXG=8``"81@`%``F:1@(:1+N=IM1E2KEE))1ES$1R(P
ME;@M2AR"WQA.X+!KX`:NW[0+N[8+XI!+`=P`2APG2CB0WLK`#0@`XRY.!R[N
M%1XAO_9+>#XNP.+GZCK%Y$XL4:ZNI%B%Q+P'(2Q,GUB+Q%*%(1PB(B9BH#A,
M(D3,<(!.QTP.4D9")%CB<LQG?SS`P9XG(7*%(&Q,QQXLQW8,>GYK#)!@#YHB
M@BJ!#/#!*F(*R;A"@FQJU2CKL:"B$AS`7NB.[OYO`.!D`OYO_P,8$4[P#B^X
M@SL*3UDJ"LXD)@90``O8C,R8"LVJRC+6+/)(\88H3V(HQF(X;Q6+J&-:T?.0
M:/1>8P%RXPJ$X`W:@-!6!CA<!CE^HSGJJA`.H!!R)J_TBJ^\XZ]>H`(*`%V"
MS[#4CDP@J$R\I$NH;]5(ITN4[UNR9`^"X&&>;Q-60!Q5QP%N`!_.H'2LT1)L
MP-7.Q<D\#19D;1F&H`!0('900`Y7P!P)S?S\0#C0`;/<@1N`S1UDC1,`0)/\
M1K=$Q'(BIP2BH`<&X/]$B"VT8!.T8`4N4B/'\=P2$`D"L"U89P&1299:R7`0
M9T561)56\@)M20.#)$@>YW'TC;=.\/\F%8Z]'FY'DL0A>.MQ?@1Q4LG>]$^W
MA(0+V$"^O``.QF`'^X0/^@O`C&=Y4&)12DXE0NK!3J)10FHH6JLC?&0@GI"U
MGM`CGN5[5*6U7`6]U.=5;.7GML?$TJGHKH=^Q#`2EB4&7J#!D&?E&$`)3.4'
ME,#$JK*`6N(AV,`MHL^F$NNEUB2F("A=:BK5SB/3R@(>TX(1-3,1)[(S.[-U
M/#,2[^*82+,T3;,!-Q$4/7'-<NCQ6M,435$4T>QA*$HWY"P5,N_.=',502_/
M1,^K:J.L7H,:%F`,3,\8TL&S=!&TA$.+F.,,3*"N;B9G>(8&LH.,@$;WB.8$
M"D"#GE%IKJ__#SZ-&DWG=-#$U-9QR*2/^;($',EQ$^!S'/=`"_:`(R</%->L
M/@WP"8:/@U+-$JAA^YP!!`H@$B0BO&*'25;`UL+@LSX+_9@#LYS!'9P!"^"/
M(44A1V0@"[*`"Z(@(O\O+H)@1`V0/:UB`)N$=1CP(DSRX31`!F3@<2#013P)
M6$1A1G"T)6G)(S2P1R!P)@TG<S1@)R6N!8/41Z7K`NDM;91!(>E'&*`T2J?A
M297A_L!A!J/`XBR@*?/K=^!G*^-'4:(AI&3!*H<0*R>E>D3.*D.%Y?1-GU!E
MG\*'"9G0YDR*(1Z""B?B56HE"P<";[A0*Z\RZY).N'+C`Z+MQM8I_U24`%2L
M`3#7T.J6QPV)XB78(!#H4,AL`"KPL((6<RL^;<F:+%W<L2N\(@B0P#-5=559
M=0!$TRYTR31+$S4E!@D@;_$D+X9$4399<S9A<P5V0#.RZH=8L5CK##@U[XAD
M\37.ZC4P`Q7?`!M^85K3`1L*S66,869F1CKMJABO8PW&"#O-B&A48`\R[3O7
MPSO7`]1"K3S3)*9(C1NA;TNF#RU"!_J^I3XYDDW0C#$08P\VX=R88!-\``&^
MH$DV8`.0P`':4:<D"RK,8?LRJP`&8)<^@+V.A+VL!`E6X-;\0->DB`K>`+/>
M``LDH`-C5$@Z5"+O10M&U#S=-7788B)CX/\D%6`AG,MR5$D#;`F4-K"65B1)
M8X2Y6"1&0L1%;(F?G(LLH^1':1)*HH0E]X9$[@]*JW1*HU1*H71*N39KK?;^
ME`$<P.%'W(`-G/)W0$XJ"VSH1@+!AC"A1FI7-N5+TRG'$J&UGL54PM+"6,M.
M(9!5L(M/-4*CV,?E0*4+C6XE#H@-9,(FA*!9!B@D=H6==$S'^$`P;VPN4<(P
MD2X2$"#ZELS)I*(;L8(.G-%+;DKM=,K)$"L,4K5587=57_4?9/68:)4!46``
M?*P369,47W,V+0,V?=44UXPVKVHS2``WC36)>K-8R<K/MBKTAI,63>\&Y&%:
M56-:L8$XH$A;:2;_]KI(&'$F#VJ/9_8*]Y*Q`@S@!51@!9SQ&>&17;^$/^<(
ML;)"U)3O'&^@/<6-3<0Q(\UM$QP@'=5Q*@3X!FX`BF[@809P'#528!%V`W2W
M`97N2"0B!IC@?2^3LJ"B&)SA&);!'I'I5;"K<5Q)`3IL`_9Q_)[`#\X@]IA@
M##9@+5QVW.A`^O`W#^'SR@8@"B9!`6(4:&_T1EE$<8RX;9`8B<N@;8JXB552
MGQ`G1A#'WNS-)>%4`YWV1SG019!X0S@$:['6:\5XC+MVC*/T0A*A(6NI`W/D
M`W!@![WT4!1%%K"RC@D,*T,B)!+*G$X,?E*B33$G#;UG3K_'(^@44Q3`_U;T
MM$]/\N=8@@O-"2N)XG*$8"9V8`<VP``ZXB.XT'DJU\0JI<",<)X4H@3FL`ZA
M8E-%[64OZ`)`C<G4Q51-M=/<3E4EL@=B`)=UV9=T&9<_-`9F]WQD-7<E9H)W
M-_*HJC5W=39[M7B1^3YU"`=T@V+R@%AW$UF9]YHW[WF7]<\B)M!,(!VF]0DP
MP`:`Z!>P@8JR%?8:C1B]]5N1D=*(Q@#<]XV\(E1=*BOP@0RF8BKT-TNZA#*A
M0OI09W_!A4T&D)C88@`!]OGVP%>EJC[9Y`;"0!=IH1!6X$T0MF)ER7`2`I(^
M1"""#F\```G(Y7W[$+&>(!<PRP3V@((M=GV.Q/^57FE'<@DI]H"BQR\=R"`;
M#]`J-H&'>YA*2@D">7:YFEA%+.3>&(`A1:2I[^T'$D$4$H$HIQJ*!0)'D?:)
M58F*W^UM\*^2S-B,PUB,P[A*O]:IMVVM+5!G>Z0%%>"?8.`!T``JMU(5RLF.
M^])3FB&AK&&D="RATO1+K8>=+L<)PG+FP(>?;NXA\E2C+M;G9"PAW.>.P;!^
MQ#`&9")_+.I9^.`O';4O/UE1'DQS"[-RIZ4'`L&"0K<KQ,X`1?4"(,C5-J@=
M6PVQ0&TBY427C\F7NTMVN*`$)H$+H(D+LB"8=^XT41%W%W`'5/.91[%X'P^:
M)Z]XH;EX5P`(CO?RJEG_\[09FUW1B/A,K$BFO*FA`+#`]$R@%<SA%\C9G,TY
M>].A#82#"L`7.L1W.O!@`2"-K\I(]P1``.J9:>17^M0Q3?+7U.;5&L&"$-&$
M&PMAF%;@H9VO`+[Q80AVN`:6N!"`6)J$"0H@#%K8A0OA6II$=TN`QCXD*(3A
M!UI\E12@!%AV#\XN*CSM*\B/I:&#"80`F6+:X3C"E2[G<H9T29`"`?K5`8C)
M`G2[NR+N167DB-W-DZB\J3<I1:86WD($1_%-JEN2BK-\:E&$):JVK,?ZS,6X
M2M6\24<DC4?DWN!\C5,I`J/+`ULP<R('$*R$!`1`"1)E3,<TKR77CO^Z4D;*
M_Z\K)=$5BK"=IQD4XDT9`%CJ1V\)N2$X@G"Q2\1D;,1\9"CZ.M&)@G$TC!0V
MX@26Y=FDYY-!98\I9:1`9;`=!7YR#%1^`!"X#I4YV!+XV0!;^97E:-565Y4=
MP)>(';A+(+@9CD-/,*[92W(`(9A]*;DIV'918`&%0&&9N?&@FU>9V5='<7AU
M"&6H.3>]FWFW^16EEV0ZYJQJ8P'26V),`!N>X!<P0!&`"+ZSEQK^R/6@,SJ$
ML0"HHSJ[`%S%]3OXYP7<=^W.@DS^<%3[H!K/4_DH*,G1[!O]=\(1^$P(C0/T
M6=PH.H$MHTV"J:$!=AP#5H)U5X*G?9<,``G"("K\`/\?5D=%2P#/WTO/)7(B
MWPX!:AATGV(\I[&F_``6CL$$"H$).J<DUP=C3U@#`IDFB42S%S`*D$0&AKB(
M582YOAK+083*0:1O2.2KW:;KTT:3,NE)T3SMSUS-Z0=NU/K>FDN5N,VMZ_RM
M[YP%2TF[B/M#HR`2/&`:P/0+[1B//_W3]?BO_WK5Y7;D9)U2?@2Q306?$INU
M+#U)-H*]%/E66,612>KE\,F?DG`@2.'97J`C"*A3/GD(=RQSDZ=Z.-?6`^&!
M^%-T.1ZVU\6FTDZR$,O)PF`,8L>X&4Z[5G#XB7]V=RY69Y5S)&99;!6&\+.Z
MB?<^I5OZJ1OZ]V`'X*R'NGO_>;^;-X-SK&*19,X[O0.M$%HA'3BKG/%=->);
M-:@!D%P/.H91O_M[.["@AY)1!0Q``)@`(/Q8XD"00QB#8<+@2_C$DJ4^%RX\
M+,C!`;X;%QUHW,-QTYX56C[N\;CBH\8;*!W<L+CR1A@R9V`Z6($$"Q(@2'*.
M&2`D!HH2'Z0(E:`!`(,?2'\,P/=P(KX@6A!L0H!DC`4D%A`@T!(DB$9\8!4F
M+/B$8B6*?K`=.U``B!`#,3X$!:1`@MVZ;HIJR`N@KU\`,OHR*".*L&%EB!'_
M2*QL\6+&BAD[3CRYL67(TX0I$Y:9LS!AXCZ+'OW9$>G3J$=O7CT-LFO(9925
MF3T8_T"9OK?_^G7#N[<;!;\59!&>A0N7$B6BL.G!?,``!=.B1:.@BD(SZ\VR
M:]_>;)HU8=:^A_=NS3OY:=FL::\6K1H%"M+A-[/&H"@#!HGPW]^O%X`3-W9)
M00HI@$@A`2`2&&C7@OX9-<V#T^@'P($#DB(!`P^6QX`$I&B@`1_7N5=-,]ED
M0^*(\UGS@Q+6B`@??-)5,YXUB2@0B19T<-"')1)9\H1"%H51"41]5,)C1!=`
ME&0?-NSH4$59#*?`E,!52>656%[YSY9<=NDE<@:4$$,)<,5@ID\H\"0$$@4X
M4$`AA;CI9IQMUFFGFP78F:><>>:YP@XDH'#%$D*(``(&M__<@NBBBC;J***/
M)@HIHY0Z:FFBF&8*:::)+H`%"A6@8`(9Z?SRRQ.*8&`#!JJRVJJK&%!#33AM
M&$,%6PNL0`,-:^S0P*\DD(##%16<8``39X"%$5CX6*315P<UQ&0?"AETTD9:
MK+`)2"!YQ)&<>_0I4@$E`0$$`@Z<P8$?M/A!A0-,Y(3$!@/$((6'1ZG7W6?*
M'%4&`WUE@4083"9IR5D(,1O60@DE1,=!.5(D\<0$M;'6"D"8"910!M8UX80R
M2/!Q47V1;)1M]\7&`&(KBW+9RY%!5IG,EK66VF?-B);S:!0(DW/./?><LVDW
MB[99:Z\E'=O2_][FM&V`_<4;`+[_]89EE%P49QQR443!7'/.33"!!0I80X$L
MU:"]'G?9J8>>>7"7)[=YY7G'-GLO9C=-@_OM!X`&`/L'H`0*$"B@@*0(6!=1
M>8D,^%$_[`<@(!^<\($3/W1WWP_>X:O$-.Q-AZ*)V:$H]P_95".B=/&E2)\;
M/011BY%,/@DD/ASP6.1#22))I,$/51(&$E7[!MQOR&>)I9?,=VE`F#%`+V:9
M:`HA!!!O.D`GG7C>N>?W?88?_D=`7"&$H"3D`0LUC#;:_J3N1RK_IIAN"C^G
M]>-?`!:AHG``&7XPQR]8M:I7%?!5L$H4-;:1BR&@XQ@F.$`(%@")7:VA5PW`
M`@E6H+"+_S3K60[XEDO(P(%T/&DA3\'(#<YP@P*,2R-TZ@A-Z+6!>,EK`V,8
MPP:`X`"'G.4,>V#"&*JR$PG,R&?"*`-O%,"%'@S`*@CH"NXJ\00J6I$#E<@B
M12)&L2X29"P3@X4)"B'$,05E2D5QW-_6V!\VKI$!HGC,8V"6M#G.+&:MZ<QH
M?N:(ZPA#%GZ4A3!ZYHB@B89H1"N:9A:9--C(9C:T>5IN=$.UXF4I2E@SSG&Z
MQ@:O?6T`3@S;`,0VMK%9@&R98YLJLY,-\$#H09SCW"MGF2&[J1)%]S%*+AG@
M!*.XH9<+*ESB"E0@*2!H07;1@,CV$Z$)48X-0CB!!%C4#(#9Y?\^]&$`BU)'
M`1&M)W7:&<_GFN$BUD4C10^20"34@$6(/.0)9`"+18;4(R7Y+DE-<LB.GH"/
M'A0/>4LT7O*H%)SF&11,"(4>]5#`4#9M#X9UTI[WQ!?1/(7+A18%%`IPL%'U
M:2I^D8+?^^(W4OSA[WXFO<7^*A"J0I"J5$_`@"(.Z"J:PHI5F-J&3H=`BR$,
MH1CN<(<FCJ$)34CP`-H#(4>6NBV.H`0C+'0)09IUAEJ0@19G<*&\$``$)E#%
M7#KLB1F'HI?[E&`%//(A!_"A!210!0D3&"44M<(5KWR%60W#HEZ]R->^2LR*
M3WB".?P`Q`W$97$?6Z-?^L/8DJ%,&2[_BUED[`BS17Y&CSKKXQ\'*8O.4D"S
M?31-(A5YFM5HII&),0PDH29)2O[32@H`!"8UR84H)*<$/?#DUYH32E'&E91B
M.Z5PM3(!0,@2B3]CV]S*PSD,88AS*II&4B*'E%FJ1U_;H5%]C$*R-"(3$(E3
M'"D*=Z##(?-O?0,0&TX0"12\0`.9B]""G``X[_R@1>[I9C=5-Z+^AE-%G^.F
M>U@WHKH!P@+X&%(^!W*[,#RD#SN"<$24I+L>^=`!)=A-U8Z7/('"UJ#-^P!0
MR$3B,,%%3#X9P`9\D#T\\8E/WH.QN,3WD1V<[PHH2!\(5E&I'KM/I""EWT<E
ME;^4FI0:!6C`_PD$E0<R8".`IJHI`J?LJDR%XQ8ZW89/MUR,(;@#'4$U`;@B
M"D,WA:M[;1H7/DCH!S^T@0QDO&&]XO(!!4CA;_A*RH-."X`8!(%W.SJ+0N0)
MPF8IS&%A>%BB#>)7BB$,804Y2Q:S6$4C.42?EQ9L&/:P`38H8"^-#;5CVPC'
MF,WQ-:C9&<X^TS-9G*VSL.ZL(P"I6=*JYK2HC<TC(=G:2>KFGP.ETFRW9EO=
M[I:WSNG!;T<)7.!:P)3"S8H%HA*5'BC`*+*$T'=R5K>Z0<BY$8I0Y"*TG_SL
M9]ROM`;I]`8P@/WG/\$<IC''F[AZ'XZ\#"(9*=B`@O:>P`,:N*XUG?]P'^G*
MS6SZS:][5&DB#=V7G"]B'3I+D(G9/=@&EHCG5^B05MY-.")IG9:/J.B``;B!
M:BBO)&\DL&&`'@\X(&8>F>0R8A.3*7K50T))LE?10H"/HC.>\44Q%J@;Y\$*
MG*H4D8%,9)`.N>E&CGJB]@<J%.0A)NDHU:E2=5.;WG136=9I+MJPY;(/@0IQ
MBA,(TQQ$!*Q@!6Y'`!-PLH$-(,$!#0FL'VI1@+=6I0>/0]UW$),;-P`B.6QP
MSK29<NF12TS1#X,\!Q[6Z+Y*6J^3GO3!&C\M"0.O+.DX@P.08"^[*%;4W77C
M&VN6F#PJ`[.9;49HFT'KLW%6%H7$_=ED+_O_HID6M8DI#*]7^S2IJ;SE6))M
M%F1+VV(;^Y-.[.THF=WLZD,[VJ=$0%;@H`7N:\$";)B:+A.1[5J^4I;ZZ=O)
MVKU^76[N*-INV]Z\&^\"?0"\AS.F4(AI."G$ED.D\`'\-@;6$P,>P`#7M3?T
M]7"N8PWKD'#Z14ZJ0TX4V#;9=%^J\QX$UAV)$`E!P'$=]R/RA#ONY!`2@22]
M4X(^]`0W@``IYP8R<'(R*%``U6$*$'->0G,BMH,U1V)F(@1UQP0KL"<^]V+?
MXV(8=5$7-3XKP`E"@&.$L@!6P#Z*XF-,=S_TTSY2MX6<$@YYP#\M%1-MIG5<
M]W5F>"GAH%.TH&5F_U=V5-`F&N%"VN)50$`O/D&``\!0<0$4,>`#0P)A`X$/
M>R`O2#``=!%;@'`<N.4<5N%67'%7!%%%5;17E5>)CJ9%DKAYG-<43N(0@546
M"4%H!;`)AB4%)^=&J8>*I_<W_X(8I+$S.2-(UA%KM"AKO"<,B31:J+$:2L,8
MPS<;K`4UKH5\P4$<PZ9))5!;77-LR.9;OV5]U8=]TBB-V@<'6K$56A`5$V`@
MXN=^Y$=+TG4?YG8R>_$?RK1&\,9R)-,W\==,=U%>X$4YE",7]%B/]L@&'V``
M;,`&,2`$6/"/@?)>^A(A@-,BHC,?*<(>$.=-ZT"!U6`B#>=PX0%QYC0?;O\P
M!G4@+9=F$(8F)`;C>2F(3YT86`:Q!]>&<C)(-==6@ROW<LB#@UVB@_0(%#PH
M8G"!`D!H=TQP9C$6/MV#9DEH4>3B%H)B/E)(#4M'4D'6=$QW4ES(A507*E='
M!E3I!Z5B#JE2AF:80)D2=FQ(=F5W"";`+>="=^>S,<LD2SLS#>(@`0CP!#;0
M.S8@/`X`%5&!%=BX!W9E$0NA:`;!1988F)&6>9MG:9BV))B6:229,"&T"3F!
M`F-2`H<X:JJ7>JDX&"O#.4B$1-;Q:K$V:[JG>[QG&H*DBZG!BZ_!-,#H-,47
M-7T!;,&V?%BC-8K(-;D%?:"4F]-G?=37;,\VC<#_&9S#M7W=EXT64`)3<H@L
M]Q=]TS?F!C![03C2:1<`,C@%0B#4N8X8(C>)X$S#9(\SN8,R*8`"V(^1(`1C
M\(__N`$H8``:H`0%MA\MDG#AQ$T+N5^LI$KEH03Y8C:A(QW-\`X*D`E"\F`^
MPI$6P7%+\CN]TZ"9=J!DX`!98'PH*8,APY)6XP8PR27W!Y[B*1<&8),^47<[
MQ`1DYI/C@U$J&I3A@C%/R%!+((668H5,"75"!G4X^I1=F&0G$"HFH'=5B0U:
M-T!;6660@I19UE-M6'8FP!%(4`+P)0X_8QV>(5V14R.RI6Q[\`3N!&%%`FF*
MUC`YLFB3)YB51Y@1YJ4A__D[(0=A<=EX$!H&*S$5A0B9D^!_>`$8UZ8!G^98
M?JH7_P)'2/%ZJ]9JM/=9M`B:KJ:HFX6+JG::N-9(OQB,OO::QQ=04_(;F'2,
MBLA)S.@<H+J;T&A]PEFJIAIMUKA]=)6-6E!<QA1;=8$7(G.*S/D7\58X4R*=
M_U=,!3*=;P0A!S*/<L$&)8"/QDJ>R+J/.(D$3-"L2(">ZQE-E\,`\H=-`F8=
M$ZAN$@A.W>20%4@BX:$AV@0Z`]8ZL6-QM<-@8:$C$L&@2D)A/?*))80/`X!R
M@7%R]UI)+!>#F)H\&[HE02$4)2`%05&P.CAB9C(`6&`N;G<G?,*3*:JB2T@^
M@?^"8U>`!U-8A4M94BA5HSKZL5&)`H4`ESYB#@"4%MCP"ZM@*D3Z=9?BE0T$
MEF9W#)"P!PC`!7Y328<72G-55T&"14;2$$9R19!F%@11M%V$M(0Y)/HD8>ZT
MIG*Y(_AD"1CGB3Y2%AHW$U1AA[:E?WA:)0#P:=<F,GVJ6'"4F9H9&CK#69RE
MJ+A'BW\TFK9F-)(J&W:[FL#X:\`&6\-1'+29C+=UF[NEF[[%;+T)C;]Y?:>Z
MN(RKJJP:%9*)JX<(JW1Q(-.Y.,%DN75!;]?)J_-&3*\Z7BQW(.&)C_4(%,3*
MC^=Y$\V*$\TZ=QM@/0SU`1YP(?K"7.KF(BB"'?/9D`[_B:VE4X'7%1[Y<5_S
MR3KQ@)&YHSL#L59@@441T23VU*#OVB/I@+7#0TDO"!BPZ1O_^@]2P`4!2SGB
MZZ$W-Z+,6A*%L$(29802*Y0J6A)O1Y0,A0)'J71:R+$Y>J,?:V1(N3\GL&0%
MT`I4ZXE/T&9I00VKP&,\ED#M@Z3;T`;;H*1+>G9I%@A7<8VLVA7/<FA@!%B7
M![28-\(A3(F21FF6%F&\4V'36S!P^HEE01!D,&@?Y`";L"UOM1.0:4:3D*L2
M$#)4LQ>)14FB4!B.H1EJZS.`A*B)>C:Y-VMQ"UJVAIJIN6O$)XP:YF%7LJFT
MN4G*\7RY*7W/"%R'ZYN*V[C"_WG&C:M]UX@`WI>-Q44E=$$@A1./^@<(>)S'
M>'S'7JO']V?'\EB/^`=>(V:LC'@56>%W\B*$)<$$@=!5S8H%/1&B``=?ZC8C
M\^E?,M*MN1L>)N)-$BB\KC,-_/DYVAHZB9`))-B)'!!/"\&N(.FN'Q>O)=3*
MF^!:EHJ2*/G#+%<EWSL77JM_!@L4T),F:Z)S!7`#Z<`!M8`/%3512FA10RB'
M;A$JH8*Q28F%0\:__)MT_<LIVT!U/8H]9W"]&&<#@94.*(L-"JS`OZ"Q]).&
M8==`%8P.9W`['81"B$9Y.0*87D1%)#S"E69%0WMI7LJ@2!*"91'##4-H03`2
M4^%W=?_G'&>"''=*)8%QDB(C`R93,O\"`*(`1W$D#H2Z:M<1:T[\F;M':[W7
M>XI$Q4KSBZNU&_RZ85/2MYQZ6\O(C-$'JLLVJJ2JQJ<DU*5*U-$&;48]C7"0
M%<5IG`*RQZ"KQ\2$Q^7Y1*"$CU/MH?<7@('<H3S(!I'P1%:1R!O<%=GB=LVJ
M!8R,,>8R=S9F.41AK>J1'B&R7YPLO!0@-Y\<O*;C;7,3.:8,<:K`!8%`!Y8F
M$:`8%O0DO4<RR]6+V,N<#A%*JWX1&"GWPQ4Z-;WQO?X'S/87OO9X<SRA8F,`
M!'N@S`<:!A)E)]$<E$/X$6\GR<2"8SR0L2-E/_*CE-_<O___BP4!C),;@`#)
M?+T.@7$'W&;8@`WKH\"QLBA("<%K2,$5[`<(0P=T4`O]7*;:[44'\<^7A\)5
MI(D/!K5OZHD2$XHU?,,YG(<Q$`4&X'^$,R54$Q@:8-FZT4:4A)E%K!A[)(NT
MZ)FUZ&J;Y=*F65K`)]-7_)K(=].;FC7'L4FX]7P][8Q`'8VEE,9#G>'2:$H7
M?M1%C7W7E]3#J7W4EHULP`7&E,=?'0,]P.*@FGU;015Q-0"1P.(QD+H?2I/$
M:B8]$-9/E'UUU15"/N1[D"U>];JP;4-`\(]O(04$9[P-EQT0&+S^.1_9(!TJ
MHB\H$D[D=A]*P#F?PP?;B5T]4`<6_]<4B3U%"-V@U'M/S;O,9T#9N]$7,6BI
MEO0;WPNZ'*/G*$YS8F+,SF%W!4`&<-D'/Q*'>B*4TQPN+4H^YU._&(N45W@I
M.5KINWT+LH(-;7"C7QC`2Y9B.G<#K1!8!>PC"`P+RRTKJGX+X2#/6L9`0P`"
M%=P&2/M%9CHQDE9IX?U@O_,[5>N)`-W*0#(3CEFG8W+1=Y$7P'&A0.RG&]U&
M)I,;_^(RCP$:K$9[L`;@GN5J*HU[MRA:4RRI"+Z:=J[%.6V;$DZX/TU*A@O4
MOQF<'*[A[X[4B2OO\"[O(2Y<'7[A_/[NU&B-"#``Q(H<B!=*IH2-0EZ7=>D5
M9GV7%K`3H/_$XSS.B'B9C4-^\1@/%45.EFB]`D*XY'5W/@8`<%!^R=I!GR@"
M.MV4'A0P`C+B'>L6GWCF'YN#?H$=H!;`3B9HWLR2.T0BM0D-<O<T8229#F%0
M`G(^YY8*Q"FYV?]J9[&5XOLGS`2;CPDK!"JF8DBP"3?0$$W"3]W3VBU*+B(Q
MOS@F*"B`!\6`E$M99%EH4N9PZ9AB#@50%4A@"1@0]U<6#H7@VP$<F080!3$P
M`*%.Z.=<.PC<!NL3#K.2AJ[.AA7\4VUPZ_\,M$V+@K,<ER('H1DQ%5Q[I_ZW
M<C)P;2&SG*1?WR5#W_:M^G]!&Y'U`Z$Q>_\=X+0/:XXZM_S"2*[_,:GDKK?\
MNL69E(S+:&R$2^&]6<;!%>_`&>_]KN'*/^_3R/P9KKC2S^_)7^$6CGW:9P$#
M<$I(4-89G_$+S_#A7_[F'_Y<$1(@<>2O^W8>_RG1(Q?WP@<3.2.E\QY;+B.I
M\Y!F`Q!WHC538LU:LW7-#$[3X,2)!(@:&#"P]N,'@T0_%KK1@J^2I3Z6;%CB
MP`$?OC"5^ERPL?+"A94V7KIT^?*EC2<<TG%`H0#`3Z`R@+J1X0:`T:)'W?A4
M\,_I4ZA1%4B96E4*("E9L7*1\J%$C!@H!@@9,&`#$B`("H1Y,O))+7P.'!28
M6V!/`;MY]ZPHL(()$"%7*J"X0F/9JEN)_Q7?PK#8,>/'D25/OA7NEA\U01S<
ML-38\JUM!;"<.&$`A8$2)3YD+6%@`))--\@\`=ERI*4G?JBU@=5FF^\V0]KD
M&D*\V)#C0Y0/`5'2^?.2E3A(IU[)NJ6/?;3#M-G=YDI+X7.:O.%@$Q`D96.4
MR))5P7L%$MQH,"H!@`(-]S4(!9K_Z'Z@?F*@#`9^$$69'Z811Q@&'7%$&`ID
MD27"""6T\$(,+W2DF0<9]/###Y411D1E2C31Q#)*+&/%%0$H8RBBW)!Q1O@4
MR`*0++C@HH0H>NSAQQX&"#+(L@:8P$@CCYQ@22:;7-*"":"4<LHHI8SR2BHM
MR'++*K>TTLLLK_\4$THGG43RR"+33!--):?4T@($X$1`"SKK#$*+(/+4<T\^
M^_3S3S_QO+-.0NE<00N_$``B+28:90(+(0P@Q0.(G-`H&VLPG6::!`]JIIIF
M0@WU(%#7H6"$@:R9YJ!L1DUDHOPTR(^/`E7EXZ($$V$CB%JRNR`\#L((`Q\.
M0'K)$NZ^FZF[FGX=#PF?`C0JP*-^,NI:I=R(:ENHXJM*@JNH"C=<K\`:0"RR
M-G@-K4T<F.V)W,(H9*Z[\N)KA;WZV@NPP2I8PH=BJ%FL,<H*-M@Q@6]).#%S
MR`BC%C_,24Q@RPX8S8`3UOO@@RS@RVJ2&`9`(#8RBAWI-I&>,&=E;';_RV4X
MY&)>3KDVIIO.NNL^`@FD[9!=J5EE:PNI)#+B,@\!)#90-X8H2IB$JO?H<\,^
M`"4H:C\`H_W)/Q<!$.7K'Q!49L$%&9S0$0LKE%#M##,41A9A.@1Q[A%'//'$
M%/-FL45I9UQJ*1MMS")''9OV$4@AU51R\3++=/--+K6L<G+)*X_\\BXI_Q++
M)LELG'$DU4QSR,1))[U()<>H$@DY$9BS4#P%!71VVF,?%';8YW1="R960*!1
MM!;%`@E(#9!"HHE65575:6B]2-5/HU<H^G6B&0%5A0Q2*!M.&9!5UHD86#7!
M\,,?HXY>D0V/)&%30I8[FI)5UKN0GMA)"RFH_]7_IZ2J-4H!&7%+@%*00'P(
M"#523`4K4N!*N<PE%K-,X"Q(0,!FR)`.>-6B/'BY2P?OM1>_\`L%A*%!.Q)&
M,,A`IC$$8V%B4'BPQUA&AI6I3!O"00V*T3`T&R"-`6+P@4E@Q5M+*:`42H""
M"0"!+F&8C4A0)AX,P&MEYH@8-;#1!BQB,1TZ"T\?6O(S[]#O5^*!%]&$9;1-
M;`()Z0&+T]XC`_S81P;^F0__`"!'K@%%%`3:XX'"%C9A-,-#S9`%VB;4-K:U
M#6UO"Z3<Z,8@$MU-DLK8&XNHY3<9O:=C@\M1"7;$H\,ACDBH8]SGG/2X-U%.
M<ZNT'"M;^<HPC>E)IO]D4I+.A#HUF4Y(0.)E+WUYNB2I#G)Q<MWK<"<[V@7J
M=K$[)J%T5\QB'BI13"`>%L:P`2%@$P42T(`25H6IY3$O?!H)%:A&E8UJ5*-Z
MW\">03`UJHD`(%;CU,BJ7L4````B$\02&FZ")2R5_.Q]R7H?T+H#+#\X@`O[
M`X!0A#(MHOAO1@+DEK<*>%%QO4=<@/B`#Q]8EG1)<(V;*`0^,!BO#=X%7W99
M`;Y:"H01HF`P/EA&,B3S0L?@]&`)$U@.9Q@.&?[4,ML(QS8*,8;2^-`K4+NH
M?+PU%2F$[`OMD@T':!,>F<3$-D^$%[Q:$L:;C%$\TB':/X<EER#L81.N2]K_
M`%`#-0WXA#YWE.=#^\.?`+UH0`P`6XFF,4@*O&UM;2-LAC:TH;@]DFZ11!$E
M*6E)OEW2;S7BI(X\"4I?)@Z7M.P<EB#WV51:SDVNQ-PK.;<Y,:76E+=<DV9-
M]TO8^C(*/9@M;7^IV21U24O0Q-V=?&L[X/ZVF<-])C0SX3HXR:EWOZ,F-H7P
M7!0(`04?D$@S-+6\\4W#FP61'J@R%;U3H2H:!F&5JAC@D.\QH"`+J0BM&`"(
M2/#*5_7[YW1BLJSX)<N@8\S)#4K@AA?I;UK6\I]2`$C1;5E4P1`Y(%2]$@6P
M1/A<8RG+!L:PQA4XP`]=]0,^.,C2EH+P+T*HP&!0_U#"A:T0AHOA*<(4-C$:
M!K4R0-W&C(%:U!L3=1L+P`+&?%B"JUCT/O(A,N"F\I77+/%=(JF-S[;*$I:H
M;WUC'<\_C5:`M:Y1/:G)RD4;:K7Z-)0^<]1?'O$I"KZ*31QE(R0ATU98.$OH
ML(U4+(@8*TF]M2C`=LS6W^!36<OVJ+8_PBTI.8M*T$+.E;H5+2L]FSG3<DZU
MJU52Z$17EAY,8$B;CNTO9_MI08=:U#X*)3!5-P;0\K:9@V+U<'-')V@:UW7'
M)::<`C&G1BD*"=*-0<;`@H(8D((BV0TG=JT!*E"URKK6,%4U*,!.5%5#><V8
M1B*<,#4).($!?-@4>57U*O\WQ-<!O0K)&*4SK&+-Q&=!"Z-!29*.,/1@P/N+
M:+6.DI0`(A@J%UWP4XNH`*]X-,+F"EF1U(7A&V`0-PG%RTI!N(>_R%2FA5G&
M"5?,XA>WN*>)D?&-:8SCC^L8%ML8.2QR08NC^OJ'0O2)U>P3'_U4R^4:D(,4
M0/8:(.RAI&0HF<*[N#YX.2P,Y0F"[]"SY:?!9SYR9?I1J"8#JMD10%Q#\]=,
MY*'#JF*PAXQS81GIR#I#TFZ2W.-C(=NWR?X9T*`<-*$W:THR(3K1<P\MW45;
M]]+*<I:TM"6;+OW:3L?VT[0%]:@-QR,>[>B3ETT-X@7=RS5-`-6[;9T6C.EJ
MS!?_-]8(H'7KY/1Y8C)7>)`ZC0%,;P`VE.9X!5+OM,G;*G-Z:E2?HH#U!!(-
M"FAO&@R0`"D^0(IL)R]3!U'5#]PPAB"H@5C9"8D_`1J__+HDJV`]%KS",`"?
M[)G>!(9Z)K6E[Z<0&>;QF5I\F@K5U!A@M@,/2\@@*`0)JN4,)[5$&.@5XI9&
MO`(G&$P7VG'#R6BQ%\NX&)NQ&/.XD,,QDEO`DH,%D^N-7(C`X:"%`@""`6BC
MU5BP`HJK`HHY.[(/?ON8#X"PD-D`D2JFMEH/IY&"]N@8^+BHJ:FK_;`:`)$G
MJ>N:`3$0-9L;#KF01.JZ"_FZL%NL25(1L^N:/;L6&E$[_\+YI,<3)<7YG"^Q
M.RJL0BNL.U6RDDG[G%M"DUPJ$DX+O%X:O,(SO!Y)O"A0O,O2$39L0S=\0\M*
MC5*+O%2CM6(B+LO+P\W;0]>!@V+JO&)*KCAY$R3X"R2X)NDR@(WYO8W!F-]#
MGDYY)^*SKNS1GFK(%&>SGNN)AE1A"%)0Q`^@%(E8KU8YB$0`@$C8`_L+@V+Q
M(G,KB93XJG6;/C"B/IL8"0X@`R0`!(9JJ*`H,"4$OZ<HOSN*(_*#"(MBC?13
M/Z9AOPL4"[$XBTTH@-G`"3^P/WW)/Y@Z`8GK@F6`!<40P(T;Q\J@&`3,,04L
MJI$+AY'CC9)SQ]W`H2FB(C*@A?\S.`,'8((QN$`@>X\"FIJEN`^@L`\QJZ.?
M($@"*Z`:8<$LF`0@XX))>,%YHRMJ88K_")`!*0-1L`@3^0$&83-#<@0*P9`?
MA+.W$22X&<*ZP3/'JJ2ND99LH:S*\B3#:3NW:RW'8;0KW$F>=+18XJPE82W1
MT24Q'$/;(K51<SS'*QPXA,,F'!PNX"2IK"RJ;$,Y'+0T.;7/JC7+X\,[W+P\
M+)0_A";0>Y-!I#S662/G`HN-F93>ZXJ.^@!NJ@AW$A5-V91NFP9E.S9-%*]H
MN,3=TX#><X'@HXCO6@@&8(-`P(=:<`#W\1GQ"!;[FHEFN2_\HK[Z(0,M*`%?
M9"ALD2C_`/H^870YB!!($+RC\BL@K/`*'D$-IH&P'B"X"2N+,0""%9"-KB*#
MN9"FB",-_ML!9P!'<O0I`_0XHD)'D2,Y&^H-6-B-<+@B:H`%;)C.Z4P'<^@J
M>,$-<P@6?'0`+6"C#SC&^:BCTR2P7MR:\\PCBCQ(BB2SO-*`JM/(L/&K#PFL
M0JJ0D@1""6&DE!S".RM"E]2^/C,RP6E"MH.\42J+4CHEG>1)!]U)2),TH+2T
M+PS#HCS*HS1#I6P:Q4O#IG3#'('*J1S1P5$`'-DD30J<3:I*)\1*!54=UJ&\
M6N.\6:M1&X63-0J$M"C$6]O#LD2`0*"\("7$0Y0N8%-$`H((_X@@!=_[/0DH
M$(WXKE&Q!O5BO00)E6S(!DWD1"[%+EB1B%LA/N*;!@`8`^4KC_0IMY`@*PZ`
MOG6#/ENT"9+@@#V(@9<\3_,,1F'\!VP#2/F(JSN**\'4J*Y0C<9KC:_X"@@C
MP8^"C4*X('BY1@?8B][D/Q1H@&\\1TT]1UA@QW#@#7:,SN9L3BO"(2M*!VJP
MSG3P@W1HU57U.3+Z)WS<`Z2Y0*J(0?[9CWG#FJTQ"O]03QL,U@#Y5?3\B1<A
M$!>1SXWT2!$9)$,ZI/S4S_WL3Y5<R;O)FY:,+&N9+,!9439T/`3%R<:IG`9]
M4'.EPBS<PJ!<U[_#M%VZ4#(T0T%#0__$^U"GC,H0)5$2Q1$5K9$:`1P_`]CW
M(-#!`81`XR4%E;QA`KW00ZY!7*-#'(,+LS")/0LL``(F^!T@#<1:2RX+8!VD
M<9U`(+TC_3W@XZ9L@P@/8%(IT+9+$951N8A[FHA)#"\NY43`-(CRB=+#K#8V
MJ*`;4`,'F`YCF;+QJ`ECX8[IFQ^PRDP'&``!_<6&PI:B\+X]_8<_Q8^E`\'Q
MI`]D'!?58$W40%0?6E2"$PLDN,V3>@+=W`LL`#;?W(%CL`)-[=228T>[=<!X
M;!D<PH9?6)E?>(+`#=RN(EP,<M5T*!EA@<5AB0NU0IH8Z)B)O,AIX9K)92A@
MM4&N\0\"61'_`PD;<1`1<1"D0)*S-Y-619(%0G($59BSQ;)6ELPS2\(K3)+)
MJ&2\)R2T!)7"TSI7WWW01RN3OKLT=[50V")#PDO*,S0<Q;/7-LQ7?-77J10<
M?ZW>?PU-[XL1&2F*JGTH;M6D@[U)U9F`&%W8A_W8-;*FYQJ+]6T_%(B$Z)+8
MX4$/]+BU(*TUD.U1E]JU"$/22HD5P7Q+X).(;_H4[Z)2]YJ('\C2=-K$F[U$
M;S(()5`O=P(G54%%-;B!&YB7Z6@)R,2.Z\"O@>(.]8G3F6!;?!B`.SU/;-%3
M801(^@#4&*:KTB34'&$@K_B`'6'-QD.-LOTULTC;&Y`'W'@+!T`"_Q0@C;#8
M`6.P@N%XXG8D5=U8&97)SI.Y8IS(XK:`%T5X@BYN59X;.@?(DRQCH_6@"OG`
M4VJI034FUF*5I\[U(Q'YJ[()K-4]7=1MFY-$++![)``U.Y=$N]!D0LOB@MS5
M77'M++G;2KL[R]_MR;@37G9M5WA-7GDU9$.FR0\E'$Z.7NDMT16UWNHULK_!
M).V-$>[U1?Z0@0!K$59690-[CT!C`[=;DLE+2XD%*?AEW^<B"[*`Q@MDOX&+
MWVLBGC7"V$19%!W%6`38"P0X4E"D%&X*'UE14E(@((GP%'-2B/)1X$GTRVJP
MGK_DE(-0'G=RI]U3`$AP@$(H@"#@IY_QHO_FHXWOD`D2AA^F!2M@"0,DP*M>
MM*MJ"<VKO2.HHV$:[EH#4B`&8L&N6&@@VYA#3;\>,9>S6`%(A9<;"`*ZN`%6
MK.+KO$ZONJK;P.*329FN`F,RT.!Y68$L4Q=^9(_VJ-[^`0I\ZER^0E8-*(/-
M[0_-[6D7F0CY]*NRB1M14=T\!L(]5DD26<FQ,\*]66$E'&1-FLD#A4+1@;LK
M'$2M9F3*>V0K5-=:\L*A?%?!L^3E75[$\Z1[U1$1_61.4E$7%.6!!2"Z+F53
MUE[NW=X8L:-7+@-6KB3`UK,]JUKPW9':<JT88(,28`/75+EA/A=?%H(Q4-_$
M5D358&S5`.)>SB;_B26>R9Z@WW$I(6#LC4E2)P`?:GZ(WAO@!2ZG=**V\%DO
M5FD&"C!@"@AGW--9;Y-$\@HWN=`7?@H/$L:.<ON.[5!:?)8??7X"?KY</H,H
M[\TW8:3A@G8YZD9&0N6*K5AHKN"*]L@*96S$*/`ALYC&"[($/TAOJZ*-DGXB
M)L.-(JZR,_IM9UZC?0QFIGFKCG$J\P0*`<V/FMXK9,4G?"HSO=)(!A";L-D4
M$$%)-XO6H^800>KCU_W/E@1D[5/"3)))J'2\MBNT!662NZ.[&15$LTPUGG3D
MK_:<QA'*"O6T'RG#4*/)U+#7$(U*3Y9>Z@T<N:;KNIYK&M%K5!;RO.[,_X;R
M:Q;YZ\!>\B5WD>@N[!KG`HX2%PF@%'&!R[A$/8$+BP$8GFN*A!]:1#%O1"!^
MW\VFV,DN1`1H*2181"954D@L'R7MO;FDO=M6B!^88'*>;6L8+]K#[4NDR[HD
MK]T#A$!@*2;8`X\HVE]IOJ1M]+#*+WN.T\A$@"P($(>"25^<+`"XVC^-08(,
M]?_`-H5>Z.W685./2JSX[BP`(J?Y"A0``I+9L`NB/Z!CVUP4EALP&KEX7+8Z
M1/70F.]FBNZ[R#+C:3P=D*K+2([DJS^:!K_Z*P]179'<.JX[ZOV4\,3R3]AM
M+-E=X0%-44";99M,T-Q2Y')EY!G=ZJ[V6(]5\?]V/U>PGN2QAO$,';5,7D.U
M!M$<U]<=[_$?#]C:)0H`JEJ]EH'NW>M,9^6_5G(F?_B]H20BD-U*<BA3_E-9
MD2?OP2<`#F!PD8)KWAC&]J%(R";)!K:VS(K?.R#?8VQA_N41*GD+0P(=_3T/
M,.V&&$7MHN8YUS9T^O/L:9Y.H41THHC:SL2_W.V>M08W8`-*;115U!GM@,R0
M@+[X>=-E,6'[V<RH-?)JX0\7!C^#M@^#%/6GVBA3OXKVV&[P7OOOQHK5A/6T
M_>U)W6A\*(]>]W4MN\"F`;*XOJ@Y^DQA+=98>>-A!8`"WZN-1)!$.!%I9Q!!
MDG"2M/:C%BRSJ5:QFR3_BC]6M"/0`NVD%J5EA-U=QQGQ$Y=1AC7Q=T=]=S]+
MUX_W*^2L^Z[WX[WW&>_[?7_#MOYD@/=Q@:]=.$KXO$;X(>?>5.:?8UT1AX=X
MYL=6Y[_P%<%PSD=\!18?B\B(;KZ(;O:>.V*PD/\`EQ^XC<$*<`&7D_WX1@S_
M&`#%162#L-@`)EB-\Y<5;:-9BX`5`%!M4M``3P$("M4H-&MFS=JT'],.%LS6
MS(F&==6:58MFL1I":]DT&IS&QTVD0$"08$&R)TPE2WTNK%1YP>6%F'ULL*RY
M\F;,G#IUKGS"(4@,`$*'$I7A1NC1I`K<*/CG]"G4J``D3!5*M:I5`&XTN)&@
M_T"!E"Q2`(GE4G:L6+)CI8`="Q:L6"E2)GV($N.N@1)V40P8<+?$)+E?F2Z5
MT-5-5Z)(AVH`P#5K8\6.A39F()0!@S*B1"G[H4S9-&'"FCEJ)JL@!5G"4LN2
MQ?IUZ]BR9\MV=%J8:M&Z=^]6)LSWY^#*R@0G7N8X<J))$2/^FD5!EBQ<INN-
MTL-ZC^S9^W(?,.$[^.\6)E@H;[X\`@OI$;!GK[Z]>O5PUL>GGSZ^^?OX]Y_O
M[]]\>."-\5UWW/70EW8))FA=%`TZ&$4)>D7(10G3F66A6=%IN&%T7WGX(8B#
M+868#$N5:)0;)Z:8(HHK&O7B43((508`9<A`(W(YZO^X(X\[#F?<<,,18=R0
M0B9"1)!E%*FDC@HU(\Y"44HY#954(D2E0EE:IH$&$DA`BEP?B#FFF')YZ:44
M5''IE11C@NDEEUUZ^4$,D2!Q`BEGQ@F`$PSPL9`U2F#&P)I?,F#-0(E6,Y$U
M#"C$D4$O.*&$0-E4I$XT&!VTJ1+3,"#!!Y$(L<$8)J%DB4J6U)3J3GW@I.I*
M,M6T$ZU//.'``)+)J)50N\:(E!M1"0M55HQ1AA55"GCU%5MK`1+66G$I\.RT
M;`'R5K,>"O8A6\QZZ!53$AC5J[A3R4`5NI-===1D[4:&F6:?>1;:;@619EIK
ML-&V+[^RF58:;P'K!IQPGQ'_E^2/R2FV'%.$01<==1!BIUV!WGD7H'CD];=>
M>QU[C,!\\KEG7WWXW4=?R>C]MW)YY`5H\005#W`@S0IFA]V##^I%88458@@Q
MAQQ"%Z*'A#7,'',HPMABBRYJ):.,-N)X8X]56^WC<0@3AZ220BJ#9'!@%RQV
M(LHDPN39QRU4D#5/VMN,,&UG5.644OXP**%RGNF!!%*`F:>:<`)@F1->\NVH
MEHUUZ7<,0@B19N$:Y$WHH];</2B7A4OP`T4"42`018UVVO9$&OPY4#.61C-"
M-`8Y=.7=H#8^1JDGI>3JJK'J!!-.-*E**_`L67+K&+L"X.M0,B:E%=+#.G]5
MNL<R_R9#8UXMZRVV:8%U[5O8AGB]]<I.I6RX`"A0E6%<-;;5452=*YEC9<`K
MBF>>B<,;W+BMMEJ^_?J_KR-489O1.$)@O"%8P;2VHQHM#&F$>8Z&,%2=B<VL
M.S'#F,LV5I^/=6P^(&./!T,&GQ&6;&3ET4+*4,:?E;D,/!>SF,QJ9C,&72=G
M$IN0SWZ6(:%UZ#DA:MA21D2B(;J(146$T?&@=CRI'8=J5ZO:D'3T(ZU1L6M`
M`MO!#C8VX8!-;%_[&A'*)B0&4*D@HRG(-%(WMRK]0`D_>&,;$7<W3UW.,H[A
MDF6VI+?`20`SGL+CVBA2D(E@9DZ1V$">XH0W!BAA4P<1%/_FNN2$'U2$`A:Y
M9#0L%\AJ3$,)G9M(,RP9#8)LZ@>-^A0@(C&`#0AA#+:;B:OZH"H;Q#(G.%D)
M35XUJ^#%Q!*5"`,2X+<\7JU(*UP)EO.$U:ZJ*&XRD3&,LKB%/6U1<YK1#%\T
M$V.5<W5%7.@Z%S@EHX'C,&`SY80C<.A5KWM1@'^N>>?__*<_TAA08`@L3I)T
MQ,"%,0^(SHD@=2)$0XI5[(+@&8]_1L9!!&@!A.T)X4(Y)D(1I@>%%569?O3#
MLI:-YV47C.',;':=F]D00CC$T'2DLT,>#@U$1A-BTH:H-"(NK5=+9.`3<\HC
MKV4-2%<DTM:V)IPC;9&+G_%B`HW_&K8D.2EU!HE;-J81U2A=B6YTNY+E8%?'
M10YJ<,WLD@82XJBV.60B`_D<*)M1R!-(`(^'.HB?#L4VA!P*;X4[E"@Q.<I-
M#=(@J`'=HE@WD=<-2@*`B,$8A("",03A5+BSR4MX4I-<0I:7M!I>&!!@O.0-
MA5V>;5$RE;F594;FF5GY"IN(IMION=1Z3.D2]10CKLBX2W[E=!1GZ@<:=8YF
M?^W\7&Q8$\]^Z2\W]>S-;WXCG"SF,T?*Z:<__ZG2"DF,#1/;SH$*9%#QG(=D
M$6U/0QGZP?"2ESWAA0,*+?K=]Y1P/QKU#P8_"E*1WJR&#JK.SB:DPZ!MJ*4_
M#")S%#!3_QC)]%?'ZY6-:M1$G>XHBCWU*16YQE.O8?&H2]VB%\6&U*0J`QS!
M\;"'N5@V))'1&G%SFXFCFA$5B^,@@%+QW%R<D4W1#8YWVRIF!O>G0+[-7@(9
M9:::,0T-/`HS!CF(*1=%$(QXQ".1)&.B?FP1@YC2<TJNB)"K?!&V>8I0I$"L
M$!"KA5K<3I:1==7O>AG9,\\*)Y:-B4^TH)C-+H:8_0RM5&A[QV.5=BO1[!Y;
M^O;G/V,3M>0#EU=X-90\UB@S\M.,9X*37/R51C7#'2YN5$//XXH&.,HM&(3U
M2:,&-L=A$%0IA;C@(#;8K*`7.^A_.*B%6=.ZH;:F-<AFG6N/H?]WUQ90;P<;
M6A\1FFRC`.HH@>1;(!EJAX8E-6F$>K9?_@[-AQ]ZJ0./N*("*W%73'0B@QV,
MG"GV=$E?%"J2TOTUHE[8PE]\MU(WS.$.T_LS(`XQ.$!,[Q!;N`R)8,!H'"(.
M@[18JGY-X^N<FO"%NTYN&]D(H*B:D"F]$4N0LA?$36ROBF`2L$=&#9"#/&,G
M1Z[$;0OEE)60"&N(TG,4^",#FG%)1G79L&S8``IB,`#;H0JRO]/=+2>[RS?+
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M`>M`1U<-N.`#?60DHBYB.4I>4B"J8(`;^O2#=8R?4?_VT@F,00P80"1H@6/!
MBDT`'9LA8$L,7:OLSD]D`?P(D_(PS],]Q3*1EC-MT_5$4[88VC4=!6V)0CEQ
M1FXIP_T(3`&5_P;`M%/_7%ILX`;`N%URS9O<'0=."1-T.4RU39=`U1=!]1W&
M()1Y(`%X"5X0:$$2*N'@-6$3BA=Z+9[B]9IY52%$;9#*L!"R*=OEA=3F,8A=
MW!>T15L.I11_09!_71N`9=NV+4TQ*1$3+5BX84VHO1NZ!0GN^9Z[Y9X>^AZ_
MV1N^Y=N]W=N^$9\AYILP$*(A)A#`L8V098,P))Q3V<OS19]#7&+T0=_S49_U
M;83UR5A&3"*220`;H$`D1$(,?$#,<=PE8<HH)4HTN"+KK,XK@E*CX%';U%\U
MX-66J56?R(W,31E<>0D;A!D!:@$=/($L!9WNR`H#KEDSOIDLW4H)P/^/ZA43
M8MS9!?Z#L72=!J+/5!R&L31:O'2&<(B=:/"6:+1@IKU@#,+3O@A0_M33/270
M#<[=/CU7@#6'<TP+0$5;@[1:@0Q("W540BG>K"5A$"@D$RKD0C+D0BKA$CHA
M11:>XHG7QU!4RIQ'!H5'7UC>LE70@M10#-B00$F;SX3>2O50M;F4B#B0@"$-
M$NV*$@T%CMSD$\&>[$'8N7T1'_8>'_9A'WJ#O14E40JB(AYB\0&?AR4B(H*#
M,!!E5":B,,!#(OJ&5$+E(H98(OQ`5#U)BE6B0TPB)H[E6/:8)6)<]&VB\RG<
M0F3<Q;G8W6B.!#@!`*21^,7B^%W2^=&B7J'_7RV.GR510"Z.7S,X!N=4@U<J
MV2@)&0.00BFF8@&>BDJXF9NI60.JRN_0!-'UTJWDRM(A106F"*\LQ39R(VWI
MV:)=!@.)@ORX)OUP!MA]AC"HHS``3"C91K\(5VNL8V_=)@WVX3WF(ZD%V-T]
M#"#PC-Z-%-\)X00@`:R=!Q)`'N+1&D-*Y$-&9'8V9$)*)'=6I.!=9.)U#'ME
MU'\$R(#`4!<J"!@Z2$DVB(1$&X6H%-"PE+6YI.FER(BXX8'59(W<R!*U7HZ(
MFY!`F+FIFX:UFU#JH5(*(E,JHC?\QB)&*/!1:(2"`SQ0*%5J*#A<*%5JY8:*
MAE:":(?!`_&=XR,B_]PD9B)99B(FLFA92E];`N/TI<[#O<Y&8)Q<DI%820Y>
MZI7YJ<,(?`/Z%6F1$JGGF%\KSF(SU"6/6D[G"%(S)(("G``*G`"=(``=W`YD
M1>-+X-*J5%9GOL03X$.NT-F!+0_#(,9I&DMFO&D9_$"\F*!N@8:=UF:]B`;<
M_!:_"-<`61K<M)W`0&4]XI-/B1IQ%B<_MI1:4`>%2(Q=*$C%$.3?%6%^--[@
M.61V;JIV/F1#0B1$,F%W4N1%DB?*O!>`0&>RJ6=(LB=)-DA)2HA)Y9V%A%YT
MA`4:WB=^C@A,S11ITAE-3HV`YDC"($Q/!DE0REOO,>AG>,,@+N568F53.O]K
M5!+J4U)EAWWHAH*HAX*HMHI&A$XEMVJKM0:?0E!)5'WER9WEB[:HB[Z-6;HK
M)K(EO<ZH&ITE6CHFC_H8D-*BD1HID>[ED@*F7PI#5_B)0OQ)7QD$`'S9`$H!
M&P3"`3K@3B`@+5W`Q<:*EP*/+.%#,+&+33&=FIH/,EW@:\[I;-ZI;QA0_MP+
M#/:FH!K0RMJCV307#M*=#K+AAT`06024WD4!JP4A=US0@!!A?QCAQ]3:$G(J
MTS:MIVIG=X;J=8(G1IKJ"G%D"Z6GS/2%SKFJ>\+G#<EGJMGJ2H9%2]TG$.6G
M3+[A\1C8C"P1N`TKN>&A4-UA@L+;@A8,B!WELSK_J/!1*/%U:R)R*-_Z1H=*
MJ.""Z(B*J+:&*U2&*U4RKN.*ZX<NI;R@JXK&*XR^:[N^:(RRJXQR!%O.Z[W*
MJ/-)(C">7$$`*::@WS>LS@@(:?KM)?K)+B8U0QGDR>!@QJ/8"Y608@R@@`&T
MB04XEF72RF/=A,:.J<9:`C#19)V-"S8VSS9^1E?:J6WJJ6C\5CO*DZ5QF@TJ
M$-WA[`1F6Q#=G11<B')6A^8EB!`6K<:4QW3:1^15YZ<Z+?[FKW=V*G=.[436
M&@==+4(]YW>D)T@B"`+W0/O6U]?&)X2L;PFH9-"0GJZJ8:DU31'UITW5)(#&
MX;#N).W1WD_F;0(YZX,F_V7Q8>CC2BM6`A^X/N[C1JZ'ANL,,R[EWG`,3Z5N
M0*X.1RZXZ@944JX*U]MN08E80I]:,ER,5B(2YRN^'O'H^A6-FFZ\/A\%L`X:
MJ6Z__N5>6E+L#NF09DKK3,.SO)_W!=(T3$6="*]AC0$^W$[&!D]F8BQ+4-;&
M-F.L."\"#%/3V1ESD.QI!LQI5%IK_$L,LF"@^B8]<IB_54VB*D<VFF^(A$7/
M^BQ\9H?F5=#03L"`3.=T6L#\SF]YFI?28F?^GO(I;\)#JC+_3FUXAI?5?C)'
MN<R`:.U\M2\NMR=\QB<.I>1*0@<%JQ:V99NO:C!G10U.??!.&NL=YB$)<UA2
M&O^?AW%HB$ZN-<OP;GBH#@?QN$9N$/-P$-NP..]&#I?S#I,S$%<NX%ZNP45B
MC^&K(ZHH,*HE],5KC#JBYKX-6ZZEC)[E%!?FZDS$'*VN7A:I11`L)JG#-]BN
MO22"&[!!FI!1EDU<0DP%G2B6`7#%`-`!F3T6+S6@\LJ*+1&=+''`)AC8-38=
M!@>R"Y;=I@4GW!EJPB!J^;+AHGJ(6.1TSY!A@UB7`FLR=]1R_,JR0B5MU)JR
MTSK`0RHU*C<UIV*GJ`[>QZC')T\G`:NJ+7>A2"HP@[QG&(8M&4:;!&\(M*1A
MT9SUT3#-$:V>38V:!\LM3TJ8,V_8LB80OQF?L\(PH9+_JS??L.#2,#;W=3C[
M\#C;\.3>\`\GME_3(.2"<SIK9;V=ZS2T6#W#*UJ^CE09W+S:LR:Z*Q/CJ^>F
M98U^KB.>E902BD0'8^SR)1>S#I&FXS2X00E\`"!(SO))"0,`P@>P0>.<@`M8
M1@^H`0=40BU=)D_D,<::&66-J=$%P<@^35(TC5:8YC8>5Z$61]HXFG.-6DU+
MLFKE-*KQ=`EH1_MJ5R>31U5C%*9F*OXJM7L'P7L[P'LO)%,[=?ZJLA;@=WA.
M=7JD]W=@-1=>G@)C\E?#JAB28=[5)TOZ4`6?[TLZT$RU[02^[5L+*+DQ5]WB
M85V3<(-2<[@:[C:'>`VG,P^/__,W*_8YHSA@,S8-MG@]0:Y6KG-P5(F]Q$T9
MT;-:(L3`6<..XSAG1S$4(['#]7-;MNL4GV6B^"YFV&4:!>-!MV(LMJXZJ$)5
MN`%D?H`4^&CJI!&7HY*8Q$"68P8;U,%PN\3&CC2;&?<#BG1+<(`#V)GT/@WS
MD.R(G&8"B4+:\,@^<7=WPR31Y'0EBS>L*G#73BHG/Z>EBO)Z(R'3,K6CPS>D
MQS=]1_JFUK=]/^0>!($J;X)4\[<G@_)5'_H`C,'6BF0N&WB!CR%*AAY9@#?I
M<<]JK6%,M2%I@JS2`6@'PS5/9CB2R.:&"Z4TZ[550J55)FZ(*BYOE'@VNSBS
M-[NS/_^[`0EN<@7?9%<BE#!?92=QM6>V/X/N%&=NZ*H1/RMQD2/Q:*MNDC,9
MH7C)7:)<R%W20K_NE/Z;`GS`;&<YYS1$&B'$#QB6WQA`6S%`(@!"8W%IT#T@
M<L<Q`I+TK:"(HJGI'Z\(=9LL/DXX).^@@VO+Z(6%6>RTK([4`@/U1Q+D=(X!
M*,<'T@:>$S8ZI<LW?+LWS+>\S#\ZI5_Z'FS"'N0W`'N,$9Y\R1.PJ&\MS2QP
M21;]@\1J6'\>%Z2OJYLM&L9ZVD)X=/.Q-2;8!\\MAM.M,S_S[R$E4IKHX:KP
M7E-S-P]VP!SVBBL[M*\]V[OX#+A=#"_BY?:8E=S/$[_S(_+_.)=O;KGO>[@C
MG(G5*_5)L;R&NR1&J>^""B#HKE6=43.HPAC79FZS05Z$N;WL>&U.PYF`BI=@
M!B",&0?@SIFC>66*J66]BB7@0R1+^,CN(U.TJ3[NX$V#"%KDM(6$]:"7=W9U
MAU"G=U$'GOU&;:6__,O+M_$[0!T8?_(COWLG/WPOO_-+NO2G\D+B_"9P^LZ/
MS*=#9RVSJH$8B.9IGET8?1C&Y_IVO*VVNEL\?>G!U+9A([#JRG\J\X-5$<+L
M'M<7HC+D];0"A#)AX(3!&UCP8$)O!PD*6^A06,2'"B5&M'@18T:-&SEV%#;#
M(T:0&T&._!C1)$J2%B<2%`A.F;)$_\JF36N6K5E.:S5W9K.),R?0G,VL"<,Y
MS:?/H#>',K5&--O3;.*>4J6J=.I.ICB?2MU*U&E8KF"9#J70K-I0!A]B1&(#
M")`$!1+H`F"0Z$<B!G<!`"K!QH`$!C_&6BT*0((;"1^D2-#`0(*%,!PL]>ES
MX?+E"YLY;]:,V=(%&Q="?^YLVO,3?`K<R'#C!H!K`*U?UY[MAO4_W;MY]ZZM
M@#5PX<"E9#$.*`L7+B66ER@1Y6^4&#VF]^@Q`'OV"6,F(+'@W3L"\>*U("BO
MY;QY].B#M'<?Q`%\!_/IUZ\S_WY^!_?I\Z\??S[YX!L00`+?.S"(3?90<)--
MM'"PO/'$`__O.PNXXVZ`";+;\+KI!I!.NAA`C()$YTP\,8L24DRNN"P4R*(X
M!0`9CD;6<+.QMAQADTV&V0#X$4@@>RP#@#*,/!+)))-4QD@FG2S#R2=C@E(9
M(F*Z$LLLM;P2)F7`\0:<+P=29J&7$%JH(8((>DA-B#J:**0XY50IHY1.NK.D
M.T_*DT\Z][3(I#SI'(E0E>RT:$UAO*Q2&0:$:>JF:8J:5)BGRFH*IZ.RJ?2G
MH81:RAIQP)+4,*6>LJDG5"L5"ZQ,6;5FK+$L16NHM*8AQ8`8##@A!E[9B`&P
M#X0%)!$`%/C`@!(:8\"F:?8:K"9G`=!@L0\<8\"-2/#AH)+,,//_K#-P,>MC
M-,N^12W<<TE;S;;7?'3W-]QPZXU>WA1H40KEFC,Q"C:DHP[@`:[;<+OM*@Q/
MPO366W@]!-L#\+_Y\.D/OXKWB_B_^^2+3V.(!8QO0(<W">)!]#:1<#PD$$`"
M//`*QE###;&+H3H107S..>A.7&ZY2514T;@7I9"Q1N%N#$['I&7;,<BF@202
M:B65%$5)*:&\FE$JL;1RRZZYC*E+F-1<4R"#7*JH(303<O.BABZ"<\ZX]>R3
M3[K_[-//0N_&\\^][084\$`!-Q2C,!>M$B]8(9W&,%);A;2IKB2=7*A/=3(J
MU*@XM:8GJJ(E-=2NOI+U\5B3\LHK6H=*_X2NUC6@]G7$/D"!!-8_^(NQQX`2
M9B^[?IA&+\1(^<"#U]T`!)]:*ON6^73#M:RTTDYS?C-++`F#B]MR?!<V!;3/
MK=YZ<68#X.H$ECE#[I#HKL*542:/82WVD-]AC.WWSS\')K;?OOXC_MA`"%I0
MR=#SOI6Q#('?>5G!T+>AZ3R01#;3V8E,-`DN?,`XQX$1T8I6(WDEC7L]<MH(
MBR0#J!5):BEL4AFH9C4I14EK5^*:UVAHN#$]Q&P(2=-!V-2VC+A-;D&\2-T^
M4B@C]LUN@I*%WY;H"$<(2G!0Y-O>_,8W*?;M;0<Y7!D281-,\615C'O<I9:R
MJ5#51%2S@ARH//^WD]!192<\B5:H'H>Z5X6E*Y@#B^B:,HT?/&LO&K"+'W?"
M@,<``C`QR!U2^EB3W_V16@HX@12<L!<WJ($.W5)7\\3EF=&$1GJ=9)YF+G.]
M$K#&-1)8VFM8,QND*2!\]6K@A0P&G@F][SP+2]`>VL-+]Q3H?AG3G_[J,#%C
M2NQBP[S/Q/+WGXT]#)H.DQ^$#*@R!'IG#$A0GX9BAKX8G.^!U!F1!$UT0>;D
M*PO(00[17-1!HR$M::]9F@A%2,(BW5.%^622*%R(M2AI*88TI*%#PJ1#M"&*
M(5D4XD+K=+>2/-1O3[1($T$B"T<(8XD)6*)%9W!1CG[$HK+H*$95LM'_)RZQ
MHWP2Z9XD6D6\'5%04WSIVPPW)66H,2=S;$:SD-*I-8**)^+PZ4];-3G.3>YS
M<PQJ3^JX1Z=FZB=%20I4H&*IH\9Q+W1Y3$V:$0\%L*$$-`N,!@C3C+,,Y7,,
M$-XDK\6`((2A$LOSEO-,TX?HD8:3Z?K,]:(03]C`*T?!B26]QG`P"QA0/0SC
MI2\/!$S[[0^9Q[R89/FW/\CR#Y@A.Q"$J"DA:UYS?=ID8#<=.(!OAE-$J1U1
MB298SA:M4SA#Z^`'_3H;V=ASA&4P(3[SB20F80VX-J520`5:W,.%26P)%8B9
MSM8F(#X$3G!CJ$:2:$66?N2B*<TN23TJC),*_R,!V-5N2C<:7D=P](D2;2)&
MR0O>B*#TO-K]4TLONMT\=1>E+JVBG]H4$R)PT8N-=-P9)T5&2&GJ<T<AJJ=Z
M>M6>&A6I<:2C'5UE1]$U>*=1&>-0K$&!:!02,G$1I%K9\"M=68NL.$7K'R&C
M@!B\H*T6V-9<YTJ];\DUKZ*\<1AZ8"/O`58&B<&-L>0UV-[`+W[SZV40&.M8
M^D#VF%$FIC&+61_*[D?*5,9L`-\S,@)&R+,'1&!W1MM`%)C6M#0#D6IO!IT)
M-N=VY^1".F&4SMGB2$>W\1%N?T1/(J$0A;U=$@M9V$^;;DEK,S3N<6$RD$:?
MK4R*@DB;)JT1Z4YW3O]7+$E+3>I=[XXTO20UZ0PXBE[MCOJ\[F7O25F=TO!F
M%*.MAG6IORO2DY*:U'AZ8DI3RK<EZE=/6EP4E&P2C;/J9(YIG!Q5C&)@#D<J
MCJBR'.2Z<A4(_R#:T?Z<5DC7[595)553G=59*3`"6V7U`Z20@E]H1C-A;156
M`<YI3=1*+5VU=0!JH`PI;8P:NXHF-.7J=_7Z$(8!$-FOBG$-*X%C9-YH@62+
M_>7&K#S,+.MO?U6.[#`Y/N7_X*.9]M.L>T:FH)*][[/7O-``QI`AF9TVS303
MIVJ?T]H385!97$"G<8HSHW86C;9Y_BN?^_RC$QHIT%,S$M4([4(L#7?14?__
MFI<D;:;"(72'0,3(I3$]1)="5+XD!4EZ-QKK\8ITH[F6Q:MOG>I7=]36:%<[
MW$]-WO226M;?30#<,?IJ]\[Z[JDF]=OO3E+VDG3O,IWBI+OT7V%XV-A!42I1
MA%H3,Y(%<CCQG$]VPNRRN`I3T&YCA)/Z@]]-OL)?Z0FL*A6ZG3H5\F>UQ@BB
M011Z2\#$OXH$S1JC`4DM15+"B%;O-."&$Q#O,7UQ`!V>0.,</X\TI>0DOSE3
M2@X,(%X_7GCV;^3PW6#LXO@0O\6-*66+8]SC';\L_T8>\2^#.66@9=D8-K"=
M!F:G0S)/;6IK7B(*E@"#/D#G8&1&AF:#7L2=@@.>_[8'-G+K:8R.MWKKMYHN
MN+2&N*!.ZFH(;)I+TB*"N1+*;:*KZSH"IHI([#[MTP(/O3"J&>[.HC1*%<@N
MUS0*[^BNU#YMU$2*!L\K!FN0UM0.[<`KHT@M[61-"-E+HT`J[V9P"-U.U$#"
M[\(K"2OJ!/,KIGAHV'[@\:*!"\]JVY@MJ6YB5:8-J")L52)GC;B"\_Q(CMCP
M=P;C]$"'*IK*51CI5&YBJLSJV"SE+-SH)AB`%&)@#,9`"-S-]SP'>"Q)`OSB
M=DAA+JJ%+M1*`A``'S1IE&R,,VQ`^LP%7<!%,ZX'^_`L1U0)SP3+^_Z!_,9/
M%;-,_);)XRX.F42N0-YC0?_F9V%0!@C$#('H;P+J#T,:".;T+T3&Z?],1``#
M\#AB!+8\Z)V"3NCVC(2B)ND$C="HIH4L\)\R<-&JCALIS2`LPNHB0NM&,-,"
MYTY^K8EL307-+K[:4>U>;=3(*PC7#KOD+NU*K;S4SNPVJ@A]L._8R]9J<`G[
MD:/XCO`",O"^R^[:*[Q&:J56RKQZ+=C09%'^BT@2H1G4@0MW*@Q]0JDX!_0R
M+\,2C%/(B`RY`A&MX?0>B5E:D@UU*E:<2G'ND`R;H21G12O2HAE^8#$B80/H
M+P:DX$>.YR\B@>4&$2D+T0#F(MT<@UK&0-_J2L?T"I2FLL9(PQ*NS\<^Z,>R
M3SC_3A$551']Q*_\R)+\U,]BZH/+:-'D.BME=)%ENH.6[@_-3JO=UFRUBK$$
M?`89BV-H_')&W$DNG#'A^$R$HH8:K_&%HN0'L#%+B$L;NU$R/_`#GXL<Y6;6
M4K"CTBO4V(XA"=(1>I`?,0JEWB[N?A`?-2JC9"'NF+"C-`HV6_.D5'/5`A+M
M9,T?9=,V;VT'`S();U`*R^XW:VV\B/,$8TI-_.O/`$`@(F\G3H_S.!*,F"TD
M(07</-(FJ//S5`RM'"Q:\@(\G<7TXI!RGLH\12=3."6I"BPG*$`G$T$#V$((
MZ(\0!Q$)`@$!F$`+F"`_6>8G=R_=&$,"G``Q>N"MEJ?Z_S"Q,S3QWP2ND^8J
M*P<`.(@,X89,%!ON%%?Q_+0,L]0R0`YD#^9G?AP$Y>!2F];G)TE+"++CS.PR
MS?`R+__O=@0P7WIN1GQ.MFCD:.!)>^"%Z*(1T!`32:SQ:AHS)F;B`K5Q&Y=+
MTC@0TCQP;2Y3;NS$[SXJ(NLKUQRA&<K.U-`+OLI+U,"4'EFS[^)K3%\M`?+N
M-@>/[LZ+-5%M'G]S\&K3!W&MU'R0.-W1U&JM(=W13VUMU=JK'_5N4%AB3*;D
MSV1C*(3O<R(EJ>;P#M.P&9C-C7@B+$!%4K.!\Y[3]%KRCQ)1+^(P=+P-/8DB
MC+YS,.[B]"RE&F1O&A`#$&(`!?^P`(&`@#]7@#^9``DV0`@*$05.[`,`H3$`
MP`D`(1`JD:X4U%MP#/K`I3(X8`+@R<=Z5`$QU/LDR_S8#V3<(T1-9@_,(\SD
M+YNXPQ?O[YM:](%4B^9L+LYF%``'L.?NQ44"$^@6D`%C0P)^]`&/9!I5B$A%
M828"%H:4U+B:M`,C[6R8=!S%4:&D-"2RZZ+$*]0D"DM3C4Q1DT_YL09W<`:2
MT&-'4S6)4&/?5&19DPA54V/=]&)1-J1\<.U6EC55-C;13J/R5#;K-`BGT!U_
M4PA=#?$RBE`1LB3RRX>0JTJ,A)6XP`U0)<%^+ZF"2L.``O2L:J<VCZLN;RL4
MYZ>BPHW_WM#TV!"0/A7U2H<LUO`[]4*MTA9:N(K#_FA:)$`*A"579'4`>A4%
MA.!7Q:K=A&58Y6(,@L`2%92NJE(J12DKQT!>MI*59`!'%!`LM77D>`D];!%E
M4FX712M%S;4NVTU=282U]/)VI"#G_%)H$K`9X4G(]BQ?]35(CJZW_I4""7:@
MF)1VN1$<.Y!)'59*(98*/PH=12U,21-XQU1X3]--^RX?\1$?2?-D^5$UGY<U
M479F7Y9Z679FFY=ZH[=EWQ1ZX=%-]P[M7I9.338T45,>!?4U*VKO_)0A`U6]
M6BHEDO-HB<0UN&`"$,`-I(H-*>5IS:A2FBUU@,(PA(K;5D7%_\9"=3PECI2`
MD%H2;>W"+M9VP%C%5)]S^'H',MR@^&('+[X3;)F%Q0*)+J0@;H5%;MO-`/C6
M,5Q,"VJA$P7W,C01KZ8O0>T*6H'C-URC*UEI1Q^76YEL/4XF7.5/FWBQY>AR
M<SE77?N/70$0`&NTSD@W,'/TG>;"7O\J,5C7`8^.`?RU&@L-:V9"=I<K)KBQ
M=FL72F]W'(%H874W(K9+HC;3T\K.(?F.[^#4B58SUK1W-OGQ>*%W-6/P30>9
MD+4WI%3SCS66!LF4-DW6>F%6?$WV9<]+>AGY8@>Y9K6W8\-W\&@6"=>48U$3
MO.:.[-Q7:(?P!.^$(N?7E:(@"/!A#/\DP%&-0G.T+5I.I]D0N%.:)54HKZ<V
M+'76J%*C#9`$*?F>1515Q:I*KYCKC2X4@!3DHBX>XUF<!:E0U9`0PP/@%A#8
MHMW8P%KD(A*"@`,$=^#P*C2H9Z\X`'%Q>`'?N?M.43R$^("`0/[J#PD&()_I
M\LQB[B[93$1PIAB%)0L^8!*$-8J!P\ZHV(,&4\B$S%T0`QKU%>EZJXNEA@&<
M1&"O!#(%RHP_N@/E1"#<6$XBEM.\J[[>.`79L>[:D4M=L-7,=#9Q-C4-&7L-
M.7LK.68+F:>SMZ<+.395EI"AMV1?MF1%-C:)$.\N.:8O]H[!5]0(#T\[MDT%
M\I2'U[WL1&S_)K`V['<^!J"+)$7!L+-I)^SU+$6`H>(G_C>/@KG"A,(]CZVJ
M_"B$ZRV;U1:$/=B1F&7X@D>MIF6#6T<*AF=HZN)9.OASWO!9C'F$/X!7Q*H$
M)*`$CM5<S%F=KW*3T/GZ7.1&XH6'JQ663O&:?G)]5@X89\:?(8C-FMA$1!=&
MX!5'"S`!._NA_\I=>J0!M1B?(G#I+CI)1,&W&Y-JC'2%^$E)/WJD1_HBDMM@
MVYBD+R)B?Q?4WFN./6V1T2X&11.C!+E-=="H$=EE\32D^/BG91:GW52HWY22
M>5JG?3JG<9IE,9E[Y[MZWY0TIQ=EA1"H)1EE-SEDY]&[E=`?P;?M_V9MJH-V
MBMA$.74+-[*@![2`#O:@!+Q(F1GU49%*4Z5J*4SU*+2BIZ8*5:C-V3"E:YUE
ML8G5F/$:D#`X55G\1PCT;1%#+M:-L!TQ7ZD9#E<2;>L-L)W@6+RY+2(!`=0@
M<"U;G4,I7-(9,\(@6A.7ME[IL\'R_EHTS?QYYF)41I5E=.M,6&4D1AA:`3N[
M-B`:,89NZ'3;=96$`9CN2(C;2)%TG^`<:S(Z`Y$[I-/X`Z/TN3<BI?O<TPP/
MU4"M=T5-!L_KI%K68F&ZHU3!HAB=U1B=D"VVJ.,[>]-;OGNZO3-]J">=OH<:
MDV\ZIYEWIZEWO6<V3>.N9E6!P&DV[?YQ-_\WUB#[KJH)=0:#31R[A%]?(YTF
M@`/P`0D8@,,PYVGEB%([12@FQ?6:12FDC0Z?#2A:52=UXCE;/&VGQ=H%"8(%
MR;#_VIC?5I"<@+%E'&Y-F&]M?,3V8L?MXMS3EEJ$Y9L08`\JL;*-W'F0O(:=
M52O=67$[FT;`\K2H@W-AU&9NCN!I5.>08]U<A`#KU9T_*'5W)%]S6[<A4$C+
MP+=_>\U9*!$`%F"9Q$ACPK@S>N.5X0<*]HSM'"-R=\\U(F(Q(J4]K;MJC;MD
M,[N-4$YA\'AWV@;#=[P]G9!)T[TOO=/W&Z?A>^A_6NB/GKX?&=.5_N<)>:KE
M^ZBIMY-?'3@%<I/_G_")0OGOJ%!0DC,1_BLV;H0+>B"3'*`$+B4[AYUQ0(=Q
M6,^.!CAT/CS#L&+#=*(IXIK#XJA3>?S;B56#BR\2GP6P$2.P%8-8KQTQ[J6;
M2R!9@M7<!0."LSEV5EQV8@`)]B"3R.6%Z?W&GH^4>$S?/YOT'?<4US5G*.AV
M)F'U<0XP-PC,==2*'=Y'([[X@$3B^8Q(U*KBC23CJ>;WR\!(,YJ?Z%R,Q[AK
MH#1WF3LCE'OE7?[/31JE87Y+O6M+-[/ZB]`V[[@U$3UF!=EXB]K2C5ZH*]F\
MBQ[IF=Z]*?V]C9[H.SV^X__H-;V^I]?G@?ZZ`?(>K7Y]`4+6#&'"9L@B_R@K
M@4%'!H4E$":0X<&'!P<2)`A.F+*-93H"<*,@"Y<>=/I4"L(@6[.5V::Y?`G3
M&DR5UH19:R:N64V:S;+9;#9-9\]I/F\&W;GRILJ5/84VHU"-0M)I,G\PN,I`
M`P``$KA*4"`!ZU8`&MR0Y:I!@MJR;+M*<*-6RH</;.@:*#$7$%BU?`$X`7`5
M<&`-"B)IP5?)DN(^%QH[?@PY<F3&CQE39FPI#!<%G!6`].PFM&?0G17\.XTZ
MM6J\DSZ4D,(%MI0LLV<#HJU`KY32O#M_#0TW]-N/93^.-3LVN7+E90`T[P@]
M^H\RHLHH8U!=F?7MVKMO5);HN_CQ&\.#)X]>H_]Z@LHN7FR_WKW\^?3KSW=T
M$7]^88[P^R_H2#,0#2B+0`7.X(B!"1H448$+)NB@@0TNU&!"!28088$:7K@A
MAA9F*`N$'VHH8H<;GHBBAAZFR.*()J*XXHH<SJCBB3&^"&.-&S(X`X8^6@C1
MAP@>R"&&/1;HT$$1(=@0A@4E.0.31N)'$9,2/3F011F!`XXR1#0G`T@B]<!!
M'WUP@,134JT$4YLQN22.-3DI!91./Q$E5)Q`R7G3G'7RM!13@JY$`51)66-5
M(F*E18H4;_'UJ`1.N)%6<!IH]==?$J05%R!SL6%`#&S$0*H!=7V@UZ-::1"8
M$[D9ID8M3UA2R:R2W8K_*V245>98)0YT!E*PGPG+6;"FJ88L:EG<=EMNN`&R
MFP+1]O:59V\%9U9H7!FW7+?>.L=`=-&%VQ%VT$TW77?;I:O,#\J(@AYZ[IH7
MGGKMP7=O?/7!)TQ&]OT+\'X$_?<??P8?E"!_`BJI2L)*.J+*PTI"Y+##$SZH
MH)`B;HSCC2&2V"*+,N(8<LDZFHSRR322[**-'8O\XI`2?BBCATPJJ:1"$%4Y
M(40+#6FE054Z'/23%WFC3)?0B38F'8U5@@\`@[[T@YMMRD23,(#^-*?6>=)Y
ME->`LC1HV<U$=6A568'%MEQSH;H;I)M>>I96?L&EE@*-SE5"#*&2.L`8`PP0
M_\-<CFX*&%<*L#&`%FK044FMM9IIY@6[YHHYYAQLTMMHP'D^&F?)CL[9M)V'
M[CEPP$D@0U?9?@O[<\Z).RYTU567+G?671=O[QNY6]YW]@Z?+[_N3:,>\@3%
M$W#S].DWL,'^-8/?Q-8W+,O"_'T\),05.RBTA<U@B'V%!99_XI$H<SQRRBJ[
M#W_\\KL<<OLCUJRRQR,RJ../!GJ8I!KQ2$,%01+YC!0B@S1)00-1R$2&Y#.C
M#61+'`%3:$0R@#(QIA)(D-J:@#*-1%3-:G"2"5&4\I.BX"1/3;&32H*2M1<.
MI2<VB1-5J"*,LA6J&CI)!*2D0`JZE&!4ICH5M+ZBJO^S;"IO?%'`V_H&N#%@
M`0E4',,81(4JM;@!$&P(1!#P00<_1(X#'$B,#?I@"<M=+E=D#$,8RI2YQG!`
M"UDHS;"*11K4C2Y9>/S-M8BE+;.X3@,RL!OLNL4`Y\RN7.421;C,-1U'OHL!
MVOF!>=J%R>]<TG?BN23Q-%*\]\@GE,XKY;_T0S#JY9`A`6JE]AYVL^TU)$01
MPQ@$D80S5F;L?R+RD(=*=#+[U6]^Q"RF,5$FS!3A3YDLFY'_G$2DA`0)EQ9B
MD(]N)I&<[6R6"F&E`A.8L`<QR6C"\$8YO;0T,7%A`$YK3&8&P``*1(,"PG")
MNZA&0CG]B88WJ4F?FH(4H_#_<T\V,2'51'B5,C"@32NI1C34$8UF_&!5<9E+
MJ/Y&*E(9\7"JPIO<I.`V4,4@$D(8`Q*8@`"45G$`D1C<&+3@`#K4@HRU(N,3
M*H'&G*9Q5QN,W!C#X(`@"#4(:[Q59A``+-`9ZXZCV2.RL*6ZUAD'.5(])'.V
M\AS:U8XZMJ-.(LJ0N^Z8!U[`XZ0F@[>13X:2E/%!GO),"5?WH%)Z!%)8@.J*
M2U<Z#'O]X6O&L(<]!NT,1(3]V(8@!,P502B9[SNF8Q_K/L;FJ$7+=%'[5O0S
M#87O0R)2'S<KDC.!&`F:`AGLS8Z$304.+4ONH2`ZRQ`FSJR3`Y9K3!_V`(AF
MS!.$_RYIESU)>,)](@6&+BQNUOC4)DLFDBP@`81>P"(<`/R`*3R\86#XXK8/
MD`H%D4#!`%"043;@10J`0"(3?_BIC`IA`%1<P1[>"]\].""F,Z7I$\A81L58
M@G*6L1RMGH"/^<XW"`@HL`4.7(DX7B`,2*BC'1^\U,XX534`D,%6"&E5V"4R
MJPJ%#KD>61VP<E5=P4L$O.1EUO&81ZV?#!B_C!?7Y^V'8`:K,<*HITJ<9;9B
M$6,@T0CX,8AQ;T&&+3)E(8OD8X[,ETE>69/?M^3\T6_*TNS00E3!9/X!R7K:
MW/*!$@:T*ZV6(>3,2-*TTYR/A&2=.+7M!=!4!D']MFH_H/_SU>+D-7\V!88I
M_%,-#?H2L7"EN8`8XD@'Q[@Q3"`&;G")@*A[**MDI:+:C0$*2EK2P`DA$J4J
MP1'W8EY/972[[$6"%N3K@!N$H19AQ&]-;2JYQ?!*,4\`JA9N76`$6$#7%J!M
MYBR!#PLXF#<19NJQ)GR:#'=+=K3[<$<B*>+LB/@\O&L76#-I5GH);ZTLAC%[
MDE?/<+\UQ@&;JUXA0KV&-2S'!/+>+6E)9%T&B4$0FB:]9U;D:4KVR?Q.<C+M
MQV23^>_(!&>9,*/LS/O-#($QX]`W43L1":G6(3Y#8)(<HD!O5J2U_=K(ERI\
M02Y,@+8\Y0`"IBN5EX@P$=.HF@C_Z_PF?\9PGWSV)TP4M=PM<H$-D9A`(!``
M4S4$6*A[$*J`'8"``0`","/,X:#4=BD)D/<NEA;"!J1(122,80.<+EP)2"$M
M:4FA!*8:=4NEB("B.P`?^'`C&?V`7_S>%(V.N9QB.("/(-Q:"[E&`!)Z'<<^
MX&,,S<+C9_`(.M$A.]G+X3!T%"FN1W:8JY&D)'?&*IZRFG5>X^DVB_<%;G*+
M?F#-0)BZO5=+"`HY8]Z+$/8H)J%Y9PBQ!6\1,/N-^R8CG'X'9V;*`L[8RBJ\
ML0/\7XUNY*,@)5]'@^TFD20R\8GX3"+>A!A%L-2OCG_)(^H<>=W5B(\!/$5`
M![5DG<W?_W(WM62%P]TSH,/UD2V68``6\*(#ZA`&.M#4IQRH+W[U7PM`%02!
M,``E0"D,4#5.,14M=Q5I`5)TL5V7-@!"L%Y"`%Y8Y!H0."H9-8$F%0@K$`2I
MUG9N1((D2%/[-1GN9`D<0`8.@&L(``>ZIFL)]FOA-VQ)=4>')V&+]P]:Q4@^
M2"[1D1WA0F*\`SR4A&V<I&W;1CQIQ5:CU&+RP3RC9Q\'\6BMA%=!HH6YQ%?=
M(PN`E2"!%4VMAS[H0V5&EGMI"#_[AGML^#(M,S_"IS^]MS\#5WS9E``-$S[?
M%''?1'VJ%7$4MR0#PEH8T2]=LGUN$%LB1W+?YRL*P!0N(4+MLO]R#)`(+W=^
M;A(G-F0G-6%/B;`56\0X%J`%(0A&^T<KBI$8-W53/D4KE4!&M<!V#K`'@6`!
M5P0(9C%"2:$35)-(4?>`<S%JPTB,@+->)H4$:8=J;,>,;&>"B8&"W_<8EG!?
M8:!W0)=K"%94D6$)#M`#-TAL2A4Z/-B#DC=YC/1AMV-YO#-MX.$N[K([NY-B
MZ;%6R,-MQI,O]E@?R#.%5%@?`D(0]*0P=M5NL"1DU"<AK6<Q0$--JR<SA54C
MMZ>&$TF1%0F'DD6'P^1["C=`F)5PT<1P"1$^/$,QT0<T&#=]3#).A6A.7%)!
M9<`T7&`!;>9FC&%R#)!#]30="66)/6G_B9=(20C(<B[!)S9A$RX1+LW5`SZG
M!76`#[6`4V:B7ZDH.:P(BU:)7P%(@K.X!UJ`!(3#!GJQ%0M%E#:D-@WH%<%H
M=BPU@6UI1<A88*B6:FMW`\SH=I.#*YA!C61@:WQG8+KF:YC3C5&@%PYF+#B(
M>,>&;+8#25QU.USU521F'?1R8O*HA&CEA/92/-PV'_E2'\S3C_X(,#B&A0."
MA=:SA>#S,;`'>SH6AADR30(',A9)F[7I6#^R>TZFFP8G9<'T(I=U?-$$-!:'
M0`QY<=5$$7_H0*RT6BE)3N74<:\%<@H@DS3(4Y;#`3'```)B%>`"&!WV2-_9
MDR+4)N*@<A\!_P@]0']Z`$91*954F1A5*3FU<E^P&'=;.8L!-F![4&""TP.>
MQAECB7.5J$1?05[":(R!8U+(2$4I=6IR.5]UV78SE1B5HRNU95O5F'?8:&"`
MESDGP07+TAL1ACJ*MWBW8V*71V+A`2](6%::-X^=MYF>-SS?IH_NX6VB64IZ
M]4JK5'H$$F3T1F\]!F]?:%A!8H8O`DP<8YO\YH9-^EA/>H;_UILT$I(?R7"^
MQ#\)D$VX9#/<(UH#@9RI]8<5P1"L]1#8UR](`P[086&RA0`)=IV.X0"`0!#3
MD#C+!7_PIQR/A(`PUUN)I``]8`'LB5-GU`=G-)6+RJB+.BO4.)]9*?]3JT:I
MS+B?6F"+_ED"`$HI<)$;GF)H''B,#-IW3/"@1S>";D2A^[6-UZD8Z1`&`>:7
MF2"#@<E&03`;G?%<.LBK.[AXX;$[E`0O9/4NQ6J9*;9)WS$-F3FC[:&/-_IM
MGDD?H:FCS4.:[(::2G)+LD=D.`.F1EIO*,*D1B:14&JNYTI,3ZH_&TFEOCE9
M$&=\$:=9$L)PL12F">,DR=DC*7DE*CD@.L.2&(&('A$F;L`%6D"3CK%3EJ,%
M)<!REZA(R@9_7V6),$FH=0`YE:.Q.H5&C>JQ'_N*3]"*]IF5_<<!=$""*&NI
M045TN,9WMS9405!T[W5K\1541[=VSOA&D2/_:Y*Q4QI+:QS0E[GV1=L8&7/$
M+."(>(?IJ\A6K**0K.-QK+X3M6JE#/H82M`J2M[&C]4J>CAF5S^:/0%BA4HB
MMB%2>N5Z(@ERD.CJMG#86&_[MG)8I5,&G,,G-)M%$2+Y90WB,TLR2V$62P\1
M)626)8;;6ETBG6&2!5E`5&Y66Y=A<ES06\F1+89T2"#1`T%`!QD;N8JJ7QT[
ME;.RBE4ILM0(LOI5NE8)BR0;BV_$:EKI1FU'N\UHN\VX=CF;J@%87SQ+.7G9
M7Q>01D%+!OCP@H=AM)&!#PC0N)VC@R5JHDX;HS`Z'M2;5LO*K)^DM>`&8UWK
MM0'S:!=AA:L4MJZ4_ZWH1K864S(E0B%:-C]J*[>3%;_S>X;Q0[=6>B"X^9&;
MU;[9-)P&HEJ9M5I+,C%1`B`&3+AJ"ITNN7WQ1YT.8*$7:CEA@```T');\2AL
MXQD7MARA`0CKA+&7H4:4LU^C^VIQA\)R9U^U@KJI2Y6L6$9C1+*N:[*U,%,W
M;+(UG,/^YU.^&[R9TU_#2RM"2V!\Q[D*MF!(D+0A\;RHHX/D&*/H$;5,>+7W
M6*/K(:W'(PS4^KWV`9#"0$]WA877RJ-DBVY<EK8L4JYL6TLI,J[T>YMP+,?!
MYZXKLTQ7VI&"92$\XT`JPB/X*GT)U$U"PZ\JJ7$'S%J)W))(`QX=86%B4O\2
MD(NAD3MXY:)FI>%'PI$M7S$2$Z`'<!2Y%W!&PBN\M.:Z)1BKL4J[J,R"*'R5
M]+F*^O6HJOM?I5O+K3BRN.Q3NAPY-Y6*LF8#2'PKEH%&]W6-F1`$MIHK@C<!
M(?I<2;6TO0'%48R9,JH1R[JLH!2%^/)M[L$\SMK%I?3%-U8]Y8M78ALD"Y,]
M8PMD:'A8X@JN\0._<DS/]0PS&FG'+*,^ST0_ZN.E`+P@Q<D0H[5C#9229EJX
M#22F!_R<6](E;>K(%P1'(JQ&CP$U/9`X:O86SCL:6<`&A)H)"4O,:B3+KY;*
MN(NS*:V[J?I&*,R*5MG"+BS3BS&5HDO3H2S,><G_`2Y88,FL8'W@`&,@HN#8
MQ-+,@]1,'DUXM9YW+V_%S>&6HUP<SCE)$`!Y$`-)SCU*3Z9'MNF6OO.ZQK:'
M9/-LSV5MUE!&,L+'MS/"O_,:/CNS3>"4M]4G6G^;<0E]IF2V<8DL08N<-`U<
M8=399I=SG9:!#P9HN1O-&<^\V%%`J'K@-/V5J'J)J*IX7T*KRD<7@GNP"5K0
MV2O@V9O`V>^%JLUH@B[=RR_MRZG+L8J:4VJ$J!J;TS\--=AXQ('G``.P+$K+
MT:4QS4A]+]:<O2\&A>%FW!<!FEL\U?,A('?%;N4,W<U-OME*/5\((:6',]@M
M/_#[QO4LI6<]QU/*FW5;_TT<(A$(]"-'0F2GE4!V[;?7-V8)37$(C'V%N,!G
MUL`@$06_.\D_3!EA8`$EH`!JABVZFAL[1W]'?!D[)6M2B4:2@U^S.XO["5]\
MMP*YM@D8K@4K(-J;$`0%$(("9KNL['8M748B.RNS7-,W'<Q%E;RS/8UTX)<^
M'4>6L`<]$**[?3K0&[T3UCN@E-1-S;V?UU9%KMS(O=Q4[<4#6<[D?,YF;+;K
MO,X*B=VQN;[@#5G?C>6V&7`;F<]H722&%9)]/#0`G$!]^TT4\1`.)"6QE"5[
M71`)S-<$81%KJKANZ@99,``4S2O]?29!H'2YF!O.XES+\L$7&\DCG%.54\*E
M7/_"8]1&$JZ?%'YK%]YWV/BRH+T)HFUT:H>S`0;J=LG*0@MKLHRZ>HF"+P[C
MTTC!+QM3-:X%4:#C.WXZ@/#;XJ'-OI/K-.K4Q6T\4NVU`!F^5_C%JF3LI&>^
M!+(P9/QZ&E+E#N)7[QPR9+WEU6[M=?SE^U.'$K?'W1YF6`:2HG4QF36XQVFX
M06/05RWG]4T0+7F(Z#0666`!%AJ\_EUWOH(`F\$%4<`&CKVI7`#P;#`!6I#H
MEN':H.M?_$5KKWB?DJ[9,MN5"`#:&T[Q?GEK';[IH5UT1!=4!9#2H:[*;D=3
M]A6ZB;KJ2-P',IYKI1A'E8``GJ;C1`W-OGW4N+YM]'C_S4Q]I]TL;DA^Y$GN
M'L*.'\(.QJ2'$.4KMCAFMEUMW4U?W:MGY>Y#[1!)]==N]6Z[KG#;Y?B#0`CY
MI7P[UP;RMW"]G.0N?56"R(B[KWQMWPNLN-LG`S+`!0B`&9-<D\.\O#W`[SW`
M]WW_T3V0"75@G8K.JA6]L`O[GOQ'LF^DRI-.=(]/=*)]:J(]VJ=F^1U>=)P^
MLR$8XBL]@BE<H0TNR2<O&:U.JT`71Y/;N+S]8$:]>#<?W+$O'MBK\_#1ZUK\
M\\`>[%7-^U@X/57=Y%DXMNB<K:W7]-,4]6ZL_&I\]<T_M_+;KOW3S]W^,0$G
M)68^)>*NWOO*0`\TB/3=$(;,__;L;M\4!`[;!Y,EH`6AO$9\7AES9`%\'P51
M,`!]OY2<2Y,,/KRO37<`T>>"P($%^_2QE-!2)88-.83A0"=,&'P5\3FXZ$!C
M$`<</0;9`Q+D'I(A28+<%*3`2(X:-5:<R$'FS$H*+?6Q<4'G3IX]??[TV0>?
M%@0(+"#0`K1G&"1<`&5Y"DC!5*I5K4[]EU7K5J[*O'H5]C7L5['*PIXUF_;L
MM+-MS0H3QC8>7+K"YM;%FU?OWKS-X/IU!-BO,%EP`Q]NACAP85F)'3,F_-B1
M*EF5&4^N3(%PY<V6/7\&'5KT:-*E39]&G5KU:M:M7;^6E<"R[,JT:]_V+%OV
M#,^\9?_Y3L";MF]9CF+7WNR;\`Q'O)GS%A:\>?'GA1,0%@;]^8SHV;U[YQX>
MO#!OY(6!4X:>2)DR,@!$<7!0)T&"!7G6YTD'00_^`WH,&&`""^J@HQ*!#KHI
M0?D6/%`G2^P[4+Z;;$!HH86>8$@FB1Z::"*++LK(I8TZ\HC$$4M\"2:(9*H$
M0PQO:M`^I6:D4:BB;@P"/Z#PL8`+J+*8"LBKW+@**ZZ.U$JMLM!""RPEF32+
MK;:D;`NNN>9ZBR\MM\1K,+H&`TP8S;!C;`;'%'N,S&8:6VPRX\ALK+(W.;/,
M$0KJQ-,SXT[;$S8__P0T4$$''<TVW(X#S5#;%D7TM]MH@]3_4>IT<]2Y,G7C
M;;KJIILN.N?`X^XW3[-KCE3NQA/OU%/A`N>\])1A#P``>L`G0AGG,^B^GOK@
M`)],^)M`0`N"J,/`G01Z\""$E$4HUUSK@]:@91.J::&&')HI(@XI^K`BC+RU
MZ%N+(%J1(0N7I?!6&M=5JI(@B-+BJ"#8=6`,+GR,JDA]I4*RW[&<A)(L*-=R
M"ZZWI,Q2+BX79KA+,0U+3)@P"].LL,"@@XS--2-#+&,YZ61L3<8^Z].TD@E%
M.6655V8YM]D^8S11W(B3-%+?A,,Y-M^,8^XX2J5SCE/AENL4:$V;*_6ZY;*[
M+E54Q\NN/'#04X^]]GJ@XX('(=3U_UBE#JJD#BW@R,2"3+0HT&L8DVT01FD+
M2M997.D;"$$$$[S)0',QK"3;,"0"?"*).A0\6P[,K6E9==EE'"@.M"`JDZ+F
MU=&G(`;P$2H%A-3WJBSZ1?+))944G>"##8:+RBSM8OVNAE^OR\N_9I<X,&$<
MN9W,AS-6<S&.-P[9N,38I+BRX3<C[.26EV>^>>=7,Q3FT&*V;(:8AZ,4T9Y[
M+FZWX7[K5%+GKONMZ4F7GL&Y[9H+[[FGG7;Z.[J\H9J(1-ASHP<.;(UV;J\K
MUTG?Z$`'?-0!'Y785=V6A:!G=0U7#7Q@`OT7(;LEJ";7:@C?KJ5!<U6(:P!L
M7`@K,12BX/_(:T#1`N8`P87-*4`JG;L*Z([TK]*1I89,B@OJ<G@>NB@,=C_\
M4NQL-\2(Z8Y-V$&3[X('/.#%J6/"FY/P/D:R*1;G>5?$8A9?0STN2D]FAP)C
MHWJ6O=O<C&>(BA3YK)<I-L:&:.!+7]),Y3[ND.]]4(.+JLHC-6^\*E8R&``"
MZ::C&$4+A'5CR$\:I"P%-I""%5R0C.AV0@<:<B`/4@@DUV8WK4DRA)]TG`-*
M:!0$Y&AQ.[&$%GJ0!7P!"4@OA.'F9-B5)OTK8`![$NK>LLL>UN4NK@,BP\`4
M1(G-KHB%.9,1C7@FX'&,=W&*C&609[PY@4QY6L1F-K7YLC"&L8O_G[&>]K(G
MG.K))CK'V=/-*E.=Y10FG$BSWG+4V)SK!`=]ZZOC=K(#OSO*CX?T4\_]RJ"`
M"3"PD/_CF@0/&10%*HA9$JI;W:R5.`9%,D:G!*4$*9E1C@:%A*-$RD(O4`DD
ML.%>KH1E+%VH@%EN92P#2XO`2L>6U4V)5;W\93"#.::ZX,YB?BG,PY+(3#3Q
M3HDAR]B<DD<=D'6F,R6[YC:E.M5`1<]E7P0CHVQ#LYH]JGITVLUQ<N;5<X;*
M44)SHW;8YZE2X7,\3>NGJO`B-:IY93T`R((%!GG*_BV2HQ7:)+.T)E@8'6BB
M#'G"39QU48QVU+&/==R[;@0'HUA@?QL=_VD0>E`"+DC!*2U,:>>`U-(DP12F
M`*/IP*34JAVV5J>O%6(Q]6*QVQ$U8L]4IL:6J<0U"2]YTVQJ<*VH)ZH6U[BN
M^6:CE*NHK[[,9NL,Z\_6>9RRGA$[X=P>T*CC/NNXSXYQ!.\<[QB_58GGG_"8
MFC+64P8N:,&B$9P;8_<JTON`[:'W56!%&<DL:ETK(7+S*V,A.V!0<D"4D`.I
M!1#HN`%$@;,GC0KG5`H(TF;%EC?$)0YK:E,>IHYUK(4MPW"7.]D6$YETT4QB
M5'&8%2.1F3\MZN]8/&.@0J:W3`59GJIZ7!XOSZK*!3(WEWM5W&!JNFB<;G#*
M*%9I/HJ<9HVGSO_0&ASPZC.>='1G'?<Y7KJ4%RY[/(]Z8%6&'N0(67+KVB3A
MV[A'[O=9_+.H?OD+-L292[$,]2N!]:P4?+QKE$>Q@(+;-8`2//A'4PEMYYY2
MX7\XJ8:.-BV3$.;AF^;E2B'>DI<T;;NZ!+5VM;NMBP^36]VE";=&A1.GZD29
MZ::39WN**G&#W&-:$RIZS.VFD(?<FZN&DS#9\U[YQ!I6C$6WC>P,3M/H>=WG
MR#&\5N;RT_+X3V703[WL*7,G`^S)@_9US8I<K"/%O5_^O7F3:\.@@00[WSWO
MN0\'1G!1`,T!I7!@LYPM`2M=*"0)7P66C'ZIZ!Q]0X+1Y715FHL/?8G_:2WA
MKHBQDVW$S.1349NZMC%N3.]6_&(DKMB*.V/U9F!]9/%1<;B@B76M56Z:Y`(9
MUXT"MLZ$'/.9,YE2Z61,='V6'>H<+6A1OO)VX&H=IID*KNF+-M1F4![S@,/:
MX%CO`&H%P9]L35W>!B4(+5G(<G<]HLHZ[`4=ZF;,MINC8?#S*"47Z`7_Q-Z%
M+D&$G[+26/Z(T3$-.*1'AY;41DF'JM-+3JW$<&&.&&)T@3%V1)T[R"AFMZ'.
M6#*+X_&S>ARX'G?3R$2>*4FE?.6?9\W+LRH:JW)5R-C5GL^$71UA4XJ<UR5V
ML..YFZ(C'8[B1?JH^+E[I4_[O.F%%1&D?N9%_PJX60]4\U\1BO6M(W_YXY;6
MM)KE9@&;G<WPAI>\C=)VGU3BWO?RT>;FKE)$`USOM=P[P?UN\%ZVBDJ")SSL
M#.^8V8TZ\8T7:J@U,U3%;-Q-(J<\,Y*4Y/@X'.N,LU*G/J&>TO@QT-.F!12]
M7=NU2%$]X,@-"^2\0_F>=C*VM'(CHMN>4A$5H&F:H&NKMNH.\^(]+_,],$LO
MJ&./":"#]](Z_TFH/&,<1@*W&_2DQH*^/-NVLK.^3WH<!`.IRK(ZG^"`&'`P
M"!L_J>@WS_F<"L,[F:(AF<(P]@.\O&"M++FT^".\,!D,GKH_)+HX4BO#RR">
M[0FN,](\ST@>RCB9#/\TCI)IP)-I0`=D'@@DLM'3M:V:F22#KD;9DS1R%-EP
M!.DR)]>CIQ$<'S@J'T^Y/>U(P12$-M[#([GRAE/9HZGI(Z\H`\MJ&W$[(?SH
M'P>BD1$*@B#`!SK8'_G@P;WRP1G9-B#DMB$,H3X(`R.,-^U#@$-ZNP>;.\UY
M)=$J/RH\ORK,L"SDI2IA"_=C/]:I"RH!P[PP/+C@J=PIHOW#BZ`:M=Q)(G"L
MN#1\0P!\M<[S..7@-<P@'](0N3XTN5G30]AHP'KLPPB\GB*3%)AK+D:QE.E0
M,D=I)YP!2#KQ-3M2,H"TQ+4R0:0+CZ-+NM[S#A?LH_H!`$&+F^33*%-$J%S_
M1+M5;`D'<$5"JB1W8R@;%$)<[`E5Y,7)NA$'F)&W`[\?@<*J2+25RH(I)"TL
MQ"4;^HIIB)(LK)(-D\:$Z;"%JT;8"9-BXC1.(RJBL2W[N[C;0IK+L+S),P[,
M2\<<XQ0YI+Q?4[WIJ2)=&\MY!!31XT.RO#5>VT=UTL>PU+EP"BOP\2K7^PRF
M(;KR&1]Y6AHU,I6_U#*E6<$N&X_RX,2Z:)56`2CU`@`$,):XV9KJTS8`0T5V
MH0,M`$G,7$615#=9_""S.T64E,PAM`0"6D4C1(H2DI>LJ3<'>[#,$3^<E,T@
MH0H*0T8KY$G34C\=&A@=`B:D3,J\R$;:`9-OW+0S_Z2MGVJ\4%,BQGM'-AP9
M-CRCZ1B9R;-.NBS'CZ&-`V04!:3'S\M#K'HYM/0B;C)$)%,GZ3C$0R&GN51/
MC!FCH?G`[$J>O8S$]EDV[;"R\$!!\NHRIN/$\``SNGH5(G`#]YK,N/F:;PO-
MQN&`TP1)D&S%1"+)A%+)6;S0E>P(7H2<&T&*()C!F&S">Y&"N:M)ND.TJK"[
MV_3))K$AH&3&N%`+WIQ&WSR+A!N\WPQ.8NJI+ADQ,OP2BALB<&3.B,$=-UFQ
M9ELQ_[-*)*VFIVHC[#PG?L2QEWFJ>,RU/`S/E=E2L2Q/>_12M?0B"EP]070Y
MZJI`<V*RUF.RGT-`\M&4>O\JNN[HKCQBR/<9S,(\3.XPS)M2S/0B`@5`4%N4
M3,^\.@<5I7=15$5MQ</!KPIE%_J*U`REQ3Y35`[%3,ZD$0YP3:=H)="JS1:*
M3?&[.QMR49]4$A@-B[XK&+!`G=3ZN[V@1AW=4;Z0';X8DY^Z'568RG`\THM;
MTG/$F)'9$W/$3K0:0+`B&E932#$ERV<EO:E*KK6LN6KU)B]RRS/E1T4\Q'9:
M3[!4TV*SCG7B&>V:/7EJG]K3O69S2!64-A5DNJCATZ@QC_-X.O7B`C/K),A<
M4`O5%4GEB1'"3,U<5%8$G%;\&V-!LUT!V'9K6,<RL):$G`F%Q=9\3<]*47X3
MU13_%3^=;"E4+0N07<;3BK1H/!UH[$)I'#R5K55KA`M/JRT2^[0B$M*9';$T
M5#PW4;'PF:;-*U:0Z1G@JDXY4<?@VDY$F=)N:CGHB5;2F%9H]4,))$\SI=+O
MH;FYQ*Y%1#*[#*LII92!7+9+@;U482<MXT^'W*>V&DP!_<^ZD*L.6TSTR#8&
MN46%ZD@,K;K+S$P()=@(W<P9--2!,#",X#Y*/4F@>-A="8,Z(!%6%*Q-A3L(
MRTG9A*6:%))%8U%3%=F8\@H8!<I5U<U6C56]6!VS@+^6Y1*'PXL1BYB',\/$
MXS2+88YF>D/,0!I5@%,V^MGH%"[R:4?JI$[:@"I9.[FT_\0JI24RJUK`(`-3
M;3W>>_S#MT3/([-`0*P92ZF.G/F>['W/#TPV3_E>^P2O$[PR]E';2L3$PI17
M\UBZ>O5$X.N!^(`^OBH[=EL77AG82]U;"(U0C`#<-5/%("A<PYV/BB7-^P)8
M#B@TI_@18J1<?\L"*?#86=K<"E:&SR6=@(NT+&E&:#1=U`&FG/I"U'48NF#=
MOH"XFQ5'P_.IG54FBHM.I3JKV@6NY$`KZNR,3(F4SA`]XYA:YBW/7-/`(([:
MY1W/Y$5BEW'+<%K/MPPV;JW>E^&>@HQB$'2G3O&N[E"V=ET:]%W;N/*]^5D5
M%R2/]/"&":@5XIM,C;3!BTK<G?^HA/S5S/PMV#K&B%?T"3KH"'P@8$4R8$IM
M6`5>8`8VT8VE"LUY(:@H50OV2<_MW`M."U85.-YLQKQ8G2_445HEX1+#'9[Z
M42%B3EYM2J@,JI_"F-_RF#@,'QP6+J:R777$N9'1C<U04S&RUMA@->>]5B'6
MY5[>Y2&^Y22.'N`@9D&T6N_]-3<=H_7T74CDWF2NI_3YC?8QV_RTQ"U+UR_6
MQ/5M7WIE.H!Z033V*P7]ME)$7.=+1;ZMXSGV6X+ES!BQ!$NEMSZN+X6E9\8)
M@XO%EQ8JQLNE39I<9$9^T2K4X/3;8%UBG;?`DAIM'6G4Y$TNL=9=W<$891*K
MV>3<5:G_3(!T?%)9N,K+&%:PI,XH3=JE^L"A/4`\'%/DA4<M==:7;FEXA%H^
MQ%WG`B,+3#V['"Z<WEZQ:M8GRUT[&D$MA@XJHZ,['5]MUM,O&^.)_`ZI,0]K
MLX"LR4A2Y,BZ?>/YX%\YWNHZCM!6O#,]YHBLOM](99'$O3.5[`,Z&.3,><*-
M+4:ZP]R=%.C-A=&!D^30C<:ZV+`//DJZ.%V(-@R]N$83-N&EI"V>M1A>;;P5
MPPPXJ<_)@%.!I)/;=64YS)0D/3):SK%:1J,U&:>3H])>-F+HC6E@CMXBOBHR
M'3*>/L3VE+D.5+(W^EI<]EXV\MVB7B--N;(M@RN(?#8N2]]N_UZZ/8WJIHM;
M!`C1;4M"`%*SJ\[%/J-CKO9J=F;4PPD#$F%-LY.)T0P@1R7"RR)K=HGGBWV*
M5W*EE4IDG#SO@*YK5,7@5(UD@L[@O#8=OAX\OWYHP>91%"ZQ_T::%1;',OF_
M9PI!\-G*^@3IZ<S6&6ZR<X+P)<LY/,&UD3OBT?YE:@UFTY;`"61+,B4G80M+
MZMIHK1V.1$R]HJZ45UNC\YFGYZ`RM8UF[RA!I%9J\@+0;Q8/,#MN/E(&+:`W
M-;:D2:4D[\YC_>5J@IWN@J7CS9QGLZL$`AK@'<S%D53)..:L#VBE8:0[E*+-
MCG7O]R8+FG(T#,;@@#$M:NSK'0*Q:/^\M/VNQFL<,4X;;(L.DVO$6:2!/.>$
M)Z7*O,BF[#(IP*I<JFF:2^!*`.\4LD+<1Z2]C0-LKB+#:9Q&,GG$<'G$-4@A
M#C(*R/,\YB?#$W5D8NZ-[67>E+*-Q&F^XBKS[13\;6P6;E3I4]];%6^V=3YR
MND00X%J\E<J112-?ESA&<G7NVW9>U('%S*G+P8<`[QH9[QR\T#`@-/#SK)RT
MW"*1B@B3@C`7\T8NB\\%RG#'3=TL'3>_41I=63A'73JG';XXTA:#,2,UTI=U
M3H^6X6D*5@)/JJ"M97D:UPCO=[`2>&DB4T.IXJ5MVB3N<`_7-=,3G[FD7G%2
M/=FC>'1B8D3_+#:<\?>]W.WM@/'TH:-H3M=K!NY8?]M-)`\^+>[YJ5>H[D09
M,*51%/+*/-QR7A?IOM0E3_)A7U21%*$"$I<GOV=*M80@&-$M!]78'$:ID."Y
M_MAN'VA(#O>`.W.UR.L;:O/U6_.$=N@<A>CA;'=.`WLD8H[:,BHEA6$%)WM"
MIY,X5,.>92I5-LC=;>:3!AG;.,>N0M-]1,3:V/1;MMZ6TW#CO71NM;DD^[61
M(PYU$O5.OVVP_+44[*YIYIFS99I4<3:R-?GWF76G;MMO/FZG<SHWB(^9QSJ-
M<K[Q[A7]'?8E;_W3/*`0RN[^W>Z53.NA'S`>&>0(Z]BD5^^.=7H*_X9Z1KXP
MJ8=DJX_1&=4AM;B+#5-W_JYS+9GW43O2LH^\M*=+N8?W9H,C&4[25]O*@RQ`
M1_?L@0?++^*\@F?+JN5P7OYA8>8UKM5[Z1JNYZKX)^X>^(Q+<UHC@)CA:(:L
M&<(2')R!$"'!&0*%*6RH$*+!BA4A4L1X<:-&C,*\&?0F#"+(D25+?A0&+B4X
M;UGP];D04R;-F)8NT,2I<R?/GC-[`NU9"5^0(%JT&$V*-*E2IDB?(J7S,^C.
M/D2+%G7`(6B8KAPX5.ICJ<]4JF;/HDV[DP."*"6X?."2!5"6N0KL`E*@=VZ6
MNWGY<ODG>##APLH.(TZL>#%CQ-.$(8;\6/\9Y,J'+6.FK!DSY\HC/U,6%J_R
M:-&F5WY.K7HUZ]:N73M2'3NUHV8#8\L2EANWL-B^5?GN/7*W0(+"<R-'KANY
MP.2Z':E"6%`6=$<%!U(W+BO!=MW<O1^4)9Y[<N[FK6\7/UZ\=>X$TZM?_UX]
M>?CTU<^OKS^^^_OV$[SW'GD`WF?>=@29AR""!Z8'WG;803A=0]0QJ-!T"5EX
MD&[%$8@10PP-]!!'%FFXT4`=C5C2#"*1-%)%+((D$HP0K>1-2RI%`9--.=VT
M(TXQE576CSD-J5951$'5U%--*<E4)49>P($#6.%#1UA<39F5`_B$\=634((9
M9E"6(-!#"6?*11?_77JMV5=?>BF0EYIS25&8G80UEJ>>>D)VV#1^:G;99H)F
MYAEGE$TV4FBIE:9:HZ]!&FFDS42:FW"V"<<;;[MEBBETO3UTFVZC,G=;J<T9
M9]U#XI%Z$'`7GOJ=>J229]VK`JY74'T+ZII>??#MAZM__\4W;*[B\9KK@`4B
MVU]Z`:ZW''++0LN@>_UE*-U``([ZX8;<-@1@10455Q&`(=[F4$8CHM@12BNZ
M>-)'!LV;4DHRJF3C`%+5U.],0)HE9%5BZM0''4HNF7"32\($998Z"EQ5'QQ<
MA1566W+)P5@$<VQ6)1/$X-9;)?`U9YQPLEFRFW1E<:?+>\(<\Y^!*C-9_\U]
MXCQHH9L9JEIHB*HTTDJ/H6;::$5+FK32M%'*]*HCS:8IJ-BUZENJJ8XJJG/(
M09>`;;=.FW5S&[;W'GH;9@?L>NBAARIZT_U*7K7."FO?L^J]/9W:OC*K-]W6
MZIV?KPLF>'=_!!Z^H'?8$1A1N-Y%5!!$(!I'N4$,E:L1B>QRWFZ]+9H4TKTI
MP3OZ2N!8$`;`,_58I.M&1@RE)?@H7#O"1CWUI5H<8,6O6I8,9;'P03A0?/'X
M5`F66$/APT'L'?,T%!(]B,Q%"7.:W-=?<J[,EQ2!N6QGS..//[.@-.^<_L^%
M]JPH:XLN';_\D$8MC&T&S;:;I\,=1ZFHFCZ-4__/2=5UQF:IX%QG:\7)3:T(
M<B+V5"X^\^$/WN`C+6H-RT++ZA6QXH:?9@4.@WLS$`D9J+?I,`YN@7/$=]S#
MPFFMT#S=.I6&SO4XASB$6^!"U^6*@Z+.;41%)*$72NPEDA<1T21*K)$W$$`'
M?T&Q=:_K5\"(!*8^U"Y)1UF841SPO)Y<Q0%/A%(E#C:\,VH)8_C(DE:^R+&)
MX6,3%C"3R-["A335)7MY\8M=I`"8EH7/,.0;)*!F]J>9]2E0B51?^MXW$J()
MXS%!@^1(1G,TT\PODTFKC:4Z";5/2@V!4\,4I[0FMDTY:#G=@LBF&(>VYBB'
M5?=Q(+(8Q#=9P4=8!"+_EMU@.4%;`G,_\$'/KM0&.<!I1VZ#LV5[8`@M62%.
MA9&;W$1T]2V',+!<$S%.1#+"$`UY\X?MXDA'AABZ(\H+7C'Z#+Y$TA(M.(]'
M\B22&Z%GEJ)LT79:3)+OTM('?-8A#%<,`QH+6E"MV+,JEN!`&*9D@0&P(0IU
MM./W2N:7O_@E3BH#Q/<"*4A"@M0QBLD9H4K*2/2MSV>.9`W2'J7)E]+FDS+U
M9*>"(RJR30VGUSGE`C6T4ZOAICBMC&`$2]6KY9QM:^3Q3JXFN*``&<@_RK0;
M+S=80NI8]5@E)%P"<36A:TGS<"H,3WBX":%JLG*;WW1(B,R5.7!MQ"(G`J(Y
M_U=$+]*E1D:BFU$[6>*-(#S)1Q>0(NO\F="@U$$I^\0=[J!R%-VEA0-;#,(8
M86=&@YYQ*<+#!V0)MKR&:N&A`^@!:2-Z)C3A$7MW.1GVNM=1CPYFD#\(*6,.
M>;Y$GN]/)_5,2C=3&LJ,9E'!/0VC*@G3X\XFIL(`CDP?>)RL>:H9NV&NU(A#
MG'19K3?,Y5IR4!7+5'8'A=#2I2SIHZJW196JY-V;L)A:+;,%KI:(4U"%`"<=
M7#5NF?)U;WAE1=^$B(M!U^26Y*9IPXU\LX;K*M$XS<DBN\;K14.4%SI'UU>1
M..!*A068%*W(DY_4,TQ(6FP^'0N5$,O$`4=!BD#!1/]0S&)V24%HL6>#9X$)
M3&``HQTM]>IH/;JD=F5[.9GW^#(7\,'V'X,L`VT':1F=0?E0E4F42E<#O]0`
MU[C'W;+]A-/E^GE9@#8%%?]L&JJGX69_``R.?TTUP^4L4#NR`-L&C[J>J<Z9
M;G*+ZIY#J*P[`_J6?+-/,RFT+.XT$SMWXVJX[`Q6]P+(/0DA5[JRB5VUIE6N
M$9EKB"AR(LPU^"(J.N+G4#(CTKF3B'N]%Q%T!,6<K&Y(0D*QF"K1V-N5N+%'
M:5AD\QD$?%R1=S!&HV8MMA6K<#:R1$&`!2PP!F?K6,>D[4%$?<P%*;1V>]KC
M"Q^Q+1<DPY9\HFAR8\PWJ,C_B%214-:9^]C-[N$.%S3&11J7XQ>;IB7W,P?4
M=T[W+4I.`3Q3HQ*JB_@72P,Z4#L+G%;EM*/*!.KMX8=&+W54P1Z+%YH]\>D:
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MR.#L@Y4U%)D>E'\=MB=3TJ*NJV[U&7_1UE</]M<-6FP'7"`,9B>+4-9H%`0P
M&[,UVQA,``%*&X^Q00E43UP$66OEG<H`1M])X`128`5:X`5B8`9JX`9R8`=Z
MX`>"8`B*X`B28`F:X`FB8`JJX`JR8`NZX`O"8`S*X`S28`W:X`WB8`[JX`[R
G8`_ZX`\"81`*X1`281$:X1$B81(JX1(R81,ZX1-"811F8`)````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>f39432a9f3943217.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943217.gif
M1TE&.#EA40+K`.8``,;&QLK*RLC(R,#`P*:FIKJZNJZNKDU-3;Z^OKR\O$A(
M2+:VMD1$1*NKJ[.SLZ2DI+*RLK"PL(R,C*FIJ:*BHJJJJJ"@H+BXN`("`I24
ME(Z.CH2$A):6EIV=G9R<G)&1D9*2DHF)B9B8F$%!09J:FG9V=G1T=(*"@H:&
MAGIZ>HB(B'!P<",C(X"`@'AX>&YN;GU]?6MK:W)R<GY^?F9F9FEI:6AH:#T]
M/6)B8F1D9#DY.5]?7UU=75M;6UE961L;&S4U-5A86%145#`P,%)24E965BPL
M+!$1$5!04"DI*?[^_OW]_?S\_/O[^_KZ^OGY^?CX^/?W]_;V]O7U]?3T]//S
M\_+R\O#P\/'Q\>_O[^[N[NWM[>KJZNOKZ^GIZ>+BXN3DY.?GY^;FYNSL[.#@
MX./CX]O;V^CHZ-C8V-_?W^'AX</#P]/3T]S<W.7EY=;6UMW=W=34U-#0T,7%
MQ<[.SM[>WM?7U]'1T=G9V<3$Q,W-S<S,S,+"PM75U<_/S____R'Y!```````
M+`````!1`NL```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=C4I3
M6H)>%1,4#P\=)3$Q,&U_2@L/%&:";GMO:DU*GKV^O\#!PL/$Q<;'R,G%2E)9
M8E]D>'=1@FE^=F&"2U964=Y14N%22X)/WN1_4%UI9GAT`7=T<7B\2EM83KS*
M^_S]_O\``PH<^,^)'3X7!+"ITV6+%2KH?BUI`D5*/3AR!%#[HR4BP8\@0XH<
M2;*D229MV+SZPV3,E"9+]/53@DX)G`![V-B!<X:*3)-`@PH=2K3HQR5<S@A"
M":9*T"=:R)AY)Z`.%*-8LVK=RK6KH"9GS-S9$\`,E:XTMTP99>8*$Z]P_^/*
MG4M7TQ(M=P0$8*/F;-T_83)F^TNXL.'#1:_^Z4+'RD]C2L9L2:9$'Q@[8M8B
MWLRYLV=@3MH$6-GO28`'!O1L3.8D39P``<B\_4R[MNW;@I0X$;2ESF/*;0R`
M,:.E2P4X3_I%80-!@);DN*-+G\Z5"9@U=G[S0WKUC9<_3O`,H#-['Q,Q=/)\
MI\Z^O7N"3+"\22!'L3\G:`0T(60%.BPR!I2Q&T!*8.'7>P@FJ&`O2Z"11P!I
M^.?/%;@XM8@3=P`@X79U!""`1PN&*.*(BH0AP!U<V-=/$V\]@<5OE1G"1!9O
M-;'?3%-XP0L3&Y+HXX\(?K':/VHDP(4B7V2A2/\7`XBAG3)8K*''@$!6:>5G
M2V31AQ@#,7%&``!H<2,B:!R9"!-;!/!%0$M4`<<:>%AXY9QTUF4%`F@,I(4<
M"ZA17B)H=/')4@%-$0`?9E!9YZ*,#J5$%>0PH>),8>@A0!B**A(H)&;XP<63
MR$Q1QQQV:-;HJ:A^)$4<?O38CQ-U#-`'B(ML^H@2:"#@QY#]4*'''E*D*NRP
M_,3!@1FN]L.$%9DV8BLD3G`1`1N@(A/%G\1FJZTG2UA@`@7!!L0$&V58\FPD
M3XCW1K/\5,KKMO#&ZX@2?0BQ`1BT\N.&`6E,&LFYDD31!@%C!-0$%P0(*N_"
M#!L"A1DBI*!'M<I,X:__)&9,=@D4["K7\,<-2R&&'@?ZHT06>5RAB1((W/''
M$GZT0$\E40SP8D!6H$$QR#Q7284<5\@)4!-J(""`T)4T.(`?`=2@P`P%E/!"
M'CL;8@4'0<!`1T!/V#&`4CV'36<9`##-1D"/`@#`%V-:TL0;:LH!`PXA\)'%
M%02\H('&C4`AP`LM4$##"FS'9#(<?(21K]B,+SA%%'+`T7:[`@R@,B9-6/0R
M`C;($$<Y`,SA!@`L*-`(%1#@<(*9?YA1@PL=Z,$Z/TX`($"RC><>71-XQ($.
M$U=4+8P4="!`QN23*!'%'&@PD48*)2P0[E)X*,#"#R@LTH09*[0PQX9/0,`*
M_P%[0"'\+[`B@(7N[$OWA!H+L.&$$UF</PP67&IR!0)<?)$!$GG`EB`*\(,C
ME,`*B[``!M8`*B6XX`@#6``:IK>/*?2I?1CTC!*@4(<\L&$M3YC#&^S7BPV^
M06&8`,5NGL`%"<3@`4I*1!\V,+4JF$,?T0J3$AZ``QE\0`S8>EL*4!"$/D0!
M#G-@0Q1(V(DK^(&)&8QB8N"P@``,H@L+0"$_P+``.6B""FTH@!BZ0`(D+,`0
M7$!``#8$AAW@``$+L,H92$`$(OC@`@2HP!0><(`'K&<):="``O+P!PW4@B5F
M6(`;I,A(88GA`FTX4!0*$`8H>N(*):O$N!R`ABH\@/\!#QC,()Q``"(<X0<E
M6,\@H"`'%]!@`310``?2H(0VJ(`%(!!$&!Y`A`=4H00[6("%)'!(053A<OZ(
M`/(:R4RAQ"@*<E*"%Q!@JF00S0X=DP04X)"'.+CA`C8(`1C^A(4%X``(!WC!
M#A@`!!&\P2-U*`$05."&,-3!"TUX0@TR,`@F?*$%+(``V`1!S$,HP0]EN!@Q
MR!``9#;SH29A`Q^0IX:)[D,)8C``&QR3"3,4X`U66,`!)##00<Q!"#<8@@?$
ML(00TB`)#$B!RIQ0`'MQ(0V".$,$TC`'#)R@$&>X@2$*>@A?)6!QP[A"22'*
MU(\\`0!]F,)/E-`AA0JC"6+_T,L6D-J(*A0`!SN0@!S.L(`4G,`.*G+"`E8P
MA`.H``^*ND(%<,``!:"`!CN`PQB<(*DK0`$%!3R"!@HA!@8,M9@RTHSYFLI8
MV\3(":Y2`ANX"HPG"``!^;.$Z\PH@AJ4P`4K*(`ATI`!'0QA!P-XTA9J\`,@
M&"`,7MJ@%=8@@1&P``,ZR,'Z!B&&$1RV$6"X0PR/H00M(+"QR$4&%9"86;1]
M80T#T((`(U$')`BA"`1XP@-,$`/Y$8)X*="!`E+0AXXQX0([6($%_-`$*D#A
M"GAHP`J.H(,4[&$"1E"!```PSC_T]K>,4$(7]OL%2U;"JV!(KH*%L00U#"``
MNSU$_Q@R28PH&$L#B[R$$CB`@1O@`0TGP`$!)K4%%!S@!S28P#(%0884O"`%
M5+"".M+`!3<@801#"`(!]$&`!U@'`8+Z;R&(&N`Q9$`"?JCF,-)0@.,N^,F;
M:`(8!K"'=PU""6DT,"6HVB<RN*%R$8Z$$I[08`88`0-(J`\AEA`&#]P`"`H`
M@$*5D(82\(`/78/"5;3PA1``X;8_`,#T(E"!I?"B##H`L"*6L`4$Y"$,`R!#
M`I1HC#%`P,E0SG3RT@"```P7$9#C6S&VEQPR*,4+LWO$%-@@@"G\D@$=4+(6
M/"`$%AS@!C#HF!8DX(,45,%E2J#"'>K0@A$D(0@;B`$[5__@Q3\8H-"$@,,/
MXB`T(B-""P#@@Z"N,`#PL`$!U"J&&[K-LR5@@0M,"X`=ME"%;&JZ$U/@@QQP
M5P@M1X()9:A#(8)&B.54\U'!*X03X&``-53!`$DH`*]"JH,W&^`A(4C"!0[T
MJ`X,80":"_8?I@`!F`)!>B\30P^&H`,<<`$"T!Y$&!3004(8$A'*$X`P]1&%
M8J)D`GB8;B_Z4`![5^D)#I#!"39``@M8@`0::($,**#*=W>"";N92".6H'-?
M,.D.%$2$&I*X&RYD(`<^V,!NGR!1-LQZ!R#(Y!4B$(0AL*`%:"".$K@1`APT
M``I/X``-0)`&.XP!#)]*`P%PD`3_!7@@U9)E*P-T0()"N,&W@]""$EY^"#WP
M`:>+P((<"I!J7R@A)SXG$4;3^P4H,.&807."%-SP/PZHP:I.OW<7$*!O1S`!
M#1D.ACZ:8&5$+`$*5D@`$3QP!2P8H)=,;L,6UB"$O?TD"@`@P@V,<(0A*(``
M6MB-$IC`A3*4@`5#(`%L_X`%9E%(`3HP@@BV\"0GT.$`1_@`82%OBP74X'-K
M%@1$#'H(/<."LIC`!`B`6-G2!`_``UY$!B20`BT@`1^P`2<@`K4`!0M0`BNP
M`)\6>Y/0!4D&";FR8IN@!*,#@G]P#X<0`"-@`GLP;X+P!BL`!!]``#*``F<P
M50N0`[9V_R]?L`$C<`.O%&R9$0%$@`-FL$%@P3$)@`-&8%=+E0@M@`,`,"9"
M-@A4L`(HT`;D``5T``>*(`5VH`A5`"$`:`E1`'N-D@4?8`)RD`82L`,$,`!F
M$`9<(!H/4`-K,`H)$`(KP"]FJ(&$X`16\!9,,(94B``9V`EWH38UJ`AIT(1_
M(`)'L`-\$`=\T`92X`1:\`8;D`0J4#"K%#.+EP)TX!=4P`<F<`,,H`()$``I
MD`(-A04JLP1M,``F0'(P(`=*A@A.8`8T@`2MZ`?!,H5_$%(T$`!R$`!]P`>=
MI`C<I@A-X`6R,@RAER!ML`,>L`0&(`0.,%T!@`-S\`<!0`0'L/\!>0`!*1`#
M#I"+?D@(3/`&<$AOH+8`HO`+3.(<C:`&33<(6Y`!"@`$1&`"!<`'?:`88?`!
M-&``4A4`.S`$0R`!7V@(]+(!1X`!&Z`&?P`&3F`X?$!X/W`"!*@(<?`",;`'
MV]<'+A`#>O!X7V$!..`!Y3)W:^``95!UY,<'C7`CA#@)5?`&P[($`D`#$4`%
M$O`"'YD."(`##J`$`S`$*_`!%5`")K``#B`!%T@&[J9I3W`&:R`'.C()?8`'
M.0D)YL8&`_`%-$D(^`AJ>L`#/S`$,C`'=Y`'8)`<44`'+O8"(Z``-G`!O0<%
M=Q`#-'`!70`&<%`'#+$&3N.#/@`#;S#_)DY`!FS`?OV4!@\0`PTPCX)@!1Z0
M!!R@`&&X`JZX>@-`#4S@!:.A"%A`;I^0!G(@F9W@!'S@4(SR!`;0`YX"`S.0
MCX+@!!U`!'8`!FA``RP0!"[0!U00`#Y0`Q/@!ZX$`N&VCF$``.I3"4]0`'TX
M"5VS`/CW"&E9;TR@#Q>``4G``B+`!@4``/4#"P,P`AC@`8K0!A\0=K!``'6@
M!FRF`4.`3BNP?0;@`QGP'5A01D40`WE`#5I``3RP`89@?#QP!".@`R<0!`&@
M!%JI<*!V"*D)"?3B`&]`89@`!GJ`*F:P`1)`!@`0`P70(TW0!C+P`A(@`Q)`
M`!Z``R/0:R\@_P*_0@`P@`(&0``2$)5P<)9-Y02C$P=C(*1G4@".F`E.$`;7
M60C=J0U9X`=](`5XL`$E<`$(4`(W8%<!('FK-`<;L`%X1@A0P`8M$#U8`(M_
M(`7I0@36@TII0`54D!QFT``E<(X>8`?'V88;L`($P%+]Y`46@%)"0`$-X(I*
M!9<=D0@!X`=:1'ZJ^0A/T`9)9`5AR0A(0R=_&0)1$`&2B`ASL`([L`,DT`67
M^`12T`8H``,;$`(Q(`$%P$7=0P&L:`(=@(69M@4"D`69:@A>``"=\`1F\*1:
MITI4X(YQ:`$OY(E10`$X,`1(0`%<$@8*0P6#)P*T]`=<P`$U4`%IP/\E3+`?
M7/``0F!]XTD$%5`%>"`H9!:L8T`15&`'#S`",_`%'K$$!1`#UH<"XS1F7N`'
M"*`XVF,'<_`3&3H)3K`'<$*"/+,`2*`'35`#*Z";@F!.-O`"9(`(7+`&*4`$
M(B`!LI0%=4`!(Y`"YHD#0<"3R;5]L!!Z4/"KBF`&!B`YEM"=5*0&O*D`#9"/
M2[``1W`$0,``'S!@UBD(%B0$$L"/&?`%7S`%8,,$()`$IB687<`!0JL`$(!,
M9E`+`1"3(_`!%ED(;#`"ML4!9(`.33``7W,^V)*PE"`J$\"%FC`&1>DC4Y`!
M,>`&=R`#)!!F5`@#/(`#&G`62^`&QXB,FK'_07;0JAMPDA]P`5<P`3'0`@0`
M`#```Q:`!TRE!&4P!Q(K$EI0!?8&!F+P!GS`!F[P`#N0`5W@$5D0`3X@K2?`
M`40`!#M`"_Y1(!1P`R\`!WA`!5&0!@.#!&TE`DZR%%\@`?!7!`8B.8E":V?U
M)Z;!5D+0`G'P)TB!I(?0L2=$2!N#F9@0!0C@B562!C20`5,P`$@P`-/E!KY[
M``%`#G0@!#2@`T?@`R&@`"X031W+`T+0`2AP`P@@,!R0BF8``31``W>+01CE
MFID0&9K0!4FY,A6@`6H@!0*@`,CK$9)U``PP!!F086=@`$"`3A/@7R[#&P[0
M1UQ0,Z8%!!D@2H2@_P<_4`-XP`V\,``WX)'8<@8X0`0LD+\WP@1KT%R5,`5J
M0`&Y]`=9P`'F.PG+(;Z4<`8`(+/140`\8`!+@`(X0,-7M@`\0`/WIP1A,`,E
M,`<PD`()H`$F0`($L`(P8``:LWUF@`(FH'0YD`$`4`6#!P,3P`<N``,$T,!A
MHP1@D'N=H!(:Y@9Y(&B9T`1(M``-(`$],`-;U6\+(`,L,`(;P`4>S`4B<`!Y
MB0(I0`!H!0M>9P1#\`-$T`)C0"M,D`)&P)<&L00G$`,]X#M_R`>;.`0C<`=]
M8``T(`$#<'E87`A;P"<7H`H](`(T@`*I-0D!(`$HD`#V5KX_H@03X`/R8_\#
M+2";N=$`--`#*2`H=H`#&8`&."`"*B-9'?`"$S``$D`#%'`@*$$!-1`#>$P#
M;$`%%Y`"/-`!<J!WA\<^5;`&`1"IFM`$#I#,;0H`:_"ZF;`_>N`%[$P$&Z`'
M'F$&Q<:4`J!S3%``$UD")'``*8``&=8@-(`!$F`J2T!I?_`$"C`$)A`'NS@#
M(W`!F.;$G3D$.``!.#4%2P`&!'`##Q#!?3``:)`%%J``--``60`%@K,!O8<(
M63`#,>`!P%0NEE`%DQHB9[`"&S`%#K`#!9`O9&`#.,`##;`$4Q`!-2`'2D`$
M!TL(L5`#5P`!!$`!*:`"#H"978/&,+`*&4`'6!#_`32P`190`*U8`0G6,TZ@
M!K9#NK[`!.KX"6`P!SJD"4_0!R&5`AM`#TOP7&\@!7-0`@UW5HM#2@IP!#*0
MGEA``38`J'5`#11*E07P!=!\DB<P65Z@`3J``480`U%8"'>@`F]6`@2`!E3@
M!5U@!R*`!AF0!"-@K(G@!E]0!QF08DLT!7H``%S@!72UL8Q`!G=5P(@4`R70
M`.)-"6RPI.[1!OQL!0,03-K1!CW@1F>T83O`!N89`R=0`)J!C3T0`"2PV"8@
M`@]P`BFP`*;"!'F@`:NP`B80`GB`-R:PAPM`0Q``N/)2!0+`!V4`T;\0!7>`
M`".4"5%P(U[0`C1``']R_P4+$`-`D`0IEG6$4`?S=0`3@"UL``.MFP>2J01\
MH``'L`)[4-H?P`,C9@4T,`0P0,6>%`1&(`0?T!%A4`8#0``!4``'D`1]A,6/
M\A9*4``VD`)%2`AM<`)",`)(8-Z)L`04P,]>K8\$P`,U``%VH..,\`5/M"!-
M@``^$`!5<`([D"]0X`!"$`,F4"Y?L`,?X`4B&<<U$`1(P`%;"@-LT+KDH*\U
M@`)K(`*23@>F4KU#U^A"K049P``@```LV0)KL*G$$JRC*0Q,<-6+H`5@7`E6
M$`#J8P>6O`=%U0)!BP)7+0<2@`$L8,A7@.1V\`0AU`(;H,B"0`$,\`,-\!A;
M8/\`Z'<#(O`$CD$%9#.A?P``U3<SDL`$82!!59`ZR'X(7S"1(W`VBB`&1R`!
M5J4$$8`!$[``H`T)?G.([.$$:<@3A.LJ3@`"-!`$(1`\>^#D`7"0Y"`%`P`"
M.5`"'/``;$`#HM5O+F`"6&8!,V`""*`YZ;`&:;@"*T`#LT2HT.,`#X`"*]``
M8S"-"E*?)CYU>-#KSCA9G9!O7H`",4``(#X(FHD#'W#SAJ,-6W`"-``!*5@"
M:R!`2]"X-BX!`<`##)!RAC"B1```.#1X)(>C7B!57G"Y9A`L,9'`>A-P`M\&
MT`@X2PYSM(@#>_`$-/&'3?$'`T`$,)J>A4";)=!+GZW_*U=)"'Y@[>P!!B8@
M`5FPGE9D"$4-U3P@6E"``#=@!DP`!),_"#\K`UA`!D=Y`699#@XP`GN``#W0
M`Q"`!R6`!`;@!HXY`4BP`0/L`G%@!6`@`S<PMQ]P`+20^#]B;D@L#%'@`)#P
M!0:0)YD@!9_R!V.`[0:0*5O@!SWM!";;`0"0,O8@`B/0WS$P<$'PW^A0U"++
M!U^@`-1W!`=0`G3@+TR@!B#``AOP!%`0`$+`RA@`"$,D9TQ3=!=K.!UA?V5=
M?W]2%B,-64J0F)F03%E2?U%X,3AXFDYP9D^:43Y%`0AU3T]L/$9">A<-2Q!&
M#5>7GP5(-D\!%)!*<`Y?OYK-_TM+S='2T]35UM?8V7]*`3P35Q0K;]%+#D$\
M)@%_5R4E86L(.S(!4)=/(2\!*1L204@X)0:`F5&BS8D29+H0P&=@@HD8:Z+\
MDB+@0XP5+F)T.%/F@8P<$QI(H.%`"C-M*%.J7,F2FI0Y`+RT5%E&'38E7ZS,
MA-3D#A\S4S+$>"`FDQ(I$&Y@$%)!9R8Q%&A\<%`B1@@]8*!8*0+E#[$3--!T
M24%C@I,_;F9XN%&$30@D!II@4K(EQ0L#=#P,X'$#"(<`"PY@N-$B08<<2H_H
M@.#I$Y<V^EY0.!M-R1@^`;+T`<CGY)(T*Y*PB($&&B8F>UR\<""BB`\)7P"D
M&-(!DO^5##LH3"D00P(;2'F,89I2YN3.X\B38ZM"8,27,1>E51%Q@`8,+'_0
M$'E0IH<,%$)6""$R04`*"7N($("TY`,Z'`H@?`DB'%.6(!"4<#$!EPRS)A2\
MM@(#*-`QQ1<I,(5'"@I,@(=<RD4HX81*7,)$5Q-6`P`3U3@A1AW)/4&&`V9L
ML<`(&5"&B14(C`"$`D+H,,0(`&`WUQ@,L"!"$TYP`2$.C4%B!A`_K)&)&QE<
M$8<-D,!Q40!XO&$!`Q>408`)&+!P0`E7K(@#$"-@\,,-,7@!@P(8,````&B\
M8>$5&MQ00!9&:1%``5>8X8(0:FC"1!HPL*```P<PD,0)Q67_XD0#+-P`00!2
MU//$`NME$L(/+Q2%R1SU&76&&AQ.PT27&99JZEPQP)`%'4(T$&0F2\0@@Q`6
MU)-`#W,84,0`D&Q1P`8[A&#!`GF\X(<F5*P@`20#T$!*)G3LT$<$.*P`00,I
MQ,!&J']@,<`&/;Q@0@T=7)'&!#'L,$`%,_`P@&FGQBMO,V,`0.J\FDAATS1E
M+!!`%<<I\48!;TS1``XA@%%*`3P`<8,$9?Q!A@1]]5"`7$\8@`,'8%3AAA0+
M.$!'`R.H"$D''&CBQ@=7R!'#7'/(8(01*53!`0\<?,#"#WXPP\8`88C1@!$T
ML$&9&A(`H0,1$%!!QB=@F($&"CLL_P!)%GSDX<87,L20P!2::+&!$$D(@4`4
M411``PM"A/#T'UOT(,0`,CFQP`)LZ*%(V!ZDH4EPTE`AQP)43&/%`L;AJ[@V
M2L0A`P%>+!##!2;SQ$8/->P`P!-5',:&&CODH4D9,W20!1X3\##'V^LTL`,;
M$Y3@`@U!A`#`&%HXL"L')03P+0P/3`##"@,L<W4<(M#@@@PX4(!&&`6X4,($
M:Z#@0@)?0+CX]L<ML04=,7&[_2G2--'%'`%LH;U*5!0@0P8-L%'&&B:HT,>K
M^J9PPP@EQ!&D%'@P`0-N8`(#F&`#;XC"'YH0!2_XP0`L8,$0UO<'`EA`92S3
M`P_$IP4A%/_@!`<0AQ.:P`8-Q&`!6H#$%:9PB2:D(869B`(;5C`"PA1`"V%@
M`L"F@``%F.`!?$@#'#J``P.<@1DX,8`";G``"+C!-$O@@A(5H``+<*`&%+C#
M+_13@!&P``,>")L%6`><3OE)?=N`%R:B``"`<>^-UDA`$0HP!A68@!'1Z$`0
MBE`"+OS!"S1`@1<&L``:J(!U36A''%:P@1,$@0@K0($=K$"#%%PA!AMP0QI(
MX`(%$,$%-4@!%Y2EP&VH003S4`,(3&`"O]D'`B?``0YV8(*NB.`'7=C"!&P0
M!`G(`8[`1`D7UB2&Q"T.`'C4Q!G6,(<N&#,;3$B`#TX`@1(0X07_-C#!+S4!
M`!/T)07'BH83V`"$(^#`#I_1`A/`$`<$X$`I.C#"`$Q&@-H<B65E\($*DOD'
M$[3@"`:`PQKZ@`DW$($!":`@-63S@R/D@*!M:$(8GD"%@_%@!3&@0.$R\002
M'*!LNI&&%$[P@Q]8`(9.`%$`8J"`)!P!"$20"2:T,,:_F5&D<W#CC6P4S)[^
MD00T:(,=9/`!G6;""QD0@A`R0*<"O"`"`UA!!B00`QKLH`4%*``,.@`!&T#`
M"M]#00UJ@((0+(`.-&@`V/ZPA/,A80YML`(!>."%DP0@=&UP@`4;B0`P0$,)
M66!#"E9@%P,000,H@$$%#D/%JI5!C3[M_VF/`!``,%2.>T[0`YTR,88`S,$+
MJ6C)#(4P@2I4@0)5Y<-&>4*'%NPO!0!8K2:@D`!'$N`*3NB8&9S0@24.8043
M6`$0V```,V#A$@^P9T%9MH0S-*`$!#`#)%;0@?V9``'$C0,>`,"&`&S`!07@
M:35VLX,;#"$?;]B"%-;PA0D``5%(5`@/1G"`#(A!?'/IB`)*4`8[4*$)69C"
M'$AP@R,0@0,D8,`&]"``-W"(IF3\0QX><(TEA($/<N`"$I\967Q-804U>`(`
MA&"U:&@!!K/D`!.8T(`@A,P'#M@&&U!@@Q58]0$%V($`-%$'!O#J#QU`@6P%
MQH,T((`"'P@""O\2T*4ES`$_[K0+=!WP`A=L!!-0V$`&4G"`!IC@!:$UV#N3
M\((&]*G#P61"`!(`APY3P7^:($`%0CL3!1@A#TM80`JV`UDNB,!%0B``AJ*!
M!@GLH`$K5D,5"K>'##``"#B8@%R4@`,G4"$`>0!;<E4&@GMMX04Y((`35I"%
M"1QA"#?(P!I@D((V'$,/08"!&3BL"@OH``,'D(`7EC"`&MA`IIAPP@!*P`(&
MM'(:3^#-"]APW#^``0M/&,`!?K"EB/TA`A-0@AL*\(4_0%@3G,J&$PCP`/RB
MF7M-:!;=,F""-T`6&$2P`0T>VX46A.`,U;3V,>"P`SN(@0XC`8`?(2'_A@^8
M``T=N$@,>O"7+IPAX7F`P0;8D(?9S5("(4C!'C30`C2P]3(G0`$;')`"%2#`
M#7^P@A&HL``;#`"_4"C#!`K%OP(<\=SX>L8VKJ!08"[!"<9Q`!C6@`<ZHP2P
M?ZC`SH!0@TPS@PEX.($"@!"#?TD#"G<8R0*NH`8I/$$+NYG!#5S*@#ZHJ`:>
M4`(4..2!E!VITYEHPAD>4`,6X*`%`0B`$(Y`;0*@80UC@`0Q#@B`05.#"EPH
M``YT<`0&>(`,Z]/"`O@R`@K4P9A+\$+J4)"&P*?A"DR(`P$8P/@C:.!>`ZC4
M$KJR!1&`*!.`LX86V("`-M!AT$LHPUIQ+B\G_T!@!PD0PP9BX!15B"`(`-$)
M&&C`@2_XH0,F@,!F_T`%%[2@#RMX00QXP(,95*`+9:CR%FBP@?FU``<]V,'P
M7("@$YCF"7DX?P?X,`41]$"VGPC"`,@P`!&LX`0%8`$9%03Z%@UR]0)&\%L&
M4("\-R%8X`>&UX"9$&-05WS:8`5O``#=(@1^44HK\@!!D(`_$`#/E`4A0`,$
M\`7P,@5RP`%)D`1!\`)$,`0]8`$;90,>"`D2@`-G\';W,A=X``,OUP5T,``D
MT`,_8`0<$`>O=PP&8`,2\"S28&$#<`5+4`#FI(&:$``P``1`8`0V8(%&D0`K
M4`(+$`9CL$4#X$4_4/\#./!H)R`'9S$`$Z`)7E`"!B!;X48-4(`'!<`&35`%
M=S!H2O!9$G@J3O`!/;`%9W``)/!NW;*##-`!GE``1$`':Z``P+(#XL$!6/`&
M1+```P`$=C`%83``0J!^/$`$`X`&0(``E,$$8@`!2"``97`%(2`!QB$'/=`'
M6K`'M@8YO]`&06``"#")"9(!,U(")V!4TQ`%;8`"0Z`T&J""AZ@<=6!SM(9S
M>Z`*9P!94/!N2P`'"P`'5O``"C`G)^$$%W`#YF4`8G`'+%`"=94)4X".#Y`%
M2\`$480%5U`!(S!`#K`%@-4`0/!H%Q,#K_('#P`"4%)0<!<X`G!#2Z`$TS'_
M!$LD`JD0!@JD!%.P`#W@`5L0#5&0`'.`!62035]@,IGG`CJ@`TAP!UY0`0H0
M`97S!JGR!CRG!&>1!6*P`C>@`RE@!CR"!RM@!#I``UM`AYJ0!1ZP!FN@(GM8
M&6X``6Q02E&@!B:S!\!VC1%2!SD@`2S&`W<@#6@`:CQ0`'^0B#00!QF0`W53
M/33P`BL@`W2X`].W#06@`'&P#370`";C!`X0`V8``8@5`R@@`(6C!`1``Q.V
M`RH``S1P`$(@`0Y``3VP`!+P`CWX!W0P!$*P,2G1!1E``S-C`@X0>%ZY$J%B
M;FC&!'4@7M(0!7[`!PKS!V-`1"90`*'R!'8P`'<P_P8-8`,@H)K#L0`X8`0C
M\`%6<`6I@!0750=+8`44@`,:X`52`'67T`4>T%!$(`(#5U`<<`!VQP!&5T'*
MQ011@"0_.!QQ,`!J8!Q10`!!P#8B\`5\L`=A)A09$)[U,@!<P`95\2Z:H`8P
M<`"U``!6P`2Z5P82L`(&D$("^@(#4`5-,`904`5;8`<Q\(4KP)N9P`0#8`,Z
M,`)(8$;?M@E/(``WM0U<,`!S$('-8`81MIH[D08WH)@?4`.NU`P0,`(R$`2^
M0`7!4@4GD`&[]P=,$`8CP`1-\`0N@`*&QP0FL`-6P`$C8!<,X`!-H`1+@`*$
MN0]F,'HF8`..MP,O4`8HD/\",L$$8V``#'`"$V``6=`"%I!V<3`"."`$VY02
M2B!#+Z`##&`$&7!S-GH-3A``=+":6">C5X<%3(``.D``@44#->`%8A`!?1`%
M>6`$$@!#F+`$?,``(_`#&*`#*A!:??D'51``@P($$I`%5>`$$O$'4.`!!\D"
M'X`%D`A8&C`$0U`YFP8)43`'#=",)%D%D+@-5.``1F!>6Z=&5;``0R`";$0X
M4V`#"L`&YRD%,P"L&``$+!"CQR`&5C`&'P!3!Y!`3["@4]`$5X`"?'<`J#";
M<(`FR@4)*=HM$2`"==@,:I>#T\`%W7:H.W$%'(`#I_`"(."H6]`"1=`#&D`G
MK!+_`60``!M0`G-`9WW``P10`#;@`CAP`#BP`1"`!1KT`&:P`R10!@;0`D$@
M!#)@%W]1`Q;P"U$``</C+T[P`BFPD%VPKF=`!@30`A[@!12P`T)@`GG)$FE0
MF@Y3`A#@J`:[#KX3GZOI!/[1#&WF#'S0?7N0!K]0`6`R``G`C,8)"4Z``#Q0
M;)Q7`#UP:AF@,$J@!UI0`31P`F%P!72B!%[P!BV6!`J@`8]@#62`!`'@3)A0
M3]QT``M@(T^08=2P!;OW<$+``D5@`%4P!6C0&%H0&BU`!AO@<OA%!AF@`$.@
M+F:``JBK``T@!I11`"7``XC3+5BK!RGP@C0P`.<9#5+P_P$:<`<>N*]>D51M
M8!IU8`<<Y@1C(#YCL*I5NQ)24`(O,`:L8@#20`;C<@`$$`5,0``^$``&@`1[
MQHGJ8@4`@`24PI=*0@$D:P)%4`1Y<`$*L#G$J@<B\`)T@`=ND+GKHP00P`-1
ML`6B*P1Y0`67H`1HT`,)``$*\`(^T`'_%`0^(`)-VQ)1Q`<UL#0*X`#Z&+VV
M>B=A<%F':$PEI@E/$`,L<)T!```2\01EP`?3=@$YR`1L\`(,,`0M$`>3-@;N
M-0(*L`!64`!"X`-WL*1N9,,(^`,F8`;+ZB=<("A!8`%5<`F,&VRCAP8(\`;\
M1P94"PEV$)Z0D`8AH)P]0`=P@/\`:<`AGR@"&+`#MWD,4T``!S`"1F``([D-
M<E`#0%`=?+`%#S`"'0`'A?,$RW`%=%RB!B";TR`%&H`!.&`#<"`7^ZH?/I`!
M<>``1`AXU%`%;&!X@@C"*H&*!0`%'V`#-;H-$"`*-"!=7M`"*``'C-054+``
MX!))&X`'$J`!FJ`$$L`#.K$$!S`'TLH!*B`&&K`!,O`=<I`*3D`001@#)(!B
M1(`#)V``(!`#`!`#*=`56!`#/]`#,3`'&:($;6`!/("1+K``"RF!2J`%`&"(
MHMP,)VP4<6":"K`"'Y`UA>L$:R`#,!`QT724(S`#78O"%%`$?.<":N`%B[E`
MOS<8&W#_9M<@H"9P+',<+/-I3TM@`5+Q"+!I`'G0SIH@%M'@!A)P`$,0!"=`
M``)P!QM%!886`:QWNC^``P0`B7+0A4>`!`^00E+P-F&08'9G`$^L">>X,5T!
M*"\@`%U04W^@)P$!"5"0!Q!`!D?MR8:W!`0US]C0!`Z0`WP@!A)@`@>M*!8@
MSB4`!@P:26$P`QH`JG"3`3A@!5A@!C4@Q/#B!3'P`6]``AJP`B;P`7<P!=[3
M`B4``#"``@2P`=SW`B>``!E;0BE0%%V``!K``S&@`230!RC0`2/I!'3``TA0
M`XMJ*HWCT4`@!"\P)ZZ)9ESP$SWGE=,9#?5L%&K0`2QP!".`_S?<Q4)_\`4$
M\`(<,`,(:@(+(+"8T`2\B`1-\P=90`5>X`1J<`*[#:QK8%1,T`7-:Q1E0$24
M>AIHP"`9\`!0(`<K8')4(`9VT!558`8"D+;-8-+1(&![]P,EP`9[\%ER(06*
MG0(BL`.D^@%P\-I9$`%"J;S8\01>\`4.P`,ZL-LN,,F9(`5AT&R8(`5Z8`(:
MISU-`)`A\`!IT'HQ8`%G(`5LP`A,X`4`$`<<IM6P,@Y>;0U?T`(UDP>'YIIJ
MD`-%L`-J^0<-T`-Z$`<)@`,B$$Z0`))\0`&AQ%*]@0!6T``'0`<00`,```84
M``-%0`0E0%47H#9\@`D^W.4&P`93X/\#'G`22I``0>`&9C``+*L&30`L/)`!
MRFTJ?N`>@IL"`_#%<*2LV^#5*&[;TA!:59`"/Y`$#$`!VZ59D##'"L`",28-
MA5@#/0`!:D`%C[5`<M`"Y;0"<Y`%6&!-(M`5!K%P*S!K?\#4<8%!0A"NX9$"
M9_`$=3``W&H4+02):"#&I\$>;"`:++";<9`'=G`,:I`"1W``>6QB&L``'.`%
M63`&2L)`%$`$+.`#((`%=B/8>L"J#K`#HD``.C$%!L!(_+0-?/`"NRT$-'!"
M4U`%>8``O+Y%B0/CH2KC,SX-7X!)4F``/0``B5.W+X`#/K``3/"[B<UN&X`#
M06`#,-`'8T#_+=Y%F*>(`LCG3R7P!J6)!Y>0>1"P`2$P4-I1EARU`3#0!&K`
M!C)@`G%0Q0L$L@4@`CD``T(@-PQ``P7?NR;6`"!``'60I"K1!'U@`3LP!#X@
M`X_[VHMC!7?@![-ML%(`O9EPVTM@"'8@=R$0`P0``J1*`P6`!G+]!1^``P.`
MX3P!!B!`76D@=RJD!BJ@`#\`!"?;5EY@!7/PH!*@`R`0!BSZ`AN`+D<+*U90
M`3UP`PS@?SZ04UB3/B4(`&=`0?1]&D,7!5*``/I<`3&`D2'@!U*X0`L026Y@
M,D?!!X'$SEX`!5A`!5(P`.]T!"6`!QS2!%80!AN0`X%=`@@0!FS0_P)E-K,O
M%W=]<`)(``0FD`%U;@91\)MF0+5*4`9[8!*98._L@>_YK@E+H`<Z$*,:L`-R
M':IY$$(C$'A@4`*M!@,2H!-CL/`K0$5%$`8[H&*<59F0@`4W@'*9<`49D`&^
MX@!M`P@#6W]_61\T9AP,.#LK(S8+=Q8[>B8IA&(*1S0\<X2?H*%@/#\E%@<E
M<UBAK*%47$ZA2PY$!T-($W5*K;R]OK^$`VB[P,7&Q\B$4G>M"Z!3:`MI7AX'
M#L1C*PI)+P%13%Q2RC0]"%!_2UX<2!Y=?TU*64]H)3\Z0S\_*7%C5D_O5.YT
M>'/NCQ0+-VA,<54@B!$&*=P1&A,`0A5@3?\0T"%&"(W$/TRZY$$0!4")'6@(
M+2E09,20!E[^6-E"[,(($694SMDQHDP5>4N4<`F`X\@/%C^$0+"SA$J7)TZ4
M2(A#I4F;/V]HZ"@02@D9#DET,/!$"`J9"'2*U3%`!105-@55ODE&MZ[=4%@\
MQ&C#ID2&*ZR4C#F!PX:$*4[DY*@@!D>#N$K"S("!A0N$'6RR$%NB9P<$/1M`
MT(AAP4P5*&9J9%A08T*#%#QXQ%A=`D0`$R*N*`%38,,.%QDLR(EA8.&4!4@.
MI`A3['B0`GTZM,@P@4,)$F3:^KJ2P>\+"V'B_HGB1P2/&T4V(-"RY"Y=)E06
MHG-/OSXK*@.:$;+_8F>-F2\6T$``&*`HH48*1HU`0P%LS`$'(4ZPH8$)#H3P
M0@=?L&&'$E4X@48+1MR`A`%I!,`#"S>,,,`49T!A!1A=E%&&%A&LT$%.H%R1
MP'DWX?&)%70$($9[Q2P1E1)1-/&'1^]HD<<>:@A@P@8`_/.)%&PD8500*O2Q
M!P#R5='`"BTXL,()#=2Q1!]W--&%`$(,<40+>7SQ@`(L)&%!D%-`,<456)0!
MQ0,GP)!`%*`\`08*"@SQ0@3:+?$%`GV(8PP33*`CA1)OB2>8?:"&ZH4$,:BA
M1PX>Q,(*&2GT@(,#4RQA``X"?!%`$`.,0203`RA0``0RI&!#$#`,P`44_PL0
M,<`%/110@`D[<`("!3)$L$`."2C!1!8%I$!#!@0$@`</!%CYAQ)7;+`!%W`\
M<`,`5E2100Y"J+`*,$QH8`0,:BSQA!L5O)"!`12LH$$`\K%21@@2I)$%&QRL
M8$$<JI8%!@%!%,%`"04,&6HO5;S!Q[T?EUP7?LU$H<8:;)RQ@`D?E*'D)UCD
ML<,--]3PP@@W9"``CLJ8F(0';%`AA152Y&%!40QP0$:F\2RPPST&F''&'P$L
M,44!+K1`A[E_3"$'#"G"X`?87;A1,3),L'''%GB,<84<?(CQA@8QS&$%*$O4
M\8$""ARPP0$W!&'`&WL3$M(#.B!A1Q0!/"$%%O]RF)`$`T$@0,4N3I0!0Q(_
M!.&&%5KD!(<>%#`@`4V?"#6!$`H0,4$6F4*H1A9$)C/%'&1DT8=XYYHL/#)H
M*$``$QSPD`9'H`C@PPL\`$`(#B6$$4,/!QRPP@XM;)%O#6$(48(7O.&@P`HX
M*`=&"B]D83L!.3P@)`$T:-%5$!3\<<8`0[1@_R<.X($:6H`#%+#@"$-0P`L.
MX(?:_0(*.?@`'AR0`QL\Z`]08$,&1N"!/&3@`!3('2'ZH(`&A*(+`X"!#P:P
MMO'HX0-&4``2-F"'X1DD`!<``_!LR,-60$$.S"-$"`I@!LCI0`1E"&(!D'"#
M(7``#$:Z@PQ8H"`W_`'_#E9\QQU<H(,\_,$)!#C`#Y*0@3,$\0]Y2,(^GE`&
M+DP!(1MXP\P^088>W.`'1WC`S#+X/_<L@0L`D(`(`,"%*-B@',#CP@P.P`(B
M!*`M7HB`$1)8@7>P@1A9<(`"-/"&)V@!1#]`@A^T`PHL?*X!3<A"$Z10AQ8@
MP0&)^P03'L``'?Q@!%G\PQ7F4A\IM*$!'4!4#X?9"R9,@`8``,,&8-!'OA$@
M!CE8P1>8X(<5B"``+R!`%[PP@`W$(`8F6,$&UD`#BQ!""5NX@P(F(`8J\`$'
M7P@%&V*P`#-`H`,^Z```+&6&&4A@;"6001(.((0/#$`/((@!'TBCA2G`H0A)
M_UE!`(JA!#\000<C4P(*9]`"`Y!A/'#@@`DTT(`/E(`#=(!"%!Z``SJT\%Q6
MN(,*8-"!/H`M"F7P``^0H``7%$!7H(K'&]8`!V$2\ZB)NH.E0(&`!0@J`T>0
M`!MF]H0$Q.`&J("#>*JP@!@P0`%2U4,`SA`4*T"`!CX0`@:&,`,R@(T04S`!
M!ZOPA3_.`08Y$$#"T-$'%=R``318`!]2H!X[```/#G3/%?Q`@@Y`0`(+Z@+S
MZD`!!>B@!PZ(B2S-``(B+*(#*#"`'1:RA#:((`<T,,H.+C"&5O2!`2$@0QRX
M8`4_$$`(!/@"\[0`@1[HH`@Q*``(<F`!--PA#Q>I3_\3R."``BRA#(#1Y2"0
MRL,J:,`%7V@##RBPUT]0`;5"L$"F]'"``JBA!P/('1/LT(('G",$*]BK$@"@
M`#;TI04QP$$!K(2'("R@`$*8@$Z#4((@/*``!S!`'ZSQ!":DP0!!X%)[Q5`$
M/F1*"B3H@0)"$%U@#.```:!#"@Y0KG>TP0.C48,R"M`"S*YA!CT80?>`$88&
MT``'>V#%%09P@B$<@`<2:"U]GA"``<!ACM2E;A/,X+X_`.`"/RKR'&@0PPU$
MR!%)V$`=$ILH%!SA"$10`1C\P(?$/:$`0,``'1PH!3#4+@P8N`%EG*`%!?1`
M#TC^@QHV@"<<R$$*@%%"`&;_4(0+#GD/"!"#%2R0A!6L(116J"P0$AS+KI1!
M2PJP`!%>X``X$$.91XA!<@FQ!2'_00)'4``?HA`%37K`U(1X`@+L"`01A($)
M_N*"!X30@CS;10H)D$-R'2`$/OS!#!]-LO#:L`(5=&$!Z!7A)_)@@VBMH0E5
M.$09MK:#/!@5"O0+@`=,``-.A&`-6=""!F@0!P[88`T06($-BL`#$&C`!@'(
M0`P>U(0M3"`%.,B`","P!L?E;@E=Z,$"KA"&.N"``'50PPEX$(0)O)476E@!
M&<F`)#!XH`8<T,,WKK"&$FS``02"`AA"8((6'.`!2_W%$JH0APV8X`$R:QUJ
M1&`^_P7,``(=IDL<VA`592M["6"``P)<D(*KR7(+`0#``Z9V%`64P`\OC74!
M8+"".7Q`""D:2![HL(6@8`$",0#!%[8P)ARD8`%58`("=M`H1B"W0&80@0YN
M@-XZ_&$+4HCZ.Z-J'S;`@;(UZ,`6S#*`.#QA#&$<0GBOP.5/I$$#1]#!`ZR`
M\`?T(`4&``.BEHS?`5PA`!+800XD<!4JF$`!0%#`#B3@!21C80TX&(+JOM"$
M*T@!#WS0@B*.(`;Z[&()5N"($_"0`H.EP>@EBP,24)D!&J2D%6O@@1"$D.,J
M--\.$G`!"B0``T,YH0H=,`$`:E`">Z:^"#5`7PO8`(,23/\7"PC8``U"X`&_
MO8`+H0`%+&!L62`""G!MG_`$$Y`#8"`!)F`"$K`!1-`#-+`#"%!Y7;$$6K`!
M$G!7::=99Y`!X10Y7]0MWS%=#J`#)N0+46`'>6``%R``;M`$2U!S*Q`"!%(@
M>.`!+Q`B)>``.]0+37!QT$==7O$".!`!OG8N=1``!:`!+%!"T@8*:L!R!L`I
M2E`'&2`$0$!/>+`&<J`J8)`!"E`#+G`'2E``*_`"<?`':7`#2:`!;T4%!+`#
M0T`$&<`&JN(&`[``&H`$+#`$">`>>[0`--`"2?0)<^,;0W`#;36%BE,`#/`#
M,`"`H-`&,!`$()`'F@4%`R`$T9+_`4T0!B1`&E'@!`T0.@#00G4@5T#@:&Y"
M!4]P!PM@`-K0:-V%#%-`!Z/&"LAR`"]0?$5('U!P`C%`!I5C`97V"5O@34"F
M2@-03@7P`GFP!6S0`BD@`1I0`C$@`F:RBBJ!0D;`!ET@!1F@`KVH!-EW!GDP
M`2ZP`R)P![&P!'D0`PWP3AN0`S]`!#Q``@7`!RV``@C``Q>0!5U``"R@`V$F
MC+S0.6T@`3Q@!$?P`7VP!%=`!R^0`A2@!DK`2AFP`A\``$V02A>P`B5@DF;$
M"U>P`/67`0D0`&M@`,L4`A=`9W+@`B7P`"K6.E-@!QF``W\E`06PC`%(!PC0
M9,-(75"P_P<G4`)L$'.MP`1:$`!FL"FML`0`0$`9(`98H`3_D`9S4`)?E@1(
M8`&&]P=/8``ED`)FX$#S``,U<`,/0#(@H08D`'N.P61>>0$4L`!'LP%'T!.0
MB"\N>`9L9TUN<$9S\&5"L&6\`'DZ@`$:$`9G]`YC4`-#L`#_8`<<4`,$,`4<
M<045H!5"8`9KTP3=DD`EH`9/H`1I,`9TT`!KX`7DA0$%`)7'H`1BD`==^0M1
M\`8Q4`(`@(%)^0OI@HAHL`,98%2EE%\[8`&QT!`+8#/.0`A-X`=KZ0;N4P0A
MP#Q*@``Z``8``%HE$`)L4#MZ0`0+,`$[``,N$`0CT&PXM`,-8/\B!,`A$-`"
M0;`#,F`*?9`#"!!K6T@$+1!TS1`$"@`#8[`&+O`#-X`"K14%<]"?%-!:N_$!
MED`Q,L$")V")K?`$D`4`6T``*"`"'+`!$``P-(`"1((`S<<!7!!$<2`!N<<`
M+9``1"@3E5*<U+4%*O!PH%F9K*"!O+`%(H`;>],%9[`W48`$(_`#.+`!*<``
M0%`#`R`&)F`XE>D$M@@#1J4$!D`#+``$,.`&3U`%31$`>7`'7R`?'[`",#!1
M=/$$`C`&"/"`.<8+4$`"2"`"O0@*`X`#-+`".M`">U"9J)E[-'`&!$`$*Z!9
M"K,"/,`'<_0%*,``+"`#%!!/3D`%:`#_`&SP>%O`!54@`3+``;A)4520=8'Q
M!UA``*H!J3SZ"W*@%**I`&)P1DP`8"M``TET!0Z8!5\P`K`$"E"``C50!Q;`
M`09@C`2`!DU@!;WJ!BG0`GJ0`3:P`CV0`PZ@`C0@!M5Z#F[2`33@`A*@C(V*
ME"#A!8Y$!6X@`2E0!G_P!3?&`&OF"UN0`2S``,-Y3E=P`4F``3H0`7M#!0G@
M`S.P!JVE*#!`GQN0`8-)"!D@`4W@`$A0`5H@!5,P!A$@!-SU&MJA!%@P`.V9
M!\TT'GX@`T2@`#=``F;P#W0UJTF&!B(P`B0!$GHP7<:@!'-P!\+D!*A&L!S2
M!$P0!AZ@`R,@_P0)<`X(=P('H`-?M@(9(*^LL%XJP`(F5`40(`0Z$+!)8`!2
MX`1G0`<%4`$Q\`93P`1>N01,8`8F0`,!(*1\HP69T@1YT')0!`I1<`<,61;0
M%H\`,`9,D)8X,`/0Z@`3``=<EP=QP54\H`%4,`/Y@`$;,P!_2@A88`!Q8D9I
M$`()A`$8D`%X4`5-(!#YUP%QH`1*X`2QD`4(H``;(%G`T()9<PQC\'QE,7<$
MT"\RRPL7H"Q,L`(F8*#G1``^4`0F0"!X\`(G@`<MX`*,(`.6^P=B``,A$``]
M$`(.<`(S@`(G8`(E8`,B@`8!)TQA8`'U]P`.P`4F@`)OI0=#4`=.$/\&@OH&
MN3,8+6`'*5!N#+`",N`J^_8+5K`#/[`#:5&U"[`"H40!L1`%`W"2,$H(*W</
M$$"4*I$$B$(#;/`'8$`'<D`38Q!<39`"*YB``V`"%V*@@O8!2``$0F`"'8``
MO-2[/;0%/#A(/+`"!B`&`2"KQ1`%#=(>3.``0#`$."!:`P"1+'``%O`1GQ`'
M*?`#"-`!08`#3JP_\`4!"4```!`#82$!"Q`"1F$#!1`&!9`#1R"P+B"26O`/
M9Z`%:Y"1R<8+60``5<)L);``W@D'DGL##?!67H"M&H``:KD##)PI$T``Z.``
M,2`#A_L")N`C?Z`"KT<##*H`#Q`*3)``-'#_`G(@`6:@`4+``CYP3R<R`C%@
M!GN0`40`NDD``G9P!5W`!(#!!9Q``3DZ0HT7A+RP!&FPD^>T!0Q@!!R0B[,J
M!270`TWP!3>P`)`85RM`!"B@!$OP!C>0`&0P`@``!7.@`$7`$RJ@`Q4``0R@
M"^<2!0V0:5'P>#O@![)@!@JP!&&0!BB`!&^P.>C0!@>P`&\0."R``4(0!'30
M!6!`!!00``=`J8M&N3Z0`L2I$FCP`T:0`\8,"E90`1AP!!H`11T)`4`@`3KT
M!QD0`!N0!`\0!GG&!$:`:SE``DDA4AC``B3@AR*-`JV@!.!F!"F09TK0!`,0
ML'?H`+A#P\,C!?PC_XJ$L`"@"[H*``%FD'RYJ3A.<`6I=01.BB<$P)Q=8:T@
MT0`Z@`!<,`;4``07L`4"\`$8,`(L8`+,00AFD&9R@@$_T`DZH`,LH`%=(,D6
M^01[\`,QP`4BI`13``!`%P8TP``<"0K@$`()F2<W``1_%@I3@`(9/21/<`5*
M,@(VK1)X,`)'\`(Y2`@:T`9RD`')5P:C@09@8`5?(`16_`8%8`0_P+(74#M-
M0`&SG=&690`:D`0WH`!H4`5*``>)H[\Z(`"D9)T78[_)(`7PXCL1@`.@.R<$
MH'F\7(1F(#%7$$#YX5H4V&U(D@$[\`9U>'T@$0<KL`("X`55<`-SK!(9T/\#
M2B``<T``_I22?S`!/7`']W8"+K!3*8`"`\`!/2``$X`#$Y6YB[0#)5`#]?T"
M>D!J*4`$0M`!$0L2O3T$$1`7`3`!#H"&@6$`^N@#?!`+3S``*1`$4C`5KEHP
M-@`!(E0"^;,"H,L".*"/.T`$/T"I,V`!OB`%`A(*4:`'`H`&J,=(/'`"`""W
M1&T7`!`"L/8'=/`#2^W*/5`":Y"JO,`%`V`&&00#/P`$DPD,$I"G?\`%&N`#
M(Y`$,!`&((`#D(4!1+#!BD,'`%`&>B"6[;P?AIC6$B",6N`^4E``.S`#_Y,%
M<S`'8.`&Y88`4,D%*.`2,9``KZ`!+L$#>DP(:G#_$@MW+F^P`&V@!0?``:&@
M!CK`"J`<!R*0.*@I`R,`!#K`!GY``R6@`D,@TQUV!F#X8$:0!")@/UYQ`FNN
M``[08(3@!EC@!AN``RQT+F9P4*S:"TIP!K2$)U5^!-4I!AZ`NSSJ!`'@*WG!
M`.J:@`N@/3$@#EC0<@Y\`'H`-E.P`C/`!1W``30@!`80!JVY!85^!FX'`T5@
M`020H'FP`C$0!C6P`4JR?#C``R&0`0TP!3/@`\G-!&#``&#P!&(08%J@!&@0
M!#6@`XGH"TU0!"Q`M:4+!`R0T0Q`D%T@;;L!F#\0JE0@`SF@!"'`#"I1!HQB
M`-/T!U00!![@;WCT`P>`_P%((`1@8@$FH-6@P*5&$`*?L'P+X&;G5`4(1J4\
M4``MW^0\I`?_7.55O@'7'0J)40!;\'B]"0PJ8.:$0!1[()8:<`Y*(`<\T`)J
M@PY40"1+(`5<5K$,<$<?`-A!D2D.?$0#@`!>(`8:P`",&PIA0`%),`(*,`"V
M9P*Q]QR,L@=[PP1;,`Q[D/)'``*A(`8,P`H:8`8:1)=,``(?$``.:@:[<`4B
M(`0+<"^L]@E0`#Q*D'%UC0,+D!)JNP1+X`8Z4`.MY@<7[D,T#O9+/8!<?VH]
M``=@L`-0WPI9(-Y"L`&#0.@1(`?I30.'Z.A_8`?$<0$',`$7L`%<ZW8?<,0`
M(/\$#=`>6&`!U0H!(K``=;`#$\`*%``(1%9.5R\P:4M_BFTT#78K+30\*Y(X
M*52*F9J94!\M8)DB"AM&#"E%+"Q!*'&;BE8/)B\C(E8+27.N8P\E*PM_9QDK
M'VEL'1P&`64$.#!3KIE2,2D+'YE;:4[037PJ#$E"(&:)T.7FY^CIZNN97T,8
M\/$81Q#DZU=["&3L!0<#VHM`$#&RQLZ`+DK^+%EP8T<8=EDH"`'W0<L44`'\
M6.E!!,4,&A2>;.KBX0"+(@TPN5(")\:1(0VJ-"DCI0P4/20.),%PPX;(3&)&
MN))@9HP+&`\S&3@Q!$4:`7&@*$JSX@8!=DO8P)@GQ(__(B\>8F`X$.4*.TU-
M%,B3!Z3.V;=P-WE)@:*-@!<&K*P<`R-&$0]5G"R@8:"`C0(#,M"PL:*$!QP=
M*-`(H`C+'1$[9$28(X?&@"::P,0@\*2+'1H9X$A)V&0.C@80<C"F44/#&RYW
M<%@P0&,!F@(Q6(SHH:$+.B5NCFY1-.:#`AXLA(AHH(+##2-#1FP0H"5A)B59
M!KPHD8(!#3;0E)R!T&+%@"\!*&QPL:&#!ADR.`R0"FT)FA02;(''"6$P\8=W
MYDRA1P9(,'!`"WY@84]<%%9HH1)]C+`6!B-4`5<38>SAQQ@(FO/$&B;`T$<4
M?YBA@0]#!#'!'7G0H048`R1`_T`,#X0QH3E.N,C`#0?,L<<87'SA1``G`*$!
M&:`IHH05`_1`9`9M&+A2&`OTL`$;47"!!11LF$&!$3HH(`$.2?#`!QQ0)!34
M4&8H(08).!@@AB(-S#`"$B8(<`<?;FPA1P(+S&#"'2JE8T4#0AQQ@P9A_<#"
M"WI8",>&&.A@AH6@HD,&#Q1D`4$0>90#0`XUU*"'$E-\T,,7$_CP12914&"#
M?M@<`(HF2K00@Q-Q4+""GIIT@`,:)*1P0@@?O'""`6J(<(`=.[;Q!QLAK("#
M)3C$84`,:"BBA@D,"-&`.GH$8<!/5AQP0!`_\,B!!A!\8``!"AAA*0\3<%&B
M(F[`$/\$`P0,O$D:,+S0`1Y*/!&&&6JL=@X3>?@`@2)ZZ'"'ENLXT0`.0"1A
M`P%FA:KRRN=HH:$\2,"A\#IE#(#>.GKL,$,;;7R@1@E'M!G!&Q1DP.(?6W!`
M@P4IJR-&"-\48<`?5Z0@!`U-*^*$`2^PP,`&RY4#A0,[[)"R&V>,H84!#+#@
M9<HPZ!`"`@AX..<F1&6"A0IX7>'``FP<\0,0$JPA0@=E:"F'#290QLX`#!R!
M01([_`*JRVO%8!S++%-1``]KA''?%S_^044#0?00@K9FP)"!%@04D65H.%#0
MA@$4X%#"`&$XP00<*V000`D;;+!##SQ\H$<?)Z`@@`P?@%'_!@(GS/"!"!D\
ML$4)+8R121-U6``#&6*0<4``$B800P\VL`&0.500L$(`B4`QP`$O$#'$!@9D
M(,(#&WC`_RCPK'X-00$AT,,5?N2%`LB`&F&(DBN8``8#S&`#`S@#R,Q1A0ZL
MP`P`L0,,XJ*$+00`:@H(@@K8@(69<>Z%<5'#RS"0@@*L@`-L^,E;G,`%13RA
M=*ZP10Q,H(`5G*``)!A2#R1`-S2P:`EM$$$,(O"K=$2!#2?0P1`8\`()H$&"
M2L#"`$QP@Q%(X`W\<446$+`"!N!A#%3``Q2RX(8)($$'1V!!`3RD"`B0(`]A
MV()(P'`#.FD"BA\H01`LX8$%X,!2_SO0@`ZI!@`8;&>2YQ##!$JP@"JX4!U+
MP,,#:`""'\1C!8V"H866\`$A=$$-,9!`.;S``0;LP`1Z$4`.1-"'>^T@!08X
M@R+`$#P$"*$],H@!$6)``69,``!YD@H<2O`")!3A+W@0P@5*A(8#7$4A"KC`
MT<QU`@K<80,AL-H&2E*#$F@A'5GX``]NI9`.W``%0&``!R*P`0)4P`4..,$&
M&I"!!?#O`3=@P0^2P,EWNH(.,EC!`\0`Q$Q`,P8-\)XYO+"!&+BA#?N@F@I`
MI88,!"$)1FA!`IZARI;"90ETH`$&6!`V$@2!`VJPD!WZ@$ES<$`!"P!(%U9P
M``P((0!TR/]I)LKP@A@,@*7E4`(7V%`%)FC@!TBXPR:4P(84&`$(1[!&.9R0
MAQ3L8$5:JD-X;/"2`VP1"1;0RQ\,4(%-]($%8YA0WEQ1!B2L``Y-4,,`##:$
M'WB@#*YX@!`\0(9/_N$);?A4J+KP`!R<@`I,D,$\-H`%EU9H"7;@`0'.4(`=
M`.!]F5C"&VKP@B*L(0I;\,`*YF`!$^AA`!_8`0YRH((.[*``(("!MJ1*!PGL
M@`,%,`,?</"Q[ZC!75D@`PE*$(<L>&<*.PJ``0!$`@FL@`!]<$,!"".!$K#A
M#1<XP`\.L(,(2`$=36"#PSS$$A/(BP6ULT`*(,`!"U#@`Q5H@0C_"-#/_E(`
M!1M(`@N2,`(4O,&3P%)#`<B#@`B.E0P16`$&2826`+S``FR80QU4H@4AF&&#
M<"'N!A2P3`[0@8^>C;$YS(`&",S!.TJX@@-1T(>*HD,*@H7Q.90P,/#10`<,
MR,$>E^"%9S"A#B&(@0.RX`J)`<`/;EC#"E`0@!)5(0`UN,$0G#J'%KP@`$*F
M$@Y<```K1$$)8&!"%%PS`@:T8`].&`,$D$`D"HB!KIL`@P[\<#-%[!4:5%!#
M`M#PWD?IH(P<:,.$IK"`$C@8&E:(PP!H8J$GU"$#,5C`YAY[`@A(4,;L4,(`
M*C>&V/5X@@D(P@IB4*<LG&`%:`#!"G(:_S$[;$`('8"`&`:S)TU8(0@4H`(:
M++`""%A7$5)0C!V"FX(#>*D`6;C"!YBKM#?0P00E4`$*3#"#%0`@`QN@IQV"
MH``DK`'%T+@`#1`@$B6T`0E$&`$+FNV!#!B@!"((>`/T10$50&`&&<@`,K)7
M@G[]0`<;*$`:%;$$*J`H!1TX@PN78*H23"ME2XB`$`@0`*HB2`M&,($'9F>A
M*[Y@`#L"P07>B^J::ZT>/U)"%YAM`6&FV`D)48*/SR&%`,3@!D#@<@#F0(9$
M/($--&C!C:7$A3VL@0MRD$`-!!"GU)(A!`H8P@%@0`<21:$`2$B!6_ZP!VH.
M``YG2,.>EI"&#?\,X08T2$#7%0(&#>AO,1381%"8\!/0''H39)A#`-Z<"2:(
M`01!&((0)I"U)7RASA./0AO6P`:+52@,H/X`%\@Q!:G\T.9G<<`!XM`$&L2@
MLZY8@@78+0+C,((`4@#W.!51!5Q8X0(3.,`&J*P(*EB%"T(HP0%TYP,)7&$*
MJKN"`CQP!3`L8`<C:#@#1,"%'6R`/TP(@P%P4(`P3,$`2`#(`GB0NB\X5A$;
MJ(',%#&`I-]`"#A@PP<RX`$.0"`%$_``O^4!'M`!&0`!*]``O.$`#_``%J`!
M$C`/!T0:$T0&%5!$85,.36`&'9`$-``#0O`#$@`'$*8)6\`"#3``,2#_!'@`
M*DI@`@#`!70``!V`!!2(>C)6#.8P!@9P`!I@(590``(3%TR@!R]P0"7P!5L`
M,DT@!R50`[>R!@/`!5H0`SO`!U"E"$S@)SMQ!!*P!-=U!FZ``/M&`SU@`!ZR
M!.0`!3&@`RQP/C2W55]``BQP!"`@>$*1"7$P!R>@+="0!E;@0EU@`/GD3=[1
M@P<P`FGD!4.3A7'Q!!R@`Q'@!IO@`(Z(@^>P!2E@`D^P!T(``?#V!W"``@=0
M!`^0"`9@`PX``!:0`3L@`1&0,FNP`P.@+!E@`C'``\)'`"30`WP@<@'`!$Z`
M`+)``R50`@XP`$@@!_8`!7>@`P'P!$S0`#&@_U&9,``T,`<#X`$$H`$I\`$A
MT`.HL7NSM`(JH!)7`'8MD`0,8`'LT0$=X`$-L`%^Y&\S$'#<*`$$)0$3<`(2
M\`$:X``?$`$RH!9'0#C[L552D`?>1P#$EQY`8`<%T`%"0(G0D`4\`&H20``I
MX`(>(%EO,50IT`(]P`(Q<`*MZ`(:D`?DB(DLXP0#(%?ID04D0`,D(&1G(04`
ML`9M<&H_QA\+03(CH`%XP`1>@%A_P`0&,`(W@`"?UAN.^`49@'1G^``C,`1&
MX#-+\`2=]04X<`,5\$Y-\`96,`5OP`'ZQ@`.X).QQP5(`#::<#=20@8[4"I2
M4@;%-E:;HP1CL&(>*/\"1W@`)]!#.K<&`H!:<9$&%O`"(K!W0$$_+ID.9"")
M4N`!2!!2KH`&0I`"0!`'2Q`%(8`#8U`!,2``$X!_I+@!#:<&/K`!/;0$75`E
M*S`!#B`&%4`#8(`@3-`&[I$(6[9!3T``06!]([`#,7``#\!2"+`#>&`",M`'
M!M`#,6`$1#4`[_<'96`$"Q`E7J``V'<I*$``P68"%[`F^B<"%C`=-7`!DK$&
M),`!D;$`-@`!>U8`&D``%D`?$J@`$0!O2T`&#7`#,""3FR`445`%&M!#T*`%
MLH0%`M`"!P`!?)"+:[<.9F`$O+$`68`#6%`&':``&L`'']"4D0E#4]"2KL#_
M!14`!`YPG>4P!7$``01Z#F3@!9H@!710!-D!`UO@!P:`"4[0!7X0*10PHTW0
M`$"@`T"0!["7!0[P`P?D8$[@`@<@!U2P!-J@!$[0!">0!#J@`P"`D^>P`B\1
M`@`AEXI0!D*```M`!UB0``$PHYMP!0,`+&[P`))S!!X@!EJB!%)`!2YJ#E;@
M'!I:#EG04R7*"0:0`WT`!AN0`@JZ"5!@4XSC(62``Q(P!@_467XZ6#10``@@
M!3#``:C%$B,P`%K`!AMP1._3!<ZB!R>PB9*@`0M@!><"`VA`'FZP!R<0`PJP
M1,>8!RL@`O2U`$9P`#[0!N_7!*[86'_0!)`SG4``_TP@T`$$5@T/4`$ET`$H
M0`$3@"\2``(&``,=$`+<"`+5(`(1`$PA(`(&\`'`H5X_8$9S,'$'D@7CQ3\I
MXP1L@`>%]`=.(`&1N@E9D`068!Q+4`<<4`+WV0(;8`%P@`Y0H`$YP"4Z("]'
M,`%-5P4-,)(6(`$PH`$`$*B)JC*PH@$UH#TD5`5S,`=I\'YJ8*.;(`5DHP-(
M(`$5``$!H*!1L``OT`*2]@==\%,Q0@&."![*LF`TT`%?@`=?4)9.X&LZT0.X
MMPY8T``KH`%EL`4/\`(DP`5AD(=_@`8;8`,+P`1/!@$%D$K0($9[80$]I@1J
M4">A@@<?D+(E6+)G`0(\4/\'6L`#&\"6?X`%&<`#<$5E<G``!=`$/L`!;)L%
M/P`&42`''$`$!A"'<!"A;]`#,."=N)@`3/`%,>`!>C!R74`'UM(#*>!Z!H`'
M2$`"A9<&'=`#""`'5L`#'``:2N`!-"`$*^!00V8"*1"QBM`!0+`"\PH"%;`!
M$Y!.>S`#)$`!'-``+6``()`""+!_!$`!`>8`(N`"!?`!'?``_@8#!C`!)K``
M$F"M)2`$\S`".9``T!`%`J`!/=``5^`'<6`%>1BP`ZL)`7``'!`.-@IG"V!6
M"^`!-M`"_YL)`5L"(>!]&]!:1V`$F+H/4U"_14`![!$#(ZNW+;<.2U`&OP:Z
M)!3_!@$P`$,7L[-D`"S`(1[P!6NP!E'"!<*9`0B``X_V`7FY$AW``C)``6_0
M!U`P)E"P?DDP!$<0>"L!#7A`!"U0+IE04@S`-DGI`:2"!="*"9I7`&EP#FZ;
M(`"0!Z-&(585!-R'#HA:LGT0!!ZP!`_0`VPP,W<A!+3[K"A0`V+@`!P0"2&P
M!B+Q!.LG!\:CFC%``SC0`@1&+A*0`\;1!)56`S0PD@+@0199?,L%=%(`@4*F
M!`VP`[%U`C8@!"&P23O0&Z%X2'+@+IG0!CW@`S9@!*,A`A+@`"#03"50`1I`
M`1VP`0L0`A9``##P`!)``B1`JQ+@7R[0`1\0S"@P`!OP_P$-<`(5$`(DT(H7
MH$P_\`,,<`(",#!/<`4C$P,&D`4*H#4)Z@K1A@,LH@0+L`+#[%!DX%THL$F*
M3$\*(0<\L`/S.2%94`$KH``ZX!AN,06RA0(>T"T20`>I#,+G$``@J0YCH`$O
MX`'`^Q91L,(R6PY<:RE(\`!["`#=\0=0P#9>R+::,-$X\`%ZT5E-D`5:D&!'
MH``64`53,,`@X&038`-%$`-W`!I;8XQE3-(.0*97B0(X0`!-H`4",``;K1`H
MJC=U:@Y-$-7L8`?"LI;IL``^Y]!_(``[\`"P0`-]4`X"<,@]L`=-D(XQH`8[
M+0(G$`0]K0((8`%%``"*8@=_X/^D&X`#)O`!'_`&S*;7F6`%RM(&4N`$#-`!
M38`@4E!P4O``)W`",A!Q@*J4/#`'Q^@!QI,$/\`#-+`QZ+`$`3!YWN$&WJD`
M/V`"!.`!*+``)Y"/ZDL`(A`"$2`!S00"Q-P!(L`_&C!@]:P"_I4"$8`"%M``
M&C`!*<"-!J<!'6```7T$1W``(=!<2O`%`N`A@]@P/[`:3I#.FO`$%#`O&Q``
MVB`%!L4C5J"&>T`"+5#/&[`"I<($`-`#/;`"A+U574":!\``)M`!6@";!$`>
M#Q`M*F`&@NO5T``%!6#5Y3`',-";%>(%<M!3+`PL9_`&6\H'E``#3$D#-=)T
M=QD)!1#_AP[,D$3@!U0`55M3`PJ6`I31!DN(@)PDO`BP!Y1@`0'0`B6PML!2
M!Q+0+V9X!!K@F6B``'APB5*R!Q2U"6&,%GXPU'%!!200`R2@5.@PAB0K8U"P
M(XT5`QM@XIE`!1)`!"_P`6I8N@2P!30@2Y7QSBE``?NQ`Q?P4#HP!E7PQ!F@
M55-,`QX0`,X2`SY@DWW@!'40!!J0!CR`.!>P`BO``SP0`C2P`7?0`_)K.B)@
M!$A@`U*N1K=&<U#0`$GP`@R&#"%POB4``1D`C["H`@H(@.++B[!M`0[@`K?M
M`10``@A@K@M@OK_]@-`L`0;@`A.@<!0P-SMP`X*SF2+`!BAF_P62<0)\T`)E
M3`8N,!P%``9YG`%Z8"!-0#9'I!=*\`8CZ0$6(`0CP%X=(*9\-;M"L#^B-K@2
M8)/;90(3T.0*#L8.;@YG@`+DG.#'X04#T,-_<.&/I6@:4=0H4&Q04.9`P`,E
M+E4L-0627LZ*$`4C0P,C-N9>D``\\!)YM#MF,`5Q:$-F$`9^X`1GQP(VD-^9
M4%P,%@.%9@5OX,7OQP0!L`8E\N2#NP<)T-4DA`8,8@``+ZE\(.8E.W[&L5V(
M^@4G@`,^,`&K40`X``!/\`(9(.8`0`1@8!DQ@`)VH$-Y@`,+```N<`(T,!XH
M0`=/L%P1\#D00`8&$`)$0`3'B`,7P/\&2``!`'$%":`!R,@'6H`PB=`$C2P$
M%9$.7U`"`NM#)Z``)3`$1/#<,#`!K6@`]RD!$G`!);"])-``&QD"I_ZP%"`"
M%?`!!)`!M=P"#S`!TLR/O5P`,-!,'C`!""T",X#Y_D7J\W`#$L!RFE`&!F`"
M+``!<:($:7`P._`&3)`(;9`!,G`"=-#8M@`#.?``&<UV),`#Z6Z#::0$:,L$
M"K,$;FT"(Q`$UR\&,T$`/$Y0)H`"73!T^4XA3I``&T`#<=#0YP`%*@$(2G]_
M:EY_2EEK`&=R*RX%2X.#3@D_/SHE`7!Y>)%*:"<X`0`F+AU>5'U*2F(!"D`_
M+PD#*RP_.`#_7X-M5G%-?79P)B\-49*'6QH*0S005(-*<`4!S\?6UE:"@G]8
M`X--:`EFU=?EY4P+-!QAYN9R;.WQ\O/Q33!V?TX,NM=O03Q`Y/RQTL$&&3\#
M8/!8HR52$S9"%CPX$*.'"08\`*B9($0.!")DE*3)0>-$#R0]\&3HL>58&0T[
MFOSAPN-.)$E.$`AY`@!!BQT%_)B(L6/!MG9.`!!Q(.G,#APP?M#@(\+$``T;
M#*B8(,'`A`-S4$AHT+6%`0@O"GC8\(##!1@$(NR`($+"A`\!9&3(0Z.`!10=
M/N39(($/#0(=7BA@88`("R,_8LBY<O/8EQY!)BQX)6/)&Q@2V$@9_Q3`!XT+
M9R)E$7%#A)DH;1340()&TA0[?R5LR+`F#)-K2O2LH"'D!@DT4I:@P6&B@`$D
M*020HT>]NO4ITZW_"4-D11LGVB4]29`FRA<N5P(LH-)&A1!XQY:`@3%$B`X%
M"I+,8(.FI:0R2!S!`Q144/&;'W3L\,,1/MPAB1)\,)`?!VF$(9,82[C1`1)&
M6:,%`3<P@,0#OTG2Q!U':6>&'EI<D0<493C0QX,/ICB/$ER46-T8!83GHW52
MG"!(%C:,8<T3!-```PXAN?'"!G"HP!8*!QR00PAR@(##`!O`H(L8#9@01`DB
MB&!'"#"P(\D7)J2P1110C!``%-LH<08,)?]TD8$$)3S91Q1+1)'!"P'@,"4/
M1K!0Q`D"R?,$"#3$$<D2`8Q@@PXZF+!`!APT\($!&8@`P0P-B``"!%U)``(!
M&S1`0@8$A$``!QI44$(#%(C`:@6$&9`"`1:00``*;6E@``H65*!!DD7L4,("
M&K05@PY'Z""$!F0\<8T9#XR``0Q@-)`#!`M(0,,$OBW11P<FJ!#'$TI0$8$$
M"@A1Q`9N0/-%#!L0T$`%?A1`0@DPW"&%C4KTX<$*1/A@`P1C.,%&!BE(0,$&
M)7#@ADP_=FR=&@-`T?$3`Y1BA[;A37%''@8X(``85<20P@4B2\)$&"H<,$11
M3RPQ0`E`,)!"'TW_=`'&30.DL((>=URAA@L*Z)!#`2@_"*`.%'C!!!E,W/$!
M#19H<0PB(@@!&0YA",($'&)[/,@7`120P0!L5#')`PIXX,0`1`AAAA(2$($#
M?&X?XP4".A:N^!]3O&",$SW,<0P6*L@`QPY[*$$'#A38\<('V6P1P`8]O"`!
M`7C`H,$5#[JQ&195#%!$`79+$@8.&9AA`04KQ`""`%TT`<<*']!A@@=Y2%##
M#CU(L,`,)^2Q@@54*`%&#"QT!X:-UBCA10@MN"'($Q`H@+T.,"RP@0<4?/``
MK!VHX$`&'1"0P0,:-/!7`QK`2L)=!+B8I^['`:Z0H`$GF,">*L`!5-%O_P4-
M\(`&.C#!%+BO!`_PP/UT8X0AA$@"<IB"-;86@144P0@`L,(?JG`'#;S@`7&`
M@A/4X``<2``!8]!"!D9`!!!T81!,6$,-%F"&$[0`!#&@P!W,@``9G(`/9[C&
M$\`P`1S@8`>',4,5OM``XB'F,&P0X>+&^(T^]"%QX1'#`FI`@CIPS#I,N$*I
MU,`$!/P`!7`HT1+`=(`;*,``XAO$$K00@1[@QP)F"(`<QK`$)6C!`#&00`84
M8(0#+"!?W;N`#RA0!Y7]@0X&6$$&VJ`C1R*`!CI@``@H\"0`>.$.`ZB=VYP@
M!@M,(`LZBL`02C"$"P`!"2/8`18PM8,9C<T)3/]8PA0J0QTGY*$-9%Q<%8[P
M`4&480<2&(T=>F"`*$3!!G]X0!#:P(8##``\Q^!`$*3@!C;@(`6&D(0#>B"'
M"_1-""^H`0A:4@`A!&`B?+C#`W(PIA?8BPT%8(`>)#$&`Y1@`PB(@Q\4.@D<
MQ.`&$!B-//H)@1)=`0<]2($.BB`"!88R@H_@0`8J<,`6>&`"+]@4!PCPJ1)D
MP`.:ZH`(VI>`%E#``#0P@`4X\(`-0.`$((C`"RJ0P0Z@H`4W@`$"3#'4":``
M`B;80`%40``)I.``1^B;"C0Z-C@\``<Z(((9!C$%"&S`!P\0Q!+H0($1("$&
M0AA`B:0@@ABP80%(@(#_(*#@$QJLH0EX\$`05J"&<IRH`T(X@`UV0``E+,$/
M&<!!""X``AY00(S1+!P3"H`/MRGA`B=(0\=Z<8$]["`)(TB!&*;0@0,D00$0
M`*TUHN"`1!V@!&=0#^O^(`4'*.`'(<C",6KV!RA0RP1PR(<%%/``?N`$`D)(
MPA`L0(9!Z&$/&O`!`!:WA6ED1PDK2($9_`"'"]"2`7L8PAZXH`0YN"$+`<#"
M`21$`R`TH&KTB`,<N!?:\$1A!S:8`'WAX-4.U*`"2V!$"IS%AC48X$H#V$(D
MIA"!$B!``BN``0V*T#P`I($`S;&`"0)@AP64``<Y>,$,'L&GZ/[A"60HP`I:
M_Q`',J1!`6M($>52<(8!3(`'(0C`&E(0@RVA\1I6,,`+#NO=%^"`"$"(`0%>
M18$,*!`%7/'``U!`TPI8(`43.($'@D6!:'G`+I(D@`@J<#\*G"`"(="5"`P0
M`@L\0`40R``(+/"!%!`!!A1HP00XL&80&.`#]3O!K#PPK!``80@Z&,$$``S$
M.AC@!D;H00'*P`0L^($#);``&JH``!WT(`>=&`080E`"-X"!!@BPQA5:\`(L
MH*$/;UB`"R20!RY<(PII,,#R<%"""9C!"F;HL`0TF`)5Z[;`X9%"'@+IL26,
M@=/:64(8XM8!'S#@!D#@80;H6`XEE`&F&6A`<81@@?\^".`.6A!$&!Y0@PRX
M@0EH^$`,9H"`91I``><VH@3N\$9NY.%2"DC!`,30ABIH(0!56$,2#H!.MVE!
M"^!V`@]84"\[*$$*.^!!!5B`!"($H`<4*``.SH"!#,!V`T.H376D\&1L:R<*
M&I@""C@GPBT,((H!L`'!3)"#$<P@`RM``@]<P`$V#$,`-)"`3."0)`:L(`0J
M8'`*E"N)`*0`!6=P`AF$$$^<O.`$;?4`#%I``BQ(P@0M``#N1/#5'V"``:.<
MAQ1D$`-R?)H&1M!!""+0+P*D+P0>>'28)Y`"/'O``2%H``J(VH+YG4X"#D#!
M3E?`AYM:-0(GD$`%3`"!H9+_Q0"[<4`)'-`6V",P`XQ7X$LE\``)A``!64$!
M"X[P`SJT8PHXP$`+(MG8/VR!`BX801"0L#I)O"$'!'#"'180!!6H5A(A,($>
M4E""$L@``7L[P0NJ?PTI)$`"^RT!"A*@3/7)P`($.,$*O.%S'UD!`3_4?];A
M!@&0`!UP`S\@`6UW#54P`3&0`5&T!&5@`44P!#C0`&8```%@#-Q``$1`!"\`
M`58``"U``P'`#2]P!$*@<\<0`"N`;CQ@!DO0!%/P!`(P`&N``Z"&`CU''5K`
M!@2&$T&``U4P`C#@!!G``GT`-U"`!"%`4@O``V*``4LP`B30!T9P@@*XA<Z'
M`C?6_P8$L`(B$`"C<05`T`%:H`$RT`%*0P`(P"4]H`$?4`!>(&IOY&T2@`-8
MP`4$$`1LP(&#@`;G(@<4H%@X`$,UJ`>4%0`QT`$0P&16Q@%R00$..`!-L`1D
M<`!&,`(;<&W7P`1LL`,34`U3$`('\%I!<#JG$@(9X``M$$&GDP$&((<&<#HZ
M10%)]0$?8%44,"L/\"E[`GL6(`(S=3HBL`$.L!OMHWXSH`$P,`$3Y`$SE7D=
M0"JA4HAD,0$/$`./I@-)0`,W``;FL"\V-P5BX``RT`()T`5I(`/U$@$:!04+
M@`-T$`<E(`$?`&,],'OCIP$%\`(&\'$3$P,1P`7A$@,A(/\`9'<,46`'!(!@
M6&0`O-`&[$)I&E`"%?`=7'@C63``*M0QZ3"*;'`",8`&2[``)[`!=6`=3M`%
M`#`':M!PQ]`%%7``*(`&-0,%9W`%'+`@0$`$$<`&?0`%F/@`/.`!1C((4<`&
MR[<#*2`'@'AC=``TYM,T?P`'8S`'!7`&4.``CT&&/Z($<;`&W&8.3$`#+:`$
M,I`"(L`"`+`$>)`&2K`#&Q`$(A"%;D"%(^`!;&`$>T`/8/"6&QD>9T`#X"0)
MJ_$",."1'&`Z:```*Z`!1Q696"<">\0&/0`!@*@$#O`">U``,.`"!T`#&A``
MO_$&%[@`1&!+*U`#"J!9I,,'FD3_94U0`"E@`A^``@`P`#W07<YW`C00!`00
ME><``3S`!Y*P!25`!#;P`SU@`1ZP%2KP`+NB`K`2`KJW`'#Q`1*`9X\6>:VB
M`1+0`<@(`AQ@`#``*B%05`;``:`W`P3@`1/V`Q8PC"[&`2#`%HJV)PO0`J%B
M%RA@`&\V`"I`<BL`!&M@#GQ!`4K``@.@+4[@8C20<J(F"5>@6&E0*"(@"&;P
M`3:``S20`A0@!SE0`2F2B1,P"%@``3G0`A=`G(/`DRN``TAP/)*2AI'I5BL@
M`<8TF.V0!@L@2]HQ!2RP`XS!``QP`#U@!>CF`W^I'4XP!C(I"7Y0`C%P`7_0
M28S#$RTP_P0,@`.N:00E``!8X``'8`)V=PU0X`$'D`$+6`<9P`!`L"5PH@1,
M,``%0`"JE053``#\@B(^$@U!:`T;<`-SH`,]J0,?`'P*@`!)T`$*T`(G,$YZ
M20)WD`1:&`]@<`%IZJ/TP`040`-X=@U4$`<2\`(4,`!^@#$$L`!L2%02X'1.
M68+$P0$(```HL`%YT`+X\@4%$`-$L`/I10.XN@%J$@7A@CMRX`5F4`1OD")>
M4`(40`8(X`$[D`$(D`XT(`-M,*AOHP(HX)M_0`!"T`,CH`.2=@*=@@(-P`$<
MT`'GJ0&K)&DBD`$4,!8?L%-LP0$6$!B+=IX^U0&4%J`?((OK`_^=7=55/!`#
M2#"C.6`!O#<#)C!F%$`"'E`!8T$"7"4!%ML#0\`#^*0FV$`"*Z"%++`!TQ,`
M9X`W/#`#7;`-;_`Y5&`8;V`-8X`#&F`%;,`!/H``&#((5,`!--`'*M8J9@`'
M#1`#'"``9`4-4U`'??6A*8"!6?`&0BL"185FI.2IW:,%G:H=95,`#0`'%?`%
M<C`$:<`"*#`'2E``T-8&81`"1*`#&X"H4_H@==`'2?D'`(`!(6`&,G$%4#`%
M`X!*(Y`!:,`$4Z0,(Y`$1W``*M`&S/4@M<0"$N`$32`'(0!J&)`$'M`&6G`&
M=[`[(A`!NN`$D2`%!="P"^")U[`$5W#_!V6@'5>@`B,@`5>@`",P`B50!2DP
M`B*@!3W``+["!B4`.'?@!22P@.9P!D+*M>T`.#B@!U`@`>W`!0*'`GY0!^H'
M`GOP`"D@/R'``!)0!\E(`Z9A`AJ0!BD0`K(D!0MP``2`DQ?``WL["$_``VB8
M``:@67Q0,[XK`VN0`R=@`B#*`@P0!"F`2?%0!B6A(PV@`S7``CH0;YD7*V[5
M`0]P`K7H+RT0`1I00.R*`A10`9FW`1I``2'`9_>#`J'':#,P`+QW++6X+#,`
M`2KE`.DI`?Z9`A"@`D'@`R/P`2$0PC5@/QQ0`"ML`4)P!"5P`QV0'8/`!1L@
M`P'X!TGP!%L`_QE$<``^``+'L`8]L`!/$``5\`($T'9+T`(E8'4P8`)"(`0B
MV@5<<)M94`,RH`9KP,8<0,<48`(E,`!-:SLBL`(\L%BY\P=@@`+I"`$?$)EE
MP$S0^R/9];AKU006$`1Q@`'#!P=)H`<A@`(!<`0T\`J\)([M\`1V@`#^(0='
MP`PG&%PG<`-#$`.Y=@P/40(_P``4$`0U0#B2\(\?3`%<$*=&L`,@\`*@A@0B
M$`?JXRU'L`-K\!MNH`9XX`8$@`,S@`?Q()8#$`<P2@^2+`F18`4X`$V3['-0
M<(^C`73R,`5FL`+F1`9S`*8!<`<P$!$Z1BAD0)=2X`0G4`)9P$QZ,/\$;S`Q
M5)(#?(`%3"`21K``<!`$];FP-A`$!:`'0M```X`$`;`$3F`&/P`$0&`!X3PV
M"24`Z.0$+\``/8`!0N``:38`H2PW!B!I"Q`#`,`!*@`JPF@`+H``B;9H$``#
M%E``LT<6!*`"!6`*")!@%`2Q"P!V>R`#HG(Z(6";,#`')>`!#<`I)T""9WH#
M3";'K_4#)X"IW*,$9J``%L`Q37`!#'`&*?`"/&`#0C`'',,$!A`$<$`'/-`"
M*]`#*^`#)Q`'<=`#(K#1""`%5[`'*2`$?8(#!F`'.H``->,]":`#,R(%:)#/
M!3`&"%.J)U`$2_("?T,%?O`"-E`'`+`#.T#_!ZZ[D3[SD=5Q`R,@!@I``^/Z
M`P``!7RP!28PP0&0JY5"!TZE!3I06O&`N8?`!&?`2S]0!#5PKC@`!Y-[#$[@
M`#NP0@1P``;0!5@P!6Q`!'CD:2P0-`I0`"*T!&9P`TD`!#K``D,P!!D0!/'=
M`F/P!4[P!#*Q!00P`BV@-=:P!%^P`)*+;4`GLM:1!5_@K>G\!"(0`C<1!=9+
M#V4@`?S"!G2`)Q2@!WQ"PC/P`D"0`!8``B5``S40&H)@E&T0`C@@MC!`!`Q0
M`RAP`CL@!WT8!S'ZB#5`&(3(`VW#!C10$7EPM\=@!2&P`M\W"!TP`CS``)H2
MC/L*9BNLPL?R`&W6_P`@4`'#`GOPFC_1D@$K+`$<$.'00@#YMP"`\8NSV`$3
MT`(8^P$>P,%R7@'5M@'N$Z`JP`$.\"E>=0+4,@(W<``ZC@5?L`55$P$Q0`?;
MP`0;8((\8%&1KN.#X`:`G051:!1-X`<:$`,TL`*:D@<+80T`P`/\1R8=]P=-
M``!"$`<#@+5;P`4HL`(G<`=/M@1WD`$E<``Z8`$J]`9"X"!_(``E($KWZZ-F
M0#/6$0,B\`<J@%M)8`%_<`5KE<TL0`?$K0!L$)U9H`,L.`]:(`!ML`1[$`-#
M$,T1<-W7P`8Q(`E:0#I(@!]Z$`!]L@-'X+G^\0=G``!W\*OWCH9_$`4%</]<
M1-`!8#`%7S`%7/`$;R`"-1#@0$0&`T`'@VP=:,#H!?8%@IS.\E`'.E`U%'X=
M>L`#"N`'7'!P*0`&:L`#2$`'QI4$]O4!-\!T79P"8\``',"!3A`&@4-$52`'
M-+"0@U`%D@0%5C`!+C<%;\``AFEL'8_,UYT"1_!W=Q"9`^`^*2`1-&`&MYD\
MK**-Q,H!*5``(A`F%V``/!``%,"N)$##`W``!AB@$E``8!,`.]``!4!FMIIZ
M=K`#%E"+$#L'+@`#`0`V@>8!**`'*N`#=X0)'$@%<*`'SRH%&C`$#-?06T`#
M#U``0P#'06`"S`4&#-`!2V`!,2"DL*L`9"P%C7G_!CK2!.%U]+R[`FR]3$Q`
M+U]`.FU0`;Q[!9`O!`PP)P@S!6O``#^`!`2@`P70!+$.*%;0`$/P`./,A5?0
M-M3Q!D"`!D"@`2.%`'T0(:/<E@V0`AL``"-P!R*``MVNW#?B!'L0`5J@=J]!
M#W+0[@]R!0<0``8`6V4`"$U,`3TK7$I_?V11B$UB6(F14@A&0$,-8TQ,?Y!1
M`D<5408"4)&FIZB)2U8G!WFIL+&I80-.LK>XN;<+!*91)XBZB4QF)R49>`@E
M)@UL&C`M#S`N%'`$"G)E?RT@2Z9*;T(!=186.!EFD6<K*!4T(2D["BP*01Y2
MN'D*"ZE3)T0L6#`PH8&`_X0+(D!`B);A@X$9$#IH,+"!`@<-$TXTX)!AP@82
M$E10?.!!PP(4#3)L*-#"@`45!C-XV.!`@P4"*%%XL!#"P08"#3[X)&'P0H@;
M.DPH</`D%9D8*MJTB1-G`P,8#XP((=+C@K<_2@CL8&/%#X<8!2`E6I<A@(P4
M*8CL@-'`2I\8&=#LD!`&P88>"FBXH)&A#PX.7Z$,*%&"BI(R'VB@L)-J28P8
M$;HX4;%C!D$M?\1L*+%)F.G3N%`H:-'&1`\?*:2$4&"BR8$@*E[XL1`F0((H
M'[B@OA(@#YE@N,P<<$#%E`D223H`".`E49,"1%Z`$<;$PPX,1T244>*EC'<,
M,__*5$$=R0P,&A&:L+\E10^`K_/S"R-`PU23%0"PMX07!O30`AMX:$`$!6^L
M$<,*#E!P0`T_C`&`1#NTL(=C3`PPPAQK^%"!!@KL@$0*;`2``P%BW<%)'AB,
M,$0!MMP2AP(WU$#'>J<T$08)!]SP`PL\+%""!`B$0`!&'+@@0`@]:4#!1!2D
MD,<'&T``P@,A1$!`"0649,`)$\!0000T%)"!!`9D8``*#R@3`04AM+G`"20X
MX,($#VCPP`=Y;,!!`3&P``0.-[P!BP`*)%!:%`W<<(<5%F!PPPVDJ*%&&1*L
MT,4`/J"P@PTO[#`!%V;P8$$!XECAQ@0[U+""$$%4((#_#P@T]4<39A!@!!MP
MG%&"!34FHL0:0F#AAAQ>@)$`#3FPT9PI"VSPA!LK:)#%'UY\$`,B3K30@'[D
M?J$&?K(TH85\3T@QA7Q.:*%$%T/4H00CQB*"'&I;")!'%OO"0HP).Z2AJPPG
M"/0`&'D`,,44`4!`@!`2R)N+$EELD(0"0&CP!@M##'%`&/,Q(<8,0:1%+BQ-
M`#`'NBO'C$H'1P1@RAP]V#R?$@&48`,%9$!0@@L%^($"#!)\8,((-P3`P0Q"
M("'#!B:L0,8)-%R1"!<&F'"B!'2<D$)S2ER0`PX%Y[(`$C?`808**VQ@AGP]
M\I$"`S_\@$0)'S2@`@0B?!#!_PP/-#3!1"!H``$,/+DI^`>";U"X!`ZHX$`&
M*K!$P)H32$!2"QYED$$(%9#>@0H5M.!!!B!43L`$/`Q!@Q`Q"(>*$A+0H$TB
M7M"0@A)+&,`##S)8`=84`#`@`14?'/"`&6AT+<0.*<"P1P,OI/$-JR3_T0,%
MI27B!`0,N!'!:"^$($!33!"0PQX9X""!"<QL\<8))GB@?2(J@!#`#@V@&UA.
M@(!$D`$&Q9*9,)8@@#64@EQ82`%H8A$`/B10&&&8SK1P\885O$``?WB!&T0P
M!!8<H`-U*$`!ZI`(*S0`!Q]02RZXH*`CQ"@%`6*/$M30`@AM4(&)Z,(%U`#$
M(IH"`O\FH($<:J0$.93@!'6(PGRD```-O,`#<;C`!EZ0@`$\H`0@$$$(9+``
M/53`!35H@`.^\*4OG`(`1&"#%L*``QB`P0H(\$$=T8"+)X@%`"APXQ+8\(`7
MI,`,/#)%%0!P%"#\8`0XH(A01)(!$<QD`2'@0)LF\($.?.`$!@!!WPKB@0Y\
M"0(2R``J";`!"WC$)1)`90<RH($*R,`"'&#3!QZ``B6EP``/8(`1:C""#6PA
M%6/XP`J("!8[F(`"6JB"!'RP`Q1,JPE^X`$!FL`!UHPA#&4PPQHVP`((O($-
M+;#`%IP0#"EDH`1>((`QXC8'*BQA"KD+6PP:H`$A\"`')TC_0`MJ\(8,R$`;
MDU"F`Z;`AK-P('HKZ(`/!`"S<2;"#C;`AQ%U$04YK$&&^8%"P$YAAA7,0`VZ
M,HT3Q%`*)8P4%6,H0`TDH``0T``$$KC!"'9``CR<H@T<P,$%L/!25"Q!#S%@
M``)`RATN<(`&%7#C1O\0!3XP<ZHQ6X)C'+``,BA`?72+P@*"$%"FJC0"9`7`
M%U;0@P[@H0`^`"4,</```N@@#'7(0P96``&`)<(-..@)$GSP`A\,00>0%$$N
MJ+!%*4@!!5<%RQYZ4(,%C"$55."`#T9@0Q@H\R03X(`((!`#`DB#`"`XG`@*
M,"P"I*`!(.!G"`*P`@)08`,34"4(_P+:`A0X(`:'<TD)[,:!!H3@`6QZP$HT
MQH(2C*``+W4##S90FB<,@`@)",T*B."#`D0B+$&H`Q;4P(,(D$&`92B!!N:@
M`R"4H!XI>``<WF""&<!!"!M`PPD\R(`5/,`%&V@##$LSA0_4,0,%L,(+8!"^
M1-!A!&BX0AJR,($CX*`$.#"K$EJPAD28@`A2Q&HNOE"`,!05B`$@`@KJ`#-A
MG`$/*97%$AZ@@Q),$`PP4,`1#N#`4RBX!P/0:"RB8(=$LD<,'5!`!6*\T26$
M6,3DDH)!E#`'&"CA"36)P0*^`*\`[-4"=9C"?!;9J0D(H`(S*$$>$&`!OL6/
M!R:PP0/BL?^#%7R`#0;8YP=@``<ED$$"/V"`$`K0X,K(`0<LX$,6I-"".,#L
M"6R@@`E08`:B^G@`$AA"$HX0F,Y1@`"[Y(!%8(*"#!BD<`3H``H,\`$+-``%
M!K$`G0P0@@]HR2(>($`+0*U**7V``\A-2=]*0(_IZ6&D34B`#P)`MRN`(`9M
M@((#;-"#%W0X$6"`4AN0J`$:X,!W`@@#'>AJ`!L$0`P#^,`.HD:$?:Y!`1+P
MPQO*\`4'M*`'"Q"`&V@P+E,XX0([:$(9[/"@`%QA$TZ@PPHFX($2D*`'!^`,
M`;9U"B;HX05,D((#@E`"(4-9%E<`P!U^.-4NY%D"=;A@+J)`ACS_;"<7`K2.
M'X+`@AO$(``>?T(<)*!FDH,E"@W"PP-/PP0R>"`&#[#=1I50!:U]?&5<&(W6
MNL"`="3B"2E`@@780#<H>(`!+?"#F.=#A18@@0-R`"R^W6``BA&J!P90PQU>
M4`*SIP`,,=B`?)0P`!Q\F.(ROFX!T!"$%5R`YQ`(0XOY?H`7%,#IIYC"!A1@
M!`Q@0`,S*0"P35V`';@$!@L0@4$\4``:=*#-"_!`!'IYZ`DTP`0&(,HSYA`#
M$DQ@X1F(0`9:P%H0%.``/W!-#U3^AR=8``F0!^P,J#J!`^1@!T+^P@Y4,(8,
M^,`-?[A""/S>`R(H``T/4(#Q(C&%%<C`_UA'N`/PKO"&``C`!$"`@`-*GX,M
M!Z,"2)!#\X?W`B/$P`"]HE0;D`)>4`!!(#P#``MY@`0```4J@`-A(`$>]W2Q
MH`<(,'X?=PWZ,Q^VX%+SD08X,`(_@`)W`#-F\`,:<`I+``<+T`<G=@MA\``'
MH`$ON#)*``87\'(4R!Y-<`<XT`$A-D@Y0`J1<`4+T`(Q<`%A(!]5L`<:L")B
M\&2G805Y(`%:=CTP8`)SX$79P@$;X`()D`$[0`5B``8TP`%M``84,#P9H'2I
M4`534`4H\`,2``=/P`1IX%H]\`-$4`*656A1$`</$`,A8`=6$#!8,``SD`0_
M<`0C`%PMT`$4D/\!%2!J$I`E$D`!#2`!%2!Z))`""Y`"%,!JR/4`(K`!;:)*
MF2@3%N`";\(!G/0F"J`#*W`#!C!VIK`$=2`#$G!,?S`(.%``3Q`&;,4#%)`8
M:Z,'4&`#(K!!2C`&!J`#5+`%`-`#<Z`%7W&#9_@%B2,#.*`"=I`%3>`&)K`!
M`4`8Y\,"/R`$(4`H,Q``,=`"8K`$7<`'$A`$)I`!%M`&:?0%[[0!,0`'MX,%
M,%`"9@`'/?``61`&(3"!.Y@*6U`'3(951L@W:%!H',4&9#!T*D4'&P`$(T`#
M;.`$3*`%$]`#27`"D1`%:8``>&!DPO`$<+`!$`)X6&4%;V!6#YD+3.#_`$(P
M`!QI<8<!`*6Q!%=P!R%06V;@#5.`!AQ@`AP0`,2'"TI`!79@A0\P`,KP$P#@
M6H("`T!``Q*``RE@`C$P!-SE`Q;@D-^E!AO@+>\H`B\@`@#0!$XP!A?0`&HP
M`RS0`A%@8J?@!&I@`"Z@`0C@BZ9@!7<P`PQP!$?``BFP`1(`:KG5`0V`6Q^0
M`9O8.1ZP`#!@`!Q@:VXB.F-"`3/!21`@6AEA`9YD$$8@.PR0!S$W#`&0`QV@
M45@P5GM@<280!#M`A+N2`32`!ZAR@&>0C0HG`@D``S#P`D60`A?P!4P``#)@
M`"%"``!P`CN0`STP`PV0`AZ0`#&P9$R`!7J0_P(X4&H&0`<'8`-ZP`9M\`5B
M4`9B*`9MX`!$X`!P40,;<%FH``<G@`)I\#\+4`K$B`<UN(-*P`0N]00)NC)+
M<`8B0`,6@'VGH000$P!@,)6I(`5T8P470`,,,`(>T`"UJ#Q2-09SL`=6T&*X
ML`1J0`+`!08/FA],X`U+X*([B0LAD`->\%).L)PCL`#%,B`00`,\H#-_H`5S
M,`/[P*&XD`4%\`(*$`!D0`!!``-D$``?$`0;X`$F(`,MH`-&0`(M<`!R,)NG
M@``'4``!L`$'8`%/4`4#8!4TLBLM8`)ML`=&,`(K@(&^T`<9(`0RX)^YN`4.
ML`..>00WL!(XL``6X/^='^"9&8``*1`!(X$"$+`!*(``MY0`DVEK']`"`.`"
M(E`37`(!'U`"1T`#![`#D64*%,``>%`:3D`#-0`:$+`#/%`";1`)6K`"''`%
M(M`#,7``*\`#*>!&$-`#>D4#:``&`Y`"-H<#@0$`',`#OPH6;@`!"P8`[2<$
M<:""+/$'=K$",#`&4W`%8G`&=B4!.;`"*H`!+&!]!<"69B`$#>`$,NA3B1`&
M2'``,4`9.QH+2@``.?1T6M!V$B`@6+`'2J@+:-`%O@``16!Y0P`"9H`<7*"3
MN2`%*7``$$"Q'X<`$U2PIG$'P@J3IW`O=;!7)""5QH(%`+`!,M`!9)`(4F#_
M!R@@`R+@!Q.I"U3`!A(@`QXP!PD0F1'`!@X0`A*0`C$03@/X!2=V!1GP`B7X
M!TY@'B\@`0"@!2_[`AJ@7F*P!CC0``BI`Y)S!JC@!%Y@HNWHAG^@58O)64<P
M!#`0`B(06IMC2C-@$)33$1*PM[_T:R6!6J:V:[FT.17P`41@!"\P`BW`EF+0
M`BW@BTU$`Q-`!8_%G1)@:4O`!SM0#2D0`EE@!0&@`3%0`R60`B7PIC`P?A@:
M!SO``6%0!6U`!'UP"B![=[P06`F@%D[0*05%=S%``T2P`1&P!]X1`2_``6[`
M`400!`H``=Z@!60@!EH@!4O@`37`!CBV`389@06X_P(G(%4H&YAH0`<8.54#
M0@`Q(`)L>QI+D`4"$`!J4(-V(+?F2@`N8`>"\`6&RAYFD`'_MP4ZJD!4T`<%
M\`4)G+ZH0`?Y^<"G(*7OE8"1`*,-4'B[&T2>V@-RT+ZY0(\7L`(X$`!X(`)(
MH`%:,`9(L`%W$`04P):F4`,@P+)80`<Y!@!*0+/LZP$'0`990`,;@`5\L(XP
M@)BF``5$*P0?X',1NG&+R@"YMP(#@!.7TP`M$`(+T`,.$`$:\0$3T`(2,``O
MT`&@=0)(=`)Y4`,B4XL(P)'`*@0/H%%\)P1^\`=9H``XP&/(00`,4`=7<``&
M($!+``8@8`/K80`^P%1XH/\`?'`&*2`V/%#'_WH`'M`'/"")/3`"KL$!:S`"
M&=`%1?`!4\`$9U``/"`$*-!*Y(4`3!`#/%<"71`,5'`&=?`&`\``.C``#:`#
MH7`*#(D/49``.V"A$.QO%&Q$8=``(T`LJ($Q?C``-HD*$RL+58``>@"HIB$&
M,-`5W#Q5;K``(YG,N=`%'"`$;K#,+?L$:+!%;I6-4Y``)O"9)J8$4&`&:=8!
M2SD?4:`'6=@!`O``)HP`\+@&":P$>[`<(JRU97`#&3`>8)`"&D`%?+`"PH@`
M0R`$&J`#1U`"$R`&`=,$5D``+[`!"5#-^`P`U.J81O`!,]`!$Q!;2B)/!;`!
MJ37_FI+HBB$@.;&D)!-``T!P`#T0!%2+"E0``4&P!U_!!<+IP`:P`SL0`_F[
M%H9D!6HP!THE0T[@`#60!Q8@`3`0`T)P`@NP3D=Z!P10!`,P`(,Q/*I#`U?,
M`WZ0HU0``$B8`0\0`'9``W,@0%79`C-@!69``38``3P@`3M``$$+`#3@`5Z0
M9`00!IM0!7:0AF+0D)%P`2?`LN;\!7[@5Q^W!%C``2M0`=UC&DIP!;B8"FC`
MOZ9`!5G`SBW+!I%!`%50H_FA!&X``'P@4N:,"U)0`B_0VJA!#!I@`A+@K[2)
M`C_CBTO0!E:(`M4Q'TW@D3'0`1.&!3C`!K>@!"M0,VIJ_PIFP`(Z\`*B0@)7
M,``[X%T&<+>FI`$\D`08L"+AK,<34`):)H6JL`<A8+=)`0(5H+QTTK06T!`0
M\$L&P6H4``*D8P(/T`$\P`)"H``Y(`:P\`$^L+&)L`4O8`+KL:M"4`(8G@AU
M$%%=H`$R0-8TX(=6(`4GB0`2\`)F,``>,#LQ4)9!<`>YLZU5P`>J^Z5QL`<\
MH`>!"=)_(`5KD`,(L$&AV]Y0FP(8$!U%$K1LP`.%'#_[<W5E@`9P$(%2$`=]
MH`9F4`,='-R1``5V,`!VT-!%I`1]``,\,`!!FPN$K:;7?`I0\`9UG@M3X!T9
M<+(B)@5L(`!'C>:QL`078`-_'?\S2B`%=#`#*2`"+*0*5%#">[(MLTO<^D/;
M+:ODDUP!RGT'XYT(:4`$.-`"+O`!O]TCUO<#;U`%<X`'<%`",*`%::!C*?!D
M3X`'/7JWM87,D=`$7=!FF3.!2R`%!;`T1_`#0'`")V`!J[.)F[,!_%1)$G`X
MJ=8""R`!26!S2C;>;(!T=@P!/C```F<".)"0=%,%_`$``P!<[@)(,6"L*P`"
MBU$!3$1%56H%3F``*U#-7W"VO6(!._`!`,`CQ*@";``#*Z#?/M`#7.P'QF``
M.```:N#P+4`#/XH*5D"39;'8_&T*8#"Y32`%8L`&),H&;.#ET\*@R>P$7S``
M9$&!`S+_/Q8@M\SQW5LP`!P>"7F>"%G@!VM0R[<0!:*M"@$`-PLP!;I-+F=@
M](@>"TTP`#T``484NB>PR>B;Y-\I`Q,08E&0!RW0M0-,=`/0`CR@%2#`W$N,
M!!A`!''3NBT@`.T$Q)SU!DV@!&9P\$K0!A/>L*E0%3ZP:97EV5O0`56S!L:=
MY!<``SK0B*NA$:_5.9O:`2)P`O_U`'3R^#=`&T0P`"XJ?2!@JP;P/G\P\$$P
MY\@A`D*`!WHQ`:;`!*77`5H3`[5Q"G2`!&:0!A[``>C-;(GP!3(<`&4=`CV`
M!/QYOS2@`6`06$TP!0.``NMN`F3L!S2P97`!`S*@DU2P`BG0__,\,`$O2`>Y
MGPAWP`+HW@7AI!9AP`9W`'DH>Y1KT&<V+P`NL`)Y;$!'``@G4G^$A8:$5&=*
MAFA=A$IO`W10AY6$%CV.A%D9-!QNEJ&BHX5294^DJ:JKJUHM/56+K+-_3@D[
M)0!8A4I8#0<?<DZ$4`$[+7Q9M+Q.#3@*+$4%8(M+"$`"61H]-`PR#R4[!@4\
M2#U[72\\)@=H4`9'266RH4QF-C0823`#595+8TH0F8!GR2$E[WJ,.')$R(`8
M*!)L:)"!``<8`4ID6/`"0X\@.ZY8FF)`!RA"6TJ8N/(DP@$:+ZP4^A(DPY,M
M%%:@:5*H&0X_(F3`$'*`@ADG4`CT2/\3(D@`#C8$TJ#0H<@6#D3\*;E2`0>,
M%#/4^!E2AYZ2*",L0/FR00*"("!T##!XB`F"`PBJ/,#QA9`42I7@C*A3R`L-
M%FQ"*6%"5\R``'V^C-E"Y0F]9;.6M+D`!K-G)5MJT%B`)0<&#$-.IF+2I\X3
M/&.:J'%`ABZI*2M.MV!2A\,!!TP\TUIB9X$7X<B%I[&AX7+R44O6;(CA05FI
M"2Y6&$#U)\J`%#$XC!$N9<$&!D:$<,"S@(4-+H2\/##!X(")%!]4X#B"0LL?
M)6`0\`43*1SA0QNK+('&##NP@($)!E!AR1@9K+""'#P=$H4#,P#!P@]%;/`!
M!3`8`$(&#FS_0`$'#!Q1PP@M9'C(%"[$,`@A=10A@A-3:,"#$!ML40@:.T#@
M1@@KU%#$"RT,(`46$M@0P`H2M&&`!CL<D$,*.<1@1@HGG(%2`S"L\,$#95#P
M0E^&M'&``%M1P(,?PQ`R10,T#"####Q@<,,).,AA21,.[-"/#"9$00@3"\QE
MB!(%"`%`(78@069BJBAA11AUF&&'''OH<=0CSXW21!C.E3H*$PF4<,!IIQ&!
MQBI8W#$`!`-(<F,J5Y@`ZP\QT."!D*JFX@08P16KK"5+Q('$'K8M&\H25'2@
M@`9O`/;'$FELH(`!9/#4"P4C>*#&KL-AX=L!21RQP`4*E,"&A$VX_Y&"`CS$
M,(,!73S`0`9U3+$$&3=@4(*,E9S5A1AD?.%&%T]$`0`2K^H`L**'R&8#$7ET
M$>U_5V0`Q`U'#/'"&BYP8!X%)#`P1`M'%)`J@"]04*<2!BC`AA)<P'2``:44
M,`099`0A@A1=M"!$"S0(<:T:0AA`5YP,E%'%$B9D$.T2:B@`@!AF4+!#`ELL
MHD07-&1`Q@H'["!#$$$8UX4).0B`!`)GP!##!S18=T@5*M`0A1H'3##U!`8@
MD.P?4#300Q^$+$&``F9`D<+.J:ZB!%U.!)#K+HQ3`<7'SZ$1P!6+2VM(%+#"
MRL(=I(?B1`$#I$Y*%2.TC@$0(JENR$T%I/_A^_!_8$$"#AOLL/?7L?L>100M
MK&`!=YM08$()`V0H!00PO&``NK10`8$+2.B0@P<%;)#R&(N,80`*V"OZ?`HJ
M&<%"`:-<(8$,$GC@/PGP(\$7E+"&%.Q@"$>@@0%D4HDO9.`%\AJ)`4R0A"3\
MH`<:R,`$3'#!&!Q`>)5@PAQZ`(%2B"`%"!K`1V(0AT(\008QL$(!=A``0UC!
M`#A8@#]T,`&$*:$!2!C#4TKP@@_8018(<`@.X=<#(9A``G2H``\ND(<>.*!X
M$SA!$`ZP@0U,P`$TP$,?:J`"$V@@%'W``0FR0($>U!!'=$"!#@NAA?N`C@HE
M<$%?V``#+J0!!7/_*-5BZ'(&.?C!D'%H0QFFD#E:@*$/XR'>?S:@N].P8`&D
M:,("]&"(/O"AD86@PZMT%S-0/B<+`)@#&_PA26EAH04E*`,8A&#)(=R`"%XL
M@!_"0`7;*<L*`^`;;3*T!"Z8QP1X"\X6`A""'!@`#-2C118"<((A*$`(&G!`
MA3SP!BHHX0P):`$RW;"$+.QA"#H`0)TJ\00`T(`$:P``'Q:P`-HAP`,Q,$`4
MGG`'#@"!"#'8@0?"$,U:6,D%&PA`)`NQA"WP`09#\)`/@I`$(?"@!+.J!!4J
MD(,]<(<+].M"%"X@!"*D0`V/`,,+2"`&)I1`//1X1PP"T``0I(`&)@C`_QF6
M@`4+K(`-&DC!`E+``QSL0`)[,$`,^/`!+SG!#>DK@@Q.(($U5(`&='H$%P`P
MA`"0X0TI<,``:I"\"##0$)V+P03D4X(]/"(`!$#`%Z90B#J8X`-T_<,74@`"
M(65A!A%@@A4BD((-\*%LQ>)1%KK`A2^\X0YZ*,L?GE"%RBQC"<%I0AG&H"UE
MF0$(E;3D`A#F0C2$P`5F,`088+`!/Y#V$6P`;6B!$(9E*4$*9Q```,B0!5.V
MTC,7V(',"K&`(806`S\P`@Q:*04'E(`&#UCG'\KP@!7D@).$T$(%2F"#"11T
M%EDP@`M8<`,3D"!]-9!`)+5`@13@X`(9L$!>0_\Q@1ULP0PQ:,$$0N4`"9!0
M"AMH`6"@```-L.`(.+!B9Q>%!P[<IX65X`)VC&N@"80"#$'0@(P`P(`"\,:]
M`[G1$B[@QC><H`02R$`)2O`&KE&)#S@@`!X:D((B*.\%/LA`'XA``%9RX0%<
M(L`"RK`"#["RKB,X0Q.HL`$9M,$V75!!"Q)``V^Y*'IB"`4*8I"&.O3@`QG2
M0@=((`'5*($#.,A#(>ZRAD6P800$>)0=2.""$F"WE5HP`QZH\8<IL,$,7/"E
M8K:`!@$(`(2);8,&Z%/)(TA`0H9```Y*0(=0S*$%-*Q$`XX06AW$``1^*]48
MUA"`-QSYM\L:``T*$*W_)M`A=\=M`:K'L``)C*8-&6+"%R``I@)P81%G0,`'
M7`"!-`AZ-5U`0`L8H``<B(``(B@!`>Q@A26<P0$R^$$$$!N*%"3@#Q*@P!:V
MX(:'86%*!9B"">1`CRH`(`,'^`$-<%"!+TBW%G!H[P;F0*Q",($+=Z`='"Q!
MP!<0@(%/>``-`+`$.-0`!T$H`&"N0``:Z&$/-1-`4$*``AB<(#P/(4!CYH""
M&A0@`%G@00,Z*X4"Z(`+9@C`"U#@AUALRPPT($!&2I"D'*!`#V!X0PE4H-0(
M#``'UPN+)<Z`@@TXA@8-\+$#3D`!9!&""QV@-"&BD($8"&H)$+#!`K[;A#00
M_R`%$AB`%YJG+,P2H@EBJ(,=_$"'.."A#EO`PK'_8X4RL$%46X"";V?QA"\D
M8`(X:-=ICK`!12WA#1PH`02T`$HL7``_=D#%%$[P@U\E(><)@(,WGT.MO$HA
M#/-%M;0R("9+0"$WE?P!2E7_!S=(8&]RL(T2``!+#[2^]AM8`;:^RPH\J*`'
M0-#!!PHP@1BD``&#L`,.:."""2ST$"M0QL)Y_@$4C`#J'MC`$AH``5]6`0$V
M(&\05G"'F:E:!@WXO;%F&$B_J%@-2K@`$79``]6,P00KP`0.<`!X4`A60``Q
MT`!D0`55D`23<@@9@`-6(`<($`,2L`":\`<$(`1L@/\))1`#/<!%\4<`1!``
M"Z``-80&#[0#%Z5`%.`#7?`&^?4"'1`*QF`!3O``.5!I_Q$&#]`"(B`C7+`"
M)9!76.`"+9!E4,`W&34*`V`A%-`&@Z<Z9S$&;7!(K"0&:1`&&',(3Y`&`[`'
M9L!VR+$$7T`!!X!`%%`&MN8!>^>%>Q$":L`!R`4$/D``_K$L4'`'<X!HM/>'
M+D0"2:`[1"``8T"&TK($6E``IP4!8D!,9#!!:?=K2N`%"%!G`S!`F/%O!>`"
M!Z``._``$<`!-6``*>(%9D``+[`!=)"'A7`F3+`!G)8$&Y`"+&`$"F`$(*`$
M(L!JH7`%`8`#-[!B1>``\W#_"%!@!OC$`:MD2EL0`B9PC$Q@!R^0`5.`!2)`
M,12@"4L``#Q@`%?0!C@0`-'B!2J0`690``7``2NP`6Q0-F40`A(@!R9P`H2%
M`R^P`QP@`!D``P)0`B%P!DY0!@6@10C%`7$``K$D"TS@!A'``&;P!0C0`W?0
M`2\``S0@`*\5!<V'`%[0`DY'#`EP`AS`!Z#S!PA0`PZ@*$UP!PJD*'"0-:$V
M"DZ0!I*X!EJ`B)(D"U;`!64`.E[0!W!P!EM@!5,`!5;06[4@!E@@>,K2"P40
M!#U@`-S&"F<``3LP`@]@!E$PA:JP!%.@!?#Q!TW0!5+@E8`X/'A@!*Y#`3CE
M`&/Y_X=RL`+400:'8``^(`-460AXD`,[4'7"P01L8`)"``0,,`%KX'T*<$=*
M80()X#<`$`0#(`;[H0\]<&4I``;X50:DT`$[\`<6H`,[@`,9``>^Y`0$@`,M
M@`"05@EJ0`,AL$X#0`2C!08AH``]H#7$L``[X`=F8`$1.!IFL`AAD$>J=@(&
ME`$1N"\T<`)T4&02L@0+L`)[0@,2``8FP`$(LP0?L`)D"05```&IYP5!!0`A
MD`))P`)[$P.$40E:@!5:0`8X``(9`@7!E0+D^`@1T`/?1@B1P@>$$`=!\`!H
MR5`+8`,I\`#REY:6\&]FL`<(```!<`=FT`:_U@1[L`9O0/]\PG%#+R`>R$$%
M'H`#%-":PK$$59`&:)`'"9!:#/JBE7`%)<!I&Z`$3T`&#4`E:Z"4JF=M`_`"
M)^``8L`YN_8"$@``68!98?`=*3``8:"3#2H&";`"0H`$0G`"-."*?R`%>-`!
M*Y`!?F`%2D`&*U8`"-``&B`!(=```A``%L`#["8*;J`"1,`#,,`!9\`&SM<"
M/+``G:$A:/``,2`"`7!63!`!&6D02J`%,``#:=`$?,`#\]8&R?*1)P`'!&`#
M%]"!.[`#0I`"QW,!$T!I2M`+<F`!.]``>)`&6]`#:Y`Z5O``!R`%;U``,9`!
MS<@X!7`R8!0#)8`#1.`!>^`&<V#_`Q;P`25@!A$`),*7>H]`C1TP!1T@)=4@
M!AD@`Q506X0`5B'@']]4`AL`"E/P`2^`(,)1=MBV`0B0DS`J"DOP!%.0E$H9
M!6Q`!W6P!$X@H68`!EIP;ZF@!&F@<!/`)LEAA@:0`P]@KH3'!75`!P$0!V"0
M!5$`I>V*:DU``$G&4#VUB@O0A:H'!0,`2P00ETI`!0YPD0:05U`P!RX``QZ0
M99AAHR'+`,G'`7V0.DM@!22P`BBP!E+0!!#0CAE``@U@$<BJ`6=E"6AS`ESP
M`RB`!0,@!!'P!!Z@`,$B`3!K"`WEI1N0`$T@!1-0!'$@"W4``RH`,1,`$BO0
MF@ZG`=6"_P-P4`WD>50.L*1"(`:7X00[<$9U0*8:,`<80[4[T`<5D@(KL`,Y
M$`)\X`9HUH%"8`9/$``M@`-"@#PED#XRT`4.8`/347[_(&EK,`424`)V4`AJ
M$!04X(IP0)J`\08KP`'^<04S,`-V^1RW9:LA0``S6;'0<05A$!P;T@$:H`$@
M8`#O^(:%0`4M<`)#^I1<<`(HH`I.H`6@DP4"\`9C@+R\^Z+.2@QX(#)F!8@&
M>P,MH*V$\`1V8`$W0)^$X`1?,#DOT`4%BE9I8`$*H`#F\$:&,`5FL`(C``%-
MP`1=('=V$`=H``8>:PEWH`!K\`1,Y@0?<`!M<`4M^P5HH`,;(/\$.1"7AB`%
M<:`".G``*W!D91`UE(4"/,``%=":"S`"M:,F)LHX)M!C:T``(5*[C*,16W``
M1:``)@`!(2`$$!`&=78&02`!6"`%:E"U)H`"-&`!9>"KK:E9'%`$9&`%'0`#
M3E!&2H/#AM`$#Q`$<A`&:3,(3N``DM,#"-"%"*`#:)`L9H`$#L`39U`X"_8<
MFA0".A`"2;N]JL`$4*`%9?`&"/``(M`!>+,MHL`$6O!:JK($O9,P=%$'!2``
M6NK'F#P+4D"N,U``??Q;2G"R,4``UR=F5>8`=1(%">!\$9"!R]`$#>`J2;`#
MN%H)6R`!B0L`'&H)3B`V;S0%.]#$4$#_!SD@`E$``3P@`%>0`SWP`A_*P860
M!BEP9!80!$<4`(09-P9H`2]@!FSP`1+``RWP`.W9!CP``A,95#&@``R0`AZ@
M%!Z``#S@`*6:`/0C`A5B`'K0`Q%P"%*`0?C6`PL0+6CP`AXP`2W0`C\P!#/P
M`F=K"5Y0`BE`!0$0-4K@;A&X!',@`#T1`B^0M1S``RZZ`$&P!D^)!S/@(E*P
M!`:P`S!0`9&<R;2`%$I0!VN``'D@)F?P!;S4!/,[TU=P!IV"!GT0*GMP'#*=
MU,(!!7"0`D``'(#(!&40FHUG"%!@!RC```90)Z<B`AA\:C/M!E[-;"^`*890
M!7C@OPV\&A=Y_U98\`,&`+0,D'LQ$`-!/00>9@`WD`$*T`*7O`4B0`E*@`0I
M<(@#$`3KO'9;UP,F(`4&<``!L`9.,Q3(DP1MT`$'H`@HZ@<KT`,/L`!N$``'
M(%F1XP8M0`*$P`<*\$F&L`!$8`9K@$XE``-/K2@!,`1Z(`&..@`\Q,""A@<'
M``%+H`%!,)8)8`0F4`.,40A=D)LWP@0'(`$BL01)@M2"A`<*L'BM69,$``0;
M$--*/0N`/`Q1$`9L$``(8*8+``!^4`;)P@1.X,B\T`1.D"Q1$`<7YP].<-YO
M4)15\!<_'=X"7@A5D`%DE0?:*RU/P!'CG'IAX`&K>`&`\00.X*L.`/_>FEP!
M,8`$0R`]`_<HY!D#^U8/^TP!AT`%$F`%=98%<L`#J>L!/H`'3&8"9%`%#T<#
M-&!]A#`&''#5.V`X5'`"!\`#'T`/`!`U44"$O4,<$E`##9``4B`!.[!@7(`$
M$LX&(A`#8U<(6?`59O`5)Q`"&X!B?@`&T0,')_`"9Q`%!,`T0F"D)C!&'+`%
M%B#B-G!G7VP!-,`&82#B\$$%<6,$/)<L2Z!"5^2?WV@08R0")YD<8R`!L(9<
M@E()0"L#$#;@I;($2,FN4=`&<9`M_Z&99C#JHU[`$+L(3W`&5B#?F-[JG@$0
M"P`#.P``/OV'4@``_D4`3DD(73!4-(``M6[_!=(QE5WI&<(>`D-`!$)@+K8C
M!A$0#G@@79`B!`5P;U-@`VIT;G%#!010`]UD`C*`!6YP`,:<!T<0`PB;!6/@
M`0L,'&$P`T[C`"+6`$[Q!QIP`N!M!3[`!U80![[A`91'"&Z@5F3``QM`N310
M`P,P!6XP`RH@!_H8!@+0`3R``EDL?'``FT=6!0*``RIPQ1_``5'0`N"Q`EY<
M".H"MV#``R1`5U#`!QA0`$!`/\'!TCG08MMRY`G`!$K0!CTP/:2G!2C0>:V#
M`J`$!7?LZDJ_]$RO&&&P`3G``9/^AUKP`$CP`7P@75^@`37``6\@"U.0FB&@
M!PD\"U1@`<^@`RM0_P#R>PAJP%TA``<#"?4+2@A6<$GOR0-EL#8MH`1H,)5*
M,`=#D`"+,`7CDP(NT`,I\`,*,`AY0`-!8`.EBQ*Z[04`0``24`0A,``2P@1'
M/@$+$"(`F`-%<`(&\``]<`$/4`2)H00/\0)"$`,K``%4QH.+`@$WP$`%4`-F
M30AL4"04\`$F4#(;4`,4T+VUAP.QB9>5E@43</D8@``W``,HL`1B,%7$,@4H
MD`-U@JH*>Z(-T">5A`0!WO3F?_ZNO@1FP`$I``-LP.K#TP45<`(K,`#%OBUO
M0`%UA@>5"@@$*2L(4DI_B(F*BXMA!"5#!S$>7DN*36U&/"HI"@Z6C%,H4/\F
M+F-L/`]5`#<1EF09*R=D37]<$!([,2%P2P8X.#9?B$IG-AM8%#@$&3L,,246
M'D5K'31Q?U)Z(CDY*!)L$2]TBE(`/`Y130P93H>(2Q-%6@$I(AXE*7A/3`,,
M%R%,S/'`H@6-!TX8_0&``\*3$"O\_&$"XL@<`Q@0W.A01LPN+(BN[%!QY<^3
M?&@4JESY!\H1##!C8F`QAJ7-FSASZMS)LZ?/GT"#"AU*E)$2/SUR#'#SKFA.
M,BF(3$A3BYB>`S4N=$ETAH80`F2"@IEQX(`.%'ZH*)IQY5"#`J`63<$1Q,"?
M+SKR,/DSI<(($&^>(`H@:<`62V,T]/"P0<$.#DW_"2_`$F,%*"H%A)1XX(#)
MBA2,Q-QH\\3-B0YJFE:18.++AQ@ID!QP4&9)E0\OW+C8D:8#D0P3B.Q8(<1-
MD`Q-)B"AL$.-PB8.D,1)4^+$%"5?<!#!$,#!D0`/IB`8D0<1DS4'"B!Z@^-#
MW*$47LH\,L"I_?OX\^O?S[\_2R5W:+!""V9`T91_?RA1!@4IP%`(*$KLD8$+
M(=0AV%T6F)`"'57\M(0:!)@PQ`@U4(#%7C!X@4@%<"E4QA$D"':%!RZT$``4
M2U#A``HF3)`%$TM(^(($:!@(@`Y(!%'`.U&\ML<?(7``4B+%$-$&&`"4$,,"
M5EBBA!HQ0##'"B'(@,,*_R[,<04>,7R`0`T5D+'`!T$H`%L,(+"!PP-J_8'%
M`BB<`$`<5O30@!8OS+`""FDH!,8&)8BA)P$&IA$#"]OML0`06#R100QP'"*%
M`2\(\$<3<^RPP%Y.1;&!3!@04!6"M-9JZZVXYFI3``J8(,`6!])JAPT[1"#&
M@?ZDL$9;B-2Q@Q`('`N4'"LH`(0.%IBQ`A>(3-`B(U>P<$,&;$2!B!PTT'"!
M%X=XL0&V;23$1!YV-B!$#0R(D<@7,ZB@!1Q^/$`$`674\@0`(PQ`P`$;"/&"
M$$@88,8`0P"0F1Y_9%$"#RX@H<`("0!P@$2)4$&!`ELXX00.!AS(A!](S,''
M`O\:``&$!3L0\%XB9AP`PA($**"B%&%,H,`/VP4@`!5@R``:(EG`$,,A4(B@
MP(7V!8"##C$1H>O78(<M]M@\/2&'"#%D8(8[MBYAQB,GL&&@>0&(@$,&:0B&
MG04OE("'(3XM4<<$,>B@P!$/7+$$BSO[F4,"4A000@T$=,$$$W)08,()@2F1
MQ0(;F`#!%4Q000,#/)P@A7F37@'1!!+P`!L,#1CTA@LGJ&A%`!_@8((''I21
M`0QN**(%`3CH,0441A0`.")2J+""%A6D$`,.*,QAR!,/Y'!!V@8P<$,(0<S1
M>!,$\"!'%2^T0,823CQ`P,DL!($!%U,$L,,$M2@1``__!*""$L:P`PE,R2E/
M:(`-`J"$%F!``6$AFP0G2,$*(D@*9IB`"S[`!RO<B@EE6(`)0E"`,R0B"F^8
MP`I`$(`.-8$,$7#!!OC`A6#EI`EB@,`*#J"`AFC@6\3H@PF,8(`O,`$+=Q#!
M"BRPAR@X00T1*`$(%M"%)8Q!`"=`0@8VP(,<$$`+Q(A`#/CPA11(0`Q+V`(`
M/F`#&'#``'"(00>R0"4K+.`&5!@#&%8P`14EPET2B,,]5E"##2R%"60X`0K8
MD((3#.!302!""`P@@0TX(`8/((,%8N""$O3!AE?H0`G,<(<4<(".=+#`!BP0
MM!^D(`55@$`/]B`8*!1@!1"(_P(3!+#$/CEE-2YHE"TRH`=66?"8R$RF,G/R
MA#F`@`$AZ-"ME!`'"C#`!5M0Q!/V(`%)LJH)9B#!#DI0O)\HH0TG`\(-A)"`
MIK`A"`,(`\YBP`9$6&$`&SB`!0YQ%`_XP`5::`,/=L""'?0@)>:A00K*@`8B
M%`!KB#`#$LY@!>JL@`[&U`,1Z&"``^#@`#FH00I2LP8A%"`"2.!#&A!@`SO%
M0`@'6,`>;C"'"XF'3@[0PQL.\`4Q],!J'0`C([(C@ECV8`Z':,((&&:!!C`@
M"5^(`@]6L#I$I"!2$YD`#>Z`'S#H8`*^7*98QTI6L48!#QY8(@"F<*L7&L`$
M/P06(O^B@`8"K$`$`3#7$\H010TDP(\]>4(8Q"@$!M"``'WPP`%6$``I."$,
M#D@!"AP0!MO(P1H6T(/*P-"`&RA`!C2071L2@8<2B,`+?;C`"C:`@#,<(@H#
M\$$!*+#:%-0@!QM8@!P(0(,!X`,`81"`EG"P@TXBX`$E,!4BN,`&J=GA"U,P
MZ7NH$($#M&$!&?@!#&B@`AJD@Q%/R`/+M/`I,"P!"B<P`!"0$`(+&"`#<?!#
M"1I`1R501P)MZ4((4L`N^S`A`C@80$+*2N`"&UB"3X``"H*P`&FV;0X?Z($$
MZ%BR`K0@9Q>"0@!0@`,/U.0G3O"#"$8P!`8@[@+=O,#JF-#_!P[@@!>(J$)D
M:0`!)I`@!V<20CL2L8<1(&`))Z"!!6300Q-D```IP$$9%&HN$)F@"!*0``G"
M,(,9F"L1:=``#+[0!"VP0)A4VAP3&A""%KA``GA(Q`ER$(<@>*`"+#B`!&A0
M3X5((`=UX$(/0K`7,9#A"!^XP0%4D*TH7,"DB;@`$1:`"#L4P0(.+HH2,C#*
M`UOZTIBNE1*@H(8,V*`#>;V5$]Q0@1IH8``.GH(=8N$!/T#!)&+@[9$/R),F
M>,$!//C8"PBP!@[4P`-TX(<7"F`"%$1`151@0P8**H0=V````XZ"!FA0!CCD
M8(Y,R$(>#-(@")0!"`NX\A^6D(4,_Q`A"E9X`PT*4))$T.$%$`#`-W*`!$&-
MX2@K(,`>=N"!/5P5!SY(;PD^0``AZ,$,G"@!21222!"X(0$T-A`8<B"`(X2`
M`0<@`!NR\`%J6X(*'I"!',Z[`!L@8%9$40(9AL363+O\Y3!W"GEI`(/RX&H*
M#:!YC14!!Q"\``5ZN,P$3&`"`(B[)Z-*P0U^<-@X:*`$+0#`(1*\@A(08$HL
M&`$/<$"R;)3`!&08`PX:<*`F&"`&7FA"'71@``HC`@`U6,``7KD"&K2@`:_>
MPS(,0(,%S*$%.!""#\R(`PH@8`<)N!`;3B"#$Y"@``C@`1C4K8(7>(#6B0##
MBS_'@_(P8?\+%U!``#`@@6=PP0LM2,$[N(""&DS)`SRP`W[8D+.6Q_SVN,_]
M391`!32@K0-W0#F"G@##NVF/&%18=0Q($(=70^$+'=C%&L*Z$R>``0+.`$()
M*L`'$IA`!`!X0A.Z4(`7;*`%)HBLODXE`!P4P`T#F(`//F`81$!!JWP000EF
M\`*#<B`!<2`!)0``9?8&9T!L*[`",6`"+;`'(:`!ZY=&?@!7<*`%6=`#?G`@
M6N!B;[``)6`$*4`#&Q`#="!\I\);?5`&+;`!66!?-P`!#G```'`$&K``8U``
M-9!X"1(`-L`_?V`&,I`!D484Y28#:=`XNI>$2IA[V*$!(Q0`N3+_!B&7`@4P
M8(B`!A(@"[*'"%OP`2(U`!#%$U/P`"^@`RS`1P$(=38'!3=@`G7@``]0"TQ0
M`$4P`%-@6R:``PQ`!"@P``@7`W+@`B8P!>>Q73Y``S/`*%7F=D[0``U1!DXP
M'ENA"%`@9$]@``V0`RW`)="S`35P!SO`>$<@!!M``V:@$$J@`37`!=HB`N8"
M!1F``0VP`$0@`#_0`%+@`$$``/#@`#L`A7^@-2*`'TJP`2L0!DN8C,J8A%-`
M!R;@`VO@0;?R!'@@`4)0`6,`(52`+CW`!WT"!6F03Q#@6C_1!%FF`PR@`S#`
M!O6@`!HP!`10`QA`''LP!2>``UF0!D"`_P!/L`16P`<[0`0N0&-X<``.D0A,
M8`5!)@5+($I:<"!VT`,!@`8?T`$H(`0>U@1*T`?I@0<L8``(T&R=D`%T0`0=
MX`!#\`6($CL?\&JAD0,<8`XW@`!,L%=9(HMTR`9[4`4;TX)_0`6EZ!Q-``%"
M0`<V%!1+4`9#@!#+V)1.&7-VP'@2\$FX`@<?L%IK$!=*P`8;(`,;T`;\Y`64
ME@+U`11<4`$[``1#8`\#10!;T@(^T`,?DP)78`<\T'6(\`0G(`)=A@`*8(>*
MD`<Q,``%4`(KT`,X(`$V%UL.@#,+4`$PD`/#,0,P@`,)\``[\`9S%0`A0`,H
MP`%^T`$O8$L2UO\0QJ0(^O,`3P`".#`,6K`",E``*8`!$;``'E`%;(!)K%(&
M+Z`!J\-Z,=!N]E$!/#`'I_F4R)F<!+8$7M``._`":/`\M.(Y`V`"@TD%<5$&
MN)8"T7D(6!``*\`#>^"3/:$$5:`')Z``&?`&4Z``"1`%)Q`'!J``AC-?.V``
M5E`53N`!0L!-1"!X!K4&65`%%H`#9D`!-N`';%!Z*T`L*[`#<!`+W)(-??`!
M/``!`:`%9D`$PZ`(HA`#6&"70=`!/.`!01``C?,$FX(&57!5':(&"\`",9``
M)8`!!E`D;T`$GX`(=+`##H`(!*0")B@431(#8*F<2)JD904@+?`"&0#_!KBB
M!'"@`3$0-XM0#R8``FB$"&H0`B\0G\>I$_9%`CB0`@G0`BV@`VOPDPY0`@KP
MIDG``"4P`'+P8@&0`Q[`!+"U`3M@)S/P`;RY`0ZV!1-0`A-@!TO`15:("%_@
M4%50`!`0`ZS%*IJ'`MCW`4*``:5@`M07$K"A!`.``Q.`"%U@F$D0`X5Y!&V0
M!2+``\[Q!T[``32@F?^U`QAS'V1``Q^PJ$K:J[YJ05&P!W9#`J3Q07'`6R$0
M!\\#!7I``C'``5%U*FKP`%[)!E5PE+M7!P\P`RGP`"?P`A3P!5!P!@C0,(4%
M!$&@`000`"]0`+.R.T+P`7"`<RE00U12!CLP_P`AI`$X0"#7L01Q\`(5X`=X
MVCM5-P,%D`=!V`&VJ@:?80(39A1U4`(><`9\T!"'<`'(LP)&$'<B$`%C<%43
MZ@4",EI1@#QEZ13@)`2J^:LN^[(5Y`1Y$`(Q(`)NIVD5^@(J`&;C%@`M4+-"
M]0=HP&$HH)E`@0<B``,;,`$GD`(=@(Q;0`$N(`1!8`(6$#M^,"M+0`$P8)4M
ML$,Y(`+.\003L`,(4*`7T`$I<`"RLP%2(P`2@`-U@`A:T``IX`(98`%X0"9-
M8#<A@`-/`EX&D*]E<%72^`<21@,E``0UP`9,D``\D+)HT`,4D!![Y)OW`04;
M@`.`!;.>^[E@`P4#P/\!,4`!<!"&_K$$`4!;'\"B3`(`&5`#&:`&K\@&:AL"
M=W"M@5-7*:`"%!`")=`!;1`%98``:\L#<JD`+A``8^`%*%`"?B`!,#`'"6`"
M24(#&C!M`B"KH\4$8+``*1`$(C`!9*!#IZ@(;;`##Q`&?0`$9O1S,@",BT`%
M#(L&9!`#*G!T-G!G)8`$(F!'-`",2[``-$"3?\`&5ANF0K$%+7`"<`"Z$!S!
MNL($K1H"">"2MU(`9W(H36$%!M`#+3``5]8$O)0"!K!^/\$'QV`!'?!B`U`2
M:6`]1=`#!\`"B-@!?=`#'Z`(87`"-F``>J`$,3`#0Z4#<H`%PLHR$_H'88#_
MOQ_\`BQP!#R0`B:`A$V#`DI0`#U@<XH0`Q)@`R>0!EH0`CZP?DW0#*?(!(,;
MN$ZA!&;@`P0@P7(\Q[5R4WQ4)-BJ'T^PNB_P`7UPN%30:R8@O*O3!&R`7"1Y
MN+76!Q/0`B%``EG8``62!@GP`D%`7!Q@!B<``MF4"$\P`#2`!WQ0.R4:!QVR
M!'30=P60-BB0%%Z\!@CP`JJ4`G"P!C8P`S)`=HQ`PCFP`&=``O&;"%L0Q']@
M`QH0`7WP!C8@`FRE!'8``Q(`1EWJ`G-K'U,0`3NPIG2\S=R\'U&@`D*`5PK<
M'TI@`$+0`H6@"&.`J1H0:@E"`0PS`#?+$TM0`')&_S-!P`%T,`5-H`<Q$`,\
MQ`-'@`/1^`=54`$*(`=T8@`K@`,*<`,J<`$-,`)T``$^0`[^(P,R4`,]0$].
MV@06T`,,BY>),`4.<`-WP`7;Y6!9,``VMP*KD@`]D+)L4`0>L%PTA[I"804A
MD`/"V<U`'=1#89YY0`#S7"M/P`8>T"9X8'M9`&$K$">OF%@KX`%L($`^8<@J
M)`$>T)D&4`=2D`:7Q`-!8(8Z8%L2\`8OT`$>M`1B@``K(!40,`8D<`(FE`BH
MO&AF0`<_0`(-8D9EH!!=\$I=,`?>94Q7H`(+@`"'<`9A4-<(%044$`-XH`1+
M$`$Y``!(&!1D8`*)(]2@'?_:-M$$53$%87`(5D0%_5A]&DD%6#!@3J"[BJ`$
M;,,23P`B3BK"Q"`%=?!T(G`'"?$$7L`W$E``0Z@337`+-O`!%O`!IG4C6E"=
M+T`$.N`#!C`&0A`!$+4$`P`$G'8!;BN@F5<"$F`-(7`$/V`"*Z`!6+T(<2`#
MB>,``8QR`1`FZQ<&,%`"_<5Q)E`3($T#`I#'0#$QO"K:!B[:&9`!?[`'0)`$
M*:#&1@`$\HL32L`!"-`!0S`$*X`(`U`"06L>P)<34K`'660!&*P$6\"#?TD,
M4Z`'*L``%J#(/`$%<L"?'#``**``!1`%X.@!CB$#0<`",.Y+>4`$<>`;(+`#
M-T#_`X6'!?:\RBG@Y`>@`4(@`$C(!D00C:U73HE`&1M`!B#Q!C?@`"Z)KQS0
M(5N`.T=]X&S>YD1!`1A0`DK`?P3``FP`!!D@!#BP!5Q@&'WP26)0!@&`!7KP
M!>]0!BM@!B_E`*]*!6)`!66P!N?[!Q90`INM$$_D`30``FM@>U``!]M%`F]@
M";9&`;++!P6>$TP0:U[\`"HP"0'P>05``S:0`T#``D.``@60"W&``B[0!DPP
M!0#@`I<,QGFP`_0%O*SQ!C:T!1Y`!&F0JR%@>XC@!'C@``$@0`20F5,W``RV
M%SW*`4/JYN1>[CLQ`4%0`G^P!5,0!SK`*VMK/2R``4GP_P-'8`'U?@1)@-YR
MD"`3``-.H`,_P`"@,.L<8.\_(%1<``3'?1-(G`(,X``'T@7B)01L``I2$``:
MP';CCA/;J`$*H)@2<`-9.05F(`+/8`.C>`%7D&^+V@0]YK@>>>S<``)5M0A7
M0(JB>P-^L#-;0`!.,`=QH)<FL,0J$`2G_0<=50<'0K;8<$X`T.\\T05.D$%#
MR`32M`074.!A0.WF_O7*N`17E0BY-@4F$,46$`2S]`/G,`-'T`(<,`1V``01
MT!+MX00WX-`[L!<&P(=```8*8!<)H@-<59Y.``N]N0<8/`5]L`&6]P8)\5AH
M(P$G5XYN,'0J,`$:X`+`%@5G,/\!*;`#.6`#&3`"*1``PHD`-$`!D'("&#`$
M,T`##1"F2I``[C<%'+`"/'LJ=-`!-_T$:$`#$G`A9``#&4!'6:`")B#C6U`X
M0-`!:(`!0,```LX(#C`#,S@"0O!A!OT#$@`],2#C?T`MU0_VYO]RG=0M+&#<
M-R``^31_>-$%*^#V`[``(S`%-V`74P`$<0P(;D]6.F-_!D0;(TXX!'^/.@B/
MDY25EH]*:1,R)F^5=Q\K)V=*CV(9)2MT2Y>MEFX6+24$&2DE9G]G#RD[.#L_
M.C5S4@LO%*)8$",MPI=-%SM^6!(V8I5+;Q\1;7]L1`91CUPX*E-_8S`F799[
M.GL:2`/_1EY656@$$U^W6`$6`P(@W$R:(<&`""DC]$SZ@$'"HR4"KN`AH*'*
M(R9"U+C:R+&CQX\@0XH<2;*DR9,H4ZI<R?*1BQ)_*ARA\X<,@R@(1@3YH`8(
MEQ<PC@QP,&+*#0-_HO3PT,0%%B\WLOR)D&A1HTDW`JAD4N<%C0:D)C61@V,%
M`BT/P:2@,:$,DY)+TH2P42%!J@5>F'#90`-&#B`LA&Q`(.2"@!XF4)CX<FG+
MAAU;^B#Q4&I2EB\-)BQ@\N2#CW!_E%RX\49)$ST*#%2N=&6%@B$$)&#`@`/!
MD1M'CN@X>F3$D1\_<&"ZP>9/E0^%'N'Y,6+#HRY'*/1F$>/M_Q\+)EIJW\Z]
MN_?OX,.+)^G"!)-?07#442`$"(T@$M(D.?-B!H8!$&Y4.?J'B8@34"1Q@`XG
M/&+``2<L$@0%'J@A!1#KL"1'!BML4`<KCS2QAPHO:&!(:'AH\$(+?IR$A@@P
M;."`!B6$@,8?:E"P@1!'),'##49LL`$!*X1`Q25E\!#"$P4HL`:&CSS1@0<2
M!#`%%ANT4,8D(O0@T!\$]'`'DI5\(400"G```0P$L-!`$E[$4((20%@PPA(W
M/%""`DDJ@,4?;FQP`QY)I?""CH]L$1T+:#C@@T5_#)##:N,UZNBCD$8JZ:2M
MI`&'$@7H*`(67[S`015ZE/'$'4R88?\'`E9<X8<2`USQ"!LO7-'%"R)@N(4=
M8/"A1!M=`%#%`$(TL9T3>RA00P!78*B$$P[<\`(;YBC!1``]"-$JHR$QT8</
M+P1P01`Q"&#%$D[480`+=#CAA!X,+'")$@@HL,<4&01;"11LM+!!!G&LET%E
M7JP`PUM62&""JZY`H,,5"0`AQEM$H#`"%C'`\$>;"C1Q`P0E'/`(%0=`,<43
M?RB@P1][S(;!#7?\(2@%(X3AP`Z(!K`#EY3FK//.//?L<TI2E%#`1TMLT,!W
M>FP0PP9@K$8%`GX^L,5%:$A0@@9VG-2'!!4Z$(()(K31Q`,X/,P!#;A8,L4#
M*_3!10DG2$7_B1(.&$`!'W%`@`0`POZ!!P\BE")&#BK\N-$"291!@+,H=*$#
M`0M7?'$'&1]E`IW]C7!&!BTTH<`#4ECA00LC\&#-&$=8<(/,/%@AQ1\7V/#S
M[+37;OOMCEYA>$=*:&'==Q#I8`,;B":IN@1FO![:&@>4$(`5)\5!!`X!0,`#
M$B5$,44(*!0_2;DTK`"J#NY2HD43#N``PQ142(!#95$XD$08?RP!`!#%=51%
M"1C\8```L^E!'I!@A10X1P$5V`$3D%``%`CG$4BX0!2.@`$%9(&!CP@!"!Z1
M!188H`A<*$`)!O@'%5``=RA,H0I7R,*0A($/4\!9>)K@AU!HX`R__Y,"`F#P
M`@^,H3)Z<!\(\/`[D2RA#R`PP0;(\!8J6(`&)$A#%:1P!3N(8`4N6,,3,D`#
M,JRF"7#80`1"0"HOT$`$AL/""TS@A/YDP`97\H@3`*`1)9Q!#E-H0A64((4?
M68$)/\)"$T0VB1"48`E>"$`XMM#&/T`!"I/H0A.HL"PI,&$,6#C`G5K(R4YZ
M\I,[PX((2F``./2M44YXPP1H(($[0(^#?B"!#1K0!G-`(0X$\-0>]D@2;1F@
M1WO`@A3H0(`-E$`&,D@!`020A3I(``5IF-L>,K4!/4QA#SR80#AVU0(+K$,,
M(8`!&!Y%!Q#L;B0"X``HU\G.=KJS)5Q8P/\*>*`:2$D!(#O(P"8_EBD<5``T
M3```"(3DA9,$X`,Q2`$:BO@(,L1@!Q`@&26H@((%%$`J&\`!8_J#@!P,X!%Q
M\,$#L#4>)I`4)"9]ITI7RM*65L(+")!`"AR0!H:&!PIRD),(7#D)+>B!`R:8
M`!JDH(0HR($`)LB`KTH"A3<8X`0PR,`$#&"`#IQ@1TRT!!8\4(<H@$$"*DA#
M*;#0@1CT08\SFP-H5J*$`/#)I7"-JUSG6A([H`(%:)!A>*Q@`!.4P`+>XT(&
M8F""/%@G"A!(00HH8-.04.$.<X#```*PSW=IX0EG`%QEPE"A-D;!+\IKB09B
MT#*ZFO:TJ*7K$KK_D(`6P,`!;CCE>*K0!Q+$0`1QV-T6`A`"&1C`#)YE`P%H
MT($]A/8[5%@`#P#01B7L(081B((2^B`#`J"%)4K`0PHD<-W4>O>[X&TG`%:P
M`A&0(5);0`$-4)"'4RKA"S"(P0?DT,@I@"`'(4``)+T3A1#X($).0``#/KH$
M-@3!`MN!@Q`RT-CP.OC!$)X=$]Q0`!><`"\-[HX2KA`'#I3@`=":Q!@$$((4
M&,`.K+@F!V)@`3J8HR5*8(,-*'#=+LP@!6500A9$\`(TR#8E5"BK'3(<X2(;
M^<B.<L(:<)`"J45*#"U@)1M^IP0SR(!68GV$%S1``PVD:R5+V$,/D-+0_Q5H
MP!QC.($+7LR2*:"@!FE#LISG3&?P,*$,$!C"!E[YJ"NP80<'D,,IEY`%`!R`
M!QM50A7N4(,(JJ0!(XC#),XP@@*PH@D]:(!$69(%(73@N'4.M:A';1(G0(`3
M$ZCL>.*R@1=(H`^-K!\;3%`##22Z#A^@P0;D4)(NF``&AHO"`PZ`"R<4B0_;
MN8`/AD;J9CO[V1V1P@`^D`,"4!)2<&A`#5[PA5-&@0TDV$$(Q,"*]QJ@!"40
M=$C2\`)]/D(**<C!.)=0KSB<U"1+,,`.`J!7:/O[WZ2NP@1>0$I0CP</)>AR
M'5;CA#FDP`0/N-)TK:8!,_1[$D3:01XFX8=OM/^1##;(P'Y9`H<5M."<`$^Y
MRD7=A0:4X`4&>,*]O4,L"FT@+Y.(0@%"T.X?AH8-7-R`&5):"3Z&``=W*,42
MZ+"#"(@#!Q(@\DB4X`4<?,![*\^ZUN5\A5QN@`\_%H\2XE`"$X!@G&)!P`IF
M4($(H4RQ&I@``N(@AP%0X`0T.-+'E'8&1U*`V-IA@@=Z<-ZM&_[P1Y89#$J`
M@&L[2@IZT,`*/O"%6%-A`"AX`0'&P`HF%*H#&>!`!D0@=\,I(0PVV``7_F`%
M9A2>)5&0P+,03_O:0[@.*1`"`;X@=>X\P0%("`&R**&D`V3`#P8O^@!VL`!A
ME0$'&=BT2G9%.-M;__K_W\7#`UJ0`@%@X>+=D4(>-)#4-(P\"PN(;P/*0(5-
M*^$)/CW!#`*PK`'08`$S)XD3$K`#`X`?^P`8@.]D!SA``P;`!;VW'4^P."@@
M!WSV!U?P`<TC`@,P!P"0`!R@`#PP!Z7P!!2@`*^W$E#@`2/P@`)X@BCX3G%Q
M;BFP2_G''5,``.IE`6<0:T]`!@$P``50`),5!DKW?"$P-2WQ!2L@`2.7@DB8
MA*#$!&"0`%WC<XZ"!79@`2O@`7>0?'/#!S)@`7*S$M/R`H"EA&(XAI[$!&]`
M`D*0`@C39P.0`@HP`6Q6"6:0"G3P@B+Q!/JF%62XAWRH0DQ8`#F@`6O0A8U2
M_P5Q``(RH`$/X```4#TD<&,+H&HD$0:GI`4;L`)A\']]N(F<2"E+<`<<0`0?
M((GBX01IL`<)@`"J&`!AD1)V,`)(\`AOD&E'V(FV>(LZ<X._A`((0(B1\@1K
M=1)3H`"S`7,U4`!AAXO*N(R/H@5()33)"!Y%]0=?D`(#$(<DT0$J@P&$PHS>
M^(V0T@1B@`)(T`%=H(DK@05=UA]AT`(,T``X-Q(#L(VS@6#@>(_X"!Y>0`$U
MX`)Y@(Y:$P0$X#U:<$5"DX"3P`9#0(_]0P$`F8\0&9$>`05D@`,*``%68(<C
MT00$P`!N0%+O5P8MH`,&D"P=007$R)!'H`(/*9$N^?^2EO`%904#=_!C3P``
M)O@15X`"+J`1''$&)$!P^.<*3'`"#*E[M0B32KF4'($%=)`#0C`'OO,(";`R
M;N<12P`&09`!L=814'`'*G``"\`%.*,$!/`#VZ@#`9"43-F6;FD);2!Y,S!T
M:(D!0U!/'F$`/L`W)%&0)9`""'!*=E"70W`"!?66B)F8EL`$;=``*8`$V_@#
M'X!R:D,!,:`'+5ET9V``,X`#?+`%8L`#_=,!GJ"8IGF:CW`&.L"0@-<*6K`#
M'!",*'$&%I`".L`"ZH::NIF82Z`!%,20.G`!V.($?Z9-@?<%FW`"!3`&T;B;
MS@F159"2#%F/L;8$%(`$I>F1'7*0`N45@L_YG?E(0PL@`C0P!'6I,D>``[PV
M!AMP`G`@'DM@!A%0`BU0`)0)GO@)CJN%`">@`#CR`RRP`#@0`I$2`"_P4?F9
MH!+I!%L@!R4P`@.`D-NQ!-*GH!8*CE3``>JAD1?:H1>J!40@`;[HH21:HDRP
>!CG@`,U9HBR:H`NP;"T:HQXJ!2UP`CDIHXD9"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>f39432a9f3943222.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943222.gif
M1TE&.#EA_@$B`<08`,#`P("`@$!`0"@H*%%14?#P\-#0T*"@H````.#@X&!@
M8'!P<'EY>9"0D+"PL%!04#`P,!`0$"`@(!04%#P\/`H*"AX>'J*BHO___P``
M`````````````````````````"'Y!`$``!@`+`````#^`2(!``7_(":.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__O,3((,0D#"5`0404'8'0J'1*K5JOV*PVZI"(
M&@V%P:``CQ2.1P$L)INW\+A\3J_;[W4`1/3`%!0*2WU&"Q@.!WU_@1B#>(Z/
MD)&2DY0^`B*7&`*9F0`!&)Z<G",%`*:5J*FJJZRM/9F)@().A8>QBXTC`*Z\
MO;Z_P(Z9;&-E#1@'&&AJQ&['2<'1TM/4U3)(3$5/&)^@2QA-1MC0UN7FY^C4
MXS"[Z>[O\/'`[?+U]O?X<O3Y_/W^_S7V`1Q(L.`_@083*EQH#B'#AQ`CKG(H
ML:+%BW,H8MS(L>,/C1Y#BASI`B3)DRA)_YI,R;*EQ94N8\HT"'.FS9OX:N+<
MR1.=SIY`@P;[*;2H455$CRI=ZB@ITZ=0MSB-2K5JE*E6LVK%@76KUZ\EP8H=
MJZ,KV;-@S:)=FU4MV[=0W<*=>U0NW;M`[>+=>U,OW[\N_0(>?%(PX<,>#2->
M?%$QX\<0'4.>G%`RY<L`+6/>G$\SY\_R/(,>G4XTZ=/63*->'4TUZ]>]7,.>
M/9&V;8*R;^OF44K$@0;?C`38M289,N`F<N^&G&#0@4W&D6V"T.>!`#48)&Q:
M]P*`@$\.&A@HQ.=/@@4&&C@(/S[Y\O<QGH_29$)!@M^&#'BZL7_0(`.?`-"`
M?_Z18HIR\"V6"?\2!62BRR<//`>>`@(\,\-^\^T7"B;SD8!@@H<YZ(``W&%7
M(08+.`"``RA&%\-^"P@QR!_(I$%(C(RX!^*.*F12A@EDB&"?(>HM$1X-^Q7P
M@`*[%-+``@J`HH`:2C*I(X]8EG!)`A`$X"6*7SQCP'<"%#!B``(4H8.%[&3I
MYA!^'+@+-@D$5\HWO?407)MO]NG+AWX&:@.@@A;ZHJ$)RO<`BP:X"$XRW(%)
M!Z&(CC6<'P\HH:8(!0CAX`B?QD%II6!=:@23GZ!IG2<'1'#`<P\4$BH<HY+J
ME:F:>))`E`D(@"$R(NPQJU2V[F;JKI[LE^LGEP2@0`!>#*M%K<5F=:G_DJ9`
M:*:OS&*P1P+1YE'M;8HR"ND##9"8S`('G/DJ>1F-NZ.O;TQ"K;Q@)1``BY7<
MBV^A_OX;:,`",P4``IO68,">5!!<L%*`B"F.$:`(D8`0!40JP@)L-OSP:PUR
MB0F3`I`<P`+H18G?"0(@X'(W4SC\L5`',"F!ITN4"<Z*E^SQ0,(D9,SP53.O
M]IVSLF+BAP`'>(=!`XBDT,5U0`,A<]$\-<=IN/09D&D#$'0J@:,D^'IT%5=C
MC9-^(QQ0@''&Z>J`$'ND@*8$$(B6MMI4+0`S"@X$H+'5?"<(D@%Y"_@WT87/
MAAX,"T2PB:]H-[[1@4-?`PGE,"R\L!5[6PY$_Z8H7L=P`Y^,R30)$GBYN@WP
MXL'Y"U/_7+GH\H!M2BU_(\[L$G4K'>S;7R0`P&]+>,)B`N'-'8`0R11WQ^PN
MF/VEQ[C#,]ZEWT$P#K;@Q9J+@\/M008`$H0G1J8!-`!`!&DP*:PF#OQ8!_4M
MW)WW[=FGHV0!PVF0XLZ@GU2Y3V?"XX;R%I`MI07N`<-)U2XNP2T_#$X+^&M!
MX"[H@]#U#P>JPQOJ$CB=L64"5P[Z%H5`T0VF!:`4$50@?4A4".;9(8,K4-WK
M8O9!>'`O`(N2%`L-`<%/M0Y-QOG.$.D'00KMAWOT>18.MS#%%'S'%%7[2`_?
M42<1*($)I-`&=S!W!O^,%0$)3UB8Q9:`!&Q\[H9$.<!P`)#%#F[Q(BB;1A51
ML`#M[%`*'KRC2_9X`BM=(9""9`DAZ^-'LA$ND0`!(#P660+]8)%_D.Q'`]+W
M#DHR`663<Z06,^D/ID4)15#C6+M*IA](=6P5GK2@)>F(25+>(TA>R)4NH]2@
M`NPA1;V()3@2-T+LV1(??12`J^C#S#`LX!+VD58JA!FYR>GMF/FHF]>8>8GV
M-,@0"HA=*X0)CBP@$IL\<`"\)/!-^BB)3$B(0!U10<X#N`P!BX/".=&Y!275
M0P#\`AT_'T*B>GCIDB[X&P`X=J.-X8@<`V7-,Z'3@EU]J@^""X2`W$<CB$;_
MM!_Y1$4IY$32DIHT<X?@H`D<I"$T<2B!(]WG1X&``%<`H`(#R*E.=\K3GE8`
M(4"\CDY8&B"7:J)#NIBI/VK:"@`,X`)0C:I4ITK5`2#$>B%%P46Y0892@$$)
MI_204OO!5%8XE:IH3:M53>"`"$3@9B\@3Q\6>HSSD`=E0)/I6'E0UHD\-:V`
MC>I:39`G&8AR!7K=JP[ZBI2_!A:P@VT;1L7).,7:@[&I..MC(2N0".R"2P$%
MI&7O@5E4:':S:(TL.,B753O>\8LDN-@(MB$"+]EVGM,H;;\<B]JIJC8[PVD5
M;G>06,8T"$WC<)8"D@'$/'I1#Z;(G#5T2XG3]E:J_[\]3\E,4UR)'(\$:>A&
M_+ZA.LE)LPKM"1RH^,#,T#(3'`]X`!(`(09#L/*H`J`L*JAK+]Y>%ZJ_)19B
M"M`Z4J@A/+U4UGIU8<8WWBE."-7!)N2Y8`D`(+X0<%0F?%D`#LM3:[S<<$%;
MP5])6/>_%PCPM!:S*)@IBVE@()N(@=@T"3R3CM]9E+X"`+\=:"U(OIF.T]XK
M/&4-9Q3.]-%A*5'B2)SXORI.J4`/LR\%"_"9:**KEKY@G+P5XG\%[,;U=.#-
M1D0O$$AE9J\P`2Y,>?,2?NM%DR'QY.L&.*BD,^9@)`>!L<UV7ZI,H/#V%2QE
M96I1(ZR9#YXI7_H@HJ#/V?]?V20;H>Q89V'602("-J'?2LSY$77N;8"Q6LO!
M:*A.OF)2KQ:J82?0BX'I0P/J```(`\"/EI$XKR\^W13_0ADA;7WK<,O"&.-5
MS`CN<P*A2Q"=!*@'%.QJ!_+<9UN9=1H8O,9#J%&KXL+J>3<*ADJV[[#MS08X
MB(=,4*<<40CYY-</:'HH.L9MAW(_-L`*,.^2>=!=TC1K'P`%1R[G;5-?VQDA
MLQQV#OH]DG4GW`E7^S<IPOK&<]`[#P87-<(G]\I'C@9#U491$?<=AV9!`#KA
M=L?%)Y5Q;B,$7?F])FE^-813=O01$G="6`67CI5GI.7F1LBSNM3:'C!<)"#W
MDK/_]Y9S3.QBR`1O*M#OC9"W/4?A7#D-AC"'*Y7&H=WK`&!^I4L-G^MCZH$-
ML!P/6NK-T)P)-A]X+Q8QW8*C&+L(63L$W*M/K7>+!(`(@/>`H8"PU5WJ=Q>L
M1@)`<F*3QN&$/;HR).#U<=H]\2E&R$1[_.W1UB<"E;>)O=..<%.$?N&>7P&/
M3Q^3T7/6!!.=7.=/,V9KM(KU+7&]6H$JOZ;-GC2UMSWH4^'NR1G_^,C?#IW1
M_GHML2C.OQ]-\(6/>S@$@`(,R+[VM\_][EN`8+I/+;`E1^'H@V;ZPF_\'`)`
M`,QG?OGN5[&^L)YUV*#?]@A0?QS8'W_P,W_W)?`LT`)7_^;W&?>7&LLD"?R'
M>2K&<OU'`HB3'9Y0=/PV&P=H#;:F?UJP@(G7@#_W@$,``0E04_;#0_9'@=60
M@9'`@7?G@6<'@F>`3WI`=D9G@2B8@@GH""R(8BXH*O\G?I-B@_9@:V%U!SOX
M:_#'@)0B>2AQ@>=`A#K8?DJ8A!VXA$)X#UQ2A'1PA`='A2WX<GPG6B>8#[ZD
MA7+`A1KGA3PH=/K6=L!W@^=0AG:`ABZGADA820="?X-RA60(`6:X!708=';8
MA95T<@M`@Q4XAOW@2X9WAE)8A8.8AB6P*/G5<:/T&DX(#XR(B%,0B%07B748
M@`M`'1JXAXKH#W_0B(#XB%\(BO^"6`(%\$R6>(FLD8GR4'B<"`6>2'JN^(FP
M2"%PB'JG"!"XN(HPJ&T_6%5"UWLUP$!20B5+@A!,2`7>1B3?$#AJ$GM_1`FV
M6`_%F`6[V'R]=HQ"\GREV#:4TP=V)2-7`A$20@('D")]4#-Z4`*XD@K=:%"Y
MZ`/A"("@EHR^Q88MLPDT`$5'!5,'4A'I\3<G-":ED#"FHCJRDFG2$2NE`P$1
M8'W!6`XFU9$=J8?YPXIKV(N\B(=R4I"[0"#LY5&1\3=B($`2$$ZA8BJ&QWAI
MH@SW$2PC,'B`N)'3U5-`&903X),A28[U!I!X!P27@A[JP1Z4-8TQ\S=_$%]M
MAB+K8"K_G6!4$?0LN;1<^T>49>=^!`"6JB>2=SB.4_@1&`,UOH$<+/D0RH($
MXO%-\O4_)("52)`I`/5-W^(%)W.&9"D-"""6@6DW9DF(:`F))7`?-;./]2<1
MC;(Q?K``C?8'^',`V!"+050AC>8NQ:>1_#"8F#>6_'B8DIB8K3B)7=`^;G@3
MN@:8H4F8I6F4&&>4$9(^A<DG07&.5Y"/Y2":B4>:/="/0/B/1CDF]0.22,*'
MI"6;PVF:H8B:(YD$CNEXB@0*?G0)E@E!D^";T^6</$"<RDB2XC@"D1,AU6F*
MUQEN:,`'83B'N8EMX+D#XAF0Y.F/L+@`+G-MB;B>3`(`>8F/__'Y"\!Y=\(9
MGM#YBM)YEN:)`.AI=MTQ2*!P-,GPFO`9FZ,YH/:8H+ZXH(BI"^GYF"EQ">&&
M0/4":E`9`P6*8@=*GQQ:DAYZFD/`<:T9$B3Z-VEP/#J3`,,7%2OZ7RVJ`_69
ME,:9EB0`<\Y8@!V1#,8&@5`3')L4HC/QH]<5I#DPI(IWG\4)>(+GG0&Q%-_(
M%%3:6U:*`U@*8/YGE%9WDTJ*$]>!!2US3W(ZIW1Z3Q9*H/,II"]:GN2&E%FZ
MF*]"=R:H%')H!0+``)C'`'>Z:WEZI7N*G\AHFZLYBS7(%`40`93Z"HB:>(K:
M<XUJIH^ZI9%JI"-PF^K5ICNA@E1PJ/^)NJAR]JDW<*;O5Z2*"8$`-22HNA/O
M4WTSP*J<ZJJ\,*:H5::Q&JKC2:NI25C*N9Q1<7M3X*MWUZGS!JLV(*L]2"M^
MBJ8F,"`/8&$U6A2C**4P`*TH)JT61ZTU8*UI2JI*@P`IUW=5$:8_0*[_9:[F
M(*R;1:S5:JSVB:S3>9<QR2[?:A1^&`7T>EWV^IOH6I#\2J0Q&IT>\F"Y"A2^
MQ)\W<+"]E;#?F:&SR:Y'29OC46`3:P/M%#2YQ&CB:@ZJ:@F;&JW`Z@KX^ECZ
MFJX-^Z</JZ"3*0%NE:G]&05CDI$!Z`4+90@:.@VV]IX7V[+E^K(DMK`SH*Y:
M>JQ>A`#1Q%W_AEH"ZL$)@L>KZ>"LFMJJGLJQSTF;#LBN]1,!5+NL,F`:GQ(D
MVDDO14L-PO6UOQJVP1FWM56SVNJO#`I>)2B&JPJ/$U9!1$80\HH#&(M:&EL-
M,1M8,\NP9/N!'KMB59`)F+E@.8:T_F`=/)"XF[6X82FV"!JY+SBYYF0%=!(<
MXP!;"E&H.>"YCP6ZN>6T,@"U?/NAM#(6!*:AL!M8LBN8M!L#MGNS'2HJ9+&R
M-M"[@/6[T="X@/6X3ZNWLTJ\,&J\0%!\%FL1!N"NB*NT]<JTK."\:06]M2N]
MURH5V3J]UJM/>/L/7EL#RIM6S!L,XHM6Y"N\YKNNM;J^5M,-[Z0&_VCRIJH3
M"/*!`%S[#M"2LIK@O0@+OJM0OU1UOS`PO*.ZO[E[%=U@);3&>,C0-$*0I`S%
M$(<[K@R<L0ZL"A`\51+\`A3<IZ0[9>Q+0I>B/$6T"XH&$6]*`_&+5O,KGZ+K
MHB^,K4$\LFLK9L>`.G\I!F6"+?48$:X;`SM,53V,IS^LIT,\+>E[OH,*!)'Y
M!2=R,D'D-4P"2LKW$)?*FU$\55/,J%7LJ%=L3EELA1N8HEN`O-53PHI[PJF0
MPE*UP@F5OU';K_H@%6IK$&V%>VDL56O\JFT,JF^,!>$GM?S[%G/[`HD<58L<
MK,$[P8!\NS)ZP5&)7ZLS(O>5&%",QY^KQ__[M<DLW,G4RZ<"%LJ?TBML%#QP
MZ9&XG(>@@LJQJ\J>QLI__,B'%,=!V##,@CGM@A$($)3,O%-#N<M@.ZV-7*S"
M##K$'"_&K`FW=8\2P<=1=:"7#%69#+/`7)2F*[D6_`/J5272B#9_)P*GFAW=
M#)[A?`'CW+33O*_5C#;7K$_/@B+L^);]6[A,<V&\V9RB6\_W'+[ES`(M_+'G
M3%Q_YR`Q-06(8&R.8B8\-\\)S<N^Z\M,UM!EN<\-T\\Q7"`"S0/;>\`)X<U0
M!<X>O;P@/0DN?0%^;,[I7)L171;@(1Y/&04\>M`+4=,P'<WGFL\T2](Q8])`
MT*3(TXYZ`@'9J\S_]!S3\CO3DD#4[?O0.IW3ISLZ6#T06@W-=2O-=]NQ7HW.
MR3K).Q"N+3'6F&#5/!S6D`#7H[O30HS71-P"[YL2=JW0=/T(=@W$>HW%2MVS
M9.99,?'7<BW%@>T(@VW%A0W'ATU<>I*#;UW51GVO(JT"7%VV:9UN._#$F=W1
MFZVP2`VYDPW)3!W+.5!X-L'8I[VQ9SVVJSW,E6V=9LI.L:W997W4M7W7H>V#
MN2V,.'#(-R';O\W9J1V]Q?T1K4VY-W"T.*'<+FNW!KK5KES!:PW*-4!@/'L2
MUKVTV,VBVOW<'13=7VT#!;L3X_V]Y0VDYWW;UHS>ZDD#L,T3[]W`\5VE__,]
MW'D-X'L]`@T0`0J\$?MMPOU-IO_=W1`MX%O\(CVJW[Y]W6:=W6CMX%VMX>L=
M`W9<W15.WA=NWAG^K]QMXM[]`K[4OAP=W("]X,/:X"C^X!P.R;WZAR!NVLN-
MVL%-V!!.V?1-BRXPPNX=XO`]XO)=XGU+XS,NW2Y0R4*1X'D,X_DJXTN^X4W>
MX2QP,"P]$E*>RE0NLU:.NTQ^Y5JN`D&M%%_>RV'NN&/^R65.YDZN`A6[%&O^
MT6W^O&\.L2X<Y*[%`O$EID;.WTCNWTHNYZ!=XZ*]`G]PX.(]Z`I>Z`Q^Z'".
MY69NXV1QYS*=Y^.[YSC;YS]>66*AZ5?-Z?;KZ?_%"^J*+E#)U^JM+M0<0>IS
M;>H1C.K5J^I9;N,(T'V\WNL4P.(,(>N.3>LJ;.NP;.F(KNN='>N0/N62'N.4
MSN=Q7NFG&]F]K>,6#MP8;MNACMM^7H/6/J7-#N;/7N71_NG3+NTK%NXR(>QJ
M_-AXP.[Z_.V`I-[*WMQ^/>YL7NYB?NZIGN[HON[+CN#ZCN?\[N;^?NL`_^\"
MC^\HX>Z*#.]W(.])3>]78>_I1O&E[>*-_>[$WL?&#JFX?ND9/_!4C>TBKNTD
MSNVK'N`M[S$:SQ(0C\D2;P<Q7[[VS6\8+U`W__`%O^D'K^<)?^R)GNLE[_"/
MCO)'KO))SO)&3]P63VS_/9_T'#_;C&OR)O#9:OWTE3/U)#'SXESS=>#UP1SU
M5K/S78_U%@'V]BSV=$#V./WRAFWV,%`UNP#W(<'V"_W`:G^7VSWRR>X#;S,L
M=]_W+;[M"VSUH=OCDMWM]4WW+5`*GS)2[H,`!'#YF)_YFK_Y`_"?N?SYH!_Z
MHC_ZI%_ZIF\*EK_YJJ_ZG7\@$$`!JQ_[F$\!B7/ZMG_[IY_ZLA_[K8_[):4`
M`[#[LC\![N/[QE]2#3`!PA_[Q,^ZSWH"<A']NGW?_#']7VK<U8_]V2^BU'_]
MW._]WP\%A&_]S!K^%V+9V@_^W5_^VV_^:TO^YY_^[-_^4C`LCLXI.G#_?I#_
M_Z,-`I@XDJ59%J>ZBBG[DBX,RS-;VRN>FSL?_W1!E6]8-`Z3AB2SZ7Q"H](I
MM6J]8K/:+;?K_8+#XC&Y;#ZCT^HUN^U^P^/9PE%NKR;N^KTIS^?YZ3D$*"R5
M``#\*38!!&`<8#@F%2R40"YB45J2)2PH)))(8F(T$.Z(WET&'#0L%`P&@([.
MOE`&)`@D/*P.$6(4!+@*R-)&^1H$W.:.00*S(K?20B(N\#8T//PE%`84(#H>
M$!>/CR@`1V)4HO(X(ALDK),[.38X&)R3&>1V-Z0H%`,PI\Z``PS_]@3,X^@;
M!D3R'AH,L`]=/!N.O"T8!!&*HP0.%,`C`RH9J105^?^4,AF)(+H]"I(U:@B@
MU*>-#QTM"'D21L=J,\79_.%HD*N<8QPL6(`,0R=?LP0DTYE.8M"J5J]BS:IU
M*]>N7K^R\18(K#8`=7(`,$2V%H"Q9]+:3&"6EH%/O%A<6IOF0*Q"+_*>**#`
MP8%*>,'6;03XQ.(K@@D;7M%8#M^`:E5,5B,*W"-2`>RMRL6WX(+,>K=L-K#D
M`+)NK`X(*%#*`*M`!_S<A@2I%&@`PT:G,WUS!.?=GY'!3@"\=)7;(G)WYAU\
M6*,&P>-LAJ2ZM>Q8^UPW<%MF,T69"P`4O`4)Y^DQFQT&4-V@D4GGR6J(8K@0
MP/GTRM%%=A5YCNS77R3_L5?_17XQ%9A.>;<%Z,9F^\G'GP@D*=?-&MV\HLZ!
ML9R72%\D[=1>%I48T`A\]<PG23+)\%6"`XGP=<XM(,(7$(E:<8@41?#PE^-+
M!%HQXR/=$`BDAXY`=:,<*#:R'XLQ13(DE6H()M$_+X&D`#;AI-.4AR:"45<`
M$(0WY(LD8?!`)Z7%$\P#L7&YS9>)S%?-F%AE*<"6A-CY`)@YZ=F2@@O,"8Q$
M@88T'TWXP&$FFDC9M:8(#PS"#1QGD;D&IS9\JE>H7HRJ2*F=HIJJJJNRVJJK
MK\*:23#W!&`=,-;!$FL7N2)3T"!+#&)=+;-Z1D>M(OQ'%C!*W?K+L7R52,6R
M2Z34_ZP!U8AG!Z^?8?!KM]S*T<]4W@Q"[E!`Z:I@MQ8ZZ6&$)XB;D5GWH3?5
M6O%V@UZ^&GT1[XR*DNO0(N>J$Y*'PJT1Y84N_F)4NEI0$I**+35P$`P*1^)B
M?-%FA3&;$IGRA<<:*^"7J3DM%$LD_($KQTOH=/?+?`]<]K`5`-",#F'IT>$@
M#"^+2Y)L$"RZULL7E2*S"`)S`;1)2!.G",Y+#'5`>@"L9P<K:1%V2]>Z('*J
MS3P\$#:(Z=!WGL62S??.*@Y\?>%:6Q/$ET=V#^9*%W3#8_77J\RG2-GS6GB>
M(Y^\VX9<<+TC0N.(S#7VS6$WE((WR*+;!R)+)&!(X\BNM2CX$I]_'CD7HC/E
@N1^?_P%Y"G-=_HOIDM->N^VWXYZ[[KOSWKOO$(4``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>f39432a9f3943219.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943219.gif
M1TE&.#EA?@(@`^9_`/___P```,#`P$!`0("`@/#P\*"@H#`P,&!@8-#0T.#@
MX"`@(+"PL._O[Y"0D'!P<#\_/U]?7Y^?GW]_?Q`0$"\O+U!04-_?W[^_O\_/
MSQ\?'V]O;T]/3Z^OKX^/CR8F)I:6EG9V=L;&QJ6EI;FYN<G)R2DI*=;6UOGY
M^=G9V8:&AN7EY0T-#186%JFIJ5A86&9F9IF9F8F)B3@X.'EY>6EI:4E)2555
M51D9&45%1?S\_'Q\?"PL+`D)";R\O.SL[!P<'.KJZC4U-9R<G+*RLK:VMMS<
MW$Q,3/;V]EQ<7#P\/,S,S(R,C&QL;*RLK/3T]-+2TO+R\AX>'K2TM`4%!>CH
MZ')R<C(R,I*2DJ*BHE-34X*"@L/#PV-C8_[^_B,C(^/CX^'AX9Z>GD-#0\[.
MSGY^?A(2$KZ^OL'!P?'Q\>[N[J&AH6%A8:ZNKEY>7H&!@8Z.CFYN;B$A(;&Q
ML7%Q<4%!04Y.3M[>WI&1D5%142XN+@("`M'1T3$Q,3X^/O___R'Y!`$``'\`
M+`````!^`B`#``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!J`P#%@F.!8L$B0("
MFP8*B0H$SL+6U]C9VMO9#A0/"!31BPH6BP&)!,N:`]6'"P?NW//T]?;W^)(%
M%,=_"`^,!`PXEVY=IG:)T.5;R+"APX>[B`U2P.!/@0$!`/X90"``@C\'OB5X
ML,#`Q8R"%`HZ.:```00+^/U)L"!`RXT=/X[$:$#0`YO)VM$$.NCG0`,4%APS
M0$`FQ*=0HTJ=RDB=(00#&)3\XY%!@`0P#0@(P$`!5JT]5?J+]Z\I`PL?_P\\
M$'#``5<$7A.,==#TCP&V']O!%8"@IR`#`0@H"&"`Y!\""RI2G4RYLN5Y5@N)
M\VLN0-!F`^D*VFR@,Z$%T0H((`!0H%^?RSQO;'8@I3]J`BC,'H!`08%D@]`Y
M^/A'*>O+R),K7SXK,R&%KA6V<^V:JZ#HSPE9=9W``H7$UF=71X<Q@'GQWP?T
MLYVYG7/F\./+GW^I^A\%"\)C%Q]ZH/Z!:BGTVW8#+3#7`[$),IU_Y,F#4`$&
M%)-=>ZL91-^%&&:8H5,$F'-`3_^$M^`?U7WH#T!JF5@:@5P%E2!_MH%CT4#M
M(.",1,']H=5]GKVGX8]`!CE94^!\I6,`(44CG?\`"614G5=)AB>(5QA52"*-
M"\3TXHC6*4!!2,NTPP`%`U`@F6T@Q020CT*VZ>:;]D1H@3NKC;,.-'Y!8QB)
MB@EB(9_.-'-?3RX9D$!/=RJ@@&'K3&,8GJO)\]A*#A@F*)R89JKIIIQVZNFG
MR5V*"7",)(,GJ*BFJNHV;$Y23B-S_?'`>JO6:NNMMK0JB7V*((3KK\`&^\FK
M]YGS$P6(JB,9`0R<I%%1`2#K4P!*A32K1@.=I!12!XQTC%')(/@EJ<*6:^ZY
M2OTQG%8,>/,8`:6-9I:-)DX9F;M(M7M`6./)6N.<"_36C@&1\;91/`O8=>["
M#..*@%T60.-,`>BHX^7_3/E%)H`#Y@BBP,3H%#8E=0R2&(U$"`G6T\59O=OP
MRS"#^M8?%"1#P`'G6=6M`RB:9Y-V.#<X",FV%0#3SRD+5(W0NL;L]-,:4IQ`
M;7\96O$R"%I0D5J#5-WD;!X3;1T"6D<(=CN^,OTGU&RW/=\`'#W6VM57*F2B
M`,\>-Y:L'WE)77Y[MTP`C<ZT(^-?8#?M]N*,3^:`D6.523?-'5,9`)TV?7??
MEQ00T.0#^QQ@0<6<#V2!4NUXB7-%""G>^.NP-S3-(`PHYL#'U8@U-#6%U*[`
M[??!>UA/"1#@DB`.W+[,-(M&,TWNT8@:^_345V_]]=AGK_WVW'?O_??@7X-[
M_S/DER\`N>&GK[XVN#/E'-[J*#R3^?0+L"=3"+H3?S.TKN___X(X@/%",0T$
ML88`#N!?*MJG#@09<!P`W![<)N@M2_B''8DPV@4Q!)FM8.*`#X!@+W[CL0.:
M)(+42XPZ%.,K2G#M$B\<A`/JE:$"'$`!))&4(A)0NUCA8SUX2R#Z4.@TKOGJ
M?(Y(0#_0@<3KT$H!M$H`!%63(Q+U+S-4G,@0D<.4^V!%A]?AV0,>H#NH4(0U
M""H+$6-FQ//AC!^N\4HRU((`\WS$)DBR2-#65![6860S"?C.`>8($O,\:RR)
M"222YBBA^`SR.KP9!P/&R"P15D8U:/3<&A>F0N&UP_\!+7F`:9H"FD$$,@$%
M0$T`'+"/0[7D:Y!Q"8W,$3<+V.5A7!'``GYS0:/UQ@*@&X!=R+)%+A*'1`=8
MP``Q5``@6G*3M;()W`""MHI0#"0"X8AS>+82$3G#-UYQF6M:MXS.O01`G[MB
M;)(AD1@N9P%X>T"S_*+,("5`C,^$)JC:F#99>8-C6AO$>Y9T$LVQB)Q<F2"*
MU)4>[1````$````P``&(2O2B&,VH1C?*T8YZ]*,@#:E(,T"`#`!``A'0:`-N
M)@&1NO2E,(VI3&>:@0XT8*8XS:E.=PH`?4:"G]9$QUN^4B92'4='UYP-QY0D
M3L*Y3#86Z9*.X"G0"4#TIAW_J&A$><K5KN*T`1+8P`8D<(&+0J"L&KU`!""`
M`:^Z]:UP[8!8/6!2N-KUKA_U*23:",H"B-(B"RA0;4PI#B\M1D&K,4='FIJX
M90#S,7?$SV_2Y2>K<F`##8"`!RR*U\YV]0(>B,`&ZII1#*24HQ>```?0ZMG6
MNC:M8=U`!UY+6Z[J]1%MM&&T^K$`#SU+$'5$R9*\A*0>+6.<SK"*(C<3,CMJ
MQZH9^$X%;KK5VEJWHQF8*VLY"@'2;A0#%8C`3:]+WKO*5;;C+:]Z.7I;1T@*
ME=<AE11G\DPE7D<0\/W83`J@*(L<([_C4`UPJF%?0EP`K0UHJT05O%[R8D`"
MZ?TH_T5!*H$*3"#"M36"#AK<U0Y$@,$<;G![&1+B!F=WNR]E:T@G4(&6UK8*
M",#!$7Q08J]>8+8UONZ(8\%?0FR0$;,:22%R?-W0>@##+\U`14/:@`UH`,2=
M%4$2,L"&!DP@"2@FLDSE&@'O:AFO.X;%G++SB-3M21!?IBV29?IAEZJUN[1%
M@$0OH(4:;#C-,VT`CO%\US!#HA]9Q*\\FHA?$4(1L60.]'T(?;X6QE>B">;S
M9\7JUM3"E*(1R#)/+]"$[6X!HQC@``DDG5/9DKJK?FX$72C@`$4^,KB#K6-2
MG!%<1/6Q(Y?+D:M-99[-R#H>T<'(`0#0@`H$P-BGGBE*C_\,UPCLV:4=T,"%
MN]J`'30!PY_.J`0X<()DQU2N$]"TMT6:ZH!XI@"V],?MQ)%*)HG#*TS:)4T>
ML\O!*:`NI$(',"]BE\C\P0*>VR6\H\-*"F#``Q!H<G7'_=$+3*#-=[V`!F;J
M`0UL5J<H`,$#H"S1-VS4RC!8,\-1^W".C]RCY5Y$=<R)E?N0")[<Q"8HU0'/
M@\H#';*12#2Z@T"-`!M`"@KU;!NP\).7=@/A;FT$7!Q3*[<8IT0@0!4Z6H:.
M7H`#07B"T4.Z;:9OG;TI9P:#%"JK7EMI-I"AH,VS`YVC?,><ZQB1="BJX*)O
M':40?FVQ<_IFDWNT`4U0`0H\:E7_CZ;A#2+X.DA-.VW%9S3L8D\)<)J9KD_Z
M?#4:L=EQG9JCG`_$3.^*^<]%)'1BV_WD&'CV:R?@=9DJ^0C=#ND.7B!NC!;^
MHT5(0@H<[U&UJE[QD$=$=1[[$EVJYG*!I`CR"XN:@Y[).OL6)E>DJ,SD-ZF4
M<T>XPK?>@-J[MM@B?REX(Q`$CX;:[QH-@4B;W'C>NQ_EP3=$=98;C3?Z6]94
M#>Z:-N^/7-MFUV6')`#Q:]@7=,5V;*=':E:V`=[G6A-P>SHE`7(``U.7443`
M`:WW46R09!O@`5KW?AOE8>B7;/%G",TT"`*V$N>C*-%C0P36#_UU@B1"*M6@
M:`+@&_V`_TJH=(($UGT)1G0C)U<-J'<:$'XP965`4'42504YT'XBE6TOI08A
M0&,@J%(3P`%>-FXE2`DSM#&ZP0H`P`$?%@$<4(77]8!>U60:0`3;-H0;!84P
M!0*89889U7U;MX63H"W/EPH`D`$:$`!P=FH>\'LE-EUN%0,4H`&))U.Q)U,7
M``,A\(%T"&INF&-X>`TCAU(CV&`2`($Z!04[4`(3!0$O8`0QE8&7]@)#,(D8
MQ7Y&2&27:`WC9EJ$2&054(D>900[,`(9U0$FD`>[YU*>J&Q:0`2L>%%J=7&D
M%HO"D&S)F&PH%8&!J%$>T`+*"%)-P%75-H?'.%$0QV?,&`P*^/^`KTAD&H"+
M&04%25"+%^5T61!2&_A9$<`$W2A1;0B.X?@+DN9A64AJ'A934*`"+N!F$=`'
MH^91\>A5H68`]>B*:9:/^MB'Z/A]&+AU9_52`BF)+J5D.0`%'25G<.4#P=B-
M&>!L7P:1OB!1$5`!+5:.>N>2>(8!PP92.K`&WRA3X&4#2[!1('E7)V"*W4A6
M=J5D$%"4PYA7%A$-/P8)2PDK_8.2AR!10N@!%8"!,`E7$\EG,[")):"*7%5A
M3@@`/6E7*<`!,5"/=X4!TO:`%'"-("4(8[8VN#4)C@:542E1%8",&Q!>['A7
M:.A^&*`$'=4`21"6.N5T$C!X$C66:7G_!&B`E@RHD$L&`%D%:2!V`1B07IB)
M:"CX7O6U1#,X-$]T#%DD%!!T:*:$DA?591E5DAHP6JU5DOWX=1!PD!D56EFY
M?A&P``,)``GI62Y``(O(BE;FECDU8?984=%U;#<E`;U65LXI@.:Q-P`(-]$B
M0L%U1\*F1X;T&-[!&-]!37^T%,ZU:O+#C!<55ASE8=*6F]!&AQD@!!BE`R`P
M!INX:1P@!`+PFYZ%`E/P`!7(BAUPE#BYEAM``2W%`9L5`9NE`;/%`5:%H```
M</BF;\%D%Q(2-_C%#ZFT&`7G2LU4,;OD#4I$'J%D#AS:+6-!0OG8CGDYF-M6
M`<R&EEP5`0=Y_P%*L(JO%9@LX)XXE0%'``<TNE,80`$0H`%M*5$4\(!K!0!E
ME0$0F@$O^AG6X7F-)4.9YTWW40#AI#<ETS)2HTR#0PU->8D8M5H@!5I5F7<1
MV)>\EUH_P`0R<)5>90,\T'Z*V5E.P)K=>`%TJE'(^7005900L`$G]783@)R(
MAG.0=*5^8B$$]4=TTR]IDQL3)!9EBH<8)0'&:75[:9(RU0"@>HPZ,`-:4'[7
ME0$F``),H`%,L`([8*1`B5<+&*!T>'6S&5+(6:34-5XW10&S]8#@)5$WB!`X
MQTY.Y1Q'U2Q+LE36P2+6`:84(!I1Q2OAV(HOFF01\)JYNE%0ZJ/>1O\"-A!M
MUQ4$-8!9$G`$*_`%`:`$.@!>-[`">$4"+R`&-;`#?\IP'3A3R`D`$&!9AOIP
M$)4!$A>A-C4`$;(U_W:ACCH3A24.2](ACS&I7SH0?V4FZ(:I4)E1MSA3'F9A
M0^@!AMJ-"6`#A1<!!(I7%Q"@;0`$HQ4!)F",'H`#!(`$;P4%8P`!$J!:Z8J*
M[^=A^=JOO+J<%%!6&V`>%6"HT5D;=42=@D2E[Z%_WD1<..,2_!>MX^D7YE$;
MUHJ>&.4!/KM^,>H!FM9D80N"?GI15:`!>=I9F8E1%W`$T_AZ1M!D/$"%7+4#
M<L!T$M`",C`$:#J)N'J$WO6V/WA1&."G=;7_F?%5@^X`8(508`26#/J%2C'8
M#\Z@@Z2B7_ZUL7!;ACO5`%1IE<C(IY.H`RZPDQHU`5C@69QV>]7&`X2HEDWP
M`ZEE`SSE`A:&85:F`2.@`EL@KW1HMJ]EE[N@48;(50ZG`<YF6ODZ;B1P!+78
M`";PO"(5!!-P;1<U!'?Z414&`Q5``9^H!(&[45<'`5`0`UA@LW2HGJUEO+JP
MNF=+4^%KNE7HD!WUEVZ%`NJ;7FV@!.*U>%4I!6;`OC&U`EU0`?<Y41J@!3YP
M!+UIAL[K6?";"QH%I6^5`2WUL9'I?BCP`!W\=QKP`VXE`ET@O`"P`G6@8A^U
M`EJ@!!UP`T`0`3C@_P0Q50-F,+_4V`(TX`$SP`6W&L!@5L&WL%'9:E=@Q0$R
M"JXAMJ=X"U+ZNU-5T`3X>E$LIL-2N:06A@$D<+X>*5)5^;R9Q0$-``=X8,#O
M9[TN)0'%1,2NL%&FQE,-$'ZBNZ9JK%Y+4)$PE;PZE;VLY0+21J>BJ@1MY0&E
M2%&T%U(5``$VT(@B%;=%*5%!H`+&.*0[M;-N;`O>>EHZI63E"%K,ZZ8U9@0O
M8)A<IWXXA0(DP`$,E@#DZYY*9@<GT&0TH``28`(TP+MH7%$=\`560,(@505=
M\&3^BE$E<)/N=P%8G&33E<FUP%$3U\E"/%*?VJT-%@5,``/@J@%D,%-%(/\$
M3(?`"GS)<O``MFL#._`$U?C+`)`&6*`!.,"+$C69$_`%6*`&'84"*@`$RCB9
M5MP%UIR)([MI&F!2SDP+'(7,,96R(,7!`6U=)_`"^*Q30W`#39<$5=QQ9G"6
M("4#8@!25O8%O-@!,T`"5M8Y+1`!53`"1\`#N^?/A-D"M@EJ"\"-\_QQ24`'
M=ZQET1BZX]Q3!RT+ZSG0Y36V3*R\,/".7*4!LQI2N(FX/&#3'>4#)J`!11G0
M:J4$HAANJ44!%.`#>"`##!P"_BQ12A8!P.RD+S"-9M51);".:,M3>@S400T+
M'77$Z@56B\RFUK6`.]V++R!24Z`"#`8%''"1'V7_!#;074?0!$50`2^`PAT%
M7C"0`C2@`70@`B0``78PD@C'415&`W>P`[++7=X;`<-IR1RU`9Q,UW7]Q@G]
MT-HFRC,%RAQ`VUWU!$R0:7`%`8Z\42<0BA=EKL3\46`0`AI0!&6``YW(`R,`
M`D!0LR`%`4NZ`C00>R$0`!=`!Z98UJTX`3W`T-YMA5/V?@N\43O[>*_]"AWE
MOFN\S#F57>%UWCHE`VG]5AB0!QV5`B^`R@"``DS`SR"%!#M@C2/@LN.E5AH@
M!A,`!&N`QAB%!E?`VR```B7`!P#@`@S0ATZP`^.-45+P41^>5FP0`JBJ>-D5
M4U**8>O-WARU=VM,U)[E_]!8&<)WQ<+:5MX+!@'3/-D\#J6(#6I)"Z00T-0`
M\`,1P`(1;`0>!P!+D%X@<`,C+E$A[E%3KE%04`:JB^(RWG`%K5$M#ML<5;ZG
M35Y&K8TA(-5IN60N<%/!O6<7D`00L.4=901KA0'(/8(28'%%H`$9S6((H`8Z
M0`3RV@%A(%%<(`8ZH(LFX.$?5>4==>4;-0=)T,U<OGX_K=YAO@H>Q:FZVMK7
M!59%R=<R%0,W(-M<!0$RP+P:8`$<#0#86]H?U0`A\`$=,`06QV0-[@(55P:!
M'`,_\`8I8-%@$`%(<`(P$`<CT`,;,`=*<.71'.FA.@%=<.)&E^(@-=>:ONE\
M./^8>.VM75Y>:HJ!40!31:`%\,U57'`%>U#*/&`"\:P#K<K0%Y4%'S`!(\`#
M/9ZF'*`$5\`!29#A-GP%*3"03-`&&^8#58D%0,!65P[IIEW;VOMU/=U1K-U1
MW,[I'M6QV`7J(99=&C`#KYZ+3?C7+]4`+]`"72`$"X#G)S`6+,#;$O8%+S`%
M,\#6(O4#-Z#R`%`#`!`")Z``$W!G`(`%1C`&"OP`7P`!/+`$#R_BJHW>89O>
M&)_QW=Y18#N89!R3*]D$=)Y1$V#CK34$9N`!3J`'$F`%:1`$0:`%.#Z8=\YB
MN)U13)##)]!6(;#VQ":**@``!N`!%(`%)!#(E+G(CP[_]3O%!35PU.J5]1?,
MQQME]5>/6J"K4EOOCQR@`2K0U!UP!/3=54KL`D@'`@!`!OH,!#JLVQH@`2-@
M`J;\452]`3[0;;QHZ2,0`D4``%U``BX;`Q]`YL7L41"_49*^?C50`]8^;O;K
MI%\.?Y)O"B`%^1<%F]XFZA^P!420LS=@!2:?8N;A\RM0!34`!*^/42.``Q-0
M!#,@\R^EV!!0!&T``!L>_BYV`F3P`T5@!G/^`9D."`""`!"#AH92AXJ%BHV.
MAD0#&AQ,*(^7F)F:FA$9@PT5&)E_I*6FIZBIJJNLK:ZOL+&RL[2UMK>XN)D3
M$IN^O\"^&1H55Q!<&#+!RX(Z_R`4)CL0-B,S'!>9)=9.+Q"BP&$W&@10*#[?
M`$5165P^/S4:)G04#X^,CXF7]\P`4%H3A`!TR.'"$K^#!QMT&,2AUZA<$"-*
MG$BQHL6+%S-EX("PHT=##2)@VXB#P\*/F'Z\&`)@`@4)%4)E:E"#!P8F%&(L
MDT"A2SH=@G8,RH'$01$L9@ZHP,%#P@*AC?8URF<OX8X(#01I&;3C"#:48#5M
MB+`)H]FS:-.J76M14P5#&;Z&G=O(AU=#&!1DB%"AQHLF/^BJ8<+DR2`/%#QH
M`J'!`P8-+X-A@!"A"`,`1,B`F'#!!X`30W(0H7#CS0<(>Y60F%!AQ"),5!U)
M_24A2?\)0TP,76@RP2#=WP`DS'[$MKCQX\B32Q1[L@%'X,`O)%%\*.^@#A$"
M4%"1]:,.+%8,"RKR94/W2QAX;/"AA,,.$!R$W-9D1`N$(2#./,EQ8L0*#`*X
ML`,7(`0`00QC:(#.9+9Q,`,9A@R'""828E)"$B?AI@@&28#@&W0?91!96<J5
M:.*)*+*ER5Z"<'`>B"A5$0%6C5@'D@0<M$!#"@CIX((-Z)Q@`P1R/;+$#!!<
M6(%.(H11PA@5)+'")4B$T(,#`,#@!!1/N`"`"E$,X4,,,C3QQ00J4`"0(A+P
MT(0+%701A"`5"A);5,`TT,4$+PZ26R,2W.`)C!U=H$$&&PS_^E"*C#;JZ*.O
M;*)!2^@0VA$26"2AJ"(>B*?(!1X40\`)B@CP`@F8=$`=`"G`H&`F*[BA01$J
ML$`'`"0@X:4(032P!1!Q5*$($DR8,,$(*``!0!A!B`$&`$L`D$4)?5#0Q!`\
MT.A(`Q-HP,00%,`01)T`W/G:)C]`P=DC;CS";14\6KH,***$U*<CD.:K[[XH
M;A)!I?(>Y$,23F"RYB-/-!$`$!$TQ]H$//"IB`YS&M+F!$!A`M,$Z35!A$XP
MI'`$`%W4(.P2.[PZ2`80'&'$($"@(((/5XBBQ0@E0.`'!F-`$&TF%W"`6K?D
MFGL(N8.4L`.I^F#2P!L>!OQ+0RMG_W@)OUAGK;59FW2P@=0'70!#;[MH$C0,
M$6@`@[&#0.P0`-]9\:P@DVF+GA"='$$!!$KD,,@/(@A"ADY'+$%#RQ>$9$((
M)JBP!!(SS)=.`9\A.00.%5BM"09QEF#3)48/X@/2%QQ1<"9(`[#"$0"#W<A8
MRVPM^^RTS[+)!6^Y#@P2.]10Y"43!+8Y!-E&`(05W2E>!`9V9'A"-YLZ<D$W
M)*3L`0XR$!&`%7B@H((@3I01;P,TG(!%`#W80$(&)3@1!F:!#>%$"CK(@,,0
M6%0@\4Y`O*"$!5!P1.B,8`,EQ&M;&]@?ZGR!H]_I3A#"84;M)DC!"OY!$Q+`
M3O0>Z`@DJ/\@":V[A`<48+8\0&`#-N!"`R2P*1)H)UYJL,(7-->(%<2!!RZ0
M`1#6Q*T6R$`2$V#:$Z+P`YT(P@-[L$&3`,"%>(W@!U7@`@`:H`(-3`!;(D$(
MMX"@A0#4H&(3.@08DJ"@TH$`"8KX@0K*X,!+P.`7#<#"#@[XP`Q4X%Z"H.$A
M+,C'/O(+:&21P-<X>(DE*.%MOK`1A7@@B)!TX3PZZ$(2+B"!+X0@"V?"XR'6
ML,,.?,%N@K@`!(!0R1:8X`ED:,(@+C"#%EP@!@',@A@L\40`;$$$!N`!%X^@
MA!`RHT`)U``(#G$G)N"`"A;K0Y%*X`9/^>)/P+@B!PVUP>NLJA'_?LRF-E.4
M"1=-,7>$5$1(%/@+1>J#-2?92R^<\*]/N`2:CV!9!$20!-0\XC%"F$P>.E""
M&I0@!`'0"0JF!`!SH&H'(=`!#Y00@!%8840>"1H$7C;%""A!<E29#`>2T(=#
M-&`#.VC`!2(PS&7`\Q<BX``17$<O@[51$-N,J4R-@PD/9.@:X30$$@B0168@
M(6.8B,`+1!`!(00.`!L0@D\^%0&?.6(%;*C`:IJB"0\(LP,?L$(($D,"#_R@
M`!CXP1V2H),J^"`(--B."ZRHR6`$H5NM8]"<$E$?"#2A,8XH00L^("R?'F0"
M6F":O*CFM.=@<Z:(36Q&W$6604C@FH1T_P'K$'*P3+1I!W!*P@WXY(,WO&]#
M%7@!'5'P!E*Z(&)M%><&KL`$%FQ@"6A`PE$]D((V`.`V!1##!S9``@C@U",Z
M8((5+]&F$.CH`R]8@'D:H0,'>`4#?CA=,!K+#SU907@P@ITF.H!(0RCVN^#-
MQ25ZVDAP<M`'%IB"1S#FBRVZP0I`"(&PG.&&SQY"`BVP@AI0,((=8I*\OEA"
M!8BDNB!$010R6$$,'F"$-?RHEQS8@QE6ZI$BF`"4CBB0!HZ`I)=BP`96`^Q+
MF]:1#&CA#3"*H"\P#-/PNOC%D7($!B`+@`J,F%`-:`(,4ON+"9#0%SY@0P3T
M@($0L.`;']9C#__U8(,EN$$F>:(!#CI@!1YY:1`T".`4-Z"!'=2A!5U@7<O:
MNL+47L`^U3S$!8:$`1JH[%,);,1']4ABCV#'EQZQ(X_5/,@]POC/@#;%(PQK
M"`]T-V!#^.U'?'R["%"'<UU(*8&#\X`?JYD#%=#`H34QA`K$02=<*,(;8N`9
M053!"%$0@OZ*4(%$>:``PXQ!!7:`QD/(.@<:8(DB4``QZ2(,G4-@FYPGL-Q+
M.,'7%`(+MS8`1I10,Q@<4T2@I_UG1T3[4X26EPO&@&=^,!H33Z!!L0&`!0UL
M``@J(($&NC`E'8AA"_;%BP:N6\X91&`.?4T'`)Y@F"R$804;L#<7A$#_8/X:
MYL!;M"W=A'"$!CC!"!O`H2&<@-I,9.$#$^B`O34YA$YL`E&H6F!8+M`%*T0!
M)2U=1K8!0.V6AU?.?5;$'0.VD:/.Y=N/@`,3U"`Z$RQWBT3P`+HM$5P:']%;
M/,?$\^QI/A20J@@V9]413%#D*9/`!RE8AR#X6X(&H($#2B@"]"`8."9```()
M(`'>;BP($=B;&_9\!$';2VP>IVX94:#<1PB[#`QTU^6`3^SK1FQH2]$D"7OV
MMJ4WE+A!D.$*2OA=T+Y0!"X7@6X<<(UJ6Z!Y1W2ART)``A?JT`29I:,$3[@!
M`(PK@;1NH`(M,$(&K`"`%^`!`#4(00I^0"H;_W!`"Y=G@N2*L`*&>B,38"@@
M!CY/YR"4E!D7V$`(ZOR;*92:']KE!R@#S_V8-N+&&R'4$&P#(ISK)LZ-1.<]
MN[P$Q`F""4F@Z"'DZ<`.A+8!,B@(`"X@12@4`0S1T@4\8`,Y@#?=X@,P0`$T
M,`+Y,1]K\'X`H%XG,$PVD"4`X`-.X`%FL&F*(%P9I#]XI`,J\`)LIPE\L`/(
M-@AW5UV]@UW`H&('D0'7U'TTZ$?+8%YTP2%T%A;F-T4T``/8U6F590\O<5HA
MM67D=!T50`/"(P)G)Q<$@$8H0`(HL`27UWZ:TC.#$C0XX`(;8`(^X`-8(`A<
M4`7\15`E@`$KH$I"T?\%+)"$-6)%1:`$`&8()-!.*$$&FG(N(#)23`!4'S=S
M85&#A%A!R[`!.X@0$`>'OV%^,?`"BL(Y+*8()$"'H[$`1``Q41,T$E!KAS`!
M7Y`I%5`$V#!]*K`"3!`8,<`%+@`"-5`!37`$'W!HG',#+U`!-I``7Z,`*@`&
M0P`A`)`$^\<'J]<>):@-'"`"W>!+2S`!4C07W`(#<Q<0EG(!5P2(EY`"AT(7
MA=B-M',(1J<(+!(605`#;%""8/%M(P!B@Q`&]M%M@@`%/>,#32`''<`R8\`%
M$8")>30#G0<2$=`#=(``*U4#MX4!8O@##!`%(;"!0X!Q;24!.%`#5=0"`B#_
M`L\"!@D02JCB`:X"CZJ3!!5`!"I`2HY@!'9P&=!Q9C4@/"OX$2@I`#/Q.=SH
MC3:9-;HQA(^`@QTQ`I,E-3[6`#:P/SI0`U_`@8=`!W(@`2`@!Y75`7(``QT`
M`6/0'1-@`WB$`4KP`2O@.<]B!P#@`B%``BW0!%EP!9,T$QL0`"Q``UL1CP"0
M`9?G`RK0`N%X"'``!!Y`!&VI23*0`^CH$1@P`.KUDA_Q48]T"3:`E-"W)C?Y
MF/MB".,65""Y"7S``;H&-A-0`QL@%_;'B(<`)Q-0B1'@@LW@-C!!:P#P`TS0
M*8"B/]RQ?R@PE1RP$5!&-X\@2D)P`B>0!GYR`D\P_P*<,YDRYB8L$Q.2@Q<<
M<'WRX@%\H0A+@(UT801\=PC9!Q;+!9G:^2BKI)./X#4=$00JP`2)1Q=1H'%?
M802^58)0T!X7<GR,I1H0<V5J](_N!`2YP00/P`(A\`6:9@@^@"0S$'6JLP,]
M@`$,8`0WH`(U$"T@H`-",FF74#I)0@<!,`4I8`5Q`D8IX&BZ@P)5L`%?)`CM
MAVE#()UST0$<$'*#,`2&Z0O6R'+;.:/]TDCE*0@\^0L>E):NLP0W\#)BHZ"W
M^0A!T`45X`2OQYAX`0%V0`1@MP4?L`4Q<`.7AVT\H`$UL`4!H$#N:$^3(5J#
MP`(]D`8OP``Q0`93P`4B\/\$)+`!,P0K-Y1#0+`#))`&/X`%0Z`$+'"*5D"<
M\D($.[9_',``R[A_$<`#+#H74;`#'\`$.X``,GF!@D@79$&CEEHBVI=FF(`"
M<'``E4D7-+$_2$`#+:"DJUD#0(`?F?2"+(``%-"97)8%$]`N-9)I@#D("A`"
MLWA?:C,G5!`!BR-%#!`"1%`%/'`FF>`].T0$"S`&6U"!6$`$1$!"1%`!`0`#
M*`HC9[8J:="?W:51=S`78M`"G0FL(Y`$32`"VP@BE]JNQ\$/X`D,TG&7,.*<
M<O$81X@)CS$!)1J8NI$=$LHR/.H($J`!,@`4]I>O'H5.$3,"`6`>.:`",@`!
M2=#_;#)&&1EP!#A@!#2P`[G!`"<0!$RP%R]@!S,P,@&S;&#D`VQ%L`:;K<$@
M47*!A1*PI83BKCB[%A`4#*#P"T'@`>2I.QCPDP!`0!+Z""D@-$L``T.Z"0VP
M`RR@`7K4`3P04C)@GXWTA93!=D'#`[)X!3RA`DVEJ8.P`LNX`SS`!#BS4B>`
M!)Z1`B$0`R0`4%<:,!+@<8)P`NOI-,#:$0T0`F]F"!U@($Y``V?`KCF;N%S#
M72HG6)C`!'?1HR^P*G\;N(Y0CAK@`S+PG\$@`4"@)@;#`T,0`SF@9>T859\*
M`)Q3!T,2M::*`F@;`Q(@!0?#!:ZA`BD``4SP`@A0!2#0_P(34`0M8"E$@"%_
M\XH@604B.2D'P1AW.19N0P)EL'AA\0"*>[T5`0#4]8+?HZ\FH3M5@`#%QCMX
MA0DZ``?>,@(M"PQ$P`,!,(GBM(^R6FQ,4*K\L[Z/@`(7@TEZ$`(\\#U3X#>"
M@`?VA$5^H`1'^QLGL%F#D`951*];5Y(Q0`3,NPQS<`7P"P!F%TK`Z@(P0`,6
M^Q$(4`#86\(0\5',T`",]`@ED`?>:2DJ<`2*T@$XX*>ELELDP`,)K`DK,`8&
MDKIT0Y4I]484``1BL`PNT`)((P)R,$\^/'LH``5:-H9-,``K?`84(`4O(+6$
M\@!N(!=);,/SIUSDH6B_\'A*0/^V)#"IJHN++C`#RA`6"6``)ES'MN``9$LA
M;<0M37"C8:$T%&:H<:<1%<`!KR(#-\IK%4`%.;H)`Z:Z1T`DT^"OZGD-=?)1
M4L4:-/",)^$#%Z`T$M``&SE%8%`$5"#&*$$$`[)*0A.8PW`$H3`$*O`AFT`!
M*Z<(ZPH2C^P$.^"OFO`'"&#'PBP+VQL,A7=?>^@Z%[`%@?RW'Y"(+IL;06-$
MF'!:$Q`#5S`!)H"UJ:(_&O`5%)`$)X"O//8#5J`R$H("6Z!I+O`!-=``U%$&
M$D@$(%`F)U`P(0!%*F`80O>'='$"9?`SJWG.0'QT0X`$&,`!5>H+^@,$*KDM
MBN`$^L/_"#HPNGY\-0Z@`,.\T:R@`!","4%C"$6PF`]4=X-P<2^L"3W4"QV@
M!0;P".V9C`!@H((Z`P)]"5QP!3BE`5_P11#P4;UK55O@B8?@O!'2"$2P0Y5X
M`)?7MH(0!07C!!2P!0BXP``@`R<@`&'0!;=Q!'7P`0OM$1]562"`<=5U;EXB
M`>KS"&1`1X40-$I@NI>0PUFT#T'ST;^L``3`T7R-"@[@RXTP<RGP`J`)(B@@
M`W@8EO8&V-\'`?+1$C:0G)\ADAR`8DYR#YPCSG)W`[?9`KPL!XR0`66`!2$*
M!%?6HN;6)U(!!0,``45@!RSP!AI@`W>P!#]``D.``"HP!ENQ_P+Y%"W!"0`W
M\`1&(($NP`?3D*C,H`8/0%X7G,$P>G9DP"U'0$<`0`;=\`$A<'+4J+H:P`9R
M?0AW(#3H,!L8,`-9@!"D8`%]W=ZD@``=P00Q``(D"+XPT'E"V4LS<0,AL&>/
M00,-$!+YZ@$]@((7"`!1($JV1@$G]7[W<P@:``$Y,!EPP=4L<Q=KML/=G6.9
MJX&"]`&9V`)X4`+DN0%]?`),``1`H`$LT``$T+VFM@0H0%$OT`+]S0]0T`7/
MN'\%E,?[9P$WGBI/(5(Y\#8X`0)A0`):X-G=_7YF0,V#H`.@V%T2`KGR%PRD
MD-'NS=<*@"4(46X$*B\B185M4P&F*O_E)D`9G%M3P@0M'!,3:)`%"'`'Q5H$
M<3`;W/)F+`N'A4"U4H$",="9'6`"(KF#C%"PCK&^HL0!9UD!0G`%%P`")#"G
MCR$!VIR9>9L"#>`E(\`',=`'NRJO"F$(ZK>I:.M;9@ZS;2.Z%P@"CX%X)[`$
M"=`%='AVJG6;18"_*N@N"731+=;E6\[1!C#*S'`"1P`3KN-!=J.^A3T(N3X!
M;8"+(N"F88U`/#`"=4`D*E`".B`L9X0!+BH]TS`'0_)2]S`<8XT$PZL/:[P!
MH[?#':`!2C!U$9##$'`#")`Y+5,"0#`#&$`'+Q/'@K#MW=X`0C`#U?X(/[`#
MX[8Q>V;-<-+_9(?*G-L2`?ZH!`.0GO5`4`@@(:(T!D2PMWAR"1L!Y20"S,&^
MT=;+#(,M,1M@\C#"`$2+C"786QQP!I&,`8]A!6TP#8[;"#]P!"H3!'?P!+G!
MW4V^(7O0;>=^3Z1*RX+PQ@X+`?1HN8/`!3<0`?XI`3T@:B:91SS]`!#P`3)0
M!BZPT$1O]`A^X=9]"#J`!XJ&!AA<\W18!#F`&EC5!',``1;`=E60`SA``\+H
M>#JP!4]=)QU``4R_7?[X"Z7P`"2<\G8<S,P``W*1`15(O&`["&/5M(T@,B.I
MJXCD`3:^!E\0,D#O`.4[`F'P`\^8!J>#!(T\"#V0;'3"`3=]""U`_Z!$\`4<
MD-!`X&;AN`)E0",AT0<]L$/W,@%2(`,QL&Y]Q?JN+PBP#T%?(#<3`P(U@ZOO
MF`DGT#-.8`7V2.HM\![N'&^#@`0ZQ`0"O0(L<09)UP&Y"QNVKPD3T`2Y3QRD
M(`!T#`A_@H.$A8:'B(F*BXR-CH^0D9*3E)66C@5_`)N<G9Z;&!P9GU(HGZ>H
MJ9\-.QL-G!X:0ZJP&A)%&A.OG@T;%3X3/!*>&$I^19\R`$95/UQ#$!2T/;00
MG1(5$SJG4@`>&U6]%1B<&#PONYYH94;$&Q>I#1%*&T<5'9W*S#]@9"M@0G@X
MZ72AR81.3&S1VA1+@HMLZ3C)@]!A0H6!G?_,=6E7YE.;42,Z\+"FJILJD@LW
MJ6$2X\E"0@XNR9Q)LZ;-FSASUDRYZ<0-)J@B$.%)=-,%&B50#.$`#Q0/5PN+
M?-@@`@)351D@1!`1`<(2`!>2S,"P!,J3$)M4`%@!H$B*+DJNP*@PK1HQ"AJ0
M>3*9@@<%$*<D:`#*R4<2'T4]97WAHX42$6K9NH51Y0Q:&BJZ+ODQH4DZ'[DB
MHB*2BX22"$U1+4;3==2%(S-$K!@Z`L`(+@!B^&B`)$6`*S50HC*92CC/.VQF
MJ=+)O+GSY]"CXTSYPPI45!U@)%[X@X8)#T!PQ.!TX@B$U*E.V("0H<DXGAV^
M6'&BQ,:'#BFX-&C_AY8$EBT_`.!&"#V\X`$%TJA"S4F>[,$#&AQ`<$8GW10!
MQ`0='('/*AOP,`(871RTW2<2\&`#"17,4$.`;B`!P@!I8``"%R(`X`,5+;C`
M20)6H8<*%$IPL$17Y*0DP0<A3%'!&!I@\,8F8@"0```G`';$"EJ$$$`2(`!A
M'"EVC2C!#36B(MV9:*:IYIJ7""`(+5'`(<I"'XR(B@X@?#$!!C[D,(`<&T#A
M1I,+A6&%!D30T,(PB>W0@AP3"/##%`9L@D*E.R2@0@E#4##!"RW8T,"7GBQ8
MG"=4@(!D$15HT50W`<R`&P`2U#'4)Q=`$(".=JXR@11*T.!I%3<`8(4:_YPL
M`4(4(QC01`LA0'$#H;3\,)<3AS)*5`,TX"`%#5$`D,(2:<B0PB9+)&!$#2#D
MDD2!H])"'"JD\M2`!ZFPJ>^^_/;[7`(&O)E*$4)LN%`$)?3:208\:/"5"T4P
ML$0#%7B:D@QF>$!""]<5E8$)#@,`L<2;C$".CFVTD`0&$$#0!`M.U,N)J?1Z
ML@$0/NR`@PL2M*!,-^-HD,0KO=P0T0F@:%"#:`I?$,$7(/#`PE!L`9#$$#46
M^X,=*[1``;X+J9!Q$2WHLAT&7RR`C-9<MZ'`)AP`D,4>2<31!P034#"%S)O,
M>PK?1"'M22$Q^6OXX8@G#I,"`N.Z@8CP;:`P`/\_S).%#R/@N0E<$3#]"<L1
M+!&ACRD%T=7EF0,F]R95)-7`"Q19M.$%'`10%X/$:)5!A$ML\`%>2E101#",
MTCZ+$1P@QHE%XTV>4:LE<'#%#@"00$0*3X:00A$@5-!Q*AAXOT2/VU61Q`(N
M8+^"]FXM,ZL37870!+6Y`N[W)X#S=$+RG11"@.(`#*``I?.`09S"!7H(4%$:
MP(/)0:`"*Z`!`(A``K#`;A2T.`&10D"MHN@@;UL``%HHN(D4(`T$:B!"""H@
M@0Y!CA.`H]G?4(&-';`J>#N(``LA8`.NS$`O(P#"&)@F#R$4R7F;D``05.`"
M#<0A!&IQP%?RL![2?2+_!;S;0`>)@@+B,2&$#AB(%3A1!!V<X`45<(&J7K@)
M^X4)B7&P`2<*4<`!VO&.>+1$P!K7B0DX80=?*<I5>@4!">"``#\H`@IVP`.#
MI2(-(?A"!]:X'1TX(1<P0`(`1/`$9)CB!%@``!2Z-`$2S``U,U30&WT%A!%X
M*#1)"P'+;+"#%]A@`C<0G&(@\`)=.J\!$P`"$<`#`Q0D8`DAN`]WFB`')V!!
M`V!+C`LN]`H11"D!?.#""DP!``,\X`,3&,(5.I?*5-S/$_DK'0PVD(<Y$L(`
M"<BC/.=)3T6<8@()0T('/$?#:";F!S6XP@R&T`0@M(":"XD!..$P3GZJ@@0\
M_Z!"%YB`AQH1004T<((=&@`%)RQA!AP`P1$"X(93J1)WJ:!=``;91R`$5#Y:
M`$`#]'**#FC`#55SW@5F``$3@&`,"QB#Q6BA`RS(80=#F(I#4T&$+WQ@#DP`
M01)*T`0`<($++Y`!#'R`AG&Z0`L!0$O-2K+*$:&`"4<8!1O<.0@%,*Z><(UK
M'N^9,+!$@`G;6`C%1E2"+I##!Q4X`@M028LE5&!EZ\'@`KN0C1*08`0E\`$>
M5J""$\`@"TA8P4AAT(0`\&!\-K!B#,N*"BLNPP8<N,\$8+:P4P`3"(X<D0Y(
ML!$`8$`#;.`!.6F!@7%F(`<0.%=B&N`&%A`@"B["P/\%N@``)H@@"U6*00MX
M(`8:!$`)LQ0M+31`VJ(4PV`$8*M<QTO>`=(U(QRHX$+.4Q0HE.%6:R$2=X@T
M`1QX2H$\T4$,**`"*&S@"RY80@I2L`,P_$`$VG'4XW"@"\$PX;96P&\;;V?2
M[;`"*EF)``(TLXD.3/443H-`F;;C@RW,2J:M64@0D@`!8%2@`C20\$)0$`LL
MV``P3'C`"P`PD!@,Q0@)D8`6(!*+&'2@`B$0C1M1FI@+U("-E=I$>:=,97X5
MCH_+"^0U.(`&6GA`6[0(`@Q4!P`4;`$(8$Y%D(?PA29`X02Q<$!>:2$5+:PA
M#4W(P`^:0H<D`(``<,C!.9S_`-+4](('/JAQ)T;+9)XHA:4=QD$(YJ"5<P&S
M";XL!R]SFI(S,H`32*#!!])\B@]68`A8\!Z>)_`!,M.""$!@01B,$`,,%&$(
M8!#<"F:0`A^$%0M"(*Q,.X0!5KMZR14N2F>8%F4`5/G9T"8@(>ZIY4X4+0PI
MG<%"GA"')*0&UF:CQ1#*-H<K7$$$?&A"$4J0A`B8@*:G4`\$D/:$&@VA@7'X
M@0]<(((=S``'(DC">W`%@2L008?*8W2R4X*!",26$V]@]1!Z%H(T@&4$,I!Q
M$H'P!FZJ8@5=Z-@(3!#N5.!)3ZZ\01#J#0`:Y"$"5^AR*H#$@6_H0)-+"$.Z
MBX"$_R:@X`4FH(((T'C$A4%@!CZ(@!#T@NRQ$J4#$2AZ)YIMB/]%^^I8MX35
ML9P6C^.*EJ@00P#\">(CBN``D$8%&:X@BAO<(P0W6(,14M"4K(RAKIWXP1&`
M`)07H*`(7>!"#)"@7IF^H$D4``+9/Z>!&_@@+N.CL-.Y4X2'=X)Z8;G""";0
M@MH`X`DTR()K5^OJ4RB7$VB8P0M,VXD2Z%9T>LC`"T0`>"Y@@?#%F$$[/&&^
M``SD*V"`00,>$`*YT_UU38(`FFEA4S=TX.A@`!QW&XV5$I#Z\N(5!`$RD?7N
M>Y\1=>0Z`-AX"A_80'E&L0H,*`"!W7<B"-46!_I3`=!Q,/^!`LP%`MQ2D(4Q
MR.`$2'`$-,`#)2<8(6`$%A!"+E!50R!W$?`"12`80&`.GL$3#7%D"9(*,H0_
M*=$`(*`"&N<)D`,ZNS-OFS`$1P`%(#8Z5^1^,N4>4G<*/^`+P.`I"=@6##@$
M*_"`$9@-UZ`!,H`!.M)#.J)_`,`!_&<"%-`$H+$#2]5'+(0-35=.JE`%%*5)
MJ@`YAB``;O)]7OB%@[!UFO`)Y$=#FQ`$'$0.OQ4^%0@`05`#&X"%M`)-*=$N
M'@`:')`W3%`%;D@$'5`")S`"2.,"`<(#%^$#$-`"7.`2*.`"D%4R`*`$O1``
M6\%3K(<*\G`%B%B&,V-R$Q`WS)?_!)F&"FSD8.&S(C*U;*:G`3M0-2D``P[0
M"0VQ$#H@`[9P25H0#"/@B,)5&W'0`&V@(PT@!/<0/JY0!3*03PW0!,S0ARI`
M`1L0`CB0=GJE=+A`&,.1"ET$BJK@`4G`APNAA87`A6!8CM\GAO>D@BFA`TR@
M>)WP!9K4,V4@`2Q%!`OP/:C@`T]!!$'R?$G0!CHT`BMP+B70%"Z0:U]1!`'`
M'GP8`JG1!4]0`E]Q`;!#`C6P18EA=TG0`LWS"1L(`#J`"R5W"EQQ?:B@';PP
M`1H@!K&@.D[C`1;W">"A`A,@?)P01".)"B(9,PX'`3BP%$H`!5@0D8&$$25`
M=TRPD&6"_P)!\`.AU!."V`9?``$C<)$Q2!2S!`,XX'E@<D`$.(J=0`(<<)6H
M4`/9]P<*<&7FN);/EI;31H;5E@HDH%2*L0DZL`85XWE04`?L10M<H`0B1G2<
MT`$+\`$N``%U0`8D``=\&`/PP`8DD$Q)0`<`H`(KQPEMH()B(&9AE1"<F!@=
M\`$V\!LGUHF>`%%7D0)LH(X+LP,C\(2>0)DK:'`;T`+*T5L@,&>;\`0>4`&(
M@BZ6N!"F-)8<,'"T(@?S40%"<`)18BR(009#8`1:-(\`0!D-\`9!T`EPL&L:
M,`)T@`.+)R8\,`:Q@G><<#]-A4HP@%.?4`0T8'FJ$%Y25G5L6?^?54:.!@27
M*0$!'V!:%Z`$!Y$K,\!,\&EM7=`D[1B>*ID%@A$'VP,`.V`'`"`$+6`"9(`!
M`[`,D`$`)<```1($62`%&((#NX5$(4`!0Q`^72!A--,``B<<%U`'(<0),A"+
MVS&CJ'!;79`55]`4'J`$J5$",S`,N0(<&.E:2=`D,K`HOO(%(R`!9J`6FQ!*
M"9!X27`$(G`$`-`$)9!9+\`6-[`"<(`#3`@$^*@P+X!F.AH1\](`P$4S&&`#
MRO&"\$845$>?]IFGXX6?XN<`?+"?H#$!$G9I$7%;248+V#`!^GBFG.`T2D`"
M.-`D/W`&/)D";%%!9S`>+Y`"3]"`(E#_`1'@`C?`'DB4-`4X&*99BQK0!'CS
M.4=@:QQ@GD6!!PO1DD<FJ,,V`1?P.!%A4TZ(J-`DD@Y%.TH@`X?R`#0`!25P
M&E4@`56P<DA0(U]0;X"A`D`0`6?`?BXX.;>:#D5VGI82"_,0!R3"`2=`CY>H
M"KSB;(80?GKZKO/$IV/("Q:8%W&F`_H5`8KE";$PIY[@`^.T!%7$<!!P`R"0
M6@/P'EB@`C%@`)R&#Q@`.T-0`R90H-M1`N3#"QV"&-0@%1$0(62Y!$#P!?O:
M9!VXL<;V>6Z@!#N@F\LC##HY%0+;E[Q5`340!Q#P!3PU!9S`!:+H`:Z6`C<P
M`P[`2!:;&%R@_Q6D<VCDT`VPU@3F4;*<D`4?H`?89B>I<0AB"*]<:T?R>D]$
MD2LV4`2^,P-'VPL+P)4`$`9:``%%L`,5FQA*!"I:2@)BL*V<0`+6&@-80("P
MR1,K('!DF7XY0`4V<`6@8I)5$"(-T`!L4`/9N1V?27`V,`4Z-!9KNP7S)Q$1
MP`/P127F@0%I*+<56@%^4`*]!`9SP`4NBP2,!`(.,%1(I`!N-[@`D!4V0`%*
MH`1#9I(GH`7X0I$3((?*=I9_L+5=F[R*XP!O)7ZXBI4X0(`0,`:%EPI9,0-+
ML`)QX%-G-KFI(`9EXP.BQP!2*B,```988&87,@)?P`'0$BZ3@P+6&O^>GA`%
M(=`"$.`&9<-/$G`$Z)$!%@`'VR%63]<"4#.]L])_F[L)=@<%%Y!,(Z`H]*L*
M>$)-;_`$U%,%6R!<3N`"2*`%))<$0,`!.%`&Q&LG2%`&.&"2>?<`9G`$-Z`G
MG@-,)6I;8V"[J$#`6JN\/`Q`6WM>1$&3#>$$?KL01[:JSU?#/&$$5G%$8!`#
M:0`83B`Y/V``5K%A$$`.)>`+@RN=<4D,/-"&JF",XT.-H#"6J.`"^EH4"+!`
M-,`$%B$!B;H)RYB32>2;(8`BC$H+N<(!.T8EG#`'1;`$2*,"5@`!1^`"1Z`!
ML3@1@[NK4ML)30B;MU5*2DM#:WP*7Y88:S7_G_[3PZ!\.%V8GR+XQ3F*QC)E
M'\/#0BDQ`2;0`I%,"PV0AFD`7TB`!>'R!%T&3(BB`K90!>.Q!GO&0YD&4`'`
M!%JA<:]!L^D1(>W!`V09%A/<J$X0N0O1QCR!KG0\`TK@!++#P#O0!BZ;BCR`
M`[&L"M8"8PI$!."X%H3!!34@/''<``&2!6"0`5>@!=OZ`XPE`5K!-$QLQIZ0
M`E:Q!/%,EAB0!$=K(Q[@$BG1R>SZR:$\T8@#Q*JP!#"@+4'0SX@\)#-0O:45
M`;%1%.TB1R<`!DB``2(`!E$@>@"`!&L@+#1`!%0PDH\X!8:Z"W98!#&P2!5P
M+)NP`CMPI*N0AG:H_V9[_`DN8IG7G!(D$'6<L`*PX\]:P!4QQ\!O(*M&,0]:
M;7*V.`R/F`6FX`3MX`0H30`:8`-K0(`C,&*<T`6A20.OH*J2\])LT`,TX-"S
M3-2>`%`:X`-?C0I/4`9VC`H_0`?8J`H0O<,4W=C]8M&HH`*?M@D_<&;:$IHA
M\'Q'(%QCS$NF[`E9P`-]L`+A<@9&$`%0P`4A@`(P4$$(P#%.0`'0(C<"```.
M\`,-8`HC\`,&\0&,Q`(K``4J$`+ZE`(;^8$74H?@)`8:D-1VD@$.1PO8'`\3
M<&)50#R<(`$F$,X5<`-7^PV>$SYYP)IW,@(:T`4-X`"[80HQP-M&$%,I8/\#
M0)`$2D`%K00&7%`"W`:2)ES:36`":)T#50`#0"$#*G`&G)<%*CS-=OE,3#`$
ML%2J'0;5BFV\R.O8&'XFU)8*'K"O66`&=LQY*B`!7[#:"R$8S*5V5P`!,1`#
M$\`6-N`B(1`%:(`%88`&?'D$H_ER+5`$)P`4$JJE63`+,W`"WNP`@@,%.G(!
M2S#8E`B;390$9[#BIL4`?]PK$H#:J3#=OA(1,<`".0E,+8`%/?,`6]T%7I?=
M9F"6J.!Z;@OD52#D1'X"'7`"5"!B=1``31`!+5`&3\`68T0"+@[C2/",4%#C
M8:!`8N4&`>#<FY`%S:V/`IT%3Z(P$Y`$UOP)T\W_V!G>Z<WQM638U6)Y1+0C
MT';58BI9IZ.'D<"$9)4I`G#0#E<``&4@7*_S!4Z@1'>8"RRC!R#PABTG0DL0
M!!L0D[2N29TD+E!'JGS<%22@DM'\9&D^(@VPL)G."5S>"4.0R6"1L2!&)$.M
M/*$`TG0,[2E)*%Q0!,`N02$P[!L0!N'N![9PJS)`-]DI02H`Z[).ZWA7!%(Z
M!5"08GS,.^9^"DMP!!VI,#^@`AYPPINPV(;0O)X^\3<!ZB(HJRE@()R`AGQM
M;;F+K1$"EIY`K('4/1-`!#5B`#HP![7A$H&T=S=`!!R3#L13!SR0!+A1<2[Q
M!"IX$![P`TR0G3%0!"##_\*<D`:R0TFG@`(@X.B)<<L][0D071A:@!$`L+C&
M&0]*$`!L(`(1LGO:3'`#H(+ZI0%E4%?:D0()H_.?]P`:H`$D$.'C1P$Y,`2M
MDO(KW_(`$$AET`:X\8N'LM"M[DQT>`IJ(`.%W2L_P`9J^_#&2_&07_&C/*]]
MA'?5<1TZ``>%KPI($`L>X`(!@"1$`*IWL!#A\P(-)5-<H$D@4`!LH0`J0`?\
M^`(NT`/,3,<1T`-B$`P@(#@Q\`)#8988P"=B@`(W4,3B!DY.D/J?P/1;T,X2
M#@J)['%3OUR0([_+!R=?W2F'A`LU``:I6`-6=%MLH%1,7D()$P,G(%Q;P`,W
M(/\`MD\Z3L,#+J"20X`G:?#ZL5\]/@`(8'A5-B83`(B)BH@Z6%\311\;#8N(
M#4QP3Y6;G)V($B]%B@B)?Z:GJ*FJJZRMKJ^PL;*SM+6VM[BYNK0"`JB;$TL`
M3R$Y%XR1DYZ(+D`;/C,<%PT3+6(2+2%1RP`20"II3$%<*`!1-(E.)A!:-E\=
MGAD0-D4S'XA&8$\G'$8`Z#1P1#BV#,V5"".T0,C`:4J.$]PB+O,P0Q0`4@"J
M)*E!"1&1!<J6B6D!Z8HT:D!<>,!1!@F`"SEH:*KD`8B,'TY00%$!@(0Y,"#(
M0("0)8D&#)XP0.`P8@:/<XE.A`$``IT;(!$Z>B+!(\+_&1L0""[2`2+'-HEH
M%U$[(NQB*54)=LF=2[>NW;MX\]HJ4.!7I6`8;,!#!',AMPM@,^S0X$/1!0XS
M2FSX@'19@R9`WI1P.2R(3RM?)$AX)+'#'BI.SI1H2]4E%#<5*GOZT24V#0U.
M.#7HLD-KVM^6-EAIP`9`AR.R+RB!X&\9XH4P>,A^":'.D@W2$?FPP5I1@QI?
MZI1`H4*LD1TX:*@`PD2BASU`.CP)4F1%C$0IAH"=SNG'#0@=A!`?)S"U!]R!
M+[F!3G&(K$*`7A!&*.&$%%:H"S`W')*(!#P,AD@:FS1`0P4=#*&!@95@4$$3
M\M@`D7,0`'$?`&2,\((S0R@1_\$/B001`X^;=%#!!$H\,<00&&3APAH[++&2
M!!$QH8$$'6A0`04@;.+!0`AV^1('!T0`I26+\1=BF5*.F:(&.RBE17,,E)'"
M)O(D<8P,B(S0@A5TF-"$5@T,X9LB$E2`#HTCN``"&G,4H8(64W*CPP05B/;!
M%Q]DJ=8$(7D)'`8<U/$6*@4\:.&IJ*:JZJJUT'G#C(A`L.)45"51R1"&8,!#
MIYQ(<"(&&H0PZ";`TE'%"'M`0`0'AC$"AP8;:""##HJ@`8$)%Y"QQ@QIG$"$
M#R0PL0-)PU;B@P83S*'C$#YD@8,)C7G$@9F>HE5%`QW0`P`*OGH0$0@:>.##
MKN4JXO^!!D.,\`$-E$0AAK!!\H#`"2#,4,$+%#2[[WK1:IK(&1"8@0474`!0
MQ!$CW#M$$V9,4+`B3@SI`@0:A'$"%UH(41E9TM2+(!1:P*I*+ZP6;?312->E
M@%^;2*`%%[&.@`T-/E3@VQDS>)6#QI9M8,W!()SE24T4`#%#:(HD0TD#DPU!
M+0![\`!""$MD4<$/7-@AAQ4FB=4)%R:)<$,%)(0`PQ$Z9""/%E,<H:;/:2&Q
MA17E`.`!$7)DQ8T/!Q6QG-^>L)W2!"9H0<$-<]R@PDR+3*`!!3S8H(&'`!`!
MA,L`L,V#&(D$\,$*+G`Q!P@^"($%"G0(T?,R)$1S!K,C_H#_QA$SU`#!"R[8
M0"_DW+3!Z]"^)"W^^.27_X>IIH0^P1%</#9##$T$$$(B2\P`@0LPS`[<"10(
M440$UN!&`R(0@#%HA01@`=T%9(44(<"@!R%``@B(\`0"G($-1^'&"FZ@@380
M``A#*,$9B)`&?51!`2WX@@:.H`#NI04#.9`-%,;`-4X`#@)%>$$&?\,%%O``
M;1)@R1`.58D!!L`&;^M)'<*R"'D(000`H,`7OK$##J@!#$[(0@YBPXT['*$"
M4PA!#T@Q!0H2H`$-J$(**J`!-ZS`A?4RGQSG2,=5/8!IG;A`!-JC(G3-PPB4
M$LV0#G2N'>0`!Q-0"I>64:=I3(`'_[GA!+`F,`,I#(`-L=%!%7R%(D_TJY"4
M>*,"MH`!$=0@"TIX#`=X`,?#1,!?EJ`4[70CRWX=J`@:"`#NR,081'!F$4I)
M0A`:L)AX!6E(%?`#%X[`@CZ4`VP1.9@$G+"K+I"!$54`@`-"L(4#&($+7ZA`
M*Y>!@0UTHH[H3*<Z[8*^/T@$5#[8``<"A@$*0")K+^N$$6S``RY`S7(:`(&0
M>L.-#K!@D-PXF!:`0(,70(`'`>`5)P:V@25<ZP(_"($18%"#$"8@"V6XY@E8
MP`%QCO-,G7(!#R:0Q$Z,8$B<T]QO3@"!`"QO$0NT@1&V$`+6$8H%`8O(!#[`
MSQV```(WZ/^!1#>!RPF4``(#.`9$FL"%$22A!$H(P0AHM!23GA2G3=`0)]9)
MUK*:%18,")\[T<(!"DQC`S@`@D.WYXD5+*8)12A!")3@KRQ0X`H^&.H0/%$/
MF49D@+'3P!)!MXE]0D`$.Z``!K0P!!7HP*0U*$$7]$"'.3P@`!*0@5>_NK$C
MB`6KB_2$02*`@?\PY#>7"0`7DZ*!)F0!>XL@0@66VHD!7F$,%$@@-TX`%BXT
MH0)S4$$8%)"$)E2!!!/P@1;$D(('?($%)*"!$DB;B!^H@*">4(4!SDK>\M91
M`.--GT1$\($+;`"CCWF<1)!``!;XRP$`>`$2!/#/$<@C!R.(P!7_!+"))O#@
MM;_)`$1GN8D5-.$#(ZCO#>[@DBILX00ENP`,M)`!,"2!`AX``;FX"X`Y#,!#
M)[`#!.B:B`U"8`0/Z!!PGD"#'E!`OF-C"0@B\%H[7`'!+S2!9+L8`@U,@08M
M@%(2P``D$GP+`1,@``!LP)X;&"*?/M/!$#(1$56TT[Q@#K/1T">1!GP`P5:`
M55I\X(PCJ.$.04"$`1`QA3"@(`5%H(`&:H`!)<Q@4!#X0ARPO(D0R($"W&`"
M(MFLC!5(&1%0`$&.&,(%(]3D`S?]:@,L(%8`J,`,.-[$&GHP!#$`80<'(D$+
M(DIHM6P`"$Z8``0:H($O=*&EAXV#!B#`_PT9M,`#JMXE(K90,AT\0`A0@+/E
M@/"%3)\T`S;@`UI2D8#TBOG:V#[5'=7+#0C(=PE=,"8WC!"!A62A9%M`1"@`
M<`(7K.`"+&!)M$C$245`8%*01(L+AM0`*20%`A%8`E@0T``HX$D1-=A!"$H`
M`!^`()MB*#>+ZX4$+*@@SH@@`;I:#8`@1$`#J01`!.8DD<?4E#D'6B"O]6@U
M2D4R(H4Z!*\[H:**,JL]2^`)%L[B@S*HX#[I!L`;G%!N*&H:!N"52"K2FNVF
M.QU""#B%4,VII=3J9EPN@((3P/"2RE5AL&30`P(H\`(:@/@E`B:"Z^80*\*4
MNSN;0"U!_+T)!?_,=0<?R`$`)@`%+IP`!@D`0`WH,`(DM!``.A`!&O:>62IH
M@>NM)($*L@EI)3@[(HJ\`S6:`*3>A@`'/H`!@#X`,8D$P748`()%-,`!`YB\
M.9T0`3[;OHD4S%5`@*U!%8*0A"=P(0,S4($'MMYU1'P=`&L(P`O>V,HM,98;
MJ?CRTZ=/?5P08&EK]40'9JZ;#>R`^958`KIH8`04%"$W(A@'_+B@`Q4@T@HX
MX)52;B`"#ER!"]P'@%)L0/)%_``&LX4(=*<(2+`#)B`!0V`V<_($4R!X^P`"
MG*("#?`$`E`%)_`"[;$":(`"83`">$`!._!+]9(!8M)=`#AQRS`:5J#_!H^A
M#9P`,![@!_LP<T/E,9V``DP`!+!4`1`P`Q;5#6/`!2JB!<\G`C@0`%T@%OEG
M"2'P`1T``A20!V&0!6GP1FNP`B*@`AO0!2E@?N@W#E"``%!3!&K@#2I0.?6B
M`RXP+PB2"MM6?7`8A[(@``S`;9P@`&9`:"@``E@@@HA`*4^4)6V`""G@!"/P
M`PTP`CR@!0S`+$!&*$!@!2_5`Y6@@FK070\`:I4P@`"`!$.P4C$`!`$P!!!`
M!0X72611`1?'!`,``EM@!+D!$4\`>S*@`EW``W#@A\`!!1G2$3]``$&U#"B`
MAK3T!?>!`4(P6(H@!A]P!"\'`-SG6[S#"47P_P6&Q0(AX`*[9@DN4`8K,#6L
M$P31(0'E5`%`D`1KL(1#\`$3(`:Y-`0<H`1$(`,@L`8^4`([\`+'@`5*$'2%
M.`+#Q",EDSL<@`,R0(R$I`2A-FVH\(9R^)`0Z89V6$0+P'`2<0+(T3H;H"M`
MT``\X0-0<`)*T`4W``18,`/Z$SH[P`)5$R+5T!@8T#+E,H!&P`-'`&T+X2L(
MH"LO0`DID`-#<`("IP0:T`.DYR(8\`-G<`/L-@>T\A@\`'O`X0+SDP@8\`4<
MP0VZH@?/AU,<(`00P00O0!B)40E+N'^#<@%Y4$,K`@1*08`O("C5X!,=(`7"
MECL=0$!ZX`$9L`0?D/\$@9&39N`!6'`ZE``-C:&6-),#,T`$(:D$0@``(P`T
M"=``"4`&C\&5"$(-O)46J%!M$1F:H;EMGL`!"]D)D](%M)([KL,$D-(>11`"
M.D`'E0(;G>8<'!``>31/EY<(_G89%5`$@90(U%`!(^`&%,`!0+`$.F`%E2(!
M%&`"<%`!,/`#0_`$19`E0\"4`+`$N>$$K/8;&'`!_6=R7:D(CA4!E+(!X$=S
M%5`#0$(I68`(9^`3&@6-38-0U)!O9DD=2ZA_\[)`K'>>8>$!`2!;&V`"'D(-
M+#`#!T,]*[`"JX0%5D`!3*`B.=``S"<#5=`%`!`&33"091``21<16M:;P('_
M"@Z`?:+9HG!(FIPP`1&`(!H6@HGP&!]``MA!!&NP0FTP>[_QGXL@I(H@!5LP
M)8IXEX3!`0WJ-32`:0]0`0-!*0[`05;P-BE0!FJ0)1B0;MBI!!1``+JX"5!@
MFMW5!#NDDAI0!'B@`3S@`MZP!0C9-'OV`2:`!TM0,FNP56?0!CM`I-2P,"O5
M"=Q'I!Z0!`G`B9MP!3M0*28B3T#0!1+0'(_1`C:P`0%0`SS0!4D@I1?@.F*`
MIG0'?F*P!GF*?"-0$P<9$3ZP!:L91Z<0=2XZJW'("4+B*1B0!&J&H350`?2P
MEBC("1`PI_;68#O0`TU`$M#0FV21`X7B!B7``FB@_V((!I42(`0!12TDX!)I
MT(#&1P8HX0*>D`(PL$N-0!K+@`1,L%+-,`F/H019,`%`0`3+`#A<(JXF`WYG
M@)]YY%:>P'T50*RYXP(40'G>$0)4$`*Z1`0'(188(&L+T`5Q,`-54@/G4@1E
MN:1[,`)>$P$&"P#X6A^6T`0+0*^=<`(U\$_<TY"TVK+41Z8:P'$IF&G>P`-`
M``2G*52X0:B5\`:WLW<4L$7;8P0(H";>$``X2RP5H`5(Q@,"\`:(@`(N(`)(
M$&<P0!@].)"+4`-C(!9<85B=,`=8(0)#X3<J,@9/=05&MPAA<`-*<`,M!`(D
M%P;IUD).(`%$ZIO+P'V3,?^-FP`$8#`=2.8O\FH#,[`]3G`$&V".;)`#9B!%
M#*9_%^,&$'`%3!"W<YMN4^$$1U4':]M==@"VD',*H.FRIIMM1<0#G^LIFP<H
M826S^@0!IK4)^2</AO4#$:`$9H("6^93N2,!^02=-B`[=D"O3+`%7!`&HI`;
M;<!P=(`#20<JR9$$$`!WFZ!'*U9,O1(PH*0(4D*/)3"6*]`%*'`"<8``4>`"
M2'`P>2N`>ZL(%F4GF^!O>2F$`*<5V&N]4<`$;D,8$O!Q%BJ5B^`!+<`$7_0!
M&DJ^`!`"Z*N^2Y`"3W`%*W5`/'92I["BIYO!8,8`AZ<(K]1*>C0!8^HI!J`!
M;`+_:(@`!A)')Q`@3(R`!1SPJK!5N%M@DCJ`7U0!``1V`O=A`P"P``@#!1_,
M"++$#06HH)]XFT7D.D0@30VG`<D(`'U@!/>A`FU0#G@&`%BP!SN`M\N@J/U)
M*&ZJI'2W!!00`!8!3``')"("`P5S`1Y04B\0`_U'G)A*`E;P`75PQ0"0Q2>0
M,B5#`S]P+0`@`A.@LN-T"G6HP8Q\5@J`PXFP)5_5EZW4`R7[2&>8"+S&!`>8
M@KN5/<%Z&!#0`B\P&4Q@!$@@`7>`"&10`F'P``N<`CC``C.B9?S&#4GJ`D`J
MRG7`!3D`5!<0`B<`!C2`ADS@$CI`!$J0#>76O@``QD.Z_PA[8`+":0),D$3^
M]J0=<`$)-Z;8$`(Q\`*AG`&R]@4P,`2K?*.R*P($1*\Z@`%/(`(H\@(S0`40
ME,9?U<CZ7%ZP;)560V(7L+I>@EW5P0414+)M]U#'K`B7N"D4@`6XYB7`\@5S
M@))3(`9&-Y8VL\`,H#@]R"%61XU90P1#\8@1,0*RA0$A4`!1RW4U\`]&``(&
MW0**B(3\V@G07*R*0`7;=P13$`$FX!//'$4V40X8<`0JH(O4,(H'4H[FG`7-
M425VX`1*<`0B@`4EH'8?^D7*/`/GZ4+['-9E]0`=<0$:\-7<PS8V`+N=(`%F
MH`+`(LX0T+6SI@$DN)R$<05IW/\`9>!V!^9"!.P'4E('\1($_@`''8<(A]H#
M`=A;=B`=#[``D<L-<*"#B(UQA[I5%@``4!`@`>`!%D`2OM(%SIS3FKP(V"`#
M'7".VV<#02`%9IT!'/`%!"$!>M!_#8##CW$%`HP6^/)Q<A`"#"&O''`$%*`'
MP^9K$L`$7U"BI&4*+"K6TFT^"G`,#=#8`,T4/L,V%1!8/$`E+$`!/`B"1;!;
M';$E*?"_0*8B7=!Y]<+=/K!%3-`8XFH$/[`&B&<Z.1O)2'K+OT%16V7?^`T`
M7)!^*7`#*X`!+;`!2'93LO;%[ZL6Y198%7"W+,#88*H")&#>K,F>,NK>*@*?
M7G(!_ZO_`4G`!&#Z`I3"R1L`!TN!UG#T!P7@D--=X^*#"$-,8HL`!3M@LIZR
M0&/`S@(Q`?OQ2%*#+B[1`)"!<:@M+1'=)?)`!5D`0"]7!%6@`AO'#=HX`22@
M(S!>"1=P!`!R38C`!54P!URP>(@``_:3!;UJ)J4=X94@#T?@`P#T2F).SO-:
M$YFL`@&P/=`T@G%\QC?`!2MT7*$,U@80%S;>Z$G3#3.JXYQ`!G%@O0?2`7O3
M`IKJ(7HT`]"5$GO'`%K@`!%-#1HP`D^.(!U`>MO'`:N\'"@*O]&@6=@=$7;5
M`Y&T58C@!G?@`DS``#(@`S;0`V*`!;\FK!#^K]I'>KN5IN\Z_P4;L`!CX,6]
MA1W*Z#,/FTM4``$R+.E_(*N.'NY%DP`Q*^F]A0!=\+%=XCI*++G*`AEP:QQ'
MT+]>R0-"72\DH+@:0`,#\`$HB8)!T`4:X`(UD+2_(3E`4`,D,`);8`,E`"5<
M,`1]\`-!0`0"OR(M8.+NK=,X+>>TA"[$8@(V61WW`"/W!SD28`,>T`&+^P$=
MU<$D5@`.(.XTKRH%L``<8.[+4`(ER%W]`BP0@P03T`1,K@B3Q-:+$`1XP`24
MH$<F#$O+8"(7FN7B"0$YL$%+L`8*X`1%4%EHH#`_0`0\D`VR8N^H1[O)SK-=
M$@,<(`-3TKWD1/4(`@;\ZW__6P$<X/\!7^XI-=_WJ'(`'4"..K\,>2G0<&3J
M$W`;RG@!8<4)!T/JP$$6>*`5Y=V91K\K+2+FEMX)*Y`$TKD$!9`E*A`%3B`"
M(W`?,0`'>7``(R#P\!!,2Q"/6DM[':_L39V1N;.X6O!(^_V'%6"#OLT$,2`V
MUQO'4BH!>Y^B?K_\$H(`CQ;I@]];$U`#D/=5[WH&V!%))FW''X#/W%`$'(!@
M*2!<RY`"8EX"#U0$#0@PZ6[$.\`#E!@$!>!N-`(`0\`%(7`'/_"D,``(6%\3
M`(6%$A43)!5=0880AI&14I*5D)68D2=)'I47%74B$7U$F9$-$5<^II@@'#^L
ME1D>$!4;'0W_L;J2?[V^O\#!PL/$Q<;'R,G*R\S-SL_0T<X&%G^%&Q>[VMNQ
M%P@;W.&%'5D:,"40,TNZ&1!')[I\-A*&#2$?';I!,!HN3$`>0$#A`$#%"QE`
M5*`P-8+'A#`WD)Q8P@,#`!AX`*`H`N(+G1H!(N2JU&""&1!#@&R!=<D4)58M
MM4T0F<D!!@T/?$`8`X4=!"UD=*&!8%&<(0P;*D"84-2HH0W2HDJ=2K6JU:M8
MJR8X4,`:``R$G(K=A8%#T[&9PGH`\J"#ABXC674`\HK5A;@T@(2-]6^""SE`
M1J)842@(C08V*`RIQ`4(E1A/<#2]HT/CC@9$`LCQD4-)AFX<>)#8_V`F2TQ,
M+TV=9A6C2%Q,ER:TL-+A"[A8/TSTT)4-;;T.&S1P\/!9W`4/69,K7\Z\N7.I
M!0XDZ&5(PVO?V`U)H`$O>Z2]#9I4G%!AL2[R]"+I<+'N*(0(CF)A>)^!0P`G
M8@"`0)$1P!09)0"`Q`4S'-%;`TEU,`(\+L""QQQ&%!*'`!%4X(,=&J1'5@4U
M+`'!:I*DE@F(E6!`0RFQM/1#!$IT,`$/+I@B@08>[(9)`T,0YITD%T@0@7`2
M]+;+!@T\9^212":I)#0#,."+(1%TLN..*(SP1A53[E7(!1!PD$$$,XB@"RH0
MD%`("3FL4@B9Q;%2Q0M$3<#"$37T\`**$?\"\$,0/V!A2!$:3.!!AB7TY@(8
M0:SS0RXZ6*&!$!XD<MTN,\J@1!(IN&3*!4=$$`N"$TP*FR3M).$#BP%&4L1[
M2]AP!"9#W-#>E)C,PD$%$>!B%SC"&/#`DL`&*^RP4CWPZY.'5$#KE$@DH9!W
M$RA020<+P.`"!"^$H<M\G4H)0!3W:&@*"B_&P(1#"%*!A0PL[+#&156(\$9\
MA<#A0@"AD@`'EC%D$X(((`#@@@T:M)`%KD**@^`',,C1!"R5B&C("CMH<!9)
M*F"S#8BU6>$$(_"D<`11(5@L2P3B+FL*6+7<@LD$V0ACP0'$UFSSS3<;,``P
M]520LLIH83`#$PO_^=:!M"]KP$0,YM"+B1$/1/!!"%$`,,0'H<:"`A.!CO`!
M35M"\,$8$9@AP1`IG+%"#6+:P(`2=3A1R&#K;)'$$R8(0(`+>MB`QA457.P4
MES/T\`46E4TB"1);L+"7$C%&@@(6*F#)#1.9E/0%2F9P\$$6*F!=B0@;9`VT
M-@T`I]0$Q2%8B#`+(""`+PG,WHL"`G35BP#3X>S[[\`WLY7NR%[CZ>G>25"#
MY6-A@/2-%9(P@13Y8")!#I]I/@,'"6?RB9=Y0-!F)#?1,)\-%W#P1`),-)"'
M!D4@,44!5=01XP\1IM!^R30PT<+/8KE`#B"0@@M$0`BI*H0&R,<##MAH_TT3
M>,%(OC2^;6!N4P=<1`>^-BD:1"!3R%.8CRK``0Y4+Q@,>$`*>_&```2`9@QP
M(044$!T7_@H!#OB#`B@0O![Z\'?1Z=TO(N$!"0`PA$:9G!A$M0TH0&QE$$A"
M"3@`@5D!8`FYXA$5NY.)("1%>CPXHB$&U00K)*)J0]"`"HHSA!,P``5FPA\`
M=,"T+JC`#)?)3DEX4+U"S"<)$'N)`2'0!`W$P!-1*AT3=3&%;56``N*KA`_,
M@D2TM.-6$3"``GZ!``848`&]",!T+*"``>30`0;060$2$(`_,&!GU/CA,0;@
M0A<2X);1&(#MI*)+8M!2B,II)3&$F0Q="F!GS/\8@`&$$8GC'*^2OJD"!\2X
M+6U(P"&+0$`54@`#TY6H`DV8%`I4``0)N`!=NT"%$%ST`1/```QI:"0(C#`$
M&!AA!"MH0Q-\\`$@,*!+W1,+'1.1"41,0`=20,(.>%`#'A`)$XQ+@@TB9Q3!
M9:*"`.#"$:@)S5W`K!`9<,"Q>K&`KAQ@DQ2P@)/^,#,#Z(Z&,?Q#`0)0`!S*
MTABF%(!.%8!+)NTR*KT4A@`6\--@%H.8R-#E*IE1R@,<8``/((`!>">)9W;4
M:#=`43BT]*D7,8$)+``""%DA@190S1!$T$L'`!J.#/!@`>)[0R1`(`(4:`L+
M*'`!#B"P`RJPP*).*0+_#\"6.9.P@`=Y4$I`QW&$HGC`!E;<F%%6$`)O7M4X
M5@4&*VN9PZ$&8`$**&4`*.!)6E)`F$U:`#!O&HR@]@*7!4#E[G;7E000[P\&
M(,`FF^2`E<96MS*M'0&ZLDJ]O90`ME.J`X#K"P=(1X?([44"$K!,7^36=CQU
M`'&G.UR>3B<!"NAM*&\7W5\(DZ>[O&XO"H!<I4Y'`-Z5KFZ+&@R=+A<!M?@0
M>3J`@<5>=JLW,!,W+*L+*,B!"B"8``Z(UM46B*$(0BB3#0(GCGTLP`EK((`3
MYB`@``0A!4@(6!B2\($1T*`'(8"`#;@HECN,#*.5(,.':F"#!?11B]Y:TP9>
M_^"T79#(%`W`PG[^*Y:'&@(8!)"=`!RPLTTF8`#`5<`#3$G*/PC3`0C@(6M]
M^5-<'F`!%/@5!0J@@``L\[DLI,``9CB`!?SR#U\^P)B'N@`W_X'.=M[AFIVD
MRS:OV;P!&,`.#Q``/C_5%P10,P7`2X$O[VRH7YZ9G`LP`*<6VLHZ5/1*QSOH
M2S]`S0&8G5,I0-1C6GG49&[T:9=1#PQ(8"D?4@H')L`4P!(9$U50Y#:BM8T+
M:,$%&+!%.PS$&P@$``2#XFA!"0J`4C0`%ED`0QCD!@"#+F(##J@:""C@@:)5
MXM5BU,&+E`T`]!BTL$:NA!%,R(T?8P(#.;FU4S+`5?]@H/D/8U8M2[%\2@L0
MH!H$$&8"U+QE7SYU`#N[)0-`669*,V#A#RB`ED,Y'0*\D@!_0(!N:09GG8ZY
MS'?^>"MQN94_Z#(`FW3`)G>WLP<@`+<T,^4OE'GGA[]\IG>FZ4Q%?<QJ&(!F
M(\=XR7W12I?#',Z;C*H`:%9FG>XLU'\@:I)QB]1C5*(3'P7`!3#@H@W$^CV"
MP@",;_TEBL:"U[KX@:X+H006J(`$@>KQNS4`!/^RH@0SB,!^(C0%,4EB!Y<L
MP0MX0(0H9*$02,"#'8"@U4*((.],J(7@/D9@3(P@$1W(.Q.'P#W><"&RJM&&
M`7,L[W`TX#J_V.$O+)!*%W+_9>"C9?0+:4I2C!=<&`/0."YOV5-=\A[AIF;Y
MS&?74[U1P.GC#7XK*XWPY2]]`0]8N?"#ZOQ??%IVZTUA*Y7?BSZOM)7+/SA2
MJX_I/R3`N;SO/O)1>TS;5=T8F2,(*S+@ZIGD%P*EDT!_;RT!+33R[,^3"6G`
M!!I3"#[@4!<P`8RW%C+@;:8P*`&C#4&0!!"`!3`0`DC0`57P>4\0!W-4!@+$
M5R_0`UC`!2&``C"P&#*P!620`DJ@!#U1!128!RG0`"B0`4K`$X5P!N]A=X:`
M=Q%0`A0X=@!0!K:&"42P`Z!G";JP`@Z0;J6'';^P5+X06CJT2P60.[<S.[9%
M4JMU_WOJ]PN\9WO&A'`QU%-WADQAZ&5J5FK(M'UO:'*ZAW&ZI`!9!G73YWXF
M]U/LM0`!H%ND9@%P.%Y[2'V8EGOI1W1[.%XM5&F)6(;EUV=ZJ`PR<F/;@`%@
M,0%4I!1+46N+M",ET00L5@EH9PIP\$0BH`61%#8YP``;(`>-ESE2DQ^L$`0-
M%0*%<`(CH'5+\`2$`0/-]@%FX`$QT`)F4`9-$`5H(`8E`$*X"`!.$&QC@`.>
M0A#`*`$CT`%44`-'0&&QL`)=4`$NT%!'Y("FMW8C$@M5``)/%(79414%8`"@
M!(:MU64$@&5>:&4#D`!NMDO\V`M3U4NWM'2]<`#(AVG<Q_]ZO<!G`E!=&N<+
MIJ:0JN=:KM05.D,`OX)SW%>(RZ0`H-1*"NE*YL52'<E#M!=5!O!R4;=^ZH<`
M'?E^Q<`*I#<6#<!UM/8APJ@$1[`#F*@R6W!(:1&`S10!;=(`_$!MDG`3+S`?
M.>"#(`4!5^!?(Q`H#;`#3U`($>)&AH`'(V!65G!:,^`!%``'AG`&85$%4:`#
M:P`+&#`%2P`&37`1`,`=8#`#%$!NB18#4UEY`-``5L!5XO`E11!ZF8`!5N6.
MX@"%1T85`F!FO_"%K$61MU1FOC*/?_9GOP!]"]=^?W!+`\<``7>0@XAI\@B:
M.Z-+!^``2U==:8A;"_!*+T>1+B?_``B`0P8IB*T9B<?TFKE'FJ])`&KHF[")
M;ZA$`;IE9@X0:J;&?J5)2ZQ&BM!$?Q(P`5Z77TTP`2"``7XW%DN0!+%8"*5H
M"#]@!>G6`<SV@!GB!.@4"^9I65S"`9[B`3_`!(X0`SX@!NGA`A^PDQ387U24
M!1O``W30`5P``!ZH`#L0!DR0*L"8`@$2`FGP!(#"ETD9*"30@YDP!$FPG6A1
M!`2PA"!B!->)F&(!%IF@',M%CXN(:!AG`*36.P\`2L"I67[X*P*)<0@0:,K$
M?1O90OJF2_P8`".5FXW8%11):8%6`#7T:;@3AX7X:0/0%<+DH\`TI4E*=;'S
M<BX*?,L9_X8YVD+/*0D20(25A(D>8'\:<`6$-`$Q@`%+8(ZQ(`%'T!/?(92N
M("1HD'=.>45*``%*,`4O8G:F,`$?L!A!T`4!L`4`4`-?@0'W:7B%T`;A40%8
ML`,^0SZ,@`<FT`=T```A0`9G$"$7T!X."@"'E`(G8`,0L*<B`P$E$(Z`!04[
M0&[AD(3,4PBGH5`U\(DD&@N'&0E5J#M:N(7$,ZS2)7TR93MHJ*+,>A44Z1R>
ME&EA>@JW\14D6I.92$4X4`%C@`#8600ED`:%E3"ER`"--3$W0!2Z<`(1``%.
M8`5?H&)%$`%Z\)V(U$\28`1/<`(<$"$T```D$($)4$A7$`.#(/\J8ID$@-($
M*_"OA>`$*``%AV<F45!*)A,+^Z`!)$!.1P0%-("4M'(!34`'S!,3(Y`$1]BK
M[$F$H30`%E!#BT9UH[5).4IJLY.CCKETI_4`C?F'S?JS5?&LS8$`!T``!Z"2
MR9`)SY0!U:JRAK!U+C(!'T(%'P`!-[`#'D`$7,`\1J`&Y28M7#`&>Z$&.V`"
MRJ8&\#H$'1$6'7,M*[8M/^%W<8`$`/L$;="766!6B]!Y0+8!`&$"+*``(S$'
M*:`#2\``WT(#+3"3E8`"",$$(*`7HO(#-=`%2(0!?M"``'`)+N`'M.JTXA!*
MGN0`/E<-K\E2!#!P"A!#O%-2_]B8M4/_4[6)K$!;N\_P`)"Y'#4%9;=E=9A`
MKBD+N@`@G?97`7NP`$U0`U_0`1&0`"%`6#[0+KSZ%2TP`3X@!$G0/;+A`A(P
M"+N01G$``MD)``'Q`O=2)D)0$=K@`P$P`Q"P!5K`!Z::.#*``1^@F._V`4V0
M`750`6,E"1TP`,&[(Q+@!US2`$E`H<*+%H1H`;K72D[F;R)5D$L&903@AN.U
MK+:[P1P\1+O``=.[P"6"`1ZP`10`!#SP(30P`4>@`6>PKDK``5BDKK_+(CZ@
M@/8J"26A`2/@`@]P!R&``!JP!020(9'`!4%X(Q,0`#0P!%S@`B1@)F<@`DQ`
M!^U*IEL")V"1_R$4T`A:]+F@&`(4$`%[*L(EH@N$R'P(AUNG99R]IS=NAG"U
M$X<:W,%V7+NB]ZMFC#I=8`6+PG4:$`$!P`)2`#F50+D5(#V7*A_O,4E*,(J_
MRP%?D`=E0`%7\`)4B:X0\&I)X#1,XP%M8"88L`4DT`!*<`<CT`7X,":!"E8!
M001JJP$R4!G[H,#(XP+GNL?<T`&,RPN1Z%OXYB2W-,$=AY'KE9M!=\?*;+NF
MD`&O842Z;!09<`-X!0`<$`)K=03_"P!J(`,9`@+5&\*'\`56T`:X`LG?M`=V
MP`*K:@@*9;;:P0--$!\!P`-#T`+R&P(^8`09"`*BHS5,(`434`2V,?^8);`"
MAB$/&K`!V7MK/@#&T=P`\A<+A,AD6?B1X+4`J3M#K*NZ'MFD&3RDRSS28+@R
M*;,!6!S-F=`!0K"+"D@#W?N,`)"W&^`#)%3&DE`"%&`P$F`&5D`I*14)6(`U
MUU$2%)`?>W``%<`"06`&`("6,M`'23"](O`%04@PAT0&4;"+(O`#3_`/Z9M`
M*FW&(+P+A%A#GN9Z-S1:1)5Q-H3,5&=[)#W76\8*3=N7A#76N[8!>]*N-QQ&
M5+0$23'`.OPB3I`#D$0ZWL@*",(#^\Q6WD-%%>($,\("2'"`-.PF[>HB/.`$
M(I`?(6`$KY*\,.`!)R#1%'!5G"?.>@T`&T#_V+,%D=('7ZNT2;ECD-+5.U1H
M.^!%U[Y]4W8M"W?=VKRQ`9<Q'T2I`3[@S1!=".<4%FF@`@S`(1Z2`^A,*A2P
MV*P0;)T!`3R@!1JPR*Q`+F$D`4`@!\VF!(80!4ZD`@Z@`@"@!RU0!^I=IKE,
MW+K`R]NP#,ZU9!/WVP#>K'(A./J-WY>8!/D@`1]``2:`O[K@`TIP`S+0'4D`
M!K!0*3Z`$^T8"4A``.44#N9M`RU`U+KPW"/0R`4*`+MH`"BP`W#P`&<0`B,@
M!!'@`W"%1!FP`X=GX.PPW*SPF"(-#$AZNKX0G`%^Y++$V#X^`9;(XV1U`5S0
M`!Z`TY&0`C8@!W*%_P1T:PA6D`T-X`8M@&P:@`5>*PD\,`:L?0I]H`%[6@1]
MP`$DH*H8$($CP`=5H@.'73UY00-NH`%-3BM!H`(@Z^2RF.:_$'S,`)-(ONB^
M$PL^#@!_3NB9,`(W4.;<$`)?(`$$P`?P'0-)``#S'`D<``1*4`%?T@*#&0E*
M(0=4OB41YFY]^0*!@^GTD`?PP`5<L!`U,`,#```6\`,_L.94\.A3`@)'D-*$
MSK?[#5]IF(6^D(7(VML*T#O;1SR]33N,GNU+$@O$(>EH\01-T,M(J`$\X`8H
M8`(^L#Q"^`1HD`%L@`)M\!:K\B/6&T5"`@DWD4=C4C(6X6[)]C$18#E5L/\8
M9&`"#%`&1R`"-E!N4"`")P`#0AP#B;,L&6"^WNZKR'X*A&9F.BNDYG=:EY9[
MHV4`+N0D@?9"78&SRP2<HJ3M+F\DW2#N%Z\-99&R)]`E7(`&=C4":4`8,2("
M]'`$"S!-0$##$W`X'T,#+#%&&0*G<T4CCY`)1"`'&R`"`"4"0<`%,8``!5H$
M!@`#,:`&F?($C:0$^SH""Y/JH(B.,_]MS>T!KT=4HB0`/(0`O\)D)E<-,Q-;
M3Q=QIL2/JR2C7/'RA-\<NJ#'6T+L;:\=.R``*\T"<O,$>0(`,@`":T`"A+$"
M25`!5QM&.AP!G7WT(!`3J+``]DH$#O4:JW$"8P#_`6<`$G60"RG@!".P*#]`
M`E>0'J.A'R![`B3P!`[@#I./%D'0!$W0ZDZ._(7``;[%?4K*4Z<IS!BWG%WQ
M2DQV2U(GUX6__5AQ'HOT)8O_X%L@E.4FR2"@`HPZ`B%0`.[\!D`0`]M&H<-F
M`.TJ"SM!IP!0`A&&43$!""E6&FU6+0%B$Q\P7"M=($8Y$'Y@;RPO00":FP!!
M#4]H`!`?6A><IZBI`&(6&*JOL+&RL[2UMJ("?[H"`[H!?PD+`12]`[D$!'^\
M?[_*`P0+`]()R+K6U]C9VMO<W=[?X.'BX^3EYN?HVK(9$K`2'K?Q\O.V81P2
M.IP>'#M)>RH`AMS0M&0$_X\7&R!P,"++184)$%1U>+AB0H4.JB)JDJ!!AH\*
M&QID@!"A1`0(2RHFH5$EAX8F.+I4D'"&!(`0#&-PVE%B@HEV\B[<HT>T*-$+
M#>A!8*#+P#)F?RP0*+#,V)]JRP(4^,-`Z@-=6ZNE&TNVK-FS:-.JU35K0RQ3
M1N/*M>7#ALU-';Y,Z``AR0XU("XH49)!IBM:#2"^2MQC`JR(&)1$$,$!`EQ-
M$T,PT4`!HX@C$#)LH,`C2P0S-`"<:;-CA(]-58Q$H7$R5*T@6"8DG<N[]Z:1
M1#T,*,!@P=-?`QP4L%#L6+*L4Y,GH*!`P0(%8M=JW\Z]NW?NLP[['D\^U@0$
M#/\W*8K!T<H.'"%4`($73^,K*:^@`#!Q`X*/0>*=\D(`=4A0P1$:D"!?.QT<
M)$9?09P!``HH`#`"&%4<5@`,"EWV"@H@8(%$>20>!<%N\S1P0``!,'`<5RP>
M<,`?5F'52P`#!'#`5@BP^%5VWP4IY)!$"LE;!B4F24\#,#2!X@41F(``!VXX
ML4=(\V@0!BSXH8(!!!K,0($36&A`'RI&'#%!!A%<X4`+1"R`I7H:,-'%`B;,
M@4H3`)1@!!(G:-%#"$^H@L(:6E2AY**U-!`!BO0HH\`?!22PBRX)6)I+`EM5
M1ZFFRER3J2Z>%FGJJ:BF.@YO$0#%Z*OKM,I)9"VT8!G_41VTX,9]IP1A0P6N
M8%`!#AQ`RHD*@6T260"WHN*H&22\0`$>6FC2Q28I'8'""0A,\`46J)0PPYFP
MEGN*H\;.H^JZ[+;KKEJT>`B+K.;6BTH'$2"YB02O&968!OV>TJ4F'FC@JB:;
M#8$*%SMPD8J^KWR9PQ`<5)""#TQL\0,`-:"`APT-,.!`71"DAP(6<]I;;P.A
MR?7NRS#'+#,VM$@`<2P;'*SRRA/``(9O,`A167J;=#G%%RESTL`&/!R6P@OD
MRB,!#Q/04,$'&)\`0`X`[$`T%S1PP`*(6RBZ<[T7M.SRS&RW[?:0B+E5L\YG
MEZO#QKU1`<0$151PP\^:X'=#_P7RHI+V#'$\&E=B/,0``A`O**P)0TB$D$4(
M?BO!Q@IUUYN!!C<;]?;HI)=>5BT1V"(!W9W#6@0<A<9E1B)`N*`"#F6,B)\&
M'R1Q&09DI-*!!C!D(I=0)C0Q`1!,&+%!ZAWL8((67'QA7^NO9D!!Z**;[OWW
MX&]3BP?INI,Z]O4.,0/11'UY1`9'\+`$TQA(@8$&&$S0`E`76,"$LG%0CQ18
M1P]A2:$$$*B#"`#0@!FTH`-C``)&T)<]"A"0*.'+H`9-1R(,R(V"L$J,!V)7
M%(YXH&\;\`$+`J`$"%#`!DLX2;\PP($.;,`Q2HO`#`)D%(ZHP"51:L(-J`;"
M5TD@`O\3[,T&E\A$F94H`\4J8@B9,$)_+<\%'K#@$#2@FPY\(`1?XL`=-&&#
MPFEB)"\PV^(FP`(94"`/!XB`&:4XGG>4IXEXS*.JD@0E.L)*#5K(0ER$HH0%
M*($#'E($"$#PQ2<@(!93JX'Q!JD'9O'0C^2)``[)H\=.>C)(MLA`$C%)1P_8
M8(%&H>$E&1@!'(!`$3P@H2H2(P4F5*@H#;!"%U9)2MXX:@(?',\GATG,M-PB
MF+TLX@^45[XCD20#,U`;+*`D37E,H6'))!&4)(!,WQ3SF^`\QS%QU<UL^D8H
MDB.1@0Y`A`HX21;"ZH(::W$"GIA3FZ))4CCWR4]OW*(#HXS_!PV;>4^Y=$`+
M12A1`RSP@2%PA`:R5(4$@*""6\HB",PL*(D(RIM^>O2C;+'%TG#)`8V2:`(O
MF*-<=@`E(11!?V*016*`,(*&W$"E)DU1.4D$TI[N,QX[S6GGEK9)W^`0`SS(
M`12%@%,`7$`./1`JK-B4@0;P4I@^S2HQXV$SN32`HU*5AQ'*($BC<H(C3+A?
M",JWM`J0(*JI,,($4A#6N=CPJXI;E%;WZLEX7"!J2^(`]^I*E'J6H#<A.-<$
M-%"$@H&`$RA0@<&F0%%G6>&=A%T<`ZNI3[YZMHGR.)]<;IC9N?1LGD5YI.$@
M,`,2,*VF1)##!D30(51(`)&E9=5@_WGZV=YJ4!X3:.HM:"C<W,I"*`A`[3RV
M$#$-N*$($+`5"7YUR1C4T+A$F<"9-K!;WOKVN]Z3!SMZXZ@+8I<64.B"PXKR
MAEAX``A#&&`+`'N!&Q3UO*'D@'CR92[P^K=T\P@JKO**7WD4(5GT6(),-Q"`
MI`%`!\`$:X%3X0'=;()>Y?JOAMT68/(X*J`31DR$YP%B6N@`!#>X:HA3`:4`
MK<Y>&XZQ$RG8`=RNV!87.((*1G2+^])"`#LP[XU/,>)]";E$,D[RNXJ8F"$/
MUP\ZL44-;F$$&`3,R;#`0`1X*`$?PTK)8%X7ENN*`@_(L1:JI869MS3FQ9#6
MMF<+LYQ/1?^/#!37*!=P<)N=M8$=2!@`:8X%"?2[9UATX,[]G;.BC:3314$)
ML(7F!/QV'(M`JP(-.S!`I&_Q9[TN^M/=(8J`?8.!$F\:,S5@`"PL?:XT7/G4
M3MV`J8'3.5#;6CO!032L2S0"`C23U?N*XJX96&1GG:AUMTXV6HZB:[MNH-DK
M#H)[>,P)-J2B+J^&=0:ZBR[L*?O;9-%HGBT\;$U@(`DUY82EC0"U<@.@NTKK
M-*/`36]QFG3<\AZR!#R4YC#0``;Y#C$-38W)>AM\546!=F_P[6Y-B$`_CWS"
M#FP`[S%K^<@`4+'*#L[Q;QAEU(Z^8<!#'(0(>``!6B9XF_&%<0#_<+>('8^Y
M^(H"<D8QO-PTG$`^=BT!"+0<`/R%N<R';@VC`!1[%]!XPYW<@",JG1,8!B'1
MI^ZOFILKZ4LOM`V??M:?UVOJ1(^+U<O5]*%D_>Q&+CC891Z7KDH1`Y!&>V:=
M/H\NDW+M;,=SW"G8`)7+_9X>V`#7A2=:/^(]YG(IO!^/&-R_1SJ?O3Q\Q^5"
M`(7;ZP($>(#7';\S-CU@Y*C(P`.R*?G2AR,!!OB>`![P@%R8'AT*<``"#+"5
MLJ3^];A?XE?"9P#66RKWWX@]`APP*>`;7ZN[SV`!G'+\;,3>`@_X??.G#U(!
M2'^)"G@`4XS/``)<_RP%0`#UQ[]VXK"^__0"F$IW"C"`[Y/__5,W@/L/CH`'
MT-X[")@__/??<07T?O;%IVS$<7M$$H#\=X#MDGS%E``.P'H&8(!A9G[UYWH(
M6($?I8#AQ("LIQPRYG^L1P`46"0A:($D>"K$UU,*4'O^IW\^M7H/X``L*"0&
M0(`E6(,%Z`!\A7H/D`P@I0#=]P`0R"XS:(-$6"1!Z%D&4'\$P'QZE``"X'H%
MX``CZ"X&P(-%>(6YEP`_F'D$X"*U-SI/B`P?*(5?.#,,('Y8F(;3]X3;=Q7(
M(`!'*"0*8'W64(4[Z!1E.#H)@(%JV(=I,86*1A7%5P`[*(;(@`PN\H2U1Q5/
M2(%SV(B->(A<:/\-Z0>",6@Z>^B'FK@6?-AQD+B(D&@-CPB)`I"'PY0`O;")
MJG@6#-"&JV@Z[&>*KSB+Y-")M#@SX2>+M[B+WF"+O/@R#*"+OSB,V"!_Q'B,
MR.@]V)&,S-B,;(.&SI@J0!B-T7B"U&@J^7>-SHAZVD@DL]>-SNB+X*@6ESB.
MM/@`PFB.ZKB.XM"*[$B.[\B,<8@6Z7<.Z5B/Y3"$XT```^"*Y)".UY".(&@.
M^.@N9QB/"'D.!-`,Y&``%M`-"VD.TC`."1``"T"#X["#X*"1W!``5KB/#,DN
MF9B0)`F2$IF*VQ"1Y3`JXB```0"(X>"1X""3'?F1XJ"2(BF.)?F*,'G_%A%I
M``-@`#BR%18P#*G'?D-I`!1``0I8E!20>@OY`$,)#,+P%0R0BNWW!SMX?JS7
M([O7(_Q(@"MR`)8BE0M@*4"I"T%)(P3PE+I@EO)7E;I0'$,)E]:`E,/!#!:P
M`&Z)E&Z9'`=``;P0`%`9`%*)AF:)E@/P``L0%4:Y%JBXD\@(C=H1D0MY`$4Y
M@X:9(]A!`6VYA$N9?$+Y`)QYF9E9`!1P`%+I?0$PAS*Y``XPD3EB`2OB?P%`
MFS3Y!V-)#889F`6@DC+)(B_YEA8)E*HYG`MP``M9?\5I#0C`E,%IF!30F`_@
MF8')#)[)(@C`EU>A(YGID@]P`+VPD#@RFIR9_Q:Q*)G':(V5^0L+.2D>N9"T
M-RD+('[A22,HV9WSV9WPN80!8"E[^0<4T'W14`#_*9N-Z9("$*`*D)L*^@<+
M\)`5687-$)P[\H4>V:"IIYK,,``*\'NY":'B9XP!('X1^81:^0N&22.-:9FM
M":$6L)TP\ILM@AV$60#S:(\(`)#JJ8JQQQTNZ@L@R"(4@(,6.0#"@)_7X)+#
M@(/`B0S-$)%2,0`](@`4H*03J:`3R0Q6^*`T&9\5F@PARJ4N*9[$0",LXJ%<
M>@TA*I,1&7["H*+),)%!BI\#0`PKDG[-P*1%BA:YV*/(B(/;4:<R*0#/V9HX
M<HA*NJ2':J-"JI(1&?^;%#`=%O"0LMD+6IJ*#CJ<7PJE0KJF;#JD"(`,1^D`
M*R)^;9H,()H,$7FG#]`C:TJG[MD,TH"DA^BHN]"H9L%^Y0BHDDFH2RA^"BJ>
M?]"`B]H4POJ23\H`+:*;O3`=5VH!?7JIRO"24LF`FYH+,@(C>EHIP6F3'FF@
MR0"`")`+$QFBF`FC:QJ1*PJK,BFKW1F,3%F=5($`N)J$U=J3Y)"-OMJOV0"L
M0GD`?$FCIQH5%`"-`3NP3ZJ;J=FL`OJ0#O"?6(JI+ZD`%*`CV0HC@3DCS+H`
MPB"F-CF=L8FQJ<>7.9(,(FL-E]FL;OH+PK`B<JJD+NJQ+^F2?-FBS9"P%,#_
MH^#``+WJKR59C_@XD$!I`;_'CSL*#,]P#46K*3PXD.'7CW68"\OX!T,XA-@Q
M*>DGKJ)(`,5WE4E[%48[D`/)M/T8M3RH``BPM%8KM2K+M@-9CPD0H]2`';DP
MA$+K?6O)%0-@M,I@A4T+M+YJDQY%`#LRH8*;N/WDCB@HG#N[:$RHN,2HD]]$
M#5X+N1@IN;Q(N>Q8A9J+C,;8H_KZN:]8M:1[NIM(F0F9HZ@[B^R)D)'9NL?(
MC0F9GK)[C)Q+C7]ZN[C+L\ZXN[Q+C(R[CKP:O,F8N\S(K\:[O/P7?<S[O/"G
MO-`[O<?WC=1+C(+:C?YWO>O)NMS[O4/WH^`[OI*G_[K,R`"92[ZTZ(_).)()
M28?J>X7N>XW+0)YI^@<*`+/FJPO5$)+I\!2#^I'^&P[I&[]O\[/#6+_E^H26
M0J4X>I':@!6[BL`*^9&CJPT`O&C>:\`R5[\?&0QUJ+H.4(7/`0Q1R!0&D+TI
MO!65LK64X@"76RE-P8$MK'Y1>+G7@!T<6!TI;`TC#"2;$GO;!X?>]RF78JH4
M#%[#.XP%X+O'Z,'7('O<P)@>*Z8T(IZ]Z9E:F9PS(@`>&PTL>J?.H)73V<5?
M7`S1<*6BF)I@#`V!F0Q4O``"',:<*B/4\2+W"VK[2XO`"X[U&PW3`"38H!40
M:L6+J96]<)4"2I0NLK,-RO\,DT)\O&"@]-G(.*JBD1R`!VF@5]$+:4G(<LRF
M;/D'H\H,.#B!FCK&MH:\:LA^&YR,]?L,R(`=A+L+J=B_-.(<SF"ETB#'+R*P
MT\@+3_&&J0S,$&A^[OD<QG#+<UPC8KH5PIS*&0RY27R%TCN.4!S"3$N)S`P5
MSKS+<OR&+Z*V%_N$R\R_()C*Y#R<I#*=1>F&N]S-UH`<NKRGYPP5TQR(M;R*
MSLN.V4PJC3F7`8V_`5W*]`S/O`#"P#"'J7Q[HYK0!2V%#:T+I<R_7\')-F(=
M%-W,]3PI2;@,G)S/BK;'F]C/_CR>-NG`^?N1"Z!]6GS0-@*AVG<`YNP+NBF%
M!^#_%+W0TD+)T#9]`#A-@*:ZH,D\QBW-`%H\S[D,SSA2'/+7(E*I#&=Y:Z^[
MBM;[CO^,*7&:GU19GX:LR\L0#"OZ(F+]%6'-EZE'UG)YERM2G;0\QL'@U:+\
MS1ZYHJ1,F+]0`&!L:PQ(B_KHK_"[3P-\<*Q<@G\-O52;HW`8))PR#H-M<.BX
MBCU\O46]#3E2P.+0UY&K#58!%CK)U1PG`.R;AH3XO96M#80\%M70V99-@2(M
M>87-P9+WM!X]*?RX?<F,MDPKDW.;M*)M`=B!BO('??RKTM(`#?;:R=N'BOQ(
M@=N9>E>YST1WP;*->]=1D3AX'8;;EKF0S`B@G`?0AE(Y_QP'2Z<M;:"+>9MM
MF<)R?`#YY[%W2I;;+9BH29J":0V!V7I,&<K5[3W4P+L6,(/NK=$',"D'F<S)
M@;_7]PMIB9K8@882NY;(((5CO-K::N`(T!64<M^V3,K/,=#]/3JV*[L-^`"T
MJ>'"B2-0,>$6J7Y*+1;&(!:TJLM)V,9SVMW"*<MJZ=K-8=.E]\K[U\>MFP#B
M"9Y&VHB64M2&>K"B#..5Z./.#`VLA])+7;/6Y^3<O-1047I578.EN+S$D+]9
M:1SX:Z1N>+D9S."]X.`RON-N:!5I:>$02K4.H,@"RN,>+M6F)[XA/GTY8K#\
M*\<0G,RFNMVBC)IK2^5;[LS?7?^=XTG3?8L=@DY[!RNMKOV45LJ8TDUT)'V`
M3BRY^-I[;\N#G@R5;&L-J=C;6Z&/J>B\,[@<%J#A"A#@"=W)/#BWF7=]]<>W
MFTXZYC<`XEFKXEFV;1/9-3B-?<YQ:MO2@&A^]4G=DFG2I%LJVB##ZV+MWH#M
MU?[EL+BVT)X`SZVX5WVZ@KRDH)T-?;VOX_#:V,#NJ/FBI5,<H^T-V*&<GZZ.
MAXW8YXX-Y?X-C[T-[&[NW"``,V(ZIIJ'Q$$`B?X,#Y@-4:B:0/X=3EB!^7ZZ
M3^A__/A[)AZ;RD"UT-VW":``TB``,SA[1WN7:YL,0JFJS,$4&)^56FD!'*_;
M5^$`.+C_\8D,\M<0[K?-OS8?,PA`F<LG(Y8(%@+@`+29O@;@WM6\'9W>?)-]
MNV](`97:HJIIX\[0H*Q'EAX+E,\@Q03OG.#-`.,MH,PYAU0?H(;+F+W`'.O-
M#+.W]M&@]?>)WTPIY?==HIA]*@6@G'<)#3B\#9(^?[S`VM)X@`<9O&_8F)Q,
MEIV,T,:P`%O!%*N=>B"<>:B.@Q\*%=FWXUY,*;_@^/Q(RF$AII,B^I$_^0)/
MY@H/R2]#Y`3HQ2[^#9@O^.&>*J'[?O,K]>ELT_8,^7I]F[K<V6?IML7:XEO1
M#-B1(S4-%;\?A=)JQ5L^R<)@`2&8%1W^[Z<2#-*W]$!^\'6X_Y3U67SU/OM$
M\IOPM_N\C\<='M,/WYIR3LH16X9+CJH;+A4TS?YC#.P$``@6!'\!?X2&`@-_
M!0X'`0J&?XF'DHJ%D9B9FIN<G9T&!PF1#P,%GID("*:&#A0&I0X+%@*&C`</
MD*>ZNYH(O+_`P<+#Q,7"#\;)RLO,S<[/T)D$!).'![0.B@3(KPJ#?P,"T^"T
M?PP'!Y@$D).%U0L"U877?]F4"(.7]-G>AN&1D^#](>#K4C1A!$K52O6KP(!O
MA@A0$*7($*@#!B*!0B#J("<'N3R*'$FRI,F3*%.J)#9-WL`%!!8H,D"!P`%%
M%!X\H%#`9J)R!0+XBM3(9CY<`4@%B/]7L5#,F(ID(0B0+R),F7]R[EQ5Z>5.
M6@9''4#`@"M)AK4../BE`&,F"QBK`1RPP,&J1/],)EB[LJ_?OX`#"QZLS("!
M!,C`1;1@(/&#6<@26+`@2@'C!QW!953WD-7,AP08(/:WN/&?!`,0&!A4<>#E
MTY,SGTZ<D`'I30(>W`0ILH#:2`D.V.:58$%'!?'B.2"XX)9L!0AJYH*^8#/)
MQ(2S!V:DO;OW[]^#F@6_2X$!N`^&.T-M78#Q7Z\2]#P@:!H!N&05-(+)M2<%
MCH9XP]](#XQ'WH'/.!02@@PVZ&`Q\BEPC@4!*E"`*.4$<R$F&?+282<*+,A)
M;O3QIDQQF8'_8F`GC<QG728)(%#='PH\L``"(15@@$Q`-8*C1P*\^."0P@!(
MY)%($KD7.001L$I+EOQAP(>G3#)46+M@">-:X_!B'GKJ"0-*2(^MR$DJ#A5X
M2HT'..D?`AV^,J-%8U')#'9)YLF)`K+IZ>>?@G4Y$$1S19)7,)=H>8JBD0@Z
M#(D6F,A+0JL48,%0N_BVCEN\V(*+E#QR**.3B%@P0)AW`JKJJJRV>DI"W]1F
MD60%(F!!`>9ETU%"JB@P0#@&>/.`K:8DIXU[</(5#R*T!$ECL(9110@#`[QH
M'IP#G6I(`-1N)EFOOR8'&V7!?+E`>J<4@-8BG.X2W&$"B3F6*-3._QF@C#_2
M**.0R8CHZK\`!^R@1#8M=RX%M-`ET0"ZP4G!6#S%8A-'"U07CD0(_#IH.S2%
M0@$DVDKIBP44B)S(`P%8PG``7`F0DS@'@W4+P@7\]VMQU4U3LP4[%<.`C9'Z
MZQM?IRV`JB<HQF<,7LV.VA_&0#UEIL`!&W`TU5@328]^`A$$#I>^_,2R9@XT
MJPUKXBA2LS?41/D/8X2L4MP?S4$W992$0$(/(@L8TG5!M!#TRB(?CS,-M:SX
M6ZX#%IP[W+N1,/`>+Z#L=8"!!8ACGP"*8T)=1M#EM.".(>LX5N=9KVI8ZJP?
M&=8ED_PSSD\5C6.`C&<S^<W%;1_RSWD"I/\3R<<4G!I*.]OZDZ%+7<$.FO*&
MVQ?-S[),+N7EOU"ZKD8W$;`<`PPDU";J-$K]YH+U&K#**]@6$V+KW1E`-/ST
M'_@Z(HK(/@CM$4US+BF#TAWT>E>(?RB@)GCBV4-ZACQ*'(IY#4Q$EW@W*$<]
M8TR10-,OT-09#L$$$@^HP`0J@"W3Y8L3ML"1CD(%G.B02A*FNEIYYE>_OS``
M4S7,87<$<L._D2.`/^$).*A%B\&-XV)JXPF4?%<.=(0I&V09`(4:>(D'5L2'
M2QG(`P:WMN@-#AQ]2D:9:L&SAJ@%<IAH1"X0$`$`N!$#'*@6_@[%"?85<0#M
MHM%.\O6Y8>!0ARK_&0T@!TF8I^0L9C^<73B*%QUUS4P;U[A83C2VQ`):`(2/
MX!!5$A"`M;0#&55<7NT0F;*OU"QCD-3<*674#'5ARC?\Z@1[4(0*5;#+`V[,
M)0`N$`&,F")&><1-#"M1G:?)(FH#RM[4"'D003+SF7^!541"AADI900Q$B27
MI2S```I9IC$)D)\&#3,:120"0WW+Q#\&((K1V*,BU32$,V4UQ)!]RQ3?7)UD
MR+4,6`(G7KMP3SA#@8DTR1,"$M"E0ALP`0BL@DUV\40?0_=".G'*A.3#1`+"
M",UH2*:C(&607)ZADX`%1SV5@\\!O(&]2+1E,PI80`842E,`5$`V\_E4_R=Z
MPA]O_&=!B:C+^E)CIY"BQ"'+-*I2DQ$/\^C"J8UJ#52#$2RG!FLG'#5&L%JY
M-.NUZ!>D<"6,K)<`"#2@IKEL0`4VLQIJT,E(*-R1"F,R"\^Y,!<"&.92CVK+
MO?JU&=-PIBSQU,&N"",<D\",U:`13V58IA@JRF!?=>'*H65":0$:R`$F<(&:
M9D".?T``!S#0@0B`EFFG>$5=21<FGQKI<TG]JS(J*MO:LH10P+#B,!#;&@2-
M%!C$J@7#S.@`]F3BJW\((03XLZ,(S#27&7B/0S:@2UZJ!9_[JE+&,A+4%ZTP
M+SRE[2AL2][RIB2PD7F8`S("SXUR(V56'$``,O_BD`"\YP$2P9X!X,N4Y(8S
M)A,Y#07.]:+BN,(04QF</I&!&<188+Y2:L1$Y'O-!1P8,13^PP%RHJ%+N328
M2!,.+3&!%H=,P(T-D,#I$@&!#C3``P3U34)IRM`VX=,HRX2.+V-4$[/(:3,K
M/*$A\&3>(AO9&4N$B0.D%<I$'/!G641$)V.2W'#8"AS7J,N34=9?27:30@26
M5B3JPH"/[2AX3ME?_N(AE/WZM(<.:`7='%!FY$RY9-DUHW5&'%#C8#`2F@K0
M`6:L2PE`8!8U8M@O%X`!M.9R`D3S%/G"BRM\`=5I%I%BA@YS9%W@MM.@5D?;
MYO8'03B0*;?SV_*$YP[_2"!.6]-(-=VZ+`YD.#F=^'`I/`2``,9=,\U=06S)
M0KN<L+$ZIO'H=?"2]]M3%`>E[%1I3Q0"'$X5Y[DUA>,?9>IH%$/@:!LIJD9N
M9"&,/<?2B-CN(H@<ZE%DM=U'AE(UQM'DY_T0?\E3UP)2EDCID2-VFJO$O"$B
M@``8G"IY`3;`!Z[(;17\X+T[1+,[(;G,('<7CX'.'T><"&RCM0%8LD`$.OOQ
MM1J"6JGI2%Y#1O%P@8J.;RJ'CL\#;U3$LN;Q;MO`3RW!W8DR>;9BP.#T-T%:
M*W+G^#94.12^9H:KV>&]=<G$-Q%9!/_1$Y92Q6\PD5)6G+C;%S"YE+QG.N?2
M_S2ZY3!`!3J+`0CDI8^>X+5;TG=9F0S'/^(%=0%DB',C5Q(2,,E;S9CBGD5$
MV;`%M$U"^EWXH!C]Z9D,?"TR&1JO[7<@OE@\8B,?<'D$!1*AD7IO.Z%!=GUZ
MIQA!8U3-HJX*$%JAT16%I48K`0W@B,4=R&4')O<`#IPUE[R<$Z4EJAN[Y#69
M^"LFC>@BY+X[/^>)?5C@Z8*._AZ@8@!U27Z+UV\-8__Q7=F)A0FUDPWCZF&.
MD`1\FV[AY@"Q*<E]&$]<PDEV%[2,\@2Q+(TFT%H*MP(5$`YL,@&_YT8J)GN#
MIDL=X':<@P`:,`&]9`KJTD8U=0$3('P;,6E&$2)WI?]1+E0`R$`M=?5\)&A>
M3<56;;4(!!!.(4)?9;-5`;(9WQ!G_;!5R\((0=*"4H(<M`!5ZV5!JS$=ZW`)
M#``2&1$L/Q%1RP)5WQ"$SQ(1%G%S[+)GUJ,+%5=U:<$7935CP:<^C;`!G05C
MOW0`N7=VO506R\(NKU=3#3!L&D%4J45NY^,Y._$QZ09:Y?4S);B'%N07B5``
M!6`T6=()4]<,Q;%I!$4YES-&P`%:UZ90%FACY_$0Q<)MCG8!$"`;#D!=W08`
M&X`I"8!7IB*%<R0`W]4A(!@`(SASL05-@K6'SM>'?N$(_#:((S)ZSW`.F4$I
M&X0CVR,)DZ-V'J=++R8<F:#_`058<L^Q6<E(C!$P%.X1`6XW'*R(--GU"GFT
M13<!9%+S5Z^H$IF3'`*P4>\6=QD%#<B1$HQ`0XAPCO_R/H0QCK\@;AMR$%CX
MBUC',_[$=2ME$170C#35`:.W`&L(>\9H#J9B%\U%<FDE=FI'<EU8"]T((KKA
M)-TU9,D74:#2?!WU48#Q<`?W*[B8):>7"98"6(SB$5-A$"=)""4)BT12>I;5
M*:EWD*-`;>`PC&<G7:MABC9!@#2%`9-#`!!P`<6("]0"`8T&`!G`*439C`R5
M3'(U:8V`"Y^3AC1",IDA@N*F0T@5&&R3,@3P"B.I"V+F"020DL(@#BF!1^J0
M*"\)_Y,-8E#RA(>Z<(@55U"_6!PCAU8'R"X;4%K%U`A]:8#]&%H4F$L20$+C
MB``5``&)R$:.EF*):`Z:EEJG@QJ5N0AUD0F\9I>#I"ZM>!)B]BOT1"V3M0@9
M,QS2(AD=E`V4X2MB)DW6%!_=<G*I42QC"2>Q4E@+43JK&84/8!?!*0V=X1YS
M(IM'82N[XIMR"1XO]4_E>%FA@(7LHH4'`)E.0BVCI5!B6#1+"0!1Z22O$`$0
MJ!"^@4O9%D=],@#JV6T;0$.?28J5H`JMX"UC`8C9<'T#4%P(<%VAF9J"49KV
M10$LHP`!L&$X%!V.``G2,F".,"4):F$,<'#)E3))`0[R1_\!`_8("*J@`Q$`
M#Y.6(1JAF#``':HW#\,M&IH4#)I)HX"A^&5P%0&2A)"@"2HE&$J?SPD8A\@]
M[L@*EQ-<U38<[O%<M7=[CIE0#?",)V>)Q*AB.)(`:1@<!0E[`\F0:#4!Z+D:
M,/6?&OD1[)0`%%`V'!8<+Q1D"?`40?HO"M(=I<D3%9H;)7-YD[<6@4<5EF$*
M5)&6?*(^)!H4#,8R='&A"3"G/7-Y:5EY\T`AJ@%HG60I`E"AMH$.X,`M%8JG
M$"&H%^H0O46BA*`(**-ACEJ6/1H875=EHQE:.()_`!&,_ZA0"XAHI-!!:@>0
MA99.D6`!9=AM$4!DDE.8-.6D[#+_`1AP@:0R'^L@2^GP8!#&9YC`E5-9/W"5
M':5I3DNA,%-1#@6'#U@A+2Q%%?NEBH'C#EE4<'@1HNH75`2Q%&EI"B1ZE@!Q
M>*!*HF[9K5`QK\V2K9\*E^HJEO)UJMV!7&+5*8H63%77>[@*`!A@6F8A`&;5
MB=&5"0S@>I-9`4VX`)!Y>P.@E,2(L?+$:&DEI;DPK9NPFZ%X/>0SGRC7E:ZR
M@M]QK>N*HB*I<@GZ*Z"T#APZ%8,0$R+:$^:ZK^E*HNA*LS=3KX4@KU*6(4@+
M#MAZ$\.UM#/;K]O2LTDK$QHCL(2Q+C-9'JD'4$-V*PB6F(X6`1TB`&O7;;O7
M$;?S``TX_VC-F`%BYP"Q"@"&!B<Q8K$8(';GH)-V"P%&@EJ>J3/9THHS)W<\
M"HLRBZZL9!X/!6&<UJ<L$Q0K>(3N6@@(NA9+YJGJRKA]X[A->R,:AAT(JCZN
ML%^B`!=.2R.0FQF96P^$2K4NJ:ZB.ZE:*Q@.`1$G]0LHHHOWAT,:T(EVBSWA
MB!P=&YZ%1KQLE`&EY4LQP5EN%'MC&Y1QQ`")QD^WVFT8(#SR])\O(C_AA(_I
M\A2(`:"WN[A+L5]P(41^DQ-,YCVJ*%_3D!0/Y@T9BJ(+L[I$F[ZJ:'Y-&QTH
M,S_-\6#R\3`HPQI7Y+Z$@K_<E[41D:'20J)3L1.F>KLF$9U\,_^=7,=.UKF/
MHZ`!5^I&&R"VQ3$!$V![?+*DNC3"$G@`[[E+&W!=.\(!'!!C`_!U%1B!&E6W
MCC:QM8!/%0F(*U4S[`@?-[*FX^,JZG,@H%52J"$**'-@_Y0RIE`M]34L3C(5
M!W9`)5-?"E%2@_/$%WI@7\1%\C5ZQ2%F:>P8B9'&.+D(9VP*)>52'*H94J(V
M\E6%%IP2?&:=I]`BI1>RPP$*%<!-+`64:46LKX!M;2>`NN$!'<`!0V&E;#@!
M-L8G:1'"N@0!'9(`%8"\`4E0;0$!D$E?,5&3B7L*TDINJI/*>_S*K()9R26V
MO,!!P#J4$=N%MM"7:L47=`N0&1`!Q;3_&AWQB-T&:3LLO,2J(\7%:Q9+4RJV
M:$L9B=00%WJ\-*,HN'HB/]K1$];1$T<3/B$1/F;!-F1W0?2YIJL*#2O"EK#L
M%P0KOB@T/@C;4I))C,BJ(Q90`0=YSVC%2T1&`5K*AA6`*C;A`;C:`!#0QIME
M:*?")@B=2Q$@MGV[4!$P$7^FP6RQ+XBK)_8'&+2X%KYA<&%2H?9E"N/*O>IW
M<"W%#`Y\)BRZ$OAULFKYSB+!M?K'">_RHR1F2^GY<;6'6P_`B=WF`11RHL)Z
M=J!E$Z4\']`+?&)WI,`GS(!Z`!O@`8#KCP"I8HG&%5>7#.%5OF%Z9)G:.#I:
M9D=M"$X$8;*`_S*947!ELZCK,9W[]M4EH;0!XK(VS<YM\D]\IPE)$VV`AG\R
M)KP:@`HXC%;?R0AD5YZ@S)23<\\7$,/DN0!F)Y1IQ\-IE<\"4%P1$0$`R:4:
M=UD:K2$;@<3+&F_FFFBG81;2DIM+48]2JV&A$&U#)V$59E\;52T/XQX!5E)>
M;!:<A**&(A&O8-QI[&?PA"<H$XP<>DV\;1S-K3[R1<:B.BP9VA:ZO=>&V"YY
MJ8B6PWKM0@")C5;$RH,\A<@*M<R;A0$DFU<MIIC]Z!OE?93(82K\]``1^W$>
M,'H#\-C/Z,&`]M'+8$<F2QXQ\AWO.J=T,6`+DJ$W47".0"CH^L!9@?_`-RI^
MM"T1LY"@6HPR%*(Q`"ROK<!)'7%P(!D\;4(!E)%%9[E?%*Q^D[$4!>>^"##=
M.V$3)6.O_?L(+E0QW+T,?=S2GE8*>PFVOI'4']N$(M1+T'(`PJK0;2RRB@FX
M#?B`#GL:">B7()M&9(M6;0<C`]"=XED!Q663F4#@S+!R#*#-W?&5WE&A<)&M
M.)K6&N:^X2"B^_;644:BDY$5:R$4ZKI5$<ZB@JXQ&B.ZG!8)])$5B9&@@`CI
M.J(W.%%<`9`9K&2[T6$(_U%P[&4)^T,+HVJO?5.T\&`A09X,J1K(NL!!N-5U
M"?$0QNNQNB2WF\%&OS>>.C+F'=`!?'L`?@O_1^&0.<4,I8[FAJR@Y`H5S;#!
M,.R``!#0WU-RS431INZS+\#DRB<AFN11W=G:-U.A22*:Y\%REA6NKB5^Z;-+
MHI)AH'D.%ABN,7@=%`_A?K-[[^W.;Y,A9X;26UD;+EDD[X.@;P:GKAJ#KFEI
M7WJ=ZIU@$Y7BJI2E%AA,%,0K<@:(PC$"PM$K719`U(6&\=-0LII-4Q>@`0M"
MWIVH5D`6#RND[)ZH$*_0:(:V6AA-Y)J@'R81UL6WSKTAH-XQJ8]@*NKJ.:C!
M$2Y.<%&FN@@J$54;HC53%X4.[ZLK\*?!=0=G<`[Z#=+R](TP$S=BYQJ#ZO_^
M[JO[VCD1[O:*K47T_V"ZRO#`]4HYO0FSI,<:5-BZU,B<8Q,!B(":S+`5T,DC
MOY,+XA`1\-AN%':;<0X30-FSCKS$^LMWWTLK1:2>8-<'84)(K%-^\:8([@I,
MWPJ6TC>K(R-$?.&<U!Z=U-EBUAQ78K4%9QL\<O13KPB-+@L9M&L5FA%B)BVO
M3S>*\*$OTC.;CC*13@T!#^J$@`QH7T!J/YQ#[_8T230\W6<#A5-1&QR]"GO"
MW"<+D/UHQ0'60I!J*UVZL6+0OH;2*R4\G*0;Y8`2X.M\@>LTM0$#8!F6G^8\
M7^!$)5>E#0A_@H.$A8:'@P@)B(R-CH^.%`$!#W\*D@$$?P,#?PZ3%`I_#_^@
M!8,"DY,'IG\(`0:"F7\$`0H!%`L!`Z@"?[*<FYVT!P$,@Q0(@PL6OIK-EK>Y
MG7^YHJ<!Q)67"PNAO,%_N`ZYQ`&SYL"\K@,4TY#O\/'R\_3U]I`)`[""#`>+
M[P8.*""PBI""`_L2+,@`H*'#AP`Z,"-T``-$B`TX5+)$@(``!0\.>&AP44+!
M`@<D-.P`P<)'!"E)2H#P#P$'DA`Q0-BEP`&!104L;+C8(`("E/OP);U'3X"%
M`0P$<.K%=-Z#?U6S.LJW\0^#`1L-['LPX%\!!&4-=B3@@-4?`[4$>?PC0--7
MCP0&BIHK]NT^`@.<<:3J5=/<653OUA6$8(&AKT?_!26P8&&17K]OH4Y6E'=Q
M7[T%`$?62KJTZ=-:%6)U4/`=V;/)"*D>-(#AQ8<-*NQ3(*!`/@@6B>H6)&"!
M!`P1%A@(?6##!8<1+)A*<*!#S@CZF!^(?#;";8<7.#@@Y&`HQ@H.%!J+UQ7U
M(P6-#<!7[O[0U?KXZUMPG-]>@06Q]2?@@`06:$]`UK0RVB.PH228(`:D-8@!
M&JCT708'K(<`!!-HH`A\%3Z4P0+K&5`!3@!<,,$!!!004`030!!;<;9==$$$
M_A1B@87?->3!@PHL,))#&#+`P`)8P=.>@8.$ML!/!+68'P)+,<ED:%5R!)<L
M!A#&@)2%N.6(F(8<Y@@J_P%0U9>5;+;IIFFO"5(`6/"@E)X^A;!FRED#6+`<
M`0M,@&)#&"#Y!TH3.*033X!.@($$AHX"P:`-->#!=KX)\(^)E%[408""[-AC
M0QM(Y]53#@S4W`6%)A`0F>\8^::<`2G"V@,)FL9`EK/F5\YX36)"GRW.;'D`
M(7,2QDBRC<CRGIG`]"KMM-0VB4"`!_&*"'4,S$;(M8(<Y$&*&QR0ZHO/`6#2
M="G9F-QR!G2T)P+>C2K!1+2EVR.&__"6P%D5=EI4;`Y4<(&E!^!J``6K7`OK
M.P5058`#G%#)9H0("%!KDM5VS`@#`3BP'R%P44S!']0YNPPI6'US9IK-/@A/
MM/\>UVQS?G8.HI"R9R*)(+*!2;80;BLJ/``$%42F4(TVKIAGHJ.JBR^$!PCZ
M7:N".*#!!!QDURB*N>U#+T025-"G`A8L68]"`TP'4UM6.@655+O<;/<Y=,5%
MG##H$*-)`6GZ1A$V"2A$B5R25$),CG(.H(LI`>Q'`2R&(YG/P@<41\$B`QS@
M^%@!&!KA`PL<%#K'=Z=N-W5)18@Z(Z\")B;K$-;V7=D+6F+[J`UHD"<'^MZV
M0=LH/Y4=:\Z1+1!C]::(([P+1(!!!QD>.@#4N'%P%$)9'<E`2'`["::!\\D7
M'U.:JFX:+06`S/,?%AR+JRRH^#VX/YV3\E'DK@1$>"+_%""%)B;Q`%S\X0`L
MHH!+L.&*`$9N$Y$C!F\HX;ESZ`(!%``4?]3'08\59S6M@<0#+``?4*$L4IR*
MV@:`Q8^;C.H"PT$9`98C%0X$!R)&$9I%5/0D%QT@`K89WIZN1Y0)]/!+>3E4
MN\YC@)UEY55RBI(U#`"@7#6E<P.H(B3$EX`H/>P1"5!;!^T!LOC!C!"H2`K]
MHA&`EJ7)%K!(&"H>(#B7"0)`;UE$`))!B[>(PG.H,,8>P9%%:#B@,5X)0&B*
MH8`L?N2+8WR+)$RU-C'&HQ/WH184&6/"1@1E>RRD&E8T$#4`C,@:A9M%H#IE
MRD@53`(>\!!O-L2CW`#+1,%K_X!)$,`;"U0@8>%:XNU*1X@'\(A()`K(Z^9Q
MK4Y2D9?\Z-/[`,*XMVQGFH;PH:T29L6M6#*2]'"<))15@'808HWR<5;>!%`_
M=K0-$\FPXS,&(8L^3D82NX#9+SH1K4RXDQAU,8<%%X#-,29@<D[I)#RDPA1T
M%-1*(V3%G&3F2830CA"R^Y8->S03H!R``SAJ$14C$+R.,@]%+'$)?*JVHK^<
MZ'8R"M,";M@C#B2)`14X9@>0I*>J!&4[)#S$5UQ"'+1HBQ$1-03='DJR:V[L
M'10%YST$`+)<[4=,LDB`/@7#"U0@H".P`$DNNG3&6&CB'_54I#@`N55"3L.?
M3^K(0/\$^A8+A$ZJA>B(G`0:L5PE0!0*2%)OZ#*-P$*,,`ZUQ&#;]$F=<>\=
MZOE@(<!E";)TQ@(0L`Y$+C6=!6@68;CZ"@<ZH**3".4VR$%(Q#["O%)&0%D*
MT$#PB`(!9["F`A8XI$ATV;#<U0,I='G*>I1JU'#!9#D,LH!"!U&^=]`M*E/!
MJX`.&J^3+085%M"K60610:TFA1>`TP25G`(YCY3U@,Q8QC-H$4AJY+,7^X1@
MQ(I1P(CQLH^C&`]^I>N)J:$,$\880`.W)$B[KH*A6P*5.0`78$U)HB`.!=DM
MNCD@X`IMF4+UV?*:9"ZA=4"72?LK`@+6$*.8@D8E21H[R0+_+)0<TT8<6(H"
M*E#*=86K%XX#XFU@*+8(D.1&"_#)'AOYS7@X<1#*I<\AFGLH0(TOFX]UA*J>
MS(CR,9F_[L%$)?I(BE30TQE=IH!;M)HYQQ$CG0L`*)D),XQBK+<6;'SO,X#!
MCFZ(&17=<`Q^UV%.+*-D`9E$0"4HM@EFQ&]BG=CCG!S`T,VA!"N[$$`&?0&_
M\2!@/`X=P'@<<%3\J&="U7S$JY*J,SQEAFF+8H"3(*"!L+ST:K4MQ$Q=&\I6
M`*='*]J3!3A0KL!@X&@T'5$O@F(>AS1@`Y3(UA,I,%QD.?EAXF/%,[OYZ3K=
MBL*&F'(76>26LV`Y*UPACF/BM99!_QR&3QPCBP+XY`RYK4?=&`T:8NABE\#4
MY3)\@8587!?-RM`[B@*&Y!@G9K\"%&`@_#2&7AD:EZ](12$=D?<H(KZ+3F20
M`&BA]"[BAUPF]0,K!!'X9'E)69VY\M40`7*SW^+"467`'8(0YFTRLA$&/(67
M"4!`3B^20R7R"'<OJ="C<N1BX30Q4DQA382(FLUI'\*'N.JWEY`NCZ<RZ%8)
MN/:<L/UM_\"\ZV!W;BT,9\ZZ+3S1>Y.*I#EAZE/EE@(.J(0N."'W37Q$G"OO
MSR855*>T61C4UJ`7*XWM.T*(:E180QFC"Q`2JS$10@:+R$X^$I(A-2#6)Z0I
MH;K&@)Y\M?^SFF^EQB3$%(<5M>V%&"HVK2XWL82P'DNEIB("HN2P,XBIZ;.]
M[@\!%=HXI44,-;LF&&X*FZO]6(="5CLD;0%!2E3CK`7)UZ<TFIQ!S*+5*R;Q
MZ,*!&D,@3+2\76MLXH'G]615R*2*30:5@><Q!P*//1+34AZ=O(Y+>5E__6_I
M5(B5&D",`E!<AQ![EJ!`(@</5W8F%1,A=;-[&99W#AB!C$`Q>Q(*FA84_-0+
M9^<+=*1IC:9J?D(1CI%%II`VLY`,#G5I_55A)B@9J+<5!'4D20(;!F$<@P<`
MG'5"2),Q*S4D#E$J>R(2QF9$>?$B'>`!AM(=WW$!Y;)R.'6#E;+_0<%$4@[!
M625W#P>A1=E$`!E$82L%-X:0<PC1@J4Q90>H(,J1@+L7%)0D@6Y84>T00(F$
M#<<B?(3E"V86,9U@+)-U,B$A&9(0"M!W4+>P&FU8AE'F+9"@3'NG1"V6/D[B
M>`]A8G0Q-`"``9S''!-P`3<2&PD``2_6$!(@2UV$7$7'.R=#'L5V(20"(6PA
M"E(!'$9Q$%$U#[/Q%0T8)@>@A6$B18?@7?5!<%''"!:C;5ZT>][SALHX)O$R
M7*G4"_]B":(@..8@,?WR/H9E6'*R6-"X)XL%>*9Q9-;$=8:@)PAPB-Q"-1/@
M?F\1/>E"<Y!'*4`&+Y21$)9X-1LF%ZOX_QT;8$*V4`$^F!-)>#V/(DMY<Q51
M=@_\IC/'90B50("&X'0FQU3+4A=K`5:O8W6%L"9R@G4$,8S?QH9GN(PD&0]T
M52#B6!7*-`AQ\@[7@C8F)%F>\&H-0(3%=S0=,A:3\ATU274',7]$H0%)HA"2
MB!$]1QT0L!,S11";^!`V=A#'M"@6177T@$&N0$?9!CYND2J2T9`#&%TK*0\$
M%QA1P4[LI%L9HU31-2':LC$2*5W)6))RJ14G62`'46OUT%.'<H5C`A9_1S6L
M,#8E89"\$9C-@VM`4@%`*2*FQH"IPAI4B!LQM#0-<2/FXB+1DP%,:"H*$7HC
MXBJA%@\*L&Y!\_\5DP!-O<A-EA!*(,%MO]@8^@<)XT!E8=@8>==<!H"7A;!4
M$#EPE#&2<QF<-=,@]U!RU@<)V9*2HV`J<X(]M]$!%<`S%`"%ZM(:"=`;L1AZ
MK503/E:3+*(`$2(]#5$DM3-_WMD9:`$L_0"4'951]!`0N[@4`7B:%+8QG22,
MW61Z\?!);M$39$%W7!DNR@4KJK(`9U@^8MAI-1.7PMF@X*278BEQ%X4/2/)Q
MR*)<@R!S_%AK`=&4PD,\*`$CL@0BQV020$%$3BE+3E$!\/</!7.#H]AL!:`!
MG6*%RP4)@"&3_><*NC!-4G%>3:4($W*CC1""QN6!IT`QN=B(37)MR!G_)6%T
MF:DCD@Y:I>"DH^^@;.*&81%9%HWXEQ2@G9,X(^>(7",U6T<I3(OR$8V"`;EF
M"1JJ*#N1;H?Y'1VP),:!0Z!D#]>RD(@0&OCDH]R@+;''=/%@`/BBG&@498C:
M"!KI21[YG3?#H%9:J1PTH6"$=$S:".:8.]7&&X$%;#,'`:ZFF40(BZ(*0\!"
MF1#1?JH5+_:XF$[I7[O#431Q*#[Q)ZN4&S_Q@G5B+B&W1504.EF"*\^V9(V!
M1_(05'?$I:$R7*1WG6J9BX[@EKPX+51JJ=K*08TE:M5$:I#@,/PW"#(H%UNS
M$YTW8L?$8X+P`"TGB@:9<YQ0(K5J(\-3"/4Z_ZI5\@DZ=ALY>!".<JH!H0%=
M0I7PP#I\N8B.4WNCT)';X84LDGWO@'PH`RK7R4XSN$'?TSA?I(:,L%2J-RV4
MNJTDFSKNB0CN28,0$QA:"FJ&"1[OHBJ.LE/#)I@7L2@<\X11DP&I.`@.D%D]
MPJYT<0"LMA^_!K1C*C0UHDL>HF'DV`C%(0`L8@].<0M2(BL3(F#OTPD>BP@4
M*P`/"1-?U1$6H$!4`7.=<!8BUYJTB:S*$8"^:B#96K)TFSIA:0C&F9!;,94\
M8WJ(4D1/`IYRY7-1\VMYLH\7\9E9(U<DFK@H]&HLP1/JFB*D6IXEX0\M.0\!
M\14*BIP-E!=JXVZ$X/\.`]%#CL"L!^0*0?8/$$<+`W`0S,4,8,@@P?JD+)*@
MP%D:(UNWO&LSF.J()@>!VZ)A,]B"4-DCND1,YG9_HU)_>;5*MV%2S3D]DQ>)
M.&&B[?JNX^E^@-%[,]DI$_"Z":LDNV"PS/6TO3A)7FB;@O!U!(>:0H4O</$`
M#J!;\6-SD:9.N4D/#]"YSI8P762Z+'B(O5O`PSFNET.NYHL(R@2A2K0/_R&K
M#W&KY%H!FC5S1VD\L.!#D>DC!7&\1/(NF,D!.S$O=?H03/AZ":"]);:G:T-!
M%.84[9!%<?NGPPJ_'`8LTT<U0GH(1OH6V-`YZ7$)886A<F*@\Q`DM5BM`.+_
M*M?J'KMKP%+<,>?H&YH:FXP@.WPIC@E`H[R#>0P@:.D:(H]W0@S!0U(2(:.%
M')XX:TTSM>N6H:%X$1N@+`E0`31E2^E8G-O7AV(A#E\19,#I/^V1P.T+M6N)
M+!UF7`<0/QC'A9V3%"A!L0<;9$O\"$N%,13Y6[\YQ9Y\,U24CU4,#^(J,W?+
M#^ZX8S%D$QF`'&GX->/Y6+B$&[L$BV#%#P<@P0"0$56"<OS(G&(QFI/[<@7K
MK&,ROI,\,<QV2!D4@%VXB(15-XK(`#U;9>=3"&2A+`+@$QW1>81P)`L,._ZP
M&/>0H*);&N,@O)^\SK-"%JT8%$6FBZFBMWKY`"QZ_T2BBDQ`80&'V9-%^$,;
M$"D$X,M.&5.%,)U1`T,\PQI%:6Q'&2@>T!)LNHN@F;M0IIO4<108-$.6P0X9
MPX4X?`@!.A^"2#64W`AFB$:<T'%/AS$U/($%0<Y,T9KI<<TSW2<6S<XZC1\T
M:"=ZVPB7HXB<-$10PULXIW/'<2D>-<?JXB&9D@@GS',\4S4W*&Q4`W_+`9FY
MA!Y44R.I%1+P0<#R\+N`2$<(-#&NLLT&]PE0,0[46@BNHA;<5L4[O"Q.REP4
MLQT=89$P82[@Z;_?,AHR[5-0>JQYV8H[G=AO<IQ:U<<PZ"JD9ST;`<(%K5($
MD%WL<L'?,0&@,F,UUAKL=/\H9^HIC..N/U8N(C4`XDG,\7@170.3Z&.^<-%$
MC8RHPS9#JM86M.=Z-:PV$],-HE#7U;H=J'.=7U*6;+F?$O=OIO%,H!G2[X'3
MBCW=;++'7N$/K(&^"%*[P12K/8*))I2O1"$>DW5KF_W!`&VZHG5#-J:$N'$I
MN`*W_M8*/F:4VP/8XDQA7.A@NS`>`[$1.;<<:9U%!!#(+,T/X@P35)O(CJJ;
M5::W@UT:F4S<[Y#.U'WA!J*C>HFE#MDV6TQ0DI'+4=,`=>FNLR69^T`W+I%S
M.Z>G2ELIHPA-`<@AVA.$S)MB2T(`)ZS'B&T/X/HM/O,*6==$"=!Y8K$>!!!U
MKH+_00_@S&V+"+TI#UU+KD0:A@8;X>%X7%'>?]*-X5ZN=R&DG]W]=`XSM21#
M>@[@G*J\#_'2%MF9N-DWRZXJ'Y5'$I=7+.*=4KW@+W("BJ54>.:V`>R7(>7J
M'\A\UESX?_O@$[U@)+O2)71!OUE30`CP)<B`OLQETTE\C'`=SQL9FL1QR5I!
MTSG'L#XKL5^>ZJA!:G,B1MV:PX9\ZF)R%BWNN$!A$P5YU&1\B0*]D^"!VJH"
M`4KVHM_-`3)3'JX5&[S1"\CS'*VRJ?OYTR>DT6G21!J3'I;P51`2S$TDN">Z
M`/HP#BXQDBE-#_BI,YZ.45C,W/W!''CAFKJ#E:H^[Z7Q_^HM>PBURSI"S7?6
M@S10T9I%B;VGN!*3IRH;@",O.W.7(C,Z3IT8X%]S(IXSQ]4S.0'EHML?U5LY
M+1NH?@H!E,R7)@KIT25MT3[,2K^+,/(,`#>?H!P!`7=UXHOUL#%H$P_CRY`&
MXMRWPAJ;3.\^OT6)".*.((,?]#--(F^?:"'S2'#)DX/4H=DA7#VAK40W_AT5
MH"-57Q(43&ZPB%DOQMKT/80L,D)HD^Z-4.@;*>2-7+_%1U038P"YW3[Q,AW-
MAZN[TA.$E4$@HQR#_,3Q(!69<WVBO@EQ,Z^X@+H_G_BVV.-^NK<&>K(H\UBL
M.H0]A*B!<6+WN&,43!R(>Q'A>_\*_S*Y_GH2]/(H,K+G,"$!)*&XS1F4]\T4
MT%Y`A1-`KK(KN\(1&P&V`MXE<!]6&"<9_1M8381!F;/1P+GE"*CIORCMAI!!
M&U\5Q*^';ZWXU/\QU>3`CC!"G6-"WC++,V<2*R=;(UX!,_A#)PX=;7SPKTS5
M8QJ$4=DU&TP0N`58<1HVBBH/HPQ^_E`R20X(!7\)#@8)"0P*!@8,?W\/#PI_
M`HL"`@P%#`0&C@21DP86`18&!!0(DHZJJZP)"`><K+*K!0*J"@0'!(*R"0L)
ML[.P!ZC!QL?(?PH##P4.#XZNL,G4U=;7V-G:V]S=WM_@V@8'O'\("-8%YP4'
M%@/EX\#_?P85#0#W^/D`'1:L"Q+Z]&4XT.@/`W<."A@8P`&#O@85'#BBE^'>
MA0FZ%#@XL"%#!@[0!AT`&/!"A&FL*#@4N(!!O&X%+*"3Q8[<`PH/&-AB\""6
M`P([&;@T-*FG(P<.&C%`M`A8@@<2ESU8,`#I`@NVJBEX<"!AL@(#4JER=N"3
MJHUBDPV8.`!!UG#!-F8%NVIKUW)P\^K=R[>OW[]PUSD"2R`=K`33%@(C\$[5
M@)4!\67X]4<A`4RY)MC3AX'R'P(0+C3P4%:!``002&:HX+/>0]*H#)PK*&!!
MQ<CW&G"(I6H!Y'L=?FW$FXT=[U6^$*@3ODAA`DH.@"E`4'C>_R)%"101`%;@
MP2[K!C0J4(0@)((%"PQL''`<68%<!-+*0B!OUJL#`P:TJUZ-`GM'`KA3T%Y2
ME8-`5$A)\EY&@#7HX(,01B@A+1:$I`Q*U/BBDV>#7#63*KY$<`%N$AP@B0('
M3(!!!.EI=("(^)28"@(1Z"-!!6Y-=P`$!\A#(V[WW#B@(PN,""0`$+T5C040
M=!`D.8)QXXN2J@A`P2X'P**<(P<JX$P"C"2DD`4*0I7`EV$*(AMW/0G@C`*D
M>,7``E<NE!YQQQBP0#&R+'4,4*L(P!\U8;WBU73IZ2776,S,4U9^`V2E)Y\3
M5FKII9A>BB)OOM27S)Q@FDC+`0L4%O]3?@;4,@`$OP&`D2"^0-;`!*4J-$`$
M$T30&#L3X(8!!P-X:DZO1P+@P:!_0*`9D`/%PA4QMDRG`0>H--H-`SW.8D``
MABQ`C@,*N"2G!=P5@HE$+E67`%:5)16>1)2H:T$CI[E$R""B(,```E?B:8P`
M^5&9#*!5(HO,6I7!IR`!M7Y3X"W3(&!!+85)$PL#`[";Z<8<=^QQ-E.J\E(U
MXW0W,7+_2>P;DK3&YTH%`#40P4S8WF:C!J@\EQ6*)#&+<&\VXT::(,X0`&YF
M1N8S&7<IWO/K`)A4N*DW)=M'P7-7UCL((UPKXPF`/14`)B4N>3W34^&!">8B
M"4L\2"$*@+G_E7\&W$1I,A9;0S"`!A_S\T1[*CC.W=@L"N(OZLPDZ"U<>77:
M?Q]'+OGDF([\&3G62#S=A]%X-F<%20,@`<[C/9!?=?1LAEMPK"#@9+$16!@-
M0ZWB,_-@*6)`6B3C1&"SC!?V;!$'W';J3904]KAM3XUTU\PDA3R7R"(%02()
M)098@HDFL7@"#/8Z-4*=1)\!*A3#73&L,35V?8?,WI/T;<S?508\$;38/"QR
ML'\XX)8@BZ,%P[ZCHU11[H`(3"!<AJ.*<Z2C0L9AQ3A2D;H,:*!5&(!`8ZK$
M`=7A9C*L8`#,@`01U"V`1Z@XS0CQT0`(J.L`KPL2CIZSJEPUQA=!_[O'9"C!
M/VZ`179CP4]WKB841OB))P5!RDXNT92B^"0I!F$*4;9"/O5@HDU-G`[J'(`>
MJT`N&>I1V)^4%,#^N*\5YXD%P*!6#<.=!7.#(`!CO$4F;04N80U3H![WR$?[
M?(@=Y*.&<1`SI$=L\`$=M$@%/!"0#01R$A7(H3XZD*UYR$0`.I*`!P%P`=8<
MQ36B@T".N.*!!JQ&C;:)3`8C99JL8$R2E"0$'+<QM5Z<0AT$H<Y1FF,(Z$A'
ME_USB7@4\0EU?,==A!B/;&;TC/Y10@!B6J8C3%>G`=PI3X&<E'Q4`;\R4J,K
MI9D%+G0A"$2UAQ7Z:R#-".`.9KC+`K#`T_]"W`(XPO7QGOCL&&%`]$6\+<`2
M'*J,`U5!@==,<@&IL(2J6!69$A&-1A?(P$E2A30=>N9'G`%6JAS0%DF!$C<7
MT$!:'A.0H0U42O^<!0,HD!!2J:<`SMB2.L"%)@9$LQC=B4Y-O;*FA&7O36EZ
M!+E\>JY,E`*`!PB`OOAUQE7L2Q9K%%@WY3>+G]R//K,@RR?&V=2C'(!*A%G0
M`S`)(-F415#A9$6`V#B/CN;SK7"M5"T[)*QC8"M4>`%DZQA*(LPE``(;V$!&
MI"6\")R,'<*[@&!WH2<.<"!;8-D`D$PRRT%\](,(14Z*DC8S%%&59)64(`4,
M<4MS.<.HY#M(N1C_X0R#E&))MG"&,.'5S$G,2QGN@F8<0[(N3(RM:W"B`"FF
M<K>G_.L5QYDJ:/&RQD**#']:344ZHW&81!EC<*&B)SK3""`!Q?6[X.6+\>ZW
M36,,1V)X04PLU-%1PC;R9#B,$<ZRDXL-=(!:U(UA/D9#SKCA3GBXF4!:%/"/
M(W6&._>)CYY\!X$'J-<;N?`7OQ"!D]IJ#4PN*1LN0B*`L/U6PP0X6T_B-CU&
M).QYA$A;B0OB"4FL30"(>`]5?K(G6Q@7&3KRBG*3@;RZ<'<6:RW(X-QXN%"5
M%ZH!:ZXLN%K.'X?WR5#&AN48XZ]@G`-.G)N$9WSAI*<E@F'+DME,Z!$Z_Z=I
MT$V:D$=\C^1(Y%2@6`"X7674DYU7:#(@#A4)249'GVUUJZ[72%Q6X:F(``!E
MQ96!!`"C=PE%0/$1G\">]C*1DTYLQR`9UHE!C%*^H'#-%AWVR64,0@GT+((J
M!TC'`,<:J,]R"14R*:^,N^H(<RK#6Y&28(],5^5@F-/6K(@N'FD=Y6(;.\*#
M.>E7F!'!553-(*G$ATGN-`X>=>^R^K@`2%)2YH!`I)"Y*&5D6LC;%$D`6)A9
MP`22MH$;1AL?&*C`U2RG#;W21(@3-MH2C0@,)![%`4L<RO<0T#TH&D+@RCC0
MOS'1RT6@0HL3N8XAP'1I8ZII(3C)CW5)=A6Q>/^3)N?HU#P%-F=BR-H4%&@$
ML!FS.5HV#A=Y=/8=%6)R8]N\V,JNBC4VI2%6/.!D\\!V;EK&"@+4J%@8Z,<J
M+`"C#Z(D%]9>T+KWZTDMVVS:G%CP!/`;=$E*``()H'(W"#F+!-P2GIN0C@7(
MYZXWQ>M$:S_*;`M`S(=Z!9D)(0\ONN1,H]TT%5"11'2"&@H$TVFI_;(&QMCU
M\5$M(K1!#L;(T<F,P9TH%VVQMP_AD]UM1O6J@+ZYZ/FH[*]58TIWI<5)$9!(
M$H)]%0@@%I!*)`_NM;4A`3DPEXY^$7+VKB*=\>@F65:KY\@C=26%4I:SD7I9
M&("E[`A+4H0B)O_9W4O_@[<I3$-1)IUFGZ=#?<]/P154U58&%D5-%P!OZPQ&
M:`04#U`.8D[!DSM6XW'>"89QGNWC:T+5'3[Q5?N#%8#T8.&@39.'1BCQ>:/7
M@'MT$*/2:Q(4+/QW?ISR9L42''F%`!H`8/@P-)5Q*QC0,K6`&CT#/.S`2/L%
M&Z;A#D/U"!`P?"SD`?03`)$Q,YJW#0PD"PXP6F9'<'74?NFG'HY@?AKA?NAB
M5;85+7@'/2&Q+XV`85T3=I`P"?HB-MD#7"$6#2.F-HO`">K@'YI08SN'7,21
M`.S18\$V0/ZB(YF'9.E1&Z'7#5$5>=L53PFW<0ZXAY*S`'B!%&VD?.G5$K2@
M_RS=%B-^M2,:1%'JYD%RQC,LQ&?C\0I;=T.I,7LNQ`H.<'0&M@`2U(&;T4+;
MT4_:H&RP1T3"10E.""#ZLC49Q@FX4!V"DBJ(0#8J9WIAIV**8&+O@6)P@PBX
M8&*0=CV5<`D*40B=$&G4<PGS0`'IH2=L)4ALV#FG\4>L9D?VQ#!3T54B5UG!
M!DUR1%;7\#CAX61C,8U,QH?JR#$\P0IUQ&/*42$AY#GNP#L+T'3YL`'P%6V4
M%1X+A@$9I"XK$Q`=``$$"&.=(TD!00&:B(\-)2K3D3%N`F;QECT!51RZD%7Z
MX0RC-8NF,3U0Y#R"('`ZH1U983V8ECTZ06DLYF`I*?\4.\%IX?B21-%A201%
M2T&23U%%29$)B&!-26%-YY0G>S(G`H`AON`_I*@*BY<5B/$\\V!_$_1S5;80
MNJ"2[$0,<RA.R`5SM*9-[9)6ZSB6$@(_?T`_&ED8&'(_O$!FHC-#`,-78C81
MH/,0+1,N,VD0!Z"0\%8!:4$`DG4D$!$+K:00]WB($^!N#H%UCS!OHB(E:PDQ
M$\,O=9,5^D9J7--OK?@9`#</3%23!-<)!B=%O\1VO/0<601,7X@=%(=@W[$(
M4&,(Y#$CQ[0O5V*;Q!8,&),E`P(JM68H_G(:99%2(90?"%`HRT==]E2$WJ5J
MI:((]N=L;A656$66UMD@9EG_G<'P8'+4.D#'>AZT2DO!@1&@`=<F@T&B`4.B
M`!J`GM(F4K1`.Q]4==@R`1@1"7'Y&W*V$$%S$=[R%!NT#;YI2\HQ`!0@'N("
M=VSG$J=U"<\#)SXQ=W4G4'=G+WDG&WM'4P"7)C'5?=B'83Q%'P?2)D"E?9;$
M'2%V"J<1G<E`CHY"'`L2'[W0#G=!$YD7F57B&;C$(+=@CM1@>0NQ/E72G`QX
MG4:J%T:C5DI7=IZ1:F,ACP+%B=G&(O2B"@\@I:LS*`I0`;6C-,3)&`.P"RH$
M8$M#EZIS(V[A"AW8`1'Q2<.7F"W7#3LH6N&!'ZY0?4*A?3%U?3NU?4%H)GUZ
MHNTR_W[A\E(&$82F]0SITEVQ92[OYS_RTCSN\GZ4P%L6(%R:H*)EB!Y'1IUB
MP3"Q)4:X$QV$J"V/B1A[1CH"%',_VE$NNEW6E3='.JO?P##$88KW(P\=%D3K
M-1+%<@$,N0H#P)>(F%"8-!TK-$F0Q73I^7"D9`^TMWO#]S28]!,^@J7W@(-=
M<3Q;PH,I9W90PW9U=(2)D!#B,A'T1*Y@8A!*N"\V]FF<`$U/V(I26#94R(JJ
ME84@)F)I8PA?V#:PL@EQXX_".!7L`8W.90RSI@C!L$;C`)4BLR>'@'X7::4;
MM&;P=F:T8'GC*"`%1!SI:!=>0:LDBPWLM'S'^9>SQ`[4R/]-*G@D<C8)(N$[
M`88Y8($K9V87R_(D1..K^5"0!`BF,L6LD\4!CR0`&$AU'D!V/A2F5C9O/OAI
M]**$-CD(12047L-AFR`V.F%$61L-`@N,U)-HSP--X=%H8_L'L08*V6.,ZM$]
MRL@(S&A[G.EI+K$3IH8Q>@A&"Q``"S"R[FAJ#8L>>)55)\6?'\0BPH)=UV!.
MLP:C&R&C,=JI)5NYW%2-4%5C@M8ZC!!:DS`2Z#F7CL(!.&()J](JC^BSG,0B
M&\41][4E7):X/:0*%N"!)05$+Y(T&9`:NB<E2WE^WS):5<BNX5&2I1!;BN9:
MX>,FQSM-GU!$EX!FE?89+GFU1S3_O9?9M1D&<-.+%$J!"/'G%%`Q$3UY<*F)
M.J=Y&K?)+X_T*0,0`#@A%HA1&.GH;%`"=,&VK69:+!+0-T7*/O!AF/8$EIYJ
MN08L"X"2"W7U.(^4"5YR`!3`"QQ%"C(V=51WGDZ#;NYU`9G8(;73>[N@"06!
ML:NSI(Y0N["S)1C3%N%RNA:4`7G&#7)8=L00AFF7"=H%%;:@KT3A;YS9""K9
M1*$FFD!,F@EGFJG2<%,$3.[2)6!23&LG-K$Y3-)D#A6J$W_')>#2/ZY08\2`
M#:<!O_2AP+2P$6;Q<W`"1"!"$*M@@\52II,@CK^YM^YAQBTLI`!B/Y.@QP=L
MP`1SE,NI_UE<<450,P":T8^&V70#41`8E0_]&';Y41`U0T(>``&L,*S%\FU5
M`E-V-GRZ,1,.4)=`"V-)-0$9@+_B\)BM@!-@\2TF9JZ&"J%RMU&UP!-$0PJS
MK!%T5S=-AJ?9DW?61Z'81S;55TQA^J%!1<;=0:B$%WZ;,(1RTHK.\``!X``!
M0+G:<B763`$DYRCGH!PX"B`7:0`=B(E,@RLS5!<!?`W8)9SG]*JOVL<E"S^3
M$GHSK%?JVS.S4BL`4P$\PC2RYVVTDA9(ZYX6X8G.5LY.)V0<40%!JVY),YB[
MQQDG$2DX<3RH+#+%TP[!/!UX2GTP%<PSA<QZRGV)YGT@.A&(.O]^J,6<JW4N
MKK4=V<,N0A@@T".+MZ41%KJ*^.);7`-B#A8XUWP-N8`M/0)LP98>(6.JO,!>
M[%'!FP2"L6MFN7:./'I_`2.R(&N&"8>'\CRK9KG'52VL]=$=8:$,I*0&\K4E
M8J&Z0,(!2F(`K8=96<%1.9(9F]2[!`!**_(?_TA)S3,`@;E?VCJ4Z6`M",S-
MX*K+87(4XVHN8)()@-@_K+8V2\$)-E4=//&N=QNOM06%KJB%'':%OS4-N'`V
M74%BEGUB`:N+:>L)L)(4,"84AL8.R6D,#F33MS"-G2,4GKL*5-DYBRE8Y'>8
MV;HEM2%)C"ES@;R=9BBJY]@PC_O5UPG_%MTLJ^),*;7Q';.F.FUV"T*G#W)6
M"\QKW`2YK!L04:Q+%DT7PXTL;2>1$((BN6Z=&Q'1<Y!IV.<!)MSB;U+(C.`(
M-E%HO5\;/ZD2O5Z[%5I[MH@FDM#32R!9/9'&'I-6"HTA1Y)@O3%9<':;/9LF
M:@10/'MB&.33>#2'"J`RIQ3R(9/,0O?9PA60D4'GGA>!EO^;#%I-P&/!L05,
MW>J(A@)H#%I=/V--P-K4284T#A;\$!WL"_9).AB#>XC8LXE%@@L!`0Y--(9,
M0@.]"@00T#I$L5OI3X!6$^^AS<C[A-=AO(#BX!D6O99QDC(*O4M!:99Y:=;;
M;]W;F=H+FGEJ_S2-L!$(=Z<+YQS8\TOHF\32LQT39B6NAC*\<90)&Y6"F%48
M@GP-A2,A%(-OC-!0=9R&K7\!?.-MI5U-Z>,.V"EA31/0[0I?=.H&8:"F@@#^
M'$\+UI]5-PXVLTJ60.L2L"*PNP#Z%8DUS`KU'1EPC1R-"&^_4('9,$$TK!S[
M_=.&@,,GV9D\K.<L9G"?.7`%5\0()\O!M%&F40H*FLL)`2;^$7_6!`R3>J'=
MRG?3!TW;QR?R7AO*PRW6,%ZLF$:W2B:(W0JE:@X18-``L`%*X@`;8-"]JPF`
MV]4&9`W:A-U$GA5VB.K&!NVK+GG1^;&L"#EKY;.SDA%QV66>@>E*P_^ZL8A*
MQ'H/WUUK[9G"?`,49)'>#J6&V!#<4,7*O+F9YM(_J%5.N#SN#<K+RH#+LF4(
MP/R@!Q+2=PO,,M4E?3K-'NH,[($M%!A^)$I^)FI^0GA:XC*2!"=$-S'F]BL?
MBS/=,1$)X0QM99VT0$))QOH9RXYG<,1Z&"")JYJ;NBF1[;/5UH74&!]>8O<9
MW?PO?#S=$-]D"MVLD]@6UTKC&P!$%&#PFNQ4''&(HCA-K+(BB;(M9`*EV[#V
MDK?17P7UO>ST(+VGPERB$C$F1-,39\+U5;32;@++J354Y/I^BWJHT#%`]Q+@
M!D&OU,[3]8*%K_B#N&3V%HLG950`Z*$?W=+_S<XN@K.7B!&P6(D<.OK8LR^[
M#P9))3I.#>0H5O*1CHH_^'!5>H=_#/%\XJF@]F"F.@'I<]B*9R9,\(=H40P-
M"!`'!`4&!Q$9`(H`%Q4&?W\($8N,$P<#"`4'CY"=GI^@?PJ;H7\/%`()%`\)
M!`RI!H4&G`0("G\)LPRY!0P.#I`.#P*XNKE_O@20#,/%#`8"CP+"RP@,S@;/
MH@3*?P(/#`4)K]G7"@2#"JT&ZKNZ?P4$#P6X#NSC"N^F\]X.!!0.-!V@5^I3
M`00(2C'HEF"`@P0+H@U(4`HAP006!CQ0(,`"!`F4%$6P0`]B(@`-/!S8R&``
MA`X8."3$]3&D(@P1_PY<\V0`$[&"H!0@6/#($`**GN*E@V?T%M"G4*-*G4JU
MJM6K6*%:`.:)P,^K0C<1_-,3P5<#"VPQ/8#@@J(&!SXAF&`SI(2!\!YH'.<2
M@TT,"Y`2J-``I4I;`EQV``"8HB8/-ALX@OCU*N6*!W(%(/!K&3AL`JX)X.99
M-(-GIT4]>+",0*S0T5(K6`UI-+O0^;+EY??,P#@!^;Q"6GWK-+17A5Q!DE<<
M]2MD#V@)-_Z,(K-G%'Q3F!E5$U=0#`)["\P@LP.\H`I88`VIIU\)$"P`1W!`
M0N$&,MM7<&NW@ME6KD%B4EV+7`!!9;5EM)-4\2Q`2&(#.,43*>WYE-6%&/]F
MJ.&&'(:"P'>="'=A@X1T`N%7+0WPDU'E<<)1`@U.4)A-$62"RP(@=0"!B@D@
M4`%(BMQ%D"0VP6?6;)A0E$!-(66PP&F976@(4J#05\`#`9PF0&@.$',E>[TI
ML$MPCCU0(FJAP6@``4B9V=QQ,#+S$S?6H>8;,M8LUR59H<U"D0!Y_L'9-;[U
MIN2'P3@0CF_1W"E4-[/$XML`%(P#T%0)4`B*`0$$9(@"YQW$G4&:.D`8)3@-
M$`L!"PA""P0SUH4!!-UTLL!)!*)4`96?"$44586PQ9&#00WPR8D=)JOLLLQ>
MR(`%H8B8(5IJ0>(K)[C0QTEB!Q`SV`01$!5L!/S_H<0!F+=2<D&X[#QPP`8<
MD`3/`701.*NQG@S@5T@=!!;JA7J-U6L`/0:&``&W9*-PG&8-MR<T"^.YTZ!\
M/N/`+1U-K-O%%M^B@`6<*!I+0-&4^''(SX`JC@'\J!?+'R*KG(^-D5Q<0)?9
M!'2S6@<Y8,$!^60WE0#B>6C!.10,A)`"`]3ZR6602!*KNCDM.-PDN=X$K2<X
M9IV!JLL-@(F$\+!:XE0]R1=P)Z-@Z\FUS<8M]]S,HO>)M!JV)!_;Z)P]VP$!
MB8(`!144.(&#A0S`00<=.*+?U(8#[HU3F@"9]:Z>/,!!N0`(:5%6ZHT*2@*=
M!O!`X(!><W,V-_=B0.`8_SUR<\HDLTS/R?"(G$!`H/(CE,XB3U,`J#;VK,#-
MN?A20"%'YV7S0SG38X`%CKDFP,WY*(],\ZN'`TS'EQQ4*=IV)V5!0J(6L)>F
MGTP)B7H;9(T2!9]8L%C6=SFU4#CHR&B3DTB1&@!TI**DG&<C5$G,Z?!"-`3U
MBE4.I)L$)TC!4/2H%'C;4$<&L""E(.Q]??-8_V;4@+O8`D`_T1SD0M(`"/!*
M`%C+6HU:$XN6<,`O(V$:>["B";=AAAG;V=WP'#`3H<3B9J'Q1>YF<A!V8"]G
M3)'7E9!S,2C"K'F@@H;*+-8>ZHG"'@P`%3+\T9Z&Y2(;T>A'-QB0I^0I#!?R
MJ/^--5;VCTS\C&Q/>8"\TD,*[[0-(KSRQ+^"$3_YJ:03%!$*DVPR@0'00WT1
MZ$!.V'&>#93K+HX90+T6D8%)MH\M@7S*>0QQ`"\*"`'-Z-4@*LC*5E+P=1B,
MH(;@U@EJ2<B691O$)8'FB27);X`+$%@D%LE"6D7MABK92$<TL!'V605J4''`
M=A:R`/GP(E++4<L9W=&+SL"L&=L\1C*J<0TWAD:-I<$%=<Q!&F^X1ASDD$T<
MX7@/=^CF2_28QFW"J(_52#,@X6,00DH!M5]0QGT>HIFU%N"!%2ZB1OEL507D
M$Y:&4F*&HJC/(AIP.(09(@+@PLLH+!>2"VQ`)\<2FRS_0V$`T8TG-$.Q6M1<
MZLJ:VC1#G%'(#I=%HK$@JS8J;4]:^,.!RFC"?P02TG`JX*J*3JT1LCL`9!8A
M`?]L`II8H4"$J((6#J+E5[$IASO7^)DDBO4<8'HG;%"SFV780TS`>9V75D,/
M0[TB."E$H'%@DYR)Z=4YUOF,H/843]](4SLT+44/%7(`Q)%%;*TH7R?4MT,V
M@NQF[^*<N=AC@%,Q9I)*F<`%,E`!AJ2K2!HX(30$=-I<70!?O=*65,IGB+%\
M;(^=0-1-=\O;JQ!@:Z$H6K."52UO(`!LIZ00A)HF1Y"190'DLLD&I$@O19@T
M'?US"P!I0E)%.$DBH:P*`3@X_X"]#6T`1&G)`G@S"S$E@$QY.1,:=Y&<-GU0
M8=7I1<-,P2:RV,DZ@>(,,8[C)V\(EF*%*G"/N/*+126@48D\6'MZ4BD&7$HJ
M$)%I+?%"K5`--!1M"Q$$,G`!2Q#BHR>1#"<>`*N2GM13Y]N)(7`EJV!F[GZY
M:B&V@/,V=P4.*$?IA!Z%^5A2$;FW2$YR5\9G04?2K2Q?"<O+5#.(DFC+5"3N
M:"\4MZ\&8'2D+$QF/L3FQ0'QRSR2M0I"\`4H9SZE1Q1PQ>#V>SIB0,\7Q3$O
MQ1[2,>/N!(PP<UW@/O;G9[2N9+=S+LQHMS+?779VAAUB\3YT/)PI;V<-&<AA
MIQ*>\/]&0J%_8(MW""I<(FU4S(FI0+B\9.JZ<'0!9$N`9UVK@5@O`*DV@6IM
M%@`OY()P*:6("SS.5Q`$^-`>2DZVL@>;9M:N-%D_+9MC<[<2CPW.HBB10&HY
MXJ,-:(`K9JZ+MD$4:AHK0B6BPM"H84OE'T=E-FD!5``.5A+G0EIET7"T['3'
M.R+>[G3+"UZ_)_V\Y.EL>K>X4L&MB/"R0:-U5GQ6PL&(/0J09'">9FFS*9N4
MIC7$A[6<R/NDFE3_+(]*))??!D`D:W,W*2)A<T@^#J'9[S[.NCEQ]W.+&R)E
M++8@'SM68I=-=%9ZI;8$7<F1ET7+M137*-5SD!H6H2/J%>#_>LL8@,M9R.X_
M=.VBMF#NA3+%B:[G$H$,8I4UZJC$G;W/V)7.'C!N)J_9W-532KSB+<X(BVXR
M.,CA?,0XR0).7:1Q&F0M)WX?T0KV`,H`VU$?+Z6"`-R^37*(O*IP/S'()777
M)AT`+B0HX%!*;,#)W@!.8B"P+[M$"7X-X&@Z>A*!?6%R.!R`G.P_V`F]G24N
M&89*UQ-3].+;=#HP+X4AT#ZW<U0YY$$&:@%W7BX,=)T`.":0KF_FFK#8IX6L
M<'-5B$8ELV\X^E+IZBP6P$%>^(+!A<_&.,;(E>N`1C1DA$XYU[F-;MCFZO%D
M#K3A3ONT3;N13V^%&Z_S#`'`#J6T_W3IL1ZDY@!IL7>!\2D5,2H6T'JY$@%.
M@PPT1R`8M20;,`'^,1\:0%)*53EVL6T=40$5X&0'$4/BUBU"QT&5UPN;IUA=
MIQ?&]X-&]Q-,TSS*!TH2A%G,%VVTY'L`$`$[)0I<1B#;M203@`$O=@X+H`&^
ML8-6@8&=8'Z>`"$:!A2)012&(#1FM5JSP5GVT`M;X@MS!29O=5=R=8#(X"=T
M*")N@@S/D";),2<?M$Z!-3&$E1@4L`O;,14_MRE1@@P#<`"9L39\]($$P'HY
M5@$,=@""<&(#4'N4(!G@UEHQP4%86(4R41(+P(&HLB/"-`"?QTCD)B#S1A;-
MMBD@H@E@"/^$NJ@LLQ"&Y;52T38W4,<V0X$MSE<B';$`PM80@H`8"$!,G>-"
M-X(KLO<`$8%062&)7_ANQ4@5<.8*E&(CAN<;A<`*47-?_Z5?*=1?BS>(>C)@
M?7(GCZ<GA#(."J9;%'<QT7`QHK`5&`=Y(%<06"5(Y8,.0I%89-<)_H`P@`*-
M`$!:G"!`)20L'?$2C(%<G>5RZR(N:[(31+-UE"`!'[@`FB5=\L)&/K%8GP,5
MFB`P%M`2NQB3<7-!-QB0UM*-$J2$/D80F*46OD*!)V$D\U$?A8%N9+$?19(9
MZ`"!W4$?8I$OBF@V3-DKUF@6@].(KG$-'/,Z^10H@!80%I-HA3;_,E>W)O6V
M;]71;_H6<&DI:8]$:4B4,Z.@:8?(:8U8):)C$9@W.D6C/E5(0$.);=L%/T42
M'\"A%Z9D*J6'$A,@>G\P`"7)0A4@4YGBB9&!496G))1R/1(H%6;B"0.5BS(Y
MFA<":R"&DR"VDQ+4=!YT2VSA):R":Z.X*F+##X.Q0NCV8:#31V;C%`N@<T]1
M"!48E=O!,MOA.\:6.VU)/+?S(6P)#0/WEL\C=U'T2-$!(U64=PT7#P^'=_7'
M/?[P@!@W%8-D$)0B(=Z1D!J'%&#&2:"%#AN0$XZA4?82+YQ'@U(H;"*6?2\G
M8YKH@AZ1?:`X;)65&8L83>SV8:))F@PZ_WZUV%.*%4*KJ9I"55P;I#I&42X;
M238&P`%U`5%[B169(E.VU)I4X7M<Q7YKPGYM5PLEX0I]ATV"HDVST'?O%PR`
M9PR"EW]R4@QH)`T\VD:+!T>LL`J2-Y6@"6ILLPDG\G'DAT&H%V[J<E+*L"4+
MI8IU40&<MP&+&8UEXA-"D8*@5S25.".`&:;V@0&D$&+M,1`#"63<,6J0L*`-
M6J=1@72*U10%@4MT8Z)99UZ"\RNT>!2+,`%.(P`5P($MQ":^AA4"L`JE@"R-
MA7Y1T68VJ1#HM7Y$,7\WJG_WATZ$9QK.H1IKI%8!J!J.UWUI\@[XU`_L\`H$
MT("98GE`P7$6)/]<#5$I>(J7&P:2;\$!5B,`A91CY_(^5II==6&4HP`9LQDC
M,Z)4D8"?#PE:#I`D-_(5%H&-P;E*`L(^=&JGX+JG=ZE\%A*I025!?&I<O@:A
M)X)TYZ"/`<H(D\&%53$E%/HT0\$:$!*+0/$WP$F&@^,:E$((K\`E<;@,[46'
M#Q%?=86'[[4F]O4F?K@F@/@FIP%@.W$ZIY`*B2@5;,J(O/(I0Q8*<@H)&M"E
M\LHK!_$C!*)BN[8!+R:<T?50,P$1'+@NFY`/$D5=FY1K&P`!`B-R\*`1,%.+
MHZ,I3PJ5X;JT59$I/!<*%RJ0LI63YQJHV$)<UM8I1]D!VF8+87J!DU?_%9I`
M%"-[=GC$1Q8@J`QR0&<+=$-A;(.S5>VHC@XS8/\E,>]8,:^#,2^Y'!LC)GN+
M"XJ6CV49$$.A&9?*E[*TE)D3(;KY-(T::KCV/S!W)3!(4>Z";=[U)#?'F.FP
M>C`!`6!R`%OW:A_(@O)35)ZP%1GU""L)%8"T86?[K4Q;N[4TG/V*FD&A+4BZ
M(3VB*1!:(0WC?`'@`1A0&!L0`&E+"-KHC:H2#W$F3,-H02@5O.GWFL0)MP&`
M4C##.F#)E8*K.C%3.R42.\H9:;W3G,"SG/X&#W"I*$D#O<_6/D);)>SW$^DC
M?N.!%-PG*2'H>O,))!NY*ID%3&V2>ZAU%"C4_[FYHKJ(5#CR@U$L<S!I&Q&V
M>J=AV[R=,&_S:[L>[`U56PK'N'36*S=2QI-Z*D>_N7?^(#8'PVI#]V;"A;4I
M-7T;1B7CE:Z5JB`IRD'_@`G->40X,PU?Q$1P]T1M-SW628[9R14-=PY:Y)U=
M%!Z9<+CDN7&K5#"&\!"<JW%.D2G&JV4]<4-4A1>9PI\E5F4]`<3N*ZVH,IEO
M,VM2:)I=<6L.)1D^US2PD#3OI;_1@GKI5@HJDA$=_,&U"RB1FQ[G\;0\@;MS
M8[W3RQ2/Z!5X5++U&K83LE_$**B,.U.UI%6%O,E3%A7J90\+\)NT0*/0X'[>
M1$1*HJ-CM$9FI#"'Y_]-]C<.SO&H\P")O>O)3>8V%I8-]&H*J/>1&V5"W`8!
M$W"*XP&2$^E#`S!56>,!'T@OD:D('="([@(!'/F_UN4XZEFTXC#,"359?OR8
M-UF_AKS.Q/B40!')X/&+$Y2NP=@+OZ6UN'#.0*'!-2Q3SH<)YOP=Z3FU:3=M
ME3H4G#&PJ3$:D%)6_'<.I?H:I[J&;O6JL+`GK?H,6.(;HL8@8L>7+P2V1Q;(
M1QF91O)>J8#-2.DU$!`2J:AR`U`8%\`-#M``!J`!B)"4]V%JIFO3G>@7&*`!
MB1!N1&(`(_9+;Y%R`'#&BE`0[$8TB<O.M5O"4!O"-3E!*'J3:CNTCD?.M?K_
MN+F[U?!`)>$<?`*2-&>3?HX,%;X2'1:P'>Z5#PM[)?)5*`_;7_R5,'U(CFRT
MCGH=,6P$1`\&J1BFOVC!H4I#JR/W'66:-8#1"8I@D5Y3`??3`!@P6AP@V2P4
M`5B3`1H`$R9H2;-BB2(1`?=1`=+\%MI&+C@!`3E=5?S10G3A`7+,TI83U+CB
MU`9A`1\HU>RLPZ<IUF]3C+V<(8ALC#O)IKL*+"'Z;N@07K';IF3])#W9M@61
M(J%<-M.$``%00);&C\\R)WO"9X';$7.R,8)6;W_FO4R3&9P2U;TTS..%DWKT
M,4^8>0O2H;^4`?0#"=Z%T]>,VXHP`1I@@C>T+F*Z_U&H'20KS>"(@."A[5T.
M277*'!(G^\T@P=E(?1-"355RK-N@H&B^/>)9#73W:A!2N9JH&0_G6K9-J\]`
MMP`@&R)V4QY;LB7C)<^80M!WRJ+_\"OW5CO\8+Z0)D3IJQKKB[[MVS.\O+'D
M$UZ!C(5`K+])6QN)BC^\]#$P*",Z0L8AN=(:?A,1\!$<5>`8H"-`,@$M]A<0
M,&*6/2.>[:MO00$A@91Q+ML;WCD-'@$(3`D@;A`V-N*"'K6U*J$DF\*/G.)W
M$\-`H0K9/3H4,&V=3-(P4TV#P`UB`PT9`=\]]GQ2H5Z::L1.U,2Y4W?7"2K4
MJ7?;L,J2\CH04<5>?3=8?/^+FB=+>`K1#^8CK]A(J.@7)03@.,&R`*#FI]VS
M.(?:%R`!$S`!)Q'FK@7!A3JL+<NR);3L!,X!%9`!I/6*!/*S),0!;OSGG,?I
M@LZT3;>G:TV_FBPW-/R%Q=TKRLC(L'O*PHD0<1JB]-'%[3P(]/&O!8&$U@VU
M"-T3Z_5WKRQ_U]"I/6I.^%=_GS$.IT`(O#P58)UY;C.BY>%I96L($M`!'$"*
MF1LK$DRZ_`(!!_ZS%?Z0PNYJ)C@U'N"A\E-5Q43:_U,3&:#,&(`3&D`8<;[A
M7A9#DF$Y2.#G@DQ0C%[N'DS5H!",Q\+#Z%JNIY,5Q@)E3ZZ?>7<C'02)PTPB
M3+/_"@&O<>O^%&W=4JN@AI])%FU8L#6*JA4-5[F`T?XDJVFAB,UM(H2]#/ZR
M<<3&P`/L?"6(B0P<$JW]5!TN/T>]"!BP\G71\B@1`3N/")VD^`_9X0)>VGHN
MYY^XX/_=>BEP!"BP".+>2XZ)]"/>[E+KQ^<N-Q>J'H!*GO?K#4X/%`:9R+1(
MUF)CM+=+,/`,%6*8O6P41+Z1#^88">@(,0RSCA31CJ<PV+TMD+1?^U)96Z^;
M%)HB0"RD95OB%-:?*R5("3??I9)1+QBP[)<=`3^R0F$>]#?1YI>]`17@/["M
MY[']_L.^YOM-V527[8J@`P4`"%MV*`"%?X>(APH6B8D,_P2-D9*3E)66EYB9
MFIN<G9Z(!@,(`I8*"`<.!9,%!`L$JI^<I@L&`A8##)H(%`RS!G^^E`@("@<#
ML(D$!\@""P<6R)<,`Q;3"[B;P9H&UX_7I`X*#`:I?[:D?P0&N:GCY8NY?PX.
M%@<)!@&_F0D+"9,/T`X5P&=!P8`'D_C%*V!A0Z&'$`MY8)2(0L2+`#I4N!!1
M0H4-'"]>J"!!8@4,'2*0;#!!PX0&A1I4F%`H@P8,$2]$T""A@0<($"+`W,`!
M)H`,$$I&B("Q*08-&1YZ-`K`"`D0)E8\G*1NT@!(L<**'4NVK-E-`@9@J\3*
M5;1$!1P<>*#@;"4%K0@D0$#+4O^!@P).&<![X%7;5W!1\;NW@)C`88FX'4#@
M*3"%P7P-O+VK#'&F4+2X47#P)^ZX!*D4.'B@RE0JT[52.R!FK,`#"OX^'Z@;
MJ0!D1`SI'M`7B4$_1`@\-(7H@7(RGLNG`FC`H0*$"AX:>(P0]:'-[DLA7MB`
M7;N&""U+9H3:],*$"MT+26!:$ZI,Y<L[5J"ZU*@.'6Z,L$02.FP523&3&`>6
M70PVZ."##&I3"3>.36+`9+E!*)!<#R20UV;`#(>(`@\4IMI<"@PTF0`"3&/`
MA1FFA8N(B#PP0%^QF(+*`@^XI4E<*&IBBRO6'/.'AP8D<(\"+^I#@&/WU'*/
M``$@X)O_/9K8"&(!-`HT'#_H1')A-`]$$%)3$5AIS@`46#"8,B]%U-]T),7D
MP4<78`!4!SY!$%4#$#AT$4LS-9`!!D9)EQ\&'$`TGWP;(:5>?@\1912@@A82
MPQQ,9!'""1#U=D"8B2BTH(:HIJKJJL!T!J(CU)#:B(RR0GCA*+?R=LABO<E%
MS*W^/$(``81MME>8#!VP0*V>'#80!17JAD"&EYA"P0,,[/(`:7\P\``I]XS3
MHCD.@&7`MJ-QN4PFOCD720+*>@9F*-0F,@PL"K#X!S=F#LJ!<P9L!(!.PYT(
MTG0<")I!!1U<M%T&XP4*TTB3-C4!?0]!<&93WTWGP00>J+0!_P2&LD=I3!Q@
M3/%#2*2P@0Q$%%%@J(D15VH_`IS*ZLX\]QP+D'19$M@`-C<B(:JTAC+*OFH-
MP"S3%K"HUD((#&`B6\]@>99DU:CU]"2T_D@`M(]`6PLP#R#4[8OB","D`_=<
ME@"T/Z("=C\#-0:C7%M:H/:^,VW@5EH0X!13!4Z2#!%+KBC@T77J/17?17IF
M6@@'#5.*7D<N4151!^R![@$&$F@0%``>;9R?3)/:9#@`/VPA@PM,K/#$135+
MTHP_.?OL^^_`7P)L*8*]2IAGJ/IB"YNJ[-7EK(+I:+6YC=6[:V/K-CA-U%3B
MF,G1?G&#BP/?)%E`MN@\H->^#!R`&_\#%.A<";Q%@Y+](:>TNTJ7"`@EE0;$
MV(L&/."!!<2C?]'1@.4RLA]*-4`#$2&*ZA87J)I4AR07*%V_'-5`1=T'`"/S
M7'YLDCG4^:D07D!"#)(`@R9PH2F(`),DQG2(W@7OAC@,7MC8\J%5=$97&CK>
M7G!$HL*`J(C(2\0.#Q&*R;P*$RPR@#H$8#US6`!:QWOB@5RUC1N]2%F::0<Y
MFN>F>C#I,D(ZCB00$!#D$.,K"5F60"R`,8AT``)18])@2G,`_.1'8`\!&:46
MEKD.3*`GVWG=0UA7",E-IR43N,`=.6`X2P%@3D=927A.5@C0Q>=.5%F!&^*`
M!1DP86:XZY;_UAK!1F0\(H>PC"7/P->;7%&"0D"$$"L*DS,?`2V7&YH,,(&1
MF71<XV_9D,M<"."`G#WI`%=+A"]L@\4?<6B88+,`D080`,,T,S9<.L8NJFBA
M^\'%`NXJS4'H5\[<<*EBE*M`/&I81XM!("(-B$!2G,*>?%+R3B!A%`1*Z#I(
MJ4Z#>5*)2Z93P4;:!SN<A!1_,(:"`I2A"S=XP`ITX`48\JTWZ&0E.65)TI*:
MI8CEF)`HOK9$5%$(-<)D(H8LM%))X.4:S_M>U31#B8%XK1%MH8``E/:U&<Y4
MI]>RS&Z.)$5H)0N;D@#(EN;2F+H4(TEJC,1'#W&`$BZ'`]P2R`"X_[.<-!7B
M`D"Q#@9TLA(.PN2#4JE`!-:ZDPF0ISLA=`I0/!>!2:5N8?#,#R8!19.',,$/
M<VB""E)`J7N)JFAI,:ED)VN771)+:+>8Y[L$LZJD'55&FE7B3B4A0TX81[/B
M&!8S2946U@`U5\L+K=!^RJZQ3<NVZDA7;=CUFW?)L5MJ61:,)N%81!Q`D8-*
MTR&F\95\#:!P^*P`:8YB,IWPA"4NN4`#\BHIC`@441A`5"$V*5A%4K(0EG(D
M)ZF3*<`^1`=(>,$,8G"$'Z!R4!!`9@P-V`A^0)6R``[P9ZI*/.\=J$0I197S
M:D%;6BH"P<@8KFGOUSX+$(!%0RU1M+;:"/^E*:.8FG#P*L0WC@5<Q@!T8U=.
M$=$^:M%+&5LZR($0`)U!(>X0!-`8Z@"H`%/4>&'ZD,`)Q?.>EP@9`H7MV')&
M,KF1G$PZ&9S`'9?"%$6=C)'UB8\75"`!&8!@`TOH:'M((HD6]W<`(Q6PFM<,
M-MKVM(>2<):J4#I$?<BY5R@JAA97L0!DL!&;`K`;$P=`B=BR(GY[EB87/W-%
MM;2IJ/WEKU&CP;?>&JU+):I`U%IU@#C5Y``'K*>>G-86"*C1`0W$B$\8%A%`
M+D<FD[OD0)<S`<7=R0,IJ0!T+,G)@AJ491CP`Q&$8(4@C/`F`!"3.8^4538[
M^]D)X2Q;KGE+`J?_ZC`>,F)I;#E#M>@W$_-`Q)/\@H"P(J!^TN0+.KF-B5]J
MR#CD'*>]K"1HW[JS(36)0%^`-%<)'(=+A;U(!O1=KS*)\"*&C$B-.;;/C`"%
M.]8-["8Q2<A\UC,_'HE/K:EB!"7LX`I-V$(!,#YD5JHI,FB&MLI7;K3B66)X
M"8K5JEY*;:@][39)Q$1!$+&`=F?/()=P%@&J!.D.'Y5!-`3IM[SV%[T0C:;N
M/``\W:/M1[Q#ZI2Z`*$3,8`)ZN=/$I@`Q%22'8&;+'4`T%/AL!NG#Q+V(9[$
M,B=!^1#R`D`'6RB,%DY`B.70W1!S_#:,64YXPM^YT&Z.Q-#0[:#M#?6S_Z-M
MQ(5QJ0DC'6+K!M!FTXP1M'2$Z0#LNM!E0(N6Q).EE3;M4@+8A%5R;I4?R%VD
M!W)*`*^B2;_\V.!%Z"Z3#:3DND4^4\;'Z[^'1%P[UF&U>R5*PHA>LOAP[2@4
MZ#"#+]!@`F)&4ST5L6)+%_[[*J?\74!L4Y>G:O$[U!%/<8P.HF*"`/,$]0("
MD.!6.*!-MOD\)[A!&KX8^!)U1A;!$4>DLA@7@DV]Q0^Q)A);QV)8UQ0R`1;P
M`@%&-$G(-2>^-C"09!Y]I1)OE3`0F!ZM%A\14!2>%%&8XAT-=W?QE0168`,-
MT'>JAF2X4UK`41C@EX.$YWBEL&B]`6?)(Q@!6/\:>5$7%Z9$F64)J\=B`?`5
M!&`U)0)_KB`9(]*`FW`+E)%%(1:%B=93*R93+F8/3SA5IU)[#G1C1T)%1+@`
MGF9\:'@A?S)[9H(!*E$2[-5)\#$HVW$!&3`!AB-W$&@1$*$!'UAEJ78R*^-0
M4=%17O`&'S<&.U`"(U0G%R%A,?1T.IB)*[=X?O%#(V9MJ()MBT8A2]-R_]<(
MVP(*`;``C>$`#+9SNU,CC#=;P,%&05);T;0)-M@(]^<TXK8;WA=#.95[7G<4
MDH8`''`Q^W8A&Y0!:A0P(B1D<Q4QLX8ZAX@1I1,1=G4RFY0G&/`>=Z(411%1
M2F:-%Z`#"4`()&`',,#_`:=T;`L(`+/W%KRBB?:H<B(6&:`H)C5U;<!2<^WS
M-(>7&&&5`/6P"SF#8C:R<TQ$$9UP"U["+3`W8-$B#:MD<D>2&?=2;Y'F3C0F
M3--P7G;T;WUD?!/@(Z$`%%K3/P?72!R@.'`'D\MA$SG1.1`(@K(V`>_!`12`
M*#C)24(6'R'D!4OP`6H``"/``T>0!&"`<7EX$4NA;/]UCU1)60.I.Z:'A&N1
M*D0U/$?84^Q6BP.@*TQB(]X6#L`A59W`$%7#;/,$+PZ0E9704I/`87`!1S$4
M/^QD5+E1#.IQ1]R#``TG`>N2`"NX2(19D?BS0!@Q5Q"!`:Z&$1K1'3\!`=F!
M_U#198<S`7?P`8B4\G<6=W=D,`%?<)0,8`,C@`3YL7'X11.29WE5&9O.IB**
MN5E?J`CDAS29)2,6D&:@T(]*U!B0UA9AM0E<\@M$DW++I37%<(KS(VUK='*7
M9C.K5PO-E@R6!WL108<%<PI.Q&SQ*!4+`$0*4`%/UD`-$%[I"12Q9XU&T1^K
M9B9W!%W4U3#+YYX9R(T8PT@ZH#X/(`<_``!<L`4RV)@7ETGJ48OI))L,RF;N
M=Q<0-@DWE7,/X@OY."M)"#V3<6$8UB)/B`I=Z%OQ0`&PR6%RD6T42@DH%0U_
M\6W70RT&N%31Z8#A.1X7J0`F\VH:4'"4:*`P81,;\/\>9C)P/7I)XPA74A$4
M&$"D$,`>ZO5\#3"9*+B9-<%J`.`"`;`#5B`%`<I1KP919A<?$=F@9`IML=6)
MC3-B,75M>8&B7>A@"2`LJG5A(5IF605Z;C1O^$(!M]ANGGA5-`5B!ZB6HA)6
MT$@I$I!."1"9`H>)SD0*151VBX23)R@?$$!)XS$3'9`R-7&8C_F2399J=_AW
M)W.?CO0$.@`"W10"0&!L(^2ID#(Y1W*;95JKE'6A3+2/1C<MJ@(DTU)S:)JB
M9I%TES>F7K(@[#21F$`AOQ4)@W=356,*"WJ)-M-U@Z1&+.)<]!D1SI@;J(82
M$2`BNW0P6&9E#T&'2:$=8I?_992RJ8\I*"N#2:6:H]*!!%J`!*JZ!:SJJ@^1
M?6F7HQ#Q'B(4B[9:L&QVE<4A<VWFBZH"+"_5;F%I%L6%"(0&+V_9)03[!VPD
MEY2`+<253NURG'=3+Q?2AI^#)5P2I!#@-'M1I(29&PAD?!L`HDQ3`5TU7N/8
M'C]9"-L*@91X*!GPDJ6#*`T%E$]II`W@!6D@!E^@0@'P!B&``_SJ,(Q*?`ZS
M;`:;M0#F;G,9>>7GG`Y"*W1Y2\`Y%@,8";B051E[@(_A'+@J;K7"):?")7`#
M:N7$&[ZA%F%T`+HG'X7Y@$<1KH-1(J,S`>OR%XSY2-IV".AUH!W1*!P46-Y1
M)X"2_XPJT:004Z24PIH(0Q\B``43\`%((`8!4`;[VA1Y%5U^5"D<4*=:^[HY
MI*SE-QS&XX-!E!E#>`EG*A:`*@E\&F'W0Z@B*U;JL[B4\)7"Z)"SN@[762/9
MN0`X8:.I$`J.>4EJHH`B,;/$(D7ZX)>;ZR[C%7!-H2@>D#!T51[<RAZ$%$C[
MD9^:LY]U$@4H,`,G0`--FP592@,X4`7^.AUVIX+P%)JP.\!K-K9`!81`!:Q!
MU!D)$*'5DIN<L(N-<#_%Q9;"2!R]>VB=)PG(ZY8?LCO$"A>]U3Z3PQ(H8@L:
MX`I,5+6+9+B-8`&VUY@+$A-%UI*6)!.1M*D#12B19*E14?^ISV="X6EC?E10
M03`&8"`$)[`#<H`$(Q``$T`#&G"4BZ.YBIB9@$?`6@Q@;RM^,Z2K#P(T*#J5
M`H'`RWJ1:$N\-T@<]<AL84(_LLM^]H.WDF$*;014]7:HV%@!"\H`UX@1SHB*
M'%",#*4V[6,==@A09Q*:""H>.X%(IK-7[AD3-$BJ@[2"4JH#-[`'29P"--#$
M6+H#("``W&JE^J$ZS9?%6[S*DJ6%*E6*6,FP7%E57LP6$4L)=BD)%:MZDK8O
M,NK+&0)O-?(-DH<.8Y@(`+$(T[HK=HL_.;L<&T`J!O#,@/R,P\(D?!M[,J$/
MAYJI<9)(D*D>Y;@XD-01Q1>OC@O_R/2Z'SJ0`F``!'N@`#-@!"WQ!&T0`&+P
M`_X*Q!"1NG`'L*P<T)-E65.YNZ0%G4CC-08L`/KUH,(@G93@-%EE9H=@HO=C
MHA308^1WA)86LK>9L7]@GNTZGC5$"LSH=83)&\A(.A`P"K90C<:(#BRY.(J<
M=CII.$%)*1Q0,1&0.=_Q=A&%=L27M&+P`1D@!0&@=1>P!5+P!'/``;?C5LEU
M<>::;`)]U295RU\[BRNJ*@NV8)&!M6NRE7<I/Y/`I[K"898VL1-+A":"1*S0
M/HCF)5CU-"'\!V/5GG[;/$&AO3XEDH4P`4;R%^++*$3C8W:%LO@VOA]Q$828
M=2=1$^'E_Q(_D0'W>3*IFX(ZD`5CT`]?$`!&8`,KH`(X$`554*!(2\1067PT
M@]6N+4L&#!=F#!R>F"IT!F%W;8HV4PPN.@E]YD:PT*+`(6.(<']V73V[!$9Y
M@P#MPP`4'0F$:I"BD"\6`--U%Q#8ZS$G+)@2P"AN"[B.3+LLH@KO=#)_/!.$
MW#$VD8P5P)/M"["K0UXKXP5\(`1C(`4)\-DI8`-5P-1/X*_4<:#KNS@[V]JO
M?>`Y!-:VO*9?7)L.LDL=,C:X@0GMLTQ\42Z5I\9T/2(KEKNS\E-)8B^XD=NE
M$5*#]L,KZS:GT!/^"S!5ZQ&C@!==`9ZKPP$V(P#I7'<8$U[R<?\>"YC34LJS
MACC$JNL=R(8"9U`$?9`#.$`&'Q``)W`$_>T"6$PY\.V9!H[@6AX\73TA1Y>P
MF]:PSD`T8#PKD,`BO&/67A$B;-RLJK3!BF:\Z69@8]+6:US<USAPM-L*%.@D
M?_R8$*`S"T#D=*)9?U&]_D(?2+$!Y-'#:O<Z=`>:FRFPY&C*0>D%1F`$5E`$
M%9`#+>#D4&X'/P`%Z=N>5>V^$;'EJHY#"/OALJQX7JLA&^LTL6T..F-#F(!F
M6=7&8<VK>`;G(^(J?T;<(HH<CFNCH54F)X,!ROL'G=:29X6&RL0]U1W`/TNO
M/CXP=144,$%Q^_2_BY*C=(<"7[`$<4#_`B9@`TW^Y"D0`O?%0/%8@M%XM#"T
MZO8>/%H]8V!+3+0;QA:&F[2@X&8^\)G`I]3B&V`;V[?"+*Q0);U;'&I$V`Y$
M`2\<PQTAHX\@`+O4P]RJ1C--AX>]XC]JI<.WG>PY'6MU.0'WTV!JM!-5""*@
M`!2P!'3@`Q]P!"VP!":P!T:`VE7=N;OWYZET[T3O.SS(&7(NVSY263DE1`Y<
M0[>NYHH7`%7DRKJ]L*%UG!)L/\C@`(D;$;,70P5@"K`:V(<[5BE!N_P2'R^K
M3@M$,.'P'M?1'92NLPLDB.;871'%:V^G`S^P`"E``1D0`CZ0[F:P!'J``*@M
MKXMDQ8R_'$4?__F^PXG3UJ=B4N:?,+R_/L903_"8X`RP#!>^,DP3>D0@-B]H
M#-S2Q(;0;KW+M0`JX30Z(JGC]=V3PCC$0CB)3=[@3<Z]?S'+#KD/\1/?2#+C
M'-\8XUXZ$`<NP`*!3P8T<`8W/_-9X*64G+CN"]2<)/G<WS/JMV?YSF(*&Q;P
M4G0.6U6XWOF8`'0&W6%E"QRWO(8E`E-]\S>/RF^J`RAJH\<#!P@+!@4$!Q,7
M&14$?W\)"Q@`D9(`$AH("@H"`HR.D).?``T4GQ$3H)\2%1D`'1P0$!X8%!&4
M%1>GIPT5$I(9&JM1/Q\C+$849#0"'Q8:"EZ3%[NG':J?T;RXIXS;W/_=WM_@
MX>+CY.7FY^CIZNOL[>[OYX0+!`7C`@,#F^`"%@,,[8X2G+N7[]Z"!]T$+"KW
MP,$V!0@$U?/&SQ\X`P,0Z.OFX$`!!`C`%3A@8)N!"ATP1!#T!V,$3]%*_GG`
MH8&U"0?H&;"`X%_+`ZNR85@PD1$!;-D:<#`5"D.&!A$T(/WDH8+-";9";0C@
M`<`&"#:S3?+505*J#%Y*,.%B(DLQ"E!VB#"QQ<BS7AH\H;+ZR5=0L9_@"1Y,
MN+#APX@3*_Y6P,"!2^,2("`9#B++=`'5638@F3(CA0Q#=I-'[]OFHMPJRF0$
M4L&`A=X<;7P`5M*%"?,*\*L`8<&FC[1P-?#_L$`!MP1\Q5YH=OS`AENY*AB(
MA$'#A@B[;FN8$#92A.#?>^V"&AQPI`Z_)$VH#:4%C+EKWL85H00%*@A_)WWO
M'DD"?O.@+";@@`06:."!`V*DT3@*/'"``ZAQ0UJ$X3AF'#L*%$)`9Q"")DX!
M%BQ@P4;=&+``9-Y,:-ID!MSS@`*>></``0+]`5PN$CP6X0%3X;*!0]L@EQ\H
M&?AF%#X0.A;!D$5N4@MT#4RPW065O(0!!*;HPA0`U3U505<`UM)=>#H\44,`
M[_$P!`MWF''"#A>L0%5RDS0`P0:@8,5?F``@Z.>?@`8JZ(`5^10.(3E=F*)C
M*%;H$3P%=/1``@2<_P@;8Y0)@,``JW7#`#XD<F-BHXP4@`\"`7"V0(W>=#31
M2&!FXX$%W5"P)R@;6%"/;@)D,@`$>DW2`8TV6K!!`U$F>@\$9;&R*B/KW5KE
M!1U,,`$DNB"5"B+2A+E?)+J`*<$07010`Q<\N&6$FT[H0$IYT'2K'[Q\1C+H
MO?CFJ^^^C&Q&SJB*>J-@J-NX6ABC"0#\30('&/H'1"11V`B+X'PZ(B<-R^88
MJ]V`5)0%L683`4+<S!@!=)]`)5H"=ZZG$41239+CKCRB8@DFDU4PP$0(T/L)
M-<U&,D'07S7099A*X1E)!A!@,T(2,<`00!=HZ#%"#RD`\8.[DFAYBB_!AO_R
M9;T!\FOVV6BG+9B*XGR:3S@$A0I28G%;3&("%#B\#6D!/^1@:11-YL"J&Q<B
ML:DD;T,`!RB?$H%H,T)`&48<!*L+D([\A0$'G&:XP+4<(%!/)[A<N7,W()OG
MP9:41(!L>*G<*IR\?@$`QA)-O#!$$VCZD&XQ9/0EK\S5C-4TV66KK?SRS#=O
M(Z-]!\YI91')-/=BFVDZO6-N$\R(PBE*&OT?AKMZO3<PKJ:``P;X6CDHES/B
M`%]1YJ;I\1AX=E+CD5P00<0&((!/!+"`(8%"`HECQ",`$RU*N.([%8C9!FH2
M)K"9Q19>T,$:8A"'%\2`=S4X`X]P\(.[+"T]H*C_RIYJA[S`..^%,(SAH!#&
M(!9)[&&%R$B!/+>AR5#@0IJ*44)`=9&,D.@!NO)83L"1F>_MP@,WTQ3MIO>'
MGJ6L$I=H4$9J1``ZP6\"M.+&`/@'OPKH+0&_"ILDP@.`[]SB2AKH`'GX=!9)
M%,T+#-A!#$!@A1>`0&I-\,$!LI``$S[)<3[;5@N3)\-&.O*1B(G;.-@VF@,X
MZ$4%BM1C*)6;?CD(0@NCV#<*]1'1O0:-G1+5`%A%F^Z8KE<.LM:S3*6T:4`@
M@7]P@,^(=(!N$(!9V2B23QP#@9OY+V9=JT"6QD:=7V2+3RH$%QNY0`4$B"$&
M5DC"'P-`!Q(X``F?:&#*_["4I]HLTH603*<ZUZF9ZOWK1`$;B4QH6"!&"0!\
MB"+`^!KT((E!)%7I:V*K'F4C*Q)I)8/0!,UZ=`KF%,QU8LF10`KP`"/"C*%#
MX:(Y._`*#-Q&F=22!M.T916R\.E;8@-3'@,0@0U:`0$>X)T51&#(-NXR$3V:
MXSD9R<Z>^O2G_=+0#;=AMT98)#5$+%"ABOJ]$W%L;X7`I#=61;@#C*^*HK'1
M`4(&"O\!Z3.[)$56$V"<0CSG%#BI!XRZHA).R8,[_2&H0<>"'0D,AP,;6`4+
MVU@3]!A0.'<2#R]0`(8-T"``2<B"`;()!SH$@`1<`Q<S^X+"9')UI_8"JF8W
MJ_].34H5;OV@P%,?XLX=5D][JY'D-^BY#0O0R#&'>PTW+,!04$3@JS9*(V!)
MQK`(<&!R!UB2?E960&C\SP$*,!$$*J`KK;+.&D6;Q']"P0%:Q"Y,UY#$T9!0
M@C;0X;`O&,$00B`'&4Q`!I$%`$Y/4<>Q#`^SDN"L?.?;2/`Q\427,8U0,UFI
M'D:L7Z6E2%(-!R.),2R5J4O*XQCA-@0D0#+OU85,&%!<`%Q@`_U<5DH@L!",
M_#59E])J;3_Q/DEP@!?/]*WLOE;9;>E`!#?`@`M"<-@DC``$-.`!$U"0WJ.5
M<T\^AB\ZZ4OD(JM-M25:I8WZ>T//7O4PC=DDDX.:$W__1H0G\DLE)Y[%8`*T
MKU)P35D%@#0_F[R2GW!MDA/WE*P798@`^CC)BDU\MPJ8AXT2^,X$.*"!.":-
MCM/U"@5)0($#H&'&-1X!'D(0@2'LA8PV/:`7A1Q?(UOZTOSJ3*=@*R'H.<K!
M!AH8/CM"JE(MT2@$VUBI$%`YW.A322C+`!7GVC^$:I*Y-:+)G"OAL`),FDC%
M\:4A9.<U+64@`Y50Q3/#%,U0A`<%?%!!`*[`A1$T80<!>($+5%"$)<!K@K<*
M%ZXH2&F>8OK<Z/83/Y-$4($9$6Y))=!2!W"Q[[V;$]O328@-9^J083&Y`^!`
M!R0PRP'4\B;Y9<0#PCH)#X38_SF0[@\$<JT!R;4/UO'BQ7K[4]*\G+0\RU9!
M")@0@`.(P`5TP/8+G)`%=WU`FC<]7IW86&YSI_OF.%\,(0+`9=`>=44)%U#V
M-I7:?C`@((BSY!^(Q9JQU@P4',T'I4`YDA%W+0#=&,!?9?:H2'GY)R])8=<-
M6C^=!!P21]OK?JBQ=?B1<VDH`8`.?F`&*\`A`!40P0AH,($`W.`)7'O)LC\1
M9,E:O=PY3[SB$P,2^X+#7X_?+X%(H^F)X,VJZ?L#DD8"H0<%J<*X2`3'"/!<
MQV45WV$_1:Y&QR,,X(0>_`"F=T0GX@-&<5,(6(4BJ8NG9IMGXUQ*SP\DD`(6
M6,$!`?_0@PBR\(8RF`$-7KA+*^(N:?Z9M.:X6+SVM^^.\S'U4%-FC/@RB3`'
M#.``!Q@`A)JX,P18(`$/H$#B8!3Q9'+,$6%V.V\7(+E+Q'XJ*O,9H#<<EH0S
MUE$!O/5TIW`EB1,)&A`6V852O]=B?*$`=K`#)]`#&X`%`<`#7#`$*C`$?/`S
M`?!7T24LE85]-L=]+-B"$B)$GT%TD^1X);))H79OK;41`\!@.2$9+%$`"Q1,
M5$0`^/!J"W`R8C9A%<91(P(Q=A433@1IJ0!J`F!YH"<<%+`-D9`58&,G!P<8
M[<5783$',[`#Q1<"(-"!7!`#4U``>Q%H,"=I<Z:"+EB'=JC_55I&6O\E#AA1
M;Z.$#WJS&(5B$DJF>5`U#Y32@PB`3'U1<$KS;Y]28FK6$I/65H-@?A;@$[\T
MAT/A2U]81B41*=8B)1R@"MD5)N*D%/`R!4I@ABR`A@'P`<N77F(H`2$S>&L$
M42J8#7?8B]N7>9,4?CZ7AP`6=-A3/?50*#LH(1J2`)*B$,-F%E;U,`I('1!0
M$`C`&URF:[C@/]-H$AQ@'ITH(;KU-93!,`2``2JA`1VG1B(#<N]5!#-``\5G
M!3$0BVJ@`R:DBI(E'D$#+GBUBX#ABP29<P)5#C2(/C84>9TT>5/V3X,@,/#$
M*`S0$2^Q`:=#.E^S$D]%:SZ"6P)0_P'N*(T70H0#X&:+V"-%(A`$)!#>X3K^
MT79B%BO7-PDD,`,AD`+R-P0](`'1ETQ3`0%OE((6]EX"N8(%F93S=9#G\'TB
M(8RCX6F3IS"4M`UQLU0"]!E``1@=$$;;H`'F,3,V<D^9@``R%TZG0TL<YV">
M`U<Y8AR<]@=V8@J^!Q@C)0E^%0F&=),T<`)F<"X^H(]X$38>(`'7-18>=Y1B
MH92,660S,EKH@%KO5&JJM"`%PE0)J6F0IWDR691ZXQCY]PFKUPC.L1Y-.!EV
MM4:B476$=XU5B!$940\5-1$*(`TT-X%_<9A>T`"1)8\3<`(M\``UQ79=10'D
M=D&=J9B-N?^<G,4P0X4.$!.1;4-OWO,91F<@DOD'3NE)#\)#C<&(P!9G!R`Y
M^M019]4U"_8'!*0Y_S,(9H45"Z&17<61HN*5F3.7=)05+]D=3S`":R`)\J@"
M)\`!8&!(ASES`9!"OZ:82,F<#JIX53E*,OAX`38@T9F,HL2,\Y!<4O8Y>S(L
M-<)J-M$`.7()2K(*$A:%785A'2(`-2(`6RD672DJHH$1"0!\YG&"?S8)1L`$
M("`)/G`%,F`$X#0OX;8+&_"/$LB@O/B@3NJ""=D-%_J4#3D@*K)N%`(P"L(`
M)H*$E#!VB00!&E$11]5*20%&6=>9NO`/Z^-E$6$X"4"4"@:/2.'_!2A``B\@
M`$8@"6@P`T:07CLJ/&61`<&!GTQJ'D]*&/B`).LT*>]0`,:QC)$A#H[*";C$
M1"U!C)<9;U0*.(OR&$]V&%2I(=%C-ZKQ*<OU``LE%-?($0RG7;TD*CRR8FI&
M80X@`(/S&#^1G))%DXD9"3H0`B8P`G"P)2E0`@!@0J=(>)4%ELMZJ(N9J((1
M``10K12@J2_4/N]P,2'V#0[0K6*T$?=`#FA$/N"*($&$K4U%F81HF02"F4XE
M/>VSD/UR`/_8`?^XA:BA2W/XEO)#;^[IH3]#+'$Y$HM@.!5$?:Q0/)(`!5<P
M!%RP!CX@"3J07A8DA_I1";P*K=(ZK838_R\34856R2H)4)V<T"^062,*P"JZ
MH2@KRPT*(#$BVPT3U2OH,[,/HP]O(Q(V:ZZE0B)5N+/JN3,F.[3F^K(_^R=8
M.@[;F1K7J503BF2D)1%3)@#PT@`/.'.BL3Z7&%R0-@%I.0#<X8V#T*70(99(
M9'F4<3T`$F1U&0E8H`(@$`%<@`)W8:`,.PG@%DYR"JW9U['O@'6?L8,!0&\C
M$0"BM70!$``(\0"+VTOC^@=81X0!D#"+>WHP2@'L<[D/0P&+^P\&P+F2.P`4
M$$8.(#H'@+@"41`'('^>&P`.$[J("Y>/Z[@!(``!H`!9V`BK\KH,@+O4BC<E
M5P^H4FCBVKH!$/\2S[(3V["XKS$`G]L(GMMN!Y)/H:J>$PITZEH84[J9AZ@3
M\)2-V"!P=2(=3N0!4&2B`Y!ZLU>O`.AJ"O`I%5`!HE-*GY<`G*>%8$@G2RH)
M-%`!+T`&4R"8<Q)NMRDT$>2W80*X@5LJ%H`0L!LIM+(3!%0`IB*Y`F$!OL((
MD_LHHC42K(*[%OS!-$(`M"(9?T#"`@&["B"X_F!^%$4K!1$`,3PQW+``_V`!
MBW"M?Z##_81U![`)!/``"(`0,-P:%N`0".``CE``#'"[5LG"HO4`B[#$!5/"
M1&'"/:S$N.4G40JS])HB4*ES#REY>P,]%F,`#C)!8^$99GH>$#`B_T?_#9@3
MA+9'>]M@Q=]C5:C$#8"QMZ$06*"@`RD@!!NP`B2`K+:EB^7+4.'!.`J,J`S<
M#HN[N,$FN#Q1K97+N#52N@.TC).["(Y0K;(UN+Q+R@3@`)IK'*-,A(L@N$$L
MN:;R#P6`=06Q@ZJ,7%+:"#K,,*6B>9N`=52L>0Q@P1FR@]6:PM6Z*0Y`,K&L
ME0HG0+W4<^.:S.-*`<LLJ8$BM8S17U<59>R:&%1):M$S,-JCRA#')5SFD=01
M`9U3K?HP(YTY`9=2;T18`$PYI[9AE,GJ`R```2HP!QU@'W4BR((Z3DQABY$\
MD)/,#K>K"<W+".>WJ+GDN3M(0#RWP9+KLP)`_P&+FEH7[='X4!*H0JT=_=$;
M33X/,*X[:\N:L(PE?2D&X+G8'+D2'<SJV4M8YPB(B\ROO*A4O!!"&[G)7+F[
M:\K63+A`G2^:-IE/UH=%:QB8B8-6"2JZJ[GF1V_&`2O*P0%=;"N`L:8/4Y&?
M`A(A82'>,#M(<;&@H`9XH`!BT`%$$`76P,^%5Y1(<0$0L-#1VM#J(+C<X,(^
MH5;:Z1NL_!J1&\HY_<M5O=@V8B,6'+HPRMB"RS`-0<PVXM+C:L&-`=@I_`_P
M'*N]\C:">ZVTHL.ZX=.R7"K-S`C/[-B7S1->:;1)O=J/K2]+.YU"2Q']L+V$
MD9V#**41D<6)L@T#</]XWM'%K-9V:F8B;KH`"^`0L_D-+!8T8?@)1L``&5``
M1<`%18H7?[5[X/T)"\K7?>+7?^T-@@O#!*0`1`&$F9'$'1TIBOW9(`+2C)`W
M]\V\>&/?%E`2@%UH`@'#2`3,X\K?1XW![KW#Q<PI%H')GJ=^((+,"/'`Y.-@
M/Y0`4/P9MZN[`X[-J=%+M6WA!'!Z^6*]D9&A"BD1IM5/#X.,+_@WC0%/FG=9
M8@5@1J1A4$<L[F=Y;G4^:?TSE?6V>AD$=@`#7K`"*N`"Z163JG><$F=`A6G>
MVH#>Z>#9'&QJT5O29_VX]9"ZCNNS+?&X2/4]9'ZXJ3+F)9?EK+$`6IZXMZS_
M58O;*;:K=++;2ZB"NV9N'$]<<KT4NAM"T\91O*^=N<G;+QN.Z*^Q".,JO#^4
M-E_L-R[>S54J('RS9`UYV4Y&$`P02T=:QVC'.?/*B#-COP*(OYX7#GLQ)KL4
M?4Y0!P;@!G*W`M\-`$2N4PVWH!D0CE0^9%9>#@0#M(KR8`^Q$;JAG@_CLJ&"
MS\6>&LINE0_!,3.+O\S^&='3*]6>"59Y[&,9)"S)"5N-L_B+OWLS[@^1X"B+
M"392([KQG/G"S6)<W!=!X_5$[Z."$24"3QQBGK%FOMH9H[5&$IZ#'?4;(Q9R
M8..@'^1FJ)\0?4L0!TG0!C"0K(9TP+VZR&)A9[T^_PF_WD@MNP^0"4D-8N+L
MU-3C$.E-JQBJ%;J[/;CYL&X6.7!<)F>YX&J-<"$-LPVSV9+D`)"U]*S)&@DH
MX#LDX`9W\`0(_341]G;9D*0;7VD=_PTZ=-.:L0">^R'8?MM%7<E0W-%S+J6I
M>^@(.0[U??+MX,3B0`"BA:UHW_+,D]OPYO96F;T#HFD-D:ZQ84-1Q0"I?"$]
M,X<`,''<,'9G3;VJ/GA[)0E(@`1!\`)$,`8G,`0UA:/CG7'B^*H*'/7@`+T7
M(O?C8,(:_B'(!6?Z4-2:H%`%H+GJF;MB)#KN[=M8KMYB+@XVK0[);`_:[`W)
M[/G+@RB?Q40J+MQ[:*$6$/\`H`3WW)DD\:J>&B^CCY()N$H2GI>VYL#63CX)
MA*P"%X`%-P`%-L!CE!7>^EGYYM'\&Z_Y4G\B5)\A5%>R@),AO]$:@@O_#Z.R
M)4'Z1O'*')%5"``(!G^#"0N#?P8(@P($"H0*#@Q_"0$"!0D&CHR.?P%_!`1_
M!0Z"?PJ0!8,.!PFBI(>'C*5_C)8("`H)J:>NC7^KK:.SHK<*`PR1AP8.J;#.
MS]#1TM/4@P8+"*W3"@\'S-$%!`L$S=7FT@6L!`>^X>R<A^'C!0(#`Y80$Q<`
M_/W]$@=2/1@`:H$%"@P*W#KWAT&%#/TF5&C@C]^)$$5`R)!Q@HR7BA(>5N0W
M`0+_17\A(8Y<"2""2I8P8\J$R;"FS9LX<^J\.<!``$?W%%`XL&``K05(C0H]
M$("!@``!"'@2.@"A@I]_%CSX)$#`(%"=G%D8!LN!(F<,`AR@`+1HI0%0!2PX
M8"#M6D>>P!X@NE7<`4Y0C1*EL/50VJJA#A.&2N#>IU!$UQ8(_&>OUEB,![AM
M]6#N@9V@<]9S/,V=KVC7<(6>]L"!,FR<4FN#E?H4@@4&KKD<&0%!@0(6"A_5
M19?AJI,M(XS\",7*BRTYDCCQ\C'BQ)41E%?T<'WFOPG>PXM?N;J\^?/HI=U;
M>(^!HLFT*!2X^N>!(@.?P>8-E>#SK<9>,>#45Z$$8,\`_UN1]@Q8SA2'0(*A
M(%!@?(,XN-5^]8BR0#@6P)(A`X9<5<X#@C!@U`"N"?``6(Z!HL!GE75E5(8%
M;'@(BQ&&(M\?%DB2WH^P)'`;6=#4)HV)%GB57H;.C*:DD\\@*8`"ZQ!@(@08
M\-,`!^\59TU`_?EHSBT%:%D!>!5Y@80.,L3!00PW,`$&=?UDMU(#%7C`FW;C
MX3G>G^,!*>B@A$X3U$^.%<#``YXPZ0EI^X4UP`'V3!4`!4HZHQ\H!`BBH*:A
M..,)+2=ZI1^I@XR:X7[BV(,I@XL8Q>"G"AA@@5&C$OA'BZ$R@FF&K5:5*8NF
M$B``!?:,4RB05+)33C100HM`3__GI0./,T)ZJ<"0SP@PK0&C'/"`MQI$4%PA
M2BID@:(+S$9-`0@.`D`&%4BPD@`,C.#$`S?(H`(6_N")9D490&!OP!!L`"@_
M'.RS\,,L+2OQQ.DY=DM0%!C4J%&2*AGIHQ(R:`&,"TX("P*S*)!I(K2%A2JO
M83D::UB<$N0BK*C.FJE=]KBL*\QK:2;C)S:?]MBNQ<K%::84FQ?N`]="DRV1
MAVQ+U[,ZM48--][L4B76V^)6@&Q**M"N*/BYAA_6TKPX2P8:O%11"B0TP4<-
M&+2A`A+]%'PPP7%7=$&]$'N@)\2(^]/TXHSSY-55"S"R%7PRCV4*!4=[8GE#
MIES*](W_)BMS5GVCFVV8(6PATB',&P^2NJTT$V#6(N&$.O/L6<UV3$-&I9Z`
M`\369RR,!PR-NR6@(_U8(8\TCAY^V6S=#3G@B$.]3@*0_&Z5CH2K&BSACI6(
M001,V]@\?R"P[CGH*B/22D&`\,`+5G`!``HZ]!WX2"$YK'^6$+L`!Q)'0``X
M[X`(?`9I$%")50C``JT+RS5,I(A33;`Q/%H1QT#ELT$4@`(IPA0L!N";%T7H
M&+A1GGZ<PK%I@4@0^[E*;C:$,[DD0(:=@84%$,``2J7O'C:S@`(LT*-Q)``A
M4NE*NV1XC7(00(@PTTH//Y?`G40+'>N`FC2,=),:N<L<7#0`_PFI"`D+%`5%
M79F2!X/#$#'.IC'(X8<.?)"_+L@@!$+P`9W^40'_^:,D<01`2@C8G0(^K(J(
M=!YIKF()ICR`+3*KCX%2<2I)MNM8OQ$A!W.E#`HP!EL+H(PHX%(8F$&02?`*
M0&$B90`*4$`0.*N145IYMD,<D3"&2.4`Z$$!`AQ17!$R4$]DB0A7#N-8`#I:
M(5292/.$C6K.D,V1[$%%:N"L)M%ZX.ZB`2)GI`.:T%A%.18RDA38P`=&N($'
MMA"$/9+$)-CA$Q\#^;`)_,V0@&JF/O?).'I$+19?Y*=`!UJ-9EU/&E?L%@*\
M5(W^@$9(*30%MYXAQB!%CB$+\:`WY/_5#R^,``0V:(((KD""%52G3O+LA\#V
M1,^'92"E^!0/06=*TYK:]*83>]H_G?',MG7C&]-@Q6JX1CUY'+0QY>AA0,%!
M$%M2BZ/\,,`(3F"##6C!!?D+6)Y60J][`F!+"HMI!6*Z,)R:%9L;-`=<+&"[
MY!TB@C?A9$VN"3Y)?.H<=*7H:O)Z5B!!;ZFP,"C;/,B]:/`U)^[0XMBPT9C1
M(2(@[&-H(=S5#QT<H0@R.,($9'!2?OB-J_M3*>'(&@$`DE6F?4TM.@`+#;DP
MHJV#X,5;1<%::LB5(;*%1O!L<MB9A2:WJB540J&ATRW"!EO:.\]?"2$`=SUP
ML,]PQVSP$[7_?J!@!G8X@1V"@(+.8B"T*'G?_TX+@`Z$E;S>"6Y?+>'+44CB
M$M;P10(PX8I2``,4\*6%*1R1@$9X(K\&,)HN8NN(`'M,MO"E4MED]ZQ37((1
MY5`(+HZ1#&L`-1ZO.!J5@&K@7PA5&`1&!BVNMXE%=(47H[BP*SC\C4MD8L0[
M56]@)SJ-Y4*+FH<0JJ"&&]L#?"\:5$+?(`;"MGY,`0@K0$(*/G+2_JU$(H'L
M@'A/.U;TIE?&.#706J95B0P]LBK&\.%@+F0@4,C,1<@*):J^G+KZ%.8`BT)6
M)3K1PR%##5D(^>!>.@0ZN20%,U'1#%PXXYD&\>4Q2RG*)_!,"0-5_V8!A/G$
M7G"I:`;@&2\(TDNA<USH1\[E*'2Q-)BQO(VO48/'MEQH@&'++!K3Y@`6<`#R
M3,&(O8`K'AE]1C^,`($@K&0#\-P3_PI)7@[(S<H1([5-FU*94*QH5:VP$HH:
M$J(`T$-6QN(8J[;B$U0%(-H^RIXH//$7X87%VC$"2W_D,F18F%D^]$E>4R7T
MAQWU*!9&J5'MW#/N70D"7Q^JMCL:(A_X.,8!%XJVL6PDQ$4PG!*.6(!3,*<\
MA"N[-*OX,9!=S5,(JGA0@GU&K09B#[8FQ)L;C89U09!5E=II)"NM2'9:&E,)
M'`[9-+DX34?%JWHP:1`P0QJPLIVJQT"*5/\_AX5\&,#GW[$C+#WZX*XH!9>E
MJ-C,VG9W*'J.+,W8+EBO"H6B&%4?"B#`*T,'^FM1=6Y[^'!4G&(UK)B$]52Y
M/:TZ+Y*/JQE84S^C>(5=5G%M,L%I5!8%%<'3S?W1U<1SX+S(]A/.<Y[W@?(\
M:4`<8;'4/O0S)S-FF7_&6+3&J$E-R"Q,WU7(0O'`2SF1Z!T,GIG'8>8;%8U*
MC<@8!$4ACJBD'6E@D5E40`%#`M%U[ARK>R<X!<[*QVJ;Z%B%%MV*B.-*#'I\
M[Q8)H7L(.7:7\:,%W+'QY%5D0\"/DU><\P5Z^<?4@WF(\/DOSG));--H/RCK
M'*G@;X"5W08O`C'_(6:3?YN3$.]5/'V6=?)6+/!W0X=P/+5#`)/C"2<G1AF"
M.^T2?%F7.O3@,J"`.Z<!@MV4/K+&,1R8?>L76QRG=]'C4$V"8Q+C+>+"`#NE
M(CX68\X@1RT'`-]U;/PP2(RG`::5?AY0?NEG0"FX3^U7=U(4.8Z!0X8P=)2P
M*/LQ00R$*DV8*69C"/5&"KWD,DA18!*'5`AA:?"@?)ST1,:P>5*$@+$5`#-4
M.PZT>_;A+6>W1'"80QI8=-/R0";C(G#82LW`1/*A%3ZA,BUT#VR5A-LC9`CE
M=GPW-13#"+="=9."(&)B#BL1$BW%'5$&7NDG0$<X$HRH3TM(=,N4($I"_TNM
MD'8,U&U@P2A2@2JIV""%X1/8H`BCT@V'P"AGTTJOI'61M`B]!#.U2!O&]!CI
MH$ILH4N_H6BL>#0RXXP>&`K`.`S7.`F0]F\<0XVE6!K0@X-#1A3@Q#4?1U,C
ML0$<T%(O%UXTAW,:,(H5\8WT6(_VJ'-B='9`MB%!=E#>E$7BJ$\!TXX(,S!U
MLH[RZ`\;T`$)R0_W^)`0&9$WI4V9J'88=H/&%3WH:"9&.#A>M24P)8\9@``-
MB802>9(HF9((U%.J(!RT,4:/>%<"%2924TOQP%#.PX4JN9,\V9,79U3]P7T4
M*0T0U7P)!")+Y4:@5)&-HY$^^910&94U-38&$O^0+`D-(:=/:Q-.D`4+2(E(
MBR*58CF69)E`")>/*,A[CNA-TA>0%*,^@Y5KRM"5B*2397F7>)F7Y_$BS3"4
MX(B1J.%CM25X.T1<3>4,#[`^S=1P>MF8COF8:O4Y5[E%,'EC,BDQWX25.$D,
MCI5(RP"9H!F:D&EQQ&4]W+<(M\*45;."A-(^SS!9*&>4SF,,HEF;MCF6?`F.
MUM<VK!E;?D<H2E4D`_!%-#E0='F;R)F<)WF9PIDDC>B/X-.6@[*5SR!.36*3
M`I5ARKF=W/F-I,D0WO)4Z!".6R28/T(FT(">KW::B"0DW?F>\)EW9L.>&W<U
MU("6,9F6-0$<+AD/APG_"XE)G_$YH`0:FM"'$T;%GMI4CKU9$VZCF60A804Z
MH11ZF["S&ES$FV(#9*:9$ZX)2I^3F14ZHB2JE_IV'E+RG-#E/6X)/NN0E#IF
M2W!V'E`!%?T)&HYQ6],@%:Y1HC[ZHSMQ;TOR+>^2H12U=]4P-D_'E5AC0^C1
M99:FFCGA&/H)"TTAH$":I5J:>H)B-;<V#2DJ+3[6?]B2",X2#>HYEUA:$[D"
M%J/0#IAP+;6P"*<1#O+G%3=4878Z8(0P9PI&"/2EI8*:I2=**`EZ:D1*E`AW
M(/:```[`6O!RHP'Z([EB.9$A'W+!4(HA(&J1.I-V48_B%EXQ&)JT*U"Q%,QV
M_XF#NJH^*J37MYOU^:6_M9D2"B3"Y$,O4B%=07&',&TV*`@/(FZ,)"DYPF[#
M.EOV\5B[TJ.LVJP3RJ5-$Z98M)8X\:$:)9L[,7P$@!!T^BMXQTFJ8C,6^2C%
MHC-6JCP=XZSJ.J"%RCCA*9M&.E<Q2@@S.BBYDGI!$SE)UT'A:J[D^ACF.EM'
MQYSK6K"UZ:JSJ6KL*:U@I"S7.9BK<:_W0#Q#HW3\Y0"O,Q;TYQ7_2GP;>ZZ6
M(Q3H:K`D:YO0FD!&%9#>HA6U!0FP^B5KFJUIY`U'Q`!)M*]]2!`NA!LRY`!S
MUK'^90",PC2>,$$D-+(EF[2/V:Z>^;+19:8D%'>-`?]KL@J@BEDH-1H`OI$^
MPM1_>.>,J72+7<>Q*F2-6D:T0S9)2*NT;(N7"*M/)D*PV))&)X8.<EEY:I0[
M;;NWR&DB-"6)Y2&B*=A*3V27?'NX2[L`+5I%YABS4E.O33-?.B&YZD%%C;6X
MSB"WB+NYW^BH9F4:F.L,P-`XFFLH*%BZ-H&ZG+NZ>;>O.!6OIX8@CFL3&[8+
MW7-#78,(0,5>NE!ALF`*N5MBO"=_RF`L'@0\M]M?\^%+DP`)/O*$QLNZTIN"
M#A"Z_/1`WB".2NJ4S#(4BJ:!4E$)G@8C6F9V<($O!M)+X8LOEU89:W%17\%H
MCR89F6H0DP8O>Y&J4X)G4CK_O?X+I+5B1C;C%,"S4"ABO3G!;_"QA_<P&1$G
M"<SV="M"(KRC/`<W+I]QK/Y&"S1(L4_Q&W-6/`/0(?@!?/R17/^;PH)*#Z_5
M?Q";'F,7*1ER#W1G,C`3P*72"7<7L&6GC]U:L9>W3>1ZB7"APD9\Q#@A%!HC
MC:52PR[#*SR3P]JZ:A9)6*$$&6D&Q&HWL/6P>DC\Q6"\HQ-X-'Y[#_#GN:>X
M.V7L%2?(,EFQ,ZE@@1ZL@$`D"*:CB*70OV&\QRH\AY[@`$YX(N1@B%AQBCO4
M0X*L$(H8M#Z;*75X"S5[LW1<#Q)WM/=P07C'QYJLPLOX2`J0#B!D%(U<",'X
MQ`SH_THYU,C4V$HP.$IJRT#VX+5%AS0(@BRIX!B^^,*;#*0)P*BLMAKS81,/
M@`G82@V#F5;!3)23<*,&J[J[K*Y*`PH@E![.61/WT%OGP*O1P$G5'`V8X[HJ
MF5\VH0OP5:4V<0G._,S-^G-^*PI,DP"9TH$>\BP.N+;0T@S7'`HJPS:?3#O;
M;$OPT(&<1!KR?*[U4-"T,+NMF\F1N2I+@B"ZK,[KO$$5=41JD0H,I!:BP!1,
ML=&7T@J5PA;K:Y'BHHQ,00$@_5II<2G78B#K<M(I;710P;5PZ-%%_!5Q8=%T
M"1>5L!;,M(PH?9+@7`TTS-"K,=027;+1_$B"$&LD*!2?'/\Y#K!+9.<`)+PZ
MJ],(N7LTR((T5JTZ)CQMVDEGHT#5J\.`E5`(EV`(7TUV/<8,P0$OS$H)7?%M
MQ_(+5RW4!#&<7[%]B,!TA='+``(L'`R7HG#([YR:IA!@?%T?L6;424VRQZ(9
MTUQOH#`MIG`4#_1>FA,R0#NR)E(/GM#9H$"NH#`R5?O$G%VV83'5!;'9_=:K
M')L*[5QTE>/90DT!1/09@+P.BN!UK_1!`^&M-$,8/K8K)!052O<@/W$L1&0(
M6:1HD;VW3.(EPA0OC.(Y`VN)K*T@'X1PN/$91%PJ+@(7W#I;Z/K9>7%&PWET
MLNTR21=!C\+=$LEN\"%K+R,(*Y+_>A\T-'FA"";R0;=L.]S`>;E$;M$&V=.]
MKDR"29W0#&N=TO=F<#YRRYOW*;#V1&RT31;N(J8P$.>Z*ZO-.I]0&*DPX0,]
MVQ4\6S+#X7H]R^.3PW''>;C"Q$Y<-8W195D7K@O>MC_75&Q4/G)!#PU$U7^\
M2^P&,P?:&8P@<;^`Y(:0SY[[U>@]U060F+LRR`5R"6QA-I"P2SX[0I(0U]/V
M5M=6=%;.;O6==>+P`"#.*SKCT!IXXZ*@V^N@Q3S>XTK[<YADT9YZ*1*WC!V]
MC/I[-`RT,M^6%JE`Z';U6G[N+J,"U*V0%F87"FJ6T9/#%#<]"(>NT\\22M/(
M%,RVYD7G_Q@5!<4FZ-],+.!9CF^#H*]9AX!3K>=**\X)[<X0;@FG\,F6D"MY
M.V"R-6ON/.RQP`FZ@&+"O@CS#-#(#J@>HE_+CM`>9`G:D"EY2^IAL5!?5K8?
MI#[$+<,GDMP$KDKG>V;C(-VTKL([Y"U\MN`)4$J'W2,=,LR((`@)P%;#_.Z[
M4N_+?-@/TE9B!`H,H._[_@FCE^[.JN`>)([+U-C1H/`[T1@0VPJYX3370O#F
M0.]ZV5]`5\P(3[(Z*A;F;$U`<D2_++JA@,TUT<V+S1#I?+W]-!22D1[`]?'=
M6="CLL\`5<72CCSUW+Q!`C[)CNNQ$&'&'C5\;O3)XR*S(>U%#__T[LP)!(V#
M"&T)+Z^$#<6LYE$(YPA&**CR-A^:GBY!4/'GJK2^8Z^U:B$5J9/1L#1HGO#H
MMN1)*"WIR(TY;F^EDP33=[\(C)'CS#;V;\5`[,#2%MT4Z^LJ]8!!_3WV##04
M(Z]:8&\32$W47W_R86^;3HW&63'F"_<;`_`B</T`<MT)S(`-/.)+&\(\ZY`*
MG3U_AU"89F'E6"Z[:@U_JL`*M+\ZI.]!Q2`.',(CKN&Y;W7ZBL!6#_+DHA^I
MU];?R;KYC[HA:1'Y_,1Z[K$^2')#U)0;N%`*K*<BZR+Q?>TCT@:L$34(%)0*
M][ZU^`*7<M']++/^E(3YF2^:ZHO94S'_"6Q%"1H/"`,"?P$%?PP#A(:"?P0$
M#@.."P*.?X1_%(9_FIB:!0,,FP%_C)"2@Y8"B:"BI*B6E96JF(X(B9:*KHT$
M!04*!*N#C+,$!P$*M`2V#@^6!Z^XT=+3U-76U]C2HP04#P<("@$/W@D+"P8#
MD;.7W-X#%A8+C0?<@P$##\<'W;@"XO`%*-A*U.Z;`0H'$J3C)3#=KFP0(TJ<
M2+&BQ8L8,VK<R+&CQXSWTC4;=3``!0)_'%"XIVO4GUDN&3DBL"#=@`25+KG4
M%HW1)9DUTR7H%\S2*)^P4,I*%!)?M)B#')4S6718HH#-"-E\D!/IQZ_8MB$X
M)&B!H5"5!AAX_WEKFX67\BX=0,9@[+$_S]99XKH7W28*O\8BTJ7VC]^`OU""
M7<RXL>/'D"-+]EC(DJ%1%-"BI#N)4>7!4'<1R&HHYZC*"EZA5A6JP-&HI*/-
M8N5:%ZY8*&%Z>FI))@$+O&8+&S3+7]S*FY@Y@S;YX[;<`PHL"&`A*DJK1A^N
M.QV@.]/>`O3:?NAJ*6'KX',V7\^^O?OW\!=;:*9,9P(%"PC@[[5`8:CYGSAP
MB2Y2`89?8MG-]\<#8UFB((.0%/#`6XPD8.`"R*222(03CM<(?=#]H6!]N(3F
MR``.%&#!*J%@%\DY(M*'@(4*)!``<_%9]!Q;R1F#(';LA*A3>`(,!?^5>$AU
M14F(C/B6GF(Y1BGEE%16^96%)B$S2CX!'-`,`MV-!6:1*QUP&7@/@2D.>:-@
M"1@N;BI0@#$4#.63FEEIN`F==D)C0``S\1@G;P02P$!W!QSPQYA6&2"/HW\,
M"B9".%H9EG8#_/*D+@(H&@ZFV4WRAP("'GF+)0B@)-UA@)G7Y""L(FCIK+36
M:FN4!0B@"2H"R#E4I+^^9$BN_5B2@"$*9)C`K\FF8IFNTN3*";21<K)LM,%2
M>ZPT]S5;P*_22H/*MLU>R^NWPRZ;(;3A&HONK9>:U\T#F12CRB#A3+CC=HWD
M!^.1%*R52C<#(!#00*"^HP`C!SND'KP01RS_\<045VQQ9(D8L%8"S20`SU`*
M6&#``[^BHY!A&V=U"S"*W4+RHGF297"D%LRL<:3-J,+QKQ[;+/#%0`<M]-`/
M>U6-P#M9-$``P4Z4]'J,K/7PT%17;?756-_Z\+:7OH21`*+J^-ZQQ$"9]=EH
MIZWVVM,4X$"*EA@`][<X^4+`4([([6ZR>L=-P"`V$I>*?JG\TG1R`CN0D&R$
M)]>XVW`?<[<TO\SM0.,&_&W9Y<AP_<JYU1ZK.$X$],WVZ:BGKKJM!RR0Z((4
MN`Y7ZQ8D6J\Y_`A"TSXHT;NT*MU=<N@^6MK."5X+\.,=+@Q0,,";K>]C2/2*
M=KE/-`H@5!,I-5'0_XCS=2(O_3B1QM5).&LE)(AWNU,@X.KPQR___(V!;8@%
M-B*S``/^]'(C7I201S@^08F,)6(N"T*)2T9Q@+4@8"2#"-LA!%@()`V"&0I0
M%`#M)Z)P1/`5=6G%71RPL+4(@`$97$ZG4M(@4C"``0MX0$!<00P#TN^&.,RA
M#JVAGG4X@E_E:=F]S!,IQ2DP.RZ!"9J2`A[QA.0`MZ`$!99$**\4@`'Y0-X#
MD$$O!'RN'I@(V<]FD@[AE(U'.TRC&M>(NAZN[&]MV90K=!>B?`R`'@,ZC9Y"
MPT0:GHH0,TF?\R;Q,#Z.*G86&(4"$+`27=$$4'@9Y"!$]B8-@0)0UPD/0?^$
MQ,9.>O*30'-`@PP5%P0X`(BZ:Q"&Z,BCRO!E@6$TS%L,*4I+]$<\;\K5"@%8
MRT9\:CRC:87`4L4`0Z!CE\^0I?F,<I.:#.>,X@&E-*=)32JA[R#2><"?4A/'
M\@0`B_)@Y2S<=Q`%AF(4MH#A6@R)O@?(0SRV$`!P+,0``MSHFIF@Y3,2B9=3
M-I!!`D#`C#)C3WQ11QK/(X7W:-@?(E;SH1"-Z&0.$K#R5125E$"`.?IDGC\M
M0*`BTN,GUC0@KQRD/VBTS-*BLZB0K(6BZUSBGL0!F*DT8Z0L!5,Z!':`]^'"
MG8VXA2"D$PE.2O2H2$VJ4C%2R:4Z]:E0C2I%%JG_0:E:]:I8G9C1/#(UBBCD
M<%D-JUC'"I^M=J2K9$VK6M<JF5^\(G-O)1PH'!`*QOT,KJDHP-W<UIH$4*(T
MJG+`S]A*V,(:]B+9>UXH?/<_WP%F`#5A6C_NL0`!,=8>=VS(C<!F#D55(E$Q
M/*QH1TO::50B`8I"X"OQA@B4I.HV8]$K7KAH3KST[F^2W=\/KV*6TOKVMVR]
M8SI<D@`C6I`\AZ#.SXJ+1Q/]38,SD40ZI@C<ZEH7JP4+E!WI<=R'&<`8B=CN
M$0OEP^@6M7'73:]ZD2HR2YS3$%PI1]SNA=QK?<J5X_4-V%"5N4<TB%KK#;"`
MI>FH>B:"G"?Y0PQA2%_U_S#@&0Z0!X+S:QU_:%-R^@F`QGH[X`Y[6(WY0*E'
M06K30D4CQ$,9L5W0M-OG20TE,/VPC&=,V&C2^,8X5JN-<\SC'DN58SX.LI"'
M3.0B&_G(2$ZRDI?,Y"8[^<E0CK*4ITSE*EOYREC.LI:WS.4N>_G+8`ZSF,=,
MYC*;^<QH3K.:U\SF-KOYS7".LYSG3.<ZV_G.>,ZSGO?,YS[[^<^`#K2@!TWH
M0AN:R4O2W*')[(_N.+H['P6K5I?7D:5UQZ?P*LFC)3B11O\O8MER=*46O4-/
M/_K1@Z68I?^8$=<X^BT0^].I'5W73HL:8BJ"DJ='3>H<FGK6W:FUJBF]D4,]
M&O]BX0!V=S)!D5W#:RJZOG6OV?AK8#.[8JON")>D;:MM=T,9C\8T1)Q]JY5`
M,A7<GG8:R3TJ39_[AM-Y=,QH98P`<-@PCF9U-MA=*T>;3=V?Y'>DS+U,^27;
M)(B"E[^E4>^%2D3@LUHXP*4)<7MV!V\_E$9_!;;Q2"TMP:9M./ZP-Q,YT8LZ
M&8*AO?_=<=DD<N7'LX:L`Z`FY)#<$0J@*(SSAE-P:132,_-;Z<05J&HX>M[Y
M@.(TOHNH5.^Z`&H:N6FG0P&IXZ+CG;+W^Z#>':LSS]+W$';F\EV)Q*!W$X^D
M#J\GCC:(VZ@[:\GV4[K3,N_\NH6HFG7XT-V=K#O:+#/_#U-/B(WO4YLI&VJJ
MDZ-3_1):$YP4[%O\3`VO"8L_3>[4,#=U$3]KO'O:W5F*QIQF/=A5&]O1*:KW
MLIL6>,GW!MB-[SLN1G]JQK,];1`G!-U3XFC9./I7EM['K(/5^GQ/%E&S?OFI
M@X7YMW<^&^9^B[GQSO<NO1KRUO]]2X&M&.=#`_764'[8K^$`9?_,T^9^--ZW
M_>BF6CIYIW9>\G%Q\/AK`NS'9K?X'YVAVZ\M]_7V%LX7+.5G$KB`?Y&0?E!2
M;_EQ<L%3?2;Q&X:7=N^&>6#W0.G7?]3@?`*B)@47>Z=V';#G:O<`;L1F;CXU
M@#*G=S/2-IK'(']W?,MF@@9H_PD'=Q(UUT+X!QSIUQTPV'M[L6Q<$6^?AG^]
M1VZ>EA\7Z']LDWMRAX*X\'*PAGTT5WVP1H*_8GF\XFC7IGJ'=W!3*'<'EQ6>
M)F[24(!W,7.'8VI**`SJUR'&QF%@%X5=APL%Z'#5H'JG9@'',W-U97F_@GX9
MHGP9LFV_LFWW)W&GIV%Y=W'.<&G59S82!X*HD'@98FEXR(1GXX24%G6X`(6O
MUQW]9VZW4`"9TT)(>'0_Y7IX06QR-W/]%V__)@TO%Q<')V[HMQM@IQC(P@P^
M97E7MVQT>%#70'MZQPD>2'_+5E>>UD(SAPKQUD(D6%=@YPDQZ%[25D]\6"*[
MQXWO1O]NT1B,]J:!FH@UG,@2A;=0SM=_[S=XZ$@-6EA]8Z1]H7@J<F=Q>,@U
MU^!H+11O4UA]U`=VY!@MRJ>,CH@)<)<->M6#QA>*_\@<GR>#J,"*K7AN[>B-
M4YA[("B)W4B)1@&)EB%IY7@UYW@+!X<,LK9,F(=]K'9%C/1H6RA[L`"$]7B`
ME+:2X\:*B2<NDQB*3T-_!K!_T1!O:W&2$6&*>GB0/3D-[.9L94@D?M<@*SF)
M`B<`[O1H'/F-MZ:1([F)Z88+`0B6":DF>+>2*\D-P!:3G]8(-,F2-HF..)D-
ME@=%Z4"$T.!IPH9]535[-7=J)R9X*5D1OZ"`'_ENU-"46ZG_;`TYE1W);BHW
M:UD9;;+'E5UICE]9F%#")6-!E.[X1YBW?^FGEJ\`C&]ICS=)>!"1E)#I>S)9
MFM%"A,O6EG&X?=1'#=\R#<[7%AUYF-SFE(IYFN^H>UHIDV@8F[M)E8G9FI6I
M-F['BG%HE*X9G>A',JG8FJ19D]@9E\7XFPDGD0B%FI976;_0EB2('PEI#5SR
M@6XIG+/(FFOIFV$278&$G9CIG0'!C^=TG(V9G&NYG+AWF=O6?R0H:WNYGMC)
M)==6G6MYG08J=P@J&P8`8-*PB(HY+5^)D_5V*@Q:D3,7<](0H-,@=V%Y=?SC
MG=5G4,%V#8PYG/]S>JJAGRPZ""2(_VE_(Y+^>3$"AR5=\IW9-V]F"9RGXJ(G
M>AMM:8&4AH;]]W*9B`LUQS]0B8:U)G`X.8G;)@T65V\%NG3\2#E;&E+V%@W1
M-Z1B:FXQ4Z/169]#>ITD&)DF.GUP`GXW2C5/220.R(C18'DIVIEZBGWF`W:B
M2:0/2)]RYWR\&*;4$&\?2(*H>*&HV:7W&:@02%+64'\^E4&NAX9J^3Z(*9-*
MJ@DS)S`K*IG_8WD98GEL*J:=.I,'&:="4VVS]H'.UQTQ]Z/HF(/R]&C,R&T,
M:J3O2(2GI'RV-X;4P(`F>J:VA'H/]F@QUX-Y20WBYSQZ>&TW^$*JMRZ]*6TS
M=P`,H&G7%O^JWIFME"!O<V=O`N``?H6MCO8,FJ:>K%HQKMI^DI9^^D:KMU!\
M6"FF;`FIO!JDRL:N?D@-(.J1>\JDO\D<X@<1V?.;9L-^ZE>L[`:;]TJ?[.F=
M]3=KGGEJX<%MJGF>[1HT[PII(JE\LTBO8OEHD="=[+:KKDAX?;EZU:!\'@J"
MFLJHP7E((6AI\X:&^G8TBDE]QIBN%MJ:[*:CCW9X$HN<,LFPF>%HG("GF\5M
M1-NE'1LT"F$35JM-Y`>@(G%B6ZM21Y<K-F$(57L35V<37.L4>]&UMR&O-KHB
M!6,--M%]-G$X#Z"V<!)O[I,2Z4!]A"H1'F-XML=U_'@\8QLLA1O_#0JA?L=3
MMVC;&SL%)W.[BMXA)S;Q"BK"A<L2N9#+A>TYM6TDC!KA5P,)&>$QNN\1'C'K
MGC9J#422NK.'NARA2ZZ+$:FQNC98)`@;'IY+/R.J5@^ZNW56AFOUJ/\(O&\&
M1?R75K:0?K9GO&O6@SN+5<\ZN\Y[9F#75&.%I\U:O6L&"?A`O5*E"@5CN]P[
M5JD!N^6;OFP3C^K;OFC#ONX;OU8#O_);O\\FG_(Y`?H;7?;;O[/2LJ<V`0`P
MP!#0EOY[P/%AKX\FP`1LP`@\;:W;$7Z%NSEBA+/&P`!0P)#ZP--VF=1POC::
M;2#L'GX*E41"`!"0PA&JNQPL:![#D"SA_\&FA9IZ:G'1"QES"(\RW,)\EK#`
MQA3*R4,T[)HV3,(.K*K]R<-_UHSRN4Y!7`U+TKQN&<6-\6#OH`GGZW>;9<*4
MD,(0L,)KI\3!Z\$[G+MN6+/BPL+8("?88H/?8`&0@,3<&0`8K,$_*<9XEGNW
MQFW95L1Q`YNDF*^W\+<F>T>8-+DU5U$1EF\/@`@/$,?Y.L=T/,`9?,1X3&?A
M@8:G!)67(7M\O#Q^#,#&5\0^?`^0:7'P=VH6K&'XH#ARS)UU;,F7+&=S;`^>
MW)I]O#PS9P%T$<A%G'@@8V[/,)[Y)@"!=Q+F:6\?%3)D.!-$B+\SH;\3P+^S
MC&>U+)RVO):YS/\2B%K#RX-Y:K(RJEB8",22BX0BU)##,_S$U7QG<QK!>XS+
MH+P\/;G-B5!SQ.&F@CRNKZ"=[GC'D1S&[1QG>GS+VCS/,;R;]CQPUE:JA/?)
M:,RC`$V_`^W.9&S0J+!M!+$\@6P9\;;1Z"@`/2@0_>?'A=G/0VQY&$#)UUS1
M>5;0__-JR3K*RU-SU<%T")TQ98*^=_K0\AS1*LW2W`F^+MUF,!U!\??1^_RS
MJKS/RN8\,V/2V&RL@!H`*SW`W-FY11UGAQNB0D$S92)#C-L,Z("V>H6H([.U
M9=T,*J&8!M2XI/#5:0O799L.$H`!>&VU>LT*6QV_6.)%X5$7LIP1ZMPPUPC\
MJ)P@N%G*$85MV/[K?/DQ&NFWO1O1V([=OZ),KHS!N#=\V7[]&^DP3YYMO($`
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>f39432a9f3943220.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943220.gif
M1TE&.#EA^`+>`^8``+72Y24T8X]4,W:(K2A$A"(N6/>QD:UP35!4:,W/U?W^
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M2%A<7IJ^VB@I;P@G3D9`@"E,=#LO<PLJ.BE+B2I,BRQ.CBE/CB'Y!```````
M+`````#X`MX#``?_@`41@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FIY*"#ZNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-
MSL^Z@]#3U-76U]C9VMO<W=[?X.&WTN+EYN?HZ>KK[.WN[\CD\//T]?;W^/GZ
M^]3R_/\``PH<2+"@P6'^#BI<R+"APX<0GR6,2+&BQ8L8,^:;J+&CQX\@0XH,
MQG&DR9,H4ZI<6'*ERY<P8\KTUG*FS9LX<^H<%V&GSY]`@\:L*;2HT:-("1)-
MRK2ITZ?FED*=2K6JU7@]KVK=RK5KM*Q>PXH=>U4JV;-HT\HTJ[:MV[<=_]G"
MG4NWKD&Y=O/JW3L/+]^_@`/3!"NXL.'#W/PB7LS898K'D"-'MJ>XL>7+'PO8
M>,.YLV?./"@3QDRZ],D?%#0D6,VZ=0(6$5+0JVRZMFV#3!(HV,V[]^X*!63W
M'7V[N'&'3+[LA@&#=W/>P(7#HWV\NO5W3(8H``)CS&XW;KK_CCV;^/7SZ.]E
MWRY>@1LHS,=+?T<]O?W[VI(O?ZZ@^?/HY>$GX(#I_*!=?\^%U]]OP05(X(,0
M=K,>=PGZUQ^`PT6HX8;53-A>>/$I@.%TYG%HXHG#&,B>=^Z%QV(%Y&6(XHPT
M`J,?@LXM*&*#,M;HXX^VW!BB>[V-2%^)0";IX_]C0K((7GPPP#B?._4I:25=
MDF6IY99</O:#;CCZ]ML<74(6%9)7ILG7'`\\5L`/&]0@IYQ;S&GGG7CF.2<(
M+%3@YY^`^LE"G7=N86@-AF[!1#E5JNDH5W-$&ND/=%1`00)>S#"#%5YTZNFG
MH(8J:J80_)""(G-$L$4";H2J::<SN-$`F^$T^NBM546:@AP@4.`%$6[L!H0;
M0(AI[+'(EIH"F8\]H(5D-7B!;&^SBF,KKN!$*I.DM!8W!Q,5:+!=L=L!2^ZT
MZ!JKK*2OR!8MLB%66RN:V*[#[;WWFJ1MOK<]M@$%0!`1:[H$IZOL*E.V^<"[
MOOD7;[??7%OO-?A6#''_1A;C6]P/:11+!!&\@0=>P23OMFXL[DJ;KKS@2#SQ
M6Q=?QS$10!3;'7_$CERRP:;2PC"Z+$=,[\M$5Z5&#2!O-\,8S`U)[,X\)^S*
MSV(&NUO0@Q5=SVA:K#+T1W?<T;5A,;>2P@_*]=;TVDU#C>[!"9/YP!8J`UWV
M-BYK/4W>$86-V-VKS$%WPVPSQ[3;TZX;,ZU4YT@MX-GP/=77/DF-TAU_WQUI
M`0R<ZUSA8S!=^.BDCZZXW($S^V[HK(?>---8=R.YWLJD&K@KND+^4`3<LM)L
M8]K&,@?:T\+@QL=`B%[Z\J,K\(6IO$/,9LH(KJU\<[$G1KE;VZ<4P0:$SDF'
M_YURZ/X0$S7T4`,=[+,_IQR6[Q4\+'-L("Y_O1U/<\V>(^Y;`C^X`+/:);BZ
M]:9FC[-6]XZRP*.DH``5(((&--"I"<(J`5LPGT-8(#!->?!CJLF@!M?10(+,
M[P&88\4<$"`N8X&G6#.PX`1G2,,:VO"&%*3`!C97@`*H00T][.'1$A!#'%*0
M"-G#6PF#,KN8I$`-%1B7CF#@,1"@[AA+Y$8%K.8;&()@62-$1Q8%<L(4MFD.
M(+C?D%JD``U48`-P1(`<YTC'.MKQCANH%`724`(*E."/?OQC&EB``#@:<@.%
M-&0A?\"H,?K$D11AUR\DZ3L(]B=GPH)A#<*("T@^AO];LOE=,U@0+"ZZQSM>
MJ,&RO!8;X6@L?HEA11/S(;@6$FXW"=ADF7:Y)16ABP',VF4C:<<+<L@F>I(2
M92\N]L`H-D=GO"'")K'XBP*\X0<_8((VF8!-;/)H&2Q@T;F>DTKA2&,.<M!F
M-K?)36^R(H4G3$L$&D>A^&B@!LG0C\W65J1O'HF8P:"5I'SX`SD8]*`(3>A!
M"X#0@LJMF0B"YFYF,$UOK!`"7_C"$(8``8Y"``(4P(`SPBDL,973%05H`$8U
MNM&-9K0$"+A8/+4RML71DY\:R"`R]%FX(L6(1)0!""1[,=2](6P.:F#"%EC`
M@#^6@`90C:I4H^K4JCJ5!3W_6Y8SC6=*!5"4D]'@10-F@"PDCE2<)E7E`[+R
MQ"@B*Z=R.R=8E5'47<S2%[UKQ=$,R![^P!66MH@G\>K9-NC\])];$^HUZNH,
MWCT@J2!(PQ`TD#3_]>8+;UB65B/:U:_2=1<IV,(,:@8L!=%,`PT`K#!(NIVT
M'A-A:F#!/C_7QHJJ<*[)8&PN[KI,?CV@@,;R:P9=F;'B^E:?82HE@U1[)H#N
M0EM'`UC^7`>UY]3L>9J=PU8EZE7;:H--:"3K#*!0O>.A%K>Z8&W_%'!2KZ&S
M`O5LD3VGV:W@F?$J%5/AX,0D7+D95Y(6<P5R0Z3<'3%WF,[%A:[DT``P/1,*
M\,$?_[I&-P8@?&$#IX(H<[CK66Y("@1D;9X7DE@,];HV=>\]5G-R*3W[=B6O
M^I66A'OSUV,@UVHCLYJ1J*3;6T5*#BQ0V1C@0]N"D<YY&.:=)3?<6>]F0U<@
M9EJ$FP:$$:\2G&CU37LE)0?XA@E']ZRO).^KE3&O8J\Z,E:-C:&BTEZ2BU'R
M)X\3K.`YU$!<R>,G&TE6N&)]@0E@7#)72]I=]+)R&+H2+>N@T((6P``*FDJM
MH6]A8BVKE1!M)2Q.Z?M;,S^E6XZ%A=]^^ZXUTEBGJ]""JE6-PK"-NM6NCG78
MQO8E!1!!=%"`9I34P&J@TOD670:9&[S3-)$ASKK.RZIV.?]+Z`YO@UEC[8_R
MH%#A&:1VE%GN37M_F^DOSY=,`G5Q54KBZE5L08W'@NLJ9,WN=KN;%<0+7829
M-K(XH[!'OY[%M[0S!@4]FJMN&*UE@0"!S+8I`MNU&KF<_=TVC16!)FW`60FM
M;;7>3@X#6"]O:MP32J(E*^=.,V\@7-M)RR+>8UB:Z$*G@#'LN!V\?4J/8[E"
MW;!N/\&:`0TJP(*>^_SG0`]ZGQH@!U8(6F<+=S)1BRH&!CC]Z6EX.@-BBFV*
M\V;;JRC`%J3.]9V_@59RU4I/A)/=5P!WQB1/Y17-MJ5V:8EX1"BLVBH0S#(A
M.-_Z1H!N#+>?8GD!#>#]+XHEY8__HRM\HDK71@2"R'C&S_P5E:YXPAH?Q!\"
M<7$F'\CC8Y&5CM]K$-S:+W]7C`8U@/&_J)?4!I3SL=:[GF8,"([@[VZ-S;LB
MY@*Q_7/U'M&:W=P+=#"T,M>:\&8G7AMV!\;7(G]UB[NB66::3$_,.%.[ZO[0
M$HFY-`I0J#RA(0U6F#&.O,``/9G__'=J0,\#!:@^#0K]/0"!#6A?C>MC7WZ\
MIS*%O#,#-`PU*X)&)*U5:&MU"YG7"F!'9FL%,55""+=W,<RW&UB'8JZ`.9&2
M%:-6??J&#=KG@*^@6]*@!6^0`0!@09\R0ZLQ`Z;F'.0U`ZM!0:,2@S+H!6WP
M=0JU4')0_P-$-(-CT`"=)S148E>P(#&X)PQ2480("&,(DW]0TAP>TP-UEBH7
MXS<:]DR$)DULDA522$EAPX6UL(7S@SF%($N$AR]9A$S/=V6MP%IJTQS;%G@P
MUH4>5X!>LU8>V&G,HH&M4&X?2`ZC@6D7*$L18$9H8H:BMFZ=%SU).#^$`7JR
MP!'QE`*\9V3(TE6692S8]1AC8S8+PU?'`AL*I#U[0X3V]XC=<X>/B`T7&(E,
M^!S\`050.(1]Z(CO-&H!>'BV9EN@-#VII@5C1GU[*%=YI6I@Y(?(I"N:-7RM
M@(J"B(S+LGAR4`#.*!QL2%M8=XP0PVJ$)TMF1PC$^$F?YUAF8O^'@ZB`?8@P
MTI&.]V>'OC..DQ$XTB`-?!@X6C)`*I0ZB@@68[B'M_5\"'`@EQB0Z()==0@+
MHA<RWV$UH#@O2D0O\C!&?H&$7Z%\/$$+?_B'7\B,;=**R]%:1!"+MJ"1Z]8F
MMWB%%350X1@!:H!4<O-J#)B(93@(*[F2=,@[*IDQ"7&'QGA&Z80`-0`"ZM=S
M<+`%",`$Y?,8U;@?['5IGI>2-[DO/3%V!<DFK/8FB/230-D`6@D"(%"4Y1-,
MWR@9\$@>'2<(+!F(['A_QX1-5UD#B_0#IO<8?BB(;0)&/4E'&^!09@)>T3,(
MOW-,8#>(_0@6D@B0;2AW`HDX0V`J<TC_*P=Y2PK@@Z$8.2*)%=!0BI6)17=5
M",S$D0M2++#82351A0)(+EBXC`B@E:JYFEHY?V8'"]S'FJP)`D5'?6\@FZSY
M!K,PAI^$/A4``0E`03/0>C/@!0DP!`P``AOP`'#`(FVXE*_E-;>)FUJY!8S$
MC<<D#;*A!C]0`RQ0`D,0G)GB0:^2`!3``"S0`QN@3>N)39OQ!G.$*`V``&!A
M`ZJ9E:Q9`YV7A]W9``Q``>$Y00GP!1#```VP`4?Y@'7Y+=[YGZV14>=YH`7@
M+&18@-:$`&\0`#\ECZGCCX99/8B9F&Z#7;X%7H^Y((4EF0S)@?M8"Q#9@8UE
M*T.3F71Y>SQ!_P@G)(E[)R:@"9(N2B^DB8NGB3`%P`(:0)[DZ07J-I*_!0L_
M4`(=A*3#67!UZ(MT(Z4>A%H%N8Q:^``%@``L``&4I7%:-@1P0`&6&!_;UA,%
M,`"_\BJ>,IQEH'3)A$Y@>BFCY3DA&G#&V5)#D%$9]8(P"`1IP$BJ]H^OXD&P
M,@,E4'1Y"*9B.IS'4F4)4`(UT"!1*8UV&J:_4ED'5&4%B@"FEY81@``#T`"(
M(@);`#\5V*%F\X\-8RP0-V',4ZO-<SKL$GHR1F'DHJ(M4XJ<AXIH\J*7>7TT
M&E;!NCT3\34XJC&_E7_'$IKC4`M!:I+=\D0<)'+1M`6/$39=BIVH,?\M"8!A
M[)@"#0`RH=,_UA:=-KHL&\`""9`TRB-M\9%KTS5C:NI\L0%%XLII;%<_%3`$
M(&,XOM<Z1+:"!9,&HYH"&P`FQP(!1_DM#?`%GOIFPT9=VY$`1"<;W+(!%1"O
MSM%OK,-WP@(!-6!ZY(``!EI(-E`#!EITMP-/[3*)`<DV(FHRC%2BYN:)^7,U
M!ZB9>,.EN?60R]"B6/&0?".LCX>-^,*$Q@(%P5=,Q%&M`SBD'<<"P\ED(/(Q
MW%J`WVHVX9IG:W1A8/=;YPH$PQEWY`4#`G-MLO!$->`KO.$ZMJIGS_F&7NIE
M:[1BFQ0\XFAG%%!9K?,ZC'8]-MM%G_,<:5#_`%W#L+J1/$M#+`&C`!2PDG96
M`M*B:4?&/ZAE>FS"!"`P!&2E`!!FN#9;+$`P!/C$"C9@H.#3`%N`2`R@4UEX
MB!OIL`2#L"`J?I:UF,48"XWC&U9#8I2I0,-*0LOHHK+8$,&#+X[;<@366C,0
MM9-4AR59M2>)K7$W)/%!!%U+&#%S-A2P'WHVKA`36@-[NNN:O+[S`^$"+.1K
MMPA"<M4S+1/894I9OV&6*H3Q`_!J-?QD//"+(]V!:[I+NJ:TN`C3L-!+9$SC
M'94++GM'M\P18<%BL\<#!"RV0C2@,M9S,R#:10276:?2`(5JJAO`)W*P=8Q9
M$F,'J[0JOP,H;8=S_[,$F9,["R^\0;PL2G^WMT08:83$0;06^8$5R8VY-;3Z
M:#'/RV1$DG/!QTMM%VIL6GS8*U#:N[O=^T5T>#O@.KY:O&([9#:BI<43E41G
MPP"C!1ZF&Z(LR+O--Q\05;]ML[_&I`8@D``UXS#^@71*^BL()#`U'#)04+&\
ML;BAQ,!L`Q_>,00]$$'?,;*%!2(VNS]O5`,0@&/,,5X)TA\1AKA>``(D*0)P
M8&=3IW[UPP"ZV:2W-0AW,'9O\`44TK,M\AX0IKO\TV^U+#*\+#)UJP"EXK6"
M2:$YS,O\X8H\O%C`R@P-I'W%6AY@\0:'@BC3'&0X4DHC,P,L<$C<W,W=_/\&
M-D#%CV7%IIF]:C``Z4M;1,#%X(L[XAN__&&^9!QB(>Q5LQ*^0`8RP/)O_J'+
M[B$P%E19`4=>R()U<\R]?(N6&SD$W''+_?PT--B5/@D"#```I&7(#>R<ASRA
M;:+(A24>,P`!*G@SP];)(=-3+/<%:4"Q(1,KIGDN`R.\ME8"IM*F<'`!F%P"
M)GL!3*#*K'R/V/D&`HNP[R'#!T0SR'.SP,Q(Y@%RGF@UAP,#R5Q[RQR24OL5
MMJ>/6GW$0INL2=S5Q_!`#::D-80IH!DZX&&O[N%2@-K6;LU2;0T!/KB-AF>M
M]-BFZ:R4Z\RN/]UI[US/N#3&OE/&SS0DZXN=:@#_!QHP+.[1-CKC!D-0`5T9
M1S4`!VW@!<96T,Y'DFZ%T&TD0MT"1>CJT"UG-2;[`\GT`-W)`(M-,Z.7`!4`
M![(-!WURL@OLL'P,'\=S,V.0-!J<!EP)`A];OPO"<@)3,T_"&QJ<G-[9P9;8
M<A66`)D5`2)`=S4`4RPP*RH[?S+5+D)-IE-TP*X]PR+Z/!?0CFQWHL;"`C]K
M#!)9Q,6$U72UU>NXFQ>)),?J"Q>I#+&%T<N!:VEM(>"=+D00>[='SKMAM5Z*
MSL%E:SK5SK?UU\<BSV9$V(W-'];6O+%A9^)"!%/V3`/S!?.)VAP;/3^P!30P
MNIH])9;T5J#-"@@@RT5-_V3'LQNJ"VYH.3P5H.*Q^@4]\$."L'@3FBK/FY`!
M/F0>SC0?TT9O!)>3(@(\.VPZX^&:LAL:,'5?R9UNQ5\5I@$(\!C7+4<LH`:I
MR03JQ]%)"`MB``$!$S"O%RLBRUW*[3'(PS]V?N<7_7IN_GH0P`0:\T.2PD*V
MQC^M1^B1V=[%\-XQ:M^8"4G'FM_$X$C,V!-J$&W&<FMKD]EJ75VV%GMJ6-=7
MS(YX/7H.KM!]K2WABBP4CC`6KB#"DN%W:`,0,"X09L'!0@0EL`$TJ:##0P//
M'<<H-0`J5G+S,P"4M;W/L>0)(*K/>('BR#$:YS$,<)T*\UN\\[RH2RZ&$RLE
M[?]5-(``7VD[#V`#8.Q"KF@U5UX#Y=.DRU(#/$Z^8W!/;<)@LZOK1S,`JBSN
M6M@MMNB3YL<^/6"D_1,?->,%%=`#ZH-^"H\GPNUT?N+P3U<!#%`!;JGPKKFB
MOSJC3>W"-JK?PYJ(7$V.Q\N^YV`(*+8LV9JX5(3!%_QH&AW#Q09,GX[@N<@F
MK[S@XZW.(@3A'9KJ$S[&?J,%(+8@3X*ZZRKN.&]K!DR_-.#G@IA"F)8".FB_
M%G?S;;I>WQ8\!5`";1X?2EXS%:`&-1H]RT('N/T<O:W!JYMJ%D@F#8M`3Q/"
M*<=>+!#N_!N5(F!UA]D?0P`"J.VU:W4V>CQ.:R/OJP#_9"OKG0,04TCOJK#F
M^(L8*8)..).[P8@^/-JA/VZ.W,'BZ<)#\D!XF:+YH\E;$_N]=/9=H\HKB*;?
MB%4MM7XX/?U]F+W-\J_SZZ/'-D1`=S]]O=$T35;/X+?DO:;>8JI=[L:RZFW2
MZEQ49=?6+3&^'25]^PHP!%]^]SD9&ZB!^^UE]5O^G&'&RK$LMLT1.DA-!V)O
MQ)W&,466<LXO]N4(3XX+]Z54P%2T&U]`F[^[APT`"`H*0(*%@E!0,`I$;0AJ
M*0\1D@^1*0400(J",)R*&C64$7,%"`TL+%L_<Y&1$92MKW>NE'.UK[</M7,(
M&@IN;H8P1$0*&ENZN,G*RZ\__PF^AM$P%060S-?8V=K:D]O,LZ'@K;/BV=W;
MDNG>X=_JX:[GL,OE\O6OD^ZAR>+\M_GC]-:Q`XB+W#EP:AH0(Z2@TQ@@8\9P
M$O3+#:>'T3(6ZJ1I484Y*<`5J-`0&#!#1$"LFE1@`+&.*(^QHF7K3J15/RAH
M+)1@PZI7*;;,"%8(R(P&]U*H(5D(6"="QB)8:_>@`(,Q.Q5XJ0%)W<A-&C^M
MI%3C&2>+#6$`T_##VBQ9K&JI81%,42<B%1X]N&.35HH-9GVY0701JQ<&;W[Z
MN[4%BB"&:6&,<0-$@P@>BN6Y*E!"6B>M7&^-*E"@G+M_N'39>J6KAA<%$2$;
M$AN)K_]M2K;YQMK7]Q63(8,D-YVH@-K4?0*3*R\8</F\?/&<[T/-C1YU@N^D
M7X.^>!WU=."B>P,?'7SW5P4:R#8$!*+$IL`P9LU(7!`1!H]$DE0+#:5*6"V]
MI!$1,H&S6B@XZ016-#UE%M10&QER5#AS_`"<9XH000,3Z$3"P$D:;=452TS!
M5(A86LQ20R\MJ&71+X(DT!8[NK4RQUST(>(+-<G4\E<"$U7$T1A>&-?5/;C4
MX-@@FW"D``0-5#../YMU1I\B(J(C26;BY8*,:+6X!MMZ)X+22F^X[=6A;Q<*
M)UA#@ABGW9S2=9G<=>8-],US7>9ICYW*X'G:==59!\]!X4W_=T]XWT&7Z'A^
M+AH//JXD5(8&"62J::9$0.3BFP]Y(>JHI)9JJ@8:#%#.5_R!:-]_LP0(9T8$
MCN7*@5L^D--&)C:HSX-$%3*AC0B\AF$Q!<Z3"SX5N!I-EEZ5&%8-8SV`P#,M
MN@BC`CVI(<J9BSZ@!@,:340$"P7,E`Y(@`7Y"T=>L-#6B/6HN"1DGR50PR,A
M^2F))59Z!MI4A$;:I6II>CF'F.WM9$QV>KY37IZ_;8+5FYKP&"B2$-,Y)Z#>
M@1RR01*;UIQ`B)[\L:33&3IIN'H2.G([C6Z7RP\((+!!SCQO`(=99U4$#%XU
M%&WTT4CW@'0-;\"#WGXF19/22INY_S2KU,ENJ=@D*>S:)(,(."A4L((,>RL(
M.VDR!!,IS-$<I9$TFQ6T)"X8#6VSO($M?]`0,@,+M4PLR@9?,"D-LOJ,PRZ0
MBFR;UA=,N#THQTH^1HA%$Z7Q"-7J`AAP70-3J3)R+4>0FRAAOK;>9P\#Y"]Y
MZZXB>3<5-W0QC!FG&R@YHH_NL3F^;P<[S%1*2MZ4L`S/\GF1[@X[/Y-"__SN
M'>N#:,?7(]^\H1`_K_SQ-/.^C&I_`2<<C)-IA4;P"JN&NGXE]5<($=3J4P`+
M`M*:->JL<.VUDSP)6S>`%2%A(8457RF7($H@A[8=BE$#J<#%0A0:TVU&6AG!
M&R7D0`%/G?\$&`W[@D\<F)T4R&$`0VF/"BFB@"\@H'>+<Y?%8$`!.<RN>#.I
M'`Q4B#E%Y,46V:M2N;`4&M%)K'?$H\0><&,;U"W,6'692.LDIIK9P4X7X/E)
M[=R$NSBE*T^3<]WOZL2^TCE*/-+SGF:Z83*3'=%UKW,9<WH'/N:@IF8Q\][T
MCL<][>GQCP^T8_=(9HL47`LV6-'1269`A\Q<XT`XK`K4Y%>V^B'0:B:R3[)H
M`C==*2B3W!(@U\96P+(=<(-I2,OABE,`]TU/'A*<6P6?9K?9U,]TD6B`%R3#
MD/<0@@@E")O;.#<'.32@%\&9"!"&5H$?&,]'[6I<U!110RM"\!7_.FQ80Q+!
M2N1IKRJ?XU7HU$'..P[*B7/(31.=N"(,27$+HLGB%;.(Q751@@F%4^6;"L$C
M0#Z0G%H:8R119K#FP4R-`_F'S+#CS^7!D7EL5)X=^\BQQ!'DG-BKXQSAZ$]&
M&:QX?#S>+IX1$1A`P54SZ,%$KVA-)R)PDLZ:P2VKEC^L56M9;*2$UP26@+#!
M8@ZDK.51W*93G=0'+&X`'#(0VHU8[@1:M+R:+7]R!Y!<"P8S&,9@,M0>(E#`
M$=:`Q!R84`$-`*%3D1D$,?15SW/\2(8F`0($;!C1B&63(7S[R$RF="B`#1$T
M;WSE7@$BN5JHDR]:6Q@R><6Z`J4Q9=FC_P4^O[9/+W(T.^`36<3&""C3T!&A
M%JV7>2@5T=+:Z9R@E>CKC/=*A;HV>BQ3K?18>TT_QM%X):OMGYX'%VN1]#./
M44!*?_+8D)[#%JQJG-3^<\F:QN0X-R'JLBJD$VV"C9ACLPM*D3(+&T!`GQ$Z
MUY>^Y[0(.)6"]))D+4]4()N8D`5>."L1>NA+(@R!`0VH0<Y`4`$(&`MS$8G(
MT-#5+_*LPI",JRPAYBK=RY+%,3#9%H^V9I!_<>:O6PGL:E/35E>@B29A6FQD
M&DLU/7(4D),E@D2$9HA^WK:.&G6H0#<[,\$*DK4.!J-!<6SBZJGVLPP]66H]
M.N2"T/9M0<;M2O\WS-<*'Y82AP1N0_S6R-!BYW3_6$5RY?=+2U)"5J"LU5Z_
M=:A:,$%!._'5)(`Z%.U*Z)0/L(%13:0((%3`AL3-K#A8,$%QTNW+&+Q;>RG1
MM31TB@A0"/!3'D.$&8AJ!K(QJ4.P<A\.J<L\"#ZJ(1C<T`=4KB@OLNQ!>7?A
M*P'VQ-R9SD\*BYU1B&)%^!H2LDK<4>>!!S"+"!IL.N)BU&9TQPO]V.@6VEK8
M8@?5T;-Q\B!KW)5:U+3)UNT?-UI0DIFQH#)6]I$=53(JY0;*SY#J#H5;Y2JZ
MDJHVZ4MTMAQ3YGX9DP/:'YEC=^;Y])2XE,AN_`QXBUUE4A,,P/,-ES?_B_.*
M4Z9'`O1Z!6&,52!6*@_80`G0&IDQS&`,%)=&#P$(S#=,M\*BR'0FV\/I[=EK
M(\OLSX0=F2@YA/-K6?JLS")0FF^9^^:[Z`69AC'KM@ETLIE0+@L5P`#=8=:<
MP]/LC$7&;9EC#XFYU:B>VQAM;>N89#:>&!U]7-H;]TG'#HUCC'/K36CC\#:'
M%#>59<?VFR=#W;A@=S1F(!/TP%M_@9/%:LJLAK)4UA#WQH6^^6;*?J=2TQ.A
M0%NL&'97&/QK,JU'`D'9\+W(0FL2'XH;9I`(2>_0#?.%#3>;9%+'`"$!S>Q*
MX$#N6TT/0JYTQ>.GX80YRY8'22['<!&W;2?9_Y$C<#@/4P+D.XSB#^/T6U!#
M2W.515N#IV)2]L7%BFY$DT]]QMA@>F2C?D1F\S[:W[>V\VP]2$41K]JF_35R
MQL[DNMKVC5LO>Z+`SHZTPV3<1*##LVF\??4&:>YU]V[.-3_'X#:]%3BTT'<0
M\"YIYE.,T6;[5GBO(`?[01]8T5-'LGV3P&>F%GGG,'EA(1.ZL24ID`(VP`!>
M8!(<41_`)324001>``')IWJ#91Y1-BMU!GL#MU&SMX*V!SWAX%>F%G/AIPRK
M-PH(4#1T<#0]@`8]T`,(T`,-P`!IP`!6>(586`'Y10=<V(5>R(5*^(5>N#0U
M\#,C!@T29G1K)#B`A/]]RU`:!+5D!&=MS"9U'75]U.-\H]4G.-0H)I9JX7-M
MY2=:XG-LM'5B@L@Q:2<-OT0'A[)1#V4/_B=TPN)N57%WRX6`L]!@0`4<1@%*
MW.(3@@>!A"=<<#8'($`FMJ,5Z'(>2B8W`O-GZB55[.5PNH$,%0("0]!#H^<0
MG7!213$#$,`"D1,2NI-L#X!@<*().<A@PO-@C$4<+N9(XR"$L;A[=]@CR/`&
M&:`!634#X)A5C=8I&L``/Z`&Z)B.:E``<J!\9!5?C1:.X>@%\NAHXFA\\2B/
M7I``"R$9VP(C4-"*+D-UT^:&R0"'RN**."9_U2-_8C>'[!<0;81$$@5U=LC_
M5/VW6WTT=8_8,F3'=:RGD>A418L8#&OG37EHB)/(98M@B6J`B?YQ4](5`3;`
M`F8%$9T7?2*$7:2X78E3+%<R;D/P0D:$'1,P!/]&1".R&70A;@PG@@\G"K?"
M!#20@H2@"4)R$93A!E[P!110`36@"AV39^KP(\O8)"0G!S<F#ST(0!6PB6$D
M%06``[KG%O2'DIP$$F]0!D3@>@US'WH!8JHQ%\0P'X:9%5TE$>_1%%K1`(&D
M9$JVAV4T)Z01,1/YD1K6D!@U44491I<&?Y!Y4>7D;+]VF4W7>(+3F>XW6[)U
M1IF9;;GB6^#%2\*U/@QE?DDF=[-"/^(`9@/2``B(_R#B@@`,L!!N@!71%R.B
MV`WZYCBF2!.Z\EW[U`F0AA<-%"[UU#9O``&N-Q%TPY2UI`EX8Q.Q20I5>1:%
MX`440`-M0`$4T`8E8(6H@`!B"5UG5)8WR#><`'N<Z0Z?]AG2Z#0WE%-S69>1
MF#+/82U#H&(C=VC4MWI.)`IR@#^':5V'21'M45*",`8ZPBVPDGY0UWW!]CN5
M68,@YWWA@EH[AI<7^5&!R'WL<(?<=I^*LIII)$9&%GYCAZ.)<Y=2QR?@$&4K
MB!$R56$P"G_,`A8346<?L"^79T(5`"$<H4*`F0L(4B$U<"%8`2/.R1/+Z5X@
M`(%<Y@7`B0P)T0O'N8)9U?^8RJ<%-3*2"$`!M><9E0$*G',_0:<)VL16>^4V
M:L`$+,`XQ$$$PV@#!1``-F`#/,`#`>`*)6B7!K%J>>)>@)&G)[&?<P6DV`1A
MZ/EZQ:$&8W8K4EDEJP,-&89LB]$7$'HK&^")>=H1OU1T;8.`#_<`%.@L%WJA
MF<2AG$<,:T.:(2J:2D<G)6J(5W>D*@IL55=1:Z@R'$ED4==C&75L012CKZ5;
M2]:B%FF'@]0/'GD+0KJD1%H#_W2D[S>+=F$7@U"DZC`'NN04P'56+@02RR('
M-5`"K[%#%Z$(HW==M4$)#2"F(&(493I,NF(E3A$1@@$,1?(#XJ`+<K`!985(
M25G_IT`$GN!5)IQ#"6]0`?Q8"!>C`26P`:T$7:QA3^^P&HQW"[C6"9>Z0YE*
M?M`8&2!$"#_T/%L#3@+#L&82B5?&2>W:JJ\'0$QR']7P+9;7#118F+G:M$-D
M<8W6B@L)FH0XHAY3K%<W6\N&H*B6?3!F;"O:FEHKHYP)DM=CHS=*M=%ZK:K9
M20G5=<SZ="-UAK294H$DK;9U0:0'7'1G8%N0@F?H"XV6!O3Y`S90`PR`3";5
M,&D*BH''G/FS72`A.631"Z''8CPW`Q30`&\@!S0G!SA3`5]`#"55L5Y0@`#2
ME)1'+91+"FD`(8QV5N;H2MWP)<S15I`T"RW;J9AJ0S+K_VE+XK)UQDK+ERBE
MQE@\>X@=`Q>K-Q-"2S9%*ZNK4:NV6@%,Z[386W%68%\.J)G5IKP&B1['2&3%
M%9)YVVD.MH:E*:W<BFP5F;60=:YL^)#75I`YEK5Y=*VR-;=I!1O`,%Q-1K;5
M.'D^*%QUMR5^%[C\001?4`(E``$?*QF2<6CTZ'HQXE.0BX,=\3='"&B=LI45
MX0L7)P@Q2`,54`%I0`$?.[31]QFGJXE5H;K3\B4(,'&2<3%G!01>``=5-)(0
M.CNX2'.ED;N4L+OZJ0C.V(;`N[<MUDIOBT4Z&XU8`D^T]K4"2KFZ>R%ILPBR
M>@N(9:5+.V(K.,9D7,;N%"HLX/^[H"E;ZK=TT/%%CP52OM:MM8:(S^9^:UMU
MHYG'8HNL>.R9W49:!J6LX`>^GMFB)L>_P+7`/?!/=;RUXE(B!4QWCG1F5^DD
MG`",[(&3+7)6$""Z@1M`V)4_3L+!HT"O.C5QB[!,O\"I%JQ6:#5?Z</$+TQ4
M>NN4W,*Z6F:]GJ),*@0!($"&-;`%9+@%QJQ?",`$YZ@+0XP+RNBR7U-R/[K$
M8IP[D-1M!2K%6E&`Q:NUJ]=;SSM$PM#%X:!NQ62]U5S&ZDS&&**P%!`Y9%F'
MC^*0;OS&5J:_W)JL!0F_/*;'+R:V,@J_[UO(UB-V0Y:-2+I'AXQ^^#NW4J8)
M1&";YYO_SW53S20L@JP1L`IL4N`H&>`H$9*V",&T`:G$H='WN+>R!<0`KY\Q
M5#-Y*S5LG"#-$2?ULB858()``5\P&38]Q1>+KJ`C%C[B7>Y1QD:A`5Z`U*B2
MU*."*DXM*JB2*4-``2Q`GZUDN\FXB$LZ$=+LHCHTQE[48+6[+%&\MSZ]JE:\
MB9(#%^63L2-FM`139N<\T^M<UV!M@0_Q!=3B<^358]]+8\KQ/4;'1T"&DI+Y
MK(<-K8089`-=9&MKR,;EK>K;;7+(T%FGK5\KH@2IV%&VF'4KT8D=4L=&P#-=
M-HX5<I9,631=&/51CFWA-2"](&J6TBN]<8I@RAM;"QO0!B_Q_XLYV=.EW5-P
MP-,VK<.L:T&S"!\3P59#_5V-EI.^F+U/M;EXAK3)B&L]E!98T=6;60.]S1$G
M00U8K%!E+<;;#,7Y"P^JNM;_(K2+K-VR*R6B4PL4J)C2/1_$L2U`\`4J46!]
M#:+(:&7.P52#_=^NB:.;V=C05H=TO.`>E="D1=E;"[=UE>"6;:0*'>$2_M^H
MN;Y;=T@*RVC$P$AWZ\CR3$L9.K!G)8*UBP`08)R7P])'I9Y1DHQ>HXH-`@^U
MH-*P3'M&`3C=TS82*V)'-:3I8U\J`0>XNI\B<D,M`1DA'".Z;$+%.0Q!XS@F
ML2UTYA".41$YS'#R`E`_TE5XA7%/$O][+\;COJ"G:*4QGED:V9P1A-#D;$M8
MS)<.*;"=;HU(9Y47QX%%K;04`WC?H+,(E.$%P02J/$K9>QA_<SPRXD$:^RS`
M$ZZB,N?7#8782IS'&Z[IY&O@.KI:H9W62AS0^"R;UD4(?D.NE0[0YI%`<F[`
M)>8E:K`!#+#"L3:H"=`&#5",N5!OAG-=$>`MHD!*%JK#W&5L!5`#:;#"6>&=
MP^@3<]`LJE@9*G%#<D`N61$5JO$&:8!,+$81SK+(*_C;_"$,(RXO.)75SR`;
M*@0$-<2CH[4%JAX-#$%]''6Q//!RGOHPUA3JQZ/G.Z'J@#FK-Z<4%$KH%TH$
M";"YOH[(F^[_OBI9*&A4<W\XQW^=K)!YV&0WZI@NR)<^Z5P[6IK]\18>O^X+
MX(]NZB=Z#S4,`10``4,@\Q!0\U\``:PNP,>:'@EP\S4?\U\0]%]E\7GR`S70
M7PD`N(PV`QKPR<G\)7-@`P-0\S(_!%9O\R70-!&P1+FP!3+O\S9_\Q20?*Y5
M&FUCK_VE`9UBH8N@`4/``HDQN0T`]E9_]1#0!JR^%YO1`!#P!74_\S;?"%<]
M"S_`]RFHY2WLLB[XC]G-T1<H3-T@<50_^51_9^6*HR[N\W]O\U%23EHCE54A
M`G]O]S5?`GEOV!UU>0_P!FW@U)N"*0D`^^:H!G)0^[9_^Q(;^["__RF\W_M.
MO?N]W_-?N05,4`T.9$$HS]@=[_D5":3L1_2=%MF>?W3H:^K"6L=M>/'H*_'R
M^\CZC+\(+?$L;V,%\`9O\`,;D/X;P`3K;_XUE_+%!AXX\P;JK\SJ_P:M),C#
M3@EJ``AO-0T5%0P,%2P--4P%<X\1D1$/$39O&YB9&TR8!9%[E'-RFC^<&V^H
M`922DJL1CX\%3%L5)1`00T.W-"Q;3&HI*;$_IY>:F&\_#P]W=Y%SQ,>HR`64
MRP^/:AL@-%XP"C#A"N/DX]_EZ.!0X>QC,V-`0"S5K6I,3,:F/S]O-IZL`",M
MBU#`V#%.R5P-%#BGU1P;QS+M>Z-J(4!7`?\!.ILDI\:6&B!#@@0!<@NA0RA1
M%C+42Z3+ES!CAD3P"Q:D2'<P7K28,:-%GCNO"=4I<.@U@CUW*IT$M)5"5DV+
M$IV4%./4I#VO!M0Y]:A/JUFM7HU*%6I1LUB=?DT;MJI0+==L/DA!-NW0K7.'
M!J/;D"%4HZ_4J'DTEZZG@9X@82-<F*X:J:\>[0TVIW`HHD^?(>;'Q(8-)G(B
M[!UX#>XRFW/H#FSVC'#E8`^TF%[H*L6%.2`2A!L3#HB&!,`U_`9.G+B&&3.^
MP6C1`@HX=D`4E&#R4ZCJQM6WMKHN5_5?27V1+NX^NGIFMCE;I[X.>_V<&AK2
MH=.P)77CR7$GHY;_+`S6=:^5B8665Q=5]9U;!(9E%"7_V&6>6@5"**&!;+$5
MU8-G.;C4@4PII!563?$D((=U:5?AB1-V*)"*D<U10(,;:BBA12^*IE-X';H2
MX&FP<"@>CGVM`@93$<@AAUPS$K51*Z]8!QLV0H5G$6H=;K0D*SMBYLQ<T(`P
M!!&[C:%``G"$])%,)K%0`01>C#$&%&ZT,PX$U(7W3X`PXA7C0E2BJ!F6`4[X
M85+IJ;>@3?`]Q\YN1"A`7RR39!E4CYKQ&*15.&;(I#5$,NFGITZ5*!5@>;:E
MJ5NA>HJ9AY^&V-5YJ*9(88XFK@A9A:+6FFN2?HIX878R=FKA*@EF!16._P0F
M<5A<&C73#$8WJ77-E2\ZPNI%F5YKJZA$P?(/6,\T^]=&R[Q!`Q'Q`$$$NAJP
M`(Q>>MDWAQIO5.!%/&ZL`P,\"D#P1I`1"EO66K*&EY.VD8:[U%&[#KQM)`6$
MMB!!C\"WZ,5B:E!#M`@6>R)0K@[X\:I<#9HCJ;8:*^NMP+*(ZZYBF0PBL3&B
M2%O-INJ9LJ]C@>K3@2,&:U>2L/H8JWD7ICIL@J\&A2524MZLM,.A=J4TSP2?
MBE2GRVQ`03Q@0@%%=!7\T!]M'H[W"!T)D+-H=!0PX2)CX`:-<\*CINRTRERG
M_7)`WT)6V7M>@&...(9K3-K(/FNMJL<_"RM4K?^.V[S@-34*_.G4O\I\Z^>:
M0]XK@2$/K37368,HJ(B@-KRZW7KGS#17>'&+UM2:YSXS["#GBC"M'3M(;,G@
M_O4A+!N4X(8"RRNPC@)#4)<BQQ2K`4+AS4.G0!I'.L+8[9M:CO7NFP?UH>C@
M!7I:#87+E_@6I,E</.@QN^XR\+&CW_'ER]1(5O'VJYK.<N<Z_35N6YX;5HI,
M!KFQ:*5HL:L<D>KV0%S-2'P#-!K?0"<H\+5N5:VBW>ZL]L'?$;!I+TK-#TJ`
M+C&9@WD-R%3M`#('KS'/#<MCQS@J<"09SBQRDH-@^>87OP.:3U<BFD,/VB>?
M;SR*4T`<6`"]PD`C:C#_:1X\&?]>%$`$RL^`"**<!!DG1MU9*(PS+*.F?#6K
M@)G(50G\X>GBB,8"_L^"9:0C\986PBN6+&>5`4%\@"`F'(Z#"#5(P=;*2!<$
ML%!=V1.'QFQR-ZH%JUA-*]_].`C&R!QKB>Y[7V4V1T6099",<L3=Z/B'.7IH
M$G\17*,8>Z?`5]XO1'T46A8U.,&81?&5L+,9B6CYL9QM,E:H#!T(@=BRR>GR
MEYDAYLJ.Y2(&Q(,W,!`;.=QU':4DH2AJ<&1TB)"],32O!&8C3"5'9SPWKLYR
M5)N=_8A%N"9*LCX^-!TG\UC+!_Z1EU]A9?]*%4N]=3)U"+5=.W>YT"'>;GRV
M_UQCVNSV/Q&>4'7&W%`7`5J_=0I0=J;LE<\PE$HW`E!J&;WE,E8(A(O!:7D)
MJ($<GF2-MQCF#7"``+K0%:?=C".FJ6'*E9(YP,5Y$([('![Y]L:*;VVIGNA8
ME*/P^4OP=9)D&"V+0ALJ/(%FSJ,%.M\\L9K5:9:U=&9]:(DJJ,^0JM*,"J(9
M4]\:4+3U#*Q^7!G,.'A**V[0D@=%(S)Y^0"6*N!-BW)#/+Y0`03\8%EY>8!@
M?E`#%E!@!@H`P@ST=8Y#PJ&'?>MK8.$JJRG^KH'HB13[#.<V'3Y*AG;LJAHC
M:$"DODR@#_BJ1-M(RD&=C[>2(V5?C_FWV;).F&E<:/]=BCC&Y`[V=$?[B28S
M>2HZQI*-(RTF0DL+3*M&H`*-(@)GP]$\(B2@!`QH``C.5`,0L(`!%$@`9@_[
M#G:X`5T*F`$#S,8*<@T7C)C\)U.M&\]E?JR>B%-4QJC:0;]&]*\/JZHSCTNY
M!>F6=/YTI^[&FM8]$9BKTR6L6N&Y5!"7%)>SY2U:.:='";=L@RCV\(,-?%;>
M)=0J6XA/3R_6V7&X809>\()PO-"H<F1SO/CU0MDX]JSADM:=$*5K1F,,4&.M
MML?@<).C8A@U$QY5P%5.G>><6=`1MC)_'^;C@_'HY"<[U[J8B6*:;YN_-3/4
MDK:D,%[/V#H-E]G/;L[EGV?_S+<'R($!C7(#-GGLG%`>CL?G(,(0&L#?Q$B"
M-7Z>GYU'O&E]1@X;B7*T!AKPBJS->;N=)NQRB7=F.0/:I!U&VUN[N%$5>[=5
MMP9I`K%KT&"6U*1Q?K4#C59`'U&4A"F6)G!AC,3?6I%`<V!"!>)SV/%>3%%8
M=FFCQU2!#0RF1PO!-*ZG7-4/+I"!Z%[=EB)0`P@4Y]T)T``$:M!&/=>[P;G>
M,(3YVM":#G2Z8EUVKCU6:[!^V**;UM:+!SUH7C=7I*HLN)<=K'!3^_;@50QQ
M=4_=$U$T(`'1(0<0<,CCYS0/''$RY"$30(,:>"\QETIQ;P\H\3L[N,\969(<
M$("`_PWP_.>9X/D/NOMK=O:ZW+T='H;_?=24AEGF:V9KH#VMZ4Y+5\IX9J;`
MKTM@W_+9H#:G];['C70[GY3C63Q,`1!0@3+,MQR+[BP,0HX.('@!`HU5!H-2
M7=RQWQGA4$=ZH>85H/UD(^NU=/K6^5YBB0X4[2:.*.2!6?"Q#]OJDY_CJP[.
M>$&_6N-E__K3'=KY8Q6D`?%]NZ/+082[,Z`&_I"B>#+OZ=%'/?.%BH!@U$,I
MG`QUQE@L?>>1IMO14S?A$!,^S5M<>X:KCJ"2:!"'9?2MRJ?EJ]-O\]0[K/C%
M-U[T`J=]I`KP`P2```ZU&`*\B0.!-%1`O321V#)^WZGB\_]]%=*/8V`S-UK?
M-21S#=$C@=-]PH-<RB=Y\<,@`Y@W-[<L%>9K0P1X1(=!9!=V71=L`16!4$=K
M-#97!EAO&X6!MN*`&OAYHY5O#N-6UQ<`EB`&+B@&J.""_I!_<;2`%@AG@(<8
M5"%VGD=B**B"955G6%>!*4AY*F)_]R=^!"B$!SB!0^.`T/=<I><['&=]$->$
M;.9\?A<ZR7>%"<<SS?2%B9=G2HB%WF>&J6:%T75A&(=JC*>$9>B#4Q&%RW9'
MH&=[MW>&6YB&S(=\37AU-Y=4N_5*-HB'R$6'9J>'1@=H:FB('YB%9"@02%B"
M_"=U9D&"?2=\8'9_#08C>Q>$`D/_>](W?!!3?3:'AD9GBL*7?Q62)YB8>/:V
M.32(;T3X<(&'?RB(%:^89T17?998BXB';'989<AVA9,8486(@`!1B<J'B)O&
M?]Q7/I`5C7[BC,_XBHWHAM=8A'RGB@#W@>+G/Q.7A[;HAUZ8$=[8>>+8C&B8
MCN$X@M"W:UBX7*A8CW%8CP=H?U9XC_BXB/VX9M8H7)!(>G]HAE/T>01IA/\(
M.#9(9GCF.]^7B#4C@E%8-'L5?<QF/'NW>5WH@9&W(0&IC0PI.T?4?+KD<.5(
M;!)(5!Z9D`6F:J5X=`HRAL:T1YY&4-Q2=9A7=*8V5]05DA_)(?'X99!(4/YS
MAX"SBEIH_TL-"7XB66XY29,E6(^ZA8EW)85-M91%IX-[)HL[TY.!]X@4`HU/
M&7ZY^&39Z))H=Y5:"8R@R!8#>!B[)#_+2#5LN)"*B)=+67D-PY=BZ982J97B
MQX]O^(T*28IM&8EJ)'%Q"(B.^)=Z29C2^!T<)Y<JDV8K:79$D8R0)U:QJ%V!
MR(LTAY"PAHUIF'PZF8J(QXE':74@J)=>J8-I"67YN#-0%'6\4IG!2&B7&%S*
M"",%$`!`&9J:F)EY.)PN&9%=29K#MY*7IWUY"9@9Y'5OB91[Z)2P&9V@J7S[
M*(&_4F/I5I"G!$#;J12NB)R1*9G9*7FA%YE2V126Z9K2R9OE>?]`0*F>YWB`
M3X&3_KB>61>>S'F*V4F7D*F+`;":A(B757B6`=J>84F<VIF42>@I5LF'BS2%
MG_B81;61&2>0[NF:^FB0]'F+O?B@PA22NJF`#^F$N86>#3JBYLB3!3J8_EFC
M[&FC>0F!."J?.]JC\^FC0-J*HWA=66E&M/>9)CF0,^>@S3=F0DA'R5B+-)*.
MP^2#0QHY>9*:T[FD8P@K1^JAV%EA81HP!)J)8(J.45J79,JD9XJ.$D2CB=F?
M:#J.=8FD^9FF\80SFQF?I<>G>0JAV66=FK.+QJ:,3-AFQ3A+5S22?>F=@:EO
M:FI55MB:/(J124IU?_=,;DJ/DGI&"VC_G&TY9_IWFDQ"J'/*B5/YEAD&E\E9
MJ5MEHO49I#$:H8]8=;C(G<\9>OAYG?=64)@IH+'ZHIJ$ITX8A)PZJ[)HJJUH
MFW<XG*`JJW%ZJ;Q)K!<ZCYXSE/BXJN+)JXS'GS7:,"Y*J8<IK0#IHF-*KC5*
MEL5WJY':$U%XC%NCHJ-Z(E"XI(CHIS^*FOH*3_`J'AT)E\")D,B90/5J07$I
MK"A2+;I(),Y8*OCGB58CK@E+A]1JJ6@1D+_*JI^RKO_JIK#*KM%JL8!:I.T)
MKT?)L:E*$`5[?>?Y8'(YB?U:>X2*?3THL2J;:@'[L(G)$]X:L\.Z(MBG1P0K
MD2\;L(9)%3#K_[,)BV?,B(Q(:YD*:UIU6JU*BXPT>Z<O6Q95N[$-HK`IJ34K
M"ZM9J:)H.K*R.7L,J:S/52VE$K/82J\8!;40ZHE)\557FJY^9;0(NHS(B9[F
MNK=-18=DRY1PNYR+I!5V.ZS6:+0U6+&6"J5Q"ZV$"[@BRZ7/R*T=:YY%:C^"
M&Y,=.8?_X+5Q6PUQ9K,Q>Q1Z2[)5R4<VRW3ZZK,@ZZY9>K/41[*V"YR(Z`H-
M&WU0ZXR(@:](*[M_TZ^)>ZL5J;MM$:+F.KN)R[NUE+IERTXV*XE%Z[Q\IK?(
M&[WDT[SU][36:SKHF:$\>;5="[QC:;YH6[[/"[0%HKZJ:2#N2[L=:_\RT+NY
MGDN-6RNV=>NX&AN]L0NP0BJCE;N_@4NWU[>LMDNOB^N*`DN(?WN[!UN-"]RN
M@^:V$;RP"5RW?&MG=MNV&ZNXZZ2T^<NR[JJIMSO`YUJMWYNVNG.>W(NE9+G!
MI3C"\EO"NIN_HMMI53F)L4O#39O`.:S"5#N<00RP=PNR;)NLSF=_$XQT.=RY
M-6S$]^K"3BRZ"VRJN"NA),QFJPO`$LS`+!N201R0ZVC$&8RF47JR'NO%5T'%
M@:N+5AF.IEFX7BS!9\S"U?C&9QRUF=N_<(R^6MS'>-R,-)RLI`NL][O%B"S(
M,NS`"JS$B2R[@'S`9FQ)1EF_VGN*%[R_#TS_QG&\M*L9M5H:R'`,M(M;P!`"
MQ7I\QWK3KX-[B!79R(H[P?)(NP_,JD6\QB>:.:<,PA/K,*JLLA8\;L>XF0(9
MNJ#\L[49Q<)+N:A<FSY;R+R,HA"'S&64O\:K(<OK"=%,L9><M7GZP^!\B4DL
MQ"3[13.\I94(I2)\GSIKOSK<Q5T(LM[YL%FL80MQQ=>+B>-,H5Y+O!G"P_:<
MNY\+H/);L5&9SO-<@`HLST0YE[P;OQ`]P6),S+G<C1W\,Z(\O%:\R:29SQE=
MA%X+G^_JO>HHT8;*R"-+P#"*H'?ILNMXR[?SQ'TJTP$<R3>*TQ\M,R\\HEU,
MF#;=RO>\R"3,E1@]_\GENL+QC-*3"<Q#/;<NJI/'!\KXN:N:*+D[JJ,M/85$
MO=6/BHK_2\G5J:3M.*`I:[!(K<MJ?2+"6<J/NU`#.Y+.?*%M_-2:LKRF#,D?
M8M?'#,8QF:%H=[)^FJAEIL;0F<S3^]8?_,K3R,ALJ=.32L%WS<%94]'.*Z^.
M6BNC6,A;R-<CF%4MJ]C\IEU9S+EPM</!>X1&F;R87*#_^K<]0\VU2Z%Y?;1K
MS<$D*-@H3'I![<?+S,PS^MICZ]HT'-;-+,@9Z]`]6*I,#5SY[,^LO-O_^=KW
M6H>,+9HFXMDLN<(A&B$U,L+\.]:HFI\J?=S8?(\E_6>W3+$YO4M=BZRERO^.
M8TG*=8S5VZK(G9R,O>W+)>S,/<W2J/+>6/C?&@S<Y'S98IU2^RU+-RN^">ZI
MS5V=8`'>S3R'"-ZMT:W([2O@N+G!!!K7Q!N?]VG@[2W:OIW,I(JT;5W>&@NZ
M.NVTXAOA#I71@^+*':G<\?R]LWNAP:F.__C21XW`DUO6<]W418[!=@R0NMRW
M"\G97,N=+X[1)Z[,]GFY.'O;W;KC4D[?7JGB>?S*-QW*V^S!:XRRDHSB&9[+
MZ2V-U<WB?[Q]1E[@27W"4:[4TNVA;>ODORS9=Q[&=,SF[`WF2<[23J[G<OW,
M0O[@"JUI(]P73,SA/(XBPKG?IKO@_5V&D([A?YW_C[X+TVH[Y(;^R'UZX4KN
MO^8\YYQ>9I"7V!]<VS%\TF9HV8Y<F!E>KD!9QN=[OY3^P!8NU^%K<S+>JW(>
MUW0<ZL-^Z]NWVFM*Q*%+[+3=R,@N0GE>YTD)KIE.N;MKYW+>WR9]ZK"VUM<^
MZE0MZ@=]Y]<:S!B1V#N\XGZ]2)0ZQ>Q]X_R+VMQ^ZGD>TE.NX6N.Z_`LS-9;
MXT@>T:O<KA@;R:VIMZS.M]J-[YE[P^X+\-MN\/L.O/<>X03^YJ1>[^3>OUO[
MQ)-\C,4WQDS;[S#,\-#^Q0//O:\NQ"+OTIP<N.Q>WQ$=[R3^XA?=T0[\S<%>
M[MK.W=Y\YFC<\W=\\_1N_]Z(KO`#?^BRK/#-_O,+3?07/_15:[*07LZ#3/4`
M/C`>K^@"G\EAOO30WN:#C/1ION-)&_4#;,\`'N(=>]$'G>UI"WTKKM$F795S
M?Z9SC[M3O+!D:_?AO?9'7\D96KP*^/?LN^EVN^+9"\D\?O>XIK[R2A".3]_%
M*_G='IP'JO1(3N/";-/BV,$A3_,-WN-GSK.J&\$.S<=]'JEG/^C+*)Q&+?EI
MG<B0W_@VZ/9:>_G/++3NWNR!'^;56\/!2:56']Y6G[G_W;`[K/="+\E[_[N&
M+-FE3;`QW.[@K:YQN?/6.\9DWN!?+.(>[N^KK^:KO/)_C+[:S<FA7_[&/\P#
MU?^W[Q[V\/_\N37Y)([[NL[L"9_^+P\($0\1$04%A(B&B8>"B(Z/C(:,A(J.
MDHN/F9J7FH6<G04!D9.?DZ"6F8J#E9Z?E*:OL:FCB["=E):VI+NNH*:LLIZ-
ME<"^K[JDN:>$@\*XL\'%RH*KMYBRK-*0R9"B@IR]S\S!A=#8DL"VF[#9H]K2
MO^;IX<OBP[OWULRKO-OYB?H@H?(735N]7JJ$\5-GS!HQ=^@"QB/HS-D\1`L!
MROM%[UJJ6NLX,B3WT*.KCK>X53PYLN#`E?-:EKO6#F0NF2_3W;29<MI,<2P-
MNHSFLY5#CB8A[NR94V5$GNL\_GS(3BA,DTO)126:5.3_4:8PD7ZU5_-848E%
M^T']R+-DJW8RQ4Y5:]:A3[=U*]+D5?92I57>!,9:*)?66G^$\<6*.?:MXIF,
M-?%K]#8IKF9/MSHV;/$0X*JY$DO-&[$90<)2#UWZW!C=8[PH]6;NF[4A:;JU
M&#VH]J\R2:.4`J><)*K4P,B[,4X^5M;B/:L)76M\%MFV=*Y_"P7&[/EJ\]3"
MIT=GJ;$4].[75V):?A;@=U\!J.E3*3M3DOL%DMB&_#C"??NAM`1,$N_-$H`W
MIDG4GSJ9F=,63MJA-U%6Q>A7'H(!W99A@/+EAXB%VS#RGU:O8*A972<9R!"!
M(%KF2(N*Q!927O[-<A%%X%A5_V*''=I"H(@>DF,AAYW<9V1;X^B%WW:IZ#?B
M4)L$)TIR\!0VDCOS`86E1,+)=9>7B81W8X8AR@@<F988.6*+_+7$YHOX9;-.
M$G?H<T>=_A#)#HW3^9*>GVCR9::/ZCPIS"<@P@BAC8:$]R&(-QZI"8%R-+A?
MGQ_>A*B%3Q*(9@1W+J9C?81(ZN>H,5FJC)FFEFKHI$[*F6FI^9DV4HMJA@<I
MIV^2&:-Q#KXTG*HG!AI)8.\X:NR91)(XU:F<V2A?/3<Y:2A<%!VE+$E!DOBF
M>1.&0]]-VTK;'J/1?L?=(Z\^5:%-MBJHYX#"!O,J<ZY-:)2MZ/V4&T->\2BO
M(9Q.(_\N3M>!Z<@<P!%39B2"\2DKNW'2:,J/$4O&W"LPPLGFHLQ^>J:_^/(Y
M#68;NGLER(RF$M^G[Z@6;;W#S<@>R?88BUN3-->HJ4TLY_ROLW:-MC%6[K$E
MM&^D+OUL2,BR`BG2'*-+8Z\9QTP5IH^@/%^CDWC:M("ZY>:BL-BV_%MKA5;<
M"L,_/2E@2%OZ^]]_7AL-I3YYDS@;?2`CT^7+2L=ELU&CZCV7R:@*-3&.3EMM
M=)6^J@Q/E%SCJQ18P68K,C(/4YOQ63]&A.BP6X_EL%TB`9SZZ#`3ZZ^^YB1H
MKH*''<UTEMGZA:5YPQ0=XGY.U:8>T:+CC&+,E.D%W+I7\<[_^9<R=ZW5HFGC
M7(RXPP^F/%P,TJ43CH.^7NS2-\:&4%5>9J-?<DS'6*:&LG"G,+/C9\)PP@QV
M'S)EI=D=R8#WM0V1CV;;"U_$$N<YYV7O1(`;$[!JPSRI%`=3?P/=I8K5N'2Q
MSW-!R5SO`(:C<C'001WA#8V@]QS2.((]TJ$2,EX3)=3\K(71ZU'*0.,?N63$
M:2$4DM)&5I?]O>YRQOO)_BKE(K@)8PX=,<5D?GB^V>FO%%%K7E@P4A<96JP`
M<W`B$DVV.*Z53575H<>ZC,@*-H;(C;P)H]#&)T&\U$*,9;N>^#IG%1G638H#
MK-(9HZ8.%M;/6=DX4`$WR$@N/B\M_S*C'`S-Z$@%S@2&EI)?\"@!AD6"Q':@
M<9W`_D2]AKUH6/MP#"&,J!W%U>YK3YF20FSW@%]%`(]1\@LH.BF>>SAI'+HD
M!_PZ5YEUQ>9FK!#-<1"6RK_PBWVT:TIVT$@LSZBP7E',D?465HX/&I`LNO`?
M*,?UE00)LC_`O!]T@@-+8U#I2[#<TR6?N)I6XF)_`*06)FF""AMNPYR(P%!"
M@+G)`O`2>800:/_>:0CX(:Q?L_H(#P_!2G96]%DHZ^-*XG.S3"@3,@LD!N$8
M`0;P"<*)/NO3@0:A2(4,4'NZ606(`B`'B[G4>42DD&:,-(EJ@`:*6<0<(<!0
M4@!"#!50E/_:D&!ANU5^DI.WS.$,`=6G`FT1&N]L1)?(B8L\5J^J?P0K"1M"
M0$@^-&N\L-!RNM,0(U$)0[_\T,RLV4.,E4.F!/7$'-8JK$ZQ***F^1A3+]E4
M6$TM=,GQ%)74](@ZY>=]XJ#B+?&9*7=%U!XLK9Y#HQJ+J2UG$'$J`&O>ES?\
M^,2N`&W&R^ZS&]#V0Q&0HESSLN,?1=5(K2!UE7)<L5<KE@=3D@+MJQ)DPV;<
M(2,`19%\"NLJ7E5(;G^"A=SL<T-$QHZ'"*6:&=6)W1.2D2#%Z9_:J@HT;G@F
M!0_8@Q;6ZUIJH/>N^P#M`U*PWCNL5PN[>2\BM+`'];9V'/QX`'__[ZN%.H%H
M-P2^;RU]9%_\\@;!][W3?-'[W^.NM[_J=;`C^JL%"H,R+Q9V<(?QJX@4O/<I
MK1V$:5+<O!2S&%003N\>-C'?`JOWQ+OQT&[VT.#;K,;!"$Y.D%N+W_C6]TY:
M,.J!Z+2'UEKX`7@;)C,ZW`P$<_B^E!!P@F^\XAUWN,E%SI,UU5``-42UQ@T.
M<W+2#.1XW8G-4$[@"Q^@!C5XT7KOZZ^67;LRRF28O_"K,7'3JP4CSC>]=\AP
MEPEM8RHWX@%O3C1[I\C>T/QW,)!NL(`#25N":-.!U2$+T+`Y'CD'2Y3S4Y`W
M:(L2@PP453^(]0\"<(7XS#@)!ZIUDW-L_X-:"S@)5\C/%:X0:S(?*`#]!?9]
M?E#F`ES!!@4H\)3W<(4W6!O:?]8"L&M=9T.H0<_CB(^V;5!L_$+V"DFHLQJ(
M_8,ZZUH+SJXUP6(=`#44&-?L5O>WU]M#94!9V48R=@'Z&XIAV]D9M3Q0NZ<<
M;QYHV=FQ#E"9DXQK43#[V]\VL<]RC6XRQU3`:OB!M=^`[@B$F1Q[`/8;Q/`&
M9/-W#P$*P*P#Q..*WV?85\AX"D)1JOZJP08K?\/`.1SR'UR!&H-@=[237&M9
MSUK<M(ZXL(M3[_ONX0=`MW;.36[.2:1`#340P0`P(-J$T_KF5_!OO--=<6^_
M?#?K#OK1.ZR*CO]>H0$B:(`-^&V-.R1!Y&]`@`V2H-Z4+HZ^2<CZ&WJ=X:('
M6[ZU;/>L!?%UH+/<!O7>0PKV0&N#%QUL]*7V?=1-[X-'H-Z33Y#,95[V':O\
MVL%N,@?1%DV<[NO4$*H)ASI*:F+F%!3(6A4\A;H>EXI6#0W(0`EP@(,2+/\-
M_!7#`)P_`.BO-P`#R``.]OX&'"A_^<QG@/-QT(#^UH#YS7=^"3*0@0E4N@#2
MST`=YJ]]$8C!WEKH/OC'/X`&W)_"N'8':H`!Z=<`]G9<#S`!ZM=\Z-=\&5!^
M>W!^ZC>!&8`!`H9]$TA]#?`&]M94C-!]#>A\[-<`\]5]&3``>Q=G^I'_?]/'
M`&_06GM`@"4P``%P`7N0?.`G?B6``!>`?.G'?PU0`TMG<MC'?LRW?@,@6M3P
M!B)0`O-7!QG``!B0@OE`9S]0`]E7!V50!S.(`=]6`^.W?.M7`_1U?N@'A"]8
M"+MQ!U=P?D_(A0,@!NJ%`$CX`_BU<PVP?ABP!Q=@`PR@?$>X?'66?8!XA`[(
M`#9P`5IP!02HA?1'?@6@7PBG!0B0`0"0`6^@>3^0?2$X`#]P`7.P!=KW@]2W
M=_P5`%@H?X]8`TVF8Y*!?&4``)Y(7Y3U##:``0SPA">(`-\&"N]3`&_0`-Y'
M?S,HAYNH?09XAQA8`@T0;6K`A*H(A3.8B6_P_X<+>(3*)P+V9H:!R(`(H%XV
MD'XH2%^)9@/9-XV-]P99J(L#@``ZE%VN]%7[A#FO,1)KU26>-#O;XTK^TE(E
MDVK_TS``4TL,\`$:````\`$`4`<U<`$7@``)^0$?,`!JX)`%4`(*^08/&8L(
M&9$="0`,T%\8X)$?"0`8<%]7,``>N841F0%[=P$UL)(1^0%U@`#T10B)]@89
M()$TF8@%=@<CJ9`(*9$=.9%\V``\^9$2V0!:<`$!@)$(R9$260?-B%ZR4@-U
M0)1%:90/"0!$4`?61RM:(`99"0`;H(C\!0<:\`$9\(E[(`(S&94-N0<#0)2Q
MF)0NJ'DI<`4X,)1#"?\!GYAD-6")"CE_"0D`3%ED$6&.AVF8$ID!WP8"9<"3
M1-D`#@D"APD`+"F1$`!]@W`'ZMB8=1"1%`F3C_D#Z*4%:J"27/D#ECB390"9
M:K"3F:F4=?");U`"'3E_=UD'>X<G+Z0%/\``&E`&#>F0-J";)%D"G[B:0JF4
M9:"1%[")=[F0+6F'CG4(0#9EJWF0)(A>*/4?`2`"DTF5#5">-NF!27"!#9"5
MA3E_$CD`_567-"F=#Q"4`,"#*8"5[SF:2[D'")"5=ZF5"5D"%1F3S_F<&."0
M;^"1)ZF(R!>1T=EA`^B>6ZB%\:EY-J0^F?-59N-"9V,\&<04V020T<,)!T+_
M"N$5(ENU%](!#('QC%B(D%3)@0Z)`%)IG$VI!@4)`)_X`PT``E@XFB#9`$9Z
MG#%YB4$*`DS:`($9@X=9`G30;L&XD(D(DPCY@`@PI/%I;S@)I9JID`V9`O9U
M!7G7`'`PFF7``$PJ`CQX`4AYB7!0`TP*`AOHD`'0EP!0`C40=ADPF67@A2GP
M2?Q9!OT7A'8JG3C*EH'Y"OE'FV=Y7PV`D`Q0D=-9`Q5`HQM8D3>(D#C`I'!0
M`G?)`*C9@V\`A@C)IYG(H*_Y@&]PA;JYH.\5'ZHQJ0K)`%,:C%OXHPC0G@H)
M![SHD$E:`B"PI2J9D"*@7BDG`E/9CB*GDCAPH`D)_YD7`'*L*9\V>*H,4*`@
MD(E[8*<UD(=9"@=VFHS,^@%26F=7.']NR50W.)FEZ9!JL*7;NJ<(L*HI$*</
MV*='RJGXR0`U\*Q;6)%\-V>$T)0_``$?@`.?&$9PQ)<?8)P.29\-0%\>US7Y
M!Y75MP<AUY[8^@,:RX=Y^JM\Z)H*67WJ.@!4V8-'FGRIV@`8$(0I@*5R:J?E
M*IT_P)$`@`,U>`$0&XO1R:!EZ8DI:Z@:*B6ZTUV:@A3-PG/G@`VAXQZ*Q!IB
MQAG-L@TI&E!S)0D7I!V.DAZFHQ+^F`T\(%HS2[/4ZI`;:9V7V)PX$+'2J;8F
M"P!QJ[8(R@!GJ[9R6Y:5JO^W%[`!+/"),#F9:4N7TQJ)*K::"TFDI7F'9ZL&
M;UL'9^FW01FM?JNV!5"O;]J#QPJ6BKA@UL2?:7NY$,FH%Y`"265R.KF0GTA?
M6C"I>VJI#DD'J2J[^2J1<*"V<X`!9;"6<%"19PL'"FF9:JNX]:FWR*>?8<0(
M^<>WLCN=3JJV&T"D@BNLL1B2#KD'RHF]^:>I?"B]7MB5Z$JPJLF:<#`'I^N0
M09F[EPNG"#D`>=N#[LF^Q<N+@ZH(<*-MD2NXZ'6VQSH`>JL%('"R[7L!J_L!
M%?"\-F"`\HH``^!].#``-:`&861BG0H`-5!H454`/!``ZWD%M`D"$RN1QVEF
MGV#_7[!+MWXK<NAKF@N9B;9JH#>:D+>YPF\0OWNPK1]PG&J;`D&)O>V;LWZ)
MI$3ZPL)*P]7KD#]@D]6J/;0R(V>2M>V1+Q"50\>63GW6%"ARQ0#Y::>GM;]"
M2N1!1#D2QAS286@KNUI0`['(A0AIF7OPMBJLMR`KD4E\F9[ZO'E;`PJ)B>T[
M!V?+QFPINTA)DVJ`NH)@`SM)E1CIN29F8O(:N9.KMJ\KD9;;P\7;HYL[G7WY
M`7!0>`#Q`&1INNU;NFUYNN4P!X]*DU=PNO0%NS*LMK0;NSU<R/1K@ZS)G.E[
M`11+QX3YR0YYMI",NJP0E))[N9`LM`F9Q$$)P&I[K#C`_X<WJ)"Z[+<MC*`R
M3*'FB[YG:ZO$>[FPZ\Q[2\UW',Q)I1O-RY4.Z[_OJ[??JI#)VKX(>LS6/+/(
M5\01:9,.:\!969IAXL&J::MM^0992:K!?+]@M(:OVY$,[+>/J[&Y*:9VFY"!
M^KSM&\<)R<,3_0%]&\0T^L8V6)"&Z;D7@)F:&;[(/$YRI4&K0\9ILSX0X1IB
M$ADP+9#Y8E:&83\)]3)A>Q31\AE4VPL=EJ1I6X;OBP"2S*,9Z9"`/)T8^0'2
M"<E@"I(#P`!679IO>:N6.@?J!HJ!3+AN.9Q+^0#5BE[-/,V(Z9`/4,$]N,B3
M^\B5O)`,4-56W8P6*<>;#*<2*?_#H4'0MVJD+,`"T?N067G*U2!@?ET'K6QB
M6L"LM#RS^TG-P(M>A0R_>KNH09N]=8F8>0N1"!G5@`S9)\8,SKFPD_W(HLW/
MRTS)(PF2;NG7:<VY!,S43;W1V8RZYGO0"_T!WXS:%XRMQ;O9"SF#-;`!6\T<
MZ06[;PHW-4:?SFS!<5H'<("F<,`"/$B7DAW,\Z6W`ET#U@8"?'JZA_!U=7G*
MYUPJ)J>XFKF%(*"NKVK"/97.-,H`#8``/_"]9TO0BYN0'6W`"DNC_6??9QO:
M/=C)QXFZ)N;95&W5]&VI&Y"J*HN)#7J"HTG2^IVE_3>EVNTRD2`V8<((6X43
M/P0/R%+_XCH11`@1&"'^-_X##`D'XCR]XBMS+%OB._Y8#EK0VG4PV6N<D"`0
M@?RMCDL-BNCKF@D9U3O&NS,ID1H``14)N2=;L@TP`%0^W8(KR(8ZY:TJN!2*
MU^++UV"DRC\@R>;,7W$ZE!))!*=\`07@Y;N<I#O>Q*M!EFAND`KYIH)\RJ/]
MJ`NYV.L%R^3[`'R\LQ4)R&IPKMA*7P9,FU%MN)P]T:S[N:C+W`MVL*4-Q(.Z
M2I/.SQ*9B(RMX_V7?650!I>LU`#`OO,%18*@B-A,L(/*FL1KP7#)VY`=1@*&
MUHD>1O+]G&NZ`4?;"NFUV8*+3_S%F@S@D!=VYI1)!!4PLYM=_YJ/3&3&V]\<
MJW$F5\F>"[J4(9S'FI#8&J"R^`-^E-Z^6N=E\+N[K-Y3^:8S^P"VZI<+R<"V
M7N`93=M&O>2<*;@_\+Y"+GX`T*V++)VP2)0\^8`5*65M`J*64UWED3IE'!RM
M,WSX$TFJT;4"I$K+`^,4'U`6WX^\,+8Q315@&N<=MI\):9FS&;'B![>GFU^K
M.\>('*&:&>J'BKZFCJT;,)D\60:3FZ1USM'\:V+Z?<IU7`8\R`_"V9?TS##)
M79B'.@`5T-YXJJ<97&B;!^?`.TO@OJ=S70%S?>5@W?*>P.>*?;I_7KMH*>@*
M:;EPA^A\J.@ZN=06>ZP5B^SS')B[<?]1S)L$SOWVK+3/?OT!GKY>K;WDAEJ]
MILZ^#JL(Z]7JBKASL*[6Q7[R,^NPMQZGV-H,ZU6-1'J0>XWWVE%34%[#)I94
MB7:LQUZM9N[T=`VPI_OL?*AA@G#V[XL!K_J]*9;C$GV_"+('X9BJBTP'8)>0
M"2S><E`IX@9VN5B2LLC-ZZ7(0EGWZ"6O-<``.GN8Y8?(7V?@3$T-<,X`<!#^
MTVVI0DR1#;J6MUG')-V#U8_/44YAT^&/*=JBFZ&B^\A.QT#_#]+QB00($8(!
M!84%@H:(A1&)@X2"D(N,DI.-AI>+F`&/BI"3GXR<H*.,E7LU```9:A=:*0\U
M90!P%Q=O=:G_N6^M#P\I-AD?`+LI<Q$/:@T`'PQ[M<^U>PW"):P_#0TXRV4;
MM36X97!P&<L#SJTI6G"I=0UO#>0`YA=SA0\_.!]UW?3'TL(,6$%[%D`;``07
M4J3[Q\Q9BD^^Q-3YD.%'K11[YJ3PMJQB0BV0M+R)=Z65%BW*`.!@=?)4JE4F
MU8CX\&'>QE-E]%F,-D!8@XWIWN0\6`NDH`>+'D"Z(Y/FRH2>)CVPA0N`C8]:
M,+P$`4<6`!'G+JCI":!9PGK'(IQ$19'5Q@(#EOV\\$#+GK@?&CA[8"S"GF3"
MYBD]%DW-FQHB<`FKH1!2`#G(\M5Q:^S0R;AEB]J=-NM<L9N</;Z"_U3WPH\!
MLF@"_*&EUX,[=S`L/EM)J3)F:O`!9+"LQEY$CS9>V//C\("J^T:WXEQGYRM?
MT8IC8."U8C&U:K1]J%%+:2]4\@0.-+ULI9H2-,VI"59F%[2_AZFS^Z%0*250
MF`YUJJ0_48%-^B'BB23Y11)@*9T40DB`]U&227\.0G@)@`8.V,@D`2CBGX68
M[(??@1H*&-4@AJCADBHLI</6/!>0I4LKQ_P2S#`)'?)`$K<Q,-XS""Q3!T+/
MO-&1>PA,!%-*`.@5TXRYI"+,9'0)HL45P=3AGG?2I&+60&\9!.1PM]`$0BT5
MIE#D!]7L>`%;,/%25PHC">/>23.IQ))=X/^E>=)8Z86E&YKBW>63%JV8%L\\
M1JE1P!ND%9`$GCX"N8<O$?!@(U6I6*105N4XDU(=W"5T"DW-P3B'%FI<H886
M;(HWEER;8B2"7,YHT1=3*2'*5R'CG9D7F0H6$)E.M?15UQ[YR*/9/TFJR18`
MH>[AUST"J8%``PPHEM=42K6F%;1GS5%/AGS.4LL/)>1"D4721F`,&$KQ(-XS
M($0:I8HYI9E0"@7\,.]P*95!WRM:)*%=J(-%H%5-80WT0[[.P"$,0FI,U%Y"
M)@[T:J90(8B?*,#U5Z&&EXBXWW\@6A()ARA#.#+*41'(((,+4FCR@"!70N*(
M_RW(W\OW>1AT*/__J6$B>#"=Q&JGY\8C9\>_3$3C0X>HL;"^>_PEW`\S,K"3
M+1WMU*I8O'U0AJ2Q"(,##G64D.YLKYQ*I3Y7JL5L">QFG36ANH%*J+7:>73!
M@,?DZ5POKJRY#-[#&6VT%NCZ)%QV3-MU8II[;"8,'*P0A]IBA&Y4KI+1W`9J
MYX8-T$!=`IX4)P!X._,7!@.P-M4MJ;C7"GCSJ%&VE4$.57NM:M30`"MA_GC.
M&^A],"9=F]'*BR!_Y5IK+V\,X!LTYWV@`<(]8\<`L?S.X=I=J0Q05-:R*8L.
M-,#0Y/7>Q0_`2J"G+5,!*XRDD`P`/TH(7S[!IW6=*UU,\U\!^O*0!M1N_R!A
M$HT_>H0FY_#+@?2!1MI*E8X4&*PW13G*M^P7C3T0S#032=,/:H``9_Q`:MU(
M`08;]@VSL0(I(R(9:4(QLIAM@A,7BE#*9I9#!0$Q0I'(&1)Y!B"7K<Q`#0K0
M)F(6+,<0T3X>XEG0%D&(:_$&`&5H``)V0D$69>E%#XF`C)9!#+3LX5MU@`,(
M&B`.=]PD;6BJP0^NX2.Q+4X@7*.)1]!7$W\9[31J^PWDJN0><9UD&OI0'3;@
M,(`-N!`]*L%&!123`2#QI3(V8M-.C**6->6D#`R8I`,1L)%Z`5",",`+C<`$
M`LRTHP:[8%8&&L`5<OCD'-:"1RI*($9`OBT<-?\P7C`:`!5)1(\:#4@F:@0F
MDAI@1AYZY`AN:H&[L@CDC+"+IC7M)):>Z`,$AWE;J<1BO+=E``0(4$,:-<<P
MDX@D%7#`97'PPC@MW*$`EE(+2E*!$%O91YG"R``+6<(9]:'C.</!P%"(*4TP
MLD)U_AJ.Q#X`!V<(PG\]X:!])/&LX45NF&_8"%J.\H">[!(!;RC.^.0QAXZY
MQ(#TZ,4T=OF&-]@``9A44CJFY$OP?<='JH,#-MS!MWS]"X5FXT=/B.E3&]0@
MJ!YED(62T""6<6B*2IFBT(0VLZ$9T8H]?%`/=49%4=@,B5U%*Q1-YA\0O0R*
M0W044L8G#">!ZP(4G$O_+7RWC*E]-'X?:*,@_K<,U=`D2<)Y8S`>6X>J,$YQ
M;7D&'LTCM2_5@H(74TH*`GFV[OB"(8YM[%S0Y:349L`]S^G$`Q"0$Y&2AE6I
M<:P&:C)8O&B@M>T@%%U<U%API6`=K7WL+L432+,Y26!!>IMJ`*`!4#7S$<Y(
M1FY;FZ;;J.M7F"5A+9`D7IE,5K?B9=YC@1LJTPS%KV6X2K?4(#%Y7.\!;X#`
M=+55@BO=06<BF0A8H#*'./65)A#824,=,M*I6&TBCG4**V::`;>%#2M[L,%$
M;`)*R\`E)_HH`2XJO(T:R!,I`;J-,+RR&M,B8V&B$=8#,+#;%8.X)@)Y4T%`
M_W@=I;`EPM[#0"TV\,?QD)8?*@9C<<6;,)G9U4%9M(2$;F8A+>;U$/DI65I)
M$2(J9MFN7F[0$<6<1*UZF4-G+@"J&E`"!@S@S0Q@@'O>L#8@;2I[)7A@,31R
M!1&L35/B\K&;!Q!G-\>9E0D!$YLA`($Z9&``Z!0(GL4K%A`4VJ>$/MY%-G*-
M0X_F@C@8P%7H8KX(U"#4`\#!H%6-Z&08>M#1_)I"ZI$(_*8:#@40H(!L7>@X
M$QH'7W)U!AC]Z#=X)@6G[G6HKW(*7_LZUL*M10&P->@!E$`$;CE7+3-0V1+`
MX0TL.0;,_O8.$3L:!^[X[-K>3&@&`"E[.*A!30?KP/]E/V,/>*YL!E+Y-=-D
M(P-E:!L<?A"6L;1YT&[.]5`+D.SMM089-8!#"1H=<`:`X'#_K83_QN<1D-0C
M&]5.)4L:'CI:2PE,`^#VN=-MBY1#H`QE(*9S]L294%$M*74I``9PP.TR['*/
MU!Y`2F]^C!5*O-&,UIY`'N*:-\19T\;PQ0]J:6Y'5\#$%T$<CN+<1F%%():]
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M,;Z@$([C+PVC%'=@'W)0`!O!%E!W*K)7%$!Q$98C'+1F".&7?D:C>^2W?^(Q
M5/@6#&V"8I0068<T+['W)BBF1A<!@M/G';U@-,G7#R[8./LW?95A-UFC4J70
M$K"'$35(>C6(%KZ`*L@P$-&'@-`06T&D17CG57]'-%UF=QWB=U.H94\F1(*7
MA:*P_T6+5S*(QW<JDU9F10F#@7[D=WWK9PSS1G[B8AD#\7D?I2;%$FB)HR;4
MAWY[:(?%)RXWN&GUL(&CL0C1MB,:H88#H30F>'R'&%N3<"IV:(&*N&E[5HGO
MYX</]TD[0GVEH8<CE0F<AXF9.!YL^`R!]HEW.%2@6("5Z(FDF$8QPGK'P!>D
MV!K&D'$%T(!J$3EEP!V7V(FG>!$_4Q=Y.(F@J`5PX1,7D8$[Y('(.!J>H(KC
MX1H)PX>#83Z'R"5]81FHMWEJ08JEV(S&\HC#R"77@2!.9H87$GF"5X:'QX4>
M\V5+-`I7.'@D@WA@-E<M,T1Z1W<$(H55N&NQ5WF?9XP%*?\'J?APG]<7=M$:
M>]:`1VB,0T5]#>D:0%%R=(B0MQ=U\F>1[A*'1_B'@(@XN'@)KKB'N*@1>!@K
MZ2!0_`$BVOAPG["#KEA\ST$U*JDTMG*0;[*'O3!KE1>`K0$)GT=]=O$9GR=C
MX5<?A4@@&=(+B;B''3F5/>E(MN>3M5B5YD.5];%KU]=!#=F0GJ@T=5>`M6@?
MXB(<L*@4YG,'20!$)A(Y5C)K'.F)KD&2/],7X6A[0NDNU-=_O<`(RJ`!XM5A
M*W,L36F+'?22:7$4LWAZ>^8:BU`?N)>!=?$FDKF4^G$LQ;!`@'@4KH"+%CF3
MKO!)*S6*`8@XW]B0X;,SG<!548C_CU"9(61EC^U(=R?C,[A)"KG)91[S5C+C
MF_ZQ(&%H=R<#AF&X15%1#X!8CEC4C8\9AVAX#"8WC2S%"-29%(\I"(#8"%))
M&JX!F>(6`-0)"9]Y?(.)">.9G=J9FNU9"EA4CVD)$?99B]9Y((,YF/G9@)9A
M4(P0GH?`EX,Q&(;PG<>@!BQY(;[`G[U`C]W9E;NR0`LDC=.X@._9G,XYH-Z1
MBHC9GFX9FHM0:M03>#MD(\7(GSDDFY/0>P@@`@P@;Q;J&GU!H)\@"38I@]DH
MG]XA)?QI`R*`4=/#,_B9%J')4@E3(?;`E\]9(=&9@9TYGI<YA@%"A_:@HJCI
M+MDYH&RU_Y[3V)[;N8[NJ(_W:(]?*(]]5R"/)V4TLYR*]V1DB*:1!U!1)#11
M:8]*6E;,B9UUYS(&&J4Q6:2$(UMTE4/XV3.`.C2]2:1\.H8[1)Y7^JA\=W>4
MN8^6:JA2F*1%)*B8^J@E$Y]/Q'AV%8J0^9N,BJ=1\:=4)*DVHJE(Y*JU-I#)
MF99LF9F[-B)-!H9IT:K<^:A>BA0>F(ZK>JOTN5:J&C.$8Z*.IZ)1M(6[>JB=
M*JN`IZD?(S)DY2!-=)QT!64`&439:H9K^H]7B*AU2E>V67B$LW@V,X_^N%:Z
M.66S.JCNNJ>-MWC#"IR^J7?*:I]R^J[`<:?TJ:B3JHZ/H*SM2O]EN=D?8'4S
M8+:>S2JO8K6M5=:I^KA61#2QP/F$4;9W6]:%7>@@2?"8WTBMF^H(3G2?BSI7
M&U@CVKJG3HJ<>7>J!HJQ6!BS&GMX8?8R!1NMN'EENPEY[2BPDYH)9\J.-#NF
M_XBJX&IE.'-$')NTW'F/=06TUIJR":NP)QN0876Q:4JT61M$E'"F8J8?$3N<
M[&JQ08ME8L6F]]JL-/.O7ZNMR>FM9.NTNMFM6$B%>KN.8@JV\BBJA,=#:-NR
M9KNL0?F5`QL!0&2W'X*W.E2`:WF=A7>P/7L@BUNU2R2W4HNUMZF.]2BUM@FX
M"<*UQQFVG+NH\+JM?NNX`:DS@9>K;[O_MQ>+HFCJJ/]1A7TK1+9KG.&ZIGEW
MM6R;CP\"5T'[K8ZK,WY+I>0ZIL,[D,/KIEB6O&R*N<5K"1%[HS$KO-!K",+I
MN_PHO5CK1**JNVD+H2(BAKK[KEKXM\/IL&5*--%[LU/+,L";NE+FO,V;1+R[
MOGCGMF3:,HD'-,@9DRECG-S[N_F;L_T;9?`:M++:C][[(>T*MKS)NF/6OV9E
MFQ0ROS#CK;S[577K,O-KIM&;K@$04(IKMYI@I_];12E\L@0<ML:K(6]UN=B[
MN<KKPNO*C[CKJ!@"1#QPKCX[MGGU0__ZK,AKMEFVJP<LK@H[N0K[P5#TA4*,
M5Z%KN3F\K@O[_[R,MZL_!(8U?,76"H_P>V7VVR'H6V;)N[8CG+\RK)P`%;K=
MZ[E9.\,3`I5ZJD/8*L6E@*B.<%<Q'+Z]>L<F>S+A:A\S7`D+6[8B7+AJ&C.6
MLL0?(\9P2[_TR+<7'`I*-*Z/_""4K,G^V[Q@:\%!O+V*=[;CJ[^F'"*9V\!?
M'&9\.[L)_,H8+,D_N[>TW+N!NA^9;$1FK*?`+,9U*[8%TLFG"Y6E;,EOJL2]
M;,2U3,#\V,O)C,':NW?2##*7C,.R&\6AS,6#"L"W"QR1C&;9["$^8[T[/+5?
MIJ0VK,G8[,:;"QR/E\N0W,ZUG!_".;9)J[U9=KU-C,M#_&7$W*;[O/_.R)O/
MV!K%CYG-$T+,7KC)!OT?*#RF$;O#&\S%?IR/CL$))^QU?0RA/>/0<I7"5A:_
MFO#.?XO2V;RN]UC#!;S2`SV%Z<S0(:W&!*VW_"PA)RS$_UO(RMS//!VKC#?1
M@8S/"'W3KWG/$T+4^KBXY\K*Q9S45+JV$`W3`LEX$%W4]#P@T]S!,OT(Y!J\
M65B]?PS*Y8S(I^N%(8R^9+W+C(#"6#UE+GS$H(PSQVS`;ZJ_(:.N=QV_`YS1
M%0S0<*O..PO88"VN<(W7)MVT`TS2XS+,)KV[G"M%<LS-Q5S8+AT58/6:$=V.
MF1T)05S)G:W/[[K!H;VUG*S/`.P)'5W65&C_ON8WV6EA,Q>-UVZ]S99KP^8+
MGB^\ST2#UF;-UNK*TSY4MXJ0K:>LUN?;SOTHL,T=O8J]UW4-S=0,TD9MV:N<
MQ!Q,RX\<PV8]N6!]U*N,QLT\9BU<5[T\VF0ZI^K\,QGMWM0<R'/*T@:<KM.+
MQK79IN![RFQ=R7M-O/D-O^[-TCBLA1L,UD"]S)'`5>N[Q&)(W\H+Q6J*SH(\
MWAW,MG/]OA/NX.CKTNLMJN?<WJO=W<:LSM<MO,I<U`*=R56&U3\DQ\*LQ>.L
MLQS-W>;MXA5,(#S``[/]XL;-'S4\X^9<XTV$VUHXS83:T8CLS)P]X7;,VN?Z
MQ;+\SRG\S@_-FS>^_\?+*:Z$D-D-33.!C=0OKL$('L"(@.2W[,[AC>`3LM'^
M3-D*&\3,?<!1;.6X;./+;-F0D`1\SN5X3C)?6,HMZU8OOM'YZ-1B2]<AS>*@
MN\ETK>8;K>#?K;,H.N:*SKU/W=%R&\94K7CT;>=)#2"T+<QQ_.AHQ=9%+M4"
MC>;`C.G';.(2;;.\:0BA[=K0+-'8K,RIKM+^L>-<V]N*O.9^M]1%^[V^#+4E
M'`I(+F5L[L>-Y]U^3*J^.^IYW=``2[ZN[L1^_=9,;;/'#NS:K2"U3ISX7.OC
MV\_CKKHGG=;WJ[A!'+*,`._3+E:M[;NX3KI3&\8Y+=&6<JSN_>WUVM3IGO^^
M/\S-**[LQ2[A!R[2"/_K`OWJ#N[K/=SL"Y^GWOS?TRW?=^[CG1OPDIS0W#V[
M`RW6393/A=?M4JO*&;U$SARH*5T($C^YR%[B>[WL?^?Q&Z[&.]W#..W==EHS
M2JS0H\N_>QWRNYGE+Q_2VQ[@1?WSRXOAXGW#GKX)\-[G@@ONSZU52P[P1+3R
MD>W*1L2X>)S30%,S*BP);W7P:ZS"-=[JK6SV7UO0S]VM2M_Q(R^FKUW;A+[E
M&OVOR/VYV'S@5>O.D3TR.PSL;OSW#6[J@EM73:O8%[OS=KTS]U'RVISQ>XN[
MHEZF]FSOPVW0D_R.C0[Y-`Z%^-&TNVWP8^UX2K__V$/.UZ/[^+;,]-I>O(+.
MYU;/YW#.V(,7UO&,^3*_QQ?]\FG6NH3_\;L_^=AK()!?N(=_WUZL^'V;,S7,
ML(7.WE-HA1T"W(JLMK-9N6'(Y'/LR`1_W&5[P31/W94P[N.?[1*^G`L?MZ/<
M]U_NTTZV^+?M_DTNZ1(,"`4%$801@@4!`8.&BH2'CH./D(6'BY"(C8P!DY>2
MAHN5@H6?B:"9GYVBG)^2E0$\IINHK+2KE:.NL;:-JK.LO8>OLDF)21%)R*F6
MK;>7I8X\LK.AR]6>P=&%B92@H=S=O<ZRF*#?UZK>XM+/S,V^Z>*+S]/PY^&"
MPI2\RXK-[>'?"+&+!,R=_[M?MZ@%3&7.&C6"[8PAFVAIHK&&JI`)2H*HFS98
M'7]=5/;PG+ED#R,\.&91%+Y^$).!D2.GP$1(Q7#UXU@)C$UBX"!I!,>3Y"":
M,-$YY&6(9L:)LI*F`XAO$$=&K:2&HB@J600PI9(90S0VPIQ#+2'B(W23+<]6
MC$Z^C:!H*"6O=`ERXS@2*+5QQ,8R@^EVKE&60]%=Y"K'+%B+<M\&0'9JED:L
M;A&!,?K0JR2N'M&R?3E9\,:;(2<1<]0OTX-@"8-E\O2K(4:7"FLA=#BJ-^Z7
M>@MQ/-7Q'O%YF"[Y1GYPZNS9-EFR+%T8+\)C&PNKI+MII2,YT+.SMB1PV\IM
M0O\);>YX\5#-4<CN)#O[GN6@LY/O%)H#?C*DS;[9LUE@VI#GEED1(+7('-<U
M1=-[!<"BG3[1<5>`4PQ:-!(C8+SV"D0JS<$@6#X=:(AZ:*'CU(0UC>33:=B1
M)0A_-?T4$":+;2B?(#4Q&%U!;5VHR$I`L6:,?BNEEIM^&HT4$CG*J;32B@^@
MYM`B_26Q!UT\`$@6?#R)Z%02=^C'329V'0-=;TE0B5@!8(@X1TZ")(E(>M\-
M\@"1C=CYV5!R`!AD?J/L*2*.27@G2(G8$>;G>)#J1!QM!CT7%"[_&-@;*9%\
M2&E!]@#S(6N95(99@^90V.EOO:$GDI/NQ+>GF7N^5L#_`RG4.J>FPK4EY:DG
M:B%L!'MHX5U>N&JAWT%W[.%LL1X6L$<*>R#Y2:*YRFE3LRNMY*RP?O+3%9G0
MBL*@2F7>8>PM*>1ZHDK.XOJ`&MU`MZ$HQBKKWKG;EKFG%EL2$FVMA*BK10J?
M[$EMF5(:6\B>N*P8WQVX1J"&O.<2LL<#RAIR[(5H4?S`EKJ,_(#!^3K\*[$B
M'QM!F<X*Q`.\L^2G[,$`JZ%2<39NG&ZSPCILITI:G+4(Q^OJ>7++'(?[S<95
M'H+?RTA76RO(Q$X++H)*5RMPL0$#&^.>S\9\B;]$*RJE&OZN)&+#`G.\,2JS
MEEGDR/*1JF6WX#YP+IG&$MSR_V6UCAQPDN$M!PXPNFD2)6VZ';3IXQ&":$MS
MG_HS#GE*$J;,;?18PQ"FG-OPA@U7I)ZZ#39L5P#KJ-^ZIQJPRRY=`+`'H`5V
MGYBN>@"IJW&PK8A<<7IPAKQQNNJLR[-Z`'//D83J9@FB[AX!O(%`#36\<47,
MGOAEU>I7N$X)ZU<$L&<DM;.%?NH__+")RO3@$H'J5PAVZ"#-)O'&!!,0PQM^
ML#X][8%V$\#`!&P@K8Y=(7[>@]T5]$07]$%L*ZNS0?Q0=P4;S&$E',0?`XNE
M!9<<*0FULQ4A>(`ZX.%O=05`F`0Y.`AZO4]XHL@>`QTAI>F]00PU0(`-+H:X
M1>@'=__H<V'Z?J!!G>7.;XOHH`UX<#4.LBX1/(@&50H@Q?)A110L%.$/&I.@
MY26B@\?;DPMA]P,8NDX:(GN=]KKW`S7,K4YWN((%Q#`!!+RA.Q$(8P8M((?U
MP0YUB)SB=H#'NB3LKGJ^H\4>IB<&!;YA9MY!XB%M`+Q;&>,\-A##]KQ'P=B(
MBU2@"E4_."&*1W5B<@%23N(>D9O=<`,:ZPA*IC!R2\?5(B6Y24PX;#"`#)0@
M`\@T9AU*\(8+[`$!.$`F#L1PL#NHH9@XL('#+E(#8Y9@`#:8FR&NT(!DFG,`
M-;B52M10S@R(0'T(4HD-HEF"$N`@FMF\P`/:B8,!?&]/Q*S_PP!^@+`Y:"$`
M&&!`!LH```#4(0/H5*=P3%B`"3#@F`QXP[JV\X9H9@`'"`A<`43P43$4ZPK8
M-"<.&H``VRFI&S\H)C(Q(+Q)Y+$&Q61H&>K`@!K\@!`I4`,"BEF'G2ZS`070
M0DSK><QS_D`+:N@F1&.(D"N0U)S*Q`%!V5G/9-:3`1@()RF(955DEJ`&%KL5
M.Q]JUJ8BLPXUT,(;DHG/.M!4"\249@.@%@$,?'0"'US$&TA:U#+LM*<$G,7(
M,.#6>V)U`&JX9C1IBK#[D?2L%?.K,;&:`;02#"4UB*8(:GJ(*C7@H8XU9@T^
M*%5SE@`"S'0F!CSJ5M5>;!4!&.I"_P%@6(C6@&.$B"H.ZE!8GM8@LN6L)PZ:
M6H,]7``!6.VJ.W$UTF6N5`VY>D!',X#4L\QKL#B`0$,?VH`W.`N:T2T!7)\5
M@!HP@+@ZA:@8+F@OP]0#<ZN2Q^8L]Y8-P?))`SF34K)2BH+@1"MJ,<5@#))*
MG@&G7HHI,"54<H4,?*"A'\@P`"[<S`O4H`P9_L``8@@P!G`883D<0(@!T(!A
M&2.F&B[JAC]0A@9$X&!S4/$'&(#=\]S*!AG`\(4!D`$;.%/'%\:`<^5JX0P0
M=`XI",``0'SAG<ZXR/3S##$&@&$64U=C-=AP0QE`T`NH`0<7KL$%+I`$"U^X
M#C-V*%(?.?\-]+Q!S!\HP0\NP)]&D)/*O&4H$2"@T1*>5LQ6YK"9W2SD#.O9
MF0UP-$']](`KE$##>/Y`'?:\!RY7F;<:QL$;DJ2E/4R@#AIF0%(CH>,98SK#
M&'@NG+O\@;U>X`=N_D`&.LS.)!MT7G[5\$ZI#(&0'DL6#7!UHS^@@1+8\=(:
MV&NNM&#I"[<8TBMVM08P@#0B):JO&\8!=EE1)1$,6<QPO4`*(CWD$--X`\X4
M09S=#8"X?BP2&)@U<8N:87$+ZP<B`'2B-[V'9(NYH?5.@8<;C?`=*UP-)MYP
M'1"PY@>$><<QW!-T-ZR!1$?;N0B8=[NOS4X0.Q2^%QY`Q1Q,&6G_P$,JO021
M-\BQ.%B2+A;(^V6E)*P<`&M%YZMD!<]#!YM@]'PJ+9=&P@IP:0#@@'L-:``&
MCKOF-\RZH4IV)@,:VDRC[6&N76:`<X\Q+Q4#X*QO.&V_]QQ4>8O8N=&*[!O<
MV]`,^%$-SH0#PL^^YPM4.,]XIQ8&Q'Q6"#9@IT9&<87J=`4<-)S'[E))R!%>
MAN::.>)J-G/3&;"]<HJY`79<E\MK:/:&EJ&9*DQ"OC/<V1]LH`;BI;@6$(!J
M7=.Q!B4`0#/5$.2S@Z`&46<IW@ONZ,`WY<8_R+W3N5<#$#3@MT?><&>UYVD6
M1P!ALW-[ANO03*@*M0&_W[I#X=#\!NQ9_PUSGS4Z?^#<Y'=Y`,XE?N45_O7:
MPS5^/^AFO;=6X+2#'PZSUE/`1W%[X'@```(7`#!0A68LMF9[@`%O]GR_AP$-
MD'BDEBCL%&X]Q@IY-%0(5UZ!9W`E\'S@]WS#EVRZ1H)1AP%[MCN@<`=@!P`#
M%5D_T`"P-7P?=F%H-W=!1G'H-V6\U0`;@'<+UU#D!P*_5P/P=GGG-E#.%'(B
MAG=XA68T)H0_\`8F-@`*!X5U\'S`!WQ&=@%6=V%P4$=7*`("53$!412<P@^>
M\PX$L28Z!SF3TPZ<,CEO,6#`,F"7(C93X1*3\DJ1LP@:TA8$4A634$(6!@"Q
MMF:.N&:S=W6ZUO],G:9H*%9P#:5\IZ=/-]9K```'SG4!(+!ASK9F:N!V\,=G
MG1(!D+9A#*!PD*AW>P=9MX9JI2B&;D:+COAU&%``ZI81VZ`%879R#A57V16)
M>[=K6G=A%*=Y:>:(&:AI(?5(GE!IJ$9<#05ZD?<&F]=W:Y9_Y^=ICP:-/K5H
M#=6,C^B`*%B**?`(0<6`F9>.T?=VIJA\JJ9/(S-7FC9KUP8UL#B&XYB.O/=N
MD'AKR@=GZ78!D59YIFAV`6F*W7,P"#,.%_-PN?<!F0>+!=A0\;B,#9B`$"B#
M1)B.BB<PT8@#<%<]@Z`%8CA>WK@'PZB+Z8B)M2:/:Z9X*SEYROB(3*3_<,EW
M85K%D^6X9K2G:=[H82"6`2,ID%RV=[9F=3(8?^S&?;!H9MU#E!LFD^D(@7G6
M88YXA;\H.K91,X'H"U\4):-C<W`X"J.R*3RC#:6R7Y/0"Z?@*B^W#[AQ2W0I
M#5[Q,VWS,L9`,OM`"`>UB*#G+)$%BY&H:T&V8\YE=AU&"#\`CQ'7``DX,FH`
M!]:FCFD6B@^`BF.G%PF(@@SPB%J@F6RE:6HVD.*F;BBX:3;)DOHT+D,2`1$'
M`DTI=D$E+`C`4`^5E<YB=LVH!DV'CHN68?"G,NRQ)R&)3G"FC+,S>)KFE8[X
MC[47C[#8+N;(8H@96:&H!>N(=\235&=V82#0_YW8Y8">-@"[:(\/<`'P(H(@
M@&I.=IFX4G6V>)2P.)``L(0^J7P#\)Q[!H$).8;U9I/5Z2$\))L0MV$=Z4P&
M"'IJ4$?<:)Z0&))Z]BR)F8#O`B_2*7:<^#?O>6<.-9(/.&;#IYWJF)78%5F)
MV2YV(CR3)U#L5Y60F(,,29)5N0$@5@=+^6$.95XN:D<-J8/7V$P_`)Q,&)7R
M"(M0F*%#ZHA3:7Y01I+O,'H$ADHZQT.^-(>F4H?5L"D2$B#W@`EQ>2FIP1P)
MU@GL,`^[T2FG,#%^*2SIDE9"]S!_YU`#P``,L%S0)VNU5@.S9EY-28E[(JA$
M]@-TT%#PEUV9J8-3%_^@3)J`IZBD38$OT?B*ZI8K7%8&O]=0XK8')M::UX2B
MINB=W_DV-J(24+EI;Y"4>T8T8L!0`U"A`(``E7BK]?B,T"B.PG-OWV9VS65V
ML>8N[-::E]DNL`BDNG>3(E*5O#=>?'I/3[>B@#>;(#-)!LA3?'I,<36/J?A,
MLZ9F"#-)P@IQTGB9*J%P8UB??/:LM[:(Z)@"[C=Q9K=7-:"::W9QL,EG=O0L
M-VDA2O.>Q.F@CB@L9R:M?5I/)H>`(%EE)<"G%P5Z@>,(B7*B]%@+''-GFC:2
M^S1>`]```["G68>)#F5/.*!0VN@RM_*J"/=1Z_>=[#:.*5"EF[J%U_BC"!?_
ML2G[365V3:H9:0#`8VJ`:JF(:[R:@!+II`QU=A';IT%9A+RU3#$+B:="2XAX
M8("X)L!1'E<B.6QBA[TQIF/Y16W9EGP(<Z02=*B0"&=J%#!';<$WMW0;?+_U
M&F-*)DB[;$!0`418E.<YBCL64USG3`=C;@VX!T>JM$";:2GGC96:L1$B"_-"
MF@K7+I5ZJZ)J;5BH:[[8H)_H7.S$`",;LNRGJEYQHC*X9JBFJT&U![/*G720
M89S7E,WXDP=ZLX=GE-CJ(P601_2Y9^S6J)7+J$LF)V:Q9@;GHYLJ)R)R`06P
MB!K@;B*VHF=G?!=R8P&@?-1+!.$JBW4`!PW``.(%_P`BL&0K<077*+PI!RT"
M(U?!JV[.2Z_R>K-`UK$<.W&#EY"#=[U660&E:W[MP@AC*@CMJ'R9)R\)RU#T
M]H$WVG`A1@1ZEBL7LQ%[@H*I^!KO\2]B(''>^+$0_`%`4(HFZVHBK)3P>1\G
M$HV81F1EB&T[%GC.^ZSMDH/,FX!%2+TG!E4FMFE%6X5CF(J].9TWZ3"WHG!`
MVKT?T'=`FVU$1E/8>@T%9@UN*P\%#*=5,15:!!";,AQ].`I;;!-9K`\P@6#D
M,0[98"&X5!DE41)SF<;!.(;GIL,A5@)4!1..%+TZ.+=P@`!$.(9PX(PRN(C=
M=\`TUF&:R6(L"56)+%`BJ_]\L:5/&)R2E5"\#J=NQ0L`=-"2FA9-1/:YXI>*
MKZIAO&LG3B*<:P:$`\"2D36KU;L'N5<&QW2.NYJ[!M5I22F>V8L8'^I<'.NN
MF4N+10-%UP>>+HF/8E(3[;B((SBW2TB3['A\2@7)P0<'`X``<V!F30G!GTB$
MT6F\8BB@^F0T#R`&\5NS<D)M%E8&%/>LN%:B>R!O9S=<"8FH*`QQ1'!A-#:-
M)!%E"+QF9O&.F5C-DOJ1P@BRP8=.>&<TK?2QCOF+*Z(2_,IVN2*T`E6Z#-``
MV6RR&2"^43<`((!W]'!`.)5K")>*I"F>VJ(GK`5B9<!VPM*_,DBW1%BJ`+!G
MPPC_47#&GA?`HT2<7711$QP#I(X<=7``!R/)52"F`92W5Z\1*1&B1;?1QI`R
MN5[+&E*MECS1'ER\0DE1Q8OCAKAT<Z'PU6F,"FGZ''WR"S#W=7O*IR-;`14@
ML0`\LJ`',8$T/\1IH=6YJ?`K8@JW`9+8K`G8FPTE`MMSD1D0`)QIOJ%(N#&L
M3Z")S!WA+):[J:6:HT+[LKX(S7BG!LZW=;JV9]'RO@:*3@B@7J.-CT/,TZ.\
M=YFWU[E[,'L=V5"$#WO0>'6'``C@=NQLBL?:=V[#($/=M)'9(P4@/);&D4UJ
M+-+)CE-R*Y/)U]6)N4W)75/&J_DRF77W>P6M9B54)T7I_V3H?"Z5MLY=!V7O
M?-/'B7#UO+Y\!GR2^MMTQ@COD0(\\,\((P=G$:&/*-N6F8#Y^@'(NJEK=A9C
MRIS@/)YU,HRP62M<28O*JITTF8KIF#2$X8#HAU/E"YL#7I_N\C8GD@)#7`>^
MF"LI@*C]^H@/9W:<5GJ,RI)[FWE&(R;7-\0%[JSO:8I72'?2]U0D(0R+4RII
M#"5P*Q5N"J:+U]6&D$5U4<6\1"I:"I?Z)1MM+,4UIZ5&;C%#VN61)2('U&-%
MI+V+^*!%7)1PD,WKMG<`$(:9R>9[EZ./^I'*6W><-MG9\@D`8W`,P)(#W*F9
MM[>9&'A<:)P75Y_1@@P7W&5[I_^OA:VDN8IPPUF<U?D&$)!F?6,AX@H`7\!;
M;([4`BYQWUI0KZ,[8%=K"O<NG&20Q2B/<A.>SNHQ/X!Y3=IVP(FN>69D!R.U
M<!Z5[:@GX\UV/G)C?\=]\DN_#=5WS-KJ\9ID/-ET"4S&@T"O%TFN_"$(!MB1
MFVO0($"[V<SB-5L<1".=&;S2-\:%@0=LX/R(N!*Y/,WB?H,?[U%',SF,S9JD
MF&Z?>4TLX=RQF'S0_FZ30/O256=RX(SK/-:[<C!$P@AB.7[@<T#O__V:+<@S
M8/T;4LP+0W>V9:P(26%S&4&'E.#D7>L,?`@E-(?R;2K5#S8I76NF+Q]@WXZ@
MKKX6QY#_1X89?U\.9<*(:FG^C27`U`T5AC:@?!!U3^]U\&9GX;/.HJT8A4;<
M"`>4F],"HRJ6HRF^=[?XDUWIB*/\X#Z2"`_`W41&K>IEJBG`L4R_B+0LR,T%
M51TE?5)(*I$ESW60!F;_!1\``7TWW6=G7GX350,@!MHL<4+Z&NZ%I$$&5Q,^
M+P=#?*-]0#Q"G@QXGF9V0%5:JO3H?HEJW6_&L\N%D&]0LV;Q`$/\:+\^&>K,
M6Q37+G@5RTR\S0G9:>-E><[XVQRZ&Q%?[?*;W`60[?_==`&^!]T^M,/GHOO3
M%.KS`!]J1VK@%,DMT1Z\J2"LB\YK9JCXJQC#+\^`4QLP\YP,_YO;SDP;,TDX
M]?:RYE"D/=1VKJ%J`&5!%7$=5G!"SZ0IL`4;5@:4=4`(``@,#7,7-64?)3\7
M>W.-A&H-`XH7E!<8`!\9BEH%`06?`:$%$1&=GI^CI9^EHJRMIJ2OH9ZDJ*2W
MM;01K;B]L)VKN:*I2;J[`<*SM3RZJ+"E/,S(M\$%S*.F`=>NN=@1<RDI6@^D
M#RD7X5KJ6L>CQ1$_)1\`=1DE]QDX-HL(=1]PYQ;5`*`!0)D-E$`<2E3IPH9#
M$!3M&3"O#H,!#.I@*O.&TD0`].S=JU-"S9X&)332*R%I48-Y-2JIH0BR)"4M
M;_P9'%`#P0!,==ZH(R>'1X$]&`Y1F/^$+N>'.C$=8F*@IA*"0_,Z7OB1H2(.
M'!E``LB`$-T#9WO>A"VSY>8%-17F-=A#*2?(,BP'E*"G-5[%$G`:X`#944W7
ME25PE,@PH.I)L?8B9T#P%L??>XNI+OKY@0'="V_*U*S*%69#-?(`#*#[0(V:
M?H@VJ2GPFD'*FB40T%7[H0Q3WB"C;NTZ#T>--PVZED%PCIRJ6#SFQ,-40UVY
M`(,!@/#X-O7V12`N9QB?H88::G("W$G2`"1)S/;>[*FQ^"[+CO,_?&A,:<XG
M<VJ(`!1F)4"0P1LIG`5*`0]@4!`.#=100W)R!?2#3G7@,(!>?*7%0%A/W4?7
M0.X16$<#6KS_15-9;S&@GVJ?S30//0-$<LA<%UPUCTA@0;59;PR`(.$`.D5%
M#2C*0+--+=5LDPTSP@AC2BKMX&(+DU3VDD24I5@YY99,;IF$,\XDJ<TTJI!Y
MC#:I7)GF*4C"^4HPO3QGCG,/D`,,*FH\4-J,8CVU3XZ'\!?.#PQ@`@!":KCX
MSV>4&/:!!MNE`(=^+X*420V??33CBT^9=%B@=4AT*0#"#:=?!E5%B@&(%2F*
MPR9I1I"$HW!`VMT\`U"RP52MJJ@H96^-BND\#"!(20ISL)+$'0-E$BPE+\7F
M40W^`*K?K#>],5BF0%U1+*:8S,C08]HJ&I,:EH&JJ6^;3?59"NW)_Z4&':LR
MY9)^)11P@3I[Z!B16;/5.P^F.)8&P"8N*=I`0"F\,0!6](@%`7,7G$6+,WZ6
MH,$'U;'S@!8_6$;I35J@)I='U1Z+\![L.+->O6)I&I06&+C\%+$UZ*=9(ZND
M+.#!\WR,JG7/17!)S9JJQE0*V"JJJ;3HE@O3B%+7O%^*,@*@U;].=4;((AM\
M^^D\&(Q(L:+Z-=`PTQOA>!8UPY2YY)1IDID-*J%LN:?>>&,I>)VXC&G,D<,,
M_@PO93HS^)IGMEE-*F?6X@HVJ[C9.)6CZ$D+FWD6(-A7#)2N6$LX#5`>(7/D
M*?%%BLS$TB0IHH,!`\;M,9^&N.-P40.3G/\S!WU?%?]58Y!HJ!CN_&DA&`/$
MGJ-&#;@W4-4Z:OS00$8&,=:`#:RMTNP5(GRUP3D08Z"7".!(#.'U39TNU%O;
MFWX1"/(MZQPK$<R7F-L9J]T/]-(2]"$G`V4H`TF`!ZD4_*`&.*B#`C,@@OQ!
MHG2F4Y[U^&$\#'ZE,*/S7>D&H*$?:&$^'[)>0)*'@PHBP!Z<:@AH2#@`'F2,
M'!(#S`\2I`J?'&]#N:.?[ZHBCJWH!7KA6"'U5$(2$2"@5?QC!8-28`.]X*`C
M,=M%^9)UD[,\CUC32XP'B\<<3K0B3V+`'0;5.``;:`$!)5BCAK3BK?==P#],
M"L#M-G01V\PQ'';_TH(-U!=!T5C$/,L"AP.3D\`,?>]?$.3C\>A8/`]6+T4-
M8LPFS+$[XX!C;`_,B&@R$*%6O0&#&#$>&'V"P.X-('\9ZY(4;S&+P`&#2="9
M1N-J-29BU&UCDZ,3X?*8)2P%HY=MVA@O:&F46*@IE\-89B=H*<U0=,-QJJCE
M,PV'#38Q*&6ZDV'&`G+"/81C#J[)DTD"LHAPWC!/Z#-G)2"E*W0XPB2ZTU7M
M/`*IV@%,GGD:F3K^-911>,0UKG&G66Z9)]T%JQ'IV.<B$OHO@?*3G0F5:"68
ME<QO[@&?Z/OG.0:JA8`XE*++2N)!4<K/AGR&I.VLYR+\><*65N*?\P+'_TWH
MV<!TA+.D/&SH9Q3$H(3V<Y\/^&@7SZ%09IGC)@@U24,4]+C^N9,=Y4@JS&X8
MCH#2!69[T.I-D1JX<4AUG@/]5Z=TM\^/?J81W1C95F6XU?V5`Z<(W><X'C"V
MMR!4G_G<Z4;!NM::5M2=SB%H)2!JTK_2]:Q7E>A'';O3<60N2V>2DS'HE"0N
M_8U.4RH3FMPT3"EY"9O`$-,T;7799.HR<8BS`3(^<3=@\DURN+V2:+O9S"KM
MHDT1**DX4YH@=J9@%4^%F$29=8NGIG2XBVV$'.0`,79"5X;P3&EST5$)JIK#
MN@WAH10?<(=],@NN(]MH$9=EV0)(U!'@52\/%_\4@3R1-*"<<.]&OUO?X9[7
M$0^`+CETZM\DQE>^UZ5$0"'6B)$=V)[@((=Y^4H*XVH,&0]&QS@"<J?ZLM,1
MW\APQJK1C/I.6!7.30=^]=??!&.U5HI,<'B-VXC]ADX7`8:N.'SQ38WNM[YY
MZBMV(>9?`D-7'<;]QAS,"]%F12"^YPRQCM$1CB,/)6^<VQLK>AM,S9$83F`R
M;2>X+,S2'J.WV63<+6>9-#(UPQ.;W>WEZ+OFSV).;UAVLYPHITOD?O><COBD
MDOGJII$9^KOD2!`J`LK?)QL8T$`K0.OX&NCD,C9!`6W=4`B="G.4U#ETNE-$
M[7J,"-S!Q./`I4`9G:?_^B;-T/]M75>[.FF^'<ZJJ<;2@D']75E#>@YR"!KZ
MSDOI24\:T:WV]9^+BVF^?K>BC`9RJSOG87$@F;FX;'9S\0MJ/POTVL[Y=#G^
M,XY(2SK0BH1HS&R="VD'69;?R&JKW<UJ1B,YU]?\A"*3N&QB`YC"()XT__`4
M46L']+2=^^XZ7DP-1QMXU\;>=Z43!(Y-XVFOI&C=EH)L;A,_.M#?*/:CF;OO
M/P/Y35G>Y8)T2V(UW9:TW9@SS$L+##2OO!M@NF4OO<0XV+Y)F6]^K3#Q9NN4
MGR(6NHC<Y1#>.B<K&:Z8HQOGLDIUP4T[%<8VIG]&`?5S._G?=M+3<UK7)7W'
M_YS3M2[F:H\4C'DW5W$,0CN`MW[NHN/25B>WIN4"&@Q9;]T1!9ANL"4-\&:!
M&+FJ./R@*8S<9EWIX+<@.V@1#V3`!S[+76(\DQR?'@:%O4L"]X\GR,YV8SZ]
MS<WP<WUM<>>X@[I.C1>?V`MW=+B"'L1I:CHJH.[JG9]6X(0CT]5#;@MRC#[K
M^H[TUZ>-"TYGW$Z@?W[BS:UZ)?_>\4H6'\C)_=MG2/'+;8(2F_.8>IT7CFY!
MGWII#9>$9M[62@'(>=!]D?XLPQE-;$)ZTH=N6]1J64F4(WYK=B1L-WE19WP"
M2`MZ0B6>TSFWU&EY]@F=UTV90PNV5V?/!#C8$`VU,/]=\:9WMU`,8?8WU)`$
M.^<Y0O>!%B@X=*<YGF""N"`+G(,FKD8FTU5\N-1R-9AZVP9],U<KKI8>R\`#
M-9APCF>`K`<G9F<-/`@=DF8E9.9ENP<T^;<+O;5,,;=R,WATN>!^-_@-`XAT
MN<5U>49VC!-LI"""](=;;79;0#-XUS1^JO8<XH-ESW=+_I&`P#5VE\=0W89X
MP.!X;_:$0&:`(/A]5%*%3$@Y:J=WMQ5F:5@`858Y5AAG-"<*1K$W5#(FD6@,
MW$1,6!)G<))O?Z-,,WAGU01GKG5_L]5:I8>(.?=_H75TK*=;M-!+RU0,V)0W
M2MB$0/A^Q)0EI3AX-^@F)CC_A@5X3'+&>KYGB[44BLJX.0^X=K;H?9(HB9P8
M@L=HBC''9H83?R.XBV[F<AA8@3[W65+B.*LEA9<#@[:"3"VG-WHG35V6<D@H
M@1(X>,88B]Z7)MGH"O>'#29H@G&&#1-HCYQ3C`?949$HB?KGCFDVB-](CL%`
MBX%7>P")663B-ZN@9E]6D"[H<BF8A8]H9LBD33](?YEX#;"%"L=89C)GCOXW
MBGFV)',"C*=0D,ODB-'03::H.2+HC@39-V+2-Z5@`^YWDVP&C.\XD&!RC&G(
M#$49?ZR%B[@%DM4(@*50%(PXD&/H6E?2C%5(E$XYD&FH3<:T6<J4E$HH)D+9
M"659_PQDF89.J0U@8I>V0I3@V)1F69>I)R=.$DTY"7[&A%IK.0UCJ828(PIQ
MZ92#8R9`1U]YEHP,:85RL`Q"UYB.R5K8Z)!Y>9?B=R9%Z7]\DY8(28E[PI=J
MV)A\:91(MR6H28MR<DUJ291G.0WMAYOS^()PJ7\L1Y-UUI-B6"OEB(6PUPP)
M>&N%@R2T)5M(.)&$(Y=J9I%U4YG,:7>A]7/A-YBF5XEQ(I.KZ)9]0Y9R*7^:
MQ9N2>7-Y"8Z:>9M^*9YHB(@^F9[.:&M`-R8<>0I^,PM<^)+I:`J:Z9:ZB'Z&
M"98H1Y=Q:9O2R9X(*I[@.`L!&I?O.)[`5*&]"'06J8Z1D_^5&<F<V:2!JS"4
MF^F88Z99X#F9,3F?'3IFDC.@$CJ4MKF>4_F@C&F'6OB?B=AGI?B"GQFA>2F5
M0OF6CEB++&>8C/F41BFBV%B6#`JC!.J,R;",H[A+9F9+LL"%L)<-MA(-'JFB
MPT2?OUDWW'!W:M:-SV2%UW"*8BB==_:+_-F%TI!,2+J?`MB9?TEB7-J7^,F7
MV2"BZRDE5/F-U<1GHQ";%$A^(:H-F1BB.T=TPMF>"[J*H*4+O22=,:>&$[J7
MZZF?9_F42!JH@6J6`"J4$!I,W3@G9IJ:V<2EIDJ<@<F&>,9:HNFI,+BCDMAS
MJ(BG::HX&_.J^/D)+\F%V=!S5*G_<S?9IM^9#(?S@/WG<C`HHG7)JI]ZEJTG
M16[9>IY9HI/J2^X0F_O944&'EK_UF(-8H"D9A\R:H5GZC.UW-[6HG+`7I6D9
MF+YHC9D#BC%'B6S&"YWU@,K:>DJG"N)IGJ[V@N$8HYJE6IQ(D)\ZI_"GBDVY
MI53IIM,ZG.]XG?X8.%`Y?M;4+&49BJ8(G4OW#J8U2[BUI[^ZB,(@H.[9D,N9
M6OLILKK5EQZ)LN^'3,50IPXIE]34)A!9F,ZT=`+[K/@7J#-+I78S@URR)KGP
ME)S)<MVXKRG7LR$HBSD9A=TZ@FKYL@HJ6IX%@DGBHO*WI'D)"C87F5_;9S\W
MK_NWM-:X_ZR!<XGF2*!"^[2IQ0JRU9U8:F;*VK-:MHYB.J9U%KA6N(&MV%HM
MZI$1N&4;N$L2*KC.R*,LFJ+99#ECZENQ^@(\,)7;2`S`FJA!RH]<B)>3BXW?
MES1#&JY)=X6*6:C`Y(1F&KA,&`%@P)5:B(Y+F7ZT&)JMBY\?BZNJ2;/(()V-
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MH*7$V1F4`[G!25**5BH-HA``!ZF/B4FK,#JQ:Z*++-K`^6BV7SG"*?S$AUJZ
M]+@@\+J&2!=\H<"J_UG#>Y*AQ<1CB&I_SWB^V`N_+HR_4A<`2&G$'?4+46RA
M'VRV20DE=G:=LH#!K<REN92O19>>7/K_P9U\A6PICU(\A.DYR-M0.9H8S%V<
M6>77R??[DR::N[+[)(A9I^T66NP+G,.*MLQZG<')GU<9F]P8RGLVR47JRM7L
MR%?+G2;L@M0,R\[D9K-\EBRYA='@?L(YSIHXNJP<BDORS]RXH;MLP6]BT&PI
MAK-X6;Q,T/Z<E)6<S[Y9FXJZS;-5H>3,.?O\P!1<)W+YJ,!@6\AD%.E+<U9*
MC]HTF&ILO6?LRLX)EBB)M!6(OJ'9SZ;LOH)I6S#MS><;S90<S-"`#4@I9CQ@
M`PPL2\RY9\"8.;,<?C-=ROP[B(P+TR;\EZU+U+^0?\]@#4@YS1VMGM9`SK*@
MU!BM@8FC9\D\_V;N:LY:"%OSR+N\M:MIIM:CRUNS)9QH.LTJ_)UJXLZ86:AH
M;70F2HZ?D],;6-@%B)(HV6Y'N<V4$]9;N-4H7-9+IXA)38//##A6O8A:JB3"
MVM)[!KP%<-2%"QUQNGX`NIZCC"4#ZLWCZ@R"'+?!]\Q#;'>5J,S=<)XMS=?#
MRF?WRV7?-\B""=S_AYI\W:&D[=:'.\2NC--'#-C?*=-!S*]Y6[?07'2*NH45
MZ20__-#J[,OIV(7VC*/19,M.+*P,7=E`S#>;#;*OM;I&1]UP1MX`>9BY])52
M/`N>K'^]>LM.',PKE]&QC'^AF=TIRI^GL-FYI=^[K9U3<IZO'*5Z_?_+Z`?7
MH>S@%H[A^IK+NARPP>WAXF?A->W6X/K=_EQ^`?U+/?G:ID6\T1FB!/Z)SB!;
M.PQO#QO.P#G$$9Y9-\U;AOM^(ZY_OOG=>SW1+^SCZ(RG&BW:NBR9N_#*VEJ1
MV<W0JFBAB9B<0:S8\XS,4(RA6_XYV2W-%UJ;T+S?4TZ$4RZ[/JZRLAW9L5#F
M@DG)OMFA@VV]T%2=XNK-?>[542S(&=ISB_K8*BO8;=[9+:G<J\SFT6W$*BS/
M51["O(W*/WVEHRV`=AW41^GH+(GI]4?.^SVY&M[`J[S1_7O4)2K::)F=JCWD
MX2=^_^R<A+N&UUBC(@VL.$S,G#DFF6C.MQW_W&_^?[P(F/#KS?\=SMY-VHE]
MM:B@TX`*DLR^PP'MG(/M)@P.F$ALM@@<@`'9V!@JQ0%-WDSXYQY:Y8Z-P//]
MYM3^XSVMWM1D[KI,KX!=SW,VVM3>U4*<P?'>DE)J[/<>L`S>9;^-Q%]>S]5=
M?Z\0F+\>PMT=P6-LW-INUOQJW#MM:RQ)[[1EDW`M=43WC`4_SSA*H`E=[X!Y
MQ-7YH7X>Z&T]S-6ZXZX=@CS6K8+\CZXX3>5.6F`>MRC\H5I9HJUPRDB2X(*<
MC/\\S(<]X9J^VC[/Z6>F\26]VD$].;K`UQE]PJR(G#B>6UCMW'""O]L.#90M
M=:2`Y90(Z@D8T4FX_[IPG9CV[MQJZIU>G^3];?;Q*,;*WN)(`J=J>>%;YO#^
MRZ]%?ZK-C/2JG,Q]_65J?MHAO.KA;,RY;3<LS.P^"=U4/K66SH1AO)LQK?9)
M>,N;7]J,X^!</[M9S<+VJ=Q3W?1C&=:H7]R\>S@%O*GG=UJ5B.M$W)LG[&5+
M;G]OO9A(_.A=OUMC5N$^OR89?/1:/HOQO71CG=%=W]+PK>#?7$M*I[)WO>$*
M[H@#;\M"3G[%'=94*^S>KY4J'TWX';GH;\S"+8_)'JYV@\OD[M3%/]W*BOX;
MC<N?-0P<#@@1!0$%!8(!A(.(`3P\`1$1C(^"BH6(@SPV/(:'A)"*B8J.D/^2
MGX.6B8R-G(J?EY:8HY$VDZBVC)JLB*ZOH(Z&I92OH0&YD(>ZEY>9DY*ZA:>*
MFK6>G<J6C9^_O-#0Q9O'E[R$RJN"YM[DV(W4A<*IY.C;WK"@U4FGI`%)QQ'\
M_?CV)6$G[M@@?[LB+1)FB1LR5J9`<:)DJ%6D7[8DTAN'BU-!<<%NA4*F;5,!
M9A4]Y;M8S5XWDM9.TNKDL=E,4XL:TCSW*V2UA,5JI8.UDZ6J=OJ`F7N7LV*^
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M]TTRGW(ZQO(BC-;TD]Y#:`$X#'3YY4CD5QA.]U!IXQ$#UGB&B<,;@0!)5T`2
MO,'WFS^%\+9EER..E0D/_PX!-Y1^,.463GVMF69,!)D@"8^="J)2)T]X$D51
M1$_IR=A@0/+XC%L$>G,:G3<=^&"@?;VS&">+AHC*6(@FBLE-075E:*%-<5-I
M;/5=ZM58B7#4J(,U$54/7ZDIQJDL19IJ47;I5-HH=K)E&N692E$C[$MF96A-
M+@\4H,F;<8478D''@@.7/JB9-9D]$:DBK:4T9>54GO%(RPXPH#F;:FW)J,+)
MI*0<RMF`T%I5X)5?"OE;;9=\N5E.C`C9R6*S8<E1<I[F%=RWT`8HI2WZ&3IP
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M>D+C:$=7Y`KMPKOJG'_.I&K"&B3QX'.O?B*;?.'D?-+*^W0[TH-GZ"PM0+X)
M9^=H5SXUX^CM'*1X4^W(,27-);@>WWA;\TN]W&C+R-W_OGN,OV2&O>'$BR4Q
MTE[":#4/:;7*5U8AWIE(Q!Q<1<ITLTB%[(0DNB3-[#TE@0Z'YH:J_V3#*ZUJ
MSH"&\['YO*YW.T)/S@S20%IAJ7'3^0_M^,1#&*JO?::;UO)DD:8<:L]B[.@A
M\?#4&Q+*1#6L(.+N1M:^14V#%Y_8G0R#F,0,LHE93&L=!;^!Q7XTKT>Z4\RP
M_-(@*=T,,9W*(+D@@L#LJ&D\CN!'503!/\4MHH]@^@Y\LFB@8B!'A5J36Y`*
M-CL@WBB'2JN)V0@XG<B4!U"PBHN"%.8LFG$/>*E:4D9NM9+O^!&-2%/;"'W&
M-@ZI)1VK#)\'5V:J-SIQBS2Z_]/T'H&OIM$L0JW897FV]XRPN*E"X-KDS/)A
M2YX12'=&6Y.CW&BP\.D2D@3K9>X>"926!,>1C=0(>9A%,C]*CCI08^3>!D@V
MVP`2$E?*(R+X$:MP($<K'*S&F3;)3\>H<(ZH$@H^V3,CJ!7I?I3\GR#8U9ZZ
M?>V<TZR:M'+Q*GA)[8+5`%B!*BE&L#RS%@7M4&]\IDW8=?%I8@FB#(_&0$19
M:Y+0_`CYQ!DPY#&E,ZF8U0.S`AYT"28S)*KD19=H38_,BF7J\)48+T-&%(H2
M2I\,Y8(86"Z>>M.:-MG6L*S:MH\"HRRL\A.V8#8D(=K./=!DH?$DNILF<HEP
MJ_`0)?_P<:&)ZNA*DO1H+_^!&WS\XZ]ZVT5`EK,9';HE0>FK'M**HJZUQ>>Q
M+"J*</(S5IEQU'B1"][7?G*>%.6,?9-SEM7HDR.2,DYS.--B+G$J+)Y.KZN:
MA5<46?32ZT#0M&E]EVU+V,M,?:4[UT%J:S<;2:CBL'#H>21F9V;,:_7%&;:\
MB$EPE[Q453&FW$,LG!!V+OB$\HW,Y2>T^!>0PT*OGOKCY0V;5A#9]4FY9=TA
M/,.4M7/YS[.5[,_6V*:H'6J,<QWRX%&*>Y:6_BF,_GF.?)@*-9\.9I!3%-XU
MOQD\"+]6B^YP;E:L!B20=+.JP(0F9B;C7G,1RT54:MB,'IC_4*QV173[A>R`
M!7.(-$D&@A\R["6MQU36]5?##1N;14GVRU$^C9=Y9=*&V-BK0GX8-^/*IAL-
M5$IW&N0WY;4*<P%X,87D3V;#4&W3,`1/C7'Y'U']%C:B)]D2XU@YPTOAJ::H
MS>DL*V?"Q//#KG)G$VL#I])#KGJQDYX.%>6F,&HH&PFKT/"X-,.\9%?RRKC+
M+*;Q%4N!LI2)9\?I[*6XO0M4G3%-&'.%D!L=3<2GY1QJF#Y7@R`MU5C80\)A
MN!=VT0WH'-6(:@]1IHS;Y+68*>T\`5FBST(&-5E-$4M"T'.#@<8G;_X*D,#^
M%9^T:6*.YA0-+KWBG6;4"CU#-.P,_]^:E1>!HI]VZ.C-0F^A)C%SU61=4NBR
MZK/25&AU?V*9*'-OW;^ER'/UFR#UG$R$7)S$:3IY&Z4A>M:K,W$]:F53935C
M6T'S).P2#HFX,CQIT'Y-==`47TD69FVQ!2G)L[U=2./7E#L)QHU/O,;J1A$<
MWV#8S@#*Y$O/AGQ^$74=?3U0.DUT4.2A.1A)")#Y6HH?^#C,"2/8/4Y\*4!Y
M*T5@!0)7%+]T2_E#I">BSDUOG4J`6(-?)ZSV0F;2BMO!-4_<5:SJ$@]T'65+
MH>CL3EO\O)J"GW:CW+M<MQH*O*32+1O+UOQ5'?$+G_TM9UFWL<>4P;3@1RM5
M+':Z2?A$/O_H)"ZUX($;7(CG1JM4RQ$QPHH[M+?SH)Z7>*,#CR_^G.>TD5?T
M50KGG^1JWGNP*BUK6#9&T4O>7VCV%IK?HPJ!TXCG\!SL/*4WY_S0E2D]R<E@
M`9BEKG(DB4)$Z7[9HAG3Z-<R6^-7ZO`3LZ,8EYK/_Y#G%CZN0COS3N>81FLV
M=7%BB!2Q?R%>*+%YV"14W^)YVJ,KI<))(X4?"%-_,#8:[0-,^K,JO\=X'\%^
MR'`7*C=H%`9+.18W@(%SX'<DVS%<OR43XJ)?;I1]*!A5#+5B%_,H1L)=,X)Q
M,TA=(B=5L-$?$%@EQS1\Z2(/,Z5X-R9_6`)UUU8JU)8C_9$?^3+_3_<"35''
M5V@$$22C03B7+WCC;<&U#S>5=^$Q423X<U>$:`KC-F08+!4!,`\E5,Y1"M-2
M%8;44^IG6^0VA[1B`8=D-$8H/&U(@BL(=!^3=^3&*+STA(NQ'L.7A@T&?F#5
MAV?SA0N#B+,@+GTH-O&F5VQ$?\*3B7?82]W4<9PR*#)!B#F8>L&T*)D&,#KT
M(_R")$=%"HOX2TX34RMW9S?81?M"B0$S;TKDBK#U8Q[V52OW=G/BAY18%VSE
M1;,P#5`7?5P"'5UB=6#7?N=#+N5U??MFC7<S?7,E=MDX'6@6)@$%&).`5W(H
MA\#"$3="(V<(691W$QOHB'(B>I,#=&WG_XCVD`FFN$Q[1T1&\B*XL"N30X0H
MZ%'?H5'1Y!6)."AAN%H%B63M$XFHQ(]WL2LZJ&^\R(""Q)`)AD-=U"U_N"AA
M(T!J)X0*`Y)]1QAQM!FW5PY`UX\I@7Z,B"(14HL-64<F*4BPZ(_I0A64%QMV
MXQFB`'>ATA:*07+*J##M.&KV@X_V"!B-@GQ^YAO+I9`--G:1`UA7=U=<DGP3
MV!-5Z0]3R(^Y8S]V:).)^","II;=-5.G,6!'EH&VE33]UF^=%7S1\4%JQ'B/
M<8N,!A*C)4<(%)B"*2):)2!Q11O6H7CF@7<&1%$YYR/-95\%Q9AEB#JW1V0!
MV%O2M68!F)C%$?]ET&6,J"E'X),H'M>2J*E&97=0=ZD-,Y%MCSEW4$4;M!EI
M2$>0G'@B@"E1=7=L>ZE2<!E%>5EWC_26<5>3L*:,8`=U5F<EVB8D*S.!6S)/
M26:.\$0<H_!6\Y5@)!EEGW"6:6B6:75_>@)K@%F9#@E>4,:>FP.!&L@::MF>
M@N0@$8*-ME8.>-@(#.0=7M.?[1F5'9@U-`6+-+)PJP.?QVF;&H07,`>3L\%V
M\GD4T--/D1%EXV(;&)H8;B.$/C*B'CJ`(C&,1L&9;+4IVY(@J,9R?O.?#`5=
MD;2A/<&AC($@%R>@_6.@8F-O'&:4F#,,R"$>*&9^ZG5[_=,4IHE8Z]G_?^49
M2'#R3E%U,UE&=NZ$93BQ/V;9-TO#9`3QA&4FD5;2)<%#BT?W.C2J%;&Q3P3#
M**IAFOWI?OEG%^9S/2K8H7`I%<H"BI^HA=ZE7>;W"8L82:B#?M-PHX*Z*G[Z
MD$FJDYL#&RIWD_I4BII`<,$U(_KG61,D74UZ)WNWJ9=TF-IRGX%9@ILZ:Z')
M$J:)?B-H$ZBH%T,)H/'FJG>!C-\5H$KA"(VYI]OBAFND+"18J&21J<@X(@L2
M@Y=ZH<I)J+1`8.Q2JLI`F3W8@=_UB56SB#XH+DCZ%V&)3`)CG<*I-7H$AEOW
M"&%9+Z+@/#U'7,Z667<R;N0Y:2G*IIMY-IO(_X?4X)*/IRV[ZEM$:@%,"8<!
MPE`4U8C'9@&.]X<Z^HP`FU/T2+#VH%%]^K"Q(+!R%JD`RIY^*`H"JV"Y*2?"
M"9VR0F!K^AF,%TW8P)`'>1W`(FPB6@P8:T%E,X!QY*%U)VDM:Y\X9Y#7L"D0
M65\+F8O;E1OZ:F/:-8"5PH#^&*R-%0OFD',="[2:IY(O2SE">!$L>7KP`*#-
MV(C?<6TLV"-T`V?4(X5H:Y1Y`Y[I19TQAE**<"7%(S%ME48%6']@&V"!R;+=
M(Y^]6!\A9$AH8F+^VI3D(CQV80,*NQ'Y)7A""DEDN7+&]C:4X9:X\:Q/>23!
MF88NMV:".ZJVMIC+N?\@L#%3)S:R.SA0\3F15.:?\+<5&TJ5AQL:@AI_@1*F
MJ)=?05I[3[*WZ/=O']JO_V473<M(*>L+<<B8MXI_GA:D6+<[WB&,[=1XT%FU
MGL&W0U&YL!)B$N91TL=*W!ANELE"P200K-&=9BF6DOI''S9L8812Z3INV,F,
M^0<XDQ5_#W:;4*0B/)96C4"LP>.<%;%1^%>G^EM&4NL-KFHJEWC`:,5M\(._
M+.H=#N*2R1BI3N*I,?EG:#H>G/*E1^F"W/,>3O%9(*PMSWIW1.I`/#1^4!&3
M]+9PIZ:Y)3&0(WR)K(EZ2M:A`5R_@;.%5;2L,I:MB6(,CX><&PM:1%P_'HC_
M%K0JPGCFM<!%DKH@Q-PKG-^HCR>,L]S";'2S#/472]G9%]?WK?N&LSB2/(K4
M-RHHO^;X5JQAA1ZH$-OGI:EW+*8X*B)U#\_R-1HU$$XJ?3RX#W5VE)9!L1[&
MB2?!72*8D8Y:KHW13.Y4&Q3+BJ:82VXAR,Y&R:6(5.CDQD:#&G5(BW.,5R86
M6+*#"VMHPI35QT-X9S?;33K7QP,"E)>8:&\K(`OT&<[*1)CI6]R@N+`:8&PZ
M=HVF7+$0B1V&?W@5RAOHCU!W&G(+DW7[A8?5$0MUR6#HPG5Y-P$A"](\7A-!
M3\\FJ1`Q6&PL;L`!6+U'P=<A9N/L;4T[QO&+GG\4_Y;))K]_%%!R#!NB"+@=
M*\BPI951*(5Q&[?=Z(ZN"PI>Z%*"E5L_&;:G[,ICPDFIN\U]B\X"C2@":C=U
M+%33:&4(&ZGX7-&=Y:5N&YMCS+AIJ\^>$[OB=J7:F=(T#:,H<\\M+=#]K'TV
MC&$I5\W^2J+UT=`(O77#^*.-L7TU+4GG86W,Y+828=0*C8>;;-")("98RH6(
MY%/O2C?DG'@JHQ_GJE9=&DV\\:SZE\@5W=55F,W>RT=TI5*<Y8&?-"8N@<_B
MMI39*:%8EG,AO<]F[=>O0QE*N*XN#8;GJ]=DDM0AC0[QX8739Z9[_9T%(=!,
MD]5H&[4S>@\CVHV8O<U1:_\.>!5U"K$_$(W3>HIZT?<:?_UM\428V[IXMZ&?
M81%82_P-B_>MP@'97!<V[@=4+$':49U@6R?/F-IK-(L1FDS(2KL_S3R->'LC
MK5TRAYJ.RJ,HX"#5:T?=:B2_2BC9?C7)`?+-Z$J'WZD>SF;4WAQUFR?9W&>5
M-6@0K@#=%"BN_J%'E^K.LWS5\R6O5"D4*#U]EZ$WD`-UZ^@<O#TFB+C7UZ';
MP2#9YM16U"IK^)Q'1NW22)R=!36-")%'"6TT?*4)>G12BV-#0",,7D+"SPC*
M+5*N`NAX1IQ$S0QVDJ#/4BE3C$$FB]>=HF4EXOG;),YU/"37SP4P^,`.(Z[@
M"U7_'X/TXTB>&2..V'TSW4N8CVQ9((*@6C5NUOY@Y.)AICR.Y%)=4IE1W9"=
MOC-NSG_MX8=`"_)LS.G(X"[^KF:Z%6?=?QJ>CD$EW5^F"L8-./B3)9[!B/@S
M;77>U6!B0"(6`'QXHV';"=/(G9`^$(M!/M.HR5):M]8X4G^$O&(Y6C[9N-Q0
MX>!(Y$>:2\5S(L159IU9XY40W@+!YW<=X'>9TKX2S1Z3SJ$8MW^-Z_-'R+U(
M4]7,V[I%R_Y9QV:*UY5M(Y;7K]L'RN<KI;2,6&<^Z;,>QX<-#])GX%4-V&QA
MU_.$QA1RS$U![&"W>_O0Z9%-L,2EOB<H5K3L6^YPZ,Y&_Z-!2=QU'I8(^WA_
M]>H8E#=3S>MA0EXVLN[1&:.A9);&<>C7.!`"6ZWMF"?7..#[)',3FGFUP.W!
MTK9;<M_A@<CQFB_KNLGV`)[WS`S)KC=H%2&:C-[/V)8_&FLB7_)NO-ANK>O"
M15PF!U0\'^Y@N-U#Z$;D?>0\T.O-_+PB-^^=+LVKL'U"*Y0I_>;D_<D@;M8I
M'\X^J.WB>>'/+K4LQS"VG875/-G'IDL+L:[)P*,(+=BFS<P`8N`8\M<=WPA1
MOM)Z@^D-:6UJ2O?Y!=2OV_&P'2Q.7]/H"_#)<]8?#!YO=>DUWAMM[0O/*NDT
MIWUDAQ)-^[GD.$#JGI^:K/%%X?]7]HS3B3GSQ\S#4>@E]TV7YUZ7NH-B<XZX
ME$]==-GI)7_9J:O/R^WJ=3Z#WYS"8XK1:2C(YM[A'A,FZ7W1,TWY^^D_<*Z%
M6HDO&(Z$'1],K"W1W(O:ZCSEJA[3\3'>EIG>RF_ZA*RVEJ7Z4OJ^GO>A<0S6
MFUR-2,C3JSG3)ZWE"DDUZU_,J\_DEJO\WP8(`3P\`84!!8B%24D%AH>.B8X1
M$8X!21&,$06+G(V'C(**C82(B)R+AJ2%!9BLK)JA-C:'FI>,I9.5FZV%-H2#
MOH.#D)JFDZ"?AIM)JZ&%A+:KF(*OB\67GI;9BK#`G].'D8FDS,T\F]L!DZ.$
MM-VNBLS_T)2TRJ.2E,+N]\CCZ@7DE)6#5&[8)T^LRB$:YB\;*V>64`D:A,M0
MOT:^+H6Z"''9LV&W#,$*%VJ3,F4C+19DB$S;*G8/"8W$YNS51%^?!FI\.6@G
M.FD`VY'\1>IG1(0E%2*C^8RD(%FT3"8;.FO@.'@6(QE<YFGGHZ+VPCI"!8R<
MIJ)(06[,YY+@QZ(CC9H,Z#294)>_N`&,RK,JPFPM5X'B@7,70GI#G4I5%]B5
MJ5N+#EN=J#A3RY[E;.&2!VS6NDZ(P*&,;`BGK+)W+:U[C+!EI]+ZHO&P19%3
M*V.W1`,M%(&'!74SSY[+-4_AI)32DE`,X!D<4^`BXV(*+)@W_W,>ZS:.LKE;
M6\*.;)G)P@IO^+3A@&]YH@A.TWC1N?:1.A^1>LQP&26J#G6L>\YM8/WSGCQM
MV31?>J40(P\CLFC&373*T6+<)9@(E5!1[+%U7W81(5;--I%!4X`-O\7'6%?T
M\>+.0,E)P]P_HS!5'E;A<!@=-;W90"&**(9WUD'(M",5*X3MYV)Q%LW$526#
M;5)D?Z+<.$]7I6QC"C7*-7?886QQ&)E7\;2RHT>S*4D6<(2Y@IR(W(AYUFDX
M80,9)[KLZ`AAPN3YR#>VT1EEA]8`%(R60`TSG2V@H</B0>Q=-UA$S?`6%%:1
MI0.*9R]:HM))<Y6I822[577=8A)MZ?_+=P^V<XY&F)XJV4LY&9I/H'=IM"IS
MG@&TI$#W$,=8)?7,PHZFU3G5DHD_64B)J"!E!I@[;>YEE&#+0BKLEN$TXH]H
M5RJ;1*X,E>00K#)IJ-N)KI;$ZU1G<H@51<N<2B"WNFSH(7)1@>N78']%-0A]
MSR5GZ(M2E=I:216>2-EC109E;#^%JJ84<L?T5"VHI8J4))?`+F/--:VEYV<O
M55$'#3<[GG?:4L>$MJC'Z>!)5&77'!,2DQ2&*$MA`U4H$R,?6]-GG8.%VZQ"
M_#@<<%.O#)N*D/V:(^QYH,J'TU?S&?<B(PW'U9%6!C4%M"?AB3><<K<F!4LP
M>`68BCGH`;O_UBA73_0SRF!-J4B]XS0[MT7BCDJ?E=GA";=B"\F4%('W\/O1
MG>4*=!)[DXVVK$&<33LD1N:-JY(\5Z]WT%`8HI>.-.?I,VQ+=(?S)+XJL2,D
M96?.E1AI<F,%E:8L/0LO0^?R%Z*0G&5+[CGW&%702SESU4]*.5?<65LXQ_.*
M:,*X`M)QZ>RBGR.S/-X5-J$5LR34AMWY"%1T=KY,RZSI4HRF)`HHK+/FW$E;
M^,D-]*2@!6)1V.(6MH1D`R0C\H6OND([_F"$?S3"U3^*Q)&GO0T5N\L6.Z`R
M"3Q1!VM[LLEI1E.::PE.718DQE/:$8T28L=LFX,(L%0FE.?L["$-_Z)'));7
ME&F,,!PM(5&9<`6/JFTD,\)124H,=[G[(`4B\Y"@8'!'F%9Y!FGJ2][:(+A$
M"]@`AR94S$;X\Z8:8F]`%,Q,)4IWH=U5*11X`B/UU#4[[*Q-60=\CP3CPD!@
MT:1N'EM-^D;7IH_9#1J+RHKU.)2:?ZSE90[2Q75Z<8XC0D:0QV'&)4TD.0XZ
M;#6GN!+D#B2W/<TP0N[Y8K6X-D+N9#&1VEO?K?+#'`N0XX,6S,99'N)%'`[1
M`K:4$(#R5HE=+DM8$W$%,.4ENE+NR5;VFV"^O-BA`P(K-4["3\G8D\#P?<^9
M*!E%A;8I(1*%SRAA<^8BHL@L]`B1-[`#I_]S`#@)3_J&A3<#I^1<EY$$3I":
MBKJF.@^6J_<`!*"U@(0,JS><ZW000]0DI/H2B1>3V)*5_PQF>4IYEP2UZH5I
MZN#NEG:2A?DKFO/*$L^.,QU3H$@GG\FG('`WPWB,K2EVB=M4QD)3R1ED.>7:
M!?RN9[-,^E%VQ2S&H4"EJMZI+Q?RBJ.-%BJ4*@*G>+=@R`-5<SKU/86#]C$;
M"-U%F;<]8SPR388)935,9U)3(D*"*KB""KE2[DQ"<+06.5[75KM6!3$H<=0Q
MN;I&;-[$.V_3WK4H.%5P0L6EWJ(@`",(3JNZS(P8X:?$]"D4]CWJ2`')2#QQ
M>M93X6L=D@5>\6K_\CA<F0<\F<7@V?3Y-+2N4RCC),E?FYE.\+DJFX72USXB
MY<PJ5J-2+O5/\YZ3#W\83QVB6-HIPODX9AR7:/X+X4P_IHFB8F(=W'/&E!CB
MP4K9#)<DA`0ZRBLX4]PSE;ZL[J(H-"H8&O**3UKA1XSX'5K*BQ/_^]_NH"8_
M\:ARDF-+[3:OUI-AX2*!K)J-,48EJ%493J$+D^L$_<(J4>7GPHUBFERQP5BH
M-M15(&83\0P<DULVL8F<<[#XQH'?J45X?5]T&KSD]R9M-"P3$C1;&7'Z/70`
MD)7((TM!#\Q@5:@WMR)%'CH\V2#.S3BI69IEMGI\3%_.#)8])@LB+R%@_\]8
ME6DS].&O/)D(OU!PDAE63W)'5RZETC=8V!Q);V"$+V,()R80M!-/*V9*_?7I
M%&.+3.'X@:_':L;(:^1QQSYK-+"@6!56E:U5@O>5?:'X?IE>;;D(E%@*_SB.
M7W7*7:`D/O%Y,'E?O54ZI]5:"MNZ,!+LVU@XC6/Z(6]K!I9P6<URNH6D*UVU
MR;6HH=5;!SML=:[U\4^_TTC.#`:9XZ&;E%OK2K,V\+&W=M5J^=3(UMU6ECC>
M=@$;6U>,8I1S&`J?62Y354RK`MR&,_:ZN^JTV$X65YZN53>NF;T*<^UD^29(
M)R:$DMM89F\6$(,8O(FJ\7VP%#DKK&E5E!6/W?]OTHA&M$L+9RQZ95!1R.EJ
M/;;20I,8=&>X5HNJ1"O%UP1KR6P[=^/*FT`6#GR=;CX-PH>^0E.<7#\&CD@5
MV6?2F>O(/1H=F9-R!7!LB^IIJ_H60#W2E]D8V-%O+J'$S`E$B0!=Z3O#-#+K
M.HV(HLK''PZ&VGD'FRM%-))3][IKD4TL"Z[S[M"SKVOOTMNG0">#T'3Y$(5N
MK;KL\9BW'-]3,)AV65;M=;ZY%I0H#UVAW]NKKXNVS5V.*9EA^]=^3SH\>^6H
MK\>IOG>:VL(0)9)>9?(4T]B$#<2``0R(P>LA(A;7U?LE]0R;KDSBSM45%/*0
M-VTM6</2N.').BS^2:O_HBG:&E_OV84Z"9AEZM7T4YW*7RU4$."_4.0*SW1/
M0C$5I]%-ZB#'/G\FK*S/>.O`?;7]*X*UE,H1<4]G)?A7&K94?HNB%FG7-(AD
M-['G?U27.[7T6I'30"1326E$6GMC3JZT&/WG=1GH3"N3(OG02'%484:T$4MG
M&"'66U(E52J7:C+2*0^H(X(7:<P@@!DG$WMQ3?)B:T=52\U!($%B2H3Q&S"4
M<N"C?THS?E6$"E[44W*C-WPQ'[=G2/0C!A,P`6)P%-9'$UM1)2[59G4#*PH'
M#G7C<\T72F*H'3BB2\^66(%'.8_!)"27'GC":SGA(KO#@?-")>SE51)"2G!B
M_TLN!QWW)FREY%Q;Y5H8@Q0KHWT0@55)UTJ!TPP_Z$P+P56&<U<.P0]!YFV;
M8A="!VZ2DFQ5]C:U\BJFD2Y_@F,C@W]#<G"]L'7%(ENT5B=M,DDCI!.,$V0Q
MN!B*5T5T84I3!RE85QWS(46/)7D;Z#:3%EAPPG1B<8S#]S5A(3-O!6M24Q>S
M9BZ#UXQDM('[<GY?X2_(%"!@"!SE(W(;*'$7=5.00D4O(8;I4Q9X@5/MZ%MB
M@RAKF%:IDH\E"!V"""F(=%V],R_)5$8)$6;2,E-RQ39,\XA2U1\1N""H57D.
MV"Y99D#T]"UV&(#>(&(8B8+<DX$"%X!E:"A$6&'`(?]2C/%3FW579Q4/FU)_
M:O9-5X4G&;0]:Q%DV1&/**18GD@[1)AT&?=7?N1#92%60Z)AUR-88\07<&()
M>0%5A_=7N+AGNW9,*Y-A/J5Y@]4XJ`-P/_5Q-OE8+9-L-70*YE1OL<(H]U,Q
MI2=\/D23&38IJ60>BZ!';)*5/4E*Y%@?2=1G"94:VZ,T;B)R>928E$(-==)2
M52*)RG@U00,L@38G:YA'Y0A=6J5:B]&+@($+\Y=3OQ)^?M0/_C-FI163'U8/
M>S-<CB1?&P2!LC9'?$%'3!,DGN5!GX)=@LE6-_%QF>AXPO2&'<6;_70:H`([
MK)9(+;1"$?80VG`9W/&7M:'_G"?64`WX-HN&+R/S@GZ9&`BC2ZM%;S_8((P#
M6/Z11/YA58,%#LZU&SRH*GO8FO%I'):"=/T&*F3'(*B'C,1WB>M26IQG(M]$
M;;CY'/`99+]HAS,!29#Q2<"8%(\A<NM$,JZ`*#I$EH@T5![3,0_8(<$S(F@Q
MF9M96IBV44GT&!;)G")#1>CS(CX32S:Z*;622$Y657T72T<I0T"#@_C'@]L%
M(`+:+&U%B^IE/3)$G<Y`8@RF="<C46N2CV2D<FB3?(IDC"]#<A.Y4+[R0<$C
MA9&VFS^II?+CH8GQB>,H<!T33[;SHS;I9&>2F#*$</(C$@(D42U">'3'4YE!
M:F[8_T,F@Z=CX1`)*$T%FEC:AD3"$XT%=J?G*$EZ,:4`=JA5`C##IA<N$W*7
M(UAB&*B]13YR-J:Y97B05BN9HAZ:Z8["T&2(B!>L:E3@AS/>XX!T9I#2]$:S
M)SXA06"J0T2?4CBS0V3%IE\Q!C#)PI9B0P^X%2&8>&"Q4U;ZT0[Q$88F]7]C
MYF!BI1<75#Q;)0[W*)ADE%UBUFEUD1#=^B-7JHOM)WMCQAE#E)S%HW>5MJ;'
M03NG0X]3$6_S6A_K<39%@C)^-'L_5@ZKL5]+)#$.0XJ:93O/ASED^2Y8XH`F
M:4D!FU/D.CE5E4/R\'R4P:XVA7_RVF;_NBLH27Q`PPL!AO\3YH-Q0-,)AL.#
M]F@=99@^H"&HS7-FZX(YR^(QK(JA=/-#XEB?4N8]OQH^];.R'DB?KE,F+?D3
M800UW[0_LW1@!U([JTF0"G*"@J,4'L%WXPA;7NNR%@I-U?HS.GLI)X9?6;=`
M3N,O>2%";=M"(H>6/'4/\W`YVI>ABI8YSDI=JL-Y6R4<B+:0#6LD216*<6)Q
M^_.G:BL^&H:4'[M4^34,&WLWOL$[^S)F`]D-Q).Q=&)/5Z0='7::/M=OQ!%T
MW/D?GY2E;VA6IVNR";(B30A;I&4+]0=[(I(L`BH0R.4Q[X6"9C<V\:.TR`,&
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MK(][*FC?QV2&;,+=P\=(`BMH!82IH!6+&GW$O'A3FLDL\18MHE8>]FNW*<=3
M=!N0K#C4-)!CPG%2-"5S=@CY]L5O%[U*_(&X03`H^L5V\UAI=U>?6PMA3$Q/
M(ZB<6'KD,)D9>T"-LKWN4A#-&RZATZ52E,)H5WC([`^-@A/S-D4%&)`0";L`
MED&Q"KKVUG?KA\,SJXQXEHSSR1:3`TC*"F>M-K>(830,;3P-F/]."`26^N"9
M^W9$N%H3*T%31)K2&W6ZU#NX\R4[5A@X+H@U?C,6^I4<XV-EC-H1:QMME4K-
M+`TW_6LA5L:2"//0RD@\B15LP'L@+DC-#J34C%D[=P1"?/$]J,8;K-HX;H3-
M#U;*/154,\LS;$L^Y`RZIV*6K=2]&,>R^6C6*4DP6?IHZ=Q@]9P//[2.!Z=O
MI);$;$QZ<06*(-$P>CD1MM+23$T:FIMW>)P4K75MUW+*`-)/XK*,!:1M!#:G
MOG:.!Z>3EV*9TM-W"Y-9,'%NQ,QXKD&$3?>GB6,Q.<+3N2UC>+H86L74;X=T
M>T1'JQ(4+#2T/[W0L0S4T)74&NF^#)3_6JX3FVT9:P[=S%O%.(SM%L3(FIAF
MRVMG%^9])#^4++2!/#\F"D\BKUL6O(_R(W&KI],2K`?A4O9;&*$1JOMY,\23
M'3]DAKA2*7+6AC\4WC3'5I-YJ&K3@[V(V3"=+<9K9**$,-#JFWMQKB:F?F",
MJ^.2'][=ICJE04_C1.W5GEB5/!<^9IU5XAE*;0,X1EE<:,KVDY%C6BV95D,B
MK"/.P(0:+@FZ*)YD?9RHN=6Y<S&)/#G4.(RFE[@MW/3,/O=2KN_-*P%+%X6[
M2E?A,[':AGK<W0YQ+^+QY=JR6C9,Y9S-U7A+X9&</*$W.3.)R=X!-N9=YK[;
M)`#C'`1^(!:>_UQ&ZT@+GC72ZV.,,:%9DFM*M==HSFHLP7&[6PENY-_]S8R^
ML(!8Z7!0;-Z@A#:6Q65)'*JS*JAMU'DYAB._V!#2L1+E\M[(UE#U2(1_QDEH
MG5]^;+0%`^5M^@S1T$\-(].WXN&S#M)IR;FSR8CR-R_@X',.97\+::$UND!>
M_B`*1,G';A4,LW[L&#:9_F\6\Q>UN\*ZL8SOX6B`@T].0H$2DQ=XAH!H@[9T
M9B"$%;*8(%P@LN&H+>W<QLU__-6JT#<MICVKED!$(MHVF0RV@UK.6TS6?C$Z
M$18^VB4+:^$&?B:T".CIEK_]6^?)<NF=8[P'S,`C\<9^O7(=BSXQ^__6GM>X
MHD#.`D77S+UCG4GQ?5*'$(%:P81UZ\7#[#TUVR$Z%3S@JA,SZ$JF?K.]29V(
MBNT<R],^`Q[;U``&K>>;35R=*K7%#1$XOX5"V2DH@9DW`&^2"2C(0G_:6,.V
MCI$_XR5W+_`6D?`"6&5)4V@\3^\W[:0I5S!;>/K3`U:3#>$P4G^_:C1[\OH[
M+*02/'`%BZP?&BR7*XD6AM]K63^W-#9`S_RP)MIM0%_YD49M;5;T$-./-:,H
M+&XH,.M:O40?JK*),$N&&>:],AI=15B/!MP75R.1R(4KZ==S>7*;+]OZ-$@3
MP@VKC!B\V6%\+PW))%(BE"QALT9$G_1`1U/_0KUD?R#=L70W3K-0&Z*Q,CW'
M-4\;KD6ZT>U#"##JM:1@$.P#/-_L()W!WJDOY[_=B!HT#$($A5[=L+\>6O(&
M"`%)204!/#PV%C81$3R*21&&`9.4B#R3AP4128F7DP6@AH@6/(.(-J&7+Y^&
M-H*3D)&*G@&:A9<V-CP%20&Y`9&7MYBTEY"<KI*#P0%7-E>$`8JINP75CKN2
MMJ>4@[V7W(._S-^ONL20UKJ'M=&'W)'CUMF5Y]:U$06YM+:5BN:NHE6B=$[;
M)D28!`T2E<A5/%>\8/7"I.O6I4W[*.$CU&^AI'SL&($"U4M7IWRB-+8S1C*B
M+U?">''D6"A9.X$)_T="DM0-)3M+"=G)#&5AP@0QM4318A5PI%.='@5IXEAI
MZ2]"0F723%7KECV!GMAA379HH<.7H"Q%M/!/ID9<V=@E9%8SH*]=21S-$K2)
MYUV+27<%XR'+`K"_A2OZE%MQWL!A\2R8125+3+*I584IU9A/U\/#Y_)9L*RP
M4,IW55,.`U,@B^&Z$1O"ZEO,V-VY>15B*QF0DV5A"^4*CRDQDSY2@Z[PE;8W
M'4_4\\("F\?+4=)<MFR0)OGMI_*\X.;ZJDZJ,T1K;($/;!5X:5J\TJIA!_E;
M\+#-@$5I,J3)$66$])%2&C&H=:=16G9-\Y)4I_0VT3M"I=1-.;T\DE=%>?^E
MIY!(W&VCGC'Y/)7:,,!I)A$AP174U4@AFC8A3@<.$E&!L2Q(8&I=B2,&4I'`
M(M%;*SXEY%`M,<32*4NMZ`TH/CTGU"8&I@,4;\#T&)Z$C/W#R&9=_557E1:%
M5=LAZ1WCERFYF$4<,6RBYDMZ6T)G&D*@_$+2>N$)QY9"J\BYH'DKJI20DXDH
M)&@T=KX))I=N^F.82'[%=M:>5$DH:"L:AL+3EHD*!99*8D[223]^7H4>7HN]
MM=0H&VTFXU7(!-FHF^#DXE!T+%T(38:E5"J77^\T--)/L*ASC9:##=>F;"AM
M!M)YELC8'3B_$F29F1!*B2%:(_EE:5C_Q!*BC`?_7902AT[]*-V$)BZI44;&
M;`42/VZQ"=5I01)S%D*9&>K),$QN0M='0S)"TU:GQ7LA14T)Z8Z8GCX,8H8V
MF"+@)XT@I\^D,,DU[:*/&)M46B%?]5*MO?[*RT-JWM)?>1&,>C*$[WD":9HE
M58-/`&+TVHDX`A9853_SV=AMR/[5>8[0T.VTYY<8)YWQ-4O_JU2\"U;XVLY[
MRO+?Q=4^^5D!<F2TW#C2[-K)H)D1_:BBA>R']C3HV43<.W<^W<J_@'J-8+4W
M\G5ARKI$TUEY&]?Y3WCWS<8)*7^'4DC72;`E*4&K3BPS0M$`39@T%=<%85=N
M#@OYX'%CA7C7MZ6$XDPR_V4R+YA."62*&(;QY!'`.!T"+W#I\C,3VS2QF6-^
M&'+2Y:Q5^B*5)LW:=E'!FPR)I3?@U>/05M3L+:$WW\,(U-Y_$])IN#6Y1]N-
M.5,4E]T9?8RQBY<6;BR:5#=V]2?=YW1*=8T97T-T5I!_Y4<X&.*&.E#QN,(M
MS&/K&YWW+L3`\2&I/:4S1:A<M:`O44QG$/*$C"Q!JT3]`@RBZ(4SSC&62DPE
M>]^RBPE1L4`"_J17@*%5A&;(,.*L@W]<<9UJ-M85.UWP8V7Q2#':EK4F-H0C
MC2H-8Z17#!G:Q%:Z68=8[A,VB*"N@R?S5Y!X`1G7C4LGIAF$!3`P`1:2T4<L
M2?_-^)0!1<;):$0Z`9*TC)="Y6F*6DW13U_:HY(A/65)[AC(3G8(DT^@"$>2
M$`MM"O+(Z14*([/0S%4@]+/(7&9V5`*)(DQ&I],X\'%/JLETY&$KD[D2%_,Y
MSGFX8C[#B&,?%5$-4/Z'24FZ[)8^:V4IP/B,5E0,:/:@!B9WA:2"F(TQ#/2-
M36B#EY-DS"1A*=S,M$3!F*2/9()YR3Z\$H!57,$3X_B@(]GU"*]A$77J$!4-
MZZ88BY`'/IUHS#ZFI4!U7&P_8OD3<Q3X%_:PBF0%B5TI'K(?MM@*@,<D(:P:
M)(QY-90RXG1E,G[!'HN10F'\*<QT'+I#=&XT(/%@2;?_IH>()9$1C67AP00P
MP$;*Q.D5<4R2[%)(31%"*H/-BE'_^!*=67[CH?=YJ8$TPKT.361X.07&PA`5
M*H%IPT4>N>.;%,8YD3E&6+SI!WN4<XL=;<@ZMR2+J+14`,OY1(OFP-U%!D.-
M;,!$2Z";RNARZ8B>#<LA8)"@)"Z)EAZ]"Q63&,TQ(3,M$L%I8Z5P$;5N,1J\
MI&]+SH!8F8CX"GQAPJS@V^DSR02YXQ`F+^>D2"BT<\R<A6@=+DH$W7XVD:MY
MQ3):Z88X<:H7GR'.6SR1;97`DQU[@"MTV.@IQ+1C`:?<C4X_F<;4-!7)8+JU
M20>QGS'G<X5K,>,GL<%=\P(:_[91?,TN;*,(I8(ZEMI@T6M1`9SK-(C3YQG2
M)9R8*0:0\CI#!">(6%NGMU0:'+G$+5D5':3*=H)%%M7->`?S+(H<1I60T&48
M]`T.J!8*,(#EH\*^"]2',"&@P2B$*N^1*O^T`Y\3Q2)62VUJ2)]:$C%J$$$R
MO!2I2/<+8:6T20MD1/5N"*KI`.4*NRK'C`01+<FB!FL@X@9K4905,*VI0P=N
M1"D>\(#8MD49`&OBK.8J9(R<0S81T<0#HO'@=.G18$(^3;B@9"8FV\G).;%G
M2HU9@#47(A8KM=_HTLR5;EV'@:JAA.A2A9]X[$PC75OS))K$'@7[#F^.N1P/
MQ%N=A?_"T&0)$PN%CNJ[TEY5&TTFD'LPX8Z*`"A[W;'%D"I5"^V`=L+&D5XA
M']:.VX@POEA38L3D%RA,M6-&9_XD=R1X2"P/2CI+;J&)`4PM)9;FC:Z:W>SN
M.161D+5%SIO#`R+@C!]<XR78DU$:O=$7LEHC+3<IB7+:T1?P"5JZ]O[<:^0B
M2BT2JUS0<\05-K8(?4A5.(%2Q'=<RA4P!)84K(D%0EASB#X)KD'[(&%_\)&/
M[Y0YR[V&7K=27"`,>VTZD9O()I2C!BZ#[A<12H(:.+[GCWMFW;50@TAL1:Q!
MJ$'GXLIK(0Y"MTP8)*6[Z2Y2]B!-3J'WEF](DYY[)#DUI-C_T0RV2W;"&9>Y
M)H&LC'G#&SS4T$=]^$_6"4`6`@`&3EGF=^J25*^RWME!(8KG^Z-?3=KI]*2H
MQ%<;[$U6[ELN8RJLT/[-C\-V.(L.5?=Y_#SV@PQ85\XE4G0XQ""!*4P_<]BR
M?=D#Y4K7&DV>.-Y5&IX='P$]@0$P8``-$,.6!M'E&@P`!S@8@`U28%KLO:$!
MKA>![*$T;AM@P/4,$,$N+"LJ#(A`!`V@:1LCT&7]'6KE9U$.YU1RDN,8RH'-
M$(0-<```!AQ&PQ]YD*W>@('HO^&GTWE,I6HKJN>Q0S9OPF@S:M"`_C=`!!@0
M`5KP>_\7?>U7<&I@?"+P>@V``'A!_S&+Y"^HT7<+<043(`(XP``8<`5NAV@V
M,%,#$((88`/C1F\1(`8-V!5T=@7'QP`:"!K290/^YW]BT&?QD%J+%"\D1%3J
MU5P14`,04`*[%P`#``$-T'*4L'"]4`!B4`(X('N.P0@RV'\#`(!B,'`;@0BQ
M84>#T7;X`3[LAP"+\`!$J`$EP`-D>&)542.WXB8.AT*B(EZ8Q%N\E4I]9"E<
M(1LE84M"%$*8$4<)H6[(=AB4,WB$]U4.,A2HIBK'YDCRLUYSHC*#-$1_9&!@
M,6CV<A<1DW=-U1*=9U+U91I-88A@42:C1@B+\6NZTX>61!@V(`)U4`894`<`
MD`%B``GC]O\&#``````!95`";Y`"Y#`(&%`"LI@!LE@#!;`'^5`#&0``91"+
M#$""<28(8D!^`!"+O%@""/!S:@82T,-NR\!ENR-DR[!RT%!O>W`''#%NL7`'
M`0!\&%``.L>,YE@CX#!P/S``O%@'&+`'>Q!24$)]D2".!O-B7#9(J6=1DT:$
MT-B/1[@'#<"+95`&O`@`;Z`%:N",T%B1T(@`6L!H1Z*#V50:KVB1LP@`W#AN
M'B8&SYB-'U!^PQ<)[%<"Y1<`PO@*-6"3L@@``]!G%@$)+@F-VE@'`_!^U+=F
M@!8PZ28NR[`0C(`!,?D#%Z`&&?`!(O!SC#!NYA@`#R`&'U`&((G_/9N``;08
MC6=YE&[19UP&%=_X8O,F"`^0`N[X@V5@?BF@D350`0T`E`2YE5VF'`/Y`.QX
M$%529AH&-1$"B&RB07C34T($+T`2&&Q":<7B8,I@(R$AB,V6/J?`<*9P'8TR
M:['Q4:X3)BH5)HXS>91W(URD&>C$+AW5B2^U8?LTF]IPFC>Q6D$C:M6CFC<!
M9J)6%F]4"!/Y`7#P`V]PE0/P`WDY?A_`C3\PG=[("#P`#39PE0PPG0/P`1EP
M!1J)`%=9`C4PG6^@!B%Y=A&PG-%9`[97!M[9C7N@#G`)$=@1D-?RE%?P!COR
M!@$`D,B0!'>@G.=)EZRE!@"Y!]BA!0R:_X!B]P8<V&6Q^0`_<)4?\`$#@*!,
MXCPAL@<)B%%3L9\[@@H`V0S/<#.4\0NYV`!UX)WE>0%[T)UE``?NZ9YJ<`'B
M&98-('8#4`8UH`4%0%8=I$H_-26F40-EH`')B0`0@*$M%R>[\(H,4`,(``<:
MH`$#L`<IL`<UT**\F*&\9XTM"HQJ,)T)"1*U@``MF@'NR8\8^@`:^0.VYA#C
MY@P<6)!,EPMB5S$>NI'0^`9560(?T`![H`5TZ0O\R8%WD`)O$)8@>8])@`$`
M@*%O@``,$),UH'/7(797D)`!R9]BX)^S9Q91]Y]JT)T9<)X(6J8_H*5:,)^V
MYI4E:`/^V65BI_\5Q=>?5Z!S!&=GK+")3:.)4,:*GI=C,T%!71*(\P<E6P5.
M;CEKI`8KH``&&L8;'B-CR/8(6*);RT,CPN9-D0@BU;5DE7=#G-EL?T=1AH`<
M-69B\M(M',5B;"8Q*K5%=$(A?R:%W0D`&W`!%]``'U`'5"F1T+@!>^"O_MIE
M4@@-2/H!"."O;V"1-5"5`)NJ`(FP='D/P,"><'"P>T`'3<H`"(H!N8>3#U`#
MN3>=#8`#_8<#=3"E20"0NEB1LB@"-O"J*#L`QU<'&;"!.PD!3UBH>W!\&)`"
M,(H``X",97"4T;-0"-"/M?@&]E@`#:"!_'>$^SBEMH<!93H`9YD!4^K_H0U0
M`D?(>RLK`EX)(`#Y`Y>:H?ZZ!R+@G52)L#!ZJ3YZL%4Y=O.Y4'_2(^)"5YW1
M"Z@ZMW#@G06@!5WV)C+W`PA:E5>)`Q[[!JY'BP/P`!>P']U9`G.+L%S9"`,G
M!I1[L&H@J"*+HRGYBPW0JFI`L@-0`\<GM>*IC1FPHPA:`]!(E:,[J`?[E0P0
MBT:9D0/HJ!>@!>PX"%S*BQ-[`1&+G%H:`+8'`=!XE(5*M<\8C3`+D%=@>[XK
M`BQHD2HYI6JP`7```C>J!3\@`LCXLIF:`C^PLOW'`!`PNZW*="1KD4O[!M57
M'L@`'[F")GXW.@7V:W5#'ACE1;&C/U?RK-S!_V*]-$;0*E'5<$C^Q2O$>5^.
M05`7!$2=ER^#5CVJ!CVW04N&IJY"4BQ+\BNMQ!L<E0FU)2V(A&JR%5D[\RN?
MTD*C-QN@<`4#H`%ET*_*RXN`>JH!VW]\F9$Y^0EJ`+`?`*@74*&#ZKBU2(6I
MZZ\F]@#9R;S^J@:%6P94V0`:@)$7$`$X\`$X\'-VFP'(&)TV`*/..``@X+4^
M6;N3RK-?BP//2,8WN@>76@(':P-->I?&*`([]@!)W)[/2*AU:K?PF0'3>96T
M2,8I8`,,.+;9*+4`*[!-3(N"O'->F0)J,,99^K8`6P8@8)ZXJYTWBK$9"V_+
ML`</8(^NG)"R5A9$*/^W_EH#/.R<9/@D<YG%)8"EEIN7%-J=<'"C7,:>Y`E\
MJ6NH+.D*>Z"F`-``;RNH)7"C.TF%%IF5$AF3WON/7=H`(``'M(@#!7`!N,S%
M@8JA!ZNF==``.PD`D/O#/3R\ZFB[`/"P.#JITJR\%4FCNZBY37Q[T;>+=SNT
M\&F4/"L&#2N+1UG(U7RY_&B4-ED'->"A^UH')="B8@FC&%"1;CP`9%N"Q')J
M<X>OSS%>)3<0@.,8=S2LAZ<5V'-#",=P$KS"#JPI4(,/M?.;D400U_$/)\*)
M],IQ!B)"J[4\D">*>">($_%2C1-&QK1;[_$"30D^D_9!J;1@U!$E;F8B]#C_
MD='\<V#]L)\<EB5@DP&;D0^`5EK0L,VYD;0HS6I`BSQ[QSAP!3!J#5G09U<<
MRC!ZG("ZO!/[`TDJS3$:G6_0OC'YL%J0!/.[C[5(E?9\A,CLGR(`Q'7[`0SP
MU]ZIJE0:`7-0"*SQ`%=@DQ5=N&4LC%=PJ4;ISGOP`V,*!PV8`G/`N`#9L(,M
ML?(L!B%9?:C`>Z",MP1+D5_:Q$TJ`EK@KRE`EP\@;D24O315H]+-?^>9:04@
MJ0!`OD*,SKN\'[5@N<<+`0A`VW.PW$+LMKG8HAC]R#CP`X@;##'[!BU:`3]G
MNX-JM#^WMKM8QN8<DPS0?T$\OT*,R72@`9B<NX;=_[;K;)&!_:?#^U0;:9%'
M^<XE@-=:$+=N"]L?,+&OC:#/W**$^@.D:P,)6`/_";#`"*=[4+@/;<\5_0-C
M7,:'70<(\`,-*]>":K&O[9PB\3_&,B>7%Z[=*FJ)AE<XHPVY$<#E5-78$WX5
MLCVFXM1W8B,F/*_&L#8:+!54!L`BXQ_')N3<`1[7"N8T@3/_XE+;=1DX36]1
MX15`D7&Y4'0NEF[767=%1G_%HEN&.,)B\0!O(*C96`)7"<:YNYT?VZ(9"J3X
MP'3'68LO.;%J8)&&KJ9.JNAR$`&1?)4=>P%;"M@PVITB:[L`K<?(Z:\_`(T3
M^ZJ_YX)K2I4($+"X>ZEP`/^Q##Z\E[K9<[WA"!O++#)NDDK@V0B2GMR=;FOJ
M+<K$"&OC(3C&#CN\P3V1#RW2E]!E;9O*VWR7_O>PA/W$P^NA978;'?W%%WF1
M&A"3&1H)<6/%8ZP!%)#1`7NC`N,3!;"E#0L"_CH'H4W(Q&[,>R#?R%G?O(@!
M#)JOZ^FE[NZD62RYK@>?+0[K=*L&"`!\7NOP3XO.N6OO&IX!`P`'Y*?K/Q"6
M06P:]-BP#QF=<ROBWKGLDSKK36Q[(`V?]FZ[98#LR=W?)3`';\OB-XKBJ6R[
MF`RPH6R53WS8*@G.5$F7SU)%D54Z3B8W<*5@@5%`MJ+D]/5K3`YKR`HU1.(2
MWM/_#1(,BHI6.RT-%&^$1;HY/GLTFOUC0#G#.\6S7?3BU!4V*$'32JVD2$S>
M1YLY14W#6&J!$FYV%S[WVF_LSJR-NX(Z`&\[N!?0EL"@D6\`!S3*CX3>HB*P
M^"8?D-!CQ9J.MUH<EG/K\S6PB_M,ZBQ_ZAL=X4M;M2IYHZ^.R:2^S\L[M[=>
ME1:)SPFK<_G`"#H<D[EGDSYIN4+<`$9K[$M,MW_^BY)_^_XJJ6QJC,DKH4D1
M"6-<NI]NRS!ZL#\0L@?[JEK9+*#P>ULPW=-]GBU"?0GXQN.;X^B)N.-V$10*
MB]'L^:"@D?N^I5I@`R#NRU@)"'M:!4D1A6]U'V4E#`,U_VH7%WL-964,#24`
M.)`U'W4_D1=J()67#`"?%QL`9:![)1\-%S]E'R4###@#`Z`_K`BB`3P\$7LU
M```5((DED+,9MKB-`\`_`Z@-E!\U%\>MH:$@MLY[<!\9D`T?#,['J>H,>Z+0
M#?+6M<@E;Q<I$0$%!0+8L/$O@,$`27@0)"1L&(\`$0HHM&#C80%_PR`F+#B0
M1T"%"`4B3"+LRL,D*%.B?)$R(\J,PBH>?!B14,"&`P_^2P(0($J!PV3V[/F/
M4,*'&2\:BFF!Q\N'!A5:Y#D3*DJ`#6%2_2@3*M&J4(4=Y&D3:\.8`[M:H#B0
MXLR1*E.*??HOHEB%%:=^+*C5Y__0KR0#/-"RI_`/6`,@J1DP3A3C9K,0(+"A
M1IZD/8L!H!.%6#&#=6H&7;SX!AH<><8@?$@<24VF#*A`B?H,)](/11N>Q8K4
M:7.G5&H^R[J`H%;N"Y\9<(YE6<T/-0]J%BC-JH[U6I`7?S@=ZD>B?9$F-?Z1
M00.P9YH!0-;R0"+`RC9PK':F1ET&V:'V?"Z#`/6/&C;X`U`$-3V0PH$()OA`
M>W]%<*!AB,FCQ7\U$//`#Y1D4(-E>T17C':L"4+>:O:8%AJ!_ZB!R'R5@7,8
M<\:HQ\DYD!BF6@.<Q*8**Z[`(HL:)DHBBCVL[#-(10LB@`P=QGP``!R*P0)E
M>"V"P./_<MP4!P`WX14F#COAV3?C9A=8>=\%\,@#Y&ZB./=&`XDP<&!`HTEU
MT5$WA>3026()Y!9/+@6FD50H5O333WO&I>A1(_%PQ4@"V7`14&3=Y%!%>Y7%
MTTL5Y?37IWLZ9=1'>!'$Z9X[Y=D755D95"E.0GW5*J0.&?175$A!)5-':;FU
M%UQQ44K20@$5(A%;F%)%4Q(R$5CLIX38Y=$5-=3P`QVP0("?DK'\8*4&7#;`
MB@V%O5'#!G0,H`%_X1T#0`/>EK&E%J(-6)HGV<"R#BA:1"(N`-NEP$]PJ]FF
MR#[>;?>#-1]H2YPBH`1'1&W$`0Q*"I^5P)N3<&R`P``X,FB0_SIUO%'8*!^`
M*PEC8`K\1BWGI;`'8]JJ<<PVD6@AKI/#+1C!,*0-4`L$\!*FCL,7+!@)`M``
M`#(FX'JH5'0&1I*"%@+SLR"#HP5PQ1L(;%`#+&>N_`$.!:3PQBF>.-+``&_0
M:P,&#4!3!P9O*&9.'>?"L2XP*;0G:01B)#*<U>QIB>,/&<]8AV+.U0+'PHP]
M3MRZ$?OHKR)T//=Q+RD#LT<!%:FA!K?<E/,!FYV48>WI`^1FWW,UU`+";/B:
M"W<W#;^NACF0)<P+`JH-((\Z):A)CV,X[K%!\8';51=0#`%-$DP(162#!0A)
M=3V?`^WE3[(-=5T2L(L>U9)3*IT5P/]:!>%:Z_4(#740K^Q#2VJMV=,_DZGO
MR\E.6%6KG@2F@"3!"E+$L)!7224IFYK5510(%9I$JB.E>HM/T@<3B]C%)CR@
M"$ATLA,(4J52H++(%4Z!#`U`X#S]R@PKD,$:-/$H<%9J(01JT"]Z60,`ZV(%
MCI)&J@C$!QE(+`,O^!&!!UQ@10`X3@H*<(KAO$$#``!&?32@B`S400-G0@#$
M<-<`@6D)%`](3FNN,4,`8`!%_XC/.BPSBUH,8`XSFP\_U`:S/6JA=LB```20
MP:59)"(5T0%(^*[`1B`^20TI.-K%!(09!&3"28%\0^`DXI&:--%G:B!01$8I
M'=*=H@P:T(#_/OHUBT'RL!NHE%<2>6B,#,@2&138QQ[>()\VUH.)MHK`&P;Y
M2_8$[D+7J$0=:H&#.3S,80LJ@+I0X45/0$))#G,-F^Z!Q4$"H!>_2($:B%(`
M0-[.,8K@QN^`6`9O5@,6+K0EF]Z0B1E"`&%-RP`"M@@FFT$@B*J\F+A8XQH-
M_(B-$)`7#GX0/8DL)%+LZU.K;.(GF<A/3R?Q'K,:*%&DH&]1PF#)"X;!DF`A
MZZ&SLL@P-D71F#S$4*]*%4A6:A1<S24A7>G(!+-B$9^`I7XAR4M'_@*HO(S$
M@/RKGT_O$A:W!&4A23%*^H;54T,<$"U1:5:D"A$8O[!J4R,$2`UV_T&-RA2&
M7IAY4R/Z(XD4_&`+.+K:&W;1`&L)C%Y.5!%=]\F>Z(10,.7$0+5J@(`?6(8]
M!=#"FB"3@CF4LP'@J0^\6C-6>%'(F1AZA"@0`%F!V6RR*>`L>#;[M@%@`)(_
M(P:&&F"#G(FB!@U`P-4X"XHY0.<'=*LM'D\'!T><KFBMB9,\VE/`QU8+!)U]
M8ETAT9[WI<VM8P69M08CH#[U1)0W@99"(M*`1L36&9%X`P`<E@(>9$.PU1*L
M*VQPWL%.]P%[^,_;OGL!Q!:$='2+6T,+,!@,@6QAU1(8AD[[@#D$SK^0I1`D
M%"P)T8;BL[O`FV>SP=!0:@^_D[5-`S"P3_]);*"[(.OP+-Y6V#>!)[X($,$`
M1(``)SZQMW!S:UV;\Z9=:+:^)O8L9V4[B[%>0K-72ZU+8P*ICIR%@C80`_?&
M]]"IZ(H@4;%516\ZU>N5%"0@30NF+GH0@-`T56CQ:$1V6CVIU`4CJ$+)^-R2
MEIWP=(`'A(E4Q;(]I)3E*YXBBZ"&'$%%OB4A%!D604!BERK'Q2?2"I5!X$<7
M^Q7E)X8Z5E/^@=8]9(T]302(@>@5"L4ZL;$&QC0='V#A"&"MOJS$:T22TD1P
MY*>)SC+G'N80D:KQ@U[]0E!]L^9J7A=88(UU<>#F8.N<H177P*R+I;6V:4AV
MVC(ID,-S3JT%QS;_$=G/QIHW$(!K(RXY(*&Q6H)"T=@"R$$B$.%T8<#!(.TU
M9=6=))VG:E*^BPR&W)L6UR\/!%]76\VQS@9']`;#:7H%F2B2,E#@L(81>Y-Z
MW0)7D"@'LVQR9RUP%S]0SCI$QUOCFFL9:>*E;8WQ_%S<P+P&!WM.?;5<)TC7
MD5#X,5EYS'LC;C`M-WFG^R&,23'P(MNS`:#6`F5$70I\4.X@0?Q!D8O\U<MB
M$,.CTE?2A$R=63RH>EQT):JC_X-/)QD53BKH9JX2(LT;?/.FKA=T128=542!
MNZOV-Y!A%>568KF)7.2W4KF<A%'[&R&FZ&1HE<1]?A<\NEG(4K^KEDHF_X6X
M]H'PBNY/+@C8@3/='(@]2IP?DTX$VIKG!P$T3@KFXF@-I5)L<(HSF=OA/I.\
M;</=5ZRU7/3$WCRMFTAL36,-TZ1.M2C'=_JK)1(ZH$;KYLT]#(6W1P[IGOS*
M-\EZ`(!I=)ST2C%L;SJ9)S*88B%XAVSOUU!5\*EU+DI6+M)705BZ)P-8*+.+
M\?+-.ZL`SA2WAP@.WQ[J_8,.1V]A\4FLQ&R7QW/_,!@+0G/!IGO$)GH+8CK(
M9X"7%QTBX2PBUU<'"&J>-VSC%&Y^I(&UQP^V96#XAB`>\DDH&'H?%P'0\7M4
M<U<+^'U\IVC#P&AL!WD0=2IU@6Y[8E$5%'0?%?\L)S%2?[<H4'5^+H%NF>)3
M3Q5E*$06:68K!Q1I%`5EGN)02&$JAU=<'#$10A<0D`<M0'5W>9)5V2,250%4
M9*<^-I$^4I42EF)FHY%^0M@^C\93YC=`2F%Y/U,1]P=[J\9?S46(HV069FAY
M@B,I8@@1+/B!2P%E=-,?6E!*#4)KH!<=XS1Q'Q1-"6B)`V*)!`>`U+-_`B$'
MSN(1B,4#<@!]!I%IK,@#8+`UG9=(-@!;FG0!J>5E%-%$/"&!FR@=9A@I2C$@
M5/,SOA)"4-44>!$6>V)OGF2!`?$&N1B--;%\GQ(!]G==V&6(<M!3-@&(Q.41
MQT*.G#@4G^10CC@UM/C_C?Q%)Y[(C>EX78D40L3@#_^P>Q\$:PE8B==EC,,7
MD`."6*%H(-;XBHDT&MPX(%/3B?ZHD.[F$>_#/<>2%_S#/Y-29YRR=%+8=`&@
M9-TC0L-P=1S$/D>A=<$"0,TX%OZC%SEH*'G'D-^SA&Z69B0QDUM8"!,9*,H"
M=V4V95AA5"B$%7Y!5%'6)S`)$@:D)TQY%877/HI64QD!AH_V$Q3TA$?&$'<G
M2F_V%0A7%*7G93TU47TXAUX1D]EU+`'P@(518/"6B!$!?6EI%@JD?D`C+>OX
M*Z$H*R'19=E7ESHY5&?(B@$`!L;BE00"'1+B4.>F45[C09D23*12;Z2(%U_G
M_RDKR15&98;96``O.`@]%P&M>&X4U!.C22=W8BM>N8/$Z&5))T+%.)?.,BOF
MTS7Q!IE#-9MT.9LV!99W%YH?<7CFHYK%J)HH!)R2J92F5YNH&8C$.9EBF%/+
MZ!9!961SIX=<IH4&D7Y4^1(DJ1*!XBAP@9(XY9H3,`'$\A1[(1="I9)WAR@6
MZ9<\]1.)-A>_LCT4Z80V&90W*"ED@4%SYV@,\2F.9YT.,1I0.3]/J1(OX#Y0
M@68_X51<Z)3N@Q;-PG9>P9]@,)$0(6\`NI)*IWY".!0AQZ$HD19)$2DZL35E
MF61>H2RD&3Y%951NEU5;&&]U1A.(Z'8!@E,H&IT4)/\,37$G5^!4!<`2!Z$]
M2T=JU-43S<@5+K5Z#`2.G"2&[_:'/ZJB?!=HP\(6.BH6*,)`NBF,9O:-E\*(
M$C&E9W93;8>,7HJ&4+I5$9H7)-HH@<9D4761!P$_!"('1B:5=NJ?%[1E=D)D
M?M*AEKFF?2<05Q"46L:?O9D3!**,>2<M&3DX`=1F0Z83$P$I1&<5ID<2;C$^
M4YIT0`@5?`IH5Z`H)/44Y,F@&;4]YVDJB,(7\=.,7T:E8HAX/;F$O5I5S,)F
M0H&A6F%T=X@5(@FJ2_4KQYD5?X)E8[8^Y[.@#'H6@`=X6J@KCS:9#<$3D(<1
M;09"I:>E606;)MJ;,(&?'J'_+)!R!8\B/S:0!1RQ=,TI/6W!0%=1;Q#%4X(I
MJ8&W*^HZ/6>9J!<TI"JZ%.9'$D7Z<P@K9<7%G^:6?I.9HDDF!NOJK4AW?B@J
MJA8+*+F"/1;`0';94RO)J>189U<9%8+V)X*"I)IJ$F!XHH/WC'VB$"+;BIRT
M$H[RKEEA4>%*0F860B!I=(9I=<Z80:0SI+^J*T07/S?UF#:5%KS(B&_FLR!)
M*V[F*4`QHI0:>!T4LA3)=O63J%)QA\I8JZA2$B8!%ZTZ4M^I*`WZ9!8P`6)P
M5$16I6\&M$HUL4IE=,)P0C@596^8M*=JHXO*E)2:0!#U0,]YA;1J0(J4K&%G
M0#BY_RAQF#[E0S^-IJ5OAU%C>X0_`2L#1#W+>;:]F@4'*K/5>8,_1S^$X*XH
M<05UY[&H\J4].!"/DF06@*0I:A%M1W?Q:0@YX:TBFV1-)I$2U11H.Y7+$E5U
M]@*Z*P<*^[F\&&_,-PQF2HXENA8O=;69JY0AE)^&NK-8RX.ZRQ?:BRD\\`:#
MPQ6U4GKB:0A%2A#&&Q)7H`(N*Y'<^Q/N^D`4"Y8Y@9_GYJ="-[V"YIO^ZV17
MM[@X&%(&'*QLF,`C6P!@H(P309'"$ABBJH.&.[`JQ2M#:X2-XA1^0H[9RC_?
M$U0BQ+U!69TV2D#8.9E=&I(%[,!)X*Y#6*U1P18=>X9-*?\2UK.&?J%H"<J3
M/FI"_C.\829G$104?X)D-6B&.%5`QCED;3=!7CM5!+JK$&2?$*2<->L42HFM
MHQ*58DLJ#'&'",L]VXF%64MT%OG%,#6B54C"0(APR-*54'A!9H@73^%1V1-T
M`D2'C#)T]/IU2\8H:"G(`/MW8$JX>4FZ'71WNFMDE@EIB)JJ[LLI4+B1(C1V
M7SBU/>A00O>'N=(2<*R$0>5F^RL7R=@5;,L6DS:%,UMG]Z>,9W>C[/FF*EIF
M&VG"/GJ9-H6L7AJ5W;K!/77`N]JM9]<K@T;(6%;"QM+&:VB?`J%D@UQT*CK#
MT7+`=A<8):6=/>L43-9X0\EX3#O_K#>9=RNEQQ;QMTM;%`C[L%P<=GYK4QP+
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M+#R%DMM<_\)*RIGZ`Q29^1=8IH0Z.D)CF;:-IW9@%9_V@W;I2G183&=-]Q5(
MNV<=Q'5$-L^(_,S7N;.@JRAI2<V8N723/;R#RQ2M:UVE75R%K(XR[#XPJ79F
M:68IA;ZA*\2B?=/_0W;X3"FDJ]QA)D`"'79YVKEHC60E&[1]YST.^LYR/<)>
M%V87*&^(>GY\0:-U;*!`V"@/-<CO3,0V:IU"*"P:Y1(E2L3`>[2"6]QGT;M!
MP=8]F\WN7=W4/9,-5,]*;-]!!3X$;99V>Z:GNH6VRI2]J78=S#XE2ROWW8;?
M8Q(H&:?;;=ED6+86=2OM?'0TL6K,F.'O["K1[;YZP7>_:9F7[/_@C.83EZ*R
MZ'S@0(A!IHJN%VF36BQED=+36%6K[MLU`]*E/VB]93;06*:.)[HL694L#\11
MS*V9V]ET2KV4.H76\6W'GOTGUEH].J733%VV>PU`?&K<"B2844EW[/.GX?O6
M).3;+G6$S#NC0?5S=@[3)-LI$>7A*'NP&Y4]X*J#03YF6VLJ;2:J*VTG@F)D
M*3QX@5[?=*Z\33BC(\YJ1^$0OSSFVDNE0DK.LV*70MG+)0S4>?BG&#H6E=X]
M!CII7;T^6!X4\&F=LPZ40&&WG'Y`)CY53YZX^E.4+J7$D)MW*KJ$8D[*!]YE
MI\XGH2M4O]F5J1F^38:&->VD&813"8K_HG.1?A`%U#);Y4:,N?\3=$,:='1!
M57L;[0)$UEMQY8+NY8:BU\9R/4J+V2BUK\:2N%><Y?3=9$(9G84JI`5\MN#:
MEQ49[+1ZU80>$&P>*&^]/U28MR<MLDP'0#)JI^LZSI.2MQK/V!KIAD"E@[RB
M$5P6H08KJ8_>/DI<MDJ%V7_7YYC>=8>\V!/.Q/X[/?M[KM0>G85]E]GNR(W>
M\H36S<,[Q591TJ:R9J*BD5I.48RFX_SI/5A_=DJKE`0B:.0(RH[:XA-)TV1.
M/5;E4L_==PL]9=(LAP2J)_C#57JVGA8\EF9A074FU%<Y%9#VL%X_Y#[?LU/&
M>)VBUD4'Y"@J_]>)"E4/OA>"?-OPSA1N/:AW>[!+L91*-].5@I,V7NPL;70X
M33[7+BB$'&?O6[AI/-<*JMY_S[Q[3#[,7/1WDK:%']Y,>7A+G]8\R?.2CZV"
MQH-TO9F#[[,2Z=*-C>[&FJ%Z2';+_).:J<V\[_#,#?M%]=Y:,<X46O1)/K+H
MFQ<`C3U+#*<C?606ZK29/?TSH<PI_%,U1=K+;?LCO:O-C'CI#0@%`0$\/#8V
M/(.%282)!8R#@TF%A0%)EYB9@I2%B(V#!:&BHI$V%I0!CY>DE8:'B9BBC*B&
MITF"EXV+C+>&J+>AC9ZX$9^<J0&FM3:@!9S,@H2OEJ&NILR&@X?,TO_0@@41
MC-L6-IGFYM^^%F*(RZZ.R=ZAFKZWUYW4NHZ;S+/,$<6H^1($;5*[?HK:I?)G
M*0"Y`,4L6+!4K]$M?<BD5;J8#*+#B>)`5D24Z]4^78@>$6PHD8>XE,D2?9J%
MZA'&53$OK>,1KN6FAHLVU:3Y"E,C0>O*)3&%#.;&>+XB..LD$Q+)`M<>*2,H
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MOEBH4"^_I7::36@EX]U7&%XXH%\,5A4908W5,J`QR%0"UCL/`D;CA;3YA5J.
MG*#(#&V0&%(9=*[8AX\_01*$#3P^JMB55S4)TT]G^-@$FX>!N40=-)/E=]>`
MPR'49#=`F029@:,]*513WFUCGYTE(>8/55ZJR611W5`6$VOHF3?7/G&&.4IP
MPJQ(#21.1O=H*O&1_T@AAL>H\A)L'#D'#TUZ\G.D&!.!(Q2@37GB22OC*/3A
M7H_\QZ"`^9U3:$F'L",->T5!)@LD_+SXY:H'P0?8H0L!PXA\.W9B@Y?L"3K0
M3&@M!DV3IR')5XD+I>972$IE(R2!J"C2$E@G^J6@(O`T&",FC'%[T55,RB9D
M8$"%6,TZITB"K[K=D.A1@YPX$N^(0E73E;TY.;9<?A\IU%^0U#FLVTOYUK.M
M0GVB2)%ID3E663W@5C5G?5")D^IL(\;&+8HMRH1DPQ0#N"]Y$8K[B96G^>:1
M+J!$/(ROCO%\[$!<)7*K>3K7-<U,MCD8+GWR!?.*)Y1R)-E7(+&;J7Q?(?_C
M9;FW%1F+>G;^UZ1PN$G(%'7G3J2;BE,&[:QVOQ@*C#LJ\MJN//+E2&0SW6R'
MIH]M`5/;;9&@9*&Y:.IG3TJGY9G?V$VC)E$2AU&VT4MI-M0G=DNYQ(.N&D*6
M9W8R^7L04)&85KF0`!&79SA$>L6-;,.A2?+:D\C($$Q8\\YN4Q#3)FOK82)2
M#-;:SDBR8YWK%>S%L/&NUL48`S2CDR$J,DA+WLMH,E-C`ZNEDR[#9=<_UB;?
M.NN%S&EEGP,/>%A!<_.F#[)T&X[K#N>09SV/3*`BG7E>L)IN\0])2V&+UP[Q
MD^"H9!*_`0LI)#,9L2A#@9>@%>&V8;+E&*<1.WG_F+[&!B02HF89=G(.;3)3
MF-:MAC4!N-725G$Z;FSG:2+#Q6VF4AE*):\](&%($4>QN'G`RUD+84IL@"0L
M,;4++_\0DHDR4YI23:LN?WN/^RJ4F`$E*#+!$Q_&5G<JSS4&4,3K2HZ,M24'
M`2<S(1$3Y39SQ/<<\7,%I)$5K]2Z.5T''%#94A+D$A?,I.1Y<M0(S-($03P6
M@#W'2V,DJN$-BT!)1A2,RXV",C<#Y61[+F1).;#2+[LTCI-*.:5^2'F(7C`)
M+T.RI0$C`\F!N`PBHU'=W"`1&_V)+%"#V*$YKG"%.69-BPX1`\2><2T,F2,Z
M49+,UO@T%6?U*Q=>HTSO_[`&-K+AHE']T@H[D!00=I$D3G4B!#OBU20HTE-C
M.6(-<)*@S)A88QLUJ^/B0,&JK`4-H%CS)6PD8YT+EC-*T:'FEI2$P1OUJF+)
M>5Z)OK*C?H1/.I/[T$D`BAH2<E)!.CD%(N^3-[J%R*2E$1/O;*<N_71H&:68
M!L!(AJ>V:.E%NTHHUGK#IN[=RQ>='(U""D$.#4F))1.IGC4^QR-G=8B*JC0B
ML?#ICF=@ZE4'E%_AC.C2DM:%6B+YC>58Q)%[?`A$^/HE`#VE%[<BDUU[\HTQ
M_Z1(0S705\3$H$1(-4<6D05#E/H1TIA((%H!!(,,^N;(4D,8_)3S%P]]B+A,
M0?]84X&J29$EH3^WTR\=]>L>&/I,(7!HGH^DHB53?4Q\F%A8(X(-H&4:&>>B
MT5#>[.E+*'FC+1+GJ8*Q+$:5'<>++M,SW53H0:@UY5?8$4+3U(-59C731CG4
MJH^5JI0<#5MU!31&IIH%LA9ZH56/53BN,HBP@A7@9$P"R&CE[+VKO`Q?!EFP
MH1VL+M7`#7SI251:D/>(L\I'=P5KQM8)Z,'"@BTWQ@E?UZ*,FB^TFF;_X4Z0
M^61GV'T+G:8$3E<8CV'0V2IN8HG01[7VKVWAX(%,4:./6I0^9+TG<&QCPLNY
M;%4MFD9OCZ$XC#3#I@\1E2'@BXL*G>ZTY,F@YA#Z0L?_E$6E_@(*,_>)B;)@
M``/KM)/X(-K$:,`N&"\HP`L"Q:H:"104\Q*JG:)1,`-7&2DWZFPP,3A/?VTT
MH<]@&5*B2ARDD$I:U%304/ZR#K(D^71]SE-X1?PE<O1$##<Z\:%3$8Z[W+*D
M3<DTIG]I:--PTJMLVAD%/R+3+?%+D1VQQKI>P0]'/^N8_*K*+)U<9\@$L&A]
MX\:I#U)28OM#G99Y(ZGX9]6G32,UL"G+LQJISE,`U9\;,L9&HDU=5M(GUX3!
MIH$/W):(]`,M6%DV??3&S'R1=5FEI"(8'V>;3F@VL8(`0V/%XJ29">-)UKG)
M9>O7G\(U513_/2:1GRP@]L3S_V`9]&&+)?&K`%RA9;FPP`2^#.:,Y$Y0CT#/
M9WRKS6YRZK^_"$A@5\P)3&9'0);Z6!TY2JR#Y+HD[ID%PV2#.U;YT#W)$,-Y
M41*NK<1K4JLJ$7W+,FH-P8G6K&;=7=W*&+,$I$*#ENEPM>C"I2\[36+Y<$MX
M(<,'/S@IG.O@;+Z;E#YI9^D^%#I<N**\^]%-%5JJ.=<(N[\1W4^4'$*FK`6\
MRL()II5HD;2<2\HO,V%=4G%1RIR*:Q+.EDI*3\E*NB7O&"<3J_'$?$&A0G[R
M9FKB&\:0N%<PLP]RH>\JI%CSW7:C#Q-=N2Z0\I0L4,)EI,J%%$C,[Y0`7$"E
MT_AI__\4<R(NWAI^.E_-=/:[-,3`<0M<).`8,KUK(I'FSY!K*$LA;`][JQ<2
M86/!"4RLA9F;'VF?I:ET$VU[X=79`AJTT)<!#9[^28TK>_>5IZ-U6C<KF+)"
MKC5%D7`=EI!_T8(/O*==<D-/S?!D9&$6+H4G$65$8V=W-R-SMB9K7`(+Q<!W
MK):`ZT<J[T>`^3(,4K$3X!(>]P-IF!%Q9")DR+"!RM`XK+8M>C5X_[17C)2#
M_B)W$>%%#T%"4"(/TF$EE[.#T;2`$I9B<Q8;F-:"U`5O2>$S68=UBO,::K)/
M+Z!OH2![Z45&/L4_@Z!/6`83.%%[M1(\^C(FF,1;;L@*M,+_"O8F>:J1-A&S
M,TAA./%WA,6&2:NE?9D@>J)W?ZZR*A,P`=(4'^&`0S?TAN<@'\OR)I40#M-P
M?.7'"YOB:<9"5X<"16'B&S]WBD5'7QF!:F!"0W3C&\/%(Z3C:0MR(75RBS-#
M7\SS0M!3+]"0?YSXB<.@16NR?S-5)\N64QN".<_&?CFX)E?@<OH''(D4(M@B
M,A)X?!9U-3,76Y)25!0H6(*ABO2SB-Z!C2O"?C]H1,4E4G%U=.+(,F_G+W7V
M*G>5&^,AC]CB:\WX%]#A(?DX)U)A$TYU+)@0AF)X%(FD0-"S$)@G11V!=\'"
M/*=".MO"5(7W612WA_NP%DG6;RX"_XL-(D^Y4EH()4+7H'2U0HF("`Z49(/G
MF`^&P!HX5"@ZM`ICR&D8LQ<:,8*8!D'S@'D=1(TNY':#YA$.9Y(MM`QIEQ3F
MPV$N&$TX4XHR1%T1L4ZM430NR$JB58PVQV)]MDW5!1Y7]FR>0AO^IQ4E`D[$
M\WME:7;%MF2N=FA/1Q_2%D++UHL+LF11%4T($P^/@';B*(5QR5SAQR"<!IB'
M"0Y,1QY3UCP5=GM88HJ<\Y82)V_&(YD0$5:"!4PX8XO%PE1)='MUA"3^-Y@M
MM"YM-PE"1SJ`L1@DR"OC:%95%V$OHCB_`Q^9((8_@157LT_5L1$3B20FDB0P
MEWM<>!%.Z?\6J82;7S-!IJ8/`=4.C<8L[/!J-.="WC25>I.(JA!]("-LFY1(
MAG@>!UEBHE,TV:")*0$CH`8L:P)&TA4M6F4P_VABM@"/H`%&ZZ`K(R-S-/<;
M/*AD']6:$#$N7/(A/J&?9UE2K8E]#E9SQ]<^1)%M3(<0.;$Q"HIE4=F@:6B@
MT4`QRK=DNL*$20@D0O==QY1_UF`:[A<\JBA@2<2<?&6@03=M/VA:G>5K;&9O
MN7%ED_51-\>9&=BBY]9MHP4]*<H;E,6BW?6*NV:-&B=-2?(W$HHZ1[<<_3AA
MDN,CFL)/HD<@@?$TZ1.1"=0)O<%$=$6/V?8>G)AZ&/>`>,A1CK?_)O#2@!]I
M8BE:6AB)6N?7'GUE*^CA6S_&3;M'5U\J>M.A#Z?F2+[CEAZU(7LR+QF1>X!:
M6`<"A:M49Q?E+N-0HHBAGA6&85>T=KFB9TVE,GQ!)C+D00[V&UF82>)"@<-)
M:WNB6+%J$?="8VV2?'LY7GP9:D6T8@.S=#9$+QE4?\3I47G:==HG+NC%=/GC
M,7&QAJ$I5'J401\&&Y6&:4YW-__)<K=G2*J&964'2-N&,X?V5,VUK;0)1CMR
M+G*W1@TCF&4'1(M'K%TJ+KQUGG-"4A"#5]6A$?8Q&QZWIFT"1#D%L%RY&24V
M&#E6+M8H6JL0$M;%BXVIBLUVGTG!6JZ!_QZ#FF4(]7MP5A@0HS=NJ'`XAJUQ
M5HR:P:78)T)<<6K(E@MYA5$<(IN#)TGAET1YM),&TK.."45<D1A)I(E]`3T.
MEI<QDGG7HCW-$8219+3W($(.<YHHXI^WU'ZD\ID>]+0@,3KK(IQ*15(ZTU2P
M>7D>J!_<LZJ`.H]J04_"`8^;D3,Z2V1NX1-L"21XM0E,6RSN)DC!L"G64F5S
MT9J#\25/,7;GM*R&2W@XTR4\B78J86'4P:^I5GFC9!POIAU`1TP7`UY->CS[
M]A0B-3^S]$X_)SM5FB6?I6N7P4??QWZPE12D=23%AEI:PGR>V%I]]$]:,W^"
M@(@Y9!0:^8I",O\R)P5.P>4G8L*.],5#[3DM0%97K+HV4L)TF?9[.D..LQ-;
M5E,(#WJ8REN'2I2!\T*B%O5H->A#8\0-H)&`E"!WIHA2NW90+-8EH)*%Z?9=
M?Y$71I(JMMHH_AF.>)1ZP"&B8K:_6!J9L-"JN#)(.D43H'=T:N-N7M$UOZDX
MB)"%<F4QAI6IGXAH%3RJ@_06:7=RDMHH$T`F]A(B%=4EXR(D0W6G;*=2ZL)0
ME7@:<JD7TW0\82,EJA."ZD>G.)$7`6<2259B-=%8KG*GR:@^(%BWO/*9EPHW
MI\`4AE`-6T:-Q7L>;"-WOFFU:G>(BCH=V$5CQ6:_)..)?0-?T`$L,)+_38K;
MBP,S$;G9Q-@D9K&[)97DOM$WC(97)UL50E^XPL;V6<XFA65D2P2K9'83FO5K
MJP?L<[-!%5U66CX17?9I11*W@C=5>:>(PA%TH,]8BT4Q8\XR7@2;+IFQ-E)C
M0\E7O](3K]E5C=Q%BL55JD_5O9@<P<;HOA\#5*KK>&YA>+-)H^EED#*4#T8A
M'9XW*:`K<I"3()"2%OL)2A2QB^4"=D.#*T&"'!LER]1AAZ[BQ&-GJ1!53X<F
MRE7;;%-)(/HD"8@X'1FW<1.AB]>"7+6BJ&OFA63QMO(7/G&8@*PY3V3D/[%U
MJX`15R%J@Y*:O?[X;"A&)F]%)-CQ$\7H'H8)_T%)&&I8HV@>Y8MW0HU,&4[3
MA,E%FLX%+6N8AR4?1='?U,9C=:9S)&1*98JGAAP8R+!$)R(RT1*/$[-YBBU[
M"+]"R%SALR3CR#$__1(_)RRNN=#&E801*C.YF)6!DD`8.E6;,C[#53'*N(*X
M]Z6BDG08RKQ@^LQ9C,,Z.+#CS`O!24@4V5Y9D[H&O2L7BVJX*5H/-9)6;1TE
MDX^Z<0^Z,D/+=HZ,H$^$<I#^HA4;-P)@YCYP5\/GD8CT"#V8%$#ZH2%D98(Y
MN!.-TSO`]457@4]1I"8S\8E,:ETS976#4!K5)&2;0CJG2;M]93MV?=:4P:NL
M:0&()#M1^RQ"*9.2VO^S$`&D824+A29NA06M07>#UEJI*]I3[A@,0M<08AQC
MB9F9"SQ?9A*;HQFV4?1=LS>*]<6AWNHPF0"12*4F&02!V6H9_'.^AG6B$S)J
M]\-*SJP1^#TZQB*8_!L5EY@BAE4;GIBUIUAR_4I,<0)1S&LPW`*]XN/<$XA<
M.!F_D))(YW@9M31R9(0YW@*2P%D+^DV75N5PYP=#G])!M_+%\4!]DOV("825
M!AUR:Y9FKVL*$R`W9KM'\&%FJ>T;R4@X2$RP0#,V$1MG4^W7CG,3B4>O?GTJ
M6W<FD03#/?/1"5O'G%J#5-*D@]$<4&05B'!Q(J0O&"/1N/0.QDDK?#3B!&/_
M4KR=$7`7JAE=);@EO4*6O?V572G\OS9R)U,8O_AQC?Z-RTQ-1^25;:G1:?`+
MO@]XTWW^+]=30S+IY.LX$]!-T!6BJ'A7*(1@YK102*$`!M=D(RM49$ZSEGC8
M,_*7TN1$Y@[;YGL9;$&;LJXWDNX$2`;WBW1)G>L4WU9R5KW#?#N4$SR`SV\M
ME5A&J+E`+N[$M.IJKF]6*Y9TH<+Y4YA:RAE1:R@<+/`KIY(4`(0U/D4G,P6(
MKLNX7Q1Z@#;V<K'^0V)D:.7@6B)6RPIKQ)7CET48*30:SN9;H/6>&ZK&JF+V
M5IX3)'>Y7_>>BS9H>!PB4YBF5_;3-`</(:XSRFR+_XTC32OIBS05LV<)\B>>
MG,K32&<R`\>:O,_\A:$U'5=`"EE`:_"_<,;FN4;A:._48)/^L&$OHA(H[U*$
MHZJT:(+&17%'+N@FK<1N_6^M=]'?>5=>V(R#<)TK_F1'=[GOXGP,Q$P*A&L(
M)!"#)5GY8?.5CD2)8+N<)0;*6W"-4\DD19A4-;WA+MA[[*AG14)Q;C";1D;_
M-&Q^TL&%9SL2.,5A/E8_,F=LXIY!I4JSFN>!HD'4P6?8$"TO\9&X!4M_V2"Q
MVI4[>^"9_B]1AQO4SKX8^."*/C"@.C-3A7G43K'"Q*+A^2Z)!!2?:;VF^G::
M+81>#5D7?W+IB-1B0=54]O]R:^?C0(?I;*YF_GS&%A>O5*KSW#>H>>BED]*B
MDF6IYIZ<G1'2FB\/1"<3-N&4?!+I9K;"\"[^@0SF/11QO:Y3U?CB-\1:%O>K
MW^#$TA8E-GO$+`((-F(V`3R"@S86%C8\A8P%!0&2DI&&/)6/A3R&B3:>C4F.
M`:&&DY.AHXZ@G)L!D8F*A*X!GTE)5[*=DIZ2EK.;O(ZPC+_$JH6+O;*^FIRS
MPZV0M4F?PLJ-S)O:J8:*T:^7U,2>R\3,M.27M+'$!:'$[XVZZ(WHW-7OT/>-
M!3R+2=U<^5/7#AVO5_I0\0(X+MDQ5:32*8O%#Z%`<]5HU;-$BM5%11;X'8LG
MK)[_L58OFC%*TH_=2H:@-.XR=O(1S)6:AJ4217(=-IKU5,8,\*)H45OV0EWY
M&2SHI*(\EBY\!$D2*G^>%)TRY4U0R)?<M/&[^HD0TGP91S&T,,B6)6WPJK("
M5558P5YBM_H3@VA0`4]_%WF#Y`YN2%LL"UW!)=8MHQ>(]S'VB+BR3&T4D8D!
MZ9`C4DF0>4)$BGES-)CN$O'X;,H5JL*,%HKBL3FQYU)N'3Z\AOORYGT(8WI*
M$L'>UMB9C&EU',XS.N(,9XT:6,IB`*V5_O6S::]X,+7T-J6V(`D[S(CAKI-'
MK[?;ZO#+MQ/:OOH=>4C^I(-+-*F4>O`'#51`<<GDTTAH_P8YQ`MMZRDEG`T#
M4A-2:L:HQ=A*+_C'%@\18/+,)1&<UU-B-DC%`V2U"'*)AR1UJ%I5%>)E222:
M7-<63*G`(\XHUDWR22NHV)*26B],@XLK?]VX#26.X')8(4C2^,PBJK7F(Y5L
M%2C7CVJ10F4]MG$"EC*,8(=,;/5LB0]XP+1#%C;@(=6)5YXLA4Z6:=(H)BBD
MQ;9(80<BEF%42]D9D9V0"1E*,@N&E*!@Y#5#I%%RVL"<HO:!-!]/&2YU5!)#
M0N:.509&(Z!ZJP$9'90S(2D@0S^R-!"!ZWG6U(>NFI63F[2]-YA&^%4(CEK^
MD3F?A):JEXM9Q?JX*6X('030/_^H1O(G?:RN$T!Q`LI'3BK45BF3M>_EN!XR
MZFCT26A_TN*7/?UDD064P8:C`@E7O!#!"U(5=&,B5X!Z+V0O<'%%52PMA"VH
MBRVF`K@!4X,`$W+T<V"1LA#UPKTJA*:C(2J$3'!MU.!!B!Q`BA*`'!7/:%$E
M>>4SRCRR52@K5<Y$E%%5HW;)F%)7$-6?<I&B]RU`08U:V")8[>2T3_X4J!`^
M?1[MFE#@V?73=)NUHR8C?*:T6%0G"LJ)H9790@Q?B8@A"CGIH*+*-'W&4F.B
MB&$5E5F@$HJH96(]PHE+WM!#E)"?.KCDI[NXU&HO08.*=]JD[FK*G$SI&N"$
MJ/ZRT;?_-':RC4<J<V)??<W`=>PZ:(I9S'03(IOC1JS(224OHLM::X&"$.+=
MLM5$FXZ8-\-^F%?%,!7[F3]&K0XS!^GRBJ-PCP(5._($[TO4KGB%6$8>X4?1
MX"$-N5A*WMPBM4P->TI4U.0P0=G&OD;*2E4LYX]RE,J6!;;U*C`)'M0Q&&R5
MI&?8:U-06N&3:6V*%@%["YA&%22EX.1G+!D5G7X#,[`Q4%6(L1:6G)(U9!%B
M(#*25J48>+7J4:(CS+@)+'BD$&=4;F^1B\Q<2)6V"PW#`D';'I>D(\$HP2\=
MD_-8H>H#JIS\[3-O81:>VG9"0B2.4D4ATZ0J)3IKD"*'B4I<_VO$)`NU>8)M
M"1O$3+"A.C3]XG:R^!T5;<$62^U(%7,YB$%L:!\JSDR-QX@B<C)&QHP)`XW4
M^`U)"ED]M7D#-QWQ(S(LX)AED#%GR-K$84)$/F8I$H6"!!M5Z+202M91("0S
M3HD6L\J0%8-IGPA6%KR"#3P,D#X\""#8+$""`.:R*"KP1@"%QJTS;HH_`NOE
MH`K!A&8ZLYD(V((T>X"`#5C3F7)`WJ(.L[&'T:-Y!=&%M`9GFFV^IQK^*\MJ
MIN?!24!";M_CIF=HE!M%^`56XZ!=E^1DFG.80F>_*0EEI-1(JVB-1YA8D]H&
M`8Q-K!!,3<0AGU"!"[1)KC*T(<2<'O\9EF]ES8/":5.!4B(DH:FFI`0+0$4A
MBA1':>1T_X&DH+!X.)6&+5%[(L:&*@%&HX`F)4"*FD/0XL)T\"("`F)0+_X!
M$+ZX-!Y9P8@'<=*NY6`E85F"AUT\RHJ,K(0V;G-@*IP:N?U4+Z>^NTZR=LJ]
MID[`I=<HZE1-8D<+3&"M]]F+U&[BD1_%L@"*H",@EQ,`I_(-GQZM:"\L%#$+
M[*"QL3N$CE2*B^$5DA_\0>J["N<NTR`I?\Z\Y@80\(9V_@5"!4``&U:K`Q94
MH`(RH,$:9KL&&>A`!R>0`0O8T`-G$N)>^%+!%3I6I+R2K$J)!*3.R.%2RV)C
M/;T[W3O8%I3_#)["D>\Y$FM,T:8<>96-!B43TUAHBH0V$A:^"(7.6'B5)3%)
M=:E02"RD,8ZCR6UOJ@(JH28J.;R5`G<C;(U$N*M.%O:.&)\:$D,2!9J2-NQB
ML^"<=KH*RXC-]"@I2:E1?`HWDV1F78SKTGZ!01';@2U3SSU,//;D"$?M):P&
M6HCS)ID>OTX5(VCD#69K42UNJ8XIS^4+ZNYD1YVX"T*+_-:>#"'D]BZI=JCJ
MDT%$">`LV:9ZIPW&AC+(R%UQ0@QW5>^4)5'9@*G'PHNY1<-"AB]97($O>4!<
MR(2;BHK:Q\(U&EWSF(Q:EC%AM%L`00-<RX)";X&T/R",')CPAAJP_T`)M+V!
MI(-`Z4HKX=)*"$)M==#;9@*Q*%?@)8,9D<U5*K"SZ_$63CJQ*#62Z"=BB6*6
M]AD9(9U4'*@;4G]T'#R93#9!N7#*?=VH$4V6TQTD`AU+8)BQ#J8%$YJ,5(L]
M^IDR\U`38SO<A7%:IJTR[;W#D\XWD]$21F0[;0@JJ;;[9@@[]6<C3RJ//.1!
MR6UO&''J5NF7^.DG!&^X<BN%&W<Z;!6EK@.NB<R%BS<:#/_EZ).$;5PN`*F:
M;IB%X-P*J%J=UCN)ST3@URC0)*=T0MA-/%)U=-U!6YI7K1B4EDV]CVHPYT"%
MV2A5WUY%DVEFFBZVB6]*1=^GA>2\?HAA@/]R^,$;EKYT"$VB80-RT7S^4EK]
M_7EB/_CS!I[)=6?VP+4RF.T-:%M;W>J`MSWH`1MT(-L@H.#ME$:!`2H=A+F;
M00D.<(`2[GZ"LV_]#:OAEZB/0HO2AB(/U(/CJB62&HKKIG$XWYW`25BYDW9J
MR.J%C<E=N)U=,-$NX7+:FX)!U#KV[)OJN/(Y@G.74D$Y,ZQIMZ?,AM]U]Y=2
M2M4R(G3EK+0TKG#;JWT821H*O(GQ;'2=CFSDIF4[WO[>@M(AP=>[%ROZ]&I^
ML[%(0+[<AEK\CQ-7N(*,>JRNVECAZ/]].5ALK.%YE&8*^M)6#Z)J\H\CH,BS
MT?@=WGOOST.IB13_*?K09<LE$3XW&/F75<92.Q;4/G[C*3Q@2WY637_V=87&
M`B#0`UMG`TQ76APH!M)T:"'8``T@32#06H6&@BEX@2BX6FS``C(0=FM`=Y2&
M:92V!IB6:2BP`'+G=G)G`$`8A$!8!&:0=T;H`">`!+PU,>W&9KVD&59$`L?3
M-9]34'-3#:X#/S0V+=]6(__$,"H6:EFC:Q'Q<6L"+"]50^[Q#N)F1DTS;'"T
M"K=#0NIT-5YV0P.&1T;6)]L@?24R%AL6B%`Q"..53\U2@*E@=%_!-%?!2I&3
M86D3?6G3;NYQ#=>F-64CB!J68817(C-!&D^2<A<#B<%G<;R'/>;R'DUF_R.;
ML7#I%%5CU364$!BJ*`8<HG^%<X`:15AU]!(BLE.X>!CP8RW]]G#?ICMKY6I>
M83?*<B9,5F_7\59WH1QMH7^LQCI;I4C1&!)\LG&`U19)(AC)4B5DM!P!J"/!
ME"_%Y68@@0<4LVA"H':X=0)'F'=]MP(^H`-(<`+\&(,YF&ET9P8T.)!!\(\&
M>6EFD)`*Z0$>8`9%$(1%$)%`^'9O-Y%R]Y!#&)%F,`4>X``Y\)$<\)%(H(1"
MT$Q580$FP(P`DQ)&Y5)@50O3PS7D@503T(J)AW[H!3OEXEW9%32:R'PS,X?8
MAQ%#TQ!X$5ZHYTZ/\@P:%1N):#$>95"6$`RCPO]BB9%P>Z)!M<-@9793FF@4
M&<4H[W%JK$%PWE:-^P`D*45[9Z%NH98^UU%=P_8_7_EOUI-%3:$KO0$+W"@+
MW-:300D@.>DA2R55AY`JVBAP./96)&>&J@.,<*E`4<0VE#`CL)(]6=$6,^9E
M"R((;[5":P0\P+=EJ-<HE*E!&2,Z)`82Y6&+[==P3I4\$X$<W3!8KKE&P-!B
M'&0Q,:&2GO`&[L@$:@>#,Q@$9M"1]9@#_*AW.9B0=!>1T!F1!!F0"6F#-7AW
M"0F="3D%4X"1&8F1%"EW%2F$!J"=Q^F1(,D!'#"2;!"//:`-5R"%+N<5D#$X
M#95<,&9#DLE<\ZEQ.87_F2L1'#+S?%ET$>61&5(9;`NH2DAIEO?`?<ZC1S*B
M&X#24)53$F,$*<K@>9801L+@;HA3EQG2->:XH/>UGWBU)D#%2F534\J7,9]A
M"V_V);^VH`4JHO=F#QFBEX?1><7FB;E1'\[Q(+IP*:H44'GT/U[$.H<@C$P%
MF^5`93A!#]/%"+$I(E4B/5/683(S26?D:@/!'"-7*F7QHB;!4#90DTRYH0%H
MAMQG.$>F5_73/=23F%*:E\;8-IR#8#\:G'XFCR>0:1#)D(1:J(0:G8A*GHJJ
MJ(BJD8WJD(\JD4(HD11ID4+X@Q"9D'F7GAQP``?@`P+@`SZ@@113"/BR%)S0
M_S&+@GXO-HZZXA!U1*82T1,^P3KC$7B>H8G$HE%=8TCQT!-9*#@/=%`$EIO.
MH%>'=85\`FVJ8J)DD16<DT=E@Q1=J6TX>CWV="X[P25RLRM-X3B59VZ!DD7^
M8")MJ11,LU.6<8=$HC&!V$3L)AK16A,\4FR1TVXR4J"VDS,/89GYIQ:]0RZC
M@8MHJCW-I8U]M%@\,5WBV&'BDXS#V@G$*`H:U(H%&Z![J8WL9$8#2R<NH4>`
MT:;(5@B`Y!^E])**4%G?>G'*97*CP"@5TJ2]Z@D/PY+SP01BX$P(``(5L`8W
M4'?E"9V$RIV(2K30N:CD.9Y(&[2-VK00>;23^I"5:O\`%RFUF#J$16B$.:">
MG;H"`A"J*\!;3``)1@&71+E4A#AY`$N-[Y$8Z>,+LL$Z:%4.DR*(S]J+5@(L
M_J%`;+@CH4-L11DC<!.KD>%"]0I?;)*'L_,6+H:*3:08V69\UUH*L!040#5@
MB>$(2"J:89-])Y)A![<)2X%1-(%(.\%^/_65I.$D0&2D>^DH5\9*9FM]`B88
MJ'-226$/?_4?Y79B:$&921"KI\64F/2&X1$4Y`!F+&M',Q(>(+LIL'2ZFT"9
M1X95J%5Q5$$/PH,ZEF!7E!2.,X,39-1"FI.'7U:-VH2[G?ERY;LFW8M_B=D(
MB]9,/8!;,N"#DSJ$1ANUDJK_J%,;GDJ[M-_9J$'0OU1[M4%[P.%I`%-0=PL,
MA!QYA%N[M0?PM0)`!0=P=KWE#AM#`NLTE0_4#6HJ(>>R.19:+R:77E)B5<!8
M2G5I++((3SR13FEB",.RH`3F>^=HOK-:E'WXK$/!&S[L1SKT8#S$B2(J2'ST
M/LCA-/!CH8X)KRIE;LQ2*%J1'Y5B+E%)K%^HJYD"ETSE"Q,[1B42FU/\N=H&
M;*[1-!!1J\81QDVY3G)[C7;S*GNY+-Y%?\X;+LG`$2UQ3F?[<[<K2M12QU8E
MOG0;FJCE;0+X;2;<I<4ROGT$B\VX<3AR#,@T90OD0<L!"P^S&)"P:!OP=6L`
MP(L:_Y'=29Z2&L`*#,"NC,!(&YU!6&F7BL!'&\!%,`5!.)Y$F)PAR0%4\+54
M0`4K<%MLL`&-P#',P4"E=W&.?"XBMW#-H;A(TD`SYASN&H@25Z1R8QV*=[L$
MD<??028IXRR#H<2Z<C-N=**^5Q++L'EQTS<KU6`ABJ-L3)OM84-FR(S$JR-`
MLU)1H6^+\&#X"A,D%J4Q\A2JVVZB,V#-V\Y/ER6%XBDY.B?']!(U([AV$RT?
M)'`(D7@NJ56A6TF]9I9Q`W,C88;B+!*#XZJ-4B">052]YS7C&[HTID7))G+J
MQ'Q..6;PPQZ])V'RA\,#EK)NL0%;P`)M<`.M/+54&[2IC/^TK/S*5/W*N[RT
M=/>#%2FIMVS+E'J16;NIG!K,&`S,&7QV;^`P]>D)\B,=.G&9!^VR>:QB9MG-
M0Q-_#8+$=ML_#6(*+(ES^.P8;%K3@<LWQL)91^2+W5?-6R42F*B40I4]RM`P
M=7NM8&D6S,I[B-5=ZL&(MK"]X;H70=,0Y#%C.$)4NU0/NJHQ'T6B_:8[0EH^
MA,<FC[1EJ/`"Y795H')KVB56H)(;S.(G_8&*`P)6OW<)QBL0,.U"B'4L^:=-
MWF@5_Q=NK,<G:1I6M.0.9N*R,<;2/6S<7$A`]Z%>3:-J4CE>Q,(77&.+8UQP
MNE&'H-U2)J`OA?4&%,,$;!!V-\#_@Q2Y`/[]WY4*M5*-J55=X`8NP$VMRE^M
MRE$]A,B9`YNJGCD0S!?LJ0=`S$AP=@@@!P#1,--HNT*2!WF@`JTV'[<V"9Z-
M%8LA-!?:4O^B2,5W?5G$DEC">P2VS3;3<,J3-(W=,UWU.`IX',3&1<9`K3T<
MU"%=)SIBV8)8+"2=-/ATC(F]D\*@&YDB$<#P&RA4)3[%NG\8`&"0NN^J:U'#
M%PPUAQQ!62RN,4W$&.M`O5P1&SD4INKSN2LZK3*Q5;NJN`WM)["V)548M\SU
M+'VNGP7A#.R$V4F9'5U!<&'J+.#BE,^J52T]E4[Z0+(QAU=&)?<`2Z($:X(9
M83R0!0-$_ZZB=#7QR05<0`(VT$RCK`-*4-7_[=]3"YX(;,H&GNL%+L!.';6Q
MW)W].P6;Z@`>(`4<8.Q40`8^8.$7CN&<1C$`TTM5LTI"LABJCJH!83C0]D49
M02FWC:YU,C8K7L_:S""5F+<-@40$!5X.)V:2K">G3M*2%+C5Q3I`U"6*42?9
M;!!C0U6#@#9,WN2`Q)/+I\8R1,U[<A:%9:5N4VSCDX='@16Q&BJJ2U+HP#:?
M<#N#P2^'I6`65!^2]5>LH%T0(7AH3*X'$J8[&BNA"29LO&7<`P[H8TF8M*7[
M`(4B=$+ALLG3P#QZZ>_U`\CED9JWTW].H7NRX'+WG)I#U-AR;?]E$N(KSDSP
MVT=L*[H+.?MG+."S`#SK_4WK4QW`NN[*_#WVL.R_K)R1OR[+#"S64B`%6TOA
M&&SAQ+P"Q7S,S50GY"J4Z#H*,RH-?A$8='HBZ##/VASJMP!QZW%OG#B]?4EY
MN]":2DH6'(KPLRIF%7<<'TOH_@0KB+*KHAMXICX-LI>M.Q'P@<C&W"5_S#>S
M&%WTW=K$1N,X%5?;?(-33K(9CYC-_X;RF7D)'MN%9#,YK)T-!GA.7V$#*=6Z
M48]2Y+H8R;#RNN$2W0C3H_FMPO_IDZQ'IN.EW9`^%KW2V]3$[+0T?7PTX=]'
MA0Q'Q`LN_>1S9IGP!V<UB*Y7'M?8:#'_(9=D%AL#"!97`4ER3$P];#(W"R@H
M!I"."Y..DHV/D)&.FI6=GI.7E:">I)69IP:8FJB01:Z1J$5310:NKE,>#CD<
M'+M4`@)4!QP'!RM4*\DZ.FP]3'(\`2\J%C;6-M%)`=8\VC9B%CP\-A;AWM?=
M/%?DV`'2+_`O[DG>YMOEZ>6#TDGQ\NK?;`08%\W=O('7+(@1:-!@NWO8'A)"
MR,V@MFW6+#1TQZ.<N8[1Q%4,4$";.((OZ'&LU@Y>OX'KKF33=J5<1H'RWOG;
MR3->QY$&?TJ$2&YAPW'H-B845VW;0G;HEA(D1.^%M9J"K%'E:3!G0FSCQ(!C
M1Q(A(7E54\+L_W:/1P&,%-<).OL37DT;*KF2&_0"J5:3'O^Z^SMN9;N*[$R"
M%3?89KN24Q%&^Q8.+L2@[`H6K99M8-,"!,?ADTR1I&ANWL:B[MMTX$ER&MN"
M;DWQ8<>QV=ZV_@DQY,-RA-3)%5<`=K4K*N!1TZ@-$1L6:TH]LG1I%*;KTK.#
MHD1]>_;OJE*%/_5J4R9;YV7E<J`KAZ]@O(H92Y;L`!(=0H0\`YW%<6>M;S'6
M$6=(-=9-$NM<I9,_!Y'#0U\V#(*43.+(-)$[$,+FVT8JL>-1019MPY9C#&%V
MS49"#8511ME`A=2!BJ'C#T"H:2-/@A8V:).$5PS23T]`SOB48,$E5?^@<0)=
M=`Z!_UD#CDC1*%349`)E1I!*/3JX34P+QJ/32F,Y)5:8;SFHEDKOH$1:@!%)
M^5=?,O7C()HIY:36@TD(1]MAX"01('!Y8N,G;_6XA1F4@PG$`SAE%8A1-[,E
MF<2<\Z3(EE:+,I=G-0449TX]5%74F6.A*BH66Y%=J0T^G49F8F62W68H;Y&J
MA(]BL^J&'*S<8'5%/)_Q\`8;)T0G2BB=C.(=>,RBL%THSR[;;">9F,<*+>*1
M]\IYN+#7'@>_4-$+,2L8XX,/]14C1#.'5"9ED1J!9D,6<I19V6PAH3I<G3VM
M:D]3]=A00`2/'G32NR)N]&<UMU[4X&0LE1C_HU;NL'EB21:WXRAEL$Z$E$T7
M!A"3CRD%JB`_<,KU*3E=!MG3BW,Z_%5KL)TXC\G&12/O-V*\>(]"+%$YH&<1
MCIPD05HQB*'#`S)5CEB<)1H-O_!(<P]'0_E;%%Z`S?HIABZ+G)2GZ3!:6FD%
M%5AFDK6U,VDXL\4VTE0@"B;8:8R!MI!NE16XJ:(3V>WVHY]FNFK/)@<7#F.;
MAD-PC;7I_-/AOC'DLT.2<E/2/3)Y60T]%N21'(1N(0*"$JE$0DFTSW:'[+2?
M+,NZM-.>,IZUIF0R2RVOJ,?>+L2$&Q]]*Z!;WPK`K,`,`F_42Y;(&LG#C3CT
M3'5.X#WV>"%/A=*$_Y-7&H^&]5*!;A0X2Y^97QAE%).$,]N*1V0HYA69+%K#
MXP?F,8YX&I1@2VKAQO2"PAB7!8DQUQ@<18`V/@&ZK4.!^0O[&*65"88#4QX9
M"#BRXB.39(DA=LK)^#[V%(`5#"T7\5*O5'0XAAU-$-+#AEI:EI-^".<O+?0+
M-CY7L.>1!5<Z'-60VK2RO@$*9-<+(@31\3&&:(DW/[L46`0(J9\E4$-8"PG-
M@,.F?%'**8LCXM'"%SYSR`MB/1K="WR5/16HH#"&Z`$+:!"$9#5B=M*BG79>
MYSH\L@YVMF.%*G+'.UK8XA;=<@^XJ"",^##R7/1AI`#((``?+(,-"&#"2?_&
M00+DL$91HVE:]0XC(X>)L&J4(M([C".6LEQ1@B4Z"CX<]!;S)5`L#)%94E3B
M%Q!-S)>>B=C@2*B1Z5W#1VG*DH7N],$72G%J!N0)<5;4L<&HAI;%N8E2GG03
MOWB$,PG\YA3!&,P(S<2#Z$CA1=XBA@FX!6@D*A38=H(AZ%43<^_J):A$:)&7
MS`-"40N<DQ;2PD09:$`181M":^1-@B:!@9%ZE(9H!<9TGN,;$[``/2AC&D$$
MJHF.RA,N0?*JC&ZT3V3#F4U$TXT(9.HT'7*222?%J$U5KF89(4G<<IJ3!)E@
M!R10C@DL((<XZJ".T^GC[.SX'63ET8]0M0ZSJG7_'6UEJQ78J@4N/#"%*;!'
M"CDX`"-YL8MB4`&2\IDD)<MU'S:@`0%E*<?H2$""MD6,-A^"(9IX.1%`P<5.
M51D0+ANCI8<\Y`6UO$T8V=*0394P29N#BJ`4$[&)=&I%L6S,6/Y&-(3]+$L/
MNI--[!'`H/'#IH6B9S09%\2@.$9\#13(VF`FJP"X:2%'<E+07O0DH.')2S!Y
M7L@6A0$,#&FE#BS(C_IE$H,$B",ZW*%1WF:U+F61)M^4'&=<2%B_38ZCEQ%I
M1K%12YQBZHI-2<RBQ$`(CFH#:N3=V16#"3'"ND-*JV+;!)Z"*O1.T9@%^0@N
MW\N<`+2SIB,D2XI\*##;_Q+4MG`S<$:1@R&D74,%%#E$#W1@+#L^*P0@#D'K
M2,''V$DUJBBNG7C"DU5:F$(6Y,%%5[VJ2$8VDAAB/2NZBN$#,E!RQY=LQL$L
MX$8WPH-E--5H`11B*'CRQ90W^^O5_%DGB=H#*H/9$(IJYJC&1HJCM<3L3`Q3
MF*-H4RD929]C!GL1K`#*2[Z:&CH#ZB4UK6-J-'P9B/"6CO`]"44$NN^((L)-
MZ?(LH:>YIDB^&0XOU?F#93&(!3`@`A$8]T&,0\B=\^R/EU3-8PGTC?YJ\J!Y
MQJ,>@E"';_M:V2B6TT]PL=)*13-8PAHVE&Q^$4OO!Q:%&,4P%$/H?=,W/>02
MJ/\H>[.UY6XEJPY!++U<ML%^V1;JE;2&@=?K3;05,@$;Y$2'XSL$$]B@`QD@
M]5B3"+&Z0ZQ'2S3UJ2B.ZE173)[TO'@*Z9'%C'41//GXV\;($*M:=UP,^KQU
M`\_HB`F"2@_M7>8R@M64PZ)\*P@?J"M5&T2DP*T;@UYV@941E)<=S#/&1JYB
MUJ9-;,<L9H+H9H._+A)L?L6T75KM?]"41]7446HM<7HG9<Y8`D_::A,Y4.9C
M:>6`@&;,-+^K@F+8!\9=\H__N=8"$ZATMQ?$D4&0.H1*>T=U&VC"@-CS+//T
M'X%&*RG,9JZ5(H55:C3ZT%]+2=A$J1NC/"5WFN*%Y"W_G*A(?IADDDS4?929
MS*E(CA4G)C!4IXH[B,@)>)(C5#/I%-.(DGW?/_/,FN@3E`Z+6M0-]&`+(*C`
M&A@!K>VL^_7M=E:)91_OVJ^..]\))"MXERTSX!L%AYQQ+LHZ#!S[.\<"]W$P
M"DX\'8#`&47]AB<[E&PFORWTYP2L5:[\M;07IC@3V&_46L60>V6,9I&FBH,W
M2)M>AJAF]ZQVI4(]RD6W,Y<@_Y5/)@3-KO<HYXY&.O(43?``$FCR,V9C3*/A
M3^`V)^NU&5#G)%72)EMS7I)B)VDG48ZW#1.``0T&-L)!):86)%LV>(WR$XK%
M#US'.>,@$X1'327B3<5&,V:3_T_P127S!1A7M&A.5(,]`WK6\#>/!R\\Z!>@
MIWBQ<8.=E7G1-46CP4"4QS'M)4R3)13<A45;`T:*]R1":`W/8`B(P`(RL'JM
MXWJOMVXC1F*XAVZV5WNT-WO6`@OU5DBI4`2^AU6(M!Z[<`2\$!_'9U9J]6/E
M0CS*T`P(ITFPH0*'@Q?K%1*XY$0=I"1M(3W=QW73)`88,`+&)5MEHD5[]A4;
M$F:4"#5HPT2R%#3:,#$/U#9CIB$EIWX)03*)8DY4X4'_9VI+HQ@WUV@$B((A
M$T$VLQ3I9RD.=&CL@PU0,QI@@4M,-CEI`5Q?4ANCL3:=LEP0`FDI!"1B%T#_
M!6IE,_\D4P<3%/)!MZ@U>V(/`^9@'^)JX;1WBS)>;=<WM09/37%Y"P4HZ\42
MH%9^/J@_.-50!=9.^F@8BP@ZR=AKBR-,D2=AJ)@XMM5MJ;%!H#1+WX1@6,<2
MAX``8G@#K*>&9ZAN2T4**R8=;5B2DB`=N_<(+=8[O6,&V')(1;`>#M"'-/F'
MR:=\D$2(Q6-)S`!]^1@T5A).L*(/ZN<O/3=9#3$CLB5M^[5?.D,:[=.$!H5F
M9P9A0U@IZ#,1HY04A+!3"N098R(_TGAQ1%,1+A%<`*0T57,CYF`5,K1:'T(/
M6G,%?V9T0Q%$9L<^3V,4K-1TC(:4N,@A2\*%&/%Q/B$(ZQ#_(GDV$%830T+3
M/<7Q)#ZS<V46(0:%)4SG/E#4--0T8.LE4%3D%-.FF9/%98E&4)\9*."$00(9
M:<&63PR3CHOG=HN!=1EU(:AA>?<CFXB#$.@3&UCW))"A9D;A%_/8)RN"<V*"
M`%O0``S0!D,`8LBR8J#PD2(6DDF%'219DK;G;M2R>ZFS+>BA;Z[@DGCH._Q6
MDV;U;U1`23A)/,QG/,ICB-=`BN243:&V:$WA%6V)9`[C:<K1:PL!6XX"*WCI
M1,IE:R98=Y*))I9R(=&%(6P2-37WCNSEE4CD02SQ9.YP%XFY7.$H=F9"&@:T
M=$$8:ZOFH&DVC$()3J.E&N54:&"$_VW9^&G`)0^=<HPV4T_EU#E@,X)$DPV;
M.1?0PS4LLR7"834=L0\4(T(7!2B-(P_`(3()")0#J380%IO+YD0A]V?1%5".
MLE`'-C[MA4&QT4M<63!6-*;9%AK@U81VPT/X\([_PAQ'XE?_\WC]\'_-P00;
M@`#/(0,T,`0)X`77R4<?]I%X9!ZX4PIW5(;<B9TB&8>Q`)-:-0OH44BRX"W`
MTX=FQ4B?"@RB6DDZF9/*P`QLP"Z'(#\!=2*-XS0;N*<DH$89>`XU,1:\*&F@
MA&GY:2$DI784JD.^%B(+935;63_THTK&*9PD)UP9,A*C-&N(!8TVJG.3.(EJ
MZ1/AY*IT*?\(1+I*63%YFI41QX6K0\0QJPF!)!-VT5@6F-AM9O<C&"8V=V%=
M.E=GBS5E2]JA(F<F<%(A$F*9GH%G#B%,5%$7:^11ZMB*=I=0#>%K)))*_\*%
MFX-?C^(J'(-;9^9SX'41X,4R6+H9C_6:/5A@1'=?5=(Q/`.,NP$P'`4&JU13
MUJ`"5Y`'5]`I<H``J;<("\!NL?>&/7N&BTJI(^FHUA$M0.N&V7%5<PB3^C9C
MMP"36_4[G8IC`"=)P.`#DU1)\KF374L?]M&3XI8D4>$V+V`!)C!X]"<RL]H3
MC841MXH/0"<HECDA,I28MB5U]E09<IF/6`9L)5*`*A-:J@@_G57_G`+D:[F$
M,XS1$.R0(R0()"#AF-LS3PAT&W]W%\?1$E8C6<Z59'V)N1E+@2.5N-KT:3S:
M%0:!B2+0`.('0!B6/4G#(*=4@*]I%-?8<)]2$[]23]S@6]@EKN6$0U!T9X[I
M<G$3/W,#&_?W<A90$K1D9;`8+V*6/P/V4+<)$1-CH)3B'Z`)-?V`;3X4,1='
M&%_A2LB6)!#E<ZTEI07F(6YA"%M0`3>0`&@8>Y$J5>`)'MZ!M)&:>ZD3"^?Y
MM*[@`5QE"UVE;S))D\8'<*+J`[^0M?1Q+J:JDP>P##V92>2G#Z<&&#_8B/9B
M9&MIH]M;EV+WH0CY?T<&2@WA9B"TIXK+_UDIHKHDY&UHX79;MC6P]H"OF*P'
MX1HK]7/::+NAQ27_I!.-JS]Y*Z41$B'\-%]_`H$1*R5,QPW)F*]W89FHB[HJ
M*`8-T`"5MHEF>8TL<Z^UZ[LX:'V\\4D;U98H(QP'5CEC1UBM@2#ED!*\&[S'
M&VPN<G4UTUT%&AMP$:;5-EM_;)5$0Z:VM8&S2&PN=&W(Y4Q28QDPB!DV87=K
M9SD44VS(D03+P1D%$(8WX`6&>JBX5V+YZPG@6;1J"(<FN;1,FV^R@$@)W"T>
M<`L'W%4+K)XY%L'`@+5<6SP/K).$B`0G<`)BNZI.O!,!8T6(\J/FT\8,,Q?T
MI+#3O&G2\RL=L?^+)\/-"',_##-YWB2NYVMFFQ%IMR&9&B.,!)04M$N`GZ8F
M6A*`$.(.W&03/P+.4G<C1K)=`ZJE#XA+C+)TUS01_\,7(9H3K-NZ\-K$,M2"
M_LJN=T)*OF6$T',%,(S1-N)I'9%1QZ$]_$0XN30TG-46CAO$BTPQ.KC)-%BG
M^/?'C1-0OEFG]6A]!1.MG*$U$H$DB5+3A:-RAXP1"[A`?Z=->.<JX"P-*D`"
M-E%43``=T8FTLD=[KN.S*:;*JXR2K`P[4@T>JZRI,R9C8<T>F&K`7#6UZ>FI
MO7RU6(LNYS*JQ`RVQ8`$='T?.M`#"/<#9^%H'GMMN"6*(?VPW\070/?_$=F%
M9Y.[S7^C5[NX=L`)7QAW&C`D0GG:&0N$8)?-''OAN>T\0.\<319!.FRI?Z=D
M8>3*7C9RC?5JK5`QITT,-;AZ03#W-%4RVR%RT!L10AV!`6`L`NX46T7##>SZ
MMIL,#AH+#BDQ)]M'<]`<3#*!7Q-W&CM]QS8E#74A,P#32TT2--`KLPNI<B(U
M1FD*;@;Y@R7G+\.%CX%1-Y5%=/G0,WP3:=O'*W\,O:'6W8B3>,.F?@.!!XVV
MU"1@#8;`!H-Z8JWG1R"9J*;\.I6Z+9R0+=@".R8FX5\=?+I\UKI,UKYCUGJH
M2&K-UC:FM5P[JJ1*/*;*?/9AS&V%!AN@UZEK_S46"U&UQ,4/BZL@=*]BTQCZ
MZ$\4,XYR@=`=2BI!BFQL84,>$DLTTCXR!U%D%Q%`R$/0=6;#G91<P2"DEEJE
M#3(+R[F4>!=K*=0RRKRQ+=G5`%^G+1&J&<2G%$P3`,9;9\E2<F<@:C[^MYL]
M`\X`46H<C('@.@A[F5D_4W;`\4FLW6BVPC9"KN-W\THL0AI;&3^J@L/6!HJ'
M84(FO5#41BHK_4K/=A!3&DSMU]YIWDTUG224^"``+A-RL`'08;]=K535>;]!
M*^L,/L`.?BWEL0GC,9*V(U7SMLK!A^%;9<!D[57><NSNX>%^".(4G+5:VP$E
M3H@G+M=U3=<]N0%/V?\53-U)V7,YH47E]X"K^V"C6V)/#^%/GP,2HU5@;'D<
M&\%T6A[3WQKDKNI:66CO#"8.D!UF1]ZN@3V"VCBBFW84OR99XE,]QU$9-\QT
MA?:`MY6R*WMW$?N)2CP0:@$<TN:!BIG.9K,]_/0/YK0.89EFY&`"O4F4@?U)
MUJ2Q=5.5XZM__]%HEB'9:4/R]BY2Q:F,_Z+)[6U%MN'7?\=D#T<8+L3>/Y3(
M)&?/(4<SFAS4DI4V?JU1%C?TX?-!&AG508M'TCD[L@Y[:QB'M#R>6<4[NQ/+
M7\T)N4-(`;SVNS?+ZC$+%T[L#B#WWM+ARFZUH`IP;UU)<$V(YO*UZ>)O=9W_
MS$45Y+^B`D.E.+`2TC'D)H>%@0F)BO=*4D=.&R"OY34NF5,J3HTI-D"!\.=L
M=%'COKK5=ER6@6)'Y]K8F,O-ECFW*-VX=-1LW1F1(S-MYK?$?K,FT!*94.[^
M$@"AC]J*$UVF$\@FTR'4PG4K%T;A)D\C-_<DHM2<):E&,23B,:W!NV,GN%8W
MO'&%??$#A'@.ZHZ'TLYOZH1BFEJ.4(:]L8H6_N7$:\^6W6FF&1%4L,OFVB##
M_EH$"#:";PUM"2TAB8H+C`N*(8Z)C9./DY8+*)F9!IR=1453H:*C4Y^F'AZE
MG:NLK:R?KJTHL::EH*B?4Z@>#CD.J`[!OL`YQ3D<_\@'RLL'5,[./CX"TP(^
M*]?8*P<KT=G9S,M(XCIL/1M,3#PV/`$J)`0D*B\J%A;K`?CY^%?U]0&"[%[D
M>Y&$AP5U8NRQ&QC@B@U\]019N!)`(#X;$:_P2)(/HZ"$`0IBM.>QHD`>#NU1
MY(C/($:0^=2-7!C2H!@Q#TO^BTA3G\^?0($*Y,=#(,:`_W#ZBZGR($NC]NQQ
M/!C@YDN9/'A8M6H!I\%Z";O>VRGH(4NR]FKZ$_D07Y(70_OA=,BNZ#R34+/:
MT!CQXP1[-ZG6ZYDO21)^;?FI/2B1)+LD!70"Q&LQYF29DY/8"'R/HTN(5#>'
M'MUVY.0`71,"])R6K$T+%_^I?LT7L?5FU6UC&SZ:5/:]DFPC<GRI>J'+`II#
M)V3'>V1+A3805!@RHP4B1H^R:\=>"=(E1IIFO:JE:Y?Y4:<\2)'BH<@J]Z]B
M&3`%2[Y\^J!NI2K/*]@O_\7\9TPQR1Q0H#+.3$.%--0(X(TWW7#C#3@4ZD`.
M&N;(<=%>[N01SQ4@5O16/BD-]L]#<!7V`D8.>5613R`6E!!B"T$5D4G/.7:4
MC&*`.-8+,CF46P!9R04;<L%)Q5$!+G4%&UEEC174E%0"I4Y1#>T56V`+&78E
M/U=4IDY496$F5T[K;/;11[")Y:24'@D2DD4N[25319\]121B`$5)DT4GV<E/
M5(S_W136<JBU!A28%3'ZUI6WE1723D\>E2*.^*185Y3W?'9;`,AY-)R26L$V
M:EVQ];5A5C?5)"I9K#WYE7&@F;@3JV(\EN=G1'8UZ66_OF2#9SG!U.NPD5$U
ME5,%*5H`:H-L08,74"`B"7>)6&===HU4,DDFF(3G"G[ZF6>N+J&@LAY[MI"+
M7RONPC>?O/;A)XJY`/X"3"^^"$/@,<@$S,$R"0JP(#714+',@]5<8\TW%"ZL
MC84ZH($`.DR`VI`%>1#T`HAPI2BD6,/9-5"S4?6(:4?LB'5:7/5HA&6O_6R4
M:*\W4:0/B#'[)!/)^#!)Z)!U2E3:<O<`6EF53/^$D@JQ_U%T!6>=[3,146+N
ME=J=MSG)M6H1X?927\8U%:9`'(UL@@4$Y9GIQA/)V6M*-5K&%VQ3K^/D5CW:
M=/9/0*XU:&%3!8;3K_X(C6)E(3=^$DF3J<GC0WEZE)5:9MWJI9\A;6;S33P(
M;:I+E]-L\XXH#[8;3AR!?NR&ZV2U;$<'(7?BC2@_Z_I7D)54^F#/'H7<5S8P
MT<.TUFJGB+;;>KL(>.%%+YXGY('"W[KKJF>N>MBG$B^YU']/WWOU<4(N*NGV
M%XP4P^S++X`"QT_P,\]$J+#$VEPSS8/7+!SQ-M>@6#F8((<"/,LA.JN'"@*"
MDK),1#-#RM2*P`:;2YG$(&,B"?]#1A(B?8S$5CB3R-H(,JI!;80E/P,)"C^8
M.9I=1B$V.5S39B@4@<`%@U#A65]JUY&]T.5%O5J;6$[T&IZ4A2LX45.B.&4<
M%FEI9ZDIC5-"1BE)T<F!-;HA=$C3#R=ML85.`\AL`%6X?DC1+!@$XD`<%Z@H
M_4IL+.Q<6ISC&M#HQ8UEY)1D2',1%=[J*ZH+7E^BU)HTWJDWIRN-:=X(.0>.
M+BVSZHW&_&$0`CC$>#3P3K:RQ3SF>2L2DMC$)CHQ/?/9BS_<PYXJ5RD%9&2/
M%.*+I;M,"9]XH=(_`&H?+@=$H(`9XT`(HI\S(H8-97##0?PSIC;^U[\#4`Q#
M!#2@:%+_8Q$?D:12;8$:4^(F%9_`A45O\LD'=38I0*[C+*@)#%_.:"<)IO!)
MP0(AD1K3)>)U31]+HR'3J+C`@T!%3N84IP\G$K)2"8MKJ2'3.UVV'#.IKEET
MTX=-&J.SQFU,(FK,$HTPU<`Q%45-M?'*#YGVE96X4RZYRF!;/F/!E;VH:+F1
M2&`,8X&_Q(9RCC0:[<Q($YG*\%.1.5R==GA.S7"&AW4*#$1@<J4[F@:CH^IB
MYCZHPD\EAW)#TVFL+,`%$O#`>&M``;9"0"UM0>&LS;M$*`T0!/O,BQ3I4Q<K
MY[JN(]B5`^Q!'WJL)XI:D"L4?C7%O-SS/?/X1PK_81\N<PDP_X!QH%\`6P8P
MFS%,<!1S&Q%Z$/XHM$QE4@P$/<B8:'+VED%!!Z=_"A3H>*/&P*4,GLN*V\PN
MNB,/?B17*#,-1<3T6HG2\RQ8413.BJ.0F.ASAI>*R^FZ&2>JD(BG@=L+WYQJ
MN%S)Z3:<:15HXC0LUQ9W3R,C+4?DH<U(YD.;@Q)$>7.DEU3)U*,CHI)`[$$0
M<=;F(*^)VAHE&%T\#1)Q#L0J4:=B`]T=#CA:*8ZK<AK"(CVIFZ`SJE.J\A<E
M+?&#S#'B1GQG%1G)2@P5[BGD8.(U7BVEPPGF001X,(&_<($B&Y#!$-3JA>9I
MZWG0$VNX@M#6\)UR%-NC*UWM2N3UG/\+R'!-,F!ST=?QV7(7P9"K>@+D+U[Z
M\K&0C=]DZ==9B`%0F5[^LF4?YED+L6`+"'B#WBIH6JRB]D4W'-LA5V8:/S8J
M(P&QT6E:PJFT&#6)%?VGDR0J5=_JU"WS3(T<442DX^Y3:;'!TD1H9SD@VK-,
M(S%4(U]C%;0<*BJ+:0P:L4C$=-X(GYIR[LI*I!%"7^$M2_G@8'2248;@`VHI
M"I09MW0XQ`!1(+B&F341M0\.ZL5$MWD,M!R<TS%-0(90^LT04]S#(AVX9IMI
M\;#2MNM$.66BFTM3IT4C;FWSF6PA3/>HTDUNA#P;-G+HP0V\0PGE74(3I!3/
M7Y.\/;FR4LO_KFPED8O<[WOM`JY'ABOX^)J>5/""/=@S1I4'Y,L!]0+@%'H&
M9YLIYOXUD^.<[0:85T`Q<IP#'3SP:D3DD4:`-$X%6GOP2GT2-MP^MV;UA9L_
M;)BD!!9+-87Q-'YS=.ISTWI4%)7C;@'74D<#+E$;`=F+/)*6RAS1*W,\%*83
MRE.J%^<T3Y7;F!9)*<B9C(KMP$L8^U%.C-QYZ:3#[YZ]:=&?A%W2.9L:/&NM
M%Q`):9&Q];.IEYHK?7A-D@;%\(ET\F?F*+B/#V[HFWABIMPDN"W3AGS+0#+1
M2&VH9IUKE82K)AK'"R:)80E`O&\0+DO0^SOX'A=]^&T>(:\'X%H>_[@SCI"]
M?A<\KGI5^%[1U=>#>Z`8$>?EQ'G)?-S_[_D24V;'H8]9:S`C&Q9B0SEZ@`"S
M;^@B%3V6Y-)H7%.+QH/]V*U%GMH3E)CP;9-O#=)KNO<,JEK0.L-2G%KM=K+`
M>;].QS1$P0\V1"0--!@Y9WZGQ0^'@A(UEVR0\E^\,79N-$_)=BP_4W6,PT9I
MYUL]`RU68RKE1(%SAVK\9!F-]"*FU2(5]#:9,BO&QAM;918?,TB.I!PX:&V(
MPD(`\2SV9$1&E!!EA#/%Q5UK88#<97^;%WF1YQ44R!,YPCF5=H'GETZ(0@]@
M!1[?80G2<Q^S9W"U9WNM%#\#5X9V]0Q'@/]7>>5[;'@>2K8+N;`?!J<O[/-8
MZ\%\_;)\%(<,>"@P$3,PS_=Q$--9$2,.F"6(V/=,"'`.!20T14$")%!?3M45
M41>)<%$0%4$<M`9(&I%S@`1/<?%!_Q<I8S=_0N@632)<</-$"^$1(,)`.U<2
M-E1W`3@E<#$HT':+A#(0@(0T`&$DW$4<-Q)W:5)IQ$,F+4$U<A-MN"9!.$*+
M0Q%S:Z$"("(/Z,2#I1,4%M1&&I$9.W)Y(5*`>'(4.V0B\S41@N=K58%;6O%L
MB$(\%&@5G_,7WDA?J/$7SY(:<%2.HC@5]#@6AS1$__!ND`.$)*%"">88SX%Y
MA_-G8=$8UR01SV;_$B:``#T@`UOX+=%#/N5S2OTFAF/(`68XDD?P#&3@#&K8
M>VW(AF^("ZAD6(=E#.R#?!:7+_QB95C6?)-%?0"T3!.R#=1GB-'P,/Q3<F@`
M37(@!SB4<BG29P\6)IB"BVCB0I/V-K(6?L=(&#)5*1$Y:!P1>'\2)&*W(>I8
M&57'(FN43[4X)5-#;)Z!&";2)(8#&QB4D%;1)Y]V&3#U0@69$]=$;(DV&,WX
M:_-@,CCB?JE!$0:Q$DN3BCV!=OBT1AXU3ZWH9PF)0';Q./?0&A^($&M#3LXQ
M004)%JQS>=M%><)X0I4#=+U8FAT6;9S98B(XA34CET+5:=$F)_SP;LJF_SH8
MUIITB9LYM0[N(`9;,!U;*#VE)$M\M0L@&9(B29)$)DS.0`8GF8:KQ(9&MI(%
MUV^+Q3YWZ%@`XR^+A8?'\$M[N)-_.#`<YW&$R$P'(`Y(P`V954R):"'0Q`2)
M(0\?4R8N$3@S,Q0L>!&I,A$]85K^=$%=%"9GP2<Z<7GRB&B%AG[?A3B^MHUC
MY!':U'1K.264J&HWI1`BFA!'58SZZ!4`@41[%XP*P194!TD)U7Z$P@/:)"*T
MDUH=H4Z28A@[LQ<E")E!@1D6>%-18T)RXUIU01/9^(DU84(K,J*%IU*FL2F_
M,1,@!D]R4Q+DEFCB5DB^TQ<@%J5K03J>%W8S0?^D]A2FF\*5Q6(;]_5=>T0`
M*B`&/<`"K*>1&^EC2D8*80B2R""=NB=,UFF=5)"&*0F2_L:=,`EE>'A[`$>>
MC(6>YME+ZDDA.^F374:(^;-,ADB?]7F(`30.VF<.^IE-?J<1,/=1>T>-/*,R
M`-5%+7%G.%=0<01%7XI5FA9TM1J%<L(1WX2.+>A-'G&.K>:"'?IT(?B!`"86
M:;0WOLAI8`.1$=IH>SEA#M1IG2<WQ,)3^/2)2`%_3=&0#(&@AEDE0!([;HHB
MPPHKS>*7=K0QY&25Z8>*5:F.@R:A0G5:O?EIU\2F2R6"D/=]M,9U1E-($[8U
MF"A)?R1X7H0;;->N?23_!CZS@XRA*!:P`T9``&*0A8T@+N/QA7MJ+G.%>]%I
MAM1)/P(PJ(-:J`'WG*K$AE%V6+@TD[]$LGP8(,20DSDIJ35[(!C'#(!(3)EJ
M6>&`!,HPGPQ"E"O0,/9)<MD'`B"``$HY$9`H#R1@`5!#2:IG`23`@!:P&P7K
M3R-"KH=)*$\B,G%C>0R%`1)+KZ!G&8>V4SM'=_YE%JQ5:\?Z$R6"@.@7K9@Q
MET4B7:3I49$B)V:Y9I,Y)H$!>E0'1N/DC*5'%#7J:Z\103J7-$SS*#)%.5#W
M.HFR=-'U&CJS48;6,SED-8K97+J";->D;#)E4X.7%#9PCKQ2.#83D;_B;DRX
M_Y"K`WHH4Q?WM5-*I1D3V2RM6(PGU+G>NE-^L`-O(`=,@)$YMIS[MJ?`)V1D
M*)TGFR`JJ[*%BITNFYU0MBXSJTH]:[.&RH?$,*GH>9-^:"`5-S#O&XB/9;1'
M^WSV*P['U"`-,W+WN7WFD#G^D`54811W,QCQ%T%,*D%@4G3G"(4Y2J)`ESJL
MLTUH*:^.H99KI(Z+B;=Y"R-I,J^9TC5WV:51U">D66(W.'-H@;Q)@1-JRF=D
M)[<H`BE(XURSH7/%%54&6B4U&D("&6NMP2BY1C,U):;QJFNV$C@ZHQ/#"$-+
MD8$/(4AG0H1CAZ:=8BOW%3I0$L0D)D59,288&)BJ]O^B,-I08N>F#@:\<>M`
M!&`/QB.]'4N]Y,&G;4A7N4>2)YNRT]"]WON]6!:^MO>=-&NS`5.&?/@?D:J3
M.FFS\!LP@7@`OA`.01M]^6NT]%D-U+"I2ON_Y8``-J"4ZU``.]=/EN,FBRLE
M.MQ^N[HGZ=<3F?:0*%QT9)Q_!5JL`IBE58<I&KR6(/.)BL2`)(HF!E%A?_$9
MBQNMN[&+C59%(7RM[Q:K73PI(=@GTFB@&F&O5\.MND4800J\8&&V*T5?3YI%
M%B$C]&A&Z.1=@G?!IT9K5;08(.1(__IS!78K%.I<78047<256:?/H!C/%F@B
M@N0[PD(DPJEJ"$%LW`H[``'_O75Z`^`"'A_+9&#XD?\&<-I+G7WLQWYL,"SK
M2^`IR,P'GN<K,("Z>VD(68M59?'3AS=KR)5,M,40R?_3J=60M)[ZDY<5G^30
M`Z0*O0_A#B3`!2;B-5&$3VTFHQQD0:V<FT:SN"`:;7CRP#U,0QEJ+&K7RTY7
MK,>H-<4R-F*TE49T6\+"HRT<JT^J-P=UQ)*R36-$(EJ#=15[$/RP-IA3;+)6
M:?I$5;!A`[`+'$3Q(H/9$#E#85]K@'$FB@M)I$B:#TP"$R\:.LM":X#=MLD&
ML1YD++`Z2>CV9Z%7>#>CI$P58#LE/"^\$:;9N3'1*J)3=!@D/'(@'?/6>J/D
M8WSU_Y+.B<<HG=(<G;(>[=$@K3`O;;[LFYXP?<B`6I)H^%@W^=PQJ7S'+=/S
MVPR/-=/79TP4(I\'P"`Y'0W[4Y\@-P[D\,D7\P]7X`YA7,\/2W15"3-+_'E5
MQQ+-=5.&@B@K5(&5*0BMQM6$22F9:"Q`FK<.D<\HJC<2;#1)@,H2<6Q);7@'
MH2BLT1A@<Y?"-2N"ERH/V4`<!#3VP)]9TC7R9*Y6:.&#M'.,<FMI9Q3KD!)7
MVLPT4Y:L!<][-AOMNF<OVK<%BU/*8CKY6#,\VKB2.*6F#<]1K'@AJFID4^2V
MPBO>!J>,T1;0RP)#L`AYJJ<7+89YK,=[#-S!/:@-0C_*\/_2O>18U(V^T[F]
MPI23[W.3R$>S>7C<E&K(\U.IVGWGS,#=/M`!W^W=F45FEX7)`F0.BX@.27GH
M@'W,=\+.,AH5#'IS"-B4$3Z;V*54*+AG>3$9`XYJ/K,4#NS?7=V"\Z5I>-G/
M%2L(]+A:.?%L#WJ:$13+FVLTJHSA+43"**I2#@AJ*_ZDFC9;YBHD87J02H$[
M+'(I*E"C>>+6J'-ID^*D[R>OBR'#I^%0-`%)*(:0!UL[RQNB9@&QE]<ZA;='
MTDY?!2V+I`-N-Y-.PP)UD:U0-V6X!<`$5,XM5SY8%KW;O*W<7+Z]'?W1?,R_
MPWT_9S[P9'@`9ZCF*,NR_@$,[F/_GGK(OC']L\U@($2;W3VYW4+9`7P.WM,P
ME.!-E!&B3$@@0*,:6H:.#HH6X_O<./87K\`<JW?T775QWPI)@7^R$\_.H28H
MF;$X="YUK%.S=(8MP0W$@B?<KYK62#-*:'$;L:*VD'N66^U\6T`(UNJ`UZA6
MZ7NG-!J,RA$N!GC@16?T?\>N14VL6TO19@J*)2GN,SD>;0O1SVK[8=?&NJ>6
ME40(VR_DA&<J:["CQ?V,.)4BCU-J?[*B>%*Z.#;`!K6]/(APY1Z)[ZJ4O<N-
M\-30O?Q[/]L[Y@3_I]17J`BOY@;#>PL/9>O#2C;IYN89\5H6B!]WYST-#H8H
M`!K?(!Z/_S`[S3^=Q=U06P,UD&;T-`\DL`,B?&[*6BL&JBF3;5_8RH^OGK8>
M;(OY-#A,7#<?;-CDW,#O=N!C,VARTK`Z]?(O.*&Y-38AP<,9_N0M\Q`-2R8C
M\_58HDU=E$12`FS/N'ZD>405]LX$!0@O`8.$@Q86`2\V%E<!/!8V/(N0DSPO
M+U>0B8^-A8Z#CX>@AX<\CA9B8H<V`4FGB$F+-I,6IJ(!-JH\KJNUAJFKA+*.
MB[:0IL6OIH^3K+C`L[NOB9F1DU>AR*D\!0&]K"\\)JK1H%MK"0L+(2WM[0LH
M!BCQ!O5%]U/Y'OM2_?[]'`(&/$*PH,&"5!(J7$A%@,.'$!U2.?\0\,"!%1@Q
M6A3(T>(!AB!#BAP94N(1#CD<J-SG0:5+!RQ?RG29(V7-FP%Q<JSHL>?%C!97
M_`RJT2(2)!Z/7A30H6D'`3Y\0(Q*U4?&JUB-(M'!@H4.-FQZ(-B```$3'F]4
M^2(4*IB@09D.75&12!`M9VQ)!<.%"I*FMY+\(KKDJ3`ANI?>#L(D2A$CPY`C
M&ZY6BYFD":IT'9ND=I;G7&J/@;KKJ=3C4*?$F%@[BI2I0JM218J=6<QL:[J2
M#<JEEY0-NHD<J5!!&/@BV9<QI[+M:E&C%\!?!Z@&]Q;?2,`T[=8^3#*/UVU]
M9;,Q`5:L6ZB]V1;F[/LKW:5X;&M^:UC_@4J&$'TZU6R[)%U),`9.)E>\D(1\
M%A"G0A;BF<(@'A`Z8P$)*I"P`R(\R/$#`C*HLPX[[4`!10OPT%.//?E,P=(_
M_NS$P4$P$D020Q%%5=112/E$D4!$134551$)0,:01!(9Y$,*(=F0DB>EM%)+
M3[($I4PUS723`S?AE(.+.G)`E(Y8%76`4F#ZX)1#9T+E4%56416F4#WE>)0.
M7X4EA!`;J-**(-^Y1IR!T^5!PJ!_;D>*)^&9HJ=ZY`SB2GC82":I)W:)D@2!
MDV;JR17DR,:7?+:E<LI_MO52"V]]24?,+-810XE<U>F%:"^J>H-*J=8<%QJK
MW^F2C5S:M16)_R."#$?88H]HIA8PG3`"7'"$A%/?8X4D>\BBIQ1HZUR&`;K8
M=+64DD@N-L3B*6^_6-.*K:]UE^AN>H+&"C/^2;),*;R(Y@VKSI![H&P'-H;I
M%=JB(@V^UXF+R6J"H,*$'')L4,$0ZH0`8@M0P"!B"R&8>"(^*O+#HA0[Q8C0
MC"COB&..'F$EU4-`PFSC"@E%5.3-1D:4I`!)*M2D2U)*.=/0*]&4998"U=21
M3SSI^%-61CF-U`IF-H7FF4_)7-6;3B>%(YU@]2`6$V0SX9DIQ+TRX9^7!";N
M?K(40UA?UXI1VBJ1:IHIGW+'I;>F5\PB!F;1,`-:JK+<BOALG:DJ2?]_GSB6
M*E^"!=[):+X5<@7AF#U.ZJUGT])K>8$/V[9>TET"')^E@%:J*HUD4YQBK?47
M3B&NKW>=H9*Z!ZYKPD##ZE[#D-L**NT%(_HHV0W/W6:+]K5N,J]*1[=GI'3B
MW#0O2-^<#8UX)L85201H@0FK1<+$!CVP,;'%\+LC/\?PV',/R"N.+)#)!J$\
MDD<\:EE59*8U-E$!(VXZ(%.:@K,&#@E)'PG)23@@A2AY($5!FU+0@#8E)QUM
M2RC12=,V,L*6<:UK2IG:`A=H-186<&8GU-'7Z$3#L(EE`V^P00$"Q)A#4(AM
M"0,'YN*#.]DT8QF?R=O?]I:>22Q14MCH"VC_'&$;'I2'/&*@%ZK(49EF>`9W
MV,/+O]1"L%N82E6T6$M;LG,J1M`MB[_2#.G6`J@TOD9UT3G?+K!(FE`\)P##
M,8S;A,B6QR$G<Y2KU2#HXKO?E0)0I/"4-\K3BF&4SC?9R$_U"!%)2C)J-]%8
M1=R<2!\N2H<SE$R"!3#3"NJ$!UBU*!]O,C&^Q,0E%7A@0@]8<(,AI.,&\_@0
M_(89@OH9X'XI"ID'1D:R_?'O9"3IFD<2@D"IO&Q--F(3FZ[R,JM0;85"<N#-
M)&*1(X`$)16$23+O5X1]W"^#4QI:2SYXM)TPK81$@=I%9,BRI3@E32ZLT=;>
M1-`O&>4$6PF;67Z@_Z'$.4-!AAM67ERC&+?IR3*?,1WMGABMR/TN$:MX%D<U
M1PM@Y,8OM<G5X0ZITK<-$1+EXXMLI%>7N+C4;?$Q37D6]SER6`,2VZ";)6A'
MF;44*BZQT\M/>9`)Z0PGD(!<G0HBD393!$PPE``&-5Q:"!7TR1DV]05]E)J:
M-DH($;F8@#;T(Y\K@B>-.?6I)E`#*E:@ZT`3N.)@KG,<_53B<?D9A&P*@*#R
M;6X">1!48ACQGRVPH`)K6,,-@J"$RBHA"`:H&#$]9,PBZ$.9S`0(1YYI$&F2
MT"('I)HUM>DFFK56FU,1@!!@5LV,^&!)'1B2!'!&SH$D9(+I=,`ZV9D/=O^^
M<Q]$*QH]5:(T>P*0)]0D*)SV^;2H]60%+/RG=ELHT&V&R;0465F=Q%(6LS&A
MJWY\#'!4H)=.%"MNBWHE'4<JF;?X[3H\$*EA]#N9*IJT/(_KJQ';J+B]O(<U
ME$N&93BE54$TC%:$N*I2:7,M6V"G/*RT#!N/09@[$B@^?T(J)M93#%Z`KQ9O
M"62Q"G$L/@6'K(PBL78$&3A330Y>?ND3,#ZW+E$B[R[_R6NY##4+(O/X>TQ%
M7F"JF%8`;X=7,IT7\@Q$5R7+BU5Y7<9W;+"^]K%`!FNP;&6#$`04?&A^%O/0
M/.RGC_PQTT4O.@B<*Q)`D-","K>-+FMCALT]NTG_*D_Q9LN")$XR\`S.49J"
M9XV+3$43%YXOZ>`'L01"YW:$(06M+E!\`B?L;O?3W.WS0/4)WC&)]RMB>QC$
MY,`@\.6A0,5J2WX5$Q=99,-:^J)O9(X5JR<K\HE-%=^R;H/%6WUUBW:K*.JJ
M96-8U+553!T>&G7%+UHJ[C-UD^(L`K<:1^27OXZ4:"CLJ@NV&,*N")Y=K$U!
M.V&9;I6V.=ROO7V-WB0/DX;H'!5UQXN+ILI:\J:<OD"U1TEJ(XOJ.=6`%^7%
M78PQ?)),S7JDQV#!B0$/>M`#'K;0`Q!\.;)D)G,PSXPQ=\!/'?/P&#ZDQ,Q*
MS_GESD6M2-[$IH=D#2I6_]'!44[`<YY;U@$'6&%4QA3T?T+$@5`AX94NZ&A&
M&[?IC<[@DUY2)4J+$.81C"Y&4EL4H'3]NIUFB@0D`&JC'^G/WA33IJ5)IC&-
MMVP0.D2AU#9K![-7,*T8=]UVL5%='X;7L4(&8_U>NI\NQZ<E#4U@+)[K`R^#
M;WW=(U8;$YRB+@->F6GCY_2*5K40;C,2!61D$G5?FC;2UKE0E7[YY)ZY814\
MOC%V1U^#U/:6(S_#,%]H-C.Y56)H</J!=S1X(VU#*37RST#XOQ4G^-<_"JZS
M4=XAQ9"'Z0Q.#%O(/ANZ`N8;W&`=G`W_,-N1YA*=J!YD-H/ZS3`%,R`SGE:G
MI__\Y[P13NL9AGZ>V<[%K`09]/P$E55T3&$52.``)R`$G^802`<G(;02Q>5T
M]W-,$'@/&U0TD39/],01+I=UF/8T&N%U'SA=8E)T8U=VH18DW51;4#."7>(E
M7Q,6/4`VD9`8K@()"D(7=]<=FS!@U#)[?O=4D_%(P]!WZ_540*@YE%1D*U4+
M$U<;E-`GO6%NOW)Y$D=@4+@7[0)A-7A]HL0J3E@-CS`!QW$;EK!(X$8(824N
MLK,?:L-51RAZE')K;T,O;74H^V$*2-4,E-`)KS0]HE!7@H49KM%7_+((K$1%
M5P0^H^`,P-<P@NAC3-9):P%\B[`N@&4MO[`KB3<X&"#_`@W0`([5?=\7?IR5
M<J2X`),5<F16#RGG,>=W3&V&7$3#<BX70M#5,@M1<ZRU`DC`<TAP%3O'<S+@
M?_Z'4,9X`D&')E&!!$IP@*"F@`WD`QM1)>P'=4[WBA.X<A6H7!Y43[;((PHA
M<PEQ$6FW::0V%$&1728($3?W0C`4@M/E-#RQ<PG%!F;1#6TC.M"A(*_2'JZR
M8YDD&48XD`1)D%V%AF8T8Y!1D$:X.4\H;->B4B9519H05HZS;*``#:AP.;9B
MAZ_A&Y$08'VAD8QS;:]2-^20.E$E&;>$<)RB'QT55J%GAHC!>IKS2$U%'\,"
M*H*A*G$Q'.*R/6J#+31U.#56_S<VH`C;T(;!T%9.MCO[]E/70DF`J'<@N4I/
M:1ET%QZJX%5ZL0.I,`&YI$LZL`8CAW*LN&:JN(KR8``B1XHG5R*MB#\5Z`'J
MUW[KMTR4EC3-!7;>M(L9H7,^5UD(M14X\G^(F9A%YQ0^`(#.F(#0.$X301$I
MX7[W\#&,AHT3J$Q21Q-&@S0Y<6GCR($UPS57$10FA(YF,G9D9X(`)6HX]Y?E
MJ'9KUQ,!\35H$(-G(0EX0`F)\%0D@$BU4Y3'H))=Q9#(.9""E%-<=9S)^9+Q
M!@DV)61Q@Y+>(SF/M!AI5#NZ<CF5XI&+J&V1E%*&`PR=4PP\*2I\\BQ0!0JE
M`0T,YO^>JA,>2;E10,@Z?_&2235D3O0I?J0;")(?X,&'IO)B>B(M.N9LL;<*
M'VDW8P14^M9$T(-P"6='6Q9+`'=]S?=DHN.56?!M1_@=&:)+8)9RQ^26E#5F
M:RER9WDQQ!27)NI9,7&!%V1<Z@=_6.(E/>)=1H%`0A&,8N:+P5B8O;@5-&2D
MO<ASB]D4/L",2E`UD!E.8_=`U'0`E7F9KXB9V?A^4+(/G"F+W`B:*"&:TY2+
M`F":YMAIIVD1J\F:K>F:6B,SU=0F64%J);0"8+,!3)!+MW<)344=WB9PP],:
M\Q95R7FHB!&H']4]J_%KB+HY*65K@DA)K;,LL01)J.-BAH/_=[B`&?=5>6X$
MDZTQ4PH7J;B1;<>0509V&.UI&%($;U0(2(G2=XO4&KX1%WB8D/T2+)K@'*CA
M&+'#;-D3`-V02;D'J^N2<(*%5K50`-T`;^(9E-H!.KCC26:$%]"J>'I$%PP2
M2+[C587@K`4`!@$`,62S2V`69I:UEM[7KFLPC#*@!&9&<IM5BB;B6<FD04RW
M3BEB!DI`:4>A6KLHF$'ZBSJ7I(FY,E-C(UM!%73B`T(P,X#&F$A09CJ`@)`I
M%62P6U2*9U3``3"!I5EJ/Y@I@8_&$HKVI2TA-!DH0CH"$F<J72"83VOJ::S9
M%&^ZCMTU:G4J:*56CT)0-G+0#8`T_R%J^)$]J0P",F^(BJC?DE^]UI&-1)/(
MR6`%%GVW@G@EJ8BN@'MO0V61Y%>W2GD'EB`NEK4G%8;7$B[A\CI^P0IT\Q?%
M\H9W@QN">$?0D61?RX:U^CNYJCL2FI2JA&#,0$O=]E&;HE2,!*C]:4><1*$P
MA@O'8:WE)@N5`CF?XK5X@4KI0PM&&*Y$.PCBZJQ@4+IRP&4]X%@5,(QKH(J1
M%5G#>`(T-+L`6&;"5$PH9Z(FVV88E$$8E*]8,C4""[$1FW,(.V:$B9@(2Z1;
M,;S$*XTZ0#5"035W4KW;)8UE]IC;Y1#8M;$<:V@OLP(@*[(C6[Y:RIF]"T_(
M91/L&T+-I?^CD[D0$40S,ENG(`@G;5J")>B:[1A;L5F_-.LT&`$V/?`&&4*H
M<Y6%=DBHO\.1K-JTR>E4P/&2OJ9ZAUICEKIXO$&)J<I%8F0KE?`6CK%CQ4,:
MGY"&;)$[5VF=IR)@PH.UU&*0\FD!&(`!Y4(>8E@.>6NT"!89!//#G,$*N,H?
MO,-BM]0Y`M*W3,E(AR(MNUHNXW9KS#!E[S&&906%N,<?6%RVWW&4YV,"WS$<
M84P(XPH&M$JZY$H,"-``+$`#[1H$KUN,LPL6:%#'/8`&=`*O2C"*<JFEC?99
M^*J^5+(E1'&P25HG=-*+\+K(1.J+)F1;:><C.,>+OQ@458&QVB7_C9>EO=JU
M)F+WO0KX%`?@`)99!.9[RN>K3"KK@!W$7!\$CA,AOQ<Q$;95OS)+CCA[L_Q[
M@CO;6FOJ@?:W:6%A%J\0G.T!A;S2;K<PQ)X`P<GI;8#7D4\F4H^*DL*35;51
M8S",8+W!D938*'FG5.SV8,!S#/_%*H$SD3G&&<V#D*10A"%Z&2(P`IEW1@+7
MP^:&D,9P?<-S5KOJG>[95M$9+&^5J=,@S=VC'=)"41WY&-+2&;_`>W.UJMN9
M":M!"EE`(5D@P^L%!N-Z+,Z:K*#P'QCPB0QPTC1``Q4`-C8$@ST@!&+3/F"A
M`P#8NBSJBO80!%O*F:Y<$_V4%(,9<LTX_YC\]W_-.Z?:I%J0O$W16TV3'!6=
MO`(`*`,K\(Q'!\HLM`(YX`'DB\KF2US)Q-,P`::?>74?(8[QZS*V[($$536Z
MG+-1:G,_XLL`_,BGN0)@$;1,X$-I,P@,(DJQNDC+W)PXZ,P,*<&T)RZ?"J*%
M/9"<8G'+X1E'R4;L]DI4&(5,"3O1TH<3M;;.<WC]6&QIBT7`)U+BC$<J=BF#
MDU=Y);:4D$:LH)R%(8>9%X9V`Y4+;!C`I[;N^5)X<5].%`[=!JZ*T*CD;"D-
MS0J\@,0V,`Z[(`YL=0KH8P%9D-%7,"@_]%1VL-W;?2QV\%0O$+K5,MEA6=*?
MV``@4`,U$-/LW?_>:,`&>2R*I7@BF(7*(--F/7TE*K$R0;VB*1JD0MJ\^3?@
M6R.-!S"[WS3)WW0F4AT$3H`$U_2::#*EAL849"#*(>O5(TL/IFRRC/:ER94E
M.?J^`<$0'V$5!X1G:JV"D#R]+I/+N@RG-M>.WB6]-9NF`4R.83$+)*`ZKG(V
M$FPL=V<HBF38SER&_8F%1KB/C@V2)A6JEY%Y-PGEWV(J4`:M/9@PP6(HJ9#.
MC#=3AL=&DST!J\&';?@;^^CCF<L;IP14NT*USP(8J8H*Y[D<KWU6K(%&T-/:
MO;UX;U-Z`R<70Y5)D#)$MW<7%BIW3V4O4'N&B2&N`5"Z1.N5C&!3A\?_VC6,
M`7FEWF51%AM`%I\N-G7L<:M+`Y(U!"^J9O2PBKIK/T5PHV6=)2?@`)=%9F(6
M<O1MZY9%I,Y+X'LVO$HM%-&K`S[`!@GNRREX`BAP`Q!^35?#CEC]3UK-U1VN
MX2?BBA`8BRI"-/(GIF4ZOQD1L[7,XBQ>CC[2`6ZZRRT4:C'SZ]\%)B*(I_9X
M7E'U.$\HHJQJ2P)C@V,,YT9>D#XI=WQQ.1=<G8<G&TC%1@$-2V6X*M:V5=U\
MAXG#S4\>&-9R2&X4J1V</:K2S8GQG96D.T5T>`VOG%#%":'`A19W.+$-/".]
M2'>%PXBDAVR5Y#WH'MOC1YK4@]J&.89WDA62_]UU0:QE/`AV\"W1$M*8L]J9
MWO1-GU>:GE>I\`94_P.?O@%H``(>)P.F?@,)X`4;8W(GU^JL*$P+8`#Z$%R5
ME=\JH7[^_?;J]Z^%J5K6VQ35^UH#Q;-AXLMWKP/D^)?X"Q52K0XGX.P!A2;C
MY$*CK&C6GI9KYL?W#77QM+X9Z+X",8Z8%NZU);&SR?DM;K,W"]=EQQ1'4OIK
M\N[455T'=0)LL`'NP5ZPPRW[=?*-@1_.^>\%64B!MZBR:BR&.AW@TPP3B<[)
M<@W"ZC>*H2L8(@IAI438(_(QYL%K=,U?[E_1)Y2"D(9I`QU!*2H'HCFI,`Y9
ME&)'"*YT&+:V/;G*Q_]5KS%5\1'$^)%&G3#$!M9ZP)\]E](+2=4;60@(62H!
M*CP6/`$!/"J,@R\!8)&1B90!+Y>)5S:;-F]B8A,3&`TBI0T8J!BAJI]O;S97
MFIPV/3HR-#>Y0R$A+;Z_P+P+"RC%*`8&02B]+;R\*!X.T0Y*0=9%9DK49F9%
MR,C6X=QF4]$Y.0<'*SX^`AWO\/#L\ROU\S[U^?KY]P(^0AW\Y6.C`\F)$TC4
MK5"X`IT`?TB"W-#QT%V\=Q4%D-FX\2$\`2LX>/#VK:3);\=.%EG)<HI+EBNG
M2?-@+H<#!^=RYN3`\P`5*CY_"J6"#Q]1@?L6\L.WCFD[INO>29@Z]:)5C`'_
M,VK=BG2?PG0,U1U`XN"$#C9,Y,BQ8<%"'A*,,%4BU,C2%3$6$K6]@HA2H[^`
M`PNN>XF'X41L+:AXT5:Q)4)^&070Q&-6VT\6/L6RP+>Q!1N5#'FFE(0'YL97
M*%WQW#>1Z+:@#6W"_&G39QNTQ5C&FYGW(46>KPQ"5#FXWKP!,O]6Y#KQZ>5U
M_<I>?5DW6U!X/^&=W'91ZT0JJ%O"'1MV8MO+Q2?_/'>N\M3KE1ONC3IP(DPO
M"NB7^P),`4C[S15>++.!(DH#")Z2"BH3:-<*)_`%D$02D\G"PBZ^A##,`KPT
MTZ$PQ%BCQ(@D(;-,"%_<L,8-&HXXA3?%G%12.#"9_X%3#CW]U`X\0@@A@(_^
MW$-//F`EM520Z[@3Y%/L(#&B#`B!)>5"2#3EI`P4;15/11QU9%%%!^0PDHQD
MEND-3&@6X1)-;-[DYHTWZ81C4.D,5:</5-2C3E?Z,`05.TOILR-55WV4459<
M)0J5D5(V6B0;/3#!!%LDP+78)2](!MX@E:A'76N#A2JJIH548H,)OR7&PR.#
M:)I);`&0AYN#G"!F'"6O=:<(==>)\9UGRRF2&+#H:6?>9_3A55RO%C3H&G"H
M&588L9L@HNJSCPP++&?MN;;7L+79$(J#RK)E0U^<>JMK9:!1:.ZLR/:EGKFX
MAM8<<8V)@2JQPOUEAQV82O\B,!B8J%!`97WQ$(LFO872H!BC)*C@N-J]LDDL
MB4S8'KN9L7"B,QH*@T(X(QYTD#8.=(.,F@:,[,3+-S1C#0K#&*/2%".B'.><
M0@EY3Z!&ZE#0E/WX[,-8#*V@0U/^G!"$$@<AD5`Z7B'1I`Q8MJ/5E@]U289'
MB/K`@0,EEFEV26FNZ<&::M_4YIMRYG@`!T%103<[0M&]`DA)^>G4HGW:(Y4$
MA2+Z9:**&MFGHWL&R0:DDUYQR:699MKM?2^(=AQTHW;^%R&@4G)M8H7PU5ZU
MML*FG'*A`8LN=;"M!EIRIT587&/GBIZO=<B2^VYOM-YNK&'R>I:[NO1EHBNN
MVJ;_>MDAZ1[677>RP4ON;<O72TA;C-!K*O#;"=N6K;-??GH6L6:AOOK?$6S)
MP)$\DL@DJO6:G8.KI'*@"`W44`,"K;`8+.9"(=<T@@0$\`S$9$`S#8TL9U$S
MR,E&-+.4K,PEX8#9%V8`!6+0S(,&4!--=L8!J2&!)R5D'*.D-A86@H6%3<&'
M.IXB!"8UZ2#G2`B5HM2.%3@@"":+FM"\,L,5'$0'6CN4X332);!E)"1C.IL4
M5P83EY2#36MR$YNF<8X;G:,G<Z.;4.KT$Y#P9&]%`912[,$/Q1'-'80J%.(4
M]<0VVE&%(*':67J`B,G%!5.N^H[R?O,IR&S*<Z,Z3'L*_PD[]C!'6.6+E>JJ
MLQQ\/>]9K\&,A`SA&VXQ)Y/(P1>M9I$;9'V&-A/@S"'@!9L^9LYUS#,6M!!1
MB$'0ISN/4-BP$D:\Z9E`<@P[C7;.!9MN.4(%W4F,]C@Y/$DBQWO$JR4C%I$N
MR5S"#G,1&";@5X!(E&X^UC&0P\8I"@SXKP8/TQ^$%M8MXO%`?6U!(`'FR;XL
M3*`"4$/(U$QX`@IN"&0U^X85O6&-7"0`"E!PX#7*$2<4@K&%2,BA"2=*40E&
M,(9_ZI$/R%*EI=!#"0:P40X0HB<8XL-I4).:$(4F-3VM8P4&0>(<N<21K!CJ
M(53(P11*8HP83?$;:++B%;<8C?\1S@0G;MI)3U!HIZ`(`"@^`=1#C/2G-;*Q
M2$R!8U7DN)4D9F0>#UF4&E^JIRFM`*I@.0L3#DFYR>$*7;@:GS/3Q59$=LXU
MB"CDZL+GG4UH#S7/(=X@]](Z65(G/*Q1A"6+*;U1KA)\QZ+D)VZG+1M4<W5Y
ML=Q=>*>LP#02.:YI9&KZJ$M5<LMZV7EL)"NAJ=<<CWG508^N5!5-[W"*4Y?P
M#_PDD5N"R4\_!="8^/#'BG*2<YP/@@6\SJ5(A1'H7%D`5J5X4"FXO-40/1#"
MXW1P`ADHHX$=RA"(CJ$F*])DI\6X`8<T9(`1>1%'#HTO3[IX$WT&\;[V/<$*
M>O0.']'_PR`4=`!%#S"/`XPH&V71(1*6I@^#+/@?/A`:0@I2I31&F*3^F"D3
MR8"H)0K@`&1#24\M^-/R"E5M:R.JVZ;1IB^"D2=-+>-/[(&/L":%;TW9APRI
MYA2/$*YP6BD:.RIB-!J/M:Q%JA/5%API.2BV$8"4C"+G(IX7'+:6=;5KJ$#7
M%PN@:CJR9,XFIKFJ%PP+%HE539H1\QQE[<HXI9+=;&^3F]W<[SRH;4PO4<.6
MP7J25[V"3V`,L0/'L+:1@C3-(?;"2=AH1G:/'/0BH*78N/9.=9.=)63H.C#]
M1.#3$>BF;B4!W&Z&=F&V^00Y]2<*BHG!%;.PW937%]W&F&!?_UFP%&#`<Y]*
M%.`':)#!#1+@A18@5+P@TQ`Q+FA>+'Z0&-J(KU+E*R=I<.--$7QPCX2@`VMT
M%*--"L(PDJ$$?A[$2B1#B#X7[-*C(6';4^'VR\RR-"%QMTH9GFE-M821HSE`
MQ",F\=E,/%"ABK"H6UPQ"5]<MZ$<Q1]$`:M3[)ACLN:Q2/NP")"_*G&P+BF)
M1;$QC1?"N!>:I<G1I%Q=IDQEN;*%FJ32LN<,R4S0X*8W$8(%E#_Y&<.LAC??
MR=7LS+6[H*?96I,D>G5XDYC5/*Q<BTYELWS5'`6NRWBB001]CL<J3ADB-9IB
ME6B;.SY%:SV<>^GYI%<^3<KA55VJJO]L-DM=`%#;_>Z@3H)^0L.)ZKA"._E#
M;L4Z$6N,3081%)J/`O=E@5SK>M>8"YA<`J"?#<B`@P@]-H@V9+,@F)BH'I""
M`Z90#"5\T29O2BJ.<B)ZHR+U)CKT60VYJP2:/:UD%<:'$C@4HI1:U&H;M899
MV%$0[JX;4#Z8R@]^(($-Z.`&7W`"O>U]D`,0V>-:V?>AFNB#')0HX#:3(L%?
M=/`4CS#AJ9\VW<#B<*%4I(Q(2E+()ZYC*NDP*3NZB)+":C0+][\??*,U3#$E
MC;)@;"`$:^47F)(IPT%+[6%E+L<]=,&`,C<JH.,:>/$NV($7V=(ON-*`Q*$M
M$?)*N`-IM,/_:-^C9XIU.\VR:+H!6>;"3)AA&;/B9CQW2\@!.YJD",_A2=$A
M36$'.L"2&A!(2,O#*^-#'EWW9*T22*T175E0&89$"?[A:7AWA7>W=YD`"OHC
M3L>%7*[P!K<!(>:3>%E@`]'E,+[!7#'W.90@:@6P@'*A'SS``EZ@`%"0(<3`
M>;D0?@3')E(0B($H#7!B?EN$8D;E8F`Q-@[``8JC`[OG0,40#D!$8,&G;+VG
M;B;T4@BQ;3UB"VL`)>>&#T(P%1MPBG10`=`7?6;Q4C+43]8G<EY%4QSV-8GR
M-2!&$N#G4P-712\R5*"78JFW,_"U5'3B<!5Q5E,%%0+Q%%=55B5U_W\OA556
M<7W]QT9,HT;:R(PXA60D]XU'HP,;D!9.5F:`Q%H/R!VAQ#UQ48%WI0B,D!G+
M92"U$2O"01?1\1V(]BPZ*`:I$4RFU#IK%BL.8AZZL8&ZD75U)CNF\8+!0CN=
M-#O4`0IY(1K-<X_1L82L%8^^$8^9]2GR4R&KH7BKLBGPN&52Q@,'`US^@85W
M5X6A1G>)5X.B8`H(8D[GY#]/EX&PL##LU$Z&`4_;@CNX@0KH)!AO6(7_`0GQ
M,WG_,0%ML'D>M"&<YU/E!8B"*(A>M`UF0(DM,4(.%10RY"3'P`U!8",=%7S-
MT%/IEA#X$`1K*2(CXF`M-7M"\SAL@`8ZL/\B3B"*2.0#!R@$&_`#&P`":4`!
M7Y`B,I![@-)/.2"`]L`5-66+B",V(;:+`B<C:?*'H#<3")=^Q4@W+S84(G<4
MT[@W&/6,WT@EZ$!$"@$V'_%_1V9D?S.;>],5&*<4[#`66R`&:6$8E[(8U417
ME<8=H(%,T-.$[FB!P&$"!8D;4F<=_>(JQ`DM*E@\O6%S":DMQ+$Y$HB!#Y-*
MOP,\1+ETY<(;#EF29Z8M;-9)OY$KBL$JO$87AY2"SV-)K7$82&AH=.$=,!<7
M5"@P5HB%P/5ID2!J_D$AP>2%JR`"`S``_%,#./D_8=B3$=(MIJ..7G9KM[8^
MA0"<E?`&(E`&`%#_!@P0'0'J6Y)@"0O8".HS`3B0`#5C#%3)>52$B%F9E7#2
ME<K0"S>@,_#E*`GA).HE,C2#`N4&82?`>^NU`")R?#Y0>^4F-`?03_V43^O`
M;6=QE]JU!D,0?4)#?$=$!S]`!W#@!!"0(HJI`S74F$'@`+<)@-G71#,5$MV`
MF68#$U147@<G5`B'?JJW$V&4#F(D8T/1#D2AFT:FFE1#<CDP-6)A5DEB*/\G
M*'^BC2+'#U,5.&N$#QR0`RRP!9("G']$5V[8<NOH&,LI*L5I9;S1(/8S3,SY
MH7)70)MU*_%!/=B)2YGD6`6"'9Q0&75&/;"T'?#9<\"B+_D)2XU`3>#Q_Y_I
MLCN@44B=\EG"T1E81WD(JA^1X))WIW=)$`$38JN<@#\.@T[Y@P&FX#_&XI,*
M(T@2(I\J0`*W!BQG&$UO-X6QT@`,``$:0`'(\1^\A2F1(1C$(P8E$`+AUS(C
M!E17N44Y*@6?6A:U5PP+X`L+D$_])")))25!$`)Y*`S6X*3EUA0RL%[CI;%2
M(Z83)C2@F`LJHE\P)8YH0`=,L`%P@)@I(GT'2!`G4+-H``<RX`0W,`0)D`!K
M8#5MB@].H@1H%%:(TP$<QA480610Q+!XJIF;V1(O47Z="3<Z$98PUG[N5Q1`
M05:,0G)2\E`O-#70.&19@7S;J#CX9YL"$1;MEO\.4J-6<J`"7,`%<D%+%NB1
MJ4.<JSH8H@-XXBE,EH5(A"!WQ8&>J?0LN?J>UCD]EV8LV$.>">EH3U>1QW$=
MHFMFZ'F?IC$!A999>Z:"TM&<@H!EB>N>L],:GU5=)%""E!<!8."MH+:[61A<
MNY)J!K(@.8E.[*JXJ%"A.N=6WK-IC%`I\SI/'XJBYK.`^F$#"``"7P`!>``&
MB?`OC<`70>EXNN:4/-``:X`V,-)3:--L68E"@7@.D<@A>4BR0;"82O`,*5$$
MCK@0*.`&"66D3Z-/X4:R!^%=4+(&*?4/QD=O(``"J@A]N8`E,(4$>3F8J5@"
M.HNT;*JE:!"T1'L#,+/_!B?`#AK5)-7`IK-(M56[-39E8]X'<`%')EN[$@-5
M!.<%C&V2B.HW-PW7?D]UFH`#C7J[?I^*#G,S-3SA0KDI@%55<72K8_0P0Q?G
M%4B6#F>!!Y8`N*8Z<XRD*T!XN$@)D;0R=6/FN)?+&3^'"-CQ&;@E&H6DG_EB
M2H80G<A2(#@HO!19:?!Y'4B7+Q,0&YK[G@H#+)9`NYYQ6RN8+,J",']!`N3K
MK$GIN[R;A;"EN.6T()J,KA5S&WDP@RR'C\B42NYD&+=K`8]'O?^1'W#(K0,3
M*]B;!@FP!8KPNO-D`H4&%Z[4HM-T"#PP`3*@BR;"OC>J-N]+;<O`(AAK#2WB
M_R0B\PT.D`XY<+$>XB%(ZGLOE0-FL&Y((`,KD@!]^6Y:>A8/C`80C)A#$+-(
M5*4Z4+-T<,Z(Z05>L`9(](DN.[18XK+]YR1!8#4:IG$L[!%$EHLR/,,JL;5=
MRS8Z;%0UH7XH],-"059&L3=Y0E:.`D81M7XNM,2/:E8S-,113"1)DR1\,E58
M=321FE8Z(*I)L&M:1I`?V1T?FF5BO!@GF)W+95=X!2[A<P7UVDH),TGZ"(..
M=F=$5V<:Z!MXI7@*9'-+]SP,(Q^6QKK6N1GP81AXECR5\"^/@*`':J"CQKO!
M]1_L0ER:S&JNY@G&<C'P>B]!:0'S!,D4Z9^ND6LV#?\9\O,">N?5\'--V)0%
M>"`&",``&C``I+.<AV$###1%#QNQ\L4!I(<":S#9(O*Q3R-N>O@T.`$6XJ90
M)#.786I$)7-$.N`$Q";",H`&W%8!%:`#='"*AJFS$\RF=VG.%3"T,*O.3:%=
M+HN7:/`S]E8-P#='6M/"6Y,HN8B9"VL2-<RU)Z9B8.MB\45&[8<G$:>,@=(H
M+_:I)71"1CQ?2*PWJYDT>,LHN>E1NWF;JPD5!6@6"/`#]U&J:'Q8\0$J-8V4
MA7P_JZ0;6G88D=L@5Y`$=T%,B65)ZD$<BGM*YW(]DP2#US''CT%-QC-;L)H9
ML*H7OH'(ET2"=V%*IM-TQ//_6MU*R5<HH+M+XJ$&26*(O/K3A0$T"Q8JOHE0
M:@6$U:<L79:2'":`/IQB:O<A:KGUXZ,V"6``OL_;!$V@`EG@G!,P`!K``"II
M0`3`H280UW]!L&]E`]T60FIR)B=A7H[-$T>`0CD@EUA3,A)1#2$``PK@!B%P
M`QR;`V?E-$^C4MXE$3<P?2M0#4H`)>U<VHF9IDZ`!DS0`S3@!'"`BG"0!DZ`
MF`GP!3(0F`1!$%B#-:Q]EP1QE_^@79G.!D."4;0WW,1].%J2;QZ!B_^6$EG+
MW,W-IP\;C%RD5*$)T1$'%(!"!7R3J(0*%G-RQ/"5$]+<14A\#B7W%9(:.!AW
MTDD2_YE5O#B-<A:#&8=01H'O^,6*42JB7-,7"-/UF!R-B\9=UB!"K:%N?(/1
M$M7BOAVR(NX-8I'``^"Z`CN"M@BK\7.V\>`6GH%PIZO6B1>`AAG4<8^MX<H"
M`VISX)*2D.+LHL<,.DZJT"`"-$"7,ZYU)UPK6&NH<LJ&0!PHB@C^P90'JI3>
M"PGS,_+>NPBT9KLY3I`-4`8E8#%ML0,3T`5=$`,$8$U9!LG,Q08@Q>4WX[['
M?`1"/^:?FC-8(WS\K.8(I0#S?.=)NE%7*@-]WD\LD@#Y_#@G$(I8\L%G>K2)
M20$-L`$UP``,`-MP4`%ID*9?D``44`$@@`;9M5V8_L';!O\H^HP/+LM@[=:F
MH;["`@VU+6PX[S!D7G4T'E#0RZV^S9W0"_TV@2K=.4*V.D)_(KU^88(.OIX3
M."$UFC_L2%QR:GO>B^.-1++L6@.-(AVI]0#M?=2.=H6=H2L<77??DB%EQ&(:
MWSYS_KU7DZMFN(-)0XAI96Q*!6E*X&.#R-D8MQ4>C,<6SG*Z:[A8/3?5]2J^
MAQ&2`U/),1D!<W#PGT;6%HX*"J(_Z/ITL!:LVIHQ>[W7>0>\Q%-K;;$^)$!-
M>3`*(A"JN8,)X[I;NP4(=G9@@V!9$Q-9%A99C3P\*@&2DBH\%F(V-64)%0P#
M6Q97)CL[!"0JJ*DDJZ>HDP5,)P;_!D6U4[5%4[H>NQY2O\`<1\/#'#D.)S(R
M:PLH2"LG2C)*-]75RDHG)P<^/CHG2-\W:^()"3<T+#T(+&TT%6AH.C(WYE\)
M$`UO;PT-"'1PTI0H06'@)P0]&FSIL:&'D(<0(W;KM@*)Q0,6D1S8N((C1&](
M9.@0TJ%D20$"3J+T@;(#RI0O4W9@N3*F@`-%#*#8R7.6SY\^<0G-:>N6KBD>
MDBI=ZL&!4P<YHN;@L)$#52I4-F+=2H7B"A\KJ*P8N[&LL1P'.#B5^M2BU*A5
M<VB,JA$CU8X8ZW(<RW<O7KYD5PB8V#%PWP-D$5=$PF9#@!>07Z2:3)DR#TE7
M%DFR9.%R_^7/H$.[FG3EL@TQJ&V(IKR9AXU%/*Z@%A/J,N9%N#<'X+R(=N90
M8B9<$L[Y](39%E[;.#V;M@U)DG&;L``Y`*I%KX=;V!V\-VX>+W@GWUWI4:4L
M`0JH+Q"AO7LP\-W+G\\^POH"R_?5P("A@8C_(C3`7PW'H;;/<C;8ED02ZRW(
MH(/W%4!)*CR0T$@6K+`FB0D#E*&!!@P@($D!\*D'1F3PE0B&A"M*,L@D$X@@
M1FR7J2=)=F+L,`%__30`1P(S)$"$!A#(*`8&7701`Q^K4!;9))6HP`0;:P11
MU%!%)07,+\(00\PQ2BBQQ@T+W'#"-T&(=*8.%<C@A!,W!)$--_\6Z?#-FC+<
M\\470Z2!@`T-E$$!"'2``(>;]R3P18@;[K@%"P.PL,46-2#PQB-XX+'0!DPP
M\1`;*[#!A@Y?320$&]&`D]&J&OD@T3<CF22K2R_11&M+M)Y$4S<Q^9!#3CKQ
MA`)0Q,Z"Y95%(<744D^]-9555I55%E>"^2`68&11%=>SQ[`%E3%KP5751E*9
MI5A&TOJ5F+J*<<3K7X4EAFU6VK#!!"62K?:9=;]%@ATDD4RH[\"3%&R)<ZM9
M5]YMG05@@PEB3!?*;I>)M]TCNUT",6[+]49;:LI=0MMQKB5GP7'837C%;Z&D
M(AD)'L>,HW>[O9:%;3:F&-]\\^W,<WO_ZB4Q"0_!^3?`T0R44$&/&-0@QH$K
M3[+@?0\"?9_""4]6\&,OI%C`%0TP4`80$(C(GM?PO6`=#XK<?/($`8`1@!VC
M[<C#UQ_SAP&`(XR@MPA)0Z"!%3,``001"3"`08X[6("*VM"))D<L5N)R5"]:
M;MFEET=0<00'T4BSQAHR/*.#$D&<*<0&:,!1CSD+!(&$-W9JHP,(.CB1@!=[
M?I$&!A;4@$,)#1A:01H4])Y&`\F14`4!662*AQ[4VR&'''IDD7VF/8@Z:ITZ
M9+0"1'>RRJH.KD8$*TFSFE0K2[?*Y)*N*_'ZT@$.Y"3L3L42>VPNEPN@4I3U
M%*@X*RK02J!6_[8B`&H!Y@!H(9=4SA*5<!VC6<\R!E7>8A%M840NZ5+,`]FE
MKE+!ZS`B#`M&3J".YPQ,0]99VW1,LX@7VA`T-#R-:D1#"8QEAX:X^4X,`\"R
MY-B&.R.;P!5>XQJ4I6812VP.;9*3G2#NT#-!=-PD7B"RWB#B$>+)PG/28R*?
M_>R,*W+/@VJVCS<@R`9OJ$$#!I"!.I;`$PVH@1L/-"()!>V,$6A1#Z,$FJV5
MR$$,,M'4DJ""'3&`"$,P6]HHP8I5M.T1.[*`C0K6'S'40`0#`.4`>B0@O?5G
M``R`@#F\,`,8P,!P&FB`PZ;#BD94LA70D<3DJ!0$,QCE*$K9$I>LPO^YSE%!
M+6'2!CA(=3J1H$$(\:A`HKS@A1OH8%3*T$$\V*2[(>$##F+@SAP9D+029.".
MHXR8":K0!1,$8'*=PD,/\!!//%Q(#SV@@9TLXH!P($$;C#G5/%3USVRP:GSJ
MLX@/VC>KP>#J)>T;S$0FNA+\Z606/>E?4(9B+&`>!1<#3$H!*WA`:*6+*P((
M"U:P98RZL,59%L0@M";8K;=H"PGBDA:VUC7"%);*!R14#%C2@I%K]H`)<F`;
MP/2U-53\YC']2@76;J@O2,@F.#L,#21(`QN'=;6(GF$8%,&(&]1<HC-5+)!P
MLL,<[?SP8%-<:A$=Y]2SQJQB.$M1>^8P!_?_]!60\F'/@R2T'-1,8#\"TN,^
M$%`#.`P`!QF`0!DR,(#%/0=C`4C"<W@&GZ96!K-;1)&*P`#8^;R@:%Y(``CP
MP(@+-4*J6RL`#_A3V.#L")7]&*6/2,E;5#(@#:I,@!6@``,H>($(1"@!`G8T
M`1,PZ6:N>)+"()$%)G0O3+RX7#"%24QB<"4K2`B3,F0`T#NQX9EH`$$:A)M:
M+PR!!:*J``4J``)#(0](&BA#!1#`MN1,P#^D=)H;%=$$=DX`#PCI'@L6O&"%
MV#-Z+*#!F585OHQ<\U0LL!,S-:SA<$1$"/M<*$-E!5&5R$]7$TWQ8`[@@9_P
M3Z.TJ(6QB`+``&HW_[M,&:E-HS6M[V9E*QQ)RU2$?$$#7O`M(TW@3,/EE)O2
M)80[C3*\NK$1BOAT+RLNBX9[<#WS$*RI1-0,%VNH-:H.[#+#R6IHN-JPLQ8L
MBU=0F'7@G)RK+N(X.F1.<,QJLN3,!L\8LUB4,B8Q+2X1KPDBHU__ZIX'.)JO
M?/U9`1:$&0198!]B8.Q^3%F#2C%VG(_-``Y""3PPCDAH7Y30VE`!QH!MK6!3
MFW02`%F?GB4!<M;Y;P,2`(0*,"'1Z2&CT+PZFTX#3D#'66S81@F'9@_`L0$B
M)2C)60(]>8&X+:#F#"!0`]@\3M63R9#6)J>#-6!.F,'HKC&_VY%HD*YTS__P
MP3_/FUX6Z,X*YB#2%CC%#G)6H`(TD&P"VG`0/%1!>O3L%!,2KO#L9:$)_ZT`
M.$*G3&5LP9YX:)-%M)&#-=E)5$?M`7PY)8$?L.Y.&I;(J$ZP`I.0H7TO+_&M
MVI?BFJ_8#!C%Z+"*A8N-UO@6EM/%SY6E%!U/T*0GQ<JTTB45G%:0R1:\8%,0
MJ.0C5]#)%X%RE/U2%A.ZZX1_L3)>_JD#3LEAJCP$,Q%G&`#<.#429M:7VF(S
M`3474@5"/.L1'P'G(181$[^1C7"ZHQSCS*9CKODS;?:>14@`K#.E(6.MY?.`
M.3BZ\I=_0'L<;9]$#EM")7O#D?A3(`.)7M.=[O3_8?=SM'[(<0`UB'QZ".$:
M,.YMK0ER]:MGK[/2_JRS`N--(P,T!""P0`ZJ)N)K$/&W:"O$]0C(=.K'"0?>
M\G9`>QM`"2#PA>%"`0HM",'NVN"8SI#`%!>JI`HB\P)!Z%(./8C&4]`]3'6O
M>ROM%A-Y-5R1$Z"7FPF@`3.06BSP!M<C!S:P!;Y%3BR01VYD,XV@!]=C75O0
M(PNV!8G0"%M``Z23$1.6#.F0"!DG<01E._]T)D>%`%N``&K0@FKP`V@@`T-P
M`_N7/D+0#=]P`"X'<RKA/K@B*Q,A42HV&!R`<SOW8C"V41^5"\=R8\Q20!B4
M03QV`$IG+MK2+4Y79$]G_V1/808&1$'@\H4FQ4$AY%-2UG4HM%,ZY15BD1?7
MM`%G]T*OAEF_43'3$7<WA#&8(!J9$1M0Y%4-8QNEP1ML]PBEX3&GL1UGA1Q&
M9%;-@58FXT1C5#/8D6BN=A][97F8]VB,]E=_E7R[,33Y(7JIUS2>A@"HF(JF
M]XBV)1R2<"06(#06(#&CT%RA$"-BD'RX5B(DXGN!U'LDDB*0@0HPPP@`PS4%
M(`8!\@4*D`:=IC=,,R"IAP#],4>P=XIOP%C52$J<IE9&$S@SX`8S$`+D""1>
MT`#,505&4`E;E#;#J`I<8`+TU#U(X`#T)P4)Y%T^=BTG,#I5D@VJH@P9UB;W
M%O\D);`%RR<<>(`(R*$]U*,'IE",CP)P'(@-:Y`.,\(##=`&Y"47J])Q)U`!
M%X<'(%`!%U82J'(G"W943+!O+6AR&P`"%+`[YW`";/`1WJ`$2)`29-"3L_)R
MN>(^#!6$-6<_%8%S.9>$0"$4,?8_3M@4#@"51J=D2&<62(>%WF)`.M:%WV)U
M6J@M%-1T98B&V)(N\$*6B7$1@%&%104"CB&'NF=J@'@=9(:'JQ%HRQ$:F6$"
MTY%HV=$:@P@>;5=H"Y-X'X,)L'$R(X.8F*!G:T5%7<1$?<B.DM=HFK>)F8=&
M]F$C)=,<#PA';71ZFF8IH=E&;_0*5J,V$A(C&/!&8/3_FBH`BZ^@'KXH'SHC
MC%/E")'0-2NR'M41`!B0`0SP!4"0."P0($T3?:)W6-O8(P,``JB8>ON!6#S2
M--!H2OX1('#``FF@`5!P#@D0`EZ@`%X``DPT&@*C`N(&=Y%P@$*P`F]1?YMS
M?SX&%OWHCV=2*O-``S)``]4P!'T"!UM@5EE@`EE@/6R#!\$Q*0RJ)#L@!EN0
M2OZX!F$2)C1``PBID6V@#4Z13!N'!))273T``DR@!A(@`1V`*J,CD`CY!BMH
M<FA`!P`!)U^06DXP$A]Q.CMY$B,6E#TZ$[QB<T;Y*TI9I#XG%$_9%%"IA51W
M%@ID%L]"+E#A=%$8E5!GI5/A_Y4%!)91J!=EN'5FN1=H619U\14H`63AH$UC
MM%1Y:!L/HT4P<P5V654TI#64<%6O,2.`:!NL5AG%^(?$-AQFE7@><WB).7B-
M^494A#.9R(F.E@*9=WEJA$CM06G*)WURE)REN:FBQXC+42.25C/GQP?3(08*
M\0-,L`$;($?0V3&KD%F)9$:EQ8O3Y0A;M2)>XYMK8P%Y0`*F6@%#8`Y#4@%P
M``*EB`%G<`9Z4P/U!0+]L*R=A@!A4U\LX*RZU2,BX#?)RA^@U``L``=?\)W7
M9@7#=8YGUP@$`#VM8*>>I0**@&#=\PW/4DS#L(]*%Q+OM@9K,A9LTI_IH!`#
M"D:-T/\$3?`(&X!-RY"O,M`#C8`'+#`$02`G`'F"VK!?\,<"Y*41X7,F&"L#
M%<`"T^-),MHZ((`&P!HD3K`TK,6J:*"J)EL-7_`Z%>`0$,$&8=)R/^JC/0H6
MNU*4M9(#.@$L1JI10P%TEK,L(H5!#D"5&@2E1X>56QEU3!J61=9D4FI!9ED8
M.M538RFF[2*F@C$8ZR(7]I)4D,$%K.9E-J09;?>'D)`O<PIW<MJVD[%5OP$R
M?':,Y0$:?'D)'>-GC^BW<,6(6?0O-4*;D?H`*;"XC,MY9S1ILD5%G^H:HXB*
MF$J:F_I&"0*J$5!Y5D,Q000Q8A"1)O!?`\$`;1"L&@`$0W#_5(\@&?71>[;I
M-053'KFWF[2)JU!"C/\B>S:``0Q``1`PO(23!L0*`J:(K!C`G,Y:?7.D#W\F
M1SA`;>3$``$B`HN#&GEP!7G0O?^52A5P`T$RKJN$H<T5D;J7GL38)*,Q@3U0
M84B00/9*!6<J%G:2L+&S3!IV7B'W*'ED6(C0!__%@4%0)>,0)]EP<='#`!`;
M!"@@)R)!L7"``'+`#C?9`>33GV\B`R"KH`T@H_4UHFDP!*QD!>^%![_+`/05
MHP&1/'R"#VZ9JM`4@[+#/CK;@SDK4?4SA"P!5$3J8CLW8S`F8S$V8T&7%+Z$
MM%"Q%E9!=5(X4]XB%U%A!DL*A08D_U('Q*1#MH7EHE-=5T+RLBY;RW5F"19B
M'`Y'=79<@+;EP:8#TR]A1E=Q&QID-EV9T1P)<C(-8QF5(1FB4%8F,T6/6$5\
M-D7CL1Y^57ESP+B0&JD\8R.0ZS"@N2--\S2:NZF,A;F?>;B;IWF;N1N-,(M\
MV;>.4#!7$)P`\`'(Y4V\]@4UP`1\^@*V";DVDK9*=42T^<F[NPJ6`&PZ\P(V
M,@'!.[P40`$:D%Q+8ZP$PGR=]F\5<$<5T`8L\(S5*`*CADH`0LG/80/-E0>D
MP%PB``'(TUX#6`T)0`-ZJIX$X*?LZHYK4UW6U3VB`A@I-A9=T4!=L0+?L`9.
ML`8A8"8C,?\JHB)0$7:1'BLI"+`(&S@.$ANQ$:L-(>JP-U"AV;!_X[5?/*`I
M-#O#+#"3Y^"Q#.H/A<(IZG4/Y)HX8B`'8O"<=-`Z%4"CY@`!`X``"F==:'`"
M-<Q0$/6#$44_M?)31$D1/^P305S$0PPL0ENT9K#45+PL2_PM3MHM38Q`2&9D
M.;#4:V'%4('%80F%6^S5"#26A@'&8IRU09:U*+01:`S+I_".9A;'ZQ=5A#2G
M<IH*KS$:*G#'#-DQ/[09%$+''R,<E2A%A856B<:Y?,7(BMW(GAQ8E&L;E(L@
MGD0@_5')H?DTH3F*IUD`BOMH[@%Z%K,(-R,)O;D>UD$".X`#'_#_`1_R(;UC
M!:X,RY0@>08#FWU4'R2RNQ4BVK8!!@ZBRQ42&T?R6`-Q1ZE4!@R01]%G6YL6
M-O,%`6V`NLDM(&?`?-B[(ZB!`?NP."=SW=V[`XNS!>?DT;L#!3>@.Q!P<;/H
M!WZPK@4#&8)$'NJ\"`PW@37+!EY!SQ,Q*BPP.KI#@QZ'L6,"H#/HCQS,!-G3
M``7NT`4,D#J@#AIHDC?Y$&R2#&]2`37@&@WPTB)1LG!``5X0?NC0``LY`,2*
M!IX"!TZ@)\)5`AG)K/95W&E``S@@`G47``IW<F;"/CO=XSWZ$#R*8D5I/_@C
MM$/[$T2<Y%BB"TOMU"0UU23U4E$>=4W^_]16G@-<7=5/W<1):V0>M+4CI(9=
M^[5A[G5?'`YL0-,`X]8WA!EWJ`(;`UMSG`IUS!M[%LB&K+=S71EMQY!X5D6=
M<1F667F+K=B:2!_J0;E+]`8[TFF<6IJ3K<FF&6>UYME^E'QLXUH80R*Y'%B3
MYC"H<04D,`$9P-J]<^KFT`"_-HN-$QNE/"([$]\":QZD35HF(B&1L#*E$<IN
M$R.H=#2C9(J4\C0`?$H,$&%#0`-#0`$1Q@!'90-KK)[\H9A'DMTBPQP!L",`
M$EF)0L)0,`1.$*PVS@A-\IN@82%;1=J0\PCOR@2I6-.=\F'>PP;(G@#A1SHZ
MT`,]L`;7%CL\(?\GRJ0#&,@"X;D`!A\[^@HK;#!/68``(!`1(RJ#J44!RX,(
M)EZL)6NR%&`%+=`")KP%BB`"<""C.@`'\K4G]C``I5`)$-HCP\Y:6:">)(`@
MUO6P-[!0/&X3-RPK0#X_*D$88^$5*P&?4Q`41[Z4_X.D2TUT23MU49Z56OET
M;^$!7EA!3J^54Q?549@648G%-J5U\7+69?VEAH$75^:U!V`G7`8):\P%DN'&
M"?,">QD*<CWG3K6'E=!6>(NHCJ.VH3%W(H,:=Q,`B:RXA=ZXDHK(]D$QEQSI
MB/6_EXW9F&V:R]%'$:")F<D=B&`"FXLSG2YIG1D<V3<`$X#:&3`DO6/_#OGF
M!13@-,'13@$3C$#3&F+4^98?`0PR-*]Y"BMSN(G^7P`"[-+(G*;$'UMP;,`*
M<-),`R'"!!;`QE>`"-0^H!":@`T@^K_+(UN``YN`;\&*L@"Z!>DA\S&_9J^F
M"N='`!)S3P=X@)VB[_"_#H\"XM<6`AQL+_L^`^$7.Q<%"$HG2"<R6UE;;3<R
M2#IL;#HRA2<Z('@\-2PZD3(L<!5#7EX)%`,38B(5%2`;/V@5%`E6LV4865D3
M#35H<$X4$,`0)2(375TF*CP\-C993$QZ>K<6%B;4S`@@0S=H0M[?`N'BX1WE
MYAW?Y4+FY.$^[_`K\#XK'$4&!O?X^_S]_D7W_P`*'%C$C)DI"#U,*3+%@0</
M#ASDR!%Q(L6(%3%2-&/1@4&)%T%6O#B1@\F)($UR"`FQ9,D#,&.NF'F`9LV8
M-W'JE#G3)L^?-5<08K.!"8\77+B\2,9#A=.G4*%>4?'BQ94=.ZX$H&9A:M2O
M8,.JL"#&!H\`-L10$U.6VH13U)0U%?N4QQ4+-@+P*!#AP8,4@`,+#NPW0H'#
M`1`K8V;C#5L$-2(C>/,&<@T$F"-3%O.F,67&9Q-'&.VW=(HY<PKHS=(L2S4Q
M)K+P'4V;-N(`:)FQQ="@M^\!P+N0V(%#@X8$LHP?3^`%`@)FQ?@DQJV7J3(5
MU,&`F:T]`/9D)&Y=#__P8G:2)*J530#.'HX(X`W>BQ#1`,,IMM=J,&B0B`4+
M&CWXAP`3-BSU0A+4\?=&`Y.QL`4##$R``0Z]G<)?<41`D<`--XSBQ`T)1#@!
M5CO$UA1Y+^!6%74\W$+"BS`^9<>,,ZK0Q"UXY*CC,TS((0<36S1`@P:B>'$#
M#31LP08--R@1Q`(H1!F$((7(T(,="+#`A@1<,B'$?QS*4`$+"%BP11I.R*`F
M'"!4@-R;%5S20!IPH&$G"&E0\(4L,Y31A8NY?)(&`_1ML<4$%F11A3$39&$'
M#WKHJ.,$>+R%%S-OU("D$%Y^LTX'[9!SCCK>E",`.Z>:*DX\\O@@P`HYZ./_
MSZRSRIH/00!-81!"9BA4!$0.8>20&2`]-))&'Z'4*T@4=21212I9]%(.QFH4
M;0X[]134MC!INQ.WVJ[0;;?B]B0N3B><P`83Y"7%!5-T@84;#]8XQ0,U7L6K
M[UU<R4466V6)\19^\^Z;C`4\D#;8PG/8=MC#RWB&66:155SQ9)1EO%EGH.$V
M6VD@-YQ>%LK,*]=LM=6F&FXV6"!A;QC$+'-\]%7<`'`C$+##`&4`8!QR7U#P
M"RF333"""!CL0`W)V1UF6`%@F'S=4^1M-]MA*<I%PKUIX?!!&<!!R``.`\P7
M,\#,4)/'%6D-P!\+/?0``A,U-+#!90&P;99J#3"0_R4("%"PG]\(X-#&`#6L
MQT(;&@"AX1"A&!E*&UM0\R)VU.FKXHK>J>":"02$3D"BMY#LHX^KN9Q)Y#,<
MV0;<%<BPR28G*"%[(6,BX(R2:&Q2@0XLQ/+%#4Y4<.@6%82I`R]IO"D+Y6+T
M#3@(GY0`3`(:0##`"#$8T00)+A^*!^G1)*H"`8LB^D8/D/CW"`@L--##&TS@
MT7(-`S#0`X^>"A&._Z(ZAS<ZA8Y/!;`#9!C'.WJR0`Z8`1^VHI4$!7*KA>"*
M(0J90K4VV!*/$$M8'?R@!ULB+91(9"70.DE).'``#CA`@QJ1EDIT$BZ:^,0G
M-#Q7#8-2PW/EA!`GV%]3E/\"+WV!A5_8J88%C*BO:ER!;7I!BZ72`C"U%,R(
MX$O87P8#LM&L;#I>5(UCZM8;BUD,,QK+&&/,DAB4@:PPAJ&.7N02&C"DS#9/
MRUO:!"8A#+R';$BSSUMFQIO\92`#(@!=`\KP,Z!!;@C'B9\(1M`%I7E,.T];
M&1U+YC'N0(U%K=D:U7"SA3(0H0QBXT\-`+:9@0FL1'B)WA:RM`$0,*!-:6A`
M[BQ3@S?\H&\(J``#MC`$R@T3`0Q`Y18RT;<$`&$,7H"<*&XPA`0,X`VX.9\%
M2*`";D9%CBGJG%-((+HL$.`64)$C>%Q##=%-0`0E\,(,9@`#X@V!3'"@4S>\
MP8;_=,E@#:HX!!-T&3LG%`\6"?B"0M.PA;2XZ09U:I,3]L0<*T2(+&7L6PE*
M@`,&#(`%O=Q!%Y;P!P(D(PO2D)2.MDD`$^2B`;23Q.S$M+\WC,^E^=L"CSK5
M/W&8BE2<VL`ZA.`#58%*`&1`U:KF`2L*2C!***@50/9Q05QI$(;)\@A&#$(1
M8(4P(@9)5@FMU:P<L'`E+VFA0X#E$AGFD('E\F%.WHI#'IJKKC@AA`YZ8`.J
MV&LN3(P*O9:H`B0&%BS5.`N_EJ$6M;BLL0B;6KR68I\"`"8U*`LC;>;P@#E<
M-@`"BUE\W-;+#:11C6P[B]/ZLD7"/"".RKB%652[VCOF__$*E:F!S';+FYJ1
M$6:"K&)HWS,`'.!@!-C!@"FM((M9($<#1$@`'!"@EJE<02[BD<LEH89)Q##E
M15.CCM/`L")EB`"ZQZ$`"'I@QAH$21?X42(/Q(`X!$"``128`2DHD(8*P*$!
M(*@!"'0!&594X'4)&`((D-0#&@R!`:OP#P,:!\UM,$>AT1R`?4Q@#6]ZK"KA
MA$J,2A::`&A'+BVC!H=#=SD5U&@'\$S`#+P`!2M4DP9U*\$JNK&!'LB@FE\P
M*#%JD`H9."$-(&C3GA2:``@TX`IBP.\JJ)>G/6D``!3`0%.4X;(18$!\>,B"
M'.1"@"4L(08FL`$>>K`%$+R/!?\@V():K#$!50P""7C6`2'4Q(8!Y<@$T1LF
M'J*AAV<(U5.B2M4`GS'44@G`5>1(8%*5NBHJY&`*$LPT56E558`HY"$%D8A'
M/-!54FLU6&`-JQE"7<*0F)4D9UWA25!M$;36&B8F.0`5=$@/;GT+*'2]*UYC
MHM<>Z&&.V3QL5*Y0+ZM00]E0<6**TK(6A('V/E8$K+Y>8((16*`O!3#47E@+
MLH4]P`9^]$U\=.'+'_R`,6WD2[D!4QHOSG&3G;1M'O62ED'>;&QE@UE]9'89
MW6+@,I2Y%#.>J,=,O6<"><,`!(@P"RO,\^)`\`)(MQ!<M3`-/=HYC':B-D=F
MG`@[(7__F'?G,CJ$-:!Q1-!`?R',@@$(DP$E*(.3!:;B@3&`!@R80<R/(PP*
M5`#`%4OR93:P@0.S(,%LD,$-EI2`"M!`F$B:`1!@,`,+$\$+7SA.`Q"6#*>(
MDRZ<DV.+V,D5UFA[*4]I@MQ-@($!#$$!4("!%WR!X[[MF.EHH$%"WX2#"60J
MG\6C\I(5"@$1[$`,-5`%"RJ0AA(([0ME*$$#Q,"'*OC!F]@==#180\XF&&$'
M7P[2Y&6G`U483T?(@X.>@8CG=*G+SS>M^Q8&C=*=>@K21Q7`-QA=P'70`])(
M/6`YR)!`<5"!`YC6]`0CR(^J+D2#`,%(J%$-PJU^)*S/&DE;_T_8PI6H!(4Q
M;+59?UT3>@A;KCB!?[;>[RV=%((-EY`LM*DVV"36"]K5@#E;T5AE@1;_$A=G
MIR_#80/@U@`XL`7RMC"GX5FGP0/O-'`'=QDV\#"UT5KTUEEA=&\EEEDI4P#+
M8`$9$UH3H%OT41^],1\8&#/8)EPVH!5R=!Z(<1@M(S".)7%$<'%C``-C``1`
MH``*0`/Q@0%B8(,CMQUJ%UN<I'(B%TYSE%V=(UX3,'&D\`E#``&_H%#51`0`
M``+OEA?HYC=I\'4_F%!!E@;]Q28!1@<(0`>2@0!;`&=MH'$_I@,TH'%.T`9(
M\G1;UW44$`JD,`1EP`)X40W64#KI)/]'"5@ZDIA=^C=.Y,1BW&0!(\``=^<&
M"F`%,D`#%.`@#,`":$`'=,`+PB,+7E!X9\@`;`('<!`+V)-@#+`#3F$#60(A
MQF5SI(4`)E`%,1`#QZ`,>(``;,8&AF(H878CT?,[FT`(>58(#I(CNB1[,44)
ML\,&^S,^9($_#=",XL$CAT94XR!\B]8_1'4`R"<.S)=4[\A\2"6/]B!]TS=5
M5-5IN`(1'I!]U8(1'O!!JI9JHI9^XV=6YW=^KJ9^",E",9%K[.A^PL9^YL)^
MY#*1.Y$NZV(4[[)_Z=1_8_%L1N0=]](53O%$/)AB_4(-R&9$2P$Z!=!9$Y`!
M$"B!"Q,!\S7_,"@8`'U!&#Z9`ET4`4X8;TZ#&BD#2F-T,\9%*+XA6F6D6_6Q
M2IS!&$_T1/!V'H:!(";3,GUD'[.%&V_``$1(!&-0EF[P3#"@`&G@7M4U6^*Q
M-5%H1P]C-2((EV=1%060!*.1!"GB.??"`EA&`;+H!6Y033,V"EY`!"702VI!
M`"(@#,Y4)-M`)[)XBG28=$@W,1OP=&KB!9W)`FM03$;G3%PW!(4X"D/P!5Y0
M!L10(B;@82L"%C`2'DP#B23I.8QH#03@36;G'190=VU`!)ZX=TX0(GW#`JC(
M"Q6P>%:@`1DP`A+"`A"F"E6&'$.PEB^B,P)C*/;!&6]P7=<E.H*D_WHLH":J
M`'2[EP65$CN#$(UYM@G5B`=WN$_\-#NSLS\I!GGS,0$VT@2[J0R%]@WMB(Y"
M4!3?P`;>X`-(<`#GV*#A$(_O*``'\$"W8@!1Q0]18H\0U&D6Q!`8U(^_@A`:
MX4$>!'ZC5I#,PI`)>7["TI`E-$,/Z9"NHD/R4)'S-VS!5I%X!A/%QI$>^8C,
MMD0OH$3ZTA3,EA7><1>[4194%%GA91?;UDTJT(`B(`<V21@1,(!X$9-7:I0J
M8T<I`T?V!DID\3(PV!O`40%N$V!F-!E\Q*1LY#$J\T7)L$;YB0$CX&43D#"J
MD18,0`1`0`2"*IQ%:(2"Z3:NE"A[H9<A-_^4:\<,;H<;F&08W3$OLUDZ/-``
M;S($<"!/D%-1\@0$$%`#+8.G&/`%"A!="=`"S+4(,M!?=/`#:O`#=W,S;J-*
MF+$%"=`)N_ITH)D`C!.&,!!=TC0*>X(#8I!-O&DOW=1BO4D==B!.+Y(4F!@6
ML;6(8@"<,V"$1K(&3N`@_G$GL0,BR"$*`[`#)",&TDD#>?(+%-`&1X<`?A`%
M5:`THY<%)C`I;*$CK($\T#A[,052.;(%-$`)@U`[VD@)239H<2.K:C"K&Q`)
M:Z`F(/4&>;`61&8*)"!W<N<YO<=3X^`IY8B@0K`")\"@`^J@\QB/`E"/^W"A
M^`!54*6AUB<0%N3_*U?%CUO5$`%)HF"%H@Q9:RMJ$@7IHFY5?@X9$S,J$^XW
M5Q9YD4_+0SN*:XW0`SS0D3_:FR5YDB))%W?!829YI#RG%E1T%MIE%]HFFT^A
MESB)*!&`&G![&H&1I:)!;AX(E($Q!TT(IH9!6WQQ&">8K7Y$'Z+5@H1K,[J`
M<`EGIYS!`^CQ,#@(2CLP(MM$`N!9E4JZ&V;C%AA0`5H'J(*Z=0H0A%\P)C40
M&MPUE"8C6R4SJ7-Y=CP0'N/Q`MUQ%KJ:8#>@#:-0KA?G!110`P4@!S=3`PF@
M`,@!!1K"(5_`7!70"N[VL+7T"?ZU3'8X!#+`!A.K`[O:A]4DK-!$3432_X4`
M4`(8H&*@(SKFLSFW`17FA(G+&A6TR79@2Q8B@`,0L*T*8"1'PA\_!X<5,%'.
M0P'\218NTP"3-R;\,2`$D@4=NPQK9B@&+&'[02GJ^1\R99\!.[":\`B/H&>;
M8)Z6$"D(X+#N1@>@D&")]YUK\4X5L*<<VP0V<@O\`T#_\PTCZPTFBP2NDK(.
M&J',YP,NZP\SJZ'YV*$$L6H>^J'\R(^>!BPF^A`D$;3F-[2VEA(O&J-)JVOA
MX$.M4G]1BZ-O-2X\B@3KDFQ004?*MK5#:@WY\A5;P<9<@2]LL8,J1G;*1C++
MP!=SP`-X``:<!;<4>!K(QEI/`[>&(0>-(0=S(/^I8&`'$!,]O009;/%;:.I1
M+0A<B<,6;W$*-?A$A345XN4TY\&74607;,.Y$X"Y-I`'LXD753DAQY47`0`"
MC:-?P*`!,S`&1O@%238@:[<8)G<B(?<T=-DYFU1B39@Y7/`BQ*2_/Z9?%/5U
M1%*ZSY`\%?!U7S!/&P(',C`+B8>*L3JK5$8\((`&/08Y.K`&:Z`#0X`D1I)@
M">`&,*!W-Q`+Q_$%````&H85V_04?7G&:4L7TR`Z+6<!E:+),C,"^3-A"@`#
M\'Q/?9,!_45Y>O(%P+`?L/$6KFG0*N4,")`C55"O6\#-DF![M1,$LF-L>,``
M)9TN&(P$:K(%D;(%L>K_;K3:)B0])F'F4C9`JZB()U8VOG!`JFP1C'V#`:W!
ML;/I.<@8LD+0`P7J#>R#H#Z0+LC'PRK[H"U+?18*LQB:CQ#4#_AX*P$Q$/GP
M:0^A02`J0JLF0B+Q:E9\0M$RM"%!M$*+:Q`)$U3@#C2Z0&#L:SD:?\.&9P@J
M!^YB%5!8B?OR?US1QLQZ,/A"P$[Q+XEZDM`F10SX``'0QYPEE)Z%&@4@!O;#
MDX5!19#A&SB0`3@@`O"&%HZ1"Q!"'\!!7&YS<+S1E)'AG2BX@TL8`*/\VZ.L
M%P0,I9]<E;RMR:>P-F>!()C#-IF2.+?]%BP``0G%7WHR`VXPG$=W*([%1G-)
M_Y?8-1Z=E,QF;!US41YBD%_4)`-M,`,V]EQ>8'$:L`H]4`&(N2?ZY00@(`2]
MT%]HL@ITP'39D$\)1=\-=D]K<`/IO`9/1Z[QS*VF68OX/*I/U"+_-YN@EP5.
M`7=/@>$O(AYGG*WS838R*"$04KP:$L\)4!_$!2%MT`8EL!]RYEC]K`QB8(<1
M[!_^<2@<-B%!)@G26`A*8%"[AP>3A\&=L'IB(M/R&:L;D(JJF%#%XR!9D*V1
M4<YT``).D)K8`P`/R!5&/0RDH]27<PO("&GOX`T]]@A0[0-$10A7C=59'0Y!
M/%49BJ%W;H]E/54#<;,8M!"@UBO&TH]N;4(HT6H..?_%"@EKL):T,T0%NK;7
M`K!K=O5H\A?&@$TN43O&E,`I'&YV:*QL2.1L81L6%J`T2C05:]&=UE98RH8;
MZU$#$9`"?.S'H\%9IU$`;Y$%I/U:!>"`)9`!/>.%PE`"UR1%*]@;<``AL@@'
MMPJ#D2$S$T!='-/)#`>Y>_G;WJ$7=S$PF`N>U<8,>9,+J8P85\#*T7.KF5EW
M;C,`)<!XV$.8T21/%3#"<D"4Z0%8)C/>(9<YYBV`4(,U3R$&-$`$84(#[EU-
MY6IQ&O=S+"`*V^`A<"`$:&!0GQ`+@AE@`88`O#!15^<@@A>*"<"'-\`"GXJ8
M:1E-A:@!7%X&F[?)$_":,1+_+QB>3C-R=C!6-JS.21.0VL6K=_).*),4,\NX
MC)>P@R,":'>H"J$XL320)@WP!BV"`1DP/!/;GA_L"^&(".9LTT+`!OZ!)$ON
M&FV&!FU2`;W3(?HE.%LP7]++"J_P(4RF`92C!RI6!50_`&)P"V3N%#C2`U?-
MP>6I+D3E#0=P`O+@#H\V#_"0U3\<*](WQ-+'Y_C8YPSAYQCT?1^D*\+RUF6%
MD`B)M'AM0@Z@0FF5:[E&!:KO?':U`H_VM/175Y?^+;5'"3V@%5G[%?VWQB89
M%N!C#?@"98.$*/Y^V1(G`I8U7S'Y6O7F,A9@8@TS&@&03#HWX24P*![52T2F
M;K:J_VXQH[AEQ#&HJQJCG$>AL6Q6R97WT=C*<%T>\[!7,"&FX!A\M!X]<_W[
M0488P)3O#@A?"5X)@S=.@Q5,3#P68A:0-CR3`95@EP69E0$JG3R=FP%@!6!)
MEP&3/"2K)!851$,),A5>,T.W0QHS1%X@-$,LL11?7C<5(!MP5C=I3L0::7`L
M#`T;&V@5@A`0##1>-!6R,K*Q@[D*"C,)$`D:A5X:U%N/%I.=]_B=)/F;]ZMX
M>"RP(C%!!`9)J2IUFH"CQ!!TZKRXR2#"H(V+3!!L8<&BP9:/&+I,F-"@31L:
M-&2L62-#AA,9+&I8L(&!`04G-UB>.*%#AXQF#2QDF5#CA_\:-3^N5:!QXU":
M!F)(@D`#YQ@=.,.L6%G7`*`(!BQ`@*AZ0U"A!`S>-+)@H@J&##C$9,G2I,E`
M%4VRX.GA0X"`#CY\J@RBA(T0'T*$K#BQHJ]?`3XB2Y[\N/+C%3F*&-C,N;,!
M%*`W@T;AV4`1S:<WIS9]NK7K*5.*3/%@QH,#,V8<W+9M6W>.'`Y^!__-H7CQ
M`\</(.<@7'?QWSF.,^>@7#D5*@+(^+W>>(5WR-7#A_=.OOR*\>?%JP^/9"<;
M!#SD?,IW;S[]^Y6N[+#0B2U_%5?@8X\*_D'B"`883&#!%978=]^#H$R0P0`%
MI,"#&`%$,,<#'$9@PP0FJ'!)!"3_/A```P!\00$$7T!`01HP,C``''"(T,"-
M.#:`(`*25*)&$F(D:,,F!9"820&H7&&#(R88>,4J`%ZAI!AB7!25CE<DD40!
M4O)@`P(U("`F"`S(:.,C06901@D.)9#&6`/4T,``TQ3B#@2QW)#`&`K0`$)'
M]/08P)%(*I3*)T022DJA`F;A("H-$)+`#2QX`<4MDR:PRPPL5#"$#K$0(PL<
M:&P03@5P#`(/`S7\&=,&(%"P"SPG>;$&"[*P$((,-W@QA*\)P``#$0G$`H\&
M\'"#@!QX*)@%"03L`Z$*+^3#"@$$S&4?#Q,,,,%:!EH0+4-M#.&&`E!XX84"
M$%34@$8-_["`$DH5+,7`%@&),8"+*RGAKQ(GM!36!!^R`(=8:`@A6`5.-,Q"
M/40A0`<:.H#@4P)6M&"%$P,@V``<'R.#1AK#%&)%&2+@D04&<8)0`8Q?Q!PS
MJU?PD`4D)DS`0`83S%77/JO0U<1>.O35@<)K-$68#H<AI@-/CODUV=2166:9
M#YEQIEEIG(W&]=>=I>::;+#)1EMNM3E`&V^Z#><V<<;%39URSPD7'7/0S9V<
M==AI=QT5Y?7E@WKIH6>>=]4AOM[B2#2N0ZF,9*$"%Y1S49^#TZK`R15-]M>Y
MM?-=`8GH5(YD`2J89TY?`!8,,$``*41PNH8=\K!#B"-&P.$#//\P4(B*%%!0
M@O`93.@QCAA4&<`;R1>I801!BJ'E]%M62P*XI8]$)95YY"'Z!&)<<>05+(M@
MPY8!8#!"30"44>_!9);90`UOO-%`&650L*<M%4P3IPAT`H`[AH"G!,3L5TZH
MP<Y$(`8>5&))0J%$*"Y!04THA!^54!08JM4)&VP!6;'000+<4*Q,S6`&;J!`
M!2@U"%XXH5ZE"D>I*$`$8K$*3`PX1JIJ.`,(G*18N%J##G:UAA;H*18P&`.Q
M8H&L=Q""!4S```-MD#E6/&@3=O!'*T30KJB8`%L$4($#6[>-&2@`!E"`@@+B
MT:ER-24$(<A)2]9``3AL02,X&`).%K#_`*7QI&(@^!8>&H"&'QCR!PJC`4YN
M,H!'2&4L/8%#&F*AL2_@``,6P$`)&``'.M1`DB7#&,HD1P(I`I!-,AJ`CL)'
M@KQ`8@<Z`T!0A`8E$@@-#UM@6@=VR09>W2`(06!:8H302Z95AFKDD8S5CLF!
MK8%M-*0!FS2W-C:RF6UM9YN-;FP#'=\`)V]RBTYU\`:=<GYS;^'!SF.XDTR_
M%$XYBEO/X0KWSL6)!PD'0((.V-`#)DAN<I7S1.H@%*``<.X__I$6@.@3KJB<
M#G524MT5>0!`&Z1@#@[<D.X"L`,_4(M$)$(%3?3WA1+`*'@0*('K#J(D1X#O
M#4.*7B9*\2&"_]D@?*$0HX&V%Q7PH6D'.^A>00YB2!N\H08V:@#!+#`"&T%`
M`RE5T<'@`!:.Q`D#9=``$6"0`">0"BLEN)'K])<`%?ZBK"N\`1I*D@$&B$!!
M$ISI*$:QB4/9YP45)`48ZNHH%02-!UM(`+&\`"H2YDE3NY"%+-3EPI^4*E45
M0,,0B*".L.(P&G`H@5EH4*9;!.,&(F1),<H:+!BX`5CJ(D0MH$"#'HA@"Y+H
MJU\'HE!JO8`3]&F%0%9!``LP@`@,$`HIY[(*"X@@`Q18UQG5F(#^_2(G25L`
M"@`F`R4X(0T5^`@+TN`2EK!`!D&0P4[$LH5&-``9=&!#3UBP!DT9D/\:$Z@)
M_(1`%0H,01!;P<&W]-5),C5#9@8LP5O#J!\$(8@>DW@2`>H"B9$P0`,#$,K/
M6ID7!N=2"!+8I1!\"4RF]4`(3.B!#)@6M<?XX'#*7*8[L_;,T$ASFJ@96]F*
M0)O9>.#&--[F<(`3'+SY6#KBI)LYOVDWXZA'G28&W'<Z((!ZVE,\Y7GR>AIW
MSWTR00Z=J)SEQ"C1^_A'<P<-$(2`2@(J.7!`8NXR/BI1DS>DP$(\T&@$"-`%
M$@3@!;J3G<>>6M;@M:@"\QM2`>80`2TM+[[)<RB##-I0\(U.=!>YJ?(2'%^8
MQC>^KAL`FW!4`SFITL#V0RY6:EA'ERT%`F7_"-,PO"J$0Z)A&`(>0$,&00$:
M))<0@B!"!<2$`"F.H(&+*A1NO>2H#.IUKK?EQ(#NL8ED!T`,$`!"(=A[VCS=
M8%->&(>>:N&%+[RD5&A`A'L)&-96C64J51E>F>25`/:"=@@L.0N>B*``('1;
M$+50U0S6P`8:L*!9$PA(MOQ!K7YHD;9S$=``B%""-T""`":(>+2,BR?EPB"U
MX*#!&BKPM!.L`9CB;8D3VH"O3B7,U0W+2?^Z8MRPN(P&<-`!(J"P%0H$16=@
M$1E6[FLG')C`#BL[;V;9!)<RO74"(^@"'VK&BKDX/0O8XH,1C-"DD0P`9?RQ
MRS[JPO4L7#C#1SN!_]*"<((>]#,C_4O882HSS\943<4"H`*+G?F9:+[XQ=24
M336M>>.^\X:;W8P.<<ZYG""3LSG>[/'<TKG,Z_1%.R>6,N&<#&4H4UXY[=%!
M/S^A94^HF3X\^)Q_4L<#!HG.$?48Z.<]\8*:("`"*0B`#?*L@AB$2!0DLH'K
MN`@$8GTA%D.HQ@^8,`="(ZFE03KP&\!G`R5!,"H(<G2B"B*&3*BA`/;K6)`,
M,@`99<`=)F4`"#XY(P!B"`0LDAEV:?0R5`,`&26``#(,":L*#*,,JM3T"6]`
M@1OD8JLGI`B:D'R.YB@.9`D4A`F:(""(4@EXE5<7]&P00"RRL`;I`GR]PO]#
M3N`KL8!"7M`PD84-(_0-+T,-0M=)R?`RFW0,--!NOZ`#31$,A3`$LH(.]]9"
MJP4%-\`&)]$#'A%!]E%;5J0ZMF0!#0!5\R!QT:(Y*M``%8<.7#4(;5`F3O`X
M:$`Q'B=>27,#$+`%;[!=&T!_:``"SC`$AU`!1R<"J/(^+J,G&&,%7Q`48E`F
M('`556%?&*,!^+<#!.`E)`%`G^93$E8%77`&9V`"66`#S?(1C+@%$[`#1D``
MMP-+(H`#LS1;>%%A>3$!+"`$NW0T,/A+9&=VC&`#(L`"'S9,4A,9*$8U4P,>
M#D!W71,:T&1W=Z<UIQ$;U>0!L>%WO7%C.Y8WOW'_`-]$-],A9-W4&\'A'.AT
M`-=A8E9#!I!W'NEQ>95G3_$D>9BG3ST@"5E6'ZN7#U\&($TB+6F&#Q8`5^'X
M(#SP`MU2`WEF`Q42`%6P`YH#!A%0`',(`3@P@4!@;^V0`#2``#^@$55R$1:0
M!U1B8)V&:#R%D(_P!E0BCT=2`S@@`IT6)G*"/%*T;C91+R^"*F/8`/:7`0WP
M`^AG0!5`!T9A*C3(#AH`!V_@*5,Q%B0#(_=%#3MS0B\D`_IS0K50`B"``-MC
M(`Y$*'2%.G:E.0@X"A9T00*%*#;P6X3`$C.@6I-2"T2@@X3P*_16##<@`W2@
M%/PW50=3+V(QEA5@4FFP_VZXLA0)T&_MYG_"H%SJ,`@S``0SD$:7H@-KT`9L
MT!%RH!>(6%O3,A#9$C1S$5A#(!-0ARU0H@(84$#GPE5Z,B'R<@Q72%\Z`)=V
M\F\B4`)T0`>^\")I8!;,T#$D,3S10!7.<!9CH`$L,!+QL@4N@U(L,@0J-0%=
M,`([,!<`T23"I0=.UP154`5+T`48\!&N,F(ZT"DL,`]L80*4:(F(B(E-D"U-
M8`0$P0)L\(D*,W8G@`8(\`8W<R-OL`BIB$S>X8KN.3BQJ#6B48O05!JR*#9[
M1TVS`1N^V#;>5$[343?&:'C=U#:!9V35\3<F5F+2*#7T9(W:*'F-@T_JD7F;
M5_]ZY[B.]W!08%:.4;*AG7`%5;)0&LH/^H(!!?``'E(D)A`#63`H$1``.H,_
M&M![1#`&)U1#S04"-S(//%4Z!J8C"9(]-J`&^2A["/(&#%(`$E("-;`O*\@J
MUB`G#%`"!\,`$-`,944C[%<"654""``">C1_]`<'>"((&K!K+/`%:U@O:S@S
M#;`S&N`&A\!$6J%&P:<61QD*_7`H-E!L1X()>W4Y]N&`H6`'!L4`'U"5)W!"
M9W$#NG"C^&8L;D!"7R`#+2ES3L`"8S@5)#.6$Y,&)4`#HPH!_B:0WO!=V;8&
M>B20RD4$[N`%]%:I4*`.*@$,*,$$N(0'#?@@T!(MAGG_.37P*RP7<5^TA!-0
M+B-T1IE2!M30EC0R%:0Y20.4`/H5FC;IIIKU.U^0`9AT/Q10DR_CAGE9!D'A
M)0@P)Q50I6#A$0JB`CO0FR[*`WJ@!P#Q$0!1`X]PG%1'DBS0$SO1$RT!$TE(
MG4AWD2;0!-BIG0MF`MX)GJ$8!&9P`N^A,B305&(@!XO`!,/4-.]I'JYX`/'9
M&?19GV$CB[@X8WMG!OS9G\`X9.$D3G)#3OZY8XHG'L^XH(_1H`YZ`%$6H4#+
M'A.Z'@%[H:JWCAQ*()_C5_6Q#XY0HOAA7`V0HA'@*!\B.?@8`$ZX20GPCT0`
M!#AJ1@H`"X"&(ZJT/0@)0<TG_R4U53\_8`-(]2[U8U1?\3'44`%92BI3JFG<
M(">"M3'(<`UIL`U9-00]0`=Z=(54L7ZGB::LT@#-97^:"0)I0`@,($7?IP!#
MT!)MH"E6P%RPY2600"4SD1#&5D$&)T8#L@ES=0H-\@DD<`4#H`N3(@.6\JB"
M15F9XG^"14)=54@_@`TR`#]C,0SH)4EE`@Y`5"S>X&^^\@L;V%[H`)"R2@2T
M>I4JT6XRT`8]\!%RP#K"!33!"B$WTRPTQ`)B<*R1J0)B4`*%<"[I@#$`$%8D
M@RK2&BL!N2(0<"-WFP858W]G\050U0`F@`$X\"8N<U+MH(?>,A?-%R0C$7`J
M0YRJ@/\MA`@^N+0%;-`_S]D_C@@B#@L./:%/.H`$2C!BWHD`?$"=\6HC?#A;
MK9287-`$#JL#X,D&22.QA8$`*B.9WI(*&;$!(;:>KMB>R71BC0&+I5&R+G9W
M>Z<:8\.+-N:+W*1X=W,WR1&SB!>,/9:@?X-DEB&-VN&@YA&T9IQ/$TJA[!&P
M",`(1QN.K"-ZGY-F-@,@X0.U_&`#<6H#')*.[UHD!8`![6,P"5!OO9<N*%1M
MP=,&VR"4/\`@26!0SI<E,JHC<U(-"$!5#5`_8<(R89)2Q0L!+W,P<9I5YAHK
M=;0!1_$#=-"X[H4,.,%^,,)^3=$.#"`F+J)(=5A?E34G3T7_!*#5F7L"!7SB
M!='I:)#``T@I;#:#$*8[*!N$"1>T;*G`E()\6@EP`N8B*7H"E%U55K<@$>%<
MA0DSFF-8%2\#(V+A!%G*64[8;K'``B<AID/`%-IF+A`1J37D!FG4`O$&$_S&
M$0"1/`G'#P<'F5#B=&]``QH0%.("<=$2+7-8+&*K`.JB`4(IN0=SA7`0,^WP
M!>TS/QQ!(Q0C`V91"/.+`3>#`-/`)O'G0VV``QVS`X2(`2'R"9/@"'BP),<Z
M=3G3`&R@7C[!$RY!L"K#B?42,"UQ`NW!$R#P'GP05#1M(Q,01JQ0%\\RPQ:@
M7C?,%#JL`SPL.071!:EP4Y*0$40L_QGM.34@&QDB2W=,;'=-;)_5!,6N<6-3
MW)\\]AQU@Z#+0;,\%HS%Z,4Y&XUB;&)&K#@0>L;;.+2,0[&;UPD<I*$1A0J0
MX#D"L:%B-IW_@<=,V0`E(`;%9P(C,`&:,V@6P`YK6,CH,`9N8+T*4&VW4`8`
MD`$@8$@PI23U$Q55TBT=HVGSPZ,@4YZ=-B<3@``EH`$MLGYK*3P4H`$?()OV
M!P?6,(9N:E\:X`Z1Q13I##^9]06\>\O(72PK><Y?$)OM<EQE0$(-DPMC,`8P
MD`[H*VC)9E?V?92+(LW#AM/,=F=)B5N";&^$M0;8;`7V-0--)`/UC(=WN0S&
M@`9C:0U5P?_1,(((W+`-\@P,_K<%Z]H#Y=(&85DLYG(N"+X+-62]:126F^N7
M@3F0\84'B.JKZTL?P.D-4#$!?<`'?`"LK1`,OW)&4:C<2T$!8=$#8Y@&!H2F
M&B!+3\I))>T$N;#`-B<4%H`'-3`-93(C'D$E!#!U57`&(X"(!#`2Y7,C(G`&
M?9"=!%`3,J!/WM$33U,OT=DLA(0&0:U>SOF<'*'"4ET%5&W5JX#5)*#5ZO47
M1R-BHA@$J`@0\-HQGB`NEF,!ZID8;%W$W;'6Q*@9<>UB)DO7>=<:*<N+?E>S
M/"9XIN[7U,$<-?N?PD$=@..,.<NS.ROKD*'6BLW8]X1/NI[&:CS_93+`!CT\
M.7A<V9P3(F+4)!E*(*_4V5`["34A!B3"FQ9@!W90`'+@.X`&%M$6VV.01NAP
M6C[$(J*LD2R)V_13/V\P`-Y:$^-7`1FP20<#)J<(%@I4!ED*O,D@,UIES+B2
M!N=\D]ME%FG*TJ),@Z12O"4$#.5IP*(\%NM:!M%]22.P+R0T"_ISH_`-!!40
M)E2R`U32)%3$E(K"*%'9WW)%"B_`07.!K!/H!;LB`[5J#D-PE=AK#+1@+#-P
MJ>NGMQM`FA,C20*<I6E@:TO1!BP0/&1"Y/;%(F3U*Y5*!%IA!5IUH\*BX32`
MP][96ELPD!DA!L`Z4:K0=#=C`2P`87C0_R0\/KK[\N/HD)4".<KBB@@>C>`E
MD"`=62].@-WM8SQ`%0,QX`>EXZ,'V7R_:@)=P)P<40&S\%W^AB]ZH885L!-_
M!.?KA2^XQ)*KO`$<\5T"@P`DP`=YL`,QT%1=8-431F%YL1&>>#0;9H;`5'8J
MDP5\8!&6#320D)YF)P0?-AEN=\2LF,2#XP&BP4?2M>E@0W>@CHNX@4W`:*!$
M!K,SBQSEY)]P0QRPKJ#9,<:S3NN.@<34N-AGO.M4ECCWQ!-LL`$#LF6'`E`"
M)5&A5P]QO"#X<'JGQQ]*N8X.)`;Z50"V`P@$*G9V<@T:$'`,#`T00$0*;C`P
M"E!6"1`990`4#?\L#'`_HC]O-35O/PB+"!@5<'!I);(5%0,-#"5#3C4X$`UT
M&QMT(!40"0D:5EX5;$,4KZX@('`47U\:RTQ;$"4L<&AHTU\)0T,,;P4!`6(B
M`W`5N#@XC#$C.&5N"2>P$!]`8V-@W&"Q10P>"S9X!"A0($D2,"\"\+!AH:(-
M%1@7,F0(I@`8=2HFDL"(D0</%>IL,)CA)802&3-F)/`RY(:7F#/6W)"A@YQ-
M+PF<N'H'1]H[5Q72:-!`BT(%&HLHI('PI0(%;N.R?F'9PHT;(L>0$?DWQLT0
M%FO6L%DC8ZT.%D.V,&&#!Z5"%4U(DB"1I>+>)EFRA.2!(0,#/(CQ5*G_8L*$
MF`DB(`S1X$:!@B%K@-*H4**"41E.CGWQ0L27"1)\,`R0=94;`Q$8)NS`0MO%
M2!YXMFR9L*7&E@8%+9AH@H<%#9XZD.A8?D+&&AI;$#>`PV:YC@HR3N@XH9V@
M'CP8$*C9HT84"!I?=/&L08`/GQTQ5(\01*!)D[TD[`<NSD9(APY"L""9$]RQ
M@0`>31`@@@@V!&"#"2=9L$-%%HAA`Q-,]*"A$#ZLX,.''GXHXHA4Y%"$`0:@
ML``*-Z#@(HHPQBCCC`84<2*,-A9AAAD>].ACCPX$F<.01.;@0`X<)'G`D!P<
ML.211`8)99)4'D#%E50((``99&CI)9=@<NFE_Y8=KF"FF4ZFJ>::!R#!YIMI
M(B&GFBNHJ:1R;&S`Q$E<<#&822KT65(6)Y%DZ*$\F&"!215:<$5(&%44845_
M'FKII2&M@T,##YH@2`!@(%".5;X@4,)8DTSBAA=?0.#J)FG4P$(9<)0W2BEO
M;%##(J8PX$0:18%`QS"R&./%#34,0&LXL$@UU3%6S$!##[X2!0X:Q5B#20,(
M;`%'9\'>LE4"L3):D1BF(*`N`F^P2\(9.-1!!!0W."&+!D#(Y`4%(""@ASHF
MV9"%#2.A]*="ZG34D3H2`7KI"R@QK`()%@R`30LWZ.#%JD`-09H7--UPU@T)
MD#S$.,[2DD92OZ:11O\U3KU<#`7HN8J)JU-]\3(-$,P+A5<R(:,!$6Z,P=)9
M--RPEEIKL-`,"SVP,($=/%C0UWV&$EJH"EDD6-$$&4`P`1X3>$H``8'9L,TQ
ME2E`#DL4X&++.TY<DT`9B`P@6Q=G=(%!`X`#IYO5%>VP@Q]_^#%!#9ZPP`(M
M#$#5P`16;\$`+=Q9EYP,-U#``F(8@!`,$S]L\#AV,M`2G0E;;%">,&A0$VW)
M,H#@AQ^&[Z":""9,;!]^^F7!GW\`ZC#@"4BPT0.")(P@@@4!2/K@A!2:A.$&
M/7`XXO;<^[#D%"BB$$00-)9O_HPY%C$%CS_^*"61',!/9?PY'!`_E$.^CV3_
ME59BJ2687PJ3F,8D@#*9J4-LFA.<%IA`!<K)36EJ4INT8R`^E010??+38#!U
MJ48IY$$64,&C5"`I<X50(AQ,(4HLL*`)R(8$+XA``!B0@,<E@`(($(/%_J$`
M&$"!)A2@0`8T\0$(U``$$*#`#VQ%"@28HA@0`,$VOO`-!(A"#1N``]YF,`9D
M-0(.&XA=4J1"`6C-H`((>%PX0``.8HQ#`PD`HPWD\(-=70X>N(``(W(HAL:0
M8"&`Y$&[:I##,X@@`_-:P\HJ4(9\S>0+#>C!8UPH!DD%X`5@Z`A#)&8HAS%,
M(YE\`<0&12B,7*$!"9@!QGK",59I@"4=2X`,:*`+_V<$D2I?:!E2:)&4IKC&
M56THPRUET0;(P>%QCO"A5XA@!2L0`2='&X(.9#`$-M#2FC+H03&;T8#<3"`P
M'-S+V="&$#$P0`-;J)H%Q-D8,:QM"#/H(4O<@(@2X&```V!`&X90!@BT81$L
MB$T7NA"#'>`A"TS`0P]TPU#=8``#!%4-+VDA@UG2@&8-,,@MP(&=:5:T.:#Y
MG`5,H2=1;``$+^O<RAK@J2U8D1C0*&,SC\6"&/#A=GV8P#TG\)?[]!0PQ=&!
M?X0@!!VTX09KR-SR[N,\,:BS:I443L$2PH0W8$@(&^)>`;EW``?<"$8H`*N+
MQEJ^L)ZO1CE:7_M\A+\B[?^/?D.R7UN-)*2WILE_6P)@7LD@@3#]STMG.F"=
MUJ1`!AK620],;)L(F[D\;<U0&KR@"@\%0H4(9U$AJ=`53G(%"DTVA0&X0CLP
M$`,3@*H`("A#!6I`@1D,@"(-*,,8@#")'][0G@/`P0<2T"\&#`$-:L`B(:<!
MAYYI``XU2"(=2A>,(U8``$LI&0A80`$T_&`8Q%B95IB21F!)0W1T..<'/E`"
M!$A$'6\`7&]THZXWV&"SXD3)%=Y`W]_@<0#MR,`,Z'71$@``"#29204DN:A/
M7E*4$@F,@D\BRE!&)"(@N92!&8:!5+8@`3H8@AM@.8YG`M%S3^%,+%P6Q$5.
M="C_BDBBRBYWN<<YCA:GL\I,(D&T?,V`"$O9V`TJ<)8,3[.:L]1F6X:`1A8@
M0`YR"(P%SO:[@G7R"C:P6`,L@`<3[*`Q5GY,"=Y6B9\!00-ED,>"%M'B!M3`
M(`0PP6(8@Y@M.,XX%7@<#5@PN2K;(PT5S8Z<FN.$N&W!`G\;%AHTQ`;LH"X-
M(A!#%B;0`#:*$18):*;.1#`!`FQA`"Q8V30J0#(K1'<`?6@/'TR@4QQ@H*<$
M^"EQ&B!4``G!FIAIC@Z62@(,)+IJ?1%#5$F0P9%<P4(!8(*Z-`2.[HFH@!SP
M@/G&RFP:F?6LZ9O"6CU05[?N+P?4CBM<Z5IM)=WU2O\3_R"7)-!7<7=)`('U
MT&`)>]AV)[:P;Y*3#MBPI[NHX`6"$N%G#Z4.#Y)04>?JHTFNT%E*[1LC>S&4
MK3&P`QYD$@']=#.K:E``PE!@#`HH"TLPP0!;Q%8##=A``RB@@^"2(A7?&L<,
M&*"*-(B"#BPH@:NH4@UKL&!78/RN-"J`#&M`P,B,>QP<`#>`#````!G(:(44
MU2`>;&0B[R5X'G8P4,C@(ER+L&<#1E`"#;CM!MPP!@UH,).0VX`B`?=+1@)`
M"#M$."-P-PG#1(E@@!6J+X`N`Q&`@I8-@^P8.*F7*\8.CQ%/]"A#X>4[&$#G
M:;``!)Z8+@.F.V=:%B,!-/`"$/\JDZ^EO-(K-%A+6YH&E[>HA09,FQ8-&I#0
M@SY6+_BAF`7R4)A$+YD$:2:U"P<@&2]$`@9C*2(.,H`!,;1+7>I%S`0&ROQ;
MC/WY%=7)G+^)!Q'@`'4?50YHG-"&+2S:S*,((PM`4Z\TL!S0C49I5=0?+2M\
M06^6G@>*TZ"MI?@BU>TQ7-%%@.I4V\<^%N!F_4%4L+8&2*`=RR,(D#$!:#=)
MCA(H&<0%!)`'(J1KQJ<N&T!4QN8#Z.95*<)L9@6"9P5M:25M[C-7\L,!#C`%
M1T(E2,)M;N5M3@)NX29`Y&9N8B(B(8(F#;18/NAN:J)8"U0G\M8#&%(H^49P
M!V<IEQ7_(5A&28["*(T10DOH9"JP`R/0!:8%!EG@7R*P!11`!"[7$6)0`D#P
M"+8U!"70<;#1=14@<@P`7'-P13]07,Z0`.?P.,&`4L9P%5]``4-P0S5@`RS0
M!K"0!F@01EWW3"4@`IPR$>:$`PN"7XYX9@@1&`I1`&='$6+P-PU@:R.``6>@
M.W4``"OS"I"'1PUP2`EP&3)0%`P``;24+Q6@&RXT`964$`V6#@FF8+=!$IBD
M29M$$CR@8,9X$CPP`1``2[/42M!R"7](1L)4`A10`BX#8[SD#8I@?D/7:)Z@
M"'%63`+B.&=1`5Y@'`G`<X_`$G`T-#-0#J<7>L>A`P.!%FS`_P)*DS1K40'%
ML07_$@!X81_C=#;XL5DV\%!E8SC+UP6A:&O[%$^2P$6E,7P88`-OX&:/PW@9
M.0!=8#B6@V<5=1PRH`0W$`1.,'W5!PIQQ@9L<(!(H!,WT`8-D`5B`#B"MFFA
M<0D4()-_(P+$0"[34#>1Y@4:T`88D(R@,`PDIBWCQ0!B8!^-@8N'Q'^XER#W
M\7^`L07,0%2OYELWH%0'E04[`!N-,DDC%(%<P`=<\`+OD@<6@2%7I3W<LP(<
M<"(@^")D-8+FDSYIU2-%`"3YTX),DB0Y(&V#&3_WXP%%@IAJ0H,!!"8WB(-;
M=6P%5"<\B%AN`D$0=%@/%"?P9EAX@O\`2*A!#K.$).$@?41"NF8!N$@A!2<<
MO6.:AD(`,=`%6:`.#0``#&!K>-,`'E$`%L``9S@O0&1^\C`=IJ@KDZ<&<[A$
M/U`!?Y@&"=`&"$`,X``+N01IQE(!;Q``;\![NFD*+*`)95`"9[8%"6$#R=(`
M]$5?!*<1#"$AG;@@@2,"BR!F$Y`'-<D)T'"*[U`"^)0!7K<OJ:,),^%[YGEV
MFV424-<PQ4AE!?:;F001#/.@6;`7@*(.+[!))J&)*P$R%04%00-X&F`-/B=S
MU=@9V$@+FT$4Z5<+9E8,4`07;2`@-``"Z<@"3$$#&E!&SX0->W>'<:8T]CA+
M;+`3^,B29T'_36LQ+8R74)64'_9Q*210-1.0A0,5&[+!=!/``&7@>ST$!;/U
M!4-D"X5(#FVP&4_A3\57D^!2`7U&`4CE!'FV>BDI.J3S`VA048'8*@-0(>U@
M%+Q41C/@?C_W4")0-_R"+=40%C,@-A,1J-0``6703QD`H!B0!WO1&#M0DV&&
M?P.)E22@E0.(53QV`TKP$LMC`4U@`HZH:XY122-D*"00FR80`YI:I28A!TR`
M/=FC@2/251]XER(8/GFIEWQI@M)65T)"/U3B`-GV5H39;56")30H;N06F6%2
M;EWR(06D)99YF6V2F9OI;N7:F4%8KFN"@!MP8"61$!@16:;9*913_R&5I`*<
M"'"*(IMZ\0<Q$`,D4`!B,$2Q(0(EZCH=08B:MWDR$3<,<)RY"0'JX@K.&5S)
M=4-E1)U95!16X03A()W7``$]H!%1E@$#P#B`@P&GX"`84!&C]0.A90,6:'Q7
MH(FP$5L08`O?A7A#]T00D!1IT&>+)'.[J2Q`X#9"40)EH![[@@!,0"'&MYKO
MV3`;D0X*P:`\P!=:$S&9Y!%OEP6.P0-RP`+/)"T:\T,@<Q-AD3*7\PJ`4Q2O
M<!3$,'E'5(TN=4[Z5$.205TW``+.0*/45`XSL7%>$'IG\30ZH!;.T:1HX31G
M47J<TP.SQ`2\44J&(I"YQZE75A%*6!*_YO^EE!&FE&`.PY>F24,.:U`!W'$#
M-\`(GG!'?>8J.]$<X3@`.A2'P8`]<$!+(/,%9<``$Z`:`Z!S[U!&-V$%/X<8
M(D`!K[AIC0H47F"4A&("PKL(^/6)^3F0G,IH`%`'`(NY3/9_$U`!.N`#1!4U
M-9&J;?$&2Z8@(E`#PD$YLVHHE,*:6,`'!5.,PK,N"+`AKP8B.3"L*D*L>'FL
MY6,C.&(C4[#`;/4^S0H_V!:M\V,DB\D_UEJ#VYJMW*K!9-`!6S4FEHE`:**9
MZOHF9S*NA`5OGQE!\H8&#0(QB>)4$R.O")=")#!"K&D"G?48(?1K]:HH\ZM"
MCX5[_^H'(U%T#7#_92+PNS\0`1W!`ZBD``Q[0V3FNF7`6ZI0`<XI"JR51*["
M`C90`+(2BQ5PG1``1Q"P!7*P$1&@0Q79()^DB1E5&"<+.*;@B>U`::O(#JH5
MM\'R#K&@1XP#`=?(1AM0A\#4#CVC`!GSDS<DG35DB0$7O`_U4&='(12BJQ$#
M*EUK=Q:*'\7(&TS``C/P"&O`2B+J=T1Y0]$P=,1%#(-'"S5:##>W#6F<7@D@
M"YBW3T\Q!#20IL:Q&1<EN#1A'&O0`S=@N&T1>D7*-&VQ$\WP%M6$%@LUDWAG
M-@29%Z=)$IB,9:0&ND>;*F8ARS]+4:R;9T[@!-P`.(R'BAN01F.7`+GT_[LZ
ME`%PFP9M0&)J6P89`!NK`2S`0`R`F$HT(0*!T:7(12KC@`S\C%^D13&39!`'
MD1"XUQX$4`4*B0%UD`'?2P!&$&KUT01&T`03X#@?0E1P,01*4"`'<A\M)!P[
M0(&=A)KG,@'XFS45TIK&!Y<:T@,MJ00"3,#%>CY?%6T,#"0.C((P**W6-C\S
MZ)C8JL%2G:T#Q(&`)5@G[)F'E=4I/"<D_(-LLAP]L`&0B`<"!S%6>'")HL,6
M03GJA,F;I=;Z%B@NL`1G4%IBL%-*G'0<D0XU\`52O&%!@4<=-P#0A5R7\P/D
M81XO4T9I@``,H9Y>6A33`6-J/*$5]XF`%%H$]_]'-D!TAH&*C.,.<)!/'H<`
MH@4LO=3*5K$40W!$06%=X0>=Y!"@E(&D6U:H0[E:+M23^"2)UK<I,EM)"*,P
MG,2@>W&,H")*!2`'>,``;E;*1)`Q&J8`L'0,Y9`&0@</BC!GDD%#-$-D/+=:
M6]`&,BDK0V#>-\3+%5!,FV%-<_8<M$0#3G`#Z&M-:H%4UG2/TYR/H_?,0U8=
M]FT<RJ=HEX)W8+N]8G!EJ49"AS0TE@$#(2`3C!<YM+`<VV=1,N`J@".3AVQ2
MA:AA,S`.1?NSQ;N&4S$T5@``99!HC>`9S/(R@4@:&F#0Q;B*N35$\N>(`M4%
M3Q`#!,`HRC<V9HUE%[W_-QAP3P#KT490!>-D!".]`R9]TB!`,@:H'2V=!;8&
MOW[420&C:V9=:892<#O@UHHB!WJ04/U+5"<0!$)-K"CR508<(T9M@@VL/VY%
MK=N&/Q8\)N8VU5,]0`0$(NK&U2B\U7"B6%XMA`TT;^PR-K!)JPFW;XDB'*L)
MJ_I*A4O(`TJ(;W5]!F=PI0-0R:J!`UM0`$[\$6+@")L'!3H##_.P&D.3!B"0
MV(N=7A!P=&F,ZKRN&NRYB7('!FX'G+9P=C^@G@L2&V*``,5U3]8(#';L1)`7
M<RSWV0P0"]\`#.%%C7B3`*;@#(XV#22F`6?1``+J-C+P../03)ZVAO>$3PL"
M_QNXR`XX4`,&9HP+=A+JL!&9]'85@>;%5`'Q!`081@/Y0`Y)XQ0TPP*8QW,7
MI0&TA'D(CWDT-&>?H)&QZ$^RR&..,\MM`-\]0#-/,_+2M+CZV#31?*3W>'K.
MC,Q.HS3-H"&?(P<(@7:8O"@W?P45G6J`9G3Q-`DS002=('1PH#GD2TMEE`"`
M\[,(,`Q)P0`#+<]DNB"7>HH"?0Q>8`4?4`:C;N[<@E)]]D9+T<]ETUD,J:6M
M>799X-%18->Q40J>$&=O!AQ79F6ZTP5*3IM+$`5&8#90WN2/$R(^W0:T@X`(
MLFBC[ED7)'>LJ6N4`RF953@[L*E5FAAFC2%LH`0@N/\B!"PC<$[G=;Y64J+4
M^6-M42(_3^WG40WHVDI`DWE`A,YN[19OZ+KHA^XDEREO!F+6BV)E\YO60OP8
MCN_X%0'$):'6CP(Q7/#I9^`\O[T@\U`#$3`'%+KJ4AP)Y*)/EQJ+S^0YEX,`
M[VP*MP"@6]#$',$#L`&?F\1V=E``73H`W=(`HF!]HQZ\XV\*&:#:)1!RU0D(
M(!49964-3"P0:2`;/VIS""6%&I0-"#0W(&AP%104:11>7@PL&1]`-S(5#%]>
M,V-6:14##1-B%C8V/#P!O6\,)5MBMUG%*KT!!05@S&`!*CPVQB34!+9R-&TT
M,PI`7BPR4&M#0RP40SIM;2S_&A05[31>G@EM0^U#VNM;6PVD^PP0*FACL8Y%
M.8-L"/:@0:/'$!D.6;!!Q^(&&QD6&;)9(W$-&QT66:Q9.'(-Q!L2A_38T@:/
M'%L68N:R,&P"AILB:NV(4<4/'P(8,@`@H@`&C`0)B$```:=$!1!0T0BJ,&1&
M`DH#1+2IT`-$&G+SD"(UA`%'F31PF';ZDL"*%:4BQ$QH0`M.FB^>/,FJ,6$$
MAAU-FF0A08!$%@MX+!0C8"2*GQT81,!AP:*"#!DG+JOZN\-6ERXX!G0QTN6)
M$0(F"#`V8L1$@PHZ?*SHP89&@AM!E.CH@4?PA`$8+.2YHJ(XCRR[;`RS,&'"
MKBS0_VC2G)!'!6$561*;,&&!!Y,>.H*@&$^^_'@#Z-&;5X\B/?HB\.%/F>^A
MOGT'^!WDV,]_?_[^`.;`@8`''$#%@0(D2,:"#)(AP8,01OC@@@E6*(`//ERX
M0H8)RK;""@>`6."())9H8H%(I#BBB@<@@6*)(J*(Q&Y,,!&3!2:(04)QUO'H
MXX\]%A>37,W=8D-,5US!"P]`-@G-+L5Q\<<22XPP@@@X9``!`*'AP$`-!43`
MC`IBE`#$&&ZX8843;4``00DE)`#$#!109@D"?(F1QQO#V+!,,E?<9$,2!00@
M!@8(O/&&#0&\04$;-?13PP8UP%$#`AN\40,#`)2```(#5/^01@DLU$`''791
MX*8&:3#10`(5-$*'5'``)%8"#(!`PQ><R/)))S.X04,#.&C@S0UN?D$$#`HD
M``<=PES1"P\QF6`+GYPV(`:C`=CA+1@O(+/+N$P>T\L+Z`80&1X$Q0,#%#/0
M4($7,L13P0W?T%!.&R@-08-!;5"0``1#R$.!O*1\2M<^#32PQ4(-;3512FRP
M<4,/(I&TD0P;Z6`Q94-<U-"_/:SA<4@A9TR##$)P%)%#6^#1``9RW=2`"`,,
M@$-H#&2`PP06_$0-"1/@,%11"HA"A+,5!)06'%+=V]877VB0P0`,5+")*J)6
MW98&5@VP!0-E0-VK$VRYE0`+.W3_9T%D(L3M<)$6$%;%$D],@,=AS?&S#PNT
M[%2%-5A7P,()B&=V604-=!%#<\WA'$,?(RSA@FJJ&>'":5O0L*''/5"%FQ(G
M\&9"%F(`E\=P3#ZWBUS"[6#"DT<.8[NT2`J7!Q_4\"`'$QN9)WQ[Z97GG@'$
MNQ=?$?--85]]^$$?8'X>Z.=?@!QP4.`*5'`H0(,+2B@^A!0*T$$''7*X884>
M?ACCB26RN&**+LK88OWPQT\C<]S%M*.3`#0.#^1RJ%O<HCA)"B"0QE4<$N!M
M"3D3@5`*40<&>*D!86)&`"R`@S.Y00%0^`($R@`!!E!``T08PQ<,MX5<7"$)
M,+R"<L20_X5NJ0`##>`3`AHU@`SDD$\8*`$$+M6&7(D*!#_X@<)*``!#(*`I
MBVB$&O:``$^T`@@40,`6$H"6M'2B`G!0%B4T\"4X4(`3$/@$',(X@W@12P,@
MY"*PT&2%I\0-`Y"S!7=D:`,1`*"%`7A.,?Q7KF0T0QF%LLZ."C"!-FR!#>M(
MP+MF<`.JJ,(+-UB#%U:&DFRPX%^U80@^:%"GR@B"`5M@00/PP`26;.%W`H%8
M#[0QL8DD)"066<-(+E,RD%&F(9992$HHIH.1?%((]>K!#?[E+Q:4P$L[8T#.
M:'$I30'#.9AK3=$@D``W&&4&HEA*`]RA"330`00,0(K:K-8`%O_`00><J$`%
MG'`5L6B@!#/K!UI$A3:V(`65$^@"T(K1O\,H)@N!84UC)K`/?KR&%`0IH;8(
M4`4<4N8RB4N<#FH1`X$VYV8QB,$9%)K-S1%@;+$!'0MN0SJ(X&%O>*#%+90D
M2&HU9P<DR`,!H'&D'-F.45>@R;96QX6B'@-X,@@"\H9'GN(UU3W$BX\!EL>\
M(MC'>=6#WG]R0+WJZ6>K^^$`$K07(N^!ST'C&Q^%SH<^#&5(-MYKG_ORA[_[
MQ8]^*$(<7N\ZHKFFB`4@J,FVMO,_`%+#1TKB(P$M(#OB*-!'0[..8ZT3`RMA
M*4M4PTO.&,<$940@`$7S`A`^"`,OC`7_`H28`1`>PCANR:$`T9CA%0K5A1&(
MH0%(5`,(2@""&EP*3R+`@`UJ4((TI`$"EOH4#AE`CB%\B0$TH$,2?[`!5'%3
M`TBA``A>]12[R&(37W`+)2J`@`:D<8U@Y$35-%`&@'R`")24%P54"P0%#&$6
M(@`:"7@QK>B(8&`@:*$QT(4N1!8J.3<J*AXF<`8;X*$-'JO3#=P`A8/1((WW
MTL9#/OG)?U7&C(9;APYH4#&/?!)C,F""'1K)`B9D000INQA&2@81DRD39+=,
M2$/60.(-D_C$\J1Q;3S&D8I\<@T58$B2&4**`;```<OI#G\MT,/\-J<*56@"
M`40``0UXDUD)_QB"LQJPCAJ4TQQBL8(H@H$!!D!M$Z!`2MH`(`+5,&<`;7BF
MSW:6E1$XKK8CR,-QK"67+6AQ9B9P01C"P"Y2Z.#1B;O,RE@P@1@TK`92T8%E
M9$"9$\!S"\WQ:&0<E^7-L09SJID`"W2`AH\D1,PR>#0:$+"W+>?7!L1AX"V:
MDR03M.Y&MZ`)[J*\K<G&!`$B4>I2A\>>\S3[>.]Y#_/FPSPS/,\,^/%/?LR`
M;0=P.]O](6M9.736\(4OK1-BZ_DNY%8,64BN<S61_$ZT5_HAX03VWFM?X]TB
M3_?@!S9(35!-L*/#_DA)0"*!8VT*M'(]]N%8>()E=08!JE$@9TY!0/^8"I`'
M#`P`C@H(N1M,6X8,U&$HWN!T7-[P@]<R81B+RD5?AH$#.%0W+1N@U*>VNW(A
MNH,..?]!`S+`7"(0`5)4\6*OY%DPL:CR5T-8(532:86VE($%_`!(%WM5M4YA
M+0&J-2U2B!)R&N`I.,^(B4TPT`4QF``#9:#`!ICP6F6$ZQG'N5%,QA6`%ZA`
M#GC(R24@4DJPWY<!;7!")[3A#@Z;XY>:KD#GN,*Q6>H8Q3W0PX-;G(4MI.SS
M)%D(5U`R,814))06(S&):Y,0CLF`(PRIU\H\_,M/MH$-J\`#/]Z`1X*CIB>_
MR4!P8H)0+0^]##,P2K.JQKB$S4H08DZ`*+S_H`$<S`QGZ"6E/Q/07@R$M*,B
M8$'<K(2!,YA`IR:H@@E$BD>&YD0$61,(`S"`!1>X8`+0K4!&,ZJ9";BF`4"7
M<W2@`ZL&#JH0,S?U&<&U`U6@.21%`(&1'931:AZC`]RT!IFA`[26!5LV`!.@
M"T]")KOF:SB2)$,R4U>P+1L$--+!*$Q"`MSQ!EN05,LF/$[E;$\%;=)&545@
M;3YH;?D1A-_F;=T6;OMF5F=%/N@F`0NB;A;";G'E(1C";_&3/_=3/_F6A745
M(O*&.#JP`=32-D&%4P`T64U"`D)EA@^G0'P@<5>")14G0@Q`-J@4)E=P!F?P
M7R$7<M[`?1D@%$01_R^`TP"3,EV^M2AO0!<8$`#$!4:R8"F1LEUPT`#XA``$
M8W/3]0,@4'&N0`044`.)T%VB`D85T`IM804V-XK?Q11I@!0H5`(U@`<\E`$E
M@#5M0`@D1`LX('W>0`Y?P`TA-P3;-0`CD$<PX8(3($0(4",&M1T$@!S(T`O*
MX`S/\'=Z@&>AMPX](##W]4DAM@YMP#&@I`_H,&*IU!"4L1`>LWH0H0=Z,(=X
MH`<3@`ZVI`,J\7H]P$LF,1$<XQ$6DQ`>00,!21E%-GO:\"_R@GLL$#ILX!`5
MDS(,@#'!H#,BD'X]00TC@`,B(#L3@&55$`,2E!3,TBPW`"N@^"SG9!<E>?\5
M&N`%$%`+U@)_)=`F90```U-"P?49CM,_1-(<B?%26,8:9Q`J[E09L?9ZRR0,
M?>!QFO`1!BA/JD"`$P`4.:0&5OD#J`(*3G"`>&`".[`#`D6,.W`:IG9J$-@$
M@:<U:.`QD,12NK&!33`"'L@+")0C0F4!0867.'(CP\8#*6A`W8%K?KD=%O`&
M"*`#2E"#-JB8.:B#/!@?SL-MW.9504B$VV8]_"%NW(.$#;*$$M`!Y-.$Z/-N
MZY,^&\(A'K(][U-7[V,_5TAO6]@B72@#(,`$RM$V?-E`D:5`0W-`:ZA(0&*&
M?)"'(F`E`$$U)<0I^&0CE=9Q95!?(3<#^%`"TE3_`G#D!FL``CW$"%#A6X9F
M`XDH-C:`3J#P%+U5`Q4`)QD@,#;G"6BP`9N@BF!W%;P"8G;Q%.?4BFYA!5]@
M"93X%&BP"7;ABH:0'#8P%W+3,`Y3`X=B%L:B`<TE6B$W9K4@+=-R)#>R!;L(
M`AO()`'`#(4B+EF`H190&)VA!PV0,B.19+-4)X;S28)P>RS*HB0C,2%A3`NY
M,@O1D"3FC@JA>>502PGP:A@S$@Q1,B3&$1]C$.#`8PS!$(Y7$.B(CCDJ>05Q
M7ZN`,T,0-\$5&#Q"`B-P-1/0&:EA'6V&?"/I!6(V+"R0*U'C!&*V7F7@@>D7
M`Y%A07,H398P#";@$WRP_QV%1AF"N@JU,#@$,`)9XTZ/]FB7`:?#8A.$B``]
M(`1"D!"4L96J,)5G@`%O<)7Y.9\W0`$PN1-A.0`[P`>:4Y:J$1AI&:"@8QLW
MH`2Q1FN%,93.\0Q78)?2$53!AB-[)$-(0J8QP2/`NATF8`/?(0-3Q9A,93PZ
MN(,["!\_:&V4N6W=!E8"(FX(4B%)N(1H)9KK1II16)INY3X?DC^M^9KV=E>Q
M26\9^)U9L$<T41U?6EA.XI<J,*R_:7`-E&OE0@*559QY6'%N0IT`X`ZV0PT8
M``'0>13RDA5T89T*<`.;``!P@)50L0J0N"D-`0*J4@%`YPA8239@4T<;H"_O
M)/\(%*!X^MD6"=!;;G9.`;I&<?(6K%)-6Y`3\000````$."!-4,WNA!;BJ(<
M`]!E"D`$HM"2T#D$L\87U6(MH68+$\!E&R`'_(4,T&`8,M$ZQ=$+8O!D+%%B
M&#,R(S-,MF0012I+X;@1'5$QZ`@1I"!,>B`'/YH%VD!CRM20%F&/^9A+*)%)
M&,$0/,9CT,5A/3"W^G![(%`0J)1D;:I*$N4PK](`TN$C!-`%6#(`LU.BJD$T
M9.,%:8H4CI2SH<(`3A"';G(UC>,X(94CD).S,2,7@+:I=,$`FJ$93K!,I<)8
MH>*J.I`X2"`#2K`&110YD]((WR%/7[&R-(`!F9M#U:7_%@)S"AKP!?/GE3&P
M!#&@,QC`!^"K4`JE96\'H`V9N$,0J[K!&Q;0!+\A7+L@'4/B-OVSEWB9KS=R
M4Y.E<,.0!ZG!`WIPF$&@;..Q`,VZ'M"V/,I#59))K97YP-AFA*KI/=_3F9Y)
M/NHVFA7R(>/*/F]EKB&2KNF*5UJXKN@:(RE"@&C`!`%``CNP+6)`AE_*FT)B
M`]"PAORZ7P+$(WP@E\7)922$%V130@@`@AV7`63GL("3$PU#`:LE%6>11-,[
M`-1)LTL!`@E``=*5B0B0!I1@<8)``SD7>:)R%V[A!5_`H6`T*P&Z736K%#7P
M`\HP7*&2,WE*3<L!C0<&GGBB_Z!TT65`H+0#DQ3UY05ID17M=XR[$``V`'=P
M0&O^<U"+'(W/@'>_XP_K8#&TL:)M('HWQ@9KD[87HS([]K:U`1Y4*DQTMP40
MP`9RD`7)I*-*>A!KHR^OYR].RFF35I"75QF=\R];T0`TD*>IQ``.8VC_P@0O
MM05E\$H\L)M@Z7$X\!=7%@-^@']EX`4A!P.4!`&.)!<ZHR4%2PNU<%.L00W*
M@4/PQSCP5YSD!W^XNSB6L;M#\+.VX&0]\'P$&&NZ)`/J`&JT@`#/]TEBAL9.
M0`,;.1=0$4]K8;,),,U\X`=^(%)8,@(2;7^IJE#JQY2MU@,],`#D,,`N5:([
M$%RX9O^_0V+#-$&8QPHE\ML<W?&E_<,=T)`%WZ$$RK94!KR8SGH\"ARM\='`
M6N4`0QT]W):9(T(%W,.MX'/!$I+!3\C!4.ANZ:,A&P+",)+56%C"\R:;JGFN
M][.H/7`<L',%>5`W,_QPPZJ&AE58U$(<]MK#.N,7XBR'A<``&E<`7)`'9U`"
MHLLL=&)!Y(Q#2,&A)D0':D!=250#5%P&2LMJE;0!B7U*)I19>($&Z'DJ`+I&
MK8@4'V`(D3(`:>%;="$4[#4`4$8D,!=SN(9KO1!PD(-#A+A==$'%7M)E1F=/
M,[`LAKQ=PH5WM=.3(M`.PL`++P`&(7H<Q4`8)>K"7<!*0:;_HS0``B63$!10
MMDBJ3"=!,6G;R=*=HW"+W:I`=V(``3K`!#SP,1@A$MIP`YEDO-JPW@)AW:@W
M$%+:IL:,>-*$=?^R#[K'`#04#5F!')VGD;-36"0@4%26`?G5-H>5!UP&1^\"
M!4BQI5MP$\U1`_R`,RPH!CK9!;8[`*!P`TY@7.<PS>G7!3ICE)@1O)<!"@#@
M@3E3B$FD*U1!#@-#,UC#V:E0BFUA%<YE"VVJ>).Q%M)'"<*7!U@0!7]P!F$Z
M`$&9JF4Y.+^!6X8F!C`V!$H@JZ;3!'U0G+XJ;`,D96,J'>5B4VW3&=V!<##(
M'7K20+Z#,3=P@TSUK'8^5?`A;0T,_X340]1#"%::R9D,XM020@90G3ZH*=5/
MF"`<C-4DTIH@4E<E+&]=G5<IXFG"D`LSA2/_8Z^&Y3].XNG[]3_40IC&T4!#
M.0!X:!9N4D)E0`\:U\)\S0`:H'QND,5MH)$Y0XEK@VQI@-B)+;*4R(DY>K$_
M@`:B4ER@D%D,\`-,0`NS@FEN;)->4`;6)Q>1LL0ZXR59(0S^QQT!D`16J08;
M)`:^50,W@>%#=S7G&=IS:!<`P`UMU$1>D$*&3`<-8XPV(5"[%A"VB0MZ=R.%
M44C/@`$+*0B8QVGJR,HE5AO>'3$=(1%]ZQ$LJO`DMA#[,*7+R!+#T@`R@`_\
ML@:/XDE0:O^C.,:D).]<CDL*#D,0JX0'OW`(N_`;6\`+%H`S&%`,TMP`"`X9
M.;(S$W`%'$@`/[$#1YL44``%1T$.^>5VFAXIP$"Y.6$EM249J^`)C7H#(D2G
M99$U\G)1\\P0&@`!6T"="$!=E-(`:8`OU,=]P)$U7I$`3L`)%,`6,U!U#*`W
M6B$+S*OUX34&'X`#9U`86$`:88H#,6`"42#EJOH;`W`IB<%E#_%H;$"KAQH7
MU6(!*I""W6$MQNI8S^#Y_,-3UF&L;1,E*I`+&]`Y05`$-;C3S';GS\K`DOG`
M'C`%UXJ9!&(@W:,@W;J$H!F:36@^&MQN<$7!%L+![6.%VP,_]2;_/R9,Z?=V
M`J5"=P=J`@-'K_>*X/[CZ0UT<,;&'5ZI^5!"`GDX`G@X`(50L"=$]EBK`GS]
M<4ASZ]H0&CK#";`B,WA]E<(.""44:0D5""QP&QL@('".:5^1$`T!`5L##34U
M"#4#$``:90T3$S86/&(#(C5BI&\V-CR5`2HJ/&\3FV(8#2(B`PP-8K`-926.
M()H@#<`5)64:1%Y?#`P:,V,*%'`#`QBD8A:P*E<VNQ006UL3%GE9I[(O8/.5
ML@43-&PU-#TZ:ST5^,E@@:`-"S8WV%1H`Y`?C7QK#M[0P68-&Q;\6+#H08.%
MD(%;VNB0,80!BP%M;K3)T(;&0I<4-#*L_T"!(S\*+H=H'/+09`4(&M691(#'
M1H,V6^3(X?%+#`\>$[HYG2`"!PX\6:@.&$%"!0D".WQ-P#`@@X@)7;K$\,/'
MA`@("8B,@0(C`84A(EJ1PE`UPZ`*--N,,F&";(-&%9PH7HR.P80M#.`LZ\%D
M`XN`7A(,(9*@`0,*AQLX@D,(FP8(97`P`QSIT9<$":S(9A`.<@72%"A$BFVE
MS`@^!+C\,7(&0X8Z79I4,>*BN9'G39K$Z$84#PD,;8;(T'&"#5$"3;H,8&?"
MPA4>%G98L$#*@@D>MN#;(&5B1[@K5U38,)''O85:`(HAQAN'*&'`@2B@L,`"
M"3;HX($0-@CAA/\0%F'AA468H:$'9GC@H0,>3.'`B`[D,&(.'*1X`!54""``
M&3#&V$$'$M1HXXT2D$&CC3IVH*,`,[HH@`]$^K#""D7Z(*2+21IYY`H'1"GE
ME$=*B00245YY999:6KGEE%-JB80.("#`1%;L7)''#GD`2$Y7M9``9RWK73&G
MFW>Z>46=>Y:7!0]9U++#"".<<<8`=90!`00EE*#!$"`LI4(>AVJ@P*5N).!$
M-=T$PX(&%&R`0`5HJ*'&#Z9N`(<@=['`!`(-T+$!'8TTD@8$7VB0@1@%%,`#
M69CPU2D+6SQE`@F[;%$#JFH$4(X-/P30JP6$,H,#)IKP`DPP"'#"``3_MU60
M1F0->%8"`\]HX$9FZ,P@UQA.H+',!.>9T@H&(V#`"UQ;X,%#`4D4`$8!M`"Z
MWGJM\,"$#&QPQ$9%/;#`$`LR%%1!10>U<='$_SS4@T$.LY&/#OG0L(8_;:3D
M1,H95--1`R%MU!$;D$J\$T8&T5!21RQ0$,P6$;>!@`UXB!&,+#Q`AH$%`5A0
ME0BP8,``#ACP@`>^`_C[3GE>J>#6M=7BP,`WQW9U'0YE$*$`#`IDI@$#6_#E
M"PO/4"`#8#<,44$#PI80KA-##+&&#(33-,D6-,!!QP^,J^I$`C-D1H0&%7Q;
M02.C/8Z-%0EH@,,$#900R=^O=1[Y`'QD88)G_^B6D0`$%)1P+08F$,`'%G[\
MT04&)0`P`@'/->?"<T9$5T53ZX6'0P(W*''R=^&)L+1Y/.QY,'UZI@?.P?+5
MEQX\9N<AH!AX]"!#$.@;D."""SY(H?L4'H@AAAJ:,<44'G:H(8DEEH@B!U%B
MD8MT%*,8X>B`!X31C#H`)`86B4E&2M*2AJ0D)SWI`%4"$P;#A"4Q<>E+&O12
M"+FS$3R8\#[BRX]7G@(G.;EI/6Z*H5?R1(*#^:>&Y7F*"K!`J#/$0`2)PA5.
M-.,J^%!J``"XE`+6=8/8,:`;HM'`%[IU.519L0;BR@U2Y/`#1G""$2#XR6L`
MT(!>%2`"/&#&-P;T"O][6*`+A5$-+-[PAE9LH5P8"`>^I)8!.!PF&340#1P`
M$XP:T`TP@)$,"-#EMV]Y88E>6%0T%``O>:GB&]\@Q?;$\),MF,("-;0A*$GP
M%*O!#`\:X0A%+,*&B3G$(1O1V,=Z@)"(W<`F(AO(X&1P`QJT80TFHP$.7.(2
M5AR%#4RP0$M`T(;+M8$!"S&)3I[8`(FIXS$&88(>\``9!,@A`'CHQ@304Y7Q
M0*6<%LB*OL;)`P*\(PM9J$37WB2WLZ1B`.$@C!]R-P(<0."1EYJ&!DJ@K'+5
MP%8W<`(-9$"#&WR!`I@8@-\J<#>*+E0&BGE-)OR&!EHY@B9>F`'GK."%<5'_
MX#8@D%=BOF"%%LQ@!AH8`'LL)RXGZ*9S&CC-`)ZPA#SD@1>_$`'?)B`@/)B@
M"FN)PA_&P@``B(``P!O><\`3'0+\8@=0-4(,EG<#])40/%V0GGE4$`![6:`5
M]P$0#TPPOH/E!Q7JZ4\IO>)3^YPB"VQ00OH:Q"`&24A]#OIK_.17!,):2$,6
MFH+^S,"_')CH?U(2X(L*B,#*XLA'/5H@!97D0"<1:8)*&M*31@NE$())3%CZ
M(`BC5-H#K#9,)SB!#BB#'@&MYUAQ8J$,50##W>9V3E=@ZY[44XO]F"!0*N##
M$P@5A1%D``!#^`($")$`&B``/ER83AF4Z(89#,&)_U!L@`82L(DTP,%4C;/5
M763:JS?\(A/+&``.6K:%,THK`E?0E[0`-HLK!"`/(RAG("^GB3NR3A4-$$?E
M$(-21L"!`K"I@&7T!H+%H6H#SFC4MQ+@!BB4A`%E\$(VO'`;50PC%O#AK0G&
M4H$$P`T#.ZB%+,@Z#S`$X%]R8`$#(E8!53KL8VP`04U8L`8A4(P)'0F93EB@
M$YV9+&4M<0E&--+C5`Z$!W)H@$[.Q`)P/9-U00E)`Q`P`3PT@`9OD$,6\/#$
M-P`*`V(3@QT@@P,1O.,75./MO9`;PUFHX$\`(D%]=G"&`(O@"A.8G0A&L`,^
M/*<+:-,`$"XU@]>4(+X51O^#2A6#T8SBLRH@4`3CT*`SR+DK`<0J@7G#^!<(
MN^NE;_/,=#--D]=880Q$*`,&!"VU`3BC#`"H0P8@T#(,G,$79Y`3#L]:YC6W
M(BTQB/98RB("X`#/"%"E*E1',)YK5V$`S$.?#'I@5.5(3X5-LZUM>0L?]]2G
M"^$0T)[$4)X<`BH+IN"/3_VK,'\$(4)^#:S`!3M8"ET(L1G:D`<:^U@`!K!%
MDZ6L92>N0`DL,$@/9-*1/CM!C2/)@E!JK6E=VR62H[9+K7VMEZXT6R:88P+'
M\EZ@\T2G__AVA;6PDUN_!Z!\_X<$3UAT%,[PW.A"0&<:8`A\2!"6#+A!B=Y-
MP[C_NO&+G"8C#2!0PQY^L($:#+($B]K"?0N``"AJ`@$#ND(!Y$"P`N07`U=(
M0A)ND:T)^+2<Y5*<J#1QT')U`P,V>,-H&GS0+';.NI]*A"+HX/5O`<!O;>`P
M%!*@*,AE0P&)J,'2YHV6`.<+`W!I0"P"$#""!0"';"TS$Q!'RXR,VR0]L$@/
M:E(1(9"L(2*#R4,>TA+"8>1B`Q'9PV2P!1V+K`(60&5+MI"%+8"&!3#3"-J9
MP.8&Z.$=#9`C5.;;`*M5Y7-V$)8(L))Z$P"HK+609YSD1("CQF`"!&#Z+U0A
M@B[4$(@9V,H.YK2#;ZGK4F,`.4`!#+%"!P:(!A6@$3>0_U`NE@H9L"RS`@(2
MDP!>P#FO46>JADCAHALA)1NQ]AF2,4AI<%->,#D9,`(FT`060!93<RW!\@UX
MX`)+X'G',A;Z(CWJ,%1=<`9I,1;9)P)]0#SQ!U5-D&UDT07>)@)#T#PG,&[E
M9@2+1CU7T`KND29/T2>$L3UG16_Y9',&0QB$T2;QP03F\V\(,G!HF"`%-UCT
M4S\=LG#\<R(J\G`#5$`P,G&6)2,7AW&?120?%UJ@U22DE4$CYT$GAUHKAR4B
M!T)(<`(;\0;NH1[#-2<DH$(O9'.^I4.V0!B@=##EH4*J(P9V<FPC@`5G@`,`
M4`:1D!U>@!0\T`0DP$-.IT10\/\%4L<I#)`!'T`Y((!U%Q9(P-`H+&`!8!`!
M28!&ZO`#9M0K`:`42O$KPD!'-Q9(?)-)9<$+EQ:!",`X!`("J+@K;R`NDK$!
MC/,#=,``(W@-0]`#(*`=FO9U?D,!H`(';7`-4.`%93!L,\`V,%`!@51G>T0?
MY;$+L%,#^0:&A`%5)/`G8C!F/^9Z0I"`/E8";*`#$[$0`4%,&#$0/*,Q"L%C
M`+$W!B$R+H,1-&!".M8&6<-ZU*<'GH$':C8!U>`O3M,R$Z`"B99_=R86[["%
MR.5G,K9T6=!^A+$#.^`'"(E4,3`H5O$-ZD$5:#,`^[<#T58%X@$!_T=)D(-J
MS,`"%6;_@+2R$[!!!!0@!B+01[9R+I`@&["1`((A44YP&X/D!*4C&S"%@5@7
M1HN"*V-4`JHP`C$`'(4Q`LOQ!WP@)RNV!$M0:+^@#B+H$@%A$M48`UTP*`U@
M%GT0'47X%515A.+Q.\2CA#>P'0QC0M$18/^!'NTA;SKD;OYQ5O[%'EU8"W^2
M!>/#'USP`EQ0B:]2$85UAFDH<&MH<//CAOL3AR4RARP"<7:8(WB8AYG%0)I5
M01*T)(`804DRB(080E]RB![T0::56B2G`W!0`UI3'K<U5O-TB3,T<S+6%=:S
M'I)(#@)B`S?V221`BEB`!:BHB@_U3Y-@`U[!0SB@-IBB*6D@_SOS!0!`0`27
MDX";D"UX5`-,(##'&`"/\0-S$`$%8`J?Q'90(0R!]`8_\`:9L`%T!#H94`('
M%1F#I'<(@!C/I0$-\`8C&&J-$Z,CF"M>`"E"E@;O*"[0)(^%0`,46!?5\$^7
M]P5^Y`UB8!^:M#L!=AO7)`:D-&.T4`F^XI5()C,7,6X!(3(140*[QU`)2`,Z
MH&,]`$UH8!*M)#,:`3<V8Q);4`&8T``10P/LP#H-D!7!8`-J=A0-@!5;@`-M
M(`*\54XW61CZ$B@V]">R0`MX(B?N5F_NH9!RDF*UT`>526C?P&U;T9!F80(!
M%IA@\199"0,B-@/!4`V'88"+X$NPD?\K$,`7QX`&<(`N(P@;'CA0^Q(3C8!1
M#F67F0$W\Q>,L@--F#`!?!`#GN<'3)<6TDH*ZI`6(Y`6(@!-@&&F&$4#T"14
M:5$89RD"51`=V$:$FDD`TR$"T`&%<+$&3<@&Y=8$J*EG$V`?A/%6:]6%\7E;
M5*A6]B(@N,4%7G%69"@#!@*<P8D@PSDA\W-P;@B'C:6<DM6<=_B<E:59'2=:
M30*(0M*QI.6'(G=:W=DEWZE:)J=R6#(2!!$+[&$"\:EL,11*\9%;\($?[18.
M4*$>U;-6,(<?]6(!A38"41`&(N`Z@8,.H0`'^4$"Q#$`DG8I]Q@[&;"B:7,I
M,<$"['`?LU#_/0'P`B\@=U11CB6:K35`1W1$%@)R#%U7GN7X!B"`E5\``CQV
M.:+61:P2%Q7`!!4`*>R(&X#Q.`D0"<%``^8U+E0&"1'691HP!E;P&NY"!).6
M`'2[#/A"*(0B/43U%%IJ>O6`,,,0`)[1$+_W$KM'3!TQ,_G`$:T'$&W`:A+3
MJMXZ`,7'`,N@#I@P>H6Z-'Q!.[_"?4U3%I_S*U.#J"3@!T89?S<W<YQ)`'U0
M!=`+O;4#3\L;:)3Y%8)VEADP`23@7'QC3A;0?J%SM90V`VX`%.B2";!JD10X
MN%\``)B@@50V!+QJ!3`5#&=Y#(-$`0[%4CGU3$BQ:'[0!82B%EB5_U7!$W32
MXW4)2%$C<0,1$3?8*@*#%%LRT(2[I`-V>JU_4&CY-P%5E6W@057'4VU9-0)P
MT3P,\P8F\&AY@3#LL!\V5ZD[D!]`*P:5*9_J&5SJP3750R?'L@./<0)FJ#[L
ML[`-:P`78E@0&[$D\C\.MR+,25D]@K$W,B,ULH<=P'$0U+%`TG$BNW%%HIVE
MY9WBR4%FC(AHS`8H^J0$8`[A0'.\E9HI1DK%E1^OB9[HZ8G#0`ZUX`<C\`18
MX`(C@+3?)8]E4`$V8"=&L`3@-FEK,P.#6P9U4`<`\`&3M@W$(@O':'HV\`T!
M8&.[D`O+H@9E-P!G6T>],#2\\W7^R`F:`/\'6#D#-'!F%``"9/L#-?`9N4++
M3,!DBD0::2`NKY$KG6$9)S5(XD+,A[=A8R#)XQ4-0``$7L`S53IZ]?`4`8M6
M3PH.5!%]+0%E4088/),1-&`9/<8S0/&FOJ01)T6G$MDOGE$#@&(4^'1CA?K"
MZ?04<&86IA!4X[2%8B!#ZA=HV5:41ED[\2?'?38+M#`G5MD6.R"NWK`#`U`&
M#"`]]_)^(M`&_\2/D4,$0Y"KQU`#LH*`]$N!5J`!9#1@#1P0]+L;D30*^L)(
M8!<)TL4HV0H!\O547T$8>O%N:J&8,TC!5+90%;`&$$P#TD/`0J5I(T$X4JT#
M&IS1:N'!.("$12C_PD48'7WP"WYPPAFPA$VH`PB@T.+!#K)9#ER3'CWL0N3@
MUD9I'C!T!7;UB7MB"_ZQ`_#&!'D5(>L3<&@XG!;BL!G2Q(S%<"G"`<LI61%W
MAQ=KQ9>UATO"A]2YL9LU6MDYB(EXB"2KQN#)G6/2`QO``X+VK[X%0RXDLW&=
MQ^^1;_1V"F<%#[5``&<@R"[P!$@K7?+X-@@`2D80!6]AH#```Y/#TL`V22--
M+*^PR'",MK&P"[M0`A:F"6^P"714+D.S!:IV4F`$C#]Q#4#1$HLS*[F:I&UY
MRSW#"%(GEX3`.:&P!2;**!\E=73YO_[GN,,,"9*K-C-``099#[#P<NL4_S>9
M1%0VR`SRQ1*+@A.7X942>3&LVTIA1`-UZJT&$3-!<13]@I(-(`?7)V8\8`<6
M(%_%PA09D-7']6=-`#K2`Q^JXTYV\&<SSKP'0P#N1I72J[R^Y=!=&ZE`K@+Q
MUP<DP*D[N&CZPC=AA1KC017<JP)P%F*7HJI;63F7=H"D$3BV%@K2(P(H)8*E
MTSGP"W.$0196X8*71`K4UI0"0HT:44T9C0$QH%2'<AM4)M6$0P'Y1\"8`)9H
M\'LRL$L44&<3$`.%UI0CS-5$2`#<%@-.:P1=P`!+J`1W\]O@$1;3PP[H<0K!
MQ84J9,.<:%?XX6[T]HE^K&+L<0;O088Z$`0HH/\^1BS8@QT_&&+8;GA8B7TB
M4"S%RRDD=EC%DCW9&NLBT^D#,T(D#!2(?BBR$,39JI7&9CQR&G0ELD5;LFES
M<`T@O35#P/6:0FP>>`QSVKQBIQ`G,;`$1:O;4L3;G5,"2V,[/T0!,[`V;-,V
M`)"*P*8VA5`N=W2G&@TM]S(,(E`""+`!VFWP8P8K\[P%JBAA9!LZ\D@$G!$0
MMRPOJS)16)E30X`&:^H(3K!JI+$;`(`#ZU`#`Z]J[7U3$!`,SR!2A_L%D@O)
M0Y`)`C(6FE3S-7^#OU"U\R4VYS)E$DA+&Q'A&M&1&%E\+P,T0_$&JR<T((Y*
M#/`&X'29^`05N0@U::3_"F0>';F%B6Z2!4UP7%`U:!,MQ!.]'O`$]DW0XS]>
M2KE,MJ!$JE5``&$E7U1SFSOP#*,@/3\-9U@YY9D1.83TE:PVJVUI%KS0`("1
M!C85YJDA/9=K*)IT\Z9``I?);=?B"[[&`-[*`!Y=`BQP!E'@K'^DS'@.&,2F
M+YA0\(US&4X0`@[U.B+@0X5VC8F>;55UF@.`A,^A70D0!(3SV\43%B,P/OCQ
MB6"HL_C1VGM=P[PED&.E0M=#.[;`!`<K(0HBZTC,A@]KG,<IAQ3KV+^.Q<%^
MQ91-[)T56LCN0%V\[!'4Q:/UV=#NG>%IQM6^`<DD#C>W[2X$"%<D/!:%A28F
M_Q8V*BH\B!:$B(D\*B1_2TMA2QD:7U]#$`D:$`UB)G]G(R4S"C`P"C-#&1DX
M)65$"AHL(`P5<`PE)1DE#1L_"`T-;V\-<'"^#2`@#=`5#`D-6PD5&]T((,YI
M7QJBV\`@:,[2<.*B7FW=+&F^ZQ44`!JC-3PV`388P!@(%#B@`88&MC00H?`,
M`A$@0!YZ85!*C(4L60(4""!&!`,<LVCA*)A,1`T$`U@@DT9C5TL:#+94L,:`
M18,V++9LP;.%P1LF/-X,&,`C``\,;1K8R#*!088&A$1D8""&HP@1$XIF242"
M@`D2*@($8,2(A`5).TSLV!&CBEM$!`@TP<B(AUVC=O_Y7;%KH^^/OX#_JE'S
M8_#@OV)(F!@P@D"7$2.N[A"#`<..";,F3!!Q>83F`1D2`%$`*\$,+Q585&A0
M`UP:"@EBBX(@(@^?/#M`9X``8=A(@UV"QXABA(2@"94-8A"Q/(.(!@,$JIXY
M4X8,)S>^,,#0100<.N#345]SHP*$,@:?%OZ[`03L%E]N]!9Q)D8J$3A$F&@2
MEX`1N?S)U<4`&/AG1`P#E)&`#"?(T(,%1C2QPU5B6*3"%1:=]<A>>RF62"*"
M6)"A&)I9P.$55QA28EDVX($'"TH8@,*,*"Q`XXTXTFC`CCSN6,2/0/YHQI!$
M$NF``SEPP,$!!RQ)!14"1"G_`!E44BE!!QU(H.6566[9Y99@:HGEF%)V((`/
M:*:Y@@]8GADEFF>FZ<.:;Z*YPITK,*DG$GSVZ>>?@.HIJ*!],HG$`7SJH`,;
M/=A@5Q8D<,$%68P4<B$)F%9RR*:-3,+#%2J(^$BH:6'*!R9AA($#``E\,H0H
M0PQ@2A_V,:`!::YX00%!^(E&1`4@T%!"#73,Q```PVY00P,4(2!"&DY\U\U?
MO"2D`0@(0%`!'6B`8%X)SWS1JA<:]`(L.W"T!D<)GN3#P$DU1#<`.-:4@`\`
MLHIH$65;G(0``F_T19E396A`P4P4>/'0:1,A8)0-^HK!+"T#/#=!A3:\(<8;
M.M4@_]"R%="`$PN]L)`3"P-LT<._,0'%@\=BR"&'&-%598%4#$R0!08XY(?1
M8QA`\FA18HE5"0&8\K`5(FO%X+33DI@`(*5U-9)77GWY%5AAAG6]]7H3%'(5
M'\'UX<=:^.&`P02V/+?V"%T0<'-H;I#FAA>GS</``,Y4\%H"K`*N]@Y=G''?
M55<9)(8-)`IG'W+0"43#Y!"T\1&!T45#;W76W0#X`-T-4,.T[54@PQ!>B`L`
M<^H=TUH%7U@!@Q4W4)#!`!/4E\I(.S3QGW\`RD5`#"(TYI\?(D`PQ`DZR+!3
M?U<9$H`%%YM0H8DH7IB6B!:0=<5E.X@X@0DH@GH6]6%3*O\B'CVPL(:,,N*X
M@(TXQM]CCT$"6>3^'AR90Y),4M*3H!2E*I$A2U@"TY?$E$`O?6E,9&H3FLPD
M)RE)24YPFI,/XF0G/`T*48`*H9\^2$(^[4E/BD*"#M[`ERPP0E)DL12FC-.(
M\YW%0H182_<^98+QQ3!L)#`"JL*0($^XBAQ4L0T6SC```(P&!E!(``TJ4+'(
M#4$!%&@?!$#P@PW0H085*`$#I`&[-,3K"W`PAF!^@`;8R:8"6RA!&L#C-SBX
M1ERFT<"YUK$.=HA+'P'CP00&,!*2"42,!!+#9<9WA0#((2\1JPQ^(/"!!%#@
M;PO#&REJH!G-4&86RNB+6.QB`>C_;`$@'XD)LTRFDYH`C`G,0H#,F)`2)OB#
M9R*`!,\(E"+\8"54GG0A(\8R3&+R!6)K:=H$NL"6M$AMAE2CU-6.R8^O=<UK
M7[/F#THT@@&0;01\P)0)I(*#L-D*!PU`S@@0T1U;X,(-=SM-2P8"$MZ4`0*(
M-`AD#!>#/IRE,@?120,0!QD1I$0UDZ.!#-9``0@TE")#V0*W0*"#F33("1A-
M@-JB,SHOT@$.3GB5%V)3+H`4`XP($Y<59I"`W@R`GV?``"WB]KNX-.&F_"&>
M"/A@H!&$Q@D-`@$>A!<9BQ2%1(C`X5XTM*'L$<*3FS*1BC`@AK)4(@_6PP,;
M9!`$'N5H_W[UF]']#``DL@II?T4ZDEJ3I"0G#=""58(@!+W$0`@>4*YX;1.9
MTF3!.E50@QC$4YX&)<(1&@J$AR*AH49HPL4B`00;X,L,)Z4I"X"E+(Y(A`V%
M]HA"["54DS"$!?R#B2B$000*@L`1$T`5"_!AB2*HPT-<D0`G!*,@(M@""[PP
M!`34H`T56,]?$/`,=A'A"S5@P1?0`)CVA.,+EQQ""60"AQ]X"P3<\J,5K&`P
MF\S$CM)H1@D2\`$`L*`OA2#106K`7H`%K)&"P%0>,E:A&AS$H"7`P4<R\`'4
M^.T+>!,7$8:PA4#>A689P(#`*+,VGCFG)RG;`@*V(`(\,($);__8FPT*P(.>
M-``/!9A`SZ!B`4+BSBHBZ`(DSI>1HA&34DTPBP76HIG@L*4+,4@+TC)%%DI0
M[5-9RR;7N'88P6!3R%^;P`@L@`%OQ@!NA.O"<@@T2'R1""LF\(Q,3:,`>$)A
M!C/0EGX-NK>A%&1?$XC!'_S@M`F`S&]I$%GE"(3C$=1$&CHX@9ZM(X,;:&`(
MR6@6>#:`!H3R=@@:4)M4[!@R)[Q&(3.(3P*>$AWJS,0)%%`I.6X'TS.`Q'C]
M$9Y<%',5/QCA/UT(S0T:Q`(\[(<`D0G:],*&B$\5)47;2P0CRC=CM:0/0Z8H
MA&9,T(CXYN'8X6,"&V*THZ^"-4=C+8+_C_2'5B.I%4EM=5(%I42EO([)@=\&
MMUP%$,$V71!.%OSKG0(KV,%^L+"-1>R?"!5">JL0LDS(0O>D60CC@"5%F@41
M4TU`2O+%T!2Z[HH0GY`)U`)`M4-`M`:&Y5HL+$$JLU6`%^0#`088-!D1[U<O
M-G`8PA"77:VJP1:6^Y>/,B`<%(CY$!C@V^](([OL\%4"B)$,Z%0L.@QH*`30
MB9QAVZ"1/]A(UJ[`N&4:+C*L47DSHH-(8&C`"YC&XR6_L!`$..J&)&(`;3K9
MR0HAIT+/R0N%\2`S,0AD`M-+'@[$T.&>B8`0R\$`L:?W%1*X^.^4R()7V!(#
MLJ]%$G&16A.B_UF7JY5/R-<LLF&0O+5N6+Z+@.D(]0:PEH+FIPM%[T@9<@89
M$Z2"!#*%@`9&TV4PSWPD%R/1!"C\89Y@`#*X?\XSH`6MB,\\G55X%G44I><&
M70=U+.!9,;JX@?;1X`9W\\('$BP57U!``S>`5@*\,`8K;)_Z()G'I?^HD$33
MYVE,K$,#%-Z?FXZ:``:-@8&Z@(,$W"#/*I&:8Q@#L6&#Z%.D<GB84CYFD1;;
M8R)/-3[(@3V4<!8D@!M@(0=,H`-!(&W.]FPW,E8\4@1F("34EE;7QE9*PB1K
MLD%PY6WA5E=A(F[C1FYF0FX<A&X8="8E&(/M=B<E5%B.E5B*%2@[B/\$S(,M
M^29,F>)9@W`A(&(*/C9CX=.`P<8(-F`]%E()I\)P8>!3`.`)H'!U;5`#9X$*
M/O4!0/`*+3`$PI(?`M$`L,$:?K,!>T`8[+$N:3!>$I8&D.5;S0!S#9443&`#
MSO`OZE(!G``$K%405&4#6S`4SY$,_>)U$),U1?,#&K,L)5$0$X`VX,)>FN@M
M!&%U1%`[PA)S-V`%N0!'6]!)%L`,^8%>=J$"=C!*40$5!6`##8!.&<$S:D,(
M`]`&N(-W:P,6/'!983%,,00QZ25[G71XB8`1E#`61H,TE`*+U01YUT1DE/<U
MEI>-VJA&DIA+--,%?N!YG'%LB=``]U0\.Q#_CC$P3AD`&[C096Y`!*PU$A5"
M&0,U`*E1`6,&>F<`'9IC.M=Q`YA6.>DT`&G@#'"`!FC0/"S@!/;'=0S@4P,0
M'F2$.G<#.&4P%.!2`:TR?@FP7=R5,SPC1VD`+9DF"D1`!&50/&>0CCN0?CL5
M:L$38[`&.KYC!/0W!#=@'17P('*!($$C>^%S(J*B%MU#@!IB"B@B6CUT=L66
M(H6`&WGP`HW`!#W`54%P@?-#/V*E@1X8)%.`5B$(0(-")U'2`=V&@N&6@@N$
M@F5REG[E5QB$;G+9;CD(;X7R;CIH*#F06$!X`FP0670Q@%,(<"9B/>%3%^=S
M(3.F2)!0*;IV-$OP_P1/$`:>!@!EX`FAX`6D\(5+,`(XL'JO$$4PD1^94P)>
MP`(;L"YT`(?#90]_HQ31X$7L!0[L$'.L]08<!D::$SF[`0$#@`"A]P;V%3!+
M)Q8%D)SH4QGLI1-;<(\CMCA-P1#@(`WKX!1[$YH*4![VT"JQL5(J@0?\<'3_
M,!**0'=V4$RWI%]P1S/`:0$!T!0$8A=%IPA%413%5!:80@""MQ;<T6!K4SU"
M\W<$^C".<C742&35>(V!L8T.JHV`\08BL#C%0S;!,0(MN1S,@5KH,5J0T0?=
M@0.A\(ZDH7%M,`N+"!H=%S+*XQS^R3?)\`S7@5'6X9"X8Y#810<_P`1H,/\Y
M0W`:,P`$)>!3)>`+,R$/J$,$(P4``("&[/(%!PD')[E2,X`>:H$?<G223(H/
MM+$<(]`TW=2DO0,\."5J/(,!-XD@$+"32N`@H]4$P3<"9A<VH,)T-X0(PKA4
M4>-C*7(QU.,9^)DB%G$95T!9/,`$"+!L09"5-[*56YF!T?:50!*6^S.62U*6
M&V2"9%`F:MDE"Q0F#=2IYK9!+RB7<2*7'>1!/8B7/$A8];8GC<4G)\`";'!A
MK6@6Z6,6`D<^Y\,A3+EB4\@X'T(`7!`%E!D&",*DG["9@&8*6!`%3.1$I`$%
MND(!)6!FS$($#-`>%,!%$<HLP8!/68$,_F*=`U#_`N>Q.@$`!@5P#$.A')5Q
M,?V0=U=1`S;P`_ZP#,N`,?_`'-$!`II(B<^P-\R!$`SQ#/3P#';'+`DP!I9$
M`Z'@"4X`8"IQ,60'$$_!8/!)3$;A4^C$#WD'GSQP/48A32^VGP1PB82S3,L$
M>GHW/A?1BD;S=QN!%W8A!W^Q#-E$&$4F7`S:7`\:M$'[%\QA`V,3'(F7&[10
M&1FPDH3SI3O@&0.0:21*&C.P*]=J$`T@#DY0HYA6`L_A$3,A1Z;3M==!`PY9
M3@,``=]!!]9)`S_*,%4J%45J1[OW*C/0?1JPDH/D4"59DJKUD3/P`2LI?\A#
M==9*L,Q!.$-1'T\F`@"0_P%=X#LVY7[\00(#,@(W^0?)LR!(`$>NQA\40B+[
MMI2/D)@7$B+.=)1UBCZR9Q%+A68F0I6@]08(H`-KT%6-ZJA<V97X,ZE`X@'"
MZP$@Z#]D>:DK\"3KUE<N**J?RB6A*JJ<FFXRF*ES:9>*]8,\.&\DZ&[RII=^
MR3P]L`&.0BH6H:OI16R:,H4)^)@\<!F.`I67:`)<X`*4&0?$4P99Z"HCQ0+.
M"JVH]40PL'$4,!+OR@!$4`+?L$6N25Q^TU!PL&$_0(D`"P+GNAM@^P81``9@
MH`97P!PFXF*-%`"[=#O+\"\(<!#),!2WAQ6#-"_6&</F409/X3$'BUW&0`?!
M</\[^`$`7W9)[3`N":P3,.LH'>$<<:=@'&L5:U,4$'-913.,F%4(!K@VP<$=
M11<^>&H!Z4D6Z5DT>3%*`8!DTQ)Y#"JT:)S&#OH7!G$%R_%-?<>.Y<0V&D`@
M7XJY73!.YU&U"K`0,\$:"."V,UJCL)$4,K$:#8`&7L0"-+`&K\)U$-`=V@(.
MP>`WIC$#2FH%*REV!Z.0[!!QIC$&&B"Y)E"+\Y`&H<"DHA"YBG@&<;$#`+4V
M.X`T>4`KA(0!3G,0=2"YE%NY_4$"""("I^8"1C`";?`%0.4\H0M_+FQP-?0(
MG@*,9Z%#N\9#%N&4AS`B$^`HBZ`"N,$'%L`^+*"[-<+_NX^J(UV9/QU8!%,P
MO,0[)->&)"*X),E[)U1@@LQ[EL[;EG)55_I<JB[85W0YT&HB6-GKJK'*O0>`
M@X1UE["J`R`0,"J0!9.A(8<PE(V@2(G)0V%#2DB%@,B4!UQ@!/?[!R.@OZZ"
M.JPU/G\0!1?G$*TPP#>`2`?\`1"P+!"`!H=!G+^`KELD!QW\`\P"P\T0#0C`
M`P4`!G;PBF+0!5=0`$DP/9-Q,7G09"@*L`BP`;[5&BM\RU?0%,U`#Q7\#`D@
MCPV```PP!)!%.B"`KLA",F7@!E?[:!^Y741``PB0;UDC(@T`G`$C!B.@=]!H
M57<A%DM-E?QP>)?Q-MQQH9H1_S[=\YAB3!:P>*#3^+.8C7EJO-F</2T_<!!?
M+0)^\!B%$]@:NC;'PGE\P`?V404[('9EX`6L!P50<%QI\'+$$AZFP\@"^2HY
M,0\(P'QTP`*>XP4C906KL[9&6I(5X)`?2:U0L)+)0YUWJU*#BP-QLQF'=!Z]
M(4<$\KC%XP=Q$0.-W06N'0/!@1\8BMZX.+F_4Z8[EAO";`3$/`(4H),R0`.E
M\&J1X:>\9CT;,@@%=WB4`"J$4(\ETDBN2SV0@!'ZAAM88`)98)4GT&SF?,YB
MI2/J[`%%X,["&\_&>ZEZDKQ/DL]]M<\/Y+PF3KUPR5<QF*K>>]![Z:KV!JM]
M,H*(,O\37F<7/=19`J?%&4)P,91KA_!_D4!:#&>L&;"_$9</TW4*41`%JO".
MLY-]`[$W%$"(R5`"(#`8MDL-Z/H4&P8&$1`!M&BO1X<B/]`/'!8JE;$X5Y`$
MS%"PK%&+SO$QRH(M6LU>"%$&P876+X?#?X$&<L1UVHH`+,"VW0("J"Q'9?`!
MQ+"+1``%-P`3L`&2L0`"\>I)1XP55+5+74`U,QL`N(H(RP09P1$<C^T5<A/&
M8NQB');9LM[9M%[KV0@8-2`"-K`93@,9A*0?]7@S36K%+6D"5JUZN``#]B>/
M1IJCX`$")G,ZKU(N6V`YZ,`.,E`!-V#<WEDNYVJM1MIGL;/_75X0W4,Q%=*`
MRH%K!40PRI_W!R;0'5<!4/.[`Q;W!`:58I0Q%"5SI!/#'+U.2.YM(`'2'WU@
M4%5P:D;@:3H)A#J``$/5!`,2-'L1"9)@(F7!5&D!*JE[/L,FJ.D%516O-*6B
M:WJ@;&M`(Q>.X;X;)$3BX2!NO&PE*'CR)BN0SRA85Y^*XBU(0?CL\_@<]-@;
MXX>EO;!Z]/1F;WS"5K(JOBX#V499%N`#%@58NDQ(/@>N5(BP<$^@Y%F8`/<D
M"A2P!6+P!RY@K`.0[%#T!<&@7\"0`,H.!QX!!P"CPG#`PD_-P6#`$7`W!Q$P
MBT=7(6+AQLQA7X7Q!G^XYU+Z+B13_P/H0@>^E>ZF,00]L`4.A09,$!CN`1MX
MTP;(P+;T@LK"\@4V#1T9@#<RH`-3JP%Y.P8P$`(ZX*=W00(&M0_/68MJPYC"
M&!9,5CR@YVMA,UJ[WP2O^.H<)A:R?L;9F-7+C\*V_OQ#:PP;,``BDF)_\!@&
M%93QBEH)-FPJH&23))K*?@,L93*!#A[990][FP\TT!/H]`P4T+6CN%T?F0`Y
M`3O4V=S9@>F<"0@##0.$`QD`9749$!`,&%TB`T]11D9=(S$Q$U5-?#%+3Z%/
MD0T-+!4T,B=.3C(R3A0#CS$C`S@CE;D$NP1&3021794N9SAE0R?)&WB<D`T6
M5R0$)CLF%O\6/%=7*E?4U!8DVMS?$QAB/`'=$V(6Y>?<*A8F\R99/#97`28B
M12C^"P`#!O3GSX!!@T423IEBQHP'APXB2HR8HV)%#@<R9ERQPH</CCX$B!S9
MH:1)DQ)2JERYLD/*DS!CEAQ)DJ;-D1\/<-RI<2,2)!I_"@T*-.//GD5['D@J
MM.E/'3V8!+C&@QJ/>"1(5%/!M=T.$N#B[;"@XIZ8==!49#7R9,23,$L.??E2
M!D("+T,:B.GC(LJ9`1H4P(`!)4&)PPQP0"`"PTH%$2QJU,`P`<&;R_@*%``#
MAD>Y*YHCV!#1X(T8,5=L3!!Q6M"/#340_'CSXT<-!HVV-*A0(4W_!1"Q$0PX
MG&!&`A!;VJ2ATX,.'3B^&0SQDB`!!!8#(,`!P9MWFA(0-&@7@4.#FQLT#A$9
M`V6,@@1L;,AO-V$'!A$BWGC&3WE"`Q%=D,"5'5F(D`%K-J@00`!<,<@#.@P&
M`&$`<O!0VX489JCAAJ]MX"$"((;H7(@DDNCAB2BFJ.**++;HX6NO#<`.@'^,
MT$4F]ADR0!<89)`!!B3,LX.-Q901V&#&>:$!`RR4\)MDSE4P1`(:#&'D=0PP
M``<<W3EQ5W7%E2'"%@R4D<:6O<V5@!5$6)=!`^6,(`(#A8B``09;B#%/+0.,
ML`0?&`Q`6BG_"3K"H3'\Q4`#((!PRBJL_\A``P0X`'B)(;CL4DDOTOA"0"W"
M&$&,,4/(H(0,RYC01`SX01.D/&.5I<T5\GBS33BT5G.6&/)I<]8$P)Z&&JW?
M7*.@#?>T<T(0!`DD$$$H'(100M0V!-%$$UG$`48:[=111S>))!-,+)4DP;CC
MVC13N.R.Y"U/2BDU%%'Q&C5OO4X!I2\2;/0P'PD\U`KP@_,$3,\U`H)ES37R
MG$865P2`,DD4.``P%P!V?9``"V+P$85?`P`@&&$)4$`!!#X"0`00,]``60W(
M:E;`/9?E`T8`Y5A&FQH(5/J&#:<%BH$-#3``7`5P(+!!B`U0H`$`+#30!@5P
M;%";&C\T4(+31/]XP0("#%#0*'<04-#;EPGD1:9OOO56`05?B`='`S@D\)X,
MNR4PQMX*M"##G5L$:\)J!R)[9SD&9C!"%ERIT*.,"T8N8382+LCAY9AW>"*(
M2XOHW.<@@DXB'9QOKK2+J*?.XFLB3&"!"",0T$6`#TZ@HPEB&-/`G;-/0,($
MBB7`V&#4+5GTD['50(,&8%(Y!`MS=L>;E]5]064;@S+@9`4E6%^=!N(9<V#K
M@P,[01>N9X''#F<<VI:=&)C"0-O@E0`[!F?<AT$-(&S)I2LTX(UU8'>I.HC`
M")K*!0)]T00,W*(245C"`(ZABA/T``^JV@%^\F"#:LPC+;CZ8#6V<:O_;]A'
M#!*:#SO*80*S6,.#L;H'K:XA!C;(`%HH<-8"<!BM@U`K(0ZY%K8H<A&E>"LD
M[1(7NLQUKI@T<8DT65<':I)$D7SD7?6B%U*8DA2BW,N+^7H*&RP#CJQ\`QX6
MV$$UH$&LL%1%C1;`!]!<)R`N1"$440A#R"X&@2]01T8DP()?1%`&!8S,.`#`
M&`3*X`4@$*$-V`&!#0*@&1Z8YC(HQ!EE:E`"$&!-,I:QP1MJ@!_+[*8!:3@3
M<&I@"NYI8`:\@4`%K.:AYZ0I`=:C`0@FU3\T;:E[X!//%M[``EE"AP*^H0``
M/@"`QU1L!C=@`70T``2^08$&YD#6@E1@.UD$_TX^IUE-GRS`H`)E``$RF]P]
M,L?.#9EN=)^+ISQ'5*(/G>Z=JLMG/FM3"AO(279=X(.01H`#'*`O`V*JCS6D
M,8)%#&$&@X%!VC0`20;\!@UT0`,<*&`%ZUG!"EX0V_'0E`:[?$\#91B`^3"`
MFY.5H2X^JA0ARU!0#&3!`F>YSYBVL(41G.$,3UC"$B(!@HQ60`:\H<')*`4G
M_$BF45PZ*@T"N+PR-.!&@4II%7;A`@7VPA==Z!,$APJ!4B5C"PC8:A7DQ(YJ
MQ.H*V<B5K1HGUQT$BP<O"!@[RL>KU)R%&F.YBGSTBCLFL&$-`/F'LWCHPQ].
MX2$>\,`0)7*1;?4$)/_@JJ(`EKC$E[@$BB91U[J2>$4L9K&+]M*BO+X(QC#J
MH%]ES(H\$@:6^EPE'O5AXQ7L:H)\\.`LL>("%O`8!A$``)>*9!X#?&>$04+`
MD#!0@!MF`+XR()2:1&A$!1I0`YYV%P,Z>T,[[$1,"-0`-N=%[R@)M8$&!!`.
M='C1!BJ@G"\0`9;%K``:T$`VLZ7!>GX4&W2XI,K^@:<X&J`!6K56`NVQ#0(`
M0*D@LC.#D(('NVY0`!0H$+AP`HN@`T#`:M81+)R:0$#Q(,0/(A"`VESF,NV\
MG(L0,,]XUJ#&\JSGBDJGSQZOSFK_N<)]_'`).=UO=\`:@`&%I,;9&0("7AC_
M3&&&D-U3_":C7+H!+M=D!0V48'?1Z\V!@PF``\5@=O<A!'Y(0YD=Y"$&BXB$
M+!`W@"Q5@`$T8(`(?@H*$6QGOSJ`PPG^1X,I.2(2L3D1"%QQ@R'<P+YB0C,A
M<1"#!.JB$DVPW0'[$@4##6$-KD!.I3^ETEJ5,1H*\X9NP0)#&F)#'O)P71M_
M6Y^Q9&4;-FB8-?2``!;<0+&+A59CB["0QT8VLI,E8A$OF]EPA;:S*'%BN3@[
M1761%B?OXD@6\<7%H-@+M4=92KXXL"\=Z""V`IIMPF`=#6]8@RNLAD:MJB$@
M/H1B"6$8P7'I4E8O>*$-6R!!<\_0@`Q`UY!$>!K*_S(0F#8QJ0*G:'"#02`;
M&R"`-&(@)@M`T(#M`*?.'(>#]GH]A*I="#;<LXL&O'`F9$*5-[_TZ`PH@(#;
M(,WCT&&$\"`@2?DX$`(-UIZ/2B`+@D)@!BWCCGV)X(8,;VQ,:"&!&"8X@%S?
M!P>RV"97?HN#!JBA`!8_48=B//86A8YT:)?,C7%,.A&5*$0^CKL^8;2%`5QA
M-9F0DRU$8((\U(J019^=&DG0H_!$MS`WF$%>LE14[OQWRW=):7U8M35&?.&X
M9:``G0AXHWGDM!SK^)4Q8$<*J*;RJ+#(P(XNU0#^-NH4.C@!`"DZ"`;(YD)T
MD`$%T&8%`*S^$C[JPE<WI?^+)FA0!#&(X%`SX.A0;T'X3:@%6L`15X,!-F'1
M2*.0'I9&M`P.&_>@Q@3$WT(V6O\:-LA"%A!0@2#H<"`%F99"%H)L!QR;L@ZP
MB+:8W>R;4-LE+/%$TB:`4*1$[>(1V)9M.K$".K%M6_1M31$OX19&JX4$9)$5
M\'9&LB4D)Q8DL<(-:;1&N?(5!-`^;S$"1O)2?>1O$-``)O`'6+`$&%`"0``$
M@J$`>$$!1"<=*Z,!2$,#\/4V)5`&G;0!;W!Q(49,-^<<5L-^AV$7$$`'(%!R
M&\!?T.$DC^='UQ%`O00"_/4VWI-@/#4`O]%+=Z9,X,,`;T`K9S$(@D(HDG$:
M!%7_`EXP!D[@2BO#,E`P!#7P,P^2#:]3%ULP%8$B"[F"#0$@!AE0`6H@!PC0
M`%9S<K718W#W=O!$!U#"=O1DB7`G=Y[H(C!2`P.`4\CG!X=R!G9B'[!C.S2%
M`=5``!:0!<!0!X8G&-3A!@F@/8O2/VD`-\Q#)1J``ZZ(9@R0`8>!&'`0&V*`
M`9A0!9G0=SI5"-HS)V)2"SB0C%A6`;&G>PF04I?BA<RQ`=P!!S*0`#?@-"V8
M&&^`-:^Q2\7A!>>8`+XW.\"G.)8V?+O@!Y%P!J"P?.9H;APW`GS0!&%E#J>F
M#0U#;R24:A\D#E41++)V%0$#+&OT02I@`_1@#0]"`@%@_P,](`/OEU@$(2WS
M1W^2=7_YIW_:PBT;D1$A\1'.QED!Z%D#&&V@-5HW@8!6E&T,Z"T.J&T3&&Y&
MX8#Z<EH_44:-HQ8?Q`,`TWW<!T<"H@X[<%N#8P($0`M/$`<]@E)]%!YXP0([
MP`=8@`7%0$V&A(MID"6E\#9$0`1I``*I9#50=1C)Z"@M"#940P=7HP;B.&8)
ML!W:(8YI<(=;\GA4D@:LM'&-8H5@:`4S`'!X<!J[85':@P.+T`@-@`#"$D?R
M`4XD1AFHR`"!43(TD`;"HP!(MS'=93YV57!?EB<3<"AW0@@80$X6D`%I\`,%
M\`:1.(F<2&._&9R>(T]K%T\T-O]/EOB)ROEC/R`<>@(@?#`[8$$`#E0I]N$C
M_:$)$\`J&;![AJ1A,P`$N9@E%M6+)O4%C$!T/O4$9X!F@+,%=Y)3AS*?_%%[
M;;`U0S`$-``>=D(G->!Z:()Z7E(&A[(H*((&W*-EN.0%+3@GLJ%1Y.@ECME1
M\C@`[7,)#&!`?C!\"H1`?1`);N$6!F*.KA`U(N`'JR(+2`F(''AK<$4/@;4-
M90$KP*);95$^KJ-7[%`K&ED67``PAH58.Q1L\2=_Q\80DI4M*:E_EL5_5X1$
MHG42-#F3-$DNG*5$,5%%'L&3"M@M1(E:#KA%0KE%L964"D,6`2,PJ?:!0<(.
MVN`-GN#_%G%0EACS!5/RE6)``"Y`EB%C@VX@47FV*(2R&,O!`A1`!VJ`-1M`
M!UIS9R4``+;'`%^`!B?'/SEG,K*D-2"P`5S2>+UA4F40&47#*&/#)8^:<"R@
M'[E6`RQ`)_]!*&@U'V61#?A@&O$C9X50-PI0*J69`"RC-RW3`'E"%4*F>CG5
M'[%94"*`#5F``Q2@FQBR-)B8B9OX=IUCK?9TB<Y1G*)SB=BZG.`J7\U9:H<2
MG6<`,+^S=]<I)H_0!?2V`Y9I-R/C!D!`4>1IF2B#&,)Z)_SX,9IP%KJQ9G."
M=;#C4Z77/TG%"EKF>W4W`!FU7U^("C?@)1I@)TX"H)_J;UN6_U+DP2B]X0I.
MX%%64!V^=Z&U0%.5UJ&Z\"DRU2<C:HYK0`/8,0%-4`5V(@X@""N]%0XWJD8*
M*:/S-A8XJWT^&T?$L@ZX<V)E00)<\*,\@`>^-A#/4J338FS&ABU,R@&5Q9(+
M>$0Q*:5/1*73]G\%2%H>45I<VBT,N&UCJK9KZQ00.)1(@6Y)J0(?E!5,"5@=
M.%M<T0T'DS"FF)5_D4B7=Z<)4`%BL!:K408U"`4P$%)Y1@C<Q0!$<*A-XTDI
M<#4_P!U;@S$U("6R`1M<8JIE`QX,P*I)`XX:Q3UQXV6924H#@'..:CT<IIG!
M(@:A)$>#-9'H4P[<Q3^E0`B6*;P`(/^>C79YF><$(%4!3/`@N893#@0YUW`%
M?O=Y]I`%V;$!!5"I:M>]U=J).X8BG)ACW2J<X!NNX,HZM7DH`'5F=Q()\(,#
M=5";5NEW!``\=I%A@X%P^4H:<@)F8S*1[M,6\=-QVM,&VK-(7S8!(.,D6])+
MLO<*<8,#=<<`\:5HJ$`!(1`"2C(`:U.87X!,4$8$%`H`78<#)7!Z1[5[P`@^
M!O13ET)3-*NRFT*0!"M3=C$$K0!Q*M4$'SH"#S-#IB8.'JA]MP)7/*J13-EN
M:K0P>I(@]*$GMY(53=L$6<!K+""U\-=#C55L2(JU69L#V\*UV0:E4<I$342E
M:"P3*G&34D3_1>%RMJ5U11NA;<P6IEXJ;FVK6D$1%G4+;VE$%MG'6_`&1WU;
M/BC&!8$[IX1D,8A0'+GH.R3@"0T``38X!H^+'G129_^A`5_`<3+[`YE[-4Y8
M4N8E-;(AA1U'NDM5&EL0&8OJ>A40'D````V`++^59F18"',3&S:`!]#``W*@
M&:E!'ZS$'Y01*$9S8Y)1>X+*`,5+'4A5-DHU`Y6+'(&S4H:PK%9G)^>0#3R@
M?I6,`'/@F]WKO6UWOJKSFZ+SO>9K(NC[B:^Q.T(F`GPP).1Q"^:S#DK6.N<#
M+)I@#&5`!",3741`A`RP!7F0!P`[JEL`OP6+'Z1JJA0P!-:3J8E2_V<PA[!'
M-;'H.`@9@`:+BF5.,!TM`%+!2!YG8II?X!OA@73@XWN!`G2IE$J[MW()5V9[
M]E/W@9U-0,.8U@4%90N"`F4)(`,Z`'&.L`OX@1I@04-*NW4BM+/10"Q_BV+:
M=T:YYC`XA19JD15,^Z,`(P<]<`,;G$-;/&S$5FQ"I&PKV:1NVQ$Z:8";!;9I
M/)-@6Y-72A)25&T'R*4^B<=B*K=9Q(`3V,<H]L<]^S"LUEMB06]]:U=A00*+
M3%860Q</Y662[`DS2-"&!$UI*;RD<5S(`7$_4,X7<AO(]*BQ<;H>\E04O4AJ
M^%NEP#\<QP+&D$@,D$D2(@;_80["(A\4PO\@-'0:(#(9\=.JJH<!UN!`)>!Q
MI5H!&4`G%=.61YT&B30='Y4`PKJCQR("C0`L@;+<Z)!^66`'6P`!6Q`!W(O.
M:-=VRUDBZ>S.[\QC\1QWM7$?W'2B^$R;[7`X$R2,@F>5P/!2!!U1"D`$0Z`]
M2*;,=D8#;;#<:G0?I,J+Y^@$YW@#)3`"A<@H(MT#+.`*:?-0W)U?O<0E7N(%
M(QLW$%!GOF$]*^T]'_4!\YL'!H(#YME'$=:6-(5U/O53!B(F/RTJ*ENSEGGD
MV<$\:W`"`:1GJE(+8]$P>A+$AWA&VA`./'J!":-J;C21XX=3['`5&%A'>,L$
M%9``(4"D\E>25YO_+2HYQF2L;>!BQE%DURBAQG9N+F1;UZ%5UU4$V($MV%[$
MM@^8+WZLV+(EM"3T0589)">6#?%`#[L`5'$@@Q`V%V7PCA``)`)G'PSP`=]9
M&/>)=8)"2!J0F;VQ`>PX&[MQC.9E`UM05%+H<=Q#`771`)14`+[MJH2"9.S0
M.'D@)^9PY1QTA)-$`H=2-`-PSAT'<[L3*`Y\A6>2<@=B"-24`$X`'@"0GTXS
M!#WP*[=;<`P01^WPVP4\`><]`2VXO9/8O<"1G.`*3V=7WSIVWYY8&Z*X6\A'
M"^[JKH%2*8N+`WE*`'Y'#3/%=(Z+<+DXW=EC,JWP"A3@,O\A9[TQF!3P__"M
M,"46RP`8Y1QH4$Q?0%U?T&409TQ(,SUK,@-=]@$_HC4`AC0LG/)$D`'"QRJ6
MN0C5Q0@'TDT[C8H9\`$#H$!=I4`UJV09H`C&D#8W$`1K<&<#P`D$90ZZ`D($
M\T)?P;/$LD8HEN@>Q-AF\2NHH7U@?9%A[;1;0`-I/K4]]$-K?6Q)2EEO#M=U
MO!$O2>=\GM=WWL8M@<8O08#_)RZ:M9.`;L=X#)1@^FT5Z!1T"V\`HQ:F!NE:
M,7XH-E>T4A]9T059*8-RL4C%H7@-D!4$P#Z``5V/JX-ZMF8#70'LYP2(FMIS
MLC5$1QL(\&=SPXL7PP"3A`Z[21H_TYGIH"=F5/\+=@(G*Q4H>F$[!*<E:E>J
MIIH!74<W%O7`\04'A]%U!@+J-R!FVXY+RXMDU>"[.-`&KI-3^&$(PGC>8D`!
M+"`'W#NMP=&)]_2)\GZ<Z6R^]JZ<IV,;H[@/`04((SLJ65D8.#@B%A@0&1A=
MCQ-=,2,9$#,*,#`*;D`:#`PX#34U<&E.3C*J3A1M`R(B`PQI:7`@+#*X0S<)
M7@-;);4@IA5P%`E$'PE67FT,$&D5(,,5%%_+R0`#.QB6M*@40QI>,T0:&2)=
M!-RRH!4-#1@3\P,X`V?X(AD?`P1&_P`#5M&7H4X&'&42)+@1Y(:,4%6:')(W
M88>%*U=4J"!A88>)'1;_2614T=&$21(;49(`:=*"2HX6Q,B<(`9CQQTD<F;A
MP:4GB2Q,6"P82A2%40,&BBB=PM2#4Z<.HD;-0;4JAZL'LAY8P37K"A\"?(@5
M$)9LA[-HSTJ0H':MV[9KX;J-F[:NW0YFR>K=RU>L7ZZ``6OMJG7KBL('D"#1
MJG@QXJR*(3=N[#)GSI27+5LPX5+C9A,J=U2\J.*C2Q,QGCQ9LF0`@`1#%'K1
M4&:`F)QY8H@H`P1(IF8,!@B'589(FAH52FQ0\V/#!A`5TI2`4&(+CP`_$`PH
MU@#6*Q$8+"1)$N!%``L3KA0H$."*C8Y=)I@0$PM\`P0;:F#`T'TX>`L-2`/'
M_X`-3-,`'`P@\T4\U*&QP0\0;@#'=!`(EX$&1'Q!`04E:#".%<RP\`8>//"@
M`@]BC("#(_.(1A,&PG5APWF@V``AA`B0HB,"//+HW(]`!BGDD,[U:.212!I)
MI)!*+NGDDT#B]Z!V8E@@P@A_C!`#`29U48\($W3CR`XQF$0`"1,@Y(5OF4"A
M@!<TA-(`'734,(PJ,H`S!`-;B%#"?70XAT8:X2B$X9\E4&`+H4X0V@L17E@Q
M`PT-X$#=-'!4<XT51!`!@`@@B8`#*!`H]$49J*(S`BQ/8(&%:/N%.0$>>-!C
MSPCXJ*B-"4T$9(0++@!$4*IE>`';#:G(0,,$$F70@/\8\UR$T7L@>639%1Q]
M9%%GV)+P44N6;6122SQLAE)).7'Q$P\V9,3#!!4,0=0"1J&05!%3>#"%4OCB
MZX%44U5%%5:#';;55CX`!M9>=\DUU\,0LR7Q6PU7S-?%9/F5<&"!#68888\U
M)IECCY6<V&)(5&;9RI=IY"UG+K^\694=?<:9!03XH1IKNR5P30(:?````PA8
MML,($(SA&PS`"1?<`(?>0K0:&]!I"H6*!*`U#PC`T<`;-H1=8@#KK<<#2%<D
M44`$-F``WJKRB-J="`@T1PJ/I#0`RA99#),I"'3@UW4)%7P!*8-$YZAW-&GX
M_(JERDC#0FR12EH!`EMLT47_%SN<'8L-Y1(@*\T6\'!%%B*T4?>-^>E8PY%0
MQCZDE+0G"7OL2<H.I90_2MD<F%?`XL<(Q,-2/'AB8F!"%1_%T`72KQ&A@`)0
M)%`.!14P``<:-01>RH#AB-/&%@TX6S5TT0$-FS@0,-`&!=%4('\:O'@!J8>4
M/B--=$Y\L6FGM>G"JT90CPP$HP)7DD<?_G`&`@Y@"02H`O'@-@'R=2<1(WA"
M%)[@F@'PRE?`"I81NE&',@"@5#.`C0Q.H(HU=*$)$\B`;6)2I7+%Y%LD*-%&
M/F.MC7A&)O.Q@`JP)2YMJ0Q<+R.!N@K1+I]L@09#J==1EN(!?N'+#&;X%\`$
MEH.K_W"@,(0YS%<4=K&&18PM'3CC7-"RQHJY\2P8TXM8.":8@WW,8(B9C,GV
M:#*5L6QE&MFA1V+VK8Q<P005,8FU^/"$#"ZA9T.(#0`\U(8:I"M+&2#"TJS0
M/G=4(`,S`,(7O,:"&N0''K$8CABTIC4PB*$&5XA`!-9SGE6RAP?/F\`;WE``
M-;P!%J^K`?D8(((:",=.MBA2CAA0AD^(@0408$&@?J`&YL"!.L@@`@-J(!T0
MH`$$:8``_"C@(6*N*'(@8("'9@"%=@Z!!5O`0T?D80,"UN`-DAB`##&P-??P
MH`$0J,&-[.:ZV^GNH,JTG4)[M"3>(=1)#*6=<YH3CRNLJO\*SQ,5#KK`!VCM
M0`S,',`$)_$1A&!H>C/@A7$:L!T0W(T.U+B!L30``7A`0$!I&`(J>F&L9=34
M3]"07P7ZMPPOS.8<LI"AWJQA*`^A0S@C6`(68N"V$52P"R;@DO.>MRJ1ABD6
M#&`!"Q@0IWJ(%%<$+`,.JA"0$`+K'UW`00E/V`O8)&L--\!`$W:0`0:(004V
MD(D%8O*9EY2K)9P1"48.*0:/2$LD+\,A27("$I68A`N$L$`3,?N&"D01!?2R
M%[[V944/9%&+7!R8%[_X&#'.$2P+XXM=U$A;B*61+F]T8QPS]I>O;$PP=0P9
MR?A(7,CX\8_A<IEI7%:S$QUR6XG_)0$!&KF:W6@@-@F`@(<@L(6-<($/9\"!
M%98V@R&4``<E8$"'>J.!"EAP"W?;)49X$($Y@$%M)L#`#QX@RP#L,B8SNH*L
M)M"`Y?S@=;O<I=X&0(H!'$@8@?(;!0!`A(!6(`%P:,X&$$"-4JV/3].9AOP&
M5`V%E"`6$"!"`F;1AN(`01,*H``"F#"V1;@M$3/1YP`F4"Z99"$`6R@#")@3
M(=>]KDD/U=U"';IDAR9Y=TW"SXW<Q@.W3:(+#1R!'V+0G1$<HC8[.%-F>B8]
M&%3/>A08:PEL\3J8IN%GV&7!A&QABD;QHA<@&D-``7K33!'*?]B@S9]@E%0(
M&#J]P9&'_P-%<`8^F&!5F:,(!D:P.5P]TL&DR!0+*D"#-L0)`AALX`!`W86V
MNC58,6#`7%'EH87@%:\BX%(&'$&`(4*K2F(`34YXP!&6'-=FUN((ML85W<QX
MRR(D,8$+?C+8*_1$!4$)K123PA32YNM?J.7B:KW86C'Z%K:QU<M=:DON-N;V
MC1F[F,:X,D<Z@LPPQ95,O!5S7$!B)F;K$.(0-S/8('I+W])=@B,K<5U3>6@(
M($@)'V(`M>G!((6&AL`U.@4$XPCS/C]8SWC(4QX[V"$`1[-E`?;PA@%@P`;X
M#%,\;*`W.KD40KM$`#3+P`"6CGB:S*&%-8A0ABV`8`@5@*F?B_^1!@_YKPT!
M2@,XE>[G8W@A#6[3+@3@P`*]A9*="D"X,#$@!M,1$!TSR@*!WR8<#&3!#A,H
M`QR(W)PZN=V@3\:=0J-DN[@?-'=2?E`-1"#@=#B/#WDP`1_TD8@)Z&,;!.@#
MF38W@(1@`J6]^$+V%.5-JSE!(5:XQB?&6HQ,R0^[F$_`4V=-=&OXSPICX/FL
MXX'6"<I#GO!I9"JUM*I85'T`;4C$?G(E@@)-`P0ZT`&>*M"(5^Q'GQDHM1&B
M`*PPA"&$1MA!XTU8!G$8RR%KP.L`!KLBY5T$/32I$LL4&9*4,-:QUY+923"3
MF<KF!`L$V,E[?,+R&TA[BM5^BOX#IMK_;2.!M043&.DV%@*`%P4X;A-3;K1U
M;KD51^OF6^[6,1TS;Y'A%5V!1XE1;\EU;X%4$D-T!9LQ&C6#$AM!`(^T&N&E
M`0KA,T&3`"R@,KKQ!0[W<!H````P`TJC2<9A0340`+)4`(MU!:QD>"IG`VI0
M`#F"`"B'`&[S+&]P(.E4`3KB-PPP!%Y04\\``@-5)]'A/[11=4`G=)F2*=;@
M(9_`8;1@"]"A<]8#`;&P#QK`(=6@23.P"5[@7A.`'B?7-@94`V(`"?OA-@=A
M=G:`!S?U`W(0(4G8/4AF=[*#)+,#=XXH=U'6'-DA`C)Q)91@`MUR!O4@")60
M`92V.57@$8SP_P6/IP#E!1L-P`(TL#UH\$V%@WE64(,F)P+:XV=$92B<!!YA
M,@`ED"C^,XQ?($/,9`_;0`)]X#QAT@5B4"L35#Q>I3@D1@,0X`S(TWMVXC?R
M,WP0H%;@T07Z4`8C\`_,YP+.!WU^,'VHTDPJB'UXQ0`6T`2-%QZ^%BV8<1,G
MD4,Y,3.2A1(\@%BZQGZ9L5S_5B+.ID0\T`-K$`+31FW7IG]0$3#;YD7#98$"
M&!8$R#`(F!8*>$8,B&X':(`:J3'M%H'>AH'%58%\E#+(96\MHUPX83H!N2W!
M1H(D$`57PAI0XS->J((5('XK@30SJ`#)\`&]T1M&Z00@0#[P-1,T`?\V[V%X
MX2$+&_`&K_,#;X``NU0#K?@ZFU8,OE,#)4`#-)``;N""-$`!@/--Q&`,*Y@`
ME.(,#1`-WH0@AF:&#%!!TP$'=!`@T8%"90`+#$!A-\5,FC0&;O`F+-`#>"`'
M579R8I`!9?`L>0B"'S$"#3`!64`2.)`&B'@CBQ@X##6)2M:(0>(C$%4[JNF(
MK;EA$_5+>7@E?6!5B-1`L>!EA#<!!"!FO=D-7^`%BZF*D9<]K_A-M]`X*^@A
MVL!2#-!YI_`S0*,!.(`/E58/B#`JQA<W!Z%/(]`'7`4+L,`"KT`\3R!J`P`X
M=/!-P5<!,G`,#'!\(N!2R.F>,G`#-R`.`)#_"&"B#Y]BCNCH?,_W?(-70B8T
M22HX!'B%GS0@!J@#``VP$HD$1$*4+=]2H;RFCXF5$IMA$?OXDIYQ$EQ``%72
M+I9A`T$Q!/9R%/?2%!(YD?WG?V#D;F3!%;+E1FCDD1\)DB%Y%P>X6^N&,"@9
M;XQQD8F11QH(DR2(&5RB6?R&+BGA,EBPDU'0D\,8-!JP+"Y!`'^``12P-)M0
M<1]`!.7@&T!``9D##Z%@5O>T2X;7`(&5GEX)!Z0``I@V#&W``@A0#7#P(-6D
M!@CP#.%@+)O69R)6#,375!6P`=D3('06'110*E?HA#6@7J``"A2`*NWC-J/V
M"<@!`6L"!&-@E#10_W5Y&)F'``'\A")N$QZ+50A9P``4P`2)6&1O5YJFR22I
MB7>XZF2[RIJOF60(0)H2]2"_A`$D``OY13Q0%8B2T'T[L#G2B@$E\`4:,)PI
M!#040%9J2(;7H'FT<5:X.`NL\#,V*$/12#SR$(CR,%AB4#ZO@*Z:F4K;$:DE
M(%+YT'N_-PTZ<`)$EUWQ8`^FM`%,(',T<&?C``#H`":5\"E_L'P!*J`$6@FH
M\AJMMA#X>0-H^J#;]Q'S@!$R`8*^IC(;P1*<T2TY\2WKQS(QHQGK1U@XJ5D,
M&00&8"](8441^112$:-7\7_#Q3$;\UHW.I)U86ZWM:.VU:-VL5N\=9)UQ/\Q
M']-:>21<CY&D+]DR_=BA@W63QN8".U.EKS&,"?`!7C`$6["E?-`%);`TTV,.
M--4&R-`;"="4T@!0!B1#IO0#Y"-0,N<W=!(X>B-GC;.HU?`@&V:G\G,,E/-I
M`E)YZ>1A,Z`!++`!+)`!+!"+U!!.S81A-@`&)3(!^C0JEXIIGF@I&7(,VI64
MTG,#((`'?5(Z^V$IEGD(,K1*&`&KHX8`M4I0=Q.LKKFK&U::M].K3@:)D.B:
M=!)1$_4#%;4J!.`\*K(-W(`!HH$0)D=I,1!F)M!XR(!2US`#%6*732>V'K)C
MR^B)LV8)AM97QH,K5?"^??`1^U%[_`$/V(@()L?_([\'!ZNPK?L1"W5*#6)%
M`TY``T-0F=WP-1#"!'3``G>F(=:J*I!@O7ZP?%$0!1(;!E'0!]T``";D(9""
ML?BYL1B@5GF(2)?9H1[1$A^8+2OL$HM5DRU1.E>+DSFQ#C_4&4-D`Y2[!D%0
M+S?K+_OG`%)@%17)DG<$@=\F1V`!1T1[@!/#1DC+HSFJM$[,6[R%DNR&@<'E
M%9"!&"I9M34,HIB!2-`%<%V[!*NADPGADY-4MEM@`]+%!SO``!_`"9R0`!Q2
M<[CG!8RY!6VP=AM0(*.V3?G!`FP)R$SII]7T`Q-2`D!#-(CL(,A!.&2H$#-P
MAWH#BRX'J=8:A_>!`,XI_S^S4`+45P(@(`8Q,`_A!S9O8`%YT"Y7P`=?ER&0
M:CT5AV8]0*L68%7E@HOAP1E5-0_\,0$GT@`]-P>LT[NXFJM$$F70K)K!6G>H
M*:S#RCN^P[Q\YS8QX#PNL@,:16ER)0)YT)M<PCR--P2/YP;V`QP'A""1^C,U
MB`Z3=CSP$`_P@&L30#R5YF7\0:]5B#W;JC=_$L!WB:BF?(OI.0WXP0:XP`N:
M!QZBX!Q"]V:2,@/^H[":"+IJ%0-^P!H7_%91L`08E0$VB*69G`"HD)]#T`!B
MUPCR@1.$52XMTCG=0A(F*T0@2%F.51F\-L8K8QJ'!1J8=05,T`,R($6B)<1/
M(?\%16P57;1:2*S%?H'%)'EN4VQ;:X1;2ML7??%;[A:`7'PRB_%N1QHR5EO#
M+8L>(6$ZR.4":JQ!E;""IS(.+6T#*2%]&@`#BPD%0%<!P]$`7SH#C0D*U)0=
M'`8*K0BJ\"1.!@8A@6,,AC8$X^.*=/`#:-"MFO*M=%H,@8*<T`')&:*%Z\%R
M*X)HH(!I")!K626$O10`@47,&"!J%S($IC`$UEIQU^J"6\"9*5(E1(@M8C"_
M7X<#9L<#6[`@<T!D^4&LONO,P!K="26)O3-W=M<CQ`HD$+)W?0<26(42>4!X
M9K<;)B>MFP.ZKS$#;K#>T^,%VQH-##!KFDH=J7TE9P#_TG[`#5X&-YSJ'ZG4
MK>!#`3O%EGH33'Y#=;@@`VD``"4`(P4M)0UPL`JAL2L&(_?A>=$)(K5(&SA`
M//DP:X\0`P#1F^98TC7X`1_@(<:RTK#!`K12`HZ0!RIQ0R&8AY`ELD;4C^+2
MTSX-U"M3$AF1!1^A1">"U$5ALTSM`4YMQ-S6LU.-DJ]5U5>=6UFM1G!AQ23)
MM$,JUBI9@6%L,B[IXRP;,^]1.A@!62QC!*RQ&D]P(:;23&4+I]X%S@#`UYP`
M=.39>_!0!C,@A9Q&!XU,37LJJT!3`1/@::+)C8FR(36U!7JZ`6A`)P<R5-::
M77RL/?NJ-Q`P2=MD`W@`+2IW_V0R`39">`5<,A\3P)7ZT1_8:2'D<`Q?H%W7
MI<XNB`#@$0#YQ:E@`HBL'+UF)W9I)@?,S8C4[<R_VF3%OE"N.:RD&2BPJ7>*
M`,XQ`)ZZE@<JTN&&IU8AO@-]8`0DP`C%P0G#203FQ<?9B8RC`"V;T\T[<`;_
MW`Z@,!WW&HX.M*^'RFFLN`4,X%+=LYX#C%TT)8AS\DV;Q@L@`L$+VWO1<0I,
MI>$?4`=G=0:&MR+I$!"]V2M&\+PX4(-8J@$I=`-XI1`,0"O,A*SJ(A)_Z!&^
M=@7EPA)MW2W$-E@O(>8`65@X;0*8Q34R,"]35`10L>11O6T'X.072=7LMI%F
M`4<X6O_E#X/E/LJT)0FU7&[64ULR()/65QM(&U$B)0(Z*+LR7!`%<?`$81!>
MK^$S"5&V+#`C&^$'NV'G3.,$@.T=#5`",[!-D]S(C9Q.P2AY>."*$3(,PR`=
MXD0!."`&+*>>,#7I3O<%?Z)RL@#8H3#Y#H8`\\`\I;,V[.&NX5?/_!$<!;+J
M8"52=?\!,R#WF2).<SBW3##</&8!>``CF#A8-F"R@L4#68`'<2+LBGADU6SL
MNDIWRLXDUAV\#X7=PAN;LT]I!/`(7%5[X$%X.&'.1L`'X(X)[-T)&I!>KW!E
MOR@"O>TVXDGW!S(+_*.QA3?QS]EYF.*>UOA.^@X'#@4"UFC_<#^5GFA`?$-P
M"LL`""U67PDE&"(X#!5I%$Z$5I`:&C@-9R-=$X@`&5T$1I^@1@0$50,``!H?
M&EXS"4,W";$T>%D#91@D7%PJ-F(373L\5R86)!8[R#LF)"17*B0FRB;$S,\\
MS-C9VB0J/,_3%ED6)GQ</'@R(0OK"R@&!D4>'@Y2.3D<^/GX!P=(_OP`#ZP8
M.!#@0!\'$0I8R'"A#P$=(DJ4**&BQ8L8,VJL.+&CQX\-0SILB'"%0((H4P9<
MR?(DP0/%MLF<R8R'39M7KLR,LB1.F"4,`,3Z4B:!EP0,W@10H8+/B`QC%"B`
M,6,(C0%8&31(HX%"C09MT*A1\Z/L_P\0#"B4@,"`R98*"#8@J`$"SB(*";Y0
M:,`C0`TX:.C4;0"'`8186K=8$//FC0@1#3!@F,#XC0T>67#:N&*C\=P&H`<P
M$#%93`,<%4#46`V"<(4!CS-HF$$AS2(`$"AH`$)[BPT+DVV*>5S,UP`<(BP$
MX)Q%'(,V3,B6G8N@NO4-V+-KW\Z]NW?M<;=;'S^>._GSV:]_[WX^/!WL/]XT
MF$`"0Z=#B`9@FC#!!(8,&5S211<Q5+$#!A`,X84;"K@1%1`:,,``#ACDL<,(
MCXE6P83(C>#A"*"!4%<%%<C@A!,40)"!")DH0B(<(E;`@B-##!'A%B4,4`,=
M/`H&BQ4)0/\`01DB8-A`!80XD<87D$"BR@`QG(%#"7:EP8A1K,Q0Q@`-C'#&
M@`V8<DL3H1A!YB@FB'#*;%ZPX@HLLM#20!D-Y,(%"6*(8<($.V`S#3+1F*`3
M-\/L,(ZAV-A$DTR\7,&%A<2HD`<?1F2!3@CJK.,./%/,4\\]^N3#CS^D\F.2
M2J:N4)(/JSKT4$@>;23KK!A%),%$''VDJT@"O.I02L"BZI))+:4*4$R+)DN"
M-SQ8X"RC7$3QA$]/X%"&!@"4450K%"`0P%(DG%%"5##``$4";>"@KE9P:##$
M:@S`\8-T/R``!R-IE%`"$TPT\!X"=,`A,"-??%$"`@44$,!;%0C_G)4B(-A@
M0W\FY#F!#0DOQYD-W]H!7&@-K+8:8:+E&!D&`U"0FL`"$Y9&!EB5\`41$`X!
M@0:$X&P%#:!=-L$(D@T0X'Y")Z?"8F)D8<,`;2!`[P8[DK?>U%2S9UY[Y8&'
M=75:5ZTUC]71$1Y\/T1&PH`$_()?%VLC2&2!%A#0!)XE%,4@%%`H0`126)V1
M"0YUE-#PO67`/""&6-E5(@TRT'!BW0RT"%A@<BV2@!4USM#&%HK0@89=<+!P
M@Q6"Y$7D(6D-DF\LEUM!!``C\.&'"((S0D&-1LV@P8JP?2B"*1HTX,DG<I,I
M"@%JHD*$)#,<=<,-0P2Y!1X8;)G'G7SD_VF".,H8PY\TR!XZS3+/*%O--A8X
MJ@(!%5N@`A=_F(`'"YBRLVD1\=!C3ZC[\,-!J0))U4L$F)"$L.I5$5G(1VC%
MP(SHZH$0[`"O>M6KD@0K6,-"2;$"@@1DF>^#,^$"%I[PA"B,P%HXJY&--``!
M$/3E&3'`@0;&4*YS0:`$B>!2`P#@!3:(@0$RV(!9H+8(?6GE,JN!&LON18$O
M`(`!<IA#`,`0@.&(0`R+2=\5`E``X$P`91C`6`#B(QD,@`8!-@!C`ZA$!Y'1
M17$28D$#).0:@;6&`6MA`2+*0#,GD$@W&D@`!7:&@"U@H"_A2!,.)F"3M`'M
MB["90'-$``$Z//]M->CQFB;9P[5,ADUL4OO.UL:V28"!C6O9*8MD2/`+`NR@
M$WSH0PP&4`<*30`'`&B`"?H0#6#<<EM3@8$"("0AK1`&#FMA``M84(';W8`!
M62%1"6I#@Q(H@@9#P$L;#I$!?_7H<TZPP@R^<!@('*("?XG7O:)GA3',@`A$
MZL(`A)0&&9B($*W[0`8P8`0^Q$`$&1"2M@"4`77!)D,#P)`,-2`"$Q@O%*,@
MP`BT588V:8`(SJO1%X;`@BQ,(`,,$`/[*B92I@`J&K\P@0IR<K1`@8,;()S)
M-;!!`#[`5`Q;8$$"ZM<.%+@C'E((:JA:4BIB:?`D!E$505BE*@$T58+_$-'5
M13K0P*I:Q%81E,@$27+`"WI56!L,B`=C2M9<N("$3\"0;#9:(TEPE&//V,$`
M9DA#*'B!`L4<S0ZAH`,QX""(/\".8.["%F\5((UU5-R&&J"4C%7Q8A%(PE)6
MFH<KF`8#$MJ"&*RS&C.&"38#\(T(*H`&$86H-<A$3`]8H#(0T,$L"*C`8:!I
M+2(HX`8H2D`@9]!.#8"`"5],FBM',``,6(`_7PQ:03&0F2VT\)(U\.0FIWN=
M4682.Z1,SRBGBUU3JB>5-<"%"3HQ7@(PHP_YF8`%3*$?M@U(&?/\P@S*!8.H
MT&9"%6A`C-)``QE5X'DWV`OGXB4B'A4F+;'`_U8#$.':>S4,25;P`LZ"A($1
M".Y%:8`3)&8P@PQ,@``8F!*)4(1/"4\"`U^R!%96_!B@/88T&/(2RK(EO.&!
M8A2B<-NUVH115\0">@S`0Q4R4`**Y<E]S3@&GZ+1O96*SP3F+:M,;C)3$O#!
MILU"@$YYVE-X>""H4A@J44U%YH`4)*FG6FJOFAK5J,;*JG"N558[,L$#6K"K
M7P5K6/LQ5BE_4!=+2"MI9+A1'P<R*9/E@YJ`0$,8W!6:$\(*`!0@@QJ@IBP;
M:",(FBFD!DP1#&``#I>BRQAG<7$IR_&%#2*0,![X0@P88,P<H7G&P(I,1)L>
MC<0&`*,TP$&_=/GC;O_>I=,*"#'3=5G27;$B&P4D`+=XR=T8O%"!-_#@BT7B
MY@!V0)D\B$$9/V-19B8``7F9I5Y8DPMWURV7=+<;E>^V[G4U.9Y3JAL^"##N
M>,<Q@ACX(0;8)LV,!P#E46"#DA#P`A1J2(09E"!,6L&UXEA`@V=O=#*)0`"F
M-P`"F7T!MX2`S`#J@I<TL(`!NFVG..G4@-P,[$2/B,0`\F#E$V8@14,J@Y#2
M520//2$&?4B;P(&&LM%TX1)/^)(MN@GE3[B`>)Y(6P:R)8F+'J5-(8#>+*H`
M.`Q,`XN#NL(QN-TG:)0=&>.(<OG\G`U%88,/Q.C,EC/59:#60\Q[!@@2DFK_
M9J,NU<X/@:J;.Q+G6=E*SK>:LT=(4D'`6]"KP^I[F?7>9[8G"]"(.X.88A&]
MH]!`#(F>*!#*I0`OW$!=!I4A#)R`L@K0X0UT(0P><_2&`H`:#`6`];P25H!F
M74&R`0@7!MY@EBH^QHQ!0\X<6<":&DQG-170N69'"R.R=;P$2P)"`D0$@94U
MLS:&\0($F*T!2NO`+@EXYPS.M<P:]-Y]5YA`0G/BK`I/H++AR(P8!/<#.<`V
MNNB17>PV->WQ;MT%;_+F;J5D'6TD-O<F1&_@=1(U#462'T0W&4\Q`!,0`P/2
M@2)0!@HB3#``)!KP<`/P<+@F(C!2`;$@88/&`'&Q_VEW,11.``O%A144H#)V
M<1BST7`S``&DH2_ZE08P]P@:\#9G$"6(H"\XQ"5;L`7\$0-+L`11<#R9\&(+
MU@9MD%!>DE::)R0B4`7#\W3'(PH[@$O7TCP-AR5>L%%M,`%-8`M>AT5N-W9[
MHEXYP63*$#?5L':61P)9D`UWL@-B8`-,``([17<^Y65"I0]YMW<K<2J1Z'=_
M=T`)Q!`+5'AQIG@/%!*.AV>J\G@%@4%GQA(=](<@]#Y+D'FF``"$T'F"Y"U,
M41\0``13H0!5H2^)`#@?,`8W`!HLH!J@(1F486T)8P=V<#20%0$1$`#C,`U,
M<6TL,A<;0!:KT1BPMT8,4/\#G#,P<%`#R$88$$`$1`"#A@$"@546`9,&0O(%
M@21'$)`&*L@`:4"/-_,%$U('Y?<%3A`]-,-HCL9\#8!%XP!)MG1T.``SRL$#
M-I`9%H!';W!)#`A*#SB``XA*G:0>"3AO55-O8+,=\3$?]0%E'H(((X!2_?%1
M`2(9P*`,_U$&,R`5CO8%XC<A,`,":)"3I85@.4,A(L`"&X`&*6(;T987NL4`
M*),!ME$!*-)$&B!.5E`&2/E%Q92#.3=0./`A(_`$2Q`#9D1T$X`'>/`+4DB%
M+K`$7?`5HD&4>8%7,*9T.A>&8TB&P^,'N*0\%[4W+?@*%+`%3:`F#>4LSL`,
MTF#_*,>0/JR$`=+0AWYH><T1B-S`!:Y4B%LP!%RVB':7#T?`#U30F6%5BL0R
MB::"$*8R$H*'B82GB9N(55FU59X8BJLBBGGV$D<%$ZCX0<]@0L1U!A_HBGE!
MDX)4`^`2+AE@6\)T+FIA3;CT`>,4(@A@&=^B,`&0!`GS`@'``P=2>QD#:^HE
M!GF0!YEP,4<2%ZM1%HU1`X9!`]S(3`VC';EV,T!``PA@&&@0E(51&[+UFTC!
M`FW@:[91%_=""/@X(0D`!%808'C1<#0T!O(I'V4D&;A$<-SV.U<$:\:5&93D
M-$.$26'321;9D?!V-1D9HN)A7=PUD1292C\@&18`#`0P_R`<.*&P(1D`@@$&
M)PZLA`.'88M4H5M?`!D@A9.>LVFZE1<W8#"'`!BR]6!,PCI`HH$`Y7TD-ANM
M\'!$=QP$U82P$1E=L`1A$`8NX`+&<`C#N`44^B%3""*@<216$F`H@D,]UP4`
M!81BZ'1T^0E_8`M%H0JSP3I'42-^.5$#H!R"Z4K*H`QYJ">'PB?8,(NH6#[-
MP0RZ\`QB@`=;<`.7^5-?!BI'T*F=Z9DM49L!))H"P2JE24$C,7@4,554I9JR
MLJJM26=U!IL',9NC2(K$4GFWN0W/,$)/D%"4Y)L%LPI#L`7>P`P34`(?8(L-
M4A6YH2\`L*P)H$-X\"W,J#`KM?]%D@5K8E">9($!-8"-^58D>,("*P@C.Z(:
M<-`&L<`"6]`&%(".YX:>;3`$[MB7+%!NI;4(2WDS3ZD!<-%,MB$P%;`6UQ(A
M$S)I7T`B:9``1#`&-*0`0\!8#'D9`9`''S@`#<EM0',:,,-(=C`G->!_F`:`
M6?.AZQ%*7=-NW:5=&ZFRI71*#C@V*XH+:(,VS2!7'^M7=<`B'4@@(28DQEEZ
M>1$91.9:I74O0Q%(01(9++,A!,,ZL6`([/,[_-I$NH4M$(`#6-%B'H(?]F$H
MT2"%41`%8?H'!V*U&^*.XU<DE@!LT248<&!/,E`!-+`E'M(%FF<XGA"F9`@*
MLZ-S_JK_6T=A%*Y0K$W0!66``Q;0+(>2#%K4#'?X)WW2F'\8C<:@#4>#4Q20
MJ5[F`)QZ`$?PJ510+*%YN@;1#Z-:JJ>R$+`9>)EX5:WJJ@S$B;+**@R!NXVG
M9K)Y9AC$0;JZJ]G`%'Q`0BTV=05CK[/Q5N4S`0Q0?F[`(&Y0N``2K<N37YIE
M`9O1"X68$_17&M`D1-0('_)!&L=EK@WC@!SW1P[+`,Y%`:^%;`)C&$99!LM$
M`4IJ1P&:8%_`?"Q0!O@[(FOACOJD+GPT`T>:?@\K3&[`49KE"_RA;6HS&0:I
M@0%@!\X%`B1K:P`(2M^%LMZAD0:(@*0T-B][LBD;%][UP4+$_Z(P>G3F-0R(
MP"(_M"7VT0550`YR);1ND#>L`QMM4`)(6Q=.X*2Z$R`38!?[A;4)1B0[P`=Y
M("6Y$5`J0F0YU#M<N018<"%E]$4+AG14:`G@ZAI,B:#U6('?V,%U,2,W4*^3
MD+?_I"XC8*=ABF-&\`=/(22GX(Y7UR8UT@`>M;43P!EVV#TP!0W(M0S1$+Q_
M")EWP@W:6P-MX+GQX`&<.KJD6[HL852C8HHYL,E&96=/)4&PBRNT6WBV>XE;
M)<JBC*N_.RJ,++S+LCZ^<T)[7##IAQ3N\PSR5P;#Q""X*&$`<C.J0`.M@0$Y
M!1JD81EOX`N280/HB9,B$A>"(38@(/\:3Z@D("!$\W(6C'`S1+`70:R"BK.#
M_,M\`^MK(X*UDO!PT+>4^9(B%,6U.NH%"J`7"0JQ;@`$$VM(Q!C!I)$G`LTG
MW-8??2$&%,`"&PPUT85)#2B`(%RBH?1=).JRX9&`7H.B*1H>/Q!>>R(@_68)
M)9E0\E<'VU9P3(9P,Q"]]WR4(B`ATGPO<,(DNJ,?58`!,!(FTX1/DK`B9W`&
M24=<H/48)_-B6\F541`E)0D:SP%2(O#3O,DEJI&T)5*WS:05(H"NV5$#,@(+
MT;,['I*$Q)65?4#'H!`%?]`%&:!S9;`F?>P%-2(">&`"`,)(A2PHS6`,3,8?
MRV!VNRS+#*G_N8TK!C30`IB2*3\U!:"+#YB<R:%*9GLW$/_0#Y!(J@_1*A!!
M06]VRG!&>*WIFDR%N[WKRD=UBK*<+$ZQE0IU"D.1?E[0!J!'`GV0";XL%5/1
M"NF2D*GP`?'Z.YNF,E@1KHVQ8!.P,,$((VT$,$H,!T,2,D/@!,?&<0,CH'!-
M<>56%Q*W)$]I!1`0KHO@6F_$"&W]`71B;3:``$)CQ5.2")$!4!5U6S20S^ZD
M.RQ@&3?A/4`S#K"F+LEQG39A!_O'`.>&;M6Q(Z<$T1%]@%E#T2%:@!M);Z8D
M,N]Q;_4R`LI0)$='7"L";NJ%(!22MS`ZI[LA%83@!>Y[<C!2)4U4_S"0``$C
MT`2N-$?#+"2Q4%`]E\5_P`<O^DC)9=1;N00_+1E'\D>YP1;M+=6!@0"EQ085
MT`9*0DZ_LXU#!`)XX3Q-!(0>\D\%-0)_X+=A:@154+9&$$-E4`?:HCPM^*<L
M,-?6$D;?9@)YL`R#0@(G]2>"H@+3P`V6:WD-J0V-BP>%?=A=9@"*#2H<D,F:
M/'F4W7>E,MFC4MFE^HFHF9J<;56I#!)<Y7BVJD&E:)NG31-90`!I14(GU-:<
M-P3-T]WKXP=?E`',J@!0,`1M`$VBL=8?,`1L<()"U!HU(!J,%8%<8@,L(#C;
M7!9C$5O-)`E`283O\3G6%*`Z,[&%@6L\LO]I,G,Y)=@`6R"#7U%$0W(*%.+,
M6["F(F,=;[`#(NYL"J);,S!M#KLYE/%%AX,5%!QBR)$^XY`%'B,A3+#0H&3@
M'HS@"7Y=&+G@)\R1!-@C/:+"Y#L9$F7AOO-AR?5%*C(9RF!P0:L!P-R";7!R
M@O-R*UZD.)"$\\ZU$B(:[LH?76JVQR-T1/W2J%<D@@:NK$&P=9LO)9`A(>-:
MV`$"%!<][D@DB`".@84&2Y)^@^`$;5U<_090`=+E7UJV41#F3Y>GA9.0U])C
M7M`"KA!D!&`+%8H,>?`,2%;GQ;#(W[`#YK7G?M;GV7`9#VG8];.(A+[8^(#H
M9L9!D+CWD]WW167_$*\2VI-NRI5>59>^*R/QB1<DFP1D$K$LRW$3`T?]JW4@
M%`D`@FT"`5L`#7`78K9UVU:A0R(72&S0`!D``F.!';WNSFO4-,7&S6,!>P6;
MO!70`XOP'INF@ODI7Q`P%\$H6"-R)=P=1C90+R>X+OI"9%J!7/Q1B'T1`-S;
M62=T,^J>3?)%%5Y`!&UP,GQ]#`!U2,=P""@6)@UE![4`'?1"'7-AX`:?X%I3
M@/%V\/*6T1W:H10>@38+#)=``'$."%T#&0,8&!D9&`0$)GTQ,2,X&65$;@HS
M7EX9#1@,)0P,&1"C9640)0,CJB-=&!,3#2*&$Q9B$X]+2T9^KS6Q`P,,_Z00
M#`TC(@,UR@AT:"!P%4YI%&4#R"QT=!L_&RQM0PD)7PEE(L@U&\_37U]6,^(`
M&H4CD)(#,6%A<4M1449&+OZ)J(-C`(XZ`(AD"@%%'(,)!$0`&"!&S`X3)%20
M(,'#Q`X+)DQ8V`CRXL8=.S)JW,BRI<N7)+ALY&$C2Q:7*BQ4",$SQ`(4*`P8
MF.(@!X>C5)(J/<"TZ8$5!Y`@83H528X<4YM*W?H4:M2G`@3X6.'#1U@?'=*J
M[2"AK=NW<./*G3MWK=V[>#N$W5NVK]\5@`'W#0R5<.`#(V$J7LR8)8^1D$8\
M.2,B`P``X89D@B`BY,8)#+PH4`"C(0T&(AHTV/^"H8X7'35*R/@Q1PV3'V\:
M,*A0`G,--$/@_."63C4#"A1*0&@#@@6+#>EJ('A6@0*[!!!`;`%6@\XS:-,2
M$&'PA@?-W-94<W)5WH:%+!8LV)C_!@$&<RP,&BPC.@&%(>"\`\YX",1'DWLF
MB%".!3N\8@@&!PU@@ATJB-`&`FH,QXUT""B3#0(@(@#=!B*.:.*)**:(8H@B
M@C@BBS#&*&.(*[JHHHDQDM@B=+AAT`4)772Q@RHD7'%%#(.(4%$)Y009)#UG
M#$)))6X0,4,B$U2&R)8X%&3(&6<L$<,??&R41P/6C*">.5W$T,42QZ0&`@@-
M@%`!#3100\Q]#"@#0C;_SK!`@SA#E($:#GUF0P<<3FCF10(W?#$1FG.F@=TZ
M"5AA10*7#7#&$S%$2=`984011S__N!`0`2,0@LPDF7C!$*0T;)%%%X96A-$5
M+'GDZTL>$:"19XT5*Q-'\]W44DXL].034`84,84'1G%PA%+8.I455UI9A556
M5W$+E55@C47666C=1=>Z[+;;5E[PXK77O'[5^]=A71F&6+'\\FL3"7^H\D04
MK6H@3CA>S%#-!'E\QD(""KA1FG]>(G,&#EZPT(D3&]0V7(8#I`%!*0WTT(9P
MW'P'QS3)M<%`#XN*2,=T<,`A3#A?I*$,,@-48#,H)5```04-O&*T&!;P$$``
M_U>X9T$>[DWP()KJJ=:S05U"H`$,[Q@<#@4RW#`&!5LX^.!]9>#@R@0H>70,
M!A:H$``&$/20X7`;<.CAS#.7>./?@.-(HXTSV@A=X8:?F/C?(/8]>(D_&`(D
M*UV,T(=%E5OSRD$B/%*%'S'PL<,`H\Q@I1M`N%%-G.:(L(H(72SB0CZJ+M(@
MF@P$$S0$&<`>)#(U_UD#"#I4(`,-X)`M0@E_:I-W!<>%PVD)N,^YLA-.W)#`
M#%9\H8$\&`1301HEI"%RIC.\8XHLDU%61P:DFAI%&*FN>@@.(T@9:PL-W=#&
M%A;H0@9*0(N;7&%8%T%)2WC0*Y%LY%?]@LFQ#J0LEO\PRUD_"8JTJ'64:V&+
M"E[IUE:DTJVK?"M<49G*N%3HE7/M!5YP88N[9LBN>-E0+_,2BUETR!>R&.:'
MATE,!(?H$INH(&`CX,?%-`"`<23`"PUA0!<2LP,10,P24+!"<E`C`OP-0`,R
MJ$$TZ'`WO,$A:$QB``(8`(=MY(TZZSC%%N3P`]6`B$[08-+W^O0&&TQ`#%O(
M77I4HPPQB,0F\@D`#YIF"T.@21:S6%X%YD1).&`-!Q#X0OH2,`3D$,H+8Q@"
M"[:PA8K$QP(0HHA[=N`CAEV!!RK(@@HFP!PZXNU#>V/&X@+'R\.UB$4Z\N6,
M!#=,%>W2F(W[T"]Y5`,,D&#_2$_*GS4,P8H))(EMCP!3E#)``2)$+&*J\Y0V
M=W`&L[FB<F>(03_\<(:J`6-ER($`#F`7O@$$CPXU@,,)HC&.&4#@/AD`P8CH
MT`#D?4\<9=@$,NQT&6EHSPN:4I@L!D&#"HS/.OT<@Q72)H)/@6D@=1A!%'+!
MCW^8E``"G*>4-!`K3-R`:'BHPD$F8`,2*,M7"EP)L'8@+!*$1(A$=$E-8&*#
M9O5D`3\I@E(Y:*T/)L4I3,%*"JM"0F^94*HII`I36OB4'88E+5]52PQI2%:Z
MV.5=-\1A#OG"E[&8"XCZ`FI0ATB`F/!!8$N($F:DIP$B)*`$&!##1OPP`@@`
M`09N_\CB%[8(C&,`H`0(:``%0%#&'X@1.2*C`1.VT("!U@R>DF*`#0I0`#&D
MYK,6+0$BU&@!87U$#(&5SWR,=(6E!<`&C<2`,H9')V1\`@0UL$7(X$"=SX8B
M`YCDCU]O``Z#;2H<(&""TTH2/B79HC+S'.W25&`'/)2@`C:PY0\ZE$P9]?*\
MB(.1,(&97K^9EY>$8T9WG.>\O,'-!/2`1!?QEX<\["`&5324,9QTABJ*8@:C
MB1@1-,``:CJR9RRP7@G:4(@)5$XU<QH>:F4@`PJT01:@:`!Q010-2YF."&50
M$_.:8:<T.&%[;MB4!C;1@/%YCP+\?&+Z-"&"";0*`N9S`O\%I$<$(DS$'![M
M0F6J@0M_&&$11FA"$V1:`G/@H`P:P$0FH,!<%N"A"3-U3TT]@I*4Z!0G/N7I
M`TURYKDNI@$A:,%14:#4(C#5@Q^$ZE2O$E6I6J4H5J7*MDC8U:VV50!@74M9
M%]VNM+@EK6I=*[KZ(A:X!L9<^W+S7%60AV,\04P2:2*`Q*.!_PF6!'V`$!$0
M.['E(,H:$H'`\":KH91Y(CG4LP$>&H`.-'SVC!#H5`!(6UH1%"/#RJ!I`1@$
M)%EH%[<5>848W',?/H$`1,/[A45]IAH<I*%FX[.HS48A"2PKA*_L8(<7*D!*
M'P5):IJK2#U'$&TQ9,$.64!4%L3_2UYF.`Z8Y^UE>^,+\($7DT0"3V8V#O<B
M#)@`I4:H`N6$Q$K754$B:KL('Q[1AU8-&0BC48@&J@R,`<1"&!6MV310X2,U
M62_"XV-!=1HECRW\5CH;H(.EVO$H)KJ.`<"M#@6P]X6$I4\#^---&0"`8TRE
MSTIJ@P0BE#.*+XR"=QW-GV3.H.1)#,`/?W#RDPD0Y2DGJ8M8UC(4AW"#"GQY
M`'6@Z7L8T;9B(1`CS\2("MJL:9?`6<X^^4FTIB6%#CJ5"GHV2E:C<L)PF1!<
M.1!A5PP=EG,E6M&,SGQ<'`UIM4@ZAY1^*UE$;QBY]MWN&Z',UA4D:@!]CS.G
MYD,7<.!-_RQBQV7`,,=EME`#"J",&]XQG]#@\`8YR`$!Q(5&S6Z-BC<48&E@
M"(#4;&">I=%$::](T`!H6I\.K<GDL7`%=S(\)Q'SYA2<\,0DT8`&$8'`$_)4
MC@:`\(YQ>$$#5L@$$6I5H)H6J8HC@`>X)36K8!`B8`$!D`7'@0?\QB'*I%X!
MAU[II2,0^%X4.$PT$C@*QS<,YT88P%-=T`<H%0,;@5+`X$QTLPD6]B0Q(`)#
MDP!NX`9C,`/?`UA98G+#<R<54"<BQ@`%T0H8]B?I4`+80RA$H#:@T!W.P"C@
MT`(]!S[`P`)!8U%.T$_<,Q&M@`,```$6A2E6,(/E0!FI<!\E9_\.E!,#<#)/
MJD`9$?(')O4/9!=E`M$[D9!VL=(_;M<$`]$`"!(2;(9Z$!02=<5WIT<"?\<3
M2*5!'B`%A7<$>(8M(<1X5$456/%X.0!H6^$`#C!H6]44.T1I.*0NFC>*:-5Y
MGO=YAV8N]P)$IE>(BK%W,0$G`M,JHA8.+%4-2',2`U!["M`0RP$*7/0%'\!K
MM,8--$,^5E<#SV<'`5`#P9`:JJ%;"#!:T6<'/%`1PQ8!S^<>MH!;&*`;(K`,
M)*(,WX@FP<"'8G!L/D-)/2B,":`QF-1&Q.%K:2`I):`<"#8#0^`]!I-EF$`#
M",`$M6!A/I9[#V(TX3-/",@#+``!""#_7GF#;?^6@1$(7XCS(A1Y@1-8(W[#
M./[6-_7%(Y$#$6UB!$'"$M:4"B9`-^5@"(_0!7S`DO.76%[@/1#`"<B@6]XA
M<Q$&#17`.TH&=#R2#O^A&4/0!@F@-CVC#-4A?`G0`F-P?^!3&>7C,_68`%E6
M9``@`G^`).]SCR,C*9?1.^&3`2,0!BZ`!4,R<7S@"&SH.JSP*@/P!V07$&,7
M9570!*V2"G#W1'=(*Q.@EW5`$;7@*[#(+PC44Q#DBBUQB(&G00[`B$UU>)%(
M:'RV9U>%B7^&582V5:/G%_,BBA(@0Z2X:*:X%JAX%CKD5811%I>V`JW(F(K!
M!5BP"F=P"`;C_T3?8RAK@Q(BH`$14QI>T$GW*$@),4DT@#(=`@WPQP!BL(P1
M,#<8T$=*LS2U%0!VP(RP)0;#]GQ2<Y#65`R4`ATS8XR^X`DL`")L1%SU]7[6
M83H/03I_H@X4X&+B00$W4PF+-03?$U'OP`+KT05L4Y8/$1]Y$!(6\0H\D)T-
M``%SI"$YAVT'5Y&`TUX8J3CNE2,W`G`>J2A\TY'#40.Q8V$HQ0H8H`IF:`BB
MT`"M10"0$`.'$`\QZ%?\60U=!'3SY6N3-&3@D&++`P?-P`(N5H6/<I1#H#;+
MLQOF<R?@8`50,`8:4`UH4P+@81U8201`\`'PTX*M@P,E@"BYDQJN4/\9`Q`'
MIT(``9,F(W"B<`F7<3D(]Y`J;RB'!'`_^6,9++5E7D`!M=($*24&>&!(>&=!
M@/@1&F$2LLD2#;``@)>(T1*9C7AXB)=X4L$!6U&)5Z&)@):I6+5X7?%6H)D7
MH^EHI6F:IVD7J2D6\T(8E488L9FH+L$%+O`$:W@&&<!$!X.5>V)A:]H`5T23
MQ%F<EK%_=L("RE`UT?@&PQ8`8+!L$Q``<Z"-UI<TW*4"8M``8O`&;_`#:F`#
MAH``VAI9S?=^RD!<W=$A[P<!Y$",:8`&M;8!#5`"US%R$\`"7P"DT"!D,E"/
M&D`,ZEID-U"%?94^4*``7M``TTA]*O`8#3#_0#0%6]-46WO'75MPDQ"I2](Q
MD1U)H1*XL<$D.!AI@1CJL2.K<+IT(N,%-SL0._BU7R-P$6PS.IQQHEU`&4%R
M90F0.N]``8^"L%T$7,W@##96DU&:&E2*!A6P/0'KESV7"'3#=%TX9.@S!BC6
M8PJ2`<*'$)CQ/9O`AF?`!U@`"Y`D)!:0)5TB`F9:!28H2/F!"+`F&6]*"#$`
M$*L"95&&4LAU#%>6IU"TIVW0``3@!Y(0;662$QM!B(3:$L'R0`Z4J(O:J()G
M9Y+YB-FB+2@T0IBJB9=8B47!F9WY0ZZY`H@6+Z5:JFQQJJF*+I;VJK#:$ERP
M!+3J.EJ(&>#P1$/0_V!L$R>&%9SZB!SWV!L?0`2^%V$=$ESR4;86D`2DI4A2
M8P$1\+S2!S>GE`6P4`.Y40/#`2*U5@,,T`;/82??T1TDDD?B,0/I*33:T`P^
M:2G/=9,#X'L^Z9,"2PQ#5F3[V5=%5K!><&VV8#19@ER!9;9J4ULV<6\3``$#
M(%X_@$OXI*$<JX&%LUX9&K(2C$P0'"+X]"$H^P8J*P(7@:(]E@=2(Z`#(*5M
MX@="8@(#@!F5<&X&8ZR#0%S.P'Z6@C/D8`W?!0)I,`32(+7YUU=..S)*&A[X
M-P-9RAEH@BB_BP@%<8)5A#^HTK)CVW5J^&FM@`QU4C,RT$G`*`*T6CG8U?\%
M<BIE<=@$+BH)JK"WCP)%,X`<G4$`@Q!<@ZIIBYMFK!M4CRMGCBJY'42Y3Z45
MFRL5WW*I17$"F_EX(Y15@-$4Y^)68#6ZHEFZI8FZJ5MYEV8N=YRH#!03\_,$
M\\1Z\_H.J+`>NE-[$S,$HR!_P?L%+,`&"1L`T'N-8E"=`0!;$]!':M"MJJ&M
M;R`USN:,P%4G)I(;6)8=!54!V/LQ/Z##\LI2%8``-)`=.HH<XY,IKT=*YF,^
MX+8.3'0<FK%@R$$)"C`&8X!8-*`:I20296L-T\8@;^/+$Y`%`>!=)?`#!0"A
M\X5/')*1#\R1!I>!&UMP_M:1A'/!)NLBD+,!#I?_(%T@<3O0!WR0!Q""/UDR
M$18!=H^0)::0LT!09`!2#/'(?NP'!Q30GU9@,*@@/MLF`TYDBT30.\M3!N6#
M*=_3T=4`#//$2IQP!FLZ`7A0METT`)_F#PE2$-#8O3+-"9.A&T"7#<1S)S1P
M//A)JVO:168IIP30!/\@94W`!Y(@NTNWQHF%'!)"`@K"HA74=X&H9H=[>GF,
MB(K8B([H5'IF%5/A>-^BB2>PUY>HN9?J9YWZJ:!G%J(JR:1XJJB9NCXT&+#9
MNHIA'ALAJV'P!(106$TTK]B!&FO:)6F`8*/A!CT'`$OW`7VE`2S0`]8[6L]W
M(-1G'F(P`A/@C#60(?6!_QNXX0L]Q@.1)6+L"1U64P;T!Z!<"*%+6(_7<<["
M0%SB5C-6JJN\IQR3!$>9Q$1@Z05^E2<)D3I04"4O4QXT$1_5]4>OT`KW<;86
M(`<*2`'%A\\SLUL0V,_^_,\%34P:29'S[9$8_(`Y-Y0.9P&PXR8IP2L7HS82
M+=,^`B9MPDK+,015<G\`4@+;`0%`.M(5T%R:LF`-%J_?-CY5*#W;@W2NT`FB
MD$F<(MJFD#LP/0(F`!_DU$IX8+:I,-1+<!_0R-S$:0U/T`ELA`8L5CPR@#W9
MPP!4K61H7#]R6':+D"3Y4PK.%8-D704D,`)E@-:,"4&(ZHI_UZAQ;2U^C'@<
M`/]5X6+7F]O7>ZVI5R7(@]RIK6DOD%S8AEU#FX?8CYR:]A(8F2R;_L<%44"K
MN1=LUX&54<I%D7"/GCT:'4T$'Y#HW_,!,T`#HR0U9:-;O#R`AF`#NH$.R@`=
MF1Y9[%P#:5`!:+`-&A*ORF'=._K,R[D;O-$.X0#A\;I\Q&4G5EJ#JP$'`[3-
MS?P!CX5)7@`$>RHT?64)3JX=98.07B)M"&H(LH"`64`Z"'#/>'.NN<2A\!VR
M\KTX%6B!][VA,*+??L/!'\$*;A(Z#:)DFI."'^@'?#!V&%`&`.(&F*`!_.F@
M#8`#<+"$3"H]5K!@.'!RGWY1WB.5_>H[9'B/;?"E\[3_&F;+IB\[)*UC-8C0
M4>D4)?TN(L4M#4[`.VN:.T";#?D*(."``U3M8U_MAK6CU4@>$;VS30#04FX0
ML`_!*M7P'K+Y*P=*+&X=9W.V07)]>'5]B=[B+69^B6:`B8ALUR/$0H91+VT>
MR6].0W*.JJH)>JSHV(J1&+1)U:I@&>SP/7V5`*A1"(-0`L#Y3?2WFZ-=9!#@
M')SE@Y_0`&^P`=JZ&GU$2,@V'>L(!\NQ!2!PK[6&3SH\,N+A!"!0GZH1Z]!@
M'2?-8&\0&SN8Q>>GKA\PY?*1&UZJ6@/$.\BU'_B[6)H$!*E3">]8-DCCV@8A
MO;5@"--V?3R0!0VJC!"*2_/U_][5[DOU;:'6;CB/,\$6V>T?NM\\X@HD8&%N
MDL:I0-Z;LPF/@(8`1C<`8B4T*+4`:D]P9*774;6].@!!8QWQP$1E0!"MHPIG
M<Y#1%M3(,$\TCF$-26YI,@B3Y-300`-.L*^2(KL#(")XD^^>+_*J``A=&`,9
M`S$$+D8$BP1-C",9(F<B&1I>"5XS;D,T#!,$764,%EDDIJ>HJ:JI*B0F.R:F
MK[&KM;4-(2TANPLH15-24AQ'1U3&QU0'R@=(2#D.#LX..=34)R<.9DK3U=/-
MSTC*SN$KY3X^Y@+JZAWM[AT2\?+S]/7V]_CW[_O\_0(=ZGRL6X>NG,$5%FPI
M7%CK2O]"$EQ</!$Q8L2@,E^^:-@X(T&%`0,&E6!0!HB"DQTAC&0``8`&(!!8
M,&#QHP:#"A5*P*FQ84,#%@ALB&#0`,2/'QN.PKE9XD,"$#4H5-A`!PT(.%C3
M?$F08`8%$&D87&U`IP:<"A02;-0PH,86!C@:-#C+H`2$,AH`E,!@0HR8"2)`
MBI#;`,,$,1<U$"$RA`($Q4`Z>AE2PX8-"Q;\8L`!@8'A084F!)##@X<=.UL@
M-"@@Y^@/.G00U*@!&X'MVSUSZ][-N[?NV\"#"]\M',%OW!N0^R8>O&QM!+![
M_I@P@<2.+C&Z=!&!PQ"!/#OR3,!19H#V,S'\$!##8`B$&3/_B&B@,$0#`^X5
ML%9(0Y]K@@\`F)<=!MR582`$".(@PH(5C=!%%7WD(0:#&&#PTP`,9(##"-P1
M!8)M(*!1P0U.I%&"A@/@4$)^6%U5`0WTW:#6`-P-\,91&X#@A$8:J$3!AAQ6
M2`@.9Q!@A"**-+(("5UTQUT=&LS@129N)-`)!DU4D4$)8I3"T)<DM#*++#N$
M">8MN>P20B]%>"`,,<4@D\PRS$B3@S-F6%--#DIH0PTTWC`#33AU'K#",BN@
M(Y``Y[`#T#[Y1"KII/;T8^D^CJX#$$'G&(3.0V>&FLH5-I@2T40-#@!``ENM
ME<!](8DP$@0FP:"`%Q0P<!\<&-(*_\$6:&V@!E5TY%3!;`U0P,(;+,$AK!K0
M_@"675NQT$,:%<`&0G[;:L45$118!4=M=.A7`H^_XF$#`D/=5%<&=ZDD`@:"
M4.>7#:3^1=T.DU2RV!<44/"%%T1(Z84&+%2H,'4#0)!!`YK1.$%FAV5A!QXQ
MR=':4=#)1EMLP2TG\LC)%6>R;<<5U]/)QI&\<G//V4:'='\18,*#V<6`P2&`
MS=MD&2+X<20C8@S@GF*+8:)!!0UP=E,:3@C,ZD:15$31@AC2V,"\._![1H,C
MG&&A8`LR0$$;;9004@-;P@$"'2"P`(<,3I1(01EQR5I!B#.#P``-0["JT88@
MO4$5'/P-W/]11AF$/2^!&HYP))*+.$(`"3'@H"&\`,Q@Q91N>)%&&A@<J?D$
M7HIJBY@F6,`ZJ*J3@(LN:[+IYC#$R&G,`1S4V<P)=SZS)Z!F:#,-H'<V,Z@X
MAAZ*:**,-CH0/Y16;WT]\$APZ:6.NC,0I^=\&GOL/)0*$1>H5C1`&:RJM58)
M6Q,X:ZVWYMH='(4-0,076\#Q5;1(J0%(!E`"#90``0VC@VLV4`,0@`4"`1O"
MWM+@++@Y\"S>"IP3K+(WJESE+`+;2`5L4#X;V.1^@I$+`MY@`9N]P@)7<`AB
M%H0U0I2!"`I(P!"VXH7(=(4(%<"`&%K'@P#P0`0.P\!E9E@A',3_Q087:\,`
M-+9`D$&G!L-QF19S(YR8J8R++$,.;EKFLBYB$3<S2PIB3'"S*G1A!":X@BD@
MD0&^B*`\,<AC'KLP`18,X0:*F=*4["-`!-%G*ZRB0%AH1)&*=`$6!+J:)&E(
M$9#@;RYP8$$:;A"P+Y0@,%O"22994`$=R,`_'VB#_,B21CBT80B!XV0"'C88
M!("%`IS\@A6LH`&N-.YK%6I:XR;7!,M9C@15P$$=G)@!`!#!"EUQPPQDD`81
M'*EA&,@"%\:GD#&Y8@>7BQT!9L<+V[TI3KI;1C-^%[S@'2\'V#">,Z@Q3VD0
MJAET8H:A.@6][E'O>@"]GCOBL;WM?2\@_^$3'S=#%<-3<&$)(WC"$R;QF*FM
M!0(T(E!W2H!#D\Q@"&F#E5RXP@802.4'>U###Z"%@/T(C`((V,(!D5(NK"#.
M,8YA`1[FTA-M8;"BHD`6T[""(175`0!U$`%U#/,7,;S!,F]XP[UL\!<,5$0N
M(-B"7`88F+J4X0-`F(\.(?"%--"@*Q5`@+Z6VK!(5&@".SC,('"@1#!D05=,
MV%@`KT@;X&SQKR\#CA59!L8PGDR+,(--;)(CG3=@`)S8N5EU3`&8D$P(;R/(
MHQ_X$`L,("B04UJ,:AH`$ETQ8("6G0`&OD8A"U7@M*]M`X+N\YD!L,BFB+M!
M1C10A@K9A5M8//_+62]JU;@@``TWE9$7H)D`(JAF$+:-6MUT:07/60$"(XA"
MV+ZF3!$L`DE#8X011+!,0FC@`[W4A!N<<)\J-(&\&.#!0A72-5IXDR';W"8)
M+,""%M!N`0LP0)O.205T[HX#'-B3@N')C0:;@1O)>P8WPF'/0AWD((ORYT`#
MRF%*;;B@EOK'I@:24(3,5U0/X8)V)?H$2&@@(US92&="HMH&,.`E)B%"`BC0
MB0$V``)>*"FV5JK2E6X`+0'[%0(84`.DY,A%_&E,'>T@!K(@Y8,Y>0P`'G:9
MV6#HM%R=UP38:`("7*$`!0A``&R@6K%92"X*&P`%9]/`GY!25W7XP#/_TW(#
M!-'@!O&A`)P-LP/$G/8P)L@"&S%C@HD5,0!#P8->&<C7D`'VKXD-8V$-^T62
M-><VBVW941X+BC)K1Q!6I:&%((`#<!Z)#[#V[%T*IM[)T&@$A=;7&\7,H1HN
M"),X<2DL9SR4$F"+!M@*]E8T`@`AUN5#*V,!O+AREX>-8``LT"17;J#<@YVW
M#85Q(@-&YP09[1(^UWU"%)8PT6N7I\Q'2L30FF"$]VH(!P``T*K4>X/3=J$)
M9ZC#"$B0!=B=V!06\.8+2X-P4Q0\Q5R(.,(K0+M=H$#`M\N=,01PC`-48Y["
MZP:@MH&-!GL#Y'?R^/*4<6$,3^^?V>NPS/,Q_]!V:*^@F3IH^$Q\<#"E&`L5
MD>@(\)V15B6@#;IJ`'@P<&,BF*1*%"A!=YS(-@WHH`?[$99K:H+D$I2A`7A@
M`4]Z@EP,"NP+HP`##T`@@BU@F3,```!=)Y89&UCH,'[)@][S<(4`J(`'N?Z+
M;"Q$P],VX#`3J(O;YB(7N;U6F?FVPE;J<PDO0($Q6(1AF`*0>!&(@:H3Z+5H
M[&!$%02@`0><M,QF8^E+(U:P7C09<XS#Z<".[--83*.HIP/9,NVZ.R.P%YLS
M4,=38^<Z\'H/E0Y6'I#X90);H^20*%*AP!3E@CBA`01@N650EH`"3F!:`W`"
MY/]H0*FZ2B-RO=61P/\!;1(5<((&K%`B&25@EQNAZV:V1.ZT6&(,.D8D1@!1
M7[,^./`)\38YC5!OD``298!4^^8&"B!!Y@%PD4!PJ=-SIQ!7L6`!L``J#X$9
M$"=Q/&`!%*<FO8!Q!)9.">9.R/,G@#(-\>1.$08-)\`,PH,HZ/`\+J<I_3!S
M0+AA\F!S\P!B_D!BYV!P&K@0I\)B9Z`J@J,1.Z8K`Z!:@0$`0/!TDQ%U*1(7
M##`#0,$"%$`'`/0&-O9])=`&6\`#,=53+>)2K-(``0`&`>!8ED08</9478`'
M68`!6S`!-H!F5R`A$K(#5Z`")D`@!!(2=/9FI'5:\R(K#*`?R:8K)3`2&?#_
M51UQ`]KW8IB@8S4@51,@"(*0(H8QBC4B&BJ0!5E@>A.@AJI7::WG>K<'>[*W
M')RF''Z%BX(%:K27&S\@!N"41P20'1R":Z^P5)DH`M@1`WT0"R:P/LKG!6[@
M!O)!(]VQ59HS`'+!$IB5:@-P%CC!'V:%("U11VPSB6^3(XX!`5P1=U48&`VT
M'Z.S%;LT)0D@"2+@+5*Q(URQ2P`2$IM1!E'720D0=[Q%(V>P;MNU/AG0!49B
M!"XPD9/#@`K"'1K"/M280Z_U;SM0"!BXA*GP0OLU)G*$<)AA*A&W33R`!PQ0
M<2E8!,$`)^G$._0D8=4`/-?P@MD0#3B)DQ068>1P_RB$LD_FD&$B!BE`N)0Q
MIP]&R`\'Q2A**)*V@#Y.J"J>&&-E,!*1N""THH7N@70@86/3M`%P``%DJ%(,
MM!3\(6@V``8V4!@?!`(8XG4`P`!B4`!@@&9"$8J681E]EV:&80$T`E55A8>%
M<6T84`,XL!-EX4!8=18C82&ZPB)O@P!G"4$I`@%@]5$T4`+MHPE>0!2GN`.8
ML07=(08EN`-O%7KS4D1B`&YZ]0.K-U@H0XME5'N\D8N'I1R[V8O041NZ$8P3
MT`3900#7X0>;Q0?<,7><@0%\8`1\\`<[D$?2&!].9XUL$4D-@"RZ8E-I<!>?
MU%5F@RV2J7T)T!('2`GC`O\;(A(XF<`J=PE]X5@!.U1_NC1(0!,#2*1(Y$96
M]V<%1-!;T)4BQ.<P3G1K2S`)74"`_?*01D*1\G8D``=\S5D'F""!5J`K(]`$
M?.!$>7`95)D0K=`U#V&BJC""+(D'-`"3%P<,4J!Q<F*3PZ-@#@`\,9@-#X8$
M/0F#ZT1/V)!RA<)RZ?!R2JD]2\F433F$V?.4WO,]/C"55+D*#Q51$W5'6>D^
MA5`8-9(!.*0`H=,8/48C7W@#=/!C9$A3W7(N&5`#<U@`569X61..(/`&`5``
MIA<`?Q&(:%8:5_!YG!=Z<?$&MD&HB-F%2C0(%X05<I%)658"LY$!%#`N"X0X
MLP7_+R^A8T/@$E%B,'5J&3P00Q:``<2'`18PBE:E47151!90`BPPFZ!FF[>)
MFR+#F[,:,K9*1KZ9,C+C,:PWG&_P"3$P`@3@!UU@`@PW=)YG`^MC'HZ$'<Q9
M!D`F)1VA%@K2'5!1%N/'(J-SB8>'(0Z41B#P?5M1;<7U(2("?N66";QD0(B!
M`^J*+5(CH#.@`77T!Y!05E`C-><%("+`GQL25X17&.B!!5B@713AH,T)D1(Y
MD?*6",;I1!S"3)@P`PI`!)TP`E7`!REB`B(ZI:<P"Z^3"BI*`E35HBAX<1EG
M8!W7@@OF@GVR#<338/#T<3@H@]2@3BQ')T6:E.]P<TN:_Z0`)81%&'-..F($
M(:4@BPHJ%E$+>D<`L&SN@U'5AXU?"@,?Q6.F14`=81404`,J56=9AE%V:@=)
MD`03`C&?9P&@JF9^IP+4$8AJ$`$\4%6+Z5@T-!<*1"Q4@44"1%=V^$%81!7T
MJ!%?5P,0D`9)<3CCN!6]@H4)(`/:]QCP`1]BIUH-8B&:HU2190'BL2`8T'=9
M@`,,P`1;1ZC!*:NT6HNYVKJ:YAN?%IR#*VK!:C,C`&O800"<-0EBUJSIP0=+
MH@(8(*V8@(\:\3`8T@!H@`;:4@&D!#!V,2_I1W9G$3B)="(5<EK;PDETHUS5
MRB7C`0'!YBWW-P-`\`&>`%$&"O\OTDI\D0,8&Q(%4?`'?7!M%F$8,7`&K#4"
M"NM$#%N1$>H"'BJQ0Z<Y7$&-8Y`K(E`%!#!T@*BT\Q5.'FB:9$(+#:>2^W6R
M+CI@N*,[1T"C+RMA.IJCT%"S[90#RB#"0NIQ19E/!N&S/RBT,LRD17NTWP/!
M4]H*$!$%3[`$83`)1Y41@2-C1(&J@_`!)Z$`F_B9XD8!EX`&-5`"()`<C%>7
M#(``::8"!1`!;,:G:&9$)*1F*L"?$U`^/U``CL54L\$=#6"&SH*94TPL<),U
M8K`%&<`T2;%2TF)L%)`7W;DB/7%+^9$&,[(^SO0%I)2)\`$%UJ@LAM$Z)#0A
MGD$**G#_JJ;)MC9@>CS``&VP`;&H6+:YNK7JNJ0<J[/:&[';JXR5%(ZU"%T`
MO&_4:[(,?86P`WW`!WZ@1W?DC@5S"6G!)4Q7`<O+O,CUO%_0$E68O-4[!-^W
M7/[Q=1-`"/Y9`3+@O?6J`3C@%_B&+5%CCU:0A0"@=/8["5D#9X@&"?%K!/0[
M=(RT(!;J(!7!71L2D0K8L-<$)$Z$`[U$C3"@P-4!":$K7TL;LF-6R5V#"J`B
M<190MVVPP2LK)T?0.R[[)WOR8"6GPC7Z#3?(H^]$*#G(@XEB#MX3PS,LPT1(
M4$?;#@.!PTL;$4NP!`Q)'E_`/FIQ"?`S`9RU`R*`8PH`!0EP_P-I@XDN806'
MYX<+XQ=^80$!8`<J\'>G:@,1T*=^\7!]MP/!5V4(<!2A^`-1]09_6QER40,L
MP$IKN1]V\;5;4`;.XAIP@S@9@2">=Q,Y4B)N@Q;_40B8.@.<V!)$,`:VX@8T
M@``B.$2(@2'401V4,`!BX+9-;0=(A`!ZA;JI.XNBS!PE4\J^V#+!^;JH7!R*
M]8MY#%>@<`C#RATC<,M=DP>D6@(.HAW$V`69^!)3(GG'7!@W$2)HT`/(U1^L
M(@I;,!18D1;@-P3+M4L)\'67);YT4V[%NQ@?D,W1#"_L*ZWFN!>5]01A8`11
ML!T6P4>-QLY.ZP)\,`E$@4GG$A;=T?\%7S.L*4*L\2:A"FC:3^A$[&.Q$_@1
MGP#;(G"2`[V!L%#!)"#0Y[--;(L`%.!?O.`+;D*3R(!@#FZC,&AR@'("]=23
M%(X$%XWA]%1/('T0(@;#/XND)=UA)XW2-OSAZL#2(!MQ/+QN9T`>`$#346)`
MAK$()C`"M'(24+"%)Y*)+@&&?W@O7^RV141Z@"=$=XIF;S`O%(/8B=H6-="=
M-Q)5"$!:&0`'")0?3784*M4`_-$29;`%:0T"*B4BYDG(+_8%BCT4VS*I9O<%
MSXUZ&9`),@`"J&>Q?ST$=MX`%7&*IB@&F#$(GO>G$Z,"=O!C6Q"+D[V+E?V;
MEXW97?39G,W_J[$JG+LGC*``D3ES!CLPW@OR1J5:9HQ``.'[!8OAURG!C>.&
MVU5AGX,TTY^$(8-,;O^X2U90'MP!`.*[KXA$,#W2SEN3H%KCAW]AVG$@;_S)
M2%N@JLS8P]H%$HMY05"#$Y$3SQ-+K-]ESPH("2+P!%VHD2;A$2%!`,DT`"I^
M<"7ZWR3@!ZUSP?I5X`?^7PH>HS)J#!&-8-T@<C"H!"17PL#S#<5#X?&4)\^P
MH^O$LSNX3TFI81\VXD*;TN]PP_W-M*F@8A*UH(9<!D-<K^`&3KI+JE>[XT-0
M!L0')8HQ`&+N5`$0U6O6MJ0WJG*E=;+1U<&Z(*J)`8LZ&X_YB`2Y_P4-8Q30
MHI8V9HZ_8A-&00?\`0?(!9IK@9>;,1)N\U,'B=<W-`-.P"OO`0.V<BLL(.:8
MH6998&.A6\EVNQE5:.AI_:I;5^F4W>@O\^BD#/>I&WM9]!MRWS$H0T;$68P0
M>1U]<#E^D-API3F9I4?9T20(8K%C,`93^*U?H5A@X1_X]S"DQ:W\X1]:22,$
M%#"=A$AJ(0ID`Y'&IQT3@`?P.P!/$`?S^P?;X6-P8!=;^@3#2G70816FY`0R
M\'@-HK_<L<`16I$*"-L#,`E.]!@:((%>\%H80.[=H7D3[]_V56:KP+8U,`0(
MOB8JR.#'<.\N6\)\<CPY>M'`(SPVR*-!$/\$!-^C!\^#RI!A*@WB35KB#A]0
M(9[2F7+N!Z=?J,##/0P(2R)U`!`)APD:90T6)`1\73A$"I0P;C.*&1EE"3,,
M6ULU"#4U;Z1OJ&]B$R,3-B(#&QNB/[,(I@TB6V(-%14@&S\_:C]P:240&E];
M(A0;Q!L@<"`-:8D092*\<`C&<-]IAHF+%A8B)<`U<`P,$``:``,X)1I`5E]E
M&D0P_%!>+#4FK,(P`<,`"#@(=IE@8N"``1-XV,$#@8$<.<)^(-A(I^/&C[)"
MBAQ)LB3)C1L^JES)\J/'E@@ZO@2Y\J2LF#`YROKQ9@*!'5U^CO!#HN@9$2)B
M^!E09L"9+EUB5#'_0:!!F61$9LQ(0"'#@`8,TH"@@P9$!0J($FG(@)1!"7`4
MT&HX!&_`CCX[#$+`MC<#CH<-<B6-T27/CA%(133`T&!`!@8CSIS9<09Q`U(@
MI#FAD"8-`Q%'_XKJ**W"C1L4KH*.''I`4".P8\=N$N-O97G)$DPB4H%!`P)-
M'#,D4+2X\>/(DRLO2IR$B1TFBN[8T>BX#1M;AK1H$2+$`@-%I$@Y0IZ*^?,'
M.'#(D<.!>_=FVIMQ<*)]CA/N[SN8?P))_1QF!.B`?@,B@01[2!R@X((K^""`
M#RL((*&$'51HX8472J#AAAQVZ.&'((8(HH4;8FCBB18*4-UR++:8'!=%_ZWX
MQQ-/+!'%"!D`\$5:BC!"`A]\_#&`%Y10X@81F6SR#@1;!*8..R4,4,--N8R0
MQQMP-$!'9G2,\DT-()S#`AXL0`#',VJD&4T:<7VQS!9IT%'+-R#4P()<APS`
M"P/?3`-'!6SNJ$$)8@2@@ABP-%:")GSY)D\"0$!!03L:C`&#`C#,0$,N&'0J
M$`9[86!"%EG\5,XJ%DB$1PDEZ(&1,*.D-!-*)M5JZT@HY5022UWFY*M*-K74
M*P*R[M03`29T84*R,<0@61=(C="%8R)$1\"URUIE"!%CC*$!!1"4$-@O:/P9
M3EI6K(64/)T%JL%<\&0@;67K)H;4+A;D<90(7?^,,$*GL"@66#L(B8"!9"+X
M1H<L9<'AA!.`4I!0HB@Q@08--`R!2#:5/1$:#J_))AL!5>"``XVXS;5;;R)4
MT80(&6`@1G0NUMQB<\[MP(=T.^!<U'79;><="@9,(1YY1YQWGGKK.:#$@/M!
M_=[3)^`WH'ST6?W>@/45>,"!.22XX`$K-`AAA!.B:**(;+?M]MMJQVWABC;7
MC1P7,)*PHA%+V!C%&3FFY84BVCP7E0@:%)EI`A7)0X@B6Y@%#!RLEO!+,,R,
M(`:6%4P3T@\U\'F0!@R0Z4R:M60&@C40:-P`G,!(4V<U.R:20`,VB,%`!6C0
MH0Z@ALPU@`V&7H&!6W__/32`8JS@D`$$0'A1`5,:S``#%%!HBB\/`03`0PW(
M8%`.*P.,8$'W*DB41040X)%1+5/*5-.M]->:*TR[_JI_2_FO-),L"PN&#7R2
M+*K$`#$XX)=D8D``'`T``U")X`0:L!=(N4$!&DB#7VH`%C^=I79?L`(1LC&!
M'4S@''MQ!P#*<)6_B,!?'EO(<SI%D('`(H&)"<QE,%.!(>PE2K!X#`C*DAD6
MR.!A#_M"S$2`@QH(0Q8@T%@"AA`7MDCF"0<TV0@(8`3@B"PVCI'60TIPB$FX
M@0:?B4$31@`R"T#';G`T#LZF0P(56&!9-/L9=A+`G:$9P`-2X`#2E$:%(S`-
M_T#S<9J`X!,@)?0G/UJKVB+?8Y^P*8@]8U-0V59`-@=12&X9:EN%WD9*4H(R
M;G2+(QSS5HZBN&`)80C#WW`PER%HS`M<T89S_"4"2%$""ESY3"Z<EP\0("`-
M%2`&*:KQEE$T0%QO<`LPAH&Z=92``E\HP033\(QBT``.ZD!+(JS`@AZD`9P-
MR$PO`I6`+^!`##RP0>B,N4YP'8("#5C%0B9`BENL`@&KT)<\*$`$Z3GF"UZX
M7@AFT(8:B&$5!>D4`S*PF$Y1ZWQ9L(`*[!"`,DW@5?#;@/R`5;^2XHI8^TLI
M1X8U4EV=U'^]ZE)*/B>&:T6%``=$RAE^!)4^-*`../^05@R@0Y4)X&!;,_#'
M$`JAJ,Y%K'8)2%<)%((!6#!@'@P80%8)<H8:Q2$*45A"#/[`QJ]4U61^`<T!
M`8,9:1Q1!NR#0%MVUSDT](`%%<C8+2'`P28^D7([\H(7O@`NIW0U!DP,*A]@
MTX0O&N%E&8"*5?,Q"2!0@`4M:P(&$N+&-ZKRLS]ZXQU[5AR@\;$["R`:()&6
MM/.01SWLV5J`#)#(^;3GD0XPD'NJYH`BQ"=J5_M/@@RD(.*2;9-H@]"$!'!*
M49;RN6XCD01.62$!Y!&T<:1;6&,9!1'H"`)0I0`<WA``$OAK!-`#@@*`28,*
MZ!`I./C`F<+R@Q1`HQOG[$W_`BJP`1J4(!A/)$T:OD`#"K1A%`R8DEG@L*4T
M.$%07\AGPKBQ@7(9`YLK%`'W>&"!QF25'>Q8GLQ,T*RI!*``*!X@*6C8@.=I
MP`OG!)<^!.N&!+!@,1-8R$.9.`$+B,$")Y39";5A!SM0<`L%R(A(.4)2DSHY
M)2J%R;!\Q5*93)E8_6.R_$1*4S'0)@9&<-90@938+F#`+SYQ!+),8-2]Z(,(
M1+CG8K1Z562P\"H(6=YYG[`0QN@0`PZM:F(0(S"G_FDO%"B!;PQBN3Y](V)Q
MN0H&=J#5!O2NPA_\PFD89U$%L\F6"?""%>[Q!<CXZS9>\8-C9\/&$2QA!+CI
MQ`6'_Y`+,,=@>8V8SG6Q6S<_0.=4I-6;#5AP6N^`9[7E(>1ZU+.U_2S2MOAY
MFH$,U![W*"%`V+8M>Q`T[6X?=Y,.\H&X)21N4(X(NNB.[BBG2]T.6)?7\(Z!
MC6(Y@C*X:8J'&()O?NRL,Y0`"$#@1P+6P([$'`4`%6`""YR`!M0-XP=@048"
M&*!P!F0$#9V31AI.`X$V;.$-+*A3QLV%S00`(,&K^,I&I.$6;)9AJIUE,V-D
M!M$=Y$$%Y;U6$PA@@RO\('<&^8KR-%&&#X2++@EX,!`2T`,F>$\%5["!.3@+
M40S\RS$XB$@`M@"!!B0Y(U>FU9-/FN7[1?GL,!V6253BD?^1!C`8JB"9K;N0
M*N<PL5IB.*K!SAN56Z^P'G">8M>K*@]-&#Z!$)1,W^(0!B.8D(E9G8?S@&CU
M":ONT4XXS8X88!#.^.+R9WG7!VA]:RF)U"S8'/44=\2OKS3@P3?(?*C3E8"F
M-*L5504J`UVPZB9$0@1/@+5C0GW!V[G&"$L90'6>LVMXWPP+O_:QSK@03Q9X
MH8_?*0(@!=G:UE)AV3GPK=.NG<CW\-:18-OV"<@?!-IB.VSVZ;;8QH;<LHW[
M0<R-6[KWSW]VM[L#S>=\=N,'3Q`%]&8(.Z(QRE`"(C`!=40".\``D\`/7G`#
M_I55Y5-O-+`!U0`"#J=,;L$F&PC_`@P0#-%@3'20:65P8#;0&)<A4N`0/!"`
M`3W'`R?T$.Q@,B$V8GAT/B@6`+GS4'F0!R1@&%(1`XQ!"ARD/`_!1#E"!!#`
M`L<0%TZ@&[>#``5A9A;%%A/0A0QA`D#V0F*0!0$@!AG``C\`4O@S=B:5$S$U
M*SC!=E$&94PF=B^U4E:&$\924WW`0(3A!\C"!_O2A9L@`KI&%020!=Z5#S-@
M!5!@!8/S&<MS!IU2408C!B9D=>>%%(%!9P3#0I]A=0-@.7CU:(`R!()B%^A%
M+@SS08S#0DX!"YFQ<3?0.J$F6#,```U`:3@0%DBT(Z.6+O'@!U40&="B"2'C
M6+3Q%XCQ_Q`9$%7%!P?\8@1_``LSPS,!>"T">!QY\!P_QF:J=AW6QQVI=6SC
MD6S)MA[R\32-A&V45&T'4B#KL7[M%P2U52#;MFWS)S;UUR#D]DGNMF[2U7\$
M:4K_5R$!N(TUPP<U$DM/D!M?($5<P0@J`'5Y,``?$'"9,@1M4`+)\T(00`$(
M`"=P\'`9`0+7=$T;B``5L#"CD!D#,(7XP`(V\#TO.`OFTB@(T%D%H4,K-@&H
M8`,521Q9<`7=4P`!\`8S)VC_T@5YD54[I(2=F#";8'2`,F"',`->H"D!45,6
M<!T-D$"N,#XRTW-?R3U9@`,58`-R0`P:X9+\PX:WHC]6%G9HI_\_(8%E=(B'
M=1A`/,&'#`0)_I*!+[00CK&+T[$#5=`L(E`&:`$#EK(50P`12#&$!;$%5148
ML+`\+]2,Z@0'`R"%?*$)RX-5;C$->%4!MJ,!.``4&0`,&]$#<"!.BK`7#-`O
M`^`PD&A@0_`NH38#93`".P`SEN-@-R`H5C`#']`4?O`WDO4\([!JL;$4"=2,
M.$!\"B`]+V0$?`!K7XB-"KD<Q`$C#8&)=]$'/E8!U[<`Y6@TY]A]26-('@`U
MV5:?VN8>8,,!7^-L06"/4I./`+J/FH1<GI0V^E<B!9F@"%HB`DE="1F>+$(`
M-!)+2Y`C.I)O7P`!$#%:PUD/_<`X;2#_B:#QC#U0`YUADC@9#MC``#8`<>#4
M$1P$*->4H37P@QS$&#@X>5]1$-+28]QS8E%W!3XFE,X!AA9P"F_@3`]A,F;%
M"@Q0)]0`I7_B%\Z#%1IP='/A)M+S`SS0I:="07*U"K"60(5B*#BG`C'Y!FT9
M8'O)$G)I/[]2ES1!97#H/W$Y4S?!=O(30%@F##459EV$FPD!)";`!WD`,QDH
M5%*!`5?Q!0H0*;BD;\Q@5F#Q&(K!`D?%A908&(X6%L?`*N#2`!,PBITS)1L`
M!Q`P8/>0`/+R!$\:#16P&<<I0N\R*&86%C>0=.X2C*RZ4V?V&#/Z!>_P`<M9
M/E'P2L^9#=+9_P1-("1!M2\X``!><$%GM#Q5T)T)`8$THVL0JAPPXF-=:`)<
MP`=B4`,RL!VI133N.4B%9!Y'D`/S*1_8=FWV*"#5Y@#ZN2"(E&WO&(]ADW[&
ME4G)53;+E7\GHB'KIJ`%V0$,RK`(>TKOUJUVTU44R@``L$+Y9IL-V"^,408:
M"0->``%H%#`C0`_&!"C!$!._PR8LU``\4`#J(">ST`#6M**%PCT#E$.7`6AB
MT',F4`4]\Z-(Z6,/51`E)$,&(0)*J(0L%AA.FB598DP@$!=YYF)0^`W85#M>
M0`,UT"GG51#.4SA#5I:H(A'-@``@M61QZ*9O6G92YJ8UD79Z.F4MA?]E8A<3
M5;9E>OD#8O!8?O`'.!5!RX(8K2`"&JH41*AF$Y!"63$#-<8XN<!6$=<YZ_`\
M+B0/8>%Y;@$H>-9UP_FD"_,#=&`-AV`%X,(63S``0S1@7_`PI?LN,Z!-D0`!
ML2<#6!E566$%&3`=3O@\*91";`%!-K($71`:32&=CV4$3!09\)4/U$H!RP-F
MD8`!.;,#X"FQQI&X0,80),`%8K`%:T".1*-]1X..KU5)SM:._KEM5Y,#EY0#
MY,>O^4%M!0*P\_<U"1(A$$(V!9LB!LNP":NP`NRP_@=*$8N]$=J]%"M+C8FQ
M@J=HXF,!584C'^L%DZ(\+U0"7@`,%5`"77+_>9WA!`@A!BG6*4JJ58N"`PTP
M*G=T1SW;I5)W!3+<I8&;46+@<SS1M:20*#37&#7@.S_\DM1`.0PP07PR%@"V
M`>$``.*2`260#^+%`%_P+EFA`$,``OB"<QQV=Q8@I'D!,&0J$:"R!6G[AG4(
M$FU[AVC<IG#+QBXQMWEXI_?3=G4I4R+!$WQ``'X`B(31'$95!Q!Q9EF7F(1A
M9GWAN&[@!A2`1@$A`M-`&H#R:,>`$`@T`)_G.[Y`#XPC5X@E)5MR88:@>G4Q
M+9G,&6R2E<JI`0/PLTR1J@XFK.\`9P`@`F0%?!^3508S5!-P0*ZV!`B#`X"<
MQ[U'`,N[+Z/CN%;,_P(#X(=!513,=[W8BS/E\!Q\P`46L`4W(+Y%LWWL^EKJ
M**_VF1_;IAZ79`9*T)_R&W_^*G_Y*[!FTTGDIC8/:TH"C&[_=\`(S")<T"^P
M%`44A+$K=!6<UP@1A0,:F9TA&F)(40(S4)(L4`(H!29_<KHB8`,1@)1BD+0Z
MI$,"80&D0APG%@$7?04_1K0UU84Y*PJHX$S+Y"F\("7JQ$/L`"XEP`P0T)*G
MEY.*,(J4D@"=47);J<@(4).GDG)BJ4\$<4)_`4]VL+@-D+9PS+9IG)?SDZ=K
M:-5NB(<OT:94W:9T+!-X"G=]T`1[3`+]0C,FL+QY8%1L88Q04043L`D0D/]4
M6K'(;=")GHP&>OTGYH(,1;Q99Q(2X).A(1FJQ0C3UL`9J=>(5A`/TQ*2R`0H
MM3,#1+!TOU$%AIMH67MGA;#,RQL;7^PIR-*%,.3+:^455#$RLF%>S]J,R3"M
M"K!?MQEF"50<SPR!GH4</O-9XUD<6>`<?L`'UWP#W6%L'L#-Y@M;\N%;]2G.
M`T+.^QD@Z#Q)^EAM_SIMQQ6P]K=)R^5N`(DA"[JP"DK`TN6@^5PS@O`$8>`"
M9W:Q%\L)+]>`U.$<`\`MEV+!:(2!CI%!/T""*<NIH[A!5\`#-OQ0/2MU7WD=
MAF*FZ6.4*,8#J_!0C-&%.R8E?3H*I4`*7_'2F8'_`,*@!AO`/H+2=0U``;RS
M.HG`&1"PG*#YQ!D$)NR#B['-`IA)0UUX=P+Q:\[<A:EB!V*@H3SP/KGB.W8Y
M=GKIMG@I$K2"MWJJU7:\MDN>4F'-$T31AS@U`D.U$/WR+[^*`7E\+8FHB&60
M`0G5`E``:NZE5772.P@@#7!``\I0$07Q%A4VFR%I.X2]S`:1N1!#NEZ0/82#
MV87@"^RD`1\`9Q10`X>Q+L[C%TUH,";@0$O@`KQ'S`_D+]!245U%(TCH&,O<
M6+'!1:'>!58TF,\(VQHP/5W0!U6P/,9QV]RJV^%9#BI``G^P`WB`S<7]'8`4
M2(/T6NDQ(&;`W.F<'_J9_Z_RT9]!('ZQQ6WYF"#K(3;$Q4F=Q$EF4Z#C5EW@
M/9`,6L^EE+`-JC8&^Z#G71PW`DMAL%DKA`^<,"@8\*,J0,P>J@`S,`3Y?55'
M]2TI(3`;75%`60X>_;(1H`87'0`)?AT\H`*_'0`35`I)FJ3+E`OY)`:J*PO]
MU.:Y&>!Z<A!3\D0Q@:KM5'M?40)BL3JI*MGP<%40L`F7Q0!H4=G=D@#<,(8_
M:@,&$<%NA!3BTSW>8P<6,"E9(.1R6-5.9H=4/:?[`Z?^\\,P&L=R+"Q3!F7&
M`HA6'NF)!1H0M`,4SQ811!A7=Q4)Q0^$===[,@U#U.9YI3$9.E6C.@T5,,5W
M+O]8Z<*:4)$C)AXQLZ<54(@!5?%#>W%O9?`.%,4*H'$MA-$I9\`0%H`'FU4^
MDVX$T)<P`G,0%?%"FRX9GJY&1D#I7T0`I!Y4O(0#"'5!1+!5K`X+UFO;=(3;
MY`Y:/M-*).`"?<`+Q1T"ZEJ^Y>'-U6:?DV3L"L(!\%$$]:IM`!J@8'._9?-M
MX'9_W2TW'A+`!.SM'#*0X6[>Y<XB#*G>87`&T6IO=Y8`XF*61<&H15)C"7U5
MFZ`,(/"]-=2SY="E`9`$+U"1/%\`:5(``X0!JD`0U0$(%@T,(!N&&V^&"#4B
M##4(A!L("#\_:I`E)64`.&(-$`V&:!5I%140&@FJ#(/_)7"E("`53E\:&@P,
M&1D?MW`50T`S5C,)+&]B$\G)(C@#&,D8.#@B%@$V%CQV/`PX>)65DI,(=.+B
MA^?HZ>J'D^0(X>63Z>7SYN-T^'0UC_?Q]/#Q\KE[-\[0CS=]"/2)08!`EQ$#
M!DP@86+'#A,BZ@SH<J:+Q0G1`)3Q`J/%&"L)AC#`,*!$!1!HT"``44*5S0PB
M&E7PY<1)&B<)K`A-H"'#"`P9$J1Y1>'&EP0SHA(!M4-$1!RZ,I1@$+'!L@%/
M7!@96V7$B#-GEDD[NR0*EC,Y]\$!P0#"C:T#1#QY@I89CAA&7`C&,K:)D88Q
M=(DP:W6(%S<*B*3)6<4(Q(DD_TBH(&'11.:*GC.+)D%@M.G3J$N/MD"""Q<2
M8EB$:!%B`0H#4Z1(.<*;"F\.P',X<&#&C!+CQ8<KSY'C@','18)$+Z[$`7/A
MPZ]G/X"$.1+GX,&O6.%\O(_SZ`4(Z,"^?7L)["7(GT]??OSZ^//KWP__OOT.
M_[DGX("AH6;@@0@F2((1>X411@P#B`2!A!!DX$PR79@P`00*P`"#`AI`D(DT
MNI21``AB;&'#%05$4,`U`<08@`HTJF##!#6\4<D;-32P3P,-8("-&"(TD`]!
M^]!!5S$UN$2))6JH\0,<)4!@)0X3;(&#C[)00`$IM:CRA0@3L$!!&DO)D@8%
MM6BPE?\N'T```@)P`$/$#%`00<$66V#PC!@6L(3#"!98L`,&(F"PPP1FF6"'
M'"QD,,$W/\"3I#_KU),I0/[\4\\[Y\03CD!'=OJ/.$>26BH=!OU@`F(-==%%
M#`Q5-<T$(N"TPQ\--811&1D,`0,4,+B1``2.-+`5"/C4``<%MA"E01D#0&3*
M3F#:)%11BV%5`IIL/N5%5-3FE.BAY@8Y@0E96,#,"&&X4$45)G1AKI\#0%#&
M2A/$L`1$D<P$`AP]H3G-&6?%,`)678P5[U@0\Z$05A'E-(!CD.EI%6!=X-#%
M9JI1=%%FG2EH\F@A9\9::[!5$,++"QA01&X<\':$;\!QP-S_<,4EE]QR'"`A
M=`YF&!!$$-1EMW-V.@_W'1+6?<?=TU*3=\!X6)^W@GKJ#0@@?V"'+79^_O7W
MM==H=R!`@2>W[3:#3T3QH`B;3"@A!2N)L8-9.S``A`*`$W%L!M)@!<$'<-QH
MP^(VO`&2&(OGL8-J8@S@2*AS(@*D&)XPB\\&E<A2`05EW%(##13048G`SJ(B
MX18(B,"L*7#P])05(7I%=PFQ^#)Z`A]\D`$#)>``0`);H4*$&QY",<06@/*@
M`@\W#F`AYQAVP=+U,3:0P1:4_B#.I9AN&BJHFIIJCOGHJ'\//N[3TXZJ2:8*
MJJL2^Y&0K*)-8#VA9UA+1SHR@@F(_Z%";9B!`H*!K`'4``-;00,=T/"*IP0%
M=V40P:$B4KLU?<$*7E`%,382@QWDJPQ6^D(94-@&KC!#!+*:UPBT9Q8,O7`)
M82"+O8I4I!I4(`%XR\NLK`<'?*`A%K*X@1,H8"&$C6!O6!F!$:(0!;%`[#"&
M>:%5(@*!QRQP"`/PF!'\-P*0C:8B.R#915+FMM289F6O$0,#7E8;F=&L-SC3
MV<YZYC,S*,<Z>B3.T8[V,^M<YSI-R\'0HB8TJ86G/%@SCWG6D[:RC>V2F,2/
M@,QFMDJNK8V@-!D7EA"W,/AA!'4`@+X``(`O4,`9@`*)"2I`A`X!+D2$PPH.
MVB"9-^!!#/\L&4#M?+2(!Z;Q"I5C5C^<58C8X0`#<H3#DZ*DA@U0R4I#:(,L
MG!"3@;U$%JA(@"H;@(`&S&4G`_.@!G!'@0;PJ24,(,42O]"F$E@N`P#00#M/
M,:[FW<"=$]">GW!EH2XDPP0(-0&B1&""&&$`%`&@%*IJ4*KUK0-]GV)'_$RE
M#GG``WZHJFA`!D*0]PED'Y<Z$NA,P`<2\(%7LGH5`?:V&)#H8E8Q\(-"R50E
M&GAA@408`@3:4*1X=K,"):#G!37`B1$THA2C@X!CO#`N-V$@!AR!2.&:D1,,
M.?4)_^J+57*"@0;@H`XXP>$?8F"5(FZ@!K&8A0Q&]TP($8(</5#_$AQD<(,A
MB',C3QB!PJ)(Q8==L2%&>!=$\M+%&4`F`<QH6#1$H)G3H/$S.Y!8*-VXFM:X
M1@PTH&/,BN`!W?3F-TWC61%Z=ISE:*<X@R2D(0V9,T7J49'=P2T2./!(YWPG
MDI$\#R4KZ9[_9/*X_!F0<8G;GD]N]KFB:8AF_`#6,/RA"_A<I2K*4((&`,H$
M,3#!`!0X!C>,09]<"2,.2O`!"ARC2`VXU@",](9C)*-Q1I+$.>`0SU.4P;O?
MHH24PD$3H0IU8-P<Q4XHF(8PJ7*^9OJFFBA`E!!6`'(\>,,`*)`)+W%X*PU@
M1BK+4($:L``"1"`"%*)2C"T<U`06L`%+_ZAQ!0MH:%W38U<`"B"&##0@HM\H
MAT`\Q;XBRV^C'E5$DN<WD"&'],GC$#+]4.H.?;SC!V)H*0'^8`2%.74Q9CE*
M-/["ASY(S"&Y@D`:$K!`8[40`PBP7%P]J%2A9-!/@Z"`E2`@+56\TEQG\0A-
M,6#0*NS@(>8R%P>!U*,,U&$K>G$J#BH@07P,3`9.D$$:*H2!*D1$=4RHU"GZ
M*E0(`/8L"S-*#*IH12,TH0D$&,L(<`(7QH[+#6[00`,V4I:\'`@T:F0;=-F8
M&=>0``%MH$T=26O:FQVAMJI=;<_^J!PS%,%HL4V.=G+`6YUUVSN-'!IO#Z`S
MJ@$WN#X8+G._EO])2R+W/L6=S[J;ZUSHVCLS?-@+%3LFDN,])7<V"("&,*(!
M("RO!3>@`0M"G!/C06`1%`!!I4#0(P9(LU*[YEPD*D%-!)"B2AF4(PUJ`#HT
ML``FSTJ`!6/1!HK"Q)MLLL6^:K`%9;G"%PS8-"N+@H'%(6.A1PFQNHB$%0!X
M`0(4ML6=E`H")F2!!]2S`##S@KV%/?,*,>)!`.Q@@>'90`[?"`>5RU=D]I4/
MR9WB5$A%*JKY2?FDJKJ')'Y@`S&0IC*];L89+'(1\1K%B04D`%(`D`$-M#D!
M-*!!D,)8NUG0\]],9<`9:#78K&1EOG[*R0B6H-,\>`+S0+**-*JUV-K_61H$
M-B<%5QD_S$M7H`U#&,*T&F!"$82=8!=TI3TWOY<GA%$$D[_B6&(]%NP"?ZSX
MU`"NO<""E?1A"59!$&@*5;+3$#M!A>J5:%YC@2T,@3:VP4VS;0:<:B/-VGPT
M)&QO<WY"^O&0S'$.<WB;6_KG5K?S[RTDT\TUM;&G:YO4'\G%;LAU2<45'_/V
M?_5V;\-V!G$3!1#"2B9B$Z"`#3:F`A-0!D#P-RW@!"RP<!C0%YNP#TX`!U%2
M*1LP""RP!<_R<!M2`980=BE8`AS63C8P""BW$WI%83:Q@JSP.3ZT)M("`5M0
M`"^R!<2S%<2C"SC`"@;4+SN0!U?0/W[R#+A2_W1`,`2C\P6.,16UP`(TIPS0
MD!<&M"@1,0$VE@S5D`7K]75A-PEC!U)E9S[R@'9(IG9,!E(C)61YJ`_UHRKY
M,'=8UA"5X1!',0%\<"B$YC\^9A%^8"]=X"[<509$``0PX`5]Y0Q6D7,T:$$K
M!"Q@9A9GD'G3X%2*`A*`9A9EU15`DH3%`T,+8W%(Y#NH@R:FABNL0''O``*:
MQF>Q!T:X$@ITD@9.\4$MH'+`PGM[X1<P=$6"$1BN%@-Z!Q',D$]`X`8S0`,5
MT``$X`(080*;@1IY@$;4-S('HGT(DGW2)1KMP@;?9QLH,#/C]QLYX`'((1WH
M]S/"81Q!@`+N=VWOI_\=XZ9'X*%'00-_C<0=^E<>7-.0:@.`:%.`$KD?RI6`
M[2%L#!A*!$!*5!2!JF037V!/T&1C%I"!&Z@`'?B!7C&*V/4!Y%0"3K`!<R`E
ME5`#EN,ZT`,!%0`ZD@`3=/`L7V`E(G`C+(`/<W%$3$&!(("$LNA-0LA4)8``
MBW,,"Y5YF`<Y-990>?`&4H<,NQ818)D!E*B3%"9[0)0`1%`"-8"&%O!T/(`1
M(B`&*F!C#Z$]OV<"V6`]8E``;PB'%*4/Y*!1<]@^=FB'>,ADII(J('525-8L
M*/67K/(D8D``KP9K:*$:8Z9!N:)!.3539((4=0$9,#`#-]`&W@47AO.)%9+_
M%Z$(5E'`!PK5#`QG,:S)&,+4`*CW@<2#"UJ1$[IP+7,!!RQP"A8T`+%9"*)0
M`3<`%9CH!!`P*$7RDWXU!!3@&"T00H2W>6B!FCC1!7[@C-#8!'XPC7F!`Z53
M2V[0!BP@`I6Q,!.P&2MC6191CAB9&;UR?:MA`=IG;%F`!RR0`"T`C\RV&S9S
M!,(Q!<5Q;44@;=1&';%U-`MJ!MQV2..6?^0&?X9T'8T4-`NY`OS7D!"Y;F%#
M@!-I'_1AD>X!D?69D2:C&@00`ZX9!0U0-Q84DGF!`?62$Q!@<"B9<#3`FHLQ
M`!H@`F\P.B!P@N"09WJF(L+DAP.C)(ZG0@S`.3YR_P@_N29\I@%?P`!,\`:[
MA@M@F@D54@*?.5"`$G`W\B<Q9B@/459%@@'[@`%P<!7-D`&HH*5[=B8_1`1<
M>@V%@E",J$%B"!*_9P%V8`?>,P%\"0[^`)CH@U%E5YB2ZCYL1U*`2"J/Z9B9
M6A"@,XB5Z1!GT%(D`"'.$"AU,"AA9BA.9:=E()HS(%2L\&5;9#%DL@/;&68(
M`R3J12)V.@T8\"^64SN]4P$TT&''<A;KA4Z2$%\-IG()@"4LP2Q)Y!0),"XJ
M5Q1'(4RCXV'5:@6"DYU+L)W,@!,C$`7@61A]$$8(DQ<#<)Z0`0$L,`"`\00>
M0R.D82#`QAGFN%GJ6!K&9O\#>,``7E`;MS&@!<H!#N`!"%HT1J./Q&%MT3%(
M?/1^]\=M`_EMBH0=&>H=&MI;60.B_9>`(UJB%(FB:+.B+)H@(?,'KOD'&)!*
M4D6!\Y4HN,(,E>@A7B!4%A(1$`$``^"EKH"DE<(4>M8`/,""AJ`/*/<3]`0*
M#]2D$_=Q^00`#+`%`<`#G-,C\"5TSU`H^BE=/$!W;]`G>,:USS`(/@)7O7-/
MQ'.G2W%->I9BH-`GR7`11'(]A9('>4!]T:,"=C`!&8`!B[HZ?2@J@ZED[G-1
MD[I1))6'?^B'CQFY%!5E!O$&KV(87886?H)H!81*6-('>S,"%0%!&<!+S`,%
M.?O_3-JS`S^'9V"F>9JW6$#RE;FP0JMI%5J1!B[1>+^C`5[P!1B`!2U!<DE+
MG%JJ9X."*.94`KY[`]2Z3D+!`""!`U#U$\OINRGFL[MRJP.@$>5ZKE;$#!@@
MJWRF0`HP!+O6,/0Z`I55&M>7K]7W7.BH,EO0!@,;?E-06C7S&U*PL&80!`UK
M'-7VOP:`;>[G1[156\!!;N16;O*G-/`W?XX4'I,$LB$;;^Y&LN]FL@.R@"E[
M,NMH!$O0%E%P!MGU>`E`+0O%*(/P`1MXB=ED3Q&!*`!0`CP2M#3Y`SX4+J!@
M`S-Q#J,`+E_`"9`S=7#0(Y8C#9D@`@@`.0&`#2\BA7K+_SF`\L0:(BNC&+ES
M:CD,0+,LX0KFM!.U0SS<527Y="::D`I:6@L,()50!W57`)IB4&,[-`%:%P":
MP77=!62$6TQL=[B(>YB0BKB+JSYZZ+A_*+F*+'>@8P.7>Q@*8SV#(BOK@A2!
MNW<FT"AYD"L)U"''2`%8$KI6.;.XVPQG,;["A$05$$^HHR]E`)U(1SLQ40I`
M,0-$X`4B(+P,P"H41`JELTZJ8!2X,@`54`MG<KU"00SL:4)J-@ML4F$IED&Q
M%JZCV*Y&8:Z"\8R!(18+LQCFDA1>-`3KV04NL`2^9D:_9A'!-FSKF!DVX'WW
M>QNE1:"\T;\12L#GYT<]`\`%7/_`^8S`%NIM#>P<XW8`V+$T&1IN'8H>Z?&0
MZJ9<QB5O(TJBF`1O'"P@'OS!"J)](HQ#4;`#^%0&*&QJ;HJ*0OHWEYAP+I0H
M,_IP30*#-#D3SLQAY`17-0`.LD"#I..S-F"$R&0506*F;]#3=9<%52`&.S8C
MR$3%(.$G1P$7%D=1&Z!7C<<50)()IE`*M<,49:P)1*!/OLQG7E(,3,#4RV`A
M=;LP&X%U^NFW-K`E-B!1?MD.AGNXZQ,_YV.82';(4P:9FMJ84OTYC?S(!'!*
M8^49`X===<`8$R!XHBL"5N)8PY*S$.#-B58"&;`3NU8E]D2;OE`*:U(*-+!*
M..`'H"G_U1N`!K]H$\\*?0X$E&K&9]5JRQ#P1")`@Q#@$T[@5U8P!D3P`0`@
M`C/5KIVH5)^($X!!17QQ!M;<!524S59D11U#>DY5$U[P-\4`0^6<%WD0C@ER
M6?J*LBTJ71;8``E0&Z,US^0G!0NZH/P\L?P<6P&<?HADD-Q1H1GK6JZ%D.#A
M2.?VH2%*7!H\T1=-7.*MT:>AG\4VPAV)`],R!%P(JU[1M;@"`"]L!11``UT,
MU)]0!H_@$E'2DY_-)@,02R%&<LZRRKI@3Q,0`&"0U($R`3:0!#(2`&R=##4D
M!L>0M2C5%1/@>;<]%[$`)%M=`78J`C5`/"_!*I6`!ILF(K5+_P1?X",58"*\
M@#NLX!7K4B@U"R@4,5#H(B10%Q%QW9>+X'9I=SY&5LAH=\AT/5)]_9>*[-?A
M8!`V,#F&4=@S%%XD$$PSA!4XBB@[$"BKB@,)8(F76*P-H%!`L@6HEW,[T7Q/
MSJXY!PM*4@I)5Q0Q@`%M($U3#0)IX%=H:1,X4,U,<0-H(BXSX`786A5B>28>
M%!2^301E@`%^L$76DPEX\::T,L*D%*Z2W##8#-W2W0Q[4=U$`1D:4`&+X0)1
M8!5\X-V<)3*O0NT)CI_6)QH6\`8L<+^VP6S[^VP>L*`R`\#M5QS^;.[_^\\!
M.7_>5M`&36VSM1P5RZ%3<S57`UP^,/])%CG@FF31!9XV&8W@".*OHX1#+O`'
M$2+2QV(EK*"FP(1BM42:&CZKD*T!<V)Q(0Y7KU`EE<TBR*2\L]OH.1(C-6*$
M3PPYC-.538UG_(`(/3*L<.`C&(`+OH-..`=R);YA150).RA.;W(X-5P7)J(!
M4:%/+(`'4)<%[5*S@XY&.&X]&J0"`<`,;\#'E@*9ZM,^D3JI;IZ8;KZ8??C7
M%#7GF\JIE3"9>=X'@B4:8Z8HW4LF"O5$;-J$;#;9JQR7RILDWO393^X5P<HJ
MA@`"%+#;05DAVF-Q5TJ=-.!7PD`41E'S>BI/XN(&7YT!72!XK^XE%J0*TZ*)
M@_*(01?4Z\+_!S#JZV"%FJ4^157D(-E<?-)P[+=-%!.?!B$F&!`1`Z_1HI<U
M4_NZT:9!WMM>`?$L,^K-&_4X!==V-`T[2/[\O_XHL=,VH=QVH?'WP`BLWX8T
M-(H4'E5C-1ZZ[Y'TT)7D[__N'P$O\`=.\"A3;%&`\'Q`-ZV4$@X_PXH8#1HP
M\4.@C6`)"`,,91IP;P-P&QLU#7!P##@X(F(!E0$V$PU;-C\V-CPV5Y5-!"J5
M!39B8F^LK!BO$V*,((J+CG`@#2P,#`T8`R45<'2*/W0,)1!E90R,)2!T(&D)
M"10E7Q\9R"4:`+T5)0D:,U9$$#5B&%VPOP,8._`F\CL8(A@FIA@X_V\!/_X;
M"`+6H$,PH,&#"&HI7,BP%L*'$`M"?"@Q(!V#=`9:),BQAL>!!#]Z#"F28[$?
M8@@T,4*`SYDN?`@0B#%"1)<)`P!(&K&CRX@)?F+@R*`!"`PH7FX,88"A`:*/
M=-"PF`IA2`((#<0(0K.!#IPTR:A]H0`APT\6%2HX^>)$[9<$,V9X28!C708(
MPF2LI3;#C0(-`V+X$1'I+@0(;7`P&##@)^$1+HRPC.'+YRL,9\XLB;*D\QG"
M.)Y$&1VF=.G11J(,"/VD)@Y"1!00H=%`1.0S`[IP(4&`A._?P&7R-@&O=W$2
M)GK_%NY;IO+E,BW80$`C1`@4*`P4\2!%RO^1(QQR."AB('L0`]J#G$>OGKWZ
M(F;BFW&0HSZ'`P?"T\<OGG[]^/[5)Z!X.2"!'Q(YW+<"?OBMX(,/*T2X@@`=
M5&CAA1A6*(&&$G3HX8<@;OAA!R.2:.&&&::HXHH5"F`"<##&*..,-,K('!=_
M+!%&9"-``,`77Y21P!<EE."."1/$,D!1"KB1@!.\+#9`!H0P\(8(N.0B0@,@
M7&9!)2J84DDJG'CBB04\J)`%/BJHPLH&K;#"B"]B-,!`EG"DI>=7$)2`@1@,
M4,#5#VKX0T<%%"S#S!8B/.,5!=6DD08V$$"2P0<)P%%#!1`00<088Q`QA)9B
M6("F!2*X8X%O2$[_D(=O:9(0P`09U%"`'/\8!-)%`3F44$(-!;O01,06:RQ%
MO"+`44=0D232LR/5$)`_*9'"DD\UB3!"/2-T(4(9[C1&7+==K%9&;##,,$0;
M+,@R0`70<`1"!314-00$(DP@`@,@@,"-!A0,X8475HA3Q@AUE@%!&FE-FH`5
M,X2:@`A&T!KI6E]H,`X10)1A4ZK;BI"J/1C$8L$.(T@211B2$5"NMMM.*<D9
MG#W1V0BKC1"%"SR;=IIDJSW1FKGCP.`&!;6QC%L7S=7X'`'QJ$`"/%2;L&K3
MS3$''0'2]4!!"`M@5\04W7'P77A3E(>=>^NY9X!ZZLGGP-P)<G!??G7K_U>W
M>``62&!_=-?G'X,'1.B#`!).2"&+*8KH>(B01_YXAXPSOGB*`F3^8HV<=\ZY
M<[YQ882./&;PXQ!E`'!5+['$8D,#&B@@NQ=0\B+(,@"44*=`"(A1IG1@2FU*
M`9>LPHKOJO!`PJFOO.'/#XMX!`(<1M:PRRT@:&0G`SZ6D56@=/PS?9Y?S*!Q
M"4X%DZ<P7U&0<:7):&S-$$-H0`3$HK*050$\F"H&8?G:@;YP,(`)B"(`PC,!
M5@*`*W_H"B0'`0BP&#)!8?GJ6!C,H$4.LBQFC<2#T(**1C:`$A-8RP@^64UN
MB+,#$V```C@0@[ZZ0``3^,$((J!2;!2@KC8P9?\+#*@`&C8"`DA1XU[V2-7T
M($6!2<W%"A`#P"1$H($RI,4)>X$BQS0P@HKAX#!@A$`=RI*!#/@"9"Q!4@/(
MU84JX*$!!+39$HQ0A2XTHC8-L!,`,D#`;HT@,SC#@<YZMJ/21$8R.;09S@8`
M`0UX`08*&$)MHF"$&&BK-\^)42:'TT+?"+!J-M):U@C@B08,`6QBXXYWSN8`
MM:VM"$$H`GG>%@0SP$T)M92;?^R6(+P=X&\)XMM\"H0$!\AGF`*BCX$.L$P'
M1:A!A\N<-!=WN<:A2'+8+%'EMEFY:6[.<^`,)V]NY`(=A2$*9RC!CY1QE4IA
MX$LNE"$$@$!/*]P@2KS_J"(`(%"/&M@@``6(0"6N<$`$^D8%/'`3*WX0$%8D
M217I$$%"HI*+6SRB+'E,PS!(^#P$(*H,%,C`)!J0!C2@88D,FY3&-%`"CR`C
MB-.K0!H@\#Y+G>L9#:A``NYG!2=5H`86@$4LVC$!XM1#!#NP@`QW0`(56"`#
M`[!!`QEJD5T]I"&]LB`%-3B19!VK(LI:5K0^&)*,A#!:%R&A&$Q(QTJ.X*TP
MF0!<7^@Q)+TU*#3!`3=DYP8O+$5:^X)&5]!0@?HYLAN22!5:9"JI+Q3L840`
M3$V6P3`GN(\O0&#I&9X@LJ8P9@"=/<,$!`@R2K)$7R+K%@98<!B;="$&^NK%
M_T5J``*T-+$$4'WK'P,I`DKR[+<\DXP11F"6..`LAPGP`A04D(`U+L$%?G@K
M)CNG-7B8*AXL_.;68.2<5##`"Z@T`-E6^9T<3`$%87ME+,F3R_/D4I>[Y*7=
MPI,#9`K3OL:4VX#JLTP&28B9#5*<`![T(`I54YHG.M$UL<DARG'SP2R:IHO$
M26'J/H<+7#"G"V+`@!\%Z5X4Z`4E@JJ*$G`,"%!(0!O*6*2KI&X=#>`!#P(`
MAE2\(117X`%!"8J3!CC/'V^HP8W?,(%7,((%_7)$]KR2%A]!8`L-:`,<"%4H
MLU;@+641P1M^$8TT\"(MEZ4&#3SR17C%U&$?\$8)R/_R@334M@U>(`(48``#
M+]!@"S690"7Z)[()J`!JZSC#+R2!)A4H!DT=30A9KZK51BN"J\CB%4>,)1%)
MFW4@S7+6KIX5UH3\X`ULK0(!HAL#Y^00!W\J`;A$8-08N'H)@H@=G;W0AI^^
MCC8$00,<G$"-AUE!`S@X`Q8&P+`\6?8M0]JI%$O6@+M<`]EBJ91N14V`*L3`
M9IS9610>,YK.Q*`I<*B-H(?`%@:(X"4-*(&;0P("'9P`BQ0(\66*K,+GNF!'
MP'7!SLX@2.,VA@')A4)?[?'</W2!AIX3)7*29#6J?9*[X]P-="PP@3;,`&SB
M5>5WP.,!5ZX-/=J!3WS*4\O_N,TM<,',&]\29$R1*S._]A4<?Y'0WYH;2$+1
M=%"!,U1-$W&HP2&ZD(>$CB((7RAS%KJ<A*FIW0H[/3C3]<W*=C28,GP!`/1;
M!E3?:0$3](\!L3'*#!*@=2I1"0`EPT"0,;"%MOOS"JDHE8Y_40/H*6).TJK!
M`'P,1'AQ5`UJ.%0:EO'D+62@`L":Q;PRU@T&](Y+7Q&&3)$M/U\PL@2.8$`:
M+IMF7N`64V2AAA?&`,D9.(%1&.A?D@;XCIL<G-Z28-.^Q,"#YTF0K%ZM8+"R
M:D&NYK[38?T]0@J2K`Y>>E?'/[Y'$+#\\(%Z):(VP0AB\)N7)?6+M1G!BYP3
M@]7(_[K.%&"7WOD5E3P9T=?9P,P`*"",-%C6U]0`]@1B(,`I*>,P&2B!N4$[
M@B<8@11]$!2ZM0XXPT<CX`=1$`/>@@AH0%N,0`%.`!8BE0G!``)HD!'M)@,W
M`"1?P$^OT`6X04!GD&^&I&^5)`E+4!,X4P;*U5?NT`62L01GP`<6%B.MPD))
M<A-%A37"(7'C9`%O-`10@''C93;@(05I@QU*6![H(7*VA!UP`R`GER!(P$O!
MY`%TTW+PI5_V@2#TP0$TMTS]13@,$DT%AG0MTG,8XF`D`CD9XH81AH:8<W02
MU@%RZ`--]W1ZN$E&8!I_,`)U("2]MD]'PC5P-P`SH`"0!/\#5<1'0U%&`#``
M0>81.846FN(\;X``L<`#3:$LO8(`\X((R3``;P0!4P9X_^`5AT$6WU,!&S`O
MPN`5:Z$!"0``;:`),F51;B$.8\<""&`#>=!L^;=F8E0'?)0J0_$!&B`,W&,_
M'$,$3E`;2F4/JI`J7&<JID(`$]`%.]`$3:`"^D`)ML<L%2%!NK=[YPAIP%<L
M%>%5E59\QJ=\'_0LFB8M'&4#*R$9)I`9`I0D<_5%[Z`M$_`22^`MW!,QX$<#
MON@4#1`-:G$#O0877B!232%3\>8^]D.+&@`!C=%_0O-6(@,S!Z=;Y/($@L:0
MFJ!W15(")/,+=W*!)Z4+DF)94B3_5^3'46BP>5\P!-8@2$M@DI\1"5TD7/DF
M&=TW`)O5?]^B`6/@!C/``'@6@T]`?4X#.LLA0/(0"^E0,J.E7<K!!7G@'*:R
M`2R0`.%5A';C`;)4'@L0-FR)`N\U2_`!2TIP<G03AH(#<PZ`2^]U3/,QA0-R
MEV%(<V18.!*R='7(.&P8="K"AI:S<RV"(6BX=&G(='IXF<L!(WPP=2Y`7#]R
M1&4`5:5R,KX#.T#@%T1`)*"5*JOA#6]@)R34+R#`"R!`*`A@#T$U`!>X`8!7
M*+.Y>94B!EM@BAPU/?UR94/B,:^3".,S/9M'#0"P*%NP?G>2)V#Q%AJ0#?ZD
M5`/T69_E_PLX44:T"&8`\`&110T4P`(38`.O$`#]4Q-=X#]-<0]B(CSZ@`']
MD(H7L2P&88Z.!A!;Y7O[&8]=96GP&(]GE:"<QE'^8`.\(5PI)`D@F!G>4@<,
M,%KK,']5('T,D`$(F0`T0!L(H`\B$%-.`)'QUS$!1`_<`R0`H#%]8FX8T'^=
MX0)YD`<HHRVO4!.,`3.?L24@@``]<)Q!5`'>J1@L8%&+516--``NU`RV!P=6
M,1<A!EJ;E1F@,0)_0)3`900N\`>,D92<50=P(7!0.0)5D!I3^3E1]QLLU(^M
M4S)8R5UYL!LRD073H5,8MQU28#8<@(3HH81*V);F$1]R*7)*D/^7_N&%<R,?
M2J`$MM27QV27@+FH_`5@9!@AB)F8BKE@(&)T/,>I/;>I22>'$X:9EZD<JLJ9
M_*8Z"9!UH@E0,F0#-9``],1<%0">9Q`RN?.:YP!X=[<O#<`(!&0!#0`!M8F*
MT$,'+$`6^H<'>'`GRI)3PR`-CD5V#%`G%6`2\W)LW5`K,G8E1;(-8;1UZL"-
M.P!1Z>`+7)DRII.:;\$]H)=<[9()";4MQY6#`(0/5V`!O=$F9I2?AC);TI(L
M_NEHYVB.Q#)I&!&/PL=\F69\$*N@%/L1"/`\A=()*I"/,[%(!X@%?N`'VI@!
M=9`OHC8<EC04'%-G]P*5@]8PEP4DY^/_1R#)FJ`%6D75$UWPDYXQHZM9&Y%`
M0.>*&WLG/6G!"W#``D*I#Y(@6!L`!R%Z+Z:#`T7F>-!#6`$39V-7%HU!H04H
M`C>4IK]U&I%!&)JA6QE0I@K0!G(5`VI*E30B'*KJ&R<##T6FE:L7#UE#`A@V
M3G@*`C<`7@N@'=UQ-DA('DN(7H1*2V8@2X;ZEX`3(,;4J'X9-W[YEY0:("F7
M`PQ"F,QT<P1VAM-$A];DJ8X#JI%)NI*I=`A6F8=S='F(JN(TM[Q!.AN&`ZY*
M#<N`:F@B5S;P!A`@.[@*`ELP?V=`#V7TFH>G!A?P/*^I>53"`)Q8!K1@*!8X
M+S2E?Q/``WFT_PC"D&0.TX$LX`RX0%L-XR.-1PF@4`^V(PB@12<R5&JF8@-*
MA0!.L9HB,Q3VTT1X86(`,Q=`A9OV8`,[(#),=3+;@B0B0T-.Q9("2U40R[`1
MA+!8Q8Y@%7P22Q%DM6@<5(\*FE8G\3PB_`/*0P`LX0<OT04V-#(S6D8J>'"N
MIH",X06RTT/MDIL90!8OND_YQW]"HX`Q8`(1E4<DHX(D*3)YE$>.H!A2(C*K
M(7GKDQ;)X",9<+P$=+'+>F49,P2J1I$B`!!NH13PUX$O^!(%&!A<>F_G)!DI
M@P$I^%9IZP5`H`#\U"TQ6&I5R1S,@8.P8"I)0C5[V[<$D`4\\`85X/\%+4"$
M9<-QLB2HBNN6ZW6YF"N%_2')C7NYE#N%4V@@]"4@-M=,B2.ZT52J:MB&J&O*
MW329=3BZI&RJFB.[>\B#*\,S6"`"`)"[T6E&^$`/TE$"<ZP`=E8!YI8M7?!%
MS(<#:;`!*9"Q!>!110)5F/`,BN`5T"`-[H-1Z]J?\])86.9/-;`O4N)Y9)%E
M.?C'L4!D[!H+."IHKV`/'\$HC!$)C$$40&`-+O8%[E<--5`/$25CJ)6S<'IJ
M&%`*/,`8M3>.$7S!_RDL%GR@&]%!D296FQ:QRE>.(3S"&%TH5_"@1H#"3$4"
M?)!#N6'+&5!D,-P'?3`3D5`48^!7/K0%$17_M)'`"_:P`S'0&3M22;`%&JLA
MT^=FQHR1Q(X@S&#A(ZB60^QC4C%%`5541?FR=Q/5/HXU=AGC,?7@")L'@6\!
M104#+J\UDC)S!FF<TY)1S"+PQL3U!31L#FL$@Z-#0SZH25;)&\#1CW)JMZ-%
MNQAVIQ:P!4*8R"@P-HLL!;.$'6UYV.81R7(CA5+8J([+7G'CA/,QR9I\E\Q$
M7S0'A@=2((:Y(`Z"F*1\RJ)MA](439LZ8*Z,8$L7N["<<%A#`OI&RR-@=3L9
M)&6`/O]$`C=A`P.P0^I2`O(<"?50!@&<!G2@K,:`*"$U`-)1HH-U@5X!G+?M
M"TY1=PSEG!!0BZ[)_S\4QYI._+Y_TG7)00([=@5#G,1(_`J",*R8-M3F1AB=
M4@T48)WA,';FI@H%A%J,@:Y6\RHY.@&^$0"IP@FV)Q!6-<&\M]`2=,$1P>`%
MBGP>#.$*@=$4/L*]V9MR$``DT`<L@1S<^!N[:D"TXC$M9`)\$+)U1$!E``2A
M,A?XLHVNAM?U4#*9T1JZU120)\R:=QAUL!.$H7^2PC["C)$?0+4Y5+W^@`8T
M8!7R/8%`"@=O,0191`U6X#TF(`)-)%/'YFOF0^)1\`0'ET-U,)3`1=:C@X(V
M_AI%408XX`MB74XP$=<0)]?-\4GT,`$GPXVK(@]:XS^'G,AA(TN%RP$=-_^H
M"P`VZ?4VL@0?C:J%NC1RZ-&X["')E2US_=&%S$1,GHNIB?/9J'U@<CC:VW3:
MIFU@ITU-I\[:K?TYKQW;+H`%L_V9J!.:#?`)084!KR/'LE$-P$U`C2$"6&$#
M6_`,ROJ*P%DIZ[D%(*$(L*B3D7AC>C<``W%F9,$,M.>>:!)WI2)#KM.O)N!J
M()BNJU<;\0Q:?X(!BR&;NJA_K0D$"<`^U]!(`\,`GR"--2$&-;$#[DD"Z1"?
M&_T;`0!'%E``!:XL!]Z?C]9["?YHP"?!Z_CP#8Y[)%$0$U[A%B_"O4DH_J`&
MQ,,#,^&VR/%'W`*2]Y`3/OY:KC88C4)/J4D#;9[_'*/6$]GBG8TA1_0VK$EF
MD=;0XTZL;DT$![K&,$R=G1G0%"WU#X0%D1I0,(=10#4!!Q0P%UBTU5P-`7B.
MY3/I/HX%,6/P`1Z3!UC0&=YB.A23;\$5@P3TDW\T`*E#!$9R;ET$YWP@Y\$1
M2L#1*JLW#_/02<UA*M1Q<8O+IW9S7H9]Z*@4^(Z[E\84Z8XK'[)DN;;TN'_9
MV('C'YK+(.(AAF,88#@WRFFHNBRB342G(IGSNJ3:(J8=VFD((:B^`JJ^ZC,R
MU[Z1&L%U!J;#@6"4WT4V`L(>.[+!DS3@G?7`D;1*`2"@K-%]S4PA"]`@/N"0
M#-$98Y50)]^9Q"7S3PBD_P(F<`7$XYZIH)5;.5=;\BR-P!A2XA3:<+3%9I$B
M]1J><B^'\9EO40&O.0`R-`E:X0[P4"Z2``AB`2HD)#P!$SAB!3^-/W0("#4U
M=)"1EP@;FIN;F!N8H*&8E9:1I:)TDY2DF9R.K["QL&JO<G(%`0$\/#:]%C%=
M77T$629G(SAU(C%\$R)=`P`B$\%^!"0$1B,#$$0S"4,4$`,872,B(@,X&0QP
M#0,,&3@B9SL8`P-P<!45:?[^)2#@&&&"&QPZ&WYL@#,$`H4O$`2*P""BQD(G
M0YPX^6*EHP8-#";<JW#CB\:2"6:,Z0AA`@$,$2F(*P,`@(8/1,H,6!(ES)*?
MR/]T_C'BHJC1HD:BX`-Z#H=3=`,FC#"2],D.+EP*%;JVE8!7KUVU%MHQ@6R7
M'19(F"A+UD0A"S;PL!C2(D0(%`:*>/`@A4..(B@6"!Z\`(5A`XB+F''@P$P1
MQ&;,(`[B6'%DRY$;+];,.$>.SIX_@^;``0D2OPYR'%C-NO6!%;!]^!!`N[:`
M#KASY[ZM6[>$W[US2^A-NX-MW`)DW[;-O+AQY\97O)Y=V\<*MV*S:]_.O7OV
MK]][NC`2HP2`+^@CRINX8\0(&S42*%!`Y`L-!@/2D1,!@0'\$B"HH<8&=(``
M1QI.R#2`!6)L,4`#FM0`!P,E9`"!3F_DDHL-&#10PQ7_N%PA8@"X8!/##F*D
MJ***%(DPP@06W#,`"#706$,#^E1`(0X=EH`#`Q4<U`@()5#`P#80:`!$`FDT
M`$*25GCAQ1`/3L##"!A8H-\(.YA@PC8BY&&!"5V2H$(B&`3PRB63D')**Y_`
MZ4DGHICBIINHC'(GG)K($HN`@`8JBX:Y[,(+'B)AH*B+75311!-&!!/#.5WP
M$8.B0455115^_/%'%$MLD\$,I'H1$0,8`-/`JBS@4$*0#510(0[YZ9<&!6GH
MDT8_7Y210`9<#E""19J@4<$7'VD`41L3B8#C0S<X<4,"'5GQ44@3,$"!1AI]
MD8`&WEA!1`83.%,A30F4H2X$_R4P\$P73\2QQ!/S#I"!"'P0=9115*4#U#&U
MMKC#&51%\40,6(G%%39?-;P=`3M$'+%;9%E`U@[7F,`@`U[855A>?/4EA0&#
MV16"8(8=IAACD1F`5Q!!3%8$S)%MYEC-+&\FFF>H,99:#J7Y9=II2+!FVFJP
MO1:;<LFM,)MQU#$7W-14!\<;<K7!QIMUU<W&='--K["<;3Y@Y]W9:'L'GL(Q
M1%'4#@R<EQZ[[K:XR!L0`*$`$%_L"M5^993P7X"/H`%"/^(,6T`!-DRP:@/H
MH+-JEKBH8/F&8EC`@XA7C)GB!,=@4`,";Y0NR23OX-,`1>WF&.0^_3@!00:*
M9@!@*_]T&`O!%_?:J^00++!``WI>S&!J#;O<DZ((9&5I`<2*.H-/ECR8@$,#
M/*P929NL@*+))=_7B0J>EKPYIRM^R@+H#X+&<@LNNO`P)HKEGC-"%XM.(_$.
M59A0!3`QR`958I",:8@``!"(G*2&<@9X*.D;:<#/!";5`#2DPD#\F%"%[B4&
M#.`'!&A(R`8J(!,(T*`-]^I".B)QN),DP`M62$"Z]E."?\A`6C*TP@R(`(`!
MB,$$#"C#MF0RA(\0X0,?2*#T@H$.!LS#1>4*QA/B)2^#B6`>^=+74:CB@C.(
M`"A3=-$9`#;&*%0E!MI96,/6N,:MF"!C%R-3N:AA@BS88`O_$.C8QXHP!;YP
M0`J`*9G'"J.RR"C!##%SF0%BII@B8,9F.//99GSVL\],,C28+-H!CC8TUSB-
M-M816W*B)C:L7:UJJ,0:<4`)-JUES95,6]IQFF.VM-GREFL3BQ_<Y@(^1$-N
M$6G7JJ81@#G8H`1$F`^3*H`/?*2C#!D0`P(8``*%U$B#[&K`&Q87`<9!#@$V
M@$LO;%`H`C3!<KBPP8H8E*BR]*%#"&C$&TX'`@.IXT$B`)(^0*@)$""(`NE:
M70D`5*-C]0V@94`'#I3DA1/N[@M>\$8"&H"`+8A@"V+`TA7N\:(NS%&%M)J`
M(;*`#Q[(P1&?V(`J5F&^.8EO%`AH_VDH-I&^FJHO?1KRA1@^>@X7*4I19]E?
MEX)!U"[$H`I4,8)7C'#%`9"E#!`H1PR4NI4)J$,#7M!``L21@0:H$`X@J`2!
M]'&@"XVC@PR`D$+0``<GR#`<][G?-@STD&U-JWA:5:((A,@/!'F+6CN41L2X
M$9$A#$%=4)W=1-0Q@C[TSZH#P!(&1$+4)_2D)T^XH@C\H,4M4B54])KB$B([
M1?MU80DN,-@9%K85K;#QM0YC6,76DJ@SQ``N6Z#+R1(3,@=,(3"&6<`@4Y:7
MS"`2+Y.)6<V6F[-)4I*2GGGN<T7SLZ&59I.M*9K39`,;IT$M:JD,;RI!&37G
MD)>\H5P!<O^HXTK;Q"9KM;RE?-4&ENSX`;6]W"LPZ381&%D@`#9@`!'TUE!F
MWC,=%JK!&]QQHP:PH%8/>D,2-+0X^;V!G+I0)SD)<4X2B.'"'S:=.FL@.C'L
M0`05H)&!]IDC"OD0`Z\*(?MH@89;>:L,'I(5'-A:5Q*FJXD)`((&<M4`9.X0
M"#-(0PVV@`=$B(!!ZL@2`2Q@@3SXSZ.%L%PZ+'#21L1II968:9SDQ*>7GJ]/
M-DVS+&P@!T+I@@14WJE(>HJ.<@1C`EXBD\3*=88N]-FHUOA*$PC`V:3^P1Y8
MR@".8\#H&'QJ"0W$`0"DY`6(E``#[4DQ*<9:@38D-BK0:$#N*@#_CH?(L-+C
M"`8#&)"&&B+H6RJQ%NVT!-78_34!'P#"N,:8GW-02!Z]#H87,["3)1S5JD_L
MT*I=-`*>\,2+\YCJOI!2L!%8=EY/R`^H,CN",Z#6")#FPW=<"]O7,@QB75H+
M6LH%C`F\(;=U60!B^B@%*4S!9804+LH.DQ@S'#((_(8999:;&<V8@;J27$QH
M&B-=GV'2,YS4)&NZVUVD=:TVX@WO*7?#2MZ8-Y3<I?@KQ<8TY8`<OO--.7W;
M2((_X/<E=0!``B`2D>O!Z`H3$$0#E(1D"AB85OA(1@-P/KK1E4Z<&-9%%@ZQ
M.!M<V.FERYP-KF`FQ\73RP22Q#X>!(U<_^W3(@C81SS85;L!).01]80#0+6J
MDW>4`'9@/9"W`#"/$I2!"`D($@VZ000-&`\./^`!'BR*`3%<D4?/DQY!#D&(
M+*@``XK(GI=-P;TW<8)/*:73F=7,>5@8:A>%"J><6\3LGDYVCA(C:J.->J(W
MQI8`7H*].4;@!RQ0Y1H$<`9-(GN_+A&`#WVX(@"0#(XOE*`!SJ!F)2Q(APH,
M86ZH4J&3#.I7:F6UAQ%C``1V57W`6N$#Y/J2HLOP_&\!0%UTY_4`SM"'M8`I
M>E4X\3RL'05+;:-6#MY="?#1;7I-:BF=Y5E1X![;EFTB$`=QD%GO,AZA(FX*
M0V[EEDMO1`(7(_\2Y9(BT8,`+)``=8%<4U!OCY$R);-OB)$74W`9P#49B$1P
MD31)QH4SHN%<J>%P$.<7'&`T.2!Q%"<=2B,;/@@VT+%Q&6=*T,%QHI1>3M-=
MM$%QRM%=UL%=Z'4=*C>%W,%&),`'^-5%&:!5-)=-__4"^',%\4$$9#@$!M9,
M3J0,C?-?BX,+5'8(@T`(9E(]%O`#;X`'I1-U<X1G(P`AFI`[*Q8K,M$`<I$K
M"#%C/U`#%#([V((/E*"(_4%"R:(3-V([$)!B^V!J&D`.VD<$7D`!-"`..U0\
M1$`!DX,!6Q`C^4$K9V%5]Y(%`9`%A9`%=@`35H)2EL`]WL,)O-B+Z-/_><!H
M*+E@.6-"#8OB3,[B+)-%%M00147E9XT6:(_R*%2Q*4HU*<]``%VP#B*`!7EP
M>WEP#8G00Q/0!TKE)7T@?W<'0Q\Q#E+1#LQ7($X00]:B`>,0.;'"?1PA0S)$
M=XI2`LMT*VZE5>*RB=00.132!NWB+JL3`]F&`T\0!I^5#CZE0O8"D5,$*NE`
M471`5@G2:D?B'D9U?UU`%/H2!OQB!']`@/.R!.F`@`H(#)\U`@[H6A`8@:SE
M1G-4>`QB#QU"`S/0`A]C`'WD`2X37()$2"7H2(^!;\A%&33#@L_U@BU(204'
M&@\G<9V4-$JS@^]U7N!E2E53A$2X2ECS2>E%_TIBXX19,QTGQQQE@Y-R.9=T
M"1X$P!/C04#*\@6&!551H3D:$P!B``$X@7<T\&#-A`_$UCB+T(9OD',V8"A9
M,)D\8%579X>14#HDMCKW(&J&4T_UU%<R)`)XH'UHL#X$0B1E\`4^5P-BL"H=
MR0]]I8DX]@8-8#M@=3C5]P&7Q@W%XP0T(F#>H&M?P`(8=0AB0`Z&ER6R:`]X
MID(O0@!G0CN2UPCE$V9BU@F]Z">T`(RQ((P:<@6BERCN$3GNX1[+&#&K-WO/
MV"@!5`A\X!5^8%1>$0/H,`)>(0)U@`,B%0/V(@*XIU3Q20@'Q",B&0,\\0<@
MY0V59B0-8`-P<Q"5</\XWL(11Y1`7=``^F1K'>$MUC(0%&$A,H$>W_(M'Z`,
MY\E^.]4AT4-ER&9M/-$,^O$@6U`"]D@KW6:?M!)6!:(KN#)07G4_H<)80\%%
MTV8$3S`"VQ8J.+`$81"39V!&2V!4-]D5=<DPA;`6T9-S,;(%<]&!>,%''A""
M@2%<)T,8Q+5(B)$R*4,SCR1)<&IP+GB5-],96!D:0>,:GK2#Y55>S_$<0LAQ
M&T>61+B$I20`LF2H7QDVVZ6$S1&7=1FIDNHP=XF7#71^SV=8_8%\;Y@$%K!0
M1#`&7G`#^)&8R(`#>5`N3B<)HG-A;Y`B5#:9L7)V$0)6DO`."I8.^D`'C4#_
M"YDX0Q/``A0`!YO`8@"I5120BCC"5EY7`1M!HGFW9`&!B<YJ:E8P!`JE`5#@
M!(9#`43@!F[@#5^P!>%D`<X@`N'D+)FS`XQV!O=`;"*E`M8S=-HS9N#CBV?G
MG6IV!8>P.<.8I7,F6::'`7UV(A$C*8PV>U/T!'WF!WP0!9^"H$:P*2)I*4VU
M`R00`QF@#(4`>?R9!;GG(I/Y%>WG/P<$+/=3!=G0!!F+#WVW56W0!J`&)#5@
M.&U5H3I$!!!`B!C@#_O@0EYP:@FU`UC`!R.@:.A!<Q2P?^<9D7$0!O$Y*=86
M#.\Z`,'`$SL0*R`4/&@@`U_`#_LW63C@<_N$06D0_Q$1P3SPDJ3JL%E)9:3\
MDEE18##UXJ0*V&=+D!3T::5<09<DD`?G]CP,\E.%1Q9;0`-V05P"=Y1)21A*
MN;AL6DB+P5P,QS(YTW"0I#,.YQ=`$QK9=8-<R82C=!R`FAQ!F'$8)ZA`J*@@
MEU[NQ99OR1S7,:FT&ZG8,"]SVT#J@AZ&);/(%TX3T`L,8$1X)Q!`%UFN@H&3
ML&J.F(>O*@:\X"2?0`F?<"!PP`(9D`$U8`,B0`'5%"@;<#CBX(X:"@+ANP]A
M14+(HE51X4&ODR,;(4,:D%!BP"'K,%`EM"ZH@@P```-,0@%E`"YNH&L@L07E
M4"Y4)@+9.PV-%C'.@`'$H/\"%I`?-O`*VOF+^FI33M<+H*<AF\.,`7N>]\,6
MZ,BNPM9GYVE4T-@IGE)[Z8B-S),'VW@O?+`#`U`&.("Q)P8L)`"R%"%24X8!
M+R+$*BPI!3I!`40`?=`'?-!`T8!56]4?Y9(/-NNLMP8N"<![%+)J(\J/'X$#
M8]1M/04/^($.]1#&H74&(D&1D]4`KD(K4F61![$!G]D/P;,.Y?`C%800'=EJ
M:$ML1@44]S15;[LOX-9L!D,OB'RWWD85P="W:^.W?'L-%H,_BK(%7GH#0[E(
M`)=O)F,R:'H8B;2FA/0RCT1PTI49EC2#,KAPG<&YL)Q=VL6#(O<UYG5>N_$T
MND'_J*I;J!^'-(TJ'5J3EM7!A&D)&ZY7N\H<@=C@<F$0!5YT(17:$*AB`07`
M`X5W!;^T0PFP?U#A(NN0(OE`Q^XP`!5`479X(WA@`TXB5KTZ0@,%30_:O6C@
M9352(VD@0U)<`P-0`S]P.&EWMA\A0ZCBQKEBMB7@+5\,O;)X#S\"#P_M(<ZP
M4#`0`OH``2^$=]["`)FC.;%X?SPBBQE;#UJA`H['`U=4P8BH$/F:P9RW"Y-)
M9>8*5&O<7ZB79U["KM3`>JK':!'CL,`P1NV:#B.0!V>0##ELU,DP`#4L(QB;
M!R<F`OU3!=!)$4*,8`/!*;[7!0N,#H`V0.D``:1B'_@A_P9YH+6Z:6KR"W[/
M<"GVLBXTL2XE4'K^1Q:0(U=42Y'X^#A;4$\B,%#,1"L(-B.@"3MI<!\;BVGX
MD!"TL`'Y#`[]P8JG%2I-1<A)9<BAXFR*;%E)ZB(2BZ1=`,GU)<GF9C$[@#\(
MT`!MD``H,,HN<S+!-4B.6\J1>Y3\EA>.M%RYW7!6.8/2Y<H/1QK7I:>ML5U^
M2KI,L\NZ+)94D[J]_!PBMX06AZC3,7+![(36D<S+O-TL!VYA$`98,`(0(#?>
MLJF"8`$C\%][E4=$<`,LP)E8`@VT$V`EP#YVN!!OASH^9`,L4`&,+2`*X4]T
M@ST>Q*,&$E9$(D.!@P&V2:P(L?\0_I`D,D0!&"#!M[E_JU8D%P)-[V)4$6/6
M><"BD_4&[8$#9>`&7@`"<Y$27K`K7\L$YFJ,0QP5)A`,C&4"/""'6A9-KP#@
M+NT(X*D+A2(_+GK5Z"G$R_A#.Q"?EB(I[<EH59".P,?$5'T.=G:1!*O`.E'#
M"IS#-0PF3-P'*N2,8-)KZ;#44"$/,3!HL%?CBC9_;_0H).`'ZE`&,<2:%-!5
M5O5V!R(.%6H3/339T.843N%,DV4.]-(3?G`I>@T53I0?^+.1(!!3A],/*58!
M$J'`KP('.A":MP)5YX=IZ#!Y<."AWR`3`^%GD'9X9Y!%`3@>`WAMBMQLE#T"
M#OE9E7+_;F"AS#:I%OC3`S20`'?!IF8J;X%QIK--VY%[VT'`E*<<2="5<)C[
M,Y44&D2CITFC24E87KC<`<JQ2K?,RZJTR\TANDTSW2>'A%Y)':&DW=S][H7@
MW>.!`1EP'D.@X',-(^UA`P5`[TE2BN^]I?;05=P+`72P!S[.SZL&3>0J+(R-
M=O64!I;VH%:%$.A+SA*?``!0`IALSJM@MNN;=QAF`1KZ(P^&'PS&KHL>`WY`
M`B*2JBTR.=D&`5``!='2!MZJ`47RB0:\C)IS!<@`12=&#AI3,2J`S1!0`VH2
M";WZXS\0/[L@>CMUGN6"*84'J\\C1^W)>BHKGRSO!YSB18RB_T(;NPS0`$V8
MUD#WXB7V.0#,0`#8.'OE^13WMY]C?"^DU]:-1M621@X80P";LNA.L85:U1!=
MA5;X>R'GA[;NDJ)C-##Y<<!\9FTBW(>0\S<XT`8_,A';T`ZY"3LEX`1G2XX*
M/,?6>;;ITBXIY"QO8"P44'[B$D._0@_>-N@T>=F&K`VRGJ2TSFVW#FY=T/)M
M1+O<<=H3P`9#X`6#4:8>@Q<H(-N.N^Q(R:;%A<IR*H.]'5V5>W`[@TDW>`"D
M4=S6`<S1;<L7-^Y!Z-Q6<TJ(VE[M/\Q\JJBBRY75W?ZKX>[OOMUI@87/#`@N
M,3@`95]?9649`V(!%A-B!6(9$!I`0_\5%0,B&)P3.`PV-0QP:A<_/VH_("44
M$"5;/`T,=!L;:'`@N$Z'$`,(8@TU&[5T(!5I%(<`#&]OLPP5<)D,)1`0924@
M8E4[.Q/@8F\U#1C@-E=Y,5WLYC4U&`T#\_,C`Q`S4$Y.;339<!1F5'ACH:#!
M"2-PX)A@P\(.=A-$;-J11<6$,@U0_=B02J/'CSP"\!AYQ4;#@F+`85B)8<0(
MEA-V%#2QPP3-">QBK.L2H\J2*D:,$"!@Y(]./SOL#1BQ`P..,CA&Q!"1H<Z`
M'3$P#,#1A687$2(FK)38283+>76BCJ!:1\17$3@&9#7GEL##GG_\\+%)P,0`
M``,P\(S!AT__'SYP2VA(\&4(!1P-',+%D:$R91R<6G99LB1*%"Q-%4IDH+#>
MB#-G)#8`P1H.G&IMTF3`##>:M-85*"1(H$$#`X0X:J`2@J;"%R]>-$"@4&9`
ME[7'*`RY<2.!%2N[$V00P7G)F8091O`)&M2%>?-&7+B,LN1)^Q&<GYA=%W1)
MEQTDANK/K[^___\D!,@%%T,AQ<<$,B00P@(,HK!`"`LN@(*#$$;(8(,39J@A
M"@88,*$!181HQHAF.&"B`V844>*)+#J0PXLGKNAB#C.^^"(2!QS``1(<Y'C`
M"BOD".200/K@@P`"'(FDD4HBZ:23'439@0!25FDEE%$*4*231:YP_V21/GC)
M99!=&DFDF&>N8,)_;+;IYIMP#F5!?DN$$88@?QWRQ34E,.)(4SR(44(9EB10
M0@D9,+!58%M98,,T/Z2`BBJL+,=`+#7`@<`MNA"3FS(0,-#`!`W`00<J=,"1
MC)X8!5"`!9TPH*BLBHI03@T3Z(1?`+Q>$0Q,8KGTW`#"O$,./4L-D($&^CB1
MP"N9?#%#&EMLL5(7YH`#ED,C3'!&%Q-L)8()*JA@P7:3?J3N%;V:=%!9+KFT
MDC?>3%!0O3BQ,UA/!#31!`%]``544$/U,<(B9TQ51QDB/*0L#F?TT=12]-IS
M;43SS";1`&6TU<4\S3WW4F`1J60"3B>/0/\N?X4-9=,.5#601X`T]Z7LLE_P
ME@!4+9F%[4JDAF7!<YS%N];&6Y4!``25B8":/:2X)C4RK@!0`CC5@%#+1B#0
M,$0"-[C"0$L#U)"JLSDG@!QVOHD%2B84W/`%=M?UE@$&6'@60T)M_4'>>>>E
M]\0(GKDGG^$NQ7!&%$9$\40,`?;'7YR2"TA@'W[$0(!%:SQX(8,08OB@A9]O
M.*&$'`;1(8A%K)ZBC"BJR&(.'-#H8NVSVVZBC2_VF"./.`JIXP%AINEDDTL^
MN2205&;9_)3/7_G\DDQN:6221Q:?/9%<_HA\\5VN2?GXY+]9$`F>F>>'"``L
MC<TKQ(+35$'W?`'_A!?+E5`:)UN)\6@:&U"#*C8"!VN\H@$-:0`=%DB,:20#
M5`B,"`-`L`$$@``.`T!4(OP4@+Z0H"G9`I<)+'"%*]B$)B8PB3,0T`EDE0,2
M&"`%:VK`FF/(*AXXT(`"6K`&&E1`:3I+0`4@88-R\2HB&!##2TA`$PN@D`3E
M(D$,)\`#.?Q@)"+A01:T:(&4J*0L9NE$MU#(@SE]4%_YNL\.@-*O?PEE+WS(
MSUJD8H3Q#(5].(A!'LZP%9GQ82J!R<,WP`*O38BF`90!``ZT@L@ZC.`K03L9
M!FP@EJ%UH0K@0H@)($D"/M"K7A"1AQ@$N8,SK&0MBP)`;_"W"#'P@2EV_U%)
M`\`R2[`8C98-R`0R6D$!"BP"+)5)0QJD\1ID,.8#$$A87#2R`1"D80A>P,XU
MPO.Q4GW!#0EP0G5V4S<&X.$3%!"F,G*F@1G,0`,?R,`97!"&*.R-$!F(P=\`
MAYXEP"<,3W#/`-QCS].<80E!Z<(9(K>?R8V/!`,:$`%T,D(+;.%S%ZJ0Z$@G
M.@QM:'4&"$*(.D2BCIIH1">Z40Y`:CO>H:A$O/L=CSC`4A\!27@_LAZ3KG>\
M(T%/2S]J'I:@9Z4IW;2F8KH>DXXW))RZE$A*`E^2AA0F\97OJ5`]WQ^BX(*B
M-$!I$$#$*T0EABM$A(3W2``1O$`!_2EJ$Q')P/\$?M```.Y!%9YJQ348(88M
MF(TCJ4I#*W*6@1H4H``VD`<Q-S$/3MB`5RK8"Z\62TIZX<2491$&`B8KCWF4
M@`&>H(HT=.F:"@QJ'CG<H0Q8\,,R]#(9#2#(3+R1D,PXD9";*Y=L"1"S-YBD
M(1.PUE@*2\ALU:0F0_EC3F)`K_S@1P61,X()=-*O+B@$`WL90%O\T(<^$(`/
M"]W*0`7IDF\@!"P2.1H.TG(T;(QL40BA2TQ&(`8Q8,`F24192QZ2DLR$Q5PU
MN8G(OD(;9!5V*PQ096/:<%DQ).4EG:`,84F#F6\E91.EJ@"M&-!+5P0&`[-Q
MS:D0D`RO'2(\?!0!URK_<(VOU4T#``B+"`X5-R<HPSKFQ,X`G,B`,CCAF8?H
MC0:(0`3`K),]>_M+!KHP3WH:P9YURN<2EE(TI_W3!5%XCG4C%T>#QBD_>4AH
MYD9H`S$,('01E>CG*"JA"V4(=1C-:!!2)**.DJA%N],=29&`!!BAE$<Y"!Y+
M?7>`X+U42$C%'O*F--0GA0EY2.IIE0RMO$9K*7O@8UZ08NHE,QE/2V=R*E0W
M3;GS8>%.+N`#A@%PB#)L-3)>%8$-"M``"(AU!J&J%5I%4`<,J*$&;E4#,8Z1
MC`.^@50-0,!&R.'9:_ABU7^5!"&=<5L>_#4+`--C"4MH8'"(Q59)#(:H:`B"
M_W>`H`&Y/-0`ME"-S>J"#L6Q<"?*0`0H+(`"-*!$SG*6!G`+YCXT2<A"+*#O
M$5@`N313019VD,%%E$,>M`'6"5^FD^%6P0\FH*Y^^-(7=IB@DW"YBA2K@H$`
M.44$>?@C:O##1PPH#EM@P0PJ,\"PM3PE,&;9BK:"=;(N$`!<6>@6K"9@@H9I
M4BPG:R\GFB(&%4CR6]\"U\3H83133D:5JMQ9">AB*QI6(`-IZ"RB2@"'<HC`
M-L(4I@_;,`17_P;#(K#%1M#@A,4P1G].&T&P0:";+T@GFE;PP@P`T(`^4*45
M^_B:=:`P!BO,0`0W9P`V$K&,1)B:`:>I$WL^-ILS%/\9<(T;P1/PZ1Z7-!DU
M78#RX&+0!YIAU\IQBN.`L#)"/-A@"VT`\^AD/V:(.LBB:,X0B$:D(C=[E$:R
MTQV,9E0[&AG?1L1G:?!\%%.7@B][CA8T]93GO)Y&O]%")>J8*OTEIE9/IL<;
MDZ8Y3?XVG<\(H#X0(7K!IP'8RP)Y"``8)I"!+^R8`IH@+/_JT(`"X+HCZ*8J
MO10J;U```?`&\0!NF[`QMA()`:`"KA(`-L!L`3!M7>1$P?(2XN`,X[`2E?5"
M7X<;Q"0-BN<+P0`!:0`"S$0':7`(F"5='P`#-Y`)RY(`,X`<:6!;%2%;/$!P
MC+`60-,4CW1Q4$0"CZ!;[77_,C&!+X.!$U50!4[E+__R1`0P1Q=W,(M$`GE`
M%2#'1/:P`SR`7%\A2%01%7SP%I3!"7`!%>)U-YT@1DG1!;`B$UT@!B:@,@0'
M#OZV$E?P$B:``04!B(_09>#0%200$Y@#<4,1<'Y!,EZQ$J@!%U3Q`;M!`8I2
M`[!B*YN2*IF@=4S#/U&C-<WD0[KA:G?S"0W`*17@8L=Q3E]@%=\Q#\D@3FIS
M'5:@`7?S2I108:ZF`7HW`U8``8*Q"5I1&5M%C.;@$IMG'_SE')>''E"F>>S1
M>?#A'6;Q+8TS>CO@!YN6'VL2(-Y@`EE@`4R``"R@(!8B9A$%.F1F4:;3(6OV
M.B?%_WL@Y2+R6%*\HSNW4WPT@E)Y5F=YQGP"Z27>EU0T%7U2,CTZ=7U48F@%
MN50VM525%F@2*28U=9!+-7[EMY'Z<3[LA!X3$&#L5U:!81`6$`""XFJPYE_$
M(ET#(`H,$$`;8'6'<@T-$``1\%<V4!88``SM)086$!+(-1(%D).4!)3BX%[F
ML)0B0$&HL&NK@7"0H151DPM:4P-4@PT,$`QE4`&UD&[[8'\0`$S,<@,LP``9
ML!O(X04E@`"/$!-P*1'@4)(J(1K'I0)-8!,S\3+ZPA/W,0%0*#YX20"8I#D$
M$"Z!1`(<,P`FX%4R!XXN00"1,T:%V#`PHP@88!<2P7)J*/^)Z35?"%$3E[0.
M6<`.5<AS3)$'[A<,>9`2`0`.OD)"D.!502D8F\,?4@AP>V$"F$0RWJ`K,O&'
M<;$LRY$&U3`J7Y>*MG`+G54U&%$%`T`+'&$+<*`G7Y`&<8$!!*=`QI%-O*`V
MYZ1(SX$#RY$)JV(=8P`$'U`"1(9AIG8-2A-UIA9S`[`$!/`'PV(6C_2;RHA/
M/#$9(T`>Z8%Y0;$>[6%/(N`>WR$5`'5D3)$YW%@^DQ,@$M-0>-`#(+`&7D![
MLE<A"T)[9F8Z'-(A'-)F;W92+$)2(;4[M?-F_ZB/_TAGR@=3E)8F,T53/Y5H
MB\:0T;.0,U54C)8E-\H]%8D\6^+_D&K"D4K:'^?#!782%`1':N]#D@SA"%V0
M!6)`GC88*O0@:XM@`PA0-A;D&M&I**EE@"J0;(]PDDE0@24A6R3``W;``[?%
M@37@#/!@#F)0`P-@*K:`!JQ1*F=9&0V@;7"`!ASQE``!GQFP!0V0`15P0960
M`,)T'!#0``D!`%#@!3[$`-)B3D"0``U@+4M($UM1%B#$6ISP;^7R+SAQ;W[Y
MA-C%!WDP0DPT7]<EB?C1!94Q`AZ'&9)YB`W#`P$R%2IQ8)*X%CM``$ZA<3V'
M2LGXJM^@G2)D#DFA+2ESAAB0!^]U!6%!28Z20B>#6UTT`5D`#CP@%L'Z'T;0
M!\3%FU_Q_UN:!FT81I[*87<6)A:BLD"UT$S3``&JI`$#4`5?9S;II@R+L2>S
MP11?YUDW0(MK8P6`\1`ED`#AY&+5H0%6D)X:P!7/\749T`804`<9H#\0QD?A
M`6I&P$=+\4@BHXQQX!W\%17/6%6"0S@'>CC>D3B=X:"$(3'<B'IP$B">9%T%
M@0<LT`;HV(ZSYZ$0%:(7%02JTR$F6H\@]7L?!2.]TX_^.'PN@B.UXSM^-CP$
MZ7U'"B58@K8\JJ,)R6C+@VC*<VA(`J02V22%AJ1)NJ1+VJ1/*A2M!I^FM@A5
M"BLF$5:AF@9E>E9;@0..,@'P,*J3Q8%74`!@@)<06)2`!90%4?]&DHE<(B$6
M;Z`1XU`#"'`L(N"HT7!!KH&H:$!:;5`((B`&(D`!*OB4-J0,[9,!X%8"D8H,
MF^4LC&%(93`&0E0!.)``,(`<,_`%"&`#6=`K`:)O(M!%A(0?`1*&4-0$Y=(7
MG4L"51`#?D`"?H<9$[!QX5&KM#9C5R!%81&&I:DR!.!$+_$5CP1,BX1*S1$1
MD'-S*F,N+S$T]J*=2I02W>(2Z840UY8'W-J:$R!(7?4-Y7I&;SDT53`T\&4!
MI=D5?%`%!!!R0R&%V?LQ/-<73Q@#@(E)"I$!E,@8KL`"718-9D,'F](U$#`$
MB3"65:`5KA$05H"PO2&Q#),'(U`'`!#_=JZ@-GIWBSC@22+92^1D';=X-_8@
M`E@`;+BDG9LD&D\0!W82!4KQ$FY#&X0#>O80%7T@H`1J!(,3'_G$'0CJ-)SA
MH%T0(,MEO9(3)^$8OUC*`&H3`BW@M!#EH6`6(;>'.AJ"446@456[(HL<(S*2
MCR-5(P!Y(P?0.SG"9T<5)CGE`T)BD-.7/)^\/&*2)1:):4`%I,4CRH4&I-PC
MM]''/`*@D7I+?OG1!$8P,,S*<C4\39#!<W$*!CP@`@!+!!K0)W&!+)0Q`2AI
M`U7T5V[**VBZ.0;(`ZC`@?[S!NU5$`T!%IMB"Q84E13V&Z,0J5LC0!O``JL"
M&.X%&;N6!J_0_X+6H1RC&@UZE0L"F#:$E0%$D`#10&%N-P,)``<]L`765A-4
M.0%7H!7/!451%'`?!`XFD*X*H3)^,;&'2!D=QT3;,A+\9B\U@41DX1+DZ7XI
MAP.#5!9*-,=&IYW$6DEBH91(U`E!0RH,`0FP$I0QP:T!',`&31,8<*Z9"0[G
M&L`F8`<>1#,U0Q3]X5QN07H2IQ]^<#.]L1M?TP;FD$%:4POF.`37L1N^T$*N
MH4TRX"QYMQN+$;M7Q;O)(#>\,0-$``0:T#`LJ\O8,!MQP0D)49]01EQD`31I
MM4_N$06I<1NY@*&9(!IGH&1EW#!%5AXW^P2.PQD)ZCAKD3``Y<5,D?\?$F.]
M!E40`/)!R[JY8L`"0R#(@,R.$O6A"W)FAHQF'H("(5*U1?!1ON<B,3+;+>*U
M+_([-G+)+360DT:09M+)U&,F=NO)HCS*4U+*24)49.*V<RLDJIS<*X`]<5NW
M2"++LPQ562:930`4574&3Y%50U`94Y="8!`!<V`'!T,H'T`!]``6]'`W*'D%
M8#`'<U``Z9`'A\4KQ*H"7G6GHHL`H5NZ>=H)JU%#W=8`I.5J;3`!;W!9PB9`
MP[:HU_`;X:(UKU$"PP3/O-$&6^!ET')!M"AC9?P!'R`J!?0!,^`&"C`#-``"
M(5X0)828!*QOY0NGSV&N?C&6^($!(ZLRL(+_&418,L2:KF%A;2XAB1];&6,A
MB3`]+G?(+4/CJU[8<9L4%EJ!X*3B@2E1#N;@*PR1$@/7<>P@18`XA$QQAS;1
M%3@QU`!<$4W`'T%1785QQOH1+B,`A59F!#"S"!#P`8O12S2P!1;0`-J```O4
M`#0`Q<B1`&U0#M&)#&DPUB&`';NQSX'QJ*]``W%#3A]`S"502]R1&N`U'P:M
M$)O73O@I$9Z05IB1$Q\3#8@*`CJ@`Q5``YZ.,(J]*$16'N@QH"Y@3XO#3V:!
M3Y4=`T\0%-\!7$SD#4DM)YZ]B.I@F./X!B!P`QO:`G\,(=V.VJFMVJTMHAQ2
MHKW7>[[G4;.CHB&%_WPNXB.6#-QDHLG<]WS3E\H\"CU%U;9QVR1TZV@O5=W:
M@Z31=VCX[@/:O=WE,S,!\MWI<9B$L,OFW0`FX"KJ/7^)1`1#H'^GKKN!PLQX
MX`Q$9%O:'(860"R)^@/??*<U8"MB02RYL#4_P*>>JAU))"N)RHF2FK`E4`.R
M:S;#U%G`*Y8BT/+9L!J[E%6]@1E;T3X,P`(E\`6AK@!NX`5IT`-O,!(!\@BD
M$4;IQ=#EL@.4X:M^P3`71ULF/9FQJ\#/*A9Z2!7A039M(80245]_.$EBP0-)
M1`),P6\GXW,1D>2=L*=>%[LO#0E*Z45S:,%WB!4V)V4NL4D\UQ6;Y!5O>?^N
M/&$33WC&0K&(_?+!8K_G#T==Y'%=>:T8=J?KA7[H$[1`Q^!J:FDW5PVIR*!-
MUF'6ZPD?S[%XC+%X?"+?\/$'0R&$CZ02XO)/2^"N"`YNDU6&F\`.0PP!D0JH
MT^`U90<5_]1Y#X,!P![L537LTLA/!CHXI['L1O`<.R`QDND-0<L?0ML'F>\H
M=<4`T/3'W6[:@@SNJ&/('P((!BB#@P9FAT6)AXN'#HL.D)`YDI$..3E(EY('
MG`<Y')P<H`<KI:0^I:BIJCX"`J6N*P(='0*MM*ZSM+6HKKBYN3ZMP<.VPKDK
MQ;')P,?`SZ6RS28$U=;7V-G:V]S;>20$)$U51B[_!#L#`!!#0QD9)0,8%B]@
M$6`3.!``1!HE#`,#1`@<@6.`#3$3$#0`.*`!`AMOWH@1DX6'B08U-FC46*-"
MA08,,HBP88$!@QH_U*C\40-."0@42H@0`Y(.'1!PX(``D>9+@I]#&DP84`%.
M4:-I*/A,H"$#!C%O7/I+4R+#N@001(P06*)?A1(ERF@@,L,+!1!;)DR(X2>/
MF`$B=Q#`@"&+"A(J\EH8@`/#%8M:+?`@84%$EQUK,<03B$$@CCH#)FQUAT%R
M8WF5\SRU($^,WPDB.&,P(:)R/`Q])WA^ZO;IF\J>)UA0/=O$CM$3Y'7I0F`W
MGR==_(R(T65$E:TF=A-0_YNEBXGD%F[;M4VMR38CV/LLQR&B2I4^1JHU&=^[
M8-<$7X:TR4J3`0@T.-,,^9G`BX8/6177*4%5:7VF'Y0A0@Q++!&#"`.$1,$_
MI]&U58%/1.%'%P@V0)<(.&2`PPAG$-A80W34`(*(%9C$P(8QC+!?3N^!0(,3
MZ$%01@8C+/'$$F?`U1=VY;C@`H_813'""%$4N,2#43PQY!E+8*>D7#O$8$(>
M?.S@1SC@$&`!"5QRF4<,?=B&!QY;L#"$%RVT$(*:(;2YP)MMQAD"G&XN@,*;
MA!0BB)Y%F)'(GWTR8@8DC512R:"7))J))$AT<HDHGW1B"BG)H'(**\$\8XPN
MN?_L8@LSGFK:#"S+%.,#*;,L(TTPJS;S3"W`4-/-K+36FDT>>833A!_E&,%'
M.A"L`T$).&QH00`1V"-&!F4``,0,;?RCE58C:#C1`!F!M!"V;_R`0%I93-``
M'1N0FY(:':6A#P-O6(!#"72DM`&+<"AU`P0#O%'#`!H5M5.]]&%EX0`45(`3
M4OYI`$`#-O#`PQLBN&,B#B8UL,,27/4#4@G[>#%$>B#@(5A>*ES1``X-1"?"
M!#R03/(.(^R@0A99I#@1!CL(!-=B`]0!P0@4\B6""71)-@'1T4V01Q<37)'9
M"`C-U!A-*UL(VH5^!7#%T7F9,,$..W1!0F[)=6$!TR;_C'#T"+:-P,>$?RS1
MA1$CW%@CA;9A0`)B8T_0VW-JWR6>=01@Q\?AXE6C@@D%F<#E-3P&/<!8&D"0
M!@T-\+`%`P;#D883/GWQQ5@?]!6E"'64(2,`&FA0ANH!#7GC'V`K5AK0B#5&
M[9`C-.![#34H5!4\TQ8+1PUTP&=43"50("#1*&_T`PCSH4>52$_<>`:&-(+G
MHX]`^CADD1"*$*&2P\4019(#DL!'##MP&:5<7G;991Y@$X#'!%LTT`:::0J@
MFMZT`#G5B4YVNE,"![%`%!C``'^"8)\40:A'.`)1DS!4HC:8J`-DPH./ND0G
M*#5"87!B%<ZH!3,^=0M>W$)5_SX(E:B0$0U,N4(5P(B&II3AJEW@`E2RLI40
MAWBK7(D#.S_*@PA>%RP(O`-E8N`!&*9H`P8TBRPE\!T&SC`"NKA#-1F`@TH0
MH"^`!&]?#5"!&!@`APV<2PT_H$.]G)@O'B0(>6@PRHC@``$-)*`,?1$#'!"P
M`1`DKP*?\XD?&2`&&]2``?SQ2!J2XA,`.,5K:J$+!LB(`8S4X&O;XPL`_%$&
M"D``"%_PW!!J0!(+$"!,:2M(;N3A,A588TB2`9IC:+05')2!`9+1V==6EIO9
M3(`$A]',<T:#@1'DH8N%P1I=-/.4W.0ND\<:F]AL>9BS`:YM93O;VG;`![<)
MQPC$*?\GD6ITH-J1P&M]ZXW?=E.%:CRG&N$11Y?&8YUW\J4+?>!#'\`3GG#P
M`4$,8-T7*$"#-@Q`#%O(``40%CJF$`$``]K!'U!3!ZNH3D,-V>*-XA"%/]`.
M-:<9$E\*PJ&M-,"0&Q!1#5B0!H\0:Y='^5=28O3+VYSD!T!%0`42,`-^Q"0#
M`ZC;$[:7H0'U"'Q/I1N1R/<$\]EH2#$@$/O.P*4^[,!QYX"?_<8*#K7@`:(T
MJ(\``VA``Q*P@'@B8)X6^,`@).*!$Z0@(BQH*$M(0A.6V&"CD""*41Q`%".<
M%"BB@4)A%(-4L,`%#E4EBU_,\(:,G>PR<IB*4;505+A0867_.Q!$(IIVB'S0
M%1+-,0(F-E%#*[.`;`/`@XB5@0A><$]E=G`&M<#E*25PP@\N`$=O&<5S^,H"
M'DI0`3<"-8\X,67!Q!``WVT`#1XQ)`@JT,<_H@R-R).C1T#'E#)@(``!L`$&
M0N(/BKT+'I51R]>.I;4K>,9W#6BI"!):AI<@D@A?J``%O,""+50&?B:8#4".
M9A>\E%4@7?@0('5'F:L%A`1T29MLY,$93&+8;+NM3#-G@YFO8>`PLD'(#HPY
MFQ5W(09YJ8+9[L*TYASM,$1+#@9ZPQN</7.98W/;D,KYXHSN.#E[\YM:;%D=
M%8Q''/S$!G:\,Q?#I)8`UC%"/PF`_R%?^O$+ZP#F!*S(GY>$SB>`Y%WVAO2A
M@*S,-F>XD9$BO"W\)L@D`^C0"`#R'N6Q@`8%XZY34,-<.*!!(_4:@@86JJ$(
M8^NZ<*!!]68P`_3484/98RID8O#4'ZW6"%Q<`E6MJB01=$C41SI#.`A@&[F<
MXZMDS1*K5=.#H::I36MM:YS>*E<%,C!/#GR@!`$5*$$-ZE#'!FQ@(0&I2&6"
M`Y%:P6%)<=C%2JJQCC65,XXA6F>P4!D\O*$J:O@I5IEJA=Y.AF6!L6Y?T**T
MIXUW-W)5#1(8(0K?PP"S(`!F)T+1`EEX3G69I0$OI($%`3E#,W.#LC<0#`US
M2,&YYF5*?/^1A'/DNHG!HBNZ-C!,7(34KE',#.8&1(UB#8"#B63TNLBT.G=;
M`!Y=@/>&*US!:TQ3#4)JT!A(%DLKHH0``V#R$L[Y!`1,`'B69H.@NEB@"EF%
M7[6<`IJ(/;2+4[/`"*(S@K'YA2Z<.5II(CP;$,M&+0AYCFQ:[347R]9L2`Z;
M"G;3M<-8)\+).2;:1G.;Y6!@:1N^66XBD^$A"<<YSDG.<\P6-@L(CE;\))P*
M<M8%@?(!2`7=LP@@\('*4<"A8M!ZAIK81`;XCG<%B@(66E,0@;B>6DNED"=%
ME),2^;QX#)ADYQ"9,`B8A@'FNBZ,O%!I"KBCBP/0B1-N4+T$6*'_TM[ET%+W
M?.DS=)I'WTMUD6ZDE:N:FD#W'M(W","'5F_)-GWH$C8`;H,M5.!,:V7KK@MX
MP+<2(H%XRI.P'4CL8A<[$L=6*)K`03G`"9-0@-#V*-0V0HF5#)WU"NCF6)>U
M*3,$*C,T;N&&6:WR#-[6#,,`*YKB0P(`;_)6@MC`!UEB2U'0*S'`+*(3+!G`
M`!A@`P4`!EX3`!C0+!HP`Q20!K#5=/@@`B9S%FIP`1-7+S%A$#Q@7<FC$X5$
M20L5&:#1`,[5$6#!;U^0`1-0``7@<!IR(B=",?]P-%GU55<0`%P8`+&1&_*%
M2YJ'`<!3`R#!%TD5$%8!%AYA>A7@1R#P_P9J$25^X#4($C//D6``1QHK,V)T
MX31=H`)/00+&D39>,X.YH5ZRP68S&!U7@!A)TXE>LXDL$P,3,'<FD`6CT00C
M0`#'H0*Y\3C%X1W%81MZ-T^+AS]_-W/X91)M\$L!X1DB,"&\<1C-00V)]V+6
M@!W6P$_B<!>$8T\$$`,!8267=WGA@1U=`!!B$2SI40*5\7JQHWG5$`-Q)F<X
MTDD,`1!A:%4Q@!HZL1,'TQ\SLC(8PCF&=ET5(`,W(#I9J#8#P`(V@5T4\!->
M0!8)H`Z[(0(E(`-.L)`W4!_/9P4*$QDQ`!Q[Y@[6]SV>AI%"$B%&LA5A<"1:
MH55"XDQ9\D[S]?]..Y!^LO8<%F`#"&`F7J!K;85`!#0G]X=_^4<(^S=L?A(H
M?7)!A-)7B6()F:`H2+`)GE"`#"@IDB(,TB8+-H0IW79#.^19J3)9P_"`%*@J
MF8)9RO!#+P1:(CB")EB6V8""]58X/O*,OO2"_A89+?,<!3`!&0``'T`$EE,L
M`1$0*+4U:2!&<P!4+%$!3F!*.#`!`:`0;E0N\$&8A;E0)J<8+$!(-Y$@S*(Z
MH8%>:NA2%J))3Z$U),`%)(`K-@`1?H@@YU@:L@$2.@$\_T*'S=0`S')P.`$6
M_U$":2$&":876T%+)$,"66`!LM@%8F`'N>$T6S<DE)<S#G(0$W`0H8?_$&@G
MG`D&-M'A8H[3!3:`9!,@-DR#8?'#-FFS-SO&3<;QC,[!B6@G8A:R$`CB#\S"
M.A8U`Y5C(0-2'/*$3(XS&HM33^(!95%F#>`Q4"9@!-1P'&[SGX7#(P0Q`!PC
M%GX$`2:GG#B7-X;13&JF)/CE.PA"F,'"'2HU%0?W4A5``Q#P$\]3+6TDF"`0
MD%Z0`)\G$Q0B`GET`R_J$UZ0HTP!`<XA`A0@`PIY`PUI!0])GY&1),5A6R)P
M?9TVDD8"DD6R%1QR!NLS)&"U:F"S`]_0!_!S9<)I`4SPDO\3DS))?W,R?W`2
M5_FWI@ED`$$@"!*$"'DU*'YR;$(Y@`2H**%`_T(G-&V3$@TG=`S;]H`V1"KL
MID*/12F:4BFMH%D0N$*CPBE?N6ZA)4-D:9:8B@W@X`+X1@!^,`!EX)8:TA<M
MHP(!,`?N4@=$]07$TGJJ62P'P3D_$)@_\(2%Z40FAP"&Q**(5)@!F09O4``\
M0!,L``?GR"`FEQ=XH0(\T)(3(9T3T2Z\=08*!X?`@P"*P2`%T9E$D1-&<120
M)!(`\1)@81+!$B,4\!``)ULJPQU*DRM?10VR%0ZVM&<(T:.)*`]_*!O1$9VA
M]S6W08QOQP-\\S6L*)QZ`S/&A$S'-!I(XQF"$2['%'`OU@6=Z3L,02PA81)@
M00&MPQ0Y2@1`4)\-`/]UJ4@<R!0#&#:*MB0.D&,$`<4CB0-E7-($%#)0!,6I
M*_B,`<$`K5-*QM<`R0$TP200VP*;3#*C&`$"*3=>%&!*(J$8;8!(%1`\?]90
M["`@5;!>(%"K>20?.3H#5O`%`C)XA/D30BJ01*H.>C,"$'`##.D31%I4%S4`
M.X`%!4(A=3D`?Q!5G>8"0_*D>U8@6V%J$0)J(A`_:2F<^1-67R5;-/.2`Z8F
MM^969HJF:6I_OZ9`=N*F=H57B`!!/4FGAG"G&118!_@)T&9M)R1MBR5ME,)8
M6BENM*N!,02!(=@!FO64Q$"5&$@,.-1NJ8*[[A8J/C26[Y:IREMO).`"86#_
M#GT`JC'B1&!Q7E,4`:CJ2V7PHFD`$--2&1EB`WG@$2E1JW*4%*8D@V(@AQE1
MJPU0(J9$M@R#AFK8`(PQ$6AG`P$@.(0A6VM(%^O;F=1Z&P,P(@B``'*8$PGB
M#Q9"C_YB$SQ1`G5@M`,@(Z;7`&9&'P7VA_&*(2YGB(4XG?@[$S:@&KF!O[)U
M-+4!'5YC`XAA8YP1>F(3-GL3/U]#`.(IGHW('&K189RQ`\')AKFA,_X`2541
M@WAH$HC4//1!?,_7.AK```/2!W,C8R205=I4B(=#C04U.#7;C*QF`JB(`V?@
M![R">4T`C:*D.NOP2]W)&(U1%<EG$K`%-`WJ$46!_TB7PV\`4`9",0!M8&CQ
ML@%#Q0X+U087*@(9P0+V,A]>0*2M,P!5,&:/N9!?8`5$);;XP1MGH*K:N!1,
MX3HHLCYR@R%E,``K^#VK]3U*0HY/,`!V(Q!GT`5-LCU<M;@H>26LM@.AIUPO
MV9``5+GS)R>\5LPVR4!VTFM!L,QO*KI_(BA`>;I_E4$$V"C5MI0->"FRRRF&
M2I4NQ&VH\(%4"8&-VEE3R2J0*H&=PBK#:X''^\[PG+S+J[S-&P;/>U!E,+U/
M9+WU,`<!D`Y$I0%I\'JE@1H9(`974*SR0GOHBR\\4`!7((<8L2TF\@\(4`#,
MR@.TA1!Y8'/X\ZR(L1O%8?^M9,1S-5`F(848^_52.>$[1A$2EO04#@H'YE*K
M+1HLTQ(Q^+(0!/<L7E`!""`R#L,#ZE40.-.=N8&)(O8&:MA(*W,%LY$TK#B*
M-<9A=9$<K(@9P7@.79`%81,NSJ$VWA0N06Q,JU%UYD@QZ.@.P5)QP=*Q20$3
M6"@ZSC>WZ-$4AM$;L,C5!)`%57!/R1AYA.,K`^4K5R8>!+%C^.1IUL@0^L`Z
M_1498H`@6W#`GO.7+/`5[I!4>R9)AH8&GR-I3(%1H$$#A]:$^>B06#$`3./2
M%#`$"^G(D*P!`^`U0_<%OGK)`TD61%`"[X,@^<#&_B8MJ)>WW","J0Q5&.D"
M&./_RK`,DJ9&R^BD%;)V#6]S)28)%9LS!'$B?S)9?\7<:VP:;'A55Q%D;,DV
M"78ZE);0;$KI"8CE**_;NC7$NZ*U0K!""^',S<7`"RCDE32T@;;@@3RTW[W@
M0IZ2X/$,SR0XSR58S_;,!QB@#TWT+C(H1?40`7:P1/5A<-YH(8^!T$:1$C>!
M%/PFH060+([DGI\$AQ-!7W=1$040`"V&/[WE(-2:21@@F'$D(B#``B=2&@N!
MQ^THAR4B%F6P!251`B!`F7`@`P)&MGN)D(#4LP!`:41`!`P0U/ZKFP0A$FK!
M-(BA<PA1&191.]2E`EO'&8NC-VJA7@DF#RTL&66WPG#'_QO=V1LP9IW5).0-
MD2`+;"+ERGM*`6;]9NAR+=>B$Y!$.K>8'(_!"";I&3-WH7[XA'G(Z,50)A[7
M.`)^T`=5L#[XMCX'`A`0<%$]Z!%;@`?[U>3_Z!%`WCR`E!ML1"Y,4*L],03#
M4A55`WP4!]O`#)%-<1@-,$E.8.P.V>@:,#0F,``_4>C.-P-N0!804`/0F#Z]
MY&8B(&I16B,&0B%-E=R,C42(RY%%DE1)LA5QUB0'XDS7X$I<\CXQP`<6$,`,
MP-VW)LRZ5I/AG<S%K'\/I"?#)KH.\),"")2HFR@<0%@=E)2&98`YX("<T`JP
MZY251<X9""I3^0LV)"HZ!(*QD/^5C1J6V_99G++@*"_/#AYOU6UO/;(<&=!O
MPV+4^IOA!:!O$.H$;N:]&%('$Y`$'1$\3<LY%2,&,[Z_SME(I?D7#8->=\&L
MI0F=SXJ_L.$6(N`0Y;(3*=<`+%`5P+1>18$&-4T'%;`>\FL#(!$\/)$`-Z"0
M3-$75Y\A3[%>8V$%1.`&%)`6:I%@P=E)$_`&)#'ULI5@]]0$-%,1B[-U/,`;
MG%'O9W=V"79V,=-X7Q,NLB5BB5@:1BLM_N"@";(@S9.'8#%)/5%QA4GZ-97'
M-M6#/8')C?[H`K)CQ*'7/%:()D!00)(X6-8$FXY/XF$"L_SI?R#J,ILC7@83
M3YM%DVW_>F@@]H54`7^FZPF``PA1`C2=/'_FHEC!Z[2>$X!&`>3EQ,.N1*4D
M20U9UW8/`&P#&B%!>L'2!OX`/`"Q!#_R!Z5.+5TPCAQB([,,""(X&0,Q1H<N
M+H=&B49+(B-+DH\B44\CD&>&,2(B>21\?`2C!"0$.Q-B;P@L%`E>(2$MLRVQ
MMK<+N;J["R@HO+^^P@9!!L'$144&!F8.9D7-S@[3U#G6UAQ(2!P<UQP'W=\'
MX^0'*P(KXS[HYNL"[CXKZS[N`N_R]AT=Z.?Z^O;T[*&K!S#?.WCXW@E<2%#@
MOWSZ)$CP-]%?1(D4.^P@Q;&CQX\@0XH<9804"1*+FNS`40;"_Q`($#+@$&&A
M0`$P$2),P%$'@`8*`T0,&-II0(8&!7A@:""B@5,,8DR8R*,B@!T5*E[8M"'&
M@@VO7+U>(:'BR@0$/]+^V$"'#H(:#5@TP("!`9R[+$#4@#N``00`&2:8P,&`
MCEJV:"HD2/!%`PLQ(ACLA9,F384*%'R6:!`4!P2G`TIHF*'!BQL*&WCPP*J:
MZX2]-=YL0#`!3Q:LN'&?'-5EPFK!6;J8L-#%PH0)62;L2#Y\A.#B)L386(J!
MA?42%"A`8%"B1(42EL$SH%"9O/;*:2!08%"A\N4*=^&`B/^^,GCL7Q:_\J)A
M,8`!&)"P0Q<$=-&%"J?X88))39#0Q/^#'!T2TH--&-%'%7WTP<@BA\0P`$O]
M,08!#AA8,()=:+1%1V+X98?#!!X.T$`%7\R0``0:6.$%?PDP,$$7`\!4F1,W
M#.'%#"U8H4$&72@%``!#YJ?D!T1HX",&`XP00Q="!=5)%SN8L!,.(\011A1_
M<#+34T8Q,-<23SRQQ`B#X'#&(HDHPD@4BG0RR9P#G'$))!AT4445(PRP`PEY
M<,&%"X_R,1P>"+`APPT+V$++++=TR@LPON0BC*C+_$),J2@04TPR9K0*S31*
M4#/--=Z,8XT#UMB:0SGER!./.>:LD!!`OM(3D$#F+%300_LH*^PYR@IT[$'1
M2ENM``]!U`'_1MM6=)%$%6&TT4CDEFLN*2Z8A-(B.PQ01GXO94!(33:!48`%
M/)6AP1<,#$644!F($$`2?%C0E6H\7*%P50'@]D(``5SQQL2J<`65P08W4,,&
M:6U0`P@@PX%9!G39!3+':OQ00U\4?$&R"7W1L<$&(%1&60+]6<$`!I'-6,)=
M[7W1&`1""5*&FPW`,82-IE&`@!C'88!)EQ]F4`$=7V5QVTFF<"15%A9410*8
MS!%GP8#&(2<8`1A,8-Q7)6<`01D_IT?>79:Y1P%X$'0'`7J7B5R!7O/-!\>,
M\#'`0!I[=P>>=F7HMY@&E"=01I:GC$#`CRKP8(J#34184D<44MB1_X5]^(%A
M2:-3Z(<@=1#AA7Z?B4$G'&BDN`$::>@G-,E`RDCC%T[@:,7D,Y"X$]WM$9F?
M%U980023)&"001GO"OT%`-@?35=051S"QQDCC'")<.UF,(*@41CA!R8:@Z"Q
M:&7,=`:<Y->)@8:,--)_(GZ:!)T$]81._.A0B9J`HQ;(!4E9@`FLH,$00I"I
M36VJ4['XU*=^(:I0]0)5IUJ&`:"A#&BTZH31D!6N:)4#<>1@5N-`0@MY18YG
M/2M8!#&6/815#WJTHR'^8,@\GG4M:F5K'PUIB$/^L0Z+4(1;W0+71*0XKG-9
M\8H14A<BC&`"$?CD)3'!P0!J`H8RWLLH9?_X0`)*\"$Q%HTP-DB"":Y@DP($
MX"L*@U@`5A.Q5*CE!PA`P,2>1I<)+*4&=-B+_.;#`K]PKVW>V8`:)KF6&F!&
M/22R``8JD#L0M.<R+4N`DACP%N[`!PTB2X/0N-<)@#5@%7!(P!BLT`(8)"`-
M#,"!&/W5%)YE`$IM.\Z"1%&*W.@F"S$8@0EX<!SB#*=$8A+0HGJS.8,%J0P^
MT<#?WL.>]C#./"4PI<CBHY<:'&XREU&<XBRCN`HH3F2+FUOD\B.Y_D`@*%)1
M9A6$(SH+C8X`I3,=`3@D(5(4M$&C6\0?,(&#T1S)"T2SP4[@H*(>P($"I=F1
M!LH`":$TKSR22\#_].;"D[PY3Y1CJ)*=,#&"!G`GG(H#T'&"UX4HA&]\03F#
MU"(CD_O)*9DB``''/@8""'R@;X&:4_YT.8+P'2(,85!$GER`B3-$01)TBD0!
M17`&0QDA41AP%*1<(`H+X&$++%C#!#ME00QF4(-P]6`OAB%"504A",I@Q@E5
M&*MJS&J&X'BA`Y"@*W)\(QWJX.$]H"40Q>Y#6-@ZR+0BVT0D!H2'\8`L$AF[
MK&99EK+XV(<3@ZBM)WI+BJ@%5Q6QR%ISC<X")]E0242@KY?L38QB*$`$YF`O
M$HC@>A_X0`;Z192@?.@-][(!#VQ@@S?40#I7R$-7;-`YR-3@!RD#I%XV_[`*
MIAA21B#;6%I`P)TAM`0J;.386N[B25%^@0(-R`("&D`'\K(`;S<0&LY(68,2
M`&!PGJQ,?C0`@'X!S$U^&<T,QF"C-/!R!(5,A28SH`$1"#,+)S%FUP@@E0YC
MY3@JZ$T6,#"<+I`@FLV,&@Z>]"0192<[CJN,7=C+7I#-Z'`N[>;BN@F?PXU3
M9#XKP=Q@`@%Z+D:-A!!!F`QE@1C$`$.D>!#7(.21@D:Y="3!$T&-D,P!`$!V
M7AB"FR3*'IFA@04TP-E^-FIA#.#`.\VCIY2(0*(NG*@.[\V/?@D<L$ZL#Q6&
M=,I<-@(D,DGB$&+@F<9*1KF`W>\,@F``"-J"AO_Y?`$(`(A))-;G9IF(P!"(
MF&J>JGI5.,T$3IWH:OBZ,)/8CL(K;T#S$'(1BUK4FA9NI>`NA"'77>N"UZDJ
M1K#OBE=6[94:QV8A8&^UJP,@`5?`(JRPDI6.<R@V']5>B#S\$8_*-BL@#W$'
M9.^!K<<RMED0L183FUC:T3H1M=]*+15;2V\KFB"V434"'T0`@00,(5YB[$(`
M=AN!`JC@MQ0^*G%;B8D,(.!>8F"%C`#TAN9"S6U7$$,#$#"SCIMS/@R8EYOA
MH-[LTJ$","G!BRP@([;<^&-.$.5B&"`&<P(-:*H\'LXJ\-P&"!D\=ML>`.K@
M)08\*0-"3L""9YD&IQ#_*I@[F"XS[]D5V))"*NK""EEP8X+>J.`XP2&T!<2T
MN0E(-#)STY[0*.`$\/18/NQ-&M#2*<[X^.LN<K\Q'&#*1NZ$G(VJ9,SDU,C&
M$2QY`J$K!5DV;`(N&O3*35!!XK?,H<<#%$*<<!<1A':#]6QA"^S)'0MD$/,0
M*5T#`^B"]>#LA)A;X4D:^`!'_1"%&-2%R.$D3%/*9[XP+&$C)N"9GQE*"#E%
M(0PQ<,K&9E,#!L0^)@-8PAF,`A\0Y$YD%.`/]@9PB:X.H`Y$[P(B\BWJ`HZ@
MU$\("JJY6J@^G$&,HBC)5]!Z`UW?H@50N&"N?PWL7LNU_R!4!,1V5ZYR;,[0
M_RI_12N$U0VX0EC.MBN(-0Y$Q`[6!BU-Y`/)HBQ,M&VB]5FDQ0^-U0\@B&X&
M$2U'Y%GNEH+Q)F_RMEKU]H(@<6\H$08=,@+7\V]](T88P`,XD1,!0"?^101'
M,Q2\1SX9L`4!H'%L40%R(2-OD!;S!16O$4B&@5T_X$G^!0`X`#5'@5UJ0#,@
MPP+YT08E4").`4B7`3(THA\:4`);X'/>,7>!ER-EL`5BL1,I)R\J%Q128Q0$
MICA_002RDP`L4`-T,2XDD$<1DX0E<!3"I'BWL1JXD06CL""5N"!?IS8[8!S#
M(1@_PA5&`1/9H3V6\7:"XT[IE$YP,!3*IWQ\$12*\_]F;?0A#"`4H($E8I1@
MEI,``$!X##`"PF$@"V("&&("&6)EHQ!0B<=A_+,('O$@'!(^&K)0(B`:BT$!
M-$!*>-`70$,#3F!D&E`E@9(HHEAD.!-[&T4F=O8$9Z!33`$)$"85=@8)E^`<
MPC<72U$"94!TZR,HD2%4,U-?&'4C99`!2^`ADC9INY,&_[8OX90EY0,D^YAZ
MXQ=5HO8(D3`)0Q$G8`6,^Z1+FV@!%H``("!!M*8I^)=_N.8IH-)_'C0J<P5L
MQA!LRQ`$)Z0,**1"*V0-V^"`'`!#,21M$CB!%`B""K$L1QE$X*8M3$DL"%%N
MZ!!9"_&!Z48/)ZB"[L:"4A3_;RX(@UYY=:5@!#08!:K'$D/P!2.B@SR8$Q'P
M`IWV99<C`FW3CD;8``&P$PCPA3+#&1NG,K4(-2(@7I,T22<'8R\B!BVWA+@#
M!PR0']@C`HDF`C-3`Y46-+3S2@BP=W#6'D*F+U9R'*"Y%)^')7()FD+!`-C4
MB$A7!C,``3S'%1NA`HPG%083&1<CB2J`81OF$5N'%<'1!<GA-LK!B<&7:'W!
M'HRC/4[@'C(64P/@8TZ!8W`0&_,%($M!&$:A2SCPCG"A,?C8%$+A&3Z!EMC3
M'S(!C&-G*%6`=1PA9<OX3R31G@&59?Y$>=2(`X/H!-GX7-7X'M^X&`,F7!@0
M`U$P_P'7U!+=PT9.82#&USZ($A3ELU-%PWM+(525U``XDI:00'WQ`30R\`56
MT!AU<`8&2DH!R0)&\@H)L!X0"8SN$GYXHB=3%060\"="83Z)$I$?N7(CR0)M
MX&\G*0LIV5:XT)+#`&PQ>:2I`FQWM0RND@RO<H"RPD+:8%C3X(#;`"R)E8%&
M.6X:V`'Q`)4:6)7E9EFAM41H.I5()*9IBBW>,EIOJI5R.A%=^95V>A(N<%4D
MZB[_1C<&5A-L60`K40?A6#M1L0.(&@-B)%$X4`$_L`=ID3))@W*7HTF2885@
MZ$G:$4YFMP77Y4D\1P=[IST%A@'--VDDF4HX0CDT!S'34?\G@R`3,C$78K`E
M2_`')!``!9!QG4`7=,$EU0@!(B,C.'(W",`S!M(%,1`FI=`:UK,S8L";O6E,
M6L=A3D8`*M!U8^<V8#(=3"$CE-$RZK$WBQ,?<#&=RL>*_2)H?+&=2]$4$X"/
M#7`<\\H4BL8S'R((V40!;4`Y[X)TD&`"")*,5$:,&-('`\4@\VE0J%-YEI=E
MU$AA&O!O:&EA-CA<W)$?F89-EQ,G[#B/@N`E4LB@<,*.9\`931$7^C@B6:)Z
M(B`?B,06GC0T%$`($S`")4`#I[0[0T`D5G`#FE9H[T$!__8*I,$8,^%G(E`'
M]=-4_6.1HA9`6)4E^5.+AM(%BB/_2%M``QR4*;>VDOMGI'2%*J/B"V0;##1I
MDV:P*GN%@,S60K0B#@?P0LWF;$+9#M=&+6%Z+1Y($"BHID>9;B5XE>@6;M[6
M;EEI$7,JIQIAIX[;$23@`F%P"3M`6XQ!-T0!J&PY&,`EK'.A'$[V.F,D!MSQ
M`Q>0,I.$`-^A'@,@!AJW?*+:8RB'EFYH`WL!2(DT']^A/;73?#^#<^GA$QPE
M!CQ@,,)GJEB"CUV1!WS@!Y(0=6^0:`V@2_Z")1^R&>Z$FBOZ!6GP7&#2K+A)
M`F-'6V4H!AE6%1K&81W688J'O@-R8B:F'$K1%^'D.&['A#.B%S+"E_G*'8TD
M1F(T%TZA_PJ)UC:?*Y<\8TAM%C4W"B)MB)HM$1,!HR4&>RB'HB&0UR`.TD_U
MR2'*6"&49P3DXV6S<R.;P0.5>SW8PV)T(T;E\P1Q$`51X`??U:)TP5*7<`FF
M"AOS`0%5,I&8L#B7P0+P`4J40QH#<+,EH`-",#.)4;0ANC?.\5ME,(I?<);1
M,SL:4`<,1\7J$SZ)`+53A0E_DE7$5YHEN@4E.00<]+7ZYU9BRVLB9+;&T$$@
M),<UN;90VK;-H(!T>PWCT`UUBUC3]D/#(FZ<58)C*I4H2%IKZD1+](%4*<E!
MA)7?LH*+"V]U^K@P&+F6,`)]T`"18UYL%!1B$`!E-`=SD`4?@O\C4$*]K00D
M-,=R);`!>X"Z:J"ZV>%@JJ`QNS,?*4(9,(&6`[`7],4Q-),&0E9D!7G*B99+
MA!&+ND0(;:.L?I`'>:`PT84!9P`U<TD^ZP,_L,&8"V<4U],=M8@=JE0!%0<C
MDF(".]`'?-`'"Y(<.``'RI4;'\$UTZIU)]%U.Y"M)H:HB*F'ZE0!1+&N"MT9
MX=G0^TL8GLH9-6`#\[5H4!%,&+`#4C,@,=!UD)8H/?$3E"I/EZ,<ZED%`$6P
M6$:?R+C2)-&,#DN?D#8`X>AO-:MDY-,ENQ3`A1(G<6`FM:=3'S(4=5*+_?@(
M,K(7*P('3C!+O$@F0&@9\I$8-)!F_7'_.5+3J+I[`Y,#/;S(41/P6ZQW`_DE
M2M&C31W5<`5Y?GDBQJ.65%B5M*%!-"+P>6A&`VN`*;_@QF]<I/SGDJ4RDZDB
MV/TG;'),;%!J0@G(DS+$D]Q06!%(;1*86=("+<-"I@XAN,SBR(*KII3<R):L
MN.`BVIF<R9O,R?5&`H]R"7R``?UF.:5L8:B,$W.@`N;\`3_1!M0;%%Q2`A-P
M!0U``71`22E3,T5&`2]R!::Z%BNBNXQ39)MAB(EI3M]!`?KR&1;01Y$I:$^1
M"GE@C.%S$@J3!S?+2[UZ!EB`!9$!LR&SBDE+&/^A,0C@%S4"`340UI]&F^=;
M%3`C&<J1TJ.P_]\:QC4$0,\FH0+O:P(,U1=(%W+]TB^Z%!D3-Q>EV39PP3,(
M)AG.E=3=>:QFEPK!ER@B8&<CX`?*.C6$*GM^$<'0]PGM*3H6_$\?3&4#U<%6
MMM*+4$#N,K$$R21=<`:("FB&!&$_XK%R0N*^ZE)96#\M2HOL$1\?>CQ+TC;<
M8:$_0`<RL!AAU@9M`"`GDE]2<B,JRA^H9TA/G@9$4M;1HR3J(WQTLH\B4`5M
M+6J)D'YRL@11\'ZGJ8^=8-<_F@"]X+46!+9^G:0R.<=CZY*^8-C#4`PCA$)N
MZPW;P-A8F@-(4,CMP`YXRU@)D<A!=&X=^+=E2H)0R6ZC#KAEJBU0%/\1IA6G
M6QE%I3UOJ.VXJNT"E]`'$Y`!BU&0!N8;9903!Y<!=8#;+&I<G^9S&*`"UH,&
ME`1(X=HR1[$*XK5>Y5%D_V$#=Y2\2:-.L4H36N<;Q:L:ME,BKOL)`](;="'M
M<!%3A#&O.S!]LDL?#EZ-J`E3VBM2%%`#FF1BG;,:)Q$Z8B(W\YK=U"J;7;.^
M4E'PLKDE)R;6`".K$%X4U)%H;A./M`H@+O46H:J[^%L#;R&<73&A\U@^4<!2
MOT0$"?`=+*YR&5W!%KP@)1%0_PXZRUCC\(EEK+-EB3`G.!LBY+H1,\P'&OV.
M5$./<6)G&N,6<'%).9@E"(<=%=``GD1Z_9'_:<XQ`%<CLVE0UC;R$B3R?BOZ
MG]DQ!(NA)/^!"J&1G+Z#,X)(,CP#82S!Q3$0QF*,".F7D=)WG`S0!D-@'6BE
M5KO`UWW]5G\-@'DU#'EUMG1%QW1L;,T0Z8[-D\Y&#I9.0[Y2;>MPR/#@V1V@
M68VL$/IPN(/[R*%>N*-56MSBIMSRZO*&R;%^VK/.6K4^)\N*`[N^'7S(@S@!
M!LK.$Y1#`4P(GB/>``%S!?T%`I,TF<^.W!<-`APGLZO[%V6``;J5%&$=%'MA
MX1/=,`VRB:H1,04<-;X*)O$JWSQ\.`.0!CIX(N]Q%\'<B#-!&*GI%"60'T0`
M`2`@48;78:$`"$8$_R19)@,E-18V64U-!(^0@RJ3E)0DCI$[)CPD(F49`PPX
M`PTB#1,-&#4-"!@B8A,88B,C.R(BKF)B+'`5)6DEOPS#%7`@-1C)8B0C(EU=
M,5VW(U%/`R,X91\)#"5E$.`EH!@3,555!(V1ZX)&@I"-\?($[O7V[_8QS1E`
M7@DW%#)@V'&&EBM1#$*U@3!*Q(@NS1J`@-.+09HT%,"!VH$A0PDX:#8@`$$A
MP1`-%"H,P""-02\*7[[<N)'`R@P-&@3&$-$F#<TO,&M:L?(!P(`=.P8``%K3
MR]`91#Z4N78+UX`Z=09T,>(B3!@78%UP=;'$X9(G3\X,H,&6!@06+&BL6?]`
MEVZ(NRWRZFUQMV^(NG51"!X\V("!(D4,"#Z<^+!BPI!1&%9\V(QE,PXR8\[!
M&<D!)#DX'!A-6C3I%2L.K/`A(/4*`:U?=^@`N_9LV+-IK\Z-^[8`W[EI_Z;-
M>WCPX\B)!Y=P>[8$YAV>2Y\^W3GUZ]BE[UC'O;OW[^##0\I#@HN+*"/.)$V0
MX%O":Q;`@)D#AL2$`1G*)*``IY2(`<Z(`(H*8C``@AH_(%`#"!5@!-0`%@2`
M0`,-+%A1,!24T(`-=G1H1P`6Q!*A!22^8<,5?<000S(33"#&&V^(@<$6R-PB
MBQ@U\`+"1!11Q$(%%`#`0(LEN-3##TC^``<$9>#_T,`P3`ZP2@DU`:$!`S5.
M8$(6650R218#0("+)NF08*:7EI#P2!^1-&(F"9,8H@$`&3"`BXRR8)#*2A.(
M$,L()B1CP@@36)#,``EXH0%0%%#@Q$60&I,*H8,.!`U!Z46Q!`XBX%#'G`Q`
M```X$)2`PPAF$F!"%28\8D\?L+8YCSJNWN/.(_-`XLYYS91`A`9>>$%!&PV8
M`)$J(P%3005.9%B'DZX,T&`:%/E2`9-E3!4+#BP@L`$=(#C!G@9$)%"D"/ID
M4$<&$`#E1$Q#X53'""Z,4$))7SCQ+GLM$*6!"#MT$>87Y!+AQ0S^#,&I@*#@
M(N"S6W45%EAC16$66F6U_]$&`S2TP08+"80@F%TMS+!77GZ%$.Q?@1$VF6&2
M,?8RS(Y!-MEB,U^F\V8Y((&$:9R=1IIJHZ$V&FL^O`8;:L/5UIMQND'=6W+%
M(0<UU=`AE_5QU5%GG72Y92<V==N)9_;9:$="GGE&=''&3NRY-P"`8H`1000!
MJ&"!@/I1P$(I<SLDX``V%'C@#W2LT@U,)6`00`0%V(!!**10*%$--A1@API9
M\!!``5>T:$/A+[8X0C)ZLI*D@I93?B@#Q2QK#(,.7JF+1V@@N<%$:8@Z%0XX
M9`!`D3A`H,$,8VC`P@\V=&$"YS:H^8@)JXI@U#)HJI"JJJUR;T'VVJO)1Q<9
M?/^@@9@--,1``X=DPP`L(79!`$&QZ((#`!\0<=-^%SUZ48-P6`6%R.$0/SPC
M8&<X@Z8XA1\`"(D!WP!'0/RT@RK$8`GF0`>NFF`F>="J5N_0E0=U92NN&*$@
M`\")%X90`19@P`)=J-`;?K"[937(63@8B`@8P`(0A&0#-6B428HT@`D(S"7,
MBLD-AI"`&5A!`]S8P0CJ("2,-`I>3SP?!@B`@3(LJEE!$<H'()",48S@$!GP
M"`\;L(46X6",#I%B\$[%%:\8(0I1J,=Y+O8$]*RA#320`0WB$K*ZA*`%4(`!
M%/:2LKX`QF4SBZ1A$$.SQ$1&DI/<F64RTS.?D29HJ$G_3=%.(TH?1(TV26O:
M;%B3'!^8,CA7$TYRGD,UK&$-.K3\&BV]%AVPZ7)L8BM;VH9)3.]P@1Z:*@L$
M$O"%,K0A<#LH0`1X@`<]!&`$^0'`5/XS-P!UJ@0(>,,`X""2B51@&-UH``_`
M4(`73$)&8M">"2QPA2L$X)Z-F$0`K@`+$X7S#1.J$(G81X<-?,M"%/(%!4[1
M*6,4]`<(@@-,F(0#^V&I!G"@R:.^D```P&$`P1N>+!KP!2`H@`@40,8UD-*]
M1YQI`J!PD06VU,$W-:%+:`(/'U0U`/-E(!7L*H$$$W"\!+"@!B:0HJ9&$*(P
M>6$,8X`"%)A)@30,0UKGI%;B_P:8#&BHJ`^T4%$,`-3`X:5!FTR$0)T&PH=Z
M<%!Z]6BK/=81#^Z4,(3QV-4)=T@$*X0#`D7L@D/I4%`T+"M4#LQ`+3H%`H.B
M@05I2)0_JKH2:7CD74,`2**<:`4OO*\C97`4!682$Z+B)`,3X(.]LE5:?WVC
M!-P4P1G^X(=S1(-%6W@2N6!++[6L:P3NL&,4JF"$*OP!"Q8;`<;"@($U#&$-
M)U!"$`"#%T2>C"\I>V1A7H:8[LZL,8T)0A`$$X3';/=EXK5,$3"3&0=TD@,Y
M&`U\.;":I*G&:/<MVF\$P,I3!D<VR.EO+7NSM>@HQSIA2\[5MI;+7@*S.@Y^
M<#"+2?_A"@^B'G@<P3*'$-J$B"!"5YCGAS"0#6V^IYMS"Q[F4@>@_JBB!C5X
MPSWSIH("%`!$)'+1Z$;'B2Y=`0%)8@(3@(B`"<V-''/;$8]VQ((!I"$F'^X(
M.9-$0Q`\N9D"$<-_P`6DE#R9/2I)8QD8<*@$*&`,;A@"C'%!@,Y5XDT34.LI
M6M4$\&5A>]SIH)>8`8"<G`*"3&(F41%&+-.A901B&("B-&`%J":@`@R:'470
MF88*+*A"78U&%_Y`BS^HZ!8-/%^H(JBQ`2R#'GZH;??Z<"MXQ.,2F(C$/>CJ
M"%N!)0K2P,%-8I(1"%5!!`$D+!UZ$!>A:L1/(BA!#^'@(/;_U(0]8MH)!*K:
M*`HPD=%#X88;%R7:F!!L!E8"V!E3G($V9&`4;&P1B7'@(E>8`J38`H=^OL"I
M)[C`MV5`EQ&\\A4,1^$,#EEN%^:R!NE2]Y!Y6>3)_`*8!=B,N]V->&(FWAB8
MQ6R[.#-`>LT0A$TZ`#,<"#E\Y2N:4+H&OTECFF^:)N!5QK(#+5?P;WQI8-PT
M^&NV=`YQ&BSAGOO\.<*TL-#-1@(]NH!\"6`2!#P\@3S,<SX%F$`VBE("%(-T
M%$ZR`1Y<Y*(KV$`1)/I<WN`TXQC9P.RD(Y$)^-F`#:@!08@#086>))`^#6`B
M(='=DY9IE!#A8,H;>-*R2D+4,K`1_Z0,&N2/OGPE_.!@3J,(4[F$M8$`M$CM
M+9T>^2IZ!15LSA*8,`&;7*I/-$D/$EWX5`;\A!]V09$]P0+L0`J2%J7LIR8(
MJ\`&?H"&QG[+G#>$-!QPD0Q]C,`/">3#IP$DO/,!J0Q#&`*IG!$#/"[!#]V+
MAPIR)>M;U=75W;^K$<J"`R\0H5P9,G45G'R,&O3^6AS]0JG\A`&7\`XFWJZ)
M!O)=!0U#P(K65EKDH@%',58.U"C+]'H=50*G\Q_DT"(M@@<2B`=;$"T`$BK.
M-A1$H`!6(GW@<`U+0!9\@P-;P6\3$P6<=@UH$05A,`$R$`(WL`8HP#+5=5UZ
MX4C:=5Z,T?]=9L"#X"5>Y74S0@@S#E=>Z848[&49[Q4:0[,:H71?*1=*_34U
M_&4U4`,=+S=+NT1S$(9@4X-@O10V6?-S9`A,03=T:.@=Y3$61A`#]P,!TN=A
M`W$%!3`']+$#GN)`5==-P,,I3C)38O`X$:`&(*(+-N`Y^T0"`5`X,[0Z_X0,
MY"`C-;![0*1D%<$N#;`W$)!W;Z<&@<<`U<8`>&`(#4!85E95:;`O^]<`8M``
MI5)IO=!L&J`APS`J,?8&%6`POP('"-`,7:`).R4)DW`%M^`B\T1K<)(]=R8]
MU`,);X*'YX-L:60\2==$,T`!ZV,"`*</#F01SY8&>6=8N8,@@0?_*1_A"Y-B
M+"/0!V[C:?J08GTF)!2`$TG')`VP`W]`#T;@)B!D*[06:R140J[2!/>P!-B@
M`58R+B4P`>N7!L?0>\Q&$_$"`#FT0[S@$U?D;$0%`.@R`E[D*&#4+N0"!!S9
M?V?$+J1R;I5S*'[B(K"06RPP#*5&(2PPCV?F%#"0DV-@!4,`$W0R`$_P%0:9
M'ZL7!6#A%6%A!%CP'P^Q!"PX`4I`%RA@2`@G53:(@RVS71*G,SZ821SW,C$S
M&>(UE1K7<4B8A)L1<DS8A*XD2JL!&SZ@7U4#',?1-#/7'+4DAKC$A0Q&2S:W
MEV*(<Q%6AH0Y'6>8AHCY"#NE)B:T`PR@_TVO!2!,)4T1(!\6@!]E\).@!E+7
M`"`6``N>8P.+V")B\'6*P`.HB0H(\'9(@@!;X"VK<"<2H60U4%`;``="E2VF
MYHJYHSL[@IO>]CXV(`*3V`LVY!/C4@9;P`2N"`'5<A$P@1-O@0/>@`BH0`%`
MD)U>4`&M4`M[1@(60`#W@0N%8@+)"#Z7T!WGF29]H!2KAPK32%4)<'Y+IT,B
M@`5*P4/+]`45`"X^!`=.H'M(@B`@\`L9$BH+0SU=D")GD"+1@'5>)"14`D6D
M@@%%QP?#Q2JB1URME@X>!)#=]X]W13'2``&_PDQC-@%9D&P!A`81R5$UD3Q#
ML@6A`"0WT"PP.O\N'-D%)+84^E):?584.001ZI$,J;`%;:0+,M(I#C,,)<!1
M&GB-Q[`%%>`%4A4L5E`R5L!,4$J1U/`5Z)$-4Q$#1\EO[N`'`-(%3MD56Q"5
M!Y=P5GF#6"F5D#1)/,B52-@8ER%>93DS?+H816"6ZY6$[L49:UDTJ,$:;KE?
M<:D:QD&%=VF%!E9+?9E+OM2%8/.7O'2IA=FIV7&8B9F&.\4%N^("?.`)$=0P
MDUF9\J$"F*E-WK299\0`)J(+-4"<R'"+,2(&%L`#6;`%C:4[Y2013\)N-O`D
M;0=1;[<[5@1;%&@@_KDL$U$23T1&D@,"=`!`@Q=_[<$*-/H-E=8-HN+_0&("
M;\,3/##A!?W``C%"#DBQ`WZP`V*5:Q-P!9[S9J?7)F_B)1RT#FKB"?4I=1D0
M)`!0$N#V:#4R$*'0`)'%GW3@HC?T!1\!`D#FB<!)!*.R>GY"`-#`CGW@!P\*
M/!%J$02C`=*G`3D4`WZ0H:XV0NQ0#Q[ZH0%)#S'K""0J($`P`XRB(7C`HN:T
M+T,`I2C;(@)2`OKB(`)()V>`#O>1+?K1'BIY"BI2!3O`!Y]IJS#Y(S94`GUF
M,."F`&>VI?Z3HS-1MKR6$:<E`D'I%>B!F238%69J!"F8'DX9!G&``6Y*,GH1
MIR@SIP\'<44P!9K4@SUXENK5IQIG&'RJ<8;+_UXY\'&AT1E-F*A+,QI-0[E2
M4S4%9JECV+G+P9?8H4MZ"6&>6KIF&*JHZU)%%Q8$X`FCHE9V4@N".`<1H`)\
MXT"1!VJG<@BE"6.[TQ^F$$X_\`:BPP-;L'O>,J"WV0W:M`4\\"0U`%%5-JW,
M!%N%PP!T\`,@0`.09F4Y*GL-4`+%8$[-1E3@=(CBE"W!(`X>,0J3$SS.J2#7
M0@0Y2P%REZ8J4EM5P"9((0978`$[P)`M=2;HJ88$3`(80%'D$#Q<FW0GD;.6
MY@H)9`I+\@7@N#NW^0564"[KTP`4L2"]<UK>-`$<VP7CXP<,VH>?`@`7T6?^
ML$Q#4BOI0$*L-E>MEO\K=]4=]T`Q^[`-9]L`>/`D_=$@^\(>!/,!BM4GTP:2
M.:H!11%8SS"K"4$A22H&>%`%SP`1NKL01`4!W;LD'\!9P8(P5'4#I74#,J`#
MQKDLD$(!V<(`M+`$_-:V^<%N$D,Q;3@WT%"W=YNW57F5./BWW]5=4^`!.O-Q
MES&HA)L8'6>$0*BXZG7(CXL9/A,TI.2HE0M@K<$:7UB7DQJ8G\R7DWIS8O-+
M8%C*IIO*VI&ZJ<N87,%%PE,&\L=TLPL&+X`-F4F1Q$<+M`!2"'"L%0!1W[([
M=[<!;Y!;>&"\D[A[G:B]O8.-6V`#][',#")\^/(%[[,+(!!WYA1&LY@GQ5/_
M:>?$`-FD31\V4X$R#=&2"A,0,*TW%7L'`%9259@V$`;,`R1B`>OY9K)"".`3
M/H]`/I]P"O@A5*-R$O3+G0X!$11R+P[Y>VH``N<W`P!@:340*HVU)!G!*;Y(
M`%A,`"H+TK9P"U0T/*%"C\9347S0!Q9D#J)7PZ%J0L7%H?7PCJ9EP0RP!<\J
MOOT#HS$Q)UH!LGP3:$;<!IS"$ED,@4BZU$AJ.>R3'QQ5,.>W0I56$E#$*'"8
M$D3\/]+ZF\]I55.,U"P8!UZ!#:*"6G*;5.>0:R-P07S<`%-9@SFY<%A9IW8:
M<87L`7KM<8.;R$`(A&9`&4&P7H;;7CSC2?AE<G#I_QJ7^TH)IG,V][D%YF"!
M"9A[&;J#.9BA.S::K<JGR\JAZLJ"0#[:-,L`,@&"6)EV0&*Y3&:ZT,Y8@`4D
MA@%7$+YT<`%[P)H(,#?D7%%@(J`(XI_,-FWK\W5MM[QP\+!`XFT_=:O]25@N
M*HL$F#F6%RI+%SQII)(L\1`QD`>=ES=21"@L`7`A50>962HS\&A"Q0(5.`'Q
MVHS).&-CQR7=\<^@-ST#C(=T8A73."I>!&Z61GTC\-3%$!+9>IM4A24%\`,L
MX)QT(%'G=-0/X=%;H2(>K5HD?=XG?=5$8'C0P++@IX_N4,,A5+,$V8\PNX_S
M4--G-)])YQ8X@*00Y&7[PO]1^%,'&/`':]T,W43%","K\FI!L;`%.Z0Q3&02
MZ[,@#$`NS+3!"0.21YX2Q\!EL6-#/6(,%E(MPT"<8A#`.Z`FFE+6PB,5Z&("
ML,"CG=+6U<>"7B$""U"#@'P761F6.VBX>JW7#F#(AKTS'X<8?]UQ'"<9B:S(
M[O5QA7K)]P5@*3=SS/&%/+=SG3O9E"VZ$?9+GGWII@NJH&UA9@*S;@B92W?:
M*G`WJIUHK6VD`X$4]]$`M9T!<*`&%X`@<Z`&=,<0$V"\I4B)``2@,0%8)A*L
MO?=^2$MO*C6QU7((N0P!&\(#JC(YW@0@J.._(.T.6$`"]10B_]$IT`X\P],^
M);#_*$^F`17P!B2RSU\""=1#/?MJ>OE*5]EC")^P$IW"+J];)6E`Y$@QX!`T
MON#RH_('6T#V`Z[8GU;69.[[#'R`Q<45`VWH!]@0:A9L/+]B/&3$!WR@XZQ"
M#W)UPQ]:5S;LH>P@%B%4JFWK1>!P$FV@TUO`).SB13CQ#:"@(M!P#DFE"TR-
MI*;`/D)56O0+55;`GW`@`^^RI3+!:_Z3!C0P+&G00S"V(\<)*;`#(*G@;I9C
M([Q*(C:@`N/'@OL``.9"#C!&HZ-0?4Z)1^?!`&\.I]?EMSHH<8*+YYGA`>TU
M]XB\287;@V5I&4:(&81KZ(9:J)XQ2HC*2F20-*R42Y'Z_^B,?MF/3;I>TS68
M'OFIK.F;7F&D^LJ&4-JAC@MT>#>6.0"Y7'7!0Q7()@(\(`:_\`-S,*`"+U1U
M4@,%(`;8*MSOAZ-C5@.R/XDTE*TX&A2$(SE.&J[8'1`K$3"_.$\GPD^1*`L`
M#!%I,>"J@"/L`SS,IR[BFT;=8`Q,!`>FJ8;V/0EX%@GF#O[I^0BVX!Z'8M#?
M4!,P0`.Y90)V)SS%4"T:#`3F4B0U4&02Y9`3`0@L`R4X&#LQ?GU+?'TQ!#$Q
M70,B.&4`7VDE&C,:$%X:`UVB73%5)@0$3:JKJ*T$1K"QL:^NKBXNL`0F)K)&
M72(9&D-?"0E##%MB#6T9.#@9;?\,#343.R9\554Q$Q@-(@-M$&40)0,-W0QE
M&I]61$16"5].%6E?\DYI%?3Z<'#Z:?G@@$!#!T2_?_I8P&DPC9H8#"(:3)@(
M<0(/&V*V-!C1)4R8)R)^01#68`L(%@QPA,02I:6+*'Y&M`G1H@44&#!JZ@S!
M,\2"GRB"!C5`U$"1HT6FF/'`U$$.!TZ?0IWJP(P9J&:*6"UB($@0JV:^8M4*
M-<=3LSDX'#BP@NT!M2L$R"5#1D!<`1TD2.C0`:_>OWSU\LTK^&_AO80!&]Z[
MN+'CQY`C2YY,.?*.6I@S:][,N7-F$D9N&>$CHDR9+V7*B<!@H4"$"&#`!!`!
M`0``<B7_,DR:M&/$@"LV&#CY,4?-CQ\(&I2``(%!C0(6&M`I.-!@&@H4OC3'
M,*'!@!H_-ABL0`&"/0H8>`0P@0$#`P:31$0\)\8"'UA\"%P)`%Q9Q$GG8#!"
M#&<,4(%`T]$!!P,E2.-,!N0PL)"!%'@Q`P7GD)(?`22HX.&''I*0!0FM-$'"
MB2>"J"()37Q&8FG;88##<J:9IP$,%&RQA043##!`;0<.5`$Q,T!P70D@U``"
M"`D6)(@SK$'RB!]\G-&(*/)58EL)%&A`A`9?<#+`(=F@TJ*99[XR2XFKJ.)*
M+['@8D0ML9P!3#%XPM.&"!/U.8&.$XC!37OR#7#=#0D0`80"_PI804$%UD%0
MS##$W(,/`S2T00,(.J)AD$`'(=0/DTJ"4!(&6P0JQJH6M&H!)1C@80$>W4VS
M104T.('#`$\\,<((530@*88@5-#&GEU$$88+851AA`D])F#333!`45-///T$
ME%!%(974%%,PY4%94J$EU5160:755EI]!=95[Y9%KEILM;666G+-U9</<A'&
MEU^&!8988HWY2S!C`5>F\,(,-RS999Y%+/'$FG&AI@L$C%#'):E-,H(%8+@6
M6P`80`A`&3B\MYL(O0T@!@\L.+%!<>'54`&7Y;F<$1T;(+"!@@!EET`9#5C`
M@S(#F*K/>PPZ9X$*39BP0P`V6&!#'O\[J%I?'GXLL40,.YQ1`P)DUR`"@PVN
MMD,>,AZHC]LEQ"U?;@"4,"&$"7CAQ1`UV-#ABBBJ0H(%)EB0A8H@GJC9B4T@
MK@(&9=2ATC?/U&9>`C!\41*/@S"7!AQHH`&'$_8`]`62#8"@Q@47&%=L2@-@
M8$(DCS@R8!6B^(B#;9UT2807Q6C`P`X[9&,*+[V@V::;J.32F6ASG@*+:%WX
M1HP5V,^0``1M?(=`=P,PT(8S\(6?`0`::%!,.\`70\%UX^3S-CWYI('/_&B0
M_6D_#.3#T/];J,$;;$#`JKFJ@%93SQ7<LP4;O`$!/6`!#29(`QG(H`+R$<$(
MEF`$#$CJ!A/_'-^`_*`LCV1C`B(8`K5J8BUL96M;W"**M\(E+JJ8ZX9.P<I5
MJ@(OL+@K73S<8;DX@(2UU,M>;,%+O^JB+\'TA6"#<6)D\B*PA`'F8`[+HA:W
M:!B(4>R+8-R,$4@DBS.<#S6Z&<`(3!``D87,/;4I0_E69B<<U"``#9#9',)3
MD*`Q9P`3F<8&!BFZZY0G`1E`0`%"%AWXI(XA[4'`%:#6!-R1(`"85,$?SL`=
M;ISA#",X`Q;.P)`:#!(!-8`#0')3B![9C3SS,`AV=$,)!C`G`_#I'P7REH!D
M>+$5C'-<XA27"A:AR'&L<`4&ZH`R#0Y@1I8C!@R\4(&B]0A"[X-4_R&=@!V`
M0*H"-6"=<13TI-7,K@L$$`4?.**+&!3*-+U+0/KR1@0(<&0)9:H%\S"3O#=E
M)C1RV@7R8A&#$=#&2S/`WA<HD-#WE4`=C)H!)OQ1`F(4XP8WL,<-*'"#(6"'
M2]I<TI(:H)`C,:`""DF2DO[WOQK41U`3.$7C5&`''MA4/9BT`R;;:`/EL.`D
M%;"@$RQX@J*R8`LC>,(2PF"$"3#@"R"L9DRK4,(P1`$2+!A""W"2DYU@2UL+
M$`H*BF(4I-!P*C?D@%K-P@&T4`5=[PH+6'2(5JG0RX@KR*N]!$"&OO#U7U7<
M"\"D2-@I3@:+7$RL8BOSRS`Z]K%-D$4,2O]P">WXB$\!>`T8Y@"&'FG);I>=
M!$0*@<<T;&"<UL'.Z3!0-8B``)44S0`K62L;3-J`&Q,8H`6N`!P;\"`+)JA>
MH-XPP#S4X'\^XDX>V+:0D2[)'S<[60/$(((2'`@-&S@.'6X9.Q_5I@3G^-$F
M8#`#%DS$!"GZD!U6Y`H3H>AO@&/<\E9QHAB<#Y??8(#);#0&+["@;SN@1-P^
M)Q"#+`D@!Z$`'-2@!D\9Q#OFP("@N.,-#"274#ZR!)@DE3[L$2$#,37"\OS9
MF3:I"4YP:EXOHO`K''A)?0E`E!LXD3Y%`6%OC[J./8RD#V[B0\?O\P<<QD:=
M\52@?_"9SS3ZM*K_)A,0.*TZW$XQ*0<;,.'*5R8;V7I0@1LX@09K"',0E$!F
M)7A%!A+Q0VB,$).(2%AZ45A"2ZKPIP&HD*O6\NH+M15#&9JU*75MJUH'O58<
M4B6N<\VA$)]BAAS<"Z\^T&M<Z**O)T)QL(2%XF(WS>E.=_&QH`;CAEH4"S\P
MH++-F<0$,OL:SIK@F<P$K8\<28D&\``#%<CN!CRU("XU1PP%*``/4.@CAA1[
M-2IX`8@P:8'ZD,`%?,@#M/HD(`R8,KLUZT?XI"$H'X5JI/T;"0`:<(419*`"
M=#C.KN%`@9,5`M9E,,<@-*``G)2W:O%-48=(!%]DRI=-Z551$_RPN^9X_T._
MS+3'BUF``$%1XAG6!=T@LTN'"CC!'_*HCD%\!"`1'/<]<6/0^T[ZS`%H.![R
M](*'(<`=4QBA#_<Q0IGF--]]GK@7D15Q9&^.XCB#1!T:L((]JA5C"@Q!;PEX
M7QIH,*P@U2"5;S/DYUC`@FF@DB$'B;#6++`#"[P713B=LGHN@@<$:(3J5->!
MVM6.A!.4F<Q>,0"WO+(&9)B@"A[).U,!&H:OT?E/-,!<5W72@J^"=2C=FJ&X
MQA5H0A,:+6TURUNWDFC)U]4J]TK+`:C@@TCG=2Y,)(-@J_C$@B%V,:?WM.I7
M_YC&AOKUGB$U+/HP`%0G.3TBF\,<+#"`#&2@#O^@3<FNLC0`&[@'!!N`.LAQ
MF9[8!-OX#4```0=XA4L&0`4I"@`/KO`&,5PA#V+H_M,ES/74Z1J52H*#^5H9
MOGY@]P=J0("OA]8`MEG7.O;`QQ<TD`&#4@("N!0^7S`&,P`%8^`<$Q`#`G4*
M_:8B;"(X7]>`C),*:9(*!&!RNH$.OJ<=(S$#1(`D$B8CT$0!V*5KQX$&GV-D
M3`("3F!=[T$>#2(IVH$/)4!@WP`,Z),^Z:-R'@@*$Y`-SE-S-_>`-8=B*98+
ML;`$OO(C'P`F5C`#7B`/_R`__N!-D#(=3V<J%-4@`U!UI50V%,$=WL<#*F!3
M*I`%64"&U[=]!(1E3`#_03W0`VS``D$U06&V!C)05$7U=EYQ`RCP$S11$]AC
M!?R'`:&A=SXG"F"S"W_"`FTP`PH`!7FF9X<G5F3E+4500U'!5FIE1)Y(1&V%
M!&YU+HBVB3=T`F:Q%D_!`7<1:6S!+W315X(A%ZB7>I)ABZR7BZOG>K#7BZZP
M(624"Z6Q8\/'6B(3`7.0!93P>VD$.QGT'LUF#OEU6?)AC'8@9040`-WG6^&G
M'A^2(LUV'#]0`-SW0,=U#MP@`C]E*JEC*N8#`"#V*@P``L=A'#]0`SH6#RXS
M`3A`8/7P*-D!CP*"@])`4E\`!`4(!"60#$9#AL*$?>W5@(@C7V?B7OU&`*71
M_PS>\`S8Q&%$0`%C$XVRQ1P%EFX3MR33X0\$,22?<QT`43_8\6,MJ`_/1`GH
M\P%-F#X)Y05E(`(64('1,U"R4'-I8H1K0B>R@`5*.`(0$0SQ8`\Q1F#\\#;]
M(!!9^#_?$&%/%WX#5$!?YR&8I!XU]5M5(RAGAU)LD)9IJ78G0%1M269["'=Q
M!XB!R%5C,`:*`@`#$`/,DG<M`0DQ(`9X4'9;X(@)``612'@N!$.(=XG?0D/C
M8BZ$9D14\(EOD1:1YU9!Q$,Y((HWE`-%540'D(IQT0$^@%=X$8NS>#"!M3"X
MJ(NPN6F\Z(NT:28G1@"0$P\=LQJM`1LC(R,9,`YSI/\[NE,X8=APJT)<-K!(
M6=`$V*B-8H`1T2F=NT4"MP8>#*8&;T`'*[4@L6-A!R(0"'`<-K,<\-A`U85\
M/P`T01,\)5`#[O$H0J9*V:$!1+.,$#`-U;4)5@`%,Y`&TA>!J!!P#_DA%@F!
M,R5P_R8L&FEAN6$>'`8$7S`V`J0<<0,!%$`#UZ5K`S%(*@D'"]4/5O@/V2$/
MYP$0SF!0&C9/"8`]]BD"=P<)?I`(?7`*[35B1ND\K6"$?=`'*_:7U?,C>+)0
M\O."*K,0Y_!T2MH>8G@%V_<TRR9V-\4$5I9E/4!2:$=!++!V;*>'<>D50>"'
M&!44"Q"(+:`WGZ`^M]$,H9#_#?CT<GS@*EG`!#U0++LT`UREF(875I8H0V65
MB8MGBI.Y%E10F4:D%J)XF3@$1&4ABF5!1&9Q`DC0%O3"+WUA+Z6IFG[%FK'9
MJ9[*,+-9F["7'\&(,1ZDF[3T,6X$&]=T,@R0E<]$2S@P`1CA6YF5C38`'#C5
MG"H0`%E@-,=19;K%I#%E`=8FCLFW)"B5!LW1?2GS?@QVC[:$&PU@?-+P7*4C
M-/+TGCLP``LU#_[`3?O7DQ#1>RDS"1"04&,``PD@$5U@#0PHD1\RH!,HK\,T
M@>V%FQ""`^'UH%\P!'FC`!HP9--0+#68'4-`A:'3#RF)<0GP39GPDB5J40OE
M@LG5_P"FD8,ZF#XL5SRTH#S[E&*8T28YVD])Z#5+P!'4)0[,T2`5P''FL&1:
MDZN\13@$X'69!);75X9E^2<:L05Q&+1IB79;R@)YR'9M%Y=F8&9!`(@[`55A
M"K!#X%%,$V'<80VN@(998&405)@TH%4W07C7LJ=\VIA^=A2!&A6.1YF%6JB;
M9T1(@*ALI9E742Z.:A9%)(HGX!9KL0*6:A=Y9:ET045X\9J?>KB(JQ>A*JJ@
MQ@>D>C$$8$:W40:T!*-@\!J^V:W!B3(PZPRKH4;-UI#9V'U<V2H.F07M`7_B
M2#9O<%SR$4CM2`<^\S.8\J\,@`!X\![991R\5@_;@R&W)?\"RGID[U&B\C2K
M%Y@``4$/I"-/>@D1IY8!'E<#%$`$8X"0U%0?AW,XPN1>Q?20[V5B%AF^33`!
MP2F]#LH<*&<%!$@!5/<>+ZEC\B`_\_,V]@"Q$3M@7!(WY1$A\*$2&F.>ZT"(
M10*CJ&"CLW"4).8F)8MB)G9B7M,27[,-6#D?Q%H?-,M;O2IVVF<#'8Q`$X:E
M1S9!%;!V:JD#2)#"*1R72B`#<HE1>((G2`<!%,0`:*<C6S"8@ZD'/*P'<J`'
M.@Q!;*!V%M117B").U%X+N03?&:VB7<49T4NF-F)F]>V5*!7;GL`<:O%:7&W
M:'4"C\J)HIG"]=*W^2(`GI>:HN?_1(:;N&[<J8O+N(]%JJ`1&@2P`P4'@/$Q
M`:Z!N6#0K3@0:QSW<")0(#Z9G&(P?A+V0-]C-"I@K."!K`6A$247C4F3;MFY
M`=-:#CO2`.C6,\4B$/6@I@RP*B(0*O[``+ODGA.`FYY##W&S?^E3")00;\<E
M7HH"#RQ0'P+E"L=4H%#C(@GJ(1`H7Q/P4!EP#O^W?W@R!@+;(%P2O_*K=%$G
MKA``.@NB#]9U9/H@6P\*@"HC6KB4#ANKES%U"*10"KS0/#?*<T:93"`[8LWC
M$GN'.ZJ"G,O%*C<U9=FH?1=ACCBLI$]WEO6+4ES:I5YJ9F7J$T.`4=@QM4.@
M*4Q3=3I2_Q(3@`<]+`<:W<-8)L1T"&8WL-!BJ\0T\54O)%9C159G"\6`!GF#
M:L4P?<652<9OD<+F0BYUY6A:[(E^BYIGS"^I&3"M^<9$C;AQ+,>/U2&O@`M]
M<&HLN\>LIEDDX"._)T?4N"L%4GP/038,\0T8X#.M*V%'@P$3)X[W>&3MA@,$
ME#*[&Q[*"J'.P0.IY*%!,CK%0`P9D"J])Y7T("GR!`IBH`(]Q4RRY7L0(EN%
M;%#/P#24A9#;FBK%:J\&JD\LH@H3&3@MXEZ-HPHF$+VQ4\LM"CQ/Z`5*!Q#]
M4X/2+,W800X"P<VI_+(JDQ+A'!&K48VR94LP)KW5`*]S8IMO8O^4($N!\NS;
M"T@\AT`@,;`LN9`U31:=DQ0`&BT'!1#=%R&=W$!2N')202)22T*')Z`#;>F6
MX6U!8891&`6P[1/1)\4"&<0=.HP'6=##/+S1<N"&<J@#1FM!31N(2US2_+W$
ME=AG3_QGC*>V@UK%/E"HG7?%*\#@GK@6GGFW=ZMY#]ZWG=<6?ILO^U*X4#34
M1?WAL7G42!U&2KUF?&!R._:J(1'5L$$"WQ"<`"`-[6%0H>0C&#&/QE$VIVQ*
MQ\5:RL`SIY6=%>=KI<P#)#5QGGP0`(M(18,`<)!=O$8/JUP,W]$C99!-_\!A
MG<!:7F<"OC$?\@%)>5!0/Z*7J:0)%\+_;B6``&;X6QP2@96-?9B-V:P0O@I:
MV1=X&]]I2U]@!7H##YBP2B^)VC4X/R<UZ`U2M>]QKI<5($S:28-"&];5)<K+
M&B0B4,9C/'Y@/',2"_(LA!6("L3C)TS69`F("S'1'EN```.DG--G=C@<ZPPA
M"%17OT2+=D%E03+@!.?=T!M%09D2#>7#WB61PSH<W_$=W<J.97$XAT9+`^>]
MT#RA9TM,TOW=Q`(^X$FAB2Y-Q5;,+VTK%YZ75Q4NBGGK%$C0J*+)MQ8^[D#]
M+QR^Q@/3QB!>[XHEXB-.,7R@.$;`5!AY&MJAXEW``Y>K62KPXJ;!`)UT!CN`
M!>XT`,25`6GP_P-[D,G>H7[ET&S2`'_&L6NBTTT5(`8!<%SAH4J@`P)I,`S;
M$SNIA'P_4RS,JG!E<$<!(`8#4`RX@3/D8%YB<`A_P`<J4+,/01&'0#FZT0#/
MH`X75Q[)L`O$8Z.2S2*4+=F4A*\6*`*WH?#ND0%]#H5#VDW:_38@QS3PP3^Y
M43[&-LC=@`%GL-M9HRK$,P(A-PCHPP*G$*.`60I5H&:P0)1$B2(';-QO7^K$
M]0;U:!S:F`=S<@;.,",_Q=7>(`*X,D'6I1#M6)5P0(<79$$%+0.YX@3BN@[J
M0\,H=2IG(`JF0`!:FP5VT/JN;P?+3J=#:[1AZK0CW1/63NW]O6=EF__2B7>V
MX,+M:UO%5IPOA?K3Y(Y76DS&GBD5Z\Z*=M&W?AMIG6>I@\'AB1%%]K[]NHCO
M^2XQ=-SO<R(LDPO`K-''(R,)E2!'_\/V#"\)?3,`(%GQ'+\!-_-'T=@`V(8&
M^@`((!447Q`E-0%B#3\_((YP%4X07U]E`Q,8#"6/%14E$`"A)1,!*CP3##@,
M`P,B(@T--6\6)D:V)%=7-F(3K#@X(EU=(@,99749FAI#:0D)#6([!-,JU=;5
M)-E-!$U-)-?@*MXDW=OCW>`C`&49KS@0"58S7@E>0#-?:6D,JP-P#:P&\.,W
M`&"K!A@2)GR%X16O"3LB3IBHL.$`'!=QE"C_XX5!E8\?39B8-JV<R9/94I*@
M%6VBRXEBWMBPP4B-34:,-B"H@:'!A&DC,H#Z0(]"!18#]77J!*>ITTYIH-*@
M,(0"C:M8:;39VN87/Q8-MHC!0S9+%FMVTJ:5PY8M$R8]>K!AP4+&FALW%H38
MR[>OW[^`^RX83+@PBL.'#2A67*1QXRD>(DMVD",'A\L<#AR@PKFS@,^?5X#^
M[&.%Z0.G-:M&4IFRZ@.9!:Q`;=J'`-N@.^C>O5N";PFZ?PL?3KRX\>/(DRM?
MSKRY<^+22$J?3KVZ]>O8J_.9MCV;D3`NFF#(D*!2NQ$C3!2($`','#"]<)0I
M4R(5,%==_(C`$``#_P40>^SQPTUP4&!(`S;PL$4-&]"!!@MPT`%"&A000L$`
M8BA"QP8<3E@A(84T<(48Q1@R$`[&L"."&";L()(%,&9AP0X39&@!#P14$4,7
M,=`XP1N\-(`#`!I8,H((\F4@$#\04.!$>370,HU(61"04A/A9"D..26-HZ4W
MVY"`P7PX^#0`!!I804\"&K0)P3X#M>+**\00,T!#(M08D8MBN-++)9@DA-Z@
MKQSI2I*LT%?%26!VH])9V4Q#BT0OP10333CAI,8/'-)1`R=+\=/`-!C@0$$"
M"A!!A`8T=,)`!?K$&E532\$:*U5>$)$`!#2\2A=8"DU@@5E9Z*&''6P=J_\6
MLG+H\18><M%EUPU#)!`888'MU<*V?^G%5V'@+H""N(@AMMABCD$F660.4(99
M9IMQ-MJ\G^E&6FWXOJ89$OPB0=MLHI5FFFCU=B``;[P1U\%S##?L\,,01QQ=
M=A17;+%VVQ'`!Q^1NN`"`1.44)Z*Z*G'GGM@F'`1!$VFHB0Q(_"Q7P`APZ'&
M')O^0,<@+`]@00$[;8"&(R"@`0>%E$"P8B\1-@B))$-0,DHI?6K"0`-UPH(!
MBR94T0<?-@0@M@H3O*+U!#&D[0<&!=6`P-L-4-`F`Q9E4$(Q]5&8P`P:L+`%
M!C&T:,(W6JJ@TN'DH`-.XH9?6<X$&0``3$,0S##_@Q7.1)V`4?]H75%""&&-
MR0A[[N"'"7T6Q,#+!V6-D$+$_'(G!BPO:A*7TZ%.Z4L9ON$[IIDR\H9.GX)`
M*U2RZL,/'"-E,L0,8ZB9@!.UIN$$54VZ&BL#:92@BD89)(-0C3!:@(TI<C#;
MEEM,"!$7&VSH4!<-=PWA;;9[%8;__H(99FZYB3F7`1Q3!'5-IEV6P4R\/$,O
M,I#!7J-9@6WR-9O5]&M@`R/-;0AV,(35RS@+BY@(1TC"$C)G8A=+H0JMLS'N
M<(P$!/`8`<3```!4`@(#*%D`3M8>E;VC#!#@!T:.E)Y7\("&%5##'C8EH4%(
M#0,V0``(Z$#%#0A"'R""_\`$;/"&!C``#L:#RB<,@8$K&,X$%HBB3,20$#'D
M(1<P]%H,:I2A70B)94K"`!;R8`)B-``2$!+$%P!0@IX4@QU7&\`GK'"/`2``
M(C(B@#7,TCC$$4Y+EB1'.+`$.0T$D7+.P$L;!L("$-2@!BZ)2!XB$HT=-.0,
M1SK#&7;4A0EL`4D""6(J"N(*K9TR(F=(""9X`8H8;&-*(FG1'+L0S#9>"G@W
MP0GQ'/%'2"!O(-R+%5/`"(<!=*$*$\"!!F"`.7HXH9202,,7O#`/^L1I`'1Y
M'1W%<",>V%,M<A!;`-K"!++T8`MS8<$)E!"$@HZK6WK1GU\4^BW^76LP`!2@
M1/\9DZYUM8LR";S,`N5%+P$X$(+VDJ!L1`,PS<PF!_ZBC0]*@QO0^,!>"#/8
MP8!CPIK:]*8U1>$*=\I3Z:3$""XP`@%$L(Y"%&0$$U`!&)8ZAPADX2(9J$,0
M63&GK;6"B_RXB12/=KTOE,`G&)ABIZY8H4'BP`8%*(`-,N&].<$"J5<(0#;0
MJ,\`7`$3\^1%#*+PAPG$`@$<LN(DYO-53+!"$!0H004@82"E$2-R98(#`Q*+
MJAE4H`<8R,]'IG')PCG*45<J'#8BQ4D(?."3+$B&G!HP`@RX)$-NS(-L5YDA
M0V+D(ON!""8`$KX29."V^SE#1%Z4C6N<0@PUR(`&ML;_"[85I">PB(7;WA`\
M3DT3!-4,U4#J,Y"E-,41;N,0(VH0#)#AX`-`T(`S-)`/?GQ"`^N`P.2$,1$3
MX&%8W[AG``JP/CF\10@`AI\.D"`#)1`T"(CQUF``<[^',C0$"W8HA!?L/Q1,
M5*($-*`''"`%*51&@1NEPF@<2&(2RQ2"&YP@!BOXKY6NM&"YB6EO?!,<G-KX
MQCA.CDY[RN,5>L<6!!C!?"AQM09T@01@:`][>(`D'-2A#G)R14'^-!.!,`(!
MU:00(1B``#M6P)1A+$%B?\L?L17@%*++T!N+>X55UI*>]+0`&^W4MAT803]@
M))HC*`0/#7`YG&G(\X;04($$_P!1R@,@;"<^X04W*.`&;)C`$YX0`RN)MARA
M_1)H+=F-(V;@M%_%&E(C@H6-\:%%+D(U,$<`D-49(QEYU*U?F^P*U^Y`ML4E
M`0\:ATQ%B``.7]#``$[Y*:=(]HO@)7;QGN(J;,+I54YI@"G#NX%,1?,'713!
M#DB@,@VL:AU`Q,B<<@L1*W76#M<(``^:]9;WQ8\U#B#HN<KU8`GG+UP4SM_^
M\%UA"Y^K"!=.%V3:U>$/*[`S'/U,B1?NP(,]L(,O'BE+*RA!D8YF-QWL3<*$
M4^,<>_SC-MYQCT=>L6QXS`@D&$$=AGRU\J)LJ?VYR),90.=6.%<F`ZA`M8OM
M"9;A$/^M`>AB0+!&U4OPH!36L"LOW!@3/JYR(EU`*G5Q@H!$&^)N&.A#%U[E
M":4P%DU$H``"3*`1$`36:'+S9$$N,I\O%D@#7FAT`M!@`5A6VMR<+:YHK3$.
MDGP6'"91`=E/*]\MI+)TNW-),)$4OI6SK#YYS!`::3$1&-DSUY+*$$6$68,&
MO/<+7_Y4L;5,`:4TN[O8[*Y33$D'P-;$)K"/IN]V<DJ`8(`;!&`;05YA>!CI
M(D'5"(`=D`[X_-H@6C(H<$$7`T``1KC!$N8WN/2-/W#1.Z+_;LP`MU_1#7/8
MX`='^(@97N+=/!#C+K6-BV<SP986S&`(HW''00CR^MO_82+_)[G^I9,Q*W'!
M%D)U!BGB52RP'WSP<F!0`/$Q<P%Q$6MW"38@$%3D%)H@%(7$`PFH5F4##7(&
M6Q:`;BI`22H0`+N``&^``,(4*+30$P@@35CV"5]@:`-`(SG7"6*U`846;%X`
M`5NP`\5`*T[P!5%#`:&02%#%#WJC`3.@``D`!Q.`'EW0!R/16>%P.)6D#9IF
M$@2`<A8P`!]0!JL`#:,S**T5*)\3.[=5$*^S'Q9P!<5U>;I6/BW27)^#`:=D
M@F]0`\W`7HJ%/"!2(250`LJ#3=X%1C5019H2>["'$R=X2J!3AUNSA=N`.G64
M(*505V.C;M?`!9S(!00`(PBP!2RP_P8%%00"9(K.-WW49V_W)GVK2'WA$E'F
M@F$$5(N-(1F5D5'AQT`*1WX+%W_P)U.C(3#J9QLP%5/`$1PS!D(A='_.^(S(
MD7_[MW\9\T(`2``Q(!^3T`:M,`)]D&1+U1XD@B+(X`L.&!!EY%Q+P@]2!D7"
M-X(%0((V(F<V(()5<A:HDRD;`!#[(3HF`!!P,#3?E4Y?0`0?P``1H5@;@A,U
MP`"%X`Q?D"<BT"0)H"J;<ST`D`!T$SOLL`\EX&V6XP45@#;2X%F9=&FXPPTH
M\0U7(`(:\`'#MA!SLEH\$2R5,@&3EP79$$EF<4PBX2.06`-B\#9OXSM&N0$U
M4`$QR"9?D/]8@?B4@:@\B_5=U/9ZBGAM)_@VQ%81EF(#'=B&/!!XIE!764(L
M,#(2,>0"X$$`>""*,A`$!>08S'<8X?(MSP=]#B5]SV>7^-9\%C:+%&6+4S`%
M9C`%!<0N&(491Z`:O-B+Y->,'Y4PO!%C'2`PI/%2QYB,(31_-%8<R[@<S0B-
MHFE3TCB-)+<=&_,-30!D?6!U1L5:._`"/`0&78@BX6..&<$*9;16T45L"%!'
M8V,-ZW%$<D8^Y<,#WT`"$]""BU@#`K$D6R,DLP)&&P)L>T,$6B0&@H@&#@("
MW"-F,3@W90-$E$`)UG,JA(2&0(1%F5,M<"`&,-0U4W@X37`6GG7_#I8$>%Z2
M!PU0!AIP'T6'$0CAB+])3SJ97R,H-O9T!6<)=5T`B7:X$W;H.QRBE<3V"$BC
M7F\B*[629PQ2;5>)E5FI;*=D*1[H>V:T:R2P`UF`=&FA`B^0H/:$G)&"3`20
M3&BY,5A@`0@P%V\9EP"G&*F(+0ME;PREET<*47Y9+O.&+K980!K&+KFHF`B7
M<(ZY<!)`!L,1?YHI8[*!F>]78S/&F32E,*&9')]9IJ.YIOAGFFY*$JC9!ZH)
M9`20:)0`AB(P`C$@FTH&!BUIFU#VG%`U)[D`(Y;(`VF4"V.3!5@2@D=W=%RT
M$X%"/A/@-E1'3;`"`64@`A8P'FF`!M66_Q,Y&(,0L#6#P)X:4'J$$`\:4`$F
M,"8;6B'60PF[0G0B8($5,@GAF0880"-I4P665C@P-!V?Y0U9HA(DD0UYH`CB
MQA`*L70(``<9@"#V=`VZ`".:1Z(U"0O*II4(("%3A%W8E5W-)F:$\";&QA0@
M`%BANHB,2)0D:J(Q49QBD`MNF"6EL`,6``8Q&J/%)2-2`J<;(Z<DT$+(A$8]
MH`,#!9?:)Z3C0BX/>Y>LV#](RF\3!K%^*4`-.T!/&J63`7X<4*56ZHO(,:8R
M%E(=-%,;EZ9;RC!G:K+-^+*_<:9L6K,2L`.FEK,ZN[,\V[,^^[,]JS'5:&YT
M*@)#AJ<C<`8J</\R,#<"OW";-9=#1_(-;;A?ZI9&NT!/9G06G<J<-]%Y/`$0
MT-`3G5,T&P("3?D%'X`#;)0!.L<IQJ-E2UFJ%M``E.`DE.`$L^H,33@B:**J
M^M!5GL1:;`=$8L8FY9$`)8``,*)W5SBL>9<2^CFL]!FYB=.H'1AG]GITBH`!
M)4`$#)"U=/@Y=VB4.Y%L=PA8-<!L1[,]W,,/4QF[)0`''<(`/;.NWJIL$R&4
M\Y2Y,S$3/'`%1V<!2(6)+Q"<U9`%$9$2?)`V(Y%,J"FT.MJ)02429!&*`S4%
MICB7^':Q=JDM#$:Q>IE@%4LN\Q9`Z&*80<JQ@VF8&G91"/0N(99PY)?_I5I:
MLO(G?S&5<<K8<2RKIIY)?QP'LPOSO_]KLZ.)LT"[P`S<P`OL4R0`9$8PD7=Z
M'F?``^S1'F#0'T];!\#0@%([@RI0/K"U-78$#<)[5PW0@M*TNK"@"0B2"6#D
M>IP"![NBJ0R0(=S#3=UCKDM9!@A2`]DS"*775>$Y`'D`.1^P.;<2@T0``'GJ
M9`#@MH.P*[FZN+30-9ME;E2HG]U0'>/0Q>)0#NE&?-5@`W\"`4```6'[.HX(
M$W@(K\4F7<7S1]FT/=X%7@NI$V\S(1%"!W#P"7?3.=PJKUB;1I#*(D>G3VD5
MCQ,1CR-8K=R&EC>:HSO@O#<:M'S@`IQX<O8%_RUL4&!R:0!T2:03=F\3>['\
M5LKT5K'H*Z0:"Z6&J1CMZP&#N2X;EHO@-[_CQW!9"IK)J+\G*Z:A2:8`/+,%
M3+/!C,P:-\S^Z[^@J<PW9LP>I\`.?,W8W,#)2@)!90NT8T,D<P8DD,%+!09=
M\+1`9(Y(DJ<SV&:5VGD&(0ODM1_UB@GL*EY65`&V"P`#L%9E$JH2`@DTD#08
M8@$3J;<4$A5I<`.4T"8X4*GP@$74@S29,RJ=JEQ>!8,)L`XEP,X:\2JG4AX-
M_0PND4QBW)/'1!V*PW>-FB4M70T\X)78"A.E$CFI2DW2IJVG]`C_$+N+Q0K:
M,YU%PYU5%*HNJ!,-8/\W<6(VPM0[,V&OPHN)8@,C^U4`QQN/`?`"(M$XM#`I
MY38EJ-DC(M%_TJNS'G/6:`0M.O"CZ_NPJHS*<%U]XXNQ2UK*Y$(83,H83IIA
MD3$%`Z0NMVQ1\2N_5=K+OMP<FYF_P\QQ+<L<RNB9Q.S,S=R_SZPP`RS-)<29
MF)UCUIS-GOW9/&MRMM`$.S`D\X%#2?LS3`L?3[L.JT5$2'(&5Y`)"*`&M"<0
ML0`0.`!%/;&0`[(I$R)F9?#0O1`+A-8DL1*#7[#;LYT!45$A>AN$B0L`&^F?
MR`T5IP)?#/`3*Y$)J@!/KR"4;\`VL2,R,[`J$%D(6R#3?/<H9J&2*[UWH@7_
M0UY-$29*$PC``&50'D:AS]!F;,>C"0JM3:SP#\1&!]55H9[R*;!`57:8U$IB
M<[!51[E0K8Q<SDOU`B^PP8N<!<F4:O(I'2W2!=(PUM/@!VDC#3"4,4*ELP"(
M!2Y0:G(FBJ3(O=W;BM^+4-)7USP>L>0+F(_QI(<I!;9\F(*-0"![&>)GV`Y$
M0OVKOXX-S,?<I5VZV,+,I<O,L@<,V2Y+S??7`9T-VF+^V5;2S4W0A?.1S@UP
M!NH!CDMET,7@VJ^3$#$P`G<RVQ```C?1(?X@K9O*1@Q0`[_-*:L[1G?#"[]&
M>E'A1(70#JY4`M%=>EA$JQF``3!"5!R].O.Q#M,J_P8$X")RAK6_.Q-L)"=@
M1P3TT"0@@B&\H$Q\(%2$8Y_R+:P,6IR8<(<QX3O5Q2D[LY3\77K.ECRPRTV+
MM2$@>FV$SN`&H<Z]Q%RN]2(6D`V[-H(;GH$8#@;78)^3;`(/.A&I-B4D80([
M$@,<PP=^P#%]D.(YRN)&D+,B_LER81?,IXJJK)?B&XL]GN_-!U&Q/)CI4E&5
M8<OO2QF)F4"+N5'S<M@XY>66W=AFNJ7.+`22N9DRQLS"S,P,#_'/D?$Y]K)A
M/N8@[[,NU$*>"(`&709W2G.D$P!N#@8VP'AM9W/"M`/H<04(X-P;L$0#\@.!
MO!%_O@4#8';5%JU0X7,Y;/\##8`F32GI2),T^Y%H3"PKJTK=]7I$(N!;:6C@
M758*V8"U0%(#6P`0;=5:_4D$0(#J;<(FWM8&8@$150#KLYZ@UN"&<O@0K]4[
MNSY[#'X\>A,/^>"ZV^0(&W+/GH+@^BA%L-!-('P0KG6B-A!7WT"6"8KAD(P-
MD[(G:-0B+B$,)#XXU,$'.\`C(V%J!:LVE6P".=ON[DX2%G"]=8%@Y$OOK5B^
M_5;7%R9`&4O*_K;74/H8[0L9"63+B(E1(,O+H$&R-F;,\]?,^7OQSQQ3`!;]
M*RO9U(^,B-TPR\^F'Q_RW&]J`MM"A@.`)-"?-B0Y>3H!&/AR6<!XQJ`1S1HS
M9R#_`EQT)F@035:T.@?2^M5$18(`"!45:11?7Q`--C6&:8U.%(\W7PDE&#LB
M$%9?%(V%"1H:&0TF)CL[8J@VJCP!K5<V;V(3&#4-@R44`!\?&FD-(Q,-&D`S
M7E9>7@F&E`@\/`1\!$TJU-74K0'5)!;<J+(3$ZAOXS_EYC\;&W0U(`UP@O"#
MC0QI$`"@%()P<"`U-0AOSI7;@,`?"'X']U48P(#!`!$B,&#HXLT""1(J>%1K
M]:)C@1<!.K[0MLV4A1TF3H*;T*7+#FXJP7698,H$`1-\^-@L%6,'@8O0^/0Q
MU8>/!5(X<RI=RL>(43QX>K!8$P0%B@58LX;8FG7!UA!8_Z^&%=LUJ]6S:*T:
M6,NVK5NV:5$8"/*VB%V[4_(6F>*AKP<I.3@(]NO!08[#@A,?H<*XL8#'9")+
MEBRALN7+F#-KUMRA`V?/E3MWMBP:=&G1I$]W?NS#A^K7L&.KWLR9MNW0H"6,
MOLV[=^\=3(,+'TZ\N'&F!((JO6BD.0D,]KX`*"$"&`\P$<!H#X!A`(X,94HT
M?`AQQQD1>6P,@`!"C1IT("J4*`&A1"(+#5C0H0.BD2!"AV3`P!8#))#&._(\
M8L@7`^QP11X-0*`!!`TQ(%X%#=1@PQ7.K!*`*F)@T$`##)4X(AQI3)(`!%]H
M```$<$R4!P8:$)'`C4-\D6.+7_]L8<-1/VU$#0]9P&2"-^!X,TY``KV!0$$@
M)!1/!172TT@:#.@C7T,05``"&G2DLX$_2Q8T(D-94@G'B"/6X`TJ%O!P448:
M40-22"*-E(T*%_5)@BD[L+022H*RY!()*4TPPD0C=($4*3=%$T,,?BAE$P%^
M3-H'"3H]:EQ*44V%%E9?:?456%U9-59<8K'ZUEIW%?%J6VD98$9=>AF0UZZ%
M]0588CDXT)=A@27&P0&-,?:8`),UZ]NSF^6&V6ZZE5:M;*H)H>VVW';K[;;8
MRO:LM=7V=EIJTT*KKFT=`'?<N_#&^RY&1KC@`@$QX%"&(10\U`4)$00<<`$[
M##!`!M/_+?30""+$<)X85S2007OOU8`B(1!0B(`-(ZJ3QHLE-))Q&3BX.4!X
M\'0"0!D48J"*#02<!XPW-O!0#@^P/.F/+0T-X<4,,VCPA1,5[).B,A3,9R$#
M<(A0Q7-E`&'%,1HD8$R-"6S!@P5X9%&D!3_&(L:39"\I$#H$K2,EE59>.4^%
M^C30SS_I[*<.E5%FV(["!O=ML`@-8)`D"<D%:8T*'.5Y.$FDU/3H#C.!8XK@
MI;04`TW@[-1%HX*B%"E./%6:%#29NI2<4C=YR@476&#AE!%<2T476::>"A:J
M"["JNZNSQNK[K&K!JI=:001AQA1K\468`PY(81@'BQW!@12`_R%V[`'()@M9
MLY%)0,:ZX--&;;C8;MO#D][DH?XX9".PW[>G=8L:^+&9>RYNZ(9O;FWMRNO_
M__[#B+WNE2\`&`("#\$`";`3,#`4@`\B\,Z+%`81$9SA#`.`6(3:\X.#5,`)
M:7!"QG"0(1%XZ6*WH``%(%"&`;SA"F(0008V@:7YE&``#1!#S8C4IRL$X!7C
MJ,6(6)"E*#&@#!.2D-`.P8G_J#!I:;@%`G]A!!),``)`&`/0B$"$&5BA1AI@
MP09B,8$M2$0B_OC'V7Z@LW8@"!YMPQ(]X%8TA-!M`^5PCSG&Z*0*4,AO#,`!
M>3)4@W"\;(=[LI-(''B-D?#I(I=*SO].:-*%&"#E)SRI)$I,T))`N:0G-Z&)
M)SM)@!U<;B<VB8%+DI(33/6D4J=KI:=RP@47-"<:>-B"J,1BNU[B+G>ZHY5<
MXM*[6.U*+[*:%5OVXH%D%L%X4[@+7YA'/>HQ+S"+H<(!./`\P6`O6<IB%O>^
MYSW]F1,WN2'?:[:%!C3TX'RQL$`>^.`"H[S)20BHV[>$,#]S8@M_T_IG:J1U
M3FKI)C/I=!<`%\K0X/RD7O?RP\D.F$`",!`[!2``1/35I094,"+=F0!W,@"'
M#:!H$""L1PL!(K$,A*QH`&)A"33$@RM8,8(Y7$4!`N`,KN%A`CLC$0,H@,0/
M?"&*481#"<K_P+(G(E6%)2A:E!+"D`S4`0<8$(,)+B(&!E3M1LA8!M`HL*8(
MXI"03TI'078&AP&P36E9<EM#]&%'.N03CVMD7U!IT9T,X)`6;GJ3&%C!"FP$
MH``[=>3AY.2G4@`*.*DS@2HA9\E'2792-$$*.,[0*,>10I4N:<D$;!*HT=[$
ME)N,!C1,$0/5(N=1T&B=4XQB@2W0X`9EZ64+3F66LRCSMW7QW3'[@DR[*).9
MS;2+&8(@*V82JYJ'L5YCMIF8;SIF>^,\9_C4&:YOO?-\`,$#-PHG%,M"!2IC
M(]L&#*H_[HYF-K.YUD`)&E#[C8^^\^M?0_?;T*U"U"DBV-<A&!`1_Q,4`#L(
M)@'##M91\D2$1!B(&(7\B-1&T`<1/"@`QQ!&(0LEC0$9LH%A"\"#L3&)C378
MPA8\*@(CKK`,]U!&?2ILH0O!PV@0^#`(".+&0`I2<&)X9,$$;+4$W.`&"?#B
M4>$X)3A6Z<ERO#$__'%7O)Z#?6OUQQG],0N)H&(6.D0D-L!6@`@@=CN)?"3A
M4@>HQEEN)JBL'&L[A9-1.NJTI=V<)2!5RI9HT@03L.1-*BGG2/&!<*;LB6MS
M<DO8$L`(?^A#2BS0`QH,055>.54+-KU;K@`S>+#"2W'OLDS?2?.8>2&,!XI[
MW+\DURYT*<*PGA?=Z"J&"@+09G6SMRQQ<O]/N[XQC6?(MT]O]8`.X.V!V"H"
M6Q/TH0JR1`K7O`$5,3'AVDR`EGOC*]#=O&:^]V-7/\=]/_WR]]S^VRH![&4$
M`D3H@`3&@`GLH)UZJX"S,BQ#T?P601)R#,;U,5H:+ERR5FRM`0W)T),"(@?$
M&AQL;Q"B.^JQB2PA!`XKS#$4_^.?*1\$!/M)B'^H1$@6)S`<%K`IH@/\U:H9
MP@M$T,2"GDCSD;,M372-4@W"9&4]EN,-!%FK&<](BW"(X0VK^%&<1GQ@!R+X
M&JVH1A,B6S@V]V2RK.U)322)6E-:5K*5--UI1:NH$7B.<"P![58!O4G(D9*5
M?$!MI9!C+SKCY);_!.!&#2J`V]R1ZBM>L%UOVR+J5!,7U8A/O*H7S^K>N=K4
MTVQ>L8Q%>5SG&GO6]<&RQMD]8'\&?^HL=K>0C3Y4X,$F3.F#I+]>+^44);*D
M."]4TKH!?@Y[V[BO7[C`W4_QU>]:L%$HNH?_J:TVH5[MQL`,64A"#%1!!?7>
MSN9&H*\T`-)"96#`.%C`U(:4P*5*2\1.#_NA)_U`CV):*RT*,@`;\F@3\?`P
MEK!4QUN(IP%C3..30(`FA_RU!N,`5*G`#5&G%-#Q53F2`%9`!%)S(T(#56XC
M9?LP-W>U1C\71&DD$8$#9$<'-C5S6..'6$T7?20(!B.Q9K#W=9'4.#T!_W:L
MY3F0`CDO""F.U4D^P68SX7:!YA.!8@J!)CD\(6@QT"C)H5")!DO*D1-UURF,
MUF[=P`)]]W<AL&F]]&FAMA?#]1?4LWA<V(5>N&K19%RO,@75%(;)4QB21WEJ
MR`&6EVO@M'G.TGF>%U"A5VSNM!_?139PP@VD$`T#Q&Y.476&)ASDE1.6)0ZT
M)R9B(GKRDWON=1FP08?`YXBB(7S$=XD.91/'UQP$,`$E\`4P9A^6`'US4&\!
M,(34AS+]1U03(D8(D!\L,");0#<_4%@?`C8\$'&SF!\UEB4X5!!*E33S<2`2
MN`]K,E5YPQ!4@D,86`,BXE&!\P]A)F))\$/8D/\$)&8>9U`I&*`O99``.3(#
M,``T,X`T\Y!S_6!7Z6"!/U`F:>2,16=TX^`A3">"29`$]98=+[`=UI`%T!!+
M.S!WAAAGEX(472=:F\1UES,I!5E*DS(I-^AF+L$2P`$Y,M%F+GA:5_=G23$4
M.U`4K92$2Z@^C'83%B`&4-@5OE0JN5-J6>@7U123,ND\S,,\7UB3.`F&I.86
M>R$%T[,K!B!K->F3:WAKN!89CW%=OC89<Y@NDQ@;^Y2'[8,`8B![CM84S1$&
M6OF'[3:0?=@ZK<,I6-D<S?&'ED(*@J6(ZO`^\$-LW()[D/A[3TF)IV&)F'B7
MT9`2QV=+!"`&W@@`HN#_$M>1'?5&``R#`X!));@P!.#(F$-0`370<^[Q'DZ2
M8BM&2"B""Y]P"%]0`FM"(KC01/K@0?N0(6J%`.;P!OSG$"/B9>*P;$@'@O<X
MFTD@,`,3`"&"`6<0`WTP`?IB0%_@!6.@1<:0`&1UC+1X#C[7CA'WCFED=&+@
M@3YTC=@H@B(H,$VG.-0`%"H(DI82'*"#$T$1@RU(2IY#65NGD):S24C12109
M@Q-A2J9U$Y,U:);09RA!`GY02<91+SDQ3]%@!*#"`HRYDBSI6X7G*S.YH#)9
M:SD@DS49+#B9D]%DACRIA5*P:GB!AK]B+-(#/4>0/4<I&;VVE$S9E*`'E=SR
M_UVSJ(>F=WJ7)(A+85E-01RS-!QD698#!);"D1*"E5Y5E@Y"4'N,2)>\1XF,
M6&QVB9>7F#I-P&XW<3(PAE4F46;19Y@15`<N!0$.J`R,Z06/N6-X5)D@0$3C
MT0``L7<JU`E1=&/(.%7[L0X6XXL,(*8+!R5M`A#SN"$!0)O84&:V.9NN\`HA
M8E86%"@3935$,)QC8`7*D`;I:&4#<9K.*8U'AW0B1IWV>(^VV4#W"`;6X">%
MHX(W^BD]RH(],1-%J'4M^#B30FB/XW9:!X-NMTJ>HY&5LTH\$9"3(I!PIQ3^
MR0<`:HBU10,)8*!F$93"11@,&I-%J8;112S1.J'"4O^AT00KPO,7@I&A=H&&
MW:081Q"NX#2BDX%=E(&B1UH:QM8#:K4%5"E>1_$H59"C9#FC-/HN2-$'A4BO
MMY03K?.'`"N@C\(->'"I9-,#2:HM=+FPZIJP^X0&2\JDQ&<3)#!`[19@3(4#
M$Y`'9^`RA*D="K91"/-5R6`(2C8$Q_D.%Z9"FP`"[@,"#%`?66)Q\5%'^#>I
M>/0>/U`+#@:`8E!(7S8!+S2;B,6I`E.;MHE8-84SJO`&P<`F$-$F@C,!,M0B
MQ&`%7G0C7^`E5#:5[Y@D;\`-+\,*U;FIG0H&2=`1VM$1VD!>JT>J7\=?L`0Y
M?B"#<F9*=I=H$`E[HT0HFP3_#J#E$S':9RX1*((FJ]%P'+,UHUP#A;XT%LRE
M/+UB>$3YK#[ID^+ZH<]::QS@H!,:369@!LTUNGQ1N<EE!M0T>2`ZKHY!&9PG
MAYY'!N6SHN!5E04K;9<"K!!E+ZS3.O8*MY!RJE?)%'$+=_^:HZB3=_&*EMXP
ME?ET5TG*L+"1L`@+7J77O#H3L1*+;A1KL8;)0B0##A`A!E:Z'><100CS"<J`
M9%-C"%530QE3'X(0,@I11W/##OMQC"."FF@S$&O5`.[Z)!NB"E=PCZTPFX%J
M9@[W(ZB@?H$UC\V91NTP(NT@.!)3(U_4OBVB`9[))O]`)DM"CP50MM<9,/BX
M2(JE_V86,*HT.$M]:'<TVJ\+]1.N9`HV>#GL&82Z:I`^"&>00PH[R%JF0PI^
MX&8Q4(3@,&C\F83QDA*V)7AA,1?&(RPZ>1>^XJ'9U!CAJKE9O,5;O+D.*J&K
M1ERF)FO4,Q@;>DT>RKKA=*[>([O.0C_Y(QO=DH=6&:.JUX0`R[L\>I9(`:-?
MQ\0PC!3@"<CWJA1<N;BJ][:'J"13Z;!OB7L/JRUT(`3'%J=/<CY:!;>HH+W;
MRU_=NY4$T`4(DP$1(0*"-`$%,`>EJ!T%@P/?\8U:FP!08`5(1@0:D`_&6#0U
M@`;OX!]T<('G5PX(`*?^,*;7FPJ'A9W8B+01<(^(I<`\]?\R>O6,!A.+"N>.
M;E2_5((#9M>-NW`/N)PQ"0``)'1TJO`A8M"GT6R=T=Q`^Z@X0/$3*.B5AYRX
MT(!*,UQUQ4'#,EBKE=5VKRIVJ.I)/I%9%%D3?#!9?0AVJ$2?E21*E!(OIY-W
M*#D$J`(6<B$\QV.A05FZE6N4VI-KQL*Z6TQ=E!?&$HJZ#M#1HFO%VOJ3:6P]
MT/.&O1;';WRBZW)?<]D!*ZJ'4`%;.LH'?\`48`F6\Y2CR0&2P&L3WDF\31W5
M)E`%5,T'?6S50L$4](H%X)D')G!>#9Q/<0K)"1NGFOPF0:V"30B69FD*GXR7
M.%%+6AD&49I]&#`"?U,#/,#*]?;_RK`LRQH`-%Y@LD20#UZBB/"A$"4U$.<P
M)A/\#P!A#H5EG0(S!P_0J236M*B08FZR)'J55CK##O?+#B>RR[@``1I+)!(#
M`"O#,@X!.%M@`;*I8;+=J=AY8&RK9D"A$P$)=WU0Q(-[$XNL%,/]UDIAMV\G
MD7MKD#E(D7@F.:V*$O49=ZW*9SLP`F;G2H+V+A5=K(&7K,P5:E<(TI2GN6SX
MAF1P>=[$QHR!>9@'+)Z+AGT1NK%RQ9V[:L=3&#2=325JKK`+;-ZFHN;3`Z9G
M),Z&E0/T+DG=;I+DG:3:Q%+=U%A]'(`(:4]M=V!]=.K%<W4SUF/M77AH5U,9
MMN)ER)9U_^$!FQ-N;=R7&-<N,-=5U&48$$$)AP!R$'VO;#":R47(`%8W``>^
M#`+G]QX;$!]P0&47"`OX%)L@F+2`>ME.CEBOD#.6.<$4_`]+0A"B[4&C^:;U
MVPDLA$!X8`=V4&(S+@);@'0-Y\YE-@=;$P#1MU,D,<\Y\;:%*+S<>Z.$K!/'
M`9(.>5FTJDH0F9>Y*M$\N)YPECIC9\."V\*(2]V0-1P-;0(,+@8-@-$AX%O!
M-2S.^JS'8M/+HDW6Q<;NC=*=6VL3Z@'TG<:5V])FH-_6PVLW_;ISF%_3.^``
M04\6N[M<V12/-ELIJ-9:O83G=A-&L)4)[L=Q)LA"D<?PLJ/`_O\H09T3?E#M
MC_*CT0D32\WK[+;'`S378=`IR:'41>C)+`Y`+AX%81`%?T`"5W`%EU`=W@%B
M;W!8VF$"?R,"-28A@LT(+LL.>%7,;>6R!<$D&_+N/J0&#[#PEKWPF+W`(/*:
M35N9H=VUE>KE\N`0"-)6%<)O647FB-,*-C!8K!PP)=^I/+!5V[G"RYNOWCD4
MP#VCX'G/R<O/=PF2K]=*/=B#F?20?%#$](DY*%$3;F=*=]:0^-)),;\3#'E9
M*C[12\'LS>&C%7"LJX*@I1M=9UR4F,>ZFK<]E\?>TX4]T'H8J4[?H?OJS0,L
MJGY-TF5YKXO3VA7@V8+K""!>P7%+9.G_NZF7QXQ,\TQ:%!;[/_^X%-4ND,3!
M;K\+^)SL*>-.EHK?A-S^XEC@\D51W"M^[L1'`'^P!$L0!5&`$7Z`W3MP4P;C
M,O@(!EF`R@;S'?-A#\H`0EP;.`&!9>/P[JH`J+9M\@I,8DQ+Y999"^XJJ5K.
M#L;(#V"B-GFSRQD`O@+R$"IF1BCW@4WGSF"0\C8@,-K))ZKE>II_[CB_R*15
MN)<3=BA!9_()D8[EU7X6D(DK''9K^(/^\SU1%*CU_K%T=U,/%3T`"&L+@X0+
M*`9%'E*+C(L<CY"0!Y-4!U275#X^`IQDGF0"*Y,KEYR8IY,<DP>/.:ZO#@YF
ML[0>L:I4'!ZV_PZNCY94`I_#Q)\2Q\C)RLO*'<X2SM'10D(]/0AB8B;;)GS>
MW^#AXN/DY>;GZ.GJZ^SM[NX[.^_S].1^?GQ&2U%12W]\9T;LN$)BQP0,`P9@
MN!*A@`H1&3+@P!$Q`X02:1A4`%&CQILW-@JH&5G`1D@U$6R(X3&GY8.7#QKR
ML($`P<>;-VLBZ-B1SH:?.CLV:``"!!PX%9+":0`G(8.G#)Q&%;$%FXT`!0I$
MV,JUJU<P/.+9X,&#!(&S]=*J7<NGC]L^!/ATV]%E@HDN&&+$\$-@6]\870Q.
M.!O8Q(0N@.7)+9?X;%S$BN/RT0MW<HQNWL[V^6;$B`D+>-@(&A1BT/^A1(H:
M,8H4Z91K39V("?`A"I@IUY58K8+T"I8L6F9BY<"52TJL7JJ`42GF20(Q9M"C
M2YLN38@/--:P:>.&F:WW[^##BV<7;[SY;R8V_UG"?LF(,WYV7(YWY<J$!B(P
M!(CPL(S$A"(,,-$`(B#P`P]810#32P6(88%6*4T@1@0IO"33&SN!,%0-/_W@
M(5`\%<41'37186(-&A[%`@,EE`%`!E,U@,&,&'AD4D@0;M62@A9Z%0$8`:@@
M9%GQ<.?'6VZ=IZ1W<>W05Q>!T5687-O(I]<.)A04@T$C1(G/8O8DQH<?>GT)
M#IDQ\$&"'XAYLYED^73VF1@LW(!"(8=,D5K_:JM%<L2?1^!V"6S",`=**)3<
MYMHJC++6FP-*!'><+\`<(<4N#OR"2:'/1>?I,L]`0UT'G#A#3379X;'-9DNV
MZNJKL'I37JQ,$M#%"".PARL))`0T@04!!&O#0<#R@`&,#8PPP'L!#K#%#UEI
M]4"%+Z70H!A9I50#`@&HX2&&-84(`HDDEL@3BD8=5=100P7XE%,)L;"%&"9E
MRU5+^"[XP(Y;@?'""T*JP&M?53K)S:RT)LR.'R:<)=@$$TB)EGQ18MF78%`&
MQ@Y@@'71<%SW@-,F'_+M@,^;WG1F!`$6(%`G(:?IR:=JD``:J*"9<,*IH:2.
MHC-NM5&Q0FV.NG+<_]&4!I,+IL0%P^FG4#,SZG0"G&K--6*HNDT^?V"A\-=@
MAUT.PF*S@_(9(N3ZAUXD\-!%?A9<8<,5!22!8``V8"""1QC@D':S"(PTQ[0I
M%%YA!`%L,6^XVWZTP4[BBHC&B9$;54$:%%Q4`8$;=F2320AFE>_@"RHX1U=@
M`!FDD&81\)8WV]Q3I&-\H%7V[=[@0T#)4L93F)57-KS-80:U"7+M;9G#,5_D
M$(`F7VBRREEG+&\A`YY%3*']S'UR`"C..NMLZ##.B%)*^`)<,K30EZ2"A"H<
M/-I+#L(-9TGZ'`A'7&S-10UU!\>8&JE,=:IJ9$-K5>A#9[#`0*_A[H$0-/\/
MV2*8CAB\IVM[4<$5ND"@'<R$;EM)0MX2(H8KC"`#N!J0@3S$P@WDI`8;TM"(
MSM61HASEAG!8%[N:)96G-,!&/+"7CD:G+]2E[E\JR$(6S,*=V!U)>N:@75N@
M2,%77>QW$-N2E&(P`2T*SP2]@U+#OF&[<C2)>;`#4V;0)*LMF2E.M;/`%F@`
M,T1LCWLU^QYNT+<SGD4#43D+GP^$-DA-$*U1O'E4TDS1&PZ<;QC^^]2HR%"=
M`EX-`5I;53Y<P,G.5/&3H)S'!$,)CKB<Y1]FZ0,)P*`"$XQ`!!.(%H_4\(8!
MU*$,-2C`&7"`JP$\)2D5H``%2O!+=K%+1,A,9HK_DI(&C"3%F#*:D1A`0A:M
M#`Y?I'M)OKAR1"2R[BS<J,(VJB#./J3G37`*Q_%(&383Z`6,=ME=E*`4/.YP
M#$I8RHQDTOD-E)VI=I(9(V;8Z#R](&^3GI$C'0UAQUW,S$^!^M,>Q3<^\DW'
M!XE"GR8V:DA&K>)]11N.(X,!B@.\`A?\(T,DI3/):5CM&MHQ@2=5QLE.3I&=
M.,WI-T:I4S5Q@00"`VJT>/"9',&D00*:@!HL@"MW0>`+&B""`HB0@"%0H`(Y
M5&:ZCD(4IK"@`E"!"E40,!:R8,6:^#(<-GO4+W_9876\:MT4S6F"!"+I=3T-
MI4'B43+A\>XP=N'.81`C_\;N4"D\\JD=F12S2;G(41"GR1X>\R@H]%7T$\Z@
M)'5JLPD^;G0VM5F%*'B3G).BE!,K0(+]2@')E4I-@!UX:0_F)8;$>C(SWG"@
MFZB8U][BCJ?L9!4!@!JP%^0(##E2T%8*@#>(B0&P&&``!!)`A#',H*H4H$$:
M<F@BRP$3K$J!YE!L`I($[6M?AE/K6ML:K("9Q0(6&*.;[G$RZ;&*M[Z%X.ZT
M^,YNV'-+D!'>8*.TI;C@]SMEBLN5PO%8AF9/3XW(X\U.$;[+6E2`&#W`"OCH
M65'49F@'`.E'*64;3ICTM,9P;3.H4\!38:<'&W@N8M83A7^0HXGYS?'M@!M*
MM_^@A0`J0*)6DGNOF-A+##/ZE4I*H`$KC,$*"?@"!=(`S*S"@450&<"&R`LZ
M>U4+FVN-25O]!3"!T:Z)JWKB376L4\SP-S!H`:-<^GH&C[DS8_,I</+.X\XT
MN8Z+W?C#'SZSA38X&,*.>(0>76/9BG;`$["-!F=U]D=AZ(PV(`8QHT#LBE4X
MS1,KB-_]GJ;B9+"X@`B@0T<@IJK![D6+><C#F,")9C;;6F$\!B4ZCT2"%T3@
M7V#P45>8FY5AB>&L*6$`$68`Y2A?%:PX8(`(V%65SP4Q1]E,;^%<PDW5L6Y@
M990+P]!\S@/?6FQ)(D=?2P8F_W)#BWB6TC:VU(V[FCO_+6SJ`O0@A@^O*=3!
MN^B>1">:4N9D-M+2R/"&!9!9S)**$X9<P48W/30D(&$4"X>T234<FU*;FH`N
MM@8=G/M<B-4%GECBZQ?);=ASN_P\N0[E6>X!Y(:H(-@1R&9#\)8-DU@`6Z?;
M2@`:H`$@:$#*6-60C*9Y%;2V1-OI+=V/F.M>6N>.OE@'!V:V]G)=\_:*6C19
M/_U",))%["XCX"*<Z=*P)R)I/,Z#$EP,LI>566`"%;!3$1+A@$0K&GSBZ^.%
M-8OP#F"TLPV'M#1F\UG::'AHF@CQXS/NC`QO(L4K/34U+EF3"9QA!WD@P5T*
M:X$=8"!B$,-2K;O.>B7%'*=9__)U@G)N."//)%AGG4-6@HU49-DH6-:L%M35
MRE;DEAG<+!=''XZD)'O?N_7J2'<X^FPE)\FE+^*<&,/H@B4\-^R=?;&WDMYY
M=\2LS`1B`,$:$&$&6TC!3X!O=#$0?JK8"L$9H4"\-!S^<(T.#?*.-WF7)VD<
MAWG^HWFH4A/98'+Q1!>7L0UY4#P1HW+<D&ZW!7T8J!:O5T7FE!G;H`([!P9/
M9SA:(&8QD3K+E3HJ.!-R,$3"EU9@UA*I8P=5)T5GPAWNH#(J$PZO@U?CX'S2
MEX'N$(2RPE?<MW5DUX'=T!<0<QA<%%@:LRIW=1Y_$0-X@`=6PC!BT`,R$`22
MDBF*=O\$!S!A%,9'!A=I+59_AJ=_T0`-A#=`<&A(M+$)CO=_`PA`H;!A!A@U
M+D4-;,`&V9$U=:4738AZH!=K>H$%?T!.5<!%JH<9G<%)0CB)HL18.K494/2!
M29`MA*-M)XB"*HB"M#<'4$>*@\--04(660!??C%7RP=%S]<J20*$L4A*]\9/
M/+A;X$"$ZT9O>Y8>FL%U5'(7:6)0=&$FSK=G]7!@\1%/?K`$,=`'/\<&,J`$
MR"%AN$$H%28,4_.&E51`&V4=L"$-`30UI0):$E<UZ/A9H6)XZ1@J!V@J/8`J
MBC,O[X8858)/7,<QJL0'^*1R;K*+E#B0Z["!$61?=,47*I#_!`RI(*68+=>4
M<_I21"'T`G`E5["C2;9&BV_G6VAQ8'#A.H:U?/M$=T98;SR(D-)S,AJ36`96
MBVR1)(;1!9N!!?P@C7C``M4H4DWS&MH8/OU'?VG(43[08N0H*N4X->P(6NSX
M:"H%#9#7AIXR*D*P+0NH;Y[4,1&C8'#&E?@H3RVY%RE)D&2)#@8)0;Q5)5D2
M9$EP+_S2B9ZX%67F7N!&:[,3%Q58EASX@[&(B62'&:P"1E="/&4'#V*Y)0$)
MD]]A3H?1!US@`M!H`GC0`RQP`I:I*?''890V'6G8F9UI?Z.2E`($E(Q7*D<)
M#9IP?P`TE7TX6_.2>FB!)H(1'T72_T;5YX#5-S*NJ)>\*0YG"4K^-3M"!2$P
M47O]DA7!P@.KB&;T!83*V)L49&XA$V[]Y!9D-R:U8TZX23PMIP[XT&=CLA>N
MHYCAL0U0@@5<@`61.9ELH`-(<`(7EYF:J5&>69_4\!/X20W3(9JPM9F$LI_(
MP'CP"!T@EX!;<'H6,QF%@7[T%`]<Z21@N0.8V#&,U9'0V9N_^4`6FI%^T39W
M$RW,I9RK&%]-5"0FP'SW0)X7&ER\A23<<#$&97;\I7KO<#*(*1]\082O<C"(
M@04NT`];\G,UT)XZH`/_)W%$28>-EZ2:@`8O=C50JA-2.J4(\!-74W]JV)\,
MUW_B(Y70,/\;6[IBST!`J5)R8D`";=$[3*B/^=B54G)08E*=.KJB`YFAN..#
M`#6,8/2(++=Z=`I]Z,1N*=F!<V9R6W(E[T1&Z6&8WA"CSWD>1'@PB?BCT.@'
M))`'8H``5_.'?\BD0L"IG\JI\QBE4YH-!P1?>&"JW)&J5S@!BJ.IUF"E&W"?
M/U&?7$IIFH4,#X>&FW<-$F(8@=6H>G$ELPE0#HBH"QJ>B+F+>/JG=6J)EQB$
MW;$96\,-X\:G8Z2BT:>,.HJ)Y#"%TC>GW)INWCJ)&YH['`.MO]BF6T0QZMH.
M9Z$7?Y8FR".NBRFM__4'+K`>2R")IIJIL`JE`CNP,*43VG"%?2K_4]R@3[0&
MK!+B7*`A!EL@(1^1J;$ZJRW664!)2<AP*%3Y4M@@F/JHK!)Z9R<'3HUALC$0
MFV6B?,WJK)-HI[<SA8_*E[M%5]*9.V83D/VDBP?%L\RW9CS+K%`4M&ZB&<SW
MDF!CM$*[%O@5KXA!H<AC)N!T&+@2,1D3A3V[,+43EOC`%^.Y)'A:HEVD6.S!
M28&)?O^:#=JQMFZ['>1F;T80#CK8%@?3162B;[9";VLZ`3H!I4.Y"5X*<O8G
M6XKS*WG@!V<`'R`#&&?`!WD`1B?[%V($M?HV1NS&3^<*LT(HLQIJ7RY[LZXH
MKDVBL_I$#H*F3IE!L_N$G<JXJ.GV8ZY[_R2Q^49Y.IV']36X^[+A$7>!T3%P
M9K>.`488@"LC@`&^$[PCR;7^V`TQ2KOV>AZW5240\WWF5U.>1*T+JZ?;FS)S
M.[<T.SU&8&,-5+X<N@/[8)/L$04,Y`)8H!>#!JP3FZD;<*59BH!"\#@Z48AV
M,1E+@`5S:QDQ<`;1B');(R6_TQA5**&<ZZR>>Z?:N@[+AUMG(IU;%S*K@I<,
MG*=D!";W@!D@$SL9R3`A,R9?HCL@HY()(W8O&<'G`$Y?@IME<F<0>GV&4;PT
MDGI[5:^@2QYI<A>*P7S1.QZ;$<#<4')5XD;FQP<VIH,7.`Y.K*).',!I]`<$
M_+[P\0T=LS)K@_^/Z`<Q4PJE^,D$3*"_-N&V@B$?!!P#?S"WLMD'4M)%!N.N
M)$.A!WPE03O$#9R!#SRSO(MO7Y+"HLNS<48P)[HU>&EU;W2BXS:,&3DF'T-V
M'[P8#$,R59*C/B:2"I.B@RP>^7@9(YNW$)J/KV07)C<")B</>FP.&L,F)[RY
M8IL/'.JP.U!Z6:NWG%%3+K`8L*P.LJ:,._@6"YNW`%97B%$%YM</4>!);/*K
M_WJ%T!S-F=2=`%&,9]#&;L$Q!*.F\_:5_@@E8-L[1KO*>]QZ?5PVY/P.P0G.
MU8D>TF,"D6LQVWO(#5NM\N9N+`<8?UG/:NF/::<9V:F[7Y+.[$#/\L3_5^DJ
M/(DQ%WAQO!&#9#-2%_%`T.+`)IM!%]_@=BZ\C+O81#J,3P<Q`>5`5TTDS#W8
ME[Q+;M5;B%B215%`KVW1L@E;TJSBQ`R$)AW3J&R:QK$SK`^(FPH=&.%*T>5\
M;N?\-5)(175[TLZYM0`U/&GS,7W1L%1R%B0P`:ALR,(XO'C9,#N0-EKM&%.]
M.[A"H_5,,.#T-B,`%T*,U/>UT>=PP)"!CPZ(N11Z&$DF&'J#H`0#UXGE3A7:
MRZXBS-S!T_S+=20]TSB(I_:&@^/`<JD7TC_W7`2<T0;UD<C#0./00)VD,HJ(
M!230!W--8/`$6-97?;0YK.&<8$0+UT6=7T>M_S!;0X1++7[H4*)Z,QCP%&!^
M)=%YH-;T5AZB=QF[<P9=1-Q?+0)Z&KD4^B1I\E>C#!B!%6MZTP7.DZ-?0ZZN
M70[L6F=^<<]R(=U0TH2&8;P8\!G".`]]<*-B2;2Q@I`I`PX[0,#Q4&>+2\!I
M6X&V+0X--*C6V;W3EY=^\`=H8BM=4*B!-3Q3TA;_@(O>\`?20]4A.7<//2.U
M++FHO+"`\9VC)P_CEK*C2]2OS6:Q34'9N]_FP!T$,`%P4Q!O(P(P'E@6!.,B
M<"L`(A!=HB:W$AAZ0^,>LP.X4J(OGC;Q@`$>T^,P+A!W0>.H''I?/0)/%+8)
MH]T2C(GF]M\R/-Z6R_^G"(QZQ7NU@65@]+!\EZ&@WYHPPNC$:Q,#[RO2%G3?
MC.78Z&"^K9W8-U:!X]O&1H`8LDEO>!!?J:??M3A.-$W2)&?DGW'/;2J6\M8D
M"UUOR3CB!%GB.M;8+YK;HE?:+"X"V_!*=0$E/9YZ47W5^2$8SP7CM07C#6.=
M>UT\\1#5@/5*&&`!>WWJ(]`P5:`L$Y#IJUYN+B=/E_%.N(F/@$8PB9%ZM[)@
M;$&;@OFN%$0F]AW928:/9K/=+FM.22(E\9$7F%%]'&U&=4R(6Q+HW6PR^/25
M!>6+DOZGE)YCELX-K\2G>-U!+'[KW,#BY_WJMWYW<`,Q,X+J3[[JYM3C)U?_
M>D0.7_7^&0%R>@@A`JKW-A,0N87N6RNY4Y`1IULT9U^YIUVTX_AD[;!S=MQ7
MLP>IQGAQ>@?QZ9#!/+8[M"[/%N0&/",?/6)N'K))3^XF)F")F.EN,NZV[A?:
M[N[NHK`#Y)Q>):_45")PZKL>7P8_Z^AW\/AN`D@>XT`^`KM%O#2>[P=O]+]B
M`@&B]$IN*["$R(+.9C&<&+W##3@ON0O:S5DK=MX!Q/)T,I\TP>AZ\@B:\OAD
MNN*0NDX]][66;_"DVC\;'BL);QYS15&H[8X>&)6<NT#/FT*?7^]N]*J7\$SE
M\/C.*Y_1^09_ZZ1^>EJ6#7KSZISN/.847W2Q\`&/__DD&N-JZ1>Y7:WE]L>D
MU+IJ3ZS![?:N+J\$0T]Z]AU'N*P@;_,9??*H7#PX;\(O[.!K06ZR,MI^AIW0
M3_SS-!^_"V\6`^PT^LB33_G.7I;V1G-47_:&$=7)C?JH!S$PGG*RKRPSHA`&
M/P"IGOK?R9T(@;Q$#@@8(B,[A28C(A@F)A.&!!@#$P2+BWV6EWR9FIN<G9Z?
MH*&BFGZ9.UTQ.S&IBUU=.R:3,:X3)B2GL)2S.Y.COINK)GXQ?`2_Q\C(?GY]
MIA,8$UTCKZXQB\;-R=J?E-W7IS'1I7S+V=N@YINJA:ZOB[-=M<:J,7[&FI3G
M^OO\_?[_`)$5"DBPX*]+R_\F34@4:P(B$1`)Y9'VL(L)08-V8(0HXM5#CH5&
MC,A4BA''C#M&8$@Y@*,BC2=73H+(:Q&?2Y8,ZO24$YR)72;XF/`Y="BJH*=<
M=9M%+*`?5\.ZV-M)L`\S9^U0%6*U+M2P<55QDLS4!Y>FG#>K?O+I2BB?I$&%
M[>J$B:K=NWCS\ANHMZ\^L900V1J*`9JA1=$,DV"$P2)C:(T(/(-<ZZ>UJX@+
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M(;-,X.<S,`I#DH7@[+@-EDK2D]1W9:4"UI1Z1BKI3DE.&ER$Y.S`3):<XBA*
MIYQN4@H!JO!DZ2=6C8,F.TI]<U1QUMRW"SL65L(40/3$__)44WE.:E4?Q;$C
MTC36,#AA*F;E9-6I_30*VRO-.7HBL]16NT^EUMZU3(.@=@LEHJ#>Y&F$8YX%
M);,$8`H7A4`A!5NQR5'RHZ9P&1-54^<F4^=;J#13;K6I_+F#0\-V84R-'MY6
M#TF]9AM*-E85,EN-ACIL\<6:8(LQ/W_\@>=5O^HEWC[D>NPIQC[&VPJ)L2Q:
M6[P'0V6G19K$<`9W^MBT72F%8FJM5H4-/+!(C:QR'[^OO+GEQL=L9S.03$<=
MM<92;^,Q60V+G.\Q?SPW<K;,&!/;*1-PU4Z'[=HF[ZU1005?<S?WLR8X/*_R
M7\7IJ9C4&2HU0K`T:?)[FVUX;_\\:EJ#VEWUXA=3S3C7.=(U2N&:=(P.Y;\8
M@0V8UJ+UHV/)D>B=34EYIV@N/CHZUY/.[5-4NHJWSJSFY/#K$#3Q$#P-+*P&
M]:YWCZ,J;G=^D%![\,A+ZGCRH%C>R;9;\W$U,AU/3U?TF4O?=9386YK-TQU*
MPTN"CB&E,CQPSOQ=4GW8^]LYP"9$:K\SWBFI$49DDC]F&$PSV@YG:(<U4M*%
M8@SE#&=@%>8<]@>P7&5XRV*>!(VTO`E:,'EHB=8.LK$=UP0P0O-K2NF4X[M7
MS0LYQ)#1H4P!E?K%X![P$9>4@C/#C%%$)(TI&^^J@:QXQ*9L0LG'!8=(1/-4
ML(A(Q-C_=7;VEF*$+@;-D0HIO(,L5@@C6!+STZ)*M3E^;"<3MR+'5"#%&B*9
M`SY)$8D/8Q&.6&6E(232RA632,<Z4NH[=LSCQ:[#NCM9Y7WU^T[;-$6^#?VD
M'7;"@#6`=Q.?Z:-U;_)9#?WR+;"THF\2@X=;"`@+-F5G?0_4HRA'Z8LCDO*4
M10IE5)C!,_O1S0_T.@K2@#04N`1K-XT,I38N08]FA'%3D^Q+)>,7E':4S3-O
MF@T)D=G#8A5B@:B,YA!-*<UJEG%;9-E%JK;#(MB,`Q?K4-3:PJ'#,)Y%ER+*
M!MW>HCA$J0<3%8)-)F&QJUF,PR@[5%@NK,E//5*SGP`M2`8=_[D+55FH.T!R
M39KP"2>DI<)^X(%.?<K20O1Q3TOER8DL+#(?H@A.C(%4:.^F$[F`FC1X_SRI
M2O4A23PICH52$5L+2_$F#[D#:<H45=:0P4%_M3`I$_U:1BV1KE;928<>JLG$
MA#2OI'!KI5"M6DJC2M7)K2:"W1%2(^U6.EH*SBAF8I4\QS*\9I%$G3_M%PR?
MA$Z1U2="55`9OW:HJ"`"18":FI4K_%6.JOHU6U/]JV`?IDIO#NHWW)37V6RJ
M3U6EPWD29>?"P!$CQ&7T)E4`7L)"HS2AX**A70IBRO"%U<&:-DR!/:UJR\HP
M;9+%;?4CD5`LA,;DO!13:(%L0"A+@/]('HZ&6"O&KAH**_-)!2G*[.0LUH1%
M:`G7D:N-[GA2*]W3UH5%K5V8AO!XJT.6R%X0JYYN_Q&Q5#2#LL>S;%]@.946
MU?)=K$(;*DSWJH2%<Q7M"UEU]^L7ZO+WK^R)BJ;L@2:[#4,5G)UO'*$(ICZ(
M=WL`45=%:[13JO14IM]\W[Q,X5X-*?85>3#**FK$VO^:^(XG3G%X-L'6SBX*
MIB3$*2/U2Y8'6X\@%NTL#<UASE.,8$,O1BAMBG-/1'IV0G%3;XJ7?!X\,GFP
M5PTE5KGYS=B=;;8*[F1=?F7C&S?+2NML48K^`YL]D;,1/BJ)PII)0F7.RD_O
MNADTGTSGM3C_N<[651$(L]I7-%5C45"9"S9)P0P;SYFP@W8JTDH!W1.UM1^K
M^MY-::2IF\S"L]LU+DT%",8_X_G3Y_`OJ$T:,GMY!ZUGZ(QGDH9?2SPJ121!
MH"]OAJD'#O30HM"DI9/C/BE:Q:*Q5=6575@S0([ZV*,0-;+YZ:!EM+-1\G!S
M/3"J'LJ28%<]%2.<J,V/*-Z**096ZZYO52@RO:B`,^).;);-[E`HN]W,GJ+]
M_(!FVWZ(K:B]D]+,L:U-$>1>E#8N%`^KG-]E&$B#K++1E`QO=K^[X=%TD+?K
M,R^M;*K1&<WPM-]$8QI'F**K""#%6VCI:<2PQUV(F_&J40XT5:=[_Q!_\L-C
MKL?P0,EI/DT:;7()O7<>+HS'&KB]'DTR7VKE0P4N-F(M_B2\"HZ#[XL0S&F>
MXIE3O8X29TYL>*@=5W.PPL+$R<X.>>Z&]C4@R[K7"/LC%R!I2*MI_M'`R?&^
MJ5]]R5:_.Q)3=<X';L?>O-!VY<"NM0BV"!P>%D8G!4KWHW>A?4VWGW,8+;YQ
M`-+E0]>[PS?HK<Y[_O.@#[WH1T_ZTIO^]*C/(([:=FIQV3KUL)<T+:)!C<L\
M,_4,0VA.8UL/6%(X9B1V,8Q`]*G8&__XR$^^\I?/_-+?OOG0C[[TIT]]V%\I
M/'XW;"YE6/W.9X(6$SO;/G$/4M@Y/CE.6_]X/0JJ<W6WD.]6[;[\YT__^ML_
M.L^_O_[WS__^GXSX$65JFH(0P.1_XK$J:,8W_E,LUE=^C;=4E$=A=)=`F]86
M,A53\!=_!KB!'-B!_I=_'AB"(CB"H;<>#&,.KG9VER!>!CA+N1,-:A0/RD%^
M&>A"D:1H0M84Z!.!4W%V&DB"0!B$0DAZ(#B$1GB$'(@._5:`$+."U:-_/4(+
M07,*J=8%T,!]I8<U_28AVC%?WA&!6R%@AQ53Z<)M/(&$:)B&:%B$:MB&;AA]
M8M)OU]$Q3DB']]<C?D(1A@$H9H*%J+>$JZ(AH[(J+)1DC9<:5X%QU_.&C-B(
M_,>&CAB)DDAZ>(+_@JHA29;`@G>()Q)3&/V3:A,00/'P'WZ((YW25Y@0(=ZE
M2>8G1;$E;\20*L)`=(LXB;9XB\H'B;BXB[P(>CU7BAR8$)^S._TS`=JF*IS0
M,=4!,IE(A[AE1GIE#8"'2P#D:RU7#KV8C=J8?+JXC=[XC4<(4MZ6%;0'"Y=6
M.\O2!U7@,>R%33BAB9?H!U=S+X<T0&2W,"[$+>"XC_PH>MW8CP`9D/S7;\,(
M"[3'<F+$5UV33'?3C'88CU(7B$8%%S!5#.DHD!B9D3CQCQK9D1Z)?*Q4#QME
M3(LP&KP6D8TG3]P"CQ#)05MG$62C'$650L#XD3:IC1QYDSJYDYZWA(U4_R>T
M((-9X766,`L)A%XU^37P)V"J$`VUD"FP)8^_PI-4>8LY6958F96IPE>69!0K
M07O#`D6<-R&OL3!,2$8,<W%W)45$)D/+T#5:&9=M>)5R69<>22YX*2M:`99A
M693TPT.*<Y;1X7?R>#S@AG#SU4B9:'-VV9A!2)>.&9G\:#E]IHKM,`U.*0V-
M,5\#R'KH,Y52.9C_X8P&U87MP&CAL3V2N9HA")FL^9J\R()RR$(X=!P4`3BD
MB'@*UGO_$9J<TG/<=)H)"9O$R8&N69S(V8@VUG.-X@HJ,3!^4C"Q0C<BMC.J
M(IA2@HI+A4=PF9S>:7_'^9WB>82&AHVI,@NU&?\2`G1`QR4,(O$NN-6=X&*>
MW.1@F2"?XYF?T1>>^MF?(=AE6G@5SX!#*4>2G[,R7(>/#M8I7?.+%_>6_AFA
MS,>?$EJA^P>@VJ91?"F*S80<M/%V"[.@OZF,SYBA26FA*/IY%)JB+%I]74:B
MV"@QFNF4\].>*:$(0B&1#`8JF-)`K*0B^-FB0NHM*SJD1JI\+^JCJ5(%.Z1&
M.X1^+^:A(S9MU^B0#3H.2KI]-Q&D1]JE^,=Y7AJF\\=*<I@N@YA7NRDXI"**
M,>5L-6)OO5<(9/J$6\DI#RFF>%H68)JG?-I\9+J$*5B4M^5;.^AL-^,^M%8C
M`[$M=,JE??JH&[FGD#K_J;`'B-##7BDY#H*(4V,H191&6;-8#EU#IY1:JGIJ
MJJAJ>I::@B'I*+"T=2,F1:U4#[NY*',Q@P5XIZG:IT6ZJZ:ZJB&S2N9FEJ?)
M:.A35#\&ABT"/;Z*JKW:K)-JJ>YX@X+(>MM2K87Z%+O#<N8)K9/ZK-[:IX!*
MD-[DIN?F5!'R+`KFBEVUF]T:KKPJJ?`ZKZR*EVZZ0;-:@=KAIO7P.8(4*+`*
M,N]*KT8*K@3KI2W7F:NBJ07::;(Z2$+6;^C#6&_BJ`<KI`9[L48:-LTQ8((F
M..SWL$P!%4A9.E34?BQGL1J+HAF[LBU:@&W#:`*V#*4CLX*VJ2G9>-J!0O*(
M_YTN6Z$M^[,I>JG".2/38$-G8+-'VXJ,]B,1&"L.U;.^*;0L*Z]4^ZO;LE3]
MBE>Q8:Q9X7LDYF<U$DE1>Y\0>K46&K1HZY^7&AL:HK,B^R$T`C4O1B.]1V0]
M*H\JN[;>J;9\FY\)R4XZ]WC,D*U/8ZS3T%>A]7V)NRV(56AON;=_6YQ^.[GB
MR:B%>S/E"B.O>C9@*Z=B:ZX,VR_*V$"D:KGY6;FHFYS5$YKVY`>:2V**9K<\
M8QN(9XCPP(Z2N[I]:[6\*Z:ENY6Q@4!QVK#(*A7E@'Y@ZXI,\0?VLKN_2[F^
M&[U>*I^;@D`E$A4BQR7#1X7Z!A7,P#X$8+I32[WCJ?^ZYEN<;FDSMOL[ARM&
MAVD;(1EUC)J^^HF^]MN8<-D)E99RL2I"73(J`)2T-^%CO7>(8N2CT)N_D8F_
M#"R73_@QL54BP0:5[V-1?P0D#E:Z)_K`DJD*21K"(CS")%S")GS"*)S"*KS"
M+-S"+OS",!S#,AS#\>AFCC=@`.>N,);`=3K#/OS#0!S$0CS$1%S$1JS"JW#$
M2KS$3-S$3OS$4&S$E^B7#T5AG]NYM":Z_1;%7-S%7OS%8!S&79;$8ES&9GS&
M:)S&1;S!XK4J;;*\QOI!?MFFTZ;&=GS'>)S'4$S&>MS'?OS'@`S%I9!R\36W
MP_!!/'B,>AO(C-S(CNS'?/S_R)(\R92,QVS<QHOLHTXU0FU#/X/$5JQ4R:(\
MRJ1LQ)%<RJB<RJKLPY?LHY';,0/A5+KF8ZY88-O$J*N<R[J\R^)URKS\R\"\
MRU:*RZ1IKO)[4%&[JL&\S,S<R+[<S-`<S9.LMYE\C+_SM0XKLX`HS=S<S67\
MS$!LJ6(LSD5,SMXLR-OLR']ZK\!FE,1@NJU[SO)LQN:<RN#\P_7LQ?D<Q/L\
MST?<SWYLJ;;Q)KF;P/Y\T&4,T*)\SSZLT$_LT#(,T0B-S^G<R-):8/#P03PW
MT1S=Q1(MR0P]PQ^]Q"/MPB7=T29=T8Q\T8>,"B-P!AX#SYF,TC3]SRJ-RB$=
MT3?M_]$['<X]7=,B_=-]S-)4&$#*88>O#-1*+<0GS<@Y'<--7<Y"'=1+N-3\
M/-5Z3,Q%N4'VI&U6_=5#'-6`_-0P+*U@;-9$?-%@K=-B/<Y:_152V=9K/=</
MIM:J;&`LG==ZO==\W==^_=>`'=B"/=B$7=B&?=B(G=B*S==)NLBWO-B0'=F2
M/=F47=F6?=F&_:*4C=>8W=F>_=F@'=JB/=J@;<*D?=JHG=JJO=J3K=F3S=FL
M'=NR/=NT7=ND;=JVG=NZO=N\7=BN+=FPW=O"/=S$7=RGC=O&G=S*O=RB_=N1
M'=S,'=W2/=W4/=,B7-W8G=W:;=?+^=J\N=W@'=[BW=S(/?_>YGW>O.W<D`W=
MZ-W>[OW>>GW"\#W?]$W>W0W<WUW?^KW?YEW"XET]40!+H$O--"NGKEP.6)#@
M"N[*57#15=#@C'W@E_T'6-"Z#W[A$`Z($D/,6.#7&6[.TGW?^,W?)%[B)E[=
M'1,%4>`"`H[#!+[A+-@Q"C[C?H#AVU)+-?[@$8[)EDWA%H[A'[X,#2XQ`R;C
M'9[7#I;C/7WB>\W>3/[D4![EGLW@%Y[)'5[E25W5))SC6$[8=3WA/*[E,)K.
M"1[?8W[34BZM3I[F;-[F;A[8)&KCU5/F6"[B22U>*AX%/JKC%<WE0)[/F/WE
M6]QE@+[D8G[F;^YL^9WHC-[HCG[_YR`.X3LPXQ7>NBT^8*T,HQ`^YS,NX;K-
MZ93>Z5<ZZ"2<X.K=Z&O^Z*J^ZB8NZ*3>CI,NZHA^YY9>XZ\\XU%PY.E=X:%N
MY*)^Z"S,ZJG.ZL1>[.]-X:9^Z41.L[!DZEB@YY8.Y'RNX2Z.YPFNXKUNZ@\6
MY+1.V;ZN[3:6ZY6^Y^OX[>`>PL8^[,:^[NR^W76-.MT`+#;!9:2:/MT@*MIF
M"#F>Z>9.Z8+^X79^V#C\[3"*Y]!.HH60XN(^[I@<TP?.[3T>\)GMZL^]Z.U^
M\1B/W7\0!4:@R5[I"HWAB5:H2'U@!#5.49Z8\B(_`9;`I-#I;%:QZ:,:Z@GN
M`A6.[5?*_S"G#M!:WHXS;03J*.V$+N`4CNVFGN2`"/32[NW^K=@[G]CJGO%2
M/_6]S?%_\$*'@`,9``%<W_5<GP%UD`$BL$&Y@`$X4`=UP/5HG_9U4`89@`,B
M4`LI`1&$2^3+/O1?KK`VENR'K8Q%7M</'B<8CC^8G/#BWL94*L"+\.=,O^5.
M/_0C3O62/_G#W;I"(0(`0`0:4`9E\`6>_P6<#P!N+P)B,#!B(`8-D`$```"?
M[_FB7P8`\`$:P`!^,@`X,`#'<1BG?_KZ01_P$2=$7@\/MN"([?>+K.(-5`6,
M(`83(`9X4/HFT.`Q@/R:[.-A'B<FP/O8'_U5O=CEW?>07_&4/__^Y&_;;[$#
M>8`!94`$)=``6_#^\/_^GE@+>*#\%B`&GAC_\%\8`P`(&AH#&"(XA#L3(@V,
MC8Z/#1B2$V*5>7D[.WY^,7^>6*!8?YNDI::GFYZJHZE_45&>?B:*CEMB%CM5
M?:^JJ:*QG%5\F2:SCB(88B:9K:RHS]"DJ]/4T=;/U,#7VZ@Q,=S@X>+CY.7F
MY^CIZNOL[>[O\/'NPSMB.!\96Q/[^A-;_?NZ2!*(@1_`??PH,2`"84LA$1-,
M8(`@J*+%BQH2)/@"H0V#`0UVY"G&IX\?5:%$<<N639HK6)M,-("@46.;!A,T
MG>3%JD\O/U6"[C!A02(.00D$X<"P3.?_3W8L6[9C*8_3MZI8LVK=RK6KUZ]@
MPV:M(FM"F0\-:C`H`X$MA+<0.+XMXW:N1KIPZ98I4:-&&0T-FEJPT```$"`*
M$BN&P1B&XL<*@!`!@$.$2'HH76AV9FK4*CY\C(`>/7K524^\9(D9,.,Q$`@0
M2[[45BHHV:$[1&0@PCCQZV3,3KK@?-KTRJA4BY^:M@UY<=KGO(F=3KVZ]>O8
MLVM'-TH7@2Y_^U(@HL&*^1GH9YA?KT']#,1`QA!9/X,(D3(-$%#0P,($GV*$
M`4#$84!D5-.!![:'6&0?E$&("29]H@H?RWE"5DS%9*)A3L048T(IL_5A@A@L
M>*&8&PH0D0`#_TQ1^)QIMBV#P0`"CF'C&)*U,0$NK<!BFH9.20.-B$T-]:$L
MQ1#IH8N;D/54<"YETZ&'IIBDTVFID.,-<EQVZ:54QWTIYIADEFGFF6BFJ>::
M;+;IIG%AOBEGE^#$8@1X`&RAGQ6">)&`%X#Z&>B@7M0WQ@R$EE=&,AGP=]I0
M#21`(!`#3-#%I9AB>L9#C1(Q!F-$9(`!`49$@<4.&#2"02:B8.%"J568@(<8
M_S3`0@4,Y)IK!2PT\`\>>!3S3:DN@&*""":ZT5AB##4@!AZVN>*J"[S$*D8#
M0Q"A`&,S0,$8$#J:(.$?FK@:QA]=V*I#KUVXT$<5KCACDA%!30#)O?^^_H-`
MAB;8%D488?B1*B-,!752*-2J,@&P6SRR3T'[?&.2B\0U$]66<Z999\8<=^SQ
MQR"'+'*9<8Z<\4KS3O!%GF*TP:<&?FI$Z,R&(AJH1E8L*D:C+/0A2JR1$DB$
M"*0:8?311A/PGP43T/AI8H/X800H&&0`@"`#^'<P3,5LP4(;0[0WH-!$(#I$
M&X@4([4+89C*![*-(3IV@0PLW*\?45!KJA$B-IW`M@I`D<`0RL(`[@1\_.&J
M)^5JYL<`?P*J`0XQO!NO'YIH8@10(B25D>2>(Z71$!"4@`PET%;!M@MG9/!G
M`I7V"V]*473B!QY;B$!1`@`X.,(((@0OP@C_E?O1Q_&H>(FQR5QNS/SST$<O
M_?0<ETR]QLV-8H19>2+0!J(PPPQHV?799[Y];MCHAAM0()I`SHSRY_,H,DD:
M&1$-6(!\E?W&0-0$#-"`8H"0`<3U@0\C*,."<&`\XY&E&$W[B[8D@Y&Y2:8,
M#'!6OUZ"A;=IH#$K:H,&"*0!!MA"=J\PG@5H%4`">:$-+*"!MPRGH\0MCEQX
M<Q4&R@`9``1F!XISAN;H)0)M*<!&AQF0?29%0@SB!`^-2Z!B2A"1H'SB5.\*
MRA9:*!D`L&@'70C>`,9XAC_$8`<E25Z7EG<]Z$2CC7",HQSG:#+KT?%+QY$:
M]_3DLCY%KC[K(]``_X&0OC&L#P;N:U#\>J:2^BUH:&+8Q/&.IXHLGM$"$QD@
M!%:U`\(H$`9C&,`W8B0&W8VP0&7(``."UP@1#(`!5OM`$AT4D>(00`0?=$P"
M_L$``2D1`I4JRC<@.(!LS;)28I#AMVHH(<SYH8,3P($2QT8$*HIK.*P`8G>*
M>!@-4"!7.`@G.#.0@;\(;441R841$J@L(#!@*$'IPS>,Q+0!0,`+72R!!F?Q
M.U<2CQXF42.7V-A&Y]WQH`A-J$+!9(V%XC%[>BP#R_H(,YF]YS!N,!\A`ZD^
M]B529SP+HBR"=C\1B.$;*<'"*V`A%`),H`W;PM$FAT(823%&E%F<!>2.6?\0
M``%H,"ML0"_'5L()$,`G1KBE!CX%@UUFH900D"5B2FB+H="*!B9*S`Q@8P(7
MQ$"9-(Q(,S7Q!T<6:#_=-"D?PJ"29\;B6$9,0`-F50P"9"@1A6@#/AW#'V7$
M:H>,&<,[-6&;H!0#`PRP0A)ALZ-E#,,;$?M#&J_4F35V0HX&=:AF-\M9YMFQ
MLV[$AO;VV+*7":I0&$V/:HE02/*!#WX[XX](S2H9$6QPI?]J&[4D28(N0,`W
M0+!F,;`%!,;@8`<$&`H><+E89PVF*3&(5:R(PC01*+";`U"&\8R`2Q#.M2@-
M.`J!/@`!9UUK-[XI(5-.L@,:-.9PXA+I4+97@@G_4J`&]3U,`?E@*L]4$JY0
MRY^'3'")*4V@!#-X6D/J"EA0OC,/0#'L+'27X,DL11E'2B-)?+(_T0[TLG',
M+&A'3.(2G^FSH,WC]B3*1_"=]CUEFUFATF<S+UC!"XI:)"CH%S0WU%9V``LR
MP#0#BDO@,C(*F$'6/!2IQ,!@`%A8!NX@0*`O:#!6$2YLC([:71L-8;U&ZRYC
MY-JO8JQ&4O!)``L8\#??J#DB/G'!#A@P0S>$:ZP[:,(6VJP!$1`FJS-H0!^*
M-8THR$($8PAP)3!WO#0BB584>%I?3="$!H=R!WW(1:PPV4)0`K.*!G/C'WR2
MI0I]>(XB-K&J5\WJIS24_]4J)JW+K/"Z/Y7/?0<JE*=PK9$<QY8%.Q[IWQ"#
MOZ+T032@0?8!1U)*!=YODP38!`$:P,-M0=FJ`P!T!<20"^/IY'A5B.Z%_,"'
M":3!4X>J&P'^P-U<*B`!!=NT(NYY&`442C%>T&<Q@F($.=,95.%ZIDJ,M)#$
M0/NE*%*`CGY!25<<.M$*``PNG!2O[JBF1,RB(A\(L,/BNC,3_C,&1;I)@Y#L
MVXJ>L%+R/(P<@EXOU:V.N<PWB^+.QIK%I?V<H-!7XT'5;%`X`RE_=@RTOZ$H
MT,K(A9DK(09^"!7-0)A!!AH@-5APO-H*&`"Y:`6!A`]A"R:(@1%6X9.HF&#/
M@/_[\KK;#3AXW\VP+$3S8Q)0@0GD87/P&C4`9P"J`D8[B)FP`-J3/`!-R"2K
M7A`!N2/L"7H="^*`2:XNQKY2OF$.#T$[C,8)<`9G?[S,B#TE>5D`:ML<3!2D
M/DGV3HW9FL_\];`/\>I5??.)EL?6Z,EH1E6[VD.EA];O$SH+@ECTQK2``F-\
MI:XJ@"L&M($FK1$<,-?+BSQT/#$,'%&3$],&L%?AAEV:10;PW0"E<?<#BO$A
MA"P4*SQ,@`40,"(1AF#2/$SKK7OO>RU5<48Q%/PW[S(BOY48!90)*!<%L8)H
M`39QBJ,9/$$NN#,$251`6,`%G;<@#'`+\S8V5E`"&`#_+,M@,*<1"A7S:JPG
M>[,7>RJX@B^7@B56>WPD.6/#+#Z&(O4V*1V%2'X"6R$U',47-S/P`1_`>[F7
M<(&3`$Z`$X,1&IY@?<X&`]DW`16`3XB1@1"2-U\2%`.@&$KF'^<'..HG<'\P
M796``4>Q(F#'!Z#`5C]3!?D'`T00<*!`)$U6((4W=E5@`=D&-28E.SMQ0`H8
M<?G3;0@#$U&&><-631/@*A>8&!6``%N4``/B31"Q;Y1U1<$F@M>@/"`&1S#'
M@J`8BA_C>C0'42O6/12E1$F441;$BO%A2,KR48OT!\,A;(UA.$L$&;JX+7[R
M39%@`F/G!R30<3<U%'M'(-E5_P53\PMD5W9D5P4#4%PP``4,X(5B]F[K18)"
MD2&+$!&)HQEL.(;AQ@!\!X?A$@,JD5PEX!B_41+TP@<3X7&;5!1.`@MO8T02
MUVW2,C5F)`MXL(>$!T1&T(C!50'&1`1?,`!@UR^9<R6*0X(E^$:6A6JD*(H6
M>9'8LXFP9HI[Y#TWI@'V41^1(1GG4S9+I#Y0T#XXQH-#5XOUTQA04#HX4`+D
M5`(V>9,9T!;MH1CD,74-A$D\5(RS0([WDUWDMF/4,$G[PP=5(`+EZ`;O%!K7
MN$L?DA+=H0EVE0<4@AH/V1,Q0([Z%W9O-0()X!A$4'@1X@DF,``"9(<8AC?%
M<H\+J/]I7)ER_X$M[%@&WF<$Q.@&2>%"VV8!T7(J#GE%H261)^B)%8F1C-F8
M=.*")(8R$=4]%/"1-@8H/B89,C8#A=1SOL8SH2!L"K`^,T!Z$>,-9P1R#],`
M(E`"7N`8D5$&EI&'6S`$BI&!34>.2612FQ`&P]%P4L%N3AE8U1AFN=14@?%,
M038<E3-V`),W>`@4I.`S<U:.H5)+H,`',9!MC`$!9U`L.Q$&\-AU`[))RQ!G
M'51$`:8")D`JFO&>Q1(#NC-#7D!Z_<)Q$-`8$$`!@$8!SD(`5?`*YU*8S!$.
MG$B1D.F8"KJ@#&HFIV@++B,H-<%:47<S%K5K,6,>@B!T(K#_.']E=*.9/\F&
M;*0Q&A#4.:`D'^5%%#MTFQ%QC+452?_B`JA@>M/9E%;P*5#9GN?7&V069Z:B
M$L>6-[K%?N.F.-7I&_OE(C)1!MJB9#OP"YM@:#N0;0-2FK@@+66EGA%'>EO0
M!0CQ,#-B-;QQ*#2``,%2!5?7&PQ0`Q4@B9(!.V*%!><2):YF,6GB<M7C#A@Y
M%0W*4.KPIW$D"@/)8G@P:Y&3%`EV*!;Z)U:08+@&?!J@ERW39^R'B(HQ!@V0
M!VP5#9,T#&P)2HA4-UEP?5DG$OXW-T9I!`!C&T#RJ@8(C:V19-6H-,RE2P7#
MCZ7@$S[")48P9T9$0!.@&56`.S1@_X/FJ0FDEFD2$7\H`@&(DQIPE42#`Q<4
M<*U#,`0)D&"1H0$08)^R(Q%8AYLS085>0`,+R8PI5PJO^B)HHJ<GPZ<7Z:>"
M"B?K4*]M1*B=-U'FL:TV8SZ(TG.%\BE0@&.W]R>4*D)PX*&8ZALBP*G8U!)!
M]`?X*:H*`*T6D$`+`F7_P1H$@@.15`6^63'?H`W%R@!(Y@59`X@CE!ANIXRT
MP:M>\JL%%QD9L`-L4ZS;-PAB8`-$`1H$0``6\%2A&G$/&R\).""&LR"[Z&0)
MD`&$P&VQ>G7%I0`96!1F*'_E)09;Z0F)HWJFMB;P.B?OT*=0@:]WF@YH^W+;
MLS(0VJ_E,_]-2T1(&D5(X)-K":L!"\M6L3)XD4$T`)-2H;!2T^)2)1!3"O!E
M0"F-UT9;^1!NBA.D0:I2K_">4=`'+Z48<G54'K0@9#8[6+"K%>>KP*JD,<`V
MF/M_:O8/&$`0K5L0N=-FKS$!4YJTH#(X0X`7;P&26N4$&+!"VG4:?/E)[I03
M$,1FQ":G:G@23.BN;S*V<E*V\WJV:RNO:QL])N%2;KLG-V9!Z/8T&S4V&34H
MM.8%>=NA(UL_/&E;1@.?[SDMQ0(*!+`%,*48\]A@4&AX+S4V<D6/W[>&[_F<
MN14&]8,CBL@W'J2Y@>$3*N4,=4FZ-1LJI^L"9H5(=T$7`-`[>E'_!I)X1##@
M!1FH:4W)&S`P"/XP"?O0`&V@+6.0`+;%;>*2-SI$O.\48<DU$TD$PAB@E1%V
M>H7H)M#[)M)KD?2*MM9[O<^3O2J#BC?F!>:#(H7T-(_!&"H).@@+H7TV9&5%
M4BG"OOWFOL5"9--24\!50$#9&`/@!W:U&E183;?0+Z'@F^#HFY7K`A-``Z_8
M9Y@&&D>&(C\:N0Z,E!`L?QD@=EAP8`2R+"/)1(*T+8:3`*571(PA<45A9H.Q
M!526(K0DF*HS9-?W<=UA+5M``[/*$"+`!R00+0\)OT#<B1XSQ*)8Q/AZQ$A<
M1VJ,`5>C)_R)8^B!6E3\J/2Q'N81,P9B_[Y8W*&.XTB^(6"%-4FNBFE*@P'C
ML;2#(!(M>E.C]E=4AEV4$$FH@#QYP`6Y`6@X,`$,[$&]`0!,P<"Q<"%B\JOG
MQH[A(A-MZ05P`1?DE,\Y"0$9\'RES`)O`!3<1<(2)SM5T"'41B!J)@8`RJHN
M0+6)43=XPPO$A&:3$3M^Z,.]*K:NW#&P'(JR7*^T7,LB@SE7!P`UX#T5A6.V
M9B/`AR`X`]-)<;ZN$KKJFQANL$\#MM,>L@,C@&`I2@048'=.Z&1:!Q2RPI;4
M2GIOB20=(A*Y46U`,`0BZC93R10-V,YXBAPT2\)V-@$D,&?P865-YQ`0$Z:3
M@`"1`IOWM5V27/_"1&/05E(/U,:_(L!OIG)UMZD,+Q$%2Y?0]C$Y3&'0F-C*
M)3W2+!C2@HK8)/W*6+E#*-TR1!`HXD--%F&P?2(Y%G$?$)IXQN,--PT#5E`!
M_U#:IEW:ML(`-&%$FKS`XKI`6)!3,$H>^H0ZP'+;LU(#X24@D;&BZ)G`CJ'.
M\45HTGDP,[L#%?`T7TW&*6*%/<W3Q,`TY+@^7K!M>3#"D]P`_Q$:8\<W!WU>
MGV*'[5D2'#<$;$H):K@9Y')8NW$86^5<(7A`:<DF0>PF'PV*BOVGC-W8'4,A
M+G46*;W"@C`#?3)!1/`!&"$^"<[98G!/=VT;'"<IRM+"0_`%7R#3O0;_DC=(
MVX.]<:;*0$P9;A,6?]3J$:LD/*]4`A1!5#>A7="I5+ZQ*(DCPQ;GO"Q!LXYA
M2&U0"0N!(HMBT-8`*;(+K1`F`A_`&.J,"1("$[*0!S-Q4;+)P^7]-+@I''MS
MT$.!6!:-3OYKIVI2WVURWXE-O4:<W_S=,?ZS`_%G4BQ0`C20!B60*S30!G1>
M`C-IYS;)`',>YS9)`S3``#8Y`+HM"($1(]OG&DT+&:#D!4-0VQ_2"?#H;`IP
M7"%.AEJNX239R^@Q(+YA!<!T0O#R"J)AY+X!`",0PYFXU5%!LX^A(PT@0,T-
MC!N]"CR!@`0@!B4`'Q^0-20@`@L"&$H.OU&P_SGD=BWQ%QD`$#MZG1@T0`GP
M$K\JP6Y&0")P*AFB4GH4Q]&';>:QQ^T+NM]GGC&5LY8-XBP(<.[HCNZ5$*;[
M4`EO@`!B`._QC@#O_@;XQ1"E9P(C0!$*GN`8,3@4$.=IX5?C-@*-@C4-M`GT
M4(8#8#5BX[T$7@8TP`*V4`D[,#6I85T5`0$C\$RF`A/N_"5&\)7A(]AL"3.;
M9#2\T%\HL6/#7@77\A>"H'&XM*$C(!MY$[]C=T;:Q^\:``"6\1V-@F-U$\/0
M7AQ1$.\-</`_GP$C4%C/V]%[ZNVO1_6.">[A3K:S<!1[\1',MWRX\B#_04RY
M,D:Z\A&O1!%;NPR;,/_R`^,(;P\)DG#624>7](,JD=``7=`,/H)&RS`!;^]*
MR;<(=-\4M)@P??/VJ^(S$!GR>&0O!+,JDM`P6[`#0V:5+0\*+S\,<Q\)QCCW
M!0$:*J7YA&HE?Z4JJ[(YBN\?>L-6Y!)=>6,M@!\)&$`\G"#MAATR8KZ"5M^8
M6)_U;0(+WV!]1Z&*)'G\U4PA_R$"AL'(DG$8^+!/0#3L6#`2U%4,6LG3VH\;
M.]`)8[?>RT`EOC#ZV)1I1K+34P)=03'C>Q.`1,%T_2*@O^#X7S+V6JDXF0:"
M=-HV$`D(?GY_A%A8A'Y\?'\$>3N/529YBB8F?7U_6"Z&6%%_ESN$?)65ET;_
M1J,F.R9&+F&O88)553$Q?WQ5JWF3?(:>FH>$PL/$Q<6UQLG*R\."SL_0T=+.
MS-76U]C9R=/<W8/:X.'BX]O>YM#DZ>KK[.U_4:=^)F\U#0PE]VDE)?K[.".9
M/O'!,&"?P8/X1&`04^D1%EAA_D0B4,7/)DX8#1'RY*GBNRA1L*RB%<./D3Z#
M.,$".6N6HF*7_@B26,5(IY"'6C84(V96%%@Y9VJ+XH?`NS`N8DPPX><A4D.R
M6@H5=M.%Q!@M^VAJ6243QHX57V'ITS)3&)!&JF""&`9+2:EN_QA!.]?%1:#L
MD+G;R[>OW[^``PL>3+BPX70AC<C<U7#"TD<[)CR*_Q$*)Y\^D!])7J7*Q*A'
MWP9UE>F5D&).A82!S`02I$9"*/WL,.F"[&69KW'Y07G(UZ'0HM[)-)G:)69(
M-GTANB6\4Z%@IYKYL>4BRB9YLW]&F=TTF,S1G38)?QY].%8_JP]Y*CD<T0[V
MOSSYJ=CZH?,_E'<O:E936'+O[8FCUV$$6G/.@=]<<V"!V2S(X(,0NN.@@0B>
M@TU&&MEUR&F;X*(6>O9]HM5%=I%8'4[5[3;+=#^I5]%%L"7XW"LA"7-)2M:Y
M,%]#6*'4!Q\EC9@C3IDHAE(>?VQ"%BW=52?2;/>]YM6&K!&)VB">>`;268?4
M@MY/?N`!Y4/B]6?()I[PYO_4*Q*%`B!IBNUV'&1O#C)31F@%M-]R?.PP"VB7
MH$0:-<-5.)TM$2:*B*'=-&BAHLI,".FDE)9C#C:,>K,76DO.@I$@LQGS32V8
M=#)?)*$D1PA]-L8F(T;"0(/).Q4%2IIJOUBEVBVH$`+?*9#U85-U,GF&17FS
M#M)+(?])EPA*C_`Q5S"Y#.+*?'Z>2=1\,YTH$VB^A"1;J-/)Q0>WF,B&;1^3
M$'+B;XO\,LRLPG2UVF6SN)KJ=`EF*LB`E1+H[S2.7AJPLYH>K#"EDC(S,,'D
MS'0C>N=&8LEIO[UGIY>+_&MG)N_%4,ESW\JXF[HQ9;1HK;LA4M%,Y2U1WUBQ
M!7C_:U,L<6:O(2>1>XN@,]TVE2?+S8=2+LB()\^YZ,6RHK:S_:D55*J$BE&P
M^+%WX\O.T`+91_)^`\\I1G@LRWP?W8+O,U02.C#`"P_V<#0%)[QPPW'G+?"C
M%,[]##C/<+>;*C%$05E#GNW7!RFGSK:DNFJ9D"5G8BP"U>%R3=>0X_0&]-V?
M@E.C"+TWM7+(*N^U%,./G6.QHQA^IO1M*62!:O2XB<0J2,>'DE)U4^Z!EN0?
M?J;VAPD,H3Z3/)7,(M<AJ8"NRBR>39\OM&+#(TJ<B_ZX"@$FN%3DZ"Y=]@TJ
MBP3Y-J)Z"^;WWYCRK3#>[=<?&/V6OB^CP]%0,EGQ\G!,_V2Z\(T^+84LA]-)
MR"0C+1,XQC$QZ((M##B;RRRN:N_9`4J"]+D_B8QI+VG*N?`3$.L<PH$C65&?
M0H$>ER%O>KU`R0-71P!!]`$K3+IA!`D8FTLP33,"5(3K#@>:IJ@K;#R9@!@<
MTY+(I/`T?7C@GS9#F<A(IHF9^9%<%(,?Q]F0#[MPC`1KA0G(A$\S&DR6(O3B
M+[C9CR_ZFTK?[#8_^;WQCGW!GZCBN+]E0$,S(AC``'`P@"X08'$$(>0`1-`%
MM4P@D$LQ01<4XJ<JC$"0@A1!23`0R$$*<@0QX,,C1W`)23PRD(0$Y>B<\0@'
MBD`$$P`?*2XY`DGX802:I`EF&O\P``PT)!*CC!=^7BD&"XCAE5WXQ"0SV07(
M<%*"JW@D,\\C$Y2(TI.OG,!E8H#+"5A@![BT!9:@MP,1,(`!.,"!"'9`@($(
M<BDOP\(9!+D%$\1`!/_PTPX(4LA9/!*=Z52(&/)0B7]B(#8.Y&4Z,P!+SG1A
M``R`I0,A.H`)5&$"(U#ES3+E1CRR@X]U:U3<].C1DHJ#I,3@8Q\CQ4I)XB`#
MBWPE!C183@BH4P2@-`(!,``!``R`G2.`*3NK,(`ZQ'0$NY%F!LJP2%#N-`,,
M*-LU,W!3A93DCZL0`0#*T`!2/&(``,@`!AR13@)2;P(]90!#+&H"#,!4$2>)
M`0ZX:@'_M_XT*0.`*3)1551?JB*O,>V")8YV.)[BP!X0$,&/_"`"AK:5JF?X
MQ#L,(<HR$$$#7["I(0G0@*WZ<D5Y&(%G[8F##S"`G2;0:AU\28`N0(`(886`
M!@`@`M@Y$`(?&`!*)#F`,FP5`A!@0#-'(8(/$(&KJ35N&410!7QJ\C;IXBC[
M3/K1.(:4&WE#*76W6PWMZLZZ%$+=(^:*`0N8UY@36%P#N/H&V_+AJ0!(K`5$
M8%3.,*`.WN2)($Q@WKP:<D=H'0`E1,!4_FZ.<\Q;8CKQ$<DJB*&W92B!-_>A
MQ%4\&`(#@$!Y)?/8`>2!+#]R*PXPP(`,3(`$?.@"5<OKB,/U_]:O$Z!J?BLA
M,9&U%0(LL$$-@CL)!^(``KP4JQ"=@X7*FK8&-=B,"3I;AAI,3Q(8`(`&MF"!
M"3#`M!9`7@,T4`8,@`^M1&`!'B90`M@V``]C?JT(]CN`#V@`EF+`P$Q7@0<&
M$&$&7AA`G8&@@3?CP9S/%4BA#-51[H8#I/$SV-WL:.A&=Y?1+`7OHSDC2:;R
M!`,-:,!,98.!,L!TD;/I<&\UG5A2]%:1&"!$*_.*`:9)$L.7V4%>=^"(5C)E
M.A7A3%X;0%\1D$(,Z&R`3<DLX276%<-N5>LW]PG3%I<D#VZUZ5A9UUB8SAE\
M+VX(/F':`$#MKA*=AFD)(#""/*RNK?\,L&E7+8<14>(6`FF(:"NCW.3I^0':
MLZ4RF;&L"A%PV<L['8(&Q&R!+20@S&A&JQ5$8`02Q,"R#+!`#>[12S\!6P,4
M2`"0(9!9/V\!`\ED6G0956A')_I]UX78HA5M\I;G3Z1S1'EX=1'E`1@3L25`
M;6=+\$I0RL.N$PBH8RO1VT7VTE>KZ*N')`E3:,VZUAB412O)O%RPGG86P"Y!
M/9B*@V(7T]\1S8"&EVW77=R0$;+VJ6<>@1).OK266<YV0P@R;E\_0AB/Z'0)
M[%&"G^[.`NME@`E(4"J,W/:R9<!P8;=:@RS3H@\8Z#.5Q5!:P5>BN%TVP4XA
MX`4QX\'@,_#_/%KSW/`)0/P-6\B`F_UN92]4H`U>@,`0*D`#(MA\B<1Q&\FG
MZ_*4#\SW=!LII'OO<N\N2M+5V&`B8FQB8V+@I=I,+9"O0-`*VK6N<UVNKL5J
M7A.XAP`O)D!)7CV`LO6AUXPYUWM<MHH&U.'3&:A#+1V8[L;G-<)*1-Y<%\D`
MM:NB['E00_M%8%U5$D!R;U?0:3B`6G+W"&%D4]RQ$:O`4R)@`V_@7P?8832&
M&J)@>AK```^$'TL&``#0`$M419WV`2P09[(U`*2`>;XD2E\0>F*P!:7U!2:8
M9K87!7U26D"&`,*66Y,P`6T0>BPP`S-``5O``$`0<;##.X.V>\0'_SC(]V@L
M=S#&-X4FE84JA0T=$TJW1%6:U@`EL(#$508,(&<@UP=/97.I18*^%G=,I88A
M018FH'0J(F**P`=G\%(*,0(@ESLE05.LYGQ"10"RQGU!%U;Y%U3KI`HO%0/@
MHV(C)F<A1P`$R!29P$UR1E\_A6VKU1"`B&E]IT&98!>[P5-IV`#I%`-&,'[/
MMTZ"P(''XX$V-PFNTU8`\`%0I4ZT%G0?@(8EH`$:IFW_)BVN10004`$E0((#
M4$Q5]EH#4&30E@%<%F]EH`$>YFXST``&9WO`1@2G%3M!,G)2J(4GYS?`AP["
M=X7H:')<B&C7$">)X`</E4Z$U%7@\WSX6/](M_!0784\YC1_)C`"^*A.UD$3
MEW0&UG11BU0VRX=/BI137;0;]Q2'?R51X%11E?!0Z^0GE[0#)P%M_Z!Y]YA.
M`S`"+H"(E^1+IG%/^*A)U$,0@F5/$JE.DF$M2B)*Z,0`[U0QB%1QQ+$1WS$!
M@[1N?Q`+;?52&="4FF0$$S5NUK8YSU=1:U008J=.-8DZ^*22^_5(/V93O;0(
M1CEBQ]1+QZ1.*Q(TWT5HO/>.D29S"C)\DY*%</E&\5B%RT`TP_%>D8$!C@$[
MX_)`$R!!H!(9U+-$?F)15@28$Y"0H,,==E@#8D!.801R$\`>,3(?M9`+J+,9
MLU!%B5`+CE,+N,#_+D_2$@\$F"(YF*O@#$:P`UT`F'EP*N-22;30!0^D"CBS
M&K+A&%N@1"H"*@(D"%PT'OXD0#L`)KE`F)EY*L@S`8"I>2BD&6?`'1?U0!I$
M`&F!%8@H&2`Q'^8%G)&T"*I081@T&<C2,5HD77?)/W9IA>Y8*0CRGO9Y1S.Q
M`^^UAT"3"`303DRC'_RB'^=R'GO83IXC$/3R+(HC&WLH+4RSF8D0H!.J+HH@
M.GLB%T"C1?@QH0_J#!=*#3_RGX3'':M#H8KPGX3"$7TY"HL5&@8X0BG%+?[#
M/@^ZA_0XH;MPH=RQ2C3ZH()"&OPI#..G>0\*&Z.CGR"4H<T0E]Q0<MFE_U)Y
MJ3]1*H_519?%T(7W.2D<T1K#T*4.DZ6%P@Q$\S>0MCSJP)?'=WP08R?`X0PL
MF@Q>JJ9.N@T;X:7$L!I92@W/H*?%$`QT"C9X2I1WF@[F`*7M**5T!)]4FJB-
MV@[U.9=ZN:5X9)=:*B%6>J6+RJ@P5T?=@*@KIZB=RJGJZ*ARJ:F;ZJ2E2JE;
MB*5[.JF&FJGK8*FNFBB'^I;U(ZKS^7*KZJFP.@Z1&G.]RJJ56JL(<ZJH.JRS
M:JQM.:H!<ZLEI:NIRJMS4Z6_>E)3BJS$BI?,RJ;:J@Z7"JG=&H789:K1`*J^
M*JW!)ZS5:J[M*J[=&J[;RJV[2JT/`T>R"J[C&O^?>_.IN-H^ZEJN['JO[DJP
M\%JOK_JH\TJOTVJOO[<7\KJL")NPSDJ?WH"N6!BPTI".RFJQ^1HQV=JQ"VNM
M%:NJ[WJPWQJK$SNC*QLAT.I1&KNQDJJP&?NQP!JR)SNR`+NO-GNSUXJM+=NL
M`INNTH"QSQJS[#BP#QNJ-*NO\=JS.GNT0>NM(@NR/WMH/#NU#/*RQ8JTA**T
M_D*R*>NS4QNQ4<NT0RN?8TNV:PNT#;M'6EL@7(N?7ONU:ENUD"*E$(NS!GNV
M8JMR8)LI^'JU5*BU_'H8<\NP7LNQ.2NUA+N.27NWC>NW-?NV%(NW;MNV6&NX
MXRJW%_NO>E.W=DNJD\O_,%"[N9;+LDU+N8Y;L@X;MIAZNH6;NL>:MJU;M%<E
MLRBKN7\ANBOUNO`3N[0KM*4+MZL+O,$KN;X+N,JKKO>YO(S+O(5!JW&[#%XB
MO2K[N'DDNM&[KKN+O2;;MZ0KOG[$M\OKO<TKK<_KN]V+OM.;M<-K#=>KN\F*
MN8#!OC/KNFQKN^6KO6:+O*/;O^>KOY>KL>O+O?E+P+T+OPJ,#?/KOME[O'*#
MP($;P$X;O^1:O`5,ON%+O^,[P,F;OKIZP'7;OI%K&-2+P<SPP"=\P1+L/A0L
MPA8<P?S;P;!;P89BPB$LP"#LP1^LOO8)O0E<PS#,N=6K#"R\PS1LOPM<PD/L
M_\,N3,3&R[M4J\&J&[\]W,#$&[`DO+A/#,43;,0J;+VY"\%6J[V#Z\4X_+MG
MK,55S,$`7"$Z/,-3G,5*;,,C',3XN\9L?#\,+,7:D,1TG+E4O+U.O,9I[,89
M#,=U;,6U"\B/;,=]O,'.J\<Q_,,M3!@IK,@K7,:9W,:%G,@Q.\>3C+J*_+^-
MS,B4;,:I;,>0*ZI=C+2D7,I^L<F0[,">?,?[R\2U?,D\?,O:8,N.O,5+*\.#
M?,62+$?&K+>6?,C+3,N&C,&'FPR"K,Q1S,O1+,M?_,F@#+YQ'*S/;+ZLO,H]
M_,J*&LNCO,W<[,=BS,ED#,RS#,Z(Z\MX?,RF#,^+7/_,F,PHLQS/]%S/Y]S,
M:OS,6_O'W@P.U0S-_MRYPJO-B+RW[8S-J$S.NDS1`VS.S/R>0LS'!1W1!QW(
MN6S/P3S1[#S0^VS-UPS&WRS.@JO.%8W,R8S1)%U\>TS0GNO1*HW0H`O1#(W"
MQB?'-OV]'TVL\OS+^'S3+\RJ0-VO1RRQ32T81@O02QW._[S2:"R[+3?3Q+S.
M>7O57IW,+WV_TVS47.S2*'T,.VW64WW2YRO36/W&-ZS1;SW6[YO4,*W/;+W1
M3#W&5&W76QW669/2>"W5>MW7H?S6CJ;5<,W5BH+8C@W6@-W+/9W7<VVL46W5
M90O9(OW7L+S0[LQ=BIW/C&UPJU]]V)I]UF'\U(1=V2U[V:T<UY1=U:^=QVI-
MU]'*VGP]SW[-V6L=V\ZLVZJ-V87L73%P!K5PW,B=W,J]W,S=W,[]W-`=W=(]
JW=1=W=9]W=B=W=J]W=S=W=[]W>`=WN(]WN1=WN9]WNB=WNIMW6<0"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>f39432a9e3943201.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943201.gif
M1TE&.#EA,@`P`,0``(."@L'`P"8D);&PL184%<'!P:*AH61B8U134W-R<I*1
MDL'`P34S-._O[]#0T.#?WW1R<Y.2DK*QL?#O[Y*2DD5$1$5#1(."@____P<%
M!@```````````````````````"'Y!```````+``````R`#````7_8%.,HR1%
MT76E:NN^9"S+$V9C2Z;O?.__P."NDA,:C\C,I9AL.I7,IU2XG%J#U:N6E]UN
MN]XK.#P=DY_F<S.M1EX,[3(\CJ;L#@&#@*`()#($`P,`?0<'``9_``$*/`((
M``@\#'\$"9(Z*CP#<QD/%CH`?QD8H!D"`1D6&#^E/*DZ"(V9!SP6#3H"&+,#
MIJ4,M02JK#X8`J\`%L+"F1<]`0`9@\2PI)#1.JNMICH$D`$/HTK./`@.`G"]
M"K4ZI0(,&?#:.\P!QSN8J@X[FHX/#J`2/&C`C)0I`JGFG<+4X&"@>PRJ]>,!
M`-<I#',L&,`(8)&>`!@2)+`PX(`E#+TL_P1@@`!!@`"]^$&@@X8<S203;Q[)
MJ9.*31T)"!U@8`'`O:([BEHX9@&3)406#I@2@,?/O68^%NU08&HC/!T&3-W2
M\7+'(!T-,"5HR.]GJ%0(B!XS=*!3LFP#VK$[!4HC#P=YL?8P<,[!UPP*"!"P
MF`'``0$)V!UPI<H"J(Z;)+K-8"`5@*\'!@BP\"D4J$#9,&`BF=?"++*!QV6M
MIN-<+EAW,]BKW4E!-%3,!#S(QU,!!K8Z!F"`1Q5#))3"!C`"-$@CM&S0.A>4
M'8?`'A]7N6SN^8,G^?+CSXM7[Y,]EO3NS;L7/+^'_/D7\M67N=_^S/YM`<@/
0'-R<DIL05-5BF0,8(0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>f39432a9e3943247.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943247.gif
M1TE&.#EAR`*V`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````R`*V`P`(_@`_"!Q(L*#!@P@3*ER(\$$&
M@1X82IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JEQ9$@,'@1LZL)Q)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*E3GQ4P2'SY-"B'#AXZ:.VP@4/7
MKU[#?HTJ@<.%"!+04DC+5@*%"!,F2-"0`4-7EV#SBMV;MP.'K!ZR5AU,N+#A
MPX@-6DA\T`-5CX\Y+(C0H,*"`Q(D0$@`P8'GSZ!#BQY-NC3I!000@&9`H'7K
M`P82&$"0`,&"!+`/P%9M@$$$"!%^"Z^PH;B&XH\9*U_.O+GS@1N>2R<946"'
M#-BS8\>`74*&"P_"_C]PH*"`>?.Q#:B?#:&]^_<7-%RH$%^#_?OX[<N,^2'P
M0:\R0<>!!E=MH,$'!A*8WW$#XI?@@L8M*.&$%%9HX7'39:CAAAQV.),'&G1`
MEP850/"`B2B>^(`""QA0@(LPOC@``#36",``!0B`8P$$G.>C`#KZ&(```.A(
M9(XT!F`CC0(H66,`3BZ9I)145FGEE5@FZ:./!SS@H@/BA2E!>-YI9Z9,6/D4
MH(=L)G55FW`ZQ=5Q=&Y@`5T6S&=!!17LZ6>??%KP)Z`54$!!!7%5`!>AA^[Y
M7:"0`KHGH1=,^NB>$QRJYP01("K!!(5.T)ZB;J45G&;`H?H;<.T)UUX#_@I`
MP$`#".1F@*VY%9`EC0,0,$"OKO5X`&T)%-L`:!-@H"P&&'+DUP<6/*32FW%6
M:^VUV&8[D6/%=5O<6\%%<&(""M2F6ZT'$````5%:"66O\!+06P,68'`!!@TH
M9.!_#52G$05K#I1!<MIJ*U7!"&LD;<+2.>87!QP,7$%F$=36[JX)$<S?!Q1$
M1+!$!WZ@@;\%:<70QPQY<`%+"S/L\LLL20!SM5MI94%<.,<E[@,3,(`0=R13
M^X%7)%87'70!5R"3M!B03)!_!1TM$`<'%Q1RR2\Y?=`%*&/4,D4>?%TU1A\+
M-I5`*RLF=4=K']1!VC/'?;;<=!O$0--U$Q0P_M@/$(0!`B]U]4$'^7)`P0)4
M21!1!1Q$,/@!"Y2\L&4*["U0!1HL8/E`,O?GN=F#7ZU0UP-Y,';>J*>N^@40
M>*[Z30&BO#E'%VP0`08,=([0RL?Y"W5%_EJ@M4W#OV[\\3-MD.D$"K2-/)L3
M<$`?!0/9JY`&=T(4`0<&!!C8R#IUW%'QSY=??@5U19#!`W"97QCI)44KM054
M#Q1Q!2HO`%ST!^6;D,D>D!K!?F>_B%0J9;PSR,;<Q\#GV:=>W-&`[AJX%`]0
M@`"B2PP%'N*!"MB/(!*@CT(ZESV"9(!Z'W!``!US,`RDB2!_Z<#I-C([G(0(
M:13,(49$9!873L`"_A+PF0Y5Y\&G',UT(>/.UR8@'P_DB2`9%`@#G%>0Q52/
M=-9;2``1\B;0+81`0PSC1!C'@`=H```6V$`1Q2BW_2",BJ,CWP;@EI`-*.!G
MT7G+0.B8`152X#$CZQM!#H@0K/R%C<<CT*'ZQ`'_(3)N-7RD1@(&(J=M;D!U
M%!'Y7":XBD0R;A9X0`4.D($);%*2J$RE4;;W'YC\4)!4V2)CHEB1#)Q2.AT0
ME`4:T`$%-("6J@RF,)L"M3\.;H8?0`!"%JA`.C93;R<1Y$6$!R=#70`K###+
M`APYS&YZDS'%VZ0L$4)`8%9/B`IQ'`P_H#B+2$\ASA280"3PR:1H``/1_MM`
M`THYSF_Z\Y\`W4CQN#:XAW1@C5,[&4CN9;^O2<0N8YI/!1K0.I$@,Z`:Z21&
M-\K1AK1-F1`YB/,@()\'8*!Y+AF)YCK*TI:ZE",W_(]4RB*1#&"S`P=XJ4YW
MRM.FY-(OR;(`.GL*,],1]:@%Z\!<9*(!,,$/J81YZK;@"-6J<H@!&=@`5BG0
M/*N"\Z)>#2O,(G8!\!0@)A``JUC7RM:V#F1.<TF+LJCJUKK:%:D<R":M]&FZ
M6][UKX#EJ!.O@H"4!O:PB-4IAO`I$(<N!'.)C:QD=5@!:<+$(BZ<K&8WB[P.
M.&!-'D@`9T=+6E1.L+2H3:WQ-O"[>LJ-KJJ-_FU=588!"APH@-Q\'8B`LEO9
M^K:!O!1B!AJ@3N4XL5I2_:URY6:ZEV!59"A4SMN6ZU4/3("Z.`&1SR"07.R2
MI+NE]8`Z,P!&[^($MN8-2>32*[`%Y.Z/X&5O1^*;E`V<-B6NE6_J3,>``P@O
MO_JUR+.>9\4`4S`K6B4`>@VLD`[*$$$$9;"$9_(7[CW`KQ,>B`4ZD`"CT5=#
MUYP(WC(\1`QXT%YUP;!5!\R2@T$@0&I]2F4]HF("D/B1*FL>`Q!:U_K-Y$!K
MVX!C"1-CCJ[WQB*69D14O%$>PX[#`![?30CXTB$CF2$.8,`"`L/D?[[X:3L1
M)`06G!$?SP0##SAR_H<&=F4.2<\`!*AH2YULPBZ;I#@F$1I++N"8C&P``7)>
M"`4*[!/6MME#5(L(!.3"YT.WJ7$3B.<R/^SH,'*@5PG(9H"+S*%14KK2_XR.
M!X!#F0A[U\[2.22H&Q-E;W8@`CP"XHW[O.IJ72"W.KT*H6N=$R%;U="\#K9"
M`NT4KUC5ML+.2#_9^QA)*X4#$$!ULL/*`0?0$`*":G55#^KDK#*%H=/>K+3?
M&LH[0H!/@96EMG_"@'&'.[41:2H!K*W%^]+DTP6C,TK</<AW^_NH'-CUT&CR
M0HZ,FM_@!.F_08UPXUU86Q08:MY,MO"#G.@Z%,EL8@1><8'$M./F(V\&_@[@
MFX$U/)66!;G*B:*!",0&`1(@\S_-N?*:^R1L$%```Z+U\8YRW.9`!XI6)J9E
M]W):E31/&)79*E[F'!W@$2]``FYW\H4_X.=YLW).1AWTB80H8@]`P`"(FW2$
M.*#L,Y.@7?+&N.?)_,SX!GK`Q8Z`WF[+>$@,X+J[SO>?``9@$+C`H:K>(6/K
M2P+4_,#3>](^;;V][XATC`3*0P!]%W5TB@<A4QXO$J/>=<:0%TEE-0`Y6Q*>
M38(ZU!U%5MR924#-;5VZ9F7/'"<Z8`$X"K'JY&.`X0K$`5A'&'F#0L_G-0ZU
M&XCNAIQ(@<H<Z\MTZV$&VJF^H]R.)QU0>.BO_DR9`6@=818L,.A'0NOYGEZY
MB]\^0-58$N5U1$333KGZ7[IH>@\E`UN>?W;/K_^D?$?B/X$[_3>`)=$SW.5X
M#Q!W^Z:`!+AVPZ0!UX4Z'4`!"7!6$8!V&<(!]H9]EH<MP4=4\4&`_^$!GC%P
MU2)MHL,5>Y<0@_8RV.$4$<AW7.$^)50MAJ40'2@X*UA%.?4R%)!^/.$!`&AS
M&B!_2+9!'[&#;_5<(HA(&A42_%=I&U@1!S@4M'<1/]B$)<%D#(@0[29),UAP
MSF%!;0=#G"=0T484^->%S;(ARJ=:TS59?N$!"*``#J![M0<>WX<2AA.%WQ0R
M#W"&M08PP[0!#P`>_F[AAU8H0$J8$!J0`(TH$EV(79.X'&&S$@@@B`RT/@6P
M(A&@B4CQ8/;Q-(H8%'M(8O:7/*6881X@`6(7`6)X&`=E'9?T5FMB2R'Q@2B!
M;$UA8G%3B4U15O/G%[BC/QL$C.<E<&NS)@6G:A7Q3D%A2G\5B5KH%#AG``)P
M`,AH$D?7%818,N.#`&_8$T98C>98$`$T%PYP?0M%C7/#$*!8/0BA`*=XCMUT
M`3'84VAV``/@'?%($IF1$.WT6.A8CP3A`%U3.:#&8J.%`;K84@.R``@@CJ,8
MA!W1@=N2BM-V`09@CP7#91BP`!B($I9'4IG78*>SC=EE%>.H6Q[I<QI0_@`7
M]2;TE4N'T2E!`80N@X<W45N1%V[@,VKY6!`3)#B>9Q!]-I0*T0%?>!`6H)$T
M`3X%41<Y89`PDP'$9A*.85,&82AL%!?))A.-=BRX9C\R\3'88Q`/9A'FY&VP
M(Q1>%"<8D``Z"1$CJ1%G@0`Z`@`PYXX4U`%R\2G.V%(3F!F9,6(SL6%9`6TN
MT9(#,68O5D/+-A'L-Q0.\(\C$9#7P@'L0Q1Y50!W*!`80!X#X)?EXT0,('5V
M:``#8`"))U@0\"NSX@!B!XDT40&^P5T&J8W5@4SKIBC_8YH6H31!498<I0"M
M1Q"*LHIQ$V)":`!5.!`3,`!*^4\<0'(C=0#"_CE",;=HUI&1IF-Z\]1'5KDM
MDE:7`I:</8&9-?&:&3AUPV:;W31%DC&0!L$]CME-7&5E%J``*LE%+G0=^$,O
M%-%(,K$8!Z(!%<6>'L><A727*W&)3"%!':(`^+,0$@"5J705"N!L;W4`#%H^
M&7I*>;6=(L4`"2!4T;$`^5E(GV@6`A%M;`82]ED3<Q04O+@4-[HAU_DS5]-(
M;4(!U6D3N32%4%2>YI-&!J$!&"01G:D2]B5DW5&1SXB5O7D1$$H31_D3QFD4
MQ;<A:0$=_?(!$````2`M&E":;-)'/#$!&W``0>,O5:,!0\A&<]DV$#!!7-D!
M#U`9]@-[)G%"$"%>_HAR$8&Q@GQ:%)?VGQJA`1W9%$/J'`0@IP3P$@.P``"`
M0G3*J#/C`0*P&071`"B4``'P&("*8TXCGP*A`#+3,PMP9$*X$G*Q&!>``+[1
MHB31`8BCJ%W::TVA&1UB8P31`%13=PY`/8)WF1IRA3=!`0X``;GUB8TE``2A
M:?ZD`"03%1!!'`2AD"GAD'!Z%<QB$XAIA<_CH$`AK`,!B7_S`0]`/3]46-T4
MIB#D/05`$)GH3X]810>S`09`,KA*HY0A$]L3L".AK)[950RF9G3H%P+``)F:
M>0>`GL@3$;M4$-#7`=0Z$*<J3`(0,/4B$$AXD"QQH<\Z`0*0I0-Q@181_G%&
MH3(F>E@X.37:^0$1(``%\!?T4P`Q>Y61`Z0@9$47,`"ET['!Y)H@]!`7('5-
MZ0&]&A+)EP!,]*Q/5&:8U8.C8[`F$0%&6S>QF('_VF`7P*K>Y`&D!$/><S6_
M`5!_XR\!\C;X6!V^IQ+]>0$2,+'KZ*$C@6T,$8<WP83',QELL@#8ZH@6(%K6
M4GXW<;BGY`$&0+$4Q+42D0`J>Q$84``(($'<%0$(H)XE\;4CF%TABE$8^1$<
MT(DL&`!&RB$]*Q%FFY4%(2X;Y0"1.CBRJQ(3&&VP>!W,=!(,H+>/&3"<:A`8
MH*X]MA+7R0"6DWV0RT"2$0$#E;,<90"?U1@(_E".*/&)0C:Z"7$OJ-:\%>%^
MR-,`W,L4T%:'#2`>Y;&ZJL29UWN(4Y-F"5"^Y=,!$$"]ATA>$9<`6CL2RH(@
M+(&P"S&8[5FY!6-,R!4!N:$_:KI1+7<``8``OE(`-<I1U>8D`@"=P'L2&D`]
M'%!W/[$`[&L2KQ9LX#M$?A$<P)9K+4>_P&-%Y47"1+LMZ*J66.L3*E0^GEL3
ML"M),9P0M:M?"W#"2YD4BHM]!-"Z).'"&S&\&.K$<J,`NOBH$W:AI3@Q2D'$
M4.A3,PP4#6P3"'F2PJ0!`5!/VL=3T-H3N)@2E9DR6HRE`6#`)8'`$RH4;VP1
M%KMZP@2C#+'#+I66_CL!;B@QMA312[T&Q191P5:%R!6;8=BAQ'@LQQVQ<T#Q
M9S5,8QL\7PPFO@S1M2PEE3>150\@0YF+/Y)L&!XP`*=L48P\$?6$4PSCQXCD
MLA+AR1UUK#AA`0"3@-@Z2J^WPDO9RF>6DTR,$66GRQ>A`'<L%-B+2"DZ$;;,
M41=Z$_<4:5ZA/!8PD0!@`.AU`0$@DF&D5<6F;19PP\RQ%MVTQEJDQSU%OCBQ
M-(&15@LP`0T``)A:`+^4$$*8)"OU$1N6$T,,%"6B(1@``*5+&%3:4H0,<)=\
MGPE5+Z37&P'@(EW3`-^\`$IB`)DL$8V&$_WL$PVPS+LHRQD3`'6Z<!N-_E$,
ML,H;$7-J^2D*O$]-"1T#($32`\'?J!&MF!,1,TG+4HE<UQ0OB!$-$,1`&<T;
MI0`L31*W=FL"4+@$42P?W(F!H2X"D-)PB:1SU`!$PB0#@`"-"&U.@=55A-3"
M9B=XU=`$:3^TJ0#(&3:!$T(5(+6O2@&58M$)\*5,0<<FA!`:4"XB'#U7P0%R
MH0#BN((1T+\_H=CH^+3AMCXC`;H,1)P_00"GXP%A9QX8#27<I6#:@SB$;0``
MH*H4(0`';1+HI$\0K"01S$K]D9HQQ@'%HC"0;%%RK-;*Q0'L#!*XS2'__!-P
M5,X672."XC0AN0`>%`$`4``3$&6]_0&^%P$*_K#<B%=;D]<:(HPC&.@06D0U
MA3*G3J'7YZC;2/7;/F&D$X`:4-(:"#%*M(M[`5"S2)%\"D``O]O>$.S8)D0`
M7R-!Y5(>4`(E-`(Y(HT23?J29/U/HQP4-R,^)ZHRYN2X!J`X$Z`D"X"D-?$`
MF/&YAST!*W(`ZP@J8R,HKHBY#E#@(]&?IHCB=[4!/5P5S)H8!K#4'P$B":`C
M_$O`%2"3#0:]#'!'GB7:SPV/9W42':`K`:```>L!=S0!^2W,&4%(/P$<!N:5
M1]5A/R'60U,I-WXK_#,U^A,PZV@0Y"43#@``0ZXO<9829X&!@#D0&J"7WDH4
M6/Z2Z'Q4^?H3!D`P_F;Q`#FB/RYD744N$`40`%K#,Q\@`),Z0AC^$9A:S!XQ
M<HBKAFFNEJ@50A8A:T>EWR9Q3P)CL?"T(@@`G:,4@1)0`))V=MZ,D=%)$[L$
MRD5AOY0[%$HJ=,V\$H(Z3!-0GL)X5+5-3F[+9':"`-L<`6?.W?UQ`-AZ4A]P
MXY&$`23=Z050ZTEA`94G%/F',(*2SEB8X-_DM(-1(!DPW37B7QUP(PK:.A*Y
M$#M:$Z(*)D#1<\3KV5E.XXPQO]WT8=P!<.;,%'09HP!P`#MNIC,2.0=P'`)P
MQ@;1/2E1`0K`FI?:`!`K9+\^$0ZPNLT'%'H$%"JN$Q+:4_;^2$P)%(+G_LI0
M70#:V!_EC``\,I%.!`#`*]GC(U2O<0`]XW+R4O$BD;Z5'E)!X;<U?A$9\)!#
MM"<7(<`]U?/5DU]G]U8D`P%;MI4<4P"X'><RF2:^$^,]>8I.:]0,U&H=P/!$
MI?03%_(=<:_P2`!#&P!**0`'HZ2":Q/*'>U"T8)30>\=!>DP8\B)1=Y`461.
MBU4AQ$</'[P?0``<I\L$#!*P=MI!D>T2H7,,<]\ZT<'=9`$O/FS>[FJ-?A+L
M>[<I]`"GGAR(-Q#;%0`"ESD23,$:]Q$KHO.\3?0P4:D>[YY!.,)L#N7E<X,\
MI3).L4UBV?0(L@"6Y5D>T".2>6L0+,*GG`$*_K\4-V,1#.#U*-'Y)\'B$V%&
M]4L3OA%NW*/*!<&JHG,!#I`!`'#KT%%JSH(`LL_,%X&RNF\4&L#I^V8^U`\2
M9N]=$V``^7CPR@<0#2XL`+#APT&$"14N9-A0X8,%#B5.I%C1XD$!%Q%R",!!
MXT>0(452I'!AY$F4*56N9-E2I`4-+F7.I%G3IDP)!BU6.+`@YH<("QX@[)#@
M@X$`.E=JX.#!80<"/V_6S)`A)`.31#EHX,JAPU2P(*6&K?C`(UFT:=$VJ*#6
M[=N;'9S"97CV8H<(!!1(L'M0`X.C!UPR&%#@`86Q!RM,H*O2@%60$XQN@+!@
M`($"!0`(&(`@PM?&_F0W1`RM$,/<TJE5/T6]VO7K@Q>RPM:XX0&``F,%4@@`
M028%"!$8&$C@H,+/`QTN]*7MD()(#P0(""`0W*`'#1D@0)C^O'E+KJ\5,/]>
MGBP"I>;5KX?-@0$![QXL>(@0@+%##@I.8H^@``&!`P"@@``+:..@+8<N*%"D
M!@ZHH#6%.GA@`-_8&ZD`!"W4<$.1&("00Q!#M$F#!1K@8(*($`!,(@H,2,F#
M#3:X@`````@@)]`L?&#%$0_`0$2+)/@02")!=&#((I-4\B(/%-`@`0^B&THB
M#!+3B`,'#A`@@``&D""##DXD[``'TD/(`PB0A"M*L#B";$GUWH1SSH32_J3S
M3H4DJ-"U"N0$"0'>,KAM2H?,O&B#!@1P@(('Y5I(O@8*T,NXLSRX0$VW.#"T
MI@>,PK,Y$S^ELP!,1042`D)5XP"!``[@RZ$(R/L`@P,N0.`#@OQ4B`/O/MJ@
ML!\O.A&!&@V0H+U-:?(@@0;P+-54:,D2X-EH-XP@V-<\D$`!`1108`)'*1*2
M@_DDG8B"8S_RH(`%1<)R`;T$"K<Q:EOJH(!*+65T@@WFU3`#TJH56"T'!EX2
M@G2;ZV`##")(@#@))K`2H0PX^!$#`%)E2(%>+=*@`%U#ZD`"#83+;`$+9"6+
M@AS#HH"!"0Z83D4&:L;L,VMG,WCGFPA`TH*6_GG^K@&-S>.I2P3F,XV![&85
MH-V59L06I;\2*OF``!;X,NBI*I@Z+`\.&$"@#S-@=0&NOV-*Z-2:2M+GAC!(
MENW5(BC:/`LFP`""S!Z(0&D))%A@`0YLG/L#?RLB((*0,`#78PJP'N`!I<%*
M8.*I5$X(`P8:J+>T@FG[',C'BPR8;@XAT'E##RAH@(`!#F"`5`,@L`"`6R5J
M(&2'*C!`<XEN`Q`""OJE2`/78V\`)K=GV@"!M%/SH,3H7=L@8;@JP/X@#Q``
M'O5L[P9?O9PTG(`\#Q;6X`#L/,!`@/OP^RB!PR5B((#,:NPR`0@P3PA&UTW'
M,$!SB8+*HZW?F6<#_KQ;2_P2<JGQK6=Z$=P0!!A(FP-`;2'\.@@'7-22"XBO
M(C7SRP4@X``#V(@``JG?!RP%`048H%DMJ8`(5_.`T%&0(1W00/5T:!,?>FQ/
M/S1/!"[X%O_%2"(3F``"&H`!S2R`.!&@U/<DXH#5:>1;36S`M>1"@0>DT$9=
M]-^NA!8JA5EQ*@[0#Q'1`K"4;*"-;BP/`HZH%D$YA`!?4XA`;*49`4@@`H&#
MP`$*P)D8'J`!BUSD8=3D(7<1X%=""=``L"@7#4A`C%TZ`,["4A7VY.T@/%K-
M!&SH,CZZ\(YT!(D'U$B1(+(R-`@HHULB@*2U2<0"-=L1U@Y9@`4<``&2_JD1
M`+2$129.0`+:4\`"$E"S`RB`,`R@G`52YI#M28!I!`"-Q2C@@(<IP`$5NT`"
M$`!()Z92(NM348;.-<3RK(I[LJQ+<NAY3WS2TC591`@#@H@!!20@H`F(P`04
M8*,:*2```&@```8P@,T$H)D,Z)5\)E"!Q5"`B3!,`)<"D(`%,$`"P8)0<#K7
MD`Y40(H$6$!;TA<!S3CTE0=QG#D'L``[.81-PEK`*FFR@-&]\739<B`^C?I#
M#@Q@IHW10%#_%Z4,4$"C"FC`MQ*`.P0$"*&X:<`"3+B!"LPF2ABX0`7`Z)^>
M-),"'JF``)"R/8:H-(8+"!8%!`!4D6B@B2L\_HY*LK25#3@U)=MBHV5L)%"<
M"G8E(SVJJ%K86-;E3CW>`PL&.-"4"C``:Q,0@%93:(`">$L!1N154S`@5070
M"``&,,``8HF0#60I`1Z!61P9(`!XAL1AB+-1`"@WGK!P1*++S,`%NKH`SD`0
MCXJE(61G@H&A.I=(.4Q-8'?HE@Z\S)`"P$T&K&G-S-9L`0HMIK<88)P!,)<"
MT`6`3\%R`7M:P`$6.]\!:FDOB0C*`!T#RY.8NQ1U2G<D:$1)!F8HX#4%^"T1
M<.=!)%``M4A@M26)"08"YX`O?0AY#4A`80YPT?:.A'&M?6Q8SGN0"2QNA@[(
M+5THD!N#60S!V2KQ_HQITH`:@T4"12L)6C"```,H-R&\<D"KC%@]IOSJM0QI
M$E1.R9(''&"M]OO*LJ@(&@<<&"$5B$`$[CL3#DBY(3E6T@:6*F`SKV27-GY+
M!Z*KELN"!@-0>B!<;?)@EDUD`Q1(+4MS,J07CP11$N9O3:YG2`,@P+(+@20'
MADHXA80-=@)(LTHNNQ-2L21QKFG=.OG)9H5,H-`B40ZHX4R`QG1@.X3+0'TZ
MMA69="!M@G/O0:*ZX\$))4<G_,`&#-"3!]@NEH.$W9(UK='_&.`!N33E!S(@
M`/YYI"A!XX`D>5CM?DFLAR*YP*@;4@$%_-="'IB`N-D,II4LT-1I4?*:_C@@
M@7(BK`,,:!>9+T+6A;@.)1PP80,&0,T*$*!@CLY?C5C:`)(U1`$8T[):-B!?
MT#+`P@!P"F4.\P$<+J0"-H),2X&<`.H\H-8B*\"GY]14B71@Y.L6"08:SG*;
M5-ME7,-.20S`0Q?.!2H3D<]*UF7O0K6(1N@Y$R!Q<X`4LO0T9V+`!@#`N-)L
M@$2:$2FV:`6A9<EM+AX0P)3X9JR6R,H"GB**R4-4%`4C#N93,?;:3R)/L$`@
M>A4K74*H.)$,)*#M#M'`RU6R@58E^CE%.9'G7)A)PE#())FE``#2KA970I<Z
M#G!``0SE@9LGQ`*218"Y%^))A<SQ(`\/._2@_K/WAG#`[S:A@`4N[G;8MXF4
M;KE`FCL0[C/=,BQN/O-%8N(![<DQ`"IM?0,05KP.3,`!YPW`-P/PY39;.`*N
MJASW(/!K",3,,K\/P$PJD+;^V>2T(\G/B\HG$0.RY`(:L,"F4#[C#$`_]J1>
M/4W(<X$.-(`I4$O:RNP,DI0"KQV;/N#0B6_R@`%8*$4A@```$"%QH8B0HHNX
M@,>KB76Q$6!Z%57"`,?I`!;[@`L0O:FP@/I3B2MK@*\H$R9Y,E@B.HFXM+`(
M,AM#GOFK"9DCBP=,"#-+GYCH.V>#,-$`"8PR*P[SJ&("`+W@KF)*-`"P`.A:
ME9<Q``&X``=@%8FJ_@`(&(`*=+8:@0"@2XD03"F8<KR_8;(/,`ZTT```,">/
MRAK;>9$I>Y`/:#_8D!BR\#S4@;4:=!Y4HPN=FZ$MM)<,B)*=BILCY!("0(#!
MN2@*:(T0A*@CK)$/.S"5*X"%XIN]>3Z+R``"J("K:L2*J+V5@(#.ZR#]8*W`
MN90AP8`/BHO*6("+<H#Q"I#9>CNH,P]9VT-=-`^X>PL+B(@,4("LR)*5:XCT
MZ0#'V:@).*&02@!+;!4!$(`+`B^OT(@+Z#(I7*@"<``-LC7A$)ND>*T%"!T^
M8\$I4PF0BI]Q9(#\<*8:440F`HT.Z$9VBP`$:#"-@+?0\*==[$<$:QT%_G@X
MU(#!_3@G_1F`:$1(`^@<"Z``NDJ+57$T>AP]-=2?@)0(P+O%#\`2BBA&AAB-
MT%N1A?N`!)@`X2",*3P?/$0)S,-'?W0CXWE)2V/!FP"3[W&E!9(`=.DR;T,Q
M>)N`"UI)BCB07F,?`E"9TVJ\![B`)BJJ7:F^#IH($ER)"?@HD^@[`/`-#$"U
M#1`,J\F[5H'*M\@`&.,0G*.(Y9#)DX@8M4R)K2P-<ALR"N@RNT$Z_9$.,D'#
ME'``^4.)"["*E\F[WN&)C+"(RM@A_\F`_P.)$[FJUBJ`"#"`)FD6EVN(3*H=
MF$&]ELB``?C"QJ#`BK"NM@P)G1S-DYA'V*B`_N5S@`=HS=:L$DW#`+-2@(ET
MB>CPB$[D'X=@@`RPD5>B`-Z1,898S)'(C@<P"$4CD`\(CHG@`!AB``2PLV5Y
MDPKP3&RB+O:P0_`QL-XS3>_4-)6S`(4L@`'H29<XB_0"@$_K@/T"`!'4*4M<
ME(4HOX7(@$`<B;C$N)FJ1H;`"J(02H3P*@WI`-?RSFO\3EEZ@/O\B/]`POGJ
MH.X$"7V;'@OHOH9PO=LPSSH)`%F4E,51"E=:"/;;D$V;B5:[DM#0%@353`2M
MEJ6#L@J!B@8`1>R:E<PZC(GA1F^9P/A034O4BZ5L18103I5PGP>8@+14EI\(
MCYJXE\\QN[!@K!:=_M(?NA[;_`H-<!*Z");U\Q&Q/`CVH9#].!"(R)NQN!?/
ME("'J8J!0`#_X(PCB35(2[&%K(`(G8@"6%`_+!XJ[=,:%$^:K(D%:8"%&B9^
MXD8!>*4,:+J)&#^$T+>/2#C$D0L/8`!WDK7[X$]+BY_TL0!NJ1D(T%.'.%+V
M<)_O7#0_I2!-D8GNT5"PT`F(RCZ(*@!+[::8BL['6X``&#FGDH``T,A03`!7
MM0B&80B]>K""4+,6HPU17;L'3=4(R@#K;`A1;!ON*AY1BR$,K$(/22U_$]82
M79<W(];6*Q58K$V=>IV^/(EF98@)*$_740"S`%"6V)U3A5:A:0VG\`"/_GP*
MO4LU'/L`8D'"[4DIF8DF[OHU_YBKI<0`T*`,='U4AK`5T.+&P$(-5](F>HTG
MI$,ZUHK&GN(TXNS'=L57('F3ACP(PZO70&4[[@J`#]D`@G(*[V*`@J*`<T(`
MV7@`!J2?K+*(`P">O]B2`I"`,&$5[GH:(J%"E0R)#8`I13O#:379CZA6JA6:
M=`%6EC2`J77+']D`[FHP-!$`?'0/)%PAMJ@."Y``A/1*BC"]XTF>&GD`]K21
M8:4)C$J)#!`C!?@^D8D``1BD.[W:CP!*PA68A*G6<F,)GBB-"2@0K6J9OU``
M70E!9ED^S%"`[%,`2SQ.BR"PBN#,JFHM`?B/_HU-"]F\G])MO[U[G[MUC<&E
MHZK!6Q;U3MDLC;_HVH5@SM!8$*00@&X*([F+D`=(FJ#)`.U+Q/,QT4`Z$]4D
M`'CC"M23C]AE"8;IJLS0U-!DF@VA6YA;&$ZI7K6T)E$)557A+D^Q@`)`08TC
M@+MQS@2`#`W(*F&T%P-XSS.LD6BL#G2S"`L0@-D+S=JUB.58@'/RI_HAJT35
M$"CU4SD\W(3PFA3-$2E="<_U0Z+C1`#("<VPDOPS`'J4@$1D#OG`C!52F1I+
MK;0!C@T^$0.0#NW4*0>`'\>[D@#@HRZ3B7=;/NJ`184#&"%5CP/0W0A**7Q:
M5R(IQ-38-I:0N,8H_IP?(53<"5PS23X9(H_\D,%'*:<NXQ8RD9/H8*UQF@A[
MJHMED@H>XMGUI='_(44`T`#0^AP/>("RB5B4>-H`&4<"@JWTT:?L'&`BDB-\
M`F0B*=&:(,7YD@K<6XD$:."IL"X4&H#E@!`.*(`$X*/DTTF:BQEV="$JPAU&
MB@#C6D-)I*B_A!!T81%!`E;ET*QH6B^:"BU@^H#U,3<D=A?C(L\%$.4<L0"M
MW;V2-34VAF"W$,T[=*%=4XF&9("G2XT74\]'Z2I#>3>6DI68*9TL-0BR[8W`
MX;">"(!N^370&@#VBPG`\R%+J9'5DS4+X(Y#4A24'5=W;0@?`5S)LHGT_MD;
M*501O0EBLLBL[QS9E'!)8FZ,/:,A0!*H?G4)?TO6!U(DKI$C*?N0S2.`V>B`
M6G&V`,"_A8`B+WG7;3Q.*8H<X*6(D`HQB1`F`)!%CC&(V)I`8T0<P1R)&<D:
MOZT(%NLP&\FE\L@_F"/BN"EHV-`)X6RE"W"K1CS=D3@`+<F1.<Y3AL``2VH(
M/&N-4-46F1FU?H&NK"J)CJ*J&E$C#BB.N<F/I_.-[+H?11P`BY"0FYB`0Q16
M/JT(X%-`QE!JN61,MP4UX+@)H/;'&"YFJ:*,;FJ<S+#CM)"-#VB1`8`Z<BL.
MAC";H*U/RU#!,WD`LPHMO1*]Y'/3-TE=A(L4_MRH%PV@CMQZN`.`@*2H3]]Y
M9:M=B.RZB?I@(@-.P(3JD^^1C4I%``08F]-0ZD5J'):3UILH1:%.TK=HDA#2
M$\1Q*IF]Y4<V"/DJ.<0I6B9+`$F:3S82R_PC`+([B#FB@,9.OI:1$&%=6^IH
M'HJ@O(W6P2T)*08"-^UAP/_CRXE0.=INJ;:S#');WL940F,RVK3!``WZBP+H
M"4,6:K=8Y(+^$C_L(`WX$5D<'59$[-!(+2!#FX[FGP_Y,9]8B`W0C`$81*+H
MO-L[`,C(J0^H@&U$C>7[M\`9YHX>8XI9O@"NSS?17HMX-VYQ*\[X78%&"`,H
MJ!?NK#+Y"NU`+OU=_KC6,+"&0-[,0("EQ&L%KW+S\(`#XP"KT(!E33T0?@JZ
MR$6$Z+"'V@Q%^C,(N!R&$$]^<C1C2JD"\,(+8`!GE(Z?()<.RD)W6A5+>2BQ
M,8SX/@"S<$XQ<LJ.;ME(>X``Z"*.W@@((&@0QZWZ50XU]A&/(#?",#@?,0A>
M:<Y=<BL($%\K'_5Q4TV#X(M5O0@.BQY;H0N(T+Q]M3`'@,3,B!&,=;GXQ3I:
M$>]T@2_XX(`C==B-F(\?>]:BRZJ?H(]%H:;^80Y?ZZHFK)5G44R*"*R%B4E$
ML:_4\V.22%1(2@@/A)U=MBY!.21)#*9K4>^/W*4NMP@EEHCT(41W]XHP_JGW
M,/$*>M\I69,+>\=W6=/4**FR(>MW?O]WG9.U8PSX0D3X,R%X>G]XAR=$A]]W
MQ,GW>K<+*G>7B;_X?^]W?^=XD(\1?)<ZDM>`&"GYD_<*DX\1DU]YP.HA35EY
MIL#WD=<431'YAT?YEI<Z?U_Y&.EX0KX)`N\)1"&S>ZD>8X:\=O>+!&A-K$%"
M[RDG)VF=OG`S1>N`U3X(EH8H[*1"`_CP2/,:=1\]UHRRPB`9]KLMA\*KMK[G
MAI`8#VPMG"K+AE#0B_`6+4<2E>-JXDB9K6A-B/(6`G@,*I_L_(*`V9&.`OAZ
MT%K(&"*.,`JM_[B,Q2=/SFA;L:'\Q8<=Z7@H_L___(=J?`_-#-$'_8>2%,^O
M_,M8?<47`$EI?,YGK<PP?=JG?<P@3X2D_=;R?-CQ?&=\8=EO?)PBJ^T(M@@@
M'MG,CG+6#B3MD^-'E>U8?-%_&.FO_.#'_=KW_,N_C-[NK-T_IP%@+=[N[43[
M\],OC,RH_/27_O(G_?0?_`//#`#1$@;$'P"9#LI/-'$&+:2+':P!B``%`@`8
M4*#```$'$#`\:`"A`(0#"#PT4+&`1080(#S8V)$CA`D:,ECX:-(C2I`21FI@
MR>$#S)@R,WB0\%(FSIPR*530&3/"!I]"AQ+U:6%HAPX79&[`P*`@@`8Z.V1`
M<"##APP$8DX8\&`"_@$("W`V.*!!9P8%`PYXP-FA@8$),350@%```%Z\`^06
MC7E!`5$,$F)ZJ+``X0$,0BU@[?LA00,%#_H6=F#`X-(/#0;`U'`@@`/'HG.>
M);H@+^H`!%&SQEL@PP8.'3:TK.W!0^W<NG=/N)!AX\8*&BY<F+#Q@@7CP(5K
M`.[<>8;A+2487TG!P@4(V2%$D(`!P_.-M2M`8$Z!`?(+&'Z+'/X\`H8+%#1$
M`&Y!@P7[#5:W[N\_+T4)0&"1`0I(4)\%Y(ED000CU0?!2KM)R`%N&GC`@09!
M89@43+BU]4$'&)[5P6@X?1A3![?)EN$'+]&F`0<WY=2!A1]L$!1M)((H_J-,
M(6;H`&L"_#<D7@$8P,`"$,!E``0))*#``01:)("0>$5T$`$+//!`8S!A(",$
M.O:5@)@Y>9!`B6D2]5M,&QP@I@0#1.!3!1%D)A,'"=PE0%`?5-#3!Q08L%0'
MDXWU@0>"(G!B3!PP4(`%%`Q0)@8%-,!H3!+@94!!73JF`6!#2>`I32T:=H`#
M?;990&E%91#`!`8<-=H&$1CPD@*>@N5IB1LXX,"L:GXP``"I9DC;C3=F>.RR
M&`PPF+#12CLMM=-Z0``"%TB`;'859%!?!.!>`"ZX$"A``(_5JKLNN^Q6`,`$
MR&*H+++(,ALN=_4=66*,]1Y;)W>MYI3N4!L<_BH4P>WB20%.!@!J:DP4*%`!
MIA]8D*1.%R#P``4`Y-K9!AZ`55I)'RS@P`0)(%#`G3!QL-D$)'HV%UP4NN6`
M`@$,0-,"!@A@0`(3\.H3!7P)M6V/.''@P,,=)@!M41($H%7"12UP00><X>19
ML"5ZP.`!:\W7ZZ`M-M"``VB?K?;9::?ZF,`*RSTWW3BAVV)\Q.4]KM[$J><W
M!B$N6C?AA=.=-:(5L,VV`W9JVX`%><=WE@-#USV;8PY`;7B:#*@*@6(2%`"!
M3A-()H!B,H'ZP`4>;)`=`5D^(`$"(L5$W@<7`,!`!1PLH*J?LGKZ)J@&4$#P
M!0D`4``#/,:X@`(*_EBU0-PS$>5F3!EL/A0%J/;%00"S2Z7FG`P@H),%`U3M
MF`<85%#2`@@X4*90.0.6``7QQ5?!=7]3(,&X#K`!`+2,<P8\H&,(H(`+>(4!
M$G@@=1XX`0DD8$M/BV`#T#0I!'*P@T6I`&<4H!WL3*`"?^/?!$H800A*X$U>
M.6!V'*.`U/GD`!Z$R0:@U@$'>.8J.=D`!!+C)D8):C(FTD!>`@`Y'6%``[$Z
M&%D44#T''$``#JC86X0D`$PQ@`($8`NB)L"``R@@9CE!`.\LD#`.M*QB/GE@
M:2QWN]TY@'1J>L``H2B3".A16H7Y75$\P*G)``\I#>@``8QVPT4>D`,"_HA`
M!A@@+/@`0(Z,O"3A%B"`#R"@::.1RPP/F`&&C:EK.9G3#3'7F0((P`(5\Z($
MDG(`4GX``]BB(9Y<YX$.F$LU"%B/1C1PM][`A`+,PZ("!&`Y#B!@/PRH'@0*
M0K!W$<1X.DJ2`@P0``30$B8,^%`$MM*7">#E)@,I@"(;-0"G+,^,HAEEQ^QH
M)A\BT)$`4`HJB\*!`SC2E)C\I\(<Z<D2+0`#`/`G0!/:+@8$X`(!D*2:PB2`
M[0'T>$*)S2(O%9-F#LT##H`43!Z`2@]$(``#111#<5G+#B@/+ZUC4@<,$)L%
M[$4GW5/(5`S@`/20Y@`;&0RC!+FM"J3,8PK`_DOLGGF:!#S3`UWJG6-&ATOP
M($`@L[MF`#QP`?(D(``5I!BF'-DJ"ZQF?#8-E>':@AL`G&^D0=4)]0!0/872
M-5H;"``'+`#1-,WP?'7]Z[H>(`!FRLB-)HH)!*YE1,X95B<-**#JZ(?`*\*D
M`Q0ST8`>IJ7;B&X!DF7FLS!%`>@EH"55J>HA8R>`!U2L`@?`(P;\&A,+?`8`
M!X@`HRS0S)MT)`$5H-%%#X(1!LQ.>GFURP`\ET/VL4@GN*D``PP0/P`LX%H-
MP,!M2,(`*L$414K30"R'@B;.80!H!TC`2PK0E@.,);L%>!-.?@<`W.(G`MC!
M&A`G$+BD\+<W_#7A_GXYQ%_9I*BR_#TP@A.L8!"E",&[1'!T?HNH`Y](P4G9
MY6TF_.`'<\C`*>+P@`=0G/'*Y`&2Y$!/+M"`='DVGQ@F#'\S3)@/W0;$"=Y`
MS#0PX!3RN,<3C$"/BZ.!#$)R`_RE3:!\K.0FA41;#'!2`C#0/_]F0,D^;H!Q
MF)K!CCSS/OM+H9)2B+6J=N4F$B#`27]"@-*$YK6'`U'J]CE7G0`+L$SI9E8(
MT#R_2"5/"^CHF2G@1@@,0-`F4HJ<)-N!;-(0`2.-4W3PO,/2]H@`+0V`3SP`
M%YA80`)/IH!EG>0`Y`!M?62!K$]XN;L'-B!V"@!U9YH$@`2@&E$%H`!L_HBF
M4L+94F<K:\O&/A"!_`E@`$$MK<>>_.0C)>!(##"?D'R6$.DE1`!Z3@`!BBV`
M!&B[V`&P=`(&,`"=O1=;$$F(M+6=D'53:64,R#9;JWBVRP`MNDYB@&6RG1`$
M0!EZ!$@(`ZJ-@)\5P$D1V;>T!R"]*NY[X.P6``)L>]Y3VM")'SC`07&"`.UM
MP$G$PA9#Q$TE<4L/`5`:P`)Z%B5UBWO?SW[RSRYCO@4P()O/;D!T&8!SG+^\
MYS>/>"L_8.*S26#G-!?IRWFN\V<K@'D:N7D7%;=TI?-<Z3KGMA+Q770&09VA
M5KI)`^`UE+#WJ;H6<8#*GA0_AC1`@@^<W017_G@!`IN(89954PE3;4E&=H`"
MM4.1798VNHIA@+US[<`$!(!J#D0@E&X1703*U`$$;*`"$0?`W5`TQGS*!`,$
M<0#!$&\!R-ULFPW82'[F*UFBV<0QMO3BN+N(7$>_)&MX>8`:RP3DBTFRM8M-
M:P-:LA^K>$Q'9PH-3BHPP"9I[@$+Z`X+[6N`!SCZ0"RL^0.A;_WL^W1E\WV6
M]J$?`>K79_L2T-R!E)>`"!0@9Q>$8'>ZTR0)F*OZ#G@^DPS0@.Z(](%HIS]W
M&,!"0(CUH=T#8)P`$&!];`R09<"75,#D_!!:P43KD,5G0!=3'4`#U$7T=$<R
M!4`$V%;;)0#T^-_)_C"`!RJ`DSA:X_';Q2A`RJ4<DBC`_<%@#*8<3TQ0RD4/
M"48<MK"7],1@-M5@#,8=DJ0<?&P`OSF`53"$R6W@`IP?0^Q4`Y@<0YQ7_JR%
M%3X)OD$`RMB(WGR([E!4CQ@;3$P``J"<1MQ:;#@`3VS$!&@2`!2(SJ',V83;
M0]B@JM0%+<F&JS2``)@53J3-(CE/3)27`JC*!2R$;JV93E2`\3B7:PG$(Q+`
M[V4/1:Q>JUW>`BB2!A3(7&G/`Q!03MA2=7T33@C*KS`A`<"%#8D&QI$AG<U/
M8DE97'0'D@C`<!1$E6`>*7D``'B+!+1%VQG9(>Z5X1`:B1A(+=W%6M0<_ENI
MCEW<A9[@!;;E!?[\SVIP2E3@1<X,G`)$1O2$XV$L``74A<>$A2I2P+!1QSE2
M`)`\`+&P5?0\GXJ5161(P#L^BJ#,TO\<!.9]Q0*4Q6D`0"\"`,><H_((P`0@
MQ#E6U0$0@&TQS04\14&<!G<4S4)4P(%80`Y=0+(DRP2$C\0T'F[A4$@^@`CY
M8P,DB5-$G`+8"1^](P5\14C`([$02Y1!5_0HD`*@()"%Y)F=!D^02_Q%`'%Q
MAP:VU*:$(Q,^WP-4$)0H4#@Y@)&(5+BPTEU8"D4L3UALDUX0BT`H',[P&Y+D
MQ?0AA)58"67AA`48I`@]'PKNW[`!28BD(K[]_LK)H!VVH!RWQ<X!D)'\-`ZY
M4(`Q^@EW0)0',,"N$8;&[)^$T=6UB`DI8<=-T(63F)CQ$`SM/("B28"6Q)0B
MY15D6`CR=<@#$`#6_!"^#8!=H%5A/`G!.-48@>2S=-[$9,!;;(ZYA,ELJ<<H
M2I=AKLE1%5*JH1EXX<DH3<`#!,!5&`#B*1"W\<5/]HQM2<\#-$`!5,X':``R
M%DZ4?$U6>9-7%H!$$D`&Y(D#;`E[;LEZMN=[UL<Y2@!\LB<:W1\3'L1.689Y
M-L#LM.>6W"%VNF<!;$Q[,H\!&*A[UB=[ON>"9F>`;DF=/"B#6M"O5"A]`JB#
MMB>^-:B!2N1$`,!J_IA<%9DG\U"HB2'`85QH=FH)BGZ4@K;GL)TCA-`D&CD)
M3=:H/LYG0HX?!8R+=V1`!FS5.48*3;YC;V0`_[SC3\G'=4#?.:90N!SID3*G
M/NJC;TA9N`#9`T'`.1)73G2,:Q@$09@GO(4/>T%/RCT03^[E_9%@@@H(VFWG
MDXRC9,1A`F`%22G%?71G8W9(@NX=)GE`8E76E4`*!>C)SW`)_H1>E"1,K"1&
MBZC7(?Y,G^!&FZBH<2[F`/0$L>BFRV!`:56,!]`4#:6/\E66*WW`!,#7I"I`
MNJA1Y=U'51@$!,P9;JSJ!P&`![",4/CG@5S`K;C,A_`)B'0/CC6=Z6!%_B2I
MB\UPCY%8#-3@&V&,6U7=TYRQBRQ*BV>BHIV-!JZ=X0-02+RL#(D@V25!0`:(
MU+?*#:&&*0#<*HC8R%FHR+N52(&A2&U$!WUZ*00\'?V(S(3Y!`=82F/]E4$)
MH+AI1.X%"J1Z!<%D`+?Y9NX84<%VZF=]%&N9B,$<$DQDP/AHP$?)$TX4'NBE
MXF>0K`<@@(Z<GW'"Q)EYBF4Y@+7=ED[`QS`21:MIFF'QT@=`P`:H!8/=1`=T
M35[-4E=$1U9,H+0@P+9ZB<<H8>I<RYQ<`%UL4Z%`!0)X9+O*Q*7L6==^3TRX
M866Q*HG]D[JR:]BN"TGEQ"BF$TZ(SL'2#9Z9_@@*SBTF446/W(2<P>PZZ82C
M;&!.@.SH\(AV>$!J<JU,^,9V`9+2'(#G,`H\;5.I*(T*8E?&:)332!(&G`Q"
M(>5=HL]F1.3'N,Q5((`"::Y;--TB"D718(!G2EE6%!YD&,"NO0YHMMK^V:JI
M]85%#060,$`&T!,PDLY/W@5@"%)3P(4`,`!C=.V;E-':6HU<7(L-.<4'"$G(
M1!XF6<`.<=[T2DNMY,1IP*U,W`6C^&S=<,`&7,?+EFI;%D6A>M"W(,Q.;<S0
M@)=O8<H&/`K%RH152%=C!IS08$H&?)0[S82ES95AH`<6F9A:K%]W?E7[S57*
MZ.(;%<!,907(QL\"_B0`Y&JGEI37QM!0/TFP3[R:E313_B`*!W3%OR4)NB(*
M!OC*`V!$!>2I4OPIM6B`M0V-S=3&:OJ.ZA0'VHS:W-55P7J``-1MW0CJM(0+
MHFS5P)+$;=@N)E4.`YAO^*9)G9A)$@O%<.!$\A".=TQ`!&QM(2G)VD;`:9(&
MD!!`Q924`DB69Z!73@GN#]TPJI%5'<_(`JP9J3J`5[RL!#S2;3S9`%R&PC6Q
M3@3M`42F3'P-(/;):08MN`G`GRD)9F2MI+[+HN$J6V`<:R1`6Y11T8H1P'5-
M!P2<TY;6Y#&M8T@RP3)D^S@&!S!MT0;%D(T;!"`4(Z&+(W-.3&4KM;1=_E&<
MY"5UT?-U,;5T`/A&R_@5CHY<`.L,HC-/16(LY@0NYA7QKUH`,P7`"N">&:7F
M!%R$(O[,E6=X5L8P(:\4QL`M0,)<``'8A-XRQ5$A9*9<B,:TY6TT9$QF9P#\
M3$T2Q,Z\\=:@5U20$X#LD%SUR&@)@'-R;Z!(3?#Y3GR`X&@@@#'_[*QQ@`%<
MR)^(U`2TY$!.0$T&<H]$7$-U2/*<"_X`U)LPP.K-C<36C9<6!0\C$.@T3C9+
MBW<*16JBU\-```'4[33S&DRDJDQ01U`_->I4UJVA5+&\DD$DC`5\$2DF7^R,
M5DY8@,$.;I3PRJ(UW=\"<@)*5B<*!0.!%(BT_HJ;:$0PRH1(>`?!K@9!)%(V
MS6'$D2P9>QKI)`K_D'(T3D5-(@24).]6'P`ZO=M:@-[<:H`[#T4T18<&WT5K
M\(=T">(#L91-?%&?-(<F'<`$R)B:]&Y?+,HYIY5J2XL8G>-+8,AMU/`H#3,C
M;:#:1G6:C(M/'&`.9R?,:DY8E*P3LVV+<)HB%?,B78BP[.F`\%#G;8S\#$W_
MFF.ZU$0X4@Q>+:[.*0;N1$QI#FY47M8D:T7MK%X&-'-._*M%3W)VZ.,DX]#I
M,49!D84@XHF23"U'#D;W.)IGUD\XU>VX_+*KD(?)Y:S5.LIZ8IQS$@7N$44'
MO!?BA4L?%87GQ(1I_H]?J6)-BOTKSLP.%"O,HF`P8Q&.Q*J&BJ]X0=-<FB'0
M=7$,;Z?V)6Y46T12:'#```2%!2AT=QQ.8EPFYRE.4(?=[B@:QD&61UF1F9Q9
M)[7%S'B)5=P)<GSL&#4F!#AGQ+[7G4!S@&M`,Y6)6D'`QOE$XGWG!Z`'/X*(
MJYI-2=1XWS&YF3R`3GW@K)VVB70BK\[KM,261T>,=(F;@"2%T#SB31\B/T<>
MK77.AT`(3`1`!T1%HN9R!5$%]6V;?AF0"^&MNK3NC*_++U_-IWN-0G/%;1F`
M!J3._*$33BRUW%P`SGP3!RBI3)AC4`O``F6,I>SYXD*N<5YW!<+$1M32_KOE
M[.T(N_Q4C,90SXR(#JP11@X7*+%T$J>MS$?A\6CL4Y:\1`4@1"U!R//M4C?3
M5JZ%]3$=XF9@'AK5B+9(C5850+60U+"Z3'8DJ/E$0&1(&F#K1#3-G5D(@&0Y
MM4]0$0*0^6"L*SDQU>SHC.+-A1@%XLLJC`*4*J<']2[]%<?L]JA31G[+Q.A%
MWEXE!TBV>D];2QA%1L>=R!]G\UPYRMT$#6&X"4+1^<;*A!1!`,3]>O*<[-8D
MTTEI1:[/2&1<%P4T`*!L0'XPX\`,12[SO`5DTV2`1T3>B+!V"%@40&.^3%P`
M+JQK$UNEL5B$Q@2M"VT5T)D,G"3Y]FJ*!K\%_@\3WBPPXU""ME`B;JTF$400
M,4S":,"64#-T;M'&/W(T_]-CQ63@LP^:3]*^J\OK.-7I^<XY>\`K.C,'J)2O
M.%H<D0ZLLPK@2L;J1<0UE^)K*7G1#V?)_F0H/H`#8*Z)-%Z<+6Y'N)%WFN>'
MT&>:J^B*;6UT81Q1?7#65Z'Y-L5IX@<[LE)$.YZZ6("LD(8$_&1<>&G$ZX2S
M#(8(%<"+"P6-]`D0W3-9M3++L-7J%2S(`<MKJTD&C+09'G[8&D!5/*WZNXP4
MP4B'<6Q1A*O<F!;_3`9=:%Y0.T^K`<2%#P,)*G@@(`$&@@0[("!0X8.'#!@\
M$)P`8<-"@AP:/-0X_A`#@@(</FY0(.#!QP\<+!1@4%&CAPH'&L#\L&!@AXXI
M/W:0,$""!PD#*S#XT$$``X$4C'+P@.$```(45':`0(!!AX\>+@P0J#("``%:
M(Z@T>_8CA@(V-698$`!```49'6#0>M9@Q`,:")!$JY*!@``9-':8\,$"!`@&
MV"[,8/0#A@0"!"!0N#'C7\T>%'PXT%AS:-&C2:N$,+1T:M4?#&0@D'EU;-FS
M!UH0``#```(##!0HT/MW`0#!"R3PW=NX@@(\:6_U$,'FY8$>"C2WGAH!S`L%
M&A#^N$"!](43#`@X0!3W2Z@`S!X\</AC`P460,^D`)N@!PH&$H!>B2`!_@LT
MPJFE!310J2L%#DSL@PD<L&J`!(@:*:<%!AC@+HTN0``!_`C:(`$#OM*H`@<(
M```^R*X;R`'XS-J`@@&D0H`!D2;PSP,"`M`@I`PD5.D!JLQ"X`(%&O@@@0.$
MS$DH\32*P+N!.*```@$*0."!#2000`$*_%(M@_/&6I',YG@LL[D.!LC`@"71
M?+,Y#C300`+%[+1SS@SN5.P!`QJX4T`T.SAP(?KR@P#.1*<C2((*ZE-@`)4V
M.(@"&O6Z@((`"K@-`#<_R``!!2W`::&0LDJK3T(UVF^`0#^Z(($(OI02@@8*
M\'"@#2*PC"`'*L@`H04<H("P#@CP#L0)-HA4_J,-)B!2)0\F(."!#!E2`(((
M=+2V3`WZ^XLC!!8@8($&%C``HYB*NXD!"%S4"($H->+`@`<(D.^`!`*HB((*
MM/(`I@?6RB^!68_"8`,-(IBL-P;*(\!5TJ#Z0`#_%+T88]HX$,!'7#/^&&0R
M?3ISH`ML\L"`T?P-^:\+*H!()8X6@*"SA0P[P`&G=OR@`@4JT,``#L"3:H,&
M')!``@8D^/=+#!Q@X%TI)3`(5PXR:"`";FL+-6(IF8)`588<4,`!MG*N%($#
M#)#@*Y+T.X`!DAH840,'%F#`R946=D#>@32`X&4-+"!@X$0/T#IF"2R\%8,'
MXFYZ;@\2V&`!@S>R_A@"!`"8>P"*!@!1`?XVD.YOF^C]B((_]<M@2@@<Q@V!
M"AYH(.^S-)@K`,19AO,!1'?_JX-;;_V=^.)3$]`F"JPE-;0"PB:^1AGC2G<A
M"1+PSO>M&[@KQP--G*!GUF3T&3?<UO*@Z($R<*"`K@>:@#NM.8`?YE<'^*RG
M2B7P&(,!:E[(`Q:(P%YJ$R(!@,UI#FA``(Z$@<YHJ0!1FXX$","KCTB`.Q7)
M`.Q6TK<5S6TTTCI`!!YP``GTCP%Q(X`!.I"!"&P`?Z4A4FNPM9(`A&HEL:K.
M!TRFD0D<224M`@!&!JB\"S"```)8@+)&TP&%5,QXBL*`!Z-XE->\IHI9_GQ5
M%2?GMW<I130`BZ*:<I.`$,4E``G!P`3L0A#?<:8`(QI(`@8`EP4$+P(7,`!N
M1@>`/48@`"$Q@`8X`$@%6,XS"I`C0<+$@.>ISP"M`8T'.$1%#2Q@`1O0&@8(
MT$4`!@\N`[A/!V""DQ*Z[U,+.``JA;9*1N'&`1_H'9PN@)HF*@``^9K*!>*"
M&YKU3D4A+$L#8K26!L@H(QPH0`2JLX$`&(P!GB**77:D@`2T*#\=$)C$Q&0Q
M+7YS11L0``8"X#%P$N^1NY,):MB2@?^=TRPG8HY5$E`^`(!Q(&4Y(@2LE1&`
M_>PM">B``D`%@`CH!@"Q?(!4%A`7+'XD`Q$T_HL#.M>>`/`S9@2P)0!Y6*VM
M9`YQS_EA`BA0@`#4JR)*BHA*MK31A3P@`F4IU`#&\I1$N5,U)O&3OJ0W+'T!
MH$.+-(O3%O"5BM`+EZ-2'P...5``S,H#![`<)C\EH9,D0(+!E-27-H``BGD3
MGJG)`%B)MP$"?&!X88UB]G[7`0Y@``,7Z,#8_&8WYJFU>KB)F'YZ5RO!^*E/
MD8P:!7`#%\#9I`(!"``#'/`9`R@D`P/00#0K8#D--"!V6[$`V=)9`0M1T0+X
MA&BH)MDG!C#G0P]8P%`.X)T.5``")@5`[9@Y%Y;2"%<+/0\GR2H;6,6&`Q+H
MR(D"X(`+W'$`#A`8_KE,9C%RJ?*&#W#*IS)"`8,HZ42X`2)!+K!8"%#D`QM@
MP``J4BL.&&F<A?'J680V``34)21?Q2MMI`O/#53GH?/]'5NK"#8/Q'8"B,2K
M!(#JF"[-"WX`4*1*QJ4L"S@``0B)0`4VI!"H)`"+!Q%`V5C:IJV45`&@Z<!F
M%:02#3P``5KS`"E78F(%3"`#VM0()^/VJ;-N!&8>I-PA5>+`;WV$`S*2J:)^
M.QO"W.H!`XC`8A;"E`#@S&";+55C@2H!OV3``AS8&*<,%@&CX1(A%H`?<FLI
MH$<J53.Z4H".$MO;V7#X=]VQ+P%R9$[]8HR_UW%S3K12V4/25)IG<6(6_C4'
M&6T20*A2NH#EI(4`@VGI`#1%D=LN<"!Z-<!C%J@DD-.FO)X8P"/1!*"](,#H
MR4BPH\LD2OV.F&6"4&`H7$F`!%!9M*2(F"]9LJA!/^"`=%['1]9QF`4:,('9
M`=D"!RA`E[3\`0H$&@,14$``%B`=#_#HN*@C%`9ZQB48;R0"^_&0:$/#20O<
ML-1[3DVB/Z8!=2OJ`:HR*P8`8.<[)\H#VQ79:/AV%P@XH&"DZ8"]02:<H;AF
MP6F)I:3J^<[(+"TG8[LA!0!V@0<D6IOMZS$!A@S`@XZ(`JJ2C(%4XJ,&,+H#
M^?K2"8^BK8Y_@'8R,9+6!HX`VDF*XV8I$@?@_A(`1U%Q11?0]VQ*"H#M!-IO
M=)01!7*F$0NX2@,]4^4#8KPH`$JS`])^LI5E28`0`_`\I*F`5P?0@`6Z1,"Q
MH<Z[R<3U*A+R0WNI][U9)A/C]5DA&Q!S:0*817+>4Y6/G)("$/#(J[5+`!%3
M4_N<5=3P8H`!:DNH!JQE&'*!YG86=+JX7.6LB(2V7EN)-@)<&A$8O1"`%+&`
M&3V(-0-(%<@5H)*D>+3BJKC.`AO`#4ZPK"@)H#HVE^2D[MK"`66/T-TWH0H'
M('``DVF`2H2/E06L52*S6*U$=P,<!F:U@91)K&`_XI%\%`"UG]&F*,5+P*^-
M9U9G$ISN99(Q\3B@_A4YA[OTX!I3%*.2R]IY8`%D124JH``NX\?"ZP!N+`$@
M(`#H;`(8H``J8`,>HP`(QZT@H.P>*>NHI<<48`'JIS9\3942C25(+UKT!5?"
MA#]JAY-(SC2N)YY@!VPTHOE00YP`8"@@+E$Z!'C2KB3^Y/M$XX6>13<(3R&4
MY@$FYS8T#OI`+5X&X@-+3@`H[/42!@)/2M>"I#3&3C*V(@-FPDJ@A/C^@GI^
MIR_@B0->0P#@+_Y6A`.T*F3^K0$JH'$D@`+83=!`L*QD!`+\HZ10[9(J1WUD
MJ@/``P(DA`/J(C=X[@!<B2`XJ0',(]$H@%H8S40"K4HVQP\+8.%BPE$D_M#$
M:$=K)L4`4"GC$&G$&&!F[$4LBN,!7L;3:D,X#H3M4B.JR&J-1J,!5N_EYL5Y
M:F/(!J4"W.L@FC"\(NI=^N<R(":>.B`!9@8V-B"V%BL`4`DM9N("Z(R]-D0`
M"$"E2$.\C*<FX(DS-H@-V_`Z]#!DW*H`%N`!%$`Y:I'0<$,=BZ0`/"@1`^`!
M$`LB4H[B+@!1]&2AI*(/OVTA'"!;5*Q*;N0C*L",$$EH0BY:3`2T:DA2U$;G
M.$[C9BP!,`U!ND1$IJ/QX$(J,$!5%DH;+X8"@&\U<F0"!L`'M0DFS"XF'N0!
M-*4;"0/-%D*@$-`_.H`Q+D0=GT(!8F@TFJ\K_GJ+`RZ@L4`-2D)#`X#N8QQM
MSL3)!]'1#>_J=_R%).8'*X\B0`9I(>AD%T?1YKJF`@0@DGC"`@BC:)(HR2KB
MG9QFO3R1;/*&*7VF)TI$`'IQ)0X1HV:,`10@*%!%7+021AJ``5BG\,8R"?,F
M@,:&,!SO0VIIR18``?PG`EY2P3"&+]A/T48#5!R(-#;$3_)(RPX#ABJ`6B!%
M+L(-)BY+2O"&I5(BN![D0_S"($DC`A8`6-XMV@`N<WQ%P!+">*`E8]0-1#B@
M+K\R480FB[3"`O!POJ*--?Q"<@B@#R%J`6RO,#`):3:E3;0"*#VB8BK@^XKD
M)H<N,FPN;[H*.=LB_@$80,P>"7X@8*PT@DXXL"<@<!]!\1$]T#LHX$?"JT96
M)B;6+'MNCB"6K#!8,2YJITS>$"7L++A&`WQ(BN\R0`(0(`#,`_72LBR\)0,J
MI0"2BP.H+I^$(RFHCR`&B3#H)9W*<#0PP$`<KC2L(L+:9Y&RX^X^Y@&L45+N
M,0B=$TZ@TW@>0#H"#"OIL,CH91][(A)120)";SI\PD,%`]$&@@($(P+XXEB"
M1UY@Z%B`I+A`PT=,Z"@*P%I6CTU5(E/N*']0`B8"[B@VK5<@`D:TTS\"PU$6
MXE<^`)#R[P.FQE_&L$Q,PN?,(OE$(Y,V4C5\8C+DXCYJ`S:>@D`53"'6_B)%
M)]7Y/N!`:&:%S`+I_J*$BFPV.H!`ZZ@G0?7N#E!1WLWX7$,>C70TSJMX)&=*
M$,``YN,JPRI+$D`@Q`O5X"<^":8`0<-!8.TVN@1]/$"9+D,"PNY]]+%/&=2'
M&$@[7(0ST,4_Q,5B)D``$.DGX/`\+"!"$*G8%JTD'((`:F?LH&,A].YCS$H=
M/X#<T((Y@;(Y`HA`3ZK:;F\!?LI5)&(!3M17\BV3S$(K1<,!\JA`^_6(/G36
MHNA/S\FL@,96;ZHYZ\Y1+FY2*@TKA;6"R*7'WO&1GD-<M&8F(.._./1<O+%5
M[D+V6HXFJD+3&%(P?70CM$(:6XM13V4K(H"%_@I#[VS4?3Q@`*ZDUJ0%Z-BD
M=OXF`ALD2J(.9+K*2290-(.$/6DC`Y:+;`+5V6#F$.^50\THW')O*T#S+.P&
M5<G$`M[Q&?-HX&IU-0K1;A,E8XMT8\E$(HH'^AHD(UR&.L.*.L2B4MNB..Y5
M`@+`+[N*K2Q`2#K@*T8%(0+#N@B@Z6*"F>150PR``5*0`B(-U>8*Z+C"!4D$
M`%JU,,I/YZ;-D@@//+;BF%QD>WH%41/5(PA"147#2^(H4:*MGCKI<P8B)3=/
M.FOI`"ICPF""9V7H3R(63D9%.""@5,M$/_(63B"/3?KV3=[PF[@/*X$%1;:B
M$/-/`_#49C*G:QY@_@(HC[_TK@'$`@$,A2-YL"TPJW:"!R5H;NQP,R9.-5J:
MCXJRSD/[9L5*JKYBHJOJBUDFR.OP`S_`*V3TZ"Y2CFT7HG)V)B;\U@*FE0"T
M@B_,(FEZ+0"^8E).HATA``#D\6DVY$VD$:),(G>M@]Y^=7<LS@+XUGNM@R.*
M9]#$-X"T-S6F2S8<(#<:(Z*D=X+*3FM<(V@^8B"G`C28\B=?<COU<SD0)Z((
M%2C5]".\I0'2Z7;69B\M@T%\""OX!UV^I,0"R!L-)@-@@\5V!X0>;S1@2!6!
M3$)71'!T[E<NY``00%E@PFE`=S4>]A"_UR_7\0S/*0(DH'M[F$Q^^'>$_F(M
M:JP#7B*,B!@QSM$L**DS-^)<8C$_W"D\8D)'*6Y>-BLQ",`;#>"%$@;N>H)-
M/"D_'&A+&5B5\L\G^'->!,9S%X+Y#F`H*<<`I)$>3YE)MZ)1/&4"%"0!GE"*
M725UUW'A]DXT8*M^?X>)5&*,>0:3QJ:"E,4ILB:1(YF)K0.`4Z..FT-(C2<"
M?(V'*3E548ME-H`M2&G/+*Z*.``WC.I@AYD@-"`!4[8H/6K&-,I:L*]\'L)#
MU()&<P+#>J@M0#<#%*8PU*:9`:A&O*0D"L"84XJ852D_)Z"P#"!4+@!79*U:
M0$/W.,:R($55./EW&I.@_V)[]H]E`@-=\&.@_D[F0THT;00@@R<J:1IY-CC@
M7D,#CB9Z-1X9G(A68^WY.F#MFWZOAH]BJQ5E@V9+/SH2<4J*E?7S/22%5]-I
MD\&F9^)"3:VBQEZ%XU3,1`(E`Z+$`]A'`%$G?CY*DK_D^_*Z`&V&`"9`@(3C
MR:#$)I@)XU8O+0U&)Y*(>6"D>![`N/#Y+PX'#C,&*`]11M#E0"XI?9D/7C?;
M8;T,1YLC<]3.1J-+!XM8JK_)R_;#JJ]#`C"[>#;`B.D.ES['0K(X/T;73N<U
MMBAX(3!0$#^"L?,C*BEJ-XPNC),DG4H*?S_%.W9X/EQL*GH,*D!P4)Q-I)]G
MLC#@L0;E,0S@?AQ`_KGRL\<";NP<@R94-4J0IGB8$@.Z=J@08&&Z>D4<,B?^
MQF&\SDLP*+89A24UXV$;8)UG(Z^/^B\V@"^3BU#_HF&S*)+)N[9M&+?;C2U.
MJPU3+BY$VG+69XGX^`"NV6^(%A^CK36V0AJOJ3<($V$FL%%&',5T=EXG`*NJ
M@D`#DY@IT8,NJ5+N=5I0_"AN4D820K<7PJ)Y5T\/44A@<"`2;BL[T7=)$BA`
MV3H4H!<#*/(Z4FP_(HH%;<F#*`.B&7LG@+^!1U>HDC2,SY/+)`*F<\,SO#0"
MEW@N(&*$9LV-AY<,2HP<@YAJ9SOD]#O?%30.2E;JXUZP$UIGXD-Y;5YZ_J;)
M-R)6W,YFR"-T@0RS[-=F,`OI&E=W=+S^@BMT%NL"+@#V8J(!T%MG<74Z8)5E
MG$:LD"8"!*#LXCF<*MQFXC:2B"E#K.(O=!PA//(@*<BTO=>%PBH",$`Q[)PV
M-$#+,::/PPJ)R>LCIF73/P(#9[2X/`B*:Z=H%K8D%F`Z]46)]!2#S$E@?@U^
MU@]!EN,G?4/$H*1#58+8&C67^R^7@J+90%6'N$I5P#<T1JS:5\.L^IPAM@2H
M`!1.*F#"(^.-"%0PE,19(IXA=+R39K#78`7C;=62(5EIJ!7:5V,"E!ICW&K&
MVC`JX)#PTBDDGE=LIC8F]`7.-$1S$2<2ZT<F_I#8`!3+8SAT'(&,CNYUH"JJ
M)Q8'LW]"JA1</VM$YR@.8.X;C6;YY%;"W&/#1F\#V\FDQ65C2NI)R>)<)0I<
M(V@2@#C40P&@J4/Y`9/D7+SLP%4CJJ;=.@YV@;F4V>NDGDM^-&J9>(B%(;J3
M[CP`-Y;DOPH@_]RI31I#(K""6_3#':D(`#L%3K'B^LBYRMP&,8QRU*@<@%H"
MQ\>#$Y\"/V2"/@=B%_,CR:P\/VRE:V3BUAN0F)Y-.-JDK.TNE(6N-R"@2'A=
M-KH*V-YBE_T6^$MFPJ^M5L6L`A%"(,A^I>K.NDIH`:B$Y+^I+H[-[U=#9',[
M(V#,?:%?BL2"N_0;_E?JQC(</[8,G<FY0]QIQ&78XBD,X'U9RJ8?+W,C*6L`
MIE$+,4``PL.'@00[.#!`(0-!@AX>++"P8>`%#A(K:+A`4`,"@10H6,!`<>&'
M"PT6*!0Y$,,$"@,6+&"@((`!!P$`'!A@($,'!2(W4&A@0,"""1H(*HB(,JE2
MI0T<+'WZE,.#``,:A(2*E2`&`1,L"$RJH.A2"%F?.MB0@`""`0@B8"P+-ZY<
MJ!LP5&@0X``$KW/[PG4+(8+?P80+]Y5@P;#B#QMV`KBZU,/7Q8,I`"CP08,"
M!$A%4B`0H0-*C0(HH/1@X<!)D1X@#*CPH0-FAC]AH^2PX("$R0P;,&`P_F``
M@.`'-&!(\$#T[04.Q(K,,-.YYH$4`@A>B`&!A@<"$B>%0&""TN,U<R[L$`$X
M@`0<>'_@0"$F@@>K%Q*`K-B#`>^4!V9@@$!XG176`01!&<#`!+SIIUQ2&SSP
ME'M)+;#!`>)U8,$#!1S00`4-RA4!?_T-%H$$#`A@@`8?C@AB!@_PQ&*,,D(E
M@6DSPL5!!APH<(&$*!W@XXU*&0"`=0,PL&)L#BB0Y`<9$-"`<P7%)&5&!!B`
MP4`>2)!1`01(V,$%,TF8`5D+74!!`@"L&4"6WP'`95(2#!!G1A=L@$`!^'U`
M@0`!L)=4@0KL&5L'&:`H8FP4*!?!`%0ER,$%_@@(($`#)WF`@909),"B;`..
MZ,$"`03@`*&5-3```0],Q)A32[GUE`1-+L09`N(MY.("!2"@0`5!*O5`E4+2
MI2!U"?P9Y:_#?M``!A!`N&RT(TKPEK10=66M800,1Q]*'6CH(4H;*!#6:1(4
M4.YY&C"@ZF0=>-#!!@SL5]]`&AQ0@)L,P6<`C")U0(``P0VU07L#=8"<O@QE
M8,%U*%6@5U(>*&"!L.]!4$`"GW[@P00&0*!``@M68`"@&1TG```"1/"I`WZ2
MA<&6MO7WV;#D$<#`HOU=D(#`!SRPP:\.)#J7=@/<>AL&[!YP0*FS3IDM70IG
MAH$#:AUP00=:9\L`_@8.10VV7Q:%/19D&T#@*T$95$OV0$02[<%!%B3)`0,:
M)T5!`:6B9($!^Z$4&`$'8)`D6@4(VT$#X>WI<0$+O-M!U0D44(#?#C2Y@=\;
M=]RKL*WMFA0'XTZP\0?IJ:3J0ENBVV"&"\&G)VL"7``=!`'D73IA%2(]8\P:
M1%`3`J8.Q@%\[.*<-6N<%D:`!0-8S%H&#E3>JZD5^-LV03DJY4&.#1Q```$0
M0!]C`BZ:F7WZ2CT==D<->B```UXN`(&RV7(7P(H<I%5ZHTB>EINT>>9P$D,`
M`I*'D@F(CTQZ*5T&,/"?F6D/`FD1P`,FT*!O,:!T:#F*@YKV``:,YF/`_L(2
M8PI@HY04H`$I'(@%B):F%56,,5?2P`"&UQ<.D-!:/PD.`]A&F0ZDB0`#2`"K
M/C`!]`V&,T>+RP8@=H"9)$HRZCM/5C0P@1.ML(4R4LT#N%C%*D:@7MG2`/U6
M$QJ&B+`#"+`:T<BV```T0'5BVN!H)$`Q]W`@.Q20D.0(M0$''(!0_]E;`@D@
MP-<ICB(!J%+5#D8!OQWI@1D(%VLBL$()>2`""-C-`R3(+`3$[#9X=),"YDB0
M!Q@`B`-A4E(8L)N"8`<C4S.,!GJ6R&@E+F40R)UAPL0N`20`+[SS"P$VT,2Y
M8$J0N[((!]CW`0A"L`)?S(`$/GE-!SS@`0Z@_ATTH9*FN'`@BU=:%0X)`P%G
M*3&,5>01V5"#`9Z)ID!7X<"&-C!'"+`2C@=8@%86@``R/H@`.A.)!@30O*2X
MK#E)>0"4B-:!$Z7Q.7:K9<?$AY0!+*0"%%C`GBY0@#4-X`&C5%L"TB62U"Q`
M+`EPSO5DE90*+$`!7]&``[Z2G0;XR"Y*V4`!(O`5QV%@J`+A@#`=0(%SQ@4!
M?_+EC#(0@9<YE4`7@``"3$:8^W"E,!B(0$P$@("G=:!(1#(`T\Z*5J8)!P"@
ME(L#UED6#'FU<@X@8V&Z]@"XLC-[&K"?D#Q0%(I,3$H.``D&@F.^*E[`HS<E
M"0)R.9`)+""IMU&`_DF2Q$D);$Q>"D@G?C80@010]CD*4(VYVG(5",Q1*LA)
M$J9BLX$-6,"J9EU`22@D(0TT@'09,0"\,$84;\E4`E?I@`$H,H%5O3$#"A#*
M4G"SD=@\8$T`8))H+2`!!#"M`4VI)8YBZS$P+HL#$CA`_*:J/MEPX#6&Z2,'
M(&`BVTJ`C&OKGOV$:(!O/B6V!-(`!:S:%@021CN%W:N!V?E`A@A@(`Z`&!LI
M]0`+[#-:%EC)K@)03((@=$\>H,#0DM2!FWAW3I?[0`40L!#G/>XT#J"3A#C`
MJT^M%`,!N`^P!NDM!U#7`!@4R0(&4*\)%,!`)7ZE:3?:RPE8*"F:*<#<_I3E
M@09$UW27>:;(]B79E`FS`N@526<'HL,)+XL\%O2K7"Q`J5YU>2D(^\``]!LK
M@KRE`Q/0[@(04Q`4APXE+66G!S+0`$HMP+MPH=`"Q'S@1,]H8A@1S44F(Y;'
M#:`Q'JBJF@0``;L*R5(5&$"111+58OW+``_P400,`%240`>K5.38B?8Y,9V"
M)0!V16@!@I:4#/`J2`GY\XD"(,JL:2`#$IIN`MY8H`68F@/<E5@$PN,!9"K5
M)5K20$1NR;T*S*E(%B+T:29#8Z7>"`.B(FA_)-``"R3``'D9=%]"##\X1T9+
M8.SJ`!QVYZ386"NN,G#W)""``YPTU7$QB0(<_J;HA"\KVA&@0`24?1K388``
M[Z,``XJ4@`GT:%D,Z/`^A=QQ;SDTP]%,0$!O(S_Q>N!8_^M)`]@CH0OTDV,+
M45%J*.#=#.2F3BE.P`$^!%@UK6FRGS)(DSIPE_GFNH@><L_*:<J0LCC`GS4G
MN>K@\^,B=8CF94F3F6]D3P`05-Q8V9'V/"PX+CM1`,B4-U08QCU<%4!_!#A/
M<=@LX3]S5.T94,AKM4*!"AAL:QRH`"VCR1`A&EYB_V[N`2+@;9$,3@'B5;CE
M*;,!OQ>L`SB,-D'Z_9X,2#:*E$?T794\-=PDP*)U%OQH'%!8]SS(B'O")PHE
MA,^?[2D[75-H`6Z7_A1UISMT"F"`7<.T@6%7@`$RZ1!40<<:C$G`NQ<@0(VR
MCI/=>@!)4D(;7#RFKS[C2"4+"-@!%$"?R8Q-)&]5GP8DH+($^.KK!910!-B$
MKH<HJ\T#>&-?0%(6H242TX=DSW4EZW8``,``@@<<P9$!=/(!.0$`"'!HG00!
M/P16```\'1``'B4`FP(3OH45&E`!-*%I!5$`.D<^E\>"_1$T9N9_T00@,I%.
M;I<5%P<`4B)D;15-.($X$@`:$F(!!(!59U)\9+1)E(.$#L6#.[);DR82'/!L
M^Y0X+G8:%-!)JK96;'(5DI$`XF=0\@<9&J!NU#4`63,9$$!V+F1N%1)W_EB!
M`1;G*`60("7U+T!21=:4@`!P4X/1`)UQ-B?%`!<T`>E1.2:Q/ISR/(L!+5FA
M']4R6,IA$$_1`:4A$2(4&YB!%LZ#$1V7/P-17MN45TYB3Q%XA@.``:C$(AQ0
M=RO5@J^8'\_T'!<@0AJP@ED1)@\P*2QD@TNQ+0"0$0Z0`$T26K+X+R<%1JAQ
M=[>1-V^T?;?F(`QP:`VU0GNABBEA`(BH:C_3)!S0-*XE<Q(61P#@'1/CBG@S
M9(1R8KZQ5A8B&FM($!4@`+_3B")QC5D!:,$!``@"55BE`"<(-INT)EA"?PL1
M7`7R)[3F)`85/SV%8@50D$NQ'7%Q'/$H4@C`_@!-`16+Q1X38$%\@HE[`84-
MP(%0&!,`$!_ZXA0](W80D$X2P(.%X4_G"(LUV1<Z5R=GPR<HED4P]CV]-!@;
M(&0#H!<1B1+W!P!UH0`$@(2&0I(L5@`9AAH(`B:HP@![@AYC<ALN@W`$D29'
M\1&/]4]G&#H@)5Y5@T*AHS=J,TD?\$EJ&"@O!TC.<B9`P6V5]W9>4H^J,Q@7
MH`".LB:8.!)ZU38=TP`A=0!\X41710`8-A(8HE$&F8-*`1T?0'&*D0%XJ11P
MB41I,7DJ`P$]MA1W<I@*,7$#L1?1E4Z()!H)0HX$T&@?0!9'`3X:L0'E9Y1+
M434?F"(VZ9MSL2)=_A-P'W!^!B(^=65%<R%;TL@\:Z)=$B`L&/`QQ8,2+R*:
MN,(K8%0@J$8H?HES$H(QF99`MI48?^8!;R9$O&(QF_1X3*8`!F!)%F`;.G<`
M;;5)/T1("H!4>V(!#7`!5$AY#W!O1HDGD5<8%D`5(K*7[$2+`E``#["&'O!X
M7765H"B8<3,JII(!@X2'AM&568$!4*<Z:(,!$I``>D5N=A-:>@$;O]$ST,%"
M5TE0$9$S&)8WJ"*@\+,77^(X!Z!GBR%$S<,K8]2+O]F"4T,!:#&,`^`G)-@Q
MO%%1$"$7CT08\@,`WC4Q*9@4?GE<I\$N]<,:+;9B*"$IG!%\""!K%&5$_FH3
M4!\3/G;U3-H5.@OU(;+5$/WG(*=4.E%&(5L:`23H(.,C$.>)DOY&;*"F<!L`
M</$#D%JRE(,*`0(@$`A@([=Y<1_*IMCV2W4W%\<F$A,`>CWU8T<120+`$_MS
M)9EA``6`$9-C`&?3`1J`7)^T?1\P7QW3*H9$&=[X`<.D(1\#`45JI#-B`973
M<<6:C<8740.":\E)$(%D7`T``0L@`+!W6"LB?RH#(7!6`5875Y.BI2)1`:V5
M%*$%4ST!4!NS+KV">R\2`5C)'7\H+B=J4!6``?LX-TEQ6$A2.*16+Q&E2K'#
M&FD22ZQQ+GV($D!X`*4#</+*)VMRBV"#<R@1_G(*5S<"`Y1*@1OEU4>J!0!:
M`P`3,3UF-%E+D41F9QC?TQ<R-1DKMV8?8C!:`H]@4XJ]"5CA-:R4X7F5L8!Z
MLB04<`#2B!<?PC)8T2,S=0%#V"&1"AGD]EZ;TFD$$*JO%+%/<0%K$A,UYP#^
MR60FER2`MF^@9AU*47U/R3=Z@Y5?R$K&@1RELRZ)23<0\T:W>6\K@BGK5CH8
M$$4$=QY;2RB2(T%E%4:%B)JL9*#LA$\!4*U-T@`\X3$P=GYNR8<>DQ@&P'.J
M-D8_BD[""H8-(Q>'ZAG\$2\#\6PD1US64HI@F+,C`C"$D1"RJ7-G(3(QT949
M^ZQ(HQ%7)K,F"IN`_N-5C9MQC8L5.#88&1`\2+&N&]<3(R&5!F(!>X*%9[&E
M\U$Z)%.T/2%(EJ0ZTO@8K[<`VJM&1O2U+590-==&H*NUA_9BV@%(PJB88+8M
M,1@UT)F)&[.@A`$O0@(?`@,T"_$3`J$!LT%S3Z1;HI$!$&FUO80]@U&QR@F-
MZ[5F\2@!Y4<!;Y$`<:*HG-(!WZNY]N*8TJ)#$5BUJYM#A%&T%>`BB&)B8!1<
MJ:0PW=-'_Z)-DW$GQ$E$)C%W\#&\N2EG:\(I4L$K'"8!!D"V)TJ,J,AD!U$Z
M;'1,6XH@K@6$=O,E"_$@BZ>O;>0C"&H5MW&8^W0O$.<M+S$KKM&L-:<R_C-[
M(U^1-PH%*LN"=(IK0ILR&62D;E_A&S22:51'&*,[&%_3%L4KH!GH)I;A6P<L
MH",A86Z2EB`\1\M8%H?%(SQ,PEE!+6XY+MR4&!SU,`OR+U_G4"G#``X`>9R2
M'5"!LGVY)H@D.&^T32W\.@8"IBE%:HBS`$]<KFB#>^`A:F<R``:B(4I4-\(3
M*$P%6>]QHOLDC\'R':3B(R1#,1OC/,2+$@JPCUF1.0L08<N2<1/RFZ!5$RD#
M>A4@(A(0`$AA&?+[`0VCJ83!`2/,/2\W`)*L)8:"`!@3,DW::3JF:]2%$91J
M+2?V`:SZN776$A,UR2F&3J-"<5%I`2B6S9Y!_A%HXAF+DEA9T1%)JD-BK)]0
M0:6$D3)B5\P?D)%-:'V!4F=("!XD)80CU203$`"G.\WN-C==&DUJP77BF@#7
M^SH/<``QK$\9\2+[))VJ"]2K-Q)L\R`(H;$3,)!9$5I_623&MV@AJVKW^XJ_
MHX$?<H':LTI&\7,TDKF&(8*$<;41C!73]V<]0P`*T%4?X$\O^!4)8BW,19SN
MS!H6P`!1%'AF?7EZW!?^15E($1$^`E)4H6EKTQ<7<"X%<#0`>4V%(2GR0S</
MAZFW20">$TD,$)U'4A3@FRL\"#'=DK"Z<3`3,4<=M76W855#<QJZ&,LF=C!2
M-@&[)V7+I8OBM5@%_L"#K?$S:W6Y2E%D%5`!TXHS#N#*06DF`5RNF%J346E0
M1#P28-@G2E4FFV(88#Q@\FR/C@,4F:):Y"(`>[*FTD+7O4D@)E(Y%]1JOZD?
MB@'8$R`!\7W1\[TH.?(K`'C75S0W#O#;"[%;A0&$\8$2Q^'(M&'4K`%=2;(N
M^05FZ%,@`FM0"A"N!E7+Q;5'4&*)I]%!S7RBFJ2W^<H:)*-R[(*IJ$$QW9EQ
M%+&'IO<>]RAGG-2!I".LXNF6<+5RPGIY@U(!P,<Q?>+7)HLE'3P7[V<8ITP9
M=H4:41<VO+K`AL$P,;'6??6;+)X5O"*-5W[E+Y$;1Z+EZ!R%R[,8'E48_AIW
M/:]C-:"=`+J:9Q"($D"QQ6"6)4A'A%@9:$UH7ET9`5E$*J6S/V/K+2>2IMA1
M.=Z%`1N2<^MF,38TU@9U(F+!@6N"7K`7.B<!'PD@'*L4LV6A`+="U2(A)MJ=
M<!@#`.CC`3M^N.D\.$(N%\I;&$WN%]:47/S]`!(`W[1NZX*D%B:'D04[++PJ
MS"QB3=3Z4_C]BH(Y&+(1<:>!QN_!UU#1<H,!DWUS,!/GL-N[5:HFM2#V(BAQ
M%BPQX:]3R]6K-[GU;$@.M*['&C*'I9@$O@<C2-ZUX%@Z/>(E1)AV%26:D5BA
M'W#S,^]1(J+!,RF#(+(*HE\1``T5DR1,8[QN_JL_OA02D$ZJ'A?G6A@27S1!
MVQ)2MD+<Q?%-T9\<?Q,:&"TP]@%A)21/A`!R1.P'S6;&SB=4IUMQGH":F;\%
M@2D)WQ>$&1<.=Z^&XJ,D9P$*0/%:$0%+QAH>(Z+^;58&_:S9%>AJXQMY.R]"
M/DX&8"FY!E#"0E[GU])#YB"!UX0\K>8F-?:"D85YZ2,!Q6P3L,W3WE%K`4M2
MKA2WDAH/P^`G3S:NHSHGEQ4/T"P6#Z)>7A8.WQ?GZ2TA@44"T55L$V4E(\IV
MR"+R$M!V31@D."]W1A2@OFC]+1?KQ1M,_8ZD?0$30+A+@=AJ0_E.;1@;4"DV
M(=`HD=FN)9U,[Q\&_O#K*:9-Z,L0+>9=ELJ#%M<F:>X9;7MC>?MX3:*WPW@:
MG>;B`U$!44E(YP=1(F/>3Q$!A"D\V\2\L7'@8(;7I$*9<1(EJE8YFI]H__@O
MK@XL;F'592%ZBE&1AN$!'<S\F=%/0!4@!R`29)$C!D(R`/%`PP>"!0T>1)B0
MH`8&'Q1X4!A1XL2#&R`0*(``PP:*'3U^_&`!I$(.#0\&@/AA`D>"$R1(Q(#P
M`H61$S.\K(F0`````Q%V4'!`Y$$/%Q[01+A!@8$*'0YV@'!@P5"#'B(48.#3
M(`<)`QQP0&CA@8,+##P(+9CA08$*"35,N+#!Z4$."PH@/5C!@(`(<PMZ_J!P
M`$&&A!D6'"",4,."`192'K3@P$*!C@G\;FWPX0"$#Q$F:`9`U2"$!PHOQ/RP
M0*$'"`]SOH:=D\,`L`8[$$!-\<$"#`AB_S9H00'P#V?I0HB@<D+)#PT&X"SH
M@"B&!P@RKB3^X8)T!+6SC_2``4(#`@@J9+C\7?U(#I0/&B@X(;$'!=X]1E5O
MX3-P!SP?%^Q*@O2*0X"`_0["(`$(6-HJ@06LLN\##11(H*V$'E!`*X,F("`Y
M#P1,@""@#O@ON`(,P,N@"PJ0+J$.$H@@PN(8&"#%@K@RP"R$ZO)*M/@<"$"X
MS"A"X((2/\B`)@,N:(ZZG7(;S<*G#IBK187&_AIP/2T[RH"`$BG@R8#E)GK@
M@0RLW/(CX8CS0#4$7T+1`[,8&VXT'PO:(`(%!BC@`0RR_"BP#W1,$R0.,""/
M3PT+9?3&$`\:("4)<(+@3H0@B/#(V!Q@,#8+>/*N@YL:N'.#"A1H"J$*%EA@
M40D9*&`"#SQXX+$,(D``@B//1.#.#BQ`@`'4.+A@NPXB,*`OA#R88('N=IQ`
M`0H&]*`")MW2X`)E#])`@@(:Z'2A#RJ`($N7(MB@@"<IPJ"``0900`(*:HOK
M@P0\L(``!@)(@(`L#=#T`PX@LL"DU1AH`-!&&74@N8,R0&X!`@B`H`(9"7H@
M@@07[F@QXC3P[:`+_EYJ>(/&%,@@@$X?D)(D"AA00($&)*@@W(Z_2ICCC\*+
M(&"=U>.@3H,<UDZDH!U(#*$A._"9N*_8#`"`Q((V($L,RK.Y.103HH"`!^;J
M`*\*"I!`TPP4Z#DI!HHT2`,-(CC```$3\@"!!+).%P%7/]@@QZPM"*`TA1)@
M(,L*`H`RN`80<(H^``"F2+(..)@``0.^I<"GL06(J0,#!MM1Z(@8@"ZB`G_6
M^2Z).N`0``%*+^@H;5&/Z`+18=-@2(,H2&X#C!H8NX$##H(@\8DV("\`W3TZ
MLX.0:8<^^AL#0(#//6%>X(+Q(ICI`@N*I3;UK&O*@*<'-E@@``J.W`"!_@4V
M.'*"NX[4P`#+##J_`P<$<&!O#!1`P)&LXC6B&$D!#X`=038`I`-MI0*]2DA)
M`M#`&T$``D92S`8&=J4!M*P@OZI82B[`$Z)))`$:PI>W`B`M#W3`+VZ2B8T2
M(H!K2<0#!MB;](!SM8L5\```*("/'C`!ZN@P.+=[C0<>M16?=,`G;XD0_&K2
M0H4I1`)?&9X1M<@Q#O!E`E_\H@0B`($%)`!&%#*C`2R5$`W:,&D=Z4`!>LB>
MJ`$@`-P[D@0Z%,$$'&!O>LS`ERH@F#=^4`$%2!NW"/"@G]B1``H!$KK<TJ&_
M$2!S";D`OXZD/P+D\$6%6Q:R0%<0,`E@CA^D_A+=.B"!0]ZE9L51"+@FPH%'
M<FEY6_P-!`Q&$:L,``"(B=T&1H;+-0%GA`=X0`-8M4QF-I.9!0B2SN3%@2SB
MTII:XL#R-NB=:LW%`N/[P+,*T@#CJ8B"$T'4=Z)F@')>P(PVXPH"&K"KUM2P
M(%=+%MTR4`#.)$4"!G!`>CS`D`9@Y2F($E9A>B-#?-'(G@6QP`((M14*#"`"
MKBI*KC3%@0BTBBX-`$`M;7)+!3ZMA=U*@`$6$($*:*!$M9I(LSQRPU->LR,S
MJPG<`)"`"V1`;^*!I1$MT,_?5(N,"ECIRRI&@05,(`)B;``#*D`!#"U`AM^1
MRV,D8`$./,^F7_V-_CL-TH#/<("JGML3!A8`@1SN:(G98=5W"@``-!&D`C"S
MV4U>QT<#%/(#'7A`:.A&`<2YR`$$\"O?#'``FFCD+Q20ED(\ISX7'4!8+A59
M`>ZV+`R\#J,8H$"JPM*8O6V`)R1-2`.NJ@$!_"JD@A/8JG9R``D,)`-OC:"7
M/O*`AX+5(QT80%N/YP!?#@<#.X57`M#&`.4VET+/;6X#$B"O"5!@`FZK;G:M
MN]VV6N"JOH4-!+KF@`9HZZ+P`6]ZV;,\AA"$<)3[P!`'T%>).(8@'$AL;!@`
MSIHLP(Z/X2C;=C2`_8;R=>D!+(%[BR\#T)<H$!!`5I+2``%4``.%RZ('_M`G
M8`0=UE(<@,``]I/(ORH`L<LR#%LBB(#`N8@!6UM6!RK`D[K2#8<1G"<_]6>5
MZ=[3`>D[0`"(2I(A4\0"N%6O1/KV&];&!%\6L$`$$`9E*GNW`F-DP`0BXX`'
M[(0G7^8)5A@P9C(7`(D0/6>27Y,!KC"``$*NIIKE7!C8AD17#```XPYP``$,
MY($28222/,@?_HY$`CQI"XB_=:3_:9AK+#)>'"VZ25A=0$8;B-O%*N`5L&C`
M`O\KC@0"X`!-/4``NDI(!`10@/G,1P)H65;URMF!!=!01G)2'MTL<(`$?+F<
M!Z&`>Q#"VY+,2J($L,``DE(!4TJ$FKNDR&SF_CP1SP`G?>1<"0>TO6UN:]L#
MW>;`-R6P``/L2;4FQJS`P$+&B'QQVMF1P/D"^&YZ2^@R%UC.`Q*`N*+D!H8)
MR4T&A#O%`]04)!.8+V,1$-FG/`"9A8E``DI5`4O:-6D:6,N8*@(!?K(O*O;]
M`%N=BBL&R*@#VV'XP]!VF0PL)T&\61:P%D`M""2@O#^Y@$0QBKX%$$8`0.P(
M2RN+;\Y@P``#8!)N$'*VB1C`=>=KVE_B7&^"U&W@'?F0LS!"@`%PW>OS]7J_
M,-+UKMMM;4A-@/O4Y:"E()W="HG`=ZGN$3]A?.[3K@":M%QU75V9`;>2:?0P
M4./8L#9E#A@T:V(5_D'&B#8X`LA005YID5/?FL)EVU&()2"C_=4'X`1@+!\%
M<">C"P#F82G``BZ6`0.@]D,8N=BND5V0G90P(@D8``+F1DK?."`F#3"`X)#\
M`0>D>:Q@)D`#8K2ZJ5/=9-;T683("@'"$R3N6_HV>!-PW2(GI8IW_UE7W>8V
ML%Q&VP3AG<'3A)SU!&"?QF-(`A+;KIDK9L^+ND`'&'!JC`Z2K:GN$QF9@`>@
M#39ZL0D0E:>```0PDY\@(TL1#\=:ND-:'W]")AGA*`-YC!$"@%]3$1%+E,'@
M"!>2$,_PFN2@M1TA@$+S@`QP08BIG@$X`$E*B'_+B>_C&`D8/MJA#P,H_AZ!
M$S@)H#X:,@@&&"H;W!"YBXT,(!'?VBH-V$$1*9`#:*FH`[_"R"]#`3,[4I<3
M2:8'((TP_!J**+2<^#_U@(^5$AFOH)]^.:?P(``%L)F*FKV?H)`*.)*N*H"]
M@1L!:#[]$8"<D0D"@+&J"+9[699_PI2?<+-MJ8H)"(")NI&U4+V#\*_F2X@K
MJKH*`#X#B$,)X(@?@S*]08!SRH`!P,&?0)8"$``":!C[@+::0!HM(I4MVC4R
MZL0&:[#-Z)0*F("W2XCJPKYY<D(*V(`Z4X@\^:%21(\K](@)B,6:T`#<T`!R
MN2ZWL:!LA(`DL2"#:T+U:("K&XD&:#D8XH`'_EB2GPB,W=L*<B,UA#`ZQWLL
MK]DD!UBTI%B`@!(R;B$<*2**,NHMOHD`,+PTE[BU!)F6GU@,Q&"TM,-#HHB:
MZB,>X]$P-\.(N&":!2RX2SDS";'"%ER+=Z'"#,"`MFBAUS!&(_*``DC%1L$`
M<2P(HD-"`%%"V,@3*XR>RT)&)1NDRSD?9XRI[JL)33P(=+$*C?D`IFK)^%J/
M=,%)D%`B!&@M3$,`?_R+":`M>.HCV\.8O<@2"G`?C+J*@"J1]JF1:D&)@@"9
M`\`;X+D8*)RT>#&(#7#(POB<-*N?$Z(?Y_@UJ^A`BO`<&SJYFBL/N-"4$Z*;
MDML949$`ZQ``E1H`_@'(0HE@Q^C1`&7;HHL2'I^X@`:PDI.K%\\0KW:KR212
MO^C1&`T0RHEH(5-QE_(ZS7>+,N`@RJ&)"P+@`';J%:[\F739DA\"@,B4E65A
MKH#,@._)PP1P``D0@)^0BH#$.`1,K0F:"PIH$3D)(@$B0,6$1Q]$C<>@2XJY
M&`<X@(#,)A]T$?(80[<P@'VD"+'ZK7^*S"P[B(Z4,=C@L9_;J:<,CMC<$@A(
M(.B9"2[3N`9X`(-QN``H``^8/HF\/J#\"(VP.]CH@`V(%@5@@`?PSXC8`#(;
MLS62L[&`QZDR"W<IFVC4F8C:DO[X)4W;HZ7#LW*B``&XEY<QB`1I#+<@_JX`
M/1O<)(B8\+W.X)>+`<OW`3CKN#B6^*8*1#W".\Y8T90+R)$LZ0!2`2D`X$V$
MF`#4>AC)_"#M&8``,+TO0M&@R@EFD9`OXY<%D(#)W!TMXJDM0J"`_(O2P`"1
MR#)@1(@'A="@`ZV=A`T*(`^K8K.<\"E^D1E6"@`_HKJ&63H*H("70`"I20T=
MH@`W?0W3`H!8+`NIVI%@4P#C*8E4^@`,2(FWB!5JL8#/$=5-Z[D;4:+`Z!7Z
MT3=+^1#&L@_$^Q^V9",%(*)E<0B]698>#-"Z,1!:^SE,C2_C,PB]H%(R^B'>
M=*+8*):_.H#EN)5#$@`$(`NFB0C^W!(."(`-_M62E137^R$(!B":%ARKH<K2
MSBC-/B4(WRNB]>"=((N5T[0*@`H76AD`9?VJHT"(K6I,6D(D#,!$G;G4-$$?
MD2K5!3@S9ND01GO,W/"`YO0`!_!!C(H*[IS+?5G/@EBI`*A$>`2@@%P@<DJU
M/3/.6J/!N23"9=$`!T!1_9M%@3FLU42(,KW104,(!SL(W,,=QGD5KCF,IV/2
MJ@#7]1BS+?H0:CH("8"2RRB<BHD([BG760D8K5W:[#@A76(4B]BW^?&9!M!9
M@0DTCM$`<ATV&<H`CE``&@(9`(C7-`%1X)@`.QJ(U\,\ND"`\OR\06,=4ET6
MF<F2:?R[97$7GP4,_GI,"`LPO5D;([H)L<150$BEFP38JU0C@`H!$)[H2(2X
MF^\+4B6+%)FE4UYJ/>L+T'NB$05-`#-)"0C85*;IVM\H@-3]&>^ZFJIC&A=B
M&DO3B*/H#1![5T<LO)0RHTEU'3,B'&@D(_T,/C3ZF0?A'8X)&W(;`+9*CPOP
M*BOBV?5PM]^(MY7(EN_9H(HPHM`U)I[PHXS`J/U+LP5"S(.`Q%-+3`Z;2R:\
MDV_+4$K-"]AC/';"I.JYF`[@-9O)V/*P&IO+$H'S6(PA+`\TB/()*?G+DKJI
M*?FAFX2]*=U!F8X1U,C$BMX8)":4"@I6CY7$)11\%%&+`)X0@+S]GP!8_J&=
M$-3C56&/N`J$\>&\X\0&\,RH(HOO&<B<"X"?T0BGHAVXW%:RF!4U^J"(N#&.
MP=S?V(``B,QW$0`Q_1R[`2`$$&,QALGOD)-":1.>&("0K3I@20"*A#!0>AAA
MC3D$0$JB`):=;"$:,8OOM0@")HJP`:A-DI\V940,2*Q;D6.Z.(R]*0G/V[@L
MQDDPU!YW"41T"95YDPCJ:TH`=IZ:,"OGF$&F4"/$:\&'+!2/V:)+(Q8,P(!#
M4:#$0!G5NEK=#91S$@XCJ8"RX:C>FLDT&8R!E![*P3UY<@UK?8JY&,!W.SVU
MY(!LB0L-""T,*)8_H1W;813/`8"M$@WY8:L2_AD@#26*P-"7S"LWOV(-OU$,
M9[E4I#*8WEB2`2D+B\)`"&"*R9DH1$&577FJO3&,-Z8?9VG=OK(?CX`<$=&`
MP1,`R&,`(XFZNBE#\-@TPCA0V!@AKW@SWE(*=X&+,=KAFI@`GYTS<ER0J[W=
MG;T3?NH,"XJX_0F7=UV/L^"`4]$B#6.9V`$`!J&XV0.<=[L@A3"`#4@0LIBI
MM5V/".#2[^BU@Y80S17*?1HE%=F3OJ`@)ERI(W%C2TDVF"((_;`S>;$9P-JI
MO;F``9`EOL&@8^D5:E%--KZOZI#'392*6[/0<!R`C^YI-E(+ZXA#1`Z8:8SH
MFM`+#-A>V`"@AHB*_H**&OGHC8GQH]HZ:=%E6VM2+0>0.Q*+C:D("P4IHZB2
MN`ZJSY^Y&YJ64R7]N0.QEHJ^C7=+N8/H%:Q,VHFXS`$@U*7<Y+LECD,#`/G0
M#@,QN0E0(W!>$>GT5@4BCZO*)HH):`&PD3%B3DB&#*G0@`&!B@*`$FI&$C&V
MF@(IIZXJ66Z1"@5FT##5I:0^B*:E"+5PNKXN$2$LE%/LB=>@M:Y@PMHX4`=Q
MLW(Y1AL6$!<$FYH8(?!CRP40Z9"S[=%A7%39"UW:B98Q#NR%#]7$)4XI,9X0
MC;K9#T"6,PD<6/@9C_!E(@?HE^]]C:A.$W=J`#$M`.M61_LQ'DQCBH*0_J1C
M^98'Q@KJYA!01(@P#6&UX:D\+"A$-`B"/4.Z(*YWI(LLL\H;442WF,$HLZ/"
MZH@]I`B+*8X-:,RMX]ZZ`=C7*)@=>A'5TK_:P(``Z%R)80!=6I%?JE"IL.T*
M`-1I\U4"CXAR(0X%\)%O0Q\-(PP.V(!T4Z!?+E??F%`M*FGE3)<(""0)2;DH
M]"V)4PA-I@^0Z"P[KMN)0/)"F8U="VIPEI^S;L>^^H_!V)/*C,F(HV[BDLYA
MH_"PL`Y4>S!D&Q"Z))O!*IX!.1L),,^4,G6!B1O[,B,`($8C2V+67#S;.)2T
M$X!W:90+$(#`9LUP.Y;6<\6F,"N>L&'D6(GT_@'=V&2`2_>MQFAFA.B?.\_S
M5T,7J1B7!)`A\UX/!:C0.*>=70XJ@<M=58,.&YVV-U8(.303A.T(KQ;7F('V
M35Z8.!*5;TP+ZX"27X6`2!P0&VYHA:`1,TT+E7K+'[JJ":`A3?$6E46(KAEV
M8)NTA&"Q1;P4L@EK"AM.)/DY?Z&[LZVZ!76V,FD4/)-WD#@Y^[*`-D48IX!4
M;<.XR-1/ZE%W]>LS\.,I([V2`X^EZ_(>2W,RL)B5GPBWT_B9^I#P+4H7@6*6
M]GR)]BAC7"HP%T$2F(G7HO@`IX/8+H\(_5F8XQH(<4(_`NC;>VH7O0P+9"/D
MUC,<BTK/4Q.L#SQF_@1)`"I/"HUM^0IV@)\.'>0E)<W*F@L0#`V)@,7^")I'
MIV*7"`JPY:)B@,,BCK*V(P+OM!>C$0TIBR]KC&/Y``)@DKME7SE+@+J0B(LB
MCLL'LZA9:#%54`+H_2ZV86S7F<"D*FORU=5`Y*0D\23;'P:0J.C/T`>P@`KH
M^;BK?I!3"%^2&H>%C5-<F*F:5S.I?F<I)XI[63QY@`#8&V#1W_CX''36"PJQ
MQ\?`SC1C#3O6M,_9^B*D*X#X('#@!PX2"$3P0'"@@P0+%@K,\.``!H4#/10(
M`&`#Q(X"`QR0X'&@A`<C!7I@8/$D2Y8=''@@D*'ER`X?.B3(8('#`P4!_A!,
MX/#!PX:5'!Q\2``@@`(%!@!P$`!A0X"1$Q30S*IU*\T$%Q9@&)F0JT<%#B@4
M]9"!0@8/;M^^Y9"AZ`8*6,GB[4!``P61>/^>C#HAL$K`9!W,-/P!`8('/1U$
M:*"`0=/*E@,([>A6`````DQVY$#!+432!"504$SSH8,`&A,04'"A]`2$-A=R
M6)"`0H6%'28,@*"A8P4##,(N]&#!`%J)"B((M#M@-,0-#1*`ADC!@(3A$)`*
MQ-!P,$2#!"#<)LB!@0'DOAM:2(^R`8`""P0<@'#!M$<.%A848(`"$K2UD`*)
MC:3!`:JQ!($%'RB0'5FS:4#`2C=I$,$""#!`_H$%%F40U@0`#"#0!@`N)<``
M1774(8,O_I6`=0\N5(%-"1$E'UD*T"A0!1@T,`$&L1TP00$#D#?02S"Z)``'
M$*3&I&$;(-#`<,D!AZ"4'C6@Y5\,7.G1A1=Y)-(#`'B8&40&:&1``QO<ID&;
M-BJTP&Q;JI?`!P5TUEF2!&%@P`%A7O0``0]*9A0!#/B%&P($Z"B0!@84<.<#
M%!#`P0:M_7D1?7IV1`$"%`V4P6T+`+``1U@6`(&:!$&`T)@W.2``=1!),`":
M'G1@`0,,!$#`!1W,ZF-;$;`G@``,Q!=12U?A>5&F'T0`'F`:@'I1E!]DH("R
M$KQZP;('7=4`GZZ=_L?B0`\4&RV>46FP0&\$G6EA!!U``("$._;X`009."#!
M!`MXH%0$$U@[$'3N$M1!`!H\QS!>]`4W@0830!`LH1+#Z,$!D2I)P*I:Z4J!
M`R,31-0'%D!0@++Z+?``RP8,<$`"`VR\I02J#B"!1@"XMV[/H1UP0&(-W-9!
M!*1"U$$&!>R+4JP+"[1`!P-$0$"7'6UPP`)>#F1DH^$-]<`%02OY0`%C#\1!
M`PB@/!`&";0WD@1]$N``!C8]B0!($7``\D*^#B``=ONQ)#/#&@@@4`1W`<;`
MG0,=T/@'%4S`D08/&)``4($G``$#$6Q0`+Z8/9G13_&)SG%+&TQ.5@<%_GCP
M4(T:7<<G`!`8QB-!&GAP@<RI`:O!W!`AX'I!!OA+M?(T9<!`X<H:8./S4MH^
MTK];=2!``+6_*G<!@)?Z``(`#'@;!Q,$8)P$$+2K&`,;/(`4XP`LB!(%";Q9
M&@0#-,`B'#B`0B(P@`&@+2($&$"_!F*!!##@51W8@`5(%+NV2>``#XB4!RJ`
M@/`)Y`$2`$JQ)K`LS=3*`1R,`)K$%(%'`0`!PEM```00@0HH1#0W"\`#<E::
M"RRM/@^80+L,`#('^)`LE!$(M`PS*`,QX`-#PHY`.,`!#2RG?1-(VH.,1Q#8
M2:\S`@!;5I#&H`W$C2L$S-X7==4GF/2N@3=Y_D`%HE@\#&Q+(!V`G,3TDI0\
M7B^0@B0(&SN2N:V()RQ1[$@$+C"!1S:`?)L3%0(28!8*8`"/:N,06N+'%9QX
M``'#><E21A.O"8#-`Q(PP%0(8@'>,.`!>X-('7O8D?\T@`+A<QN4<O:D!1#Q
MEOR[%4&^`@$<:N<"#A@61`:VS.HX0`$02.`'OO*5SAQ`3;##V`(6T)<-<.`"
M$&!,8\#)$@Q88`().$`D"R2I$I7F`6D<25^*98!5-2!J6@G>(@EIHP%D0)FU
M(X``:&0\SGG2E1H10&,B0$:/=.``\R2+3`R3@-IYQ`('`,"A5*.`G&7H`@=X
M(00.H(!.=>""[M(+_J8`.<B7/J^0VIFH1S3```A(QB,$2$!0/K"Y`EBG.S9Q
M6@,*=Q;@K:\`!&!E$A'9'0(01`&>>:`/+^"Y-&9@@7!<2+P*,"_<C--YGJ)A
M&E]IRV8R1J4WD8``U&K5CWFD2IK93J?DQK2-`D"M!<F`A@(P`+!\8`,2<5F'
M@,<2#8BT/L;!`#N)HT^/#"D`,G780'8#&).I-``[P8H%+I77N"EG*Q"00$D,
ME2JTT$1P9`DF8!X"58@BD4$R#6Q8,+``#GC`+F.ZHO(ZD#S(P#2XS\-(4S\@
MSZUX`*=T[`\$$E"`6")N`D4=`&+X-LX"!*@"H\0`>W:3@>*>Q"O;(8@#_CIC
M)=XM)(/4Y(`"OE::_56D(T\3*THJ<(`"!.I"&5@`0+D&`>:`#`,#**=O8H6>
MCDB@`2`4B`)$V1%\8<TF#.A,PD:R`0RT+#\24,C%V*2UAZYK`A3XKT;TNI4)
MO"];`REI%0>PX*Q0P&7/*5`&],2`Y/7D@`)`&[$,4X&)",`^R!0N2]C[@=D.
M!+Q:X5$&YK(6##0YRE*>\EIH*B4_\H;(6G:7QUBBKBW]Y@"4ZB:UUJ*`(B&H
M@_?)&W(R\%_TQ7>?(G-`PC#B&4P2I%MF3(X#[#,K^U:O(S8U@!P+8C,&-*`"
M;#S?;6])``20L0-J$RSS\KQ3D&$*J-49#C$O_G(!`\36IYWI9U8X`&@"+(!&
M%%P``6+S4'8-!(T>2<"+.R(;R4'$3DRL-&#4@@!='2`U0AG@`HPH$T8M!,^J
MV8`'.0H6*P>W:Q@="0-4NQ6I>L8UKA$SMP5E`/Q0:JF5(S7#UO.!9VXYW4P*
M)0(4H#4',*#5J!9A)C.),()):7T",(`,%<(KZ3)`;S.YH@5>R$XXP:XG'#JP
M2ZQFQ(5D0(R=]%6BI4B``B1`;SNS'L01((%YYL9HL]+`D]72@9+<1#>R7HA@
M`^Y#B#%+*"R36R[C[$H$I#I2ZJRPU!@UN2&1",0L(4H%).,^4V5@`@SPW`+N
M9:(&I!8!";V(`#9@_@`06FYV)OYD78IM'PM0L"C1?")!6/LBN:B34@K@^):-
MC&2!5)M!:$&X%5_5R"JBY#;H["W4(U!H=0,^+Q2T`.$)?X'":W0I([6`T`UC
M'@#<C-9);L"C"802#$3``&QV2^I4M.>.F&TY'1%S>1N)@*^.-'I],L`%/2`H
MEW(KEYW6HT_$2NOBJ%"^`H"Z1PQ(S+G<Q-T^W%3=('*!`2B@6!5`?MS<J.12
M4\!<`CA+40R"``$\!P+H';H[6[*S)4%\D5>I-6"<QE;\Z.<W7T7)VU73P0DS
ME%%3Y]BG/6`YC\1=-;SN2`.Z,Y(,L,U*+<@T!5X!OHLXA8X&6!N#``RV_O5)
M#7U4WC7$VM"(!]@6?C@`V/'*?C%%`Z"-!V#%KP@:4DP8VM".'IE:K;#9RA1)
MNW#(/(G+UU@$"%Y``!0`"37-2>%61S"6`H"0*D$-R*@-K/G&SIB=DJS3$=X$
M9^S?BUB@!"2`#<H3KU2`3PP``_S(29`=35"$!?!<!*2&QY"?:G3`^K":`"R`
M!`3-?DD,%49`%**A!#">?R!>'3*>'>)A'AI)`8"-D;V61YR@:DR+1Q1)K6G`
M]O51%#&'`3(B&2K=`'C%`L((?3Q%?1`+!BC`S6C0!62&![A--T6)!=J%YBU7
M!U"`VOP5Z12$2E1*[^T$`M09U.V,X@S%53`%_@^!#;8<0*%=C'`8WP5`'LA<
M0/\-WXWM8,H<"=.`5:-51P*L7]L\```5RT;A#,-L0.;]Q`/,A-F4%/Z`"T38
MU#YAAC==`*'`T60HABEFA04Z`+#)DG'QGO)PP!OBU<_TR3WB8S[JXSX"@!Q=
M0/)4!;7-7TM\STA44@`\U%KPW0<L8B,ZY">94.AL'9YXRP,PP`0@`!CZ!0;<
MXP$$#$<0'21M"^8Y`#O1D5L4'*MIC;B\6$HD``8$0*-D0/^E"A@V0"RI84!5
M0$GB#RJI4LQ$BDWE1\YL0&>XE"K=5%U=S@&<7K'4SS<.CD,<Y?YX8*@4@)6$
MAE)`(C5MB0=$P`/<_H<-[8<9^L1%?@AM:<7`>$P:$9"A0%M+>,#SX<8$](1K
M!*#R*,397`!OG&4'\8:-?(B_">90#"9I`&$!@-`&",#LA)<DKD9X8<3?[9WK
M=`#4>=-#8N9)Q"4$%!M6"I($8-Q01,29V(SNY"/R08="/)D!6(Q%6,<!)8`$
MR,<%Q`9J,5*?/$B,&4\`3!A31,"^B=D6#81(E=B#12-]S1$:#H!\Y-8&S$]'
M7$!36-A&)>;2K->-O277<,;N7`\<P2(#;)1$*D0%&%"P',A`'E,&","8U$YK
MC&%F.N16+00&`*06ODC^X-^DO%@FR2.M$0#L%>!WP2>OM&,->>8@>0SD_EU.
M>AP3:1V`/>;C`2"$864(J"5?CVD`3S;&67X`!6Q48[#=31!`9W1.GUF@/E;*
M(2Y+F'0`8.'&`;G'2M#F549``2R$`S1AH?"01UC5Z2$D1`3,#UK`@$7*`GK`
M!+A)?0SDY83.E'0`3@SG=8#$A1Q$#0U1CXT$4F00K@1%`$PD?#:BO(0&5EC(
M2"PG@P1D?Q0?#SZCE*C%TE5B`+2I`6I`=A*9V[`)`C2+<!7EBB@,4:`8L6R`
M!!3=^?0)!1C)`+B&,R*(\=@'!92A3T6&BC3&;&"`,DEH;,[+!F";!^H)?>@C
M0\'B^3#&Z+A8REB``!"*TJP,YQC$=2R2KR&G_B=J2#$2P&"D5,.<!&/Q'!,A
MID=$SXA"(@`HI4>,"&<,1SG^Q3R61\_\XV[@EBDV`,V$1`8L&'1X!?+8!+R!
MZ9;QQVK,Z3_NR4FTWU88@`A)0(18$FFQ:[NF8;NB6[ZITU(U0#Y=P`78:;>^
MU&\`"T^])UX()W)Y2YF:B%J`!\IT``9,0.9ID$UPJA@UAGX(!0!^QTT,'!Y!
M0(,M@'!,T(B95!IFU5(@T)[@3P54@".5Q'8^X'.A3WJ8CX`NA#)%DE"<A8-M
M1P387!6-4T[PX`-`26:XAP6,RH)=Q5F,R<E)@`/,*04PRO\<S/@LZ:T:!/T$
MV51<P)#1A+)]T4;<_N1W#("`R!-N=1;-Q`SY<,N_5./O&$`.?5`Z.J:^_A]7
M$D0%^,7:06?RM%^Y:@4`.$#]^"R=-4#`0,`0?<<0+2P$($Q#GMWCY`?CP>U#
M;L#`%(`"4(!<_D7WK>-4I%$%(.*#80JJC1.*]M_(%,>8\`4#",!.6<"5B(<#
M4%YG/``+045UF!`!+-2;J4@$/`Y:1(JI_<G>M`H"%,#L#053%B,K70CO2%K>
MI!&09&MYC`H'<00:I40&5,`8;84&Q&-N:,`(C0@`O$GC"00")%#&NMYM6(#"
MQEOJ(I$G?@6E&`=0@"6N4`UB*`8%`.CCOH@Y'5FXXBVYODCR[*IJ9>&+_DP*
MM.IO(Z:4]"S3OY+ADD8$;J51]-%$!_EL`ZAL/C)%!5AK8)PBGWA%F-2.BG`4
M)%9N>>269VP`)!K$SR0L(OXCN<VC8N9-SJ2$;2;']?9/S"Z'Y/G&<N1?PU">
MT_E&3@F$!01`:Q2&5HC30.`:$$G&B/2$*IE8!]P3\CB2`-^$*UGD`!!`L'&$
M:#A&O/30A2#`MFQ*`@M27$*PF$+$XQP9`*O&I+!$1WD$![](;=RE&I,%!CBP
M5J04;%SE'[^4W^4'1#PG5UP1?^6C]T!L!9#?9@IRA\Q$H`#`7!1.?<1&O"Y&
M`+`0:&Q`O$@4-")$,R4MON%&C2;`\#$E5P9(_NZQ'`(\7#,J8Y[!XFW42F?X
M(%G\5;MY*80([8#U8^IR9VC\SZP@!02Y!!8]*`'(DD5T0+RURG"4SDH4#!]?
M#P4$0+[V+W1B1?OQ$6!40)KB'XC-*5EXY5Y@LVH$[K*B3090JWYDYF@8`-@8
M3?EAK*XL4\$A"V=<H0,XB(XXDE!T0(:\#:LI*'\)A^Z^#4]51*!(EIRF%ZBY
M&2N1T=)=LG88@+S,BFVQYJST2LP(VCAAK=QP9L!>1+HR0&*L!XF6M%9P%Q8Z
M1=;`I&Z(Q-(1KT#$8'4\1$@8BV9&;@.(V7.`W3P6VP=<1\K@YSI+C'9QA3.&
MRO^.A-[21`4``$OX_M\=0[!'B([E,C57U8^#_$7I%`3"V(<\#ZB>DIM`P!,9
M6E6J2,!>H@H^GH<VZM''D5;*M'`#!$#G2NH"V:,^>8"B,MR-MAOCO$J\[')U
MW-<LT5+-T%=EKLBL@.!N@,P`$<J$<10WCT3P$,A$$$3^HL2:.E#Z%N1-+&D9
M/H#W+`KE8<#N*;5B`.!7LP2':H57,9)4>P15O\Y5G\0AW;'X-LA:T[9+L`4"
MM,P>T\0`'5"''".84D5,E@=OKZ/U*04_=@;49`:^9*A'<@0F51#;C-/E=$8`
M4`#0:,8#18I5L9XCM?5+],RLS.,KS5.WR(@RI<P+.0#1HJ%\/8EA18>B_AJE
M84108#'34+#H'];4CR[$2CN`%O_%D]H64%!%T+B>^Q4WD]CM&S_$VQF9:L!D
MXM"44P-&5A$R4^_-02#W`V@$<A:9KWC/GCYN]-D*KL1C5XY8)>ZC:]CU4!P%
M*RH$`+U*NR%U>0/CQL1*6%B=FIP<3UG$^TB*YPBC;E!3;OVG0FC?17B.7P>6
MYMUEUR0&R2'6=@[`E[)$09T;B;3I-?]VCNX)!P#`(B$J`Q)0PRQUAH-X9AP,
M6:A*;I^;',NV;Y=*<IQ$!7!V@WLU4W]*S.Q@`C@Z]_PF*XD''S_%7>(QQUBP
M`W+N5VJVFX`AC>C)7'N&X/(F!_R,<=BH'CT._IC4%_F*TQCK$5)K0!VMC:`E
M[?I=",L@"*TIQ`C=9;7($)<D<N#@RW82(6!$8V_HTAOR]4;[&W@]``AYH08`
M0&\$SXM40`-5)H;C^4)$0*(?V8*]C;^<A-0QB*)Z#_:YAMHYP`*TE[MWD[MM
M-`'(;4L@2[<'1I`81VSHZ8)@H6:RS$%_^U=#0-5U!"H_3P<H6JJ<A17?H_=D
MA`(4)8GDX\GFE4,Y1(#/UO*YR1<M@)Q\FXL'UJM,&"NU#FXH1`7Y<,I0WF.-
M!43,C9^H1C12A.M%4W/Y,4C6^^54U$)XA8;H45AL-7%`1$`IQKTZX5M@*:YT
M:Z]2BTAP^4"$LU9\_AY*/$BN4I!R["1O:$I\:)?)'GJ2/0R^MP0KIE36',#0
ME`:VU)"+%G?-@,QZOM0A?AN$[GA@M7MY6R0`I`1&[.6O%9I7Z@O+T0^:^-#?
M,<OUZ3+B2,H$"`\9E<Y^\V`'0]SJ?H`=&T96Q5L:CNC'9)Q%-$#[<61]0,1B
M.F/!\,FYC@0'9%PF*C=2Z,9%?0"S]!X$.?KM._JO;!&O9`:V",PC`3^*X;Y8
M_8;GW&,`.#KC*PG&&NXC\4;PJQ6O/.G2^\86#8M.!/\CQ4>[\,K<?.UD0.IP
M2@62&#UN1)&$PVV6D_U)X,L'',#2^;'2ED=1V=")=VL%!0`''3M,Z82Y_O`C
M0$SX,/##A@,0*@``(&'``P`&%#CH0)#B!`09*#B@^$&"!0`4-@[L$`'``PD.
M&D"@X`$#`@82/ER8P*```044.$0@H#%D!P<+,(3\H*&!@`H$/<!TP&##!@D5
M*$P4.I5@!PL</G3`&@%"@:Y'"S"8B`'``JH?,@0`H&!C!@(>"'#HH%!A@*`;
M/7"DNW#J!@8?#BCTH"%`7J$<Z`80(&``X\4*&U``^8'"W@!J%0I0NQEK5@0"
MZKIL8&"O68H$]J9.G4!H0KH/IG8`;7GV7@@A.4A0H+KNS0\8&#0X@/E`9,,9
M-")0F.%L<^?/H>--(#5Z=>O7SW;(8)@@!PL6_C9B>-"A0P,$0BDP0!#@@0;L
M[^$?YOX\,-N0,^/'OW#A`X<-N3'80";S!M@K*`DVB$D`"<B"0(,$%`**@_G0
MBL`"]SX`2J0+&""``-PF\#`!!$@<$8$$%!,@P?\&RN"!!`H`H(`*.AO(@PH2
MD(#"_BA(P`'F"+K`J0,ZF&"!"#AXX*[J/$#`PP,LO.H#"#HPJ0*8/O!@`04&
M:&Z#!HZJB"G69*OM``P)HL""VDJ:J@*-2`*@`P58HTJA"%BDJ,@[D:KO`@TT
MV`^##C;((%`@.X!`(04"I`B#"P)KDR`(`8#@@D<O%72_"H#<R(&Z(JR1H@(_
MVF^[3"_XM"Q'U1(@_@%+#ZB@@@L>0`V`!JC[-``&$C!@`0H"U:@!``2@+K]C
MH\,1V669O<"`!!(DZ($"##A@/@8&,(!"#2QH0`$%&I@`36;))=<#T,+<B($E
MRW7.`U$UZ,"#"`C:0#.%(,"@LQ,'(F"B81W80`$!"L#3@WDY&)2@"6[+H(`#
M,F"8H@T<**`!=FU,&("9"*A,``0<P,#@#"I8@(`&(K@`@@4@Z)0B"P:(@,(.
M+@`M@&=%O0ZY+#&00#D&*(AV*&HA:&"SZSB(*P*0/-@-@=T>FF\N`!`@K=*I
M&'#O@@@%X(^J`0(8=Z-A/VQQ4>@XB/%JH3K```.!",)`K1V=VP"U!"K`_HS>
MD"(E"$N*%E`HR`(+$+KL%CT,X.]6"=*`)@0$F@"`+IDUMEV"'$CW\LVIBN``
M!0S(N3\'0,-X(PXN@)&!"2SGW/6"A'9N:P%<EI;NU\\ZF"`&`HB8I@`&N*`#
M`PKXP`("#.T@`*DXH&"WF@"(O;^#"-@`V@?`ZP^"`!"0?J`-*L@7``X"5\@`
M"H@G(%;#.L!1H01$K[*!V@>JC*XS\V.@]@PB^`Q*]S@P@0<\P"D!>(ZQ,*`M
M`O#'`P5B``=(];</1`!L%HC3;4*R`0/4CRY[FXH&`!"`/UWH0A/1@&O^MH'-
M,``"#X!`U0Q@'FK5B`(QNID!6@8HL5&$,`!@_J$+6PB!HAG``'#3$VKL8X$8
MV6<C,1H`>:!8%0X!X``#21H`WD*1.FU$`]RQ800F("L-/(![&2!-%9?%`2:Z
MCDJXPUV"*H"``9XO9Q18P`3HUYT*"(``$/!>=43GQK-@+SI;FTQ($N`UW%!@
M.X(,20//X[<'&`!L*E).A`Q($0H@P`+H,P`"\&2C__5'2Q-QBP%TA)LBP22!
M'[!:9@R0`0$%X``/J,!$.J`!"@3`@UF!F<QZ4A0LNNIVU>E>7U16-9QHTCG#
MHR&5"I,EU#1@2G7I3`;,AQ:%2)`@X>/@VJBR-=X,0&T?R9=(V(1%(JZS0**Z
M$1$Q$QKL68XLO)D<_M@`P!.D3.`R:)*`0HQ(D/(-@*`$(%@!H`>`"$C%?OH<
MB`"<$RE[TJ58:8RDZQ[DR,M="C`<6)<5`T!-Z&B@8@$@@`5:9YT+%$^CS?%`
MT*(S+,UI\78%X-(!'.``"`22<]O+GA6SU)0KV>J,-J)``W!5%0H\`&0-*!!L
M"+)3"03``3O*"0(.J=-ZJL]6Q"*50@9P,@UL8`"=FD`#'C`9#S#'`[0B:@>F
M<ZP-8)"'!G!/!]3$OP<LX`$.F(#I#D.1D$EN;Z0YCY;P]8$*$(X_P^/+4#``
MI`1@*`,%*J85%Y6R"H@+?)=\P(1$\M2F=/%T&S`,!S@0KX%<(`,2@$`$_K9$
M&@($E`*@`=0&QHI;K33%<I*;'`1RZM=A&65LB^I0<!X0`0=8+5WU-(U(#D<1
MT`Z$=RK*[5AIU:/E+&NMN,O``GB*FY9.A3D:6&AE(K"T(L;-.=Z9)`$8(*24
M8B>\XZT*="RP7(=21*1"812AR!(KC3X`C6>!0($L$("CQ+$`.RQ(`I(KG(9$
MBYP/%$H&!`"!^1"`I`180%X(%0&CV=,`#QA`7M2H`.;4""I=A0P&*IH?Y0H%
MJIX3`)JJ%*,$8"L!EQ6H*STH.9XD!6Q0&\!DL/E8J#&(I1\8L8\1`X"?;B1.
M:()+`:#J'-)QCRHO'8[0?.MCBNPQA`<X``+._JQ<F\5N6``0"5X6`+8PP958
M/_7`^%Y6``'42%$0W4B5*!-"!]MWI(I)@`**<P!*%F`!-B4`01DS@%C]T748
M$`Y$&Z1"8A$@`@68$"414(#]#J0"#&`,DN9+Z,U-()7.:<!<_]@\JLQI(AQ`
MHP;.0S,QQ\=IP?F.Z!0%@(0PH$/`#$D</>B!3WZ,-+VLB@(D,%V"5(_#;/-9
M/$T]$Y!,8&E2>0H',B!,A1P@@"++8GX20#\.'&4#9L$A!A2`@+R\JX8&S3)5
M,L`6`61/-E3K3CPE]1O08(D!BRK92+H*985,F2+B_"D'%M/CYR0Y``RGB%L`
ML"15[3HKMAJU7K!(_ITVM_:0]5++<SU0<%ZB>(.-(TT`:C1<"EV`7O\$0![I
MJX!4+\MZ`+<,9@I`HA/9+*ZOPVMD=L.<#@S`+"Z,D<\*D(`#4$`""))NZ@`P
MV9VK>G,KVW76N!FWL%<$/*D:2*W0<N/&?#P_';#W62%T`(:C!@$)B>$?'093
MP<HE<`98BH,(HI-6\Y!866=`!0!+LPDH@`#%TY#N&I?RDFQ`S^WY`-`$G)^D
M">4I'W@`-7&88'E3)*T<0(`BIR)`#?AKM73IE&NB)JUMDCHQA;^?<\K7WXV(
MTXB:GMP"&`!\`B0`18OY"W7IDH`&H'0@K%8;`[BSY0"$A:\,V&OP@Q^4_IR`
M-9!34RA!2$6!4(;G;`0QHT((8$MY6^!-,1(`]*V(&IBW!38D61YW.7XL*.Z?
M/!Z`XGR$R*FV3O\:8,=,"]JR@@$.8`$0X-4@QR_.B8>ZY68:8-#*)4^X[CHN
M0`'>92HD(*"JHI86@#4XJ3^<!"T>X`+@2\K*A2R,;2C>J^XT`,-\B$3HIGDN
M@&YTZJ4VR`,F(`$&('.L[W;Z!_;J(@4[HBUN18TV@I7RAEN<I^@RQ`,R*3\J
M"V\TH$80P#T:D`,,H"D&@%TZ`(WRK>0&0K4^`*N^120D@%<4('8@X%MBI[44
MP,Y4IO$8XW,JT#GB"`&%PB#0#$-ZY&D.`*$0_HJ<#)'1>`@"$L!6+J-5$(J;
M'L<0^0C]#LIB/L`0ZVXJ4JXF!@`KO/`S\NO""`8`4`^O0JWV&B\L1*4#"J`Q
M0H+F/J!BJ(7GV"X#%>LWMHA<K*("DL(G#&4@,.!#0`@!P$;>(&]BX&T`(&<`
M<9%SRN,Y+"`IGFLCWI`J*,"//H`UE"VL+D\#%(`!/.*14BO_U&4O#&!IJJ)D
M4F.'/.!3&F!'7JJ/5*B7[$8!"B``)HL[+,``4(,"OHH"MN;1%*(`6BU20LI&
M;J2<J(9JV"7?,N"B\L,#&/$R,HRCC$?/BN=31$5B"`)*-@+P-,``9`-+>@99
M\.H#/-*1Y-$Y%&8B_BZ+0N;#'!\).Q;+<CJFD6P$.BY`@B0`];HC`GSQ&?.#
MLVXQ/M;BT*9#N[S&+":`<NCFI<A)(H@R`T?B.7"+``#K`YZHR^8#J2@`>0Q`
M;DS*%XUE/6[E/0PK`@*``4TJ`4(I+TZH$6<2`@1``1S,C$R,)J+'J/9-)$S"
M51A1Y\PH`X)/TE12A`JB`IPJZYA+`H;/&%4C`%0L)"2`*^YM64;"`&[&0>8%
M?W)J(R8@H$8RCRQ`?.J+OO;F**NR-9>E+8DO-DN$^$8P-FU3ZH9/-JGH-BD%
MG%RS.@3R`B2262S$`V(%422.03;`XH:"$6\%*'^SI9SB.73L@W8Q)`9&_HZ,
MA5.@)`6I:6L0X"=_(RET+SJNJ%<.R0(D8`$^9@"R9_R:#R+RJ`)`ASEL[L.J
M1-)$QP/T3-(:$?XN#R14XG2B)"P<AS<.8`*8<R`60&!FBEPXH"L8HP$N`"L6
M8*8L3[J2*B0I8`*TI5PBX"[&(SI)E%EVI0&(#46);46)CU>"`_N(3<1BM`(\
M1$55=#;,L$3/0B`CX/CBXY9.1R,88H&JKBNG(G42X/TF`#IU5)#<QET"XT&M
M*+Q<A.:^Q9:$!,44--QX1#TBR:/&SCD*3MB$XAV?Q5?8LC,L@`$!RRDB0BIZ
M2",^R73:*F6L:$T4,+(6*`TI*T'@(AYQQ',R_J-`$F`"+BL#J@C/<.<"[`C-
M4D9H*%(H+*#N,`!0Y`+Z%F!!FZ-].!%_)@CGFA0[?&8!&<09+P?>R,4O,B@!
M<C14:2QBKK,ZP&=*@#+ET(*O*`9R*,0[1B2&)B`U795SQ,\E0V@K$8(J*K,"
MT@L#,J):(B`#F$<H5JH\HR,P/JY)-*Q%DLL#!.8```O<ULM1TO'F4LJ,*A,I
M_$Y&U`)*J(BW\D*%<`6IP(I*?/!5*I0J)&!^W*RE7(3N=@H#]HM_#N`QZH(`
MN&?^KL,'IP+&&"HS@Q4[S@<#&--#',`"(D:C+&"-CL560X):'W9L"L5A75(@
MDL8","!6N<WZD*D!_L("CS[6OM9J*)M#<DYL*D)F*I*F*8#'H"AT!J?%P\1E
M6_Z2OJ8O@^CECP!2`E)*C9PM2QQ@1&[ND3HM'MO"6U=BN1X`:B*D4LM'?3S`
M1[)U80;F[D)B72J@P,8K8A!*`"H04-Z$Z20@7HY$KR;)1YG%(@AB4E_V/?+M
M=+*6,2J`M'`G8\L%!`>"<O:V8R_``D0V)`#%`RZ$K/J#,:R'0C8``=H(*73)
MU+P"6!.76=SI2K1L5::B00&KE2BOQR)&.1X&6):+8`AI(`Z,`*1T=,MS`@1`
M9!/E`/".2W;D0:C(UF:J`OR.;@1O(,;2\^Q)P5SK7!ZF\=(16H?"`FC"_J96
M8B"H"6]P<0R?LC1J1(U,M<L,E2K0*DCL]G.?0W0I`G*S\'4-@%->AS[+99DV
M`G'1=R`")@(:UU$(IFH6HFMJ2Q\%`(^F\8-,1A^EY'X%B6,5*P/HBBH"IW8%
M9@-:-:U$`@'N0@-8IH56`B><1]0D(`-0:U:PXP&(JT6J!CJ3(BQ:!Z]*#+"P
MI:HH(\MRXD)W9"1F1`(@[!/3D*HT`#))A4@5P,3B$#4$('`&H%3[@X@(((88
M`"_WU2H;@'P:5(".K.'@)R0PX(%GEM*:1FC$0X&A0SS'[!7Y(P,BADNP3%]H
M4AHU]EB>-23\3(SAI'$%!F\.PK'P,:3"$@(H_BF$"N?/T&<`5H?2Q'AS9*E>
M',=+0HH(PQ0P8B>2=#)CGM(!\(1#XN(]NE'I.H1)M_$:\:(K,I>+SH<Z4-6C
MPG!':)0`UB-$T,\J,KE(_&_U-$`\)(<ILL([1DQ&)`U^_8]_N(5,,Q`#J&62
M6Z<?+2<9?[0:A_60FT-F;:2J7FAZ$&)U@(,Q.,DP&"D_Y/<L<.NVT`*WW"93
M0G1QSY4BJE"!S6*IIH*`_B,%LX01-8!HJ,G__(,[$B5;_$A>G%FC.O![K*(Y
MMJ<:-R*Y/JAX[$8<.4F%F/4EA,1X%D`"(DZ%+'!F%6)U^JAU'@0!4HIX(U"+
MBXA"7"+J%O1=<@.*_LW'+Z)68;.BK"@C'ZN&4;H#.7H3>!:`.GSP``9``?Z$
MT/Y)4WDH5G*P7#)'DSRYGPN"B[4D1&!C`B"&>XXO82#`H,JNHMUX83LI'Q^Q
M0"YCHJ)V(Z+K?LU"?R_./3\`+P?"M88B+&]I&ELG0AL`OM`0J5MJ2;#GD4EM
M0:C"H*55`"@`*F+$6D($=:3.WP2*YO`J?#V%+O8T)"C@(.B4`0U94>PB),(S
MI1Z$.])*G.I"+<X710;6FF[$=%+K1=1F,0B`0:Q(APE*3=J8USSVXDJ-(&4$
M>YAO(BL[\`RYGS>@:2E/,?WXG\).V3PW?=]X(`;6'UGH`T>SN2V@N27@_J^/
M))G#&GWYPW/\8SH\`GE8=4J<ZB08Q`(CH%!9AZX)[=[`D2IRPK=JUPOGBP-@
MI"RBHOD""@-^*J+3&J]SYY/$42ZMQ488CSDKP&)X2@$)BFH.3"`,,XF%8KG"
MEC^W&%_\;[R)90'XXWDZP.9"*)'^,%K>I<V2E&K2Y:44`'@"QHUL#6<'_#):
M%%K#!T5"***+NS7"NFDWMMJJDGK'90/$0Y]NNC*XJ5N8A7"%`I6Z`OC>9`$6
MH`%^15:<W,D=C*!/AULS.%`JH%!XO&UDQ6O8#_%D91H-Y5(DECLD-@/VP_R>
M_,LU0(@6P`&J[DWD33EH)XD1M8488(.6BSU9_C!NO%RBUU7);4E6F/Q(PH@Q
M947\4L)(E#QS(MK)L['1A#+-9>6U9&5U^.K0(8!AKN2O-]W)BR9\(MV69OQR
M,C6,C6?GS"S&0L*,-M5MF,HF+O0PQ)$@+N(]"",=9UIV#?*M@\/!/$H<B_C$
MO.45960!-V*37G`H)BNQ]*1DN$0ASD-5)L`I#'8`M+?+`H4!Z2+HQC<FTL/,
M0G1A7YLB"L"(\F*3^*@.I7>M=(]32H8SAR]HS%$=S>^X)[)V56WH'N;5<H-U
MH(W)\\)(K-&JJZ-OBYP\+@`J_GKA%QXJ''Z3WK@#I'Q4GD;)%6!++O[BE7P$
M;6H$(6)+0#[>N$?C_C4>Y-,KXRU^2R(`Y;=$)3+B)\)%V>PHN9*C$)?+H&Y#
MF27'IA0TLKC%8A_>X1>WX8D^Z(M>,A3>Z),>Z1O>S1^>X9<>*BR66:'BDY[Q
M+I1Y]\#+W@MBZZQG'1W`0^X(2"3`8N2E9>S7.H+MD((B+#_+<1GO6Q=@ZK3$
M`9IG@U@HZIBN+;O)27:$GZSF?/^LU"1*<U)%,>B$M+Z6T7Q1LS$#;!9@DDN&
MEAX@&9,D/U;O8/(M1M(1FG%V7%XJSM3B:0JX.2)?B[@862"W-3-JW5;\9!(D
M@0:@9#0@\\ZPR9"%R$."AZUC5KEHXD4"^$LT"VE4@\CB78Y"8HVEK?RX_B0B
M8P(ZE.J@?_JC'_J%J/JQ'_I/9:TZU+ZU'R.F7Y<B"W6855P8E?JG__RC7R8D
M=MTFQ/^&0O!;BB+O`F^QQE"&4[IBIZ>?PXY``R`02+@`P4``#!0J(/C`L*'#
MAQ`9'``@H>&%!0,X0/Q0H8"##1LM%(``,L*#"Q<^),B``,""AA0.?/!`H0"%
M#ALQ0.!@00&`"!4\;&S8H0```D,O-&AI(,$%#QLL.!A@@($'H1\R1"@0``"`
M`@D$"O4@%4&!!1,P8!W*]N$"``D$"&```4/;AQI2;LQ`@<$```@20-"`\P,'
MNQD80G!XH8#&NY`ATHQ,N7+;"@8>\F0@X,"$_@Y"'0!^6+!M`[N5*RC8R$&`
MQ@X=)ASNP`%V[0R?:W/0P`!BAI=#-1C0H-LV;8:@&6(5FMQ#;:S&:4O/D.$"
M;.F%L6/7H`!#!PNP/VP`T'4#`0V)-WI0"GA"4P;PXS-X`!_!@`0,,#)(8$"N
M_/]^F95``@<44``!`B`@UX(,RK5``8$I*-\!!R2@@``+P%>`7`<P0``!#/0G
M0``#)F#9B90YT-`&%#PFV7`85#34!!4X9(%>E'5000,?/B!!!A;T)".*']A7
M`$XT#<``:@YU\,``$4A&@0(,4,!0!A!X($$!#<@%@`)8:8#``0\@@("+#7E0
M05P6-&3!`0,4(`$&_F@ZE`!<3:9G44$!$`!!!;1MH($%".Q4V`82\-@5``,(
M]-@&#O!(0`0<U%F9>0V@9.E=E*[%%I8)#!!`H^XQL,$!0D7)$`<)5*`BD6UY
M\"JL;*GI*64\3N"0!XFMYP`!'B647$,,S+K1!H5EH`%D%@#W4`<"6/"D5P$$
M,&*UUUY;;;47@-F0!LY"Q,&BU7I%7H)Q-85`4P0>(`"$?P%@@)FB;JNMO018
MVZ>%`X@Z0+;_6LOA!Q,0(!H&($'4P08-'%#H!1H]0.O$%)\H@042K%;QQ$Q.
M@`"3SUHUV%`>++#LQAYH0,&O_26,H@1>1=`!!A$`H&>:$A`@06%$89``_EI8
M11"`!1I=`*@%`UAP%002;)#`CY*M2<$&$!"`0`3>71D!RQ&`UQ`&U;H\$\^:
M83!!`@8V$,%3&E00P01=-\2!:OEZ9<`#GS&T000%DEF;90]\B;78D3FY*<D:
MF`TG`0=`L/4!-7)P@)4;*[Q8Y;O>G".@9&LPP`885*C!!AFX7<#=&PC5P*VU
MDCV4!+U)E@"K#V"`\`8;<(![[KL+"GH!I#L$+EL<.'`!!N@ECK#NO!]VN_(8
M7$!=!M%G@/OHN%-P`>^Y,X^[LD+Y[,$##^!4*6W%<T1`G+>R&")=)RNG*N;T
M5]Z1684[0#0'4+%.Y-R/X4`#"$<4[/GO`QH@_L`!&3*!-IWH`@[0%:Q\`H`+
M6*`W,MN5QQ(0/[DI``$27)'/!&"`TUR%`@;0B0`F\`#\/,0#&%#``7#$@945
M8`!X2]T'.K`U8%4@=2T!'HHX,`$&<,4`%%@6I(R'`*5]ZP$38922)N"RE7UH
M`1+0P`*)$A=S.4`ME+$@K6"X)0%0ZTU#JI_>U$@K#EQN5P_P`'P<0($W.0"&
M#DA``$ZW$`],8(N5Z<E&.K":*IUH=IJ9'T2BPL8FN6Y5<_N9BB3P,1@VI`&%
MD=@$")(9AA!$`000#`%GTLE&FM(R&OB9`"*3`6J1\"A5X8\!9CE+"S6@(`90
M``1VR<O'!*5&,QFE_MZJ=:2A=,!8&[G8B3*@,5I14$;6^1HA!1`!UF%``&]\
MR-1P$\0(G`P#_0E2`'C&`2AV,$T3*.-7'I`P7D7@0UZ1T\0V4#!Y,8U_4])`
M-=.$)020JRH9&`N6'/"N`@"S+:0KTU]`5(%S^L:!%,N`4;SRN5-:]$05H)Q#
M.&`J`@B*1^[B&:)TF94"`)(R$&@`:S+"`$5"A@/%W!7('F(!C5X49P/(U0<D
M)H$(#$!,"?-0`3"`E`A09P`5D(`!CH),B%SPIE"=40`BD$VV3,`K"B"?5C5D
M`+A)@`):?0`$Q$I6!YPE/0J(GP=<ZI#QD(<")\5<!QR*2FLMX#$.T%.!_EJD
ML`<08*972@`!](0ESA!`E\29B0(<6`$"+(!U'H!``52UFPB@32!9;<!1$)*`
M!D`45BF#@%]("%>&8.!!M5..H-YIKE!:X&0\N5!5V_*=!W0E``9PP$&?A;E3
M#>9P40WN32""MQU]8"MWC"->4`/<$S&@F6TU0`<8$,+(;&``KKN``.CZ`<^2
MAKN5Z\`!&K`LR^;G`Q+8XX@25``+(,\#)IH`!*X:`,\0!C+D"ZY^&5BAIJIG
MLG&UC.Y0(X$$?+:M7B'`4IKZ`)ON=R@6`,`!F,2`976@`1*PU'0+0,5%,@`!
M@-H52!Y0`?E:C0$7X)L##K``,&J33)HS[0#<_N42G[S+/D<)90.4JS?P#O("
M,0FE`BJR@0I<8`(+R"MR$,*W1>5R)SO=+64.(U^C@`A-'`C7Q(HHS`=#U0-7
M+"U#,-G`#Q`T,:M[B`)B3+$&5%=N)C+DI;`K/"H5P*$=>"Q>`ER9"&0Q`=Z)
MDV[!3(&_XD=-)0X2SR:PX@,9@,UL.4"7@UM@`WSH0TVIT(<<%I@2K4LP;8E`
M!!H0.\@,QZ)U.:!FB\F;6]WM,@Y^J8\CXY,`Z`ET!,#1KBJ`14NQ*@!Y>Z&K
M-$H;V'6%`$Y\R`42\``V<Z<`%^".M0[TX0(!@"2)FE>&/Q`B*)W(.=(RP``4
ML+:%00`!H9R`GC@@_H&J>84!K>&S>BH0N`$XH#`>>"2L)"`Q+_N;HU05MY)0
MHP$!*&`!!YB;`3PE.372Y5BHDC-ES/,0SWC@`&RU[$7-JB#&,>P`R/X``=@-
M`64I3"D\4BH&)!Z9":C4WPZ)P)![*CT)V)Q.NZ$`%6VN\PB<ERVP\SEE$#!I
MBWJ`@@M(+99<A``?C^Y$?J585U:IM_5E\(6"C?5QYZ+#%RZ`1[HV+0'^N!$4
M:KT#$"`33@9C-KX()4@)H`!?G2,J`?R5`/JFC',H20`#8&V'$&Q5R=,D0`"8
M,8UW(4O0;]20L`Q-C>8I.LP;B2SE4.#<`DC`9S)ZX88AGM<.USJKN*UU_N)Y
MU"()$$H"SSGDBR(`)PRHP'A-HJIH!\<"2V4`)8MDM@!(_I*`]?)`'O(`#&UI
M`!G8#S(IH.6'&*^SE*FP1>^K'@(8?D`!0,"4"I">L$,D`;_?E;PAHH&N`$=+
M8L:+O2&[%6$2%?PVH^E5-M(8'N.E*O%[20=TK<,(>T9:BV(NS28\\R5OL;$`
M(S)#>E,U"Q`!.B0!2$8MVE<KO%8M`R)#$H8H[;80;.0`;#5Y%V4RDF$!82$8
M%K`!].$Z#_"!%+,`6N<T'V`3EK$!`I`PK0%1'M@D'!:"0K%)&``6,-,?C_0=
M!Y!]#(`3';`0:Q8XX4<H(-@0F[11F+0`!J,:_@)@/`\!>FS1=/1!&:=V2BNW
M*11`'NF1;PC1``/0=P+@?;NR7TH%`!6``0U``:X!$4JE`-[G-&*Q$7Z%`15@
M`1-`9SOD``L``8_D-"OQ2!*%?.C%'"_!`?LD+A?P7'I$4>;"*`;`8E7B&422
M,ACP)`B@6[21.(28:S-$%C*7AHM%%.R$.[=R3.,"3E*&.5GVA%$U70O$`=3Q
M`/V!`*8"'7A7/Q9@<*P19XAW%QL0`"?C([MRA*LR5.-')!+P6"<A'JE'/6HE
MAW#R`%JT*S(Q0[PX90/`AL)WC,5S)A?&`#R")F#5%@KD79%!=/NU,$5Q%'GG
M.0#0;^KQ8&]!+2H"_E@*T`"6HB9CQQJ_TF\@L0$OP2N/QAI^<6"F=4-Z@@`]
MV!L3D%5Y9R,58$:7&``+H$<"@$,G4S+--13TUA48QS\LH5E^,G]S@X9P02#>
MPAIQB"H59$H!8(M0!8ALT1APN"H>@UMKMI$9220;,%%(\1`P*$]S5A@SV1!N
MPQ`.X%^-Q#A)HQX,LTZ0Y@$J=0`9T"4ER1":IY/HY6!RM`$*H(LR0A(.00''
MZ!!XMV,[5"D+U)"GM']*>8+_\I8-,1%=I6^0\T#1N%%=40!+LA%I-Q0<8#6C
MA`$(L%A8H1&0DP'BQH9TR``Q%EE^PC-:PA#:<UQ=`5UWD0&P8WT?XTD._F!$
M<)4R;H(WD'8LT[A''0)6Y20GGH45!,$9]Z%U%X,1E#28E+$`X4>6M'*80\%!
MKJ(92&::]%,!`>@2G@*#2&09[Z08;.4!P&,>15D_Y>2,35)H7P*1+P0F7AF.
MD,%KP-E(+MB,%?$`!]<`"G`V9..6;2&<<",:UX(`W`@17WB7CW1-1P$!PP41
MF3(!9,(Z&;"=$#%A$U,!/S%*TV4`L[@>#0A9%0`EGE(1!Z```\"6$%$P;S83
MO'8`YU1B6I(W*85;-A>6*P([)40G!`,!C.*+>M%9HV)4?Q,99.$E`I$>*V<F
M-'0!5;$1%9::?T&1ZLFBQ`DK'6`B;+$`&7``_GQYE`I:&>D%``[@BPGF(J-G
MG)11:(8QC@S1C0P!.T\#<R,%+%$(&>*%G1E@G@CU4\0)`?SW+U;Q7'(X`%J6
M$&T!)IOT3D@H<P10/@[1GXWD8KO2=^TQ:KHTH#H"$T]3I:>$;I.E;*06HN/#
M;#&F`:0V0))Q`1@'6!V0?)@$$9/H`-M&?`GR%S-F>"XA`;^29$855P31`$UQ
MB10%'WOTG/;F7B7)45F64A22`)W24.("$=>$81PQ'Q3RF,FV,0XP:TM**T4A
M&T/Q&_&G'C*!.5)AB`Y00^3F(C`8<I61`1YE,)=T4&"F9_N58A)!1Z^I'JG'
M?7Z1D2G3=$M*2?&!_F$FH7M;0SX>*%IS=`!4R1`!X$9PHV60V%GI0:(612E.
M!5>-TQ!OBC88![$QEW"T8@'Q&ADA&8SR$YCB`A^Q]AWDJC!+]989(`!L5CQV
M^4)-:B5-ZA4),AH<D(;QXA'2NF1287VX^K,=B4T00#3)U"+-I!4%<C>SFGC2
M8QUV1QP0E*5TD422RA90-JUJ=`$!TT1HDC@0T'Q0^7)J))Z&L1H/H*2>I&`@
M^P%&HQR-]90W136"93R#F6=NZA/"-%UK.*W3.)4/,)7/U0`5$(>V<V1_.Y5F
M5;`?\!)K(W/JL15:E'H6-;AVZ!UO.3,.8%>[)1)V07:6(9P3,X8<Z)FG_C-*
M2F6H#-%8`A!\.T0FV=H0$?!H;%9\")"9&N`P#D0U\O(D$+N8M8$!!$4>!@"E
M?-81&V(@79&:&W*)'$FS[=5!:<D!WC<S#<`5ADDT9),[XF&@LG(`KA-A-P1+
M(T,DI8:UF(.=M/&F-^1W(,$!9O*:#$"V%1._&Z$!%:$`5?L!$79Z;G(R9M4!
M@P55W?(5`PI:+P$F"F!2@V0A:*M?P^<0!:,`+,,BA_402-86)M*XY?L0E'E-
M#?P_L_@23%,K=+$`!E``Y)88T-(2'<O!`I"_!)J/RI%.9+I181%\(+HIH=.A
MUT0V'*!+`VE$`249$701,L(9`+!C?9<[!*)1_H<!`13D6+/8%H^2;$3T)/U(
M+?QA?;$W$R]!(P@5`?X4`,;R*T:T<OI+0"9\%4%2$.]RMED18+-EOA$E9?H$
M2H:9H+4B1&RTGN17$2QK&:TT4]3!:QQ$,!L,>685`/M9,?!5%#]<2C%GF.GY
M*:Q[(FL:<S\,5@J">_,)MGVI$A50+&V!-`5P49;4)%G26<62?L@!3%!14PY`
M)083HHGWP1#1$H!&%W^'%YWUK,C1+*D*1TEV`0!00[;&$1EERPHII:9+%SC!
MQX8W$7M4$10@,_C[0H.R%;"T8RT\,K%&92%27Q969!ZBIFD)&2GC-1OE-NBV
M`+A5+!_!$8W";4G6_KZ`N!]]UU)WX21T3#]HH9A%=FY/ICE'9TJF4K\JM7"6
M$3JWD@&]BF\BR)U0[(N;-)SJ#":#52#,`:O/11*57"N5LS8?RHNT<1:+BR9:
M.!0Y&7N!<1="^F"[T0'75FD,"Q-L!D/4]&`=*A=.D1,#\()5\X%.8P`)DY-?
MRQ`+L!"XX\M$BZS=`1T'11XDQJ'+,BD?D%(4&`$(&$\WPF8=L#/Z>Q<DJ&#'
M4W`(8BY8`S%$,LNXPP%+U5JC+&&&@61I*+AC,5T)UL@0D5'_C#D,RK2VFGV,
M]P$Q8DHMEA-1(@#RMM*&+7.`I1!KL1OD%SUAJ12&*1N091>'(2@;=3PH_A$]
M(`&C,P%OOF<4_<(A\_S7F1(2"R%>+_%Z;:FX`/`F40L9\JA?PN%/9=@7Z781
MPK2R<BI@$64SP.8Y8KM#0SO%IV)_+3HICQ%A:)@I%YH80'$`;8(EQQ,2)(&H
M+@8S8#%12E-,IU(XD#)12:PY&B`Q?&%=O`@70$NS=%IYK'1OCP4!7=$?N%I=
M.G*1PVL=HF(NHS*'9"-]?[TQI]P6ZI@F!#$1',:4;&0`;$@S'X`J@$,`VM,L
M/W%`AZP2U8)!B1W7(FPI1R9NK3(4$-!%`8XM_Q+@N#HJ7X(<9Z*,;CD!Z@;#
M.6(7&K`8N*&.L0<I2T)$,S$Z1W8QI361NA8;_NX+`,R7+^Y!-@LPQ0TQJ-#6
M(::6$:>D88'CI#*U'TG,A@TFOR8)RJE1@Q9>%$C%$1[).A>&<?^9>;IV5=0R
M42EQ;P&@`.,1P!`Q%7#[`7#E,]0B+Q4560UQE7JG&I4H`'`\IM_!E^K1Z%T4
MWR0R97%H`#"52RFC`<%K,T$M&:?5O%^A`7:-H?J;W`?>1N3X+9#5`9<'`)=<
M,:"+K%&BP-$'M!@"'PM`)?EA1`KT`;EU58"N(AX@%C2M:SYE3QG92G5DXS=Q
M'7/E[-=!)V@I(\.^F#L)`$<)/,#&`!*V;)V!0P``%7-!(IB95>5'.>RZ*O:A
M/Q:R-Z`6<Z]^'DX!_G*0D0!3>4KT]A`K1^OU^P`6T``?"3]9<6TH4AT4D\`(
MD&;K09D!()"+]`"%:"F,=AH0X4VBLB9>(1L@-G62O"J4M-I-DH;S\10EA'#E
M,WBINZTG8C8M5"W&PS03C2+.P<D_2^8/81(40!WA/J8E`1B0>#*E<S,4Q"_*
M)!KD(2II=>H44Q>T57K/>$K<I]C'91E74?4((7=8G_5N*7="`9E#Y1[;BF((
M!!>3N-08IJ`J`Q$0,)4"Y"=K;ZH21)))B<H%,%Y"(1-%81C<IR84L!##F#$-
M(1HUXT!>-;@TDE&#6V(E)J`V#A22)>4&2X*$(IJ2@;\I9$IS]1":!1@D_B'Q
MGR4M(8GG&%TYK40>$H0!K42B505#!;E((.(I?`J[=21=@F%6F=<5B/>#X$=_
MI[E3:^0!!N$5ZCIR;?2J$R7;&^,V')GJ#]$J#@-7]%2H`%`L7-[W>R2<8.85
M0L$B!O&<YC)>P*STP8FE_+,1"V#SIS43C<3'^JXBVW53&O-%<.,8I)?5%(7R
ME9&32HE>`#`Z&`<0%CX,)#AAPD`/##@`R$#0X4.($24^)`#@PD`&'SH$T$`A
M(\$(```@L`!`P(8/"PZ(1/E!0@$%"Q;$C#E39H($,6':!/!@XH<#'Q)<.(#@
MYP<.03$X.-KTYP0)#Q4`"%"!@8``"3!T\##P_@"'B!D0+'#ZL$/#LA(U!)`@
M\$/"!F@C0.CZ84."`P<?>KA`0`/$!PTN-/"@H8'#"AD<B.SP@`!8A!`(7(3(
M08(!`R@W_-7PP(.$"`/1$FS@-BW!#0H*+.@P0`"`T*>;<JCP`/)1#`PV"%@@
M@("!O!CL^N[0(2(&"@D"B#P,L8,"`LM%3C^`4\)MV=FU;_\P84&``Q$J<"6X
MX*/$!1(Z&!C-/6*!N@\Q@!40WWU3!1?$"@T00,$'!A*`8(#EA,L.@(@X<*``
MXQ#8@#*'&M"K@P0X$,"X^YQ**((!&AI`(P`PN&``X[ABJ@($,$@`0P8\6(PR
M!B"$2(.6(EK`0/0\_E```P0(.&J#`@8R`,,,*R,`QP\&`*`!##&HH+<"'M@/
M/=UDPP""^Q8#8``.+"@@,X<8H."#!@J``#N$%B`I(@8"$(`""402CKP/+M``
M2Q0)HJ"Z]@C2@(`%-M"+@?\LF,`#"F1TZ`*C9$.4``LR,("#Y0@@LLCL.L``
M@]@X:*#-`2#X4J'')NH-@`,8:(O(NS2XDP$#IA/)30$0&`]37#/<P(*K!!C`
M`0P\Z!,B`CSH\E),7>R@@@DLD&"""SJPX"+X<C55)`?AT^"``1,H@+`'QG3T
M/(>D/!/`"?Y[2$*$%%AH6&M%2^"#`ASP0``0MTH``>46_$"#!"008((*_CY0
M8%<`6B)K(@/(?:@"-"EZP`"B@OH)R($<$#=>#;8BR`.JD!W(V0(*8``"12T(
M`((:RZ+1/0X*0```"RAX(-J'.(`JJAD?<.#0B"10Z-\&#`A`,`$,P)*#VQK"
MH`$'3/O8(P?`RD#<0#TP0(.2-M[K@+_2TD"!!_X20`(4P;,OWJ82<H"`!BK8
MH"L.+N#P`)\;C<B"`19@2`()&DC@`0G4[!-P!J)30%,*>E15@I;9EORG#BB`
MX(`#%(`@@[5%T[O(#G26`((&9GY-UND,F'CRG"\0CB\)'GB@`D7+\B"^S2"*
M?=J8'D`.H@C0ZF"!=UDGJ`.Z,K#M($2-0_19_@[&1/3.!AK@``+C@#8X8I`<
MCA!)B!)([H($F/J)@R$_L(`NMON<`(!Y)XK+@@..C`NL"NHSWB'RW@?`@,X-
M9`,+^,W:/)`_>SFG`D)S"^W24X$&+*`"!5A+5HK#M(YU+@,RJQ$%F.*!0V4@
M*!E0ST0&DQ8*#&P@E-I`W[RV/XG$3$G3(8!X"@.6/7F/-$H*`)$ZL"4%#"!*
M%XA8!1*@.L/(B@`0*"$,G3@0Y"D@``:(P'P<$@'S94A:%4$=50B```>$,8P%
M.)U>M".LMQB(`_8Q%D$X("A^$8`!&>!*!T#3G@W$YB&,JA!(UJ8\!V@J`B)#
M"O&@2*HGOF4#B^04_@4B<(%=66"1>:3`)#60F`U40`/V80#X'((!'TE$`06;
M2``N8(`*#$"'#FFA<8`4P`RMD7]%V4SD!M+'@73&`(`2(BS9)AXRB<0GE3%B
M0S;I$!<9P)-V00`D#4`!XS``8&^#GP,4D($=!8`"!/"5U!!R@0*0$C4HN<"8
M.L"DDMG2C<5J6P/>Y*<)_-``ADPD1%3619'\1IH7("+#L(7,-7$@`V4J@(#0
MI+,'%`"?`WCF,>MI/*X=@(P29-I7M"B961&@``0`EE\BX@$,/.```L">=BX@
M`+`$0"`'$`X#C&,!!$P``D:;3@`V"H$),`!S!+#80/*$$*T`I6AZ"\!O_C!S
M5)4<5:E*59)>K,*!4#KQ`?W9:,DTJM$"V+2J,L-J50&`I?+\I`+JLI$W'X*O
M0`[N1T'"""$SU(`:@;,G%""@ZI!D5J1HP`!D?:('%#J`8?*O9)1Y`)&(LJ*(
M/""H'Z#`1H6F)`$P(%0%2-2-_/.__SUD@_0L%P5VV9`#%(QV1]G141)"@/9`
M0`,=>-/0'OJ0.RD6G],I@#H',K.OPC9^QQM0#54+$=S.%E`W>ZWQ-C`Q`;S&
MET[I`#6S,DJ'4"J`%K!:11`0MM-4```'2>X&4@2443[`)#<3[XX*()>7\.R3
M`!0-`.R%`!?U=(F)T<`$,J`?^F9``\J#P`/Z_DL[,#&VDP-8KK4<`,F)M`Q>
MCG2(NR:2`3-"9&&FVMY0?A15"118-AD0R`$)@@$)!,!`RW(``R(0`0HD1B(=
M@.]#66R`YCCD(`Y%2K2\$X`(K`UY#(BG!L(X@4DF14H84(`&.KFO`1S``A$0
M@&UXNP`](O,!#!#I?@'0D>T>Q8-NC5[#D`7-."$``<0M[EX@4&*%SHJVXHSN
M#!7E@0/4+G0>/(`!-%87"Y18.;)Z#4D7,#@4EWER&\!`A,]'@0DXT@$GCD!%
MYJE>_@4@@`A&`$81P+V?1,#$'^"H2NP[%04HP**W[`JOJA8N#J@).RJJ2P0^
M]0$#)""RQP,,\;!H_H&EN)8T+?'(6FS+MJKEK(ET[0K`#M"G"T#Z9AG`0,V8
MC0$.NX[0A48T!7!]`+<.Y#&9,8"A(8*Q@?`S5R+L,$$>D+2/5L`!!!HELK#X
MVM2@BB`.:$"4/S8`#51Q;@_A&U@_\`"#.,;.UA2@F!=P@0!,H`'"@8"_`>:D
MB&R@`6#[``DKK@`/!""P.1-1@_`*U6-WK@!)J8@#IFP]04/$`P_:49T%X&#`
MY+-SH/G)R@V3@`$(YG42EVCJW/B:>DDIY7UU4@.XB;HT`X`"OMQ(`*'R`:.`
M$@"0=DIU4%L`#,1*5G7;;0>BJCX)B&\@]?ZD>L$#P$MOVH2"43(!#A;G_G5A
M**>M?&*PHWND@42@6NK;+4$N$.$X`0=S@Q^\``A_^`'4SB$%$-AKJ/YMMJH/
MC%"CO`,0L,OJT5OSE'<U^Y#I`>35969\!0S@5'+@EBCYM1`0B5XP,``)8-<A
M&2!P1!KS79!`40$1D(`4$]``[$J=1"F)S9]<"I$,),X!`B@8Q/WK`0E*1+P`
M6(`'+-#W%8YYTM3WS85N"YD+0"`"F.[K7SS`H5J9]4D4\$_$-UYSG36`H8^$
M8N!B-0#Q84`ZM+T9^8>N1?\!`),!',"Y``\0$%/ZB9((H$I*"2BZO&S[-IQ"
ME2U!@%`A@"?!J0+@)Z8AL#R3@##BC0:@``6(_K$/`"6"P0L)R`O>^**?R#HQ
M^8``R`A)BKN!R*D,0*FZBYA.(@BRDH!200SU.D#.D8@,V#<;.1\`&`_ONHV.
M^;:H6@H"G$(JC)TJ)$!8&AKVZY%ID;X/\X[D2@"&>*T&$`G]&A!O^Y<>H8`B
M&H`BXY^#P2FTZ)+K(P""T8W"P)``V``%$0#9(XC[:@N-N"V!>"2)8QAIT;L-
MN++9.P`3?(@4XX@R-`"[6)@?PCF6$C3#F)L(4`!*C`A@R4'N<9'LL#X&^))Z
M,[\)L$"JF"VJ&!QX^;_M6!"@HZ/INB__RP``""`,0`G]J3C&$QM^,8!*ZPKG
M08H,N)[+<R`CBX`$_EB`CI"=O6J9I$"``DB\.K&`HK&["<`7Y`N`E/*1A7N(
MXQ,P(DLDNPN3$>,K$5F7(?P<B(`Q"IN(IR$(?U.D;],;#=N.-JH3"-`IR5B-
M&A2-]TLC[]A':]$ND:BSQ7&.B:L`#QC!Z%*`!#"K=+$S(L&I%3H[!&@`E.D*
M8^D(6TJ*3$2*@[BOB@N-!BC(%<)&#:B^`8D)#]J[B(/&H%A!'"J^_SB_P]B`
M>ZP[!X"`_`&`5;HT$)R(5=(0.\*<00+)ZSF``>`I+NJB*8*`8)%%[<@-D>B;
M/]0.Z0J::&FQBLN*II"6THDI7UHD5UE+5^%#&G$5IN&*M>3#CS$@9%(4_FB#
M@%!+H?#`Q@B1.\*9,!A"N8?PC('`@!%R``V('4B$-,&$"(.8"-+3K-#H`/)I
MBN,RM[AA2[84D0K``+:$C`YXF8B(J5O*K+?X%PCPE6L*%XDHBM?B@*N@F8^2
M+#V*CX10J8C8%F^KR*00B0^RO@;P#P((PNA*@!9QB.BC.9DRF%7R+Z8PS0\X
MDZE@1`I8IB>1I'LQ``N`/K<0KXQ("J_[2<D9GKKP`/BBJ26Q/03H@`/XM<<L
M1:=)B6)IB?.4S?VCBKJ9@%'I2JR4B`U@`&&BDPQ9P(B0FZ\$D?C\&`N`#FDJ
M,`QHQ>4`CXHH*F)<C9C`B@!``)?#J["P-PR(_C[D0(D42TW2@`R/&"MTC!@<
MX8#8B`"9<+=W?`H/=4!Z7+Z1>+QO"RP[<H"9,`F:F(D@C0EO.:+?8(T#=:7E
M^$2S6$7W2I2U63?%^PD*>*$,Z<4/0X`W_+"NZ$:80Z8RU*%:L1SX0`O0`R&9
M<#LVVZ9'!!!$F12#H9$!\%!VTIJP@8"<X!&4``XV6:V&<`"C60EIV@`,7*'J
MX9*/XA@]48BL6I)ETK\@(K\%/0T*,%,[8:P+&"60ZD@`62"_(<H;A)^B4@#M
M^4_($\`IY0X#!9Z*<J.I4[GP4XYR;`H'T-&Z/$_`6*:/(H"<Z-7JX3%$"[6<
M,("7Z]6$&PB/*)SM_DC5GW"`\FFX:DNT1(L`@Y"`:+U6!!C"R(N(9IF(G@H+
M_-O6BYE4T($BL(C(5Y6(OM`T7U&/4@/'[-``_WN(7<%,E!B>)H,(!F``!"`I
M9.&+7]$<R)RZ#,@?BQ+0D:B+/S$?3EDL9+*\&>P*^,@-3`NB!-"`7_2;/[4^
M'3S,@H&J$S(8/JP<;H)*6UP(`5@FOX*BVT'(B7!&/<&U<\L*[J&`Z;`M3[F/
MX/D,+FJ1`^HD`65#LDJ,>5F/+AH`%)O7,O,`=O//^[C,`ZV;&/,;)$$>`X@2
M"W!:B3!.*%H`1\H`Y2`,HW,8!_BUAP#"?4U;M=W7![``MUV?MVTLN5.5_BRB
MTELQMZQ46PNTP+ZIE=]`@`#95YP8*=]HF<ETB$1AF)_`)O0L"Y6)1?<P%G$)
MT`^(@%@YL&1$%M`D"&U4$Z,#`*6]CP50'8C`&8SHB"BQ/9SH)_D878$@FPTH
MD:N!FX^!Q@]P@`!P@/8@"Q*RL\YIC`)XI(9(B//SMKHA(D=2D7`).VRKW$8+
M+/T+"HSE%="LVBJ%E<1[GU5*I;<(#YV2`&8]"OTBB`J`*=;SF8^JSHZ%B"O1
M(BDB5<?`N/(`1^\HS!,,``*9K8#)VM"%(8!)0+;Q$HF`G`X8/WXB5LV8@`7)
MC_XE1V2S1BI3S-!Z#-(3.J<8K16[#OF9V]YC_J[^8IK_9*UIX2<2=IT2/N$2
M/@H"H(`/:0JP90#"L!;%PZW=D[]0N0W?D8@)8*_)B9G78Q+$A0SH>[F(618^
M=8[+$2>P]95]$8!K1`D+")3J6,UO_1=271*1X0!1:][5FL[[>B=R[#[*6B,%
MV%<E^0\(`.`5$H"&:+22T$_3>IW2.-OZJ(`C&0`/RC`;.@VMX0"/D:!\6K*/
M2C/R!*H:12%<0@K\*Y@-.!I8,[0Q2:B*F\HNZCZHB<#]@3.+F)P+V$50Y("U
M0!WPR(L&%J6N9+#9Z0[:BP!X5,PB60NM91!D9:*ZO1@LLM4R>YNH+*JH[&4"
M\&5@=KN:X\XJEH@$_F@('K.6*(.1+3E/'BFHAIO2UT/2R3$BC3B`+`*I%2(=
M=0(21_Q)85F-B-F@JWV-4F$4D>@VK'L([<6K#""`![@+9.66'+.<B'A/C5B*
MI`F`X67ERGV_Y,.(H)P.776.!&`SH1B)W*6]EI"L*4))IP`G.,NP49*Y&)H.
MA'95K4T+=9./=2N<$$F250N-7<(0Y:%DD0B-^K(\E"EE7%D)<BT2^M%AE'B`
M3]V_R"I"[FA/W8'G:^H.]3F`QX2KLN"`"%Q?B&C>[G"66C95V3!;V[FDSS6)
MI@C1PQ1+MHF*UH"?SLFWZ(BIR,E4`0C?^]#(:Z:,Z#G!;.V<`Z(LEV@9_JM=
M.K/@E9;0ORV9H_T*FR\=B`5@R>>8#(UHCND#W?KZ0P[8+1`:`'73*&`Y.*-^
MB_-RB?C)"]83`'N3C:TVP_>).@89FPGP"<$@K<!ZE3@!U>.8%5VUXR))I573
M"#'D"""Y%(-`.`%4ZHISC.G8D;KXU)=CPT0R#^.Y/HF8CQ%1DK+-@`RP7&QQ
M:76$B`HP`!!4`&<=S2A^")8IBU>;B%^T$0Q9@(9K:J>&(9`B(/@9G"7;Z(%`
M&X*@.<E!B0FHB%^C*[T$K"/L4KJ<'/3DB@2(70I""OK!0!K3"!+4W;>@(RA"
MS.1$)OHI6]0`OCMQM`28@"X^3)U*'_X!5(@)_K>P*6T`J`A?Z>_T#BQ8V9K0
M41Z)THK5ZH#D;#@A09_D0N^/F:E!XES>NPH-H"P2-:,N#,:?`#Z"8(`%B0X$
M"YJ%!-!P>N49C-T-"&C6`H!"N4?WS*2$>QJN\+?"\*Q\*K'\-(EZ.4+C$<7@
MWFYSE0SP&)M+2>S_@>J)2$>_^YF7I*(-P(P7NFP38M;:DPB>KEP2;-/PQF_%
M*$[=#?"R;,AV<5G9B*=_F2("AXB16Z%\"Z*K*&9KV8`QL=F!::RQF"--^581
M6@"=)AUD=<.(T8".1!/%5'&*X</PDZBHP2*$@D2.NA19TH`DZS-WX8!X)H@^
M*N#=(A=$V1>9*2$Z_BF8*0II#4F`1D.;@_*ZDY%-];H*;C+;@=(3G5$W)DTL
MJH`70DW#[:@`-\E?WSB5T-`8Q/414/^8B%FYZ]LH5Z2*>MG<>%D`FBP+7):(
MZOZFO6TR"N!S*'J?1L^.`!&C15LTFW&=33GX38&*9H/'G[B`0_8_0H>6H^QS
MR:D`N4ZE3D)"1X$[Q&UJ8=F47UMRIX`PP('*!E`O]Q29L:&^>#V-!PB-EV^3
MVY&_NJ"-%1(U\,&>CE#LK@Z5SE&`RZ/FCQF1?#HE?Y,X,/Z8#)N`&1(`W(6/
M>T$+(_N`YQ8)+/$QS=+JQO(-R+$+5TGGM/`NHMB3@O%ROY,L=3L:-\3`_JL]
M"A;WJ<V0":<GI(V@BI'LP5S)MY>'&+"8`(Z`LTO1M-9H)GZ"H,PCI-M1-PY=
MB4JVP!K"Y--H9(:/%VRJ&\E2)0-T%PM@R7(A2N;VK-,9B:+@4-(O"HDJ@)60
M&:&&_/0V$_%38)NIGNH9#-FO_>'$$`5@:HJ7G,7`.3AU#\3D[KU(,RM=[VN?
M"!5["USOU]"J`#JOW.K+#NI*D(CH(]_F3PN(CI8HPOQ)<,XEV<)RCM'-Z(%0
M`$03&;`]$X#9DH)I:]/])%_!J"W1/_8B$L,0%5"Z6)?PMMNL&Z@$"`T#*C0`
M@,##AX0*%S*,``#``0\".GQ`4('A!XH8#`QH_A`AP0<(#S`R9)!!X84-#!X2
M0)"@`06$"CNPQ,@!`8(/'C20[.GSYX<)`SI8("`S80(,'00`:!G@80$#`"P`
M5<AA@X*G#QMDO'!@``4,5<=N""!A+%J?$P($$-"`P]$''"Y``.JA(,BT"CUT
MZ,"!XD\/".'J39AA0`*<+0\0..`2I^/$CQ$<```8@@4)#@IS[NPY+<RG!$Y^
MKGCA@P4!!0!3H,#00X&'=7M:,/`3PP$.!$XSY##!`8$$$2YP8)C@@(2CI=<&
M6,"`>$8&&"V\A)``888-B7DRM`!`0`+2"SU$.!!!><(.Y7-BS-#@@-B9"#%0
MYKZPPP4#$2@6_(Y@_N@'&$R@D$,(4(2`4A\P<!$'%52@00</6#!!`;Q]H(`$
M!&C`U`!I=3!`!``2$,%*XF$D&&H6>&"``Q%LX!,"+WYP`0$S^H6`!00-<``#
M#FC`@0,/;;90!0/,EL&`I55E`%<)Y*70`A]P\%"4$"R@@6`4HK=7`Q8FY,$%
M#A00U03N/=14ES)VA@$`KBG9DP<9Z&A`!ULVL,$%20960`!J*BGGFPQA8)],
MA?J)$0&`*9#!`UP%^BBD/TT@@`07($#`19Y)<$!"$AA`E4(*^/DAE;UA4($%
M"-C64P88('2=3PML,,$!`2BP0*8'C/0H`UAN`$%E3XW$`0.U'F`A;A$(_H"`
M?0MA((`!\75WP`&`C1=!`1F"NA<#`6S+T`,+$`:N`0<,F0%39Y[W000*/?"0
M`C%5T"T%`$S`%P4)`"#:!0$`A@&P%=0+0`$]3;``!6I:$!,!&PP,0)1I;=`!
M`FZVIX!"#,R6T0!G>OQQ?!P\4("LD2I$P:X+O3M<HN-%6=``WWZYFT\(21!`
M`>V.!V:0'S\40`/2IE4!`&>9K`$$!`3@XP32D?36!4_^M`$`3K_9@8F!2B`T
M0[1NJ1"`%V)0P)`FFQWI`O$)MH``&WO89T(3&%"P5376C<$`$YW\':T`K$H2
M!R[B7.AH,T64$`<4+.`8`G`7IC-#2+]6`01B_M'G8(8'G.3!!`!`SA`%-&-$
ME+<DR9U7`<UNT(!<)%6@@-M6+4"`:\6%M$!3'B25D%@:+.Z@`T\E`,$&=PT0
M`&\->H"``G0'=<$#!^@+@-1[&=`\O%@F=$$'!Y1+>Z004)#!@1W(F,&^/I_9
M,0(/])N`EV:GK!`"4T'P=T**PZ:`4`,8N!>GQG*!/!6``11HE@?FI95T_2P!
M"+,=4#A@`*.]"0,7^`C)I#6!V-&/`PW04V"D=[9'5>PGG\-(`@"3``LPP%$C
M?.%G-,`>9S&@`%S[FD(D<,*2Y1!R#JB6!```00A0+R,$P)].T,,`$)KH=22Y
M`%,HF):L)60#A_I2_A5AI9-/:>``"K@5>CJP`!^=Z`)@:=;V:D@:#1@E/0\(
M@-46LH$%%&!^7[)``)A5D@8"8%<.J(T"($B4!R@`6N)S`->FE+()1``!$N!3
M'DE"`0-@IP)L(P!,K'43#Y9-23"!``(\N`$$>0!7";0`*C,S)@+LZP(-8,``
MK@A#G11@*!!P8?["`P"Q=*`!RP+,API#%U@NL4XHF:16/"8`IE@$APII@!0]
MXX$-!(<!^NG.!/HR@0E,+"'56B):*."X678&`IGJ2<1(LB*9-,`""S@A.>-9
ML[Q9BTAN@>`'J)B>PWW)`[UBR.$Z0(']X-%B^TJ2!-+).XQY(#,7B"9#_LP)
M.`28Y%&:LTD`0V*`!#``=Y/,5`0<(),.2("B)XK0`.*G$Z%`8(@0X$L$`I``
M?%:Q`09`HTZP8@#>8"`O4V()`00P(`]`!*<+L4`#"G"`.\%%)@H`E0<@P``"
M^`8U%EL(-%\#O0488$%_.8EP`M6!W8AK`U2YB0,$L)=ZQND_.:0I.=&G`-AD
M35PW4UC5.)`:)$HL7]"R0%]F8AT!/"6`>#J``")0`6-B1%6?08@&XF6[*]U'
M63]["M!$\@$*@#`P`,#E9ZYB,@JH="$'Z4D',(:45)U3GJXEB0-6`E?#+&``
MR?G`!EJ[$+(!,`'(Z]J`<-<6PJY&)P:1"04R_KH7G2Q``@T`K;.J=[(!&+4G
MNGT-53$2)MS&A`,:&"`%V(HRBD`@`G`M)5]YUU6,8*8!B,$IYPPP`;AV(`$%
M,!$'2+.!COUL`?'*SU6<^24\N9<`3_6``X:D`09$(`(86-A%4>@G#TC`:-/$
M`%>14UW.?$1*.]E`!C3P$$YMB@"-F8T$,/8`IVE`NI$2Z'@Z]H`-^6F.'[@>
M0VBT+PV]R3T)Z&I*`!.G8^$&?M,#P``(\(#B.2L`^JS*KPQ#18'6BF`7R,YW
M)^#+CB3`CCZAR54_4QZ3+<@G5675DU:(H->RN3M<R>Z7(V"`\/8DM\JY"I,;
MXH&@DN\#1--997:5_H"6^>0!Z>V4:C'RG+3(T)F:5?2`FD>1""0L`]9Q9&Y7
M4BUUCJP!]41<4O7)`&AQK8H+T"-&-M*`,,ZJ`5HI8%(@4`"E0:4!&1!P>E)E
M8@+$\@,/F,`%-.``2P)`GZL>3Y=U4JRZD#1X!TA;-SUCKI0HB`,2Z%R;\/BS
MA[CF`2-9$6F*Z]JTA@2TJ'((/`,DR]($CM<'L,!DV56Y^JFO`,P"3(H_31)]
M8V0#FR'/\1)``?Z1)#8<2;<Z^QBH"'A920L@G@:L&/&(;V#B$J\X!7(D9Z?*
ML-1MEN<"3D-5OECE4*,4W7AFZY,%-T4A1"M`<5C9L`H,[B</A5.TU+E"_@&M
M>R&,_(D#.IN1B'`@L1G!V2ZEA#('=*P``@@.!2!X`0HX@(IQ*D`"9/FZ6]L$
MENOJS0,$OB4(#(`!;*(>3H4]:Z@X``)/9D@&$BJ`;B69X:B9X7V@ZV#<=E4`
M>()`2BH`G`!,$-?JW.F"8)/`8%U``0E00$HF<"G89(IY&1%`:5_(`8PM>B&N
MT1=$9]F!"A@`6H14$.(L+16?&;("Z.MD3QR@\KV\5`%-R10X&:*=U51`Z#V9
M$G0[8_=(/7),'Z/U=\[4$@2,B60RB1(",F^VQ7X\(1HH`$*H&KJH&(`ML,<M
MM`PP-Q9U7_Q=+=<!K#3^KCJ)E9Z;"2MSLH&8_J:KC9WI0.H`]QU]!4`#&3!O
M3YA=S?R/[DE'*15`!2!`E&",6:V8B:F(7OT8U%V`#561M/R*`KB*[E6`;W'0
MC.0,?5'(7&$$TCB`7P@;9=4,P##&4Y!,B-D%!%2.3<5+182>!H39!P3-!X1'
M1=Q/]_&&!P#,B'"&0'@0!]R/!F#+OG"$0HV5G"G$AO#$!/G$!F```TC`7P0*
M!IS'`:`1`WA`Q^"@/&F`!112+04;8R%-]ZF/^UTAUU61]NA$55@:[HA*Q@B=
M2"0'!/B>)"G<FT#`]T%*B&D`(>X$(58<(?);0D0)?,B3(LK3`YP%&'+`$<9@
M#+K/0OA?`PR/)3X`_N!%P!Z*A"AB72?&H`40(H0LA'>I"=)$0,1]AF;`B018
MTT,LTW>\6P7XB00\HDJ0Q!XJQ!9>0`(%0$LD0`5<!5PUR*DAA@,01W'\2C,Q
MA'JPB`4,`'J$R3'V6P4$A[XMF#$Z"&&]5!S:16X5THY!FSHI0)T`GK\YP"["
M5C3I#FYA7_?(2(1ES(;Y!`.DC`8,RKN<"0&ZG`/,C^+,2.@%R`"8X`/P6G/=
MEF<,!P=43P)^`#$:'@R9W0\E1G#T64XE8;=XC&.<2;;D!P$L@$5^R000@`9F
MS`GMEZ>H!Q]B!.Z\G5Y@2_55Q:((@,?=Y`@M3W$4W>QUR@!P4TW29#Q%_H#,
MG`@C_9C'(,9`/13>:9?OS10POLX`Y$P&<$""`*-,2)";S)]]%4"7Z,J6=(`!
MF"1JQ-$B7I<1'<L3(<!+/0`'5J,CY5$#$`]:"%0$N-_<E1K#T4>`U`\?IE5'
MN(D_941.6(>4*(!:?D##%,98>4#"?,`!;,#JG<GW58!:C<<77J$Z\=;V(,`/
M"0!B6-!)?@GV_49)2$"1Y&,\;<8(2LD$),``S%D]`8=(D`P1?8Q039&E"0!.
M[2/HK$:U$%Q5Z(;S*`FP\.1/B,MO,2<Y29!"B!M)J,3N%,8"&*76/*)"546<
M,,!_!,``V!Z\9`"\D<0_O<9];6/'9&!^\06&_D34'ZE&J?G3F?!(!1P%!2"@
M0LR7&R7*EOA;`7B@I>Q.!X@%`C"%8CU7XPC`4VGG'97'0R2D,*9'*%&%!#!%
M3")-@T[`9%Y(`NAD+WW?A@3EOO7?G&4`L\2&W[C%%4%`HCU3D80>C#*$HP#)
MI7Q'`4R`:Z9'P7CF;B$86[Y6X`13;UC``6!?`_#$"^J$;OP,`S4%`R1E&?D-
M20@<0]Q*-=973"Y$D%!I9V0E=*+34NSDF$**!6P,G+U&4;Q49^C@+`F8&$J*
M6%A;E+(.C]@$S)$@2YB7M="1RE$&`\C2@O7%Z-7/W''@@V`5[SR;46W`L\U6
M:L0$XH!*8.463YB/_DWAC`&A!5\(X7?,W?P-@+>EBW;ZAJRYA04XS$F\RW4A
M%6=(`$@XP`8T"@?@#@!8APYAA(2DVE.46F2AA^R-Q_RQ$LZTCD]L(1C&3Y1@
M"G-20`7D!^`8TP0H0$L`AF6J#V\6D`6(FK[(T@H!5+M4RR_V1/1<&RN9:%ID
MQIEBQ**L6;N.D(.@A#HUE[K&"H1J'L)]&02=Q_\M&1;I7O#%R=>$!4D@:>6,
MSA()'=9P!$0,&T5$3074T6QUT9(^35?5DP6<1FY]P((EEP`LE:N`R6SZ#ZYX
MJED)Q5,H0`0H0&7$)EHT"`5,E7E$JZX8QR/&BHJDA`!D`/0\A`X10/XI_D32
MZ%.U8D1Y)&-NG$@04D`#'-%&75==4(=R1"*D0B>SY!Y#2(",U$F_'!%;I!3E
M7&;R^8RM:&T.%EOL><F*;``'K$8,^D1_E`JO!-^8FB"\QJO9K,6S945D+`#@
MTB9BW`K@\M!Q)F"^CM"U%4:SF"EPZ04&7-&M4M<'5*!"(*G=4ACB6%(RF06_
M_0H!>.#J["G<A8['Z(Q`T1VE(03GL`WU7"Q:Y%8&C-I#@*EWCMY4S5F>28ER
MI<6_!85M^-9#Y"<L94M6>MULT<=1^%/_]<3P_80&S,M#)`"/(D5%?(X_@<F^
MRE-9[-EL81^-.``%J`IW3%53N,C4.0#9MDD:_IW)2\A-[R[$2RQ$2/E:7:!M
MOPU,5)9&*D(*!.2L7AS$TNJMV52C`-`1DK%H<P`NX=X*O:DD6C3B32(24#0C
M%,9H6MR47FS->$R*&':`Y.6G33@22>"-D$B2D:C37K+EVUY)90!`(%I`N("'
MBR3$O#B=`8@/`&=B94A?6N@5GQ@8-QD:9Y!'1<@P4FI%`-34QRPDOQ6$SB!8
M`FS8GN6K;XQ:'AF```M*3@SP34;``BS%;&D(V1H(0KP3KCS<QFA`TSP%`A"E
M!TC0Q\1O#OD)X/J:47A:!'44RGEG:5@DB@0L``=R>AAJ7YCDIQBR(9.<3BBR
M(7./(QMRJ_2%5D)(_B17P*!$LB9OLB:C2%\P`"4&0'CQA6!0A*'^8V/V1(R0
M$PYU`-!`"`X9['(5Q@;XG5Y`<$:077:^1D,-0!B_1B\)P'7%20/43P%,6`>(
M"7Q=7T5)H[8DQ$?0R2,JX[(D`!9B1XBZ!21/38XF[EBL6((>,&?\GQ@I2&3A
MJMWHQ$(>L-,"P)9D@%+!'%U616P1H044P(3T[D-E0#K?Y#O=$C!#`&$EDT@:
M0&/X<#X35HB>"4'?"WINRU)T&\Q9T@1(0&8T5T4OP.-=FP01@`3X+&=)P'?-
MKK?!3],L0"1"0(7)ZF_@1&)(!DQ3AD;C!'BZQ!6"HJ=0R^.EWZ@YB>,Y_LGC
M/9X"&/07)09;'+5,Y>`RY0U3+Y/3?1%'+)-4L\4RM<51+[549S56-S5I=K57
M4S534_5P-357MT7>5/4R;917@X?3)6@X*\!9#RA'H86MD5/#(0Z)1(5[_@0J
M<883>4A\8`5>8D0%F,<5>4#S1)U-*("G14`T+5@&DD07*0!.);,CG=8'+(!9
M$.-!RM$-LT@V>:RN*95#DR#NA,V9_I%YUE?@6$"0Q"0)YUAN>,`#U.9*!D9Z
M%D:--'.HX`G,?MPHI19WZ!6PR!<E.LQSL>B(!<"]5N$%P%+'(!]4_!H^Y7:1
M&$:4JL^JXHEX:NN$!ML`X>I#4!H%W!(@TL76_F``!53*`+7W=[4W?&-`B%D1
M?=,WQ2$BED5N?>\W?T>08`08%OV%V_XWGKGMEQ@38ZD3X%C142!CM"TX0O3%
M-+%N*X\.:W2I_-HNI.QP/KG7LE"J17FS2(E1V>G;30PI/`^K-(9(DH2K&_'G
MB4S5%Y)@`:AC1&Z/QP3`,9[D!I28`F0C;A78`ZE,Q]`Q3^[BQ&"%GU6A-;(*
M/UG%=<IA6D`/9V#`7`T`/J46N]P)A\MKNR"(I8BGBM^10L`SO#PYT#5&U!UH
M5J@/_F1=#JFI=U-)15?CG,M&@[6LQTCJ:\Q?;M&W?(=%G@\ZH9=7@RE`VU%+
M1S%VRU*+HT<&M7C$_CWFI8P(.(._B/E8T4PP&87?AX%[I^W(1+3MKEY0(E!D
MW!RFRKVZ%M844G"TE)+HQFGF4W+MQXEP56F)C.9L25&`\G2^"(4)W&P9&HBK
MHC4Y],S:\":NQ,]P*X];4LB:DS;5D%(=T,2RTIQ67VI,P$B0LZMDB$^45&]T
MX6?45Y<3R+U4CP9P!7D6@&*W6:-@0`M2[Y8DT`<8C142HS>O8`Y?A0ROW4/H
M"9("8>=I@%:,T8.Y'LIPU9CHRD"VAIA[VT!VB[T]0-N]D1"5L')XQU4*K0%8
M_-.2S`0XB,7'EL5[V\D/I,67EPX)3`:TRLO+-_2D_'I'R2R:'\[GO!9W_HSX
M1<4`_#R?..Q#F)_,C=^8X#PK^8_.ZWS0&[3X-<73<]_23[WX+=./;=3'`XLG
MJK>&%S*JZ6T#EIY88L"J=X>+F=E54L6AJ&C(29*]):.LB7!Z4-)^4K9D_YK'
M41/,1JL-0P2O-85ZQP9*`^Q8-`B,^C+U$<5_V(L';%J[>IMJ[N'U[%D@)H1P
MEOG-ED;0C<[+\YLUTD6.<=..@M+/0U[9OPD'5(8`D)%/C-=I<*UP.2Z<1&]Y
MN+M.7,#B0!#N''`2-L5'[Z9E5!%:3*3NO89#R!(-7N[_0F<IT<1=+LR#(,DI
MAMA\^Y__*3+U6S^2:#_W9W_VYY?U3W^:RO`!_F7`>GL_]Y^_]D^__\D)TKC=
MA(BB)\Z_0#=*Y4OC`'CSQYU*(R&&V0'$A@\#"18TN.""084$+SB8(/"#AP0#
M/4Q@`.&"!X48$D#@H)`#A003,!A\,`!!@H0;&RR(\-%@!@44-!C<L`'#`P0`
M$@A@,*#F!@$+'!``($"!`P@9%BKT@(&"@P0(&CS8P*'!AIX*.C3U^A5LV`\%
M*C2XH($`A`D$&`"HV72!1@X5%DB`*=8KA0%W/U0H````@0<&,3#PP&`EP08-
M$BP@V.'"!)T%7+[%>[EB`P8&"EP``-%K@PP<)'R@@"%`8(V7068HN9##`,"S
M`1=`D!HPA0]S08.%_F#XJV<`?`E62/S!PF""'!PC'YB@:X,(`Q409]W40X,.
M`ZYW]_X=_%<&&BA,#^OA@.7PZR];B!#A-H$(7;]Z4+`Z[-\`]"U,B+C`@-(,
M8N"!J8XC2`,#$/)`MX(HZZT@OQS`CZ##`)A/(08*:$"V`@@0P``!!%(```LB
MPJ`!`69+0((,*/P*@P@.&&``""R8S3KVP(O`@PQP,N""&P$HX$6",I"@@Z)H
M?`VO#BI0"H,+&F)`,+X,4*`"#1(`P#^"*/`/`8,\0&"#`Y@T2+("`CB@@3/#
MX\"!`0A`4@(*8@NKIH\XL$""!88L4L?'%CA`Q=D"*!2P"0H0((``%"!H_BTY
M!U`@,0H`4*XI2S];"`(!![*@P8$V&,"##?SSK#0)!#1`/1T]6*`#`7(,E-9:
M66,`5!/%.H`I6WU=J`($!!!@``8@7(X!O#A(30#Z.N@@NPD7FI&"(C6@,M2"
ML'IT(;3N6TB"!S#(D8(#/NI@@0<J.&H"#[24X`#\.@B)`=P&2,""617JX*4+
MF*7OU^LFJ&"W#R(H3\@P,^TT``B<5*FD5A=Z0("=`#,``0:(HX#;YVI<33L+
M#HA)W&;KR^"!OP9H@`*`6>-@`@,"0.`"^A[H8(*.F^IS`P/Z8L`E`)(-F"!C
M.T"+-MHFN$!5"1+;H.D$$K#,@[]ZY12P'!.X_OJ#";+U($0!IH/@@)%9'B@K
M7V'ECNBVW1YH`3AU#2L!?=]FKX,,`'1T/(.2PVN#U(;^P`$!"&B*`P1@78B"
MAET>J`,($#@``H4T&-1-R*?*%M(#"(#I@M$"0"W9O"7*_(,.*)``MP(NLCLB
MW<I\]FZ\%JC@O0X(B/$!P$KZ;8$$M/M4(PI,C(``C"\0X`+-"%X(`?^>A;8I
M`[J$G``"N#6L3X,:L,`!A<_K@&(`BJVVR092:T`#"F\N@'.%:$KR`P0R8,`!
M`%"WM5[7+<C``7]16ECJY#>D>`4"@#E6Z@QBG(+8QR+3&4D`/O"`E;#*5J_:
M3NTX6"N@*6!N8&F._MN<=*"P5&!ND0/40##PF^PMH%/!>EY8,G"``#A@-Q(8
M29$X\``%+&"$!"G,XA1B@<I`(%L:>$!='O>!#13(4P5IB$<>\!$+!(``",`8
MJ0Q6D@F8!SOD@8!LUB0=B45$,.GJ8%CXY8'07:``&O!+8"RP*-E<[",:>T[7
M`!,``T!``0IH``$R0('C:&``39P6&(DW1AA^P`",Y$`!.L"BZW@@)!'0$`(Z
M%<*!:$"3E$$B#Q^`E@469#"GZ8`!*C`!/\%.1PS(`,X:X!\/9"<!1KF>5Q[`
M2(\I4G>-0MU2"F(!G<GD`X7!@/8`(!('5*`#!XA`!4[Y'5@)8(5K#(L/_B.I
M@=L$8`+0^8!=8A:`!F3S,C]!@">]\JVW1:``Z;G,52H4H?@)L0(*,$H`SKB0
M+0'@``MPU+$XD(`!E`8G!2F,69Q2@0.`$&YOT0`$Y+,0#Z3L9@K9``0:MIO/
M?:`!LU$`C5BXFGB)I504,,!L_HB^@60`,+S2)HP:0)`'&!(#LN&,!2KJK@'<
M;(0+,)4?`:K2@<3K``3S0&D>0`!%*B0#\KGE!9;X@;8`('2;@A0$QO34RV0@
M-8XZ&`4:L"@0HC,"X=*9147%@0Q$8&J6@B5[#J!("WY``/TLR`+B%[@9%F0#
M85KA!?AB@9H^IG*0L9%I)"`YQ>D3`$%<CP;9_C;3ZQR``@YESBW!Q@$/$+(`
M#H@``+QZ&9<PX*]?(1,',1#(!-!DA;TJC488<%BKXC`L&&"G5P18@`B@#@,&
M."?<8,*@D2R$?`.8(4PC8LR^6<X`XA33M>SR2:9@X+$+(("C4N<I!^PV.'1I
M%`#^F)&8`6"MOMJ?5RRP$K"19Z6T^6L$ZC*XWX:3=3D9V0?J"@""-4Y(_A4+
MB9)FP]1`S;;/R=<N*<(:#R!Q-_\<2LL&+($"5.XK*+QEUW@*-0!$,6!UG=AT
M$MF4#2RN``MT`&YM4H#Z4$@"ZBG2AKV"3M:LS;+=X54-.4``71V`)`/0"G5*
M6V,/0*L#.FS`A)"<_DW)!JP##)`,;OJ8E=6L)#$=V(`&-H`?!NM(`ZE)`*`V
M0"7UP*2&",A1!A#P``I90"5:-&%$U.)+R"V@`&?B`+0P(!`,:"2:$U@:02S@
ML^_@S',E$B!X<PR<W8SLJK/A'`=4%"H+5,"M%R!8H9V8``Q$UE(.&0`%($`>
M:#&:`PQ0]47^%Q$$C.E,T=2R`_8\+PEH2`%ZK1!V,0"9S0Q,UPHAI)#!XH`6
MA@D!"O"9`_QH8_88X'&87,`L=Z>!#%A@>K5^5DBX5IS]&@21T"I5.*<B-0(,
MX`#E;N:K4D(`J:5$B[(I]U1^*#6#(N">#K[F7'-,$&+&K0"#J1H!%K7,_JY0
MLCNK')8`7+=J*JDHP0^4;MN6^H!!4OE>"AA:MR.2S#=3R-EA\=.%G-(GEQ:D
M`YJ90!/AI"Z%L$[*"]FH`8P-+`-@2C$0P'-7:E))"#C@;`/A@`$8+9;"$,`#
M*JI;OQ?"%1ZII6<J.I0!7O395QMI*9Z%7"#)HBG`&':URP*E`+IS`5D2";".
M`>N0_"0`-NTDWP.1`&=:LN25I`TO&9@`,L%B@`U08)87L1.N1N<V:#]PI`-@
M%&T:I:)AT6@`8;5.K#*W`0)H`-ME:9X"_AF``I0W7Q7L5&0FT!\IG1[U`M'`
MZ37.'E@%H)I,]QX%1"*!^VCD``!H5`8,@#^D_D.3-:;JBV:`N(!`EL8!3Q:Z
M\MTFQRL!4J_N$M-"C!6>*+?%E]&TL\&NM=LR`QFY]F,KO([E`?CD*)I3&5KE
M%$#VA5B@LI>T\)`VT,=@KY$T-:PD!F`(F!I5+\$X:KLNK,N<Z"-FXE`<8TL"
M(`)"Z@$>`,-8PR$J(`('HO2L2O>N`D,BP@!*S'*VQ-T\8D#NS]]@)N(VXG"P
M!'S(Y#W&(J_:1IZ02P.B!`,PP$<XX,_P0P,HHRG`3R%"RJF6*,P:H@*BQ`*&
M9<\B`N<&XJ8@1UHN"L3*8K+V3?;$HBTZ0R@(KHY(8CHR@$9T8V588P8-QIT&
M8GF@Y92B[&Y0"")J_@*3@$\,86,]^(1#0*,#*&6!*"".FL(S*G`Y).!>WL\`
M9N4"?NB,1$8W&B*9%N!&_+`@%`#$Q"(#$D`!)B``*$"@2"+D.&AU%J!]U$P`
MU`<`&L``9`JPE*L@$*`T0(E0!"/T(F(&L>VGE@@PAB7NO`(Z*M$@N*H"HNNC
M"&,O#"+*1I'CO"3V`*NN*F``_FA6?BZ9D@0M0*HD)HF0B$;$PB.XTHLZ(M$T
M`*,7$2!6'B=.\*-(>H\)2R1U!*.!6`P\8(4=J_`KVD=4;-`Z-L!9KH,#$F("
M_+"@P**2[L:82K$&Z>G0,J)6(F`"$$!A(D>:FNC!4@PVX*,8KV4"TDU,_E*$
M1_:EK#)2&"-@+RS`C32"JBRO&#]E(C"#`D*Q(L(DIXYQIO!MEN!$*P@,?!K@
MI"AB`62E(`C@KT+B`4*$`:IKZQBQ3,HG%$NMR(1N(A#@3#P`AQ2`JR"`,RI0
M(@I"[S8DV)CR/":`1GK.(I81B?AB[XJ0<.",OR!"`H:%&W4D+L!CS_P%YPIP
MG,;,<HXBROSC`%QLKZBNGF:/(O9C("C0(,AJLEJ$^>!1&!_"#%?.B5+'LTA-
M`C9Q(2ZP("1`?+PBM=P&110@`O(%D[SC`!Y``K"M8,`#/2J`11[&`4S(`X(%
MJYR";*")+BP#9<2/)Y?#(F1I7\R.?1@'`1P`_I3LPF$Z`"0EX'M4ZZMT(B,Q
MH`*R`V,>0#+4XL_Z+394YP.0J$U())'TQIQ"IRS0RR#X:=<:!&H>0-5$J\]T
M:`PG\3=R:0">:5PP\P$R(.(FRO+0C&+,XZ(.Z@&WQ`%*TB!HYBN@1I!R@@`6
M@"1NP@*`)B74Y=+Z@IH2`&@ZX.H&`@)Z0LH,TBLV0`%<DB`JU#O@+($`1DM&
M@@)ZIP9]Q-I0)&N@<CO`":<F0$684TH28`-<`T==0B`\(``JH%IRXM)HCSYG
MX@*^I.@TX(LD(`(@<'5$$_8&-"H>P`$@4$H?<$HE0#*FM$JU=$J58C&JM)=$
M4[0@(*V@LSQ$,UQ$_K,`Y*0!/Z^N@,*8(&`H?@@"I-0!"&1*-[`I*@DIK#1E
M!N`"EA1+(0")OF1UY`,"_DXC_H[4N+13PL4A:,]K#)4"/!1R)%.CC,)\&(`Y
MP<.P,,`GJF0A+B!C:`_D),#'')(!DHH@$`Y.$$!/"R)!M+$#^*^*A(X)/V!Y
MDNXR)V;.%,(2.;)K&N`W\H=&J"PIM@\@<\W-J(D1QT1`X(\VD@?G$@3E%)()
MB2(B_BX!UA3M&DSHEM0H0NN>/+&6#&)0>S6GB&(!\><A@E$LIL8K,L`VKJ:Q
M9F1F_A-RC.B&"$*3D$XR%(*B`"-ZXO/E].<RG.K0""!_```_RN,]+I0V_B34
MMP2H3"@1,`B@;!0G-?J$37@E`<JF;`RG+0%`*1ZLSC@O`N@4AJ0I.'KI/2)V
M`?`M`&!'RW"B3LJC/(PCK=R#RV[B[PZFE8PG9G]V`P(52R$V9I?6(U>./*!C
M.V!*FBIV44E":2.`3)^J5!Y,.L@4:PWG:+&6:;$V9C`@,AM$=9;61V["1V\B
M`@+U:OEM-S[B5\]#`U*DCXQ-;FT*(9#BY!Y#V>`0L'IOSG)*6@+3,2[@0/MI
MHK@QFK"D2$HB73C@PQ:BA:3D;L&".0X@A+Q)<0^@%!D%-P[`8FCD`)"$@QP@
M*DP$(0[J,.0%7E"KDKC&(KRG<HXP?SB``Z2)_K!2;0`N+$=ZA`%V8F4NX#6L
MM4T&!("6D(_(B]9DE7F;(@)*4GU\"29J-8`"PRP$0LH,:4SN9YSB!Y.T:#88
M;C$DH,\\;!GE%2RN$1^/R]V\8K1FT`$4X`%,9(RXA``$(O)Z0Y\>[)1<A"(&
MQS5\)7*&#C'!8N($!(0`"J`\8W#PL7(LJ2`T"2RD3YL:*V+6`P+6):8L=:^.
M@ODV@&4N8`'<1#D7XGXHA4(F8#%><U3_!ES^KR!H34M*8@"N+8)W$@%D`ZST
MJL=`U`S5130`+5AN0P`>(/>.PG/<KFYKY7/&0XE7=G)$V`$@Y#!D-0`.A.@^
M@#/YJSDMI0#T9$[T_@DL-$"'5.0`&"`!!H,`CB/E(.EJYJ(``DY#T<3OPJ)(
MH<H`,.B"<2?W1N9S-,"S!`#J$#8O("MIQHLV=G@A/)`UZ)6K/@!?$*B9C`2(
M[NA)3"2R#"*`-NS!@L\"1OE_*-,TT?<D$[@IEBQU#J,K%"`#R*[WFHH$9:XK
M@`Y=>U4C+0M3J^<GJ$SW_HB0;S0L4@0H($>(-$2[QO@Q+-/-0*)`'-%@!,`!
MFBC)5.T003<SDPTPSJ)N<!FZ;@E=A,LT&',Y`N"9O<?VS!9"3,4\3;;+O@0^
M$L`!)`"$N^-1V@6UJNC(:I6^$(`M%LO:K%(GA2B1MH,#PNS(QA%2?,30_L[C
M2W[23IC9WQ)5R"9`*H2K.<'"+Y)W7G6&K*RG2&ST`LAT<FV*4YU*8RIR?PLM
M*?-1`E9LQ5ZX%O45+$SF.EK)`I&NG1"YP1[@4-Y*`B@PM8H"8!2@\1KEH81E
M4K*H^.J-\\ZMZ"31*N)/E6.",@;`/2B1D,C.PGY25/3H,BY`(+2H`L[ZVG1"
M<[]MC<9EO<0B)!@C:6;C0!EQ.0ZD:@!CAPSIQ*J,+_PB`A;H`EZK2'!&B(L#
M8SCNP:1FM]!B7)CB2S[`)18B?X8&5MBBCQ"@)K#TE*;&OS*33+N,A&>F70Q&
M4]'KA&W%H7;PT[8%B)#(O3AF2`S@3-I"FIXG_JV2:3@<P&<>;`"8A#DXJ3O\
M8\6\!P=U[\+N^#PHII2P0SO<I?TF>2&R)Z;,IP"8(IKD"(>FHT/#I"H>XYX[
M((YH+"P.3RS(*L$FZ19[V(022'\V8V5M"```&G.2R0+;A;,J1"/V.U:325E9
M(R>\\*HWU*955R->X\C>HB*N0P.`\RE4]X<>2C<LH)^8P[):+5#N=O$(]DF,
M8FL6FD)@*@#N)P%&%X@PS2HW`W70@B^+*/>>C#G(`C8HYI[*#``JITZ]V#\*
M3R$,H%)=35>18@,J(*J,PI$I`B7ZB"_"3*0,*9^FPF0%:#:D230%.#Q.V"(J
M(`#&1(`:Y5`P8K\I_D"S*:(!L,0F9^9V5H.W+_''M54Q'!::`RDS#>8#;K-"
M!,AA/+4GE/6(YSOV=D):A@X"QA@M(@>,8"5,NIB%;G%?[!POW%=;<&4@RL7/
M'^/ST*G-@.5B`F!2`HE0=.\H`HFG[61`<"LJ)$)!7N0P+R.S-NA7WC$\R,,&
M:8_VR(,F*O4&0\*0^'H3Z\_+KT0!]&.\3E#HM''`->JY!T1FWK@K'@PP8)E"
M.B`P`'=6>N:YT"0M"IMLP`?G6A/=%"E!V-<@%#=F$@)(7D57M]QR?MM"GZ=`
M/@(MKD4O(P(_QHA,V<*3FZJ6;@.@6&24?W(V5K5\AV0^P:.N#,DE/."._@"@
M5RB``1BE(S2@P0?"J`&K*(9B`N:B).JE)Z(H<5YDE70O-=X1*\3[62+#H.(H
MV`]F;[TGE6TB>815YGB<A3B$U'R&E5KF51H+/9+2*V)E+9M"815"6$Q65\7:
MWQB^/@;@RV)#-@B50&ZM]"Q@`Y)/U<QCL0KB-Z@#09E2Z87(V"T*4/@OIXZ=
M(7##RX?E4!AEX=;^4-9>:+Q#`\QEG1A(7RR%T:LP<[!"W*TR(=D$2ZG,-C!"
M[Q2OO<))?/FO`:S#`XPI;D!"I:2E&B,"-9M;H^"#G7I$<CXQ=<AB02M(^<:9
M4S^L*S!?),AB3CY%3I0C77`%(PP":^%,+FR/_E!NJ`B+E"A(Q)R.=GCIN5)]
M'D%>33L.P'C+ESA@)F1]ZW)N4J-T@E"BAS1N1QCWUY.EBGR8T4M(@IKC:20X
M5R(`:5$"BLB!'VV.G#4XBB\.0Y9$VM.8DIZ!0G'O61A_BC40#MRHCG0M*@("
M(.A9J'(!XH-`@1X4``"00>`&#P,;-KQ```+#@1@>?)@`($$$!AL0-IR@P*'(
MAPE%7IB`(>3(E2Q;NGSY88.#"Q8V;!#9H:&'B0,=,(`Y$@&'!1A><C`@@4!)
MH$R;.H7)(0/##`H84"`@X*!6K0@:8#4`8>'`#@L2W#19@*-(#PX$+,CYP4,"
MAA8*--`PLH."`136_F8XD&"I0`P1+E;8@*"O0PH0*-C\$$&!`8,"!##@D%6B
MP`H5*!2(2<""@0X&!',H4+C!`H<>+#08<!!!A9T/"#R8P&%@@8,#%EB`Z_*!
M8P0;"'A`8.`@@>!NS[KL<,'!``02<C>4D.#S6*4-*0`8@/>#`P,$"EB8Z.$G
MX[$57G]?<($GRPT%Y#_]4$!EPP@$$@C0@(%&%7QP@`0"?*"``_=MIR!3`MCW
M00:K]2<28@6$UY)_P`W4T0`!6"`0!=:Q=$%R!23PVP<7(/`!!08$8``"&@"`
M(63Z+=BB!!AHAV./0'7F4`4*,,0!`44))*-#$_QTGP`3R/;2!"!BP`"$_CY>
M^9(##8BXTHA'?M!!!18DL)4`1VY@`0("$-!`!!`0(,%('$!0@&(.95``<0U)
MV,$#`A2V%@.VK12!`11`N--%'EP0@',#(9```0,D<`%<'11@&9*KZ:3:!Q9<
M$&`##0X$P0`W76I1A1A(L```!!QP5P72`>;`5KP=<-N((AU`)0,!:@#C0:,Z
MQ,%&==Y7[`&P5A`5`00TRJ%'UV&`0`1^*@#M0!I`\$$#%ZQ5P0&P%;"`!!LZ
M-*:/'0S`K4X(Q-9M6+DM`&D''_;8`0$&-"7`N7$QM(&N'SP00`'??L!!P"-Y
M,$!](F70P)Q.N7F!5QK!*E`&$7AP0'E*`MIC_@058#``EB:O-,'!%`60TP4#
M@.AIMJ0R^=1T!X"\4@<HXH4`S"?#].5]#S!00`$W.TH0!!8$/5`&%D@*0`#M
M*F3!`P4$L*E#&A!`LY('#.@0M0<L4".'"R@@V$`67&8E!TRFMN^=#78P00((
M/)"!`QM<<+`"N6V04P<,*)"3`0,0H$!-#770U4#ANI1!!A(DA_7($SQP@*UE
M&H#BN09L@`$&%F3P@$$'E4V0`@=H]M3:!NP&0&7?1>`H!PK4F`$"'0LKVIVS
M<2U57A7M-9VYYTZ`,[)NB00!F0YX$)I`T"F`@09S^?@BZBPET*4'%83'@00,
M#+#QH['+-=D&$SBP_IO*W3U0[$B(6=E`D+YJ?8'`$'2](`4CE_RS`$8H50WI
MET`H%9?,(6T"=G+*`(;"-)$X8&I4$J`%!S*B.:FF*Q+`D&L$D(#&8$`^&"@2
M`*86DPS<9((ZN0`$."`PA%%@:.[K"8K64A$404@#"D@`V!K"@8HQ($X:<`!F
MAB60+6VF,7DS@+(:`(&@(0`"$^@-0^22`;``P'W%TM4#?-:2#D1@`0LH``$<
M$($,:"`#$%``[``P10<LX`!@L99-:-8`N9`)`'%;2[46%*XY%BV-:O37!R`@
M`.%8:P"P.DBC)(!"3W7`,PS(".OD%X$&O,X`$:!`0CQP24"2)V@6$!<`_C#@
MF0T,2`(K^D`%N.>C!YR2*;`4R60$$`#VZ6L!::-236QC@`<DQU56PLY?Y'<]
MD30@+6Y4P`/(N(`(B*PS9$1``0S0``8(H($+NAS)+G@R#<3)(;7L&2@/\I;N
M<!,H&PA`%EU2'$<1!9PL&=E3.I`VZ55@`:]R0`<7X,D(.*!C#0"1!<@F*?F0
M*20'X(G.$&!(#B!`+2(14A^!"`$#@'$@'GA`!V((IJ[,!CF)00S3.M!0@12@
M5%'#2P<V@$A11<`Z=;.-!W1V@01,X`!W`L`X!5(D[;'$>^P+``$64(&<:"`"
MTUE(3CA``08H"TXQH4#/.BDLEGSS/@4EB`4D_@.G$K*F`@'(2D;<Y"8&<&\!
M2'O>`"0@@88!`&E=BL#N3L2C"1C2)<?1`"Y1@@$'U*T"`^A`\]CX`:FRJ*L^
MP@``;N229#KD``&(W0%P0RR&%+%%JZ&``]X%1RM%H#H1$TF15I*`+6U@C1GX
M&P>2&A<,O-0F'="`5:X$@9'QB)X]$IU(:DD]#RS)`,_[R#IAX@&6L:@E&@T;
M`JQ$SP[4SRD-$,``#!!!A!7K:EMLB`:>*9<(=,!5#JEDY'YZE1\ZI#;)`ZI4
M!;#<AE2W2B/A(60'<H&52L^LEFF`MQJR`9X*Y(S8!:!N'F`U`=P,+R<1[N40
MX`!NQO5<&#C`7EOB_H$-U"9V=GF`!EQT.`A\E`'$P25J+$!%T'9W>Q=N28D*
MX`"PT2T!`W!24<('8\`]IB$52$C6!G*`"SS(`2-D0(O70H$&C`W(?2DH&QD[
MG\]4X(W.TL`$EF.`"4CO``HX%'?0Y93CS!(F>1S)/N$+Q($PP"(>Z*R".#`!
MC!@`I"I"P+N0B+#EC$0!2*-`4:9\@`V023$;:),%VOL4QCR.MSY*F4@>,!$\
M*^FG3I&:GE<RPY$P()*,1EAV6U(T.]<X0?[R@`;B,Y:)N,T#&>`-`;2<@:R`
M\B=Z"0V$ZM*`#D`HOY<Q@'J/8N&5"(K2&)3,4CPPS(,((#D_U-%FX)B3_@,U
M)"QQX<!!`W!9A?"3`@DX5\]&,A,<>>"U#4"``MXR[B?)+@#>`0!@8@>`2L:.
MS@)10'S#K+'L-`"V'VW`=\I*UX;XS78?H\!JBFNN!0$'NT)>%P',S0&ANK)!
M'84C7SC&$8=Y:@(%6.V].?H4#]@%*`84R=/03)`D?8!D$0\)MPU#@-"R!+3$
MCLM&'U6V<_M5+@%0P)MRLJ@9!F"((8O`DCK=(Y!<(`,56'-\-&"!E'UJZB>A
M"4T6P&F2CZ\E`CB8=,]BNP?4G+<)R>=*WG4D[SW`FE:1+4?E$_&,Y<2Q98KY
M``JR9N+N4`((0/6=-J"`;R$[/*"TM9E%Y:\Y_B5``O*I@"-WPWA=#V2>.DLX
M@412%%"R%9\*(`!A)V``ZQ$K`*@39`WOXP$,-$#+8R%9SS4'DH/4LDL&;DH&
MUGRJ?4Y42[R,NE0/0(%*L>8G&W%(HQ(G78$8\4JHN69RPY-?#W22-0I0+]#!
M-`"-"?@#"#WD=+$D@0)\VB'WS5BD[KT3*IE[Y2$1]/@"D,NQB<\^T(/-.CGP
MZ1LV1+!T2FS'BR,?I00!7*8`#5`]T+42.G(!Y8=T0!%KE7$X1I4`!P`I"3"!
MR`$8U_0ZST)`3<$!`<!Q6A5?%7!O%'`>#:@30%$06.,`2T$!K`)_8S-^'_!<
M'I`50V0K<P9"B>(0_F$"6Q5B-,[!`=SS6ITA6B\#(7T")_XB`94E`.3"$%ES
M*;(2<_M&5`(1?ONF%-ET;BFG31+P6#_V`=]U+@*X%_S3%#!%`!$@-0X1`0!0
M4*^5%)J3=>YR9",A3+`!(Q```1!&`0:'`.7"`3NQ@-858]+#+=6W)T-R`!R`
M8"N74CBB%UK!9[&#%PF`%`'0@6`B`&9W$=S3`#_%2X<R`*R'):01;PBH4E:B
M,0.PB=)S%CRH(KNQ*3N1A)GC4P]3AP60-OZ4)H<$AX@1)("R$U6#`#T''S"!
M-EOU$F$B<>`D);9HBV-T*`L`/V#R2?_R`?KW%.QV:2*Q`#SA`$C4<2CH_A3G
MD0$&%W.)T8$8\$K8-AM!X2G?$1<WP0&9HSIP%'PZL2.2-C!9YA`RD46A-Q)_
M<0!FIP%C(U2UHA6;HA\<<Q`3<'OUH2\CY#UJ!0"KL0'SM"T3I"\C@S1K<R[V
MU"*IDDG!IXH*028-D`$HM2$,XU.=*!`?M@"5=1"G!XYAQGWCE@`P8I,.H`$3
M$1D%8(J>X@#]E``E5``;4CKV(AZ-P4EA9@&S,1%;PD\NQ$L"D1Q9L5$8,!K"
MED>!)A`Y!5#Y%4".EQ&JZ(^M&%\>\(=O"9<[,0%9(1QO:0%_*!:D<A!CMQ+(
MIDS5`7P]]W`?]P#?MR<P2`"'TA(B$R`N\559_E%9V/2,`>1HW6%&+A<`WU(W
M(B$E"[)-TL8\67,!&:$K7V6.ML<I6J%3@\@A6`$C+8@>N>$=D(5U)>D3UX4;
M'N`5`><V058A`4`^$"(3VU1J:M)>X=@!#!DUY8<!B=D6G$,!8?(N*"0Q6C(0
M(H,=T3D`[M,:^>1O">$BN=&3\%=[%8(M>),QE_$0Z)21`@$_$H$KGDA^]"82
M'Y9<KN)1,_D:995:03EXDB,E.2$A54)6\8@DK.8J7'&'/0AO"(!90$4@@99Z
MEY66;NB/#),_W[=Z[N0?`D0P`%!<*R&&/;$`*'=(\`="QV@T9**'"?!,!B``
M/<0UB-,0PU1S&%"4_@W1=XO!8`PP(`;'-&SE$AS@%>6":?AGF%H#HW?Q+1?`
M`(8SF2?S`#6D0J9)`0>2+YS6`*\($V-"&G)2<A_0A!FQ7HAVFL\A.!8PE9*A
M8(+ECC;7=#V4``[@0^,F7@"62(?T)2LR*7`2E!SEC@K`>*:U)?["=(`109/T
M1:@#2A9H5NSR0*[T+:J4E&/!;0/@3PP0/`.Q4T/2$]X!%HXH'ZU6<PP`,\T3
M:.`1(=#B=W&Q5`>@GFHC$<`!A@9`8G$B<M3",;C2C`2PH+7E&L[BB=NR`,DQ
M'=AV31WC%HZA:QX@`8#19<_JEGWAI/3E%!(P(.I#+PFR=..&.21(.P%`_FPB
M)U09P#*>-1`2<!4<4X?J`@'?,1.04BUPX8\%,AT#03@X8:X5&D1((R$Z>A#K
MI`%)2BI?)"47,#*@HK`8<`$4L"02,`$5<&5%\5(+>P$`PK#N"`'EP@!;@@&Y
MY4*ALY8&@),MXC>=9H`CT57(1@%O>((-(1SW\540X$[41VR"<RZVDY)G*A"_
M,3Y<:@%EQ4=`>$L0EC:RU!<`8!W.VHAC2`$'0"ZM16(!)R'6!2$&HE[3=D;:
M<Q0)P`$=8%;%ZC`:(!,/!UV+0F/*LGP8\">*P18-<Q5]B"Z%)1*NF%0NYR$.
M(QN-F6&:-&8ZH25Y@Z_Q%@%'$E@N)'(/$'#$_A*)?3FPSR(!&;"`,`$!)^%?
MI@@=[A%,4@$=#_!6W$>?RDA7A`&UU2$?$V`?]\@2%%`R1C>3"S`X'Q``])1D
ML+$5/Y$!LP>S&S`IDZ<38P(;`Q@`@TB!=$L1Z@5:H>L0R.%?_O4`^N8M?!A\
M?-.P?#,9`_,=`Z"]VIM:_C6!$#!!D,1'9E6Y!*LBP]L2S1FE5_(`$5013?,Z
M\">&B2.S%G%1(<*E*R&Q//L2#9.9!;DE'-`6`$8[K?<:U1*/'6"1`K:1FAHV
M)',0"E#`WD4=!1@V@&%(1204\L-/LS27CZH8^:%R+Q%85T,I!A$WQ<(1G*&(
M#4$8]=5#&7!Q7S00_F)7`!6P(I;1*O<G?CH!&X1U%N4B=D.3G_#DC]#Q)HRT
M?`(QHB/!ER[\)MA6$R-"LP?0@@OR<3!U%H&E+SZT5Q-@ONY9/PA0$AI`@E("
MFN!TGUH1`-7#@`_`5""3*A=@5^C$>(R2>C)"(PWA&C4:L$S!,3<'5!2XN(<6
M$P(0NL!!)3<5(/T!)WD))D09)=]X04"I-0=)(*43)];R:(+\$A:@(/>[C1)@
M$V+U4O5H$ZF,&`MZFLZ$.C(Q9QGCME?J`(D'.^22(HT1/@*0=4,8&H'5>;YA
M:C!T$VC#41&@$8D7?DN,4:\&+`R1.'X5-7&21?Z(89)C-/&6&Q-0*AI`_C8-
MX"CV\F->2443$2Z14L3OZBH"8$1L$8ZF54/MYC'U=AH34%GE22BO*$[KV)*_
M%4`?UGF6H0%X8<;205PI`A07L(G?"2:-,88"I2R^L2$B,R=\^%,%0;8EYV>(
MK%.,AB=:$2.2FZ,U?`"\#"8+:``O$C5&8XK[(@$1HZK:DC4BMY=-81Z8]DK^
M>)=)M(DPY="<`AQZY3*==T92`45C,4X:<"YFP5N.H217XXZV>A.R.!#<V!11
M]P&B3#S:NVQ?@0#E41YK8D8SR+\+PQD3S!8SB1P(^0`08,9MK61/VC$(U(//
MJE=0#+5P%#!R01`8,$>((C9T=5.E`R)1M1,'_L(HP&D;^-A:RKL25I,GCGR5
M2[F>@H',J.HM&C"(N6L`AST`5F$=.X*&GE(`(Q+(`M`I240?K49>S]%M!+$!
M405?$""?HAQ.1\E($Z#9^"<9Y-)!1^8;`=E0N>,G![,3$%,TO)03H@*944-`
M^](`7CL5:Y?5GD00"VJ+CNU*-ADU4:,OD:,PUTDM-S&:9=(7,7M`DT0<IN+"
M-),O-:V"O!@7D1,Y2RLJ`*;9WDQH\JTM7K''G/ICSW-["=,>10,`AP%#,LP3
M,`1#%^$8J\7@`</@K!%Q]&WA#=Z#?S@ZX)W@,#30]'UH%1"Y:I08,HNZDJ9K
M7\M:&!`Y"[ZS96T2_@E@9`\A(G/4JF:3KZQ182)6(:#WLCHA&8<!`86BO9*K
M,7^Z&`\'R011`:_C'/'X<BSYM2]U:MI4&40IG_HK8A_U)MEDJ@[!A_*QP6"R
M+6H%?&0E&;GF2F'Q+03'&AT]$#.T5!<"5$8WY'_L$JN2>E[QV6&1DBQ)3S?E
M0AUS-WH%5;C=,W36N`(QY(E5&-_69B4Q;@97)<!)%.K#93=!%=##S47!``N@
M(*4-,@L:%;G[XF+ZI"#XL<IIZ57A$S3F+(_Z627QTS8(.$:S6ROW4^T$W\CU
ME>^M;$6136(>.Y5E)[T#YF7E.$VK9AF``66U)LZR&_#E+)5UC:?A'VOB_B%E
M!>V5`>V75D3^$9ET-$R58:TJ959L7!GKCFUNPH=#?N?*5K)/`F'.LJT#]838
MM5<=(`'X_A41EJ@,5+*IEP$CW6D,T,:_Y1^0-A*@IY@(#28+$,:,XYLF<3<O
MZ6_>'4&`=P!"9<]T!$)19$";=UPRU'DK;0':/3!J)E4EBC,,D^O/!2;.XGD(
M4]*T:,[>8AD4^#!Z@J]KXT:IEYS[%"`'L;@<50#:RSD14+(CX:0-^%J10@"$
MMP%V]7`&VK,C_3D$DAMWURV('#:Y!0#M2'1U^2#2X[DPU*X7A-X;&=F:HSFD
MQQH\X1RZ'3:C@AF]_A(B5Q(J]E@:T-G[P=T`_M!`"R`P[S*[";11(L/:H_&U
M59\;062[#S04AX05L:/*J8Q_TW=`RWD!CA+;,4?X`O<=#X!&TK1&+J(E1D5L
M$'P0P5:?MT+NRG(XV`)M85.B`)`GGT+[O"$8[QW&8F8<O+6E:N-,,51)68D3
MYL83S-*S=6)(TG%<MB4`@BP!@@I)"N:C"#,!9,.*,=(N%R`^,3<XLTO'?.5"
M,?>$JQ>ZRT?'*(4GM84>US@6[<)&^'<:-39"&#$`;1+:`)%``88/!0T^<&"P
MX`$/'R(PX%"`PX$-!3H(`&!`X<:"&@X8D&"A(4>2&PEP*)E2Y4J#'3(H^*#A
M`LH/'"0H,%#@P04/_A4;4%`H\@.##A<(;#`@`.9&!AHH!*!I\,"!#`$P0'A@
MD`,%`QXF6&`95FQ!K`4O4-APH0*"CPX>#```H,"""AP,-'CPH,'>O0SV3N#K
M@((#O@T*,#`8P0`!`$#'(B8;-P"```("-##H`4%<SA<4:HB@<,%D`@4K)-Q(
MP4*&N)`_=*A0D.N!SAP07(!@8+)KE1OB+B5Y`4'E#E(!8"9)`$,'`QQ&=L3X
M8#,`"27C@OWP_$&&#P_B(E`(@7.%YPT[6&!\.7,!`!!23@``?NQ\A1X:<E`P
M8`+)T]PY<EC``+0RVR\#`A3P;R,,YB)O(P\B$*"!#?A+X#F7)D!``,:P_MN(
M`P<.T``#SZ+B`+`$CK.@N+`\N"""Z0)(8`+/2,(@JPP,B&"!ESX0L*`(`"`H
ML>H^J&`_#W*3(*H+)IA@@0(.8""VDB28T:`+,I@K+0KLH@`!#>)";B,-+%#`
ML@7HXZB!,]%D<R,#UAJ@S`0<8[&!!`Z+``("E((@R.X$&(`"\>+C"+P)>"OH
M+0D`0`H"#K)2`(+0=&RS4@T*,&N_S$:"0(,!$NQ``CL12"`!!!Y(X`$F&7@`
M@@D0(E4")C5(+`,,'$@P+`4HX(Z!`@[D#`(),?"`@;@F,"`N/[-KSB#&`$",
MN5P+DF"#+P$HK:`-'*.@(0DP$DD!`AR`J[W7_E1,*5D`+*"UI`[:+>A$!3SH
M("K9,J`@(TU?2S:`#^`#0(!E"\(@+L>"*LZ!N++]8%%LIU5H`]H`R(PQ]U):
MX(!*Z:.`@0R>:^E4DC1P\F,Q_<(59-D.0&#"#M=ZP-Z".&!@@0$0_8#,",YJ
M``$$&O`L@P4&:JB""S8(8(`)'Q@I`K@"(&`!"'@*:P,,*/A1K@,ZW0@!#QP`
M&P,&/+.O(`6`,]ME"P)FX("!.\`,@PHBJ$""MC;J(%*%+CA``@H&:#@""1)H
M0`+OE#9H@PKR2Q4#4M%MTS8.-Z9O[@`*6`[?!1#8];ZK&[CK*@0(.,"!"C2@
MU0,-&$@`<HD]4""T_HT:B`L"I#^FUX((-*A*9<K#ZD"B#RY`+<T-"!CR]XTB
MR.!&"BJ`OH('HE?S^0I<3N``!1;`2(`(%*9,,`C*_>E$`%1&CR8/O#NS@>(5
M4H"#@N,:H``#X"+```5&OTP"QQ5@R+,H$P`"%I"`@$L<LM@S@`$8P($(,%V5
MC#/``CIP,0-PU(X*L@``#"`V?L.(`B#W@7P!H'02H!OT)&4WRCBF(L=:B7W0
MQ0$"&F`!-]S>`AQP0]JL27DEP<#^FN4@#`@``2/\EP"Z19(''*@DAI%2AT@W
ML)E%`"T)F-Q0!B#!F#``(]!JU_KD1ZA+V<<!#%`79S("`5[YCB0>H(!A_NBW
M*\]H@#'?L@#B,K.EC<#D:LII2`-41)Z&.$X#EG%9ES8R.,@!S#(&@8`%()(L
MF'@@`PT@'5#LXQ<WHFE!,OLA2P87/I-EX`$%B%2#-!!%S1$@``QP#!+/XAL?
M%L0#'`2280RRNO@U8`"=#"5)#K"?AY2D`'9,7C`1Y)7MB4M<VAO:V7"2@()X
M+5X9*8BQ`(`2#.R)(A^@W?D*);L/<'`!%A``*,OY@?EYCP+/NTD$\A,7U'`@
M`A-*CW-RA@$+4.!J<N/(?;XG334B2"%Q*<`[%?K.Q;EM@Z;934,<-:BLN$F-
MDOGBPJ*"-+D`TUUP44HTF[F`!R2+FL'D"`86_A`!WV5`8>0,F0"XJ"U4E<2.
M!G405ZB8G;4X!J<?N%&%2-(!PITR``8@EL84IBF4T)`R%^7,9+#%Q[!<P$Y2
MA<"@:.=+R%%``"XS"`(B$(`#'`@#=C$/7`;@``\<`)-5HD`MAZ(QA:C+,@X(
MURTY@)$Y#>``#T#7!CCG4?HT`&<H54D%,C89!$B@./8<C@+<1Q*;,`8!W0(9
M3Q1`P*AXH`$*Z.`'$@"!LJ%P`9I!&V)3X@#W0""9"DF`IU[[PPCXR3[TNFUV
M.F`?"U`3=@9Q@``T`E3VL!2T`-!4">NXG`EU@"%FXPQ,18.!^<F5:=D!;0`N
M9A#X"&!%K"-*22[P_@#2H,ND):D`!B9``-"]IEQ0I9^]/!"7!$"O2GN5ZDD_
ML($O0@QO99N9*[?+D0IDX+#!=&,'('#4@7G@6^\C$/*F94D$%""+V;&`S\":
M&0LLIET:.&D'&$``ECIH`PN8`+S^Q0$RP;$Q'8!Q=IXR)@4DP#)Q`0D#?"4`
M`3@`QH0M2`<FP.,#ND@O&Z&:+>%FF0`\8`,.4(`%`H``@IRG`0*H"P&$6I`&
M9+%F&\$(`2P@6!Z+.:N2,>%NM87)"_\.`EM6;5A6Z4H`*&`"SMF`!!@@W8UD
M0`*N%,`"-F"?"@6@K:WKP`:BQ$',',`"AN/`%A5P`0#,-,X;@0!X\%*2_@?(
M5K41*("I#C``#4$-:L-A<@"6<C$/)&NX,;FH?@<%E$%ER[4%H;-<1</.N%14
M*X*L%XZ7%S`@.S<NL]W;L<,J`#@_AP//%A5!LM:`"EA@A]2>6#(=AAP`@Y-'
ME$D0^`H`3-:$-LAP&7!J-G?IU_BL`?R43E(H51]D-<"-&8B1U28GV`1LV):"
MA0#$/&"!K362M!`H0%U2>H`$^+=A*9(J_48'@)TTT%4<R`!;$%`!%0U*N`X@
MUHHP+K2G#&P`R)E``1"0HIZ,-]0,F(!J0$:O#JR\(#<"V55`YM0%:-(\>@JS
M_"X`0+8H)\[%:AF[Q5*4"AP`:@0XXM)7Z4"H_J,G9V%^Y0#&2BP&?"T#9&(M
MPH&L6DIO0'!O=)L`D/V[#I0KYAN`.]PS,).>P%U%)]TK-FW)`*DB("K>V69,
MV$/6)(D:H<`\;77[7.$!.&P!*K+`6W[C,V%M3H<2$)6V)D-6"`965!Q4`%AQ
M:0"-LPP!FSL]!!>0`*E:L``%F)!G*9.\"TP&.8FV)0%N6;O,_-F$#5*(D-.S
MW8N8,"4+?G6<_3R<`V%0Q1T1B'\5;8`9==8!!.AZ0,E58KPE@``',TCL6`:Q
M#HQF[1FO]+?@"X`"\X0"=QI;B+Q_`*=!%97W%$N*T_D9`&0`602(HCYS@/GC
MFIM3CBA+%+DBJ8T`_I@[\X`$^!#=&!2M&[3LX*?1<2L-&#OZB`#L4R>E`R(H
M,SI/X@"@F1D)(+6$JP#=(QD,H!58.H`*\`L03`D+.PO*DBFU4ZVUB0M0>K0W
M0@VX*97@*QT(@)P$,):18!&^*Z@&"`#PXX@:"Z<PJ;D#&",UTC($T!\"(``&
MRBBH0J#]PA#.()VI4".+4`@Z6[_HZBW)V`D1P8#6@2@8^@"MX@CO.(`OLB:#
M<)S)4+D((+A1^XW)X0`P*0G?T+LX8R4,`B78Z#F2V``(V)KGL,*86+T`3)SM
M0:*8B+)-+`#]H!$$L)V1Z9D*T(A%:3@7$:`%$!&MD,'#N)ZKV2S.$(`"_LBO
M!H``3,0;M$@W#8":8=I$!2DI`6"`,<N9`="R[+`YA;"PC?`.`R@*"!``8,2B
M+QP7ESD2!]"-K?&WWW&<;Z)!X'F^^9#&V%$1#Z")NJE#5XD-!!BR2!O'<!0M
MU?"UC2B`"]!!Q,H:1N$`UXE''E$)W4D)..N("7"+<=.`U.((/8$Z`IB+K#(`
M3?F:\?(^]HH`>W$.ZK(5#-A(6\$;/T.(!V`9^J,NF=D`H.%(C90;#)``6^G`
M<9D>IE`(#/@>3=$`A-!%E;(AD90+O'J.6QD.,L0+*NJ`'5J[HMRA#U0>EU&I
M!ABFC:B(!0`E.!*`"5`9#'BRA/*=\BL`9(M#_@*P-`,;HN!SFGK4BNMC*1G<
M`+@@EMB#C[_"%I"+"B$CO4A1';$Q%P[R*[E@KSX!)<RC"F=TG`*8FFXL"<#X
MQ#<LEK.2C\P(O>`KESTI`*L$*M+"'(Z$`)NY'(_1P)IX%6*D@,Y4GJ]1.\.4
M1T@*$_H('NG0$!V)"L<2+6QD+4$;M]-,C02(2&/"Q[6C'![<IAB!K70S"#1D
M$Q=\#Y&$PA@ZKD";@'=I,]O4-8.@/HEAR9+0+S8YQQH9M>R+F.8Q&=N<#[6H
MD0EHKI^9F0=`0(Z@@$B)QP@H'</,L"3AB!.C&]]YLLU(MT=)@`A`HJ]!'I<A
M"A'K"@W0B+:J,]4)_I$W.X"#X8`Q88#]V<]JNP`T(H"I>8U^JK#8@DUP^KI@
M7*7<*`"\$HMMP0HG&8#3@\K'S(X,J`!DA!Y[<8";!(`.G)%W$13&T#+3V0`6
M.Q14<H`+^,?YV!8-P1SP;(D"<#B6T!/N2(M#&8!4L0"+^!(5X8`*2("S,$O;
MY(`NW(]WB1B!R4>4*K=MZD>%X`#3O)]?>;VSR1Z'5#F'=%,XQ8A?@1)'@1^"
M7`FAV0X-J%([^2LCW0@\Y:XB83:'HRLVD8G_.)08V4!`92+A"L`CN9J3\YT2
MC*VA`C5U(CB_XP@%(T;Q2@`)\(`!@)R(&,N9G`L5>[P@L\"8D"H">(#E_LB.
M'747?#L`5.(.%NF3)0$JI,`(K8M##4@WXED62^(>I727/`N`:9$)#KB`"_H.
MDI@74LD`_KQ#`V$`![!%6!VT#:C6S2*=(*TJ*D,N1]VA2LG*J,&./',Z`H`-
MU^BG<7L`/K--VB$(DN$_3]/'Z>C&"1#.F8$[FHR`@=V="O`GM9B`:HD[JZE*
MT,B-`)BWL5DZ*%*9KZ%7VU11CE@`"1C`MGDC=VT3,DF)%7Q.1XVA/.E&I#DF
MDHA2[F3`9.G&O-%*CL`2<.P^7!D>M*&`A.M//>$^2(H0D/N,G-@`\SFY)%L)
M#?@S!W*`#1`7`9!&"@",BQ*N7#DNOPI`XD03_@IX+:>SC*:8G\;,C*P`2YO*
M"DI!1WF"FEC-#IM@``;J,C:Q@"QS5`(-QK'P@%OIPHV5H>)H"NYR`/!(.I,E
MEWVIC^;PH$][%E#2(=6BB\P0UJAIM;L-BM,K#C6+.91@#9L%3P_8/Y(8V`>P
M@(@HB65$DX%3"3LJ69,]Q$VTJ@CAB(34VL^@OPPXU"!S&K::SZ&C3#&QF>1A
MDIO3UIUZ"Y<-"@,P%0V)DN*@EYBHERXQH4@RS<^X`.XQFKR=@#*)@'"ZJ*2)
M$MKX1#(475EM$]AIB`V8@!.)T8Z31K$U#81HCV[4C/TH"S.]%1X;B""+//VQ
M@-$="WMK$D`M/UVL_I0.4*FRDMB]>HZA<2SA,=D?0380^X`!0-9*V<=NY%CE
M*<JRFI!7FD_)VRF%,##D:8BV<APM#(!^FC(#2%*E\P"&T5CU(CWW#:M&[;,#
MLQ(Q8]VQ\*<^&Z:S,@!X43!'0R(RH;*&&9A64:<N<;CQX3B%\#N:.2??&1_Y
MI-F_HHD+(1<H`40.H9>K<*4#:<G,<,_]=)GG;9(%^(GTDMHT\IFK04P<D10R
M(4.Q6MV2.!+2B9$`D"")L8!Y@ZVG4!:HS)CB<!QWX:>A@9("4YWT)3VZ".&.
M\)H&$-=+PX`_52T_@XISE0W<W`"195U?C&"B&(`[;A/P$0`D&M@?2H`X_JP.
MB"5C@Z@*:"P)#YGBS"@K`#"5_NL8(AE!VWSA#^S'O,5*RH)A^K`CEK"+?]UA
M!S'+]5HBH%J*G>W=#E&`*(([6\H+FVH@=0HBXRV(:0P`")L9UE$G#C@1PYW5
MG<T>R=!%=%Q/A!KC%57%QU4(Z&4O8M'E^)"@K5B85XF/FGD6Y(GDO<F-Y"V.
M)ON,7*Q-,UW0W]B(%N7C\*L:>:J?[2"8F^!"H>4(M?@`&J;!&[G84(+&.='F
MM>B`(]OA21N9KJ-@U>)>4/J>I02/EX9EDAB4`X@F9!P:6P0`)'**P6!IKJ46
MD`7/?GFJR1@``@*`C+FAS4'>!8@:RMB8L2N6_@K>80^((G2*G_I8@(0T`-+B
M"#P2X=#0ZB?=1&U59UMRSYBA68@US+?07?4,T\\X/0ZI@/&)CSOCCRN+#XRN
MHHPQG9R3`-T(`%"CC*X<L[>%JEQ!%:FZ9M]A$="BY0\P*)61`*=H:"N1FD&V
M)2E;@"HYY/G``-"9S+*I4JDVH6IN`)0X9AK$`*U3.J6M"A6YB.?YZ.0TTK.+
M78U(7'WD#%#BZ-]IG0&@E::NY<V+FJ=V%0D8C6I."0KPM3<S4@,0#*F)'ND1
MG.Q6DYZ+GIVM%%!F"0M(S68.*.Y(Z4^A$8H#Z@C8B3Y;CN@+COU\HPY$-JT^
M`$NCF7ZCD9XS3+M8_E6H+``>VVLU@THOJL5B5!%VA1$'C)CA2"@(X;$O5*/3
MRP`UT^H1^PY"X@!)-*+*V,]^_`@@@6+BP1GH,1\-*(H)6.IT&VTT`8W[@3E]
M8DDYP2L!L("L.LT.^)N"_J$'D!7]FH"MR0"DF=[3G%"2R(!T(H"U5A[&9I1"
ML30V*6Z4&.>!O![\(PF;B6;=@K$?BZN6Z!'H7`G_Q>/H%`OQ7HD.((!*WN'!
M&(#KNF'MZ=1,`ZR.-A5D&[K0+N*S$;CT'8T1@IN$HY'MH:K/4(`0#:@NP0Z:
M3(`&PD7_<@!143E!TA:>08!L%0J":1*=]A\-\-<!WSR^VDPSOQK:$"XZ_MRO
M"S"<%:S%SC*`/*2B._NBRB#&`IQ)-%>)S'0MCGPT-9ET%5=:4;FGR0REA_C1
M?JP72Q(5<0EM&@R]=SL("G";G;7A2^.;D<&4ET8I$9.`3/>=IU0>>SLFW^#-
M>=DOTXWH4H0QW2`U4I,`8:'=:Z><MKI;S2!@6])UEEB<L>@MK';4DKJ>^5X.
M1#%%!U"GC.-KO)%$I%4(-#+,"14T#]ALKYC$@,HT)R\GS"FP#L%-2[MDN(`2
M%6L7^6%Q+E9Q@J'VPS#PUZ@`T"D=FJ``6"T*U;D`JSK1[557XOFL*;,T+]6*
M<H'"O`$\1T%6CZ$/N^@9TBB<INJ84)L)@]AW_OK`@%=Z*B)C#.:DW&`Z'KAY
MEX]).%)]Q&86#M^1X.]#+(EQ"'7JFQ\"BN;H`(I+B67$1Z6\@%\Y&G^;`$QT
M:WEL-8\ZK93P`']I$PA02,&/'?.FK$U\LGWQ-0-3]\\>FG=V3T$+J(>HP`Z1
MZT+JBG+.[^#0,L-L.@DAH<YJT0/HSY\4P<;*?%FF15W>'15A2;ZA&W2!C>L3
MJ^N!&/P`%%(#.72QHP:B"W@I4]>/CY!K"0UG/VU)G9GC]K&HSIC`D*QW*X)P
M5FV<EP#^H1U2M!"AKN_?>L2"@(0X+=8B[V\_'H"G04J#F#(*E+1/IU'D"/Y6
MG@=XBF#CS9.P)<Q3_HFML&Z`Z/!AX,`)#0@.S``!(<.&#A]"_.!AP(:("C)`
M])`@(D<+"C@RK/`1),F2)B-"`*!`X$`&!0E(<.CA00$('AIJ6%#`PD,+#30X
ME%"@`0>"#PY^T)!@`DN$&0PPP-B0PX(&#P1Z:%#Q0P4##C`XW*``P8,,10=N
MH'!@0($%$K9J`#!`@(4+"@H((/!@`D$.$`HPB``A0],,-`U`P*#!`P>?"AQP
M\.!!`\T!@3MT4)!@`````1!`H#`8883.(Q%2D-`9`-@/$2I\L*IA\0<*!6Z>
M3,VPPX3*``Y$T+"!@P$/"_B>C'C@0@0'R9^73*!X)80.#RR`5@M].TC5_LX9
M:C#`08!4[@XY#/"`8"O#!&?-?^#`E^*'`+`?!L#]H<-MCAX8$+#`>Q`\P!`'
M".@''TD>","1`SP]]!]W(IW4P0'O*7@2!`U<@.%`%32@@(@49*#?!82A!L$!
M[DW5'`4)#J14`?<U9-<$,+J&``,>&I`!!@DP`)2!#"C06D@+*!"!?A0<I-8"
M$"+D000(1#!``@880(".H6'4@0860.!``@\L```#$ZRX``4:9$"!F`<P<`%!
M&(AD`(E;^3A!``#@92=74$JD`0833*"```V0R-Q?9C*D```(-$50`Q9T5EQ+
M-P'V0``$1$"`!1Z"%$%,#W4@&@(&;!J`H^7!_H?=!PS0F.%V'0R@%&05=!`G
M>7[*JJ`$6L(8WGB@*HB>`U0VY($!1IK'FP8!5&0?J?DAQ,"H'&7@@`$/W`1!
MK`,I(&>O_C48D07LH4601MQ9L$!RWHY;4@>K#5`D!KBE1,`!!G0V@`$7",F0
MF!O@N$$!!)RU`7)2$E`!L>'MR2<%!%FG`+H)Y84`LP1=8(`%.'XP00%7[98!
M`P64V-`&<!95X$`<-$`O!`%_H!H``F"EV5I%>M#!!0P`X-4$9_D,@0$)&*QM
M5!A$<,`!#[+*$`88(,#GF!B4"D!Y''0F9`4+Q7?!!9V-NO('%P30P7@64'I!
M`9%V)RY('#`=&LC0_C4G8;S0<9"`!P10()UK#53P=]1[GR3!`P`$6]P!=\/'
M+P`$X+C`QMMI$,$&EC(JT^-.N0Q29K]=\,#$$B46&]B()TOM=AX<P)U9R65P
M+>L.5;":[OXVP.]]&UP``6<!J(E;!PA\;J`!"."J+D8PL]A0!4['K+D$<&X@
M5.@,7>\`CAY`(,#I4@-V\4`44&D^S!YO,!Q2'XCE0`0)=!:`X&ZO=A]Q&&2_
M`)61/:`""`B``!90G@[4*4`7T(\&[A*TLACH8`%X0%KZ=0``C"\#D\,-!>XS
M@=)U;2`7V(@"%F(!$EH.`'#C2`7&=[N,$.!$WWDA230`@0T(@`,2`,KT_B[0
M`;_1\"0-2,G&<L*!Y,5K<;]Q2/3@DST.O"TN-&M/@CIPN0A-@`*:$D`$!M*!
M"$P,`NX*XD`\,+D#-*`!"!@``1*0QK4,`(X$&("_YDB`<N$-.2;90!?)B)"J
MZ:XS!Y#`]0"P.B]JH)!00=0&WD>0"@C`)N`Q"&!PI`$'%`!K$1``;CQ@*)2%
MI6DK/-L`'+!"A2F`6"$#8D,R@`"DQ:8L+JF-I_J2O:H-(&*=$<!6+G"`G,#*
M``)0@&4P0P$&.,T@#'```3``LU,QX`%G\4#VZ$<`PA7E`H`,@--V6;4"W.@#
M9?I.![PW$`ED8$^42XC'&O:JF0E@`M=+#@9F_NA'A&R`<GNY9T1>HQG<5-`L
MV^/G0Q20.P0P1#0<.$V\RK3$AHQ1039\5@?,2"@(,*`!&3T*OPZ5408@X)H9
MG2)$=&B^#.B1C/(1#"$)R0!K$?("J5&<2UL**'JFM"208]V\&%`7S&``HQ+`
M@$(><"@(3"!@'@A>[VZVD4<NP*<<B%H#"N``DG9``@N864'&R$<"G.RF&&A`
M`E[9$`LP8%DP4@A90!:!J)JO=-;2CV2&:("?-*0#;.N-[@C`'@P4P``*8(`U
M(?`7!U2@`AD-$S/-)!4/2.!8"XC`I[R(`3()(`$2L(`-U;@:L/C,`0I8`&>D
MHC"").!X!MA):RK@_@!)(H\!`SAB'TV2@=@1E&/.0<!-<SN0J]*%8Z.MV15]
M.Y!)&6``#)D`!/K&.OJI)%D(4"7M%O(12D6@``EP`'>YBU1"@9=0_EO`LN#C
M,^.BMT*][=5P&K*XRW$@`F-9P`57<\T*;*`I/2,101P0)!'2Z)(5=4@&P!JI
M:/Y'`!(HB@4L59`99::V`_E+X:0G``>8[P,9*,!'+B<!.X$,,>O-'`,$HL'5
MW)0JG9R>HW:IE]9D0$0",(":SK(^`<!*J6--P`0KRH$'*$`OL7(``!P@-[0L
M0#T"(.!O&F`DV+UE.3A+#G^H2\/O%%C$.Z6ADP'`G@/LQ`.@3"]#")"!_MPM
M]X9/W5N5!B!A@B"`I-"9Z$8V`(`*-+@D&CC`QJ2T@#^CBBW<_/,"",!-+15@
M@F26788A<F8'$(^T<T$``@H=($,'(-,%\"-D]Y3#B%``27D!&KT:H"2&N$T"
M.++0\GK;`?*"JLA68M6&:N/&@JB$@R4MP"\)+-N/<06?`NCU;M3"4'51(`"K
M"Y)K!WO6QWE`-`$RU*-(30`'4"`UO`%DG'"C@:\5H"8)\@!D$-)@TU"`,ZN)
MY`+/5@`-T+$B/P[I`5YT52]2JL);_F-Q@VA0W*!5`/5:$T'C^P`#$&1E".?/
M*-%;``Z@)U8$ZH`CQY42`+PY7@I3RD`.4#@W_B/$M3;A(T(*<"T.$*!^E1XM
MDOX\6@EH=`(M+%1.%\TZ2GE&`9%F.<L[Z/,6'OEV&P!D9[X5(6T)4Y>"3(`"
MF**!46+`G4$9P$#18DAB]6XG!+FX`!Y`&5!%6P%WFP`"S&D@RT6(`@:0`$(9
MD@$!M'U.G=1,0S`PXTB^AVH3$$!G"+`\RWA1C`+7BHFXQ9`'V),">J5)IA.S
M5`CP.``G>\T&I>89`%ANP!W3EW)+\A3C7B#E![``2P(>@`8,F(Q:Y#!!M+H1
M#!Q[T6_[0!L18M@-L#)>1C/D"VMW1,G@EN,$:7H`F+9I26&%*Q,S944Q,VZ&
M2$8^X%4\9BK:L^IC_C_[/9-,!S+0OJMT0&'@U4!XZ408'WKINZ3//ONKK[#V
M2Z:,&;``S!?3<(EPO_W.US_\X_^08UJ.IT6`E4V%!1S3'`T``DC`)E7;`T0`
M9B2%7:`=3F14T'G1`M@3Q5R`:.W&9&'4\LB/!%``\'C)!&08!2@`ZB&$</P8
M.*V0R13`5JA:&3%)`MS4!F14:\R$<TQ&65E5`%B@07B`!9"=`&02:"1(!2S.
M\K@%P:B,?DD20I#=$+5&8\A79Y28NBC6T!A@!#3``CS`4/F,"_E'`G31`Q+4
M$/;&BBB`&,;72S6``YC@OG''5@V`W,S,C3A`1-G<!\P65R`<03#7JQW`_I^M
MW"M]H8B,Q2N-!=,E@,L1B2)R5QKM4E1EE`-H5)(@W@-P(N*)R#)QEZC$X2AB
M(B;2E^(MP)4`P&S4#(:IS4]PTE,0!@?8QHIP&%0PETHL$S(U8DBE8EF%5``8
M0`0(1@0\0,KU'3+J#O($4@#0D;H%TI9`P/P$4@$$DB%AHE%=XS7"R4LYU.[H
M"Z7IB)1(`(&4%3"B8V`)`(Y]E.3TRS9>&S$R0,1L2L9Q#%CX5,Q4G4E\T3J6
MH[IM"A<Y(#,9(-,QA1>QG05J&*D=CC8MP`847Y2LA$10BC,J7=?AQ`$@P.%,
M@#`=DA1>6%-(@)QH1`&0X0=$W6JPQVL-T%)\_@@&-81_$82/P$\Q10DX^43*
M%0`8+9-D;(]:P(B=K08:.1-7=`:K6,BF?1$"G`X?&8H"WE\K"8`-1640(=`"
M[,E#FAA:Q9&3[0WLA,<&>(\G>8L&]9MQ_:$%$(`4?J2<<`#`:,`":0#=B,U;
MW@M8`$^'<$!<!@R__`N1;6,@U878?&-@_D93E$:_((\RKL9&3(1A!I(>Q0QD
M/A3&4.8!<,H%%*9A,DM<0":T<$!%62-EEH<'*%U@8DV,4.;-S"4'*,QJ"@C$
M:<!H=H8](D1\A0RDP`?=B!9CWLP!#!-AW9#)8,2&#:#*I")S>!E"=,!?&%ZM
ME9'=5`"2*,9D``@R_JX'2WS1`B@D?S#`%7'`L=R4!E#),,H98&+A,:T%WP4=
M!9C9;C#`1R;%VC$$[G61!UP6;8)&2C&3"4[39C0'7JP&!?#=\2'$P3G`B@#(
M!U@`,0H*,Q%`&Q+@A,V2S6W`6!$0=][$$.)%O57E2:`5!KP%@DS*DR1H'R($
MPDA$#&Y=`DXC,<9A!##`9!%CC;YHC<IH8!"C_(`196E*T&C`9%+FC9(:9')*
M-$6`.QKF\C#H:JX&-SG-:=[,.NJ.`3@-9EY>_5PC&Q4B-%*FE3J-;QHF6SAI
M'#F-DAIIF'J&E(+C'37C-F9:RO&=[MB.0^Q%KE2HK&2.,.E.[\B/J;5$_IPE
MBU`T%U?@$8.V18+$S@9`0-5@1P!(6/;$"#']1IQ8P.&($`'(Y_DTS`II0%YT
M)P;4UVIDBEEH2Q2>4R:!!P'4W(;=8`*P2NT<(P"X#'ZBT04=BFL66<)YA!%V
M1MS!V:=.)<J)&0'HQ9S0!&Z!1)*A*%I<#QNYQ4V@5$@9P$'"AW=9P#$^BR>A
MW#Z26?(H`)10QL$10`&0!2:%6[E:A0/0Q,$@T\$<S+YHR1I5FI5B6@'045O`
M*[R6*Z]QHG^-!;NN5K^&U,%LRR9F2;B)B8X82KD.STS@&*6)AFAL(KLB'ML0
M5;:R:P6@4_A-%8%$0`;X"%E,@$_X")M8@!*R_FM3T(W($A51M8G*DHB/B*S%
MLJO-;N(#G`A1$0@8,L]E79;%4H#&_FLG&J,\^4B8(-X$&"-B^47%%FUUH,67
M!%`&V-#+GME;5(0$E$IHG,A.F8PGW>'>>$E.(`#?&9I<7),(8D!E(<1EA:ND
MN,P&-D#*'*B87(=<+$#`R*BXKL<FJ:/IV&U28!2F_DRXJ,P$+%./X$1D>>D`
MP`W07(P$U,INC$SCQ,G;[B2.+)-`:$N2E6`T`0WJL4G;-DU]Y6E2'$0YGHT-
M1FAO(55)2,!_-:L7@4BE"6[WM4M9&=GL/`=O)8`&9)O;9(![L$9Z95%#_&'-
MU"G9@D=%0&!NC>1^_MP0_$3&CJ27!EA+MF5;"W40!,1>[8IO;!!,#`717@;9
M-?*=H$H$H41-K?C2`&#J!RP/4$A`1*Y@@@#9QXI0`E@C6('O5.Z'VY650@K/
M?6@'06COIER0,$4HLC!$=GF(`\33;@Q2*PU`G<+./B8`TC``R*01Y;+IY%@`
M4<VHONBLV*$=9!U`I!B.281>`]"A<4W&P24@.NU'Z>`%.$THQ1C`;"9<!FA4
M`J,H;WP:2J:N<5&<'_''35'3HND5^)(%EB`38MBFS<TOF6&`,R8@/X4?!*2<
M,_;=IFA+QG5`\5&)G'G+'DJ$QZ$%`YSD!^A<$ELGO<BCND!:Q;W,]1Q9_@),
M#/CPW5T0R/7MQP!4G"<!JT0T0.4RIZ;B1`!XB,%L6*3D4T8]Q!JA[0%`GO@X
MZ>0<\=`EB#8E1W@D\?AN@$@\REM(!*/B19%,:)`*L2`JBU(T[Z(-R\MTGBW?
M4Y+J;RF/;WK-Q$,\I/A"@#IE\0OID(H@0`/,::5,"D(XB@SCS@%P2P?@#/+L
M!X*.THR`C'%T"&7P2P!00(<T*-B)#+!)9`;XRX)Y0(Q-$7K4*:4D<K29[]M&
M4D.(C/2D'-STS:-8Q0*]Y3S>C`J>C31U!G"IRNRN$2&M&_,\0.HBUG.4Y*:.
M+RVNT361I`ZU\@A"Q&:!(4$L0%>(V5FB%WU(_@0C9Z^!!I$GE8?=R1E!H10%
MO$>;L,I+^Y'1_?)`8(!@X30_K=1+S87_]IT<`LAZ70#,T0@889X`+<`*>0"(
M0*[*D$FL0!:0X:L##!5XS"BZT**,+AFJ:MB%)0@&3)93:$E4,`087\Q.U]P$
M3*!1^%6-#)!B-K/*B2`"%(IGV"^G"`DM-NJ8-)5*/-D/0X<'**X#?E!.WZ;B
MS"BBG$OM](X"F`XZ#T07`8<7-9)S\"&*WO)`(`9SWDB#$B.AI"PQJEH&4!9S
MR$E0!<=SC(=-[XU=X,878A@P1Y57+M1@]9%Q^&]/HQ?$B2]VU2[X@!G1]0N,
M6,<!1$V+[22FPMXB_B>R6"H;@<VN8=.$7%``6#S`O5`,B/`=8C2G(<_)G'YP
ME/`90@B(E33$(D?-)#>$4&!(!="1T1EVD*7<`+AU%F&E[J33HQ`$$1)32-]$
MJ1P3=)E&18@E?,Q$I9#T0Q"5;\%>+MD@_KE6/5;$3'``M.BTHPA'!O;AL[P'
M332%]N*G06B&9J@)!/"$#8TSO*0%5R6'!4SW/4'0!U"00I(9C)2.AO4P/ZER
M[=)/^))1+$.$\/XHV81$YT1)I1Q=F-6$%I92A(3(-!&&4*S&0CR>E0QD@C#M
M310I[[UM,\U)=@,>0_0.C%0``<"-)SW<.94%!4=;3HE,A!Z`9*M+J;3V_IXD
MLD04[V35VTRN7F<P"46?Q"#6TG-<0,W=$S7USF<,#9]#6H1^A;)R`(C4AF^3
M653'""23&7IP1RU'A)?\R`=X.'J1V_W-L&(3U!KU^-ZTB4G(*%@\H/8&5[+L
MRV9+1)(&(JT(R="EDDQHBAYYDKQ-5@70C[]@7+0]F<*DQ@@?FU(0#!\)P`7D
MDX<3EO2<]W(]W.8L%1P/(X:4QND-A*$]C>+I!P;49A7!S\N@2KD+"6198P!P
MA)"G=6CZLJK?)@IRTP[=1#W1R0!4V)GP!>**+[J_1UQ<\780884$HNH-S8P!
M0+.>97SBN\2W^MZDSG.,\\A8("M7((`M%7U!_@D48<:OE!OT=>1+3='C<=;7
M6&("H-$$\$\%R!>0Q.<ENF,<X7=?!-7-6&,"J+EZA%-?O!*,V,::-ZH;?X!R
M$YF1H,U@7,2<2$"0;=<"78"ZM=$'685QH-80*M;3F*!`3```S*"#@X28N4;"
M5SS%/`#,'X#,+T:A6&F8+$74P39Z;7%3S$O#2\V'GL<Q3T4NTW@`E+KXWD1:
M3$;/K#T-7_Q7%CY(2&U>&8U!_$RO8T!:1<TF`8VBUTR$-IQH-8`SXG"N:Q'1
M]9'/8(02[AE;5$2!'<L%D44%!!;"Z6Q2Z`N,],[%8!3<=`"J"(E2A'=%[-T8
MY0I+S%]1Y`HW95M@_E[;AA[;%PF%6W!&X>\X1^"@LN#XXLM$\&!)`#P=2@H&
MIOA];NVT_AZQVS7^=F"`X-_3>O5A9E#:!(`<=C33[&G__?M*O'3P>YR.82,&
M0'#X,'!@!P,"%&0@N'!#@@,6/'R@((%@!P@'$3B8(/"#!PL&*GRXT(!!`P<#
M#C084"&BAP@6!GJH$&&!@0`%'B@<N,$`A8$38&I(N;!C@@81%RHXT&%A`P@-
M#'"T@$!#@P0;"!!@VN'"``(1/B@`$""!!0T+-A3(<&```+=OW1Z($$$#48(;
M+CAH$"#`1KL-.-I=:($"!P%U!2=6O)AQ8\>,(0@`0(`!S($6%CS6O)DQ_H8#
M1",`P,"9=.<'I5$3Y$`Q=>O'&RH4QB#0PX:!B%WGUKW;KH?`O#=S.`V<:`<'
M'CHT4!#2[H8!%P1W>&```M.=`CLH6$!9IVH$"$:GA3Z0P_<``,!W?%!A00$"
M#D).Q3TP00*?SB-XT$"``M*8VHM+8(&(C&.@(P4:(*@""R2(0(``(M@`@XPX
MH."`"P!8P`&;W**.(`DND.`\MQ1XX`$`J*/+/Z(N*`"``1:`(`.DAF.,`0TD
M,)"X'5V3H((*-KSI`0H$8(U'US!P@"@/#!CMR"=SRP`L**ET#;DJL4RL@PFR
M3,R"\8CC8`$),)A``@<86+$@"KQ24R0#"K"._B`--'B@@`3<?).Y\G3:((/A
M_'Q``01<!$`!VPCRJ(`-D,)``0P(P&Z!`3,HDBBLN"2*@04T@-,Z#Q#H[ZX.
M!#"``0(*8.Z##`@`0"<-+IB.@`0@T("##KCB:RP9#_BS@`$2H(M1%@7`@`(%
M"D"@,@GR7*@#!#XX(%,JF\72`2<_T(""!`I0J\O-/%@@``TZN/*#!Z:MTDU<
M.?-M2;N80HY==CV00(`'JOU6WP\XP';?*NG\-R:JH)2`7.OD[*`"P(8D2@/M
M.%@Q`P,`N/<W@BAX[U,#QG/`6[L@0,`M`BP;:.**!_"I`;"<LRX"!2C(H(`$
MG0UUR0,.H$#.#[*+_HJ@"P)H[^(/-@@`S)@D/"```0J0H(&W6IWL@;HZV$""
M[1`XP%\3*]+6/08FV'FA"B:H@(&A><Q7L(A+$]L#)0536^`/0D.9@`$44`!5
M`A2`$U7W``><OP4:*("!"`+?NUO%#]C;``10_8Y0`I03?/'$$T!@.@5*->``
M0@M`EE#/%Z#`@`8.2/;7K$:<;V[@-J@1.+1?K]TQ?WG#`(,"'/Y@-`HBN"!B
M"12PH`(-CI=]`@(.0-!8-RM`H`)$.T+K`P8<Z(`#UXD^0(`'QSK:.+>*76D@
M"`I`3`-E*;9,6P@XN`ICP@WN+0*:5R/``^74[,`M"JAW&P=HX'X4>XN$_H!7
M@`"@*FP\`](`)$"!T;1H(;32P`8N`JP($>5:$TB7[7BT@2F!\#$2:`M:+K`!
M#G"`)Q&8``4F<H$)S`5X<YF+!"3PP@O4Y@(VG`L&0&3#!OEP+A"PX00\D($9
MFHF(1*Q`!JKFHQGY*0(2R(!9-)"!%=ZJ`BS<@)_.@P"YD5`S[B*COGQR1AY-
MR#$=((``!C"```S@`0+10,@&^#(%L(LA0&S@SR+`@0@LI2`+X<!4X'*`"@A`
M5>K9CF?D)`$#?(H#(2O`!"Z0'9@\@``X7(#V>,8@>$%``1IX&P0Z(H$$X(Y6
M!,#=!R#@`(H8A'P<P4`'&`2!636@CCSK``40_K``O7E@-!TX0`+D9#4?K<P"
M'4#>!RH@-C7JIHI5S&)J7@DE[;E)1]-,#.V<I;852M.;Y2SG&,WY&`?`C3&(
M'$L!(D``L@3-`QZ@P`X%L[X$"*8^S0M@01AP.@K`)7T.($`&%`+*#UA@`*@<
M&V"(,@$!$$!D3!,`H0``DR_Q+`$?[`@#$&!,FGG`3KAADD4N9)>,U#,!;G%H
M;RC0`,@QH*,SXE>R(,B6HRT$B/7ABP46E4YJ7F"5.12JE@1R@5(6I)FC0:@%
MH,H@#H0HJ@OZ$@6@>D4,^.:+C`D8:OX9DZ..-6[@%!@+R;J;`(25(`SP5P=,
M"!?^V"0`#=CI0$14_C)#YBQ/0$6B!VZT`/ML0``;R)@!(L`7@F$@:#[BR`4(
MN1`-I(\`$T"32`(`$PT-A`$`\.@'$A!0FEU&C`/!$'0R]L&W+0`#'6KC+]$7
M``,X(`!01)S2EM.=OTR`<_<[7EK!%=)(`5<Q#]"1/1E5SRU18`+PDX@'/8C5
MLAEK`MH:3ST9LX'/)DJW[R+N=\$;7L=4X#.*6=$%VK-5XLD3+FZ1+00BLDCL
MV@52895.`0SP`">MA7H6N`J;/+N_TPP2+M+C@')<=P&2240"'5@``E)&`-MD
M8``6R*A@)`"`-!*$E$A!@`+P*H"AU0T`HWV,!RXP$0`H,@),$:%8[%.N_H5D
M0$D7.)XNT8/.M`*6;!T1+UX3:U8H6<#$=KG`2W^<9"4O^0,+:&1BJJ)`V0TD
M-A1U``(,^**\L34M;F'`L`IR-5$-)@&!F<``_`0`Z#!@45I)@`%@$T^HB2UV
M'H"9KLX#X@\X;54"^*Q3B%*>HY!M7`,!IIL<X!8CM>L`$%@`'!F@LXY0H"8P
MPFJ]4)F9BASG4DFF-$(;HF0BL74W^>(SM>8VW_DFYF79]*:DF3Q6-YKWC@D@
MRQ_C9H$(?*>]+PI6%R,"@:O$CR\#"%YM-IRH>PK*/U,QSBH%`($)%,`W##@`
M4C:@:P,8H#X=+=<$I)<7XXQ$`!&QV:H.:I<,_@1@RJ`]%)/TO*KJ[M4M3]8,
M,'UL@=@:1<:_Y)Q-6#*`QK#DQQ4VF9#'N@'/+F8F#88R!.ZZOG8OI+F@^N21
M($!J*K56`#R39[(7$IK(`G<#"Q@A;[8%$S+%&C49Z.9=)'`1ZF!`XX*Q&BE+
M];2W#"!TMU0-;"J:@&@R),LHHMX&$F3<B`#Z)PF8CWX&P.O)0`X!B,)`!B"`
M(@R4FR`92$^BQ`6`-#EK`@8RX:?89"1<5F"2I0'5:0RKYZF"FWF/VHEM\M(8
M8B8*X6?T0`$X`.+#*=D#H5V,`>]Z&0"TFP/H64R%F@R`FF^&G,7!4@4JUA&*
M);X#2^/>6#F`/8RY_C4W$UAXK!E0^<;`L"*"_!4#[/T8T@\D`@ZP]5M&E)+9
M).H"4_'*`1QPJZR_!0%O#DQ>*B0]@Q-$)>1:R)E$<K\&M`H!8.+*`V[2KP])
MF%](#P#G-+PS#O#',,FN0*$3%6_.=$4A['FE$J'2:.$)Y^2.:0!""C-62B<'
ML*H'+@4"`)P,J/Z(::J8YBZ\R'`6HX>D1/(((DD&B+O.I,6N0P,,+XFR!@'R
M0]T>0``60">.Y\B0R2YF8C08Q#9JPS(,*P*$;3P:K^.B!0`^+^O8B6?.)`$<
MKOM6`VQ8J$'*)":D!$28(XFT*P<7HS8:A.!XYE;BINL`P`B7A(7$9H4V_L`Z
M+(Q+5F@A5HWD4B/X^&5Y%FB[-,.F6*3V#J"SX`(A%,E9+(`!!N![VDL!"J_M
M!H)_!LH`0,8`#@6OMN3B!B))Q.4!`NE*3(\`\)`@EL<-W>(T%`Q%`B.0%F`"
MUDVW@`9;/,+MLH(I(H`.<^W*X%`,%<-7#+$!?*Z<'$0N/(/)%([4+N"B<JPI
M""HB-*"]>"<Z)`HN;,/!QN)%$"/KV@(`]LD#1L3Q3*\`'$`RD"Q;Y`D!EL8V
M!FIDI"G1CH+Z0$OL),(M#.<\PB/S#$,&!4-DV`E4)N,\].<#3&\L6N4\?M&A
M3&]IW*(N%,Z])N]MX$)'+&"!I@K+]&O;>$8I_MQ"TX@B23ID/%A0,M##&;WQ
M(`X`,1S"_UCNHZ:#Y_S"-6)C,63&/891.RCCZOA%"BF`S7X1`,`B.S9L?Q:@
M/`#/+H@'*=J.?SJB`<J%&?&&`7+(`I?*6:*&`.C&5M8B]7Q'X#C``"0`RWZ#
MIA"%;3A#.@``;A2@!A?#3Z`H-0*E``[`R<HI`VPM`!;MQSA`*Q/CS!C+`6DO
M`*1-,O!PZP+@1UPD&0DB-`*``4[$`4T/SA;`&HM&!KL"`.II4`:`T[(.OB@@
M)X@BPT)BH$*BM5#D\[I2*T?F+GV"2.1PS]3,=S(O!KE'&$6LK1S/ZR9S%C4L
M+);R62;S[T2C/!;O_@,2+4,^CR@&J@&P[D%:XD1"!CTBYD'FQ%#"BDDRI+,&
M("+BPN5.T_280F9*;%5DJUE6(]8P8/JHPP*0,C>8CC&TYP(H1@(L0(7L13O@
M2$Z"LB^0(ES\$)K>Z&Y&[),X`,TZPM&J!EHZPH4T@`&&<<5^XQG/AF>^<U/(
MXS\PX-'TBE6<$R:3LE5\4B1<C4HZ(`-BCX2N$\S2YCL<DC>H,D^P3%M$LB#>
M*-@RI!KUC+'JCR#$HG0\H'&8@C`USV@R[-K,L4(/(IDXYR'^:;(,H"681R1*
MK%I:*BZ?L-[(X^IH[#-G\1`IAGL:3^#(HRT0`*%"`Y5"0\\.#99$8U7<_N+J
M$HUW3@1/&L.-1.."GF9:I@\`@LH#WN@V]:KKVH2DC`9##L/C4$DX8\(`]$<L
MBHPHG"[):BT`(&PK=:-7.`/IW@C"1L90-.!:*D`L!"#97")E?@9^'F#D8J(]
M1D).'.`,<>,L9N+^'.`B%BAX8*E5O@=/KP=U`L,B-L`-X8L@$JU0.0,#3DC'
M'E(S(*]*^`A+5$*:(.`\W#$`F&*@-&W=4(EBIB4CUJ8`!*`!0L)C(B(!>O-\
M/(L&">+[/.!%Z.L`QB+9,B!#!T*!WO,T%<,S,P0NMJ*EV.UI*`+S8%!:N:<#
M%`A1-"`^)0/$JA5N;`^O)A/S=M$M!(Y9K[0M_OAB1-3N:4J&*F\3Y.JP.*\5
MDX`Q)G`B1>5D`MCM16H.`B8.]-HP`*0E8HB5.`@(K#!@U_I4\F3B&-^R+3XH
M`O9I2>P#7J;O-SP``GPRRB`%3VJ17TZ54$Y$2@*P.?J214;C977B'%UMUX:.
M/,1%`!+OG`J42O+N(45D:`)1`K#/&P=J0S.K&L>.H<HK(`44`UHQ,SMK9_DB
M`X!FK<XEP*!U)X(G8EKKY3A`@02B*Z\MZSK4D$9DZQ;Q)P#`N3`O),B59]KB
M\R!LA#K+.54H_T+C$!4@`$;#]+Q6`*Y3"A=J*1U#-QL7-OPCPZRQ(XH/8RK4
M+@9*1WA"$E>,/.Z%_FX`0$Y4]1^E$P'&=*P2BS+&[`,&X$%3-6(;XX+((V1N
M8K9629"DE5`635,OI5LNI@,80`%2*%$.X#3$0O(RC-NTT&.8D2\D\2,%@SJ+
M+#DJ(.NT$BO&8C4MEP#J`@,H)DV)@@RG:?P4Z6B/A%7):@,BTUF\`A$7[N]@
M,-%0R<+TLAH!DBA:)23&KQ9-3TE,;Y\0LPK/8X?*]AH7KG-94\-"SQHSC"TU
M!46(]W\&XD0H`@-.!"P&*@`;;S+M0ER,I"ZGI+-\PA>90F2@0RR@PXT&H"XB
M`%BJL60;XT0RY?Y80P/B:%H'(DQ-9G.+XXT$HBZ?J#(;#\2R3D["Q44\_K5\
M]]><",A['.`"MBH@G5(W&*"[6@.7(.`AD-4V8(,!!`!G/HPZV1+IKC91((=Y
M-"<#'H;F,-@W$L(N&+9BFFL!E*9)[")^D$C7<"8^Y6AD+'(BA'5I)*#OU"B)
M*.`D@JEHB4-]8\TT:^0>N<_"/"<N.L+T/L=>$V-W!N`@W`*,Q4)8M89GL.^-
M!B!!.L`KJ&<"E$8=GZQ>^`(DF(+MU)=D0^(!ZH,CS+15[B0!4BP!=!*HN&^/
MQT(G0H\M7&2XJI0^2K<:6YBVW!&"0M3Q!@(!'B3Q*L5+I;57.L#6EN+\/`M-
MY1=5EZ2SN&7%B&DL?IAW1$;\3&6,KB6=V`Y%_JI#,>88.$A%BW,#*1B@BV^D
M(_!"50W`PN+63'J#ES+@6-"C<39"(2)H.W2K"E<T401%EQ\``@`(8<DQ)X3G
M2.LI+J_8B0WR?<6+F"+53@^Y58DC01G"FIYW/"I`CAH`J^Y"*0;(D5U".V)#
M3H[%*2ND5A+%37@H3_J%*8SG-]!K4A#9HE]$M[Z3OC*#I`@68P#H.U4-J[5P
M/R$B)E:M0E:37XX%03@B`ZJ87[36L#;L3R!@=7FF>*G9T#+%4>[C`90XL>)6
M,(!DFCR"<Z+-(0U#=H-#)Y^D-MC#3C6:*:3U+4I5"SMICT6O(V+#)J9$D,I$
M;`D"^QI*3<X3AUR$_DLBXV[MHJ.N1T?CQEXL.#1H][N\CP`6H*N!8P_3SZ59
M6LE6(R(H!OU6)3:"MEUBM8P66;!K>S$V<2PT;N\(XDA)2#\N(MH<V8I_#)<"
MBGEZS4O/!MN,43`68.QBH@)010%HI5P\QC8J($D@Z"V-K.J()D@FQ3L-*57<
M:S5UDY':TE4>DH`6`%@>`+9;PS`N)I/$2Z@38R1HJMOL>C$LT$J)8T7R.N0@
M^4>$NTJ4R`$FCZQ>%TF,)ZQY9C[^I'9DZ,TZBD$;8VU1=,D^N+HG2EFNLW10
M5L%-)GDQP+\>PG1N*?`RPU$XA2ALN2N^+"\NJJ/\8TO<@CV]I+=+%!1__DP#
M]$T!X-*M-2/"E0Q#$F"*,:.JHP,VB2-CNJFIM;OZ_.X/W>*YR0K%H#PW]*KP
M^#DU?JF-)B`!X"B0DE("HD;,TXI>#05U>FUF&.!4B$QLBG=%M,5)1B*.4,+"
MTBA^"%NRVD-M/T!D*.HH)',R$J-:)BMVA_LV-A$!H/#26P-#MH;K)#M$<..B
M*J**(FA%X,J*M)!!(D`)9<+H'M"*S&HFFFDA.@M?,"8VAE<"$,698.B?M(>%
MLK#KKLZL)F!J,,2^8X*%U(2KFIT)(TI@&2/-SRF+&5S]8/4]MVV>V\6@"HS)
MZ!6SS?H!'FU^J=,M<(U?""`96>5BB,?"J&=M_F.94*1IE7%B`Y<7V_&*VB4B
MVCC]0QS@(P^'OQ_OWP/R2?\C``ADL<<B)*KU$$G7O3:0;@J%+",B?N!"E?VT
M0EWB+00@S9=W,C0`DT3&+2P#M2>C;>>B579H/^!BPUS>XZTCM'EX;=#P+1"#
MP+Q4)V0"#97[3PBLP3=#P\L)V@O"RP$&`G@NXU(C7`0@X-_PXY=L78V;-5V.
M.K*H4%YD4:]+TP=3O1<"`)7=M(SF^2B#4</BC49(6BV]--BBS'_,GDZ%,IP\
MLXG^(;%BE30``UJ*9C+L2,4"#S%$X7GFHI1(,@0B'B_5RVBT`("(G<%<N45&
MOZ1UI#]`["C`18+)_D\J/R(Z2]-=9$I&Y)-6>2DO0&3TC#3U:WD%8J`>(K>U
M6!CO5D1"63+O92\*K1TA1]+CD6(AF:4OX.5N0RN.)$D<0NA*L;];GS!0A'V]
M"5+<HOY,AU&`!W?;BRP>((56R6%<25/0WNMT`@"C:5%UZT8@"R:27?@W(RU6
M>[B):0*4P^G@OE4M#%5`>7ZWM`,8"P_7M61#`R`F?/CP`(`"#Q$`'.CPX0(%
M#!\R2-Q@0<"`@1\T`(#PP0(!`!DH`AC@`2/&B@4H7,C``2,#`"4S#`B@X0.'
M`@0V:`APP`)&APPM!$@P<$(``2UO%BCYL@$'#@<VFAQX02'#!@%`=D``_D#"
MP`4`(GB(JF`@@@!/`PSP.;6MV[=PX\J=2U>NA`5N'PBL6[<#A`0%&$QHR;=N
MA<`='$0HS+BQ8XQ@`4A.4!,C!@)L/W@H4$'"1\F@"1QU6G)@!J(8/1`0\*`M
M!@02-@@@0#@"@LH?(-3$4(!#APL%O+Z5@($A7`<"-CQ>SKPY7`T6<`K&[;RZ
M=;X2`+#EH`"``\V2U0H`8*`A`*(>QE=@R"$KAY=[IV8H(,```+Q4I5X8(%E`
M5@`0I380!E$%H(!Q'[P4$WFE60``!1X$P(!)'CS`0`&3#90``!,.%,$!&O;W
M&4=330!`:P.MUL$&DF&D40$;'$58=A=T,$!9_M?EJ"-<'90VE0>H59>!!`,8
M``%A.GH@00.O[>@D7UP!$(!')&(DTP6F#="2;`!@")H`+PV```3&78#B!QL0
M,!\%;6T@IEKX?2`!CKEAV9$!+84$EP(6.;">6PXN]N2@3G)P000)"'#``Q@@
M2>BCC&$`@)T?4."=60`T$`$%&[14%6H;'M`2!@$0X($#Y'V`@0-.?1`!3U@F
M$&="',D4U@8Z6>!C1*6M*($`<797DD8",.0!?!\8B-%6`4!@04(=6CJ`<AHA
M,!!_`T2@;00!FF1BAQF,!Y%]QEF*@&P!5#"0I1<X2">D\!96$P7"M05!!LUE
M`($!!C2066$>(!@7_@4,E-1;O/!&%D`&P.%K$F\M08`C!Q(<4$$&#IRU@`<4
MX"EF`_@R8"<'UE9`P)D8;7!`;`B.A6(#52ZPU%P=5,`GL!=<L&L!#2#L,W,<
M3`#!``1`0.G/2)O7;4'??=#`@V@B,.&G`['8LVH`"&0B;0EES<%X7K7786Y2
M?;#AJ`D@(/!`#0Q@;`$%8+2A<A^<55,&5FG$9M67HAF`6!9T()G.V5G[07?"
M/3#`WB:Q&(!R3T]*4-8#1>75AH8'0%-"[T+:@:-)8Z3`0Q:[13+H=5&P``$)
M'+EK8ZC_^,`"QB70;>@Y1B9`21?T-%7'&`S0]$`<-*"N!PTL8+M1H,%9_FH#
M':#&P0)[86!`608T.]4&#M`.@>&YW4YS!A0H<,"-$F3@@0$7X>[^7!YL4`$#
M"BA@]/N/=F"?N@,YL%I)Z"I`5M@$EO)HABOTR51).+"A!!9``QZ8@$6R)Z6X
MU4U*WZE`]LX7EK5]8&L'P%#3=@(``NQF-@H8@`!\XB`0#:0#!Q```B@H(0YX
M@'PJQ)`+>1.`!7#E<6W9#'DV)!F(=$Q""="<<H0B@`;8AP`=2(@!<U,`E.T(
M`A;$'P200P$/#H0!5:++!1A0'P9XT4D3F.(''&!%_#$G2I*SR0$$Y2+[B"]-
MK='`[";0`0DD$32`S,H`'#8!_'A`@Z`9&T8B_C"`!L2M1PTX@`)B-Y<-(.H`
M/SR:&S<IGPLEAY,[\H`%''5#C'!'`0F`D&8\X",/2"R5%-(`!?SD(PLD0`$-
MN(`&`A0P##BL`_6#Y5LT<,L$2,!'NNSB"R^D@)%1@#H54H"1)D`!CJA.`0O@
M0$+`A[P$&"";;U%2`@:P`#^EI@&W=`"2,+``_JA2`_?""`420,="4>=]"&G`
M/5-#F[FP$T,,V">A_N(H`H&R.:@:W$\&.96OH8Y%BAP(!`A02$!:U"`%J5=B
M'C`>`ZARD0B(&P:`(QE*\N58DBF``BKPNH.Z46<NC2E<6!+3^-6E0H`4@,,@
MQ4KWD0^4)AV(!7KV_I8,W&P".T78!8AJD@X@1::-B8J4DGH:@7&`/`]-5UL<
M8JF+AN4!9\F*6.0CU0-```,E40`4=8:A`#AG?0RH0/+X8TQ-OF6E4,VK7A]E
M1DC5TTF'K(!@L30!NNV5.0QS2P?V]AMX]6RD<0&2834S`09$P+*!2YH%#J"<
M"D"D`U=)ZF&'Z=$*,-1;"&"<S9PX@=<!AUMM04`#NM<`!M#O/A,8C(.Z!#/&
MD0P"E^4)`X@$QI=PR#D5H-P++2`!!ZC4`1"(35&#.EH=56`PU<VN<R)P1N8$
M3+L/Z^Y;J.L`QA&J)DB5RY`^\!L&$*``1W+?!'R7W`I`X"@:Z!YX`84>_@!M
M-0!>@:%/?B5:5=VH+=ALJ`#\-QZO&E,"1R)`V"YPF)D`DG_,>4``[&H3"C3`
MD008DP;$N]^,2$!7;_W>`!A0G!*[6"X"1>X!"CS:!/Q+NQLH0'S":5D#!`>M
M[ZN(NISJ-@?0CS@S>W%'RJ(:!+2T=QHP48`H(`#Q54H`&$:3``10KX$8P`&@
MC8`#^.-57-IGLA&!HP'0S!C]!0DN'A@C?PBPJ9:Z>'8%0$`$^.B</N99`1'8
M`(F5?-).=8H#@B:THN&"@6U%X`&2W%8DS>NS#31``B;MP`.R1P!*XTX#MU%5
M=QK@@78*@$TZ);0M-42`-;?I`7Q"$#I;R@`G_KMD`;*IIZ128ID)$.`S%P5C
M!9"4T*QQF"]@Z;)</+"JU12@=316+%2)DAW)K#BSSLG`ZA35*>XN>BX2X-<!
M##!N`(Q'``4@6AB_K>CVP->7&"B(!>)-L#@A;=[K1E.C9558!D3[9QI80&6X
M-X!%X;)#%%6U`31P`2<[(`%LOB_X-,,`D&UO`1'`5T*P=`%`$P:&F%PWQWR<
M;LET[[T(<(`##-#@+#X&`L=US`8@P(`#L`X"PQXO(V^\2?U=T*(%?\#]FM.9
M.&>9W6YQ`%(GD$)S^\<`@:LLTK_=`2AV#)MI4SG&,1!1A'$LT*FY0*(88%X-
M'.1]AW$4!Q8N<*@,_D0".R[Q;LVM&?^A+E$WID"23>+$A'2Y`702RM/L/9`*
M1(`#9B?`HBZ@D_^`1MD`Z\Y"G,,!"ZA8`0_X:!_YPYF87D`@&\``%BVZ6<)/
M?5`.P%(!%JZ!IVS`U\QNX^GWRP$"9&1C%"K+JI-6(4YE9*)&XC`;WS=.W?Q$
M77H74]5,#UZLT5TSD21EJ=0V%<#G!0!Z;J4!A',L,H.9O0(!$IB,/`#^;/FB
MPVLSYNP,-`F\A``*&+-D(,!^_'TW96/VD@<T\&_K<``#?\)N#N`5HK<]"_$`
MLC=[VL4!%^$1NQ(AO^%R/],!&#`!2;0`QS80&E``@T8HVG0AK7,!2+(!_I@&
M&1R0?OLE55F$/&<W(`=0:F^F&:TS%=%S(L=D$C*Q4QI`9ASA$?T#&@GP`(C6
M-L`V?VX1`3%6-5Q198,2-`@0)7]U4/<T/6B5`2S%5(.B`>X%+$?W8@Z@'`^`
MA3;Q'1>0;WKU%`IH$FZG`4R8,I,R5'RA=OM7(YV2$3F3%#62,P*U6!60A"8A
M`5W(>QIP604P@!9P3PX004IV%N;6,L!%-V3D``$GB8U3:R6Q6`;@;YCW.J\Q
M5K<G)8\V9-TA&5,T2I\3`0M0*FM3@?[!``^E8>31?SF2'4>1+1;`9LO!/;:E
M&!9B6[[XBPQ@9,"8*!"06Q)0/B=B`887`47C_FB.5G^#N"T3X(RXR&QW00"6
M14T2X(S<J"T0`%S=J"T58`'DR%S.F%M[MHT40`&.%G<--0'710'D>&*VQ"8;
MDHG':!M:\A?A"([AZ&C0961;!(RVE8F^J"BVM0#LLV4)L')R80'ULP"KDP#P
MQP#"(Q<0()$+8#ZK<0`^M&4(4!\QE&<"D``6Z9'T@0`260`+L"@6B6[DA``*
MP)**,VXI9Y+FPW.I<0`6:&XA](0?D3-1N'P0D#P2B4T:B92RY0`*0#^V)70/
MP$:L`GE5$X<+QTF-`FE1D2UVPE*$]A\2:#;E$2/LHV-M0U4)0$^BL1YF=Q]6
M0CRV<XM"91\&HD<6_B5:&&`!'2-:;@(:`U`EKJ0Y!F%#7L<`Z6*!.F19]7=3
M`1,P%D!AC">/%$!-E$F9DSF9#9!;N;6.]3&9U"1-#;DIR0-K"5!_W`%&Q?07
MMV1E/_(;:<D?`T@]L_0`CX:9$J.-QD29KY0`Z"0K?G1+#)"6PCF<P-EU:B@K
MY$:<`?`=7&$`PXENAV-6MR0TD_D`N5E-</>-$A"5W#D!>9DSFVF9-1(PH.4!
M_S<8G4*>/0(P/=68`/,4O=(C/=*8[FDLK%0:EZ@9\ED2]ZF?_0E:Z\DCY<%1
M&W"?$?2&&=A3@X(09@@7L\9)0((EF#@2+8F"^Q4E4U(:&/,!*M40FG$!_OYA
M;@RS?4,C)=GTC1I4('&#`,4!`5SR(/Q9$%[E7U,!$?@I6$1B4<6"BEYB;M3E
M)##'5++D`*6"5[AC+1L@A*ZR=VO$FC[#;/ZS``\@B^[S.K@V.5-A`7E$I6F8
M5\63(!'E`9,R`1;J,V%8&!U0`%P*+S2A1NQU%QA':)$A&8*">%]$>#4SBC-!
M3O/U6!(!$:C"@0:Q@962%>]2:EXE28"VCNL8`?4SHY!Z(*&S`?4#*&`1``C0
M6C_SI:,(&DEE>YQT*#[&`"B65PX`$0C03QB11DY#E5TZ6K67&^MV&1]4IF_U
M$";&*%MU78P!D6ZD1^ZG@!X0):E%`$<W/0%H_AD;HJ5_@R8#,(T:D)D)LEGS
M40`1H*8;0`$#8%<)16X-9E%9L65'L7IS)$$7I7A(J%<8$$D%AX$%"BD9$`"*
MHZ.R@GB=LTD74#%2XUD_FC3#E::^U`$CE@$3$#>7]JHEQH`$H0"::0&Y=0"-
M9JN()34&4`$2"3-M`15K:A(*H),_HS.^,WMS-Y8(<&-IVH(OE#UZH1.BQA7,
MJ"X'X1%NDY83X!26TQ898&NDVCN+TRZ@%A>^AGT.VZ^@A`$$,Y(#N+&.\7G!
M&:*`M(T3%U-1QG(,ZQN<M`"W"'.`A$NM=;`("U[M$4)>90`A*;'+07VOIW*/
MYA8CUAC1BC\B`P!^_JAD).26#3$`4\B24[%P+X$`+($!&,"&KT=A+#$!&C$!
ML)8!!.!++Z%L.\$1!F!GHJ(9`L5TBE8S#?`1!Q!7BUD=&V"1//A)A\4!$'`^
MF=B';;8C8/&MUH8`!Q!"`/:U^R57'_9A*F$FLV5Q.F)`FI9""Q"(P=H8..<^
MW#-/:<B`_;&JF-%0!?`OZI,8LX&NC.0OOV8T"=`!C@2)YK8^VF$26I@!I&)G
M"J`<PE2C;DIHC>9L"Z`G3C)*FK%94M*!!^5*&.)1&3@5_J8CH0>X_-LH@&M?
M)2B[`KP<TR(G->>D[,5\<Z$!DQLZ%*`O9DMH[2$9H%H4!S"%V6=*&K"!_O(8
M`>$F&9G*?R.&>!,P``'6>NPU4912=9]1IJFDD#2&-T2[@&3ZD\`UMZF[+!F`
MPU!U0Q;@0\K3ARW5`18P9@\0B`.<Q,ZQP3GR&@9`47X+I`H,+Q,R8VDX=^WC
M(@6@26Z">P6K0N36)1[Y`!*P'T5"<O1!`,]*>"#:-'AS86UA(A(;KS\JOS+%
M;)D;`%6$74K,%QL`&`3@`#0U$#W:B`OJJGT,7GS\,#S,&&TK7@A,,WB;-&9'
M98U<8MJB`14@`'$<`)2V'R^8F9_#7@SP3:W7$A:``(C&?S:!4E;V*VRBM:"Q
M;N^!LFZA)G.Q+YV[5_N'*.9&JKB8R(!2<QYY_@&D<A1F99PY$H/"O%]*ZD80
MHD_+8;%)HSHSM,LO-CH1D2YK8R(WQL`9X,$F85S(O`'DXQ\6D1J6Y18E+!&.
M)[I?-!-BV!;.F1&1U:`E1A$4"2:%U<SP4X:PZUD\=:_^G%VXZD:?TU?+(7!(
MDP'1,\](1W8V421=%QVODV.QFQH:8``B6#,3\CU241E0`7F)P9)JH3GQL0$.
M,7,0;1(9$SR+B<W-UW%E.6\SW,=Q%E+TU&)/TM(%?5C!"$H!^A@Y>]/5@58Y
MT:6"81-F5(@XFVIJ&!R_,Q-Q1;:%%[44AX%MTD2'I$:EIAQ<)Q<9,W/"S$H6
M$)Q#X2QVK,2L1`%F_O4DBOC3^T49H%1*S*$8/A-EK*K4'CEN[&4`<1=G`1!W
M^[%36P.BUL80&@'18,%F-]%ZZT9,JL+,4Y$Q<HTFDK0A310!@E4!P7S9.A(]
MH*U=#R#3\6+7RY&F2ML<[#@FKVHB(&P:B[M5R_L3YZ,<FR$_&6$_VO$UVDIJ
M;3%;KX,W]"1RG#4_<L$NIEUB\$07"S!2-F14WUK`HQU9S.%SU3U:"LUN\V74
MRS&`GORJ%D!FG#P@8^):%XP1]V*Q!=JQBP$51M(0>90`[HB]&.@C;RP9<1<!
MN33%`P(`:X-H2KQJO/D!+`5I#?:7#KU)RYTT"J!G/`TP^)S=!R4!:\U3_M:Q
M`#ZM(RWA-N(-&FJT%?D&/)4#&^>3RG]Y7S8#&Q-P8@RQ1>]K$A70K.L"2%G\
M0C-&T`]S'_^B04BG2\M699N1`&)'$*^AD$:6DN-+F*'S`!Z+E7=1DM[)%Z)-
MX7LE`.[H/NM8'<?2X(YAUI0]=;)L11P<QP*P&P303BS7:K6;;IS6=.HT`)X]
M>1AA,B12R``0W(4D%T26KVDH77%1Q+\W'CWS`+@R%;*,?13`Y*9TW<^\(QVP
MVGVV)`,@*TC<5,ILY:`D@G7M0][=%GC]*)M2<0@[=VT$`0)@5YL&.J3+2KAB
M'(?!2AA`+27;4AK&)EV3(5,!:UB]/>,!7.R5_L@.FQOQ*CE-V2H#<2HK)WH'
MD!409QQ^`310DR/K60$NA#2?@T4TD^F:[D8D<^&0L@$&T!KW)W,&`.Z,P4=)
M_:JY/@!`]C#NWA820'W>XEQ;1B>P5J,)]R-DU.*S42JH`Z+7_A88L&4^84G)
M3B]P0;I9#H]TP;)>5TTOU"F?`UJJPT!11A)`PG(+L<'!*##F3*0$H"F)MAPW
M]-F,L7^+%2"?/H%$!4P<W>V@9*PNM7^NLA@5@("1S,X%DX40H'=>OE]=%1Y1
M^,<\=ZU(PC%$.J5)?Z9-)5NOPVSBPC&4C3<!(%[FF3.(/E5OP2+G*S@W#A?L
M@^Z/416U(AKE9Q$S_E$J':0^!+(P['%59?,[69-$-S*E^",4IS5:461*9+3S
M,H\PI<U)T9[L>D80BD>;#E"JRY8`DLX7],(J7SMW';M";:$1-^8!#W[Y+/<O
M8R&&B@O1%+`P#5'UED@S-OK>_Y&`7U,L/V(;=#&3U[$B<H$`6@):)=2'.J$!
M.B$I34,R9F(E.?M1N]X^T#%1!N*)DWK)/F.U\I[XC=(0)Q/X;O3X"SHVMK$8
MUZL9!8=]Q-&Y[!3T=-$CYE3JH+$8H%9@(/H``J/Y^98=ZP9#CCO;P0U%NS<5
M97@P5)X1#>9"&0<0'SA`.,```(`-'SI@*'"@`0`"'R1.G*C!08.'!296_KCH
M`,/$#A8<$%"04"`&"PD6?-@@84"``Q`H4M00@$`!!A<`()@ID0,`"Q(?))BX
MX8("!T@[4,3@@,*!`!0P7,B@<$.%`P0&1,"@X8.'KB@Q>.C@P('7G@H]:(C@
MT<,$!Q,X%.WX\635#QHZ9##+8&E:E@W,7O!`D8+@"G\52E!P0,)$#Q(2#'`P
M]^M1`0,:6/[0U,#!`0($-*`P@"A@U*E5KV;=VO5KV+%=$R@LV_9J#@P1`!#P
M0`,``QHX'/#`8<,!``PT7#"9MN3MU!XH="#P&/IU[*\M'`0JL0("O$P+R*3H
MP8"#KQ@6#"@P6K'$#C%KPV>`?F;-T`'>2W20_G)^:P\<V$J``!+J("0!"$!`
M```"\&H!``Y`@`"(`*N@``4_T^@#"AHL(``!YNH@@0`,0*Z`N2`XJ,0-5#0`
M@0``L&NF"@!0X,"?#-@@@PLNP&"I";K[0`$"EM*`P`84.,@"PC)8D(`8`8A`
MQ8B^@L"F`E9<(((&`Q@`@-"@#.""M`QXB0`&16.P@`XFJ"!&J`"HX`.=]/M`
M330!L*XG!1B$4L@-'@H-@`0Z\"`#*`V(D4P/&H`I2YXZ@PC&"'WR4C(;.]"@
M`01>%"X[4$,5=53H""/UMN,FZ(`K#!!P@(&Y.K2.`0D\4`!&!C:PX+^O'CA5
M@P>V:^Y48FU[:,F*_@28<R9;EX5,`08P4`"N!X@D(#SX'"#O60@X^T!%[C:L
MJ$B_8/.`@(@PT',B)8-*`+BU8IPKR"I[.F"`PG[3R(,O)_#@W08^D,#&KP:F
MX`.#$-"@,'4C4&@"P)`+2J$5N0,`8@>Z.[>`VAB<[J`)$MC`H`8\V`X`DRN4
M%``.;'UI@@:^%"""&!/PP*"#>S*HR`<:["H`CK\J`($*&%PI@X.64A*!XBA$
M:Z;=ILL@`(<_"'*!#CH$0`-U+QX2`%\W```]#R!<*N.`N9Y1``4XZ$"!&84V
M0+2S1KW``@N\+79OOET+NF_7.O!6/;068$ZBE30@R@-;`2@@9W;)'/6L_@("
M!OQRU2!$=J,B>^IP6XEL%3=T!?:<:#B(RQN``8JRM'BF!EC?#+8.7EK@70-J
MVTDB#08PX(.,;19:@;1Z_EVB!#3:H,3"?L*70OL^0&"`#]Z57*!W`T`@;I`8
M//ZG!,8R]*^,??W``'$9E.X@,CGP6"`*.4"ZRG=9S^L``03RTB(O#:A`2<O-
M!$('VPYZ,I`@"C!@-Q;3"-(`H+1U#6D`^PD=XR[0``%$*DN^LF!G0E,8LDA$
M;`F`@`0^8Z1W.>0]$-)>]"9B`']-8`&*(L`$GA:;1KV$.S#!%N9\V#<'\.J'
M,[F`_4(R$PX08%D<"%B'[+<`#R"@,2N1"**$_GB=#6R``'H;H@\;T"(A;41D
M/:D``2CPGT8E0`$+4$#I/N`07FD@)LPRP)X&]CJ0Z`AX7.S)<29RQPB!:2EB
MB]3Y-/*0U/V+>CT9V/$^T(`&!H"*TAN`V`"PK6HA#`"0DTA3>,/'SUCN-RZ<
MB+HN\!CTO1`A.@%`^THT$2A9K4*UNZ0(#<`ZL6WH`0$@TD%.,Q.#S*EGZ*D1
MF"!@R0+T;"7+F^`'8I2ZS]QP(A9X20&R=`")0(E72"MD;;IFL>MYX`$,"J`'
M-N``$H&N,6B\``2F!P%3N>9(LV-<9R)`@$EV49_[[%L4YT*B`2Q`5?Q1D.)D
M<H`)?.1<$U"B`&2"_I(//$Y4(YJ`(_F).044Y@#.F@@ZI=D9`<2SHPV*"\0R
M4("/:E&:6K1.C:)4-8FT4R(1X"AN!,D?.0GD2T$)TN^X-("Y;&>1,\$``;XG
MF@UX@$%+>4CN'A#0K]1H)2H*(`;.*!"P?:6>$E$1\3Z`-%)Z1T8K2:7^4,:O
M5@J$07-:'LNV4R5UG28"`E">XY#WP.H=1``J6=A,912@!BU@`:)9"@4"X"L.
M!,`^7S(4A?`2S9[T+J<<V(I$E.2K_^$R1E4IGZ0F)IW"3(`"(EI089T%H^LI
M"#47F`",%C"=*U+$28E)"P<6$-:+YM8UYHRM/A/"Q.)<D`$)(*%>.K,4_@)$
MH&4(D$!4#IB;#':&`,.Z#@0<@`#SZ;8GAAI51CE$@.MM!*%]',!5*1*!`0S@
M`#E#74^&PTF6$,`!'3!`!C@@`=-AP`!_D<#$5&.9C$UR>9W;30$<$*/?2=8!
M3^4-=?W*W,]LS0/(.8`#UGJ_F?4L`!\!X$12*('=R.0!Z#*)!H8FD<^EA4L6
MR,"(%-O:@U3``^RS;'(RH+D)T"MT$NC-E8#S2+M^X$M5,9H&+,``:Q9D3>^"
M"')S]X&G4N5=`^!1TH*4U?-U;B8="D`%&`J<N0P,O`\)T0<HA%"`L00X4_G0
M!3J0I01,`+T!F`MRIK5+`]CE3?9+#0<TP``&_@P``=U*2]D</),'P%>[BT:-
M!_ZF6_I^P`*IHT@[A_:C3D)EE^;Q0`0>X#+[/0"FV-G`F[G':)J.RGXZ$<"N
MB$B;GJA(I"(T2'8Y$)R>8*#,-"&`HQ(2`<AA8``SD@`?M_N56W%4`</V#H5"
MPV<!!0!$;"JT01JD(!$-%CC1X\!N0)2Z:LU(BPR2)(HA^31'%0:#OZ3(]%*G
M:^YD1@(7"(VS>@8:S=![0V2Q0.4HQ+H(G%@#4/+*@ERX@<-\6X+$>W-4!F*Q
M&$&@:!,T[``898#]IN58#0I3<>8&FHEU8($P,0D%&,0;KW(@T'!B;Z!#@U*?
M,,ATK+%``RJ`7PG\_D6<,NG`O"GX%78S6NAIH;1VH<B`HG?`6:TRT1?-R:,/
M+,!)"3C6:6P+JILO[]!##Q4"#J"``D0@:F1\]$0@(`!*=^"<$/'6P,/;20/`
M=^`($9Q=-B#1B8@6-WS&S5C2HH&/]L1'#LY-3SQP@4^E9B&!GXA.6!?"OW\%
M,CZZ@+?T9@$(^/UT$K$`@0Z`7BE%WB>`N<"H*0)(&9V'`[,6"(`P,($'&(@S
MN7'S3"Q0`?^&;O#NQ;3@[6(>`$#1-KH:-`(H,->EJ$L`&>^)<KG^?(KD7K>5
M!RI%,C8LL%QH6G]Q6P3FJFW+Q#X[$6!Q`*$_*B8#Y69;9)8";(:WT^/Z_E\6
M*R3G"2!]#\)W`YU:/L1T[=6)H("9ZX#L`HE]JJF]L8!\<B_S8XKKL#`*";W;
M8(R?X[+'`(]BZ2%B@:C+@(#>>HVF$("<^3-AX9T(0(M)RZT'0,#SBSJAXP"N
M("ILXCPRJ;F\R;$%8`#?^(JJD);:V`#AN8XOVIX6)!5KDY&OX!3\:ZT&.(#W
M"#B(81(?J:@'P)9^T\!YF@DE"1>BZ8DC.S;`Z(H;HHHB/)U$&Q4CPXZ6T8`6
MBXT)4("`^0P]\L*J0)2]V3J[,3U160#+0*\!\*X)*(COT<,?X@`+8+SGDPZA
M.SQ>H8#3&#@*V+\'>#*?B(`&G`D'(,37$*<W_C.V,K2-D4,+#S@[_+,`[YJ)
MN8K"!UA!#(@*VRL`#1P."/@+ZJ`_TJN_U;"V&3FA3_P-).RCV+@U`9BY(1HX
MGJ"`(SL-(/RJ!\`T.?O$U("98ED`KQ@1""@`D\A$"J`B#BA`:+RH"\#%B\J`
MV-N/:/DN.BNJ!7!"BB!`Q3L`#7P-3<D`?/G&[$B_\*(`)>J)H:`@1UF`L%L0
MS#L`Z;O"[7((5>(.`+0]<4P-<&$:B7B(#Q0ZKKDBW%(-7[PA#.B]M!`<U#`R
MCH2/IA@6D%211P.TO:BPT%@^X*&`"S`+%K-'_O#&/9R3"X@[1W*T`)@8D9#)
MW,J`H+LHLGB*"@@/_I&9L`8I#0,@`.Z1@'BD"`BXQ-=0E0B809^\C6,)`%YY
M*EY1N2"L-&Q$L:HPK`U8#[RP@`-P,/HBCWL["*G\*N)P#<HZB!G$G_EX"Z>L
M#>&P#,[`@*?\@`K`B*M:O0N*NW8\#-+XBZFX@`2XI>;QD<NX@.\P``@X10P(
M-`(@B*)K/.1PG*6X&;T"'<AH#\3JE-3Q,=X@CWLY.0%`"ZRP&-HPDPBP%='@
M#M/@B?0["(N"Q@SX2^Q8@#EIE8)H$0XP#H20B'F[RHOZ.7YZ#`VH@-NYI4CL
M)#ADFOXH#^&+C@10-`"I#`/`/^5TC<X["(4ICP28+F:!`.9K-W:4*9#*_CF*
MJ(!*$CR'<K0)***1B,?:8<ZTZ)",Z1P*^0L&(#<0^8@%*#>3,P`."))=:\<%
MF9#NN*,7@0DC^8SI`9,ZHTL*.Q3>4+L5Z12(*(P-H*L$.HB%/)TD:J7"H)`(
M"$>"Z2,,$1BVLQI)N@`*@)%2^Y*+429)Z3*@=!S`XKE_D\P8*;8BO:]/DDF]
M(Y:!:[N$4I0@;)OPU*<$$CH)F!&P@``H`0\0RD$!&)8B8HUMM(U_Z3Q/G-+4
MZ,P5X:3AB,LM6T_DC!!AXS,*4%#;(X"/TC4,^C6V&!W^:$7^;+X)>HB`^1*3
M(!$,X``E<1@M0ID(K``5L4K9&ANU\I6>@37D_AC+X`.ZM/J,Q[N7E,D?]]D)
MQA&-PG@7`R)/P*"E>=G4J$O2GH`1_2(4B3`(*NJ98F,0!M@5!*T4X-D=6:DQ
M\H`J+H'(B((U>RRA8AE%0EP+O>0[-,6<!1VZ'S0?<Y*`K(@]DY&^*F6-!<##
MZ#"+$XU6UNA,!]DE;+$M:.6/!)`F'LN4TT,`O9$`+6M')4D(>%H>3-R`F@C4
MF9@`!WDSVF`L2>.-"F"MY(C3RR1/!AE7&24/)<D`=:$B",$8,*&`_^E4KY&>
ML>F0_#F?K9&(Z>$06"U6P!A1)(209:&.+]4X.7F?.ZF8@_B1+VD99\*F@5F6
M"P@`UAD8#LH2RE@>_HL]#>K8S4_,L;UI%-78`(LCUQ_2@,UDM`>0U*BB@*'9
MU?]H`/!,"_R2#7,B0J=UC9'["@:`TZA+JIGH`$A"HYNA206@20CX2LA0(P4(
M@,<X`%#R5^L+O8'Y$*\!)&E+6*RR&+WBH['+BP"8`*2A`(@AI$;M$FG[".1`
M"^38$=Z0B*7\B_9@G`-`$87X#)H4(0;YB)[Q*I0%3WH\",\=5>"DJ<KX59M%
MEX+-.(#EB8SAN<P8#@9@'B6AL[SX,24]M<EA@-@"PK<,6V+9`.'5+C>!C(#A
M``>0@`V8$BEZ`,6ME]6XN^6-QKM#1.2=B<X<JH"+&PU```300T";"$3)_@T`
M:(#W&,4$Z$L"=%.*T!R0N4Z=V=[0^8MA$@KNJ(J3F<T.`$Y8^I("T-&@]`Z'
MLJP!T`M*A;)+BH_VY9W[U*2<00ZPN%R0]0K*"@")")(;:2XL<R\&P0MY:90F
M`PQPN9[M^-:;,0#?J-D5;!`Z`9D+8)"MR!+649<-`=@&OIT`2``)@)`B@5X%
M\$VIC=I1&<5!*[7QT0#UW-KOG>*.G(A<$:'D\8F%W)0">XT(6,#5:)1[HN+5
M.#F+$CON&2PAJH^O\!\4`YM&--;^>J1:H8A154@!3(L!4&([]J[^98F3^\P8
MR1LNX;/.C)V#($:?<!P!U!Z)\!(+$+:0[5NJ_OB2S3B(846(&A%5!N%@$&F>
M7;(8AY6E#H5@].&-OU21^?2):P):33F(U7N7_"F+*-%-M.I9I/JJ+QF`8CNI
MQC@(Y<T,_66T!D!B4`$LWL@2GIU(,J;B`18AJUQ4H8"8LE&,8)%'6-2.!J"Z
M9D[3@\#>[T(C!(C:6\,:9+UAQ>*5""#>\F@`7`L=US'1;IV)/7:-SN*J+ZF-
MHCFY39J(F!&`D$@O_/O,-]$KM"!<F$+-F]J-JOF0PV,/EDBO91D)G]"B6U'5
MCIRTDN&JS`!;U&A#FC``C&@C-[-1L#"*&<$`C&"2JE@]KR"+ON)7)0%85$XA
M9AZZ)04<'I&`!X``_N_M9J#FP8EX*I[XEP=XFP8M%-C8QINVK`IPXZ!FE@;`
M`*A09]$\CE.+#P8X``.PQ`U#E`8L&W:.OE7^FA6Q43!^)#ZNK9#\JOG(#0AP
M)^H"5X%1WXVT#'W!@!:=B99P`-H2B/"0@)^N7U^"%!9$#;U-C996B(`QE'\9
MR\8[T_)0B$1U"8B`B,'FNIR.ZK"=WA>4(K\.TV^I`*]0G-UPI`O"H048YM"Q
M&A-+[.\M/8$!:&9)`'F5+:@NCVUT@`.>S;P8@)H2:[UIK6I,``LPH8_XL[1@
M@..]#IMMQ]O0@#I2B-B`[="I``I@7+E@C0,1"+U]WZ,&"8=9"\3;U;66_@T_
M.Q3)ACZ!ZDB]\$C.MD?&'+J>XVW'26[=I<PKV35@0^_0922&N4B@OAG$&:CS
M.N#P,K&-1C2'>0]$>;NRR<Z)&*QB@\ARR8!U!9X$/I77N@T,>`"W26M1Z9'8
M0+KIN9X'6%>&@JFU<+7O<6>@VKH!SFS9HO$6E`#N9`@C.^_XYCJ5ACZP.#`%
MB(!2DSB)*`"LX0\;U\*;GLTY[O&\\PH*08!A,93)X.OZVBXSZ@EZE*:;&6N?
M>*H!38A/`TQ"G&\H5XT,$,WM6LC$L*]V])8Y2>^9R``1Y;Q:D6SKKHBF;D$%
MD.(T#_10*:*9RPT'.("-JCR!F`]%;HVH9(T"_F@5UB;CEW@)JJ[7T-GJ]RB:
ME*KGF7`)[A%K7K$`H#DE`?B(`GB[F=IP0?\*?U6YV&ATIOA,I58-"]CSL$T`
M56]U>X1O[2K.]U!4#\!N!H"`K7ZMPZ$`-M\M!`!T@6`Q/^WQ"(P(#DB`L%+4
M(XZ^9L\U>$Q/@F26:N&,D^;G`B#U*PH97A<Z$(</UBBV0#?NL!6G/I]2--<N
M#?SQ$K&<XA@)2;);Z$@B<.T*90WTN003^%`)"FJN&R)U_$,4#:294WN``BA*
MA:B`@N<.JFT\5A<5O\P.=R?7P\/U=/>PPQ[Y(KP`$5\TR42:H"P.FA'Y3V_N
M,_+H-`]?D%@OPY,`_F@M(P?31PW4QX\*$O^Z8^Y8WI0`G`J@Z];0/'*%`&,V
M>9WA<:CG.GYMP5GLC'-,"V.5M%U?#21'#8(X3D'O3(LZ#D4>-%0LZ\9CRN9K
M6=@9ZW.!S:VSHF*!EJF_>^>>=[R_J$-DM-P8EEP)"O7@VJ)+5-GX<+#_YE;G
MYZNG#[GED)@P+RBC^4Y:[?V8Q`S0^=HH&R1DVMLA%#Q<'KV'C?6.]]?=^U$9
M+=0O0^YBM+MK@`E(JA8;1EU/"VK+#JT$#`[0X<77*RAQE@D+(F;IE/]HE3'Z
MU^=V]08XP>YFK7_Y5L41&G!5JM%??>LG%<F_?NVO(`44``8XHPL*W<2"_GFN
M'>6H4W2"CQ(=:0_.$+FM#QUX+X_.W<H@8^P&&"PO60LN1?32*,MZ!(@/`@<.
MY!#``\&$"A<R;.CP(<2($B=2K&CQ(L:,&B$JR+#Q(\B0(D="W-"!I,8#"Q9(
MV&`2PP,%$2)@6$B!`4*0'`[D3(A!`<J@0@5N"```P($/'A9$2&BAPL`-%CQP
M*%#S0P>:'0)(4&J!YH>5`K]&X/!A`H(+&QP\,.MA`H.C1T\Z--!S*-Z\>L^:
MW>OW;\>_@@<3'CB!0F&&&3!4>,`6P8()$PX@*,```H4-`R'T#<FAP5V!C1.3
M5ECT*`(-J@]$:&#@M8``%3I`*`"@@`0&!BQ`_B!P%$(%`Q$6'`WPX$.#!W&/
M*L#0X8$`VP3:"LP@0"Y.A]E+<^].X6KW\!056!!O_CS$#J&Y>V`PMD$$#10L
M8Y6P@("""Q@(=`XI66$#%Z!7F&VW`7"=`0/()9<`"B[HVX+,(1`A`,I1&$`!
M$,I5P`,+&+4@`\HE\`"))3Y@P`+@*38@BRVZ^-$#FKTX(XV$=?6!!!!8<($!
M%T!`T`4G#F``72)Y<%Q""*Q7(TD%?J`!!YIE4.!192D0860.1&C``QH>90`"
M!E`X880(,.#@@P8T``$$$;#9&@0#"+#`0TDQJ5%@$<5X)Y\4T=DGH'AQT-]Y
M'3A@``$!!+@0!@*B_N1`>0-I\&>@(F'PH0,4."`!!O:!B`%Q"SJ`P:4,(G3:
M40(@Y`&5`"A0P8=R3>`!!!0*4`$'SBE4@0,$Y"7CC(16.FQ%K!)[+$@40-5B
M!P<<H%Q3"EE0Y$@7%%"DF\A^1($"M1[0``,*P/=``D@ET$`"#"0P0``((-``
MO*&^*VD"[DY0$`$$N.ONN1,J*("[^?*K@+L*Z(N``@LD?!\`T0X5*4E1:CLQ
M81!02S'&#NUX'JX")2"`!!%T0`!B"76PP)(+9;"L1!/\*-``?1W9P,49,T1S
M!@K<I=RTU0E0G@<U!W`O1!XHJ9`'%FBP8P=J,6`!!QH0Y`'5"3W@D4`>_E3`
M0`/"9I2!`T%Q4+/-98/D`0!8F[VV0!`X*IX&9E[@@=3<VJ70!`E,5/5$S0K8
M;$X'$""`PVPG-`$&#!"PDJ-B$D#7!@"\O!``+#O400-/5M#Q!T@ZL``$$GAP
M@`,;4-#A`ET/=,$!`1C5E`<-Q%I`RA:99/@'I.)NG@<#O+U[QA1`#/<$]PG`
M607`$C0!V986P,%P&FBVM`9J?U0[>A-`J,```PA4X`,U50#`=KG3_($%`*@H
MD)8`#.``0AE`T#X`1WNP@88"7("``U6YZIM[SG*@"!C%>V@30)0$@$`^80]X
M#A1(CQXH0<)H8'+R0U@%,$`H!%@N*$I;``,8_M"4"TRE`\K+2`02D++[-?`O
MM;K-6?CS`2I-@`,2`$``Z.0!+=D&`1%(&U4&$I?%*2AL/T3*`L1$.[21;P,(
M"(":#A"7'VW`-@*J50$VD($0*J4`7,G`"6DT@3!.L(QF/*-?+O`^A+@F``R8
M@`;N!Y2\C&\`&K@`P`2@@2&V<",<8(#7"G.!H_AJ`@W8XE$2\"&C!#`N#,#<
MAC"0.8$X!B$W1,R$`K`6^2"&`P=22/O>J#T`""@#!X@-`A[@/8%0(%1(0B,L
M8RE+,TI@,CWAP+IN0X#)#>4G-QK(?@@PK:D`+P.^`8H&X'.`HVR`.,TAWY-2
M58`&L`L`PM*`!%19_KD;UN\#_=$``"@UD`84IT%R4I$&(J`@I00M=[4J&9,Z
M.,MYTK.>#+&`WA2RL@%8+R@5F(`#5"@0#1BL/%5Y'/`H<)2D;,U-1G%)``00
M%Y:0<P`RPL`Z$R(!URG,50H$``$0@H$(0"4#[D,(!0Z@,PA%:Z1C&TY?:N7$
M`O#D`QL80#Z9%#9[\K2GL.Q`D3:0`*DM!)=Y><L&%)##ZCR`+A[(0"#+QBI7
MX4@F'RK/,K\4EJ-`A4='^5U1^/F!\0'``)$CY0YO0S>C4.`Y[AO?A!2P`8R2
MD@,(RL`#CJ(!Z-R&>P&`IT\#*]C!#J8#@7$B&04"EU\9@`,&P.COS*A0_JH^
MP(</>%U80N4>!MC&`!DHEU&(EC5%ILY!B(G3`+Q8(:5HP(N^(0`&IK2!WKB.
M`+.R:6NBXP`!:$8J)>HG88,K7*R(=K@7X<"/%)"`]1'$`9%%28!F>Y8`%B2Q
M"VD:LK@)%$,F8+()F(``KN2^K(A)+L*I7$(VT#J0@I2H&`@3`D07E02TR2P2
ML!-M($!4@O1E`?LU+H"-N\<#2*:/`1YHKL#V2E`V3R040"[1&J"BE!I8:\@B
M)U7AA8$-1!$M!F#-JS!P@`]+L0/I8XA+(""`!C=D`0M^2&K$^%^)=(!4I,J@
MIA[`&^#T[P,9F,ES%W*!">R)(=!S@.56!@'E_IF.5`YX\I,9X``W,1=]3VF(
M_#*4+P(D`,DGE,!W2!55"LRO`IDY,$5,LH&HHID@$$#``0J@@*O5K#UL_@@N
M.V``HN(S(0W8*?#:EQHS7>3$#+F``EAL9`)85R'^I5$<+=*[5.5K`%NN-,D^
M,$BJ0N2%OU0(.)%"$).N=B"D=I^E,9VHLIX0M/WQ`*C8)8`/1T`"B+J.`."W
M.APFDFQ&6Y`\V\Q3#@!6+T&C@`'F-,:"%"XH%&@`!090I&<1Y#EC:39ZI/>1
M3?,ZIQ0QM,E`:."$L,5/59Z8@B2@GJ!133WKSLEUO-T0;I[;ID:QDT`V#6B!
M7`<`Z_YWT"R0*%XZ_HY:9/WKNKV)E0Y,]@!8TX"EY;+O<4:HWL*>9P2`NQ<Y
MMLXR%6A`<8-2XS<3I"CK,^Q#+Z)HAGC@TQ"9\K9_T[1Q$\301,T*P.ZL&`)H
MO,7#RYB8>-D0#QA%W@SA9K';MH%0X[N+`)AXOQW"S4E^0)W6C(J";*L`!=10
MUP/I``<>X"@/*+![.(PLALMU%(M?O.T@N8`$N`>`I`>%O@FY24XT<!(W.=<B
MH,((VQ-"\X9@6)P64:A21(9LJV!D="^&B`1ZKJU3OB\!"@/AY1<`N:-0W2$O
M)",&J'+O:A\%ZD=YR%$*,!#']>2($$@:!R`6&KT+Q"!SWS21"*+VQ*V=_C2!
M=[M0#K!R]#QU+QQ@M$)X[K'R!,FFYY,('G5N'@S/\2(9$)-*91URBG0`SL,G
M2`5^CC$,.\MUYG?=U97RFXA,ENX#Z2'IGYX0M3_$-Y0J5],59(#T]IM"6#MB
M4[S057B`OGW`<OQ>4!@+\!'&\XD'8XC'!%1?R<W1H9P25.15YV%9MTB?>80(
M`;A<120.`US`!7"@8O#/X(U5L$V,;8#@UQ$$?KB@0@"@0RS3OFU%KOF94318
M!]B&``S$E30=AJW/TEE`!ER`!KQ7V@P49ND9#GE$!5S'`I@%<:Q88IS,`A*&
M"4Z0`02;T;@7!%S%9P0>!G0AH``%`4Q<8;0<_@!DX$1PP`IJBX)LWT(PD0P>
M#N<-'0(,@`1J@%&XG),T1%ZUX4`L4],1'4@UFF,MH3>QU5@8!9(9Q4$(Q`T%
MP(S]A7IEH29BA">)GT!$`'59A`4X''KHQTR$3*V=XDQ<ED%(8&(T0`'$843(
M(K'8%32E1^E%Q*8)0,]-5G'U8,,D1+^M1]+PU;4,A)8TW0>\4`$$&;%!R(V<
M1O4=D:Q0G/J0QO=M8AF!W5YHP`+583-B!`5<8G=HV:41`+Q0QI-%@`<8@-`5
M!@3H3$9L`!UJBQ\"@-'9Q%$,P(@YP`%8'L)``"EBA=41P`@N73H]P'KEGF$<
M17&A2@*H5`3`69RE_DH$`,M4[1]_(1L.488%8``%Y!:OS=U8,$=4:,CS#$2H
M("!*()HV]A38[`6\.$05I:"+<!`2JH9.ZB2P:-Y$/``M9L2:9`2MF,T&D$B0
MZ9.)5!9;&`!;<);UT$J7V(:#I%+&A4;8A<^H=<@#<,A2/D#&$0IM*(!\F4P&
M/!N:W$8"9$`%40?ZD`A@$5LV*8\19MP5!N5+EDU;A0<#L!T#&%Y!D..+?$QT
M>(E<8`B'@,Q$5(!@?H1))>4L"MM)Z)T&W)9Y1(UJ2%Z?=`!>YB7&4("R\"5$
M0)RP6)TGOLB@8,72%6'D68`VU<]J<D<#W"'D>:8F6IAM`D\VYD4'A&)#_E2`
M.!'4`8C8:?+)Q4S`(KF.I74/`3!G]Z0.9.J$&TX$`N3F`A*@=6;G6-'FUQ5`
M>4Q*`DR%$VTAD^@;W$D`>J8G!+`$!:!G?.&%!ZPE1@"F=@88]-0GV^@8=UC%
M!TI$!2B)T82-!'S@`;SCL=B>^RF$!$0G2$@81O@F?@(*>:)$W$2HV<1):1#4
M!)`2C0F'C]4+`BB2@W;.;KK(IB5H0HQ@7H0,1JBAA=Z)BPZ&3;XHC3`HRX5$
M!BF`1OHGOM$*`F#-C+;(AI(D+K(D1K0)1CP>C2XIDR;&W'`F1:A;LHR.9BZ$
M`Q`-UP5-!BR`'5%,^A#I0UB`M*VHDD;$*C4I_IJFZ5\X%S8)DA^2IV$-A`2H
M%I@BR\@<!8H*49Z"A`1,9T3L:'UR3J5`J9H&6&-NG"&IGD6`A3<-F6V)1`8$
MJ4B$RIZ.S(1:A`3$*$0H*G[J%['@9J&B4<)IFLY=#6F<3@$8:$G$C$`8BG-$
M@+/4XT0@%'<@'43PCTQVIJ2<!..%JJ^&Z@94`$FUW`"D4DW\Z$#<3\V8$&F\
M"@`<JD,H9+Y%G@]9@`-4IT8TVE]0ZD-@P#$>E0Q1!!)^``?]JE\`YTIPI[GB
M3@7-QI/\366!5\XTQJS)C]K0BOAE@+H*1;!:`*!6A)Y%"P=,H6+M*XV8UN68
MH5X43T:$Y[I&1(DF_D38O="E/NR=C,T%P`=6-%4'"$`#O`IRV$E1+I=!&228
MJ,BFZ!.V$@9-1(9&6`=*645YT$:5UDAY%:>A0*A0)(#!+D2Y6FQ#:`I(?!C0
M#DL2_M>U6@`#[,L`**0)S9UCH0]4Z$9.W`L"@*8W\=8EE9S7E.A_?,0(/II&
MO)%2+%,`R%T`Y..=3$!+-)KW:00'UD;$;H:N%BTG2JK=_DJ.:)#"C=6]Y80%
M^%#.:`8'W`O-6(!$L4JO2(T_+@M4($#@=L"&ALT![.F3%`O>YEM[X!FV4L4#
M3`!4N6;FD@8<K6<#[$N^2$#<-&W*M-8`@.![;98`^$JW)D#%?J*JYJWN_JY-
M!`@'V^Y&`HQ(>Q!3JS)`6WV<1T0D_-P'`6@`SS8O!GAL4K0CN4)*92B--]VN
M7G#2T3@$J+`96&Y&061`<=*(\"S3`+Q1+8'.D$:5\_XL06!`66D:!)1I=UJN
M0[227VCO[@Z%!/#O2XJ=I)",T#I&0NS5`WRL<S2'0*02`U#&D<`9!<2.9IP$
M5"U<"`+P13#`UOAIL?R)G@''TL+97_0@_K*?TM8IW"E5^B7$N")-!9#@_"[$
M!C2`Y<2'UI0,9U9`[7#F</#PZ0P4O,S8?:G.0&P-DG7&E@8OL'2*;PP`MO5O
M:3S8KQZ*V#9'!F0.!.3C!.SH+V5.>V@>W;@K_D4<H0@E';@<56B.&KG:J$38
M7=4M0('HD6`TD*E*1`4IB`V#9@*SCQ7ZQH]PP!P"(]%X@)<D!3G-D?,N2`%0
M@-HMB-GBZ75YB0(\&8XL2,EP4ZJ4DK>@AFC<A@,81:0<11(=B+9*\5_PK:^^
M%P_G#A_>US+*&YO\RS0UH*2IH`,HE5$@#,@JA)%>1%$H%?^,H_3L*-_489ZV
MULML$>CN".@X1,NU2'E%R,M87ML\JU*(R5"%5@/WR,E0E9;\"!-M%N>5"B\"
MX$Y(#J.D;?(^W0*,3V-90`",Z1^VHW%<<N9P@)9X1*V`1HY,#PY-!9EI,"IO
M&[2^Z+.U$P+H<P#X_DK8.458*LM!8T70^$A,1.0"5,::3("@.H0;:X0"P@2N
M$0#M9$V])0U$F)+5)$"J$C1A+(=EA(AN+`#^V,GX1,H/6<QUW,L$I*]BJ?,/
M`06IU80&:(EF3`A4;"BV:HD,!DW3^`:L7,>-1%KD<.I`Y)4!$)F8`(T26<P1
M)PJTC6Y!;]LI6^A-&86.;`38:<`_!51$'H@"&<`;82]&3#1(+X#U-(HZ<0E4
M92X$J$T%%$`4\XEX`5;+$0>V*M2-E,L$SV'5@6D!Z$WZ`(5"W8T``05Q0(7\
MVLDRN6#LX%"_C6+OE9RB*,0+=4]LB!8&.("<=$;A/E%*AH=+!PH'B/5@_@C/
MNMX1!X+=!J0G>K[U//,AO#C7W/0)1RL&HN10S3[$E/17;V$`D@)*@="=;@@$
M.;W,,O&P8V=``.S4I0!%7`#%6=4$J1V/@D#%#]'N,BDI.>%UYP"`!W#=``3R
MG-F;JBPCZ2PC4B`$YH3>F>5.`#3%5T1*K0QVQ<SMQ)1%H)"4[KJ$%@W'`I#.
M*<D%_ZQ)HV"`76M$W6;$WPF1U"S=0$5`0!%LBQ)-#:N=`/RR;),)=>-C,ZDS
M'JFS;1"-ODC/E>R?E@!%>TC4UAR%,7'5>_O*/;IA.X;3;!''!6A26:WV;9R$
MF.2';^P?!<PNF_@&:"A2&!)'YFC)+KW9T(PU_G<P^%]\M!EU@&I(!IM`0`,H
MC(X*#DES"?L>AGY@.-NT8][94:C\CI@BN$V5M`F!#6S=A/::$I]?A*TFG_O\
M*.<5R(\X]EG$RH'T)J=Y$V<Y"`D!>:TX]'5,)_XPLA<AAX,$@*.(V(80E2FE
M2J)AQ7KAT%7\9W'H+)@+AIAKIQ:I!ILH1X(<9@$40"J1".A&JHO$ATQVQ7ZX
M!P)`0`!`C`4T\D:P2;(.500`C*3>SV!@&#E*1F\.F6[D!Z3@""`-A+^Z8_AY
M4Q(J!8DPP&?IU9O1GIG+B&ZC&&7`D4#8R6PA6;7IY%U4YI*E5RV=D&J4=:SC
MA59JHA:=939E",(;_D4!<$F:LXG2:!N@P-I>2%*2R]\I[6AK+?=#"#+6;$X$
M%$"&F\>=WO?0P;HH]A\`S(J(A41:!/SN>.J!0=5<@>23W1HA.8M,D)2#V_8$
MZ;-(#\!*_%F^T;0&]VFK;AW`9UO1080%>'!%#,K23;!`A!1()`"9N_RP]+(]
M;0`)I>>?.<#I)DAX61ZXS&8$U-":%3J@/$#($Z7>:(##V5$$=HZHH_3U?)?'
MF/R,A)HKUF&X!H7]5H3#8CW;D$<9D1`)[8AR+*T"-<@N/T`M@=G8C(W:)\MY
M%*Y?/))2/'H;[N&&,_W=Q/>PZ'%$0(#>;T3Y:(35$S[;[+O9Q-[F`-1?_IY)
MJ@0O?5&`9&2&4U=^7ER]7F@J2C"J35'-3\SV.,EJ;?L1J_92(D4$T1F_2HZN
MZ;/^VAC^I[J$L$*``4AB`6W=UCT`:/;UL4#W>1"97^AOR2VT4#@6H3S5'M+G
M0K!]U@Q&7*2M1"R`[T]$ZF?$8E%_V0!$@@L?"!8T>!!A0H4+&7[P\)!#A@P4
M*#90H"`!@0`&.!I``"%"A0H>&I8T>1)ERH(<.*AT^1*F2P\*#%8@L"&FR0@'
M#&XPX(`#!@<J.]#,Z?("3I03&AQ=F,`IP0D,HE:U>A5K5JU;N79=Z*%#!PX/
M'#A(D#&`@``%&$1@\(!"!0L=O-:-JD&I79,;_IKJE5!P0@`,=15H($A!P%\/
M#?ZFY$!5+\$(*B],T+JA0-6ID3EW]OP9-&B2#B](D``!0>H!`E838,"@P@4+
MHT/71FG8]L$,D26TY+!@=UT)?340L&#!P8,*#U)2&,K9@DH.?;%*@!J5`N3<
MV[EW]UYPL%6Q&S*$C(#@0('4!P@,2-"@P84+X;_75_C;OET/!XX;CYP@N@\N
M.*N]!"C8@+:&\HI,`0HDB$`!`PXXH($%(@#IP@P5R`PK#Q`8*"H,KJL*@^`.
MXBN_%%4,S:B3.L!+@^/D>M"!]`@@H(`$&"@K.0SH6Q%(@S)@+LBL+#@`@``R
MX(`NNSH0H,D.'&A@_K<%W#/I2<\B`"!)!![X\DL%&GC`@`+,+&`!GK"J8$2G
M.N#0*LN*G)/.SSC80(,))H"`3`,&`&``,Q?XT@*)EJP3T2!QJVN##0C8+8+)
M_(+,@PM(N@`!"P`P"0((/&N`RQ8_0T#.J+*\2@($3$R4U591ZH"!#):38,,"
MU"J`HP0ZO2`##5IR%=@54W4R4TD[>Y(^3QMP`,62,$A0KPFX]!2T#`YH\BX!
M.L3@`>V"_7;.H'R\H"P&V/L3`%P?@$"""C18%%R$%FRU`F.W>]')#B:8ES=J
M/U!@`P4:HY(A#2CXC`$N%Q!M`7Z/:O.J#+"-EV+0&NW5@G8?6+:!`6Z4_O``
MCD"28`.2H:U8H0@F9K6"YSQ#,+0))!A@5<XZ0*`"@BPHX`##,B!``!`3DL!E
MSD`%P"B6#-)@M`P@D*^@=Y,ZR,>3("B:H)I5\J"`#1+(^2J8/;"W@951/ANE
M2BT@MP%S66.-``40<,`T"7QEB<D.1GMH:;3]/H@#>SF#0.O_*!C@U\\P&*!)
MOB<@8`(+$D>H@8.UG)8@7PV:8+<&##C+Y0M>@_<#"WY4J(,'KD6(]*T%4.!0
MK&*]0-2_;2]H@PYD.^XU!@0H((``SEJ@K,CUG.#DE!"X_6^B2Z*@@.1S(CRT
M"#90D\7E">+@+(</BM7.`@`PH"'I8_+P@,*=_F)`:*P"!HIYBCL02:0'%E@@
M@>"3!/YU!AJ(@`)@,9M5"!`_OYEO>PL(4-@24K:Z7.!^M?.,!PP`MK@\Q`,E
M4Q\$O.<5#!```-K3CP8N,L"HD,H@)-$;@EZ$&PS2!H$((L^26-*!#&R``P_1
MFP%%`Q8/:"`#/G(.A!2P@`TA@`!E0H`1%Q`7"B0.@5LYP.1X6$6*42`#!3C=
M9RK`N.T=+5VM^T`%_-69+0'`<E[Q@`4,$``B;04U!BD`!R`0``0$+WC1>0`>
M#;,GAF@$CX$4P`*`%ZJ&=`!_'4S)#TU2J7<I!&8,Z0`%]$3)D6Q%@!RH#/[.
MDI$DI64`!BBB`^12_J+/[/`D$B3(#Z-H15<JQ`,,4&17PD(`$W:F`>'9``2D
MM0`F">X#%-BB7AS`I5)Y!4?"2>-)J'B4#,RE))6J"@<:TQ#1)8!\"1$F0Z;#
M&EP58`"SE*18=">S!B`@`0CX4_`$,,BW6"!R8K2-!00P3(44,"$:8(`]7]G/
M^\1L`R*TS9`.,@`!$:",!&E`,_52`2XMLRL<Z)I7VE+%#E2S/CB\$TLJ\"`$
M""!)`&#-``8`G_A<P%>W!%8V_=E2F#"I6A<X`-9JDP`3L6N/`M!<0<`2FH0!
MX)A>&8Y0)4<=EW)%AV%IU`8H0,0#+*"=`KC1`!3`([F01Z5^8R@/[X1*_F`E
M3X!A"6M8Q'*GI3;*`I%2:Z26I0`<B5,K#L```/B)D`MD]2@:""=!*O`A]CG`
M6S8,#0(>&AD/010KSOD`7H^*$@X8K%,0X`C/)E0FXGU)`A)IE-(:6Y.6@M`]
M"NA4A#I2VM+.+5<=P:9J$_``C'2D`1"(;60=8``&0.``NHIL9,7$IP0<@$^N
MS6W(L(DKTQK@8QPA0&J6BYX)F6FY7TK.NH)8W1)QUC,6V,#"'-O*HP#6(!(M
M0&$,LL#//%4`0?7*!8R:E>ET5B5`M$`""$E9<'I31X2[0`X7"U^4&-2?(/S=
M>(VX+M=^B9<3>5`$#&P!/O&)`0HP\(,G;&`+_E,8`@OX'`.\]#GUV+9"$7[P
M:21B@3P=!X@ISET'\$00N-IG`Q%H;VX\E!<%#*"V`2"`I`C@72EVX``4D*=6
MN$?+&;MT`Q@0)EG(XM8"W$A\!L#M;B&@79CZ]RCM<V4&5(7EEPXY*NXB`$8/
MTE//5.``)/%`PQ80*\E^(`/<!<W"@OR`Z^G%6^Y5)=H$B('Y^)E<4W(``LJ4
MQ`.L%8`W7*J7NY)G*T(`L8QNI):Q`L``=#`"9([,`H1FY^W9+0,^O@Q4!'"P
M#+#4*T<6CT#=9"F+R6=*\'G-`"CT9*FF9HFFP0#><LA82<.QI16(WJ]5D@%*
M6Z6)^.0,ITN2Q=$(_J0@=?2B:`BP@`!8)@,0XPK)N,(!5A_E,:)V28R.<YQN
M?50M7!)I)Q^@)PD$T*O$_DX`6OH:>:=D`JM9P`2.'9,[A<0S&&!L`2QG`8\U
M(`"=&H"XLP)"-'X``W#R2@5\_9*;=4<#&%B._8H82';F-@$*F,"!]%9ROMV;
M3O3.25V#%&&4+U)T`MCJ2S`0O)GG)@.;6F5J``#`!#`<*T<S]1L]V)7%(-4A
M2;_`<B;`Q"(.(``A!0"2*%06BE0@U$E_>;RP!Y,(W!Q(%=CSUO6R+@"G"$+;
MZS%?Q4VPJR`)`#X;.U8F`.:C>(`Y0.?I0Y3<]->:Z4]J,<#]]BV27KT+_NQD
M/YNR7UFY5M'-@!_Y=GT(,!BN1:=J*<D=5A3`)9Q@P-%;2<"+8=(R.9>YY!N8
M0`4H`(%.)D!\7.K?:RA0[K4I'LL)M2)<<*\0O"@$]$(RS002#W%"$ST_%M`>
M%C]0%MM(E$LDR4#HM:+[Q`)5DW63P`,0$&60!B!0;6.,;.1SU]Z?OXIO:=7F
MNW-EUGE+D]PG@`,X>,MW!\"\^>%:^]KM$!;K_2@Z`%UV8_KT8^X"D+V21"U&
MBCV6)0+&I?C0C]@FCX=<CE4@KSM<C2B&Q+D@H'46``,HL#XH(,VBQ@,H@"->
MYS,<[F`XH.NXPBVXHBCP3Z,B20)OT*YHJHH@_N``543(O*,`^LU%4B7_/B`"
MC&A.*(0@+@`D;(H#)D`$NP)=L`W5MN))U"<J)`#\<)`+)4G5#`@Y6B4"[`Y<
MF,H`U"M%Z(DD+(`$?^4!R#`KGH1+6J(\A",*W80"'@`+NQ`'K8^'X*-5$`"8
M:D-E_.\JP"(`A-`D%%$K&.`OSF4^9N9&3H]10`H`+B72#C$`-"TK[(8//]$@
MJ,^`'"`3@\1!O*,"<(+CXJ,J;@;O1"D54^*9.@,SH-`#*H##N,0!=H;EPB;J
M`"!G1,?H$$`!`#`E*@X4MPX__,D!!K%(("T-W2I32$\A^,0AJ.D``D!@X,H`
M&#$.=W$T.,`C#H`Y_O8K,N00`'""Q1K(&TV"`HHQ&>WD!@.FWGHP13`P14ZP
M`8!'`8KP)!2(:E0G`!2H@V+$3@C@5T[0(8PQ)N:*2P8B^!""(0O"6B8R'B^R
MD<`-6!@`#8NDB8J$`QRD3`X-&1%`>D)R`0A@IIII`/RQ+BX/SFPPX))-^I#/
M*C2%&LDNB#!R*RJ`$E\B)[^#`4HQ["QR@ICBJ<8DZQ9"GTRB9>*F&7VC'8E,
MG2H$34(#`\;P$N$,#BF#`0R@%]%/`Y"1)V^#$RL0;!)E`LBR/HX$_!I@+!.B
MRE(B*\WE`.H)-.0#G<`J+.RB7C[`)(/))6$"`ZSM`8SRU^*M+*MB`Z;2_F\0
M@"A7I`&"TCXZP,'\!`$>)'$2H"L18@(BY#TR"S%-0F(V8``H;6>29#"M(BOW
M@R3BXBINS#'1#P(B<#%1H@#]Z0!F\SL*X"Q!(RB<`@(T8M]88MA<(C@7*P(T
MH@"LARV)P@!:8M`2I"@:H`)BJRXLX"("8`U%\26\[3D5[P%L\S87,3)OQT!:
MI3-Y8P$@(!9C(D9DRT^@:9%V\2`TX`(V)D<J@#P=`TY@@Z>"+&MX$RA!ZCI:
M#RM08S0E32;+TYE6DWD6X#=Q[PBY9",@(#P+(L)N1""Z,NT6(BB0JP#JCNY<
M!@-DCB`$D#PS*"<XP$#YZCRWA@#6TT%KE-%X_J\+)<```$`CT@5'F.\E$"`L
M\G-'=44QP\LZ32)P0*4`]+`5)X<'HPUR/H":JNHK,J`C3\(AKP.'LD)/;!1,
M>^^V^%"?$*JI%N`C%@``<DDZ"F!B\J0!,F(,$\(!:#3)<&NFP-$JKB=Q0"\!
M0`H!^$D#_!`EMG0),_0K)C1,%Q7+AK(+Y21PZ&8"ON1_`J6(W+,7EP.6)(`!
MW@,N$B=+E52VT*D!)F#7G(("J&.7(.!U.@`#B&\K')*[*`!1%X(!%I11<_5L
MTI,+\X^:7F,M#_,#8@Q),A,+1Z\D\O.CXH,^\9`!5F-$CV**4N@!.B`"HNXG
M281+;@+.^O,DA%17_L/5RQR5)ZU5PU:%Q10@+11H<M[$-O7E3PS`&6'BAW2T
MG11U(2A`H.YG1T<T';7"(9.$5@@U)U9'7`^VL=BG/+DE(4[P'0%`(%I"1%QB
M`6Z18,_GAQ8*)C*3IQ0@`AQ@-S"`,DO"H=`H`)9E*[HL'C6@0I@-84EVC/RI
M01+%`:`N`+RS.[`N\Q8"`SB5`.+T8A'B`>:5.SY(C#"@\X(6*:).^?*01K\U
M5"6PMESK#E]V`-($`&S2@``(4?;#,B:UY=[L-J"JM?:P(!"I^+2K*S0P(2)`
MXJAT2S;`H<S6)3(@7GN.P;0"`9[VY:@G!%^V(4J07?H)1^ND8@6$;K=#_C9>
ML"1VT0(\)P$DH"\5`G8:J68]MD'=1*J<TVP6("TC3L/TB&\9PB'MR,02UR7`
M-1Z5XPG7#G`5XN<^8.3ZB2.[EBTFH+5,$:%.`B*,BF4]IC=.AD;UE=9,QBK6
MZ%EUC#%,I`-8:J@\ZRK.B$MQE2!P5@(?P!*AY'43PD53HP!T,'[(M4Z8`D?P
M=3N@I_BLE<MT4'30B0&89K%&5G:_\@#ZT3'`;D@TK`0)P@'DY&?"PP.LY9*J
MX@%6@TB^+BN4K%R#R%L9=4`2P#Y?:6:]HX&!9$O2<B%^A@`J0*<8HE(XXEG)
M*R=LR'Q3%'@JJ$DB4`/@I$L_@%6+"4)3`F"B_O1?1I<AY&I[_8UZM\R&$Z)6
M/X-7NR-&$<5M\2H#!O)GJ/3FO`WNT@5\[&)+;@10V"*]3H)3A>0`9$E3$*<J
M9,DB"$)IXVN.<CA73?4J?M@S()-5Q+&"/0-D3Z*8J.H"@`9\-8"P-@)I]H30
M$L!4%]155TEU'H*P-D:DFM1L*2@MSZ(\#.#4P)=B-X`L)`.->0J=R#A7*R!J
M;T=`$^7HBJ34HFD"(L`2N<0`.!'([N<C>/!_V"4;QQ&`3.PHT&S^AA8#(.T`
M%HY3+P"D@G8"CA/(!N\,9S<JW+-_^7=!(:2-+1D'QU0WP](^\&Z'$SCN2B).
M/^"G#$!K^8JE-(#[_BA$LM)"`=*G@).D07JX9)`$I,1GX9J$`0(@\=9,:!*`
M+EP5(QY@/H[B`;B$2##8*4YMDI6Y]YZFI7KF\8HDEZ*H]4C"4135_<XVSO[T
MVOB3`7X6B)ZUG0Z`XEX"+$36(<W$/4/I))KR,(@D8$1Y6[$.)HH)J`@B6^F5
MH`%Z41\@AFT'`>37-C8`18$$N1#(`EQ7ZQC"T[Z"`QP@`&8J`D(9*H."D-;"
M>AQC)=)-W=;T('[3<PMB/G!E80K#`T*01V5:)1Q23EH:*08@C&$Z'AL&C'NX
M53BS54Y.13P@B"521_FY)(BG%P/8.E0R.7A0Y&I/`C1LS.+"5T[RC4[#_@-"
M<CFYQ$"6<B'F*W&LTVT]XHE6"6GEA@%@.5F-J7IK=3ITQ:P9=?56J?&BV2YF
M`T@B[F0>(E6=64@$8'_I\@@'(#,C8/#$)(`IX'YDFWUJQ@**&D-GJOF>!0%N
M]3I70P&&$B_X11A7(N_D)GD@:"UDVGQ*5DX4H(V9:@"R^;/+$ZW]J:PSR@!(
MFS4%0*;)"@,0S@".="$9PDIJ5<E:N:0LP'\^)&,2(%TD3$]R1\EF;8X&HP,`
M8($L,SL$3P',SR`JER`D@`VQ6:6L]:-D6P).1J7!1JR=<J6WFU$!5#?%VRM0
M-S*.S5K]I)U(2@'>4R*/Q'Q4KQ6%#+#<@R.G_L.(?'/D&D``.@(!)A/B#("\
MQ><LZ>A92VHM,X?HT%0=G:\A_*P!HBN2)(!+PF.([V.B,'Q1DQE<X)$+EV2S
MS*I1PK%\'"^N#0)9M@)+F]$B@$8`U&FX2?&H=P2PNJ\]`$"6;HXO]C@">MI$
MWL4"'@"$M)MUF#"W(B#.N"1`K+<A0EG*#QU<;K4+'^#)/*:0N"3-DLP!(B1D
M)(0CX(-"'%&O[+E3'I`@:FY=3`Q&1AU/\$(L8"1W[B0E8L1,*.1"=J13[7E1
M2/!/#B"5$>]7L"4H)J"V#$!SD&-'`2!Q.J5B]P32,DZ[F.979`7NJ(6U8:G"
M$5W:@<3*X8NSNLI:_EU/0CJ2)/@+B"1B8@*86PAG4A]``LI]/+<D4-1C,N#Z
M:AE`/<PD76QEZJ".I,HDZFH\&[^I3/J=W_D]B"@NSQ_@3R7$(KPDMZ3L:HYP
M8[*WQB>ZR@0./`;,0,:&<&@C.S@3`@`OJGGT=RR'R;D$5P;@MBH,PPQL#`^/
MADYM++'%S*8=YO/CI<'%SQ;"AMZE5XR-<#KEMNYHK_81`S3`<24B>:A<(N/2
M(!:G=7"CQ5[$Z3\`UUOH7::>ZJN>/U_>(=ZEEAT@1PJ@<KK%MTIUD-^E4[`I
MZJCJ)^!=<F)D2'8*1*M^ZMU0%YEPE`N`RJCL*R<+5Y@+A-JCP]KCR:`K_O`]
M9[RX+S7LYRVDJ]T&?KH4'TP:GRPHY$NPB<G`9%`4?XG`9&/&I%L&A?-K124Y
M['Z:M/(=O_-W1/,A?^/6I42:"B0,I41@WU"J2_9KWX9J:)6,\9^/<?=O6DAR
MASQ2ZET4>O:IU&[<!8AB'^N2`H@H(JTD8OMD6CZ"*_K)(C-31W(P"Y!-GR(J
MGY!P1.]K=G/_F@3'9+M@;_#P9_,9`$W'*SD(H+7LIUM:/?7K_\``ZRPVIOLX
M_TM2,O`!H@"!!04$%B2@P*!!`@4.)"!@(*)$!A`@3-``08.&#1\Z>OP(,F1(
M#P\\>!")$B0$!B<[1L"0,J;,F3--+E!PP$`!_@,)'$RX\!`!`@@/(%AX8`%#
M!0@1#N0,T)#`@```!"S`H*$ES8\0#`!XT)&!A@@,##BPP#&F28\>-C"(L&%"
MA(P;ZM:]("%#70D1YO;U^^``Q;X,#C3HR]2O8K^)&RMVO/BQ9,B))5N>ZX!I
M104-$$1`X#3!`J<&G)HN3?IT0Z<"I;IV/6``[`$&:*]>S1J"@P@.&O1\:$!!
M:08.(B(@`+JU@H'+$3APP*#![@<1)#QX`-V@3@(06W,_0"#!`X$Z%2#H^?SY
M`M'8TR^0D-Z!\_CTXR/HX(%W?`P4'%`H^MQ+SWF0@0$7.(`!;V7!1(%$!@AP
MP`8)@+=3`;(AL)T!_@@(1.$&&3CT@`2%'0#:`0HH``%.3JF8DU,+D.79`PLT
M<%A?$W0`EP<60$"!1Q5@<$$%%/2%P8Y]48`D4T,FQE`$&53'P4\1<&#!7XA=
MB>5EE$WHV5R@0=#``9F1=AUI*CH@WF*0S47!!$E=L`$''VBU59T=62`2!0I<
M$%MM#-CI`5%R:A#``78>BFA*'72@`5\I;E@``P,P@-4$:":`80,,$*!!!QQ@
M0&5A!00PP)X7P+35`U1=,*<";+EEX0,7R#D3!1DDBFNNNN[*ZTALX;?HHAX$
M2VRQP7(0K`?(;N`I!QS$Z2RRGA+K++0>QKE7!L]N*VVTS2);;;/0/BON_J+6
M7J#!I]P^VV@$LU+YX[,)2F!!!1OP)0&H<9[$@09PDMN6MOU&JT$%<X+;08*S
M=M#1M-,.:ZQ)$<])YYR]7KR5`Q5CS''''G^4%D@.<,```C>""=(%%M"*TG@6
M(```GA_/_-&B##QPG@(0-O!``Q5DT,$#!#"U@`,J;^#!!#C##(`";ZE\*TKF
M!2!!1P6,9`$#`03@JDQNT@QVV&*/37;99I^-=J\';)QVVQZ'_-$"'E3@0,-=
M6PT```2`E9(&"N0-@=L>=U#!!.L1(,#6`"1@P7\,3""!50Q4L,`"!:^7`%4!
M('`SR`8S$'4$BE[`JDP4E"YXZJJOSGKKKK]N_C7;L,\N$LL^+O`!`P#@WL$`
M'RE@T@8$8/`050;8KBP%MM..ZTD2&_`H``$80$#>")P(P04-S'BZ!QATM;55
M!PP000!I5;TK7,ROSW[[[K\?]@51?[0V_/9[E.`'`G3Z@05W?[`3AFT```RH
M"P$H(+O[X6H"@9N3!C*0%,IM#GL\:YQ\=G*`O`T@`QE0%:I\IRL/U$V!)"RA
M"4_H.H>$I`$)1"'K,'``#%#M)#/RR+TLT)(_?<`M[UN+QSR`@.6!I$@4:,!*
M"I"W0DE@*@$0C080P!$/)"!7'%A`:3K50A=J<8LNU``7:]*SD`"OA$%JGX0:
M))L.[`]_(;-``A@&_@'<N6\!/?I8!1I0IPM$:@)4:@`."7```>2-;W7,U0`2
M,(#=52"+7VRD(YD'Q4<JJC^<N17?2`@T][$$?WCTB`2$,B0!&$!N8GJ?`@SV
M,2"B3E$/(-](")`!)$J/5030E1OGI+(-70]NDNRE+U>'`%3]TB,'>,\%6MF!
M`C"2=IIR'\,\,JN/*.L"%(`66!#0)E2N;P++Q-4&.HF2#CA@``YX)D@R$(`*
M4`4`MP)BKCHP/&E^Z@%"'*:O[(E/C$6@FUKLG008E@$!<.!_^73F!_#"OGN%
M;0$30$DL%2!,MLAI@`T0)`!HU5!<O:6@B((`/SD*TH\PP)SVK`!X$"``_A;*
MD807R"@)_Q/-$VX@HA_+@`X_HH$%","E*!F@!*H'`(-)2"0=@$`%O(@2!ZPT
MI/;+P"J9VCJ/@O13:9%;"34@,P4"D2'PV2$&/#6_]GE@`;S\X0&R>M`"G'(F
M`W0`4$MG`)%L0*=4^^I',C"A>M*$`T:K9P=&"M7`VJFL\!L`88?9P`\L5;!F
MXP`]3\*`APB@/Q:J&EY;)\0-2!51_-O*!A!PDIPJ`*FU`L`$$@F`*(Z0J$.Z
M5`6R1D>2'LH#%(@L0BA`V@]PX*.,E:2S4$);$RXVG^`<+OP:\%3X30``Z--C
M!AK`,'>=9$BMV]AG<)6!;F[``0)0@%NMNA4._NQMG:A"WTPB`(!$'D`"O$4)
ME49U0)KV%JH4D*\6K^;(L<CDIJ(K(0,("K\'++(C?/E`'160EOXR#Z)BPVO>
M`!##P<9LG5&+*TTZ@(!T40`!`3A+KX:5`>Y"2'WS1<D$"EGBF(`S=2OF(@=C
MT@%PMMA^/E0@`F062P-XH&H>(`!'L,(^"\AV9AM89][LA`$"]"YO#/->G:IC
MPU8&0,!ZG:UC#P`5!QRVM^T-;)<_%@"F:B6Q*6YP`PRPM5@6``$'%8`'"C-D
MUSE5;!W`5`8P`+K=YM$`$[#HK2PPXY1<P%`@F6D#"I"`!F2W5XRB7`(,X*0O
M/Y)197X?F_$IPYMZ_H2G][NQ"^7$`2$=M`$<&(!]7;<`;=)L;G'>"GJ]DC<&
M&1>X!Z@R!AH0FP38]6)D`>156E+E81:ITL16W:)``EX%4J#5+B1+^X+9/@I`
M^,%>Q,"LI49FE&C@T)O3&,8N4!@-Y4O2**QQL6F7VV%R8&L'X&-'KMV^":B:
MBTEC-NL(Y+X(#,`"5;GH#@.=DHK4:2PZ88`$TJVK#42``%!)=CX[L.5SKZY^
M^)3`K#X9``AL0,<E?,"I:<<!!<?$`?.>G<7SO;\%7$``'X^)M6?+'YPY+9.]
MVD"5)%`Y)]E;XCS'&*=_B8&0V?ROY!8<S5$N@.2")%#N\[C[EFL!6!HV_E$:
ML#"N,("S\$"@Y3!O@%3\&/&>BWWL(ODYV44"::`)C`,-NK&H7>@!`-..WV[=
MP`;[)_*9B(A7'CBFUP4S@;#7*3]%V9#!$7[VQ,]$T^J^#E%"),6BIQ@"#TFD
M``1`&_1QX(TNQ/#[*$"`-WO`U`8F]%8RPK&$>5T`9PDVHC3K=04@1?**+W/H
M\XF!`>Q$(O"D?=I&-CN(8S5.*LD[">5M-@T0P.PS6<X#TLO._F5;)@=`/*\@
M/B2"'`#U%TL8!1(`_@F`2J:NKSV=+YU//7\$X)H4/.QZS'7V>2!"9E-6E_6-
MWKS=B@+P!HEXW;\K'`!N4@$!8<5WVH-F%%%^_K-C*>8G.,/"6)>D0.Q%0AA@
M`#NW/CT&/PY0`-+&9`96<BG1566C(Y"62E%"'22T$0[H-G/%6-,'/P40?^_'
M5_=10K4%/PGA@0+`,`X@@6H!2VCC>XYT*BS8-@/%6.SW;`#H.C9'$@9P<#7Q
M.@I@?,PC-,_W@2&R%8:#@8WT+$989E3R.IU%-DA80HIV0AE`$(M6.ZKB<`^(
M8NU#(AYX:1$0@B&14UV(-B>"0$/H$0$5'%OGA[LRB&"X%1T0AZJ#%F?3?^M3
MA0H44`*0+]TB%^3A9B^$7^_C5A60-X2V5C(!1,RG.ADP`2@%`#G2,<=4,@30
M`!A0B(C"8(:8?'+'_E&-R#P%P(3,LP'4@6L#@'FU$6'P9'UH0Q3P\V8I]6`,
M(V`RD0$(\(.STW<.$`#(@2"2=TE])P$[X1F"@S2RF'RF!U6V2#LR6&Y3,A,A
MQSI!9(R;LEP`P'$-8%XAL5T#`(.ZB`$3P#.O^`$=4(3>B$\<$(],I8092'\G
M%&K+A``&F#;N9#\,4`#Y=VGU-1(2\#<+H)#^B)'N@Q&,Q7C&&$DFE`$#,(SG
M=`!Z2#,:((JT$T@.D#>W%P&)6&H/P(:/U!9ADQ49B4)^\X(F9(,F1!PFB28F
M^3$6@%;N<U))Q#!1&!()H(^M$U`DEXMU8G<$@"!">8@X26>/6%!WZ#X'_F1"
M%;"`(#$!!W"19+-)]F-$[7AI@!42H#-,<8$IHY07J?<]A3$4B]@K#V"56'DH
M"B58S[B!,PB-"Q"6*4,``0D2%F``B=@K3$EC.X%.R-$P*"%PZ;=A$($`%(@Q
MWH,3DU)-?+D^&K!:4%64]@,!A?DZR(==!=!=:(557H$``["7,J&3]V,6&<`4
M`,`P[A82X!92!%**NH<4LYD2`!DF"W`SJ`F:8Z,!C%E0'6``4=DZ9'@_Z1)"
M.\)AHB1(`0!=N2.8=<(S"G0`,LD4GAB"?-*4[A,77A<`!O>=-.$]OF$`2*&<
MRSDS^A58&51+)%1`+U6?*=$XV55C?O.?*3%&_O8#3T;#%)=F.7)%BR!E<T1Q
M'B$RDHB"=8%A1!5`G/;)*QKPGHZT`4AD`!4*C0E0H(*S<B=J)Q2`F+FRD?<3
M4#<C$)?VB?[WH($5)`NP.=F#'QC3.!'Q`,O&H68S9X$5:E^9GA@S;)-9-@R@
M=(E2F0@Z`)^4-_TE`?7T7#Q7`0RP`+'!?1@C(@+@C#@TI&&3`<Y9IKMRI??C
M`0/9,1Q@`!\J$F.5I*E$E;!&<3TEG?25``(`?G/9?;75`!2P=7N:ILPXFH<J
M276**#%V(S-!.,;UHO?3.^8A/0-`(D+AC-51'1#`BGQQ$6+'*)37$!;!+!>S
M;0RU+XKZ82K*JDLG_A/'9C9L.:<;FCX/F1+Y`2%K5'PD!$\6L``$Y%43<&?\
M45_\81;/40!N6F;>,P%:,S2?N15CL29!YR$($6DAL5N>\JIJ8:M\F31S@9R9
MXA01,"'4XQ`.T"(M4AJT(93?*B-ZA2!NLWD&P`"XI1%/`@&(MDBW%A*AJE4&
M(J+/5)I>Y4DD>FXVUTI-<YHS81HDD@`%L1!Y(P!(M'L1L1-0$1NN>G8X4A$?
M6Q'%,4H)`1$&L#VC!'Y'9`!<R9=%-DK7X7%'H:,`0"/<Z17IQ$$YRT$L9"??
M>E"+B8>\VC'F2!/_$;&)4Q#OH16<]Q$LNSX60(\9=):$%0'F)"M@R"A*_E,J
MTCH2CHD2$M"*SE(`#R``A3>?#Z0!7LNAK40<#R"C/4%Y1/%XYJ$`,W(S<GL3
MBKIQ?5.`Y_$!UW%J]6BFUQ-6RC(S&HHHSL(V%0!:;"&GK6,`S[4XXR=0'M(2
M$Z"V"U"P#J@!#KEF!4@G'%``K19B-O<!&O$!FOFWG",TM+J<#2!XYB976LF7
M_.A>\3EH'-``UBD2@ALV'I"V3LL\%Q!/NL6Q;=,[&"!+IO4!`/`!"0``,"$T
M)/4U&#DL5((A`U`ZXC4ZF+*/"F`!!F@N.G68Q\MS]UH3640YBHHC*`%#&4<H
M&R`<58,L*O&`$7`83[H^./@!;GIRL,,![+2\_JSR)S*$D@50E!)@J&37`8^Z
M0^"X="_R3!"@F^[5*!*`IMZH`/59%R"!<XJ*;R!1`0.`0'J&2BTA`//&K!QS
M>7[*`)&5-PW@)@8G`2)RK_)&E$3Y6J15EF.#9UP:$U4$'CX[$XL&042Y0]:G
M1FKX8."+%,&:``<:-X?*O>[%O!TA;:V6``NL>#WYAP@1$\M!4DBBM\,E;2VW
M?""1P8BB,O52EDAR8DAB*PL`,P/P``H0Q7A\(GA<$#K1QX^&.(W;,B(R(W98
M`4*"0+F:`8=\R$$B/XSL@7:(%:3S0'=DKQ@@IHW,R'=4.9U,Q^&#9J22$R.E
M5Q(@$1);(5Y<,P+@_F`/YLK68U2;/&C:$G0@H1'F6V*:E1(#)$S0*3NTFY$;
M;,L`D(DBH6\DA9MZBYB=NP'IHA$6T"G1W(&%YA'<&CP:@<W/7`$1,*YUBP`Z
M:F0T6R=(R`'..'BP&A/V0I'O442NNW04("05`+:54[=4V!050<?2(ST+(&!M
M(F\2P)WQ#,_PS!_Q'$4=T1+`=H=TLDP>$)W+^\IZ0SCPO,@4L",1G5Y<LP`#
M@9R<X=$*H"=Q3".R5TT":!(G_2X=`$'&BC0G[=(O[8HO_=+XX=*(C#1G6E_R
MH]+>,U,IHBD8C#2(+,?U-=1%75_0PD$M+20S!;R+!-/PS(G!00`1@$1-_F8Q
M"#U@%",[_2*[B8=P&)!>-#TL<HPL!"'"$<=//I30SG/25STW.J+6U_O226(=
M?.322-/2*],X0TU;1HTD)F&L_]$?+"H=(/V22/)?3F,K,WT!R3/4+\D?O8$D
MC0W8L(;1#]9A_J$GP8%2-W'9KWQ`2/)31L8T`)"H,1$!I"4!F_5(1U4G,8;+
M(E%@%'S9_X-:GTW,)Z;2N)U$%5$!=\S;&C2NP:TW3:0`X?S9`L"EFT+<`K8;
M.L7;!8"<-$+<R"$4MXW1#7#9,HG'R$&5+%D`."<]X<$SV^,7&91>/?&L<R$=
M/3,!)_;>\&$IFO+>;2+#_ES7\!VR$5#?_7UB_A8`WY`C`?]-.O^-`:3XWT5D
M$>(G+,*"+L)"E/X,-"!V$1`S+!!#34+64LP",4#3HQW!B<&=B29!J"H3X/[,
M83(,WQ2A5-$!?E',<)A2MJJR.)A=$(\V2HE#%20"?1C]S5SZ-[QMLD&*W9]-
M%0H0.<%M`/52.$"%V_,I`140Y+P=`-VE.,'].&T"O5C.HA8E/5NS.4YZE<@V
M`,++.M]D)Z++VBEA@2G5E!B\9+7-%D5^V0.P/72.T87RS9:-V\OWWGC^RM##
MSQI0W1#P3U..VY@2Q1/@Y)?=1->#Z)^-:$-!`1!]V5T2Z9?=@<H#UL3MZ9U8
M+T5#W(?=9\$-TDH!_M#!+<?YQ]N<<Q:9_F"W34XTCMN96&I\CM&R26"`_F#P
MW>B.CE4,U([1;7"E2-R0#@'HC=L#T,F>#KU-1-R/OA.>?AX;0MS:=`&>KE:T
M[<I5WL+?WET1D,-[V@'&=0$2W#X/="B;=U9L0R"5DUT@?2B?5!(S`;7$(SW1
MD3WXF&C5#!V^0;,T(O!W'AL6<B$ZT:6QX8N^^"";HZ,Z#O'ADT1Y\S=7?MD'
M0*@'P.K(#=H(4MIYGC@GHBFA_.6)@]$/&:RN'/$/%AP@K3O!?0&+P@%>7NO7
M,>RX#7@F%=P[!0%E&]R3@IQ6Q.MYHU8,Q>VXW0`Z@^N.KE0;3=QV#@%#_D_,
M;!$!-(_1M_<!L/[*3B,<H^XT$[#TV6TOGR+U-/L<A9%$FA,^H!Q'N(9YXZ/P
MB;/P"P\1`L`=53XA+CX5<C\JW^[MOA@^$,]PF#HJZ85Y%%$]58X5>H%2)BM(
M)NMU4<^*#@'2U'0ZI,/%,['F-7-:Z[4^@%D3HJDA5J*N:C4_.[;"04,I.Q%V
M#8*(Q!Q_")3LA&B\V/(LV(+[VY*S&,#[6/$IO7_@O']G=N@FXL?['EJLP*_\
MRP_\>M',+]'[S;P1<?)`S+_\>G'[OQ_9/GC@83(!!6#HI\+[$\`UO$&ELM<7
M!\)GTF&LG[&R8.(9\F$6@,0=$.$4TG$<LM$;_NL!&L@!?@"A8,$!!P4;%'10
M(,`!`@0./"2`@,"`B0`F#A`0`(#%`@X/#`B0<4'!!!4)!$B`8(`!`PH(*$C@
M0*##AAH=E@0I8,"!`"<%`!#``&-#``$4'/A9H.#/HA^<.@"*\""&"!@P3*#H
MU,,"!@!B-ECP8,*#"`4-'&`0@8*#"`^LOL5`H4*$D@H*6H!;M2K<"@C9QJT`
M5[!@#1@T9#C,8<,&Q1LT'-;0P8,'IUHY<)CL5#+C#A\Z<.A<V>EBQ8TE=UA,
M^3+CU1DR@'9*@8"'!J'7:N#@N3+E#QXP4*;]X4$%T<6-'T>>W/B&WQ]R'Z]@
M(()RZM6M4^>`X3IR_@L-.G8\,)SW;@4(+F!/<"`WAP@*-"CO0"#!@@L3+#B5
MD-S!AP4!MO\',$`!!R2P.@;VV^`X#<;[(`,&/R`N@P@>O*Z#T*ZCL+@$1?,@
M`ZT\\]`S#@[#X#,,$$--,>,<3'"#$)-+$#(,,.L@LLXV\&"##E[[P,4,3MR0
M@PQ"@PH"`39\8``&1'-0M+XHPT""`@"X\+@,"\0R2RVW%(X`#`)X[C\.&OA`
M@?NX_,\#!9Z#X$HTWW3*`N+@M-(!`ARXDH("*"C.@@(:F/&X#`9(@,_KIC.2
M3D47910Y@@I<\@$`"BC@@1>SG"!!"L(*M%%/M>R@``X6$*W*#]Y#[@()_KHR
M]5-77QUP@0$ZF,#-Y#K(KX`Y877*-5[IM,!6.$<]P("P''B@`8<,J(#"#218
MX"P"%B#@+`1^4K6!!RC(X`$')/@1L0P6VR"!#A@PX%=UUT4N5`4*A`#"`PI3
MP(`-(+@`QP(QZTV#"20X`($(%F2WX#@'\"!>`:,D@$J#'U[7@`&$;+4Z#A#P
M`($S>:5-6(BK\YC.SS:(H.2J)*/.PL5FM-`"`'[;P(((+J"*`@@<"!@!!&!J
MP(,)#O@XZ$^-_6""":RB&3>KA"SL1]$VV,\!A2LC6:4#)KBT0-0<V/E."4(6
M&E,`-BA@P`LJZ"ILM1=]@``-!J#HH(-D<H"!_HD:4M8AN`G(((#\?I4`U;4'
M7]3E`QJHX`+%+VA@\8HE0(!PR;$\@#BN!RA@`(L"@/LGC32"N_,#.D!@:@XY
MN`""B1C0CLL*)(#@SP<$GSS+"P"P(``&#J(@V=T;\.YWX`VP6R(*-*\]>0$;
MX%-5"9Y_0`(%&'B^>NLQJ*""W!S(NL`,4H_@:/C`5K[\XQ38*'WUTQ>@?0$*
M<#\`_\RGW\H"$N!M,@LM]&!_T#[K@`4`2)D,;`PY'KC``Q0P`(VA:0,3B!T"
MW%(_`%T@<@^$G03&8C0-4L`"]M'@ORA``>U$(%T41*%H(*"Q8)WH/J$95\PL
M,$,:SG!5`S@/=310_L,9/H`!/V2``MJ7`*\@(`&[6E$*)5<C`5F``A-XX@(D
M8+,&E.P!";A9O4J2@(XHD8+Q`<``HH4`KBS`C&=D`!HA(,6YF%$ZV_%`!<#R
M@(H1*$<4\(X!O6@<"`R`.!TJ3@>RYX%@C<@PGJF`!:0$@#TF)S>,V1#VLJ>]
MT"AFDI>\9&X0F#T.#/(#P7(*ZBI`NQ5I;B,:.:7\/H?*]:U/.A78U!D70$99
MK4\G"E#`$Y\(RCH6)TR5(5@CA0FRW@Q3>1X('U@$DDMH+1.7SB1B*PD`15BN
M12XCK&8V1]C'`L#$`?GJC0<N4\`*;`";Y[QF.JLI@8T02@%0?(\X1Q@!_FUR
M*R[-N0`)T5G/:A(,.!A($'"<<QX=%5.@!S5H0J%R2H8697VL;&CZ&*#.?>)2
MBAJT"P6DMP"+=M29'(5)`LHCD&(5P`#I$<A93`HWEI@T(SH!748<*C^'"F`!
M`C#`SLZX3([NU(P"J0`$!.*`GQZ`HSO[Z#(1`)2>I-(B)RF*1@HPQ1$Z`)T.
M0-L4K4I".5G@`C/\D39AJ3BYG`@T.!+HFWIFS$:2BJUOW<YE"%F9",CRC/)1
M"$MT:M<%+B`!-(VJ_.9SQ@)0BY:TM*L9AQ-+:J'2J`](;$]GB8``%-:-\IN6
M+'NB2LYVEJ:J3*5G12M:RAJ@L@A("]<:D$8I_IJ1`;!DP-FR)P&BSE(!G,5(
M`!";6-8FMK9@B:PLZ5D!R$K@DCGLY".Q1TJX-M>Y:_,`<Y\[W49A("9X(=]U
M&(>66BWJ.<_I3#`M(%WJEO>YV37OVJ277O9Z]V<MB0QZJ7,!`]PO<+UL;W[U
MNZ_]TH^)_04PEE`#K9U%@#%;,N0"[J>67P;8P0^&,/V<%F$*P]$"+NGFN+A4
M&`AX)P$7(&^%1=Q?4(X8<`0P<8KA,P$#"$`!$.B>UC)0$@/@2[XJQG&.C9.9
M[73`='"=P'YT/.319.!:?Z)`@[6F`02P!,9*)G*4I1R@PTP7;5,F\H@F,!`$
MX%=`&4!;2[P<M!MC_MG,[&I`B(4)FS,;#,J#$^>B/E/F7ZVUS06SP)OOC+'I
M&NW.[-+`DO[\*P;0>=!8FMVABY/#M>D90%=6-,>&N2/S+L#0D180OC#]`=@1
M;LS7">:FI7SAA4C1T0'R``,0\*?`%.P!EQ;U=JRR:0(@,84)$[1Q$A?K,T/M
M)!%HTI822"T`*"!POVH3KZ_#@%/?NGX<2(`P-\``/5:&MLH^,R$3(H!F!PA[
M#4-`ZUQE:6PSRL"2"W:Y`V15=6=;S5G:X:>Y5.AVTXD!,29SM\EL:^<^@-'U
M!OC:Z#VYSXSX1)'>P&P"OO!A6D`L^@90!X"](2T-'-U"KC#-&-[(#OQ[_N-W
MIB_\&``!BFO)`P^`WP,TC26+?YQ`$O"XR^D'`4/)?-`:H*\`$E!M+!6&BPNP
M0,D!].I81]?F*2;AT1$^@2#&)#"P=HH&ZJJM",B[W1RHN=(I'`&>:_W.&TA@
M1!`'<>S()'-_ZJ[7U>[@!;Q[[5BN4=L*P`!_#PCK"1!`SJZU$9QB[>U_9V_D
M`+_IZ#*=4+4!D*PF@+)0[LQ??TV`!JT^>,J7KP+XKOR=">E#,D*@6?!9P(20
MX_G1:``"#U@U5MV>>=8/3@)";SVF+Q`1H^BK.,:F#K6/8X$5<HX"%X!Z[(6O
M*`3P>_B1[F1_WLF;0&N%`M)MOG(<GA$%I/OX_M=',^RQ'VDP2P0"$]!5CY#R
MLN.DV3H<@)QNN[Y]]BMJ\NV?,@(OP``!=.;:"6B=!I[W'H?#,8$3@+\`9)0#
M$#<!W+0,$+)D<Y+CF8X,>!<#A,#_>+_JR#H`ZX`U,1]^4;<,4)BOL9#*D`T`
M\!`+B+8(K(P)-#$4]"(`?#!!HI\$6+U!,S*GH#L"()-3T9D"H(P+,\'*(+D_
MZX`;9!<!XA45/#K&*[<-.(`=-):?B18)L(`3L@"W2HX"'#X(L,+K0T)7:;D>
M'+3J\R74P0BW6H`*-`XA/+Y.`3S?6!L#R$(O;+,+RQ"PZPP,Z#+J$+SK:XX[
MJSHYHT*A(0#M@\,S_C,`%DP._*L._,$^!C!""-N`$VHO/AO$0[L8,PRE!?@Q
MY,"\3PJ^6"/"-OL>_9J?23RTK1@`/@&.#;@IXSL.2`0P#:2?Q>/#,V%#\RH`
M021%,Y,`B%H(7#2./Q0^!'(5TVNN7:$5H>&61?'%7#2S`IJA&*R,$KR^3=0Q
MQ]@O5V1&F9/&X_N\,X/"_4J`900\6(R]![P^>VDS!A#'YI+$X;N:XU.`3@RX
MC"$[Y:``>52>@LHOU&BO"UPS?&RW3"S'YPA%*0/(8V+%YUK';/R5F(N]`H!&
M$9.`-S0O-&3(C]O&X;M#,VN`>APF![Q(F=,`<SP^!82[_MH`D@S)A2-!_NRC
MC48$L(3I+PX02-:[`)AD.`XPQ.&K12P[L/W*`&",/8R+O0RP1-831C.;CE?$
M/HJD/`LZR':+RO+*R)6TRG5QRLKK``/PR`?3@(5LKIBYRIRDQL'S1RP#/@"[
MBK%<N`PP@*G$M@YX`#,K&[9$(0X@2JJA/%QQR:YT,'\)L((3P$>DO)X\/K\,
ML+8+,`RP2+O$MI;40G.9LO5+KRUT3&S+#I?$R96$R\NL,`V82\^DKGO\R[\1
M366;O].<+L0T)@RH2=4LQ<X<R_X1F@UH3-C$30*9L-PT)@I82MX$SHN4R2B3
MS>!<2:-TR:P4,0Z(1^-TSKAB39F+HRB#(`BC_LWCB[/A$TLMS#4=:[4'DPLM
M/$K*XT#L(YWG1,]-<R*7=,CT=$\LPY[WE,_YI$]L\P#:XB((B$YC4ISZ],_R
MN<\4@X"<BIX5LBFP/*__5-#:,<P(D\M//$$*0,<%-<[+P#Z:5)Z$')9PA!$8
MI-#@K,[K,[H*0P"W.X"R_-"Q1,X471<>[!&Z0XZY8%'<5)$9_17)_``(@`#U
MB+I/S!@;5<W4!-)702;>>(`#P%'&,1;*4``$'5)2W,^/&U$(^RJGF!D(,,TX
MT<$/&)@G]=)RXS$J-104DX#0C+H'>(XFG<DO95-&>18*8TRG^),:VPWSJ`P%
MV$P4.J(VY=,WX<<(_E,38$*,)NV`/:T,;&PO-NO31<62$:FPG?.E'OF:R@@R
M1K74,]/)S^2;ZD``)V6KM+S4?HQ2%+(]`V0R6YD`E<PO/`G51(U(MLK3M2.N
MY/B96.6O=2G.5E70/\42"*!,"FH`!)"`7Y*-M--54<O2_S0GD\M56(&:EH`)
MW>G&8V7&0Z+6-R&D1'K5:U406RVW*C)/;V5&<>56M;',V,M,]VS.<F77,$5/
M3V57\W&1[2-74AS/>-VC\-3"]L37?O77?TW!4078`LF1@358U=0`#3W8A67(
M'6+8AQW+A(78B0W)*G-/@&I6BK5+P:Q0NCB)`#``5M78*4O6''/8X/29_L*:
M2*=8(2\9V=H!L9=5L0XX@-_4D->26<*ITIP5L8RQV1U;`'CEV:%=.->L#@VX
MUU?YP$513J)U6N@Z@'4DNJ>E6J4SVMLK@!,5#7"IVJZ5.0?0(PUP@"_Y-ZGS
MVK-E.$@MCJL)``892;2%VV?+2^5I@&H;2?([03.-V[V-M9$SCK$0``9)(+Y-
M4;-M6+V-$P7P.+&8KHPE7`A;489T#^M`O.>JT<?%W$_I`')3CBC)W,\]M`J(
MVN3(@%L$W=.],PT0J0:3N'`K+QY!W=C%UMA1N0C040)@1/-:#-GE733!.A^Z
MGU]EJP;MW>(]28";4N-57N)4V.6%V.MTWNC%%+'DE=[JK;!9L][LI3!RU-ZW
%"P@``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>f39432a9e3943248.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943248.gif
M1TE&.#EA>`*V`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````>`*V`P`(_@`_"!Q(<&`$`!$**ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'AAY"BAQ),N3'DRA3JES)LJ7%@PE=RIQ)LZ;-
MFSAO4F"P@*?/GD!_(EBP0`%1HD:/)ET`88+3IU"C3L#0H:K5JAZL?LB:LZO7
MKRTI(`1+MJS9LVC3MLQPP4+;MV[CPG5`8(``NW8%%,"KH(``!0D<,$@`@<$$
M"8<3(T9L@0.'#HX[>(@,&?)C#VHS:WXX`8"$S:!#BQY->O2&"ZA3JTY-H8%K
M`P-BQT806V]=V0<2!':=@`%@!1,>1)`@87AQ"8TY;'!,V2KFTM`E.A@;O;KU
MZ]BSU^Q`,.3R[\J__F_8H(%#!@P8+$1PX&`]^P0$%A@X@(#^@?D*#BQXT#Z"
M__\18+`!=]JEM8!G!2:HX((,-EC3!A@\(*$#$_+'0`$$8%A``09TR-0#$(0H
MXH@2:&"BB8]5)1"!#E+$`'4MQBCC1BS.:"-V'&!P`04@2IC`AD`"20``1!(I
M``%U<3A`D`7TZ"0$$D+YY`499*!!E5=F8(&56'9I)8'FE:?!!AF0E\%S,RD`
MXXULMJF0>6[&V6(')U(0H@,>*M#AGK`)4"0``0@0``!'(FD`DG\FJJBB2]9E
M9`"##@H`D@4<H&&&F%Y:``(3G%<E!IY&I&9,7M6H705RIJKJJFA!-MYX_LPM
M)QEW66D@X'ACOJKKJVU9X"L%ZDU`006(#>>?`T;E=X!P#!QP`'O.*GOHHJ*N
MN:`&T<%9D`:?7:0!FJR&*^ZX967EV'+*<5`MJ0Q>D)$'[-)DDD+87D0!N`VI
M2^Z^_/:;TZC^?E`OFQAPQ`&^`7]`9\(,BPMPPQOIFZ#$"BV<007N#M0M8@IU
MZQ&JH9D*\<@WJCD!R2@S5/!"8RJTL@4#%X3P!V<*M,%#%=R<\LX\2_2BQSW'
MZ4$&91$]D`;<;?"<R`(!^X%C%`A4`08SHXDO!Q`,Y,')`ZT\<]!@*TBD!6&+
MBRK&.B\4TLIG&;T<T`,9_0'7`F%&M+H>5'">_L(-A$3V0E--I'39A),%*-.%
MN_F80Q=P\'=$'E"000/Q/M1!VA`];I%D"HTG$`<::%[0P@S56)[CW2U$\=<V
M<9XXJX!2_'KBH&-^4@4-J$=!U!1-$!+O'4E,M\(+19#!`W%[@/Q`RW>-M$`9
M3P1R11?8_M`%K,\>':#9:X_CYJ*E*SM$5'?@,0;C=]=]11X,++=#D-D<D8!-
M3PT1U]UB`$&)YF=_0?.NLPB:TN>]EG"`2.\K8((8P#;(-?!&!X.?[1XH$+<,
M!$(.4!W"5G:P"`YD`13Q@/4@`K+G:&```2C`!1!'D+1E8'@$@9M`,FBSJ'D@
M:RN2@`<5J)+8\?"'_@W!GG8FHS41:K!T2/L600A(.H)TH'$7`1W7++"`P*A+
M11E!G,0\0,&A:4D@.-Q*&#G@K@Y,#X@/$8``T,A&]7DO9A/1P`4B@#<*D(EL
M%Z@7\"A"M;]5X(Q.+`@4!P*9\F2`15S92LX4UJFFK8B`LR/`&MM(R4IZA(40
M>4Z9&!*]%8$K)!=S&^4:4B]]D0>&"EL?R@AER5:*ZS0D`U<'-+<`#Y!M:%09
M74%29+D1^HN5K@QFJCC`@`9`DF83L(`J5X6F,F%@`AJPXQ(_``%(*L>6OAP(
M!^BF'*VQB'X3&5H%#[D98`KSG&[J'@<H$(%E0FR%`6RAW-RI-HGMT(&N_C)1
M`A^RQP\\X#`]G"0Z!TI0-RW'B9VLF^@($H'Q/,`"V?S@0ARP@0<L0$`2N)=`
M*+C1"YQ,9";JW#$C8LZ"FO2D`3/:2"O2@7Z6CJ,-.6A&-E!2E-K4>YB\Z5<J
M4%.=^O2G0+4(3P4:U*(:]:@M["E2E\K4DVH```-HJE2G2M`7,8"J6,UJ)0]T
M5:UZ]:O>XRI8QTK6L(FUK&A-*\3.JM:VNG5<;'TK4&$JUX;%M:XMHJ=,'L``
M""C``0U0@`(DP!T&1&!X&2!`O>8ELX%<`(1X5=5=([L@#E3N*V+I35`6<+,(
M'$``V-KF`Q#P'#51+`,):,`'-A"!(QUV`A%(_LH#5M@UI>F(`BM$CP4F`,E$
M4O8LD_VM`B,0@.Q)``$9,```"L"B%U&,`P10+02(M("#`("W`IG`DK@C%N`P
MX+LO`H`")+G/@20``,T3+EB"JU[M=:"6#T%`D<[(@`#(#K<?:.T`<D2D/4H`
M00=10$$8@`"(O!<`!M!K>U-R(%2"K0/E52\$`I`KB.:Q(`MH`'IW>4AT*6P`
M9`-=`E8[J#UVH``%.R]D![(3$A8)CF;9``W5JB:7ABVGD7W1`)"D1@&$\7,-
M2`"^-H"`(2&I/AO.`((55H$"-/1@&X``\!8P8X%0.7/-`D!7U2)#LCYLP0J4
MP`'PQIP:$1F%(X[A_I@S$*L!N$O)!O@``ARP@!0>*@`#`%D'$*!:K16@RJHK
M@.0.A6,PK^1`-K8)75="1$.WI`$"8-T&G'6!09W1`@?8%@#.MN0%7,``%*C*
ME1``VJ<%H,H=(`"@%=*``-QL`RIT-$X.M&J;:`"0,@&=K%<"H8AZ0`!$HX``
M#)"V"0B8($I6K9*OBC$&=F<_']!PE3T0F(<<9,=^VO*N9W+>A=J$L32YW$D<
M<(!%4S9O!X"`:M"3%0P@(,T?P`">GR,?<&'`Q]04[],*`(!.;D``JGT```"]
M'O@-P`!DC,`""KSM-ZGD``#P]LXP(`%P&WJ."$#`:!-09`YD?`$U<C?R_E(-
M`(I)8``)F6Z<>3IPF'V``O7!C,"KK(%G.82FG1Q`H=NKX(@,2>(IN4"?&62!
M+K<7`PZP0`5\M?2E#^N/2K=``PDD1WQQ+@/^B?<$&M`A0A%``?JB,ZH-4.L5
MU66)`@!ZPT_R<WGU?.VAR8`$!'N``0"@[@!`@`(D97<`*.4H?S\*L?ZX@3].
M;3)4HQ)5*E`OS$4NPJLE3D$H<("WPSTB!XSXY0LX,PQ4X.EVDK)AD4)Z%`(J
M4H.B30J)HMPE&<`H>-?[CXHB6`7L[O84F("4<9_[S:=D4&KW/=@2FFO0(2V/
MN#J1K08?]:8[GXH_%G[$QB9]MT/&+5>R_$:T_M\0R%?$W-5G"`5@G).G]CO\
M,FFR;&IS;*1;&P$-%+/FJLVX!6SJ`>"*%0<8+_%S09B<@81^-5$>9?%4`2"`
M+G$!YZ=-"*`N$<!P##%I``!O<Z,7$N,G7Z,!$?!UE!<`"O`<'C`D/18H!,`0
M:@)5?C(`,Q8!!^<L]>$LJI4W,`4FLF-&_J%VM(*`-V%^*Z6#&'%B_01-'[!W
MK,,!?E)<,10`6R8H$;AC`S-ID.4!E2(^CJ$Z"L!`#U`!$?``!*`S&B8Y&&`K
M6!<U%B!)@.0!^2$0&/(<%?``=B%)I[8B$<`GA_)Z'R`??*(`[=1]3>%1(6(]
MY$&`/B@P@#(NST-0_APP`-%7(A]@=RPD`0_@)YC3:@%`-G1R;`HQ8:(#:3>C
M`000?3%%5!9@`,OC`0>@12?$`.!2)FGF7`+A)\;T-`LP`$1C`48");B800=!
M&""B7$.G$`*7*%WX-`Q@`'Y!)`/P`/JRA1="B@A0*6/R7>/#`83U-)M$2%7R
M>=QG4P8XB"JA`<3F*1'`==Q1`0&@10SP0@``/!A0`!!P'UGA&ZKC+&]"&/YT
M=^2G$-,Q.I5G/@K@2QQP7@`0,R=4@M248/E5B-HT`)EFBP``BE9&-QTP`0+@
M2R&B`"=2`?F1%2DT(FY(0VJ2;@K`'PA@`!5P8@A2$`=!--/!<"UE=\IU_ET#
M$1SLH2$&\#C!D7$/I5/FYWW>B!$5X"=^LEQ<PU-?PX68T1N.10!;"&(>,'<L
M$P`0^8`?(`&0T@#L<64,X2?;,@`F8G</@!Y;`4[Q1B2D$CIWP5TZ\U^;AFPW
M@P%VAVL?]HL?8(<+T0$`\(M$YCCZ1A#M*!!?R$EYAR]/133R=FPA"64.(`"U
MU`&!`H/.<@`G<T.$4B0!<%D#U8T_>1(<X&2/X1AH\E2(<Q_Z06H&L0"HX@`@
M1@!(6!`5H'<*<0$J^#05H&K5U1.E8W>"A&(*HQ[/V"<%L"(.P'&1)A`($`#/
MR!VMQ1T=``&LV0"T%4,04'0>)2'**0#I16TZ_K<0_Z5MQ`1A`[<M:38=B09=
MZ]A"_&8T#)`QED80,'<P`J!M3J1QEP,Z&H:9YZ29F_DQ>1:!!/`UL?5,$I``
M1@,OZ(.&`HDP>0.*:!@U%*``$.@0'K"8"F$`V**:M%(9B'2%;4EDQ))I&V!W
M$F-&1L8`(PIQB>(N:D*!'V".(Z0F\1D!%E!?`K8!^2$WD],MY-D=8`)Q*W8!
M$G`!P+9:`M`M_$:7'Y1H&1``PZ-T$24N8;B#"KF?'A$@#.&)7P-_`]$`D`4!
M6BH0&AA5=YD`_>2)V/(``9!I$6$!=-D!!L`="H@X(0I_'AAM!;`!!%!@'=".
MIF)+#H``O',F#A!J_N7A%.JRI'`C;R-D`7LVE!-((-,%*8RY7'XFJ8&"G$\3
MDP-06@Q0`0M@F!OV`9^6=]%#-!W0+,H1=?72`4=2`=O8)@`X@%-*I1R!F@S!
M`0[P>063-Z!S(&E37]E5I$=SA[?*`)M*$+!YCVH*$3M2$!B09A#'0A!:EX#2
MEALH$$.B+G_40!YPDP(A<"HCDRVTG0I1`5L73;O#(A+0`+@'`:5&,P2P([>G
M>ULA`:0(`#<SH7U'-!J@A!?TCD2YIPHC*9(2JB0Z@>"7G[-*JQH!`>1')S"7
MIJS7&@KP8Q.P`$B#0G*C(YA8/!)B47$X$'\E$7,7`;OSC@*PC*>641MP_GM$
M<SQ790&V\323HC""PAW*%6=:TP"99FP#J39DND0$\*8+(18069>`!B)@!`#E
MA1D4P`$&4$L"5P&?];*"MA4@6`$0\'KU(@`',"R@TC(J.2D.T(.MI)\,"Y2Z
ML;8.`!5MD7LKM$*[)2R\Y1RS<AY7D14@F*%;44$^`4,10'P,80''*2@`%STM
M2VJ0`BE^%V_TH88;Q@$I%&\B*C#R10"'U`$S1S-V%VI881(M.2LR&P!R^0&[
MA:1@%"\2@$,2,(P*$3D?V!D*P'71UI;)]1D;8F)KB*<=FR\.$``L6E!*=H!I
MFQ$:D#M^Y:EJE!<]UKQWX;S,Z[S02YP(9G>1_ID`@K4I'#=8BM&]$C"<&4>F
MH`-V&OJ9E4%&S/D8BR1'+J0O<#*CI#40%K"8R/B!3T.X!8LA<<8`:H1@1E*Z
MHHH`$F>7`P$!D+4DEV&^6Q&)YB$IRJ1<9,-3(,13_TD0`D=&*5D0&Y``\3)I
M*6%Q/(.VQ8L6%"-'J$&=)ZQNRH$:$("]#%`7!A`HQ>0:LYL``[!PJ!<;1%*P
M1E(;M/&,>?IN&4<?"W!<"(`<YN$6S+'$%R!8$8!(GZ(:F*,:F,2F@BNYO4N5
M'_!91,)O.TP>/B0?2*AAIFJ/4(M@C;$!8@9"&-"6G`,J`M%:T7,YR_H19E0V
MNSC"-C(@#F$K(34W_GF$'H*L+X*,'CMBKL/B%(CA%"&"E>S!'HX,R8^<`$B1
M`/-QO2]XO1$`7H8%(IS,R?T!(/[Q7:)\*^.1`;@U%1?P1Y*1'@+Q0B!C`=6T
M%59:01'0&P=```]P,\T)>^^F1C>3`7_:&_"1P1\Q`66',O^U8GH\+AV0JV0!
M(9X"*M1\'O/+']A,(=HL'"\D9DBR8]],*>*<(?U;)#FK7#"\)TPA(JXQ(NXL
M97AS.;EB,P-R,>C30I"8="EAA.FE%N*D&2_"S,T<+AV`NJ5Q3SS:MR#\.:!3
M)0[-)542`5""R@;PFU%[(1RR(<:H)"F$(03+(8/B*$B"BQMMC,8X9L?,_EF@
M@76;\0"D:!84-]!E@]"MHGPVG4<VK;4/D`#09")^.,LR'=1"/=1$7=1&?=1(
MG=1*O=1,W=1._=10'=5'+;A27=6N=))6G=7D\JI:W=4[HS=>'=9B/=9D7=8K
MX9-F[=1<+2Y;@R&3@B14G=9R[2^?9@`0\!W$0@``/-=\'2X3D(YW2;1!!2\,
M(`%+M]9]_563!DD9H(H_A0%SJ!NYO"%[:$D3L',RHT^'F-@GD0#Y.!#0K%,6
MM:MU$Q*>6E08L'=?5T4!8*&<[1$:()]/TQH<U,\FA<P.,:A`U0""1C'F0P"8
MK2HR118C44`6`#R`]30"5XJV35!X.E)?:E-H_FAT`D/=Y+(!#K:#7KK#<0TV
M$Q`]1/'*!8`FL7A2RA-\JQ6\!.4!Q?00$H#6YY0WS<(`P++*/-'=/--(KQP3
M%U``TU.-)Z5P,:0OJ$P0GUI0MU9!1^M$=6Q3F\PT&[``9CLR@;/?Q*.U`R';
M`[4`P)-J^G(!$3H!>QU,##`PBU.5Y2:_P;W/*\XF&I``D"1TKT.6C3V$$Y"L
MQ(I2)DH090M&$=H:-C5TGJA:>.H[1X/>+4&@_I(!`X!?#5'>A!/38"I@&8`A
M*Z.Y-J58[DDK!="QQ(12<D=(#)!!$H"=F)-H-/&DJM)[%>-!>\,1&K`IK.(`
MB%0W+#)**`5R#*4N_A`7`,"SRB@EY1OU&<HA`=HFT`4%X/[T9K&1-@C0X@KA
MD*Q2&!+JV"C%YC.D+MO$`"RB`/C=2D#J1$/71#F.4D-GA*BRA13C`-O8Q@#`
M*J:(F1O<W`,%:PSA6YV)V(73/NX9</5!*FQJ4QOPB\DD9P$@X:"]C1LP*#@Q
MX3*Q`0:@Z*]L`)9N4\@"$5!R4ZX:-Y^1V@D0/;,EW>DU+'(&`07P.`T`Z8)$
M)#B1L#6A/`!73`D0*%3S4X7M$&*F4Q"P/AZGZR03:@[!S,#2`2H(J!^$&=:=
M.>P^+NNTF*#F[][C`1J7/IVIYL+$`$\:[J[4/3T>QZA2Y0#`-JR^6AHA_NES
M/>P!\`"2LU$;"-_"A&FL8U$^]7D082L=(7`1.BX0#T2L%1N6C)SN?DZU>2]6
M\ZRN>U,GEE.?[C/B2BX<0.M%Y3BQ&E387='A&Q]+CTX5D``LA#L>\2*]*R[.
M_MI@X0%SU`!@;52C5>].Y%E<_3/\8CQD']2M"W\#HL9#^]D6\2)HGBI\//<R
M;4:DAD+>>A)\#_@ZJ.[\XL<J<?B(CW[;!%2.?]T[__A#/?GC(@$6;_E9C?F<
M__DWXOF;P=(MX0!!#_J97U#*U?=RT@";C_KC\OKA8O8L(?JLXOJPCS)&_C2R
M+R>LKQ$UQB]`G?L-TV@BU/NS<UZ_[R8$</K$_A\N;#;VL[/ZBU_YSY\@68]&
M0[+\<RW]N^;]!>0GW'_]AK9_%W1.Y^7R;$+G/^4`>L^PQXTFSO\ZRPX`UA\=
M)=[^"!G4[,TVR`\0'P0.)%C0X$&$"14N9-C0X<,-`0!X>%C1XD6,#3M<R-C1
MXT>0(2]*`#!!Y$F4*56N9*DR0TN8,65JD$A1YDV0&!#@Y-E3)@<!#GP.)5K4
MZ%&D22MB`#!1J5(-"Y["O+!AJL4*0J]NY=K5JD(+`U^^[%I6Y(6F-LWV_+H6
MI%JW!S-(C5NWJP2R1]LRZ`#7+LX-)E>B=?H79@<*AA6+3+S8,5$%%906B,`!
M`X;'-S5(8(E6@-_,_B`W8`Y=VO1IU!\I8,B0P`/IU'4)@XZ]5&MMW+EU6YR0
M]Z@$"QX<=,C,\?'LW18[P$Z>D'9SZ(8/<$Y:X,`%!`X>/%Z`H>]BY-$9:H@@
M'B%Q\^GK=C#`02D$"`@V\'V<0<&`VW\I`"CP7/V'#C3X;T`"XQ)0J0@46."!
M`"!XS`,$`&C,,+3Z*["@#!R\<$,.._P@@9<*2.!`Q32(BH'R%$-K``\!;*M%
M&%O*@,08B:I@@PT*:,"_KCK(H(&F`GCQKQ5Y3*\#]VI4,J7O_LM`L*T8<."`
M`8Q\JH,("A@`@`8P8&"`%'UJ,J,*`"#`2O$PH&M)-MMD"+VK),"LS+#*_O+`
M`@@44`"!""BPRH,',#``S91P],@"_@B%3@,&W'3TT;@XB`!+`"3CJ@($!@B@
M@2$)6@V\1#W<P#=(2S4UJ>&`I#&I)Q$@`((-X$1(`P46BR#4#M4\=5=>ATIR
M`0"8.\J"!P`P8%*'.CA`T:>`3*!%#E;M=5IJ44(`LP7UNH""`@30L0)F/WB@
MSK\4`.!9#RE(LEIVV_5H@@LPD,`X,1\@X%P&*`B7(`D.4&Q+=#ML8%UW"S:8
M(0\J,(!4F3I@P```!H#RHPX*(#BN`\YMD8"+#_;XXP\P>&""!2:05B4/*/BR
M``I.]D@"E\LR-V`.Y0/YYH\G>,``B29,R8/-_A@@8(`&+I#U)`Q\9JRE"&G>
M<(&C<9::VADMJ&``#:+N*,`($A"QMTY_;D"E1ED">&JTT_ZY[*TBX,R!`02H
M4^MD51[:``>$C8GMDV(&Z6P/*Z!;;8$RH!<G#/PF7"D/.("@3-(4/RA`"`@@
MX`$*!H<)@8[-@MCI"SE>'"$_?<+@\-&OLD"###8@0(#.%6K\@IT-8$"#?5&2
M(#^W`._0`,UC\B#L`7-/O3D/%@A@X@\\8%@@QQ,@(`$+.#`^)0XLK,MW#H<S
M"K'CPS>K@P<>R'A-@50N2`,+$A!`@0EB/^IVN[C?T&+Q\X^1@PLB>(!XQ'0M
M``:``.[*@H&Q;4]C_AZJE?X<Z"'^/8!A%V!```3```B,R2S:ZQT`T+<AX#VP
M*`R0GPA[\J,#::`!!A@``EIV/:)0@#H=!%V!&A`\$[9$A3#,X?4VX($+W&>`
M&7P,!WA7EBTQ[T(\S.'6F&.!N1V,B1I16D/N=``#"&`"@C--`SNH(0YQH(9-
M'`H&K"(H@Z5L*\N10`->=Z_G<6>*,4FBASH@.C)>*8\?&5X$J(2`>67@-0C`
MX5\F0*ZR9$`B>B-0C@JY1TAVY34)\N#_"-(!"22``R6D4`)APLF%,`4`CXQ.
M!.88R5T),C8<X)8``/D\"CP``:=,B@<&0$J,C,8C$1GES[*V&`V,$97#_IR*
MXS3U`/EQ8(4%D)QA$&`IEG0`EP;)0%.FB3`)7#,I&H`F,;V9%!PQX``'*"#Q
MQ(*!+6K3+!/P9%=HTLL.40"1WZ1G3S0P@0,$H`"P8M9HJAB:#NS$+*)4)VXP
M2"!0UG-#*5/`IB*0`6UJ``#S#(FA1OC/BB0T(P3UD`<*&IH(Z-.<"BT0>090
M``EH5"';40D%4'<3LLCP(PA0HD@XVB$)8!1Y&B3IAMHW@`3T1B!&4X\':IHP
M@5B`;QCQ`"T)<E,.Y;2G:F.D43R0H/<Q(([JH6A!/%"`@5K30P\(TU3-ZI"D
M->"D#=CJNUZ*FGP=,"WIZNKHG'K62_8K``%@_D!=47)7I6!2KI])UT<+IE*\
M(@PQ#3@``1PP`<!.SJ^A,:I<X<DA`\PPL9$,7L+RB0`+M'57'YP*5#?D@)&J
M"+&;-0P)$;(!/_(UM;UR0#=+*]9X&E9ULV4M:ACJRAO=+),K,2RBSM1;Y"*/
M/`U8`-XLP-MJ96^U&OG(!,P4V>1FUR@;H$"F%@`SZ+KK`#5%"EK\I5WTED8#
M#@@`('7+DA\FIP)+54JQ!)I>_/Y%`Q0X@"O).Q5D[>:.S>P)D,#(D`Q4-;\+
MCB:>%)"`!F3S@0RP+:I*\A`(Z-11'`C`9!ELGE%%(&X.F.[4)F"`K0"+I5/K
MP`4_?*'Y-*6OV*U6_D!I?!$&`$"SR<G`$7T2F1?_)V'F"E2)%T?BJYB+OC?S
M7Y"CP[\I$4`!>/&F4*>2@`M[3&L:4+"33X,!N!W``:+-HP8.G!0L_]?+:[:(
M$?/)J:F:^2HJ;M&-V8P:#E3`CP*X7'C%DU+%."S)6>90,.^,$YZZ90-Z1L"#
MOTMFA+[7)PMX:U'2[*$,W/?0,%%771:]@`%,QX#)I=V5";U026]:=FYQ7D@)
ML`!(FY4#LWS*I55]Z*C<:P'@@DE61$B`\&H8).92<WHVL./%'%L@'<"1!R1\
MZX(L)P(+*$`!\F9DWE0Z=0X0-D&PW1!;<R@#'F8U`3BC``/LJ0(-$$"G_APF
M`**QTST1F``#&B`E.Q^O`@L0@)B]D^\\`H7`>YMH>B)0UPR%Q@(.H(@IFR>0
M!905>D$]I`<40($*-`@"`@B`]PAR)ZM5CY['1D``",#%)6E`V[EAP(J/`JQB
MU\8_BPX-!<C2@`(.Q`+MA)[+-X"``E@*`EWU`,0@!H!G`GQ:>69O`C"N],P@
M.SG=54JX-[2!@7=EQ0FPW4`29!`.:&J&%EB`313PUJ(GB5&9ZO+Q/)J54$O<
M3;!2#ZV1@F5RBR=/("6-7RIPY@]P@&\;H!)U(.!R@I!V`[:#>IN<EX``'$!?
MN_KV8ZB,E'NENC3,#DT%)%.Q!""``12).-@-_B`X,YZ>*9))@(,L4Q#2"@0"
MC:\1!Q;@/@$L(.N'3EI2,I_8GS<O`@UHP'`J@,>"3"!3"+B`@X`HH`A8I0&:
M_H#<]4?V"%&:J-!NR'P:DO>._-X@S-X`!Y"$(_2G?P(18#_[87NZ"*"S`A:(
M0%72?W_\HY\#.+*>1]'C_UB1)@&DO6;IF`.HL((8*1_Y."]RE,9IB>&Q@$SA
MMK;COO$[KH60NI,0O^0C@&I+@,8J``9`@`=P`.+SGZS0#@=8$`=0P1)\01=T
M@`?;$\LI`,MQ%6OS0,LQ``.X&Q[TP&HS@`/0D@$P@`+@01Y$`/A80B:$C^9[
M'&[*@)91N7N*`/9Y_IP(@`_B:T(N-!$NK`#6B)?5"0SO&(CS,Q&LTX`TM`HD
M<8\`P;K&838D\2B$`!JLLRB-H+XVP11?BJ5QLCD"3*ZX.@H.-$-WFI'`*!\,
M<,,/P#J(PI,'.+SRV;BFJ$1+O$1,O,236A!)])HC%!%RHC8!X#,CU"<CK#94
M1$63^\37R<0@L4%-D9Y*[!9-T91JB\3R*0`%B$0LJT0!*)_6DP`(&$(C=(#0
M8IT,8*8^81UF3)()D*8,<`\_D[F46"]C:1D+S(D&)(I"7+;<X+=(9,()B`\#
M6``N9,(*&@`_VR2*>$"%2$,3B<<+6!UY-!%A;,(I-)&_DX`LQ"(D1$)S_H0`
M?G0C_H"8`=H2B;`<`.`S5XP8&S03`5C(;M%!$O0\VU&``FBT!_":!6"KMFBJ
MMRB_A=@D53+$R?$1BM"<_8.HC.B`"@B]Q`G$_!(`S+NLYMBGU]`SMP'#R^A)
MG^Q)]V``L$J-#7@`$M&`0?D`@?R`"T"M6!D>\Y,`'-DO?GPN[C*9XF,_"/`?
M(1PG`L"B<<*B!'``!#B`!%``("0`H7PU*5N`&RQ+:VM!N6S!!9!+M!R`N+$<
MO=Q+R^$S;SE"RQD`OM1+AFPL/FNLP?Q!`N#!(4P`*2%+RT%+M91+ZQB:B*G+
MN6Q!!"B^N9P`#)@_N:2`%NS)^8,7UAF5:"R__M&(1I_,&M7</]C4`-C$)8_R
MCZ8R/V:#S3K4S4:TGFB#3?/#LVE$B"KYGE'4O+78)PD0`+?A1S\J2^@\@,WD
MQ]T9`(5!L=3(EW6!@`!P#PC`#/@P"`C!)N=0K!6)3O24SG'BCX5L"K]TSVC<
M)*SSO-=\3?/;)/F$S?K$SUC)3_V<30$4P$U*&C`\MD4\-@#8%'Y<-%:B3K=Y
MT/+[S/C;$^E,``DPGP6`SD8C2^E$``1P'Q[D.%*TH"U)T%&T(!3EN!2%MP'H
MR"^QM^FC$KPT2[QL(1$)/>)K++P,@+@141:M42`54;SD.""MT10MTA8B/B5M
M`+*Z`"=]4B>MO*YH_K*,D%("T$/=Z(`!6(WIX@@CC`T%4(OA@[`/N!9Q`3R=
M0)AN8X@)N*6!8)VJ$!`XL1[<-#^/X@!AM(L[R=!GZXF^B,/^JU/^C)\*D``Y
MP<\V[,6&7-1+A!\.B,_[[`U#G8!YP4]NLIH,8$T)H%0+,!K\_,P\VU0)V!,$
M,$)&3="3&@`&L+=5O3=6C1N@8E59=55:7=4(R(IYS%4+F``*&+I<A8`&D*=Y
MY(!.+59=I:"!"1GT:!*@Z0@>TM+SBHX"V)8U+0@K'$4IG8IR%$(+$``U#``-
MX!.EI*\+$":"D*"/L(`!X(#^BDB)D`@1M2`?;2\&4("^VCNWH*`KG9#]_GN,
M+%P.SPP,>`E0@A78&1E'`D!.B_`_:/1,:4*G":#4<4P`BJ6WB-6939T`BMU8
M`TB`NMQ8D*78"+E$D(4W]Z022Y0(1F7(>+6@!1#*!ZB`B)T_)PVY<9F_D!.0
M<?N(:L)2W5B`7D6\ALB;CHT-&=03SFM$H'$/EBR("XC6A>"A!U#'2FDJJ[U:
M^EL.H-FO;1D`61(`A14)#F`0`H`SU!B`YYJV!5A;MLW0R&NOMFT`,&S$A%VB
MIKH`D!R(JVW'X:$`O_U;0-S;.\$XJTF:Q[J54W5%B7#3C@`*J/TX"YA"[OK;
M/%G5/8&`NNQ8;J/<1M,3S_5<S`%<T1W=X'@-_@S8V^:YVOA*79L@*WH3B"&L
MJ@L(.HB[`"ESB+S-#0[8QI80IPV(O88`EPC`SJE0*AM4`+JKC6MATDZ-EWBI
M@!F9$1.)W@NH``H(4W.IP(,!BFEC#3BM`"?%./&=1_&]50VLB!8Z"`]H``6X
M-R&LRWLY%[]-,#"+'\3`.$IE'PM(&M$]O')D@+7-%P#.E_FC@`B[-WXK@+TB
MT@)82`LZ@`I:@(;BL[-L+Q?[@'R*(P[P((&XT%',6-$,V0:@V`EF`).Y)QFB
M-]'DU7'DU?B3IDTB#O^K30#YTX_S1IG(@&CM@`8(CI60``.X`.!E"'EJ-,;)
M@`<X0HP;SK]8&)/!_@CKB8BP;9-JP@`0Y+JOZ55VLE?'9&')6#F'V(!^0X@&
ML([VA0`0#`I7755QPD((,)8)T,6796,Z7M4)4!`%^5`]"3T%6$$)SF,)8`#'
M-.$(@)OBD^"QC%AYB=AYK%<%^`H_4HC+$8@'&$4`4)`',$<H>H`IHX`((``I
ME-DZ9E([7M4'8&-*',51E!Y5OB`%4.5&8:[0DV`!Z%@$^&-`6K],>@"<D\%I
MN[<(VTA%YE4*.*2,S20OJB8`\+A+^HAAE``"T%M.6A>VRA16X;HNB0XAB4:,
M,"7NW#UV(0GPA2*K8>-!-N%5M1WEJ8`","R@P%),,E3XX%$&Z+>SW-A,_BE"
M";;!#/50D-78L]P3'BSF3`)@3L9+#RU+`PA=O]635XE(,SEDY,T8Z0'!&+;3
M`#D70S54=7G48B$AZ^D+*!(1CC/+`WA9LBP`=6W?%:38VTOH#PV]0%E;M"S4
M>JL<$]XB2MWH"E##68->0XTXK;0`"=BK`%`0O_4\J_G;+.S5!<@G3+P7O%P7
MG:D`Z?0-]NACBC54*=GH:?O0"!A!/JF`3:J<-D4/"?#9H0H`2U$`"5Q7_I%-
M_)SKOFA#N@[0N<[K&&ZJ_V.VM)ZHQD'4VH3A`&W'Y@D>::)AI;#.8%DV'E%L
M4V*O;#45(-$S,+96(`()#L-2T[V`<>Q)](M&_C4D#M^T'BY+G,39/Y^.E<`C
MO]&XC'@Y'=B>D<]T`('DS&+^2=E.$`F^/7N;'G%2@`B`Z$75)^L8)P$HX\4<
MIZX,RZ\$PG&:44U92#Y+2"F[9=L>2^Z$R!9EK$HL51-DWSR^G(6+5RRCDI<U
M-PS($X<>`'LM`%FBDE7E,P@0"M\4"`PHCSMQ.IMP'@?(0A/4$YQKBB-45>4)
MZ%=#`#YKT8$HVH2P+N,HQ8C)/>D<FH8ZJ?NP'&"VMY/:E)BFX.)SI1;D9/;M
M2BUA`-E>Q,HE2ZX#R^4.2[$LRUE>VT;K[0P-RW1KM`/0DZW,DW%B+O8#P:UL
M/R)OOR%WOPV(7$_N_A,,(&H_P1%*(P#C<!7YT8`M%8CZ8R\SVH`+4$/T^S\`
M&9[TLUX<V?+TD\_[2TF95`I$6;@A/@AP(0#P2XAW+A!U,\:FC%FWR;$/2@#B
MX&8`28A%DTK89AW+8(W+>,08].3RB4$5[$$/5)"XO-+(5$'(W,N]$DQ4)0!3
M-``EQ%R@"X`$R$*NX\'ZS@ZR`A8&L#^*/:FS;(`$R1A>_MQ"ELLFESM^,QD(
MF,?HP[H.@`#&70T+>&3^6,Q;%L*OA#R(L4&]U*<&*5464I"UE<ZU'<N_R[$K
M;:'XR%`_CCCX^&_;7L(L%,H`",=37L(%D<J#Z]6MI#"R<SJ5P<L\`5K2_EVX
MF/U<!4$1,6,O&1MQ?_\2"ZI$TH"\$CJ`)'DH!^`/;RE!-_*:6W85(W25&M1+
M&TR`+3FI'61V'<PJ]SY'^$@<9#01C4JTKD"4ZA.2@DB<YMNO"3%*`G"XCJ@F
M<VV.H%*(Y?FX`F!BKV#MT6Y$9"06@62-3.U%M^F?'K2.C3QH`&BL[#!5,T%%
M"3^I'MQCH:FB8FG(^&6>_.XX`AA'\Y'$*<F82\2;]LW*EL/%6,F0HVL*`BI!
M/8E$)CV\^A;&Q_+;<IR`7T2Z47RU7K6V@,Y(R-L=3^:6<C\\B&:93%7+RBS+
M$3S"(4S%"C5++(.86T:WRM?%44?-IN46C_)R_F:D;?SY@`SAY'&2)27$Q:&#
M&Z]9PG`\O'L;2[_-PL/#(/B(Q/7\8UW$11DT2Z"C>&]Y7RSZ1",<?E=/XN'_
M1`^-Q.8BH):9D=J'#V'$17IC'^(@V!FI7MD,D$PE"Z"APP\HD^'S6H(@#$ND
M28%P`*347H5XX_-MC@YHBJJ2J+(*J`T!$K#B,K62E@T.`-^XPY0$B`D<-FC@
M\,%#AX0&$A`X\.$AQ`L``!R`P,#`1``"!$R$`/$@@@@:-$0P4!$"RI01*F#0
M@`%"A@8-4CXPX"`EA`D'`""@(&$"A`H:*CA@T,``4IP0%AA04#&I`8X$4LY4
MP!%``*0&"DS,JG4A_H`"!`H$R#B@`-FQ`P@,4%!S@,8'#QPD*,H`P8"\&1G,
M5<#7@=NY<PT\J`"!@T0"!+!>S=A1;@4)&28L)J#@\N4#314,*&N``@4(H$=3
M:$#@08+2!>8":$O@*,:N)A?03K!P:P(%!M0N7KTS`5P`L14T$&``P00*#P0D
M*!"!0'(%R!ED7"S\:X,%KQT\:'#@`(+ON1VTUKJV`%*T8L.>Y4I`P(`.!B%N
M:)"`H_$!$!M\@/#@(X`!"OB!!`!(,""""2JX((,-(KC`!A]Y4($%'@R8@001
MTL>?@QUZ^"&("#XPD0(!**!!`AI&Q,!D"CA@(40<`$;!?!]=H(!0'U2`_D"`
M%2BP00<0N;0!!QPT`$"0$'5P`(P'-0GB!A@XL(!H&3P98HQ`!CC0!BIZT&6-
M0G;9I09C$D1F2QM8L":;%+*Y9ID99&`!!A>L68&;=ZX)F@421`#!!0E,)(!E
M,WW7P`,*\+02:!%$0,&=CDI@@4[$1>#GI8Y"L-*>%6AZ:9]K2@#:J'Y:M)L!
M#!"0`*L,!7!``@>@%5YXZMEG0``(.%74`4SQQ)1V1N%5P`"Q3037`T#M.H%T
M,AT`%+$)/&#!`Q1$D%P%,T5`FP*Q!D`H`(LY`&27"'(@T`<U'BA!!5@^-.*!
M[LH[;X<&:""O!AS2NV^''MPK;VP/<&#A`A]I_N!B!@]M@``""7=006Y)?C3!
M`@C4B"&`'3"<H$X9)[#O!@\4H$`$8?)[,LKS8D``D5<^U$$!)EN9,H,>#/3E
M0#D3)($&UDH`@0..(F"?HT9%\("D#=`*'M/A5;P`>`X<D!5;`@10ED;PZ<I6
M9P#(U.UK#.3%=5Y71\"`!`_<14``Q1XP@$P.6*!BG0S4><$%&'B@P`5!RPLO
MS8'+B\"_6&I0L.")?Z!!`/-BC0%$##1Y0;SI*D!@`17(FC"`'CPWP9-`=3Y3
M!@,(X`!$%C20P=07?,0!XEAZWMF/BMM^NX!'JAB@!O$!2$'AN#-H<N)!RE<D
M\O+!F)`%%4P@0=K/_O\$O01U3LI!!`[<!+WTS]_%<%>*28<15UQIE-%_[@(N
M//L!)L!`\_$W#_E#Q'M@`42EM7_R!A[)6U;L/L"`#US@61DC``8Z`!<!!.\A
M'K`/\2:0O@"]9`(\^D`&"I``O77@21PP`)8L@``!'(`"$ML?"MV%`/Q!!`,:
M(1Y$(."[CRR@@2GLW`U1"($.7"!7#\G`QSJ8D`ZDS0`1^)N!<LB^#"P@,PG0
ME72N5A8I4A$K5Q,``DZH1!2R)8`+T&"%:A*CB30L`Q0P0.4V\,5V!6@#?$/0
ME-)W@08814!&\A`%FD,`FW!NBWYLD`&>Y"^728B%-/PC(O?G@0'Z:P,'_OH3
M!2<P@7FM+Y&*],!J".`Z"\&(DY9$H04N<+:#:&`"!D@8!\SWD`MDP$62@XA3
M"#(5`6'@`65YI0,_LH$*U*@"#&B@A3"@+P5E0&0`@``AV_A)/S9N7AX0P#*C
M&3@/%&P"#F!C`2@`(.Q5:UX%JIPT;]>!7WXLG$J4DP(6X`$',,=_(5O9.BM@
MQ@Q,1$7D"8`-,1"!`"R``X*B"*LT:)MNM>IHK3HH9^`"P@1Y(`,,"$`"))!,
M`2U`F^;<'Y/H=;F+<M1="K`0`7BD`0!85$D3*)T6/_3-CBJN`PJPP$)9VCX+
M1$!0!AA``B?Y$;!]P(43(0",+'@77"HLI/3C_@";>(4`!OAG4`QX*E2CR@!6
M,8"-`>I`R#92PP\=P*HR59QF"-,`"03M6C^9P%V>2#(%/$^2/['E[KXJUP$5
M[";J?&9)'Z*!Z5$RB7--F;1B^E?;840`KGO(4RU`1-I`H``3$"4%YA@!.A[F
M`PH\HN<64%4!)81^#IS($3_T)0FHRBV&_!#A!BLXGTQ6)C*9BVM1`EOMR80O
MKFW`1%7+TB5]H"(-Z`#C\OJ!#3PGM.KSJV[IA1'!)I=F''$(1';"@`4(@(T8
M&.#+6$>C=#$%<AUP0#8'5`$#Q'6D).U0!RB``%S-!(8>"H!GFRO?^6ZQ`R"T
M0`$0)X#X+HX"O^PK_CCIZR&8&4?`*>-(.1^B*`1<0&(<P"Y,2TH9"%E6LX3L
MP`,&$%?++L:X#-6``_)2$1MB*9`&/C&*;7>!"0Z$/*^!B5[KQ%\053+%#-*8
M&&WL.``$<%A)2LX!'"`!D]`O`\?1D`.R*"`/0"!5*4W71`(<H/LA```):'#*
ME*SC+7,Y1!:HD;$R4DX*5*``V#VN3KN,H`T\B[EJ;E`'`/@!"C"%9S9YB`06
M\(`.1""!YUJ(!+"ZL`80SP(,*$`#3,@[">P$`&D&$`9(JT$()#!P%7TSORQ`
M8DQ_]6<X:<X#))!H,P.8TP+:P`!R;.H&+5`"`WB>-C50@"0YX%\>*.`"_EAX
M`09NN`,,N<"&":BK8D890!N8@%@40(%@HVP!AUTUEBZP:6@O\[2G%F6@Z51J
M:BML`./E]H(6,P`L)^<A"7CL`23*9*0`P+O@%>Y#+$``!SRY/@+0:07@8LB8
M!(``)1.>`-P+;@5-X,D#3V1N.8`!Q.0-3_-:`'*IS0&V:60`$;#*5"R0@*-5
M"-BKI@``K-JS'R;6`ZY.0(4HH.P!:%E"A_9?Y_9);XAXH"R(.K2)]-:^`#S[
MX`V"`+-][L<)#`"JUF+`!$*Y$ZQ-!+KNHHY7D[N!/GI(C:VZ"D8.2A:L!%VF
M9K2(GB-@`4C%KP*0DN`M\V="4;>+`^D\+!&-_C.P`%E``96E(`(>H/,QAN4F
M%,AMXAHP;:$3?K=%:U4#DNR8`N1D`<,,T7L,SFT/4/X@$O+`RB0OTP(YIO.>
MYW$ZA70``KSRH6Q\(`$@Q4``%9`!,'1C:B>FG9\6!KAXPA,&;G][S1?^=C/N
MO30W4!J]`=Y#8BE^X35P9MUF0"26[RGER2Q]5FX@F`[T;Y`DD'.]"N"W#PFQ
MQ#)P[R7O\\P80H_2+)ZMS[/_@L!'(?+?O\4%5*#K6!I+_+D<?Y_(%VGHU:>1
ME84DC07]*!\"(!,-T5MH%,",;0!X.8!!$!$"\!/PW$6-1)I_D9GNW1X%>)O\
M?6#OC9>UT8L'-(3/_B5=@R@`U:D6!:`.@G3`WKU,N$R25:2;A72`!<'<1RB0
M`#">R=P/RFD`Y<2*`D#.7EV9:"T?".*._2UA#NU3U`T$OE"$SXG&\,R:?(%8
M@N#7[AS;@,B;$CH0!\B0`*04[.Q1:R2`X"F,:3Q:A]R1$PJ/A\4A(DV5<$V&
MO)2@T^V+%,Z5%2Y(!KB@?"F`>V4``L3,1\#/5=7$WTW9B+C>`.@@`2T&!3Y)
MF=4?EDQ`U-&AX.0?)^+.!!R3L8U@U;T*RL!%/_V1!MC@@ORA@CS`"NI6MR!(
M!I@,NT@(!!!`*G:.!7S'!5A(!A#`O>`@0S@`\!C;=,6BASQ`$WZBO'"`_I0Y
MXPU!W."%R$CM(;T$0)ZAD3*V#ZH=`%OE%@20HK$=`.\ID0<D2_Q-W.\-B"9"
M1$RLSI98$-\\"08L`*,=`#-N203H8TIAU<M48P<\GC06)(I5F195G[S0$S;.
M"W2-(0)(@,#=CJCI2+=,&Z4IB#_A5CCUSEH0U18&D(+@R)QMCH",5XIDS`-4
M&0#T7`NA!4<&R`6L"LDI2%%L43="&Y\9Y/PUT^MXHH`PY"G6"#41P"8*CS#5
MSP-4!`QQ@.9YP/L`Y?Z(&I\5P`$T(0<@0#L&B-WMQ`X)2*)4`(Q$B359!ULT
M$)\EP-T9FU@@6H-,7#4JCLFUI-"-$T\JD:*<_N.'".7)%``O(H`ZH9#^T,>A
M;1B,P5%&F5-2'D0#,.""4``!3.1^`(#K<=8L'01=]!L".$"_B>4]3DQ(U=MS
M+(`0-<@HW=`J[L11WB5KADB5;266\"6_^*22#`4#7$`$"L]@?D0>H4L,=>.M
M-4`S;I$%"**.D-[@+1*%$5.P\9D!L!*R'<!8$4D_1D`GJ24&,07H7)6K">>5
M<`"\1<0,[4^^2.<'),!JMJ9Z.D@NKF"9R(L"-:2\$("P?8L4,0"?G89DGDQ,
M?,!ZZ93@-4``5&9_*",&+)54IE!%2D@!"0R">``%!`#O;1>`:,`!LE,`_):%
M]$];:)$'C-!5$M(9_D%@DP2B`[EDC-@+"@UDZL'(<JZG[^'/?F(:1O`7A<8F
M%9X,ZO@+:1SC0:@*.:;,!/R67GR4`4R2!MQ9@0:(3J3G,I'5!QB`LV$0V@@H
MBR"(>@6I@&C<7OPB1!#=`Q`25+8;+2D``6@I@F!``:#H[5A`6^R."L*H[7!`
M<"@&_OA))$[@@$9H`#R`\BF?PI&F!?%3@#"1&W)4*$W9O,CFOHCD@+C1?WA2
MYU2>I'(6I+@C;A7`FE39`-B:=`2BEU2`9LE516)$GV(8-(D2="33!9Q%-_Y;
MST"`<8SCDY2.W'RAMW5'S&TF#&W*@U)&>":.OS0FO+VHG`K.`0";E#S$_DJ<
MAJ9.`'J2C-<,``?<6P1HZC%%`#0!2`3PQ/-U5&K0#*/2R\=`*/Y@0'*LX"*M
M2EXTD71<!G"04%;`2K5H(K0VP`1<Q5RH)9UD0*3QAY4@1`;L#I_MQ`)<W'T,
M0/7X*P8,;$(4R<-J0`?X:YDT+`8`">517D(@A/$(40<Y4(+:R']<)098Q0`(
M(@8TQW9.&5W,3:%B`$PU10,V`,PN&302XD-`P+_4AP$0Y$'`U`'\'D)`#9MV
M(L00QI.%X;&FS!D=D:C=ARE1QN@A0+94``!P1I2>Q@&4A&6YC$0(A_MQU`3^
MX*+F*+\X!`;PW`<X0%1LU$%(0#9!3HT4R0>L_LF3:`"U2-4X*LJKL0D=/=5F
M]M1]=)$@K<P!7,13)4!9$,MT;83C.NZ@K,7C<@1&Z(5C&$M9G(X$*$:FI%5:
M(8!:M55;_02E.%ZZ*,@B;6U+/$\&)$2\F01@0(\,7>W'TEVP_JRU0:4#9`>S
MP0X"VM$#"&/[V!<2/LC2WD[!W42^78"]S%O"E!D#`(]^K!=%V`<&"(#;UL\(
MU9-,O52AEJU\N@M]>@`X:JO*<0A4>M^^D&_OXL]N&$_Q+LZJ8-GKY$9NX0TA
MW0W>["__LI(08@_68!&^WI914,"0/M%-Y84"FRE_6,`.74;#;`G9*/"W'*!I
MF(7I*'"X,`P'@T\'_B]`1/F$V*0;]=1BDD[$6%5`[5K6!1".S>0>!_B2L&BC
MA4#L012)S<P=OWB`*>E@Y0$7_1CG\:*,/YW-94!.3QA`F;$0+[U,`7SH!BA&
M8R&57R8BO0V`HYJ3TM)+@4S0OE1QRB)'DIA<`0BQ,V5OA?)'ACE*\`9)*Q%`
M-#H0L^CEO%3`>\PH@D!I&<N%QB!`DT!D+!8$R)'1!,3@#\W1[N[&[BYRXB4>
M1[0-6T3R6C!=O^&'57Z'=81+5WQ>0U"'1LB*1EB'26R<HQS-=YPR*I-,*9<R
MJYQ-&0<(TKBI1B3,=S01>)2R/CT*<96RM>1RK47)F'R)F8S)2MRP4Q*)_A1*
M#+DDD\W4L,GTXZ'2%X9]"U`$B0/<HPC13X74#\M0*V1F94?\CN5F<?`1#QXG
M"`0`P!P^(QH[D.9H9<@B"%IA*?[PL-J\5#HB9\ZZ5V,-I[PXBKQ`*0-(!:ZX
MK>8D`(F=RUA0&N!ACW!RENJTQ)84T^;:C64Q+,/0K,4R;)0TK-C5B>(&;>Y%
M&@90@,7Z!W=L9GX)!G>TM,@HAEB,!0+[Q5HHUD=41#I%*`UNY@/HV6XHAF*L
MA2Z.#`(`M=+$=%#?U$9$\E@H1GB\Q]N@!<L=!ZP4BW%\Q5>P#7KDQ7HU16SH
MAXX5A)/0G"#17/5Q3I)@@"$KC"8:8_<*P`JN_O6'I/,ZN\N-;),I_1O-'`V"
M*("'7MR7?41,GAI(!LZ)R,LUWS!+9,"]A(QTNB=:]>P$*.15T0_F@9=<$U=/
MN,QB<8Z??@0&*/&`..6C,H`9!PX/_9J07'"N&$38XA`='\3QR(?KTASR`,G'
MV@R1('.1:("<^#9CRXEP,_9``'=,#,#M+LBYL%1C%D`&,.\L743FV(:938IU
M-M34`5>Z(--0Z.Q?+42`K&6(C$A=8XDOZ9))Y"2]9,^#2&1$%(#%!`@Y1TYY
MGTSL84D$9TP$#`U1SM%Z,%5N?>;!I!KQ?)=-$%+IQ/=#($"$N)$&D9@;P?&:
MG0;[Y"LX-1)$S/=?_HG2,[(40M,1]&B`S=@=<7C-8[$%/J5M4:>S2P2`!;2-
MZ:!I-$44[\3V@)#WR9B=`XE-(R8.7P\(W+J@JZWF`0S>!NR7XFAX@S`8@."7
M%T.C8K"(YM1,`'!FH`F(*+W(J>E*CUO6Q\SD9*?4`[V:9*ZB7PM/OC$`LRFY
M7%UJEY&,M.1&A+SC0ZRA?RY%"T941=$N``0OD$C&7&%$C2-1?8.(I_2/M,3E
M>I_V0SR6PB795GZ4@DB`I`M.RX5(I0ON5RH<!!1U"27)E3/(6)!B(!9`0L/M
M.F/2:Y"8R;W/<.X-HP>.D2#:AK'Y5S6`C,\7W]:'E7W`M&1X`&B3LXE?_DOZ
MB=56S5*DRSE;TJ703"@6^H=8+439^#][,8!(@-78RT1]Z#G21B<ZM[P@C@4M
MVP5`ZZRV;B)&\X!4GK&!L%Q_`-$I&I.&G'@AVK(?!,JU#P]CD8K4G8#].I=Q
M`,^58:@%$P0"BJ9:R#4KD%]"C-5J#&4>$Z[`IC0A!\W4F#.94#R#2#'?^&:C
MKK6/=H*ES(=N_'E2C)5UAIDIELM(@!]CR4"6<4IM@+3E-^N%!P#D4W<4[>((
MW`4@8OND[-8&DZW+5&%T&090*]Q,C8FD4ED4R%)10.;XYR2=$<0MS@&(WU:X
M64=EZ,6?EV[]^)+!V6LC"(&FS,1YTZ!42RQ*_MO+V/R'V)=68CD6L;N$T%%+
M!-P.<B8$)@C`#\BYI9!Z/:>H"MC9;YF%%$3/7"KF!4EH;!RA/1_EE8OEE:RR
MS94#;]B]@Z6C)9?8!T@=,4@"Z&6&3%/9.\B7R%!$-D@KA<B$&"66RVH[LIEQ
M'8!!6(C5[J*$@&?\[5H.08"<T1>NWY#)X\MH_&+&.@DG);_9_5WQ^U$&F;$_
M(\B1)'='`?1HJ[NQT2>#D(3@9'J#\/!Z(8>B9SC%3]GL7.64-::7%NK0]-SH
M?ZA-!%OJ%G:")%H.A4S(RZ)Z)XZN`L0'@0,)%C1X$"%"#@LJ6*@`80&#!1,C
M4I3X8*+$`0(B)/3X_A%D2)$#,3S04!`#AY$)&0"PL!)F3)D"([Q$*.%"2`\(
M1')(,!.DAP,=1'K8T&"CA)D'5([<,.#`@H,>-"#H>%"#`@,V"1984("!AZD/
M!C00NY*"`J!KV;9U^W'!AK<K,2`0,(#H7+H3#)[M8.'LA@E-!T8XJ1>Q2`L9
M#'8XO/8!@`J)*7^,@"$AA9Q!,>M42YG#@*`4(!0(4`#PS`Z?1V9H0)A@!P0)
M.A?T$($`!-@"/11H(/>@!0()\L+T8*!R<N5S%SQ>+K"#!`(5/#QXGM`"WX$>
M)B#7("``4PT$#G`52*'V]<H6T@O<0*%M9//J$U]VFV%#=@L6(O2G$*&"_@T$
MK.LLQ$+SZ((&"`"@@`DT*%`F#2!PRP,+#H"OKZH,:$\@#B)S;J`.("``PYD8
MH`_%%`U:H+CGNF/@L,E4[%`[@30XX``/,G#@`@`R8$"!%@6:0*D9];*@Q!"!
M@TPR(_6RCRT(!```@"D)N'+!`0H8@$HJ=WN+@P(,>JB!!ARXC#&W-CC`3`@<
M@(`"G#;00(,YZP21MP@4X+$O"Q(PH,B"-`#RPX(XB``!"H2,*0((G7PT,07P
MI.P"!1)P3L89.:A1H$H'LD""WJ[,=$@'('6+O<H4:/)4MJ`$R@,')$B4@\=T
M)*J#DBB8P-&W.B"`H`L,$."!).?:H(!D"Q!@_L$NG>V2`9-"5""N@RY`0%*$
M+LC-,0"<NZ"`!]*<2@,+-,B`3G31/9?=!L9M%5ZV%'BW,BDY%8C4%`\M*(//
M?!((@@TL+0C`>(&RP("K$%O`)8-GHHVM!#.P#E(%-HC`@`((B&#)Y3CX:P$(
M()B@`CHUH*`E5C_PX()>/[B``0YM1(``X#8@H*G2$%CT`PX4\"KE9X7NDF*'
MC5Y)@2_UPJ``!)3.%\4)C,U*(`8:(,I-!$XD2`*%CU9L`9GC:_CKD0X0VZD#
MNH;TN``&>,`"GIW<"0$#'%"@@0_RVI'/HH/K>EP.>,J@@`0HZ)4[`B8X@$H$
MNHX`@@@:B("!`R)__@!R7LO>W*.M@;JWH`D*N$!N8U'4(-\-3FQ@R@'01>"`
MS3Y%FW."%C.(@XYG,H#LVCUJ@/:0%BI)Q=L8F(WU#>2&M(,#$'!VHP&D-X!-
M`]R6'GL$M#]`6H(X$*```UH^J#L'/Z"`2MU]7S\DJ=9R.5;NU>?:R>^EU[X!
M!JR>2`&\R_R_`?AC`.C8]RD!""EW;/'`@N97P`_`B"T^@X#?GH,!"&R$`1+(
M``?R]C4+#(U*`K"``S3`@:`-#0&]0MCX#.(G!91H`P%0F0-IB#L"*``"%Y``
M!>9T`0OX\`(Y21,&@/A#(_IP`CYLP`-:=)0';(DXJW'2"*6F`0E<40(3_G@`
M%J\X`05H;P$3T)X`.EC#@4C``/GB@-)6P@$9-K"`[EM+UQI@.LIL``(*$$`"
MF/BI,CJL`PRPVP`4H,4$)&`!,@1``&2HOT,>DG$`"%E!CA(`Y!AD`PXH@.YZ
M!(!`F1&44WH6(X4V)?`(C7="*X"C%M``!F%``'5BC8H<D)X.`&<_'YC3!S10
MQX(D8#XU%$Y[@A<2#:0/E+P9"EL>T(`T*F<#:`R`51:UPZ\I(%3G^^3*/-#-
M#KB,8>V)@%?&69`.5(``"_B2!V18S&1N[@(#<$`W/?!->MJ3`IK!``8VN*D'
MT;.>'N#`K!#0L08D@$$*&("`9IDB":1'`=;!_M8+`0`LP]%K`L&DX0-J69``
ML>68`(#C^H0RTI!D\9F(J1"0M$8!-GY@;4:K@.<\(,>1K&HS'I``]U12@:*]
M)P$0D%FL`+!,DFPQ1@E<&4Y6EH'#\>8"[GPG8J`V%=F)I`)>.<P&`D0:QIC0
M20\EB!8Y`("8?0`!#@A-`+(UD(!-]0$3XM?R1!)2D]9N)_&A@`'L.!,/5"`!
MTW3I2>7JL`HH+*\KZ0"7E$*!`(AP(!7@B^`"4*T6ZE&1!,'-`@Q@`*,$(`,`
MB``%&E`!`3CV2F*)0`#2.544>2!OV:&,`P:@T9455D6O>IE)"."``'#@`*82
MB-H(`@';%E!*8WII_EV1^<X%N&PE$@!L56%RL<!65JH"D>[1,,":"=@T)*&5
M9`(8L)N'C*A1!SF4Q1Y(I8%DP&D"F9S5/G"`RDXF80885UJ@Z]KD#$5YE9%`
M`"#H4<^EZ%>PN=8%3(6`"RQ`N.<C%5.FZH'LMG%*=^7<<33L$9P4H*_"DP!2
M$/"`"TSJ(TP]FM4P0`'%P42\N<%3!4XS5`P<H`!I<B4`"E,;#$BD90-`:$X2
M$(&-Y(4"`J"7?Y=#@*M2II>;A-"/C;38]"3H9A$`P+74J@"F<2H!2UZ?!;2W
MUTL2I,,>B:%(IPI>F2Q@2B%.2$E^-K(T'T0"QZU,OKIYD'-RE+H>$2^'_CH@
MQB=#!V8D)(AO>2R0!Q1-AWS\0`!@>X'0*(``C,D`S&@C(+K6;@,79HN;*Y,5
M!.BF4P=^+5\M(*"/J00#2>S9!BI4K%O*A9V@1%\`('":_OP:26VQ:YO;@@$)
M#$#.AD*9`!:@Y^@>6CGPO8!U%D,:ED$`>"NC`&?[ZQ%8>K(@%V#3O`R"`?+@
MZ0$8:+3>1B?0!011`!Q@S#>_>P$9N<D!"R"`Q@+MNPY\>BX:('5R+)"LDV#@
MCREZ7I<L>0#J=78!!TB``QY@`$Q3J4P!`.5QNC0`!!3@`%<RP,!7,NQD>J"A
M,FG`1(IIX9`[[LX@B:EZ(I"!"0#`BXI::$5C_O<!ICVZVPE90`8&$*CHB.]\
MMAQ1W/H"'V!%%GQE`1AL,A!T)C]'X/J:P`WUYZ0$7"`#88]`NL,>]NR8/>P3
M?$`"I`?*"#",2\Z>B<E!V;RV(&4Z";D-I@G0/<2H6#U)DP"#`G"X"YGU+'61
MZF"YI@%`=<KC3:&`C/!X@/+ZF0$0Z(#&O4<GJU_=2!;`+7TV16`C"<4@&8@`
M41Y";P@XJ@,1IF$\,^"84C<7E&%JBP,4M&0,O#TBX@+X3,(47_4X;>L,@\\"
M!GQY7A;Y\VZ&@`8*`(&'&&`"Q4EBI!G`=$H^@`%]1]^9)E#^J+:X_.E7?T;S
M2;+R.V2?\=]5_#%#_G\,H.Z'Z9]4J.V_SYC+=/0$HNJ>(P-$;2Y"HT6RHDT,
M@(\<8#9D;V5$PXPD8)64@^[,B`.>;BT:H`!\)$0HX`"83<P28V0D33W2361V
MXD$.H`(D<$<4I$SHRR-XHB!X2X:HPZ.8Y374JP$.@#%`Y0,.*P(L3P&<!T>P
M*0*ZAJ.2,`&,,`%@Y^UP!'88(-\0!>0`@$L.`"H8T.$6Q'FP!PP'@+6X!.2H
M)P010,B&SVA(*SA0S+\0T"!.)@`J8,`"@(@HR`,$`)3RR&,Z\/\<YD#8HFLR
MS>=&I``D0`W;PD-ZI@`2$:3FB2`\X"?2)`/R#`*T1VL^@@4+8OIP:/H,_@)E
MV,@GDH8WFNT#T$4YQ&*-[&EE>$.@H./58O&;.H`#"D2@\.BW:H@T0*\GXLT@
M7L\`-B`T!D`#'J"A\A"4].WS@.(":RBQUJ("J,0`M(0!!I`^DG!(1C`Q/&#T
MQ$6!'`4"CNU+$`ZTIJ*5'*4#I^0T]`?'%$!_EN6QP`,\+&\!M$0`Q@@3P2<>
M,T)_+"!_]"<B@.1XM&:`S@0"]$<B$'(!\%$L#&"YRN8A>%$G*.@43T0!LJ,'
M;6[T;@:4'N``EJ.3_M!@.N`GV$+=`,`!Y(XRMFX@?.(ADV,988Q*G`/A@&?H
M#&4B(N!+((!!\FE7VN\_?)("'D08.8`T)JC\_HI%B[*(2$:+`A[MT=3.*7\R
MGT[F*2GN`:2&*K>2`AQ@`C:`!FG(I]9"J1Z%`U32>R3PO:*BQ?;M`D9$`)YL
M4$!)=-S0+9J1ACK@S&`"X5:%2@)`)".(PMRJ)/WKY@!@K\2B][1K26)E0Q!"
M=0`@Y:ZCGCZF`H22UK@)H%;F,O.).MXCM%[R:';QG6#&.,K#J11%H.P#[*#C
M)#:S.D`I_`+3F*I$-#<'N%;"*$`P`!Z@`GPF`PA112#,G!+@-GU'O'!M5@@C
MSWKF>2#P4R0.XU3$`L"#D1CIXZ[S.M41"TU#.QGI`6+H.$]%,\1B\C[`(6+2
M81I@FT)BX12)2@[)_E(28#XMA0!$Z9#TT(R2K#WUPI42KH;J0B<ZX%J8S?L^
MX+F(0T6HCWPHTDDPP!''A$HB#CHI0/4V1F8X8$1.8DHF<SEJHJ[*Q1J-0@##
MC``B]%$B8V=&3,L\L(8X)B8DI?:0)"5%;S\H`%1P=#]V]!(_THP0*BPI@R=]
M-)FRR".,8J;V*)MB(P&0145,J#/\I$8N!%[J9"UZ)#R^SB#(PG`.`J@8("]6
M!0&T$3H0`T1MHP(FHP,HH,1.D5H.32@D@#9GQ)7`YR\/8$X+2#82PH243._Z
M#5(X`-H&@@*033DBPT,+2*S4"S<``.800C8X,D6H$#J:32TIH##?*1J)_I0@
M)`1G^N+^)N>7/$GV;JDXCN.6*H!G;%%Y.L#F8`\"3#`V<.AEA(HI$N4K'&6!
M#L`NO^;8NJ0_)9(@&@#%*L`=!U5O5"U%?@\[^JWB/`)%#0*A`)2&%C5$NDMC
M;@=:%TI,4&1;SL(G,&``"J2/IJHE*/(!!.!G^F)5@NDI>B<(N22%Y(MRXA,G
M"2!4_H1!N&2&?,Z5ABI3)+&F>"GEK,R,-."Q'%0U\O0Z.J!;IV*1X(A!G<3V
M9J+B^@M91X)A`K!:.T,#](0``@`11<+*-%`]$H!4I`,`:B,#.):&6L)K)-%B
M8L6<C@?:.JDV%BM:TFL#XFWM6C!T(D(`/$"T_M`EN)ZJ)4$L%_LB4U#F`Z["
MS3;`6Y(1+46"66M'7!-"W'PP(3*`Y&JG)5Y*/1'B>12V@"I@`8S1\O9C/,/$
ML7I5+]`60C8`ODZU2]]I5;9F8AQ'+`:V9WQJDN*0M'#O-DKK+![M?`R@XEHD
M`1J2:(GU`^H('(ECH1!"1DQ(+!I7<#!I:E4D[,#N-V>B.83U([XK(2YRB1)B
M@D")`Z'+PMJ"=UQV?30``YX0`JPQ)GYEZ\9V+=AK.P++6(Z#=QV&8?"4[7YC
M6C9E``9H4<ZR0=P&7G6I`#"C9\7B.P(`1!KW`X@#`)`N?#HF`VEM7ON"+V)%
M.Q)``C""<^&6,CZH_DNHM6JPA`#:XR*]I\4`-3/UAO[&\U$R*B&RZK14MVH!
M2<A<AH>2+21B-T"-C`!@)V-#8K$D]3I4KR^4QKC>":$8R5VDE5F"-0.:,"<8
M``3?I19'Z`/4]WP0H+1^"74`@&@WPP`.XS`8`&H30B[(#'PXH`7)C9).=$8\
M@%^I1,PL`#[[50%(1;R@,]RP1Y1""&@*"38Z`(`:P$UR:+3^QY8N0'(`R,18
M*"9&K$R2,*H*9(UB(TU.@H=KB&&4QJ4,T"`4^&SEE>F$*H)HPV2C39XHQ[C(
ME'#XUV`X:`($P&49`GX2`%_/XFH6($DP*SQ=YSQJZ8Z_+1BW3"#8:\"B_HK-
MGM;$?JB(KHH6Q:(X/O<D-F`O4X1*-D(R<2>2NB1?$(!4.DEV!>(D'8>+'!!V
M9*AF0D24G(=FAD:NUC2('=4NNH0`,.4N[L)2V!,I-B(!)F>:M*=9CCE_CGDC
M6D<>`V"`'69+Z$5<Y\F/WQ@`8CE>G(H!0`X1"\1:B:\:'W8Y:I=Z#LDNP(,`
M.FOD>BMC7NQ@8X93W8.T@G0@BE%Q(221DT2@,&/F^FQ1RD4L-H@W>$-1W&0@
M:$9C]HVB"6``R",!DL5Z!*"SM&1+YGDC#I0^I-8E6O3)'(!*@N;)-G$[GO,C
M$!;GY@RE;8IQQA4Z'./?_NTQ!H]!/B8O"JT!_F1(`!J3F#7&J*_DJ&NDGOYM
MX0`@*R$TIW-Z\+2FM"@.(#-(`^2F5DHB(9$2`WIE3AAV(&3UO7KS+]H"H<09
M4A#&;4289^AX+8["Q5+$%F&3GK@IF:@OR5H$!(71GS]@1*C#40::(#*@LX*S
MJ*)I,I2"`01C(NQ(BIO-AS[@$*%#>_L,LP$*LR'TKNGI@[QQ6:GD)1"*DFUD
M022@K+!02%C:M$7KI65(=GUB`,ZL-RY:)/Q288TR);>#2UJF;S-[J4QGQZBD
M`)3&C?[2D"W%'8=PD3;&(%;KE`_@9YREP'C#>@`3,NOQKQ,"Y!8%6\(.K</9
M:#Y6`5BK?#VB6-A"_C;0,%I)-^"ZCTAA*[XVER06(%$=,H`C6H1[R0$(P)FD
M0BT`)7R2I5<H`"S\&R\F@/-\!B&RA?J<FP'<!D\*M;W;0K31LW&(PH0J:F4Z
MD)TKF50<-@"\QL_N@DH8YX868+32%0#"C"!Z>=_Z1\9EO+#`99$48+2"#HBW
M["SZEF!V`P)XYSU.?"H8AR=<9@,81C^A8\>`!T(JA'%.JT!21FR(EL-#HF?W
M69>0C439`HY/Q2@<(+!*[#;362:.^X[=N[C(]"[%)6\\@$T_:4+."=,>`'$P
MPI(0DR""!&``NPFE`@&$0V!LC@#`6JUB9Y7XL&?4TGN*^0,<X+`*("M(_AET
MXJG"H?'".2"5JJX#&T8H&,0@(#"D2!QWK&0B/NXKX/.`"@+.!$`B`LLZF24`
M,E5$%K)+OBA1)@!W([!9V,JBBXH^"RI1O*<#M;?)#^)YE'4[T$<##1L+W1"F
M8[IJA#@AGD?+N1LZ+:1GW+@@OOST-L6^F(]_`:_DFD(O'57-M65X5P)9$D``
M=NHG`JGVDKPZ+T1]_LH=:XI*2*LI!F8NO19E$;2^,$#)J?57/`F(ZZ+1,M!R
M'T0J@`MS(A=TT`<!N!W3R>;3MR2EK9M!5#']*K<EIX34^85*0&>E)C02>4>)
M_>R;A@0@!0#FJ002!Z*!R8L!Z!-(+`4-/[B,_G9BWP=B`=S]2U;E`-Y/47S:
M`E:E-P?"+X-U()1H2=P]EO[-I_^MFUHBS84.`':CH]["V^GCG"3``9R'A-K;
MS$4"M#N@E90]W=6#<0*@EHBB/$Z)C#1G3,`B,V'Z`O)W=).\T#("K6YD"`.M
M4@2@`L3+O7IFX(8R:^O+%,,H#A'STF<"?7J'Z+KDS`X>>WNFB0,V`V1HY=^+
M2CR4&Q>)*SI@2MC>4#9BX`J-2XJF-TH[(2(@IR*CHE)BC5"ZXPM"`KBS2JX'
M/IV#=WP1)M9.:&3HHDT#"T<B?)S#[O1FW0GBZY]CH,A#5O+T[&'")_ZD[8W$
ME3A5`7P^E?WL$CMF_LW>A7MT<EE0\@($P.$<UL"!`P)X5;,P)US<9D'J0LP1
M0C,62V\``@$$"A\$3/B`,*&&`!H2.GP(,:+$B1\:$!B`P>$#```,<$BXX6*`
MC!\R+!``H$`$"A$2<`R0@>('#!P93&S`T4+"#B@3=/@HLP#'!Q([*`"`(*$'
ME!=D4MB`$`)'`0,`4`U`@".`A@ZE(M!P`4,'KAL<!`@``"I"EP`BR(R(8"B&
ML&$Q4'``00#6MP@W!"C00:/-F1[XRC0``(+AQ1,Y4#@0(():QA0=D*3LD,.`
MOY@[>_X,.C3$HTD3.D"`,H""B"U]/KS`L7!"BP0L7#A=X0,'"8$19I"-_N$!
M4(0<-GB0D$%GA[D%(`R0&$&#!P01("C@('#`Y(0<#(A.^#NT!PP89#_4T!MA
M!Z%:"R1H$%.F5``))C+@N"#A!*T#!!@X8,!_"1B@0`(D.8!21PUPE8$$%+!'
M$$(6Y"13`P40B!8`#3B@@`00,(#!`1P=``$$%517U6KG?12!4`<A1,&(YD&$
M78"Y(<3`9MLYY`&"@[WEUP#I?8#`8!W,Z!EBBGW76`80_/<`5TPB],!EGF6`
M4FE3;LEEEWRY^-H%%UBPP%@9:*!!!A,DL,%P"J&%)(UHIHDF!W86MT&>;<YY
MIG0T:KFB;@H4D)L#!$@0T08%N`F:`D-&=.26_@-DD`$&$#!*$0>4[I@9!`\D
M()L&#XSJ0`&FGHIJA+I!8"A:!K`'P``$J/I!!0!<]&JN%Q;PP']@5<41`:<*
M6P`##XC(T0"FW@=`?@_9^0%B`*AZ'%H(A/>0![8"$,"-'A2`DI4\+F"``X9E
M`,`!#M$4WP52>L8!6DMRN<$%QS8`@5A>(H1<:!DT0.Z^`@_<I5!N?;"!!`40
M<``"%\:EE7\&7'29IAL!$*=&`1J`;Z\'-(S`QPTW/,#&!@R`Z+,")#!JRRU;
MD%P&%%#08`,NCRK!I_1EC!D'//=50'QO=7"C0PU8*8"[!'_GP09S6A"=S]E*
M9T&)5E]=H@<:6%V!_GE(4H#6`!]U,-5$;!7P4`8N8<6KS*\2X.J+'WA`0+@2
M><"MBD`*($!Z!6A9]&<;<)0RD\LM$`!U0@\\[V<8G$C4TI(O[8%.C$U0\@85
M""L`4!HLX`"W$K2IW@%-?7`!`0]D!8"X#S&PN&Y2;X#!V&*Y>8'<W`WP\0,*
M+*#``0T$+^Q_!PCP\7_&&U`D6N\2C&EF$T2_TXRU_SQY]H+37M@&$$1P<$09
M5%?X3@X<P/I+`![@P)`>9.@Z0C0A99@&]"<$@.4?1$#]8H,#<+K0=.`!_3$`
M_[#')6>!Q@(*($#XM`?!*2'P605`"]\FX($#]"8D!U@`IAR0F^XT!"<#_L`>
MB!R2.L5(H"H-B-:M'D(>&IEK(I%2#T56^*@(@N=6.9Q(YW0(Q"!&I&EXBMVS
MBL,S#41@0X;IP`!`A1#,F0<"1J3,_YZ'F0LPX``=ZEH$'16:">5/B&0D&&P`
M(`$.]&8"`K`051"0L00$`%&R.<IS*&(`W76``!FQB]HLD`#[!?`#%G#=OX8&
M@1XZQ'X'Z)_VJJ4[F4"QC)2LI.3L]\,/*$!O)5&D_SB"1;Y(8(L&O`"GM+>`
M"<K$`FB)I"5?":^S,(H##)!``S"WHPKDZ`(S<LF/)$*`1SE`:%%R``4\8`#]
M?>!2$)'`("6"KBHZ9`$I465$+&``Y"V``45B_H`"&+!-"%C``C.SP`:2,\[E
M6$`#0*&``!9PHPW8I@,4Z,`X+3"!+7(2EOSL9V<F!!C="&!Q\:/,_$+9&$,M
M8`+EH:0"/V,!`2`@</ZLJ$PPN;@(A.PB#<AD7QRP0HA4Y0`_X\`^/W"`^)RH
M5@2YCD-XT\P9'D::"6'`@#XC`8X4H$##2\"%`I`@K=Q*J!GBUEF(>M0!1(!;
M5DF?NBP*58-2THF#P>9K/&F8*_+%`Q.`S-%@^4O/="T"Y8NJ61,2H[:`Y``D
M:<"#$**M!2"J`][)S`$H4,+&$`!)*=6-`7C)`0),`"8OS:$S^=+7"BA2`1KP
M*&4\\("P*@6N4,G`_D\JT!2"%$8#ZZQ<``9@2@I4@&8=.%-&"I/3%IYUM1,I
M*`3WL]<,'.HA%3@E8]"UE;MY8#Q'48D_&^<9"3@L<JP]ZT`44)X-+'56:G2`
M!0J0P:,"0`%8V@D$_H97BGA``879[6[5X@`YKN8!"VB<!R*0PP<\<")41%<`
MVI<M.!8`H7S9`*U"PP%>+88`Q>UO/]GHEAS-J`-L"HU6L]6`_S`@.L:I*'`[
M<Y<$W->__J3N`Q#`O+`P8,-;?$``7").`&P$01V(`(#:I(`UM;8J`2(``0(T
ML@0@(`$R'M",:SRQ'#*4+PFP+'(@P,722H#&LDK+9RY0UL\$5J9\>2B%_I\<
M1*DT(%[[[(!J07-&+#I@`<^T*'$_H]BO0MG!&7B`9:#B@3O1,@#>D<!%HO24
ME*`L,,&QP%,C$CJ.)$!,1Q*3GR\0S@M`H`'X:H`$&GH>:R+D1CSA2`,N$(%D
MNI8O*YD2Z18CV3%K6G(;@<!^GKE=T8B1OJMU<F<P1]A-\Y,!%7A`T3(07@(L
MP(&GY$!B`E/:?U&@/A+AP`,:<`#;>N8!Q0(?^$+&O@@XP-C'UF@V=1I9BG8F
M`J[,'MI4C>VE2:5%=4V;:+*LZ4Q39@)U$W:V*>*G+NT98,/I`.DB4($&Q&D#
M>JL`<M\8P16Z>$-F-O,""N"`?@><=P$O.(<"_G!EQU5[<@$XM\.]M)$8/9BK
MHCEHN$4S@9/0].$123>7CB6`"@"E`S8MP`(&`#8,_`X""SA``MRLD/3!$8)5
M&IJ=6"(1#!C`W'RAP,(E)VZ."YTR$0@``PK`*9F)!K>D/JNI,<-&`&Q\Z-KF
MB%HVT,%X3:``>,U`5012HM0I10,-0,O3"?;HMTA``%E9KT,.,`#A0/3GW\GU
M8Q00'82`A>I\G[:>$]5ES%A\S$%?#`40,_6^[VL^3B)``B"3%5/%Z(E6(OG<
MM)@GM$QX:7@'T@&J)NV^+$@!`GBP86RSKPJ<1*@O(0"P3ZKXV$=D/ECT`%87
M,VI-,]DS)I:Z[+4W_A^46*![Q>&`L@>`19(_2``$B1<`Z+XO`[UE+B5![Q()
M/8"DW&5N#&0`!\!R@=*.R395Q$`"=O^=S6D%=AAHT_B0%<S?RQ\B&^FV0DYV
M9XB"<LP>X#5H\.I[\Z=M6)$!PS%HYO1K:/,`,7$!!1@2SC4<50%]7H(`@><0
M6%<?5=,!$]`A.:,8%B!3&'`6&:(7P1(R_8&"5#$5/+<8YM<?"P@M$)%F%(`:
M"1!ZYS(F+`=.#<!J$*!H,"1H#,"#0RB$1<B##_"#X^9(,G%[0"05/_(O1Q<L
M2[=_8W9VC.%SC22`56=_]K81X/)6D)$A9R$`$'$?FT<P%2@?L[9,2=87_C;1
M`1#`1QU`AW5(A]W5`>%7AQQ`;H7'&!C`-P_0A+HQ'G%A`/5$&0I05*PW%0BP
M31/0A!M`;HQ(B4*E.C<81!G`:FZ6`!L&3QG`@A"!AO6R2#-R:5%!`!]!2\!R
M*)TH&C$2?V.&?E#758FWA:$!&WN5$!7000'P(`JC&Q2@`1M`:!L&$7(T@5V"
M`)/V+R#X`1*@3!?(9<>#AF\!;]_Q`'PS:0\!<-PG%`?0=!*BB$*E`!3@331&
MB0A`=T7W$M\T`<)X`3-3.3/C("VA%:8G$9"V&:HA`150`?TH<E>B2\A2B=S"
M:@&Y5;KE$/RSD(-T'_(D+1#08.$G&DMU;5!F_GFA<2P!$(JW^!GVXW\SL0`1
M\#M*55?&ETH?D)$.@1C)R"5J.!&!DP$W.#@%T`"#"!T6N!@:$!?@R!AFIA01
M4!5(>#=8PA\1P#.H10$G]Q*)Q",Y=2L/,'R,X6M9$6QW8U\X050%*6%+R'V'
MQWHEPRTF]SN+2([AJ!1-<Q?`(E0&()'SEF`<80"V2'0IH6D=<(689A$>.3#V
M(R0E1D>VIS4\64\IIA8K&6]'`4!)*!H)X'@%D@"0^4T-0&/?M$GN(9F560`:
M%!H1$(V4@26U@1EY`A$6$!>,I106D(WOQ&K;6)J&,EWM)P'CB`!II&0:-5UP
MI0$91WK<XHCPQ!47_N"/'L)R""!=[N$`@^0!,M-1[7A+"-EK'@)L2<4`GJ9(
MX\$66C&"V\D?"W"3$C`!7154"P46NQD6%6F78V9EHG$I^<>77#(?J.$`8%$W
M>M%&JL$HX9F'5N8!9Q2>$%0Y]R2@JJD:`NH`>"&5%I!3`R!.:"D3E296HM,9
M(RD1%0`N8Z.8"T"7-Z2=`C!,4V(6X,0ZB;.`&SHWJL>6J612TG(K'RHXSZ45
MJN,^$)`A!,!-#\!,#F%/^<2B+Z$5QIF.Z'F13[:>H#$="?:>^R(M#J`6UZ)W
M-EE%9`4\"?$[.P=+F/@!$X!Z4Z(`6*I=)H>3$`$Z-/1OJ-$1KKD8VX*/_KC8
M'K55<9&6$EKAEFC:@@BB%4CH`=?%+0M``5X)'A<`,6>S`0(@A.%):`W@I7RQ
M'T-*847Z&=/Q0DG*)>N!86^':Q7@`+87$1*P7JGHDD)4-%HZJ5J(&=/AGI3!
MIS*!;!#@H(:'7%ZR'@S:D8;!`=O":G[:&9((+!:A4ZWZ$"6&32<A$*5''J3#
MF*R1+II&C*)1G?PEJ5NR`0R`EPZ1`2&#&O#$,.7U/=8A`-&H02YJ2;^S`#C*
M``''30&P`-NT3>TG'@1@HGKW8F$:$:GZ<.P4?;/8)7D8.H3ZF8RAJ3XS6EMS
MH&:&-EV*GGEY5LL:&O?AK,_*)&5F4IF1`#Z(_@'FLIN#AA*F8@#/DQ\.@*N3
M<UX.LRPF-ZZ>TC)'$0!7^1G4A1D=1:<300%?YK"5E*?ORA>8HA@'\*D3L53X
MREHE)A[4%)(S"QH1@(0J8D^E-S<(,$/G53NAU)]BTR*U.0&40BETX2D84&:C
MTEYJHK64DC.%A*.CTJ?B5V96.Q<>(@&'5K56Z[9OZ[8`YQZRL0'R>@$!L*82
MH0&@11PVX6LMDS.C\F^F(IJ^D1QI,B1I0BG'2K3\Y';F8CKHZ8=FI0$^NQ@G
M`RB-ZQD3$"7SU0!%UAO;1X-EHK=+"0!J1(SH(Z?KLSPB0TK)`[L`XIV/%R`#
M4!6\P[H`(F,?,VCH_O,P&[4^N>MRA(0^+L9VCOEB"Z,Z$8$!\$&JF1(?1Z%$
MF`J.2U606N%!"($X3"4K+I8^4O<19&(A3'N@#$``"H``PC(<E5(!<^&/=G&@
M!QI`8L$^ZH47(!B_0#$JZ4$['$`>$@!2L\I:C"L1#^:#!O"R$Y%3,NM?JBD>
M#M.PFNL9T>I$O&)*#A2/GYL`"S"5HAB9%]`=Y=*^*OE]Z"$=/A.<[(15FE(>
M&<!+;5*WV5(<*BF8<S,C7L-.6%1\=?L3=5L<FD@C!9`1`/P6CO&,TP(UGY(C
MURM4!6"[F\'$>N:A><;$CR8FWUN)X<,`056)"/``PF45M@LW5L%Z'HHH_B;6
M`"3),836*^\!'WVAI<`C5Q.PMG0,GF!1`1,P)AYK66%1*95"`?VX5?%H6Q1`
M`$X)&AH`G@P<)9S9F0`PN5'5`6[HKVQB?Q(\FE;A&NIQ819D6[PD3FB5++%"
M%7QCGY\%5%5!ABG(RGQC01:4(ZW<'WHQRWR3`+)<RJ=,%8.R8<"6?2=SRP/P
M;U21GTT[41+A-`D!B#^B7-_2+`UT3FJF9K9G)X"4`"AQ*&NKS6M;HPB``!WX
MN67<>E',+2AHEN2,SE`<Q=M$F>0,.A'`+&2<(&A15)&1Q_UA4PE&%0U@IE%I
M&_@4(,`6+`J0?38S$.8$,Y"&6;;1@$J3.G_W_A#.E;F\)V)WF;=;92H(B\F9
M@A+HYP$G`7L=D+X040'99WLS62=J-!9V6(=J$I[AZ7,O_=*6M1PO+18O+9P,
MA0'3,R;O(=,_;1OZZ=*>]M,OS:GA.0"!LP&3A#H&(!M,C4\)(2)%PP#_X6@.
MD'`R8:%9$7H<8`&W%"?G16,6<"2U=21T*(D30)GH84_#&)ZCPH&V>TM%/3T:
MP$U$'9ZM@8Y:82@70L[(PR'H;``#@LZW$C*%C=C:R<1&QY:GRJ01_!E+Q<#]
MU0&6NU6GN=$3/!0/$1(S>5(98$"<`AL3S7'4,4UEQ;0((0`9,R$R]2V6E17&
M`GL2L4+PU&L?ZQ1O_K%;-S0W%$&,QJ&@"W!.O+1;1^*6#&![6D3'5=-3/;5)
MD?EX&/0!>[N(WUP@"B`M>=4CC,B66A$!8F%[Y'Q7,W,!!,G$I]HFD$W1DUU<
ME2U`"K`!&LTD7M,78]==<-7;LM%=6A,G:M3;_SU$2^-\"O0Y'I%FKKT!Q%90
M1S&T0K=L:-7@&V``@>%8"8%A,Z*%0@$!Z6M-"]#@3'**L$2*H@&-'D`!/A@1
MV'%E/T$>QP17^:$ML.,0,S-:HD7C%&`A!D`4FF-2&NOC"W,K4'RJ2_L=DGV7
M65VJQ3+;77*@SZ@N\4(03M01:_=]`7`!`X`36LL0T@(H_3<4`8!!*%,2_@6"
M`7:-&CII.%F1'R%BI<1A+L9'%8'GPHI)V@_W`*>S`:5QUK)12+8R80OQ0'0#
MBD/A8M9DG)E-,`VF/:+RJP<LP-!1T4+4-/C%WHOAS.J]+Q'`7\<RW7A;$8AZ
M`)NC-;Z8%HEC:Q701N:T2",!,U^A2:/C<@B`<M-%(HD^%2*R7OF5C=(G@UV'
M4O?#=^JU%KGQ+6@1.>N1%0R,+MN!3/ZKV'Y:6FGB)>9!D9@AKP">V='8`22U
MR44;Z5#F:P)T%O+]'7=KU^J24Z!2AG#5'$4W.!S@$E,M8DA"8*CY(8`(C?SU
MT9NC1!<M&GL4*^@+$7XQ46%]`1/S(M14YPZ7_L8?8([FP0$"("7E'0&F1FSN
M,U^X!7!#3B-.?0"53A$W24,N]0$>BQD\2:MN$5F,<>W91G;9PE8<3QGW0<FL
MY20"I+.6/26P]1<$QA$8D%>Z422W'"]X$\OQ\KQ*08,<\&_7W(^\-A"Q@@#]
M"JV.ICDP9#-#5+'+Z!"A$P`$S%I"S`%]E1#9>!E>IP$-#I0/,9>V1NO0-7VF
M@QB^6E'NMAB`!E<58+,?&45>J370JBEA)=('+QK(E%MCMM/B0:A(GND5-"($
MX``&D*[BI``L)U"P\3[/J!W(1^].\P"'UQ!=)"0TL1\)_*C.`5RTQ$U)MEU\
M!!$9L)F*5QM']S5-_MN)5"$NY94M3OT_CBDD;Z&A@,I#MZBI_M3R%"%;[@$1
MEQ+),N'V>P]+_PD:%9"^5-\E90X6X!D3&D`><%>.G:,99+(!S_';0*5?"7$!
M0A%R"``5`_$!J_-92]6G2X.7`4!<&]A&^_-+7"58$A$C`!'`PP>"!0T>1)A0
MX4*&#1TF1&!`P(:"'2ADN."`((4%'Q`@&-#!8`$(!ST4L,`!`(`#"0XT]/`@
M`08)!Q``N/!0YTZ>/7W^!!I4J,("+$TBX*!@Z`</!@!D6!IUZ`0)4QD0P"!U
MJ`<.3"E^^/JA:\$-%"!,0*BAJTB#'B!<X-!!@X>!6A5:6-GQPX4$!G)^_I!0
M\D.&!Q\M)-P`80`!!'8=.RY:P2`'IP`D>T`@LD,#FR/1MBV`@4,```8<!!B;
M4$."`1PR:-#`^4#8A!D^$^1`^_%NWKU]WTQPE`,!W3X[#`"@P??R@A*J"J7@
M,BOS#Q4>U#UHP8$#"U#!BL40P4.&#1U$>MC@`<-Z#NLQ;,BP/CU%MG0_=,B0
MFG?$``PP-"C@.8(DP$`#"0@XX*^V#$R@``(X8(`Z"1M*H`&$.M@@/0X:N"T"
M#@J0[`,-`HC`I`)<.R``!!H`0#^#-C@`@`0XL,##!P8PH+@7'S`H`XTF!#)(
M(3^(42F#.F"`@P&P`ZH#`9X:TC$%!`1J@@`"_E!P.0@`B$"YM@Z0H#L!-,C@
MQ`$<4$"!!1*0``'U#L!```2Z#.`!"3HX@($%#GA``"31<H`""P800(#I>%O`
M`P<&4``#MIH38$H=;5O@`@\B*"G"*('$``&H-+@`@PM"O4`#"PA@@%0-)JC1
M@*X<$,!%#Q;`LRD,"C"@M@4$@*"H!1`@P"D#O%PH@Q(W13;9W9QZZ<@$,@AN
M*)6@5':H!PX3*H.5*)!0`0`"*.!1IA0XSP`(,B#`@HX\J&`"!B0`8`(*&L`@
M@;J,K*X##IX%H(,%"OB`@0D0@(`#!PY]#+,/%`C1)`488-(@"02PH*X,+-2K
M6M_@!6``%3_ZJ(`K_@N(:*4K!?!`S8"3,RG)`3X8%L&#,H`W@,,V6&"EE1#0
M\2`R-08ZZ)Z*PI>@#A"H<*EIO1.ZIPD:!NH"B1#NS8,$5CJV(`R,XD``%0^(
M`*V4Y-T```$,,(`"`-Q4:5B/#C!@@JT[J`"`!A*@@("(=U-X3H0V0(YJ@BX0
M8`"$)7@@S:9WTR!<\]J"8,R!/#"O<H(82+PUDV9<DH`*!BB`*POZ9`F"L#R8
M8"7#%V?=MPTR8ZYL`'@\L@(*>N9I-)9;URD!J'^B`(&#J9O@`@9V+VBUKCB`
MP((`#'@@29(;8*""[0!0@`)ST3N`VP\2."T#M?\LBH(`-K@`*=\Z,O=(_@B&
MA?,@).V-V-C8>-?*@EP/PD`!!`0W204*$*N#;"`!F^D``19`FBNMI`!9.Q*.
M<">_!7@/?Q=4B`<L("[>:`!K!X'0`@#8DZ5AD"%6H])/!I:`+/7F`LC95EL(
MX(`*,"\FQ(G4`PW`ID0](%0(H("H/$<!#G1D3>-;0'IP<@"2!$`PO#D@`FX#
M`<\-B%@>N$H+"U(W&9EP*!G8GWH6,(`!_*XA!4A`JI(7H9L`@`$)4,[D'/(C
MA[#+BW<44M>XE+@T*6``$/B?TE;"-#P:Q$Y36<D('T,3#E2`-AXX0*$P`+5&
ME@@^%N`6!V!C``(\``-[JI-&^C>!1#6K>"_L_@\'I40``)3D0%02X6"N9D$0
MVFDE="PD3S9@`#0&0($I?$A?$O"\!+R/C8/TB8L<(I=<-I,W12G``")@`0E4
MX#`.4&4RD>E,@BB`6%6*D2*C%)<.7&`"Y'E<0?9VGPZL,YO,6<`#9'0`K!SD
M`0Y8P`Q'Z``"9("+N.2F0TQE@0U&C4<=L``#%`H5CF'K(?NZ4T46H(`(1*`"
MYL'.-`.ZS'5N=#+(2<"#Y'+.#DA`F=JD%C>?A4@`B%-("R143&.:`)JZ)$T)
MF$`$UD0H3VI,GM]2P-XB<"8=>2`C&\C*!D@#S*A8A`+MY``'Z-+(N6!@`E*5
M*CNU"A8)J*6=7&%2_EWHHL'WB"4NE!O(.YFBK[7:YT4$:&<[7T0:#^FD`PG(
M65ABPX`&$``Y"$#<9FC)G(Z^"*!#"91'&5*9RNCL6RT59$J=R<*I-&!U0$M`
M>DP"EMQL(*J$*8]!6*6QT^#D0HK1(E,BH``'7!$YFK(+!@:P@.HEH%`,B!P!
M)B!/`@B@;MQ2(&":%;P`**``"C6`N)+X`0PX8&($@(`'`E`H!5#L`R!*2`<X
M&:X)^+4!&>"9=C8@)P<A@%@1V)D#3IJ0"7CK-LRM:`00((`&N5&C;<$`+3T`
M&Z.E)JK_52M9X)-:@E#.+H55;,">M!("-"`"#H``!6XGR`!\LYD)<"A0_LX"
MQZ!EK"`0>$Y2XN*``PS@O8`AL)#::.%.,2``@LO`E"SL`>30SBX<.$`#!O(`
M#50@`0^(@$@H6YX!('5M'XA.\C2R`9&Y"`(EHAZ'/_!@B]1K+@-(K0;@-)`%
M1`!>$CB?3#P(`.@*`+8<(Z1#)A`C_6Q-``AR$`&"1>:#7&`EV+&S4C(`NH%,
MX$F%(G-T";+:MHQ19WXA2`8@`.*Z=&`[R5V(4160MM.A9P,:N/1Z=7+I`"OK
M<V]FJB`GLM&5"F4!%@BDQIJB&P-8:,H5+@B'#B*!P6[J>*8U6E\/D^J"+.K$
MN'G28:-B,$`-\,G8:XI!,L,QBP",(!K0U`4\_DP0""B@:P^P['40X%`JLA*`
M(_K?W#S2IP\XX`%[)O,$!B`@]$)V)^HEET$\6+#W>K`Q1WH2=O#"HPRH:"-N
M?,`]GW0LY%2$10UNP$T$`)74K>0YXUW)>JWF6`#H)6^DT1FOF!N1!J&M0?:"
M0&8-\A_2$&`F"W&-BW(SE\UJ96!E20@%$*R3T9R/U"G620/2AW,AY6C6QZ(,
M6_S%P;#Y="7*<4T\QQ)(N?!%Y"9)S`=Y<U4&<`=U#$B/S]MY`'^MI`'!*PC8
M/V`!5QMD2ZQ\P`$6,`$-&.`RY6Y`SIBJ`0$LH#W]NF[7IOP`"EP`7@,XX!97
M\L2'-*!QCVRP!R10_A<-=,"-",DW668G(G\C.5X6(P!J(`F`@N`E=%L<@(74
M=LMG8[RCWEJ[!2('ZS'[\,FD,14"&&#<;QG@C=+%->H*ARN1&:HZ!$!C71S0
MRB/Y=0!,LZJP@S+\$095U)KV8JF#DBA>*^MH$3M+03*64(3<5UDN!D`UHZ>?
MH*J[F&DF"`:ZE[/)ZR2_0<R/>^2_GHPX(`$?F8X$&H6!&\DY=7Z&@.%K``$@
M$+=P-KY`"'I:"08X+@R(CS,Q``0(@(N(EP+QF?^1*BF"@`#H`)MI@(`SG0"(
M%JZ8LD3:"0](%X!2*E^2LU1A.^R!/`'H$;MAB@&XMZT1M`SH`'F*KB=I_@X`
MR#"M2J`G<;;1`X!U\B`"2C]P$9%O28WCR3!X(;RK^8NZ>9#)J9O@D)UX(0B\
M>*^RD9.R8PJ7Z@FG,+P+*9J@T!;-X29(@KY@J@`$X#D@P0P7J:@"BY8/L#N$
MN``SBI(--!MRB1@OHRB%2(IM8XJK",)BZ9@#B"16<JP8<2`$<,1%*2XD8Z+H
MNIL:6H#X&)`,<,0*@P#:V0`SZA)YF8#WX9(/2+CHJ@"Z.#<#2*$*H">]21^_
M6IAO&1T(P`"_XI$',``4W":=:#7.FXPW<\3YZJVM>9F#>+.QD)LC^P`;_#=L
M@0`-0"\&Z$!CW`#@ZPH-Z#M282Z=61+MTIEU_F(1,?2(A:N;_4E$(!0M=R.(
MJ_&.+0$H!QE'DX&*?1LY!IN1`JL`=1R*6R,\QX"7:6NF>Q,*!9`:"TL6+:H8
MW+BW#7"`O2E%C;D)FU$(-5(("2@`F4NTE?@UA:"`>&.G_XHJL2B+@C*:)"NP
MG7C##'K#=\*H`H,*=HFCKU(;33H,%L$UG2`98PP[XFM)W^DB>9NN1BN;>Z-&
MR\LP;4F5E2"(U-$+/W*LLIBGI]`6G0$@.;,P]$I%U2F<!:,->8(@!8`U)6F_
M@J#":<F+#T@=&]-#SV$E`?DQN]B2542(F'P(>%%(9VJ<K0B79M28#E``@B(H
MS+D6P5@GJ:*F_-`8_A9QQQ>Y&@"R`%RAC:T<R9B#H.I8C,T0@`>`$`$`J-2*
M,,30#^^00&=+".-QP*YPE`Q0J*JX`(*B"`XHGBZLG@^```9(B4B+@'["C:(H
MR(8HE1/3%L(SJK)IH=%H%H(HF^#0EGM3FPQ+G:@TQJZQ.<K1%Q&\#QE1FU]Y
MGCO;RP#`LNR(ER2LJ30ZL=\R"&_)"=FQL`XD#P!P`,`)"7X<G-`LMZ-$,K[<
M"9_L3*;(0Z&`%[EL)B4!T`P*#<*LEN-```5(@#2)L/9:@'BZT(GZ%;73`-E:
MQ"B9%1:!&@E@$QS3#PYX@`)P`/23@-K<S.[['='P(PY1"DC*$@U(0[$X_IN`
M9)+`2![4^``!N`";0XB$HX`*T),/*`P'\$TX"8`%L#T::P"T&8[HH0`)`)T)
M`@Q(\Q8`J#6&D#T'M3P;^PK'TZ(M$1!YXA8:H\Z?7)D2,4_MHT&RN$25T)LV
MDB;R1(BK05"0**?2:(@M:1C,0)G[B!&`@A4..-"Q`P`T(DH]=)!_"9:ZB(`Y
MY(DV0E""4+Z>&+Z_;";"V8HD$M-DV9"_>46FN``=E+`6B@F-H9'`Q(T)70MW
M5`^D*:K9`A.=.`!E*J+Q<L3[$%."2@BT-!MQ&:W+@<<SF4#56*X*R`IY*<DV
MF48+"*D&4`KMNLPIRPH@<PC`<:*XX4*:XY5I_L,+5SM5L&C4/E(`'9,G`8@`
M"?,:BE"J-O4D#;J:1`E28PR,CI$K#KB)7%&;E\E+G=/368NX@D@=I1BS"5)3
M99/!J93&@E"`EZ@;VN&8]FL*BH,2#[!/NQ!0A%"8I8`7UG2FD`T*Z0*<H$&H
M/54@)Z&G4IS2B$'(<7JJX%"\92VP&^2DB#2)]`&`#9"U8!I6J("6ER"[@RBZ
M@S"?M;&PPY18JYK&J_'#ZMBV=@F8G'J>JF`EXH@`VF%(Q@B)@,E4I?68;2D;
MAV2(4HP8":@@:AL+\,J\*[D2TY'`C#N6=AP(8G4L-R$(TE"G6VL)2.2\U,F5
MO*S4@CV2&#D`>1DJ_BQIPLE,"'DZE)-XV/N0LZQ*F8H;1]IQDL'##6D*N_[0
M5-A:BHP-UR,1R)\8OIG%(P04BI-(6:`Q,*0=+_6`&>5P@,XTV62Y&,")`)+)
MD@Y`B;X:R?%``![+C*!UB!RM`$'#CT2AK+;8RUCYL8@YTH'`B^=!EZ.9BXC!
M7CM!BP6P5@$)VD]B"GHYFV#4P[$M,#`+@`JX`(;L-RV5-]_)49K+#H4*BPXX
MS<&HCNX(R$>AGH-HKT(!+&%-*(V0S8J,`#DIK+I="=+<3S9,B),@D9$HU(T@
M#?J*8*A`+X6\-1Z9E?#3FK6A"P/HGO:8@*M:R!@"H4WEB>$CW00EV9]H_@J0
M")H-R%3P:48+<#XPXB#G4Y9&^A`6EA\WPH!ULAJ&)`AS(8[>B8O4&)T@PQ2I
M2F*W*K??F17C.P`FB8``L(GW78V\`0D,D$5[XB1K*X`4B4.@"Y<"4SNT\<BN
MX1;^K."<P;JI)!/):@B@M3^&L%0O`I51\=X^#BVM:0!QH<@2BYNZD(`/+(B+
M<3"QN`K:(#%,$H!H<A"I`XIV0S\+H-^'N(D9SB4/J%R@X%@RRN%,_9"24)1'
ML;:/VA0JX0`*@+:$V)#G-`F1^";V`]!V!6-'%.8#(+%AIB='=#&F>@W\X,.#
M09@.2&*Q4"7V`(^D$CI"T@`:2H^J((^]^+9#_L6.QBD*M%6(5:F``&`(<E::
MJ5V.3EL<+]DO49FYAG`*(,V.%^6)G&'?.S+,K;B_4446U_@;JQM@Y@$OVN@:
M=Z8.X2V`&D8R;$O=")"^@KBU+V4O3^*([7B`%88_!UP/U3.W`0PU7<(43'D8
MSY*+J<HTBL`T^#A7H=`C?"T(MT2_A=B`-\I#YD&+"D@S)$%A-MF;5`RUJ&(Y
MA7BD0S8:;*PZTR&A#TTP8FQ4BPSE.5K+DB7EGK`:ULCA6E,HM;B2;6MH]9GI
MJQZ2!#**F;X;B]!EYO(?M.4BA=;#O10)YLF*"#"`-'..H6"R3&[HAC9/Y&AH
M7EIC`_B7OG[?+T++_EB:#)VI:87`@.8A`"_!"[UQUK88/L>*Y8J(X-284EP!
M-'NY#RC-";YPHJ$L4/;3&?-JB`EP`-CIPD6[/]M;+K%XC0Q0/0-1D,1(Q:EN
M&F&I#=YF"%@1-@S1P<EXVPQ`[OW"#02#ZV1*79XPY1++X52)CX!K41[C@%(!
M9==`[NY6-+(6DN-HO_GY#'\M,`I0J)=6IPN01*=&"$]54K3(GAP#+$_UH6$K
MH`(ADP<($2+*CN*$20HHE-02;SX^H?NX`+90B0I35(,XC0J`C7J!0772F:R1
M)["I`"3%G@RA*Z;`..\9C1R9@+NRSU2M@"]^D,7Z%F)QO-)H`&MMU*ZX_C6S
M`;Z(-5UVYAUAW)_92Q.0V.=\KNKT*]O%D+-(RB''VEJ_NC\$D;,FIR<BES,'
MD!L*V(XJ#Q0)V(X'VPX+F#_WJ`"GP/$Z<@#7U9BR&6RX<41>ZJUD3)%(BF"/
M@=Q-,>M=':I_3+3&2`J2(&<,8,"5<.^#.*P+*)C@4!L($%ZD_?.'\!&3`"1]
MB8C(CI,6\CZ?.)[#SBZ,:VS$.`!O$8L:>C.Z,,D/Z)BWTN6M],\1$9#,30GD
M$(S*:):NL1?78$*#\+&BB@L8DLNS'A=X/)X+0&D1>93A6(G[Q:!_)8B;:(`G
M6X"1YHE>&5NDRB\(:`D)\+**JB;/0I\)@`\&_J!$2K2)#U0`.['VBNIVFS#W
M<D=W)H(;QYHNKWO=OPZ:^]E+KCAD$L20\LB-'Z=#2#R;%G(2!JQ(7"86+@)0
M4GYL\*J.>.EG@["HH9`M<<&B6.F`"5"4`CD^>])WF_88=MY&Y.E6M.`\A.I`
MAZ;*@Q@FIHDDO`C;A)=+.\N5HOB+R[8,L1!=1@7O"I8GTEAYF"%=PD&+XRDL
MNBL*=,ZE?]&QE:F+K%J*F\AXV64*E)2+X1M0GMB:40>:#0"F"(@0]AX3++4N
M]RE,5IJ)O1D1.P?93BJ(HF@1G8!O14/!72J,%SJ(!J@AH?@/D(6@'XF`-",,
M&S8YZ#N)87R(@6":_N-PZ!CYG=3Y"Y50"GJ$6`]#00*XKK77PP1`+XHE2A91
M#@K`D2E-<87(&9_$%L^KS0MH`%\2B>.QO=GCJ["`%W/,]-8Y"0-P%-X\PI>,
M"J;W*+D*"AB1B1S^-0TP(AK!)^%/H>$(>_^D]093B%ZY$^QH.+AN>^40?IGK
MKM]I@`5U;(3,@(SAR-R4-P#O8X\A0_9#OT:R%`NX*.B4C,+_S%N>QT>-_[_`
M"S`I"O51*M*UT\GW'KPJ08!0``%`@P\?#`!@\$$#A`D3$`#08'#B1`X"!FQ(
M`."!00X%`"08(`````<&'9!,H#+DA8D-%'S``)(BS9HV;^+,J;.F!P,%_B92
M`"#2P``*.X\F$,#Q*-.F3I]"G;@!0``(4:\>W2"A)H8%'A!\X*!`X06%%#L8
MP*K69@<"&VE6*."@04&:$QQX\%#S`<D.3!,@D%`A@X8.%RH@KH`!,07$#19`
MJ&#`PEH,)N$>,#A!0`:#"RA39/AT@]L$.SL,(-F9I@*2`4@2""";*@`#L2.D
MY*#7(&[3%%L;_;``@((!"D:V#`ISHH22'SX&1P#S*^WES9=/'-C2)E_:?6,"
M`.NA0P,`F3\P`.!WXFX-$EX[&`X@^-KZ3E$O_9`!``0*#1R`MA9$^=E7H(%.
M326`50>NI1577A7@`0<16'4!6!1Q,`"#6+7U_I9!&$!P``8?3.";01XP8$`$
MN]'T`$+K[83``0L8\-IK("D0``$*+*``CSXN,-)6:G554P<3?-!A`!S$Q"1%
M&2S85',$!(@3!R1%Q!,%3.KE00:(3?!8!1IP@!H`$:RGUU0'L-A<A."!!8$&
M!_#W`6Z7?>"!1EM]-&(%!Q``P0,78%F73!A-U(%&45+D06L*4`#!:T95`,!/
M$Q60%HD`L$B33`8X$,%(C&Y8J@<%"*``D^6MAL%V`@(P9*FSSGK!`AG41>MH
M(]*T@5<&3+"`!`R()6M'!.AZGUM+>0`!GF%^&"1]C6;PWG=(5>3DB10HL,%-
M"JR&E01*T=7`!!1,_K"!!AMT(&$'%'1`V)$89*!`E4?E&*Y.=%Y:$P2\VO19
M1Z\)H));3+9V@`10CHJ!6.%-U%H"CIJ'[@1T7O91!)L",%@'=-9I$$(*7.#>
M1R'3U(&.$^'&T97]/B<`D^EU^IN)O27+H(0%Z.A7:JU*M)8'J=V;L]%11<!`
M!A<>O=,&TW9$V09T<8!K`S5GV+1.%EEJ@<(I+X!!`PA0`#!-$#2``0%NP9@N
M3IK>9`$"VM+4`-U1=6#!70^$^@`#?P,>>.`-,!"!V3IYT$``4%L)6\T&5?"J
M5`]0<`!H'02^P-]..B"`YP$,4$%8%FP^409_9X"JYZO7=6K''U@`L4%F_IH5
M%@,"W)CJ`8PG3A!S``BPF.PBOPX18,<G@.0$OG](E>A:JW7!!JD-X%=ZO$I?
MWY4`Z`N]]SD)JL'SW]LT9X\0C+5``Q(LS`$%[,,/__O%D5\3!P9`1"76`!#`
M.&_C<R!=2V(*W&R2@0$$K29IN\GCZD<1B.!I)ZZ#6:^\]1L,O&8Y'>"5!\9'
M$R\ACBD;N,!N2D:1#1S.(!FX0`H;11<8?4`":=.`!38V.PID[P$7&8!(>&@Y
M&>'E1!`H0.T,LH&BZ:0#'-`-##]XMZBX3F8?@`AH)M#`IVRO>PYTH+THD,`M
M:@8!<QFCCQI`@`$0@(AH+``"$K"``1B@`0)@_MH6.8`!#2#@<1Q@`'9HLC0'
MP"B`'QC`$V]20)O\YR8-^")%]`9&/Y*DA3>IW-IP$I=.)0"#<X3<`;PE@11*
M8`,<,)8!']D4#UC02KO131(9Z30'.(`!$A"-8.BS`23A1`*%9`]=;.2G"S`)
M`Y^L3P=&HD530@]<%$CE(PN3$PVXDB(R-.4B->>OXY!2/PI``#,_L($5#>"8
M-J%@HSQ``1MRY8KM0N9)$N(4!70``LAB8`%PJ1F-7(X^ZZ2),YO(SIUH0)+_
MC,HNV8,!"HSDD+.S3P=4,]#O(:`"$_!@J3!`()TLH)NA4<`!_`F47&W1`1M`
M`($JX`"K($!R[HNH_C^_%#N/VL2>-8G``A(@S@4\]"89","M3ME)""B4(A?H
M(P<(Y9<)%32G4=&`_Y2Z(0@DE"WVR:)3FV8O]N4LJ30))4[D]`"0;C6"7/3`
M`VQX@02(R#-!>Q<!T'03#!Q4`##U5P8>8`$R98!)&XS`!3+@U\YL(*\9J2I%
M;C=7ML2IJ1-)P/@28``#=&8"!=`H82O[3]<%-9I0N5(`-&M9`UU5L=^;0$$I
ML``"7%2:2/P>`SK@`+\F@`!VF\@$6G(!-")QCV@EV&$I8@`!N`5XP#LCEHI+
M@)%\3JO()``=CV+.#PAD:P9X(HBN^-GK.I`#KPDJ93?+/^S2RBNU92<$_@KJ
M@<ZALR98?:0$!@`Z`DB@B3SZP`,FX-$,3"`"&Z@4<9H"@0[$2P(1,!P'*B#*
M#1R8`P@N\`7>1-C]R/0O[A6K30!4DPEX%KP:UMI4W/E!"A/TNQMFD+W&B\SR
MXL0#$DA`01MBRN80IY`'`"M-:.HD,X'X)J2JL6=%RTXY]M8F$/%03CJPHM#D
M>,1*SEE0/.S'J5*ENTN&B@(P8&)3DA8G'1A+3E1E2MP$0*,66$``CDDZ5E+$
M+<W%209$ZP#-;MFRF6)*M2:"$B+G)&PG%.>4^[PAW*",/7QVRI7FZ6>UX/3*
MCXR`&Q?@Z$<_(#'_>8RY(B"!1Q=`N4>CJC0)_C"!H&;@`-VJR1G7?!.3YL0"
MDCN+B:I:`!JG^'=X3C&+,B#E0^.Z/DW>L8$*G6NL;-,`J]YB!*33H__`4@$$
M0$@!>M2C`K@12.2L'XS#Q0$9Z478&)H,3MR2S9M,*"<,:&J<";L!`:172B1)
M[4WX"#OG_#K>!0I*1&U"T:M,I<SR?HJE`S!L!P(R)WD!W[^_UYSJ+00!J)W(
M`5KB@;(TO'SQ(LFW;7+09_(9IX25R:!QDAX/J:O(Z9+.ODNNEMBM]MX$!5V0
M3>X9UQ:<?!"P[@=@F1/*&:@#*F=*!61C40)4H%,(L``%#*"TFUP`Z/N!]TXX
M<+4K+I$]C>+U0/>3_FZF#)E7$B``S3$XV<IDV.7@G4J$*S)5-(H=7R2)^?=8
MG!,))/D#$&`[%LO>E.7QKX@308"._.>E,(V(`\MJBJ4&@(##(UX!$GB`!!#/
MQL,W``*FKOJ9HC+D!MB5*4<_9;LZI<2T^SEVXJ3Z:$0,>IPHNP!TAQZQ<L*!
MN%?9E%P[)EIV?FT$4H1.?=2)JRXPZ4F/\5\7@(`$+C`!N#=@YY=MH^5=(P`V
M=<2ZHDE47A!\Q`$S29YH3$#<3Z_AYCA@]5B)G:&]7Y,%Q%/\3>-F3C80=P0(
M%'JXD2*&*,``?]NO1!5HHEN@;_Y)$L"MW<20#1V]5$`$#,`!1$`&6,!)_D%`
M!%A`8#T`\6D`KD2`!H2$`%Q:P%5-!!P``]B=E80=H?W?@<3.3,P*^95@31P`
MG:C?T;B=E<1=`[Q@LDQ)IS38S*F>I\"736@%`AA`R[D<@CW'Y.7$D#E?<0V7
M$C(AEGS.1?`4!`@*`C#``,0?6]2@3OC8"C:%3`"`QI7*?DS;_Y$,`V1ALBQ`
M4G5`ABT0&'W%1X"&W-B70:141YQ5`:S6794(%U($VL1$`,#:$9+$2%#`G6$)
M7G1'$Q87`X@2C!47R)PA'_Z31@0:@S1'JW&A`,B=`"83`\#2V"`;+(GB*)+B
M`03`%1Z-!W14.`F'4K"(`NB%!3#7?VD)0D")_A%Z'XCDR7#XWU%\W&M(`-YA
MR59@D!+^BQ*"RL,4U^)82@A*HF5I`$GPVFH]Q24*39]A0.$$57:=U`',Q:4=
M@(R(8SB2XSB>%,TUC9Y<207\#2,QU@)8CDUX@`:,C05`"EJAH_FAB.%Q(AT^
MHHQ@R0"A1T!*@`&T1G$1T98IX0'L1P!<W3-^%G_Q6L<QA37Z$>&(A`)@Y``4
M``_MD.?T$!H13@,DP$@R@$FB9!Q=0,FLD*I=@*I90']`@`7XDVYTAAVI6LNM
MH0;LQ@8D#D1NR`0P(O=XE*B1$`.-FU[,#5T`9<H@@`#0H$TLT6I8P$A$4EXL
M$0>49($5CL)9"O`P_@`2^L8&G`QLM$9G-25X16,E)HG>785%-DJ\`--=1(!#
MV*5#M.267,`&V24#)`^C^64"^"7AE(A*?,2-,*$!J`3NC`7@)$``(!=B!L!8
MG!3@2&$#&(#?N%=X_(D;E5]:KD683$]+;5T^LDP'D`UH3@2AI(3@/.;*=``1
M*29(=(J>&(>3<`WW?`"WK,L`X)(Y04!JD$P"%$#%J>9#==B.=9!]P&6!:-H'
M(2$3VI`A*B(`6$!>>(!\5&<X5=]!`L]QU@>N;$`0T@0#P)<F-L4#O,9SNMS^
MH0>+>(`]6B43%@3Q64#DX0ZCA!^5+$2)8`E-8<!N;)VW:$!\M$7XY0EX_EK6
MG?':"!Y%<T8-!5#`7?T581R4A&*HA$[`H!"&7P56!79HB)+)>%A``:213Y@H
MJJ21=&RF(H+.N$GHQU5GJO2'!(",I2BH6A03_B0*!I1D6S8*?5V1!:0&>YK<
MFTW1X^C%EY1)@NK%!%!&F+Q6<>)7`A#C9)3E(PY`72#@`RR&M\0.V3P`%6:H
MA"H`!%8`T35&7U4@!BS@8RC`!/@5O?A5!88)Y=B?CT!IAE+HA'[)HT5`F0Q<
MYU4@B+998^B&A`P<*RG8H:X03PY<I'9)U72H3R;HI>:)7I1)YTE0EYAFW`PB
M/#4**AX%7V#B0ES:5PG``B``J_K$`E1`I"V>_G\XF@$<`.[(!NCH"'%NDXGF
M*E5$0))1@#C=3T\FQ@4\@)[IAQ&1C/@H1H&]ATCD*(>0A'B4:`-8$.8($:)(
MI02<C)&6'"UVU%-H``%08O7LU!<VBO'@*@&0&4G41;T`P*MT6'7:*Q.FSKT6
MUWWJ*_"L1W0J(GPAQGQ6)T]!AG;:ZXRPZB`F8*8H@*TN8VQ,9@(H`,5:;,5N
MDVO(1GR-AQ1B0+M40"'"'<;R9)XTF;]2!+TP)PJ2#P5`!`8`"^KMTE`]#FIF
MDP:XY0?0R7E,:U1,"7I@:Z.\F0-XHT=A#J3(![CNVX(@@!`FBG%]!0-T9&V&
MC4)\;`Q9CFZ4J`7H_M!J("Q52"9BZNN-]FN*]&MXR%!JW&ORZ$V6*F+U`-C)
MVFL&Y$6'W.ME]$2_UH4CWBNP0(1BEB4!I)#3WAS+?H^%S*L&&$!\V81IP13A
MN!(>-5%VIB%KF%[/WL=(?"9[S%'$V40$%(`-#00`**V\69#2J@R6I(5>+2Y[
MG!4KJAH=,J(!K-4#+,?)HEL&&`8+<4!`C9OQ?14(1EY=OJ0#X)`,G:1)3FA_
M-,#[1$ZH2.'Q08`GKN2`T84L)>]).MI($HX!T`@<`5<;]=`.V:I(4$5(7D3Z
MDN](9`ID@JW&FJ]L&-[AB6UU%F?CG6UQ4J(2$L#D;B%2&*[WX)W#S1=/_M14
M`R4.`;B2W'23HW@%193'J6*N!"&$!*.2!$N%LGK311"NV%G14[@.2<`B>TP&
MWR!`0P!7<9@'H)#$D4T$`_Q7(GJ1]WD`!G07W6P0"P'3,@74F'C+!D%3`_Y'
M!?P'VLS%?_C'[QTQT<H6&A7'&4$Q&FVI'.$.[O`02*%9?6@$!A\-C&V'!]R%
M/$[`"#=N#++'!#CD!VDD16@$STYP4[QL35R`]^;L8I2/>8!FTX(PV4X7>R#`
M`#S`?B&@YY3$?*+1%ZF,VF))`3CH<3Y7.L[.@3%`@3*+#@V=?9BJ`WDQ1>27
MDBX`NQF$&8F9`$"-H[S*2(#A&V,=`!P.38F2_MYQ0'#RV@9,)F@&HL`I\D4L
M"`?`*OZT*O\$%AXNC!RY!L"@D`,,@'8ZF"IW!!FO!078U%I<&Y;\[T[@3/VD
MAT">"$?I$0*$("]G&E<<`"/-,6B(,#/#\;S.SJ<MA;:>B+?2(D^@,2`/Q@=]
MTP-0SF[8V@?YU6#XU6%U0&`I*3_[51;KRL"!L")?8/^$B,,L#^/-AV:0KD$D
M@.3QSZI%SB`V,CH_A=JR$881&L.0A.;THS4',/0TV:JI6!!]$`AZU'F%LUW,
M#69X"TFX,4<S4&IPQ`:,Q5'FB54X71M15K/P74#R3ZLJ&W/9ZF.MC5L`5U.O
M#0\MVP%(]=K0\7\`_H9M$,`!F"A4[XBC[<@9'8"M-K5!IE&HS(6MR@@$+(`#
MB%%\G!1<610L!6M$R36(0`H*!=9=NPI?WQ$>_>=Y68H=S8@&O-%\@+5/!!UP
MY2T!Z,N?8`DHX_158%"-..%93X`-*UB3GH@=#9F.P)-Q/L5`Y&S3#+!-2*$\
M)NL55<#,79@5\I,&VK36%!70=$0TY7!?7Y?K]$@=-HI@^N85I4V``MK;JFQ8
M?&UQ"<!>!LWH-J&*_`<&$.F]ZEN>!%<3*D5A!'3]*O=*+M,(N2CPE)6E,5H3
MS@:6N.MF#L!KG4BEU&$#Q,L`#$0`Q-%^7<0,R6@`B/9D8U'@24#1'9=R_D/F
M1<@645CEEEKJ@:1':1_-Z((+3W"9_;C1%;4J(G&=753K32?+4UIG!,@&@.#.
ML*E9^N:196W/9/F3!Q#`)`O<;E0`_*S/'S=`L1T>Q?Z6&!$?J[811U$/^9YP
ML:T-X@'AYPB%+PLY`I0E&Q$X5P\9P7XA`]AN8AI7JH0)WS9A`]20JLEH=;HK
MDEM:#WJ3&;W.!\P6YM0&.O$%KBJW7[%0DKAD4["+TV0`7/FTZW:PRZ'2V!PY
MDJ/WX1F'V6RT3HQ+CD%I3?B5D3``J>Y%>"!@BC,E3Q2.3G&&D<3CV<#WYM**
M!L"B_06/7U6%L/3*`_A%**%%28,1:BB%3<A-_BH_"1<'*3]=K98!V*S79FT"
M6&$@]`=U`-Q]+(!U29*TRZSSY89*P']M:K#O.KFHA`S5%NGXI4:"X`,8IFNH
MQ!@%(^E8);,<BZV=B^#YIMSY108@Q+2@B*@#V-*]+_`@YNKPT'$\X>K@Z@?^
MUKNOSGFKNP"HCHW4.[Q3(>",A:!`^>UP]45`J048_,&3S@0B?&9+1-7@,(`A
M/)_EU8E8@$%OR-]1P&Y0"!W=^4UH!(51P(W4SL>X!EYX`&32"8,7K@!D!*MO
M\U"W]5OY]EG(-USPU3:6R@48Q7[PK$D\CJ_HA:5=`/W15G`<]R,U0`8$:TWP
MT=_8C^WB=LRYE@$H_GI3#)JW^`E^-=*MT5!,Q+G982I=\0U/^*1UP=@X]TH`
M.`!NTHF-O`8/X9]O74V>D(05&0:P!&B[,-6YH`2DE,P=S2,>[<BY$#Z\W$\`
M)/IXY$6:JN+N8"6;HI)_C#'&6JGZO,:,X0^ZT)0B/FP!G`SNI+O$YJIL6/$?
MC_[I@ZUED_X`--JC.9HIGCZ/@+7\!@#%RK[KEU6D(888?=%^,\7)6^=>^%5Y
M&$5L6F<&N`5E:(3@EBY*:**>C"M-7!M.),!JD:4_D>6T8!`&:#BM#)\V84?W
M>Y.[;D"(5!Y%G*SF?'(5;F:F/):)]G'.#`I-500\=L:18(@$*,#.)=U#_L8$
M0"2HX.%#08,?)ASH<-"@!P<++#`L6&'!!0X2/V1(0*&@A8@&*6BP<%&B!P@*
M,68PT$`#QHP3/BS`@"#"P0T-,&S`6"$!!`\3*"`X$*#F!PX)*A)@T/`"`P``
M%$RX>('`PI\/-C"H\*$"`@81-#A`0%+B`Y\$&5)(<&&AQ`T)'+1EN,$`1XP>
MBF+$`)'LP0L-/A`47-!#!@P5.`Q&:W*`!*N!(1_&F2&#A@PD-S@X4"%#APV5
M06<XH(`"!LN5-6R@"Y6"!9$8*%^H(,!`!<L6*%1H36&"@`EH._9U.=Q@AZ<8
M)$(HN&'`4@P"!%QL`,"!!P,`[!)W>9-"@((=_A8\P`A!/$8-!'3N3`#<X$FY
M%1PP**^=?OT/&Q9P:/````8*%P#8H((-V./`+N4@6.H@!Y[*2SL/QK)/0I<F
MF"""`2ZCH`,+T.I`N?L6**`!X0H*:H&6)-)H`?:6N^`#V#"B@`#`2I(``>0D
MFNF`]#YH[3L,<G(I`P0J<@G&NR(HP$6("#C`H`L"F(\A"'(C:P(@!8#`,@<(
M(^"C@C`@@$4)&)"``)(X,&""!(T:`":,)+``1X8N4``!N1AR@``4&<(@@AM+
MDI%+C#IHP``\GV1`2_,H`&L[-C'*ZDR7NLI.(@X6L/0@"PI`Z5())ACH`A:'
M1,``B20@<<+OCI-(_JX'`M"`OT$W($`Y`P+(X"`)MJJO`K`":,N#!-X\R`,%
M/I2H`O3N,B`!/MM3D*OKI%S5V@\.&&"`K``(@*<!"!B@`+(V>'-$#7RS]`(.
M)5SQ6FMYA<"!"0S8\Z`,1I)`1!:_>^"`.>DD("Y7"2B6H0X.B/!2`^YT=8(-
M`'Z1I`5HE`BW#=AEZ$KB/)#``9+D*Z`F#2!H0%>&/#BV.H8LT%4#D?LL0">*
M)$@@`O8\(```:3^P0```%D"```DPLN`!`Z#]3@(!'E#U@@/R*PD"`?XMZ0$$
M,F8H@P$60-0@!R`@T21;AX.@@(\#+4`"?@-KH`"V[W,[XH*..N!DE)\S_N#D
MNS/:(,X*%#@XZ7>-ZR]%M!08H`,$`DB`[@``<\K!A^PSF@(!#N)@@`80/8KO
M@Y;ED:$&!F!/MP,>(*B"IQ9X]]T-+DA/`Y)*MF!@PH33(`*>K4W@<]>U:QWJ
M"T;5N-Z&8YS1ZP\ZB.\NTK_,O`.2^>U8R9(XX$`!$E4]J(,+!SWX@4DQXJ`#
M@WNV@($%>JO6H`6(CG$!!1IH0("(!=U>/P(0D&#=#C@0@08$0'0<*,!:!I>!
M!XB(1%`Z@*H\0`'41<H`J=/+!596$@ML8'"!X<Q=+#"!!D2O.`Z@0+*,A8$"
M%*!7*#/3VLKG+PNBC`,'<%">F@2!B/V$`#CB_D"U'.`=X+'*<*-;R`0`L)5:
M%:`#QP)`V!```!?U+0("6%Z*)("!`<S%`9R;"P-(^*0%B&Y7#6#1!A``F-7M
M;(AM=..J$A#&-S+D`0L0P!11%I_E=6P!)RI)!"9@,T29A'V$XH`#XG<PL$6`
MC/?)P`T),X$.%L0R%?(:?L!HO@8@0(D0"-H`H/8`R^SN60P;#04$,R`-8.`!
M#4"?!U3#@*ALH'D#P`P%5/(47>XR`'8+S/S0TH#,"(!/%=B0`Q30-+<8JG@,
MX0`$Z-=(#3!@`"T$G0*BUA$&8,`D!V!`#Z6F@%;=2P%UB50Y-640#31`ATBR
MX=QZ9B=42JT`".B@_@7"HQ/5W.V1%EA4CP80``C$[HB\(]PX#X*`-`)``#KQ
M@%,(4```&"`Q`Y!B06#5K2M*Q)5.D@A2)/(R2!9D`@60XP<4D``2'0`"$'@*
M^N884YFZ4J8ND0``"("1)#443LX24@(8P#8,K$15G$KG?<QVNWLE@(EZ,14$
M-6``%&8.6811`/T4MX``-&D#9QM`_P*@)XG^B0`"_8!+&2J```043QAX2ND.
M`H%#Y:8E$=CE'6>"G<P-@)$=R(`'IG.J@F2`FC`-C`4$$JEOWLQ5<MU@BBZP
M,9M\$P%JTX`"(O8R`#B$`7BZW'I*4H$#6.0N#E`;H1+0DT:^B&'=VX#G_E(B
M`04LY$]\NX``PD?)>A'@9P2X0`*VV,;"S4U69A$=*Q_@F.7\59T)0("$$M"M
M1G8@F2$];8RV5;YZ`<<"GBGK4PQ:4_$"#RCCU1@`X%J<!F!6`4DC9`<9DTUC
M0:!@_#(,2R(E@!'M)$M>.Z0!NENT`KCK4B?YDG46DIH"I`8!#C'*OW(%8**,
M"P,,R`!Z#\";]0Q@BDV)(GI9Y`!0]BJ`3NF6;4R"O(+<%`!O<LIS>S8`9;KE
M`,\J20.4`D^JC,15571?VP(@``1``%$5(%T%`H"S+!8`GAH($3P_X&1/S67(
MJNH``P008%<IX(Z$JF(+W1:`SG[`?B>E&[ZB_AO<(0Y7IA@(@&$QHK,G$@H!
M[GL9E$7+MBN;<3D$61QXS4LI;_K5`QCH0(4G@"A:&F4A%##0`ZPYH0G\N*8;
M>,K=+E#!A6SS(#-A[*6^`D%9AO&']H+3:`D%@3BZ!`&^,X\$(L!<MQA`OH%9
MBE0D4!Y;?K75%)BH`'Q]H864<RP>F\#F[NBA++%X9RCRT-4PFT(Y`Z``_&EP
M8&X3UH*D^9F;89L%E,(O?$9`56_9"$9^:QN7<(`F&8#`Y@S"@9I9X+D8(@Q%
M"N;?D\QP+A$@P*=M,K[YM/!\!#`GNE&G*M$TIB'(R4`!`,R!1GI`55QS(YMC
MZM:18B3-!U!J0[["_B(GS]-B!#Y8II0%Z$`GIP)2Q4YC`D"!"C($F++]0`)4
MV/)(VV>=*R_14[`&.`?,291&>0!0LV80Q%:M).MK9G%*1H'51B`"&!#;!!00
M`:]5N(EZ0>;.)Y*!"LR-`[[9P'\.T))QU1@`!]#738-M2_`<`#"\"0K$Q8*8
MP%SG*4IJP`4T=$@F]PD!OGX*_0P`-IQ8X`(+_L"'"\"`P=$EBX.SP%7A^4-.
M\DM`"OC=!R)0U;-_IW4\@4[JJE*D<MT(EFY1P$F)]Y7I;E("@]L0:0R]3`0,
M72](,:;W="BOA+R>(:)UG$0H$#CA(O2-`#(S0\1IX0%,E3`F#:E27()-_K;1
M!8\34;G/H8_D`6K`.P)D".,ZL+K0.X!+%#@J?3I`Z3:#&`(/FY*[U:0J\U5`
MRVFI(+\TH"<^#XWNAU#J1U48X'I<HG[8A@,TH`.Z[TFN(\@*(`,"8`%.@@-R
M10`8@`*82&8(H`*T10`J(@`N@"8BP+EV!H\Z(``8ZK)VACU4[3LF0#:"[*T(
M1*)<AB,88#VN@UE""I'8I@+&Q4@J(+R.1?F4A0*PHOY:;954S=^$J>NVI:$>
M(#HH!6X*XIL2R7L>8`"V)R5,!9XVP%\X#2/T1+DD0FC\ARV^,&P^`/"RAVV:
MX^*8+][^!]VTT*T^#R.F8RDXP%:\9DB\1@,R_HQ?KBR#Z*B(O(^-P,][2D,`
M=&8#O$,"6B?>[.@"<BT``D`!"J!'*F95NM"\"D<\&ND"_NJ*-D``1C'>&":,
M:JD/#\MK`,M+=F)'-FHX1H)*U&.#.*`"$HUYH,DSM@("-:`ES$A)G,N>0,^;
MGBE*&@9'"H<$[:0J1H=^#F"7+,J8'FJ!$J`M,B`S+`H`0A%,4@IN&.;SE$V.
M-(!(5*4[/F)9[J>*<,H#$,5?&,KSS$/$].P!'L*USJVQM"U&TFBU?L)HEN>'
M%.<Y&$J7(D]FB&/Z[)`1XVVM&F.*\.7F&`KL7J3%[&,!'/&VRA&C<JLA#D".
MAB6H=,K>&C&\5J[V_F8"B;KCAXYOL%P0F^"#*`+GA-[E$E=.`W!J`PZ`!!V`
MQ\Z*(PDC%Z_HF7)Q.#B@_[1FM>A#**4R)I"2.!"#IU"&I.#)`PI@`.XG981&
M+AQB.G;I4`(@3CS`13H@`92P,]`%O1@B+&#H8!I`I=9M<[I'3OB%W<;(6-KB
M&-DF@B:@#R_K`6BQ_GS")9+DB@QQ`0:B),JI*H="CMI2S,JC`S13,UE,_K[C
MC5JP`%'F`%(&6Y"C)RS`;A!`"5%F`*!,(J(OWK#FQBCJ^L"N+.^B9M!BC5QR
MO,`#:!C@3@Q`G("K"[?I+7(JJEI.KB)00DIRO``D`)Z#I=:'?UPP2EH*_B@:
MI:6XLZ6H;@(D($%XI0+(<^S(<P+*A#S'<SG,8NQ<!#/(I/X6HNM^40)X15>(
MISS+I852PR`P0`+8J4K<@@PCX"$60"P4JH\4=`!PY0#`LSOCHRIS!KV$Y6HH
MXR#X3I=<\-**PRM:(O=<JB8':WE(1D/030)D#65P:3CP10O?90)X3R^\R*:J
M8S"U@N1&1S[+QP$TH#0E8G=&)0-:,34@,`%P8CA@="+A*00+@B9RA@+V@RL`
M8-T$0!89(AMSQ21'BGXB)2U1*[M^]-K6R#/%RP,N!H_^0OZ`XR<4H!4/X@&'
MPX]6#HFLB`&X)`-J5(O"2C?69ZT4@`"PZ:KF_H?+AG,!=*83NT67W#)0`W5#
M-311KQ,`5C,!(G67#F#:'/51=VE3GT)G5G,<=6G:`#5#\S$`TH@"9.MGD"E1
M^^[=^JX#F;`!J.ZJLO$IJ,31/.!H`"`"W$_JXB.Z-E4F;(,#5,**2C.Z"H\"
M0@0H=*,U8(DW]$OJ>K57%2`MN4GB8*-7#Q56_\,#*()7<V-:H?4KI*[0",/=
MFD@P@*-YJ"^2CD1(7&(QC"0!JC(HH,P#-(#D.B!^DD27BL4"!@`O[T))K^]D
M](0!3%`!N`3<J+0W\X2A#H9A6&18VA4#N!0C&&!'7`5J0._['O$1[7$X'N`U
MYX@_<DHH*,!.T>("_M*K,X9#)[HG`!UM._B/4O:2/#N-;Q[+*,A3WD+0ZB[B
M(@3$R#*E/(WV5R#M:,D3)-7&62;P`EWP4'D"*1;``+X*I^`'6+N%$Y_"5+%V
M??J(OD*UCP[U.H>R:QV5$PE`0154HM"6$^$V;H.F;+>6$W%%0[FV;N,V;[>J
M;[EV-'Z&4Z%"*#SU+@_`65**RR35+1/@`>P.FJ@F<9$BI2```<#0_8`B<WE#
MG.HG*K+('CG`0C:"2G0#-M8D/AYP5/RJ)BP@B>SJ4M<4XKAI+MS46C#N36=K
M(6J5'&6+NKJFZQBB#NO#*0)`.*AK))GC.:/,`)IS"UWR7T#2$3]V>I$T_@.:
M-Z8H-:>^$N!Z9`(08%08`(*^L`_#Y*AZ;CA44B]JUT6CS.I<(E_C-1?-%,8,
M358.[:QZR'M7A#U*HSB>@J>`A+G\94PD*CN.!3$#K`-6@B#$R02W(TL&IS#<
M8B&>KD3L)<'^*4<B)GMLAP%&R"-`&#>`B@%(N(2[B(1'N(15&,L*0`%6F(0M
MB@.A0P"`BK>@(ZUF.(=U*8=YN%MX>(;),2;T2V@RP">GR8YV=2Z?3T(XX`Z9
MQVH'("@\1H>:AS8T0`(&8'!2JCX"$6+]D,CF`BY2HH_$YD"3AO$20*VP[Q$!
MZ"(HCGW-2X26>(@\8$<,`,M&TI,2YL<\I$QL_H],)`]E+*`!9*(D,,CD&@)*
M!ZK`I@QE9.7S@N(!8.I[TBBN2()D6D+-0.\]Z2T]3`)F`BEBD$B7+A5/4O`!
M*:9:G\(MTX@#?HO?:DA7HDB3)20"./("P-A[.&>!5*4"KI=Y,J)[.&9`XO4"
M-FXB2H-M_@)BA(H`'J""Z08"*@.URL-,R_4[/@9&[41T]`7.5@4H`<!*6V]5
M@M,^_A<=W4>!#4MERD>AV(9(@.ICD2Q*),I+#L#M0.V>/:4M48D#,G9=A,*;
MYT*P2%$`K&-IJ,^$`N,DC<7?M`Z[6'*^7,U5W*8P9VTQ?S1+A@,#1/1>A((,
M6_ASOI&P9.Q%A,@H_B0`/P)*4[X0:GZ'E5;G*WW2('"L=05W0Q\@`S@0+0S#
M-7^&EK6#6.-U2`;O8+YJ1KWG3Z%,BZ#,-8;#R0R@`0^`A7(3,?7,;>`KLHAC
M?-J5*U0M?C@%7,[F4@%'H/!"=**H=D51+BU&+N;IH5"'?>&-/BZK`&AC>=K2
MH!9GG7W)+0:,7R@BGC_V:J`)`VHL\:1S+@W@,*ITH8<"`THJ09&BHW4QIP*M
M!<7B`PH`A3(M5CH"A3:I@Z3LJ%(S?;VGI/C->Y1B$'OP\P((QOY(["B$JB4B
M\:J-+(0(0BJ+HZG/@!1`STHJ.4OZ25)KHD@5`(!*FBEI1B;"GYZ"G0S"_GOG
M`_#4Z0O!3GWXBD3V%0@;NLX$;;'+)TS@B=X.[BYFUU4R[:C:DIVL+&/[4+1R
M62(2`DB(IE;V)N82@EY=P@75>D*<@C4-(GP)0TTR0D2L2#O`L#X:0%E58N,6
MAU]ZHWG)9/ML"3;M>HYCJ@?7I!UY`Z5(2#0((HM?Q*"9<(S>0O)2TSX"<>4Z
MP(H"I]J^(P+L1F`]8(R>R0$,TM\48.+HZS=TJ@!PU"`N='EZG!87""M28CBW
M[VCD*`,`-=*.CS\"@'G7:BWH)@$92CA^B.X:3[<&0B5<\Z&"B@G=]BFZ[SPT
M8\PL(`"^Y.PD&:/`4E=F0Z':XF@D+XVY-[JS_@6V91,!#&L#RLEEDV.%R,YL
M@OS>#*`J1<LRZ06CYV+2D/I>$K!=3:*J[J.^"2`DUFFBYFPX7/`JVX6M&2)]
M+?!.M^FW$7RFAP/`6F>HLN,"S*+JY$-#GL[?=`5VR$*65(4\R*B!J3>"#*XY
M-!&E-$5S#"VQ)Z!URO`20P1<!/I-TVN\#`A"UIP!<#F-%@(!>(0"OJJ0G4E9
M&Z`NXPT]&8",()`)@?=>O!<6]P+G`J4G:#%?'0#L#`1U3K$'^8H\_\,CK+=1
M*N0_E%4`+8#6]@.WX@V9CK0MU6G`B*4MP.--=%J7-'E8V@Z/Z,=;KP9@M.X7
M5<V:J$N+F.;S_&0C_A#+>XAPI#I`+1[Z4AJ`F'.$8E:K*<XP113*31'+VYW)
M`6C-2-!SY3/G"#-X7P]+EG#%E?BD?@UFJH5Y0NPJO##:/I?"U_B'/@K@V0N"
M-"XQ3=Q%W@R@-A)`9R;`LS^``:"X.]I.6$)DM0P%3VZJ>$%6)]:\`A($?A4@
MTB3`HTCS10*G`AX`U6G8I9JR.#XQT`*1`/;DB6"-)#S@I*OV;03L`>3(`WU<
M(H+FT`^KKP_&N<:;@0A%Y\M-KAA)(IZ&JIG0`+P):NSZGN7E`8+S),*%H0Y7
M)CS0'LW&BP#]`B[QT+;&HQH"TBHL4Y4CQ8346[X&L,B114@P6_B/1\4H_J3+
MI\=)JF*B*M%WHE&:MXC5+:3N61V_SDC8APQ[$,HR+;[GBP/]BW3&S'MDPI_+
MQ4%3*`(LPF(]SFU!W3Z<@O</@L_&W@7KKSKR'"`^"!S80,'`@P@_+.B@0(-`
M#@46#'S@X8."#`@*$!"X88&'#A$&,-A@H,)`#PL25$2(4L'*#Q,`!$A(LZ9-
MFQ8&*!!`($*&D@4:!#"`H,-`"`<$!M7@022!"@<B0"!PH$("`Q2,WA288,/6
MKUL]&`#0``,`""P#9!#8@<,""P@Y-$C@D&:#`W418NCY\F"'!P<PT'0PP`%-
MMPC@TJQ@H$'?AQ`26-#J-P(!#(_9(KC`H::%_@T8-E#^T&'``0$).@N4$```
M@@V676H8,$'O``"X"3C`<$&``Z)U$P3PZ@'!@`6J$2(P(,$HA@-H!2Z0D!QA
MA@$)*%MH\$'#`P7-$W*0\$"P>`,.1M)\0(!!Y@\6"CRHR<$!`8,).T`8X)AF
M!@8$C'80!@J\1M,&&>5UD%C078!==6(]D`$!8Q&PP`$.++"`5V!M!0%9-#'`
MP`0B;E#@`PE0<,![!TV0`%@1+$#520B8)T%%D6UP0`$":2#!0!$8(%<$"R[@
MGG@(<">0`C)UZ.16/E[P$6GC,2`!!?T)A(%Y%T3T000(..`!!AEA`$$'/B*P
MUE>!/>FF0`P8<,!8_HH=5$``>5%@&$<,%$`!?1*HE)]]F-$$`6J95;3!GPEE
MX-M['#RPP`4T6;`<APA%($`!F!ZDP0("F-<H!!"P6``$&_3UH4P!U#A0!FI]
ML$$!M^%&UDM,_CA0!PMPQP%N2AYD@0(4T<103]U91T"-?4W0@%`/""A0!`$P
ML%@"!=16J9S2?H"!`0ITJX$#$$BP9J8'/%#=2:`ZL.X''ER`P`$49(9!`WS1
MY"("$AC'E$"4PJL5!QX0?-B;"#$9[$$;./"``VMUD`$&#CB@[4V1@55!;@PC
M\.>1(WZ4W0<<1*<0F`/HNNMW[W)`KT!CS83PS#3#^QZ+;(I:\TT)`*#`_H<*
M<D!!`'62;(`'&<0(0<`(->#`C9G)I2Y->FK005\>4,#`P@=%4``'W4X+P;L8
M,.#`OPAY!W%F&B!%'4T79""W?T:UB9`$M@IPKD`5+(#``F/9*I.1#"!`X@%[
M;T#AJMQAVH"&NF90@00,1-#``!!H<(!PY';7P*GO.E"``U(F%,%VJ2)$`6P/
M=#H0!A)L8$%F'3B`0`7O4;``Q`EYYRS3#,<Y-4(;-/`W\`/)E0"JXD&`0`0,
M`#"=J!P0$(``J!&`/?8!+#"``->OI3/",7$-GP23HU\!!Q540.D&[5>`@?SC
MSP66!P0`P.-!'"0@@0-&40"C#(`YQ96K5PRP_@``QK>D`+P+04:IT,XF2,&9
M[::"-NF9`B(`@#PMP'D).<`%VH,S%O5+5C21@$<RT[#=9$9>$<"932@``0PH
M:"`:0,#R]*6G8O7N`@U`GD`\$`&\=,!`!ZE``X#U(2*QQ8:80Y$"$J"``PA.
M(E\*@*@:$)G6@`A.DR*>!SQ@@0>\#5ZBB9?U?,BP"O#'/QIY5W<"<+&T*6``
M#"3-5`JE%P8(BB8:2("[:D*!`N`NA02H5TW8PRCK?*M4-E,=`@1'27I-0`$[
M48#K9K9$\S$`DPM00`%D`@`!A/*4!"#```*POZ.\Z"MFT9^^($F!G?Q'``#P
M28;^!(&4"$"(.L+B_DD\]X&>S0>#R$PF32*01PPV)9<7Z"#)'H"`,5IK06>K
M20<FH+*$D*F9W>E61YK9/B$.)($VR<`-7X6LPQC`G*1IP)4F<$EF4J!>M;P1
M:398E^IY#S<242`%,L`:(E%`2&D+0`WKX@$&""!&70.6!RH`EY=0#)0)0`VX
MPJ4EWNSM)%"AIA!5U$B:L,@##OBC7]C'@'5^`%8,D*-`+-!-AE61/GYK9@82
M<(!-OM0`Y<E=`1@`JZA0H`)'K4#KX,54#"K,31[8I,D`5@`9/B1_`DC(&!<P
M@8_T10/PQ,``Y,BO71D@`;C3G$S&R-:K>35L%+2J,A/RO[F>Y#:G`X`%_C!0
M`%VA9%<=<8!/258T)TW4)A(H0#/95Q,-F(1F'>B6!VK*D@O<BY*8Q>R>")*_
M/6$@`*MLY+>&Z($)&&X`-\36^(#%JSI^`$62F@#INB.ZE9B1/G\S2@*`U[\L
ML60KT,/)5`_BH,?6)`$?39XHCVFZ":SO,)81TWH&8%R6E)92L,H,!`+`W=94
M(`*#==,#OKB@"D0G4D;IGP%<^X'-`DP`<BT-;AKIE@-0R+YSTM`I"T=%_2I`
M0P(XP`.KPA$.8M8`5+G-];9'@`3TBEB/T]!__XL`3&X0`I5+@!\3H,->)B`!
MCZO*EK:$/GK24P(FIL`$+*#.+55@Q9;=JP4H_G"!%8=FQ#@>L>PN@@&#C=%F
M;!586^2Z*R:Q,L"G.8"(%B"]A\UI1QB:0`1,7)`!W(=$%!CQ!1A`4>?6<HH,
M^$Z.+8L!"R3@.U;Z9)9Y,X&C:@"L]'1`!'ZSNLAN0`.BX<"654S/-<\NLD8!
M-(XM0.C(:A4C9^I`!0JPHP@\P`)2)K2D<W*9T3`&`'O:@'`*2R+`X&8H`$#H
M1!V@HFL.<9*%W95,P\N6#:A'.I1JBP3VFI\[.U&9&4BUDS@@4UYOY0$M70S2
M:M)0]W(@`/`<R'=93,&>F0\D^)F-439FMX,P=XA5!4MKN.O$B74M:&R)@,$.
MX@``C%6K!(8/9@/0_@%,UZY3;'6(U8CW@0LXA`.YOH"^+V"!??M[WY;;&J0=
MT&\)-,!]#FC`UA*@$P8<0.'/VEK$N8AA!2A\.9]4I5-HA9H!%,`X"%B.QRF4
M`.W=1@`A3WG(ISC%OX5\E+9BKP=>R3`O"JZ.),DL;C:3@0U<@`('ML#I:&H!
ML.J;IDY[@,UQ$X%]NU'GN!E`C?E-`5R&&I<!.$"MML9UF+=*Y<81P%P^N1Q<
M#C5,$DC[`QZG@%3B$D/FLJ+T>-T9#""7N+AL3*MJ-8">`Y`T"7R)!`2`.>,]
MR^6T"E/*%3`YW?`K[9/3`*\KT)J/IYSP5FQ-NGP2<K^!C[OR=![:51@!_O11
M,^1F/#T"'B!Y7FN@S/),>]H)*@'.M)[N&:![!RX@.[`AI`.+PK/N>2W9AQ2,
M`QAHBX"FE!]D?X7?%72V287I$EFMW=0#<>\<X4HRK_2,`11XRDN+YI;HH)1#
M$]")7F*$4.(9P"N6`6UOS)T!3&\@ZP?`Y(Y&%X'^JS-VW[4!&R`T0E=Z4\8!
M`XB`%=$6"#B`#BA7S&=76T(I;\8;O/%Z%3&!3;<;$P`!C^8T$X`!678!("8G
M)35$V`<P^4-)$\`K5%0K`/!P"F!S5/%!GH99"<1[_==_W\5,8S0>E%0M"]!_
M<J=SU?(`$:`!.0%U!,!["%@?4(=I`T)`4'=K_J31,U!G`$M#`7VW&@'6)]73
M&92'2\"C`0'6?^46A;9":O>T1&H8@WME67*(`!`P4*!1`0ZP=+^T`1FP*E'X
M<$X#<U'($W+RAC+Q/2<G.$AV`(RX@J24&U%G-CLX+XQV`*!F;JU!%8S(B`6P
MB'3H<&/!:!>"A-`C0D#22CLC?30A3,^31`F1:AP%);BA$G?!`:47%WNB0,%A
M=Y9&,!PF+1K@&-'C&A]@/0CP*UU10[*U5_/C,`X#@Y3D<7-1,9YF=52A/9^V
M@D,A)]SX9-P8<J:QB0[F-$K&B-UH)!I&*E(!`>O8CA#P&5+!&6B$9_0(&_5H
M-5K1+0J`@,26@K("_AH8,#'W\G[\UG8!T``4H!I@M5<00(V[T8S]5D6I9&4'
M@``6X@!*1A36@QX5TY$/\P`%,"Y.TY$5LSLZ)",8TI&I5`!METH3:2L$$!$6
MZ9*JI#W=&!%)MFTU"0"Z`1B^E$J`(SB*%1G8*`!P@3==Y4N=X0%#=3E28BD(
M,(R*&"8DV9%8:(A""5X*4GT(02&"<P`?Q&1JZ#$3\"EOV()(8X@4R!!O6$,V
M]%F&.%"S@97LB)72,Q$($'WDY1?X\0%J\@%NAI#EA%0+@%3V]F:!H0'J]&:*
MN6\5B!L&`1(LN9AO=F<"-$8&X!#7$0$4@`!Y`0%KT5#^^`&U-XP$D`%1_G5G
M`9`:R;8:#_":%9`!W)0!TC)1K_F:#7";#V`2BBF`#F!A__6;F+09@/D`<0.<
M%B:<"F`!2L6.OU$`T!F=C&8<&`*<]E4`@9,;A&=QF'05-HE@V(F=1-$SX-5C
M?(@F;X81ZS([Q#-)I11#&?`P0V4!"S`^A'83<(5O!P!7UT9!$G.?8D0:WL)5
M<M,9""D[>$8:?"A;F"18X]8!&E%*A]0C5929,:$M53=EGR,1[)$24].0CDAP
MWU6'[0,7CL6.SG6;N8EB9D0!P/:<C)8E&L"2??%=;@A4KQEF#P":A/8LNOE@
M%B9QSX*<W:E#/-6=9[8`T@F=#E9ARY%_^@>=_OEG`-BY/!#P.=&)21ZG$5:&
M&R+"`%MJ8;122N9V&]C!)%;&2E4$G:)D=0#P2AF@.WII/O`B*JF3`;E)*CM*
M*I9"*H)TI:AQ%1\FGM@)<7)G2CPE<M@YD0;`2O)A91H1`"3W2P(!F@,A0`0E
M*87C`!MC*XYZ)Y@62'(C-RRFFVOW&`(XJC)E4G;U).P9%XK)F$SA>POR9N:U
M4"H&FAQ@=H2'2V8*DU]Q?[.8*6JA2%]1EAW2`'!%)&C3JJ31%^LB)^NRJ@-1
M<K:"7!CP`%@!$T2Q0!/!*1^@</5!*PEY,6"Z<^J(`5)!&S-S1@?!`!V`3@2A
M9^:F?<Z:3'>FF,8R_D0$TYC]MBX?P7O)MWNV^&8$XU//@6RJ80$9TVQ[21IF
MDF,2"SL/B0'L%5-@8478MZNA.62&4643`!K[:``P0:D><Q(]4Y@44'J2MUTZ
MIUC;>!=R\CSL2$W)D0%^\Z0$5)'_I2%_@V`$\)HN.9(E63%@Z22Y]S"=<0%3
MUB%@A6/M@S.Y]R03(``"*(!E-H#DD1.PU!K,XQ=YF0#@)"S#E4%P91C^0V3.
M2JTV(1:!(TI6]DZ[4FXJT1D@5D.Y5``1T`':4QWN*84(@45LFT)6^`$-^5.4
M$40*=)?WVKB.:Q.*(P#),2:4-3/1PS6N5C%%=!K;F$J,."\5F7\)\6KX_GD;
MV-<!W](IE.(!2E<7$``>6I(=8NL7'R8M*ZBK/B<`UI(Z-`,VHU$13_@1#BAE
M(0L;U#&`2#M1>_M230L6%H!_%U*17D$8U.DWGB=Q?0D3QL,?-71'W=,`J#F!
MWY(!%Q`>-_$KN$%X5D9%ELBZW#<0&]"?VM1^*51,94HA=Z1U5C8`^QN]=V%Q
M"><TC_,L`IR;/V>!`4QJSV(Y#2`5`BB/ZT*^\W.!X(,;G\&2YV%N5DL`+BL3
M1V*+*J5UP)(0`_"^-M$V"`&OJW$Q"E!F`/6X,.RL9Y(IN*$@A:F7["406+(Z
M]V042KA)TL(`8RL00O&F!]&')1>']B:`GW(!_D;A@`KX/P;P43,W7(N;O1Y0
MD8JV%<XB<5SW+">X>T=78XY&8^,#&F.\;\PF'G@F@&#C<X/+/Y4++P1C,*I!
M=[5WQ+R6>U<C(Q73`:O32_VR`/')83*T`3NG<]%C3I;U,]<G`!6JD9M3<E$9
ME?IC9?.B/4JV$W,2-[(G>V`"'A+@//G7+_[SR:@,;&GG-W."8"'7+R%'12I'
MI:7T/>I+>*5$%+%L<R3+5Q7PP'=V`9U*IH(CMBQV9Q:R$DR2OC3F;P+0%J_1
MQDS,NX`D$0U8-GQ89DT(-D(L`;>QCZ)QM=(<QR2CMC'LN!Q4PB!505D,`/#D
M`0WQ<T;1AU<3%_*K_C=?L1`BHCKT1"M^-$4#H$,(<#W<56%@.47XS!)T>!!X
M`P#=='\;$@`*8#;T9"4/L&+,>4\:?26@U`#,)LRZPYT0<RBM2%PF=M)2=B2[
M\DFONQ.M,D6N4P'_A8@(`#X"("><5CA?^DG84UVR\J6GHW`Z2IL'X%RC<0'O
M2&C?=Q..PI-B"V@?XD#N#$A`=C57PE9>!2^K>S5&Y%:`ME59XS`[/=9QHA$[
M,50[35&?\2H(.!FDA:K.06B8X0$:L+**>4\_EU2$%C$;@$L2\6(+T#T`LIK<
MA'^8-@%>U&!4M$%1:1&MT8&X,<D?=C3%>!_(*6`VP;=E,X-O.D4.!BH<_A9J
M<L>25=0SV,)=I[T]-KT]"V;3$OVEV%*VAT'65K(5'2!TM/V.CR9I&$8>:09^
MV^$^DS;<,T9PN2D[:Q)+*U8PF1I7,N%2\$(`^]*"EC*A)\%`?[D5$F$9;#00
M%Y`4P[0D%%$1S5(4"4%Y3#->`'!M87BE]]1F;?8S"F`Q?O0`*O;>]UTX,L&2
MR\-R$\9RGPTY?:,A7*:G#*`A\3,>O21A&Q0_L7G>]X14J8+5"U):-*1BN`.,
M/\=-8!8!,&V_K`):OLIPF&0!3=BVV(DXJL-N>-(A'3#'*;RJ$B&6C4$J]PW?
M]WW?O>39W4HTS\LJK')6W64]W45*V-E=H&8]_IZZ=/IC%#5='4;2'7Q$:V/E
M,I^250B1+F8Q`'M%`*ZCSGRT(%LAT["6$.7Q`4)2?P!P3>3=5E4]1K))`7]&
M8T*SX7I"+&\!%O="0PC)387K30`>Z'^K$?S=G8%.13<=.+<!GJ@Q105@K3+Q
MMY_F1<,Q01Z`&\F&$B+(+QDE'[@XND/,`0:!)^*7$!A9$UQU7/9*FL[GES`)
MB:X18(S'5#\V3&U.ZPDI*ZI!WN%-Q!HPC+<A$2LAK#J7';19$0\`C8*C2C^#
M5+74/3`G')9=(*<D87V".1%^3__%$]BAT4C5J%+7YL'6-<+TBC$G21U`L@L"
M3M#Q%5]C$VC!>"G!_FHW83O+^0$]54NAY*;KAAO%XE:1]&/D323DK4D*4>FO
M$P!_#D!$M5MPDB6RV3\?\A1VIR42818O/HN_CEQN<9H)!R]IF)?%R!LTQS`_
M,E:+2Z?G/%<";UBTOA(W8S/EQBGD;8LG.#.7WN):U1T8FEB<\5$<(/+O.L09
M8!`2P;?2A1#LX4[R2QJGLAY'T]=>Q*GMHP"F-10NG<@2K2&KA.1(;HP[012X
M;-F6?95`+A.&[G5,+A/R=$]`"'43CM4JI',K,N&DH>RV@A;G`A&8M1&7FFH<
M,)KPXJ:-GBKE9I0I6#LL@F%;T=>]5A0#X!7/.\,=,B;@,5FU00!]D>X>_C?$
M;]*9.['>-E-+B*TD!7-'@J,8\'PTU+06/P&9#B7P8Y1MZ2%T6B<I:^<S!A%-
M5^I$,ET`JE]2\#I6G:KR*W_\;[*?"5-30D/.88'IB\$8#-MI$$`4A247H/X5
M0>OE)'/Y"0$!.8Q2NC:C94M$%T8Y*D4D#7`Q(:&%%9"@SK,09A8@DWMG^9IK
MB\F'>#8AH4*;=P80&31<L%`00X8-'CALR)"!8$$+$QY$:`#`XD6,``@0*,!Q
M8T:0!P(0,("``,B+!!`HF-!2`4H"'V12>"#3ILT(%F[:[$"`P0"+`@)@;("@
MP$ZD.STPF)#49H8!'9QN4)"A@`>9'28<@(#5_JE-"@402/TPH8,%`!5N=O#Z
MU>W;!@<N2H!0P,(&F1H$4+!0("C&`!"R&A@@H:T'OP`",$!@P,"!`@LH>/"@
MH$.'``<##.#@04"$IA\H(&C`P29+FPP$W+0`M,,"BPS>SJ9=V_9MW+09D+69
M`,-."[]S)_6@6,-;#1,O2WC05B:'!D@I7)@]%(`$F8@C($5\/"L'\!D$9$C:
M`8%@I;`G1%@@P$,$O-L58)?9P/O1#Q4,1,#`P4!<"H;K8``#AG.J`X(N:("!
M!")3;:@`!!!@``H-@*`!`@+04+&,K`,@`91"!"F!O`(@+RD,9.-.J@P8:$X#
MBA)8$`$!3%-J`@\T_@A-*@_,"]`IJ'C;B0,&,CA@IPP0.,`"YVY::H`(>(N`
M`[06L&F#\QY8J4D#;8(-(P%"L\F_DPRH0`,'`!!`@@!(I,`G`11P4H"+'I"`
M/0@(.`"!Q@#XP`,#+MB@HX0$:,#*[!)P0*9!HY-)`A5[,P`Q"PC8KDM,,]74
MP*AV.N!$FRC;](,.+!*.M@XVX`"#"%J-`%+T6-/I+>LBW2"!"IJLH`#O(J#P
M)``&.'6M`H;-3@$[+0B@`P/(<V`#`FJJ3ZT/'.5@T0\P,!8W#PZH<52W$!+(
MQITVP&`##3`8"(,+*(`O@X,Z@!>#!AQHH($'+I`(`PD:N.`"?B%P0`$;_BM8
M@$LOJ=MI@J[T1%2FKC[88#6D,/.`@@`V>)/(=`E0&*D@IUK`2*0X>$"`W92*
M0($$A/S``0XN`$#:#R``@#2@?AP5K8OHO-3)`@S`JRP`(@`1`&]_FV"\,2\:
M@``!'&`N.(`I:/:#E2U<(`$%#H@`@58;B.``;.L=(+0((LW*L@,JBQ5<N./6
MM+GG%B([@@O(R@#'33<8@.+:.!`X@8T0<,`!`N3<J8)9W:KU)JBHO<F!!`[S
MFST!F$1*`P.VM0"!"198%H'C'MC@`)HQQ*I`B3/_P'1,-1A*3'![M"U'R>5V
M,N*L0KTL@[=GV@UJUF4Z^`,+%$<*`0\>`,`"_@EF/D`M#`@P"^1.DZ**Y*0X
M+V`R4I/TR>6:.TLKJP(*,`WC`LCO,GJ+VO?U5`X8_Y`L#";]`,0%ABYK``MT
M@$@7L9"CD#*TI3!`(8]!%Y\&QA'R:(``'<#``+I"`;7)Y``:.(H"@J<[$(;0
M+72;&$@N58$`Y*Y+I7*/IJZ%%,95)S;E,IQ2*I``TR108:>CG4TN8,&=:*`H
M`4#`!U*VJ`/0IUHGPM8&*B`5"&Q'`^Z;300T!"IP9<"`5;0`>KPCDPI\D%'#
MT4"D*H5##R#@:04(0`\QF$8(*.\#"L`*=)S2,@0`H`$0$`H`O+.!/`4O`Q.<
M2@*X!Z0$,"`L""`7_E)@AA9J/4"!8^H<N.`'`/Q@20.W4H`&FH?)XT#K.'G4
MF4SREP`)7%(`"3C236(&@0<P3`.SG"4&"C)+@:BKEE?[@."XEL$/#"`#\E&A
M"(UYS`\<;U`/<`!0`F"7O%S/A1;Y6)?L")Q2.@4H``"F!Q*0S0](@``8THA8
MCL.!`BC1E4O:B5\\MK_?6`EU-C%)`1P@@`(\@&5VXL``_-*`H.$&;^>26XMN
MLX%+#2L#C=N)&-_B@04\S#$"L!*Z+F``3#9RH6E$`,T^<)7\`),F*-/(9B!0
M%^=PP"@0\,X%2.04#2`@`W+4WC:QB)0I888^$L"63=@Y*IM9Q$0S(9`2_BM@
M$0(P1#$T$@`!3H6F"7"&9VHBS4X(%S3'8#5H#&"``;#J50-8)W@7.`!-/]K4
M!Q2@A\ADJ^Y2=I.E]30_"!.01NAZFQ<"9ZT[>8U<@/DG:#J)`@)`G0,.8("6
M[J4\8PG528J83)DT10$_8Y6_C+8`"#"@K,B#``4ZX"[<7,`##O@9N*B$5_I8
MAC9;7!S"G(<H#5BI`FISZ0%*R:P*+D".`3#-!%AK1`&<%`-:@4`&EF*5AUTL
MCPJP0`*R!T,''!)%T3(:`1JYD]+(#%L2:!M/%#LJYSEM(W32R$:"=A$$?"E^
M4%O``:#V3#5MDZJLY0`5+]"5"C@``1_C0$RY_M0!!>3S1!UPP%1+VU8$PZU]
M.Y&``#RJ2"KB)@,``.=P%`2R"M]D8D-94U(J8%VD7"`"'D"7<R8@M*2,33@3
M1II,KN99KA!';A"XP&3EAM#;>*`!6*';;/XJDRB!K"1-K$D%;]*`#0"X+:4:
MR:%N<KS9EN>ZV>GE34D<EP-T-RD9&)E9LV-8:GF@+@>V"00Z8#/T')7&#LEC
MA'.3Q_CEQ`*;G/"Y5*4!D6!DLJ[ZS$+,%0%F?DD`?&KHL`3W@0L(Q3(4T.-:
M$O<T!?SJ;T(=@`(<T*:+%#/!8YHEP#Q-8D%MCET$1>8"7`8;!FA@7HF\ZVT,
MNBDA(@4#>]T)1@%`_A@Q8@!T2.'C``[P4IOHVG\WR=-O6+S=]9V.S/<\&U\^
M`+Q,04`"-H[;!G[L%$!-V2W7)@YS,_N<!%S@`0$84^7":6Y2620"FTS*A3O`
MF#T=MJFDV1J#&I"`1,:[FU^Y@");Z:0')("ASX%`)1?F`9D)!^&VQJ1A()<@
M@`U[-@T@;P#4F2V!AVH@%C!`-ONMPO=89``(`+;Q:/=N4G&0>LQ;RWPD,)U_
M_2L#X&'7;"60@?!>?-,V\75)^$0:!@TLO<Z=D%@:@\]6;^JSCM1(T%.I[>$L
M=%2'MN%L@!6<``Q<)A<@@'.L,FX*"&LG&.@?=PR;(W5K$(P?^.GD.@"I_L.]
MKG@&8BD#JCGU;;WEA(&[C7D\\.IP!L6']/$F63P#@+Q'5C8<.$!+)E#?RT3D
MB1VH0`92Y?@'S'TV&["3YG>E`(FSQK:+>QWB7=D2##A'+R`A@%S=,MK$R"6;
M&!LX"@GPQ>=\ER=R$0MK"[P6]"`4*Q'(9@=*3IL34WCGLMYQ6S#@@%RU2"T9
M<,!PO=(\U^LN`\=_W0"XC2F%3/WNQGL+BY^7GP7SFG86H$X%R+8M"#PW5//1
M@$40A>+H)!$I"]C(!!!G1,W+#6E#`$W+E`W0NK>`F3_1'0CX#0O8(C%[K"6R
MB0E0'$`!@(=!B@D@$<[;";JY@`68DK#Z-Q>[_@V*2)Z;$*?L$S(!.)4&.(OS
M014*2`BVX`#N6@S:"#"+<``^NJD)X"V;J(`*>(FDVCKC8@`_V@D.JZJ;R!LG
MH8\'(`L'<!D"PXVC*<`$<Z*=,!H-\3X`H`J3V`F7.B8-&(!J>@]GTA`U3+S<
M@#K;8!4%^(^DR,"DF*I92;344PK7>10Y\8#H01C]XI)N0<*+Z`GR.X!M60"Q
MD)B;B9-,X1DR>PNJ4("*$RI+5(S'4``%$)VGX9!;PZBA,(!-U$3=HH`XTBW"
MTJU1I`#HPXH,H`!8C,49[`"0L@!$X0#RD#9&P8_L`!O`*IJO&)!>>IN*(#%[
M&@`-,I85Y+<&Z")3_M(3-U2*/+&1`$%"!+R-#Z,-J$D[Y\G#U'@L;YH`8-&?
MF]`L(0D*)BPSW/-#1+NU9AR`)N&`2'0+.,-"!".[I#B`SF`[SR`,,?0H$)(@
MZX"0BSB`2ML,@E&Z3;F`,%I!D/J*$@*`CTDT^>NE`J`6#J"`PR(Y7MP)Q,&]
M[!@LBY@4A3$+_?.4'S08],(`\!D.#+`(D)P-V1&("U`U@:"E31J(AA#",\%)
MGTR.CC,`Z*L`"8BH!F`8GJR`<8NH!%!#-80,17P,Y=N?6R2,H<(:FJ+%O[._
MF4.1`L&YG:`C,`H0\V"Y7KP-#;"`0>(N!6##KY!'!-@`4V.T8E*I\<N4_@'`
MLY;<``-H)`^H@"+"K&"J`#KYC-V),8D9"0=@``/J(CWQ(`IH">(#-'U:#Z[A
M&KR)@+Z\C7I</N"@0^0)C0<@CZYAK<AL*UHBL0P!2,]T"WE,BHY,BHH8"G7"
M`-VS"0F*Q*[*.Z/YKVV2P)IANVUY/)9D@'ZA"3:)R<!)GVCLGMCDCJ0#&:T3
M%1FCC6_+"_]9*%!),NF80HLH*T**+,7KI0,SH"C,B@$8-A*\":/!-Y+#MP)H
M`/A1*X8A#2UA$-!@F)8(H'_A@);`*`'XK!@,E;B#FPVPC@H0C@UH,!5JK]O[
M``*@B\SZ0A]BQ0.0"@90')XR)0SD*@8H`'Q*_B0$\%`2]5"H$8K?"D;KN$;:
MT!$<B8@%,)TGLKSLN`Q2J8`)4"$.`$TD^Q/!Z#>^3"E:.R8D9,U1<3/<<("[
M!,TMI(L'O8G\N:D/X"!^D<\$X)-^,TOL*@")*Z';5(MY^A/P:,XNJ;\DQ,8`
M:#7IH@V242V9L#NG2%&9,*Z\(!U,Z8`&>$D,C*.;6):R.`I`VHFHN!B"X1?G
M(9?1\K#%N!?&O)<'X(M!B[15NI<%H53&;-0NG)"GB8OV>4D5,ICHE+`%X+JC
M+`M[^9O<X229&(`SF:"N4;T"D),AE(E="R>Y<@ZVF%()@#I3O(TK[!)O"8![
MVPR&`]&(``H"(,S-_G`]AO1(*)FV$;6:]ABV^]HY#K`((]T4,K6-_4J*[XO+
M!\A+7GM!G,H0BR`-"C"-QDL*=,H@J+`():H,S*@MAB.MPW$5?,W7*:D-^-&Y
MM\`,Y0P5%@62(RFE=AF3MIC'UR&+\]24-%DE!G@;(-P*B7&]'#(``AB`!6@`
MU#@R#[NV8<*-6:I#Y!G0/UD`!]BD;;4-`^B`<`V0A."\<"47(FF]#T``[!"N
M`'!34VJ\E:%51WD`AXJ_TJ`0I@$9AW**\`K8'(P9`V`*F7"`"1BN`[B``)B.
M_Q"`T'NV;,J`?JF7>J&2/,6FG2LAUT-2V[A+`TG(Y:D82,DR-2G,PSH`_K$Q
MC:\Q%H2;GC#:H^=0@`KCLM(R/YU)(T"A",<+#@I(I5=)7.*;`%.4`,>MP&Q%
M"@GP)[1E,.#<L@"<"L'`L]-RB@-`H"$5+9F(5098@---7=1=7:Y:S(FH`(0B
M/@C8@(KXD`FH)C_MEUXBB8U<B1%E7>`]74)#"N@I#S]46-QHBJ.2'&MS@/9P
M,*HHB;^,6&S1+SZ96P,X'J3@"`B!V06@%\3)+Y5""&2),0!3%_[#/0*C**E@
MPHDH#R7MU`[0VNYATJ\@1*:5Q.V87Q"UD@18`)UHGZ[K104,(L+BDXA2DO_E
MJAA=3-15`"7Q%GL,H3?AB$9*6MQXHE&QW\`@_HL%9:,"*"YA"<&9<C"1$";1
M>,XI90#P,$@?`B"G,),@W*8M@AD`ZJ%1S0H>D0#I;<()+K.9R0T,^E<VU&"E
M6!)RW+^AL8`,2Q*OD!>#B<\'F&(JKF+&3!\LSF+K8`_:&:K%_!.;W!O898B&
M&*8+<(@(4,K1W%KYK`NP\JKQ&M+D?9D!?0!$2=EJ*8S]2(#LQ8]8/8@,>-JP
MD](YLC4ZT0G3N`RCB:,!@#X,\(L`$-JQD9>..([',QZ-,(F@_:MW^\'C>!.$
ML8!E=(J?.#^7K(D.\!H).`[^6Q0S'&"9F"PNX2"$L!%<3&2U]%JUG(Z&P(!U
M+5MV'95>74@NF;;(_C"/H<`5FS@<H8SEXYBIK+O92"2[D1LV#DC6Z1H:!O";
M(,Z.'5,D@+Q:P*H)S9P``&BDVZT-<X9EVZ``^PU"M14-+,*+`<$`+*P`&['G
M`]$R<$&7.0O!/L4*Z-,=!>@WKCCC"YFEE5TM(P(`4&&DTM6)(D$>ZAV8^O"?
M"=`)H=V<I;&(OBA"]M23E_P>E0H``X@E`>BW2RN0!0@-:%$34YYBIX@`-DHR
M!+C&8:X-N3!9W/":7PNL[UW5$Y.`V8JJ,[ZN"W"],I*8C&V(O\DFR%V^1W*.
M'ZX-JP$J5=$6=0FF20,*U'&.^%,,</L-'0N`FDQIX$B,>F$P+DT*"(C+_ILU
M/@280:Q(Y=R\./E\T^@XG?9R#@F(YX8"`"][BPGX/F^<#3&3"9"6R8!-$A"J
MKV>Y"=;Q%]U1'T4:$W^-MH;V#I1S,;RHBFPY%!Z4E@88@!\!X"D%S0JP&E-!
MDQ9T$E$T9S-+IJ/M+#"Z/>YL:,'.F)E@PRIDCZ]H0-O8T0;P4P/!,X)A`.%`
M[8]*4(PR[3[*(&>$4EEM``JXMP]C+=#8N6XA`%.[B9;,E#>18[>P@#TI@`08
M-*#(W@4`"O(J`$(^%(VXDI8F%7%4E]'#S=4VF.P#P;PS&#Q+)@I`%JDP#[^Q
M[2?[D0G`CB1A`...+,"^">?)7-HX3;D!O6`4_A/P@*DDWI31:A&&Y`VR>E/D
M[9("Z#>=<3:WB"E)XY."#FX(92SDZ2E]3*:::`G24`!'&1FO@(!9@6CP%DG3
M>SL4JX_KCI;,DIT,"1"5:JFSN9*3$(D3P2&G<`"AK)Y*<ZW\';NF0,8NT1:`
MV9;P8Y0"OV7L*J;2F(]K]2.<K;6M/::_G+(,$V)N,A`!ZA%:3"?P":^YN",(
M6:>FZ*<B$@_E-)DIJQ3E].4"<:Z/2>5K/JFPI):HWFC.2,$([PU,NESP'MAG
MV_*D2-=@).3RB!M`X;*Z^)AN>=.JS@U]O&PP*O$I'=/^*LI;B\0I?*Z_]A+3
M*,,!R!C=@@W2("+[_J@6A9&IQ0D+4UEFL:P44L%PY4X+H9#H?WMDLC@J;D+$
MJ#T3F5N+?10@46<IVXB(#P"<T`*6KA:`DCB`]C!:=O^;D6ND--;`,R-J`JF`
M`6"MBF2K^H'U+HF`.L>41Z;?9<Z(>23$F'`E`@PY[(BH(/R)/E(?XGU2X%B3
M`/AN;^XG!,<)A;F3UT'W`(6K2S]9VLV-G+A?H5@,]"8`"EA@U?#0M'(1`IL/
MB!"@@X"(B#"6W-XZAC#0*=4++$*49M0=Z[H3"S"-_C`0G/,R):70.55.//\3
MA6!)AL$WM2CZ^@B>U:Z34/G?-/H1PI0`!'A)D6"C=#5KG'@L/<U0KSBJ_H&4
M$'SJ&L(Z4;>7D$3Z"4\/MJ8@M^$8F,M@"\IS/&V9/`$2(%4S%\1Z,BG=C23Q
MVP^UN';2]+B!,Y`4=3K_OK=P'@4`L5`1W/L5JLVQ.+3H0WLB%7-WW`9QZPZW
MB7[MG?(A`$@_$+SH$0H`R5R?C6LNRMS`EZ^P#OFZB*-!B0@!B0T!_F=2`*=4
M0PZ9<VY1'P6H@,`=X'#3'<X(J@UQ/2:^4YA)T_+@20I(RJ2DC@SP?MBM%H#,
M>C7QRZXJ'D8#Q@:[(.O2IS'QM?:^"&$W/N)+B':)W,CL#,I+E]D'B`X8)BQ8
M($##AX0*%S+,X*`"``X,)U+\$$$"PPH9/FBH_E!!HH4%&!D^0*C0`8:)'A)6
M@+#!`X4+$PNLK&CS)LZ%"``$V,`P9<Z@$0`P"#J10P0"!#1X<""3(04%&RMZ
M*`#@*@$*##E`H``@0D(-"AQ\\.#!0H0&#C8T,.!S(8<'"MXNA&!UY(*R"C@,
MH$!@08$!`90N4%"X(`/#APTKR!JT@P$,"HPN;/#`9H"O#!9<$)#@[@,`2@WP
M-#!@Z-74J@4[4"!AP@,""A0<2!U@=N:K%BCG3,#3`0.)"9$F9/"4=]`!'!@\
M6.D!`UB%'`YH1;YP`]F#"ST02%"80(,%EB$\(`^AP@0("QP\")^X@((!=!-V
MS3UAX@(&+\M^Z-"@_D,'%=24P7\#.-!``0*HMB```A#0P4096-"!!`HT5V%T
M##4P'TX;Y&82<@X@`-<`!W``W@('7```:1-%5A<#["E6T`/L41`!!3=&4-X#
MY04`H75!,N3```,`*>1-7D$05$T)66!5AF191R!6"@!0`4,>#%5=0CW6Y`$#
M`G"@90+"528?25>-E%('"/!5$0<;?!16!4]E4`$&9N9THHC60;!;1;=)L.0'
M&_B$5)-PG36!`AY5(`&$%`@&P`!6!7``6PA,,,!.""3(``,99IFH41``,)E-
M3B%YDW(,<,G!JP9,A61<'PB0Z'04F>1!!A)(!$$"@"J4@7@3.4"!5902_JH0
M`SOQ))L"!110VP"&)3"`;0D\(&`&V+(XX@4+`."FAO+UI-9!"8#([+H=YC8K
M;PZ,I!`"0'V`P9*^`3!120LMD``#+3GJZ`0%#'PP!0$(NZIU$C3((<,+;1D4
MJA]($(`!$C29EW4<6.!P7@H88-9P"#0``)=E(6#B!(XE!&8!>B;40`*)F@K`
MO/TE@`$!$1O5`:8('&F4`@LSA,``$TR@00<=<1#@TP!*S<$$PC4P40>782!0
MS7HE!-8!$CAP`$X/%#!T4*8JG.IQ/BO4*I=L#0<PDC5A4-2MUW%<&0`O(6"`
MM!XNT.X&`!1@;`4$_!;`4S!9X(%'SUW`@00/_AP0;`89J.8`VG$I/D!";0+`
M^78+3-=!!@'D%4&['T#0NDT:Y":S40Z(^@$#LRJ@P08(1$`V0P6LNSM5#01P
M645NN8W<3CW_Y+971E/49ED.C$[JWKQYC.UD'B``V`,)(*`@BZ0R@*T`"!#?
M'P'WS80\?5=5!Q;0$@Q`ZO)9?DX[3D7;9!J#`'"`2040>`@@%60B`"$,7,TB
M*.O`X29#`>#9Q#M^X@F6*J*J_"7$`!UPE4(DD,$%P"](4KE7`SP@@*%MH&(*
M6=%&(-`!""A@`@+,8`@+X+Z%5,`KE.).QB!`FG%9Q0`0D``%,@`@7S&`)PH(
M5W,8LH$P$2``PI&`_H+:IH$!:.!J&3"`5B*P+'91A@.S"Y*\CG8?F.2E`?<A
M`(<6@,,/!,!>4('-X9*'-@[:9"<]X6-"'+;#EVT@3ALX4H`,4(%#%K)0'$C`
M8Z*2@`0<(#"IF8`$6C@``UB/`KZQW-`R,(&P22"3"FDA!$CUR!3&3S23&U$'
M$I`!`4`,D+ACD77\=Y,Z8:`"#P!,6@YTD0=<)`(5B(!/"$`[MGCP;@DYP"@[
M8$4#&$``@[0(<!BP&PH4!3FA`5VJI.<S#](L`N94`%@T("4D68`L&/`.`!(U
M-HH$0"%-60D&_)(HL5'$`AA0T*4$(%#PU"@UU2Q2``+@+0!`0#A@FLM"_C!P
ME?$!Z979`YH%>D8!!!3%`:U;7U#XPA,AV8XA1_2`E5PU0084`%X?$)"_8*>0
M!_"O@_BSY=$HA;9K(JF);7-@@QIT@,LI+C4*$D!M>"+3A&P@`00X#>\P8('<
M*,`WT,2`?!Y`D`"`:9T*:0M//6``GG*@`%+2%\X^<)E'^@6G6:J-`7(I3B$!
MZ*MV+$L'O"<!R?3'00"P```P0$V:,(0VA/G`!*UCP_O91`%W=9MRGHH`!RR`
M`!AA'<,X`,L$(#51#'`>0^H9R$$><"'\9`B`.""``8`'`[PBUP;,.C;"-B"I
M\NN/66!&%X=1"I*AZP^:7C8!#]2,IK+RZK!X_M.!HKJT=OKAW7PT(%69;&!K
M4A1>3&^2O8FLT*T5+$``7+I4Y#31:+S*``<R5X&0N#)S[GWO33:5.U*=C$5H
M(98%#N#!U.4%,O!BJ>*VRQ%%3F0#`I`)6C.IE0D@0`*@]6X'L(5<BJ6,(G.<
MB&M?F*%2-D0`=]GH!QH@E<_0D@`8","$H4)!HZ#T*A5(P)$H0"C]`/(`L;Q/
MTQ30@.E(Y",>2`]7+,`!A+PF,3;.P'E>UK6Z,D0#>0QM(`-0M0D8P*G[+*'K
ME**@"37IEQ-LW"8U\(`->,LW$'A(!UY2F)I`)#4-@``$PN9D`I0'SJ]S*@$J
ML!,!U/DI&HC1`6H(_N?RL)2:!T`/!0HV4H58@'=!L2$!``JXP5*Z`)2>=&;:
M!F.;-)I5>_1N0IQUN^6%IL(4J0JYD--4`5#@TPUH@`#@/``/HRM!`)C*!0@P
M%2H_+0("Z*?!)O*D#Z9&`AG0RMTD\&10DV9$R#$,3D:]D!)B8"K5'6-9!A4!
MLQQJ):C;MJ]:@A-/6D=?%O"@0F2<D`5@VVT>%,!N%E!E`ES`V5Q$``$*L(`(
M(,"3A>,),3L@4&N&^K$*62Y/K]84""#`31<`X;0SE($'<$I681J`O9KBX1[5
M*`%^*8`(QQ<3@MO3`%&D>``9%&OR+#2`TJKB`2#0Q)2OYBJ^98D!!#P]_J9L
MX`)+0[(8\_FG"S0Z/1HXN@8RD"@#+%4I[5;(S4%]M&K*[,)(,D`=<0*FI5@'
M:`CX*:/)`C`.Y+P\"\A-/%_HQ@^T]`(K>8"OA$T`Z>UHH4+6R@<3=U-`^B:N
MSY9V79JKD.QA8'(<D%<#*>+S">`)`XZO-@:DZWCI4L"?3#N2!SX][H3F.L8-
M3$#;)J!YY.1%.QC(3P8VH*(+&&#8;'>R`P1`L_"89'`-Z*;,;5*5`+A1:;['
MY`0B<""E><3GO9P`C2''J=V\3K,,98@%`+89;7[``OZ[`-->.H"%?9$"&R"-
M0&E^E<$H!>TT7^U>)V#^E.LKQ5(W%@1^+W^Y_CS@`HVGP.,Q<("]>[=Y$QDO
M;RQ:DCP?<@`-EA76H!B.0,F%JZ270ND)!)55GGP`!\#:BBF$!L#147B+`!2>
M5FP`"76-U)&&W_&&+@E)*L$%NGG``2I$`1`3`PS5R@S5`0S&`-'@4`6`0"U`
M+1E%!&!+!MB1\"6$`B2*U0F),HE)Z!C'!P"._/A6`;10L4D4XWR``C@(4(Q2
MD@"+`!W`ROA.,9E3#.*@@GCAF-37:D6:$[I80T3&NDP`+47`<?S3&,56^.1)
M7*"3.5W`%"&5\$F`.8D1`00B(=;6`N";I1$`#:X';2``)0E4)6'%^^6$V7RA
M^GBACH5&LA0``R1`_D)A3'=-(KV(QO^YC0#V$0'P7ZH0EDT,P)A5@`;LQ$9P
MP%@4%<DEQ`0Y2`)`P``T@`6<!D7\$\1$(ED<VP<@7[^]W[^YG^Z9&`<!R0Q5
M1`:XT%%`2%[!!0=HEN!5A`9$0`*DQP5XBP0D`%U<1$*`'B`=T+^\&LW0U/YA
M``+DU]L5"B<9B62\Q5C`3P8XVTV`B>D815D)BT31603D2>J9W^V$1M1A5;X-
MDJ3,1PL9P`5<P.E)"03(A"-2!+'@Q#6.7G]`2.H8SC:*X@<LP$A^@-ME8TUT
MP--X@,Y)W4X8299`UJ_U(U$TS`"<Y+WL$)DQ0-9(@`6<S/G\U4),E2,V_MA*
M=(NIE:0R+<1R78616(!6*$",Y(Q;_=L1XH1HY<\BH22[)8!5PIE"0$"D)8A`
ME>"T*5E-74>8%`!8$D#&N!'3!8="X$A9Z%I.>,!:3L_^59D$#)'"Q!56R0Y'
M%2,"],Y+!0M&>L`!F(0&/)U*,$``:`Q.,)A)L$4`L*(]<18`6,[HD(05C:4%
M7(!;_L0!V,N8),M5--!0G%T+6D`++D0W&46>3$`#'*8%=!I)NB#_C1+_@9W4
M>4^^S>9PF.)62B,!EM$W!H53@8[F"-"UW(SW5<K06`!=3L!;M,FH,>:#O)!X
M"%#UR02H)*/4213*%."MZ0K295A%8!^$D$P^_GW&55PD0Z3'VV2`!E!`-Z;@
M5M2D]_1C!=26`RA=<5#`L2"6!_Q'72[)?_)17)@1A&Q`5ZS$H>P&6R@`D!S2
M1A#+4&%5!2*/;5)&."X`J3"2GB$`0FQ`A0"<4T)(%0'``E`(40Z+:`B'1Z%D
M<*6;1`Z9A-S,52!/C.P$93896E($IE`&4Z#'V:G/9U`?22JA36AFECS.;EJ,
MVQ483>+$R0#G34!`*.+$S/650P@-:D3H`!"G@VU?F`P(`3Q=!%0,G$G&B*S7
M,3*8P7$$!VG`?*I:;:R?^*D&UMF&48F'L^"/6#*5@?C$`J2$5*)'[87.!6['
M0Q"HO^2(1`B8TI3%_K(M3UQ<0-1Q1(X@A',04G]\Q+&9A:B^3'%`IDUP2%(%
M``.8!#=A@,-8)0?TD&HP`$R((`5J275TDU?D:+VEAGRJAA)ZZLR<2H'QXZE1
M8_]`#@7D!W]\0`9H2P_:$@_>!'%*T?Y5*>/1CBH&X'$::6CRAF4916CTS*94
M#P1D!OQ<0+GB#N2H"%<I1`4<F$H@0'-HR;88`-GX4YU^G3+N:9!L0&YZA`4X
MRJVN%\).``6TQ$.(4`\]0,"H!V#<%DF,D4/D13+^$F<]!:IT@+,JV5+BS@7X
MCU3`BUVJ$"!-$;*^#'A]8A4EE&$(P"?>[&`XXEC(YIU2QIW4R2DYS_GL_A$M
MCM^BGJ-6-<F)[$8W7<!MRL>YC4X%`$>(=<M5"%1"]!*S?`61WD2M4,;^;0`%
MD,8`)$"5&80..FQZG%F%Q"@?E:Q"U"M%R$V5CN,>`9YUG")%1`MRS))'VM-0
MC(S]6&%J2&DG>EN]():',<3%-!?/!!9Y9-392.4Q-DO/<M"*!`#>XI15+L1&
M'>9$'"I_N&1)`AZ)]D>1*@2^V(1X5-X')`!M+(0#K!$SKDH%DN9*^M9-[4=%
MR!Q/<1!Q[89$=>[+0*53UL8@G1M?H>1]V%``R-!)$(@9024`R,3J#D<U#5('
MU"Z%F*!+BLLWYN:$](>7'L!XYL<5[F605,"X_DX$QE7$!ORNU-4;Q&2E=214
MM#U84#A`[2Z$OD@99W6`PR[`K-F1]_QC!GBA:9RK:2%`<VU1>@2,E&B`1"`?
M`UQN_NP(W.UFZIX2@!@J_'3BM."._%9-?T0J!W`ILR"9QE@(LS+`&G7F!%B7
MVU!-ZKBE^/B6!,B$@7:)(LHJVL"$6X')2#B8[HW?NFC6$U7`>@BP@T#(!632
M`R"5GFC``;0/V@4`0DQC-F;C!UA/!'2Q&'-`Y.%G%S\F;Z10`^B?>66CG$37
MY@I)!<C'&,>)2K()2V9C'HM2E8*@2$B1^E*&WDX$!=0D9:"H4=07Z,294ZX,
M2EZF(@I'Y+U44RZ$_@V9FNHYBQ):P$8@W\Z\7T%&,2`1IQPMA`I[G(Z%[J4$
M6HXT0"`JC05L0`;PH1V'1>I"0.)5!&=X10'DV2!!`%AX`*4(Q@#`5,1033AB
MGY@UT!=1B+.%<=A0H'(0LELIFW/(GNY1U3XI2&3@<J%LVA8!`"2Q%*F41%%1
MG58E5&KHUX(4%52R%@'A$F5L&XDF`'*%\ZGD)%.U%!]MT8N.GPYBQ5"%'T#;
M7)6N"*4LS`7HI""W;T;<8DY$&`!^%7C%4T&@E@!`2HR)<Z*9R+J-#.,:`+C.
MG$SFYC%:"08O3P3L&_$R#'<L!*4^$T?2#AD;TV<I1?FQ%DXKA;?HU^*2_D1.
M,``2_:CNR>0TWD:XAI13P(]_#%Y#54R"E@4O6F->K83]1@QW9&=GZA[Y"("N
M?I57N`D%-)#ERHZ"5H6-F3*#!.$%8$K^.5Z[)A&U/MY"2)X%L"I%I%#(G*=3
MD@=BW8_WR*_;2%[D4?#C!>$#T.I;3^!N=L!5-&9$_2UE5%%.A`22RB1SIH:(
M&+)"P&$GRJI3[4Y,BTB[_`[_8)U,1L!N()\.@3+1X?7539N>=.M-F))1'!+6
MN!=0R@SCY438/&<NXT=$>4=2XP3EO&Q_))[(>B'Y-M$:)N)H,(`1V9ED\X8$
M\./P'C&EG-A7D^\OS=I3W%[.+5L%.D"3['!N_B@(`[%;LU[&!*AP?[1T12Q%
M!V)=*FY'JDGP-%<I?W/D52!7=1N%S>9EQCR&!G2P352K7T6JP'7FD;@$?)!*
M:Z"-S*$-!&6&1(2QQ80'W'*0@3(`;,NQ3NC)R#(5D,0T'WD`I.2$`GC??^M>
MD9Y('.=$ZCW<P9504\"2`"WTF2$5+$H7>:B/`C(T91"7O82&"@MS@QP>`71W
MV(TE8C5(HC!F$<Z,-*F&3`0A512`EP;W5L@W11P0C.G0)#6)`PC+(W%=?Z\Y
M_+ZX)0>R4>!O3F#1M8:.(@;`9/&O`>QT=ZQ'#-:;`,3H`R@,KU0&K*$.A/37
M'S-$!&PKF6R%MY#%_I^4KDF^WW<+-I+0[3/-QTM6;2`%.!KU;W$PWFIRM;`%
M0(?G!`;T7'@]1SME"3E^`%QB%[52A`2$C0=``)'?-K,"5I)?!4B#"5A@0"\_
M50?.#)EY:87Y1Y7_1VXH3I:S*K$_[TUT+V6,S(`>P&A6;^A(I+&%Q5RQ^9K_
MFU7BML\,<D4D@)=/Q`64[P&LM.W8#FWDAQBFQH@0R?>(QE1(=X/0TNM"B`9X
MM9YTRZBY\G98P$Y,QK?+8>*6IX)<M=N0#G*(LBW%74X<$$*7>%DPG;%(*7),
MET!7DV447C82W>^([406GLH+1ZY5AREE%"LAB;AU]HQ&2'VEI\KH9\`4_F0$
MH#KNM,65!S=C+LD:+XA,/$IM)R=%4`YOJ*.344!3P,\0B:KOB+O5.Z6;#TN=
M\X9@Y+;,$/NZ8PUEP&:1J!65I493.LM5I$0J>>E$U43/-\@.H51FC-$0Y04%
M_(H&#,[[V1"W>U=*4X4M98U1D*B><FU&?!7$0"B21%Z]>?$'-1R^Z6##H0^P
MCP_@F"6V+`MF@8?/(TE#-7)60HY'78GJ>G6BZ)\0$>4!A`:6\44&9`6?E5(!
MR$2%5'LO5CN83\3^'1"L$N%;J&@&20!+@?K50QA4;CV2R+GL2HNTP##1616H
M3+^#=(>KY.;CB:_//0!:A$INCJU2:,!4+<AN_H1&:DB%R2P(#X:C:D`*=]B&
M?GJ`APC0/D6?\MO$-?[,'!M_10`(0@`$!PX6+'CX<!!A0H4+&39T^/#@A`D0
M#WI`X,'#```.%EX\^&`#!`P*&VR@Z!`#A@H2&GKHT,'@A@@7.,#\T"'#A`0$
M&$C08/"@!),%.#`8>;)AA`X*(51PZ"&!``-`#VY08$#A!@(`"A@<H`'!@*,(
M+QP@D"!!Q0$7;HYM:$$`!X<<6"+]D,"#``\`CD:`L'"#@0T+G-HU?!AQ8J06
M``"@0/5#!LB*#P((P!#CAL:;.6]^X$$#!@X&.I<64*'#A0H,.OLL;:!`:=D`
M#"A(T-E`@`"=$P18_J`@MF4%`APL`+!5P`(#"Y@O<%!!=07I%2@PJ$[A(`4$
M#%9>Z#`=?(7B#79?V%#0PLBE!VM>R&`RH0<(!'37U]T80?(#`1(T#TM@`0($
MH,\`!R1(0*7G"K"`LH<F6`\B#@*@`(/&%%C@@83J^F"!#!3X*R$,(J`,@Y`F
M0BB#ABI88*$,*)",(:$^(&"T$Q5CH`'P,&!`@`DTB$XZ^#S(@``-%EI@Q/@0
M8.L#O3RH0(`4$^*@@`D\"HS)DR)(DJ$-,K2K`0\6\(!&A!+(\B`$3)+@@`;=
M?!/.A29HK(#"#H(13JX6*DZ!K6;;;(`(&E@`@C\W$X"""AB\8+?-BBH`_H'-
M')#/3_P4&*XS@SP@#;\/,')@,P0\/:@#3O_LD0(*)*AT-E$]-72S`)YCP%18
M-S/@@`/Z5$"VV@ZP]=3;-BL@5>HH,`\A34=5%@-E&QR33`%8@HRC@UA4R*`,
M#IC,+M$N8#!9A^"SRP*Y+F+`QL1`Y:Q1V0[8DBW;;CK6H`X.&$E9!P0HB('U
M)B``7+)(,ZA"MBJL38$(*)A`4`F*;0#A!B)P((()$EW8,`7(U$K*#R9@0$,"
MV!,YSI)-1DR"QNP\^0,`0%9(@0``;&Z_LPH(SK<5<0RK4?ONX\^``01H]S@/
M`IC`@T$G_:`!1AMK@+T![FLL@4OIH_.!02.E_M.!!QR@H`%;!TB5@PIX-=15
M#8"%-@,--(*5@`K"!O;$H('%+@.B3]W*@`3"LE6!"0)'$@((&("@XDL3Z#@#
MR6!"P()"`5!@X:4]Q@@J7!=H@(((!O`3`I<P@HD#T6'RP(*%FUU*-`N6U&"#
M#@K20"#07$H5<]-'+]TF]DPRH`/N-%46*(PJPOSTIR`0X-`,*CC@;:X*\#-*
M#R@`X.TP(V`-@:T&,&F"[QGH\`/6`(B)KYL@8*ZZ`II[/X+)%QB?.:G[6YDB
MC0FX`("`/U!@+&UBCP!95D`#*B0#*CL@`*YEF`XXP``6.!UD+E``"'U@(`F!
MB?,LD(`P+40"+A&6_JLTB(&V6:!QGB*(!1K0$PQ\RP(/8,#X`J"`7VU'`-R!
MU`H?(``?ZF9^$I#8#,'F%^Q\H()"&]H2F1B`H3GQB3Z#HGT04(">6<8R4Z/3
M!,@#+)=Q46_1X\P#)`>L+GKQ91]X@*T"`!\)!&``8BS-`OPV-#8.2`!6M**A
MIMB8`00G5K'2#0+0,KT;[J9O0R.D#6U#@`*@12,:@:.L/J2`!NA$(A-8@`#$
M&$=8?:XS<=2`!IA')[FDS)1O,\#ZXF(7,KFE01>1"@!`=!`+;.L##JCE!Q`0
M@=C!Y"4O<0DP@RG,$YKP6\`<9C&9*<S</1.:QEM(-'-WO.-)4YH)41L`_M!T
M,I<I1B8R*X!@-)2`"RJD`G))"-*R4K[-0(UEH+D@MX*2EI/0KB+`9,_Q-J#.
M#?RS=+"#CT`W,,H-7,`];7O//S>0`0L@=*$/_19"7SC1B4[L`ABXY`,F4#@6
M&FY0`S#`=J#'24X*36A0S*/4`%!*=O4,414QCJT2T,]5V2H"M..`L`RU@)KD
MTE8$R(!`YF0KD+QG77PL$>RN![<2-=2+FUD>N\Q#`:+U*WZ<85!3G\:``_"O
M,0T\249VV:!M;2`EDVE`>LR9D`L(\0`#XLSG!H12!$!LA@P80`M#:@`"^)4`
M*`4L(4]*@+\>P`")+4"N$)LK7$T/`9&5;/=N_F98PX[3L)$U9!7-,E($F&6R
MDN6D`=3),@"DRX$?.,`>=]D!`GS536=K3$$**`&69.@"7%((`^Q)D0(<$+@G
MVX!+$()6#F04N28,S05H!Y0,<`X""#C6"U_(I@8TH%*70BQ//C<`WC;`+/<1
M0'\24(#K.N"\#7B;2"VSDS@&=@`*N*L#6-48`1R@`>A=+*2<"`#H_0I0<?S<
M)!OC`+]!+Z@10%)2O?BW845`1("DY0<P0#3LK/%6"%#`<2.0FP?,!"FOA=-H
M_HF!LGY@`P&`9[(2()#QJ8H"#UC-=8]H/..=$S,."8U<7A(9'&.0NC%,;D&3
M*YD,9'0FU$WNDBV`_E[.C60#$BBM-_UGF`H8+0(9P,`Y,Z`O^/SX(5#16[5.
M9J`/#,!Z!-PM"1^B@<L$%\YQ=B5#U-F!E.!/7*$95TM2TF<CA;G/?09S/P/=
M9\E0)7:AF9@#&$T=E:3$`A)X805,[(`"%(=B!@H+`QC-`,/&\6NH'!"!9_,E
MGF+E`XQIC,P:0P`'$^`Y)\E`3-^T@>G!4<T(0>]"AB.UP!HVL;@2]FH3ZT@#
MW'?8&,(5Q!![E<8*.P$1.`#B'E"US35``0SPR[8QH($,1,"VVT;<N,4M[LZ1
MNRG_E,`$"LK0"T0*S08$`)[MXN8TQFC#4982/:=T2P:*QZ^^+"`$)H+F_E4U
MA`$!X/<Z42UGAS_\)"SJ@)&.#'&+PPD!'4,(02Q-2`J8))T-=:AMZ>B``8"(
M`]W[;$4>4(`!9,@!TD5Q!D)HEVH+M\<+.<"?X],V(UVPH2KI7.-$TCB'&AT#
M#U#Z`R000PEPM'&J8OK2J;Y:!E"=ZC=+0-8.@`"L8WVU"G@`;-QW,[,OUF\N
M/WL"K*,0,"?FM)21D`(@@I,.6V>Q_+;``J8GH@8,C0()@,`\%VX8XYF$N`QA
M`-TIDH`J7QSR#U\<!XQ4@1-''O,/V6G).&"CV(U*@PAY.T5D['"B-$0#$,@)
MU3O`@1)E'L[KD<\'?J)!C;O),0TJ+U(\T$/I_A'@`=V6"77@Z`">DZ9`.3_(
M!>X-YYM3Y,VPESYPC;)WII%Y^ME'2.=*EGI=PU(AE%=,!PJ@V^`.8,IN?39B
M7:Z1+T7F:TA<RC^+Z\]F>0`#,=\S1.3C'$9+P`$RJM!2@M$*,`!'[RD,@#QV
M*?]*!@`V)#$TX_8T;[C`8M7:90'V;&YBHP+VK_!8!KPHH@+>3_M*D&64SP2G
M+P&PSTV\+R(8CV46(`!X#LX.`,<X8/\J`JU<D)?V8P$02XU::`#D)BXD@'D.
MX'JLJ)L>0ENVY*8^J^L.`"URY;,40*0:(%+,SRY8(P`T3@/H33'ZQTW0(OU.
M(C_B*`($(OT2*`(D_JCT,(]'/I`":#`%Z]`.[]#P"``"W>0";*2#:DMF/M!D
ME$-HX`D"=".-/(<$KR5R/J##MB.7)`9[XL?-**`H-$!CRO`A,&!#/$`N/@\'
M#X)62$53$&`/[<(X`L`MLNE-'M!-J(18[$(""D`!&H<!^"TJX`/"@@NU%H*W
M(&(E\%`8AY$8W<X5X\3$-DZLX&0PCF,)@4LL4D*=W&/+V,-':/!:'H!!2@4!
MG.*2XL=/6&-(/,5O#@,#4&M3MLP`7H8"8!`A(."($.-Z`@!-.B`'*4,,6W"-
M#D`3DV4U"N`!9,\A"``&I<R`8`3*^O$/YV)!BM$A'S(%.^`8X40#;,1#_DI&
M)C2B`)X1&A6@`\WD02"B6IKN(&J#)9HF`HB"-%*F`V3P`O;%'$]Q%R4`1"Y@
M3)BB%Y&""^\Q3O+Q3=X-`+9N#D'/`R1`(X`GQ,B,*CP@)RE#)#A@1#RR(>@(
M(JO2*O'0`\JO^^*10^#$>L(1QP313>(+"1%B\;B2(1I`+C!`NGB+OK0CMP:@
M`]8(`P0`'B<D`.1"+`^"$Q=B%[GO(&(M(0B.(NCI-@+@\1PP,16C]Z8&V59M
M2<@%CA`03B8@G;##`193)QR"(Z]2&.ME*5C1,P](`;LO712.,BS`8OR$'E6D
M'^,$_<*%WR!#!@$`VW3#)&00:C"@*SX@=&8M_@`&[SZ:DB'>"H1&A`(@@`-"
M)_X2@@'H,/P$0"T7XC`+HG=,9@`6DS)`PZ$@0!L)HC,;@KXFL(`LT0,XPF(:
M`@$N[SQ)<#2)<><RX"\8S>)$\PXC`"_>1`(6('*HHC<38S0.133BC%LX(#8]
M!0%XT^L$A[D*Q_$H(#1'"2DP`"TQJ/8HD\(FT`),0B5"`CC2KP&@4YL6("P.
M0.-$K0#RB)`N+PRU$_.TXH/@[&LT@$4(I2'`9B$P8*0P]#VUST1=Y/H<KO6R
M$OS^C(YX\N(VP+O>9'GH*Q8_`#4/XTFVPC?<P^&,(BNF`B'6D@$>B0*2BC0X
MZ;DL0RY@9$,]@`$"_B8C6$)*6K*74FX`WN4#,*8X&^#IFDX-\_0F!$("5L)/
M"T!$BRM#W!1""B7>:*\-7Q,Q?%+[**"5XNP!8&<B&H`\/\"V$F(#+"8D>]0A
M3=0F4B>X.(`C]$KA#A0AW$8!MLE%+4X&'Z-!.D!H&@-$#M4PLFHB'2[*IHP#
M'K4A-L`HVD1-QN8`5',I!H`C"*"C;/`=M30`6&(""B#AK`@!)B!%%F``&J(N
MXZBD9,:.QBMH?JV[-")0#T(#WN\!(A.H1$;\,&@O3X)1LR\J%-5DG.(/`:@A
M&B`MEG-YFH]3AW%3*(\MO"VX=H27%N#GJ--15:4:LT])XXX[Y34M+:-?_JRE
M70="KQH#*2%.3.C05.G,.03@`@@@;"H@/VE/`$1EC>0R60#&4P(`*]Z*_/0*
M3V[C&?MR2TT")T1#`FIQFA)@7%'L_7HOOC(@-MHH\;P)8BV.E'B593!`61VQ
M]>C.3M_B`.A(87ZV7^OP@3Q%+J@CN"1@1!!G`8ZBH`3J7$YQ^MBRAH+COC`T
M`ZIM-Z0S`Y;"1W0L]8JC-RQC/6GKXAA@RCJ`:1?"`J#5G(8F`LB$M#AD/G("
M>WCN`33F`U8#``9B0`8/0*1D\2:"#FU6(2R`[L[5$AG"8-NLRF1'<@1@N.SS
M3:)/^_(#_)"B`T*WYSK&`\;%;]4(Q?JU@K2P_D<]P!T9!K@X`$#4:0(X@I2X
M]0$(('AZ*P4U`,`V`PRK8A;I1"4`13D:X`&<9^FNKE:D`AZQ-DD#5R$,3#O.
ME40U"CX08#<V:3^O!5:=PEXB12*48T/_LRXYB2&.!3/X408;4N=^]@+<TRSM
MR[)NA@4;A'6G3T(``'P;(H%6C"\;XW458D#"$R*T@P`JU.+X1WFSEE34K"D.
M@T?9PP%4<2D`\Y^&%/T4`&VU+R,XPT9Z[$MCKI02QB#:$`)RPU82*T23-O("
MH_`FP(D"AQ\!H(=6L#HTH!WI,2-^8E`,@C$@H`$>B=,&(&4XS>0@@'].\0(T
M>%.&*\H.V#=_MEQ%_B]9MB8`#@=Q&,""#2.!I6].(#<Q*B#NXN/U*$+_/IA?
M'<2(1Y@BM,R/$:(N%2"0A?&YXN,PH,0=*8(##/9DUX(A9`@Q*2QZ8:]6@$9`
M0&DSD'#*'HH]Q.-=)F9+1(3=Y(P#*M4N-L`CYF(F,")%2J=S&&"X2`4^+@`C
M=JXJCF@#YK`#V&U[[NIPD6@)50(SW/'R<%E<`M(*Z^JKWH..8_1DWCCS?/>;
M%(-_T-(#O@7%'`;;5@(!Z&@R2D=`LD0#(L<[%,+;KB<Q?P2A),I'LIF=IBE2
MV(ZO),JBVAFA\!E4I"N?&Z=TW`.A'C(Y&\1+_(M'/3$R`IHA8M>6[?`G_FIW
M;+K8MH1HHM<MHQ0/31PJ\TIX5?E/CA'CH!!*BRM@25@(7[_JGBT*E;&5/%MR
MIVQ(@#EDI;WD@1F#5RXD<@7`"J6L)$J&9"!..TMEWDZB#+,YG=P.<2RUU6(C
MLE3,2*!5+J3-43@@;$KI:3E@/[!(C.>&,^Q2,Q@X_$J'-'8#4H)-L8Z#>0;D
M+&S#JTHC;IFG43S+<&Q+OMANM?+(A\:+`@@"`U;(H;8'761(A@B"\YRB67*I
MD.?$ISSX@D6114\B4N.C@0VH)04@(!%C+))&,69Q`/P&+0C);PC%P+9BCT(%
M>U9Z(=QC(,IE(>BB;LOTE,MG]&*L,7V(-M)S_J96+0-+9H\QCP-HPX<Q0RRR
M0CH]ABM&XS281@SCE"T,8IPP@G^F(@-(@T'JL@"J]U;)PHB[.#5L^:OI$"@0
M9'U"TU/^26T>0X:N\R8(,B`%PI:5:8/*QFLX(%4NB0*01%,7)E7`I@%Z6<,B
MJS82(,`!3(JD:$"^^9MO\T(0P$E_93>P,%>ZICB<8W.DF."0Q+8DHZ@"Q8/`
MEGZX0SHD@'Z8`].^6:0H)#PJ8'NV1SKN+#P*0LO8-=6RN9_V*4ZTI4$H)R%0
M.[A8@SCMH@+("3&><^&>9(+@VU,T^"%*N%'*;SVE1J3HPSZPR(F0E&G`)<HP
M1Y`!X)LW%'9*AG<Q_D,OV]5!+F@]>$2,4[EP2(54=KM0\$8IRB>8PP9<G-:>
MK@MJAN2T'BA]/B`V>-?-3L1.W!0E0&^:AGM*8N+J-!8SB,=37`2M/NZ%5&5[
MO,9ABJ584,@F)\!A(D`!OB9ALHWF-(!S?B/FHL)/%D<H\"\Y-<*V_^I2',"&
MZ$BG?X6E.,,L,AC5C\.M5^UJJ)RE6&TWAKVE5HW7_:A/.D/#@F,Y.$>7_.9"
M+N4WHDW!=C:N@G("\N^U+B2_M@?3!^-2&@`"N'WQ-B=5!.<WHCUP%F]0+J0F
M4H57+)O3/WU0%L\Z5B3=`S#;-,E.(6@`>%SQ8"FIBW)[MJSK0@>=PP\B_OHE
M,Q)%)0H"(TJ'>`RB`G[K(0Q@I3]]Q!BBX:1/(F'R<A!#(O<P*YVB4-AB%G^G
MK;9B+,8I*.RK-X[&M>)"+@I%1-TL`6ARW29"207HNA#O-Q;$98MK9P7<B"TU
M>[>/:FS+)"0HZ9C.SI3NRK93(!X.)T@$>^J1S1NB)@JYM3>1+"9"G0I"(/I)
M41YM.BR3$_LT/*Y..CJJ*6@R`LB(.AC&8?JT<-9X.W`$`G0I`BJ@H[S&.0A.
M7PFN<,B()J7X<++&\//>\>'1<`@%`)EG`2Q&.F0L=0PG8?+^NAS?+^3K*\C\
M("AU?$<$=9"(4B<E3>/CL5%OX7)XD8O+XAU"_@)^K`.F^+H/Z*>ECXX#H)(I
M0B*UT.N0:,)L_@-(8R)X)6#,8BD*A3]AO"8$1)T*92QJSU/D2!6_^\P`(#2]
MAXY1+8%L$\.@AE>2I%`*`)7BCE/^2I`V@K$;PBA541B#&REL[>TP5.`$&8(1
MHW0HPWD!XD"'#P0+&C3(X6#!#A8\*'RH\,&&@Q8&$N1```,%`A8B.#28`:+(
M"185<G"0``%$#05$$HSPL`.&"@`(7'"),^>`G#Q[YO0@`,!.GS%K(CB*P`&'
M```^0`#0X`,"`!DT!+VI`("%@@4`3'0``('#K!0^7-#ZP0,!`#`)*ICX`0,`
M!Q8N8+B@X0.'H'D'_@#XR$#H!@`&""ZHF?8`U`\)`$P@:`!`A0]@'5,&4,!A
MT`8='LPE"CJT:*(5`D@8C3JUZH,(HJIFD+=@!06K4V,(('8TA9*B$<"5G3!M
M`@P$+1P(P/L#`]`1DA?T,!L"1`X+<,)&.`%!5@``B-=^6/C[Z@T*`M!.;8'`
M@`,#!A`H(`$SY0"<#02(8#]`V;63/VQ@FL!`BAV050`3645?8P!4I]`%`3QV
M4`<$")#0`01\U-@`@PTPD%_]#1;54V5E@)A_C3W6E70?K$4030Z(!V.,!7DG
M8XTPEE:6:@;$5MQY-O*D0`(?A9:!<T0Q:%`%-WDP`0,;<.!!!QXP$%Q!_DCV
MY("1'T2@008J/:3!E0\]4!(&`B3`@5P`'+"5C0+\2-1O$[05HP<8#,2!!G!5
M%<$&<"7EG0<7/)#E!QU(D``!"D#X@08*%%!`D&TZ%1Q8*AJDU@`)=>60!UD5
M8$%-#D76I@:+R379?RT92A.*W1&$VTN?P2G>!KQM,"2MNL*I`0&7IK:C01V(
MN6MM'G"0IFH*Y-IH0ALL4``!!U"`0`(,,$MG3QY!U(`$%20PG8\0':!G!4>%
M9"AW!$2@``(&'+#M=P$4BY,!S-+K7[8YUJB8:P@QI0%0`C@4`7<%#!9>P2H!
MM1A-IWT065X3<#<!!WZU90"X3LV*[V@2O%C0_@"3=DQR:@RLJMI>Z!:D<<FI
M(0O!3:D=T,`$$-P,@<TY4P`!EQK\_'-5/U>P'%$8W$N0!P^PN=(#+JFU@'GQ
M?D"BP9!"ZK1X*+N\6@15HD;CBC]&,`"C!0UFH`<-+%A`4$+%1\!`\4%UV&)3
M94W!NQ5$YE@'%Q,TP)L?K`TRUSY];)"FAB_>TP8#\)B:WS(7),#*C/?DP0(O
M:NG3!!DO<%3&!C#P[@$.&#``4P$88`"D[XG+DP-7%W!R`0T\\,"CL^\N+4X-
M$$`!LU47O1",X5VN$),..`!YH\VGML&+P;UJ8P?.>>!GTA1$T$#/#PR`0023
M8M!`5P=`4%8$##Q,_A`%"O!-4NLC!B`X6%\B[U($OW*(?_\&04`\U7B@`,TC
MEO\>X@$(+,`"[*-5!_)4)0\@+2<(F(">+G`S_?4L@QR,69\8<`"<1.DA@^$8
M0297F^,9;@'":\!Z`D"`V)P$``%@@`,FP@$)3.``Y)I``_IS@09L"P,/B,`$
M)N`0#+0&?(/ICZ!F\@!T:>2(D,/`7122@0M,A"%'`PWLGO,;A4A`6N&K"7&D
M]!$.P*4#MCH@1"20K<>Y$7\2(-=W)!2V#QAPC@7AP`0:R,>'F`V+9(+(!@)(
ME*H5KD8JY-K7"/(4Z5B@`7GQ@'TND)X%?2!4W%F6F2HG%0#<!",#0(``_@ST
M@:X`0`$:*,W9N,.=TQ0L<$*Q2&FXHR*4^(6&"7#;`/KS$`PPH`$-J$@'"K.!
M"C2``7GD0`4<D,<"`<!)"[F`Y=)R`2T&LB`1"!M)MFDX#P`@:[61T#47<$UP
M%B2=ZG3`!#?92(,\:S0E7*2,XEDR(1TD`ZA#X0<.4#02A?`L`<C`1Q1C`9J$
M\`,T(0X%7M65"SAD`PLUU%JFY8&J_:PK=^H*20XSD<!`14T"V,!4ODB0`M"/
M;PS(P./6$BVV)$T"3*$803+@``)$!@'!,:G;"O"ANM7PG<B30`,/$$9UXLL!
M`2`J:)IX$`H`4ZE4Y1;G.M`RA6B`G*"9FSUC_E31<))P*O1)6@!P4QY192``
M6>W``7*G23U.\UL`D(#?CH>!L%KK(Q,(P%#B@T2_3&1B+UH;`[K)G9L\!:5^
MD\P')D:E\]4D3TR!2<%*JICP*"9@ASE/9!Y`T[`0I#'K"TJVW/@`%"IN-6JL
MP",/DBR%.&`!KXT)O<YR)0]\%30%R&,%IEK5X!;D`;4M"`&*NX&M$65N!(`3
M/B^W@4HZ0``C$HH"%`!:!70@`]+*5?G\`J&U#>!JIXF409J;-`(4+C!ML:0#
MGI(9P^RD,1+UVX4&MTJ(5&`@&BA8`S:@GL5\('<3R<IR-,``Z>Q%<1R@H08D
M)!D[40`NASE-!BCP_CS_06"J&JH-)U%Z4Z8\Y##^?$A7DFHC#R3JD4[-B0%.
M6X%!"C>XA1+)`9`;5J)$(%KWX]<<+VDG14EPFH;:@``H=)9&F@HS'XG/32R@
M`.(4H&P\4\"56%>04+D&L!:8<D(XD"C\2L=4%%).?A_RE#7=3:0]9IDHH\J=
MF@J%(!A80.L4T("/J(TI!L@C:E%H`,X1A9-4@8A:T)LT"6:EQ`I96XMK<YCB
M`NN:%?B54C-@::HJ)2U(8_$ZV^P3Z#Q6TJO)JLLDD.D(,.64&3%,6""P%B&=
M1;EGD>E-Q\F!N_F-?F<50`,-P%6^9("CH21.?&!RF*B0.2&!02D%5A>2_H=&
M0`(,\,M6-K!7N4H'`PEX4<$4P`$+,+`M`V&(8F@C0?]8(#",[A]Q#;+'T)#5
M,L^90`(2H!@`).18:^,;(&>$DFK_A2`=F(#F>(/@!$!@C3*!P(L\8`$(:$>B
M!_D/(LO)D8-46KC'>O0![2<4!C`@`0LX8@3N3?*1&^`H*5&N3Q#\3W9^Y[GX
MPD!M.\`]`TSJD-P90`,2HH';'<0#^($<`VJJ,9KYYY%[V1H$Y%S2+07@`%%[
MU5I@8JK[=@6E$[MQ!AKC@.Y-A;:<=,C$5$*BPL@%9%Z*"@4$<)X.'%EM!E"1
MD3/MOW=;J9P"<("T#?+0UJRE*9<1``AC^1"+_DW=;9TZ#)^#\]!3A@5[]%-7
M!\#"5CZSI@"DIN<`F,6S&1=\QAH(XC)/?_IA#C/U%,#D84?3@>4\P,_B,77)
MBBLEB&01Q3WQX<@@^9`,7--1"&#FC%H'JA[A,`&N&>;OAPM+`4PY``O0P%3B
MS$*S1,8`0:%-!R`@`!Z>LCH5"`H"QKBFQQ(@``^P0+*W9$0W,@`!`#TYWD.#
M*L5;Q)**4Y"A/OL!<[,O!N$946%D`^<9#X!@B\$P>:(8N^$7!"`!"?$4""`3
MW9,D'28C>:,0%7!:2H4],^8RF/8!"B!SM6%[(E@;!^!QM)(!5F01$-`F%"`!
M>!%5M-,0`+<`X--'_A%``&04'+K%';XV*@N08_B3)A]S0[61%=(2%%D3'^=Q
M&RVQ(0.A-`-08I8D`+'Q4%%R9`-!(A0"7PX1*@:P%`!P*7)G1K<B`!_X'>2A
M$!&G@G/8,10@53EX$3$2;W0H&@(@:%Q#;9&#.<*787S8$WXQ`(?'@H^%A@6A
M'6G1'DWV9K`E`*L5'QEU9A)B(/'Q,`UV,+@D3UX"`(9G$9[S(^F!9H:HBC\B
M`4<65K27&GM(+[#8$QPP@/[1@ER1B_0B`?ZRBF[T4(726%NA`0-@+P$H'Y9D
M&1K`%%E88?[A%]BC'@,1*@$0;J/H$(<!`8U5.!20@Q80&<0!8+X((\FE_A_,
M<G&_.!H9)7R[R#@>H`$0@`'")WQK,XK69`'M"",I*%R/5#&A<8P?UV[JN#@>
M,!7[%QGWI1AXX7\E&!874#>W2!"!81.>H6\,!0`39E@$P1^W1!R1<2F-(1&B
M:%?/QGNK,6RPM&E[1Y"J44+C%%Q^4P`&H%,'0).PA)/4\QVRV)(K`6*,8U0]
MV3\-0"!#@FD(D!?D04,]MT6>`T.F\V]I\5"C&"G2=5:K]!%?QQT&4`$.<727
MPA*CR!TL=#K6&",<T`!^M7Y,T6IIP9-"*1+B9!SWQT=8)4%#,C%M&`$1T'JX
M`B-O"9<&L5N7(P$_&9C^<RPOR`&\$25_"'&+_IE1!D$^4Y,6&2`!N6(]F((L
MR*)GG2<:'3"*X<,1`%(0Z7B8(H0<!Q"5@11["E$PJT1,/^2..`&8I_F'@*A@
M`R"1I]F2A:@:L`@=V=$SP'4XDZ$!+[(!__@2)$-T@4112S&8?`1F"O$4;*4`
M>YD[MWDDO*D0;D5]OO=;ZS-;=-DQ-9@TW$DR'1`P+;DD$A0^VJD0-+(!Y`A\
M-9<6@90!?MAWP95KU$D8(#&;+E&;!`EN@Y>3`0".R$,HZ`D:`1HAUH8_,S&0
MBQ,!7,62#"I"`*`!IA-<S7D03S$4!*&<XC&@OXA52Y:3-,1M136AZ$D>US5M
MQ8<!%K`![D.?//$4_A9J.!O!':9)9PTP8:L!'<1QERZA1`\1G4^3;NSY)DDA
M7$@2)0F$&12`+A<`)7^)H1>Q`!V@`")G'P"58,6HH+N9I1A0@RG*'>=7:$1A
M2?'U'(;C%PC`%,0)?8ZE&C2Q'%D!:H!G0*9)/O=V1(B"<BG2D[=AD+0X1YE#
M.2E:.-4'(SX*$04771M@F4;U?,D3)8LI)9L:I6C4*5':8I_Z:">!*:#R$1U`
MIB2#.%D:A_N%IDP6`(@J2#H)<060`!(0&P^D`4:UF&;:14E3<*ZU?Q*TJ]II
MC,>$%A#!270*&J;B=@P@8Y*9@H.Y3%)%`6E)0P.`J\JT3:$G$F!V+4-7_@!N
M):L'U`'^0DP)4%,"0)YWVJ#9!%IAUP`.X(8'X0`'$"VL\RX_J![(=P"APT/X
M^J\\1'\#.[#O,I.C$P&:TS/3MI=P)`$)FF4:&AN.XB<>"$<G*2Q^HD;68X4(
M<9\/A!,1RZI:E1!6=`&SE!*T07A$X1D\DA5!,HHA43!^=59G%1D5!0&T)!@=
MX#I"$:VR57E)6C46`6;_NBP$=Z\%"TQ$]Z_V$17AUBD/I$1(L@'$M0%A<W](
M9)"]E4P90!->`ZF,TV#\6!`/I4_/01L(4*[^@U5BA(WKY*`0T;;5`X\O>"<:
M<"=ILC*6Z0#/]``;9D6#:T45H!'+LSP68F7T_CI;#H``OT*40U(![F&,E?B#
M'"H28S1X/VB,TF*3!Q!^TG)1H$,S`+1!L!8I@2M$/<,S^N.Z&_2ZS8$3'H@7
M$3MMT:5#_9,<',!Y!F&V(G%O0X)O:3$QIW%W<7&/'C!>!)<Z&F`!C;$5D=%W
M'A=[1.82G+1%Y<$>,&EF-1$4J[(!]D&OH`@6D^&#2SDKCN,V/`03F79(QL@`
ME;@0SR9[%W%R"Q!&X;-!"-$S>`A)$)``EPIX,7,ON9<6K9,38&$YEB05JYDT
M;31"/P$:\&D07W08(:H7=>L3S'J8$A`VSRLL%+"8>N$0PJ>QYTF/PG<7650!
MPF<![:?"N"/#,SQ=_@S0>KC3`$F!.]!".S2#73.,`*GZ$@\0+9#R/E>3&V,%
M`:-C``J`,T]\,PJG`51T%T!CQ3]3)7FRG@P571:1`0*Q$$?H8O=S`4&1`!2P
M=@'HA[#R&&JQ90(0-QU`$Y/Q%$&+0)E$+C^C>]R1%QA1&)GS)0O@*U0#`!HC
M%PPR%5MA*<B[2AF0%>+H'C/J%[112`N1.D>V)A!"Q(T1J\O!`8'1%4@YD;W&
M'4!T?;9V&4/(P:$U30Z1)Q>0*.,*25\2=B$!CWJ<%@0P55-"&0+`.@G[R[_L
M5S1IC-H1S/J:`,C7.@:P``G@Q#?CN._3Q.6C*-J!,]BUQ`JGS0XWDPIQ_JN6
M<W(Q`ER>@SX-0<00X`$4@!(.7%4>W"7(\G946A5$<\(]D46IH1;]DRL:!`&!
MV\__'+C^O,SZ.I/1HE/NLLQ(,67K$3K]VFU^03,I!V+6)SNTH\,-4(F`(13<
MUQ[7F5G];!1IR:X[JRY3)@#=\BFW4T0Q9E0S;$V.O$J[Q!WR7!4?48T3B6NV
M6%#(0JD9,#%94QX/\Q\5(6UI0C\!$RK!DQ[2H5NX<1(5@RQLQ)469(P0D$4U
M1!/<<6.!H12&M9APK`%@IDER!SYYI11J%!93W#L/@;88L!9D(E(!1B4>P$,)
M$1_244)M860/,"0<H-=!`]A=$MBE=S.!.P$1_D>E&+!A$Y!-6?0`K),2!N``
M_OP`M_/$IS/9CEO83SPTSW?&$5+/H0%<Q\(![6<!S'.K[.I:ANC!D><VL%1R
M0AQJ%(Q`<8,\<@@C2[H0#\3;UK.8FIJ9,>/;VP5B43*I#^:Q[E(03P$3#T2C
MI/0D9*&>-:2>H?PDSKN8H)L!DVJ+KWNZ$3`5$Q#=!L,Z"S!_%G'3#FD!<](O
M;0-#CIN1'$D`<+$4#0`MA)',H[@`"A`4QL@4D0(M3,$>!Y`2]W84\3MXTE<3
M$7`<?O<>1\9\J'9O@3$`?^L9#-(8VD%_U4)6CQO!"A$8SEQU;5,3]Q84[\$4
M&LX4YMUS/^AXI10M_JG#`+-G11G@3-/F`!,@$3G1)8.+M_/($S*!+E""`;:2
ME`4AV!1`*,N#QABQ`!0P`>K,Y'/;@?LT$4!JU4K[B]XR0&BZ`!MV.99T@@Q*
MC+&Q`!*P,D%'),=%$*U8`-D4&17`C+:=%==VT@2QD0X))9`B+"T,$9X!1#0T
M00U6:,?F'^$G5_HD%^@2'R!3OEM2:&#1%HWA6GZ!+B(R>B#!?;0STR2"=LL1
M)9[Q@1.@2F[#(&BY%E%'9^=[?PV&)`K<&,'12VF"E6Z!A13#L0!6.4]2HVCZ
MVG%&`)J#`.IA0S<#I-CZJK-G%\M^%\V>-^H2.'YAL^M'N:I#0TO+0Q-#_A]?
M;D.@0]LYD501,!D*4`'9-UJ@9(AO)WDR'6?L=SEO6[(?.A_MX4M`-1NAH;P\
M11#%"$O78E\.L19/5E94PQ3M\9_*BTJ-XA=N>A!R00`,D%:K1'LT,2]Q$7[]
M=1^0OAQN/4X#(1<WEDG2L0!1M\C_]&8T<1-8%=\6^B[#,C'QM3:623\#8)G_
MN25O,6"X]D#;+2PL`3+((I4$<*-G$7<S2=<`8!$(K!;$\U"ALC7Y:4\\;513
M[\$2$+@2L-\XS'U(P?6/2_53CP#LGI/C=12.V]^C.!4%T/7KPP"C[1?L7!O%
M54P/X%H24<FJR$9'!-76H_>>N2O'%._R#IIH_NH`A<D3U[0V[#/%1W2JL7$L
M"S$D.'=OE=P!*(2/T^&#@1-%?I&.W](RO/MX!.$90<%6[.J6J5-39L@=(7$8
M19-8:2$!`Q#Q96%I!8!4N_0P%B``<P)+:,P=R$)L<I%G@T/=UC(9;A5"^6F6
M%J.AR5,>`S$QD^$7>`*Z_L&][=,8`\@2`LRFW^ZQP_W]F/G]AM)IZ02]!N&;
MJ%%<H+*A,*1J[P+W@2\C`_3M0LDNJI2B,VF8%W&+&97^`/%!X$""!0T>1%C0
MPT*!#!,6O$"!@@>!'#9DJ$!APP>''SA@S("A@P<-%2ABH(!!8,:-#"04D!@`
M@(4/$3(0U&!`Y@,&_@H,+%`P`$"``!8@2/A@80!1``PH>G@00``!``,V4D``
MP(#0!@(O+#5`]4"'@Q:JZA2@X4,!`!<^4``@X$,#``\(+IA:T`$!#@_]_@4<
M.+`&"@8-`*@@6#'!C0<;/_4P08&""(LM7\8,46UFSGX[R.T<6O3H#A0R4K#`
M0>)J!RI'OX9]&4-CV!$`:)4Y02`%NP4Y((`0@8*"H080"!"@($#A#QTB-*!)
M,,-JVA\D3)Y`4>"&R0LHD$4HV;C*#CTI<F?PH8("W0,K`$A`L(*`KK'M"YX`
MP2"$MO?E%XR`@.C\([`S#+0K\++/$F2P00<?A#"S!B)XX($%'-!.@O8*_K)@
M`0\]E*`"$2N0@('-(I3PML0$TH"J$U&TSZ$.+HA(*`(BZ,N_'`>ZX($-8002
M@@&!1*B#`8A$,DDD+]A1R80.N,D@U)Q,4`,&"A!@QP<&0(I*T1S*0*;;QNQ-
M@_I>JZZA(;U,,`*WV!1H03CGI+/.UZ`\B`+][.233@VZ[*"""R8X`(`&)`#O
M/M>DJZQ/^XZBTTA')Z6T4@.B+*B"]"KE%,8,]KRKOP(3':B#-3O%#+I(04.U
M55=1Y&"`)@?R8(%7;_5/@T8)2D#4"$_%%3`%>H-3TF#OZR"!68]UU`,%$/)@
M4V:GQ:R"-#\0"C@(MLT`P0(QI=8OX>B\X(!P_E_SP*1SF\73H%C7A?<O")@C
M2#D(,A*Q6P8S^#'>@A(`5LD.;/6WX'7-BL\@#U@UV&`)%ATH*P0<H-B!"ZZU
M+X.`_>4K4@0:!OG8#0J(0`!P&V(X9'@S`*Y'"%`:,V8!'$@0@@/Z;5A6.C>0
M5F6?.874`6+K_3E>#P*,&0`"$$A``J<EN.!D^S!X@-Z0%2"U0`XV-FB"78L&
MVT[NM$-`Z@/>##M<#3I@FX,.,E@`[0=I]+F#`K(F\#""_YK@S+3_]A*"#2'P
M6Z`$<`9\V@HL\/9!C7S&0`"\"=P`XH<<X#IQS1GT@(("FB2@.@\&D'OS8SE0
M8$7YNBSP`8S]Q>!C_CJ%-)T@K$0KK?:#,.B8H`>>I;4`W<\="477(2>@<2HM
M'OX##1"WK`/+=??`@-(%`J[>99MOM8%>'U`^P>-5QD"!\)5TD_L/,IA<_<LH
M<%KHAK1K`$$%MG>_4MN6,U[J@C=@'9SDES\"<L8`'`!``?:D`=D]8%$`*V"K
MX"*`Z3%H?"'C0,+F1+$(=E`Q?=M`5?9$@?JP;""I\R"GX+(W!UT@**^+UP9`
M!:<'S#"%-RP(R_I2(0-\X`(!8-T!]M0W'$YJ@BB*%@SAA8&>L0D"U],<!\Y7
M1(-T('0$<<`&)-88NU%D`DVDXIR.:#PEK@L#A?,2\X:WK3#^Q6D4J<#$_@Q@
MJ@048%$6*,P7VV@G#"@-1JF!'!B7]S7336F/1:+90"@0@>A@X$4?.,!'!'E(
M)3V@*@4IXV@>@+]XE:].#4@D)2,H`0=D@$;^*\@$'@8\4:8Q+CELT`5!AH$`
MLLE'K8P@`P10J*$@1P'(`68PFZ(47+HR`.UK72;#A8%0PHEVQ23@0CPPDAEI
M8`/3Q"8UI2D[:"8)`@@H"HKTI3(./-(@6(/1`U#9S3;>CYU(<H#2H*>C#30`
MF?"Z`#=IF+EWWA"=_801<1!000)!0"C*I)8%],DF!4P2H#@<Z$-11!4`6,U!
M$)CB$H=&):@(8#D9E6@!&0#%&X(4115(@#T9_L.Y`_IL<7#R0%;&M(![%JUX
M(0V,`Q_2$?=EATT66&>!G/4S62I)`VQ)@''$@M"&>2"+.`U,!&J)27-"%3,+
ML`E.:CH:%H),BFPZJET6,)L#6,^J*40`URQZ5LQ0(`/@^BJ#$K#5<$&`DTEJ
M#5LA2M**Z)4S1YT90>Q:*I,J2(,ABP!3(Z0NOWHPHHVUSWMF@A."Q"ZHF>EJ
MPW0Z)P^8JWEWU6L"-JH7Q4)V);>1&\0NH+K1>.`"$.BASP9+)T*:KK!6E0`:
M"<)3TP(FA`$`;6PR6%:B3I5*F>TM]R1@P^1R!H&&0E&R?O94VC:7@!)`KG4M
M\]R>&=<^TO49!8(+_B,/"$^[ZLO`D6##N,9ZX#9#(FALM/BSV<+4O.?]K'I;
M.TZ_#F6\L<E`;%7V'3IY@`#XY1[J$)P9LU1E1[?MS'Q]QE[.IFS!43SPA2T3
MPLD.9)ZPR0`KP]6!ZK"MKP4^K(8U)V+RTM6#&Q`*:QUT1GAU`'\/D#$2-Y"U
MSJK8MO\$$DEP*5GF%J@"6\FNOQSP7P))``#-Y$B*??PW($_9+Q.XS8?MPX'E
MEO98&H"P?R`0`!D/U<J)4]:9_T(8_KX3RC`B,4DP@(&^_$;-@).`ER^<DPPX
MM)7>C5`$F-8`!"0/JW?^&XX0G9#I:*"JQ=0MBA3`Q0(XJ[:+#ID$'KUH_AGF
MN)M%/BD!&*#+]#04TV!+P*81_=:']B7)$4()A;PXVE,WS)VUE@]P?@1H*CI`
M`Z^.$`=V91I<H\A,>A;-`I"-X`6@]J&@AA$'#J`=0Q;[01V8@*H+E&:$:!N_
M\40`DXL=.T5ZVMKPJF^Q;0/L&''`;3[C`+11Q#MJ\_K<E_$VD"8@;AA=TX-.
M9C>`GT:Q"46@`A:)EZF\9"IJKU5SLP%<OF&D`1>NM7-4NJSNL!QP`DEOSA0[
M``*`$X'@D%SB[NL``MJE2(??^UP<"``!\)8N#5\@`=[B#XN-^E:>O]7%[CO:
M`QZI)Y=3BR04%]RVXBF`:QU-PQW"^6TR;FTN_C_`>X61P*6+7J>W9>`B/*<:
MH:DB@`(80`$0Z%5BS\T?CA?[`!*@0``@(`!+;QU)/`T)!B+@`.\E0.5E/X`#
MA&@`!P1G-A:PIN\@L&S\+F``"/AYK8]\@$TN(%I:M[M]'(V!"WB/``,8P.<_
MO\N0"\<B&W#W93@0Z47+M.5;3SS+F^>!^*:M;PUH``$$L!29B+QI$["`TU`?
M><!PX+[%;O8`3EYK"QR@`1NIWZ%FCWED$;](%@!J4C@)+F;N/0$,2,!4D'.<
MW2>`/1-`O\^MWYGU+[C9?KZW!@00'`0P```;6("6)3BBC'AMN?<2$;5XGF=Z
M"`U1N_"`@$T:""M9_@`9([EM24`(4(`#^)!YV8\%@+R#^"(%H*BA&(H%:``(
M=(`ZH@`!8``/"8`">`"A<8`)H``79"`Q^1P4\;?,>PL*X*NB0P#@<:$/4`![
M:Q4G2YHA!`!SP3(`8#>ZJ*B$$`H`P)0^`@`;XJ4=Q`Z)>`!>:L!0`0!K$A'3
M("$B!(#N:,(!D`BR$,+;$+!,^;PQF;K88(#VLS('\I:UR;P.>*0!X"=402`*
M2H@<L1L@^HL+N`W6XR5,X8"MV*AFL["&R(#;"`#A<,&@<$2BZ$`!R+9`L1RH
M((HSB9TQ"2=,H@HQ<4(;)!+NL!I%@Z8P@Y"%8I;W8$6$(`YS$ZS;H#6!_C`H
M`$B4S@K#@F@`!@@`X/.:!!#&`QB``A"3`/B^!Q"`V]B5F!H*6<0)!.$)!%#"
M+"F(9KN_V[!&4H21!'@I]^"W".J1.M$O:I&`%,0]W%,`W+,Z8MF`97R]$]*)
M*;(-Y7,WU6"+`V``IO$0;;P2W',:0>F+1@P`:<'&';$_0`00P@E!=L2<@?B\
M)8NGIA"LI9@`#ILC;H01^*&P=\H`ZD,2SSH6C!(((1P`Y^,[YP,];MH`F8A'
M@8@`J1@)#A`4DCL`RNC`H2``BK(8#(@2MH"_`RB`4)K('9&I?LF`SPL]T%O&
M*!R(!2"`9S&P9Q0("Y`)6^&P#-/("&$+`<A!_DKZR`(+@&G9&PD@@"1#D);L
ML.9`O0W8`&O*N@20B9V,.5&SF)0@#@"8`(A+2@$@I`4X`)$\B/EP2H%@"P#8
MD2-LJ8?8@$(!E:5()`VX#:O(@&4$KN:XC>/;2@<Y#)"D)+>J$\1D%MJX`!/\
M"^D9Q`A(@+V(BR8D@`)H@,-T*_]Q/`!`$`[0/8L*OT6,$[8(`$SAI2910FY#
MB`V`BST9'0&(K:.1B:6X#>;H@-MXL\U,D,.`QMB@/3C$E0P(QP89'3,2.8F8
M@`JYPI`S.Z#(RP!81\%QM+<!LX80"N]XL(LHS00BB`;KJD()`)_LN9"8@,,P
M@`"RORTL"`B@BJ@$_J2!,$YPNHT]$<3;H)7#&!,#T([GTCGJ+)##&`L'<9;N
M/!8*(4?MA!`-F#-FXKN=)`"A1%$"D$$#H+R+=+?86Q]/##T4A4T$()8CTT:[
ME,LQ28#JL*0G(X@'!</;(``"4]`QN1X-D,`=1=%E-``)W1,H',N!D#:98+J!
MB!P_PM`&D4PD?*@^JQ/+<Y*MB0B^&T^Q"[UC#$P&B`"2>U,W<<LW]2F_X)DX
M?=.LDRK86J@-B`!>*L*928#KL0@+@)BCT30\E=/IF+F/C(#V\8`-*$^5.P"#
MXPA=612](R0;0SW?N(`\[-+0""$!N$Y*HALZT4S_,"5'NQC.HY$1_*70_C,.
MD1,YH`C(>ZPB#_T+WFH(7!71%'(-"S@>W>#.16/1ET253IV3]Z23-`R,K:D`
M1L(^[-/3X!@U!C`[!=A!811&4!(<])N`D5#%BOA*?+NPSND+LN!5']L`JF`]
M5TF].7'3.N$UFA01#U$.+.U1^%"`!(#$%\P`9IVX"LB:"O`0$X&6;@F1"C@1
M>VU##A$1Q@O5AGDN4+'#;GH`SX202/V`QLP(!5@`I))+40R]JD$-[?"Z<;TH
MZ!H(VUC#_30(M8R9^*#)PP2`7>F`>)+%`(N9B7"2$O5"?`'5B;T/W$2,W8(0
M1BTF:7I!RNB;?IU`1W3$!0#`"G!!:WD5">@5_OBP4O_Z@'BZT-M8@%%[F:^M
M"D$+`%MQ+5X"M>K1B@:(BB54D@'UP`DE6B`Q6M6Y6`:IG`X@C@MMGK;A/$.U
M`'`=06'T"8^BP%$[6%*:UHOH'6IY@*T``&Z"BX1Q,IV+3LFQ&O[HC9BD/>20
M":T+H5"J@-<D"!-CD8R:IIO:+==U(WDJ5.Q[6(,8P>6[VX%H,&=E$`X0@`0X
MFPFH79#Q`'<+/@F@55$L@.,8``-@@%Y<')%8/L#],C#ED2B!BS>SC<JE1K>(
MEE&TCJ/UBILMSLH-'Z=:QI"S&&WUW@E``+5PK<,L@/3P@*-`FNC@@`J!FO`8
M@%>[`*<)U]U:K:SI_I5WS5V$L,H!*-78N(#TN**BL0C5B%:;H50$*("EV#WG
M@UM7/9#7D+]XD4SDFKL`N)9F,X`&.(P`B(C;V)&0&XA&)%V9,`#!J8Z<@XLB
MG`OH<EN5:,2F*)0,"](B/)"YVSVEP1BS,`"IRM,ZG8#=LQ'MN``'6,8".`"U
M&`XLE=B$4X!R+9IR8=A?L0L&0%94B51KPE0+@%/!4XX:71J*J0`(H!C&V;$&
MJ8!R#!>`ZYJX0*XH5E?'O.$348#[>@_,8R;*A8^;R%LKPF';`!Y+2@Q!=(H/
MH(J2S++>',4`N=`O39J.:43/LC^DT`"BT)BL8)VT4Y]?K;&-6&#8Z+RO_JV]
M`G.;>W2T-TXJ`\`2T"N`7,YE"U[-V4#ET:``WIT6MDM=_B@;WU*@'\+%B@B+
M@2@4[[((BI">K(@/^\O`"0B`CXFG1K$_U_`Z#9A(@6BV7>EA#7`W8L2;4(8`
ML"O6#["D]_T(Z.*/`[*Q`'B`XE&.+,;0YIL`M%E7[!Q4JZB3MU*EW]%E+-D*
MLB.`$YX71S/G=Z,4[(H78H;(`LA!!MB0,'$*_F@,+%,=NJBJ0^0?^'P6R=R4
MT;$+000>VU`)#`@_(5I&@>AFW77$`;!,J8%DA$"`,92)K@A2IJP+"]@(XAC>
M`RX?7:$5E;6,"[C@7][5@,T[WG``#EQ1%$V@_K(J/`ALS[><II%L.U2)I[TQ
MBYGA.P:(#M45"OTXJJ.-I_2P.1(^(;T,#_C($0M(#H$HE)MHMJ[(7HXX#)5@
MBPB8)F,4"+I8E`LP@+2P)@?88^NUW<JUINFXB@#`P[?$`%#)BJ+.79?V$.EP
M$!M[#1N;LR@&)>]92@],T=*SB=G@LHM!/:6>%&4M2?B[%;K8&P@H@)S$Z,_K
MDNUET2+LBPH@"N?4)[9HN0XX#`)@[$KVP2>SZ\KU(;*C@*W5C4(9JT)TY[6<
M"VMLR2PMB!5"B$X>W\HPL-CZ"E;*[,0QYP[ZTF:";=B(5+>D$1II@*BA$:LC
MM+**4N,@-*9YFH=Q_C>G?A47%*Q4G19:6A1IND=?CJ?V\`!2$CG!UET&2-%C
M5B0)6">XV8J=-)\X:0`GQN'PK0J10PH+.$P!\+T/@,H``JS=K!_;'0"':@#*
MUB52;8X%*,@&$(I$<MN5"YOLBR`L,QD(P0`+<(!1DP#LP]83!*;A%D8<E0S$
MA;L-N`!L>N^TB=:_23GQW56EMO*8)8D4U`ZVX3$F(14/.)7(F(`$0"5L>HA!
MR8]<+)_'DP`$L3$)T-50#=(5X5BA`C\/,3_S0S\:(3$[C*MCF9$Z$1'`45TD
M0@J-R-GI!(PKQPQ*/V"!L"01L_3`G<$Y,=A+-RU4_)FL^.HPRBHQ6F50_G\G
M.BP:^Z/>5C*S.6F`,5;U6G\-^^--7)*P.<$Q6_=U!G&\2+I'`:\=^<MS`LGR
M7U?V^Z#;,3'P0_(`*:.29%_V:N<JL:68=62G4G^01;?V;^\,BEJ<"Y#18N)V
M!WE!<%=WS&CVH1!,7#IW.I;V=:?W)XE*,YYC:`(O3Z_%>O=W@GC4D!K:"&F`
M5/_W/LE98L<AQ@*HB*@3%#KX"`'"11L`;_GG/7JB.@F`38_X`T:`XGVH_-#X
MCB?Y@6"`T*.58U<?-J*3*BWYCK<_4.'XX<':EO>Q\E#XET\V+G\GHJ,3.T8P
MU\IYG>^,953Y`EJND2?Z@Y<)B3)4I5_ZAVJ`_K*"VOH+3`J<0)_HB>Z@$)(K
MO&L=VQ-DW/K6%9*[`$>*""%Q)*M-"6MRR[=\>[AWR^`C,;=TFZS0Y^N2-R1Y
MQ:B')@IB'ZH!JI[3@/YD'][@B0=PFAZ1`!_!@'X^^__$0`L^Z-<\Z%Q.P<NW
M_(/&Y<.,N<-,W:-O'NRKDUP'G+SW>[PF,>"C&O*L$*$9M0I9W@>(&CQZJR(W
M_+?:B$09B;<Z$1)CG_$RL8MPM',&@$6)UV)*-S9Q>=TQ8+#A@`Z&K+DR8?T&
M#L#4%L*9#-@*@"C5[_W>"A<5_[!@X]`3W165BO[=216D&`Q<WIWT$`)8S76>
M`(HYC"?4[`(JVY8?_OI@F7F`^"!P(,&"!@\B3*AP8<(.%#HPC"AQ(L6*%B]B
M%'B@@X0%%#MP2!B2H(<-)CF8W``R94J4%BY8B/E2@\R8&C)HJ!!A9P0*%`(`
MJ##0`\2,1H\B31H1@@:E3@<J>"IU*M6J5J]BS:K5JH`.#SQNQ8H@Z$`,%L*B
M39L0PEFU$1&XC2MW+MVZ=K,2\+``[-V,'020%:BA:-^D%4;295J88(#%CA]#
MCCQU0H:^!3PXX"N9(0>@0@5ZV(SQ`N&Y#R!`)B!Z->O6FS-@Z-O5@0/7(A<H
MB&V;X07$$SV$MLHV]>[BQH\CMVB@PX+:R3]TT#UPPW.!*BMJ$`!7>-ND_F:=
M-JXN?CS=X%@W^(Y;@+GFXQLH0.^0@31YBS>O[G1Z/ZF'\!<U.-!!4R1Q8-YQ
MI=678$&5996!@7$EX`$$[1GW'@,``"#``.M=Y8%.$UPP`08J%:A@0=(M5H%J
M&6DPP00%7<#`9][YI<`!"BR```(.["3!3@Y,T%-!'A@PX)`6P">03A)0X`$&
M&(2&@8L7/#@1!Q9T@-X&\\%TP7PQ55#!!!+@U(&9(I4X)$H@?5`@4:YIV691
M'&2Y)FCFT<D041RDB5"6):&4)Y_H"51G!CAIB2!"#'`@053/<1#C`Q1PD$%Z
M4W50`&T,)%!`A@(0<(`!!XA::JFC-M#`3JI"_K!3JZU&\.J(%&1``0:NVJI!
M!!IH,&)HEWY0)49&+H9!DB9^`)L'L,'VI+,8]-K=0#@=U($#$@S$P9--!1E:
M!+0]H*A$S4$`:JB9(<``;<TUMRD!!"#0P$$<(!#``A",.FJI0`D@0`($&$"`
M``HD<``&#40*P0,1+#`!812(NG"K#)1ZV@$/,!!;!A,H$(&-"DA[T`0-C+H`
M!Q'H:P"&`)0[``*=%D````040.H!CHHZ@`$IVY@RJ04,D.'.-SKPP,4,'R"S
MTAJ&:JX`"QB@X0(QOUNUJ?G:_!D#!HP5*Y8=XX;`C0JD?)JJL:)--JE8,X`V
MVK!NW3;4'5/@8P49_DA@D@4;0+L!!",2FNT!@*U\`+!6+9N!!7?C+4$%K3X@
MP0.33QZSY9<O\(`##&!<0`$!!$``4#-[3K/H*^\LP,ZK[UP`ZSLS`('LLT/@
M`.L)[$R[[KM#T(`%O&K@)5,W0=NK[!-LH`%*RG?@`0>#`0]\0AX\0,",R$):
M49]#WL2G!8=.?JCXELIW*$@:+.M!!`MC\#=A&CS0P,V4TZ]YD!=\8-*ADD^Z
MD.034``"'K!`!#+P-PE\+SH9N$[S*I,X]-S$4E>"`-X,^+WQC0\#]9M<!#"P
M0/$Y+W$#JHSY#H+!0V%``KP*SH4R)`$>J6]R7CIAK3BH,,?AK8"'0I+D_AB`
M@`+H"(@*4!?EB%B]RUEN0S3;$-5TMKH(\(MF!5"`L-S3%`Q4`'T%X54&*G":
M+T)``@I3V`3&^``#&J!3G4HC`Q2`@#$JC`&N*X#JYF@`.R+@CG>4V<I`M;(!
M]$MG@!%`%`4&@*"M#$.N^Z'G;H0`/@X`>Y*<)"6/DH$`(`!%CR$,89RT*\5I
M`"@,2A!P"G,X@V0I><S30/+XQ*;W/$`#$*``*VO)R@A,0`,=(2($&!`["CP`
M0Y$\RIDJ:<QC(B<`I[1-!F8F+F1"\T016*9$WA3-:V+S,1RJS@4`X)]L:J4#
M10(G.<MISJD$H(J[Z28`SDD5WRQ`G>[$YM[F_FG/A"A3/!8`0`+NZ93K4<B?
M`ATH*I]IH@%0ISH8`,!V@C5*@F(D`0:%*$7=68&`(DL`Q$+.):D(FH=6="(=
MZ&=(2VI2$P4@H<]IYJ-.>I&6NC2F,MU-.L73S;S,U$H'R"E/>QJ9`%P/.=V$
MJ4\1LH&=%C6I2G5+?^3I&@D`@*A+G0X#IFK5JU9EGR$[#@:`A%6":*``7QVK
M2;&UE5""E#Q!3>H&#$!6J1#PK5+9P%JQ5]/J9*``$7BK!Z0JUXR4\J]*L68E
M!>#4UH02`1,MJ@8:*MC'"I8C`7A1=1J0(?R-]0)FA2QGWYJ!H*WH.1"(JEP/
MV]G3]G0#D]4G`)`:_BQJHC:VLO5G9TR[FM$BE*P54.EL>\M3.=I6-!-@V5L5
MYMOCYA1?XPD:9J&ST:1>X`'(G2Y"H"501XG'`Q=J[E</1=WO$F2QX(2`8Y%#
M)`!PM[04)2QX8XNR\5BVKF,5;SF=U-[96L"MXG%`8.[KW_\JJ`*N?<X"`(!1
M`",XP:Z1XWAD)ET%0SC"K"&8>#@`F)8^5\(:WO"0MJ(=\82UM<'9*X=+;.(/
M-$DK4PON9CS@NX$<2ZF8.8#K8GSB&Q?'E_`E%F^3:N'>M`W'0JZ*!RA+E03(
M2SP9(ZL'MF,!U/B7.0IH[9"W4B(':-(IG3&L>!+`71(O-5,@48"-'5.K_G)J
MP'H3&.9_,Z"`*2L`MEC13>">T@$%@`X`24Y.FF<6G"S[5$*#&X!\D=LB@>S9
MOQ?0*P0*T&.U(,8"<J;(^D(CQLIBZ%B3KK(]-9``/OGUNQ=(4GKG<H$$`-HH
M6!:(L:H32N*^%JL68'%L.3``T.GWOQ"8`$H&0&NKO&0J'8F`WZ"<'`N3-M97
M=<"F>\O*!&,`D=ND"T@,4.:C1*!J`T@T<H(&94]C=;.<[FWY^K*!765XL!4&
MS*]C>H!TCSO>%*E`JN=Y`:"4VJH5:+>\^PT=/D%TN.7%*K?]S=DK+88#`[X*
MO&\[L[1:]=T&1^V9S2V!>KMSH09^JT0GCEI^_E=E`T8FJ,8'!!.L&@#B'O<L
MF.\B@69C4P.'S/=46[[R:\)<RX].C,KG&8%#[OSF0C?1?OI2((`/U`)B#/K0
MFSZ>+IJYHMH:$'V=;G69/KM-/2\G!8(D7<Q</>Q+_1X6(4KL[PP41,$24P5P
M5(&8T%SL8>]``S!NS@8`,>[V?).`,J"Y:\L][&J':#!S&_C#]Q0#50=G"Y-D
M]WMN'?%-]\"G(7J`H`&>HDR7?-,Y8.R!6E8`6^4\Z0FO@(:;<Y\!>'SI6Y^<
M0E?$LI^_9P<.8&#4^Y1-KJ^R`Y1'T%?CWJ=\VWV5<Q[-#B`2Y"7=@+CE'7RA
M*U^2&D_Q6)EO<`O@_I2ST:?*`#\I4`\$;?$YU0GQ>;J`YX?E+P@POC&C#8`(
MA"9+6#VW@I&>8&8OAOG7$:C&<1HIK%Z`WE%7GBB8`VR?5"A>50U4!@#&YB55
M!MA<3HG?RCF@6[#2`$P@,FG7`*!?3A%@[I6?75Q`O0@@.+4/Z_G4]X0@CJ$/
M!BB@/[4(E;R5F*S@C7F)!S3?/!W,NX1&!>94JT$:<C7/REV`8@P45#$4JWV5
M]5W=`488^[4?AF3?5_U?@D5>"';`R-V3Q@V<53F`#QZ7I(%3!PX4[)W30J74
M6YU?#9Z8@`%`YI63QKW@5R$`&/J6$UX=!IQ:!I)'Y&E<A)"5`M@A64')_D)P
M@%@I6!9*P")*`*_IGEQ`X7A0TVAE"!X>X2".U?8<Q`8\6(*E40,X``6$2`,\
M0`&0X5.(XNBY4X%MQ%M-$QN>U*.@1."(""32X$`90``4``KR%`1@(BR24R;A
M72,=P`8L`!\J!;UPF4#9WON]%:\!8TD10%<519-Y120>105T$R]"DVH%S2G&
M%#1&8T4Q0`?,X00DP``03`+8"C)BQ!<^P"\:DP><SF>`8TFIT#A6U`)@%X%L
MR?IDB!D:10=PUUE8``-8(GD@6T-A(T09H3X2E*,=F$!4R@`<P!5>A(#`R`%,
M0$*2AV;58K!\U1<F6!9"6`,P1T1XQ7*\$V]%_L?O.4\)^A3RU!^$+<=$%L0&
MT(8[_D9#8H\#9))'^E,\0B1$W22+,0!.DM4(HM=;R6!1#E0"0,!=55,!Y"!2
M5-P'7)Q`T=T%W*-+,0I4#M0!4$"H*80&&,Y48&0Y-1,`F.);X1^"::2"-<`%
M',"O58`!#L0%"&11;0!@$,!:\I1'(1A[`5@#3$`71H3)$,2L)476<:6G3.%7
M*:6A529RQ<PR5@2M$,3)(446?24E(5\2OM4<_A>`0-C-(*)%<(!9&D60$!3X
MD69/>4!34(>7J-2R&(1*^>1258J"90`!Q$A&*(!,5L0%"`!*<N6%T>8CA8X?
M>9/I$(`22:>YT%$"_JBB6$[2!!P``URE1"1`:!H$`#F$4(Z'.`&`/-X3`E``
M2YP$!42`F!0`K-S*K8A(!.37[&EG)1W,I6%$>QH$%.HF1/TEK.64?2V$4]G*
M?D+3J74=1:#(`Z3'2"E5JO1.JF0&A@@``S3`<,245QS$!0A);4)'3%0)U/F6
M<5Z38*9%^SC.D?C(CR0`Y_B2+ZG*CAA$]'5B.=F:`X"B`]1.`R!`<@K3=U(4
M!X360%A`<2[`]S1`D^71CBI)!*(6-VJ@:?;%"#*`D=7>Z+AE`JSC.B9`!`AI
M`%#I49BG<0`A06P`<^U;8+E4:QK$`X3&!#`*D%958QD$O3$HD4$&!C2*_J85
M)P+`Z?1,!7KT927EQ$'0F)OQ2&]&D\(9Q)9*"`0H7"\M"P86Q%;VJ3%-4[!1
MY`48H[.!&7`84-"H#&Y`*C1Q0,%I4.;PB2DN0,&LU2(^%E&8298H7JY"1#6"
M1O.82:'*EDX69[8@3\%UE@:`19-YJ3!Y`*7(%`?@9$HJQ(O*56(2CH;FV2%I
M!T/ED8[DX@``TK;]E?/P6J4LXI@T(KZLC([\4*@0P)M%``.PZ%(MZG2HB`%4
M`)GP5`8@:WAEIT!TT%\%@`,$X,$Z26L^:?!@$7S^3^U0!P5<ID^%DKA:K#JZ
MC!O)3Y"`HITN@/R43`#\JU,*Q0`)T`<X`$GU_A0'.$>V5`!A;`!W-8IO0("*
M]E3+%L3(J"P&$`S-36Q/68!B5L3;G98&P(<$Z,@Q`@Q/CH:"^$U!5,\I/4``
M<->JO16U&H1$]5,&C%21Y1O6DE7D)(4HI@73UD>K`8FGM=4A62E2C,H/'<`,
MF<^6Y(]\`(>`B*=:9`"A)H2*&$@QD=62#LD"X1VA0@0%>([QE`;8CI78(D41
MIL4MEE,%),D")$DP`<"J1D1?)5(BW=K,!("XOIG,!("Z9$[1H.Y78$RH:([C
M`&G73<`#P(0&75P*D491J)2`A(2`6->\/)3(`8`#4*ZQ/("S5(`!^!I!M.U,
MT=60$$!5[9]UJ,3G_O38S_+4M12$!?2/49%*0>`26J"/D4)3F`3+`@1FIF"(
MYC)$!71N^Q8.A[JA^ZX,4/E$8\EO(NE5VT`1M[Y+`'"-N`8`J`12Z$[-`+P+
MCDCF=+[+_2925PP$.C:,'J80?(8B!13-!3P)!H-4<#0+!A<B0X"$V;*&_4'%
M1$G`9.K%7S%)S@*`%H97`:@LHB6J4G1`!;`9.4$=?F8`0O*1^BY$A_JH+[D1
M`KR9V,P,EIW;(7F*_`J`!+01!A08`WL3D%(&'TEQQS!``#/P`$C06$BQ8UF6
M%'M*`"3`Z(3NQ6I(T)1NJI",N*:CRZ0*C4VGSGS%M>`&P"S`Q5HDT"A`_JJ\
MT0V)4>1,3JJT31@QHN.,VL'R)5_2B@<%H"9Y)70L[P=80)8E@/`&H#8&#Y=(
M@`$\B`B'U,L:Q`+P5M$Q1_,I)_BZ<'T,84+$;``"$`?$3W-\`"OV76&8"1:9
MHTI@P`$D0+I,0,I>,IC"L`(00`)(0,'490(4CH;VR\MDJ_L&S0#XD!1C"(,H
M0!IC2!J]S,L`@"=_0`40DA3;B^JTD!0_30+,J!4S<`/DR)8:<+.VKP'X$,'(
ML_R^+)W(LOR**X8TC(LL0+_TBS<-M-.(34##,.=4SY`>0`,`TW7V2Q\/5_L"
M1;,N`.>\'0,T\03$Q)7LQ(8\&0,@21CMA$Q4_LI!^A);Q`1'QP2#>%X$D"6/
M$!!+QT1IP`0%O-TH&>:TR$3>3H4#@%1G!,"-]`OH"#1@&(!,A$;'Q`0I0@#E
M4D`]"01,@$GL-(`"R`Y^7DE-R,2\UFB0<'5,A!$@S:B&Z$A-T+32O4PV@XJ^
M>D"(>)%,,$"\'O7`+(XO)<WS^E("U/40M1'4U'5@]PL=T9%`Y[4B_?(!/">\
M]!'H%$"]JH4\!4>5$`7?`6LIX6IF!RNP<D#7O5W-NDC7V8H``)-0=``9WZVP
MXEUH&&PPU8L7`T`+J?$W4P!L=Z[*Z&(Z'X!M,_!>3(K$(M(?N:\`++$U?_/G
MD'%PWV^Z[`4S2['U_L0$.\LOF0U&!O"7%%>S-8<N``6)=D<5B#"@_((.)G$W
M!3AWYXZW43?`EDZ`P(C.>./(14\-#(.I.H^WP,`,)@$1T/@OC:5W`NQ%JL@W
M<J?WYPR`?`/X7B0EGH%.-H..@B]`,QHWAFSKMKG(FA%.>AL`8M)&:'.W+Q,,
MP9#*6"1`:$]9AGRS@8T%D%P``82V!3BTS*A,BB?2`[A(9Z\,'P%U&$>5L@"K
M<P?`"Q4A5JM$97-$3_`)+<W:WC3/P<C(0X@V`!$%?]$IX&Y`:H\F`"C>8,R4
M!^SB<%R)/+F(0'@$.HKDH80&<*CY9*^YT:;8W;Z'3XBBG/O$OB')0WB(_D]`
MP)O]-IU?><S2FT]<=1]SJ,;BR+P>NHTTHX03-E"`:3/B650I-P,OS#VW+YFU
MR0:<-Q,'RXQ;<\%TS(03`#]NNOR.^EXH0'$S<'SGL36/^OH`I'&'8O48][;9
MB@5H,0,7@)X;-P.((@YZ^G030&:<N/M6-`+@QJQZ4U392\=\+H:\F>3<;T6[
M)>A(N!1?W@-$\_RB-U",A:7GN&+G$5#0$;57M.A$^OP:@/EB4NBL#")_``8\
M.([DXKO3YBXRP"GN2NQ$A`]+A4%Q`+UI2UXVA9F@!$72506HRKV$2<([3DQH
M)8Z0C0&LRUY8?.9P"NYDR/.N>QG'M_!>?(MX_A..@"M#M8K%IPMSK\ZLSFH>
M&;#KC(HOK0[0<(VHG$[&2@Z9[@S`[+PB]?.N^\2MY1FXQVO\-".XHTX!5,"W
M(WV&9(X>3OIP]\3E6;.1C=8X3[><\[:Q/U*J3W@`GXX84[QB=_NR4_@Q*P`@
MB7&$SZAXY_A<_XMVVP[9&#>H5-6USS-J3/(YU2$<)@2E<.A?*9RQ2,?6N5A;
M>$G;J<63_,Y!+(N1\.7B0'RVT,3;+<Y\(!"0_@YU*,[;O9#E6WX#>-'+!<OB
M]`3E7K17IXLO2;[$)F52.L[K^Y(%$\`)(\"W",S'DFEPJ&!P@HQ.!/2HFT7D
M-.+BA(GV)N4#+$Y3_F31XGCLY$B.$\MW=PQ\4K(%Z"]_F^"K5+N2XAA$3FBO
MY(")TAE(3"#0VR$Y08;+="Q.T;R^?$_`XPQ$!RQ.`_00QHLT!3Q-4GY`&$T.
M0#!80"```(,`*'Q8\(%A0X</(4:4.)%B18L7,5[D``"#`0P</'3@X+##AY`0
M%7B8H"%C2Y<O8<:423$#QPD;8%*PL"#!3)\_@09UF:&`AP,>&'I@V;)!0J%/
MH4;U^6!"@P82.3`@$.$"PPE2P8:=N1%#A0$#$!@`<``!6P$'#@PXD(`MVP$<
M&G1UR0&#6+]_*WH(0$$!SI<9,BP``)AQ8Y\;B@:(6:'#@*^.,6?&N`!"_H4*
MFBM&$!V!`X<.IU&;1`HZ)MF'&&"7C0U;@^R^'R;H;=E!-VO?,RL@='!A=4L+
M%Q)(_KT<,U'!Q5M*X$#@*G/KC`L\:``!-?2&'D*69/S`P8,'!PH,('#VK($"
M!0PH@#!_000-&N93F&"A+(0)$#*X[P+3[O.`@_ONVP"\D>X3;Z;*"#!`P@FW
MF\_""QLP8#X#"%CJN@^EVB```-DR``$'(#A@P@3F>V#""0G(@`$(0*PQ*@P.
M^"``O39`\#X,+H2`@@(W.!$`!#+3P`$;&RO`/P(0.`N^%R5\;P`#O`/,0`T"
M#%`#"[ZL#8('+(#`@/8($.`]]]R#;\WT#%KO_B```B`@O0+HM/.]`A!PL0`&
MS",/`04."-30!Q2;<X`Y&6UT3@0N0,Q`Q"BM-(.1(A*I@Y,<9-*W#@(0KX,,
M>NR22R`?@"!2+KG$J39/89V)@J(4V+,@@P2(\#T&`(7ORA,Q0*`ZS&"+52P%
MNBJ)50D@J`V##,!LU=@/3J,6TXDZ$!,"#'RLH%D$-[@@R`,XJW"^".9S0$4#
MUFT`16XKL*"#"C)`]SY$@[PP@@HDI#,!`1RE,X!<"R"`@($*9N^L]>Q4P,4^
M,XSO``(<:&"!!08M3V/R.-YX`:HR`/*"!R2H0%#R%'#W@0B>;3GDEUN6@#P&
M'<K2IP!.Y"^#,1$E_D\"EUO&0`(*,GC`X&F1QB@#+!G2H$<$07K(,)$8R@`!
M&C-3,.FH%`C@8XTER&`""2:(P+P++"#9J:W9QLB##4#*`.T-Z*Z[M'I9CH`"
M"NB^J4<,**C@`@D.4("N!11`-X'1(JB/`@:N+IS0!AI/?+0^$W!//;@(A0LN
M\ZYNR_,"T)N80[E*5[%.TCUOG</UFB*O8M%@N\#=`RJ>`#8'&@683@$&N#7@
M.>O#H.X-,+A@=PLH8#GYV8P/.>CGGR>5;N,W0.QZY:L_WOM2ZW[V-+H-A)M:
MND'J@.Z*UA?I6HG`@VD#`5)VH.**"X;+8/4(.IC#`A)@D`2TC'O*NUYL_NA6
M&PK4CGE^.YZS"EB!^PFN=A@@#P7N5S&#G4@"#N!/!19X`739SUWNTAW@[`<!
M!S!K.Q)4@+H8(,+[,<!P#E``NW"G,@MDL(0DY&$&(]!#%:UG8>H17IT&=A`!
M,*!M372B1<+C$J1,$3SB0<II2I.^TX0D/%D\D`3`&$;1D"QE8(2<_;R81M-@
M46A@1(P:.4`!=Q%D``E`0%ONB`",M:4!$M@C'M.2QSNRY8X&2$`"[!2`@2'@
MD'?D4UL,,+``\$\`DZPD`"K)E@((@),#Z^0`@`=*!%0RE`HS925!B4I3KK*4
M[1F451H@I09$Z2P!P--!Y`*`@N%1`0Q8H004_H``&@X*`@[#6#`%P*&XU$DM
MF)P+(:^6@`8PH`!UXF0C!QD!"3#@4A<3Y`$@0,-M.H!>%9C`?C#F``1HLX,(
M"*/,I"F!/+*ECV#4SSO?"8%WPLT"%2C-!L((@08HX)WU+%D8!S0V=I*L9*8)
M#VK>6!I-9;%:3[3H1363&R:EIB4V>\AJ-L71[WQ'4ZA!C6G6.$64:F`"'-A`
M246"`8,L8&P<L``'R);3#1!M;&/K8$]SVE,+9&]`';CG!!B0``;D-`%`!8D&
M*&,::ITD)INJHE4UY5&3K+%3&/7J5\$:5K$^Q0,]88P&`HB`KHZ5K6UUZUOA
M&M>,:#4J&5C49^2J_J6\[I6O??7KUBYP@`C\-2H7(`!_>+,7P[BU`Y<AK&;H
M^EC)3I:PI7'(^RAKDL5F]B\=&!9G01M:T8Z6M#_Q;&E1FUHH1O:RC=G45UC[
MUPY@3;5".6UM4>M2S$J$;A8PF^<,L+:/5B`":8E`!BBBO@0J+VP16*L'+D`!
MZ/@6N1#Y9[@PX%R89`"O4/%`=6-RFP]\9+0XQ:UM/WO>T"H&217IP/`L$)$)
M-%.)X(5(!`PBO`&D9[<=(```).`0_"H@(A<HR'X+4@#[8K0D!B+MO-0+E-M&
M.+0,`(!C)W(!@Z2*PV&+"`<6-0#.:`632XJ(!`PR`6AEH"1K98B%!>"A_@T`
MH##>J8E:Q\N``!@@(Q+HC8T2.MC1=D"\%*YJ>HVLF0LLA#D/`$!W)^(!``P`
M(QH>P&([`+``[)8A!?GQ1!I@$*9]P`)K>0!F:Q+@ABP@`)M-+E*T]H$%+\<#
M""@`AD';HR3+9,)[U@S5F(-B*,,/DUR^+P"8>-D*%/DABOFR1,(L0*0$A\`0
MJ0EM/\"!$4%D`@FH-$02(![A+H=O,2ZM3?T,DSZGFK`0>/)%$(!)$2_@+*-F
MB%I,G+P+L(3%UOT`GJ0)2P48N@$QQM,#/D#IB&C`:P^!"T0T`$;X;?0!`9"`
MBRD;+E:[9-7;!HQEF>/J1%-$RFMAI&@2H.:'_JAE*;Z39'HYT)7_3MF.H\1S
M0\(<LK-H(,R?=HB(VML0"2#9B2KADJ$GNZG6>AM;/&9X8YAG'0>(&(H&8;1$
M#@"`I6!`7F4&`,$_$&L-%$>K6D$*[TQ$XXC<^"&$>WBL-@!E-[\\*1>GN504
MSAP*O#HP!GGTH>^-@`"`/(!SE@B;XSM>-JL<(B)2MTD20.667&#F-Y?*3:T^
M+9MG_2F"AN*B?OX0"-E7PQ_'.$<P$N;N:GK*64KS=RPL9*Y?9P*VGOO=Y>IJ
M!9RS+"J&R'L!0`"E5JP!38V(`C!I@9!`X%8$KPD`F@I,":#+Q8I!=D,65>C7
MZ)(J9@*`PS^J'YLA_IS.L<5[@8U^>M5+Q<+Y/0B-WH<!3G(RE9PTL=@=H);,
M'P3D!O`=HVSM@6,[1`(!.,!N@S.GH7O((4[F.=((=Y^VQH_/I/<+55>??;!<
M(+K&XS[5/P`!TV.+N"0[SJZQ\H'O<S]D68+N!;HJ_;^'[/S,?PAW!\0VEM@?
MK(B9R?H8`]RT;P`)D&W&C[#DCS'BK``9L`%MI.I"RWP<<`(G`@(I\`+#0@(Q
M<`.M;P,]\"?LXP-%<`1)\"?(JP11,`55,"*&9`5=\`5)4*H:(O4>;JA@\`;Y
M+%ZLPP-,!@*2CJ_XYM_N+@'"#@=ICG`ZI=IN+R)H"#8&32(FP`'P#$_^_DL`
M?O`A'*#(YL4!#O`B/&#>#$+N/&4!?T*ZLN\!BM`(QVKK_@+Q^,\B/L/5Y"[>
M1HHA#D``BDQ$>F(#S@3C)`.D%J4#DX+Z!M$[\(L!0,)BMDKQBJ-H2,,AY,8P
M0B)PNM!M7(T`TC`CQ"_[T$\-Z4P(N^,T,M%3(J#-'`)(PF5,]FX">.(SK$(#
M+`P!Q&LDEFP`\L("JHD!'*3,*DW;!.H#T.HSU"(MANT#[&136"HOJ$4"#FD3
M,<!@$$+.HJX@,&WGMH(!5D,QDD@"BB0`Z((`^F(#NL8@%$`#8NU?!,`"8V(#
M:,@#(L`C@`(!!/'A6M`3?T.0[,SW<`5@0.\#_F9IH"#G`?#1G1P"`@;R(-7-
M`_H(729/FQ)`(,%(%B]"QYBOS,Q)ES(.9P+/`P"FN'0)RC)@Z";`&RU@41S`
M03A@`=B"`2A@)#CD;:SM`P`&J0*`FS`),@#`3+8,`@J@>0)@21H@`"SH*UQ-
M>8SOL@[@5B!%_33N`[1BIT8N..)+,1R`I6BH3F8+`"Y/*,HC*8SF"F,B);)O
MT>QQ)OC-)S)N>,3,(=)2+9<PTM3R2!PBUN(2P"XB`@:@4R8``)@'`*A.Y3#F
M`Q#O(L>-(<*,)19``$"%`"2"^P[)`Q@@+[,,V>B$(8Q&`P)/PP0@`GB'P(PJ
M*+\B6VH%`_S+W.3"_CN49);:3`$$8"0P(``\H'DP!M%"$@#>IP$.0"MR4R@@
M<]028QXG0AZS#UEN$#@K@@YEPF@,QD[LISF=LSAJQ9`F9CD58#DQ#0*6DW^(
M:"XB,^!D"I.6,SP-IB#`4B+PB_DP<T`NS+\60EUTY,GV,@#L"[]P(@(4<Y(Z
MA3"JBP,$(`/29%0`8$DJ\P,H8``TC`""XR?M1P(T@`"VI0`H0VO,!+\00D&Z
M:@&J0_:F`P!PHOAJ0C%KP@`V8%&^0C0T0`"0K0,\#"C*RM\:8B>P#2/.[$5C
ME.$TJBSEJC@`[7P:(E).<-EZS2+L,T"R147A\\EFK``^0"U`Y4@O[-\$_D!8
M:(P_3;$A,+-#H$HQ&:`U\>LJ_BO>#`DS$4*77`H"-H!WJ(XZ]I)%UL,LM+(!
M^.0ARDQ"O/'7`&`!U"(!.$`M%&!1Y',"!,`J,`DO/R]X[@TF/&`![(XA*,``
MC),B7NKN;A1'@4)>P.H-F<)-TB*<"N`"^.4!^'`A&.``.F"3N.\]GD[.:F4!
M3J-@W"RPW&2P^&5BWL-/Z,(`ALH]V#$!W@,!H@V:"J!,5#*&3B.(>ND*-T#%
MS`8#D*+,4.0!2H(#QH1H0A`#[.<!^F)>4H4&.RH"RO,A,@13+8(XLF]2*=4G
MHN:K:C0L=C1^'M)%&\+%WE"J-'`BTM4GC`HB_IQ,7!FCK`J@`[<I)A*@$E/-
M7,^UME(UY\#B0-BPB8AL7?W"'*U"#"?B%U_B6^?.8`\VM1A-;FYP`5(U,%CD
M)0YU[NAE8\]KT)3B!3E`FUXB42O@`)EL]7X494&#7V&%6X$B66W4"F6"`9Z0
M(D*M7$?19L&BL:8E:/T".5EM`@B@9-TF6#&B`\QJ]=#0:+T-`UCS:B#6O8K6
M(29``<16`19`9R'"`AK@46%E`@;`;"VB03$6(AK6ZL`$:P'C`G*C4_#V)K[#
M`LX)+*&*^3P``^H..M[&>!ZB-NROBJ"--`,#Q1*``M@,Q\A-JQPL*;HV.'*S
M:R@6(@Q7;&I&1V&#_F`SRE&C+"(\2@,,0&D?0BQ7+V3M-BIVSB!NKP*44CR<
MCTX\9':CT22*SR#&+5'CI+LHX%8<BP,R1RN_XP$`A@#4<2,^;6?@QHXV<9:(
M*4T>0"7(AJ8F8%--(O<$8`$T@`,$R0SC]4F=,KXZ0""%R3#;(@&LQI$@AU34
M*2T2POD&(&X_)`*JUG-GY>\TQ&8\@#@K8FA7#VIC=V>%1P"2(E$,0LW`4'DS
M37B.@D#G1#%?3/EX37B:TBF52#Q:CW:3*T#O2Z!>+>,0+_``A@)0[%$"$;^V
M!=%F+`!2N,AJ@@'012C]L0""J"DM3%%%)`"^0C$L`,4>0`,V"<0^;UI4_D)/
MX<<!%,D[A*]WH8U40T/[9C:!HR+Y<*4D1&1.D$TPP)@ARNX@XBN`Y@13=@]X
M!9-16%5,#Z(K9FQ.^K'I`*!S*]@`=/$_"2(K$")W`V]];1-@D(+69JPGU&*S
MR@P!_#9&/D!!^.))@](P!@!K=JZ(`6P#,HX#N@8IN`16'*``8A0!Z@Y>^8U0
M4L\"#$!<.6`)3P]>M?@G1LZNE&@I'#@`DBZ%Z<0I;!>72H)W-Y(AZ/(@$L+`
MYN19`-DOJ86^=(DB7I/)8K.#0F5)'55W":(#$$]RZ83QVBQ#OA``D*(!G%?E
M>*?(RNPR9F54&,"0^%(P[X(A"*#2I!+%!$]P_B"S*'CT*=2QHQ[`B5$W"@L9
MVF@D10QM`OZ5MS`-[Q(UEJ$"_C*M:QB`61F"-]@B`U:#`XIF6XH#`\+L`,2K
M`M!#?+^#+@5@`J:H(P+/L7BW@L=KW@8`9TNQ4!#/`/;2889N(XKBORI@A1%/
M,?_+'-L,,_4H`")@Q@@,3Z"LILDD@"#CRO!K2>X04Z"$(8*#`C3,@]:#?,$9
M+$CWHS`T=0-8F%&31@8WBZ5F8%&W:QF:!#M%;3]JY#"B09JN4SS``HJX4QJK
M9B6B`RP@+2BF)-[13D)B4,A7`$`Z`92$QD)T@`WT`X!)0T1B``A,IYO/('Y%
M\2B`8<[$P`*`)2H#_FN<]B1=Q$1,>F=@!7D7P*.,8A.!T92'I8,FHBIVRUJW
M+5O6.LEXL*,^:JWRTZ,)5"\4EB1&PK?PFFZZZFVB]9$7ZUZ#.VD&SJ.RX@HS
MP)2W\@/H8B**RW/5FF-A][9%ZVUJ!F<G4-.VKB,H5FLA0H)JQET$&%&ZVKM!
M*]HH;&5K)@71=N;"=N:0`R+FXZ,FK\`.ZZVSSP,26@5!%[[]Z@(0`#H(`RL*
MO$P.+T=(`@'F;$=/K\X0W"<\H&TI+`@I[`+&K`(67"(LP)0+W"36R2$:P.C,
M9L`#+L-5K34IS**3S'XV(`((`.%*_&Q/W"0(RB3&9*^WF^%@&<8SHA@=_H)<
MF;AS_X)ODPP7$9LB=B*]J_NC.@V`L"T"$)ANC1Q1R9>B2L.=4`JEH"5]['6*
M7F+(':(P&:,E_4P&)\("^I>,>[PABB7*WCO)BKP$"5$SBA=75JD@.$E@,&D8
MZP*/V$*7[.S0&1W1$3WJ;HH#_(F%M5QL,'KRP"CF+L`!="O/,X(,;V['Y;3.
M,<);M<^M'=!3?Z,C]!HWQ)<O?H3(,&"=H2<V<*>`G),"R"6[:KVO<49=G--^
MUL,Y"8!<EK,`]EDH6FKNY!S:OA8K4'W/*@#DNCPP%`!C59G+8O-0W;'*OX.`
M/7<!#&U]9\Z5`0-4K\.\YG9KIKSE6!<C)N#=_F].)VXP>Y?#`0A``MPO`EC:
MJTM6"GEK@"0B`SA]K^&W=9/$TX6"X!G`I`<%H]J](,4[-+S=9)F\VH\S-QK;
M<_O$9F;E#2O`>26B0;=.H+`M`_R96JB=KR)D;YZ=2=*&OR>>(B#@XK-.23">
MVY;$'(U.^'Y.DXU.`I24MV@:=8,HPP;@-EHV:T!$`GPKVD$$;67>)_I[]3B@
MXG/>7M5,'!_-L[CPPP[^OGQUKU]((BJ`S2'QH%/RTQW:)UZ^9I0'*BRZX+UJ
MQ2%B[&<"2+(O<+(^(ZX^7@^@YPO`K!N"#^W.L`RMSGK<MS*L)[+B(C9@Z0+U
MO>6]8GV'<G]B).HZ_MF1AB4A8I7=GO,?;K9N4/%^`WD=`A:U?9H&'A,CHI@P
M%9MAN<X:`-NJ0NH#HV"4!T_V/"PP<P)X(TH5'CRPWHD:'B(88.8GPH!5X^XZ
M`.U3T-Y]`_4=P@(042*J$GY<M^4D/%.PW@/.`^F[F_BJE`?UP@$6X.O]B&P1
M1U'5;V@:X.PY`R=:^6*0BZ7.WLU?M'?M6LY`""`B5.#PX<,%"A4J:"CXP4(%
M"A@^>.@`00&%"Q`8:MS(L:/'CR!#BOSP@`)'`PM'?C1@@2$'#RICRIQ)LZ9-
MD1PBW-S)LZ?/GS<?P`1:D\,#CA4>$.3H`4'&CALB;.@H8<'0C@\J>*30_F`I
MQPP*1%HXT)%`@@D$)'0@,`!"`0$/$@#`X`!``0,`!#``($%#@`(?'`384`$`
M@@4`&&RL>!C"PKT)*A+@@`$NA04$.FA($#E!@0P"!$1`W#4ET=,R&5PX:=KF
M58FO4<N>3;NV[=NX<]/NT,`J1PD"6C/<0.!H1PL$IB)%$)MAAP,7FG^(4,"K
M1J,B)0#>:`$`000&-A@.C.!#80L3`%P$``$#@`7==78`<"$"``T<!$CP>($!
MV;TP>4!`!@5Y4$$!WJ47$4,-##`!9!8XH-MM#)BDT7,=\+3`A!QVJ)('%GHH
MXH@DRM:``=)5<`"!''&PP'['%2!<01(DD&%'_A@8H%-'$0C%$08-B)0!?3!M
MP!D!]WV`P``?&)!`DP5X8)^+`#0`06*((7!!8A\,B8%]&G0P`(P%:>"`A1H,
MP,$`Y4E$P`0=1)!671Q(D"1#"0@`P006;."!<B7^Q(!P'$RF(:"!)GI;?8HV
MZNBC&[EHG486*-:1!PF$N!$&""#*4`0(W,B1!LEY!&IL&3P%D@<*`$#``0(`
M$,&6`U1&`)0?*$"`!P<`\(%<#?2:U7C"'G`K!8/EI\!5Q+5%70`<]!H!!\A*
M!8`#1MUW00`4;""!8P0$4!\""IPX(Z0J,="<C3PA<"ZZ\-*D@5;QUDOBI![F
MEQ9_"GA:$&@M=42!_@+G5I!`P%\U\.X$76DTP8XA@?B``[/"=,$#"SCVP03[
M?>O!Q!L[<,$$9V;@P'X=8##!!`1>@*U1ZFJ4000../``@?8)0``":GD`@0,_
M`^V!!0:$%D$'%]<<`07%B6JO2`S@&]9./N/[]-4?86`IUES;5H%T$^:$`0$+
M_K:LP`,T()T$S'5T@0!E;U1!U)<&6W8&9.KF-$\/J#=2!QWX^\&-[Q;$@997
M%_#`!1=H,,'%ANZT0.%=<VU@Y9AG/A('BF5`P&H=96#<J&==>MG>!1&7MT81
M'"!X8`4L:,'JN-%^DUL(V_12!PMLD++@<%Z=@0$%%&_\`5;+1`'8FC^=_D'<
MS4>O.0=3>XYZ0159W=2[%1A@M09P>X3!AOR1SW&'UX\X]@,&*/!`\2RV"+WT
M]-</DN/VYX_U!JIFD,#\@^,*`#>@`-!Q)`(0$)R1?,01"SQ@81MJ@.UL(QP,
M3!`W'K@`!J;VD@_,J`,4R)W^1,*J](VP4160T`E7^*BH7`AY'M'`=IB2@`E>
M`"67`MKUQ@;`#V#@`!+L$/D:I1FF=$0#%['7<]HBD24-@'*;8V&\*+`U*39O
M6O#"SG78U9$*!`DJ"J`74A@@N`X88`+B*]5QG((^U&0`C3>)0`\WT@$/,$]1
M#GR```97@/1`T8J:T\`<`4G(VG2``4-D2(W2_N>`+W)D+?'CS@&DPX$"B)`A
M6DL?PSAT2-3\J9`J>9P'&-"`#O3K5J#,GP4BF<I6SN9@771=#M5T'`*\*P)G
M&Q79/#(!+FXD`V+4S1T]5$42/FU0$JE9`S8P0]U5QY6!&B8TG[:90-'E7)7Z
MR`.*.9S(<80!N=Q(ZUC)$`ADAB.+JTT%!JDH$UXJ>8U239\^`,X+--,F%W#G
M-&VCL7U.CYVXV8``VL81QH$M`I<L2`42N9&J2.<"H?*(!,)9$`8`E)`=S)^Z
M=+6!"2CNGC5Y@#[].9L'7)2D*/V1!":0,08@(`,<F-U*-6"!`=208Q*(GP?:
MYZ>)`*Z.+`6;!4IY_L0+4F!Y&F%H2NVGK@448%D78"9/<K+4"2FDJE@-R0/(
M98!7Q2H`11O`77:&`+:PZ54(.``"`@``NPR``,4;J``&8`!RU4BM:I7+`!X`
M@04@P*X1&`#%)""!"!26L!`(@%I/UCT)A'`"?\QJO1C0`:4<P"0;(,M.-&!`
MR7KVLQS"`($Z(`'%P/,#E,&`:E4[@75R8`.4J:,'2ELSD:U6M10H@`14FX'G
MJ=8!@J68TFQ;`0(TT@$[<P`#+(H;"R141">MW$916P#-@'0F$8`C:&6#@9%N
MEZ08\,II9;.!UWF7GM']B<N^ZQ,&0&"/YG'I=642)O:BA@+GM:\K$Q*]_O]!
M$U`>&&_F.,"9`E%'NS:90'KUR^`&:T0#K\-:`B([0J]P5L!+M:.#?9(!"F^8
MD"F+'@(P;$4.>)BD4?TP3P2BXI1J6',?BW"+I7C5&==$FC;.L6T:IV-08J!_
M/0ZRD(=<H@X@&)`OE@B1Q;?D)CN9)SA^,B$C0$XI6_G*^S0LEK?,9:YUH,I=
MMLD&3MSC*(?YS+G1`,30?!,.D%C("V:SG$]#F#G?9")A!K.=]\QG1P&NSX`.
M=$]2+.B13$!5A4ZTHC]"Z)$DV<Z/7O2>WRSID&R@LY7.M*910Q<]GX8#%]@M
M!BP@Q]M21BH?V``&3.HH59.9DQO(@)DW36L=_F\)`,&LS9#:RNM>YZ6M0>H.
M`%#4J/0$8-83\D`!`G#.#D$``@V(MK05`,X&:`I[#9@`LE/YVEKKV#VX[HF;
M21@K7YL;`&3A`%N)K:@,L'7;N<E/6RD-%`2<V]=/TDBK`)!?5T;:VPXV4Z_"
M?9,*!&`P(Y'+`@"7VMMV."57TFP[8P5O#*ZVXGP#0``,>S*'7&"H;7UF0>K"
M;X";/%X/8&NO+S@283_W0FU5JD?D(O%$::"MN<9J>I@4P[8:D.3]/KG0<1,!
M!AC`KSC?+%MS/BI@JX3FCKKUM74.`)Y[).(,&7C0A\[UYGKG(R"$0':1RA"?
MVD<!$Y#Q3M&=+K9O_L0#;V0I?L&6,I(II3DO!E':&=W6J7_$`XZ;0$8O)=LZ
MPH8I*E-`!E!GQPS)>G"&A_NA%^^1QJ,G0XT7R<Y!LOF"V'L`>_.I':4Y>HQW
M_?05!0`E%?#5`<0J;1$AE;D-L*JVJE`DO9JD1GX8J]"T=0#7YD`#REUN2^Z>
M``*(T`#Z_G>V`M1`QNIU`2`0&TXM?Z[#/HMP"-CK`#P`P,9J]@?:6E>\\'KC
M=&P`\GFM'P,$(-^<KSI(*#"``0Q%,"4W,(*838"=K5FA)[,!"#!0=64!IH=Z
M0H<D"548`=`PHQ0K#C`1#D!J")(`0002"3``ZF)X;Z<1",)N!D%^+=$!_O:6
M%Z^Q;XIG'@-G&AQ@?N27@AZQ:W[W2[R6*;WA=`P!/AJG@4[U>Y$D)G9A`2[3
M5E6T%Z#'$$O25G\!`0^P?%]73DH(-,/':Z@4?U9W'!JG'(B1?R2AA/7G>FWU
M?P/':TYX+0AXAD_G*Z.R=!O1-P2'6LMW47+A*OUW``>@``I@A['#$!]X%7M!
M'S+3*O'C%U4B*J#Q'F67<FV%:/S!?"'1'0&@*LK65J)R`<N7.QBP?*,C)>,!
MA7/!(%4G*OM6*\[1*T/4`;'2%YC$?IHG?Q[Q'(D!:H%!B07R>O%#6K'265?2
M5KOE`1B`(`#@:6AXAFORA+O75IYB00^4@_;&_G1OAR3WQFL(@R`25QENIV_H
M%B#[5D&NF&HH*$U2%Q*%PB5;!``!,XD"X"E[`5^IYHAE<HD,07)>46Z8EAY/
M4D=[484,00%MQ8X?86QA]"T6P%G0AB0"T`$<D"%`5Q#V425O-W`:87``$$X7
M@!@O-XQHB"27(A<%0%0?(5!O"!+4N$X8<%0/@1`4X!74Z(E3YX8$<AF(N!'B
M`8B#TP#OAV&H:(XAD1XZN1&(,37FD42;4@"G*!<4]657,7!>T2L"$!M,<X_J
M-I%?\7NM&(V\=GL;0XL-00']Y!(38``UQP#%@R@;L!='AI%HN7PQY(0-H&<;
MP(81LWQ8"1*((7%U_NDVL6(2<WB6K$*.;\D>,1$K4&0GXK>*QP82&Y`ER61D
M;$4`"A`!:S-O#.)Z'%&!!<&3M.,S>2$2NV@ES^8`D1%M$!`=E!**(9$!"^!]
M&K$7C/@K?(&6L,D0:AE#H-)6"+!.:QB2*Q&3(M$`UX@8W)1J>&$2=O*);^>;
M,!*59QE#;"6,)1A<Q^4``_<:,U,S%Y``*D=[&G&=O-8`X;48>>$5ONF/(P<`
M^=:0HZ,1=:&/'L$!X1D3N^@TOA@A#E``T'B-'X`8<_F7+!>;7-<!".)I'E"?
M5&@=&[!\S@ASKJ(2=YEZ,@=N.M&0``2!AC,``4!AX4B75ME60S%;*L=^_FU5
M<P:6A';16?QXA`7!E$AAG@4QA_]7$-T1G!MQ<PBG$FXH*A]C;L"HCW)13`/Z
MFOZ)D5?B37^7$['B31:P)".U4Z+A:/8F<?:&3)&")'K95O/C`6T5,/(F8Z5I
MC![QI!H4IOC18>>XA0D0IKYC'VW2$::T?.A7$'TC`.*YF1M1%_G&?6NJ$4C"
MGEUDFBI1%U%2$&/C*@W``!;@9A^S5QHA%]JI$6S5GT%Z<H6AAFS*%*RI2)T8
M$K=V43<GE2E*IP\6*PD`$[LVEQ]@)X?9CB@J$EL"?Q^1,Q^1$A$0*ZUI)R+*
M%.3'$/F84;V2IP7!>OFV=GRZ:S('GE<H$@A"_E!(<J&_X9@:X9NN6A!X`:F1
M"G!1R1',%`"V<R4&M"5`"1*6:)PAT:D2MXM'1HB6X@'+5T5NAAA#9!^-RIDL
M*HYXP4IB\G[8\YX;86\[X@&]8:K"@B?9R!"YNA'+!G_O!0#IJ21MM;`=P7JW
M"A)(`B.3VIJ'F$AXP8C\2)/5BH#7RA%(XAL/AB#:19A<&H+B6B`=$942UY`C
M=AU[81I]XST:T11OR(^%R7GO)TW=L3K@]A3C.2F[1B\YN:H%L0`&L#57$AH2
M`!-$R!'+!W]FI'&K84>32H[Q-U]LNGQ'.)/<)`'#J1%7PHCV$0#"V+'>MFL"
MPU;`5WBM(BX,P9-._G%:/`D]9/=@(>H2P-@O'9!"2%)%`C)L@N<MRQJ1=A$3
M$IDVT58S"\``G*$<[M&`W94R"#(@J8,D"H!YOFA^$(!Y).<`%2!;%6"A1-LK
M!D`!"&`!X!:M\N:J&J`K=@&-*B>C98<7\2H22+*F>,$M`7(!-@EL-[)VC&@!
M"()I:#MTQ2D^'\H6(1I)ZJ9R,WBT1C,2&RNB$G"?O-8I&W$!V-M6:B2]S#H2
M"U!NYW=PY>85$NEKA7EKYIF$'VJ<:\5^3GA[DT@`J-L`;GA/J_NP`E``%B61
MM%N+W3@22,)NDV@7$[!OY`L`4S&3&NMSQXMZG&6\.<B]7R@`CO1@G!4!_L(1
M:7A&0HQS267YA2'4GLA1?PM`P1YD9J#&.(P3)KYC4##[A0,@LF7G%F58*X*A
M,Z:16Q;:CRDI$1!0)P]!2HTS@<6$-#SF01+04:AC)QE\*8R37@F05E<Q2O6W
M@Y#),#6<(0`Z`/_7A*08P1&\=0C)8!XP`12@;662/AHP,P2A'$V+D`1QO1TF
M8%2"GQ+!`.$[(;U%QH",>@FY`5_T,1E``1DP9CEU:2/Q0QKG/DR(&0%PD8%<
MR98<14NC;0LQGW7D.X[F1;XV`"=[R:1<RMN)`0^QCS7*.#%!$<_V;*-LRK),
MQH-G'KVE``M`&2%RR+-LRG_6RS;Q>,-1`1O@.P"9*Q18!,RF;&+*7!/E-140
LX%QOW!UGZAFOULS8#,Q%(A'<2Q`=&L#9',[9/*!OPR?TECF<%<LB$A```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>f39432a9e3943241.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943241.gif
M1TE&.#EA,P%'`/<``````!@8&"DI*3DY.4)"0E)24G-S<X2$A(R,C*VMK<;&
MQM;6UN?GY___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````,P%'```(_@`;"!Q(L*#!@P@;,$AP(*'#
MAQ`C2IQ(L:+%BQ@S:MS(L>-#!`H4!@"PH($"``-">ES)LJ7+ES!CRM28`$`!
M@0<`-&P@`("`F4"#"AU*M.C*F@(8-*@90"`"``!4#E!JM*K5JUBS8LS9="E4
MI4Q+,NBI4JO9LVC3SLQ)LL$"J`W?ZA38<Z?:NWCSZG7(`.K-!@-\"@S<M28`
MI0;L[EW,N''5D3]YHA1H0+#7`"5/`G#,N;/GE@0LLRTI-Z3<G60_JU[-&N+3
MJ"(!&!!80';L`4X!(&C-NS=KP[L!SQUK6W@!L)-]*U_.N"<!@:$CCVX07:#<
MDLRS:S];N>O3`,@!_B3P"KO!R-G;TZLORE6IYMT+1HYG,#)X[;_K\^M_*7>\
MY.<-P$7;7-19MM^!"&I$GTT#XM9`;>"9E-QK925HX840U994`]TI1>%2([D'
M57`8EF@B06Q9)Z`"J9U&%P``GB@CAH;--U)#Q/U%F$(]X3?CCP?VQ>"#Q07F
M8&6P=0CDDOOUM%D#.4D'5690F38EDUBJ!V%)-;H%U7PC#B9>EF1F]Z$"YRD$
M%7HC.5@;B67&V9J+4,+XHI1MG1090?YMM,`!@&(WT'@+""KGH1E!AA,`WGWI
M)6;D]2F08519Q`!;4&7ZI&&,"J3I@&N>E<"HDB*T`*FE'J2``@FHE(!2_H8B
M:M%3#E(J85N&A20D>@/U9Q*<$:&IZ;"39NK@IT0Z:I:F%1ZDJ8,.?2JDLC(%
MIFD`(Z%4`*\P*5#`MSX"U1-I`DJ&VI#.%41G3Q4Y.6RFUA5`P+>>PIOLF&;5
M5BY"G.(;+;S]INK2NP2'VU*_1.DF9F3WY;8AA`:-5-B0$LGE5Z4+%-#L0,CB
MA23%!UD+%406-]7OQ@,3_*[`'GW<55`'.-C3D<EQ5>QA!2&)7%=H1H3IDQ$A
MG->T0!NDV94/_4S>R$!INA"I"&3+]$OZ@KQ62=/YVB6=`VEF);YU0:0T0IC>
M-+8`3AIZ0-4V*6;2QP(`6A"@:ZM4-LONLEPU_GYT`RIIV4L7'5/'@VH:ZTI[
M%_6>0#?&]I>&!2TN'&[$0>M0?)E66E#5NV':E=,"+4APUVQKZJ/A_69J\+W`
MAL[L`5(/>X!2@`NMT,=0!2`5N`=EG-C&MA=N[U()X!Z`QKTB0.JD!@0@0`&2
M)MXKJB\M>*Y]/BE5F^6,#UG9ACLJY!JS!U4]'N`!VIOZL"&M/^S+IJMLH/"=
M&O0Q;O)#A1O@;.,4NZ9),9]!0!<YPN7&+S=3V8;NIC+_2*\!K]&?YCS2HT4]
M*4H6C%5."(`UIAD&.P(XG$'<51Z""!!P1]N,Q:B5@`$D8(4A-,G/`$2PM;WK
M<`:LUY>0(C=0?4ED_C?I7[\*8$/5<:I4G(H1GPRX`'>II&IT$]F8,(4V!?KP
M+RM4(DL8):(Q84Y7H2)(7R96'&R!T%\)(9K""**I\ZG.2_"*8`D)`C?-X6Y5
MP[+<SU*%*;=148;.RM00[W43J=D%<U]ZHPF'5Y"`C0H!!9`:M+[5K`C>A(1^
M*8`4Q]1&,>5.A!V!'AP;(KG`N,T\L!'2X_`%,8E(\72"3!\"E28U@4WK98M<
MTR`+(K)4K9`@*71("ONU&RARBEL0%&35"I*MU05.9:TS"*<N^2Q!(5)AFBIF
MIB($$T*5JR<QK$Y!Q.FD147F@Q0A88PZ:;HZP2N'"5P=`QDY$`&.,%."_H)B
M[WZ6R%A"T9[8*=O1RL(I4/*S8`]AT1M#@\_-Q=)T/P,E2UKY&@]5R:$XVQ)Y
MOL:R-,8N..33U&P`!\]D(M`@\ZP?,S.%LH^1B'R#VJ33.@E%F2)4D<G"94$B
M>#QPL0U2P(S9NV[23HQR,E-1^R10;(5.R0WD-;O1F9H4!AS:4(0XN=/ADSK9
M1UD*KIY(/4A*5U?2H_WE8[R2H[$^Q<Y,';2!]U)1F!`206024B#>RA]18VG4
M\8@4IS,1`$=?I$6%QN6;=I*,=)R9D+$ABZMN]2K9`#L0ANIDFH&<V@#MY:Z`
M#DN47EWA>-RUQX<4M$!(*Q]?"?++]6D,LYWL_JM7$^"NHK2),BIUW9`:)IE&
M;>@M=DW:8^W52=*B,K5+U)]!B)8`2V;VJP,1F0(LAA^I%<!0;'VH(&&:D*.]
M*K()L6=!LOFL/AUQM@8QWQZ/MJ&@:(9V7'1HHU:)LY/P["OAW59RLRJTMCJJ
M:H)];JF`>*_@EG1I4JR4L3;;3_Q^BG,0:68$'R)>^MF$LD=,X03C^C/M92JX
MW6P?<MU))5PA]HR,O9=/WM40I?6K))HZ;*;BYA;:-H1MUX42"4.B3P9#EV,L
M9N-)A=S@K0)LQF*#2A6MEM[56H>$F$*B(']YSY&-33(C!LI(PH4Y,-D&<PPK
MCKY0!E;YX6ED`?/J_D[>RC2%Y@\]%4[@GD+VKI6.:`&L\FON^FNOCT*M-@1]
M%YG+K"V?QJZY3KY7J^#YJ2M'D'M`854!UWA;5>(V0OJ2*%X%\#]&E053N$DS
MX1+0:<N5;L:5BC,<F4S'80'+?3J$'NB0I<8Z$UFY#\E?.XDV`-Z9+WA`MC+A
M1#;GJH`S@\DB5UO8<DIA^HUD?E.)`@S`$)3JBXA(/`!ILQTHHR7F`(->=9;Y
M^1<C#E>SIZ8GVYI=$$S6<"`'O3$^@:U5KQ9MA>P.2J[<.1[-$*IQ0H+TDC1=
MO`.T*G0,$`NIL$.J9GG+I]^*5?]<`W&(M\X`D;0)\A+`NX?3*[W?P@VG_ADE
M.*YHEBC7B51L2KS*%,MJ*+U\>4+HI.1%G4M*Q9:Y42R6<YV+J5$X:X])_SU'
MGQ=%9""6N52Y4I+7C`>=Q(FFT6-2DV])3:=&+PUY9'R3=<UOZD%Y-]C=DB94
MZBA[PB%C1\>>LABS/4<#^DM/NO(]^+:%[4)AE<%?A?=,NQ/96N<:W@=/%'^K
M7$C8"X[$-DSXQL.DRU-%CRE?1%_&._[R*_$Z@,0Y':]A_O-4JQ]3#@A&VQ@>
M]*CWR(=LM3C,X:CLJ8^]1BZJ^7I)28NRSSU%,/[S!@TH0O;5M.Z'[Q"IZBL\
MI@D1\9=?$9]\;2>T'S+SI_^0`>QF09'I"9SC*TO][F=(S,G1I/"]3_X"1";E
<2R&_^B<"R7RO__WPC[_\YT__^MO__@\)"```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>f39432a9e3943242.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943242.gif
M1TE&.#EA_0$\`/<```````@("!`0$!@8&#$Q,4)"0DI*2G-S<Y24E)R<G+6U
MM<[.SO______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````_0$\```(_@`9"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MNH``&C1QCQ00$%*MV7CRI6;8,"!!3(!$"`0@,!)OPL/!!A@%^6"
M`XCG*I:[@`!AO`,7$#90\,```G`%'B!P%V&!`P05#(`L4#3A!`,3IR;-0`%H
M@@@@+V`]$,#``:A+#F`H(/+)`@$2'#!`NZ1D`81?,S``0+E.W"PS+T9YP*T"
MV[?=%B@PL$#OZW`!_BA04&#WP<\$RW,O+9X!`N5GNS<G&*#][?6J"V)G8%D^
MVO4,8%>80.7QE]9^")F74'\'70<@`^@)A(!;"&RWG7)L(72=AB8-@,!!`13(
MTWP;U0>`@@T"\.%/$5;5&X&4";1?`*D!1A""Z2FW```+T*@9C@(-(,!K>BF7
M0',Q"B1`>_G=&)F"!?BUH8P"&9`D`*@1QD!Q!J%XT([.I58?0?')")IK>D$G
M4'U<&O#@0`:$R<!9K`&P9`!),G"DC0J]:!"-?BIT6&>P%8<8EQ61F-$`,1J0
MFT&6(9I3BU/U6!M\FJ$())`$*N?FG++9&2>9@AF8'V<!$B0``C0V69N3_@2:
MMQ]V"?C(X`!O)N3E074!D">H`<`W9H#P.9>`F[\&F2L#J!*T(P%YDHC@D#XJ
MQ&!EE!'P*$*"N<GCCX2-5AJ>!6!Y6[@%[2CII0PEP.><2PI`&HG-%J1`M00Y
MYFAEVQ*$V+^507K`BO[*>9[!H5FIG'3.YK1D9D/>5AJ*"K)EGT$MJ@BA<^2=
M^*IX'F9(Y9P$`WKA0?N)UEV(``"X'ZYSWI86P9XM:]"]%$.HH%T"<'?Q@`2Z
MM>N<RP*M&7?XVI?R;D8?)')!;?%G<VUP;4=@KA&WIB"^Z=&<D**Z2B>RRA+:
MAL#0#&0=FH?\%<1U>A9J/+';V[4\D(/E,HPQ_L(_;L<V>*\:B!;:$*)5+0*&
MTVQW:Y1.9$#%2?I9K0(V'B;BW@+M2!AR-[\\IV/\F7<D88.]>J^K:Z8&Y6":
MP@GHN:AW.76Z]@&'V,O5!0#F;<[Y&.A]!]6[IEL(VDF8C58NERRV(+9V+4+[
M,?BI?O,.]+O$A'[-][AM!ZG<M/6]F[F=C@'X?(T,G4W0ONAO66T`58L/]?9:
MNOV:I?S%J':^[]8ZFP&ZJXVM`/`VB<!,27$"FF,0(ZZ"J&E^`JD7=A8`EU)M
M:3?7V0V#"`"9(P7N`&`+7-H>59X>/6H_.Q*`C0[($,*A+#SA(E%A'F<N[\EG
M`/61$P`/8C3-G>5*_H]SC@"0,\2%N`ME,=3;C2!SJ\$D:4>P(E;V\A>SA820
M=H?QG,0Z9:!^&0@RP=*,_+#TM.;=K57L"A(8H^B9[8&0@_XR3[,V$R0EOFT`
MF;E,IH(SIRE9A&VIB1K4;(9';A$(;OPQD0#@0IXZ!FED2GI-M:X8H+H]*$*S
M2@^"A&2AA;C0>7,S4"!MR(#ZY/%[KSF?C')EM`A=:S[V09Q[KN,U@W!*.59+
M2('*]::SA"<SU1I8N>CS2"MNSVH@S,X6DYDI2.U'1"`D8&:LELN#J0HT"E)4
M8<@&R38RI%QRJV+TTH*VMR$(FFSQ6:HLHLJ(6+`BZ\J<A$(#&8(E@$O__F*8
M:P1RSRHE+(Z.>2`/%](8(<&16<I1'[.86$.$\K-X#>I+E"!#@!,5YH&S.I-Y
M&`6G]?0E>&&<D#,7\KAR%2>,.A.C[)I9185PZD9N829_``/%+46O<N.[38P@
M8P`_"<AF-=6,CW:F')^J:B&-TY6".$-'S31J64!:9'?,@QC1-"9M%#$``0JP
M/(=$"72*D=]/6$.:S,2F-:QY3?UNEAPE%J"6D)(?2@W$48,\+D@",)%81>BT
M$^755];;'&G*@Y@`BC)3QS(L,?44+,&H2::8@>D%[_:MJT9P/7I42%(1`E8]
MT2DUJ43A0!1[V32.ZC)X^=9T7/))JFQ6(WX,_LU+053+ULZV,M>K6<#N]EH?
MD6<[`<C:/HO9G26AQ4_1]!(XX0I!7;4,.'3SUW,7M\[6M*R1UL6FGPH#W3ZN
MEK7;HTIX*X*`GDKG/3T=[V'NVB6&W-9?!>Q(4TGEM*ZVE"'QY*)"7#/%63KK
M7S3C$UN`1KG+9(8X6VJ4%[][DOPRN$MR&E1#&O-:^_)5(74)2:T^"F$>2JJU
M$6G:@T=,XIOD5B[[*[&*5\SBE`RLQ3".L8QG3.,:V_C&.,ZQCG?,XQ[[^,=`
M#K*0ATSD(AO9)98!VK8X)L^!O.=0@T+,68],Y2JG1$0'A-(S,7LC"U7G1':"
M7^=`/).324B?07NQ_K_6W)`*;61V5HZS17*;Y:P5\KZ<BN]RAL636L4)K%RE
M+PC#)2\1#I.X'DR-7W=%.=(LH#S)&:@#P[76CY"&N4<9KIQ5TM!1$BM&6NSF
MA8\JO)[B:EOA"M-6M>6OO32P,8,AS>-$O-+V/I2ERON@8BN&0CWCBC5;]8VM
M(:S$C<SWQ`\1S7@Q\NB]0JVK5MTT2$`H2/985V7<;-V?-*1!BH$&<9G!3MYJ
M,R$[L:>3JVQ-U7P$9Z))FC\ODNG3:!3;ELH;;=4DMR<3E%`OWPUCU0Y,J+OS
M$"$5FR.BP33F#K*D92\%G(M[:]>NMAVX6@C=%W=X2=@RF'`?9C>V&0Y?_BV*
MHA.+O+IS2J6-2)2\D5E0IJ.F-6E_Q.I\2;*"V(G4QVC#Z\A0EXT#X<NZT`8T
MX/SYPH.N*[1L&E>UIF<P'+:6EZ)\J$P90#K"4;-FJDH?VE0'-,79+.*.>#<,
M^4MAI:FG;#('L)DHM'OL'5ZG;I>LVS'5I@Q<\$MVV"E4,>U1)4=9@N($PCQ&
ML8:2N91E0LOU*IW(2"="\&T0U5-%93BH2<?AO&#N6443I%>%)E":#DJ@^A"2
MWU.U967$!S(O8A.2<1<HRBCHZ*\S!R]QRF)NW'4[AE[F>[^JR^;>=KGUJ5,^
MN7G99Q)0`+Q@V3RVLLOC(!-##)VH=/GZG62$_I0;\R1>(<(;GVRJU2*T*2JH
M.-E/A<SC-S*Y?]CZL5"9[IM-P\NHX8K.M]2H2Y[Z*!QJ%],JYN,GW&0;1G,M
MG"=ZW;$>]=8:2_)N#H1+YE09NP)"!00:$K<SYN-"B&,G!`1P!I%BQ'(T]M(<
M:"$GJ*-_Q01(A2,KHZ90'UA*N/9!T0-];N,E0`)]T]17#)=*`!(AQ7<CSO%>
M>X<BP74TF_1^#O0EE5-#%;-R[9,JH_(C"[(K(0(1B@(_I/<\V>0^TM%S/6@F
MUH,0?+2$/(1+%G5"E9&&/C<T8,<C.Q-'FE4MJ^(L!=1I3%<E;P)"CG(=V](C
M8;<\&_6#D?8R>+(M_B%'`-\!&.\TAH<5.DI2,/D1:/J1<HIF,!5E-&330`'"
M5)RH'T/8=C&!'*2C'][G,8Y(7$J8+]N")T%">(IE+H)1/=[U106Q(BWW*&JS
M/([64)81*#+U?5AEB[`77WX2)5L$?\D8@>>B>JW6):+A>IFR,YDQ7^>Q,WQ2
MAJ.%BOE"&CA45X]HC357&2A(0&G1'0=P)`GP.XJH6G;QCG416I,A0!VG:#@4
M*-^R-7+".KN%$+U"&KY#)G9A&5UE>6E"9C^A1`83)N]1&A8B'99DAE-R'6DA
M28;C'S^79]-%,PXB77$#3/(Q6CU3+@0C,L4G9M@%(2OR=JM(7['BC*!E_B_<
MP4VI,5I0LEWA52UWYA[+`CCLX5;Q%CT`PI*(Y$`0\QI6TX%AR!_)=#NJHWIB
M%I,;(WIU8SW[Z),/05V?D6\M$E^*TH`_UI#_Y35ZAQCLXR]D]2]:USV:$1GE
M,8Y;$E"DYQZXPB>/0XI<@C;CF'F007*HD7DR0GUAXBDH]'O=Q2R<PBBNX2?J
MXADTU1RH41R5)4.`AS#(6(FI-Y4!PBD1@@`/>"3!M"NV(8Q,J5(IQT#XL2L8
MI&=DF"3#\8E`8WY#*&U:@9`8<7"\4AW.PER/8Y=3<YG"%VF8&4&/!R>$TS@*
M\"M415,[,Q@]TV7I]E"LDWP_PE"_N"(*DFC,F#*0V%DE,:*.D(*+7!.#H_4:
M]P(]LTF;6&&;0*%G6*E9R!8DF/9:,U%&K9$>_K(=%41P#M@@WO%SFN$U$'<Q
MH`ATZCD5%F84UY-D.^F/FV%;FJ5Q*L8P$GJ@%FH1PJ%W$+&6%]JA'OJA(!JB
M(CJB)%JB)GJB*)JB*KJB+-JB+OJB,!JC,CJC-%JC-GJC.)JC.KJC/*J>`0$`
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>f39432a9e3943252.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943252.gif
M1TE&.#EAIP+2`?<``````!@8&"DI*3DY.4)"0E)24G-S<X2$A(R,C*VMK<;&
MQM;6UN?GY___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````IP+2`0`(_@`;"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIPI$0'-
MFSASZMS)LZ?/GT!G)@A*M*C1HTB3*EW*M*G3IU"CRK0IM:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3-ARJ=N8!D0L6M-7*H"W5B'61YIU[4,%5MGQ7^AVY-[#A
MPX@3&P6L&"3CBP@*2#90@++DRY@S:]Y\&0&"!*!#BQY-FO3GTJA3JQ[]^73H
MSY4-R#:0P++DR)YK@Y8,.G)FVY=K<_X]_+=MX)1;\PZ]6?9P`P<N`Y\\O3AF
MVM01T$Z06[3KT=M#_H?W+CM!`=+)3]..'-[S^=7PO\.?3U]W;^T'1%O6[GM[
M^<K<519;`=J=5T!TGKE'H'[@F=::=KI!Z-UDGQV@G0'=44:><Y1Q>)UU(%XV
MP&4!`$#BB`4$$$"(+`Z'0'0`@I9?@#)^1AN&PH47'(#N<??B=C9.5EM[O&5D
M'@!()JGDDDPVZ>234$8IY9145FGEE5AFJ>667';IY9=@ABGFF&26:>:9:*:Y
M90$:%:#FFW#&*>><=-9IYYUXYHEGBDRZB62)>MYYUT5^RA770`G()1%C@\FX
MP`&01BKII)1&&E>EF&:*:0*:YI<IIS).V@"G^36P`*<"'3#808\JNI"B_H"Y
M.JI#J"+*D%RK3B0K08<*]&A!!YSZ**2)%A37`@K(2"JD<E4Z[%O,2@HKLZ.6
MZNNID9(:JJ0-9,NI`M!U*NZXDP[[Z+)O);IK00JL^]!CIAK4ZT!R/88K=(YV
M*^ROB3J:[+`)@$OLJ=VR5:Q![7[DKJZYQ@LOHF\1;.Q;\4IL;+.`95SLK]>"
MV@"2#T_DIT!L,1"P7PHH8#)H*R=[<@,)"\1`82J%W-'""R<TLT#M)K!S`PS(
M-;-?+3<\\\ZG!LPNT`;1K)#3$T$-L\P#2>V3U579S#31"W'-4:X''Y17S@RL
MFFS0IJ:<K,HPA^:RR_6!:EK`JJU,M\]NUZ5R_MFA+8`U17\_C1#(;2*9<IZ`
M/IFXDBH"*AD``Y2X8@$#+*FBY94'JOGF5R[.>9B>#Q`Y``&,N.**E4\.N>F0
M(UDYZY_'+OOLH$MIP,<`:`W1R`G0[OOOP`<O_/#$%V^\F#81GM'("B#Y'FK=
ML7;:]-!U&"*&+6:O_?;<6_:?;\IAEE]N.(:'X0$<<N@;9@]&YR.$"^(8'88%
M.E?@;3J*9U][H)6'FW2@Z@R%)J,9[!"(>]:!$6>J@\`&2@9%(A(`]]:W&0J^
M)S?=D8R%7/,_^B&(.^:I38*PUZ$+62A`D4$?]EJ$/O=8$$3T.Y!Y8M.A^<@'
M/N]A`(Y84QKE],]`_@0\$'!F^$+I7&>&`.04<-!70/8(R'M^&HKR,)(YF$VQ
M,5C,HA:W^!3"7=$BO/LB%\=(QC*:$29>S%WA`&!%-9[Q*8%[HQSG&)0TZNXA
M870C'??(QS[ZT2!V7..HQ/A'Q`RJD(@L9""7AZ1!ZC&1D(RD)-NR2(SD\8Z3
MS*0F-PF52A*JD;U[)"='2<I2(L635)/()4W)RIGDK)5'B>-/4%D3@:P2EKC,
MI2Y70DN*W'*7P`RF,#722Y&!DI##3&914J9,LX",`<A4Y3%%V<QJ6G.8"RBF
M--D82DQ>\YO@W*0V(_++<)KSG)P<Y^ZFZ4UTNO.=9U0G'MD)SWK:<X_R_G1(
M%;MYSW[ZDXO-4V,TR4G/?QKTH(?)9T/*B="&.G0L`07-0-?)S8D^U(^RO&@9
MN\E/1E:4FAKE)#-#:D9HYLZD[5P(0TG*TI8N):*X2ZE"5NK2FMKT)_RTJ#X+
M>M.>^E0G.07I1`#E2)G^]*A(=8Q"&4)3GF0TJ5"M9D1AZM&B%N6I4<VJ,&&J
MTX7R5*M@#:N10-91C`C@JV)-JUK?1=:N,A6M:XVK7`L2RF0A":L):>I<]YK6
MNM95(T0M*U\'J]:(AG(C@74K81<[DX9%DJ.*G2E<&4O9HQK6<!HYZT>-6MG.
M-C24IVHD,2?KV9[@M;2*@2P`'`N15>61M:B-_FU#8'M-U6XD258%"6UEVT\V
M]?2R`#CM09`D`$<*-R'\2PC;!@*NT(P*;Z39+6_+>#;G,K<T;7,;RPX"&KIN
M5V8@-.4K$>)7S&8$MX?MB)\DB"1WG8<@3CI`DWP[W3UJ5DF#N:^2$J#?)%&L
M($ERE7]-)=\D"6"\N@0M:$?[4>E.!`%JC`PU301?O[A)(`&0(GT3$(#Z]M%-
M`TA6B093N;J8+,,-J!P"^"895KVN:JL52.5\R^$!U+:M,3[O-(^;D-ZMR@`Y
M%@B$V3@0WUY8`9_Y&'T;<,B;\GB2%![D[1IP8>;6Q4V`,1E"_#3EC_$LRE_^
MKS*!R]F#Y/')W-4C_C2[W(`,`Z#)51X(F#L\JO?V$<U0C3*$J1)G)-O2C0I8
M<D'.HR*VQ+AR@!2`@V&IVC(;)+'!]0B$<P7FZ*28S@2)LT!(]T`B0YC-'C8C
MY+@#``'D!<2203&5(9=J06?:9RJ2BT")3)`2.5J3JL7SJC^JZTP_<D4R4R.0
M'Z/ICPV@-[2^=:@I>3D;%SEWW!G`E-V$G1'E=2BAA.:F:?UL94]2M8MNB&8=
M^1'Y,B;*?DJ2H(L-9E<O.YX%R&9QGXTHMF#95^ZV)5OD>]9M&^2L"&;T-&\[
M<(]HNGE4"8"J`E9LR@%XR65[]QPIW#OZ%OMV]V8J8`K\9UE!<][-M.UH_HN;
M7O7F6+YT1H"S259J7S^<("$.M+<E3I9L^A;(?.9V`FR<<9@WC$"U)C)*!V)K
MH`V@UW\4N8X_ZI'$9<X`=8&PP@>2.6?[Z;T!+;62I$SS,?H)V`PXZ^-8G3GM
M_&E0%6=NB@+096CF)>PF6GNCA(K+;)<<(^@5[==FUEV"K,Q5*?,9ST*3%^BZ
MC62%@5O<%L_XQCN^/@%'[6A\I9KG?A=1A3F\E0F"Y"031/#7?;S^>CCZ\7AG
M1I%A#GS6=K>[N<QNH$$6Z'F6W=:/!O;:K<O)8@\TM;5KM^7E]D7R+OREI/MX
M<)IYUU%R_"Y=;DFC2Y+HI)^ZL:?:>9GC$_*9_H3I-`<WVPPF-Q\COWQ(AOLE
MY(\):+-9_(H07_GEO^;YD1I\Q)(V_O@'9D!-9EY+WC__`"AP#29(@A6`!EAW
MAG-WP]=R?W6`#BB`$D5W$7%6Z:)W#WB!I*1:Z:<0^W17&/B!G`1NX0=^(%B"
MDJ1T%I$RD#9_)MB"8U1_!!A9+CB#6(2"G_11&TB#.H@8"F:!%P%I.QB$;V1W
M/F@1Q(=T0IB$5_$SB-)(0-9^%'&$2CB%65170T9P3$>%6I@8AS4R(UB$6]A,
M2'A0AW6%7RB!O)6#8<A%AZ6`1KAC:QB':M&&8!B%<"B'>%@61`B%$T%\+)B'
M@/@4,)@1D`9_@7B(_CAU5V[H?G>(B.(U6'M($6*V;3CHB):(%3W(APOA-'YX
MB9XH%72HB1'Q?I]8BDX1BECH2']HBJPX$_R7A4LG?JW83V/82JAXAFHXB[K8
M$K<8BPVXB\#($[V(=_\7C,;H$L.X@)MUC,Q($\GXAKS6C-(($\_(B+`XC=C8
M$0Y6C798B=GXC2?!C7TX3:L(CN88$9%XAN4X1NN($[5XCF$ACA)!?/!8CQ\A
MCQ$!:>\X9O:8@07GB_U'4DW6CR?82&8(D*)(D`K)$/@($?0H$NTH$R.UD(S5
MD`\AA2$!;!09C&58A^-XC1ZQ?UFTCQM92H?UA*FXB!OQA(PQ9$SR<UMW_E]T
MM@#I%CFJHB3(PCA-`G(#<0"`$@"#X3D>V$9,XI(%8%)-4A=/6#I+=GR2,1A,
M`FHDLW(IUB1"*8,EV18=F9`/,6XJF1'L!V:K!BDM9VX$8995QF]#46`1XR81
MTUZ^TG(4Z);\)7QB)Q=NXA>A)"EN5''R=1[]]I<\(W:.5"]J))@$08%UJ49[
M&1TM!RQ!UBT`0``D<U8"\!;]UCN&F)5@<5@<=X8AP6%_LA>4L6E&QAC]!C0!
MD!=OAF&/="`81I44!IO-,Q00QGFEMA<E<F5$EBBTP7*F:46#E#%N)%IQUF*?
MEV,<MIH?@VDEYG<ELF2]\U\*<&PR1F=HR)F'_G&2'CF/_VAP1Z)FBA)E3-@`
M9\46!J"7C`D`DU@KR!F<>]&7+I><-M%G#Q-EV*9'FNEOJ\86@497009-R6-Q
MC[1SN]F$%*-E]&8J)*F=F.B$W3F*!@F&RV6$CD25<I9O['=T36@3MUDUHD%E
MJREX8ODQ#U,Z!0%-/)<[+_*>\"6=;[8RP\:?`24`4CE(E,8FD,-RW==F2`8`
M759QGF%M5,>5#KJ=C>2%""DV&&$`&?:$D?9R",$`F>.?LPD`KD*E2'([?Z(D
M@@92):IDJX8B;#=<,,HDAD9KU>D\-+.?&=IF7IIXV!FEH=1J07>D&Y6D$>J0
MW\D13%D`F@4O85H0_@B@(KH'I`T`9+LB6D0:G/!UHCV:=G$6&69*GTUH:)%:
M(J#FIIMV.XA&;04!9".")%0QG3S3E$:*IWS1A7MZD7VJ$;T#7V$ZJ)!RJ<%I
MJK)J2TM6HB!5;*9:;)5JJRR7IK9$+S[8.ZZ234,A`/,&EP-Q8*2"G^RY9:FJ
MJEJII]6Z$,0EBQQ1FD4:I6]J$`8`<CYF1;X5`*:6JVVVJU_Z,,VS9,\)K(`$
MH\1)K,T3GX+FIC09::+5.\PY*E0)9.HYB7*6K=:*%JQJL`GQD!P!8>]E,F6W
M*KUCG>SR9KMQ.PO@I$<Y2!FV,@PX:B2S(B53<5#CL+L1`/7RG,JUHS+S_FEU
ML0`J9E4J8B.J)C/4)F'6.62JDJBD`VO_"K,]6R**9A"AM&('6X5WI:3$")++
M<QDP\QNG^D!FEB*2<663XVPTF2(C,A2!%AQ=^Y1/.QD(`;0C<FJI9C.1XW!U
MMB(V(0"F@QDA1ADC0K&(DAF`P3X",1WT4D'B>AD->K10D;`IV:J`>XZLBJ'0
MR*VQ5+@!R)V(:XV%N12;R;AS);@CMVN32[F?:+DZ5EQ*J[D$R;G$2'*$ZU`#
M";J(@9*?F[A#%I'U]+>H&Q57B)+AM[JQ:[@3JK"#,YF[=KNABZVI>)#-Y+J^
M>T:BJXQ,5KK%RY'`&W["N[S@>+RL.Y30&[W-_OL0.8,DE/F5U<N,TMLU"PNA
MNMN]FWN]HZNX<P6[Y(N,>MJC;\@FS[N^(46\6<&J[LN(Q16_\GN,5^@F^3:.
M;,*]^ZN+]CNXXSO`#3$O.LAQ_DMP^:N\"'R)!3Q:`5R'IQO!%@$UZIM53G.X
M!/<6^GM4GJ=1]-M9_3NH=O@6M#L2F8O!L77"CYO"Z+L1&^S"E:6Z*#R.E/F9
M'$$L^&+#)9&+2,7`.>R=;&2[%K%SW'>C0'R`(]/`#!9H$,PT*K6ENQ;#4&$Q
M"",1QS614\,S)5R*?K-)3US$$LJT&3%D5(%;M588F4-D`85I#/"3KI-C"'!?
M&^MK3/+&;Y9U3^)8_H6:)#;AQR;"%B[I.E#'LWU28$EB`.ZRIL25R$X2QC/(
M`")B9%)KR94C&WISQRM2PV=1QO]KQ#/<I,K#QE\V*%H*&":R%[6Y<\<&84/A
MEGRC(@!V(WUL;9M\J*TY8\E2J(^!<WXCRZHHFH/Q:<GB)LPYL>+!)BH*+M3K
M*RHR&"@G8UC*,W3[B0%5`(V"KD-1.J!1.=^,KBHRRA^FI^;,IVB,$1V%RJO&
MDZ;RF+%:$/.&G.\AEKBZ:<-:9Y+)RD0F7_]E9W&Y9,S*G[B:=JE"<7I'DXYZ
MG@#V2&BI<T),A0Y=9&_)RE+$*0:2242<SJZZSI!!JHO)9M-',\0\`$UF_K8\
MPP#$#%\\.1BU27N<VJ_3VC:$6J`Q1M-3)J`PUV'O2G3A*LZX67Q7>EVS*-06
MO6D<FJ@K%G=0U\*&<<(>[1#;*L`4L90EDLW1H:*/=CHSA:J`%)E?QAB]$QXT
M?1Z%NFZ1V3O)PT9K.G>,(;#^:AFT!J0_FJX#`6&(2SIC61LU:XI7!)MPVK'/
MUIJ:A,-8K!"LM:TA?!$%&&RS#*Y?)MD&X:+`BM3)2=:DL]DT+4'1.6C"EW:,
M4Z\$,6S;3#F8YJ5$&Z:1LVHD`M4M6'1);<VDXUJCF4EEK+!0P]A3W!!#=J*M
M8\4`1K"#AJH-`X:<.IP%RW**HAVANM:S!DW__JK<],;51I>A0":5_CJOJU9O
ML]AS5"9FH02N!7:_A23*#ES*-P@O"I!A*4.E[ANA&IG*N$G<R=T[\=F;-0TT
M;,;6)).\=7%,*^??P69CS4.528:H)3*)<)=YK2FO80'*NP3>`Z#"J[)G2H,@
M!\Q%Z#U:%;CAU$I-EKW?_+FP@E;0SPJ%]ZU'H@7034C//"E!_$F!+$=?#MT[
M,=XN%,9^C]$\,7[-$&Z*;EEA5+9AN0.;[@/B6M3A.O862%P1-/F3:`<YBJ*E
MAJU#T21ULS?'$D0Y('4`KV,P63TS?C*WI789)=K>9!II0W8[VZS$JJ-&5H[F
M6)HZ%O9%$RL9#OV$_@(`VS,84`B0,JW-LZ?A)I;\9JB=V.=\Q&:LSLFKY+RR
M'LE!$+Z1H)AALY<!6YB1*PP`(^FY9=*AJ[QAR=;A6.`R&42#&;K'&1E30.WR
M1$`S0TUC&4J3J)9!R4F8L8Z3%^W]=3:A0\I\P7_$Y,3HY+U-BRR"([XA0KG!
M&[.!/MXA>M(^[=1>[=9^[=B>[:AA$>@C9.4\JJXC`$ZG=9C3?-P'*-/':ISF
M0,\A0TO4[@+R1.=C/JC7&Y4A68P^U0V!)"!\[/<4Q\']?-LW\`0//#.'1-N#
M'`ODZ>L3(/'.[A#//6*7:B@B69[;Z*[:[Y`.B&C#Q3Y3GC0S-`%C8KGB_C?O
MS3>*URX*>C;OK30FHS++Y3*U9WDG\S==G*)+4YY`XS0FUGNMEQ(2?A7$OH#0
MXN]-O(9N0IE0W.2]>_2Z./1OJ/%.__3H3'#P6X1!/_7+U\!+3XP57'Q9K_4T
M!_6,6/0;+_8Z2/9VR"9/CO:!J/8`W/1N[XEP[YW&?O9SWX)U+Z%W;Q3"GO=@
MM?=\VO>`;XF"G_%R7_B'>/A4/:UMK_AAR/C[?J5X3X5A_XU<C_&-3_B0__8M
MU_4+R/9&3U*7W_F^U$B?3<&)#Q6E;_JMY"87K^__O;N<[_IR..2@7Q$F5?LN
MA>NV#Q-#[CP:85*B7_F"^/O#9#69+_O::KY`_M'SA('\X33DJ<_TCR\160NV
MGIZWM\'V#V^TG"<=9JLAI1T<4]IVG?&;X5\9X+^&K5\6OB\5(S-C'[SZ'G5@
MDOGYDYE'2[(J80D0!0``6-!`(``!!1LL/)APX<.'!P`\7##0(D**%P$D@-C1
MXT>0(46.)%G2Y$F4*56N9-G2Y4N8,67.I%G3YDV<#`$0,`B@P,R!!WI.M#F`
MZ$($`1;Z7)B`:,6?#9)N7!A@P$,&5I<"4.#1J$BC'!\*U!G5```&#10$0)#3
M[5NX<>7.I5O7[EV\>5,*%"HP:LR@0V\&.-H@P4\%`*XR%,MT(0,``1@@X`J1
M<ENR'C-_/$#8`,3,_DZ)&NTJ];->U*E5KV;=VO5KV"H%"NCY]R5D`'T'KDPK
M<O?#PPN-`F@+$<#IA1(3?.W(=&!OT(6;(Q`(/?/LA8ES/X[=W?MWNJ7!CR<?
M%_K,@PT&VGXYD';ZHH6#-V!P4')3XA`E(F!N_.KOCC;KZ"RUCAO+)\\4,FR@
M`,0J[T$((QQ)/`DKM%`O[`ACKR7<?H*O)@`-LVT!@>ZKJ+CD-A)PJ9]"/!`D
M#05:K#;'(&)`(K0NU'%''GOT\<>2,JSQ)=%TDTZF$(-SL">.$K-MH,.DJT@H
M%W7ZJ"*-Q")+`(*`BX@J(,,4<TPRR\1P.RXW9$D[(V_J3RH/D7.JL;^<_KH*
M,A2ERM%%`>HK+*L&!D`1LM/(@BR`@IP";D@S&W7T44@C_<BO!C0$:KL/:7(R
M@00ZXT@@!#Z]3T9.S^ISH;,26$`!RC[3+E1.OX*2T^4*2&S)``)08+D<*:/*
MIU(KD_`\28LU]EA)*5U/IB(;..M(F0P@#*'B*)NVP9ZN+2!/J:85M"J-(CLH
M7.V.&O>BM`XR8+B!D$/V77CCE3>OKK!;-B8V!9MW)`4A&J``@`,6..``!A[X
M7Y_^+<"HA<7U]N"!!2@88(4+L`I@`0">F&*#._;XXX`-*$#DD`\#>61.!3XL
MY8`1,`#6;1-XN8`$0D7@9EI#)1E@6&FMV6<#_GP^P.688;VY9Y^3_EEIIIMV
M^FFHHY:ZYJ"G9EIDI$VN>62;H\[::K!I/2!L`[#FU.64C08XZ)@[I9EI!J).
M*X%=Z::[-`9*V[6K7=52J*NX#>.;0JQ>JI>IL#PBUJ1\,]WW)&DA7MC@A$^N
M&&3W-`;Y8H\1MG@`T"^?&'2-$3H9X\L#-JKB7#=>>(!I!1ANVG`9O+9VBVO7
M?7>-:.?]=^"#%WYXXHLW_GCDDU<^^(*7=_[YXM5\R"C=N&T)RS8?UWY[[LOL
MMT(%55W@@+$-$ZJ!!0I*/R)^%5*54_<74/6`KCHEOX'RR:=_)+YJNU0HT71/
M@!UAP.(&>$`$PJM__I9"$J:JE$`(PHMP$:1@LK9S+YC@)GL5Y&`'/?C!\2S0
M0#'1H+Y`>$(4IE"%<.D?J&120L>M4(8SI&$-02)"Z:D$>R:T80]]^,,/]B]-
M+PQ,B8!X1"0FL7O]PZ#ABOA`)491BE,D$Q,9Q:$G0HN*6^1B%R&$0R(Z4(M>
M)&,9S9@:Z@7JBBS980S/^$8XQM$M5CP?3!H'13GF48][1(D5K<<2&.+Q71-$
M(B'Y>$C4&#(E:6Q7&#>(2#,9$)(^5&29EB1"=[6'*FXD8=@\23?YU<TP\J-;
MWAPTMXZ`4BP%)%:3#*,T4])*`06T&Z?BEA92SK)^"IAEW%;UM%?N*F]Q_H-:
M`7^)M^RDA9?TZ0T#"J+,WLQRDM/<'F&HE!\29A$GSX)>-[WY37"&4YSC#"?M
M_H6PBQ"&7<!3&,-`9Q'?148QI)M8ZV0'.M^ILP!<RA4^[1-/=2HFG?8!'F$T
M-)!U6N4B]XSGN6QW$8#U3C&Y\TGMWADN=<(.H11-9Z[6(S&#CDNC\-1=/!'Z
ML,BD[G0K96E+3[8S@<'H@F""2;,XZ9;O7>F5(.&(_?"GO[%Q"JCD&]_^[#>_
MH0Y550HH:OGJ1LJ?)G5L4B5?+8'Z2J5VRG[Z2U]3.R6_JE9UJV"5ZE:3:E:J
MIE6M:=5J6*F*UK6FM0#Z^U=<Y:H_GPS,)P>8_@U?$8([+EE$`(%UCT5P1%B)
MC`NO&AFL1O;)V+D&=J[D0XC^!$#7R_*5LACC*P$22[YQ7=8GGM7?9!\;6/(-
M%F"DY1+Y&);:`PP`M%P2;?`(R]C=>7:PI9WL`3(+6LN:UK26)2?PSG5;Y8&D
MM>JAZ6VT24WH1M>'!DR`)*W)W$RZY+G23:$DN?O=&\YT22X)Y!C!"\'QGE>]
MFA$OL[:[7OC&]X1^E,D=S2M?_.:7>]>%DGO%J%\`![A[@>EO3&PJ2`MY][N5
M%'"#1<+?YKKDP/>M4&_2ZV`,9YB1$6Z)?3/\81";B<`<9LF$0WQBU"@8Q2@9
M\8578N(5QUC&#VJQ_G\?.6,<J_>/%JIQ-O^;8R`'634]MN,39W1$N@E9R=PC
M,DS>"T0&+UG*DFJR)F^LWBA/6<MY&?&.57+@'&*X?%LFLUNJC,4?EUG-:S[)
MF0'Y9#;'6<X/<?-*[GCD.8LDIWF6<9U54EX^!YK-?DX)C%]HR[W9J#=[?@CA
MJIM,^C"N(\BD3Y85"9VZG6<!"N:46AI-P/.()V_TH96G(ZV61V>'D`6T$7<>
M8T`5"WK&A$;)@6DS$RPMM#0.)7&7\%,[3H6KCA<1BVCZRVN%$&!W`BAV[1J[
M4.42F]<%7I!%>AHNL2B`L%$1S:V'4AC$+B2P2TJ`M[]=&&C3N78+"#=S_FF*
M(_?4L2,.60B6_H*C`B@[*!(9(D_W2K..'$!!4W(0B=1*.'E_)$IO,RM(UA>1
MH88DS`%?3[D#+F_+4LBWI:4K:!>5&P>=%>("'WE2(2*_DBR`>D3=*U\SVZ_+
MZH>H8^FM6Y>D@*I]KU/X*\U4LSP76I_DP$JAB<J!-97/,.`L-$L*G@N4)X$8
M8%6>H0^H%%`B]UF%W.T"'.PX177T@8I7@LI=5*R%,M(8A6TCA,A90B40NATD
M5L<YCZ^JFY4!T"IQ3F%+S1QC]\=8[.9J;[1/SD.@1OME2=+R"842H,^(RBQ!
MPJ%[XB=:H@G25.D%?GR#.J,8NB'4Q4XIW7@+_M;HX?3&5\/A-404!1(&K*YA
M%:462$06'<7P<W&)B77G`^:B?V'E(`!_R%3RNM&#I"NOEKHZ0BT2E8,L)BOK
MR=WIBT]TD60E8QI:_7JH#1ES#S_P&UUG9+2DD0$HY%D!$,I:J#WD]N(+SC4%
MDY_:,B>D1'AUS3$[-COSZU,QB`T)$>K0"6%)#/Q`#J.XM1I1@*MPBM)X$RL1
MCOMSC!5A$>'`/OIH$-P0#Z<X'XNPL`UQ$JP0EL=X/_P+$`X3$`/@F\B8'NM)
M0<I@CZ5303`IP`6I'[;[B.#;P#SAN^9X0?Q0CT39I,)@F/!R$+(XBX0KP1R9
M'J*`#*<S"B_+CLB`_@[(@`CM.`\)Q(^H>),&21S\N+7JH#RQ\)6_^#ML>HCK
M$@FG4(B)(0KKJQ%?.0^Y>Y&MR`X7TI-K>T+*F!%IB;6Z"#J3,+292,&E>,`;
M;*ZU6!&+P0^BPR;2L\`!+`P<7)A<<4'\6)+^JI'%0#PU8J_B6";2TXG%80H\
MZ8BW8Y3G4(^S(+KYZ(C^6)<!B1S76T%<C`CQH(P^X0^%`Q.GR*2*ZI>&@45N
MXXH/'`G"4`@<!!<35`_"N#5%*0[\N[K":\5)6\.E6)`F1)6!@+JC((Q4DB?^
M><*Q4$+"`,=?C`HA5`M>8A0J[(G>@#M(!!.^VD3+F):1H(SS68M.4X_%_D"Y
M#!R2TIG'HU`,?ZF,%*2V_N&]UR#$DA@ZFT!$>72[FLF5`4&`Q#`W?G26@=B5
MHW!`_]D6CP@1@&&(;4'(UPO&Z"B`0\$8HH`[F=G!QXA&%"E%>2S)GZ!(*/R>
M>$0+7HP;-<%);,$*I:`,!^%)-4HOF43*Z(`=ZCJ.KS-'TP`_T.@4II@/IW#*
MD1"-%IPT7=E!%5%)#53*LCF+[*)'+?3(;LR*Q-#`T&`4E'G&DCP25E,+I<!(
M/!S'J,@58LH[)E1%ILB,!2`,U4.+*\2?8\25F:Q"W!B`S!O!`3@4ZZ"?Q-R,
M(=G*!>$(\#N/="Q*UX!(DK`UFU".Z`@VP?H>_J(8B'[9"?7@B]A:%'$CB+FJ
M2_V`/J%HK94DR`NZ+0-LHI,SK%^;0/[;S$DY$B;:BK&1GMUX/>#82=?$1Q5D
M2HWHEQWZQ70[QP;@$B7D".[42HM@-!OT-8;0#>-(GZ!P3N-L#O0T-YW8LV3T
M"(L3"`7AB^%0S8)8(SISSX#SD,*XP`6)"N2*DH1+K-HXB#HB"WY33.E$']IP
M"OX<1]8LSHO#G^THS^W$",PT-ZBPT(M`./>(#='LRB>:N!=K+K+82HG`LQE4
MEY;\C\BHH]W,E?'"#="`/LYL%Z+`29W@",>H")TP`"[QLAOY2&XD3N.`S@M3
M2RCTT5\[R8^XC-OS_I>"&8[24$HF/9"T@(SQRM);/$.V2XQ_`3N#R-$&.4:C
M0)2(-"CH"("@(0TZZPHL:<;U+#Q.X4X5)*3X#!#`9+L2P<:'2)7',Z]VY,&@
M,96]O,6^W(BOBY+QFL&>&(X?E$/B@%)$7!?4)`FC>\8K<E/J0$@,G;[#\+;,
M-)"M7!>$(!8N^3F[&%&1N"/LNTLBH:D.Q;]6\1>C`53`>\5;_+A*!(U"H4:+
MR+]!,=(:N:54*4RZ%,G\^PR<7)&V<`R:S#_;L%'UR`C]?$M=T<(&D1DDK%.U
M\),EV;3-V#2-(S$^A,*QJ!@C#91F<PRGV#RZU$('<3N&V)@:>4+1.#*>_B2=
M`>"23.+*<;PPA6(0A5#0(:F(=M+/4`0),<4G,%D1'63'&:FNQ$@X%Q((G$O,
M_*O)>^%*W(@,@)6XXBM41GD\@A&6VC2,:1DVV[#5H[A5_:`P+HN_(G.@OW"F
MF.#*.EQ/,:2,F2W6'=5&]:04633!;34(Y,`1;SR-Z0-!V]`5>GQ+`A(6_(-0
M)%V.US1#K"B;2J&IQ$F,7618HX5!)YR;YKH*C2V\YK,,VS#-7UPE<:0/<]3,
M,CV08SR<^Q`<+9R1Q$@ZFL),RRA4BH0,Z]A;*V2/K@#:KC6(&>G(GNC1L=!`
MHX@FP>269?H6_%B,-P$4G"Q4<,%"PCB<%)E,_N(4C<5$"MN`'55K#N@`'8C0
M"M`HUL6XT&IS6:R`R@59%/:0B.YPU9``,TU)IXICV1B5U[PCC%4*+!2!TDI)
M2G6*W1&D/KU\Q7KE"N.K/LX</G895-GR2,1EKC%5BD$]#L:#'<EBO5F*$=U3
M"RX9T_R8/L0%T`9E@#2Q,`:)DHW)%5]QTXCB"L^`20=!P\69/H7Y1IT0#QQY
M&<50D-.+$L#]1C%M#MF*DEEBTMEHS.@0OAUD05`-5,,+EM@#N:^CF0_VE?4%
MDW34DYQ=G<E@E'2D%6E1@/VXQJ"9%6^5C!(IH/<KD&Z=BB99X6SA)3'TR)_P
MDR-VTX1LD>:BT1>^_DE=74/M,`#P&]M^;."I!-/Z$>(#8=5!M%DGP]F:2!H*
MJ1OX(36?:299H@@'D28]?!D;N;`%H`Z21$GB0Y6X@9E0P8J<J1I669LSO&.I
MT)JYP1D9?AE:R6,#.``1!)CQNCJ:46-;L@R1H&*L.(`I-1^B69N0N;I241DZ
M%IA!X>3THF.2T<BF<&0]-)A3:HM[RCL[69B&#50A-;\"<8R0O0CDB#TH_%AJ
MLXA,*M_&F[9RZ0V3VHY]M0B]L8B\NR)N4@P>;L=C)K9I'J\%8#QH=L:()1>:
M4R-F;E=C8SQY6Y?`VF5XBD!I5IA<&9D-]A5=+HUPR;OST&78`%Z'>Z((_I4U
M,O&M`7)>'A'/>_9B"+)G[-0-I]-GP^D.T-PO@082.ETA@I;/^4-H#J%H]8KH
MNC1HB][H',/H(#020>1HD>:19=(>C[Y&(PE?&:M"/0OID0:PDZZW+"+/6>4J
MF5.JJ!JJIM)IJMKI^Q$)FU:+1=9I^>0JJBHY_1$JH"*WI0:J?!LS\Y'1FDMJ
M]$FJG(*KF6N*L@HECA#(C@"KDQLEBLCJEYZFF%;.;,DN#HF^-C:I!M&=\F.]
M\OO(V$$H`WK%.RQ?@V*49QFID7H^;7X^=Y:G]*.\PB+>&A&_:FN>]:A`A^%8
M*\PKY#J5:?M?>AX0#+H6;RSG!EL+<T*`N[ZD_N<SJ-G1B+&!IX+YRD,Z:^:Z
M,I@HXA/,V8VX#Z<<`'O-C%\YBBP$R/QSNJ`TQ0+YBXR)#N2@1U14RW9\/+J=
MB+CY5J=DBYSL09D&1C`IU5];DF_=6O]9$!0I0#MI5J_X9<ZE;A,]+^W8E=RI
MT1`!O=5!6?N5RJ][4/.C#N5=;3`FK\#(;O28UV.M+C!5->@C"D:.W-;E[3SL
M"-FE,W:,BK@96SPS$,<P4`-WQP-?;HYP2I<D\,F8V59<2/88V@;$('@50D0D
MQ7S=$+[;VY-,C#RAC(:&+@"9OL-K5_50OI[Z"8G`-#HY34EA,)<&NOO6KC3;
M[\BLF[R[Q<59$3A]_KS>`-7OUD)M)'#'^-X#L>:N0,4AW0I:.<C"D`AG;2Y0
MI#@27,@'WUQAL>T3%^H1[ZFU\$(W5\%#P<`5@8SR!J\0H7.C_%OV6A*)N-(T
MM(T)WJ.@P`T7^[.)=@DO=3=K:[MY79%X@N>$40Q'BS`K`NPJ!XG'MF1%!Q`7
MR4H4U2+?%;OJ+LNA9<F*P/.M^-!?L_1#B1+354$CWMH+9%CXZG3LNSW89I*9
MA1V+^?,@Y*.S-D292'3'N)4O9:]?'Q]?&PA]B]MYRXT.S5`>_PB$6"YU2Y'I
MAG(EG5F0\%WF0F[Y&%KF:@`"H(U\?5#L.%*L!$`HRHS6NL=9IUD[EPX`_@&X
M/=4)C*.]-#<.>><B8T77E3CTEB#V.JF[1J=W<[GVLBV\3/H*$C0?1E?KUR1T
M.@/$$_S/_$@51C<@;W?GQ@CW(?S#7_'UV=1!)73S7&>(6YL^ICB+4*/U]>KT
MQ=`.=K'#'>QSU57P7Q?T('^S[1@.FV!2$M%NI!C@7$Q(UVL1I9B^[$IPNEUP
MAP7=5=E::VERVPB:<;?"^Z#(,.=V`Q2+N6T*6)P(]X-Z#)1<BNPT5!Q=CP!%
MU"V0)7'Q!DN2$1(9&>[@YL)YBKARVY!9/6)M@?^S07V;I9-"GTE:-;*>(M:.
M3GN\ZA)"W,#<5-W`'`ETSC`\M8BZ0)<(R6CU_K-!QH^45[&(Q_%++S]I4S`Q
ME5EZO-.@C+1`/"F4:<E@%2&\C*9X/)`DND/Q27.LP4#96R#<3L27+P#Q;%SB
M5'/<PQ3QP%\!1!K/(\`?<I@8;(BJ':(K%VWLWFK#-F*K-L4E+,CT4#P2YB.'
M)\/6'>KW"85@%P:\B*.-<9IZY@"'$E[.96<['(P:[*YXEN)F$/$`B`(%&C1@
M$```0@`#"0H`D(`@Q(@2)U*L:/$BQHP:-W+LZ/&C1`8#$`XH,'(`@P8)$!J`
M6`!A@)0O`01H:1`F280*1M+D:2`ER*!"AQ(M:I0@P@,-$#X\FK3!S*-2IV),
ML`#D`:54I2J8N$!K_L6K0K^*'1OQ:].+6L4V79`V8]NK"\J^58FQ[-:\5?52
M_)KU;UF_8!,`;O#W0-/#?PLH$/R7+^3(DH<^92KU:=3)FC=S[NQ9Z,R$HD>3
M+FWZ-.K4JE>3#N":=>F#K44'X`G[=MW/%@_*IGG[M^G>L`\.J"WP./+DR$LJ
M;^[\N`'D!A(80"`P`?;H!A!'+V`@.M"*E1T6Y)@V/%(`2C/K;N_^/?RI"11@
MQTY?`?WZ^O?S[^__/X`![H?`?P3JAU@!"%2'P`$%4(<`@_5%%V$""7KGG((5
M(H>==QPZ6)^!`V(78GWHQ1>1@L@IF.*%QS'8W'??&0BA?M/%.)V`$H)(_EUW
MU_7X'',F)1>D<D0"N9P`!02PG$`G,7;1>+D%M9)Z4"%T(I99:KDEEUUZ^268
M8?(5Y655OA2`F&FJN2:;;;KY)IQ:6F:94V9>&2>>>>JY)Y]]^AG?G.35N=Z=
M?QIZ***)*KHHG'?2:11FA3(Z*:656GHI9";&2>:@5@*`*:BABCHJJ7XRQ8!.
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MPL,R713464O<,M=E5^QUJD:%/:_9;>?EM-N6#FLSW$2_'#?>>5-[I;Y@1RJ`
MWH$+KJRCYQ)U]^")*SZJT(93YNWBD4N.Z;-#"P6QT9-KOGFBMAZUMF9D<SXZ
MM3]3.K?E4R*>E^BDNZX17J.G.K?:J[]^.^Y;!EJW4*#G_CNS#)BN;N&M8Z1S
MYL`KOWQ[Q:MJ._.O_L8>L_!M.X\UV]%KO_U6?*<.DN_<BS\^NJW2[C?DY*N_
M/D>>&X5YU$;EQ\!\"0S//O[6`W#5]Q_!+W;Y@I._`>;M>D5!7OS050#Z)40E
M2XJ(`AC`NZ&8:&9-J>#]W'._E-3-?AG9(`%#6!#W:00![TK?9;I"I599AR`+
M,$!"!C`]B<`P(0;(U9)D\Y(!H`@`#4%)`Q00FN)X+`&R&8#'7(-$@IB+6Z%I
M"D^<IH"8N"0A@&-B;UI"D!HF9$G8\8T)&\"3,*ID-`FBR!(A0I,%$F0E(SG.
M`)"H(25E4(2<@U?Y=G:4*ZZPC0/9EE(.\)2*K"20"FG`MJXBR"M&1)#[_D-D
M4@C3D(<L,BL-Z<H"&L+(ERP$(@T9S"$A(LBT9#*4HD1(`?#B2.Q\L@&:K&(G
M">+(K`Q-6F\!Y"FUTDJ;"6"&=L0='BD(O9$UD(D-.`@9S36SE[AD(7=:22S5
MV"K7A,<@\Z$)4`PB`)F@DB"HJENN.FE$B8Q$BVUTW$MR0Q.7*,4@5%S``R=R
MR`4@P)0$J2>:(C*3M`B*F64$RR^7%S+'"668=I.4,O4)@)9\AX8`"",#M/A,
M>ZH13;DRYQ:C\U"%MD1)!VG)2G(S$K%X!X*NH>(Y<Y/.B1R$B61T(U10*I%0
MHBJ:`!@)W$Q")P!XC)GU--YFZAA0>T6R?P5#_B%5^EA%M@ER(%F[B0#(:+-S
M1G.$/`PI140&4X$H<R6\J^=`OJE/!6TTI1-9J40.@IUX;M$W$US*`+"#TZ>A
MI*P$<5`-4\+3NSX4`-4;*O,&"E0HH?"MJI-4/=D&397PC@$SX6%ZJ)I5'J)U
MIN=:"9H$8AB:Y$I*!U$``B"K1ORLTZP2J2PLNPF1F_C29J&1:ES%Z%>74/*F
M2^EI0@8+V'&U%E#D,:I'#-J[8IY3L0L]RVI=^!*)MFJQ\D035B<RDK?4D[(+
MJ2Y!P3H`J28V(0N)KD)5FD_JG#9[$3'E7,MH&S*6U$K3Y>L4";K;URT-N"Y#
MJGR("TFFRI>14_VO_G/;R+]/2:NJFP7H2];3R8:8=[^/;&96,@->NVC5E8Q<
M0&.J"*5.HM6'?_%A,Z7Y8&9NR[`?Z^U\J5)?^1X+OU)1*D1@*$[;-J`Z,^6G
M,YMK2FO^-[U;M!\VO7D0F<RXP:ZDL0MG2Y"1F!"\J+)96BH$5XAT5L/"ZN1<
MP8M6S3(1(4!Y24JHA-$4N^YB]FV?BXV"@-XXJ)%+$H@//8;D)2M$I_:;R71&
M\F8E^76,PG--@P1"12,&`$*NN0JAT_+3L-@U`9/T)D]T&B37U)`Y;W3D<8;<
M5H7DQK&HU.E`XLM>A!@Z`$[SJ@,7RH`%1%JH9`[<BG4KGC0?L#Z(`>=Q_MZ"
M'XED1R`FC&AR?N0@T!ZG*\`6R$]6VQUS]B@BR:[(LU5R'3\^IT7*F>.&FNGK
MB0@Q.1=$MC>;\Q;&.#;7V);JJS<7ZXPEKUKH3C>\Q80V%A]5C_&^-ZQO9E3C
M";=:KL8WP/6RXG\3UM[B(GC`$UZG+]+[8?U6N-0BFFZF?"V/[>Z3K"&N\391
M_,P;>;@&L8.>_$2$?O8+C\BYW9^0:.H^Y<%.1>B#GKI8!8+V6>U^2JX?])A<
MY/8I"^]NOG'MK1M[8=H6[1Q9)88@I)=T'IIIWA(=B2A]6+FUK"FE!19',E(T
M30G-U3TE&JV`?33%/<W0HU?4AM^74*(UII:B_N-H\M24.GLU0`#6RD,8?H>B
M"Z42@;AU$PAR>NX2)'4/SR7CU<[$8_&%6PW7NE!BR;A"J?+TW6\J%I'DG65R
M57+:@3=OT9DX/0:/.U#(4\_4+["LJR?0DJ.93R_76-%I*V-;?EM:@AS$IH^B
M4M[Y&I)"<1+W?&T*9B'2TM$N.9\%86/H1;^_BE^D]#8CE/.W@O"+P).;58SN
MA$U=$4VG=?%=WBMC9?O@-=O3B&^$"#1I[$\J2^JST7VT>B%23ZVL6?F=-'+T
MD8Z9L1V:G9[\<`5//,3R60GYK806L=^825/='`":^%BEI46"T%[>V5/>F0O\
M.43QS5]QA1<TA5:0_I61\ZU*2FR7-`D:``;@'9D/`7X<K64)`UC'.NW>2RQ:
M&7T7G\T:S]V4`O`=!$7:DED>`DS1?P610\Q=&*T$G6F41'C@]V&6:IU3]O%=
MKH0'4QC`2,"@]!&+QVD$0A#`Q8&)("T%(TV2H!32TSR81#0$U9'&6:'.%PF`
M`"A%H51=**V$7(@&KTG*)!722YCA!\Z+M`B`E'G2KKQ@>Z`8&(())'*)3E#?
MXQ@@EZQ$1.V*:RQ%4_!@E\T*[2F?(G((>01?>CR$0ZS*7A5*H=7'2(39KG17
M(.Z*!X;43119>9V+I"R`@;W'7T7&)$;BPN@;^L7+&6X)S(E16&U4/9E0_FT4
M1&U(T)/@W:Q%V;PH$U>-T&\]!$Q-60/4TQN"%.A%#95@40`@&MTUQ'=EC;1D
MWQ(ZVB^JS/8!(S%:3!/>'E'\CR/"1V\`43CZ4)`9D6\\!$\0$47T1E,TW5+5
M1$X<DFPH8!+*1I(@'N\])"H.'OP)!V<%$6^8$#S=U!"AQ]2U$8/1A&R\VSV&
MA."8BQC.(!G6X(F87.P($0)4TP'<$/PM(T5$4,H%$7VLE@I)T!`B@%B`E@?M
MI,@1B!3Q1S6]Q0TR%MST7#:)",\])8[HQTIB1#WVS*F,848T4`)MI:_P(6N4
M'7"D!@&<Y&F@)5NF)5PVG6C@(2HI!(/1Y6CD_B$>"@`!""0[*H0/,5@!'`!=
MLJ5;AH9`,!@!#*9B-*9C/F9C$L9C-`]/66)!R219PHIU+$D<(<=K!$"25)MH
MPM%H)J:1F,2>>>9RU!EIEJ:2!(E"E,0/\9D/E01OL&;9Z9EHG(1M^$87E41J
M<*8//59QD(0.T69<)J=_=4;1H0\FBHGU969F9A-\&)#%C:6:1*=T;F=URF#&
MR1-F<J=XXLNG],UU`M`^CJ=ZBDISGF<_=H1V>H32<9DHQ9(FE845F<9I$8S2
M_65"`-1Y*11>`J@:P<Y)BJ"T6032$1YQ+1)>)*9BS:/9U!S\R85@V(57!!'5
M(=(43@]>$,8P*JA0_L0GMK3GX83GY82%S%R4Y;T=JL@4^XD6#`V`C/&9G:V6
M785$[S'(&]70`<Q*KDC1F13`#TU$/96>.QU'UL#0K*Q$14(6`YPD9'$2-=U3
M#)&3A":-0717%X51;^96`BI?:G#1:/2&^+$?3C31<=&?T^0F&ZEIDR7$FCT$
M%RU@&:$73*#(V\T$NE&)3K6&$$6@GGB@>9[H0&"G!I5'C>V*->J?/N(9;2VB
M/RU=0+Y=1+P71)3$4LPC#$F5<V&JF`IJ1%2I::6'2GYA&74%DWK39CT$JH11
M!TJ00F7IT1A$,RX4?:372OQ:A=B/GK&%IJ+*5=$'%=F66QA1`M33-BWJ_DT&
M$3,5ZC,2GAP57ZJ)5G'PSS7]FIW>Z07%45JQS4E\JY<V87TXQ!0MJZF4)UB>
MT',F:AF%T4[H4[BZ1'&2G:L*GX:J$:CB:#0)T:8*"_F-D!:A%J$!X*Z2D]/$
M:%8U8DOPADXNH9)4:K2I1&<F"OU,2J-"F94B'[<DH=A]G3-UT@LA12==K!NB
MRI@%WRA*$SS25*'@C"8B1;*6E4'434)\62P!GK/=7F)]'=LDVZOZR2VNK'M^
M203)E@",&3S)5INVWG'%EI71U:I,Q,%FU2\J2*Z04=`Z$GILUY%:!"@FY!`>
MHS2IT4!H5)!=C)50+$QD4TS0)]<4FC2YZDL4_I&@-,A=:93X<9G++B26>6.5
M3%@0<5-.;1?9]J&D8%;5AJ/PH%*8R5/R046HW=6:91_[=5)M]-.\R)0@=>66
M#"U,AN4A)9:88!Y`_JL#AAC+M%G4NH0)+5<@JN2_HI$J.I^:RE09(04\[NR]
MGA4/">M$5!Y8]9`)$=^\U),6R:VFE@UXD4:1>===#80@O>U"CD;U>MT_6<FM
MR*&C1M"<T81&*>(N&AA!KNE,+>HVT:=!+*HY4<=*K5F5><IKS$MT>>Y,FN@E
M)B-1S$5>$.;2K1!#1J\L">2X90\=OB&!DFQ/6N\YT64T]:5H^-(H"8M`GD^2
M8>]Y.16'L8UF0:'D_IK-!*>'@_BO5A325RQO'O)5:")%'C:(H/B07Y"'&[Z$
M+_5E1'"OI)C=PBHH!!-HJ[`C?78PB$7O.0YF=*535MCP>7VG,E;BNA+60)PC
MF*3@G1#I=6!J$(L,@DX(A!!M38E'+%4/IYE@.SJM%#V4^YKO%*KQSO9(CD($
ML13'63G5KGBK/@T$1[ZQU(2PQH[0>`D*/1VAD.T4A[%>C*E0E83M#2L9*]J0
MV=Y$`B,HW`4DZ"'%V9D31Y(4'8-9UN+K7;U%Z(;).5IF4#"D%'^)7:T3JN"%
M_)6L6BE46F'CF*T44$#(["Y9%SO-M?8@)*$BD8YJ/MD8,%?3=!P30'4B_D5$
MJZSR7DL(DIRUA"Z#5'W41E)J3?-RRT2]!0]!K32^<"P-X2U_8#M15/5P;XV]
MG1U_\=7`LCPY#0S5Q:YLR\":F@1)L68E5ISZ;$@LA"U1A>QN!OY>IE+44)AP
MDD[=Y$B`16)5I%WQV*8]VPZ&&TN47(\>=`UEFD-,=#<G"6\`;J$E5A$=A`"8
M"]Q,44T(&F-P$E`0Y$BO%@(TQ,#Z4&BAE))42$R\XV;6S?+22C`>W9JN"H[`
M;J76CTG8ZAO^VDWIQY(`KT0,KY4TZPWFG0J.4`%[='&A6\"Z!!4)427'K)4V
M(T9UDTEPXSEID8\E@!T[<U)I4$"#!#^*LONV_EFY09^PM5<;N?-Q`(5VA!NX
M\1IT1)!VJ(B&P&MSA)&P(9^+H%K)X5U)_%IW(/:TW5-)G!ITT)!`Z'5Q0!^*
M_/.HV+*:>"$3EFD8H:5"](:SP5EI<&E9Z&:KX%T7`9EWP<11FD978-K9L3&9
M7E9"-"TK)E%K&,:AKD93",#NXB.&/3$%MZO)>'#`24N(>@9A3(4JN06']J2@
MHH5$!$8C=818>"BE[HD4(_>L!?=[<@Q/!MQ8\XQ(H"N?C+)X+ZQRKV>[/"S-
MP&U[MW6+13%ZRG>*\C>E@"Z)LJO^^C>!_PJ5N,5[@R=Y%SB#?T0U4XI[AS)A
MF2&B-OA:6SB;1/A4_H`<AG?XI$0X$Y_7(56XA]M+@+,/?A\5X)"XVYQXB5MS
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M'K`7.KACN[@_CI&;^[DCRJ&O3[I?YJRW.[U3A(8?;?EP^Z1\N?CPNZ/'.['[
ME;4/N[\C.L#G=Z;7.[@??+TEO,*/SE=\"\/+N+X_/(:B3,%_D,0S>YU\RL!;
M/*^+>SU^.KN#?-OTM+I,?)P[O,GGS:JY"TR=<K=X?+"W_(6__,6J1%-X3,X?
MK<P5!%#P_*FEQ#(O<X;U_.8Y'M'S?-!3&?QYTTH_?1LQ4=`3_05=D-"[T$I'
M?;X.+MP!*1.QA=173\XO\WQ<BLJC&<V7O,T/_H4@'4`BO7W#:-V1P?TAL:,:
MAG;=[SW#-,1<7,DD`5(F`4Y?*L4D>6""'=E#?-+@?P4`&#G#.3[@Y`K@O/W>
MMQ+:5'Z5)'0B;I;F\X_F&_[T78G<!SZ(8?[^+-*!.6LJ&0;<8W=6(!)BJ`3<
MT[XL*059R!*BE7"(>T3:T^#:MSUGP$0-F6!&QR93?)I.P`2>-Q`J81K)7'3D
M,84.-7_R/]0JD83-Q-7:E:^YX"`(+K^7=1/S-UWD1>1N*__Q?PI+[!-O8-H^
MP41BH783^:G[YR!+U)`7DAHJY=7-`@0```@,"$P0`$"`!@4`#&@@4``#@0H:
M5+1X$6-&C1LO)A#8_L`C`(XC-TK\R%`D294K6;9T^1)F3)DS:=:T>1-G3ITD
M#R9@4""BQP(,`@A0X-$`@P%&B1IH4-!G`8<'G1HHD.#I``0_"RSX&<`G@`)9
M&1R\RK7!`;!$`S!8$&`L`@!8#6A]VE5I6[D"G@8X*F"`@H(.U5:=V]?I`+`*
M`O@MJ!`!W)]S#RKT.("!7`5OVQ8<.X"R9(8^$29@/!;AV-$)!.@5FW9BR`1R
M,2,TX%$APMH`!$]DZ+"@4X0'%$S<R?.CW)0X!8I$J9'!<>G3J5>W?AU[=NW;
MN7<?R2!Z@P4L*58,WZ#\^?(DU[<\[]9\]*,5%40O:[^\SP9E*=[?GQZK_NU"
M`NFCG)I;J$#O%%R0P08=?!#"""6<D,()<2-PN9L.?*["#CW\$,0011R1Q!*Y
M&W!``P$X`,$,37P1QAAE?##`&6V\D;H!#TA0P]<X+$FG\W#,3L@AC3SRHO:0
M7)+)D094+B>35.-Q/^J*;!++++7<DLLND1,I1>9.HM++,LT\T[P.$5!R):N<
M@DF!`A"`R:H"6,3H*SG'^FE.-!6\,,P>G2/3ST(-/32[UU8JKB+=8OH-)N5<
MQ`V!YPI*Z4KQ6$K@S4P1M>A)0F<2B(`6/ST5U51K$HHE`?B";2R8=HSU)8'N
MM,B@BG:$M:(:DVPU5A<7&.]4%$65"2)35<W2_M-EG8WITO<2,.THTQ!<S+.R
M:M16/VTW\RG..:N=ML9IU0MK18P$>O,AD.0T;]KRJE7@J//(K6B!W\BE=EKT
MXJVW5_V\#-5%FDP:M.!G%5X8480&LJBXABX=("2!"D#)8:<F`ZVMB)M3["/0
MFIN+J(04PK"Y5RT2H+FM*'(8Y8]'3HB!B$&;<F:Q4$H`I>:N8IGF@3\*U*8-
MCV48Z:2U/&"`QRYB:"R+$8R5H;9$1M`IEA-+:-9+'RI+:H800&H!@TRZM5>'
M<QWPP'5#"D`YGC_*]68,#8@89<]28[7+`;U6$6&E!1^<V8:46P_JAWQ4-/'G
M<MU1H<0KH@V]!A`Z_EF@QFPMT-:,E&I.(:]A-BBD.4D70,Y<I99-<?2DIC?S
MJR5D,R=6B:[)Z(0)WYWW%^7JF=;$PV9\<9$>'Y/6WRN*MB*W3=LQ):E!?96!
M2Z?]:&*:63>;Y9VGQG"KCR*.=?Q[^WX-2A5+_;'W]MT7T4Y=$Q1^\5<;_XAE
MK';D2W("^2K;1]"[TP$N-9[.@0H`Q%)<;_YGJP.,9WMS<=QA5J<Z,$E/<;'R
ME982=[N91(Q_1WO?"$GX)T4I)P#C><REVH*2WR2D`2++3$-,,B='32YDZY++
M`5PX@*B)13D106!;]I.<CR!$``@8&]@`D!2!2,J%,309QD1VO:!)<2`%_C@9
MEVPG0I=X3%DE%.,8NW,P`T@*(35+#6"NHH";56P`''.*I)S"F*L=3"R72XA7
M4((9]'"L,>_JU<S`8CF+J4T@<<Q9`":FFP5<"C692T@!+M40\VB1AD*;BA?=
MDSLR?I)"S0*E=,"#$:RPB3_DNE(@+Y;&!"R`(OT1#U9J!C%?G=(B"L0([;)T
M&0SI)%GL&^4PC\/+B]22F"62"%@XQ<A1^O)O8@J<A$293&M>LSL':0Z[/LDJ
M8>)N3+K#YCC)64ZAC<6#,JE8&#]43?>Y<T+P-&=-^C1/$GFF`93#24A"*$Y[
M_A.@`1T1/@=3NV!R4J`)Y4XI%9I05A5TGP?U_F=#*4HD759TGOC4YTW6^4V,
M?A2D(>5H_7("1H^*%*4I5>E&"&K)B!9OI3&5J4SQ>=*8A(1%-IWI3GD*T/O1
MRB8X96=/B5I4<]YOBT$=WD2-VE2G[BY32#4H`-:'T*=>%:M*^^E4<VK5K'X5
MK*F2ZDN[RM2PGM5,QLQJ2X&Z*HFB%:YQ397R^F<3D_13KGG5*YJV2M:A[A6P
M@452XI3G5YT*%K&))5'B9L75OU:GK3M1JV(I--DS5=.R&_'515U23QAE-D1T
M5=1(T]6SG)T6M:D-@")]>#'7OA:VL97M;&E;6]O>%K>YE6V==-M;VE:J4KZ-
M;9T(8H`ZW69L!+G*_KZ8NQ_F/A>ZT64NO?J52G+1:S_A`4]XVJ-=\VPF/`(K
M(6B;FIZ,>'.T2@UG:MG;7O>^%[[QE>]\Z5M?^]X7O_G5[W[YVU__IM:U_Q5P
M>S4'7]W([&,.:TT?Q2))1*)VM9E#9($OATG7QE$J2%0,7(3K6Y[!]@"5XNUP
M"<@I2BYW6A>[#;E6+-WHWL^LFY):<#MLX==&N"$X;DU[4<>QAK3FP2,+\H")
M7&0C'QG)25;RDIG<9"<_&<I+GI)#<'*V:\HSN_0YYI6VFZ:;7*D^^*+==4'B
M7;?4#+N@0J9%P'-*T_A$ND<9FXO)-6<ZU_G.T6WQ;8RK8A7SC"`$/'&?_D4L
M)T#7&-&)5O2B&2T5D66N9X#1G`]!9UJU%662$&E,'#&,247F>-(7+O`BHVSD
M*45V)A5#\JP.T&I7OQK6L9;UK&G=Z@0<X-:W=O4"'LAK6;^YUKI^M;!S#<MA
M'5O8OM845N(U+0/(^C8$;/6SA3WK:D,;U[!^-G$,P.M^"89%K>9UMQ^8RUS"
MDK)$'4]Y?#V><HN'.""YR`-C/:Q:PWI8O'IIJ?G=;W__V\"2%/+`Y3MDT.6Q
M(5+YS6I?*_`I=EKA6FSMA1N-:!I7'./"O;AL9R.G$<_639S:^*)YZR8E\E"Y
M@[:*LW&=9Y?'&>;D6L";R3P??W%V)G6MB<<`\=YSG_\<Z$$7^M")7G2C#YC*
M48)8D+@['U6.RUS[JAET[_/*EU\=NM3-,]3S3,GGMGPV=KZ*$I]K%;!#U\Y8
M9^Z<*9EV7"?7N"&>\]CTQ*DSAGCM'3?NAU]+P(_/EM.Z8>VE?=C:RREFP573
MXN'U")=')X3`@#RXPPQ^=,M?'O-*3FJZ.4\2+"OH\Z#/I4^F_DI_V2>ZU-7Z
M=?]5>G#-QS[.U0^UM.YZUJO=Y97:E]=G(W<\WP;%9S3QL\\H8N0.]V*=5_[R
MF=]\YS\?^M&7_O2I7WWK7[^HY,7^]KE/QC5W'_SA%__XR5]^\Y\?_0T("```
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>f39432a9e3943253.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943253.gif
M1TE&.#EA<`(:`_<``````!@8&"DI*3DY.4)"0E)24G-S<X2$A(R,C*VMK<;&
MQM;6UN?GY___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````<`(:`P`(_@`;"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*5>""
MKF##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MV[:KW;SZMW+MZ_?OX`#"QY,N+#A
MPX@3*U[,N+'CQY`C2YY,N;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7K
MU[!CRYY-N[;MV[@)*LCMD0$#R@EX3]TMO+CQHK\/)C_.O/E,!<N=5_U-'>%R
MZ%^)-UB0//K!W=45_GJ73KYV<`4*!C`8D*!``00,WB<X8"`!@P3X%R!(8*`!
M@@4&*%!`>PH<$!]_#12@GP+U#0@@`P(.,`"`"2!0@`+\C5<>5'AM2-4!"QR@
M8'[!+>`>?@E@:,"`!AR`H8GS'3!?`R*F..*`!^288P$R8IC``C_2N````BRP
M`(:K_08>A-OY9M]NP2'0`''G->!;=E/>U\!YZ*4(W6Y2&L``?/NYF&**]U7H
M86(-)MA`?P7X=Y\"\-&)X9@"OJFGF`@@V1]\4;X9WY[HV7EAG`;TV5X`JN5W
MH8\$8CA``P!@*""=4[+7IP'ZU4=G>Q6J"&`#`P@8'P)P6@@DJ@BTBI]V_FL6
MMF)P]B'`7J;\):#IF)L&5Y]][>TGY7[\'1!`A07<EZ@!+3*0Z'NSMKI?`0&F
M-D!]$/:IZ+0,DKH>I0ST*":."3KK)H/H,2!`N>KUIUZ<\!HZIGX!:!CK7\]^
M"Z><\!G(GZ4VN@E?@`$CZA^I-'8+[Y%W!GB`?Z@R<*1J`P[DY6X^0GAA??L5
MN&6X:?ZH;7O.XKE@@_]E>*B,@E+KGWWW%M8E@B#!&I'&)C;*8WLR]LQ?D>L*
MD$#0"0``XLX%`-#>D$43,!^*`,"H8)Q15]T``3BVN&Y[,1>FH-4W"9#CNJE5
MFRYW1BIII97=-3GEVKH9M!N6&!<T]Y4O(]SU_E8V?\0?@%(.=*26O@D$Z$#]
M$3QE<%-2.>=_!$,X**#F"H1>BW&FYBI^.3$ZZ-Z"U0<``XP*-.FQI5X(*GOU
M"4#Z>@I46JIZC#):ZNB5`M!`[?HA$("`+0Z4;,ZI7:BW0!+[5CAW7UKY5:!U
M0[FE?4?^ISQU7XGIY)&,,YLKZ((M79]`C+LTOI4!_)<Y:A*23'Z9!5RK8+U*
M'WL`JK.ZYZR`NLYG(:JCFU"]:K<[!1Q+`.A!7IQH!CY\*0"!NK/2I`C2GX14
MBR&5L]SZ["80,1&L@NSS%?D89R^#A,=P!3%>0<9T$"FIZ4WUF53?&IB7]P"(
M.&)R">E(6!_BH69H_GG:SODJTB&O7(1L&Q3)#&G8%*$I+8)#HHG11-0H=R$/
M9B_9#_D&=*TE=N0K)9Q,&/^"JC<1)XDKB=H(`^##TZ@I15-2H0X)(D,T9B9,
MWEN?>TRUN+=MYCVNBV#L7@*K9`D@<*AQ4.#2$Q,D34]78W0,<>(#+>EIASC:
M(18B,6,N^`@D63I<'[(FAAIE+6""6_+B2<IW,$Q5!D#,P@CA7&49AR6@=+M[
M271^YQ[5)&I4GXPD28)(K/1-ADJ<XPB$DCD9794KF"X)XO2BMDG3L(QL6RHB
M2XQDL4]*II<CT<[#(L,C]I`MBC-9E]-4XRH]JM(D"=R2@F+YF/;(D23A_@J0
M-A7#("!U[YTDF90+8VG'T6@Q<QF,9N`J=";')`<Z*1G3BAY3IE89KIH118#0
M6J4Z$)X&53Y4#TP@:J4!W1,Q*)()2;N2G#B)-"0?K"`S9=*?)Y4/H)<I%:E8
MA-&5Y'!Q^.FI1B`JS*I<2*@K":I'AY-*[Z&*/G@*";7NQSA'SF16G2K6I?I3
M-\W\:(';H5%-%A"T?6J$K#M;ZE8>QLJ8P*@J1A(:_]:G.VR"9$`8.N<X9U(`
MK'U%05,*D8S:`X`!!0=$CZG;L&QELZ*.Y(*)HD](LA4L&`YLK\WL#P*CTIY?
M'80_)^U(#SF%0IK<AV6^2PB:&#11Q7`'=N]A_I&/D,K7-Q4T(VA*(G16I-:F
M^(:V,:F83IDBI5*5$(BXO.O0/N?,YQA``'&RU86$MB7(*`H_>*W2D;A:+)N\
MIX/8?6RHON,?[SVE8SOID^J4LAM0-L1%[KUK>UOJ6)-,*KK)@I>N+*2N5A7N
M,#5EDD&XHQ[^`+<ERXGN@3&"RH0XBY1*,4"#<>*;>2:4**Q=<!QS.=G(-E>:
M,<$/=>LEM\4=R#T31DQ-*T35H[:6)HDR''Z8A5.*;&S!-M*P3JZC)<N%53MJ
M`Q/RLO0;6@G.-^GJF+;2]*M<N0Y1X:U7:`<B9(FU%28&C@A]+JC<9WI9I2:=
M5JX$K!R))89']`$5_JU"1%:QCI4@#VNC1XP4I(?<UB5X*=%"`'LB$24M:5B#
M;@&@6]@=M0=K/(*NV!0-:),*X-$-$)I[]MBB7+E(:`]34.Q@Y**$Q&E=41M0
M77VTD!\!*41N,FM$[IP0]F#V(]#%$!1??1*S%BEJ)H*1TH!67<:L!W:H]>/+
MZ!2\FF!Q/Z>LKT2P>V7Q]!8CS6-(KEH5(/;<DI$%%1&8,!6G(`M[R$55MD'.
M]"+HZ"I$2X2.E%YK)6:K>B"\<I:%=E<AT@'.P.%"49QDE)SP'JRH@XSO1ZY%
MH?>QM;K]@="7%``D3(5)3_V24ZT$-:Q(LW"&%9,;BA(E`&8QRZ*R^C9!_L*T
M7_6XKB9]LARGN@62`XD;7>53WI"[-*9?%XA`L2T@G\98Y,+]5]H'VXFR#F#.
MAZ:LQAAAI2<-AZ&.*7P_X2(6IWX7@`$45G;OD5*RU`0=ES9[(ZK2(L3VFZ@N
M:1*T!E:O@9<5*N\1B#\!@ARH##(`'1<JAHAQ$D/U.SI&V8>-99;YV[R-L269
M^V/0*=R7E&=D(Y/TEJM2HK.:?3U:K0AV%NI2?42$JD<M0,J68IZX+X(GN^:$
M02.C[I2(!<>=J%LYU053/K=;=[PZRSW41E-&D"WVUF?DJ*R=VJ=B&ZRE^F9"
MFKDO_[@FI<8^<#PS,Q6BUM-P'V'H0M>".YTV_F:BFA]*89]*^9;^,V^//`FD
MU('6?.*G;4V9:O,,&KU*4/3NF1CX7\^G<M:M>I-$Z?@[A_(DU9,M!]96?:-(
M%31$&/$>LS4T<%<A__$N;44@]?<8OL%5#G$LW@&!Z)$R$#<YCF)6RX$]0P8W
M:V,?_:8^SR81&H,A]-$Q['%*0L9J%C,`)+9C*=):%R83/"(ER_0?!L$L"G<3
M0/)S%,$YPS41+(9B^!$?Z6)8Y^-[&2%AU"(?'V<KOW(K!0$?$<0:ZY1"2U,T
MD48I8S@T(0)8&T%:";(`!,!-%R$@,K(UVT%G;FAC,E*!+_$CKP(D)H6'*J$[
M('(`<G40DT:#*O$\_H;H$'5(1'/8(S,&:=C$,D9T'D`25BEB))5X<`51AS5"
M:Y^%:J-A+XE3$+FB*W$R0()2*0%X+!O!0I8#.,A39!#X)TAG$(<B?P3!-116
M(!ZW3%G''3*!(#9B)P@15%+82$4(;<G"*%V($<#X6JW2*1=5+AM3('22>R(#
M/%S$2`-11G'$40`%/*U!:G8S,$'2+O'Q(`QRC!?A7H#4=*TR*:M59Q5Q(:RX
M@+5X$K[Q.U8B(V77(#VF4/=Q2@GB1>$'A#.A41IA9AP3$C&(2AFG-M%E*,_E
M7^66(N+W91#X4@JA+:UQB@U!.L<C$,G%15SC=]/V+_U#=;82::W723.E_DQ<
M-%2ZF$X-.26'Y'9:)W8LP5"_T2=):!W^1Q,,E'3+Z(0?L7PTLX,KA!ZK$G\=
MQW8(D&8B52!C(G`(82M?5QK]U1`#8V\JMT)9PAU29R(PAR3PX21OPCCPD7%2
M=2D:85@)J52"(V;(LAXQ>1)V<A^NDV()42:XR!%39A%/IB<?(6^"TD&XB#&M
M8I75IBJQ15*BB$6KH2,-059%4T2Z`T?K(B*@)B(A\F**N#6):&/TB!&:Z%9I
M1FL[<X9LMI4A`23^F"+-*&W[%F)^^!#.M"ZE&1&"=7WDLX(/T8SY821U)8A4
MI#L*TB$@4INI<7->:2D+%%2I$R`Y)W(.<3YU_G=(_R<1HA:8I`AU,2$L6/E)
M86=@'E-KB3)CHND0\R:<):&`9W4@'-D1.O52O:E:Y;-).+=W>6)2Y5(I-96/
MFB%9L?A:"G=#;%=);IF?"`%DB=.=$1%W'9$?A(0?]U-"-@0H]I1P^*0?*%)W
MN4E!(\D2]+01SY=?4A54@7.B%9%<WE@TZ;&"]W%B#S0M*P(P)^09,C(L<S4K
MT:(K(+9)_$<1D/5<E_>6@UD13>@2*'*:A/@HA>(B/#E9U`)W5RH1#V1`.@2?
M%(%`&!D26O13?KELVK%!#T*#2,DV[?8;8G(_BG1,5H(D4#(F.>)_F-(W3GA/
M\>6@"]$M>:E,)BB8_N!I$<[B(IW&$+92+P52*O+9$8P$/"[JF^HAH6?%CM!F
M)H_5(MY8I=_Q3B)%(0-CC?&S,<.F&S.Y$$4VHH7AIA;B'C&V5=*V/^L33]-X
M$>=C2%SV$=_7&UXJ$MCW;D2*77C%+%L'$F:C7IFD;-]"H+(D-(5J0LOHK`]A
M4:A4IA,:'.OBJ+QW*JG3/QM$(*\1B-)F)(@55G9UKA91A_OFIW8VAKS:$K+I
MB0N1(Y#B'HG*$:>VAJI7C_"JA*Q*$*'Y$:=4DP0['RY(/O0*$60S5Z"B-";%
M-0!*$*'V&B:21,]2+-K"*M`"=164D4Q*)<(2K9Z6'M3ZI[_J$>A2G@S1_D\M
M,BL6VHJO4H7N6A#MHA+6Z#<$1K((L:')P8^XJJWKJ#K&@C]]XCIMHICUN1I!
M18KR<7.J0R?^8EB9\ZAF:CG!L:09D2TM9ZE)5W:C1TD?UR"!2A&7,R%6:YJP
M^1%IJXS8J4Q/57Z>.A&E$T4+NHZ.^C(7<A_8Q[.O!$["$[6#Q5#UP3'JQ708
ML73K&3$PQ5!W9:(O9*2L$A^<M[;9*749JA'V4;-F>[(8)#1+6Z'JDQRA*Q$7
MA'/7HFW4LA^RLXZ2PJ6P46]O`TN7LE'K:"$8R2"3$E47T7K]5+9Q::L>D;(R
MF:06(2#4PG";XKG;-7P&THJ30KQ;R[FE=B1`_IN4$G8_'VNY#(%++)(K'F0A
MU>)_'\1'L,%16)J#1[MQ56BLV(*XN(I#`Y"E4@4[+?>V(<$_GIN+U1(LKZ>E
M\'6-7BL>C7D2;MD;P5&Z:=A>9U2H8L<`SGD<>(%61>(B*R)H>84C".0>15)G
M,]*[`V&O16E^<J:OV`H2(6*PZVJ6MYDC)XP0G?DCT!6P#4$N)E'")MQ-!"N(
M##=.BVAC@<N]MN%)ZO9@R4(P#)<XYB(FNP5"]WB\#\4I++L1[\)P*#S`$@&B
M6"PWZH(@$_(?*]6RSQ4JF+I[(#L26UQJ`U(O+VP1\=,[[X,1/R6$Y'$@Q\M`
MWF@1<PPJ^[L08A*S_DGIMPIA'UK8$60B*#*BM?#V1@$`N,.[JR(1N2`1'&,B
MQ$J(*"U:J.Y%Q^6A'WI,$-=;$8\G4-3[I^8+$FV\$;E2R@CQ+NF((@680ZA2
MQKLG829AA![QG@8DR,A#)PM24I;L:4;7Q^4A*=T8S`BQQRH*4W."QB7!/](K
M$?>E+IL7D,HAH#TRQ;(D86KX6,3L8,_SS0`(+\GQ4VY\1@K,1*!</C=XO/"F
M:<@<$2D5R6FLB-0F$NHQ(=[*E%M4+._!RQ3T-\\,T!;S9+#KJ[ZR4&F,2UJI
MS@K!AXQ3B4>$%Z`&I1TQ($4R$O$\$07[PQ[A4CY3'P3PB0*1:2;!RN]E_A*#
M%1*2I4<9(8EMYM`.)D?F+,KPIG7BK!QA_+CXY"WXU(,#,SP>RG2[(28X7*'/
M4A+U/,C<0:4ULR)`(E/1+#<0J<T.?3G"4Z@@!"<;#1''DESW2Q*9E].#G"\K
M8B#NV"WPH8$G;1)+G1!W(D.->SQ6G9U4`M8H0<.=@9>(4ZC7P2FTG!&[D<K'
MB]<0@<M9F2`H[1#LH1YI,C$*,E`O4A('8GJ'.=41P7"P)59D\F#$YI&)PS4;
M7)`K%B!_\D^DQ]!MZ]"."TT7@4@!2-#!9-@5BG1AY!U08FXUK;+"HT"`>B</
M5&_O"T\,ARCI<2#J96]K%SO^YVC?HCM?C'ID_KU"U/(;R>*(E^)/*FE2E:R\
M-=H?^F&/VP%U=*+)Q`%R,OU9->G1$A&)\R'1KW@0;J@=9H59*4P2=15I!9(C
M*9PGRLF&,?(P%HQ=J*8T?B9/\&0Q)KEH1+<==X@2(#(I13(U8A4G>;9%TP-8
M9H*)/])>;G(4@SL`8C,V>IU"PI/1Z7T0'$G8#X$DT74J]\,Z,80NK2)IC6EM
MUR8FH^-!B^U@Z(6TU<,C)0-WS_,J#^-"930L*];51ODO;.P?Z)(2M1=T)NC`
M7`M/+/X0#V91/1;8#7'<G^3E3%0AN`2\=G9+$*Q1"!(G2Y)-(CBH(I<L66X1
M^[':>NQ,D/S,?:*<_E!^2(J,P!73?`=3)75:*'5Z)O<AZ%)R/P]GP#^R(K'%
M(C$D8B9;+^1G3^E#+?GL':P,D9C=-0TVYQ9T<6_B7[)$$,GB2B1!N$V2>%>B
M)562/)+#,-(#+)*3*+)=C/<\*9.B.]*241IEHQ$+JS%TI>PQHYIN8+C7(!VH
MCXP"?!Z42L*2M11W+C5Z=,(+7@LH/&<<&]/]62T9Q^WX67)R7R:U(L)R+.ZB
M*SFZK7CI4I3RUATY>?.KZ2TR`&F6*`'`6_MEBNN![N]Q+=9Y/]\.URA#[?72
METGU-$A29`E4-\KS/!@T)::-$M\N)K]#52BS7<@M@]IB*=A()A6".9\>_HJ4
M72G(,SJG+K!U%SFIKG"<`\OVX2])CLA=_.$!U8$07QUZYA6"9V8E:#'I6-<<
MX259=I0]GMFB\SJS^S;2PR1J:6Y6EB55PNKP1,Y\\B;:_8#1NQ[!+F6V$MZ.
MRJ#74E[$=RB9IS3H'EF\Q8#48N=,9"+8A(9NO$]T]M%D6!)/L[!'E"`$8-GY
M2[7Z36=5P^07(9L*4E91(S2\EF:WYH`\DC1DA9D"?B*U)E>+1E9C$_EDM1NZ
MD]\]DS-.$X>!Q68-YY+D>EC5!2(_(L+:G2,JG.+!*7Z.K7=K0QV2`U%%_!LK
M_2>I%.5/@B>Y"W5L92EU$W?Y)N8:H>ZVS';,_F(LJ'?=?\Q1C/YQ?AX_K5-W
M)H$B+PC82K9:*;&.LK-QX!M_#"@LB$R,?V(N1TQFMSQXO88=:N/TMP^,/L]P
ML-)8$$'?'1,PL@\0#00*9(#``((#!1(@4*@@@8$"`PX>>%A`H<4!&"T>.%C`
M($,##T.&Y!@2@8`$"D)F3&"18<0"$&,:&'!@`((``W7NY-G3YTX&!AH(+1"4
MP0$%#!8D2-!`00,`3H\V2*"T0%(%"(8.9$"UZ4^P87LB;&F@8(&A*A$T9:I5
M[%NX`ELNB%O7[EV\>?7>99!2(<V]@04/)ES8\.&W*D->#=F@ZU?'2L4^?=J5
MYU."B#5O%FM@@0',_IR'MD2@%L':!J<E'J#*X*KHG2H5H(5=VS;L@DROTK[=
MV_=OX'%=;U4PP')PY,G!NJY:>_9"!8J/EU9@<T%,R+8/TE7>W3O!Q0NS?R=?
MWGQ8AZ6OES[?WG;+F+45'NC;\KA`HJ=/1QR_F4%6[MP34+.@/+J.MP$35/`W
M`:!J8`'6%I10L-D0U"RJ!CE*(,*=&@1@J:4:&"!`S@Y(*+0)4ZQKJ00$J"DJ
M%6.44:^4!F@`*=1FU-&GH`#S3RBA./+(I^=&:HFB_@P[:K8=F^S),P66LM!)
M*G?LB\F'JJ22`912V@P!!FQ,X+KF?%J@M,6J2TLTAU#4<L8P=2KJ33IO_KMO
MK[;:`JU.'9$J\S`P!U"IQ21Y*BB`!'**+BHW":O0+3YE-(N@*2.U]#P;!X+T
MT@FOB@ZQHD)**@`2Q6(@@*.$>J@@Q`9((%-.)RQ.)T%CM?4[I@:"L-2]0KP5
ML0,$N.XPI`PX@*X";-H)P0;E:@I"B*BZ$<+#-N3PUP01K!1;;F%CTJM)NQ7P
M*O8*(XVQE'@U-26#HO-LV[Q`@U?<[KX5:$YZ\]TLUX%&U!?3HN[<J[036^+7
MKB+7NF@APOX#\]_S`G;J3X@KQI.W4P6V.+BU&!ZLXY0&+10NT$CS3-[!!FUT
M8^""DJ@EXUB6V2ZFG@U3XYE[,\A+"A7J<L_`_F8[K26AA0ILZ)R3<VUHE7!.
M^FFJ'.J19ZA]^\OIN!8*2:25\9IZH3"EU@NKJH$;*;V'RU9[@0]9\U7MV^8S
M>B^*"MAU7KPXFNW8N?:R2%VX]V7*H3$#3Q'K+UVS"FC#1?O/HY'?LG&W!O#&
M*[J_P#R5*<1[6JC<QCGKRZ*_0G\Z;(4.-IW`M4"WZ[J;1]_L*4%#O='8NI1*
M;W7.%#:V7=XGE`PVLU("H.G@-</)(+P*-\Y8RP6KO26G%-H4+-UB3A[4A6;:
M?D'J<4,4+>:_Q_ZNG2/W?"U!'9J;^()2#?M]'DE3WWR$!S^`(?P'=*@VK;A*
M`#'I6O_X@IKK+><Z_@GQ2P(Y8Q:[/>0S1P++`D;$.`/NI2`.68H#,Q@<P(F&
M-5&)W@??TB`"*"0N)E)`ABCBFP;59$,-0.'(CI40$P9F835Y80Z[T[G"0,15
MQ?+A7C+BI[?4YT2R^8U*%I`5AKAF`?$;3VE46$2]""4G5P$B%JG4IHQ\RHM\
M:=%I.E<RPH$-..YKFG$H<B9IR24Z]QMC3]Q%*%35D5,I80H`#$`_/:ZK3>B1
MS=;P%1S=7$5128$<N((22+L(*B>-@:2=?",;K<2IDG$Q2]IZ\D2/S-&3R6F*
M6?2V-<>DIG(%W*1.V&.9$FHFA*WL5;!,M(!FT3(L;,/E3ZHSI@&V4""S_D1,
M?UCSK-1%A(;6TN4N>3/#9E:I>XH;931C8Y1J;H5=-.%-4GK3J*YXYC0'6=+G
MNKC)1U+*FE^$E+W6R1.S&,="H&%AEMR3D+XXIF;A>N=.[.D40/:&F/WL3&@T
M2="=@$8H*"$(\W3#RA_JA(\#;68Z'1-+A.;EG'69E4`ZFE$Y#6=NQA%`F.A(
M'J90M)G_1!Y(4^2Q>[ET6;^LC`)(-::3>B=\,@4/5P)Z&Y7R="#/Q&@SHW+,
M!['-8!+:J5"9(BP`X%"H"\J10&`E5+1EI7+7^>EY5#)55\[F,QZT35"%*E*J
M=#6C9R)<2`2@5K`*J#1@N@A$XZH<D_3ECW>]_NA'$&#6Y,QFH]:,WU^OR%?W
MF(4H<`7I;H:7(`MZ\Z[ZH:%-!XO8][SJ=F25:7&*`UC@(.2#&LN.70=2IGQJ
M2HH'(25F/;=5M+R-K[T\EFOIABRTV-)G"0$E2A)2@*BBY4-H$0`#26@PNP$@
M`3"R+7EFX]:L6$:Z=DRE=%&4%`9,MXBZR:9R"L):$P9%*^,ESD">0I^N8)<N
ME7&*M-+K7G).T;2;*6IG'X*0@X0D*+#KR#[3)ZJ&E#0F:,F)013JFOF:;G`H
M'7""0P<?CA@E63O+"FD4,X`!"$`V44$4AU\5V0!PMKG*H1YMJH+3)^HN2O]I
MTXHY-\?_Y#.]E(G._A2]F-/942R'`.@*>2FCRG2E)KLZ8:]`VLF5\H!VI:1U
M"UJ*\Y#/7N4FB#J(H&XB``1(Q,`H"?'Q2,B0)VL8BU)T,&%R$L@R[T6,)!XQ
MD:WJ4:F\MRF5R2=FO)F4!:QWR$^IRH^3)N*?<':L5OOH&`%=F,NV&39?R66O
MX+(A)6]/6(O&,?YJJVA]754O75P5)(L#D43[<J^T'#6FZ55?-4=Z>]GUE1GO
MHM6TQK&5:[Z5JEUZYMM$*YI@0I21=^91T"A%)M"!\ZXK[:1K89JQAG$52.?Z
M%:W212MI'J.F38TM5-.(VM?^8+:YW21O\P77WZ:E,,G]JW!'<MOGQM]C_FUE
MZXRZTUOK9O?WY%WO2%F;,^G&=[_]G1=^DRS4_^9=S0@>J8"_174'#\YL``"`
M*6WHV.U9[L,GSO`!)3PL%A50?9+T1[=4IZJ]L<C(*I3F"I%.Y0$X'GF&\Y-7
M/5SF`-C4PS6>'`/(_.88]^[.B41O[3Q<W\`U\<,/?1B;P]SB=ZGXS)U^\<,8
M@.4_8<#,"\#RAW,HZ4["^L-YKB6?/VE!,^<5T>5B=.!LW7-+1YC*'QX`E0.=
M,`/PND]R_J'3RCPT.I91Q>FN7%]2;,&&JMEX"#?PKX=EV4%;D`*LSA.S4^7A
MBS?,Y)4.^+VH'3$<#`O%PN1UC0&7N59%^\3&_B.3IT#$SM&"V6'E<G6(TT<G
MKA%Z5H"KD[L#H-=A`:ZK-%\YB-^=-@B8>0!01/RG#Y7MB3],V&-S].30/2/+
MOQ?$STYSB<J$<17B2LDU99%A"I$E.K'Y9R+"SXI#)BA8?XU8Z%XIA]O\.%4_
M'O)UGQVISUQ[Z1<]VYT^^H&X.RS#&9;#F*[S([:KN-Q;OOZ3N3QR#*<+`*Q3
MON2C.LL3@(>[CP;T(\D#@(Q@N0?T.X9X.PJ\'\0[GVNC%MB8M`3)NHI+MLA+
MOX$X@/_C#K9AKHKC#>!J%@+X/ZT#``R<.0Z108&@P9EKM)_XO0?YOT9[N""4
MN5QJNL?K0"84B/];_CNK*SOKJSX@#!:9^XJF,Q'1HPW'`\(\"\*O$+TN><)A
M>C@".$,@Q)ZE,\+L4,-;HJ$MQ$/:Z$'FXL,9A+B!<KYO^RK1."0!J;BG($$Y
MV4(B+$.(ZS_N8#OD@Q7+NSM7R3W+F+F#T+OK`T.CVQ#+"XOWXXF_:YU0A`JT
MHSW,H[L\6@`0O#[LH[^62Q2+*Y0-U#T4&46G$+H2O#[>F,`'`;7K<PNLDRZ9
MPP_=,Z^'*R#@PC5>I,#0*$/(R+EQ"PW1NXMA8;ZZ$,3*.4';8$4N1)$89+N_
M,\8,%!$.!+ZZ*T,^`S]DQ+RWXXXR++I5],"\X[&P^+TRY)"[&XAGW$7,_NN+
MX[C&#L0UT4O#NO,EV#M"R]!%Y%._!&3`A)2H@[3"/%1'@6`Y5QF<TC,4M1.]
M@9Q(Y-N:ECA'CV*(KL-&;_RWET.,_]@?!;E!MU#`1:3'IJ`_;5DZXLN4KDN]
M9`0*6H3'=*R^,R/"Y:,_]?F]BGLBIKB[2,0^CZ*^T>D_7^Q%C%2XF"N]R+N[
M^XA(?.1"KL@RI].*%UQ$&/D_G;.[MR,=F9L;@N1"M$1(H0M";?06Z+,+AH`W
MVSC('CM&Y:-'5<DZB4HZ^EM"B>!`NIN;SSA`H:S#NI-!6?P_N"K`A$)+P43%
M]V&[SW-"8,S!`&2[M^0)SEF6K8N\T$3*ZS/+_F%BO[58NK*D0(L,@-_ZB$+Y
M.[0TR(F\NZI8BL<0B"#$#".L2]%HJL+(QIBT3(FTR0Z\%L]$15"D".MC.R/L
M0C2T2,>$$1FL.`$(P@+`P&3C":5T0Q,93Z2P3O+#/-&+D(JK2BZ42Y]HSGND
MC<@SP@`APJ6$S1MY..XP2@`@`)V@2SV$BS(L+O(,0NX(32),*[=1._H4SGTC
M$+FS#?M#2U@91\!+T`XT&JGK3N6BO^`D/<Q[2(O,2>Q<.M2T"\H<3,SK">KS
M/ZA,C<=4.]T$2Y\`01)!/OEDQ(Z<T0X,R;-,2!%M`*SSQ+ISRJA<4;-T$YJ\
M2H+8NL_+"?K+%$?\_@H>=="C@3H>>0X)*<7""TI8TE&H=$):\<IE5$=['%&K
M5$3'2%$BU$CS@CN(TL>/3,CEDT;S?)#.5+L@!<F5R;VMR3V$_,7)RTK,6T_\
M#$+0L+_AD[D!.,`FG3R<^,G8\,N=B$<F-;*U_$+?M$RYQ%(K!;;#"`I/O8TR
M'#=,A4H+I0U+9(J_PYB9.]47E;FU`%2+M+G\*U1)%#JF>,5\/%.SA+M6?51(
M.5'VLTU\A,^*-%,`I$`?5#Y8L:F9"U)$Q$]7U$0US;WQ24@IU+W04T)TM+[0
ME(NN,SZS!#Q=%+T(S0N]1*B;@Z()*<7+4,3(&TF",-93!%%Z_,JA<+J__LN4
MR7O"H4S0!>16L?A'W',Z!#G%,C2:H(PJ.T76,EU3-15-BQ"Z48*(]_&XKM!,
MBSB."O.IF'B,A>.7<*T95GJBP;"Q3PV.E@R,DQE5DK.(/NW8U!@2JO"^TY*)
M]I.HT70,5,H^C\@N@_.*'L-9@NC9DTR6DQH\GF`1JG&6^Y"LH^6[K(%92J$D
M"$32S(/3@0#&E>46%AD,$ZF<KUV0&\0[/%Q6O0A"`N7.LNV6A6N>_WG;!;%7
M;\V+;>7$![NVC@F,IJ1;"5D_1N6GE,$(N/LKP/V5N5(SJTU<QW6M,+E+\T**
M='U<RT4LK(6+^F"HRW6I_^C<:LFI!6)8T&TL_K4M7;R]GPWY*K=8UVY)K<*0
M6O.J7`WB)-IMG/)Y7,K+FI\XB"SA1N^@NP)BE0K"&^)#NC0T&G?<"5>,V;AH
MMC;[7-%$$1N;6X(06LRHCV@,#=ZT+>5=&D7Q%%MQO!#[B>7U"1I4/'T=#,"K
M.FC3F/2]C8OLN\+)C*B9VE+Q.")1BM%TB)V]6=<[$Y>8#I?83\CXEJ*P"86Y
M%Y5HU+D)"IO3+'B"PB;+/PFT#)NX.@G$C"P;Q>6:/J,A/LP0@`?$+*'X#[9(
M%;]R7<V0NY([W<K1M*<%+H-BVMN[C(FQC$'RJ/G["L#+N=>@-8\"KC))#_7K
M,W("VO+$#P#&C+M+_B"7J0G+`!K:$Y3&>(B8$[-WQ$4*##%<R[V2Z@G1`\''
MP##0"X#ITQX@CH@2'JH"I#N<X%!BA+NK6]2;B&/\0!1:[(KE7:X1]0B<L$B3
MB*I[,;ZCF$A,Q>"6(^)[R10:5-ZB!+PH2<?E^@H,V]?&W:3OE(L\VY`ALA3`
MT]I:A9'^F[3^:XKIU%'1A#B9@\[+7-X;5BXIK)PI.>7\A,*S>\)<,L+JA`JB
MT\];_L[M3(@XA`I&(]`R33\:;!8:?);M+,(+K;MF7D(D7$)HBV:D>F;?7%`.
M*2[(:SD\/%"T\.,VI`MMA1%OEKRFZ..SY`VI*F8\M&;EXXFQ]<=U?B;`_HO?
M)>0SYM+G>%Y"&AXQR^F+CUA)\Z#!KK@)S\$PMH@J5G4R(LXN/Y*V651;7"R.
M^X.9>]'!LVSH)JN4&ZXZ,L2^Y<JC2H9`2)$(*\R44S&:^=W%+[6JAK8,XJ.+
MY0).?(R/LX-`WJ`[JYH;<B8R!.FUY3+&T`ADQ1DJ0%*F1@Y`M#A?[+/>XQ41
M1-%`?+9"MSRS/+R]HM:4TVT+1H9JK9`J*SPFYO)5X/-JX!VC!/N:-SG31/$)
M=PR`N7&\KHA?=R)JB_;$F21ECK;"AD[#2HG?J2YDR8,40FZ-?J&-%77'EW:\
M_ZV<IA@@KB#DH#9FG9"2J#CIG?9EK9GFRWB)_FC.NXS`"'R<2EV4$QTDJF^=
M0IMX5:?`.MG<Z+P#[*'RU[^^[,LF"!!,%L!S/0Z$ZF.BQ)QTUC;;W=,:9R=9
MKM3A[&5Q,B3E0'WNBX2@NX9F44_T1-JN/MOF;/!+N;$F9;149W^,D`))2\S>
M[I>FPBM2H8NT[*NZT'[UZ9NN[0]6N<@^%8A;B_(-:N+KTJHX%;A;B5I>[:$B
ML*L(<&^"X^L.R\2DY=I.;PCWY7F^[)R#O(2]9_)#Y?AFC:MSXS&-2N:>JDP.
M/UC3$5;4O11][EW,#NF&$0&'G&:[<*#X2LXF9UCN:,E3WG$FG?!N9``G[[)>
MTXV<\,9F;'C)"@RD_IVF>.]C&C?`@SO[7M&I1E(=^_"N#4QEC$8M7VP,/W`P
M9^J,U(K$AE&K"@UPA14:;VQ_=<MV7LUEA4K:6^<'!"X^QCRIX^XV9-CVU>OA
MDUP],FB@T(JU]H\RA]&R8^R:0V52CN]26E;'RSOMGO"TQFS'$^R>(.S1XQ_G
MMNS1RPC;5N^(@_*F:#8[QU2SWG`)O[VJRR/]MBJ6#F@YB77KNVPT[@H+$A-P
M)KX"!W/\@&Y#PL<`Z!+DLZH0*TFRI+F2U''#IG`]OV\27M8UACOLT^"(P#P:
M!-;=NV%QU3VHO&1HUG">*W1@B7/_9/'*V66\B]_NE'3)*Q5>.KM)O^$;_NSN
M+3S?/[3IQ&:;<5Y13^<./UQUQD9;74ELNC-G1@LNP;SL4(XJ+X21>?1+MBDN
M,?4G(&3;?L]LIWM***QFRM[N&V%F(81FF5.J!WG"T`A"`HA?SDUW*_SK81K;
MW89FNZ$*W%J`%`J0]*WG8>H/%22WE8S;!9'RG:"[.P%BR1N@<4SP1]1@(`'G
MO,.,&R_1--;Q*!612KG!1Q^@6Q=RJ&"-)PT^9I]P(W03,/Z*W9N-C*@ZU@CD
MKN4SNGNKV;`SF0WJE"L4^&`+H2!$G](O\S(8H;V,[>6*&NX/GKF3E:$WHPA`
M?9/KP89AAK/:'>Z41B$:H-"UHS#:FGV,`?:2_NJXD\6_*.F"%*Y)K3(YDSGK
M&K$QO2,^COHEVF++#NF-C)_S'(,B>.'863$WG5/92-!^"WRW2#TJ<<.P7L%X
M(D#_5$:>#5/5W(S^[^2!UN"KB],08W+G*:'?M-Q%W?[3'FP<8^)'W:<9N<&(
MG_9"7=@5_[AR/<+(?O5_?YYRG5=;&?F'_V^S)PP2T(`3=-XA?W,!"`4-!A(L
M:/`@PH0*%S)LZ/`AQ(@2)U)<R*`BQHD7)18XF``!P0`+$C)(D#$B`H$G5PX\
M`&`@`),2$[P\R6`CRYPZ=_(\6`!GSP0=>Q)E8,`@`P0(<"HX*A&!3(,%5.9<
MD,```JPF%0PMR*!K_D$%`:(B3!#@)$VB.@N0=5A@@,$%`+HB``"4X("V:AO$
MW,NQYMV':4]2]6OX\.$$>G5R=8HX8X&S!!7,+0#@P,#!$0>`)=AW;>6W6P/<
MI1FX0=Z%EFW6?#SQ\T/*A2G/)<@``,B#`W(?AMU`P>*"BH$"-T!6H.+@#8P:
M4.!RH`&<"`HT)QC=P&Z"FKD"`&!@Y&VJE%V3+T]4L>'.YMW6)B@`<P.7(_GJ
M]+VRO52$K6>J?[U>N'*7S=?``@?`A]!J!;U7`%@'"'"02P)T91D``Q:P`(4'
M-D!A>S0E($!W\'57FUPC+N:2B2V-","##7P(XH@(E0AC39\)\!Z((\DE_B&*
M(PU&V7LHPG2@@_\9>61$Z.TE5&%(>@1``%$6!(!*MX&D`%P&S6;;5CA991)L
M)25PFE4X)3"@9XY-UE],0E4WT(4#)<562<C!-5UT!T%%D%($%;"4708PR!L#
M!PPPUT97F756H0%`V22<79D%IZ#=Q1G6B!TQ`.(`49X6@(8(P,5@07+=95D`
M3@V05Z<J6;;;H;E%!E5=R'4'58(T51>```EP)9E7EP$7V6^(NM@735-]A9MN
M/S5@0'<#C16?73!U1-E0-($TF$L;U642=GZJZ22YY8Y+U'3E(C2=45T]YYFF
M=]WF[6<%/$CJLP"LZJA,-'5Z&4(!9(F`2`;I_BHH;PIUQ]FA*@'<0)0,1FD2
M3?I&!JQU6:(&6$RWI7H5LZ@)`)4!I%&;ZE$#""!078'A>RR<?3'@J'XR';H1
ML0?M-^^&G=G'EU,Y]PPGL.U-&^FQCGW6%V7PE710R;;]Y!Q.3%,I)WX#R445
MB#"9Y-)2P58-EV8;+;O5U7PU>9JZ;1N6TF%-N>V1N_L)@+%!J6WHW9!#4R;3
MMS#E1MFYMXUY=$%U>7<Q0_@%,!3`!$^&;(58M_5C=RS;93A>'4V*UU$NR429
MA>HE"/.&&@=ND-51A6?P?GJ_+&W"M,.4EV+04@IO6!\]?FQ42\ODZ`!O2M6?
MBQ)3/F5G[ZKH=<SZ_H8]'D'/:2;JPI]-*_3<W9.7YV&USRU4]1HWT'5"X4+\
M5K&[O\QY70J:KYW`_0EE-J\+I3TT7Y@57U!J-,,7O2"+04?!UWY(5;*K4$=@
MU-).:"*S'Z1EIB8OPY;.*#9!^V@&6LE956%^9Y!IT<91C-M05/`%K<K\SD.>
MD<EG2E(R*/E$/91YG*^6Q[N"..^!`^2298YR&QZ^9#!W\Q7P!B(JSGFOB8]1
MDF'F-SY@]9![6GK)UEXB*O>IJ2\K7-$$\1+&](W1,P5!(&9\PY8&Q.^%S=J0
M4N`BLP1V)#(,NF/H6N,A`PB*CSXYT.<NF#7H"?"'PFG-H<!8K8%P1C=7_AHD
M(QUS@&O!YD])A-X/GS:0OTG%?%,YW0\%.$@7#@1]:Z2.GXJ8MMMX3I5=\2#6
M+,,V)])2)P=`TUX*Y,0/56\_!$">UR9Y/J'(A%2SZXM\2I60[BB'B/I+(>0P
MTZLSMG)*>DE+FV)2$[E0DW\&<9X`<0DG`D"0@L?2$"'W)Y?+E7%VWO23B%KD
MPY?]$G6E;&7P8*A!JG`P;33!4.6HI4'F'>1&%:S)-)-YOA:UQR68&4RTCE7)
MA]6RHCT!)D\8H(!9.HE\6ELD7S"Z&V919Y'&-)\.M;:8.YILA/+<F/ZZV;_4
M%61:HES,7&K4R.70\5@#:J3S.,E(O.UM(X>*_AG.0.J9W/`*9T2E7@U9IY>W
MV&HI9AE*JJI'2:@(I3:D-*3`0,(KXW1*7H[BX^_JPK`H'464ZO%79-#WF4-=
M3""W.524X#,8LRRL+HY9G44#FY.I/$:C3?2HM)Q2JX4H3G/`0N4_*V@25E90
MBJ99']3XQD:*ZH<J:"Q62KH*$MVY43?ML4QN!(@O7N$*F0GT#LCTHM:WT"Q?
MCSO48DKFN;O1=C&@0A!83*4G?67&4=[92%9+F:49"L`XUR(LG%3BIN5,DCJG
M*<F@M$.=,2G`K@F#8N_&9)5-FFDX6/O-F,+"I<5L4;#N78EQGBA.=<TN68="
MYT%H4\$)#>55_^I7_O8$4)J0-0U"QOU9L*#9-Q>9T"S@PACB$C<RZ`!++`7Q
M(W4/I3?$9N:.D.KPGXP2J:\X*R%(W.2>R(B0F\COO4Z"JD1N$@#QN;C&#HDO
M8K[21,-ZQ;P-*<QQO(3$TBB'H[UCR4:M:6,_8;0B5F+(5Y=<'AA'Y%52OG)#
M2HR8<V&YRU!K:<NN[,Z<F(6C`\"OEPW33(M\.,U8;K*;X^R7$HT(S>\=<TYN
MN1`[R[G/?G82G'?2W3^[>4[0)?1_VHSH13-Z)7![C`)HW.A)4[K2EK[TEHTL
M:$DC6M&8_O1#-&TD!DC1>`,0-40\?4A5@]IMX'M,BBG-ZE:S1),Z::Z:_L-8
MR+VLL<KC`FQ[RQ-E6COQU8A1P'R)766BK@=:7!XLGY_$$TCR9-=)>0R"%4)E
MVI`EPD_,MK+;!EZ*)#LA!YAUN,U=QO*`Z*73CC;LIAWHC.R:)^5>IW`.H!QA
M*DAT/$1>`B;)S@?I&4,%(8!,%D`C`*\YW4A2TEDZ`I>\8,4`!U!*2M:8EZG8
M)293.0M<*L['K#B<(CU,M#;+?1+.EB39:0$.I'Q<%L7P\R?3F4T?HW*=-2;E
M8V$!$5;"B*7H4J@_AH(@Q2H%I<!DBD`<DF(DA7,6WWQ.*H^SHYPLHSRT$71F
MJ3H`+(==<G6A9VIB4J(FK^VK0E'L-RR[2)(/_G#MHUA\?.!MUW'8V.OI1&5;
MU$&34!BT$:XDK\2QCD_M^%UX+1>^.;RY:J^A8T!1ATMEU@3Z<A)YZNH9U]M\
MB='>NA.`F.NKZ3%;%8+MJ'68F+!AT/%.5C2[,%P+#&39NLQ'(GK(F+&E+O@%
M9U^"2*!.U:R4+<U?!B<')K*\#E/X&VW(`N?68N&DD6(?^Y%8_)&/&&?T$V?2
MF2_.%MR-)3JGIM*I!T"ZK&`E\N6:;4,M]KCYZ`OUMT7M[7;#+\D[EW+UNQD;
M`<N3_1O1M)9,N`19M0>TM)93U)Y0,-M!9-5BP03N'4YT8(AD0,M01(W.P$?)
M.-63I!;ES(=L(,5G_K17=Q@55DF23O$)L&P-Q&@,:>T>3<4,A.A1\%78SU@-
M;P#6\\C)T=B'?43&F?A*(UF>Y=A32`$(P>`3]KF&IW77143'58C:13"`R@76
M;>@5E1!.+,&$4^@*=&0)<?$4HXQ>YQR+QDQ+\X49`0K5AIR%%TH+Y/"&+!G2
M5Q@996P$KH%AQDP)<H#%&#U,R/`4.P%0'8%%<MF&OJ279SP66(B)7-DA[B@&
ML\#&K@W&RX#2#R;1,8D/Y41%LGQ3:Q!A#AF/(:42&,'%;[G1$/&.45@*UEW?
M$YK'-#E=4S1<G(73WEA(C>13!6&2#QF$A%P2"E'0>]R@$GK(5PE39+D1_HO`
MVQG)D_-44I`8"&<%'/JPCHB013]UDR)!$HJP"/WQE];02$1-%!AUA&_HF@5-
M2!@!GTD<DWJ$(@0U3VN$XWX,(9N0DQMQ$^_X&]+08BV2ATR0&LF@6IJQCU3L
M1^#L(X`)HPL-2]$EC9_DAN20CC*VD>7,8/(H(5]LBW%E!T,<V(CD!FQTRAUE
MEP+`"&<,(F8TG^`8#%BP3R,FQXEI25>9#'X(BK2,Q9B\"^+@&6Q0&>IL8CSB
M(+@((BAJT.,58B?BI*X4QA!B3)_<H2'"Q.#5QNRT$+@5)*2MG6(LP*--VIB!
MD@N!U&=`E#>:Q*K0'*EHRT5B35-`W7-XI.%`_@M5I$LA027(>-JWX.2J"*,(
M;9*T[`],SF02TB`C)6+BM`7A)2%^D`H<)@AL<*#M+")'EI,W<2*U)!6X+)(;
M*MFFM!0`E@J""6&38-!F'06VW(1E#,]4\%5'+*!BF)`Q@N5Z7,E7*$;84!IF
MH@8?@11IJ65$AF0J*:'U%2(JC:'G[<VQ[*4J.<9.,2>57)8P(L1.\<G57.8B
M/1E^;*9GP,=@(A7LB*"M<&'ML*9>+B'2L-*PI*/KS$6DW<U%^%[NN:,Y>2;$
M/$Z4!)\L(IB&#1^40,E\S5CQT4]9')AC)$`BP9)$C44Q;LQ<<%]TZF;V8:%B
M_`FZI=EM"%AT4M9F_FF*<08C7Z"A7[F=20!4*TT(;^@7@M1$I_AFR+@$PR@@
M;H!,ED1):TUA/Q&0')&%2I[0JUS,SR32<D0,B%Q3@6*>$JT(EU4,E,#0A&0)
M7^$&#/H&EH0(4P!=9(9%MCP>FN%=25P$@T1:3B)%3B:'0@2;:LQ;@F*H8-W$
M`GP%LFU>I775E&I-(B$H]7F&=$F&=^#5@1#,7)!5L5#%_Z2)N3G&#%G2FGP2
M77!&Y+4+=:@$5S0)AVG7LV@J@Y#%1^Q)DJFI*(Z;;2"'(QY9H^&93:"A12B5
M1'REG';/@-S2EUI:P!V$+L6J+CZ$K"K$`A2&O<SJF\%I1"B>N;D;KQ+K_IP6
MAOJE*J<E!'`@Q+0RVJ\^A'@F27O,3+22BT)BJ/ID5),QWD2D*K/6TK5E!IZ>
M:VEE!+=EA$L(C&:Q*[W6:Y^A:>)\*_:9*T:DJ9/1G+T&K,!VV9@`!00.+,(F
MK,+J)H_Q28<N+,3Z!:L]K)$,19\LQ.?X)'FP:L3ZQ9GPD#36:Q9VK%H@&'PH
ME!-5#L>:Z,J>1Z^2;$Y4JX[AF+T:946,ZGJT+$6(&-T(UL^DR['HZWH$7Y/5
MFT4)+<RBW=$)K-&^QLM>E+$^A,8>C\].U>W91!1NA%4DC/8=9%9XHYDB3\[5
MQ$?`R;,('HE%7N!%7DH0S"(N2X5*GBKZ*<1@_L_2*1&,/&?2&@1O",H"/!NS
M-NVR]NMI^.MRY*1/EHFTWH3,908488C>3,9;:@=6*%I30&JGKHF<"$IS4I>'
M7=A9#<B6_HE]K)"@&BKBB(7H+8;JFM!%+"(G^0MN59"CG(5+,$A9:>4[:0V/
M(BG_L`A;1,G'`"!^KH[6W6:+O&57"02^1(;FD"?39)6(6M'>Z@E>%$JW^EFA
M<(92"`2&X`2D_HKT:)>^D):B>!6%^"F6."B4B$AW"!&%1&Z;9@I.?%'D?I&S
M1$8B4=M<=-[H@,C%F.G"\&W$$`V#<!8$H97%7LT"2._$N*VTC,P#.M6&7LW,
ML$57M06IZ<V4_LHF_H4,M`2&"#5P1TB.$L&%4%V6&)9$(2Y-V!:4:;ZCM7PP
M;_0%W9HP0T(G<F;&"\M%WW:G8\3EPS1L]2*$@?C(@R@KHP$PBGP-;+1'-'+'
M1Q%`@404B@@3`"#<WJQHB#B(/6Z(`(R$06$L`X^Q0Y52B[C0CNS-R0YB0$%Q
M0(TQGN'+,\9F!WX4?!0CBY@H\`A0,:*L5[4&OE$M)G'+2TTH!-5JC;@'9LQ.
M,C:CDOW0F.&')D;31^637!B(@23(RV@B.793#Z6E*$*.I3QMQSJBI%I:"G_Q
M$F+G#X4K)Z]E0/T090P.%%/I)C59>?(4\]*%C&J,,)W.`!(4A17+@+31_M3*
M5+C>QKBX,A(F2[V8SSQB3"/%9G)$2PZGHG5TQ7=:T&X81Q,:#,9<5G:\CNH=
M<#4)A]+IT^ZR)H,ID25?J-=(Z8K,HZ142RPNS`N'L@WWW5`42OP6L;:IA-^2
MZZ*%*VHX<?!TAE7T15'6Q,EEAO0A)N04$VQIVDU:XHO>9HV(3S+O8(.>A7@6
M$'"9DWOVDB*ETH&<I2)-73B^D^=-K5H:\$K6CH,&BT"$"PY7(L!N!V\9(4K:
M\WDJZ._"1PEZS1XN!R'K\&0@X-#P\_*YX.%R)\4N[&\JA<[*V>STVA-OX(C,
M;CMV8KY8"AM2M#!BQ_LVSM7=T8H23Z5D)SQ'_O*4]&!M;A#%],=J=='\/$>=
M0)%QX8SI],?=(`A*6:T9'?;L#!ICHLYM+`!)9G-\054(EQ;1ZHSJR/!,Z2[T
M%.)BO4P(#W,U=X0/BY%`P`9?!M11"[3!3`9(&#2B;34[SS#!1,6T0"5$M\8"
MA<0^[5`,S8?OZ8^:;-1=<294_L0Q$1`\^A0$W2=>]Y?&B&@O487&?N!I"6!,
M0,M/M5*5=(T;PJ&?9`D,PL23FLV\+E5(:(SO%HMZVA,L+4M%[RZU-`=?41!%
M/?&#L84&[F>U1$;[70V^U`7NOG$*U03Q8)UJ0XW#3EBEU<6`)%<,<>5S]\4N
MM]'IO(_55,U[[[![_N:6QFB+7"9I37P@4GTT`?UPDH+H5RS7NGZW0-3R;U@&
MI$Q,[CU47Y!PDF)P6<V,!-MQ'$*%HS#5C$D0DT[%(`N5UJ%*8,BNODA'UBA.
M6ML3W"X.Y/3RNN`5T`(MXJPK=`E*6/')XQG>Y[I(5%SN;[H(4Y2JJ1ZXBQ"$
M5>B;I97(2)PQ7SR(PM6&OWFQ$U,QG`^C0P4<,PDC%$^39=P2B-B*7I0(-C+4
M97CQ-D4CB#2R("(W9XYC=\Q'Q3R)!:T(FM%9H/>2CXQ(&&L-`:2(*JX,FUL&
MPH7Z#0;K+)^;5B%PJ6@RA(C3$0L'A+"YFA,;>I_9BC>:E.*?1.%&,<[,_DG^
MM^BUT0%0\['[9&I/J%HM1_Q6R7/N)/@`U&Y\Q7S$XMXEC$'3K-SP"8<"2)*/
M>>-Z1*IR5+`>!(OE.KL?R>@HQ56`VD7(+]*6A_RV.[[O[(%OH-P`KEEF;]M@
M2;WG.\$?.'>=$:V19,$O/,-+6:A2+JU5=<-//,63B[M$;<5GO,#J65R8<KMC
M'`!I/,RN^XLII(Z)N4<`/$*T9XS!FV7"J1@NM<AG':<Z'-M@H;2NV$2TF<0[
M!!'_!E8D3L9]F)&MT:VNRZ$Q4L\S6<Y;O+_'&WQG=5GL#T3PYQG5B+%"TL]K
MO(,:UFBE6\5T1I0_GDMN1(6NF\(PZ=(KQ`4G_LY<'$K0D*Y>Z"WO".ZQ^(S'
M\ZW*5^S3T^!98OQ)6'URGK28RPL2:3VFHA>_%OR82!Q`IULV?_=%T(1=G5:V
M_`3:FUB27VM$J*YCN/AG?N0.KED@0]F?MVMB0`K,=;Q=`46YAY=GI00?@2J>
M2!=F4U/@E?G?GBFU@BC)+`RF]ND\IHBA/OG+\VF!BJ+PTE54S4RR!S#%7T@=
M;8B6@-J8/>/Y8$:1F.@D*5Q]Y+U"1`AL`"3T&`CV?["&-`7'MW+F0[-<5PR?
MA3W3$\BHXQ[DU'D6L_F*R!.=2<A0`,0"`0`(+FAP$&&#!00)'CA8@"'!!`</
M$"0@L4$"``\+)'S8_A"B0X4`!!R`.-&CQHD0!2PX(*!C`P$"#@ZL"<#@0I$5
M#4(\"*#C0IH->/X4.3!FP@(T%^+\F=1C5*E3J5:U>A5K5JU;N7IDH,```@,*
M#B#P:+!K6K5KI3)(4`"N@@8*"@0(4$`NP@0!I,)-"&#E5Y0(Q1).ZA?P000$
M`QA(/'<`P0(,HFHTVV#Q8(0`###P*U6C7+D,T")4P+CC7J"140+-N+&J8P:N
M?Z)T;*`N5(0&`B!`$&``QX,!`"!X2QM`[^,&A@>0N]@L@P`"%-"E79=RW=((
M!\0\V0"B:`#!&W!&>/>U<(_A%0.@')DR>+XI$T.,[_CG9;K982L@7QL\_O<:
M"&"BS,XS2Z/X3M,-O(Y.$ZE!MB2<D,(*+4S(,__$6N"_"SW\\"/C'$O`K0$&
MT`PSO"(C4+WA+ILJP8/@:V"VB1+3Z("OB)MH@;L8\&P^CW[[L;BJ"GB1L,@8
ME"HQZ9+Z[:GT8ML(.@`70FDV!M&;R[O4G!HN)O.BS!`AOQ9+J+N1!MORK_]0
M^DPFV$CDSLL6R^PP,:`2V-.QO/02$$Z-A@,*`3]],BV!`U@+4"[7(((++D?Q
M9-`OE<I<$L1,-=TT*P48$/$MYC@=-2V-2C/1SH\"(&U$\)"$<ZK'DD,0ML0&
M$/4UN>I":#8(E2H`52,IA6B`^*IZ;,Z#\"NO_LZJS@R0LL0J4@HV-#G3S"]8
M<0,PRH,40"#2CF#UJZ*[(JWVS^0Z:W%:+HF33$I8[40O(H90M#10V!C`#=X`
M#Y)NO"/KJU5<SB`],L+-AI4R55(=?EC3L0IXBT.(+38RR'@I%5!&<:&2-RIR
M!P`7/%'SU`R`1H&"2\FV"+H*Y(-ZQ/0O+,\E+DI!I^0NN/H^1G>WR*[S.*&W
MN&5V4+@22'/<CBK:$VH4_WUKQX2)VFBV$WMJ%F18\_05M)2MUGDP`P_EK69_
MD;;/-+F6I9&V7QFV^N*Z[58+K`2,$T#JNR&&56>0WVX`;:^1E$H!OHH[;;:\
M3OXKVA.CWHY7@HR=_NI67OW$#&@F)Y).<BE=TYDJTD\S&]U#$\KK4P`<\@OM
MW<(<S+7%C$W3@`[3?%KVD%EWW>II26\@S<`I_>\TN::+;['-7ULI*4%/_W?@
M%K]CV[4%J6=N-E$?#=G+P6+VF_SRE2(J4;K,OWBIHF$#>?CVO>X[H2N_KO;K
MM$E*Z`#G:YII*%2!4[L^<I4;?4ETS2I=ZC!2E)\0("J/*<_KO.0GY-".)J1;
MB)=$LL&?#&4A$/0(;71BM9?AB"*C>]_&CC*4BA1@`1H)X)^@]Z>;'.`E3GF4
M2X!R@(L,S$8Q^>%``EB1B%`J@\!KV/J8:#?<)``L!T@`KIHX*E/=J6$U_CJ/
ME]!BNZL(34;CV<Q*@M0JWKV&00G2H@"3<AJ4+(2*L6*.I>:",Z21;F)1>1;U
M'F.7'T&$<L0CT'&V]A&677`S&SE-=R`"G(]TQRXQT4AWDA-(C=Q%C"9\'T,:
MLQ'CA6P`[W(.0HPXGLL=)#16.\V_'#,>U@'+++@I0(Z,DY')$&XP=!G9Y::(
M(/]5!Y6K\U\5B>DP3T'1`(F*8S$S!9%DMHINNUE9*./S*&A:93$Q<<R+FD0<
MN%0M0,`2D_LN@\*IL(EPJXF;D9(3(,8T[X[X8]#@,L(B&M7%E&WA#5#RXAN]
M&*`S?EG`+2DB*KK,\BLOBF$-69G'J2@`:J8Q_E8,]9(`M+#N7Z?\UT:9V5&/
M?O0J8$FFWG`(T@I)S21Q(<SA]`(7!/!2I5C9%UKV9:RQ3"V9&3&6W@H%&LWL
MB2K`7-V>`EFZO$`T+V_4J$9)I;XR+1,K2ZL<2TU:5:M>U6YZ^TI8](;5M=#/
MJV&MXFGX-D6Q=86L`+6+6-G:5K=*"(IB2:9#WVH5!LRPKGG-*D3XN18&I/2E
M>A7L8/.:*.X4E;!S2>QB&=M8QSX68IY9#V3!"EG+7A:SF;7LQ'`E`*H*]BN:
M%>UEF0HB<.54<Z-5K8?V<S['#G.U@X6B7Y^(%V?1##.?C6K&I+*8E>%V0AI1
MYZH*&%OC2NA3".&;_F,K6U755`92@TG35CQ#$OVX;GA6*0!40>30=7(ED@:B
M"CW7`]RJ$/"<D_&,>=FRO']M*;3'E6]:4*NLQC;7I%E"T8(2U9OB9B5+$/6O
M=/K7.38Z3&Q96HL$)30^K*"722*!56F%BJ'9PDB)BB$/1!&R`+%XZJA<6E=+
MX7(Y14T,J*B,S(CGVU:C482]5$%LBX-KX/:E$)4&I@H!7U(3N>!56`CFT>BD
M9E@,'\`@2%9(DDLJ,P@EJB27@K*OK$/7UP`&PO6+R%N2,I""=-C+CS&)EX]%
M@*(>JBD$@<E3&!+`1^40)4@Q8DQ>^!(@T_BJSF&.`0;*EM(R\<]ZF>CF_A80
M'[>D>&K)JNA^$8VX/<5G`=MT7I&H)Y<3;05.C&-`<&H9%;#`)4<<X3(5!PH<
M_1#4EJ@DC@"@:B]F"2TIU24(BW/,&$LMC3C>+*Y&PO602"YJ+@&+3%+'@P`P
M3L4M)"&17^XZ2.W0"#A[$@!Q>=U5`:I+T6IS+Z]_,DI+S>9%F7M0CF/2&.K%
M&,_%)-%+R\(6V*XOT'=EB'?..J-+ZOHUE(R)=&!"3;C=Q2[^:S8^)[*T8H\0
M9?AE$A49'+9D(D``Y"&6WFA3[2J5AYL.*M)>&+1&@M!*)":B3(]:7?`#HB25
MAZ(T[[#3G@]BD7C[?MFQ)-P1>`XGB<8R=W9W_LS7?-;S-:7YS#B!YY;;B4MW
M%>2.CM/]T0$D#C,5&XM<%DHCTM!H-*0YM''<PBL2%5HT"O=0?,\I`,I(1U2A
M3"=:Q&09<&\OG=S9,\?0&<9JSH?G2//6=[/"X(9')7>D?%^0DC>@`"[&(+&S
ME+GWKE%9)24R1\O[R3F7-I7;\U(V?!!2S^1&P5M%B=EB(-UVE?>J@*6=_AK<
MMLI#.Y$<=-ZD=UJ]9M[TJX(%+."9R*T.YANQ3`PN`(74D`#*Y>V"RZ7;1;7#
M*GM%Q<S'2?:,$2J3K11.NVYSCED^AC*LQ;Q#9T_$X2[H$RY3O0TD.U"YE@1[
M!3==#25@AY3:X\N4_D034?*L:<,7NA*S+-40JD4$1;CJ94_0)<M&J.;`8X9.
M`G#X8B^N8HH\PO,$98\2)FZ*KMB6C6@R[P!M[ZI<PB2@3"T$@JT&D"1JC]MR
MK#)H;R,$0LW>J,W`9FY:;P;+Q"*N!,,8@G+\KKE<,"(>`F4F!FB4:+F4B"1F
M`H>6"^&Z!3P@"$=P"`H]YWF(0OTF`KV.PV=L*._HZ&I`+P%5)T`&ZF.2"&;P
MJH2$)_^&#D*`)W[$98;6[(S4Q@.KBK/>PMJZ8M,"S:.R"3>0[T_<I'/J(FI2
MS"W$"5>F"-]L2/^8[D>.1@(/)H*JT"I"J:=H$&$VHS/\3B3`994<,5;B_B-N
M?&+Z%*)O*(]DQLA?/`/2S"-?@JV-)N;M_BM6$K!/SH,FO`A,,J)#'FJ=`"D5
M]\<5F1!X9(/<@LWLTJG<R$.&YM"JP,(XN`QOF,YONLXJAH<:T8[QAH>KT"4"
M$>U,#`!"Z*G]]DXNON]%1G$K`D\%R<\&5P)YQ(9-Q"MK<"58@LU_Z*^XV&17
M(LCD3,[RL*;B6#%Z8",R7FHOYD,0OZ7V9E$XFFU/0@DMH@WBB`M*8,XC',-<
M@,W_),-$PB0IBBZ2IDWM,L++@&7?WF6<F!&DBB]17JPK4JF*KLZN@.+L1A)5
MOFU+*N*E*@X]>,,@@"1`+F,DJ24Z]C'O^L0M_A@/#\UC+\;O/)P-(YPI_"1)
M3[+)6OPD<4[D>Z+"+D@D%.4DDI)#:B;0-6('0`Y%-<2O8Q3QKQBB6%A),CJP
M3&SC,B(ME%CL4T`M/B*0,+C+PX+/6+ZE:!CJPC*"IB*JZTX)<+)-)3\*H'S/
MP:K1ML1*N'*-,M!/638.)24))=]RTSAI-,)LE**BE-ZR!L-HUMC"X/BN+2(C
M<_+(-[Z)U*+K$;U"ENB'+I8-*R$D+QE3+P0-Z[P"-#:G$2V+"Y5R*_;BHO*O
M,;UJ3W[C+791*W)'[![&-T\/T:X3E<;2-RL,."]$#YM3/).F+H@K+8@CE%AS
M/"]FQF#D=1*E/=E)_@;)9S[7TSY'*X?J4RN@L#KO<WW$Y5/>(CRE`J"<LF[>
MS3\35$$7M*/\8XKH(K"X8KWZDU,0E$$O%$,S]&)XBLL*4RO>0C#7QT`UE$0;
MTU-*U&+`PNB.9$"%Y"Y&%$5C=$*,SD-\4SL)U$*[HKZZ(C(3(G:V2T8=QI\(
M(T?UJ%!@%$,I]$2I,25B4IO>I$5W3!JK(KD^].\DY.^N-%8HU(#T$V9B+,5Z
M-$A/RE<6(#[[PB2:S&_.5"HXI"'N+&VF0BXO1$NW5`X_KXET!I'88D[/:TKI
MPTO3XN_8%!7I-%"#C"O$M'0(-4@[35F*M&ARC3GK)DHOLMC,,E;>K4\K_J1.
MI1`,9>9/+88:+XT&G4@ZJX(+/2VH/"U:BDQ!YJ+1:@:B?@HS2*3"F#147.^@
M-./3:`WY_%"/.O(RC$TX2%5&;..=-L.W(#5(H>)$I],M0XE+P5,M/G4M-I5"
M)I4=K74A."HM..PL/+308+6TJ-&>$N-64>XKMHLRZ.*F%$*;\O(248E8AM6;
M\J*56,P_U.7O/E/-0-&W,NG*QB-+3<[G3G4\((ECDD,B6E$^OFD^<DV<+D._
M(@,MZL(X6L9%]T0GXRY"@,4TQ"8Y*(..Q%*WQE0"$Z(2`8Q7\`(!&/5#*K5,
MO.E([^E;ND-\\L(D]"2%C.WG:,0U48VO1@8T_MZ%H(#"RW!EH&+O+#MG@QCB
M'%&2JH`%):6+8.VI/!EB/@.G-1A*='X-*.YBV+IP0*+M-D*$XLS".DAD-@B$
M+N9C09+M[P(.;L)DE*9GW`)D_DQ.5'!PA*`O]4)Q((,-)9S*<M82//YC`&BB
M<=[K>(A48W)%6:Y/?&9G/?6064-F:<AB2-$*W:I(-0I%3_4$FOJO.,Q*+LHE
M_,@#[2!JVAY"<MAC=8J$0^9#+%M';9-#-*:C:1WO+5L%[;P%\]JQN)Y-/BCC
MC,:6/A["9'1E<,L#<!?6+-JE'G\40CZ#6--)YV(I2"[.1RLW/S)/'3V1!D<Q
M)<,WA8@$?%50.@)`_HK^HEJ&CK/V":)29YZP;2]7:#A$Q;^(!5+LJ%/3C:+:
M%(H^-US!0_?6PH`]Q$P56$YJ)8!LPA*K9;D<B&QF*$\.@W(T2"0R3*`\N%96
MPL`D"``@"+VZIEHL)<-HL,=RK,C>IX,+:1TO4(20IEVB;!V+9LU(\B.@\(7&
M1DM=8BLE*%LD<0F'!X?CE'#;4!%-L#7B-TQHKP"+9DERZ,L^B2B80H=<QX<[
M>%HSJT6_`F:Y<C]HXE2S8H$MI$JK]8&94.5$>#)Q;!V!!6H6PBP>!3?'PZ*4
M&%8@ZC="F%$BR%A\(C?^-Q`'LCH8;'<&$GHJY7TN(PMG^".O=_:`4!&M_@,U
MUM$U&=:_IHMP]0@U(NYH$.-C]G9N0$:"5-A0GA>5<D=DW<QRES?S'NH@(Y=P
MU5%V@[-445:F)B8XXIA'[T9F0Z:-]4YMFD11)`-Y4UB',`DP,F=?O,PTJ9@A
M3&9]\>E6(F^"F81:'O9@EBE?DDTS=B=(\`52XL6:@5@8*9EL_8M]E4T]=$:;
M>06([T6"VH6(D4Z)49&)E_`C6G66X\X__J(C])$\V$0V"@]Q$T(I15%_963:
MKBLI'&F7>=DJ"&0R^.:,0RJ-_[.8O](16X<Y".B*8L;0K!)#DJH6\SF=Q`>0
MK;4\;F<CQA=6P8>&UN@GF"-?7O@A(-EKG^4"_J_7"F&#30007:;K;,XJ>(F1
M<U"D(@QMYE@:\5R8'^>F[LKC+5-0@D9$P``2Q5;:S?#N=!=#P@9)^P#O6BIB
MCAZ:<S*F(KI#6LG7HJ<"+SIBHZ]"LL0*+0G&!@$$&".$I/LO2.`(XP):68*D
M<5F:;>#FI4?XNAS"\X9#.AW61-"B%DV"AE90."S%)^N)KXUBB]IY<&>CK%:$
MW#PEHG_#/.U"+#[N+"*))02$I0/$+L!I$1F:00A6F>%F,/P5)L#2UIC0+%7#
M6`EG<<."JI#/H?BR<UW%*US*6"*T.8N3*BZ'.)VG$2&J6/`B93H:@?7ZHP\#
MD!WC1*HDL'_2U`Q@_MHH0_O`I>&R!F)'V4O,A6&;-BJ:0C:E"6(U*IRA;3S`
M"4[$:W9ST?/\M9/66>[(EFA5S5L&HC?R.G'[";IY!5P,<JDJG&0SO&TZ#*BH
M6Z*"B5?^+'/GFCZY6``(X`!P`R988B"$@@"60D]>2-F(""Z(*$V!@@2M+%'9
M:J_=&)")AVD#.R]\T,QL$"/NNR39KC0P>RZ(R$R5#(8R8CZ1+`[I%<5A9#!<
M@G]PJ#3`52'J4R2R?*A(G,SK9C%"<F08Z5$,^;^!Q43"EC&2`STYJ2#!18J\
MV[O]:E-N%$/*W,__'&)F=1"?<]")RNCV1-"_XM"JX]#;M3/`$9BI*\_3_F*8
M`=W2+]T#?8.DIJC2O_MA.AW30UW48^LM-#W2M^*N1UW55]VXGE5SH`C1O^);
M@`K6OZXZZEC0]Z(L-%UOCF_!6!W82=3+%92OBETRPFPF8ES-&.+%5[R$<2(B
M?DB9^B>!!15BQCC8_=STM&O2FRE451+Y<N=@(*7?QGW<94GYS!W=[7IU3K:Z
MOYU"0!VSBM/5T6K$$XOUM#56NAU$MAU1JPBFLUUE;^?>9>33F\C=^U0]V>(S
MD#-1E\2S+@MD*_J\W#VKX!W>8.1.!=XK.H0O=;3@7S)/IU3A4STM&M[B#XP^
MOCBLA@XW_TR,VX(Q%UU(^"PCO$[',23XM%%I_E064OKI17CC2$C&0?D*5_;)
MX:4IN`?D9OQ$:.P"XU5]98<].4->0D?>*A2>9FBT,HJ,H21HH3:GX`;CT>1E
M7SC#3UKRSWK]PKH.PUEI7^9UUK$W^"YV<VSKK_!X*EKIYUR^,KSL7+6)8$UD
M(M3;Y\1;G$[R+B(.7:>#:I?*NHZM;,W*-@9IO1-&$+$PV`:I8VUG`4YCF6I1
M/G["-9SDL-MU(3G>(]RL/-2"Y;<"VQ^,)%LBG+:#)0H7*7)BB-!"Z^F:V=DN
M`;PL@!9@B';X,=*,A(W(3(M?-TSP)M2LJ$H)&'FMS7(,@$H8E<+L:F;IRW9X
M)`Q"SF[,(RH"R8*__DO(%_ME`OZ"(O0.R(5@8R%XWRD(:"`FPON]O_Z4"S8<
MZ(8_\NL!(D&#@0``-%@`X,#`!@(*-"@@8.$!@0L'-ER8P&"#@A(U)EQ80&/%
MD21+FCR),J7*E2Q;NGSI$@%%!088*(#9P(`!G"\9\$P)0$"``@$`%!A`-(!/
M!@`")`@I<$'1F@J")D@P0.,!D2:-EC000"8"KQL!&$@P=F>#HC)#.MPHD*F`
M!`Q"^MSH="?4G&0K9D0P$.Q-!@,"D*P*N`%3@1F5-LAX,^/;O7\?,U5;U2$"
MPP,W-ZBZ8&$`M14'#%B(X'1.U0`H8FP]\"E!S9P5P\XX$W;=UP*'\H:+_AK`
M7=&)'WM\:UQA`*<C"SC<6C&D[9L#G3=(2S?E@J<>168DZ-H`UY_DRYL_C_ZG
M@IL%%#B&F8!T>I+#YQ=<"D#UXH?".W/^GE-M^T&'4E^E%2?=1J19EU%H`_G6
MP``"$571:`0E5I5K$%:4X84+547=0@QD]R!C`!0WP$X9W<640P`:%YU!3%$W
M`&#2K:>`:2AQ5QUKK@W$E%$(#.>5=0M):)QKL"D67TBP+0E>8\YE!4"(X'W8
M74%:*I1`44$E9IT`7$G'U'!&BE<0DB-AE696!'EG$$*NO3A?G7;>B:=*"B"@
MP(0(%.=2?'E^EN='`]6XT),%7!7?;>.-.)9`_@2>9.!(?1H@YI75.71410:\
M!5N*T8%*'9U&^@4;B!5!*>)31#EJIHM<-05C8%P1*&J9_&E94&TB4AE`88&!
M^N-`"KQ*5I'(/62BDG$M5P`"X@G$:FNX,7H525`R-5N?=#'@X&,(B*G7<V,:
M5%6L?G7IZX,#4,=M6:]IRM>@]MZ+KWDTK;4O3ZKA*5^=AD;H;%F\5EEK75KN
M-6E7R[[6%$0>N6;=J3F]Q9Q9HVIJZL/&`;;BJ@%7A=0!.9JX,9VTOIC@0%OY
MU.5UJG6:$E(4Q?P0L2/9%-Q-1?X+'&Z)3EA;I&N1AMM^QGH<5G`$_7NL0.^"
MQ*FL%`69)-4Y.SW2_HD+B><S<@`&*]IX^9Z-=MI4%\"`4NVV!+2=]0FL$+U/
MUKVF1D2%"UO#)55J&VD$0EGQF&\ABM3&P-6Z*4E",U6<TE]SA:30ASH4KVTN
MU@;90IG.QMQU`(3[J;84<Y8@JWPYN)]78Y4*F]%7TMPV;-,>5)34`X36]MMC
M\5Y4;%ZYQUEAZVUEXV2CI<91YXUG=-9F`:\UV@%4^L21\,;F=U1!Q:H-?OAW
M)A#:`0O@_=+YX<ZWP/IV#@PE;`(0L)"<M9YJO]_:>MQ@HA-K[3R&O&4N_*F?
MH69%O]DXSE`"B(C+S-8RH4EF(/9#2-VV@K)$O64KR-F*2!`RNN1HRX%._M+>
MX@Q(@(DT4($,20B5)!4_$PG`@TL24T'$%)6#N<\B6OI<`V@8PH/P:C+(L2&/
M^M>X706E)`NPH4,(.#^,./`Q8C+?[L2'Q2RFAP$&6(`!9)(`*[&$`28;W]SH
M)IJ"B6<GO8-9:^H2@-"XIV\B\1A>L$6^C;"-3?_KT8.LY98'8<XJW'%C>(S"
M)CM&[#.(3,MAN)<4%?4JD(P,5E;J1J>,-"4HP\D(T!)@0\`9IU>=2]WW0)DF
MB@A`+5QTSGX0T!Z04.=3!=!+8D9$OAD!Z0"U/*-$%O48#D6K/B,ZBXA8%".5
MC"@EOM2B,Y\Y*)I$"XQB9$F?[+0G>\&O8#_T_M)[UO)&;Z9F)P2BD_\.9J*"
M(``A]"J=8CRHD\.QTDELHV`],9(51C'12%QL2#6-]:FX-"L^<S+(58:SS(K@
M\HS?^PR)2M),\F1K:#CYT[S`ASP@#0R:'.VH1Q4CH>C5A"?3,\](!Q71N3$@
MHA]M*:J^ESF7MF0L(+,+3L0CDP-8*'PA08K&9`K4H.9+)GT"(T_L2)Z$"G6I
M';4<JO[)U)&@*3\-90DLG5-2M%V%3U'MJE?)(Q,#T$0F_D*?>>[YU;2F[5C5
MK`M+U0K7N,IUKBA9`$T.@->JJ@0K\S%K7>D*V,`*=K"$+2PS7];%N+4$E.D9
M4DO>:MC(2G:RY`F1_D\&HQC*:M92)FM/>Z"JD@-`=B4+`-1F3_O5,)K$KA@)
MYF6ARL7U0-,F3SF-9W-4%X*F*"$Z$>L7!?`NNPP%+`:04"VC5:/=884H3"EM
M?&"I5]02%C`W.2E,@&D>T4KWF0K8(5Q7JA*DKDFEL#Q`<;)9%^N6Y"G&?&88
M^307GF66,802B`)&1-N5#@9<ER44S`@5S/LJ1HX`WBYE$68LT[;$B^91,%T9
MD!ASFL>I$#U`5D7C5[7NJ;\F4>])`!6?]J(FC-L)XX5C$SUGFM@]WH6H@5^,
M3:ZT>"49?DF-Y6HD"9>'P@N,[D9N[%7SQ>8D@@JO@ZY"P)$LX#F,]?$/_HN<
MQ>UL9R,PKK+:!/R@GYQX)0,8[5<M5B<>Y\W'&X6KB%'RMI/49"Y=IL]I;.M@
MD[!-`%[.4VZ1(EXKZUE@(5*`=F$B5O)LV4[DHTF@KQJBTM;RO,61S77VA%6?
M;&8HZYG,59`BG]1$:\DE.=9PEU07HL2R*DT!#!>]=$]#=:D@:(UJFBO"8*ON
M!LL*99MQ00O1`E@8BUY\2DZ7>9-@?X9G"[`)S[J[GI72)8S&#K9-^G19_"[;
M,G3!]9XU_!9<6MLD$[UIG=$3E*$41M.%N:Q0G$,66()$;\%*P%949)IE=V>:
M7C/.64JXLZ&@Q7N*:?=3E,)%H]RD,(76T8\9_AD5874U6BEICY,_(RV4L.V+
M#R_)KK'X*6DM*D7']?-3V-O%6GZQ1M'2R56&XAQI(<!D-3F+3F`)\T7MR>45
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M7))%3?$E`G'@C.UEUWOCM?7D1\\7<725;7=:_<T)W^V1`\S![\2=]T.:X6O5
MEYBERX#2=_R$D*H;]89_9L4=[*=%7/10W-90$,95[;=>L$1WQD(8?@9=X*,`
M<Q%6]%=^&P@?B_(GM51S#M@2@U8H>,-PU=$;4[0?Q;5NU6%_2<1T8@,J"V(V
MXG$71E-U1^(0B$%T+:A'`8(E(8A%JL5,!;!#5]%J'^)@IH<3*V40B[(3LI4V
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M0*$Q05DH`-_G,N3314!&$@2(/@*9$B:S9+KV_D/JJ%6>!1%"Z(_EMQOMT8!F
M!UE2R'J:=$,1:&#D*'?18H1">$6[)$8C:1+@$BT'=2S;6"?NP0`"D!J[\9%!
M&1U<=!WQ`88?XF,0MH$+I8D:2&0TV1)^!A)GM"<S1E36<Q58*3Y#XBVJ(I1?
M23`",%8$*6=]=Y1@25FA2!(?:``3\1+DJ(K9UU"?LE)TMAYJ`CZA!A$JAY9?
MF4U[-(\F06N'$9A]N5D01H1JEA/[F&QCI!&)^&=^(49801.G81.+0I3@LU42
M\B<Z:9@VIWUWP8O7I68J^9F$)2CA^'F?$35E=Q(Y5BK>-9*UU">JD1JR=9;G
M`6&?XF?%59BG67?C_N&10[9>$`F<FN6,#<=MGO5]HX.1X>5N[G8^"TD0!S&$
M$W(^PWF<5I:<H\E]WN69VTE8HJ),.](ES+9#V]$O*B%6`V!%U"66N3D?"`AA
MUD.6XKEGS?4K#,EM?H6/^"E=VKE>[5E:];$H7/>6E<9:6704J0%*0`F@6!B7
M%*22ZG6!$6I@B7D2<+<2K=B>HL$3&8*7#.I6B66:&(I:K@%AQ883V&<LAL6?
M`*J640<N.%%47AFBT'12?R*`*+J!>-4^Z?<3X>)H/KI9[$1:Y:$0]QE4W1:C
M1EIE4?->1L43QA:>4`I7`CJ06@I->B<BJX>,*B4B6*I%-?&!7O2D%3$1_J;!
M@F1*6>LT5$P*5-T64W6R3C2!6SMS%L<RDG3Q1:'CIGGI@;B$$PUA7-\4J(4E
MGS@1DW'5DRJZJ/_8DSG!F\*4DZY)&`^1F8F:-F&5=U"I3+PT&B#(J7WYFT"%
M79T1J:0'-6$T15]D:G\2(IY8JFCC5H"Q2J?:BUE15+4Z6";Y5^7!<]_5F]7F
MG?,1,$CH$SKA*S3!(HKEJ_G21`]!K4RZ'>[Y$#.4IM$J5+.GB=/979CBK792
MC;`6(M2)$<@Q.L;)K7:*+5&S6!?X)\NQGNVJ60LJ=Y2U8>$W@7CB5C7)E6MR
M,\=JK]J4J>_RFUQD/=*BD06+A5P*3?'A1>T!_JWH0;`<$C!D1!V>A9@.:R^$
M`2DMQWUF"+$>BT6#261<&EMRY:!B%1\GRIX5>XMG1([.VF4R:[+H`1@WFU0Y
MFX4P^TQ[NDX-^J)V\D5+T59Q$XS#DED^FR>`D8=\]1,EZ[0Y*W-[.5)*>2>.
M!5[-P3]O`8M5BR?L1!:IFCYBB[;IHT+NQDMR"A-+5BQ$.'Y^T4';E[:N1Z=7
M2IQWR[<F$5)=Z;8X@1;A,B(.4J"M0AJ)T[>N5T;&(J"4N+AI0UL:FB?0]A.1
M%WEZ^S6Z2A)B-4UB`;0K(7K/%G@8@9@V\8C]%KE;!&5]LJVKZTR$811%,:/I
M\11W$7TH$22,8H<"_BI*+L&`?.*>JUFYT9-Z/R)R6/&3((&SL.L2O,0A^,I]
MJ^J\+Y$?@[%&9R-FI)<]0"(FIOF[(Q@UMJ6YI(ES:ZF/'A:XU;M>UU>O9\N^
M][(5>`-"KH%7?G4^<WL00M:0+I._[:,0QQ(4YJ._/W2LFC02&'0D!6%63K)]
M9$$`X6L2;@E*O)1`\5N.I]$GD5=9&#PH"HP1%'-\;>:*P9(?PJ,DLI(F?6(M
M6>$;67%+)ZPMXX$0A],41?$O,$Q)/S@6B+I7WAI&R>G!AG5?9KI5BPJY0WP>
M".'#U9$J,KP14Y,55J-!C/1&69.061Q])+,_HE,WM_.#T7@Y94AW%'DL_LTK
MN;%!E5&HQ"]!C=Y"JX'2QH2F)4YQ-5!L-&+2:`@9/SL(Q2&3D*1V$\MQ1EC3
M-9PR*Y/1HV_2O2[1EL](O0-937\"2FTZ8K`$J'/,GE$3D(_[NAP5NMQ8Q-W3
M'U2%A$^"H+^A0`G9@ZS,056158V,.PXQQ9%'%@I3(U:W24+(DH\6RCU!O"#5
MBIQR,T4UK)JLA1[H13IQHE2K-DF\G2RJIF8AB)@;2[*,PE6<&:_A1LOB%@@V
MPPGL-;G#*,`Z1W%4'0%0%6+Y6.KV6K\,:-54I(>"&I$<O]WWOVYY5/;<QJQ<
MQ:)4$$?8QP2!-TAD(!YDMZLR'A$\(>"LSP^=_CT7L14)?1((^4/M0]'X8H1)
M1D%V:R01C,P#&2&@][[`&]+""G0=L1.69QPWP4';(WRZ(2:#Y'^,M(P%D56D
MAD]D(1F1\5,RC,#4HQABHGX;S%9!K)FYE8A'TC48P;DA+2'EW&TGG3:>A+U-
M45U-85[=2[N:)$=^B&J:\QNU`\Z%:"D'TQ0_0B54LK'<XX</XD!808(0MB?/
MM=1HLV0\J5!*X6PGA7?WQ<_5"X[2DHM4_<P'$YFK)G`BTL.IJI?KT[5ZTG1#
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MP?74R#S/T@*S[4U7*][AGRC:;9.Z:K.R7OL9Y`DD;[$`&PZ%,Q["Z\.E%BE8
M#2[D+/$46R'>4;9#!;TF1"H12?XA(0*%0#O@5!Y8MWL=&I?E6@X^,D?=_L$\
MWV#N*2RU4NN[,U^.'A`:&S)NYAY53-WE6?])DG$^W!#KYBVU'C_BFO>2;,X6
MQ'X&8=(&&$-2$YIQB%U4UV(%YYJ,%IH-A21<I<4AWPA.EFK.(0=N32/+(;U\
M+VQ32VOW*5]D/80A&_'$)[1\=P$95D9IYA;5%C<>HJ+IS.S;O+U:'J".+W4V
M(L`*2VP.VL)NYM&Y*!/!KA6Y-$E.D$@:678UKM:2-N@:YRCUXY6I3SMFP)P.
MN\--O1/:47U^,F#TZ`-)=Y$==[G$[6V\&Y2<32MN;(T"Q1A.D&TS67BT9!EM
M+_E-9-54U^/2Q'%>$^]U@6'K$J]"/FBASB^1_DU#O.>".6&:?B^$+:L!"3YD
M7M$IMNFB5]C5[M2MV26KW:&%@56*J^24>\]OE2.ZR><YM85+O>Y$YF7K%$:M
MMH7Q2.S5.W/I1['`VLZZ!A;\;BG0[+QN!=B$0EU,<DW"%AED%&"$<A,@8U<2
M;V?,C!9?)!\YGQ-1>2*F41]#0J1$3^4*,4/K;83\VZ*\U$#Z#FML7[T22\#K
MG97+5_;(SDO3:H2ZAE<2,A>M$=4>A83QP4M7@>39M:V<YCBP9H0>O^:)>8A#
M"BS*1.EMS"=PS#/D,V4!6VC#YFR`S5_"5F#0=*.4W$M8--R6$C?S'(N,OS-3
M4\])58:XMK2L_U4(_K@>ZZ036<3K#9>L\I%>M.\I\.BX.\9OG;;PP(\G]#WX
M&^>(653HP,O=QB)&FXK\,C$<8I7L&VH61WCZR-^B].V!*M=%,>\2(D]V:P(T
M;.7]O<@SCAYK4QL`C=M[HHSRCE/_4/J<D$*1&'>4T2\N`,&@P4`&#!`,1)A0
MX4*&#1T^A!A1XD2*%2U>Q)@QH8($"QHL.)"`HT:$!P`<*(F2Y$J6%1,<4-FR
M````$6D6:)E3YTZ>#&,.[(BS)\8#'BL*,(JPP`&A#0X82#I4ZE2J5:T^-&"0
M@0$%!A(D6,F@``*P"II>1>N09LV<,P$(?'@S[5RZ&A.<9?"UKL.#%@?`_DTX
M0`%0!'_W'D:<^&H!!0@:BTS0EV0"`PW.*KZZ5J=;L'$!7,8<&NU(A'FYBFZ`
M`/!$QPL9"$:P8"QJVK5M,\SJ]0`"LI(S%F!\F^K:U23=%E\H5_CREF9;(Q1,
MNW+%UPP9R/[:F?EV[G,-((#JE;3&`@&Z\R1.,;OVA,>_/AVLD&8`!0(`!`C`
M/J](A901_#PO-)&^,T"H`FOC+T`%%V0.J9->\HHD`*)B,"/-)%K`OK4*H-"M
MM39D3\,/;TKJ0J5HJA`S!198H*,$`.`(J=H$2+%&&Q,;8`&R./*-.@%ZO)&B
M`&B*#ZLA/QM@+=\\_.RN^0#S<*R[AC1O(`-H_IJN`0:.#+(N!F`BJX`$!D@M
M2]0BLPP[KG@#X*X&!OBO0*XH$Z"KK5Y;X#L$"HBP2S\K/$A,KK@*R:+J_K2(
M,XA>!,"P@=(;R$/`&&TJ20#,O/(SH&@B<R`%E$/4*K(&-.NK(FU3S2/5.EN@
M(+#`8D"!6`UJH#+5*CN@L0820"Y47X4[*+L]4SL5HM=Z_94A13T#P#<$:-+.
MK4ZA0S%2FGHTT5*$,F4O69[($N`NWA28UEMSSPWPJ5'OZJI;AQQ%MZ%E&_J4
MR(TX/;%9A=Q2B4N%+.TL4QK?K#;>G#@""SPQ"T#68(<?/LRK]Q#B-:+O(%YH
M7F5!S3??;AD=V-^$_I[5]U&:\L(78[NJ$V#+R-Q5.6:9IRIJX$@Y?`BFF:UM
M,V>.>?:XOPO=6HA2A#0,Z>>=%[6L`1IQP@GFI:>FVE"R%`(/V;L:[HYKBC0N
M6FFBK816H7K9&CLAHWD>P%*OJVZ@JUI?)+<!^B@J%FZ]9]9KHP%@'I-JL(76
M=-^"2>Z6@:$+1HCD+!G]<&^'Q"(7ST[SECSSS&5-*%99#P#LM:($+]NA3`,H
MCDJ*KS7\))Z+A=3D#37O+TNO&-:R9]IWWWN\K<A]MC.Q@)QY</E*1PA4R/\M
MV*VSEA\Y<M[C9D^!4S&?/GN5$XS;L:\$O0Y[F8U/R*3[$LI4,LC53]FR_K7X
M,PMY3]>J<G>1HH+];>WW]U;G@5J430,(`$#)N65@+(()3+2S%I4<0$-J^Y``
MF+*6I##I)+-;B/D`)#D64:AO0.%?"'?VES6AY&_B&]^(5,@6+5GJ0]%970`L
MB#N*C85),%0(`S0DM:K%RDT#49BS]"="(@;I:IZRWF.ZLJ<A.@QAZUD/YSH'
M'."@<#_<8XA'"F*Z^>QN/U*R'J]B-;(BEM%<6P1B`NB3@#H])CAFG`MEE$2[
M)W($=`;(T0=KU40X]I$[IP&*0/CTE)=1AH9^'`Y-?J2YE_!F3P8(3U_0U#A$
M5O)/3QD(3+Q2DYH0`#0*XN&O*+2WCA3E52\9_@#.,JDV2[:207W*8;@XPA4Q
M3;)"?'0E;0:#$]ZL20&%*DU[<CE,[J!Q2V:J52HEHQIB^@J%A^&ET\@UIB,B
M1&[6Q&4SM2FJ4/8&:\_<YE548SW0J<95"QC,7QRS`#*ASBO!VQ-8<%(9P;0I
M/X+A$&/^DB.=Y*E4'*)E-3MGS?K)#)SA]!,::Y4WX!3MH!.1Y_<BP\X[_6TL
MOCS`7Q@&-4@^4H?5\4J..#(6)D+R;E1K%U0<LU(FWFIB63E(KCQGO:CM*B^I
M&>.K=A6W^N3D)8T1B[C`0[QK@A"A1T4,+!V"NHU\!9F3$4D8?VF9K3A%)'F)
M%>@ZHII@E<4@.JK5_DX3MJM97D>@,Q-+:!K*DCG)LU0%PMY-"?)4I-9U+@O0
M70:3`A*H$*`E-L/,A*JF1\2P4".R0:=2&M`F'O[0KH^ERW/BIK4"7=$LP"1)
M-J="V)DI]3##(DECD$FN`#Z$/72%;&IU(D5B34X`>O*>*5=2+L5XMGC/S-M@
M!M.J@O2V+'$#KE=U6II/4L0QR+$H1(I*-<VJECFP!.>.R'([K317/[O54G89
M-LZ\>&278A5>1RKSVQQ>=4<H55B!]$C-/0W```<(0#S;=%&+JO$NXLI5?,/D
MV*5H)*4*8>I%<.A<`K/D5(=L2/B\5R=>">:A^^H<))^BW@$P98G?49>4_L0%
MR8[:<$S+K54T`SPU6<D*G;ZITZPX-QB!L/@ZH8L(9A=[D<'LQBN0=,J;A@B>
M`O>8)X#,KD0H,R9VFD4!J-M@1*Y'/)VLQGH$:3&)#4(9@@0K-;)Y\N=4PS"P
M2`QA8-4H&_=(PJ8-A)\5X5&+1L6;TF9DQ#Z&LTO:,\J&"(!#`WQ)=J!BD9^T
M2*=@04E'.N@1%KD()``LBLYT6E.PT`@D3FN16!]&Q?K`)$/_6\I2)%@`"7Y&
M`)Z<[TPX;>=PI3(D"ZMTN$Z"V<"I!Z^+5>![#(NA),?9UA-AK6257)_O`!5"
M3YZ(F$HS)F*'9S>II*(`VM;>.`E&O>6A(I\N_EI9+0VJ*^B$$W`"@)('=X=7
M%J[E=;IG%H'HQ7/!E:)ND5.0%HWD5CO-2JW45VN&1&9<)VXD;24RGK#NK+FW
MQ@SW*C:1O,`G*W_;ZL"5/,46<Z2[!9%JI($+EU4Y]4[C;)%`TDHYU%Z'BEA<
MD(ZJ6AG6HD\L&F>81K$,)V$9>2$(XW)C_M,8C@S&E@8`[$/`,R@V[NFB&-&5
M-0$^=-,"AC?4$<G?N%(D[TE$V)YB9E:@EB=(=N5V0.*5D7.5'81-)\LKQ:WG
M0,X<6KTEE(VK>6K*4DN:^V=`5,[A+R4JL>](R2E9,DM$\M*5QT!%M,75NQ#]
M3?0%21;(%!&D9SG2_BJ(^,:I(G%,+47"F*^<.&,U?PF?(/]>[S9T2W8C^"]=
MOAW*@'A1E=,2E_%$>3ZMR)%`ZBZWQ?0?WD2F[GC/^<O?VQO1[B8__F6/P@D_
M?!8IY>PYR[$P55GG4YD*)Q-""51"$A+3.V7Z=7JO4]I-HZ?MRB,R#O;R=?D2
M>ILV.VEZ+X<FU*9P]??Y+P()3.Q\$AI-B#'Y?`D[8_)HAXC)*+'.*,";"(DS
MJN$SP+_1B511BH]ZHXC0LZ;!)[ARKU1ZC6GB*(5QJ^1BC/QX(\90*+PI,=J@
ME3W#B"TCB)0#BGD:LHQ:K&L3E/6@I6E""?,@D_#8%A[*"\D8%!YC"5JA_B0#
M!,+`^+>!,(^8(Q-G6ZK.T0MUJBJP4XW=F!5Y,HAV<9/QFIN:"A::`CZ&&<*#
MR8J.\*\DHBJI>Y&KRHDMTZ$BP;F%\"?"PB>?.JT@'+[?*T"2*"<=JY,C3(U%
M&3+%";J<"*JQ@)-(F:7)`([CDXJO:+J5X(H`@YIR:[*:J`R`@HXLBJ=_@;N6
M&"/%DD.B4R@Z7`G'^`L:?!.J:L!2'+;OV:/^((G*N)VF(8N3:PE;2@N).AB$
M43OZ\(HZ$;I@4@\M.0@R.20=FJNM^![<R0MIZQRX0$3=&[9.)+J3VL.+6*;2
MJ!PQT<-\PIY189C\Z!;4^AK_<!3*0R%@,Y:T_DJ+V&"RWSBR*JN.+]&.+)$K
MB`*]FJBPQ\&)D[N=R/B+K7B+8A$WX+J(>:PJ:#3`O&J)2ZL)J%FL^XH4A6"1
MO"L_C&`,^PL@-YFUE1BNJN`LEIB^5\F0#'F1B4P4A8R*'%$_IRB5^ZH,.M/(
MYWD8ES1(8"F2DFL.RM"3K=B-<4E&:\))/#HKCS1&&K*VG0@)9IJ*0^&)6&&J
M0C(QW=(2C2,(%U.QX#HWR_@4TI*,'!%&`Z`/!E/$7Z*5@[`Y6;FJ2!NK).JM
MC#/+T#$/J(2X+[DI7OFSD;"3D8B,68D\7ADO=.*//O2AVKLB83DY[]&*B5DI
ML3C*/;$C,^G"F92*_E-YLYS(D])3.KHD$/:0DNT:HX9[RNS"KLG:1!=[Q#7I
MGCOAB?MZ3'H!PYYPC'A3.G^RLUXS"QTA(;DC-N`XM2/#HS>Q+\%HF=*`D?L;
M"2G9QS:Q)\5A%[(8@)9)N:Q$'6>#/)_K%HV*IX-CIS?YE+EAR3WB"L$`'?.H
M"74TE15AC$$QQ5GAD(XP2X\XI?V0C>Z*&JQ:/%?Q(7"$3-%`L*G@$;43BM]I
MBJU``!IA3N<0$PXD*?O21MB`"D$I,:BY1+5[B:'H2`/3MR8#K:X#E[>#$SL3
MQ\KDDSU1$S<Z.8:YL6TA*V%TR)UPLB`3C=7$B#S)3^9@+?QLCL@3GSNY_@L"
M4:D]49C7<B34>8OSC`Q].I:0HHRJ8A<!;$4<VPF'FXK;,4\[R0KG]"K&L[F/
M8#'0=%&=:C%DW,4<K,&C6J29E,H$@T2"$+HMTJ(MRE+M:)6:]"[1!"X@XQR!
M8#R!C$J%@I7L^BV;NRGK>46U^0X?FD^I;,O=RKHQRM/PB4KPL+CK.(V3F\<?
M6R>=$#[7/+(6"SZ<I!BNRCN($!,:<93PJ`YA3*5N\R-:A%'-&27Q\[[O^PA%
M^PCMRQ7$"B"_8@J/R+1$(S_QBL@\,:6,4J`&M:/LV#H7"8D"\;^2>*\EO:^B
MF!`VHJ*0D*@5-"688XJ,<BSW')VGD[36%-7U_H1(`OR(J)%6J[C0WZB*4<VD
MG[B=F/BG"1U7!\*D7<F1[\,K,9,90D,("EF1&-TIEZPPA-*S%U&<&9/$=F&8
M.N&]V+`3;?S",-FCE0HK7,'*\C25Q(RFW""KJ)K5Q>,5SB0CR-.+D;V.RBNQ
MHG#%L#H(C[VCG>+"$[POZ^%!ZKDQ<6V(`=G$2!$,!`2*@"E4JFA0MB))MB*W
MUDH>^_*4R+!9</H<>;,2&YLN*#S/DS.5\YO$/80,I\5*QGC9/6*8W9"YR$")
M^Q.+!<B/@XB\IN$R>YN]994;G$"=A5%.&[(,QH01E7([0V+6`B"3>-I1DL)`
MJ$DE:EV-7$$H5>TC_G*B.1_=EB_)E7@KNO@"LBA4F[(XN%;=69NT"%V;BO.T
M$LF@G+Z94K.P47D##J"%*Q_]I=[H#="I'-G82=%21X>3FS_#*9UJ%<=H3['J
M+A;#2['2K1`4-#6ERNZ:++@4.BT"+JH<*'&[GH`,IC]TFG6<T8S@7-3PGL9H
MBA++#IGT%&,<Q*:M36OJ"XEIQE;\P(H`W:G`4<O0CH]R%!U:#^P%(O&8C=1H
M/>\]VEMZN:ET".V`RBW%'(V3%5>QRH`]"(T+E^?-7LT1"R[;EG8Y(8B`J:&R
M)G.TDO$2$]"YBH)RB?5E"7TB#'6;O+Z07(:-",?XD9,=T%GZF\DME:Y:_H\\
M:4+*B;PIFT*IHRJ72J*HVAI\>A&[8<R6E3HU,]D\R1I#*KU&))8`\$J\*@P$
MB*\?B:_9&S)(TDTX2=5:"M$"L6+`+8S5=39!<21P=2484U,\78T^M8Y>7,;>
MVJDMA96XC%/,;5FP\,LH;)5%[3*NM<I4&9>LFRS((+GEE<LL#;2P\BJHI$N;
MK8R]8SND-)TC&Y5>G*I'1*)3I`HFK3<.K@J+72A>\E%'41.*;;ST8\Q!XF+*
MF#!9$3::VHH,J3T<FUR]')`U8I?#[(B"V"B;RCK1.S=(+C@M^6,OY2FC$*,M
M]9PY->0"WJDHT[@M<N-@JN8B"9VB0%1BHMU"_N$D2)NON[@T[G,3:UV*56N1
M#ZX/D2R0"4&*I+D[39LE:^6^&:L_2U.U%4$*#JF_D`0+^[,T]DL3`"``EB5G
M`N"D,K0_^$,)I*B_4JF)?QYGD\@_E`@)&7D(!,JS?WV5P]T5E.@@-:Z*W-OH
M-EL,?G7;=DLT:_K@[%N45XL)0/N*>-ZF_SL+ID`H[[&RJ-*56_$UJ8J5.`TR
ML9NX5J%<$\VN-HT;QE/A8:[)[%+@WX(+=9M3;8;@!&$QHPB?FKP>GO(JUS`-
MI9";/'V(,'J)T!D,B$V-H\N[=8U,4"X-4+P*5<0I%`R)`#.5?7J;QEC6Z8CA
M'>VII-PW=$$6A(Q@_MI1&&L,1'=YX\(8J<;YTB1](XW:WH?8.XABW)40W=3;
MPYJ[V=+#VS5:(G^J07)[HX,E%[E&I$P\U\2>GC"Z02NCI;QPMKK1Z=GP#9+#
M85IJ:W:9BX?:W[G@)8$@Q7I2(Y\$'JY@/%MYE5CQW=(3GC6I*F1D5"ZMZC%2
MMQ)[L2>+,JA$)XA#9@B.ZJ&&L+A,7C?54R@SJL,49N"5E:Y22[K$JHGB%8O=
M#;YT$C2Y;]@^C,N6"/V!;KP;C$4:%V?.2R'N3R!*X`UT2%WQ7->0:A=E;P?<
M0^2`R_`.0=[*,C^=+-$TWCJ.ROFVGFR3NTD<J6`&BH"B)R,CBR(CXCH)_K`P
M@=0<84XQ1F.%N:B[.$1I^S"GI4Y!K#W@\-$"P8[A^0\?9VY63%FS[7'$,HL!
M`PRC"#,9!X]2^1MGLU_@^$X=V3(V0NT]H5K(X%;'F$P?<\G1Z:!3^B`*03@H
M9Q$.B4CMZ[Z%:9H5H=V[\*NS4\4[(S]K/=KWJS\QJS_Y;;_,0ZSN<Y#,NZ_G
M<YH\(S*<@.B="F=J_0SQW15.8XKO`8!/L[/1,3\:B9'V*P`"N`NFF`ER1K7U
MVU;Z<Z!._PP'HM:,WO3Y2B!E6QCRZRGU*T.;R3]_;L@$@I#\$VA-2A[L"`DR
MT2F,/C1FKM55*C0MW2EHWRF1'C3=G?/_P9!R_L4('BJ^G@#:;3*+A=&\[SB[
MNC-0G!R3H,(P"'FD'Y$V2(+;OM,3Z]&1TNO>JWLGEIJNX\N-*9NN/%D*KP&?
M?K\HOMNZUX#ER//A&V,S'G&J-V$,WI0IP*81U&$J/A'0MX$BAQN5",>:X"JG
M<?K3['OD:1]8S,8E=0K:=H%''BRX+=X5\6@K=BF0EJD?5^2[,PLG'R0,R-I2
MLD.4J_QAF=V2^J`\EMLNN<$[GN,J)76,C!P-9"G(ND#/6@%1(VL*H>J-'^&P
MKI@P2-T1)YTYGOM?/^I9K/3OW:D[BC&(ISGB%NDH\`@@BY(,+KP3G&!=K-J+
M<-\(_*6*MI6WVFND_J2]7ML#Y0(!'1J:+AZ3>J$O)K,!KFK*;*A<^[WQ^6`.
M2@DO5-)=*6OER[BYO__^I$PE[D/A,CRJ#^!I6K'7GPK+%:YBH]_ABI:1%>>6
M?<<@I"]<4MJG8=V@.1.]=]X+'(OCRZ!21[O9XI^D/6C5I\K*\B.[+P[$R0FK
MH@)Q+Y_+-![G#3[)\DS+_MO!\<+(0S5RTG!B7O+B4D^I5?4>WZ%6-SP-KN=5
ML3CE[L\6Y#_+X\S^+=TU2X!HH(#!0`4-$!`4R$#AP`0,'"9HP.`A`X0-&3:`
MF)&!`04&)"I`H$"!``8!%C9(J7)E@00(7GY,.6!A`@`-9A9`6:!!@)4^_G\"
M#2KT9P*#/A$.3:I4J0$$,44F".!P0=.($@\@:/DRJ8("!@XH&."28X("61D,
MN!DUP4P##+0V,%!4;L<"5#VZ5("UHH($"W(B2`!19$C!!S@N0!BX0$B"?<<Z
M=%OPH<"1!!DLF(S0H<&($1$(S"BZ\VB,%ST3+(K9H..4626F/.`VM-&EMF_C
MSJU[-^Z_"Q8D.!#Q0$;9HH$7M=O2<`/@P`\(6'#@+UO/!PHP#DZ\P`'A@NT"
M$.R7NW#LW05<KPG]P`#LZ`L((%"6_(#TP0'HQ0Z`^W[XUP7L)P!W\`T`P`$&
M"F!`>`*BMY^!^\D68'`%]"<<<='9%IQ@*OW5_D!WTWWDF7*\D>@3<3[M5***
M(V;T7'3"8=B<6,(!M]0"`TBW@$K$_2:C4#JJ&*200Q*YH4IB$9FDDDN2:-%C
M!T'YD91Q4>D6:)XID)B'%3VDI6`Z&O719BTV]%!#"TP4$6FDI6109BL99=!`
M.GI&6V@H38223WJFM!"?>ZHD9Y]&QJ4=3W_^)-(`3M4V&W4B=2113D4QN51?
MH:444Z5++9;13,0AU!)C;0JV&&A#]85=5SH)8!19F\(:*ZP)]=GJ2HC*FJNN
MEC+6D5_BC8154P8TE9Y<(@E0EDL&)!827M_1E1915MV&`)"VA91;BMB65"US
M*14EGD-<=;6<2L1Z_K32AJIMN^M*(MU:F[M'7II1;5T1:Q5F+35U*JJ!.9MI
MMQ(A<.*\!R,<E%PK"7=KP@_/6VJXZ3(&6D=BOO567!4!-U)1AXD$6F>3(;JJ
M4'C2AI*@0LV%LKP__>6OGT)Y;-6]0`';:'(,&"P48V)1ZEJXUR[\5KT/4TLE
MQ#F%F%.@K6+7)E@U)R585V'I!-:1UT+<M;M'<_2RUV/GNEI(@2$@P$MGOYSJ
M8V:YQ!;`/B$GL6$MF0QGEL]"59B_YWHE'$%->87=GW(7C$!['ED+KT\&+)KE
M2X)5I6F@CXD'Z:5.*?66Q"JM^ZYG<K5[L,;-69XPOZ[)"]QLX&;EU=]!_CF5
MK+]63Q12SV3SSJ1+*O&<=._#+TF96YS=A5#J$OE%6%\ER=77RP0U&W?'X?Z)
M5F)Q!P:6141-!'D!8CT4&5!G,NH6LV7]))G5(T&50.KA_FIM15-E-'M0#RE.
MK=/M#L`H.9$6TEREOWF)15JCDAH"3O(30<WL)WGB6@-V8I:U49!X&BS10(`W
ML`V"<$@6K"!;%A`=NPC/+^O[506;HRR@3,>"->G+;^SB$[^DIR6RZ4JRA)<1
M&UK(:J(B"G$,]!\3TLF'Y:$0=+Y3'77)I2S3\6&0?G.=E=1H`0#H4->`9).N
MD2<E/<)B`TYX(N\0ISO,$A"-X&.U9`E(5>5A_F,(Z[B;J!V)BG;<8U(R=A(K
M5=!HI1L(:`+#OAY2AEIRLMA!NE+!PH2D1A'QW+*&M3W`>.@@97E(Q9Q%E\F%
MZ&J@P<_%.%(HC8P%++^JV:7*I)7+!`9="-F7QAQB'.5EI2E]R0IP`.:X-GTD
MD5T+2T;TZ*ZT*%!/)%'`2=(B%?DYI2P>\22_H)DJOG1$.&\S)A^[V2<X9=";
MXA1(W#XBE@`P4P'XF8E-VMD`FW0D/(;<"0#.(A:S\&TG/0$`6AZIE<1,+C#^
MC$H9-S;"73Z&/2UL24_<DI-D5<PD?\G8`.020!PQ1@"'$HM-3L*8G8"F)SGI
MY*("D)A>J;.%(2V5_E,JTLB/3.IX(MF)4:0BD)D$+6$::Q@87Z/)J"#F=4JZ
MSMH$.LZC@DM3Y4,J4_6D3*:*TZ5,FJE`3"61NG2-2U\$HRG]V3^U<?,VM+HJ
M2[\"U7%B)E"[.RM;B:2U)3D2JEMA4LWZ.1-P]7.8?;G,TN8JDEJR94AI[5/=
MB!7.MFYP82IQ&F(;ZU@-EJY('5H.^X;HM=]L%6)%3$ET;)*L[D0V2,'YBW(R
M^U@5'19G0=$1:\5(G.&DA4[-.2UM:ZLKQ5:*)`L]5PLAYKG4[FHUI_+5/W&K
MI)>T!U>-5:58XBD_DQ1,?LPTI5B<LBBP$,XL%VQN5K)2T>!TEU_7Z5=V_A;5
MJ[#:-KWJW<T!A41<POR.6'/U;6@1-I/8JH\C;W&@DH*#%\4!ES?2<XARA6(_
MJ)"H2Q!!DV@V0R,L1>0C!;F30M2T$3F-52()V5L'1U:9B:PWQ"+FS2")Y">F
M]=:ERSO82,;F.=#\921TX:+O%D9`(AG`+#`E%%/T`I$.DC@FC(O(3CK2*NZ^
M#*8#."<3`Q/`]I5%O@5B5GL6]9,!\'?$6M[R4/YV8P["K5GPB\M+ZNLN'C_,
M:#`&VMJD"5>FY=BLFS))B<QL&Y3$<J-="6R.?YG4#8'F4]=,E+7@%BZPT/2&
MI>(RHQN=*96U6+`"\5YO;U)IB(D-8>6#\5]%_D652F5&,$_N[]^`O)11@ZM$
M.T37JHJ,`/QLYFBNZ9)6NM)+I/BDHE@I3.6DNZ>X.CK86E83C:MX'>GLY#<Z
M0N%:#^:7L3E'HQY"HH5LV-_RR,]6ZIIM1(#K0R`!J73>YE`%P=VC:[763;.E
MDW+8Y]F%3A9F(X2H%GU#0>1DR=,[22-0:B3L?Z\7<RM.L$$`5A?6F,]K!48@
ME&X4P)!$+U1NTN^38>(5U*'%*R3A"'9TV)6U%6YR&B)<"2&'EJYH,W9I(U:O
M#(=<[#BE7]TEK^1>`A/;Z;AP9<E*E,O\%:^X9%(>*Y^<Q`,;UE`F3X'ZW4+0
M5!`.%\5C"A$-\UR'_EZ`8QVIA:$4S(,N78'V2RX`'8E'.BD9O(4ERAX9N+LX
MIW";2UCBUG*(\CQ$0TJ):2-#2Q6:=$F]%D^$P9RAG(61GAD0@Z8B3>G[+DLE
M*,XPAGH,"6I1D-(QV'`F-&K*$T%`1KGF,#0J-T)+T+'=DG.NG9XG'^E$22><
M12GJ`,U4W`_[E^FLXQZJ6Y_U0F#:0NP*IDNFS+MCZ%X]4\8O]\2LE$N_WA?A
M6,F0P"O+IW?LK%B^B:IX&UK?Y#XNUE6>A-&,V[TL:$J0.LM(X@%+PT3F=)/3
M<"%S.OI5XR*HVF`FK4;Y$FL<EOO_.Y9E@$ZNI,O_F<6F\!JK4<Y(!%!+_M`$
M^T1=7DP,I+0*L1!0=I3/LD3=]F`1HT@?1&P@G!P$7_S82#T;2$0-5CQ.`2K%
M-"V04EC7[0'@#"+6[_3)EU6*#>9>5]'56<221]R%U5S'0PQA535&=3F>J;@*
M]$B3+G6$4T3>#9T<5$23;&0/T^R95JR-IB`=L*4$8"P<\#A%>YU/CH4A#:(A
M4NV.G26)M.5>2\`*D,"1>9"6%(&(M9F0`,01='"'@!1%C+2)'OY'N?@&=_P$
M=$A'66B4<CB'B:Q'LNP'`3@'''[A$$W'2@"`&RI%&-G&<S1;&H(B4WDAVR5)
M4P"@5"6)RM@,9V2)8QB$-G4$39`=V46@943>_B0UQ]-A!F=4!)*TC?!!'6&@
M2>X`1Y?(26;\59D\1JCH28Y=7:;((%"8(FZ082A:8]?T!$N(59T!X.KXW,<X
M&4%!U'Q<D5G4TWY4%%W<T(!TQ9)%17OH6#U=%';<R-I=EZA$T_A$6>@U10"I
MC79)$<N5B^S)7#@JBZBP18X-88YEE/SP"P,DBTIL41_U"5^)QLSTGIU0Q$#0
M1(,%DHS!QC6*9._,1++('%NL2EJ,HY,=QD<QDUI@QV#,AV"@TPPBQ&M51OY<
M"?+Q199`B498!$>(#$J88M1)Q+7<GYT,HZL4'OTIG9\HG9Q8AO!`):;$"_!$
M&LQLVO$$&/-TW,\U_E``P.-8*J3BC`]$YIA49,61-1!;8,>B5,5(RJ77],2S
M-8::7$R@Y`Z(K<RM1%!(7B-A")@$#:5,!(K73%)74N3Y`)\N?1#-)%Y'`B9L
M*!TNJEM5@HD$?=-<<N;#T).&=*8=\=1B#1NX..0[*:8FNLLGAF9K+@F_=`PI
MNF9688E!L.%I`=T8%HRE/$PUSN9OEHC5A(<7`B?9S%/PR69MV1P-12.XW&9N
M%6=T#@FD!-]S2J>N*-BSX2`($5U83,W:'$8#:LSIK8K:Q))@E$2HP,<NR==>
M)$QS7F=\&AA,#8Y\>LUF`(MUCDW.F,F5_$HQ@D:BB0@TY5B60`3U8$]1_@"'
M?J9B<MKG@\H$#0T0A*;9^ER*@Y)-;:*-R/%3D7D..BT*.\F/LFA(13&&;"3D
M:SQC\2@FA<KGE_`(:[HHK(#(@EY:'2UH`@@(`:#'A*A3O8&';YS0GH%6<N3A
M3KR(=J2*ZLQHD^J-7IS-&3IID?@8W7U'<X50\TBI4`"?*EV=O\V+K$TIA88,
M_8RIKGQ);LI/J#'HP3SABD[+/1$+1)ZA#D;,F<YHW.`-AN)I<&H32BY&3/Y(
MFKF0U/GE;.F)(H%.N^C%4H`8PK3IE,)G&D:1_"A-GV[*FD:=T2`'3`E(>\R'
M><;.@(Q/N8Q/[$`.46G%Z<490Q9``'0<]#$._MHLAT+JHP[)(^3D4@#0GCKQ
M"0^B"I_V%Z9"J)[F);'FH'0=(!RZA&!"2>Z$1GLYE9U$8Z91T%\"RFQ=B9T$
M37B\BXSR%L*P(+)>YXN(!KB2*XFH4H]$AR2B1W=P")VTQX.H!X,@&P%<AX.P
M1TP*"`^Y!X7`!X`<"(\>B(ZR!W3H(8#P*(/@AZ@`"!.QB*Q)QU($1\*T:+K*
MY5C@1[9@;"GRW"9A&8I""M<H2UKLA#]JC)@@HX85T@A:2T$06&F$B+T0TN%!
MJXY4I?SMR$MTU0D2EJ->;)*,:\?^IDVT;#82K9"D+->-%GGMB5],:N_PCZC]
MT"3QA;8-!65H6M):_DI_@LYE(.=2O`XM3DQN0.FR=(U`]9!O<JUM&%<[4@7[
M?!D-H=H>02E6\<S@@.`9BJFN#&W;^L1(#-'WZ9-WH-D!^8OTL%R&*05X74W4
M5DI#/=)V`BYNH.)$G.A+E0Z(62H?I0M4T-1TY*.O<06<)DFD$BM.@MZ-2B)0
M(*E/;!68$IFV&,4404R.;!&:5:ZVD.QU5.F-0N`[[1'[?*$)95(%Q5`#R(=2
M%)N[H"ZFDFX&O@N#/9!1@0X7)@W'6HK/_NTQD85#W-7N\L;LS,2RE1G+7.H&
M:>^RL$:R-%=(F-;)O*?XMD\T&HTT$N>HY=076JZF?,>6,DGT,(;VTB]N_D3*
M2N08<@3:45"+1FR0?K&$I9Z*].S$]W79\ZH(*A:P[QI3>_D>GQ#*T<SN;C`@
MQ."4EB!M`=]&M@B*5-!4800NG_R5!J'%6#D$8[GO?ZEF4.QO<*DPAZS-[>4-
MAXQ%"K^3*O*EFV7K9!Z%$3M;2`PPV_ZPNA">>MZ%,SV.\"3;\,38R_1$6GS%
M0#A4_C$%``NML&*LQ]C:XV103<C?[)S*0Q0HW@!/6BR&4+[@D9AQY!:*0TWQ
M"C.+8(J%COA*ZI@:,%'=V&Q<Z="=2AS9-(E=&3/I'Y/F[B@4&5F%U>R(NEC1
MFRS6:*D1?-RHC8*1%34'NE)RH5*'=`"?T5'Q_B'61^]<T4]X5H?4$/OX9-5@
M\(JD\KEHR:(&+F,]T1<:$,)-3]X5'!/W+<)<##ZAL0K/5+.2Q:@@Q)<=X+20
M3<8A"EVT[ZSJ#J>\YS,G;1[CD2]7S(B>BZM$&B5:;E%0[KPHAG2),_V*"\_*
M!=00SJ_QL`7KE'$`A=&<A)-Y()W"X#P'R2[CZ9_\LM0X%=@-%#22"DK@B!2#
MDT$K2<7(AO7V\C[+%TP4TA@*SS(G5=`NB9TR\+@L8+/:CU&FVJ'"SV%TF`^)
M=%*0K$6?J3]+I+S$\N5D\5/$\:CUA;#^KU5Z9KFAV$;3C!Q;S3U+8.H,UC[O
M,9$(8%`P$_LX&:AV_L\.+9!05=#QK*GLR%C2?(G_*46"``]"C^E<<(X!J`V<
MC*8&2TIGV-1!X%J;0&X^9L?%)4PS/PE2*\R(*DOPQ+,A5^LU1\PA)TJA2`0_
M549+'%[0!,QB#0[UMICUYHZU'";U<D@$Q0Y*F#0]ZZB&O`QZO#(MBT8#:_%M
M_$9:A,<L)PP<[99?]]N^&>].$,"T&2(6`5<G.UN`_8IUH%M-9-`E<LARD(>H
MB(J/M1O0F`=)P(=OJ)..FE!-:,@)I7+3E4A4'Y5;M,IGR_8CX8=T4=](61H"
M2[%&R\IHG@Q(D1-+,(O8Z/6LR8V9D%U%`,9C=.2V5F2+:01F8(4[/^IW_BM?
M0XV>$W^W(_GQME2S\$BQ?9LNB3`+I[S*.U&+XAQ&X-;UN82HL.AFC#F@<WO%
MC$@%K!X:Y(0%=NA23U"T@&^91T`D7K#X2N`$HS@X)LV/@P;'`<,*577.ZL`A
M2O`J/Q.,_A!$_!@2X"G/J!09E>SE2-P(E$P.0C'Q%*\)98*$8^QBA>G=N8+M
MT(6+0%E8;>[56WD-ED:&=HOO6\18@#+`.DD3L'3N^2293;=@#PO%P66$[9"3
M5)P.J?QST&&M<^;%BA]%@A`OH1/M>8:<=L6<_'Q%#NT<Z?#<Q4!3I8\A/B*D
MS3DZ6A>)_D'N%"-$2>`CVCB2"DV3GW%%%-(5_E!ABUO`4\]0X>S\;9SM$HH0
MQCMW3F)`3D;0>9_J+DDSB6O?KEU4(+S&N,_LR&BA%BKOQG-<+(O46W0,*3:K
M%E6_UH,SC',@1R\#:VYD)O[Q"<YJI@AR2*\+202BS;%3=>+.10;;N0B9,5ZH
M>-0]X1"KQ'R!3C52<)TQBL9Q>]O0ADM^!F6@$,297]QD8"=%V$'B"\=Z-\+$
M3PFKNP11R[!@.]W,-(DPUFU4ZF(SCI3(M)`+!"E^7N"*E01G)25W>S1_G"7A
MA:'!X9K\G=-I6)$Y7G-89&"-S9OV]<2KB\$,G]*^.X1'=9$3&]L<8(`SSV$T
M'4WHK-@L*9SDA:-&_J2C;S1B0X7!!-W3HK%&'XV_;#P8>81-$*_/G_6]QPV.
M:7:"/>],.-!X+O7VJ`8YJ4]^5&WC$5K@NKBCC@H!4[)ZGVMSQKEJYQ287@O@
M>Z9TL(G9<XC!<(?NEDA[!,D.WX:XK%N'V$1W$)YI@D=!$?N--&_SQH9J;Q6G
M8RJBY`X;<D=4RPM7G\O%+TF(E`3B3[P.\EJ2#'WEHSF5I,BKF81)H#/C>Z86
M<TS=/@Z4D`C9D69L[/YQW82.H+K/\R#\?+K8AKT![[+EHU!>9)/P(PU1R'T%
MNXH'*71"/!7%B[5GF_Y!/X1-5)3W;T2@A(R2N/@>DT7U'W\VZBA/O-,:_LL*
M0"!HL(!!`X,'$294N)!A0X</(4:4.)%B18L2$RA(:*!@`XX(%!10:"#!`H0,
M,B)`8`"!R(P)&2@`B9"CP0,)+N9\6(!!@00H->H4.I1H4:-',8HT6$!!`IQ(
M&_1$T%&BS`%4+SIUVJ`DQP`,0#Z%BC`DRP4#&@3E*G#D6+=OX<9UR):L6H-3
MQ1I48)(F5P8&9#;@J?`OW;L'$QR0.S%`@P$'"B#(NYAR9<M0%:A5.7-L1JP0
M0Q(5B3:M`,&"&028#!4LR@2FF>K=FK#Q9=NW<2/TF5"Q0M,)"]R\J,"`<(2_
M&P#(O;#`@HS.5R^7/OVRT@:*>[L5L"#[0\C1_BLZ=7Y=`6SP;JTOY0N9]W6^
MU.''SZG@LV3"L_4BI]@R@0&'^*4#JP$$3+M*O@,1/*HF@_IK"2X#WG,(NJ)*
M>LD`DEH2B:2X6D-()9SV&L"N!%1+T,03$^+L((XF6XTDNR*B[X`%$2(MN?@8
M`"L!Y;A"<2P5$5H-1JX.""HFF&@T$;^KAD3JM?/T6J#)BP";:4.-L(P0O?0$
MTT@JSA0HDDL?R:2.OH02B$RQGT:+$('N)F*+OBD3,$PZI@;`2<0RCVI*(0#3
M&M-/!C,C*\D$`4.,)?\L8@"MS"Y\R2.UZC0(,`$B:TJ\V#R$LK_/.*HI-+W^
M6JPFE`8\4U-&!YR4_L]7IYLJQ0$3R%-$%ZDD,,T+@U+`1AZIZVE`D52"E:A1
MR;)3)OW2*M+2_MZ;TT=A+?4H)YP@"ZE2O>QB-*,"F.))L@5D571*@P08=$69
M-"KN(/KL=$O;X'BR+K+(9"O5V'TO^RPMLNKT%U"(0)*LSLS\'0C*RP1BRT!^
M=1+P74";TO)-Q,1#[$P4![-4)58IHI8YD`7;["#7&#3L@')'2G-CQ#H$UU"Y
M9,K(`)[$TI8XKO0\%^*?C3I`RS$M^XV[^!)+DP`B@;;(IP7>$WJR&0'(RSKG
M7E2J)"T1Q`^GA1O2DR&BA<X./YD9K+JAFYHBN;FG:DTHW<7$FBPDJ*\3_@GM
MIOD^2E+$EA.K8^I&$[OOB0IB>><@!UR`2P$ZVADY($W<<*F:KVT(69HB9UED
MIVQL*['/,MLJWH21TM&@L^@JK"=(L3Y<]J$T=0HH_P3H3]LW<9Y76Q&+7,F`
M/%<>(%+>OTV3H$P'F#O8J9J/*M[9__2)4;`4J.T@M)PW:(#W;M;(7K"E>WDT
MU!^R?*'I;_9/=8#O8I8A`!U7@$<$`$!U*F#?0EFP;:,BG(P4RC[4,^!^0J,I
M=GW*/X#YB>-0]1/Z%$0Q6.K1G!B@&"DA+$<E*1BJX..HU/SD*P=LB&L@Y!%]
M'<0ZH1/9A6[4P.D=2$6`41=%^N,7.ZUD(1>*_@S)5!@HT`!@2"#9$+'8M10.
M)>8@!C/(7W""IX+D,"TS-.$5%>(SN?PM/B$A#DX2A<6-8*Z*$K.6?P@BEN^M
MB%$\\0\7$]0Q1Z4)?0[)#%.`U"'"!*=8:!((&244QNTM#G\]>1T0G42NO)2$
M03/BF4;(%93!B9&2[<'-`N07'^Z(CVMBO,F.&K"=QUTG.>\Y"V*0HYS=^&@\
M"('31'9$@.UHZ6@*40P`.LD5QQ%-(01@Y'%X%DI=^N27<6'B03"Y.@#T9I7'
M/&8EH7F8W!3J0,(B#2*QF,&:&5)=!O-F1X+S1-L1*C-:G,XB79:5-1+&>#UL
M"N6JZ!1S<@6(5QF,_@'2Q1_'D$\H.^P(2DQ"S;A%DZ#OLN)B0M=%E8234]#4
MW5X*14W)8$@K;$GA7=(#Q3J:22P.G,^4&""E/0IDG&BB(T3^<B3=O,XCBJQ3
MK?A94)G>YJ`SM18NB;-1ZF$O3;8K%UC^R""XY<PP-<ME?`S#%"J&)Z$GZZ.A
M.@+/*AHF1T.:$5;.HJ^W?:@`%[7I5Z>CTMLL[D`DT8ICYBD[M)U44F1E4!N?
M`A:0L=1'8!I@3HBWD)).[*DWQ%Y",V,GE+#L+B$IR(N:HI&F2B2@[^I10:@2
M$U5=<"!^LF!:<I0CL)HP-9O=HV,4HSUH@G!E0F607AED'6J>K$Q6(TY:_F'2
M,!)A;RD?<QE(P`4Y$0DR*@W5B_J>N#<6.DH]'YH*+R'B.`2(*`!EB<QQSW*S
MGJZD)7?[V*(:E)%U>I9ZR)5+*P_DDJ>L$IIX4\A1#5A,TZ#7(2+!CN,0\\ET
MO48P\&V.<ICU3`;!]T]_XJ_-#G`3_E9$I#T"T7B^IC"HO<0D#48,U!IL7NX:
MT(RVJ3".V-35F$ZX;V8,ETX9LD(8Q:0G((/1W8Z"EII`2#4SJ2E#PL1A&2/N
M8;:Y(8;3PB80S[AI&7W?6P1P4!G!-I"+>XRP`H``T>)PPSS>[(TM<V'XX,4G
M%;LB-@WJ5FL)I#&"2RE)0&@MX""(4Z6:)%0N_O:0ANUX)V*.XNO$9Y$PL?E0
MXOP+I0K"+C8[^41UIHQ8Y2.3FRUOS\;2,D(B>=*)A8:8J?5(I#;T$:K<L9J=
M*F&C!N+8/$MV-S])\-=(S!,,AA15".-*H4#D&8VDB8>"69E(&N-="=&Y29+Q
MR0#8PLB5G)G/Q@JSA66-&X3M94"%AA4<FVA0=RUEBI?K+62?"+FH^"<]BY5.
M6Z-8D>6"*P"W9LD`P$6?YY*()<M]4F1L!2[`D$0U>O/5DVQ;M6\_!2U*(=;!
M>F01^L8(S**C)ZLLJ]E>_ZPY,R[)`;Z72=D-C)1!XHY8X%0W+=4-.4VFC'Y\
M8IR(,'%KF<9)0*&C_A13)L3!7"DXUPH\/W3]MSMIF@][E]+3,=OK.!H?^,]>
MW#\L+X?*][YB$A.2F?<`E"\W#@J`I**Q@/IVRD\)S(;))^A"UVGG)]3@5&I3
MS&#*6=H/6<"%$$DCVM+SYGPC,E2"C1L-W?6*!=Q(GH`3%"!)"E]!R@L"I,1T
M,XV1O"BMNO>PLF,2RYDM("%-P4]V]B<*#9:3:6Z0%%]V%.7\+9&7RQMWTW?J
MY;1E?V)48D^]RDA&Q2D"F"M3@(M4I^>(L`_1HD"LU\Z2Y;PI_L([2$7R]<`T
MCBQIS^(!=@P2VY_DJ4Z5_+Y\[Q:++R8P?Z0\Q/P<+]"G:J)`_Z1,)-.]_M4Q
M/*R&24E,#\W"\E2J7*LE&("<HG>,/E)KDWD^FM+JOV371;"6/_YR7EF9`<O'
M)2+-'18S:?\.(CNV0S'H)3^N(VF@#/$0A/$&`N9LR3L80I1@B56:@RF.JH*>
M!EW@)/^2:[N\SJL:"4W.2^ON;UK^#B[>SS*@1S%6T%@0B3BX),U.HR]*HZA6
M0ZE,9'!PB\V62B'@;B'L9\].27I<CB%8HEJ>`N].33WTS0.%\,S,#X`0P^U.
M<%I>T"A62#Y(@BD@Y](.R%<6HJDD(]?FBE7`,$1(;ODH0XXD8T\DPL^LA6A&
MJ")>+2IZ0O-.YHU(@E'RQ#4^YB(`2B+&[HEX_@OHO`?9KM!$=@\WV%`NID(R
MH&QVD.O7+$<,:^2)^*=9/D,'$V1C9&+PJH)]6HTAEBQ&%B?U/,2BA*54OH4^
M4C"+N@XB`@8F!N<'8^(1%[%?LK`H`"T^,"0!PR*D+JMO&$YG/&8CR,)&Z((^
MBG``=3$NX/"0Z&PU#(9$"N#Q5K%)/(W$2@>,CB1,P$-8@L</OX_J!!$"\V6,
MG&YO7*,DC&T7+V,2*8/[KHWJ;@O2`"-<\!!B4L/,'(.%ND0EU$(J_$-$2.,U
M&("(\.B5@BP:WZ)C0D(EV*SX>D1#K`D(QW"Y;F)XIB*%\K!9PB8H5*RWBBTL
MD@]^,`+X%")<A*<C_J2D8%I/'LDL-]31-D).:$R"\?`&6ZIF.U;'6`X`OQ(0
M.7Q):/H.OE1);DC)`8,N%G$R/;"%(FR.::XC429.X4P#E\IFWP9".1ZN(=P+
M,O@B.!+#<:IR(IS2Z]9R==*%2\(D=P2,)D]$$>O1_N"BG%)H']$'+'R""?TQ
MQ!:BV0C#T,01'XE%LFYF(0?`VIXH0JHL&?6J%TD/?\02DJZB-M`B3R@R)9L(
M"K,(I#J)(&*"(.CR1/!2**0L6)SB]G(Q(F(",BCS5>(Q0>3*.0Q0,H#ON/("
M$YE#+"2QB<"#)VKS?Z!06%Q&*1KCB](O)]3/*`KR-)4D-76B$0--)L!%_G=X
M;7[P33HI@SZ"+"8X8C3<*.C.A5-6HC?!`S"*,R9FT3Q/"RW`XNML)N7VHTC*
M:5S&T\P&BR,^R=9VI&;R)`"^[H=4T3NGPS'E0N`.)+$DT1/WXT,0!"7"L?DD
MZSEJ3U;`$20J*!1A;\L@ZLLFDD*I+8@LPV9HY1I7IB2T,;@:HH!N;!AQRZ)V
MI@L+S8G^A?C6XB5Z0KMZE#(OI&`&4D=(JO:VYB?\8]5LQ]-^`B@0]$!^(C?L
M,7"X"C4\4S8DHSA98Y-J9;<@9SPS`_BR,Z1(A#A8`ER.RR/JA8[*8R5"PWW<
MM,I8Q#;<2Q+S1&^,"#C0ITE+<47R9%$<1##0_C1IH/(N=(\Y"B*K&D-80&)G
MKO1)P0J\;N-1%^,"3<X$86D!U`8^)#73XH,!ZY$]GN8[D#*4\D(`[0Y4`:=4
M->YK1*I0!T)H,BG`W,.\=!!<:!52CX\ZA0)6*8.B?D(Y3C$\>+4H?/5$+>P5
M&P,O/.*L.D5SPL\R9"_H\B:!T**ZPD)7=[58+T)!<^/+H&;Z>I5!I\GBAH2`
M0E$(]XQ;1Q'V1H.D.K,^PN8JJ@JSJ@I5ZC5'O>1K2N>)I"4Q,A04CQ!$[./K
M\+4DP.U3*%5;"RI:%Z-/@1$E+F0A`Y(H&C5!+>)0[H@X+#+'WN\Y=<YJZN0L
M`@O^&"*2,B1AF6M'_DA$R;;-``+@9I1L*)6,1$*)70!#-5ZK##'%FT@6];ID
M*XB#-&,B4!EVX.QR,<@51VYM>:1J.)9V'IM,%04D$O7*80E#2X?#2*(BL5KS
MSF;E3U8&LJ(61*+62Z(B;2/ON/P%C[@"!'_M:/EL-H5B2G/CC[9"1!9V)(@M
M-[PU1;I3430G7*#R+VZ20M@B47%-(&XE2CU$(4!B$\OG3]'$>M("N$!6;C5W
MXR!R+*3&)8+C<"'"61QQPP0@5^VNOEK$/9JL<R>BEI"I2W*G4_/-E3+W-C2U
M4T7"-`8F:3>7AGY1&J=):]V")&:$(*["=65C.0HU<6#$8+PH.N!0(DK$_C+\
M*C+DB<NPHOC^(@@/)*O4PG&H"'.5]W?S\OM,@GC_0WVS@F[1(R:^9X[V]FJ%
M;05K+^C0HFI:XC-`)V22M2!;<P&2;'-<)<M.!&Q7!S`>9<38U7SSDB.P1B#8
M%SYQ8PL_E?2D9'$[HWP)\6__!$9,#)&\-VO'Z#(2XVU*HJLR*-(V(B\L&$'(
MZA4-0C4R"XH<>%J\L6M+)DF10@X?EH.+@B>,1Y&,%BGH\8$K`FO]->BLD.1@
MQ&Y9XTR+K6K<[0A/)F>.U3:H2%&#J<I*]H9/Q#D*`%-,M4+^94V*`E4W2SQ,
MHR-%E[%`TRTD;")4U;^TY'0IHH[CHCG61">W_A*3DFG,T.78KN,[!@(V?$(N
MP1A%PC?/BJU"_M)3KV6"PP.(+798<.(KLMCU")AFAM6.?#?'`B^4J;5??,)M
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M?UJB#!GJM2!$Q5:"7`#ZS>Y*:@"*7[U6GDIB+UAD@T#DIF662'5YI^'"/G-B
M)P'@:2*$=BTCCM4N:4Y#CX]B`9:F'M^X:!);)S[I1M`XFB77ZS"B1R#,P:1F
M`#V.2Q<L7/V$K7ODO8ZF?IRBHP';KCMLH=ZF"7%C)@D'GGWEA:%"F"NOKN%B
MG^$"8-VH/XC)FUK3B)!YJ[L*`%PV9I/34=[-1KMMN6"V`)H'3VJVJ_0V_AN+
MA[G!I:OJ!9_NU%?4#=?2XGM^Z-U,.YIJIP^GR7W'@IB4(Q*CNK\@$4(:M5)N
MHF!>:J)Z:MUHNJ-]J#G>[91E<[G24WC^&X;F44;R!/O^(AL=I27.E+::=#;N
M2E-R1$HZ*-/ZU5[_*1?)UH((@F@M"";Q,+(N"._JQ$W'.;SE`R6^![O66\U*
M/)?[(TGO]&$?^C3DR:USB">"IU2NKYRTHH9%*L%(TTM2ZI<'@J2T^$)N`OB:
M"WDHJ502MJM-O))X^VF9+ZB+@B"7TTV5EK87$;<F!?M^AY("(ZO[-\J7([/2
MUL+)%D2(#2>,/$M?DV`O,*5R(YR#14,<9J!H_L:\3W`SG$-\FFW%F59\K<?^
M)DTOTGQ6-JB&R>*Q,HO+;TZ,(2-/3A>73"-W,#UWQY@K!^`G,>DQ`BQW3I@[
M(/TB:-ES#R[3"!OMMGF19$J_K-(.0TD`"K``9.DUQMBP(2/`6);6JQL`,`78
MP04`A#W)?_?3P@P>G3'"U6+5^M'9S3E-1.2(MTC0\>I_+,6VH:+4CP^X6!N+
M!#A%LM"P1LULT=REA5RSBA&2_L7:'7BPY,F'%Y3;C0+U-(1C*P.A-=>MB(N@
M.O;L_GFC;29(&]60PJ4L,H0E3.^'JMM69,[,!=&',H*4WP)3J>,CO>0K3CTB
MUOE)FWCC7X6`AQJ6_J9B9;J00U]'GE1((/XY%`-#(R0X@R:EQ8?"RGG:K"96
M2NF]*!*+6'2:,B!V<P'$.BO)Z%;P=B$>:7*'*P^T'D'^*`JN-V*G#1<Y;U>G
MM*D'CZ&1(OPZ+A8[Z0/#HWG.W2TB>94B$+^3YF7L8/+G(&$X+J@ISV3;(>@\
MZ<ODX/-4V&3-YM/'N/^'XGE^YY&V4I1*[>5#>2*CN40%(_C<[F5<Q?@>I0P_
MCW4DMP5?KR8?K#0EJTXY>[(()@X=;1FGP!++)-S<2&NF]GZY4$)%0/`HL1HH
MI6):1YHSUA+G#=-3P!]BL!S?1Q8H+!I?SA(DNUYJ>DW%?`W2<.EU?],%_B''
MF+K^DHCRN[H7RGA>+52*PWI:`C(`]4W*C5?$Y<Y2?"U0'KM2(K!"PVK=35SD
M3J>4N?<;%/9$YC8^>3KPJ#B\B.Q'VGROIS\@!R`2-`C`H('!@PT6(%S(L*'#
MAQ`C2FR(0,$!`P,&)-AHL,!$!0,FBAQ)LJ3)DRA3JEP9<4&"!01<+O#(LJ9-
MFPL4WB0I8*?/GT!%SFQ08.B!!@*#*EVY\4""`Q>?&NPY,>G2JUBS_D3`0(&"
M!0HJ>E600(&!!`80G$V@%@';MVT/($`PP$"!LP;"*M#*T"W?ORJM`F8Z>*77
M!G@7J#5;N'$#!@;`#@@`4B!DD0@<:]Y\U6T`_K1$W:Y%K,!CV9=[4S=(75#A
M7@8;74(N6'@OY]L(&>,>F7GWQ+2KO99UV]OW4K(]-U;\'%8D3>/0HSL.^[1L
MWL8AI3LN8%N[]Y%DYX)T>3;S7@.P5Z_NNI'LWHT%&,17P"!S=:Y<OR:874"Y
M`;P7M<56?P8TH%9_!2"0H%UW)5C`@P_^!V$!`RBHX$`)<%>@@R)UQQ=MWX7H
M&&0OG>;A7\V)R!=9*K9(45CUM1=<@@!LA-%3:LFGEEP$(I5`A92A]U]:82$@
M0&SQ)9C?1JC!5A]23PJT``-4<E5@0?0QX-IAW0G$G4L5ZE52=BZ6::9$U#U%
M7X&%[7?F4L^]669Y_C-UQ=5!)\KYT&4#@,2`1B45I^>@9F9(U*&-Q4EH32\M
MZJ)+3D6FJ*,/>>34D2661!6EG$K'EH+*Y<F78)V>=%VIVKE5E$?<H?K0CT3]
MR```HC[$XFX@NKHH;`@L$-*D?+6JJTD<#6L<DVF516:(KBWTVD%4%D3E8P>A
MQV-_AU%+;:Y(J1>`L>`.AA8"<IW66'KA.L=MNHX-D&M\*F:8X(#RV467?`$H
M&,"#M`8P0(+?%IB71@Y.:%9I)%+F)KL,*V4GE,!JA5[#$,&F$\6-%6N06BHR
M<-23W;T'+4(7&Z@?M2EV]=B47:E<UF/P8BPS2SE5AU;)@)%:$\XM.C5S_L8+
MZ:S=S0`<4(``"S@%55%&"R```/UI]%+14!TIP`%%FW7`U=PE</61!1!P)%0\
M_VQV5;%)ZMBW9Q\4<=M*5820?/$F25]%`BR6UVG#*2@?9&1E"-D"Z/7'UEG<
M)=E5G?T-MB[<-SUK4+14@I7:850*1-]1!7(EVUMD]2EW8X*:O2SD5RE*GXKN
MO3U1@@N-+I+'J.]Z%L%U16;7`6;]J2IW5EI$7%B$P]A?G:?_11G<&M=^G(<'
M"U2Z<>0^F9+U!OE)$EO.+RHYR@G1!N+C#L%V`.$QGCL]QFQVGSI98/G(Y&72
M@=J^J5YFJ&"MY2?O/NIND0O]"N,_BE')=?]C_DE>=%>?N12H@+@A"[HF,BV$
MS,4E<Y%52>Z70,C5S"Q)*UM61$@Q!'90)0HY"M+.EY.]%"6%2)%)64+8%!`*
MY"A**Q%WH)*A!=1(:48SFKQF(C:L/>@I!0CBT<1V-*P1``!/@V+8H.BEI!WM
M:(WBR0EKYQ5R521FXB(4"4=RJBWZQ%VW(]%:V%(:"`T)+3>RBX3^E"'JR"4M
M:OG13`+7%+9H*2]CZ=5L!*88N>U'(=)+"+14QH#EA>4`&G$704HB-#/.C$6=
M(Q]6^,>NA5ER)R])HD#@@Q0E":9EC1I.>KAB(Z2X)W,;$T^29!62N=C2``'"
MBY%N21<*^1)QOLS0_D;Z%"NG<(<^G&1(`@#PR;:!!$$(:PP'*5:12C83)5P9
MP$RJ$Q\`N$MVCSG-D0SPF6J6ABYH$29:$K3-VX'E3WI!"Q]+`Q*BI`=XB%FE
M>O;C%2I91$SLK!#4)CD2E5WS9UTI2D@@B)67-8PV+CSH35AIG;?XZ&`+J8ME
M%C)&SN0QG8@1Y5E@1!*Z251F="J+">/VLWJ>M"9"FHEIW/6@^G!+(]&,5U@$
M\*?)/=!/R^--X/K#%58AI2UI(=RG7B(D6_*N2$6]"QZM^=*_<,0CFQI,46:6
MQ:JJ9%5.@4].&H"TK9+,)5]ID2@OTCA++>!J3"H),WM2E+D^18BL.E]__IP2
MDI[4#"E'6=5!`NO5S?Q'-"9M4S)=I:7U%98D%2'7MY)$5A(I*B\!%!%[OM@`
M=QFH0)1QE]0HIR7UJ.8UJ]N/:M,SEJY\!9FL;5E%G`)5-6$V6X\UB4Y2^QC8
MOL=E_,P2N4+"ML),[*%=S>U)R")*K]B%**(]45*X%Z(_L:FBG86-7?J4SD@^
MQ5<@0<!GV**1@2;@,]ZE$$;2@D4'&4``"J#,9_Z33N*<]V_35&Y'Q/LO!P5`
M0A3Z5P;+HR![$;7`>4R+T3J[G<66"ISZ#513"%)4LIZ3@\)*D7>(N1IFTD0M
MR&L-M0CG%BQ-KEES<TM:'U/!QQT7(MTQ:(3Q_J2>[&EK<M):Y.0B\K(^K30H
MGDP7;F=<DL0E:$T%\F.0A[P137I4,-PAIFK/*TR-W,XLAL(3K1)'-]`.9%VX
ME$\Z`3"K[/8E,P0AR(^)S*BDE2:NC>EHIYK'YI'L50$]B4H(C;F0QAT$--$)
M7&Z&T@"?G86%89O)6V&",_B-DG??/1]#%#*`JR&R6QZI4=!@1=<Z:T5KV=5F
M8XJ;KOQZ.B)@?,R]>OCBU=P)6G3F#&P<>A#X>O8R5&)09.92H5Z5KCV'_4\7
M_\,0K_AJG6X19D6X96R":>_42ED3:#CL.,=VZ@#8@[9(3A>>.N:QS]RJEV](
MM!#Y],Y`O>G::@YW_C?$!$T]>2F*?0S4D*_`!IDF6MV._0D60.I;VS^9]:&L
MC152NVH_=P$X9*%WH29S&UCDODU8ICDK[1G.;Q#:CP/OHW$$W:XI#R+8'_52
MS0<Y59Y2)2IS[6MR)RL<)<Y%'T.OXF`]U<>L+W_=0@J'Y].43E@,\;-F2+0N
M!L!7;@F*E"P%)R1[5K..`KN,P/(Y);$07;5.-ZUK6B;H4;H\YR6Y-ZQFOA2#
M=RJR7P>[06A]U)`LN-6WPO;<YJ69\#Z$S*T2>I!WXL^T%[MDR9VQQF*-<X0<
MA<<N24A.Y!R4I)7J?#Y3^TB0MF[`'F4`3G'\0612J6YES)H^7#2B2DG5_LV#
M12&7/A'J=9*4FB7>($?1W.)C&'N7Q%KR)WG*AOZ&G9J+:"]6_C?N*^9C]#D(
MS]\4E`0A(G3`\/3P#3%Z3TNY=E/'SBOSJM!9CN3C/\E%+79A;AV_Y>QU`I.Y
M>(Q/Z8<O$?8(D.Q*6;^(1GE>]H_)+'D7#Y)*%U2'M'$P9&%]!D%FM#)Z!O)U
M')-OPC$6EK$E8[%NT>)*8Q$X_61LZ^$YGN8FK,4B[\$B6(<>PP$6PR,OY:%-
M?0)_0>%[TC%KR^9W]J=J(/13*L5*N:)A>V)V6.$7,,9,V>%92(&#?=%E=%07
M\(59YV4T$9(@`A`U&8$8Y`1'#P(2(%%I&`%-_G46.L(4'P01;\F2%IVS0,1#
M66OA'A5!..Z6*"XX'>&A&/52(?(W-R_8$8.#'CYF$7U21C8F$1!&<^LW*R9U
M/SX(8_253LC4+2*S'R:F.=N2A^H!(K:1AG'H$!IG*&OV$RC(&>%1(Y,55Y#X
M@NS!)'K1-6)Q2J]6,;"3%;H1$1*4'0GG:J^S.%U4&)T8B3)5:&3E&)'G(DF!
M-%##$8P7B45!?TEC-*6A:#7V5B/QBRRA:1,!`,8(?3XB$?)R>%D6B=\16?36
M:G^!AV_B)6)AC:C&%A>Q-S(12`8``#=RB75T%=3&8UIH$!6R,?)7(![",>#H
M'6Z!/@)X%16T*.-B_H;WJ$P@1!SMDQFEB!)G$3>^YS%L.'H#!!$*4G@WHX(J
M09'6J"209(!_H1@6R2SC$I`005`^DI!,T9%H8H]5@6W9@1$^]1N)A1"T,HL@
M&7_Z\9`;F6J<0ATSV1#%8H:!F!(8(9/E@RTNZ#45=X:/`7]SD423%A)OJ!)"
M:7^)<Q$:N8TFR3K4M9/PZ(B@4A.M>!.YB!E@01/,N(<-$1^FQH):N1EU=4.-
M`17@<D/0"))"QS0X`9>,LDS*:!"^0A0Z\9=SZ1`YP3N"&8QK*4V@LE!7N1)1
MV2+ZTYC0%B<$LI@(@5DPM6(D41H#`8^O@9(041:8J4QH<8F'>1.0L4N:_MDF
ME:@GMD>9I\9AL+*:J$8N*^$WRQ5E!I&0]`%_&K)W0>,QKEEN-S9CTR)B^P8^
M(B,ME>-NF0%I$A0P5?DAP2DB(CB=1%:*4?.4[1<9@=%\F:EQ\(@G\A<?Y-)1
MO:*=%'1JI<%>2Q@A^)<1!/(@^T)?_X(17\0[#**$N)DH#P691`8;',:&I"F)
M"R$7*7$K!T%PY<93V1%4+L5CBX,9Z/F">UD2+H%5L?*6&!.8<2@8D%>A$[%@
M)H&7*.%#B/(<4B$13.-[85F:<2..30<T%(.@UNB#:-6.LR,<^70E+X$^"`$:
M_=$3/[5VO4&2Q38<%I$K*M8;@((4O&F3$I$7_O[IHK9R03%:&#A9:D`7AR^F
M(9`H'`(5?@;!-L_F2@VRF;EI=+V1FCP9?AY1.CV1'1ZR4J)3H<=$I4&A*ADI
MFS:1E0U#@34*(HH3=HZ54.$4,P5`:K3!%0%P,6GQ.$>2;O"5&[S3H(^HE%!:
M%86FH.F)IW@2.)G!IR5%/@?)+HTE?,/G6M5"4MLCDGVV6S=#%+5B*0GJ6(#&
MEX%H=&BZ+"O%7,O%1V@2)67A3YX:.PF6BD&1J0QV20.JGB!B=6&'H]F3FE2"
M>?21I?U17#KB$''B-4%S1[EI&T8*$?1(2>9V8.%4=#82&SBBC9YZ0X=V%:_G
M/&,5AS@7I!4ZKPQ1_H";9Q99]:.9YC:,AZ$P::**Y#8ANHXBP4P,^V;G`RL,
M459>@Q:'5Z_%:D]1$YT[@7W2):J4XB2>&(@\1TE]TH^3PY30@I;E^F<.<GBL
M"F,]]Z,J!8_3M8]RJ)W6DQ1=D2RBLJ6U>K$^Q5S("A2SMBX>RRD3RF9-ZBLO
M.3OM(6JP1BI[9'*6P2N`A4PKE2Q!PU/?TC+9`W^QR!ODXYVY64D0>[%)TI<V
M6YLUI4QMPXV2QZOT%'8'=DK$YBQG`4N$PR:&4TC2"#^QXQ29T4ANXV`"L;8(
M`2Q8!BP^>Q!-RF;*66/#R6(Y]BS8YB1)UAQ851&(>STTNG9)6RI_`J(S_B8L
M'-&L`L<0\E$VAU4MO'I$TIB6/4&FT+*V)\BA#@%!=F%N@EHK-CAC9K%Q%D*'
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M(X%YJV=CH,,75,!F$M6Z3`%B'P*&7>BV((+K+%/,$;B4%AI%L7]6J4EI&V>[
M)S,K5+DK&($#''L"M,3!8)T+<T8WQ:AS>P`W09OYDQ_115U6+>Z&EE^K'$=6
M%:^&GR0E&&O!)CXXM/66*>`1,4;RPX1;;X-\CW13(^1+M"A+,BNL*Y^;<P%J
MM5DQ%[3!.ZQ4;D)I)-8S.JL<?48U$M/KN,""'U-ZD4,1S$I15SQ3O:A">9*7
MHAWA0S%L$YDGLP7,%&PU%2P[$66U/<G1EQX!*9"'*(LV2L7(EZ0;A_&UK4=+
M0>-*I+5SROI5)Z"K_LB:&KGN,6+Z9CXJIC+QU('KL3+T=F_QLR2CE)MKC"$=
ML5*23$;I%,;>UT6?$AJW15N]]<(O]Z:'XA'^FR73<A2J,26L@5H`'3][D1ED
MIF^OI=%R,A>X9X/QYH(!,AD@(0#D1$>-JA%I)E,8$8\$`21&AUD(PCL%<TX(
MEB$WLAI&W1%X8D*`4WBJN!XBK;,M9%I831VH1;8N*CCE,E3C$A8[E"1T832@
M,B]KT37DN;B'$EI$\<X/=LP'9;K5!!X;Y61:8B>3ZA`ZZ"QP6#&9$1D<2";#
MK+J)@R+F6R0G[!'D=X#H+':%YEIE\52!Y(08]%NUA&=RS5@N;4;A.Z;8_CMY
MG9MKI>>N)=$<=40376*SYO;**6%[IDVEEX%M&H)_D'%83=%31`4:?B$:[:%^
M;(3(M6.6`$?7ZRO&NT<@C21]$='708,XY!K81SP0C[A8]7'<Y784@?TDMH1E
MXM$Y]J1F8C9QG5W<ML@TBP9">V4`,3%7'WP^8,-#V\0[/5$C_6'""235"A<G
MYX/?$0$U#?&A/8$T5A.:>QQT2/-6"RQI6AS.")'-#'$4&2P1!"-,DUI7!6!7
M1=U#JX)G,R&B%TL<&I)'VI1'J\.TT-T>/R(P,+)3+8,>O;)%A5W<K3<<!96E
M&Z,;&&5T\C>]>-$50$A]!!9.27$AJCAO:**!_B,V,CL6?;360)O]<NL4R8>"
MB,,A%>2I(YBE(/!U%PY[:/KCS`S3N-HV&WR9Y2/AQ;]IQWX6XR)!*BR);A8L
MJZO!M:X(R1'Q)SF,)CC>Y.6F$'8R/4-6K%-7$#.4U[V5&[U1=!"H2&(NBZPU
MN5=!Q65NH]JU/8]S7J\1DY.3-Y@Q.M5H(+C+,6%VON)J0F2(-M&G*G91+(.S
M62<<=GY<;PKJFV7RVW[3?U@!UR>5BN`UV@"P/EX*M0IMU]R+2]Q:$.1B*%F)
MW="R4$H,<;=C)`^2/8=&Z</GYM!;>H_;$+I^)F@7JAJ;Q8]^4@-D.9P*+;BK
MVZ4%+?Q:/K!&E;D1_JNFW%EBNMS6?I(F^Q#<J;IX""+MP4E1;G^H]YFHMB@#
MOAJSIQ5<#6W(F#W.J-]W5S8O\<T/[A"$U99[)6DRVWF`Y:W2['FH]O`\YC^V
MUQ![M(_KO)-BQGP1(:US`IJ]0EE9H:S0-D'%D^Z30V:2&'%X0ICE%EG-\71Y
M$3^5]RH/I%2/05#?SI/GH:E\O3[TU7ZQ'GU3XO)8KR<'8SCJ5O.,G,CM4R>E
MBL<]:YL[5TDFYH@=(7?]1*ZO43CA!"W6'3!]..&Y@8?.]:!5'W:*`6.2OJJ#
M$F^,L2%:`=.2AZ+*LCT27$`*\.XDL4U<W*88,CI^UO`_*NXJZG_Y8<=9_D+L
M&X-C)K;WE,I)B42@@R+97J,J6O&\8+]YDE105)QD9UG-S2W<3BWJ939D6=OX
M"\N37K[)^:Y,&12%HD\R!+#`H=X0SC@H^'I7?W$DDD=HJV$:)!$3$6Z+@_FC
M+`*BM>>.MVA6T%]H<M8H`ULI1G$_(3]8'+[R,RDX$$E5?:Y6;,38OPP4L9R!
MS0'C!F*4$^<QH0(0#00.'"@@`4$&!PPH,(``08*#"`0:$&!@88(!#`AN1%@@
M@<>'"@I(Y.BP`40&!DX:T-A``4F.'14,.!BS8TP%$!L4<#F0H4V@084.)5K4
MZ%&D294NM9D`)L<$*H/R9%K5ZD:+'A4L@/CT_BK0CU_%CB5;UF74!`)$(AC0
M($#8A0:X-O1*4$!+@3HQ#AA98(`"@3D7%LA9UV;?N`BH0E7Y]J?(EAZ'*F#`
M`/#0`0ML#D`0`._`MF9%CR9=FFR"`T$99`Z*X++ITB(AMET8&K9AV+EU)V7`
M$\&"`KV=,JCX<B-EH`?P$M:M$ZCDW@BD)F@9=6C"G40-I"ZY\W/@Q;O%CR?_
M]0#N!@S0NUQ8GJR"EX2=.C=-T_U]_`T0I"2>?F0#N6C[S#J;`+C,-H$T>HTC
MO%ZS++V--%I`(P868`DH^':R\"`"3UK0)I%.(NJW"%-K2Z()7T--Q/7R<_%%
ML^BS2:KG:H)1*8BZ_MK)*=@6<.U&($E+J;.H4K(NN.$(,L#&$FE*0"2/1G)(
M,0#\PLB`*J.R2"ZV&BI@R0+")$P!A?B:Z:.'O/11L8,,Z"N]UQZZCB<:@Z*(
MH)PP<DN_J$@2"3@&`I@I2$(+K>H`)C?23*CP#!T*N`-XRDQ&T@!P]-)#@5L`
M@(_2RHXG`!;-JTZ"-FW`(*Z8$T!$#ED]B:L%8A4QM8,RH]7#6"$]X`"N1-RJ
MUP8.V*HF2_/BCM'L'EW00L!X,HB`%04ZH*U5.6T44VPOA4A4CA0(`-ELI_KL
MVVO+4F#5<-/5+B4+>U,O`4XI;;'/[W*#Z-B8Y'HR/=OL$RJG!A"TR4B?_H)3
M]V"$8THHT:-Z2WBC'_W+T[2M'K88P)0H*FRP!3(2%$]2[3+)/>:`6E*A!'UJ
M,3V)!)Z1NX7J51BA@2B\^.;<'I(YP9`W^OAB&GD*KERRML,9X3R7W&\_B`!@
M8%\E,>PXOR5-!@XPC%KRMS7`/CQ,6,5<<W/*EP20#KXP=V+((K[DD_-HN,EZ
M&CWUP`7:LOT\HK2LM^,.U[6H#"+L3:&/ZYDR@_.+."8I3X*)1Z%22O9?`4::
M.R(`,W\RI\I\U.]SY21BV&_2DX(,*(>#@MIB00EK.?/1)"\]W!.!PY@ZM2#W
M268V8=S/ZP3:]6^@"__M>BBG/)]]^?P6J-BF_@7PY0C6FP\0/%BNI#^M`&Z9
M)U0SX`CH-<=@)Q=(UHVBO7%7J'CE"7V!B-[(HV*3V]5K[_//K3?\$QR=H/^I
M2R5+FY9Q1).2_NG/1=19"**T!"GX>*4A$?I/D!`@/:%A;3$_4]V#6H.1!"I0
MA'PKV6%4([]TL06!(`F@51RR,['`<(1@R1%J(NB4D;SD,U6KF0&!]))(`7!P
M9ZD9"D&3NI@\I(0S9*)9A&,GU?3L8#IS"'"D(QKJ-/&'#-&24UP#$H9\IF^6
M::%XOB.2XF5'3C^9"%$@PL-N]4V+<Q2+1!((,-1)45WJR6&D]F,68-'113G)
MB8\8XI`"**1#"7H-_AM?Q+LL`@A1/$$.SZYCJ9X11H^"Y*11SB7#3;KK9H.9
M3T/*F!2);+*3.3.20:(2G)`X4B!_;(#P+N60#$F$*B$2"`?!0AF&J7*5!SLE
M('D%%-NI#F<"B-6*>*4]JT!SF.)!R^"B%ZMIO6I^TMJ:MA!UJEWQA#Y[FYY!
MT%60:<9-)]TSC5I0)\.>W`R77U1/"%%ISW26IE%/4HFDS*<?L3DO7-:9%-9@
M8L3`V%%)^,QG0R?20EX"96786A)-?J.W&%*'H0XMBXP"%<95U068W$M7A=3#
ME8.HISI$,0Y5(+)1CN;3(*AK89*`YI#!R$8L$8SI>!*7T-8!ZEL$&<GJ_O)3
M&9H%IH?;DDR'X(@A0O*SF#U-IQRA8L2?/NPO#[E@XZRRF@Q1=3=RS-B3@A,R
MB(1)6`R\8ER>1B:Z[.0AUF')>8:6D_,T9`!N`A`NT1)!G$;*BQ>M9D@D\K2!
MD--P#Q&L>^`I5LC>AT.I"15"W7BJR.JF4=R[WJK.F1>/",M-T4-4:IQEO5J&
M*7C.BQ)F>8(H@Q0R>+RR5.%2$ZOWE>^U+H$5:IR'/ALM$GK<6RM:#&(?]NWV
MLYEE;OX>^ZAX-C<V=IR07'''D,M0IS*=TPQ@)"0B!=52(QRJ264::5(1P>E!
M&JVAJ"@S(8T.:ULY^LM*!I)5F_AI54/DGMA>_M*IALA2N@,F<(&5LK2T$')H
MS))26D$8)C8II@``8)-'!J"0D01`,0'SRZ!H,@`0]V9P?E'M6S3,J;C,Y%PB
MX2*:+")AXU2H9BL+BU+`:F`<:RO'D<7+>"%DL\1&-V4PC8F!$K08RPH30Y;=
M<9/%0^2O.KG`[-P-E*7LJ.<V-,M7KLKBN/SE[TU9-%0&<YG-?&:<H%G-:V9S
MF]T\PBV_6<YS%M+!XFRQ\*K+RG3F<Y_];.`[_UG0@R;T4NH5Z$(/FLR)9G2C
M'?UH2$=:TI.F=*4M?6E,9UK3F^9TISW]:5"'6M2C)G6I37UJ5*=:U:MF=:M=
M_6I8QUK6LZ9UK6U]_FM<YUK7N^9UKWW]:V!+.4^*#7:Q2R<F9"-[JK=)VVY$
M7,R/`$#:TO[2=R8\5&-GVV+3YG:WI>E3:5-3VM\^WP"FG<@)3YM;Z=9VNQ,V
M[0_-9-PNDG!BI<VD`'!*+/`"`+D!1.WTY1O;^FFVNPV>K6D?YMY!XC>3I#U1
M-\X;0].N%Y:,?'",JROA.-FXW+RVZ/0M?"#25G+$^ZTZ@$-%Y$1!:N1>NK-A
M$SL]Y*-ICO:<<51WG",ZCS:U$_6TS4T8145*-P#><A)NIW$E/$E(NHO:\[<P
M*0'YEO;1NU7T+TF\*2F/T$L'HIB0=6;:<:F3:J<U[0"0JC=4GW9%&,26_G.S
MI83JZ38`VH/S6^M\(QVON[KMW>W7]OW>?2=JN/G-[0(0H.[G$WS]XM=X<A\>
MY/<-]T`V=>YN_YW;`I@VOHJ^*\ZO_/'2OORT;51TYQW`[WBOM;D=7W@`A,;I
MWK4XM@]_;XVHONJ(0SR_5L[NIUE<*USQ>4U<7UZ+TXC?T/F\4*B>D:&PF_)V
MAR_;-5\EP%C<G2ZA.DQ<CZ#+VT;W^D9Z[/%$<M;76N\L,WWY+YX>JF<7[009
MOXVHOICE3__O#K>[3Z2-H$"IO("1M@5)-W\C#K2C.8Z0/I>H.KPX/,T+C_9S
M/P#2N=![B@F<-J]PO?2C-;:+/:/C-MM``&E;_JYT(XG#8Q+=*SL"]+\JT;^\
M$+V'^SK1VXEY8P"]LSA_(Q[7FS::^`P&),$7]`FJ^SN!F<"G$98*%,##6Y#C
M:\`65)(:[,!6\\'G(S$F2;?N@<#R$QC=8Q)S0Q`%F,'1VS^"6#F*BY"$XS>O
MX+<=O"JJ\PP8M$&GF1\FY#J!F,`(40SKFP@\+#\.^3^5&T(J?+4B'(K[^Q(Q
MZ<$8)$1I$3T&++^@N4/RR\-*=+UD"Y,UK$$W-#2+.R@!C,0R;,1&@3>?F!80
M6[S1VZ>%NSW!8[)"%+7U8YS&V[C\HS](=,2&F\-='+E*#+U:!,20.SFP$*B8
M6(#0FT-1I,._*T61_BN]$MR5CC/`80Q$:HL4`A"`RN&\-XQ%613`H#B^&JHA
M^7/$8,G%@1M#0F3`7K1$&S&]<:PA85Q"<DM#6JP?!DR^C>!`4MP[D1/"2N1"
M"B2()^0WE_%&69O%!9S"86R4+X2]\UM'`51'_K._*-RZ_HM(<J.Z_V%`=A1$
MS6M&?R0_#5S"@=/#!F@_'+S(!)DKA*Q"<`2+/[S%6QR(AQR(?'-&)*-$_GL<
M,G3!8JDZK-"ZF*A)A#A$9DP0UUN.CC/*E!0YE"RZ4OF_K@%&8JE!BUNVE^PT
MA3P.4P0-,G3*F^PE<%3'G:P?HT2_P!`XA'`][G`])R3*;OE*@A#"270\_H!4
MB,SKQS,4N?L#RM>S.!#DMIH(O\MX&K;<RE7KRJ&,/?KB.J=,-S`TOYKA.@9<
MR2J1BN>#&9][&DQTP0#PC1X\P+';G,-#D&44S"IIRC^<P-,L@`_$0[ISS"?T
M0VJ#S?]#-,7$M&0LBO'C-@)8PD91O$H\%5W4ND@</Y?BMO/YS7-+'V`L06Z<
MC,9C)H@4BMXL/^D)/1N)SGE+I&]*#M$#CLT[IMWT-3>!,-T4#V23(CX*$ZF`
M*2A!ML<"N@4)P-<SBH\PI9V)E*R*/ZC@D/4\3P*-&_R\#(;X2='0/3D4B3\L
M4`BMJJH+D^<;4*(H.A&TT`C=T-F)BO\K*@UE."EDZT8.+5$3/5$435$\4U$6
IG;.;:U$8C5$9G5$:K5$;O5$<S5$=W5$>[5$?_5$@#5(A'5(7"0@``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>f39432a9e3943236.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943236.gif
M1TE&.#EAT`*P`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````T`*P`P`(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQHT,,"BA@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LB5"#QY<RIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#A
MPX@3*U[,N+'CQY`C2YY,N;+ERY@S:][,N;/GSZ!##]4@NG3:#AQ,JU[-.JV'
M"1<ZM(:H(,+LV[AE<@#`6W9NA1@&"(SYN[AQD`UX-SA^\`*``:F92Y^>,$.&
M@Q!X!Z!.,`(``=S#_G,G;G`W[PWB/R``D+Y]>]X`;(O/`&""^\T;R"/L4.&^
M0@&\'=#2`XXYYYM_I7F`'H+8\09>>PD`<""#%+8&7W3B=8"`!14RMR!U`,;7
MG@;L=6A<!QB$%R$`!KAW`04<FM@2!]?)2%<'\-VWWH<VHN0!ACW&-<!Y]RU0
M8I!(8C8D`!3<-V2-248I60;9`;"<>PX`0`!I4G8)68[W/0!`C`)E<(&7:!YF
M)`!`IF<``!YDH`!\!:1IIV!9CHE@`=`!4`"`"7!YYZ!%>:!`BSAM$.">`;S9
M*`/?$2KI4!+TAE.EO.D7G@4!@,=;`7G6%Z6FDQ*%(Y,U52#`DKQ!R1T$_@$\
M)UL'37[`FWQ("EKJ47,F0%-V$'R``7P7B5?`=@=ML$"*/-I(ZJY"T7=D2Y5B
M6("#Z7D``($(;0M`?]"&>Q-O,@T+KD!5`N`JB-,6=`!O!(@K+TW7GKN2E051
M`!^NW%D`0(H'<;#FL_,67%)V$K1$XH0"A5BL>!$@:U`%`"!@\,4J^2NQ2@I8
M;-"UD>+6;+<;#^3O`+&V&=&Z&+=<4*8FK2M`L!_#!W!KKS6D[[D7%+`F``G8
M.Y'*+A=]+9D.03!R0K%R*Q`!-Q/T)F\TIU<`N!&&BC1#!!?M=4%9^OK0;E43
M5$"M!,4JW$`%+/TN;PGWU/5=%3RPG78`;"#`_ID0+?WUWP)-\%Q$`S!P4``>
M$Y2E@!]PX)SAY1$`0-P\Z7J7!P>@YX`$<TI``,@)\`WXZ!I)&Y'@!\UY.-#)
MP;?UW,41=VH!Z8I*^NT:'1W1OP8-._+/\.E)H02L`DC``BSCKOQ#E3KMD`'Q
M&A2``P9)^YP#"*#MGP>L,A#``,DO+WY#PT;_4'+8(?HRN15F?^R0;VH__OP/
M#0E[0;N-3.)!2U;XIK^2XTW4Z$=`ALSI(K1RR+8.`@#+?0!2MG./!AHP-0,,
M*0'R*Z`&$T(Q\`RI;`E)P(.$A8`4&>!*!-&6G^X#P0C%"@"BVZ`,%<*^`"B@
M(103R)R.Y@")<>``_J0!4WI"-(`E!2!\,TRB0*YU)@:(;2':(DT`@I4`ZDGH
M`\ZYP(HL-1"B664"!`C`_99"(@)T0``"H.`3E<C&@ES+8O11(/4*4"<&&*Z!
M'RCB!P1'+((@<2K.$>!4#!7&X+&HC8@\"*8^H"TH,4QQ=1*<Y#@D..L9LDXF
MH8#?:#(U-D7%DL%S7B)'*:W4P/`#F.*=0?PUD#F=J76&#-Y(.J`!#(#LD34Y
M%0`>QA0-!6]8"<C`)D?)QB'9)P&^`@`#=F,?!M9H/;&,YBD[@H$-/`""P;OA
M3O0%LZ5X`&3P\17WB$E.@D"J3L.RU7(PB)!W=5*:L63<1L`IS9Y`D)='_AE6
M\,PH$`Y\#Y?EG!]`_<4>'&'``R$B"*TJL(`0P?.A'`$E`!S`@51ZD28JG*91
M-@!++<7P`Y(;8T!)=U'>G"D`,?+.`SJP@50^5)IG>MM%#1*!`0XD5@%X``8P
M-#7*Z22`[0I*!L0$'P)L;2#R'&DBKT4]!=1JBR^-9@,\H($#4.D#TLK@0;S#
M&VT6!%('H=@A=Y+171+%I<)#2``D(%*97.!,'.#`!C:0`0Q88*9*_4V6MM.`
MZ455FO89`+<((#F*\F:-"'%IX@BB@&861)<Z\4"HA/@3";QP40M9SV)Y0D]#
M'C6OQ]'G!XCZ5]=9!`%GVD#TZH-062Z$1/#9_JQ`&.#3+L)':#-15#0=VQ.@
M*@>'O,%K33Q0`6@>%K3IB54&.OK0">R&2R"+"7N<TS`"A.@!''B``QC@P`_,
MB;(#&4!M;WK<FN@M>`RX0`#-EY,,.*"OP7-`6]\T3)V<*@#I12YW*L4`/L82
MC0:HYH(*<!T,!(`#"A!.?'0[.*X:$H0"87`$!Z*NQ/)&?3)Q,&\@IYX+FP2@
M%C;D`'CK$`1X%2@=N&<"QJO?XN!(`+J$3\D8>\-*89$]!Q!G`[BE3T-2SR`Q
MWBQU$P+>E52`5163V:U&$D@.+T2L\`$B11#@`,3JA`,4_&6+PQ.K#U3)`6?$
MY$'VMQL$=%E?#+SP_EROA1`D%V0`6AU(`/\XR[?Q9@%$XV90.2*X"60)MP7!
M@'$!$`";0H2//F%N\`"]Y=S8#U@"P2P#2<,!8WZ`1+HZ`#BKE@!1"@1X!%E/
M9JFVD@U`=4LT[&H'(@`Z3T.$/G'+4D(Z`-4)8R1"PG5)E2NP@;AVP`,4*&&C
MI9,="M`'K@,85E()LD"#&`!#`U#`%N6Y&]Q:$CWG90@$UR:1#!C``%9."/`F
MQY".IK$"$W`810RP6`!`^(&&'"%'(L"!M@[[:X>,E`6"-:QG'8#;>Q2`!`[`
MK0`4*U0$V<UXP;F`Y"C@?E"F")1!/!`H+[DA@1S`1S_`*3SV394"05_"_F/)
M8HS0"N3VK36_;K+R>^-%<K9J8""#>Q#!^<9?TA(.?<@#GPEI*P":%`ALM:.`
M[G:+-XQ>B$458@'?5O@A%T#A5O>LD/VE$`!>K9U90S(DH],D0@C(@`8V0`$C
MR;LF$FBYRY-B[X\\Z5KVJ?("WOT!'-4(7Q\(0``4Q2]HRN^;AK1SG)EVYZ'!
M9_"#WCI(L@,1""Q;6(1./`1R/1%ME7PFL&58E@:_DK:O_2=B=XF8+D!0AQ1@
M.6@6B%@Q_($\R78X%Y``:5KG:H6T[NP/>>&)!Z)GWKR>(ZUEV08NL("&3P!@
M#OAQ06H=;I"D<R<T5YRM/S\;^B23Z@:Q<5H__O`NR_6X(;H%>$.L1_F"$/3L
M&7#H]#M25:0'6IHM:H#4;>MAE"@*GS9Q3@`:``'MNI#BU&<:`!)S&Q<PG](0
ML"5^1&92N\,;)/80%R(0P1$\O\=GP44`)-9E!>%MO]4<:[420\(3P](ISP%N
MY1>`G_$N%B`FE^=&<.(00[)["3$U8E9BDA81`00JWW5G7J<1'?`_0/58'E<0
M&Q"".`$`CX>"@,-5^I*$!W$`N*<0;<5-K,<0,T<1X\8;XC42'.`='M,!"K`!
M&,`P$E"%_71%.,%>D84`#]"#2J@:NA5S#@%6(@%9$#%T%-%C1$<2UE.`!K%^
M'U`!)V@27(03(#,`_@YE:&^H&ID"*8KX?H-8/T3"2``8:;S!>:FV82:14>93
M5F"#?3I1*4G7$N_2`!@B5J"A((N8$.NQ`(*C=@P$BQL!05<25PWQ-FKX$-]E
MAB'18XZ547]8>SMQ>CFA@:$&BJOX$W[H%8(3`(+#BP8!*6%T-94($0<($>:!
MC`E!4#,V$K`T(4/R48KB>2T11T?H2<RFC<FX$Q,@BUVA0E7R$.X5`>F"B0VA
M(/"A4_5%$&\SBM4!'_O8$?#A9#&'`!.B>#\Q+-#($E6R``K0``X`('2WCCZQ
M?6,Q)`]@))&(57A'$1S@=/E(9P*!``3@``%Y$"!CCQKQ+@+020G7`/93_B8@
MXXXX(0"?-1,.8``@$P!G4HT4B1$<<"`7$(9]$2$'X"\/Z!!1V!!\HGY1AD5O
M(HP9(%D^DQ&MTWP;X0%^=R8ADB(:`$VHYDN']Q,>P`!#HI(^LA<>X),4,BP_
MADT3.1>BI243P0!QB1"]%TUB1A\8(@$[A@$2I7P1\3,A00&2(W!=I&<%0``;
MT`%K@TT71U;TIB7>HTSD&!)^9I<#(2:/B!94A29#DB+OX@!$U1<`<BIN6!%/
MMQ`;H`$54&L.F!K92!#Z\EZ&M!Y#,@`@XY'PD9J[<P&GV`#!P2K%D@"=A7\Z
MD1PTDQW@8Q-:=P`XY9L_.1'7\FON)A!&N!?K_F%+0$,X,@@V"[`B&#A9H@1-
M`M!I#P"2+,([OD(`0S814T.0&3$!1W8@8E4!>8D`=@8O)SD3`X`KES@N):*%
M$'"9T]D02&>,QJ@7CU-Z#_$`"B@0_)$<"#`!M3D0_E5;:!5-W.(`!W`!*4(!
M#$``"*"*$?%=$1H17PD?KL0J!4`:&#!9AK2,.B%"2%4Q&_D1YF&)!VH2L+0V
M1C)_>9%OZC@0"1`C%O$=#S`UZQ$]0(>A?31RTC1Y&-(Z!2`!T'0`,!<1#J81
M1A),&_!L#;!O!1!@ZV-(:(D3!B`HK=6?(E%6O$%1!"",/9H1&L``=*H7`,)-
M(CD<^,4`3ODM%)8:_A$2$Q$R`!N">^I70FH'07R4'1V`(@%`DT0('S2:$((6
M?0S!G<'3@CWQ@P5P0QNP@BG*$ED(-W4:,Q&0``:*%ED"D72I$+^6>(:$8:CF
M78B8`#?T`/[R2!K@:Q.#50S@7@K``;SV`040'>E&.(4G$5GB4\9::!/FF/^5
M%*UC9TLY(V,7E+]F`6R9JA$A`2!3@WHQ+%?*/BD4J1<0J-IQ61ZG*!_R.+7Z
M$)(#0>!A`(XE`"5*$:VSD`?Q`,&"CBNJ3##$)!L`F;'4F3^1CQ>P`8O9JN!*
M%!,P`9#YK6]Q*OKD&VN9E[=9`,0!0;%"1\&5`9)S6=]SEJR91@)P+0KP_@`%
M`*B?(Z&3^`'(F1!7Z!!#=TUY`Q\"8!L%8`$2%CQ-`C(W!+$9D*,4L5WD42FY
M&+%2@60D^X)78:(G05]&XE3OE$T*8)-I-@$/P(85$RMK`@$+\+%35!X<<'QA
M4U1=1%I1RI$?AZX*<0%#<A'[TT#UBE0<LH/P,A`9I;!#\6).>Q46P`#0&3P6
M>Q14:Q+>,:S2]++(DQ`Q(0`,$`'QD@!6>@#XIR@.T$QQ<JH&H!\:X!T&T(:`
M"2050*X,`3)_-'/GPB'/H@`24#M;>(P5\Q3.`;B#VQ06T$E""A5NNA&[L:L3
M)8%RFQ`#<`"HD6Y:*``<\*NA1@"P>F'1)`#)_C,L#7``.HD0"."/!K$F="H!
M\D,@V%40&N``G<5BUJ.[0N$`I;J[4?%K6TH5$!L1IS(<!#&`'-28`+(D$#`!
MRZ4?WO9`KN@<`O`NDJ-3R;,!E^4`A20`GM97$D%0>X8B%.`!E&,!`+*JAD.E
MZ_I@(':S3$$BWPF_3#$!0BHF@"$Y#A2:8`,!,AH@!H!+WC%_&`0U.V40YYN/
M'2`X,/PML2JA((-N`@!F"L0;2(,I0T(Q&Y`N-,,>`J"'RE&)-?P4^FG"4:%;
MZX*^@'$M$#9)HX5&L41EC;D0Y&:^T^,;HUJX+Y1L'P(>!&"76IA"#+`@%V"X
ME-L0*Q(C%Q`K$1`3_CU3*1!@`,X[$!+U'-(Y%6,U7*B1'UAL>+SS(P+A'8`A
M.(@5`9!R`.N1)^*E`8G\`0WP>I)C&]*B=P[@0!%I*]8E)GDJ$+'BAFLB`!4`
M*;M'`$<V,F[K>V,1(<$;40]UDX\\:^SS)B$GM5_A9Y^\$/<K5Q3PLKMT`)K&
M``W0I]VR+K`E;>QQ4=I"250SK'T:(9UI231"$!A@&^R!CJBTG[M4OTQ1N]3"
M`,GG?B^2S&&A-%UR*A+`1RL6,E]Q>_O1=KIT+7V%`9!B&_6[F@.1R6*K$"HL
M@0H`J!!!,3T8(CYE8`)$91`@B(H6=F>1?#5!S':1N/?120-@77[2RE4!_F7/
M`A,1X0$1(JX:\,`HEQ$(+1!5UK]#4G*".A`>R@#>2Q`:,#=$=4,)P`$T2#V5
M)A"U5G1I,;,N823!#!+LK!39^-,(.B3N!+(PUA$(@'O6XRO9L=5^U"X>@%]8
MB1`5\(@4_`%%2-"ZXBMY2:E?$<4BK1$2,+M#'9X,,-5.:T=`[80GP=<0P0!T
MY%`HW1"+DR,$(`%&DJ8+82`&0515`RD^)2(%P=CORS\E7'<VLQM/B&0>RQ8)
MP$\K(<6&A+3PFXUCH@'?)1-GC!(04$BQU+0481M&;44T>YT<02*NHG"#0\Y;
MIR^/]#;L.UOR21!+0B#V8MHSK19O(MA1?2_L_B%AW"43.942?(LW\,'.<51"
M!)(`".`=C-D1#%"BX6EF68(``R"8=7>:FC9UU(R_"[$F'D,]&5!KQ;W+J"*Y
M(R$!=1W=D?8@[W*7)P&1*7%M;.-^&U$ISC@FL?3??WB)8P@\$/9E",%1R1P;
M"8%P'Q`!"Q!`*P(N$*X5V:'-^>T08M5,WR77`&Z)%7!&5J(!#^"I)($Z*L$R
M^L3>$A$39F>NW_$N`7#6E:?#NUD>W5D116XR+5C30&VIEE@?A!83/UB\;[%C
M.T[3$10G^MOB#/%0],P1J3<3UL,1G1H??XP2+W(H*V00`60`S>+25.-<V)2M
MR,@JOJ4WL@%!+GOB_EYA)&W7RP.!(U8F:EQ./E\^$CE$$]E8W(RF','!YQ(A
M,&U.F.97(A&"I#>U(@*`4E5",/ZJ:.RU'G&CKV^Q'E8-?&L^$+H%W;O;`0WP
M<"XQ+*C-$5.3E'Z[EDO2M(:I$I628XX%'ZQ'`+C20;YQ*A8P)^1ACA,12`90
MAC2C`2N&+(+SHF_A'9<*$H$T,Q400*=>Z&Q=`14T$^B<8;J<?1/06?Q,FT6Z
M$8IB.49MZ@1!,0RSG1]@F)7"9F83;A9PJ>8AF-B4/0$:%QJ`?^6<`/Z*$6#D
M(*KK<JP.10X0`4C6\/0*Z1^A0MRFKNR*.$QN*YL-$@U7$!X`\=U)'%1>_A#9
M89+QXBB\]-LC1ZEO<R8$%7>H.A<4H)L.8`$4`&4VYNW)<O`@H7[90=L1/<,4
MT5@VX3KG%4T/O0"R,0!F:)8IP0#?R>!<XMD(T;O(0@`UO]-R>'5RS4>$7+QG
M@I!R`:'!XUP#X?,0X0$-P`#%AP$)X'B$3/%8O&J#]M-S(P!"OQ!67A,O94</
M:-D$0;<7<-@9\2X'L46R@0#''>\$X$]&$C6*XE@[BG&N1<RS_A7D01KZP2G.
M!T\#T.U<+J+P,0``B+U>I$P/0546D"6/7Q.PN0!V=%'ZTBPX(ALFZ$>.W>4.
M--K@K"T@%J/?I<&"1&%K@R,$(%*6%"&-SQ<]_E,240;HA:X!&0!&>,5@SY(<
MMEX0&A:!,Z%+"#!5#I$E((28M@0!W2]D"_"R$N%GU1,`UV(=0551T+3>&%`K
M:Y*_MD$Q:C];,@80#C1\(%C0X$&$"14N9-C0X4.($1-NV"#18@,`&2QNY-C1
MXT>0(46.)%G2Y,F$#P"L5`C`PL(.*E?.G'D`I<4`*U]*S+!R0(8-&@`D.'C!
MPX<#*XE2*+#R0`(`$BRJ3$@3``:"'2XH2`I`08.=!CNLY%`P08">#R1RH*G@
MYENX)X^B=##3@@<.&BK&Y=O7[U^^&3H`)EQ2P<H+"1DX*.BA@H7#5@$(2'`@
M;&&$`U9"X%BAZ\H&_@N]3I!08/''"P`2"I`P<P+&E90I,'R``,#<#P\X<S0P
M,P!FX(0=$#C94_),C<&5+V<.5P/NYM$5"CA0`'K!`0TP1#@^<[=T@A!B>[R>
M<&R!!0>2%WR]4?4'#P,Q5%@9@,+,!UC-.Z[`@*9-@C"22J'R"MJ`ILO`4]"B
MU`8SR0,+'*B@@PX\Z("!!1)<<$,.._2PN:X82"@UR0H8(``$$/!PIIOPL@T"
M`0"HX""A9I,(``>XRPD`"C:`BB$+(,C`@*9F,@`!`@`HP*`#(-!@O:(F4$BS
ME6;\\$J$$+`22RZ[]/++#XT#(`*$H(H--@D6P-&`%5>R420.*(J,IKT._C*`
M3(ERO$!*#/3+"4^"+N#@R")7LHW%#R`P@+B"%J"2T8-:4\@!!,0K$,SH+CA0
M2I1*DV""""!XP($'RKH44U13514\`@B`X,T.,`#@`0M6$A&`)!EH#=`-(^,T
M)%F/R\F"">HDR-6//'@O1@`,X$`\`%#,B8`!)ICL`S4I&*RU!@"URD&#E-W2
M(`78O&I5Z9353(.O3HI@1\D&\O)4=.NUE[!:%RB6`#5QG'4F`@(H8#`H.1P+
M`!5%\F^FKQQ(H``!Q$OPOH)Q:C8!!A@XL0(*'E[``ZA"N^N#`1;XX#TSYY*@
MHI7T.^A:A!X0X&1>[V4.`P(2<`LEZ``8P$MC_FT6>FB^[CLN.X'`)4B`7SOT
M:20Q0ROH/*D/"J!FB));H`#;+JB@`0,.L"V"T*X3[P.AP@-`WH)J71LAH313
M^@.VV%J2Z.8\R("`N4^*]N:(Z,6;N:#K[9NC`P$0,21F-Z,()@`*7W"FPSFR
MRR`QORM(`+8APL"_A1'&J"N(`]"\(%EG&XL@!2J=.R>U#F*`S23?7#J"'P=O
M[H'*1ZKKY^6,TGU5P3$M2Z1@`P@-@P<&M$B#`#QHFJ'>CN_03*P[.G1<!03@
MRGKL8F_H\Z]\HBG)*AWR"KNRW.8U<>#;YI$@:P$X@($)Q"/`-I>'#PZ!BG$D
M=%910._\=T`$+D=9_E:965P80)0/'>QN(9&)\^#S`2TEAB`8Z!=C%'*!!FB@
M2,Q*P`5"1IS6G(LA"8`@01B0L%KQ2EV_,<B8#H(!VP1@`!"8@%!VED#,2,"`
M$.'``9ZB@`4PH`&G`V(3G0@8#W#'*B:+RP`DUQ$'`.@D5"K>0X(%J6/1Y`&:
MX>'<7G*B:"G%*S&2EP`R1!P`<*!^'D1(K6ZXK*$<!#9U4A-$!A"_)_IE`"T\
M28P">4A$GF1AA/0+=\!''@5TD2/]>F1'@O6>1JU$>LTR%H4T8`"!Q6@`0HE*
M!BAP&`T>)B\3P("\C+8`\,GJ=,HB")4TM[!4R@@BMI%D(C>R@0HT10/B_MLB
M)GUY3&1&Q'Y#?,OLKD0?`%`Q)#/I'%L&P)@<$60N`JB+`%Z$H(&Q924#$0HH
M_V40"N0$`<?+8V:TB0`#`+(".B1`!6QCNX:DQH+)](C#`#"!&(T+)4WI)3_K
MQ4&#=HD!&MI0XB8(DB(Q$@&QZ\#/.+##:#$-?6M;(MO\\P$!+$DF2K+A02H*
M@`901R'H41L83T8GBS0KH1QA'L-0PH%/Q4D#&JA5`V=ZP$K^="$,:`IEB$2`
MJKWE/LQL#K,*NA"9N+19T83`!1!0+<D<P`!,E)5&"L`9^A`49$'M0&^B4LF>
M$,0V@%26B@+H$,T(52)JNJ)(ZG<<E\I5KT\T_JM9=:A)OF"$J<N)C$`[(B;N
M'8=9K])@2ZIF);;0,(G3R0")F(A)!`0`C`)@4T>@TMB]+L0#HX4+!S9:GP#\
M,+2K32!+/F``*B;EJ1SIB6$7-,>1%&EQ!$F<QA[P@`(T!;0KU>+)!D(BM4@J
M2PG[P!QQ@U*"M.:A=?$(6Y+*6H0L%;O;Y:Y#Q'DL`0PF2;/="'?PR:&GB81$
M+NW``A;0DU89H'6V+4AKE!;/YJ[$+1M`0.?R>Y`-."`G#D@,?8XRGAIVEB,$
M\&EW"^(S!T=8PO#I#EGXTI2Z@@=1(1$30KA#@*9D`"OULRU;B/F!#'"*.P^6
M)D%FI1`,Q(@S[Y%)_M-ZXY&F,'2[Y-U(!Q#`XPD'>4,BULL&.%`ATO*32N>E
M[88+8E8E3F"W,CG=`!X:W=M\@`$!`%!F#9*`!B?DDNPTY@<JD->(B$>U$3X`
M(%%R&"''F6A`WD@&).!?#BULMR"9"3[I<QAH14HI9?DH0I25F,C,9@(T-',<
M&1(!#'@@,5(;Y\OV>2-&<]<#%1'*]$Z"$3F'.E7UDP`$<B(`)I_D/DS<D-NN
M[)%#,;<@&DB2!J!RZ2`=($DZ%H`&V_R;U&0E(PP9R_$*P`&L=(4"/AR61W(2
MYP$,MB/*%76UN<2=SP@@1K)^RP30C-Z59&\CXLPT01(P3S+9L26;20A+_C]P
M-1IF0"VX<HAMMDP3-)[Z`CG!<T0.--SNUN7$)J&*M0WN(;8T$&8FZ@L&#$#G
MN,0)Q7.*%@(BP(!1'2#5#&&60*%)0Q4>!`$FNT",KGNR&2U,V`R?B`:TG5&?
M(:`N#%8-9>[6DWX_1%E[=G"M^G>2LR5P`Q`_.+H.!$%ZYR;+?!GV0N@+%YP%
M`%X5MLH`###PA41FX`O#2LCEA\YP6^]J+L81VF8R`-46,8W^$=@?!^FS6C&@
M+%'YP+XWKCX%1W@#$0@J259<=,"#1YP&,%,!S/KTDMSG5(KS2V8;1W7(HZ@!
M258(M(H;*$8C0$/_C)G)CS(`_=Q'@P7`2D4P_A(`_T"`.Q6034TRPACN/`!]
MB?9(`KZ]735YFD$+:0W1`_][D53']I]:P-5AV1</..!P]7MU28()^1CMKUD.
M&`Z(CT1U#05E`Y_)3$ZDQ,*#&!+&28K1DCI@^SU/8-7^FL!A;,>!!#P+.M-J
M`&P`P&J(J$G:/SW0Y$%R*FOQ/>`;P%3)@`+YI`$(,Y'P``@P$P:*$;6H$)W#
M@`T@$:LH``V(DPTP&JLHC_'HB3HY``$0'`^@@*V1BKHX%V9Q(^^0"%FAB@)`
MGQ9["&#2,R'+`#<S">TB0![$#)#1O;BH%?P#NC3JCL6!N`N@$JIKG.M:()19
M'/$PH"+1"`5@E%II_IZ5""[7V(BDP`B:R[!PR0`'Z*N/D;.20@GZ`,,>7$.2
M,!')^+FW6`"!60@(H*./Z("I\PFF&2T!-`C6.XX(.*Z5<"D/@!C5N``(V!G.
M@QP.>`EF40L%N(_(&`!JT:6-,!J`:XA^L1_>$359L4.34#<V',6;2))*H0`+
MD(#1\8OZ6PBC40LZ<QM<60DU'`FUHXDW,2N`ZXW04("?V1^&*,%F28H"4``,
MR`#_J`M%L;(9R;F'Z("W$BV$`3R,J$6."#92S$:3@)D:*C?GT+&>F("K`PEQ
MRL2&V\0`H*)^,2QF(8@=&8CK&+H*,`"WR0`%:)T/:(I#`0`*"0[Z:*()_D`\
ME#@`<0N))-1&A!R)E;`@H_D+3=FI"["`"OB5&7/&B$@`;BN,2^(DW3H(MD``
MGXH`"W@`#6``F]BIUHB1!0BIWDB2(BF7!1A"P'`4_QDM#:"2>QF2A,22(Y.K
M%"H9C%P)K).+SZ")Y2F+II`("40(.62.LCJ.O".(!X"2'TH*)?2)`,`*\FL=
MF0R.5KD7#8C(#;@KR5@`!2BA?DP(TI*X/HE(##"*"[B`#`C+"8A(CB$-"=`,
M.!0M^."`OANM"G&`YMM)PHR(?8P6@:2@`0"9V)``"8B_`:``D*P/(W(0\<@)
MVVJG@["6Z(`FJP`X:LN938R)>$J`O?P0`?!&_L*(@&B,B(V,O#R$/-F<S21I
ME01\O-GL#M4L3-ZTB`!["VA)DIP`GX.AL'E3DL-D,O_HF[%H3<!X2IJPH&%*
MGX]+D@0`0B^QC0KH0Q]LI46C.ALI0030F21J@-^*@%&A@,>X``I`Q:"(@`A`
MQ0ZP@`LXQB*CD*,0``;`(:FC1,,3&R1:@`8@%=63@/9<SPK(@`HX1@RP@/DX
MS=Z,4(=(RIN@CYR0`+Y#B'_+2P>4C.Q1"32S.O`HRJL1E<C8-P7`08>#)R7)
M04S91#0ZN7DIB*]Y`.[@.;[0&^Z4T$/:4599.I08"DI$B&!Q0`:0HID@"@=0
MP-SPQ1SL(_`8*<G@_H"V\AE*9!8#N#LPN8\=\M%`NC\@ZCL>!0ESK)?Q>@L2
M\<;4`TDN2Q2=L!!M>IN#(("RD$,HZ0DQ!8Z\I,0-T(BMT(!W2:.MB@"O$9K[
M2$SLJHL9')[]&U,@FH`3B<U&M8AX*K,/.!#Q`*Z*8RBZ\T/,T@D+")).!0\,
MN,>H0"F$`1F3&QSQ0%36L@#_6%1'G=7$\YFP00`%V!%&,HG(8E*:<(`,Z#6%
M:(`KLQ^#X`"*$P`(Q8S#:(`_\1=>2I3=-!P`*-/MFLB9\`]KI%5N)<=)W8B%
MB<H/F).*J)6@"KIC<=$.D14"P`"K6P`)<!@/\"DOC8ZGN"`)\P!S>H#4_AC,
M;OW7+Q$G#9%%M:B5-2,(MI`7J0.3""B`#4B2#`@5HG`6%[-659D?(5,*NHF*
M":A7@/U8OK@J)BV2WW`XT4@`"\B);4V7R2B``UB`@)F)A%F`C*R7?X2V^-D>
MD-U9+\F)`0`X64Q")2F0A:E9+'&;!;!0E$J1VV@-"HA,0YU6[DH;A'4MGKW:
M#VF`),&Z2)T,6IR(!EA9!2DG34J`,9**`:@5,7'.+SFE8[6`(N$;[*(`+0(;
MSL):O.T0-;F,79&`JVJ6^[!(59&B`,#(JQL3!CNSIAB`/&58`BA!!S2`"U"3
M@[V2HX@`CY7&&>F`?_S6O/U<N,B))3$O@*%%_LQE`+9%E0.H0I)Z*<D@`!U+
M%5*:C`90F@`05YY4$E<M":O`+]`%V`YHW.#!$0S@,LI)6G:B4[R)C!VQ%BE3
M$L,;G*7,#'_U$`M`*LPHU>\(FX+\7;R%@&4]"?39D;,L'/H0WE3QF0YM&43B
M#K%M#@ZPV+_X6N^MWT\$#*Y@H09HW($AF@G0JJ%8(F2Z#^P,K=RI7^]-#5"4
MCG))73#!PXF2541Z,0F3*03^W?O=D+6)77OA1WZBEGP=B\R]X!X4BNX%CKEH
MI>$A*GYJ#0?^*5D981+FP5%5$"?#&PH^IM8H8+T*%L^=X=YD/.G@7-@X-O])
MC?!-(*&X/.PZ$'4%_F*`W93FV``+<$#YM1G_$-S@.#)"%<<?AHC4K.#MA&*\
M79_E,))E>R+Q\#^U!([#D`#\.8SF@0O_0-^?N@HM)N,Q'8L%+HRF0R0*<,D&
M38SXT-*;R)"T!;!H.HA-&XG[N#366F0]YMFQ8.+"B"1DVIOC*(Q26R$Y?1`+
M-@G+$`M#!A,1.^%)'M-!+&4>9`L#Z-C"Z$ILL52%I&6YX&!4(2493F6#PP#;
MJPG'Q&64>))DLA99]@@*P("`3`@'M@V44(DK_JGAY&6>I>(&4,*7A>2;\$LJ
M]26,&$HRU8ZAF!4Y`I<&V-6ALF.)H`\972V5I68LR6-$F@!Z5D(!W64!_D%8
M?4X@:TGB\?&SE0!%$GD)95%GALA`CTBZ[G(CHX5G1,*`+UZ.#$BI+#P`!\C<
MT+F:]/(?H8AFAA!#W*@5;?Z`6IF0ADX(#4#%WTH`<#'6BV!IJ^4N279H[]T`
M!2@4^WG?B%B/"8`*5EX5_?2(![`)5K(`J6&+/C:(U$``'%6,J;(*EX%2B.#`
M"'`_!W,`!0!GFL[;"*C4E1`,G5:F%TZ58NNG&>.1A!$`K2Z(U)!@I@@NU#M,
MD'RHHX.(NI`*%I[&A<[AK29AK>C0QU`U(=:=^UAG@S`1/(D3U1"PB+BF=6.6
MT`$]:!$?MD!EI9.7M`FN60OK)\+4OIYD!_V,_J_@X8@X5/]Y``G.K@L@``>`
MI04B"E7<`,X@@)]^G-40@(WZ``QX$Y60M0#@E,^I`#Q+PQHJM6K-BHAN(B7Z
M;%[VRTTD@#L)"34Q:$S)4HA@`):9D=:(R<G8+>$)B:3HK[<Z-\SY*ZMHFM02
M.0'0C,4,N':&Y^3^6(?#-X_6(^C2':]#B#C!#5GZ@`2`@*/HG`UX;XN`1H8P
M3S#E+6I"6&A)#D<SB,0)-\S8P!1%E;AB;KK992[Q`'\&RW..$7I:68P@<*.C
M9;R(@$-Y*+W8B`0]B0AO#,HY")4(BN93PA_Z[H+H9L&>:2^!'EO&\$32\`6A
M`.`:7P?`4'I)P:D3_I)[H25T@I:F6!AA+@@8R8K$Z!?2W@CT,0A2`C@IFD$&
MI(G?,(!MTP`/VK8+,`!YGNJ5R'(.P60@CW,-D++&68`20@B=V`!E?@Q`+8#K
M[."YA``UB9$$.)%"N;2A-H^9@18(ZHVQ?H@=D9VR0XC:TB9'Z8X9&;H-B!&@
MJ``C(Y7ZUL0V1Y76WMTXY^4*M+\CD1=^68AB[)A5\0_.H@DDF8E=08B#"8!^
MDXD/.)B9,'4P=@F#,,7I,`W<O,#&B!5/#]Z@@+\U=XA^&>FLQ=A3KW:#&".G
M6(G!*(^$C:*?WA!9*0`.[`I^"]Z$*&P,.!T*05(E<="WL`TP0A0*L8"B_CR:
MKJXP@)*,*0_V,P23!'AT:P>\^+Z)RZP/'`$?8LWQ4(_2(NG7=O)@TQHX!;B`
M3L8+#BB4`O`:@-\(!:@+MEE0'C$KJB-(3O%U8!6QB"V]HZ@([DQ!R\X?F<D8
M^8HT*M4`B":,#C`RO!`QNQ0,O\Q`G@_5B:R`"#"R)]&`^03V@$\FZ@8,V)7*
MZQO$)_GDNDN5`_&>*LSX0,$DO5;+#G4`^@0,&1$`@NX`"8A-R>"F\Z(2.*P0
M;GZ2MY1("B"-4'F`^C/&AIB+J-J@!JV4[80*G-9-,2=(B]<+B`G5N<=047&`
M!F"`>S1<(H&GIB``*/&`:[[*W%R)L+&*F(6P_J7/6PG(Q$9L'&Z"972!EC+#
M6`AXM0T('92U@(&W"`KD``ZDN@'`W%-10K3/?)HX*FIY.9H(?-X??N*7S1@!
M?GB1.N\8`%P=DZ$0&)50D]-;"71<1*&*_<]_"Z@P?860.M(/`";EDMGE:YQ+
M%)-A@`MP`"5$_PZ'"^&W"HPSLH<H?OJO_[2OS2*T?_T/-S&*%JD#"`,`"`!`
MD`!``0`*`QAHH+"``00*+WRH:/$BQHP:-W+LZ/$CR)`5.8@L:?(DRI0J5[)L
MZ?)E20\``B@$0#$C!@`6-3BH*:```IA"/RK4L"#H10\>/E!`0%-A1`E#62:L
M:17A`9,<!%SMZO6K_M<``@9PK;H0@8"T`PA`/(!`@8(##1P\($!`PM(/>?52
M*##`K<298`<3[EHAP8<&`B(`2/#4+`*!"B<H?)"T(@8#`C1,[>Q9I87/HD>3
M+FWZ]$7.&B0L`-#@0P>+&P!LT*B!JU4*L&4C11UR@H$/`C!<1'!APVJK>WU[
M/-AU0(&4&"9(F$#!0H,%#1H\@%#WP8,)=`O0I-"!0X0)%49>\)#A,O,.U2M4
MN'`A`X,&$")$D&#!0GWW9;"!!1#<1X$&&G"PP08+QK91!DMUT$%>&Q!7$0`7
M8@3!``.\QQR(0I$4(HDEFGAB2Q%8=I%D!RS%`0#+710!<1$L8!8!%>2D_I``
M,IYXP5,`,/`!!X'5M``&#_A8&@$?76!5`1CHAB*557)D`6(:2<"5AE9Z^268
M88J)V@1=5K0:36OIM%$!'U9T00042'95`C>A^*1"$`"@`4(TF?AAAAMQP($#
M'5@%P0<29#4FH[Y15EM&"AVP0*.56GII20]BZEN.'%6@T(@:&6`G1AR8914!
M"81:XDP+"`!;C`,,A)J,#S80`$8;G%?3;#41!V-HFPK[D@*O990!``,$.RRS
MS8JYJK.?5;`D9@H(H,"0&A&P;$9Z@M4`!IJ"&-T'!4@@$(,*K3<:!QTH`$!P
MLEUE(08.Z;0700H1)Q.TT?K;T;ND6A3``/\:_GPPP@EK)%.#!R@40:3]7J2`
M0`P9\.Y5*,[YGL,%3]7!!)PE^@`%#G#K@048,/@4HA@]$&1!&$Z@,,T?N,;1
MNU/6O#///3.GP<P^&N`QD?8B(#*,*$V`+0,MEPAC310M,``%;KHDP9$++PS`
MBF<2U`%=C-54T;OB^MRL8N)F(`%;!TEU-MQQR\T2!0#T^Z33(P$'``0<$&#F
ML*<J\($"$'@'TZ<-:`"I2`Q0.L$!`W`P0-<V+V31GG,SRYBQ'T">K[J:BSXZ
MZ1A9;=&G'%V`&^/,[EA3D[U"K%)D$K'$IWP%D)I!`LC6]&"/I5]*&0`*))20
MK`HU*3SSS?O<;P%9_G+D`*71BFV591+E;5*@&*RK$K+9?H!!`,3'AC'?%0T@
MO?-A,@"`!084H*=;&=0'@`/MZ[^_OX%:U-KL.`*`[S7K5`H9'`!%$A@"PD0@
M`G@*@PRPK)K@BG``,!O_3D09LXD/1H#+(`A#^*6ZL:AR&H'7OW`SO@-^X`$`
M$,#I3A@>!"Q`9$/1P-\T@,&*;$PO:Q*AB0R5MPHT8"\R82`0DQB2\RA1*(R!
ME`+>II$-`.5?/0'`[-[E,8+$,",['(H+/7*]MP%`9TWT#0HO$C_&60``4CPC
M'.,X&A?&:8`;P=._VJ@0U('J`T_Z($88$*^A;,`Y922*0I!"$&K)<2IZ_M)(
M`I;'E!\VLI*6?`EN)@`II7A``Q+I3;3R)3Y[S<Q5@U1=!5V2@0LLH&-^$]A&
MDG?!%@)@9I?TS).X51$]D2IFM_PE,"\20W%Q``-&LDH"&-F9#2AS);Y+%@<T
M,*=[P6M[&OEB23+0@7P5H`#+:Z9%#+F4-MHRF"\Q%+DRPH&NS<:&YGQG(V,(
M2`]@0`.^0QCHOL*9AWR&`Q:X8B(?%)TGA>1ZP6HE/%W"F(UT@&@5"0`2$RI1
MB1K.8``%RWO&]I(,#.H!"LA7`!#5``*VS(17J@E2NCE1E0#KI!;)Y4IC*M&Z
MM8Y9AKI*X2#0@=8`@%(5&$`Y.<*!4R8%4@Y!_A_7+J*K#RR@92,"9T5`1Y*%
M-@J6!],`!20@LIYRQ`,<T-F3H"K3L3;1=OXR$@W=>=-9#L"=&\E)1C;POD-R
M@"*9P0`]8:4I#!2L`05S0#H]@KX/"<",81(KIMP#@2N29)%"M8#X^"0QLE(6
MCA)(9;-<J)`N6FY/?!+21P(0V`\0A#[+V0`"`OB!T&P`LQ:AP.!`@B?_+;:R
M%^G`!1P`@;SDQ*H6(=3W7#A9VQ)7A![`2[/T6#R.Y`M1:QGN1?`76XX4L@'1
M$4#^+&*`VB`()3P%;;E,:EL;!F!PC'R7^'(2U.*R-X0[@BZC9-D1G@8'60[E
MR'0^X@%FUH:J)(GB_OC.9YD*O/&V%7#858RE)VQ6-JP?T4!P,]?>"8<P`>S;
M%/I\^Z:Q32X`\"T)25H'US!Z@"(;D$H"Q/>F8W8E6#E1+7MG(UZ,1$#%P@$D
MA7,\.G=M8+J8@EJ>$)F^FB"V(Q;(2BT_`#0/!&=R*^Q7!_I2&/_9;,:5)<"K
M0-*![R&K2QW`L8[#3#,/V*O(59))3:RID:=02E;9;0E"&9`_K&F$`;&IIP<F
MP.*P(*">%VD-A1<,$C[UAC)J%C.B>S89FX+.RAC!&E>'YE:5-("H.LE`:"X@
MQ0T@F#`$F71%9,+98%Z@`A8P[`>055/\#J`W?()QHF,]9E\.B\DUT65'_GJE
MDT\58%$L059%+%";O_T6`1QP3&$@`*G1JI&2$J6.@3`B1)-D^0.ZE36V=^;-
M9KWND(CE56==8H$*FLR/K]%`!#H-%@GX^;?.QDCZBCNTDB#`UQ61`*JSK6]G
M16#5EC(D`$;-$9:UD`*;:<D188,!#E`&X%`BP,PL!.H,N!8CDB5N3O+=D0N4
M\UT%WC?(A67P6JM;PT:&RO@08!!5"HDP!S!/2!AP86F_>ZSQ5N`L*X*L#X>\
MYV!:>6*])2DS1U<A2TD(44MB%$$.!BBP]HA,-(XYXD[M)`.RT\AE"FJ?*SJB
M'IC02P[S]),`62%O3DE-UL,87`N500Q@@`%1_@6``U2`P2?O",AH/=8GV5TC
M#G#HQ;DN^$:%J@,`@D"^JJV2AFIT)?92"-5:$IC!,6``25>GH@JC``I,@.B1
MZIQ%`&1PA3@&S.8TE+U%(A,;(FOK'V'[X&,_%0Q$`&82V*8`^MX1&&4E)_X&
MB0>0NER7`'F2BYEB(0L#\0D(G-HUQTU3(V"H]4XT,BIIC$4>*?OM>PEC%L@`
M1RWR+I;,"D,?]X@%)'#1GGI>@`H)#8S>"#F8><7R$67)DYAMD0&TS@$^GBA<
MI80++8<=<9\!G@@''%H'#(A*B,5>+,#,<<0$"%U-C,I4U,20U$T"J,@!X,97
M0)S4K40GZ4GU;`0!_I3@!\B*S9V?ZEU$&!T@#(;)07"6`]A>LXE8S27%!(8%
M[*6(\I1=TTD`SZ$$A-V:1V"?1;C0_053`*2>23R)SM!9#$ZAE2"+;\V$!5S`
M="A$MB!A=$W:!B#>8)B<2TP95+#@2ZQ?#D:7F12`C;U3!52<22"+S@1@$K4?
M%6I.!"@>1E0:1K114-A-1@Q'Z-F(I^&A2$Q35QQ`!`P`(G9$!LA25\`797P(
M!W@``DA20MD$_L&/15"&$GE`".;A_KQA1;13J0S`^&6$9DR@)'X%&DZ%(M:$
M+5&`)JJ2`^335U!?1KP+!#R%ATQ4U;&$>%P$C#QBW"`C*>X,^$$:9WEB_J2L
MB5)<@!@6Q@8NH6<(W0)XP%Q9!`&,W4G4S6",R!6!XTN]RP'PHCGQ'?&)CQ3J
MFS(NHVAH@-`9CPG^'V8DP`;,XF`<P.^1QF<)(M1@SC\.FKJ!Q71]UGU-F$R8
MHT@LP`-HB$SHWH05I#R&2&QDU4!T`'DHQ`Y-P"VFVO5,&0&086D\Q91P!=F$
M)$A@@,/0GU_4A`$5'6V,%39^P&RP)-HMRT'$XTKYY$6NQ`2\'0'8"TULB4'D
M7*GHQ`9,P%!Z8&$<@#Y2"8)EB4!HP+L4607P(^FI#P$L14#ZSVPY)##!UQZ]
M!)\P#M:X7E"V94A@S2QVVI0T@!-BB!D^1`),_LN70-J:\%0`4.1(+,17U(9,
MN*!5R,]AZAB^"84CAEY-NN6),%.B"48B.65%:):"E5,81H`:UE\#X!M@@HBN
M<09C7-Y'R,H#/-XA(13#:%?3D:),O)D=0B9M)F)/X2/49-D%,``&2``%@H4`
M3``370HMXN1,H$1/!("N:8@=719UO")4&$D/REY"M$ZGU"9V@H1U;41-X%MG
M=D7A6,"##&&5(-CRT`1;;@2:W<998@A%B*,!0,#:8(T":$J^1*`!SH]K`F5V
M&B`%R(J:0:=7S,^@A&:8*%=M2`0*BH2L$$IE=%)"E$4$P)<XRB$5'N/<I&=_
M[EC4#.)7B$6O'9JS_M0$9PB$_GW$NTSH53!`C9GDF1!9'@KB+C4?S5CDAHY.
M9F!11D@$39`,!F2`AD9+P+U059RH1WR*BSQ,W:'$4TPG,%&(:3"&IDA``?#G
MC<J>`3R`?BYE!\H-=O%-#;412N#)9ZT$F\D4E)8&UC".G@1IHR@%>QDHHC'&
MI_3+5O+A[+EI:;11W@B`DV($)G;%2E0%GF**B\I-?%J$PY#GF.@0>YG>V;3+
ML-C%8V;$`!RJ7OC+M56$H8QBJHT%5`HFHV*$.*ZAI5AIL[Q;I5XIP@D/V`G+
M!@@`*&&$8XB5GHI)`52.`ECH3HG%5V3+J&;$4V!JI4CFZ$B?160&JRYK_D6D
M&U=URR'%C;4D!0%Y0"/27VXL"$SP%.@9(*!E7\`QZ[+61,D,`,2(84+(#0F5
MROL(J$(T@`4(@&FN!*3-:^RYD:*:JKA"IM\\14_(B@$L14C%#4BN)`2$ZE7H
MQE[HED^"9./!H([L1*'N*Z(9:V=T@`!\ET"HF)$JC$P4@`"\W&`.RD8(1+?&
MA%Y\BF9T*`R>RT6L*\5NZ&=AV>+<!8LL:,\<1'#01``0``5HZT=L`&JFA$S`
MD'%RX13JCD7D8LQ>:82XFR:VT9\>#)IY`%?(Z0=\"J2*"BC)9`RF'@=8:-/V
MIS6!8MP`$&.H(U%X:D;`+`_]CD1I`*IR!-TI_NK$CFU_'L#VI%C<($L1E1^(
MS9U':)J91&L2DJM$R6AIO$^7Z"O>?H;:$I=,0(!A%:#/R`2N])%(M%%=*M7#
MSN:+5D9"D0<:?<^N/NZFV&@<)8!#_*'C'LP>243D)@5-W*22@5M%+(`<6@4\
M]81OU(T-927J7LK<DD[K942NPHW#4$#=S*H`X2Q'2(;X,(#S"D=Q!A.R3.U0
M4-($5.GPLJIY6)/B\LR3)$"9@D0"Q.*&7$Y%,,#YR5+'QE'Q@`UJ(,OWD.7W
MNB7;9(28/L\><87J4M6C'4`,-5YW:(1FW=PM81FGHD;_5L1_YB_XNDJDX"/-
MP,S4$E1&.$<!Z(RN_E&(!R1`]7Z`1#@:'$EIB%!2>V9$\2):"\-@46#$D]"H
MOQS$6`@N2$!C4KB1V!"':EK%UF%M!L4?B3A;#GJ56][JC4:21K31"Y](3@B`
MMX2$<Q``XTA$D_DEPL:(3!&`*9X&E74N=C[Q`0+N10S`%R,,3>@1#=<-![Q+
M`4Q(`/CN;\'*0FS'9%V`$._/;)#Q1M2-A@"6!"^KK(`AE=5,0D1`0IP=1Q@*
M271`I\$(!N'&*`8K".%P$>^%K&SM(,LC05C5.]:,GBA`&RTD=W9-!LR%S6AF
M;`0&_OZ2"IJ(4M9;)U^I!PPC\NJDP?!)`*"9ZBJ`*0]`=AT`3:`%Y,F-_A_+
ML(2%R"TK;D\D<RW'VJ1PIQ)O"DU8[:IRA-N&WJN04+>%*]RH[@6^LF@8"N,T
M1#1?*8Q8E0#3C*Q8P-#J5[@&*FCIA!2^2E5P<B5I!HJLL!.G\X8"+'?JL[#H
M"0'HR=W"&\2X2@>$T<%A3'!\2I)-%&7$8]6`#Q?GKE("-+.T!QQE@`%HW,OL
MS$T-)$@L0)-@%X9\0`*LR*<@BK?H\B\I\.W0\$8D@+W=!D='RR7*T768H$Q'
M"TUXBPD'FTXXA,SI!`5D"]8(0#X)HQB#2*6^ST[WYV==(3EOBD1PQ\U\0.WA
MS]80!V7<"$X&`#WJ4T+5S1X/!<H(P/<$P`B'_IG%5O5+P(AB0,A&'XP+Y=YQ
M\AJZ:,0`M`P\8Y&[UL3)SG11G\;D7@0$Q&_(I2E=@P1ZF')%'$2-'N=Q!N`R
MSTB,R,==!K4<^867_+,/.3;()4AD)R)EFQ_-<$6@Q@;/OAOG"=]=,HLEDT8H
M4\EQ[84$K'9J+V/80N+K"DMK4$#&/51J!IL$;,E=RJ157`@X0;-'5#-IP(CM
MGDB'_'9M>H"LB#$$*LR3%,P+G6*R7,">F2&Y&(GXJ.T;Z^@EI[%OJ%]644`$
MJ%PKCX5V7R2^083\S-6HX:NE."K4O=]!!,5OFN$!&(`^'H2>>?$Q>T0"VVOI
MT#&*T/95@'9^<]V)_K&-8';%%WV*="^>1D"/D)1J<S_%:QP;9H#'0ZWP1BC7
M<,]-U#4R-+^+F\".I&3X`4[``W0:342$4SP$30<2?EH*!E&&(][E4$-P&C4F
MK2H/]=3;83\>L<(-&D,B-&.RM4E$\>GXX$&`<;PB`1A%!0#%!F0`?2O($=IT
M@._1=WU+*[<,`KR=3@0`K)DX2DV18>^/!E.)W^KYP9D&T'JY)4DTWW"%GNG6
M>E#.`83F!(@ML[QK`B<8!FCA:V79FARU\P+AHFE$I^F/!UG);)AUOQ0/V];U
M;<NC.,L4!K0&`1C/8<#))\;X&4NX5D.35ZAGIN-%&1G*"4$>@#QK1CQ>_JHG
M#)]`KXE(QH(Z1T(3ND6$^"7#J$48BD-D];-[H;_DQ`#<5%ZX>'3I!D#51D8;
M9E>3%B-?9G<Z3[*`R<-6!&40@*T[NY@I)`+/1&)KQ-(<S#T970NYA4[R[6HE
MP(,LP,?-E?0D7*[41%3'36X#'YNG!(Q$H'?DA[P[RUHGEK<7A_K"S4U10`(1
MHN5>1,,K&9[.UD7DA`F57?,8;DE<]TJTUD;,E<M7/)BL>K:GD:=;^\Y4.WV2
M5D:9HDR4$YJE:S1N-K+H3JA8A?;NS`.%R4U-@"X9.LV'W%Z?4([0.L_H27#L
MD=!]T;5X8WR^GZ6:74:`#@0`7)'#C1Z?A("/_H8X=FOQ8/C4YYBT1U>B;/SE
M^M"K<`6B1(`!C-H+_F)%.(R/0)K^(<<#_`1:-8^9P2EI3$1<!9S.SWUEW92=
M8$"].$0".#7SM,PU.\3"&S6&B`S6H%JI?IA$QWM[R03;2;2(HJZD"@\%0'MG
M2(0`4$0'7`]T##GIM(:RC7<.:_U%B)8ZI;M'K!7MWV%0#<I0*<0"G#OE(QIE
ME,\&U,W2:T[Y6@[/M:L7:41@(#M&Y,O,$]<#?P#<>>`)1G^V<460TP1!S\T]
MR<KL&K7V?OI'\)0%AUE.&(#\D(5@`$0$``8Z?#!X$&%"A0L9-G3X$&)$B1,I
M5K1X$6-&C1LY6FS`_J%CR(<<`!```(""R0<B6;;4>)*#!``K(7I`.7'`R8@R
M`01P^1-H4)$/'#!@@&%"SI45"`@0^A1J5*E3J5:U2C4#A`$4..0$(.%JV(L-
M9FXH*3%`A(D>+A2,>!*`!;%SZ6+,X/8#@`IU^?;U^Q=P8)<<'%`0_)<!@`%Y
M`8"$>*``4),`'!RV?/6"@H0)$ESV_!ET:-$A,608;36#S@6-(VH`<*$"!0T>
M1*X&<.!T[I`,?!Y4@$!W<(88-@@W?CSH`K#(G\)T0%FB`;@G!USH>`&N8^8M
M:?=-C9"`VNW!.>`=?QX]1)GI728`@(`D@(L63(:$NY?]]>YT,73V;2"__@`%
M'%"T"0CD*+X/`F#-(@'PXT@@`!K8B##I@#O0*@CD,\BFR##\$,00H[K`0!$M
M<F^!!1^<B((-KSL)P(LFF$Z`!8LS\2G<$*(@1AQ]_!%(B`::RK3@5C/@.<TJ
M*F`YAQ00[R&S3C)O(@MNL\X@!A8+TB69;LQK0B[%'-/'N*2R"8/@,#C)+*<H
M^NXA#6^"2("35J2HMX,*`&`_,C>2H,>\W)SH2S\-/10TDJ@,J@$"&)+KLO@Z
MJ%.[MR"`2,X\G3R)@8M(*M$@./OBH$_A+M#Q@P[>0Y355IG+H+*I"*`IMSHG
MHQ4B!SQ\R+63-,`4KE(E0H!!@P"XE"^!*A6._@%'#[K3(0Y`=97::L6J8$NI
M2((6M,3@RI;.11F""\MHX8+4HF,1VE-8JRI0ESD->NP@@`LC$I?`#-*TEE_+
M7"M2JAEU>Q>`Q`9]2&"$)8BPX+=."K,B#0^"P-NZ;%(2N0X(V)6D0`_=8-E^
M1>[+`'2CZJ``C$53M3%?'9+S)&01\B"!"&">#MR%(%CP)&<K4E4`KPAP(&2K
M#CCX.%5QG0#ID9U^.B%2?W+/L#.M^RJWU23("5H.I)L.QH,T6!@`VQB@+36X
M$L*@@PL6.(#G@EVVR((#9O5KS4*9R[:#`XJ&&G"1&6A2I!:AI.K=W`1"X#FU
M-+C``02(!7LZ!`SP_@J`7[%#*&Y(Y05[``O<<N]PX6R2F;D-"%B1@`5<[>#O
MP&4'*F&K!,`5M-1\HAQL`Q"@#?.9#$+`*2L/6I-WN!Z(H%R#9,HY.`-0'8^W
M@VR"WD\+]IV=^Z`@$`""=J%2%>#0[*R3]]*M/$EE`(K+20#T*1^`^>818ADY
MLV(WKE.#2'*]51X07_<(N!$*%*!J5UG-:5;#/+#I[5EP@1A)BL2[!F"``_LS
M"/*.8Y-8H:=\'V!`TPI80A,>1";3LPJ\0B.3E2BF)M.9@`;2)H$'3.8D#Z``
MMQ9"@1;IQ#@$\$]Z'J`R`83PA$DLX`82:!7:&,\A'L!76`#@%"`^)'E@_EN8
M_1;B`1_:IB<&:&)N'N"B]`0`=0L8HA+96$"/6<5R49SB510@GSKQ$"%?HUP&
M!!@1"AP``3P+0`$*`#'AN,:0Z%G00<QBLC8^$G`<\-E<W">:U5"`++A#R`4L
MX)[I+$"*$<$``A(0-P(0()''656`&G80!*0R*MN#Y"R1,Y`!2F5-HDG,`$BB
M29Y,IP$=$"9$1FDYN&RL`'VZI6@B0,+S/.<@JB+<5/"R3%I>\S`+K,L(6UC%
MO`0`)!SPUG0@0`$(*J0#:L0A``@Y1O0`0);L:0"N`O#!J_P*FRPQSP;PF<^0
M)(XO9K(F7;I2@`,D#P(<V,`<#7*!/^*,`.';_@C;/$.`-Z9G`4:TES]/<P$"
M%(<#Q`H`3:##T9`@,2P`]8P>Q_F1A4(D`PU```X7`(%I3G2@8H$F@1*S'Q::
M-#0S,A/85C(TH'+$`3<52R`_`X`)4/0#H:O)T>(V``@\()X'LHDFT^.:23X`
MED<]S$DJP[(,""0RA11K1CQ0I[^8Z3(1,%D$-)40!QA`CQ%]@"-#5`#LL:=%
M8A/>6CWS+O$(9#E[^L`!`$C8BO0JIR<SHV!(TD^;H(L#$$B``N2G``B@SD?O
MTN!X)$"X`#C3L7TA2Y'6XSSY%`"/J6W(01E:%0)T*K)5,<LT,V"!MX'M``R8
M%I`J^R$*H,X"HY5M_E@$TC_%&DL^!.#K<AU22<#HQ3*J0LASIA.`!#`@K$`J
MZ8&DM!^C4A<P-G%J'?NGH<X,(+;H10@@`[.FVHH%``K(J/P6L+Q622=$$;`7
M2=8H7[Y,[B01\"0`3!,`=QHX(6;A:ET0\%>^_+(`%P`9M=:DW//\QGJKA'!?
M_HC&#Y!E3DX=<4-(DE6^<"``]PT+!AKPX`^$DDS_"]&:IA4`I:[88OU4T(_9
M$]_@,/8P'%"A:/I(IH.*R`,8$'+F@/P9`91.0![NJ)"OB^4J'P2*(8*`QV[S
MY;FH,50WFI1UK&IFN];U+[5SLT%<8YA;P@X]UPLQE^<L%0!T1IH;%%X]_OO\
M@>>`%C`,N&B511PB#3R@3ULI=%6@$^@/[#8O?)ZQTZ*LZ;=.>,0SRNUY8E*^
MGTX:*@VSB7C,8B`&]T7&?GK7D@'C&B,O]U,^N@`#*O5J5/L9@/!259K@66BW
M@>;89D[`KDQD`97EA8N_!DI^C46KUT`[RR@]3P=L+.VY["G6^<D)(Z_M[>9H
MAB202HU<X#IGB9G;+RT:KHA(0CCLPALH\9'?=/9R[SX_X`'AQG=0)#!J]BQ@
MD@#P\L`YHM[D&69.<]XIP\5*`'`-EN(LX0`&-0"R#O0I`-$&<BXS?E0%#%%5
MW2[Y3P3@Z16W5>0KAV0!^I<JK,D\)`G#P``V_K:<8KE95?;$.2T%8!Z%#YTC
M<KHQV*P3`)>/6%6+7IF6D=Z7`7PP,8BN.HMB]@'L("`I$LITH6<D\*T'C@#E
M:T!XS^Z0/>%'0_OR)I4+7>RV/_(`/;+2=._N$+(<Y`%YJF->M+UB*U&][T'J
M@(NC&'&;%#CQ#I'.C89DK-TQ_N4'H+6!.2!D/E*73YR;=^0?5;`-7-(@901+
MN?L<43,WF4,&?V2Z$0(`L[>=97#A-EQ,\W/`R;XC=B=]";%3KC4]>_C#@4MG
MX'*AT,MN`S%_RKB3'QKI`T8!J!((W[7JM(\;)`*XLNZ<>_7TZH]L`A$P^N@Q
M=$ZHV03QLIV;<"P`_OSS_V0#7U)5_.]_$-^;6>R.(W[ZKRX48`#,0P`:BP`1
M0E\N@),H8`(N(`+$X_^^;&&8X^@6,"P\(`.:9$U`[?S6)WE^A>[FC`,N0**.
MX^]FZ0(@SU`BH`$&A>0T4+""YI3P"I#`R2S,S\`FKI:T[H3.PE460.@(C08E
MPB;L;ZW^;#M<P_T*:/#8@RU8`KYJ#_.@0@%_S?8*30-JSB!NCR]H0Z642/A:
MQ0*0A@"N+R/&##(*``(<H"@RZ@-<H\JDI;0^RP$:@`'4J"`FR\W>93_X[R\"
MP`M-",FLA0*&:$W4$"."AW(NS0_E"WF21\,B\<L@X`IUP]?^X@E/([#X_H4"
M5"8`;NTB/*`\.-`"-&!/=((DE/":I(0ZB(,H5J(5)ZT`!-$R*@`X7)$[XJ7=
MJN5.RE`HO$5)2*+*/*`"],@(_>?Y^JQLTL/?"*C,^"4U4.6@NH,7&X(G!$#_
M+-'`-D#`X$(`#$-5P)"PGA&$O!%J!$)D6J2?ZHU#<+$A&*;@$&)-LI&C<(A4
MU''%*@\]0*Q[4FYD/$!FK*2:-&YRLM`@Y.S+)J".3L)-^''$N#$_HC%PKD@L
M:.@T.H!P"(#(-F+!4$D/3\YUQG#%.*`!XN8`0$4B(4P`/M(X-F=V9D0>3ZH3
M/Z.M@)`C'!%L/B#,1@S&X$*,UJ8E#8SZV..[_F;GU/CEM@X".VY2(S(H`S+@
M`DI#`S3`,&1RQ6X&D!``;FQO!LT1J$X"'P/CL@(G^Z`F`PIE$ZMB!D>,NY*'
MGS8$S]Q,`%QP/%(2<,PB$UN%.,1FDJ+"`R(@,D0%*!L``B)``B9@ARR`1.:0
M+OO,`&JRJ82N7\:K6CK@Y$3J-@;@`0:@3BSS)SQ``E91/AZ`V5#-+-Q,BMIF
M319N/(IK9-S#,KCOS.`B#\'&)*!2(Y!QG1!`+AP@,`UL;!9%`X##&+],(!8D
M;BC3,\9L9$RR6A:`V;SEH&B,-R]BG&X#AIP2M98K,4"B[`RB/NC%S$9H0>0G
M.XU#`)SS0U*#$?U$_M$0XE>*(\/&KR5XYD(*P)Z:J<HTA#96\,3D8P+@#,(6
M8``JS#'S8CV%@R%=Q1_[I0$N2DJ<Y3A;0AP38$9PI;56+#$*XMT&]`,>%,)<
MPZV&YP`L8(8$1*VFLR@-)4010B9*"2;9RFW`I@+P:0+PDKK"\P/8T2#@Y@,^
M\3_5)DB!24!^D54R<&1B%,Q>XT4U0@,>\F$^``$44K[<HR!DHCO843I/`\<^
MA+L\YE<F0"P_@TA9I0$LC%K>9;H&X.VF(AEU`@&03[Z(13Q=9(%^4C<V3D0@
M8#B'IT:/PP#L=$Q:#6I4!8+B$@1_@ML^`"!7C"P*X&OT<'(^X"U7C&7>_L@U
M!E65&C1$F-`]1:1%%J5%%D0TH^)MJFP['Q$##-3`1)!**(A`.M1/"@!6^46T
MT(F0;J<J-DN$I`[7)*`Q+Z`#'>"S,#4U1VP"BV(A`@!+SZA1381$148@(.@"
M>"Y0FP-`Y-#;,F!;Y:M%RJ@L<\,)R4152-$O2S":>H)=HT(`<.,`8!.]-J`T
M$&(##&0#V)2Z*(!8QJ@+F71`RHA,:%,ILZH"'&"1JF(`.H4!IC6U8,8!.$MM
M(H!?EPL[J,T@J%0`V(\]%"!&-J!<<R,U>-`E4M4X7$,[U&)">B)5JL+$?!7(
MRJB**"<ROF=,8.\R*&`!&B##BB,`100_ST-G_AM/Y?J%)+YDG/;D8C/BN`!.
M7RS``MZEJ%"V(>H2FZ0C3>1D`C;L`R0@5T6D`TRV+A8@`0D@``8@)T:5@8:V
M"65,F[B'2BGQ)R;1@CZ@15>,6)AQFJI5OA+CH*;C1]SP1[!#)YTF`Q1``8Y"
M=1*@MTZB\#2B;S9K`1A@8I%)+0YQQ0QV6Q(B35<L<?]L`18`.\ZTSTAB\[B'
M`M!%`]CN*4BIRJ)05>PG$0F$`,@V>MAV.T;6,IP4"MTV*-KF`MHE`0Y7ME;C
M5_[E`S*H(.B#0*0F0.[&3QR`=P5#(Y5H+0^"+$!U(FCV)/C*`-15K%JU)Q=@
MHR"B/&2K3JKW"#%D_GB=\EU#0KT<("?>*.(:HN/6RGOGQR>%=<46Q'3;%T=H
M[DD#6"$:R2``+"$$=L1`QA2+=CX+[70$V&DP0`$`!FQIY]X03B'`Q]QT9=):
MC((#I`(,."%F!%W,(G*==@M%J&FN[,LJ8$$.`%IN*"ATEU5.=#P^#R-P&,+8
MUR`FSE99HF0W]GRCRE/7ZI?(,B%P%O_"E8!2PU"%X_LPPH2I!8C]8HCC]T6J
M"'WRK@`<Y`/$&,BDPS#JR)'HZN5FRX>/$'=5J;&4Y2<R-GE:]HV/BJF6MRU'
M-$I-2F07@B2<;H0O\W"TTB6L,O^DQ8<J`&C[TK&$5(_'Z'/G[`':>)#E_DDA
M`L!CF\.1*0*J3,AE;6Y9^-3-4N*2^<4#-(^1PK8YXG,ME.AH/@X[NE9??F5"
M)\TU(/:4N:0T$R+MJ$A\\3B+%H,S4&T"EG67$84![$4@[E@D[A?"%NPD`N"T
M`D`S5I7LCCB9#T4ZC*Z37:*%@4R8Q">"^ZP#;'.;Q80D:BXUN-<^LAB;&`"9
M001Z(RPT..!H@P2<DMDL"K*/62*<D\B9,\(`H)A`BC8W",-5@/24R:*QS"*8
M*6(#*B"$\*D"9T<5@78J]`O5FL55!H!'/0.?@4H#'J2,(EHBA"J_)"!HZ@1H
M+1E'-(!A]'@JWA"7+WI,%%43M9F6?LXC?^*'_N2202_BN%9WD\4L>'!#NZ0B
M`@K1S3`242PV-Y;MJ-+V(%;CBJ]Z"^,#`J;2,?88(G*/``[*SG!D`R#`-%T6
M&YLQ(5Q9(BJW(CS`G94H`%983&XN-`S3GS84A7!:(P14`(Y8&"$B,4JS6_TZ
M/[HCJ"5`G.HJH&>FAZ\J%?,H6JLL4Q$E->S:+]!Q+,LG`:IWXI9RL+%(+:0Z
M71WM(!@F34J)`1&[(O2H2H=GBC45-JRE>KKEGTV(+!)HDD,B1#'36.+ZU?S3
M+/)9.&Y2%^&".6>&K3<"?0S`?$\"@!*`IT<NM\MD)>#9@,`ZNP(D`^@'\+@8
M0E@C-9RZN2'"`%HN_HPOH$8$)*>26[D-@Y0S(B<,R0.D`RP6%]78B5]6TS/N
MDLFR.C#R)#$TVR+(MT:F)`DK(BBG`Z9SHP("5SXN&R-LXHU4Y5(6P+CE*S4,
MVD_B5C`$0L"?1@$*@"W=>B)2LBE*`FSV4?82]P#F^GDE1J]?8LELXHQGNX$C
MM%J"%C#>9<2?QBQVI8R"?"'&%B1LPLC%I,8K'*]#[%(0P'C;R!53X\'3P\H%
M`^/$JILY9WPFP)'@CXWHL"-L0IL;QH--2@-J$I5&A@)8F8Y2EZ,Z`%3\MB-8
M>CH2`"^`=R$>P"O;T.)JI+JY)#7PD3IJ)&[417H+S0!<%U%&6RRL9*"5_DB<
M:D[)@0*,$MW_)L*33NL&<T+'@434[".+U.*\^DQ_G&9G_F(`'!V;?-`L1IQK
M'0,#3,)#SKN`_#,D-L`Q$;D\\(D_]WO##06\M1LBHC"UWF50R&+$07,A]I;,
ME2B#I<(`OIFZ5`6=684OZR+6EXM2-XG/->+K=&8FHCTC])M5>ALCFO(#*-H@
MMATX44U`1T;$Z8+''<M/-]TE9D2I2`("S%TB;B:'?B2#'.)++\(UE"0`%U%!
MLIWS(-U:CF8NYCVU(B!\:T_`W^6B!,),_[DDB*6IE314PW:^+\(L_",`$=@B
M7P_%#V7EI6+=ZM6,WL7:)P*J@]0I:K%*-N0`_D^L:5EIMBW@Y]%WE="Q<Z'9
MS$I:=KZ;B@;]J)XC6X98).3$`7Z%-&W=YL*M=#^@T=O=M0,D`.3\54-"58*M
M:@12Q0J-H0%'DZVBY`G+2;F[(Q`,AY3$OR>"9=XE`/;UNK?#)-+6`*@;KYJR
M`>2<(G#<6,I%Q=*^T-I&=J3^*9[2)7G-($#\D$VS9HX'SA5"0QX`%H>=/=8)
M;)Q"UQLNOR::,NSPZ&"8"\5;9!)T*LP<PNI=T+3[?>VQ[YWGRCW#K]J&*B7`
M`G8H36R8U)/'U:8<PMH\/79_@>F5)0K:0UU$.K3[CW%?=J:1(;1")`8@;7F.
M4GV'-4Q,)&0\48%[_CN6O/1LW_7QO1`?FR4L0#A/(@'*Q9`G`O@QE0%`GSVP
M?R%*/]4`0L.'@00+&CR(T(,'A`P;.GP(,:+$B10K'@0@T*+&C1P[=D3@P&/$
M`!%$FCR),J5*`!8(7@#`027!!@!JV@00\@,&`!81`%CP84'-F#*+&DT`M&$$
M`BHQ$.3P8`-!`$Z-6KV*U6J`C%F[>G6X`4"'JS2_FCUK]L(`@@)@%E50DT&&
M#Q08U)3P(0-/BCLG$-3P$ZU@C@X4H.0P`,#"!#9S4AT,.;)1#FXE6T[Y8&]1
MRF,O>_[<T&]!`%)5>@`0X&!8GA0T2SS@.FALT)<I&#X9`/6'TP`,U)0*_N`"
M[>'$#PXX4#PY1`+(37\PP$"Y],$`\`YT(%JE!0`($-+,H&$M10EB"9XV,!VK
M!@\<-FC(@`%#!:<0NIO,O"`F!`!^*P"`\`%+Z0TX6`4%$(@@`!3(]!*"#A;E
M05L+#>1?:2DQQE5!.UD`F$4U#;``;)4]:!)E-YVX%@+VB00;03Y-U9V`),YH
MU&,T%M>:3``T<..#+8D4@68$S&:2`P"4=)!0'D`@@$8+#`F`7#UZY$$!!@Q`
M0``!""#```.$I,"*'A60VD`M#A1`C!E.R:9%>HG7YF<!+(@28W'>^=`!'!#U
MP03H%05`<P8)D)H$96JT'IY&,?"G2(R5%)9X_CMU%X!UBE[*T$Y-8AJ97GQZ
M9.1<G&(:I*69K7E230>(ZL$%;1TX`9%M:M#951,6Y($%HG[`@*`>K0:7@A_L
MAU&`/XZ*[`<*))#L8'"9I)=PMS;+I@81/$#0!)O*Q%M-/GD[4*P567A!!,(5
MIU!7'"RP0`(1^%<3G0WP>%)B-GU@KW@C4JLH9?P*=J5(`##[;YRYU1K6M"K%
M>A.2'_@WD8D#T5034P4;E-N)!=0DW`-BBJ0!`PTL!!<#$^Y[<9L$.)QR5M5U
ME&/+;,)&5,!8R5?K0!1L"U%N"YZ&P`8T?7HQ:AQL5YY>`!J`K5>DR=SF=DU#
M?15Y1!_D00?M90"?_@46M%;555=3C1(!E@[$LUD>2T2>J&4--##4_)FI&0#8
M$I!35\62W6,%N_(-*&J"GT@XX6D;]3?@)V4@P+D?.'"H5VD^[JM#!6RK@*`&
M'"CSR\/NU8'='PA`KTD;;+!01NG"G;CB!/H7MNLI!3"`N0(0@`$$$4B`00<4
M_%Z!!1S`IP$'!!PNNW3D'6NG68'RVNA#+Z*Y(@"<IZP7O1)L&M9<!T1G$F"%
MUP1W[,FGAT$!X)]O4N@5P)T=00FT/M!^[`^8`9QYR6H53A\T<+V';&=!L:)3
MVV0&F`(\H`&)@8`%8#,7!-Q&)*L9WUQD=+\!&4!A&=3(RXR4E*?\AR'-_NM@
M<B)TJ^V<Y64/L!A$3)2QO`2+@_P2W_@`A(#2A2\#'=!:!Z8%@/>94#D4<.$0
M-W*DS]UF;U%B"`"'@[HC`B9G_#,*`0#$`/U!A`$+8,#[AF0`"[6L,`YX@`,@
MH#L%%$`X"#B6R^)WQ#C>*8E!8A9YA!.ZLQ5D`5J4HV<$L"()%<5KOY-`!-!H
M)`!!H(\1HU_R%`#'CE2``A.80`0H8,9Y[>9I?J3-`SOIH0.1YT0BFII!W@9*
MSR3@5F$9Y/AJ$I((K"^5$6&`'CF"M/&-)0`Y2\GP:,F7R@&S(=S930,2H``&
M!"`!#8!``5!UG2H.TVEAB^1).%"``5CI``A`_B:C_/*`6:;R=Q,PY`,DX``,
M."`F9CM):V["3`8PH#NA&]LTS1(6:]YS*CJD2&;V.9@.N2AZ9HG`!,?YRA$*
M@&4=V<`!,@:``<3N-/;,H!LM$SKS`70JX.M`6V)B(K_0<'H;Q:>P)F:CE&P`
M=PY!YC0/8*5N(D5D!7#*`$QI$@L8`*('<,IIQ'A$C4J&``<M*=H,([ZI$:LA
M!#"B4;N"@0DJ<#-!_,`&`J#1!!#LJ00A@#XI:*^][(VK7<F`4Y\:-__TTU@,
M,0#RR*J2J_*,/#3TB'_>]Q+'$21$<!T(`:`ID@XT`*(?`(PC^ZJ2K?0U;D'J
M9VOH=)`#O!6Q*`D`_H#@5AZ54&9!>M$H%X>IE[9P)TP'@(U`"B#$DVP@`KZI
M6`0R@C+*JB1TO31J`)##&P5\C0+?:@@"(B=;E'@@-Y=]G#0WLIV6Z.6B'SC`
M5QWB`04,H`&U+9A>7NF4`Q272F']R9HX&5QN%1.N!OA3!QAC$P%`X+")":],
MJ%N0!C&H/#MI'4DLTMK&4.T"&-!`9AAP`0E4<BP&8.Y&=F*3`C3@`1-08V$5
MX]ZB3+>OVC0(!BZY'$9&F",:0`"?)/"QCG"@,[#[P$MJ6[N*9`8"PL&`7>IJ
MW=AB\%<)O6!%-[R1R0*T`&=U46`0<CP<ER@W87N63')9.+\$`*<0\=Q4_O(&
MM?I>)+4B<4`9(2`!"?S.`B$)G9!30@#(<G5+!ND`!%K;`*%^(#=?-HD!5C0Y
MF>PD`$,2;<8`A+>*^&\T8I99]R[29ZM0!L9MGLAVA%G2'W=@*0`@5%4;8J5"
M=V0`%*@5!PB*E0YDQ`!K?4AK!,"[(.FX6>WA0)!*X@$,_*A2**$`!S<`H--4
M5](3Z<#&%AL2),OSI`SQ$JTWTLL*]+@K!!!G1(1RDUE3ZYWC4S)#.5*A#VRG
M-*T92VQ_/1$$*'N?HI-V!42DJH'0<$C8CLBTUE,>\@30>4R6B`8@L&UJ(7A+
MMPNK3:G<D>T()$@_\D],P%ONB7@``8?E=B1;_FB39P^$3%@+^!Y[,SX##-ME
M^-[G#PDR`+P`EB(O$4BL)@07:V_<X0/)0`(*``&A0-0F6:IX*D^C5X/H19]&
M4@W)T58=#6P@=-6!>+N[(@"7@R5Q#B"TS#BPD)6=Q#]SJ?9`5!B@>#N<8@!H
MJH*\!H$'U"<!HY:CDR]``34?A*0W-XB1!W*!!SS```GX+74"W9`,P.:V31U`
M6Z`V@1[K92X"&#G''[,=HOQS)X"S@-0_DP$(++.IVR5(XX%YFJ9EIB;/)<B9
MRFYA(@4`+L#]RMPD\JV:B!8`12T830@P+:25SYU/.S&%>*(7P$5Q0$$J0(@+
M8ME]GF9!K4%.9FX\_A"R8WX@9W\XN:\R`0?&G-</F1`!A-XR>`5F`ZT%7TH]
MDID$5*`M#7#`8'G22M<9_3.,@3)!,$`!\L`]E2P<88"`BI`2#O_I/]XC!"Y?
MD0@`GV$W@:P`*G\0&`!\*3-*K;4J4Q%S'$$LX_,!_J(<"7@5LR<=#+-5&J)X
MUY9*`P`@08(>C($7&U!10C%_!0$O^/9;SZ,1AN<00=)HR&031#%6P\1L!!4<
M)V%F`E8!%7`!%Y`!F-2`Q^5P$J!&(600&Y`8`QA'(V0DS<80=C&"YH$1>N0;
M=S=?(^(!U[40`$=+"&83%0AA%#%^#.%E3_@7&U``!M8J@P90HG,!ZS4!_A10
M`1J``5S3$$Y(AK&"*MIE/6\16ZTA$#$(2K8&2\8543\R8Q#A=V9V/'3F,&-(
MAGU2$P9&$-"QAN;W%(1&A4\H%`90.0/P/D2($JA4$'IA;04W1$L8-AN`7G!S
M>!)A(J0T$`[XB/CR:`;Q`-\#A$E(+WGU`1U@+Z775;F(;35!9:=!'JU8$:+X
M%V(E=D=$$[45)#^462*16P"R`4L8$C'SB'`Q`-:D-92WAM$1.DQA(A80<@QQ
M:V1XC,9Q+S(A@@<A7X>X43"(A!&1&:7'9E#WB';Q>65F$\#(?D"Q'27A$YU1
M@PCA&X^8?`@1)0(@B1X!&W:W>6_66U&'6%I(_AA$XH3R]8@4HW"+MF;U.$2D
M)VUVTQJ7Y1L0^`''-X*R1A"=80$+T$P`Z1'(QH`!8A%$DVI0LUH(L0&&Z'<3
M88<&X82$-XM&8@"/5Q`"L'Z@-%XW$1.JQQ!D)A/(V$GD$R[=N`#Y910[.(<Z
MMR<]](-A.!":MB,74`%OF(XM\X[/.!#O"`"F.!$U=Q`U%WNSR#`/H`%I=A`9
M!5"WA7;<9!T9L``J&2"@>$UD]2$9<`'(!E%=5Q2T-1&CAR)00Y<^41IO<WT=
MD1FWDB[/(E"/F!E0,A3O$1\7$"N0.43&B$05.'\@-GI"L3(*,HW"=9J[)0$7
MP`$"44\4`1@3T$,__D26G/)/RJ(9-?=3)T$Q*U<3!Q*:9,@!/G$`6,*<";>&
MMR01$46&K/26AV(`--D1X%8XFV25_Q.4_Q(D"_&.'U"<P@@15#>>03*+"/$`
M<W$K>[)1[N<AB/:$>>82_.D1$_!0!0!3"#!Z<#.<[`,7"S&4+326*/$>IS-B
MZ3(7%M!Y\SD!"=I)I_&0#Q$W\TD0YC@5B!F9HN47H0-_[B:7S9*.Q?D!V_.@
M71$!JEEVD0)7+Y&B$2$`F$:&IY-:#H`>Y0F&_%@`$Q)^%;&`>R8SY'%.;7$!
M7C.=/RBD&R$N($H0>G&A`+43T/<0=F>EHU.D!,$`!S*ET$5_=V$0[CD0_I/G
M@OV8,OQ8.$TBF5U!'E\ZB>`Y3931C`Z1)5^Z`0]P+F&Q;BC!<VXZ$$<Z$<PW
ME"FCBLG4?2%27H9!45[AHE\*B"4%&(;Y$$UE0AE*'*=Q4!*@81[!@L6B-1'Z
M8!6Q'3D3%F7J2^B"@4>FIB2'E5P5%LIU``EJ,R"*`04V%:,Z:0EE56IZ&MG1
M`9)U&:Z:%4TI$_9CIT:H<`!%&9]H/2!(*QTP'PV!K%^J5U=5%,J$)58B``F0
M&$VBAA3!CPZ`7IKJ7HOJ7AK:$(ZHF`L"GR<"D`_UI>YSJ+UQ%F/!`31:$!(`
M)0:PIR7%)"]Y$,H87!O`K@+WA5P5.GYA)`B0_F5OJ(-/2D*SBFTTD1ULAA8<
MD*4W1X6[2A"5"J*G86R)AA=!<IX$47RS"))7&JVDVE3>QT51X1(:^V72-1`)
M:8L31X85P*/Y.;,/L9ZS&)W;<AH%ZT&OI#/"B`&&I"L<$A\,H*Q^9(=T61`S
M:J?$=Y$`P@$VRRX+$":-TX0Z*VG8JAFG`:`PHX/RM&#(=B#Z^!"O6#C,6E)N
MM::SH4PT<K5WP@$`.$RBPR0Q=2)"I[#[*$1`\Q4>D)!T6[=:%H?L(2(-"U!N
M]S^'XZP/DC6*$Y>X-G8U`0$YRIYH6VC^$3_NBA4OP0&)*Q'H!:_`Q!@9$"&D
MT0&))Q`[T[6TN%C]_F0D>/L!PJ>0X(615Z$70@.L#0$OEHA8P<*`$-.US(=6
MZ],!R#86'A`!LU:KL_@2`;2YQ,83#C"H#R$TUB.2&[4?6$(`!`HE3&$!+M0[
M('H`P#NXAO$2XT.B:P:T&Q&[J80!^M.G1]9]\I0`%+``N8$<#K"_,E<31=MF
M?+4;EIJR^4DP%Z`!$X`E$%!Y5*E2P46W"L"\`O-*"_$`R5L04*)72(=C%;`[
M.0/!7^H!;<MMMT<0T/>AVUD:/DLWW^JH#I!%"W!QPT*C"?5S`)4!GR(!&\-R
MI>$G/8*?5/.W)C1>!=$!"HRF#)F_\X>]I(.`@C$!(7L0]Z<`"M!%WH<E_J3[
M5"*R3-^R*0VPP,.G%_V;A+YB`4F*G7`SP?-'>+52IU:A`9GC`&)TP!(AQR4E
MFWH%%[[WQL-W.7#%FM+''8DQ<CH\G[[!%0$PM"(Q2C<1`$3A`%E,JT1";HO4
MM='9H=/D'PMR`9<3%P7I$"0)HN-8*Q5`P]@G>L*37S%1`:Z)>93!H_NQ`=K2
MM3L)5X`A9G)H$P>@`-$ZQ2"*<N*&@BD1.@&`;_<8%)GL<-NAE`UBH%W[IWT%
M&-"D`8;"KP@!F"!:`0/```Y3?RA!'@I'/F%"AJ'#HRVB`-@\@CNAE%H:@_&K
MH_A<=JUB=HM,$8Q!0_+9*X_(&'VF;L$[OK/(_FIDI1<E00%*;#?#TP`*<,?K
M^Z4`Q"JPG!(;XW)ET0``76[W&R4<P"21&+R\/(O#!<X"8B0"$$XGHI($8,(W
MYP$-0&79)!/^H91[^"1(6SA"I%6[FP!@/$UAD8!#THV6H]3#ET3[X](BK`!$
MT0&B^C(!$,*8UP$8P!BH=2L+4,M/&!9X.DS32H($8``#J+<@JM(&85`UHBKH
MM6<:F*\'D=!V:F9]%3ITT@'\2"\6`'V8.Y\+@98C:A0;$'J!8BD$4,004<AD
ME0`FC7E1U5?%^F#C$ZW"2X8T41IA`<K0<DL*QA$2^&L'0-`ZS3N._#*^$P'7
MXF(,\#,,\;*/2`'1_F/`@O$]NUL0SE0PDUT<2@=74YVB#&!/F?C2VR="5U&8
M!F$!V876CWA%!8/&,W(:7_L_F[FT",%S5MJ&AQ(ZTVT1N51L.-T6S)(`=VRE
M_LDF*QK!>%+.BHDM/B%2"1`380%8VPNSC[8=90UL->%6A#,7`7#*L\AI<7*^
M\GW=T^0_I?)@`.(?T,0;5AH6D8,`J\TVQ3)<^@DW]$N&!S#:\R>+BAD=WV+7
MK>6-5?>E56IBAFH2=$5\@RJ]\]=#[;$!7)/C,2%!I0RP[!<=&;!V;W;/W#$G
M";&'(,HX^H,`7+H1KJ<L^,C>)$>9]OH!1VVG)<Y5(*UG(UYVYWKEEEL1_JWA
M?*6W4`K-R:/7'62\NP$@N+1TUG0Q``G:;7!-`'P"XR(!U&C)'6&G`3EQ4S![
M*_S7$@H`XOR[X.SWT/M$&<R2&:M"V)24O<34U<,'&+$39-J14$HFYB3'CR&T
M`%-.C2T+>08.5^31'4AV(FK61%:ZJB6WF:834>O+B=TTQC%1`/`=<!J@Q&)4
M``X,75$\32\AW!G4>R\^/BK9SONH1P=Y%C7UDL6.6-%5$Z773!S1N9(6J_?4
M&GCQZ!3!Y8\8.MME`$[>$0O1`>[Q=*M7EM(.5W`:/Q."UW8*O60UD+MQU>!>
MU2.8&T01*^:>8SQ".$[A[".87UL"3RM9Z2.H_M\W&NL)T4.G\Q[-+.Z69"$U
M;A(;(_"4^8.=3FL0Q9SH$72[^[EDA6`2QR4)53AE+>Q<E0$*(`"WDN<>01X$
M<$'8DIIPX_&[+A4J/#J=)A&H+612)M%5UU3E9>M=M&`/L#L6:P$\Z-E/L8_[
MW!&UVNI&XA?;OIULE,>^O4\,L/!=VHSN_E3_#NO`[B$A=,//\[!6:F9Q,P`[
M[W`H:N]M;Q'U_HB``64>WC[1_-R]2)*U*5LMWV'_R%9=6P!>GDK?*1)FB[29
M&!:1+1&)H]R.5U5:_U2)?A`">Q,+4!64UK4F)^JTY)(><0%1?7-N9-H>80'3
M<GJ[X@&C!#<-7FY<_M>%.W+";UYVBD=6!;#H>G;HV-9@!8$416&`%6"3UG&I
M`6T3UB=F,T^&1HE6M!\1+GZ'>],:7=\1-ED3"7`NO4F&Z74`Y'$V$3V"&I"`
M%K#OP_2<`B/WDN:0707@'I$^KHFH+9G;-Q'W&!?\-S<!`*'APT""!0T>1)A0
MX4*&#1T^A(CP@(&(#2$`J)A1XT:.'3UZ+(!AX(0&'CYFQ`"@PTF6+5V^?.FA
M`@$`-0%(^!``)TR>/7W^1&A!)5"B13-V`'#A)0`%1IT^A3J0`8`)!#D`L!#U
M@U*M!4UV!?N2`X8"`!I\()`A[%JV&K\:S`!`9%NZ+"5@?!GW;5V^?3UH_@#P
M=0*`!%K5LMW05_'#"VI#+H9,EP/"FY&)>MC;$D`$G@&:6@8--0.'#2L'$J`8
MNF=FU98-<.7)NC5HUBEASVZIP;3+E#T!XP8.\^(`JP!2!T>>O.$`!Q^2^N0@
M6WGDN!`B=SB,VP`#GP+F3@</4<,`O!\`2P^?7G7<JEC5O]?8(0!MX%=WPVQP
M'/[^@1009/_`@)WX(W"Q#=P#H(("%TS(/0:A2@`!H`2P[L'W#C`M+H$LY+"K
MJQ0$@((.&;P+O=#N:\N#S8"Z:\3I+DA`08(0(,!%&XM2442J;N2O`@$^,-&R
MR?@:;,B?5N2QJPN"1`@I`KX"C+,DI]Q(`PPN_M@@@PTLL"""'06X#:8+C*02
MJ*O*?$F`SX"Z",W0A'KN@[B^<[-.A%2T*<^:.!M`1)]0M/,EI`H+E*.4`.UI
MQT+[PB"K@A+D\`$R%VWH*@$&$*`F`A"H2<?$*`7.@?E`K2B!'XVZ"]&%/*"3
MU)8&*T[&!YET]2#,#@I@PUI!2TG771DB($R@!M#O(5I_=<B##LA4E,=6?U6V
M05^170P``*D]Z,R&,GAV(Z&PC:J#"$[]H()F;[RVU@[*(@Q0N<`UT%IX$9K*
MH0FD/.G<>7\Z4-8/$*AP7Q=ILDE"@]X5F"X/$E@S80`"=DJH:1.&B0(`XZ38
MPJL.^`"I41]U-..U_ARHBN(2M0+@`9%[:D`#@Q-`>.4%KW*4TX,`^%1FK50\
MUM4#N-,*,%5U;N@!``@0(%,]V06@.:()1$I&!(@[..2.K'XZH:PP4(``F"/P
M.H!N=\49+`+.RAJBJPAS`($))(C`Z)KZK"QM^%24,0&.#0I@:+M/\G)N30DH
MX("FX6V`7*V\_/LAYA#B0`(,YH.`4,4F;IPA%1FH@`(#'I:@@042$V#2S%G*
M8+`\'U7\UZN$A>KPTQ62':&4:O)W]N3TU),S`$S7O2,,.`4`@=SU!M?F;#G0
M0(-T8>JM(@ZP'*AG4!-`NTF;L`X>N`$*,.``!!)88(&IE/J]>Y88H*G!_NR1
M;<#R@>#,4W'K#<*NP04@DEO/EDPK#4$V<#_<#"H`2"J(ZBA`0/5!YEIE:Z!'
M*%`3X`V@8?L:P`(4X(`'+,`!Y9&3WQ1R.WP59(+'FHJ(,*`!<V%.(Y_R@)&B
MPR"F@9`@!KA(SB+XGN?M,"(3A-1!-F"P@;BP5D-Y%.!J`K2;[>\A`M#5@1AH
M)P@@@`,'@!A!E.8T'W81310P54(00$2!Q>P#L/H($)EH$*$<RP!TDM>^)LA%
MA)!'7U[$8UTXT$.77`!WE"'BK>!5`*L9CB'+8AZW&M6YMTU@`NQR(B`=`ICO
M(`5VU"K`DTIV$`48@$)Y!.6-/FA&@@3@.!T0_B&H'#20X0C@@+R#92QM<D$3
M!L8A,;./P#SPRKH59&T?"R58EA7,HBB->RJB);CB<I]1RM*9L23C1B!0(R!]
MX$!\!$L,6T,CY[1N($DY@!&)210*Z'"</$D:$@TB@$T*['-)8UA-'H"!N$$@
M`Q7(``4L@($L:6`#'$"E(`ER%Z9\I'\`4!KPV#)%J*2$,]0SB(HRA<US5G0V
MVI0*!1%2`*HE['8,6$!-+ED1<]TQ(QI0``8@\(`#2"!&`HL+'0NR@0T<(``=
MM6A.D_.6P+63(`4`IL!"FIB:L*0!>QHG80["``,<4"C>U&E4@9,`FF#``QOP
ME01D&IHLTD4!OUN;_D(KPB[N>=%<%%#`!&B4@!K:1*Q2A6MDB)<GV'!`9<!A
MJ$_((Y"BGD1I`T!`)C%UM*YVCP,'#(``",`<"I`G`@S(5%GC.MG%B"0`S3P:
MTHJ7,3QE`$]OA0@0$\``!G`0`BZU(2@=0"@54=:ULX%`2"5``0>`3V1(>5=-
M4MF0(*46CPVXC?%>.USB<@1/Z(NC3^I%S-H2)"6@+6YTHP*8`A`-3Q;`K3CS
M=5=B^ND#'S2G=,7;E0DD(+S(065=_MA7GT2/F`7P[@<PL-OQUG=7`F7+`=OC
MV__5+I@.X"(!(FE?`CM%`MS5V0&)NC>>F(N:Q#2:D5*"X`)7V">`87"M_BQ`
M48+HUCG59<EN%N;?8&[@<P29BG8MO.*.3-"GH%+15AN$%P"`^".`80YY2F=1
M;H6LC2P&\DL64%A*M>@A!_SF@STRE9HH0,5>S$`&"7(1R089/.<5F0<X[*8"
MR(\AF?HF3CLR2AE7E%PTJ;*5E9-74EUERV4Z4$3`W$V67"1E&O%G]XYJ)*3$
M5\U_KHB*W@>J!MC8(>0!$@""RA$[EYDA1^41='_2OHRR&=!`KD"&294^B+3O
M0(O>"$$'#1$`/'D_].5)J@K2MTNW&B)(D325\E.1$\>%OQDAZ!HCPH!H-JX#
M%B#BR7R"95='%8VNNG-$D+PVEABNH/&!H.[P_C7!8E=[(7XT=9(`0^P9HY*]
M'B&>ER/R0=UE0`%ON4JLK?WG9!/:T`ZQ]0>`>!)6U5C3$5%1"1O'7B.OV]\#
M>8"8%Q6BC/05H2I]P`,<(+H%)$!O!N"HCRJ@@-$2Q@`6F$H$/C<@C7Q5=P*-
M"[?__6=M@<J]$6F45%QIG&>VW"8<UP@I[<8!<O5[Y-8VG*X#15KA;=`L&@R`
M/AL`@0A4$:43M\`%&'`!HDO`D5L"`!8]H@"!IXTF7_G6S=<]RDVS.;&WKLA%
MB`R1E(R-:$&4+]BU;F6DC+I.$U#R1LQ5K(W$A0&65E[C/$<0HZU]W3*O$\$]
M<L"Q1X2@V58(8!"__J_;>"EW?J>LNH4(@*JC:=L?*8NC(Q*X-$-$L9EKEJHA
M#QK)N\@#G5](`BJ/)@/072.9ZK5&[C+@CO2Y<0$PT@E'3QM++\H#"R@]AU0T
MTH@8CO8;F<`!W]R0D#:.FP/YH-EW;V&DP-Q-D&;)LSU2TL=O1$6HIUC.)BCR
MZ1.X`V,:N)\S,AD\47@CHUS\0I:;-@-PEP("0'7YI6N!317*7!ZI"9,HNY.X
MB.,#P.53I@#(G@=()OVS,`@`M3(Y`,V[I5&AB=C3B/H3,@,4F0@8@$T2"NES
MP/H:#)TK$W7:"$5+M,TZB<_1-X^(B^!#%@6P,08(@-X;KF$:.0DH`!E<_I`+
MN+>,0+)O$C>-**G"BSD,I)B4")D-B,`1)#`,*(E`"0`.E#-YH32/0`H'Z).7
M$)JG&12^>T(HK*^X*,(DF9./(`^1R!3BXQ^UXP@!4$*!63KO>H"X(T,[T0`<
M9(OYNSZHR@A$<XX`_`B;(+^,H#:BF10)`,0\+),.X,.U.!`33!*,Z8CV02GE
M^XB0XK27D+*?`"C3<X"`&8#5<T3I2@D\1,,QC(CVX0`"H`"!T":UP*J!`@`K
M_":-@@D-T1G=&X@,:$2"B,13#![JJA,<.HFU,8E.\@YS\2.(8[GA2)!ER8JL
MB(`*X``(F"`!Z+Z38*JS"QB;4XA#),9@@@`D_AR11/P(.%F)SRD;!9D`M6`>
M@=@`@KD`\C":P9"`P+J*H.L.-\26"+@`?#FY<APO<WE!'A$`]]N(VUD)G2@U
MA9@@Y5$5J@(\U#%%<.&`BR.(WS!(^[H*=+20.$,=7>1!/(DEPVD`!QB-"^B`
M">"`"*``#ABE,VR))Y&9HR$(<OO(^FH`5NP0CLJ-FD@,`_"X#9"`"JB`"\"`
M#-"`R:``@L$`P[F(J<``]LDL<MR(!FA`>/&2D(F+<8+$GH0V!"20`Q')ASB0
MB"2/ZE(*M6B>#AB@G_0X^:.\^(N(D%N9`"`BG22FJR3+C&"<,H$9'X2<FE`+
M3D&`HPJIJV`8@$$H_C![&`A0@%?\-;6@B98!"J42F4XLR#SR@+0,S()`C3)Y
MG)98&[5X`+YD")OX-0W@RM_[@)^)B\\!OZOI1(<)&3\<S>'R(_6S$1$\BIH0
MB8!KB@MP.@I8*0<`J0+X*EK2(=DJ"@=P/7`YN9`:QMY4G[LPR_L2*>=P`*7A
MI9H0'YIP+`5H@`F:(+!Q`(F"P^RS/G@1@$@"#,/43CR:``'H3K+!"SO2%=:P
M@.HJ*@UHCL1@R3/Z3J+X/X^R@(#II/LD+@4(PHSIJZ2A10-0D?(Z``LZ$'RI
M`)TXB,5:)3.A&)C9#7&$T+C"#@J<%W,KHH*RJP^8C`J0"0T0"N[R`-5!_@`'
M6(D+X)2N'">>&XB\2]')JH`"V$]J08IW8Z,$:!4/\`]%XY@&.`"MQ*,,V`T_
M*E+7`@S@7`S\4@WZT9,`4,`$B)LQS"<5,21DN:JU*(#L68#JW%*+8D`K#8OT
MP@T/^*`8VJ<*V$,*:,H*X!1*+`AVR;\RR<Z(@(`=&X@+8-(YS:D+8-&$>2J_
MN0I")8BARTTZ32Y.251(I9@N&1+G@<IOLRZ"&8SZE``+R#0,^"`@'0@?B3:=
MFC\%8$A0]2%;J[$\\1('L%-P83(-D(`.J$S4B!P/.*J$9*.:P$N*"<6*H``$
MZSM<K:CIL4\E_2HY'0A<)(B2^M4($@I\60"W_J/6';*B")H*`7"`AALCB%NL
M#.JEQ-M4BZ()(Y$`52S7!3G4V('5M`&,3)%#ASN;!FB`[]'%A3@JH`0E"N"X
MILK7$;E6H*"GCQ,?&8W3AJ@`%OV<`?C6!KH`7WD`3'W8X*$`<GV:P%$6=K(`
MF,D3PBFJI&F(`I@H"]&-\(```[#7]QS9S&&ZC%P9/[(E<X$O"E!*###:T5B)
M6VP(ENU&^!C+\/B9&YK#G>T>M$L;AQS$`DB,R4B,/;02#6"GAO@J6W*MSZ1:
MH_A4Y>B`!9C0T'#)T+"UR7@2F_J@N/`C+\F5B&0()MO7'9H`73F`MCW;G["J
M0O$`!F@*!A#-MGC:_HT8(**PM<3PH"5I4Y%8B:_XJC@U(IH`2%":@/LXML'-
M(ZOLD/,@"L"(2'<T(A-C%[-CGP%(VZ>!@$UJ$]$%)3^*7;YX`&UMB;54"R\)
M1HAXJF9M">&LD\/%%XBS75!"T05YF*)@MMFTK8\P')MT"N/XE0&0GPT0V>75
MG0.YU?UH7IY`"JJY"GRM"`28L[`HDEW94X)X*>^UFS9=6H5-#P$S"J38&P]\
M5)1H/K:(NETY1R,QFMR5WUTQE\5-#J3H6[?`WD'T68>X"^M]BN0B%0V()`(0
MW`,^'09H@(@-C04(7I=0$1`[JA%6"`_0.`OH1Q#^B'&IE7/MR-ODX+2I_H`!
M(-[9^(\*IB;"Z5^&N**:2`"!R(#.-8H!H&$>0<Z06=,:CB`*Z-[PT%G-H)H)
MHN`&F52P($E0D0`%8"(.^M)J<N(%>8`7XP\$4%:?0*B!L",[#6#0L-I""0``
M65#%V*/IFR&BH;('F6+-&)4(2`#LJH@(:."GJ`#CI9)(0H`-[@H#EJX<)A4,
M\-+W>(`?]HV^>KYQFPW<"Y2DA(`ARA1[*AYN'6.=J5DL!1(,D)SX!(_G?8JU
M'`CR65PM;8UI"I2:R!2:4!KR+.73R4QGTQ,!F&3DR+JGB%Y8AH@)R&*ZF-<D
M\:/=8#*;L.2<@N212Z?/"8#J\JP/>(`KQHWY_@R7"AT,!E(6KMT`1(8*"ICF
M$9$`8-H`F?R`J5CF7A:8KR(`SBCB1^G7V?!(J$#F#U@`,TZ\(<N3\:SF@<!3
MCU`1=&:0VC6(#Z'GS'&V(JRB]W`XK7!'E:'!`KC&MRFZ:6HXIDB`;.:=3"%3
MI;&T"WBE2W%E;^GC!1D/A`!:!4:3A([HAGBD.)91YWF/B^07!*`ZE\L3.]*3
M"0"LO]+;CLB4&'F`#"@<`#1B!O&82;&U>;YI8(TZGSHL5$Z/.GZ*7<(+238.
MN+&`!Z@`"6`Z#W8`"9``#3"O#+"`"5"9"/@@!$#=)$Z(`RM41F:("N!=#L$M
M`%BCBTCCJ^Y`?9D;_A=FBS?J"J4=B`,AY87`4QR,ZU5;YX9H9K;(8Z)`"B@%
M$`H8#*LV[*<XO^08)5W;QY9N90^Y1=-(B<CFX8*`&8/BZZAXW**8(-.YG;\>
M;<@1BR1=##LR0`48YMG@293!ESWFBQHK"'!6Z*3FD<`NH?Q\8^^E7Y;X"U>1
MV>/C*`M6#M4F[>H>C,+6B@TMB`P0;7J9V@<IWX,X@`APF]XFFK)H:H,X*K,(
MCW'NBI3@F.@H"]XVY@0![<8RV8BX"H86WQ&-9058@/66;VR1G'@EB`$@;]4`
M++#82#NCO`>NBY)2-*0Z"=6CDLH\B,!"P0>G&(*1,0D`;LF8U9T1"9'8_D/+
M*.0[47!VCJ0,R``$P*&:H&D4)Q7<FKP?YPL(["(%L%_^.*K#0%U-$6P@%YE.
MFHH#$`!\R0#T[0D,"-\41/"G`0R\5H]1&H"OVY.:@&TH=Q66S9,#8"L/<XIA
M'-_NF1HEOD8$F"T.-P`L1_-?Z0`J%1U/<@"JN]D69XLN]"*D`//],-K=()8]
MEQEN<>2BZ&<ONHA(AXR4*@B'KJ]GS<.X8.7@2)Q00J`D60!\T5Y'7YE`?X\!
M^/0&V@`47A#%+0@,@'54KY4(0-+T*#E0RFP.*<$9J6TT[U@;N5?%#@OR(28>
MGQ*9S`X)`'`T/V@+>:[P.'`JF7'%\.X145Z"_J!!6\^8P2#TMK"`9R^0FK7C
MRR:0T"XE=/=V4@D`(N\+?SRG&X\4.N+"=D^8T%6.:/?7&N>)`&*3`1-A?!>8
MB2#XA7@``S8`,N+!@U\HY.!DAQ<BK_`)+;FA))=XGMCL6G;P@\]VEA"*`1G"
MC$>6U23YA#@]GZC+ZDGODW<6P7-YH_#J6H]Y*@'1FC<*@BV(!\5Y4O&1GC>*
M",@>$@-Z.]'OHO<)=?R7?8X)I`^-.W9ZGL"`S^VP*(8)?H_ZEV``?\]ZA4@`
M+NKUY#!VG+?$KF>)A2^(",!XU;AVLX^(KVIUMQ\K=1(`JY?[!3%32X]YN2Z(
M4KQ[*KF(L3?[A!N(_I3PYK\OD)30>Y='@%PA"`)(=,1/CP@X<\E/"`,HH0*H
M?,M7#W.)?,YG'R,Q*<XGD=$G?8;X^D?9_-.?#IAIVL6H@&$G)L<FD`]RFJN(
M>];OZ9;OBO$;KY#B>L@@``AX"\K4?0Z9H.`WBE&7KB<GD(^=BZLH\.-7#P9@
M][98^_]9_!$Q%]F/#/4<"-RG_@?9CMF8UJB(%OKK>."0@`P+G_%GD#!J#>87
M+S_R_L7P0_R&_P(9G]:`-8#X('`@P8(&#R),J'`APX8.'T*,*+'@@`,3+V*4
M6*``00(-,H(,*7(DR9(F3Z),J7*ER`X`,+`<J6!!S)HV;Y*T`(`#SIHN_C,(
MY`"`0<^B1H\B3:ITJ<H%`Y@V!*`!*M6J(A5PM`KR@,6!`"YH#2MV+-FR4'4"
M+>N@JTT-'LS"A;AA9UR'"P"\%0C@8]V^?O\"KMM@0EZR`";@Y!EX\0<$#A@;
ME$"@@T`/`!1`SJQY,^>0`&B6G0"`<N?2)+-N!F"!H('5IE_#C@V9`$S#?%=V
M*"R[+(+;F1M\%9@!P.[BQH]7C6!6`UV6N9&/M<R9`-L/`JI#SZY].TD,$M0F
MX,Y]`>C,&()_&$Y`//OV[A=^9@KVX,_WR(5N%C#5:WG[_O]GUT`"&RPUGT$7
M!`"@<0`\H%D`X7E5FX(34F@:<`2*A0`%%<9V_AYIC"6@FE?[<5BBB7]Y9-B)
MKPWP&&12$10`42O26&-8`A`GU@1/G<2!;C;:-!>&BRD`P'=Z20BDDDOV5(!R
M8AF)$@<?,AF3`P)`I@`!BC7V9)5?@GF2!%B&-=>/8?8E@(&`08"70!>(B*:<
M<T[$```;:A4?G7Y9@)U?!K!%`8-[FL@EH2$=T%Q5%;AYJ$H51$`E2*,MAEYZ
M`+CHZ(22:CJ1`3E:M8`!2VYPIDTZ`5`!26M5FM8'&GC9J:QS(C!C599Q.BNB
M$(YDV9`.D:@4`-5)@*>NQU8IJ%8[(EL6!;S^%2><#39;K8W#:E4`!-9&)``!
MY"60``('$`"`JR,%_F!H70NH.M``VW(;;XD-K%?57.K*FU"1`/#;[P(0_"H2
M!*/^-0"9'U@0:[X+^S=4J`DRW)`&#130KZDA699D7*(.Q)RQ$8,L'@`&Y(I4
MJB$[!!R_!)MD0;U]!="<97ZB7'-QP`6K%',V,Q1BJB5[IK%9#QR@V%P\)^0C
MTIM-`+11#?2W]*L.$!`SOPKX5I($+*N$0<`9D4R0PSRO&=3%4O>%@0#M,D4I
MVA]8W:_<YY840,XG75!V1CJY]@``""!]]MN5,O#U41`<C';3!'F`@=,A.8!9
M70"L7=F@@V,.609*MWTDYA401M`#^([DTMUC55"8QYFS'I@"$`A^DP2*_J+M
MDL4>S`YC2@E(;E;C;@VDGT`=P-NZ\609@%C;MKY=,07,]1L`V^U%<*?8KH',
M`=W'+Q;!RTD)%3O*!=2+@)&/:\?<?#H9SKW[5"$P?5+HHYPH!]`'I?Q[#!9F
M[OO_:T4"/`)@3\HE-[E1RST'*,]PMD?`!Q;E+A#$2040H(`+2(`!$I#``P!F
M'QQA:"Y"FR`)8V*G$D:,7R0*@-Y0Z,*3&``U+^06M@0B&NS-,(<DX<`(=2@K
MR[!M+O+S(1$OTJ@BZLIO`S'?QY#H1(?(Z(FZTA.2I&A%AA3IBIW"`/88H#\M
M@K$C"@MCF-ZBF[F<CHQJ7".0/#"``<0M``-(_L`!!@"`XI6F?6RT#P0"$(`%
M$(!\!/"6'_<($0]`((';&9D!'&`!0?%+`+.+S1<-Z9^Y3,!J`WA``!QG1QQ:
M,B%VU)UVJC>D"^"(417S7"AOTD-9?8H`GX+6T5JYD`=4C'3&@8"?WM*O5]H2
M)>)[3P=TB1&Y(0"/U@EF2H9I%C@QSRO\,B8SN>5,AW1``-XZB*#H1\8-%.!(
M$'C71-(8$3VZ\C('L2/$JNG"`6#@=,JJ)J,`4"\[7:XH`!AC3^!D.'[1S)T/
MS!TH/S!)9EH&`*4:2`8J=A0%]`XIWSJ(Q02*0APIU"`.:&<P`R!#@53OFB:)
MIE$L`+B"0.^(%H4@_@`2D+B!B*LF%3`GYG#T@`Y,A7C\0LH!^(F3EAJ$.7;T
MYDHS%\F#''0EPP'FX(1R0'XU$2<7"*A-A!*U#VS`:D0MZN#,][V!B"8F620@
M!?:E+3-*E*8QL0"^G$H[KOZO7P=Q0(X\T$*1Q.E]&I!06CA`S9C@!RD!4.8'
M.#```S!@JW"56@$.$("O><"GW>$H]X3BIQ`II2)'\8!'#>(!`Q```8I=+-(V
M`,]<N2TE`6`E]Z8UO';=1:TL"6Q1F,.KR'Z``>1["6D!>"4.:,D`"1R.2,\)
MJO>=QT4%().='(B3`S@W)N!\3O6*A-'>_F]F,;.C`V!RE]2>I`$D/=YP_A"@
M-GL*I%Q,7>MQ;Y)2`,0M1`&@*G8'YP'S1:]?`@#M2OP'P+D\=93%18D"ANB3
M"8S+,0EX3`>^6M_C<8X!%.A`)5$R`0>[KP,+2,`"&-``!]SEI$IQR5*@=9[H
M/KAU?R5)E&;X``P;Y8)*X<!MZ+K>%+]M7#6!TX!;-[L>XPW&-V'40`0%9!R'
MC'<UH9<.NPD52QDEGT)9,9*EMK.8Y)6`'O``!;RV5PR4Z\@FH:N806*!WH6U
MRNX;X$K@1,*GZK<JZ#5*!0;P(9VHV7T7R!I*"E!A`&8``18DCP`&$-&EJ,\H
MG-6=$O-\/$S-MKT$O`"*X4?9JD+`<V9R=$AD_KLG#K#V).0BH5,-@H"7=JXH
M'MB`JW1R8TXK)`.CA8VG19(`-J,DHQ.<"V@R`)J8:24!EXZ)!Q:00+]1&=8A
MD[1)TCS!C.DE1W8,"V]Q<N7A,5O92YNV2J)(ZJ%X@%$"*.9.`\BU#Y0Y*FQ+
ME+8SAX&HD@1.R6X=G(]*[1_5^B(Z^1")VSTX-Z=$`"(F804H8($+8``#&=!`
MOB,(K<JLY$$#&:N_D[+J$FD``@V'B$O2_6#+5+HDY^$2HV9=<61Y@`/HS,BU
M=6ARG"Q@V"DYCX3FB1&/GYQ#GUTY1A9<Q,.492X%3<E<V,*O(Z<\YYUZGC"S
M[<([FJ4!,C])HT&J_FNEVZP!YQX)U9"83\/,>U)=)"S6(];ODP0@4SZ$M%DD
M,'"5#.=7H2X[R(IF$G]ZG<]AL<S&+Q(!7H6(YW2OE@86T/>%%&#K.1R;6=H4
M$]%XJ7J#KQF46_)6'5+1+-9;"0?6I*7)K\0#+^=.(L?\T;4?FBQ^$WQ&U"D0
M"Z`:]"39,I`,W/K#Q_7A92'`GV=_+I?`6_;6TDG8%P)[*?X-0!00L0*F+OQJ
MC=X@:GJB2^BK'4;5'+S/CQ?9+W(>*X[L/QUHY$`,H/CM-PL"T2>(^<!_>O80
M&:;O1S_W!#!T'5IF_MSI@`0*$P'GTU^G9`"DU%<!X%I[5(`$W(:A!2"W_K#:
M@R$``&8'HQ3&]S6@M6!%?042@`"50"S7!5I3?;&=?32``!3&!>@?"*J@>U2;
M?<")J^C6"FH&[<D@2'#`IPA``:@=>R05W#@=^M$@8*@<7'C`#A;5OO"+$7)'
M!GQ/^\G@$'8*__46)$&5?R3`AS3`7=4@G3#'^H61W*!3\3$&G%")(FWAH7A`
M`;P="8U2\N!4!GA-N!53!$1`(CF``U3,WR!`#!&`P02``5#``O3&!]333FV`
M!3P2!6P0!DB=/2$AY8#6(!D`U`AB!"B`!A%``D2``X@A4E1`IG#;&3H*SB&-
M6]7;*:)B*O)+W*AB*]9;7+0)]MB<*!X*!]@>_@%AE"OJXB[RHB[&Q7!XB2S1
MHJ9T@&0!4+](C@10C0&JH0((@`+PS@/@$J"X70)L4`-\(@1```=,``54`-08
MT`(D'E>TE`(X0`18``1LS@1T8P54P`9HP,)M``9$@*B,"WSE(N.5Q0O"U%4-
MHYQDG`O9#BG-7+DU';^\&D;4$DB((T%0W#_2B>,]';]HX4A`CQ<>A%M5I$@(
M1?`=T@AJ%D2*I#XA)$L`F$H`6);MS@\Z!`6P&5V-Y)X8X_O`24FNQ$FFA&C8
M)&ZTX,VAQE[$))V08LV<!T6RQ,RH1.ZP)$D<0`HV!`/(T4`<@.X%)9-8H@NA
MRLFPQ`!X9$CXS4ZR_@1!2D0F$01P5"6:T-A$=&*UJ(Q8_D7U\,M,DD1,8<3L
MW$;5G66US"+2C))6=D^_=*7(7=Y#L%O'2&!>ML=&?L`!C-="$(`2UDQ?KB55
MI%3WH80!4.5#8*.[I!YR=$!@(N93*A9SL%Y18.1FM`E\949"M5A-,$="%D0$
M?-&SA&:5:,#Y)40/6@7GO$?NQ!Z?]`MDIH0$342;I$4:9F9MFL@%$$##,<<M
MH@PD'699%")L8LS50029#<0?*B>I=&9"5,!OV@P^32=9#(=1AL0%.!/Y3`0%
M<)1#=2>0;,`:*L0@#@X59H9&8DQ$^!=_/DE]Q&>-3$`!B!1V2DU6:D:__LP=
M2R".1"#`]PA`8P9HA7"G0P2:9Y5FL]3D4L*%U>C=4;:F0YS'?EB&D$WHA*C4
M0@2`&4K-AFH&1GTG2Y@E1-"<5(KGB2J(`$RGVK!.4:8H8(Q2[T5:R)5EXG0=
MCIY(!RBF0-P:O1U=9O2+7`XG;A[$INF%D"*I^%$9<RSHTF#4:1Z%6UDF2PP'
M40W2G7%HEK9'`CBE0.CFV[C59%*%`;'H31P`?2)$6?4.`AR@FOY'TC7$8QK/
M*&6H6.2A<!*;@2:$`TS/C/HIA4P,0Y!FZ[!FH6H%:WZH3<200U#:D"2?TDV)
MS5A`G19$`\0H8ZD0E/*+A-;$O30$!KF*7SZJ_H(P"WS@WL)\2G\&AEN=:DVD
M"$/T%$$D`)7.*GMDD_&E:<VPIG5J14HFITU8X$)`0`*DA4N,:;%R2`$\J]3(
ME:IN7E+,$1:UX-=AJWUTG$)4'N:D5&:D%&A*EZ+&IJ5T8+G:!^Z@&)Z1U\ID
M1DIV*4ZLZ$+L55[,!:+2JX(@0+]*S7FVZ7)$J7RPY#,ZI(D6+`>":;-`C\3"
M!5Q"7=N0ZIMLGE!DZL1FQP;<8H-R#X#UJ5_HI*PFA;,=Q$8(*YZ*;':T7$&D
M:^;8SHW^8K]8JDKL4T*0QT`TSLR6R'"\3SV5IV&`I5*\Z4#\G=@@+-'"!I=<
MP'?^J_OD3M**A5MU_FR402:_A,ORD:O4%D<=<1A^"8U+]&S(N*BW1BT%9=M[
MP2?9(L>&]LL0/>3Q^&B"\DO71MF"_J$""!<#R"S=FD;<A!:SJ:3Q("ADL*:[
MX@1F<>(W,L`#>(U`,,"GW*KA]H50!(`"*,:`,$`&9,!J>=O[K&P@D<L`>-@?
M_LT!Q-``Z""6"A:_K"WG?8L&#-(;N8U.$JGL`2J=\*-P9`"]])31`A`^_8T#
M/``@)1X"\(X@)L`#Z-;/:@6,6H5+E,<!-"];6`#5_"[P$@J_E$>;M$GH8NS;
MK.M#E.Z-Z&M5P(EK&-"W?F7X<NYB0(_GX-*&00@"+"S:T!4`I"Q"/$#A_B+%
M*'U4!Q#5CYC4DJ(KM2@PP@W)5[+J_6K&<#A`ORI1J?!F0W@`[6:$+HW>4,(O
MO_PO2/EM1`3AS5D-E@0PG&T`'VJ3*IZ;Z''`?RZ$4%1D'DJI!3.&1"9$B"0*
M`QR`JBS`:B#&!$S)`UP`X#C`!52/9#1`!FP9:20=!O`$!7C$P27,=X@7`FS`
M_P''=Z&B<D3``W!0!PS6)2Z`!&"``6A``6```Z2A/5$`!P@`!3#``#"<02FP
M`R``@DW`!ER``<13`82O!5"Q`G=`!D!``\RQ.7+`$6^2H.A6`""&6YP-#>)3
M`T`--(X+#L:-`00:IFP./,(A%R6B!-3A`SC`_B<K0"CCR"#)30!00#<F'"IC
MP`580,%-@`(R+P,(<SX6``/PGE]]0!9^;[$Q`/-F6K%P,<)E`*O%#068ULH(
MP`/H1,4(&0+XXT!43#;[L&R4RX)ZP`$\XP5T'AT:0#X>4)&$,W!\2E_VCE#4
M$^+(32S]S2CI1P<\``7<LL%90,)I`*K<!7,>QF6,C!S=1;FLZ%0BD#W="8$`
M#R&^+HY4!+_\;DK*#0'0,K]8P`#,#J1,P"7R"WY9;T'XZ"GZT0`$$J!84![V
MX@%I4R`];[@\8BN6"^_"ETZ98+Q]8P-L0'=QXH-B`!//%T)D4P$T@"Y!D@./
M\U\,!XZ8"@3DX0=X_F.FQ3$'-&?\3,`3@\5W;,X'@$5.C:K&=$!3;PL8;T"I
M)-!;/&._:L!"B0Y,P,1WN`90!(OHE>;HHEL&0&Y0S#4'W#%$*.,TLS+00/&&
M:(`$=`#Y/"MK;@X%/$`%.'(%\%`%/(=:4@9A6\"J`84U:T"$>A9(-08";*Y)
M!!*U(H1!1_5K8,`$&)M"J&'%7L1Y/FL':,GM!H8#Z?%!G$?(?D";3,"U-MT>
M,MMY0$#E&H`!XX1+QPIFM_4'?,8CO;9IS,4@YDT&_/(#^!KA#J91)(`&-8CZ
MJ><WGO:<08=;BAY%><O0?D`E34"#W-5GBP0?>]8JPI&@A*UD.,`FA4@/_L<$
M<S!''[;(9^`C@QCW=0,&&=/T`4$%5.J6.^?7`LAI8.3*!OR9S_"+J5[&(RL`
M.F,-RV+5`$>$@;E$XG;X9VAN@8V&ZS'%(^)(D9A/`]B1^3%X:<@-,3]HOUSX
M2+0E?)TT?&U7`.!(:F]&61D$!Q2`D;MBZ@&T2+P%IS"*2_.++/7E4VWK36"P
M/[?T4,CTU>0X9Z0AJ^4&B2B'!S"<<.-$9''`MAR<0&CCJS0V=,;&!KRM([\>
MI46``$RK!2R8!"C`8U>8_3)$YB%,`YRQTA#(9U(`I27<PI$P1G3`_:';F*O@
MP!*$`U2P1/!:24`305"`]6%ZJ2?$!ECC?*SP_D3(L4!H`!,+^$.X1`&01N28
M^JU+A,*Q2IEEXAFCMTI``&I#<K+B>K&GQW!T^D+`I=WXA-5,NK'?+Y(/3T_8
M-K1;^[5C>[9K^[9?^X]S^[<?1;6#^[B''KF;^[FC>[JK^[JS>[N[^[O#>[S+
M.VKR]KS;^[WC>[[K^[[S>[_[^[\#?,`+_,`3?,$;_,$C_+H74\(S?,,[_,-#
M?,1+_,13O-D]>\7?^@:(.\9S?,=[_,>#?,B+?$1HS\BS^W2;?,JK?+8_@+2O
M_'4;@)V__,S3?,W;_,WC?,[K_,[S?,_[_,\#?=`+_=`3?=$;_=$C?=(K_=(S
M?874^\)<7-.CG-13)'W5=\;%6_U9/GW6<WW7>_W7@WW8B_W8DWW9F_W9HWW:
&\TQ````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>f39432a9e3943237.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943237.gif
M1TE&.#EAT`*7`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````T`*7`P`(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRI3IP4,'
M#S-SZMS)LZ?/GT"#"IU9$V=-@D6/BNS`=*C3IU"C2IU*M2I5G`*3%AU8E`-6
MJV##BAU+MJS9LQB5,OQ:DBW:MW#CRIU+UZS;NGCSZMW+MZ_?OX`#"QY,N+#A
MPX@3#[W[DK'BQY`C2YZ\\VO1IHXI:][,N7/*S!8M:P7=EJM1TIZ%HD[-FO-J
MD4FYWCPX^Z/H#[%;+^;Y6K=OQ9DMXS8Z,O>'#ALZ'-S0^V#SEHZ?=U:+>R8'
MKUQ_:W]<VZ!R@3=M_GX/2UWU]0_7QV\ON.&"3>FP*U#(@'V]?<-;LV;/7MXE
M?-G=!<4!!`8<H``"#61P7T$80(#!`Q.H]](&"SCPP`+N+:AA8!Y8X(`$'.`5
M'F\%<1"!`@"DN``$%82XGEL=5,"`!!!(,-,&!QA8``(7;.BC7Q80$``%^OU8
M$&,<7,!`B@`<`,$&^VW'07(#=:"`!14X^%]''DR@``,-#&"!D62*2$$`"Y1I
M$'4=9/"``"D&P`"4/F9`@098=7"!`Q8T**%+%33@P`)CJFDH7#@.0.2APW$5
MP0%P`D!`!'3^J,$%XWD@*`86_*D25A@@($`"!MA8)*.H6B4!``5DL*5O_A<L
M$$"*`CB`@8L^XK2!`PH.E$$#$'!``9VO9M1!`P`8`(`"N*;J[%-L>>#```YX
MJE&Q<7%@`00$I$C``A1@NQD'$S2``4$2).A`!3-AP$"!#6#Z[+Q!,2:M`1I$
M*9>X%27I0+>2-A#N5/SZMRY!&D0@@04+PX25!@]4<,$$%%A+[\7^.4:!`!)8
M3-%[@UG&09AQ\A@5<6-YL$&E'^S9@00V%AS:RADXP`"N,F.LLT3]"81!`004
M*JX'%RAP[DY,Y0S1!**F.``$^2(UU`:WDC7!!`2YF0$&%40MDY<'X+OSV#UU
M$`$`"'@L4081>)U3?J4)E`$#D1+`I]H[;4#!_@/O$@"!TI\--#&>65WP`-41
M.#P0A:PBT"O@9$<>48P'%(#UOBMU*(&RDB[`+E",;3R``@>@2;A86>HG;07E
MN@U3!*4:P(#KDM>>T@4->&FT1Y!#6P'``BA00>\9W673R@X(D*8%#&A9'5@6
M+'"Z!Q@(*L$#M+=$0;`7(`"![>"K5($!T4]Z[6`F%D"K`_6=ZI/*$I"ZP`,=
M/V"``QF*M4$$#;@=P9T)Z)A,.D`!_#U@4>%+($DT,*@!-.EHNGE9`F;%J@D(
MYR?4>T`"#$0Z!5"`::030*E8!I:Y@6@@&I"8FWKDGRKM20(44Z`,;>,S`C``
M10D@H62B10$%.+!)_A!@X4\Z8`&%.4`!"FB`#Q>`@?@I8`$$J-4!`)``"(JE
M>H42"`5N5B.L$,\A'KCA$[,WPS):I`,SJD#I+C<9MK3)`104``-Z]3RB<"`#
M&=``!1:`@`0L0`$.F$`%_,BP`@B```1P$HH$``&\[>8#$?C;0-S5@"R9*B9F
M`\``&#`[,WK2?1'Q0`86T``)&,B*P$'*!DSIM`-(X(L-B=9-VE2!"SG`9@>4
MEYO^!8!1/2`""RC`$Q/0+0,<#98FP4`@"6(!`UP``@M@3DPZ1``#/$!1G_1D
M@"0R@00@0%F7G$P'F/9#HYT.E"R!&(0,$``Y,NP"&MC:`PZ`2`88Z`+)_D$.
M!C20)!0%X'-D`:8TT4.C"5S(D2;A6P00X``=9A-\Q>*``PR`+`5$!BO"4D"D
M7.E0_TB``=U$&P4:@(`<(0`!-"K0`!`0@:XEP`$)@4"*+H=,DZPR`E_AP`(D
MD`$!RH0#$EC`N[)8TX?.BUN#'$#B$I.G/4:J`+SZ%$+T-(']%:``Q`3D`O[X
MKL[=<`$!;.($&`!0@U`@10XH:FE&R;*KC:A="4C`C#IJU+H>A`(HG4`!!C"\
MQTR`@@00WDGL99,,5,`"%)B@`A+0`&!Z$%GM%&8":G0T"%C6`."RUP<P4$PA
MCD4#$*``KCJ@`;IF#C<2H!8#8&K7UBZD`BR=_M8!FF68#BP@108H*TM$V40$
MM-./ZH-:NA#0K0!X<W0#%<AB+7!.A&@``2E:*EFHQP#/ZBLF%AB``.3H*M=Z
MUSN&.Y$`=&L8!P`@``H@8UMZ^,>KTA-H'N2C(0,0@`$L8`(14%\"W%(AAVS@
M30!@;5DX\`#K]H3`!IAL%K_+8($PU+R.4PP&E'4`.O+..3*B40(&4``--LEF
M!<#0`X1T`/I5`$H<@*XQV?*`!]`6(1UR8)K.LH$*6-@GPG(`BURDU@:3::L-
MZ%9:\0,>\P*`O![AP*5H]``%"'.U#4B`C#B,`$/>[X/S,<C9&*D<4+74(1R8
M(@*22Y;!"06--NR?_H\9O"?+"N``J"2,!QZ0HN]]A"G:`B8]!1``[S&@I4U&
MP``PJ]T4S38A%^A6-!EDX*DB2U$]-HD':!1IGMU62&Q<LVLG5LL&+-@P9P/`
MS2"R&@]4X)8%,``!"E`!"0A:2`+@,`,&H-0[6F"*!&BTSRCLNMYX(`)P6D"E
M2S)2'O\D`I.5ZXTU;=1)H_2)RQZ,!685X>:0]IE"E<`%GKG!$&YRK*ZTP`-F
MY3D'"-,!!Q"P3`,0`6O]&@$N]LYW0.,!"JA/;&=)H7II<AP(H-33S/9N,Z<(
M@`9XL3`4HB\"&T*N`Y6.595S\K(XN=@#0B`!6(4AU#Z@1@ONC4YT;E*T_L&3
M`3)S'`&=E-J1GBNI"B`T*B;"P,%[,DH-,C'@K9VT`.;;[L.\#$X-@`@'&!!9
M`V#V7P,P$`6X-H&@>K-``29(#SM5@14A-@'G3<#('1,]`S`42J2Y;:U>+)8!
M84\H&2`FM5Z.\X<,&S`:`*EY<WW=M\-DG`Z$,XR/]`'FZ7BA6B<08REJLT@F
M0``(P,"!A/A?)_GVJ@BZH04NJ)`.O/0#&;`<4CK@%;8LJ<_[MHI$D;P3B1Z`
MH1&Z+E/_XH'VJ8EZ.EY2O`VC@2D.()P)(2(%/EJY5:,\Z01G5;LGC3_J14"(
M&@@3O)<.S^N0F4HJ!X\$!#NRE-?[0'/*"K?._GN`T%=%4YGV20=T/%9G4J;U
M)M?+-M440`^0JD=NL7MC<`/LJ//].!?8FY.!9O1!&X#/`A`!;G);`'`Y&!`!
MYS)6$:`[@$0!%F!:HM0`!Q`O#)(O&5`J6+$!&'=$Q&5HEY,N%Z=)<68U#S""
M1($;<]-8"J!KB%$3Z]=V,7$]$W!;#"`AXN$4+Q@:/T-%QL,\[,0DYS4C&O1_
M`/``#Z,^#Y`5YH9N$ZA$\V."=60BBT5*+*(<%H``"\`_BS80W?1$#*`^<J(`
M$O`H[!)JX5<6QY*$"R%_`C$!@=1JW@>#X?-HDA)^K<>&8,0!;!=+M<<JRZ8!
M6-=+A98L"R,!J=9D_E[C`="5`!H03PU07W\V`5#H7)YS'*:$``X8B,:5/5@Q
M`>?5`&`E5\JQ*@5G6L5!$A#``/=W'!JPAR)!+GC5<W*831-031BW`-U5&+=5
M:P61?,(D`7O$)`1P>+6R`;2%=0&0:O=#'T?Q'#\C-#'RA13D3-'1=]W"(W9"
M.!4`)Q561V510,TE.`A`>BPQ2B>U<+-81AT``7"6/`(F-]KV%T9&`#Y5.`_0
M*=;H+1""3P=A9)B(`::X=P)1>U:$',P#)V.V$!D`7:UR'+Z"=0*`CFW1,QZA
M`3!D@QG0=&WCC=KC=0=PANDH0W$72;1V-&SC9"`Y%UA!`0#3`#CS`?]%_B<X
M<E[LHQ`3X$!IDQ$78'X&<8$B1V^015ZA)ETH09$>L45_XB4,)#0O@0&DH@#?
M$I`A&3D=DFX-$#R'I40-0#\8X(ICL0$H`@#2PR`1!I/^E)*3A&LCYQ!Z(@$.
M8#)K`I$XM1">"`#!H@$6,`%8LB3V-UAK.&\9`5LZQ#SE<D)2Q8JQ<DC%-613
M64::4B/$E4AS-7Y5A(<L860%8%U7V"L$!B>J6'E+TI`4,4Y5)H9D)RTJ0GD$
M40$I$D`00#H,@(S+0G8M<1T%8P&5:1#1`P'`LEL]%4SU16MYEXN-J4#2`@'(
M]DW'IT1(!%)=MA>A]D\$82+9AQN_0T6T*3A@_A*'")%Y+JF':X(;+-DDV:E%
M3&(T*_,!%)!TR7),TV24$A$KHF40&L!$;^EZ)I%:U00T`927"D!1Y5F<8R-*
MYK9JR4@JHU,!C\*"<K&-T25UN0D>#-E7X8D;*^.5`VD^"[$!T$5W#)**2`0P
M8HD!B\(_ZPD`1#E-'*$W$J!#!!1:$R!)*6&(.R5H![!3#0`TF\2=`GHQ3IDL
MP8-N!0!#_S>6>Y%V*6)P`]E?!2%V#_"<:7$0'*``<[D0NRA)2S8H@#1BHX)6
M-3-]::6(8AD7R6=A>7)\O\*C&T%@"O`K@W92JS9%>M>C"I1H]*1M"T!1@C91
M*5H7'1!R$5:?#:!#_L@RFR-Q+&K&D00!J!2P)WU4(3T"6C;F0#=S`>JCBAZ`
M(CGY%AQ*>AL0H_BEIAIQA:>V(T$F0MZ4>G2:0`MY7B*D`.VT@FA4DWMQ)IK$
M4W_T:6U83*+*$$E3)6])CH*C+/3E3040-=2#4C"I+`B@A__Y4HK7GI;Y$2F&
MEB35/1))$MI2=3O2--*ZJL9I;V]6.6YY8K#3IW6!`77S9S)W$#LI*0PJ$>N8
M`!'`8_EE9PH1*K124HJR,GN4>E,J*6,B,!W0(-WR-!@J%"-#CA;06+>D($6E
M)V9C``X4/"<U<^!J.R9B(!OV)%=8`,'2%YEG:!?0+-$B=O58H:O8C\M"_DI=
MB2PSIA":TIH6T+"#\H.4(A#7Z22+@E>S@EX!6A4O,WD)P32@A:\@P1;*]``-
M0*P)$"'<LI89JS,8M5!`<P!7]Z1\@1,C`R=JJ*@"L6Y:QQ&UZ(9)9#]4M&Q&
M47(?4)<*H!RCY"THYR#(07!RXH9[Q20&()4$@R7$8A`8`"X,`U"`@QQ$!$4;
M]20"<6L--;5B`9]BP7(4NX(<LH,QFQ!!TDN?1DOMBAX8T)4,T4U@%S\5P@!?
MBQ0R<C/3)K`?`(A^LS7X12,0H#Y`6+N:1+1G(4K'EQ!$PVH>DK`,(2R-%47%
M='8#82*)%WV.^Q2DU:LG<TW=,J>`$69HDWX$_@&6*8*.%*`L8WDL`8"UI*$D
MJ?<>$F519G6C`S`!EIHB[+*31#EGYV6[MBL`LV<7&0`!NCJ=+&50^)AD["@D
M3'(`^<-,!;!@.;B\[],4<@$[?$2_@[$D0:-9QU&HTB4M"7`A!\`N'0!='$,:
MH'4X!<&._1@T67B_=39I!P`E110!LR:_\@MZ:.$!<8=[1Q(KQ]>FQ5,E;M*!
MN`4!Q(DP*Q(B*(/`&(,5YLB2`8"6=+&2#F2$"Q%JZ37!4E:W26A;*<(`I$%`
M520W[,(T@_DEYK,!ZA-B%"LH\^7":"R=N0N6Z%H0JV4V$Q"TO%L0;/-PN&4K
M,JM&-$S$)R,7%)#!_BBRA7_!H=BY$!<`)]*Y4%DD5]:I/H>V$#_3(X$20"Q<
M,0;QKJHX86B\R>=EBR(JHV:A4TB+$*<V+`R0K6LQG7I$,N=5``#GJSL"F'P\
M-O]5(;CTDGO!`5@W`%"H*T0'`,."M03A`(D*P9U;H<]5`17P)20U(R%;$'HR
M``0`BA3$R?+K2B5G9&+IO$/1/`V!;'LDBSPCPZ]Y`!5;8FY#&K/6QK-,+Q*5
MQ'_5?8&Q)`'H,>,$)Z*%PP/!/[UR-K>G-AL`4J_)4Z;[*R1D(A/42Y%BS;;[
M-#CA@+78GF`+%HW%<,"T/:@LD!P7941XJZW8'!,V8]/:SH0Q8:'%3C3E_A>D
M&,7Y>HV6U2P/8D''\HE"K!`>`C,)UJ;N%ZENR0""5LV;S&=0-6*"TBWTBT>!
M`B6R`@![+!80(K.^XCF1A#=L\2NJMM`\@J%.-M(D71C+7",!$#2`80'J(P#Q
MFF*&]L,?P"U1AL@&<&-XA'E-MW0),+"20@$LB2`;QM!,4BMX77)%Y!6%RB[V
MUF%-!'1O03]LN444D"42S!49"5U.HUV"3&IMZ$K`V]4:`@$?`ETU^!=(RM0+
M<2QP8@`O5I=Q<EYCTGI>P3<63$\2:(3KBTA\#83)B'A"=&IT4I>-],=/!`$3
M`"<)(,=2X0#L;!`<*D@($'H<T%M,,BL&0`'U_HI.;/D`QZK99,..$!``;TW=
M*FED+EEY$>!`F>D6U?-$4/2@__4D#X``[M>HM'9(]`34#$U?)(L["J"7K]E(
MBTMNJ:A+C\@JPEH5'^)V8P4L((P0`R*BWXM#$QT1ZSDPV*TS$C#-_]?4>$&*
MR<N[?6A<-Z8R*V,B:#4Q]B3=*V@`J4;??'U2\#H^R1(B6\2.Y\5$NI+0F,B*
M`*9)QTW@&.X<%O)<YW(7@U3-*Y@!&XP`&[&3N#CA.A.X]*IJDS@7%U"Q&3T0
MD@T`+,08G`5Q6#AH]`0IM7U>TCQ9$Q!W:',NQHP>$BA';FDS2[<`<$(M#;"5
MG)W0GVD6?Q9+`\$P_AIP-2:[10"S4CFKL_0J+B82D4RN,]'S*-7K%W$W*Z-\
M$)?H`/N&`<''W0O-UT#S9O]3Y@-!.M/G)N<UEV]B9WU..O3D+7\$(5"ROH]<
M%GD.X82B`&J800O]M+T&17S+$!K088F.,>NXZ0&0LGFQCI[)<+B,W+\<YN<U
M*P=@XN@H2MZS`02P>[.27KO2C5-R*3[T@P5<(@PI+]#"$`4>$;^C+`10YGI%
M*U#54=M-H16!$W]:7;].+[T+=67)%Q8@W-[W&NO+[.C=-@U"7K6'4GRER2`[
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MX@`1BDYG)6H0R'+'R@`5PE@YFB(]?C+2TO<(L3&]Y$%8;XD!\(X3D2=\)(=)
M'\-%Q4#"4P##OK5D39X;,9/)R/+LPBL;D#OT_MI##&0@?%5UH-R=X<X0*%+`
M9(4;#T*[M"H6?TKUSA'<10@?'3",_/(HUIOX?J'`)I%8^(59F7T56%?>UX)U
MY`-;Z?L!?/(@I@80#QXTJ'`A`@,)'#A`:-#APT.($3]L:!``P`2)&3\X`"!`
M00(+#SU\B&#Q``:-*56N9-G2I40/&AI0>"E10X($%VIF1(!@P\Z5%11,<#@2
MZ%&D294N9=JTIH<.1IU.I5IUJ@>I5E-RF$!P`0&=6L56-<I1``0.5!L`,("!
M@@4(#S`XF#!!`0,#""!(<)#!0P:''R842+O20P4!`!RTY`@`P(`*$2M8%!!Y
M[&65'C`\"/D48H:A_DH?%)#`U*@&!@<R8&;=VO5KD5%ASZ;M,FMKHQL,.%``
M0,%JD;6%0ZQ```""M+>34A`@8(%JF0LD0(!@%X$$#1@06(;X8`!*EAJ,)P@,
M\32%"`D(&##00$/$"P4<8QRNM0,%"<`]/VS0H/!1#=A3#BD/'@"`N_HR2W!!
M!L?"JD$(M=K@N03D8^"G"&'C8(''P',J`P0>&Z"Z_F1Z0*(.#BCM@PXLF.`K
M"LK;JK<"PK*I`0,.F.F"]\S[@(/&(,B0J0X>F."_`7_D0,:',F@@`J48&.`"
M)I,J#JTA8<IRR_V&>Y!+,)_*(`$'(.@(P3"UXB@`-(_*BL,`%%B`@0C>_FN`
M`12E^\`#"\AL0(`'_DNI`S,'H"DC";9+;B3E*'"LH31KXJ"!"9*,B`(';(SH
M@04L94DH"*I$:@,(&/`P2ZP\C735V51E-<P*[@RQ`5=?W6D"QT(-3JD-QNR(
M`@TTX&`D!QAXD"L(%'C`@PTCX,`"`Q+0;U`)!@"``4$?>B`!5S&P-H$>;<UH
M)`X2.'3<B#1XCH+;,&``RZ,(16Y/(BTXX-PM:Q5W7W[[=<H#!0B@H``!\/5W
MIY$LL%:!<`U328,(%#@@,0'H@\B"3!^*``$'"$```PP.>*^#""!3T(.!.U+V
M5`<2<$F#W@CH3%\P-T"@LXDH>,#@AR"(DX$C_O=DUH$"IMT)6@MH7FF#`DY$
M]6"HHY9Z*08(P,""`A10>FKM'@MK:Y%\=LRQ`*3=,P,+."V-@@0B`,UC!Q)J
M<@`HT0T[,<?:DP"#GQY`P"4.(DC,Z:@I6HV#"QBPZ+N,)KA.S@@FD$"""!QH
M`,.C*$K@5*4`OG!JT$,7?54*%HB,Z$I'9VE2QU9D*28,L@6RN1RMG?(#=0D(
MH&D.$&C@(9L!(`^B<AT8><G;0$ML``4N@*"`MC6WS0+CYJ777PT@X/L!XQP;
MX/.((%C@H;D4,%\!"41]J8,)SIHJ`M-5EW]^^FNK8`%UC\NV_H<<!8!6AXV)
M`(&2B`46T)<B.48G_A0X0`4FD``$S,E&$6B`IDBV``A48&/N"4X&,%B7_$!E
M`Q50SP`6`S@#`$`U8,L2119@`(L`H&E2PAF+&!(;A2A$-DK1`/0:II0+'`!/
M_"-B$8U((!91$`$#&,#ECOB!"U@$7"S9``,<4S0?9:!,#K&`8RH@%'9]H%#X
M4@A,.*"`W32@0J[S0`3:(K2(=&`N#N!<9A+PF`BPT"IZ?$@')""?O,E%,P=P
MP'\NX`">704"!G!=YSQ@@`)\Z8F3I"0ERU4`!!A``#CCHZTR<```R(R*H'R,
MT4AEMD^R10%U^T`&Z(0DE5A``A;`0'2`(P$560HJ3YG`PCIIFJUEI455_KOB
M`RX@E0M<!R+%4E]3F&6`\>TJ*1"XV2\K>4ULK@IE!X!>`9QH1"!9A)4J6<NO
M?/2!XNCD)HX98E,XP``$9`!FG5(0PCIP1P/LKU4#\I0'-G`![WAO`9J"R`(:
MHID$"`DS#3B)4S3`S&Q&5**BJTA>"#!._MW'6K]CR01BB`""9J``&+F)12S6
ME.(\QP&8.R=$.K"DEEXO(E:T6H)T&9&L8&`!UNI(`H*F$8#F1X@LI0HR%0!`
M(C&`,!-E:E/[53("Z.XW1\2`<;3&D@ND4(4,P!?,(N"00QI/IDAD$=L:J!%)
M0A$"-=0(!WK$D0&DSZ8[60@@54B!#33S`Q)H_L[FI"F611:FDW\DJ%,->]@L
M94!\.2*`0HO8@=ZHYJ\1V1`[2^6`"HR$9'5ZB$*LB=,+7"!;3FI>1"A"@`0P
M@#O^W,!!(E"!N*0P`(4<4DP:L``/<4`"O7$,(>NHI=9J;[+_\B?:0N2LIM@+
M7HAE;G,9Y($)K"<`".C19\'$*`D$0``24)69%,,!$C+@`95K``1^6%0M/017
MBI&(HS*)ENPPI#<!8`"'QD8`VF:H0`A(0`/X)A2+3%>X.$V)=<,S'0403(9&
M&Q4$_.I<"$>8-A@PP``PJ:LN[>LP\EF`7C_@/^K^Z($"0.U/9^,_!;#471S`
M0`0D4+7FL+-C`K`P_@)VYN':>`"S%N`O`A(3@(L:F"J#F5@!)L8FIU0UD1)F
M<I.OTEH'^N0I:167!D!Y`*)FY`+=HT\'.K`!Y)'E)1>PUAOIM0$'6*`!!8"A
M8PBP``0<(%I[`W.J$KN`YL10``RP`(Z%TTLV'Z!"`<AC4S(@``<(V<F+9C)7
M*&!%_XRYD?SB$`'\LA*86>2$KI&<8#-2V8M$Q(`\]2F'%L#B!MCXMPV22@="
M-+8$5"#+$:JB=MDC109GSJ"Y9G2O?;TZ:A(L`.?RE`;[991"R34S'A7>K(%B
MJ1&^6``!<&Q&M&.<!E(@63G*I(JJ*(`$#&2)*M)`!=C*Z@N\V,T*,&^D_G!%
MX@,J8``G34H'2$CO7^=;WQ(A8;@)P(#SCFL#`;=5!:RU`&=_QEH%./?K5A(5
MMZ*M<DHU27DZD!VW!$R3`-#N`0XP``),X+**&X`F"[!P.K:,2A#R9P0`&2<*
MZ'-+!C?```_)7G?N9M\[YWG_Y%*U23N\7R!:\"@?$_26W`8K%W]+LN1MJIB$
MR`!][D`&7E0`W07@``3(,Y(%IT:\D1A]%E``QT+U3BP_%W&\!;*R606:C_?7
M(J<>[D[DI.B>Y_V)[*O0M80>M0Y8$<E+>S7A[/8Z#$A@`6PN@-;]!A(6P>D`
M<"9``>QJ$:RS>0`'0*,!'"=#CAW0`A&#(%A:_ED!/VLE*Q=(,-D&BG?6L"\Q
M!#CJ;9<,%`>`M.YZYSUS^?J\`.!;?A%P3*%50K*#MR1Q#+!1<2G0``<\8"]L
MNVC5#>"T!7PD`%KEN@$4X(#%PQ.3%@Y``.Z4F`9D``,)&`!.>`H`\#"J/A50
MZMA,ASG87X8K$:!`[,X83:;0J4WK/0*$,+*#`**)I]V;&O]!.,/8@"N3.8CP
M+@;(`.=1(S3ZGV,BGW#C"@$X@-"*H`DXB+RHD+C!E-V0M\I#`(_!`)'##C%J
MO-GBC>]+CAVB#3X)J%!"GX3KE]1(/9;`"]C(OP(LPM90&!<K``>L'PM(#`,H
M+)@(D1K1*_]AI`C0_AWF88`.#)_4&@`@\YT#0``*<*7LDS,MY":V0``V<X`(
MR""HB`HY`CF)H:5:*HQR(\+)>BD)Z![F:1-Q29)%"B.F(!H,`$+3V("\,D)%
MC)0-B+7VJ:GZ"1G'N#V(N","<#N-H+!)Q)WR&A828JL'6C,#B(#T($5(JCR"
MT1W'F#;?X2P6V0P&>!(**+FOT$*.29H/2S37,`I[P[/>0KWY8:`',,24,"!=
MP4/@>0`%\,-%;,8&Z8#<2X"/&\:Q$ITJRA7&X+A(4PE0PX@B60"_`#^4P(`*
MT!D,NI\/3+#UJ+#Z^QX&8``VK(!A^:<&D).C<@!-^A,@$P`;FQCID)("_HB^
M4S&P5G,C/A2D9[.5]4,`8M0(U"B`'B2+^_$F"60T9'3&HFK$```Y`V#&T$&,
M:U$524R[C$";6,$;CMJ0!%```<B:!,@+'Q,`_WJULN&XU]H`"NB)M1J)#7#!
M4KD+Z0.6/T*MTK,6D1,P+80^KFHQENHDJ="`1].S"FK(V'@5!Q``@GL)HQ`<
MCU0]JXNS[(.@!XA(Q!H6C&05HQ`I`-@IW:.?'CH.7MN4CNB,+[L`#:H0_EI)
M/+J:!:",.U*ACR,;:4P`.!L]O3@->((`"Y0`-4(`>&R88IF`'/D(W:$3\<H`
M#@"SGBRWU%JUI.``ML$;Z,$7L(&*BYR*]LFL_J;(*N1B#:D`F,=@#^;)2N:*
MB8H\R[^;#0GP/.-8C-,<#BM[C-LS"@EPC`7HOPJ8,8L8(`V0HQ`I.2/S.`R*
MH)P<`!I+#+10OY&H@`.0BU8*D99$K0C``.68D/1!@-W9.@BBE+',Q`BB3:'#
M"B?!F^F*D7]YE62"`+)L"0\2*]<`K]PS'D:Y3>:Z0=Q$F`WXS8APDKZSGAQS
MC5KSNXX:&QGZN,92G`H`F1>AG*-2K`5X`"EQS.[!+9`9EB\YC)JK+PKE';12
MO)#0@.FH&@/0'@@0`./#J0VIM@S+@-T<&\^#*6?RI'>$3Y=`LX'ZS^>!.@4]
M4*<R3>'`@%(A@`$P_CS:>!8"78K`20R1\11-Q"0YVPUJ&J#1@R0+R$ESV:GR
M$P#O>P`)F`#:Y!/%^SX'8"+S2;^,8!JDRAT$&`H_`H!&RJDQY!4'"$P9&L\E
M9;D?622=Z*3[.("&4[WLN%(F[;U#11$7\X[;<1BQ0!RJ?(K@+`#51"L660L)
MZ$EJ*A4:NXA>XD?TY#@+X[RZP,6:L,`-X*N1H@`Y"541.RN(L"(Q+"\W^JIJ
M[",B;2G0_,M02K.(VC+A.XH,8*1=++<1G)RZ@(`ZJ=1)=492L1SY^)@"DYJU
M.`L/RZZ0:"/"7"+TZU&RJ;P%L`"S5`JB(X#(T!PWY4!=%8P!V`Z"*9:;_LF,
M,'L)KE"<*U*`1YVD<EDNI>B`ZW,-O@M#]1B;D\#6;&U&#5BB"@,`:AP7B:T*
MOA*>;+D-@UL6!N(+K,N1FK.H)L*`2VN*X+%1D;"+OO@P`_@A7(I%D(.G`%@1
MY8#*/A,Z#C`06-O`B0J<=ITLFH&L_")"9D'$JKO*`#C28]O8B7V5OU@`Z>"O
MPF*63LT0:)$A^%08`X"GB]*`"0A#=]D.C$M0JK"WWB3//4FFHWJ7;*&_EN$Z
M,MDN;L0/F7M-Q_DHO)):5.%.I'LVAHA+L=B`@1C#K7VN#;"`8IW:;$J610(`
MC.HCP'4*R'J,\_*`"Z"`KK`K$K.QOP2:QR40_@X`)9`J#[B(JL(BF9K[29*1
M&[0"J![T4+Q!`+<Y+&8I`#RY&EIZ3:U,G&:UBF<9C:>]`+=8V7V1(TF%W&LR
MH)=DBU6[W*8(5^T!&0LH4_$Q'S4L.3?KWD`S7,R%$X0MDNX\+PK0ND<;*0=K
M&WW"``[2B%HE)1F*V>:J.;YP`/VM#L],K][A*,PX#!R)JNN`G_9T7@0FB]U:
ML[6<G^*,34@".=0:+]1S);+#(_Y36<!PS7(J@%/1`(-H&]&2#-I3C_+K"(Z[
M5Q9)FUE#&9[ZM_YE*@9PCKJH@-T2HAC."$%KC1:)5:+)H+I0VP0>XN2ZBP98
M#Z$5G2"B4,>H)CMS_A(-,)`!Z%D[:XUR"H`:NA/UJYIE@8CT)3%!^PH(.@M/
MPYT)B#FTZMIY:]YL>K322)4O8X#2J@F)V4]@@JVGRQ@BWF/3N(#G<`P'8!*E
MXY=KY#AE>4F"DHD1M!`V=JB_W$:`\4T09HC.V$TFRJ">P(OMFMME5)_@$24)
M`XT![*QB`0Y7V98D'HLJ"K=RQ..,Y6-8]HS]BC,""+C$L^/:>H@'9IA60A^)
M"!R.Z8W*`)[%K0EH!.3D<!($(16@08]%TKK4`#^0BS2IP-4>Y!"Z:>1K\@!X
M,E80M>,*X)@%9(J?'2"UQ0J\*-U87F?-D`[B$U:7$@K*14N@FKO"P!B#_A$I
M@<B5#F"]"D)&F9B[]YB4",@RQ8,F-X+8$:RP)Z0L<V.)M8@3=<XFHGE740/5
M6KF)`\!#U(#$"109>EYGY]J0Z%-3NFRM3!H`_!GGIYF,4.(.OW%7HR@7SWT4
M"[`BX3'EL2`4O!&2^&A6>WFSB:F\N-*IW5DN"X!"B7A@`Q#?IG(Y7%PZA4@4
M$X-H`RCFEK@2A4!$!KHJD?[JEL``-%*`V6*1T;@^OB#8,.&G0]*JANZC"!"T
MF/NRA(*`A=.@XSB`X:4*F&&G#-@8I?X`=YG1P40MOM"NE7Y#^5.)XO`:)A,*
M^LB`YZLYCG'J";0TUD"<C;E.!*AJ,+%HL#:-_OE)#PB(*OT=CP@P$@RJ)PAI
M$1IL,\?@9>*9`$Y9@`H9H)Q\%"LJN:X,4GOQN,@`829YEGK,/N,AH1C:"[(1
M+8)8[)5HC,$]K%-Z`-X0K^JP`"%V"<GL6=;8&/'BKXFN#P,-;=$.G9'(`!`]
MLK%1K3'$,QWUI\``7#ZY$[MB8@7,"O`JE83"3._ZOLK+B=:8BPSRW!YQ*PW2
M7RW\/C06H_8;J>Q*H?33'AQ+F+G#Y4JJYNV+&\=U$RCZT.08"]#TY5:R'+>=
M*.IMJO&6&I+!NKXCX`@HTQD&01%RP66$D'=BXB]\R?*+;HFHJK6$+?'!,,Q`
MC>?Q#0>BCA?2D?PP_H]AV2W^G0#Q:LD<[O$4,KUA-:PF[.*E0%QO=9"!`3B(
M&(P4"^G+8)8$3G&I2:58#,@'.`#M*H#QW*T1TG&,C9`'?@SH`<;@'.6'N2,5
MF8ZHVNNI(#.R`3DCHR.+YDF1HSSGB!V,60]*S$12$O2F"AG9[9Q>*EB6+16C
MP57NSB8S=U[G#IW`82+_4HCTP*SS7@`H9S/LC)`H3JA::LX^VBGP"0]0`C+>
M%:<R%XEJB;6WJ"6'T`"I@!\WG[884@SG(37E;8G\`0`=12R>I&Y-'S.\5>6.
M8:L]!,:(\B?RYI?<:(`1$>R(T8L,X-$*20V.8Z<3_Y$-MHGZHI-Q#B>V_BB]
M;XJIJ:@Z\`:M=FTMWJJYX]`@-[^7"I"/*07MEDA?W[!P(U*.`B$`7N4A'6'X
MI_#C_K)6$/4=8I>HF%"=*C8L-'<-[0@W-P>RR4N``,,D2')S2`D3W5HK+7P)
MQ"6`!J`>%1D];I\*#K!`3+%:C^.N%@-1X^!=-0S(SE5KF9VZO3*R63+$`.D(
M2L<F?[H`N)"/@B'GEJGVI#B-ZLX^O=#F^?'VI/M#(#6LLL=!^UH/%G0S]H@S
MSJ@`5^)Q"/%CG<`1(+1MD<H1VA%$K32C@8-2G*`8D[><[G%5?IP`88\X[&XE
M*>VS!\(Z*9,4@07@27+X-_RGYRO\G,;W]:$`_FC%#6'I++"7'U?9)0V3]@0I
M^,;J$XX#,O2A@!'^LN_#:LQ8B`3XB8JNB><@%1:$'O"+^JUHL:VCF)9Q&S3%
MF[Q),PU(T)'`E,[-&`R0#P5@&[Q0(0LO]09FJL;5M@3(,[+Y.+JY<JW4C6AW
MD(3A*MJ7FM+?Q5'_=I?H@$H[B(`T-\!@$N1-_[&@)ES\(_MT"1P!"`L+"`@X
MX&##`P<>/C!LZ/#A!PX4)"PX8`"!`@(&%"2PD!'!@`($%#Q@`($"!@X//2Q0
MT($#@PD='@``T&"#1P06-T!DN+`GA`$`$'3H:?0HTJ1*ES)-FH'"A`8@!PBH
M"2#``@D5,EP8D*"G_H4'%)AV(-"@*=J?8!%$4(GV+=RX<GL6G6NWIP>U=_'N
M[>OW+^"E:C$T4(#R@EN('CA<X!GXKEH.$!)4:'@AP0+'1W].2!"ALP`"##Y@
M4#!!;T\.%BY$:,``@8,#`W1>-$```8.*LPT\^(#:YP8%""PPE``A@P0$`ASX
MSIB``8:&OQUFL`"!0$T#&*8_[L[T=P<,$B(X`!G`:M4"#B10T/Q!@8&B'2H\
M:%#2*W>(&^L&[I`!0P8;<*`!!A@P0(!,WBGHG0?\+?A=8/D]."&%%$KHDP8-
M3%#A6QV$%4`"&&B@TDP%9,"4!@XPX($$5!U`P0,(//";!QM<\%\$"AP`_@`!
M"0S7@$8`R!;`C@IHL$$$/CHP`08;H-8!!05$T)`%,7E80`)/*7`5`P?AY8$&
M%E1`@0,^'E#5`!$XR"&;OG&P`08P(F!530($P-L$#Q#7DP0&31`!`P<<P(`$
M"BAP84.!5O;8!A*4],`$$##`0`(.9(!HFYGZM*:FOC'(::>ABFH4I@Y%\(`&
MH_:$P0*8)6#``A&D2D$`%Y#E``&LB71```$P<*FG-188@5DZ+A!``0<0D*Q0
M`8BF0`0>$'L6!YY1L&P#P#8DT794P@:F`05(D$!&``PPP)Z>=D!@!0L(,(`!
M,6'0P0(U+9"8JG)QEU>#83E@`)WG#0`M!.D>_I7!G#T:7$$#H/8TP0$0=-<!
M:PPHT``$#CQP@</Y9KJ8Q]YMH&W()><KH0<6G&CR!QUL\/+($U1$@04!C.43
M4AXX`$`!(!D`@6$-A8E!!0D(H(`#4BH`+YTU(3!!H:;E-8$`!5S@00(2?)!!
M!DEJ[9,%[3W$0'P4"/7<:P01X(!;&E#`P+E85;`5!VXU4-,![K%L%P802$70
M>>@UH)6`'=`($0,"-*87!0TSA0%NW>75`>4-5B><WGM7"++F?;U4:N>A3^B!
MI+:*'MZI"_R<>4\7``R`HP<4_4"<#U2T``15>19:X'<>X-D$)V)`0`002-R!
M;,0-^A-.9"I@P01&_B(^P)L0V(;`VP$@D$`"#3C0*@((#+XV4&A&)SI?$''0
M=V$&5&75>:914$'FB$I@(D2%-L4!1H^I%=X$',"1K'0,?1%BG0$%D\`%:LH#
M%2#``A:8@0;\SG1)<5U-'."W<1G``%0IDY``<+0Y\2Q\$+A`DQJR@3)Q`$@+
MV=)I$N(>#MA.)PVXVD,D8("Q:,!H!4`2`#IX'BP](`)[BM'*''*!'05`30Q4
MWU.^1T*K#(``!]"0!!#8%`L89(8/D%A35,<!T)'%.@@8"0-XEJHG+JA&;'PC
M'$G5)M*!,8$:*(``%J44"%B%`3#*#78&0($("*`JMA$`;A"SQH<\X`"S_EJ`
MK>ZV@'5M17T&2(`&M#*BGV@``KVQ@%!,1('W(>L!:W*`K_#%D#0&0'H,7,R;
M*E"FP-6DBCV:0"7]LL(#G*\X$%CD4AY0@`J0<2DKQ(Y-+B"`%<51<JIL)C2C
MR:#Y%7-4&7#?S91"`7MAX`(/@&`"K&*6'`F*;0LYYT,HD+6%9``"$DC9)9OD
MO8?02P$GN@!\(N`DWVP@51@`F``>,*[00.!4B+OB`_1&$YY9$'T-PD!"C-:T
MV5"`:_NL)E(J,(`-,80#)'E+GT[S&)<5+23FXJ@T_5+`E+)45/S25`06H,?3
M7:`!YV&`6R2$@0+P"`%X=%H$(E``>WIH`5AR_J)B/!"^NK!(`2J!'D\6$,%M
M%6I1_DD2`B20*@YXZ0$#\)X%!"*`#A[*(1XP">1>Y)"%`F"FJN(.!\B)1UJ>
MRP&KT<!*[Y*!`MSK`Y?Y55,64C2D^L]&%X"*`A9`LI;&!:.,?:SD'+L7"T@@
MB:/ZS8`N("GXT+*.2-F`3:^B$0+X:B$0@.36C/<VW`&3(3F:Z00,X!C#?:!5
M2GR17AQ8T`ND:`!:FX#V9+>!<-:D`(O4V4T^P#`%3,I[.ZK)E$*5GWYJME7O
MJU-!"F:!9WIG/AAQ5`-ZV90,Y*8HDFU*G,8(V;CD=;WN?>Q3Z'?>[C1*JJ]K
M&@"^<B$/C#*(Q:,4_@2*(@&%96A#%[#8>BS@&`T$S2'7:BV@NO4!Z^!++6%R
MEUJW>96"D9"O%:C+M;[&D`F$;WLEJ8H"M-BF=7$M1PG@J3A_MZ3@L>DG'#"`
MKRB`T18.P+)^48T$)D"!(4\`,>]]2X..K&0E_U,[\^T+OSC03EI>)0"A.9.0
M]IF4.^:W4!5A0*KX&`!3MLK&N)*1!C*@0;U5P`!6+0H-RWJ!AJY$`P^X"`2B
MTQ4>+>`!WP2`'R'PU$KQA#O!X9'!%#2=R?TG>@C`,14UD@`*<*"]BE9F`LZ+
M2AU["LI1.@!/D>6^!'!WR8HIM:E3W4P.C"<OJEI?NZ@2L.W)*D/FXG12_OC'
MLP0$0"B\_``?!3`E\FAF?9T)'_X>DB(C248"T4G.8NQC5H?0BP%A+<^1>&K%
MBWV3+5FZ``(6T%J(;("5V1R=6=<GS$+2U5`4.)*3GKP7#VQ$.G&9@&\MS90-
M^(TKX8M.`PH@857C!=4$/_@"Y^-611N%*XT4"9UZ)"^\,H2/`%!(SB*R)0.0
M9P$8F8!'1;@AAM'Y)7<#`+3<`R7MT$M<'XA2!OSLL!2-M54)D)T$:G(>`2P@
M<0/8T6V.,VV(=(!J`.@-A\)S`9E9Y+K:6X`#WJT!>0.&`QKQ\5LLL+9"RQN?
MT?4D0RS0$7V_UXT(]PO5S_Z="A0L[2BJ@`2D_@+CFO2HYQ55I0-Y2A2E=`"5
MRUS20!;PMMN<AJO,-&L#?J:B6.%P:P:P@,ZD](%RZ\0!-\I+/S%@@0B`1.>U
M3``R\]N`/I.VSPQH"U,R@!T%3"@\8:/@3\79O>"I=V^+48Z(XP(Y!$3'U7LI
M359)?``)5&DX;H\CYR)TY..KG2D'9EL;*<>5"N3HNE=!@"<IG90.;(D`XB55
M!6!,+H`1`"6-D^D'(A`?L[[F?*PZ@`(J2[GP?J!/"H@.<#%FP@GD"=0:4=95
M%,"Y#-6K"(`$7$:2$$\Q;0#`:`?.H-VZS!D$8%G$'0!&4`#9C<J`C<9<:``#
M%$"BW0648`:EA!NE_H`9\S53"CX@8[U4\W$(832`P:7%M'E`!OP)`E#959"+
MT#5%&@G;2ME@`U[+HQ'`B?00`"R`!T",9GA(5BG;G1G`!(R,2M`*`$2+!%B;
MK0E)?0B@`\0)!,R)%!Y@@UR`2/#:2%B$!%18KM5+`'A68`W=0A#(N`A%TXB&
M']4>"X8.!UB@77`5`2S<7KC,&#6([[U@A;A,!B90DB$B!.9'AAS`#&9<:EQ`
MW+F/'=(=`T#*D90:=["2N"7%8@#=J>Q(`6Q(7+G&FVRB8UR3*:W$FT!4N&"2
MKDW)/^&.`IQ'`B"&YET*Y1!-!E!.772`^\A&`9Q'();*0G2`!%0%!\8A_M%9
M(N<10"::BZ'DV<NLX.@\FF1U0`0``$H!AC8Z8LXLQCBZ%#FBG1Q5P!5-8OJ8
M%0;DR8M9'\I]D8(M8D-\(X]\GU&PTJ1)!02,7,\(DC<F%X.%B%$8F_<,![`I
M0,$XP``X"VD=W5MLR7G$BVT\0&+H(:E8@-[]A#FBA7C$E`!2&;=9@`907#09
M%4>^Q05<W#FN1#K.))+1I'=`P##A(T.\A(T$T'/IG%=\#P2H&%ID0#AYWU)<
M"X^0AT-F1LZ=QTU$3ZK<V?>I1>,$SV4(WNB9!_R\2PC*I$-`0*]D#6D4@,`Y
MT/?0F6)LP)R8R#*VI/K$29Y`&IW`2@/H$V0I_H``#!Q<;`!?$:5<A`=?VB1A
M%J:FO,U@BJ(P8L"I'$A7%H!]:-]C$(LKY=J6+(?/Y!&2;$F6:-WEA*-TO,2X
M0%U&6!E!4%%(7(QD;M%M.$:;"5ONU$3N'46]#(!&YLPOLMU/5EE!0)U:MI0'
MZ*4$Z&3+6`P_UB1$7,`"R*!A-J=S5L@--IX<41M4W%F5B9,#5(`%&,XA`H:=
M.<"X&<7)8<9R0D?+A)\`4)IBE811\)OJ4$7-`0RR"."+J(PA%M,=Q4??X-C/
M"<58'2=$+!0"A.=.BH?U]$I=NL84&N*1B1US!N9D".)>4$#$$.=S7BB&'H4&
MR,I+&)QX"!`U4AGV_IU0(3*(M_QF3^R,31"-?21(!52%*<D=20"6-WD<50!-
M1`J%K#D+ST#>?'%FYW&)H?"?2ER(V8A0:V52`S3`/-(2`1315KR,A3(B0T".
M;,W%RD674NP75QR62$!>AH:IF$)C1UE/`#&7E_B&?PP2!>E@`7Q1!&#=A*C>
MN2&%Q4$'L9@E#Z71:/1-00F'`U1?<5F>>"A`LIQ>D.5)G<Z%/E[?X*1DJM"6
M4B`A[`P(!60,K]%)(25`0(+IV7&`NZ"H8)CA6;SCP8S)I5H,N6!&@HRIJ[XJ
M76Q>H5C9`C0+.'(`?3R`1*''4/G95W)(M0SG4CP0CTB*N6R4;\3638P,_HQ\
MSYE`9J#RA%N$A70&1@8,Q/`!)E*H:+SH9<1A"_]IZY(]0``0TUS<V%1MZ?J(
MR9"5"??`G_>L1V+$)*S28+TFD!F*DW`(BD58C/7URC)I!;TJ15SU8%*4&W3A
MVZ00![U@Q'+R&K+<20$\H[W>19A4FKW!1<XU32$)`&54P!H-K$.ADDC-Q>],
M#G?RRV+T$QV"WKD81`2P1WAJH\C>J\VVB0;42TU`1V=<T618WP+\"<A*JJI0
M3`,L*ECJXZ28RQN&G7P.T=REF*CXQP-(*%.\*/Q@#PIM`'?2).G8ICL>!9-"
M!;F\6X&$A0!NZF?P'TI66N6@V\UVR)3&;84L_MM7&<X%"!#&"`7VS,_4S>W$
M0`M3U$P0Y:!0N(3+/$!Z9,>7R2E8*I]/6$Q.P851U@1E.&[-L@QJF*$]!29,
MA`0R\14#N`;&&`\$#"W1KAC@AFDCTBT?3H8@,43.SL;=H$L"05WJ`<R@A%O/
M08J-*(MQ9,7Z'%_KBF3/)>92=(#%,<?CVD5W/E%N#4@$"$KO"4:#:(#,)$`U
MFLO:5I3)4([KDFGX[HW64:1OV)1A;(_CLDQ].(:$K%"7V4>[Y)<&/)!QC6-(
MPH78)=2Z]).6*44%6.[Z.B]</A%C6(``^8C5#)U1>,AI;6\A75SG9.[X5G!W
MT!"@;0M4I$S\)5#C_EBM69G-`&@,V2!C!FC4E79..SU%SW71XPA%(.[A(!8P
M`T6`5QR-^N61=#RO0X!6N(2;BMC)I%B>!1?Q^+80HC4$^+(EQ8;.!"&=4JC>
M4"1-2(2;5I!-FDH.9%0:<CA`=EJ:!CP7'/X%#S-03=D'_.$*`)P;RA"(B`A(
M<!A`W6@9!1NQ'3-6T55%J3Z$T=!,!7",#'M,83#%C9E+S_F-23B*C^!4IVE.
M>!R)OG%55:0K3:Y0O)"6'2*MJ9K*5]RQ)\=M(3<Q0]3+,EG1KWI,C'R'SCY-
MWF))N0S``@!HR%2'N)K5!6"'(]4Q^FQ3U7C0><RFQCK5)P_SO::1$DJ'_I1M
M27Z=AP.D;LE,``/\[V:T"(\DA'((#&D%`/397G``,R$#':[1I%&^(43Q%!3#
MQ4)TQF(1,SMC:&PAP*)XP(?.'=YX*LOTC;E&\8[`LEE:A.6I68\,L*C$U1<&
MLBC.24"M+F-=ZYL^!78XSEQ0`/8H=#M7]'IQ!G;\#`5-Y`Y6BJ$^*,LHKS`;
M]$Z&TW#(K);=,IAM3ASRVQIF;/.RG^52-#J2,7"%!@$01.=&=%;1M$7_-&.U
MV41AQM%FP-2!6PH_8E\@(6$AQ=T4``9V5/VV!E_)\JC$E9Q:FE(:UTP.A@`:
M@(9X'`@#,*>&+5"?M>:4\5W`!+*,E5UQ"L(H_@Y@O.U>8)``G')8%M>\N%C@
MY+0F>\?ZS(M2-`J^O(1U:!7?U6:K&M!^49U$2*8.>?-X34HMH[5EAXQ:W\4'
MCL=V&H49-A%%9S9:]!UT):6R!(#WY'15O$M5@.:\M8R44D[=Q!6\=#9,;TOP
MF)=J)-YYW(R$B%DTBP[HN.!<3T`!C#%:\!LF739S+Q#SR3/'M*1>M,@VZ_)1
M*.TDI@@>%4"X8`>"6(#X"#0Z5X!R6)$%=I`'F4N`Y=I3^!GQ+0TR_;5#:!3]
MIG5C2<Y.[7%CZ9!X-[=_/Q;H?&-EFLR>&8"H*A$)48:8V`K_'+B^3)!_XE>=
M7%&@6""AA)5UC!^:_D":>HQU1-R9(?6WJ#!F/C>07[*>79B-5?\WBU]TSDQ`
M3CMXC?6PSDJVO2TAN="99!3I2"T=F?@(7?+([X":6;J*182>#BY3D:%0-\W9
MD32$AND<7N?+=2`WE'V'`1S`>8V2A[=XBUOWB@&7EIJ,!\)H(W_6J0%RZ]F(
M`,'?=O9OI3'&]S"7NZ@'T)R'LX`:VK0$N6@0_8`WE058@W1HI8&Y0SC*BE/(
MBQ&H\Q'`.WDYI..%3W>.!BR'YBBE38AO1T5%96NZ;TQ.W8!DL*CL?&2-2F``
M#`^G?SB*GR4$I8C$]N87+D&-!#C`T>J-:&LQ<?L/4[R&B!O%/]UFI`_[_FV7
MW3:Y1*?HA91YD\7,7015TT(<V(=UCAGNXA8*P(88R,4,#M<>20/,!GD@><^$
MCX]@A)F@=[+@CA^/B5:8-63\18&@18QT^<%<#*/;I*$3NZG)\ZL0AW4K]Z/I
MX`'(^&9<@#TG.U*\9'ZYZZLH`'D?@%0]FF(QQ*/UGC+CS9`-F7:R:4M(E<=[
MC\UQ3\]Y<6Y(U84#2).OAKLK2$JB1?38^%)X8"Q?:+[KNZH1BY57"&A)>(\0
MP)0W+XO0NZA<DPC%'Z0833@]P`WFB)#4E*\TQ,G5A'['=#]MGO%\!J!4Q+*8
MY48T5VX,T$E`!?])`-EO14K&>:@SG/-USQ_J_NK/.V+-V_R2?>TY9\KPZ%RO
M03RE.1LZMTP&"*[HT!!I00O\:=L:'[I9(E(O1?U0_#I2O$3*WJ"*=(FMUX=L
MV`F"(LLF8LQ$!-5V%7JH+%$G!Z8%[)!SQKW<SSVJ4W*FY*S39"=>Y44N)7>!
MD"$#EPPS8H>SV,95[(AG><!"C;G%X<WYG!<Z;<IL)_^;6")[Q.P?1P6HD7NX
M]$Q"A0H&^"&6EKYK-R?JISZ`\Y&6DW2$H),-FD0&Z"'P$WP.R932DQC(=0Z4
M"`S/&-4`P,V`*Q,X2D<:41',*TCE`(0'#Q\^<,A@H8(%"Q<J4)#0H``%@A,I
M5K1X$6/&#QX6&.B@_A&D!PP#((`T>1)E2I4K47)@^1)F3)DS:=:T>1-G3HP>
M*A0P4$'GQ($6!5+D,)1BAP025UJ0L`'#A@D)(%!P&92F!PT+$"`0,("!`0$,
M.I84"@$``PP2'#`8```NW`1(:]*U.4&`!*PH&Q#8('/#@`=["1?6>-1P8L6+
M&3=VS)+"@09VZ[Y$BD&!A964"T:@\''C8XIV/41(8&"`@0-O"SPHP&!B!PX4
MOA:(>QM`@,DT98,FV,'W2<X?-C@H`#2TXP8#,@P7?F"P:.DR.SB??AT[=NO9
M]UXX@&`[2J0>@K/<(.&I30V>B2JVON$`7`,-(B#(W1<V<0IA`^".*\``_J9H
MTJ""#(32((/R7N*@/LVD8R"`"A1,R8,$&KB*NPPQFE###CW\$,24T")``YW"
M:X\@"@RX8*;Q.-A@O,>*JHBGU"[X"RT`"`B`@+96ZP^W`19PH*KFA*(.N-$X
M7(E!!!P4+0(")EC2)`\82(#%$#L\4<LNO22*RR]?R@"!`BX(4SB9*E@``M_0
MS(B#!AZ0H,3&.)#@``<H@T\`IC`@P+^X"%!@3@DFL$`##JCL\,X#''S3I@H0
MB`!#ECR```$!Q=R4TTXSG-'3%B>RX``)*MU)HPX0LF#1C#K`(((#%&CU(LZ.
MTL`!0`=`KC#R,J@@@@80(.`!RC2(+X&/HKQ-_H`"#F"S@K]"G8B#"7Z:S@($
M&I#6,@H4F&#:<,4=UT1R:;)``03J;&\X@3C@`((!P.)V)<P&.`"""VX\,J7>
M/#C/VV:_TC1-\<C#P`(*$A@@``,F<$G!#A0`(($,(B@`R``FC<I<@F:[5KH+
M$$A@W9<L6$"OY#I>F>66^749)0T8("!+HJI362@+&(@O+0,MRP`"#"S&C]Z6
M,'@@WZD(0(!G`*(3U2*#'B!@4`(2L&"#CS3`X"('`"A`@C(-@.L`%D$EMP.%
MGWP,,Y)ERH!0F.6>6SH/$*.[,`H"(%BHLSMHR($R^XNHY,UD(VB#7QUPP.>4
M*B#@@`(&$``N`2Q<_N!KKC.BS+H,+IA@`0(*`+3'"BK5>0*[:$N+/[@*6%N\
M+JM5H.;'<%57)@X.2`#OWJ<[VU.!(/6]):\A.'&#J0&-:\67:4J><2XO3<NV
MI2&0``,/+EB@@<8QPF!Q5C'Z-=C(NS+@VX8T]PW>I8*S0"RP&J`<+K,6/)6[
M:AO07#0.'CB@<"SI"O$(N!CA%1"!)\G`PA00P)=5@'YP&4`"^*<37&W+>5&3
M@(7H<P$,O2IAO,((`P3P+&F1IP,9<,C,=)0`!40``T<!C4LJ`*ZA="`"#'C*
MBSSP@`&,;@$4F``"^I.?EVR@:/F;``0<N)@.0,``%7R)`Y*50"M>$8ON_JF`
M`HX3D@_@)2XDH95,,$#!E%@@`;KY"`K7,H&+@4<C#'``!A9@H`T@9(@`$,`"
MOJ.I@53E`R6B`..2,@$B&:H^.GH``U@4@;<LP#):V@`$F'@=VCQI(#$B2"9#
MP\D'-)"3613E*$EILK<P93B37)Z.4F<8GF!@C!DX0``"P(`5&@"7S:(8B@AB
M@0:<!@(/$(L!`B``!;1)`TC[0($V0`$/9.!%"U`(!%H9FPY<@)H-8(`V%S``
M!TQ@>0B`$<LV$($'-'$Q$QB`@%"H(('(1E%(=(D#!D`I#:"SE/D<C3ZM6!P`
M-"`CD^S*`Y;8`!%"K2(=:.:5=O>93<*I`?U1_LW2WB(DMP"0,TB<@&T`()F.
M#"IHS=2`0C_P``H<[44(LLH'),"`4/Y&`U!)G`_3<@$%#,Z9Y'P`(>L&`8TQ
M0`$*`*H"%E!4LB1@9$3E(P,8@(`%"'."7)'`\/A95:NV+`,#$*=%SJ.``S"`
M5T.A:JT2AX'/-4`!;XE+1!;E`0LP;`"#XHH!$N``A05`3QO1@+XF<"4^&@`!
M!D#:!#1@@:MX@'%_NV,&"KLU]C2G`G.A$8TB`)<%:`"<]\'J-O%IF`X\`#<9
M`P##<B.OW$@NL`;@HP!X])8$)/&JUP%>;&EKDV>.+JP<.)JS^&9!81U@1W$)
M`&D!L`#\<75L`$``_ID*T(`%]*FRQU&A`XJ*,<L9@%(72)N`.*"!9W[@9)I)
MW`8J\#EP.>`"ZPF/!0!E``D\#BZX6YG,&."]QU!`<@1030(*4`"A?A(!1%J`
M3X0*@0B@)ZT"&!D!&-#9VKKG;@^6<(LP0,R4?0`#PF*`!5Z*E0QP]#8!H,I-
M.WK<BG!@8L659;.TB@$,V.<K\R'2H6`Y`:#`Z)T3`)H#NHO$F'ZV>UC:Y`2X
M1IJ+:("(!(``>^%"+!.'BK[V;8RO*F!6"4#``9ZQ`)8;0*0"E-``!)!FE`@P
M@`:@$0)&FO#OUMQFF)`'R;!!(P'.[-W8`2;%<&$`-3=@$/L00(H7^6Q__A[0
MS`58Z`%,.[1=,1#3K!4E*ANH[T;^]8$+/(4"!BW(!YSKO\1)!"DI?._FP)F7
MK(8QT.'2@#93?1/IN>M%BOH7$I%HU@P@+,T=H"*X+%V@L;H9V,%NC-<.C8`'
MV/?7P@&:G"8PSHDP0(\YU8A;`;4`)!H'`5Y-<Z+@5)`&Q'0"+.I`3+>FX[1]
M(`(+("GXD-A2H(X-DCO90`($D&;\QB4"XJ*+S(0<E-FZFBS[2<!3,M``P8Y1
MV`E7.%;L@F0].L#!H_EW3D"K&]B.9@-_QC(1<W/AR4X$*AG(F@:P[(%P3])N
M2*14!B0`S0LTX*M\A%P"0A?OV#`6FY&AV$DA_@27!N*,4UH92-HB</&L#"\\
M=AL;U5*3+D`9<>%1WU2RR46>#30@-\?;3(1Q0I?*`B"*)\%<`$:'RS(_X,D3
MN<">W?HJ=;\W6[K5;@P-0H%XZ7$`"FCY52XPQ^H8Q)<1R%7HO@;%!/",``?M
M5`:D69`>*^IF.:$Z1G2G,>`"M]X(\+C4.1\BX$P^7(SW"2T?@/!]%J8"%:U=
M1G*$I9UNCR0FP6'I:2>R1+VH`J'&P"!3^X`+0#/REE8`>J=2`,T?Y5>V,<"5
MU`J7S7<J]1X-:@(20-"T;X8PVONJ+P\M5&$]O_/A_Q3HQ407_SU+`A>@0%>N
M3Z&<X'`^1D^..D?+_E0V80[J&>FKJH["HGNF/-,.CX\2("%B:'P6IME4B`(6
MT,::*<S0"^OBXFE"I0)T9`'(@JDRL-4\1"DPZ)YN+:;81/RRB/Q&T%(J`GRX
M8G\FP@$$0,HLI01!+@*:[21>S.<&K,P"`/PL8C^`(Z:>B8JVB2N^`V4B0/&`
M#BT:0,?(RP'2ST#(1+G.XS8<0%PL```@+@.R\)XPP'3$!'X4+YH<P/1,L&-B
M4$O,,$3^Q5NL9FU0#`"J*2;(P]]>;@,KPFN<1E@4@&K:9#M4:*&&#ZD,@,#R
M90PO@,X4P*`.+"H0)FQR8P(FH&GL)U3@)N*V1.UTZ%1415@*C0P+:.*Z_JX3
M*8^.C"E['@K#Q@:#0*2,8"<C)$""J&(_]G!S-NF:ID:/E.SWQI`BOM`"FL,E
M+B`!1"<"(N`!22XN]`(-$T,K0".3.BQ$KBX!\&<VA"G?0M$3K=&5*"(RC(]2
M*"-M%,",*B,GX(/73*("^B,`YB3,Y,(Z=(;ZMJDJ8N@3%8@L(*`"$JV\:,P#
M**"B4",N($`J=#$[X.5Z#NS`%L>A/@0IPB;W+&+M,F#/L+'SDE&4*&.+G"H"
M."PC,&"6>BM_O@4E;/`-+6"XF(8!EH0#[".(HD(@,V+5[(H"8$A1)D(#$B!0
M"B!H*)(P7D4"%ND"(4!8'$#^LD-F))$B,`MN_JI1(J-N'IG2`A)M4DZ%,F0)
M`.Q')U_BB4P%Z*(F`H_I-((*[>@BU(9E]6SB3A!`+78BL[KB-C`J5-Q*`D[J
M`AK-.*Q-2SI@2#B$`Q8"`8QR*86M);>2G^QFB`I`*%'BB<:B_41#51Z`%6M%
M`H!$[S!&Q.RL/0RI#F>11C8`08Z&<AC@XMQJ`?`J1RH'[4*%`]JBV11%9_)D
M**=C-I8B(UBN`]#R+V_3%&,+*6I2`+H'X7B"^LJ2._YE`902)##`-AR%'\/,
M3+PQAB;`]VR"CL*,1Q[@`;H0(T3&S!()+@)``1;30^QFBY9F=/:'ZSJ$(]G)
M(@Z'^EX3-\6O*44I_K+$+%HVXP+$HAS#,\!BQCZ6[ZFZ"2>9T9=HCG'NQ"]K
MA:NL3%C09\DD@%)D#4[4:9TL(((,X`7%).-TI(@",_L0!\OD[P+.*<O>$S?C
MDX#H(L.^8]*.*`($@`I#1*A:(J*4*P(@(!BM1E^N!YL:("[GTJO&4"0ZX@*#
M*OU.ZM;D;RA&`@`B0`.:+R\XM'\@@*B,<)"$ZF%`9`)^3B-4!'5<YBI)5.IT
M;X/RI!)1)#`00$N`,N)4Q39`,W)68X_:(F@J(%$JX,KT*^VL3E^PIP.P+@#L
M4;L^@.4<<Y#:#PH';I72$7^^="8V(%TPJ:4@`#P;(P.(Q"1>3E+R"DPW_M6+
MY(8P%Z:.LL(0+31$UFX'U],^G.0`OH,`%"QU<.B%*(![I%0!U*QO@&,M=@90
M].2FJ+"[TJ;!/(B.VN^SZL\K*B<"@H-1L\+$3-0Q'B`5-0*S,G59E9%3KW7:
M1@4U\N4\WTP"0!)$)"W_-L<^P*8G&XH"3*J9-%*%H+,K[$M_AN5K'#3O*H1Q
M.)-5(NMF]C(\\#(WCFEY7!1#R(/\DO$\"H<GOFU+'/5%02(#FBT!3K(,#1!;
MPZ5:&^.)RB0!KO3C8`("<%)+`B<E_+2^(/$UL`PHQNT!BM,@X\-`=I2+"N"I
M,JU6TX95&J\@T$M5EHE.TRL\H.@KCC4WL.1H_KPJ4Q"*X?@1*$CN(SH`3S+3
M,3Q`J-Q3A2H$H%8F:RK68IVU_'0&L"`N*/#+YC1D*,+&/2UM;`J@KUCK/DI$
MH1Q`[RQ`:!R)J:B/^HZIT41M2CX`.!8@*EA$!%.$R-+U0C<)`S`%2&[#OX;*
M+<8V)H+O_=!",^[3;?\':AEC'Q$@2_JPZ%YHE"[6&NWFU[CV2SI@-:0M-VW"
MX*"4,+:(8T-B[`Q.P>SC`&+(SLP/BNBLRFX7:(@,XEP,+S$@2^_D2M^%,^EH
M]60#02[`-&8IM,!BS^HDAP13)9+$WRA`R<I)R6!E=PIWRH!3(VO0`=#H5'L'
M="62`P(UDEK&;N*F_C"(L10_!!@SXT1`J]ZTJ;P.("]X:=P@IH86XC.4Z4;B
MDB/,:G]$KKNLXE<IH&2D0EB^+'&%"T`D]4C,R4N0<[@HIYA&*UJOXTZ&;U*!
M1E*,,X%(5VNG#7(K<@-0IC"4(@#V]D,F0(^T%%7033X8K*52H]5"3?UD:NUT
M#:".PE`XHA>S[%V\ZR/LE&_WBBV$97(BN'((P#-<2$':PM48[E<6<`$;PF>Q
M8R\_MG;#Y(ZV@H01R!E/>"_.MVZ`L7SK(FPNA'JGPQ5SXP@MP@)LPSO3!4+J
MK:W2%<.@`CQJM%H@((BLI`'2BVO>A3B6:0&@4P%0`XKU:'>"Z'^BY30._HL@
MX.9`R=9+QJTC\O,DL.D#A@2-0]>$Q^5O-,\PXJ0`O'<Z*LSYLC60;')OZN,!
M*(>&75(SXG*+$,8S^BI3+D5A]>H@&`!:,2904@,ML:?/O&UC9TE"0$Z.SO:J
MD.*I6.+EBK*40]%N6#?HT`64@X(C!>`QL^.)X&(W0((#H.T*[Y'>!.`T:_A5
M[B0NEXSE2B+#P.507L0"W(B%`N4K!B4"/.@B:(.Z'&4H2(YVI`Y8ZSB#"B)A
M-FR;N5F-UQA<"2-.UBE$*$`N(@ZT;K&_=D1BC_.;;N\HM()KGI)%+""'4$,`
MV#90>H0"@._?:&/#1,YC'.``4&E<*GHB,L``_K1N)<AKA<-YHL//IV5D[3PR
M)_`KGI/Z(JA2HTV"H\F&C_27C]698T+#SEXD5K(-N"+Y/[YJR;K5(5MUH(\-
M73+%F]VC8PT((R9I17?BN%+HQ=+YJ/.Z_#"CC6V"O1#@<A\C3BAG`C/"$.O'
M._R+:FAEW!SB6XWY2D`L4,AN=QJ``@@:0:-F9BX0[-"RG-W/,8379S!+?!AC
M`_0E0<`KEVLEA065L"(6JLU7K_'FF?`E,3"C3X:31NAO7(^,Q-+LR]"JE6OE
M7WXEF!ZY^0*E<N**KAR`F6#B+!<@Q0[`E2^BNT9J.C9JH1]GM0T#LT8M>:(#
M4KSE`RPU%%M[MEE&_GLF11DI5+QUNR#X4;G:#UXH)X@N#Y<HA=+<9??^6;E#
MJX2:4,<@12S!1\&D-&(#32Q/K*]09E)U(D41H(:,C9HEKZ0`FZK6I$\WN?-F
M,KWE)FU*)3'^IK@Z1*&&*+B:\U(IQS"Q#K`((&54:)&&);C^>ZQY%%$@;_+^
MA&J,;[0<6M"<JP).%W,GHB==S'D'0"M%@XX:UF3J:#_9C&ZP^\-A!CC[6CU&
MIKJO^"(2IP+02E[CXK+"8P,XB@`)RO`<`.9:U<:[LX2,F0)ZT=EJ6"7<2@]C
M;%6=1#B$URTH***<7#&V(KZZ:7>B<LI^XP(QF26V:($XO#`4N7>HO,K9_O=8
M"ILP',"]&'/W`&R5;L,`/OO$1A/L'E%*.UVYAPNP,#+<'KPEF'B1ODP/T7)2
M;@0I]K("[-0Z#0Q:X1%1/DRR&*,F1T>#WXOFRA0GX$7/94(#9KKZ1`.)?,>L
M)SV-E1'%'+WK'`G0TQC.<E2RNQ/5Q8(!P#-M=(6_;'RX?**N)"#'@T*A$L=&
M5XE8<@@<C6TN?T]??*@_R#.N$B`CQZ-,A+-7]FK+OFIG&NR^U#;9#&+>C$M&
M8MM:9<+AI9TH8FHQX$,!1MS%IN*E(UG!^!V)8C*PM2*Y_KO,!F6F3WI&S-!;
MO"J"+$L@)*#,!'$^@#8WXH(*^_>`*,(UK)WA_C:B`T"GKN*7,3"CNQ==`:Z.
MYQ?NE-<3O24>3.`Z,>"6==L%5KBHS!27*R@G0.[I*BP&U&DDSW"CD2G@UA%E
MZBD/L\"2B.@G`-#/)_Y"IZ]$@\7:TNWX68H\H1!DSADC;,XDCD]BB^2.U<71
M=YJ^SMNZE)<^#CL4+S^]!%_%3B$"-P9%CK#F`FSCXBOBRK9\(EITK3BJBQCN
M51SBEX*Q.T<GC+02`GK$40$D@B9XFOK#<4_O6`@`\4,%8:037/0EXN4FVIW>
MWRR\0S?SCLC>+<""0\DC?1\1YIS4OZXG6NC")A$@PBJD[J75)CN*^>*KPF5/
M/ZPS+"*(EDZKOZ3;_K8M[<M8:+APN,H01P(H)]O7<V'\WHI*D+S@!LL5[O>!
M_TNZ^3<`@@.'#AX^&#R(,*%"A!X:=MB0P0*$!0<*$``P@`""#0L['O30X6$%
M"0XN`C@9(*4""A8X>&0`@,"$@A\\:#`@P>-+``$D,%#P(````1%T=J3YT0.'
M"Q0P/#@I(($!`04J'DA`0`$!`0X*.C#@TD*!DP`00)A`H4--#A8<'"!P0,$%
MHP8C#'C@DJ[>O0:1\OT+.+!'#0X4#"@J.+'BQ7S],DY(\+'DR90K6[Z,F6X'
M#"MK5DAP(,(&QX(W6,C@H,"``PU,D@VP0$-@#!(:&!8@@"R`T&<U--3Y_A2`
M`[4?.$!PD"%P\`$*+%00"N#!8XE:LQX(,`"!`0,$A,*F`"'"!`<,#$[\L$$!
M601S"6J`<,#``0=--PS42P%N\LS\^RNV\%9/_@TXV4.D$8A@@@HNR.!B&!R`
M@&\0)/!`81(0I]@&7R&0&T\$-"#!`@`4X(`%&F#XT4*F0<#``1V2-4`#$4AP
M04B.'9@?`&`9)$$"<^V%E`0G#;#`5V0M0->!&3#5P`(,C`5=`!T*0``!"Q#`
MP`:1;=`D5@/\U``")R4@FT$/F#7!:0=&ME`'$S109H,UR7G9!05(60&=>BH$
MTH%[_@EHH(+J50$`$WQ`00`.?(`!A7DIID$"_D,V0$$$#W!D)P./SLGG4A`\
MH,!89`DP0`$-0)"61WY^D(&8`ECP000(Y)GB40E9D-L`$DB0D5`&9$#:C9M1
M,`$$"!`PP(@')"N``AS"M94"&'C`P*+%:2#!L59^"L$&$YQ$`*P&(9!`D@?2
M=&*"'#S`P(^#/A;!4#*]2V^]]MZ+;V88$$`C5AQ-@,`$*"8&`48/.+8!`PQ@
MT%$''&QP001NZ4;EEVA5L.I>,`7`P`1299"N7A!/4`$%Z@&09\D&&#SP00Y#
M'(&Q*0T%8X<$0-!`=AE@4"1("BR`P7@+)+!`!0PCA.M)%!P4P<(Z9:P7U(%M
ML,``"5A@WP;VM9PO_F0-C*AKUV*/37;9]29\T<UJ06#`M(_9.8"X"'$0@0%+
M)V33!.PFJ]N($%R`-67QCNB`3P7,VI=.ZR++<<'"T?0U``ML2A,'%3B`%4]#
M6<3`E2<=`/H"!@B5@%H4(*!``J2^1:$%7&N@G@"TFEDZWG^=VU^D`)SZP*D8
M<#VV!Z=;1*O49A^/?/+*-\9!!F@]RH'Q=&$P>@2D6<#O1Q4TP``"`T!'E@(2
M-!6]G](G=,%%[*''U`+-*;X``A90W_%)"W#T@02^XF_0!A$H4!$J<4<`"&B2
M`08P@-P$``$4V(`&'I";`V`@`PH@(`(>4($*7"`#]UF(!YQ7`?XQRED2_CB?
M[11BH,Q0X"3D2ET#*@"\L66@`;G)R?)NB,,<ZI`AWOK1!2#P-S8M1D.DNML'
M-(`!"WQM`1:(0)-<@Q'.18`"OK$58W0W`'=YX`(+8.*Y&&``6G%/`KDI`,.X
ME!$R;0!4##A33"J($:$PQS`$P.#X+D`3#(BJ2`](4XV29!0,.,!]O&N`;9R6
M.!1>H$1XV]1D/@@!N$C``A:XP`4P,)KEV>DDA]JA)S_9M=_D4`,+*`"L3F>`
MPPGL,1Z8@%"LQ8$6B2DF?$,)`0Q0H@M4P)&9B24G$V*<!>PG<1V0P`%L^('M
M#5(HW7H`NQ#0L1;=Z5@CHN&(")@L`B3`B`SQ_H`#"/B`5$D&*16(G_NT8C\1
M+N0"L#%A8CQ@@04T0)TYS``#L,)-4.ISGW\2)0XO(``&=,!.!Q@)+GDI&`KD
M9@%J@5T`"'"X9&%G`+@\38,<ATR74<HQZ>MD_RR4+`.TIEAP2<!=&F41!"9P
M`<7RI0`>$$,-&,T_#W')X.+6$0YH8$D&0,#1^J,4#0PD>AW00,B6!Y+T((:?
M3&VJ4_FS+]$P(`!YL@`TZ5F:!01`@@;AF0(JP+8/5=(W_E30"H4S,'A.0)T3
MR")"J%8`"/"-*L@2@%"L)+H`&.`G"I@`4?,GE`/$B5-]*>LC3U@!OMW-+QZH
M&UP*4`"/`C5A)(J8_GPP)AAW]J<#(`/*4S\+VM`*1@,(L`B67/*``:S2@W\Q
M#G;$E1[Y82X"0J03!L04(9=5X`&B6P`%\&@0+OIF`C_QWD.A`U'YR(<!%R$2
M`B1`&Q\A1*$\<=>?,B`JZ22$E"\T9HL@0*!&M5$!!EC`A`S@UW<"J3\9"&<!
MRB/:^,IWO@6Q2006((&\5&`F1C'L42R0K'F"[`'E54U&Y500#C1`2@^X@`2(
MVQWD6JLM!^@B%'7S7/(D`)H9^(Q&9(0Y."$D`Y(:P$_Y1*`-5*II?$/`,!E%
MM!\](`&P&9`'A+0T(>5$`PK#JKD`Z9_3-4J[\RURO42I62.C<+`?<=MF_DJV
MP0Q$9`+`U8R(OH0`!\RXPO*T0)(M4\Q<U;)O.@*/J,BLFP.D20+DE4\$9*H=
M+2=`6G[I@$0DX&/^*`4B$_`)^,(7IPX\0+!]N4"R!/OEO80Y)Q'HR08P@#,F
M`VE5'L`D@2K`@!O/3LF<5A6!0%+;3@LF?;0BSKK(=,2JZ16`/4T`!&[4D4AB
M!R/03"\%$K"?1$LF?61.B92\@^:^00<"&``C9',E'P4XP&B/,IY20LU*@OP0
MC+KQ=0(!D%$+/`!8!]F`F`S@9:!.@(!N(6#\]IKG##V70,[30`3D)NIX]T4#
MF:0IM.6]%UP=REL)+@Q'!CJ>[B6P8YMNR+FT_NJ="6!@E_V[[XOEM($#].VY
M#_Y,L/M6@*'IR*2D>I$`2C@0_Z+X(!7HZ4]U?9!XEG)F,`*1T908@4=)S&M8
MLFYFW"V!#%:@DI;\'642S"*;]W+G!P`OOO&M@2H#E28H5_*^X"37O]4M`2($
MB>7N9(!7,^0H/T05!6ZL`/Z1V'IT*D@'(H=?A1L\5A?7B`,4#K%:IN2]EC+`
M4@/#XP/,F&$F])-8JAVCBT7O(!1H@-QZAS>[@+OI=.$`!1X@'HD1^^<I+\"F
M^W,!2F7]Z/A.X648?_2$R3-4U2+O/!&2]`NXDD1R<R?;+M27>.:3095V$E;_
MCI+#+2`"1D.*!W*&_J4(3#$O1:H5:Q7R$V!5*-U;/XA`D$(]LB1@`FCA6BOK
MR#1KO75E8?>/<5*7@,,YBP'<I@R7%-!L]A+;+)QO/^7=_QB`.P`")>LSE=4R
M4`H\*8$!F$D,Z>(MEX(0[))K9><GMW4265<!DG80&L`2+5,M'O1\#7,Z'D4>
M1:5+R0$U,_0`9:)@!=`ADN5!WU(N!C$!=W<0XV8`#%@9%E`6A:<H&0`?#L!\
M@/$_5?1I#H1+\,>#BB%R/0@D#B1E&``X@\49%58A#_`IG@4IO(<A%-0`@^(8
ML',2R&0^A-47'<``1I<0[04!.)@0$4=V/)(`MI$L"9!^*!0<2V,<&!0Y_EQX
M%-@5+@:Q7XE4:*YS.X$A%K!B`6US1.3!@H+!@0JB8A1@=_0">D`H)R&AB(+Q
M(!!%--QQ.%GR`47E0#LE91F@)>JE`2"R*1"@`('H'U+3`0YP$G!X.Z!X>76!
M`*`#`<113'UT)M;U0`I`?[:A=.@A'BF890!0.AM0`$OS+;OS?Y[11I=#`-J'
M-S\X<GI(`'EB)S42`7$ABH!!'@C%'Y@V0R(8*`[#C(UX9(D8>LZ4<\MA7GGA
M;DE8(5OX<("Q1M+"*1WP/WDACI,QC"[6&-U&(O65$%UT`;V#7X^V,A3U=6'8
M$L41,TBAA0"@``:1`47"`0B@5PF`:@#%D&6R_BI]6`"6D@`HF!B,&!@94%X3
M$@#*ECH0@(WY^`$6T%<+D@$1<`$(X)&`TB?@B#SUV&E^D0$^\0`GQF,%H&Q:
MUCO948Q/HT>3@WHL591R8F@8,7MT01@^Y4'B$UR=,V/043M8B!``4R;R*"EA
ME#":\@'&4@`)X#89(''/2!<7$!]OIC62$6K&TP&/)W$8P5(74&]75'1+61D;
MD$$%0&1.A9,V29B*L1E3]2O%$7(K>4&.Q``"D))1PR&291-,9"^1(A1%<3X<
MD!J8A4(,<'</V1T8\8I&H3\E]`%LB0'Y80`S=BC"TQ)(0369J1?8LE;CU(QZ
MP5G9PAQP-QET<P!"_C<@D$9*![9/@UF8R0D8=&,2'Q(JZ,8HK;A8K,(=D9DD
M!'9@'&"+UBDGZY(;RFA%Q5%*#-=\"4.9S:,>`=``Q2@6B,8N'(`!W,,`^543
M%B`!#P=@NQ,U(*F5\2<]"5->%$`LJ6&630<PX>:2DY0`QJE/]Z:<#XH9?J%'
M"UHRE3)&+C&7%$$NK?A>;C-$RH8W%["@1T9="E"4*O8_#>"AUQ,P6ME6NY%G
M_48JJW%&G_)'_=,`^W9?D)<;:-A/<ME6,4<0(5$WH<@8MZ9U_;E9.^5J3X6<
MK/2D$'H\D6$!5(5"?N&`0CE_W-E?YG$`!8D0$]&.@'(3.N*A'I%8KZ40_@^S
MF@1F>2I28B?F06*1'4L5(GTA91]0?(4A3RT2$ZMX.PYZ&?((`*@8`5A2@XJC
M``H0I3KA@!$'GE(*&-\HJ:`U>(8&`3N#`9N:1.6W%E(&$9K(ET91`;>D3IQI
MHO2RD$1!%V>%CR-6&-OA+`*X$#`A`&#J$2263Q.P(Q3@)-Q%6@Q0,J=R$8$9
M&$J!.Y<!.T7G'-I68=787X,DIXVZE;BV@Y6J7MC::=C54]NQ'1#5`'GA/V]!
M+MUQ-9)Q6P60B\G4'*.*(!T``4(!7SI!8B,";YQ)%E%H%`6CGLP'C#;T&Q5P
M`"HF%477`.$T$:A#']SG@YZ6&6X")0R&C<[V_B`SJ:2744Z<8;':RK$]"%#"
M:DDABTD%P6-9=@%&%305-AEU`T-XPY7O<GUE`37&\4O=]@![U*H]6HT<L'GK
M(I.^JFTY:BD"ZE=U4S07L#((`#Q?]C";M9H9A`$[A8/N!#ODUTT*4@%A-Y\=
MBR#4FI/'0V*`FH("@)0(436,1S?2E2()TX%2V`&28D90PTXZ<BJR84^'NAM@
M6)[J00!\YQ&EJ*(5`)3R5"R/5UXPA2V,LBSNDRRF5&?N^A&<Y0`;BQD<(`&B
MD8?%P3;PQCZ#1R`7P`"&B(I<JV>42KKX,E"C`6H/4SXK:0#3ET2_-0$*D&F3
M`8S<B!X=22_\Z@`I_OEH^D-K\F0R5"<I_/)_7*(T5K1%6Z@_9Q(;9)(^=>0M
MH5$2?7,7F\*?X8D0<ZD>">"U_=,[3`82K:IF"(,!GCL@Y00PE'NZCT00WRM:
M\&L9E48!NW*YDO='<PD:J5.69,NE>T$WDU<K;\*Y?U*JNS&FS0.*L^13A`&"
M71$4NT,Y`N%`NU671G>)O-0!18*T%1%SP>D!;),`3W)Q9)NH#L$6GFH0QG$1
MB#:H#G2)](9I(K:]Q>@!O`4HV;(]3]F^\TNZXXL\I(5`D+4=$-*[6=AAQ((J
M_PLD^^*C>&,;D.L?NB,`0@><6UB7`F!T"Y<<.?+$Q8$!3@1`8R90<#4O_@IQ
ML/`4*ABC`+PG*9IS<3HB::0Q4!(P:#08H@MF>?7(O:#CK2`84/0$-3Y1P"?D
M'VS)(>P+LSTL;_);&=CU-Q-$A)L*AMXR`1BI2XGH`;3+-?%T,(*B.RBC$!-P
M,_;1:/;C,@9!6B/B$L662D5G,B/"7/8JN*`H4`J1D!\`$QVC&B`8QQ0CG,`T
MGQ90L`4L:*4"4\HJ,0[`S$KX`-#EKA_$&H'B`1!#E:&$OHRLS1'**@5E$%QC
MN>"7J=NC=U*L$[+"H/DCE=0<.<E,$Q1P`&+)*-"Q@CJY,K!1."<X12$1*@(3
MP?0'`)!6MF]%'O#,$V?VRWV3S!?;`=HQ29F7_J1($58KB!DU)1"M&Q@-K0!C
MVB"KV5BX6R^"NLTCS1@B*1VH<3UNU@!Q(14+(XX80%$=L0''`:T)DB@CHD6B
M\X1\(Q,%L21@!47M4F^?P0!VFRS(D0`.D&59:!KU*W%_EM`8@4X)**<+$2\E
M.-.8.UU7\BKW`IR%+"<6T"Z[1])E/5\PW0`>4`&Y%1+$<3IYDC`+RL2`01%I
MU3]?U4\..4O(!+IW5Z9#,4_Q"2$K?="=\[H0(!%)+1?H(7%HR`&2LIZKZ6=1
M#7@6$15<`A?)>[&IF1T'P46TZI!GD@">22\4X+C&1R?N1@"*;-:M[4D8,!3L
M(@`Y"BHHF4SK,T,Q_H<>-0T8G\TU<_F%FYT@%'2*!T'3;_68DW)'$.,`V>1E
M27>S'6>E9U<6K3P5H9)`+T+9NX&7F?=>9C$XQNI!%8$0H-NV*3@<YCR*1]0[
M(B32Z5LT(^K:\]U4'-!G9_*ZH#'::H%2K7A+\9&,E7N^J.T!"R#>BQ@<M?L!
MIP(9=D$690DKZU(;-?NV.&$!Q/55"9,295@UV[U`4I$;`C#8K827O)5?A2(Y
MW!DFZ'-?\L0]S($O@R:^CIP0^1$!TT??.=Y4,D5)U/=3&5J&O9,Z+5D@(2%3
M]T7:6UDTJ,T@2>.''_#,D$%=/-%&S`P4'8#BZ)=,"^`NI=HL=[+=*#$5_K+S
M?1-BLF^;$_"I%G-K`,&,$-E2D#3A/Q1)-+IK+Q?`A(.":28#TCKNY_!G/A7L
M3+S58H.%%/<UU_RA`4_]:@F#BEND`$*AQ3)8W#`](E';5_81Q@PP9@F=$AD1
M4.4T`'E"`8NB?Z_Y6]NU,@"@R!24E0RQ4Y'[W@ORMFG])[65=`7.VG_.ZSO$
M6.J55/:Y`"]2*B$5S.V%%W^2'D)A%F+"4-TD:"=1`,GQ3:KU=T0Q`6JVTJON
MX5DA/K?F0)@3(3WB>R>4,+FAKT_C$]PICZE"XVUBB.F<(`UQ24HQ5*.QU+VN
M[\<I&3)'7J85$Q*Y%:$1&C%DB%7-('0C47P3_@`SN4D`(&4,,#_E1!95\E#:
MG="S'1X@PQ$\MD99XH8#_;<O^NHH)-8908DZ`8QMGM>,?<1ZXB:#'3_0!),R
MJ>_JO>].U18.$";?\U`*,[D4\56<A5"5XT2R\>X'@5W5]CXH9(H,V4==)2)A
MKANNU@"X5HG;FW,4Z:O.M&PQE$=C06C.EW3W%7ZZ(;;.)R:[/B`/N<XP'\$%
ML#(9MQWKT^LXG_-,%7TQH=\PM)J%MVV-`11)_Q&SQ!QXYA'#J"-H01ZS1/7J
M*1!*7=5V=K#&$AJTD?**(R8RL5,5T#1G_QK0P;["$U"!(@'@!B@?.'=6,FCV
MFO>O+V^FJ!H5(3\1_H,JF6\\Q`76"O+T7]P150H56T'94H(;<0$ELA$!5)+L
MV\N6:0$!$B`;ALC1";$Q"$`1PE:60#'U\AR'MX3WC^0<=MB=K':*S#R[K`K[
MZ6]D]@07/H\;.M)&XM08)/,GFY2J.K$O4'UQ4I(1?74F`%'!@P0``2A@B/"`
M`@()'SYX</AA0X$('SIX@&CAP(6('3UZ@!"@H$@```8<4`#A`H<.'RX8`%#`
M@D>:'Q`0P`"QYDZ>/7TZQ/A3Z%"?'1P@>`#!@`0-'CI(0$"!Z%2J5:U>Q9I5
MZU:N7;U^!1M6K%`,"0(LL#!!@8$##BY8>!"!`U&='.:.)=HA`8`#&GQJ_EA`
MLN1@PH,=<-"086X$`AL^6!#9X,(#`08&3*#I`0$$CQD82+C;$T.!P0@:/+"0
M04/H#QD$F*SP,X*!BGA_ZK1=M4,$!`D8)%B@8,'O`0US'T>>7/ERYLV=/]_I
M@0%?"Q48%-A<H8*$!GZA:YT^8&;TAQ->%P9`8$!)`;U1.WZ\H`&&UC`+7,B@
M(`$$^!Z38J`@KKG@R@"HGB8`[@$,.FB))@L6**``"%C;J8("%/@NPYTZ4"H`
M`0@@(#T&"!``,PU/1#%%%5=D,<,'3$K@``%$$J``!A+JKT6?"`K@@1QKTB#$
MDDXZ@`$*(`B1`-`D4""N!R*$X+`/'"A)*HDZ_L+-I0824.``I"R@(('Q;LO2
M(P["7(`""QI\B*>7#OA1Q]QPZZ"!`0@H((`"%I!@`@08*%!.00<EE,4R"]70
M`P720V"]UP+P+0&Y$*W)`M(,")0G#A`H"=(".T"L`0`$@*`E#RBP+,(!$.`H
M@I(X^\DL"CRXH$L$!+#R4*(XD.``X_)Z0($,=*44*UTY>("`!9!4H#H&&)B`
MPF*GI;9:JXBUMCDJ1QW`0P,,6`N`!+RKEH-%!Z"O)PX:.(^`"#S`P`$-+`1@
M@;D\B*``T#2P`((&%H"I7FEI:H"`F3S@X`('#HB-JC)1G0!;8A&[*%NM6.JL
MMP1"_#:"#C!`P`&+_BG%=F23#92SY.\V6&``X2:@8((+U)S``0K8K-95`'Z-
M[J7T(I!@800@6@```Q9+H.$/.$#2PY(,&),GWF:-2`,,!IX*@P4>P-HBG,D[
MF2ZOS:P`@PLFF,`""2H`==FP!0WJ;;F!4GGNKBP@H"]RYZZ@)`4<*[EH`S;@
M(#RVP\/`N@DZV"!H!WR3``*S=NX)H@H6\#BSK)3ZVB,&P;;;)Z<BJOL##?!K
MP,304XQ[=9,A*AVZV)>C0(`#NJYI]A,O(&T`I7FBDH#8*F`KS:(#8"#DQAVP
MK,F[*EA/9)\R>."!SK5:.#,&ZW9*=Y-!!;VCC[4[`%;73QS]?/71O_X[_@D&
M,&""84/'X("2>-[IQ>+ZO1E`^X<D`+@<8`$.Q(U6(4I``2L7M/9=90,-8$"6
M.J"!F,VO)XUKROJPT@$*."`"";#2^6`G.^]IT%"#*F%N(&`D#&B@@9E1(*$V
MP`"1/$!S'1&5T1CFD`PX@"2DPD!J-M`Y#9"&`%1S$P*.]I5XF0@#$$!``=1C
MHSAY!&\3,B'IB+*!"UR@`@H(H>L\X,+OI#"+9Y2;!+:FIA=^I(VLHX!(%E"Y
M#/QO5`Z00%P@\`!.`8`CE2L:`")8DPU,8`'N>:-/[%(7!]AH`</96L`(D*F=
M7*`RZ3*C^B8C@02H[GP80V,H12F43/J$`A&*_@`!5Y>!2UU@C!2X`,X\4,?!
M&&`XJ?-+WP!0F]PYA`(ANEUF)A"A^222)QR$8`@MA!T(Y,1T]@M`U`C)@.*,
M4B@=F$#J.FE-;G83C1@IY4XF`*X+;""<<N+`7I"'(*,%"C<O*HE,/(*!]=CK
M+YP27IDX$`$%[`TK&_C?'(%B%RQY0%0">!?*/$>!`4@/.>=DS@4DH!AH>=.B
M%UV=!P@7EE,F0#40;1$'`E.0\]RG3.^+IS0UP"D#I"LZZ2Q(`ESJD`Y8QY\.
M7%2]/M(1##S)99/:*5`P((`%@+1RU:*5_/B$4:8V=63=XZ@"4F+!.36'@T(B
MJ:]HDH$^`D`J8W0`_@0LX,,`>+)-9X5G2905-0LPX*97J0`"=76!!&P,6L"9
M:>Z"]3NP/.6/U,)F`RC``+XZU;"';9%1:U(!+E6@BF(I9.84BI=-C4H!$KC`
M"AN$&P@,QH9U6@!P'/`:&\Y2E:2[`(1HQ*64?+6#C\62NBP0`0:\!E,ZP8V%
M?$,!5!T@KQW(``;01H$(.$`!9MV*3F:X`$Q.BP,50!L($8O8BDU7@W%-P&:/
MLRYY+J=H1W3(!AX`&H]4@"0,2)BP+J!$D21@9LGCY0?*<A`^5L0##T#)!&C+
MMJH@#%0298"70C2`4M%$`Q!`,(0B=+`-;``#CJMK@%/RUJTPK0!AG)9I_E$5
M7^MB=(@=3NQ7ALDP8W)%O`^@Y'%$%8`&W"4#G<P2WOQ67`M`Q#SL04GR&F#.
MAT@`4P^18)@`@(#'E@EVC)M9Y%QF`;]$0([]T<EZ;T52`#@`N/[R$@0D8($@
M!A&V6EG(S;*%S1L=`+D@[F;KT!RZ8?Z-6(J-2!TYG)L)K*<`@>(@`A3PUPWL
M950&X%IX'U!/#:SFB2:JP&:P]C$UQ2Y>"4#``0Z9-SQ9R5SI\<X$XT4`D1B`
M`0`+@++&N[6KL:1[:O9*!AK08HMM8(46$.R:93WKY1@5;PFHR>?P4MR\VH:K
M!5':J1B@GP8X8`%8O4]'.)"6O26ZG,GKW.S@_A5<[D1@CQ+`K`)P@H$&&$!>
M'\CA9R1W@(#YC0(2J*T!&J`2#'RY*^_\F\DD2E?\T5K6((4S&JL+9K8X5H(E
MOLH>E2.=@EA/V0_@4H*H.63X8&L##CA*L[3(DRQQ(`/;@4!P%$`:MW8$`GWY
M0&<+D#8_HP=2#=!S`@8HUD(#/+ETK4V^!SZO+Y[9WM;U'FX-&$-[0T37V"M`
M6VH\\=Q4P`$"24YGAYSBB#2H`_9KZ5%[3)NS;O'C!-`SA$*&UZ5-D)H'X.,!
M(I`0THRD1ES"(K(*8$/HU!&])ML`<0/TUYNC&=6]7)H"N;B@I35`FG4/IZ@\
MRO.J.N3C=Y%Y1R9`_J._9TE1Z;$Y31@T>8I+/@+K:8!3GCB3U$;@B=4CS0&D
MV*2P0G-9$5@)5#$"2N?PZ@`8SI8%P(B`.==]NBK#35D8T.!&G<6%9KXYG"U@
M@`+PMSG<=@"4\:*!G.8J.M,QF@,8H""\:Q&W&FA`O3MB7@"P/;404+4"HFB`
MUTAZ)*,*`!Y9SGH40:1^DDV\<FJ%(.V/,OYK9KX@!Q*3;F4>^%6WO:S0`$BS
M`'<#B]R+G^0@B.[["0M`@``X@--P@&0JL76!#9Z8@))@B,?QD$A+`,MX%+80
MB9"IGEB:BOO;B0>RIY.I*02+BFX"%=P)0*J0@`#XFPX8D19BBW2*O!FD_@J-
M$)8,<+FNX!"T0`[($!<*ZPB)4J4-^""D4$*/Z+.28``W:ASR.X`$*``!F)'T
MJ*L8`9$#R)L(D(QB^3BFRQ9^20NJXR;&D4$?'(K1H@\,4``&:`D&&!P$Z$$X
M'`I4,0`*R*#G`(XAK`I6BHGQ\!X)((`JK#R:FH`048`CXP#A,@NBH@"C.Z0!
MN!`]4R)(4S<T'!15,Y^3T:@+J)]1_"8^]`H'0!>7"!F(N(XZVL-&Y$-4T1>J
M:@Y#FL6M8!F1V,7<H8`F(25#/``A5`L%0#D(Q*P,@(NU((D",(`$>(`*6`W"
M([H6J4-"E!-^,<7+PB@4!+$:7(`ONK":@L`-_DC`J2`H570([&LQ</2)!HC$
MW-BGUV@`J>,)_&(-#X`+#%LO*IP`^_F,$(&60]K"IV$`#RH;'KLAN/$3V!L9
MIA&3!B@L?=LW=JR*^BD(OKB`'"H5K5)':_3!"V"`^6#(Y\"`Z7O#K*"5]2C&
MR1J*X?,\+K*V",C"`J+)`!.]DX.TD8)&$$&`X1B@BX#'W+@`D)0;#IB`:1P@
M`-2W#\/(:TFT")DH@G2AI8A*JU`*TW"E#+&0,9$Y@#()"=`=4"DT"+B0A*@K
MAN@V",@F3M/$!Q@M)5DQK,O"+5O):=&:W8/)5IN+8(3(,P*GK+P6!ID+O_(Y
M?3$65>2G:=3&K]``_H@#Q7?SH2J;G0Z`"S`<``9XD'$)FMXAO@`20Y4[@`%X
MC46L`)8@O*)$#B2AN[?!"`XR`%0DS*M@33FIK@Y0S-HD"OV*$A/,$,`@2[SP
M`'I!@#922J!9N`)8#P"8/:,!$>:4$`IHF8V1HI(PLPR`2M>I%2L+G0T`D\L)
MS%"Z3;HHSPS)`-0;(U4:B(A!2M[\B<%2B4#,$`>LO7>KK$DJ&0T8D?/(PB_\
M#>#8"UM2HF(C#2F*0&SK-=<)K;RDELR")8J$3Y9$HPH`.Y#P+8GH#9NHOPGU
MB'$2F;M[#GE\3*%8E"-ZH0Z`IQ[I(9OI(`$`(<;`#M/\%DE3R($Y3^7X_J#Q
M-!FK28RC0ZP<[2;9@P`/<`"<6)KAZ``V]-">"!/.I,_@A("$&@LJ02@9M(#7
M&#G^E$8(T#:[?(T/*0#!XKO86A]X*1\1`I4,$"O#$E)O>A#.>!*.*!Q[V<TF
MY0D*V!(%6%#HX(T2W9$G<\J.J)TA(3\0P3HA&8#-K`#M+*`WE1W30<;)/)D,
MX*T*0`VG$M$)M5#.Z!7Z\(#@X(#_@U2+2C0$2$T524DIR3=:`CF:V``*`AC"
MX$))4R+X48ER*E7T\;&_FQL.V`!+W::F&J-=%24+D,8/X(V<R`\[_#\\W0G=
M,]:J&[[7]`H<'!4^2QSC2H#F_#/?2!XQK*&F_NJ5B+E&V`3/!TA'ID*8:44C
MNMH,&5FWC2N5=3U30<F/?NI+Y_`Y!(O"K("G^;@X@#D/]O@6!0FN)S&)WO!5
M:^HS7%L?;(JP/K46=[TYWND46B5+K/30DI$``;@,!U4.<S$..%M`;A$,DI*0
MC7*(PO$T0+38$WD`YM*@^X(?H()6Q'JN")@`[8`9WAJB.ZU9.6$7/<&B%7D`
M0!$+"_#63C$`TR@;(?R(6&6]F'T.A-D:$Z(KD`VT[Q'9G.VOB%C')>W0N6'9
M[Q!)AU!7$D$`BH6.=<F\?;T*#M@63[,9#-#.>P.*DOS7M['0U_`=4K3:FU/*
M:,&7X(@8#WC/3_I:_K%(VP_P$_48`&N-5(>HE2(-"_%RB](9W!2Y@,O((@N5
MM*2Y6K'HW#5344AYKL$(@(TMV[`Q5I4)2&^AW!,)2+<%V\[@VRRB@")I,%-Y
MM[#-W1:)*P)8G!>90)=9TOO,*#F1@"W40T!=OCWJV^&=#4JUFUHY+ES4"O`Q
MS],%6\J0"R/M"[TP``U(1_#5H.>%E*'3$3DC3ML+R`++HJ-<V(:]EK)DO^%-
M$7;Q"^:[1W";I&?EWP^@%Q8S0'Y]"`3#WMP]DL8=F0P`F-#"W^.`J@)6$0A`
MJ(>C"(0A-W3\1?CT&:1(8-EIH2Q*'T*Y2!,JI`DXL`K&X%#"FP%(@!JQ_H!:
M2;\E#6'>K)]QB6$S*>'<W0#MH+<?OBBZ)8D%N(`0,2FA)45KF2&9.LD8WM05
M45_*>HL*4`ENNF(4#J\CB0#M3(`R)-NPV9YL<4*/J6(C9N.G(*PM9F-#6>/<
MZ`_=?%V2D=[OP%29R6,^[.(T2Y;BJEW;L-@53AE^)<KDF#S5,Q4F+>`5BHOJ
M-2&?^^/<5<H&B``CY`KNF6.KZF,Q4HX.N`">51.?A5F.S<K903<7GN(T6XTX
M7I&W^!AO/$`SE8BKF;48-"&--#N1Z!$/<&3^10B;">)[[6187HY)M("Q@F%U
M#!`$FU()2`BVD:@"J>1$^3GU.;!5*[8)?!:!_I"N0?7CNNE(P8I29%:1:QZ+
MXA2KIH2H%_,0330`]1`77J&^GKO7GN@`!:A(^QL+0Z:)WN73QT7G]N,FHROB
MKFB<8HN+G+),7J,U<%+G:T&,6"VTQ!#"4=UA8W:.T;@/""[HAYIHL+@<;MOH
M+1JT7_:`FL'=D$8."8X0*3+-`,AAX!MIQR5HTW6(!PD99W+I=`;IL&&:?MK.
MKR`>HZ&:E7Z`00:QFR8*#"BWDTL>UV6J,VZ.*4V,H/[I=7;JKC"ZV6KIH8BR
M$7D]*#LW2=YJQT7+6H*`1K4()_Y&YD`Y,1.AX#LLV$F<-/$*"RN)!TB,F1D6
M+=/JM.Y>+5X`,2R`_DZZB&`>7BK9TFSAW*Y&'W9-&'1K9J)@6K62JF_93*/P
MD4*1[+`YL.9\%Y`,[9'I%;#SZ8KUB;.=M3$:;+LYDU4C77&F"CHD-VADBYMH
M`!7][$0)GP*^PB$1B,4=WK)8@-5P:L81G=-VCI?@T5&J;,Z\U@:[:`T@G`+B
M$+_6D1'BWU<Z"CQ9`/EY"#"2VR:]G/%>;6HYDX3"/5G3O086)5YQB^,P19#@
M[A,!5L?#+15V[H[`/JSB$^UTBF$UZ/^>"B8ATT]V#C]Y*P1GCADB,DV=%VN3
M;ZO@(K40@`@2$-M>#L8Q,DK9WY/!V'@*K0/P%=VDS3(Z9KM9B-W+:1E*_@JT
M!C'F86J'G8!HIG'189P,F``\5"NRQ",&7TQD?C&38`LQY$*N(0"V:S^`7I_Z
M$8"NA6S>.6F=%0X/MZ9)/!((V/$+HBT#H.D`*`Y3Z7#";HY2;*&_Q@\/OF/F
M@/!=.:3UMA:C:(`+[S!C"^OYMHM,ONRAJ(#S<(`G\BB@P.381O/^<NWP&B("
M%N8HD@`Z+Y<%<"C`6Z\WGYO8H96$D+BN*'%`.R3XP,&CW>KS[,A9&66_F"$'
M`&9,AT^-T!?@1.U.?^VJ20E$1Y06#Z^@@:`;GPI1GMD\*8CY**!#+_7G@!AP
M$P"!X*H(0N4GAN*$U/)B*4(B%TQ4V7,S%EG`_@X:7[>*`U,B+JP(!S#7D-9U
MCA*[*2D`^L@/5C=NR+:8]!RO<\Z6>"$OO76),2YF:!\*#="O<\/S$P05)QS3
M*2GW@CYWL%B(AFB``OA?9%1<5T>AA%>1/+I$63>9W@WX;T0X[XCSKIB7MP#$
MW`"N8K_R,KI:*(]?K]PF?;2(X8AXV)QV.7'`%B,CB\$-INF.\W8JR?'V;B(<
M?BS#KS@4N]AGB9]L?L68C^<)QO*1A;D`?OD3Q65>:-6+`P!QN?&`_;@WKJIT
MG0569#WYJ8"@K:]Z8J4IIJ^)]9(T$N$2>8UY@[8F'Y<?C!\XO,BF/[>H#I`/
MOU![A8X96.MGK:`3_@08&@4X^[O.(J@F#)H>E7<91YZ?4(@88L>RFW^Q]I7G
MU^$;>S2B'DPV[]P8ME"ETD0?6;7I$[2!&0*2#KWG30W`-C#!==L4B^^[9HK?
M"M[9L7.]J+HXFZ3]>7S,GSEB`/HU_8?B_9<??*N:?6J)*R*[>:N*/\;J2D11
M^;%8EQ^SNPGREVS_B81YBRY:YD2K0DRV]K\/I3.Y$0P(HAR/I7#>58M#?YZH
MGP6X?D*.\:S8)Z6U_O(\"H#(\&$@P8(&#R),J'`APX8.'7KHL(%#!XH=,F#(
M,.$!AH<.*QP(&=*``0("''Q@(,%C0P\>6,*,*7,FS9HV8WJ(,`!```(#_@(`
M$`#!PX&5-X\.?(ET*5.&%Q`LX,!!:5.(50UJ4&"!(-6K7K\.M)``)=BR93U@
M6#!A0@,(%!I(Z*#APH:E%@X@0)!`P8(%"A),\`!X*8>Z9@\C3FSS*0$&"```
M,,```H8.!HPJSJR9)H4""SI<J-`AZ>:O'20TZ'BU*T+62UW#5*I`@>'2MCUF
M*,!@`8`"!08@<)!`-5(.&B9*U*`\0X<.15^/OBU]NM?.#CA8*&#@0G3+F*F#
M+ZUA;X8$"R(\V,V@0OB;@AF4Y9!A@T3F7B/"7BAU@W(,'#YX,$$"[+57X`<9
M'/`33P$,H!T!"A!GDU(;5&!!=`0Y]UU-^1G8_J&'!%4P&`<-P(?A91^BN%H#
M!"S08`&0009!B@\I14$"$=S7P0,*0``!`^M=R)0'&W!X4`<6./"C7Q!^<($!
M%'`U8VGE!2#``0M`(($$$3AP`)1(;0`!`@($X$"0'=PHI9IKPA1B!&@I8":&
MS[%9)TL;\!9`BP,L<,"#%]C)D`,(U"8D!P8(D$"5C6%0)$V.8L4;``102D!E
M)`H4J&(;Z/6C:`-E`-=_2$T00`$*"%"`!52AJ:&FKTHIU@,?8!`GJW3"FFM!
M#0#@90(&3$`!`P,\`"F;&J17*%,2(/#;`8EJL)I'+WE``:(/:%#!`QM8@$"$
MNGZ5@5X40%``E!L,_JM`ID<Y,("%$21`P84=((`CN/=VZ"1P!@``'`)%<5"`
MO?C""H$`"GS0+5XO&J#LJTIA,&"42SW`$P%Y.9"!L?$]8-(#&=AX:F`$?Z6!
M=AA0`,`"`"K0F&$;+^0``=%>H!)5'!PP,,D[VY:!`E4.X%,`54)PJ*L)N<1S
M>!Y`,,!E;Y6DW;8P2^E!!0ML)22]D`E`P(T:3Y>5E0A06D"92E^U@4\05-!`
M!1E<(/.;2Y7['P8,?#F0T6CSK=B1$E!@`06#5R@5`GE/;%!$?4O7P8H'%'#C
M!!#$V2C552]P75,=,""``$$'0!MU&@S*0`)!Q1LDXS9I@$#0#1PG'`,!_CR@
M>DTZ4:`!!`<\<('O].&ZNO"K4<0:!PA,,/R,#1Q0@029HU:`4#Q[D($#R3=U
M]5X.I`JV=!R@MH`$%4"0FO(WA;I3``<P#]R#Z]X405`*PAC`4,&?GS]-&S1`
MDH8X8^\@%-&?;1PW@`1((`&?,PD`R,*S!S3`=C9)CG(H\*GI>*`PT<H*!2Y'
M0()@X$6+^LD"4!:!;]7D*;XQ0$C^-2`/G.B#,O3(B&!D@$819&^MD>`,P<*Y
M`_*+:Y!A@`?5E`$&.+"(&"*2FA(8K1ZRA`-KJ0`5R16!"F!``H!"2O5\AX&,
M9"`#&H@(_J!H1H)DIR@*`-;-8K@0)9[Q(1U(_A(%!("`!CA``@Q0P`1X"*X*
M',Z/'I$('!5#`>0),HYO=-X$)`"_#3&$7D=3Y`P/F3RQ2.!F!PC@HR@I$PU$
M0`(8@%U!"IDB:@$R:YU4TQP78$HS'D>*%!B563K`1T^N;F.`7$FW(#"O!1"(
M)L;!)4PX(*8(*.N5,]J``S(FO`B8CYA1K`A;MEA+8$H31<H<4I$LV:1Z%:0#
MV*Q)1;+Y$&0%AY;#\\!<'*8T,9K3(QN`&P11Z!4T$4B9\5Q*!UZ9P2)9@(7"
M$8!D%L``"W`@7DW19_XXL,<,J)-&L*(*0]E44?UA``(.R-P3W<,0`++DHOM,
M2#_/<B`$#*U*`H!1_NT4@#B<)&ZD!N'`7Y0H4IG.A#4W71T&($@B:\8'6!+]
M``<N8$$,6."1.#7+*S>PD0=$()02Z-$%/*"`8$HHD=F\0`*:5\3%+75I)5TJ
M=@#G-B%I``-$BLA%@,=)ATB``#QIF0(B&E:3/JHB4FF.7C.(O-?<=2`3\`P3
M5QE8VPQ)JY[<P`.`61E^2L!LP5E`5PWPIC(JI'H(4,#L)G?+PU9EKX\%RZ'>
M"MJ:0"``)8K-::D#UK!>``(1F.52)A`TR''-CE55Z$,X,"BX!2!:#4!8:V]2
MU`16("ON9$IIBWN3SIC+KLZ=;GLNHBT(*)4FO)JE`WHU6X%P8)P.X<`#_N(E
M`0!,H`(*:`!U8V,<"S3`;`"@``9F%E33EF:G:X)O2'#8WO^"!TD]HJU5&+*B
METP``:HDZE5)TY`-*$`[O?):=@%LI%'*UTHKN4`!.NH5'5K8(^BY`$3U&^(3
M+X1T"6@`@1GB$D<M@`#_@5=5N2+><\IL?0P`*HH-8H&6$0!R`X#02^[BX;0)
M%3SE)&`$>&2!Y?8XRM-ZR`8H@)X('!EICK)J`00;E8(D]*7C_2)$I8P0^?&D
M1VD:R`44D&6:'"E+-?[`!H1JXFDI5FD3,,"`QFCF/\.D.0W!@`/PB.6E\&8R
MB%HO`U(#TI8D[2"1!C17JS0;R1BFS5`.*9+D_DI04IH,OX!.6%Z2>^>OG'K4
MMQ$T0S(`30<<&BFI]1RE5AJ4N&!6@&QY0(\@\(#T(%/5'T#6LWAR``@`ZBF;
M]DAV)O47N7YF`P68)*!]MDGOV6G2PKX7S"@"/@?8<\H$R0#@".>\"$S`K0Y.
MB`86P*`!!(T`TE.7L"/"K=U!A@`7P$##;M)N`6"K/JZ3P*.WS68$`*NP@4JU
MP3=3)-E^H$=OSFETYOF?I*%)S*V9IQB/LP'^2'?4%WE>`;!H@(E#9#36*10@
M'U!P@W.NK@Q?N-)>?%?=32;6,%TWK>);@#MND:98E8E$&A[.)U?@Y(_ZSV`S
M61!FNOROF97R'!5`_A=3SCPI>99)UE^C[3=VG6`<:#*Z4>YBUC"6`#TQP$\&
MD#Q.#5W2!KE`*"-0OMX9_2"#-?O9/]"9HA5$`PQP^285IVH+4%:48=\0JS^L
M@;$N<P)^1O$%GFSW"K?D(!4S`':+:K`#B/%P/$>:N*K4D\CX-^\#L1;?'6(M
M"(Q1*AR@`(^D+>K%R[!;*"DD[LN"I`YJDR`3(,"""WQ7\!T43,U2%@5XAS.-
M)X2\!V@T`FKF+=47)$3+_L@`4A4UM=,N8$>#?)1[.O@+!GKRB6$XO*B5HJ>0
MLL>SA\`$P+US'T__(!O8R_%$C1`(+T`&))UQ+`![8=_J)<#V-40&Q%B\_LE;
MY,A+DG5%[WT0W45`4FU=*4V%TMP-X`&(AW!.`N+$`.%4S30:[)%*8PB0`A"*
ME]`0`Q!`5`&`EDP?!?80;"28`KI8!EA`!9#8OF'`&-&+__W9!6#)!Y#?#%%%
M0,6=BV5&>?&859"@3,$-XFT+4H20`:@.2*2&Q'R@BV'``20`Y23`GZC:UQ5$
M\^G@0LA%=+!*88B>T7$5`F!1!@[/'&$+3IR:9LD(H#$3!*QA0S1``$0`<PA<
M]?E,\0U:!=!'>BBBE"D'#ZGA381()E&`YC`6(+J1P5G`CBQ`ZQE>+B54'WYA
M0PP3JB&A`^0A),E4%NU(%-9$!:C=`#B`F*S4_JPXU".^4938X(><VFXL%^L]
M5P$4"_.,1JTPP`84GM&%B%;HH,TI3Y/I8F:%G-R%5%*D$J!Y0`)E#N;AA'K]
M1)40XW^$UU;`#(6,T52!8OY`XU=`3LC92"`FQ&`-Q0)H8<*,Q?%`7TX%EK5\
MQ@9"1"]FAN,D@!U.G4%\7$QT2P08)&B]!&,U4[BQEMY8@)9@$4&,1Q,B#9ZH
MBP>TBP-4E$"Z!QHVQ0*8B\=]G`90Q`1\F4TTW0<PSTND1=$LXT(MU5W0H4&*
M)%[5#$,.%=B-VSHJQ8@4I*IA@-U)P#H&&GUP17EH)$+X%K$,!/_$H9#$$V\8
MP!V12%_T#@6T9$WL_AE[,,`!3(4&-`#A$>&C[*2:W`4M5J-TN-]T`))$QL04
MQI2!T<9:#@]C)<`#V!\_D1O9W,@39<53ZM^5K,L1K19TF%-WP<AC$L`$_)@\
M(D1G8$N$68`&"(@#A%I5D&0V38`83@"VM<<\-615,!8#>.,UEB)+<)4#`1H'
M8$`%J,1;#E5.[`2\`04""(3@3:,`,8]1>,`#(`"UG=BPP)IL;8D$2%X\/A=0
MR%6_[$0#29MQLN)(1<#%4`!E(@;<8-!`F`PI&M9$"L8"<&=Q4<1X7"%22$"#
MX,T%/(]J543RT8A9%@!>L)V<<)%,Y45^",AY%D2H_$I>X`54(-0F;EO$_DR;
M4F9&8;1'DQEF+0%2,.FE*%K`9``H5B1(A'@`#$Y`.0X5.ND%9QK?=/V%)(K@
M46301!3&!BIC6IH9<295A>XD5>"19E`%`U9`A2J/!\#7`@#?4426`0*(3"(F
MUF1>DII9H4E0M8B.>XC12VC$=@X;;S6<N"`,CWK(1JRF:0@+@_X7ND"&=;($
M!"`H45%6K?RFBK:F<TE%]$%3AA*$M9@)OP&%U8W'/DK+,JE?=YHD$H'I!^G(
M:F5=9,D+)R:`;SB`G,ZI`1`I07"5:C;8+A+5EC`=PI50)&DIWQB3YMA$LP$B
MKY@DP'&*GEZ%<6PJ$BH<8HAI3\`B+B%>D+:I_E<(7@/89H\16H3Y$E+84@!0
M*8`XB0&\C1=&D@,4@(Q<`*4HP)`525Q25]OP6H_\&MN0&P/<JB`"@"]AP&95
M1%ZT#HPVA06,3(?T7NOTAKZ-E-58G6)X`!ZEZO#<C5SM*E+(XH.@VXHT4/7<
MF$)`0&,(E[NT:\FIFJ0\)F30H;!<ZQO%&-/Q%@,4`(*8:E7,YKMN1NOHR0'0
M)26-B#,=1@=,@$MQF[/6B038VB<R1;?8&H.XW('LF!.2S7_8$G&]YD2>EOGA
MD2KV2&:R9,(NQ.P`R@,4`*`(1@N"JY!0;&D\@`$46J#*$#L=&UYI@`$4"[?U
MJ8$42<6LE,ZH*(7T_@4%V`=:1%.1^,EH9$6)(..V4912>&PRW@0$]$KG/&S-
M"("M)MEA'.UM.,#:9:PG/4\^?07_,,#>K@E^O$K30,6.7H5R*$4&C9+@MDM@
M1(!E#<0#N*![W2V*""`64<"OC<SF\JQ"^`R,.("3]$:C6"G,*0!D@%Y8+0`"
MW)D$8*PVYL<HZ44?`=9!5&1&-,"K&D3$#%D`5!^2`$!1+N5IGI&U#(W:\<0,
MSM_G*@3.85D8-@]1K4?>9<4!+6I8'9)/5H<"S,V?)2&&T%X,WMF@)%<#K"F(
MD`T!;&>+/`G7A6^Z?L#I2)BY4,"05<#D.&_**87/1*B4=>(5H6!8F2G3_D)$
MGQCO73D*#[[%H5IE05`.!1@A[TY,!I$C?>ED-OV30VB'?*A@ZSA`1:[L=;(;
ML1H<-#4*0"[5W43`_CH$!)BP-D(E#S9`-)'P042`8VD%_%YNG<3O0>C&0'`>
M@"S``U2DI]8$!U2`N0T.X(C1Z6Z;F]3LI+(I42'`K!R@WGBE!WY%DGS1#BNI
MZG7`SPV)9Z!%<%P`6[CPW$%.I0C-M)5JWH60I23P#?8M<]6P`9]8!QPE\NB3
MQQ:QKS53N]!&6F1-#]]@P`1`#?=$`RR``.R8!"`Q3:0%"^)%`G355<4Q,ZI=
M]H+6;-1Q]AE`^JH:?$8``@`BF!!LP2;C$9%R_A9GT`%`!E`\)HME22B_&%_A
MATMH0.4V7()=<9>:4]L4[0+RFAZ?6`"[%$-IA`3P6MTAFWSL;A;3"`9,@%1)
ME>1=P`-\Z-8VQWX<AUQ4I<%)0)6T<&MQR5W"A`0\*37#C9N$<E(@57.\A+>Y
MA/6HADVY<QZ%\A'IQ5\<0$EL$H1%;)1YI5K$,R);Y2C%A3H[A(!\B4*O#G;X
M2+`=!?^0Q7R4$J$);FMF4"A*&3L!(1!B`'?T%/>"9<&FRL^-)I*B+9NEUVB-
MYP<%2-`F<0(LY@T[UP9$`!*AWV(<`,+4BL[P\33?R26J8HOUV,T,"Z4$C6^X
M74:=\Z?^!G0^P-M0_D2;O3**_1@#/-X$2715E`>).J&1I$<^WV"'9,OSR.IB
M*,"L]%(IA0H%ZQ_W.,W0:&V4L1.J^,9O=)\`7.`MWX1<Q-:8],0F\3$5<^*8
M6*M'W2"_%;-!E$=D(PV^_/!TC,@JWD2;S0I787%2(!Y=@]DI@]L&M-EP1!GD
M7008P8WO<,<%M$4=IVV;08:P1LS_EM_I"&L\-RU!4,YL]$5P_P4FYT5>O'4M
MEA>]39`*WP;6T:@&O$4J'X41RDA6Z(R/AFU#]+*MCAM.H^(9:1M;E5)8J(1L
M<X5FRC(`0,AMRW%`!PYO0U'4`@!4[)%(\%FAL6!>^(7I#(#3%5(;YLJF_NK.
M>NF<343,<$B``4!(:#P>;(LV0>S?I(;)FMT3?./+D!`G9_V:>BSQ5>.R-<N,
MLY$H>S.C9]#S3N.%<:2DQ\G>:&10&,V>L*KH%ZVQBH:U0Y!;^4@`HX+GZ2`<
MO)'$`,!.6FP1I!S)K[C%(S>`B4T$):%%$-4/9%R/AV]V=`[O!>R5!W`5;O=8
M@@%&U1Y6Z[!7^40(5[G9>'/8N/+CV"5E`=7XC%`$,SUX;\E,@?[+LP0N1[=)
MC#&(:JH::%A9&;(8<VH`DMBN3:1,_;#0@]#7.&^;"8[FC1N(,B[YKP`*^+`3
MGV69D[3UM-`'/U-&[WTFN!Q'&)*IIX=1QX61_EI1R%]Z>N6I%5Y)TVE,+Z2&
M<"AW"PL5=X(,B%8[-`#7,'U)>H%`6+&@2A_!L`5$P,%L^BC'QDOPL9,PP$7D
MCL,Q#@_&%=O6TB7N;;-:>%B%R((AR:H,-D9DA`:(41`J,0,<NL&QA1;9!WK&
MR0?HQ%C`6U<)@'D>!(?-N=91RP98,[E+)H!Q2X*1=7R\14>#QC5+,(E%%7/K
MM51H0`)!B8/&C0.3TP9.6F'4C&;'D7XE35=,`-X4QK`O#5$@3-PDP+_\'!(1
M'.ZB*TN<N/Z]N33)YEMT\[8'[D/X3/==C'D$0(J:&3N-Y:\`QW`-!Y)PQTW`
M[H[:75@TP`GMJ_PQ_F5!!)0"$&YQH?P'&L=>S;R//>RC5#U(:WT$\$Z;2VC+
M.@1CE80M;U2[AW0&6#E/V-IL[>XK/8``B`8+#D0"0<"/;?4ZF=CB=`4#%@#'
M.E=>#`1(E`B=2E!V"#-)3?-$J"2`5<_FDOM^1A]+=C0[:0ES&(=*FGR@=,#F
M/G-4V9UFWGW;#D!'_,M`-)D$B`67]^BWCS="C(>P\GAK$)!>)$P!1&:1F03<
MAX4!1'YK7*"R.]6ZC'YX7)P#8#QSJ1-/VS"E7O:?Y<=+T*:%M"T!"`1E>9DH
M*;89O59BA%!!7E3YG\^A*`#G`(#.U!%W^]@-;<C8J85*P(WMSU"AL^1Z_DH(
M0'SXP,$"A`8,(%CH,%#"@PP"(4:4.)%B18L7,6;4N)%C1X\8/6"(8$%BA@87
M*CA0^'%B!`(8/C!8()#"@@@9%I!DN9-G3Y\_.UI`8$#"!J`1.3P\NI3I10\;
M"BCP`"$``PX>%CX8`('#Q`L%E'[T(+"#!0<)$#A@D$!#4[=OX4+<X,"`@@A=
MCW)P,`!`````!$3XT&$"A+!Q$2=6W)/P@`$4(`H%,.'"@PMC?48H8,'#6JP0
M$D"HH$#G8M-,,9NV8`!!AH6H4Y^6G?$`@@\:&`@8P+I```(57D>\8`!FSP<'
M1E[8L,'U;.?/-U!H,"'XSP<!##BH4*%!`0$3_CQ0,/R<?/FW'C(P`##@084'
M`@(HV,!=0^R=$@`0..#7@('U#RA@X(+G[#//0(D8(("Z`QED"BV!-H!`@8,<
MH*`^BH8KCJ?"C!)(@\L:#/$H#-JKKB<,#C#@`KPXN("`!32@P('#1*S11H@H
M\(^O`1:<8($-"OQHN`$$,."``@AXD0(+&-!PL2!O)#!!PZ",TDJ('HSH*0TP
ML`"XB2PH8,">-,!+H(),O%)-B&*<H`'.CIK```@F8H`!#21PP$F/JES3SXTX
M>.`O`!R`:(([^P3T`@M0JN`"#,K<@,G23/,@T3_=RE&!##!($],:QSH@`8&P
MZB"#"A(L@($.(ZI`_@!*6=I`@PY:9&[!3]>T8(()%)#`4Y8HL*M.KMS<$]=C
MF\(@@?7V"V#&#VK*X-*-GIK`@0DN+"NGV6A%5K$*$&B`@PU^]=;`#A!0X`/T
M#CU````.6&DB5V']B-8+("#`LEO-M7&A#11P@%6?*DA`,`0?B*X!8RG"S-*(
M.NA@VGYO[(`"`@!(0+D)>BM`@PH6D-:GL3PXSB\!]!W+@FUE>YCBMY050-R7
M6\9H`P,8^`""`O["#H`&+'*U@I&YQ*""MCC`8`*&:7[N`@E2DL!,GRQ(T8&#
M&G#@/:NX8WHB#R[0&NH)@FU@X*9;GAAB"'!N2Z`+%`"`@J[5MDBOO@)&_N!=
M!SJ`N]ZXZD:;(PT24+!<P7\B&:0,"IC)/05ZP_B`"R>B0("A>R+(`J,XF.`!
M"T1&7"Q:`Y^W@0<:^!(H%/L*(`#=,!:WV(TR4$```0Y00($%!K!*]+0#1R]T
MB#K?P$<0?9H@@`,D$(@@`@RHH/:_?U\S`P0.N(#RZI=R^:+A<H9()`8,$``!
MJ><5`#+&-+#`P@P<@)'+J;EWBH.K?.J;@@<@</NGSK/V`/Y!(`*6X4!#:&01
M#9PE`0^0@`1V-;SZ12DUL8G``22X$P@,8$P0D4"OTD.]"=YH-0!8`/)&.#*(
M5`D#:2'5N@0"OP3\"$R/X4EJ#GB!UW3``0JH_@#^4K@46G%``[/:0%<\8*T.
M(H8#%8B`_YP20PR4#H9!?%(&*/`0EW&``AV(0`+HIT$"2-!'(SF)%=7TE0&@
M#XT[F19Z7/@!29%M(;0"$I@41,6)2`QB'Z-`&-O(IZHM0`$(.,ZF/E"!*>:E
M2QJ0508XM:(-1*!_'?$>1_08R(YX\0`4F,H$NO*5IRD`D!_9V=F8]`!K>4V3
MYAF-0QC0``@\X&H):%XK^421='V@A:+J9)\LL,9,?HUX$7C3"W%IR:H5P``$
MT)O!))2PHU3`/P1P#/0,,(`(3-(A'SE@A5YSJ6$FLR(=R-<?$0"C1`*@`L$"
M8D\DL)6Y56`"(`O-_NS(V:""3<<QA<Q/`<0U3C1N``,9N%\!$!"H`6@G7&>3
MB`4(X$FF],V)#;@)!DJ9SXI@H#]#T0_9_+.J$3$@10=8RZ#XEJ<$8D0""3A2
M73"7D0[,2J-`(4P"+,"!!=SI`\%$B7P$2H$`$`E)\`&``<AVQIH:2`,+*$`"
MT&(G`BB``0]8Y%(OP@$(B.H@`&C-`N+55`0`AUP%&LX2@8*;QNW*F*S$JD`P
M0(`$.``!!7A`!S:P`/6Y)6+0<@P".C6!)W*D+`6PJ[7,YU"*F.IP;\6(.<?:
M`3L]Y`("N``%$G!'JO7'2`BHZP!R@BJT.E8VX`J7`I*D@/TD((.D75=3_OV2
MGXQ=H`'0TUL`%D!+U44D3*/UB5:W$@$BT;"*KB45!A@0`>X@,CT,@!-JYG([
M:7;NCQS9P`S#$JQ;&O<M/,S>!ZYFE`Q85@(($.A@BIA>#7#JB"OS+7?CTH$%
M`*``74J``1;0G04T%JL><`"2<+L`7RF-?`,P*0,FY-"JN55(2!I*7P0&7RV!
M*P(7(!]):F>3C%K2>6P30`*J.Y!=*;8B&D``6SQX@`E(F*_=:8]G)5`9`#QM
M5(GQP,I$R&*FU,ZK$H.`@"70N/,Z9\@?40_*),"`0L604:>BP`6:\]#)-:5V
M!-#:`1:F8XBX"`(8:,"<!K*`JFQ8F0E`601B_A.AHA"68P9X@#$'(!\M"W&#
MT+N=-?TRRB(C<X5^FS,3'Y"=L?30>`-`@&;AZP$-\*PO"0@``F@E@?5)IP%=
MY'-/7](4#:"V`5^V"8E=^Y4#.$!K#EF@@,G,$1?]I0`CD4`$]+3`;7J$;<QT
MYGO_+!8FB:J0!F"F`29I7C=N1%LYSK5/KK,JCJK(`>9C\(T4=QJP[<<[?)$/
M?E@K`0$4U0%AA*BQA62D`;AN`)O1LL6:E1,!.L`PY-+(PZK$,=T0"3Y^<8`&
MW@QJBW2@`A)X[K$3%[&(W>]^1H$`I!-SP"P#W"WJT1<"#'RD`"3@JI_"RCL5
M\Y3R+H`RN=-`;2TD_JH,A`G%#P5+4_A]$`):9L\3]``U"^`8!&\;P;B6"%X/
MUR(O[6I7,EH1__1=7(8_9^3!NV20,,,!6*_T*%AI.?<ZL*SR(:EQ!S@J"BW.
MWZ9X@(@T35<'M#)#`-")`EZ%HD"HR?2>;(D#I)NSQ61B)UI"X%$,X)=3^%B1
MV#1Q)?^BY-E+3($(#'Z6$!"/1(<NHC0Q)TB=TQ/@\BYA@!'@R[Z>Z@$HGVH;
M/7TGGOW`!:P.``6TQ0$!B$":*#``M8LE\:1:;P;2*RE(.8"-1ZE,`IBY``@L
M!-\AQL@%"N?K="$`8PG0>NLS7I$O`FDY2,$G\GV2X0Q<@)(%A(`$`,\@_LYO
M_0.U61<%THD7\7C*<L^&?D\@X%P&(/Z&.#+`ZWS]K@7<KT0:T0"L!T^!EO[E
M`4(_?X,:(`!T2&L@)D#,[_\J0BB`1N\`[F9J;%T<YB(J@`!L#@'1;V&<:RE0
MA``BH%/X33T>0.E\CR.TBIDD8/LLD"?V@EP20%T@`NXJ,`4KH@+<1:08$%10
M$"@X`*$^HK=DL"DBH%?`Z2C^RU<<9@>;I-(T+R)09*$J[@</I`$&@%Q.#&*8
M)`:AL%5B;M;^Q%)R\"<8YP$YH@(X*`N/XN#2KP*&K#;2Y&H"I/8L`C/PS0`2
M8+?,T$"DL"MV"F)X!=SNL*<0JHB.KWNJY\8,_F`!.\)R8NH/=X(NSN+N>N(`
M#J!`U,)-0$DC+`8!Z&MHQL6@OI`1*V(O#&H/[^<I(N"$4N@3?X*C(@KK3*-;
MABU*+"`TM$0C%!$4>6(!"$!"N.(H&&"-@N,I\,O++"TCOJ(OIH.6&J!75!$7
M(P("!("`C.35`.1IQJ-^+LE*K@<`>,HYL*@99>,"#.DC;M$9/Z*N,$`E!A$C
M)F``"&#-7BYN?$65-&\6^Z,V3@SB'``<S1$"!N4?X64").`:L=%/_&OTR,/M
M$$<<^\\CA`8!.<_,DFSU/B("X$,_WD]F:,7P-(^((.DCUPM20,(<F0*Y8FGE
MU*+"5&J$^)$G="IZ_G0(^N"H_RQ@S30BF-8'`2.FR!A@K!:`_7["8AH@`1P#
MU3X@/>SP!DG20%+#5#"*>%9I*24"]-@C*5UK6J[G`3Q`%R%`5HZH%`L$)UN2
M)142*$BMJ7H1*)KRR9BP#K</*Z02-3(@`GS-[HR",!8N+H_R(.2%N]0F*SO#
MT$CM^@0H)J<RCR`R&]L/=>#&5Q*'5&!1CO"G=JSR*")3+WWB8@"#+R;N(0P0
M,T4,(?J2M.!R(TRL4!)D_7ZL?%Y$P0S'_Y"OR"1@.A(`/)9B`QY`I`;I(7"B
M&$&3A,:M#O%%$U=%.@XP"V_,`9YH+"T.DS9@U#Y@*`<$K[I$D=)$:)B3_GLX
MSY@F``%.SS(;(&/:8ALG9P,8``Y_4T34@POE*$5>+2_C\M0L)#M_AP-,BI<B
MI8ABPSXF<!'34R(:X(0:ZBB$*[+6)1T!(&%29QW_<S$T($7F97=HB2*;ACY5
M[4@H@T'[2R+L<R:XY`'0X@!^TDO2!/34L$$G8AGA)BW7KOL*H$-2(W?"YCA1
M5#%0)`'LP\+LHBL+\D\X@'PF`-%$Q$+=J`/NL[:VC='R`P$`;S5HE"3SQ`)2
MY[QVT#8F`JJ>KT8/1`-\S43*ZSPK23NC34T^),J&%#9Q4.B,5%TVX%%BQ"\4
M((O,:LJTU(.P+SN6,"-\S:'2"6Z>L$[+8[X6_@!S8@1W+J`P*+1?%#-*M`H"
M%M4\+$5#B:Q`/$!46@7!<M+_,@10!>+-/,"6))4BJ`(!Y"4=!0#[<*H\@@<Y
M%1/TUD/)F@4\/"=16XD?YZ))0A5P'C5$JH0.!P)5_"(G+JM3P$1,`'4LE,P#
MX/.W&"``&D<MRD<!9LHM$Y)(WXKK)`(S<`)C`$-!!B-/GC05G8,@(@#[=#60
MO&\X_L+0<`]/BY56K<A:*>)T="I36S10RH?5NHV7?"@[(X]:Y+40J\14*$DY
MQ@*`X#6(O-`YKBMZB/4MQJ6-/(`UY$A"9$G2*@!TTB1,$C:%VLY&Y@9@(JQ[
MF@@"L.4U,."$`O;=_E864XJL+`\H3)<J`F6#`YII7-XR5[VE2M>E%,G"6M#S
M\TZNOUH6KLK$[H;,>TH3KAB@8YD231/M7SFL(@[(7#&SJ53L3Q]3D]##T%8(
M`UY-)@`DC#:U3L=B;CJ@`1P3*`HHE)1"Z2`I51NTY?K*+29IL#!S90S)%=UH
M:8O6-"[`T&XLR=[E+Z354WQ0+06G:*\&-];V)W"O/A+`=S0@&A?MWWY3:J-$
MUH(.;?Y6(L@0@S#NAASI<T\CKHPO-WK&71J2(B;`LE3(#'O(PIS6(F1"8M*)
M]UKM0<.54[,U+G`3;_4RF`A@-->N3,C)9D>E11Y``=[/JS)`2&GB57ZK_G-;
MCWSTK[5V`JK6Q:3&`BJZ\@!ZUW>;[B(B1&;C$J+,ZV5-MU(<<(762TIS)V@M
MQP\O@H_:EV::5TJ!,A*M%#H'XWR>$PO)%SIF*?L6-W\C`Z%T5BGCD'LR`&=F
M\%K"Z"'--B84(&7OXBA<ZGZPC#I![$'MMX#?XF,NX(07Q4MD!0+0]W=V540V
M+7H:&)->F&9:J/\.M5S]#266ID`L&%!=*@.NSWHU0J\Z;=L.`K4J8`,0@(!)
M>.O"\W9NQW6X$0.N+T_-$$0Q0'KA@H@4>!4/H/^DT#>HF+Y\$R+(T%YKM-,F
MZ8Q[(CP!\B]>):]J]XE_HCL]JY#X0O3"9@1[_M1*/`!RGG(Q+M.%(SAG/@8#
M4O8O*`Z0</)8H_-.!G4IL&A7'H@"Y@D]NM&.:Q;VB*CTKJ[WL!@*<2*#M\?&
M1BB"77!=-F[%5NBA$!-0"8EP[FUK^2PXD`N!.3GC.`:T8.*`@C0+-9<B2`24
M:`KZ'A1HGD83,P:3)6UC?\-WP0ID:GF:!@O?\HLDE*6.=]DEF62H'!5"AA@*
MN6Y:PN:)N!C@GB)<=,8[Y@T^XJQ)B<-W_TMK=+D'K6E`U,,OZBN"Q[>;O4DK
M3.@P\(T]4U!M/$>U'K?UF'@F:&7D'J6@RB0LQ==WMZK+TEDLXF;W[',S-NA.
M_QF@.\(?&9EL9@GV_FB/?A86%VDKYA`2^FXF9[#H,/HF:#'@I0%5V\RG?UD"
M;/#K3&BQ`[*CA;A9I#%IGV_''>TM`^CQ:[Y8=)`K20#K_&PV9[9J?<:BJ4HN
M(M*#B.-R9UA7H`CC'05"0L8D7&[ZGHU:+<U"@!!LIQ``6R+`CY?2PHADGJ'/
M2&?BRX;F:0IKJ\6'27V7.[[L.T<&`YXJ*4042.+*(7":R`#Z>Q-BAI%YO@!C
MA"6L4M4%-)9&%P4KGHO5B:7R1_O"E8'"T:!J[)+(S"Q$L-=Z-@)E:1B@,LU1
MLIRU>,]/LS_`)5[G'[<BC&ZZJ!E1J"Y[*:CI+UZB`A@Y:0Q`K;D/H/G-_@&L
MK@&:BJY)\O::";,EK`K;="#+=?`VIT"(FIY516.ZYVDH`VQ"XR$F,*3MY6,+
M6-'Z3:\`0T7,\Q(QLZ5OQS\9;BP\[WZB:('=&SD_`.A8)G9O+CC@QKE1;G0!
M%6[>Q2]X)*OM;I1_\%,!P[S/[\0\0`($C$M.F%&X6)1\-P)`B7E4,6DH^[6I
MUK+KD"XZY.,P5RJCSNP(D9PJ%4<Y9CVF>#U8-#+P.J=OPF!6/".>.BXY8%F.
M*OU6&=^TEB2;2E_P(I-JV(IVT/@V",3(A@&BHK7"9,!EER@JG,5?YL868"C>
M):*,`C>>W!SW)XLLW*EK"BIP-"4ZJ$40&/1$_GLI42M8W%BDCQPC\`2U4`:P
M-HV_E])'NG*8&S`J>I8C.&K/25(F(@3,03/0'7@O_6.;J#6_K>EH,/U*%*T`
M#F`Y"NXKQX4Y)+J((F0`M+MF:@H"NFV0U[K*#1)_L")"M*=?0;-V5,QX^YM+
MC\JPC,1(4L2P"&#>Z.TO;/-,WRIKF/@$7]O6_<1$%H(R0YU["D("(*7(\^F#
M*J0A[$3)2$UKM(:%"6@@\XO!N<7;7T9W&&?WR+S,LU6KM"<GW)WA*F/,97(<
M265<VHYT%I5PU/A`ZK:F2&IGFGW>/3<#3.BZ)/W"<\,&D8^)"WXCM,:K2?+@
M2`K1&=Y;2&8#K.Q!_B/^!^F21Y&O+!ZOIS7XE1OT%'G%XS_>7(2Z?[X+-'4J
M8V8<X*[GQXV,`:C='!O@`/)ENV;>7)J2Z`<X<ZVNR[+]1E+OU:?2)IX^B'"/
M`@Y`YH_^2B8I:ZJJ(<(S?*7^!W.SK%I/`PQB(8;I4/+]_$A-ITI^Z\TC3.+X
M+T)N["&5>_JM=%N/.S*Z(Z(#V$$3:M#EXL_#V?]3Z0(&=6+I+*_'TEM/ISCP
ME(V<M-Q$`T.F1NU9F[B6T>/2"R_N*_E5N&>CZHG-70P3)$Q?,?2B==M/CB89
M1;6&<4S;QE;6Z5!T`V;3JJ;2M;MP]6UF`>HPIXP<^!$#1/%^CP)$)XS?_G,-
M@@(*P/!A`VHG]=+T4K(&I:*W;&BIY6FY!U_\S;IKT>6Q*G=0+HQE?_V\%8V:
MGWMR!*#<A4X6F$+;/U?.D_I9##V$I2FTINT3#R`8,-B`@,*'@P@3*ES(L*&'
MAA`C2IQ(L:+%BQ@S:MS(,>&$!!`X4$``(>&%`A@H>EC9L67"ARYCRE2(X<`!
M#1M@SMS)D^?##@X>:.B)P<&$GDB3+M2IM.*$"!<85.C8@6G3JUBS:L4Z08%!
M#@TBF#204N)#JUO3JF6HP0`"#CDKHEU+5^*&`T>1-E!0MZ_9JGX]-'"P@4'9
MC2S]*E[,F&<%!1$\7%A0LD.'#Q7(-MYL=B9:_@L&#E3`,!?B6<Y].SP^[)B!
MA=*HLWH`[#>!`H(&8^O>S9LCA0,)(B08`-(!A`V@,_26"=MB\Z46:7\`'6`!
MZ8N)EU]]F('!!`Y*/V[03GXF`P49#H0LS[Y][`D#`,B?#V#`!0P%E+N7ZYG#
M996GF94!>`=UL$``#XR'G4;/[7=09JSU9$$"%S3H($<6)N6!`@,ED-N%((9X
MU081#/8`!"A&$-(%`N@G(D328;C!?Q/-EJ%_"350``49(D;CBPM%<(""275@
M`01#`=E1CU=%(,$&"TSPHY)45NF<?Y:QQ-T#!%IY4'9+QAA1@!AE@$`!%F`P
MI4H5P<4D>Q90MB9/_ATP<,&7J,WFI40/-%#!`9'M^>:>7NI)J&=8P722`1=8
MT&5/'7`P*'D.(!!74QY($$&2>8IYZ$$)'$!!`7D="N:GJ*;J8)T'8/"H3Y\V
MP(!L=9:DVZ0@>K"`=0B42FBDSJDJ[+"*"0G!!7,2N^`'&T`@P58/,,"ILIMY
MP$$$$UA0@`.O6KD!D6.>2NVXY,ZTP``49(!KN1]H"NZ("RBP[G;#+B!JKZ@:
M6B.[_/:[$0>A8H"LOQ<!_&Q:$NR8+,%91>!`414L7.6\#%?L;W=V5M"MQ0IQ
M(`$"4T&7U`8/(#`MQSTQM=(%ZE:@,<HPQTQN!O&.=AJ9*&NP@`.<4BSR_D(7
M,"HSG1MH8#0&%5R@`+<87"JSST-'O9O.>&EPF0=6&PTUH1Q,,+!:S4:@X-8Q
M=T"!`0,00(```A2P0`,+\,@QV5+7K5L&#SA`@080#!;O`0I4"+.U.GFP`04/
M/%"!!'(CM4$#=W;VDMT*71`?``8D4$`"#2`@@*\QTTWYZ&OAG8!K!0`0P'P"
M-"XU!?$9L``!LR[D:4,=7$!!A`<U<'"!EAD]I0>NDHZ0!IMW+E":#`A@0=FB
M&R^]5@8"0$`%#``@P`!H*Z!!](<ZH+VL!*!'P0045&!!!4YBD$$&C6(@,`9&
M9V"T!`<,L$#2&W!@0?H*"([`-,`^"3CK9!W8_M27Q!4Z"@1@`A4(0``<\`$.
M*(``SX.99:;'0?9XX`&TXX#.2*(!"KAN:-9*@/42X``#!*``$F3;``0@P0$4
MH`!J,P`."6``'2+@``5PB^8*(($&T'``\0F`#@42&@=\;7(?L%8&)&8QD@$`
M@MQ[G@,'D,$.>O&+=8D`[3R0@00DH`(;J-1KI$:\!Z0N``<(P``@D#X+-.H^
M%DA3!N2WQSVZ#WX8@`\`1$6:#)AP-'F\P`7Z]ZV%;:`"Z=M81L!WJPD$P`(:
MX%!*TK@`%Z6%DAH"HR@W4R<`(*`#^!$`5`X`@`>`<F+=V97^$*"`IFE`8._+
MP/K<=\=$#G!&%DB;_N\F,(&@:`J3WY),^B!IP+PY8#`1X$#7WB8VYKRR,19X
MH`40("<.Y"UR6[G=*,<ILPP8```)Z,`&+NB`"B"``">460<08(`6*N``)(%`
MM!;`@+W81B`*".@]\9D`RD```?IC@&WH>8!=-0`"$7A`!!;0P]#81(@)H.5Q
M,+``V_`.,==<C`<B6%`!&(``LC+IAZA'Q9:$E)PPU8JV`,``#EP@<1!%``/$
MB;(&R$<`\BE``TZD(HD:1U,22.H$#"@K$S7@G``H@-A&<\L-8,`"$^B;IAZ0
M5`OL42<8..,&BB@!24Y25<&4H]KF$P#G%8J!,8VK=C(358?1D@'GW"GE_B0@
M07M!3IJ6"2R6`EL5RP#6/QX(IBF'LI+&KL2PA*T*F#J0`48VTFX>&)5\X$B<
MO#7@HR)"SG7D2EKRF',`#K@<?0Y@5I1=@(<:>"KH,H(!H"Z@I0!"",42\U+%
M8(!#STS<G6+;Q411#R>E3>YR-&!&##``B`5`0`,.X(#>*JD"`CA`*1_`'X94
M0#Z6@J)NZ0+7/:%R/"(D$'.EI-SVMK<["JA`914I*>1&L6X0P!Q'"?"[C9@3
M<XK+8P70]S+WVLX"1L'MA:YI70/7C0,,*,`#OM/!")BR3OQMB=GV<@`"!-$F
M!4"7@Q,"%PU(P).D*^^(#;PALCA->A$(`%\6_B"`_C(H4AO()?UTZ:$5'\2`
M'&6L]!KLXYAQ(']>)3*58"(!)![H>DHA;I$U8$BI*GG)1<[R!S)```#04<&]
M`=]<&NN1+L/P`.#D26RKZ6.X_`D"8-:RG"L&):D^440X0\IL?@2?'<$M9'2"
M0*NR#.0%%'?.B);:(]&HI$C%62Y6L0H%!'"]"3S@T#(Y6UFS;$<-2/=D%KMR
MHH=&@6A.$4ADWHD^NS27D031`%S"$$,^*-36*M<!G8R;J+6SZU''C&0)>("Z
M8F8`ODAD))=#`(HU\JT-W!2O#2!0@WI-+[]$0`$2Z&3HJ.UKBV$`A/:96Q0U
MX)V)P$X`#&CK;#'R_C@./=<K^TJNB1F`@#2'NMN)CM,!I/)H874@J>_RK@T3
M)N*.9%-[QXF.I`3%[8/,&P&8)EC#\<TP"S`@`L"ZMP6["!OJ*`"'*]6(`TVY
M[(A<``*`7O(B&W.?3*:<XISI@-5@OA5/FVSBL6%N2IZ#@7,:8"]BZ<C(%2!M
MBH`E`=7^Y(P:4TP*!([FL9%YOZ&ND?]^%N>,>8C'$CZ1GL_QJ4'GB`6`F@!0
M2^0Q:U0*X>I"[6)V!;143_$X@S8`Q=EZ7!6@D(5JLJ/XV#@C+"(Y1LPFK:90
M=NI`HA\'0!;WV&!]Q1CP<&4?SY@(&"#@#<$``K2WO;!O9.R"QTAL[>V3_A<3
MJW]MX5;CO4CY$`7-E'`O%[GU2I$*I*X^!/!\U5<W:(Q(!@([UU#KLT),@KS<
M2L,?L8J-%[0)8IY?$$!/AB:-[OB49,^(A8NCU8G>`75I`IZKY4:P'4IVK4];
MZW[1\E=OS7'BQP`:N#NU^'D1*)6=E0<HHJQVY0`&[(J?"J4`Q<0A#[`[#P`<
M$B9_#&%`2>(SUL(P(Y5A;W5?[+=Z&A!'4(%XA&(!#9!^$$$!`]$`JT,?$O1"
M729!F[4]F]56\M%EMK(1>3,3E)5\GT1&]68J%<A^=S%(:4<P#D`8&%$I'0!"
M".`DQ$0!C9)C)G0^#N,`7094JK,ZJ:-[&-$`_@FP->LG+)"D>;&G?CG8>&E4
M3R57+AT`:QD!`8QR;<<A62KS6)&B,[[#3>@#`?]C=A91%!-`@PYR)!!``*KW
MA8"H).VV2'H83NX4<A0A:!?0`+3S?$M!AUO6@`J!*Q6P`(XH/1F050:P'H'8
MB2%2)][S/9RQ:SJ3<$QR4.N$.:(X$?XSABX1-I<X.!`!/Y-!>IYXB^Q1:CFF
M@;*Q%35Q?!21;>16';$X7A3H$Q<`<93S'(K$4150B+@8C0GAA`U``;R8%-*D
M%IF%'AHA`0G0+)PC.!1A-H@H$QR08&RT?!7P@\HHC>ZX'!MP3@TP;*B!(UKQ
M$-]FC1HQ`=$F@MPH_CD?$`$#88PQ04;ME(YC\@$:4$P@`XVXF&J>R%S*1H]Y
MHA84<%O,%B\]!P#R<A$:$`%0L3$4,U2B])%6"(SON!/S8BT\M7K_5E8%!I#&
MI8TELA&6A"X$$``0D"$PD4#$5"$0V1(5`'QXPD$7^5RVF)+MAR&(Y2`.N14<
MH$\L\QQ/*7:^LQ$58$,6$$>N-$D0!C(:@$DS(0'<Y46JH3Z,IY3EAR%5^0$9
M5T4=I345L4%[HE!V.!$6T&4Y:4JFIQ*WY$X!0(4<40%<TI:ZT7\8`#EJZ7@+
M=HU<TV%VI&!T:24=T%!B=U*,R)&\R&4`T``%64%9I8`RHTCDUH6+*7<5_I-)
MO6(!R6*8#!(G!C$I6TDAP_%W&!%6!8"2QWB'WM-!L_&14'::PMD7%M<`7K4F
MKKD10QA-''$!!Y!=:F.;L]80F=$`=[E`%M$L=T8Z0#%#`""=PQF>34$!'N8U
MPY.%0&)!Y6@1R1B%Z-27%O$G!."!!;)PG2$9=K*;E+,!*E10URF>`+H39]-)
M#H!B>78H9924%9$>FS5(L7<^/S*9$P!4X/DE+:D0=;*>=2,8?AB3`?JA2+%-
M"=!DNIDJ&N``;+81%WDF+.0LZ;.$%*!4$0!#<;-4_?<`N@-)!7``$=<2%W!B
M0_9!!"!=KN@OZ`FB_3)3!!!NY.).14H1>R$!_@(!`5GE?P*Q*PJ```B0`#34
M4`MP)OL&@IO23Z:I$2HR/3JC/5?T-,F)I&HQ`:DS``U0C%P34:+9$`X@`,$6
M.WM36>HD3<VF`*[$`?:S1Y)2%;&U(TA1:O8Y.HL759_CII(J$\T279PX+#!A
M<>S5$0^@/=P48E'R@R");1-%`:$R`3HS`8$D-O]C>ZWC$!TQ5A7*:WUA0?7Q
M)%'3II.:%1#0-@GPI.$S)!0#`:M3/F]3`;=T`52&K&%)5]6U.X2:$G"1`6A(
MGQV!/?]Y*]2V(0"P`)NVJQ*7)0^6/?6AH)_"`;L2$Q`P0S:T;Q*0-"[3*'64
MIZVT$/2#')8W6T<*_A'-`H3ML:])H2*:UZ/@2BV&LXI1$UMI@P!EZB44X$0Q
M,:-IDY,!0`#`X4,=]FK1)0$T8I`,``$J]$!+`37XH:&R."!W8;(%2RRZNA:Z
M0BI(@G<40*<3,:,[BD.N\4<XT3^1<@%>@Q;P,P$'LJ;3V1*>=JD>I!@FI#,-
MN[(X2#H4E4SCDHT1JS:`DS<*T`#[%R\*T%'TU"LT<P"A$2K`H0`&4&-*H1H&
M()A#DRT<0"J2VK+]TFLZ@QX4*2RBTV3:DSEFU#=#I4_]UT_Q<0#1DC@_:$SX
M$ZE-48"C(QF*5!!(VC_D)+<7D7<+T"AWBC)Z.X+\94>V9"V$2@$H(ESV_O,2
M8O2=O4@YA`D!UH&D$F"N-`>P2)&,:`:?JKNDYX(YSY0T$-!.V3*A!I$[$R"V
M$D!E1G)#7M9M#P`9N8FD+"-*>[85LML349$Y^MA!#G`;S^6M_[%V"FDO#+`W
MUG*19_L=0@(`;.MC#Q&6"3.K:GFAC6M=,-%K7:,XH\5!!X6N0SIAO1NX#S--
M;+-OK%E"<&,O%-IM\J-Y)2J<E#N*+/N#^L)!3AA6]3$8_==1'(*JBRA'Y_&Q
M96$!#S`[]>IK$M!.D.NT*"P1%]@Z=RL]:,A1<F0=5&8_5@-(K"0674-/$7`=
MWB15W38!'VL`')O"1,P6"C``WN&8_1(!#'O$_@%0$!!P<?]S`8O#H'`F7R9V
M05*11\7C:PG,HT4<Q@FA+0+`,U_T``;P)]I#&#;5-`5(Q?S92N1V'UZS51F5
M``1;9#Y;Q6+<QWR%)DK<+T]U$@7``#9F-=;B:1-$0.^#+%;EC?*1OD7V/]_6
M@WV<PA/Z%O`;-:SK:1?W`/(S8!2P/LQT3@D`04>H5$]!;PN\8OV#'Y(\MY?,
M+B=Q$[9+.0));LES3SAT0SJT;ZE#`&8D4`#X4+H#K"N661(H;K-L?BX47PW<
M%T$CQ*R$.>=Q:2QS5>R3.JM)Q5GUKL*1.NX[8D;S6N-LL-/;S$JB6:(1S74A
M`4"UI/LV5.$+/WBS_C,*($&&3)8_V$\%.*,&D,<^ME1F(M#C<J#J/"S:LB-J
M@JE(0:RJ@T]^XC[2I*P&)+H=5HW\R+_&46I::M`CA@%D&=`)C<+I018-G2]-
MX0`OQ$WUD2YPX3ZW1#]=80#UC(3((5^+>$,JJWS,X@!@7-(KRZ"&D2HB!$H/
MX*L)\$(H$A02M:*Y:],X*LI)XQ^_47A]X<X]$97(+-3AV0$?1S]:O1!"J!2]
MVJXZ90&6)4U&$Y:IXSV&U93_IC:M[&"9E2X*`-)>/9P<]3`30+,7T@%P`TIB
M-`!M51U%>B0*"CM$NQ8"D[G#0F6C<LY[?9I2*E$4=BB6UM4;8;-`%%4M_GP1
M-2&R=)$!>D.0<[M'F6&ME?VOTJ,T(PK9[G$Z36)#%]=#]YN0"Z'(K*T4B-.H
M$I<W?Z+7K;V8%S25A](!P785$I"3Z&*%N7V;!UP770-G'#-OHE%D@>Q[VTTE
MD[FA$09!LDT>_Q9?1=D3$XIN3T5[&Q%YR2O-<QIJTO1;30M3X^T2Z7PHWS(Z
ML36/7>PER/,`W<T0\`%'7;8`\\*?@>D77;-IHI.<9Q$GL#NI8PT1]F@W%K`T
MA#K@C3%2)'T5C%T`MK69"!``E#TRE\L<^NF4B7E&8KS)2.I.'N*A5,(W#CZ>
M:0-^G=D2D4?:M3IA2LR&(K*J:-;'%0Y&S0+*_K<<(G'"V4)7/ID4``V0X%%R
MW\R1F#U=(S`>9E<E`6E<W`YM,>C**%9^*U$T41R^@-EE)N_9$4&3`/6M%(9\
MW@R"VBJ9*)%RD<0=M\`=YCF#-FF2YHI1`7[R4A(P2,R%Z.OBWB^8%C&R.(!-
M7I^$2G`^RV0DZ+QVY"U11G#.FC]S(2&\%?`L+]F#X+&ZKK&L9TU9()K"&T'I
M&=C'UA?``9&7Y>"JZ1/QEA43)]7H*,BGM5MA8:=T((V>$>JD,[G18&C!CYCN
M4OFMPDR((OEG-IO8[&">=;C.$1/P<S9%C[0>Z;I1B;WM4@<1`77W`0O0K1K&
MNGO^Z<N2$'@3:[LA_F:V9TKTID\?6]3JG.VC`\^BTC<<PKIRVN?M45!E+A=0
M@FXT8P!2HC[WBE5)LSY+14S8HCX@&5%G8NLPHD@#!E&A31%GDZW>X@"AHJ4V
M'5&<X^3)S.\Y6._(JSTC>!L@P@&;>(_N5!_\A"V=`QS^MZ0]Y&'QO#D=!D3%
M&D?79R-NZ";:=UD)$58VT6$U]B;KZSL'WQXGR@"58K$#@5U!#7,7?NTSH7G:
M,T.<LS8,#R)&\C`KGC*/8]CHYD:8,T-0F#:&/4,OI!X*4!]'3`#10CO_$Z-+
MF%1Y@S@0%2U_#1?^,0%+6LBS(P&30D;[0RS_1FEH\XWMLCWMGLQ@SQ.__F$]
M&F.J'39!($)N0[P5F5&Q0^I"]0%4,<1"W/2U0"1#ANT`ZI3N<B1',D1#LN]A
M/J^E-B$0/W0`LF+BN`+6&I^>^64<TRX9J77BFX^+8Q5B0['M=H3US]X7YC3A
M*IG4=P]\5D5E.S8@6-,_B-]'N?0?_H.$21,_7,Q'[\-'L].,3K<`,+0Z_[B/
M"B0L_?JC\:V0!P40%CX,)%C0X$&$"14N9-C0X4.($25.I%C1XD6,&35NY,C1
M0P0``S1\8%`@@X4%#49V9(G0PP</%1BL;.ER`X,!`@@H8`"A@@4*%"I0F`!!
M@H0&#R+\K'`A0P8,%BID\-!!ZH4*69G^!!KA_NB$"1(B%`@@X4'4`P@2)#B0
M0`*'BPT@$'Q9TRY%#48K+#A0`>8#`@@RW"5<V/!AQ(D5+UY8M2YCB!H.`%BP
M0<,"`PX*"&!PX3'DBA<<7.B0V(,&!@(&!-C,^@`!`@<,&""@6D``UP82,."M
M`$&$#QP8&$!0X,#Q!`40()`]8``!YZL+)#`P``*%VPPF/&B`H6+="`J\@UZ,
M^O@```DH1"``@,!X\B[CSZ=?W[[=SPP[9"A]'R&&Y"+8X`(&EGO.`0SR\T\A
M"1*`"R,%%?(@@\F<$Z``!XB:0"@+-,B``@DN$`NL""BPX`(-,,#@P0W,DF""
M$RL`"\:GHK(`K`HV_IC0NPH$$""M`0I88#"+-FA`@0@7U.BF````(`#:H%R@
M`/CNZR!));/4<DO%KHRH/RXW6,"]!A)8C34!%.``RRT?0-*BJKQ\R`,,&C!N
M@>$<B+.#*U_J8,T_^134`T(?JXJ#005=L]`]^R/T`PP4:&`!M@Z(`,R*)#"`
M)BXSFM"!`YH,B8`'+$B@2OO8['155ENE2-6"8+UOS`,$<-+))C>5U;\+&@#N
MHD<A\H"#%%$<D$CZ]O/P`F8?O$B#!AC8`"97+>)@.P<<:,"O#0R@H%IPPQ5W
MW(AV!:T#!0ZXP``%N&O`@00<T!%<[IR%T-/YS!5VH`L*^);<.0=R+#@=_C/P
M%V"$$U9X8?(N.("!#BBP=]B)]*W)`P=^C<_B<3G0%E6&&9(`@@L0N(!+CD-6
M>666)[+@``4T<-;0:CVPP`&_6E[PM`/FTEFA!T8S^6>BBS8:X9('8,""E`F2
MD[P.%HB@Z:,W>BRENJ@.-P,-C`1Y03ZK%GOLEC.H;@(,,*U8ZR43$(CL^'J=
M`.X/,NBLTZ?IUGOO5B](X(%@OZ./`PH>0)9OQ1Y@0.RL*2#@7U;91GQRRCF*
M@&0+YB4WT@CL75GRFBA8&O1J-X!``,@K5WUUUKF#X#K/P9U@@)-9OZNN#1Y8
M(/:?]XO`@-IM%WYXN!\8X(`)-"`=,@X@4&#:_I;S7G""`H(W&H.A!LB9>.Z[
M_WF")B/@-%P)%/!,Y\"51$V\JHGJ=WOOXY>?W+HJ4$N"M,E](('Y:\H`@=01
M+0,5*-_7^@>:Y0GL@(B#0'>H1:X;+;`C'K@`](X6*>`)+X&K2I\$JP8>(6%`
M>>0*FP?O!9,-HJP#!#*@"15#N@ZZ\&@1@%(%\B>N%,J0:(2*P`0XT(##32Z&
M&W.)VH#ED"'J<%P>.)W)2*-$**(,1!88FNJ2B$"7K*E+4518!R(@``-DA7=<
M).-!<FC&@70``@5XFQ4C5\;^5:`VR8-C'1$BJ,-P("ICL=[JSJBP/]JQ)<*)
MF1$%6<8.:(XN-<'>_H<&$,!#`NR*D502!H(&%`M2DHQ5&4B*QKBD:4FFC9JD
MWR1)69\)[&8"`CHE%S^#/46RY#3$8D`+*1G(5HZM`NR262[A)BO)!9(#$5B*
MNGRYR'#A\I@2D4!LO)+)9?YLEH11)DPL8X$"P"^:G:KF-B6B`04DX"F&]&;(
MAJ6JEY@R8"UA(@0L0`!MEE.>W$-7]10XS[VIDSP>>``$,$"`4=:GF_@DZ$,J
M,!G!%%1O`RW2!B@4T)TI5**+T10!%E`!<DYTF1<0RI"TM#R&:I2+FFH`![0H
M4EEZ<)47>,#X4A5,?:*TH!`8``(J\,G[A%2:.M4I8=8C.EON$W0QE2D^_FE:
M`/'5S(5RPN6$^'//A''@9@:`*""+>M6#4*``"OA33R?"@2=ZL%"(Z4`%&E!5
MA&U`,VC%:EL7-H':-.!\J]IE4+TW4'[.+609P(K;W/K7E5F`-A1PJ7]PM[_"
M3M0"[F28!D($K3X"5K+DHH#4-'`!G-I'4Q;(J$05QS`.-"52=IUL:;FD.PJ<
M)+/U:<`!O.I"F22HBXMM``$B*]/7FG8CLTN`S'+K$`T\0`)_[<`$&#"S)4J`
M`9.ADFZ=6RV/@?%4G8J``Q([T;I<X'D)^P@"FG2`(**4J,]5$@?&Y*1X+@@!
M#9!L[CKWP'%%"@`"6,!U)3K>E)+7(A1`P&T`_I#>5%4@`7IM:UT`1&!R#1,Z
MTM(O?GY+T*(\``$9?"%$S`N!U6J4GPOPSH,M@@$('&``XFPP.WU;XHJ$-F@0
M@*9_-@#`TIX&`0Z0)#9#8D\4=T1Z.7Y(!QH0@`-X-*(?$"R`V\J`WM(O`N@)
M``)(FQ`/\UBC&%A`DYJ+F($YQ'1`/$R4?Y8!N0`,`^4C@`&>W!`O2UF>U5W`
MC\+KX!TG1+MSO4N<RUC9SK)*`PXP,[#2K.9Y.D`!VK*NEBB0@!;+4@-YAB(&
M1L-H+EF%PQ=!%*`M'1'`0."<$;6D!"!]0D'ZJ7#3^O.<-,`>MB+QTJMVR`,H
MPR4(+,#.[*0D.-_<_BK?3?=5K.:UR`;@K40GBP'LU2\'^AGL+=5E@*D\<Z^=
M[9`)S,:?I39NSDIM0@I:*KXR`NBSO9T1!PS`?"-<$$^0/5D/2"K#6>)`,U/]
M;6>K\W0"4$EY,Y-CE&AL9W$6C00$?%MX>UN=&D``0#^=F+*JI\&/@=>Z7SC6
M@VS``E*AL.UF'7"^;2"<&[@X8R[S7OB2ET"7JAD&.-KG:],'OQ@_6C,/0-@T
MEPS@Y$VEPU6>@900Z-8LYWE!:&JR@Q\F8C-1LZG.K22)W^@`S29;RGL.&@H$
M28P"_<`%+AITP46S11)K%05UA)*=/YWGFI*7!6Q>&,!@O;V3AJJ6H*(!_@NP
M3^!B;T@$SAKR^5R&?]1T.MDZX``6NZJZFIJYFOO.3<2!6`(9B&5\RD>!0/Y)
MGJ?Y&S(_:O<(++W7PSH[XNJB=I8=VKI/K<\"WE28PY--`5S5\P8V$.UWHUBJ
M3!?B2?D&U]XV'C(>N(G&4@]%J_L,;T]95^%SS`&N'9!BDXNVM&R_3[$<'<40
M0`#H&2.CT=)=^P-QG@0V<,/X=(`!D+2TU3WM$;M\2`)"WKX;*7<D&$U`^H8!
MIY&E[`$)(,"^]HF8`OK<?MOYO<(0'0A0K?EH-_-YMKR8/V'IN(G(@*(H-`!\
M.FAY@`]PP,)8E_.+M^?+"`Y@P(BP``;PC;#3_K`)O`M3L<#ZH#(0[+KYR2')
MLYI.`A7-*S`4.L&:<(``6!R!LKXW>BZI`@NX$$`_(L(&&Y,%4!(C1*(EW"&,
M,!(%N)P6]*:LP<'T,P`VXJQ]4IG/**O8NZ5@R@`)<("$<D'/:\(2^Q^3\3XH
MNI;,$:ZIH,*5.PBX,!(GJQDTG*"VLT*.^+$&.`T?9!WA>`"-$Y]`W"2,,+F;
MJ:]JP4`AJA@K=(#T.$3;L0R"X"@@I``(@)<2O"_TX\,/@"LGZCSY*2'3&A;7
M$\%.5$+NR3)0A`BXDK5%BR)33"/G&D)FTZ\^D8@Y?#8("(`%Z$7W&X@-R(H/
M^0D*H$3ELPO12!?:_BLQ8>RUTQ$G1<I#E3.I"S2N"(B7HB!%*-*:1R&4#FB0
M!&!$>+/&8UHCP$''^\B+DJH;?R,LO-.D:+Q`8MF`#\R<JF.`5;PKEF/'AX``
MP^$D*"O%#Y&_X*BT+`'(.=$:\R``XY"-T3"K?NP>940W1U28U^&KC!D*L9`+
M<IN?R[@MAMP]/[L(#`B5G'`2W8@7V2*>7:G'&,O(A)D`GB@)W/"1)A$`IHF?
M/[DL_IJ:>62,8J0`%;$ATO,>G#.`"=#!!*B`->J+BUP9FGQ%A*&0`(B7`I@O
MY@``,RM)U!,1YH``VH"`J803"?"1!.@O!,`P<.&]LX0(#"@."_BQ"?``_NHI
M`-H)0(ZSRJ/!N9UXO2`90P)@`+`LC+)"```H@`<P@/28PIK8@,*1L`+02_MS
MNP;@NL5(275A``"8FPE``*6`S*,Y3+]<B/63E`_8@.,8("$9RD^\'2Q;%P!`
M'L5$@`YDC(]0E\FPE;L$EV%"@"^4P:H[E8^`F+I)+=WSH]/\&0<H,P?@$P08
M@,6JS3_"Q]N912S#@`(@`+$P``&(SL&ILC*Q%0'80.A2@.$RC:I;`(&@``6X
MRV':%F]L3M-R-0`P3`Y(``*@/LJ(2Z=A++NPBOJ<B+*JJ?S+"?&<#[NY#;70
M"?)CE<4R/AW[@,LP`.5:3!#9RC*T3U;[,<Z8_A`\.;0"0+`)R@`%L+:+Z9)F
M"@FO!(#J>S`(6$R()(``N,R/$C_A0PPC@8T`&(`R,8ZU?$8/+:T&\,K728ZT
ML!4:2Z%A.@N&X3WEDHL*Z"<`K9B;R1@(8(`%2,9QP1,LXQ?TP,(?L2C%(;HB
M7;4'*``&H"%<L14`(+:62$D<=96L<3T_6<[%B!..ZP`-^-,EK!^I48Q3BX")
M>Q$!&:;`2]-+(\NS6``$6`#`>X!2L8L*,`G+FT#J*]!R20@-D)%%951`:Z9@
ME,G&&(AA8K!7K!,?B@\RW,3]$]7GN@P"D*MJJDLZP\&ZH***E"6.XBA^E%5`
M>S$SXYT46C_3;"6"_H,\T,#'%JDX8<TQZGD>/>T(T]$W/A0U!7@;G<*`HC"F
M:.6Q`G&`$+E2@Z@NTNPY#[@WR-B`"!"N>@O7')N4"<@19>J)(G4`MEN,"Y`*
MLXA5>94L!W@`9J$*_"!&!EA/OZP+\Z(QQNB`J*"`>`W8!I-8I=#".N-2"L7!
M"."PD`*Q"!@@3J58B7H9>C/8N]B``5!!^WP)CT%.Q8#`L&`EDM4OK;(.<Q68
MN.NP-+4?(L4($22QFB6O"G"`G@C)E@@NFDW3#`"\=+6("]"+D1U:?&J^OKP+
M^^E5`#2P!%0,^`2\(:1:W0J/5JTSY<I9@3N*I\6+!II8L2TMU$+9FC"K_I<4
M54)Q`!,E#.0K'`GLLK<ESDS5&TGDGS^"EV3%)\##LIOIIY;",K15.4O;-+XY
MTB2L,S`5UKH8F:EU"*OX2*T='E/%)U<4F-`%&,U(@*5EB8X=3K]T5[T*I)C(
MF`G@,AVJ2O&RW:.QDP5X"[N8,9(UKLUM#/M!W;YUH=+]VXEX@*R46X_0N+P5
MUDY[W+]`74*4)M-(H,,E+Y-5DT':CI^U0IMI@+5]B!K9#H`M)?;<B$227HW(
M7N^Q`'_CCPW2./0,V%/#J,*H0^<9C.P]7M/`W0I[MHZ5B\]MB/_9V.9\C*8=
MCS/Z5!E!4\!-E3JJ15X#C!!"OVMQ6Y+5CL+0_@`0&</S;0SVQ2=L?#;C\J=J
MI0CM*EM$#$#O/=B!<+3BK8A$<M]6=+:]6!JDS0A-*>"[\E_08@"6Q0_D8UXX
M@4WD/:0(6"\+,&*,@(`$&.%?(AZD\&$T"T7MP-@D!JS*<@"N69[*JE.Q(AZP
M<F*.:,P&Z%!\V>)3<C3Z[`@N#=R`K:;"66($9N."0HIW"=X?VE$\UD-OG;H_
M;BOJ,4P8HH#1P.,_HI,)"*M!OJHU=8#<3#$#`)P?!$69>`#-?.2B0F3\N4@.
MB$_$.TT)"++JY>2B<M?.@:$,"%X'.\W@ZHGQ1652FH`@`[_VY28;CB00@QU:
M5K5HHAX@G64SW$,<_LR`33SE7X:R76X5-R'@9D[37J'4$!YD(%Z@!<"P"HIF
M#_W4H^#=93[5:$H*^)7B<)X3";``Q2-FL8T3;M:2<!,`!SGG2IH2<Z1G,WIG
M+5G3(+EC?#8,J>(.>?GGF6(7"=AA*E2H7L&9QEU8'*ZI%,XE?0X7(W$+#>9#
M`"XM#3`3MRRG77ZMS]`:9,X8=HXW'%Z]^HVF:V9%'.*K,1QH@L8GI9`1<[YA
M8UZ8E6Z(%+EI\MW2:*GFF(XD<HU:H#[-G&8(XSI$O!PV\0WJA/Z`ZA+(NO5'
M&=(IE/#29T&*4'5JOQV>J(6`Y)GH7AM'_<.(J+6[HN;J5Q%KB;@9'U*[_M^#
M7;=:E]_\#J#@*U=6:V;FGA![`-P]:O0#*;9>F'&L)3B1N*#(:[W&Y@&XJ$EF
MB*"(G-(%;#BZFN>%"-/)9L5>[/Y9+I"TF(WF06[*Z`8SBOK,OP>X*<Y>IM3@
M1X[1U^]%F,%>&&-3V'*IDT&[Z-76I.5*":#V@`-@V=D&+$%+F3\1C1G>;=Y>
M@`4@@`DX.`IZRL6N2PG@&,:+6BU6;E)*XW?);H8P$G`.ZL=(I2GT`$W4%D?6
M;DT"#)7(R+F$C^&6K+CS;C3SH@)H:O4FI?!8`,.YX@LL92L>Y+Q([N\.K08(
M[WS*;\3(O&U!:#F3FLT66RIK-@K*%O.EG-%5_O"6:"+,@H@&J6E93:<2<12'
M`#&EV.I\BG`-Y[[*5&:&,#8Y7>W3R)"(&`EWQ>45KR,W.>A=8:D(U>N!%1:3
MPQ[5SG%!<I[KB.C@X(GXUB\+B(`[/I&O+FDC%Q[G.7`'CY4,*$P-WU+,)IQ!
M2^LJEY_R2>W'IHM4NFR]?HGR47*!:1"0&_,[&S9[U0])#5OU1N8X7X@_*9_G
MEG,X.N$Z7P@.0``U7VT*J,$7#Z[@5G%`WQM!2YY/\I-_DR3MVS,4-Z-B1+)-
M?G0H&H[,S#.[2=UQ(>T<NXEW,^^109`F]W26@.($>,>%X%6%4<BGDP"LAC(H
MA\^>='7@$XI</8AQ_JR,*A^6I4`SX]ES7W>AI%@/G+*D7#=RWBC(U=R+;07Q
M96\9M?@)-H'B,S_'M[JHA?C4@9WJ8<QVAT@7F%L(2*4[REZ,INPLQ_()1P\7
M4_=T__.53SHT/_['DL0="DCO6+D`8D)PON$\=)\(OA#B3S*]E6AUUC'-B'%Q
MNKB`"#3X@X=X`)R24%>(]1KC9(OX&%9583?O^*QW'$KXB&```L#6@I`T,3[#
MA0QIBQ2+@'<*N-N0Q4MT%J:<>P=T*/:A$X$*%5&1\DGIU=$`L""*%VGBIWBM
M_<"*HP`*PH(1;+?3+2<5;3&]`ZA,K]A=E`<7"E;YA3!Q!@B`V(`-'P$C_@4(
M<*.1@">!C9PHL\"@\G+)BZW\4;(@%0,X`-;]I0QH;,DTDVV)POUX@)XG^_X)
MF@EH;DW&=05@4Q.Y>L%SDN>&BD.;K]BF-.X4`+3IUP8)`,]O15PG^*8\BKY/
MD04(=@Q7_+KS%>=)K7[UE?7+]-6A`/#\%=[KOBPW#+QT#D_CD[G\$7^&F^;A
M#>.8#?3()OA,?->/GS',BN6`5+VD5-4@T@U*.92@#?Z.EEBWH7320X<X^YZI
M+K#`PHY&HUP&9G'>EXQ`E]EX$K0O@+X/B@5P_N?O'@:0Y'=RDK4'B`(($!"X
M\.$@PH0*%S)DZ*$AQ(@2'4Z,^/"#!00&!@``_A"@(X`"%3I(O%BQY$('!1Q4
M2$!@`0,!!!YL0'GRI$F3-W?R5*C3`X,#&B%$L(#A`0(+%A1@T-GS*=2H4J=2
MK6KU*M:L6K=RM;I@@84)"P(4D'"!PH(!`0A@2.ATZENL<;=NB+GV@%`"`1"T
M?3J7IP0$"1(@*%"`@(```B)8I#@Q)\(.'#IX^"N5,M7)!SU<,$!V`8>#%0PH
MX(#A0(3075>S;NWZ->S8LF=G7>!@PP4$$"I<\-"A`8$#`"Q\\+#A8@<-#SML
M2![:0P4,&S)PL."`0G&?":<?G$[20W4)&"YH^,"A,H?I31'^Y*#9/'@-&FJ"
MW[!!`\D-;<$C-%T^_CM"%"B66GKN17#``A=@D,$'&7Q'TG;X869>!A081=P'
M&$2@@73F65#30APP```!$2RXX`4+$.#`9!HH>$$&#VU``80+>9!!!!-T0,$$
M%XQTP0,15,#`!1Q4<%`&O$E0DWX1-%#4`Q-``,%D'&A@`8\P6L!;!12,=P&8
M&&C(``,-&&1><;A5D,&5/29'P040.#!!EQ5L64$!8$7`0(Q).A"!D^O1-BBA
MA1IZ***)<J4`!!A`(,%#;'Z@@00+%&#043&Z.-V5$$R@085G2:#4`Q1(L%L$
M]*F6G'H98-"CJQTH."11#BR0P`,-,+``:@O^=U!Y%D"@E'089#E>=5-*_B#D
MEA38Z>!!CE)``9O2I6?!`PI8(-E\Q-)I5*CN*;?=<0EU,($%\[')@8\<!,F<
M`A2\)2L$-"*4P04,2("O!A5,8.J&'CC:6T,<.)OA!=R%JB%U<%I9P;($BWC`
MK@084(`"KNHW087I5D`4C\LZT(`#V@X9U)$9+J=@NOV65]V,HQH[ZP86A*8!
M!,HQ>0&@JBGZ,]!!"STTT58Q@``##[`W;@<2?,K!!`QXN:4&/$*P``09"$OG
M!%TW$!JV#C!HY<WHFJA!`PCT"*59$3C@``$@R;W`LA0TAQM+$#0P`:!A)2`U
M!EU*\,"C#@09G:=B4D9!`Q`H(`$%0490;[X#_@DE'`+GS:?!!!)$%Y:$[F6P
M[GWZF;6!E1(P`$%SA-]WW60=?(=0S3Q2X(`!!AQ`W`5\3WOJFI$_+9GL[DUV
MGWSR^9B!>B\Z/L&K$)1*708*(+"``0(`(,#C49YJ@02>N]T`G`]4BD`#3'4@
MIEFRBK<^G,]:6(&=2EV`I9`*^@;JB5BNF>\"&%2T`1*P@`8\X&P<```$4"]T
MZ9%/6+I6-V%%P%0/\%?\:L4G_3@+1ABP@*ON%[Y_G4IZ(]-5X_:DH@!L9`"(
M$0`"YD0_"31@`0I0`/D^YK0&4*R"-*2`N@S'&S&!B7Z1(YGA'G`K!23@``8@
MP``2@YCM/8Y-%NC;_L<(][ME$6YPNG*`!!*P@/$A1FIT@M'H?/0L#@5.`0+0
MWO8L=CUTE0ERGNK<U>"$I6E)$%!34N(-/6.X`R3```MH@&%(=LB55,`!+KE+
M``;@PL$@`"^YJZ0!CL:`J#D):Q::UOP>4*8I64\!N;+D``12``,,1'<'4,`$
MW+4`PMD*)H/Q#`((AL!=\E(NO?PEH52$`$;=BDQE:H"NG#A,71US<C6DFY/<
ME@!3'FT@P_S*(=.G.Y@@TW!DHJ4Q'Q>!![S*:7P3I0+(=(`".)&5-U0`3+!I
M0R;BD`$)6*5@I@G/7>T*GF*\U2QUI3<A[8F$%/"4X_J9M+?="FG(["<3_L5H
M*Z39BDR,2IL8F6A+:Q+&E@_E9R&'J:_!.4`PZ9OF5X[&SLNE$YXP&1E1R&2K
M)S'@;36M8>/^J"M`.?,!A`-4YY+H10DX0*80*!.@G'8J)!IN69"#&)UX9,1I
M=>D"]-J-@L04EE'-QS+`_"I8B^/5L)+5*N,)W`?K9[_[=<D"6043FUSUP?N0
M1VODV:.=ZG<_'UDH3*-S%9NF(U<,&*\XE/&-?L"D1J4PUJU^)>)>E4*_R:HU
M3&_-*O-(1Y+D/&1_'#+*7D&%KRV)*827U8]1DL>OQ=KI?GBE7UQ1=Y\T.LM7
M@B76!]=:)[V.YZ_VL<_H!/M`WX['/NZYC^RX_O7;V#$'N:!2CV@5E+S?CDX^
MLIV,;RJCW>QJ][#(S8GL-E/6\9*U,N0]+WK3J][ULK>][@70>^/KFK'"=X#T
M1=1]&R/?_?*WO_[]+X`#+.`!$[C`!CXP@A.LX`4SN,$.?C"$(RSA"5.XPA:&
M<'XOK.$-<[C#%,ZNAT/,X0R+N,0F/C&*T5NC%+.8P"1N,8S;^^(8T[C&-KXQ
MCG-L(QWSN,<^_G%/9@SD(1.YR!:>D)&3K.0E;]B\/!8RDZ,LY2G'U\E4OC*6
MLUQE*&NYRU[^,IC#+.8Q2YC+9#XSFM.LYC6SN<U5T:Z;XWQ>,\OYO>"A<YWS
M3"@XZYG!>.XSH&/S_N=`KW?0A#XTHA.MZ$4SNM&.?C2D(RWI25.ZTI:^-*8S
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MO.<^_SG0@R[TH1.]Z$8G,\*/KG0$MGSIIVYYS`&>=/9`J.EO=GJW7SSH5R]$
M,G%ICD/*-6ZLNQPS-7=+M7?BGK?06CL-F<NPK4YV7WL],F.GBF]VTG:<W%WN
@<[<WUS]`\JOX_>^7EGIG96QXC..'(6NO[^+)'A```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>f39432a9e3943238.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943238.gif
M1TE&.#EAT`*S`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````T`*S`P`(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L`/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*=*&'IE"C2IU*M:K5JP@Y/,7*M:O7
MKV##BAU+MJS9LVC3JEW+MJ"&EA8`5&A+MZ[=NWC#<AAP(:_?OX`#"[:Y@<+@
MPX@3*UY<T2/CQY`C2YY,N;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7K
MU[!CRYY-N[;MV[ASZ][-L2_OW\"#"Q].O+CQX\B3*U_.G#2'YM#1=E`0G>G6
MZMC!6GB;O;OW[^##_HL?3[Z\^;L0-IQ?SU[R]?;PX\N?3Q]RA^?U#T-PG+^_
M_[$9O/??@`06:."!"":HX((,-NC@@VM9`.&$%%9HX8489JCAAAQVZ.&'((8H
MXH@DEFCBB2BF:%P'!P#`0`8JQJA@`@#4"(&,.`K5002J4=`B`-3E*.2`#0R`
MP%Q#)ED?!P!L``"/2D:YV@,+U%2C``!(J25J$V1)DP(,"%"``5N629H!5<[D
M08TU<E>2@&;&:18`&-"TI@,`%'`2`G+V>=8#7LX4EP8`P.CGH9<-<"--$@B`
M`9V(1CH9H355P&::DF;*&)8U!<`F?YJ&.E@&`+@9$P(`6&"`;Z*V&I@!_H'*
M-(!``;AJ*V``+"H3FS7>ZBMZ`(#J4EP'H+J`GB0V\&MH8\)DP0``"/!!``YX
MFL"RV*K%)'XK>0`K`(9]$`&;9&9K[IR8HM0!G@`X4)"E+4IX[KQB%9H2`S4R
M@-`%I!)`[[]?15"K11[`:9"3`/BK$`8=-`GPPU@!<&U%6BW40(UU+K3!CX9"
M['%4%)0J4L@`S-K0!`)@&>O'+"LU0+H:9?!MQPT=D`"G+>><U`4`&%R1`C6Z
M&]$%"#`@K\Y(%S7`P!=Q@"H`$E@T;JY)8X:!J1:F>A&^`"A[$:DU"ELU9![0
M?.&CC1$`0`!(9M0BTV/'O1.X`EG@00<78'W0_M-1:\3D!RO++;A-:O/**[(&
M05`CXARQF?'@D,\$*YD%#T2HR0/Q'*W/&'6)9;B1A_X2E`<-T/;%II<4P0'K
MBBWZZS`1:@'0[9[D00`=#*`O[+S'Y&F-!)A-4KZ!]ZY6!ZZ3R'6-H*/4P`-=
M&F\7YQ]2P"ZOY:JD>`$/2._]2!<;'@"LS:.T`:#2?J^^1C_R>H!`#2BL$LHE
M[[[^_12MR28$IL*=$@<LRA[^!@@1"=0(9G]CB=JP1#T".K`@%GC<0*+7D@00
M(`%">Z`&(\(`F*D$2`"8P`9'Z!!(N<12-6H@":D"P!,!@$\QF0`"WK="L.B*
M1&J3B0$H<`$)UA`K_HHST0MWQ:ON_9`K'."6B'H%$W@YR0">4N$1U4>`HZUD
M`J1ZGP:<I#O235&#:&/)HPK@K@8T(`/7&I=ZOKC!(:ZD`QAH``,",*X%U$IQ
M"!`>&^\7%R6FY%&>6UNT4'7#/0XP`IA320)HV"Y."6`#`\B@(0<8@+ZI"UI9
M@J(!$%``"72)B9,<8,B2]Q&G&>YQ;)H:#2TDR5!^)8<E(=GB:F2`!*!*`1MX
M#KB"92$/M`TJ%""E*P5B+Y%D`),E>TM<:L0V@@#@`CP;ILZDJ!`*?F29O++D
M`#)0O@_$Q9K2_-@:+4(UCCRM1K/:`'\,$"2#X&D`Z0OG]P@E3(A\DIFL_EI`
M`CR@MG$:9)<"+(L_Y7F@VEW$`H6KD0@+TB+&'21DXQOH6*A)T/E8RB(:^-8!
MDU=/@:0L3Q7U7M<HHC@VR<\BR+1B2%]'*HDNQ("&8]5%4I4`#\J(HBME";X>
MLH%S\NJD%D&CI3J:FPK8KRDRS>E-#&HQPQFNE1;QE$.%XP$?*A4SXUH(H,1G
M`)6!\J`)*(`;BX/3S\"Q/!YX``.`:AD!')4@V,2>0!K&)B-BY$>)O*IP'L7,
MS01.9DZ%&D':9T*,K`UW>BT.C6IDR<LT`'$<"-]/52J0A/9,(VQJ;&*!\[OB
M4<93$!"K4Q?Z4%Y-#",%*`"E-CL<-NF-,I(U_ASK%F)9C:Q);7ID+6[H&JW,
M'-.I!7"I0<"6+XUX]9>ZO4T%#A``9`)@`:]EC&@-%UV$E!1C&>$9J4B;W-IP
M0&U&-)Q-%7//(D[$N9P;[T%<U"7-=A<VX\H@89\9F8PZE0#570A?:P3#BW@@
M+D![[VQX-I<)E)=-R$6,!1;@U'U>I+89L0`'&("`TWK&`WX4<$*<1*O>'H"Y
M?5W,?$M65H2@L$9VO4@>:R3<S)0XN2T2R%#AQZ:W!N9ZALOPSWBE$0A<0*Q3
MU?!JGB20#""I`\NC;%XJX-P(LBFW%.&5US`2@"XE6,@]"A0!3*:YW@9F:LS,
M&,GZFUT>:P1:/B8J_I9#DR<\70M/#%CL"[V(%0],@`$M1DA<#8#<)W-$SIZ5
M"-!H%.0UGR9/&J"`IPP3UT!#Y3XG+J1"GL4KE\+4T1.1LMO8E``E&_HT#"8=
M<4%*%0TDVK)LRK-`,.!<1R6$35"UB&5?7)"&&<!F9/[T:?@)J0/(T:E2P4"7
M#2>`WP6T(+PVW`0JX+/K;22V8PUJ``A`;5T/V4NT*S:OVKD40!MNC8Y#"&^O
MI-$K"P23[I7(B0T'98A`RU/MMC9HGBL0?'DDKOD=2F>OQ,EBJBR>!`$S\RH;
M0O\5A$T6V6_0/B#:55Z$9S12M;SIH@%:*V1-`WD<H"V^5)-FD'L#89,2_@6.
MW8$4CKL%87"T'\(B7F402PA0<T-"EL")XV7=)?-T11"`.0=D`-4R=PF^\OV!
M#HS/(`EPT_($\F/#'01ACH:U1#I+9A>%Y%,9@4`W;:X4S2D@`QG8@`5010")
M/V1-^M*`<Q7:$^OQ,LI*9%,`MNIT@G2`1K]S>$'H;M6%@,V?";`P1PY@`;%R
MO2X<N(#!@)9NBHR:5P'HNTR2B`$&X*E%?)Y(-`ER8%Y!`)8?P",Q:Y149UXI
MTP<?29<\-67$!UW#3BI]17!>V)IP8`->_98`)D"`UCMD32C_@$\'(-:,#2`!
M%?`4?P`EUN3M5^<?@)7O`<`M5I-D7$'LS.NG_GBQC=SS@C:Y&[07P&"C"N1I
M0<=909`9+KI%'WBUSI.1$D([S^+XX.-T`.)")A`Z6T3.VX<86R=-6Z5C$)$[
MO*)>;]0!%#!=_)4!NF1`:_(TN;80##9<O!)/E@(!GL)L![$\PL5;FH50AN-%
ML<(`/$(`'4``!;!?\?806*)^AW<7/]=,%Z%1)J411)<52.94%8`!$L0S:E-2
M$*$!8I54:'=/_%$C"9!GF'1L`W%I6S%N@L5_,@8W#-`]L+)VL381/`(TYC:#
MTD$C;"41/U=CR/023'(I=&.`@+,V>.<0)%.&'Q`N[/(6=.6&`P%FU54X#U`V
M&<@M`;`H]#80%?.&_L"F$714:/XEADH1,@+`<46W/`R`)%BG$@BP;S4R+K)G
M`1,@`1'@`1F%0@.X=S9R$!>P1K_C5J3&$,N35P1!*(%E-FL2`4#C1P:@`3Z5
M,%]U$>'C?_XE>8[X$QR`)8(W$=<%`#2$`:*%`&9G$<@S`0'060KP``9P,1B0
M``9D,A5P:TZU'1]0`3M8=,S$`.5S,:B&`#O(:UY5BI=V)0;S(Q+U>%P&<(95
M(R\XC%PABPH5`8\E:0O!C\"5``P@B4ZA</C(-EFB-BBC:,S5;YPF`=,U$0F%
M+&BDB4SX$`20/F:&$"IC<`4!`7WG7*T$A11!`7PV`,"HCV"A<DZ%``A@_@`$
M4(EYHV/S50`*T&DGD8S*B"H6("TO]``!L#S%:%(U97J8AA#+XR+0EEEZ6!`U
MYY)A>$_JQBLV]@$$('L$(S(L6186(`$X%EAU10&@&`$NV2L,$'P@<0&6%9.E
MH@$<H#CXTB("X&T`8``%8%,_$H8)89>FM0$04%8+0&9IF!`JEV(+,0'(M``^
M$Q<;02ICDI1=V14B"78C)I8)^`&#.1(/(`#(M&4#@(.PYB)TLH9L0CTP58$,
M\7A=`Y;"R!!$-A#ZTXL$45+0-Q`XEV\!P&T7(0!1LY*3B1:0B&I.%0&RR)<3
ML917(C%+0R.6`H'41R>\.(T2@E`:@W`2\8H9_H%Q!;&%7/DN=]E1IDE+,R>9
M#O$HJ#*.P5D6$Q!X:U-%[\=8L8<10OEO+D)(!H`P&0`!$ED`%0`!7*,R:F-)
M#J,0F(2<!W%/("D1-3<0="<\:W*;]?9M&JF`$>&8YKF>;#$U%V`8>()+!G&(
MUO51O((J0(F5'[`!M608S\0FQ!=,]'6!Q`2<$RH7$@%UU)<1@>,!T`*,U=94
MO/*:")&A#9$EJ**A\)./9X&C4/(T5<(!#_`TB4.B>8*7#5`K''``:,)@'>`H
M:E,XQ%<`_+%:I"(0#$:'`X$PJ@F;F941`E"*!K$F?`E8Z'25#>$`)CD1[2.A
M2*H6.#IE:158&>,`_KS%/85B&$<:`1DPC;#R`2-VC,2T`6K'B[J3E"$6$=.5
MIP6$IHF#IAI`=X,X4[Y'3JC2>'U*%YV5E0AA)--8@Q)S)5B$D0I0;"&#+P7P
M(PL`>@1!7`H@`:$*.%TX$$]38@+G7]*HC`XA`!"Z,7*%$9N7$5/#FZ=J%]"&
M$&RC4:@B5K0#.$`6,D98=Q_`%\0$5Q+99@/5,&I)$#"5K@JQ;D^Y$*950F9#
M=VPRJA4A`!8*$0IP`!0VK7FQ6(SX`9=SJ^4&+H;W`!T0/K3C+LLU$`(P%\!W
M`8WR0@N0KC&V$&NH=P[16?;SKG`%K@SQJQ_@`;NXIA23HQGA)`P&D/[J_J?H
MY'?!@H\`\`#(TB3X,HU9\A[<.7J0AYCK9:JFMZ`6Z*(IBIT,X222I;$)(0$F
M<Y8)HY47,0'26A&*TR)`>RY0&QZ7B!"0A`$VHR=W*4N\`HN`4R<8H#@2L`!9
M6Q`!UA"B):0'\8X']"A2M"840#)">Q"#Z(/#LQ$=()/(RC+JB1TJ`ZG.U"+4
M9CBWA@#UMS>I9(;?N1`D@Z!QZE0.8"E^%%TA`W64NVKB-;@384!PZQ#*8@":
MVK)F`5-Y&ZY70FA::BI^MH=M1B,LJQ"(]!!@8[(&RBL58`$7P"V)MCC6F@`D
M8X\(D0$XM@!*BA$-$*P2H0%=<KJH.Q90=W$$_B`!!(`!"P`J)&A>1>M^`ELC
M'AMRM;M>M%F>1@N]NTBV'U"F3\.IW^JB<,H3*+1ESQB<$P"Z4\$F</HCX7*E
ML!8!''!IQ#2UBB-S3&@`_$FCPE=R$6%:35DRNNL`0+F))F8X]@H4LLB!YYL8
MR[M9S0BOZ'1`$E`^"%<`&1RN/JL0-VNT%SQ2$N%5XG.*L%D!IAFGEJ6T04&O
M=149`:A4[,*IB+@!G,,U!@2O%!$7U*,_QML0L/(T!A`!U>8D*VP0A((!A4,S
M\Z6_-)&-GK)@&)<P"S"_TPL6)[80/_*4/YA]KT9K-JH0X181.&HJ#@`M#@$T
MGS0P10D\[/H3SZ(R_A^0`!S8%T1:QER!8+:[<`QQ47`<@*2RMFT:$>-F85ER
M60SQ-X5#`/3:QT(!*!\@`#QS`%W&Q88\%5M5OOHCO76(:2@KN5;$7PNQ6#I\
M$!G@$;-9KW7H+R'D$&HEMN@TOC^A)\NT`4"C-@-`QJ6,1"\+QQV,;)8\I._Z
M(WT3>!RF$&NHNZ]61`DP`)K,<+/\3Z,E%4^#LVB6S&E1O<Q,7S6<$'AZ$!&0
M?X*4)9M7>P211(B8:7?Y.1]P,<_QK"&K:5(!-*HR1\MLSFA1.'"Z5>Q;$$ZB
M8P16$%TF$'):`1LI5FGB5H[[0G&,NZ1'(WSB)$+S=@IQEKDH%<P&+;/C_B4%
M$`%7:]!=`393*[LIU!"W"-'@&W*O>B,@I5V@!$[]5R@1P`!<D\+[8CA\TG0]
MLP#FIJ*BR<!&@2>I=9=<64N%[-)3(8NKZUH+<0$"X`!#B`$64`'&TC"8DY,>
ML'LSZR7T!)6M+-$SVP"I6"/?[)$_!3CJ84"*!D%:"ERC.Q1RBR6L(IW`O)Y]
M716\]9K?XKPDHR\XJL"(F#$Y^DQQ85<VV@$Q"2-O?'#!LE].D3B&8P%,@T+A
M>&LR7&E2P3,X*#99`@%-[*\<(%8M?17HELA>%G`%>IJA)UC$U"**0RCE4DX$
MX=6(:*1*^\0_Q0'[V4IK(E%.U3SU%U@B6=A#_K%8GV0P.4O/+?NX91$^1,V/
MMKW,R#1M.',`L[+26\4=$.`UEB)"&-H]6;):`K$!Q(R9!1UR;*6)`D&S#L@F
M!Y`!&/#!1H%.OSND`E$`ANL4@]U=&F46$9W.AL)V,@I34Q8F1QQZW?,>_/<H
MT.+>[X<GQ#0!'-!H]&UCQ<5YAK.1@:6\:QL53A*P7E+-$3'`8B@`%;;B5X'(
M"5$X[@).#M/@`@$K0E-S'?`6&,=A0SDM`E%23T'?EHN]*V,I<<$X.!I8`<`O
M.J$!#G"_X@8TW62-<"RL^:JA"@`MG'P5['+@XD)+:P*[4%(X&.Y,ZK$\#6,8
MNTDW"F`83LODO.(8_KL\$`Q`'73U`$0LXF%6OC,!6AC%*P*B`9R:V<5DR"X<
M%N'#J;,Y`+YG,S)6(PEV1H##(\^$<3(**SSBRWKN5$84>,XD-!N`8WLM,4)=
MYC2AVQ91+-"B66JG$(BU:ILAHEM",E7,%?LE3%Z%<NO=`+AJ=Z>I`+I<`$Y3
M=,C"+J*IYWFI+,25Z0X+B^\QLV0QV2M3C`8Z3@VS&089(C`U)QF9$.W#W.(S
M6)4L(5Z");M3ZBE>`12`-3^R%71"5PUD[&6A,BGFT_CG3#^L(!T`X*(1DQ*0
MX%"Q6'E+E>!,H0+AX39*`%6BG/+.W\((4XLB9QY[TV`!9H\SYG#L3_[,_B$8
M1AOMT@"&7A7W!'VXS%#$=P!^2!#A(T+1+N\'L`#*LDT*H3G(XJOW.RY\RD(2
MP#-/\2AY%KF`$]OK"2V<1!8]G,T6K&<UPIL7'UB5>'"W&>D089NRZ15>0C7`
M/:0^%$GF'#(((-U0\3N<>L;IK!Y4>/$&X``,EF$)0-0-K#44L0%BQ8)ATQ5X
MHBSU[9%)U5+)_'E*[Q7.IA`9$(DB?/6R=0"DHXT&L5,*03MAKE42H_9)$6,5
M'LM71LJ.R%MC89J=JQ"[J.<$8%0T8A``SR3"Y-T684!.+16$L@!,(J&9O8?.
MZU_C;D@&=+%A(7470>IB^0`4P%T!D&$%2A"]_O?X6EX0(6/C4@$V'\`SV.SQ
M'^#)(C'D6$:B8L$U`>L04X[!$[``+B4`/CMWE7^ZBQ73#;&1'S'P+?%V,#RD
M:DGCYMQR#8#-4P$0%```&/#!X$&$"14B5##0(0`(#"PL1#A@@4($!`P>@&!0
M`P"*!QL.#%G2((`-)@UFJ`#A@LF6"1MD4%G3YLV#`4">?!`R0(2%&0!PP%G4
MZ%&D294N9=K4Z5.H4:5.50I`P(&=5+4N[>"P`],)#@L8F%@SK$()((4"*$`T
M*\6T`U\:Q0#@:\(,1"LD2%#@H8:M@1=R>`O``T4`$Q!3$-S8\6/(D25/INRX
M`5:@E25O`&Q@H.*E_AX<%JTP],.&N1]0&IB088##U(@'EBUZX>V'"GX?[@;0
M0//4MP(1WU48`,/4P[^5+V?>W/ESG)X+'(<>F,%``TT=IL0)0,)'``1H*D@`
M@.:'"PT[EGQM]:@%D!HR4"C/F[?&ZDD!]#Q8?B$!VA*JZSRH8LOO0`035'#!
MFB`8B#$&G8+/O:0VD,"S@1PH:@(#'M"H/@(>1$B`V]!R*+FB[-N-@@HJ^``\
MPR*L*2WJ#%J@Q`)`6PB![&3T\4<@@Q02*P`@%-(HAP@LBC#>C!+``04.<I`D
MCP;RS22'7%Q210$00$`AW0`[4J$,E%1-H0'X6Z@!(\=T\TTXXZ2J`0G\_I-3
MI?K4+&JMW9#L,B3;4*J)1``2,$HTAP8@3\O_K+Q3`0,=3,@`#2EBH(`[,]5T
M4TX5&BB`3F7#+Z0(""`@`#$/2FN##0@U\(/Z`$"`48-(O&@A@:*T:4)#C:JO
M()4<&$W.AMK\`$"$%KA5ME";=?99!CT+0$=G`RT1H=(<,A8^@\("8-D/$+!*
M`@DH()*[#SQ8;R&L:E3)VJ.F9."#`!?J:B#BX,3*4Q15J@M:@`,6^+?P3&O6
M6BI#>D@A;D\;]@-A7Q7WU<$:2B#?DI(T:H-/;=()@,SBY#AD@X0MZX%U$1L8
MR'Y7=OFY!^QZ\TJ*$!:QI`A.]%3,]FC*V5V$_NRTB41T2ZJOTJ(^)DJED6B.
M<X`>$<J9*`R,]93DEQ'T8.FLNV:N@8&^'+-E@S;0;:`!*%;HWH%2-2@`3#_0
MC:8!G$Y(-*!-2JL`LA.*:U2<VL.:(F_M?E,"8/T>"N.%;"O::\@AXYHR#=R.
MG'`)=`+U3H$<^@FGCV\V**V2!\KKVHIZO2D#G4QB4M"BIE2])!@S[2IJA#I_
M?*'I+O?=L;Y_=XY(\^*LZR'#5;K.*K`!$!,^[DPGS"0'Q$YQ]X1&8EPEMCT>
M"/LQQ84+]4G!%?Y\])W-.0`$M@<20X<LMVG*@CQH7N,/.&",8Y,F.``G#F!`
M`P.PWD(F`)YZ>:]X_LH;B`3BQ($'P.=_%+F1OQ:8/@QF,%.E@<#@?G0!^$$D
M*<?+"@<RL`$.,*XK)FE`W$S2@0QXZV$(P8"7'F*UFA`)<"&)2P&I4H$!$$``
M'F1*B!Y2@`$$3S6XHP@%U*9!*$911@)XC0"$A(%8L<5]-W%(RC+F0(4E+UT9
MT,"43'<0F04M42$:0-YJ$JC$E>1U[5G`%I6215D!(``ZL2)7'A*!Z:!.`AIA
MHD(>H$0I)E*1T!G)?H!THT0]$2?>VF%(8A:2?0GH4KN90`<$L*R=8$`".6-+
M\R"P@"`B988X$T`!(E`N$NE**AD0EWTR8`$*3"Y%$`@BV":8L7F1RGR+_B1F
M,9<#+Q]USB'!;,J$R.>IY*4E-AHXVWGX8I!_G>0`1K1*`6B"*@Q54H'4P@EX
MMM*!$-JG``Z07TF6MQM)=N"7"\&;,>UYS\JTC9D*HD![L*/+I;S.C0OAV$^(
MXZ#D=&!Y`3!0S#*``1)1H)$`,$`!RE*``H2H(:79BYD8V!NEA$@P'+"503H`
M@8SRA@(>&*A!2&F5AY!M`Z#))@7UA$^<YI0JB**4@BK`30#,$RJ$$B-%B.<0
M`F01*^U4T0%D:9!807(@'BA-40FZ2J,,8)^3R8`"".!/BAX0H&<*0`,<@`$#
M>!0A\$G@028P3)W&5:Y*>1TYG>.!6L)&*U/J_F-)<GF0K1UP>0EP4%D2$"`,
M3,"76,'*`,JR@0F%Z'@3P,`&1,,8T:S+`T]=B*OH^LS(:$`"#XC90QQP`0H`
MA@$!V.I"+)`XCMG5(-.;:VUM>Y27YH=C#UE`2YOR.CO6<G8&88#UTD@``VA@
MFP\9P`&J]R"2#D0W(=+-03[2(PV0S(X?(!0153(!0AVH`A8PXT/Z^@$%M+8#
M`>H*^-)[6_C&5V\Z`:-S0G@`6FG%B+(]R/W(Y$(*!$"J5HI9`]Y*(@Y,@``:
MN$"(N.F!E&2H`82"75&$%52<H*8^!WB`6J'#`0ZP]&Q?)10')(F;-/K-JO)E
M\5P!4!?O3F;`PPU,_FF%ZJF$61<_%V@/!1Y@@.]\@"/8N4IO>!,!KFE``"1"
M0$H0D`!$6A*K-7-(`C@+I`TT``$1"!T`%%!9D#'LQA^H:8NU$F4S(ZB=1^D<
M`_)+F0&#5')3/DBV#':0KD!`A@/R,B^E"H&C6H4!<S';!^`W0/J@"P)H1LAN
MBZ029[;V317=@(>0J@#6(*3#"Q%:FJ4R5D\OB-$U\:]F.`!4!8!Z*XB*$4+(
MU9!&<L<"%I!G0YQ*T6_!M*D+<`"K<@>`"]<EHV`3EXL:``$*;#<A#JDO0BY@
M`3X^Y,IO6N%:@<I:[;DVU-N6*PDK4UX"*%LK#LD,!A;J@,,0:5XJ2M1`_B!9
M@/]A``,#P%@,">5`DCS$`HT,70(.H&I-8P<A)U61`6(\I@5(^BOF.D"L!,"`
MRAZDD-RF>#$+A8!I!\:9:/M-:04PI08$Z$8?>\`%,(#*!Z0%;@-1@`)>(P'B
M;,"K)LUK;S1`E(\@BD0&(,`!*%!)!S6;(LZ4-[L'(DXY64X!</T`!=+)%O.`
MK^)3A^)V'L.!+E=`W(%A6^(Z@,<-+,`S1$D`!2)PO/(P@-X9:-F%V5>H[U@.
M`"YB.:S"$X#S'H1C7ER;T54D=#D)F(9\3\C%.K"!"G2Y+P\`.-4=#SG;N.8Q
M1[5H<SX&E`M;B0,#*$U:%E">F+T&`S^N`"+!_DJ1%59`(A"Q<Z$6\A$<5L3O
M>IP[BCLE*X1$N9\T-(Q`0L>`!!S\\<,7F&=.(YB7BHXY`YE27O]7@/OMQC,K
M7C9!EBP_C"-$)T*A$_D@@#2*E-8J=WF`3HSU]4YQ@&904LD`-O<V=V69N222
M@-2)?_].P8CP3L&`XJNSVP?XEZ'PLIH;B`,X``\KB?+;E_)(F:[(%YU`@,L0
M%NH#%(=HO`]H`*:#$P&@#48C#$:)@+S+G8HZJ@[C`/O#/Q5\$R,"/Z>@IB-"
MD`P1BH;@`/@ACP_@+YL@(:`HC;YB@!W""IIX)P]K@(G3OH'`0._H%&$YB.NP
M"0W@#M&PB0M@``@`_BHV&:45W$(X(0CGB8IWLHHU:X[[D<"'F(`3`QWS.PAQ
MZ8@*,X@)^8BO^L*K,@E(VK^#L(U0Z8!#.H@$3`@(Z)$I-(H*P(`*>+H">(FM
MXT)&7([F@0H/""$?.A#2:8L7TSM?"XUO68#)42:%0!3&>@U)@T.3V*TX6HAO
M:18%F*`,V$!/F2`O:XH(0(#5^J,,>+9&S,7J(!0:.XJX,,`_=([769C$NT"F
M@!&WB<1K:8@(8!T!.$0!2)Y>K+YG\HMGV8D.2$,\HR@R`ZVCF`!_VXT'2*U%
MU$5SG`J.Z8`)`#R<0!@$&,/\8#<#<`NGP!`OT@T7K(L%V("*2I-'4X@Q_DL(
M(FFKYBG'(UF`_]D:`!(4;U2*$U*H(_(0/%00=CQ'-X''R!"(GSD*FWFS!?DZ
MAQC'97.*CVFVLQ"697$TL,HQ@]!#O1F(UK*-"PD/%]04_T&Q"KC%UVBKW'NQ
M?W2,KN(-C(2.%+1(>Q*-;-%&/,L\@C#(YR@C[&G(FD`;P%G"#UB+PU"F\,@H
M([JI]W*=C@F)Q)J-3D$`*Q(M`G`0!'"`FE2(`0J/R3B,#O`EHZQ+JF`2"=!!
MA6B]!7N@HBD-I_``(^J5AG%"MC@6U1B-`HB9`OH(;:2SA!"7HCP2$A&I#]@N
M#R`2>DE%S7B`4[1+T%P*\+A%0*FS)H&37^0:_M=K"K99#P!XE=<I/8HZ``2(
MB_,"-IO0C8I,B%GL%`5X/^ORJ`VP,BN#$)>LC$L*3>5D"H$(D012IE/Y%*)H
M'>:8R*DT(OS(I*9`%+[1@&I;B-?0B3G<C;(0'YN("U=$"*D,$CE#B+5TK5?!
MO<K(F>6L3Z5HI#H;HH?`D!IYC>9PRDDI&.*ZH*;@F`1```M@@$+BPREI.@,X
M-)JQQINXE\]T+?GDE`-4SYN8$,TP/OO\4*-HB`YT4*MP@&FI&LYBR2-)`)N)
M/:5("\7("@_0@`=8'@)H`!3Q#I"Q(@LP(J/XF)#HJEI"`-]R$]M(E0"H4(JX
ML,Y<3Q!]TG09BM+@_B:3>BLU<M($\2J'J,!#Z9,/,*,"@#(:0@"IN@`!T`DE
M-8FC40@MLPH%F(#)')/V&)U)+(F)(``7%0S/&#4H!5%"&0`F`X")^!@C>:4$
M`,XQ^8@%F(!WI(I??`B72(@*<`#Q&XCD2].26(N\:P^]S!2X=)BB.(ZPJPSX
M`-`^#<T)X0"_V``&`$*B$98)8*T`.``!X%,%(0P?10Y'@:R%>+J!P`!AB9F`
M-`E60P@9PD`XZ8"[F(B?G)\,O"G(*-53G59ZP@J!>``#4P`KTA\[HS`Y`2J>
M7(K=RI<)<(`&:-7V()$)$E'?"*^C^!CJB#Z>1%8@B570N(X!>(T\S<#\_L%2
MJ)"4[2Q2:GV\/`*`ZR@/,H4(VEN8!RH8?[T)S^BCC4L4#H"/6V&2##"C82V)
MO%K)2Z0GA5@I-S'87[J`"4L7CG6@08S+.!U8^[R.`!"(@_4+J9*(C!K!,7&`
M6&W6I\`W+TR4#8C4DW`0H!B--PVBA\6C\#C4CX46`SB`3.LOI!,)L0F`E@T-
M3*NHS-A8EWU2;Y&;F#&B#1@`([FS+G0F6V4//:(P\WI#N3E+D)B2`ABD`+``
M%U*)#:"`6G0($J&9Q`@8"J``\^R/W22SNZ"`N]V*Y'.(].S:#Y6N7(N`5DD@
M!L#9QX"PJ)@HKA`M(WP(G8``#KBY7L7&G;@?_@MX4)Y5B-"=*.EBG`M]ENE)
MN)'TB:59V<:8T4922L=5SN,9`%XJB8>[$]'H0"Y-"-&:M]T0HL,(BP08PX_E
M&)H@E-9+'A/2`*G*I6]2FR<$F`Z`D`EZ-G%Q'P^8G8>MB="E"!@YPMU]4@]`
MMQ<2/B!Q$`$0B@G]@$=UB`D00=R[#!B-SP)Z@.=KH*^"FZOT@`NX`%9ARL28
M'`:`5H-(3H"Q7H-]B#H-(W3D.QADV/7=8(HHC6#\$=T0@'!S'0^`V8=(``D@
M$9K8-S1Z$0<S$K!QFVRJCTOY4ACA+0'J``(`&N$8#*N$EMWB&&35`.`DJ<9@
M2@,`4@Y>8N.=6B%Q_K16"PJ@HJZ,.`P'N0A1@L6#P`"_:!^.R:]+`L>?O8YT
M$MV#J*!E6S-N#!@Q\0!,/8@#P!HG?@H/@%\F9HH4,L>QI5<9F;N@:I,4VEEM
M,<"WN$)A$:6Z*Q'..$Q/\5F%+12'<+D2H;UE<V"[&Y@W58VA1(`VZ6''\+$&
MT%T,4L@[#I*<R;@CF;L$\`Q(ZC+I.PT4R;D/6("BW<</&`#`$Y<0N0"W\0^V
M(26BO<S;>$(*9$.D"PN!S90'B)+"#(D!P!JSI0KY@SH]LN/T(>52_A'X\,@Q
M(1[6%0#":(`'F``/>`#7U1)<FF60VKUDV0D+\;(-6#B0J$40ZSF_H([:_CL(
M`8`04JHH?'D]@Q68`P"6`TA/16X,^%B7W<IF)I8`5`Z?;S&`Y,`]H9C(!1B5
MALB?!&VZVWA#/F$\PX`C],JU7J'-@X"/R<$`(2H[A;'<VS,NJ=.`2HH`:TX*
MVW`7[3P2#^A4:AU*X1$(G@820EE,&P&)S/P`G8`K$4(C!VQ:C`H*0"J/I0F=
M+J$2P/R`G*EID8CB9RF`]UOFD``OA>"?P&`2!F`IR&1H:A4-K@V2&\D98(F9
MGC!@^S5`[7-!%,0+7>F*X+$`2(H>=_/$D]#`U$59DQ"*?<V4L04L\G$?EX:*
M#'@I*]1JM;9/TMD@AH4/3'$N/,.*!3C=2<ZO_N\[B5$4BB;KK9/8#\^(DH"6
MF[:IBFF\/5FJ49PHL\`@I;2M[&:)0F?IBM@^$H0)"[\&"0?8*D_"JB;D`"#\
M#N>Q3(68`%ZJ`+/*P8D:`$,A"(^XVL91T69Q(O5,H*X8JP0(ZM!0)@%X`)_6
M;1!M0DV9CK'(D+:AK67C)6#CFBGT`!+1D#A&';&#Y*`J6#T:.U+B8XI(L(=(
M9CF)@)2Y:MZKC$")`!81EC=6[R=%XTP)BY+"[T<+,X1XZJ9[C;0R"`7HB%8Q
MB.9A`)^C%YXSNBA9E06HS5]-BLSSC8^PSDQ)BW`UB$`<'ZB0GYQQFNVE\*[-
M`%-5D+<25)!@$HU@_A]7NXVQ)0GQR1D$>(FSR;718`PH06TI*90%,+NP:-RK
MZHW)^51H*8U^Z=&$4+M/-`BMVHJT**#F$O*Z5%8D^>U4-LM;B8NMN=O";E\J
M^8A_RT&0*1AD$UD[W0V=L'.*X)B\86]HR8#$58VB\8!ZP>;`$,Q2@B0PE_/Z
M;,]'\<*)R(X7XX!?`EB"(HQ@>@!,(8S?3,+NB-L)B!E0Z0!N#HE.T_'6AI:O
M,M[@D+IHIHI(UFY.!TTROY,PY*U9?@G;B+U]V3R72BE"=E)$X9H;.9N:GJIE
M4]]-R6F7&I4?5@@!T':GR)F#$N5AK\NST)32DM!:4@V-X'"%*)5C.=,)_BX`
M"CN`]%9/LI0`K`@`^"F*Z]`31W^6RYY=^5Z(WMP*$5TG#,GQ<U].^M64CUC%
M7MDMHI`6A4`ICT7TO#Z*UW%EF"3$HQM/!(\3Q`F)T\62W+Z)NC@.1RGYAZ_+
MU=24%1(A^<!-JSC@Q3P`)(J?Y!,`#&B`!.C#I&`U_-W.&S&`DH(6/J0(!>B`
M"$A/`QC%IA`*!^I;2X]Y*"6`N<B`7HN3!%B`+HD;L#$4VA2-2C4P[I@PSH!$
MAW#XVN#P6`28<$=X/:IU@R!3F_"`M#UV8]1Z*-7PA15W&;$S8*F+NB4`O^#Y
M.J:`#W:*EN#EIR",5+'P9[%\A"@LDTAY*BR*_DJ+@`F8@/$B+\`_U=+0"<\@
M?!EQD`!0DY%K&_S<C")/B```G*D)&-]%C"(]SM+O?79!B09H@`F7$0_H``7`
M*&YZ6@IC@-DO>BU<"MM6#;S/%`MH2^*R3A#R?>U/B+#@I;A([`C9HRY3QE9M
M`&&/B@AH:PM2"`.HX#C)@.+:([=5STB_&T_??M_G#;A?D!26/K$'B```#GPH
M:/`@PH0*%S)4"`$`@0\%`'!HJ/#!@(0%`ECLZ/$CR)`?`$0`@`#``H$=%&Y@
MP."!Q0P)1-*L:?,FSIPZ=_+LZ?,GT*!"AWY@`*""@PM$ER8$X/0I``H&`3A@
M*G*#!P$`,M`\P*"@_@0$)YVNM&H6X<F14#DFE+!@I(>&#1"<K6OW+MZ\>O?R
M-3NA0=^<$Z4B+/#P*=V"`#(&/@B@@,$%93TV&.@4@8(-%`!@:!RT`TJG&P0(
M@)QPP82B`!I:6.WY->S8LF?3YIN`:VV%%PH0@)KP,%0!!7MW]DS@K4$/<4%>
MB)"AXM29N7$>`*!`@(<""E(K+`M@<L(,`#98A3[]//KTZM<W-+U>(-3Q"#?$
M)_NA,N#&&X-69A^RP$1/&0"`!0DQ5E!B"[D6E'CQ<><?A!%*.*%9'228WE@H
M/0#`5PC51\!*FUW(%P`:!+694A0R]!0!$!S6E&/%*;3@3_05H-D')=$8_M@&
M$JCX(Y!!"G428>DI\-14#Q:4```-R&A06H%YL&-/H"$G)$*34?F!DAILJ9A0
MFR$TP)=8FGDFFKE)4"9ME=GW`091'11!1`A1$!9%-FFPW$Y3)L3!!`:`5Y-`
M:2:T@9)P[KB`<`HI4"!0$T&`E`0;LFDHIIEJ:A5]_CT%Z0<.+&:!!AP08!I]
M]34*TI%.L<43C1@L\)1Y-HFZZ0>%.N;C01Y@I1`'E]HT:W`)*(`KLLDJZU,"
M5Z;'I%,>0C6`J/'Q%@!,#5%``&GP79;M3FLRH$"`ON74&D&:%FE0?@@9D.Y\
MPBX[+[WUG@5:HN<!5VM!'9`''W$?D,>O0_59_D=P3E!MY%0!%*28L+Q`CMNK
M0N*1AY"?_`ET;*X`/'P3PO:*/#)Z]/&JWJ<,/=2A8R$++%-\";A\TUCPW0?N
M1P\P`"I"&UZ<*00'@F9B0B7-&-2:"U3PE`-/WC0HR5%++9MX$+!7+<<"+^#5
M5/`6U.E"ED+E=4<=[`E2M.N"M#0`NAY*DJ93\MP0`G4Z!K5.FW766P53\\6G
MWX'_%,#,LT'K,;&T#K=C!J\:-`&9'/K;6[L?;6`!W@H^EMS:)BDV=W3(+O=0
M0R4BA`'@/&T67&^"V^5!X:[+;GD%J9^W)E0-G$T`T3XW9.D`#^!V5JL$$6"W
M08`F-"7+`.!\T*V9_GK`0`#+$9#U0IG_U`%P`W`0`>BSBS]^;`T<J-X%&63P
M\W`R$GA0J?<]M4#X5EU0;8##/^`M2@8=>5!*EL>!`6$O,$0#BIC0AA`"Y$LH
M?6M(!&)'O@E2L$]4"1*-+EB0UK`(`K:S"U1D9IXU`<8"%1A018YR$`LX3@-&
M@<H'L509$UU`6`KPV@4,0!0+7`!W%?PA$/%2/_]8`'D;DH"./*:<QO"O=@<I
M`,YJN*:FD&I`!AM>FB3`*PWHL",`>)`"1M2G"!Q.A><98A#3B*:E`>F+!KE`
MAE*#1KS$"2K(,T`7#?*0$6V@-_4I5U4R]1V11.PF;(/*Q]2HR#0>,"?!_OK1
M`])%`:T@R2!&><VL3L*`/'Y@0T4SS?<,QBVNO!!Y:7+-`.8X%4AYP)0]D94?
MS;A(IFR`?;.4&@,2Z9\:(B!Q%:G,9#;PO\"\4)9WBY?!!C``6ZJED!-:S`=X
ME[-716`I%]#`!$QWRVUR\R-1@A!H8"@CT)RL(/T)3"43<@`"7%,#L8Q/(#4'
M`*MEBB-;01MW(-#`H,2PF_[LYJ2<=A[8<9`D+&298LC&I7T"10-A'(B!R-3(
M#92JC$\1`+<$JA`_ND<W/^H;:$(2K!3V\R9B<XH`M/?/E=XR6NCI0"B=0C_S
M,,D\U5%(G#CI$YDDSBDZ_0`$!&">#?#O*0$8_H``&+J0:CEN>3^Z0&\*V!'Q
MM$:E-<FF`6K)0Y>RM*O<G%)':8.!ZC@%`O4#&Y>:=)`CM<HG'+@`!B+W%`9D
M@)Z_6<`[ZZ-0D`3+*6HS$YTB29.X$$""(:$/%F=E6*\R5GQNI(T#B@D!729$
M`<CI:P0HD`!*/H69-;G`20$@``@@X($C^6M!Z_/7FOBQ<FD:@&L_LK22UD0\
M!X#`!B[05D5V@+:-M<D21^:!"ZCR+AH06],,>\F"U#`^P7/*\T(R@4@ZEZLK
MU*9!.)M.GL12D,X\""^!`CD6*6"U%0SN;]WJV65UX)J>T4`%(G<;PVK`30!8
M#B"#>QF&F!8A$O`6_@%65Z?5*,4#_151OPK"OZ;J1&R+A9`&*&#5ADP8)Z))
M+X;3&*?UVL5+3O$*%AOB`?LNLR"KVZM:%C+%@U```60%0+-,M!H$*"4C4*PA
M^S2`@,B-1*Y.\2TAH8NIUEP`-0>()^SZZZ&'=,!A#VZ(`PC@8PYGN,KKR8!&
MM^>4)_>$`QAPTP`PL-B">G!.42EO@IE$2L[(TV"#O(]$,/``R*S$`RNA+)<Z
MD\*Q_41`0!XL3#>@/@P0EP(4F$`$7-2`:H)$.1S@`$4';0$+'!K1$'C``P8T
M(*TP0"L'"!!I#!`!*Q9@`%:$"D)OTBH_6D`K5GZU8^]K%R\GCJXTL6*J_HVR
M'.?%1RIDBJ>)BVP2J/RWD\*A"X'6]$@/S*3$OHT/@W-23*B4]G(9F$`%%N"`
M"8C%`+Q!@`$`YN9Q&RP!!_#V\01P@**2F]QX[4`V)STE&<^J0:=VU9'<I&2;
M;&@E`YB)>"H,ZX$K*P)2'4I[RT4!*EOD<`>)$ZBTB](/;*:+'L#`O3E3@`4P
M^@/<NT\'#C`3JZG0GAQ@HT4&"!6!?P0X[7XYS&,N\YE7EW\O9AB7%!4`@523
M/DH%B>\"H,/><)G@1C>4!E8EE+?&D@)%S])3W"<=L-2'(U,BT#L#(`&OT04#
M=EM.QR]`D!)-H"IY:DA0H=)(G>".YFY_.]SC_EZ?@VP`-`3H6P6TOI/4HOKH
M?A?9A8?T%`@\?2%6O))\#$*?5GDL`6EW"I,,((`.9>`KPG%>2-<7`61W8-$<
MX,@"[.H1E_?/)V0JE]S7$@`"&)P`>(1`>5V2@090@/1&%>WM<1\``0P``0QH
MP`0D8($'8"`#&JC[!1YF.W<>`#-^3)T%JE.9N_/D>QD@;O%%__?M)\LIP-Z)
M9B+'`):'Q$ULR=A!.%#0T*[&=CK4880I7I0'U'`DPM3A:C!P+`G`%?(-L>B?
M@<1DB,KN%8`#+``"()H$8$#Q'=^C!:!%M!<&:`!,U=E=.,7#),``5(=6M$;'
M<1\(SA+K\00V54OH_A5>1]31@BR(H.6(P=0=;?6(07"%!MA3\F2$CWB84=W4
MBE2+4ZS=-MV<FVD?0Z!@"!YAIK2&3F0`(&59GSE%<30*XY5;1Q``_:V&`@3+
M5ZS&`312!W1`Y!B`"1&-`3BA$$;7+873N)T$&OX&^2$A'&J*G-1$!T@`_DR`
M>0D%606`1;G9NKT90SB``TQ)!Q1``DR`<`B'!LS$`Y#8!A!A`7P@0C3(1:V4
MF'``>J78`Y13'':B^+C0DU&`7#7`&_*$#\9<DQ42WE3`ZCA%V>7AG$&9=JV4
M,:W5:@!A8&0`!'HB+YK%`'V$!R!7<2'<N/'A2M@7?"C=0AR`C-C9HQG5_@=H
M@!.BS;T1X2)M%D/TAGC(1BGF2"]^(U!,B;,`RR(Z17GMHE#D5014`$)18H`P
M0.'@UDADB%-4`)XE1`4`!@4RQ+1!$S?%24.0"<,9'4R!H_@PR4+8V:E)P$#6
M!5F)4?*DS$G@XD$\GO\!V@>8FK;$1S=IT$(4RF,9I$B23`*DC@2`VJ3)QNK\
ME&,\!48\"D,D0&\4P`%PHDU$`(H5Q`28RE/89!J=FT6XFC*.)%':2P?`C"M.
M8U]<'9NP&TL61$G\W&`U1%ZEFH8!XD+TAI=88U%VI55\(5^X$.-9@%)Z1H#L
M&[L\10:T2LA@@%32Q/MD3WP,91!Y9#:N1FQY_J5>+L51Z@4&'(Y/YD8V;4[8
MP-"&V`[W3,GWZ80!0.3CQ`=%4M"L>,2`",Q>7B::;$"M,<!BGH<:,H0.^DCT
M%$0%R(I?^6-/6,!3*@8B#AYOW5-'W)1=8B91&B%L;,!8.04#[*-:I0=8-E/I
M>%\S'<`U081C<"7(8->?S*4BP9@WK08!6"5M&F2(1<@%E)(%L$\OJ0<'E`6Q
M!&8GT8H508",8$`$^`@!3%U#",2?.<!JRD09W:/X#)-'W%0J32=0Y"5^\L2U
M,8UYG=UZ%%1P.L6:I,N:/!=R&*="]&-#ADJ94$!N]F00B4=93L5J2.=^9JAG
MP-M30%%#U!^$;%="_KS0`!`+`GQ9QV6`%=D-!VA`!`C$QCW`6\#C1P`D0_04
M1`'1`>CG0M0;`("GA@:I75"`V!#>A-%'M-&&>5"2]K3=V''(!P@?`2[`!1@+
MG#07AQP<VMRC?9D+!9T3VGR'N0DIF>)%!8A-`O162,1)'L;&9!S>@,)$_W@)
M!TC`NDS+L22=3(Q$!SP`6A;A0=1AQJG=#X7D1ZA$D96IHEI%03D`<GI$@\(&
M[H050IPB=,40<55`WX#(E'2*`!A`)J;@!Z@FZJE*DLH.;\!E5$#IHK8J4%@1
M`G3CPP'H3T3F3J@@A:U%X`7B!QS`E9!'7-C:1V"IFPE`E&TBZE#09J`C_F>]
MI:L^:T-LP(LQ)$]H187&1LHPQ(NIQ<\U0/]%DX]4!`(T9!(9#`(XP`%UX'?9
MRY1(XD=,Q*S()[3.:T(T&7Q(@+/RE0"<:FU`BY8RUU.0E4=08$1$DIAH!9YQ
MP`%(7,#R(/Q,RP0YK$AL&H;2J\4:1-L9H*Q:Q-+D9&W@ZH"ZID4`SDI0A(VN
MT*FX60!4P,6LUE$)1,5.36L\'9D,R*/62ZA>[*8X1699Q6RBAUJ&[(#$['49
MA!BN$+F4JE%5`'A4`$0ZP+YF&OG\+$B<!`8P0+XJ2Z3J;)"T3H6L:V!8D;O:
M(L/\J%7]Z`;D4:9=0`,LC)L5P)\R@&.RDZBH_J?@&`W--(D3<2W?>I)9H*9Z
M#.9J4EQ]S`S@N!/,*<#-&NH,/@;NM6'4>`Q.'`GI\"W?5J99G,2?UL8AS8Q1
M!5P*-H`0&DP!5*="(.1"9-.1D(GL!`"EBL1D;JVRF*[E0HAO1<#Y,`7@ID?0
M,D2&\.E"8``%&("/N9D"Q(]'Q`E%AML'G(0K24TVZ41:U*+4;&[MKL=`+I=9
MK)Y_D!7M%@2.T@@'F%O,"8"\)L2&\&CS>@R!/("MU@OUTH0V_NO(V.;UH@>W
MU(7?K@=9Q2PE(H8")`"[K:%(*&P`P&3(XF[NDLP!+'!-H-`<WN^\5L?&U@3<
MK$=ST65+NAWO20`Z_NI@FY*FPKRNO6S83KB:QTHPF7[3UWK*#S;$H+H9`3A`
M!12>![1B`XO*]W[`D3!)IXTM_([C39")":LPM(J67025?Q!+9QJ$"KJ9!IS-
M37A`\6X%M.0E!$C91`APJU0PEDA93Q2I$?,G$(?C+%F758@'T:KD?C'$$\_5
M-:$C`.V>P01`:]!G-#9`^,;',&;*(_6$ZD[6&(-$`A3'`I`)=RC`\P:%[`J.
M@M9%G'BQ<8DH,HFG[,;3J`TPDISG:?&A^;C9`KB$A(Y,`*@O3623433Q($L+
M8'3I6SB``R.A<UY@",N&']FJ'QD`Z_D>35Q:7KG*K%3+NEG>'CL/EO')_@NE
M\*8HH4^THBJO\N(,TD14"A(_@`8?H>=<H/7.AA6A44F(267$<D)<`!T7(^BU
M*WQ4<0&0)<+HH,@$RY^^+W\U20.L\1B'T]<`0!<9Q09$P#4/Q:/5Y>`.!03P
MZVQPT.`&RXEVC+PH+<YM!05,VK&,[E,HP"9Z$0;:2V\ZE4W4D65!\SQSAY<4
MQV;`FT'SDR3/RZ?EQ>2QQU/8*B4-9EPF!-%PUKTZ!YQ%P'&-6[,H`,OYD3VG
MR?$$A=C0[RK7D'0L38I,9@(-<F]D;6!$SC-/H6XJ1*"<*;%\!4$<`$P0!#U.
M"P/N\(VV\;($2R-[1#$%M1%O6<<41%^Y(#2K_G%R9`"0!@9P-,1@/D`V.6P'
M],T%#$``$-53)("/M,91O2U.XP0ETHOS"(6;_#-(EU%$D!5@L'`(;HO]Z@23
MW)]/3<=+NW%G9X1TM-)BM(V`4!)',*PY:ML,!G`$-'*JP&:R"/!0B(H"\"%(
MKV?486EGH!P2>IT^2[%>N(I6V.UL/(7UMHU,>IK!4)*ODAL#4,`XED0`B)Q`
M)(`\&\0I.J:A!$M*+\1#N$@9Y[;'+0>SR<AHPN$IAM$V\Y-3#,!$3`1W-\9#
MYNI<;85)0,`">(G]]:%H,:!&"<3'3(":>813?#(:RZ$0^T02C3?X76ST=B+?
MQ2]3'%(#V,P'M'=>_AR21<"8+G/&7\B::OM5\K6'K"5$A.MV05!B=NM$SJ))
M$I'W0G#`:I%E42BST<FW^D3Q=U^53\5)G5RK1W2`D!MX@GN(%;%1Y/QR!&#`
M('9$L#CA#,N%-E&BANO$/FJ*3)_O(+N4C$Y%1*0W-CNX76C%D2PR;-RRB*V>
MJ,ATS%2'6$,/"1>$]L[(QW1H-\V*4:BU"GLM5WUJJ)RTT27`N!+:J)DR4:P8
M>@`'9'^J&H^-4T!*#0WT5"RX$Y=)`)$MV,I.:SQS;D^$8BS(`!2L./^=FX%?
M*:9X;<S9W*E,?00PPO1578^$?&+`-0^`)$H6-[6&5I#Y((/Z2,!+`0B'_C]W
MHG5\0&7BBTZH*4V<1&;_!('[]Y%O<'E-F`^5#AJI^@+94C'A^`354"U#,_$J
MF+#3A:++,EV0R0W/-%X(`.3>Q0,H@`+$\%.<[VY]Q)H`J08V!![W#"?J8!^/
M#T!*KHPCQ+H5A$86A`%415/+LL%<N5`D@*\3A?X5<T435\N]L$>(R@+0%E9Z
MR(*GYRP'Z@04^?C,[`2TN!&?!!+M''QE4U6(^1'V1G9V@%$SZL=;A0:(RB]3
MF_#1A(?=_`<$,T-<'24A#.M6\L0Q5FMH`-P6/$)(NW-6;ARB4(8W35],1(]#
M63_6\<T:.61?'1H5U'_-D\<]6JL1O+1`1`6H_KP:E432N;T$!PUQ\][Q``8$
M&#<(#H9,:87<!T6.!L75?K5>U3QW_5BT*N<'&!C//$4UV9Y5MBAP!+PB/027
M0SU"W%`<BF-XCJK:ZX6K_<0)M5LJ.0Q0$(M11["#.O[B/T6[Y*R@M03#P$>X
MWU))-,Z[8SY"+,"<^UT=Y97>@]"FT[0%./3@X:'3#44=#72;:_>/#0C_T"4'
M-`!3!0=\6/H_K4ES\+F0RG&&-[9$?)@Y43K!=<#QL%X%Y'T!F+Q0>!M.T#VY
ML3_$G+A<UF-1:,5*A)P@4K)]D>)(`$0!#Q\B`#`(X$-"A0L9-G3X$&)$B1,I
M5K1X<0(`"PP47/3X_A%D2)$C29;T>`'D!8,0/APX"*"C@@(F:=:T>1-G3I`;
M`"PXN8"!RY<O+PS4*;&`P0H2`3A@<-`#@`<,!1BDP$'#!`(&,RS4`*#KAPHO
M-1PU>_8H!0`3T+9U^Q;N38,-$B;E\`%`@`\/!L3U^Y=BV(L6`@0PV+&M!Z,0
M.X"M2('!TZ$''TR8L/CO`H,S(TI-*.'`AP0)&$J>#$`"0P`0+%00NA)P;-D9
M`!1,+1LW7`\8<NNT`(#N!PX]/R.4(*!W<K@4/#KH*4'"6`!WSW:X';&@Q`H3
M7@^-(&$"RMZT#4I$@("AVO0'$P)8FCUAAXRG\RJWKU,EA`&([_>GB=D__I%^
MNXVGLMH3#;D`%?1+)0-44ZZQI1BZ8($&Z!N@@`(,O.^@#B)2J2'W5#/(0X3:
M@Z`"!>A[:4&<F(M-K0@>0*_%&FT\"P,`"$A(+0L2TNR#`O2ZD4B<ADLPH8P\
M3,XPHS(@C#X%)O!Q0<T`>!$BQQ9JBB$+`?!0``HVZ&[%@P0K$B0$A@1,,\U"
M0Q/..#\:0*JO3(2@/.?DW#,D\A+@P```.%-N`0+P7)$!(M4"X$V(%'"`(3P9
M:@R`!#8PK$SZV.*S(CUE<XXE3D4=-2$O#2(@*H-"^XW45B.JRJ`$&F4,0+/H
M$Z"`",0C,L?R(E)@U@]878B\3*,T:$U7&1IN_E?`'LB+@#.5G;9%"0[20"5?
MQZ*6VX3"^E(B#JAKBP-,81I73E@E&G8A`3ST@%)CAUK`PP>V,JA690%P$+=G
M90JVVX!](ZF!)3]X2F!N&Z/2/H.0Y%-%$SMK**-[Y:VT`@XZ,,#`7@WBE]N,
M>BN(`0H@31CE%CWU:-.4_?LM@OM2E9C/16F$J$(+*)"`SHL!$&`KAA3H"R\H
M]X7(`SJ;11.`I0&SMJI\79X:-P9V_$AJJM_BZ258?;H/@5A%C5<BTRX.K;8#
M%^)Z,I`G/>CA(CE*+J-GM;Z[K0X:$!,##"ZH@(()EFI@4+QO1):`!'`MH&7[
M$C#HNCW9<\B#L'T^_NBN`(Q*>\N?`2@K*7`;FAF`#>!4+SFUU)+0\-9M,G>R
M'1VXVO7::_+`XD3YM#+4A+*]W#N\(M"`-M]#=_O@@PKX>J%G#>*MR,:PS$WD
M#3:T'7N0K,U+@`$((,"``A)=@.CLS;=H3`22:B!L%9F7\Z`*+`=^-0M[1FRH
MJA"`8"J&K#R(80HYR/MLQ("XQ44E!WB*E3ZP@.O)Z8'G2TX$#BA!"WZ@+,R!
MR59\%"@'-,9@<0K=Q02P``2$IB\+,(`!]/(XO5!*`/QC#6.")S2'%2E'66L+
M!6#UDJ>P;D^]NV!OK#5$"S+@25>RF/.&DCP^%>1B,5N(`A+U`-,U\%2<_JM(
M!BIP`0THX("_(1&18(*;#O0*`\,YB-.,.$0*G!`"$XB`C!YP@-"(K(W9,V"O
M(M.314TF(0$@(`[+=,*818LA>%0(%"MXD1*&R"#]JU&@<C,6`B`@8@#,XR;)
MU,2P;9);%=#A>DZ3D$-Y[WMAB0H0F3:42QX@@,`*$;I2U4B+#(=V[1%;C7(4
MPMC41BT],\ST0&G!^2F%>!3P$;LT5LQ113`BQP2+`!!@NB,]1"6^)-)K)`"]
MAN0H1$+$RQA'HD8'8,MC-%.0`*0%&.?D)0.!FDX$@@-!9]8D@AQ@HHX:9P'^
M<&"4]U26!9:GD@`@P(02")TM#U`^-'DI@`WA_LD5%3(`22;$<MK<2=?BUZ(-
MV-(O/QM`:$(W`7&B+Z`"%94%WGF0U*A(I7!BHT=J\[G?6(@Y%6A,LA@2E<;Q
M"G),$6<1%W*HB]9D4?P)$&I2ISS+;46*,1WB[T)C(:D6*:5ERXL%-H`GS0Q$
M,A'Y#;IN1"GD-20!-Q,@0QB9$^D4KC\PI=MI?G/4JV8/`YGT">'NZC*A#``!
M`HA9SVX8D0:<U4:P(BM;)>:2WUSO4.ILGD'46I'?:;0W4:%H;Q3X@`:H<2D_
M[6OKWOB2!X1E9:,-6,$(((&-?6`"PP&6H"8"`&\2R4K$#!%*PM:KHQYDLZ:,
M%00,0X#@,B622]5=_H`BY#W5NFY['_/E`_3B@79:-JO/_:6Q)I+:&]FILB'*
M@/0^0!N>?J`!]53(5H0XGXL<A#1QE>Q?%).E`W!@N7'Q0'RU&YN6Z@A8!>C>
M!R"`G.SVMT@C7!$T&Y*4`_?&(`YU"!49I1##8'8A+KFN52LRG_GBAC;7]0L%
M;KLVU%`R)QRH`.`F(`$Z-L`G47DP@FL"Q=/H)0+GI?&HME<`ZVU`8QUX\%I:
M6;J(Y$C"%`%2EEC9&8/,-#:7Y.5J/+!8FD3W-`,!P(QW7!(.8$`#&]A`!S)@
M.C'!]L-=WM.]1'P1GF#8/T*)ZD-L^Q$M.H0O%NF9:&7S&SA/$#C"T8D&_@(`
M/@,@]"5:_K.:XX(Z1H]J/NH5"8?+^C&)*$#2%/E<1!R09(ALC[\05JJ"\+05
MQ.9$C)[!BY4?C6J0&>P!,]E6JT55+%;3]*0+PI1$O@*!#-PZ1'"N`$B79>GD
M$+5&S@E;?H]B):4:F=8>V<"!@_8!%(L&(7R--I^\-&J1-"9R*C,(@Q-BIX,0
MH,DALNM"<GR1GB6')VV^#YZJDLN<8$#.JB'WMDWB*P,@:6@?P`"Q^;V@0X6:
M)#DZ;H"@N.Z%=!$#&7!`529"`(<G!#X5>1RT+7FRN`"`V7!9.':0=1;+>7Q+
M\B[X2`R#48FUO'@KAY-D`#82[R[(V!5!I$3L_O:0QLRYM@[;F%0,`NR<.)J^
M'H%:G7,2+Y]@)0-^:X_*90X2BF-;(1/?BZ>KWB*HV$1'-Z*3CA\2V(I4!9KU
MF4B8_WN:=!]%LT7*"+[?7A(L3Z9$5.^Z(TTD5_0ZR`+VWON"G"=XDD3EXO;Q
MTJ(_$)6(1D0SMZ741#P\%'P?N@%;R;19!G!J!:GE`@6H^^$G4QC#E.5*@Z<)
MBAFPI@RAU_"J[X^7PFV2K]BH5PA_R%,.[+P!#$!=$)%G_@(@Q0T(.`+G&0"4
M;S+K(HW%`P8PNJVF+_N)F"K"`S#,3/1C?8_N\B8("+E_2E[;?4-D`BI"0+JQ
M/Y0!`,@EY\E6]?N-_O(;_29C#ZFO3BJ`>N^39.-.`SDR[O_ZHU<(+B28JD4L
MQ^@F(+QV0R2("W8.HB,PZU04JRT4)TY`I%(<@OX^H@*V@C>VK`!%0F,&(F,L
MH,H\1`+(K@1Q0XU6`]723#GFH^XB(%!J[L$L``&&[R`,@WP"(-<2XC<TX_&.
MHC%*[$9R1*$8KR0P`/ON@@1?\"84B0H!K6F.XN;NPT\8(@,2P``L1D1"0L%^
ML+CVATY:Z[EH0P/V[RB&#6XH8',^\`H5P@%?9`,NP`)(P_GJL)*^3B<Z$.?"
MKH%D@CYT[]+RXE8N8`(&`,LJ`!%CZBN>I>9,@@,4C$Y"B`#.SP_;Y2`(_JL\
M_*X398-K#(#++$(!`T0H)O`@#L!<*.+NA@*F-*(""D`EV"L#:N^J>`('.3$D
M?L='>$+?1M$.\\5*CHE.8@;9B!$PI$,);^*Q%"2=7D(!HDZ7IN,A,H!]Z","
MY`@OHB*30`[(:&PX,@`"*O$)SRU%U$E+F+'L3*17O)`&W1%'DNLLM&VISBWJ
M?.E>@LLY6+$\$`+D2(>R`$K-AL/^<.("$@!V&,";F(X>(4F`@$X"8B\BS^*=
M+-(F!,`7`6/CQ@_C#$)W&*`!0+%#8&4"`L`'@6\([XD#J*XQ4&0>3:(#_J?H
M\(+YF/'J\(*5&,#S+O(H8O`9;R+F_$.>H.R/_GIH,NQ%`](JDQX@`KRMU:("
M`<#)+3C`<I9"(X"2(>A$@`!D=K@2+BB%SW(B%>]#,H"NW$IR110`WZPE!A%B
M_?8.`!#@<?S"(7E2+->K-G!P7RJ@`0X@9O)L+]N":Q)2)TZ17'+N`RA@&]UO
M+!S``!JJ=`I`V4#.^NHR`89R='`B]0K3)%]"+PJL,/,&N&J',AS`)BFP4!Z`
M-'Q$4,P%)*ON-PJM(^DP(CC`+?%"%R.2`AY%`8"B`1[@`>*((%RP-&M"C=!Q
M:@Q($4U1*"P$`Q9@`PY+$0V"+<YH]&0N1R(F+C(B9F(H.27""L<3)V8&-[FE
M(%BEI?!D+`3`7!K`_M?JD#80$"?&@BVP,3DG8`%T<1G-\R8\!GMT!%E.);(.
M(@(@0#'Y[2O<)?%F$/7*,B)%LR$0!D`#\<D4HB.I)9@$Y=_VQ2!B9D%ESE\2
M0"-S0B5,)P".,"*=@P!"AYCN\D*-),*<,&':1"\,(R?]T&,B\2B^@CD,0.\Z
MT2O;@Y5D:4:A\3"PIS',9B;]$$_HI"5+H@$"(`$4(*TZSS#RDS/=T24$:&D6
M`*Z2U"0,`SFI1L!:<>28L:UTHEA.0X-V=!35#B_$"0)^<B\W="*X1K<,)T<.
MP!H+<V;4\C\PP`(X@`)8YV^TC$7I<<"FKDO&5/7TU"UF!C%[(SU+8DBG_H4`
M[!-.*..7MI,8[X45^X(PR10D?DT>=:0W<V-3[THS;+1(:*,`)`!/24(##L``
MCO`S]U(I\X?`/'44*?4A-$";TG"05.HEO>)&RI%;["0"DI4F#M1IB*PPORP#
M-$!<A&PA6A!5;2)0S.Y;LV1*.65FI+7?UL(Y=.\LR;1*QY4F#.,`UE0V1A24
M'.!,1:4G%L!'2\):SZ,AB@]>D4ZEZ%597M$_B/6>U,)>%Z37..!$18(V0L4G
M&V(`)#0B9%7V)&47709S>J,Z^0TS`V823[7YLG`O#H@`-B\BQB2+GE3U/@E>
M_75R<.-/HXW2NJ4Q'.!2:8)S#F!,"Z!+1R>+_@K@-\*K!+=P9CW",)`6,&BC
M3Q&LEQ)F.#3#:=/UA"),`*HB-<:P(JQE!'>DY^HP9Y<6)#)4.13NT2HL81IC
M`;HOQ<K$)P*`91_B2_&"-`BVC306),AL::S&;$>"LNY#:2E'I<JV6Z*"-&:S
M)#H``C8@@(@G(;#T(CR%2V04J_0+/80Q+0)P`'KG`6X57CT`8]FF/YR+(@S6
M@GAB:%VE4GXF-@P@:B%B[%ZB7/U#=?%)GCZ@,=(";@Z"1K0B<$5"*%HWI.14
MI60P96X69LU25'O*)GO6=31@)=4&)^:#`:X(BNC"9(?WO0CQ/@CPN60V9<;B
M`/X3+GK5([!E==NO_G&F\":VXK@`H"\*@.N\%[E,D?RN-J88=FH:Y'F/HEWO
MZG<"(`1Y2C]OP@`\K5,_`'WQ-^C45SF&PWB+:61=QF/N%RT$=B3X-F"BJU1H
MIC$R=2+^S2%<\0-$$8(G(E7R-3;@4K4>6&#JDTL`0SPG0CKH0W13!OMV5R&*
M4BXJZ"[O=H4KHF;]PT+O*BHJV%7,338LBB(T`*'2"P(40'8E$V/O1C)?(@$D
M8'-T(BG"@\7``S/)MXB#+F)Q0Y#ZBF[OAB?NY2RFA"'Z)DCJ]JXVP,:*CG5S
M(AS=#\W.N"("15@!`]IB:FRI9C@:P`-:U21Z!@$F;H"LC7$K@H1=)@2G_F,X
M=((".L]["L".TLI!D@^0-<U7%B2)DS>+=1;D7/,HQ'`HF.,`T%7_.H`#K$<#
M`#>/RB*3_P+?1EDB/*9ASV)E8\J`#"<J&*``*KFVWL0@Z,4@/P"3:&HRZHF)
M\:9W<R(/'4(#6*(!!AF"K\5&(+*8HN)5IZ4G#F!V2<)M$^*4$^)*+P)/'L`Y
MLJ*&>7=OFU>:$R+6!&A'\-&7'V(KO+D9\=EV&N-!$Z92=O(FHB)4S-B=`_A'
M3,3(RM.(9"PGM$^7%&+`[.6?(P)34CDY!$!Z)2@!)-4A(!I-AF,TJIFFJ.3F
M&`"D%8+#ZE+@$CB/1"=^.:.4OR=8.SI++CB<_CWX;KY"F4EE7S!`@SM8>5U"
M`RH``RK`=`3`CAM".J`(VXIZ:FRZ)NRW+B1&P`B,H"$84Y!W9,(:;SJO=AIC
M1[!:_\J$-*+Y(A['B@YBDL]'JU<O09;,VO3"`?K553I`J+.G*NKZ/HAXB'*$
MK?65`"BZ)G"%48*3)/$5E@E5(I9D`R2`2H)98"8J)PX@0<BW`#I";Q/WJE)%
MEI>*?VTGT%1[^78X)P3@H"N"I;EED9E"82?B<2A@42#``9P'MIC3EU.%L.^#
M@H>HY094+X";)E3SS!2B0CZ"`E""`QH`I1-F[CICMDEY10XFC<_XCZXH=Y-#
M`;I;:PKW;NCW]=[0_I6E+R$.8*K1ZFBR):91QCGH%66A,8X<$P)@+#)\9`&4
M>Y1#YV0TNRTDV':&(YVUYF?2>P8/XP%Z:"`,8+B]I2>NZ`**U';P!,,<CY<!
M')!=PK6)V\#YA)9)(BG.QS#:&>Q4S;F)`ZXKPK"MMW9HX_?@<RC&RVMQ(@*H
M0P,HX$]^),17.&P0@,#A(D?*.6#\['R\\K1%`C\=HCQ&HW+5B5U4>T4TJ)4#
M+2ZYV:1]NOSDQ+RIYIU;1W+?)2,$``IUXBFL#$B0%!5![DD"I<NU)B,<8`+Z
MILS&C#FBXK8EPDNZPB6V-NPXVJ<=0IXFG/PH>W@KYCKA1B?PY+HH:0$4_MWG
M7,E\1GM+L!E?,OH#M@*_DMJ7>R:P>P.Q`3G5:L-<$EPD5`)I:2LR0,(#AE."
ME*0SJILB<F13@#0AF.4X"KTAU$BM-B"[<4.O5_@K"D+!`D#512*2%D.,IL(!
M/!R4?L.^E]TC?N-%<@1Z:`-PS-I[WVE+'OE3$?TCNDG@<$,",`D#[-?:I\8`
M.L(`NOF(741Y3$5W$N"][TGE"AF?U"XIO@4A,-VG0P?<L@A.:".V04*-`C"Q
M[6PS-N-\GH(W#I1.PEOA07$`/(X`(J"Y_=Q$-J!GYM69-@TGDJ*'A,5,]V+.
M_]E4Y!H(1]H_+B#A/Z+]K#6DZ%<!OB+(489._I*Q9QH5&IO,,BLB;(B&3K(V
MM6L'7JBC'6WB=];B=W**O(NXAR-@`\8BWUWF2/#$.8:])/CBT&[Q?'I-(SR;
M?AV@W7$"WV%Q9&6KO;V=6MYT,KI"G&_B`BZ@*WB"=2+`KWUYX\3B.>+=U@,F
M6P#32F.C`W[/<D"=:G*$M]<"5L3WWM*0`0Q&?"B"B&GCBIAE01I^(F+Q)6"3
MK&TBK7R](2RD(Y+/`C#@<6YW:MB&LBQ>+@3E(++>97"'/J;^(]HN1-D975D'
M<Y\%>AIC]/VBR"5BVHKBW#$H`[1L\$OBOTV?(4*G.^ADYE$&`0:@`\P%Z,V"
M`\"C`BR`JR(^`2JD_K?QQ`"^XR@D`P&Z0@(BQD=>'/*8#G;=&>[/.^W=#$L`
MVWKNHF(!XH/`@00+&CR(,*'"A0P;.GP(,:+$B1`-``!`@`.`!Q`$"(!`,:3(
MD0XO>/A00<.$#B1;NGP),^8'``HH6)`Y\*+!"S0_*$#@\*($!``*"%P`(`#.
MI4P+=N"PX<,%!@`&Y)R`\Z+6K3H=&&T*-JS8L2XO&DVP@`&!```TD'T+-Z[<
MN1(!()``8"E5!@<%Y&5PP"&$K5*UWJ2+&"%2KA<%"`2`528!QEJ5/K":.+/F
MS0PG:$5:(`$`!E$YFSZ-.O7,`QP"XRP`X*3!P1\8&("HP>T'#04LL%0]_I=Q
M!@ZP)<PTCO,WPH[`$5YH#IVD1;[1F7K@4#V[:@`'%C18&@$`2(,Z'WS5#KW"
MZ`\=[.;$#B""W`A*T<M&CU_AQ0?Y^_O_3U![!4RUE$8$&.39`A\<<&!F'"@'
MX`8`E":`:QH``-]X,64`P0,/-,```P],8$`"'^!%%P?W`<@B1`,`H&"+,LZ8
M6E7L,641C-A=`!L`&7PP`'\T9H8!A@()<-MC40'@`$6E(?0B93I-X-B05IIF
M@597;LGE6``(@")3!U!6@4`0)-DE7!D`<-@`!VI0I%L`("?1BN1M!68$$A#`
M%P55I@GH6T01@$&@,])F*$Q)?7#>4A<\<!$!_L\-),%WB8JUII0^SO2C3!CX
MI94!V`U4`9J7GAK39*:BFA^3K))TD0:6RF7`K*]FI6FA`$RZ%`4*;(7`CJ[=
M2BQ%>*U7;':P)4L16SK!10%6!U#'[$L89)"!6U%A]QN;8F6IY0/#5DMN0J()
M4&BYJO&D+D1^C1E73PLHT&Y8`)39E`<:$'414`NL&I:*]6:GI:'I^@>`B;<>
M1I%6MGI);P(*0P2!LPD/?-"H`%"PE+YC:J7`80TT*I:=&&_W;*`8^:=`?2<G
MY(%6O))U\4\1B;:1`VS16^Z7W!%@P&1L<0P93A1L-8`&*SK0X,L]?WFI>ZT>
M[/1!A,$5@+_C,E1D_F0"A:>NINL)(-]"H[JXU0$*0,#``DTR5S6Y1XL7-=75
MK15W0CIM+19W'XP,$57D"5EMAQ!((`$%%5APP04L">!U0A`Z%*64']"7=W.3
M,]7CYETZD)=V1V>.4*RL+<7VKV89X!=(7D&DGH:U&9GW`&5O*'$%BRO`0`,-
MR!<FL[KU=W:^SA8?:-;9Q3QSN1X\J5#,>1D`O:*:6N4`P`OAK$".$SO?P5.Y
M96#!200T&9=GI"<[6&RHSEF=:.M;[5CH.&V@P08<J&@G!'PS-)2++$!VU1+;
M=UPE$PTPC"`7X!@%,#._5[W(99>*F>=,$[/JS4]"!\``SW`BL(1$X(,1_ME?
MO22DJ0-2RWH"L4A.\J*>"!+O@@^)T@H390`*UNAA,M0)\A0%E`]0P&X?<,#_
M(F*R9+&D2'3*">%@XL(/6$0V?BF,#//3@21"1"LT[!+S@#,9+:XO*:];"@)M
M5)`"D+`A]A.(!O[4KHV0AV,R$=P'B"(;I%PNB%<\57CN]2J>B!$Q1^M4'X_4
MQJQ0)SX&.<#WHL<89T$PCCSTEDP:$#H$N`R3'U@`'P]I*-!-$E6(.@W\0"D0
MMG"`AR^!T6,(^($$D$PA#;!(`2(P@0,<``&L+"#Z"`)(F2PKEO9+@&,XB4I#
M7>2(B4(69P(`QT.V9T*)5!3/$$@0!3R2(=5L_E<&*H"X^&P`6PE8TB]A\H`J
MV;$VMW'`*)/))9P5*V;#R\R:!CF_6'6S+-=\XE&8B9`N%E!3\JD03B!5@!PI
M8*'ET2$\M_2KIMUJ3?5$#`!Z><7)!$\F?FE;50X0M`#PQS8/!9)9*N.70I$-
M)Z"R'`3>6=(A+>:<KP*=9GX5TV$R16P'`EQ,%3(`6+9$`VI30`8DX``(1"`"
M9<+<3[=$E6C>*JB)N9!`(T@4"?W0)1A@@`,H<+@)*,X"A;I,234H$`S<Y'QR
M41^J0K@^2,'T5?NDF?9`293$P"V9$HH100;#EP%@E"0=\(P`&>;6IUHI1^12
M"UU*65+YW54L$9`H_BHOXK(.1*E,!;CA2U#(%?3%4+%6FLRF"CC8I@"`B,E<
MS"S)(H%M'K)(%YD`S@30*0/XTR73Q&T'-H`S_EA`JJ1ET;&NFJCV--%+?HVI
M5O`5$3J.!%(_G=M%%CB`-;I$--`5"`I1,J'BT@@OQ"76FN!2)-)>+;H5G4@%
M7JN0Y=:F7M.\"-46T-R7(+,@\IO`7,7;G[E]8(')4MM;"'"[F&HD*6@=2W<>
M\H!?J1$!"#A``!R:+$B-9C&2$@@O<<*6@]AT`98%\'\6TX#\)FM78TGL4RW6
MX+!(S"'2HPQ\;Z65R%3`6?(9P"=;J3V<^M3$+.+7*<F5I9(Q4K$U9FU,_B!5
M(0@\R8@0D1"$\,FJB]@)DP=Z0(E;X@#'E,8#)PF`4;Q,Y!;A3+8%9C-,H"G>
MBRA`Q3!1#V/2=::()'A@%]AJ!^@5`/FVA"J:^L!+T\RBCQ&87!MKBD9B#,_&
MU)4DX#)`F7)96T/?^*D?P0GHI&24O2*Z/YEB<;O8M=/(*=:^#$#N1/S2W0'W
MI`%?9H@'&N``5Y]*?P?90%2"M)0L:G&CH\:/:8/9+L?BA-BKS@NAS*@]`73Y
MOPC90.4NHFMEAHZMCZ%7`5*[%!<7&SWU577/:#K4)<=Y>EMM25$.0H`#0>#'
M#'G1`C"``=!AF%CKB5F,)/0=`WA6+*,;=WZ0_J(4+-]*0I">2`#H_-2DM&>G
M7R8`2")07H2HIWJF1NUCZ+2>!\=EM`9'SX7">[+]MB2]1$Y*:R@N$#(_R`(!
M"(Q_(2+NF32O6*Z<B89<B0#MB@75)=>.AJE=+0$,O&'2!;"6)ST2BS$&*-^.
MR$7H2(')P.0I`.K)3`C7$YO%Y0*U+KIJ>E0UC60[(>LT<14[T-ZR:(I>$=CT
M07C"%4,6L)\Y,=$"`,J4"93=[*B1GMXQ5G"1A,?)BJVB4,<2](EDP$VQKA9;
MYE45`Q1@,O[:K5@D1/CL\"MO.1R)U]/\HIDH'(D-$7ND-=6D!M"[)2'^P'4,
MLJ?0QV]E>>OY1`JP_N_B:KT`JW](/>-M'`Y8X*7T^GM),]``I4I`K(MSW-\R
M+I+4F]0@[M1]='X5_.PT'2SMJ7Q#DESL*;K/:)JZ#4D;LABM".#"[\X<XG""
MMYE44]3>%XE)<&)8;E8=:S<2)#<0)P$5&I`!C:,[$S!]19-^JV5W(L$6"?!'
M50$T43%D"Y$4;I)0!]!2XS8<`U$`F(%3!>%4_3<2X_<2?R1H)V,1!J!Y/B,V
M!5-L\`(`!!@4KE$D-V16%,$O<3=JK",0-E40.:>"G`$IX3<C'""$$W$T48(D
MT\(AJZ4_PK8:2[%H]9)7JO45%X(\_%<2%S%9HV9A`G&"!)%X27@:X-)N_C1R
M`8PG$:.SAK;730,P@12Q<_7R*Q8P>V71(.>%@DQH$!VP&'MH</+S`7[A`4^!
M/^#U5\7'ADT1)3I(+#&4)3?!:QK17O%F<$BA'EOH;@T"60+!;`JA82]8<CAC
M.32GAI.H&<>"??62)1Z0)=EU$1DP)NU5@@:G$QL@B5L4`!"0/4R2``C061\P
M`7]H$!O`%H!G<,?2@5MQ($0'BYNA.NO#+B?'&#]$A./F%UV(*X4&-FS4&)K4
M(_77)1!P>*0&==<(%SU2AO6":@[0.UDC`;AT$&<X;L_XCB&1`-KD'34'`;0F
M'^7($%+'&/VW?'LV`80(CV3Q1\PX,`CI$)ID_G!LT0"SV!2Q]1#!6&QAEC:C
M8@%Y&)%B,7JD@WZ#@3YL86X^\8\_56,F:330>)+$)&<Y$CJ">).(\3'KHQ'L
M(34?\%T&H4?CIA7H]ED5P`$2H`'A,P'15R8*8),1"2XI(1`<$(,?0%T]B1C.
M\H0#<UX:82M^L6>SXXNC$9,3(39&L8%>61"UET9Y<8IP23-'%C>H=A$#8`'@
M,GLJAV@^!)(.D8Y;48%%-'@W&3/_HQX50`$0:9>>)A2D<R$#H9,!T(ZIM);.
MU1:T$Q<_&)G`-'`:H3B;&9HN\6D`$Y;)XF)G4P$'P(+:5VRI9XDM(8:1N2B-
MM"OH=YIDT3ZKV2[J_K$B'K",%[%S6H>4>2%T+C$!#N``(*(`0X&,WU&7<@%7
M\T,4X_==O-F;8D%H<E@OZL$2%1!TH8(0.C5J]K5^,E&#RFB:AS28#E%?!$`!
MA,9(UMB=8*%ACX<Q[>$!&K852BE%ZXEH(5:;#,$`O(-)\<$`S2D?CYEF#5>`
MQZ859<-R1`:<P(%VI/-HIJB3<])>\`*.>4&@2V%Q!O&:^4D0&:`6!C`!]X$!
MB:FB+F%G2X<Q%U)1CQ(I!C%_1`8IQ8EV\^@2W$80'CFC"O%&1PH6=O:2)[,F
MAG0?''"6C/*>,B2->*@EN!4655<0$H!T,UJ=2MH2HB&C]<)BTCBE.?&E_O`T
M&1'`:S8(%@2P3<XGI@>!9G6*$]EH`39JIH_!)"EC-57)-0?PD'RR6NIR(41A
M(.LE$P7I.W(&4GS"3OD!C/-CD7CZ$HLQ&`3P(F-"D\UT`!"0`'AS(3\BEU:S
MG!(!6HQ:+:*A.EO!IZ:G*3WUJ:<9IIA*$7:&613:+NV3E,=R;=@T$*=J>IX1
M`$5RH%N"20Y@`1JP8*,1GPQQ`0J`:QRA)Q1``<\!FKCJGG)A?O!(:(MC%W,"
MJ-42?_UR1_&6`!8@`0N0`#N74"_!.V&F(*KX*C&CB,X2``J0K"%QFW5:A]PZ
M$D4Y.K)2I6ER`&$&`9XAI`31E>YV+,_8+I[Q_@`4H(LYME/4EH)VB0&K9X`"
M.Q(_.1.\015K>BH=$`"B@0'L4C$"\3$!8#**2!*K.IGEHA%^\1-<(8JP`E`2
M`)GP6"H@M7D#\"(5)FL@2Z//<A$+>K!<<H$X$P$\X1B3(4L02!"<ZA)K4@`<
M\$W7R2P+UE+&B2UFQ)_*R)$G:624\0$7BK2RRI5)@1$!$*NLPA?\(4@Q\YQT
MHQ[R]8T`Y@%T5"9C<@&9618&H$`6$"T3$`$/<!/<>9H;L+#8NK+RM[:;^88@
M"RY[L@'-JHX8TQ;ZIQ/3U%[B.&I4H3.7*Q+MF0`-.[/1*D.JHP#8@0$FRQZ>
MURZV.R-[&:PE6B[(_EI$F78AYB>SH^87&]"O"<$6`N"!!K!+"(`5"""`D6E8
MEO0!&?"S;9L0M-6Q?'&,%G@RE2D0%LL0:2@2`NHTD_&P,=$>?)I+_[&SQ()W
M&[$B9(>]([$8J-LN00D11UE="U&!K"L1[2&`[Y>?BT%<25J_(:$Z+/@R[4&X
M"&&$,KD0'Y.#R0$`9?B6H>FK`^!5*<8[4G&]"5P0>!?"2O2Y$,:[)O8B-]<K
MB%B$M(L8&9HLTJBV^"G"'WD1T=LN,1,1H".A$4=-=.$`J>J5&_``$E!]&+``
M&O``9=.T"1PE[ULO,2.)I9AF.E&K-TP2-JS%#+%@6;QB"$B83WQ()^BZ_EW<
M$&#SL2U"9LV&OW'TMA`WEP9'%<&+QD:CDU8T)(WX5(9UMF$#DQ=E`1Z28KNU
MB_W()G]\QPY1`:^*$1S#MHM,2_LQ1AUP@5S!0V-RQE<$.N`KR1_I%$P+ISSY
MR0G1/FEZ,I_+>]OCF04Z(5)<R@11/?9I'&W'Q9GSP%MB9Z@\,#'S(ZUL+F3<
M1Q9AO=\:RPOQ:6SB`<B95F5Z,F],(^`"RZ<APX[B(RC4(8^*EV@HS)R,(2=Z
MS!'1`:SX7`.A`3!LE4P1OQQJA69V;0:P.51QO!&$28UCON&\$!-0F!?3LOAL
M$.#"P"=3)`NT3%H$F&F&%SP";OZ<O0NJ%!O+_M"_6ZY.4W[>E2,2L`'65Q`1
M/(0Y6+$1+1([IL<@39291CKWPHV8;)0H-VI$420+3=(*L<;^C$+37"YK@A6)
MLSBR(5N*.FY4\9`Q31$9P!^@]Q\_#$\+AKL#(R%G.17(-A#DBVCA014V+=17
MFQ>.R]`323H\H2&^1L$LZ!E('5-4@11$?-4'(3BW'!/0#(]:$=":D<MRT1Y-
M4FJ8A1!(J,+DNLG^+#B?4C+Y"2YRK!GS;"T3\JP@HW$I#&!LL29EF]8&T0!6
M0<H@#:=I=UH;D,PF31!98MCK\R(.,'V1_1""8]0DC4(`+#F?W1P78C<<P(Y(
MC"`57&R3T0""1]I=_OHE%@,J1J&_6NS"U?-I:-T07-=,B+A51V/5)04;%V`!
MJHW/Y[J0EYK`Q4=;@EHM[=&QE3$`SM*.D$+6)>5"&`#3U9$!K)TWRH=O#/`H
M)B';&"?4A@7&Q*+=M;$`TD@`"F`RX6',Q34F$K*:U>S/MQK+Y9PW]3T05/'`
M10*>BF5DQ$(!Z$TLD)L`#O!#>AW.[>/,7=+@!!$SQD$E6I&P!L""X6&OI"4:
M%K'4,5UC$SW3^"R+R>+6CU$H'PJWU10>+EQ<KSJW($T556NU`J'5#+VC)WWB
M!6$1D*U82($4.@S2)R@AJL;6QVQGA#TPKK(X!0'5+MMHQ485!&"\N4T0_NNT
MS9',T+0E1YESJ!?,'H>QR@-!%$?^5*"34F(^$/NE;@)1V=X5SM)XSV;ZRX$1
M'N'#YOS%V.+UJG$MU!%,-[+<37U=I\[RY^K2'@H2CE('2[\BX7$S&"MLYV:"
M$0K0VP2`))5[U681*!C0W[CA2O:Y%>V(%#/^4(!5`8I<+LMM*`"JME:,Q@^R
M'%KAY`!B`)/N$!+2)`C07!JPAU01W@^%%QQ#D2<#Z4W(`!`05F-5`5C!Z_@<
MOXJ>OX!T,=DRR7.M6.%1DBO^Z6G5S4A;7Z33'CW&%14B7YT\;D118>6=[D)]
MV4Z#MXMH8P8!*;(.3[`V`<2=[U=]<MC-+(MY_B(,0.YX@>NOATD"?O!WS`$Z
MOI=CU*3#P8#93@&P$?')9%H!T.P5W\6VF!!V5L(K]B6DKI`$-6Z3L1@FG^]X
M9^O,@G?+NTMHT3L.P!&(DZUXB,CH3O/Z_N95,P`*_P&_C6A^L0`1T.-%S]"O
MFCDQT^$&(;?%9F1*+_4%'BMY<]`.P8FC)O,AW_6?K*L'OLTN@LZH9!%9(N=G
M'\YHGC=F#A%Q@FC$+/!R3UA[WW]T'S=>-1+Y1V1CT@&$RO>1+3TK3U=^/Q#W
ME&9YQ=*)']//&C<8#A&D*UZBH1%Q3_F2K#K$SBP!L.H/D0">#THXA0!7__F2
MS!9MSRJ>3!),7USR_CSMK0^RJ.XT(E<61._V$LCUN"_"AN$TI^42!P#[]+PK
M&##?PH^]X&+PQ4+@=0$7MX\>D*(X&^[\-\R-NQ_M$X$`-S\2.IXF@W$!`Q#L
MVZ_%C/4RQO\28U]<5#T`UJ_^1RH]WU\L&3RDP4\Z>''Z``'APT""!0T>1)A0
MX4*&#1T^A!A1XD2*%2U>Q)A1XT:.'3T.M`!`I(./)4TV!)#A)``-)UTF!-#A
M)44*`!!\D#E3YTZ>/7W^!!I4:,D%(@%X&)J484B7$P`@U+!!Z42D4PU&L$G@
MJ56N7;U^!1M6;,*0``2T'"O4P("7`#"DA<L0`8`*`$C&Q9M7[UZ^88VJ_NP[
M$T"$EPL"!,8[8+!;Q(T=/X8<6:%(MI([=H@I>,)'#I8O-@"@`($`SZ5-GT8-
M5(#(U!<E+-!Y86M'P*T1<MB@(0.&#`4`2,A0V?9PXL6-&ZS+^OA#NCL!6%AN
MTNAT``=6"T4;7?MV[A45_^Z.L"Y/"@G";WQ07;$"HP;.OX<?7ZA1^0,-2.@Y
MF^$&Z/4)7E!`@J<8$$D#`2KPKSL.<DJPP8TR,,H!!P1"X((/*.#.`_T@J"`#
M"RK(KB,)&G#(-P$B$"``X=XCT$``./!-I`(<I+%&&Q,R0$8`"#3J`.X@T$^`
M!P14SB`/.L!M@]VRVZP#"P?*0"4**#A@+A`9_LA@`@`;H$`""3K00"0@16)`
MK*I\"HF"LK1:C;32I+HQ3CDS,@JSW@!03*#M=BPHI!RI`Q30/P.EKH("!A6)
M@**,(F`ND38```(WPPIQIZ(F`(U'`Z(T[<PY/P75(?K2,P"T`,K4#BL&/P``
MT;D<0`#$!#P@P(`*-BC@``H((!$ZZ#(X<B!/6>U`IJH<D$`!!C1(```",F``
M2-CD8Z```@9(KU4$A@VU6V]3H^^#,)$"X,GH#IC1()$4"*#9,AM@@#304L*J
M*-\@\(`#E3P`T<!FC0H`3Z-BM&M@(7U;P+WX$L#J-^JF_39BB2U;[3`-9VR`
M`#V7"Q-.@A8X`$N1_NIR8#I'"27470`F,*``(!,88`*M-"@S`J2THDZ^N@H(
M&,)6$Z@M3FXG)OJQ9MG*((``)FAVX^-\.P@S&%.:;H!KJT,``0468*`!!QZ`
M(`()U%P-SP\Z,PC"@E;]8%X!WL8POC&=36`U"C#P<4X.ABZZ[[TP`R"`DAD(
MN,CE!HMZ.@W<VWLB#$0R#Z8'B(9P<H_]QCQSKS0TZO$`YM6ON#!A>JXHPBIZ
MW":%0",ZS`<Z<%ISV6<'BO,"BI*`X,N-XYNUHB9O"&V#:A)I@@H>>("!"<X$
M(.[E/."[HI*13Y=VZZ_7">"0&/#```<0C`^T#E8CL:'3#7K\;4"=3^"P_N@Z
MB)ZB]!K8@`#L[\?_(QF)R]<B]CI0#*HZL@#\$.0Y$DL/`ZR6/P8VT"*0LU'3
MG`(QCIRH()R*&(08T!\'=C!S'J@41<)%HT4%3`$>"4G\NA42!13@?!Z$X<0Z
MP,$'`J!Z#L**`;02N8UHZ(5%<PH"6!=#(A)Q?S4BE6)NPI'`::XN%"QB%!O(
M@439B'@1<,`-+Q(F`.RN:*"!P&BD>!`/>'&,1>,<`(#G("`)1`!:E,@%'L">
M5LT.=&P[8QYE%S#WT8A'>+)?1;(%@`;@T6^/,\"DQ((D/382,8!K#HW8LQH(
MP!$B=%PB[1"I&$=VTF]IY&&#BE(F0EID49F<_EV8"&`!2WK2E:$RB@K/0Z0/
M<,TB\UKC[$(R``;\,(\A?"6H2F8V&HUI+N6CR#`%.#LJ]C&8SP05%1]5(]"P
MIS<6R98O,X>9C(42FM^L$1>/8B.Z$*``)ZR(4P``1<V%J4/@A.>-_K6B!$$(
M-`VH'O0ZD)L,=,!#!#D2VC!`)%3*KB87Z%(\%=J@SMGH.W/Y#LHD"H!F70]2
M%:B5%+6YT#D9I:#^D:91\%4!"4S`8PTX`-@B4!0$E*QDK&*GYFI20"FVDJ-Q
M,HKPC+/,ACP.`P*82^PB8KC9U84"#W#F396Z'4>!SSA`DF5!7$2`A%)D3(J4
MG6Q89L:E=I4X\XH._G@@@@$%K.8"NK)(P'0JN\=%X`"A\VI<;6,4IQ(GA1&1
M#:.P"<&*>""7-*+B7>0ZV.$8)::I.4!2&R(@<Y;K(B(Q)$3X9"-(.8`#6"5L
M9BTSPN(<,"(Y+$`!N,H<QE@$2#<2T/?@JEG6.N9/R!S.:252,@)HI:X2@91C
M'^L\-J[S`YAM;7#[\IWC!("F$!GDS"KBLXS4Q$;UFL!'A3O=O/S).)BQZHZ&
M&56$9$MACZ5A@@3D3>HV4`.;<9"CC!,!V$)$0`=0`)`VVI#<1C8BUJF14Q)`
MH/+V-R__0F=AN6N0DK6L>6N%".=&.U3T-J@F=O-OA--"1\6>AHH+5LA!_O/Z
MEHJ(9,`+P<J'EU.7`018PB?VREOIF9H!5-@A6*%`7L,+D?'992.(:U!(?+-B
M%/=8*-LE3B0G,A?\=/$#9LQ``Q;`MJI(\Z][=5!>5>=C*@_E3PHP\6FPLE>!
ML&<#BIE``&134KH:P"D#\$U=>(3AH;8W/H\[P$NK/.>?E`W'J0E`EB/R.U:M
MK`,1N,```%0!#$24,!N0"8?[G#>-R*9!7+0OG25=DO8@N#1&KLBK/J`5@4CI
M`Q,`4P!.!IK7S$@``G*Q:=WL$A$/!5($N,!\)SWK&XND-L"$C&PKHA42J>@#
M#Q!`&#_0(0P8``$$V$!G+`2[#UA@7L?5R&I-_M(XO%!14JFF=;8OHL[2HH8E
M%]%*F;R<$!X]20,(XHT!Q@<LCPQ`L/&AX@,2`&UMU_NQE'EW:1Q]D;F4J6P"
ML,#C")0`(.W,610ED`7*.C*/J*T^F(%`S.P]<8S\R\:H*<"J(\(>!:0'`QR(
M5W7`-)!YS=B`3?1(\^JC(0NTFN(O'XA(6X-IB_RQH@-9`,"?`\D/B)D`"6"=
M#LU2DBW+!U(6$!#,E2Y9HI;&N1A!E&X)TBP*%"Y*B%83?B+@%$65Q&7UL<L"
M@C8Q#RB::&5L+5U38P`]#UDDG_.L01@PI.=P2`&="58M>=L1IL1'0P(QU](%
MCY`TIH:*+C?(OP!^_MN#E`PIZ`H<=4RN$2S+9V7L&7SF$6*4P'L&\QDY&7F-
MQ*?^%012!:`W1P*`^-/@B0%FU[SF"V?IR!2@P1AY*T55GA"6_U%@AS'+L'`M
M/Q[OR0'[CGWL%V53QV!W(T5Y]D(6$($-1``#&[@`M;7"YL<._SC<3'[X-RV2
MR3\&V!M)C@TCM1"5YTLW%["`2IKN$>2'QR8.%__@"W?[S>;;(AJX+/*CO8&0
M,CP1@+<J"L40O8Y8P+`2F?S+O#_9N\@(,?0[`$<[`/O2$-@XMP_P@"<!G+'C
M#.8S#I&3-@BTM]QK/9ZZ"$@)&.5*B`LXIQ)J%J08D\ZC-.YK#0TQ@`WP_C\4
MG#A':3O'@)0!I`C%B!'8*P@/^)R$R*T3Y(@'^*[MD`WI`D+M4$(;^1,1?`P'
M"*2-P`R@8I4AQ`DU`I"6&0!'R2LC9"+^XQB1F`O6N\+(B+0&B1%&DPRIVPC?
MP)DL)`BMV"'D"1OH\`V-\PA(L;_52+TYS#8>$2K'<(J/B)&Y*+\/*(#^&+F"
M$`DVY`@"D#7;.+W,8$1'HC:K6)32(``WQ`AIZH!Y@8`.8(`#0)?:.H!!<0"+
MHPYLZXC1V8XPJ44K',4B*L6IX*(I?`S,P$&,2(X(2`\"P("J6Y<#&(`_.0`.
MXP``E`G,R#B>D#CMH**UP,.OX,1@Q)]A\L/`_M"*C]`0`8!&8&0(SOE$OH/"
MUH"0@#G'J6`\<NR@LGE$Q$C%CU`E5JFJB9"F!BR).-..W/I"?<RV[]!![M"4
M]*DA[*&B`R``,F1(*ALF[WN/;/F`E)I`B-"*)YL)#;A'"[.+!RB^C%0JM-LV
MSDJ0,4D`W*&*!X"1<22[';$6EM2CD]R)+:P1K`"^N'N(DA$UBB+!H@D-DN3)
M&.J`D/P)1V'!^B`2`LE'A:"B`HB;M\,>U4G&INRQ86+*^.`V,8$(A!P(:3HL
MS`D-!5C(TUA$L*01GYE*^:B)&4$`CM1$G?*`N?!)HAD,G(PKEY1+A*`CP=R.
MNK@)OW2(^L.Y>?06_@K(NP]@CPPTQL)$,9$`KOH8LSZ+*@YPPX`)QZE@),?@
MHF;AM@#X2\P4KFRIP_.H"X'0$)=3$L5`3#FA(^H8@+=B32K+%CD,,HKZ@%)Y
MB/0SF0"XRN"ID`J@@`F``+TTCK((H,Z!S-X,KH91`"3)`-W`@$J,CI,1B0>8
M``G`%O5#&2`9I"]A""3A%M#A//GP#0R``'4*`$1<"'VQ3M8"SW6:#LLS"ID9
MF.F`@,))`%P\.*-@@`05C008M>F`E00H%0C0&$3Y2NV0,?>\CH4HEOS4+.*Q
M"0-@@)*9"[]C";=8@+*H"ZVPC@C!&4"#C;@YD@CXDW^)`+<JF`L@$$=!_IZB
M"),8>4CBT`I.(IC7Y%#-(BY6@1#VT,7E@-`2VX"Z>(`+6(`+^#B)>`NTH`#^
MX`"!H(!B.:$V24NSF(NB(-+B8"RHB1'\+-((HZ.!"!/#@"SX\)FG*)<#HXMU
M.JL)&``)\,0YFH[O(J3IR+W(DZ@'P*=`!<[2,``+60R1B,LU;2WBL0_'2H`'
M2%3+R+VW2<#VF`[?:P`+H-((X*"7F8[50(!I-(`$N``$H`!8X0!],<_YXX[M
M04Y`N51(_::&L8^>PPJ#7`X.4(P!4(S$^@#S`(Q#ZZN'T("0.+;BB8\-B!;U
M.YFZQ%7-XJ(/L-$"2(#M@XL)&,L!2@`+L!\)_JC0G0@XG"A3A2BQF3.`!8#.
M:O6J?_%"HVB8=!6*1OD6_@(7`2!3>)TN`RV8.$V+%XD8->()[Z2TIUA2?^TJ
MHQ``F>@,#'"2V_P)"G!'.:E.C>B`Y%P)%\I8AKVI;.'"M-`0BDT0[_&)&7*.
M![`LD`VNLOA8KD@ZS\B`<CT)"+G5A[@`5?P(2"F3U?2*=W79^/@.DTV*BRP-
MZ`D*QZ1#[8K9H84G(OE1JQ!%HA&`G.6*#70`A(7:A6J8?A0+7BP:&32-T*"`
MS837R>RJW'M+N(`OMBS;T719I8TK.EI)L-"0S*F`NPV,ZN``N>W:I>(1>U6*
MB-.<<=JL`XB`M@W<_J7*K:3L"K'"G/'8K`(`N<8=+$?!VI>@W,PI0LL@`'G9
MW&SCV@C[$\(="@18RXEY'-05BZ$S6LSMI#%QW:#H-LT)MLB`E`&H":"%U-)U
M)9G$BQRQGI_2W:$S1-F-IX:IVK%8/^L1`)[]F\#)`,;UBI%5W@8A$INU"K&E
M'2J"#`U1FJ<%BMK-7NT@GHNUBLK#'@4`7N=]([X]WV<JM[AH7DU:6+CHS_F]
M*2F#BPJX3-J17,1X3_[EJ$&:VI\@3OQYG,=P6`/FJ$7YP:Z@(J%52K#%"QL2
M3PA>J"=,BQ%E(*;5BV^T`+3E8%?*%@R>B@%FM01NC8PBX`)`'O[U`.E]_J5L
MB5V=`&'NN(#1?0CP)6#2@,H3=J5_^5:EN#@'"H``C@M5TB$BAJ?DP,BD$&'\
MP3^^P!,(>%0H;J2\4E^A0`#`Q9\T[%O5)%\NCB%E"@M(,=^^.6.E$-^:>%\T
MCB'.F>*=P!<"0UP8*@!J==[FH3DZ]J3DX%[;]6/\L<^]V$0Q%N0\@DFK(!`?
M[A9^Y0NH*>1&)J(U`8LI*Z(KQ@O?D`U)QN2^X2(5KITWGIV5460ZS6%ML^`>
M(Y.O2)@S2I95SA%1'N76B66O"(`AGKC<^IY<[J202C%4KC)Q(@!<%N:(44NO
M4*#8>\)X7.8.@J0V%BX,4&:/"*E#GN8.XAP;_I9=S@F83]G0;A:,E"!BS@F5
M;#9G+H+<QGT[4S9G!E*G=PY<D6@`WYWGKEPG=N9)?);??<:?>?%EY;6A2!9H
MB1C&HA$G[#5HT6+DA.:]S$D=7Y5=9[&`@)9HZ\DM:8;G_-WHO0"AO@@8>?YH
M5@&*5P[IB+!FH)`FC;YG.EUIR;CDKSC2B*GIE5L)JIGI#DJ.+1::;O%H$:(+
MD^YIS$D=HYZU'';AARCIB#YJV5$,H-8V!9C@I$"8/8[J^UD7S6O=KV"-^]UJ
MVH'9V.,EL,ZIL;X?1XR]O/6*D?%GM7X/<9H/F/:D77GK5J%JN9X8+BIHE_BV
MI;I=)*X.8U:H#EC=_J9DQ:"0LZ6JXI1F#;OV*H=N2N+)Z8ZXLZ4:@%;F"'C4
M0[YVHCH!"L/6(PFUBI"R:-">&)&`:J)([6^2#<[66(!1;;*>II^8K+C2UJE0
MY\2N[>C@V`0#C%WN"0A1Z5=R:\+N`'#^[6Z1B;P*@):6")#)K`9@8I^@J,YM
M;K8L)>R6;4<B;8DX$PT8`&9AC>.NUJB(IS22[B64/NOM*@?P;8\X&D#INRA"
M[_E-/\Z('B$CK$3>"4C*&<K>;F\1B>LNB<<A\+"(:X7PF&5-"S+F"3A+"24K
M$((M\+Z9%P204`9``,+@Y@>2[*G8`'B!G`97%^JXXZ08[)<($_XB'@Z8_N,,
MOQ&CX%/J"'''"62\*)O":6WI&-\V2@OOY=S`B;KAI/&^X1R96)G`2<>2J):^
MP`P%4+'@=HFBN!I5'MC\E@@!\?(%8,(237(T@IR`%9@%GP@M5V0"`3:4`PK%
MD(U3BXO&/N=2D8JP'G-=;H^Y0.P`F/'@"6^@D(U!'7&.,(``>!NS@@L-V6N,
MJ(D<&;B`@92FSG/YR"L'Z``$D(#HEE6,@)7``+;<O.J7$'#6CHOD?HG$<A1'
MT8!MJ72)X4,.072SP'#,YO*AB`"M4;/73G#C`=7+'@I]SHB<>!06?O5/X1P(
M."T;6@WFE@BW;`RDT(VS`160[@C%B(`!:&]X_D)QTG50R4NY+R8LHG0.-?)O
M8L2?[PZ_Z9C0[\A"NI4("*'TZ\%FEP!PG>"BMU+W8]<.&6$`"HHLM84(TSXQ
MK<1NBN)U?@<I1Q6,OV:MHN,)D?AJA0<5+LKQF@MTCC+8B'^*<*7X4`D8!,^(
M"Z.RC&\(=S;YCR\.P+'VB=!N%).`'X\VFVATE8>/-$)SBA``^/8OL9:.E:EY
MFS^/9C8).9ZSO=V)GM%JH:<1Z-YV@^`D.O-Y_7D*D6=Z^?B.H)<L*^^O!IZ)
M<=Z]JZ>1U!'WB7@Z25OQC,A0L;<1<9IWA0#1PDS'61G:/P\FSJE&2KMUS0OK
MO6?[N1+.CQ@BN60-_F?\>QJIHH\P+LR4^!8_?/@@DB.FB,=F2/+C^<>W/S?G
MB`HP87(,P<_&_/>PG71F^-!/$)D[83BG*M,'N\`_88E'@*=G_<<@9B*VM=EO
M?:O'7,UT?,V1V*WF2MMO<MG'_<80B:'NVO#<\>+'PJ[V";^O-SB<>N8_#A44
M_DZG_A)T%B@6DZO-_NY0#-V'Y\&`?@>!=Z4H_RO,/:XG1PZ0?*:KBVZ_KK<7
M9I&8;WT<EUK[6WW<]\'B'(!8\&$@P8(&#R),J'`APX8.'T*,*'$BQ8H6(1Z0
M<+&@```?`&C8*'(DR9(F3Z*DZ"$ERY8N7\(T"`"`@I@V;^+,J5.A!X\C_@EX
M!-!A)]&B1H\B3:IT*<0%`!(PC2IU:LL`(47._&B!*M>N7K^"#2N2PTR?8L^B
MC<I!P,BL`%:FC2MW+MVZ(R_,'&!W+]^3`!Q@]3BT+^'"A@]'+8MX,6.#$LQ:
MS!J@0>/*EB]C=CBSID4*4#.#/GJ`[46@'RYP"*UZ-6N[92=$OM!Z-LP,`%);
M#````X*KM'\##UZ4+(``%CT8%ZY\)`/($V<N&"![.?7JUC<V!["AX@(#U[]#
MW!T9@`4.T\&C3X\>0=:*?]7#-P@!@<6.&2)DB(_Y`@;]_A%V),!@$FW@W'_H
M&1@>30=:!A>#!^J6@(,1+?A@>@C01Y%N&3B@_I&%'X+(UTRD260;;IEU<&*(
MFIU'87&WK1BCC&(5,!-L$B60(6@>J#AC0A`DV-"((/E8I)%+S53`1!W`>&1=
M@)EDP80/S92!`!0XF:66-\UTP$0-$+!E<`U0)M%,6(J9IIHE,0D`B0\5..":
MK"7G(@5!SIFGG@D-,-,#$=VY)VL,,&`F`/@).M64B8*677X0"?`9HZ#AF5!9
M`_0XJ5$M:HI97A'UU%^GF$7PII!_$3FJJF(:,).H#EE0Z:J%`5`!1+IAT.2L
MNQ99EIP,$>`AKXQ-(&M!;CTZK+(A]NGE0STMVUB%#744K;4@SN3=0PE(>FUA
MMCW4YP<,_.FMN?`I_D;EHN>ZUJU"-6I`*+OS?O>8>`T]8"R]!FW@FU3@4GN;
M`^6NMM6^!\L$@%X.%>`LPJ[=N-`!'B%0YL,7TPF`D@V1]2K&<N7:$'L<3"#0
M@QW\^G&:"K3'4`1UJBP7`&@JE```^1(<L\Z,S63Q0O?NG!8#82[$L@4F!YVT
M8;H!D&Q"C\W&@<>3WKP04(\)J[36KCW5$`%3AY;!=J,"^?-;%$2\M=IR`:GM
MSVNC!0#2!^F6-MQW.\1!ICHYH#!#3N$=5@5X=C2TPX$C?E`'Z^8T4Z$_^YPX
M50+,71!0@]LJN>9,U6CJ0?K&[&]7&@09P6X:;YXZ4KFVC%"LJG.EP`(+_D@`
MP0<12-`W`,W1#+OO.+%WJ$(`V)VG!F-7-],%$!2[09\:@_Z[]"0%SU/TBTW-
MHP>,M]0!!5<&0!8#"!S.&NDSV5S63`X<8/OT[[O$\L((&;!Q:P04>_E3`.AH
MT^`C9@=]OZD17FP3`)8)!7X*;$F^V.*`!>AN?#8#6V@.J#`()(!I]GM(!YPV
M$7OYA'0#P("[5$.Z`RQ``P(@P`7R!1+B+3"&)>E3`8I5*@8X)5VSL8W`QC4B
MB71P(S:K$0<2T#?.T"8`^<G<!YAD'.[),(JW*LO$#'"!`VS@>]=;3'-:-:(:
M(0\G``#*&,N2,]8TH``VFX`$)M`1CUR@=U*<_N,4!:"!`'1`-Z:+E>=40[L`
M+,`#4"E`!HH'D\%A@``>H`!OA&<2#W3@`IQZ%LHVP`$(9``##HC``0Y0``(0
M8``">.-,(O`!#VP@`AQXP.QR1+[Z@7*43%,?+0'@I00@D8ZZ;$@#%'.G6*D/
MBIBA@/TPP(`!^(8#PH2(!E+4`0D0:G9;L=D"*.,!!]2(`1NPY`4ZL($&,*"%
M"T``!!P`@0(@0`$!F&4M:>F`"G@&`1%8@`"\V,Y[XC.?0WJ1/FD9@5XZ[P,&
MD.,N"WH0!'Z``!9X@`$\(`"$BF5[*=JF!C(@`3E-5`-2NX#8*'"!VD&@`168
M)SV[5(`:W;,!'/BG_@-PZ$I/?G(`Z^PG36MJTYG,4@`HI6*K=`,4W;"3EJT"
M2G2*(P#;6``"WM$+`CIRT0$4B'0.R%6K,M"G]-6REQ)@#Y!L9-"O`L@M!OM`
M`'(%)8.@C""I6:0&(.D`,BU``3DZP``^28!1VE)4&J"`U"+04@8D8`*=7,!)
M[RJ`H/:3E#>]J6+5EX!6-3:?S]/871]C@0#TYG06F`!@@O*!`1C``(B]YT<V
M@*&/F`X"/>E)L2#@0L_6JE@%>.,!=,.>&@4O+S3I$\OLJ;X!#(``$-AF$P=R
MHP-P0$D>>(`'(-B`!T#`M?`$*W4+@A?U/3"WMB1`C?HTVL6"EZ:X/=0`_AK0
MJC4*P`$#0``&!$`6!.+39LUYK`-ZPB1!-J!L`CE`F(2R&Y8UM:O\_&V-6#:X
M6-K&H0,%`)`F=E?HZ89E83+``"S0$?9@LY/\G9CZ=#-*G1*@DW)-`#1AL]:!
MP,62Y?R`V&JR@?Q,X`$/B`#N*$`!"QCL>-7=<4OXZY$#*$"_FV4PD2-`QGQR
M-WP`>,SQV/*6F14(+QZ```.89)O(YJ4YS5&G[;S3-`/4[F:UDIM,YWNS`Q@@
M`0>H``[5YY3.C3&'MJQE4.D:@+H*Q&,3,,`$TMDPEBEU`1H&<@(:,(`@/T`"
M$K"Q!22I`='Q.-(#W-\$#CBQ?#6U+%)E0`$\_@`4NM;RC4X!"@+&&UG%;@"/
M@_M`W\S[T$@AH#F@SLN=@]O)',VN`0[8)`0NFA`/;.5/B68>JR/9QAOS)P./
MUMOB).WL/7FF`.9]0`&&C;8*6``#_4D10E*TE0G(1@*I5``X&?#<!UA`E9+\
M0$4]^.QWPSO>\IXWO>MM;\1`^M[ZWC>_^^WO?P,\X`(?.,$+;O"#(SSA"E\X
MPQON\(=#/.(2GSC%*V[QBV,\XQK?.,<[[O&/@SSD(J<NCT9N\I.C/.4J7SG+
M6^[RE\,\YC*?.<UK;O.;XSSG.M\YSWON\Y\#/>A"'SK1BV[THR,]Z4K?^=Z6
M[O3&8#%P%UCFTZN^I!<*6CWK6M\ZU[ON]:^#/>QB'SO9RV[VLZ,][6I?.]O;
M[O:WPSWN<I\[W4<^UKKC/>]ZWSO+F\[WORL.\((?/.$+;_C#(S[QBE\\XQOO
M^,=#/O*2]W<$"#IYMV/`W4GQ^^77[H$#3++SHA\]Z4MO^M.C/O6J7_W!.)`R
LUL,^]K*?/>UK;_O;XS[WNM\][WOO^]\#/_C"'S[QBV_\XR,_^<HO?$```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>f39432a9e3943239.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943239.gif
M1TE&.#EA[P'A`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````[P'A```(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!?>C@XDV#-
M@AXR?+@9LZ?/GT"#"AW*<N9-HSB3"N0@8`/1IU"C2IU*5:8#!`0:S+20`$$#
M#A\P3&C``*R'#A$J@.4`8`//JG#CRIU+EVH'`0XR%*#@X<"""@(D?&`P0$)7
M#WT7&!C0@:V&NI`C2YY,.:&'QQ0]$-#@X0&##Q8>4`@\&,*'"P%R-M4PX`*'
M`$XKRYY-NW;0MQ`]#.#L@$$'`P<B$(@PF,+IU!,`'"C0=$-JV]"C2Y_^4S<#
M"@0J:`@@`?`##PDJ_H1-G2&`!@X+-&RGSKZ]>_8>P'+T(*#!`@L[*0"/T*"#
M!*<9+(!8!`,,H$`'O[VGX((,-HB0!UK9)%!-%$[X00=N6>C@AAQV"!UN'H8H
MXHA#>8!!;CNEN--;2%UXXD-Y<6#:AF>1:..-&ND$408,1-"!0*&]B%@%%1CU
M0`$U<2#?0(@Q&<`%'DQPE(0=@1B3DCAF>9*5#7I@P`,&.!`E`0X(<,$'"PAP
MP'`>`!:`>-@9R$%G"A#PXDYF;C`!:!,LH(!3'EC08VP9<4"HEHB^]Z.(%QCP
MP086].4`!PF(F0`#)A8@$`4)G#4`!AL0(`%X9MIDI@4'H"D`!0TH\$$&_@94
MH$"GB=9JJY9<>;"!!G<9D,`!HP(;EJ8?/."J!0`@D$``Q%6*TVZH>L"`:=@5
MBT`%92YZZ[;<<MC!;@LT@"8$$`J&@'$8T/I``A]LAT$&#6``WIXV#<!!M,)B
MYX$#7S[P'75<=BOPK1,8Z!:L`B30`7CBI2L0!`-DX(&?#0R`W[4\W05IJL!Z
M0`$";2;`P00%:!N=R0.GO&V+B#6YXLL7\HK8!!%DB,&2$_)U[P<5Z(3!`Q<N
M,``"=TH7L,I()_W1PBJ['-)E2D<]U=$/4:VEU1=1C;747'OT0-%=7X1S24Z'
M;;9(?1$GV]92L8W1G&?'_72LLV4H]]V)'@K2_K5X]UU7V;6Z+9$'?,\FN-\W
MQE?5X7,A@!_BD$=>V4P)8":YK8!O26)C`%=^^:V9FQ0?XQ^REX".GZ<N=8UK
M(X"ZZK![2#IM7M(;^^T.,BV[`9_-CCNB;G/>GMT=>E"`8&VWB+:&OV.DNT.^
MSQ7]Y`:H#17AM%+))$VY41!!!!.\OCS>TS<_DI?6/^6<`$N.SF394T)OX`$(
M6$PV`@X,7'Y<4.ZD7M@&L-U3#',\@3```0$0V0<BD"8$/`8"#C@=6@PPJK!`
MJ0*/PXFF$`,!`07J`1/X40<TD($)F"4L$H#;62CP&-QT0%XS^=;8;(4@!AF%
M`^)+6E^,<SU@00!3_A\@`*88\!D$'$`##P#9`08@'@@@X`(%*%(%"#`!`>1P
M)W:Z0*-&=8$!..``KL*`<A1P@!\]@``*$`"Y.%``!!1`0`71"_T0A```S(A;
MH3/?7`R00:(XAP`#8)_Q(@5%\`#-.1LX@&EV^`$'B.D#"0``\@S"%@4L@`#F
M^<"]X`6R#-A+-QCX%I2(N,!."J!H$R-7>#0Y`+WI\95H.T`?A_*`(V(@BL:#
M4ZH28)H+".`W^/%2D?B#&`4$()B4',!,.&"G5Q&@*ZG2"Q8O@($![&0"F%I6
M`080@*)]2R<_?!1L8$E.DAQ`/$_AP`!XN"[=)(`K@DD``3)@2?KPL`']_N'C
MF!Q0@#F%DB#JK,DYQ^4!"*3*`AO<C9<NT`%G&;0Q$<#9#B<6`<2TDD1Y+"=E
M^H).HKRP)AVP0`<"X!D>"I&7/[)`;-!3O9T\(%)IH=2A.O#(#TS`-!8P`'#>
MB0%7@<<M)"M``,242`48<6P3.``#^AF?BXX(91I=FV8Z.K5&:FM?\MJ>A>+'
M/.W=I(9=10Q6'O"I"9$01!JH@+:@&M6V6J0OLZ0*3_97D9RXAFUT=6NBL@J3
MO>CUKX!-RCJOUU60<'4C&=5>8!>K$,T(\'P3>0!9'N"`]'V$`Q10P*000P%7
M9J8A6&*L:+4J$"J*;H8-Z2!PII4BELVUM5K=_@K8P!.F!!C@+`HX4V%5I**C
ML(BW.`&.4GZ;U]$63[&-%8C>'/O9B!QN)A`P3DTHP`"UZBHT-:U``QP03$BE
M92=Z68#)-+:3>%WH1Q_,@%,09`&^S&0#%8!`;'(R`0MP1B`8D(#$#K*=`,@'
M,9%ZU'X%$E+4(M>X60I4^"AT,R[=9#O/(]PDG<M6@DS@OAB)``\_8)B/D>N2
M'=1*!M3X@%_2-@((D-(MQ6L3!"B``OOUDG$BH`"((2D"0TW``C0I``8T`$DV
M+4`##@"`.47@`&>\XT`TL%T%B*<O9.H,`BXIL0R@<;`*J3""1P2!`J119TLD
M`,A"P\&%H5@!)\+`_B];O&&<<`!*1KD,TQ17H2;-Q*^9\8`$*NH`'FKFQ0[8
M\0),HX%4!:H")0;+Z:(T(P14U"8=H.X`#@"6`DCL`#HQC)X%M(';!BJMC"&<
M<;:S`:9<>`+L*LBW*"`!G]*M`_/L0`.`=B]**7G+`JN>!JX29%DKTXD7(D`'
M1FPL)%F``+RM'8@06H!YMJN.!1#9!?*W`0<LS`$$8-,'+,TX67?S`]$U2@&0
MW(`]-8`X4_1`HQ8@@4\:X$S\$<BYXXBIL\3*>!)S]@1`)MG+(*D#"#!``X2=
M2W%N``,!\/(;WX(:(S+F`PA8BP`$$,CO='I-0,.U_@*9;7$A`&A=]$`$_MC%
M1LZR2MC'3O9P:&(`"G1@`9B*@`$XP`#_[OLT_][+B)UBZ<PT``!:T?.&'?``
MS(JK1R92Y@/$2P&%$@`_$?C,!VJ<,8OEA`!0,H"\9ITN!(#[,QH@@,<,,,+;
M%DMD$3`QUB_S:"8I(.,)D%(!8F.`#(24+PSX3MZ+J_'V'&!/%MA3H,>T+TQM
M`$G5]/%M<SI7(0/W-``@P&*\KH`]53/27K\\SQBP`/]Z"6P/L4`"T8L!W3XJ
M`0(HP(E>^BI7:6";OLH?`TZT9X%\T60%S;87$;,`B6T@X&(6.;DV@"DV%D"G
MQ&DH`9CSHPIXN3`%\64+.?4;'1D4*U#"CC%+_M9W@4UQB<:QP``&#C((Q$H!
MRF3`@<ZH9Z\71($&V8``(H`!"N`]?Q6`#;`K<-MJOI3@6C<1:C9S[R,A2%%G
M9T$A![A5."%G%5(LXY<=+H,4!58C#T!2`G=#H&(0+3,ARI,3$'!"]0=6D<-W
M9/-XE*$!G340&4!9!X`8_$)TND(`J0<L?0)<#!`@1=)BE1(F']!T$K!$'I,=
MQQ<H6)=V=F<G;A,JFP$4ZF8!H&<9&%`!?(4[T9-88F-8TJ(`)@@3N)$30+.`
M,=-:*-,7`@``=J1J?<(7UT1$8L=A"6!_Y34`"?``?&8YT"-/<",4<_6`'(B"
ML-.%&&&"'C`KR2*(_GQ($2.&A@"0/TIA$QSP+\SCAQ'1`0S@;%01`1+P`.32
M?7\H/1G`B'XVB;`EAE.R@''66ZJ(BJ786JS(B@Q(B0]89SL1*HSX*:;HBAHR
MBX#($(A1,?U#%1"`A@$P8)Y(8'1ABP$``,!Q`$I%1)RG`)8T*PF`3Y;4`)<"
MC7X"<T1$=`S@2`X@`31#,QH&`>8(0FEA?ZP&`1,@`7OV/1``/JQFAS_D%YQW
M*48EC0FPC\J2`+.B+$2T``*IC[-&60Z`3YOHCC+'B`"0`!)``?1(`1/0C@H9
M`1#0`!!@`412`>HXD1=`A1@`*AB@`=1D*+NB`;LR)PAB9@$@)0G8,@D(_EQ<
M-9-4$C\=*)-==7AHV(3'*!EBU)`5<%,6J8D2X`#M&`%$!T&<:([QZ(X.``$*
M:9#^LI24A93G"$';15G^8HX.8$D6Z6,^EI04``$/4`$,($^2MP`'T(QDA`#]
MZ(_2N``)$&VV943TXY;[2$;["!P$P)!*A9?[N);'=WP&('EK4B`"`$@#D&W9
M=GR8%``"`)F127$!L(R5.7$3!YD`$`"`1(.`-'$T*``Z50"D:0!OZ8_*<HW<
MR'E^HH_2N%T'B4\!F7JMN0!&272.-!9022!H^!4].1DTY2A'\UJ?V(O)A2*%
M%3"DHRO+R(P51IRRV(`4(A\8HB2-L9(4D(;J_I$!4&@!%V`!WDE-(5E?$T`!
M&TDDX%D!W[-G[CB1#RD!$%`!"AF/]!F/(`1"ZL@?3RF0@V9,:/B"A/6;#@%P
MMB(!._E?+'%X7%B<K\6+R5F`T8F3LR@MRWAK?(B(4=4!J1(X#XF)QAD2&DJ`
M<1$?"_!8JJ,\$T%7&'I@!/%ZF+,34>2!*=$9`H"'B_,!Y78[)J(KGE4U6C81
M/SH?/8H8;/2A3Q4Q+3$:52@7"C!AJ1-V3!97$.$]&]$!KE(2&>"(!B$6&J``
MZ%$B$842K&,9S;02@-%V=.%H?<,RN\BC]+<3C3$G&[`P*VF="*(D>`J5C:$>
M2L*C*8FG)KDK='H6_@BR`0=BG3")&'2Z,/'!`2MY7AL0J==9:G>*IUEZDB24
M`1E0>AJ9`/675D1B?Q>@J1E``2%Y`>>1`1H`*I'JJ.JUDK"*('&6J!THACL!
M1&*Z$)H1A=RS(G7:6]LYG7=::I$*&`S`&1GBJ&`5'Y$:J5M%JZT(B%8SK?-6
MG$IS2^.6;6L)2&Y9F-F6>L!!F=Q$<1,72)@9`-QTF0"0F9N)F>Y*<6B8F:")
MF.Y:F8%4(/B*KYA)FI`)F8L92)=IKN8:F959L.C*F8N9F`7RF/;Z3(4)L*4I
M>:G'F!3'<<MG`*))L)?9F?HJFMY*FLMW?/O8%4#V$\YQ11PX)ZAZ%63D_J43
M$FC2>%\OYV)NJ2P&P(QJF8WRY&)PY"7\6!;*95N^\BMR21:\)`''ZB,'46H+
M\3P*@0!.BHQ2,VR:JAZ12G\5L`%CZ1EJ*5^^-ZKW@@`G>7#PA4,*P&?AHH(;
M$`$:4!88$DH=<`$B,Z>-,9(;X$0FQ`%'1*@/L`$74&KG@5F"D@%J\;<XU(*J
MVEDCB2#V]Q5S"B^AQ`"[0J@:$"D_XP"1*F>-\43JY18D"2$A"#7TQQF[YG(6
MP`$(``$CV0`D::A0:)8:Z1MYT0`\(HX)%Q2A:%GGPT9E=!IW<AX%(2Z[%5M&
MNA/?LQ`6@+(3TA\-,&&((0'":Q!6:J-OA:M&_C,ZG!%IDBL!'7!AL\9$?ZMN
MYFDH\9*#$Y!?'!!1#K1G7R$!*,EY%_``EI@!%14N.>ARVJ%A+]5>-$>%WQF'
MZ3NXD_*:=_MR/&*H&+``&,"ZO5>B";`!E<-""CR7>2&V#:`?Q`<F&#!["7`!
M7NJI1LD`<KL!"P`FQ$<!BO'`@?<7$_`=7FJJV7&LK@-C"E/"7;D`462'QV9V
MI-C#AP6=7A56SA%@/;R+I$63S--0<[<4>ZB*'%;$C^>@S,,!@D&<#/B(;D&"
M,]'";&H4N_:!1TR\6[6@TS$Q%.``ZODS%R"VE,)N`F!)]`2["GP`;RRW7"&W
M\0M&&(!DCN-`"Z`G_BB\P!M\)!9PP0Q`,Z."C9);/^6+'FU+Q9&8`0D@<R6$
M'A=P'4?BJ==170_`(Q=`NR)\0'_\P)([I_N;=K,2D@'2`5/$`!:@P*.L)T@;
MOY]<?U0X?AJ6``.P`)],`!"`(08@7MMUP070ML2W`=ME92"#IZV*7C`YJ$2Z
M*(G*J';6BM!*AJMB*"BI@N^RJ=^I1>FYD100>!5`3::J1=^ID>?97@Q@1Q\Y
MA1@$A1RPS:I*N)O:S1QP,X:BS>J1J0=W,RB9`?.,DAO`G1J@NMY<>AC@G3T3
MJ?T<J\LD`3?#JMO9>YH:DID5@DI2T"Q$0LQ<J'&ZSYAZSZ=J`8YCC+9!_B2@
MPLH8T)6&ZLGEL2HPYLKT=SH1=RUBVUGR*0`F#1P:P,M'=CJ\S,OQR8EE66XM
M?%/^TE,9X#@630#ID;<OM\&!5FT+G`$9^<<7W+PC!)]:!\K[IB0M5ZJ@XCT9
M7'<-L,:7?'CP%2`_;0%=R4?<:Y8]8JK`LL&)],@JK*%9BBHD'(\8>0`M'8]G
MV)>6N9F2B9D8RQR+&9KY^J^)29H@VVR*:9INM!@&0)B270`,V=F>S9#-N9F(
M_=FD3=JA38RE?=JFC=J'38S-J=JBW=J,>*Z1'9F=#=N,B-NY;;"BS9"3#`&6
M))`^)ED_UF<K*A/>(R]9JP`EI`$FU`")=):[_O;35XT5]X%FF/85Z]:V$-#!
M(LS`''G)9(E^9SR1FLA=>W&L$Y`5AJH!,S?!"7S)#F`QN14ON_G&\7539QP:
ME]S2W`G=>ENZP\8`K885A,L558L!`H<!].<Z$'`!4!E=XWS('0!"V9$7R^'*
MJ">Y.,S<@S8MJI?6"M``O'-LB'V9[HJODN=&A-F,-:N8(!NRS3:9-#X`7O::
MJTD6">1(4PE!_`ES^$064W:0??NW$RF08"2;:N*60A,`"P`^[?A%#TXDY\2)
M$=!>6A1?K#:1ZO@7XPR>WWF^U/12]M=>]@6>&JG`(?DNX)D!J%K"&"2.]D>4
M6(G1(6D!%AGF:_Z1_@]I?QR)Y^]Y`>79'7)N?Q>)DRMBO1]2:^?KYDHE*!=0
MHB9=`&L=DO<Q`8V"`8[SX&A6;I3N)T1SOD>RR:\,X8A&%H@,E=#+>6*QQJJ,
M?O=17>[;>]A2OH("D=B$`>SXCD5Y0-K5TA101H11WVNK`*H'/B]&N[#,UKP\
M>R*\;[*DD1)``)R8O@%DEH?WR;`2()(\,D,VV`:EP>&R`,KAJ*6F0KT5MQ+S
M9A,@)K0XH3>I;D[3(J_!%VXA4CJ"HLEV0O%S`9,D?I;E,4MB;<L4DI5[%JN:
M;`[AJ/&7<4QB.2&X$^CT3PD1OZ\S,BJ%//&Q,)*(7)^<9>XG'2/TG0]`_LL-
M4`'IP4`1MT1ED8/7_7($(-B>>@`7<$Y^PL$5<#HB?``DK)Z?+%(5@RW>(U^J
MJT@*W'3]T1A']$ZG4]^CP5`D_/,0$X<$KHGT-WOP+0'LQDS$5WH<4'GQ*&8=
M_!5/U'1$<T3,32Z:>/+-VR/WLL=CH>D)X]Z[S"/UH6<T9NP!LL:'1P#RYWX>
MTT]`0L;`7?+UH59AU:L3LL!(H?7BYQ0;``#$P:,NLZG$IUX>^&0$4="EF(!=
ME'%[6%#W!1YS=B'B@O#T(N\I:<W1NA-STA<(.B$_,GL%H6%_:!1H+,WQ$6@Z
MP0&L^T!XF!.H!->-!:#3@>7CK%T#8``D7*IZ_I(FA/O3!U?AG7:WZ:(!3W2V
M9J++E$XT/^;'J)K&\7@!$NG<]%>T:\OWVB%/@OTU1$,D$<")LF*>9^P963J6
MJMY!F%M=9HEIAP<0"2AD\+!!P0$,$!P0P,``@P(-&S@8R-"`0P4-"BX\6%"`
MPH,*'0H\L+A@`(0,$`=H:(`AP88$&0YH8$!A0(8($3`TH,!@`P,'%P@H\)"R
M0``,'SYD@-!!J8</'CQPB*K4ZE6L6*%ZT*B4@X<(%3A<@+H!0(6G5K=&Y<#!
MZ0<+&T!:4-NA@P<,'30HW8!!PP`#3CU`>&#UP08/%#P4L*OA0H8%A=-V4.``
M*H<-$3)HF+!`[P2]_HC;;N4@`<*'#@+(4JWZ\P."#%<]+%"LU4(%!PL90(C@
M0`$$PA`F.&#`0(*#"0IB6R68E8*#K+(91*=>W?IU[-FUJQ5+0<*%"@LP++CP
MH?(&"@$8<'B@`<).F`8T(L"`8".%"`L<R*2@8#P%`S1XH+<*,(+```(D,*VG
M"RC8H(`*(MC``@+H6T"#`SIP0(,-^WH@@02XHF"!"BRPP`,$%IC@@0E8NF`"
M^ABP@*"/&/@+`P[H^B`"LB0XX(*Q'EN``P84:,""!%C"P`'O*+A``PH@2$""
MOC:`S3,,"E@@`PH(2,""@Q[(P`$+&DA@``D2B,"`!A1`@`,"%O@`@@+Z_IK*
M`@K>4DJDP+:[RJZG+MA`*8VV>H`L"P"@0#M#J6S.@PD^F,"OBZSJ@``"OHKJ
M,:6&&S0J`[ZBH"T]-ZU@(*PVN``#@CB`L@(,)#!@T+LLN"NBFG*$"K4*$"-`
MS\0$RBH"".R[@+X*(.")@@(C+/$["BCX$JH.,-!1M@:@JXXF/[OU]MMN,9@@
MPKPX>$F#"`:S8(((!.`@W2<5F.``"0K(Z(($&MI(`=6ZI(B\^N25@+WA5F31
M`@7':Z@`!6`"D$,.'$``H@=T7:`WX3AHX`+@)(A``0L>D(""V[@<X``+(/CH
M`88D6``"/#O0>(&05\0,`YT:@("`"U8ED8$)_B8"*H(',"``S&,%L-$GU60\
M(*4+#."X``,FL-H"\I)LH($,!&B@H*2BLB"`7[&*Z%L/6-YU;4`UZ`#(#RY0
MU#G6KHITUSV7BPJOO.#RH`$!"I1JKZT&6SN!NZ3:NRY@U?IJK:HTP*"@GJJZ
MH(,))%B;*JIFZUQL`\)6*ZH$'ICMLD$]2'9=#SIX``*I&MC+/-.KPEM9ZS98
M`&]O(;<=7."WP^NB0R'0J`$%*VI(`/(:Z(`\"<?[\@$+',H`@PIVRP"!GH:+
M@(#LE36-Q0$(B$`"!B"[0`$._&O1@00T^K*`BK"NF:8"(M`@`X_YQZ#J"?3D
M([#R#]$DD#D(["]P_GZ)$@1@U0`#/(!Z#+@`3S[&@/!<@$03$(Z8'N"Z!+2D
M`BC20$R*HY,'L&DG"(``QP(8@0+4RP$&*-V0$("`K'A``GH+GJ4^)1NKO,PJ
M<EM4#K%B%\3(YH?7^\!7[/(``$3``IJ!4F,2\T&E:,!>I\EBI-Z%@2+FS5(5
M$!,/E9(!MXAN,ZI*UP<J`!&[+.8N&7`*!\03'101Q`&#VL``!M6^I'@@-Y,S
MSZ[>8IH,9"!U$FB`=32P.W#M90.640H%9M=#3%)'=QN1RFQX0ZP-5JA!9<K>
MO0@`)3`EZST5,-\#!&``":RK/\A)64X20B`'-&0\.&&`O2XV*X<0J6)!_KI`
M!`(HL@F\J`(9J("9)I!*\AAG``W(W+@,4(`&T2:1MP$1!ZFVHC(%D`$"F,"1
M5&2:+#&@`1'*@`$JD``[%@`!6(,`.1T`IXI,@``<-``"'*"R"S@D)@4XP`("
M(*>X\3%;L\S)`LB32:7@R%9/R8]4*C`WQ?&N*AV`P(2JXA4N>L`"HF,`%"6S
MMW%I8(H<@``'\J*``O"N(A;IY%4BP``]`2E6U^J4!CA0Q*DX1"D3K<"DR&B^
M=D8@*@X1:>V><JC?%`8"#)"BZ[15O0.H2FJWHLH&).<6#[A'`M:!#"9+!5&T
M9B6@0'H1A'C#RC<IH$)E^M@;`RK!AN`&.,*Y_AB,+N"`"IAFGT2+4IF$@H!U
M'N"=&FKG0V`5/WQA8``XLX`#&"DR3!ES8^2ACP%ZDKV4R&6=$V``I,B8'P&$
M!:<10)X'X@>2_!2(`A@X5`:`EIGL$0=KZ.FG@#Q`$?I82601B-^II+8NG12`
M`0LP``,,`!P;3N<#V1J,Y@KBE@Y(1'%H79ND1N@!(MZ%+!_=U%J@@J/1Q:V[
MZ?D5WB[ST:9HH'5Q>DM8(_`Y\O[.O/5MXN>ZF\74J<4#3^,*!S&`D-9=,BIU
MI$S[%)``X*!H;ZI["'@&Y=-=$:0@#CA?=50'R;0*+\39P<R%&H:0GEE`4!\X
M``)XU*(HC>@!`V"7_@082+T#3',"!$4@*:F'$I<BIP$30I)<.D"!D:PJ`PP)
M&DTR,$4*7"W*FGF;Y&BF@`B&)R-E(M+%GL,2CV3@2YY)5]4X!ACDA:0HDFV`
MR&8+GP,8#TEV].D&-A"GD$E@`!@[VG`(,-L!1(8"LBLM!1/P(P`@M)-OBHY>
M-`K1M3FF`@%@UP8B%978".;([L7*D]RK@0`@0+X>4XOF**J@$6:(HLZEFJ:H
MQ#LD/9J0Z]R*Z)C3'-D<@"HGNDL"RM.!L6+%+7!1TP=&=(`$,.DA"Z!781Z=
M%059)SS/'C$>JWV=N_2%*K\Q$8HFQ0`$4*0I-K;Q>"!@F@I<()8)/,QX_HIZ
M0`<<0+.2>Q&1I@H?"4T`)@+J50(C)A(PELA!(YU8,C?0@73G"60E8<F8>#(F
M#&#O/11:Y08"*X$.-*`W&:@Q&?_Z4PX\,WTZ6X\E)R`?<7%@)C![R,@B9FD-
M(*#&*"&.`R*C@"@I1VFH<5.X>0@9`P2=?9-":T`#%12>C:YUF+'XD[,;5MYU
M4E.H:7'GDJ@5J&!1*:6]BH#LO!6,C^5$;#&O4D:HE=FM90/+P5L'#/!?^T2%
M9++!`&)<)I;^?D7-.4K28[I[W0EL)7/47@K7KSUB4X,++P4I"E[B.*?):21H
ML>ED02CXMK&H-`,/4*?1,K<9IC#S>G:.2"+7_F[G:AW<(78>D:O>UE'4MZ4M
M'&N,S,KU@`VY2B)VWE@90][1);5%NR!14,>R6W>.+R"6BES[9OS3%C0N0"+9
M=4!CLA1`"N&H`D^;4XEL]K4-<:1KI7U7X2;C-M)TE+R<3DMZU]9)MWDEJ.,M
MW`0H+_72HS$J?D'-IU2N:LSX"L+ACDTS#(3;%2BQE/>KBO:QBR=Y"V;*+ZBX
M',?XG8BS"ISBB\G9D*6@B>U*BZ!ZD[K#G+:`@,C0'[!B%?E:"LQ`#1T:*_83
MF]/XK_5KOQI,K_:+P?^"G*ACCKNXBP5CE`(H``%XI0(8@``8@"$T@%<R`+(9
M`"@\B@"8P@``@`$H_L(BO$(BG$("(!L",`#`$(`<N\+RP10NI)HEO,)7@D(!
M4,(O)``!*`!,(8`CQ)0HG,,C',(VE$,$R<(D))LMO,(I+)_R8<(V)(`HE$."
M.@`#.(`60P`009"3H<-K@D,H1$0!H,-,))M,%$.J"8`$8,(!0(`XA$,BK,0N
M5"Z':H`B>;`$6(`'*XZ)40`C00#GHD4020!(O*$;<D1'#+IP(Z@S&4($D$-'
M!`PE7,("2`!Y4JY>[">J";>@HQHZ/!-D2X`N_$(P##<$&`I>9$0$T9+(@``H
M+*D'*$;:>(#?4)"<^!@'>!W\R`T.NRD"X##>V"N%>$=;G"IU>IG>()96_LJ6
MD7FN<_0-!2`6X'B6;.F,0&/%-B$`%'L;W*.I+"J^ERF6TL&]W"")K1D0R3`-
M$RRB#F`M5BR.!5`G=?HGC71(O2&MK7F+GRB.Y3K)%ML:=7*OQ-B5AC@`G/L`
M1CJKZO`JGW(]NT"BT`&Y+CD1S&B,R<(1-!K!TM@+B*"6P3BXUOE!D6JC(Y,9
M!YR<M8.DUE&JUI&*.`H9K!S+M-$PF;&3^]H/NZ@LB4B@HH24.Y.(MA@I#8@(
M.[,6')$9V=L]V6N+<BF([`I`Z.N9B$NDS=!+NY0]F7D2Q<Q+TK.S1`K,MO`I
MMQ'*O%S,B`C,HN3*_>&`Z]F,B/.I7DD]O[0S_E>1G(A#OC5*33A1E`,``"I!
M#-L#D@!4E8BHEI+!")4JD-NP&ICQ#JL)H&B)LKDP$0D(+'&1@(.,%@<J$1/I
MF551S@`R3MDB&7HZGP`2N"A#H+W*B]8T/=1(B@[(`"!I'8+0"+]`3Y88"!-1
M,2=I3061BC72+J?0"["J,[W(RZ'$+B"<L*OT2Z:[E8C8S+ISJ;_T*E@)BU[!
MBP:I&^O(.%HL#A"11AIZL&Y$@`/@"73)$\<`B9:*,AS1'XW0(">)"`I`+#L)
M"8L8%QS!D99H"H<(/*:P`-%4N;K3`+$`#V-[G;01*0'Y@`VQ")R:B@^HF,'X
MBC%QB\K($8D0E!1Q_L1D6RX%<"B93$D':`!;5,?X*0X-58`!P#(R;:X%R$64
MC!];!+=&5``&B)_X<=,4.;1&3`!P.X!E]$5'[,4;.C0X)2A:/$D(DL-BK--'
ME,/X<2@WQ4:(=%,NY=(XA46'.DDCV9K<`+<!````$(!$X[SEXDD&&-,,90!&
MY,F38;:@:ZY9Y%!DZ\4]39&97(!P`Q%PT\6"DH]7A,96C,4B:1,L.X`WO5):
M=!-Y6BY(#"&9M$=IQ)1,!,-*#(`XE$-$),,#2,(O3,-2]))=Y,53%(``P%-%
M),0VS,(C5,)K&D(^I)IK2D(L!$,X1)`6HT-,649(9$2"&@!=I*%$I2HW_I44
MJP%*#_L`B?@HTIB*/+D`-)$<DKF>"$(7,H(Y,[$(%_N.%K$1_Q`/O_BGP$F`
M9+DI/P.:``(?X-@)C`B9=/LK&*DL]H":6]PEZ;,(`Z@>F7BDXO@?F*B/AWF[
M=[$.#"B/Z@!"J:B^FH(45Q$48QH5)!HOL/*J@^N`'[E*L/JHI].OR[@D7'N*
M'T2-L0@KF<DH6]D*F.FHJ*L-V5C!JXA-3:V3#P@DJQ#`BS`OQ!C:!6L^`HTC
M^$LD^<JNQORZRG.;K_"JNL-1S@@:]40C_^0]'KVO%<D2E3H2QV"2"_&IPSBX
MAIF*9=)+`5&DB)B*_6'%D;J>NNO9F+@I.G(;_I7J*#I:2E=YG:443Z\*BJY5
MI*6;ODY*'(Q8,+HPI)&L/N=IOX=`FQP)F;8-)!NA$.4;`(T9CNP!$PM`@`P2
MM0,`D`V``)Z4%O;`UR59'SQ1)O*XC0NP%=P8H1UJ#\W9/,VYK[K#*<#".(OZ
M7@%A*<=`/@]0IT=R&^=,FWN2KX.+I0+`GJ])"\H;*I4"VJ=@VUT1VJ=HO*DX
M.-O9C,1(S]^9WK\#P1RDX+5801XDV`6CBF+2E!6DGK1;O[&KX+@9$TT]X709
M%`B.BB0"NPI`@`TP-:EP%8&-EJWX(:@XC@^$BA74KK2HOJJXP+/=FQ':T:<8
M$I<JB,`K`+=0#(%+_A(W;:ED<KOVP!.7JAB$Z5$@:0XIVHR02PRJ0Q@R0XVW
MR9-J:;SLNIP6.:`)&14"6SP5*\^>=:*GN*>HV*,&+HW'"+;SPHOI(#Q-PC#!
MD(JF/1(`41D!.+B\4(P!4DU6\:KS<0OI8Q5%PE&=<HR\C!F_P!&_I:*^N*^U
M##NO(E#LX=PZ*P@5J9;*1",E_93EF]]APS25FPT%R+:^)-#)Y%PTTHO/E!F8
MT8IR0B<6EIS\Q"X[*V+^B3_94+.Q[$_ABPM5B;ULLZ3`W#T[:SK%!%T'T8!K
MJKL2V4S0_5PTJA+2`P]./6$`"``5&REH%DJ\G<MQ!A3%0*)3P=JHN[JK_B`D
MV2`+I]J_K,",P@$OKT+8O'2+%7':HN`20=DCV@`KP8B)RF,\[SB[@G4>33$_
M\+6_3E*5W9F<RI.4'!7`UI'@;-.+!0N\.$H<\+*5M230S0":G@7=!BFFTHI?
M0+:*\=@:GF3&+[Q2DE`(@B)"`>!0="V?)817#JW$,YG%!Q.`7/Q26YS&4'RP
M@S`)60U%1&1&!!A3@F*N1F1"B+PA>)4G2OSJ0SL`I^9&1(S&4>1)1S1#.JR,
M876HD[%36F1%!RB`W%B`H9C48JT07`S%6813AZI26!Q69@S4@RA6$*'J!6#%
M*WW%F91)0<V6;/'6R'@=X"":XM@:S]Y(C22,_@%9``#X)P61QVQY1R/YI)Q0
M",)`YQ-&GGF\*75*;<YC$Z!HKJVQQ:M&5X:!U<@&-S,!BLX^TY/<U0<[4WD:
M5ERL4%F]QE",4YX&``;`E!:CH5#A$0MPCT=JZ\6&2*>&1@[%,HAD1JIAQ&)\
MI4.KUU(=Q7#D4`[%QD?$;F2K:SI$UP/`%,'V4UK,;S>)TV%EQ"L];)E$K)$X
MTS8K*>!8+F`['X!MM'2YE;C=%=GA"I$B+45VB[\**PE`%T6""_S@"MP$C2'#
M(D?CN);2GQ?]"GD9B`PH@,";BI:RO;18J1$JCQ.!$NL"+VH9D@!FEJFH/L60
MBKS($*)#BUU!C&5:_KOA:!(G*ISF^*XFZEH!$QNTQ!M"HA:E(F,;E)DG&[NN
M;9U<`X`*P5,"B-M>(M9PLY4'($(E+$(O`8`&@,4C;-4"4$J^#M?4Z@]TKD+:
M1(FKP&$6%EC*(!S62*`)/)$9EI!7.Y&^6,[R`*_.$9.UH,#RJW*\:&$LMR/A
MNPP)P*'+&)7U$`N"*'58WK\S7A?GV:[+F1/0$)0![8#22HX81Q?'>!O;F>&R
M0PQ+`XW'F8K!P33>L9;$P!P>CYN_P@@$*(BH$`O<4#P*O@KVK>7`HADN^8B`
MXA+TY+B?6A\.`5;;N@@CV8F,@`PDB1`-"1D@OQCLL2W.4!46[14`U2:Y_M`5
M.MJC/;*_CGKA]+DOE:IE#9*<"!C)BV&,<4E2S1"P2&>;HMA?@VMV(+Q=V5`1
MI2BFN-&1@AB4'.<BLYNMJ[@>J4.L<YLBK"4HYOG"`"@6R(BW(TP`VG23P,'3
M`7"`0`N`@U``LGFP+CR,:.&9DQ``EX'M`;@`3NUG[.`*UJ!!&P.BW[D9JV2^
M*N&=H+'-KKNTCQH5M=B`JD'X"GIAIX@+#&D^6^$:1Y>WHE#0HM&)9\IA0%&`
M)3\@R6F=`T".BKD<(0^\KQMXC/@:5LD3'$VNVQBK[&HIEKJ+P%.+"T&,1&J*
M=(&(_1`72T*,F%V1X,%ZOD@7D8(*,INA_`B9_BRY4O6)B>K[I_0)G0N1$1AV
MB/3YW@_IWU49K98"'XL`D%QJ&)S2B-ERB)/LWQU*GQ.1%8>(`/P8F7+'.!LI
MJMB'C-FJG\`((+P@"'&Y"D[!Z;V@X>VJ@",T$?[229]5P*=0#IQN),<QZ1S2
M,//#"PFP0]JNQU/RB*I!D]0B@`;XLP`@0EN$J:&O[PN`\9GO4#P%"`D!""BH
M$```0@0%'BQ`2(&"`@X>.'3PX.$#!0P7/G#\X"'!10X7.'S8</&#!`P>/US8
MT/$B3(X8*H3D8*$#1YH6%KCD&--CA0P=?;Y,,*!BAP@6&BP8T*`"A0P')&C@
M\$`#!@X1-D3`<,!"_@0($B)(N/#`0(()&"),L/"`I@(*%28XT.!@0P,."39(
M:!!!PP(-$B0@V'`APP(,$"B<;9"!+`4(B]<.SM"!@@0+#"XLJ&AQYH8)#`(W
MV,``KX8*""@0P(#!P(3(F#$4@##T-N[;&RA0[`@8YP$-'E8_0"#A`(8%%AQ4
M2`"8@P/$%S10&(#A;((,%B8F4("!008.=B<TL*!A^00)$"Y`,,"`P^"(G3DH
M"'Q:08:Z#R0\\.#@.V.BC0?!!!/L5T`"FDT`00(%9$`!`T\]H-8"#`R@P`0;
M;>#26"=]T$$'>=U6@6TG7?1`2S1Y-`$'$Y!%%$SFF?@2!`UXZ--&0WF`_E-/
MMWG`6T,.#,!:`P%<@$``"$#`0`0#J#8!`E`J,``#!%PP0%\7U*:``PE08(`%
MK5DIP``!T(80``5@0(`%`S@`0`03D43!!AS(M5D%1'6P@$423.`2;R5)T-H'
M&"!`DDP4)("31QU(U-E+'U[0``$1K&1!5LR=)!%'%N2Y4@<&;"B!!QK$>0!Y
MR6EP@5ST(1;980E`,*$#%KAEP6*V5J#>0Q$@\%8$%S"`05X*$.1K!@IHT,!W
MG%F@`*XD6H``>RDY0$$$%1A;U@(+;E#7KXXY,.E,'2BP06(1<*#<N`DDAP%F
M%2CU``:7.9`;OCK>2!1'/'EP0%)J(;!`LAHD_E#<8WH]B^NL>V*0T@,9%*!9
M5!L0N&=:#D207P7#JID`?`S0"0$'"&B`W[`;/^"``1?\">P$%1C0``013$A!
M>HE!8`$'N\J%P9!^2J!M!`;\:$%)PJUT&X@W[C@42>#YF&$&*F:`@*<;5)0!
M7QH,E4'##7C-T8,Z*M<C1W9^\$!D!#P@0`(V;^:V`!.4J>0!#:R&P*\%-#=0
M!NZQ.8!41U)@7)<-,``!F@"(%H$"".0]`6XA,6H>5\GQNW0$#$C0**,^E;IT
M1XC"N!T#'FZ0@:EQ>K2`NN)=M!9%!""%[@,<.-6Q11<XP$$&&'@G@0.9%4#5
M7<5'5D`#XSJ0'GDG_D_J\K3$8@!R7P3C]T`"6*^768$9'$S!4AC4&C$$'DR0
MWW4>;%#!`1DP&S$#'2`F-@/+@<6J`AU4.H$"((`!#50-=_DZX$X\-",/5`!$
M!NC`63;@+N<LH#T:$&!Y%.`[!`C@`A8X0`&F]P"V7<!E#8@-8S"CEK8PRU@,
M$$QS'M0SOIF/,\F)C`5BQH#T8*8!7M(*!4X8'02(3`(X<X"5`#,8QOR+`@+8
MS04\D`'*+<U$)=O(OCSB`0QXH'XPXDBM1#<GN7P@-=NY@*,FDCH/H+%R.GKC
MASK"``44P&X9((#X(K"`!QP@`AUTD@"\XD($1.``"3"``Q"`H0.,,(`&_H``
M`2@0``D4H#H&0$C+*BF``"C`B"_A2TJ^1A/@->`!'6#1AA#E`119)E)#Z0`$
M*N+*DX32`S;B%P<`5KI27:!_'[#51`H0NL=<@``26(!-DA:Q:P7E84?2R(,J
M`)9LD<J#VVD@)5\8)XT$A@(+T-@+28,M>5G,9[%!@#1-69;_&.``%5C64A[3
M@0H$15B`V<!V(D*!59J%1)2$'SVOPBR%O.4!!\07`U6YJ@^T"%X%X!,"($BY
M!"2&)XRY2P,XLZNQ0.!:3FH`A"8PL<$\("Q_.20$R+DSGNSEA158@'.8$YP(
M>)-$!2I`02S`JH==I8@[49`>YR*TXI6*`"E-_M\J(T"`#3S`5E?9P,,\0C*?
MO`\CH?/(T#SR'H]XT"(ZZ@`6^=4!E60D3QQ0DT:\"J,LEO$B'1C;!QKR@,4U
MX(3H),`$$L"`O3+@`0/HGE/^2$G&!4``#G"0D]A4R00P!0+&,8`!`K`3!@C`
M`)$4P'9>,A*GC=4B._2`>8+G`$9IL(TPL=2FN.BZH2S41&>+U%ME^46/".<"
M`3"H1S#`(@$@(`,B`]$+!\B<6S6%=3%;0&0JX+;^["PH&?B(P5JDE_Q8((0@
M78"PHM@@>2V(FMYDC#UKE='_O)!K5RE+1/?)`<5H@`&(7(OY+/"0G7#``+NJ
MJT2^I8$"W.N@N9GG_@8(R$"/=$XS6GL@87()@<3PAP`58(YK4HJN<U7`20;*
M3/&,^"`!FB]8Y*NH!OB8'4\90`/"$=X$/!`L*8KEPAD8BX$F950.,`NYF_D5
M@4AE@-40*X@8T"F;"*#B!EY@)@F@B8H3*H$Z,=1#&6AJ3\Y5Q@.03"5DBPO2
MN#J?KG(D3AN8RJZ$)1/S(5$H*UGE`SUBYK@*P(D7$)4QZVB`M_E1D@P(0`*Z
M%R&].J4``A@480HPF@8(`))7<FPA]58="`A```HXB`.\FH'PY$:^).FOFBGM
MD;PDY5JTA<F.4LQ%'3E'1_%#T8Y.$BR+G:0#!\AOB0Z0(P_,[+`B.0S/_E0R
M$;&LREWE06:&=-O7S3@&`WA9W;FF*$]H=4R/>`1/L!9#T]VX92UU))9IA`56
M!3B&8!4PC6ZQ!5572<"W#T*C!8;&%0,<9SV=2=^ZX(-I__J(:SV)B11!B\>X
M><I!FV%/U<J3D8A5`$4;((!@M,.`.HYE:+[3P,RR);+<O;.WP\)51BF@`3Q:
MJVK[!"!OIKD46]K)=TO!F9>P9>RQ?$!BI`(K@RCYY'?_)(Z'H2(L?UP14^'D
M(EY\6LN'PN33XH0#)HG4=USRDZUY"E%H[-F].Z(E`!26``A2`!\9\E@)/)*B
M!?#S!`R+TX,0(`$`2`!F(QD`"-PV;SB]T)\%_O```BR@[`68I$U<??0/69FA
M)>&=U-TWD0:$D*%P?6X']CIJ3GF&/`LD)*.^[9.U+(U$[G/='1FE/CH)FLN1
MHLZ/J4.`NA!P.N]<7'_L!U9PS=.>`L16:W;H&*@&4=KOT\Z.)H,N\[GF.T_&
M=G1:U++P3$0X'NCD>DWEHCHMX`/U<Q%-&M@`6'Z.WKG)T4OV^0%1'1\PB[)3
M<$5JOFB.BR\&V&<"W+F=I%P@)<_5:02NE1^MI&9'BL2G5XZ-3PA4!5YV2C>+
M:(?VO5B"8`1\15I?54#[J4]P51EH>8`$G!7.[--=L%%8:=&L2<2/+9YZ;56D
M<(KJU-PL$4L6V<^,_FB1T9$12Y3$`I`)`@!6<!P``0R``13``````2!'89')
M``P`W0F&(NU5A922-UV+(BE`?2S`DM&)7_&-0AB``*!6'+V$TUB$F7D(%W&`
M5O3$WH%*%''$2-!'_#2*6VT'GZR$L44*`^%;VGB$,#4*JW1`1*7&IY@(BE1`
M&FX3!%F$!8!-+*7-1%C$QD"0H[B$HZ3.`Y",QHV5$6U@5@S0!?P%3%"$9>S$
M]'%-!+S5>0!<`U%B%PD%&UD`/FU1_,0%>PA>4L"8];V2@!G=%M6+H]`'/F4B
M@9@8!5P`'JZ,9`S&KF`*A$P:7AU&D96;?.&B4*T&^62(IZR<=ES'Q@"/_F*L
M5X`E'U<4V6%,V@!=4-78B6$$6`*D1)%Y@%AHX3O5"8CTH='@BM'UG!;=!*<L
MC65H3=-4A`(8P',Q$$Z,E2M-0!J=&3]^"`:Q"JA=Q'E8A%LYBF<8'50)!44L
M1@=P10:,Q(88AHF!GD9D!59`%:9`V*K,1/"X!E;H5#D6V:J\D_V$!SF^!P9P
M33::V$>BI*/`(KY9Q"E)Q(RP8Q5Y%3M*A$VL3W"8EN;YA`:`2!51#JV!3:G(
M2Q<)QU#*I)S\R,M%($V"2%6<1B9JX8Z`2`/)XT0@Y`"8G!9JS;(P!T)2A-&-
M!)U,I`881FG427A,AUO6"?"LSF&4QD-JQS+._H6AN,Q@I!OD0`D5K>('0!(!
M0%8-IDD`!(!E!0!."<`"R&`!$(!B6I8-[A@($0!FSJ#5^1ED'8!GEMT+=D=]
M3,F.H85G'@#?Y&!WS.#7%8!EM9-GNB:9\"!F?EVCE8EB\B"9$(``U*9K#H0/
MWJ;5:68`U%UA0N'76=T`]"9F-MHF)>8.)N9F(L``',`"7%)U;I)>5<@"(*%1
M4)0#1`ZWZ0T!(,E#(2$"6%9O@I``%(`,;F9D:J8/^B`#>!T-HN8,]F!\9J9[
M^F`[(0!F!@`-1H@`>&8-0I9[>B;?Y-EERN"!0J$"6&=3'$`-QF=KUJ`,]J"`
MZJ8+NB=D#<P!C*9J_N;9:#B`WCP4@H0H$GIF]P3``;1G>@[`UQG``E2(`J"=
M$R)`72E.H[E'Y.Q88AJ`#PJHC$)A#U+=D?*@#V)FF<CH<K;G9K8G9"WI<MY=
MF;#F</8F;)[F<FYH#VXF;PHH;VX2F9)):[KFC.;@ASIAGAF``A@6$NY57550
M6@BFCX@.C%10%ZE/GCPE0V66%JT$^6B5AYP2O\`$/WK5C'SA%AFE1RC=6E&$
M9[B519B$08(:!10E%[W5I6:ET:RE!"UD\.A116BAI++?UJP.$Z&1MJS.>OV8
M$=E*;$#%2Y'/+6)+E]#4`T@0J)IJ>(`(L&X-DGG57#`0=O6'%EF$35;1_H<H
MJD742.X,QT\(GAJ6Q'.]A*L5BE"DSYDQ5.A,9;),I*F.8T:5C$8\Q$K2DS3I
M5`G-!#@&SW0T0`12#W:YAJ<@!E3<(CW9RDZ4T`2T3'6!352<BZG&(HA`%0$1
MT(-%)`&=JF5T*DS4BT><ZHZ8!`2`HD_\!;,JJZ*>V88@A5H99+>N!`B.[(G$
M$1L6CYWFQH_<B%\<'P1EF?UP!/FPU:!^`$ATA,7@2\3@2_45RJ<PU,_>1BCE
MAFWD!MH8($NH2.`A@`<$!@<P`-/@%FY$Q6U0GKNXR-6N&=%>5:&8$D(V@(^0
M"M)F64>LQ9$$&+=VQ&7DR[Y,@-MD!0'@QAGB_L9,^(C1*.">WL94X09BX$9;
MH,2CX(;IC.W;RH4"M-R\<41@^LBG)-Z'."T>:HL;L:S7=L3TL>S0LI9ME(:.
M+!G+'BUN>!"^]"'+1IKF/BT$PE4@>MK*RI85GMF/=,:B8%?K>L1#&.0\SA-O
MU)?(\ERPQN)5'&RGQM(Y9NI4)NNE:MS3=&R*.:M%#"51K,>'O&.R'H!IO`]N
MM1KR^H@HD@Y8?$"D:2T6SAJ,>-&9L4<?%D;S5='GG.#(`D5FT`13.>MZ72H9
MJD336$3D0$"`#4!6,@J?R-*E5LVT#L"$P$6WJABDQ@2K18I2#`=3&<#FD*TK
M?4"*\6T426U^3&OW_GZ@HTJM!Q@3?_RMZ#R(`IW9V)S@/X[@!>\(%_DOZ>QJ
MM;($J!'%6C*K\NJ+%"W-I()5O&&*T8G'CU'+RE88@JJG?A8`DG!;@0[$BTJF
M#`IG#SKIF&KHA4;F@>;G#`IG956HE3XI#7[=E^IG%?.F<EI69O*FD);GA0Z$
M8;(Q"*&%$\9FFB`($GDGW\B@Y%#HURD2W'0/1:6?CEI=>HY&=_J0QHS0"#D`
M@?219$2`)#^F`\`4R^SH:!A+C2+AC7;/'AOH8BI$>E;6<O;@<S+I8MY=%R^G
M9,)Q`C#F)HVQ8KIFA4+G<!KFW3TFWPR`0F!F#19I?/+QBT8H3-6'>[0'_H`B
M\,J8:`,<0(0P14E)1HW4E0-4L]XHP,+UA8\VDGM5\S/+*0,H2?.XS:,5AW4*
MFA":YZR,D%A0@`,P@'4*X2:[UPO6<7KB,HUV<IMRT']R*2BWIG!2)VRJ,9/Z
MIQ.VYVD.-!0F,2VW4P[BF7OF67=TQU>N;+-2A/OPS!!S@%B$R-5DH55PC1%)
M*L76[-/JR4;TW/Z2RHUXQDV`2,P8I#2&I1;"--=HH8E-Y._4-+`^(*C]QVY$
MH*1"U04<0*F8&$\HI$C$TEJR#C;F#U:44"1N#%9TU(_M*_1YT%P4"``9D;I"
M1'D$S^&XQJ1-V@2`:H"-FTYA]+.^;P<LAYR`_HB=*&ML585$\K0/967=:M%>
M7^J&=&O)J+2-3.I@FJ5<&MM8D_6DR6OPO$\(M:MK1(5\R<6^IIM4_]BS7.QT
MU`B_:D2ZS80"VDI4))>GR)JBL&2_4@"J8,N1N4C#.3(\K\P>-<_*H!-/.XIH
M521:BP?/[$7P5H!-IEHL#B554H2)K:2XFF5L(<6D[BWI?(A)\,E-^(AC6'2D
M[.STDLH.!8=/E,4'S`6^I!1'&'5'/`:^(!/+2BWN!B:\7/#:K+".+*X<W<8+
ML43C.A\'N$U(+"X)WND?Q@2)=/?:7H1W;ZP%PT3[E1'_]747P1$#F2WC&I3[
M,,9M@`V^B"VI@8D"_@X`;B``OJB@S@*`<.!$^PY%W\X(0^R+V&`%0QW`R-[2
MQK9O3+Q%2%@>4<#'M'($7[A5`A2*"+M/?W3%2B#K&W46%?9+%DV$I3SW=W\.
M3^@(D3/-DOM(L.!+*Q'N7@]%^QB-B-`WUUJW5>A(E-27JTA=G"Q&>"-O`:C.
ME-_&D^.&N71$@70$6YSWEW=$E+]$XA9%%/D)?=<7%P'YC3Q9>'LM9J3-XMQ(
M4^'+H=Q&>KA/:2PN?6@NA&.PNDB1>MR(6?R7TYI-B=G?OJ1.I66JT*WYZAP?
M;G3Y;3B`B]]&:>ADC]-WOG@X?:?;/"G);2P+OBAEY+8<`XP+C=7*E*^2_DA4
MK>BZ.;Z$^:C36M)F>>E0[6W0U(7#%=3`>(4;E-'XDHXHBW6S%K0_+?DX+<&4
MC@*((ZE3N:Z1MTP<^U"@KX_L.4:<NY_GQKC#>8G+NH=@%TH,[?'ETD28Q^):
MN-%Z[6!TA+Q`.?;=AK;[!/F^5:R_Q+T/Q:(/A2JR!+M'8FY,^FT(*1YFJZFQ
ME;1_3:SO"(8/Q>_D1C.GNJV0S=S>B'I73L3'U15F"]/$/,V2K1RVG+^P1#-?
MU0(81^&6A*C3+5LI.VZDV[]0N^KFAEW@B\96CKM7NY6G&`7O18=?[LIN.E'X
M"01Z@(.\1.J@>6X(^0<(@(>PQWD'/4=X/$H$_N:\X\:PI+?<0[Q)'#K$<X``
M<(JN?TV;FSC!!Z;-*'JE8V[AJIB7L9"/O+R.B/=01,9)&,B-A"_A/KQ/R"!2
MM/I0&,VH7^W#3[K+LA6K4[>N39F/Y'F[AWK?4;C0V3P#'6T']+CF<,1^4>U%
M:,PWZ@;FZXBU0PVT#X5\?4!A*#Q;38K3WSE'9"Z<EWR%?TX!X+>/6'VW@^&\
M?<1;1-+7$W[^L"Q(700`2QV[=X2SKWVKBZ/;W[<<]9V.*'Y1*#R'W+>RM,RJ
M$#]K];U/Y(ZC\X9!A064#SY'+#SC`L0"#A$46&CP`2%"#PX\)'0HH8)##Q,@
M)+P@P>$'"Q0R)E30_C"AAP0%.'SH8`!DP@0I'4:8D%%#`H4=#F9LP!)AAP4'
M.C;`X*&A!@49/?#L^,$#`IP*,"A$4-&AAIH=*T!H2/.#!@(3K@K0(/$EAZ]1
M91YET.$HAP='-7(\@-;A`K@9-T#M*"$#VP9S'79P<-2#!@D=>#+`*;(D6\4=
M,3!TF*!"!*4+\B:L$#GBT0@6$!Y(B<%JQZ)\$W98B3#"!<L8S385S8"M88<,
MODZ0P!(!!I0>(&1PG!!#!,`1QB:D6&'#APH46#[@?%1N1@H",VRX`#LD5M$0
M7">$L!8I!MD6.7;L,%2B@@(-*1C(J!/PA.X(.7CFP$`!>H<W.W)8(),E_@4$
MD*"I#<H*:0&VDL+))Z0\6*"\A#;XZR@+P,L@0:$0TL`!`3#((`,,1%S@`@M,
MM*`Z#"K0+R.ETJ*PHPM>>BNCZ!BS*R,"]2(M)QP=NB""#88:[['B%CM2`_`4
MDH"ACQ*83P,&-L,)(>X:<L^BEU[CT20$$GI`-80DT+*GY,Q+\#66%JB-*X<.
MV("GA@S*R`(?$VJ``Y9L@VLCB9RC\@,;$XJ@`@\LB$"\C-0"5`(C>5O+@PKJ
MS.BBHTQ[3[V&,O`R(R);"E-"I3S`P"^<'.!QH0,5:H"""=`2DB4/6)3(Q?U4
MZZ"#"")$:`,EZ60NJP0I&"H#!1X8(()D'6B`_H$')HC``0><_:X!&#/ZZ"@-
M[$3(@I<0Z(`E_AAC[:[Y9N-R`^PZRF`"#H82M\@CY<T*1P\*X.PC!N83J8'*
M.D(4(2P1P@#8CKX%3#8/)`!U@EU#.A6PWR0",*$U/YC@.84H,RHK=3<,K2,&
M$DN(@@@\B"`#"0I&Z`%_;<))`HPVL`"#J9!2:SB7/WB@@I)&O<VA"GPMS>,/
MZB/@*SB)*CHA"3(>V`"X/!CZ`XB)<@`VEASH+B:BX*T1J=D6L("##71EJ5>V
M^OP@W0\H6"M$#00PTP-P)W@`Z`]DU(`#:Q\#-#BV*O"6-*J12IFM"716R`)`
M,P`Y(PPD,-`#3Q%2_L#,>8E2:(."&V(`7UGI1LK"O!IBB3ND/`N;X+`ELNKT
MD!8:]#D/*`#5]:H32ZEND$%JJ%Z1L\K3]0S.`XD#<1LR^_>0(O"9Y(4]>%PX
MUR=7Z.77(^I`@PBR1DJ##K3DW>T-8O\`@@(BZ!>"ZD%2L?FP,W/]`00*W33^
M!^)OJ`+3);R75!50%T@>@);F3<1F#;$80@2(/:38#'L>4!Y"%H`7#F3`)0[4
M0)M<UY`+<"0PL*F*C"Z``?N%)P$=F%;8+F"^2I%/@H#I``@=Z($2?B!A86M<
M2"14F?,I9V3G(U784B(8(F*O;%-ST!%E-3+-@6\#4=Q`!I"C@>H\CC.&_CE`
M!BS0OPR4*`$4`%&(,'`!,S9`4A:P7Q<)MC41E=&,%6@`S3:@`0QH`(^2"]$%
M&M"NZM`1CU8$$0845T<-;*!L480`'L<HH@M4H$1=O(#]-GB!,1ZRA*LSV@+J
M6,<+0H`#N.H`!TC)@0N$$EQ`H<!@0MF^NIUN`ZG,W0>^QIN(7``"%#`,N$9Y
M02("A9=U$Z5?]%<W"D``D7G,@`:$B2M2:L`"AK1B8U:W@0)8DHX;^)`@0<2]
MACFS;'+T0"PQL(!7BI("I<P34'K'SE3N!3B&`8J#?B(U[*7R=)6;H@8N<IL\
M@4LL#FIF!^Z(*UQ^0#P<&%QD3D7014X..4")_L`"Y/B3E*0R`U3R@$)[&4J@
M<``#>3(GKL+'`;(ETI!D%-$RN4=*#$3QD(P<Y$K-6*+EX(6+7&R8!"+`TP1$
MX`'M<U:T&E``+AW)A`A`0`(2@``!$`"J!BA``+(H00,HE:D*0$``#K"``B3@
M``G8R0$(<%4""&`D!=!J60W0U@.\%0$#,`!3$Y"?`MQ5K@>0:@&P6M:Z%N"J
M@#5`7I4JU:LBP``*2(!A#PO7OBXUK`2XJP'(JM:$<&``2Y7L70GPU@,`5@"A
M%8!<!6L``4S@`LR4P``*((#)$F``DD4`7]]J6L!RE@`!*)2V+A!:UHZVM8QM
MJP%@6P#/OG4`$:(`_E0+L-FH4I:X@(UK;*$J6R\!I;-*16P"RJK7V;J5M8'E
MJP"FXH&V%F```PB```)P5N;"-K0`6*]\`S```20&I/5]:FL%0-_AWA6O@F5O
M;HNSVN:^5JZ2E>IG^2M9^P[V`!JX3`7:&X#UJE<`!FBO:2V<7M=2]ZRC72][
M67M6#>MWM&7%:UD#4%K*EG6I2\V/`ABL5\\JU:]:50\!%,M6QR)`L77-CU@7
MP``&-*`!"C#`!!+P`"=38#D50,D3)>*0#6#D=Z##H>BJ++S<\<],X]FH#QU8
M*`<Z2'\(P1A(P'5FX+69B3]QLVI^!\JL).<S'/`2+V&TO(C$[G0]RPAJ_L,&
M`=C5#8^(1"0I<;6!-3&ZCA#`,D'/$LP.F-F!"F4F]G+9M(SELX,U+,T#Y.(`
MRD4P<[D+'P\3I1!YIF0PKNME8]AI$IWX+(2,YN4%`"W*!\TSE;1IFIE/IP'F
MG$].O*:7H9@32HCP1@'@T@`"'A!M"PC%`-]1'(@2;9U%HC(G/ZOU/.L6Q5H!
M9W\F(5Y@)F`;.\9/(1GE(5(N?42%)/(O)ILWC:B<+7)5*=IKNN_5G.@0"-SJ
MW!N,#:!BB)KYB8@M#TAU2`Q7.9MD%,J=Z@!)"J4`R!G-<.B;>`7(]2R)D`U0
M5AL4<\23@:(-)''FRJ"8?/1!2_GH/@B8``,,_O0>")(,=PAE@*!GYR>-ZK(C
M"M#T!S(`P0XP+2%,4\!7+I"K^0V,3#FJ3%UHTH"==)$C3^?E`]:M;IZ9JV*.
MRWK05&/.['5$,!-*``0J`,WT8;I3@*J+X&AV$*CSN]\PR1M"(&.:^CAQHUL$
ME,2!HDF-K+UB!7>U=^9W&;9@#C`?GSS%2P(1B?#\30THH5V`4JGMS#-ZQJG>
MDA:'$)6CYB5FD\I[).800K>D-TB1$DM,OS26F.8`5NE:7W[.0)VYO,U3B]77
M%(*UI"\``YRA0"VWI?M98KXA#K@Z0JM/H(;T;9*F%I\"RH.!!&2``Q7)IU0B
M$W2%I'E=_W8(!2QP_I)8A3PF3_KRSA,P\2T?)6U$0T5JYO_ZPJ@";]XV(.L>
MI''T1^+N8F52(C5,XD"F!^^(2/.:;TFZXX;F#7W@#2D@YW?^(B7(3B.>9GA6
M`BTZ`$<Z(`-HB(=BS2'6YF)V:%#&`B=@QWD*!2BT12(49I:00D>PQVG,9#D<
M:)0.8R)J2`$LIN<DXN?`3")\0R$J`$U2@LYX2&$H)"70Z'0(\**P`R>>[LRF
M[DO"Y'W^#=::8J-:9N9J\-Y(30'03T6:)3G0[\R"L(A@T/8:!UL<`E*(`C2"
MD.G&Z25X1][.S-@\D)[6`M/8[#0`13%<L.ZBB&"XJ6:0@^=TCMOPJ`*P_L:.
M[NB"[HCNK&.+.LF3N">*JJ-7`DFFK$@^7JH45_&.!.F-KN..0F05ZXAL`@G]
M1NE#*C%=@M&2'.F#(J#_@-$!?/$%0>F02LD2HZ@#8DE\**#-5(;>>M#2X,QD
M7@DIM,^&Y*.A0JEL7@J8@*D#6F@:8^D^&J=N(D,LK@A$%NVERH:+\$B4%/`M
M".I-YM&*O$BEC(<[H'$#/O&5)F280BF=W`F8+.`*P\;+1N70A*D"DH^=).HB
MP44NZL9=*""6\.B">!"@>HD"/+*.$*`!7(E_&,#0ON,!'"`!+"P`%@!O>"I9
M6O(["*4DGV5,!L<"BM&9+G)F#@ES0$J;DD>*_E(*`Q2@`HSQ$U\*D"C@0Z8H
M1%S0BKBI6S#1D702,AY@E=JM6A@@:MXF68YJT(QL`?*CR):*J9SJ/PB``09@
M`<R*`1!`+`4`R.RJR!:`M=Y*`!1KJ9IK`08S`?ZRJ;"*KK)*+0<3J@X``<@*
MLH[+Q6[,,0=KMIJJJ2A++@T@+=4#,`T@R=1RJ0:@+NW2ZQB`KM)R,/\#K-X*
MK![S,1W3-6GLL^9J)!)+JA`KK.IJ-_/R,!%KQFSL`+0*K&:L"6EL,7GS.(/L
ML.IJJ>:*LFCSL)0J/P9`K`:@JXK,R$H3R1C@/Q0`:[R*,[6*`;KJ.*.S"1%@
M)]SJLU2,LBI+L0!S_K'2DJFNJJT>\ZY<LZZ*<S^#;`&T:S^3[#$/,SY5LPGW
M$C6#[*OV$S_54SO1DEFJQ0$ZTT&-C#8!E*[R`\B*[#"%+,C$2@"&<S`5`#4/
M@+62+,F:ZK/"4ZL&0,D6P.M8,SX)0#WSPT)3E`"2##^PYB5?4@'6Q]!<HMTD
MP#W*J"FIK'F2KTH"8R@6P`&`)+6N(L(\$CGZIV]>PC1^YU"(B)D`[9?FHB':
MC3Y0;Z.6R%]ZT'1R(Y_<D0&`Y'0:`&4N8\S"!Y3^8C#@#'EB)8(4@DS]9=UP
MS<T"M2&&*&RB"-E^1`NQYTCS2=YZ<(EFJ6Z0(J@.R-Y0+1&)*#G`M/X\_B<P
M#M6`.LBDTNW+0FU/\RE2^0944LU30>HG@>)0,D=/1373_NRR2'5F,NITF.,`
MRLZ&>.,BQJEO*@`!2F1Z%B*CED/.\(Q_8,D%67!3^*D#!@-EV`91",`"E$XY
M!I4P)+'?7,5V2D\LAD(!G@6UZB17F@IE'@"H+B`M_X(P3D5.L*,#3`1;YBE4
M30D-T4),)T#G%(+0*`":]"T\V.Q;.$A$3N))&R!)YLZ$%$`U7JH#<D,F'`"D
MFD9,J,0!'":B*/`=S<,!7$57FJ)+!0KU/I9/GV=S2H,078];F>DR:N>'D(+:
M$%!!D"EE(^4#@L0UQHEGWV,0>664C`0AV*7N_H*&]ZZ#=X`".;:(.Z22*WYG
ME9;Q`72#`(X*9[DU*MQ.04IB@_",F;BB`,Y4@B3H`#YDAC9B(U2#BAZ`F:`%
M5W#H52]`6D@I,%"I57PB8QV`9A3F,K@C02(5`PKH``-/V7*G+NHF:C3``-*E
M?1KF!3DD/P;G;J(D8KGB`MY"8?XC-":"W,P(:E&O>T[&<HF'3T'04$XG8D,M
MEM:D-T1F7`OB+#8JI/J/,J(M=E!NWJR1;"2"4._CWF"U<PCJE0S%<U\R3]AP
M:IT)=S8JAW(BFJ9P0HJC8H=G8&)'80D&GA)/-F8H*-#N@^8#GX2BZ7;':.8I
MI%#7@[R$`NZEUX#&_H:@YYZ$$$SY0D[\J<K.4:"^Z&0@R2`=Y#2&-@*S8GHV
M+2IPU>6X-?UVIW%$)#D,@)FN#%S6@D1*<B%8T&G*B#=84I_T#:@T@),2@`,`
MEE1$YB?+5J&<)65``Y<D#@&N360HE@.F+/`,1<XN*V4D:&$*P)IZPR6"@Z<<
M0'TL1#"J`T)LQST,Z9A^9Y[:9<R(AXM\AE3&Y(,"HR\NPFSPU("DDB>XAU<D
MS#I?$%Q(-`.R;8L00"C4R@`NX/Q<8B&F2"*X;MY8\$__5@+H-H*:$DQ-8IO@
M8@*2)%H:18-"!"GTC8;-IS2^R($C:"(00%ESHE$"`Y%R(J["]I1X[07-_N5D
M$.4S2BB/)&@"D@-?T6)Z$:KN3`0VIE$P/)+7=(F93(HHIM$&-RHH*I(NYA!*
M@.(%S4-.;0<"HHD%"0`+;3#<U*T_DF,Y5D]MEF><(B@"<B7?#A@!',`W\",!
M4-,!%"#)I&5"^<H[8?("E$YQ"ZC^1BDOG,:*O'*5ID<"(.!N*J?<0`0O9+C?
M0OB17G`E-J-07,6#S4N.0N0[+(`E#>!M,.2;A02U)HIMK".HD((K.N<BU;,`
M\.0`^F4"M,H`O).R&@;U*H!&L9-6IZ8D<.5O23<K&!GZFL3E)F!-4`;Z.,E+
M8/@V3,1D>KF4#RYVTLEH3(+G"&*8.>"3Y2Q/_I870BZ594SM?%N(8$SP<,(F
ME/(P7:ADG8BB.`SH*IJP3(VF_B!BTZ@Z6U#/1LKTE4C7&MD&ET`"D>8B2D")
M.5XB%RUIS4C&?("ZJ9+#T5;P$+F">Q;1(?3L.1I(.2A`D\YC+OH&_HY$4D("
M#UV5#649?-I,=^E-A1ZD`L+H.B!`JOKGI?Z(74-1/-K%9,QXCJ8.^MRF`&P2
M2%!$-RS@JJ1L=JMR`X`9`7U:H#ZU;I"F6,RKI2E`;YME`7C,`LX/<R2@F@?G
MN@89`F2I>:+D=$7"(SF`R!S@`)X6H9J9EI#%)5@.G_3&T33%?S9NBZ"O`0A@
M31)``D0&8*6L"0.%_I3.M'SGJ2D7`H_V-#F4FW<^52$*=TWGC>Z\=)!.!R/T
M5I@%#2)Q=DSU.'=RY=,^X$XIRRJFD4M'22Q/*3)BR74XJ(+Y]#S\1W6A`MY,
M0\S8QI61@CG0C\R*[71R664[B'P$RFVJ9W5CIW!-PO\4@P;9!BWJ;WJ-)]:6
MB3XD8D4DP"X/X'9R4BIY#C5C%P+2\BP8HF4ZLHOXJ8YX8R>O]1,_\0$8@$GN
M0WSE`CGDN=]0EP5YAP$R`*P^H&QI0XSPA%7N:HX0(`/(KEGJQIP@H*DX2S9M
MC*]^&P*01BT&PM&0S`&>HH[6$2E:RSKFR#M'-#X1($>=%$:QS,VGKI>9_J)9
M"B"FV/;\#@*(T6Y*:!ND6`-1%-"*(``]0.*0'`:`)4^A+F<^KDYAS*=G%#`G
M@JK_\"QAFD+.EEF;<H(X2`<M<!6;!4.OXX+7KH*?J.A4O*B,:(F`J9LC11Q,
MXYHQQ`-M5HV'E@ED=)>@GH-8-T28"WC[-((U0OA_:?:R4!TP3`)KO_$^)*-1
M@HKN<M3(+:".I9E4'H1B.;9N&N=)&[8WN.-)!0*98B9B:6-AK$(WUOU(],RD
MP#1%O.0`1(:BL+P[,:!LZRXU&L`ZIW$H&/G*=-C7>"E/)B`E?8+7X(A#'`!:
M*$JI-VXM2*WN4LO8GC$F2"E9,,0D"H!$P&0"_A*K+G3;($##/"OGI:C"6#E'
M8U&&;YYN<CY6G'X=]4Q"/N`N3/0V)T9)4;*1/O#,!:/\`S!G5.X]U`Y5W?G4
M2>?M*N!,-#(*7!)Q+T1$!NDM)[@%**3]\_B(]](I5X`CEOP497SZ.5AE4[W2
M57/'I,)=Y8?6XKUT,4A:JN7%CO#T?GV&(5J8*4UMCN!R`*9(/`@IR=+RMWTC
M'6DR..3XDWNR1!2*8B4-3LU)+F['`O5,X1>#W.X))<HI*9@I$QEB`2"``71^
MVH:2*<9I)5:'`$-B9;)PQ14&(P!JJPD_)0PY@A"@)&+)G47B5E&$1#+6`%R.
M8$P#H'=FQ?D44D7M_OO<#G\)BGNNFIACQ6?:5/%KU8;6)7R:)YKX(Z1(R6U"
MB69(93X`(H.'#P0[-`BP@*#"#Q4Z9+BP\,)`@AX@<)A(T8&&#ATP3)S@H8.&
M#10]*L1(\8/!#R@G=CA)$>-$C!8J;+1`$><%ARQ[SB0X(<+,!"\C:%BX$&,%
MDT@)9F@*E><'"@M<:L!@P`%+K0@J'("PL0*#`!$>'+C`@4&##0PX/,C0@(-%
M#QX27)"`024$#Q8<')@P`<*%P1P^1,`JH<,"!AH6=)"P@0,"J)2C%E;YLL,&
M#PX\8&CPX8""#A0V9."`88+C!AHH=-"H`8'1#0D\*!B800+%#1HXO%S8_A'E
MAZ<2*GSP[4$#W0R:/US(8,'#A@X>*,PLX-&U!Y`>&%2X,($Z`@4;*ECH[;EB
MXP\,3FZF._/RPNC"W:J4F/3#1@P9IN<]BM)&'T#P&U(-")>4<DAYH!N#,M'5
M`40S;50@2]5%L.!`PN4%TT5(15!!2_IUP`%$!-5$78&1*;3!`RS)I]!3335'
M&6\46)B2;Q2XY4&([RE4P0,8LF22!QQ,L*!S",X(06644:=A9R$-U`&&WBVP
M06<:,!"=0PTLT$`%"2AP0`0.9.`:!\HA21=!FS$4XG,/]$@7!2"VM98&`)XV
MF9-/1J;!>1QL$-D&&&#0&P8+6'``H2-M8$$&_@HL=8%%_9FF``6M)9#!`AQ$
MD`"!(F%`**06G#=2A!1RP$$%&S0P@6D9:)"!0!S=^A)\1%Z4%D>]L1H2`H]N
M%I>1&^S$JIH;+-!:;WHN-2A:QV(PZ*`C(;K1E!VUA4&N%FK($GY4FF9AKAU`
MD)=,U'T+(913AL02<Q?!=RNX*H4T+ZL<%9KECKZ5JAR)OD9&(JFL.JJG:13$
M*G"RONE)'T?_3H0<10)Y\!25+*W;)ET81)!BFSV5YI%($/:F&:TD<M`?8[Q!
MD*9R$K[H+KM3%F8D?/#YQJY/R`GL4D@*[!=7`@1P,,"D%P2*@042/!?9P=*5
M6$&MI#('@;RL]J<!_@1X0??QJ7=9`"L$#5"P,&`2,(#`DDYZ@````0P00-UV
M!R"````LH$!6!!1`P`!Y%U!``'\+/D#@`]!M@`(,%-#```<XL,#B@@M`@`&)
M)VYX`9KC+<``@-,]M]YRYYTWXG^O+CCH>2-PP`$&P*[``@$4@'GKJ(>^>.B#
M-Z!``@A@#GCFO"LNN.(%6(X[`0C`+CSR!AA00.RR3T\XWWW_#?@!L!.@``*$
M%V^YZ-.COCH!BF>.0.4)'("\^80;@+GZGENN?O*8+W!`^9D'KKD"((!ZU$,=
M_@1P@`48X$NY$X#='$@W]=GO`.,CP-R<MP`%!L\!M:.>]^`WI@,D0'BQ_AN`
MYJ@W/A(JT(2:4Q_H2N<ZO.&M=WFC'_7^EC<"Q`X!EWL@X0@`@,0A+W3<"UP%
MB:>\]]%-;DP,@`(<(``%"*"%X^L<`((H0!>J#X4WS-P!=N<Y^`'.<XVKW7CZ
M9@`&C*EV"_`:!-KC)Z@,JE0L0PNN#B"!";0'`>_A"$LF4)@JN4LQ$.%`9X12
MG9W@*U?PV<O&NL41",&,.LE:V:T>-1(]12!9M'D)L!+3G4@:R0&L(M6MIL.R
M]LP*`XZ$%\%TMC.5Z$LN%BC/!R0`&4)%:S#3XD\&%!4I#;A*`YP:3D<:4*M9
M78545:O58`[E2V6>B2_5`:3`--.?Y+R)+I4T_I)F'."B2MDKDN[254MPZ1R]
M0,A8$4!E)3733#W1"@&E<0!I&F`!:/[R.0G3I<)PQ1\#1.`"(6J`29"#'EU1
MI`+Z0I$#+'`N#SS@/*7B#<K(J1EL]9,!D-+(`BY@J%JIR4/X\DT'0M0!%YWJ
M`-31C6-^J2'X;$`"#6C`&[_4,9_HK"<]N8R],$(!@7`((RN)(U10\LNDO`4#
M'#T:3PGR``\QP%X/[98"(-"HJ;#IEAE3B"/UDI*!%.>I*I%1CT@R$0ULM2Z,
M'!!=;G,2`GV@ED\U4@$8Y)`FI40#^(%)=<AZ*@V`9@),80E]DC2DE#S@*#"K
M@%X58K*FP.NI#!#(_E[,@U22I$2R%*%*9X*$%`[<*#\,^4F/A#*G3\%D*F3=
MV&AYVA[5+@PE'<`)::M$5HX^YP/V_,D$9+3:KV(61!\X4&5ATIK-*D0"+=E+
ME23J(85$MRF%K$K5#D`7%U5%)0KI5DQH=9'"*C=)MX013P4RT.K\A"5P-&I^
M'L13N-$*+&UK"BDY$BN=5;4#!;!`GP@*'PIPR$+6L5C/)/!:GRE$0)`%;DI1
MHIL/P%4A0_(N4C:`@`Y,E0,17K!9-]M7A0!&`X<TD4)"C)0$LT0!3W$`!BK0
MX8((1(["65MW;',4TAYU01<80%5:M"#S*@2B[**`2R/SV).(+"F:7<B!_K(T
M5Q4O>4$58J^QBEMEYN@X.H8USEL,<X$#F%=-1W414II4D0\\H,DQH8RMG-L!
MECKH-A<8K71F8IJ13#E)M!7)NE*R+[B@)55ZJI58W)L4`\CN>O;[V_,`T(`$
M%`"*UL->X>*W/,ZET6@*\#&9\K>YZLD.=RA<7N`4%\#K46^`932:]YX7NS0J
M('@)B``$;FT6F@X`=M.KG!G/.$)>%R`"!GB``TSX0U#GT&X&R!SAGI>`73_N
M<0FH:0,8P(`,/@#;N'Z`L:U];080@`*\?``"O&WL!<`.V^S.8-]FG4$$,&#7
M$H`<!K77MU=;C]$%2,#L^A>ZR24@`(JV'@'J_G=JT2WN<`(`7``08+3,B2YU
MLIMBYOS=OEF/<(0.P/9?(*``FB[`U@]HP+89X("4U[3=LVZYXPC0@-A-P'FE
MEB#@FDTX[SE[C)53RZX1".M1&T"#+1_AKH,>[0@PH-C.>]_&JP<[5E=0<Y)S
MH=?`5#PRXLYSRW,@WM17Z68#4'("A#7G,F=I%&YN@)+;H>/DC>B%@#>9@\DD
MH?`IJ0P<C3<6W=)I(A,7WTC&`N"9JD8R$`'(L"J?]>*`8W3IJJWUI@&'2::>
M#J5+!F#@F1B@P%N<J8!3.<T"";``!0SPRV0B8%8"YL^A!G,!!5#K(5$=B;5.
M8U+J1*:6"1N)`]"%_IH%X,679)M`!<PC-B,G8`)I6Y@";)J`!RC@`12H0.)/
M]9V:5/_X%9B`V)XYJ60BF%;R?`@TL:5,BSHJ`@IX#@7LJ2^,V1V5*K%`[D."
M2WKM1?`<T13Y"\U7Y+9YFU<!]&0>%-``#G!\-4%0$6!Z$P`>:%-]3R,V?'46
MKE=ZM9(P_'0MTW$:"Z"!Q4%BKA(9#EA*_($V\I1)%]`TY\<?JR=,L0%2(\4!
M]L<R(J%,:@4=',4J!@!RA-=?E+0O-H4R^M(!@0$R$E,J@/1.O@(E\:4?AK$9
M3:8ARQ)WE4%X23$Y6_(!!2!D&G$O&:80[==Y4Z4`!-%]%$%81'6&+Z(5_DEQ
M-DW!'U[%9AN06!IF(B!3%1V0`$@Q&H:18SGQ*KMA9@HA8)2A%2@!(MXU44C!
M95#1'C)163V2`=V'$C5X5,R%%"#H528&%$(F'2KV*>3!%YH(64@"%?:D5,;!
M%QI0B`K1&5"A`3'&$G.R+H"1%*GA9E+6)P2!`(.R$(N%B!-A>NRQ25#%9E,A
M7@H!&ILX$+4T-&<F9`31&:_1$Y[B9P;0$BZF9#@S)Q;P505A6_85B&?6'8A"
MB\,Q55<(%:>BA0S0-QU``,DH821!$@8U$9FR`7H$-T:2`,9!$`8%'`=P$E%E
M(*BX$)U'AW)WAV\8$HJA$O4UAH41`<!U'.WG_ABPXP"TF$>4T8P+(0%B-A`/
M!8=N,V$4D0!Y01U.@Q1H0AFFJ!!V06$*(F*@B`&OR!!\$QT(\(8L@I,*X1A(
MH8`?$!Y<B!3MA108D([@HU<(EA06`!)0D1M(T0':*!%P8UYK01EBR!#6P27S
MHI4+<8B2M8X+$90$D0#E6(^4$5L.20"U8G_:*)8#`",0,`!/L8X0@)`?`&50
M<2!'M1>:!XY-T2EN$W<=>1(,L$EM(Y=^B%:W%)42=B,8T(>341&HR!DF1A<$
M21$N@A(,L)=``9`?P"P,N6!ER2!]&&=)$905B1$<8!<*P#*S2(N#01DW`F$`
M*5&/2(U5%I--@0!Y_F%K$:!B:+(DQ;(0,DD0%2F4],B7.-DIG%(12:8?/XF6
MPN$`-T(=7;,@'YF4Z9AA!7862`%C;A9C(:&-;\)'0CF.SEB+2'(VUA$!`Z"6
MY$89VV66C$2?1[DD-Y8!Z^@!!X`VL3(`KZENT_4!M7%C*X81&="3F^B<$N8!
M#;`TU#D<^#E>B#96*2$`U#)5!B!DT>@4;>@!"X`DG?(!!D`=U9<K#N")&F``
M+.*=`1F:RCB&Y7@!B84!L>@9%;``KL&9,?D2#S!@*L$`L===D4D0%-">"Q&+
M(#E@7W82J@@5C0F4'O$`E:)B!'6?PO%1%&:1$N6<%C`G<D<]8E6F"_:@_@O!
M`%7V`+I1@QF`DR7J9C7:APK1B`LQ`>FXI(E5$)RI&060C&`(%?A)G'!3)*R1
M8IYX$AA*$`>`>`0!HBCQEU"!77!!$5Z8J06"-FV!%.!!IVCX6AK@ITXVC>QA
M$(BB8CFY$*<:1\4A$QW*%AYP5TTAHL=1JW4!$A=0%5=5)0NS%47*AS*Z(-[1
M%-4'E.4(6@31-711$PFZ$P2)$;?A`8<A71P@>W#D&:6*K)*5$`;"4`,1)BCA
M*5NY(%]*(C#SJ:/)GTB!`'5&%Q)@D<5%CWP1FA@@0@0A`6O:ETU1&TA!?42R
MK#'1AH29C@7+6TT*8TN2HTFQFL55`5XH$XHJ_EE.=4L281<Y5IHG\1U;Z:5M
ML@%W1:EN<ZGMU9BT6B`<5:DL41YZ2!$I%2,6&I"^68OLP1NEVB-WRA*EJJ%%
M6A?4TADJ"IR!6!<XDRF<D1`$@"[$-1!K!AR5FA8+$K`I-HZ<""2%R%0#81VV
M01W8999-"US!PE0G1HMHLR1IRHP&L!2\E6`32K/L(1SONATY&II<*EDKRQ*_
MF*.GIYD#HI8$<1<H<0%#IZ\X>0%K.H;"`0&:BC$XJ6%+,HNVZJ1-"H&W6:H<
M(*V;X:BD&:%$L9QY`8(`0K%#5J0G(9$Q"2$;(+1.UI^W(5B;.B4%\&<WPJ/L
MU5M/RB!)ZI%O.R>5_E6,Y`D:$,*S[F5\P"$`_5$5+`6<;):GPF<8MX%M')98
M3KM@55$8]@&PJSJ6I&F19!HC#_I@`9H4U&JMD)6M"U:V3<J,PC%1&0`2#%!@
M%(&WR1FW.$&AB-E=JTH0F_N+K<(6C`H6[1B:$?NO>_JI,ZH0;7IF7T6J23&A
MYNFO&)&G:LBH0^:)=%$`.58!!-`2!NFM$T&D'_"N":R6YG%4)TD0MP$IH5%E
M#?"V4_6ZN#H0:&&5>[J1"``!$6!K$E`3"!9R>@D8$Y$:2T*E3>$BLED3P@%:
M7Q(\['@BY4BK).;"IPN4W5NF!^`1@M4=+`&K4#5=5C@0J@6'ZMNQ,SL?_AV6
M`:O766T3H)_Y$L@$')6EP-#!K?.*IXHK$2_QHT)IDG'K$<Y*BPI)EBV1`)I5
MK5!L$5`!K_/Q?'01%$F)E$ZJN-PQ'#@KL\-!BP$*7!#`KE-1P4M*BR&[`5O+
ME;`8H7!5$1Z1EA/!44DAKT<UOR=9RK7H-NUA`4/"`;++K(WRCQ*8`-LG>H,!
ME9L'E28VE:G(NW4!*:MJ?6G!35<X$4&5%`G`*IPR`+^!$9Y[$L&;DA]`F3[*
MQ78&`508P\<Q)#.Q**NU%!-!2O/Q6AGPKP/QNJ':$^NX(_'%'R&WDO&+AGV;
MP#+!6P/VI05I+R^;$#+QBVIV%ZQX8D.E5%5V_I:<,5UT(AP88UO$"`$+@"B/
MS%.82%H1-A/&)B'N6U>)A1*;9\0\%<(GX8[C9<)REQ`XH[P@Z9L#H5<5\134
M;"$S/1&NTEJ/VZXB`:*;I:0PX2(-S!(%@(H68`!V""XEPQ)BD3%Z5%@#82CC
MI5ZK11`>`7]$>R(6D8B;2QFH\7I[2RV1D0$",%`%0`$%L$_4PBH@B#"O,2AO
M65R,<8898`"N,1(V,1T28Q$7X;ZPE%(-@2L.(7@3>A'KHI2_D1OR+`$<$+Q3
MI7]A#$LA@:\'TAK^4BWH-R\ITA"5)-D#-HD^L4U0.&,\Y:*[F:6;)3(S01<,
M52W)P4?/F*4'0RC!_I1ZYW<!V+<49A,`A!4!%-HT+$@!G'Q\Y/8<:+(495U,
MEP>_F^=,A[$T2S-'5Y$PTO&?AL(;9Q)?(/7:&L(S,V$0&"%G,<%<[:+=Y?$K
M;[$!!]`0A\(LJ-0;FH?;=T8H.D,BJ\=-,*A+?)%[*S,HI)*CA=:_=&$`9`H=
M(&4:D$HK$#@K-H$6M5(J&BA2^P25HE<US+<P$3`!L@$!X%1RV^9OF_2&ZDL9
M$;!H[Z-HT&9TS]$9U3,]+C0X"V<\F1,`3W&3DK&<HH-#811`==-PH3,]'F1#
M!S=#=;,ZA=,[.D0W#:<Y7Q42]D0!R(8[=4,XB^,Y@8,Z?TD:B8-$#6<__D5>
M<8230X*CP.PA.47.:1L7;!!7`&2B:-E&`,9Q$0]0=K#S15-4Y&040#\T/0&0
M8Q4Q.Q`'<0:0`.J61FI$084.<9+F``9%J@?`Z.&S0QL';WRS&-A64Y`Z$:J;
MZ=G6/M;S/!#'/O-#.-2,>)TR/P6$.5-D/7Z.=ID610L1:XOVYZ5&0&W'0]XC
M`-9Q%`U`1C8'/\RS.GP^/=8#N)*Q:`0P0EY$ZJ\V`.]3=ID#CD;B/`3@`&,B
M/@$```600?P#CQ_T1<\C0>1.02+T.*\&<0N0``P@?7ZAPWE$G-6W`7II2!E:
M&>&=4P/1%AS6QC'%$EOK$TX#-[GMPG>ZAES,_DCXUQ.:(?!J=C&+K1\*PA>H
MQ!$`%B^H6#":!RHUXRE&@AZYYWD6@YL:<AZN;5@%_0"1R24/Z1!5,Q)@TQMW
MP7D/,1K=H5:1G7O(<=DY5<\:<@%195HX`ML`?9/K^%`_T1Q%;\B=:6)WX1/Q
M`H6X<94^D8C+R1P0`BP!GB)JPO5J4I8B_-<RM5,\92+5>A%7U9D-?U+O84XY
M(Y3,V@%L[!/>,O4.XHXAH:#3T=2>R:S39TWO<A2L<M-AE??1]5,MEAP3W976
MZ,2DVZH",,HN'*0+\8>MVB3O.E&D]*]/@Z?ER&$L(F7X1%V!V,ZZZQ01IAGE
M[<QL:M-L5AWO=RS._J%B1D$9/]G:K*)Y`/NVG<P>DD*?]AD1O"F6PM'*R'AF
M-$O\)P9W:F;\S=^NP<@4+*GY2](T5%D;K5)<YF5_2S(K2*$!V#$1LUQ<_=E>
MXRQAHUG$!)$U1P7\;2%,;9P4B$L13?*L%SDN!G"30Y%C`'$!08(*$38<0-`@
M@88/#3]PR.!0XH<&'B8ZA.#A@(<.%RQDP#`A0P4%$R0TN)A294,)%R1V**#!
M@0.-%B=6G-@A@0<$#"TXX%"20X0+-AEPL/EAPX.&'CA(N+C`PL66#A=TD%AA
M:D,+4)MV:%!A@X(/21DTA,#0(0<'%1YTV'"A`H2):56>3?H!@DNG!C!(_O1`
M,V]3IH`7;'#J@<)6AQ3^7O3`(*^'!%@U>'BP`?`##BDK/'8H@4'A!Q4F6C"=
MDN9$!A@XF*8P(:?7BW)S5F[:0"W&W1,E1)0X=@.%L@L&-\":4G+#MY0[ESWJ
M&WA.!Q,]*.@P4N?@Y1<[T+P`U4,%!!@,<![@@/$'"JF36H3[`'1#K2H?#'98
MX?KW!1`L7(@`I`4FH*"[E0YD#S&)L.L`@PXVNDB!YR0"JH"(+LA(@0PPP\"F
M!B9\*`*'-DC-H<A<\FTW!Y)K2"2'-)`@J0X8Z*"#!5@K2P+-3/2H,`\P($ZB
M"'K+:C`(-/-`@\,F0M&[ZF[RP`,)-)A@O8>B_O0L0JPL.A*P^4S,8$>'@/1J
M@A(;PL#*QBYJ@*_QK!Q*I0N:;(B#LQP:$K`.\*/ORPT2V("A#@R8C$:5&&L`
M,4`;T@`G$R<@LJ$.[IN(+`<CF^S,B3JT[8,)=FI*LM4:RH`!"%AL"H,V+^(`
M1(DLX/.##A'(8,6+`BP+P8LRH&"Q-!V88,X+-L"`@#3EZTD##3CH`"(%7-L@
MT$`AH,"`"S(0+8,$+,!@KT`U:"T#<<.<@-E6F^6(6<H<K+%=##9@MD&D.$I2
M@W:7:I6#:!W<8$6.:C0NL1JCS,Z"MS[H:()F6]7@(V6E10JNA:/$;,,H,[,H
M8RPSSC6QCC^@T8,)_C;PKV..$-NS1G,OT%=9#3)0H`*0,EC`,6$M"!:##"QP
M[+->_YO3@@@26$"N!AB(C4`@(PC6`J<K@%J"7GLU"0'U(#BI+:B=QB`"#+[^
M&EX.4/M6`V*1J['?#%J%E]C+"&X777I/SBA*#G;ZMU66VW69V`<R>)F!:&F-
M=BQQ7V96YGSU+?P"LQ_'(`'7(&+@@G==UGG<KS68TS$*Y)M@@O+^LT!R!CY*
MT^D)#GA`I`LF:.``R^=\5U_'71[W]9:"YKD""B2`8`("))C)@0<:.)H!`A2(
M8`'G,](5,P,4:``!YQ$8"`$!"$!H@``$&`"!`PP@@`#P`RA@`/()0%^`_@``
M2``!`P1((/P$"MB^??S='\#][P787@',M[T#!,!\`P3?]LK'/@+LSW\`]%X#
M!S"`\@7```4P8``TJ$$">&^""?3?]S"XP0!\D((-+$`!##!!`*@/@"I<7_\T
MJ+X+IG"!"5"``K)W`.Z)3WX("``"%!"^$B*@``?P'P!FF,`%+C"%!H"B`<:'
MO8'@,(?.4P`#%L``Y#'``0O(X@,@,$8=+L`!1T->\1ZPQ@8LX`%;A``#Y(B\
M!LSD`0Q(``3>Z#SG)2`!#%#``N*'/83@T(A/A.+X#$#%!'30B2H4(`"W=\+^
MR5")WQ/A"M/7P11V$I%2/,`!PG<`/R*``$(T_N+X$((0*I+R@@.)HA3C%\H"
M^-&*XCOB`A(92B.>LI$#2,`%%>#'4R(O>Z?,80ZMIT,YBH^5C42E$/FXR#06
MSP%C?$`$M"D!\46`9^UI6*LR4)IXZ:HI",L`NLX9,0\`"`,(R(A^-K`G;WI@
M0Q5XV088$`"&D,1.&V)`!3AP&0=<:V`D2Z<'-C"!)(D-9!3HR,8X0`$.O*N@
M,(+(Z[KF`=3(JC-)<@I0-M2A!EA``]I<'$2>@H'E)$:A<=N8W?9D$XV935T*
M%=?7+M"KK3DM:!CPB,ZNI:VUY6M@&\M54FE:EJ4J]6-,M2?!SEDGG#&U*<]Y
M#L>6:I,]E26KYZ37_DR=.E6.U<A$'`-K6.W6-G/%;6`SI1B6QIHK!R@(JD]%
M:UDVA%>GTA2I>;6J4B*R59M(`"L6,U%3)@-6>*&UJ8F52.BV!)\G;2`"736G
M1(:BEIB"RP,1$(NU=J<8#S0@`SLED-!**X#.=,U.'<+:BB"`O-=T(`(<N-%M
MLWG;M#BN/$FBP,XFNI<C-8`"0(%(!#[GE)UVK",/.8`#,B`;RM"D/,VZ;?4D
M8`!])J>I3K'M8"_S$+MF;&?O24D'*/">91WL`WM=`$0V,%@D66=9+_E+!QBJ
M&)4DIU5E><QB-;#&)'TTJ;L9C,;L*2GHW357<IG7V[Z:5/9,1Z[I5<G&_@#D
M&*S8%BF`>>][(MH`"$0$)"(:D[X:HJ`?982B2M$`/A$KL@G9;3Y8Z=!7*.`M
M'75D7_UJR`4Z,MZ$HA>]%)[J0Y#<,9IPJL,H:E1\,PN9ILRE**4"D'X8(($*
M2&`"MXT``2#0E@=H8#%A&<">?J=/+IDVG<\::(Q@5IG3RJX#0G/)`1@`N+)<
MZP$GN<`#LA@7#K3N;_<9HT4VH*,".(MF^L3M22.`@(%R(%A204F8Q"2!BI[U
M,HYK)T0_L"P,R!G%^&$O;>"CU-(BM6&CU@_"_@79CQ4ZR9!];*X4I,_JV',X
M'YYJ4:8*D1_EBBVZ5@"=/&:O4"LZ6LBQR'UW_L39J2[4.FO)&*PRUH$*-"A(
M;;UV9#";`1%M%<0:&_;:++>7\<+G;8P:K(G4&[+0.4``L!,`A)JRMK)PYIU(
MNHS@3&0VP`#;(E7RT@>PMR?7((RAHX;`;:?<WY0QM="P,L"7@T>!"$B`>:JR
M0)L^Q```,*1;%[B17B@*,S!2"7`:.,##)""!,@<O20A@FK@^$/()M"8SVRK7
M6^J8`,!A2-X1<,H!$I5LX0FN`4!]2CMS6!'LB.DR(`*I9CL#KY>%+D"`5>A[
M_CMPP'`7K"BR29J4-=BBD&A#2-D`K,I"E[/6B=]E[5>T&T"I*)G9(FEZ35SD
MFN`Z.>JI(%8L?)HE_H&_?-8U1+KO@?CRJ`\Q%0/4_NQT/_->6&W(`@JH[X!]
M5O<ZV36Q93YG6CJ#N,2.)U([?Q)3+2?NE7P7*69FU'CV2NO`GI4G"IA*5[]C
MKW'&ZD`##;ZL=O2:IP<4`P=PRY=;9P$"A,X#>P$^!#`0`!,+`)#%`7U="\J`
M&*O*>?I40`$X'BQ%.2!`O1(RSI^N`(1D8"\,F`#H]VP2$Q5:H0:8*`QXEIYH
M(P.P@-,)D`.`'9[PB@]K)P-CF1AK/87)%5[YB..:EQ_Y,!53J)>@EJPJ@`ZY
M/(MXCF9Y+]GHLW92*('"@*NH`$/A`&$K/8[ID"3YB[7)&`I(`!^A$O%H_@H"
MB3;,T+YYBA(AB[OJN!9T>C?VJ`"6>0_,V!*'F`"=^8TH"92&LZ?#HK#(H*ZF
MD"Z(P*P?@0]\*@N(VI,YL1,*$+)VTA%[R95E@1=&40LDB8BM@PB]8`C\>)#&
M*PK'"+X"P8K_$IIYTK4/ZYIK\:N3TBH'R2;!^*QH09B!*C8*RX`",+WLN),!
MH[2)B\3U(@Z:HA*RV+@!,"X'^)T".0#MN[\6'`D!0(RYH("K^`!3?!8'T"$,
MD(\8,P`E>1V%62C_V`!X.JYNL0@)6(!2"48LTXT$B,61B`"ZJY/@@9D]>P"<
M&8##R(PR:Q,(<)X#X``$Z"H+0(H:9(])Z304_N0*!W&("S`5CIB*)%DCDU(H
M96DXAYB4&:,)#K1'@V,4)..8D\(*K7"*'?DL%AG(LD`PEN(TALI#P-@]$BP*
MK7B7[%B67K,()U0R63&-R'L(J!D,QKN2][J<HO@/2U,0M1@HB<$3%>.1ARP+
MN=.K*/'&EUJ=G@,O18,++T&2Y6.Q"-`034$8&8P2EIJ*,Q*<R[I(,R0*#5!'
MO9@GK(O#T$"**C07!]D0IBR5B6S(#Q@?B>@6%!LG`YFRC$$2$D2,^<*:YZN`
MDC+%%3F`D+@`[&@)R>$NQ0B>`7F*`QB770R+L-`C]8B`!T@`Y:H<&MG!ISN2
MC&!&\J,`4L(`!X@<_@>P%M,J"#$IK2P:`)H9L.?K%Z`XD5(S@.;1@)W@.@,#
MK',##-\9KQ%9JJ^9J/WZ"+'2#PY9&R(IR1%!E3NT1Y@D%1:A$F4[O`NXIB5#
M&`1AEJ]X"+(8EB@\37L4DXEHC_YJ2'N1)ZT(DRLI+'S*"WWA*(>PL`/<$UE,
MD@N`M@:)$?*Z"C[A$S.Y-CVQ#KL<J*8@3]-R/PM8@/-<,K,B3A>Q#O>0JC*T
M@`X8@`(PJRCYLFASKXE;L`XHL9$H"[AH@`@PK@X@@`]YBPZ9`#.:%&*D`,2P
MD%[)D,YHB7*)#**H1L7PBY$H-0!9J#T93'$1IP&[BO4BOQ5YE_^8PJ-A_IJ.
M$8M&:0V!1`"**C/YB#:B0#H(J`#CX3?ULB<:R8Z.(9$<8Q02":XY/#`+J"^:
MTAFF7*\0(P"!VD+%:CVP2JKINK6EZBKX$,&.,3/#2RH2'5.S7"H..)6&7+#?
M\1C%TIES`HYY?(@P1!@I=2RX4)`8M"?!:+W',K=9]"Z>(2NHZC10_"N$1#V_
M,BDR=:HF3`H"L3E[00J0H+9<^8VF,#U9:3>O:B?O3"NDB*^$RLDBY#A0F;(8
M\YW3^@R0N-%C+"EMV:FI00W9D0"G(9TJB8D!TZ.*F!%`81;IP@"Q&(\R6T'3
M@HM\Z0F!.I?,8Q<%<`RVB3&F9,.4@8N=T0`(_FB99<&.BN*T9=$;"1"1RX(Z
MN&D6L>D`AEB6N)(W2#P\8X.,C%E-`P6VM<C2F8J;Q7F8_U@[P,'5.0$<U/&(
MGP$)FW$`ZWD:J*&:+C,)=IVY,:)8WZ&:V)`:("$=;DG8M0LJMED8Q@D4A*T1
MP&D7?6FKAP'7=%$9'(R2M8F6MWJK2LN7TMH3B#@M3\V7:!FH:+&IN'G*@;J\
M<4JG:,F;Q2F<E,55;>*=KO!5D!"(V1$6-0R3,#E87&U6K2`=BJ6:BP6>;,(F
M`2@`6QR(\8$A`3@NXX,,0+*B*Q*B`T@?+I(?_/&C8;);4Y(?55HD\0$`^3$?
M`8*B`26?2IJ@!B(`_@!X(N^1I`F*($^JH/*1H1+2($EZ(,U-(+MM'PK"($GZ
M'\5]H0%-(;3MH`$()4<2H`5:(?5QIO%1W00@I6&*GP;(HBR2(RT"(T'RHSJ*
M6"/*MP/0(5?J(/*!(2CBI%/"'BF")5JZGR.2H@5@)>P9IF3:HBU*"/J;@)E`
MHP:8GB_:(BZB(^-1"#!2`%O$HCE"'AVJ(BNR6P-@`%!*(2.:'P)8'X1X(AN*
M(@7:).D-)20"G_D98!CJ)"E2H?ZQW!-Z(O3!7RFB7PE:7!2"H4IRGP%"W/*)
M)56JWO=='@/H(V0Z(@?XHUI*/QPJ@$#B(@8X`##"GOA!)C!2I``>IA=6_H`[
M<K^CN:;0F1H*."74@!2:W;F1X<0P!:N]@S4.,`!,_9*DFLGPB)/,HQC#BJLD
MR95F>:LHT1"M`B]W>3FS68Q\Z99XL9>XH)FY\11FF:=VH1<*T`TLF==_\:ZX
M.BJ5.9=F`0DD?1RS\0C:^0^=X1ENL1S?&9E6*9JQ^8T,Q,X5.RJ3:;?%RE<C
MCHA22Q4[C42R,C(3^1)4H[7!^U/3G)M)A61[=0I_3%.FBDJMFCZ\NC,C5K!.
MQE3BK.)<V3P*X*P`_0!*^9B\RK4CB\)'-;*TB!;;2(K7T;<B3B\"8(IFU0`$
MP`^Q-)%&VSF*>A*@<`BQ;)`Q"1*)6(!(,0B'_H"3"2$W*[RM]5J*E[@3B0.3
MY:I`.C%._-`9&2$65%&)MQ$9%,Q)W5P)H%R+LM`*>IXXI@B/%>,R*M-DK;-,
M5T%FJ2E5CLUF59TR:`R.P>C0]UR`YK&<B2J+<OE7@GS.M>#-.5E-E4#:Y1,9
MFOBZ%9L5AZBK.?S7S-*^&LO#U\O0.*-GJ"F,L4P9B@$K./R,&<$U']E"`O`\
MQD.)TOJH\>#EJV*QINCF+>PVIMHKFW",5"&.ZS0VIM"87H-)LIP+BIDOM!LK
M+@[329T75][E[K0(;2,6K4JR(W,LQ]KEQ(/CC)$-1_V[]>+I[V*U0($J"C0W
M1>TKC#PG,LPK!WS4_BTT3;XBTZ5B/-/@:9!Q:Y.9["TLT`E+L*6JC\V!%^FR
MD0Y4F;(8#K5ZT+Y2,#F.1'6-NY$X,5KIN8(8(PBX'WZ;LN>3(1MJ7<;EGE":
MGQ66(^<A`"M*`./Q7@/"I?0#X>`&I`<P@&MR`-_FH]L5).QA@`&XHM_&7>=N
M(ZPA$`H(I#K"(Q#.(3EB(P2`G0B-``-@5Q+#IC6*6*53IE/JW60J)2]*HY/8
MK6?4H];IX=`)5IWRB(GUF=A`C=W:KC'"79,0HS-*'MZ](ELJ`/$))MZFW-W&
MGPT:8,MM(%*B7?RU6^+E(?6!I`66I!$JW`NZ(`#J(`A*)46"HM8E7C_B_B('
MZ"%2^FV$P-T;=N\$B)WQY5TARJ%!PB%2$B07QB+;W5O[3IXA(IH;)K$[$H`<
M[B(M"B3J`=X'^"(&3QXL"B7;W2'>?G$;.J#@5H`'KO'Z:5W)5?,)4B%.RNT4
M(J4&,B7)35P3DEP#RI\MXV&@6J@(N)/,<@JS"9/(^&/HHY[LD!D#^)W0`9()
M4'0S:0].E8`!B+,I`11NXS*.6P#P`8!.#X#[#!T(B"[C$2,($+-MFKDPXR+@
M28!.=W4`:("9$PUJ,1L@R:,'2,5M`E\OPG(["DQ;M-&,U@`QZQ4#8._8UB8(
M*(#UKJ;GAJ?G_FTYNL8%L!XJPAX!N%X!^+/0_JDWGC(`'E>(T7A&X/$Z9NRI
MQ9`+_V"\EVM6;=6*V?D:=A67-RI"I*,I2YQ7T.L;H94)MU*7I3`;?M<9E@*;
MG.J5XZ'81EL8G1H7;>V5`C`3;2J(W]DNJ>D5T((:"$"`)@P=GNE5`HB-2$_%
MB$-U\WX9!V"\UD`-`M"F"%AVD^CN"<!RUD%VT"H=;_H:U(`:\O`IH,J<#-#+
M.#*.CI&[=B(Z_SA&08_!KW&_GT?86KD6MJH1<!$KOUJ1BC``]2H7+U.2`E@2
M9&Z*4[$(!2ACQ="1!'CK!K,.`A!1HUXO"7&(/\N;C;<)6P,,4'D/!=A4`2@J
M)6:1UZDQ-20>P$`)_KW("9S19?A`@!UY:G\4ZJ2H@(>S#EUFM5'9"(]Q`'O9
M$^1`"X`NBZ,&C"1!,<BR9L@22$^!'@)QV;(H@%!1:*4H?"3#+2IC4-Z3BXS!
MBP\0-IKZ<V@VBEX&_=:3U8W&#^AY1#VR&[*PB.%/*EM;K`3@1Z=.B;'_@)9`
M`*7J-5DY"X/(:0H[4<@8E>TD"_O@`)0X`/VB*#6$Q]?C1$/Q@&[^G&WB@`.`
MC.M/+U?,9>@G4`\`0*-H0(#@<(#"AX(:''3PX.'#0@<+"Q;TL`#BAP<),G1@
M2"!C00L$(6I0X.&!`XH>#!1D\+#@A@@4(!2\L%##@(<,,E"$Z*%!3H@3_B3T
M+-B`8\Z3$5%ZT%#PP`8/'#ZH7`B!J$D$*RE>@-ESY].>$RHP=%F0PM`-&!@6
M>(B@:\X-"8)^V*`R*(>W02M\["!2@H8.$7#:C,B`8=#!<!_`_9!@I0>"'A)&
M?/!P@H>6'S1DL%I0`=R65R$NH*IS[M:W$R8<B+MP9](,%P9SX(`XZ`.P04/3
MM4O;0H,,`YKJ[&#AP87$QG,RZ'K1@8.O%S8@Z-G!P.>"'`8\C3!![L+D@B4H
M1+`!`(6'&P0,,'#@0($#`0@8(%"`P(`!`8A:C!"!H0"B%1A,`%$%BV%0$D0<
M</9!=!1M`$$$!BJ$@08";)#265M1%Y0$0&VE_EE0*!64(6$R043:4$%Y\%9U
M%6C5DP)LZ?2`!05IQQ`%"G0`G`<"/)1`A3UM,!N0I.7$@6%>?;1!`19`IM`%
M'##Y5D(>]M1`=0SQA.(!ZJUGP``(%"``?`6HQQ`&"C3`P'Z7.9129VL6E0",
M.BU&ETC$\?00!QDMA(%*#5Q@8$\.S+@5`Z(5E$&"6SF@P6`#4+#`2AM,T,"%
MQQVWP%,>W/28!Q9(4(%(12[8$P<!<.#!AAK`Y($"/T*UGW#3?914<GO&IM>+
M&\2V@9(K06`54![<)R`%FU8@J@)H(K?951=0X(`$&"BTV@$<+8!3:83E-$%Y
M05T+%X@GZ5GI0REN_@K!G`5U,-%6+%[IXU826"!5@!^\%!%:/:Y;&017&@D7
M!X)VZY@&=EU5(:<0'7!EBE=^L&A/!R3PP`(+($"=0@DEY"X%K@F@U`<79.DJ
M7!BTF--:<%%IDDK2,E!!!YOBYD$&$TV0`<$4$0?7H4%9L/.!#/CI05J?>1#!
MI8E!#-&+"RGPD@0<2,```KH=V/*!`TB`9@49:/6J8!$T^)@`E[(89Z$4U5D0
M!'E6P$%_$+ETKP9!=O`:10@NU'9,TA+`@`;W&IWJ!PW`:I+$%.D'5P*(IO20
M`7RB192(#JP;U^(""HG<E;45M"%#$J3<`0'69HY!YUAEV1/)<'EKD*1P_ND%
MD8@]/0Z7N^"V^D$'?CM->04S]MEZ:D#_6UB_"@+\U@,4`+@!8%::%:B9JX.F
M;5&'5A?HE>T6^`&(52:.:5$*X29^TD!]A:!TI?9$@`(5.%#!!@9D8#2L#4"0
MP%D="``C&.@`!CA$$01\1"<(F%F%'C`7"%@`51"1@&-B@P&"9*!U<;'+J"!2
M0.W8C"(&Z`KB4#0[KQC0)+D[GV$\<(`*7$!D`[P`M1K&D`>4CR7`XQR*B$01
M"'R$7AG!R][&)Z^B!.ED0DO4[DQ"`;MUT#%94POD7`6YB,'%`PCX5P?J9T.3
M%,"`"\A90?P$D1UV)&5LRZ'OM&:=MT#@-=32_LD','"!"<"D-G#*2:.N%"[7
M:9`B[4J;B`S'D)69;RN/@8I"/G"M#@SQ;IN3".T&`,D&6&`#$LC(SQCB@`9T
MQ0,$P,`"#."2%!XRD*+L`)A<I1F;\6B"H'+*!BSPE`SN;4$^O&!S/B.B!HBL
M2!W,"0506:(K;6!W5HE-02BC@0JXD",E!!+6*&(!-8+F2D`,704T)8$(L.5^
MJQ%/4*Q7SB4F)9`3!`QT5K.5!&FQB@N$R^8BLD4/#.\"MW/:2A(@LS*V<'PY
M49WCV-B!M-!E(@Z(@$J*<\/&:(`"$5!55G2G`3]"#@-6"@KX]O-%PEPR<^8[
MUZBBZ1%\80`#.]0+_L!JP@%`/4``B$%`,!UP0E%B(`((K,`>&9*`>^E$4EN2
M2)X^D('33?!KW-(`!S)PI`]P8$$GC`E94$FN@LS35/5LC&VVAZ(-),AT5+G=
M'Q%7G;I<B8A%^4`!,@<!VS3`-F3Y464*D$V@+;&.ZBSC1GOR@`N%))ATC%B/
M&ED4-Q8DKPJ"``:>@@'X140W(S&3S4B#1J-*)BBOJ@Y+@W(S#T!@`A,YUV`6
MDC8/7-"$VLO)9<W(41F!,P$7W=O`V&@^H@QE(==RP`,R$`$-:*");Q080@E%
MOX5H"B+2HD@!YO@!"_34A4MC2&H6N8`CF6XE+I&B[SSP.HC(!:M4P4"E_M;&
MKLEA-7-U@<OPKC35O8WJH)!IYKD\-,VVJ*@G'JG.PW:SD+B&Q2J-Y(!=#PFY
M2L'ENT4)7U`<<"'Z?8LAZV/(HE;8$^$&-3$)V'!&;F2JACVE`P^X:$:"QA*$
MNJZGA)$M1S',DI+41HW!?(F(GP@74,8KHWN-2QS51:5S@3*1*$H)1Q88&PYL
M@(!/9=<P!6G)#Q`J:-#T$*>Z>JH+?4K%@2N*0!EP)*,110(8&=9"7+-'#KAK
MR>0%L+ZTJ);,U6XK$3#O:+C%(+MTH&'.C7"*."*9LU[VCO2$W&^%$J"DP20#
M@!$1CLYYLB5#I)AP86RB$'.N#&Q`*9Q:S7LI_N)#G>Q8,0<PW)FDLR2<!*HX
M%;K`FB@9%)1=I9')E0ZDK5.2N"8O(JW#2P<H8&-#L7%A6RE@9XCSK]W5JT17
M-(XAA<*G%UT`+YETK2"Q:9"CR0A*QR:*`]H:D0(`9V1J-!I0[;D2!K3I`Q.H
MR00;.P$+&$`!DLFI($>[9`VP&IQQX5-6/QV9PW35<T$!:T0XHZ,"'&FT'Y@H
M76KM76B6AM#:(I3;!)MG<P_;VGH]F3'=IBUS#M9W@O*W3[/H8NH"U0+5]-T)
M)S#`B&A@-JZZ$K&#<B)3=9I=)9$`@J&:D+XFBR$9H#-HFNWI*V6@XW&A%P4Z
MT$+&4$;($3E76/CT_J\Y9YH#!:*Z[S)+F-5$]88X,=R)%`*!J:V&`)L:6;F7
MLMK(E:BH&$"H:><HO0=D1`/[64V0RFQGA5#`H8UEB*0:0O753/;K$8D`B=QI
M^,./CEVOM(X[24,9KBN$X>YDB`4T;>?#;7XU8E[(7RMT6J6XQ2:.CPBQ5V^S
MO>M+Z&!9_<))W3MNK4;F;8(\:0XOI,.+)5%^6TB["--Y;A60T[@GS`5#SY"I
MM%G"L,=]V7B.=PXP=69-Y8!V.)"L"HBL6E@R)&,TCWC4XAV2CSER1",@`7T^
M<4,3T`\$_CC2I"0``5MBCP`.H(`%#(`"K`?%)`![,,<GI0D#&``#7,RR_C!`
M`WS2`#!'`9S=-S'``#C(-QD`!8!.BCS`_%7-H>F+`F@%27V3?AB`I4T`!Q``
M$)W&=3D0`B``"4*``FP1<T1``QS`AJB)?D0`!#S``RP@<S1`$3)`"T+@`4#`
M$CX`$#H`$"+`:?S$"=:@=GP?7M"0`F1`2G&A!J34`OC*8V%&!L3?AE3`!!A`
MLNB4MQ33!$B+!#0``C#'`Z!)$-K4`R8@`UX,`3QA$))$$<:;EQ7`=6$,`GC9
MQ20``2R``ASA`B3`(B;`LBB``1B``RA`),[@`6",`33@LB2``S#@)S;``Q2A
M!#Q`!%2,@SAB$'K+!)SB3ZSA#Z8@*^(1!$C+_@YNB(/\(!`JP`&&%@(N0'N(
MC`44@!T2(0,4`,P8XBXZ4-0\D0'\1#3Z6J#4A@7@Q?P]$0*X'P.\#7.@&P$4
MH`SJ'WL,@``8@`"@XY<0P-60"9D0`'R@!SJV(R6R1P`,8)<80`$40`#.8`%D
M3`+D8__E8_YES`&`"9@L``'X(,^=!@5DE9`Y1:[TA;I@@,[D2`9@Q@5(P`)8
M@`5<P`58P`4Q)!M20+)(@$QU4P)$P`-LR!A]TP,<@"UQ2"^Z7]5$#=5L4@0,
MP`(\"7%H@`04@/O-'\)!U=0,P"DR%`*PI$=X"^E$@+PM(11N2'/@D2GR%KIU
M9+1Y)`+(WQCY&EY\_M,2:N-"AM:-C.(<0L!U*<`@>ED#)$`<RB`X7E?@7`QO
M%>,'1L`!S"$#-*%$N5]->N57?I^#?&1*2=L%_%1)5D"H\-3\?*0"1`"+)`!C
M76$">*3*P9!K5.0%N>+0924-W9$#*!H&X(5B;J1'2M2&\!Q?SB$)+L`H-J%-
M%:$2`B)O!6%4.H@!J.9IA)9+I&)4:H?[!<ZH9$:R=&3@3<!/>8MV^)JOH2(3
MIF!;IDD1+N(<-N$2ZE1--J2W7(",8$"F`5>2Q5S>5`#>N=,<?8I,)`6LI(KV
MX=#,J-]"<,"3^(JOM&<&'-KA152T#4ST84G3,(U)](YD@!#XL<I@.47(_OE.
MPX"6MG0'XD&00B29`="54QV+KPF'_PT0!51D_U`$;^5(&W&+TN"+0D"<!A`/
MNTS?YT%`#I$&0IB$=6`/C0C62FS49\B&A/V+8:U6NJGG5LC<0`7<N<!H[.&+
MPK1H6&B/4RQ*[^E$!D!<3T@47.C=WS73CY`7V#5;!X"')S%&G<7>9&313P%'
M!:C3[RB,P@C(VI1$K!G5:IU+EWY>8WR>0>R'-4Z%YW&+M_RDR[GIX1AI1-R>
M3@1=G6J21V@42-CHLB5&JJP$A*B$KQ"&!ISICKE00X3?8['%\_C.<P0`K$!+
M]$%FC&K0$P+18PR33VI?`40+!PK2L`1<B3C7_C$Y&UWLE0<TRF$@$X04@,[H
M";O,7$'@'4>E6TYTY)4X7*Y"Q8\D:41`QQM!#JLEF(H9A,9)`):N"0=`@'>4
M$3R1G+!MA;4M1`$$R+2\C:',3'D6#/'EU?`X#IPU&4A,%/]<'DC4D5]4Y&DX
MU*`07TYTP(ZUU\"]'P5L0,GXCJ`RJG&<2ZY)2DI98P<<:%%8*@4FC6#)R4.,
M44(DQ:<^1&IMWJ@Y7K`**V-EQ,5!!&,YJ)@-70J)6&+%VK_:1FP\AGU!3L`$
M!02\7609%D4X"L9)GDZDVP/`V8Y-`(ELSY6(9F)1RTA\IWP^EL\2$[6.C-)=
MTY5<:QHE1A<5W,Y"_D2<`6DE`46.;"O2B`>E4`!3-=4'%*K7YH2[;D7Z^.N.
M5>DI-AVL=-5?*$1(^@S`N!@^$1U+O!N3M(ZB^%I%0!ZF*(0A9=:FS5F:8-_M
M@=WRK88"7-2U5IX[;>3%0.!O1,0%+$`$=``1I0@FJ<I94-)#Y*4?.@"5#=ZY
M]`EW>1=#T-74X6PS(8!,G-"?19]?<-WH`,;?>9V=::N$%96)ZLOBIFB8$@X=
M?>?RT<B7,L1V/-]L)1E3V!KQ0B]J%0?F15O(58:<XMZQF(F<<IW6*D20ZL3"
M?.E"M!H=@=;;V&$+Z<3>05(09MJG0!QH0:_:YH^51MWRM:SB/899$-`W_O5*
M?0*7Y_[5'3W)D=5G,JE??/I.O8C?QH06)&%P4Q40$&H'`N#%&5I?`R!<`LYJ
M8F3`/IKCEIBC/HJ)`,R@`2!`?3``FEP7`RKBQ3S@#.>?`+PE)ZJ)31TE$R(`
M!/*6!`1.FC@B9#)A$!YEW9Q&!`0E_15`Q=1D`?"/M"Q`$-)?'5XB$1;A)UK-
M:V:QQ23`ER"@`L#CQ0#@)4:B)3X@0([B7](?`F1Q9#;G:42-1WXD2.)%U"SF
M#N(12Y+E`=BA`1!Q'BYB`7@B0<XEPC&@'B[+.JHN$;:'EP6@+<(P'U[-`;CP
MEGR)&B^R`/CC.&8,#,_')1(@0<:'#'K9(5H-_@VNY0=BY]DME`[^H`/,(DD@
M8)H$#@,NRVN"8B5"H!%ZV5HVP`+P%@(,IULV8"4JH`TJ81#",&]!@"DMY!8W
M@';881'JX!/:E"3FWP`0Y'KHGYAX2?_IXP"\8SDJ\B3NGPS&QP'4QVNF99C4
MASG/ARC+QSH.P'R0B7JTASY>3<4LBP^.HA3Z&D9^)).,U/;Y"G!MIJ))RS,9
MIQ[?T;MQ)AM^GS5&6R_NIA1NR$KB)OWQ%@(>($DH(78VH7X$80-0$!#>)G:Z
MW[;B41R3!`<[95H*)4+7I$=@I\NE%`,_T4^\Q!+"HON1Q&EHL1\V89J@22NW
MI3CR91PVM>8FI$E;_F<MZJ)1-^17\N;PE.%(-F<Q(:6#%--'OX2W;+0><Z$%
M-"0-?6<M?29<5R1<>W5'7N8WR=]?2D`?QC1+R]]/+%0QP;1,\YQ8NX1QGF$&
MNA^'DE=S>N09[J)^+`#/E65S4A"+&+9J`E%(^R'I9"`%;4@,6:.BV2>O[$E\
M>DI16%6=%H76-45"=$6.,%![^J>Q"I;4*6R8F@2F6>G^*JAIZ6F,!BKFZ42N
MS:GS6NG?[8FIK,W^NFGONB]O%W>,;MY6_+;#(&B@4O=U&RGM/6DHK=5W*VAR
M=_=M\Y=RF_>?.J]T>S>";J]Q`S=QNW9T!_</G=7LIM1Q7#=[2S='B91N_@OX
M@`\9@0N,@3,-@"+X@C-X@SLXSQC=@TOXA"/X9$44A2.XI>6$!@1E$'87AH,X
M?X?X>#^X@I?XB*-XBANX`R29BKLXBK_4<\7JB_?0E?1%!D0XC4^X=W&MCOOX
MCP-YD"?2B)FXD!MYD0Q&;QVY3L0KB2\Y@_?XDTOYE%/Y@D]+E6,YNX!'S@5Y
M9;AVEB]X4GPYF"]YD9/YD9OYF;_X:A1KA5?W=BN>>JLYE"?LG(?XGQ+0G,1:
MM:SV?`/K8W`$TL!Y>==I]BZWG2/Z@HN8=M.WA.%XUYY&H+\$1I2L+8+3]S)'
M<$5-HG,ZIVO1;$3+Z!!``$A@=]!'/\_(!*#C_JH#$WI!60HUQJJ_A]-%Z0=(
M@`P:I)4D@$.-A$-EP*[+[ENV<@PM;C7+CU*(&&`4:J<S.]/H72,AWFT/;]*]
M9A`Z!<E`'T/0T+M%BQ?>46.5IP8@4&\T>[F3^8Z<3=),Q%'1)P)I$5\T"$J0
MIP"$I*\\F40@MZT?0!<J1KG)6U:>Q3''Q-$<#@#D"?<YP`#P#P;`FR<=0-'J
M(&H!@`T]H;F7^W5#1WTH,L7`!R7",(EHDLUL*^<U@`%$V[YJ@,EC)&\P!-5\
MYV-E,=7,%HA#DL7;O-2=2@!^P+E"X$.(BA85B@8@E4;\R'4PU:^G#&C)B7V>
M1`IQ*K?X!B?-!@MF_DQ5;(H%-,P&_(:U>"J]0UF^W_R<S]?7Y8JG:&P%7X9D
M^,I?'3,'!.ZEK,9W7I>B58!&<>2_]%;%S#R&IWG8FWL'`(`^9<5$]2I(W`>8
M<+R0=`#G7@:IJS,`=$ZLUT<`\(0"I-`%S@>D^(X!4`L!B,P%I(7GGXO:Q41J
M).=Q,Q8T%H"(S:C?N_[>8,RN6P!/$H]]*E)3)*[-[&N$9-+K^_Z+=P"J1$`*
M_HME0L0%;$0",$`QM>!#++[A9(``[$F5.1%G`+IB[)$"3`!P]45B60I2<8KJ
MPX3"8$?I+]Q4Z0<&4(=*\M;ON_]T@_>7&W=]OW_]\ST`8`0""`!,,-1#_O0U
M0'A(4.&#!PP*/B3T0("#AP\9!CC\P(!@PH(/&%A,V*""Q`\+,FA,J&&``0@*
M"2A@<,!`!@T%!S3\@.'`0P$<%":PD*'`S``!(H@4.I1H4:-'D295NI1I4Z=/
MH4:5.I6J2(]5L69MZ@&`!H,!3G8H``%#A`(O$U!(6`&!10Y=$V8@(%&!6HL>
M'A"0\("O!P0)($!XT&%!`PH4(%RP:`!`R`\6YA8D4&'#!PX!9%HP4%#!@X84
M#'BPT-.#`P`.M*:V>E5U:]>O8<>6/9LVTPX8,%RXD`$W;MVZ+02_@*$"!0L4
M+EC`7>%W<`L5H!\V3F%"!0NZK5^'7B$W;]P:_C1DV,`AO(8-X#EDZ."!?8<.
M'-Z[+^B0/GOR[^'#WU"Y?H>"M0$,4,`!"2S00`(S2&"!!!A(0($$&D@`@;\2
M<%`!!198@($-&^C0`0<:<("O$2/`J`$&0`SQ0[X$<R"""`33D($.&5A@P@H5
MN#$!`PHPP(`##B!```$*&(```GSLT<<E@>01@2*/1#+)'_T[4*LJLV+-2J@\
MP&G+J2AP[,LQJZ+O/_;^2U.HJ\Q,TTR)M%1(3HW:](@]UMX\4\V[YM.333++
M5,U+0)V*,RH\7=,2`S&M(M311R&-U%%#)8U-`R\]6$\U@T*BM-%*00U5U%&Q
ME,K34<L<(".#$/BS_J`-M*SL*,T`".`!.^G4R`*$YD35UU^!#598K#@0```,
M9FJU(`QD]8""!83"0-FB/#@@@@XV*``#^C1-B`-8$Y(@`87,.W78<]%-5UU'
M-R```@9$RXBP`0:8X(,+Z"U5`P,$V%8S`Q2C<X!..<`)`P,&0*`A"^AMZ0,(
MQO6``0(*.$#6=3'.6..-ES+7J&S]PD`">"\HH`,-YO)`@I/HK""T#PZP8(*4
M[VI```8>R,"A!"3HP,4/&I!`(+4@:,`#GN"S-D`T.6[:Z:=?*]4I#B*J@(`-
M\7*`O0(JFR`HD7CR8(-6%WKI+FPCF#@##ACJDP,(%!!`,0A0@T``!`X8T``"
MCZ'NV^^_#Y2Z*8C86P``>"E`2`.3/_!:J`Q:/:@@KC6J@/'2(J#ZI9TZ0,`!
M#!:PX&'4)C@@N0FV!5SUU5G_50,%'&(;6K$@T+"@"!)@3:[U"LB@@@/8+*`!
M#B@@`-D$'"B9L@$PH$#OK#]`68+B16_=^NNQ?[3@@C1PL4H-KJ6S>\5&Z]VJ
M"Q((@("@,F4`@5L?,P"!"'K.P+$+4*SH*<&S[]___ZGU*3@I!5>KV9.;YN2J
<J/`/@`UTX`,!Y`&S885O$+3@IBZ80:8$!```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>f39432a9e3943240.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943240.gif
M1TE&.#EA.0`7`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN_O[_?W]___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````.0`7```(_@`]"!Q(L*#`#AP@:#!8D,.%
M#@PC2C0(D6('!P`:5*PX$"$#`1HXBIPHL0.%#1!'0@@`((`##@<[:F#`D@#*
MCAX04N!(LN,$`A1@'LRP@"6`HP485-B@08.$!`*.(H60H8-5AP<T]C2X80"`
M`088,"!@5*K9`&B1/KA@0&H``0$,1!VP<&O!#@G,ZMV[=P"""E'Y`D#`TZY`
M"F7W)MZ[(`%@P0$FY#1,D`,!P0`""RXP8/'9#)3O-L!,VBUF`T)##YQ0NC7F
M!:H+7O#LNK7DV`,Y-"!@``$#`PV".T!0H,$"`\<;'WB@`$$"!0H6,(@@UL%-
MW`>M3IZ<<B1.[MIC?&+_GI)[S(W;Q9L?+WYD^?+;M://"1\[4>C/I2=@@`#!
M@0,*'(!``P?L)U8"^>%7P`/L"<1:;1`N4%AL%$`(H0/IX::!5Q;JY1F&$ZH&
MP0$&#$!``9P58,"*__6'H`(,1+>`=`<P<`"*$31X7FZIW171?"'J*.201!H6
$$```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>f39432a9f3943223.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943223.gif
M1TE&.#EA=0!8`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````=0!8```(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#B@0)`<$!`"A3HCQP((&'D3`Y0E!)LV;*
M`!EBZHSHP<))FT!M-L"PLVC"!4&3!CU`U*A3"@.42@6JP&G1J%.SVJQ@%:;6
MKS8I=`69`:Q9FF+'<HQPMFW*!&HU6G!+%X"#N!?9UJ5+`"]%#GOW%O`K,7!@
M!H0?"C`<&&[BA1,8&V[P.&$'R8PA5#[(`#-C"YL+>I8<>F""T8P/E/Z`6C*"
MT'-;?]Y,0+;D#I5M8WXL0;=D"8D[^Y[MM_9PPP$('Y>\`.^&Y9(YQ`4,W;"`
MZ=4SJ\60G;':LMT/_H^]$-[P6.KEZS[HBG[X@`)8:RXVB]NI!^CK/VS0"^#`
MA`_M:=6<5=#=-1!*!A#45E<%+&>@0"A5=>!9^1EEP'($,(```PVL-%"`6B7G
M5&_E)3@A4`PLP$``-FGFE&X)H?2:03.E!%I!L:4T@%7&M8;0?0"86!!_]1E4
MDU61R19C?P?5F!!_*56X$XB8=<#!!AL4":1C`FF0I0-V$<0!!1;DA(!-5BDP
MW(`?`-G7B2@1E*12%SCUG&^433@8G#O"F=2,1IVFVX.L`?`FA"D!)Q`%6G7E
M&YN%[HDH2FE]0.)431D%IFT/`BEIH2@I^@%W64%:%(NRY8GHH:`"\.E7_ET!
MV9JJA8HH4(<I$7195F,Q.JN"<1(D'`"5"N3!2ZW65&=79Z)&:TJ($80J``EI
M$)2H5B$U6K23$BM0!O.EE&E!X=(DX5@7>H9LMP`\0"4`"6PPD`>X`G6C6FHR
M-D!.`_GJF09^/<"8E!^4*]FZ<8$7F&H":3M:99ON=0`'#:+FXF,=])A>4JM9
MH/'&-$FWFGXU@IQ2!",7M$$%'W?'<,H(8>D``_D>5R3,#F4P@00,$%"``?$9
MQB7.%V5@P=$65/``!!`LS;0#"BPP`$L%*)"`U1Q"(`'"1'?M]==@ARWVV&2+
MK8$``0!<T7\HEPV1K1LT`!P%#6A0P0)<>>``A%<6K)=!`QUXT!=1$ZRG`040
MB.RV09+VM<`&!51P6<$?#%9`!P*@/$`'.ZIF0`</7""`M15\NOB!(B<'`08N
MJO9`!GTQP`%<&C278',+`%[Y!5R=>_J'``30P7-5,3P``:HY(,!=>_8\V([K
;G41!!L`1^CM#OE^O_?;<=^_]]^"'[U%````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>f39432a9f3943224.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943224.gif
M1TE&.#EAK@&'`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````K@&'```(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#A
MPTP?)$B`X``#Q)`C+WPP`````@X8;)#,F?,$"PD`,,Y0<(,'"1\D&$#=N;5?
M`98O'[P`($!L`P`\N-YMMT,'"94#",!`<',!`K$%"`C`NWG=`K&9&XP=NP!"
M#Q<Z.-^.UK;E`!,(_CJ@'INT00B8%^CFSCXL!LL&$!#4\($\@`<?UG_(8"$V
M`P`:<-#>@%YY\)V``S6`&W40Z/<!!P=0!UMX!%:H50>6'4!0!QY0\``"%62`
M`84#A48>!Q48Y*"%+#*5@64$%"0:`*P91`%RU.%GD`46/-;BCTM99MX'%U20
M0(P)+(!0;.,Y8-`$%3BP``!.`FEE41$(.1!TL2%X$``'1`B`EP+11MZ5:`[U
M```*#%1!;1$@0*9!#U@0``,6;*B`A`4,F>:?/`%`G$"5`7"!B!/]%UL"$0#J
M*$\>-$#!0%DB`)L$>4:4)77T/>HI3ADH*1".L`WZ4`<(+&A9`1=\ZJI-_AX@
M*(&$G3XT`7D!:/?JKC5M&IM$$W!IF7R\%BO3FM2U&1%YUIDUJ;%V;4`=`2E"
MU(&O!ICZ5044O(DC!0500$&FT+J%[*\$46#`0J2!!H"H84E;FP&-=K!`!(5*
M5RY;\EKV[(,9K+MB019`X-U8MUIV`0<:;#:0`1/.N6]9&,)(;GVQ#4#B0!,T
M("T%6H8%FY8/0/`OI99-G-9XEC5`T)O4.5P0`R!;IJU7-<NVL4'C/3"PRE]I
MP"1![YU)D,$)&-`?`:V"Q<&L*:_7*$(LUPAT6"]:IN,'Y]Y6W`(/'&"BKF#E
M+$!"UF70*;I7AX6;TIU63)V#.<?6=%@)`\`0_FPI-@!CVV%%$(`#7JKJKXSD
MW0T6!-\Y9.`'",16*^!;;1#AN@+Y"M^0<B='%N,`G%WFR2I^4#2-E'>5@`)D
M8QPS05U;=O'BL4'PP00)-)3U?:ESQ8',`I&G(4%31F?[Y]0=X*="A0)P?.]9
M5<"`?I%;]J9^&51?GEF@QP:O00I,?3KOT&<UP=3[:1]`[AS;U[I8W<,GP7H9
M4"AMIUT_7_Y57KX8[@#?,Q!U`O`SVMD'`.N2@'3^HQT3Q69K^]N*YPCB0/B@
MA67V21'(!&0O(MFG2A'4R@(VH`$#@/`#F@.`C\["@0,Z[P,0$)WI#->E$&ZE
M`@AX@`,@6+S8`,]9_O9A@`1NA3X7$LN&DZ,*`]8%`2^=QH'-2DO=+*.!#AB@
M60?P#GD44,"K<4`_M%E>5!CP``X,H""X6=,`WC<6Z."G;NM:C$#VY$(Q4BX"
M5IN``+K(E#8Q@'T"\8`!_$8``5CM*[Y!CP`@8(%.P<QFO&NA"RO`1Z!AR`#F
MD615&C"!FYD0`@\@P,V\8C`$1F!G^R$/?LQDGU%"[T7#0Z'>JG*?UDE``A$H
M@`(DII4+1*!F#9@=011E&=LU[S;"!-Q_3(4<!C1-`+QL2LE<1A`N/2:)6<%`
M?V"DN.OT\)@`8)4-(S>0#IBH:<J22@(V\+X)$(``$TCG5G)&`'DR1`,!_BCD
M`A0`33L"SD'(T94D`>!/BG3@BS?9``&.^`$,:2`#!\!<5CB``!P!()D5H:@"
M-LI1CB8`E:^:I4"RYC!?Z<\B)CKD3`802R(%X`+ZRLKN++/"BS3@`?AR(77*
M!8$H?N!-9Q3(@GQJ$02Z4B84.`#9*""!T%`@FD_YS')@E`!L1J0#%,B;3NU3
M24#M23]0RY,&8$-4B`Q@``D@3D%GL@$2;0`#]*'`6IG2+[91!`,02.%6[2,!
MJ_[)B0`8`+DL,P#;8:B;"VD=83%ZD[MQ(`.38D!9FV*:'L+HJ`SQP&8LNE>=
MQNA5#@"A`#\+-0!,X'<1F0`"J*F``$1@KCJI_L`"0-J4`]+6(1CL+'7$-;+#
MO>IC`V'9\+`E$9@I0&T_%$H!0LE&IMBG`"I]R!3W:@`&<&@]K,P-K_8$0K\!
M@%@9:PBJ[A:;Z`9%6A8P8U>'4H#>6D:&$>%`##NKU-\E5ZAV=57%]..=/-6,
MH0GISPK[`T&CO(A(3]'K12E"3/O89@"+9,A`RZ6U@="Q`!KH9$)*:"KH%"`!
M)TV*`\*3K:5$P++%G$@&$N#>`>KMM@8QT7H!5<.\A7@Z`!*(T(;UE`(P0`$P
M!DJ++7-"Z>X5MD1[+[2BV-M)U<R5$R!;\3(U'M(MA0,/B"=2.A`[RP`2(H^T
M3SV+O!"A*6!^:;+G_D%L0Z'HE!$`Z"L(<JKY'=U@5BG]^<!]?Z)%ZIAW(30T
MVD,X,+("6RD#:U3(CC/GYRHB1)-S](]5*K"!+P-%-P?\;$0:`,[OQ+DA%2A4
M35G4@>,2Y$4W1AD`4H0L5"[`ISAB#7+@6Z$^>RV^%:3.G0^B@#6!9\\5VD`#
M%/>?5.>'`7.6P`+(I1]I6:W0';#`;%L49N]!%2$9*&WRJN40+A/VSRQJX>1H
M\^F">`";#X5=;3J5,P!7J-J643-#LGL;Q"8D`Q<`'0+*C:8I.2A"]EZ(`O07
M&V5M3RW73HD+)]+I%SJ$`V8*P&33Q`')RG,Y&Z/`J'?TKN-1%$8:J$"0_HTB
ML4:A3VPR(]$>!4(!!#1,(%'4M$FT&AO&7B>W\0;V0#PP`0G0<0%6?I0`T6>!
MROP+`P9(`)DF4%._">!9JBIQ5%!I*()8@&PZM/!ZUL,:"[`&W!]9>$1P#H"@
M'V2;EDDXH"3)[?X,P%0MY.3.#X"`(<$F`'G:W0#`[A2]#:I-IQ4(;#I55OQ@
M8(4B+4GG#@X1SJJP(;,:&4++53%JRK+L`\D:06:E:;0+:%9XG^<L74:`N(4Z
M>`[*P&8<H/3@H21^\8[(=/WJ`1$)X)VUZ>O[,D`:#@P*`V13W`90>Q`/8$#G
M"IFQ6XI6*Z@5)V4#^0_3&#TL.U7%F09IJZX0_E``X(GQ1ENSHNM/HM?F*L36
M]]6.MA%@;R>E;#R^@;ZT1K7:!L1R\JZK%08:(Y`P)>``K/$`\;%@?/%?JD8N
MOL8`G5(T/B(L95%&#($!/V-S'@%[,M<0%81*NA$_#L!O`S%+JV8P@K=JKH=/
MNL$`L<0F`S$`W1=A`G!&J_,!_W$!:R(0D2-LB:<7)H(@'C!E'R@[`H%VF[%C
M.6@E]B%O"I$LV4<=!=``QO:!`H$:C.,!D=)>`A$>W<=R-?(N`R$`2C(`"(`A
MK.%W`+`9VL5]F6,3##,0&\`C!S4=;=@!0Z(!/.(!%:`K%]!-`4))`9<?/`)Q
M%Y!>@50!>1B(7C(R_ND4&Q.@&PD3`-2D1?+Q'_1C`7DHB.,R,!7`(W^8>93(
M(TU#B8$X*1U`B)1XAW5!<TB($*H"+S`%8;%Q`&;W)7>C`06@*XS3*O0!`,T5
M@X*'&H+U>+>C-[0A(-H5&C9Q`,<!(Z216]6R`852,U[");8A'=`W$-I3A.7T
M';%!375%@!Y$4S]H6E=8.P\B+/)!-IS5*J'Q0]XU-#!''0U`C#OU`=-8C1#A
M(.9G$'/R.VI3&EWT/O:E<PSS<@1!A1=!'NZ6$&8D.1_@`!0P,LO1>A`1>Q^P
M`!KB`=HA&]:AB\4G4:@C`*"1B*F$>A]@C&3F$FO2`$5#'&LR`5DE$!63_B*C
M2``!\"S(@0'($CPQ]0%[<@%0DA!3LDL_%2&3(DD)0(D%H0%BHBP]U#1Y(Q_C
MPVU9<Y1-PSAD(BW<5C3]]UT?@!P'8"!O1Q`1\@%^(U$.488#<0$R=`&6)VT$
M899%\R8$-RA/=6HY*":Q6!\($!H.4B<#<7@281_?DX3)0AY/N!`F0AKSUP'$
M<7IYPI&I029H61\+4`$%8`&*\8$-X%0+X"/K>($O41G!(RA<DX/_02:T(3I3
M\@&+5A^TMB<,L296`XRPB6T%)Q`]1$V]A1_>128>`!L0!!V38QLS(QJ0PSNP
M08QF^0%CB2&#&9NU<BO/N1]C>1#L-Q`G0YID_CDY'0":/Z40&W`\0J,?H>%$
M$H%V=L,0N?9`&<$XNP0!ZD$0!P.9?G-L]/@L:S(U/_:!;\<FP!@:;Y*/*K$F
MF9AVI3E$J&$@M(8QVC$E"P`;!K>3>Y(`XI(0!A)GX200H=%KD&EUL9$B`P4B
M`J%%$7`!2A5CT:%^5#(0VU00;Y([,,,RHWDPS*DWLA$1$#`Y`Z"`^[%4&O):
MQ;=S->(!3?0!=8F=QN<GV;%A)^-3M.%7#]$`?68;"^"$[A(`6!HZ(Q,?&-FE
M&N$W3T5`<E@F"%0?NK*9>F9:`D`L#G!$^QD\$_`B&?"FQJA\)>$=#V!=`L$X
MR^$DD8=C5!@=@_6:_K$1B_V!H1>9,0;P,WDC((A6<\%(CM;Y+KXG(%FR5/:8
M&ERY((Q$'P)4`+ZWE;B!?`>1HP,!<?61&C(3`3$R2Q)@'A3P/I;W`050;D)C
M&R>T5J%2',6Q`;-R$1RP>#KE7B)!`!ZB-[%"IF<D4F@:GD8J'0B03@W0+"WD
M01B@(!J*C2\!&[-:FAM2@X@3J$48.@6!``L@H$8*9P2QH@VIK6E)'55"':31
MCI9FC>3#:`Y"G,238Q'R99)$)F*"0&I7$`Y0*V;T4P"F1P*!']Q9KB^#306`
M`1>PG`N1&0DA`<1!`2<9$9D8B![;B1Z;(D(S`$@F$:(3+ARPB/D12+<B_H/*
M\D<K&XRCDDXI6:/!DR)C4I*S9*<C`1NDDY\E^H.F0D4C6E9I5P&LD0!GQ'L)
MD243L`!S6J8-]1]Y"K4)<3HNHU6E=V"V&4X.8&I9TIGI=">W@[12&R$%YF65
MB5\5J8(0(8$O,RKJBIW!PP#Q&'U>0@':PC"DDTX`9FPET[1-HT(#BQ%"XYT8
M88S:Y3<'<),P"8)`]R[O$86D:1EDH[!.^%.8)SBT:CLM*Q-L5A!=4R7=0P"5
M,2@"Q&VI1!T-Q"D(`7LYQIKDD9?1,2F<%8_`MGB;P3A9JFK5\3``T*VW,4NX
M,:+B^!`2`$&):'D8(#Z$ZR;P`H$R(B/;=S(>_GB%L%,XYL&")K$F&XL1\K$>
M2,LUVJ(?'*``E5EQ`H$!K;=18!0!$#`HJ4(?X<.3T'2O,/$[*](!P_<[9,-.
M$K`PP*-9^ABL#N`P_/L[4#5\_4M\`M'`IJ$0FN-^U#&=&\(!_IL@^0$\IM$G
M9)+!Q8%:G4)\^@L1$!!+"AN%SY-4IWI(3$.)`Y!$$&!I)*(`D[-6"A6(;ID@
M@V(!$U>![JH4NH&N?7$F"TFT20$\I880JD$T!6$F%"L0168J#.`GNP8S+469
M`P&E'3&%-M019[(@//L7I-J]"9D28\P6?/0S:9P0V34I<_O%8=,0#*6Z2"@]
M!?$LGY$N!;$Q&7"]_D1!1Q5<0<6S``L0&K]$`$F392#CPSZL0N]T`+\$)020
MP!(P+FTE+N&A`1#`M`S#`1'``9F"**;#$-WH`0Z@NMGV4ZV#6;OVEPWQRH/A
M`%E\$`5P``Z0*=H),FDY)'EVJJ+Q'@\0)89BN5?84COZDAL0`6RD/Q@P1+JR
MS&T,$KSW4`^%`7"U`2,$5^<C(AJ0AVIS7!$`8DLT`&UX+PY``.X9`)$'&PC`
MSM\46`IP``M@KH$56%_[7I4A`%FD'%,U;DQ8$%E3*/X,&P6]'/ZLI?XL'`N=
MT`?-T,K!T`JM')AW&'.\$),B`<T2O-%W/(X17(DW*ZDB*#3"(,&S-?L)_C+<
M$KL)(E(9!J$E&2$_O!3$P2&JMQFD00'#!WSAD8D\DHD4P',O21\4\AD64`%`
MW2%(C=2QBD9S8W69Z--+'=53/=5'7=58C=17G=567=4ZC1C3NA"9"Z2I:ITQ
ME8,$-;E+VTCL"CRS)(;@8A`&\#SB-"9^.;F1$2??RQ6`+!'3_!*T6%`;L&\"
M\1\?L*""5P#54IT?^#PY.X[/F8,2`)K&:(,#<`&Z$3E]^,4J\=<&@0$E>XQ!
M=1`=H"\'IJW(D2EO0KT?J%BSVD(%-ME/(E*A\5FW@KB<[1-]/103\+W0L1Z3
MJZT=8']0N*XIJ%B)UT(WPZH&40&VH1L"A#E0_E/&4<%.I4$F#0/=2:0!!)R4
M#77=$5Q.I!$@,\.:I4'$5[$PN<04T59`LX(@IPT[0TRD1X36Y-4Z<@?,RRG;
M&Z*I^H'$/-85;ON#!)$E^"%;^_H`B,4X:6L]!/%./,G2_H/6D[D6=$@47I<0
M<]LC98V;N@$;BCR.T]O:ZSJ8GSL0_/W`,*)='Z@LD1+$5!%8,A)3$*)"X^$F
M[HHCY>K@`@&F'G1$9G:!-PH][T$A$)YX*6(!\K$FDU*;/1[''5H?1;;:_:>I
M9)-G\W<[K9(R*4(;7O$F+84O\GG4R.'+'(V,'FH9;OW8*JXAH28S.T8Z,GXU
M+JFR71@>]5L?%&(!_4.,((TKNYE#C%Z2@Y6]KBO8(9^U`6TRAJW2A%K\&+_<
M%0'P/1$['[HB`#*#'7I3Q049(`TPJQG`1AX@'[58$.J1@PL%-!Z@1:/-F@(`
M'8,".I6<KGFR*29B`+:155PI2P!%@L71`#L&-6=%6)AC&1Z0`/BA`!M@V,>>
MV]LA0/DU)9:W`5HM$"FK'2%'29GX5A7P.X2H8T$-U1(C']WB`<@&,AK``&&)
M,>^Q4*C!OKSH[,T![9GZ(@)05?*>[^=YFT_<:_K^[Q&!80`_\`1?\`9_\`B?
K\`J_\`S?\`[_\!`?\1(_\11?\19_\1B?\1J_\1S?\1[_\2`?\B$1$```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>f39432a9f3943225.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943225.gif
M1TE&.#EA-P`I`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````-P`I```(_@`_"!Q(L*#!@P@3*ERXT$,'
M#APZ,)Q(\6`'"@P(`-BX40""!QLJBDRHH8$`CBA3'JC@8:3+#@\"I)R9$D$&
MEQ4W%*#)$V4`"C@97CC9LRB``!&")L1`U*A1"$H-;FCJU&B$EE$_>#A0M2L`
M"5D_3/#:-0!+I1T&D"VK0:F$M5X+2,1I`*[7!3@SV"4[P>78O5T%M!7)`+#7
M!%@I<C7<%6C%Q8R="I@[<6?DJ@\JUKTLF0-%!(892.`J0$'AG@THGMX+5@.`
MOA:*"O#,,(+A`PL2O/X0NRA4AGKA_KR``0.%W1<=;'20@0.&!1L)4+1,=D#B
M#;L%QG8L\`%'#!,AS0A?L.#"!]=],RQ`@*![@@4:-^)ER($J6;`<OO+>")MF
M@,0*B6<76-B!U9MY;]%4P40>4'??!_FUQM\'P<V4VD09R+06?@`XH!5T"@A4
M@0,1J,61`14=MR&$``P0DHI]#?371@&(-&-5@GV`P48#-(`2`A-0\(")/(YD
M@7T])?6!CV2U-Y(&NE4%@7=K*>D2!0YR!@`!`+IT049:!C!85AYL<,$$#RA0
H@(9K'3!F6!9U@,$$$DCPP)T.-+"``N0QP,`#%W0)YZ"$%FI00```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>f39432a9f3943227.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9f3943227.gif
M1TE&.#EA(`%*`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````(`%*```(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ=/D1X^>!@Z]*?1HT@M;F"@0($!!0@:3`B:M*K5JP,W*!@@`$$!
M!`P,=,!*MJS/#%L)%"`00("`L6;CXMR`]8("`6P',!AP`*[<OX!;<C!0P&D"
M`@<.!%[,^&0&`@,"%"A@8$""QI@S>ZP`0`#?R0G$:AY-FB(%Q`$"#$!P``'5
MTK#E<LB@00/M#!8LV,YP(0,&#!,T7+``G`*#!0D8(%C`H$`%WK<I6*A`-[9U
MHQP.`-C.O;OW[P`(_HSE4/W#!?``$%Q?S[."`/3POQMX/?`\>/7L\]?DH"!`
M_/_<X5>0?=\)J-^!+V7P'H``&E@?>@XB*"%*'2#`((,1F@?AA!RF-,&%&!Y$
MH'<9MA14!QT015].'J#(08L<=,B0!2`".$",`VXHDP8)).!5:`I@T%,"!1R@
MUF$9R*C0`^BM-@!E`P`PP`!/'?:D`%]1Z0$',7*`X@5NX46``<M%,-.(W$G0
M$W@4*)D0`>AA8,$%&DQP@0,64,#E!AAD\%P%&G"P@`,(&`#!`%`U0!YQ&J1(
MWDP8@*>F1QA0$($%$5P0@5\3^===`!H,A`%8")0:U8KZ15G@1!=,R94`_JD-
MP*E(%3!@JP(/,,6<K0PDQT`#"R@0%`>>=F>F1PQLQU4!`3Q0$0??!2"D0)QY
M=QF'!=PWD0<3,'"`<I7--Y('%C10[(4$!+4!G-XYX)$'%GJG@$717C"0!-]=
M.^$"X,DJ$5I<&="6:CB"U`&[-6YW0%"1?E?!1_QZUT!%'IP+0`#V"H2O=^E.
M2*RV$ED0P+<3/#`F`R)5F'!W'3?\:<8=1=S=Q!1!ZQVH`U'PG7@<JNJ=LQ)1
MT-4!3Q70P`.H;J2!Q36Z]L'2#K\K,W?SUAQMD@(Q:6V'\7HG;D2M+N"9:D;.
MRI$"X+45YMIL"\!`4%![][!'"+@U<`!.3Y0!_G@P6]!VWA)VW1W*#/G%,%X"
M"'SQ`@.]EO1$#8`W`9>45VXY5=5Z-VE''7!Y`0<:6&#V0QO4V[CE7J['006L
MM\[Z@B2Z+H'KKD/`>@0,/!#!!+M+\$`"#RA``>L/S%[!!-->A/9WFSND\W=M
M[E3ZS5AW&/G*"3L8%)H!9K2\=\<^]#SX-)%'&P8;Q+CW=S!OR\%O%?RFP>,4
M>>!;HPV1.]7C'EQPP>@#20#VLB<B'2D//$`3'WB.I;_<Y&9R".F?`W-S@==,
M<`(3D,`$$M*_6GF%`&Q!P`-^`QX+#"0##X"`!"P`@0?,S2!R:L!AW'*Q`!!@
M`1-T8,D:`(&Q>"`"_KZ3@%0>4!X.6*!7J6E-[LSF`>/T:CL^>H`%"O:!#2P@
M`#YZH4&T-L`+98A[VRE11*[GG?8U!(R3\D"VVH40#<"..R]$&'<6D+0?7@P]
MJ>';0#+''9X51&1=Q!D&F+;!#V3`9]\90/2$@H'O@<<!5.F``GK5``<L#"$?
MZJ(7#S(^$GEO@6`#Y0<Z0,@VOG$[BUQC=ZI&$`Y`P`#8P]A`N,@=?0GD`@E@
M6HT"D*1!?F=.5_P/`>QE%P8=RP(&<`\!)N"`ZA5D8YIL4`%!=L#O;!!5CB.(
M+S]52`_(<3L00`@'3@F`16I'7@7A@``'**V!3`V*K52E)C<(1@3H$CS)_I1G
M?`@@)`L@P`(%&(`$*+#(@D`@FB$R"!C3,Y$)6(IW$?BFPAI`40<T8)(+.$`"
M-'H`F('174)!Y'9`:I`-D'.1ZUQE*U/J'<\HX`#Z_%2H!!*!?#7.`>AI`!`C
M@%/P>`8RSOD`C0"$F'-&RVL*>"=W-K@!!"0`@PP@@#,)<E"$_L<`5+RE`1_B
M`:,B-)P"&>JGHJ?&[X#5(!E@FCF_(ZR!9#*1%8"+!Z**GD)^(%E;$T@'R`F`
MLVH,/`EP%%4T(%*.'<"$'^@I?`)`Q[^R52`3"$"F!&#+@E"`,JF!#%?NF1J!
MV7``;(F59Y8%*P/HM'@]@L`K`V``$!)&`#2#_DA7K;J=\+FL.VF4:/@*LE?H
MN7-GKXDI`!R0U2IZ=3LX$TA5NZ,O,/I5(!Y8+G<$D#R!'!(^#)C5/2F+/^B2
M,X$:`%8&BDN0L=2F<UQR)'<:H($->&`#C?(2?#=`7\IU;@,2L.%70/BM#H2J
M<T,A+T.\2=OABLIB`4"L!V#I'<(99)R^%<AQ`5``JM0TD0)6:G(_P$=X4@L\
M6AR(6+MCU[!B%U6Z%(`9A4).!U\$KQ*;"(U4LY;6?NV35@W`"V^;)N@RV%@(
MZ:UW%JE>`"3@1(450$$M&ZWR=-C(>TSDBC^PS>X\UZ0[>]M!F*;D@WB`G(S+
M"!F[DT"(/,94"`#A_I$W\H`GK:4`?,T+`>R&%\F`=I@/^B5T=2O.PBY2J54#
M8VP/\N1V"J23'N8PFS@IN1Q9,R%JC2`Y27J1"S=8;XB93$`)@```3@1%>OU`
MD0$P112E[]2!VA-!G@R`N<WV9Z:,\`<F7#56+SF=WQ%`P:2;:`ASK+K&_4X!
MLJJ@1R.$:8@UR)>_0VF+P+@[%99(I!`#IRGY\2-CYDZR'3+BI0YDPH,N[TD'
M\F/N7-+2N%6(!J(U4T7G=93")0"@:@,!OKI8(%CV3HD+@N`IL_BQ&5%L=V[\
MD`P8`#D&2,Q:/(V143>O(>O3MX_-*LYQ2SA?07EK=_PM$)N5,<KOUA#V_@AN
M8F,_F&DA;APY67D1@7/GW@[1``+T`IG4`,XCH]YM0^(&9($4^=8=M_@'6+H=
M<6F<.QRG<I,'DFTH$\1<"2-`>5;=:"]/6M+?"3-&GFUNHGC)2^-!$7I=Q(%6
M$4`!A,)+`^C7\&@)."$\WHZK)]QL@6A`J0"8UJM5ZFX2T<\#2Q<(UYT^D`Y$
M8-3](F[2?$WB"$;:ZM^!^4(PP!0)2,`!#DCJ`2`0`2`Z(`(0*-5Q#!`:UBR`
MTXD94Z&,!,O(4!BH#*_FIZ;>D&Y?3,'EW@[+;RE<`,`,T`*)>WAH7WBB7ZS=
MZ$XT01#=':Z`L`$8H-\%2GF0#2!XVP19]J4A_C)]U<Q9+08`^@0X_>8B34E,
ML`(A:TUE)&8QJ\P>:3H`]LT0-'X;X-"=`%]1^5N_&U*X!U!<'6!\QS=+-D40
M^(5(1D-1#5`!%.!>,U)U!L%SVH9U,081@W0:!"!`H$5_B?4DUL8LKN5:5%)C
M>(,E9$)9>!82HX9]#)%641-2N898&Y![LJ94#K9NX/$V5+$E-HA<!?-DM@1(
MW!$`$/!VDT=]6Q:#RD9.SS4CDY0`#@!:_.*!.C,9D!%"(+2!:T$D:P$9>$$9
M9R=5(C%J0*<08`0S1Z<L&75/W?%G^/<!@@-M!^<`/UB$,".$.6,Q!,=V!L%J
M'O@!'X-.D`=K&,A:_D034&NA<S0E&05P10<0,&U!&0>0.(52&&/2&:WUA!TQ
M:L#&$%4&1P;(((SU>!\`?&[5>R"2AP?H`02(9H4"BZ7R`!DT5;8W?Q;8>(4X
M.!&1`0>P``U0**DA`%;X?5,X@FXQ&:QA0S"E`(_HC,ODAVW'A`[!/;*D5_OW
M*17`>$@W$!*U>Q@@43XU8:0&<LP5=-%$AB*F1[OH;>T(3KWH(UT!5`8P92;#
M&@(#6FL!6D2R4?Y1*(2!`$XA>3@G2@]!@;6U4HLU`!70(D)G?)4E5(H#'P(0
M/U<SBN<(60@U`.TF?(%8,11W$!U06!&Y$"85B5$2)0DP9?IG0VH1*X[8_EH:
M!5J$\1D1\"(ET2JIX1_9\HDFN6DV5#<AU@$24#=%>$-Q!5VZ`A7.V&X0L%%C
MHE%KEGT=4`&)\1T'X`#S(RB%H7D,4!X8L`!B&2P+\$(=8`'!U$4.Q@&Y`T1B
M243B]``.X%`/D"OM9A"YX3MX0AV].#L.9'F8TB."V2,2<`$4<`%]\AL4T"?Q
MXS^_,2>^$3\I05]\$E<NV!!\L@$6,!00J&P84`'#@3X/EB0OD@$90!\:\!N(
M^3X),5X\Y0#&XTPOPB6&Q$&I,R#G\HMD.99))8X#((T[P6O*YR9D<1K-1WP#
MP0')MQUWF12#1WC$B16AB(L+H4\!$'L\\9Q:JA>=5N&*[<)V'D!+VT&01O&<
M6L:=5A%W#0!`'G!W"-:<SGD?P(F>.#%XC+69T"44+,174WD5XJE[]&D5TP<A
MO9(`"Z"*HD$6YAF@5;$!!`@B"@"?5?&?`$">#+H3%."&\0$6/ED5&;```NDC
M8,&(%^H3;%E8>'0`%#"?)=JB&E&5$'``.SFC<Z9"R.FB.)HRY-%>\\6C+)JC
40!JD0CJD1%JD1GJD2$H3`0$``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>f39432a9e3943223.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943223.gif
M1TE&.#EA=0!8`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````=0!8```(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#B@0)`<$!`"A3HCQP((&'D3`Y0E!)LV;*
M`!EBZHSHP<))FT!M-L"PLVC"!4&3!CU`U*A3"@.42@6JP&G1J%.SVJQ@%:;6
MKS8I=`69`:Q9FF+'<HQPMFW*!&HU6G!+%X"#N!?9UJ5+`"]%#GOW%O`K,7!@
M!H0?"C`<&&[BA1,8&V[P.&$'R8PA5#[(`#-C"YL+>I8<>F""T8P/E/Z`6C*"
MT'-;?]Y,0+;D#I5M8WXL0;=D"8D[^Y[MM_9PPP$('Y>\`.^&Y9(YQ`4,W;"`
MZ=4SJ\60G;':LMT/_H^]$-[P6.KEZS[HBG[X@`)8:RXVB]NI!^CK/VS0"^#`
MA`_M:=6<5=#=-1!*!A#45E<%+&>@0"A5=>!9^1EEP'($,(```PVL-%"`6B7G
M5&_E)3@A4`PLP$``-FGFE&X)H?2:03.E!%I!L:4T@%7&M8;0?0"86!!_]1E4
MDU61R19C?P?5F!!_*56X$XB8=<#!!AL4":1C`FF0I0-V$<0!!1;DA(!-5BDP
MW(`?`-G7B2@1E*12%SCUG&^433@8G#O"F=2,1IVFVX.L`?`FA"D!)Q`%6G7E
M&YN%[HDH2FE]0.)431D%IFT/`BEIH2@I^@%W64%:%(NRY8GHH:`"\.E7_ET!
MV9JJA8HH4(<I$7195F,Q.JN"<1(D'`"5"N3!2ZW65&=79Z)&:TJ($80J``EI
M$)2H5B$U6K23$BM0!O.EE&E!X=(DX5@7>H9LMP`\0"4`"6PPD`>X`G6C6FHR
M-D!.`_GJF09^/<"8E!^4*]FZ<8$7F&H":3M:99ON=0`'#:+FXF,=])A>4JM9
MH/'&-$FWFGXU@IQ2!",7M$$%'W?'<,H(8>D``_D>5R3,#F4P@00,$%"``?$9
MQB7.%V5@P=$65/``!!`LS;0#"BPP`$L%*)"`U1Q"(`'"1'?M]==@ARWVV&2+
MK8$``0!<T7\HEPV1K1LT`!P%#6A0P0)<>>``A%<6K)=!`QUXT!=1$ZRG`040
MB.RV09+VM<`&!51P6<$?#%9`!P*@/$`'.ZIF0`</7""`M15\NOB!(B<'`08N
MJO9`!GTQP`%<&C278',+`%[Y!5R=>_J'``30P7-5,3P``:HY(,!=>_8\V([K
;G41!!L`1^CM#OE^O_?;<=^_]]^"'[U%````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>f39432a9e3943235.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943235.gif
M1TE&.#EA0``]`/<``````!@8&#DY.4I*2E)24EI:6FMK:W-S<WM[>XR,C)24
ME)R<G*VMK;V]O<;&QL[.SM;6UM[>WN?GY^_O[_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````0``]```(_@`I"!Q(L*#!@P@3*ES(L*'#
MAQ`C&DQ`@``#`P882-PHD>)%`@<,5%3@@*/)A0@49"S((($!!"=C%CR`@("$
M@PT2)!`@4V9+!AH1ZCS0H.=)BP86&E!0X*;1A@XB#&SI0,'"!`P:$'C*D`&!
M!`,1`+6JT$'&`R6Y(HR0,B@%`PT4/&"84<%6M0<S6A1XT6O1A183',!KD($"
MG4$3*&C9\`#0!'\)"SQP6.?DQ0&<*J3L,C+>"1D7M!7XU6M#!`L:`)5,X2);
MP1HC4#;=U8"#JI(C%-"(0"=8!U@K-F30.\)=O`@&4R"@H'EK`UB3=EV@(#EA
MBA`$0L?Z_+#RA<0/_BC&JQLL:<%@6RXVO]!L2^E/)S`GN%1L:P74/2=LD+*Z
M6@7?:3<4!0X0@$"!PZT'TU/&I3601:O)!A0`PR5G&(.[&=3;:F\=YI9"ACWV
M%`((2%702REIAP`$"$S0E6+X&>65@_0Y%M12.NEW$$TMZ<C12GF991Y6/S&D
MF%>:G01=0B\Y1X$$!8RF%'$+QI1C0H&Y)=9X"LDFUH<<00`D0KV%-!`$%\&'
M$'``]F2=:@XP<)L##<0)W45HXI@``DD:!%UO/;U4$48BB42``-4M1D`!+Q50
M'74)B4E<GV%*$(&E%$`0@8D"?4EC:[VQ1Y`$XMG$FI_N^7F1J)U>].FI_A0P
M2MQ!*C4)5)I\PFH0`<"Q2E!X%7U%J:[+W4IL3/U5>1"G`C%[+`65L0>H!`(`
M!P%W6*E$P9$$7&O8JT;9)MA`$MPE9U`V!2`03Q24")2)X`;*@&P$H45@1@\P
MD)FE^I(F4+E$$2;!ER0R(,%-Y<YE0'8"@9;=7=*YV,`":L8400`@$??318A2
M0-F]?#'V`(7M"J2:0+Z:)`&1(=X*U%P.,.R`6%(Y]D`$6-DG`5!U/EO4AUD1
MU(!J#>0[-`/Y,AS!NSZZ^:$!Y=(8`4^`'O8<@631INM6GR*XH-7+4<"N=JSM
M7%0#!LQ5$`0\_<6A:LJ"^=2U%)QL:D%3_\H>GW>ZDB6VQ\N.W9I;MA%;Y5:"
M[T2!<;\Z:.]`SCX%WU9JPI7I<:U%QK;0DD&P%4D."!"9G%$/5!7F$4@W[ZD&
M+V[0TLQ&D-V'*[<NV00'"P2!!&J/6O>S"&FJT6U/EI1=4JLW<.G-N3\+09PK
M)Q"!:@3T+$&<?[<F'O"+-P#!!/G6G9WL#WAO\`.[:X0I\)<Z=>GB-\7<+(&1
)<V___0\%!``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>f39432a9e3943226.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943226.gif
M1TE&.#EA/@$Z`/<```````@("!`0$!@8&"DI*3DY.4I*2E)24EI:6FMK:W-S
M<WM[>XR,C)24E)R<G*VMK;V]O<;&QL[.SM;6UM[>WN?GY^_O[___________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````/@$Z```(_@`O"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(,:$%"!`J:MS(L:/'CR!#BAS9<0*#`@,2/"#)LJ7+ES!CRO1(08&`
M`BL%,CAP(.7,GT"#"AU*="`$``-R1D@```"!G$6C2IU*M6K!"CT?5+#0@```
M`0<F"(3`($&"!A:LJEW+MJW&"0,05+A`@<````?F7EAP]ZG;OX`#!ZZ[LH*"
M`@GR"GQP=P`#@A4H")Y,N?+,"GXG%,`H^4*%!4@3I*70`"6#"GHMJU[-NF*!
MN0P`/'C0F4*%!@,B+!:`-'7KW\"#&YR]US%4@10R>A[`_+'PY]!_BUUPLT%"
MS0,*2(C.O7ME!4V/_A=D3$"Q]_/HUT9`NF"L09,'"JA/,.``@`2ZT^O_C1+!
MX@81=+88?6E9!=X``SU0@'G[-3B9`W;-M4`!"U@W%ED&^#85`O=)L$!J"SHH
M8F`]S?4`4@-TQD`$.ZT5VV,61K`2!0`X-^*-:CDF4`$HM;?7`0@,(%:.`-!%
M$`0'7$"`?,`-.5`%0T;FW@43;(?C5)H)1!T!!(P%`$K*6=7`?1>$25`!`#CI
M5I(7.*<`FS8RR9A..0F@DX97#A6!=3262-<`!@"0GUKVI60CE0)Y)1Y;#*R4
M4UD"'?!831D1UV9.<)J9IYZ5\FAA3SZQU=.790[4'HVR#8;GIJUU)FF7_LNA
MY%9L30VP`'$)4(!FJJSV&M1G";AIUZ%J32``;P`X$-8%C-7JZ[,_R6@><P.L
M6M5=7T*@P`7V(57C9`(:.5Y.EC([J$`-'*#56`\<H,"BW9TKE(S.U:4C6Q%(
M>@&:D-+J;%45/*`L0;;F.Q`"!4QP@(#Q[1BF`<?E>D$#5A[EF97=8966ND7-
MEE.P&:K5+DX#68!FE]A^B?%4Q(5K@$$+;/M``@/1N"-!'.O$YI%%GA?!7!&\
M1L'.0LW6V0,+$!O5203(*U`%3'UY@--2Z5M0`>'N)3.3`@T`04T$J3003P99
MC![-%]`']=+./="`TGIZI8"UPR66G;M234"`_@-7RPOI`R^;^JZ98D=*-')%
MTLW:;1=80$![ICGT&;P<N:VE`Q82Q957!*B)T`03>NOML;`651?1!3"PHJDX
M,>@9`<06SNWA$]?8<W3M_ME>J`H]($$%<'NT+@,34#W3`U[AI?@%$23?U///
MWV7\3Q7<FW:C!"V0Y&L%P5Z0[`9?=3MT>AW0WHGO4E[J!=G%Y+;Z+V'E+?Q4
M[IKREPW,1A\`60<E&0/;TI)XTL4M3<E.@&&;BVT$,H$BD08ZEO*)?0)8$"OQ
MA38%>LF>:"<3E#!G>G0!SY>>5X#,>0E!4=E,`E*C/>T5R&T5@("/!B(!SS%@
MA@+!W`(*!($&5$A3_@O!R%_,$C"5)>4@R/-=`4`X$@8T8'DCP0V*5F80!S2F
M+T\\R`$$X+F.0(")K4+;7U!B&*=DK7ISN8L)9_*FGX`&1?TCR(%J%3QN<6\D
M"_..ZZ+213Y]"2LX#"!X9E-'F)3K)0_@S0`(0#==00^'!8%+`3(H$JQ0,2(6
MJ)"3*+"`+HJ+(&YK0+B0YI^)8`6(09E`3A:@*0@0``(GZAP#TZ(@K3!'1$=!
MB@`N2<,!".`NRSH(Z/SRDM)-A$\[J\#X<&80FE$`*K`L4QP74@&2325_D1+/
M(,VD*X&`1P$+;-")"O#+1J9LC6&SWDL@@+6)6,X@RQ3(>@Q"NP904"+!_K)*
MSG*&$#;Q13?,@2)T>(0F]3F2.?!:"@`@:<AV1N0`J(PGL\Y2$`2LD"`F$TU$
ML%)*??(-*Q_3R^_*U#D+`!,"`GT.!+)#@(X:Q&1?.0`E/=,``R!@74%)Y#03
M`M&#Q),"C5IB01A0K:$:DR'5<ZE5K'E$-%Y``D5ERA?QTC')%,]<S&*>;AS%
MK)TZ9$(\4A]H;%60H0%``4ZZ5006(*.L(BU<"0B@Q#C6KD+"+#<0Z2D\AZ,5
M7A'DAO0$(W(,P$&J*',E1W%441DCEKNLKBC1)$N95E*DA8EEK6WR:D,FU!-/
M_BDN-<,-A0H2`7;N2YEIXY9AN"607"G@-$D*_I:,H@D1!1S1(9C=ZU`C=:CS
MF7!;$F-(!-KWEQ.M)#89L:U8"D"`9_J5*`\(D&1A&2"3E(D!G&Q32A.2`!Y)
MU)M4;9-]^`E*`.V+6XZ:T6GWLJ\DQ=9CJ&0(7P+7$%@V($P42``$$H"Q#U$)
MAXU"2_98V9#83'(B-[0.TA9@U07<BBX.7@G%QN)@-?G0P29RL&1.Q+<$""`C
M'D8I<Q9@P0KM94C[=7!&'*!BT-U7,VV$25I0LQ$KHB2.$G#*A!Y'/Z_MRP(5
M\`]QYL+B"R"@0DF:#6%5>>2)#/>V;7'D/2,"@.HA20%;K5;U%'"4"@A@:#XR
MGX;P-B>K+295!;T`_F]F$]X+`$`Y*%2F9)2YE-G@!(4G<K-"**";_.A&+SD9
MFE4WC!QY!CI!FD4(2IPRJ-ETZZ8/&:Z16YL^"<@'-^P];Z,FQ"S:2@0N;58+
MK1@*$4%Y#6&GX55W$XN@`WRJ/+[1%YV[&TQNR4:9LLGES`CRI6VAT&RS2U<)
MQTF;+REU7-=SZV/0MJTD`>\"`0RFC_+3*+2),M,,L2WTFI*Z;T4:*Z>E@,)8
MQ%K&?.9F28K9;#7RF5_NL"H*<DI\'R(;L1Q`OR:U4`)>*1O)'(!OW$*`O,Q'
MERJ?14V.2U8N64PJ7BN'>SF>B^,$EC!FV8E*`+!H[](K`8XKN%(9L4Y[_B:0
M`(`K9TC64669V@-PAT@`(QA;:40@8-%JWC>U#O9A)A,@EY6W!Z)G2<QVA=D7
M^L7$TDVQJT-N%Y_3,(;-I66Z2BB`,'#B#"<DBT^MNR:;$\EF;@4Q-OM"9-M:
M:DV>=\%/E:V)Q..FC:OY;"MMVG2:S.9$4VTK%0/F[9`8MT:$0IV7"*&\$:C(
M:%UKG7O`!G)XYAF-((>W4O$6M1[^B;#MNJ&NH:TT=&0G>27M`3=ZQ<BF;5F(
M7'>RNG6<N)%W!8>=W"9P3"K@@%T)P+_!B8W7-K.1"6#D]\"'HEXD?A4SZ44L
M!9HI[45::(T<L+7Y2\#/RU0IYY2PNP6P:&07_J`2%)9)+$+G]$>HCJ+4N41^
MSP,[2!Z@NI@!\&UG44!<W<63^MN__F^ZO_[M/[:FG#RN'A.`A+1_/"&``IAH
M>P9OQ$(<MZ)>;\,\%N)?[9$O0X(VN9--W&(;V!02S9(\Y-41$D!4T&-UW$$!
MH,467X,<OH$Q@O41AX,]#6@DN8,T6E*#^[)*`\$U;71$34,2R(,4=O$E#*81
M[7(_>.%9PB$E:R$>X>))2L<1>300KJ<2*_%G\D&#F>8C>V>#K(4<5R@HF,82
MGX$F*&$77')D2?-[4")N+R=#,7,`7K$K3?%OG0<4-H)BJ%$@1?8T3K*%$"9@
M>Z$<$H!.1P<93O(`_BC%AS*Q>`.!33&8$1,"2\[A(SZ"B*V%'&PB`?M&2S2C
M7S"Q$RA"6,QA%QY$+4"8'03E@48W%>&C,)%2``JP';FE$]YW5I'"+#GA;0HB
M%.%$%ZFQ50?1@AO17;HQ-'NQ%.82,%C&8+N6:7[H3*6A79T&3DZ$/;/W`#;Q
M/':Q2&6($AX4/<\'&%2W$A+`)@N#5T$#:4,#:5W(+3LQ)`(00-$H%+0%5+YQ
M-+51AQ)A@N%E6["Q,,0S,PR```N39%J8$U@!43PA?VU2&BMD%D,Q`1/`8F5A
M%O?F8#\T4JN!,;Z1&N*&$$W8D0(!9-#R-,R1.1]8DBJYDC7#DB[YDC`9!Y,R
':14!`0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>f39432a9e3943225.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943225.gif
M1TE&.#EA-P`I`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````-P`I```(_@`_"!Q(L*#!@P@3*ERXT$,'
M#APZ,)Q(\6`'"@P(`-BX40""!QLJBDRHH8$`CBA3'JC@8:3+#@\"I)R9$D$&
MEQ4W%*#)$V4`"C@97CC9LRB``!&")L1`U*A1"$H-;FCJU&B$EE$_>#A0M2L`
M"5D_3/#:-0!+I1T&D"VK0:F$M5X+2,1I`*[7!3@SV"4[P>78O5T%M!7)`+#7
M!%@I<C7<%6C%Q8R="I@[<6?DJ@\JUKTLF0-%!(892.`J0$'AG@THGMX+5@.`
MOA:*"O#,,(+A`PL2O/X0NRA4AGKA_KR``0.%W1<=;'20@0.&!1L)4+1,=D#B
M#;L%QG8L\`%'#!,AS0A?L.#"!]=],RQ`@*![@@4:-^)ER($J6;`<OO+>")MF
M@,0*B6<76-B!U9MY;]%4P40>4'??!_FUQM\'P<V4VD09R+06?@`XH!5T"@A4
M@0,1J,61`14=MR&$``P0DHI]#?371@&(-&-5@GV`P48#-(`2`A-0\(")/(YD
M@7T])?6!CV2U-Y(&NE4%@7=K*>D2!0YR!@`!`+IT049:!C!85AYL<,$$#RA0
H@(9K'3!F6!9U@,$$$DCPP)T.-+"``N0QP,`#%W0)YZ"$%FI00```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>f39432a9e3943230.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943230.gif
M1TE&.#EAZ`'``O<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)R<G*6EI:VMK;6UM;V]O<;&QL[.SM;6
MUM[>WN?GY^_O[_?W]___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````Z`'``@`(_@`]"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;,
M"!9RZM09X0&$!SZ!_@Q*=*A1H4B+)CVJU.>$G3DE+)W:E*E5JD=Q0MW*M:M7
M"QXR?!W[%8/-LVC3JI4H82U!#1@N8)A[868&NG/CYI6+MZ]>OWPO<`@+>*_A
MPGTM2%C,N+'CQXLIR+T`N;+ERY@S:][,N;-GSY/Q!OX;6N_HP13OCEX]=T/:
MMFYCRT;886!M@;<]Y,Y]<+?MW[B!$_0=O+ANX<2/&T_.'+GSY06;0Y^NO"!<
MQ*0/DZ[P>33BP(J[_HN$/;N\^?/HTP]_7KVB].IU0TY03[^^_?OX+YH-23Z_
M__\`!EA>?!;Q5E!_`B:HX((,FK0?2`@V*.&$%%;($($?16CAAAQV*."#&7HH
MXH@DTH>A1QJ6J.**++X$(HHMQBCCC":=V%&*-.:HXXX.O7@CCT`&*:1!-G*$
MXY!()EFBCT8JZ>23)1:YT9%05FEE@$Q.>>667`HHI494=BGFF&YE"2:9:*8I
MVY<9A:GFFW"F9&:;<=9I)TML8N3FG7SV:=&<>OHIZ*`:Y7G1GH0FJNA`@!ZZ
MZ*.0(F2H18A&:FF=C5)ZZ::+3EI1I9R&*B8%XXEJ*I^@1I3JJ:PJN>I#_J^V
M*BN0$AC8Y*RX=AEK0[OFZBN+M?+WZ[!/]KJ0L<0FNV&P$"KK+*VE/BLMC<R&
M..VU+<XG++;<EHAL0M]V*ZYZU<(X[KD6AGN0NNBVNU:Y/[HKKX+L'CCOO0'"
M>RN'$SS@04\";="6!`V@YH%9F>)[9[T$,5R>!!E,$(%`$VC@05O^"I2`!PXH
M'*F^6G8HUK\3N,;`!)1YD+'*%:SLL:(."Q1S1QO8BE$#9D'@@`415/`4!1-D
MP"@%%9CDVLLZSCPS1Q2X)@&I&G$PF-12'^P!!PEKM$%/9BV-]'U*K[D``!%\
MQI@%<7%G=F840(;V!>%E9@`"$'R=8]BQ8>`:_@5FO9=<;^SYO9YQ!B4G,,0<
M>&TW?7B[)=>$BB^>'LAGYNTIV)++V/A:CTL8>>;F44ZGY9"#WN+F:FUP=(-@
MF;XBZJ['[A+LLM>>$NVVYTZ2Z('J[KM)N/\N_)0V5S[\\?$VB_SR8!8_.O/0
M?QIM]-2KZGSOU6?/Z_3:=X\0[XYZ+[Y!P8^?/?B:EB3!3XYY5$$$$[3-6`1E
MK\W8!(PYP``##F`&P6/P,U^%RL>1#DB``2/!@`0L4(&<O&]KU!'<0I*S&`Q4
MH`)`.Z``*41`IKGL(_$KR`,B8(#]-6!_##BA"5&HPA2B\`$HC*$,$6"`&AK@
M``A`P`+J5A`$;M!S_MP3B04R``&#?00#K4N+#W_(H`Z>B8$BP8"VE,C$!CEQ
M(TD$B0+7LL0J)NB*&LGB$:$61@L8$2-=]&*^@C@2,4:D`DADH`7:]@""[4\"
M$5C=133@@`KP4",*B(L%?I:=G*AQ<FP4HD4B,!<+P"T\%W!`V>CWP8H@\6(<
M.8#$'A`T!D#F<H>D"1@SXD:(3"PZ<M%C)2G"1PB<4B,^[(!<+%:<SH7R88D,
M22EAY9!5SB2-!XD+Z#A`1A*-$B.[=,@K%^)+F0#3('#,'`4>4#05'?,BR6S(
M,A72S)@\LR!H6]P&'E`;`I3,6[D$2389LLV$=!,FWR2(,+^V18'P;(HB_KJF
M1=:YD%=B`'X2X`!ER//.E\1S(.%$6D(%D@$,HG-;)N&G0O!HL8EU``)SA!C4
M"NJ2@WK@@EF3EUAHF<]T?D2BX(I`74[Y-`DX8&4<;8E'(>`SV05T1/JL"$HE
M-9>+66`#I,)@3U6F%H\.3'8::&>Z3.J1G09S`F;!VAD'$E.6K&R+&E"=S#`I
M.T-Z**<4<:I!D-BHJJX$-ADX)?VT-;#K?4VI'!1),4DBUH+DA2%F50EY+IF`
M!L#FJ+7C`%R!"-&2U%6>$C!47F\G$*E90`.NW$];;;?0I1:6KG^J+$(6BQ+R
MX+$#5=OJYX95,0Z!=2*'991F#\+9DU"I+2%]_ED%W"J@TTHDM3)KVU;FR0$+
M_!$C0!%:R,#E`5"^#*C+8FI'<.L!!D2``3#4G_XB`#4*_$0C$=O`;WN7@0:4
MK2`-N``^I86UCE1`N'&];!L721`.W"::5-6(!B3P3Z8QU)/;!2FV*.!)/6:D
MFNE57D0MXLO$$J2U!\D)>I^7D'D^BP.>],`"V`7!`%MKP!6IFP(9,QB^'5@M
M8;*ELBK`@`=AM".2L;"Y,$R1!F"R`0O@604:4$P$JX\A#DY6'0N2U@6W::I?
M5"Y'F.L`!2"@`04H80(>L(#]7``"_DWP8@:2`8MQQV")LY%P:7E>AX0XMINR
M``**1-V.)*YTZE7D_J<X$+0$$"`"";!`B2=RSHLML&B>K6]!.D;4!_`,R.3#
ML7$MQ8$'I%6I;*;P7(.<9EU:!,8E7,`$%A#G.:N*I8<3&D$](##PUL;%`J$`
M22=Z(3!#:I`=Z$`"QCN0"3C`QP'3Z:@9+6##6F1G?4P`=/^'LX!A`-#0U`!;
M.U"_@!7-@`>2P`84()!Z,B1,.9;5!H+F`0@P(,KQ;><#%(#;P?K'MA%A;D\0
M\``$'."Y$6ARP"P0T[GT9,<4&PA+"R(Q/%Z-U2ICBB1[`H$%(&2HLYHO!S;@
MW84HL,O-3@#$#"V]!8$;(N)^7P5V2`$'5!Q#!:4`!Q".[*R6;&(2@(N/_O_W
MW0=@NWZ5">!![C(K-D]LFA)M(`0RT`$+..!H&J1(!;#];2%CD<`5GW3_%,"U
M#T^0X06A`*DJC++"@=8U=00PX`@G*5B'ZI_<Z9\1-3#K@KQO`G46R(DI,MJS
M^CR,MY9``B!P@+4K0'\@LG%,HATJB?&-`5WWMD`X.=6Q2Z2A!+F`U.WS\(>(
MN]Q,?C4<'P`B4*L'X*&"L`,`W37^UA7LE@1+SSS`7)L4WB'B]H`&:CX0#B1@
MP0,@V%KHWNQ!WZGF_5/(`C;P/@^4%B(4Z(#CV<*Q#"2V`L`.W=E)26"$^#@!
M'?`H3#)@@'^;VDX2>,I!M'HQ%P--[P>A:086_@TK#C2T;OA&S^<;PMQ*NB:T
M>V^N6Q#`4TY!V)?CE/?)1!]\A$!QB&$UXWD?4/_9C)\AH4=U;X$`DP83^%-'
MW+=JB\9ZB3)M?=0;_M(S.$$J5O<0?N8!W.=E6S-X]?%_"\%<;\<`DJ9PC$%2
M<8%<+T$P3G,039-8B:47%>!Z:C)?#8!MXB5J<,%5%\$!!<`!PB8]13-M&8A+
MC:9.?U(:<K%`[65Q_@83%C!A2C5QE<&!@R)8C'<L`916V.4O7O5W30-V?,-S
M_C=\R-14+P(6RF=8(/<]U+$HXY1'/<(W_?<0$F-[<QA,0#5MF%.$)V6&]$94
M,($!_I(BZ$,H$[!S_BP8`;6A;&%!`15H$27&9A2AAY*!/]@'8F1X$3*H$)JU
M/TWH(FNX+J;"`3-G$`UE0!L@7`A',WAW`3+X@VV1@^1"6PW'8EATANKGA'Y%
MB+1(*!-'$#S3-7>($1@`?I^2`2-TB9C(ATWEAP0Q'VE($A@@283(*A'P1Q/#
M`*AX$@U09>&G3?CA@9SHC`/1%M%8$LYV(+V8*%>(24"U0$5D$AL#>!.A`5)'
M;><AC@G1>0GV(D(Q$RDCBJR"C*U'5%08$EIH1F$U-0`C?IFX3^2H,1ZF$65S
M`0*S3!?4%B?&'?,!`:22C@VSCHE"71UCB2O!>&=&$1.#-MJUB2VAC_87_I&<
M5T!MH8@I68YS9`&W`3$90$QQ48VM0HHWN1*FIP%=&!$"-6T+X)(O^9`Z%9%#
MB1&=-C$UU38"\3[BA3A3)FQ8PXNMHC;*&!(;T#$6E!I51BY.&58RJ2Z=QG\:
M`FIPDWZP$9"!=BH:<#(WY83S\8W/-HPVP9?88VO+]2*`*1$_D5'%U#81<&@*
MU#:Z=3!>*2H5L&H'R1(.P'6X-81N`9,)!I5E%QV#`5K-!I2<PD<!)9(ED0$.
M($M=YQ#TF(]IB5HRJ9DK`9+EB)IVD@$(((9."%@3$0%^.1.<:1#\2)R$B46/
MI1^D:2D1,'EK`0%<5YD`B)LP,9S@U%0/8(+[_M-':`-'#+1E.?%(<"074Q,7
M-,5(JT%+LD0:&9"*G.=<J\1?CR@H&-``TMEL*982J\,!'2-B$&&/L,F,R^4^
M$4!2R"@54I-552::G+8!6:4![9D!+,=0!_J"?4%+&T!6X=E`LT4!D[0NT@<I
M/S&'U-5`)R%L/T5EX!><`X&(1%AKF#68NH1_8>4OX?>9-%)EZL80',!M'W<2
M<+A,*%F8Q/6B%R:80_9\)7$!-LJ&BZ)U#:&:8)%4*`%4%]1#'3`R$T%[1KIB
M2'J+:>%;.F@OB2)8UL6;G.83+J%Q!A%_34,1#'@6U@F,,MD`:@H33&I[3EJ%
M<=80'+"C-F&B86D0_D0J$W.*4#)Y,O=I$A6@0\O))T!UF0TQ<6CZ$OPGBQ(A
MB;&QBEX:HTEZG3)1&W2ICGYR3U%:-BR:$AW0,2[Z=TJ*$G$)H^O5$5J*J#1A
MFUO5)Q*P`/-9CM''E"81,6,:$;>G%I<DJVK6$=M4G!R!JQZP>W%"1&X"80&%
MJ5RD.K%2J"YQK$?JJ1R11LRZ$<YZCE8R;4H(@`S0D_SSJCMHH@VA79S7FE$J
MKS/!K9TZJQT!KC4QKIBB&)7Z475D`33V$CNW?0[!I=F:JB=AK\GSI1NAK[>:
M(N2J)(FF&.2G`.(UF;VZ7H,!H;`"H=VFL.@8KG5IBP]K5S4QJ@0QL4DR_D@2
ML*@?Q:L78W(I*%S:*A!4N;$(X9YHP;#[XK"PM&?[*K$SN%8,<9?;A70IL7%7
M<W-Z^J^--3&#ZG7TZB(D2Z8F&[0-\Q#N=351A%:A*1`L&R0=,$U5*Q`:,$U6
MMUTGP1U)532/!4IW04P5`;.U>;5;>Q)XFXOE^&PS6S1`T7Q4Q0!G5$UP,4W.
MJ1!;%#$^04MCRR,9P`!LNA"0-5B=MA+4];)[R7N+6;=G$:O=BJ\<H0"CE@!$
M,U&/`QOSA5`8@&P$P4@7\SC$EA#>QQW%95TTQVD*(+(SL@&^-2F^=9\04YM(
M%"OCU`$W6Q`7H+-RLK>YFK52:97E*##`-C"0_D4QF_8O2><O#A`?3<>"_\,S
MNJ$_"V`Q#&"[6[)AE1JI9WLU<H=CWTL0=LN)\9.M[=N\`CID'S%[KSN9I"9L
MY#&YI_1!3^&[8-&J!M$3#?`_Q259&&@`4,LC+DM;'(``M"E/4QL1-LJN"#$8
M#(!;R2N-SCNLHKL1-?B,'$-J\68QN2<T^/=!&J=20^140H@_8GLE]EB*#.%=
M$2R`$-&3"D$JND>=#3%?/3P<\!43H'NO(O&^!Y%&YCB.W%$T]-,6""`T+W5&
M9E$RJDD_N$<!"?6X+4)$"-S!A!O"E$*0PV$PMX?&/?(J<).[<S?"H^7$!G%M
M6PNM<P<UIR3&)6*N_L.[$(DS>Q4W$5$9I<M;EJ/9'\.;P1#QLA2!/\"J$3X[
M7"5AQT+[ND3$NR#1$]_%MTER%WI\$!!631><$!5PO^`T1P.!7`C",T<<$4L<
M$1C`OWA*QRB!R2O+&_B#HQ-4@C>L)*9I*!-PQ1KAM!"1H:57-+YG2(=($OT2
MRZ7GRV.%RR>ARP.1KG1Z%EOS`,L;S$-";-#)$.-4QA8A6!EV,>C5-!Z+D/;Y
M)\P[LOF[$=@L$`X`(HY\4HMQ3FFU`.WHQR)S@0Q!`8"Z$:^IP6`Q1:NU$?US
MB/%\$)P:B-9L$O7<>P1QRB4Q20IW;PLD7`"](4`!L\TIS0TQ`:G:,[YK_C'4
M!!(94+[LQKOF;+7SK!$5+:FVRA'1E*$&DZ%UH=,'8Y&,TA878%TK&R0;<#*T
M1400X,:]A)LX43<CO#539-/Y4<G&<\D?T;VOVQ$E`WQHLS*RU#&)-1A$5%$N
MR&F,X=%`0M`ZBU%A+1*D*!%-LP&3C!#\I4<=@`!$C!:S_+,D4=,@@M%T:$_Q
MUJ)M(4D,=4HM4T_OMA\?+2$/D+AF@HRN(:8#H<KU(5CME&7^8=4,]M<?P:GL
M4DT_5324$1\-)33:DHI4O$6DZ!I]K"-CJ3=7:;&$6J#3]EM)A=GIH0$RFWW(
MFQ]];<F@[1'%2L(7D<HTER5_U5AHTR\&5!NT_I=$CYT@M`=EK18Q^#@0#=#5
MAL8;<#2_X183#I40&TC2-N'9@>D1\Y4`@EO1!C80@DV'I"))#U)H$"!X=MI<
M.@P6;<&TFEK=`>)[GX@!,>R@9`19PB5&K0,_'`S1O`U"E31?Q80VG"P3ZAT^
M(8&\K5/1HK;5&L$=\WT0UWM13U--`OX?\]6Y0GBEQ>IJ8FA@!@"@(/3@F2IG
ML`87>@B,=?T2PWW5[-W=<%C/3XA/,)0`E)2,$+#4C4%R)S[%C7DRW:MT\<,W
M<"09HH$7VW<`$""XG-:BEJ8BF890%4-?D,QY4T:<K:-T&G#A_;37K(1!MF(Q
MM"<PJT-[3%VO$XW5_K0:WP(A`$G&/T#1G,FHY$M>Z/^#1_A#``Q@`'C$&$O>
MG/4&0T`Q0B]E70R```/@1NPVPNAQ44!\-8)W7I5UNNO"9FSF2"2AS"=!&4"3
M=',$-%!4$*GXT&>1X>E#T2"D1PO@`&`W2>L#[.]&/Z[4$U(1'M8U0O$S2`:.
M1X-$7?!S3SAAB=ZU`-R7XO8!8:57,6Y+-$;$9E*'C+_&?YY.J!&N4T5$X_(=
M;SR7S[>ZY\6-8B"B:^=^1'6$`%2([>J15'QVE7!1H!6H[O$*G`$SXA=!\")!
M;*<492:=I0H1-.@]QS-MR/(C-!7-J1#0`'"^$9`UF:UI5!ZJ=/OLF`!5_C^)
M?O*+44=2L1C>Y<G-Z4HO]5PZT^KG:GLON]1T/8X$H3IY)$41/Q$&KRJ%NV`S
M)X8\L_$2/?$2D?.8=/$+M@`+@/`N@8PD]O''PE48(#0]I2U0,Q_(1GK:"XA0
M`QO:4O8?!3QAIX5AWU@WJW%N_D8C\<VM;."CQG,#9^L]"^\>X>H6']H+A@"F
M&Q/,IP`)`&1&A?5F$9<WU3IL=97VG'YAW]Q<U1;BG1IN/1!%M'WVB!JI[4;-
M;'L6HT#L.FW;/?7QZ'4A%],#41<=D+;UGMYZ[Q&]!76AK4=(3A,5H`#8YE$[
M@U%##<:2#`%S\8(OB)Y\<P&,%+E9'S2^YXU9_I5'OHN"(-%`-"N_@U%A-0>=
M$X#'=`K]`7/A^Y$QOOL0/\]Y&)!5%F<USR@7I/+,!E%QQ5ON*('KM?@17`=4
M=5/1<B\0"*"(,P$0$Q!X(%B0(`.#"0E*T,!00X4*&2Q,R!`!PX4)%Q]HQ(`!
MPD4&'4-:6&#!@@,+%1A`A$"!0H.7"F7.I%EP@H0',S%0V.!!PX8&&`A>B#"!
MH`4)$@A"J-FT)H6)'CI,L$#!*<&'5VE*@*"!PH,,,BUL6-"38`6K!F]ZV#!!
M@U:X<>5JQ6!A+ERE=^%JB!"!@X><>I^&+:C`KV#$,R<L^*L084VE>3MZJ.MA
MPM\*!(T"UDPP<.#-_GD#1^AL-['B"1%,*^3PUH,%!68);G#=@/+?RXU/%^30
MV`+NO4+O1L@\87-"#A0JJ%Z=`4/C#1LIR]Y=_?2%U=8+YM4N<RKG[AXB&D1`
M.KQ@"0FH%WR\U4->YQXN7'C?,VU:\YO-!\[;GZ!YI3+KKH,'*.C`J0P>>$`W
MWJS"X*VQ(!#P/`<*,H^NN2S8:*(+#<(`(@L@@$"""AJ;P$&F-M@@N_-:=*JR
M%H\[CP/G+#@PL.XJ<(V@`&1T$:X)%&"0O:86F`""FQ@H*H(1&TAJ1`F<E&"!
MI!HP+@$)%I.`@I5>@JB!"C0,$P(+.MQ-@@C6DVF#"B"@;R8=WY/HN?.$_BMJ
M(1JURB`MK21\CX(W$]H`S0<BX%(#)&>3``&[,I!@R!\C50C&\[@[+SH)3,-1
MNPH"]0``2R5U2@(%=C2HO9F4NLPGH300RJWWI.KOP!(Y6)`#!VA\<`.+'.W(
M@0L:PL#'Q`K5JB^G!#3.Q64YJ."Y"A[%"RX%*J3@,.2(LV!/!YPSH`!;">(@
MI)UVVX`P4>.B-+Q0ST/+,W?1]2"`=M--M2R94)4IL@,O$*JR">SKS`.F8@4O
M,`'S,L\\!ZMSE,69-.3S*>%^W$#"Y!Z-X$"X.`BX*0@>Z*"OBCTDTR4',GU@
M`I0TF.!`D[JR;D)[KUJWNWK9#6M3ZRB0%X""_FNNJ8)N\VTJP-G"BJ_$UP;.
MZTV%%Y+:X,VL\E2PY>2EJ8(%3&WJXT@EZL`V-;7*V0,.9$8*4H+JRB"#;B<R
M$BFF,@BS`HZM@UAHF6[6[FQSYU2*Y^HD^!EPG\3CJ:TP#;*@Y+:QZ@D#K66J
MP("R]77LR!$9@"`"!T)^(.4%*("``303,$Z!I+"DX(#4L)R220601`!-U!%W
MRE9B94JP7@/3Y6`#2-O:>Z^RT78K485D4\JD"A)(X(+2G7N@JLH#Y[LI[%S4
M/;$)&HA@9W<]!?5KPPU.KB`*AF?Q,0<>I`QRA2Y`P.N#CK;LK\D`AG!@\PCH
M,_\YRM2J1AG$9,``_FS;EP8JYQ?"N2A,]$M>=9;#MK>A:W@1&(`")D(BZC6$
M@;O)WO8*XC?K?,\Z$4P,!RQB$``0)V\*H8!7+,,6;-W0`V9:P$)<(Y&:3(0`
M^,/`_6C2`7YY(#YVLXS`#`8@@E0(/`6S$P%C=36M;(`"+!NA0AXB18)D@`.O
M>LKQYB(@RMGK)F5#"M<,DH$#&.XF>U(-TWYDQNVAL'`U8R%BVB0CV&4`?S81
M3T78PA<+P<L@$6`(!80B2)H\[@$J@=C*S)00BWP$.Q/`C@0N\)$,4(17Q&.8
M(D<C%=-$S0,-FXNC^AC)H%G&-)=,R&]V(S\==F<#)<O``K*G18I8!ET=_J@*
M2C*0`$"5<#</P0`#+J!,ONGQ3'P,CPLU*``#:$XMB53D$S%)HOC@,341:,`0
MO<@`9>)*0U1)"EJ((Z5"D1,G#BC4`@I5G@<8H"_E<<`"Q)<`>B*@`1`P@`,2
MT$H'U'`N>3)-!5;TIYH`13"]X:9)SF.1GJ!I)NHLR`8.\$8&-.0!6?G1VRQJ
M0IW@,3$JK,XK!>,S@P2``H`SB@8X\*@,?*=4-@*B0:ZG215B($W[TA_3EIB9
M\:1%E6F1HA1#,[6\6$6ES6/`#&?R-L5PC"=,`1M-VC*7"R#-0GRIH&"FXBC5
M>*=,7F,D;SJ`DF=)R@*#1.D)IXH>:H;'D08I_H#I(OJ:X%5E*3T93T(.Q($.
MW%2C37%4]B;&&J6TCRWT8=,J"0O`LRC2/`7##U2;)A>\,38"FMLB49(R5ZO6
M9*AP>=:@D,B6GI0U,5JDI508<#S5F"B4DF)3:^I*$VF>AJ6[<:E>,F(0`:3F
MMQZ"E4(0QX`&+``"#5```^AISP1$8'0/2$]2<J>Z"3#@2L8I77A-@A(-G;=,
M"P5<@90HH\?9Q2S#15MQ'?>7!ZSH7-H\#:7HU[;5KHD#VYJ@I#!`7Z$%=Z5Y
M[<[C##(`XLC67D+=&^*,DA:L[LFR4QG>HUS8`3;1)K\;<(`##5>1CGP$`T$Y
M,$;N0B?6:$LJ12,(_HB1M($.:%@N=SUP^S("$1J!>$;'I0DCH;E*"UQ`H3^B
M$5V7:U?O,5@[#B[(`!*:6A.&-7N`\]@JW[(!^C`QKDJU8EX*)L7\6!&**AV+
MV0+T,B6RS9-VE,NYN#>_@A2V11XIX0:JJA7E2`HB3W[17?6"8,38=RXP+4@!
M$.VB]1+U*:O\"VV4B-2P*,N*`MK/U-)2,/^4\%F,U-U+PO*5QB`Q,X+50*01
M(^2:',?%$I160ER&$RR;L-5=)/10#'V71^M%T:"]YJ]+^H`1K<JY!T#``1;0
M[&8O(`$+*$`"$,``:2>``=B6]K8-,+H$(+MV#[`G!,)M;G&'C`'(#O<#_O!9
M;FU#=P';WC:L;LK8015`1I']K*434Y?>+3)=6T)-;4W8Y5X7.LKV&K:Z`M4!
M`_R7;U!!R@'8AEB.]:0#/Z$-QVES+A4)\B<.?!OEDAS?BUPD)1"Y6YA.7A40
M3=`YE"OY)T_(/5+IAJ<&LPZ;MA7PI:SR1Q48*9P<$%I"7X#7"6^;L>42[+LT
M'"Z3*0@!'GL:,;(E?8H*6$,@-%?Y;`MS3)<4B#.5H+:-\2]7/TTQN:>!7)_F
M8LJVM0(DCE*:D1VX3H\+U.<B=;K\+.^)N0!:Q@B>,#JKZTJ<2*<Z0H"EZQTQ
MZ2$>8#*3E<@V=V8[%)H$6H4`++8M`9&W5YPD_M\4!4]>RGJ35X^T<Q_-,,@!
M;;F`QA%B'@PHX,CG<0WE>NM(Q#IYMLO!@(J4&(&W*-6A+<J`A%?()NUB60.H
M8WJ;3X]ZOD^+X75:30<&X/>$^.=CG&2?!L+Z%H^AB41C%YI1MK6G76XI.6P_
M3;2R*U37)$6)RLE^7)!^Q_QREMJ:OMVKF0H`NNOSD/Z["O"+"\"["CWS@`&@
MOT,["[J3BK^0%BKCI`.A``(H0)QYCS%*C0P8J-<`P;@8D0LP*`4(*Q6QE;00
MONIX+1?!%:-HIO_2@`78F%YS#AE,P*9;N'1YP&21%P)80)D8%X3`"1F!KI1P
M`-M8-QNIE@LX@+MS_A&KL":[V)('H;+J:*;'80`#D(AIVPRR(+W=V*L6L96T
MR1D.Z)J$8S0@5+@6:4"X(,*F\$()1,(WHCJIN`L%<KX&LPK:P+\1$9<9O`#Q
M>A`NN8`$\"!7F8U8DA0>;!$-29XC04-1D<,YQ#XA%!4\I(F*X),.```%,`P2
MR1(2H8J4<PY_$22)^(GAR0`E`8L/`1'E>!N(\+QG,8FZ"),%<``$J)PV&2TH
MM*YCY$.YRHR;&I^D6!F)T*>=Z`F^`"-1^8DZQ!=!H0`',+CML9NXZ\2$Z)XZ
M7+W=&!?ND(`"@+9NHS=Z8I(%"$8&J"X$",9N!!T&$(#TT*Z0X4?NZ@O1_H&`
M8`0=[I*``V"`!,`?B_"D\)..ZY,`7AE&REB)Y)`NCY'(9OK!3B2.F4"=T$.I
M2!1'NE!&]]B^\-B6@M``!UBWD!D1[OJ<U(`21DJ-<3*.(_D*$5&.:-FB$T&+
MI#B15.3)+2&`(Y&)F\"B+%&IQ!J>ZB">C;,JQ%J/1P&C^7@=`8B?T%&RU"!)
MO0A'N7"407*AF]!$B[E`D?3$<K07;Q2,8-([#D"`:]F7WHF2!,"CK\`)KPG&
M:E$(<D,`E$B(=5.`!_`4#M`V,UF)"C$+DAB1F=J2D_C(TJL.J(B8V$BXE#A+
M=>%*24N7M=0+<M2[A.H=E'0NTO#&#TH*U&P)_N+H"]1,3<_YG-:424*!DA'Y
M",`DBXZ:$@R8))<X'<@LO?[K%+8(.$1!0+X9,,R4B]3#*Y/$&7FA'!C#3/T#
M'#W\PR`LB+QQ%.QTG(`COU/Q,[3Y.`HP@(8H$SM,PQ=K`*0@C:TK"+C12'L)
M);+$S.6LP.;D%'G9"+.<L*%XSOE@//<AC/SS2].$3#W:S:NB/R)CCP$(BQ<$
MK#*9J?FLB>)#C,X4BPL@F]30N?9\LLM,3N743.<RQS0LF5`\C1J"2!?$SD$1
MC]AR&8(!HJ0XLHM@#RV",LKXSZ&@(K`["PQ3#==00X-(#C&R*1!SE$QI,$>9
MT#"B0._(T&U!$C(I_CZRJ$1".T\@K$]@(]'Z\Y03!9]5"HL#,P@JF;Y5*9<T
M84\)\,K1Y`_W3*5<XA6IX1.DF%/"$,XW^HOQ(1Z`N]"XN*PETXOXT`K4X8!G
M(D3WRY6$2R,0?3$1#3\N30PA1;SM6;5=6:6ANM$',8K7X@KZT#_4>Y,T":N"
M($?EN)`/68BH:!O]*#S7B"N#2"RT4;H3I#/)G*73N-#PPANJ,`Z7T8!"@<]T
MT=)&30AB?;I(]2,3K2NK")C!$P]N0AHU9=,WV=`>NLZD"+3W6@K/20O!>J\5
M/`O(820%\1S4Z;]!>B@2RRCY0(S#@PQT\J2.@XAMNT*^@=%B]<Q'-0@L_G6*
M+Y4)3OQ7P0!6%4$V@U@.5>F5MC*=L`!5"EV-GD`72D&LL!BC"5$1X=!.RX$<
M$B&YM_%*FO"Z?#&*P=RA".R.W,N,?RD\HK&GA%.19\W7+#).U;O/F?'2?%TL
M<9F]6J+``\V9M0!8CB5)CP&SJ_.8$ZF+76H1+5J@$DR9VQ(JU0BPW[HI8959
MF1#8S03%\UA02DW.0SS8I-B1ZE1`G0@5CE&RF9C4]^#*_/+:4D6K'#$(1$F3
M-F*(+;3-7CL7)L7:;F*79,6:92U6[AI'^<B;E$B).:&XE*N+7Y2("8@6DP@K
MEMN6E)@/[$BYB3`^5;6.C7D(J_JJWP0V\_!(_@]@@'/AI&<J$)`U0!3TVYG0
MVA&UV>KHJJ_%S,+E#2;1V0I@E"SA1_7CKDZ)EJ282<\SCJ)018'8HFB))R91
MD'0442U*B2$11.7\QZG<"9.J"SC<6R>%7:V074BEW=-XPPYYQZO=GC*A6L"P
ME%M+FSR+6<I@$9-`25ZQ*`V`4?[:%Q$=T_V1E`%;CJ!#V@E`MKZME-<%W]C]
M1$D17[11DH-E"WM=KI>I3B=)B!%)*`\1EXO(*5]+B-1`(KO(X(G(Q?U5B!?2
MCJ%BHA@IB!X5#R5SCKI,.*\X8`7^VQ`DW]-H2\\@FM%=+J%BB(1(&8,8E`7I
M$.%X*XMXDYO1KJ':_HGB79D:.F$,EE^MZ(`#C&">ZXY0^LCU=>#$&+0;/@TP
MGIHAK)2)80J&3,ZDR)OH*!U4J9@"()</'E*V((SF$X[#HV)^_5ZG,(H.*6`:
M.X\&L(W8]=,)F^`QOHHRWN(&1F"?>H\?ECR'78@LF:$W^2KCX)_LXR\D0I:%
ML.*F,`N53)_:D]7S(!!:2@ET6E2:7>3P9>!(`6.>\*FIF&2]:^..8HIPN;DB
M%H[/3,$:&Q+ZJ#2(NHO)Y%>@V-<\\R6Q8!(:3E)8)BY9_A$P]EID&U3IY!FX
MR2%'-ENBD@!K)!+QL!4JHYR6=*'^(YR'<I%N5(R&0.372T)1GF8'K&87_KGF
M_)Q&$)T2MN.3"3"`O>L;",`OHWD/OM!;?RF3C#*V#G`)RWB(\;&,0`T/O46.
MN]R>C)J8,5)D>X[EM#QC=J&91AXX]]J.*BF($=G>JJC?8.ZHUYK$_`$QJ*C$
MXHN`>KP88\.;P&AETK#>+#*-$\&R`UR^;]R0CI*LCVXI?&X1,'[AVSU+"6``
M7@L2I&A-U%1/F6@(^OBOQV#;E,.QF:IG6Z,23M*1?MVA;A'G$IHI9HZ+AF@`
M^_#HI0;I2@G<0\O/G-4=G(C51>IDX"K!9R0X0%R1M"Y<[LJ>:C2A2<I:H*YK
M?VWJ\]#G2"[62IX)+-X*P-:)_1,*$A'4??5%_O'@62_28!.:,\>I-<AFZI#F
MVO"(P)(6%5UN"@'I`-;!D616HI!LBOU]&Z5@D\_^RF@)CULFB_\:%-NU%R5+
MLAW2.!Y>;=:^:QT.8WE1;3;^GK08EP*VB=68I-%CBYQPR&_+'\Z.)S1Y:[W0
M(M1=$R>Q8;PZ@+;(B;%P;^A.B$9.ZUAS%Z1K-;K.Y0N=D-O;CM4P%#`Z@*(0
M$-/>7Z%(F<A`[[F(CC]+B)D*B>UQ(%D106?!Y?J^Y]:6J_-X'*AAVY?Z5GNY
M[(CIJ/=0%C-Z#D8]%>#:(49RH0C_K>AXUA7QXTMQ%&VEB&%IW0V7B_NN&204
MJI4D@``@``(H@-&!_AI]XLC$*&AYC@L-Z=#WT)T,D&F;@,B4=#X%!PSNNBE_
M62[0,3K"KIEDS@D[6]H?#X\@MY<AMZG*ZPWQHC&R2`GP(XU71F;)#;_.U%F%
M*."*J5"GT)Q=,J3G$*/(J"M:/)Z^-B%>,1SIJ(C'7G.[!EPW1XQR00Y4GHV-
M<^\#PV^TJ='PX^NBN`E5Y$D+2("*"?.$:!P7MV^3(-E)<I1!GC#,Z%YC?6=F
M/2N[T'!*!W+)/DE,3V#,-([A;@K^UMS(M4E/&134]!<EPVIIQVJK\"?#"6X#
M9!/F^?,%>;(M6B6R_O6H"_8&P_3^GCJEMCYMGE^OD8V_0$Z]4(Y:KIF\_JGW
M[7R-+&D('$?9+T]"!\CS='&421?W2L_A=!ER9@ZI#&R^0GIAY!,9@X#HD>$5
M4AWC;D'2?=<.\;DZ8E)URSQW@N=PZ3YX3,_XJ6NKSUJE#B0(F*+:R]18@CF]
MP=&+3[\I!U<(1PD]7`%U0:7RD->.-B=YP6#A\Z`/X@B-#_T8+6>?N0KNZ-RQ
MXDLL'$LUY$A)81[GJ9./%DL7-G$`+".9A!/CGW=J<I\R3$?OS$A,\T`XE)Q4
M]QMNZ[N+!MBV!#``!+#[`R@`9C,`_<B+`&!/EE20Z9HN9!N`1-$N@4#(>)0>
M!6`V`O@/<3O=E*`2DT<,5^,-WJ%OUAM[:RY[_KW!=/RF#Z9(T[^8$Q?#\QDB
MC?P:GW"_J@M@'?-PC?Q;B+3X>SRCB8&8#9@PH\?@3=)0+$DV,`I'83_IP2CG
M_+_S_.H8<BQONX]YZ+?H`(PX4I\PR]A2HHH08L%`G;4WB^N?7O+VSIG(?3/N
M2/)V+E]_\$)A&Y]Q\N5B'.2?9>7?C2'G^83C?JSH#=K0#:I[##\$"`T>+G@H
MZ`&!00\2$C(LN-`#@X8."4JL:+$B!P,3*CZP$&'#Q9`B1R;<\(`#R90J5[)L
MZ;+E@Y<B'\I4:4$FA@@U=_(<R4""S@T;.@C=H$&@!PP4(R:EZ.%!!9H'$TKH
MD-`CU8),&TIPRM.D_E4+#;P:Q"!A`H6>/-&B5.OV+=R=,>,JI%OQYDNS=O>R
M_/E1`T@-&3!PL)H4@]:"%A`7C`!!ZH&L5RLD3`NQ8E>U%A9L@+!`0MN2%"1(
M0,IW9&>0IU>S?CLWKM33>%UB@-#Z=L.?#S!8V*W40P>=24E+:)!`P0'&%1$:
MC)T!)(/H"J(GP$SV)5`-$R1DD#BA`@7EN"5*L#S^/'J1K^'&YCN[)0;SZ5?_
M/&#!`@,*$23<U,FA@G@*79<0<P4U\``$#SQ`DVF)D3?@2AP0L)!8JB7$@00Y
M=3=?0@Z\QR&(Z:WW5GM[?;@2!KLQI%\$#88XD@4.M,C03PA$\$`"#"!P_D$"
M"RBP@(^$`0A29A85^!1)6S%4I$P.-)`!`P-FL!\%AH$X6F@O:HG;B&Z5:->)
M*E4PP8B[,;EE2!%TD,&'/Q$070$,*(`!`@THL%\"B$500$QG-G2D`QVTM:%"
MQRF0XP(,+%`=510L!N%(.1V0I4$09+#1BQBZB":G?'6IUI=TA9D28A]R8`&A
MG5JDW024_@2`8P=(P``&"41@``,/+*#G?0)>="0#4440`:9/*1<5!160-:N<
MGX[$`8*4_C>!!:&.EQ.EJFH+E[,\60O7J"0A]NVV*?UDP'T(`)5B!0Z@E>=3
M#VST;60&.<"1<J.%E"U)8DGY6*H<EF=EN06K_M7M3N2Z%6ZD=1DLDYL33&"`
M!+L>\,`!$$1``$$6MD<<:00D)"MQPAD;G@<4-'"?PBG-:F%"$R!@`64A9@#:
MPSGWA'!-+??$L$BEZNR2FPH:\$!$&#B`:P,&Y(N``1)9R6A!#G``&&`&[>8`
MTAKP%F-/'#CPY:S\HC>!R4.K#9-=/O,$=$CCKKW2JPD<$(`"!F100`(]'K`C
M0U'_FI"2">U6K7S.70`R:19%(.2,#64`E98=^#DWYNJU?1O<%R%6<^8B_32`
ML@E4L+6""R87>$,>\H:!X`7M=H%2Q<J+@5(8J!8;=]QE<`%X%@6K[ET.!#S?
MI:$K/Q+/,KF]4^<6_M&<]O(2/9;`40QH4,$!#D"0,00<!ZX@9P5E,)A2@.*N
M%*$*XD[[[DM&\+?=!DP7'?[X)S#!@!PP0/U\-`"!`%6O@%K;7&NB5Q'>/&]M
MI(D)!VPCF0B0)7;+(1Q'2A0;@KUD`PQ0X&FP9,`1,J1YV.$<3N1#PN8XQB'$
M09!P'J"3G`#E``(AC.Q`9L'\2`QM6G,7:2)0LP:*9`(-,-MX@D/`%1;0A"XA
MXDM`V!#>,'%)$EB/E0P#`<H8A@$.`,D&I&*8!72((P!T6$\TX``5SL<L2*QB
MZ)S8$BBZ1(H,H2(<7<BSQQ$.9QPH%H$,ET'R:(8!;\2-!$"7QQ'*D25T_FR)
M'1."QSP")6T<],"-@)2H[SU&`3&QP`%ZM``$R`D!"#B.!$()M1SES0":7`#X
MZB5)F(ED`Y,#)(<V\)%%,K&1*V&CB7`22;61A@$%,``RDXE,!!`@`=4"F28A
ML)C%Y.Y][YL.!&BW/FUR4VD0:$!QN'8@!76SG-:L3>->M!U>5M&7*OD-:X99
MD$D:A`-*N>17SD)+OCQ$F]6L)G\J`)YD)0MWSV0<0A.J4.(L!GU0>MP__2E1
MI3A@B>.Y0*O8V4Z[X"Z!*00/6KZSH-$D$IA1)(Q%:X*?CBQI))>3FD&R&-.9
M%D2FOEK>8C0*1W>2"E+@PDDW&;@?<%YQ84))_BE+*I"HZ%#@`OF3CDM]RAZI
M&DP[BM0I"7DJ+J2^19XIN9=:PBB!?>:E*]M<'^Z.9YW;O%1G&,`E5K/*4:IJ
MYC1DW%:O$D;7JYPO`YN:R5X[Q8$(>#6N!M-JI+BJE@M80`/X5$OA.$5/[`36
M`QKX"-H:V-:"=>:0AE4>8H-669E(\ZIPB2R:+.>MRK+)`]O1[&A#]!_3?E:N
M=.GH:@1:6)'(TB`D72AP@RM<XC#$)*M5B>6,H@$[;E95NO1L;4$[5]9$\)$^
M:0B0^'.?[7*WN][];NK"FSJT*2@"=KMC:)L36^>M-STW@VYTX\A1Q7ZE5@"B
MG5_AL@#'0,!)CR&-_C7-F3MSPK<AET5H"_7*UO;:90.T5<B#X\O(Z9ZF`[33
MYGW46I-J!G6BY^0P`X<KXOT01\,K:>Y4.34!6FH`9Q)>9'H]1]_XVA0X-+7Q
MC7/L/*XA2$%PE8E'>HPCLH((K`J1V(O9&6.+P#/).;L9XQI`X@@\M<I6KO)_
M]Y-@3FG'`^VR`(.=G+,E+W#&8M[28W5*I@,(-,UG7AZ9)=+D-]-9556J\T[G
MB^<]<RK,?-96G*?HYS\3NM!O#O0=S6SH13/ZS(B6Y*`;+>E)Y_'195$TI3.M
MZ3S?-M*;_C2H=6;I>6(ZU*8^]9@IC.I5LQISHSY,JV,MZX>]>LZSOC6N_D-4
MZU*CQZ3;*L_DRK(URUS-`R96U;%S'=U:>_HTUAW/'^4U@>Y8CC(1:$L'(H+:
M7RN;SKM^V+,1N9\Q"00"%+C76POB00KX6E7A[O:$.PUNM0V6.X-MC.[FLCW*
MZ>S=\&ZBG@V6%J6UFU/_24K,YL8?E/C[WW!6=;DDD(#_BKCB%F?<?4&LS:A<
M_.(!_OB`07YAD6O<FMMA0`,<[N1O&VPA;)I-C6-^8YG7]'<A'SF(SVDAFN.X
MYUF\^8<]'-&@G_6W"U743WZL<L,R>^G:BKF%"NSTC=Z6UU._^M2;CO6M<_TB
M9^P);KLN]K%K?>QFWSK+SZYVIY=][6Z'=]K?_KYV#2@H00](MJ;;+O>N5QO8
M5!N3$%<=][UO75\&F4``<%F;:YM:[X1WNBY=Y,D!5&0"?YWTX!^O\IM)9`$%
M``!J!WOY1CM>\_#6`#`Q(``&!```9&OVL@-N>H??6\X$$`#H"7!Y%V>Z]+/'
M->,E\H!C`@``#S`R5S:=^=_?^K(6>4``HN\``01@5!7`.Y]]S_Q8?[T@`'!`
M`0A```<<H``6;3C39;]]7(=J`P8H0`%.&0`"&(!J#&%L[R&^?EEO(%P2$'\!
M!``#X(H!$("SO!HO+=_^K1H%(%$J$4`!-```#`#?B!^_("",Z=\"LEJH:,``
M%@#U04``_,T`$$#*_G'%Z/V9`FZ@J7W)'WG`9@S`]`D@`@P``@0``7D-I6D?
M"X+:C^E23.%(`L#?^R4`!;J(/>V@^O4@JIF6!<!5&!F``PS`ZKV?`JQ("F:?
M!C)AJ%U57DF$!23`ZA7``#S``+P'\I'>$G)AJ$D%!2C=54BA`!S3%=I+_LD;
M&Z):1BE$P24$!(QAG!C$76'>&N;AIF4`9?`>26Q``PS`^W7']MQA7-B:(7X:
MVA"92&0`,T7-0RB`U*U<(59BIC4`>%3`$XY)>`C8\<S/.DT,]KW9;C$9[(GB
MBYW1!KR/LM#,&SK&%6G9!*R.`5!``"``)M99+)89+;:@U0F2X9".917:_C'*
MV2PF8WQ9UXHUA#`F`#$26C1.T3)2XYM%T$LH2P?TQJ$<@`+0GP%(T)]UXQU-
M(SC65G"\8F7<A`@:P`&4H/@]AJ&YHR1]8SR^&8HE1(LYA00(@--\83]N84!2
M6@4,T!M5&RV9Q`!`@#UEX9GYXZ4UY*F9!7_<$7%@H@<"0`%$&)UIY#S!(T=*
M6&\(&5ZX66-L&YZA)*RMY-9-&Z/1)"7:)$\.C4X"9$\&)7KHI$H*I5'&Q4\>
MI5*6"U$NI5-V2E(^I52^2%-.I57.1U1>I5;B1E5NI5>N1E9^I5B*"D..I5FJ
M5"B>I5I"4EFNI5OV2UJ^I5Q>!$VZUES>94K4_B7ZX:55ZB5?_J7T[,5>`J93
M^B5A'J9B""9B(J9A+B9@-J9C\B5D1N9=3B9ERJ5E7J9;9J9FJB5G=J99?B9H
MBJ5HCJ97EJ9I:B5JIJ;:4,`#1-V-I.&%/$!:F,1-H(0MR<A_R)`'@`1**`UB
M'`AO'!_,W(A.3,Y-]$9:H,0G@LAJLF;.8$AOEL>16=:#;<1-+(1.Q`1X$(;A
M89)2J%%O8E)C%`0@;<3UV<:*;2=Y4@!&;LES0F?+M07-F`549$A%F`>%Q`=4
M3(">Z)-K?4<'O.%-?!"$#5!"D)AT@AE!Q(0#"!!,HDE\RB=36D8B$DO*F`U-
M+,18M8KKI,R&7@;#_I$G>59`@X"&3G!H&"$)>'"'SDPHA6[+=EP`1;RA95G4
M!JQ3BR5G4AS8<I'&!A`$8FQ'6NQ'_P%'J@BI/=FH0'5'M1S%BRIFC)*FE$[I
M:5:IE:HFEF9I7VXIE^J,=*H$!Z!,87A`6Z!%=[26861)L@1&S>!?A&(.C&K4
M41#*1?8F!^1I<]9$GL+,!NPIJEW`7"0BN92&0#1.D3#&M.44_I6%;68(!3C8
M?724;"K/G*Z0!@`)`C"&!`1``1B&ZO4)[GGJV(C$!1A`]!5`=T!?\;5>\2$&
MZQ6?Z13$#18?GZ@&`Q2?KB:`\1E$!0``'(9:</SF$Y(+(BH&@3)&J>"%_GV*
M!U$]1#J1QD;(I)QZ:5QMP#$I"@`D8OE)D.K9A@0,``8HU?PQ3`7`WQO>WF`\
M$`!\!FA```!0S`*0)$@PDT`9``#4"P,,P&MQ1P!0'JT.0)Q^&KEQW$A,B9=5
M`$05!$&`&<,FQ7L\I,-0IT+PAP"1T*6.$`4(P$9H@`$J1``@DU5<0!DJA``<
M'@&PHT0T0`'@Q;Z^A@2XGHT10($XP+8>1`%H30"@1*XBQA@%`(4`0!]^FG:D
MF]4H5E0T@%&0"<(AW)A&P&!`;$)0QH-N1P7DZ%F`!@,$Z]QDK`%-#F)D0`"`
M*[#B8%*4;*=VB/WE!JX4A-<02J?2!.@9A`7(_NP!Q(X#!(!`]*PDM2LF`4"N
MX1&@M@1SNFU!%%M;#*ZV>.T*05]WQ&P'"(!M8,#8*@3`5LV1-(0%"``!J%7,
MRNU66`#0XNR?9H``,$JN.A8';,CG>2P&IB;CCE`&#,!=Q:P'.(#(A*K)$LX@
M+M#MR>;G&H0`TJW=NBH`U"%$Z"H`!`!EB&T$G.R7OHVU?M8`!$!S`&[=AD?E
MIJV]K*U$9$`"#&/BC*[WA>[H,A."W`UCY"H#:./,5(T,1J_T(I"$-<"$7&]!
MU!_EBBKODL3SEF1S#`#H)L3H'D"]=(`C:@4`;$K,%B.K=4>08E\&H(37J,:&
M8``$_\8MJD;6/*-._M7ET"[2YBY`:-BN:P6`,(*K]1K$<5S$K#!&!0S`5H0K
M30RO\"X$`LB2`3`'WR[)"N<:M'2'/7&M0IR/9>%,?`!(2'5%=_`/:%S*P`7/
M<0)EN10;70RFVB!``<","7N``*"OY1J$QU:J0>@(8UA`_#J$`!O$`%!-W=X$
MU!A$'"?O/H5KM[U@68B$!5@(7FCG6_7&AO*&<96&3C16U%#+(E'Q`DG8J=I/
M*''BY4:`*?7)FQQ'^1W;K23`6=2@:?P?38B@`YQ.`A!`O>JPX.SK_="*0T"O
MLKV50"2A'E<`2EC&0F#4F(01(E,`Y\W%6<!@9VA'7;Z((LL92YZ2-B:`_@%8
MSN5Z@.?U2?PA4P%@Y$%2H;A2A<RJV^?AG@`\1`ZS\`#PK*L&@`#0\C+?6F%L
M0%I86";F!$A@"D31SA^5AE5L1*MLT=4*T;0!1?+DT3!/T=4-K-M]AXY)A#VU
MA840AJ!85O]9GD`D='XE!06_<B)SE/Q>93_?445;95%>=$;W($?G<4<_Y4:'
M=,Z0QDTXL`L]A&J817<(JH.M$T@(RLVXISY[),$DKN5T18L]P'NJRD?/$TF#
M6P?,RTA4"4Z>!(FJ%AI%0'@HC3W)<F*B4<HHQHKZ5N;\=-,&=;GLQ^..!-3*
M<O_-D+X(ZLU<@%40J"D*B'^F#-JD2LV@"FT>_MY54[161UQS1&BQF)MM$,EX
M+HZOWNZ*6FQB*N);5W5!A+!/TW5=:POH@)-(@`YE1"I)52S-(!EEK)A9-!5:
M+!=P*%*R>`WJ7<5<W]9B&R568W5I/]Y(IW9/GC9K]^1JO_:6W$Q/SY-E.$IC
M-#'4LK57A`8Z?^1#FF3UN+9L;PEH+,30XB0,CBF23)N>(`E#F`Q+_?4BQ79Q
MAPA-$#$:+43_/01.:F?`F`Q0N)AV*P]Q7S=V;\"]*,SD1H69NG?%.HQ?&X1X
MOP<6HXEUH_=\-``$;,1^9:)_T@QODHD%1%"U*,2!:PVJ/(54E'?HG+=^5Q$M
M70U`DY!PXT2$QZ.#_K,$:F>XV-UWAWLXUX&XB"<CB9?X>8P&05#`!ZE1.C'$
MS1A/3N@$*G)V;SJ80C\AS+08=Y.)8!@;F_3R=J0AP&#2PG7G!!N;<2LVBK/5
MU/9F@Q+289MI@O<RQ'8$;_P8_BW$'W47?7M92W%H!PP00232<VO)B3>YD],M
M<#3`&DFY71JY0]1,ECO*6P&A)&7G1(3R!8S&JDZ`RGH`..DY-<&@0*'SDI.V
MFM^&HUC&1K!)<,C9?:!>?&1`HU_`X]C2@3\`1J5;0N`?@%A`6I0'ZCT'DE`/
M:!#U:_KG&[[5?<]1A;_3HN-&DN/8&_UX4FQ(?@W&4'!`3!?&!63+H.!0_IF>
M2I7X)D-8Q0V-56\B!A@I+GLP^:RS8)I/.[5+N[7O7[5GN[9C.[>_Q4RS7ZR3
MRK<+9JP#S&BD\^&:Z;J[4)(B:$'VII4D2&\N"#UJR[:7NY>,UD/4C-C`X$(@
MF<F$R4/HQ*BSHU2$^&KDN[[WQ$>JQ`+T1\U4!\W$MW03D'<;VS,9Q,J`=.@P
M?,,GC"--.94_(?\X1I=%=4O5A5^]N%04Y9I/8LC#!4IK;D$@2P=H1Y`2A(5)
M3':ZJ&A/)V7$1R()>M$KN?*`_,S+G=(OO=LUO=.K'=1'O=E-/=6?1_^)QZGL
M<6\>S];;4TZMD-5??4C8!H"01%.YED#4[F%?_D"J6!@$$$GPB/H\K76+7;C"
M>3O9JT1D,,`K%CT#6%BOS$6K)U^)`CS#(C4,*OQYC/W>$[1'I+5+-:"E<#I[
MPB!F.,14PW>3A3T)W?>]/_Z%U`;MD$17>(B@7H!M@-6#0:M=&E[I*P;CCX?C
MBWY-",2?#L4S2LSY`"E#((7E4#!I%,;PF^FX"[6BVS[F'/_0U+[R_YOS/W^W
M1;_TFRD&CX3;-X10H,<])<1@;(C9Y/[V+[S>5S\A4<M`:A>8CQ5A3?`5X=%B
MG-N8'FFR$);W[\=_``7FQSF/&DB!`X0'@1XP3)C@@4,$"QXV9!CHP$*'#!8<
M#+1X$6-&C1<E;/3X_G$@!I`C298T>1)E2I4K6;9T^1)F3(L2+ERP,$$#R(X"
M-53HN!/#P@T[(0@\^,!#T0<4,$XT.K`!PXX6BN[T4"$CA@L>)'"8P('"08%6
M/8B5J9'L69%GV;9U^Q9N7+ES4R;P<#/G1PE=!1(0"($IAK4[=S)%.L%"A9L.
M!VY0Z($"8PP4*'>@T#'"0`9,+PJ&C%!"!<X>'FP8.#JNA`YNU])U_1IV;-FS
M8TK0(,%":X]6+6A`NC,#UJ%C5Q]EF!DUS[6C*SC`@!M"A0E6DPO4>K6#A0R4
M!V(=:#;U6]VTR9<W?QY]3(<7-'`8B2$"TH4:-DR(@/5R!@Y[W7MPN/`N_O_X
M&X@#QC*(H*,-Z--@+?8>Z.B!!P!LS#0.('`H`PP>R,P^TSS8:JZT9!HOO1)-
M/!'%%%5<42?Q6'P1QAAEG)'&E$2,B<0:==R1QQY]E.M&F'+\D<@BC3SRR"!?
M&A+))ITL<B$+-C!M2H\TF.XBGQ;*@":+GI/`P\;VRHNDQ!@3Z"8`*PASH#&'
MDN!,V%1C[<DZ[23R@:">(XU)K@;*+8+]VBQ+K,P^RXTIW/IKC,-$%S(T0(P(
M.Y`@WF:B34F7^KR3TTY/["`J^#Q@H,_+\GHPJ8YZ&HO5#^\JB+0+NK3(K@A$
MBL"P@1X`\=(`,<C0J@;.S#2UU=K:U--DE9V-_C+%)H#@NHW(>DRL"P8C[M#)
MUJS`6$:#@K,!!38H"LV,"H,,6&,G]',V8EE"=MEXY84+OPPTT"Y.C!"3,B@(
MQOW5`UNMI2`Q@9C*C30.*M`JS`TNVT^L"1A`+&`*R&SURHZ>LS9@#/)R]ZTY
MCYV7Y))1Y,`"*3TL4#OK>)K0/0[<JS#E;CV2&2&<+6I8(`XV\"PHQMB4TT63
MC3X:Z1I!5@G>I)U^&FJZEDZIZ:BMOAKKE:9&J>JLO?X:[%Y'#IOLLLUN=>RS
MU5X[ZJU/ZIKMN.5^TFV3X)X;[[Q[K+NDN_7^&_`7^2;)[\`-/QR]P=]#G/'&
M!2_:\<@E/T]QD`J?_ASSS%FJ_*/+-?\<]!;I#)WTTEOBW"//35_]<]0W4IWU
MV"5W7:.%K=7J5VNGVXOWWGW_W7<*K+U]>,&*QYUXW)$W7OGCG6^^^=U]9S[Y
MZJF_?OGLG[=>>]RYWO[ZBV6WFO:L0.H6?828,E8#0XWEH`/Z%,Q`00TRF(`"
MYO57'OK];^^??[>SE4`Z,"4#*J:`&Y#9@NB3(84()H"",<C_DN<_"%90>9<!
M7@42`#S>Y4\"#I@`!2^HO^)IT(,I5&$*'9``!P`O`@C:C`4H4`'%:,4G$I#>
M"GG8.]M9H(=!%.(0B5A$(Q[Q=_%AP!*9R$0',.")D+/1SBIR$HO!YBL>_HG`
MT#"R@2INI&!NZ5;+"#@0FUF'`H%"2?K*V$8/L/&-9I1C!:+CH?1-)R("X15&
MX-A'.;KQC'^,(R`%Z4="'O(BAASD(A79R$(^$I&*'$GY,'*Y*UD$*2G!B6LF
M,#0.?%$@F;P9>#)2@0<LRBUI\<D#\D4@"$0(4K.90)XTPB4'H)(@X\.4%$\B
MRKOL\21J9!I)-O``\7$E(1:Q`##-U4I)X5(F]6E,GJ8D'69R!`*X"J1;-B`=
MVV3$,:&!9BYU*1M*=D8E$SB35U@RG)0X"R1>P:5T5N,PB\126B,98%LJ0"9A
M#N1^>\'`.`52'PD\AC41V&07(P"!"6PS).4T_B<O2S(M@I:$G2>!$T(VA4__
M&`"3.W-70BYZFG.B+:,909E#/X(R"42(E"MY#D(K^=*21E2B1!O=21:*$(^F
M!&'$W.@;"::1H0SM2Q.RC$74&<^?8D0#%("H2B[@'8)<\R*W"8TS.Y/-O2R,
MBQOAP&1P$]:A0&!=ELNI3M-6DLC<$T=8S0AC.G"`^QUS,F?4@`(<@(">1N!B
M3[T(ET8RKK"J));5^4C*GO7-CS!(B`V0``7,:I^8+FZMKA$96^#628M4@*M,
MDVM6;QF!%XI&-QR[2`PG0,<X=8`LT@0)94=BF<NBY#8#46U*.K"[T$*2D8OU
METPSJUF*>H2V3&7+_C];JI0\468M0;D(!TJC``8@(*V5LDAP1I)%C:`&5BT!
MCV"M&"$'*/2F[VS):(LKDY/B=)+YXNY98)O>@M(P`@G(4#^E<Q''*"!"TLU(
M4P<2@=\2,"I0A<``X@0?^VX$/%:52<80Q+=E6B29[VIOB(X[W316DKPLV<]A
M^2@E!!A`)/WTKP$8H``(+."W$;!9_D`B6]V^V`(,F"YN5')%@8`2+GN!@.^<
M!T0A`PJ@$J;:AH'4X0^]>*@8UG&02Y(;)6^W`E"DP)0]LH&TGA(D!\(E2!D@
MFM5>N;L664!LWI<R-Z<,(V#154M@QV2]\#(L]D%S0<$,EU65:4@7V/*5_BY`
MXL^NJP-;!$G[;.:;`EA``8#=KJ)+`MN0LDB4BK6;G:G,FK'N[I@8$<V#6W*O
MDE3)(K`]P%YR;#<E.[;+:9E2?C,`+8YD=R/<VIEW4_36JX2Z;YP.V5O"TC0+
M/."V;@%M15%)PPTT(+<G639/#&#7&L<4`CT9P`2`;`%)@R2F]3%PBCK@G=ZR
MA+W"7HFFEU11*;$[E0?&I&DHP%><)?LCAN(``C[)7'`2]B+UIH`#PK+C=&L(
MUQ1@)8JL@N_.U5G=&$GWNCWBP!CV!\ZO43%)F'*A^,`:)?NIM:T:L``(7-0G
MW\+E?@*\\>[X$HS3P65V?&+HV`Q5<;2,N%J&_KVSF^SE`LZ$N5S.7='VO7`I
M\O9(8GQ"``DTH`+7K"%DL,*7[6J(CD.>[GU(<E`*S-Q44WV-30RF$MOMG.>I
M%`B7'H3KBP35-=0]M:&>[I,'CW-A4#_`R4NS8]WJ>)\$,JTI?:U,!P";H;B&
M#\19DO'!=<3A<B'USC8R<<+!1NEP83Q&'%I6D[RWI9'_DT+PUY/,,]@B]H/,
MK_"7`0:`O*?^V:)]*@GUC5@FQ%X*RS$K@"#R0"KW&;GB2260@*(<X`#55L`!
M$``B#20``=$_P)[]>X`"&`#[H\D`]@&`@`4LR@$$J#8"''M]YL,:`PHH@``6
M</@V03\!!_#L0"`0_G\/54`!"\C_`A*@WP.XN#$68`$(`,"Z18G"),O<+^W:
MPNTL!]ZXZ0%WIB<:RH:L3B,Z20#9IP/TZRZ`"(C@@\"<0E*D"C!028="+P(;
M0SJR"[9$CRU,#6T^+P9A0@(00,<&X/JPKP`&8"LB(/D,H/^8#]P.0``(H``(
M(``4X"\"8```P``"H/M`A`&*\`D!H``$@@F;$`"4,&`"0``$``H!@``X0P)^
ML``*@`$\9`,*(`$,H(HH@``&P`P%0`,$P`;11`X-@`!.#`$8X[H,@%RX`@$(
M8/-<9J=0@HQ>([RZ2SL68``2(Q`QHMY<R.H>``(<P`!6`RLR8``<0``C_L-"
M-J(A?,H%=P;92*T@+)`G]L+F9$)0>H;ZI.5CV$("T/"J&B#Y@J+<</#;(@"D
MEN[Z$L!#(.TN`B``%@`#NJD``N`*1\4)1P4*30,*%<,+I=$8(T,"P'#-N((`
MH@("XA!$(,`.JXTG:H@!T#`L-D``;+$#$.#ZP$0"L"\!W(,!L$\`,BD>"Z`0
M7>4044(5Z8+7PBPG)J"#,N[MBB]EL((#=&P!?$,P)B0#&E*'@$Q?^N-`$$^L
M(,(D#D1$WD1JAF6*L,6]6$Q7D.\AGE#L)(4`"`":((`9E0D``&`AIA"D.```
M!&`K8A(K!D``*,(+40D``B`S)(``=&P#K%`*_K&/&2]&`@9`E`2`)"M@``:`
M3"Q@!V?2`(Y0'[D"!RUOT_KQ)*(J-D;,Z"(D`0HM7QZ$)@S%`CA@`?9B*&%&
M&$4BX^".(_K#-Z0*$:-L)%QNNZ(C+A2C,4KQ.\*$^`C@BQY`_`9B'1.L)`S@
M#C'B"=/B``)`QQC@)G$1``9`(&(R`C`3`#Q@`0#`+M0,`"J"*-TP#A&`2@8@
M`#S```2`R[A"``+1"B^S&R_"^NR"`09@``<@`6`+'#G+R4ABVN2$U+IB-.R2
M`U@LP;3CA12%TAJC*#`@$*$%K0;,/8I"`R+1)(;"WS3"TC2B?0C3)):JP'"+
M+(B/)$.)#1ES`&(Q_B.L+T>0<#P>P`HU`#1CTI@Z,R9CLB,(``"\DP$"`*2:
MD@#6,0W_HBBY,0`,LP!$*0`:=`#3:@*^4#_1$`.8$=F"<A_W$;Y6(CSG8NC$
MRCL3,91"*5`TX+R&0@'BA"KL9?Y&"$V^#9,(S(OZ+"S';;'"!(APB45;T1_/
MI*B"B2-HL4'=\Q<]8$*W\3$1X``RX@EG$S8#H"(P$P<'="!B,@%0)6">T2*F
M\#<,="HG9"H7X`$*U.G:A`!$R0EU+`%LD58&``%&A20?0```(!L#8!^]DFM<
M8C\PDC6FYA6_HXLZ8`$FX``8(-NF8\NXB\?P1TGH:&BLXI(&!"7RPR,"_M&&
M/!+##,(5S2*,3`(&!R4FM",>N>P!WC.45E*I2M0B*&`'K<K27)(`S@0_`V`F
MK;`"8I(Q8A(U+``*6\,"!'0AB+(!>I,`3*,")M0+)S3YV@00!R(`[A`.'S$D
MBI`ISG'*).`F8_)#B],D?.PU4@JS&*+,4FT!2F[A+`,!SHL"%J#WNN66/B*-
M&,,@(<!8'$,^P8@O"VQ1K&(HKBP[7P(\S/,O_,M)72(""D#_(E17XL\B=!!!
M&@`R6PHR!Z!B"Z!..^`)-38"1E,`#`4SKW`T2],8TV(T!V#('&`9ZY0K&V`#
MXA`IVC`-X<<1"<`[FE)"DU3]`F`"@@(JMY%;_@?"`)I0`,(5+%>"P#1.4'<-
M(28&?XRE`=)(QL:*`1`5TD`KN>ZBE1[DL`+QDB9-WFBL,YC+G;QVL'C,2Q!6
M$LGD'T="2C@B^`@'^_0P$!4S2AM##R$3^V"VXH[0&/-T;S,`"8VQ"1N@/]3T
M0_(4*X(R+30``8+2&)/P8PA@S1Y@`&YU<\U"`ZQP&XE20N5T`[#/^OK66`J4
MRS0`"0&@3\55HS)/)HZSQBR&V^+CY$3SDT0"?Y8(`[YO,DS1J'!%7_SI`OL.
MC$H3([@.319ESRZ`IA!BX9BF-?[L.Q?V*H!()BY``3CP3T[P(@AR41M04MJP
M`6)I*!)@`9KOLSXL_F!\;T-(A+K6-](614,*Q1(#+%8M48\D1%<``Z`6#`IC
MR90D[$#F;T1@5]J>EBU0=+$(PF(20+HR(-*N@BDRP&&]#)AVPD("R3<.(AG'
M$R&\LV&X(R-D!7NW:R\"YD]BT<P(1(<8>'FG29-P:2C1+H&7MB52<+E2\I[:
MYP'05,`<HSM%X@J%)^``A+)8C:&V:$T*[(5R`BQRJ*G>!)@ND2*SBF)F<*[8
MMJ!Z3Z/@=O+6+CE4#/2$S4_?IBUX^"RVI@%6`RC:4M\4H(8",D7OF(4W`E(V
MP*Z\8D,:1@(80$TV`\/>QMCPB5)(8FRO0G8O3;G8!8?;38=;(I%?H]PJ_JTB
MPF01$>(VCHF,0C`W"`Z7+NPO8%69ABPG#J1K3<([/R)M]:B5T6(@%GDC\P5,
MN#B2J4J!4Z)078/LJJSB+@L].T"4="Q!F%<@]EA<2,*/I:2W)NLDN$2&DUD5
MO?@"%R66XRFFK.*,.0U$#;$M,NPU`&XDO&*;!%,[!:(","X#YJOHU'8LV!B@
M%(ZRN`2!N\MM9D6=DTT$&=E&AF8ZN]G.TO@KW8*ZQK@E)*04=8:I0LLL`C$S
MS@0\?&D`$)H@<H.E2"/V6HK@QI4L$B*L(,4N2Z*?K4,W!)K)OIF<WB(A?)@&
MW:,#)FXH<`GDLN1CV'DC"N\!^E4C(.4V.BEC_F3W,NS&`LGRLQBC.U5"1$@)
MI3>,H(,M+A)-+FIM*+9B81:+E'YT-WK&+,C+*A+BJ>>+0'HO(K3$W3X/E5[8
M/WAE<)#8(K+M[7)9DMN*I;MY.X8C`QS`83:%3<Q5I<0BJ(*#/3(B$:E")5+X
M3QC`(3!`L;MN:P*/(!2BU0RFD<7&I"5.KC5EEUVB?804MPZ"+U:M(_Q2U-;B
M)D!"W[ZH*`*QIWR)5%(B0^P5?ZYBBS_B0(1:-\9JH`K*;0/FC!X@D%2:TYZZ
M3.(N;NEL-)CB2H::=O6%,@X,M@`DJ+KISZ1Z[:S*FF5P)`[D`L:*1V6[).A)
M([)YMO+EB3$[LS5,_NWBKK<U`E^F[$`$([E_:[=W8SHG)#.PFTP<TP.RN+#D
M&3X6`@/X6ZRF,_2$K[(-U><T0K@'NN=<XY590C&V(]JV8S`18YH'*VAW9C0J
MPBRHPRSZ2Y-20E,GBZ"$YKCG2L923YZ9"I4<XW726[W;HJEWS*)GXGXXPZ_+
M@DNZJ9&[:84#[O[NIS\$+(]!P[/]BWSSR=OH1YL"SJ_:A(T#SY07"YCPK<&9
MC+@G23;V8YP4Q)654Y,5:T*N.M\<U9ED2ZHAA3K*W+_!#;:9P\!N@U<V8`%J
M2*39V,+U.B5L#$UB,<%E/$3/@J?#640.9$1[YB>J,O@<>+H<;IW7SF&&_O'#
M+:(!EEPC=IS++\+V9IL@D.*6ZCMX"<<Y$`LCJGRE!?TDMEQT9,,WH#92NJB3
MR,+,W4CX$"_R1F,J3%4J_N3-/P+5&?Q&BFDBLFB9^.Y"T`3376*5R^*FLGS#
M5+K&,YTOK+>^.J.?R&*C7T^NFGOM'.Z6KVJZ"NQ]R+MSEET2/<+N-CPI%B!D
M#9L@"IUIT@H#^A7:VXO5[XP\?$9[PS=@I00\%F!HWJH"9/:[(OV1MUH@J!3#
MK"*O=4Z[5UT^&1LRQ&(A)R#2.-`@SV+'02;?,UO:S>,"A%DL)&"@4$-$Y.[E
MQBF@^*.7A6\8&28CD#<IA,+6*FK$[74_>J//_AQ**12HUF7"HS::P5^$>[8G
MT),FY,W#GLR%L@IN[>*6F),C36YOXR]P4*S"IR'ED[SD/GRXQ;EZL9:C*Z"9
M/A3J`8SO5=H8EXR\<ZK*>I!([H%'>$J(>>8>[_->[_>^;D/2/*+M(DZNT$(B
MK=!W*=86W0<L+WZEZ7\&8#4CN\+IHC0=)(#[9F(+L`"NWBP@`3@C6E["@448
M)-C+D2()N"2IMDY?]4V?]8.K]5-M]5U?]AUIZ<^#E@-F(LZDZ0LL`Y!MTI3,
M-Q+_LPR5S6=YCQF>0#8DGZ)YR=%,.@OJNH[Z)<3Y\2]/U?]TO=&CG7O&8Q+1
MAA()**8V)!2"3;+,_J7_9"VB:A&Y.4P<X,#&!>$MFR1"++8)VR;ZL_Z_(^GE
M_RJZYN,!PH/`@00+&CR(,*'"A0P;.GP(,:)$#!(?2JB(T6&&"AH<:/`08:"%
MCP4K;""808*$#@,W3#`Y\$'$D`(G>*`P<,))#QP@#,S`P"&'"#!%DM180>$&
MG`DM))UPM""%"QD]3,@@U29$BE6[>OT*-JS8BE3'#KQHMNL%M!XP4.`@(:K(
M@QLD6"#(P<'%"5PUWA48EVV#@1$XG,7ZD,,#MAX2_&VH->'@A74]2#!\D,).
MB13Z"APZ,:WHT:1+F_4\EK%IAQ%4(DZ)N2"'R`8WMZ2@FB%-D!XJL/1@_F%G
MA]V5)6Z(\)9"AY2/$W9@BE`G0PLJ9R,V&%>BAMRY&Z+VL,&!5@L.=JHD>.$!
M`\\4&C"0@'4[6NHJX=L5V$%"@\@0^)<UB-MYVVU6%U-P_5677*LM&)IHW3%X
MD`9:70!!!;%%R!`&$M@647\:N&059KM)\%\$S46TW6X81"`=0I<EA$%2"VG@
MDP8A50!=029"5!Q!V35(4`0%$,"2!`*4Q4!0`B40@`$$!$"3`0`HP(``%T40
M0`!).0```0``($$`057@I90%G!0``$P1D"-!"Q#0@``*6!!`7Q`,4$!2'`@P
MP$<8$'`BA()F.-J#@PY$050N0:!@04XI-,&/_A59$(%M&!RUFP<.7"A1!+_Y
MN*%!'+19$&T'<6"!3P(=EX$%_Y7T'4*@%91!K`V]NN0!5EI5IT`+."!0!6`*
MA```%7"I%0>&20F`JAX`8$!;8F8P)4L<%!"4``#TJB5"#!#@@0`(7-"K0`8,
M$,!%'`QPK@88"!#HH?(69.M7AAXZJT$5-'#=04`U>I9,9E7P7P,5/""C1!F0
M^MEB!86*D,`*55#8PQO92D&_"9DJ$`.</H2:!<8FD(!5`G#%`+`>,!#`7]1*
M4.6%PC[@0`"8`8"`!Q<`X("P"3,0[0`2&&``!VIZ6T`"`CQ@P9$"T1E!!$5[
M$$`"!*S7\KQ:'U2O_E?W#OJ60K@Q+!)\SDG@:4-A,^1L!RI+^")$7V\7]G$)
M5=`U2&1'H`'!"!654*(&Y9<1K@@,X,`!`6P$`,H+",3E7Q6DRP``MBD`9<T"
M-]D6S\)&!K0'!=C%,P#QKDR``SZ)C#(!$3P@P`3K&@S`!%EOC;M`>5?UM:#4
M:6P0A9HEE,&."&UP.D$5+!\!\`3%*!)M'4Q0Z4.9)K3=2PEMD+"_Y#DOD&:U
MNHCK\_&NE!%J33*``)P4J(G!!@PL4*L&56-@@0%'2C!E!AGHA"ZB!4```H$6
M<`3``/L-X`(8J!FP=L6RV'DK`"(YF08X0(`"+.!-!PC78-H'K]SE;G<9_ND=
MV%JC$`[4I0$?0Y0)$[(;B1U$8L5#"(O`1Q`+X/`@$[!`"^^U%`ODK0$N*=_3
M[H80LCG$,T;2RN$F((`LJ6<`7^*`L+[$,X$<`(L`H):2$+"X9^5,9$%Y%Q8'
M8)AA:>IH!UG``"KXI0<,0&`)0",">7*NY(F0023$B!*WA@'J_3`!&3@.!';(
MD/-(A2O_.TYP:!49'"DD)48<B,J$HH#67.!3-P$8>"C@`!)>9GETR<U:.*0[
M3WI'><H1R`4R]I+.6(`"$QA/?92G$B&22'?P&8I-;"2C0*J$)/?Q0'[`1YV6
MU,<U`DG)=A`$L3W.JY)?Z>.\B((KQ7A@`9I1_LGPHD--"74O,C91SO]RM*G/
M+("3?Z-`]Y0I*Y4LAB0FVJ`$)E"6A6T/9G*[U/4$H@$EX8=C`Z'F$J6)'["P
M$Z$,;<MHK*FU0'ZSE@:3@`/B,X$'V(HZ[QP(!OKR2`^TJD=LN<!C).F0"VB/
M((>D5Z1HDTN[(``!$'C``R9`2X3DAV"(-(A3)'0JB/WS>6IIJ%&/&A:(1D2I
M6I.032R0*L<\SD<-V*A&#9*I$8$$,QBXSB4WT,&(;."J/$%`:W2(-H(*I`$0
M@(N)&,"H!3#M($*D@!YA9*&A\D:("F$JO9`*V,!*Q*!=\:O67`*5WBB@?$LA
M2G1VJ;O'=/4S4.F._A7/<E<816!%%I5``N*FD`Y`H#,/`*4%%)``&T6%EFK5
M2'@2`@'4].@F116L;6^+$,.N$K>(ZL]"4:(25/:&F`/)ETUDQ\.=T*B%#TG5
M`1*048@4[RI`@<Y5C/F2S"[D.1E["`5D^$(8\7:\N"5L572;.QME=@'WN@Y'
M"&,9%R%*NQ-S(XGH*Q":1`I$`^'7!/CU%9N\L%+@K2UY#XQ4]"Y$P>GU;0K1
MILKXUF0VF.$K8(2C5X@XX*8:@LAEFRDI@=S4`K^52%),R$`/%/B\"&ZQ4<V;
M/A<7EYD)L:)XP`<!JOS/*CEI220CT%(_`AEM/24(QRA0L55]U&Q=N8L)_M&2
MJ6]BA,$RKC)8J)Q;*^,'-WK<0/$>`+P.7"!J%\(??`?"@).D"K_%C8`"%G``
M&3;D0<A]&',?<N*&0+4WL7%756"LY4"G!<M<RS""+5!:A""`O1N@DG;9LI28
MT`8#8(;(9A'0@`2$\B%U/DANX%*5\?W1R,BS37BY)NA40PC0%>EJ1ZN<$M`:
M,VH80(!=W1RK,2_'NIAAE4\EL+9):@5Z'&V(H8=:%^$RI%5'=$A@@L1B54N[
M-$6>,F^D/9PZ5P`""+CI!@I@&0MP4T$X'<CT$"5G@G!/UM@9"%!UUQI/M@@A
M?BY(1T;M+QEQP).HC&Y.(MS7:0O<00_EB:&K_ASOF_#3LQA@@`(68X#.;.PZ
M"[CK4,CV8<M\+%(16\BC4(*C8#=D-I_),`8<@]7-Y`M(`V^YO0H.DA('>@(5
M$BD%*A0`!&R`B-QKP`-^*)*#_X0"I(J;W2)TSPNU5G<7J,!U(MT;OC1WH#7&
M26(5<DF6NWSK&$'?H%>%;RMK`&'-I#D*$>4`!B#&R_H4L;)U&ES\L(7=!7%)
MD@_.E<16@#;^>W6[`5/C![@K)4N?]U*YCGB,^+V:`P%<R^5C&`LD@%1COREI
M";-TA02WSH1CR/14(O/7#J0_',J+JU+X`&LE^2";Q0`#7U>O45D[\;1_"*M9
MGNZ!P^6ZVR./\4;%_F:#.`SPB3&TG%7H(O\E)&Y"-\@.,R_>VDM_P3!_&J%O
MNQ3>$R\[=HWF1!"S9Y#)^^T\/-V/Z-X5P6G=(/]577$=@``'/(8#&&B`_-E)
M`088N@))ZG^2=D(>!D,0/H=(%)``!W``,@(!RV0V*M$]8Y-#$H``D/40&>``
M1*0[:0=2-J5B40,!KR-BF^4C(D@?04(3`5(?!+5OHH$:82=ME+)XX4-TQI13
M$L$!"R`BE$9?#/!;0T%^T:%^9_$1<'%GO$,6H95!!Q`MX&$U!E```W`7W_8E
M`S``";`9&4```K!##S!``_0DC0,Y:5(R`R$`!J!'5E,`[<,M!$"%`B``_DDA
M`&SX'THXAAD@1P6`AP206@\!-!&''P1@`!)C-1TD`$_(A@3D`7A"`+'AA!<!
M`8!($&RH1<7BA@&0=43U=3XR?<VD=F(C5Y62(D6('3?X%FC10'F#/Q7`':*8
M$(L1&R]"*:S8=:TV2922AI`S``3P`$03%+#3,D8R`'TA)9FG`5!5+/+G0^"A
M+5^R&7B2/.]"`!2!&P+1)`WP2E(W`.U3`)B1`$0C$`3`AO<T`6#T0A/`AD,2
M$^SR&4XB$P&0.I&"%F5(`#DC$`5@`%>BAP2!)^;RA!+P`*.599GH8YL8+#@E
M<X`A`1RQ/++X'`G`/LY"@R)X*@(S=C+2`2%5_A&S(2."TS>ET7Q_Y7'V^(U"
M<Q/N:(<&,!D%`(8>``$`D`"RN#(!0!L3``!*"`!3]2R`0CSH(A=Q*&<!D(L%
M\',><``%T$$1D(MLT9&LP2X#$$(\D8L`A2XL48BJX8X%`"7$0@!7@H<$40"(
MZ(3TJ!"W!Q'AAR@P.7#<PS<*$0$JA4\SN!`9<)&$%"\N$2B.9Y=2AA$=L`%N
M<1(?91JSM5L*80&0Z`'G0A4=X)11P3\`P!+D0D4!4&D+43G=`Y0LLBTDL2UZ
MQ`!4N`";T24..3]W,4`4@"YW44>/XP#@^!D1T0$9E`$(8``X64<V\2U3E26:
MEB34B#A4F!1)V0$/_B"29`@NATDTZL%>`7D::3-T!/DPK2$!\6."%-(6D3(2
MD'*/;8<0:[%:=!&#G/8:/X@7&[`=%Y`!&@!PB'*0P3,=!-!!=!*,O.E>7X(6
M+7F3:7*)!U&9[@8`(;0M,I(E=\4RN4@3[H@N66(360(25"AYV1@N<R1B3^B4
MYL4!0%F2?5(38B(Z.DDU?`(`Z,*;*A8`!:`!Y,B2`Q!6`A&'YO(D:>*2RCD6
M%F(J+KAU:#$J`O42!6"';H83$>``9',9HX)2FH=<4D<7P<=#S51M&E(=5D%+
M*J$7#`%J(#,=1EF/4%A`!?`?4B*6"@``@S$Y7429;VA)7V*,``!NSV(Z_@M!
M?TA)DA\J$\IB&&[8,0`P/P90,D"3IA&`10*`;Q(P1T+TA+L!E/8CENY8&,KR
MC0!@&`Z`.$IC$T@YA@(!HH>9-(7T=F0),H))8L[Y&2"U=X9Q$H3D&`5``<G9
M&:1R27JY/9V!?@!5;=%A&/6V$#C2J=M32XYG;]!74.T95D.B8T_(%?QC`"2Q
M`6GR2VF2-RS#%BKIHE\B`"R1)GK$`;]1E`I`-05P/0I*C4`Y`-B*)6'$$AE`
M1=_I`0H`CFG"ACC9F0L@`+OQH1!)-6C4%KGHCE01`?-87%C)CV(9?0/C/QIS
M:@+'%H\D9OBT*JWB=`LP>1H2-7<!-T=AKNIV_E<65A$G<9X9@J2JR%PNL9ZZ
M,QW>V!A52',H&BQ?`ET0,*HNN6U9$F&=R13P211(IBT7H2O)HP$.B3Q*8[,(
M!(]44:DB9:!AU9*NHQ+%@JVUFI3+8SLG\S2`6`"?PB<+4$MH`92840&YN$#@
M`90O<2R&231F2#UJ=7TY1!&J(7+2EW'7XTR`\7-R]8^BBC8AYGT,D7L`$JO%
M-1<II*@843U!=2M52H_7$H?L(A,;X"7/2A$9,$!1A#,,425:T9E+2"PO>BX9
M1BWGDD%+Z(1L&(Z)B(B`\264^P#]Z:))NQ`+@`"3Z@$9-!D;0#0I2C5.@H<4
M]*"Q\28&P!6.&H=#_I*5'B";Y_BE,"H6,&%X&J"IJ584M7(<DD)+,6N!QY(7
M;/4QJ5>!?32Q/^$;.F.N@E=8)^(VGR2*NV,!!8"Z:X&G:+$`88N'!\`5%H``
M!V!K#0$!!J`5!SB3!G``C7:/DV0`\;N_`J$`1!._]FN<"=,!W8B35M&-G]40
M&4`R.1(!JSL0JBM0HN.$15F<>'(4&-"(:/:$3@@="%"(>"*4Q!L63A<^#T.0
M&5=.^74AC845'%`\"U`!!]!I(A&KO*ID#K$!90&8*<0`R6L0$O(;=G@2&G"1
MY%>VGMIB3:P[YN$HZ3EMD;$1P"%W%N(HL;5O&6``YODW2T3%^"%TRB=2_GU&
M4,T3%E,*;"NCPCL$Q4Y,7D1,*"#&PM*GG2&1&\.'%Q?5%I^91.+!$#3J47H$
M4O.W`""80V9!?_F5``U4,1C`7'$LQ[P5QTQTQ[4''<78`1=\&TGA-P5Y5_^C
M4<R%O&01*R[QOD>A`1F@`!NPP-UE%OQ54[=V$GY'R95\6W1,?=I+$,.!QXU'
M?$6L`7:5`1`)%W4K&Z]#5IJH>'+!7P-"$)E4`0E`$W8SQA$Q%$I\''RA=QV5
MR[HL6)=<*HY2>T8W$N7A;FT%.9`U5&C3-?N&([%AEK187%R1<3P1*0D`R,'R
M$Z.A?`Z0KY,7+!H3SN(,6+P<<"C!(0-;9?]Q_A?O]!9N@2JI*F%TE73;P['#
MC!&H,JZ=JE+J-GD/D`"?LDG%E;V3@A438(7*TR\'C=!'1<Z9S-&`I4->LQ/<
MLY0`)2,NT4TBY7>_(:1WUA$)F;<(T2H]%,4L5;^.Q!(;+16C(40K%RR2%=/2
MI]#_>A:VD<_21#`O=1D.77=S5ZW>6Q/V)B,/4BLG#1[W1$V4(IY2*AW/$143
MX``7I7_A`S"=-V@`8V$P?=4,-=-XH1IBS<CT%R`_9Q(EBJUW2Z4]AL6?<2+'
M@2JOAI[^8RH5H```DQ)Q76-QTQW0-2=/LT-4+189RT-8`=B!+4U9C<)681NR
MS"#5BBI>BU,6F%%0_@4F)L4H/'P\"6.]9OEJG]="?5DK7<4I^O%;?(&61>Q1
MS(6M?TE"GCTI?G<5J\W:(C384>W,"^(4Y48K^N=8^3<!#+`?Z!ECJR(CD4%R
M2\5`Y&G<G")QV'&KTE46NEH0OR';VT7($<%L""&OV3UPVTT0;6*QI&$C=[8!
M&_!9JE@8%F(8+)(1D?3/3]/<;7&>7D:>_A-(]O9/;!<1T1D^159($>':"''3
MJ";@6W?B!F$KM'K6I.$4,J$`'3M/2=%5.$5+%_X\.0U^YB;6YGF>A12PQ5CB
M9_;+![X0+0+&T]'?D2T:*NSB*[YU!&YD!9%B9J%2_[@!",``%1`OM<*`_AG`
MX\I9XA>9$V6.X:T\$JU<2(,W8\%CI'%I&*WRL;UQU(VGYGJVO>A!Y2YGY8C"
M(2GM$)2"%1%0,L(I`3BY(O_H+GO>5WVA%8SQY+E5*^<I1/%C(/\T=D4(YK,Z
ML;-!W2HN&C\,DG\N<"U.+]<88GP=/I!N;BK5+QMQ2";1=!1(&N0D4HK4&W?N
MPVU^Z1G`UOP%<DW!2"8T*J/N:;"^7<V!W:A^*'%LYS)H9'+AVTUQG=A12#V4
MS>F7TU>"%ZJNPQSN>O=<=V!>&X(S*D56%\S./:5!PQX%[:G.@IYQY,9T(H9]
M$YKM,2C>QH(R=S'>3)7>$$XWY!<0&_C-(GB#_K%,D1(I1>@+0?`0(68@.^_2
M%L=*WCW2Z6X?V1(6`!5YT4*JV.U@X660O3";@:2%3L.7DL-T1R+U9V&-[!TK
M+S:KD13B?O%[=,FX(LF+3(,NX=FM0C]JETL![`$2DNV'`AU,X2F5W9<1_Q!B
M=MEF9A3^@D^_`3TU;Q8I3AK3,_$[GV"BT1'-,5L7\0`'X(\7'3BQ55H/X*,*
M,+8<L!9:/"^H(N\2$&0_''R(98W3@;SU\X#*%DA10\6M3'"KH>]B?U0ZWTS(
M_3RQ@?>-`2R&1AVBF6-V`55GJ\:X<TDIE@".[<,_SJ;^XR[F*?E2?RH?,AHG
M;QJ.S_@1Q8)W01OM_@UXKD)+?5D;;J$>_+<>.JN02[\UK+_")1KVG<02K$HO
M717L5XSD&6'$I;'X(&,7KF?]UL]`KB?F#,C]W>_]W^_]_B?^XY\D-270K3%:
M]=$:`8(<K%4?8Z,2D:**L80VJNA-[@1L\E^U3UH?>P>/`!%A@@0*$BI8J$"A
MPD(*#1=.:$@!H@0)$RP.E&BQHL:+%"DV]$@1(@8/)4V>1)E2Y<D-)"EP.#GA
M9(4-%PX4B.!A`DP/&Q)"R"F!@P,''"!XX&"QPDJF39T^-;FTY`8+'BPLZ`#5
M`@64&R98Z!`!`DP)73-LR'`!0P8-&=BZS3`S+M25;NG>7;F!*UZ^)3%<_N";
MM:1@#X0-FSP\&/%BQ7T=%W9,N*GDQY534H9LDJ1EIAJJ>MA<4D-H#Q$Z*+"`
M8:F$#01A=B"P@0&%!1C01A#*6;=*#*$?@'X`V*D%"WKG>EA8,H*#W\A-9I@P
M&NU:MA@L7%!['+1PQQ*T[VXJ$SQ3M>/-GT>?7GU?TN:M^T4I7CE:"P(L<#"(
M,@*#@QPP0%Q/-ZD\T"`GNHK3#+B3%MA``PV2,JDEMZC#8+3[5HJ@O;O*"C"E
M##0\[Z\.1R2Q1!.;`G$WSTJR0+L!D4IH@M8V6(F"#A+"@*<3[UJQI`HR^,PI
MO4["@#645+L@`QM-XN##Z=JB"3,/+BAN+[Q2_M/11`[7*V^E"1@H"4C1%GBN
M@`+$HZ```P1+H*P%$$#@@`4X4``I.)?2(($PO_,@@P2JTJ`L#A)0P,H=64))
MRD/[XNZ\'DO33S4)MBIM`08,1$E)"C18E"_N-%B-KBU5PJ]1JRB(JS>WI%M)
M-:GDHPO53OT+4,25&#C`K\\PR+4D!UHTX*\!,&#@J`W4)#`#`R*(RP`/$LC0
M@)8"D*G+DRX8@$P,'NC@@`HN*(`]&L'3P`$K-S"@@0<>H(A4!<;M-*44=7O/
M+WA[0O"D!L#,E*!X^:*UI+TVN#>\&F$UZ26ISNHMRP@C&-"[N[QR>,<7T;,V
MI65)JA<#!$QRU@,)_HHU\+<'(B!@+@3$"]8!Y23`(`$];272@#^WW8!,#QR8
M=R4+4F:/N"PQ6"#(""(HV`,*(&@@`002,*!BE#B06KV>+0NT-9B#S"L!3DT:
MZ=^^*(!7/`ZX9NJZE&9<*2F7"6PQ7\0*BBJ"KZ'2*^E#1SWOP[H6H,#ECGO=
M-DP$:CO)`6P_0X!#`RIX>X,$,AAY@MY2N@`!"QC8=C^!CYJX@`<**!B#?>U&
MJ0(%$%!@@@6VK-PD_E2BX*\,LGH[)81@RM!$4\<+Z_>[,!6;K]!DC$I(LH]D
MRZF$K&RO@PDN$(P#9J^\VL0+K5[I@0;2G'+7CY7F%P,#4#MI\@B::[,D_@,L
M:&X#`#*`P/S4Y%WS@&TG>)N"D.FJ0``ZL#D.W$TA?6).228@,X]PZETE8<"D
M!J.__3``;5,A%I$>8(`"1!`!/B%>A[+WF$=!A3(<N%CQGB*?)A'I;B@IT'<\
MPZ>4R$@"2?*017CB%>$Y!6'_HAR7NF<`!H1K<"9YF[(0QX$'8(``"I"9^U@&
MOS#5YB@R^YWY2D.`D[VM77>A``(HL,$&7%"!(Y-68SP`)@T48`$'B"`$'G`I
MP.`'='U*P`+,5:<^,6`!14L8TOA(HA[J1DQ.R<#)3N:P%*J0*0'324I&E0$'
M;*")-?RA2A("L0AD"3^&VD`(-^1(OQ22,RD2_J`'%F`Y\8&L)!)P@`3TE`'-
MZ<D#`2A)X]Q'-.5DZ#<<&):\PL4!`3R@`CKCS]GHLD$"1&U\:XM``'PR-0:\
M$`*%Y)?($M>3`U@`81MPF2U)-$+'M$0EH\'(<;R2*#.2$B56@A!*MM0`&O%-
M:48R(0.:<Y*MW"LYCWF).S.Y&^%Q`)=6:6("&#";`4`@EC9A0`*R$@`&-$X!
M!BI`7-KG`6=%8`$-0(!_0,<Y>0V@)`LX"M,B\+$+#-(I"N!628R)DJL(0%W'
M.1M0*'-)E60@FR@!$P8<0)D,-"`N$&AD>LCIF,TDQ2+,TIM5*&,H=Z8$A0G3
MY%P:Z1E%T84J^/3+_DXX8T\@OA`\EUO;9SA`-H\DDB)5P<"Y#B*RS4B`4U]!
MBH$J8"0-#,RL!'I;7%^9FPR(4B7=.@F=9I(`!\3%*`XH%@3`HI+ZB89)$E!`
MU70&68HP[0'(LPI9E;J>H_5.5#2E8565QI.KTDXT]RIL5.^BFGMYIIT`2VJG
M1%N9`BY5M8^Q35=T`R\)N-$``A`MD'Y*-4U2=3V^Y<MMF>+<W9+2G`JL6G"U
M^4KHIF2O9H5(5WE3@11M0+P[DMMP.?9;]MZE2;(MC.6@\M?GKD>Z*[E1IN"K
M0E@-5(%AHIYS*F,!NQXI-W>!3H7^,]G$^G=1U<5+P*;WE]ZH12T4OK"%_@<2
M$@YWV,,?!G&(/4(!"U>X("`^L8A5O&(6MQC$$%AHC&4\1QG7.,:098#B[.N8
M#&1)>NWMR8"B8S"!0:QJ3TF(#,&*MQNFY*\=,.6.UI*IK7RD`D<>C'RB[)3$
M9,;+708S8[XL9J9T><QJ##.:Q9SF,[>9S>/I[FP=LU::`IDT]U4F9SZDH25#
M)8BM(I*Y]GNB+1'+;G-IDN5DR[4X`]G10(8D>N[+%+ZMD[T#NO)3)NU##7ES
MT"PA;U/RG``(T"BW\]TK0PH"D8YDI"(AV;!'&K"?#E+8UA1>98DQC!T*G_K1
MOP9V8;8\X,?X!RTY+@V6X[4D'VGETU:M@%@C_O2CU#)%25`14004PIIG:](R
M/)%2!YC;`0W<2S`=V``'Q(UN\ZI[V,&&]V\;K97*%)8!.O)UIZPD[:=`6),'
M-HD%KA=A?O>;0!*9#<#YXN]_S3O>Y]G*=\Y&G&Z[\]V.V6=?/L0L6.JDXB2R
MP-T8+M/S1@@AWZ%<M9O";+KT=6<-X%^D\>)<B_M,/&3Z$@1U@L8$$.".4BQ)
MG;R"OMV(]>.[D4`#,*"`XRP0J3F*$$6.?BB'.P\O:<E`M.VV'(C=[N(DZL"Y
M5#ZU22?:8?\9^SF;K'&J%&L`?4V[MW5C`#A",(\N!6ZK&N`^#SQ@?A[XF`0>
M4)/84&8`XW.6`YB5_M'=4(JDGIJR8_A(@2#-#B4/2,!!=!:5!)C)L(NJ.I'+
M?`&/J,5A=H.<5=S)M<]/URG_D=>F^I(WRU1E/P92.%T<C&`"%&``Y&:``>+^
M^E;Q*U<;_%BN!$^@_YT$`-[BJ!8]X-#=8*!^WE,\14Y&4QB+!P&*?X`"*HFB
M![Q08L&1W7<J\+]!AA$"<=ETB4+/E,];[V17BX`!Q&BYX9.(A?'7C*@B,+,"
M)P#DI]SKCMK*MQH"#P,8``$`$PMHOLI(D0O@%P:P)`E@$.7[#711B?DA$P3(
MG%<2)]RR``=PFFZ2@$YJ&P0@@`!(@`GX&*ZQ@`30D<)"002(H.TY"0I(_H#0
M8``%Z+T$&)?14"6I\$%EZY3YPQ`F48@)2(B28Q&':H"E6$`2N:[MXHL4BJL`
M,XE`N<)^Z3]$,JONVKV[>!S?.X@)S#O>X!<%^`\(F`"0$IG?T``V]```Z);-
MX96I*$&"BP"PN("<*)>V20#HR9WGR(#-4XVQ:X#OH0V8T"ZZ*0D.N!136Y-+
M6P_^:*+NRCH46AFA.,,2"9*V<(P*(`SH,!7H&,,O/*3QH*H.&#FLVHT",`H!
M,(`)P$/V6(D+V+LUL@XP.8#`LT,\!`"J>)H1U(D_G+,Q>@`'0``(6``%<*F<
M:PT'>)&K@*F<PXOJP0J4\!H?:9TBH0"72@HE_M22]:`YIV`B"9"LPDJDX".8
MUC,1M!(PC:N*UD`;RFDTO$J/$(*N480*`LB*SL/%ZBL^"`I&D>'`/C%&F""`
M#XH:G=B\OO`HI]&C'*G(FDF`P5N;"<`-`^0G&[0+7Q$MP$D8`X"`'W2D6>R+
MD=N*@<@TS5@+!L@OT(H7^9@F@!HR4/NZ`YPZ4;F7G02@!LR*8[$9@LH+F'*`
MS-H<`@F7Y?/`E#A&G7`6",`)Q@N7OC#"G2L)9@P0R?&C`X.QB!*MH]D+"!B+
M/J%'0EN/*Y0NBFB`UHF+=2R1M$B>RC"KL*,J%!HTA)!"SKB8,-1"RXB`AN(4
M#1B`732>SJ`(3K&T_K*@DI[X.9-X`)XP$+'8BXSCC.6IQXK)PM=*B@2X@$'9
MBI>X`*`@)9>,KL%($N^(J_X+.4MT`)F0@,!,#^@12::@"E34#PGH%:90#73<
M#9I(K#`42*=8G\:JQ+:D"R9\.+"+*"L)%'5Q#7=B3;P0B*-)+Y=4B""1.>TY
MCNRTJO\`D1A<0=%:J]VT#*J(C[M(3FP+2D"+SOIT-/(LRKK0CI[Q3%JD.LVP
M2[RA/#[)``58`(]R$V@CS/%`&P83M0KXJ;Z`,H^H@&%)SP"-%8F(-HN0")'@
M,`A80=Q@%_!32W9QL1.EB`J2L5@*B11#T1=%41N3T9.1([$`BG61(QB;_B,%
M6"@>C3%+"<(&<$<054N@P(W26L&&V#%KFQB$\9M#&1#V#!,`T1W%*[<'(+'+
M"*].(<I7:@K/4)C'X,OCL`#)^L)`G,_LD8S`9+,V7;/).`DW5;,Y=;,WI=/?
M^LDK&0][PM#TR$:F0AUYN3^G&:."P8^"6Y3O&"@-@$+_Q`N*<!@$>``>A)L%
M-8D\M<],E;\EW8T\BPKB'(^[\4WWHCSZ6HBD<QW_4#A0":CBN9B0@Z&%>*'X
MW!,G"P!N^:%R8RI-Y=6:4X_[JCBT:2U2)!*O0@BHTYV">``]F@#.[!-_=*2P
M>R>P.)M&38D^31T:6@`!.`H$#,^GZ"%3))!,_C.GNK0*DHB+N("R3)F*GJ"O
M7M54Z)2DQFR*B\%/QV!4DW#.#E`2X^1-P(E!?WT.RONM"2`J3UN)0KR+F>R*
M`1`=@:D1>KW6!S`IQ4.`PGJ_HO@]9*D3,E&`?3F)8&D-CSH`W(377\-4NG#.
M([&Z'@15SI"/:ZM7?WD*#3A0I3L]2ZW',?RL_J,9>1J``6B./@L3`QRH&`D<
MZX&EO;.@]]D@CDJZ-9):D)F3D0FMDSU9>;V\\^C/GL!6W1@@1XU3*I$]KP*3
M>P&)ESV4^#M6^#@ME=@``1``+A);L'G4&B&O9WR:<KFW\(.6"W"68N$<Q1F5
M91F(&8Q0K+5/K8T)_J[LJII(G7&ZU/;HS9ZL-_)Z5W?2+O+8T@2!BF&]O*`5
M6LTPU6X3+<H;1)B[V`*PCPF(#0'H@,"]``"H@`>@I9/`P#8ADT%4W%YE7)-@
M.*X9.X316;[(UV;3C(I06]Z`&&!SST>2('E9IKP`@`>D*";)).L9)=I!@,3+
M&6\J4_!QEL`E)L"3`).2G;A*.L$+I=Z-U_5@.)@8/H3QU%^%EU?YBOE,F.A]
M-,J!L`IX5W(:J`,(``(0@`)XIL+DI^%+KO=;+?BIIT@JBZ!0O=K-N"%#10<X
MBJ]U7_;Z72_M&ZHJ7KKH@-#`#IKE#%!)K_92MP;X%?P3SK>%H0`8@`"P_N$$
MQ@_>>+=[[>`>QC;X_<<^T4"::$6\(`D4`DR3;17L`+8.D*PB01E870F&E=X5
MDAH'D%L!J-[@]!&I^=HJ]+""2(T,LS5=,V/;*>,T)N,,R[J$&..L^Y`+(PXH
MY+"M.`A7(8X8(2^$^,Z#^!9>&^.U"&3KH+`64>,*0^,X1N3L@(LR/HM5^9`Y
MKAT_Q@ZU,&2U(#%+1F/LB&3K.`A64L?<A`YZ8@"938\%,";]/8G'!#8-P#P,
M.!H.F+4%:"0*&);;&B&R`J8!>,$""(`$SBN5$,B+J1ZD8"V"2;=5(1BV2#?;
M8)@)L8T&615C.QL@B>9RD^8/:8N06^:V:)"3_N@Q;WX+9B88;RZW5>'7MGCF
M"GED;UX+VSAGZ=BSM^@-57EG!:MG;7:+)CD+=?9F"9&0=YZ./1N-ZM@SXK".
M%BEH5:%G3C4/")&`Q]D91]FK`ML-Z$!4]FH2`RW0""B`VAT_XF@K2S*FHXEA
M@^N*![!A+;[AM)I7J$A9'Y9I%'%H\_B1+\'&G]7+A-!5\&@(9'6T&PF.E0P.
MZ&B1K+-H+[V*G$ZM8;.G"JA>`:#A`N;BNJW,DY[IK-:-F-8T]>BQ.H$]#JZ+
M"2CB![U,8"L(:($E<QF9N"C`I*&)MFO6I!JA'V(``7A``*A>!%:)"R@8@>1J
MK1;L#U:]].#+`\T*_O),BB0IZ[RP""]T-";R&SE*)&EYB:^0KJ7(B41BN6N!
M"K[)@)4.``#08@*H:I.H3($L+PC@E`HH-0_8.^-D#A[ND`O8R%?:CQ,,1&D<
M87@E;"G];/CQJ"8!0+WX"B5V'D@%-@(;E=34DW(CB$&3B2\IM=;@#:@0V#7"
M:[FMX;D%YB^$)\#NGJ4[P3]9O[XC"0-`X=^ZZDJLG_N@'U42;/I,#^!&LG2S
M/`CS#XNP;V&>@`?Z-:WA$U,<B.0T0J:Y%+)Z-TS)`+RV81KF90!`@'?=I_OY
M8950%PT(*0=).@VX)@\H`(EIKU_L$RO)$&*)()D@\?F>B9I^:(?2P`-X_D7=
MX<[E)3^D6:U?PXU'.IDB;@Z@P(^*(2<27P`:/N"\7AF=:`A#Y1`6O'"KTEN3
MR*-M2>\6`3),@:0&X`#ZV/'$97%:U=/U^"RA^$%[NH"%:&RFJ.CV`/,3*:SL
M!F?E?8R=T``&F$M*+%8_6XH,```#'@``$)WV4!++A119O(L>.@H#R&F/LE'`
MV,HKCY"YD!RZ*@@,O&T6I^VFZ&\AL>T$"HL2-X@T'^N,%A@;'Q&+J+:WXHP.
M^`WAZSOG6BJN6(`7I*@H^^2ET`LG?W*:XE%T@18PB2`>'8"%4N7U^!+Q`)62
MP"%PRHG]R%RMSO2TZ1"[(HRC^1&NQ1%1.VN!_C(ME3B:8G\E%&*L*F%9W9M=
MG'A9^EF?^"1L%N_5:/>9#A%KKJ3C+>LG4L+H`!X(]"@+>`FAK_L34]\`"##9
MP'9W'X9WE=CTX3#XJ2F2M4,R$5>AN$HJ%*)2]&A57<ESKQHJ$A))\EKC119Y
M#!OY,PYYDD?Y,UZ(0TYYEC?YDG=YER_VM(#YDW_YEK?YOVAO\%AXIYAW\IL4
MXDP*43^/"NCV?L'Q]7A>X/7L"-/9'/:4!_$0XJ#ZJK?ZJ\?ZK-?ZK->1B=OZ
MKP?[L!=[JQ\C.7H`LT=['!W[M5][9V70YP()SC@;5<<+BP#WHALXLAN(N_>A
M=X*7[BJ0BMNK73WX_L)WBH37G1#QB!4VGKTJVRLA=<N2OWTGE8(@^BW4#DN;
MDLB@@+Q/6(MX=II6W)'IT7X##,@U?`4VC_X.NR(9B(8G""D-B]22GA4<$?_0
M]:Z(MM!/#\W_+[=]#-*#^)[XC_5VC(:OJLR"(+>/"EWZE=17_;?OB[,Y&<1_
MI30_^DPQD(PY#Q1B/+6S?K[(?>T%C>),.K'(7^2N8MT!@$D%@`B2`+V._SG1
M(A?\C5FW%.A+'\`100*K;X!@X*%!`PL>#B),*$%"!@X&$D*,*'$BQ8H6+V*T
M*"$CQX0&,6Y8&($"A0P=.U+8<!(AA0D4,4CXZ*$#A948,T!(T$`"A(@P_B=P
ML"ET(H>:"1\<Q#"T8@8-,Q&:W-#!@TJ,2B5>B.``PP$,""1,P$!!080'$PIP
M6%#!0=D*%A*L-7IP`84"%A@X6'H10H8(3BLN\)#AH=["AO5N/!Q19L0*$R:`
ME6OSK\4.CVWVG2HQ)&6$0!4799"!`@0&"Q14[;#0I&+$$#=<F!F;XUT)%1XP
M8/#0;]($!B`?Y`#`@X2\/:U.Q%!Z@P$+""8H6)@`0NF\='<V<&!!@8<*"!(F
MB)#`@P+)K0<ZC6!10]ZUY]_#CY@8/N,-&1Y`>%!UZ(;:$H):9)!Y%V7@0&<0
M8>#29@/:Q`$$_S6@@0462-!54!(@%=]0%UR%_E!BC%UT5T\96C!!8$E9P`$#
MB4U0D`0!>*`><EAMA8$!")3X0`42&%"!!P=$,`$##^3%``07?)<!=PA-=P!Q
ML[WG`&L)6.`5!0Q@`!-+#"V`004`:ABF8?.]5Z4$$4AP`6M#9;!0!15@$-0&
M/E9$H6`,3F0;11*""!$#F@F5506:61#D!`]DT*8$!XK)D6H0R=AGG0$@]<`"
M+I6'T`4.+/#@00W`=.:9&76(X$86''!!`F$1)]`&#*"I0`8,.'C0=_D=Y<&?
M<,)'08<&.%#<!``4MZ0'#U#X@`0"`-JHLRN1>5X%C)X$VT)I[I<K14`9%>V"
MGVT6TT6P-?C8F@=U_A"!>A3H^:Q0T4KH@:04.;?`!L=Y8$"'&$2@5&((,!"=
MJB=>5&I"&OA8X$`4X.=`3Q3XF%\&$T106EF=@JDK`PUPP*NT#CB`5W:6'F"`
M>`H86_$%L!Z0K;LO:Z3AO!=Q<*VO%T7@LF=3=:O1EQ-I,`&>$BE(6TO-)C3:
M!#K#G!%-$)W:T5VW/:"!4_IJ2N>1&!29I@6$%=RTV.!!>=`$&F0\MMH>RLQ1
M!A6H^T`$::]')T06_#6A!T/W1>U!%,P\408&4[3:2PNM;5.T$V00>$0:J#<2
MP,11UM]!&.KH`60J%6T1X8F+R<%W$#E`-^AB>ZO8S!J(%=FT2S%8=)OR_IX;
MG`1#0UY[1IWG*0'3!^WH^.D280`BX,,3?:WRRS/O*X?,0Q^]]--37[WR#+1$
M$@(+5(D!A]Z#OZ/UXRO/KO04</A]^EFF#QGYXS?0=D*JH0GG[S;Q?GFN8D&=
M/T(UVVTE,I*(!=A%D:*<#7DVR9"'A*<VI0`J@@B1($0H^!1T33"#&*R@!B_H
M00N"<"DAW.`'.SC"E9PPA6R+CP7Z<R9E:6B`"M%6_/XVMVVEKB,AD<^1*+*!
M!S3@?@JT2$KN-L2$?.Z(2ERB:^(S`8^)*742`%1BD'(OW4%E489AX-Y\1Q'Q
M,=$F-0D*!(KWD@W81W,E68A1.M``7-WN;BZI_IE!]*8@R#"H;&'<(Q\SDD/#
M./`PCX(4$@T"DP"^AB&MJ4F;3.>!HD!`B'V4R'\$`($&3&!F/&F3D.PU`0.<
M*P$::$D#[):!54T@/`38P`*0,AX/+*`IQ)ND#B'0PB#*"U8'N2%NE((;O]&R
M,'\L3"`/XZUH#?.1CGG/0I*H-*0%TR)S.IM)9C:!`[3I`7'J$M@.(I#`=$`@
M!\D``C+`',%T0`%%F@L&J)7$E<6R`P<H5`(8D(!Z)E-MH&*`!:KF`01@(#`8
M(``'N!(7MT@RFHJ3W[.\!:Y=UJET\%%D1#)02H5"RR.%LT"PM/E/A_C)`P7P
M9D(H,`#GF*V?LSI(_@(\ZI/DQ$0]`*@)EN["QP74;#0CC5^P8I07`.A&`8[$
MZ+L8ZBQO<:!S>.H+%@V3U,6(BZ@G(9,F,;`B9+''`\-)B),$@H$:>@!AQ!F`
MO%*)(W'BZZ58V<A7`JHKQQ0@K4=T0$W2-('210!N<PO6`@8@@`O01:K&-&JC
M_">CH$VD)1H:)$(*!4S!^K!H,\MK!6SI&X-LE4G=64`"Y*(!`V`O8`<0J@9R
M`@$*+`!-6(%I6BQ5@%<!3@&/35RA=GF!3?4S)`D`@%(XH!T,P!"RB('F88II
MF#A%1#T)HJ0,X6-&EC15N!89X,PX("</>$]PP:';5<S)FJ9@(%$MG"56_BSE
M'(?<I8"QG*W:$````#P```\9C#@C8`#?=I8YY93N4O(Y%.,69H>00I]/)J!'
M^,C0`@?F[T66=A``ORR)/YQ;3PH8EJ^N:(E6,TEX#U(YE6R`O0S&B'^%`N$F
M'JQSJM'B41/2W!&3^,%,3"*,:QR?$MND`NL#G_K`QV/V^7C'0@ZR-G\,D_2=
M"<A&'G*/FPQD)WLO3=Z[S9.KO.0@>\]J6(8RDZW<Y2MS><M/3M,%BCDX)HMX
M)32V,9L5@^.56)<#(19O]R94)3OC.<]VKAA^^IR?/@-.SX(>-*$+;6@]E_G0
M=L90?AKM9T5#VLZ.=K2?'U#I2U,ZTYBV])\[S<UI3C.ZTIKN,ZD]7>I/G_K4
M"#C`JEO-ZE=O+]6FGO6GRT)K6:/ZUIUF@*M[W5)<`UO7N?YTJ$_-`%@CV]7!
M'O:RE]WF9T,[VM*>-K6K;>UK8SO;VMXVM[OM[6^#.]SB'C>YRVWN<Z,[W>I>
M-[O;[>YWPSO>\IXWO>MM[WOC.]_ZWC>_^^WO?P,\X`(?.,$+;O"#(SSA"E\X
MPQON\(=#/.(2GSC%*V[QBV,\XQK?.,<[[O&/@SSD(A\YR4MN\I.C/.4J7SG+
*6^[REULD(```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>f39432a9e3943227.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f39432a9e3943227.gif
M1TE&.#EA(`%*`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````(`%*```(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ=/D1X^>!@Z]*?1HT@M;F"@0($!!0@:3`B:M*K5JP,W*!@@`$$!
M!`P,=,!*MJS/#%L)%"`00("`L6;CXMR`]8("`6P',!AP`*[<OX!;<C!0P&D"
M`@<.!%[,^&0&`@,"%"A@8$""QI@S>ZP`0`#?R0G$:AY-FB(%Q`$"#$!P``'5
MTK#E<LB@00/M#!8LV,YP(0,&#!,T7+``G`*#!0D8(%C`H$`%WK<I6*A`-[9U
MHQP.`-C.O;OW[P`(_HSE4/W#!?``$%Q?S[."`/3POQMX/?`\>/7L\]?DH"!`
M_/_<X5>0?=\)J-^!+V7P'H``&E@?>@XB*"%*'2#`((,1F@?AA!RF-,&%&!Y$
MH'<9MA14!QT015].'J#(08L<=,B0!2`".$",`VXHDP8)).!5:`I@T%,"!1R@
MUF$9R*C0`^BM-@!E`P`PP`!/'?:D`%]1Z0$',7*`X@5NX46``<M%,-.(W$G0
M$W@4*)D0`>AA8,$%&DQP@0,64,#E!AAD\%P%&G"P@`,(&`#!`%`U0!YQ&J1(
MWDP8@*>F1QA0$($%$5P0@5\3^===`!H,A`%8")0:U8KZ15G@1!=,R94`_JD-
MP*E(%3!@JP(/,,6<K0PDQT`#"R@0%`>>=F>F1PQLQU4!`3Q0$0??!2"D0)QY
M=QF'!=PWD0<3,'"`<I7--Y('%C10[(4$!+4!G-XYX)$'%GJG@$717C"0!-]=
M.^$"X,DJ$5I<&="6:CB"U`&[-6YW0%"1?E?!1_QZUT!%'IP+0`#V"H2O=^E.
M2*RV$ED0P+<3/#`F`R)5F'!W'3?\:<8=1=S=Q!1!ZQVH`U'PG7@<JNJ=LQ)1
MT-4!3Q70P`.H;J2!Q36Z]L'2#K\K,W?SUAQMD@(Q:6V'\7HG;D2M+N"9:D;.
MRI$"X+45YMIL"\!`4%![][!'"+@U<`!.3Y0!_G@P6]!VWA)VW1W*#/G%,%X"
M"'SQ`@.]EO1$#8`W`9>45VXY5=5Z-VE''7!Y`0<:6&#V0QO4V[CE7J['006L
MM\[Z@B2Z+H'KKD/`>@0,/!#!!+M+\$`"#RA``>L/S%[!!-->A/9WFSND\W=M
M[E3ZS5AW&/G*"3L8%)H!9K2\=\<^]#SX-)%'&P8;Q+CW=S!OR\%O%?RFP>,4
M>>!;HPV1.]7C'EQPP>@#20#VLB<B'2D//$`3'WB.I;_<Y&9R".F?`W-S@==,
M<`(3D,`$$M*_6GF%`&Q!P`-^`QX+#"0##X"`!"P`@0?,S2!R:L!AW'*Q`!!@
M`1-T8,D:`(&Q>"`"_KZ3@%0>4!X.6*!7J6E-[LSF`>/T:CL^>H`%"O:!#2P@
M`#YZH4&T-L`+98A[VRE11*[GG?8U!(R3\D"VVH40#<"..R]$&'<6D+0?7@P]
MJ>';0#+''9X51&1=Q!D&F+;!#V3`9]\90/2$@H'O@<<!5.F``GK5``<L#"$?
MZJ(7#S(^$GEO@6`#Y0<Z0,@VOG$[BUQC=ZI&$`Y`P`#8P]A`N,@=?0GD`@E@
M6HT"D*1!?F=.5_P/`>QE%P8=RP(&<`\!)N"`ZA5D8YIL4`%!=L#O;!!5CB.(
M+S]52`_(<3L00`@'3@F`16I'7@7A@``'**V!3`V*K52E)C<(1@3H$CS)_I1G
M?`@@)`L@P`(%&(`$*+#(@D`@FB$R"!C3,Y$)6(IW$?BFPAI`40<T8)(+.$`"
M-'H`F('174)!Y'9`:I`-D'.1ZUQE*U/J'<\HX`#Z_%2H!!*!?#7.`>AI`!`C
M@%/P>`8RSOD`C0"$F'-&RVL*>"=W-K@!!"0`@PP@@#,)<E"$_L<`5+RE`1_B
M`:,B-)P"&>JGHJ?&[X#5(!E@FCF_(ZR!9#*1%8"+!Z**GD)^(%E;$T@'R`F`
MLVH,/`EP%%4T(%*.'<"$'^@I?`)`Q[^R52`3"$"F!&#+@E"`,JF!#%?NF1J!
MV7``;(F59Y8%*P/HM'@]@L`K`V``$!)&`#2#_DA7K;J=\+FL.VF4:/@*LE?H
MN7-GKXDI`!R0U2IZ=3LX$TA5NZ,O,/I5(!Y8+G<$D#R!'!(^#)C5/2F+/^B2
M,X$:`%8&BDN0L=2F<UQR)'<:H($->&`#C?(2?#=`7\IU;@,2L.%70/BM#H2J
M<T,A+T.\2=OABLIB`4"L!V#I'<(99)R^%<AQ`5``JM0TD0)6:G(_P$=X4@L\
M6AR(6+MCU[!B%U6Z%(`9A4).!U\$KQ*;"(U4LY;6?NV35@W`"V^;)N@RV%@(
MZ:UW%JE>`"3@1(450$$M&ZWR=-C(>TSDBC^PS>X\UZ0[>]M!F*;D@WB`G(S+
M"!F[DT"(/,94"`#A_I$W\H`GK:4`?,T+`>R&%\F`=I@/^B5T=2O.PBY2J54#
M8VP/\N1V"J23'N8PFS@IN1Q9,R%JC2`Y27J1"S=8;XB93$`)@```3@1%>OU`
MD0$P112E[]2!VA-!G@R`N<WV9Z:,\`<F7#56+SF=WQ%`P:2;:`ASK+K&_4X!
MLJJ@1R.$:8@UR)>_0VF+P+@[%99(I!`#IRGY\2-CYDZR'3+BI0YDPH,N[TD'
M\F/N7-+2N%6(!J(U4T7G=93")0"@:@,!OKI8(%CV3HD+@N`IL_BQ&5%L=V[\
MD`P8`#D&2,Q:/(V143>O(>O3MX_-*LYQ2SA?07EK=_PM$)N5,<KOUA#V_@AN
M8F,_F&DA;APY67D1@7/GW@[1``+T`IG4`,XCH]YM0^(&9($4^=8=M_@'6+H=
M<6F<.QRG<I,'DFTH$\1<"2-`>5;=:"]/6M+?"3-&GFUNHGC)2^-!$7I=Q(%6
M$4`!A,)+`^C7\&@)."$\WHZK)]QL@6A`J0"8UJM5ZFX2T<\#2Q<(UYT^D`Y$
M8-3](F[2?$WB"$;:ZM^!^4(PP!0)2,`!#DCJ`2`0`2`Z(`(0*-5Q#!`:UBR`
MTXD94Z&,!,O(4!BH#*_FIZ;>D&Y?3,'EW@[+;RE<`,`,T`*)>WAH7WBB7ZS=
MZ$XT01#=':Z`L`$8H-\%2GF0#2!XVP19]J4A_C)]U<Q9+08`^@0X_>8B34E,
ML`(A:TUE)&8QJ\P>:3H`]LT0-'X;X-"=`%]1^5N_&U*X!U!<'6!\QS=+-D40
M^(5(1D-1#5`!%.!>,U)U!L%SVH9U,081@W0:!"!`H$5_B?4DUL8LKN5:5%)C
M>(,E9$)9>!82HX9]#)%641-2N898&Y![LJ94#K9NX/$V5+$E-HA<!?-DM@1(
MW!$`$/!VDT=]6Q:#RD9.SS4CDY0`#@!:_.*!.C,9D!%"(+2!:T$D:P$9>$$9
M9R=5(C%J0*<08`0S1Z<L&75/W?%G^/<!@@-M!^<`/UB$,".$.6,Q!,=V!L%J
M'O@!'X-.D`=K&,A:_D034&NA<S0E&05P10<0,&U!&0>0.(52&&/2&:WUA!TQ
M:L#&$%4&1P;(((SU>!\`?&[5>R"2AP?H`02(9H4"BZ7R`!DT5;8W?Q;8>(4X
M.!&1`0>P``U0**DA`%;X?5,X@FXQ&:QA0S"E`(_HC,ODAVW'A`[!/;*D5_OW
M*17`>$@W$!*U>Q@@43XU8:0&<LP5=-%$AB*F1[OH;>T(3KWH(UT!5`8P92;#
M&@(#6FL!6D2R4?Y1*(2!`$XA>3@G2@]!@;6U4HLU`!70(D)G?)4E5(H#'P(0
M/U<SBN<(60@U`.TF?(%8,11W$!U06!&Y$"85B5$2)0DP9?IG0VH1*X[8_EH:
M!5J$\1D1\"(ET2JIX1_9\HDFN6DV5#<AU@$24#=%>$-Q!5VZ`A7.V&X0L%%C
MHE%KEGT=4`&)\1T'X`#S(RB%H7D,4!X8L`!B&2P+\$(=8`'!U$4.Q@&Y`T1B
M243B]``.X%`/D"OM9A"YX3MX0AV].#L.9'F8TB."V2,2<`$4<`%]\AL4T"?Q
MXS^_,2>^$3\I05]\$E<NV!!\L@$6,!00J&P84`'#@3X/EB0OD@$90!\:\!N(
M^3X),5X\Y0#&XTPOPB6&Q$&I,R#G\HMD.99))8X#((T[P6O*YR9D<1K-1WP#
MP0')MQUWF12#1WC$B16AB(L+H4\!$'L\\9Q:JA>=5N&*[<)V'D!+VT&01O&<
M6L:=5A%W#0!`'G!W"-:<SGD?P(F>.#%XC+69T"44+,174WD5XJE[]&D5TP<A
MO9(`"Z"*HD$6YAF@5;$!!`@B"@"?5?&?`$">#+H3%."&\0$6/ED5&;```NDC
M8,&(%^H3;%E8>'0`%#"?)=JB&E&5$'``.SFC<Z9"R.FB.)HRY-%>\\6C+)JC
40!JD0CJD1%JD1GJD2$H3`0$``#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
